Файл	Сущность	Оффсет	Тип сущности	Окно±25
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	13 : 19	CM	             AC0010 is a novel, potent, smal
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	tyrosine	68 : 76	CM	ll molecule irreversible tyrosine kinase inhibitor (TKI) t
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	330 : 336	CM	  safety profile of oral AC0010; to determine the maximu
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	MTD	379 : 382	CM	 maximum tolerated dose (MTD) and/or       recommende
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	RP2D	423 : 427	CM	ecommended Phase 2 dose (RP2D) of oral AC0010; to asse
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	437 : 443	CM	se 2 dose (RP2D) of oral AC0010; to assess the safety an
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	482 : 488	CM	e safety and efficacy of AC0010       in previously trea
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	532 : 537	CM	y treated mutant EGFR in NSCLC patients with EGFR T790M
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	557 : 562	CM	NSCLC patients with EGFR T790M mutation.               
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	681 : 686	CM	-small cell lung cancer (NSCLC)       accounting for 85
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	807 : 812	CM	o       chemotherapy for NSCLC patients whose tumors ha
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	tyrosine	897 : 905	CM	s have       established tyrosine kinase inhibitors (TKIs)
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	TKIs	925 : 929	CM	osine kinase inhibitors (TKIs) as the gold standard fo
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	gold	938 : 942	CM	inhibitors (TKIs) as the gold standard for treating   
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NCSLC	994 : 999	CM	  EGFR-mutation-positive NCSLC. However, patients on TK
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	TKIs	1022 : 1026	CM	LC. However, patients on TKIs eventually progress, and
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	1162 : 1167	CM	al mutation       called T790M. AC0010 may provide an e
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	1169 : 1175	CM	tion       called T790M. AC0010 may provide an effective
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	1316 : 1322	CM	l data demonstrated that AC0010 inhibits T790M. It      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	1332 : 1337	CM	ted that AC0010 inhibits T790M. It       is anticipated
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	1368 : 1374	CM	     is anticipated that AC0010 may promote cell death i
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	1422 : 1427	CM	 in tumor cells with the T790M mutation,       thus pro
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	1519 : 1524	CM	ients who have developed T790M-mediated       resistanc
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	TKIs	1563 : 1567	CM	  resistance to previous TKIs.        This is a two-pa
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	1621 : 1627	CM	open-label study of oral AC0010 administered twice-daily
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	1681 : 1686	CM	previously       treated NSCLC patients who have docume
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	erlotinib	1831 : 1840	CM	n EGFR inhibitor such as erlotinib, gefitinib or       afat
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	gefitinib	1842 : 1851	CM	bitor such as erlotinib, gefitinib or       afatinib.      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	afatinib	1861 : 1869	CM	inib, gefitinib or       afatinib.        This study will 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	28-	1956 : 1959	CPR	e-escalation Period with 28-day cycles; Optional Trea
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	2109 : 2114	CM	n patients with the EGFR T790M mutation                
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	2368 : 2373	CM	     advanced, recurrent NSCLC.            -  At least 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	MRI	2430 : 2433	CM	surable disease by CT or MRI, according to RECIST Ver
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	2701 : 2707	CM	hin 28 days of dosing of AC0010, and have tissue availab
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	T790M	2826 : 2831	CM	especially the status of T790M.            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Erlotinib	3271 : 3280	CM	r at least 30 days (e.g. Erlotinib, or Gefitinib, or Afatin
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Gefitinib	3285 : 3294	CM	days (e.g. Erlotinib, or Gefitinib, or Afatinib) with      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Afatinib	3299 : 3307	CM	otinib, or Gefitinib, or Afatinib) with              inter
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Erlotinib	3434 : 3443	CM	n              EGFR TKI (Erlotinib, or Gefitinib) is at a m
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Gefitinib	3448 : 3457	CM	 EGFR TKI (Erlotinib, or Gefitinib) is at a minimum of 7 da
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	EGFR	3538 : 3542	CM	         an irreversible EGFR inhibitor (Afatinib) and
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	Afatinib	3554 : 3562	CM	versible EGFR inhibitor (Afatinib) and chemotherapy is at 
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	EGFR	3653 : 3657	CM	oxicity related to prior EGFR inhibitor treatment must
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	3744 : 3749	CM	  or less.            -  NSCLC patients with asymptomat
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	EGFR	4131 : 4135	CM	disease related to prior EGFR inhibitor therapy.      
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	HCV	4272 : 4275	CM	          -  Positive to HCV or HIV antibody.        
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	4510 : 4516	CM	atment              with AC0010.            -  Clinicall
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	12-	4564 : 4567	CPR	lly significant abnormal 12-lead ECG, QT interval cor
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	ECG	4572 : 4575	CM	ificant abnormal 12-lead ECG, QT interval corrected u
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	QT	4577 : 4579	CM	nt abnormal 12-lead ECG, QT interval corrected using
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	QTcF	4639 : 4643	CM	a's              method (QTcF) >450 msec (males) or >4
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	QT	4724 : 4726	CM	  Family history of long QT syndrome.            -  
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	5396 : 5402	CM	minary Efficacy Study of AC0010 in Patients With EGFR T7
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	NSCLC	5440 : 5445	CM	With EGFR T790M Positive NSCLC               Safety, To
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	AC0010	5527 : 5533	CM	 Anti-tumour Activity of AC0010 in Patients With EGFR T7
./___Corpus/ClinicalTrials/xml/NCT02330367.xml	TKIs	5649 : 5653	CM	 Prior Therapy With EGFR TKIs     
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	oxygen	605 : 611	CM	sels on the tumors bring oxygen and nutrients to the can
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	adenosine diphosphate	809 : 830	CM	ing protein called poly [adenosine diphosphate-ribose] polymerase      
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	ribose	831 : 837	CM	y [adenosine diphosphate-ribose] polymerase       (PARP)
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	PARP	1099 : 1103	CM	damaged DNA. By blocking PARP from fixing damaged DNA,
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	RECIST	1581 : 1587	CM	 disease progression per RECIST 1.1            -  Progre
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	MUGA	1966 : 1970	CM	0% by echocardiograms or MUGA            -  Urine dips
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	QTc	2361 : 2364	CM	tases            -  Mean QTc >470 msec (with Bazett's
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	ECG	2415 : 2418	CM	correction) in screening ECG or history of familial  
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	leukaemia	3345 : 3354	CM	c syndrome/acute myeloid leukaemia            -  Immuno-com
./___Corpus/ClinicalTrials/xml/NCT02340611.xml	Cediranib	3707 : 3716	CM	              A Study of Cediranib and Olaparib at the Time
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	Mitogen	115 : 122	CM	d/or       chemotherapy. Mitogen-activated protein kinase
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	MAPK	149 : 153	CM	ctivated protein kinase (MAPK) cascades are key signal
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	MAPK	308 : 312	CM	       Activation of p38 MAPK has been associated with
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	temozolomide	405 : 417	CM	 glioblastoma during the temozolomide (TMZ) era and represents
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	419 : 422	CM	during the temozolomide (TMZ) era and represents a co
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	MAPK	606 : 610	CM	lective inhibitor of p38 MAPK, and reduces phosphoryla
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	phosphorylation	624 : 639	RN	of p38 MAPK, and reduces phosphorylation of its       cellular ta
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	MAPK	670 : 674	CM	s       cellular target, MAPK-activated protein kinase
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	MAPKAPK-2	703 : 712	CM	ivated protein kinase 2 (MAPKAPK-2) . LY2228820 is a good c
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	gold	797 : 801	CM	glioma resistance to the gold standard treatment combi
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	851 : 854	CM	ning radiation and       TMZ by acting on both tumor 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	1020 : 1023	CM	n       combination with TMZ and radiotherapy during 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	6-	1109 : 1111	CPR	nd to       estimate the 6-month progression free su
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	1292 : 1295	CM	py and concomitant       TMZ (phase II)              
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	dL	1971 : 1973	CM	, hemoglobin > or = 10 g/dL ), renal (creatinine > o
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	creatinine	1984 : 1994	CM	> or = 10 g/dL ), renal (creatinine > or = 1.25 x           
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2022 : 2025	CM	or = 1.25 x              ULN ), and hepatic function 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	bilirubin	2057 : 2066	CM	 hepatic function (total bilirubin < or = 1.5 x ULN, aspart
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2080 : 2083	CM	l bilirubin < or = 1.5 x ULN, aspartate              
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aspartate	2085 : 2094	CM	irubin < or = 1.5 x ULN, aspartate              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aminotransferase	2108 : 2124	CM	, aspartate              aminotransferase (AST) and alanine aminot
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	alanine	2135 : 2142	CM	inotransferase (AST) and alanine aminotransferase (ALT) <
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	aminotransferase	2143 : 2159	CM	ferase (AST) and alanine aminotransferase (ALT) < or = 2.5 x ULN) 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ALT	2161 : 2164	CM	lanine aminotransferase (ALT) < or = 2.5 x ULN)      
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	ULN	2179 : 2182	CM	erase (ALT) < or = 2.5 x ULN)            -  Patients 
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	carmustine	2943 : 2953	CM	 chemotherapy (including carmustine-containing wafers) or im
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	vaccine	3014 : 3021	CM	              (including vaccine therapy )            -  
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	temozolomide	3120 : 3132	CM	 Any contraindication to temozolomide listed in the local labe
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	CTCAE	3691 : 3696	CM	-  Diarrhea of any cause CTCAE > or = grade 2          
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	4466 : 4469	CM	therapy Plus Concomitant TMZ in the Treatment of Newl
./___Corpus/ClinicalTrials/xml/NCT02364206.xml	TMZ	4598 : 4601	CM	therapy Plus Concomitant TMZ in the Treatment of Newl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	52 : 57	CM	andard of care for stage I-III HER2-positive breast can
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ii	267 : 269	CM	of i) tumour downsizing, ii) higher breast       con
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	iii	315 : 318	CM	 conservation rates, and iii) enabling the evaluation
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-HER2	579 : 588	CM	ion of neoadjuvant       anti-HER2 therapy to chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	2-	626 : 628	CPR	hemotherapy results in a 2-3 fold increase in pCR ra
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	pCR	647 : 650	CM	n a 2-3 fold increase in pCR rates in operable       
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	879 : 888	CM	udy of       neoadjuvant lapatinib combined with weekly pac
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	922 : 933	CM	 with weekly paclitaxel/ carboplatin in stage I-III       HER
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	943 : 948	CM	el/ carboplatin in stage I-III       HER2-positive brea
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	1123 : 1131	CM	fficacy/ toxicity ratio. ASLAN001 is a small       molecul
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	1158 : 1166	CM	s a small       molecule tyrosine kinase inhibitor against
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER1	1192 : 1196	CM	kinase inhibitor against HER1, HER2, and HER4. Preclin
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	1198 : 1202	CM	 inhibitor against HER1, HER2, and HER4. Preclinical d
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER4	1208 : 1212	CM	 against HER1, HER2, and HER4. Preclinical data have s
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	1248 : 1256	CM	al data have shown       ASLAN001 to be more potent than l
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1280 : 1289	CM	1 to be more potent than lapatinib and neratinib in inhibit
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	neratinib	1294 : 1303	CM	otent than lapatinib and neratinib in inhibiting HER1 and H
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER1	1318 : 1322	CM	 neratinib in inhibiting HER1 and HER2, and       earl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	1327 : 1331	CM	b in inhibiting HER1 and HER2, and       early phase c
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1472 : 1481	CM	t inhibition compared to lapatinib. Furthermore, ASLAN001 h
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	1496 : 1504	CM	 lapatinib. Furthermore, ASLAN001 has demonstrated a bette
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1557 : 1566	CM	     safety profile than lapatinib in early phase studies. 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	1635 : 1643	CM	igators hypothesize that ASLAN001 combined with paclitaxel
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	1669 : 1680	CM	combined with paclitaxel/carboplatin will       induce favora
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	1767 : 1772	CM	f at least 30%) in stage I-III HER2       positive brea
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	1773 : 1777	CM	east 30%) in stage I-III HER2       positive breast ca
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	1851 : 1860	CM	able safety profile than lapatinib combined with       pacl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	1892 : 1903	CM	ed with       paclitaxel/carboplatin.                       B
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	globally[1]	2092 : 2103	CM	ojected to occur in 2030 globally[1]. Activation and       ov
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	trans-	2164 : 2170	CPR	on of oncogenes encoding trans-membrane receptor tyrosin
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	2188 : 2196	CM	 trans-membrane receptor tyrosine kinases of the       epi
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ErbB1	2276 : 2281	CM	(EGFR) family, including ErbB1 (also known as HER1/EGFR
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER1	2297 : 2301	CM	ing ErbB1 (also known as HER1/EGFR) and       ErbB2 (a
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ErbB2	2318 : 2323	CM	 as HER1/EGFR) and       ErbB2 (also known as human epi
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	2383 : 2387	CM	wth factor receptor 2 or HER2), play an important     
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	2474 : 2478	CM	ancer. Overexpression of HER2 has been shown to be a p
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	2686 : 2690	CM	 been developed to block HER2 signaling       pathways
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	2888 : 2892	CM	ular       domain of the HER2 protein. Treatment with 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	2971 : 2975	CM	omes of women with       HER2 over-expressing early st
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	3092 : 3097	CM	andard of care for stage I-III HER2-positive breast can
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	40-	3230 : 3233	CPR	y [5]. This results in a 40-50% improvement in 5-    
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	5-	3253 : 3255	CPR	a 40-50% improvement in 5-       year disease-free s
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	5-	3318 : 3320	CPR	, and 30% improvement in 5-year overall survival (OS
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-HER2	4328 : 4337	CM	singly important role of anti-HER2 therapy in both       ea
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	2-	4679 : 4681	CPR	 reported to result in a 2-3 fold increase in pCR ra
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	pCR	4700 : 4703	CM	n a 2-3 fold increase in pCR rates in operable HER2-p
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	4965 : 4976	CM	kly paclitaxel and       carboplatin in combination with lapa
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	4997 : 5006	CM	atin in combination with lapatinib in patients with stage I
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	5030 : 5035	CM	b in patients with stage I-III HER2-positive breast    
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	transaminitis	5576 : 5589	CM	nic infections (25%) and transaminitis (22.8%) [19]. ASLAN001 i
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	5604 : 5612	CM	nsaminitis (22.8%) [19]. ASLAN001 is a small molecule     
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	tyrosine	5639 : 5647	CM	s a small molecule       tyrosine kinase inhibitor against
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER1	5673 : 5677	CM	kinase inhibitor against HER1, HER2, and HER4.        
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	5679 : 5683	CM	 inhibitor against HER1, HER2, and HER4.        Precli
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER4	5689 : 5693	CM	 against HER1, HER2, and HER4.        Preclinical data
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	5730 : 5738	CM	clinical data have shown ASLAN001 to be more potent than l
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	5762 : 5771	CM	1 to be more potent than lapatinib and neratinib in       i
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	neratinib	5776 : 5785	CM	otent than lapatinib and neratinib in       inhibiting HER1
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER1	5806 : 5810	CM	inib in       inhibiting HER1 and HER2, and early phas
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	5815 : 5819	CM	     inhibiting HER1 and HER2, and early phase clinica
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	5954 : 5963	CM	t inhibition compared to lapatinib. Furthermore,       ASLA
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	5984 : 5992	CM	inib. Furthermore,       ASLAN001 has demonstrated a bette
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	6039 : 6048	CM	tter safety profile than lapatinib in early phase studies. 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	6124 : 6132	CM	the novel combination of ASLAN001 with weekly paclitaxel/c
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	6156 : 6167	CM	1 with weekly paclitaxel/carboplatin will       induce favora
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	6254 : 6259	CM	f at least 30%) in stage I-III HER2       positive brea
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	6260 : 6264	CM	east 30%) in stage I-III HER2       positive breast ca
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	lapatinib	6338 : 6347	CM	able safety profile than lapatinib combined with       pacl
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	6379 : 6390	CM	ed with       paclitaxel/carboplatin. All patients will recei
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anthracycline	6479 : 6492	CM	wing       completion of anthracycline-containing chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	oBilirubin	6997 : 7007	CM	       Hepatic:          oBilirubin ≤ 1.5 x upper limit of n
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ULN	7039 : 7042	CM	x upper limit of normal (ULN), oALT and AST ≤ 2.5x UL
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	oALT	7045 : 7049	CM	r limit of normal (ULN), oALT and AST ≤ 2.5x ULN      
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	AST	7054 : 7057	CM	f normal (ULN), oALT and AST ≤ 2.5x ULN          Rena
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	creatinine	7106 : 7116	CM	al:          oCalculated creatinine clearance >30ml/minute  
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	MUGA	7217 : 7221	CM	% measured by 2D echo or MUGA            -  Signed inf
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	carboplatin	7786 : 7797	CM	 with weekly paclitaxel/ carboplatin is         indicated, as
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	T1-4	7968 : 7972	CM	 carcinoma            -  T1-4 breast cancer with measu
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	8234 : 8238	CM	m            -  Tumor is HER2 positive either by IHC (
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	FISH	8270 : 8274	CM	ve either by IHC (3+) or FISH amplification (amplifica
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	LVEF	8929 : 8933	CM	or systolic dysfunction (LVEF <50%)         oHigh-risk
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	AV	9021 : 9023	CM	 tachycardia, high-grade AV block,         supravent
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	BP	9268 : 9270	CM	ertension (e.g. systolic BP > 180mmHg or diastolic >
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	anti-	9897 : 9902	CPR	         •Treatment with anti-tumour therapy, defined a
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	10315 : 10323	CM	se-confirmation Study of ASLAN001 Combined With Weekly Pac
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	Carboplatin	10360 : 10371	CM	th Weekly Paclitaxel and Carboplatin in Advanced Solid Tumour
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	10442 : 10447	CM	y in Patients With Stage I-III HER2 Positive Breast Can
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	10448 : 10452	CM	atients With Stage I-III HER2 Positive Breast Cancer  
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	ASLAN001	10526 : 10534	CM	se-confirmation Study of ASLAN001 Combined With Weekly Pac
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	Carboplatin	10571 : 10582	CM	th Weekly Paclitaxel and Carboplatin in Advanced Solid Tumour
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	I-III	10674 : 10679	CM	y in Patients With Stage I-III HER2 Positive Breast Can
./___Corpus/ClinicalTrials/xml/NCT02396108.xml	HER2	10680 : 10684	CM	atients With Stage I-III HER2 Positive Breast Cancer  
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	58 : 64	CM	nter open-label study of BGB324 in combination with erlo
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	85 : 94	CM	B324 in combination with erlotinib in patients       with S
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	IIIb	124 : 128	CM	atients       with Stage IIIb or Stage IV non-small ce
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	169 : 175	CM	-small cell lung cancer. BGB324 is a potent selective sm
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	IIIb	604 : 608	CM	ogically-confirmed Stage IIIb or       Stage IV non-sm
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	667 : 673	CM	lung cancer will receive BGB324 as a single agent (Run-i
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	751 : 760	CM	) or in combination with erlotinib (Arms A, B, C).        R
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	839 : 845	CM	fety and tolerability of BGB324 administered as a single
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	884 : 890	CM	as a single agent.       BGB324 will be administered at 
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	1135 : 1141	CM	be opened to confirm the BGB324 to be used in combinatio
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1179 : 1188	CM	n combination       with erlotinib.        In Arm A the dos
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	1218 : 1224	CM	    In Arm A the dose of BGB324 will be escalated in a s
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1317 : 1326	CM	   combination ( BGB324+ erlotinib) is established. The dos
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	1356 : 1362	CM	established. The dose of BGB324 to be investigated in ar
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	1533 : 1539	CM	lel and will investigate BGB324 in combination with erlo
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	1560 : 1569	CM	B324 in combination with erlotinib.                        
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	IIIb	1778 : 1782	CM	al confirmation of Stage IIIb or Stage IV (unresectabl
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	1823 : 1828	CM	resectable)              NSCLC            -  Eastern Co
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	EGFR	1967 : 1971	CM	lder            -  Known EGFR mutation status         
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	2021 : 2030	CM	   -  Has been receiving erlotinib for treatment of NSCLC w
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	2048 : 2053	CM	lotinib for treatment of NSCLC with erlotinib-related t
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	erlotinib	2059 : 2068	CM	 treatment of NSCLC with erlotinib-related toxicities      
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	2325 : 2331	CM	king their first dose of BGB324. Male patients and femal
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	2735 : 2741	CM	s after the last dose of BGB324.              Female pat
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	histamine	3497 : 3506	CM	th any of the following: histamine receptor two inhibitors,
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	myocardial	3701 : 3711	CM	 cardiac event including myocardial infarction within 3 mont
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NSCLC	4130 : 4135	CM	non-cytotoxic agents for NSCLC in the preceding ten day
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	NYHA	4304 : 4308	CM	everity according to the NYHA defined as              
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	4642 : 4648	CM	              A Study of BGB324 in Combination With Erlo
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	Erlotinib	4669 : 4678	CM	B324 in Combination With Erlotinib in Patients With Non-Sma
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	BGB324	4782 : 4788	CM	Label Phase I/2 Study of BGB324 in Combination With Erlo
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	Erlotinib	4809 : 4818	CM	B324 in Combination With Erlotinib in Patients With Stage I
./___Corpus/ClinicalTrials/xml/NCT02424617.xml	IIIb	4842 : 4846	CM	b in Patients With Stage IIIb or Stage IV Non-Small Ce
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MK-3475	51 : 58	CM	hat after application of MK-3475 activated PD -1 negative
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD	69 : 71	CM	ion of MK-3475 activated PD -1 negatively regulates 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	163 : 167	CM	ppression of the path of PI3K / Akt.        This study
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	247 : 251	CM	ss of oral inhibitors of PI3K / Akt pathway in       c
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MK-3475	291 : 298	CM	in       comparison with MK-3475 (pembrolizumab).        
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	IgG4	361 : 365	CM	  A humanized monoclonal IgG4 antibody directed agains
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-1	420 : 424	CM	an cell surface receptor PD-1       (programmed death-
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-1	573 : 577	CM	, pembrolizumab binds to PD-1, an inhibitory signaling
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-1	709 : 713	CM	ing to and activation of PD-1 by its       ligands, wh
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-1	847 : 851	CM	  cells. The ligands for PD-1 include PD-L1, which is 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-L1	860 : 865	CM	ligands for PD-1 include PD-L1, which is expressed on a
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-L2	974 : 979	CM	ertain cancer cells, and PD-L2, which is primarily expr
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PD-1	1035 : 1039	CM	on       APCs. Activated PD-1 negatively regulates T-c
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	1116 : 1120	CM	suppression of the       PI3K/Akt pathway.        This
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	1206 : 1210	CM	ss of oral inhibitors of PI3K / Akt pathway in       c
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MK-3475	1250 : 1257	CM	in       comparison with MK-3475 (pembrolizumab).        
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	1714 : 1726	CM	t least radiotherapy and temozolomide            -  Be at firs
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MRI	1861 : 1864	CM	for tumor progression by MRI or CT              scan.
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	CT	1868 : 1870	CM	or progression by MRI or CT              scan.      
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	CT	1904 : 1906	CM	     scan.            -  CT or MRI within 14 days pr
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MRI	1910 : 1913	CM	can.            -  CT or MRI within 14 days prior to 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	2776 : 2788	CM	ommon after therapy with temozolomide).            -  From the
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	temozolomide	3028 : 3040	CM	rapy (except 23 days for temozolomide and 6 weeks from nitroso
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	nitrosoureas	3058 : 3070	CM	olomide and 6 weeks from nitrosoureas), 6 weeks from          
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	3173 : 3178	CPR	r is shorter) from other anti-tumor              therap
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	dexamethasone	3853 : 3866	CM	rticosteroids defined as dexamethasone >              4 mg/day 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4263 : 4271	CM	tic anticoagulation with warfarin at baseline; patients mu
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4319 : 4327	CM	must be off              warfarin or warfarin-derivative a
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	warfarin	4331 : 4339	CM	             warfarin or warfarin-derivative anti-coagulan
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	4351 : 4356	CPR	n or warfarin-derivative anti-coagulants for at least 7
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	prophylactic	4454 : 4466	CM	 however, therapeutic or prophylactic therapy with low-molecul
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MRI	4798 : 4801	CM	l hemorrhage on baseline MRI scan other than         
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	MRI	4931 : 4934	CM	consecutive              MRI scans.            -  Has
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	6815 : 6820	CPR	         -  Has received anti-angiogenic or anti-VEGF t
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	anti-	6834 : 6839	CPR	eived anti-angiogenic or anti-VEGF targeted agents (e.g
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	vandetanib	6916 : 6926	CM	 cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc)
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	sunitinib	6936 : 6945	CM	ept, vandetanib, XL-184, sunitinib, etc)            -  Has 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	7720 : 7724	CM	h The Suppression Of The PI3K/Akt Pathway In Compared 
./___Corpus/ClinicalTrials/xml/NCT02430363.xml	PI3K	7896 : 7900	CM	h The Suppression Of The PI3K/Akt Pathway In Compared 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	28 : 31	CM	          Glioblastomas (GBM) are the most common typ
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	415 : 418	CM	ularly observed in       GBM and is thought to be a m
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	EGFR	530 : 534	CM	y.       The most common EGFR mutation in GBM (EGFRvII
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	547 : 550	CM	 common EGFR mutation in GBM (EGFRvIII) is present in
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	EGFRvIII	552 : 560	CM	on EGFR mutation in GBM (EGFRvIII) is present in 30-50% of
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	30-	576 : 579	CPR	(EGFRvIII) is present in 30-50% of GBM.        Previo
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	586 : 589	CM	 is present in 30-50% of GBM.        Previously MAAST
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	MAASTRO	609 : 616	CM	f GBM.        Previously MAASTRO lab has shown that expre
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	EGFRvIII	650 : 658	CM	shown that expression of EGFRvIII provides GBM cells with 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	668 : 671	CM	ion of EGFRvIII provides GBM cells with a       survi
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	hypoxic	960 : 967	CM	oxia, reduces the viable hypoxic fraction in       tumors
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	1068 : 1079	CM	s to irradiation.        Chloroquine (CQ) is a potent autopha
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1081 : 1083	CM	ion.        Chloroquine (CQ) is a potent autophagy b
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1210 : 1212	CM	reviously, the effect of CQ has been demonstrated in
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	1283 : 1286	CM	     controlled trial in GBM treated with radiotherap
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	carmustine	1317 : 1327	CM	ed with radiotherapy and carmustine. Although not statistica
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1475 : 1477	CM	      patients receiving CQ as in patients receiving
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1541 : 1543	CM	intracellular effects of CQ are       dose-dependent
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1630 : 1632	CM	ncrease in daily dose of CQ may be       necessary. 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1689 : 1691	CM	more, the combination of CQ with TMZ may induce more
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	TMZ	1697 : 1700	CM	e combination of CQ with TMZ may induce more damage t
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	1820 : 1822	CM	 the recommended dose of CQ in combination with radi
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	1866 : 1878	CM	h radiotherapy       and temozolomide will be tested. In the p
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	1976 : 1979	CM	histologically confirmed GBM will be randomized betwe
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2075 : 2087	CM	urrent radiotherapy with temozolomide and adjuvant temozolomid
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2101 : 2113	CM	emozolomide and adjuvant temozolomide (arm A) and standard    
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2156 : 2158	CM	ard       treatment plus CQ (arm B).                
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	2301 : 2304	CM	ients       with de-novo GBM.        Eligible patient
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	GBM	2487 : 2490	CM	or newly       diagnosed GBM. This consists of 30 dai
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2624 : 2636	CM	rgin in combination with temozolomide 75 mg/m² per os daily (p
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	m²	2643 : 2645	CM	 with temozolomide 75 mg/m² per os daily (po qd)    
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	temozolomide	2700 : 2712	CM	d six adjuvant cycles of temozolomide 150 - 200 mg/m² po qd.  
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	m²	2726 : 2728	CM	emozolomide 150 - 200 mg/m² po qd.        Arm B (exp
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2851 : 2853	CM	ly intake       of 400mg CQ. CQ will start with one 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	2855 : 2857	CM	ntake       of 400mg CQ. CQ will start with one week
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	MAASTRO	3063 : 3070	CM	y recruited within       MAASTRO clinic randomized to arm
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	3-[18F]fluoro	3129 : 3142	CM	e invited to receive two 3-[18F]fluoro-       2-(4-((2-nitro-1H
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	3-	3142 : 3144	CPR	receive two 3-[18F]fluoro-       2-(4-((2-nitro-1H-i
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1	3150 : 3208	CM	two 3-[18F]fluoro-       2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scan
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	2-	3208 : 3210	CPR	ethyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scans 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	yl)propan-1-ol	3210 : 3224	CM	hyl)-1H-1,2,3-triazol-1- yl)propan-1-ol PET-scans       ([18F]HX
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	CQ	3281 : 3283	CM	e first on day -6 (start CQ), the second on day 0 (b
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	TMZ	3347 : 3350	CM	t       radiotherapy and TMZ).                       
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	IDH	3475 : 3478	CM	ratentorial astrocytoma, IDH wildtype              (g
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	NYHA	4653 : 4657	CM	 severe cardiac disease (NYHA class greater than 1)   
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	cytochrome	5953 : 5963	CM	           -  Concurrent cytochrome P450 enzyme-inducing ant
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	phenytoin	6013 : 6022	CM	iconvulsant drugs (e.g., phenytoin,              carbamazep
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	carbamazepine	6037 : 6050	CM	 phenytoin,              carbamazepine, phenobarbital, primidon
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	phenobarbital	6052 : 6065	CM	          carbamazepine, phenobarbital, primidone, or oxcarbaze
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	primidone	6067 : 6076	CM	mazepine, phenobarbital, primidone, or oxcarbazepine)      
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	oxcarbazepine	6081 : 6094	CM	obarbital, primidone, or oxcarbazepine)            -  Known glu
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	glucose-6-phosphate	6116 : 6135	CM	ine)            -  Known glucose-6-phosphate dehydrogenase deficiency
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	dehydrogenase	6136 : 6149	CM	nown glucose-6-phosphate dehydrogenase deficiency            - 
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	4-aminoquinoline	6238 : 6254	CM	nown hypersensitivity to 4-aminoquinoline compound            -  R
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	4-aminoquinoline	6364 : 6380	CM	on prior to              4-aminoquinoline compound use            
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	6423 : 6434	CM	         The Addition of Chloroquine to Chemoradiation for Gl
./___Corpus/ClinicalTrials/xml/NCT02432417.xml	Chloroquine	6539 : 6550	CM	rial for the Addition of Chloroquine, an Autophagy Inhibitor,
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	13 : 17	CM	             PI3K signaling is a hallmark 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	98 : 102	CM	cers become dependent on PI3K       pathway signaling 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PIK3CA	159 : 165	CM	sult of mutations of the PIK3CA gene itself or of regula
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	198 : 202	CM	self or of regulators of PI3K       (e.g. PTEN, HER2).
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	HER2	221 : 225	CM	f PI3K       (e.g. PTEN, HER2). As a consequence, path
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	335 : 341	CM	PI3K-pathway inhibition. BKM120 is a potent and highly s
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	FM-11-F01b	430 : 440	CM	ibitor.        The study FM-11-F01b is a phase Ib single ins
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Ib	452 : 454	CM	dy FM-11-F01b is a phase Ib single institution study
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	505 : 511	CM	using the combination of BKM120       and cisplatin or c
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	522 : 531	CM	tion of BKM120       and cisplatin or carboplatin in patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	535 : 546	CM	0       and cisplatin or carboplatin in patient with patholog
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	667 : 675	CM	r which treatment with a platinum agent is indicated (pref
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	NSCLC	732 : 737	CM	lly       head and neck, NSCLC, ovary, endometrial).   
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	865 : 871	CM	dose of daily oral       BKM120 and cisplatin (Group 1) 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	876 : 885	CM	ly oral       BKM120 and cisplatin (Group 1) or carboplatin
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	899 : 910	CM	d cisplatin (Group 1) or carboplatin (Group 2), given intrave
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1408 : 1412	CM	titumor activity.        PI3K signaling is a hallmark 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1493 : 1497	CM	cers become dependent on PI3K       pathway signaling 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PIK3CA	1554 : 1560	CM	sult of mutations of the PIK3CA gene itself or of regula
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	1593 : 1597	CM	self or of regulators of PI3K       (e.g. PTEN, HER2).
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	HER2	1616 : 1620	CM	f PI3K       (e.g. PTEN, HER2). As a consequence, path
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	1730 : 1736	CM	PI3K-pathway inhibition. BKM120 is a potent and highly s
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	FM-11-F01b	1812 : 1822	CM	     PI3K-inhibThe study FM-11-F01b is a phase Ib single ins
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Ib	1834 : 1836	CM	dy FM-11-F01b is a phase Ib single institution study
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	1893 : 1899	CM	the combination       of BKM120 and cisplatin or carbopl
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	1904 : 1913	CM	tion       of BKM120 and cisplatin or carboplatin in patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	1917 : 1928	CM	 BKM120 and cisplatin or carboplatin in patient with patholog
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	2049 : 2057	CM	r which treatment with a platinum agent is indicated      
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	NSCLC	2114 : 2119	CM	rentially head and neck, NSCLC, ovary, endometrial).   
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	2184 : 2190	CM	study treatment foreseen BKM120 administered on a contin
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	2295 : 2306	CM	80 or 100 mg (p.o.) plus Carboplatin or Cisplatin. Cisplatin 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	2310 : 2319	CM	.o.) plus Carboplatin or Cisplatin. Cisplatin 75       mg/m
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	2321 : 2330	CM	arboplatin or Cisplatin. Cisplatin 75       mg/mq will be a
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	2416 : 2427	CM	 infusion every 3 weeks. Carboplatin AUC 5       (or AUC 6 if
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	saline	2578 : 2584	CM	uted in 250 mL of normal saline every 3 weeks.        Th
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BMK120	2680 : 2686	CM	o 3 dose levels of daily BMK120 will be       studied. A
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	2981 : 2987	CM	dose of daily oral       BKM120 and cisplatin (Group 1) 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	2992 : 3001	CM	ly oral       BKM120 and cisplatin (Group 1) or carboplatin
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	3015 : 3026	CM	d cisplatin (Group 1) or carboplatin (Group 2), given intrave
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	3093 : 3099	CM	y 1       every 3 weeks. BKM120 and carboplatin or cispl
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	3104 : 3115	CM	very 3 weeks. BKM120 and carboplatin or cisplatin.           
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	3119 : 3128	CM	KM120 and carboplatin or cisplatin.                        
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	ECOG	3407 : 3411	CM	       -  Patient has an ECOG performance status ≤ 1  
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	platinum	3560 : 3568	CM	        treatment with a platinum agent is indicated      
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PI3K	4457 : 4461	CM	 previous treatment with PI3K and/or mTOR inhibitors  
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	mTOR	4469 : 4473	CM	eatment with PI3K and/or mTOR inhibitors            - 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	CNS	4709 : 4712	CM	 Patient has symptomatic CNS metastases (Patients wit
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	CNS	4767 : 4770	CM	trolled and asymptomatic CNS              metastases 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PHQ-9	4988 : 4993	CM	off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in 
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	GAD-7	5035 : 5040	CM	≥ 15 in              the GAD-7 mood scale, respectively
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PHQ-9	5206 : 5211	CM	thoughts ideation in the PHQ-9              (independen
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	PHQ-9	5264 : 5269	CM	f the total score of the PHQ-9)            -  Patient i
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	glucose	5702 : 5709	CM	e to glucides or fasting glucose > 120 mg/dL or HbA1c > 8
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	dL	5719 : 5721	CM	fasting glucose > 120 mg/dL or HbA1c > 8 %          
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	HbA1c	5725 : 5730	CM	g glucose > 120 mg/dL or HbA1c > 8 %            -  Pati
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	GI	6130 : 6132	CM	atient has impairment of GI function or GI disease  
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	GI	6145 : 6147	CM	irment of GI function or GI disease            -  Pa
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	carboplatin	6862 : 6873	CM	rsensitivity reaction to carboplatin or cisplatin            
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	cisplatin	6877 : 6886	CM	action to carboplatin or cisplatin            -  Patient is
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	isoenzyme	7210 : 7219	CM	nhibitors or inducers of isoenzyme CYP3A, and the treatment
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	7687 : 7693	CM	dy of the Combination of BKM120 and Cisplatin or Carbopl
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	7698 : 7707	CM	ombination of BKM120 and Cisplatin or Carboplatin in Patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	7711 : 7722	CM	 BKM120 and Cisplatin or Carboplatin in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	BKM120	7813 : 7819	CM	dy of the Combination of BKM120 and Cisplatin or Carbopl
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Cisplatin	7824 : 7833	CM	ombination of BKM120 and Cisplatin or Carboplatin in Patien
./___Corpus/ClinicalTrials/xml/NCT02439489.xml	Carboplatin	7837 : 7848	CM	 BKM120 and Cisplatin or Carboplatin in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Phase	13 : 18	ASE	             Phase Ib/II, single-arm study 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	AZD6094	46 : 53	CM	/II, single-arm study of AZD6094 (Volitinib) in combinati
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	55 : 64	CM	le-arm study of AZD6094 (Volitinib) in combination with doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	86 : 95	CM	nib) in combination with docetaxel, in       advanced gastr
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	152 : 155	CM	ocarcinoma patients with MET amplification as a secon
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	371 : 380	CM	 c-MET inhibitor.        Volitinib should be administered a
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	507 : 516	CM	titumor activity.        Docetaxel 60 mg/m2 will be adminis
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	m2	523 : 525	CM	.        Docetaxel 60 mg/m2 will be administered via
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MTD	813 : 816	CM	nce daily       ( at the MTD determined from Phase Ib
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Ib	839 : 841	CM	TD determined from Phase Ib) for 21 days as one cycl
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	876 : 885	CM	ays as one cycle.        Docetaxel 60 mg/m2 will be adminis
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	m2	892 : 894	CM	.        Docetaxel 60 mg/m2 will be administered via
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1032 : 1037	CM	selective small molecule c-Met kinase inhibitor. Voliti
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1093 : 1098	CM	s       found to inhibit c-Met kinase at the enzyme and
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	IC50s	1141 : 1146	CM	yme and cell levels with IC50s of 4 nM for both       e
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	phosphorylation	1185 : 1200	RN	oth       enzyme and Met phosphorylation in the cell. Consistent 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1273 : 1282	CM	and cell       activity, volitinib was found to inhibit cel
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	vitro	1319 : 1324	CM	o inhibit cell growth in vitro against tumors with c-Me
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1345 : 1350	CM	itro against tumors with c-Met gene       amplification
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HGF	1394 : 1397	CM	cation in the absence of HGF stimulation with IC50s g
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	IC50s	1415 : 1420	CM	 of HGF stimulation with IC50s generally below 10 nM. I
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HGF	1477 : 1480	CM	      potently inhibited HGF-stimulated cell prolifer
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1531 : 1536	CM	tion against tumors with c-Met overexpression       or 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HGF	1572 : 1575	CM	sion       or carrying a HGF/c-Met autocrine loop.   
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1576 : 1581	CM	       or carrying a HGF/c-Met autocrine loop.        I
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	c-Met	1638 : 1643	CM	ograft model Hs746T with c-Met gene amplification, subo
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1697 : 1706	CM	al doses 0.6 mg/kg       volitinib and 3 mg/kg docetaxel in
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	1719 : 1728	CM	   volitinib and 3 mg/kg docetaxel induced TGI(expand) of 5
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	TGI(expand)	1737 : 1748	CM	 mg/kg docetaxel induced TGI(expand) of 55.8% and 80.8%, resp
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	TGI	1823 : 1826	CM	ombination resulted in a TGI by 101.1%, and statistic
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	1962 : 1971	CM	oup. Plasma exposures of volitinib and       docetaxel were
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	1982 : 1991	CM	s of volitinib and       docetaxel were determined after la
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	2151 : 2160	CM	t on exposures of either volitinib or       docetaxel. More
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	2170 : 2179	CM	ither volitinib or       docetaxel. More importantly, combi
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	volitinib	2375 : 2384	CM	combination       use of volitinib and docetaxel in clinic.
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	2389 : 2398	CM	    use of volitinib and docetaxel in clinic.              
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	3011 : 3014	CM	h solid tumors harboring MET              amplificati
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	GEJ	3158 : 3161	CM	denocarcinoma (including GEJ expand and maybe include
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	5-fluoropyrimidine	3350 : 3368	CM	t have contained doublet 5-fluoropyrimidine and platinum            
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	platinum	3373 : 3381	CM	t 5-fluoropyrimidine and platinum                   based 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	5-fluoropyrimidine	3546 : 3564	CM	      containing doublet 5-fluoropyrimidine and platinum-based regim
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	platinum	3569 : 3577	CM	t 5-fluoropyrimidine and platinum-based regimen could be  
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	3717 : 3720	CM	adenocarcinoma harboring MET amplification by MET FIS
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	3738 : 3741	CM	ing MET amplification by MET FISH.            4. Prev
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	0-	4307 : 4309	CPR	 ECOG performance status 0-1.            8. Patients
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	bilirubin	4862 : 4871	CM	                -  Total bilirubin ≤ 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ULN	4917 : 4920	CM	l upper limit of normal (ULN) (does not              
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ALT	5021 : 5024	CM	           -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x instituti
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	SGPT	5026 : 5030	CM	      -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional u
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	creatinine	5189 : 5199	CM	                -  Serum creatinine ≤1.5 x institutional ULN
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	6000 : 6003	CM	 previous treatment with MET inhibitors            3.
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	docetaxel	6057 : 6066	CM	 previous treatment with docetaxel.            4. Patients 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HER2	6345 : 6349	CM	 ≤5 years.            5. HER2 positive patients (defin
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HER2	6380 : 6384	CM	ive patients (defined by HER2 3+ by immunohistochemist
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	HER2	6415 : 6419	CM	 immunohistochemistry or HER2 SISH +)            6. Pa
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	bisphosphonates	7039 : 7054	CM	receive a stable dose of bisphosphonates or denosumab for bone me
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CTCAE	7268 : 7273	CM	any ongoing toxicities (>CTCAE grade 1) caused by      
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CTCAE	7371 : 7376	CM	ntestinal obstruction or CTCAE grade 3 or grade 4 upper
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	GI	7402 : 7404	CM	grade 3 or grade 4 upper GI bleeding within 4 weeks 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ECG	7487 : 7490	CM	t.           11. Resting ECG with measurable QTcB > 4
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	QTcB	7507 : 7511	CM	ting ECG with measurable QTcB > 480 msec on 2 or more 
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	BP	7707 : 7709	CM	controlled hypertension (BP ≥150/95 mmHg            
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	LLN	7886 : 7889	CM	ography or institution's LLN for MUGA, Atrial fibrill
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MUGA	7894 : 7898	CM	or institution's LLN for MUGA, Atrial fibrillation    
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	bpm	7962 : 7965	CM	 a ventricular rate >100 bpm on ECG at rest , Symptom
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	ECG	7969 : 7972	CM	ricular rate >100 bpm on ECG at rest , Symptomatic he
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	NYHA	8010 : 8014	CM	mptomatic heart failure (NYHA              grade II-IV
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	AZD6094	8882 : 8889	CM	eiving the first dose of AZD6094, medications known to be
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CYP1A2	8949 : 8955	CM	hibitors of              CYP1A2 or CYP3A4, potent induce
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CYP3A4	8959 : 8965	CM	f              CYP1A2 or CYP3A4, potent inducers of CYP3
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CYP3A4	8986 : 8992	CM	P3A4, potent inducers of CYP3A4 or CYP3A4 substrates wit
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	CYP3A4	8996 : 9002	CM	nt inducers of CYP3A4 or CYP3A4 substrates with a narrow
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Ib	9088 : 9090	CM	                   Phase Ib, Single-arm Study of AZD
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	AZD6094	9112 : 9119	CM	 Ib, Single-arm Study of AZD6094 (Volitinib) in Combinati
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	9121 : 9130	CM	le-arm Study of AZD6094 (Volitinib) in Combination With Doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	9152 : 9161	CM	nib) in Combination With Docetaxel, in Any Solid Cancer and
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	AZD6094	9228 : 9235	CM	 II, Single-arm Study of AZD6094 (Volitinib) in Combinati
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Volitinib	9237 : 9246	CM	le-arm Study of AZD6094 (Volitinib) in Combination With Doc
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	Docetaxel	9268 : 9277	CM	nib) in Combination With Docetaxel in Advanced Gastric Aden
./___Corpus/ClinicalTrials/xml/NCT02447406.xml	MET	9327 : 9330	CM	ocarcinoma Patients With MET Amplification as a Secon
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	13 : 22	CM	             Volitinib is a potent and selectiv
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	64 : 69	CM	selective small molecule c-Met kinase inhibitor. Voliti
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	88 : 97	CM	 c-Met kinase inhibitor. Volitinib was       found to inhib
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	125 : 130	CM	s       found to inhibit c-Met kinase at the enzyme and
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	IC50s	173 : 178	CM	yme and cell levels with IC50s of 4 nM for both       e
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	phosphorylation	217 : 232	RN	oth       enzyme and Met phosphorylation in the cell. Consistent 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	volitinib	305 : 314	CM	and cell       activity, volitinib was found to inhibit cel
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	vitro	351 : 356	CM	o inhibit cell growth in vitro against tumors with c-Me
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	377 : 382	CM	itro against tumors with c-Met gene       amplification
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HGF	426 : 429	CM	cation in the absence of HGF stimulation with IC50s g
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	IC50s	447 : 452	CM	 of HGF stimulation with IC50s generally below 10 nM. I
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HGF	509 : 512	CM	      potently inhibited HGF-stimulated cell prolifer
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	563 : 568	CM	tion against tumors with c-Met overexpression       or 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HGF	604 : 607	CM	sion       or carrying a HGF/c-Met autocrine loop.   
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	c-Met	608 : 613	CM	       or carrying a HGF/c-Met autocrine loop.        T
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MET	758 : 761	CM	adenocarcinoma harboring MET amplification as a third
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	802 : 811	CM	s a third line treatment Volitinib 800 mg will be       adm
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	volitinib	928 : 937	CM	estigate the efficacy of volitinib in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MET	1003 : 1006	CM	arcinoma       harboring MET amplification.          
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	GEJ	1280 : 1283	CM	denocarcinoma (including GEJ) that has progressed dur
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	fluoropyrimidine	1379 : 1395	CM	                 -  Both fluoropyrimidine and platinum agent need 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	platinum	1400 : 1408	CM	oth fluoropyrimidine and platinum agent need to be contain
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MET	1893 : 1896	CM	        5. Patients with MET amplification.          
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	0-	2165 : 2167	CPR	Group performance status 0-1.            8. Patients
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	bilirubin	2720 : 2729	CM	                -  Total bilirubin ≤ 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ULN	2775 : 2778	CM	l upper limit of normal (ULN) (does not              
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ALT	2879 : 2882	CM	           -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x instituti
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	SGPT	2884 : 2888	CM	      -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional u
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	creatinine	3047 : 3057	CM	                -  Serum creatinine ≤1.5 x institutional ULN
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MET	4130 : 4133	CM	 previous treatment with MET inhibitors            3.
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HER2	4422 : 4426	CM	 ≤5 years.            4. HER2 positive patients (defin
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HER2	4457 : 4461	CM	ive patients (defined by HER2 3+ by immunohistochemist
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	HER2	4492 : 4496	CM	 immunohistochemistry or HER2 SISH +)            5. Pa
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	bisphosphonates	5116 : 5131	CM	receive a stable dose of bisphosphonates or denusomab for bone me
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	GI	5570 : 5572	CM	           grade 4 upper GI bleeding within 4 weeks 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ECG	5642 : 5645	CM	t.           10. Resting ECG with measurable QTcB > 4
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	QTcB	5662 : 5666	CM	ting ECG with measurable QTcB > 480 msec on 2 or more 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	BP	5862 : 5864	CM	controlled hypertension (BP ≥150/95 mmHg            
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	LLN	6041 : 6044	CM	ography or institution's LLN for MUGA, Atrial fibrill
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MUGA	6049 : 6053	CM	or institution's LLN for MUGA, Atrial fibrillation    
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	bpm	6117 : 6120	CM	 a ventricular rate >100 bpm on ECG at rest , Symptom
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	ECG	6124 : 6127	CM	ricular rate >100 bpm on ECG at rest , Symptomatic he
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	NYHA	6165 : 6169	CM	mptomatic heart failure (NYHA              grade II-IV
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	AZD6094	7037 : 7044	CM	eiving the first dose of AZD6094, medications known to be
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	CYP1A2	7104 : 7110	CM	hibitors of              CYP1A2 or CYP3A4, potent induce
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	CYP3A4	7114 : 7120	CM	f              CYP1A2 or CYP3A4, potent inducers of CYP3
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	CYP3A4	7141 : 7147	CM	P3A4, potent inducers of CYP3A4 or CYP3A4 substrates wit
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	CYP3A4	7151 : 7157	CM	nt inducers of CYP3A4 or CYP3A4 substrates with a narrow
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	AZD6094	7246 : 7253	CM	                Study of AZD6094 (Volitinib) in Advanced 
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	Volitinib	7255 : 7264	CM	       Study of AZD6094 (Volitinib) in Advanced Gastric Ade
./___Corpus/ClinicalTrials/xml/NCT02449551.xml	MET	7315 : 7318	CM	ocarcinoma Patients With MET Amplification as a Third
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione	95 : 180	CM	radioactive tracer       21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (FFNP)       uptake, whi
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FFNP	182 : 186	CM	rpregn-4-ene-3,20-dione (FFNP)       uptake, which bin
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	progesterone	231 : 243	CM	h binds to breast cancer progesterone receptors (PgRs) on a PE
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PgRs	255 : 259	CM	 progesterone receptors (PgRs) on a PET/CT scan before
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PET	266 : 269	CM	ne receptors (PgRs) on a PET/CT scan before       and
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	CT	270 : 272	CM	eceptors (PgRs) on a PET/CT scan before       and af
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	319 : 328	CM	 after administration of estradiol for one day (estrogen ch
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estrogen	342 : 350	CM	f estradiol for one day (estrogen challenge) to determine 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estrogen	499 : 507	CM	       hormone-sensitive estrogen receptor positive (ER+),
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	ER+	527 : 530	CM	rogen receptor positive (ER+), human epidermal growth
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	2-	578 : 580	CPR	th factor receptor       2-negative (HER2-) breast c
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	590 : 594	CM	ceptor       2-negative (HER2-) breast cancer. Estradi
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	Estradiol	612 : 621	CM	e (HER2-) breast cancer. Estradiol is the most potent of th
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estrogens	674 : 683	CM	aturally occurring       estrogens, and can be administered
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	endocrine	980 : 989	CM	to be       treated with endocrine therapy (ET) (tamoxifen,
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	tamoxifen,aromatase	1004 : 1023	CM	 endocrine therapy (ET) (tamoxifen,aromatase inhibitors or fulvestran
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	fulvestrant	1038 : 1049	CM	,aromatase inhibitors or fulvestrant as       standard of car
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	FFNP-PET	1129 : 1137	CM	l undergo a total of two FFNP-PET/CT scans; one before and
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	CT	1138 : 1140	CM	 a total of two FFNP-PET/CT scans; one before and a 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1216 : 1225	CM	ly following the one day estradiol challenge before the sta
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1287 : 1296	CM	rd of care       ET. The estradiol challenge will consist o
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	1356 : 1365	CM	ering a total of 6 mg of estradiol orally       (three dose
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	estradiol	2178 : 2187	CM	pausal for whom standard estradiol treatment (ET) is planne
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	AIs	2965 : 2968	CM	patient was treated with AIs or chemotherapy, but 2 m
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	tamoxifen	3074 : 3083	CM	patient was treated with tamoxifen) who are going to be    
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	ER+	3258 : 3261	CM	            metastatic): ER+/PgR+/HER2- or ER+/PgR-/H
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PgR+	3262 : 3266	CM	        metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	3267 : 3271	CM	   metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.     
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	ER+	3276 : 3279	CM	atic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.             
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PgR	3280 : 3283	CM	): ER+/PgR+/HER2- or ER+/PgR-/HER2-.                 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	3285 : 3289	CM	+/PgR+/HER2- or ER+/PgR-/HER2-.                 -  ER+
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	ER+	3311 : 3314	CM	ER2-.                 -  ER+ is defined as Allred sco
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PgR+	3388 : 3392	CM	ater.                 -  PgR+ is defined as Allred sco
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	3530 : 3534	CM	ry assay methodology for HER2. HER2-                  
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	3536 : 3540	CM	ay methodology for HER2. HER2-                   refer
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	HER2	3570 : 3574	CM	               refers to HER2 of 0, 1+ by IHC or negat
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	MRI	3819 : 3822	CM	ultrasound, mammography, MRI, CT, PET) or physical   
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	CT	3824 : 3826	CM	sound, mammography, MRI, CT, PET) or physical       
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PET	3828 : 3831	CM	d, mammography, MRI, CT, PET) or physical            
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	lytic	3942 : 3947	RN	eous metastasis that are lytic or mixed                
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	lytic	3975 : 3980	CM	 mixed                   lytic-sclerotic are eligible. 
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	18F-FFNP	4468 : 4476	CM	patobiliary excretion of 18F-FFNP.            -  Patient m
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	0-	4778 : 4780	CPR	e status              of 0-2 or, based on the judgme
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	PET	5298 : 5301	CM	tolerate up to 60 min of PET imaging per imaging sess
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	Estrogen	5715 : 5723	CM	 of Functional Status of Estrogen Receptors in Breast Canc
./___Corpus/ClinicalTrials/xml/NCT02455453.xml	Estrogen	5832 : 5840	CM	 of Functional Status of Estrogen Receptors in Breast Canc
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	13 : 22	CM	             BPI-9016M is a novel, highly poten
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	91 : 96	CM	ll-molecule inhibitor of c-Met/Axl       kinase. In pre
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	vitro	174 : 179	CM	rated strong activity in vitro and in vivo against     
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	206 : 211	CM	nd in vivo against       c-Met/Axl kinase and its downs
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	MTD	377 : 380	CM	 maximum tolerated dose (MTD) and       dose-limiting
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	485 : 490	CPR	ty and preliminary       anti-tumor activity of BPI-901
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	508 : 517	CM	  anti-tumor activity of BPI-9016M with single doses and mu
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	Ia	594 : 596	CM	         This is a phase Ia study, first-in-human, o
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	657 : 666	CM	dose-escalation study of BPI-9016M       administered orall
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	900 : 909	CM	se and multiple doses of BPI-9016M.        All patients wil
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	1127 : 1136	CM	       therapy only when BPI-9016M is well tolerated, and t
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	0-	1677 : 1679	CPR	G) performance status of 0-1            -  Adequate 
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	HGF	2023 : 2026	CM	treatment with agents of HGF/c-Met inhibitors or HGF/
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	2027 : 2032	CM	tment with agents of HGF/c-Met inhibitors or HGF/c-Met 
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	HGF	2047 : 2050	CM	 HGF/c-Met inhibitors or HGF/c-Met antibody(Including
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	c-Met	2051 : 2056	CM	/c-Met inhibitors or HGF/c-Met antibody(Including      
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	2147 : 2152	CPR	 etc.)            -  Any anti-cancer therapy, including
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	anti-	2437 : 2442	CPR	dverse events from prior anti-cancer therapy that have 
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	3776 : 3785	CM	 and Pharmacokinetics of BPI-9016M in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02478866.xml	BPI-9016M	3870 : 3879	CM	 and Pharmacokinetics of BPI-9016M in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	76 : 87	CM	rolled phase II study of fulvestrant with or without       th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	126 : 136	CM	ut       the addition of vandetanib as treatment for patient
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	977 : 980	CM	hway in the cells called RET [Receptor tyrosine      
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tyrosine	991 : 999	CM	lls called RET [Receptor tyrosine       kinase RET] REarra
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	1013 : 1016	CM	or tyrosine       kinase RET] REarranged during Trans
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	1091 : 1094	CM	wn increased activity of RET       signalling pathway
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	1163 : 1173	CM	ant cancer cells.        Vandetanib is an oral drug that inh
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	1204 : 1207	CM	 oral drug that inhibits RET signalling in cells and 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tamoxifen	1404 : 1413	CM	ne therapy drugs include tamoxifen, and the aromatase inhib
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	anastrozole	1451 : 1462	CM	matase inhibitors       (anastrozole, letrozole and exemestan
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	letrozole	1464 : 1473	CM	tors       (anastrozole, letrozole and exemestane). The inv
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	exemestane	1478 : 1488	CM	astrozole, letrozole and exemestane). The investigators ther
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	1545 : 1555	CM	elieve that giving       vandetanib together with hormone th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	1725 : 1736	CM	l combine this drug with fulvestrant,       another hormone t
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	tamoxifen	1879 : 1888	CM	aromatase inhibitors, or tamoxifen. So patients entering th
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	1947 : 1958	CM	ill have       one drug, fulvestrant, which is known to work 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2034 : 2044	CM	experimental drug,       vandetanib.        To properly dete
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2078 : 2088	CM	To properly determine if vandetanib works as the investigato
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2171 : 2181	CM	 compare the activity of vandetanib combined with fulvestran
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2196 : 2207	CM	vandetanib combined with fulvestrant with fulvestrant combine
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2213 : 2224	CM	ed with fulvestrant with fulvestrant combined with       an i
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2341 : 2352	CM	 with single agent       fulvestrant is thought appropriate. 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2469 : 2480	CM	lf of them will be given fulvestrant and vandetanib and half 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2485 : 2495	CM	be given fulvestrant and vandetanib and half will be given  
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	2525 : 2536	CM	half will be given       fulvestrant and placebo, and the tre
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	2728 : 2738	CM	patient is       getting vandetanib or the inactive placebo.
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	3075 : 3078	CM	aboratory studies on the RET pathways carried out on 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	ER	3431 : 3433	CM	ological confirmation of ER+ve breast cancer on prim
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	HER2	3562 : 3566	CM	ological confirmation of HER2 negative breast cancer o
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	0-	3830 : 3832	CPR	ction            7. ECOG 0-2 with no deterioration o
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	BC	4119 : 4121	CM	  advanced or metastatic BC or relapsed with metasta
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	endocrine	4413 : 4422	CM	   12. ≤3 prior lines of endocrine therapy for ABC         
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	4754 : 4765	CM	 Previous treatment with fulvestrant or inhibitors of RET pat
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	RET	4783 : 4786	CM	estrant or inhibitors of RET pathway            2. La
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	nitrosurea	4943 : 4953	CM	n <21 days (<6 weeks for nitrosurea or mitomycin C) prior to
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	mitomycin	4957 : 4966	CM	 weeks for nitrosurea or mitomycin C) prior to study       
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	NYHA	5486 : 5490	CM	a              syndrome, NYHA classification of heart 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	QT	5894 : 5896	CM	ycardia; Congenital long QT syndrome; History of QT 
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	QT	5918 : 5920	CM	 QT syndrome; History of QT              prolongatio
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	QTcB	6044 : 6048	CM	             medication; QTcB >480msec on screening EC
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Potassium	6109 : 6118	CM	  7. Electrolyte values: Potassium <4.0 mmol/L despite supp
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Magnesium	6223 : 6232	CM	limit, at randomisation; Magnesium below the normal range d
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Calcium	6348 : 6355	CM	limit, at randomisation; Calcium              (ionised or
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Creatinine	6510 : 6520	CM	domisation            8. Creatinine clearance <30 ml/min. Pa
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	creatinine	6557 : 6567	CM	30 ml/min. Patients with creatinine clearance <50 mL/min wil
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	6638 : 6648	CM	at a permanently reduced vandetanib dose of 200 mg.         
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	CTCAE	7126 : 7131	CM	            greater than CTCAE grade 1 before study tre
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	vandetanib	7298 : 7308	CM	r inactive excipients of vandetanib or              fulvestr
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	fulvestrant	7325 : 7336	CM	ndetanib or              fulvestrant           14. Evidence o
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	7775 : 7785	CM	         Fulvestrant +/- Vandetanib in Advanced Aromatase In
./___Corpus/ClinicalTrials/xml/NCT02530411.xml	Vandetanib	7963 : 7973	CM	 Without the Addition of Vandetanib as Treatment for Patient
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	207 : 217	CM	ther decitabine       or cytarabine. Pacritinib is an experi
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	336 : 346	CM	ia (AML). Decitabine and cytarabine are both FDA approved dr
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	FDA	356 : 359	CM	 and cytarabine are both FDA approved drugs that are 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	FDA	537 : 540	CM	and Drug Administration (FDA) for approval for any in
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	870 : 880	CM	ther decitabine or       cytarabine. In this study, approxim
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1100 : 1110	CM	nsists of pacritinib and cytarabine and will enroll 30 subje
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	m2	1289 : 1291	CM	h cycle: Decitabine 20mg/m2 intravenous daily for 10
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	1407 : 1417	CM	      Arm B: Each cycle: Cytarabine 20mg subcutaneous twice 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	pacritinib	1488 : 1498	CM	bined with ongoing       pacritinib 200mg twice daily.      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1673 : 1683	CM	de to give decitabine or cytarabine consecutively for 10 day
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	1911 : 1921	CM	y on which decitabine or cytarabine is       started. First 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Hydroxyurea	1991 : 2002	CM	place on Cycle 1, day 1. Hydroxyurea may be used at the      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	WBC	2099 : 2102	CM	s on Cycle 1 to maintain WBC <30,000/µl. Bone       m
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	22-	2186 : 2189	CPR	e performed between days 22-56 of each cycle and the 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	22-	2276 : 2279	CPR	 be started between days 22-56, at the investigator's
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	28-	2363 : 2366	CPR	 will be administered at 28-day intervals, but treatm
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	2425 : 2435	CM	s of       decitabine or cytarabine up to 56 days will be pe
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytokine	2591 : 2599	CM	locyte-stimulating       cytokine support will be permitte
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	ASCO	2713 : 2717	CM	enic fever/sepsis as per ASCO guidelines.16 Bone marro
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	3936 : 3938	CM	    Patients who achieve CR, CRp, or CRi will receiv
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRp	3940 : 3943	CM	Patients who achieve CR, CRp, or CRi will receive sub
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRi	3948 : 3951	CM	 who achieve CR, CRp, or CRi will receive subsequent 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	10-	4299 : 4302	CPR	 will receive       four 10-day cycles of decitabine 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	4735 : 4745	CM	  Patients will continue cytarabine 20mg subcutaneous twice 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	4849 : 4851	CM	p to 4 cycles to achieve CR, CRp, or CRi. Those pati
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRp	4853 : 4856	CM	 4 cycles to achieve CR, CRp, or CRi. Those patients 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRi	4861 : 4864	CM	s to achieve CR, CRp, or CRi. Those patients who achi
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	4893 : 4895	CM	ose patients who achieve CR, CRp,       or CRi after
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRp	4897 : 4900	CM	patients who achieve CR, CRp,       or CRi after 4 cy
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	4977 : 4987	CM	e monthly maintenance of cytarabine 20mg       subcutaneous 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	5902 : 5912	CM	bined with decitabine or cytarabine in newly diagnosed older
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	IWG	6064 : 6067	CM	n       according to the IWG criteria.        The fol
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	6224 : 6226	CM	on (OS) rate, defined as CR + CRp + Cri + PR based o
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CRp	6229 : 6232	CM	S) rate, defined as CR + CRp + Cri + PR based on IWG 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	IWG	6253 : 6256	CM	 CRp + Cri + PR based on IWG response            crit
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	9-	6557 : 6559	CPR	 median survival of only 9-12 months.       Older pa
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	6714 : 6724	CM	 Decitabine and low-dose cytarabine are frequently used for 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	AML	6782 : 6785	CM	treatment       of older AML patients, however CR rat
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CR	6804 : 6806	CM	er AML patients, however CR rates are 40-50% with de
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	40-	6817 : 6820	CPR	ts, however CR rates are 40-50% with decitabine and 1
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	6853 : 6863	CM	 decitabine and 18% with cytarabine.       Pacritinib is a p
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	tyrosine	6894 : 6902	CM	  Pacritinib is a potent tyrosine kinase inhibitor of FLT3
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	FLT3	6923 : 6927	CM	sine kinase inhibitor of FLT3 and JAK3 tyrosine kinase
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	tyrosine	6937 : 6945	CM	hibitor of FLT3 and JAK3 tyrosine kinases. The       objec
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	7107 : 7117	CM	bined with decitabine or cytarabine in newly diagnosed older
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	AML	7143 : 7146	CM	in newly diagnosed older AML patients.       The prim
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	t(15;17)(q22;q12)	7445 : 7462	CM	e promyelocytic leukemia t(15;17)(q22;q12);              PML-RARA  
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	hydroxyurea	7677 : 7688	CM	r hyperleukocytosis with hydroxyurea                 -  Crani
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CNS	7723 : 7726	CM	       -  Cranial RT for CNS leukostasis (one dose on
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytokine	7788 : 7796	CM	        -  Growth factor/cytokine support            4. AM
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Hydroxyurea	8060 : 8071	CM	disorder for ≥ 6 months. Hydroxyurea may be used at the      
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	WBC	8177 : 8180	CM	s on Cycle 1 to maintain WBC              <30,000/µl.
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	0-	8284 : 8286	CPR	G) performance status of 0-2            6. Subjects 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	cytarabine	8991 : 9001	CM	 2. Prior treatment with cytarabine            3. Prior trea
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CTCAE	11226 : 11231	CM	rse Events              (CTCAE) grade 2 cardiac arrhyth
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	CTCAE	11524 : 11529	CM	hythmias of              CTCAE grade 3, corrected QT in
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	QT	11549 : 11551	CM	CTCAE grade 3, corrected QT interval (QTc) prolongat
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	QT	11667 : 11669	CM	at increase the risk for QT prolongation (eg, heart 
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	potassium	11746 : 11755	CM	alemia [defined as serum potassium < 3.0 mEq/L that is pers
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	QT	11857 : 11859	CM	r family history of long QT interval syndrome).     
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	11941 : 11951	CM	bined With Decitabine or Cytarabine in Older Patients With A
./___Corpus/ClinicalTrials/xml/NCT02532010.xml	Cytarabine	12055 : 12065	CM	bined With Decitabine or Cytarabine in Older Patients With A
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	sorafenib	23 : 32	CM	             Recently, sorafenib which can target VEGFR a
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	VEGFR	50 : 55	CM	rafenib which can target VEGFR and PDGFR demonstrated 1
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	PDGFR	60 : 65	CM	ich can target VEGFR and PDGFR demonstrated 13-16% of r
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	13-	79 : 82	CPR	R and PDGFR demonstrated 13-16% of response rate in  
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	VEGFR	187 : 192	CM	cancers, suggesting that VEGFR and PDGFR       might be
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	PDGFR	197 : 202	CM	uggesting that VEGFR and PDGFR       might be important
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	anti-	307 : 312	CPR	rials with various       anti-angiogenic molecular targ
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	dasatinib	357 : 366	CM	 targeted agents such as dasatinib, dovitinib, or sunitinib
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	sunitinib	382 : 391	CM	dasatinib, dovitinib, or sunitinib in       salivary gland 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	455 : 463	CM	oing.        Nintedanib (BIBF1120) is a potent small molec
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	tyrosine	508 : 516	CM	molecule triple receptor tyrosine kinase inhibitor       (
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	PDGFR	541 : 546	CM	 kinase inhibitor       (PDGFR/ FGFR1-2 and VEGFR1-3). 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	FGFR1-2	548 : 555	CM	 inhibitor       (PDGFR/ FGFR1-2 and VEGFR1-3). VEGFR-2 i
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	VEGFR1-3	560 : 568	CM	     (PDGFR/ FGFR1-2 and VEGFR1-3). VEGFR-2 is considered 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	vitro	718 : 723	CM	of tumor vasculature. In vitro, the       target recept
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	anti-	876 : 881	CPR	, nintedanib showed good anti-tumor efficacy at doses o
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	50-	908 : 911	CPR	mor efficacy at doses of 50-100mg/kg,       leading t
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	0-	1905 : 1907	CPR	 ECOG performance status 0-2            -  Adequate 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	dl	2049 : 2051	CM	/ml, haemoglobin > 9.0 g/dl), hepatic function (alan
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	alanine	2072 : 2079	CM	g/dl), hepatic function (alanine transaminase/aspartate  
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	aspartate	2093 : 2102	CM	on (alanine transaminase/aspartate              transaminas
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	ULN	2135 : 2138	CM	      transaminase < 5 x ULN, total bilirubin < 1.5 x
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	bilirubin	2146 : 2155	CM	aminase < 5 x ULN, total bilirubin < 1.5 x ULN), renal func
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	ULN	2164 : 2167	CM	 total bilirubin < 1.5 x ULN), renal function (creati
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	creatinine	2186 : 2196	CM	 x ULN), renal function (creatinine              clearance >
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	DM	2353 : 2355	CM	systemic illness such as DM, CHF, unstable angina, h
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	CHF	2357 : 2360	CM	emic illness such as DM, CHF, unstable angina, hypert
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	myocardial	2417 : 2427	CM	 history              or myocardial infarction in the 12 mon
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	pneumonia	2709 : 2718	CM	ts with post-obstructive pneumonia or uncontrolled serious 
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	3110 : 3118	CM	                Trial of BIBF1120 (Nintedanib) in Patients
./___Corpus/ClinicalTrials/xml/NCT02558387.xml	BIBF1120	3248 : 3256	CM	       Phase II Trial of BIBF1120 (Nintedanib) in Patients
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	PARP-1	53 : 59	CM	n oral potent, selective PARP-1 and PARP-2 inhibitor. Th
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	PARP-2	64 : 70	CM	nt, selective PARP-1 and PARP-2 inhibitor. The objective
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	MTD	315 : 318	CM	cokinetic       profile, MTD (if possible) and effica
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	PARP	963 : 967	CM	revious treatment with a PARP inhibitor.            - 
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	hypomagnesemia	1401 : 1415	CM	ntrolled hypokalemia and hypomagnesemia before study entry.     
./___Corpus/ClinicalTrials/xml/NCT02575651.xml	QT	1887 : 1889	CM	the drugs that may cause QT prolongation            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	13 : 24	CM	             Selumetinib (AZD6244) and AZD2014 ar
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD6244	26 : 33	CM	            Selumetinib (AZD6244) and AZD2014 are two new
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	39 : 46	CM	elumetinib (AZD6244) and AZD2014 are two new anti-cancer 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	59 : 64	CPR	 and AZD2014 are two new anti-cancer treatments that As
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	177 : 188	CM	for clinical use.        Selumetinib (AZD6244) is a drug that
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD6244	190 : 197	CM	use.        Selumetinib (AZD6244) is a drug that acts by 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	248 : 251	CM	locking a protein called MEK, which has been       li
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	332 : 339	CM	wth of multiple cancers. AZD2014 is a drug that blocks a 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	mTOR	385 : 389	CM	s a       protein called mTOR that is involved in the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	479 : 482	CM	e action       of either MEK or mTOR alone may slow d
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	mTOR	486 : 490	CM	n       of either MEK or mTOR alone may slow down or s
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	609 : 620	CM	r more sensitive than if Selumetinib (AZD6244) or AZD2014 are
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD6244	622 : 629	CM	ive than if Selumetinib (AZD6244) or AZD2014 are used alo
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	634 : 641	CM	Selumetinib (AZD6244) or AZD2014 are used alone       and
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	719 : 724	CPR	nt may lead to increased anti-tumour effects.        Al
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	756 : 767	CM	effects.        Although Selumetinib (AZD6244) and AZD2014 gi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD6244	769 : 776	CM	   Although Selumetinib (AZD6244) and AZD2014 given alone
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	782 : 789	CM	elumetinib (AZD6244) and AZD2014 given alone and in combi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	838 : 843	CPR	ination with other       anti-cancer drugs have been te
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	939 : 950	CM	fic combination       of Selumetinib (AZD6244) and AZD2014 ha
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD6244	952 : 959	CM	on       of Selumetinib (AZD6244) and AZD2014 has not bee
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	965 : 972	CM	elumetinib (AZD6244) and AZD2014 has not been used in peo
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Formalin	2057 : 2065	CM	rogression            7. Formalin fixed, paraffin embedded
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	dl	2705 : 2707	CM	    -  Haemoglobin ≥ 9 g/dl (transfusion permitted t
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	creatinine	2849 : 2859	CM	                -  Serum creatinine ≤1.5 times the upper lim
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	creatinine	2935 : 2945	CM	ulated                   creatinine clearance ≥ 50 ml/min   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Bilirubin	2987 : 2996	CM	l/min                 -  Bilirubin level ≤1.5 x ULN (patien
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	bilirubin	3078 : 3087	CM	o have                   bilirubin levels ≤ 3 x ULN may be 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ULN	3101 : 3104	CM	  bilirubin levels ≤ 3 x ULN may be enrolled)        
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ALT	3148 : 3151	CM	               -  AST or ALT <2.5 x ULN or <5 x ULN i
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phosphatase	3239 : 3250	CM	             -  Alkaline phosphatase (ALP) <2.5 x ULN or <5 x
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ALP	3252 : 3255	CM	-  Alkaline phosphatase (ALP) <2.5 x ULN or <5 x ULN 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	aPTT	3373 : 3377	CM	              -  INR and aPTT ≤1.5 x ULN; this applies
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IUD	4209 : 4212	CM	    intrauterine device [IUD], birth control pills un
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Ib	4379 : 4381	CM	e Escalation Part (phase Ib part):            1. His
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MAPK	4529 : 4533	CM	h frequent activation of MAPK and/or PI3K pathways (pa
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	4541 : 4545	CM	ctivation of MAPK and/or PI3K pathways (pancreatic,   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NSCLC	4681 : 4686	CM	ancer,                   NSCLC or melanoma) OR         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	4775 : 4779	CM	n in ≥1 gene involved in PI3K/AKT/mTOR or Ras/MEK     
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AKT	4780 : 4783	CM	≥1 gene involved in PI3K/AKT/mTOR or Ras/MEK         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	mTOR	4784 : 4788	CM	ene involved in PI3K/AKT/mTOR or Ras/MEK              
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	4796 : 4799	CM	 in PI3K/AKT/mTOR or Ras/MEK                   pathwa
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	KRAS	4847 : 4851	CM	way signalling, such as: KRAS, NRAS, BRAF, PIK3CA, PTE
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NRAS	4853 : 4857	CM	gnalling, such as: KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	BRAF	4859 : 4863	CM	ng, such as: KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PIK3CA	4865 : 4871	CM	ch as: KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR, 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PTEN	4873 : 4877	CM	RAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR,       
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AKT	4879 : 4882	CM	RAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR,            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	LKB1	4884 : 4888	CM	BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR,                  
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	EGFR	4890 : 4894	CM	PIK3CA, PTEN, AKT, LKB1, EGFR,                   FGFR,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	FGFR	4914 : 4918	CM	 EGFR,                   FGFR, HER2, MET, RET, KIT, NF
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	HER2	4920 : 4924	CM	                   FGFR, HER2, MET, RET, KIT, NF1     
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MET	4926 : 4929	CM	             FGFR, HER2, MET, RET, KIT, NF1          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	RET	4931 : 4934	CM	        FGFR, HER2, MET, RET, KIT, NF1            2. 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	KIT	4936 : 4939	CM	   FGFR, HER2, MET, RET, KIT, NF1            2. Metas
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	NSCLC	5629 : 5634	CM	r              recurrent NSCLC; recurrent disease must 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	TNBC	5927 : 5931	CM	n Criteria unique to the TNBC dose expansion cohort (P
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	TNCB	6006 : 6010	CM	Histologically confirmed TNCB defined as tumour cells 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ER	6074 : 6076	CM	         -  Negative for ER with <1% of tumour cells
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ER	6115 : 6117	CM	umour cells positive for ER on IHC or IHC score     
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6121 : 6124	CM	cells positive for ER on IHC or IHC score            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6128 : 6131	CM	ositive for ER on IHC or IHC score                   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6250 : 6253	CM	cells positive for PR on IHC or IHC score            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6257 : 6260	CM	ositive for PR on IHC or IHC score                   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	HER2	6351 : 6355	CM	         -  Negative for HER2 with 0, 1+ or 2+ intensi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IHC	6386 : 6389	CM	0, 1+ or 2+ intensity on IHC and no evidence of      
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ISH	6444 : 6447	CM	        amplification on ISH.            2. Metastati
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CNS	6880 : 6883	CM	          1. Symptomatic CNS involvement or CNS invol
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CNS	6899 : 6902	CM	matic CNS involvement or CNS involvement requiring st
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	7452 : 7457	CPR	AE Grade 1 from previous anti-cancer therapy, with the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	myocardial	7870 : 7880	CM	           -  History of myocardial infarction, acute corona
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	bpm	8632 : 8635	CM	   ventricular rate >100 bpm on ECG at rest          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ECG	8639 : 8642	CM	ricular rate >100 bpm on ECG at rest                 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	QTc	8942 : 8945	CM	rolongation defined as a QTc interval >470 msecs     
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	QT	9021 : 9023	CM	cations known to prolong QT interval            8. P
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	prednisolone	9161 : 9173	CM	corticosteroids (≥ 10 mg prednisolone or an equivalent dose of
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	9205 : 9210	CPR	equivalent dose of other anti-inflammatory             
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	prednisolone	9557 : 9569	CM	 stable low dose (<10 mg prednisolone or an equivalent dose of
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	anti-	9614 : 9619	CPR	se of other              anti-inflammatory corticostero
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	glucose	9911 : 9918	CM	ificant abnormalities of glucose metabolism as defined by
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Glycosylated	10090 : 10102	RN	ent).                 -  Glycosylated haemoglobin (HbA1C) ≥ 8.
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	HbA1C	10116 : 10121	CM	lycosylated haemoglobin (HbA1C) ≥ 8.0% at screening (64
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	HbA1C	10200 : 10205	CM	            equation for HbA1C [IFCC-HbA1C (mmol/mol) =
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IFCC-HbA1C	10207 : 10217	CM	     equation for HbA1C [IFCC-HbA1C (mmol/mol) = [DCCT-HbA1C
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	DCCT-HbA1C	10232 : 10242	CM	IFCC-HbA1C (mmol/mol) = [DCCT-HbA1C (%) - 2.15] x 10.929)   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Glucose	10299 : 10306	CM	       -  Fasting Plasma Glucose ≥ 7.0mmol/L (126 mg/dL) 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	7.0mmol	10309 : 10316	CM	Fasting Plasma Glucose ≥ 7.0mmol/L (126 mg/dL) at screeni
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	dL	10327 : 10329	CM	cose ≥ 7.0mmol/L (126 mg/dL) at screening. Fasting i
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	retinal	10689 : 10696	CM	al serous retinopathy or retinal vein occlusion          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP3A4	10783 : 10789	CM	nhibitors or inducers of CYP3A4/5 if taken within the   
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	ketoconazole	10934 : 10946	CM	nhibitors (competitive): ketoconazole, itraconazole, indinavir
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	itraconazole	10948 : 10960	CM	petitive): ketoconazole, itraconazole, indinavir, saquinovir, 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	indinavir	10962 : 10971	CM	oconazole, itraconazole, indinavir, saquinovir,            
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	saquinovir	10973 : 10983	CM	itraconazole, indinavir, saquinovir,                   nelfi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	atazanavir	11015 : 11025	CM	             nelfinavir, atazanavir, amprenavir, fosamprenav
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	amprenavir	11027 : 11037	CM	 nelfinavir, atazanavir, amprenavir, fosamprenavir, troleand
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fosamprenavir	11039 : 11052	CM	 atazanavir, amprenavir, fosamprenavir, troleandomycin, telithr
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	troleandomycin	11054 : 11068	CM	prenavir, fosamprenavir, troleandomycin, telithromycin,         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	telithromycin	11070 : 11083	CM	renavir, troleandomycin, telithromycin,                   fluco
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fluconazole	11103 : 11114	CM	mycin,                   fluconazole, nefazodone, cimetidine,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	nefazodone	11116 : 11126	CM	            fluconazole, nefazodone, cimetidine, aprepitant,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	cimetidine	11128 : 11138	CM	fluconazole, nefazodone, cimetidine, aprepitant, miconazole,
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	miconazole	11152 : 11162	CM	 cimetidine, aprepitant, miconazole, fluvoxamine,           
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	fluvoxamine	11164 : 11175	CM	 aprepitant, miconazole, fluvoxamine,                   P-gly
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	P-glycoprotein	11195 : 11209	CM	amine,                   P-glycoprotein, grapefruit juice, or se
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	amiodarone	11300 : 11310	CM	                period), amiodarone (27 week minimum wash-ou
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	erythromycin	11393 : 11405	CM	bitors (time dependent): erythromycin, clarithromycin, verapam
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	clarithromycin	11407 : 11421	CM	ependent): erythromycin, clarithromycin, verapamil, ritonavir,  
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	verapamil	11423 : 11432	CM	romycin, clarithromycin, verapamil, ritonavir,             
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	diltiazem	11463 : 11472	CM	navir,                   diltiazem (2 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phenytoin	11535 : 11544	CM	            -  Inducers: phenytoin, rifampicin, St. John's 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	rifampicin	11546 : 11556	CM	 -  Inducers: phenytoin, rifampicin, St. John's Wort, carbam
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	St	11558 : 11560	CM	: phenytoin, rifampicin, St. John's Wort, carbamazep
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	carbamazepine	11575 : 11588	CM	mpicin, St. John's Wort, carbamazepine, dexamethasone,         
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	dexamethasone	11590 : 11603	CM	n's Wort, carbamazepine, dexamethasone,                   primi
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	primidone	11623 : 11632	CM	asone,                   primidone, griseofulvin, carbamaze
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	griseofulvin	11634 : 11646	CM	              primidone, griseofulvin, carbamazepine, barbitur
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	carbamazepine	11648 : 11661	CM	primidone, griseofulvin, carbamazepine, barbiturates, troglitaz
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	troglitazone	11677 : 11689	CM	amazepine, barbiturates, troglitazone, pioglitazone,          
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	pioglitazone	11691 : 11703	CM	biturates, troglitazone, pioglitazone,                   oxcar
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	oxcarbazepine	11723 : 11736	CM	azone,                   oxcarbazepine, nevirapine, efavirenz, 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	efavirenz	11750 : 11759	CM	carbazepine, nevirapine, efavirenz, rifabutin (3 week minim
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	rifabutin	11761 : 11770	CM	, nevirapine, efavirenz, rifabutin (3 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	phenobarbitone	11826 : 11840	CM	d)                   and phenobarbitone (5 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP2C8	11945 : 11951	CM	nhibitors or inducers of CYP2C8 within the stated       
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Gemfibrozil	12071 : 12082	CM	          -  Inhibitors: Gemfibrozil, trimethoprim, glitazone
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	trimethoprim	12084 : 12096	CM	Inhibitors: Gemfibrozil, trimethoprim, glitazones, montelukast
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	glitazones	12098 : 12108	CM	mfibrozil, trimethoprim, glitazones, montelukast, quercetin 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	montelukast	12110 : 12121	CM	rimethoprim, glitazones, montelukast, quercetin (1 week      
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	quercetin	12123 : 12132	CM	glitazones, montelukast, quercetin (1 week                 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Rifampicin	12213 : 12223	CM	            -  Inducers: Rifampicin (3 week minimum wash-out
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP2C8	12378 : 12384	CM	ing              enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP2C9	12386 : 12392	CM	         enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP2C19	12394 : 12401	CM	 enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug tran
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	CYP2D6	12403 : 12409	CM	CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	BCRP	12450 : 12454	CM	nsporters Pgp (MDR1) and BCRP              within the 
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	TORCMEK	13946 : 13953	CM	r guidance issued by the TORCMEK IMP              manufac
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	IMP	13954 : 13957	CM	ce issued by the TORCMEK IMP              manufacture
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	PI3K	14173 : 14177	CM	 1. Prior treatment with PI3K inhibitors, AKT inhibito
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AKT	14190 : 14193	CM	nt with PI3K inhibitors, AKT inhibitors, mTOR inhibit
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	mTOR	14206 : 14210	CM	ibitors, AKT inhibitors, mTOR inhibitors or MEK, Ras o
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	MEK	14225 : 14228	CM	tors, mTOR inhibitors or MEK, Ras or              Raf
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Raf	14250 : 14253	CM	MEK, Ras or              Raf inhibitors.            2
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	14440 : 14447	CM	              A Study of AZD2014 in Combination With Selu
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	14468 : 14479	CM	2014 in Combination With Selumetinib in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	AZD2014	14552 : 14559	CM	 A Phase Ib/IIa Study of AZD2014 in Combination With Selu
./___Corpus/ClinicalTrials/xml/NCT02583542.xml	Selumetinib	14580 : 14591	CM	2014 in Combination With Selumetinib in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	73 : 80	CM	ermine if treatment with PLX3397 and Sirolimus will be   
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	85 : 94	CM	eatment with PLX3397 and Sirolimus will be       tolerated 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	MPNSTs	603 : 609	CM	ral nerve sheath tumors (MPNSTs) represent up to 10% of 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	MPNST	691 : 696	CM	. Due to its rarity, few MPNST-specific prospective tri
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	MPNST	1049 : 1054	CM	ays known to drive       MPNST will likely result in su
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	MPNSTs	1456 : 1462	CM	ral nerve sheath tumors (MPNSTs)            -  Extent of
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	MPNST	1677 : 1682	CM	             -  Phase 2: MPNST with 0-3 prior systemic 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	0-	1688 : 1690	CPR	  -  Phase 2: MPNST with 0-3 prior systemic treatmen
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	2000 : 2007	CM	 available on the use of PLX3397 in combination with siro
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	2028 : 2037	CM	3397 in combination with sirolimus in patients             
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	dL	2449 : 2451	CM	L, hemoglobin (Hgb) >9 g/dL, and                   p
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Aspartate	2523 : 2532	CM	0^9/L                 -  Aspartate aminotransferase (AST)/a
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	aminotransferase	2533 : 2549	ASE	            -  Aspartate aminotransferase (AST)/alanine aminotrans
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	alanine	2556 : 2563	CM	e aminotransferase (AST)/alanine aminotransferase (ALT) ≤
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	bilirubin	2687 : 2696	CM	nce of liver metastases, bilirubin ≤ 1.5                   
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ULN	2723 : 2726	CM	 1.5                   x ULN, albumin ≥ 3.0g/dL.     
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	3.0g	2738 : 2742	CM	        x ULN, albumin ≥ 3.0g/dL.                 -  B
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	dL	2743 : 2745	CM	   x ULN, albumin ≥ 3.0g/dL.                 -  Bili
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Bilirubin	2766 : 2775	CM	g/dL.                 -  Bilirubin ≤ ULN; patients with hyp
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	hyperbilirubinemia	2797 : 2815	CM	bin ≤ ULN; patients with hyperbilirubinemia clinically consistent wi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	bilirubin	2886 : 2895	CM	   inherited disorder of bilirubin metabolism (e.g., Gilber
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	3.0g	3045 : 3049	CM	            -  Albumin ≥ 3.0g/dL.                 -  C
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	dL	3050 : 3052	CM	       -  Albumin ≥ 3.0g/dL.                 -  Crea
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	creatinine	3110 : 3120	CM	 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CrCl	3132 : 3136	CM	ed creatinine clearance (CrCl) > 60 mL/min            
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	3904 : 3911	CM	 sterile. The effects of PLX3397 and sirolimus on the dev
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	3916 : 3925	CM	e effects of PLX3397 and sirolimus on the developing       
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	4645 : 4652	CM	           completion of PLX3397 and sirolimus administra
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	4657 : 4666	CM	ompletion of PLX3397 and sirolimus administration.         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CTCAE	5154 : 5159	CM	vents must be ≤ grade 1 (CTCAE v4.0), except           
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	nitrosoureas	5366 : 5378	CM	6 weeks for              nitrosoureas or mitomycin C) prior to
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	mitomycin	5382 : 5391	CM	         nitrosoureas or mitomycin C) prior to entering the
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	5594 : 5601	CM	ys from cycle 1 day 1 of PLX3397 and sirolimus.          
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	5606 : 5615	CM	e 1 day 1 of PLX3397 and sirolimus.            -  Patients 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	anti-	5752 : 5757	CPR	ant treatment with other anti-neoplastic agents (hormon
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6494 : 6501	CM	          composition to PLX3397 or sirolimus.           
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6505 : 6514	CM	omposition to PLX3397 or sirolimus.            -  For Phase
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	tyrosine	6573 : 6581	CM	r exposure to a receptor tyrosine kinase or mammalian targ
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Rapamycin	6625 : 6634	CM	n target of              Rapamycin inhibitor.            - 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6712 : 6719	CM	 from this study because PLX3397 and sirolimus are agents
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6724 : 6733	CM	tudy because PLX3397 and sirolimus are agents              
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	6972 : 6979	CM	tment of the mother with PLX3397 and sirolimus, breastfee
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	6984 : 6993	CM	 mother with PLX3397 and sirolimus, breastfeeding should be
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	7075 : 7082	CM	e mother is treated with PLX3397 and sirolimus.          
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	7087 : 7096	CM	treated with PLX3397 and sirolimus.            -  Uncontrol
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	myocardial	8616 : 8626	CM	coronary artery disease (myocardial infarction (MI) more tha
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	QTc	8765 : 8768	CM	.            -  Baseline QTc corrected by Fridericia'
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	QTcF	8804 : 8808	CM	by Fridericia's formula (QTcF) ≥ 450 ms (males) or ≥ 4
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9027 : 9034	CM	inetic interactions with PLX3397. In addition, these     
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	cytochrome	9348 : 9358	CM	    -  Of the five major cytochrome P450 (CYP) isoforms, 3A4
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP	9365 : 9368	CM	e major cytochrome P450 (CYP) isoforms, 3A4 (BFC) may
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	3A4	9380 : 9383	CM	ome P450 (CYP) isoforms, 3A4 (BFC) may be involved in
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9444 : 9451	CM	           metabolism of PLX3397, with possibly CYP1A2 pl
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP1A2	9467 : 9473	CM	f PLX3397, with possibly CYP1A2 playing a minor role. Un
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9623 : 9630	CM	ilable with              PLX3397, concomitant strong CYP3
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP3A4	9651 : 9657	CM	3397, concomitant strong CYP3A4 inhibitors and inducers 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	9762 : 9769	CM	the systemic exposure to PLX3397 (see Attachment 1 for a 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP3A4	9822 : 9828	CM	t of              common CYP3A4 inhibitors and inducers)
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	mycin	9886 : 9891	CM	include anticonvulsants, mycin              antimicrobi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	erythromycin	10003 : 10015	CM	ors such as              erythromycin, fluoxetine, gemfibrozil
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	fluoxetine	10017 : 10027	CM	           erythromycin, fluoxetine, gemfibrozil, and induce
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	gemfibrozil	10029 : 10040	CM	rythromycin, fluoxetine, gemfibrozil, and inducers such as ri
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	rifampicin	10063 : 10073	CM	il, and inducers such as rifampicin, carbamazepine,         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	carbamazepine	10075 : 10088	CM	cers such as rifampicin, carbamazepine,              phenytoin,
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	phenytoin	10103 : 10112	CM	bamazepine,              phenytoin, efavirenz, and nevirapi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	efavirenz	10114 : 10123	CM	              phenytoin, efavirenz, and nevirapine. Concomi
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	10310 : 10319	CM	         the study drug. Sirolimus undergoes extensive hepa
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP3A4	10391 : 10397	CM	abolism via              CYP3A4 and CYP3A5, as well as e
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP3A5	10402 : 10408	CM	              CYP3A4 and CYP3A5, as well as excretion by
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	P-glycoprotein	10434 : 10448	CM	 as well as excretion by P-glycoprotein. Strong CYP3A inhibitors
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	CYP3A	10457 : 10462	CM	y P-glycoprotein. Strong CYP3A inhibitors              
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	ketoconazole	10495 : 10507	CM	ors              such as ketoconazole or grapefruit juice are 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	10626 : 10635	CM	rapeutic toxic levels of sirolimus and PLX3397. As bone mar
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	10640 : 10647	CM	 levels of sirolimus and PLX3397. As bone marrow         
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	sirolimus	10795 : 10804	CM	      patients receiving sirolimus monotherapy, these adver
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	10892 : 10899	CM	        combination with PLX3397 for which patients will 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	warfarin	10976 : 10984	CM	      -  Any patients on warfarin therapy                 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	11015 : 11022	CM	py                       PLX3397 Plus Sirolimus in Unrese
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	11028 : 11037	CM	            PLX3397 Plus Sirolimus in Unresectable Sarcoma 
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Tyrosine	11184 : 11192	CM	herapy With the Receptor Tyrosine Kinase Inhibitor PLX3397
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Kinase	11193 : 11199	ASE	th the Receptor Tyrosine Kinase Inhibitor PLX3397 and Si
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	PLX3397	11210 : 11217	CM	yrosine Kinase Inhibitor PLX3397 and Sirolimus in Patient
./___Corpus/ClinicalTrials/xml/NCT02584647.xml	Sirolimus	11222 : 11231	CM	se Inhibitor PLX3397 and Sirolimus in Patients With Unresec
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	AXITINIB	23 : 31	CM	             Axitinib (AXITINIB) is an oral, potent, and
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	cytokine	222 : 230	CM	       phase II study in cytokine-refractory metastatic re
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	429 : 432	CM	d tumors to benefit from NSS.        The Objective is
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	604 : 607	CM	t primarily suitable for NSS (cT2aNoNxM0) for       s
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	cT2aNoNxM0	609 : 619	CM	marily suitable for NSS (cT2aNoNxM0) for       shifting from
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	NSS	1068 : 1071	CM	easibility and safety of NSS in tumors larger than 7c
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	RN	1152 : 1154	CM	ted that NSS compared to RN offers similar oncologic
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	IRB	1629 : 1632	CM	   -  Patients must sign IRB/EC-approved informed con
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	RCC	1733 : 1736	CM	ically proven clear cell RCC (obtained by CT or US gu
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	TNM	1830 : 1833	CM	 tumor according to 2009 TNM classification (tumor Ø>
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	MDRD	2071 : 2075	CM	  Normal renal function (MDRD creatinin clearance ≥ 60
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	dl	2233 : 2235	CM	        hemoglobin > 9 g/dl, absolute neutrophil cou
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	Bilirubin	2283 : 2292	CM	ount (ANC) >1.5 x 109/L; Bilirubin < 2              mg/dL, 
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	dL	2313 : 2315	CM	ubin < 2              mg/dL, aspartate transaminase 
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	aspartate	2317 : 2326	CM	 < 2              mg/dL, aspartate transaminase (AST) and a
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	alanine	2350 : 2357	CM	e transaminase (AST) and alanine transaminase (ALT) ≤ 2.5
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	ALT	2372 : 2375	CM	nd alanine transaminase (ALT) ≤ 2.5 times the        
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	cholesterol	2435 : 2446	CM	r limit of normal; Total cholesterol ≤ 9.1 mmol/l and triglyc
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	triglyceride	2464 : 2476	CM	esterol ≤ 9.1 mmol/l and triglyceride level ≤ 4.5             
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	AME	2733 : 2736	CM	 social coverage (except AME)          Exclusion Crit
./___Corpus/ClinicalTrials/xml/NCT02597322.xml	myocardial	3102 : 3112	CM	 history of              myocardial infarction or severe or 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	13 : 21	CM	             SNX-5422 is a pro-drug of SNX-211
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	39 : 47	CM	NX-5422 is a pro-drug of SNX-2112, a potent, highly select
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	vitro	177 : 182	CM	n 90 (Hsp90). Initial in vitro evidence supports       
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	212 : 220	CM	ence supports       that SNX-5422 may be active against TP
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	243 : 247	CM	22 may be active against TP53 null tumors irrespective
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	337 : 341	CM	he tumor suppressor gene TP53 codes for a central regu
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	602 : 606	CM	ctivities.       Somatic TP53 gene alterations are fre
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	667 : 675	CM	st human cancers.        SNX-5422 is a pro-drug of SNX-211
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	693 : 701	CM	NX-5422 is a pro-drug of SNX-2112, a potent, highly select
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	1060 : 1068	CM	ility and growth.        SNX-2112 retains activity in cell
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1117 : 1121	CM	l lines with loss of the TP53 gene from one of the all
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	1158 : 1166	CM	ne of the alleles.       SNX-2112 displays good activity i
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1209 : 1213	CM	ivity in cell lines with TP53 null/TP53 wild type (e.g
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1219 : 1223	CM	ell lines with TP53 null/TP53 wild type (e.g., MEC-1  
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1289 : 1293	CM	mphocytic leukemia]) and TP53 null/TP53 mutation (e.g.
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1299 : 1303	CM	leukemia]) and TP53 null/TP53 mutation (e.g., EBC-1, N
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	EBC-1	1320 : 1325	CM	ull/TP53 mutation (e.g., EBC-1, NCI-H520 [all NSCLC    
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	NCI-H520	1327 : 1335	CM	3 mutation (e.g., EBC-1, NCI-H520 [all NSCLC       - squam
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	NSCLC	1341 : 1346	CM	g., EBC-1, NCI-H520 [all NSCLC       - squamous cell ca
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1421 : 1425	CM	st extreme case in which TP53 is lost from both       
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1506 : 1510	CM	is totally devoid of the TP53 gene (e.g., H1299, KATO 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	H1299	1523 : 1528	CM	 of the TP53 gene (e.g., H1299, KATO III,       HL-60, 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	KATO	1530 : 1534	CM	 TP53 gene (e.g., H1299, KATO III,       HL-60, SK-MES
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	1564 : 1572	CM	       HL-60, SK-MES-1), SNX-2112 retains activity        
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-2112	1613 : 1621	CM	y        It appears that SNX-2112 could be active against 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1695 : 1699	CM	olid tumors with a       TP53 null status.            
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	1806 : 1810	CM	d solid or hematological TP53 null type cancer.       
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	anti-	1882 : 1887	CPR	 prior lines of systemic anti-cancer therapy.          
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX‑5422	2417 : 2425	CM	rst dose of              SNX‑5422 or planning to receive a
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	2700 : 2708	CM	rst dose of              SNX-5422 and throughout the study
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	cytochrome	2895 : 2905	CM	lism by the              cytochrome P450 (CYP) 3A4 isoenzyme
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	CYP	2912 : 2915	CM	        cytochrome P450 (CYP) 3A4 isoenzyme within 3 
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	isoenzyme	2921 : 2930	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	2993 : 3001	CM	stration of              SNX-5422 (Appendix B).           
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	ECG	3064 : 3067	CM	tely corrected screening ECG QTc interval 470 msec fo
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	QT	3197 : 3199	CM	dications known to cause QT prolongation AND correct
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	alcohol	4027 : 4034	CM	B.            -  Current alcohol dependence or drug abuse
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	4246 : 4254	CM	n.              Study of SNX-5422 in TP53 Null Cancers A S
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	4258 : 4262	CM	    Study of SNX-5422 in TP53 Null Cancers A Single Ar
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	SNX-5422	4298 : 4306	CM	rs A Single Arm Study of SNX-5422 in Subjects With TP53 Nu
./___Corpus/ClinicalTrials/xml/NCT02612285.xml	TP53	4324 : 4328	CM	NX-5422 in Subjects With TP53 Null Cancers
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	116 : 119	CM	agnosed Stage       I-IV ER+/HER2- breast cancer, wit
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	120 : 124	CM	sed Stage       I-IV ER+/HER2- breast cancer, with the
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	cyclin	872 : 878	CM	sible inhibitor of       cyclin-dependent kinase (CDK) 4
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	CDK	897 : 900	CM	cyclin-dependent kinase (CDK) 4 and CDK 6. Faslodex® 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	951 : 956	CPR	Fulvestrant) is a potent anti-estrogen       drug that 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	estrogen	1000 : 1008	CM	 that binds and degrades estrogen receptors (ERs). Interim
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PALOMA-3	1078 : 1086	CM	ase 3 trial       (Study PALOMA-3) have shown that combina
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	estrogen	1243 : 1251	CM	patients with metastatic estrogen       receptor positive 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	1277 : 1280	CM	      receptor positive (ER+) and human epidermal gro
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	1337 : 1341	CM	tor receptor 2 negative (HER2-) breast       cancer th
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	1396 : 1401	CPR	ogressed during or after anti-endocrine therapy (Turner
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	1652 : 1657	CPR	stered up       front in anti-endocrine therapy-naive p
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	adenosine triphosphate	1817 : 1839	CM	n intravenous (IV)       adenosine triphosphate (ATP) competitive, highl
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ATP	1841 : 1844	CM	 adenosine triphosphate (ATP) competitive, highly sel
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	phosphatidylinositol-4,5-bisphosphate	1926 : 1963	CM	an-class       I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K) and mam
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	3-	1965 : 1967	CPR	ositol-4,5-bisphosphate 3-kinase (PI3-K) and mammali
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PI3-K	1974 : 1979	CM	5-bisphosphate 3-kinase (PI3-K) and mammalian target of
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	rapamycin	2011 : 2020	CM	ammalian target of       rapamycin (mTOR) (Fry et al. 2004)
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	mTOR	2022 : 2026	CM	rget of       rapamycin (mTOR) (Fry et al. 2004). Prec
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PI3-K	2207 : 2212	CM	       Activation of the PI3-K/Akt/mTOR/p-S6 pathway ha
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	Akt	2213 : 2216	CM	 Activation of the PI3-K/Akt/mTOR/p-S6 pathway has be
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	mTOR	2217 : 2221	CM	ivation of the PI3-K/Akt/mTOR/p-S6 pathway has been as
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	p-S6	2222 : 2226	CM	on of the PI3-K/Akt/mTOR/p-S6 pathway has been associa
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	2290 : 2293	CM	rine resistance       in ER+ breast cancer. There is 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	anti-	2392 : 2397	CPR	n combination       with anti-hormonal therapy, increas
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PI3-K	2696 : 2701	CM	naling through different PI3-K isoforms. Also important
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PI3-K	2892 : 2897	CM	 surrogate for effective PI3-K/Akt/mTOR/p-S6 inhibition
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	mTOR	2902 : 2906	CM	 for effective PI3-K/Akt/mTOR/p-S6 inhibition, once we
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	p-S6	2907 : 2911	CM	effective PI3-K/Akt/mTOR/p-S6 inhibition, once weekly 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	pCR	3448 : 3451	CM	gical Complete Response (pCR) in neoadjuvant       th
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	3490 : 3493	CM	nt       therapy against ER+/HER2- breast cancer has 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	3494 : 3498	CM	     therapy against ER+/HER2- breast cancer has been 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	pCR	3631 : 3634	CM	ave the potential to use pCR assessment as a strong  
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	4674 : 4677	CM	ated       patients with ER+/HER2- breast cancer. Bei
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	4678 : 4682	CM	       patients with ER+/HER2- breast cancer. Being th
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	MTD	4882 : 4885	CM	 Maximum Tolerated Dose (MTD) of Gedatolisib when use
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	MTD	5156 : 5159	CM	atolisib       being the MTD determined from the curr
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	5454 : 5457	CM	       -  the disease is ER+ (defined as ER expressio
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER	5470 : 5472	CM	sease is ER+ (defined as ER expression >10% of invas
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	IHC	5561 : 5564	CM	 to immunohistochemical [IHC] staining)            - 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	5590 : 5594	CM	 staining)            -  HER2- (defined as IHC stainin
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	IHC	5608 : 5611	CM	    -  HER2- (defined as IHC staining of 0 to 1+ or f
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	FISH	5671 : 5675	CM	e in situ hybridization [FISH]              ratio of H
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	5699 : 5703	CM	H]              ratio of HER2 gene copy/chromosome 17 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	IUD	7933 : 7936	CM	auterine device         [IUD], or double barrier devi
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	glucose	9064 : 9071	CM	sting serum              glucose 130 mg/dL, and fasting t
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	dL	9079 : 9081	CM	          glucose 130 mg/dL, and fasting triglycerid
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	dL	9116 : 9118	CM	ing triglycerides 300 mg/dL).            -  Adequate
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	WBC	9174 : 9177	CM	ology (white blood cell [WBC] 3500 cells/mm3 or 3.5 b
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ANC	9333 : 9336	CM	phil count              [ANC] ≥1500 cells/mm3 or 1.5 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	dL	9394 : 9396	CM	nd hemoglobin (Hgb) ≥9 g/dL or ≥90 g/L).            
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	aspartate	9451 : 9460	CM	equate hepatic function (aspartate aminotransferase [AST/SG
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	aminotransferase	9461 : 9477	ASE	atic function (aspartate aminotransferase [AST/SGOT] 3x upper norm
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	AST	9479 : 9482	CM	artate aminotransferase [AST/SGOT] 3x upper normal li
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	SGOT	9483 : 9487	CM	te aminotransferase [AST/SGOT] 3x upper normal limit  
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	3x	9489 : 9491	CM	notransferase [AST/SGOT] 3x upper normal limit      
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	UNL	9525 : 9528	CM	rmal limit              [UNL], alanine aminotransfera
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	alanine	9531 : 9538	CM	imit              [UNL], alanine aminotransferase [ALT/SG
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ALT	9557 : 9560	CM	lanine aminotransferase [ALT/SGPT] 3x UNL (≤5x UNL if
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	SGPT	9561 : 9565	CM	ne aminotransferase [ALT/SGPT] 3x UNL (≤5x UNL if live
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	bilirubin	9626 : 9635	CM	s              present), bilirubin 1.5x UNL).            - 
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	creatinine	9692 : 9702	CM	te renal function (serum creatinine 1.5 mg/dL or 133 µmol/L)
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	dL	9710 : 9712	CM	(serum creatinine 1.5 mg/dL or 133 µmol/L).         
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	INR	9797 : 9800	CM	tional Normalized Ratio [INR] must be <1.5, <2.3 if  
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	warfarin	9880 : 9888	CM	le, therapeutic doses of warfarin and has no active bleedi
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	QT	10534 : 10536	CM	baseline prolongation of QT/QTc interval (e.g., repe
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	QTc	10537 : 10540	CM	eline prolongation of QT/QTc interval (e.g., repeated
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	QTc	10582 : 10585	CM	repeated exhibition of a QTc         interval >470 ms
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	Hg	10970 : 10972	CM	c blood pressure >160 mm Hg or diastolic blood      
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	Hg	11016 : 11018	CM	         pressure >90 mm Hg), or peripheral vascular
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	pericardial	11622 : 11633	CM	  clinically significant pericardial effusion.          I.Dia
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	.(NIDDM)	11724 : 11732	CM	endent diabetes mellitus .(NIDDM) that is         controll
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	dL	12198 : 12200	CM	        O.Albumin <2.5 g/dL or <25 g/L.          P.L
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	12888 : 12891	CM	aslodex in Patients With ER+/HER2- Breast Cancer     
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	12892 : 12896	CM	dex in Patients With ER+/HER2- Breast Cancer          
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	PI3-K	13007 : 13012	CM	sib (a Dual Inhibitor of PI3-K and mTOR) With Palbocicl
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	mTOR	13017 : 13021	CM	l Inhibitor of PI3-K and mTOR) With Palbociclib and Fa
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	ER+	13118 : 13121	CM	 Untreated Patients With ER+/HER2- Breast Cancer     
./___Corpus/ClinicalTrials/xml/NCT02626507.xml	HER2	13122 : 13126	CM	reated Patients With ER+/HER2- Breast Cancer     
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	254 : 259	CM	MPDL3280A in EGFR-mutant NSCLC patients.        The pri
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-	369 : 374	CPR	ate the safety and       anti-tumor effects of the comb
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	533 : 538	CM	atients with EGFR-mutant NSCLC.                       T
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	T790M	955 : 960	CM	 EGFR TKI, regardless of T790M mutation status, will be
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	T790M	1299 : 1304	CM	TKI,       regardless of T790M mutation status.        
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	1646 : 1651	CM	  advanced or metastatic NSCLC, with one or more activa
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	EGFR	1681 : 1685	CM	h one or more activating EGFR mutation (eg, G719X,    
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	G719X	1700 : 1705	CM	ating EGFR mutation (eg, G719X,              exon 19 de
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	L858R	1738 : 1743	CM	       exon 19 deletion, L858R, L861Q) and absence of e
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	L861Q	1745 : 1750	CM	exon 19 deletion, L858R, L861Q) and absence of exon 20 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	erlotinib	2095 : 2104	CM	FR              TKI (eg, erlotinib, gefitinib, afatinib). P
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	gefitinib	2106 : 2115	CM	     TKI (eg, erlotinib, gefitinib, afatinib). Previous che
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	afatinib	2117 : 2125	CM	g, erlotinib, gefitinib, afatinib). Previous chemotherapy 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	2154 : 2159	CM	revious chemotherapy for NSCLC is allowed.            -
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	EGFR	2207 : 2211	CM	 -  For Phase 2 Group A, EGFR TKI treatment-naïve and 
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-	2623 : 2628	CPR	herapy (eg, anti PD 1 or anti-PD L1)            -  Prio
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	L1	2631 : 2633	CM	eg, anti PD 1 or anti-PD L1)            -  Prior tre
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	CD137	2670 : 2675	CM	 -  Prior treatment with CD137 agonists or other immune
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	anti-	2755 : 2760	CPR	,              including anti-CTLA-4 therapeutic antibo
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	pericardial	2835 : 2846	CM	rolled pleural effusion, pericardial effusion or ascites requ
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	bisphosphonate	3030 : 3044	CM	nued use of              bisphosphonate therapy or denosumab (bi
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	bisphosphonate	3067 : 3081	CM	te therapy or denosumab (bisphosphonate use for prevention of sk
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	QT	4172 : 4174	CM	ms, inability to measure QT interval on ECG, persona
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	ECG	4187 : 4190	CM	o measure QT interval on ECG, personal or family hist
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	QT	4240 : 4242	CM	ory of              long QT syndrome, requirement fo
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	QT	4333 : 4335	CM	prolong the              QT interval            -  H
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	pneumonia	4412 : 4421	CM	ary fibrosis, organizing pneumonia, drug-induced           
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	5070 : 5075	CM	r Metastatic EGFR-mutant NSCLC               A Phase 1b
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	CO-1686	5152 : 5159	CM	Efficacy of Rociletinib (CO-1686) Administered in Combina
./___Corpus/ClinicalTrials/xml/NCT02630186.xml	NSCLC	5314 : 5319	CM	-small Cell Lung Cancer (NSCLC)     
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	71 : 78	CM	n label phase I study of AZD6738, DNA damage repair/novel
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	237 : 244	CM	ard chemotherapy.        AZD6738 is an orally dosed selec
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	344 : 347	CM	 and Rad3       Related (ATR) kinase with good select
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	Pi3	392 : 395	CM	electivity against other Pi3 kinase family members.  
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	426 : 429	CM	e family members.        ATR is a serine/threonine pr
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	serine	435 : 441	CM	members.        ATR is a serine/threonine protein kinase
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	threonine	442 : 451	CM	.        ATR is a serine/threonine protein kinase and membe
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	phosphatidylinositol	485 : 505	CM	kinase and member of the phosphatidylinositol 3-kinase       related k
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	3-	507 : 509	CPR	he phosphatidylinositol 3-kinase       related kinas
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	578 : 581	CM	ring normal replication, ATR is recruited at stalled 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	693 : 696	CM	eaks if left unrepaired. ATR is also       recruited 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	895 : 898	CM	itment and activation of ATR       leads to cell cycl
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	1124 : 1127	CM	s).        In the clinic ATR inhibitors are expected 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	1216 : 1219	CM	lls       dependent upon ATR for DNA repair e.g. ATM-
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	1306 : 1309	CM	otherapy       activity, ATR inhibitors are also pred
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	1446 : 1449	CM	y (through inhibition of ATR-dependent DNA repair pro
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	1547 : 1552	CPR	gnificant enhancement of anti-tumour activity may be   
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	1601 : 1608	CM	     achieved, data with AZD6738 suggest the potential ne
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	1650 : 1653	CM	ntial need to reduce the ATR inhibitor dose and      
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	1951 : 1958	CM	e mechanism of action of AZD6738 suggests the potential t
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	2019 : 2024	CPR	t with a number of       anti-cancer treatments, result
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	anti-	2175 : 2180	CPR	ty, pharmacokinetics and anti-tumour activity of AZD673
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	2199 : 2206	CM	 anti-tumour activity of AZD6738 at       increasing dose
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	2538 : 2545	CM	ral formulation of       AZD6738 will be used.        The
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	2645 : 2652	CM	e starting dose of 40 mg AZD6738 OD will       be escalat
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	OD	2653 : 2655	CM	ng dose of 40 mg AZD6738 OD will       be escalated 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	PK	2847 : 2849	CM	 an independent parallel PK expansion       cohort w
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	2889 : 2896	CM	  cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherap
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	D1	2900 : 2902	CM	th cycle 0 of AZD6738 on D1, D8~D21 monotherapy foll
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	D8~D21	2904 : 2910	CM	ycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	3136 : 3143	CM	from other studies using AZD6738.                        
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	water	3869 : 3874	CM	lly, patients must fast (water to drink only) from at l
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	0-	4030 : 4032	CPR	 ECOG performance status 0-1            7. Patients 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ATR	5589 : 5592	CM	 previous treatment with ATR inhibitors (small molecu
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	docetaxel	5676 : 5685	CM	eatment with paclitaxel (docetaxel is allowed if in physici
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	taxane	5782 : 5788	CM	absolutely refractory to taxane)            4. Patients 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	bisphosphonates	6664 : 6679	CM	receive a stable dose of bisphosphonates or denosumab for bone me
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	CYP3A4	6870 : 6876	CM	tant use of known potent CYP3A4 inhibitors such as ketoc
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ketoconazole	6896 : 6908	CM	YP3A4 inhibitors such as ketoconazole,              itraconazo
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	itraconazole	6923 : 6935	CM	toconazole,              itraconazole, ritonavir, indinavir, s
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	indinavir	6948 : 6957	CM	itraconazole, ritonavir, indinavir, saquinavir, telithromyc
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	saquinavir	6959 : 6969	CM	e, ritonavir, indinavir, saquinavir, telithromycin, clarithr
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	telithromycin	6971 : 6984	CM	, indinavir, saquinavir, telithromycin, clarithromycin and     
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	clarithromycin	6986 : 7000	CM	quinavir, telithromycin, clarithromycin and              nelfina
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	CYP3A4	7175 : 7181	CM	t significantly modulate CYP3A4 or Pgp activity (wash ou
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	St	7263 : 7265	CM	eks, but three weeks for St. John's Wort). Note thes
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	azole	7307 : 7312	CM	ote these include common azole              antifungals
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	macrolide	7339 : 7348	CM	            antifungals, macrolide antibiotics and other me
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	CTCAE	7476 : 7481	CM	any ongoing toxicities (>CTCAE grade 1) caused by      
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	CTCAE	7579 : 7584	CM	ntestinal obstruction or CTCAE grade 3 or grade 4 upper
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	GI	7610 : 7612	CM	grade 3 or grade 4 upper GI bleeding within 4 weeks 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ECG	7695 : 7698	CM	t.           11. Resting ECG with measurable QTcF > 4
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	QTcF	7715 : 7719	CM	ting ECG with measurable QTcF > 470 msec on 2 or more 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	7930 : 7932	CM	rtension or hypotension (BP              ≥150/95 mmH
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	7984 : 7986	CM	despite medical therapy, BP <100/60 mmHg or orthosta
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	BP	8048 : 8050	CM	ion fall              in BP >20 mmHg) Left ventricul
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	bpm	8193 : 8196	CM	 a ventricular rate >100 bpm on ECG at rest , Symptom
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ECG	8200 : 8203	CM	ricular rate >100 bpm on ECG at rest , Symptomatic   
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	NYHA	8254 : 8258	CM	          heart failure (NYHA grade II-IV), Prior or c
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	bilirubin	9378 : 9387	CM	                -  Total bilirubin < 1.5 x institutional up
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9433 : 9436	CM	l upper limit of normal (ULN)                 -  AST 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ALT	9468 : 9471	CM	           -  AST (SGOT)/ALT (SGPT) > 2.5 x instituti
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	SGPT	9473 : 9477	CM	      -  AST (SGOT)/ALT (SGPT) > 2.5 x institutional u
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9607 : 9610	CM	ich case it must be > 5x ULN                 -  Serum
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	creatinine	9636 : 9646	CM	                -  Serum creatinine > 1.5 x institutional UL
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	ULN	9669 : 9672	CM	ne > 1.5 x institutional ULN                 -  Glome
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	MDRD	9850 : 9854	CM	e (i.e. cockcroft-Gault, MDRD or CKD-EPI              
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	EDTA	9894 : 9898	CM	               formulae, EDTA clearance or 24 h urine 
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	10304 : 10311	CM	                Study of AZD6738, DNA Damage Repair/Novel
./___Corpus/ClinicalTrials/xml/NCT02630199.xml	AZD6738	10452 : 10459	CM	e I, Open-Label Study of AZD6738, DNA Damage Repair/Novel
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	13 : 20	CM	             SHR6390 is a small molecular,ora
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	65 : 69	CM	r,oral potent, selective CDK4/6 inhibitor. The purpose
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	192 : 199	CM	armacokinetic profile of SHR6390 in       Chinese advance
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	561 : 565	CM	le pathway abnormal (e.g CDK4 amplify and/or CCND1 amp
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CCND1	581 : 586	CM	(e.g CDK4 amplify and/or CCND1 amplify              and
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDKN2A	615 : 621	CM	lify              and/or CDKN2A loss)            -  East
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	0-	703 : 705	CPR	ECOG) performance status:0-1            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	bilirubin	975 : 984	CM	elets > 100×10^9/L Total bilirubin <         1.5×the upper 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1026 : 1029	CM	e upper limit of normal (ULN) ALT and AST ≤ 1.5×ULN (
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	AST	1039 : 1042	CM	 of normal (ULN) ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if e
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	ULN	1058 : 1061	CM	T and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver      
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	anti-	1419 : 1424	CPR	usly received therapy of anti-tumor agent targeting at 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	CDK4	1449 : 1453	CM	tumor agent targeting at CDK4/6            -  Less tha
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	mitomycin	1571 : 1580	CM	s from              last mitomycin or nitrosamine therapy  
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	nitrosamine	1584 : 1595	CM	       last mitomycin or nitrosamine therapy            -  Le
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	anti-	1651 : 1656	CPR	n 3 weeks from any other anti-tumor therapy (including 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	hypomagnesemia	2428 : 2442	CM	trollable hypokalemia or hypomagnesemia            -  history of
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HBV	2548 : 2551	CM	ion            -  active HBV or HCV infection (HBV vi
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HCV	2555 : 2558	CM	        -  active HBV or HCV infection (HBV virus≥10e
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HBV	2570 : 2573	CM	ve HBV or HCV infection (HBV virus≥10e4 copies/ml, HC
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	HCV	2596 : 2599	CM	BV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)   
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	(3)myocardial	2891 : 2904	CM	equire drug intervention (3)myocardial infarction (4)heart fail
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	nephric	3018 : 3025	CM	ysician); any cardiac or nephric abnormal ≥grade 2 found 
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	3720 : 3727	CM	harmacokinetics Study of SHR6390 in Advanced Melanoma Pat
./___Corpus/ClinicalTrials/xml/NCT02671513.xml	SHR6390	3825 : 3832	CM	inetics Phase 1 Study of SHR6390 in Advanced Melanoma Pat
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	13 : 20	CM	             SHR6390 is a small molecular, or
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	CDK4	66 : 70	CM	, oral potent, selective CDK4/6 inhibitor. The purpose
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	193 : 200	CM	armacokinetic profile of SHR6390 in       Chinese advance
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	0-	561 : 563	CPR	COG) performance status: 0-1            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	bilirubin	900 : 909	CM	                -  Total bilirubin < 1.5×the upper limit of
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	AST	975 : 978	CM	              -  ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if e
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	ULN	994 : 997	CM	T and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver metas
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	Creatinine	1048 : 1058	CM	ases)                 -  Creatinine ≤ 1 ULN                 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	anti-	1396 : 1401	CPR	usly received therapy of anti-tumor agent targeting at 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	CDK4	1426 : 1430	CM	tumor agent targeting at CDK4/6            -  Less tha
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	mitomycin	1548 : 1557	CM	s from              last mitomycin or nitrosamine therapy  
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	nitrosamine	1561 : 1572	CM	       last mitomycin or nitrosamine therapy            -  Le
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	anti-	1628 : 1633	CPR	n 3 weeks from any other anti-tumor therapy (including 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	hypomagnesemia	2443 : 2457	CM	trollable hypokalemia or hypomagnesemia            -  history of
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HBV	2563 : 2566	CM	ion            -  active HBV or HCV infection (HBV vi
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HCV	2570 : 2573	CM	        -  active HBV or HCV infection (HBV virus≥10e
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HBV	2585 : 2588	CM	ve HBV or HCV infection (HBV virus≥10e4 copies/ml, HC
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	HCV	2611 : 2614	CM	BV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)   
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	(3)myocardial	2906 : 2919	CM	equire drug intervention (3)myocardial infarction (4)heart fail
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	nephric	3033 : 3040	CM	ysician); any cardiac or nephric abnormal ≥grade 2 found 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	3691 : 3698	CM	              A Study of SHR6390 in Advanced Solid Tumor 
./___Corpus/ClinicalTrials/xml/NCT02684266.xml	SHR6390	3786 : 3793	CM	harmacokinetics Study of SHR6390 in Advanced Solid Tumor 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	142 : 151	CM	rapy-free combination of ibrutinib and obinutuzumab (GA 101
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	447 : 456	CM	sis of the study is that ibrutinib in combination with obin
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CR	525 : 527	CM	 achieve response rates (CR and PR), rates of MRD ne
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	546 : 549	CM	es (CR and PR), rates of MRD negativity and PFS which
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	R-CHOP	667 : 673	CM	apy combinations such as R-CHOP or       R-bendamustine 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	R-bendamustine	683 : 697	CM	 such as R-CHOP or       R-bendamustine in subjects with previou
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	736 : 738	CM	ith previously untreated FL and a high tumor burden.
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	FL	913 : 915	CM	ith previously untreated FL and a high tumor burden 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1036 : 1039	CM	 a central monitoring of MRD by PCR, a central pathol
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PCR	1043 : 1046	CM	ral monitoring of MRD by PCR, a central pathologic   
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1217 : 1226	CM	s an initial 6 cycles of ibrutinib plus obinutuzumab follow
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1290 : 1299	CM	 additional 24 months of ibrutinib plus obinutuzumab mainte
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1356 : 1359	CM	       In patients being MRD negative at 30 months, i
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	1402 : 1411	CM	nths, i.e. at the end of ibrutinib plus obinutuzumab       
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1518 : 1521	CM	treatment is given while MRD       monitoring is cont
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1560 : 1563	CM	ing is continued.        MRD monitoring will be regul
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1744 : 1747	CM	pectively. Subsequently, MRD       analyses will be p
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	1912 : 1915	CM	of the study).        If MRD assessment on peripheral
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRD	2136 : 2139	CM	   In patients remaining MRD positive at 30 months wi
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	2211 : 2220	CM	sion, single agent       ibrutinib therapy is continued for
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	DMC	2373 : 2376	CM	d. The       independent DMC will review the safety o
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ibrutinib	2660 : 2669	CM	rapy-free combination of ibrutinib plus       obinutuzumab 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	3A	2843 : 2845	CM	r lymphoma grade 1, 2 or 3A with a lymph node biopsy
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	GELF	3327 : 3331	CM	y entry according to the GELF criteria (nodal or extra
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	µl	3677 : 3679	CM	granulocytopenia < 1.500/µl, Hb < 10 g/dl,          
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Hb	3681 : 3683	CM	ulocytopenia < 1.500/µl, Hb < 10 g/dl,              
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	dl	3691 : 3693	CM	ia < 1.500/µl, Hb < 10 g/dl,                   throm
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	MRI	4062 : 4065	CM	 CT              scan or MRI)            -  Performan
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	ECOG	4111 : 4115	CM	rmance status ≤ 2 on the ECOG scale            -  Adeq
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	NHL	4203 : 4206	CM	rmalities are related to NHL), defined as            
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	dL	4280 : 4282	CM	   -  Hemoglobin ≥ 9.0 g/dL                 -  Absol
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	3B	4991 : 4993	CM	 FL)            -  Grade 3B follicular lymphoma     
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CNS	5051 : 5054	CM	  Presence or history of CNS disease (either CNS lymp
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CNS	5071 : 5074	CM	y of CNS disease (either CNS lymphoma or leptomeninge
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	murine	5211 : 5217	CM	 -  Known sensitivity to murine products            -  R
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	prednisone	5366 : 5376	CM	quivalent to < 20 mg/day prednisone.            -  Concomita
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	CYP3A4	5418 : 5424	CM	oncomitant use of strong CYP3A4 inhibitors and / or oral
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	warfarin	5466 : 5474	CM	 or oral anticoagulants (warfarin              and/or phen
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	phenprocoumon	5495 : 5508	CM	arin              and/or phenprocoumon)            -  Prior or 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	myocardial	6156 : 6166	CM	estive heart failure, or myocardial infarction within 6 mont
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	creatinine	6611 : 6621	CM	caused by the lymphoma): creatinine > 2x normal value       
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	2x	6624 : 6626	CM	 lymphoma): creatinine > 2x normal value            
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	creatinine	6665 : 6675	CM	                  and/or creatinine clearance < 50 ml/min)  
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	3x	6796 : 6798	CM	mphoma): transaminases > 3x                   normal
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	bilirubin	6827 : 6836	CM	               normal or bilirubin > 2,0 mg/dl (unless caus
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	dl	6846 : 6848	CM	al or bilirubin > 2,0 mg/dl (unless caused by known 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	6992 : 6995	CM	test results for chronic HBV infection (defined as po
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBsAg	7027 : 7032	CM	ion (defined as positive HBsAg serology)              P
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	7086 : 7089	CM	nts with occult or prior HBV infection (defined as ne
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBsAg	7121 : 7126	CM	ion (defined as negative HBsAg and positive            
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBcAb	7159 : 7164	CM	itive              total HBcAb) may be included if HBV 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBV	7185 : 7188	CM	BcAb) may be included if HBV DNA is undetectable, pro
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HBsAb	7368 : 7373	CM	itis B surface antibody (HBsAb) after vaccination or pr
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HCV	7523 : 7526	CM	is C (hepatitis C virus [HCV] antibody serology      
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HCV	7591 : 7594	CM	). Patients positive for HCV antibody are eligible on
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PCR	7625 : 7628	CM	ody are eligible only if PCR is negative for         
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	HCV	7658 : 7661	CM	egative for              HCV RNA.            -  Known
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	PML	7774 : 7777	CM	h a history of confirmed PML            -  Vaccinatio
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	alcohol	8513 : 8520	CM	 of medication, drugs or alcohol            -  Any other 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Kinase	8868 : 8874	ASE	of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in 
./___Corpus/ClinicalTrials/xml/NCT02689869.xml	Ibrutinib	8886 : 8895	CM	rosine Kinase Inhibitor, Ibrutinib in Combination With GA 1
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HER2	239 : 243	CM	er.        Patients with HER2 positive, metastatic or 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MTD	581 : 584	CM	 maximum tolerated dose (MTD) determined in the Phase
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MTD	973 : 976	CM	ial will be based on the MTD       established in the
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MUGA	1658 : 1662	CM	 Multigated acquisition (MUGA) scan or       Echocardi
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ECHO	1694 : 1698	CM	or       Echocardiogram (ECHO) and 12 lead Electrocard
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HER2	2645 : 2649	CM	           2. Documented HER2 overexpression by local 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	IHC	2686 : 2689	CM	ion by local laboratory (IHC 3+ or FISH or CISH posit
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	FISH	2696 : 2700	CM	al laboratory (IHC 3+ or FISH or CISH positive).      
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CISH	2704 : 2708	CM	atory (IHC 3+ or FISH or CISH positive).            3.
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	RECIST	2778 : 2784	CM	able lesion according to RECIST criteria (Version 1.1). 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	TDM1	2941 : 2945	CM	one trastuzumab based or TDM1-based treatment regimen 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	TDM1	3094 : 3098	CM	ab              based or TDM1-based treatment regimen 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	TDM1	3204 : 3208	CM	 includes trastuzumab or TDM1.               Patients 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	oestrogen	4566 : 4575	CM	thods include: combined (oestrogen and progestogen         
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	progestogen	4580 : 4591	CM	 combined (oestrogen and progestogen              containing)
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	progestogen	4727 : 4738	CM	travaginal, transdermal) progestogen only hormonal contracept
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	bilirubin	5313 : 5322	CM	ent:               Total bilirubin ≤1.5 x ULN (<3 x ULN for
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5330 : 5333	CM	  Total bilirubin ≤1.5 x ULN (<3 x ULN for patients w
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Alanine	5382 : 5389	CM	with liver involvement). Alanine              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aminotransferase	5403 : 5419	ASE	t). Alanine              aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aspartate	5430 : 5439	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	aminotransferase	5440 : 5456	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x U
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5470 : 5473	CM	transferase (AST) ≤2.5 x ULN (≤5 x ULN for           
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	5582 : 5585	CM	           Lipase ≤1.5 x ULN. Glomerular filtration r
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MDRD	5707 : 5711	CM	f Diet in Renal Disease (MDRD) abbreviated formula. If
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MDRD	5863 : 5867	CM	ding to the              MDRD abbreviated formula or b
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	thromboplastin	6093 : 6107	CM	 ratio (INR) and partial thromboplastin time (PTT) ≤1.5 x ULN.  
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ULN	6126 : 6129	CM	lastin time (PTT) ≤1.5 x ULN.              Patients w
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	warfarin	6207 : 6215	CM	ed with an agent such as warfarin or heparin              
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	INR	6492 : 6495	CM	 will be performed until INR/PTT is stable based     
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PTT	6496 : 6499	CM	l be performed until INR/PTT is stable based         
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Hb	6772 : 6774	CM	            Haemoglobin (Hb) ≥8 g/dL. Absolute neutr
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	dL	6781 : 6783	CM	   Haemoglobin (Hb) ≥8 g/dL. Absolute neutrophil cou
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	ANC	6896 : 6899	CM	one marrow infiltration, ANC count ≥0.75 x 109/L.    
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	glucose	6949 : 6956	CM	           Fasting blood glucose <125 mg/dL (≤6.9 mmol/L)
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	dL	6965 : 6967	CM	ng blood glucose <125 mg/dL (≤6.9 mmol/L) if not dia
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	dL	7009 : 7011	CM	 not diabetic or <160 mg/dL (≤8.9              mmol/
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MUGA	7192 : 7196	CM	as determined by ECHO or MUGA.           12. Patients 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PIK3CA	7416 : 7422	CM	 Phase II:           13. PIK3CA mutation confirmed by ce
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PIK3CA	7516 : 7522	CM	jects (who are confirmed PIK3CA mutation carriers) must 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MTD	7585 : 7588	CM	ated              at the MTD in order to proceed with
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PET	7961 : 7964	CM	 by baseline CT Scan (or PET CT/MRI if as per RECIST 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CT	7965 : 7967	CM	baseline CT Scan (or PET CT/MRI if as per RECIST 1.1
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MRI	7968 : 7971	CM	eline CT Scan (or PET CT/MRI if as per RECIST 1.1) th
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	RECIST	7982 : 7988	CM	(or PET CT/MRI if as per RECIST 1.1) that has not       
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CNS	8125 : 8128	CM	           management of CNS symptoms            2. C
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HbA1c	8639 : 8644	CM	tes mellitus. Defined as HbA1c >8.5% or a fasting      
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	glucose	8684 : 8691	CM	ting              plasma glucose >8.9 mmol/L as determine
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CTCAE	9126 : 9131	CM	fections >CTCAE Grade 2 (CTCAE v4.0).            8. Kno
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9243 : 9246	CM	         9. Hepatitis B (HBV) or hepatitis C (HCV). A
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9264 : 9267	CM	 B (HBV) or hepatitis C (HCV). All patients must be s
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9304 : 9307	CM	nts must be screened for HBV and HCV              up 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9312 : 9315	CM	 be screened for HBV and HCV              up to 28 da
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBsAg	9467 : 9472	CM	ts who test positive for HBsAg or HBcAb will be eligibl
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBcAb	9476 : 9481	CM	st positive for HBsAg or HBcAb will be eligible if they
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HBV	9537 : 9540	CM	            negative for HBV DNA; patients who test p
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	anti-	9577 : 9582	CPR	ts who test positive for anti-HCV antibody will be     
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	HCV	9650 : 9653	CM	if they are negative for HCV RNA.           10. Patie
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PI3K	11395 : 11399	CM	ational drugs other than PI3K inhibitors less than 28 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	prednisone	11890 : 11900	CM	y dose higher than 15 mg prednisone              or equivale
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CT	12060 : 12062	CM	performing the screening CT scan (or PET CT/MRI as p
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	PET	12072 : 12075	CM	he screening CT scan (or PET CT/MRI as per           
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CT	12076 : 12078	CM	creening CT scan (or PET CT/MRI as per              
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	MRI	12079 : 12082	CM	ening CT scan (or PET CT/MRI as per              RECI
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	RECIST	12103 : 12109	CM	/MRI as per              RECIST 1.1) and again prior to 
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	digoxin	12781 : 12788	CM	herapy (beta blockers or digoxin are permitted).         
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CYP3A4	12847 : 12853	CM	 of strong inhibitors of CYP3A4 is prohibited from Day 1
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	CYP3A4	12971 : 12977	CM	  31. Use of inducers of CYP3A4 is prohibited from Day 1
./___Corpus/ClinicalTrials/xml/NCT02705859.xml	Zoledronate	13071 : 13082	CM	      up visit.          Zoledronate or denosumab for patient
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC1	71 : 77	CM	t the dual inhibition of mTORC1/mTORC2 by AZD2014 combin
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC2	78 : 84	CM	ual inhibition of mTORC1/mTORC2 by AZD2014 combined     
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	88 : 95	CM	tion of mTORC1/mTORC2 by AZD2014 combined       with inhi
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	150 : 161	CM	n of aromatase enzyme by anastrozole will act synergistically
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	2-	360 : 362	CPR	o conduct a multicenter, 2-step, randomized, Phase I
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	478 : 489	CM	on treatment associating anastrozole to       AZD2014 in adva
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	499 : 506	CM	ing anastrozole to       AZD2014 in advanced endometrial 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	681 : 688	CM	the proposed combination AZD2014            + anastrozole
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	702 : 713	CM	ion AZD2014            + anastrozole (Arm A) versus anastrozo
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	729 : 740	CM	astrozole (Arm A) versus anastrozole alone (Arm B). No dose e
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MTD	843 : 846	CM	 maximum tolerated dose (MTD) defined for AZD2014 and
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	860 : 867	CM	d dose (MTD) defined for AZD2014 and the summary of      
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	931 : 942	CM	characteristics (SPC) of anastrozole). However, dose de-escal
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	977 : 984	CM	, dose de-escalation for AZD2014            will be appli
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	1140 : 1147	CM	enefit of the            AZD2014 + anastrozole (Arm A) co
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1150 : 1161	CM	the            AZD2014 + anastrozole (Arm A) combination ther
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1197 : 1208	CM	mbination therapy versus anastrozole (Arm B).                
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	1318 : 1325	CM	nts will receive Arm A : AZD2014 plus anastrozole or Arm 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1331 : 1342	CM	ive Arm A : AZD2014 plus anastrozole or Arm B:       anastroz
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	1359 : 1370	CM	strozole or Arm B:       anastrozole alone AZD2014 will be ad
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	1377 : 1384	CM	       anastrozole alone AZD2014 will be administered wit
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	D1	1583 : 1585	CM	se of 500 mg/week (250mg D1 and D2, 5 days off) Anas
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	D2	1590 : 1592	CM	00 mg/week (250mg D1 and D2, 5 days off) Anastrozole
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	1606 : 1617	CM	g D1 and D2, 5 days off) Anastrozole will be administered at 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	8-	2097 : 2099	CPR	lowing the treatment and 8-week follow-up of the    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	2176 : 2183	CM	experimental association AZD2014+anastrozole (experimenta
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	2184 : 2195	CM	ntal association AZD2014+anastrozole (experimental arm). By  
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	8-	2810 : 2812	CPR	a       minimum success (8-week non progression) rat
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	p≤p0	3059 : 3063	CM	 the null hypothesis H0: p≤p0 versus the       alterna
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	H1	3104 : 3106	CM	  alternative hypothesis H1: p ≥ p1 in a unilateral 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	DATA	3477 : 3481	CM	rol).        DATA ENTRY, DATA MANAGEMENT AND STUDY MON
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	estrogen	4271 : 4279	CM	           -  Documented estrogen receptor and/or progeste
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	progesterone	4296 : 4308	CM	estrogen receptor and/or progesterone receptor positive endome
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	formalin	4539 : 4547	CM	t tumor sample (archival formalin-fixed              paraf
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Hb	5343 : 5345	CM	100 x 109/L, Hemoglobin (Hb)                   >9 g/
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	dL	5370 : 5372	CM	)                   >9 g/dL                 -  Serum
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	bilirubin	5398 : 5407	CM	                -  Serum bilirubin ≤ 1.5 upper limit of nor
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	ULN	5437 : 5440	CM	5 upper limit of normal (ULN), alanine aminotransfera
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	alanine	5443 : 5450	CM	r limit of normal (ULN), alanine aminotransferase and    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	aspartate	5490 : 5499	CM	se and                   aspartate aminotransferase ≤ 2.5 U
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	aminotransferase	5500 : 5516	ASE	               aspartate aminotransferase ≤ 2.5 ULN (≤ 5 ULN in pa
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Creatinine	5590 : 5600	CM	ases)                 -  Creatinine clearance > 50 mL/min (u
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MDRD	5652 : 5656	CM	ng Cockcroft formula, or MDRD formula for             
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Creatinine	5723 : 5733	CM	er 65 years Appendix 3 - Creatinine Clearance)            - 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	cholesterol	5773 : 5784	CM	        -  Fasting serum cholesterol ≤ 300 mg/dL (7.75 mmol/L
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	dL	5794 : 5796	CM	rum cholesterol ≤ 300 mg/dL (7.75 mmol/L) AND fastin
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	triglycerides	5823 : 5836	CM	7.75 mmol/L) AND fasting triglycerides ≤ 2.5              ULN (
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	lipid	5861 : 5866	CM	 ≤ 2.5              ULN (lipid-lowering drugs allowed),
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	glucose	5921 : 5928	CM	       -  Fasting plasma glucose ≤7 mmol/L (126 mg/dL)   
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	dL	5947 : 5949	CM	lucose ≤7 mmol/L (126 mg/dL)            -  Recovered
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	CTCAE	6162 : 6167	CM	rse              Events (CTCAE) v4.3, except grade 2 al
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Hb	6224 : 6226	CM	 grade 2 anemia but with Hb >9 g/dL.            -  M
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	dL	6232 : 6234	CM	 anemia but with Hb >9 g/dL.            -  Minimal w
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anti-	6376 : 6381	CPR	:                 -  Any anti-cancer treatment approved
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	androgens	6529 : 6538	CM	rapy, radiation therapy, androgens : > 21 days (not includi
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	G-CSF	6929 : 6934	CM	                 factor (G-CSF)], sargramostim [granulo
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	OATP1B1	7270 : 7277	CM	porting polypeptide 1B1 (OATP1B1), organic anion-transpor
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	OATP1B3	7342 : 7349	CM	        polypeptide 1B3 (OATP1B3), MATE1 and MATE2K : see
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MATE1	7352 : 7357	CM	lypeptide 1B3 (OATP1B3), MATE1 and MATE2K : see the app
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MATE2K	7362 : 7368	CM	1B3 (OATP1B3), MATE1 and MATE2K : see the appropriate wa
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	CYP3A4	7623 : 7629	CM	nhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP -
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	BCRP	7648 : 7652	CM	CYP3A4/5, Pgp (MDR1) and BCRP -              Restricte
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	CYP	7679 : 7682	CM	              Restricted CYP and transporter related 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	7902 : 7909	CM	during administration of AZD2014, and should             
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	8043 : 8050	CM	nal              dose of AZD2014.            -  Patient a
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	potassium	8520 : 8529	CM	evant abnormal levels of potassium or sodium.            - 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	sodium	8533 : 8539	CM	l levels of potassium or sodium.            -  Use of an
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anti-	8650 : 8655	CPR	:                 -  Any anti-cancer treatment (approve
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	CYP3A4	9211 : 9217	CM	nhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP (
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	BCRP	9236 : 9240	CM	CYP3A4/5, Pgp (MDR1) and BCRP (see                   A
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	OATP1B1	9443 : 9450	CM	orters                   OATP1B1, OATP1B3, MATE1 and MATE
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	OATP1B3	9452 : 9459	CM	                OATP1B1, OATP1B3, MATE1 and MATE2K outsid
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MATE1	9461 : 9466	CM	       OATP1B1, OATP1B3, MATE1 and MATE2K outside the w
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	MATE2K	9471 : 9477	CM	P1B1, OATP1B3, MATE1 and MATE2K outside the wash out per
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	anastrozole	9675 : 9686	CM	nown hypersensitivity to anastrozole or to any of the excipie
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	monohydrate	9737 : 9748	CM	ts              (Lactose monohydrate, Povidone, Sodium starch
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Sodium	9760 : 9766	CM	e monohydrate, Povidone, Sodium starch glycollate, Magne
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	glycollate	9774 : 9784	CM	 Povidone, Sodium starch glycollate, Magnesium stearate,    
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Magnesium stearate	9786 : 9804	CM	odium starch glycollate, Magnesium stearate,              Hypromello
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Hypromellose	9819 : 9831	CM	m stearate,              Hypromellose, Macrogol 300, Titanium 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Macrogol	9833 : 9841	CM	           Hypromellose, Macrogol 300, Titanium dioxide)  
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Titanium dioxide	9847 : 9863	CM	romellose, Macrogol 300, Titanium dioxide)            -  History o
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	9943 : 9950	CM	r inactive excipients of AZD2014 or drugs with           
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	10019 : 10026	CM	al structure or class to AZD2014            -  History of
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	QT	10885 : 10887	CM	  Mean resting corrected QT interval (QTc), calculat
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	QT	11077 : 11079	CM	        of long or short QT syndrome, Brugada syndro
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	12144 : 12151	CM	e adequate absorption of AZD2014.                 -  Rare
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	galactose	12200 : 12209	CM	e hereditary problems of galactose intolerance, the Lapp la
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	lactase	12232 : 12239	CM	se intolerance, the Lapp lactase deficiency or           
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	glucose	12272 : 12279	CM	ncy or                   glucose-galactose malabsorption 
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	galactose	12280 : 12289	CM	                 glucose-galactose malabsorption           
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	nephritic	12439 : 12448	CM	ding glomerulonephritis, nephritic syndrome,               
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC1	12607 : 12613	CM	arcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Ana
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC2	12614 : 12620	CM	a Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozol
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12635 : 12646	CM	RC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)              
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	VICTORIA	12648 : 12656	CM	hibitor and Anastrozole (VICTORIA)               A Multice
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	AZD2014	12750 : 12757	CM	el Phase I/II Evaluating AZD2014 (Dual Mammalian Target o
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Rapamycin	12784 : 12793	CM	Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTOR
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC1	12807 : 12813	CM	f Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Co
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	mTORC2	12814 : 12820	CM	ycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combinati
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12853 : 12864	CM	tor) in Combination With Anastrozole Versus Anastrozole Alone
./___Corpus/ClinicalTrials/xml/NCT02730923.xml	Anastrozole	12872 : 12883	CM	 With Anastrozole Versus Anastrozole Alone in the Treatment o
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	91 : 100	CM	se Inhibitor, PCI-32765 (ibrutinib), in       combination w
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aB-NHL	243 : 249	CM	ll non Hodgkin lymphoma (aB-NHL) including any subtype o
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	313 : 318	CM	e B cell       lymphoma (DLBCL) primary mediastinal B c
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	PMBCL	357 : 362	CM	astinal B cell lymphoma (PMBCL), double and triple hit 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	387 : 392	CM	), double and triple hit DLBCL,       transformed indol
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	481 : 486	CM	 B cell lymphoma between DLBCL and       Burkitt lympho
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CNS	529 : 532	CM	 lymphoma. Patients with CNS involvement (primary or 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	592 : 601	CM	 will be excluded.       Ibrutinib (IMBRUVICA®; PCI-32765; 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	IMBRUVICA	603 : 612	CM	cluded.       Ibrutinib (IMBRUVICA®; PCI-32765; JNJ-5417906
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	tyrosine	751 : 759	CM	le inhibitor of Bruton's tyrosine kinase       currently F
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	FDA	783 : 786	CM	e kinase       currently FDA approved for the treatme
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	(WM).It	929 : 936	CM	nstrom Macroglobulinemia (WM).It is under constant       
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1053 : 1062	CM	nitial approval of       ibrutinib was received on 13 Novem
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	MCL	1193 : 1196	CM	t of adult patients with MCL who have received at lea
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	1247 : 1256	CM	t 1 prior therapy.       Ibrutinib has not been approved fo
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1424 : 1433	CM	een published. In Israel ibrutinib is       registered for 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	MCL	1475 : 1478	CM	red for the treatment of MCL and CLL.                
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CLL	1483 : 1486	CM	the treatment of MCL and CLL.                       T
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	1602 : 1611	CM	st the efficacy of       ibrutinib in combination with BR i
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aB-NHL	1647 : 1653	CM	tion with BR in relapsed aB-NHL either as third line pos
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ASCT	1680 : 1684	CM	ither as third line post ASCT or as       second or th
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aB-NHL	2447 : 2453	CM	 versus relapsed disease aB-NHL histology, and number of
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	2534 : 2536	CM	All subject will receive BR protocol and ibrutinib 5
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	2550 : 2559	CM	 receive BR protocol and ibrutinib 560mg per day. Ibrutinib
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	2575 : 2584	CM	ibrutinib 560mg per day. Ibrutinib will be       administer
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	BR	2869 : 2871	CM	t the end of 6 cycles of BR. Subjects who discontinu
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ORR	3447 : 3450	CM	    efficacy analysis of ORR will be based on investi
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3854 : 3859	CM	Histologically confirmed DLBCL, Transformed low grade l
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3895 : 3900	CM	ed low grade lymphoma to DLBCL, primary              me
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	3986 : 3991	CM	ifiable lymphoma between DLBCL and Burkitt             
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ASCT	4125 : 4129	CM	          candidates for ASCT or in second relapse/pro
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ASCT	4168 : 4172	CM	relapse/progression post ASCT (as first salvage       
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ASCT	4247 : 4251	CM	relapse/progression post ASCT).            3. Patholog
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	(ANC)≥1000	4729 : 4739	CM	bsolute neutrophil count (ANC)≥1000/mm3 independent of growt
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Alanine	5020 : 5027	CM	mits:                 1. Alanine aminotransferase (ALT) a
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aminotransferase	5028 : 5044	ASE	              1. Alanine aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aspartate	5055 : 5064	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	aminotransferase	5065 : 5081	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper       
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	bilirubin	5165 : 5174	CM	                2. Total bilirubin ≤ 1.5 x ULN unless the i
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ULN	5183 : 5186	CM	 Total bilirubin ≤ 1.5 x ULN unless the increase is d
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	creatinine	5304 : 5314	CM	                3. Serum creatinine ≤ 2 x ULN or estimated G
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	gonadotropin	6128 : 6140	CM	n chorionic              gonadotropin [beta-hCG]) or urine pre
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	0-	6313 : 6315	CPR	 ECOG performance status 0-2.           11. Sign (or
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	6780 : 6789	CM	h either bendamustine or Ibrutinib. 3. Prior allogeneic ste
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	warfarin	7026 : 7034	CM	res anticoagulation with warfarin or equivalent vitamin K 
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	vitamin K	7049 : 7058	CM	h warfarin or equivalent vitamin K antagonists. 7. Requires
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	CYP3A	7114 : 7119	CM	   treatment with strong CYP3A inhibitors. 8. Clinicall
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	myocardial	7267 : 7277	CM	estive heart failure, or myocardial         infarction withi
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	HBs	7804 : 7807	CM	biotics. Hbcore positive HBs negative patients will b
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	lamivudine	7884 : 7894	CM	 need to be treated with lamivudine 100 mg/day throughout th
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	ibrutinib	8198 : 8207	CM	orption or metabolism of ibrutinib capsules, or put the stu
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	DLBCL	8319 : 8324	CM	or malignancy other than DLBCL, except:            1. M
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	8703 : 8712	CM	                Study of Ibrutinib in Combination With Bend
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Kinase	8869 : 8875	ASE	of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ib
./___Corpus/ClinicalTrials/xml/NCT02747732.xml	Ibrutinib	8898 : 8907	CM	se Inhibitor, PCI-32765 (Ibrutinib), in Combination With Be
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	thymidylate	37 : 48	CM	 Raltitrexed is a potent thymidylate synthase (TS) inhibitor.
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5-fluorouracil	88 : 102	CM	inhibitor. Conversely to 5-fluorouracil       (5FU), raltitrexed
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	110 : 113	CM	to 5-fluorouracil       (5FU), raltitrexed can be adm
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	dihydropyrimidine	230 : 247	CM	well as in patients with dihydropyrimidine dehydrogenase deficit. S
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	dehydrogenase	248 : 261	CM	s with dihydropyrimidine dehydrogenase deficit. Since raltitrex
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	15-	314 : 317	CPR	is       administered in 15-minutes infusion, complic
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	572 : 575	CM	 potential benefits over 5FU,       clinical trials f
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	641 : 644	CM	emptation to replace the 5FU in colorectal cancer pat
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	m2	724 : 726	CM	titrexed toxicity at 3mg/m2 every 3 weeks. Oxaliplat
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	Oxaliplatin	742 : 753	CM	at 3mg/m2 every 3 weeks. Oxaliplatin has demonstrated a      
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	TS	814 : 816	CM	ffect when combined with TS inhibitors, and its asso
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	901 : 912	CM	evaluated at 130mg/m2 of oxaliplatin and 3mg/m2 of raltitrexe
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	FOLFOX	1074 : 1080	CM	ts is the biweekly       FOLFOX (85mg/m2 of oxaliplatin,
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1093 : 1104	CM	      FOLFOX (85mg/m2 of oxaliplatin, and infusional 5FU) plu
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	5FU	1121 : 1124	CM	liplatin, and infusional 5FU) plus bevacizumab regime
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	PFS	1205 : 1208	CM	ogression-free survival (PFS) benefit was observed ov
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1434 : 1445	CM	ociation of raltitrexed, oxaliplatin and       bevacizumab se
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	TOMOX	1600 : 1605	CM	y       between biweekly TOMOX (raltitrexed 2 mg/m2 and
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1631 : 1642	CM	(raltitrexed 2 mg/m2 and oxaliplatin 85mg/m2) and triweekly T
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	m2	1648 : 1650	CM	/m2 and oxaliplatin 85mg/m2) and triweekly TOMOX    
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	TOMOX	1666 : 1671	CM	n 85mg/m2) and triweekly TOMOX       (raltitrexed 3 mg/
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	oxaliplatin	1703 : 1714	CM	(raltitrexed 3 mg/m2 and oxaliplatin 130mg/m2) regimens in me
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	m2	1721 : 1723	CM	m2 and oxaliplatin 130mg/m2) regimens in metastatic 
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	PFS	2079 : 2082	CM	    RECIST 1.1 criteria, PFS, overall survival (OS), 
./___Corpus/ClinicalTrials/xml/NCT02821559.xml	Oxaliplatin	3410 : 3421	CM	iweekly Raltitrexed With Oxaliplatin (With or Without Bevaciz
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IDH1	179 : 183	CM	all gliomas that show no IDH1 mutation, the latter    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IDH1	383 : 387	CM	as and III       without IDH1 mutation, with the usual
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	GBM	686 : 689	CM	                   3% of GBM and IDHwt gliomas have a
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR	793 : 797	CM	igh       sensitivity to FGFR inhibitors to tumor cell
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	vitro	828 : 833	CM	itors to tumor cells, in vitro and in vivo. Preclinical
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR	936 : 940	CM	s confers sensitivity to FGFR inhibitors (including   
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	969 : 976	CM	ibitors (including       AZD4547) to GBM models.AZD4547 (
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	GBM	981 : 984	CM	luding       AZD4547) to GBM models.AZD4547 (AstraZen
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR-1	1053 : 1059	CM	d selective inhibitor of FGFR-1, 2       and 3 receptor 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	tyrosine	1084 : 1092	CM	, 2       and 3 receptor tyrosine kinases. Preclinical dat
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	CNS	1135 : 1138	CM	cal data have shown some CNS penetration. Some of    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	1326 : 1333	CM	o assess the efficacy of AZD4547 by measuring the rate   
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR-TACC	1460 : 1469	CM	ioma patients with       FGFR-TACC fusion.Secondary objecti
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	1586 : 1593	CM	, tolerability and PK of AZD4547 in glioma patients      
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	1647 : 1652	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	1670 : 1677	CM	e anti-tumor activity of AZD4547 for patients with recurr
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	1862 : 1867	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	1885 : 1892	CM	e anti-tumor activity of AZD4547 for patients with recurr
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	PFS	1986 : 1989	CM	based on the duration of PFS          -  To further a
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	2024 : 2029	CPR	-  To further assess the anti-tumor activity of AZD4547
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	2047 : 2054	CM	e anti-tumor activity of AZD4547 for patients with recurr
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	2151 : 2158	CM	ased on Overall Survival AZD4547 Exploratory objectives -
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR3-TACC3	2404 : 2415	CM	        diagnosed with a FGFR3-TACC3 or FGFR1-TACC1 fusion po
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR1-TACC1	2419 : 2430	CM	ed with a FGFR3-TACC3 or FGFR1-TACC1 fusion positive glioma p
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IHC	2679 : 2682	CM	            centers, and IHC for FGFR3 hyperexpressio
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR3	2687 : 2692	CM	    centers, and IHC for FGFR3 hyperexpression. The inv
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR3	2768 : 2773	CM	a wide use            of FGFR3 IHC in non participating
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	IHC	2774 : 2777	CM	 use            of FGFR3 IHC in non participating cen
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	3013 : 3020	CM	   Patients will receive AZD4547 at a dose of 80mg bd on 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	alpha	3165 : 3170	CM	=15%, P1: PFS6=35%, with alpha=5% and       power=80%, 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	anti-	3258 : 3263	CPR	be treated. If objective anti-tumor effects       are o
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR3-TACC3	3574 : 3585	CM	reatment, expressing the FGFR3-TACC3 or FGFR1-TACC1          
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR1-TACC1	3589 : 3600	CM	ssing the FGFR3-TACC3 or FGFR1-TACC1              fusion gene
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	0-	3874 : 3876	CPR	ation performance status 0-2 (KPS>50) with no deteri
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	4575 : 4582	CM	ng the whole duration of AZD4547 treatment and at least 7
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Nitrosourea	5387 : 5398	CM	wing:                 -  Nitrosourea within 6 weeks before th
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	CYP3A4	5862 : 5868	CM	nhibitors or inducers of CYP3A4 or 2D6 or substrates of 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	CYP3A4	5893 : 5899	CM	 or 2D6 or substrates of CYP3A4 within the              
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	6039 : 6046	CM	tment in this or another AZD4547 study, or prior randomis
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	6115 : 6122	CM	          study in which AZD4547 is/was under investigati
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR	6176 : 6180	CM	Prior treatment with any FGFR                   inhibi
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	CTCAE	6513 : 6518	CM	eria for Adverse Events (CTCAE) grade 1 at the time of 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	QT	7008 : 7010	CM	                 -  Mean QT interval corrected for h
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ECG	7255 : 7258	CM	or morphology of resting ECG eg, complete            
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	QT	7515 : 7517	CM	alaemia, congenital long QT syndrome, family        
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	QT	7569 : 7571	CM	         history of long QT syndrome or unexplained 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	QT	7700 : 7702	CM	ion known to prolong the QT interval                
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	myocardial	7742 : 7752	CM	           -  History of myocardial infarction, unstable ang
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Alanine	8160 : 8167	CM	0 g/L                 -  Alanine aminotransferase >2.5 ti
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	aminotransferase	8168 : 8184	ASE	              -  Alanine aminotransferase >2.5 times the upper lim
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8223 : 8226	CM	e upper limit of normal (ULN)                 -  Aspa
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Aspartate	8247 : 8256	CM	(ULN)                 -  Aspartate aminotransferase >2.5 ti
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	aminotransferase	8257 : 8273	ASE	            -  Aspartate aminotransferase >2.5 times ULN Total bil
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8285 : 8288	CM	notransferase >2.5 times ULN Total bilirubin >1.5 tim
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	bilirubin	8295 : 8304	CM	ase >2.5 times ULN Total bilirubin >1.5 times ULN          
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8316 : 8319	CM	tal bilirubin >1.5 times ULN                 -  Creat
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Creatinine	8339 : 8349	CM	s ULN                 -  Creatinine >1.5 times ULN concurren
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8361 : 8364	CM	-  Creatinine >1.5 times ULN concurrent with creatini
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8381 : 8391	CM	imes ULN concurrent with creatinine clearance <50 ml/min    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8523 : 8533	CM	ion of                   creatinine clearance is only requir
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	creatinine	8566 : 8576	CM	ce is only required when creatinine is >1.5 times ULN       
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8591 : 8594	CM	creatinine is >1.5 times ULN                 -  Corre
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	calcium	8624 : 8631	CM	            -  Corrected calcium >ULN                 -  
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8633 : 8636	CM	   -  Corrected calcium >ULN                 -  Phosp
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	Phosphate	8656 : 8665	CM	 >ULN                 -  Phosphate >ULN            7. Refra
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	ULN	8667 : 8670	CM	           -  Phosphate >ULN            7. Refractory
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	8905 : 8912	CM	e adequate absorption of AZD4547            8. History of
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	8991 : 8998	CM	r inactive excipients of AZD4547 or drugs with           
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	9067 : 9074	CM	al structure or class to AZD4547            9. Judgment b
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9395 : 9402	CM	e or previous history of retinal pigmented epithelium det
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9766 : 9773	CM	e or previous history of retinal vein occlusion (RVO)    
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	retinal	9854 : 9861	CM	e or previous history of retinal degenerative diseases (e
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	10123 : 10130	CM	          Treatment With AZD4547 for Recurrent Malignant 
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	AZD4547	10332 : 10339	CM	and Clinical Efficacy of AZD4547 in Patients With Relapse
./___Corpus/ClinicalTrials/xml/NCT02824133.xml	FGFR	10400 : 10404	CM	y Glioma Positive for an FGFR Fusion     
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	181 : 185	CM	      body radiotherapy (SBRT) to the liver.          
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	284 : 288	CM	t with pembrolizumab and SBRT.          -  To find out
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	438 : 442	CM	e and being treated with SBRT and pembrolizumab.      
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	PD-1	544 : 548	CM	y to evaluate the use of PD-1 blockade in combination 
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	755 : 759	CM	actic body radiotherapy (SBRT) and       pembrolizumab
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	910 : 914	CM	at for many patients the SBRT therapy will be complete
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	MMR	1508 : 1511	CM	must be mismatch repair (MMR) proficient as determine
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	MMR	1613 : 1616	CM	nohistochemistry for for MMR proteins                
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	MMR	1740 : 1743	CM	           -  Or IHC for MMR proteins must demonstrat
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	MMR	1777 : 1780	CM	 must demonstrate intact MMR proteins            -  P
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	1838 : 1842	CM	nt must be candidate for SBRT to at least one intrahep
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	RECIST	2366 : 2372	CM	surable disease based on RECIST 1.1            -  Fresh 
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	oxaliplatin	2827 : 2838	CM	           irinotecan or oxaliplatin-fluoropyrimidine-based s
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	fluoropyrimidine	2839 : 2855	CM	rinotecan or oxaliplatin-fluoropyrimidine-based systemic treatment
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	3148 : 3152	CM	pleted within 10 days of SBRT treatment initiation    
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	3329 : 3333	CM	in 10 days of initiating SBRT. If the urine test is po
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	4410 : 4414	CM	eks of the initiation of SBRT            -  Prior anti
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	4435 : 4440	CPR	SBRT            -  Prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	4536 : 4540	CM	irst              day of SBRT treatment) or who has no
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	5601 : 5605	CM	           initiation of SBRT            -  Participan
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	TB	5662 : 5664	CM	 known history of active TB (Bacillus Tuberculosis) 
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	5804 : 5809	CPR	ticipant has had a prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	SBRT	5905 : 5909	CM	tudy Day 1 (first day or SBRT treatment) or who has no
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	CNS	7318 : 7321	CM	at least 6 months and no CNS progression has been    
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	thyroxine	7622 : 7631	CM	eplacement therapy (eg., thyroxine, insulin, or physiologic
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8914 : 8919	CPR	ed prior therapy with an anti-PD-1, anti-PD-L1, or anti
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8925 : 8930	CPR	erapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2     
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	anti-	8940 : 8945	CPR	nti-PD-1, anti-PD-L1, or anti-PD-L2              agent.
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	HBsAg	9152 : 9157	CM	ctive Hepatitis B (e.g., HBsAg reactive) or Hepatitis C
./___Corpus/ClinicalTrials/xml/NCT02837263.xml	HCV	9203 : 9206	CM	is C (e.g.,              HCV RNA [qualitative or quan
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SGC	394 : 397	CM	is the most common       SGC histotype observed in me
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	sorafenib	635 : 644	CM	n. A phase II trial with sorafenib carried out in 37 subjec
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	VEGF	832 : 836	CM	. In preclinical models, VEGF seems to contribute to t
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MEC	952 : 955	CM	in particular in ACC and MEC.       Remarkably three 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	VEGFR	1132 : 1137	CM	dy with Inlyta, a potent VEGFR       specific-inhibitor
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	FDA	1175 : 1178	CM	ic-inhibitor approved by FDA as second line treatment
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SGC	1316 : 1319	CM	lapsed and/or metastatic SGC.                       C
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SGC	2128 : 2131	CM	is the       most common SGC histotype observed in me
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	25-	2434 : 2437	CPR	lure, being diagnosed in 25-55% of the patients. Only
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	sorafenib	2740 : 2749	CM	ly a phase II trial with sorafenib has been carried out in 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	6,2-	2907 : 2911	CPR	ate       of 16% (95% CI 6,2-32,0) was observed, 11% i
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MEC	3035 : 3038	CM	ients with an high-grade MEC. In one case the metasta
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	VEGF	3167 : 3171	CM	. In preclinical models, VEGF       seems to contribut
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MEC	3300 : 3303	CM	   particular in ACC and MEC. Remarkably three confir
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	ACC	3597 : 3600	CM	tastatic and progressive ACC patients. Results were 9
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	VEGFR	3724 : 3729	CM	ponse. Inlyta®, a potent VEGFR specific-inhibitor, has 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SGC	4312 : 4315	CM	n relapsed or metastatic SGC, progressed within 6 mon
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	2-	4400 : 4402	CPR	rolled over two years. A 2-stage Simon design will b
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CRTC1-MAML2	4980 : 4991	CM	is will be collected for CRTC1-MAML2 translocation analysis i
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MEC	5018 : 5021	CM	ranslocation analysis in MEC;       MYB-NFIB transloc
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MYB-NFIB	5029 : 5037	CM	n analysis in MEC;       MYB-NFIB translocation analysis i
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	androgen	5069 : 5077	CM	ocation analysis in ACC; androgen receptor and HER2 analys
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	HER2	5091 : 5095	CM	C; androgen receptor and HER2 analysis in SDC and     
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	SDC	5108 : 5111	CM	tor and HER2 analysis in SDC and       adenocarcinoma
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	NOS	5137 : 5140	CM	and       adenocarcinoma NOS.                        
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CT-scan	5600 : 5607	CM	nal measurable lesion by CT-scan or MRI              acco
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MRI	5611 : 5614	CM	ble lesion by CT-scan or MRI              according t
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	RECIST	5641 : 5647	CM	            according to RECIST criteria 1.1 (target les
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	RECIST	6013 : 6019	CM	rogression of disease by RECIST is not required.        
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	dl	6360 : 6362	CM	    -  Hemoglobin >9.0 g/dl            -  Neutrophil
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	bilirubin	6472 : 6481	CM	0/µl            -  Total bilirubin < 1.5 times the upper li
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	AST	6542 : 6545	CM	al            -  ALT and AST < 2.5 x upper limit of n
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	creatinine	6673 : 6683	CM	ses)            -  Serum creatinine <1.5 x upper limit of no
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	ULN	6807 : 6810	CM	kaline phosphatase < 4 x ULN            -  PT-INR/PTT
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	PTT	6832 : 6835	CM	ULN            -  PT-INR/PTT <1.5 x upper limit of no
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	coumadin	6955 : 6963	CM	ed with an agent such as coumadin or heparin will be allow
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	TKI	7969 : 7972	CM	allowed (chemotherapy or TKI)            -  History o
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	NYHA	8042 : 8046	CM	ongestive heart failure >NYHA class 2; active CAD (MI 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CAD	8063 : 8066	CM	re >NYHA class 2; active CAD (MI              more th
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	MI	8068 : 8070	CM	YHA class 2; active CAD (MI              more than 6
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	anti-	8176 : 8181	CPR	s requiring              anti-arrhythmic therapy (beta 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	digoxin	8218 : 8225	CM	herapy (beta blockers or digoxin are permitted) or uncont
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	Ta	9516 : 9518	CM	erficial bladder tumors [Ta, Tis and T1] or any canc
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	anti-	9710 : 9715	CPR	steroids or              anti-epileptics)            - 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	vitamin K	10024 : 10033	CM	gulant therapy with oral vitamin K antagonists            -
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	G-CSF	10421 : 10426	CM	ponse modifiers, such as G-CSF, within 3 week of study 
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	G-CSF	10458 : 10463	CM	n 3 week of study entry [G-CSF              and other h
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CYP3A4	11130 : 11136	CM	nt with drugs inhibiting CYP3A4            -  Current us
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CYP3A4	11217 : 11223	CM	ment with drugs inducing CYP3A4 or CYP1A2               
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	CYP1A2	11227 : 11233	CM	drugs inducing CYP3A4 or CYP1A2                       Ax
./___Corpus/ClinicalTrials/xml/NCT02857712.xml	R	11268 : 11269	CM	             Axitinib in R/M Salivary Gland Cancers
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	95 : 99	CM	ive copies of either the cMYC       (Myelocytomatosis 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	144 : 148	CM	osis oncogene) gene, the HER2 (Human epidermal growth 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	514 : 518	CM	ls       over-expressing cMYC and HER2 genes.        T
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	523 : 527	CM	over-expressing cMYC and HER2 genes.        The iMYC s
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	iMYC	546 : 550	CM	d HER2 genes.        The iMYC study will assess the ac
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	585 : 594	CM	l assess the activity of ibrutinib in cancers of the oesoph
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	anti-	759 : 764	CPR	emotherapies.        Any anti-cancer activity seen will
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	FDG	843 : 846	CM	ith metabolic changes on FDG       (18F-2-fluoro-2-de
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose	854 : 903	CM	ic changes on FDG       (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) - PET (positron emissio
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	1707 : 1711	CM	cer biopsied to test for cMYC       and HER2 amplifica
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	1722 : 1726	CM	 test for cMYC       and HER2 amplification, as well a
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	1893 : 1902	CM	nts will be treated with ibrutinib until progression of the
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	2097 : 2106	CM	 dose       single-agent ibrutinib delivered orally at a do
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	2449 : 2458	CM	ive the study drug       ibrutinib.        A Phase 2 study 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	2910 : 2914	CM	 disease. In the case of HER2 positive tumours,       
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	2994 : 2998	CM	herapy with or without a HER2 targeted agent is allowe
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	3131 : 3135	CM	rescreening to establish cMYC and HER2 status (which m
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	3140 : 3144	CM	ng to establish cMYC and HER2 status (which may occur 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	4058 : 4062	CM	sted for both            cMYC and HER2 amplification. 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	4067 : 4071	CM	both            cMYC and HER2 amplification. If there 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	c-MYC	4434 : 4439	CM	 cell            number, c-MYC copy number variation (b
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PCR	4482 : 4485	CM	tion (by digital droplet PCR) and blood-borne biomark
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	cMYC	4900 : 4904	CM	ding to the the patients cMYC and            HER2 stat
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	4920 : 4924	CM	ents cMYC and            HER2 status.             If t
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PIS	5009 : 5012	CM	 be given the main study PIS and ICF that has        
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	5797 : 5801	CM	ample details, c-MYC and HER2 status if re-tested     
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ECG	6146 : 6149	CM	          blood pressure ECG Tumour biopsy* Tumour as
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	RECIST	6185 : 6191	CM	psy* Tumour assessments (RECIST v1.1), consisting of eit
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	CT	6239 : 6241	CM	ither            staging CT or MRI imaging FDG-PET s
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	MRI	6245 : 6248	CM	           staging CT or MRI imaging FDG-PET scan* Co
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	c-MYC	6473 : 6478	CM	Tumor Cell (CTC) number, c-MYC copy number variation (b
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PCR	6532 : 6535	CM	gital            droplet PCR) and bloodborne biomarke
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ECG	8243 : 8246	CM	 visits).             An ECG at baseline and on compl
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	CTC	8530 : 8533	CM	sis            including CTC number, c-MYC copy numbe
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	c-MYC	8542 : 8547	CM	   including CTC number, c-MYC copy number variation (b
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	8790 : 8799	CM	sess pharmacokinetics of ibrutinib on cycle 1 day 8 (predos
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	CT	8962 : 8964	CM	 status of disease using CT or MRI imaging at week 8
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	MRI	8968 : 8971	CM	s of disease using CT or MRI imaging at week 8 and th
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	PET	9053 : 9056	CM	         Assessment with PET CT scan at baseline, day
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	CT	9057 : 9059	CM	     Assessment with PET CT scan at baseline, day 14
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9534 : 9543	CM	y 14 (in all patients on ibrutinib) at week 8 (on those pat
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9599 : 9608	CM	responding to            ibrutinib) on discontinuation of s
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ibrutinib	9701 : 9710	CM	progressed            on ibrutinib)             Treatment d
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	adeno	11385 : 11390	CM	d inoperable squamous or adeno              carcinoma o
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	11591 : 11595	CM	            disease. For HER2 positive tumours documen
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	11703 : 11707	CM	otherapy with or without HER2 directed therapy.       
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	11749 : 11753	CM	.            -  c-MYC or HER2 gene amplification as de
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	gonadotropin	12516 : 12528	CM	n chorionic              gonadotropin [b-hCG]) or urine pregna
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	b-hCG	12530 : 12535	CM	           gonadotropin [b-hCG]) or urine pregnancy tes
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	12771 : 12775	CM	of c-MYC or              HER2 gene amplification.     
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	0-	12862 : 12864	CPR	ECOG) performance status 0-2, minimum life expectanc
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	alanine	13296 : 13303	CM	    transfusion support) alanine aminotransferase (ALT) a
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aminotransferase	13304 : 13320	CM	sfusion support) alanine aminotransferase (ALT) and aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ALT	13322 : 13325	CM	lanine aminotransferase (ALT) and aspartate aminotran
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aspartate	13331 : 13340	CM	inotransferase (ALT) and aspartate aminotransferase (AST) ≤
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	aminotransferase	13341 : 13357	ASE	rase (ALT) and aspartate aminotransferase (AST) ≤3         x upper
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	bilirubin	13411 : 13420	CM	it of normal (ULN) total bilirubin ≤1.5 x ULN unless biliru
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ULN	13428 : 13431	CM	) total bilirubin ≤1.5 x ULN unless bilirubin rise is
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	bilirubin	13439 : 13448	CM	irubin ≤1.5 x ULN unless bilirubin rise is due to         G
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	creatinine	13522 : 13532	CM	non-hepatic origin serum creatinine ≤2 x ULN or estimated   
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	creatinine	13563 : 13573	CM	ULN or estimated         creatinine clearance (CCr) ≥30 mL/m
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	RECIST	13664 : 13670	CM	le target lesion, as per RECIST criteria 1.1          Ex
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER-2	14132 : 14137	CM	e histology for c-MYC or HER-2 amplification testing   
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	myocardial	14311 : 14321	CM	estive heart failure, or myocardial infarction within 6 mont
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	ECG	14550 : 14553	CM	        -  Patients with ECG abnormalities considered
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	QT	14698 : 14700	CM	on of the rate-corrected QT interval (QTc)          
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	vitamin K	15204 : 15213	CM	g anticoagulation with a vitamin K antagonist            - 
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	P450	15263 : 15267	CM	 Requiring use of strong P450 (CYP) 3A4 inhibitors    
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	Ibrutinib	15604 : 15613	CM	roof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplif
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	c-MYC	15617 : 15622	CM	pt Study of Ibrutinib in c-MYC and HER2 Amplified Oesop
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	15627 : 15631	CM	f Ibrutinib in c-MYC and HER2 Amplified Oesophagogastr
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	Ibrutinib	15709 : 15718	CM	roof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplif
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	c-MYC	15722 : 15727	CM	pt Study of Ibrutinib in c-MYC and HER2 Amplified Oesop
./___Corpus/ClinicalTrials/xml/NCT02884453.xml	HER2	15732 : 15736	CM	f Ibrutinib in c-MYC and HER2 Amplified Oesophagogastr
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	354 : 358	CM	rowth factor receptor 2 (HER2, ErbB2) is a transmembra
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	ErbB2	360 : 365	CM	factor receptor 2 (HER2, ErbB2) is a transmembrane tyro
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	tyrosine	386 : 394	CM	rbB2) is a transmembrane tyrosine       kinase receptor an
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	10-	454 : 457	CPR	xpressed or amplified in 10-20% of gastric cancer. Re
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	ToGA	528 : 532	CM	umab for Gastric Cancer (ToGA) study reported the clin
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	595 : 599	CM	of trastuzumab for       HER2 positive gastric cancer 
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	856 : 860	CM	 the survival outcome of HER2 positive gastric       c
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	PD-1	1243 : 1247	CM	 the interaction between PD-1 and its ligands, PD-L1 a
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	PD-L1	1265 : 1270	CM	en PD-1 and its ligands, PD-L1 and PD-L2.        Based 
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	PD-L2	1275 : 1280	CM	d its ligands, PD-L1 and PD-L2.        Based on strong 
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	1369 : 1374	CPR	mbining trastuzumab with anti-PD-1       inhibitor in H
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	1398 : 1402	CM	-PD-1       inhibitor in HER2 positive cancer, we sugg
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	cisplatin	1604 : 1613	CM	zumab, capecitabine, and cisplatin) in patients with HER2 p
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	1632 : 1636	CM	platin) in patients with HER2 positive gastric cancer.
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	1722 : 1726	CM	 Criteria:            1. HER2 positive advanced gastri
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	RECIST	1968 : 1974	CM	surable disease based on RECIST 1.1.            5. perfo
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	2982 : 2987	CPR	      5. Has had a prior anti-cancer monoclonal antibod
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3883 : 3888	CPR	ed prior therapy with an anti-PD-1, anti-PD-L1, or anti
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3894 : 3899	CPR	erapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agen
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	anti-	3909 : 3914	CPR	nti-PD-1, anti-PD-L1, or anti-PD-L2 agent.           12
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	4118 : 4122	CM	brolizumab, Trastuzumab, HER2 Positive Gastric Cancer 
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	Cisplatin	4255 : 4264	CM	zumab, Capecitabine, and Cisplatin in HER2 Positive Gastric
./___Corpus/ClinicalTrials/xml/NCT02901301.xml	HER2	4268 : 4272	CM	tabine, and Cisplatin in HER2 Positive Gastric Cancer 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-5422	13 : 21	CM	             SNX-5422 is a prodrug of SNX-2112
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-2112	38 : 46	CM	SNX-5422 is a prodrug of SNX-2112, a potent, highly select
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	201 : 210	CM	itors may overcome       ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-5422	309 : 317	CM	er the       addition of SNX-5422 to an established dose o
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	344 : 353	CM	o an established dose of ibrutinib will result in the remov
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	398 : 401	CM	removal of       mutated BTK from blood mononuclear c
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	500 : 503	CM	n of       subjects with CLL                       Ch
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	694 : 697	CM	 transplantation.        BTK is a critical kinase in 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	796 : 799	CM	ay is amplified       in CLL and results in amplifica
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	anti-	850 : 855	CPR	ion of proliferation and anti-apoptotic signals. By    
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	894 : 897	CM	als. By       inhibiting BTK, ibrutinib eliminates th
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	899 : 908	CM	By       inhibiting BTK, ibrutinib eliminates the activatio
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1029 : 1038	CM	gnals. While response to ibrutinib has been high with thera
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	1299 : 1302	CM	. One is by mutations in BTK, which both decrease ibr
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	1349 : 1352	CM	ibrutinib's affinity for BTK, and       also changes 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-5422	1500 : 1508	CM	 whether the addition of SNX-5422 to an established dose o
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1535 : 1544	CM	o an established dose of ibrutinib will reduce       mutate
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	1571 : 1574	CM	ill reduce       mutated BTK from CLL cells and/or pr
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	1580 : 1583	CM	e       mutated BTK from CLL cells and/or prevents or
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	1659 : 1662	CM	n of subjects with       CLL.        This is an open-
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX‑5422	1702 : 1710	CM	s an open-label study of SNX‑5422 combined with ibrutinib.
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1725 : 1734	CM	f SNX‑5422 combined with ibrutinib. In each 28 day cycle,  
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX‑5422	1764 : 1772	CM	each 28 day cycle,       SNX‑5422 will be dosed in the mor
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	7‑	1850 : 1852	CPR	r 21 days, followed by a 7‑day       drug‑free perio
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	1925 : 1934	CM	ue to receive daily oral ibrutinib at their established    
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	2182 : 2185	CM	       -  A diagnosis of CLL as defined by IWCLL 2008
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	2265 : 2274	CM	atment with              ibrutinib without evidence of dise
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	2397 : 2406	CM	a therapy (not including ibrutinib)            -  Presence 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	BTK	2442 : 2445	CM	  -  Presence of mutated BTK in ≥ 4% of peripheral bl
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CLL	2489 : 2492	CM	ral blood or bone marrow CLL cells, or ≥1%           
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	3120 : 3129	CM	periencing toxicity with ibrutinib            -  Prior trea
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	cytochrome	3482 : 3492	CM	lism by the              cytochrome P450 (CYP) 3A4 isoenzyme
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	CYP	3499 : 3502	CM	        cytochrome P450 (CYP) 3A4 isoenzyme within 3 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	isoenzyme	3508 : 3517	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-5422	3580 : 3588	CM	stration of              SNX-5422            -  Screening 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	QT	3729 : 3731	CM	for developing prolonged QT interval unless correcte
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX-5422	3818 : 3826	CM	s prior to first dose of SNX-5422            -  Patients w
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	alcohol	4449 : 4456	CM	B.            -  Current alcohol dependence or drug abuse
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	ibrutinib	4545 : 4554	CM	al treatment (except for ibrutinib) from 30 days prior to t
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Ibrutinib	5036 : 5045	CM	ctivity of SNX-5422 Plus Ibrutinib in CLL          A Phase 
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	SNX‑5422	5093 : 5101	CM	e 1, Open-label Study of SNX‑5422 and Ibrutinib in Chronic
./___Corpus/ClinicalTrials/xml/NCT02914327.xml	Ibrutinib	5106 : 5115	CM	el Study of SNX‑5422 and Ibrutinib in Chronic Lymphocytic L
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	13 : 19	CM	             CK-101 is a novel, potent, smal
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	tyrosine	55 : 63	CM	, potent, small molecule tyrosine kinase inhibitor (TKI) t
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	317 : 323	CM	ty       profile of oral CK-101; to determine the maximu
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	MTD	366 : 369	CM	 maximum tolerated dose (MTD) and/or recommended     
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	424 : 430	CM	se 2 dose (RP2D) of oral CK-101; to assess the safety an
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	469 : 475	CM	e safety and efficacy of CK-101 in previously       trea
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	504 : 509	CM	previously       treated NSCLC patients known to have t
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	T790M	537 : 542	CM	tients known to have the T790M EGFR mutation.          
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	543 : 547	CM	 known to have the T790M EGFR mutation.               
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	686 : 692	CM	cacy study       of oral CK-101 administered daily in as
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	956 : 960	CM	e documented evidence of EGFR       T790M mutation and
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	1026 : 1030	CM	atment with a first-line EGFR inhibitor.              
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	1373 : 1377	CM	able and where targeting EGFR              may be appr
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	1861 : 1865	CM	ents must have confirmed EGFR T790M mutation-positive 
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	2084 : 2090	CM	 prior to treatment with CK-101            -  History of
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	platinum	2505 : 2513	CM	pecia and Grade 2, prior platinum-therapy related neuropat
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	2687 : 2693	CM	qual to 14 days prior to CK-101              administrat
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	3262 : 3268	CM	had prior treatment with CK-101 or other              th
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	EGFR	3325 : 3329	CM	eration TKIs that target EGFR T790M mutation-positive 
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	NSCLC	3354 : 3359	CM	 T790M mutation-positive NSCLC, or have evidence       
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	3486 : 3492	CM	     Phase I/II Study of CK-101 in NSCLC Patients and Ot
./___Corpus/ClinicalTrials/xml/NCT02926768.xml	CK-101	3653 : 3659	CM	 Ascending Doses of Oral CK-101 in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	13 : 20	CM	             SC10914 is a potent selective PA
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	PARP-1	43 : 49	CM	14 is a potent selective PARP-1 and PARP-2 inhibitor. Th
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	PARP-2	54 : 60	CM	ent selective PARP-1 and PARP-2 inhibitor. This study ai
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	205 : 212	CM	ncreasing doses of       SC10914 when administered orally
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	324 : 331	CM	  safety and efficacy of SC10914 in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	ATM	404 : 407	CM	tive expression       of ATM or BRCA1 or BRCA2 mutati
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	BRCA1	411 : 416	CM	pression       of ATM or BRCA1 or BRCA2 mutation will b
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	BRCA2	420 : 425	CM	      of ATM or BRCA1 or BRCA2 mutation will be evaluat
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	Dose(RP2D)	516 : 526	CM	     Recommended Phase 2 Dose(RP2D).                        
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	18-	639 : 642	CPR	nsent            -  Aged 18-70 years            -  Do
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	ATM	1055 : 1058	CM	           expression of ATM or BRCA1 or BRCA2 mutati
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	BRCA1	1062 : 1067	CM	    expression of ATM or BRCA1 or BRCA2 mutation       
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	BRCA2	1071 : 1076	CM	ssion of ATM or BRCA1 or BRCA2 mutation            -  E
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	PARP	1528 : 1532	CM	revious treatment with a PARP inhibitor            -  
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	anti-	1575 : 1580	CPR	    -  Patients accepted anti-cancer therapy including 
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	mitomycin	1893 : 1902	CM	gs used eg,. 6 weeks for mitomycin C or nitrosourea)       
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	nitrosourea	1908 : 1919	CM	weeks for mitomycin C or nitrosourea)            -  With seri
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	CTCAE	2163 : 2168	CM	      -  With persistent CTCAE ≧grade 2 toxicities (exc
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	2438 : 2445	CM	              A Study of SC10914 in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02940132.xml	SC10914	2607 : 2614	CM	 Preliminary Efficacy of SC10914 in Patients With Advance
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	131 : 135	CM	     cancer cells called EGFR mutations. Mutated EGFR 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	155 : 159	CM	 EGFR mutations. Mutated EGFR is important in the grow
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	256 : 260	CM	shown that patients with EGFR mutation-positive lung c
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	351 : 355	CM	ed therapy drugs such as EGFR inhibitors than with sta
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	539 : 548	CM	 to the first-generation EGFR-TKIs (erlotinib and gefitinib
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	550 : 559	CM	st-generation EGFR-TKIs (erlotinib and gefitinib), indicati
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	gefitinib	564 : 573	CM	EGFR-TKIs (erlotinib and gefitinib), indicating the       e
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	687 : 696	CM	nitial response to       EGFR-TKIs, acquired resistance is 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	826 : 830	CM	ipto-1 overexpression in EGFR mutant NSCLC       contr
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	838 : 843	CM	xpression in EGFR mutant NSCLC       contributes to the
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	893 : 902	CM	 intrinsic resistance to EGFR-TKIs through activation of th
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	929 : 932	CM	hrough activation of the SRC oncogene.       They hav
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	1010 : 1019	CM	ion of an EGFR-TKI (both erlotinib and osimertinib) and a  
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	1194 : 1203	CM	ombination of two drugs, dasatinib and osimertinib, to over
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	1253 : 1262	CM	come       resistance to EGFR-TKIs. Osimertinib (AZD9291) i
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	1365 : 1369	CM	y blocks the activity of EGFR mutants, but spares that
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	1495 : 1499	CM	not only the sensitizing EGFR mutations, but also     
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	T790M	1530 : 1535	CM	ions, but also       the T790M mutant, which is the mos
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	1603 : 1612	CM	 of acquired resistance. Dasatinib is a       potent, orall
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ABL1	1649 : 1653	CM	potent, orally available ABL1/SRC TKI, approved for th
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	1654 : 1657	CM	t, orally available ABL1/SRC TKI, approved for the tr
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	imatinib	1765 : 1773	CM	ine and in patients with imatinib-resistant disease or int
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	1959 : 1968	CM	ding the highest dose of dasatinib that can be       given 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2097 : 2106	CM	cts seen       by giving dasatinib at different dose levels
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2184 : 2193	CM	ring the levels of       dasatinib and osimertinib in blood
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2316 : 2325	CM	ts of the combination of dasatinib and osimertinib and dete
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	dasatinib	2493 : 2502	CM	the       combination of dasatinib and osimertinib.        
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	2749 : 2753	CM	h       factor receptor (EGFR) mutations are one of th
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	2862 : 2867	CM	-small cell lung cancer (NSCLC), especially in adenocar
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	2935 : 2939	CM	e most       predominant EGFR mutations are in-frame d
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	L858R	2988 : 2993	CM	deletions in exon-19 and L858R missense mutation, and  
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	tyrosine	3099 : 3107	CM	ive to the EGFR-targeted tyrosine kinase       inhibitors 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	3273 : 3282	CM	 to the first generation EGFR-TKIs (erlotinib and gefitinib
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	3284 : 3293	CM	st generation EGFR-TKIs (erlotinib and gefitinib),       in
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	gefitinib	3298 : 3307	CM	EGFR-TKIs (erlotinib and gefitinib),       indicating the e
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	3421 : 3430	CM	nitial       response to EGFR-TKIs, acquired resistance is 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	3563 : 3572	CM	o overcome resistance to EGFR-TKIs. The investigators have 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	3650 : 3654	CM	ipto-1 overexpression in EGFR mutant NSCLC contributes
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	3662 : 3667	CM	xpression in EGFR mutant NSCLC contributes to the intri
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR-TKIs	3717 : 3726	CM	nsic       resistance to EGFR-TKIs through SRC activation. 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	3735 : 3738	CM	nce to EGFR-TKIs through SRC activation. They have al
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	erlotinib	3818 : 3827	CM	 an       EGFR-TKI (both erlotinib and AZD9291) and a Src i
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	vitro	3880 : 3885	CM	bitor are synergistic in vitro and in       vivo in Cri
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	4026 : 4030	CM	y blocks the activity of EGFR mutants but spares that 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	AZD9291	4098 : 4105	CM	advantage       of using AZD9291 is that it inhibits not 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	exon-19	4150 : 4157	CM	 not only the mutants of exon-19 deletion and L858R, but 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	L858R	4171 : 4176	CM	 of exon-19 deletion and L858R, but       also the T790
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	T790M	4197 : 4202	CM	858R, but       also the T790M mutant, which is the mos
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	4270 : 4279	CM	 of acquired resistance. Dasatinib       is a potent, orall
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ABL1	4316 : 4320	CM	potent, orally available ABL1/SRC TKI, approved for th
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	SRC	4321 : 4324	CM	t, orally available ABL1/SRC TKI, approved for the tr
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	imatinib	4432 : 4440	CM	ine and in patients with imatinib-resistant disease or int
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	4931 : 4936	CM	cally confirmed advanced NSCLC. Patients              w
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	5141 : 5145	CM	ious biopsy to determine EGFR              mutation st
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	5421 : 5425	CM	 Presence of sensitizing EGFR mutations (deletion in e
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	L858R	5458 : 5463	CM	ns (deletion in exon 19, L858R in exon 21, G719X,      
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	G719X	5476 : 5481	CM	on 19, L858R in exon 21, G719X,              and L861Q)
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	L861Q	5500 : 5505	CM	 G719X,              and L861Q). Patients with the T790
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	T790M	5526 : 5531	CM	861Q). Patients with the T790M mutation will also be el
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	5605 : 5609	CM	 prior treatment with an EGFR TKI for the advanced NSC
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	NSCLC	5631 : 5636	CM	GFR TKI for the advanced NSCLC.            -  ECOG perf
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	0-	5679 : 5681	CPR	OG performance status of 0-2.            -  Patients
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	RECIST	5739 : 5745	CM	ve measurable disease by RECIST criteria, defined as at 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	CT	5969 : 5971	CM	or as >10 mm with spiral CT scan.              See S
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	CTCAE	6238 : 6243	CM	eria for Adverse Events (CTCAE)              version 4.
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	bilirubin	6439 : 6448	CM	nts > 100 x 109/L; serum bilirubin < 2 x ULN; alanine      
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	ULN	6455 : 6458	CM	L; serum bilirubin < 2 x ULN; alanine              am
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	alanine	6460 : 6467	CM	rum bilirubin < 2 x ULN; alanine              aminotransf
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	aspartate	6508 : 6517	CM	inotransferase (ALT) and aspartate aminotransferase (AST) <
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	aminotransferase	6518 : 6534	ASE	rase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	creatinine	6611 : 6621	CM	r metastases; calculated creatinine clearance > 50 mL/min). 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	myocardial	6691 : 6701	CM	ontrolled arrhythmia; no myocardial infarction in the last 6
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	nitrosoureas	7109 : 7121	CM	ous 4 weeks (6 weeks for nitrosoureas or mitomycin)           
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	mitomycin	7125 : 7134	CM	eeks for nitrosoureas or mitomycin)              before tre
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	pericardial	7930 : 7941	CM	           -  Pleural or pericardial effusions of any grade a
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	pericardial	8037 : 8048	CM	  diagnosed with pleural/pericardial effusion of any grade re
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	WOCBP	8513 : 8518	CM	 childbearing potential (WOCBP) must              have 
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	IU	8608 : 8610	CM	 (minimum sensitivity 25 IU/L or              equiva
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	HCG	8649 : 8652	CM	     equivalent units of HCG) within 24 hours prior t
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	anti-	10231 : 10236	CPR	 one year (e.g. acquired anti-factor                   
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	VII	10261 : 10264	CM	factor                   VII antibodies)            -
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	10448 : 10457	CM	y.                       Dasatinib and Osimertinib (AZD9291
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	10528 : 10532	CM	ll Cell Lung Cancer With EGFR Mutations               
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	Dasatinib	10577 : 10586	CM	     Phase I/II Study of Dasatinib and Osimertinib (AZD9291
./___Corpus/ClinicalTrials/xml/NCT02954523.xml	EGFR	10671 : 10675	CM	ll Cell Lung Cancer With EGFR Mutations     
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	139 : 146	CM	m is the group receiving ODM-201. The group receiving and
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	168 : 176	CM	201. The group receiving androgen-deprivation therapy (ADT
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	303 : 310	CM	e is to demonstrate that ODM-201 produces prostate-specif
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	300-	690 : 694	CPR	 be administered as oral 300-mg tablets. The dose of s
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	300-	782 : 786	CPR	600 milligrams (mg) (2 x 300-mg tablets) twice daily (
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	874 : 881	CM	. It is recommended that ODM-201 be taken with food.     
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	979 : 986	CM	 may continue to receive ODM-201 at the       discretion 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-	1218 : 1223	CPR	tion therapy.        Any anti-cancer therapy other than
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	1410 : 1418	CM	 stage of the disease is androgen deprivation therapy (ADT
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-androgen	1594 : 1607	CM	24 weeks with 4 weeks of anti-androgen to prevent flare.       
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	leuprolide	1647 : 1657	CM	re.        This includes leuprolide, goserelin, triptorelin,
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	1850 : 1857	CM	e is to demonstrate that ODM-201 produces prostate-specif
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	2128 : 2135	CM	 document the effects of ODM-201 compared to ADT in terms
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	EORTC	2292 : 2297	CM	ptom scale of            EORTC QLQ PR25 at 24 weeks;   
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PR25	2302 : 2306	CM	 of            EORTC QLQ PR25 at 24 weeks;          - 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	2359 : 2366	CM	 document the effects of ODM-201 compared to ADT in terms
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	EORTC	2466 : 2471	CM	rmonal therapy, based on EORTC QLQ C30 and PR25 at 24 w
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PR25	2484 : 2488	CM	sed on EORTC QLQ C30 and PR25 at 24 weeks;          - 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	2540 : 2547	CM	o document the effect of ODM-201 on PSA complete response
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PSA	2551 : 2554	CM	the effect of ODM-201 on PSA complete response at 24 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	2678 : 2685	CM	o document the effect of ODM-201 on objective response ra
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	RECIST	2753 : 2759	CM	patients            with RECIST 1.1 measurable disease a
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	2851 : 2858	CM	fety and tolerability of ODM-201 vs. ADT in subjects who 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	3001 : 3008	CM	 document the effects of ODM-201 on androgen deprivations
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	3012 : 3020	CM	he effects of ODM-201 on androgen deprivations symptoms us
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	3194 : 3201	CM	 continue treatment with ODM-201            beyond the pr
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PSA	3368 : 3371	CM	a ≥       80% decline in PSA measurement taken at wee
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	3461 : 3468	CM	t       baseline, in the ODM-201 study arm. The ADT arm i
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	QLQ-PR25	3632 : 3640	CM	ptoms scale of the EORTC QLQ-PR25 at 24 weeks            c
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	3692 : 3699	CM	pared to baseline in the ODM-201 study arm. A 10-point di
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	10-	3713 : 3716	CPR	the ODM-201 study arm. A 10-point difference is regar
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	RECIST	3857 : 3863	CM	4 weeks in patients with RECIST 1.1 measurable disease a
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PSA	3922 : 3925	CM	    baseline          -  PSA response at 24 weeks def
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	4279 : 4287	CM	 continuous              androgen-deprivation therapy (ADT
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Tc	4620 : 4622	CM	nce imaging (MRI) and/or Tc bone scintigraphy.      
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	testosterone	4799 : 4811	CM	d            -  Baseline testosterone ≥ 8 nmol/L or 230 ng/dL 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	dL	4833 : 4835	CM	one ≥ 8 nmol/L or 230 ng/dL            -  Two subseq
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	PSA	4865 : 4868	CM	       -  Two subsequent PSA values ≥ 2 ng/ml, taken 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	2-	4904 : 4906	CPR	 ng/ml, taken at minimum 2-week interval, with the s
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	0-	5039 : 5041	CPR	rformance status (PS) of 0-1            -  G8 score 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	dl	5368 : 5370	CM	     hemoglobin ≥ 10.0 g/dl, platelets ≥ 100 10exp9/
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	creatinine	5437 : 5447	CM	Adequate renal function: creatinine clearance/eGFR within no
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	eGFR	5458 : 5462	CM	on: creatinine clearance/eGFR within normal limits to 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Bilirubin	5628 : 5637	CM	patic function:          Bilirubin: total bilirubin ≤ to 1.
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	bilirubin	5645 : 5654	CM	        Bilirubin: total bilirubin ≤ to 1.5 X upper limit o
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ULN	5689 : 5692	CM	X upper limit of normal (ULN)            -  Aspartate
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Aspartate	5708 : 5717	CM	rmal (ULN)            -  Aspartate aminotransferase (AST) a
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	aminotransferase	5718 : 5734	ASE	            -  Aspartate aminotransferase (AST) and/or Alanine ami
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Alanine aminotransferase(ALT)	5748 : 5777	CM	transferase (AST) and/or Alanine aminotransferase(ALT) ≤ 2.5 X ULN            -
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ULN	5786 : 5789	CM	transferase(ALT) ≤ 2.5 X ULN            -  Normal car
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	12-	5859 : 5862	CPR	ing to local standard by 12-lead Electrocardiogram (E
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	12-	5928 : 5931	CPR	 (complete, standardized 12-lead recording)          
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ICH	6152 : 6155	CM	 Practices              (ICH/GCP), and national/local
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	GCP	6156 : 6159	CM	ctices              (ICH/GCP), and national/local reg
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	GnRH	6579 : 6583	CM	monal manipulation, e.g. GnRH              agonists, G
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	GnRH	6607 : 6611	CM	H              agonists, GnRH antagonists, anti-androg
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-	6625 : 6630	CPR	nists, GnRH antagonists, anti-androgens, oestrogens, 5α
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	5α-reductase	6653 : 6665	CM	i-androgens, oestrogens, 5α-reductase inhibitor). For         
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	6885 : 6893	CM	tional agents that block androgen synthesis or block andro
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	androgen	6913 : 6921	CM	rogen synthesis or block androgen              receptor   
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	anti-	7004 : 7009	CPR	s that may have hormonal anti-prostate cancer activity 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	glucocorticoids	7143 : 7158	CM	-  Has received systemic glucocorticoids within 24 weeks prior to
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	glucocorticoids	7243 : 7258	CM	cted to require systemic glucocorticoids during the study period 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	pTa	8436 : 8439	CM	       layer (i.e. pTis, pTa, and pT1) is allowed, as
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	pT1	8445 : 8448	CM	yer (i.e. pTis, pTa, and pT1) is allowed, as well as 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Myocardial	8707 : 8717	CM	including:            -  Myocardial infarction within six mo
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	NYHA	9143 : 9147	CM	congestive heart failure NYHA class 3 or 4 in the past
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Hg	9752 : 9754	CM	c blood pressure >170 mm Hg              or diastoli
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Hg	9805 : 9807	CM	 blood pressure > 105 mm Hg at the screening visit  
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	9844 : 9851	CM	ening visit              ODM-201 vs Androgen Deprivation 
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Androgen	9855 : 9863	CM	              ODM-201 vs Androgen Deprivation Therapy in H
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	ODM-201	9972 : 9979	CM	Open-Label Study of Oral ODM-201 vs. Androgen Deprivation
./___Corpus/ClinicalTrials/xml/NCT02972060.xml	Androgen	9984 : 9992	CM	tudy of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	13 : 21	CM	             SNX-5422 is a prodrug of SNX-2112
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-2112	38 : 46	CM	SNX-5422 is a prodrug of SNX-2112, a potent, highly select
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	201 : 210	CM	itors may overcome       ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	309 : 317	CM	er the       addition of SNX-5422 to an established dose o
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	344 : 353	CM	o an established dose of ibrutinib will provide clinical re
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	457 : 466	CM	t have not progressed on ibrutinib after 18 months of      
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	568 : 571	CM	ression of subjects with CLL.                       C
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	tyrosine	860 : 868	CM	oduction of the Bruton's tyrosine kinase (BTK)       inhib
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	BTK	877 : 880	CM	ruton's tyrosine kinase (BTK)       inhibitor ibrutin
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	898 : 907	CM	se (BTK)       inhibitor ibrutinib.        While response t
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	934 : 943	CM	       While response to ibrutinib has been high with thera
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	1296 : 1305	CM	ty on single agent       ibrutinib has not been reported. S
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	1579 : 1588	CM	es associated with       ibrutinib will result in more dura
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	BTK	1733 : 1736	CM	is by mutations in       BTK, the other is through a 
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	BTK	1820 : 1823	CM	ate downstream target of BTK,       PLCγ2. SNX-5422 i
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	PLCγ2	1831 : 1836	CM	eam target of BTK,       PLCγ2. SNX-5422 is a prodrug o
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	1838 : 1846	CM	get of BTK,       PLCγ2. SNX-5422 is a prodrug of SNX-2112
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-2112	1863 : 1871	CM	SNX-5422 is a prodrug of SNX-2112, a potent, highly select
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2026 : 2035	CM	itors may       overcome ibrutinib resistance in Mantle cel
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	2134 : 2142	CM	 whether the addition of SNX-5422 to an established dose o
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2169 : 2178	CM	o an established dose of ibrutinib will provide clinical   
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2282 : 2291	CM	t have not progressed on ibrutinib after 18       months of
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX‑5422	2359 : 2367	CM	   Subjects will receive SNX‑5422 (56 mg/m2) in the mornin
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	m2	2375 : 2377	CM	 receive SNX‑5422 (56 mg/m2) in the morning once eve
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	7‑	2459 : 2461	CPR	   doses), followed by a 7‑day drug‑free period. Sub
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2534 : 2543	CM	receive daily oral       ibrutinib at their established dos
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CLL	2756 : 2759	CM	       -  A diagnosis of CLL as defined by IWCLL 2008
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	2839 : 2848	CM	atment with              ibrutinib for at least 18 months w
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	3033 : 3042	CM	a therapy (not including ibrutinib)            -  Life expe
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	3527 : 3536	CM	periencing toxicity with ibrutinib            -  Prior trea
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	cytochrome	3889 : 3899	CM	lism by the              cytochrome P450 (CYP) 3A4 isoenzyme
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	CYP	3906 : 3909	CM	        cytochrome P450 (CYP) 3A4 isoenzyme within 3 
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	isoenzyme	3915 : 3924	CM	ytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	3987 : 3995	CM	stration of              SNX-5422            -  Screening 
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	QT	4136 : 4138	CM	for developing prolonged QT interval unless correcte
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	SNX-5422	4225 : 4233	CM	s prior to first dose of SNX-5422            -  Patients w
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	alcohol	4697 : 4704	CM	B.            -  Current alcohol dependence or drug abuse
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	ibrutinib	4793 : 4802	CM	al treatment (except for ibrutinib) from 30 days prior to t
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	Ibrutinib	5320 : 5329	CM	o an Established Dose of Ibrutinib in CLL               A P
./___Corpus/ClinicalTrials/xml/NCT02973399.xml	Ibrutinib	5400 : 5409	CM	udy of SNX‑5422 Added to Ibrutinib in Chronic Lymphocytic L
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	70 : 77	CM	o assess the efficacy of MGCD516 in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	295 : 302	CM	te the safety profile of MGCD516 by assessing adverse eve
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	CTCAE	387 : 392	CM	ational Cancer Institute CTCAE version 4.0 criteria) in
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	501 : 508	CM	o assess the efficacy of MGCD516 in patients with advance
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	doxorubicin	1450 : 1461	CM	n advanced disease, with doxorubicin or the       combination
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	gemcitabine	1490 : 1501	CM	the       combination of gemcitabine and docetaxel eliciting 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	docetaxel	1506 : 1515	CM	ation of gemcitabine and docetaxel eliciting objective resp
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MPNST	2158 : 2163	CM	f 4 each              of MPNST, synovial sarcoma, alveo
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	RECIST	2772 : 2778	CM	ve measurable disease by RECIST criteria version 1.1.   
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	3570 : 3577	CM	 currently available for MGCD516 in patients less than 18
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	ECOG	3769 : 3773	CM	ents must demonstrate an ECOG performance status of 0 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Creatinine	4025 : 4035	CM	0/mm3                 -  Creatinine ≤ 1.5 times upper limit 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	creatinine	4084 : 4094	CM	 of normal OR Calculated creatinine clearance >             
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	bilirubin	4160 : 4169	CM	                -  Total bilirubin ≤ 1.5 times upper limit 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	AST	4223 : 4226	CM	ormal                 -  AST/ALT ≤ 1.5 times upper li
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	ALT	4227 : 4230	CM	l                 -  AST/ALT ≤ 1.5 times upper limit 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MUGA	4937 : 4941	CM	oracic echocardiogram or MUGA scan showing a normal le
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	5042 : 5049	CM	       -  The effects of MGCD516 on the developing human 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	5761 : 5768	CM	nths after completion of MGCD516 administration. If patie
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	mitomycin	6296 : 6305	CM	rosureas or              mitomycin within the 42 days prior
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	H2	7082 : 7084	CM	roton pump inhibitors or H2 blockers (patients may s
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	P-gp	7268 : 7272	CM	herapeutic index for the P-gp and BCRP transporters an
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	BCRP	7277 : 7281	CM	c index for the P-gp and BCRP transporters and/or (c) 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	QTc	7346 : 7349	CM	dications known to cause QTc prolongation with risk o
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Tween	8204 : 8209	CM	H302) or polysorbate 80 (Tween 80), which are          
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	8269 : 8276	CM	ents of the drug product MGCD516.            -  Patients 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	8994 : 9001	CM	e teratogenic effects of MGCD516 have not been adequately
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	9285 : 9292	CM	tment of the mother with MGCD516, breastfeeding must be d
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	9497 : 9504	CM	ombination.              MGCD516 in Advanced Liposarcoma 
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	MGCD516	9589 : 9596	CM	     A Phase II Trial of MGCD516, a Multi-receptor Tyrosi
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Tyrosine	9615 : 9623	CM	GCD516, a Multi-receptor Tyrosine Kinase Inhibitor, in Adv
./___Corpus/ClinicalTrials/xml/NCT02978859.xml	Kinase	9624 : 9630	ASE	 Multi-receptor Tyrosine Kinase Inhibitor, in Advanced L
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	TVB-2640	74 : 82	CM	rmine if the study drug, TVB-2640, is able to affect      
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	malonyl
      carnitine	368 : 391	CM	 on metabolic endpoints (malonyl       carnitine and tripalmitin levels) 
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	tripalmitin	396 : 407	CM	onyl       carnitine and tripalmitin levels) following short-
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	TVB-2640	452 : 460	CM	hort-term treatment with TVB-2640 in patients       with r
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	myocardial	1624 : 1634	CM	schemic heart disease or myocardial infarction (MI) within 6
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	QT	1955 : 1957	CM	hy (ECHO); and corrected QT              interval (Q
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	GI	3194 : 3196	CM	cations or impairment of GI function or GI disease t
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	GI	3209 : 3211	CM	irment of GI function or GI disease that            
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	anti-	3433 : 3438	CPR	ntacids              and anti-emetics is permissible   
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	QT	3594 : 3596	CM	  family history of long QT syndrome). Concomitant u
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	QT	3671 : 3673	CM	low risk of              QT/QTc prolongation (includ
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	diphenhydramine	3722 : 3737	CM	ding, but not limited to diphenhydramine, famotidine,            
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	famotidine	3739 : 3749	CM	ited to diphenhydramine, famotidine,              ondansetro
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	mitomycin C	4155 : 4166	CM	6 weeks for              mitomycin C and nitrosoureas) or 5 h
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	nitrosoureas	4171 : 4183	CM	         mitomycin C and nitrosoureas) or 5 half-lives of that
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	TVB-2640	5182 : 5190	CM	e (FASN) Inhibition With TVB-2640 in Resectable Colon Canc
./___Corpus/ClinicalTrials/xml/NCT02980029.xml	TVB-2640	5302 : 5310	CM	e (FASN) Inhibition With TVB-2640 in Resectable Colon Canc
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	146 : 158	CM	e-operative therapy with Mocetinostat and Durvalumab on patien
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	529 : 541	CM	tion, with pre-operative Mocetinostat       and Durvalumab.   
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	610 : 622	CM	l involve treatment with Mocetinostat and Durvalumab, tests an
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	SCCOC	1317 : 1322	CM	            oral cavity (SCCOC) (floor of mouth, anteri
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	T2-4a	1512 : 1517	CM	        surgical rounds (T2-4a, N0-2, M0; without evide
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	N0-2	1519 : 1523	CM	 surgical rounds (T2-4a, N0-2, M0; without evidence of
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	2248 : 2253	CPR	s team.            6. No anti-neoplastic treatment is a
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	0-	2446 : 2448	CPR	 ECOG performance status 0-1.            8. Patient 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2580 : 2590	CM	Renal function: i. Serum creatinine < 1.5 ULN (upper limit o
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2660 : 2670	CM	              calculated creatinine clearance of > 50mL/min 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	50mL	2686 : 2690	CM	reatinine clearance of > 50mL/min using the following 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Creatinine	2724 : 2734	CM	g the following formula: Creatinine              clearance =
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	140-	2762 : 2766	CPR	           clearance = [(140-age) x wt (kg) x Constant
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	creatinine	2796 : 2806	CM	x wt (kg) x Constant*] / creatinine (umol/L)               *
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ii	3029 : 3031	CM	ount (ANC) > 1.5 x 109/L ii. Leukocytes > 3.0 x 109/
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	iii	3058 : 3061	CM	Leukocytes > 3.0 x 109/L iii.              Hemoglobin
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	dL	3104 : 3106	CM	oglobin > 90 g/L or > 9g/dL iv. Platelets > 100 x 10
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	bilirubin	3176 : 3185	CM	Liver function: i. Total bilirubin < ULN ii. Aspartate amin
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ii	3192 : 3194	CM	i. Total bilirubin < ULN ii. Aspartate aminotransfer
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Aspartate	3196 : 3205	CM	otal bilirubin < ULN ii. Aspartate aminotransferase (AST/SG
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	aminotransferase	3206 : 3222	ASE	ubin < ULN ii. Aspartate aminotransferase (AST/SGOT)              
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	AST	3224 : 3227	CM	artate aminotransferase (AST/SGOT)              and a
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	SGOT	3228 : 3232	CM	te aminotransferase (AST/SGOT)              and alanin
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	alanine	3251 : 3258	CM	T/SGOT)              and alanine aminotransferase (ALT/SG
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	aminotransferase	3259 : 3275	CM	             and alanine aminotransferase (ALT/SGPT) < 2.5 x ULN  
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ALT	3277 : 3280	CM	lanine aminotransferase (ALT/SGPT) < 2.5 x ULN       
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	SGPT	3281 : 3285	CM	ne aminotransferase (ALT/SGPT) < 2.5 x ULN            
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	ULN	3295 : 3298	CM	erase (ALT/SGPT) < 2.5 x ULN               - Cardiac 
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	pericardial	3455 : 3466	CM	y clinically significant pericardial effusion, as evidenced b
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	palate	5225 : 5231	CM	inoma unknown, lip, hard palate, skin, or outside       
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	aspirin	5616 : 5623	CM	              (including aspirin, non-steroidal anti-infl
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	non-steroidal	5625 : 5638	CJ	     (including aspirin, non-steroidal anti-inflammatories, ant
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	5639 : 5644	CPR	g aspirin, non-steroidal anti-inflammatories, antiplate
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	anti-	5707 : 5712	CPR	                   other anti-coagulants) must be disco
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	prednisone	6828 : 6838	CM	day of                   prednisone or equivalent.          
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	7847 : 7859	CM	tion to any component of Mocetinostat and/or Durvalumab       
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	8850 : 8862	CM	events from              Mocetinostat or Durvalumab, or compro
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	PD1	9200 : 9203	CM	revious treatment with a PD1 or PD-L1 inhibitor, incl
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	PD-L1	9207 : 9212	CM	 treatment with a PD1 or PD-L1 inhibitor, including dur
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	10069 : 10081	CM	           Pre-operative Mocetinostat (MGCD0103) and Durvaluma
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	PRIMED	10120 : 10126	CM	d Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carci
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	Mocetinostat	10203 : 10215	CM	           Pre-operative Mocetinostat (MGCD0103) and Durvaluma
./___Corpus/ClinicalTrials/xml/NCT02993991.xml	PRIMED	10254 : 10260	CM	d Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carci
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	148 : 153	CM	-small cell lung cancer (NSCLC) over the past few years
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	283 : 288	CM	r patients with advanced NSCLC (Table 1). We are beginn
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	391 : 399	CM	ce following exposure to tyrosine kinase inhibitors in pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	453 : 458	CM	s with oncogene addicted NSCLC. The advent of next gene
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	1999 : 2003	CM	 Growth Factor Receptor (EGFR) mutation and Anaplastic
./___Corpus/Medline/xml/PMC4346098.xml	ALK	2046 : 2049	CM	plastic Lymphoma Kinase (ALK) rearrangement testing h
./___Corpus/Medline/xml/PMC4346098.xml	ROS	2213 : 2216	CM	 for alterations such as ROS, RET, BRAF, and HER2 whi
./___Corpus/Medline/xml/PMC4346098.xml	RET	2218 : 2221	CM	alterations such as ROS, RET, BRAF, and HER2 which ha
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	2223 : 2227	CM	ations such as ROS, RET, BRAF, and HER2 which have sho
./___Corpus/Medline/xml/PMC4346098.xml	HER2	2233 : 2237	CM	h as ROS, RET, BRAF, and HER2 which have shown initial
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	2657 : 2665	CM	activation of particular tyrosine kinases in some patients
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	2705 : 2710	CM	e patients with advanced NSCLC most notably mutations i
./___Corpus/Medline/xml/PMC4346098.xml	EGFR2–4	2737 : 2744	CM	ost notably mutations in EGFR2–4 or rearrangements of the
./___Corpus/Medline/xml/PMC4346098.xml	ALK	2770 : 2773	CM	or rearrangements of the ALK gene5, has led to a para
./___Corpus/Medline/xml/PMC4346098.xml	NCCN	3372 : 3376	CM	ehensive Cancer Network (NCCN) that newly diagnosed pa
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	3444 : 3448	CM	ed disease be tested for EGFR mutation and ALK fusion 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	3462 : 3465	CM	ed for EGFR mutation and ALK fusion testing. Addition
./___Corpus/Medline/xml/PMC4346098.xml	ROS	3572 : 3575	CM	rations in genes such as ROS, RET, MET, BRAF, and HER
./___Corpus/Medline/xml/PMC4346098.xml	RET	3577 : 3580	CM	ns in genes such as ROS, RET, MET, BRAF, and HER2 whi
./___Corpus/Medline/xml/PMC4346098.xml	MET	3582 : 3585	CM	 genes such as ROS, RET, MET, BRAF, and HER2 which ha
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	3587 : 3591	CM	s such as ROS, RET, MET, BRAF, and HER2 which have sho
./___Corpus/Medline/xml/PMC4346098.xml	HER2	3597 : 3601	CM	ROS, RET, MET, BRAF, and HER2 which have shown initial
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	3796 : 3800	CM	 with the correlation of EGFR mutations and sensitivit
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	3830 : 3839	CM	tions and sensitivity to gefitinib and erlotinib in lung ad
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	3844 : 3853	CM	itivity to gefitinib and erlotinib in lung adenocarcinoma, 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	3929 : 3933	CM	 modest tobacco exposure EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	3934 : 3942	CM	st tobacco exposure EGFR tyrosine kinase inhibitors (TKIs)
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	4028 : 4033	CM	therapy in patients with NSCLC known to have activating
./___Corpus/Medline/xml/PMC4346098.xml	EGFR.6	4072 : 4078	CM	 activating mutations in EGFR.6, 7 The majority of these
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	4132 : 4136	CM	ors initially respond to EGFR TKIs, but subsequently d
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	4348 : 4352	CM	f acquired resistance in EGFR TKI-responsive patients,
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	4453 : 4457	CM	n will carry a secondary EGFR mutation, such as T790M,
./___Corpus/Medline/xml/PMC4346098.xml	T790M	4476 : 4481	CM	y EGFR mutation, such as T790M, which can now be succes
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	4544 : 4548	CM	ed with third generation EGFR TKIs such as AZD9291 and
./___Corpus/Medline/xml/PMC4346098.xml	AZD9291	4562 : 4569	CM	ration EGFR TKIs such as AZD9291 and CO-1686.8, 9 Additio
./___Corpus/Medline/xml/PMC4346098.xml	CO-1686.8	4574 : 4583	CM	TKIs such as AZD9291 and CO-1686.8, 9 Additional mechanisms
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	4626 : 4630	CM	hanisms of resistance to EGFR inhibitors have been def
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	4883 : 4891	CM	                Receptor tyrosine kinase gene rearrangemen
./___Corpus/Medline/xml/PMC4346098.xml	ALK	4928 : 4931	CM	 rearrangements, such as ALK, ROS and RET, are identi
./___Corpus/Medline/xml/PMC4346098.xml	ROS	4933 : 4936	CM	rangements, such as ALK, ROS and RET, are identified 
./___Corpus/Medline/xml/PMC4346098.xml	RET	4941 : 4944	CM	ts, such as ALK, ROS and RET, are identified in 1–8% 
./___Corpus/Medline/xml/PMC4346098.xml	1–	4964 : 4966	CPR	d RET, are identified in 1–8% of lung adenocarcinoma
./___Corpus/Medline/xml/PMC4346098.xml	ALK	5026 : 5029	CM	nts’ whose tumors harbor ALK fusion, as well as ROS1 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	5049 : 5053	CM	r ALK fusion, as well as ROS1 rearrangements demonstra
./___Corpus/Medline/xml/PMC4346098.xml	TKIs.11	5116 : 5123	CM	 to crizotinib and other TKIs.11, 12 However, similar to 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	5154 : 5158	CM	owever, similar to their EGFR counterparts, these pati
./___Corpus/Medline/xml/PMC4346098.xml	ALK	5310 : 5313	CM	 and the clinical use of ALK and ROS inhibitors with 
./___Corpus/Medline/xml/PMC4346098.xml	ROS	5318 : 5321	CM	 clinical use of ALK and ROS inhibitors with expanded
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	5376 : 5382	CM	anisms of action such as LDK378.                        
./___Corpus/Medline/xml/PMC4346098.xml	TP53	5523 : 5527	CM	ma, such as mutations in TP53, KRAS, and STK11, have p
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	5529 : 5533	CM	ch as mutations in TP53, KRAS, and STK11, have proven 
./___Corpus/Medline/xml/PMC4346098.xml	STK11	5539 : 5544	CM	tions in TP53, KRAS, and STK11, have proven difficult t
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	5617 : 5624	CM	cally exploit.13, 14 The mitogen activation pathway (MAPK
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	5645 : 5649	CM	ogen activation pathway (MAPK) is often implicated in 
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	5801 : 5805	CM	ost common mechanism for MAPK activation is through su
./___Corpus/Medline/xml/PMC4346098.xml	amino	5875 : 5880	CM	s in 12th, 13th and 61st amino of KRAS. Activating KRAS
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	5884 : 5888	CM	, 13th and 61st amino of KRAS. Activating KRAS mutatio
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	5901 : 5905	CM	mino of KRAS. Activating KRAS mutations are observed i
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	6075 : 6079	CM	oking. The presence of a KRAS mutation appears to have
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	6184 : 6189	CM	atients with early stage NSCLC, although some data have
./___Corpus/Medline/xml/PMC4346098.xml	RAS	6302 : 6305	CM	rts to identify specific RAS inhibitors for KRAS-muta
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	6506 : 6510	CM	m effectors of activated KRAS such as MEK1/MEK2, PI3K 
./___Corpus/Medline/xml/PMC4346098.xml	MEK1	6519 : 6523	CM	f activated KRAS such as MEK1/MEK2, PI3K and AKT. Rece
./___Corpus/Medline/xml/PMC4346098.xml	MEK2	6524 : 6528	CM	ivated KRAS such as MEK1/MEK2, PI3K and AKT. Recent Ph
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	6530 : 6534	CM	 KRAS such as MEK1/MEK2, PI3K and AKT. Recent Phase II
./___Corpus/Medline/xml/PMC4346098.xml	AKT	6539 : 6542	CM	h as MEK1/MEK2, PI3K and AKT. Recent Phase II data ex
./___Corpus/Medline/xml/PMC4346098.xml	MEK1	6623 : 6627	CM	metenib, an inhibitor of MEK1/MEK2 and docetaxel has b
./___Corpus/Medline/xml/PMC4346098.xml	MEK2	6628 : 6632	CM	ib, an inhibitor of MEK1/MEK2 and docetaxel has been s
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	6637 : 6646	CM	hibitor of MEK1/MEK2 and docetaxel has been shown to have p
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	6770 : 6774	CM	nstream effectors in the KRAS mutant pathway is crucia
./___Corpus/Medline/xml/PMC4346098.xml	PI3KCA	6867 : 6873	CM	loying the inhibition of PI3KCA, MEK and PTEN are in pro
./___Corpus/Medline/xml/PMC4346098.xml	MEK	6875 : 6878	CM	he inhibition of PI3KCA, MEK and PTEN are in progress
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	6883 : 6887	CM	ition of PI3KCA, MEK and PTEN are in progress.        
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	7065 : 7069	CM	getable mutation such as EGFR mutation and EML4-ALK fu
./___Corpus/Medline/xml/PMC4346098.xml	EML4-ALK	7083 : 7091	CM	uch as EGFR mutation and EML4-ALK fusions. However, there 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	7327 : 7331	CM	ar targets including the FGFR family kinases. Fibrobla
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	7400 : 7408	CM	ceptors are cell surface tyrosine kinase receptors that me
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	7495 : 7500	CM	n. Gene amplification of FGFR1 has been detected in 7 t
./___Corpus/Medline/xml/PMC4346098.xml	FGF	7667 : 7670	CM	lterations in all of the FGF receptors.16–18 Small mo
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	7716 : 7721	CM	l molecule inhibitors of FGFR1 are in clinical developm
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	7773 : 7778	CM	t and a case report of a NSCLC patient with tumor regre
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	7828 : 7832	CM	ssion in response to the FGFR small molecule tyrosine 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	7848 : 7856	CM	 the FGFR small molecule tyrosine kinase inhibitor BGJ398 
./___Corpus/Medline/xml/PMC4346098.xml	BGJ398	7874 : 7880	CM	yrosine kinase inhibitor BGJ398 has been presented.19 Ad
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	7973 : 7978	CM	 have been identified in FGFR2 and FGFR3, including a r
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	7983 : 7988	CM	 identified in FGFR2 and FGFR3, including a recurrent f
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	8022 : 8027	CM	ng a recurrent fusion of FGFR3 and TACC3, which provide
./___Corpus/Medline/xml/PMC4346098.xml	TACC3	8032 : 8037	CM	rent fusion of FGFR3 and TACC3, which provides much nee
./___Corpus/Medline/xml/PMC4346098.xml	SCC	8115 : 8118	CM	ic pathways operating in SCC and makes a strong case 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	8156 : 8160	CM	strong case for applying FGFR inhibitors in this disea
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	8278 : 8282	CM	o include members of the PI3K pathway, DDR2 and potent
./___Corpus/Medline/xml/PMC4346098.xml	DDR2	8292 : 8296	CM	ers of the PI3K pathway, DDR2 and potentially the NRF2
./___Corpus/Medline/xml/PMC4346098.xml	NRF2	8317 : 8321	CM	DDR2 and potentially the NRF2/KEAP1/CUL3 antioxidant r
./___Corpus/Medline/xml/PMC4346098.xml	KEAP1	8322 : 8327	CM	and potentially the NRF2/KEAP1/CUL3 antioxidant respons
./___Corpus/Medline/xml/PMC4346098.xml	CUL3	8328 : 8332	CM	tentially the NRF2/KEAP1/CUL3 antioxidant response pat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	8687 : 8692	CM	he treatment paradigm of NSCLC continues to evolve howe
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8798 : 8802	CM	 small cell lung cancer (SCLC) remains elusive. SCLC r
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8821 : 8825	CM	 (SCLC) remains elusive. SCLC remains an exceptionally
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	8940 : 8944	CM	psed/refractory setting. SCLC has a high mutation rate
./___Corpus/Medline/xml/PMC4346098.xml	carcinogen	8999 : 9009	CM	ely secondary to tobacco carcinogen exposure in this patient
./___Corpus/Medline/xml/PMC4346098.xml	TP53	9228 : 9232	CM	e of difficult to target TP53 and RB1 inactivation mut
./___Corpus/Medline/xml/PMC4346098.xml	RB1	9237 : 9240	CM	icult to target TP53 and RB1 inactivation mutations. 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9316 : 9320	CM	 has been applied to the SCLC genome in hopes of ident
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9459 : 9463	CM	icantly mutated genes in SCLC cell lines. These aberra
./___Corpus/Medline/xml/PMC4346098.xml	histone	9532 : 9539	CM	ic alterations affecting histone modifying enzymes CREBPP
./___Corpus/Medline/xml/PMC4346098.xml	CREBPP	9558 : 9564	CM	istone modifying enzymes CREBPP, EP300, and LFF as well 
./___Corpus/Medline/xml/PMC4346098.xml	EP300	9566 : 9571	CM	odifying enzymes CREBPP, EP300, and LFF as well as PTEN
./___Corpus/Medline/xml/PMC4346098.xml	LFF	9577 : 9580	CM	zymes CREBPP, EP300, and LFF as well as PTEN mutation
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	9592 : 9596	CM	P300, and LFF as well as PTEN mutations, FGFR1 and SOX
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	9608 : 9613	CM	 well as PTEN mutations, FGFR1 and SOX2 amplification. 
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9618 : 9622	CM	TEN mutations, FGFR1 and SOX2 amplification. Recent wo
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9653 : 9657	CM	fication. Recent work on SOX2 demonstrates the prevale
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9689 : 9693	CM	trates the prevalence of SOX2 amplification in SCLC ce
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9711 : 9715	CM	of SOX2 amplification in SCLC cell lines with expressi
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9746 : 9750	CM	lines with expression of SOX2 strongly correlated with
./___Corpus/Medline/xml/PMC4346098.xml	SOX2	9858 : 9862	CM	 authors to postulate if SOX2 is a genuine SCLC driver
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	9876 : 9880	CM	ate if SOX2 is a genuine SCLC driver mutation.23, 24  
./___Corpus/Medline/xml/PMC4346098.xml	methylation	10081 : 10092	RN	sis through aberrant DNA methylation and altered chromatin co
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	10105 : 10114	CM	 methylation and altered chromatin configuration continue t
./___Corpus/Medline/xml/PMC4346098.xml	CDKN2A	10733 : 10739	CM	le in lung cancer is the CDKN2A locus, encoding both the
./___Corpus/Medline/xml/PMC4346098.xml	p16	10765 : 10768	CM	locus, encoding both the p16 tumor suppressor (a key 
./___Corpus/Medline/xml/PMC4346098.xml	G1	10834 : 10836	CM	l-cycle progression from G1 to S-phase) as well as A
./___Corpus/Medline/xml/PMC4346098.xml	S-phase	10840 : 10847	CM	e progression from G1 to S-phase) as well as ARF (which c
./___Corpus/Medline/xml/PMC4346098.xml	ARF	10860 : 10863	CM	1 to S-phase) as well as ARF (which can sequester MDM
./___Corpus/Medline/xml/PMC4346098.xml	MDM2	10885 : 10889	CM	ARF (which can sequester MDM2, leading to stabilizatio
./___Corpus/Medline/xml/PMC4346098.xml	p53	10940 : 10943	CM	 of the tumor suppressor p53). Comprehensive genomic 
./___Corpus/Medline/xml/PMC4346098.xml	TCGA	11035 : 11039	CM	the Cancer Genome Atlas (TCGA) Research Network has de
./___Corpus/Medline/xml/PMC4346098.xml	CDKN2A	11075 : 11081	CM	Network has demonstrated CDKN2A loss of function in the 
./___Corpus/Medline/xml/PMC4346098.xml	hypermethylation	11215 : 11231	RN	, site-specific promoter hypermethylation leading to gene silencin
./___Corpus/Medline/xml/PMC4346098.xml	MLL	11519 : 11522	CM	 mixed-lineage leukemia (MLL) gene family of histone 
./___Corpus/Medline/xml/PMC4346098.xml	histone	11539 : 11546	CM	mia (MLL) gene family of histone methyltransferases, muta
./___Corpus/Medline/xml/PMC4346098.xml	Chromatin	11655 : 11664	CM	cancers, respectively.29 Chromatin modifying enzymes which 
./___Corpus/Medline/xml/PMC4346098.xml	histone	11704 : 11711	CM	mes which add and remove histone modifications, termed “w
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	11779 : 11788	CM	rs”, affect the state of chromatin compaction of DNA making
./___Corpus/Medline/xml/PMC4346098.xml	methylation	11974 : 11985	RN	 the vast changes in DNA methylation which characterize cance
./___Corpus/Medline/xml/PMC4346098.xml	isocitrate	12276 : 12286	CM	.25, 29 Mutations of the isocitrate dehydrogenase genes, fou
./___Corpus/Medline/xml/PMC4346098.xml	dehydrogenase	12287 : 12300	CM	ations of the isocitrate dehydrogenase genes, found across many
./___Corpus/Medline/xml/PMC4346098.xml	CpG	12440 : 12443	CM	ung cancers, result in a CpG island methylator phenot
./___Corpus/Medline/xml/PMC4346098.xml	methylator	12451 : 12461	CM	, result in a CpG island methylator phenotype (CIMP) with th
./___Corpus/Medline/xml/PMC4346098.xml	CIMP	12473 : 12477	CM	nd methylator phenotype (CIMP) with therapeutic implic
./___Corpus/Medline/xml/PMC4346098.xml	CIMP	12525 : 12529	CM	ications.29, 30 Multiple CIMP-like states have been de
./___Corpus/Medline/xml/PMC4346098.xml	methylated	12728 : 12738	RN	ecting the metabolism of methylated cytosines as well as mut
./___Corpus/Medline/xml/PMC4346098.xml	cytosines	12739 : 12748	CM	metabolism of methylated cytosines as well as mutations in 
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferases.30	12777 : 12798	CM	well as mutations in DNA methyltransferases.30, 31                     
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	13005 : 13020	RN	nical development of DNA hypomethylating agents and histone deace
./___Corpus/Medline/xml/PMC4346098.xml	histone	13032 : 13039	CM	pomethylating agents and histone deacetylase inhibitors i
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	13040 : 13051	CM	ating agents and histone deacetylase inhibitors in various he
./___Corpus/Medline/xml/PMC4346098.xml	hypermethylation	13524 : 13540	RN	 capacity. Site-specific hypermethylation of promoters for genes c
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	13676 : 13686	CM	licative immortality and clonogenic potential in cancer.34, 
./___Corpus/Medline/xml/PMC4346098.xml	demethylation	13723 : 13736	RN	n cancer.34, 35 Promoter demethylation by DNA methyltransferase
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferase	13744 : 13761	CM	ter demethylation by DNA methyltransferase inhibitors such as azaci
./___Corpus/Medline/xml/PMC4346098.xml	azacitidine	13781 : 13792	CM	erase inhibitors such as azacitidine can markedly reduce repl
./___Corpus/Medline/xml/PMC4346098.xml	methylation.36	13923 : 13937	CM	ncer-specific changes in methylation.36 Mutations in epigenetic 
./___Corpus/Medline/xml/PMC4346098.xml	BMI-1	14021 : 14026	CM	pressive complex protein BMI-1 and the histone methyltr
./___Corpus/Medline/xml/PMC4346098.xml	histone	14035 : 14042	CM	ex protein BMI-1 and the histone methyltransferase EZH2 c
./___Corpus/Medline/xml/PMC4346098.xml	EZH2	14061 : 14065	CM	istone methyltransferase EZH2 can enhance clonogenic p
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	14078 : 14088	CM	sferase EZH2 can enhance clonogenic potential of cancer cell
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	14155 : 14164	CM	, genetic alterations of chromatin regulatory genes with es
./___Corpus/Medline/xml/PMC4346098.xml	histone	14559 : 14566	CM	ample, inhibition of the histone demethylase KDM5A has be
./___Corpus/Medline/xml/PMC4346098.xml	demethylase	14567 : 14578	ASE	nhibition of the histone demethylase KDM5A has been shown to 
./___Corpus/Medline/xml/PMC4346098.xml	clonogenic	14628 : 14638	CM	preferentially eliminate clonogenic survivors to EGFR tyrosi
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	14652 : 14656	CM	 clonogenic survivors to EGFR tyrosine kinase therapy 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	14657 : 14665	CM	ogenic survivors to EGFR tyrosine kinase therapy in EGFR-m
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	14696 : 14701	CM	e therapy in EGFR-mutant NSCLC cell lines.37           
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	14802 : 14817	RN	y regimens employing DNA hypomethylating agents or histone deacet
./___Corpus/Medline/xml/PMC4346098.xml	histone	14828 : 14835	CM	ypomethylating agents or histone deacetylase inhibitors h
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	14836 : 14847	CM	lating agents or histone deacetylase inhibitors have become s
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	15114 : 15129	RN	py consisting of the DNA hypomethylating agent azacitidine and th
./___Corpus/Medline/xml/PMC4346098.xml	azacitidine	15136 : 15147	CM	NA hypomethylating agent azacitidine and the histone deacetyl
./___Corpus/Medline/xml/PMC4346098.xml	histone	15156 : 15163	CM	gent azacitidine and the histone deacetylase inhibitor en
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	15164 : 15175	CM	citidine and the histone deacetylase inhibitor entinostat has
./___Corpus/Medline/xml/PMC4346098.xml	PD-1	15655 : 15659	CM	ent the effectiveness of PD-1 immune checkpoint blocka
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	15864 : 15869	CM	tation, up-regulation of PD-L1 expression and augmentat
./___Corpus/Medline/xml/PMC4346098.xml	cytokine	15916 : 15924	CM	tation of interferon and cytokine signaling within the tum
./___Corpus/Medline/xml/PMC4346098.xml	hypomethylating	16024 : 16039	RN	ition to next generation hypomethylating agents and histone deace
./___Corpus/Medline/xml/PMC4346098.xml	histone	16051 : 16058	CM	pomethylating agents and histone deacetylase inhibitors, 
./___Corpus/Medline/xml/PMC4346098.xml	deacetylase	16059 : 16070	CM	ating agents and histone deacetylase inhibitors, there are a 
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	16140 : 16149	CM	etic therapies targeting chromatin modifying enzymes now be
./___Corpus/Medline/xml/PMC4346098.xml	EZH2	16250 : 16254	CM	 and other solid tumors. EZH2 inhibitors are currently
./___Corpus/Medline/xml/PMC4346098.xml	EZH2	16418 : 16422	CM	l lung cancers, in which EZH2 appears to be frequently
./___Corpus/Medline/xml/PMC4346098.xml	MLL	16546 : 16549	CM	efined by alterations in MLL, a gene family of histon
./___Corpus/Medline/xml/PMC4346098.xml	histone	16568 : 16575	CM	in MLL, a gene family of histone methyltransferases also 
./___Corpus/Medline/xml/PMC4346098.xml	methyltransferases	16576 : 16594	ASE	a gene family of histone methyltransferases also commonly mutated or
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	16683 : 16692	CM	cancer. Beyond targeting chromatin modifying enzymes that w
./___Corpus/Medline/xml/PMC4346098.xml	histone	16731 : 16738	CM	ymes that write or erase histone marks, bromodomain and e
./___Corpus/Medline/xml/PMC4346098.xml	histone	16783 : 16790	CM	and extra-terminal (BET) histone binding proteins possess
./___Corpus/Medline/xml/PMC4346098.xml	histone	16867 : 16874	CM	ing” function focused on histone acetylation; trials of i
./___Corpus/Medline/xml/PMC4346098.xml	acetylation	16875 : 16886	RN	ction focused on histone acetylation; trials of inhibitors of
./___Corpus/Medline/xml/PMC4346098.xml	chromatin	17074 : 17083	CM	 identifiable defects in chromatin regulators and DNA-methy
./___Corpus/Medline/xml/PMC4346098.xml	DNA-methylation	17099 : 17114	RN	chromatin regulators and DNA-methylation phenotypes suggests a la
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	17513 : 17517	CM	ars.                  3. EGFR MUTATION-POSITIVE NSCLC 
./___Corpus/Medline/xml/PMC4346098.xml	MUTATION-POSITIVE	17518 : 17535	CM	                 3. EGFR MUTATION-POSITIVE NSCLC                   
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	17899 : 17903	CM	s had tumors carrying an EGFR mutation, a biomarker of
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	17990 : 17994	CM	trongly with response to EGFR TKIs.44 There are severa
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	18033 : 18037	CM	 are several subtypes of EGFR mutations, but the two m
./___Corpus/Medline/xml/PMC4346098.xml	L858R	18076 : 18081	CM	t the two most frequent, L858R and del19, comprise 90% 
./___Corpus/Medline/xml/PMC4346098.xml	del19	18086 : 18091	CM	most frequent, L858R and del19, comprise 90% of the cas
./___Corpus/Medline/xml/PMC4346098.xml	L858R	18211 : 18216	CM	erapy.45 In this review, L858R and del19 mutations will
./___Corpus/Medline/xml/PMC4346098.xml	del19	18221 : 18226	CM	n this review, L858R and del19 mutations will be referr
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	18523 : 18527	CM	                    When EGFR mutations were first dis
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	18681 : 18685	CM	d lung cancer and common EGFR mutations did very well 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	18726 : 18735	CM	ery well with first-line gefitinib and erlotinib therapy, w
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	18740 : 18749	CM	first-line gefitinib and erlotinib therapy, with response r
./___Corpus/Medline/xml/PMC4346098.xml	60–	18782 : 18785	CPR	, with response rates of 60–75% and median progressio
./___Corpus/Medline/xml/PMC4346098.xml	PFS	18827 : 18830	CM	ogression-free survival (PFS) of approximately 9–10 m
./___Corpus/Medline/xml/PMC4346098.xml	9–	18849 : 18851	CPR	l (PFS) of approximately 9–10 months.46–48 While the
./___Corpus/Medline/xml/PMC4346098.xml	platinum	18974 : 18982	CM	current standard-of-care platinum doublet chemotherapy reg
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19094 : 19098	CM	zed trial would favor an EGFR TKI or not, because EGFR
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19181 : 19185	CM	ter on chemotherapy than EGFR wild-type patients. Howe
./___Corpus/Medline/xml/PMC4346098.xml	IPASS	19248 : 19253	CM	ate was settled when the IPASS study was published.    
./___Corpus/Medline/xml/PMC4346098.xml	IPASS	19313 : 19318	CM	                         IPASS was a large randomized t
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19391 : 19395	CM	ents done in Asia, where EGFR mutations are 2–3 times 
./___Corpus/Medline/xml/PMC4346098.xml	2–	19410 : 19412	CPR	where EGFR mutations are 2–3 times more common than 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19605 : 19609	CM	h increased incidence of EGFR mutations. Patients did 
./___Corpus/Medline/xml/PMC4346098.xml	NOT	19634 : 19637	CM	 mutations. Patients did NOT have to have an EGFR mut
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19654 : 19658	CM	 did NOT have to have an EGFR mutation to enter the tr
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19739 : 19743	CM	had tissue available for EGFR mutation testing, about 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	19797 : 19801	CM	were positive for common EGFR mutations. The IPASS des
./___Corpus/Medline/xml/PMC4346098.xml	IPASS	19817 : 19822	CM	mmon EGFR mutations. The IPASS design compared 1st-line
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	19848 : 19857	CM	design compared 1st-line gefitinib to 1st-line chemotherapy
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	19888 : 19899	CM	t-line chemotherapy with carboplatin and paclitaxel for up to
./___Corpus/Medline/xml/PMC4346098.xml	PFS	19962 : 19965	CM	h a primary end-point of PFS. The results showed that
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20036 : 20045	CM	tion-to-treat population gefitinib had an improved PFS comp
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20062 : 20065	CM	efitinib had an improved PFS compared to chemotherapy
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20319 : 20328	CM	all positive results for gefitinib were exclusively due to 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20443 : 20446	CM	 an even more impressive PFS benefit from first-line 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20471 : 20480	CM	 benefit from first-line gefitinib, HR= 0.48 (95% CI0.36, 0
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	20527 : 20531	CM	, 0.46). Conversely, the EGFR wild-type patients showe
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	20574 : 20578	CM	s showed that front-line EGFR TKI was a harmful strate
./___Corpus/Medline/xml/PMC4346098.xml	PFS	20666 : 20669	CM	, 4.0). In addition to a PFS benefit, patients with E
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	20693 : 20697	CM	S benefit, patients with EGFR mutations treated with g
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	20721 : 20730	CM	R mutations treated with gefitinib had an improved quality 
./___Corpus/Medline/xml/PMC4346098.xml	IPASS	20857 : 20862	CM	d significantly with the IPASS publication in two major
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	20968 : 20972	CM	ated and giving 1st-line EGFR TKIs to patients with EG
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	20995 : 20999	CM	FR TKIs to patients with EGFR mutations became an acce
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21116 : 21125	CM	 so poorly with 1st-line gefitinib in lieu of chemotherapy,
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	21233 : 21237	CM	atus for a patient, then EGFR TKIs should not be given
./___Corpus/Medline/xml/PMC4346098.xml	IPASS	21342 : 21347	CM	                   After IPASS, several other randomize
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21466 : 21475	CM	benefits from first-line gefitinib or erlotinib, primarily 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	21479 : 21488	CM	 first-line gefitinib or erlotinib, primarily for patients 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	21525 : 21529	CM	for patients with common EGFR mutations (Table 2).7, 5
./___Corpus/Medline/xml/PMC4346098.xml	50–	21553 : 21556	CPR	R mutations (Table 2).7, 50–53 The EURTAC study was e
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	21732 : 21736	CM	TAC, Spanish and Italian EGFR mutant patients (common 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	21801 : 21810	CM	 treated with first-line erlotinib had improved PFS compare
./___Corpus/Medline/xml/PMC4346098.xml	PFS	21824 : 21827	CM	e erlotinib had improved PFS compared to investigator
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	21881 : 21890	CM	ice chemotherapy (either cisplatin/docetaxel or cisplatin/g
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	21891 : 21900	CM	herapy (either cisplatin/docetaxel or cisplatin/gemcitabine
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	21904 : 21913	CM	r cisplatin/docetaxel or cisplatin/gemcitabine), HR = 0.37 
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	21914 : 21925	CM	n/docetaxel or cisplatin/gemcitabine), HR = 0.37 (95% CI 0.25
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	21999 : 22008	CM	ies examining first-line gefitinib or erlotinib have demons
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	22012 : 22021	CM	 first-line gefitinib or erlotinib have demonstrated a surv
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22115 : 22119	CM	rapy, presumably because EGFR mutants have a very robu
./___Corpus/Medline/xml/PMC4346098.xml	PFS	22165 : 22168	CM	robust response rate and PFS when EGFR TKIs are given
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22174 : 22178	CM	sponse rate and PFS when EGFR TKIs are given in the 2n
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22425 : 22429	CM	 with the 2nd-generation EGFR TKI afatinib as first-li
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22434 : 22442	CM	 2nd-generation EGFR TKI afatinib as first-line therapy fo
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22469 : 22473	CM	s first-line therapy for EGFR mutation-positive patien
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	22548 : 22557	CM	the 1st-generation drugs erlotinib and gefitinib, 2nd-gener
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	22562 : 22571	CM	tion drugs erlotinib and gefitinib, 2nd-generation EGFR TKI
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22588 : 22592	CM	efitinib, 2nd-generation EGFR TKIs are “irreversibly b
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22746 : 22750	CM	l covalent bond with the EGFR receptor. In addition, a
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22774 : 22782	CM	R receptor. In addition, afatinib binds all the ErbB recep
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	22822 : 22826	CM	ErbB receptors, not just EGFR. Lux-lung 3 was a global
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22868 : 22876	CM	a global study comparing afatinib to cisplatin/pemetrexed 
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	22880 : 22889	CM	dy comparing afatinib to cisplatin/pemetrexed and Lux-lung 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	22955 : 22963	CM	in China only, comparing afatinib to cisplatin/gemcitabine
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	22967 : 22976	CM	y, comparing afatinib to cisplatin/gemcitabine. Similar to 
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	22977 : 22988	CM	ng afatinib to cisplatin/gemcitabine. Similar to the prior st
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23024 : 23032	CM	o the prior studies, the afatinib trials showed a superior
./___Corpus/Medline/xml/PMC4346098.xml	PFS	23058 : 23061	CM	trials showed a superior PFS, response rate, and qual
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	23192 : 23196	CM	participants with common EGFR mutations. As a result, 
./___Corpus/Medline/xml/PMC4346098.xml	L858R	23294 : 23299	CM	herapy for patients with L858R and deletion 19 EGFR mut
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	23316 : 23320	CM	th L858R and deletion 19 EGFR mutations. At the 2014 A
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23422 : 23430	CM	tion mutants, first-line afatinib appears to improve OS co
./___Corpus/Medline/xml/PMC4346098.xml	p-	23689 : 23691	CPR	 with highly significant p-values (Table 2). The L85
./___Corpus/Medline/xml/PMC4346098.xml	L858R	23713 : 23718	CM	 p-values (Table 2). The L858R patients did not have a 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	23767 : 23775	CM	 survival advantage with afatinib, similar to results from
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	23820 : 23829	CM	 from other studies with gefitinib and erlotinib.          
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	23834 : 23843	CM	udies with gefitinib and erlotinib.                        
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24036 : 24040	CM	anced adenocarcinoma for EGFR mutations and, if positi
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	24112 : 24120	CM	on, to treat with either afatinib or erlotinib.57 If patie
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24280 : 24284	CM	apy should be started as EGFR TKIs should only be give
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24366 : 24370	CM	atients known to have an EGFR mutation. There are unco
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24451 : 24455	CM	onsidered sensitizing to EGFR TKIs such as L861Q, G719
./___Corpus/Medline/xml/PMC4346098.xml	L861Q	24469 : 24474	CM	ing to EGFR TKIs such as L861Q, G719X and S768I. Howeve
./___Corpus/Medline/xml/PMC4346098.xml	G719X	24476 : 24481	CM	EGFR TKIs such as L861Q, G719X and S768I. However, it i
./___Corpus/Medline/xml/PMC4346098.xml	S768I	24486 : 24491	CM	such as L861Q, G719X and S768I. However, it is importan
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	24603 : 24612	CM	pically not sensitive to erlotinib, gefitinib and afatinib.
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	24614 : 24623	CM	 sensitive to erlotinib, gefitinib and afatinib.58         
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24712 : 24716	CM	ecial considerations for EGFR mutant patients         
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24808 : 24812	CM	ons in the management of EGFR mutant patients that are
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	24922 : 24926	CM	cancer: 1) When to start EGFR TKIs if chemotherapy was
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25012 : 25016	CM	 availability, 2) Should EGFR TKIs be continued beyond
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25077 : 25081	CM	n and, 3) How to work-up EGFR mutation positive lung c
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25150 : 25154	CM	 resistance to the first EGFR TKI. There are no defini
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25368 : 25372	CM	 were unable to wait for EGFR mutation test results pr
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25494 : 25498	CM	when and how to start an EGFR TKI after the mutation i
./___Corpus/Medline/xml/PMC4346098.xml	TKI	25570 : 25573	CM	range from beginning the TKI immediately after the te
./___Corpus/Medline/xml/PMC4346098.xml	4–	25724 : 25726	CPR	 approach is to complete 4–6 cycles of the first-lin
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	25868 : 25872	CM	) and then switch to the EGFR TKI, similar to a mainte
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	26085 : 26089	CM	umstances to continue an EGFR TKI when the patient is 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	26204 : 26208	CM	 observed that even when EGFR mutants are radiographic
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	26261 : 26265	CM	y progressing through an EGFR therapy, removal of that
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	26592 : 26596	CM	e still sensitive to the EGFR TKI and remain under con
./___Corpus/Medline/xml/PMC4346098.xml	TKI	26690 : 26693	CM	moval of the suppressive TKI can allow many more cell
./___Corpus/Medline/xml/PMC4346098.xml	TKI	26766 : 26769	CM	 keeping the suppressive TKI on board.               
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	26818 : 26822	CM	                         EGFR mutants have two distinc
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	27243 : 27247	CM	n) followed by continued EGFR TKI therapy can yield go
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	27325 : 27329	CM	udy using this approach, EGFR mutant patients had cont
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	27611 : 27615	CM	 progression while on an EGFR TKI can achieve signific
./___Corpus/Medline/xml/PMC4346098.xml	RECIST	27685 : 27691	CM	on therapy after meeting RECIST criteria for progression
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	27781 : 27785	CM	e documented that 88% of EGFR patients received ongoin
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	27812 : 27816	CM	atients received ongoing EGFR TKI beyond RECIST-define
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28130 : 28134	CM	ther one should stop the EGFR TKI and switch to chemot
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28182 : 28186	CM	otherapy or continue the EGFR TKI along with adding ch
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28298 : 28302	CM	 flare in disease if the EGFR TKI is stopped has fuele
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28513 : 28517	CM	tes may be higher if the EGFR TKI is continued while c
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28667 : 28671	CM	ogression on the initial EGFR TKI is an emerging stand
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	28704 : 28708	CM	an emerging standard for EGFR mutants.56 Initially thi
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29074 : 29078	CM	nocarcinoma harboring an EGFR mutation to small cell l
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29128 : 29132	CM	ung cancer with the same EGFR mutation as an escape me
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29176 : 29180	CM	ape mechanism from their EGFR TKI.65, 66 This transfor
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29417 : 29421	CM	ting that 3rd-generation EGFR TKIs may have high activ
./___Corpus/Medline/xml/PMC4346098.xml	T790M	29504 : 29509	CM	istance by virtue of the T790M mutation in exon 20, the
./___Corpus/Medline/xml/PMC4346098.xml	50–	29569 : 29572	CPR	tation that accounts for 50–65% of acquired resistanc
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29842 : 29846	CM	 initial therapy with an EGFR TKI is quite effective, 
./___Corpus/Medline/xml/PMC4346098.xml	10–	29912 : 29915	CPR	nce still develops after 10–15 months. When the 2nd-g
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	29950 : 29954	CM	 When the 2nd-generation EGFR TKIs were developed, the
./___Corpus/Medline/xml/PMC4346098.xml	T790M	30159 : 30164	CM	evel of activity against T790M in vitro.69 Unfortunatel
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	30236 : 30240	CM	all three 2nd-generation EGFR TKIs tested (neratinib, 
./___Corpus/Medline/xml/PMC4346098.xml	neratinib	30254 : 30263	CM	ration EGFR TKIs tested (neratinib, afatinib and dacomitini
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	30265 : 30273	CM	 TKIs tested (neratinib, afatinib and dacomitinib) have ha
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	30520 : 30524	CM	high degree of wild-type EGFR potency so dose escalati
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	30630 : 30634	CM	resulting from wild-type EGFR inhibition. Hence, in pa
./___Corpus/Medline/xml/PMC4346098.xml	T790M	30740 : 30745	CM	ns sufficient to inhibit T790M.                        
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	30825 : 30829	CM	ssful clinical trial for EGFR acquired resistance was 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	30899 : 30907	CM	ining the combination of afatinib and cetuximab.73 This tr
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	31094 : 31102	CM	served with single agent afatinib. However, the toxicity o
./___Corpus/Medline/xml/PMC4346098.xml	ADLs	31233 : 31237	CM	m rash (rash that limits ADLs and covers >30% of the b
./___Corpus/Medline/xml/PMC4346098.xml	T790M	31358 : 31363	CM	mbination suggested that T790M mutants would preferenti
./___Corpus/Medline/xml/PMC4346098.xml	T790M	31491 : 31496	CM	ghly equal regardless of T790M status.                 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	31573 : 31577	CM	 class of 3rd-generation EGFR TKIs have recently enter
./___Corpus/Medline/xml/PMC4346098.xml	EGRF	31670 : 31674	CM	the prior generations of EGRF TKIs because while they 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	31741 : 31745	CM	ition of both activating EGFR mutations and T790M, wil
./___Corpus/Medline/xml/PMC4346098.xml	T790M	31760 : 31765	CM	ating EGFR mutations and T790M, wild-type inhibition is
./___Corpus/Medline/xml/PMC4346098.xml	CO-1686	31975 : 31982	CM	 abstract form thus far, CO-1686 and AZD9291. Both have d
./___Corpus/Medline/xml/PMC4346098.xml	AZD9291	31987 : 31994	CM	rm thus far, CO-1686 and AZD9291. Both have demonstrated 
./___Corpus/Medline/xml/PMC4346098.xml	T790M	32078 : 32083	CM	those with biopsy-proven T790M. Mature PFS is not yet a
./___Corpus/Medline/xml/PMC4346098.xml	PFS	32092 : 32095	CM	psy-proven T790M. Mature PFS is not yet available but
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	32306 : 32310	CM	rapy with 3rd-generation EGFR TKIs. CO-1686 causes hyp
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	32547 : 32551	CM	d stage disease, such as EGFR TKIs for patients with E
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	32575 : 32579	CM	R TKIs for patients with EGFR mutations, there is inte
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	32780 : 32784	CM	look at incorporation of EGFR TKIs into multi-modality
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	32923 : 32932	CM	nary data about adjuvant erlotinib. The SELECT study was a 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33010 : 33019	CM	y of 2 years of adjuvant erlotinib for patients with common
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	33045 : 33049	CM	for patients with common EGFR mutations.75 One hundred
./___Corpus/Medline/xml/PMC4346098.xml	2-	33172 : 33174	CPR	the primary end-point of 2-year disease free surviva
./___Corpus/Medline/xml/PMC4346098.xml	IIIA	33239 : 33243	CM	tage: I - 96%, II - 78%, IIIA - 91%), which was signif
./___Corpus/Medline/xml/PMC4346098.xml	2-	33332 : 33334	CPR	fined historical control 2-year disease free surviva
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	33365 : 33369	CM	isease free survival for EGFR mutants followed with ob
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33538 : 33547	CM	nly 4 recurred while one erlotinib and 25 recurred after er
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33570 : 33579	CM	ib and 25 recurred after erlotinib was completed, raising s
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33722 : 33731	CM	y of 2 years of adjuvant erlotinib vs. placebo that enrolle
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	33828 : 33832	CM	among which 16% harbored EGFR mutations.76 Though the 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	33910 : 33914	CM	the subgroup analysis of EGFR mutants suggested that e
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	33938 : 33947	CM	R mutants suggested that erlotinib provided a disease-free 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	34135 : 34139	CM	zed trial including only EGFR mutants and powered to e
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	34237 : 34242	CM	      4. HER 2/3 POSTIVE NSCLC 4.1 The role of HER2 and
./___Corpus/Medline/xml/PMC4346098.xml	HER2	34259 : 34263	CM	VE NSCLC 4.1 The role of HER2 and HER3 in NSCLC       
./___Corpus/Medline/xml/PMC4346098.xml	HER3	34268 : 34272	CM	4.1 The role of HER2 and HER3 in NSCLC                
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	34276 : 34281	CM	role of HER2 and HER3 in NSCLC                      HER
./___Corpus/Medline/xml/PMC4346098.xml	HER2	34303 : 34307	CM	CLC                      HER2 and HER3 (also known as 
./___Corpus/Medline/xml/PMC4346098.xml	HER3	34312 : 34316	CM	                HER2 and HER3 (also known as ERBB2 and
./___Corpus/Medline/xml/PMC4346098.xml	ERBB2	34332 : 34337	CM	 and HER3 (also known as ERBB2 and ERBB3, respectively)
./___Corpus/Medline/xml/PMC4346098.xml	ERBB3	34342 : 34347	CM	(also known as ERBB2 and ERBB3, respectively) are membe
./___Corpus/Medline/xml/PMC4346098.xml	HER	34382 : 34385	CM	vely) are members of the HER/ERBB receptor tyrosine k
./___Corpus/Medline/xml/PMC4346098.xml	ERBB	34386 : 34390	CM	) are members of the HER/ERBB receptor tyrosine kinase
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34400 : 34408	CM	of the HER/ERBB receptor tyrosine kinase family, which als
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	34444 : 34448	CM	ily, which also includes EGFR and HER4. Although these
./___Corpus/Medline/xml/PMC4346098.xml	HER4	34453 : 34457	CM	h also includes EGFR and HER4. Although these receptor
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	34547 : 34551	CM	vival through downstream MAPK and PI3K pathways, they 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	34556 : 34560	CM	ough downstream MAPK and PI3K pathways, they vary in r
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34652 : 34660	CM	he presence of an active tyrosine kinase domain. For examp
./___Corpus/Medline/xml/PMC4346098.xml	HER2	34689 : 34693	CM	ase domain. For example, HER2 has no known high-affini
./___Corpus/Medline/xml/PMC4346098.xml	HER3	34800 : 34804	CM	tion for activation, and HER3 has no tyrosine kinase a
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	34812 : 34820	CM	ivation, and HER3 has no tyrosine kinase activity and reli
./___Corpus/Medline/xml/PMC4346098.xml	HER2	34953 : 34957	CM	g heterodimer is that of HER2 and HER3, which can func
./___Corpus/Medline/xml/PMC4346098.xml	HER3	34962 : 34966	CM	imer is that of HER2 and HER3, which can function as a
./___Corpus/Medline/xml/PMC4346098.xml	HER2	35059 : 35063	CM	               Oncogenic HER2 kinase domain mutations 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	35111 : 35116	CM	s were first reported in NSCLC in 2004.78 Since that ti
./___Corpus/Medline/xml/PMC4346098.xml	HER2	35198 : 35202	CM	he rate of kinase domain HER2 mutations in NSCLC to be
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	35216 : 35221	CM	domain HER2 mutations in NSCLC to be approximately 2–4%
./___Corpus/Medline/xml/PMC4346098.xml	2–	35242 : 35244	CPR	SCLC to be approximately 2–4%.79–81 These mutations 
./___Corpus/Medline/xml/PMC4346098.xml	amino acids	35338 : 35349	CM	n 20 with duplication of amino acids YVMA at codon 775; infre
./___Corpus/Medline/xml/PMC4346098.xml	HER2	35604 : 35608	CM	tations were detected in HER2 and found to be oncogeni
./___Corpus/Medline/xml/PMC4346098.xml	S310F	35648 : 35653	CM	e oncogenic, including a S310F mutation in exon 8 detec
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinomas,82	35699 : 35717	CM	etected in 1 of 188 lung adenocarcinomas,82 a S310Y mutation in 1 of
./___Corpus/Medline/xml/PMC4346098.xml	S310Y	35720 : 35725	CM	ung adenocarcinomas,82 a S310Y mutation in 1 of 63 squa
./___Corpus/Medline/xml/PMC4346098.xml	HER2	36025 : 36029	CM	          In contrast to HER2, there have been no repo
./___Corpus/Medline/xml/PMC4346098.xml	HER3	36078 : 36082	CM	orts of mutations in the HER3 gene. However, HER3 has 
./___Corpus/Medline/xml/PMC4346098.xml	HER3	36098 : 36102	CM	 the HER3 gene. However, HER3 has been implicated as a
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	36187 : 36191	CM	nhibit signaling through EGFR and HER2.84, 85 Attempts
./___Corpus/Medline/xml/PMC4346098.xml	HER2.84	36196 : 36203	CM	gnaling through EGFR and HER2.84, 85 Attempts at therapeu
./___Corpus/Medline/xml/PMC4346098.xml	HER2	36251 : 36255	CM	eutically targeting both HER2 and HER3 are ongoing.   
./___Corpus/Medline/xml/PMC4346098.xml	HER3	36260 : 36264	CM	 targeting both HER2 and HER3 are ongoing.            
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	36400 : 36405	CM	atients with HER2-mutant NSCLC have distinct clinicopat
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	36492 : 36496	CM	hose whose tumors harbor EGFR mutations. In the larges
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	36578 : 36583	CM	atients with HER2-mutant NSCLC, the median age of diagn
./___Corpus/Medline/xml/PMC4346098.xml	31–	36635 : 36638	CPR	is was 60.4 years (range 31–86), 69% were female, 52%
./___Corpus/Medline/xml/PMC4346098.xml	HER2	36732 : 36736	CM	nocarcinomas.81 Although HER2 mutations are relatively
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	36912 : 36916	CM	ous histology without an EGFR mutation, in which case 
./___Corpus/Medline/xml/PMC4346098.xml	HER2	36979 : 36983	CM	 is approximately 14%.79 HER2 mutations are mutually e
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	37041 : 37045	CM	 with point mutations in EGFR, KRAS, BRAF, NRAS, PIK3C
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	37047 : 37051	CM	point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	37053 : 37057	CM	mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1 and 
./___Corpus/Medline/xml/PMC4346098.xml	NRAS	37059 : 37063	CM	ons in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1 and AKT, a
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	37065 : 37071	CM	 EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1 and AKT, as well a
./___Corpus/Medline/xml/PMC4346098.xml	MEK1	37073 : 37077	CM	RAS, BRAF, NRAS, PIK3CA, MEK1 and AKT, as well as rear
./___Corpus/Medline/xml/PMC4346098.xml	AKT	37082 : 37085	CM	, NRAS, PIK3CA, MEK1 and AKT, as well as rearrangemen
./___Corpus/Medline/xml/PMC4346098.xml	HER2	37201 : 37205	CM	r therapeutics targeting HER2 and HER3                
./___Corpus/Medline/xml/PMC4346098.xml	HER3	37210 : 37214	CM	utics targeting HER2 and HER3                      Bot
./___Corpus/Medline/xml/PMC4346098.xml	HER2	37304 : 37308	CM	nal antibodies targeting HER2 are under investigation.
./___Corpus/Medline/xml/PMC4346098.xml	HER2	37564 : 37568	CM	how promise in targeting HER2 in those with HER2-mutan
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	37595 : 37600	CM	n those with HER2-mutant NSCLC. Below are several compo
./___Corpus/Medline/xml/PMC4346098.xml	HER2	37735 : 37739	CM	ntrast to breast cancer, HER2 overexpression or amplif
./___Corpus/Medline/xml/PMC4346098.xml	HER2	37861 : 37865	CM	wever, the presence of a HER2 mutation may be a predic
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	37936 : 37941	CM	sponse to trastuzumab in NSCLC. In a retrospective stud
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38000 : 38005	CM	atients with HER2-mutant NSCLC, a total of 22 anti-HER2
./___Corpus/Medline/xml/PMC4346098.xml	anti-HER2	38021 : 38030	CM	ant NSCLC, a total of 22 anti-HER2 treatments were assessed
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	38142 : 38153	CM	rastuzumab combined with carboplatin, paclitaxel, carboplatin
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	38167 : 38178	CM	carboplatin, paclitaxel, carboplatin/paclitaxel, vinorelbine,
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	38191 : 38202	CM	 carboplatin/paclitaxel, vinorelbine, or docetaxel), the resp
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	38207 : 38216	CM	litaxel, vinorelbine, or docetaxel), the response rate was 
./___Corpus/Medline/xml/PMC4346098.xml	Afatinib	38403 : 38411	CM	R).                  4.5 Afatinib                      Afa
./___Corpus/Medline/xml/PMC4346098.xml	Afatinib	38433 : 38441	CM	nib                      Afatinib is an irreversible small
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	38490 : 38494	CM	l molecular inhibitor of EGFR and HER2 that is approve
./___Corpus/Medline/xml/PMC4346098.xml	HER2	38499 : 38503	CM	ar inhibitor of EGFR and HER2 that is approved for use
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38585 : 38590	CM	atients with EGFR-mutant NSCLC. In lung cancer cell lin
./___Corpus/Medline/xml/PMC4346098.xml	HER2	38630 : 38634	CM	r cell lines harboring a HER2 insertion mutation in th
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	38661 : 38669	CM	nsertion mutation in the tyrosine kinase domain, afatinib 
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38685 : 38693	CM	 tyrosine kinase domain, afatinib was effective at inhibit
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	38740 : 38749	CM	biting survival, whereas erlotinib was not.86 Interestingly
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38776 : 38784	CM	as not.86 Interestingly, afatinib was also effective at in
./___Corpus/Medline/xml/PMC4346098.xml	HER2	38862 : 38866	CM	nes transformed with the HER2 extracellular domain mut
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	38925 : 38933	CM	The clinical activity of afatinib in HER2-mutant NSCLC has
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	38949 : 38954	CM	 afatinib in HER2-mutant NSCLC has been evaluated in th
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39119 : 39127	CM	herapy were treated with afatinib, which resulted in 100% 
./___Corpus/Medline/xml/PMC4346098.xml	SD	39201 : 39203	CM	PR and 2 stable disease [SD]). In the only prospecti
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39242 : 39250	CM	y prospective study with afatinib in this population, 5 pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	39287 : 39292	CM	ulation, 5 patients with NSCLC harboring a HER2 kinase 
./___Corpus/Medline/xml/PMC4346098.xml	HER2	39305 : 39309	CM	s with NSCLC harboring a HER2 kinase domain mutation w
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39351 : 39359	CM	tation were treated with afatinib, followed by the option 
./___Corpus/Medline/xml/PMC4346098.xml	m2	39417 : 39419	CM	eekly paclitaxel at 80mg/m2 to afatinib at progressi
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39423 : 39431	CM	paclitaxel at 80mg/m2 to afatinib at progression.87 Of the
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39564 : 39572	CM	ad a partial response to afatinib alone and 1 had stable d
./___Corpus/Medline/xml/PMC4346098.xml	afatinib	39609 : 39617	CM	 had stable disease with afatinib and a PR once paclitaxel
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	39747 : 39755	CM	 an irreversible pan-HER tyrosine kinase inhibitor. A Phas
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	39831 : 39836	CM	t included patients with NSCLC and HER2 amplification o
./___Corpus/Medline/xml/PMC4346098.xml	HER2	39841 : 39845	CM	 patients with NSCLC and HER2 amplification or mutatio
./___Corpus/Medline/xml/PMC4346098.xml	HER2	40047 : 40051	CM	valuable patients in the HER2 cohort, there were 2 wit
./___Corpus/Medline/xml/PMC4346098.xml	HER2	40117 : 40121	CM	onse, both of whom had a HER2 mutation. Final results 
./___Corpus/Medline/xml/PMC4346098.xml	HER2-mutant	40255 : 40266	CM	clinical mouse models of HER2-mutant lung cancer have demonst
./___Corpus/Medline/xml/PMC4346098.xml	HER2	40302 : 40306	CM	r have demonstrated that HER2 inhibition plus mTOR inh
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	40323 : 40327	CM	hat HER2 inhibition plus mTOR inhibition results in si
./___Corpus/Medline/xml/PMC4346098.xml	neratinib	40460 : 40469	CM	data, the combination of neratinib, an irreversible pan-HER
./___Corpus/Medline/xml/PMC4346098.xml	temsirolimus	40525 : 40537	CM	 molecule inhibitor, and temsirolimus, an mTOR inhibitor, was 
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	40542 : 40546	CM	or, and temsirolimus, an mTOR inhibitor, was studied i
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	40693 : 40698	CM	he trial had HER2-mutant NSCLC. Among them, two had a P
./___Corpus/Medline/xml/PMC4346098.xml	MM-111	40820 : 40826	CM	se.                  4.8 MM-111                      MM-
./___Corpus/Medline/xml/PMC4346098.xml	MM-111	40848 : 40854	CM	111                      MM-111 is a bispecific fully hu
./___Corpus/Medline/xml/PMC4346098.xml	HER2	40902 : 40906	CM	human antibody targeting HER2 and HER3. In preclinical
./___Corpus/Medline/xml/PMC4346098.xml	HER3	40911 : 40915	CM	ibody targeting HER2 and HER3. In preclinical studies 
./___Corpus/Medline/xml/PMC4346098.xml	MM111	40977 : 40982	CM	expressing cancer cells, MM111 inhibits cell proliferat
./___Corpus/Medline/xml/PMC4346098.xml	HER2	41061 : 41065	CM	n combination with other HER2 inhibitors such as trast
./___Corpus/Medline/xml/PMC4346098.xml	HER2	41145 : 41149	CM	ultiple tumor types with HER2 positivity is testing MM
./___Corpus/Medline/xml/PMC4346098.xml	MM-111	41172 : 41178	CM	R2 positivity is testing MM-111 combined with various HE
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	41371 : 41376	CM	atients with HER2-mutant NSCLC.                  4.9 ME
./___Corpus/Medline/xml/PMC4346098.xml	MEHD	41483 : 41487	CM	sly discussed compounds, MEHD 7945 A does not target H
./___Corpus/Medline/xml/PMC4346098.xml	HER2	41511 : 41515	CM	D 7945 A does not target HER2, but instead is a dual-a
./___Corpus/Medline/xml/PMC4346098.xml	IgG1	41552 : 41556	CM	d is a dual-action human IgG1 monoclonal antibody that
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	41590 : 41594	CM	al antibody that targets EGFR and HER3. In cell lines 
./___Corpus/Medline/xml/PMC4346098.xml	HER3	41599 : 41603	CM	dy that targets EGFR and HER3. In cell lines and xenog
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	41667 : 41671	CM	 tumors resistant to the EGFR inhibitors cetuximab or 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	41696 : 41705	CM	 inhibitors cetuximab or erlotinib, MEHD 7945 A was able to
./___Corpus/Medline/xml/PMC4346098.xml	MEHD	41707 : 41711	CM	 cetuximab or erlotinib, MEHD 7945 A was able to overc
./___Corpus/Medline/xml/PMC4346098.xml	MEHD	41818 : 41822	CM	e safety and activity of MEHD 7945 A was studied in a 
./___Corpus/Medline/xml/PMC4346098.xml	Nine	41888 : 41892	CM	 multiple tumor types.93 Nine patients with NSCLC were
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	41907 : 41912	CM	es.93 Nine patients with NSCLC were included, of which 
./___Corpus/Medline/xml/PMC4346098.xml	MM-121	42128 : 42134	CM	er drugs discussed here, MM-121 is a monoclonal antibody
./___Corpus/Medline/xml/PMC4346098.xml	HER3	42178 : 42182	CM	tibody that only targets HER3. It is being developed i
./___Corpus/Medline/xml/PMC4346098.xml	HER3	42333 : 42337	CM	 of known alterations in HER3 in human cancers. Specif
./___Corpus/Medline/xml/PMC4346098.xml	MM-121	42370 : 42376	CM	n cancers. Specifically, MM-121 is being tested in combi
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	42413 : 42422	CM	sted in combination with erlotinib, with early signals of c
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42492 : 42497	CM	atients with EGFR-mutant NSCLC and erlotinib resistance
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	42502 : 42511	CM	th EGFR-mutant NSCLC and erlotinib resistance.94           
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42559 : 42564	CM	         5. ALK-POSITIVE NSCLC                      Chr
./___Corpus/Medline/xml/PMC4346098.xml	ALK	42616 : 42619	CM	osomal rearrangements of ALK are present in 3–7% of N
./___Corpus/Medline/xml/PMC4346098.xml	3–	42635 : 42637	CPR	ts of ALK are present in 3–7% of NSCLC. The resultin
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	42643 : 42648	CM	K are present in 3–7% of NSCLC. The resulting ALK fusio
./___Corpus/Medline/xml/PMC4346098.xml	ALK	42664 : 42667	CM	 of NSCLC. The resulting ALK fusions, such as EML4-AL
./___Corpus/Medline/xml/PMC4346098.xml	EML4-ALK	42685 : 42693	CM	ing ALK fusions, such as EML4-ALK, function as potent onco
./___Corpus/Medline/xml/PMC4346098.xml	ALK	42883 : 42886	CM	tumors to small molecule ALK tyrosine kinase inhibiti
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	42887 : 42895	CM	rs to small molecule ALK tyrosine kinase inhibition. Crizo
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	42943 : 42951	CM	zotinib, a multitargeted tyrosine kinase inhibitor (TKI) o
./___Corpus/Medline/xml/PMC4346098.xml	TKI	42970 : 42973	CM	rosine kinase inhibitor (TKI) of ALK, ROS1 and cMET, 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	42978 : 42981	CM	inase inhibitor (TKI) of ALK, ROS1 and cMET, was the 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	42983 : 42987	CM	 inhibitor (TKI) of ALK, ROS1 and cMET, was the first 
./___Corpus/Medline/xml/PMC4346098.xml	cMET	42992 : 42996	CM	r (TKI) of ALK, ROS1 and cMET, was the first ALK inhib
./___Corpus/Medline/xml/PMC4346098.xml	ALK	43012 : 43015	CM	 and cMET, was the first ALK inhibitor tested in the 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	43071 : 43074	CM	 and helped to establish ALK as a therapeutic target 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	43131 : 43134	CM	C.12 To date, nine other ALK inhibitors have now ente
./___Corpus/Medline/xml/PMC4346098.xml	ALK	43345 : 43348	CM	d select next-generation ALK inhibitors in TKI-naïve 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43400 : 43405	CM	tients with ALK-positive NSCLC.                  5.1 Cr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43566 : 43571	CM	h advanced, ALK-positive NSCLC. In the phase 1 trial (P
./___Corpus/Medline/xml/PMC4346098.xml	PROFILE	43595 : 43602	CM	C. In the phase 1 trial (PROFILE 1001), the objective res
./___Corpus/Medline/xml/PMC4346098.xml	PFS	43687 : 43690	CM	ents was 61%, and median PFS was 9.7 months.95 Update
./___Corpus/Medline/xml/PMC4346098.xml	PROFILE	43763 : 43770	CM	e 2 study of crizotinib (PROFILE 1005) were recently repo
./___Corpus/Medline/xml/PMC4346098.xml	FDA	43810 : 43813	CM	ently reported in the US FDA label. Among 765 patient
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	43868 : 43873	CM	h advanced, ALK-positive NSCLC, the objective response 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	44026 : 44029	CM	as too short to evaluate PFS. Based on the response r
./___Corpus/Medline/xml/PMC4346098.xml	FDA	44195 : 44198	CM	elerated approval by the FDA in August 2011 for patie
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	44255 : 44260	CM	h advanced, ALK-positive NSCLC. This approval occurred 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	44334 : 44337	CM	fter the first report of ALK rearrangements in NSCLC.
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	44550 : 44555	CM	n advanced, ALK-positive NSCLC (PROFILE 1007) were repo
./___Corpus/Medline/xml/PMC4346098.xml	PROFILE	44557 : 44564	CM	ced, ALK-positive NSCLC (PROFILE 1007) were reported.11 I
./___Corpus/Medline/xml/PMC4346098.xml	platinum	44654 : 44662	CM	who had failed one prior platinum-based chemotherapy regim
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	44786 : 44795	CM	herapy, or pemetrexed or docetaxel chemotherapy. Compared w
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45352 : 45357	CM	in advanced ALK-positive NSCLC.                        
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	45465 : 45474	CM	han either pemetrexed or docetaxel chemotherapy in ALK-posi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45583 : 45588	CM	d patients with advanced NSCLC, the efficacy of second-
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	45618 : 45627	CM	 efficacy of second-line docetaxel in ALK-positive NSCLC wa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45644 : 45649	CM	ocetaxel in ALK-positive NSCLC was minimal, with a medi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	45978 : 45983	CM	3.5 months in unselected NSCLC patients with adenocarci
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	46234 : 46239	CM	tients with ALK-positive NSCLC may be more responsive t
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	47172 : 47176	CM	mized phase 3 studies of EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	47177 : 47185	CM	 phase 3 studies of EGFR tyrosine kinase inhibitors in adv
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	47216 : 47220	CM	e inhibitors in advanced EGFR mutant NSCLC. In these s
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47228 : 47233	CM	 in advanced EGFR mutant NSCLC. In these studies where 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47577 : 47582	CM	izotinib in ALK-positive NSCLC remain to be addressed. 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47701 : 47706	CM	h advanced, ALK-positive NSCLC with no requirement for 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	47841 : 47845	CM	le the first-line use of EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	47846 : 47854	CM	e first-line use of EGFR tyrosine kinase inhibitors in adv
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	47897 : 47902	CM	 in advanced EGFR-mutant NSCLC has been established in 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	48458 : 48466	CM	omparing crizotinib with platinum/pemetrexed chemotherapy 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	48533 : 48538	CM	d, advanced ALK-positive NSCLC (ClinicalTrials.gov numb
./___Corpus/Medline/xml/PMC4346098.xml	platinum	48804 : 48812	CM	first-line crizotinib to platinum/pemetrexed chemotherapy 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	48853 : 48858	CM	otherapy in ALK-positive NSCLC patients (ClinicalTrials
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49037 : 49040	CM	     5.2 Next-generation ALK Inhibitors: Alectinib an
./___Corpus/Medline/xml/PMC4346098.xml	Ceritinib	49067 : 49076	CM	nhibitors: Alectinib and Ceritinib                      Ale
./___Corpus/Medline/xml/PMC4346098.xml	TKI	49153 : 49156	CM	hly potent and selective TKI targeting ALK, but not R
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49167 : 49170	CM	 selective TKI targeting ALK, but not ROS1 or cMET.10
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	49180 : 49184	CM	I targeting ALK, but not ROS1 or cMET.103 Alectinib wa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	49330 : 49335	CM	h advanced, ALK-positive NSCLC who were crizotinib-naïv
./___Corpus/Medline/xml/PMC4346098.xml	PROFILE	49385 : 49392	CM	e.104 In contrast to the PROFILE 1001/5/7 studies which u
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49421 : 49424	CM	1/5/7 studies which used ALK FISH only, patients were
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49483 : 49486	CM	ed as ALK-positive using ALK immunohistochemistry (IH
./___Corpus/Medline/xml/PMC4346098.xml	IHC	49509 : 49512	CM	LK immunohistochemistry (IHC), followed by ALK FISH f
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49527 : 49530	CM	istry (IHC), followed by ALK FISH for confirmation. I
./___Corpus/Medline/xml/PMC4346098.xml	PFS	49721 : 49724	CM	 only 7.6 months, median PFS is not yet known, but du
./___Corpus/Medline/xml/PMC4346098.xml	ALK	49874 : 49877	CM	rly, the next-generation ALK inhibitor ceritinib (LDK
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	49888 : 49897	CM	generation ALK inhibitor ceritinib (LDK378) has also demons
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	49899 : 49905	CM	ALK inhibitor ceritinib (LDK378) has also demonstrated h
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	49982 : 49987	CM	tinib-naïve ALK-positive NSCLC. In preclinical studies,
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50013 : 50022	CM	 In preclinical studies, ceritinib is also more potent and 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50084 : 50087	CM	an crizotinib, targeting ALK and ROS1 but not cMET.10
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	50092 : 50096	CM	tinib, targeting ALK and ROS1 but not cMET.105 In a gl
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50141 : 50150	CM	 a global phase 1 study, ceritinib was highly active in pat
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50261 : 50264	CM	 who had not received an ALK inhibitor and who receiv
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50292 : 50301	CM	hibitor and who received ceritinib at doses of 400 mg or hi
./___Corpus/Medline/xml/PMC4346098.xml	PFS	50360 : 50363	CM	 ORR was 62%, and median PFS was 10.4 months. Of note
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50509 : 50518	CM	tients. In addition, the ceritinib study required only ALK 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50539 : 50542	CM	inib study required only ALK FISH testing to demonstr
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50571 : 50574	CM	H testing to demonstrate ALK rearrangement, as oppose
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50609 : 50612	CM	ment, as opposed to both ALK IHC and ALK FISH. Thus, 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	50621 : 50624	CM	osed to both ALK IHC and ALK FISH. Thus, these two fa
./___Corpus/Medline/xml/PMC4346098.xml	ceritinib	50759 : 50768	CM	en between alectinib and ceritinib in the TKI-naïve ALK-pos
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	50831 : 50835	CM	ion.                  6. ROS1, RET AND NTRK1 POSITIVE 
./___Corpus/Medline/xml/PMC4346098.xml	RET	50837 : 50840	CM	                6. ROS1, RET AND NTRK1 POSITIVE NSCLC
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	50845 : 50850	CM	        6. ROS1, RET AND NTRK1 POSITIVE NSCLC 6.1 Biolo
./___Corpus/Medline/xml/PMC4346098.xml	POSITIVE	50851 : 50859	CM	  6. ROS1, RET AND NTRK1 POSITIVE NSCLC 6.1 Biology       
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	50860 : 50865	CM	, RET AND NTRK1 POSITIVE NSCLC 6.1 Biology             
./___Corpus/Medline/xml/PMC4346098.xml	mRNA	51056 : 51060	CM	s and result in chimeric mRNA transcripts and proteins
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	51230 : 51238	CM	 genes encoding receptor tyrosine kinases (RTKs): ROS1, RE
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	51255 : 51259	CM	tyrosine kinases (RTKs): ROS1, RET, and NTRK1. These g
./___Corpus/Medline/xml/PMC4346098.xml	RET	51261 : 51264	CM	ne kinases (RTKs): ROS1, RET, and NTRK1. These gene f
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	51270 : 51275	CM	s (RTKs): ROS1, RET, and NTRK1. These gene fusions alwa
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	51592 : 51596	CM	oligomerization domains. ROS1, RET, TRKA (encoded by t
./___Corpus/Medline/xml/PMC4346098.xml	RET	51598 : 51601	CM	erization domains. ROS1, RET, TRKA (encoded by the NT
./___Corpus/Medline/xml/PMC4346098.xml	TRKA	51603 : 51607	CM	tion domains. ROS1, RET, TRKA (encoded by the NTRK1 ge
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	51624 : 51629	CM	ET, TRKA (encoded by the NTRK1 gene) are not highly exp
./___Corpus/Medline/xml/PMC4346098.xml	KIF5B	52028 : 52033	CM	 encoded by the partners KIF5B, CCDC6, EZR, TPM3 and MP
./___Corpus/Medline/xml/PMC4346098.xml	CCDC6	52035 : 52040	CM	d by the partners KIF5B, CCDC6, EZR, TPM3 and MPRIP fac
./___Corpus/Medline/xml/PMC4346098.xml	EZR	52042 : 52045	CM	e partners KIF5B, CCDC6, EZR, TPM3 and MPRIP facilita
./___Corpus/Medline/xml/PMC4346098.xml	TPM3	52047 : 52051	CM	tners KIF5B, CCDC6, EZR, TPM3 and MPRIP facilitate dim
./___Corpus/Medline/xml/PMC4346098.xml	MPRIP	52056 : 52061	CM	5B, CCDC6, EZR, TPM3 and MPRIP facilitate dimerization 
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	52419 : 52423	CM	hat ultimately activates MAPK and AKT signaling, which
./___Corpus/Medline/xml/PMC4346098.xml	AKT	52428 : 52431	CM	ately activates MAPK and AKT signaling, which leads t
./___Corpus/Medline/xml/PMC4346098.xml	IHC	52861 : 52864	CM	tu hybridization (FISH), IHC, next generation sequenc
./___Corpus/Medline/xml/PMC4346098.xml	RNA	52902 : 52905	CM	tion sequencing (NGS) of RNA and DNA, and polymerase 
./___Corpus/Medline/xml/PMC4346098.xml	116–	53055 : 53059	CPR	enes.108, 111, 112, 114, 116–118 Typically, these onco
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	53193 : 53197	CM	 demonstrated overlap of ROS1 fusions and EGFR, KRAS, 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	53210 : 53214	CM	rlap of ROS1 fusions and EGFR, KRAS, and BRAF mutation
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	53216 : 53220	CM	f ROS1 fusions and EGFR, KRAS, and BRAF mutations, sim
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	53226 : 53230	CM	ions and EGFR, KRAS, and BRAF mutations, similar to du
./___Corpus/Medline/xml/PMC4346098.xml	ALK	53280 : 53283	CM	al oncogenes observed in ALK positive cases.117–122 T
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	53324 : 53328	CM	117–122 The incidence of ROS1, RET, and NTRK1 gene fus
./___Corpus/Medline/xml/PMC4346098.xml	RET	53330 : 53333	CM	2 The incidence of ROS1, RET, and NTRK1 gene fusions 
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	53339 : 53344	CM	idence of ROS1, RET, and NTRK1 gene fusions appears to 
./___Corpus/Medline/xml/PMC4346098.xml	1–	53388 : 53390	CPR	rs to be in the range of 1–3%, although in studies u
./___Corpus/Medline/xml/PMC4346098.xml	116–	53527 : 53531	CPR	gher.108, 111, 112, 114, 116–118 Although associations
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	53985 : 53989	CM	ave been associated with ROS1, RET, and NTRK1 fusions.
./___Corpus/Medline/xml/PMC4346098.xml	RET	53991 : 53994	CM	en associated with ROS1, RET, and NTRK1 fusions.108, 
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	54000 : 54005	CM	ated with ROS1, RET, and NTRK1 fusions.108, 116, 117, 1
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	54059 : 54063	CM	126                  6.3 ROS1, RET and NTRK in other d
./___Corpus/Medline/xml/PMC4346098.xml	RET	54065 : 54068	CM	               6.3 ROS1, RET and NTRK in other diseas
./___Corpus/Medline/xml/PMC4346098.xml	NTRK	54073 : 54077	CM	       6.3 ROS1, RET and NTRK in other disease types  
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	54272 : 54276	CM	e in other malignancies. ROS1 has been detected in gas
./___Corpus/Medline/xml/PMC4346098.xml	RET	54391 : 54394	CM	thers.113, 119, 127, 128 RET fusions have long been i
./___Corpus/Medline/xml/PMC4346098.xml	CMML	54490 : 54494	CM	 also been identified in CMML and others.128–130 An on
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	54527 : 54532	CM	ers.128–130 An oncogenic NTRK1 fusion was first detecte
./___Corpus/Medline/xml/PMC4346098.xml	131–	54709 : 54713	CPR	er tumor types.128, 129, 131–133 Many TRKA inhibitors 
./___Corpus/Medline/xml/PMC4346098.xml	TRKA	54722 : 54726	CM	s.128, 129, 131–133 Many TRKA inhibitors have activity
./___Corpus/Medline/xml/PMC4346098.xml	TRKB	54781 : 54785	CM	nst two homologous RTKs, TRKB (NTKR2) and TRKC (NTRK3)
./___Corpus/Medline/xml/PMC4346098.xml	TRKC	54798 : 54802	CM	s RTKs, TRKB (NTKR2) and TRKC (NTRK3). These genes are
./___Corpus/Medline/xml/PMC4346098.xml	NTRK3	54804 : 54809	CM	, TRKB (NTKR2) and TRKC (NTRK3). These genes are also i
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	54985 : 54989	CM	           Inhibitors of ROS1, RET and TRK 6.4 ROS1   
./___Corpus/Medline/xml/PMC4346098.xml	RET	54991 : 54994	CM	     Inhibitors of ROS1, RET and TRK 6.4 ROS1        
./___Corpus/Medline/xml/PMC4346098.xml	TRK	54999 : 55002	CM	ibitors of ROS1, RET and TRK 6.4 ROS1                
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55007 : 55011	CM	of ROS1, RET and TRK 6.4 ROS1                      Cri
./___Corpus/Medline/xml/PMC4346098.xml	ALK+	55082 : 55086	CM	been approved for use in ALK+ NSCLC. ROS1 has high hom
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55087 : 55092	CM	approved for use in ALK+ NSCLC. ROS1 has high homology 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55094 : 55098	CM	d for use in ALK+ NSCLC. ROS1 has high homology to ALK
./___Corpus/Medline/xml/PMC4346098.xml	ALK	55120 : 55123	CM	OS1 has high homology to ALK and many ALK inhibitors 
./___Corpus/Medline/xml/PMC4346098.xml	ALK	55133 : 55136	CM	homology to ALK and many ALK inhibitors also display 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55161 : 55165	CM	 inhibitors also display ROS1 inhibition.113 An expand
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	55257 : 55262	CM	ort clinical outcomes of ROS1+ NSCLC patients treated w
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55263 : 55268	CM	inical outcomes of ROS1+ NSCLC patients treated with cr
./___Corpus/Medline/xml/PMC4346098.xml	6-	55494 : 55496	CPR	 rate (ORR) of 60% and a 6-month PFS rate of 76%, ve
./___Corpus/Medline/xml/PMC4346098.xml	PFS	55502 : 55505	CM	RR) of 60% and a 6-month PFS rate of 76%, very simila
./___Corpus/Medline/xml/PMC4346098.xml	ALK+	55563 : 55567	CM	dies of the same drug in ALK+ NSCLC patients.95, 138 F
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	55568 : 55573	CM	of the same drug in ALK+ NSCLC patients.95, 138 Foretin
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55677 : 55681	CM	or with activity against ROS1 (as well as RET, MET, AX
./___Corpus/Medline/xml/PMC4346098.xml	RET	55694 : 55697	CM	against ROS1 (as well as RET, MET, AXL and other kina
./___Corpus/Medline/xml/PMC4346098.xml	MET	55699 : 55702	CM	st ROS1 (as well as RET, MET, AXL and other kinases) 
./___Corpus/Medline/xml/PMC4346098.xml	AXL	55704 : 55707	CM	S1 (as well as RET, MET, AXL and other kinases) that 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55746 : 55750	CM	ases) that has a planned ROS1 cohort in an upcoming cl
./___Corpus/Medline/xml/PMC4346098.xml	Ceritinib	55886 : 55895	CM	68587"}}NCT01068587).139 Ceritinib (LDK378, Novartis) is a 
./___Corpus/Medline/xml/PMC4346098.xml	LDK378	55897 : 55903	CM	01068587).139 Ceritinib (LDK378, Novartis) is a potent s
./___Corpus/Medline/xml/PMC4346098.xml	ALK	55945 : 55948	CM	potent second generation ALK inhibitor that displays 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	55980 : 55984	CM	tor that displays weaker ROS1 inhibition;105 however, 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	56065 : 56070	CM	linical trials enrolling ROS1+ NSCLC patients. AP26113 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56071 : 56076	CM	l trials enrolling ROS1+ NSCLC patients. AP26113 (Ariad
./___Corpus/Medline/xml/PMC4346098.xml	AP26113	56087 : 56094	CM	ng ROS1+ NSCLC patients. AP26113 (Ariad) is currently in 
./___Corpus/Medline/xml/PMC4346098.xml	ALK+	56139 : 56143	CM	y in clinical trials for ALK+ NSCLC and also has activ
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56144 : 56149	CM	clinical trials for ALK+ NSCLC and also has activity ag
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	56180 : 56184	CM	lso has activity against ROS1, but is currently not ye
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	56221 : 56226	CM	rently not yet enrolling ROS1+ NSCLC patients ({"type":
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56227 : 56232	CM	 not yet enrolling ROS1+ NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	ALK	56379 : 56382	CM	er) is a next generation ALK/ROS1 inhibitor that is c
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	56383 : 56387	CM	is a next generation ALK/ROS1 inhibitor that is curren
./___Corpus/Medline/xml/PMC4346098.xml	TKI	56446 : 56449	CM	ling crizotinib-naïve or TKI-resistant ROS1 patients 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	56460 : 56464	CM	b-naïve or TKI-resistant ROS1 patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	RET	56627 : 56630	CM	                Multiple RET inhibitors are undergoin
./___Corpus/Medline/xml/PMC4346098.xml	RET+	56676 : 56680	CM	going clinical trials in RET+ NSCLC patients and many 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56681 : 56686	CM	 clinical trials in RET+ NSCLC patients and many of the
./___Corpus/Medline/xml/PMC4346098.xml	XL184	56783 : 56788	CM	l trial of cabozantinib (XL184, Exelixis), a RET inhibi
./___Corpus/Medline/xml/PMC4346098.xml	RET	56803 : 56806	CM	nib (XL184, Exelixis), a RET inhibitor (in addition t
./___Corpus/Medline/xml/PMC4346098.xml	MET	56833 : 56836	CM	nhibitor (in addition to MET and VEGFR2) is currently
./___Corpus/Medline/xml/PMC4346098.xml	VEGFR2	56841 : 56847	CM	 (in addition to MET and VEGFR2) is currently accruing R
./___Corpus/Medline/xml/PMC4346098.xml	RET+	56871 : 56875	CM	2) is currently accruing RET+ NSCLC patients ({"type":
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	56876 : 56881	CM	 currently accruing RET+ NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	RET	57181 : 57184	CM	linical activity of this RET inhibitor in RET gene fu
./___Corpus/Medline/xml/PMC4346098.xml	RET	57198 : 57201	CM	of this RET inhibitor in RET gene fusion positive pat
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57265 : 57275	CM	ase II clinical trial of vandetanib (AstraZeneca), a dual RE
./___Corpus/Medline/xml/PMC4346098.xml	RET	57298 : 57301	CM	ib (AstraZeneca), a dual RET and EGFR inhibitor, in R
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	57306 : 57310	CM	aZeneca), a dual RET and EGFR inhibitor, in RET+ NSCLC
./___Corpus/Medline/xml/PMC4346098.xml	RET+	57325 : 57329	CM	T and EGFR inhibitor, in RET+ NSCLC is currently accru
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	57330 : 57335	CM	 EGFR inhibitor, in RET+ NSCLC is currently accruing pa
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57498 : 57508	CM	reated off-protocol with vandetanib 300mg once daily showed 
./___Corpus/Medline/xml/PMC4346098.xml	vandetanib	57605 : 57615	CM	reated with off-protocol vandetanib showed prolonged stable 
./___Corpus/Medline/xml/PMC4346098.xml	VEGFR1–3	57723 : 57731	CM	 multi-kinase inhibitor (VEGFR1–3, FGFR1–3, SCFR, and PDGF
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1–3	57733 : 57740	CM	ase inhibitor (VEGFR1–3, FGFR1–3, SCFR, and PDGFR) with a
./___Corpus/Medline/xml/PMC4346098.xml	SCFR	57742 : 57746	CM	itor (VEGFR1–3, FGFR1–3, SCFR, and PDGFR) with activit
./___Corpus/Medline/xml/PMC4346098.xml	PDGFR	57752 : 57757	CM	R1–3, FGFR1–3, SCFR, and PDGFR) with activity against R
./___Corpus/Medline/xml/PMC4346098.xml	RET	57781 : 57784	CM	R) with activity against RET and is currently enrolli
./___Corpus/Medline/xml/PMC4346098.xml	ponatinib	57967 : 57976	CM	).144 Clinical trials of ponatinib (AP24534, Ariad), a mult
./___Corpus/Medline/xml/PMC4346098.xml	AP24534	57978 : 57985	CM	cal trials of ponatinib (AP24534, Ariad), a multikinase i
./___Corpus/Medline/xml/PMC4346098.xml	RET	58024 : 58027	CM	ltikinase inhibitor with RET activity, in RET+ NSCLC 
./___Corpus/Medline/xml/PMC4346098.xml	RET+	58041 : 58045	CM	or with RET activity, in RET+ NSCLC are planned ({"typ
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	58046 : 58051	CM	th RET activity, in RET+ NSCLC are planned ({"type":"cl
./___Corpus/Medline/xml/PMC4346098.xml	Sunitinib	58167 : 58176	CM	"}}NCT01935336).145, 146 Sunitinib (Pfizer) is another mult
./___Corpus/Medline/xml/PMC4346098.xml	RET	58364 : 58367	CM	 benefit in patient with RET gene fusions ({"type":"c
./___Corpus/Medline/xml/PMC4346098.xml	TRK	58497 : 58500	CM	7).                  6.6 TRK                      LOX
./___Corpus/Medline/xml/PMC4346098.xml	Loxo	58532 : 58536	CM	               LOXO-101 (Loxo) is a selective pan-TRK 
./___Corpus/Medline/xml/PMC4346098.xml	TRKA	58572 : 58576	CM	ctive pan-TRK inhibitor (TRKA, TRKB, and TRKC) that is
./___Corpus/Medline/xml/PMC4346098.xml	TRKB	58578 : 58582	CM	pan-TRK inhibitor (TRKA, TRKB, and TRKC) that is plann
./___Corpus/Medline/xml/PMC4346098.xml	TRKC	58588 : 58592	CM	hibitor (TRKA, TRKB, and TRKC) that is planned to shor
./___Corpus/Medline/xml/PMC4346098.xml	ALK	58720 : 58723	CM	 inhibitor that also has ALK/ROS1 activity with repor
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	58724 : 58728	CM	ibitor that also has ALK/ROS1 activity with reported C
./___Corpus/Medline/xml/PMC4346098.xml	CNS	58752 : 58755	CM	1 activity with reported CNS penetration and is curre
./___Corpus/Medline/xml/PMC4346098.xml	ALK	58836 : 58839	CM	. TSR-011 (Tesaro) is an ALK inhibitor with ~10 selec
./___Corpus/Medline/xml/PMC4346098.xml	TRK	58880 : 58883	CM	~10 selectivity over the TRK family of RTKs and is cu
./___Corpus/Medline/xml/PMC4346098.xml	Fms	59035 : 59038	CM	itional activity against Fms, is currently in clinica
./___Corpus/Medline/xml/PMC4346098.xml	TRKA	59305 : 59309	CM	e cancer-related pain as TRKA signaling can modulate p
./___Corpus/Medline/xml/PMC4346098.xml	NTRK1	59356 : 59361	CM	e pain: Mutations in the NTRK1 gene are the cause of th
./___Corpus/Medline/xml/PMC4346098.xml	ALK	59513 : 59516	CM	focus of next generation ALK inhibitors has been to i
./___Corpus/Medline/xml/PMC4346098.xml	CNS	59548 : 59551	CM	tors has been to improve CNS penetration to more effe
./___Corpus/Medline/xml/PMC4346098.xml	CNS	59706 : 59709	CM	 crizotinib;149 however, CNS penetration may not be a
./___Corpus/Medline/xml/PMC4346098.xml	TRKB	59787 : 59791	CM	nhibitors. Inhibition of TRKB has been linked to ataxi
./___Corpus/Medline/xml/PMC4346098.xml	TRKB	60001 : 60005	CM	ophic factor (BDNF), the TRKB cognate ligand.150, 151 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	60130 : 60134	CM	to cognate inhibitors of ROS1 are similar to mechanism
./___Corpus/Medline/xml/PMC4346098.xml	ALK	60208 : 60211	CM	erved for tumors bearing ALK fusions or EGFR mutation
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	60223 : 60227	CM	s bearing ALK fusions or EGFR mutations. The first des
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	60304 : 60308	CM	nce was a patient with a ROS1 kinase domain mutation.1
./___Corpus/Medline/xml/PMC4346098.xml	G2032R	60351 : 60357	CM	ation.152 This mutation, G2032R, is analogous to the ALK
./___Corpus/Medline/xml/PMC4346098.xml	ALK	60379 : 60382	CM	32R, is analogous to the ALK G1202R and adjacent to t
./___Corpus/Medline/xml/PMC4346098.xml	D1203N	60410 : 60416	CM	202R and adjacent to the D1203N and S1206Y mutation loca
./___Corpus/Medline/xml/PMC4346098.xml	S1206Y	60421 : 60427	CM	jacent to the D1203N and S1206Y mutation located at the 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	60599 : 60603	CM	 PF-06463922 can inhibit ROS1 G2032R and that AP26113 
./___Corpus/Medline/xml/PMC4346098.xml	G2032R	60604 : 60610	CM	6463922 can inhibit ROS1 G2032R and that AP26113 can ove
./___Corpus/Medline/xml/PMC4346098.xml	AP26113	60620 : 60627	CM	bit ROS1 G2032R and that AP26113 can overcome the predict
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	60655 : 60659	CM	n overcome the predicted ROS1 gatekeeper mutation, L20
./___Corpus/Medline/xml/PMC4346098.xml	RET	60727 : 60730	CM	Resistance mechanisms to RET inhibitors have yet to b
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	60770 : 60775	CM	e yet to be described in NSCLC patients; however, ponat
./___Corpus/Medline/xml/PMC4346098.xml	ponatinib	60795 : 60804	CM	NSCLC patients; however, ponatinib has demonstrated activit
./___Corpus/Medline/xml/PMC4346098.xml	RET	60849 : 60852	CM	tivity against oncogenic RET carrying substitutions a
./___Corpus/Medline/xml/PMC4346098.xml	TRKA	60927 : 60931	CM	r residue, V804.145, 146 TRKA harbors a bulky tyrosine
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	60948 : 60956	CM	146 TRKA harbors a bulky tyrosine residue at the conserved
./___Corpus/Medline/xml/PMC4346098.xml	ROS1+	61148 : 61153	CM	ntly been described in a ROS1+ cell line model of drug 
./___Corpus/Medline/xml/PMC4346098.xml	SLC34A2-ROS1	61229 : 61241	CM	carcinoma cell line with SLC34A2-ROS1, HCC78, with in vitro in
./___Corpus/Medline/xml/PMC4346098.xml	HCC78	61243 : 61248	CM	 line with SLC34A2-ROS1, HCC78, with in vitro induced r
./___Corpus/Medline/xml/PMC4346098.xml	vitro	61258 : 61263	CM	4A2-ROS1, HCC78, with in vitro induced resistance to a 
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	61288 : 61292	CM	 induced resistance to a ROS1 kinase inhibitor, switch
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	61350 : 61354	CM	ene dependence away from ROS1 to EGFR.157 This mechani
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	61495 : 61499	CM	nce.                  7. BRAF MUTANT NSCLC            
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	61507 : 61512	CM	          7. BRAF MUTANT NSCLC                      BRA
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	61534 : 61538	CM	CLC                      BRAF, an oncogene encoding a 
./___Corpus/Medline/xml/PMC4346098.xml	RAS	61563 : 61566	CM	, an oncogene encoding a RAS-regulated kinase that pr
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	61678 : 61682	CM	158, 159 The majority of BRAF mutations promote kinase
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylate	61763 : 61776	CM	se’s ability to directly phosphorylate MEK.159 The BRAF exon 15
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	61789 : 61793	CM	hosphorylate MEK.159 The BRAF exon 15 mutation in whic
./___Corpus/Medline/xml/PMC4346098.xml	glutamine	61820 : 61829	CM	xon 15 mutation in which glutamine is substituted for a val
./___Corpus/Medline/xml/PMC4346098.xml	valine	61851 : 61857	CM	ine is substituted for a valine at residue 600 (V600E) d
./___Corpus/Medline/xml/PMC4346098.xml	V600E	61874 : 61879	CM	a valine at residue 600 (V600E) destabilizes the inacti
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	61960 : 61975	RN	 to continual downstream phosphorylation in the MAPK signaling ca
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	61983 : 61987	CM	m phosphorylation in the MAPK signaling cascade. BRAF 
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62007 : 62011	CM	 MAPK signaling cascade. BRAF mutations are found in a
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62132 : 62136	CM	ing selectively targeted BRAF V600E inhibitors has eli
./___Corpus/Medline/xml/PMC4346098.xml	V600E	62137 : 62142	CM	electively targeted BRAF V600E inhibitors has elicited 
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62239 : 62243	CM	ncers harboring the same BRAF mutation rarely respond 
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62271 : 62275	CM	tation rarely respond to BRAF inhibitor monotherapy.16
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62344 : 62348	CM	ation targeting specific BRAF mutations in NSCLC is on
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	62362 : 62367	CM	ecific BRAF mutations in NSCLC is ongoing.             
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62415 : 62419	CM	       7.1 Prevalence of BRAF Mutations in NSCLC      
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62492 : 62496	CM	, two studies identified BRAF mutations in 1.6–3% of N
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62679 : 62683	CM	 adenocarcinoma of which BRAF mutations in codons V600
./___Corpus/Medline/xml/PMC4346098.xml	V600	62704 : 62708	CM	BRAF mutations in codons V600, D594 and G469 occurred 
./___Corpus/Medline/xml/PMC4346098.xml	G469	62719 : 62723	CM	in codons V600, D594 and G469 occurred in 3% of NSCLC 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	62742 : 62747	CM	d G469 occurred in 3% of NSCLC cases.163 An analysis lo
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62841 : 62845	CM	Italy in 2011 identified BRAF mutations in 4.9% of pat
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62922 : 62926	CM	to melanoma where 90% of BRAF mutations are V600E, app
./___Corpus/Medline/xml/PMC4346098.xml	V600E	62941 : 62946	CM	0% of BRAF mutations are V600E, approximately half of t
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	62974 : 62978	CM	pproximately half of the BRAF mutations in the general
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	63004 : 63009	CM	mutations in the general NSCLC population are non-V600E
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	63110 : 63114	CM	l lung cancer identified BRAF mutations in 4% of cases
./___Corpus/Medline/xml/PMC4346098.xml	V600E	63176 : 63181	CM	ch were non-V600E.27 The V600E mutation has been associ
./___Corpus/Medline/xml/PMC4346098.xml	DFS	63287 : 63290	CM	s (significantly shorter DFS and OS).164 V600E mutati
./___Corpus/Medline/xml/PMC4346098.xml	OS).164	63295 : 63302	CM	ficantly shorter DFS and OS).164 V600E mutations have bee
./___Corpus/Medline/xml/PMC4346098.xml	V600E	63303 : 63308	CM	 shorter DFS and OS).164 V600E mutations have been repo
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	63466 : 63470	CM	th cigarette smoking.164 BRAF mutations in an Asian po
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	63590 : 63594	CM	  7.2 Clinical data with BRAF inhibitors              
./___Corpus/Medline/xml/PMC4346098.xml	V600E	63642 : 63647	CM	          Vemurafenib, a V600E BRAF inhibitor used in m
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	63648 : 63652	CM	    Vemurafenib, a V600E BRAF inhibitor used in melano
./___Corpus/Medline/xml/PMC4346098.xml	anti-	63706 : 63711	CPR	has been associated with anti-tumor activity in NSCLC.1
./___Corpus/Medline/xml/PMC4346098.xml	RR	63844 : 63846	CM	e arm trial, the overall RR for single agent dabrafe
./___Corpus/Medline/xml/PMC4346098.xml	FDA	63941 : 63944	CM	ted.168 As a result, the FDA granted breakthrough sta
./___Corpus/Medline/xml/PMC4346098.xml	V600E	63991 : 63996	CM	status to dabrafenib for V600E mutation-positive NSCLC 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64015 : 64020	CM	 V600E mutation-positive NSCLC in January 2014. During 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	64080 : 64088	CM	 trial of the Src family tyrosine kinase inhibitor dasatin
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64106 : 64115	CM	yrosine kinase inhibitor dasatinib for advanced NSCLC, a pr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64129 : 64134	CM	r dasatinib for advanced NSCLC, a profound antitumor ef
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	64269 : 64273	CM	e-inactivating non-V600E BRAF mutation, Y472CBRAF.169 
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64312 : 64321	CM	2CBRAF.169 When studying dasatinib in NSCLC cell lines with
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64325 : 64330	CM	en studying dasatinib in NSCLC cell lines with an endog
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	64374 : 64378	CM	 endogenous inactivating BRAF mutation, the cell lines
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	64534 : 64538	CM	cted ongoing trials with BRAF inhibitors              
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	64682 : 64692	CM	 and in combination with trametinib, a mitogen-activated pro
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	64696 : 64703	CM	ation with trametinib, a mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	64763 : 64768	CM	, is recruiting stage IV NSCLC participants with BRAF V
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	64787 : 64791	CM	 NSCLC participants with BRAF V600E mutations ({"type"
./___Corpus/Medline/xml/PMC4346098.xml	V600E	64792 : 64797	CM	C participants with BRAF V600E mutations ({"type":"clin
./___Corpus/Medline/xml/PMC4346098.xml	NCT01336634"}}NCT01336634	64875 : 64900	CM	"NCT01336634","term_id":"NCT01336634"}}NCT01336634). A study evaluating das
./___Corpus/Medline/xml/PMC4346098.xml	dasatinib	64922 : 64931	CM	634). A study evaluating dasatinib in subjects with advance
./___Corpus/Medline/xml/PMC4346098.xml	DDR2	64978 : 64982	CM	nced cancers harboring a DDR2 mutation or an inactivat
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	65011 : 65015	CM	ation or an inactivating BRAF mutation is currently en
./___Corpus/Medline/xml/PMC4346098.xml	GSK1120212	65187 : 65197	CM	bel second-line study of GSK1120212, which is closed to enro
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	65239 : 65249	CM	 to enrollment, compared trametinib with docetaxel in stage 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	65255 : 65264	CM	compared trametinib with docetaxel in stage IV NSCLC with a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	65277 : 65282	CM	th docetaxel in stage IV NSCLC with a mutation in KRAS,
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	65302 : 65306	CM	NSCLC with a mutation in KRAS, NRAS, BRAF, or MEK1 gen
./___Corpus/Medline/xml/PMC4346098.xml	NRAS	65308 : 65312	CM	with a mutation in KRAS, NRAS, BRAF, or MEK1 gene. (Cl
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	65314 : 65318	CM	 mutation in KRAS, NRAS, BRAF, or MEK1 gene. (Clinical
./___Corpus/Medline/xml/PMC4346098.xml	MEK1	65323 : 65327	CM	 in KRAS, NRAS, BRAF, or MEK1 gene. (Clinicaltrials.go
./___Corpus/Medline/xml/PMC4346098.xml	NCT01362296"}}NCT01362296	65425 : 65450	CM	"NCT01362296","term_id":"NCT01362296"}}NCT01362296).                  8. KR
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	65473 : 65477	CM	96).                  8. KRAS MUTANT NSCLC 8.1 Biology
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	65485 : 65490	CM	          8. KRAS MUTANT NSCLC 8.1 Biology and Nomencla
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	65557 : 65561	CM	         In lung cancer, KRAS (chromosome 12p12.1) is 
./___Corpus/Medline/xml/PMC4346098.xml	12p12.1	65574 : 65581	CM	cancer, KRAS (chromosome 12p12.1) is the principal member
./___Corpus/Medline/xml/PMC4346098.xml	NRAS	65665 : 65669	CM	ludes HRAS [11p15.5] and NRAS [1p13.1]) involved in tu
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	65720 : 65724	CM	origenesis. The HRAS and KRAS genes were initially ide
./___Corpus/Medline/xml/PMC4346098.xml	NRAS	65982 : 65986	CM	me Rat sarcoma (Ras).170 NRAS is so named for its init
./___Corpus/Medline/xml/PMC4346098.xml	RAS	66064 : 66067	CM	neuroblastoma cells. All RAS proteins undergo complex
./___Corpus/Medline/xml/PMC4346098.xml	farnesylation	66147 : 66160	RN	l modification including farnesylation, gerangylgerangylation, 
./___Corpus/Medline/xml/PMC4346098.xml	palmitoylation	66189 : 66203	RN	rangylgerangylation, and palmitoylation.                        
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	66243 : 66247	CM	                         KRAS activation begins with s
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	66319 : 66323	CM	upstream receptors, most EGFR in lung cancer. Adaptor 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	66399 : 66403	CM	 intracellular domain of EGFR and recruit guanine nucl
./___Corpus/Medline/xml/PMC4346098.xml	guanine nucleotide	66416 : 66434	CM	main of EGFR and recruit guanine nucleotide exchange factors that in
./___Corpus/Medline/xml/PMC4346098.xml	RAS	66471 : 66474	CM	ctors that interact with RAS to promote the exchange 
./___Corpus/Medline/xml/PMC4346098.xml	guanosine diphosphate	66502 : 66523	CM	 promote the exchange of guanosine diphosphate (GDP) for guanosine trip
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66525 : 66528	CM	f guanosine diphosphate (GDP) for guanosine triphosph
./___Corpus/Medline/xml/PMC4346098.xml	guanosine triphosphate	66534 : 66556	CM	ne diphosphate (GDP) for guanosine triphosphate (GTP). With binding of G
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66558 : 66561	CM	 guanosine triphosphate (GTP). With binding of GTP, a
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66580 : 66583	CM	e (GTP). With binding of GTP, activated KRAS phosphor
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	66595 : 66599	CM	inding of GTP, activated KRAS phosphorylates downstrea
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylates	66600 : 66614	CM	g of GTP, activated KRAS phosphorylates downstream signaling cas
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66662 : 66665	CM	ascade proteins in until GTP is converted to GDP thro
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66682 : 66685	CM	ntil GTP is converted to GDP through a GTPase activit
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	66773 : 66777	CM	. The end effect is that KRAS kinase and signaling cap
./___Corpus/Medline/xml/PMC4346098.xml	GTP	66846 : 66849	CM	n the enzyme is bound to GTP instead of GDP. Key down
./___Corpus/Medline/xml/PMC4346098.xml	GDP	66861 : 66864	CM	 bound to GTP instead of GDP. Key downstream effector
./___Corpus/Medline/xml/PMC4346098.xml	RAF	66903 : 66906	CM	am effectors include the RAF/mitogen-activated protei
./___Corpus/Medline/xml/PMC4346098.xml	mitogen	66907 : 66914	CM	ffectors include the RAF/mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4346098.xml	MEK	66948 : 66951	CM	d protein kinase kinase (MEK)/extracellular signal-re
./___Corpus/Medline/xml/PMC4346098.xml	ERK	66992 : 66995	CM	signal-regulated kinase (ERK) cascade (controlling ce
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	67043 : 67047	CM	cellular proliferation), PI3K/AKT/mammalian target of 
./___Corpus/Medline/xml/PMC4346098.xml	AKT	67048 : 67051	CM	lar proliferation), PI3K/AKT/mammalian target of rapa
./___Corpus/Medline/xml/PMC4346098.xml	rapamycin	67072 : 67081	CM	/AKT/mammalian target of rapamycin (mTOR) cascade (controll
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	67083 : 67087	CM	ian target of rapamycin (mTOR) cascade (controlling su
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	67259 : 67263	CM	sis                      KRAS acquires tumorigenic pro
./___Corpus/Medline/xml/PMC4346098.xml	RAS	67376 : 67379	CM	 activity. The resulting RAS proteins are locked in t
./___Corpus/Medline/xml/PMC4346098.xml	GTP	67407 : 67410	CM	oteins are locked in the GTP-bound conformation indep
./___Corpus/Medline/xml/PMC4346098.xml	RAS	67499 : 67502	CM	 marked up-regulation of RAS kinase activity and down
./___Corpus/Medline/xml/PMC4346098.xml	RAS	67573 : 67576	CM	otic signaling. Overall, RAS mutations occur in appro
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	67641 : 67645	CM	 all human cancers, with KRAS mutations the most commo
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	67699 : 67703	CM	d best characterized.171 KRAS mutations result in sing
./___Corpus/Medline/xml/PMC4346098.xml	amino acid	67731 : 67741	CM	tations result in single amino acid substitutions primarily 
./___Corpus/Medline/xml/PMC4346098.xml	G12	67778 : 67781	CM	ns primarily at residues G12, G13, or Q61. In additio
./___Corpus/Medline/xml/PMC4346098.xml	G13	67783 : 67786	CM	imarily at residues G12, G13, or Q61. In addition to 
./___Corpus/Medline/xml/PMC4346098.xml	Q61	67791 : 67794	CM	at residues G12, G13, or Q61. In addition to lung can
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	67824 : 67828	CM	addition to lung cancer, KRAS mutations occur in 70–90
./___Corpus/Medline/xml/PMC4346098.xml	70–	67848 : 67851	CPR	 KRAS mutations occur in 70–90% of pancreas cancer, 3
./___Corpus/Medline/xml/PMC4346098.xml	30–	67875 : 67878	CPR	–90% of pancreas cancer, 30–40% of colorectal cancer,
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	68061 : 68065	CM	         In lung cancer, KRAS mutations occur commonly
./___Corpus/Medline/xml/PMC4346098.xml	guanine	68221 : 68228	CM	f codon 12 mutations are guanine/thymidine (G/T) (purine 
./___Corpus/Medline/xml/PMC4346098.xml	thymidine	68229 : 68238	CM	12 mutations are guanine/thymidine (G/T) (purine for pyrimi
./___Corpus/Medline/xml/PMC4346098.xml	purine	68246 : 68252	CM	guanine/thymidine (G/T) (purine for pyrimidine) nucleoti
./___Corpus/Medline/xml/PMC4346098.xml	pyrimidine	68257 : 68267	CM	midine (G/T) (purine for pyrimidine) nucleotide transversion
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	68382 : 68386	CM	 tobacco smoke exposure. KRAS mutations in lung tumors
./___Corpus/Medline/xml/PMC4346098.xml	purine	68450 : 68456	CM	okers are typically G/A (purine for purine) transversion
./___Corpus/Medline/xml/PMC4346098.xml	purine	68461 : 68467	CM	ypically G/A (purine for purine) transversions. The two 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	68517 : 68522	CM	most common mutations in NSCLC, G12C (approximately40% 
./___Corpus/Medline/xml/PMC4346098.xml	G12C	68524 : 68528	CM	mmon mutations in NSCLC, G12C (approximately40% of cas
./___Corpus/Medline/xml/PMC4346098.xml	G12V	68561 : 68565	CM	imately40% of cases) and G12V (~20%), arise from G/T t
./___Corpus/Medline/xml/PMC4346098.xml	G12D	68641 : 68645	CM	ncipal mutations include G12D (17%), G12A (7%), and G1
./___Corpus/Medline/xml/PMC4346098.xml	G12A	68653 : 68657	CM	ions include G12D (17%), G12A (7%), and G12S (5%).175 
./___Corpus/Medline/xml/PMC4346098.xml	G12S	68668 : 68672	CM	2D (17%), G12A (7%), and G12S (5%).175                
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	68746 : 68750	CM	nce                      KRAS mutations occur in appro
./___Corpus/Medline/xml/PMC4346098.xml	20–	68784 : 68787	CPR	s occur in approximately 20–30% of NSCLC.176, 177 KRA
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	68809 : 68813	CM	20–30% of NSCLC.176, 177 KRAS mutations occur predomin
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	69004 : 69008	CM	.178, 179 In contrast to EGFR mutations and ALK and RO
./___Corpus/Medline/xml/PMC4346098.xml	ALK	69023 : 69026	CM	st to EGFR mutations and ALK and ROS1 mutations, KRAS
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	69031 : 69035	CM	FR mutations and ALK and ROS1 mutations, KRAS mutation
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69047 : 69051	CM	 ALK and ROS1 mutations, KRAS mutations are associated
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69139 : 69143	CM	mokers with lung cancer, KRAS mutations occur only in 
./___Corpus/Medline/xml/PMC4346098.xml	2–	69168 : 69170	CPR	 mutations occur only in 2–6% of cases.173, 181 KRAS
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69191 : 69195	CM	n 2–6% of cases.173, 181 KRAS mutations are mutually e
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	69232 : 69236	CM	re mutually exclusive of EGFR, ALK, and ROS1 aberratio
./___Corpus/Medline/xml/PMC4346098.xml	ALK	69238 : 69241	CM	ually exclusive of EGFR, ALK, and ROS1 aberrations.  
./___Corpus/Medline/xml/PMC4346098.xml	ROS1	69247 : 69251	CM	lusive of EGFR, ALK, and ROS1 aberrations.            
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69326 : 69330	CM	  The prognostic role of KRAS mutations is not clear. 
./___Corpus/Medline/xml/PMC4346098.xml	meta-	69360 : 69365	CPR	tions is not clear. In a meta-analysis of 24 studies in
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69442 : 69446	CM	 stages, treatments, and KRAS mutation detection metho
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69475 : 69479	CM	ation detection methods, KRAS mutations were associate
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	69633 : 69638	CM	ith resected early-stage NSCLC (of whom 300 had KRAS mu
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69656 : 69660	CM	e NSCLC (of whom 300 had KRAS mutations); there was no
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69711 : 69715	CM	difference in OS between KRAS mutant and KRAS wild typ
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	69727 : 69731	CM	 between KRAS mutant and KRAS wild type cases.173 No s
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70011 : 70016	CM	             In advanced NSCLC, KRAS mutations predict 
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70018 : 70022	CM	      In advanced NSCLC, KRAS mutations predict resist
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	70055 : 70059	CM	ns predict resistance to EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	70060 : 70068	CM	edict resistance to EGFR tyrosine kinase inhibitors.181 Ho
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70126 : 70130	CM	he mutual exclusivity of KRAS and EGFR mutations and t
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	70135 : 70139	CM	 exclusivity of KRAS and EGFR mutations and the strong
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	70215 : 70219	CM	atter and sensitivity to EGFR TKIs limit the clinical 
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70255 : 70259	CM	 the clinical utility of KRAS mutations as a selection
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70362 : 70367	CM	to colorectal cancer, in NSCLC KRAS mutations are not c
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70368 : 70372	CM	orectal cancer, in NSCLC KRAS mutations are not clearl
./___Corpus/Medline/xml/PMC4346098.xml	anti-	70433 : 70438	CPR	d with resistance to the anti-EGFR monoclonal antibody 
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70511 : 70515	CM	        8.4 Treatment of KRAS mutant NSCLC            
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70523 : 70528	CM	Treatment of KRAS mutant NSCLC                      At 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	70628 : 70633	CM	clinically available for NSCLC patients with KRAS mutat
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70648 : 70652	CM	 for NSCLC patients with KRAS mutations. High affinity
./___Corpus/Medline/xml/PMC4346098.xml	GTP	70693 : 70696	CM	 affinity binding to the GTP substrate has hindered t
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70771 : 70775	CM	utic agents that inhibit KRAS directly. In late 2013, 
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	70819 : 70823	CM	2013, initial reports of KRAS G12C inhibitors that bin
./___Corpus/Medline/xml/PMC4346098.xml	G12C	70824 : 70828	CM	 initial reports of KRAS G12C inhibitors that bind to 
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	71053 : 71057	CM	eutic strategies against KRAS mutant cancers that have
./___Corpus/Medline/xml/PMC4346098.xml	Farnesyl	71356 : 71364	CM	ittle clinical efficacy. Farnesyl transferase inhibitors (
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	71418 : 71422	CM	) have failed to inhibit KRAS due to alternative preny
./___Corpus/Medline/xml/PMC4346098.xml	prenylation	71442 : 71453	RN	 KRAS due to alternative prenylation by geranylgeranyl transf
./___Corpus/Medline/xml/PMC4346098.xml	geranylgeranyl	71457 : 71471	CM	ternative prenylation by geranylgeranyl transferase. (GGTase).18
./___Corpus/Medline/xml/PMC4346098.xml	MEK	71697 : 71700	CM	al trials have evaluated MEK inhibition alone or in c
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	71761 : 71765	CM	with other therapies for KRAS mutant lung cancer. In a
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	71817 : 71826	CM	hase 2 clinical trial of docetaxel ± the MEK inhibitor selu
./___Corpus/Medline/xml/PMC4346098.xml	MEK	71833 : 71836	CM	trial of docetaxel ± the MEK inhibitor selumetinib (A
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	71847 : 71858	CM	axel ± the MEK inhibitor selumetinib (AZD6244; AstraZeneca) f
./___Corpus/Medline/xml/PMC4346098.xml	AZD6244	71860 : 71867	CM	K inhibitor selumetinib (AZD6244; AstraZeneca) for previo
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	71914 : 71918	CM	viously treated advanced KRAS mutant NSCLC, selumetini
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	71926 : 71931	CM	ted advanced KRAS mutant NSCLC, selumetinib was associa
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	71933 : 71944	CM	anced KRAS mutant NSCLC, selumetinib was associated with impr
./___Corpus/Medline/xml/PMC4346098.xml	PFS	71974 : 71977	CM	associated with improved PFS (5.3 v 2.1 mos; 80% CI, 
./___Corpus/Medline/xml/PMC4346098.xml	P	72013 : 72014	CM	 mos; 80% CI, 0.42–0.79; P=0.14) and a trend toward
./___Corpus/Medline/xml/PMC4346098.xml	P	72086 : 72087	CM	2 mos; 80% CI, 0.56–1.4; P=0.21).15 Another phase 2
./___Corpus/Medline/xml/PMC4346098.xml	selumetinib	72143 : 72154	CM	 randomizing patients to selumetinib alone or in combination 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	72184 : 72193	CM	e or in combination with erlotinib has completed enrollment
./___Corpus/Medline/xml/PMC4346098.xml	MEK	72320 : 72323	CM	50"}}NCT01229150). Other MEK inhibitors under study s
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	72363 : 72367	CM	er study specifically in KRAS mutant NSCLC include MEK
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	72375 : 72380	CM	cifically in KRAS mutant NSCLC include MEK162 (Novartis
./___Corpus/Medline/xml/PMC4346098.xml	MEK162	72389 : 72395	CM	RAS mutant NSCLC include MEK162 (Novartis) combined with
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	72421 : 72430	CM	(Novartis) combined with erlotinib ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	72529 : 72539	CM	59026"}}NCT01859026) and trametinib (GSK1120212, GlaxoSmithK
./___Corpus/Medline/xml/PMC4346098.xml	GSK1120212	72541 : 72551	CM	1859026) and trametinib (GSK1120212, GlaxoSmithKline) monoth
./___Corpus/Medline/xml/PMC4346098.xml	NCT01362296"}}NCT01362296	72649 : 72674	CM	"NCT01362296","term_id":"NCT01362296"}}NCT01362296).                       
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	72737 : 72741	CM	   A possible benefit of BRAF inhibition in KRAS mutan
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	72756 : 72760	CM	it of BRAF inhibition in KRAS mutant NSCLC was suggest
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	72768 : 72773	CM	nhibition in KRAS mutant NSCLC was suggested in the BAT
./___Corpus/Medline/xml/PMC4346098.xml	BATTLE	72795 : 72801	CM	CLC was suggested in the BATTLE (Biomarker-integrated Ap
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	72932 : 72936	CM	1/14 (79%) patients with KRAS/BRAF mutations had disea
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	72937 : 72941	CM	(79%) patients with KRAS/BRAF mutations had disease co
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	73034 : 73038	CM	, in preclinical models, BRAF inhibitors appear ineffe
./___Corpus/Medline/xml/PMC4346098.xml	RAS	73077 : 73080	CM	pear ineffective against RAS mutant cells, paradoxica
./___Corpus/Medline/xml/PMC4346098.xml	RAF	73122 : 73125	CM	radoxically potentiating RAF/MeK/ERK signaling.189 Th
./___Corpus/Medline/xml/PMC4346098.xml	MeK	73126 : 73129	CM	xically potentiating RAF/MeK/ERK signaling.189 This p
./___Corpus/Medline/xml/PMC4346098.xml	ERK	73130 : 73133	CM	lly potentiating RAF/MeK/ERK signaling.189 This pheno
./___Corpus/Medline/xml/PMC4346098.xml	CRAF	73194 : 73198	CM	h has been attributed to CRAF activation, is evident c
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	73255 : 73259	CM	ly in the development of KRAS mutant cutaneous squamou
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	73336 : 73340	CM	ma patients treated with BRAF inhibitors.190, 191     
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	73466 : 73470	CM	ials have focused on the PI3K/AKT/mTOR signaling casca
./___Corpus/Medline/xml/PMC4346098.xml	AKT	73471 : 73474	CM	have focused on the PI3K/AKT/mTOR signaling cascade. 
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	73475 : 73479	CM	 focused on the PI3K/AKT/mTOR signaling cascade. Speci
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	73538 : 73542	CM	s under investigation in KRAS mutant NSCLC include the
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	73550 : 73555	CM	stigation in KRAS mutant NSCLC include the mTOR inhibit
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	73568 : 73572	CM	mutant NSCLC include the mTOR inhibitor ridaforolimus 
./___Corpus/Medline/xml/PMC4346098.xml	IPI-504	73598 : 73605	CM	inhibitor ridaforolimus (IPI-504; Infinity Pharmaceutical
./___Corpus/Medline/xml/PMC4346098.xml	mTOR	73732 : 73736	CM	8675"}}NCT00818675), the mTOR inhibitor everolimus in 
./___Corpus/Medline/xml/PMC4346098.xml	everolimus	73747 : 73757	CM	675), the mTOR inhibitor everolimus in combination with the 
./___Corpus/Medline/xml/PMC4346098.xml	HSP90	73782 : 73787	CM	 in combination with the HSP90 inhibitor retaspimycin (
./___Corpus/Medline/xml/PMC4346098.xml	retaspimycin	73798 : 73810	CM	with the HSP90 inhibitor retaspimycin ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	everolimus	73906 : 73916	CM	01427946"}}NCT01427946), everolimus in combination with tram
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	73937 : 73947	CM	imus in combination with trametinib ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	PI3K-mTOR	74056 : 74065	CM	T00955773), and the dual PI3K-mTOR inhibitor BEZ235 (Novart
./___Corpus/Medline/xml/PMC4346098.xml	BEZ235	74076 : 74082	CM	dual PI3K-mTOR inhibitor BEZ235 (Novartis) in combinatio
./___Corpus/Medline/xml/PMC4346098.xml	MEK162	74114 : 74120	CM	tis) in combination with MEK162 (Novartis) ({"type":"cli
./___Corpus/Medline/xml/PMC4346098.xml	NCT01363232"}}NCT01363232	74292 : 74317	CM	"NCT01363232","term_id":"NCT01363232"}}NCT01363232).                       
./___Corpus/Medline/xml/PMC4346098.xml	FAK	74390 : 74393	CM	A-focal adhesion kinase (FAK) axis has emerged as a c
./___Corpus/Medline/xml/PMC4346098.xml	RAS	74438 : 74441	CM	s a critical mediator of RAS signal transduction. In 
./___Corpus/Medline/xml/PMC4346098.xml	transgenic	74466 : 74476	CM	 signal transduction. In transgenic and orthotopic mouse mod
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	74508 : 74512	CM	thotopic mouse models of KRAS mutant lung adenocarcino
./___Corpus/Medline/xml/PMC4346098.xml	FAK	74541 : 74544	CM	ant lung adenocarcinoma, FAK inhibition resulted in i
./___Corpus/Medline/xml/PMC4346098.xml	FAK	74683 : 74686	CM	ter phase 2 trial of the FAK inhibitor defactenib (VS
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	74759 : 74763	CM	viously treated advanced KRAS mutant NSCLC ({"type":"c
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	74771 : 74776	CM	ted advanced KRAS mutant NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	74946 : 74955	CM	ized phase 2 clinical of erlotinib ± the c-MET inhibitor ti
./___Corpus/Medline/xml/PMC4346098.xml	c-MET	74962 : 74967	CM	nical of erlotinib ± the c-MET inhibitor tivantinib (AR
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	75068 : 75072	CM	at the small cohort with KRAS mutations achieved a PFS
./___Corpus/Medline/xml/PMC4346098.xml	PFS	75094 : 75097	CM	RAS mutations achieved a PFS HR of 0.18 (95% CI, 0.05
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	75219 : 75223	CM	dback loop through which EGFR acts as a downstream med
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	75257 : 75261	CM	a downstream mediator of KRAS signaling, interactions 
./___Corpus/Medline/xml/PMC4346098.xml	MET	75324 : 75327	CM	ocyte growth factor (the MET ligand) and KRAS, or non
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	75340 : 75344	CM	tor (the MET ligand) and KRAS, or non-MET mediated pat
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	75426 : 75435	CM	hase 2 clinical trial of erlotinib + ARQ-197 versus single-
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	75510 : 75514	CM	viously treated advanced KRAS mutant NSCLC (NCT0139578
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	75522 : 75527	CM	ted advanced KRAS mutant NSCLC (NCT0139578) has complet
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	75739 : 75743	CM	 of a second protein. In KRAS mutant cell lines, RNAi-
./___Corpus/Medline/xml/PMC4346098.xml	RNAi	75763 : 75767	CM	 KRAS mutant cell lines, RNAi-based synthetic lethal s
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	75871 : 75875	CM	mber of these, including CDK4, STK33, TBK1, and PLK1, 
./___Corpus/Medline/xml/PMC4346098.xml	STK33	75877 : 75882	CM	f these, including CDK4, STK33, TBK1, and PLK1, encode 
./___Corpus/Medline/xml/PMC4346098.xml	TBK1	75884 : 75888	CM	, including CDK4, STK33, TBK1, and PLK1, encode protei
./___Corpus/Medline/xml/PMC4346098.xml	PLK1	75894 : 75898	CM	g CDK4, STK33, TBK1, and PLK1, encode protein kinases 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	76006 : 76011	CM	.194                  9. NSCLC WITH PI3K PATHWAY ALTERA
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76017 : 76021	CM	           9. NSCLC WITH PI3K PATHWAY ALTERATIONS     
./___Corpus/Medline/xml/PMC4346098.xml	PATHWAY	76022 : 76029	CM	      9. NSCLC WITH PI3K PATHWAY ALTERATIONS             
./___Corpus/Medline/xml/PMC4346098.xml	Phosphatidylinositol	76063 : 76083	CM	ONS                      Phosphatidylinositol 3-kinase (PI3K) signalin
./___Corpus/Medline/xml/PMC4346098.xml	3-	76085 : 76087	CPR	   Phosphatidylinositol 3-kinase (PI3K) signaling pl
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76094 : 76098	CM	atidylinositol 3-kinase (PI3K) signaling plays importa
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	76308 : 76316	CM	ulation through receptor tyrosine kinases. Class IA PI3Ks 
./___Corpus/Medline/xml/PMC4346098.xml	p85	76425 : 76428	CM	 The regulatory subunit, p85, is encoded by PIK3R1, P
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R1	76444 : 76450	CM	unit, p85, is encoded by PIK3R1, PIK3R2, and PIK3R3, whi
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R2	76452 : 76458	CM	5, is encoded by PIK3R1, PIK3R2, and PIK3R3, while the c
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R3	76464 : 76470	CM	d by PIK3R1, PIK3R2, and PIK3R3, while the catalytic sub
./___Corpus/Medline/xml/PMC4346098.xml	p110α	76520 : 76525	CM	unit has three isoforms, p110α, p110β, p110δ, encoded b
./___Corpus/Medline/xml/PMC4346098.xml	p110β	76527 : 76532	CM	s three isoforms, p110α, p110β, p110δ, encoded by PIK3C
./___Corpus/Medline/xml/PMC4346098.xml	p110δ	76534 : 76539	CM	 isoforms, p110α, p110β, p110δ, encoded by PIK3CA, PIK3
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	76552 : 76558	CM	p110β, p110δ, encoded by PIK3CA, PIK3CB, and PIK3D. Bind
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CB	76560 : 76566	CM	110δ, encoded by PIK3CA, PIK3CB, and PIK3D. Binding of p
./___Corpus/Medline/xml/PMC4346098.xml	PIK3D	76572 : 76577	CM	d by PIK3CA, PIK3CB, and PIK3D. Binding of p85 to phosp
./___Corpus/Medline/xml/PMC4346098.xml	p85	76590 : 76593	CM	B, and PIK3D. Binding of p85 to phosphotyrosine resid
./___Corpus/Medline/xml/PMC4346098.xml	phosphotyrosine	76597 : 76612	CM	PIK3D. Binding of p85 to phosphotyrosine residues on receptor tyr
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	76634 : 76642	CM	ine residues on receptor tyrosine kinases releases the inh
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	76717 : 76721	CM	d causes localization of PI3K to the plasma membrane, 
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylate	76759 : 76772	CM	a membrane, where it can phosphorylate PIP2 (phosphatidylinosit
./___Corpus/Medline/xml/PMC4346098.xml	PIP2	76773 : 76777	CM	ere it can phosphorylate PIP2 (phosphatidylinositol 4,
./___Corpus/Medline/xml/PMC4346098.xml	phosphatidylinositol 4,5-bisphosphate	76779 : 76816	CM	 can phosphorylate PIP2 (phosphatidylinositol 4,5-bisphosphate) to produce PIP3 which i
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	76829 : 76833	CM	bisphosphate) to produce PIP3 which in turn propagates
./___Corpus/Medline/xml/PMC4346098.xml	AKT	76887 : 76890	CM	racellular signaling via AKT and PDK1 and other PIP3 
./___Corpus/Medline/xml/PMC4346098.xml	PDK1	76895 : 76899	CM	ar signaling via AKT and PDK1 and other PIP3 dependent
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	76910 : 76914	CM	a AKT and PDK1 and other PIP3 dependent signaling path
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	77003 : 77007	CM	eleted on chromosome 10 (PTEN) dephosphorylates PIP3 t
./___Corpus/Medline/xml/PMC4346098.xml	dephosphorylates	77009 : 77025	CM	 on chromosome 10 (PTEN) dephosphorylates PIP3 to PIP2, thus inhib
./___Corpus/Medline/xml/PMC4346098.xml	PIP3	77026 : 77030	CM	 (PTEN) dephosphorylates PIP3 to PIP2, thus inhibiting
./___Corpus/Medline/xml/PMC4346098.xml	PIP2	77034 : 77038	CM	dephosphorylates PIP3 to PIP2, thus inhibiting PI3K-de
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77056 : 77060	CM	to PIP2, thus inhibiting PI3K-dependent signaling and 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77115 : 77119	CM	g as a tumor suppressor. PI3K can also be activated by
./___Corpus/Medline/xml/PMC4346098.xml	RAS	77145 : 77148	CM	can also be activated by RAS or by G-protein coupled 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K-AKT	77229 : 77237	CM	o the catalytic subunit. PI3K-AKT signaling regulates mult
./___Corpus/Medline/xml/PMC4346098.xml	bcl2	77301 : 77305	CM	m pathways including the bcl2 family members, forkhead
./___Corpus/Medline/xml/PMC4346098.xml	MDM2	77354 : 77358	CM	d transcription factors, MDM2/p53, mTORC1/2, and NFKB 
./___Corpus/Medline/xml/PMC4346098.xml	p53	77359 : 77362	CM	nscription factors, MDM2/p53, mTORC1/2, and NFKB path
./___Corpus/Medline/xml/PMC4346098.xml	mTORC1	77364 : 77370	CM	ption factors, MDM2/p53, mTORC1/2, and NFKB pathways, to
./___Corpus/Medline/xml/PMC4346098.xml	NFKB	77378 : 77382	CM	 MDM2/p53, mTORC1/2, and NFKB pathways, to promote cel
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77492 : 77496	CM	1 Genetic Alterations in PI3K pathway                 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	77565 : 77569	CM	tions of elements in the PI3K pathway have been descri
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	77643 : 77649	CM	ll as other tumor types. PIK3CA encodes the gene for the
./___Corpus/Medline/xml/PMC4346098.xml	isoform	77681 : 77688	CM	s the gene for the p110α isoform of the catalytic subunit
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	77762 : 77768	CM	r gains and mutations in PIK3CA have been identified in 
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	77806 : 77812	CM	entified in lung cancer. PIK3CA copy number gains occur 
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	77954 : 77960	CM	200 Somatic mutations in PIK3CA have also been described
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	78016 : 78020	CM	romote activation of the PI3K signaling pathway.201 Mu
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	78056 : 78062	CM	pathway.201 Mutations in PIK3CA are clustered in two hot
./___Corpus/Medline/xml/PMC4346098.xml	lipid	78222 : 78227	CM	ations lead to increased lipid kinase activity and cons
./___Corpus/Medline/xml/PMC4346098.xml	PI3K-AKT	78261 : 78269	CM	ctivity and constitutive PI3K-AKT signaling.201 The mechan
./___Corpus/Medline/xml/PMC4346098.xml	E545K	78385 : 78390	CM	e helical domain mutants E545K and E542K interfere with
./___Corpus/Medline/xml/PMC4346098.xml	E542K	78395 : 78400	CM	domain mutants E545K and E542K interfere with the inhib
./___Corpus/Medline/xml/PMC4346098.xml	p85	78474 : 78477	CM	n the regulatory subunit p85 and the catalytic unit p
./___Corpus/Medline/xml/PMC4346098.xml	H1047R	78539 : 78545	CM	the kinase domain mutant H1047R is located near the acti
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	78641 : 78647	CM	g through the kinase.195 PIK3CA mutations have been repo
./___Corpus/Medline/xml/PMC4346098.xml	1–	78680 : 78682	CPR	ns have been reported in 1–5% of NSCLC cell lines an
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	78688 : 78693	CM	been reported in 1–5% of NSCLC cell lines and tumors.19
./___Corpus/Medline/xml/PMC4346098.xml	al202	78735 : 78740	CM	umors.198, 202 Kawano et al202 found PIK3CA mutations i
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	78747 : 78753	CM	02 Kawano et al202 found PIK3CA mutations in 6.5 % of lu
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	78854 : 78860	CM	 adenocarcinomas (1.5%). PIK3CA mutations often do not e
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	78950 : 78954	CM	other mutations, such as KRAS, NRAS, BRAF, and EGFR, i
./___Corpus/Medline/xml/PMC4346098.xml	NRAS	78956 : 78960	CM	mutations, such as KRAS, NRAS, BRAF, and EGFR, is comm
./___Corpus/Medline/xml/PMC4346098.xml	BRAF	78962 : 78966	CM	ons, such as KRAS, NRAS, BRAF, and EGFR, is common.203
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	78972 : 78976	CM	as KRAS, NRAS, BRAF, and EGFR, is common.203–205 A stu
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	79083 : 79089	CM	ported 70% of cases with PIK3CA mutation had a coexistin
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79243 : 79247	CM	he tumor suppressor gene PTEN encodes a lipid phosphat
./___Corpus/Medline/xml/PMC4346098.xml	lipid phosphatase	79258 : 79275	CM	ssor gene PTEN encodes a lipid phosphatase that negatively regulate
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	79306 : 79310	CM	negatively regulates the PI3K/AKT pathway, and loss of
./___Corpus/Medline/xml/PMC4346098.xml	AKT	79311 : 79314	CM	ively regulates the PI3K/AKT pathway, and loss of PTE
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79336 : 79340	CM	AKT pathway, and loss of PTEN leads to constitutive PI
./___Corpus/Medline/xml/PMC4346098.xml	PI3K-AKT	79363 : 79371	CM	EN leads to constitutive PI3K-AKT signaling. Somatic PTEN 
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79391 : 79395	CM	K-AKT signaling. Somatic PTEN deletions and mutations,
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79441 : 79445	CM	ons, and inactivation of PTEN by epigenetic mechanisms
./___Corpus/Medline/xml/PMC4346098.xml	methylation	79479 : 79490	RN	netic mechanisms such as methylation or microRNA silencing, a
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79547 : 79551	CM	 in multiple cancers.206 PTEN mutations occur in appro
./___Corpus/Medline/xml/PMC4346098.xml	PTEN	79733 : 79737	CM	207 Reduction or loss of PTEN expression has been repo
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	79926 : 79930	CM	tions in elements of the PI3K pathway have also been r
./___Corpus/Medline/xml/PMC4346098.xml	AKT	79999 : 80002	CM	e, a somatic mutation in AKT, E17K, constitutively ac
./___Corpus/Medline/xml/PMC4346098.xml	E17K	80004 : 80008	CM	somatic mutation in AKT, E17K, constitutively activate
./___Corpus/Medline/xml/PMC4346098.xml	AKT1	80062 : 80066	CM	e protein kinase.209 The AKT1 E17K mutation was found 
./___Corpus/Medline/xml/PMC4346098.xml	E17K	80067 : 80071	CM	tein kinase.209 The AKT1 E17K mutation was found in 5.
./___Corpus/Medline/xml/PMC4346098.xml	adenocarcinoma.210	80157 : 80175	CM	, but not (0/53) in lung adenocarcinoma.210 PIK3R1 mutations causing
./___Corpus/Medline/xml/PMC4346098.xml	PIK3R1	80176 : 80182	CM	 lung adenocarcinoma.210 PIK3R1 mutations causing trunca
./___Corpus/Medline/xml/PMC4346098.xml	p85	80311 : 80314	CM	the inhibitory effect of p85 on p110, thereby activat
./___Corpus/Medline/xml/PMC4346098.xml	p110	80318 : 80322	CM	ibitory effect of p85 on p110, thereby activating PI3K
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80343 : 80347	CM	p110, thereby activating PI3K signaling.              
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80437 : 80441	CM	      There are multiple PI3K inhibitors in developmen
./___Corpus/Medline/xml/PMC4346098.xml	isoform	80522 : 80529	CM	m pan-PI3K inhibitors to isoform-selective PI3K inhibitor
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80540 : 80544	CM	ors to isoform-selective PI3K inhibitors and dual PI3K
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80565 : 80569	CM	PI3K inhibitors and dual PI3K/MTOR inhibitors. As a cl
./___Corpus/Medline/xml/PMC4346098.xml	MTOR	80570 : 80574	CM	inhibitors and dual PI3K/MTOR inhibitors. As a class, 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80685 : 80689	CM	ht to be due to the role PI3K plays in the insulin sig
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	80880 : 80884	CM	o the phase 1 studies of PI3K inhibitors that enrolled
./___Corpus/Medline/xml/PMC4346098.xml	1b	81077 : 81079	CM	ve been multiple Phase 1/1b studies combining variou
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81106 : 81110	CM	tudies combining various PI3K inhibitors with MEK inhi
./___Corpus/Medline/xml/PMC4346098.xml	MEK	81127 : 81130	CM	ous PI3K inhibitors with MEK inhibitors which have en
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	81197 : 81201	CM	cohorts of patients with KRAS mutated lung cancer; eff
./___Corpus/Medline/xml/PMC4346098.xml	GDC0941	81357 : 81364	CM	y ongoing trials include GDC0941 in combination with carb
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	81385 : 81396	CM	0941 in combination with carboplatin, paclitaxel, with or wit
./___Corpus/Medline/xml/PMC4346098.xml	BKM120	81443 : 81449	CM	without bevacizumab, and BKM120 in combination with doce
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	81470 : 81479	CM	M120 in combination with docetaxel or carboplatin/pemetrexe
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	81483 : 81494	CM	nation with docetaxel or carboplatin/pemetrexed. BKM120 is al
./___Corpus/Medline/xml/PMC4346098.xml	BKM120	81507 : 81513	CM	 carboplatin/pemetrexed. BKM120 is also being tested sin
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	81566 : 81570	CM	 and in combination with EGFR inhibitors in molecularl
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	81694 : 81703	CM	therapy agents including docetaxel and paclitaxel.         
./___Corpus/Medline/xml/PMC4346098.xml	PIK3CA	81837 : 81843	CM	 activating mutations in PIK3CA may be among the most se
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81892 : 81896	CM	ensitive to single-agent PI3K pathway inhibitors.195 I
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	81968 : 81972	CM	lly observed activity of PI3K inhibitors as monotherap
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82079 : 82083	CM	molecular alterations in PI3K pathway correlate with a
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82194 : 82198	CM	xperience, patients with PI3K mutations who were enrol
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82250 : 82254	CM	d in phase 1 trials with PI3K/AKT/MTOR inhibitors had 
./___Corpus/Medline/xml/PMC4346098.xml	AKT	82255 : 82258	CM	phase 1 trials with PI3K/AKT/MTOR inhibitors had a hi
./___Corpus/Medline/xml/PMC4346098.xml	MTOR	82259 : 82263	CM	e 1 trials with PI3K/AKT/MTOR inhibitors had a higher 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82324 : 82328	CM	ponse rate than wildtype PI3K patients on their best p
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82418 : 82422	CM	 rates reported (18% for PI3K mutated patients versus 
./___Corpus/Medline/xml/PMC4346098.xml	H1047R	82469 : 82475	CM	us 8% for wildtype, with H1047R mutations faring best wi
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	82660 : 82664	CM	geted therapies used for EGFR or ALK inhibition. The f
./___Corpus/Medline/xml/PMC4346098.xml	ALK	82668 : 82671	CM	erapies used for EGFR or ALK inhibition. The frequent
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	82762 : 82766	CM	y mean that single agent PI3K inhibition may not be su
./___Corpus/Medline/xml/PMC4346098.xml	mTORC1	82975 : 82981	CM	ve pathways; for example mTORC1 inhibition leads to acti
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	83016 : 83020	CM	n leads to activation of PI3K pathway via a feedback l
./___Corpus/Medline/xml/PMC4346098.xml	mTORC1	83072 : 83078	CM	p, limiting single agent mTORC1 efficacy.195 Finally, it
./___Corpus/Medline/xml/PMC4346098.xml	30–	83270 : 83273	CPR	s trials has ranged from 30–90%, and it is possible t
./___Corpus/Medline/xml/PMC4346098.xml	MET	83432 : 83435	CM	211                  10. MET POSITIVE NSCLC          
./___Corpus/Medline/xml/PMC4346098.xml	MET	83476 : 83479	CM	                     The MET/hepatocyte growth factor
./___Corpus/Medline/xml/PMC4346098.xml	HGF	83506 : 83509	CM	epatocyte growth factor (HGF) pathway has been identi
./___Corpus/Medline/xml/PMC4346098.xml	MET	83648 : 83651	CM	 lung cancer.212–214 The MET gene on chromosome 7q21–
./___Corpus/Medline/xml/PMC4346098.xml	7q21	83671 : 83675	CM	e MET gene on chromosome 7q21–31 encodes the HGF recep
./___Corpus/Medline/xml/PMC4346098.xml	HGF	83691 : 83694	CM	some 7q21–31 encodes the HGF receptor (HGFR), which i
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	83705 : 83709	CM	ncodes the HGF receptor (HGFR), which is a single-chai
./___Corpus/Medline/xml/PMC4346098.xml	50-kDa	83764 : 83770	CM	erodimer consisting of a 50-kDa extracellular α-chain an
./___Corpus/Medline/xml/PMC4346098.xml	α-	83785 : 83787	CPR	f a 50-kDa extracellular α-chain and a 140-kDa trans
./___Corpus/Medline/xml/PMC4346098.xml	140-kDa	83799 : 83806	CM	racellular α-chain and a 140-kDa transmembrane β-chain. B
./___Corpus/Medline/xml/PMC4346098.xml	β-	83821 : 83823	CPR	 a 140-kDa transmembrane β-chain. Binding of the HGF
./___Corpus/Medline/xml/PMC4346098.xml	HGF	83845 : 83848	CM	 β-chain. Binding of the HGF ligand leads to dimeriza
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	83898 : 83913	RN	tion of the receptor and phosphorylation of the intracellular tyr
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	83935 : 83943	CM	ion of the intracellular tyrosine kinase (TK) domain.215 T
./___Corpus/Medline/xml/PMC4346098.xml	PI3K-AKT	84036 : 84044	CM	naling pathways, such as PI3K-AKT and RAS-MAP-kinase, whic
./___Corpus/Medline/xml/PMC4346098.xml	MET	84270 : 84273	CM	s also crosstalk between MET and other receptor tyros
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	84293 : 84301	CM	n MET and other receptor tyrosine kinases, including EGFR/
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	84321 : 84325	CM	osine kinases, including EGFR/ERBB family of receptors
./___Corpus/Medline/xml/PMC4346098.xml	ERBB	84326 : 84330	CM	 kinases, including EGFR/ERBB family of receptors, whi
./___Corpus/Medline/xml/PMC4346098.xml	HGF	84372 : 84375	CM	ors, which can result in HGF-independent activation o
./___Corpus/Medline/xml/PMC4346098.xml	MET	84406 : 84409	CM	endent activation of the MET pathway.212, 213, 218 Li
./___Corpus/Medline/xml/PMC4346098.xml	MET	84448 : 84451	CM	213, 218 Ligand-mediated MET is tightly controlled th
./___Corpus/Medline/xml/PMC4346098.xml	CBL	84497 : 84500	CM	d through recruitment of CBL (E3 ubiquitin ligase), w
./___Corpus/Medline/xml/PMC4346098.xml	ubiquitin	84505 : 84514	CM	h recruitment of CBL (E3 ubiquitin ligase), which binds to 
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84590 : 84594	CM	 juxtamembrane domain of HGFR and leads to ubiquinatio
./___Corpus/Medline/xml/PMC4346098.xml	ubiquination	84608 : 84620	RN	ain of HGFR and leads to ubiquination of HGFR into clathrin-co
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84624 : 84628	CM	leads to ubiquination of HGFR into clathrin-coated ves
./___Corpus/Medline/xml/PMC4346098.xml	MET	84754 : 84757	CM	berrant signaling of the MET pathway can occur throug
./___Corpus/Medline/xml/PMC4346098.xml	HGF	84802 : 84805	CM	hrough overexpression of HGF or HGFR, decreased degra
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84809 : 84813	CM	overexpression of HGF or HGFR, decreased degradation o
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84840 : 84844	CM	decreased degradation of HGFR, MET amplification or ME
./___Corpus/Medline/xml/PMC4346098.xml	MET	84846 : 84849	CM	sed degradation of HGFR, MET amplification or MET mut
./___Corpus/Medline/xml/PMC4346098.xml	MET	84867 : 84870	CM	FR, MET amplification or MET mutations.212, 213 In NS
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	84893 : 84898	CM	ET mutations.212, 213 In NSCLC, the most common mechani
./___Corpus/Medline/xml/PMC4346098.xml	MET	84939 : 84942	CM	n mechanism for aberrant MET signaling is overexpress
./___Corpus/Medline/xml/PMC4346098.xml	HGF	84974 : 84977	CM	ing is overexpression of HGF and HGFR. HGFR overexpre
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84982 : 84986	CM	verexpression of HGF and HGFR. HGFR overexpression is 
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	84988 : 84992	CM	ression of HGF and HGFR. HGFR overexpression is associ
./___Corpus/Medline/xml/PMC4346098.xml	MET	85197 : 85200	CM	he prevalence of de Novo MET amplification is low (≤ 
./___Corpus/Medline/xml/PMC4346098.xml	MET	85295 : 85298	CM	ognosis.221 Importantly, MET amplification has been i
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	85375 : 85379	CM	r acquired resistance to EGFR tyrosine kinase inhibiti
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	85380 : 85388	CM	uired resistance to EGFR tyrosine kinase inhibition in a s
./___Corpus/Medline/xml/PMC4346098.xml	5–	85420 : 85422	CPR	 inhibition in a subset (5–20%) of patients with act
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	85455 : 85459	CM	patients with activating EGFR mutations through ERBB3-
./___Corpus/Medline/xml/PMC4346098.xml	ERBB3	85478 : 85483	CM	g EGFR mutations through ERBB3-dependent activation of 
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	85512 : 85516	CM	endent activation of the PI3K pathway.85, 222, 223 It 
./___Corpus/Medline/xml/PMC4346098.xml	MET	85634 : 85637	CM	oth somatic and germline MET mutations have been iden
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	85701 : 85706	CM	iple solid tumors.212 In NSCLC, mutations in the extrac
./___Corpus/Medline/xml/PMC4346098.xml	14–	85811 : 85814	CPR	xtamembrane domain (exon 14–15, including exon skippi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	86015 : 86020	CM	cluded 106 patients with NSCLC who underwent MET mutati
./___Corpus/Medline/xml/PMC4346098.xml	MET	86035 : 86038	CM	with NSCLC who underwent MET mutational analysis, app
./___Corpus/Medline/xml/PMC4346098.xml	14–	86122 : 86125	CPR	-mutation positive (exon 14–15).226                  
./___Corpus/Medline/xml/PMC4346098.xml	vitro	86179 : 86184	CM	                 Both in-vitro and in-vivo preclinical 
./___Corpus/Medline/xml/PMC4346098.xml	MET	86248 : 86251	CM	tablished the utility of MET pathway inhibitors to su
./___Corpus/Medline/xml/PMC4346098.xml	HGF	86283 : 86286	CM	y inhibitors to suppress HGF-dependent and -independe
./___Corpus/Medline/xml/PMC4346098.xml	MET	86314 : 86317	CM	pendent and -independent MET phosphorylation and acti
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	86318 : 86333	RN	ent and -independent MET phosphorylation and activation of downst
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	86456 : 86460	CM	s.212 Dual inhibition of EGFR and MET in in-vivo tumor
./___Corpus/Medline/xml/PMC4346098.xml	MET	86465 : 86468	CM	l inhibition of EGFR and MET in in-vivo tumor xenogra
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	86564 : 86569	CM	tentially synergistic in NSCLC, including in tumors wit
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	86619 : 86623	CM	h acquired resistance to EGFR TKIs.227, 228 Recently w
./___Corpus/Medline/xml/PMC4346098.xml	MET	86671 : 86674	CM	 we have also shown that MET can synergize with its f
./___Corpus/Medline/xml/PMC4346098.xml	MET	86720 : 86723	CM	ts family member RON.229 MET targeting strategies hav
./___Corpus/Medline/xml/PMC4346098.xml	HGF	86805 : 86808	CM	-HGFR binding, including HGF antagonists, HGFR inhibi
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	86822 : 86826	CM	cluding HGF antagonists, HGFR inhibitors and decoy MET
./___Corpus/Medline/xml/PMC4346098.xml	MET	86848 : 86851	CM	GFR inhibitors and decoy MET, as well as small molecu
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	86911 : 86919	CM	ors of the intracellular tyrosine kinase domain.212–214 Th
./___Corpus/Medline/xml/PMC4346098.xml	MET	87060 : 87063	CM	trategies to inhibit the MET pathway in NSCLC.       
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	87075 : 87080	CM	hibit the MET pathway in NSCLC.                  10.1 M
./___Corpus/Medline/xml/PMC4346098.xml	HGF	87136 : 87139	CM	nal Antibodies Targeting HGF and HGFR                
./___Corpus/Medline/xml/PMC4346098.xml	HGFR	87144 : 87148	CM	bodies Targeting HGF and HGFR                      AMG
./___Corpus/Medline/xml/PMC4346098.xml	AV	87196 : 87198	CM	MG 102 (rilotumumab) and AV 299 (ficlatuzumab) are m
./___Corpus/Medline/xml/PMC4346098.xml	HGF	87254 : 87257	CM	nal antibodies targeting HGF. Rilotumumab is a fully 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	87700 : 87709	CM	luating rilotumumab with erlotinib in previously treated pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	87746 : 87751	CM	ly treated patients with NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	anti-	87871 : 87876	CPR	 Ficlatuzumab is a human anti-HGF IgG1 monoclonal antib
./___Corpus/Medline/xml/PMC4346098.xml	IgG1	87880 : 87884	CM	umab is a human anti-HGF IgG1 monoclonal antibody.233 
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	88028 : 88032	CM	ed when combined with an EGFR TKI.234 In a randomized 
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88082 : 88091	CM	phase II trial comparing gefitinib to gefitinib plus ficlat
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88095 : 88104	CM	l comparing gefitinib to gefitinib plus ficlatuzumab in nev
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88357 : 88366	CM	 between the two groups (gefitinib versus gefitinib + ficla
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	88374 : 88383	CM	groups (gefitinib versus gefitinib + ficlatuzumab, respecti
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	88497 : 88501	CM	ivating mutations in the EGFR gene and low MET express
./___Corpus/Medline/xml/PMC4346098.xml	MET	88515 : 88518	CM	in the EGFR gene and low MET expression appeared to g
./___Corpus/Medline/xml/PMC4346098.xml	PFS	88633 : 88636	CM	70 versus 44% and median PFS 11.0 versus 5.5 months).
./___Corpus/Medline/xml/PMC4346098.xml	MET	88786 : 88789	CM	ies directed against the MET receptor. MetMab is a hu
./___Corpus/Medline/xml/PMC4346098.xml	HGF	88868 : 88871	CM	l antibody that inhibits HGF/MET binding without indu
./___Corpus/Medline/xml/PMC4346098.xml	MET	88872 : 88875	CM	tibody that inhibits HGF/MET binding without inducing
./___Corpus/Medline/xml/PMC4346098.xml	MET	88901 : 88904	CM	binding without inducing MET dimerization.236, 237 In
./___Corpus/Medline/xml/PMC4346098.xml	MET	88965 : 88968	CM	LY-2875358 is a bivalent MET receptor antibody that c
./___Corpus/Medline/xml/PMC4346098.xml	HGF	89009 : 89012	CM	dy that can inhibit both HGF-mediated signaling by bi
./___Corpus/Medline/xml/PMC4346098.xml	MET	89050 : 89053	CM	naling by binding to the MET receptor, as well as HGF
./___Corpus/Medline/xml/PMC4346098.xml	HGF	89075 : 89078	CM	MET receptor, as well as HGF-independent activation o
./___Corpus/Medline/xml/PMC4346098.xml	MET	89109 : 89112	CM	endent activation of the MET pathway by inducing inte
./___Corpus/Medline/xml/PMC4346098.xml	vitro	89238 : 89243	CM	tivity in in vivo and in vitro models.239, 240 A phase 
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89318 : 89327	CM	 and in combination with erlotinib has been reported with n
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89520 : 89529	CM	randomized phase II with erlotinib versus erlotinib alone i
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89537 : 89546	CM	II with erlotinib versus erlotinib alone in patients with a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89598 : 89603	CM	anced-stage EGFR-mutated NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89742 : 89751	CM	e-agent or combined with erlotinib in patients with MET dia
./___Corpus/Medline/xml/PMC4346098.xml	MET	89769 : 89772	CM	lotinib in patients with MET diagnostic positive NSCL
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89793 : 89798	CM	 MET diagnostic positive NSCLC that has progressed on e
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89822 : 89831	CM	C that has progressed on erlotinib.                        
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	89960 : 89965	CM	 patients with recurrent NSCLC in combination with erlo
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	89986 : 89995	CM	SCLC in combination with erlotinib versus erlotinib alone.2
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	90003 : 90012	CM	on with erlotinib versus erlotinib alone.242 There was no s
./___Corpus/Medline/xml/PMC4346098.xml	PFS	90074 : 90077	CM	ifference in the primary PFS endpoint in the intent t
./___Corpus/Medline/xml/PMC4346098.xml	2–	90221 : 90223	CPR	n (defined by a score of 2–3+ by immunohistochemistr
./___Corpus/Medline/xml/PMC4346098.xml	CONFIRM	90315 : 90322	CM	or higher staining using CONFIRM SP44 anti-MET monoclonal
./___Corpus/Medline/xml/PMC4346098.xml	anti-	90328 : 90333	CPR	ining using CONFIRM SP44 anti-MET monoclonal antibody, 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	90418 : 90421	CM	associated with improved PFS (HR, 0.53; p = 0.04) and
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	90529 : 90538	CM	 this combination versus erlotinib alone in MET-positive pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	90590 : 90595	CM	ents with advanced-stage NSCLC who have received prior 
./___Corpus/Medline/xml/PMC4346098.xml	NCT01456325"}}NCT01456325	90720 : 90745	CM	"NCT01456325","term_id":"NCT01456325"}}NCT01456325).                  10.2 
./___Corpus/Medline/xml/PMC4346098.xml	Kinase	90783 : 90789	ASE	       10.2 MET Tyrosine Kinase Inhibitors              
./___Corpus/Medline/xml/PMC4346098.xml	MET	90836 : 90839	CM	           Targeting the MET tyrosine kinase has the 
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	90840 : 90848	CM	       Targeting the MET tyrosine kinase has the potential
./___Corpus/Medline/xml/PMC4346098.xml	HGF	90890 : 90893	CM	otential to inhibit both HGF-dependent and independen
./___Corpus/Medline/xml/PMC4346098.xml	MET	90942 : 90945	CM	nt signaling through the MET pathway. There are a num
./___Corpus/Medline/xml/PMC4346098.xml	MET	90977 : 90980	CM	y. There are a number of MET tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	90981 : 90989	CM	here are a number of MET tyrosine kinase inhibitors curren
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91129 : 91134	CM	ved for ALK-translocated NSCLC, it also has in vitro ac
./___Corpus/Medline/xml/PMC4346098.xml	vitro	91151 : 91156	CM	ed NSCLC, it also has in vitro activity against MET. In
./___Corpus/Medline/xml/PMC4346098.xml	MET	91174 : 91177	CM	n vitro activity against MET. In a case report, a pat
./___Corpus/Medline/xml/PMC4346098.xml	MET	91242 : 91245	CM	ced-stage MET-amplified (MET/CEP7 ratio > 5.0) and AL
./___Corpus/Medline/xml/PMC4346098.xml	CEP7	91246 : 91250	CM	stage MET-amplified (MET/CEP7 ratio > 5.0) and ALK-neg
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91281 : 91286	CM	 > 5.0) and ALK-negative NSCLC was reported achieved a 
./___Corpus/Medline/xml/PMC4346098.xml	XL184	91426 : 91431	CM	           Cabozantinib (XL184) is an ATP competitive i
./___Corpus/Medline/xml/PMC4346098.xml	ATP	91439 : 91442	CM	bozantinib (XL184) is an ATP competitive inhibitor of
./___Corpus/Medline/xml/PMC4346098.xml	MET	91468 : 91471	CM	competitive inhibitor of MET, VEGFR and RET with docu
./___Corpus/Medline/xml/PMC4346098.xml	VEGFR	91473 : 91478	CM	titive inhibitor of MET, VEGFR and RET with documented 
./___Corpus/Medline/xml/PMC4346098.xml	RET	91483 : 91486	CM	ibitor of MET, VEGFR and RET with documented phase II
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91586 : 91591	CM	0 patients with advanced NSCLC (overall response rate 1
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	91687 : 91696	CM	ion of cabozantinib with erlotinib was also shown to be act
./___Corpus/Medline/xml/PMC4346098.xml	IB	91736 : 91738	CM	 to be active in a phase IB trial of patients with p
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	91781 : 91786	CM	 with previously treated NSCLC, the majority of who had
./___Corpus/Medline/xml/PMC4346098.xml	MET	91887 : 91890	CM	3 patients had confirmed MET gene copy number gain an
./___Corpus/Medline/xml/PMC4346098.xml	non-ATP	92148 : 92155	CM	 tivantinib (ARQ 197), a non-ATP competitive tyrosine kin
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	92168 : 92176	CM	), a non-ATP competitive tyrosine kinase inhibitor of MET,
./___Corpus/Medline/xml/PMC4346098.xml	MET	92197 : 92200	CM	sine kinase inhibitor of MET, with erlotinib in previ
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	92207 : 92216	CM	e inhibitor of MET, with erlotinib in previously treated pa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	92262 : 92267	CM	d patients with advanced NSCLC. This trial was stopped 
./___Corpus/Medline/xml/PMC4346098.xml	vitro	92371 : 92376	CM	t was not met. Recent in vitro studies demonstrated tha
./___Corpus/Medline/xml/PMC4346098.xml	MET	92508 : 92511	CM	ell lines independent of MET activity. It is feasible
./___Corpus/Medline/xml/PMC4346098.xml	MET	92563 : 92566	CM	hat tivantinib is a weak MET inhibitor and has differ
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	92656 : 92660	CM	248                  11. FGFR POSITIVE NSCLC          
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	92714 : 92718	CM	        Dysregulation of FGFR family signaling has bee
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	92951 : 92955	CM	oint mutations involving FGFR family members have all 
./___Corpus/Medline/xml/PMC4346098.xml	FGF	93130 : 93133	CM	                     The FGF/FGFR family consists of 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	93134 : 93138	CM	                 The FGF/FGFR family consists of 18 FG
./___Corpus/Medline/xml/PMC4346098.xml	FGF	93161 : 93164	CM	FR family consists of 18 FGF ligands which bind to fo
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	93203 : 93207	CM	 bind to four homologous FGFR receptor tyrosine kinase
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93217 : 93225	CM	homologous FGFR receptor tyrosine kinases (FGFR 1, 2, 3, a
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	93235 : 93239	CM	ceptor tyrosine kinases (FGFR 1, 2, 3, and 4). A typic
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	93267 : 93271	CM	 2, 3, and 4). A typical FGFR is composed of an extrac
./___Corpus/Medline/xml/PMC4346098.xml	Ig	93338 : 93340	CM	th three immunoglobulin (Ig)-like domains, a transme
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93392 : 93400	CM	rane domain, and a split tyrosine kinase domain. Binding o
./___Corpus/Medline/xml/PMC4346098.xml	FGF	93427 : 93430	CM	inase domain. Binding of FGF ligand to FGFRs induces 
./___Corpus/Medline/xml/PMC4346098.xml	FGFRs	93441 : 93446	CM	Binding of FGF ligand to FGFRs induces receptor dimeriz
./___Corpus/Medline/xml/PMC4346098.xml	transphosphorylation	93493 : 93513	RN	rization, which leads to transphosphorylation of a tyrosine in the act
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93519 : 93527	CM	ransphosphorylation of a tyrosine in the activation loop o
./___Corpus/Medline/xml/PMC4346098.xml	tyrosine	93558 : 93566	CM	e activation loop of the tyrosine kinase domain. Activatio
./___Corpus/Medline/xml/PMC4346098.xml	PI3K	93631 : 93635	CM	stream signaling via the PI3K/AKT and RAS/MAPK pathway
./___Corpus/Medline/xml/PMC4346098.xml	AKT	93636 : 93639	CM	m signaling via the PI3K/AKT and RAS/MAPK pathways wh
./___Corpus/Medline/xml/PMC4346098.xml	RAS	93644 : 93647	CM	ing via the PI3K/AKT and RAS/MAPK pathways which are 
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	93648 : 93652	CM	via the PI3K/AKT and RAS/MAPK pathways which are centr
./___Corpus/Medline/xml/PMC4346098.xml	8p12	93809 : 93813	CM	        Amplification at 8p12 was observed in multiple
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	93892 : 93897	CM	g cancer,16, 18, 255 and FGFR1 has been identified as a
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94011 : 94016	CM	 focal amplifications in FGFR1 corresponding to the 8p1
./___Corpus/Medline/xml/PMC4346098.xml	8p12	94038 : 94042	CM	FR1 corresponding to the 8p12 amplification in a study
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94231 : 94236	CM	rly, Dutt et al reported FGFR1 amplification in approxi
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94352 : 94357	CM	noma (3%). Inhibition of FGFR1 in amplified cell lines 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94407 : 94412	CM	and in mouse models with FGFR1 amplified engrafted tumo
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94555 : 94560	CM	 remains unclear whether FGFR1 amplification is a progn
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94634 : 94639	CM	cer. Weiss reported that FGFR1 amplification (copy numb
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94746 : 94751	CM	d to patients who lacked FGFR1 amplification (copy numb
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94861 : 94866	CM	ntial prognostic role of FGFR1 among patients with squa
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	94946 : 94951	CM	ve reported no effect of FGFR1 amplification on surviva
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	95037 : 95042	CM	d inferior survival with FGFR1 amplification,18, 258, 2
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	95330 : 95335	CM	          In addition to FGFR1 amplification, fusions i
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	95369 : 95374	CM	ation, fusions involving FGFR3 have recently been repor
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	95442 : 95447	CM	.20–22 Fusions involving FGFR3 have been reported in ot
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	95661 : 95666	CM	ed an in-frame fusion of FGFR3 with TACC3.20 Overall tw
./___Corpus/Medline/xml/PMC4346098.xml	TCGA	95763 : 95767	CM	this fusion; probing the TCGA dataset revealed another
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3-TACC3	95822 : 95833	CM	 of 178 samples with the FGFR3-TACC3 fusion.20 Majewski et al
./___Corpus/Medline/xml/PMC4346098.xml	kinome	95864 : 95870	CM	n.20 Majewski et al used kinome-centred RNA sequencing o
./___Corpus/Medline/xml/PMC4346098.xml	RNA	95879 : 95882	CM	t al used kinome-centred RNA sequencing on 95 lung ca
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3-TACC3	95971 : 95982	CM	s cell lung cancers with FGFR3-TACC3 fusions.21 FGFR3 fusions
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	95994 : 95999	CM	h FGFR3-TACC3 fusions.21 FGFR3 fusions resulted in over
./___Corpus/Medline/xml/PMC4346098.xml	MAPK-ERK	96127 : 96135	CM	activation of downstream MAPK-ERK pathways.22 Studies in b
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3-TACC3	96256 : 96267	CM	transforming capacity of FGFR3-TACC3, including constitutive 
./___Corpus/Medline/xml/PMC4346098.xml	MAPK	96332 : 96336	CM	signaling via downstream MAPK pathway,262 localization
./___Corpus/Medline/xml/PMC4346098.xml	miR-99a	96459 : 96466	CM	y,263 or loss of a 3’UTR miR-99a binding site resulting i
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	96599 : 96604	CM	ave shown sensitivity of FGFR3 fusion cell lines and xe
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	96647 : 96651	CM	 and xenograft models to FGFR inhibitors.22, 262, 263 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	96754 : 96758	CM	      Point mutations in FGFR have also been identifie
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	96838 : 96843	CM	 particular mutations in FGFR2 and FGFR3. Analysis of w
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	96848 : 96853	CM	r mutations in FGFR2 and FGFR3. Analysis of whole exome
./___Corpus/Medline/xml/PMC4346098.xml	TCGA	96889 : 96893	CM	of whole exome data from TCGA identified five FGFR2 an
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	96910 : 96915	CM	rom TCGA identified five FGFR2 and six FGFR3 mutations 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	96924 : 96929	CM	ified five FGFR2 and six FGFR3 mutations from 178 tumor
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	97052 : 97057	CM	ar and kinase domains of FGFR2 and FGFR3, and included 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	97062 : 97067	CM	ase domains of FGFR2 and FGFR3, and included previously
./___Corpus/Medline/xml/PMC4346098.xml	W290C	97312 : 97317	CM	ellular domain mutations W290C and S320C in FGFR2 and S
./___Corpus/Medline/xml/PMC4346098.xml	S320C	97322 : 97327	CM	main mutations W290C and S320C in FGFR2 and S249C in FG
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	97331 : 97336	CM	tions W290C and S320C in FGFR2 and S249C in FGFR3, as w
./___Corpus/Medline/xml/PMC4346098.xml	S249C	97341 : 97346	CM	C and S320C in FGFR2 and S249C in FGFR3, as well as kin
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	97350 : 97355	CM	0C in FGFR2 and S249C in FGFR3, as well as kinase domai
./___Corpus/Medline/xml/PMC4346098.xml	K660E	97392 : 97397	CM	 kinase domain mutations K660E and K660N in FGFR2, sign
./___Corpus/Medline/xml/PMC4346098.xml	K660N	97402 : 97407	CM	main mutations K660E and K660N in FGFR2, significantly 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	97411 : 97416	CM	tions K660E and K660N in FGFR2, significantly increased
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	97537 : 97542	CM	 wild type (in contrast, FGFR2 E471Q and T787K, and FGF
./___Corpus/Medline/xml/PMC4346098.xml	T787K	97553 : 97558	CM	ontrast, FGFR2 E471Q and T787K, and FGFR3 S435C and K71
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	97564 : 97569	CM	FR2 E471Q and T787K, and FGFR3 S435C and K717M were not
./___Corpus/Medline/xml/PMC4346098.xml	S435C	97570 : 97575	CM	71Q and T787K, and FGFR3 S435C and K717M were not trans
./___Corpus/Medline/xml/PMC4346098.xml	K717M	97580 : 97585	CM	87K, and FGFR3 S435C and K717M were not transforming). 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	97651 : 97656	CM	 ability of the specific FGFR2 and FGFR3 mutations was 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	97661 : 97666	CM	f the specific FGFR2 and FGFR3 mutations was inhibited 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	97725 : 97729	CM	le of the small molecule FGFR inhibitors currently in 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	97833 : 97837	CM	                    Many FGFR inhibitors are in develo
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	97941 : 97945	CM	r kinases in addition to FGFR, most notably VEGFR, PDG
./___Corpus/Medline/xml/PMC4346098.xml	VEGFR	97960 : 97965	CM	on to FGFR, most notably VEGFR, PDGFR, FLT3, RET, KIT, 
./___Corpus/Medline/xml/PMC4346098.xml	PDGFR	97967 : 97972	CM	GFR, most notably VEGFR, PDGFR, FLT3, RET, KIT, among o
./___Corpus/Medline/xml/PMC4346098.xml	FLT3	97974 : 97978	CM	st notably VEGFR, PDGFR, FLT3, RET, KIT, among others.
./___Corpus/Medline/xml/PMC4346098.xml	RET	97980 : 97983	CM	ably VEGFR, PDGFR, FLT3, RET, KIT, among others.261 S
./___Corpus/Medline/xml/PMC4346098.xml	KIT	97985 : 97988	CM	VEGFR, PDGFR, FLT3, RET, KIT, among others.261 Select
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	98017 : 98021	CM	ong others.261 Selective FGFR inhibitors are also in d
./___Corpus/Medline/xml/PMC4346098.xml	BGJ398	98145 : 98151	CM	ials. A phase 1 study of BGJ398 is enrolling patients wi
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98212 : 98217	CM	 solid malignancies with FGFR1 or FGFR2 amplification o
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	98221 : 98226	CM	lignancies with FGFR1 or FGFR2 amplification or FGFR3 m
./___Corpus/Medline/xml/PMC4346098.xml	FGFR3	98244 : 98249	CM	r FGFR2 amplification or FGFR3 mutation. A preliminary 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98349 : 98354	CM	eated, including 10 with FGFR1 amplified breast cancer 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98390 : 98395	CM	breast cancer and 3 with FGFR1 amplified lung squamous 
./___Corpus/Medline/xml/PMC4346098.xml	hyperphosphatemia	98506 : 98523	CM	ea, fatigue, nausea, and hyperphosphatemia, with dose limiting toxi
./___Corpus/Medline/xml/PMC4346098.xml	FGF23	98681 : 98686	CM	ffect due to blockade of FGF23 signaling but seems cont
./___Corpus/Medline/xml/PMC4346098.xml	phosphate	98725 : 98734	CM	 seems controllable with phosphate binders and diuretics. O
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98791 : 98796	CM	ent with lung cancer and FGFR1 amplification (FGFR1/CEP
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98812 : 98817	CM	and FGFR1 amplification (FGFR1/CEP8 ratio of 2.6 by FIS
./___Corpus/Medline/xml/PMC4346098.xml	CEP8	98818 : 98822	CM	FR1 amplification (FGFR1/CEP8 ratio of 2.6 by FISH) ha
./___Corpus/Medline/xml/PMC4346098.xml	AZD4547	98901 : 98908	CM	e.266 A phase 1 study of AZD4547, with selection for FGFR
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	98929 : 98934	CM	4547, with selection for FGFR1 and FGFR2 amplification 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	98939 : 98944	CM	 selection for FGFR1 and FGFR2 amplification in the lat
./___Corpus/Medline/xml/PMC4346098.xml	hyperphosphatemia	99105 : 99122	CM	ting toxicities included hyperphosphatemia, renal failure, mucositi
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	99237 : 99242	CM	rted on 21 patients with FGFR1 or FGFR2 amplified tumor
./___Corpus/Medline/xml/PMC4346098.xml	FGFR2	99246 : 99251	CM	1 patients with FGFR1 or FGFR2 amplified tumors on stud
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	99296 : 99301	CM	 study. One patient with FGFR1 amplified lung squamous 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR1	99386 : 99391	CM	ith another patient with FGFR1 amplified lung squamous 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	99506 : 99510	CM	e selecting for specific FGFR family alterations, othe
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	99683 : 99687	CM	effects of the selective FGFR inhibitors are thought t
./___Corpus/Medline/xml/PMC4346098.xml	hyperphosphatemia	99722 : 99739	CM	s are thought to include hyperphosphatemia and tissue calcification
./___Corpus/Medline/xml/PMC4346098.xml	FGF23	99772 : 99777	CM	sue calcification due to FGF23 blockade; while this is 
./___Corpus/Medline/xml/PMC4346098.xml	FGF23	99847 : 99852	CM	erse event, increases in FGF23, phosphate, and vitamin 
./___Corpus/Medline/xml/PMC4346098.xml	phosphate	99854 : 99863	CM	ent, increases in FGF23, phosphate, and vitamin D levels ma
./___Corpus/Medline/xml/PMC4346098.xml	vitamin	99869 : 99876	CM	in FGF23, phosphate, and vitamin D levels may also serve 
./___Corpus/Medline/xml/PMC4346098.xml	FGFR	99939 : 99943	CM	biomarkers for effective FGFR inhibition.282 Most of t
./___Corpus/Medline/xml/PMC4346098.xml	MITOTIC	100104 : 100111	CM	ns.                  12. MITOTIC/CYCLIN INHIBITORS IN LUN
./___Corpus/Medline/xml/PMC4346098.xml	tubulin	100403 : 100410	CM	cades. These agents bind tubulin and prevent polymerizati
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	100621 : 100630	CM	nt including paclitaxel, docetaxel, vinorelbine, and etopos
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	100632 : 100643	CM	g paclitaxel, docetaxel, vinorelbine, and etoposide. These ag
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	100649 : 100658	CM	etaxel, vinorelbine, and etoposide. These agents are routin
./___Corpus/Medline/xml/PMC4346098.xml	platinum	100699 : 100707	CM	re routinely combined in platinum regimens in the adjuvant
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	100767 : 100772	CM	advanced, and metastatic NSCLC; and platinum/etoposide 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	100778 : 100786	CM	nd metastatic NSCLC; and platinum/etoposide remains the es
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	100787 : 100796	CM	atic NSCLC; and platinum/etoposide remains the established 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	100864 : 100868	CM	ted- and extensive-stage SCLC.                        
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	101373 : 101382	CM	-damaging agents such as cisplatin/carboplatin and gemcitab
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	101383 : 101394	CM	agents such as cisplatin/carboplatin and gemcitabine and from
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	101399 : 101410	CM	isplatin/carboplatin and gemcitabine and from the effects of 
./___Corpus/Medline/xml/PMC4346098.xml	Cyclin	101446 : 101452	CM	he effects of radiation. Cyclin dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4346098.xml	G1	101535 : 101537	CM	 progression through the G1, S, G2, and M phases of 
./___Corpus/Medline/xml/PMC4346098.xml	G2	101542 : 101544	CM	ssion through the G1, S, G2, and M phases of the cel
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	101931 : 101940	CM	t.                  12.1 LY2606368                      LY2
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	101962 : 101971	CM	368                      LY2606368 (Eli Lilly) is an oral s
./___Corpus/Medline/xml/PMC4346098.xml	ATP	102020 : 102023	CM	small molecule selective ATP competitive inhibitor of
./___Corpus/Medline/xml/PMC4346098.xml	CHK2	102104 : 102108	CM	, and to a lesser extent CHK2. CHK1 and 2 regulate DNA
./___Corpus/Medline/xml/PMC4346098.xml	CDK1	102164 : 102168	CM	e response by inhibiting CDK1, and preventing entry in
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	102288 : 102297	CM	sis of damaged cells.272 LY2606368 has been shown to potent
./___Corpus/Medline/xml/PMC4346098.xml	LY2606368	102427 : 102436	CM	 preclinical studies.273 LY2606368 is currently in a phase 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	102515 : 102520	CM	nced refractory squamous NSCLC, head and neck cancer, a
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	102762 : 102766	CM	clib (Pfizer) is an oral CDK4/6 inhibitor, inhibiting 
./___Corpus/Medline/xml/PMC4346098.xml	Rb	102807 : 102809	CM	hibiting retinoblastoma (Rb) protein phosphorylation
./___Corpus/Medline/xml/PMC4346098.xml	phosphorylation	102819 : 102834	RN	inoblastoma (Rb) protein phosphorylation in early G1 and disrupti
./___Corpus/Medline/xml/PMC4346098.xml	G1	102844 : 102846	CM	phosphorylation in early G1 and disrupting cell cycl
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103086 : 103095	CM	n were randomized 1:1 to letrozole 2.5mg orally daily +/− p
./___Corpus/Medline/xml/PMC4346098.xml	PFS	103226 : 103229	CM	as investigator assessed PFS. Palbociclib/letrozole w
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103243 : 103252	CM	ssessed PFS. Palbociclib/letrozole was associated with a si
./___Corpus/Medline/xml/PMC4346098.xml	PFS	103302 : 103305	CM	gnificant improvement in PFS compared with letrozole 
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103320 : 103329	CM	ent in PFS compared with letrozole alone (20.2 v. 10.2 mont
./___Corpus/Medline/xml/PMC4346098.xml	1-	103387 : 103389	CPR	.488; 95% CI: 0.32–0.75; 1-sided p=0.0004). The most
./___Corpus/Medline/xml/PMC4346098.xml	letrozole	103452 : 103461	CM	ities in the palbociclib/letrozole arm were neutropenia, le
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	103560 : 103564	CM	planned investigation in CDK4/6-amplified recurrent sq
./___Corpus/Medline/xml/PMC4346098.xml	6-	103565 : 103567	CPR	ed investigation in CDK4/6-amplified recurrent squam
./___Corpus/Medline/xml/PMC4346098.xml	CDK4	103798 : 103802	CM	competitive inhibitor of CDK4/6 which has entered into
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	103845 : 103850	CM	ed into phase I study in NSCLC. ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	nine	103953 : 103957	CM	36"}}NCT02079636) Ninety-nine patients will be enrolle
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	104067 : 104078	CM	exed (nonsquamous only), gemcitabine, ramicirumab, and tramet
./___Corpus/Medline/xml/PMC4346098.xml	trametinib	104097 : 104107	CM	tabine, ramicirumab, and trametinib. Development in other tu
./___Corpus/Medline/xml/PMC4346098.xml	AZD1775	104275 : 104282	CM	g.                  12.4 AZD1775                      TP5
./___Corpus/Medline/xml/PMC4346098.xml	TP53	104304 : 104308	CM	775                      TP53 mutations are the most c
./___Corpus/Medline/xml/PMC4346098.xml	COSMIC	104459 : 104465	CM	34% of adenocarcinomas. (COSMIC) These mutations render 
./___Corpus/Medline/xml/PMC4346098.xml	G1	104494 : 104496	CM	ese mutations render the G1 checkpoint defective, ma
./___Corpus/Medline/xml/PMC4346098.xml	G(2)	104564 : 104568	CM	 more dependent on the S/G(2) cell cycle checkpoint fo
./___Corpus/Medline/xml/PMC4346098.xml	G(2)	104693 : 104697	CM	ome in the presence of S/G(2) inhibitors.271 The WEE1 
./___Corpus/Medline/xml/PMC4346098.xml	WEE1	104717 : 104721	CM	/G(2) inhibitors.271 The WEE1 kinase coordinates cell 
./___Corpus/Medline/xml/PMC4346098.xml	WEE1	104855 : 104859	CM	competitive inhibitor of WEE1 (IC50 5nM; EC50 80nM v. 
./___Corpus/Medline/xml/PMC4346098.xml	WEE1	104898 : 104902	CM	50 80nM v. pCDK1Y15).275 WEE1 inhibition leads to unre
./___Corpus/Medline/xml/PMC4346098.xml	CDK1	104935 : 104939	CM	ion leads to unregulated CDK1 (and 2) activity, overri
./___Corpus/Medline/xml/PMC4346098.xml	G2	104971 : 104973	CM	) activity, overriding S/G2 checkpoints leading to m
./___Corpus/Medline/xml/PMC4346098.xml	G1	105107 : 105109	CM	onounced in p53-mutated (G1 deficient) cells in comb
./___Corpus/Medline/xml/PMC4346098.xml	platinum	105147 : 105155	CM	ells in combination with platinum and gemcitabine-based re
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	105160 : 105171	CM	nation with platinum and gemcitabine-based regimens. A phase 
./___Corpus/Medline/xml/PMC4346098.xml	AZD1775	105207 : 105214	CM	mens. A phase I trial of AZD1775 + cisplatin, + carboplat
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	105217 : 105226	CM	ase I trial of AZD1775 + cisplatin, + carboplatin, and +gem
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105230 : 105241	CM	f AZD1775 + cisplatin, + carboplatin, and +gemcitabine in ove
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	105248 : 105259	CM	tin, + carboplatin, and +gemcitabine in over 180 patients wit
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105408 : 105419	CM	rted in combination with carboplatin/paclitaxel in patients w
./___Corpus/Medline/xml/PMC4346098.xml	platinum	105460 : 105468	CM	atients with p53-mutated platinum-sensitive recurrent ovar
./___Corpus/Medline/xml/PMC4346098.xml	AZD1775	105508 : 105515	CM	rrent ovarian cancer.276 AZD1775 has entered into trials 
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	105607 : 105618	CM	andomized phase trial of carboplatin/pemetrexed +/− AZD1775 i
./___Corpus/Medline/xml/PMC4346098.xml	AZD1775	105634 : 105641	CM	rboplatin/pemetrexed +/− AZD1775 in patients with nonsqua
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	105671 : 105676	CM	atients with nonsquamous NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	105819 : 105828	CM	omized phase II trial of docetaxel +/− AZD1775 in patients 
./___Corpus/Medline/xml/PMC4346098.xml	AZD1775	105833 : 105840	CM	I trial of docetaxel +/− AZD1775 in patients with nonsqua
./___Corpus/Medline/xml/PMC4346098.xml	platinum	106029 : 106037	CM	o ongoing in p53-mutated platinum-sensitive and -resistant
./___Corpus/Medline/xml/PMC4346098.xml	PLK-1	106144 : 106149	CM	        12.5 Volasertib (PLK-1 {"type":"entrez-protein"
./___Corpus/Medline/xml/PMC4346098.xml	ONO01910"}}ONO01910	106238 : 106257	CM	1143735306","term_text":"ONO01910"}}ONO01910)                        
./___Corpus/Medline/xml/PMC4346098.xml	PLK1	106317 : 106321	CM	     Polo-like kinase 1 (PLK1) is important for cellul
./___Corpus/Medline/xml/PMC4346098.xml	G2	106363 : 106365	CM	r cellular recovery from G2/M arrest due to DNA dama
./___Corpus/Medline/xml/PMC4346098.xml	PLK1	106412 : 106416	CM	amage. Overexpression of PLK1 leads to chromosomal ins
./___Corpus/Medline/xml/PMC4346098.xml	PLK1	106540 : 106544	CM	nger-Ingelheim) is an IV PLK1 inhibitor in development
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	106573 : 106578	CM	ibitor in development in NSCLC. Recent data were presen
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	106663 : 106668	CM	th recurrent nonsquamous NSCLC randomized 1:1:1 to vola
./___Corpus/Medline/xml/PMC4346098.xml	m2	106706 : 106708	CM	:1:1 to volasertib 300mg/m2, volasertib 300mg/m2 and
./___Corpus/Medline/xml/PMC4346098.xml	m2	106727 : 106729	CM	0mg/m2, volasertib 300mg/m2 and pemetrexed 500mg/m2,
./___Corpus/Medline/xml/PMC4346098.xml	m2	106751 : 106753	CM	/m2 and pemetrexed 500mg/m2, or pemetrexed alone IV 
./___Corpus/Medline/xml/PMC4346098.xml	PFSs	106813 : 106817	CM	y 3 weeks.278 The median PFSs (primary endpoint) for t
./___Corpus/Medline/xml/PMC4346098.xml	CDK1	107319 : 107323	CM	is through activation of CDK1, and its overexpression 
./___Corpus/Medline/xml/PMC4346098.xml	taxane	107367 : 107373	CM	ssion has been linked to taxane resistance. Aurora kinas
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	107731 : 107735	CM	patients with refractory SCLC, NSCLC, breast cancer, h
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	107737 : 107742	CM	ts with refractory SCLC, NSCLC, breast cancer, head and
./___Corpus/Medline/xml/PMC4346098.xml	BID	107899 : 107902	CM	e II dose of 50mg orally BID for 1 week every 3 weeks
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	107957 : 107962	CM	 ORR in 23 patients with NSCLC was 4% with a median PFS
./___Corpus/Medline/xml/PMC4346098.xml	PFS	107984 : 107987	CM	CLC was 4% with a median PFS of 3.1 months. However, 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	108019 : 108023	CM	 months. However, in the SCLC (n=47) cohort the ORR wa
./___Corpus/Medline/xml/PMC4346098.xml	PFS	108122 : 108125	CM	relapsed disease) with a PFS of 2.8 months. Grade 3/4
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	108347 : 108351	CM	n patients with relapsed SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	108476 : 108485	CM	a trial of alisertib and erlotinib in patients with EGFR-WT
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	108511 : 108516	CM	in patients with EGFR-WT NSCLC. ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	PARP	108766 : 108770	CM	rs.                  13. PARP INHIBITORS IN LUNG CANCE
./___Corpus/Medline/xml/PMC4346098.xml	INHIBITORS	108771 : 108781	CM	                13. PARP INHIBITORS IN LUNG CANCER          
./___Corpus/Medline/xml/PMC4346098.xml	ADP-ribose	108824 : 108834	CM	                   Poly (ADP-ribose) polymerase (PARP) inclu
./___Corpus/Medline/xml/PMC4346098.xml	PARP	108848 : 108852	CM	(ADP-ribose) polymerase (PARP) includes a family of 17
./___Corpus/Medline/xml/PMC4346098.xml	PARP	108974 : 108978	CM	 function in DNA repair, PARP proteins also play major
./___Corpus/Medline/xml/PMC4346098.xml	PARP	109272 : 109276	CM	ingle strand DNA damage, PARP is recruited as the firs
./___Corpus/Medline/xml/PMC4346098.xml	ADP-ribose	109368 : 109378	CM	1 Subsequently, multiple ADP-ribose units are added to the c
./___Corpus/Medline/xml/PMC4346098.xml	NAD	109415 : 109418	CM	dded to the complex in a NAD-dependent manner. This c
./___Corpus/Medline/xml/PMC4346098.xml	PARP	109730 : 109734	CM	, massive recruitment of PARP leads to depletion of NA
./___Corpus/Medline/xml/PMC4346098.xml	NAD	109757 : 109760	CM	RP leads to depletion of NAD, resulting in necrotic c
./___Corpus/Medline/xml/PMC4346098.xml	PARP	109815 : 109819	CM	eath. Thus the extent of PARP activation could be the 
./___Corpus/Medline/xml/PMC4346098.xml	BRCA	110049 : 110053	CM	athway. In subjects with BRCA 1 or 2 mutations, the HR
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110141 : 110145	CM	overwhelming reliance on PARP for DNA repair.282      
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110224 : 110228	CM	ion                      PARP inhibition was initially
./___Corpus/Medline/xml/PMC4346098.xml	platinum	110330 : 110338	CM	nduce DNA repair such as platinum compounds, alkylating ag
./___Corpus/Medline/xml/PMC4346098.xml	alkylating	110350 : 110360	RN	h as platinum compounds, alkylating agents, and ionizing rad
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110427 : 110431	CM	ssion of DNA repair with PARP inhibitors in conjunctio
./___Corpus/Medline/xml/PMC4346098.xml	anti-	110496 : 110501	CPR	ents results in enhanced anti-cancer activity in severa
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110588 : 110592	CM	th deficient HR pathway, PARP inhibition results in ro
./___Corpus/Medline/xml/PMC4346098.xml	anti-	110622 : 110627	CPR	bition results in robust anti-cancer activity due to th
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110681 : 110685	CM	liance of these cells on PARP for DNA repair.282 This 
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110799 : 110803	CM	is for the evaluation of PARP inhibitors as monotherap
./___Corpus/Medline/xml/PMC4346098.xml	BRCA	110917 : 110921	CM	tations. In lung cancer, BRCA mutations are rare and h
./___Corpus/Medline/xml/PMC4346098.xml	PARP	110951 : 110955	CM	tions are rare and hence PARP inhibitors are unlikely 
./___Corpus/Medline/xml/PMC4346098.xml	BRCA	111082 : 111086	CM	own to have ‘functional’ BRCA deficiency, and could be
./___Corpus/Medline/xml/PMC4346098.xml	ATM	111268 : 111271	CM	ers harbor a mutation in ATM gene, a condition with k
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111355 : 111359	CM	echanism referred to as ‘PARP trapping’ has recently b
./___Corpus/Medline/xml/PMC4346098.xml	anti-	111417 : 111422	CPR	ribed to account for the anti-cancer effects of PARP in
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111440 : 111444	CM	e anti-cancer effects of PARP inhibition.284 Retention
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111477 : 111481	CM	ion.284 Retention of the PARP inhibitor-DNA complex co
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111552 : 111556	CM	 cells and the extent of PARP trapping is variable amo
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111608 : 111612	CM	 the presently available PARP inhibitors, contributing
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111769 : 111773	CM	       A number of novel PARP inhibitors are presently
./___Corpus/Medline/xml/PMC4346098.xml	PARP	111901 : 111905	CM	ially considered to be a PARP inhibitor, had been test
./___Corpus/Medline/xml/PMC4346098.xml	platinum	112021 : 112029	CM	ncer in combination with platinum-based chemotherapy.285 T
./___Corpus/Medline/xml/PMC4346098.xml	PARP	112196 : 112200	CM	parib was not related to PARP inhibition. Recently, th
./___Corpus/Medline/xml/PMC4346098.xml	PARP	112281 : 112285	CM	ll molecule inhibitor of PARP, as maintenance therapy 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	112313 : 112321	CM	s maintenance therapy in platinum-sensitive ovarian cancer
./___Corpus/Medline/xml/PMC4346098.xml	PFS	112396 : 112399	CM	gnificant improvement in PFS compared to placebo (8.4
./___Corpus/Medline/xml/PMC4346098.xml	P	112438 : 112439	CM	lacebo (8.4 m vs. 4.8 m, P < 0.001).286 In another 
./___Corpus/Medline/xml/PMC4346098.xml	BRCA	112563 : 112567	CM	ian cancer patients with BRCA mutation.287 Veliparib, 
./___Corpus/Medline/xml/PMC4346098.xml	PARP	112609 : 112613	CM	iparib, a small molecule PARP inhibitor, improved the 
./___Corpus/Medline/xml/PMC4346098.xml	PARP	112790 : 112794	CM	idence, it is clear that PARP inhibitors represent a n
./___Corpus/Medline/xml/PMC4346098.xml	PARP	112884 : 112888	CM	r.                  13.2 PARP inhibitors under develop
./___Corpus/Medline/xml/PMC4346098.xml	PARP	113017 : 113021	CM	ng evidence suggest that PARP inhibition might be a no
./___Corpus/Medline/xml/PMC4346098.xml	BMN-673	113133 : 113140	CM	 have been reported with BMN-673, a highly potent PARP in
./___Corpus/Medline/xml/PMC4346098.xml	PARP	113158 : 113162	CM	BMN-673, a highly potent PARP inhibitor when given as 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113216 : 113220	CM	therapy to patients with SCLC that had progressed on s
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113311 : 113315	CM	e for the sensitivity of SCLC might be due to the high
./___Corpus/Medline/xml/PMC4346098.xml	PARP	113343 : 113347	CM	ght be due to the higher PARP 1 expression and other D
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113394 : 113398	CM	r DNA repair proteins in SCLC tumor samples. Based on 
./___Corpus/Medline/xml/PMC4346098.xml	alkylating	113443 : 113453	RN	d on the synergy between alkylating agents and PARP inhibito
./___Corpus/Medline/xml/PMC4346098.xml	PARP	113465 : 113469	CM	en alkylating agents and PARP inhibitors, a phase 2 st
./___Corpus/Medline/xml/PMC4346098.xml	temozolamide	113541 : 113553	CM	ating the combination of temozolamide in combination with veli
./___Corpus/Medline/xml/PMC4346098.xml	veliparib	113574 : 113583	CM	mide in combination with veliparib, a PARP inhibitor, for p
./___Corpus/Medline/xml/PMC4346098.xml	PARP	113587 : 113591	CM	nation with veliparib, a PARP inhibitor, for patients 
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113641 : 113645	CM	with relapsed/refractory SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	113824 : 113833	CM	domized phase 2 study of cisplatin and etoposide with eithe
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	113838 : 113847	CM	2 study of cisplatin and etoposide with either veliparib or
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	113937 : 113941	CM	nts with extensive stage SCLC (EA2511) ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	1–	114105 : 114107	CPR	0 mg twice daily on days 1–7 of each treatment cycle
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	114175 : 114184	CM	th the administration of cisplatin (day 1) and etoposide (d
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	114197 : 114206	CM	of cisplatin (day 1) and etoposide (days 1–3). This ongoing
./___Corpus/Medline/xml/PMC4346098.xml	1–	114213 : 114215	CPR	y 1) and etoposide (days 1–3). This ongoing study wi
./___Corpus/Medline/xml/PMC4346098.xml	PFS	114320 : 114323	CM	oint of comparing median PFS between the two arms.   
./___Corpus/Medline/xml/PMC4346098.xml	platinum	114424 : 114432	CM	                   Since platinum-based chemotherapy is th
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	114508 : 114513	CM	ajority of patients with NSCLC, the use of PARP inhibit
./___Corpus/Medline/xml/PMC4346098.xml	PARP	114526 : 114530	CM	s with NSCLC, the use of PARP inhibitors in combinatio
./___Corpus/Medline/xml/PMC4346098.xml	platinum	114562 : 114570	CM	tors in combination with platinum compounds has been studi
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	114654 : 114665	CM	dies. A phase I study of carboplatin, paclitaxel and velipari
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	114858 : 114869	CM	domized phase 2 study of carboplatin and paclitaxel with eith
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	114953 : 114958	CM	line therapy of advanced NSCLC was conducted. Accrual t
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115283 : 115288	CM	ctable, locally advanced NSCLC by the Southwest Oncolog
./___Corpus/Medline/xml/PMC4346098.xml	PARP	115472 : 115476	CM	       Olaparib, another PARP inhibitor, is also under
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115526 : 115531	CM	 extensive evaluation in NSCLC. A European study will a
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	115595 : 115604	CM	arib in combination with cisplatin and radiotherapy to pati
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115662 : 115667	CM	h unresectable stage III NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	115824 : 115829	CM	nce therapy for advanced NSCLC following combination ch
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	116081 : 116090	CM	ination of olaparib with gefitinib in patients with advance
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	116117 : 116122	CM	n patients with advanced NSCLC that harbor an EGFR muta
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	116138 : 116142	CM	ced NSCLC that harbor an EGFR mutation ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	116645 : 116650	CM	death receptor ligand 1 (PD-L1) have shown promise in e
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	116733 : 116737	CM	 clinical trials in both SCLC and NSCLC. This review p
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	116742 : 116747	CM	 trials in both SCLC and NSCLC. This review provides an
./___Corpus/Medline/xml/PMC4346098.xml	IgG1	116956 : 116960	CM	limumab is a fully human IgG1 antibody to CTLA4 that i
./___Corpus/Medline/xml/PMC4346098.xml	CTLA4	116973 : 116978	CM	y human IgG1 antibody to CTLA4 that inhibits the bindin
./___Corpus/Medline/xml/PMC4346098.xml	CTLA4	117008 : 117013	CM	 inhibits the binding of CTLA4 to its ligands (CD80 or 
./___Corpus/Medline/xml/PMC4346098.xml	CD80	117030 : 117034	CM	of CTLA4 to its ligands (CD80 or B7-1 and CD86 or B7-2
./___Corpus/Medline/xml/PMC4346098.xml	B7-1	117038 : 117042	CM	 to its ligands (CD80 or B7-1 and CD86 or B7-2). Inhib
./___Corpus/Medline/xml/PMC4346098.xml	CD86	117047 : 117051	CM	igands (CD80 or B7-1 and CD86 or B7-2). Inhibition aug
./___Corpus/Medline/xml/PMC4346098.xml	B7-2	117055 : 117059	CM	CD80 or B7-1 and CD86 or B7-2). Inhibition augments T-
./___Corpus/Medline/xml/PMC4346098.xml	FDA	117197 : 117200	CM	mor regression.290 It is FDA approved for the treatme
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	117351 : 117362	CM	f standard chemotherapy (carboplatin and paclitaxel) with two
./___Corpus/Medline/xml/PMC4346098.xml	P	118219 : 118220	CM	vs. 4.6 months, HR 0.72; P=0.05), and OS (12.2 vs. 
./___Corpus/Medline/xml/PMC4346098.xml	P	118342 : 118343	CM	FS (5.5 months, HR 0.81; P = 0.81) or OS (9.7 month
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	119223 : 119228	CM	 observed in nonsquamous NSCLC patients or for any hist
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	119468 : 119473	CM	ients with squamous cell NSCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	119664 : 119668	CM	nts with extensive stage SCLC and noted an improvement
./___Corpus/Medline/xml/PMC4346098.xml	P	119820 : 119821	CM	vs. 5.3 months, HR 0.64, P=0.03) with a non-signifi
./___Corpus/Medline/xml/PMC4346098.xml	RR	119880 : 119882	CM	d towards improvement in RR (57% vs. 49%) and OS (12
./___Corpus/Medline/xml/PMC4346098.xml	PFS	119981 : 119984	CM	oncurrent treatment arm (PFS 3.9 months, RR 30% and O
./___Corpus/Medline/xml/PMC4346098.xml	RR	119997 : 119999	CM	ent arm (PFS 3.9 months, RR 30% and OS 9.1 months). 
./___Corpus/Medline/xml/PMC4346098.xml	platinum	120344 : 120352	CM	mized phase III trial of platinum based chemotherapy (carb
./___Corpus/Medline/xml/PMC4346098.xml	carboplatin	120373 : 120384	CM	inum based chemotherapy (carboplatin or cisplatin and etoposi
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	120388 : 120397	CM	otherapy (carboplatin or cisplatin and etoposide for four c
./___Corpus/Medline/xml/PMC4346098.xml	etoposide	120402 : 120411	CM	oplatin or cisplatin and etoposide for four cycles) with or
./___Corpus/Medline/xml/PMC4346098.xml	IgG2	120656 : 120660	CM	limumab is a fully human IgG2 antibody. A phase II tri
./___Corpus/Medline/xml/PMC4346098.xml	CR	120848 : 120850	CM	ts with disease control (CR/PR or SD) following four
./___Corpus/Medline/xml/PMC4346098.xml	SD	120857 : 120859	CM	isease control (CR/PR or SD) following four cycles o
./___Corpus/Medline/xml/PMC4346098.xml	platinum	120886 : 120894	CM	following four cycles of platinum-based chemotherapy (20.9
./___Corpus/Medline/xml/PMC4346098.xml	Nine	120974 : 120978	CM	on free at 3 months).296 Nine (20.5%) of the tremelimu
./___Corpus/Medline/xml/PMC4346098.xml	anti-	121140 : 121145	CPR	umab in combination with anti-PD-L1 therapy and gefitin
./___Corpus/Medline/xml/PMC4346098.xml	gefitinib	121163 : 121172	CM	h anti-PD-L1 therapy and gefitinib in patients with NSCLC a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121190 : 121195	CM	fitinib in patients with NSCLC are ongoing ({"type":"cl
./___Corpus/Medline/xml/PMC4346098.xml	IgG4	121503 : 121507	CM	558), a human monoclonal IgG4 antibody was the first a
./___Corpus/Medline/xml/PMC4346098.xml	anti-	121531 : 121536	CPR	4 antibody was the first anti-PD-1 antibody to demonstr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121577 : 121582	CM	 demonstrate activity in NSCLC patients. PD-1 is an inh
./___Corpus/Medline/xml/PMC4346098.xml	PD-1	121593 : 121597	CM	ivity in NSCLC patients. PD-1 is an inhibitory T-cell 
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	121661 : 121666	CM	is engaged by it ligands PD-L1 (or B7-H1) and PD-L2 (or
./___Corpus/Medline/xml/PMC4346098.xml	B7-H1	121671 : 121676	CM	 by it ligands PD-L1 (or B7-H1) and PD-L2 (or B7-DC) pr
./___Corpus/Medline/xml/PMC4346098.xml	PD-L2	121682 : 121687	CM	nds PD-L1 (or B7-H1) and PD-L2 (or B7-DC) predominantly
./___Corpus/Medline/xml/PMC4346098.xml	B7-DC	121692 : 121697	CM	(or B7-H1) and PD-L2 (or B7-DC) predominantly within th
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121829 : 121834	CM	 trial that included 129 NSCLC patients treated with ni
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	121966 : 121971	CM	f 17.1% was noted in the NSCLC population with no signi
./___Corpus/Medline/xml/PMC4346098.xml	EGFR	122323 : 122327	CM	een in patients who were EGFR mutation positive or wil
./___Corpus/Medline/xml/PMC4346098.xml	KRAS	122360 : 122364	CM	n positive or wild type, KRAS positive or wild type.30
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	122902 : 122911	CM	econd line chemotherapy (docetaxel) in squamous and nonsqua
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	122941 : 122946	CM	squamous and nonsquamous NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	123300 : 123305	CM	vailable for assessment, PD-L1 expression by immunohist
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	123451 : 123456	CM	ts with tumors that were PD-L1 negative.299 A phase III
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	123583 : 123588	CM	therapy in patients with PD-L1 positive tumors ({"type"
./___Corpus/Medline/xml/PMC4346098.xml	SCLC	123922 : 123926	CM	ct tumor types including SCLC ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4346098.xml	platinum	124113 : 124121	CM	bination with first line platinum-based chemotherapy in NS
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	124144 : 124149	CM	um-based chemotherapy in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	MK3475	124430 : 124436	CM	                         MK3475 is a humanized IgG4 anti
./___Corpus/Medline/xml/PMC4346098.xml	IgG4	124452 : 124456	CM	   MK3475 is a humanized IgG4 anti-PD1 antibody that i
./___Corpus/Medline/xml/PMC4346098.xml	anti-	124457 : 124462	CPR	3475 is a humanized IgG4 anti-PD1 antibody that is also
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	124507 : 124512	CM	 also being evaluated in NSCLC patients. Preliminary re
./___Corpus/Medline/xml/PMC4346098.xml	RECIST	124759 : 124765	CM	 rate using conventional RECIST response criteria.303 Th
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	124874 : 124879	CM	sitive for expression of PD-L1 (67% vs. 4%). Median PFS
./___Corpus/Medline/xml/PMC4346098.xml	PFS	124901 : 124904	CM	-L1 (67% vs. 4%). Median PFS had not been reached at 
./___Corpus/Medline/xml/PMC4346098.xml	MK-3475	125278 : 125285	CM	o different schedules of MK-3475 to standard chemotherapy
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	125312 : 125321	CM	o standard chemotherapy (docetaxel) as second line therapy 
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	125392 : 125397	CM	rs that are positive for PD-L1 expression ({"type":"cli
./___Corpus/Medline/xml/PMC4346098.xml	IgG4	125894 : 125898	CM	MS-936559, a fully human IgG4 molecule, was the first 
./___Corpus/Medline/xml/PMC4346098.xml	anti-	125923 : 125928	CPR	 molecule, was the first anti-PD-L1 antibody to demonst
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	125970 : 125975	CM	 demonstrate activity in NSCLC patients. A response rat
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	126171 : 126176	CM	squamous and nonsquamous NSCLC patients.304 Despite ini
./___Corpus/Medline/xml/PMC4346098.xml	IgG1	126363 : 126367	CM	   MPDL3280A, is a human IgG1 monoclonal antibody to P
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	126391 : 126396	CM	1 monoclonal antibody to PD-L1. A phase I trial that in
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	126431 : 126436	CM	I trial that included 85 NSCLC treated with MPDL3280A r
./___Corpus/Medline/xml/PMC4346098.xml	IHC3	126571 : 126575	CM	gher in tumors that were IHC3 positive (83%), defined 
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	126653 : 126658	CM	sitive for expression of PD-L1 and in former and curren
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	126973 : 126978	CM	sitive for expression of PD-L1 are ongoing including a 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	127308 : 127317	CM	o standard chemotherapy (docetaxel) ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	127483 : 127492	CM	bining MPDL3280A with or erlotinib in NSCLC patients ({"typ
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	127496 : 127501	CM	80A with or erlotinib in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	PD-L1	127693 : 127698	CM	an antibody specific for PD-L1. Binding of MEDI-4736 re
./___Corpus/Medline/xml/PMC4346098.xml	MEDI-4736	127711 : 127720	CM	ic for PD-L1. Binding of MEDI-4736 relieves B7-H1 mediated 
./___Corpus/Medline/xml/PMC4346098.xml	B7-H1	127730 : 127735	CM	ng of MEDI-4736 relieves B7-H1 mediated suppression of 
./___Corpus/Medline/xml/PMC4346098.xml	vitro	127781 : 127786	CM	 of T cell activation in vitro. An ongoing phase I dose
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	127853 : 127858	CM	 including patients with NSCLC is evaluating different 
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128110 : 128115	CM	nd responses observed in NSCLC patients.307 A phase Ib 
./___Corpus/Medline/xml/PMC4346098.xml	Ib	128137 : 128139	CM	CLC patients.307 A phase Ib trial is evaluating MEDI
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128206 : 128211	CM	ion with tremelimumab in NSCLC patients ({"type":"clini
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	128694 : 128699	CM	aluated in patients with NSCLC are the tumor cell and t
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129123 : 129128	CM	 made of four irradiated NSCLC cell lines (H460, H520, 
./___Corpus/Medline/xml/PMC4346098.xml	H460	129141 : 129145	CM	diated NSCLC cell lines (H460, H520, SKLU1 and RH2) mo
./___Corpus/Medline/xml/PMC4346098.xml	H520	129147 : 129151	CM	 NSCLC cell lines (H460, H520, SKLU1 and RH2) modified
./___Corpus/Medline/xml/PMC4346098.xml	SKLU1	129153 : 129158	CM	 cell lines (H460, H520, SKLU1 and RH2) modified with t
./___Corpus/Medline/xml/PMC4346098.xml	RH2	129163 : 129166	CM	s (H460, H520, SKLU1 and RH2) modified with transform
./___Corpus/Medline/xml/PMC4346098.xml	TGF-β2	129306 : 129312	CM	d cellular expression of TGF-β2 increases the immunogeni
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129407 : 129412	CM	 trial, 75 patients with NSCLC stages II-IV were random
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	129759 : 129764	CM	trial, 532 patients with NSCLC stage IIIA to IV were ra
./___Corpus/Medline/xml/PMC4346098.xml	IIIA	129771 : 129775	CM	atients with NSCLC stage IIIA to IV were randomized to
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	130043 : 130047	CM	 490 patients with stage IIIB or IV who were randomize
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	130317 : 130321	CM	f 99 patients with stage IIIB or IV non-adenocarcinoma
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	130617 : 130622	CM	of belagenpumatucel-L in NSCLC.                  15.1.2
./___Corpus/Medline/xml/PMC4346098.xml	α-galactosyltransferase	130890 : 130913	CM	ngineered to express the α-galactosyltransferase (α-GT) enzyme, which is 
./___Corpus/Medline/xml/PMC4346098.xml	α-GT	130915 : 130919	CM	α-galactosyltransferase (α-GT) enzyme, which is one of
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131095 : 131100	CM	8 patients with advanced NSCLC received Tergenpumatucel
./___Corpus/Medline/xml/PMC4346098.xml	SD	131285 : 131287	CM	 patients (29%) achieved SD for 4 or more months, wi
./___Corpus/Medline/xml/PMC4346098.xml	1-	131382 : 131384	CPR	 therapy. The median and 1-year OS were 11.3 months 
./___Corpus/Medline/xml/PMC4346098.xml	docetaxel	131492 : 131501	CM	ing Tergenpumatucel-L to docetaxel in patient with previous
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131537 : 131542	CM	 with previously treated NSCLC.                  15.2 A
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	131857 : 131862	CM	ely 35% of patients with NSCLC. MAGE-A3 vaccine is comp
./___Corpus/Medline/xml/PMC4346098.xml	AS15	131925 : 131929	CM	rotein plus the adjuvant AS15. In a phase II trial, pa
./___Corpus/Medline/xml/PMC4346098.xml	MAGE-A3	131986 : 131993	CM	with completely resected MAGE-A3 positive stage IB or II 
./___Corpus/Medline/xml/PMC4346098.xml	IB	132009 : 132011	CM	d MAGE-A3 positive stage IB or II NSCLC were randomi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	132018 : 132023	CM	 positive stage IB or II NSCLC were randomized to the v
./___Corpus/Medline/xml/PMC4346098.xml	DFI	132251 : 132254	CM	n disease-free interval (DFI), disease-free survival 
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132280 : 132283	CM	, disease-free survival (DFS) or OS. Nevertheless, th
./___Corpus/Medline/xml/PMC4346098.xml	DFI	132345 : 132348	CM	ring the vaccine arm for DFI (HR 0.75), DFS (HR 0.76)
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132360 : 132363	CM	e arm for DFI (HR 0.75), DFS (HR 0.76) and OS (HR 0.8
./___Corpus/Medline/xml/PMC4346098.xml	MAGRIT	132424 : 132430	CM	he large phase III trial MAGRIT, where patients with res
./___Corpus/Medline/xml/PMC4346098.xml	IB	132467 : 132469	CM	ents with resected stage IB to IIIA NSCLC and MAGE-A
./___Corpus/Medline/xml/PMC4346098.xml	IIIA	132473 : 132477	CM	ith resected stage IB to IIIA NSCLC and MAGE-A3 positi
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	132478 : 132483	CM	esected stage IB to IIIA NSCLC and MAGE-A3 positive tum
./___Corpus/Medline/xml/PMC4346098.xml	MAGE-A3	132488 : 132495	CM	age IB to IIIA NSCLC and MAGE-A3 positive tumors were ran
./___Corpus/Medline/xml/PMC4346098.xml	DFS	132746 : 132749	CM	ry endpoint of extending DFS.                  15.2.2
./___Corpus/Medline/xml/PMC4346098.xml	MUC-1	132775 : 132780	CM	                  15.2.2 MUC-1                      Lip
./___Corpus/Medline/xml/PMC4346098.xml	MUC-1	132895 : 132900	CM	onsisting of a synthetic MUC-1 lipopeptide combined wit
./___Corpus/Medline/xml/PMC4346098.xml	monphosphoryl lipid A	132940 : 132961	CM	mbined with the adjuvant monphosphoryl lipid A and three lipids forming
./___Corpus/Medline/xml/PMC4346098.xml	lipids	132972 : 132978	CM	phoryl lipid A and three lipids forming a liposomal prod
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	133053 : 133057	CM	 171 patients with stage IIIB or IV NSCLC and no progr
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133064 : 133069	CM	ts with stage IIIB or IV NSCLC and no progressive disea
./___Corpus/Medline/xml/PMC4346098.xml	cyclophosphamide	133327 : 133343	CM	 preceded by one dose of cyclophosphamide 300 mg/m2. This low-dose
./___Corpus/Medline/xml/PMC4346098.xml	m2	133351 : 133353	CM	 cyclophosphamide 300 mg/m2. This low-dose cyclophos
./___Corpus/Medline/xml/PMC4346098.xml	cyclophosphamide	133369 : 133385	CM	300 mg/m2. This low-dose cyclophosphamide, administered 3 days pri
./___Corpus/Medline/xml/PMC4346098.xml	anti-	133460 : 133465	CPR	oes not have significant anti-tumor activity in NSCLC a
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133483 : 133488	CM	t anti-tumor activity in NSCLC and was used to increase
./___Corpus/Medline/xml/PMC4346098.xml	BSC	133627 : 133630	CM	ng from 13 months in the BSC arm to 17.4 months in th
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	133783 : 133787	CM	 with locoregional stage IIIB disease, where the posth
./___Corpus/Medline/xml/PMC4346098.xml	2-	133881 : 133883	CPR	ched vs 13.3 months) and 2-year OS (60% vs 36.7%) fa
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	133982 : 133987	CM	ted Antigen Responses To NSCLC (START) trial was a larg
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	134107 : 134112	CM	 patients with stage III NSCLC who did not have PD afte
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	134798 : 134803	CM	 patients with stage III NSCLC treated with concurrent 
./___Corpus/Medline/xml/PMC4346098.xml	INSPIRE	134897 : 134904	CM	2014. A phase III trial (INSPIRE) with an almost identica
./___Corpus/Medline/xml/PMC4346098.xml	TG4010	135004 : 135010	CM	                         TG4010 is a vaccine composed of
./___Corpus/Medline/xml/PMC4346098.xml	MUC-1	135109 : 135114	CM	ing the sequence for the MUC-1 antigen and interleukin-
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	135187 : 135196	CM	 trial, two schedules of cisplatin plus vinorelbine and TG4
./___Corpus/Medline/xml/PMC4346098.xml	vinorelbine	135202 : 135213	CM	edules of cisplatin plus vinorelbine and TG4010 were evaluate
./___Corpus/Medline/xml/PMC4346098.xml	TG4010	135218 : 135224	CM	tin plus vinorelbine and TG4010 were evaluated, includin
./___Corpus/Medline/xml/PMC4346098.xml	TG4010	135282 : 135288	CM	rent therapy upfront and TG4010 followed by the combinat
./___Corpus/Medline/xml/PMC4346098.xml	SD	135411 : 135413	CM	 sequential arm achieved SD for more than 6 months, 
./___Corpus/Medline/xml/PMC4346098.xml	1-	135657 : 135659	CPR	an OS of 12.7 months and 1-year OS of 53%. In the ph
./___Corpus/Medline/xml/PMC4346098.xml	IIIB	135723 : 135727	CM	 148 patients with stage IIIB with malignant pleural e
./___Corpus/Medline/xml/PMC4346098.xml	NSCLC	135772 : 135777	CM	ral effusion or stage IV NSCLC were randomized to cispl
./___Corpus/Medline/xml/PMC4346098.xml	cisplatin	135797 : 135806	CM	NSCLC were randomized to cisplatin plus gemcitabine alone o
./___Corpus/Medline/xml/PMC4346098.xml	gemcitabine	135812 : 135823	CM	omized to cisplatin plus gemcitabine alone or in combination 
./___Corpus/Medline/xml/PMC4346098.xml	PFS	135901 : 135904	CM	endpoint of the study of PFS at 6 months was met, wit
./___Corpus/Medline/xml/PMC4346098.xml	TIME	136195 : 136199	CM	ory phase IIB/III trial (TIME) started in January 2012
./___Corpus/Medline/xml/PMC4346098.xml	platinum	136273 : 136281	CM	py choice among multiple platinum-based doublets.         
./___Corpus/Medline/xml/PMC4346098.xml	OPTIMAL	136319 : 136326	CM	ts.                  16. OPTIMAL TRIAL DESIGN IN THE ERA 
./___Corpus/Medline/xml/PMC4346098.xml	TCGA	137181 : 137185	CM	national efforts such as TCGA and the International Ca
./___Corpus/Medline/xml/PMC4346098.xml	imatinib	137595 : 137603	CM	 targeted agents such as imatinib and crizotinib in phase 
./___Corpus/Medline/xml/PMC4346098.xml	321–	137857 : 137861	CPR	upport this approach.12, 321–327 The expansion cohort 
./___Corpus/Medline/xml/PMC4346098.xml	30-	139393 : 139396	CPR	een the development of a 30-point checklist to determ
./___Corpus/Medline/xml/PMC4346098.xml	gold	142691 : 142695	CM	mized designs remain the gold standard and are being i
./___Corpus/Medline/xml/PMC4346098.xml	erlotinib	144188 : 144197	CM	rugs like crizotinib and erlotinib in targeted populations 
./___Corpus/Medline/xml/PMC4346098.xml	ALCHEMIST	144999 : 145008	CM	nder development are the ALCHEMIST, SWOG 1400, M-PACT and M
./___Corpus/Medline/xml/PMC4346098.xml	SWOG	145010 : 145014	CM	pment are the ALCHEMIST, SWOG 1400, M-PACT and MATCH t
./___Corpus/Medline/xml/PMC4346098.xml	M-PACT	145021 : 145027	CM	he ALCHEMIST, SWOG 1400, M-PACT and MATCH trials. Though
./___Corpus/Medline/xml/PMC4346098.xml	MATCH	145032 : 145037	CM	T, SWOG 1400, M-PACT and MATCH trials. Though each of t
./___Corpus/Medline/xml/PMC4346098.xml	RG	146592 : 146594	CM	         Acknowledgement RG thanks Johanna Duke for 
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	450 : 454	CM	ic cancer cells secreted PGE2 and TNFα that stimulated
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	459 : 463	CM	 cells secreted PGE2 and TNFα that stimulated IL-6 sec
./___Corpus/Medline/xml/PMC4364666.xml	glyceraldehyde 3-phosphate	567 : 593	CM	t stromal cells secreted glyceraldehyde 3-phosphate dehydrogenase (GAPDH). E
./___Corpus/Medline/xml/PMC4364666.xml	dehydrogenase	594 : 607	CM	yceraldehyde 3-phosphate dehydrogenase (GAPDH). Extracellular G
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	609 : 614	CM	phosphate dehydrogenase (GAPDH). Extracellular GAPDH, o
./___Corpus/Medline/xml/PMC4364666.xml	N-	646 : 648	CPR	acellular GAPDH, or its N-terminal domain, inhibited
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	745 : 750	CM	d in other cell systems. GAPDH bound to E-cadherin and 
./___Corpus/Medline/xml/PMC4364666.xml	E-	760 : 762	CPR	 systems. GAPDH bound to E-cadherin and downregulate
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6	793 : 803	CM	in and downregulated the mTOR-p70S6 kinase pathway. These re
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	1005 : 1010	CM	n of cancer growth using GAPDH could be a new anti-canc
./___Corpus/Medline/xml/PMC4364666.xml	anti-	1026 : 1031	CPR	ing GAPDH could be a new anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	α-actin	1501 : 1508	CM	mentin and smooth muscle α-actin (SM-α-actin) [1] have a 
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	1510 : 1520	CM	d smooth muscle α-actin (SM-α-actin) [1] have a high ability
./___Corpus/Medline/xml/PMC4364666.xml	ECM	1573 : 1576	CM	 secrete growth factors, ECM proteins, and proteinase
./___Corpus/Medline/xml/PMC4364666.xml	anti-	2134 : 2139	CPR	an attractive target for anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	13–	2320 : 2323	CPR	s and adhesion [1, 5, 6, 13–17]. Various growth facto
./___Corpus/Medline/xml/PMC4364666.xml	factor-7	2461 : 2469	CM	], and fibroblast growth factor-7 (FGF-7) [20] are secrete
./___Corpus/Medline/xml/PMC4364666.xml	FGF-7	2471 : 2476	CM	roblast growth factor-7 (FGF-7) [20] are secreted from 
./___Corpus/Medline/xml/PMC4364666.xml	vitro	3172 : 3177	CM	o nude mice [19], our in vitro co-culture method mimics
./___Corpus/Medline/xml/PMC4364666.xml	vitro	3403 : 3408	CM	thermore, we used the in vitro co-culture system as a s
./___Corpus/Medline/xml/PMC4364666.xml	anti-	3481 : 3486	CPR	ify compounds that exert anti-cancer activity through t
./___Corpus/Medline/xml/PMC4364666.xml	23–	3676 : 3679	CPR	s of bacteria and fungi [23–26]. Among them, phthoxaz
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	3696 : 3710	CM	ngi [23–26]. Among them, phthoxazolin A and leucinostatin A are 
./___Corpus/Medline/xml/PMC4364666.xml	NBRI16716A	3914 : 3924	CM	 24]. On the other hand, NBRI16716A inhibits the growth of p
./___Corpus/Medline/xml/PMC4364666.xml	anti-	4586 : 4591	CPR	ese findings suggest new anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	DU-145	4716 : 4722	CM	   Human prostate cancer DU-145 cells, human colon cance
./___Corpus/Medline/xml/PMC4364666.xml	DLD-1	4749 : 4754	CM	ells, human colon cancer DLD-1 cells, human pancreatic 
./___Corpus/Medline/xml/PMC4364666.xml	BxPC-3	4807 : 4813	CM	cer cell lines MiaPaca2, BxPC-3, Capan-1 and Panc-1 were
./___Corpus/Medline/xml/PMC4364666.xml	Capan-1	4815 : 4822	CM	 lines MiaPaca2, BxPC-3, Capan-1 and Panc-1 were obtained
./___Corpus/Medline/xml/PMC4364666.xml	Panc-1	4827 : 4833	CM	ca2, BxPC-3, Capan-1 and Panc-1 were obtained from the A
./___Corpus/Medline/xml/PMC4364666.xml	PC-3	4920 : 4924	CM	). Human prostate cancer PC-3 cells and human embryoni
./___Corpus/Medline/xml/PMC4364666.xml	DS	4987 : 4989	CM	cells were obtained from DS Pharma. The LNCaP-CR cel
./___Corpus/Medline/xml/PMC4364666.xml	LNCaP-CR	5002 : 5010	CM	ined from DS Pharma. The LNCaP-CR cell line [27] was estab
./___Corpus/Medline/xml/PMC4364666.xml	LNCaP	5087 : 5092	CM	om human prostate cancer LNCaP cells (DS Pharma). Other
./___Corpus/Medline/xml/PMC4364666.xml	DS	5100 : 5102	CM	tate cancer LNCaP cells (DS Pharma). Other cancer ce
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	5248 : 5252	CM	Modified Eagle’s Medium (DMEM) (Nissui) supplemented w
./___Corpus/Medline/xml/PMC4364666.xml	FBS	5305 : 5308	CM	 10% fetal bovine serum (FBS; Sigma), 100 units/mL pe
./___Corpus/Medline/xml/PMC4364666.xml	penicillin	5331 : 5341	CM	BS; Sigma), 100 units/mL penicillin G (Invitrogen), and 100 
./___Corpus/Medline/xml/PMC4364666.xml	Invitrogen	5345 : 5355	CM	0 units/mL penicillin G (Invitrogen), and 100 μg/mL streptom
./___Corpus/Medline/xml/PMC4364666.xml	streptomycin	5372 : 5384	CM	vitrogen), and 100 μg/mL streptomycin (Invitrogen) at 37°C wit
./___Corpus/Medline/xml/PMC4364666.xml	Invitrogen	5386 : 5396	CM	 100 μg/mL streptomycin (Invitrogen) at 37°C with 5% CO2. Hs
./___Corpus/Medline/xml/PMC4364666.xml	37°C	5401 : 5405	CM	ptomycin (Invitrogen) at 37°C with 5% CO2. Hs738 human
./___Corpus/Medline/xml/PMC4364666.xml	CO2	5414 : 5417	CM	itrogen) at 37°C with 5% CO2. Hs738 human gastric str
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	5419 : 5424	CM	en) at 37°C with 5% CO2. Hs738 human gastric stromal ce
./___Corpus/Medline/xml/PMC4364666.xml	Hs371	5514 : 5519	CM	roblasts (CRL-1459), and Hs371 mammary gland fibroblast
./___Corpus/Medline/xml/PMC4364666.xml	ATCC	5580 : 5584	CM	) were obtained from the ATCC. NHLF normal human lung 
./___Corpus/Medline/xml/PMC4364666.xml	PrSC	5625 : 5629	CM	man lung fibroblasts and PrSC human prostate stromal c
./___Corpus/Medline/xml/PMC4364666.xml	DS	5745 : 5747	CM	cells were obtained from DS pharma. All stromal cell
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	5793 : 5797	CM	cells were maintained in DMEM supplemented with 10% FB
./___Corpus/Medline/xml/PMC4364666.xml	FBS	5820 : 5823	CM	EM supplemented with 10% FBS, 100 units/mL penicillin
./___Corpus/Medline/xml/PMC4364666.xml	penicillin	5838 : 5848	CM	th 10% FBS, 100 units/mL penicillin G, 100 μg/mL streptomyci
./___Corpus/Medline/xml/PMC4364666.xml	streptomycin	5862 : 5874	CM	 penicillin G, 100 μg/mL streptomycin, ITH (5 μg/mL insulin, 5
./___Corpus/Medline/xml/PMC4364666.xml	ITH	5876 : 5879	CM	 100 μg/mL streptomycin, ITH (5 μg/mL insulin, 5 μg/m
./___Corpus/Medline/xml/PMC4364666.xml	hydrocortisone	5930 : 5944	CM	 transferrin, and 1.4 μM hydrocortisone), and 5 ng/mL basic FGF 
./___Corpus/Medline/xml/PMC4364666.xml	FGF	5965 : 5968	CM	sone), and 5 ng/mL basic FGF (PeproTech) at 37°C with
./___Corpus/Medline/xml/PMC4364666.xml	37°C	5984 : 5988	CM	basic FGF (PeproTech) at 37°C with 5% CO2 as described
./___Corpus/Medline/xml/PMC4364666.xml	CO2	5997 : 6000	CM	proTech) at 37°C with 5% CO2 as described [22].      
./___Corpus/Medline/xml/PMC4364666.xml	sc-8018	6080 : 6087	CM	   Anti-pan-cytokeratin (sc-8018), anti-STAT3 (sc-8019), 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6090 : 6095	CPR	n-cytokeratin (sc-8018), anti-STAT3 (sc-8019), anti-GAP
./___Corpus/Medline/xml/PMC4364666.xml	sc-8019	6102 : 6109	CM	n (sc-8018), anti-STAT3 (sc-8019), anti-GAPDH (sc-47724),
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6112 : 6117	CPR	), anti-STAT3 (sc-8019), anti-GAPDH (sc-47724), anti-PA
./___Corpus/Medline/xml/PMC4364666.xml	sc-47724	6124 : 6132	CM	3 (sc-8019), anti-GAPDH (sc-47724), anti-PAI-1 (sc-8979), 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6135 : 6140	CPR	, anti-GAPDH (sc-47724), anti-PAI-1 (sc-8979), anti-p70
./___Corpus/Medline/xml/PMC4364666.xml	sc-8979	6147 : 6154	CM	 (sc-47724), anti-PAI-1 (sc-8979), anti-p70S6 kinase (sc-
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6157 : 6162	CPR	), anti-PAI-1 (sc-8979), anti-p70S6 kinase (sc-230), an
./___Corpus/Medline/xml/PMC4364666.xml	sc-230	6176 : 6182	CM	979), anti-p70S6 kinase (sc-230), anti-14–3–3 epsilon (s
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6185 : 6190	CPR	i-p70S6 kinase (sc-230), anti-14–3–3 epsilon (sc-1020),
./___Corpus/Medline/xml/PMC4364666.xml	3–	6193 : 6195	CPR	kinase (sc-230), anti-14–3–3 epsilon (sc-1020), and 
./___Corpus/Medline/xml/PMC4364666.xml	sc-1020	6206 : 6213	CM	0), anti-14–3–3 epsilon (sc-1020), and anti-phospho-MAPK 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6220 : 6225	CPR	3 epsilon (sc-1020), and anti-phospho-MAPK (sc-7383) an
./___Corpus/Medline/xml/PMC4364666.xml	sc-7383	6239 : 6246	CM	, and anti-phospho-MAPK (sc-7383) antibodies were purchas
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6332 : 6337	CPR	ti-vimentin (V2258), anti- SM-α-actin (A2547), anti-α-t
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6354 : 6359	CPR	nti- SM-α-actin (A2547), anti-α-tubulin (T9026), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(tyr705)-STAT3	6378 : 6405	CM	 anti-α-tubulin (T9026), anti-phospho-(tyr705)-STAT3 (SAB4300033), anti-RPL-1
./___Corpus/Medline/xml/PMC4364666.xml	SAB4300033	6407 : 6417	CM	-phospho-(tyr705)-STAT3 (SAB4300033), anti-RPL-18A (HPA05525
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6420 : 6425	CPR	705)-STAT3 (SAB4300033), anti-RPL-18A (HPA055259), and 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6450 : 6455	CPR	RPL-18A (HPA055259), and anti-FLAG M2 (F3165) antibodie
./___Corpus/Medline/xml/PMC4364666.xml	M2	6460 : 6462	CM	PA055259), and anti-FLAG M2 (F3165) antibodies, rabb
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	6497 : 6502	CM	ntibodies, rabbit muscle GAPDH (G2267) and human erythr
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	6533 : 6538	CM	7) and human erythrocyte GAPDH (G6019) were purchased f
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-Ser	6574 : 6590	CM	re purchased from Sigma. Anti-phospho-Ser/Thr kinase substrate (96
./___Corpus/Medline/xml/PMC4364666.xml	Thr	6591 : 6594	CM	 Sigma. Anti-phospho-Ser/Thr kinase substrate (9614 a
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6629 : 6634	CPR	bstrate (9614 and 9624), anti-ribosomal protein S6 (RPS
./___Corpus/Medline/xml/PMC4364666.xml	S6	6652 : 6654	CM	, anti-ribosomal protein S6 (RPS6) (2217), anti-phos
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser235	6670 : 6690	CM	rotein S6 (RPS6) (2217), anti-phospho-(Ser235/236)-RPS6 (2211), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	236)-RPS6	6691 : 6700	CM	7), anti-phospho-(Ser235/236)-RPS6 (2211), anti-phospho-(Se
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser240	6709 : 6729	CM	Ser235/236)-RPS6 (2211), anti-phospho-(Ser240/244)-RPS6 (2215), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	244)-RPS6	6730 : 6739	CM	1), anti-phospho-(Ser240/244)-RPS6 (2215), anti-phospho-(Se
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser473)-Akt	6748 : 6773	CM	Ser240/244)-RPS6 (2215), anti-phospho-(Ser473)-Akt (9271), anti-phospho-(Th
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Thr389)-p70	6782 : 6807	CM	pho-(Ser473)-Akt (9271), anti-phospho-(Thr389)-p70 S6 kinase (9234), anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Tyr416)-Src	6826 : 6851	CM	9)-p70 S6 kinase (9234), anti-phospho-(Tyr416)-Src family (2102), anti-phos
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Thr172)-AMPKα	6867 : 6894	CM	r416)-Src family (2102), anti-phospho-(Thr172)-AMPKα (2535), anti-Myc (2278),
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6903 : 6908	CPR	o-(Thr172)-AMPKα (2535), anti-Myc (2278), anti-caveolin
./___Corpus/Medline/xml/PMC4364666.xml	anti-caveolin-1	6920 : 6935	CM	(2535), anti-Myc (2278), anti-caveolin-1 (3267), and anti-β-caten
./___Corpus/Medline/xml/PMC4364666.xml	anti-	6948 : 6953	CPR	i-caveolin-1 (3267), and anti-β-catenin (9562) antibodi
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-14	7028 : 7043	CM	ll Signaling Technology. Anti-phospho-14–3–3 antibody was purchas
./___Corpus/Medline/xml/PMC4364666.xml	3–	7044 : 7046	CPR	hnology. Anti-phospho-14–3–3 antibody was purchased 
./___Corpus/Medline/xml/PMC4364666.xml	Anti-phospho-(Tyr705)-STAT3	7084 : 7111	CM	s purchased from Abgent. Anti-phospho-(Tyr705)-STAT3 (612356) antibody was pu
./___Corpus/Medline/xml/PMC4364666.xml	Abcam	7206 : 7211	CM	ibody was purchased from Abcam. Anti-human IL-6 neutral
./___Corpus/Medline/xml/PMC4364666.xml	206-IL	7285 : 7291	CM	 recombinant human IL-6 (206-IL), and recombinant human 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	7316 : 7321	CM	), and recombinant human CXCL1 (275-CR/CF) were purchas
./___Corpus/Medline/xml/PMC4364666.xml	275-CR	7323 : 7329	CM	recombinant human CXCL1 (275-CR/CF) were purchased from 
./___Corpus/Medline/xml/PMC4364666.xml	CF	7330 : 7332	CM	nant human CXCL1 (275-CR/CF) were purchased from R&D
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	7378 : 7383	CM	 R&D Systems. Anti-human CXCL1 neutralizing antibody (L
./___Corpus/Medline/xml/PMC4364666.xml	LS-C104351	7407 : 7417	CM	1 neutralizing antibody (LS-C104351) was purchased from Life
./___Corpus/Medline/xml/PMC4364666.xml	MO1	7476 : 7479	CM	ciences. Anti-α-enolase (MO1) antibody and human reco
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	7512 : 7517	CM	dy and human recombinant GAPDH (P4547) were purchased f
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	7570 : 7581	CM	 Abnova. Anti-mouse IgG1 Alexa Fluor 546, anti-mouse IgG2a Al
./___Corpus/Medline/xml/PMC4364666.xml	anti-	7587 : 7592	CPR	se IgG1 Alexa Fluor 546, anti-mouse IgG2a Alexa Fluor 5
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	7604 : 7615	CM	or 546, anti-mouse IgG2a Alexa Fluor 546, and anti-mouse IgG1
./___Corpus/Medline/xml/PMC4364666.xml	anti-	7625 : 7630	CPR	G2a Alexa Fluor 546, and anti-mouse IgG1 Alexa Fluor 35
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	7641 : 7652	CM	546, and anti-mouse IgG1 Alexa Fluor 350 antibodies were purc
./___Corpus/Medline/xml/PMC4364666.xml	RNAs	7829 : 7833	CM	       Small interfering RNAs (siRNA) targeting RPS6 w
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	7852 : 7856	CM	g RNAs (siRNA) targeting RPS6 were generated as RPS6 S
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	7875 : 7879	CM	g RPS6 were generated as RPS6 Si#1, 5’-CUGCGAGCUUCUACU
./___Corpus/Medline/xml/PMC4364666.xml	Si#1	7880 : 7884	CM	6 were generated as RPS6 Si#1, 5’-CUGCGAGCUUCUACUUCUAA
./___Corpus/Medline/xml/PMC4364666.xml	5’-CUGCGAGCUUCUACUUCUAAG-3	7886 : 7912	CM	 generated as RPS6 Si#1, 5’-CUGCGAGCUUCUACUUCUAAG-3’ and RPS6 Si#2, 5’-GACUG
./___Corpus/Medline/xml/PMC4364666.xml	Si#2	7923 : 7927	CM	UCUACUUCUAAG-3’ and RPS6 Si#2, 5’-GACUGACUGAUACUACAGUG
./___Corpus/Medline/xml/PMC4364666.xml	E-	8047 : 8049	CPR	ool siRNAs against human E-cadherin and RPL-18A and 
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	8062 : 8069	CM	nst human E-cadherin and RPL-18A and control siRNA, ON-TA
./___Corpus/Medline/xml/PMC4364666.xml	lipofectamine	8196 : 8209	CM	s were transfected using lipofectamine 2000 or lipofectamine RN
./___Corpus/Medline/xml/PMC4364666.xml	lipofectamine	8218 : 8231	CM	ng lipofectamine 2000 or lipofectamine RNAiMAX reagents (Invitr
./___Corpus/Medline/xml/PMC4364666.xml	RNAiMAX	8232 : 8239	CM	ne 2000 or lipofectamine RNAiMAX reagents (Invitrogen) ac
./___Corpus/Medline/xml/PMC4364666.xml	SCADS	8342 : 8347	CM	                         SCADS inhibitor kits I, II, an
./___Corpus/Medline/xml/PMC4364666.xml	U0126	8693 : 8698	CM	hnology, Japan. PD98059, U0126, MEK inhibitor I, MEK in
./___Corpus/Medline/xml/PMC4364666.xml	MEK	8700 : 8703	CM	, Japan. PD98059, U0126, MEK inhibitor I, MEK inhibit
./___Corpus/Medline/xml/PMC4364666.xml	MEK	8717 : 8720	CM	 U0126, MEK inhibitor I, MEK inhibitor II, MEK1/2 inh
./___Corpus/Medline/xml/PMC4364666.xml	MEK1	8735 : 8739	CM	tor I, MEK inhibitor II, MEK1/2 inhibitor II, and MEK1
./___Corpus/Medline/xml/PMC4364666.xml	MEK1	8760 : 8764	CM	MEK1/2 inhibitor II, and MEK1/2 inhibitor I were purch
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	8806 : 8810	CM	re purchased from Merck. PGE2 was purchased from Cayma
./___Corpus/Medline/xml/PMC4364666.xml	GFP	8933 : 8936	CM	 ABIXS.                  GFP transfection            
./___Corpus/Medline/xml/PMC4364666.xml	6-	9004 : 9006	CPR	 x 105) were cultured in 6-well plates in 10% FBS-DM
./___Corpus/Medline/xml/PMC4364666.xml	pEGFP-C1	9155 : 9163	CM	I-MEM containing 1 μg of pEGFP-C1 vector (BD Biosciences),
./___Corpus/Medline/xml/PMC4364666.xml	Lipofectamine	9197 : 9210	CM	BD Biosciences), 4 μL of Lipofectamine Reagent (Invitrogen) and
./___Corpus/Medline/xml/PMC4364666.xml	FBS-OPTI-MEM	9331 : 9343	CM	 incubation, 1 mL of 20% FBS-OPTI-MEM was added to each well a
./___Corpus/Medline/xml/PMC4364666.xml	6-	9794 : 9796	CPR	n glass cover slips in a 6-well plate at 1 x 105 cel
./___Corpus/Medline/xml/PMC4364666.xml	plate	9801 : 9806	CM	 cover slips in a 6-well plate at 1 x 105 cells per wel
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	9836 : 9840	CM	 x 105 cells per well in DMEM supplemented with 1% dia
./___Corpus/Medline/xml/PMC4364666.xml	D-	9876 : 9878	CPR	ed with 1% dialyzed-FBS (D-FBS) prepared by dialysis
./___Corpus/Medline/xml/PMC4364666.xml	phosphate	9912 : 9921	CM	ared by dialysis against phosphate-buffered saline (PBS) an
./___Corpus/Medline/xml/PMC4364666.xml	saline	9931 : 9937	CM	ainst phosphate-buffered saline (PBS) and ITH. The cells
./___Corpus/Medline/xml/PMC4364666.xml	PBS	9939 : 9942	CM	osphate-buffered saline (PBS) and ITH. The cells were
./___Corpus/Medline/xml/PMC4364666.xml	ITH	9948 : 9951	CM	uffered saline (PBS) and ITH. The cells were washed w
./___Corpus/Medline/xml/PMC4364666.xml	PBS	9980 : 9983	CM	e cells were washed with PBS and fixed with cold acet
./___Corpus/Medline/xml/PMC4364666.xml	acetone	10004 : 10011	CM	 PBS and fixed with cold acetone for 2 min. Hs738 cells w
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	10023 : 10028	CM	 cold acetone for 2 min. Hs738 cells were stained with 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10053 : 10058	CPR	 cells were stained with anti-vimentin and SM-α-actin a
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	10071 : 10081	CM	d with anti-vimentin and SM-α-actin antibodies as described 
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser235	10150 : 10170	CM	 cells were stained with anti-phospho-(Ser235/236)-RPS6 antibody and t
./___Corpus/Medline/xml/PMC4364666.xml	236)-RPS6	10171 : 10180	CM	ith anti-phospho-(Ser235/236)-RPS6 antibody and then with s
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10214 : 10219	CPR	 and then with secondary anti-rabbit IgG Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	10230 : 10241	CM	econdary anti-rabbit IgG Alexa Fluor 546 (Invitrogen). For GA
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	10264 : 10269	CM	or 546 (Invitrogen). For GAPDH immunostaining, cells we
./___Corpus/Medline/xml/PMC4364666.xml	formaldehyde	10311 : 10323	CM	cells were fixed with 4% formaldehyde in PBS for 15 min for no
./___Corpus/Medline/xml/PMC4364666.xml	PBS	10327 : 10330	CM	 with 4% formaldehyde in PBS for 15 min for nonpermea
./___Corpus/Medline/xml/PMC4364666.xml	formaldehyde	10380 : 10392	CM	bilized conditions or 4% formaldehyde in PBS for 15 min and th
./___Corpus/Medline/xml/PMC4364666.xml	PBS	10396 : 10399	CM	ns or 4% formaldehyde in PBS for 15 min and then meth
./___Corpus/Medline/xml/PMC4364666.xml	methanol	10420 : 10428	CM	 PBS for 15 min and then methanol for 5 min for permeabili
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10503 : 10508	CPR	 cells were stained with anti-FLAG, anti-GAPDH, or anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10514 : 10519	CPR	 stained with anti-FLAG, anti-GAPDH, or anti-E-cadherin
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10529 : 10534	CPR	nti-FLAG, anti-GAPDH, or anti-E-cadherin and then with 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10559 : 10564	CPR	E-cadherin and then with anti-mouse IgG1 Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	10575 : 10586	CM	hen with anti-mouse IgG1 Alexa Fluor 546, anti-mouse IgG2a 54
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10592 : 10597	CPR	se IgG1 Alexa Fluor 546, anti-mouse IgG2a 546, or anti-
./___Corpus/Medline/xml/PMC4364666.xml	anti-	10617 : 10622	CPR	anti-mouse IgG2a 546, or anti-mouse IgG1 488. The stain
./___Corpus/Medline/xml/PMC4364666.xml	FV300	10728 : 10733	CM	microscope or an Olympus FV300 laser scanning confocal 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	11415 : 11420	CM	uspended with or without Hs738 cells (8 x 106) in 0.3 m
./___Corpus/Medline/xml/PMC4364666.xml	pentobarbital sodium	11963 : 11983	CM	aperitoneal injection of pentobarbital sodium at 66.7 mg/kg. After mak
./___Corpus/Medline/xml/PMC4364666.xml	30-	12231 : 12234	CPR	n of the stomach using a 30-gauge needle (Nipro) [31]
./___Corpus/Medline/xml/PMC4364666.xml	AUTOCLIP	12381 : 12389	CM	 skin was closed with an AUTOCLIP applier (Becton-Dickinso
./___Corpus/Medline/xml/PMC4364666.xml	96-	12596 : 12599	CPR	s were inoculated into a 96-well plates at 5 x 103 ce
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	12650 : 12654	CM	ls per well in 0.1 mL of DMEM supplemented with 1% D-F
./___Corpus/Medline/xml/PMC4364666.xml	D-	12676 : 12678	CPR	MEM supplemented with 1% D-FBS and ITH. After cultur
./___Corpus/Medline/xml/PMC4364666.xml	ITH	12686 : 12689	CM	mented with 1% D-FBS and ITH. After culture for the i
./___Corpus/Medline/xml/PMC4364666.xml	3-(4,5-dimethyllythiazol-2-yl)-2,5-diphenyltetrazolium bromide	12762 : 12824	CM	wth was determined using 3-(4,5-dimethyllythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) as describe
./___Corpus/Medline/xml/PMC4364666.xml	MTT	12826 : 12829	CM	enyltetrazolium bromide (MTT; Sigma) as described [32
./___Corpus/Medline/xml/PMC4364666.xml	GFP	12869 : 12872	CM	cribed [32] or measuring GFP fluorescence intensity (
./___Corpus/Medline/xml/PMC4364666.xml	lysis	12949 : 12954	RN	ission at 538 nm) by the lysis of cells in 10 mM Tris-H
./___Corpus/Medline/xml/PMC4364666.xml	Tris-HCl	12973 : 12981	CM	 lysis of cells in 10 mM Tris-HCl pH7.4, 150 mM NaCl, 0.9 
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	12996 : 13000	CM	M Tris-HCl pH7.4, 150 mM NaCl, 0.9 mM CaCl2, and 1% Tr
./___Corpus/Medline/xml/PMC4364666.xml	CaCl2	13009 : 13014	CM	7.4, 150 mM NaCl, 0.9 mM CaCl2, and 1% Triton X-100. Fo
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13065 : 13070	CM	 co-culture experiments, Hs738 cells were first inocula
./___Corpus/Medline/xml/PMC4364666.xml	96-	13104 : 13107	CPR	re first inoculated into 96-well plates at 5 x 103 ce
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	13158 : 13162	CM	ls per well in 0.1 mL of DMEM supplemented with 1% D-F
./___Corpus/Medline/xml/PMC4364666.xml	D-	13184 : 13186	CPR	MEM supplemented with 1% D-FBS and ITH. Test samples
./___Corpus/Medline/xml/PMC4364666.xml	ITH	13194 : 13197	CM	mented with 1% D-FBS and ITH. Test samples were added
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	13348 : 13352	CM	 (5 x 103) in serum-free DMEM were added to the monola
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13384 : 13389	CM	dded to the monolayer of Hs738 cells and the cells were
./___Corpus/Medline/xml/PMC4364666.xml	GFP	13708 : 13711	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	96-	13789 : 13792	CPR	s were inoculated into a 96-well suspension culture p
./___Corpus/Medline/xml/PMC4364666.xml	plate	13816 : 13821	CM	-well suspension culture plate (MS-8096R; Sumilon) for 
./___Corpus/Medline/xml/PMC4364666.xml	plate	13881 : 13886	CM	 with a standard culture plate (MS-8096F; Sumilon). For
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	13945 : 13950	CM	l experiments, 0.6 mL of Hs738 cells (5 x 104 cells/mL)
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	13979 : 13983	CM	ls (5 x 104 cells/mL) in DMEM supplemented with 1% D-F
./___Corpus/Medline/xml/PMC4364666.xml	D-	14005 : 14007	CPR	MEM supplemented with 1% D-FBS and ITH were first ad
./___Corpus/Medline/xml/PMC4364666.xml	ITH	14015 : 14018	CM	mented with 1% D-FBS and ITH were first added to oute
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	14271 : 14275	CM	 (5 x 103) in serum-free DMEM was added to the inner w
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14386 : 14391	CM	          Preparation of Hs738 conditioned medium (CM) 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14437 : 14442	CM	CM)                      Hs738 cells were cultured at 5
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	14486 : 14490	CM	d at 5 x 104 cells/mL in DMEM supplemented with the in
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	14541 : 14546	CM	icated concentrations of D-FBS and ITH for the indicate
./___Corpus/Medline/xml/PMC4364666.xml	ITH	14551 : 14554	CM	centrations of D-FBS and ITH for the indicated days. 
./___Corpus/Medline/xml/PMC4364666.xml	Amicon	14666 : 14672	CM	 concentrate the medium, Amicon Ultra-15-3K centrifugal 
./___Corpus/Medline/xml/PMC4364666.xml	2-	14727 : 14729	CPR	r devices (Millipore) or 2-D clean-up kit (Amersham 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	14848 : 14853	CM	d into 1 mL of the CM of Hs738 cells or assay medium al
./___Corpus/Medline/xml/PMC4364666.xml	PBS	14949 : 14952	CM	e cells were washed with PBS and the cell lysates wer
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	15098 : 15112	CM	or the identification of phosphorylated proteins from gastric ca
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	15149 : 15154	CM	om gastric cancer cells, MKN-7 cell lysates were applie
./___Corpus/Medline/xml/PMC4364666.xml	Tris-HCl	15244 : 15252	CM	re) preloaded with 50 mM Tris-HCl pH7.3. Proteins were elu
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	15306 : 15310	CM	by stepwise increases of NaCl concentrations. After el
./___Corpus/Medline/xml/PMC4364666.xml	pyrophosphate	15366 : 15379	CM	 protease inhibitors and pyrophosphate were added to the eluted
./___Corpus/Medline/xml/PMC4364666.xml	SDS-PAGE	15455 : 15463	CM	ctions were separated by SDS-PAGE, and the gels were stain
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	15591 : 15607	CM	tern blots obtained with anti-phospho-Ser/Thr antibody were excise
./___Corpus/Medline/xml/PMC4364666.xml	Thr	15608 : 15611	CM	ed with anti-phospho-Ser/Thr antibody were excised. T
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	15839 : 15844	CM	h-inhibitory proteins in Hs738 CM, the CM (50 mL) was c
./___Corpus/Medline/xml/PMC4364666.xml	Amicon	15887 : 15893	CM	) was concentrated using Amicon Ultra-15-3K centrifugal 
./___Corpus/Medline/xml/PMC4364666.xml	PBS	16040 : 16043	CM	 Proteins were eluted by PBS and the effect of the fr
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	16099 : 16104	CM	ed proteins on growth of MKN-7 cells was determined. Th
./___Corpus/Medline/xml/PMC4364666.xml	MALDI-TOF-MS	16323 : 16335	CM	subjected to LC-MS/MS or MALDI-TOF-MS analysis (APRO Life Scie
./___Corpus/Medline/xml/PMC4364666.xml	Cytokine	16393 : 16401	CM	itute).                  Cytokine analysis                
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	16475 : 16479	CM	d at 5 x 104 cells/mL in DMEM supplemented with 1% D-F
./___Corpus/Medline/xml/PMC4364666.xml	D-	16501 : 16503	CPR	MEM supplemented with 1% D-FBS and ITH for 2 days. T
./___Corpus/Medline/xml/PMC4364666.xml	ITH	16511 : 16514	CM	mented with 1% D-FBS and ITH for 2 days. The CMs were
./___Corpus/Medline/xml/PMC4364666.xml	IL-6sR	16593 : 16599	CM	and the amounts of IL-6, IL-6sR, and CXCL1 were determin
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	16605 : 16610	CM	nts of IL-6, IL-6sR, and CXCL1 were determined using a 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	16729 : 16734	CM	R&D Systems) and a human CXCL1 Quantikine (R&D Systems)
./___Corpus/Medline/xml/PMC4364666.xml	cytokine	16815 : 16823	CM	 also applied onto human cytokine antibody array (C series
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	16879 : 16883	CM	 RayBio). The amounts of PGE2, 6-keto PG, thromboxian 
./___Corpus/Medline/xml/PMC4364666.xml	6-keto	16885 : 16891	CM	o). The amounts of PGE2, 6-keto PG, thromboxian B2, and 
./___Corpus/Medline/xml/PMC4364666.xml	leukotriene	16916 : 16927	CM	 PG, thromboxian B2, and leukotriene B4 were determined using
./___Corpus/Medline/xml/PMC4364666.xml	xylene	17080 : 17086	CM	s were deparaffinized in xylene and rehydrated in descen
./___Corpus/Medline/xml/PMC4364666.xml	rehydrated	17091 : 17101	RN	raffinized in xylene and rehydrated in descending alcohols i
./___Corpus/Medline/xml/PMC4364666.xml	alcohols	17116 : 17124	CM	rehydrated in descending alcohols into water. Then, the ti
./___Corpus/Medline/xml/PMC4364666.xml	water	17130 : 17135	CM	descending alcohols into water. Then, the tissue arrays
./___Corpus/Medline/xml/PMC4364666.xml	H2O2	17179 : 17183	CM	arrays were dipped in 3% H2O2 for 13 min and boiled in
./___Corpus/Medline/xml/PMC4364666.xml	citric acid	17215 : 17226	CM	 min and boiled in 10 mM citric acid (pH 6.0) for 15 min. Imm
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Tyr705)-STAT3	17296 : 17323	CM	ining was conducted with anti-phospho-(Tyr705)-STAT3 (SAB43000033) using ImmP
./___Corpus/Medline/xml/PMC4364666.xml	SAB43000033	17325 : 17336	CM	-phospho-(Tyr705)-STAT3 (SAB43000033) using ImmPRESS anti-rab
./___Corpus/Medline/xml/PMC4364666.xml	anti-	17353 : 17358	CPR	43000033) using ImmPRESS anti-rabbit Ig peroxidase (Vec
./___Corpus/Medline/xml/PMC4364666.xml	Ig	17365 : 17367	CM	ing ImmPRESS anti-rabbit Ig peroxidase (Vector Labor
./___Corpus/Medline/xml/PMC4364666.xml	DAB	17413 : 17416	CM	aboratories) and ImmPACT DAB substrate (Vector Labora
./___Corpus/Medline/xml/PMC4364666.xml	phospho-STAT3	17484 : 17497	CM	ated visual intensity of phospho-STAT3 immunostaining was grade
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	17613 : 17618	CM	sitive.                  GAPDH activity GAPDH activity 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	17628 : 17633	CM	          GAPDH activity GAPDH activity was measured as
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	17743 : 17748	CM	struction of recombinant GAPDH                      Hum
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	17798 : 17803	CM	an recombinant wild-type GAPDH and mutant GAPDH were co
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	17815 : 17820	CM	ld-type GAPDH and mutant GAPDH were constructed as desc
./___Corpus/Medline/xml/PMC4364666.xml	RNA	17893 : 17896	CM	cations as follow. Total RNA was isolated from Hs738 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	17915 : 17920	CM	al RNA was isolated from Hs738 cells using the RNeasy M
./___Corpus/Medline/xml/PMC4364666.xml	cDNA	17966 : 17970	CM	sy Minikit (Qiagen). The cDNA was synthesized using AM
./___Corpus/Medline/xml/PMC4364666.xml	AMV	17993 : 17996	CM	NA was synthesized using AMV reverse transcriptase (P
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18055 : 18060	CM	nd the full-length human GAPDH cDNA fragment containing
./___Corpus/Medline/xml/PMC4364666.xml	cDNA	18061 : 18065	CM	 full-length human GAPDH cDNA fragment containing NheI
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18123 : 18126	CM	I sites was generated by PCR using PfxDNA polymerase 
./___Corpus/Medline/xml/PMC4364666.xml	5’-TATCTCGAGTTACTCCTTGGAGGCCATGTGGG-3	18271 : 18308	CM	 and antisense primer 2 (5’-TATCTCGAGTTACTCCTTGGAGGCCATGTGGG-3’). The NheI/XhoI fragmen
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18338 : 18343	CM	he NheI/XhoI fragment of GAPDH was inserted into pET-17
./___Corpus/Medline/xml/PMC4364666.xml	pET-17b	18362 : 18369	CM	 GAPDH was inserted into pET-17b vector (Novagen). For mu
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18399 : 18404	CM	or (Novagen). For mutant GAPDH (C152S), fragment 1 was 
./___Corpus/Medline/xml/PMC4364666.xml	C152S	18406 : 18411	CM	agen). For mutant GAPDH (C152S), fragment 1 was generat
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18442 : 18445	CM	gment 1 was generated by PCR using sense primer 1 and
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18580 : 18583	CM	gment 2 was generated by PCR using sense primer 4 (5’
./___Corpus/Medline/xml/PMC4364666.xml	5’-TCAAGATCATCAGCAATGCCTCCTCCACCACCAACTGCTTAGCACCCCT-3	18606 : 18660	CM	CR using sense primer 4 (5’-TCAAGATCATCAGCAATGCCTCCTCCACCACCAACTGCTTAGCACCCCT-3’) and antisense primer 2
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18710 : 18715	CM	. The full-length mutant GAPDH fragment was generated b
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18742 : 18745	CM	ragment was generated by PCR using sense primer 1, an
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18857 : 18862	CM	/XhoI fragment of mutant GAPDH was also inserted into p
./___Corpus/Medline/xml/PMC4364666.xml	pET-17b	18886 : 18893	CM	H was also inserted into pET-17b vector. Deletion mutants
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	18922 : 18927	CM	tor. Deletion mutants of GAPDH were constructed by inve
./___Corpus/Medline/xml/PMC4364666.xml	PCR	18956 : 18959	CM	e constructed by inverse PCR using a KOD-Plus-mutagen
./___Corpus/Medline/xml/PMC4364666.xml	del1	19022 : 19026	CM	obo) and primer sets for del1, 5’-gcagttggtggtgcaggagg
./___Corpus/Medline/xml/PMC4364666.xml	del2	19099 : 19103	CM	atttggctacagcaac-3’, for del2, 5’-ATCAAGTGGGGCGATGCTGG
./___Corpus/Medline/xml/PMC4364666.xml	5’-CTTCCCCATCTTGTCGTCGTCGTCCTT-3	19145 : 19177	CM	GATGCTGGCGCTGAGTA-3’ and 5’-CTTCCCCATCTTGTCGTCGTCGTCCTT-3’, and for del3, 5’-CTCCA
./___Corpus/Medline/xml/PMC4364666.xml	del3	19188 : 19192	CM	GTCGTCGTCCTT-3’, and for del3, 5’-CTCCACGACGTACTCAGCGC
./___Corpus/Medline/xml/PMC4364666.xml	5’-CTCCACGACGTACTCAGCGCCAG-3	19194 : 19222	CM	GTCCTT-3’, and for del3, 5’-CTCCACGACGTACTCAGCGCCAG-3’ and 5’-accaccaactgcttag
./___Corpus/Medline/xml/PMC4364666.xml	N-	19354 : 19356	CPR	rColiBL21 (Lucigen) and N-terminal FLAG-tagged human
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	19403 : 19408	CM	man wild-type and mutant GAPDH were purified using anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19429 : 19434	CPR	APDH were purified using anti-FLAG M2 agarose (Sigma). 
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19442 : 19449	CM	ified using anti-FLAG M2 agarose (Sigma). The partially p
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	19482 : 19487	CM	. The partially purified GAPDH was further purified by 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	19620 : 19625	CM	              Binding of GAPDH to cell membranes       
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	19789 : 19794	CM	d with human erythrocyte GAPDH at 5 U/mL or FLAG-tagged
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	19841 : 19846	CM	ged human recombinant wt GAPDH at 5 μg/mL for 2 h at ro
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19917 : 19922	CPR	nd immunoprecipitated by anti-GAPDH-protein G agarose c
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19927 : 19932	CPR	recipitated by anti-GAPDH-protein G agarose complex or 
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19938 : 19945	CM	 by anti-GAPDH-protein G agarose complex or anti-FLAG M2 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	19957 : 19962	CPR	ein G agarose complex or anti-FLAG M2 agarose, respecti
./___Corpus/Medline/xml/PMC4364666.xml	agarose	19970 : 19977	CM	 complex or anti-FLAG M2 agarose, respectively. The immun
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	20079 : 20084	CM	              Binding of GAPDH to recombinant E-cadheri
./___Corpus/Medline/xml/PMC4364666.xml	E-	20100 : 20102	CPR	 of GAPDH to recombinant E-cadherin                 
./___Corpus/Medline/xml/PMC4364666.xml	96-	20134 : 20137	CPR	n                      A 96-well plate was coated wit
./___Corpus/Medline/xml/PMC4364666.xml	plate	20142 : 20147	CM	               A 96-well plate was coated with 100 μL h
./___Corpus/Medline/xml/PMC4364666.xml	μL	20168 : 20170	CM	late was coated with 100 μL human recombinant E-cadh
./___Corpus/Medline/xml/PMC4364666.xml	E-	20189 : 20191	CPR	100 μL human recombinant E-cadherin Fc chimera (648-
./___Corpus/Medline/xml/PMC4364666.xml	Fc	20200 : 20202	CM	n recombinant E-cadherin Fc chimera (648-EC-100, R&D
./___Corpus/Medline/xml/PMC4364666.xml	648-	20212 : 20216	CPR	t E-cadherin Fc chimera (648-EC-100, R&D Systems) /wel
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20259 : 20262	CM	s) /well at 1.5 μg/mL in PBS at 37°C for 1 h. The pla
./___Corpus/Medline/xml/PMC4364666.xml	plate	20284 : 20289	CM	PBS at 37°C for 1 h. The plate was washed with PBS 4 ti
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20306 : 20309	CM	he plate was washed with PBS 4 times and blocked by a
./___Corpus/Medline/xml/PMC4364666.xml	μL	20344 : 20346	CM	nd blocked by adding 100 μL/well 1% BSA in PBS at 37
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20362 : 20365	CM	ng 100 μL/well 1% BSA in PBS at 37°C for 30 min. Afte
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20405 : 20408	CM	 min. After washing with PBS 4 times, human erythrocy
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	20436 : 20441	CM	times, human erythrocyte GAPDH in PBS was added to the 
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20445 : 20448	CM	man erythrocyte GAPDH in PBS was added to the plate a
./___Corpus/Medline/xml/PMC4364666.xml	plate	20466 : 20471	CM	 in PBS was added to the plate at 5 U/mL, and the plate
./___Corpus/Medline/xml/PMC4364666.xml	plate	20491 : 20496	CM	plate at 5 U/mL, and the plate was kept at 37°C for 1 h
./___Corpus/Medline/xml/PMC4364666.xml	plate	20527 : 20532	CM	ept at 37°C for 1 h. The plate was then washed with PBS
./___Corpus/Medline/xml/PMC4364666.xml	PBS	20554 : 20557	CM	ate was then washed with PBS 4 times and 50 μL of SDS
./___Corpus/Medline/xml/PMC4364666.xml	E-	20733 : 20735	CPR	         Construction of E-cadherin deletion mutants
./___Corpus/Medline/xml/PMC4364666.xml	E-	20798 : 20800	CPR	         Human wild-type E-cadherin and various dele
./___Corpus/Medline/xml/PMC4364666.xml	RNA	20904 : 20907	CM	ome modifications. Total RNA was isolated from MKN-7 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	20926 : 20931	CM	al RNA was isolated from MKN-7 cells using the RNeasy M
./___Corpus/Medline/xml/PMC4364666.xml	cDNA	20977 : 20981	CM	sy Minikit (Qiagen). The cDNA was synthesized using AM
./___Corpus/Medline/xml/PMC4364666.xml	AMV	21004 : 21007	CM	NA was synthesized using AMV reverse transcriptase (P
./___Corpus/Medline/xml/PMC4364666.xml	E-	21064 : 21066	CPR	 and a full-length human E-cadherin cDNA fragment co
./___Corpus/Medline/xml/PMC4364666.xml	cDNA	21075 : 21079	CM	-length human E-cadherin cDNA fragment containing NheI
./___Corpus/Medline/xml/PMC4364666.xml	PCR	21137 : 21140	CM	I sites was generated by PCR using PfxDNA polymerase 
./___Corpus/Medline/xml/PMC4364666.xml	E-	21311 : 21313	CPR	he NheI/XbaI fragment of E-cadherin was inserted int
./___Corpus/Medline/xml/PMC4364666.xml	pcDNA3.1	21342 : 21350	CM	erin was inserted into a pcDNA3.1/myc-His(-)B vector (Invi
./___Corpus/Medline/xml/PMC4364666.xml	myc-His(-)B	21351 : 21362	CM	inserted into a pcDNA3.1/myc-His(-)B vector (Invitrogen). Var
./___Corpus/Medline/xml/PMC4364666.xml	E-	21417 : 21419	CPR	extracellular domains of E-cadherin were deleted by 
./___Corpus/Medline/xml/PMC4364666.xml	PCR	21452 : 21455	CM	 were deleted by inverse PCR using a KOD-Plus-mutagen
./___Corpus/Medline/xml/PMC4364666.xml	Lipofectamine	21673 : 21686	CM	ession vectors using the Lipofectamine reagent described above 
./___Corpus/Medline/xml/PMC4364666.xml	Biotinylated	21854 : 21866	CM	            Synthesis of Biotinylated MEK Inhibitor I         
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21867 : 21870	CM	ynthesis of Biotinylated MEK Inhibitor I             
./___Corpus/Medline/xml/PMC4364666.xml	Biotinylated	21904 : 21916	RN	r I                      Biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21917 : 21920	CM	            Biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	acylated	21949 : 21957	RN	ibitor I (b-MEK inh) and acylated MEK inhibitor I (a-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	21958 : 21961	CM	(b-MEK inh) and acylated MEK inhibitor I (a-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	S26	22022 : 22025	CM	sized in our laboratory (S26 Fig.) [36].             
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22055 : 22058	CM	) [36].                  MEK Inhibitor I binding assa
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	22106 : 22111	CM	say                      Hs738 cell extracts were prepa
./___Corpus/Medline/xml/PMC4364666.xml	IP	22146 : 22148	CM	acts were prepared using IP buffer (50 mM HEPES-KOH,
./___Corpus/Medline/xml/PMC4364666.xml	HEPES-KOH	22163 : 22172	CM	d using IP buffer (50 mM HEPES-KOH, pH 7.5, 1 M NaCl, 1 mM 
./___Corpus/Medline/xml/PMC4364666.xml	NaCl	22186 : 22190	CM	M HEPES-KOH, pH 7.5, 1 M NaCl, 1 mM EDTA, and 2.5 mM E
./___Corpus/Medline/xml/PMC4364666.xml	EDTA	22197 : 22201	CM	, pH 7.5, 1 M NaCl, 1 mM EDTA, and 2.5 mM EGTA) as des
./___Corpus/Medline/xml/PMC4364666.xml	EGTA	22214 : 22218	CM	l, 1 mM EDTA, and 2.5 mM EGTA) as described [37]. Stre
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	22300 : 22305	CM	) was pre-incubated with b-MEK inh at 2.7 mM for 1 h at
./___Corpus/Medline/xml/PMC4364666.xml	IP	22355 : 22357	CM	 RT and then washed with IP buffer. The cell extract
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	22408 : 22413	CM	 were incubated with the b-MEK inh-treated Streptavidin
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22478 : 22481	CM	n with or without 100 μM MEK inhibitor I or U0126 for
./___Corpus/Medline/xml/PMC4364666.xml	IP	22538 : 22540	CM	 RT. After 4 washes with IP buffer, the bound protei
./___Corpus/Medline/xml/PMC4364666.xml	SDS-PAGE	22588 : 22596	CM	eins were analyzed using SDS-PAGE followed by LC-MS/MS pro
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	22747 : 22752	CM	PCR                      Hs738 cells were cultured for 
./___Corpus/Medline/xml/PMC4364666.xml	DMEM	22807 : 22811	CM	s at 5 x 104 cells/mL in DMEM supplemented with 1% D-F
./___Corpus/Medline/xml/PMC4364666.xml	D-	22833 : 22835	CPR	MEM supplemented with 1% D-FBS and ITH in the presen
./___Corpus/Medline/xml/PMC4364666.xml	ITH	22843 : 22846	CM	mented with 1% D-FBS and ITH in the presence of MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	22866 : 22869	CM	d ITH in the presence of MEK inhibitor I. Total RNA w
./___Corpus/Medline/xml/PMC4364666.xml	RNA	22889 : 22892	CM	f MEK inhibitor I. Total RNA was isolated using the R
./___Corpus/Medline/xml/PMC4364666.xml	cDNAs	22941 : 22946	CM	RNeasy Minikit (Qiagen). cDNAs were synthesized using A
./___Corpus/Medline/xml/PMC4364666.xml	AMV	22970 : 22973	CM	s were synthesized using AMV reverse transcriptase an
./___Corpus/Medline/xml/PMC4364666.xml	RNA	23035 : 23038	CM	mers (Promega) from 1 μg RNA. Real time RT-PCR was pe
./___Corpus/Medline/xml/PMC4364666.xml	Ex	23140 : 23142	CM	akara) using SYBR Premix Ex TaqII (Takara). Specific
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	23297 : 23302	CM	 cultured supernatant of Hs738 cells as described [38].
./___Corpus/Medline/xml/PMC4364666.xml	S1A	23726 : 23729	CM	uorescent protein (GFP) (S1A Fig.). Setting the same 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	23798 : 23803	CM	n gastric stromal cells (Hs738 cells) that were a mixtu
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	23867 : 23877	CM	blasts (vimentin (+) and SM-α-actin (+)) and fibroblasts (vi
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	23917 : 23927	CM	blasts (vimentin (+) and SM-α-actin (-)) (S1B Fig.) that res
./___Corpus/Medline/xml/PMC4364666.xml	S1B	23934 : 23937	CM	(+) and SM-α-actin (-)) (S1B Fig.) that resembled oth
./___Corpus/Medline/xml/PMC4364666.xml	1A	24082 : 24084	CM	ously in nude mice (Fig. 1A), but co-injection of Hs
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	24107 : 24112	CM	1A), but co-injection of Hs738 cells significantly supp
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	24158 : 24163	CM	suppressed the tumors of MKN-1, MKN-7 cells, and MKN-28
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	24165 : 24170	CM	sed the tumors of MKN-1, MKN-7 cells, and MKN-28 cells 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	24182 : 24188	CM	 MKN-1, MKN-7 cells, and MKN-28 cells (Fig. 1A). In cont
./___Corpus/Medline/xml/PMC4364666.xml	1A	24201 : 24203	CM	, and MKN-28 cells (Fig. 1A). In contrast, the growt
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	24250 : 24256	CM	owth of tumors formed by MKN-45 and MKN-74 cells was inc
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	24261 : 24267	CM	ors formed by MKN-45 and MKN-74 cells was increased by t
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	24307 : 24312	CM	eased by the presence of Hs738 cells (Fig. 1A). We coul
./___Corpus/Medline/xml/PMC4364666.xml	1A	24325 : 24327	CM	nce of Hs738 cells (Fig. 1A). We could not detect me
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	24756 : 24762	CM	tended to be higher with MKN-45 and MKN-74 cells (poorly
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	24767 : 24773	CM	e higher with MKN-45 and MKN-74 cells (poorly or moderat
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	24837 : 24842	CM	ated cells) and lower in MKN-1, MKN-7 and MKN-28 cells 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	24844 : 24849	CM	lls) and lower in MKN-1, MKN-7 and MKN-28 cells (well-d
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	24854 : 24860	CM	ower in MKN-1, MKN-7 and MKN-28 cells (well-differentiat
./___Corpus/Medline/xml/PMC4364666.xml	vitro	25441 : 25446	CM	we first developed an in vitro co-culture system of gas
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	25498 : 25503	CM	ic cancer cell lines and Hs738 cells as described befor
./___Corpus/Medline/xml/PMC4364666.xml	S1A	25670 : 25673	CM	stric cancer cell lines (S1A Fig.). GFP fluorescence 
./___Corpus/Medline/xml/PMC4364666.xml	MTT	25769 : 25772	CM	h cell number as well as MTT assays (S1C Fig.). To re
./___Corpus/Medline/xml/PMC4364666.xml	S1C	25781 : 25784	CM	r as well as MTT assays (S1C Fig.). To reduce the inf
./___Corpus/Medline/xml/PMC4364666.xml	FBS	25837 : 25840	CM	nce of growth factors in FBS, we used dialysed FBS (D
./___Corpus/Medline/xml/PMC4364666.xml	FBS	25859 : 25862	CM	in FBS, we used dialysed FBS (D-FBS). When the gastri
./___Corpus/Medline/xml/PMC4364666.xml	D-	25864 : 25866	CPR	S, we used dialysed FBS (D-FBS). When the gastric ca
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	25929 : 25934	CM	es were co-cultured with Hs738 cells, the growth of MKN
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	25956 : 25961	CM	738 cells, the growth of MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	25963 : 25968	CM	ls, the growth of MKN-1, MKN-7, and MKN-28 cells was su
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	25974 : 25980	CM	wth of MKN-1, MKN-7, and MKN-28 cells was suppressed by 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26021 : 26026	CM	essed by the presence of Hs738 cells (Fig. 1B and S3 Fi
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	26076 : 26082	CM	g.). While the growth of MKN-45 cells was not changed by
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	26128 : 26134	CM	d by co-culture, that of MKN-74 cells was increased by c
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26174 : 26179	CM	eased by co-culture with Hs738 cells especially at lowe
./___Corpus/Medline/xml/PMC4364666.xml	D-	26224 : 26226	CPR	 lower concentrations of D-FBS (Fig. 1B and S3A Fig.
./___Corpus/Medline/xml/PMC4364666.xml	S3A	26243 : 26246	CM	ns of D-FBS (Fig. 1B and S3A Fig.). Although the magn
./___Corpus/Medline/xml/PMC4364666.xml	D-FBS	26324 : 26329	CM	on the concentrations of D-FBS, these results from in v
./___Corpus/Medline/xml/PMC4364666.xml	vitro	26353 : 26358	CM	S, these results from in vitro co-culture experiments w
./___Corpus/Medline/xml/PMC4364666.xml	1A	26424 : 26426	CM	he in vivo results (Fig. 1A and S3 Fig.).           
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	26758 : 26763	CM	ated onto a monolayer of Hs738 cells, the change of gro
./___Corpus/Medline/xml/PMC4364666.xml	S3B	27050 : 27053	CM	r suspension conditions (S3B Fig.). On the other hand
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	27130 : 27135	CM	ealed that the growth of MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	27137 : 27142	CM	hat the growth of MKN-1, MKN-7, and MKN-28 cells was de
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	27148 : 27154	CM	wth of MKN-1, MKN-7, and MKN-28 cells was decreased by c
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27194 : 27199	CM	eased by co-culture with Hs738 cells, whereas the growt
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	27229 : 27235	CM	s, whereas the growth of MKN-74 cells was increased and 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	27268 : 27274	CM	as increased and that of MKN-45 cells was unchanged (S3C
./___Corpus/Medline/xml/PMC4364666.xml	S3C	27296 : 27299	CM	-45 cells was unchanged (S3C Fig.). These results wer
./___Corpus/Medline/xml/PMC4364666.xml	vitro	27345 : 27350	CM	 were consistent with in vitro co-culture experiments (
./___Corpus/Medline/xml/PMC4364666.xml	S3A	27387 : 27390	CM	experiments (Fig. 1B and S3A Fig.) and indicated that
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27438 : 27443	CM	at secreted factors from Hs738 cells instead of anchora
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	27683 : 27688	CM	itioned medium (CM) from Hs738 cells to gastric cancer 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	27734 : 27749	RN	cer cells and found that phosphorylation of Ser/Thr residues of p
./___Corpus/Medline/xml/PMC4364666.xml	Ser	27753 : 27756	CM	 that phosphorylation of Ser/Thr residues of proteins
./___Corpus/Medline/xml/PMC4364666.xml	Thr	27757 : 27760	CM	t phosphorylation of Ser/Thr residues of proteins, es
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	27848 : 27863	RN	y changed (Fig. 2A). The phosphorylation of ~30 kDa proteins in M
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	27887 : 27892	CM	n of ~30 kDa proteins in MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	27894 : 27899	CM	0 kDa proteins in MKN-1, MKN-7, and MKN-28 cells was si
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	27905 : 27911	CM	ins in MKN-1, MKN-7, and MKN-28 cells was significantly 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	27969 : 27975	CM	d by the CM, but that in MKN-45 and MKN-74 cells was not
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	27980 : 27986	CM	, but that in MKN-45 and MKN-74 cells was not affected (
./___Corpus/Medline/xml/PMC4364666.xml	S4	28023 : 28025	CM	ot affected (Fig. 2A and S4 Fig.). Proteomic analysi
./___Corpus/Medline/xml/PMC4364666.xml	S6	28132 : 28134	CM	es was ribosomal protein S6 (RPS6) (S4B Fig.). siRNA
./___Corpus/Medline/xml/PMC4364666.xml	S4B	28143 : 28146	CM	somal protein S6 (RPS6) (S4B Fig.). siRNAs against RP
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28169 : 28173	CM	4B Fig.). siRNAs against RPS6 decreased the phosphoryl
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	28188 : 28203	RN	ainst RPS6 decreased the phosphorylation of the ~30 kDa proteins 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28239 : 28253	CM	 kDa proteins as well as phosphorylated RPS6 (S4C Fig.). Further
./___Corpus/Medline/xml/PMC4364666.xml	S4C	28260 : 28263	CM	 as phosphorylated RPS6 (S4C Fig.). Furthermore, immu
./___Corpus/Medline/xml/PMC4364666.xml	anti-	28316 : 28321	CPR	recipitates generated by anti-RPS6 antibody were detect
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	28352 : 28368	CM	ntibody were detected by anti-phospho-Ser/Thr antibody as well as 
./___Corpus/Medline/xml/PMC4364666.xml	Thr	28369 : 28372	CM	cted by anti-phospho-Ser/Thr antibody as well as anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-phosphorylated	28393 : 28412	RN	/Thr antibody as well as anti-phosphorylated RPS6 antibody (S4C Fig.)
./___Corpus/Medline/xml/PMC4364666.xml	S4C	28428 : 28431	CM	horylated RPS6 antibody (S4C Fig.). Thus, the ~30 kDa
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28491 : 28496	CM	as indeed RPS6. Actually Hs738 CM decreased the phospho
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	28514 : 28529	RN	y Hs738 CM decreased the phosphorylation of RPS6 in MKN-1, MKN-7,
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28533 : 28537	CM	d the phosphorylation of RPS6 in MKN-1, MKN-7, and MKN
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	28541 : 28546	CM	osphorylation of RPS6 in MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	28548 : 28553	CM	lation of RPS6 in MKN-1, MKN-7, and MKN-28 cells, but n
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	28559 : 28565	CM	PS6 in MKN-1, MKN-7, and MKN-28 cells, but not that of 1
./___Corpus/Medline/xml/PMC4364666.xml	14–	28589 : 28592	CPR	8 cells, but not that of 14–3–3 protein, another cand
./___Corpus/Medline/xml/PMC4364666.xml	3–	28592 : 28594	CPR	ells, but not that of 14–3–3 protein, another candid
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28630 : 28644	CM	another candidate of the phosphorylated protein (Fig. 2B and S4B
./___Corpus/Medline/xml/PMC4364666.xml	S4B	28666 : 28669	CM	ted protein (Fig. 2B and S4B Fig.). Furthermore, phos
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	28690 : 28704	CM	 S4B Fig.). Furthermore, phosphorylated RPS6 in MKN-7 cells was 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	28713 : 28718	CM	, phosphorylated RPS6 in MKN-7 cells was found to decre
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28769 : 28774	CM	se when co-cultured with Hs738 cells (Fig. 2C). Phospho
./___Corpus/Medline/xml/PMC4364666.xml	2C	28787 : 28789	CM	d with Hs738 cells (Fig. 2C). Phosphorylation of RPS
./___Corpus/Medline/xml/PMC4364666.xml	Phosphorylation	28792 : 28807	RN	h Hs738 cells (Fig. 2C). Phosphorylation of RPS6 is well known to
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	28811 : 28815	CM	 2C). Phosphorylation of RPS6 is well known to play a 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	28932 : 28937	CM	r results indicated that Hs738 cells at least downregul
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	29018 : 29023	CM	suppressed the growth of MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	29025 : 29030	CM	sed the growth of MKN-1, MKN-7, and MKN-28 cells throug
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	29036 : 29042	CM	wth of MKN-1, MKN-7, and MKN-28 cells through secreted f
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29092 : 29095	CM	actors.                  MEK Inhibitor I modulates tu
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29535 : 29540	CM	er cells with or without Hs738 cells and as a result we
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29577 : 29580	CM	s a result we focused on MEK inhibitor I (S5 Fig.). M
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29604 : 29607	CM	K inhibitor I (S5 Fig.). MEK inhibitor I, unlike othe
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29634 : 29637	CM	nhibitor I, unlike other MEK inhibitors, strongly inh
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29726 : 29731	CM	ls when co-cultured with Hs738 cells compared to that o
./___Corpus/Medline/xml/PMC4364666.xml	3A	29800 : 29802	CM	lls cultured alone (Fig. 3A and S6A Fig.). Furthermo
./___Corpus/Medline/xml/PMC4364666.xml	S6A	29807 : 29810	CM	tured alone (Fig. 3A and S6A Fig.). Furthermore, CM p
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	29848 : 29853	CM	ermore, CM prepared from Hs738 cells cultured with MEK 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	29874 : 29877	CM	s738 cells cultured with MEK inhibitor I also inhibit
./___Corpus/Medline/xml/PMC4364666.xml	3A	29999 : 30001	CM	culture conditions (Fig. 3A). However, MEK inhibitor
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30013 : 30016	CM	ions (Fig. 3A). However, MEK inhibitor I did not show
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30124 : 30129	CM	itor was merely added to Hs738 CM (S6B Fig.) suggesting
./___Corpus/Medline/xml/PMC4364666.xml	S6B	30134 : 30137	CM	erely added to Hs738 CM (S6B Fig.) suggesting that ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30160 : 30163	CM	6B Fig.) suggesting that MEK inhibitor I affected sec
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30207 : 30212	CM	ed secreted factors from Hs738 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	U0126	30271 : 30276	CM	            Unexpectedly U0126, a well-known inhibitor 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30304 : 30307	CM	 well-known inhibitor of MEK, did not show the same r
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30342 : 30345	CM	show the same results as MEK inhibitor I (Fig. 3A and
./___Corpus/Medline/xml/PMC4364666.xml	3A	30364 : 30366	CM	as MEK inhibitor I (Fig. 3A and S6A Fig.). Thus, it 
./___Corpus/Medline/xml/PMC4364666.xml	S6A	30371 : 30374	CM	inhibitor I (Fig. 3A and S6A Fig.). Thus, it is sugge
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30409 : 30412	CM	us, it is suggested that MEK inhibitor I could act on
./___Corpus/Medline/xml/PMC4364666.xml	biotinylated	30494 : 30506	RN	target, we synthesized a biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30507 : 30510	CM	nthesized a biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	30524 : 30529	CM	nylated MEK inhibitor I (b-MEK inh) (S7 Fig.) and exami
./___Corpus/Medline/xml/PMC4364666.xml	S7	30536 : 30538	CM	inhibitor I (b-MEK inh) (S7 Fig.) and examined its b
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30584 : 30589	CM	ts binding proteins from Hs738 cells by proteomic analy
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	30643 : 30648	CM	(S8 Fig.). We found that b-MEK inh bound to RPL-18A, 60
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	30662 : 30669	CM	 that b-MEK inh bound to RPL-18A, 60S ribosomal protein L
./___Corpus/Medline/xml/PMC4364666.xml	60S	30671 : 30674	CM	EK inh bound to RPL-18A, 60S ribosomal protein L18a, 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30721 : 30724	CM	a, and excess amounts of MEK inhibitor I, but not U01
./___Corpus/Medline/xml/PMC4364666.xml	U0126	30746 : 30751	CM	MEK inhibitor I, but not U0126, inhibited the binding o
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	30778 : 30783	CM	inhibited the binding of b-MEK to RPL-18A (Fig. 3B). Fu
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	30787 : 30794	CM	 the binding of b-MEK to RPL-18A (Fig. 3B). Furthermore, 
./___Corpus/Medline/xml/PMC4364666.xml	3B	30801 : 30803	CM	f b-MEK to RPL-18A (Fig. 3B). Furthermore, MEK inhib
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30819 : 30822	CM	 (Fig. 3B). Furthermore, MEK inhibitor I treatment re
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	30869 : 30876	CM	 resulted in decrease of RPL-18A proteins in Hs738 cells 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	30889 : 30894	CM	e of RPL-18A proteins in Hs738 cells without affecting 
./___Corpus/Medline/xml/PMC4364666.xml	mRNA	30919 : 30923	CM	 cells without affecting mRNA expression for RPL-18A (
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	30939 : 30946	CM	ting mRNA expression for RPL-18A (Fig. 3C and S9A Fig.) s
./___Corpus/Medline/xml/PMC4364666.xml	3C	30953 : 30955	CM	ession for RPL-18A (Fig. 3C and S9A Fig.) suggesting
./___Corpus/Medline/xml/PMC4364666.xml	S9A	30960 : 30963	CM	for RPL-18A (Fig. 3C and S9A Fig.) suggesting that ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	30986 : 30989	CM	9A Fig.) suggesting that MEK inhibitor I bound to RPL
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	31011 : 31018	CM	MEK inhibitor I bound to RPL-18A and destabilized it. Thu
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31072 : 31075	CM	hese results showed that MEK inhibitor I had a differ
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	31119 : 31126	CM	different target such as RPL-18A other than MEK like U012
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31138 : 31141	CM	ch as RPL-18A other than MEK like U0126 and modified 
./___Corpus/Medline/xml/PMC4364666.xml	U0126	31147 : 31152	CM	-18A other than MEK like U0126 and modified secreted fa
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31188 : 31193	CM	ed secreted factors from Hs738 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31325 : 31330	CM	me secreted factors from Hs738 cells were suggested to 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31370 : 31373	CM	gested to be affected by MEK inhibitor I (Fig. 3A), w
./___Corpus/Medline/xml/PMC4364666.xml	3A	31392 : 31394	CM	by MEK inhibitor I (Fig. 3A), we examined the effect
./___Corpus/Medline/xml/PMC4364666.xml	p70S6	31478 : 31483	CM	 a result, we found that p70S6 kinase (p70S6K) and RPS6
./___Corpus/Medline/xml/PMC4364666.xml	p70S6K	31492 : 31498	CM	found that p70S6 kinase (p70S6K) and RPS6 were downregul
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	31504 : 31508	CM	70S6 kinase (p70S6K) and RPS6 were downregulated by th
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31543 : 31546	CM	regulated by the CM from MEK inhibitor I-treated Hs73
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31567 : 31572	CM	 MEK inhibitor I-treated Hs738 cells (S10 Fig.). Furthe
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	31618 : 31623	CM	rthermore, we found that STAT3 was activated by Hs738 C
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31641 : 31646	CM	t STAT3 was activated by Hs738 CM, but the activation w
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31687 : 31692	CM	ivation was inhibited in Hs738 CM pretreated with MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31712 : 31715	CM	Hs738 CM pretreated with MEK inhibitor I (S10 Fig.). 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31769 : 31774	CM	e results suggested that Hs738 cells secreted growth fa
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	31875 : 31880	CM	ypothesis, we found that Hs738 cells secreted IL-6 and 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	31905 : 31910	CM	 cells secreted IL-6 and CXCL1 (S11 Fig.) and MEK inhib
./___Corpus/Medline/xml/PMC4364666.xml	S11	31912 : 31915	CM	secreted IL-6 and CXCL1 (S11 Fig.) and MEK inhibitor 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	31926 : 31929	CM	and CXCL1 (S11 Fig.) and MEK inhibitor I inhibited re
./___Corpus/Medline/xml/PMC4364666.xml	S11	31990 : 31993	CM	ose factors (Fig. 3D and S11 Fig.). Furthermore, siRN
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	32024 : 32031	CM	. Furthermore, siRNA for RPL-18A, one of targets of MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	32051 : 32054	CM	L-18A, one of targets of MEK inhibitor I, successfull
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32111 : 32116	CM	ited IL-6 secretion from Hs738 cells (Fig. 3E). Thus, t
./___Corpus/Medline/xml/PMC4364666.xml	3E	32129 : 32131	CM	n from Hs738 cells (Fig. 3E). Thus, these results in
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32169 : 32174	CM	e results indicated that Hs738 cells secreted IL-6 thro
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	32203 : 32210	CM	ls secreted IL-6 through RPL-18A-dependent mechanism.    
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32270 : 32275	CM	                         Hs738 cells secreted IL-6 and 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	32300 : 32305	CM	 cells secreted IL-6 and CXCL1 more than did gastric ca
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	32368 : 32373	CM	es with the exception of MKN-1. Conversely, gastric can
./___Corpus/Medline/xml/PMC4364666.xml	S12A	32453 : 32457	CM	oluble receptor, IL-6sR (S12A Fig.). Because IL-6 acti
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	32488 : 32493	CM	. Because IL-6 activates STAT3, the activation of STAT3
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	32513 : 32518	CM	STAT3, the activation of STAT3 by Hs738 CM was inhibite
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32522 : 32527	CM	e activation of STAT3 by Hs738 CM was inhibited by the 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	32637 : 32642	CM	l involvement of IL-6 in Hs738 CM (Fig. 4A). Moreover, 
./___Corpus/Medline/xml/PMC4364666.xml	4A	32652 : 32654	CM	f IL-6 in Hs738 CM (Fig. 4A). Moreover, IL-6 activat
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	32682 : 32687	CM	Moreover, IL-6 activated STAT3 in gastric cancer cells 
./___Corpus/Medline/xml/PMC4364666.xml	4B	32746 : 32748	CM	-dependent fashion (Fig. 4B and S13A Fig.). Actually
./___Corpus/Medline/xml/PMC4364666.xml	S13A	32753 : 32757	CM	ent fashion (Fig. 4B and S13A Fig.). Actually IL-6 inc
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	32844 : 32850	CM	cancer cell lines except MKN-45; in contrast, CXCL1 did 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	32865 : 32870	CM	ept MKN-45; in contrast, CXCL1 did not affect their gro
./___Corpus/Medline/xml/PMC4364666.xml	4C	32905 : 32907	CM	ffect their growth (Fig. 4C and S13B Fig.). Anti-IL-
./___Corpus/Medline/xml/PMC4364666.xml	S13B	32912 : 32916	CM	heir growth (Fig. 4C and S13B Fig.). Anti-IL-6 neutral
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	33064 : 33069	CM	 inhibited the growth of MKN-7, MKN-28, and MKN-74 cell
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	33071 : 33077	CM	ted the growth of MKN-7, MKN-28, and MKN-74 cells co-cul
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	33083 : 33089	CM	th of MKN-7, MKN-28, and MKN-74 cells co-cultured with H
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33113 : 33118	CM	4 cells co-cultured with Hs738 cells (Fig. 4D and S13B 
./___Corpus/Medline/xml/PMC4364666.xml	4D	33131 : 33133	CM	d with Hs738 cells (Fig. 4D and S13B Fig.). In contr
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33138 : 33142	CM	Hs738 cells (Fig. 4D and S13B Fig.). In contrast, anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-CXCL1	33163 : 33173	CM	S13B Fig.). In contrast, anti-CXCL1 neutralizing antibody di
./___Corpus/Medline/xml/PMC4364666.xml	4D	33229 : 33231	CM	show such activity (Fig. 4D and S13B Fig.). Although
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33236 : 33240	CM	ch activity (Fig. 4D and S13B Fig.). Although the grow
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	33271 : 33276	CM	. Although the growth of MKN-1 cells co-cultured with H
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33300 : 33305	CM	1 cells co-cultured with Hs738 was not affected by anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	33326 : 33331	CPR	s738 was not affected by anti-IL-6 antibody, this was l
./___Corpus/Medline/xml/PMC4364666.xml	S12A	33409 : 33413	CM	crine secretion of IL-6 (S12A Fig. and S13B). With reg
./___Corpus/Medline/xml/PMC4364666.xml	S13B	33423 : 33427	CM	n of IL-6 (S12A Fig. and S13B). With regard to MKN-45 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	33445 : 33451	CM	nd S13B). With regard to MKN-45 cells, growth was unaffe
./___Corpus/Medline/xml/PMC4364666.xml	anti-	33504 : 33509	CPR	d by addition of IL-6 or anti-IL-6 antibody. Whereas IL
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	33636 : 33641	CM	cell lines, it activated STAT3 in all the cell lines as
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	33677 : 33683	CM	 cell lines as it did in MKN-45 cells (S13A Fig. and S14
./___Corpus/Medline/xml/PMC4364666.xml	S13A	33691 : 33695	CM	 it did in MKN-45 cells (S13A Fig. and S14). Since IL-
./___Corpus/Medline/xml/PMC4364666.xml	S14	33705 : 33708	CM	-45 cells (S13A Fig. and S14). Since IL-6 reportedly 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	33821 : 33826	CM	c cancer cells [42, 43], Hs738 cells possibly stimulate
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	33952 : 33956	CM	    Cancer cells secrete PGE2 and TNFα to stimulate IL
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	33961 : 33965	CM	r cells secrete PGE2 and TNFα to stimulate IL-6 produc
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34237 : 34242	CM	M on IL-6 secretion from Hs738 cells. As a result, we f
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	34285 : 34290	CM	t, we found that CM from MKN-7, MKN-28, and MKN-74 cell
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	34292 : 34298	CM	ound that CM from MKN-7, MKN-28, and MKN-74 cells increa
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	34304 : 34310	CM	 from MKN-7, MKN-28, and MKN-74 cells increased IL-6 sec
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34347 : 34352	CM	ased IL-6 secretion from Hs738 cells (Fig. 5A). Prostan
./___Corpus/Medline/xml/PMC4364666.xml	Prostanoids	34370 : 34381	CM	m Hs738 cells (Fig. 5A). Prostanoids and Wnt signaling are kn
./___Corpus/Medline/xml/PMC4364666.xml	Wnt	34386 : 34389	CM	ig. 5A). Prostanoids and Wnt signaling are known to b
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	34553 : 34557	CM	secretion and found that PGE2 increased IL-6 secretion
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34588 : 34593	CM	ased IL-6 secretion from Hs738 cells in a dose-dependen
./___Corpus/Medline/xml/PMC4364666.xml	S12B	34641 : 34645	CM	ent fashion (Fig. 5B and S12B Fig.). We next examined 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	34707 : 34712	CM	in the CM and found that MKN-7 and MKN-74 cells secrete
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	34717 : 34723	CM	and found that MKN-7 and MKN-74 cells secreted PGE2 (Fig
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	34739 : 34743	CM	nd MKN-74 cells secreted PGE2 (Fig. 5C and S12C Fig.).
./___Corpus/Medline/xml/PMC4364666.xml	5C	34750 : 34752	CM	ells secreted PGE2 (Fig. 5C and S12C Fig.). We previ
./___Corpus/Medline/xml/PMC4364666.xml	S12C	34757 : 34761	CM	creted PGE2 (Fig. 5C and S12C Fig.). We previously rep
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	34797 : 34801	CM	previously reported that TNFα and IL-1β stimulated str
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	34872 : 34876	CM	 IL-6 [48]. As expected, TNFα and IL-1β increased IL-6
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	34917 : 34922	CM	ased IL-6 secretion from Hs738 cells at very low concen
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	34980 : 34985	CM	 (Fig. 5D). When CM from MKN-7, MKN-28 and MKN-74 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	34987 : 34993	CM	5D). When CM from MKN-7, MKN-28 and MKN-74 cells was con
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	34998 : 35004	CM	M from MKN-7, MKN-28 and MKN-74 cells was concentrated, 
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	35029 : 35033	CM	 cells was concentrated, TNFα, but not IL-1β was detec
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	35065 : 35071	CM	ot IL-1β was detected in MKN-28 CM at concentrations tha
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35127 : 35132	CM	 sufficient to stimulate Hs738 cells to secrete IL-6 (F
./___Corpus/Medline/xml/PMC4364666.xml	5E	35161 : 35163	CM	ls to secrete IL-6 (Fig. 5E). In case of MKN-7 CM th
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	35177 : 35182	CM	-6 (Fig. 5E). In case of MKN-7 CM the amounts of PGE2 a
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	35201 : 35205	CM	 MKN-7 CM the amounts of PGE2 and TNFα are less suffic
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	35210 : 35214	CM	 the amounts of PGE2 and TNFα are less sufficient for 
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	35324 : 35328	CM	he synergistic effect of PGE2 and TNFα and/or addition
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	35333 : 35337	CM	istic effect of PGE2 and TNFα and/or additional factor
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	35457 : 35461	CM	ic cancer cells secreted PGE2 and TNFα stimulating the
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	35466 : 35470	CM	 cells secreted PGE2 and TNFα stimulating the stromal 
./___Corpus/Medline/xml/PMC4364666.xml	S25	35560 : 35563	CM	 growth of cancer cells (S25 Fig.).                  
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	35610 : 35615	CM	   Stromal cells secrete GAPDH to inhibit cancer cells 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35661 : 35666	CM	lls                      Hs738 CM downregulated phospho
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	35684 : 35699	RN	  Hs738 CM downregulated phosphorylation of RPS6 and this inhibit
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	35703 : 35707	CM	lated phosphorylation of RPS6 and this inhibitory effe
./___Corpus/Medline/xml/PMC4364666.xml	MEK	35758 : 35761	CM	t was more pronounced in MEK inhibitor I-treated CM s
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35801 : 35806	CM	eated CM suggesting that Hs738 CM contained growth-inhi
./___Corpus/Medline/xml/PMC4364666.xml	S3C	35858 : 35861	CM	tory activities (Fig. 2, S3C Fig., and S15 Fig.). To 
./___Corpus/Medline/xml/PMC4364666.xml	S15	35872 : 35875	CM	s (Fig. 2, S3C Fig., and S15 Fig.). To analyze those 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	35933 : 35938	CM	 we concentrated CM from Hs738 cells pretreated with ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	35961 : 35964	CM	38 cells pretreated with MEK inhibitor I and purified
./___Corpus/Medline/xml/PMC4364666.xml	S15	36004 : 36007	CM	d purified the proteins (S15 Fig.). Proteomic analysi
./___Corpus/Medline/xml/PMC4364666.xml	enolase	36103 : 36110	CM	 candidate proteins were enolase, PAI-1, and GAPDH (S15 F
./___Corpus/Medline/xml/PMC4364666.xml	PAI-1	36112 : 36117	CM	e proteins were enolase, PAI-1, and GAPDH (S15 Fig.). W
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36123 : 36128	CM	were enolase, PAI-1, and GAPDH (S15 Fig.). Western blot
./___Corpus/Medline/xml/PMC4364666.xml	S15	36130 : 36133	CM	olase, PAI-1, and GAPDH (S15 Fig.). Western blotting 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36218 : 36223	CM	ibitory factors might be GAPDH. In fact, MEK inhibitor 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	36234 : 36237	CM	might be GAPDH. In fact, MEK inhibitor I increased ex
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36339 : 36344	CM	 intracellular levels of GAPDH and the extracellular en
./___Corpus/Medline/xml/PMC4364666.xml	enolase	36367 : 36374	CM	DH and the extracellular enolase (Fig. 6A). The amount of
./___Corpus/Medline/xml/PMC4364666.xml	6A	36381 : 36383	CM	racellular enolase (Fig. 6A). The amount of secreted
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36409 : 36414	CM	. The amount of secreted GAPDH was higher in Hs738 cell
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	36429 : 36434	CM	eted GAPDH was higher in Hs738 cells than gastric cance
./___Corpus/Medline/xml/PMC4364666.xml	S16	36473 : 36476	CM	stric cancer cell lines (S16 Fig.). Furthermore, othe
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36531 : 36536	CM	omal cells also secreted GAPDH (S16 Fig.). Although GAP
./___Corpus/Medline/xml/PMC4364666.xml	S16	36538 : 36541	CM	lls also secreted GAPDH (S16 Fig.). Although GAPDH is
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36558 : 36563	CM	PDH (S16 Fig.). Although GAPDH is reported to be secret
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36796 : 36801	CM	es and human recombinant GAPDH were found to strongly i
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	36847 : 36852	CM	ly inhibit the growth of MKN-7 cells, whereas MKN-74 ce
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	36868 : 36874	CM	 of MKN-7 cells, whereas MKN-74 cells were weakly inhibi
./___Corpus/Medline/xml/PMC4364666.xml	6B	36909 : 36911	CM	e weakly inhibited (Fig. 6B). We also found that GAP
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	36933 : 36938	CM	 6B). We also found that GAPDH inhibited the growth of 
./___Corpus/Medline/xml/PMC4364666.xml	S17	36990 : 36993	CM	veral cancer cell lines (S17 Fig.). In contrast, GAPD
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37014 : 37019	CM	(S17 Fig.). In contrast, GAPDH did not affect the growt
./___Corpus/Medline/xml/PMC4364666.xml	S17	37072 : 37075	CM	f various stromal cells (S17 Fig.). Furthermore, we f
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37110 : 37115	CM	rthermore, we found that GAPDH decreased phosphorylatio
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylation	37126 : 37141	RN	und that GAPDH decreased phosphorylation of RPS6 and its upstream
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	37145 : 37149	CM	eased phosphorylation of RPS6 and its upstream regulat
./___Corpus/Medline/xml/PMC4364666.xml	p70S6K	37178 : 37184	CM	 its upstream regulator, p70S6K, in MKN-1, MKN-7, and MK
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	37189 : 37194	CM	am regulator, p70S6K, in MKN-1, MKN-7, and MKN-28 cells
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	37196 : 37201	CM	lator, p70S6K, in MKN-1, MKN-7, and MKN-28 cells (Fig. 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	37207 : 37213	CM	6K, in MKN-1, MKN-7, and MKN-28 cells (Fig. 6C) as did H
./___Corpus/Medline/xml/PMC4364666.xml	6C	37226 : 37228	CM	, and MKN-28 cells (Fig. 6C) as did Hs738 CM (Fig. 2
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	37237 : 37242	CM	8 cells (Fig. 6C) as did Hs738 CM (Fig. 2A and S4A Fig.
./___Corpus/Medline/xml/PMC4364666.xml	S4A	37259 : 37262	CM	id Hs738 CM (Fig. 2A and S4A Fig.). Thus, it is consi
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37298 : 37303	CM	s, it is considered that GAPDH inhibited protein synthe
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	37346 : 37351	CM	 synthesis and growth of MKN-1, MKN-7, MKN-28 cells.   
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	37353 : 37358	CM	sis and growth of MKN-1, MKN-7, MKN-28 cells.          
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	37360 : 37366	CM	 growth of MKN-1, MKN-7, MKN-28 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37469 : 37474	CM	wth inhibitory effect of GAPDH required its enzymatic a
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37527 : 37532	CM	vity. FLAG-tagged mutant GAPDH (C152S) had no enzyme ac
./___Corpus/Medline/xml/PMC4364666.xml	C152S	37534 : 37539	CM	LAG-tagged mutant GAPDH (C152S) had no enzyme activity 
./___Corpus/Medline/xml/PMC4364666.xml	S18A	37565 : 37569	CM	 had no enzyme activity (S18A Fig.), but it still sign
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	37628 : 37633	CM	 inhibited the growth of MKN-7 cells (S18A Fig.). To de
./___Corpus/Medline/xml/PMC4364666.xml	S18A	37641 : 37645	CM	e growth of MKN-7 cells (S18A Fig.). To determine whet
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37792 : 37797	CM	eral deletion mutants of GAPDH (S18B Fig.). As a result
./___Corpus/Medline/xml/PMC4364666.xml	S18B	37799 : 37803	CM	letion mutants of GAPDH (S18B Fig.). As a result, we f
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37838 : 37843	CM	 a result, we found that GAPDH del1 lacking the C-termi
./___Corpus/Medline/xml/PMC4364666.xml	del1	37844 : 37848	CM	ult, we found that GAPDH del1 lacking the C-terminal d
./___Corpus/Medline/xml/PMC4364666.xml	C-	37862 : 37864	CPR	 GAPDH del1 lacking the C-terminal domain of GAPDH i
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	37882 : 37887	CM	the C-terminal domain of GAPDH inhibited the growth of 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	37912 : 37917	CM	 inhibited the growth of MKN-7 cells (Fig. 6D). While G
./___Corpus/Medline/xml/PMC4364666.xml	6D	37930 : 37932	CM	wth of MKN-7 cells (Fig. 6D). While GAPDH del3 lacki
./___Corpus/Medline/xml/PMC4364666.xml	del3	37947 : 37951	CM	s (Fig. 6D). While GAPDH del3 lacking 98–152 amino aci
./___Corpus/Medline/xml/PMC4364666.xml	98–	37960 : 37963	CPR	While GAPDH del3 lacking 98–152 amino acids in the N-
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	37967 : 37978	CM	APDH del3 lacking 98–152 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	37987 : 37989	CPR	–152 amino acids in the N-terminal domain also stron
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38040 : 38045	CM	ly inhibited the growth, GAPDH del2 lacking 4–81 amino 
./___Corpus/Medline/xml/PMC4364666.xml	del2	38046 : 38050	CM	ibited the growth, GAPDH del2 lacking 4–81 amino acids
./___Corpus/Medline/xml/PMC4364666.xml	4–	38059 : 38061	CPR	owth, GAPDH del2 lacking 4–81 amino acids in N-termi
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	38064 : 38075	CM	 GAPDH del2 lacking 4–81 amino acids in N-terminal domain fai
./___Corpus/Medline/xml/PMC4364666.xml	N-	38080 : 38082	CPR	ing 4–81 amino acids in N-terminal domain failed to 
./___Corpus/Medline/xml/PMC4364666.xml	6D	38132 : 38134	CM	inhibit the growth (Fig. 6D). These results clearly 
./___Corpus/Medline/xml/PMC4364666.xml	N-	38179 : 38181	CPR	arly indicated that the N-terminal domain especially
./___Corpus/Medline/xml/PMC4364666.xml	4–	38207 : 38209	CPR	rminal domain especially 4–81 amino acids without th
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	38212 : 38223	CM	l domain especially 4–81 amino acids without the catalytic do
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38334 : 38339	CM	           Extracellular GAPDH binds to E-cadherin     
./___Corpus/Medline/xml/PMC4364666.xml	E-	38349 : 38351	CPR	acellular GAPDH binds to E-cadherin                 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	38405 : 38410	CPR	 Immunofluorescence with anti-GAPDH antibody (in the ab
./___Corpus/Medline/xml/PMC4364666.xml	S19B	38555 : 38559	CM	 cell-to-cell junctions (S19B Fig.). The sites at whic
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38586 : 38591	CM	ig.). The sites at which GAPDH bound were similar to th
./___Corpus/Medline/xml/PMC4364666.xml	E-	38627 : 38629	CPR	 similar to the sites of E-cadherin expression (S19B
./___Corpus/Medline/xml/PMC4364666.xml	S19B	38650 : 38654	CM	f E-cadherin expression (S19B Fig.). Confocal laser sc
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38711 : 38716	CM	microscopy revealed that GAPDH was partially colocalize
./___Corpus/Medline/xml/PMC4364666.xml	E-	38748 : 38750	CPR	rtially colocalized with E-cadherin in MKN-7 cells (
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	38762 : 38767	CM	lized with E-cadherin in MKN-7 cells (Fig. 7A). We then
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38857 : 38862	CM	H as well as FLAG-tagged GAPDH directly bound to E-cadh
./___Corpus/Medline/xml/PMC4364666.xml	E-	38881 : 38883	CPR	 GAPDH directly bound to E-cadherin (Fig. 7B and S20
./___Corpus/Medline/xml/PMC4364666.xml	S20	38905 : 38908	CM	 E-cadherin (Fig. 7B and S20 Fig.). Furthermore, GAPD
./___Corpus/Medline/xml/PMC4364666.xml	E-	38944 : 38946	CPR	thermore, GAPDH bound to E-cadherin-coated plates in
./___Corpus/Medline/xml/PMC4364666.xml	E-	38954 : 38956	CPR	GAPDH bound to E-cadherin-coated plates in vitro (Fi
./___Corpus/Medline/xml/PMC4364666.xml	vitro	38972 : 38977	CM	adherin-coated plates in vitro (Fig. 7C). GAPDH inhibit
./___Corpus/Medline/xml/PMC4364666.xml	7C	38984 : 38986	CM	ed plates in vitro (Fig. 7C). GAPDH inhibited mTOR a
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	38989 : 38994	CM	ates in vitro (Fig. 7C). GAPDH inhibited mTOR activatio
./___Corpus/Medline/xml/PMC4364666.xml	mTOR	39005 : 39009	CM	ig. 7C). GAPDH inhibited mTOR activation and its downs
./___Corpus/Medline/xml/PMC4364666.xml	p70S6K	39040 : 39046	CM	ation and its downstream p70S6K activation in MKN-7 cell
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	39061 : 39066	CM	eam p70S6K activation in MKN-7 cells, but not in MKN-74
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	39085 : 39091	CM	 MKN-7 cells, but not in MKN-74 cells (Fig. 7D and S21 F
./___Corpus/Medline/xml/PMC4364666.xml	7D	39104 : 39106	CM	ot in MKN-74 cells (Fig. 7D and S21 Fig.). This resu
./___Corpus/Medline/xml/PMC4364666.xml	S21	39111 : 39114	CM	KN-74 cells (Fig. 7D and S21 Fig.). This result was c
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	39154 : 39159	CM	sult was consistent with GAPDH sensitivity (Fig. 6B). A
./___Corpus/Medline/xml/PMC4364666.xml	6B	39178 : 39180	CM	 GAPDH sensitivity (Fig. 6B). Anti-E-cadherin antibo
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	39240 : 39251	CM	ed the activation of the mTOR-p70S6K pathway in MKN-7 cells (
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	39263 : 39268	CM	e mTOR-p70S6K pathway in MKN-7 cells (Fig. 7D), but nei
./___Corpus/Medline/xml/PMC4364666.xml	7D	39281 : 39283	CM	way in MKN-7 cells (Fig. 7D), but neither GAPDH nor 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	39298 : 39303	CM	s (Fig. 7D), but neither GAPDH nor anti-E-cadherin anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	39308 : 39313	CPR	), but neither GAPDH nor anti-E-cadherin antibody inhib
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	39370 : 39381	CM	ssible regulators of the mTOR-p70S6K pathway, including Src, 
./___Corpus/Medline/xml/PMC4364666.xml	MAPK	39411 : 39415	CM	way, including Src, Akt, MAPK, AMPK and β-catenin (S21
./___Corpus/Medline/xml/PMC4364666.xml	AMPK	39417 : 39421	CM	ncluding Src, Akt, MAPK, AMPK and β-catenin (S21 Fig.)
./___Corpus/Medline/xml/PMC4364666.xml	β-catenin	39426 : 39435	CM	Src, Akt, MAPK, AMPK and β-catenin (S21 Fig.). However, E-c
./___Corpus/Medline/xml/PMC4364666.xml	S21	39437 : 39440	CM	APK, AMPK and β-catenin (S21 Fig.). However, E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	39457 : 39459	CPR	nin (S21 Fig.). However, E-cadherin siRNA attenuated
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	39507 : 39511	CM	ed the downregulation of RPS6 by GAPDH as well as anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	39532 : 39537	CPR	RPS6 by GAPDH as well as anti-E-cadherin antibody (Fig.
./___Corpus/Medline/xml/PMC4364666.xml	7E	39563 : 39565	CM	-cadherin antibody (Fig. 7E).                       
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	39646 : 39651	CM	h-inhibitory activity of GAPDH was correlated with down
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	39694 : 39705	CM	th downregulation of the mTOR-p70S6K pathway but the mechanis
./___Corpus/Medline/xml/PMC4364666.xml	E-	39761 : 39763	CPR	hich the interference of E-cadherin function led to 
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	39815 : 39826	CM	e down-regulation of the mTOR-p70S6K pathway is unknown. MKN-
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	39847 : 39853	CM	0S6K pathway is unknown. MKN-45 and MKN-74 cells express
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	39858 : 39864	CM	y is unknown. MKN-45 and MKN-74 cells expressed E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	39881 : 39883	CPR	d MKN-74 cells expressed E-cadherin weakly compared 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	39993 : 39998	CM	wth inhibitory effect of GAPDH (Fig. 2B and S17 Fig.). 
./___Corpus/Medline/xml/PMC4364666.xml	S17	40012 : 40015	CM	ct of GAPDH (Fig. 2B and S17 Fig.). Although E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	40032 : 40034	CPR	 and S17 Fig.). Although E-cadherin-null MKN-1 cells
./___Corpus/Medline/xml/PMC4364666.xml	E-	40042 : 40044	CPR	ig.). Although E-cadherin-null MKN-1 cells were exce
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	40048 : 40053	CM	Although E-cadherin-null MKN-1 cells were exceptional, 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	40104 : 40109	CM	hese results showed that GAPDH interfered with E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	40126 : 40128	CPR	at GAPDH interfered with E-cadherin function and sup
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	40193 : 40198	CM	 synthesis and growth of MKN-7 and MKN-28 cells.       
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	40203 : 40209	CM	 and growth of MKN-7 and MKN-28 cells.                  
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	40376 : 40381	CM	study we have found that Hs738 gastric stromal cells se
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	40421 : 40426	CM	l cells secrete IL-6 and GAPDH for positive and negativ
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	40592 : 40597	CM	er cell lines used here, GAPDH suppressed the growth of
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	40623 : 40628	CM	suppressed the growth of MKN-7 and MKN-28 cells. Overal
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	40633 : 40639	CM	 the growth of MKN-7 and MKN-28 cells. Overall it is con
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	40677 : 40682	CM	ll it is considered that Hs738 cells suppressed the gro
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	40714 : 40719	CM	suppressed the growth of MKN-7 and MKN-28 cells through
./___Corpus/Medline/xml/PMC4364666.xml	MKN-28	40724 : 40730	CM	 the growth of MKN-7 and MKN-28 cells through GAPDH, but
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	40745 : 40750	CM	and MKN-28 cells through GAPDH, but they stimulated tha
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	40780 : 40786	CM	 they stimulated that of MKN-45 and MKN-74 cells through
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	40791 : 40797	CM	lated that of MKN-45 and MKN-74 cells through IL-6. MKN-
./___Corpus/Medline/xml/PMC4364666.xml	MKN-45	40818 : 40824	CM	N-74 cells through IL-6. MKN-45 and MKN-74 cells (undiff
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	40829 : 40835	CM	through IL-6. MKN-45 and MKN-74 cells (undifferentiated 
./___Corpus/Medline/xml/PMC4364666.xml	E-	41040 : 41042	CPR	, because they expressed E-cadherin at low levels an
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	41204 : 41209	CM	        When we examined STAT3 activation in human gast
./___Corpus/Medline/xml/PMC4364666.xml	S22	41327 : 41330	CM	 adenocarcinoma tissues (S22 Fig.), consistent with o
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	41387 : 41392	CM	ports [49, 50]. Although STAT3 activation was not detec
./___Corpus/Medline/xml/PMC4364666.xml	GIST	41424 : 41428	CM	tion was not detected in GIST tissues, it was detected
./___Corpus/Medline/xml/PMC4364666.xml	S22	41505 : 41508	CM	 cell carcinoma tissues (S22 Fig.). These results ind
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	41545 : 41550	CM	e results indicated that STAT3 activation by IL-6 is in
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	42169 : 42173	CM	 cells secreted at least PGE2 and TNFα to stimulate IL
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	42178 : 42182	CM	creted at least PGE2 and TNFα to stimulate IL-6 produc
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	42285 : 42290	CM	cer cells did not affect GAPDH secretion from Hs738 cel
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	42306 : 42311	CM	ect GAPDH secretion from Hs738 cells (S16 Fig.). Thus, 
./___Corpus/Medline/xml/PMC4364666.xml	S16	42319 : 42322	CM	retion from Hs738 cells (S16 Fig.). Thus, the PGE2-TN
./___Corpus/Medline/xml/PMC4364666.xml	PGE2-TNFα-IL-6	42340 : 42354	CM	ls (S16 Fig.). Thus, the PGE2-TNFα-IL-6 pathway is a paracrine l
./___Corpus/Medline/xml/PMC4364666.xml	paracrine	42368 : 42377	CM	2-TNFα-IL-6 pathway is a paracrine loop for gastric cancer 
./___Corpus/Medline/xml/PMC4364666.xml	Helicobacter	42415 : 42427	CM	tric cancer progression. Helicobacter pylori infection is the 
./___Corpus/Medline/xml/PMC4364666.xml	H	42486 : 42487	CM	se of gastric cancer and H. pylori not only directl
./___Corpus/Medline/xml/PMC4364666.xml	PGE2	42684 : 42688	CM	matory cytokines such as PGE2, TNFα, and IL-6, our stu
./___Corpus/Medline/xml/PMC4364666.xml	TNFα	42690 : 42694	CM	 cytokines such as PGE2, TNFα, and IL-6, our study cou
./___Corpus/Medline/xml/PMC4364666.xml	PGE2-TNFα-IL-6	42796 : 42810	CM	. Furthermore, since the PGE2-TNFα-IL-6 pathway is considered to
./___Corpus/Medline/xml/PMC4364666.xml	anti-	42938 : 42943	CPR	 a reasonable target for anti-cancer strategies.       
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43102 : 43107	CM	ected that extracellular GAPDH secreted from a cell has
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43181 : 43186	CM	maji et al reported that GAPDH is secreted from some ca
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43299 : 43304	CM	h inhibitory activity of GAPDH against cancer cells has
./___Corpus/Medline/xml/PMC4364666.xml	S17	43418 : 43421	CM	ls to GAPDH. As shown in S17 Fig., only some cancer c
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43546 : 43551	CM	cting several mutants of GAPDH, we have found that the 
./___Corpus/Medline/xml/PMC4364666.xml	N-	43577 : 43579	CPR	 we have found that the N-terminal domain of GAPDH w
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43597 : 43602	CM	the N-terminal domain of GAPDH was essential to exert t
./___Corpus/Medline/xml/PMC4364666.xml	6D	43663 : 43665	CM	nhibitory activity (Fig. 6D). It is interesting that
./___Corpus/Medline/xml/PMC4364666.xml	N-	43806 : 43808	CPR	vity. Unexpectedly, the N-terminal peptide of GAPDH 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	43827 : 43832	CM	he N-terminal peptide of GAPDH has been recently report
./___Corpus/Medline/xml/PMC4364666.xml	anti-	43976 : 43981	CPR	 immunofluorescence with anti-FLAG antibody under cell-
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	44045 : 44050	CM	conditions revealed that GAPDH was not incorporated int
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	44077 : 44082	CM	as not incorporated into MKN-7 cells (S19A Fig.). Thus,
./___Corpus/Medline/xml/PMC4364666.xml	S19A	44090 : 44094	CM	orated into MKN-7 cells (S19A Fig.). Thus, the mechani
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	44208 : 44213	CM	                         GAPDH is found to bind to E-ca
./___Corpus/Medline/xml/PMC4364666.xml	E-	44234 : 44236	CPR	APDH is found to bind to E-cadherin and to downregul
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	44265 : 44276	CM	erin and to downregulate mTOR-p70S6K pathway. Anti-E-cadherin
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	44330 : 44341	CM	ibody also downregualted mTOR-p70S6K pathway suggesting the o
./___Corpus/Medline/xml/PMC4364666.xml	E-	44405 : 44407	CPR	extracellular regions of E-cadherin results in the d
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	44449 : 44460	CM	in the downregulation of mTOR-p70S6K pathway. E-cadherin has 
./___Corpus/Medline/xml/PMC4364666.xml	E-	44470 : 44472	CPR	 of mTOR-p70S6K pathway. E-cadherin has 5 repeated e
./___Corpus/Medline/xml/PMC4364666.xml	EC1	44529 : 44532	CM	lular domains (ECs), and EC1- EC4 are involved in its
./___Corpus/Medline/xml/PMC4364666.xml	EC4	44534 : 44537	CM	 domains (ECs), and EC1- EC4 are involved in its homo
./___Corpus/Medline/xml/PMC4364666.xml	E-	44649 : 44651	CPR	ious deletion mutants of E-cadherin (S23 Fig.) and d
./___Corpus/Medline/xml/PMC4364666.xml	S23	44661 : 44664	CM	n mutants of E-cadherin (S23 Fig.) and determined the
./___Corpus/Medline/xml/PMC4364666.xml	EC1	44768 : 44771	CM	d to deletion mutants of EC1, EC2, and EC3 to the sam
./___Corpus/Medline/xml/PMC4364666.xml	EC2	44773 : 44776	CM	deletion mutants of EC1, EC2, and EC3 to the same ext
./___Corpus/Medline/xml/PMC4364666.xml	EC3	44782 : 44785	CM	mutants of EC1, EC2, and EC3 to the same extent as di
./___Corpus/Medline/xml/PMC4364666.xml	E-	44822 : 44824	CPR	 extent as did wild-type E-cadherin. In contrast, it
./___Corpus/Medline/xml/PMC4364666.xml	EC4	44901 : 44904	CM	y to deletion mutants of EC4 and EC5 (S23 Fig.), indi
./___Corpus/Medline/xml/PMC4364666.xml	EC5	44909 : 44912	CM	etion mutants of EC4 and EC5 (S23 Fig.), indicating t
./___Corpus/Medline/xml/PMC4364666.xml	S23	44914 : 44917	CM	 mutants of EC4 and EC5 (S23 Fig.), indicating that b
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	44952 : 44957	CM	dicating that binding of GAPDH to E-cadherin was not de
./___Corpus/Medline/xml/PMC4364666.xml	E-	44961 : 44963	CPR	that binding of GAPDH to E-cadherin was not dependen
./___Corpus/Medline/xml/PMC4364666.xml	E-	45030 : 45032	CPR	lic adhesion activity of E-cadherin. Since various s
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	45078 : 45083	CM	us stromal cells secrete GAPDH (S16 Fig.), this negativ
./___Corpus/Medline/xml/PMC4364666.xml	S16	45085 : 45088	CM	mal cells secrete GAPDH (S16 Fig.), this negative reg
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	45179 : 45184	CM	, the mechanism by which GAPDH inhibits mTOR-p70S6K pat
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	45194 : 45205	CM	 by which GAPDH inhibits mTOR-p70S6K pathway through E-cadher
./___Corpus/Medline/xml/PMC4364666.xml	E-	45222 : 45224	CPR	R-p70S6K pathway through E-cadherin is still unknown
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	45255 : 45260	CM	in is still unknown, but GAPDH is newly rediscovered as
./___Corpus/Medline/xml/PMC4364666.xml	anti-	45289 : 45294	CPR	newly rediscovered as an anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45357 : 45360	CM	                 We used MEK inhibitor I as a tool to
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45466 : 45469	CM	c cancer cells. Although MEK inhibitor I was original
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45524 : 45527	CM	eated as an inhibitor of MEK, we found its new target
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	45554 : 45561	CM	we found its new target, RPL-18A. The siRNA for RPL-18A s
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	45577 : 45584	CM	, RPL-18A. The siRNA for RPL-18A successfully inhibited t
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	45635 : 45640	CM	e secretion of IL-6 from Hs738 cells like MEK inhibitor
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45652 : 45655	CM	-6 from Hs738 cells like MEK inhibitor I treatment (F
./___Corpus/Medline/xml/PMC4364666.xml	3E	45684 : 45686	CM	ibitor I treatment (Fig. 3E). However, it failed to 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	45734 : 45739	CM	o increase extracellular GAPDH (Fig. 3E) unlike MEK inh
./___Corpus/Medline/xml/PMC4364666.xml	3E	45746 : 45748	CM	xtracellular GAPDH (Fig. 3E) unlike MEK inhibitor I.
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45757 : 45760	CM	r GAPDH (Fig. 3E) unlike MEK inhibitor I. Exosomes re
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45887 : 45890	CM	 as miRNA [38]. However, MEK inhibitor I did not incr
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	45920 : 45925	CM	bitor I did not increase GAPDH secretion by exosomes (S
./___Corpus/Medline/xml/PMC4364666.xml	S9B	45949 : 45952	CM	H secretion by exosomes (S9B Fig.). These results ind
./___Corpus/Medline/xml/PMC4364666.xml	MEK	45988 : 45991	CM	se results indicate that MEK inhibitor I acted on at 
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	46022 : 46029	CM	itor I acted on at least RPL-18A to modulate tumor-stroma
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	46121 : 46126	CM	her target in respect to GAPDH secretion. We previously
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	46166 : 46180	CM	previously reported that phthoxazolin A, a natural compound, dec
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	46230 : 46240	CM	reased the expression of SM-α-actin and IGF-I in PrSC human 
./___Corpus/Medline/xml/PMC4364666.xml	PrSC	46254 : 46258	CM	 SM-α-actin and IGF-I in PrSC human prostate stromal c
./___Corpus/Medline/xml/PMC4364666.xml	MEK	46379 : 46382	CM	 in co-culture. However, MEK inhibitor I did not affe
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	46440 : 46450	CM	xpression of vimentin or SM-α-actin in Hs738 cells nor inhib
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	46454 : 46459	CM	imentin or SM-α-actin in Hs738 cells nor inhibit the gr
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	46492 : 46497	CM	or inhibit the growth of Hs738 cells (S24 Fig.) suggest
./___Corpus/Medline/xml/PMC4364666.xml	S24	46505 : 46508	CM	e growth of Hs738 cells (S24 Fig.) suggesting that th
./___Corpus/Medline/xml/PMC4364666.xml	MEK	46545 : 46548	CM	sting that the action of MEK inhibitor I is different
./___Corpus/Medline/xml/PMC4364666.xml	phthoxazolin A	46587 : 46601	CM	s different from that of phthoxazolin A.                        
./___Corpus/Medline/xml/PMC4364666.xml	PGE2-TNFα-IL-6	46771 : 46785	CM	cancer cells through the PGE2-TNFα-IL-6 paracrine pathway, but n
./___Corpus/Medline/xml/PMC4364666.xml	paracrine	46786 : 46795	CM	rough the PGE2-TNFα-IL-6 paracrine pathway, but negatively 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	46837 : 46842	CM	atively through secreted GAPDH that bound to E-cadherin
./___Corpus/Medline/xml/PMC4364666.xml	E-	46857 : 46859	CPR	eted GAPDH that bound to E-cadherin (S25 Fig.). The 
./___Corpus/Medline/xml/PMC4364666.xml	S25	46869 : 46872	CM	hat bound to E-cadherin (S25 Fig.). The balance betwe
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	47059 : 47064	CM	ivities to IL-6 and also GAPDH. Although the precise me
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	47128 : 47133	CM	ch stromal cells secrete GAPDH remains to be elucidated
./___Corpus/Medline/xml/PMC4364666.xml	anti-	47368 : 47373	CPR	cells, is a feasible new anti-cancer strategy.         
./___Corpus/Medline/xml/PMC4364666.xml	GFP	47519 : 47522	CM	tably transfected with a GFP expression vector. Photo
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47680 : 47685	CM	. (B) Characteristics of Hs738 cells. Hs738 human gastr
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47693 : 47698	CM	eristics of Hs738 cells. Hs738 human gastric stromal ce
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	47785 : 47795	CM	ressing vimentin without SM-α-actin and myofibroblasts expre
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	47844 : 47854	CM	essing both vimentin and SM-α-actin. A photo of Hs738 cells 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47867 : 47872	CM	d SM-α-actin. A photo of Hs738 cells in upper left was 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	47975 : 47980	CM	in upper right show that Hs738 cells express vimentin a
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	48008 : 48018	CM	lls express vimentin and SM-α-actin compared with MKN-74 gas
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	48033 : 48039	CM	SM-α-actin compared with MKN-74 gastric cancer cells exp
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	48139 : 48144	CM	fluorescence staining of Hs738 cells with vimentin (gre
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	48174 : 48184	CM	s with vimentin (green), SM-α-actin (red), and also DAPI sta
./___Corpus/Medline/xml/PMC4364666.xml	DAPI	48201 : 48205	CM	-α-actin (red), and also DAPI staining (blue). Scale b
./___Corpus/Medline/xml/PMC4364666.xml	96-	48394 : 48397	CPR	cells were inoculated in 96-well plates with 10% FBS 
./___Corpus/Medline/xml/PMC4364666.xml	FBS	48418 : 48421	CM	 96-well plates with 10% FBS at the indicated numbers
./___Corpus/Medline/xml/PMC4364666.xml	MTT	48524 : 48527	CM	rs were determined using MTT (left) or measuring GFP 
./___Corpus/Medline/xml/PMC4364666.xml	GFP	48548 : 48551	CM	 MTT (left) or measuring GFP fluorescence intensity (
./___Corpus/Medline/xml/PMC4364666.xml	GFP	48618 : 48621	CM	ers correlated well with GFP fluorescence intensity a
./___Corpus/Medline/xml/PMC4364666.xml	MTT	48656 : 48659	CM	nce intensity as well as MTT in gastric cancer cell l
./___Corpus/Medline/xml/PMC4364666.xml	DU-145	48701 : 48707	CM	r cell lines, but not in DU-145 cells without GFP transf
./___Corpus/Medline/xml/PMC4364666.xml	GFP	48722 : 48725	CM	 in DU-145 cells without GFP transfection. The values
./___Corpus/Medline/xml/PMC4364666.xml	MKN-1	48999 : 49004	CM	after the inoculation of MKN-1, 7, 28, 45, and 74 cells
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49575 : 49580	CM	gastric cancer cells and Hs738 cells. Gastric cancer ce
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49656 : 49661	CM	ono) or co-cultured with Hs738 cells at a ratio (gastri
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	49695 : 49700	CM	 a ratio (gastric cancer:Hs738) of 1:1 in the indicated
./___Corpus/Medline/xml/PMC4364666.xml	D-	49744 : 49746	CPR	icated concentrations of D-FBS. The growth of cancer
./___Corpus/Medline/xml/PMC4364666.xml	GFP	49803 : 49806	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	plate	49931 : 49936	CM	 in a suspension culture plate (Suspension) or a normal
./___Corpus/Medline/xml/PMC4364666.xml	plate	49970 : 49975	CM	ion) or a normal culture plate (Solid) for 3 days. The 
./___Corpus/Medline/xml/PMC4364666.xml	MTT	50044 : 50047	CM	lls was determined using MTT. The values are means ± 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50203 : 50208	CM	ono) or co-cultured with Hs738 cells (outer wells) (Tra
./___Corpus/Medline/xml/PMC4364666.xml	GFP	50311 : 50314	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50495 : 50500	CM	he conditioned medium of Hs738 cells prepared by cultur
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	50529 : 50534	CM	ls prepared by culturing Hs738 cells with 1% (left) or 
./___Corpus/Medline/xml/PMC4364666.xml	D-	50591 : 50593	CPR	icated concentrations of D-FBS (right) (+) or contro
./___Corpus/Medline/xml/PMC4364666.xml	Ser	50632 : 50635	CM	) or control medium (-). Ser/Thr-phosphorylated prote
./___Corpus/Medline/xml/PMC4364666.xml	Thr	50636 : 50639	CM	 control medium (-). Ser/Thr-phosphorylated proteins 
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	50640 : 50654	RN	trol medium (-). Ser/Thr-phosphorylated proteins were detected b
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	50681 : 50697	CM	roteins were detected by anti-phospho-Ser/Thr antibody (9624). An 
./___Corpus/Medline/xml/PMC4364666.xml	Thr	50698 : 50701	CM	cted by anti-phospho-Ser/Thr antibody (9624). An arro
./___Corpus/Medline/xml/PMC4364666.xml	phosphorylated	50815 : 50829	CM	 Partial purification of phosphorylated proteins in MKN-7 cells.
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	50842 : 50847	CM	osphorylated proteins in MKN-7 cells. Phosphorylated pr
./___Corpus/Medline/xml/PMC4364666.xml	Phosphorylated	50855 : 50869	RN	proteins in MKN-7 cells. Phosphorylated proteins were partially 
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-Ser	50943 : 50959	CM	c column and detected by anti-phospho-Ser/Thr antibody (9624). The
./___Corpus/Medline/xml/PMC4364666.xml	Thr	50960 : 50963	CM	cted by anti-phospho-Ser/Thr antibody (9624). The ban
./___Corpus/Medline/xml/PMC4364666.xml	14–	51102 : 51105	CPR	bands were deduced to be 14–3–3 protein epsilon and r
./___Corpus/Medline/xml/PMC4364666.xml	3–	51105 : 51107	CPR	ds were deduced to be 14–3–3 protein epsilon and rib
./___Corpus/Medline/xml/PMC4364666.xml	S6	51147 : 51149	CM	on and ribosomal protein S6 (RPS6). (C) Effect of si
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	51186 : 51190	CM	 Effect of siRNA against RPS6 on MNK-7 cells. MKN-7 ce
./___Corpus/Medline/xml/PMC4364666.xml	MNK-7	51194 : 51199	CM	of siRNA against RPS6 on MNK-7 cells. MKN-7 cells were 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	51207 : 51212	CM	nst RPS6 on MNK-7 cells. MKN-7 cells were transfected w
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	51353 : 51358	CM	 by Western blot (left). MKN-7 cell lysates were immuno
./___Corpus/Medline/xml/PMC4364666.xml	anti-	51401 : 51406	CPR	 immunoprecipitated with anti-RPS6 or normal Ig and the
./___Corpus/Medline/xml/PMC4364666.xml	Ig	51421 : 51423	CM	with anti-RPS6 or normal Ig and the immunoprecipitat
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	51553 : 51558	CM	Fig                      MKN-7 and MKN-74 cells were cu
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	51563 : 51569	CM	               MKN-7 and MKN-74 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	51606 : 51611	CM	cultured with or without Hs738 cells for 3 days in the 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	51846 : 51849	CM	ndicates the position of MEK inhibitor I.            
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	51933 : 51938	CM	      (A) GFP-expressing MKN-7, MKN-74, and DU-145 cell
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	51940 : 51946	CM	A) GFP-expressing MKN-7, MKN-74, and DU-145 cells were c
./___Corpus/Medline/xml/PMC4364666.xml	DU-145	51952 : 51958	CM	ssing MKN-7, MKN-74, and DU-145 cells were cultured alon
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52010 : 52015	CM	(mo) or co-cultured with Hs738 cells (co) for 3 days in
./___Corpus/Medline/xml/PMC4364666.xml	GFP	52110 : 52113	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	52179 : 52184	CM	eans ± s.d. (n = 3). (B) MKN-7 and MKN-74 cells were cu
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	52189 : 52195	CM	. (n = 3). (B) MKN-7 and MKN-74 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52221 : 52224	CM	cells were cultured with MEK inhibitor I for 3 days i
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52278 : 52283	CM	e presence or absence of Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52309 : 52314	CM	CM prepared by culturing Hs738 cells without inhibitors
./___Corpus/Medline/xml/PMC4364666.xml	GFP	52393 : 52396	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	Acylated	52613 : 52621	RN	Fig                      Acylated MEK inhibitor I (a-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52622 : 52625	CM	                Acylated MEK inhibitor I (a-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	biotinylated	52654 : 52666	RN	ibitor I (a-MEK inh) and biotinylated MEK inhibitor I (b-MEK i
./___Corpus/Medline/xml/PMC4364666.xml	MEK	52667 : 52670	CM	EK inh) and biotinylated MEK inhibitor I (b-MEK inh) 
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	52684 : 52689	CM	nylated MEK inhibitor I (b-MEK inh) were synthesized. G
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	52728 : 52733	CM	thesized. GFP-expressing MKN-7 cells were cultured alon
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	52785 : 52790	CM	(mo) or co-cultured with Hs738 cells (co) for 3 days in
./___Corpus/Medline/xml/PMC4364666.xml	GFP	52884 : 52887	CM	 determined by measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53081 : 53084	CM	paring the structures of MEK inhibitor I and U0126, a
./___Corpus/Medline/xml/PMC4364666.xml	U0126	53101 : 53106	CM	s of MEK inhibitor I and U0126, amine of aniline moiety
./___Corpus/Medline/xml/PMC4364666.xml	amine	53108 : 53113	CM	K inhibitor I and U0126, amine of aniline moiety was mo
./___Corpus/Medline/xml/PMC4364666.xml	aniline	53117 : 53124	CM	or I and U0126, amine of aniline moiety was modified. Bec
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53202 : 53205	CM	ost the same activity as MEK inhibitor I, we synthesi
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	53234 : 53239	CM	ibitor I, we synthesized b-MEK inh by modifying the sam
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53323 : 53328	CM	Fig                      Hs738 cell extracts were incub
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	53363 : 53368	CM	acts were incubated with b-MEK inh-pretreated Streptavi
./___Corpus/Medline/xml/PMC4364666.xml	SDS-PAGE	53443 : 53451	CM	roteins were analyzed by SDS-PAGE. Coomassie brilliant blu
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53558 : 53563	CM	h (Arrow). M, marker; 1, Hs738 cell extracts; 2, negati
./___Corpus/Medline/xml/PMC4364666.xml	b-MEK	53603 : 53608	CM	 2, negative control; 3, b-MEK inh-treated. Bands speci
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	53729 : 53736	CM	everal molecules such as RPL-18A and caveolin as candidat
./___Corpus/Medline/xml/PMC4364666.xml	caveolin	53741 : 53749	CM	ules such as RPL-18A and caveolin as candidates.          
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	53816 : 53821	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MEK	53879 : 53882	CM	icated concentrations of MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	RNAs	53917 : 53921	CM	 I for 2 days. (A) Total RNAs were collected and RPL-1
./___Corpus/Medline/xml/PMC4364666.xml	RPL-18A	53941 : 53948	CM	 RNAs were collected and RPL-18A mRNA levels were analyze
./___Corpus/Medline/xml/PMC4364666.xml	mRNA	53949 : 53953	CM	re collected and RPL-18A mRNA levels were analyzed by 
./___Corpus/Medline/xml/PMC4364666.xml	b-actin	54001 : 54008	CM	y real time RT-PCR using b-actin as a reference. (B) Exos
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	54197 : 54202	CM	Fig                      MKN-7 cells were cultured for 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54269 : 54272	CM	es with or without 10 μM MEK inhibitor I or Hs738 CM 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54288 : 54293	CM	10 μM MEK inhibitor I or Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54319 : 54324	CM	CM prepared by culturing Hs738 cells with or without ME
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54347 : 54350	CM	38 cells with or without MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-(Ser	54427 : 54444	CM	zed by Western blot with anti-phospho-(Ser/Thr) antibody (9624) and
./___Corpus/Medline/xml/PMC4364666.xml	Thr	54445 : 54448	CM	t with anti-phospho-(Ser/Thr) antibody (9624) and oth
./___Corpus/Medline/xml/PMC4364666.xml	RPS6	54537 : 54541	CM	ndicates the position of RPS6 protein.                
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	54603 : 54608	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MEK	54651 : 54654	CM	ed with or without 10 μM MEK inhibitor I for 2 days. 
./___Corpus/Medline/xml/PMC4364666.xml	cytokine	54729 : 54737	CM	 were applied onto human cytokine antibody array (C series
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	54852 : 54857	CM	he positions of IL-6 and CXCL1 duplicated spots. Lower 
./___Corpus/Medline/xml/PMC4364666.xml	IL-6sR	54976 : 54982	CM	               (A) IL-6, IL-6sR, and CXCL1 in CM. Cells 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	54988 : 54993	CM	   (A) IL-6, IL-6sR, and CXCL1 in CM. Cells were cultur
./___Corpus/Medline/xml/PMC4364666.xml	IL-6sR	55057 : 55063	CM	and the amounts of IL-6, IL-6sR, and CXCL1 in the CM wer
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	55069 : 55074	CM	nts of IL-6, IL-6sR, and CXCL1 in the CM were determine
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	55192 : 55197	CM	noids on IL-6 secretion. Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	10μM	55223 : 55227	CM	cells were cultured with 10μM various prostanoids for 
./___Corpus/Medline/xml/PMC4364666.xml	Prostanoids	55365 : 55376	CM	eans ± s.d. (n = 3). (C) Prostanoids production in cells. The
./___Corpus/Medline/xml/PMC4364666.xml	PGI2	55413 : 55417	CM	in cells. The amounts of PGI2, TXA2, and leukotriene B
./___Corpus/Medline/xml/PMC4364666.xml	TXA2	55419 : 55423	CM	ls. The amounts of PGI2, TXA2, and leukotriene B4 in C
./___Corpus/Medline/xml/PMC4364666.xml	leukotriene	55429 : 55440	CM	ounts of PGI2, TXA2, and leukotriene B4 in CM prepared from t
./___Corpus/Medline/xml/PMC4364666.xml	STAT3	55729 : 55734	CM	 IL-6. The activation of STAT3 was analyzed by Western 
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	55785 : 55790	CM	lot. (B) Effect of IL-6, CXCL1, anti-IL-6, and anti-CXC
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55792 : 55797	CPR	) Effect of IL-6, CXCL1, anti-IL-6, and anti-CXCL-1 ant
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55807 : 55812	CPR	6, CXCL1, anti-IL-6, and anti-CXCL-1 antibodies on grow
./___Corpus/Medline/xml/PMC4364666.xml	CXCL1	55896 : 55901	CM	were cultured with IL-6, CXCL1, anti-IL-6, or anti-CXCL
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55903 : 55908	CPR	ltured with IL-6, CXCL1, anti-IL-6, or anti-CXCL-1 anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	55917 : 55922	CPR	-6, CXCL1, anti-IL-6, or anti-CXCL-1 antibodies (Mono) 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	55978 : 55983	CM	days or co-cultured with Hs738 cells (Cocul) for 3 days
./___Corpus/Medline/xml/PMC4364666.xml	GFP	56047 : 56050	CM	was determined measuring GFP fluorescence intensity. 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	56116 : 56121	CPR	eans ± s.d. (n = 3). For anti-IL-6 and anti-CXCL-1 anti
./___Corpus/Medline/xml/PMC4364666.xml	anti-	56130 : 56135	CPR	 = 3). For anti-IL-6 and anti-CXCL-1 antibodies, cell g
./___Corpus/Medline/xml/PMC4364666.xml	MTT	56381 : 56384	CM	wth was determined using MTT. The values are means ± 
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	56475 : 56480	CM	Fig                      Hs738 CM prepared by culturing
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	56506 : 56511	CM	CM prepared by culturing Hs738 cells with or without 10
./___Corpus/Medline/xml/PMC4364666.xml	MEK	56540 : 56543	CM	ls with or without 10 μM MEK inhibitor I for 3 days w
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	56617 : 56622	CM	rated by gel filtration. MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	MTT	56732 : 56735	CM	wth was determined using MTT (left). The fractions wi
./___Corpus/Medline/xml/PMC4364666.xml	MEK	56897 : 56900	CM	 in which expressions in MEK inhibitor I-treated cell
./___Corpus/Medline/xml/PMC4364666.xml	MALDI-TOF-MS	56982 : 56994	CM	 analyzed by LC-MS/MS or MALDI-TOF-MS. LC-MS/MS analysis deduc
./___Corpus/Medline/xml/PMC4364666.xml	α-enolase	57048 : 57057	CM	AI-precursor protein and α-enolase and MALDI-TOF-MS deduced
./___Corpus/Medline/xml/PMC4364666.xml	MALDI-TOF-MS	57062 : 57074	CM	rotein and α-enolase and MALDI-TOF-MS deduced GAPDH.          
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57083 : 57088	CM	and MALDI-TOF-MS deduced GAPDH.                  (PDF) 
./___Corpus/Medline/xml/PMC4364666.xml	MEK	57184 : 57187	CM	ed with or without 10 μM MEK inhibitor I for 2 days (
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	57220 : 57225	CM	or I for 2 days (upper). Hs738 cells were cultured for 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57382 : 57387	CM	ured for 2 days (lower). GAPDH in the cultured supernat
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57541 : 57546	CM	d with human erythrocyte GAPDH for 3 days. Cell growth 
./___Corpus/Medline/xml/PMC4364666.xml	MTT	57592 : 57595	CM	wth was determined using MTT. The values are means ± 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57699 : 57704	CM	 of the value without hu GAPDH.                  (PDF) 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57811 : 57816	CM	ype (wt) and mutant (mt) GAPDH were detected by Western
./___Corpus/Medline/xml/PMC4364666.xml	anti-	57853 : 57858	CPR	ed by Western blot using anti-GAPDH and anti-FLAG antib
./___Corpus/Medline/xml/PMC4364666.xml	anti-	57868 : 57873	CPR	lot using anti-GAPDH and anti-FLAG antibodies (upper). 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57898 : 57903	CM	FLAG antibodies (upper). GAPDH enzyme activity of the r
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	57939 : 57944	CM	ivity of the recombinant GAPDH was measured. MKN-7 cell
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	57959 : 57964	CM	nant GAPDH was measured. MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58000 : 58005	CM	 cultured with wt and mt GAPDH for 3 days. Cell growth 
./___Corpus/Medline/xml/PMC4364666.xml	MTT	58051 : 58054	CM	wth was determined using MTT. The values are means ± 
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58158 : 58163	CM	 of the value without hu GAPDH. (B) Human recombinant w
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58226 : 58231	CM	 and deletion mutants of GAPDH were constructed using C
./___Corpus/Medline/xml/PMC4364666.xml	del1	58276 : 58280	CM	ing ClearColiBL21. GAPDH del1 lacks the C-terminal dom
./___Corpus/Medline/xml/PMC4364666.xml	C-	58292 : 58294	CPR	1. GAPDH del1 lacks the C-terminal domain, GAPDH del
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58310 : 58315	CM	s the C-terminal domain, GAPDH del2 lacks 4–81 amino ac
./___Corpus/Medline/xml/PMC4364666.xml	del2	58316 : 58320	CM	C-terminal domain, GAPDH del2 lacks 4–81 amino acids i
./___Corpus/Medline/xml/PMC4364666.xml	4–	58327 : 58329	CPR	domain, GAPDH del2 lacks 4–81 amino acids in the N-t
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	58332 : 58343	CM	n, GAPDH del2 lacks 4–81 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	58352 : 58354	CPR	4–81 amino acids in the N-terminal domain, and GAPDH
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58374 : 58379	CM	e N-terminal domain, and GAPDH del3 lacks 98–152 amino 
./___Corpus/Medline/xml/PMC4364666.xml	del3	58380 : 58384	CM	rminal domain, and GAPDH del3 lacks 98–152 amino acids
./___Corpus/Medline/xml/PMC4364666.xml	98–	58391 : 58394	CPR	in, and GAPDH del3 lacks 98–152 amino acids in the N-
./___Corpus/Medline/xml/PMC4364666.xml	amino acids	58398 : 58409	CM	 GAPDH del3 lacks 98–152 amino acids in the N-terminal domain
./___Corpus/Medline/xml/PMC4364666.xml	N-	58418 : 58420	CPR	–152 amino acids in the N-terminal domain. Estimated
./___Corpus/Medline/xml/PMC4364666.xml	del1	58493 : 58497	CM	.1, and 30.3 kDa for wt, del1, del2, and del3, respect
./___Corpus/Medline/xml/PMC4364666.xml	del2	58499 : 58503	CM	d 30.3 kDa for wt, del1, del2, and del3, respectively.
./___Corpus/Medline/xml/PMC4364666.xml	del3	58509 : 58513	CM	 for wt, del1, del2, and del3, respectively. They were
./___Corpus/Medline/xml/PMC4364666.xml	SDS-PAGE	58552 : 58560	CM	. They were separated by SDS-PAGE and assessed by CBB stai
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58619 : 58624	CPR	t) and Western blot with anti-FLAG antibody (right).   
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	58725 : 58730	CM	A) Effect of recombinant GAPDH on MKN-7 cells. MKN-7 ce
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	58734 : 58739	CM	 of recombinant GAPDH on MKN-7 cells. MKN-7 cells were 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	58747 : 58752	CM	nt GAPDH on MKN-7 cells. MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58904 : 58909	CPR	ions, immunostained with anti-FLAG and anti-mouse IgG1 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	58918 : 58923	CPR	ained with anti-FLAG and anti-mouse IgG1 Alexa Fluor 54
./___Corpus/Medline/xml/PMC4364666.xml	Alexa Fluor	58934 : 58945	CM	FLAG and anti-mouse IgG1 Alexa Fluor 546 antibodies, and anal
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	59023 : 59028	CM	 Scale bar is 20 μm. (B) MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59072 : 59077	CM	d with human erythrocyte GAPDH at 5 U/ml for 1 day (lef
./___Corpus/Medline/xml/PMC4364666.xml	MKN-74	59297 : 59303	CM	       Cell membranes of MKN-74 cells were incubated wit
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59370 : 59375	CM	an recombinant wild type GAPDH or human erythrocyte GAP
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59397 : 59402	CM	PDH or human erythrocyte GAPDH. The immunoprecipitates 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59500 : 59505	CPR	zed by Western blot with anti-E-cadherin antibody. No b
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59550 : 59555	CPR	 No band was detected by anti-integrin β1 antibody.    
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	59629 : 59634	CM	Fig                      MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59678 : 59683	CM	d with human erythrocyte GAPDH at 5 U/ml or recombinant
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59724 : 59729	CM	combinant wild type (wt) GAPDH at 5 μg/ml for the indic
./___Corpus/Medline/xml/PMC4364666.xml	mTOR-p70S6K	59766 : 59777	CM	for the indicated times. mTOR-p70S6K pathway was analyzed by 
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	59823 : 59828	CM	 by Western blot (left). MKN-7 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	59872 : 59877	CM	d with human erythrocyte GAPDH at 5 U/ml or anti-E-cadh
./___Corpus/Medline/xml/PMC4364666.xml	anti-	59891 : 59896	CPR	ocyte GAPDH at 5 U/ml or anti-E-cadherin antibody at 1 
./___Corpus/Medline/xml/PMC4364666.xml	GIST	60130 : 60134	CM	human gastric cancer and GIST were stained with anti-p
./___Corpus/Medline/xml/PMC4364666.xml	anti-phospho-STAT3	60153 : 60171	CM	d GIST were stained with anti-phospho-STAT3. Numbers in parentheses 
./___Corpus/Medline/xml/PMC4364666.xml	Myc	60349 : 60352	CM	(A) 293 cells expressing Myc-tagged wild-type E-cadhe
./___Corpus/Medline/xml/PMC4364666.xml	E-	60370 : 60372	CPR	ing Myc-tagged wild-type E-cadherin or its various e
./___Corpus/Medline/xml/PMC4364666.xml	E-	60567 : 60569	CPR	lot. All cells expressed E-cadherin or its mutants o
./___Corpus/Medline/xml/PMC4364666.xml	E-	60607 : 60609	CPR	ts mutants on membranes. E-cadherin has five extrace
./___Corpus/Medline/xml/PMC4364666.xml	EC1-EC5	60650 : 60657	CM	e extracellular repeats (EC1-EC5). The numbers above the 
./___Corpus/Medline/xml/PMC4364666.xml	amino acid	60703 : 60713	CM	the columns indicate the amino acid number, counting from th
./___Corpus/Medline/xml/PMC4364666.xml	P	60787 : 60788	CM	gion. S. signal peptide; P, propeptide; TM, transme
./___Corpus/Medline/xml/PMC4364666.xml	MKN-7	60916 : 60921	CM	5. (B) Cell membranes of MKN-7 cells or 293 cells expre
./___Corpus/Medline/xml/PMC4364666.xml	Myc	60952 : 60955	CM	 or 293 cells expressing Myc-tagged wild type E-cadhe
./___Corpus/Medline/xml/PMC4364666.xml	E-	60973 : 60975	CPR	ing Myc-tagged wild type E-cadherin or its various e
./___Corpus/Medline/xml/PMC4364666.xml	GAPDH	61075 : 61080	CM	d with human erythrocyte GAPDH. The immunoprecipitates 
./___Corpus/Medline/xml/PMC4364666.xml	anti-	61120 : 61125	CPR	cipitates generated with anti-GAPDH antibody were analy
./___Corpus/Medline/xml/PMC4364666.xml	anti-	61179 : 61184	CPR	by Western blotting with anti-Myc antibody. L, 1/100 of
./___Corpus/Medline/xml/PMC4364666.xml	Hs738	61285 : 61290	CM	Fig                      Hs738 cells were cultured with
./___Corpus/Medline/xml/PMC4364666.xml	SM-α-actin	61371 : 61381	CM	expressions of vimentin, SM-α-actin, and tubulin were analyz
./___Corpus/Medline/xml/PMC4364666.xml	tubulin	61387 : 61394	CM	imentin, SM-α-actin, and tubulin were analyzed by Western
./___Corpus/Medline/xml/PMC4364666.xml	MTT	61485 : 61488	CM	wth was determined using MTT (lower). The values are 
./___Corpus/Medline/xml/PMC4364666.xml	carboxylic acid	61618 : 61633	CM	        To a solution of carboxylic acid 2 (ref 36) (10.5 mg, 29.
./___Corpus/Medline/xml/PMC4364666.xml	DIPEA	61676 : 61681	CM	mg, 29.4 mmol) was added DIPEA (5.6 mL, 32.2 mmol) and 
./___Corpus/Medline/xml/PMC4364666.xml	HATU	61706 : 61710	CM	 (5.6 mL, 32.2 mmol) and HATU (12.2 mg, 32.1 mmol) at 
./___Corpus/Medline/xml/PMC4364666.xml	0°C	61735 : 61738	CM	 (12.2 mg, 32.1 mmol) at 0°C and the resulting mixtur
./___Corpus/Medline/xml/PMC4364666.xml	MEK	61815 : 61818	CM	 room temperature. Then, MEK inhibitor I 1 (10.0 mg, 
./___Corpus/Medline/xml/PMC4364666.xml	DMF	61857 : 61860	CM	 (10.0 mg, 26.7 mmol) in DMF (0.7 mL) was added to th
./___Corpus/Medline/xml/PMC4364666.xml	0°C	61899 : 61902	CM	added to the solution at 0°C, and the mixture was sti
./___Corpus/Medline/xml/PMC4364666.xml	TLC	62028 : 62031	CM	 purified by preparative TLC (16.7% MeOH/CHCl3) to gi
./___Corpus/Medline/xml/PMC4364666.xml	MeOH	62039 : 62043	CM	y preparative TLC (16.7% MeOH/CHCl3) to give the probe
./___Corpus/Medline/xml/PMC4364666.xml	CHCl3	62044 : 62049	CM	parative TLC (16.7% MeOH/CHCl3) to give the probe molec
./___Corpus/Medline/xml/PMC4364666.xml	olefin	62155 : 62161	CM	 of geometric isomers of olefin) as a colorless amorphou
./___Corpus/Medline/xml/PMC4364666.xml	carboxylic acid	62394 : 62409	CM	e preparation of 3 using carboxylic acid 4 (4.6 mL, 32.4 mmol), a
./___Corpus/Medline/xml/PMC4364666.xml	TLC	62461 : 62464	CM	 purified by preparative TLC (9.1% MeOH/CHCl3). DIPEA
./___Corpus/Medline/xml/PMC4364666.xml	MeOH	62471 : 62475	CM	by preparative TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diiso
./___Corpus/Medline/xml/PMC4364666.xml	CHCl3	62476 : 62481	CM	eparative TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diisopropyl
./___Corpus/Medline/xml/PMC4364666.xml	DIPEA	62484 : 62489	CM	e TLC (9.1% MeOH/CHCl3). DIPEA, N,N-diisopropylethylami
./___Corpus/Medline/xml/PMC4364666.xml	N,N-diisopropylethylamine	62491 : 62516	CM	9.1% MeOH/CHCl3). DIPEA, N,N-diisopropylethylamine; HATU: 1-[bis(dimethylam
./___Corpus/Medline/xml/PMC4364666.xml	HATU	62518 : 62522	CM	N-diisopropylethylamine; HATU: 1-[bis(dimethylamino)me
./___Corpus/Medline/xml/PMC4364666.xml	1-[bis(dimethylamino)methylene]	62524 : 62555	CM	opropylethylamine; HATU: 1-[bis(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b
./___Corpus/Medline/xml/PMC4364666.xml	1-	62555 : 62557	CPR	(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]p
./___Corpus/Medline/xml/PMC4364666.xml	1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate	62557 : 62618	CM	imethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate.                  (PDF) 
./___Corpus/Medline/xml/PMC4364666.xml	Dr	62689 : 62691	CM	                We thank Dr. I. Momose, Dr. D. Tatsu
./___Corpus/Medline/xml/PMC4364666.xml	Momose	62696 : 62702	CM	         We thank Dr. I. Momose, Dr. D. Tatsuda and Dr. 
./___Corpus/Medline/xml/PMC4364666.xml	Dr	62704 : 62706	CM	 We thank Dr. I. Momose, Dr. D. Tatsuda and Dr. K. N
./___Corpus/Medline/xml/PMC4364666.xml	Dr	62723 : 62725	CM	mose, Dr. D. Tatsuda and Dr. K. Nakae for helpful di
./___Corpus/Medline/xml/PMC4364666.xml	Dr	62764 : 62766	CM	 helpful discussions and Dr. R. Sawa, Dr. M. Iijima,
./___Corpus/Medline/xml/PMC4364666.xml	Dr	62777 : 62779	CM	ussions and Dr. R. Sawa, Dr. M. Iijima, and Y. Takah
./___Corpus/Medline/xml/PMC4364666.xml	Y	62796 : 62797	CM	Sawa, Dr. M. Iijima, and Y. Takahashi for analytica
./___Corpus/Medline/xml/PMC4364666.xml	SCADS	63189 : 63194	CM	an, for providing us the SCADS inhibitor kit. This stud
./___Corpus/Medline/xml/PMC4364666.xml	PGE2-TNFα-IL-6	63756 : 63770	CM	lls: Stimulation via the PGE2-TNFα-IL-6 Pathway and Inhibition v
./___Corpus/Medline/xml/PMC4372801.xml	Histone	30 : 37	CM	act                      Histone dacetylases (HDACs) are 
./___Corpus/Medline/xml/PMC4372801.xml	dacetylases	38 : 49	ASE	                 Histone dacetylases (HDACs) are a group of e
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	51 : 56	CM	    Histone dacetylases (HDACs) are a group of enzymes 
./___Corpus/Medline/xml/PMC4372801.xml	acetyl	93 : 99	CM	p of enzymes that remove acetyl groups from histones and
./___Corpus/Medline/xml/PMC4372801.xml	histones	112 : 120	CM	emove acetyl groups from histones and regulate expression 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	350 : 354	CM	e variety of inhibitors. HDAC inhibitors interfere wit
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	381 : 385	CM	nhibitors interfere with HDAC activity and regulate bi
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	507 : 511	CM	ncer cells. As a result, HDAC inhibitor-based therapie
./___Corpus/Medline/xml/PMC4372801.xml	FDA	600 : 603	CM	 treatment. To date, the FDA has approved three HDAC 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	623 : 627	CM	e FDA has approved three HDAC inhibitors for cutaneous
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	694 : 698	CM	l lymphoma and many more HDAC inhibitors are in differ
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	919 : 923	CM	rapeutically efficacious HDAC inhibitors, molecular mo
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	1159 : 1163	CM	or structural classes of HDAC inhibitors that are in c
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	1320 : 1324	CM	e to discover additional HDAC inhibitors with greater 
./___Corpus/Medline/xml/PMC4372801.xml	methylation	1652 : 1663	RN	odifications such as DNA methylation and post-translational h
./___Corpus/Medline/xml/PMC4372801.xml	histone	1687 : 1694	CM	n and post-translational histone acetylations that can al
./___Corpus/Medline/xml/PMC4372801.xml	acetylations	1695 : 1707	RN	st-translational histone acetylations that can alter DNA acces
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	1747 : 1756	CM	 DNA accessibilities and chromatin structures without alter
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	1827 : 1836	CM	uence. The basic unit of chromatin is the nucleosome, which
./___Corpus/Medline/xml/PMC4372801.xml	histone	1922 : 1929	CM	erhelix wrapped around a histone core consisting of two c
./___Corpus/Medline/xml/PMC4372801.xml	histones	1977 : 1985	CM	 copies each of the core histones [1]. Histones are the pr
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	2038 : 2047	CM	ry protein components of chromatin of five classes (H1, H2A
./___Corpus/Medline/xml/PMC4372801.xml	H1	2065 : 2067	CM	romatin of five classes (H1, H2A, H2B, H3 and H4). H
./___Corpus/Medline/xml/PMC4372801.xml	H2A	2069 : 2072	CM	tin of five classes (H1, H2A, H2B, H3 and H4). H1 is 
./___Corpus/Medline/xml/PMC4372801.xml	H2B	2074 : 2077	CM	f five classes (H1, H2A, H2B, H3 and H4). H1 is a lin
./___Corpus/Medline/xml/PMC4372801.xml	H3	2079 : 2081	CM	e classes (H1, H2A, H2B, H3 and H4). H1 is a linker 
./___Corpus/Medline/xml/PMC4372801.xml	H4	2086 : 2088	CM	es (H1, H2A, H2B, H3 and H4). H1 is a linker histone
./___Corpus/Medline/xml/PMC4372801.xml	H1	2091 : 2093	CM	1, H2A, H2B, H3 and H4). H1 is a linker histone and 
./___Corpus/Medline/xml/PMC4372801.xml	histone	2106 : 2113	CM	 and H4). H1 is a linker histone and the remaining are th
./___Corpus/Medline/xml/PMC4372801.xml	histones	2145 : 2153	CM	e remaining are the core histones. The core plays an impor
./___Corpus/Medline/xml/PMC4372801.xml	N-	2295 : 2297	CPR	ticle itself [2,3]. The N-terminal tails of core his
./___Corpus/Medline/xml/PMC4372801.xml	histones	2319 : 2327	CM	N-terminal tails of core histones are flexible and unstruc
./___Corpus/Medline/xml/PMC4372801.xml	histone	2487 : 2494	CM	that occur in DNA and in histone tails, chromatin can ado
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	2502 : 2511	CM	NA and in histone tails, chromatin can adopt different conf
./___Corpus/Medline/xml/PMC4372801.xml	histone	2701 : 2708	CM	 eight distinct types of histone post-translational modif
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	2750 : 2761	RN	al modifications, namely acetylation, methylation, phosphoryl
./___Corpus/Medline/xml/PMC4372801.xml	methylation	2763 : 2774	RN	ons, namely acetylation, methylation, phosphorylation, ubiqui
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	2776 : 2791	RN	cetylation, methylation, phosphorylation, ubiquitylation, sumoyla
./___Corpus/Medline/xml/PMC4372801.xml	ubiquitylation	2793 : 2807	RN	lation, phosphorylation, ubiquitylation, sumoylation, ADP ribosy
./___Corpus/Medline/xml/PMC4372801.xml	sumoylation	2809 : 2820	RN	ylation, ubiquitylation, sumoylation, ADP ribosylation, deami
./___Corpus/Medline/xml/PMC4372801.xml	ADP	2822 : 2825	CM	uitylation, sumoylation, ADP ribosylation, deaminatio
./___Corpus/Medline/xml/PMC4372801.xml	ribosylation	2826 : 2838	RN	lation, sumoylation, ADP ribosylation, deamination and proline
./___Corpus/Medline/xml/PMC4372801.xml	deamination	2840 : 2851	RN	ation, ADP ribosylation, deamination and proline isomerizatio
./___Corpus/Medline/xml/PMC4372801.xml	proline	2856 : 2863	CM	ylation, deamination and proline isomerization. It can be
./___Corpus/Medline/xml/PMC4372801.xml	histone amino	2995 : 3008	CM	ifications for which the histone amino terminal tails are the t
./___Corpus/Medline/xml/PMC4372801.xml	N-ε-lysine	3044 : 3054	CM	ails are the target. The N-ε-lysine acetylation and deacetyl
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3055 : 3066	RN	e target. The N-ε-lysine acetylation and deacetylation of his
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3071 : 3084	RN	ε-lysine acetylation and deacetylation of histone are controlle
./___Corpus/Medline/xml/PMC4372801.xml	histone	3088 : 3095	CM	ion and deacetylation of histone are controlled by two gr
./___Corpus/Medline/xml/PMC4372801.xml	histone	3137 : 3144	CM	y two groups of enzymes: histone acetyltransferase (HAT) 
./___Corpus/Medline/xml/PMC4372801.xml	acetyltransferase	3145 : 3162	CM	oups of enzymes: histone acetyltransferase (HAT) and histone deacet
./___Corpus/Medline/xml/PMC4372801.xml	HAT	3164 : 3167	CM	stone acetyltransferase (HAT) and histone deacetylase
./___Corpus/Medline/xml/PMC4372801.xml	histone	3173 : 3180	CM	tyltransferase (HAT) and histone deacetylase (HDAC). The 
./___Corpus/Medline/xml/PMC4372801.xml	deacetylase	3181 : 3192	CM	ferase (HAT) and histone deacetylase (HDAC). The balance betw
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	3194 : 3198	CM	and histone deacetylase (HDAC). The balance between ac
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3221 : 3232	RN	AC). The balance between acetylation and deacetylation of his
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3237 : 3250	RN	 between acetylation and deacetylation of histones or the rever
./___Corpus/Medline/xml/PMC4372801.xml	histones	3254 : 3262	CM	ion and deacetylation of histones or the reverse activitie
./___Corpus/Medline/xml/PMC4372801.xml	HATs	3292 : 3296	CM	he reverse activities of HATs and HDACs regulate gene 
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	3301 : 3306	CM	e activities of HATs and HDACs regulate gene expression
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	3340 : 3349	CM	 gene expression through chromatin modifications [4,5]. His
./___Corpus/Medline/xml/PMC4372801.xml	Histone	3371 : 3378	CM	tin modifications [4,5]. Histone acetylation by HAT plays
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3379 : 3390	RN	fications [4,5]. Histone acetylation by HAT plays a key role 
./___Corpus/Medline/xml/PMC4372801.xml	HAT	3394 : 3397	CM	. Histone acetylation by HAT plays a key role in tran
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3454 : 3467	RN	onal activation, whereas deacetylation of histones promotes tra
./___Corpus/Medline/xml/PMC4372801.xml	histones	3471 : 3479	CM	whereas deacetylation of histones promotes transcriptional
./___Corpus/Medline/xml/PMC4372801.xml	histone	3562 : 3569	CM	s. An excessive level of histone acetylation induces apop
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	3570 : 3581	RN	cessive level of histone acetylation induces apoptotic cell d
./___Corpus/Medline/xml/PMC4372801.xml	histone	3639 : 3646	CM	ereas excessive level of histone deacetylation has been l
./___Corpus/Medline/xml/PMC4372801.xml	deacetylation	3647 : 3660	RN	cessive level of histone deacetylation has been linked to cance
./___Corpus/Medline/xml/PMC4372801.xml	HAT	3768 : 3771	CM	ory genes. Disruption of HAT and HDAC activities has 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	3776 : 3780	CM	s. Disruption of HAT and HDAC activities has been asso
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	3873 : 3877	CM	ty of human cancers [5]. HDAC inhibitors cause an incr
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	3914 : 3924	RN	cause an increase of the acetylated level of histones, which
./___Corpus/Medline/xml/PMC4372801.xml	histones	3934 : 3942	CM	 the acetylated level of histones, which in turn promote t
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	4090 : 4094	CM	ype. Due to this effect, HDAC inhibitors have recently
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	4206 : 4210	CM	    2. Classification of HDAC Family                  
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	4269 : 4273	CM	e human genome, eighteen HDAC family members have been
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	4377 : 4382	CM	 their homology to yeast HDACs. Classes I, II and IV ar
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	4409 : 4413	CM	Classes I, II and IV are Zn2+-dependent metalloprotein
./___Corpus/Medline/xml/PMC4372801.xml	nicotinamide adenine dinucleotide	4464 : 4497	CM	, whereas Class III is a nicotinamide adenine dinucleotide (NAD+)-dependent enzyme.
./___Corpus/Medline/xml/PMC4372801.xml	NAD+	4499 : 4503	CM	de adenine dinucleotide (NAD+)-dependent enzyme. Class
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	4541 : 4546	CM	nzyme. Class I family of HDACs consists of HDAC1, 2, 3 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	4559 : 4564	CM	ily of HDACs consists of HDAC1, 2, 3 and 8 proteins sha
./___Corpus/Medline/xml/PMC4372801.xml	potassium	4631 : 4640	CM	ology with yeast reduced potassium dependency-3 (Rpd3), and
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	4736 : 4741	CM	s [6,7]. Class II family HDACs are homologous to the ye
./___Corpus/Medline/xml/PMC4372801.xml	histone	4770 : 4777	CM	 homologous to the yeast histone deacetylases 1 (Hda1) an
./___Corpus/Medline/xml/PMC4372801.xml	deacetylases	4778 : 4790	ASE	ous to the yeast histone deacetylases 1 (Hda1) and are further
./___Corpus/Medline/xml/PMC4372801.xml	Hda1	4794 : 4798	CM	 histone deacetylases 1 (Hda1) and are further divided
./___Corpus/Medline/xml/PMC4372801.xml	HDAC4	4855 : 4860	CM	wo subgroups, Class IIA (HDAC4, 5, 7 and 9) and Class I
./___Corpus/Medline/xml/PMC4372801.xml	HDAC6	4889 : 4894	CM	 7 and 9) and Class IIB (HDAC6 and 10). Unlike Class I 
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	4926 : 4931	CM	). Unlike Class I family HDACs, Class II family HDACS a
./___Corpus/Medline/xml/PMC4372801.xml	HDACS	4949 : 4954	CM	y HDACs, Class II family HDACS are primarily localized 
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	5024 : 5039	RN	wever depending upon the phosphorylation status they can be shutt
./___Corpus/Medline/xml/PMC4372801.xml	HDAC11	5109 : 5115	CM	plasm and nucleus [8,9]. HDAC11 is the only member of Cl
./___Corpus/Medline/xml/PMC4372801.xml	HDAC11	5266 : 5272	CM	 Class I and II enzymes. HDAC11 has been implicated in t
./___Corpus/Medline/xml/PMC4372801.xml	OX40L	5349 : 5354	CM	n-10 expression [10,11], OX40L surface expression [12] 
./___Corpus/Medline/xml/PMC4372801.xml	Cdt1	5434 : 5438	CM	ication licensing factor Cdt1 [13]. Class III family c
./___Corpus/Medline/xml/PMC4372801.xml	Sir2	5564 : 5568	CM	information regulator-2 (Sir2) protein. Hence Class II
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	5602 : 5607	CM	. Hence Class III family HDACs are also known as sirtui
./___Corpus/Medline/xml/PMC4372801.xml	SIRT1	5685 : 5690	CM	mbers of this family are SIRT1 through SIRT7. SIRTs are
./___Corpus/Medline/xml/PMC4372801.xml	SIRT7	5699 : 5704	CM	family are SIRT1 through SIRT7. SIRTs are located in th
./___Corpus/Medline/xml/PMC4372801.xml	SIRT1	5871 : 5876	CM	vided into four classes (SIRT1, SIRT2 and SIRT3 belong 
./___Corpus/Medline/xml/PMC4372801.xml	SIRT2	5878 : 5883	CM	nto four classes (SIRT1, SIRT2 and SIRT3 belong to Clas
./___Corpus/Medline/xml/PMC4372801.xml	SIRT3	5888 : 5893	CM	lasses (SIRT1, SIRT2 and SIRT3 belong to Class I, a sol
./___Corpus/Medline/xml/PMC4372801.xml	SIRT4	5930 : 5935	CM	lass I, a sole member of SIRT4 to Class II, SIRT5 to Cl
./___Corpus/Medline/xml/PMC4372801.xml	SIRT5	5949 : 5954	CM	er of SIRT4 to Class II, SIRT5 to Class III, and SIRT6 
./___Corpus/Medline/xml/PMC4372801.xml	SIRT6	5973 : 5978	CM	 SIRT5 to Class III, and SIRT6 and SIRT7 to Class IV) [
./___Corpus/Medline/xml/PMC4372801.xml	SIRT7	5983 : 5988	CM	Class III, and SIRT6 and SIRT7 to Class IV) [14,15]. Si
./___Corpus/Medline/xml/PMC4372801.xml	16–	6183 : 6186	CPR	rative related diseases [16–19]. A recent review has 
./___Corpus/Medline/xml/PMC4372801.xml	SIRT1	6262 : 6267	CM	 of sirtuins, especially SIRT1 and SIRT2, for cancer th
./___Corpus/Medline/xml/PMC4372801.xml	SIRT2	6272 : 6277	CM	ns, especially SIRT1 and SIRT2, for cancer therapy agen
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	6454 : 6459	CM	tructure availability of HDACs. This review focuses on 
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	6548 : 6553	CM	al-dependent “classical” HDACs (Classes I, II, and IV) 
./___Corpus/Medline/xml/PMC4372801.xml	anti-	6609 : 6614	CPR	re in clinical trials as anti-cancer agents, and differ
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	6690 : 6694	CM	s for the development of HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	Histone	6727 : 6734	CM	ors.                  3. Histone Deacetylases and Cancer 
./___Corpus/Medline/xml/PMC4372801.xml	Deacetylases	6735 : 6747	CM	              3. Histone Deacetylases and Cancer              
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	6780 : 6785	CM	cer                      HDACs play a major role in the
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	6889 : 6898	CM	r effects on the compact chromatin structure. In recent yea
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	6927 : 6932	CM	ucture. In recent years, HDACs have become promising th
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	7075 : 7086	RN	h cancer. Alterations in acetylation levels and overexpressio
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	7124 : 7129	CM	verexpression of various HDACs in many cancer cell line
./___Corpus/Medline/xml/PMC4372801.xml	histone	7255 : 7262	CM	ational modifications to histone H4 in a comprehensive pa
./___Corpus/Medline/xml/PMC4372801.xml	H4	7263 : 7265	CM	modifications to histone H4 in a comprehensive panel
./___Corpus/Medline/xml/PMC4372801.xml	monoacetylation	7376 : 7391	RN	ests that global loss of monoacetylation at Lys16 of histone H4 i
./___Corpus/Medline/xml/PMC4372801.xml	Lys16	7395 : 7400	CM	ss of monoacetylation at Lys16 of histone H4 is a commo
./___Corpus/Medline/xml/PMC4372801.xml	histone	7404 : 7411	CM	oacetylation at Lys16 of histone H4 is a common hallmark 
./___Corpus/Medline/xml/PMC4372801.xml	H4	7412 : 7414	CM	tion at Lys16 of histone H4 is a common hallmark of 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	7490 : 7494	CM	ating a critical role of HDAC activity in establishing
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	7597 : 7602	CM	ions where the classical HDACs are overexpressed, inhib
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	7636 : 7641	CM	expressed, inhibitors of HDACs were found to be effecti
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	7797 : 7801	CM	ncer therapeutic agents. HDAC inhibitors have the pote
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	7917 : 7921	CM	th and induce apoptosis. HDAC inhibitors can not only 
./___Corpus/Medline/xml/PMC4372801.xml	histones	7953 : 7961	CM	tors can not only target histones but have the ability to 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	8186 : 8190	CM	 have been identified as HDAC substrates with diverse 
./___Corpus/Medline/xml/PMC4372801.xml	E2F	8277 : 8280	CM	, transcription factors (E2F, p53, c-Myc, NF-κB), hyp
./___Corpus/Medline/xml/PMC4372801.xml	p53	8282 : 8285	CM	nscription factors (E2F, p53, c-Myc, NF-κB), hypoxia-
./___Corpus/Medline/xml/PMC4372801.xml	c-Myc	8287 : 8292	CM	ption factors (E2F, p53, c-Myc, NF-κB), hypoxia-inducib
./___Corpus/Medline/xml/PMC4372801.xml	NF-κB	8294 : 8299	CM	actors (E2F, p53, c-Myc, NF-κB), hypoxia-inducible fact
./___Corpus/Medline/xml/PMC4372801.xml	estrogen	8345 : 8353	CM	factor 1 alpha (HIF-1α), estrogen receptor (ER α), androge
./___Corpus/Medline/xml/PMC4372801.xml	ER	8364 : 8366	CM	-1α), estrogen receptor (ER α), androgen receptor (A
./___Corpus/Medline/xml/PMC4372801.xml	androgen	8371 : 8379	CM	strogen receptor (ER α), androgen receptor (AR), MyoD, Cha
./___Corpus/Medline/xml/PMC4372801.xml	Ku70	8477 : 8481	CM	7), DNA repair proteins (Ku70), α-tubulin, β-catenin, 
./___Corpus/Medline/xml/PMC4372801.xml	α-tubulin	8484 : 8493	CM	 repair proteins (Ku70), α-tubulin, β-catenin, retinoblasto
./___Corpus/Medline/xml/PMC4372801.xml	β-catenin	8495 : 8504	CM	teins (Ku70), α-tubulin, β-catenin, retinoblastoma protein 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	8642 : 8646	CM	 of multiple pathways by HDAC inhibitors and their lac
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	8818 : 8822	CM	udies several classes of HDAC inhibitors demonstrated 
./___Corpus/Medline/xml/PMC4372801.xml	26–	8977 : 8980	CPR	ipheral T-cell lymphoma [26–29].                     
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	9038 : 9042	CM	          To date, three HDAC inhibitors have been app
./___Corpus/Medline/xml/PMC4372801.xml	FDA	9132 : 9135	CM	and Drug Administration (FDA). The first drug, Vorino
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	9166 : 9170	CM	 first drug, Vorinostat (SAHA, Zolina), developed by M
./___Corpus/Medline/xml/PMC4372801.xml	Zolina	9172 : 9178	CM	 drug, Vorinostat (SAHA, Zolina), developed by Merck & C
./___Corpus/Medline/xml/PMC4372801.xml	Co	9202 : 9204	CM	a), developed by Merck & Co. Inc. was approved in Oc
./___Corpus/Medline/xml/PMC4372801.xml	Inc	9206 : 9209	CM	developed by Merck & Co. Inc. was approved in October
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	9292 : 9296	CM	taneous T-Cell Lymphoma (CTCL), a rare type of non-Hod
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	9412 : 9427	CM	 trichostatin A (TSA), a hydroxamic acid-containing natural produ
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	9481 : 9485	CM	hat was found to possess HDAC inhibitor activity and o
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	9565 : 9575	CM	l drug. The second drug, romidepsin (Istodax, FK228, {"type"
./___Corpus/Medline/xml/PMC4372801.xml	FK228	9586 : 9591	CM	ug, romidepsin (Istodax, FK228, {"type":"entrez-nucleot
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	9842 : 9852	CM	ment of T-cell lymphoma. Romidepsin is a unique natural prod
./___Corpus/Medline/xml/PMC4372801.xml	Chromobacterium	9911 : 9926	CM	ted from the cultures of Chromobacterium violaceum, a Gram negati
./___Corpus/Medline/xml/PMC4372801.xml	bacterium	9954 : 9963	CM	olaceum, a Gram negative bacterium isolated from a Japanese
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	10021 : 10031	CM	mple [30]. In June 2011, romidepsin was also approved for pe
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	10082 : 10086	CM	ipheral T-cell lymphoma (PTCL) in patients who have re
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	10453 : 10457	CM	number of small molecule HDAC inhibitors have been sub
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acids	10654 : 10670	CM	rent classes, comprising hydroxamic acids, benzamides, cyclic pept
./___Corpus/Medline/xml/PMC4372801.xml	benzamides	10672 : 10682	CM	rising hydroxamic acids, benzamides, cyclic peptides and sho
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	10716 : 10727	CM	peptides and short-chain fatty acids [32]. Vorinostat and bel
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	10774 : 10789	CM	belinostat belong to the hydroxamic acid class, and romidepsin is
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	10801 : 10811	CM	droxamic acid class, and romidepsin is a member of the cycli
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	10887 : 10891	CM	widely explored class of HDAC inhibitors that have ent
./___Corpus/Medline/xml/PMC4372801.xml	anti-	10957 : 10962	CPR	l or clinical studies as anti-cancer agents are the hyd
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	10984 : 10999	CM	ti-cancer agents are the hydroxamic acid-based compounds. Besides
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	11070 : 11085	CM	ostat, some of the novel hydroxamic acid based HDACi that are in 
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	11197 : 11208	CM	1), pracinostat (SB939), resminostat (RAS2410, 4SC-201), givi
./___Corpus/Medline/xml/PMC4372801.xml	RAS2410	11210 : 11217	CM	at (SB939), resminostat (RAS2410, 4SC-201), givinostat (I
./___Corpus/Medline/xml/PMC4372801.xml	4SC-201	11219 : 11226	CM	), resminostat (RAS2410, 4SC-201), givinostat (ITF2357), 
./___Corpus/Medline/xml/PMC4372801.xml	ITF2357	11241 : 11248	CM	0, 4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	11279 : 11291	CM	sinostat (JNJ-26481585), panobinostat (LBH589) and CUDC-101 [3
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	11335 : 11339	CM	101 [33]. Interestingly, HDAC inhibitors share common 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	11483 : 11487	CM	c channel of the enzyme. HDAC inhibitors generally con
./___Corpus/Medline/xml/PMC4372801.xml	zinc	11598 : 11602	CM	acophore features: (1) a zinc chelating group; (2) a s
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	11806 : 11810	CM	of natural and synthetic HDAC inhibitors have been cha
./___Corpus/Medline/xml/PMC4372801.xml	histone	12007 : 12014	CM	part by the induction of histone acetylation where the ch
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	12015 : 12026	RN	the induction of histone acetylation where the chromatin conf
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	12037 : 12046	CM	ne acetylation where the chromatin configuration adopts a p
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	12332 : 12336	CM	 of different classes of HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	12429 : 12433	CM	     To date, only three HDAC inhibitors have been app
./___Corpus/Medline/xml/PMC4372801.xml	FDA	12471 : 12474	CM	ave been approved by the FDA for the treatments of CT
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	12497 : 12501	CM	DA for the treatments of CTCL (vorinostat (SAHA) and r
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	12515 : 12519	CM	nts of CTCL (vorinostat (SAHA) and romidepsin (Istodax
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	12525 : 12535	CM	L (vorinostat (SAHA) and romidepsin (Istodax)) and PTCL (bel
./___Corpus/Medline/xml/PMC4372801.xml	Istodax	12537 : 12544	CM	t (SAHA) and romidepsin (Istodax)) and PTCL (belinostat (
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	12551 : 12555	CM	omidepsin (Istodax)) and PTCL (belinostat (Beleodaq) a
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	12583 : 12593	CM	elinostat (Beleodaq) and romidepsin). Currently all three dr
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	12969 : 12984	CM	    FDA approval of this hydroxamic acid based drug for the treat
./___Corpus/Medline/xml/PMC4372801.xml	CCTL	13044 : 13048	CM	taneous manifestation of CCTL in patients with progres
./___Corpus/Medline/xml/PMC4372801.xml	IB	13189 : 13191	CM	4 patients who had stage IB or higher CTCL. The obje
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	13202 : 13206	CM	o had stage IB or higher CTCL. The objective response 
./___Corpus/Medline/xml/PMC4372801.xml	temozolomide	13673 : 13685	CM	stat in combination with temozolomide and radiotherapy are cur
./___Corpus/Medline/xml/PMC4372801.xml	anti-	14039 : 14044	CPR	wed potent apoptotic and anti-proliferative effect in b
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylation	14303 : 14318	RN	tat increased the IGF-IR phosphorylation, up-regulated PTEN and p
./___Corpus/Medline/xml/PMC4372801.xml	PTEN	14333 : 14337	CM	horylation, up-regulated PTEN and p21 expression, and 
./___Corpus/Medline/xml/PMC4372801.xml	p21	14342 : 14345	CM	n, up-regulated PTEN and p21 expression, and reduced 
./___Corpus/Medline/xml/PMC4372801.xml	D1	14385 : 14387	CM	d reduced p53 and cyclin D1 levels. In type II cell 
./___Corpus/Medline/xml/PMC4372801.xml	p21	14454 : 14457	CM	 up-regulated IGF-IR and p21 expression, and down-reg
./___Corpus/Medline/xml/PMC4372801.xml	AKT	14513 : 14516	CM	 the expression of total AKT, PTEN and cyclin D1. Int
./___Corpus/Medline/xml/PMC4372801.xml	PTEN	14518 : 14522	CM	expression of total AKT, PTEN and cyclin D1. Interesti
./___Corpus/Medline/xml/PMC4372801.xml	cyclin	14527 : 14533	CM	n of total AKT, PTEN and cyclin D1. Interestingly, vorin
./___Corpus/Medline/xml/PMC4372801.xml	hyperacetylated	14564 : 14579	CM	nterestingly, vorinostat hyperacetylated histone H3 in both type 
./___Corpus/Medline/xml/PMC4372801.xml	histone	14580 : 14587	CM	rinostat hyperacetylated histone H3 in both type I and ty
./___Corpus/Medline/xml/PMC4372801.xml	histone	14670 : 14677	CM	es, implying the role of histone H3 in endometrial cancer
./___Corpus/Medline/xml/PMC4372801.xml	murine	14930 : 14936	CM	ost frequent [39,40]. In murine and human lung cancer ce
./___Corpus/Medline/xml/PMC4372801.xml	cyclin E	15076 : 15084	CM	ll growth, cyclin D1 and cyclin E expressions, but increas
./___Corpus/Medline/xml/PMC4372801.xml	histone	15128 : 15135	CM	ncreased p27 expression, histone acetylation and apoptosi
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	15136 : 15147	RN	 p27 expression, histone acetylation and apoptosis [41]. Unde
./___Corpus/Medline/xml/PMC4372801.xml	vitro	15277 : 15282	CM	reased colonogenicity in vitro, and inhibited tumor gro
./___Corpus/Medline/xml/PMC4372801.xml	CHOP	15410 : 15414	CM	stat in combination with CHOP (cyclophosphamide, doxor
./___Corpus/Medline/xml/PMC4372801.xml	cyclophosphamide	15416 : 15432	CM	n combination with CHOP (cyclophosphamide, doxorubicin, vincristin
./___Corpus/Medline/xml/PMC4372801.xml	doxorubicin	15434 : 15445	CM	 CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone
./___Corpus/Medline/xml/PMC4372801.xml	vincristine	15447 : 15458	CM	hosphamide, doxorubicin, vincristine, prednisone) that exhibi
./___Corpus/Medline/xml/PMC4372801.xml	prednisone	15460 : 15470	CM	oxorubicin, vincristine, prednisone) that exhibits poor prog
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	15570 : 15574	CM	 patients with untreated PTCL [43]. Vorinostat has als
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	15962 : 15966	CM	ibits Class I, II and IV HDAC proteins, but not the NA
./___Corpus/Medline/xml/PMC4372801.xml	NAD+	15989 : 15993	CM	AC proteins, but not the NAD+-dependent Class III HDAC
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	16014 : 16018	CM	NAD+-dependent Class III HDAC [45–47].                
./___Corpus/Medline/xml/PMC4372801.xml	45–	16020 : 16023	CPR	ependent Class III HDAC [45–47].                  4.2
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	16050 : 16060	CM	].                  4.2. Romidepsin (Depsipeptide, ISTODAX) 
./___Corpus/Medline/xml/PMC4372801.xml	ISTODAX	16076 : 16083	CM	omidepsin (Depsipeptide, ISTODAX)                      Th
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	16117 : 16121	CM	              The second HDAC inhibitor approved for t
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	16162 : 16166	CM	ved for the treatment of CTCL was based on two large p
./___Corpus/Medline/xml/PMC4372801.xml	NCI	16249 : 16252	CM	ional study based at the NCI in the US (71 patients),
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	16440 : 16450	CM	was 34% in both studies. Romidepsin also induced complete an
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	16535 : 16539	CM	h relapsed or refractory PTCL across all major PTCL su
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	16557 : 16561	CM	ry PTCL across all major PTCL subtypes, regardless of 
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	16708 : 16718	CM	approval of single agent romidepsin for the treatment of rel
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	16763 : 16767	CM	f relapsed or refractory PTCL in the US [48]. Similarl
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	16839 : 16843	CM	rolling 47 patients with PTCL of various subtypes incl
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	16874 : 16878	CM	rious subtypes including PTCL NOS, angioimmunoblastic,
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	17042 : 17052	CM	sponse rate of 38% [49]. Romidepsin was also implicated in i
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17129 : 17134	CM	-small cell lung cancer (NSCLC) cells. A recent study c
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	17173 : 17183	CM	ent study concluded that romidepsin and bortezomib cooperati
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	17188 : 17198	CM	uded that romidepsin and bortezomib cooperatively inhibit A5
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17226 : 17231	CM	operatively inhibit A549 NSCLC cell proliferation by al
./___Corpus/Medline/xml/PMC4372801.xml	histone	17267 : 17274	CM	feration by altering the histone acetylation status, expr
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	17275 : 17286	RN	 by altering the histone acetylation status, expression of ce
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	17384 : 17394	CM	s [50]. Investigation of romidepsin for the treatment of inf
./___Corpus/Medline/xml/PMC4372801.xml	IBC	17565 : 17568	CM	y induced destruction of IBC tumor emboli and lymphat
./___Corpus/Medline/xml/PMC4372801.xml	Romidepsin	17624 : 17634	CM	cular architecture [51]. Romidepsin, either as a single agen
./___Corpus/Medline/xml/PMC4372801.xml	SUM149	17795 : 17801	CM	iple sites formed by the SUM149 IBC cell line in the Mar
./___Corpus/Medline/xml/PMC4372801.xml	IBC	17802 : 17805	CM	tes formed by the SUM149 IBC cell line in the Mary-X 
./___Corpus/Medline/xml/PMC4372801.xml	depsipeptide	17871 : 17883	CM	l [51]. A combination of depsipeptide and gemcitabine was test
./___Corpus/Medline/xml/PMC4372801.xml	gemcitabine	17888 : 17899	CM	tion of depsipeptide and gemcitabine was tested in patients w
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	17980 : 17985	CM	ding pancreatic, breast, NSCLC and ovarian and the stud
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18048 : 18058	CM	a dose level of 12 mg/m2 romidepsin and 88 mg/m2 gemcitabine
./___Corpus/Medline/xml/PMC4372801.xml	gemcitabine	18072 : 18083	CM	 romidepsin and 88 mg/m2 gemcitabine for phase II trial [52].
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18135 : 18145	CM	n another phase I trial, romidepsin was evaluated in patient
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	18321 : 18331	CM	g to clinicaltrials.gov, romidepsin is currently being evalu
./___Corpus/Medline/xml/PMC4372801.xml	BELIEF	18638 : 18644	CM	multi-center, single arm BELIEF trial of 120 evaluable p
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	18682 : 18686	CM	 evaluable patients with PTCL that was refractory or h
./___Corpus/Medline/xml/PMC4372801.xml	PTCL	18796 : 18800	CM	histologically confirmed PTCL (n = 120), the overall r
./___Corpus/Medline/xml/PMC4372801.xml	FDA	18870 : 18873	CM	8%. Similar to other two FDA approved drugs, belinost
./___Corpus/Medline/xml/PMC4372801.xml	platinum	19255 : 19263	CM	belinostat in women with platinum resistant epithelial can
./___Corpus/Medline/xml/PMC4372801.xml	OEC	19293 : 19296	CM	stant epithelial cancer (OEC) and micropapillary (LMP
./___Corpus/Medline/xml/PMC4372801.xml	MDS	19742 : 19745	CM	yelodysplastic syndrome (MDS), a cancer in which the 
./___Corpus/Medline/xml/PMC4372801.xml	platinum	20062 : 20070	CM	 recurrent or persistent platinum-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20172 : 20183	CM	stat in combination with carboplatin [59]. The overall respon
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20259 : 20270	CM	ddition of belinostat to carboplatin had little activity in a
./___Corpus/Medline/xml/PMC4372801.xml	platinum	20296 : 20304	CM	had little activity in a platinum-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4372801.xml	carboplatin	20417 : 20428	CM	sted in combination with carboplatin and paclitaxel by enroll
./___Corpus/Medline/xml/PMC4372801.xml	OEC	20664 : 20667	CM	enefits in patients with OEC. In patients with relaps
./___Corpus/Medline/xml/PMC4372801.xml	AML	20885 : 20888	CM	ngle agent is minimal in AML patients [61]. A phase 1
./___Corpus/Medline/xml/PMC4372801.xml	cisplatin	20957 : 20966	CM	stat in combination with cisplatin (P), doxorubicin (A), an
./___Corpus/Medline/xml/PMC4372801.xml	P	20968 : 20969	CM	bination with cisplatin (P), doxorubicin (A), and c
./___Corpus/Medline/xml/PMC4372801.xml	doxorubicin	20972 : 20983	CM	tion with cisplatin (P), doxorubicin (A), and cyclophosphamid
./___Corpus/Medline/xml/PMC4372801.xml	cyclophosphamide	20993 : 21009	CM	P), doxorubicin (A), and cyclophosphamide (C) in thymic epithelial
./___Corpus/Medline/xml/PMC4372801.xml	PAC	21092 : 21095	CM	stat in combination with PAC was active and feasible 
./___Corpus/Medline/xml/PMC4372801.xml	PLC	21214 : 21217	CM	ar carcinoma cell lines (PLC/PRF/5, Hep3B and HepG2) 
./___Corpus/Medline/xml/PMC4372801.xml	PRF	21218 : 21221	CM	arcinoma cell lines (PLC/PRF/5, Hep3B and HepG2) show
./___Corpus/Medline/xml/PMC4372801.xml	Hep3B	21225 : 21230	CM	a cell lines (PLC/PRF/5, Hep3B and HepG2) showed that i
./___Corpus/Medline/xml/PMC4372801.xml	histone	21319 : 21326	CM	endent manner and induce histone acetylation in all three
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	21327 : 21338	RN	anner and induce histone acetylation in all three cell lines 
./___Corpus/Medline/xml/PMC4372801.xml	all-trans-retinoic acid	21449 : 21472	CM	 and in combination with all-trans-retinoic acid was characterized in pro
./___Corpus/Medline/xml/PMC4372801.xml	HL-60	21517 : 21522	CM	n promyelocytic leukemia HL-60 and NB4 cell lines, wher
./___Corpus/Medline/xml/PMC4372801.xml	NB4	21527 : 21530	CM	cytic leukemia HL-60 and NB4 cell lines, where belino
./___Corpus/Medline/xml/PMC4372801.xml	G0	21662 : 21664	CM	cell cycle arrest at the G0/G1 or the S transition p
./___Corpus/Medline/xml/PMC4372801.xml	G1	21665 : 21667	CM	l cycle arrest at the G0/G1 or the S transition phas
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	21750 : 21765	CM	             While three hydroxamic acid derivatives as HDAC inhi
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	21781 : 21785	CM	amic acid derivatives as HDAC inhibitors have been cli
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	21853 : 21857	CM	the indication is mainly CTCL, not any solid tumor for
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	22058 : 22062	CM	with regard to using the HDAC inhibitors for treatment
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	22159 : 22163	CM	ap limits the utility of HDAC inhibitors, but more imp
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	22358 : 22362	CM	   The exact reasons why HDAC inhibitors are more effe
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	22721 : 22725	CM	 5. Different Classes of HDAC Inhibitors 5.1. Hydroxam
./___Corpus/Medline/xml/PMC4372801.xml	Hydroxamic Acid	22742 : 22757	CM	 of HDAC Inhibitors 5.1. Hydroxamic Acid Derivatives             
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	22845 : 22860	CM	studies established that hydroxamic acid-based compound vorinosta
./___Corpus/Medline/xml/PMC4372801.xml	CTCL	22922 : 22926	CM	lerated in patients with CTCL, and observed promising 
./___Corpus/Medline/xml/PMC4372801.xml	anti-	22951 : 22956	CPR	, and observed promising anti-cancer activities in diff
./___Corpus/Medline/xml/PMC4372801.xml	36,65–	23104 : 23110	CPR	ogical and solid tumors [36,65–67]. Vorinostat was also 
./___Corpus/Medline/xml/PMC4372801.xml	anti-	23298 : 23303	CPR	 [68]. Given the diverse anti-cancer activities of vori
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	23373 : 23388	CM	has been made to explore hydroxamic acid derivatives as potential
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	23487 : 23502	CM	past several years, many hydroxamic acid derivative based HDACis 
./___Corpus/Medline/xml/PMC4372801.xml	anti-	23576 : 23581	CPR	l or clinical studies as anti-cancer agents with promis
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	23655 : 23666	CM	bexinostat, pracinostat, resminostat, givinostat, panobinosta
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	23680 : 23692	CM	resminostat, givinostat, panobinostat, and CUDC-101. These HDA
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	23714 : 23718	CM	tat, and CUDC-101. These HDAC inhibitors are described
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	23858 : 23869	CM	  Abexinostat is a novel hydroxamate-based HDACi that showed 
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	24022 : 24032	CM	the proteasome inhibitor bortezomib, abexinostat was tested 
./___Corpus/Medline/xml/PMC4372801.xml	caspase-3	24140 : 24149	CM	s showed the cleavage of caspase-3 and PARP, indicating apo
./___Corpus/Medline/xml/PMC4372801.xml	PARP	24154 : 24158	CM	leavage of caspase-3 and PARP, indicating apoptosis as
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	24348 : 24358	CM	ation of abexinostat and bortezomib. This oral pan-HDACi was
./___Corpus/Medline/xml/PMC4372801.xml	PCYC-402	24470 : 24478	CM	e agent phase I studies (PCYC-402 and CL1-78454-002), resu
./___Corpus/Medline/xml/PMC4372801.xml	pazopanib	24952 : 24961	CM	apy. In a phase I study, pazopanib (PAZ: a tyrosine kinase 
./___Corpus/Medline/xml/PMC4372801.xml	tyrosine	24970 : 24978	CM	study, pazopanib (PAZ: a tyrosine kinase inhibitor approve
./___Corpus/Medline/xml/PMC4372801.xml	ACSO	25156 : 25160	CM	results presented at the ACSO annual meeting 2014 show
./___Corpus/Medline/xml/PMC4372801.xml	cisplatin	25512 : 25521	CM	stat in combination with cisplatin in patients with advance
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	25798 : 25809	CM	  Pracinostat is another hydroxamate-based HDAC inhibitor for
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	25816 : 25820	CM	nother hydroxamate-based HDAC inhibitor for which clin
./___Corpus/Medline/xml/PMC4372801.xml	MF	26101 : 26103	CM	ctivity in patients with MF [72]. In another phase I
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	26276 : 26286	RN	relationship between the acetylated histone H3 changes and d
./___Corpus/Medline/xml/PMC4372801.xml	histone	26287 : 26294	CM	p between the acetylated histone H3 changes and dose leve
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	26463 : 26474	CM	                  5.1.3. Resminostat                      Res
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	26496 : 26507	CM	tat                      Resminostat was evaluated in a pharm
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	26712 : 26723	CM	 molar concentrations of resminostat abrogated cell growth an
./___Corpus/Medline/xml/PMC4372801.xml	melphalan	26890 : 26899	CM	used in combination with melphalan, bortezomib and S-2209 [
./___Corpus/Medline/xml/PMC4372801.xml	bortezomib	26901 : 26911	CM	bination with melphalan, bortezomib and S-2209 [76]. In a Ph
./___Corpus/Medline/xml/PMC4372801.xml	S-2209	26916 : 26922	CM	elphalan, bortezomib and S-2209 [76]. In a Phase II SAPH
./___Corpus/Medline/xml/PMC4372801.xml	SAPHIRE	26943 : 26950	CM	2209 [76]. In a Phase II SAPHIRE trial, resminostat was a
./___Corpus/Medline/xml/PMC4372801.xml	resminostat	26958 : 26969	CM	 Phase II SAPHIRE trial, resminostat was also tested in relap
./___Corpus/Medline/xml/PMC4372801.xml	PET	27161 : 27164	CM	ron emission tomography (PET/CT). This study achieved
./___Corpus/Medline/xml/PMC4372801.xml	CT	27165 : 27167	CM	emission tomography (PET/CT). This study achieved cl
./___Corpus/Medline/xml/PMC4372801.xml	HL	27239 : 27241	CM	s in relapsed/refractory HL patients and showed exce
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	27331 : 27342	CM	ated patient population. Resminostat was also tried in patien
./___Corpus/Medline/xml/PMC4372801.xml	HCC	27410 : 27413	CM	epatocellular carcinoma (HCC), either alone or in com
./___Corpus/Medline/xml/PMC4372801.xml	sorafenib	27452 : 27461	CM	e or in combination with sorafenib [79]. The combination tr
./___Corpus/Medline/xml/PMC4372801.xml	HCC	27586 : 27589	CM	8.1 months) for advanced HCC patients who had develop
./___Corpus/Medline/xml/PMC4372801.xml	sorafenib	27660 : 27669	CM	disease under first-line sorafenib therapy. Resminostat is 
./___Corpus/Medline/xml/PMC4372801.xml	Resminostat	27679 : 27690	CM	-line sorafenib therapy. Resminostat is also in clinical tria
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	27928 : 27943	CM	         Givinostat is a hydroxamic acid-containing HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	27955 : 27959	CM	droxamic acid-containing HDAC inhibitor which has show
./___Corpus/Medline/xml/PMC4372801.xml	JAK2V617F	28190 : 28199	CM	inostat in patients with JAK2V617F positive myeloproliferat
./___Corpus/Medline/xml/PMC4372801.xml	MPN	28239 : 28242	CM	proliferative neoplasms (MPN), a type of blood cancer
./___Corpus/Medline/xml/PMC4372801.xml	MPN	28415 : 28418	CM	igation in patients with MPN. An in vitro study deter
./___Corpus/Medline/xml/PMC4372801.xml	vitro	28426 : 28431	CM	patients with MPN. An in vitro study determined if givi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28467 : 28478	CM	rmined if givinostat and hydroxyurea induce synergistic cytot
./___Corpus/Medline/xml/PMC4372801.xml	JAK2V617F	28514 : 28523	CM	ergistic cytotoxicity in JAK2V617F cells [81]. At low doses
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28570 : 28581	CM	ses, both givinostat and hydroxyurea potentiated the pro-apop
./___Corpus/Medline/xml/PMC4372801.xml	JAK2V617F	28641 : 28650	CM	cts of each other in the JAK2V617F HEL and UKE1 cell lines.
./___Corpus/Medline/xml/PMC4372801.xml	UKE1	28659 : 28663	CM	in the JAK2V617F HEL and UKE1 cell lines. As a single 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28710 : 28721	CM	le agent, givinostat and hydroxyurea induced 6.8%–20.8%, and 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxyurea	28925 : 28936	CM	ment with givinostat and hydroxyurea is a potential strategy 
./___Corpus/Medline/xml/PMC4372801.xml	JAK2V617F	28983 : 28992	CM	gy for the management of JAK2V617F myeloproliferative neopl
./___Corpus/Medline/xml/PMC4372801.xml	PV	29260 : 29262	CM	 with polycythemia vera (PV), unresponsive to the ma
./___Corpus/Medline/xml/PMC4372801.xml	hydroxycarbamide	29318 : 29334	CM	tolerated doses (TMD) of hydroxycarbamide (HC), were treated with 
./___Corpus/Medline/xml/PMC4372801.xml	HC	29336 : 29338	CM	MD) of hydroxycarbamide (HC), were treated with givi
./___Corpus/Medline/xml/PMC4372801.xml	HC	29397 : 29399	CM	 combination with TMD of HC [83]. Complete or partia
./___Corpus/Medline/xml/PMC4372801.xml	HC	29592 : 29594	CM	ed use of givinostat and HC was safe and well tolera
./___Corpus/Medline/xml/PMC4372801.xml	HC	29652 : 29654	CM	 clinically effective in HC-responsive PV patients. 
./___Corpus/Medline/xml/PMC4372801.xml	PV	29666 : 29668	CM	fective in HC-responsive PV patients.               
./___Corpus/Medline/xml/PMC4372801.xml	Panobinostat	29703 : 29715	CM	                  5.1.5. Panobinostat (LB589)                 
./___Corpus/Medline/xml/PMC4372801.xml	LB589	29717 : 29722	CM	    5.1.5. Panobinostat (LB589)                      Th
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	29750 : 29761	CM	                    This hydroxamate-based panobinostat showe
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	29768 : 29780	CM	  This hydroxamate-based panobinostat showed activity in clini
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	29891 : 29903	CM	he antitumor activity of panobinostat in patients with previou
./___Corpus/Medline/xml/PMC4372801.xml	SCLC	29964 : 29968	CM	 small-cell lung cancer (SCLC) was tested in a multice
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30043 : 30055	CM	 II trial [84]. Although panobinostat was well tolerated and i
./___Corpus/Medline/xml/PMC4372801.xml	SCLC	30135 : 30139	CM	tained stable disease in SCLC, this study was prematur
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30249 : 30261	CM	vestigated the effect of panobinostat in patients with primary
./___Corpus/Medline/xml/PMC4372801.xml	MF	30362 : 30364	CM	a myelofibrosis (post-ET MF) and post-polycythemia v
./___Corpus/Medline/xml/PMC4372801.xml	MF	30416 : 30418	CM	a myelofibrosis (post-PV MF) [85]. Panobinostat was 
./___Corpus/Medline/xml/PMC4372801.xml	Panobinostat	30426 : 30438	CM	rosis (post-PV MF) [85]. Panobinostat was well tolerated in MF
./___Corpus/Medline/xml/PMC4372801.xml	MF	30461 : 30463	CM	at was well tolerated in MF patients with clinical i
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	30650 : 30662	CM	ents. A phase I trial of panobinostat in 14 patients with adva
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31028 : 31040	CM	phoma, good tolerance to panobinostat was observed when admini
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31182 : 31194	CM	e safety and activity of panobinostat in 129 patients with rel
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31420 : 31432	CM	 another phase II trial, panobinostat as a single agent was te
./___Corpus/Medline/xml/PMC4372801.xml	MDS	31529 : 31532	CM	w or intermediate-1 risk MDS patients, but did not de
./___Corpus/Medline/xml/PMC4372801.xml	panobinostat	31624 : 31636	CM	89]. A phase II trial of panobinostat in patients with low or 
./___Corpus/Medline/xml/PMC4372801.xml	MDS	31681 : 31684	CM	w or intermediate-1 risk MDS observed only limited ac
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	31827 : 31831	CM	multaneous inhibition of HDAC and receptor tyrosine ki
./___Corpus/Medline/xml/PMC4372801.xml	tyrosine	31845 : 31853	CM	ion of HDAC and receptor tyrosine kinases (epidermal growt
./___Corpus/Medline/xml/PMC4372801.xml	EGFR	31896 : 31900	CM	l growth factor receptor—EGFR—and human epidermal grow
./___Corpus/Medline/xml/PMC4372801.xml	2—	31944 : 31946	CPR	l growth factor receptor 2—HER2) in cancer cells, an
./___Corpus/Medline/xml/PMC4372801.xml	HER2	31946 : 31950	CM	growth factor receptor 2—HER2) in cancer cells, and di
./___Corpus/Medline/xml/PMC4372801.xml	vitro	32032 : 32037	CM	oapoptotic activities in vitro as well as in drug-resis
./___Corpus/Medline/xml/PMC4372801.xml	CUDC-101	32329 : 32337	CM	vanced solid tumor using CUDC-101, and the drug was found 
./___Corpus/Medline/xml/PMC4372801.xml	histone	32372 : 32379	CM	drug was found to induce histone H3 acetylation in some o
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	32383 : 32394	RN	und to induce histone H3 acetylation in some of the patients.
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	32835 : 32850	CM	ble 2 summarizes all the hydroxamic acid based HDAC inhibitors as
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	32857 : 32861	CM	he hydroxamic acid based HDAC inhibitors as potential 
./___Corpus/Medline/xml/PMC4372801.xml	Benzamide	32971 : 32980	CM	s.                  5.2. Benzamide Derivatives             
./___Corpus/Medline/xml/PMC4372801.xml	Benzamide	33014 : 33023	CM	ves                      Benzamide containing HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	33035 : 33039	CM	    Benzamide containing HDAC inhibitors are another c
./___Corpus/Medline/xml/PMC4372801.xml	vitro	33102 : 33107	CM	unds that showed both in vitro and in vivo anticancer a
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	33154 : 33166	CM	r activities. Among them mocetinostat (MGCD0103) and entinosta
./___Corpus/Medline/xml/PMC4372801.xml	MS-275	33194 : 33200	CM	GCD0103) and entinostat (MS-275) are two examples of ben
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	33222 : 33231	CM	275) are two examples of benzamide derivatives that had bee
./___Corpus/Medline/xml/PMC4372801.xml	Mocetinostat	33308 : 33320	CM	                  5.2.1. Mocetinostat (MGCD0103)              
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	33358 : 33367	CM	                    This benzamide derivative HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	33379 : 33383	CM	his benzamide derivative HDAC inhibitor is selective f
./___Corpus/Medline/xml/PMC4372801.xml	histone	33431 : 33438	CM	 for both Class I and IV histone deacetylases [103]. A ph
./___Corpus/Medline/xml/PMC4372801.xml	deacetylases	33439 : 33451	ASE	h Class I and IV histone deacetylases [103]. A phase 1 trial o
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	33478 : 33490	CM	103]. A phase 1 trial of mocetinostat in patients with leukemi
./___Corpus/Medline/xml/PMC4372801.xml	MDS	33547 : 33550	CM	elodysplastic syndromes (MDS) showed the drug was saf
./___Corpus/Medline/xml/PMC4372801.xml	Mocetinostat	33713 : 33725	CM	ponse (blasts ≤ 5%) too. Mocetinostat was also tested in pancr
./___Corpus/Medline/xml/PMC4372801.xml	MC1568	33919 : 33925	CM	ated in combination with MC1568 (Class IIA selective HDA
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	33947 : 33952	CM	568 (Class IIA selective HDACi) or tubastatin A (HDAC6 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC6	33971 : 33976	CM	 HDACi) or tubastatin A (HDAC6 selective inhibitor) [10
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	34194 : 34206	CM	h advanced solid tumors, mocetinostat inhibited HDAC activity 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	34217 : 34221	CM	, mocetinostat inhibited HDAC activity and induced His
./___Corpus/Medline/xml/PMC4372801.xml	Histone	34243 : 34250	CM	DAC activity and induced Histone H3 acetylation in periph
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	34254 : 34265	RN	y and induced Histone H3 acetylation in peripheral white bloo
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	35263 : 35267	CM	t is a Class I selective HDAC inhibitor and is well to
./___Corpus/Medline/xml/PMC4372801.xml	13-cis-retinoic acid	35431 : 35451	CM	stat in combination with 13-cis-retinoic acid (CRA) was tested to dete
./___Corpus/Medline/xml/PMC4372801.xml	CRA	35453 : 35456	CM	th 13-cis-retinoic acid (CRA) was tested to determine
./___Corpus/Medline/xml/PMC4372801.xml	CRA	35575 : 35578	CM	ofiles of entinostat and CRA in advanced solid tumors
./___Corpus/Medline/xml/PMC4372801.xml	erlotinib	35843 : 35852	CM	o evaluate the effect of erlotinib with or without entinost
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	35898 : 35903	CM	nostat in advanced state NSCLC patients [110]. No impro
./___Corpus/Medline/xml/PMC4372801.xml	erlotinib	36016 : 36025	CM	erved when compared with erlotinib monotherapy. Similarly, 
./___Corpus/Medline/xml/PMC4372801.xml	exemestane	36179 : 36189	CM	 the aromatase inhibitor exemestane in breast cancer patient
./___Corpus/Medline/xml/PMC4372801.xml	exemestane	36286 : 36296	CM	herapy of entinostat and exemestane is well tolerated and de
./___Corpus/Medline/xml/PMC4372801.xml	ER+	36367 : 36370	CM	ctivity in patients with ER+ advanced breast cancer. 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	36735 : 36739	CM	present another class of HDAC inhibitor with simple st
./___Corpus/Medline/xml/PMC4372801.xml	Valproic acid	36824 : 36837	CM	tial in various studies. Valproic acid and phenylbutyrate are t
./___Corpus/Medline/xml/PMC4372801.xml	phenylbutyrate	36842 : 36856	CM	udies. Valproic acid and phenylbutyrate are two well characteriz
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	36952 : 36956	CM	ounds. They both display HDAC inhibition for Class I a
./___Corpus/Medline/xml/PMC4372801.xml	IIa	36984 : 36987	CM	hibition for Class I and IIa HDACs, but they tend to 
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	36988 : 36993	CM	tion for Class I and IIa HDACs, but they tend to be les
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	37045 : 37049	CM	potent in inhibiting the HDAC activity than the hydrox
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	37068 : 37083	CM	e HDAC activity than the hydroxamic acid based HDAC inhibitors.  
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	37090 : 37094	CM	he hydroxamic acid based HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	37292 : 37305	CM	13]. In a phase I study, valproic acid (VPA) was tested in pedi
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37307 : 37310	CM	 I study, valproic acid (VPA) was tested in pediatric
./___Corpus/Medline/xml/PMC4372801.xml	histone	37423 : 37430	CM	 tumors [113]. Increased histone acetylation in periphera
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	37431 : 37442	RN	[113]. Increased histone acetylation in peripheral blood mono
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37656 : 37659	CM	 a pilot phase II study, VPA was also tested for the 
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37756 : 37759	CM	lso to determine whether VPA can induce Notch 1 signa
./___Corpus/Medline/xml/PMC4372801.xml	VPA	37827 : 37830	CM	. Overall treatment with VPA was well tolerated in pa
./___Corpus/Medline/xml/PMC4372801.xml	NETs	37867 : 37871	CM	lerated in patients with NETs and was found to activat
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38044 : 38047	CM	                         VPA was also tested in combi
./___Corpus/Medline/xml/PMC4372801.xml	115–	38134 : 38138	CPR	ment of various cancers [115–118]. For example, a phas
./___Corpus/Medline/xml/PMC4372801.xml	anti-	38208 : 38213	CPR	bination of bevacizumab (anti-angiogenic agent) and VPA
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38235 : 38238	CM	ti-angiogenic agent) and VPA was conducted in patient
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38345 : 38348	CM	ation of bevacizumab and VPA is safe in patients with
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38466 : 38469	CM	of stable disease [115]. VPA was also tested in advan
./___Corpus/Medline/xml/PMC4372801.xml	NSCLC	38504 : 38509	CM	tested in advanced stage NSCLC patients in combination 
./___Corpus/Medline/xml/PMC4372801.xml	5-aza-2′-deoxycytidine	38539 : 38561	CM	ents in combination with 5-aza-2′-deoxycytidine (decitabine). This combi
./___Corpus/Medline/xml/PMC4372801.xml	hypermethylated	38643 : 38658	CM	ffective in reactivating hypermethylated genes as demonstrated by
./___Corpus/Medline/xml/PMC4372801.xml	Hb	38704 : 38706	CM	d by re-expressing fetal Hb, but was limited by unac
./___Corpus/Medline/xml/PMC4372801.xml	VPA	38796 : 38799	CM	tively low dosage [116]. VPA in combination with S-1,
./___Corpus/Medline/xml/PMC4372801.xml	S-1	38820 : 38823	CM	 VPA in combination with S-1, an oral fluoropyrimidin
./___Corpus/Medline/xml/PMC4372801.xml	fluoropyrimidine	38833 : 38849	CM	nation with S-1, an oral fluoropyrimidine derivative consisting of
./___Corpus/Medline/xml/PMC4372801.xml	5-fluorouracil	38875 : 38889	CM	derivative consisting of 5-fluorouracil, was tested in pancreato
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	39048 : 39057	CM	. Table 3 summarizes the benzamide, short chain fatty acid,
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	39071 : 39081	CM	e benzamide, short chain fatty acid, and cyclic peptide HDAC
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	39102 : 39106	CM	acid, and cyclic peptide HDAC inhibitors and their res
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	39229 : 39233	CM	              6. Natural HDAC Inhibitors              
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	39284 : 39288	CM	       A large number of HDAC inhibitors are of natura
./___Corpus/Medline/xml/PMC4372801.xml	Hydroxamic acid	39323 : 39338	CM	s are of natural origin. Hydroxamic acid-based trichostatin A (TS
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	39391 : 39402	CM	was one of first natural hydroxamate compounds isolated from 
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	39497 : 39502	CM	hat was found to inhibit HDACs at IC50 less than 10 nM,
./___Corpus/Medline/xml/PMC4372801.xml	IC50	39506 : 39510	CM	ound to inhibit HDACs at IC50 less than 10 nM, with ov
./___Corpus/Medline/xml/PMC4372801.xml	300-fold	39538 : 39546	CM	ss than 10 nM, with over 300-fold selectivity against Clas
./___Corpus/Medline/xml/PMC4372801.xml	IIa	39573 : 39576	CM	electivity against Class IIa HDACs [120,121]. Another
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	39577 : 39582	CM	tivity against Class IIa HDACs [120,121]. Another natur
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	39610 : 39621	CM	20,121]. Another natural hydroxamate found to have anti-proli
./___Corpus/Medline/xml/PMC4372801.xml	anti-	39636 : 39641	CPR	ydroxamate found to have anti-proliferative effects aga
./___Corpus/Medline/xml/PMC4372801.xml	Nocardia	39727 : 39735	CM	amistatin, isolated from Nocardia asteroides [122,123]. Sh
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	39770 : 39781	CM	s [122,123]. Short-chain fatty acids, such as sodium butyrate
./___Corpus/Medline/xml/PMC4372801.xml	sodium butyrate	39791 : 39806	CM	ain fatty acids, such as sodium butyrate, the byproduct of anaero
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	39941 : 39945	CM	bit different classes of HDAC [124]. Both TSA and sodi
./___Corpus/Medline/xml/PMC4372801.xml	sodium butyrate	39966 : 39981	CM	HDAC [124]. Both TSA and sodium butyrate downregulate the express
./___Corpus/Medline/xml/PMC4372801.xml	fatty acids	40077 : 40088	CM	cells [125]. Short chain fatty acids like butyrate and propio
./___Corpus/Medline/xml/PMC4372801.xml	butyrate	40094 : 40102	CM	t chain fatty acids like butyrate and propionate have been
./___Corpus/Medline/xml/PMC4372801.xml	propionate	40107 : 40117	CM	 acids like butyrate and propionate have been shown to incre
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	40179 : 40183	CM	s of neutrophils through HDAC inhibition [126]. Both p
./___Corpus/Medline/xml/PMC4372801.xml	propionate	40207 : 40217	CM	C inhibition [126]. Both propionate and butyrate based compo
./___Corpus/Medline/xml/PMC4372801.xml	butyrate	40222 : 40230	CM	26]. Both propionate and butyrate based compounds are bein
./___Corpus/Medline/xml/PMC4372801.xml	cyclopeptide	40310 : 40322	CM	r many diseases. Natural cyclopeptide FR235222 isolated from t
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	40323 : 40331	CM	es. Natural cyclopeptide FR235222 isolated from the fermen
./___Corpus/Medline/xml/PMC4372801.xml	Acremonium	40372 : 40382	CM	he fermentation broth of Acremonium sp. caused accumulation 
./___Corpus/Medline/xml/PMC4372801.xml	acetylated	40410 : 40420	RN	. caused accumulation of acetylated histone H4, inhibition o
./___Corpus/Medline/xml/PMC4372801.xml	histone	40421 : 40428	CM	cumulation of acetylated histone H4, inhibition of human 
./___Corpus/Medline/xml/PMC4372801.xml	H4	40429 : 40431	CM	on of acetylated histone H4, inhibition of human leu
./___Corpus/Medline/xml/PMC4372801.xml	G1	40518 : 40520	CM	cell cycle arrest in the G1 phase via p21 [127]. Oth
./___Corpus/Medline/xml/PMC4372801.xml	p21	40531 : 40534	CM	rest in the G1 phase via p21 [127]. Other natural cyc
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	40608 : 40612	CM	n demonstrated to act as HDAC inhibitors are chlamydoc
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	40681 : 40689	CM	ra chlamydosporia [128], apicidin from Fusarium sp. [129] 
./___Corpus/Medline/xml/PMC4372801.xml	Fusarium	40695 : 40703	CM	ria [128], apicidin from Fusarium sp. [129] and azumamide 
./___Corpus/Medline/xml/PMC4372801.xml	azumamide	40718 : 40727	CM	m Fusarium sp. [129] and azumamide A-E from the marine spon
./___Corpus/Medline/xml/PMC4372801.xml	marine	40741 : 40747	CM	d azumamide A-E from the marine sponge Mycale izuensis [
./___Corpus/Medline/xml/PMC4372801.xml	Mycale	40755 : 40761	CM	E from the marine sponge Mycale izuensis [130,131], and 
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin	40811 : 40819	CM	the microbial metabolite trapoxin [132]. In addition to ro
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	40842 : 40852	CM	in [132]. In addition to romidepsin, some other natural prod
./___Corpus/Medline/xml/PMC4372801.xml	largazole	40950 : 40959	CM	antitumor activities are largazole from cyanobacterium Symp
./___Corpus/Medline/xml/PMC4372801.xml	cyanobacterium	40965 : 40979	CM	ities are largazole from cyanobacterium Symploca sp [133] spiruc
./___Corpus/Medline/xml/PMC4372801.xml	chlamydocin	41218 : 41229	CM	rs. Several analogues of chlamydocin, largazole and apicidin 
./___Corpus/Medline/xml/PMC4372801.xml	largazole	41231 : 41240	CM	nalogues of chlamydocin, largazole and apicidin also demons
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	41245 : 41253	CM	lamydocin, largazole and apicidin also demonstrated antica
./___Corpus/Medline/xml/PMC4372801.xml	Stilbene	41314 : 41322	CM	ties in various cancers. Stilbene-based HDAC inhibitors su
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	41329 : 41333	CM	 cancers. Stilbene-based HDAC inhibitors such as resve
./___Corpus/Medline/xml/PMC4372801.xml	resveratrol	41353 : 41364	CM	 HDAC inhibitors such as resveratrol from red grapes have dem
./___Corpus/Medline/xml/PMC4372801.xml	Resveratrol	41470 : 41481	CM	eatment of cancer [136]. Resveratrol and its analogue piceata
./___Corpus/Medline/xml/PMC4372801.xml	piceatannol	41499 : 41510	CM	eratrol and its analogue piceatannol from blueberries are als
./___Corpus/Medline/xml/PMC4372801.xml	SIRT1	41549 : 41554	CM	ies are also known to be SIRT1 activators. Similarly se
./___Corpus/Medline/xml/PMC4372801.xml	organosulfur	41585 : 41597	CM	ators. Similarly several organosulfur compounds such as dially
./___Corpus/Medline/xml/PMC4372801.xml	diallyl disulfide	41616 : 41633	CM	sulfur compounds such as diallyl disulfide and allyl mercaptan from
./___Corpus/Medline/xml/PMC4372801.xml	allyl mercaptan	41638 : 41653	CM	as diallyl disulfide and allyl mercaptan from garlic [137,138] an
./___Corpus/Medline/xml/PMC4372801.xml	sulforaphane	41680 : 41692	CM	rom garlic [137,138] and sulforaphane from broccoli sprouts [1
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	41729 : 41733	CM	li sprouts [139] inhibit HDAC activity in various canc
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	41936 : 41940	CM	re also found to inhibit HDAC activity. Two dimensiona
./___Corpus/Medline/xml/PMC4372801.xml	Thioester	42076 : 42085	CM	   7. Miscellaneous 7.1. Thioester Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Thioesters	42119 : 42129	CM	ACi                      Thioesters are used for prodrug str
./___Corpus/Medline/xml/PMC4372801.xml	Largazole	42163 : 42172	CM	 for prodrug strategies. Largazole is a depsipeptide with a
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42198 : 42207	CM	is a depsipeptide with a thioester moiety purified from mar
./___Corpus/Medline/xml/PMC4372801.xml	cyanobacteria	42236 : 42249	CM	ety purified from marine cyanobacteria and it is a Class I sele
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	42280 : 42284	CM	t is a Class I selective HDAC inhibitor. Largazole upo
./___Corpus/Medline/xml/PMC4372801.xml	Largazole	42296 : 42305	CM	elective HDAC inhibitor. Largazole upon protein-assisted hy
./___Corpus/Medline/xml/PMC4372801.xml	hydrolysis	42328 : 42338	RN	le upon protein-assisted hydrolysis liberates the bioactive 
./___Corpus/Medline/xml/PMC4372801.xml	largazole thiol	42363 : 42378	CM	 liberates the bioactive largazole thiol. Disulfide prodrug strat
./___Corpus/Medline/xml/PMC4372801.xml	Disulfide	42380 : 42389	CM	oactive largazole thiol. Disulfide prodrug strategy to modu
./___Corpus/Medline/xml/PMC4372801.xml	largazole	42419 : 42428	CM	rug strategy to modulate largazole-based compounds resulted
./___Corpus/Medline/xml/PMC4372801.xml	largazole	42512 : 42521	CM	e to the natural product largazole [140]. KD5170, a mercapt
./___Corpus/Medline/xml/PMC4372801.xml	mercaptoketone	42539 : 42553	CM	rgazole [140]. KD5170, a mercaptoketone-based Class I and II HDA
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	42575 : 42579	CM	one-based Class I and II HDAC inhibitor which is anoth
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42607 : 42616	CM	hibitor which is another thioester prodrug demonstrated bro
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42758 : 42767	CM	mechanism of action, the thioester prodrug undergoes hydrol
./___Corpus/Medline/xml/PMC4372801.xml	hydrolysis	42786 : 42796	RN	oester prodrug undergoes hydrolysis to generate mercaptoketo
./___Corpus/Medline/xml/PMC4372801.xml	mercaptoketone	42809 : 42823	CM	s hydrolysis to generate mercaptoketone that coordinates Zn2+ in
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	42841 : 42845	CM	oketone that coordinates Zn2+ in a bidentate or monode
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	42906 : 42911	CM	on in the active site of HDACs [141,142]. Similarly, th
./___Corpus/Medline/xml/PMC4372801.xml	thioester	42934 : 42943	CM	Cs [141,142]. Similarly, thioester derivatives of the natur
./___Corpus/Medline/xml/PMC4372801.xml	disulfide	43030 : 43039	CM	quiring reduction of its disulfide to the corresponding thi
./___Corpus/Medline/xml/PMC4372801.xml	thiol	43061 : 43066	CM	ide to the corresponding thiol monomer for the potentia
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	43107 : 43112	CM	 potential inhibition of HDACs, exhibited both potent c
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	43203 : 43208	CM	vity against recombinant HDAC1 [143]. Among the three t
./___Corpus/Medline/xml/PMC4372801.xml	thioester	43232 : 43241	CM	1 [143]. Among the three thioester compounds that contain a
./___Corpus/Medline/xml/PMC4372801.xml	oxime	43268 : 43273	CM	ompounds that contain an oxime or methyloxime or ketone
./___Corpus/Medline/xml/PMC4372801.xml	methyloxime	43277 : 43288	CM	that contain an oxime or methyloxime or ketone moiety on the 
./___Corpus/Medline/xml/PMC4372801.xml	ketone	43292 : 43298	CM	 oxime or methyloxime or ketone moiety on the linker tha
./___Corpus/Medline/xml/PMC4372801.xml	ketone	43353 : 43359	CM	nects the cap group, the ketone containing compound was 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	43430 : 43435	CM	tent against recombinant HDAC1, displaying an IC50 of 5
./___Corpus/Medline/xml/PMC4372801.xml	IC50	43451 : 43455	CM	ant HDAC1, displaying an IC50 of 5 nm. Preliminary inv
./___Corpus/Medline/xml/PMC4372801.xml	hydrolysis	43506 : 43516	RN	stigation discounted the hydrolysis of thioester under the b
./___Corpus/Medline/xml/PMC4372801.xml	thioester	43520 : 43529	CM	ounted the hydrolysis of thioester under the buffered condi
./___Corpus/Medline/xml/PMC4372801.xml	acetyl	43600 : 43606	CM	d direct cleavage of the acetyl group by the deacetylase
./___Corpus/Medline/xml/PMC4372801.xml	deacetylase	43620 : 43631	CM	 the acetyl group by the deacetylase enzyme. So in this case,
./___Corpus/Medline/xml/PMC4372801.xml	thioacetate	43745 : 43756	CM	ighly plausible that the thioacetate group can function as a 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	43788 : 43792	CM	can function as a potent zinc-binding group.          
./___Corpus/Medline/xml/PMC4372801.xml	Epoxide	43830 : 43837	CM	p.                  7.2. Epoxide Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Epoxides	43871 : 43879	CM	ACi                      Epoxides are another known group 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	43921 : 43925	CM	n group of inhibitors of zinc dependent HDAC enzymes. 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	43936 : 43940	CM	bitors of zinc dependent HDAC enzymes. Epoxide bearing
./___Corpus/Medline/xml/PMC4372801.xml	Epoxide	43950 : 43957	CM	 dependent HDAC enzymes. Epoxide bearing natural compound
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	44057 : 44062	CM	form covalent bonds with HDACs [144]. The HDAC activity
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	44074 : 44078	CM	ds with HDACs [144]. The HDAC activity of these compou
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	44217 : 44224	CM	etabolite containing two epoxide groups, whereas trapoxin
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin	44241 : 44249	CM	 epoxide groups, whereas trapoxin has only one epoxide gro
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	44263 : 44270	CM	as trapoxin has only one epoxide group. 1-Alaninechlamydo
./___Corpus/Medline/xml/PMC4372801.xml	1-Alaninechlamydocin	44278 : 44298	CM	 only one epoxide group. 1-Alaninechlamydocin isolated from Tolypoclad
./___Corpus/Medline/xml/PMC4372801.xml	Tolypocladium	44313 : 44326	CM	hlamydocin isolated from Tolypocladium sp. showed potent antipr
./___Corpus/Medline/xml/PMC4372801.xml	PaCa-2	44426 : 44432	CM	ic cancer cell lines MIA PaCa-2 at low nanomolar concent
./___Corpus/Medline/xml/PMC4372801.xml	G2	44477 : 44479	CM	ncentrations and induced G2/M cell cycle arrest and 
./___Corpus/Medline/xml/PMC4372801.xml	epoxytetrapeptide	44567 : 44584	CM	le potency to the cyclic epoxytetrapeptide HDAC inhibitor trapoxin 
./___Corpus/Medline/xml/PMC4372801.xml	trapoxin A	44600 : 44610	CM	rapeptide HDAC inhibitor trapoxin A, but greater potency tha
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	44637 : 44641	CM	but greater potency than SAHA and apicidin in pancreat
./___Corpus/Medline/xml/PMC4372801.xml	apicidin	44646 : 44654	CM	er potency than SAHA and apicidin in pancreatic carcinoma 
./___Corpus/Medline/xml/PMC4372801.xml	PaCa-2	44693 : 44699	CM	 carcinoma cell line MIA PaCa-2.                  7.3. E
./___Corpus/Medline/xml/PMC4372801.xml	Ketone	44737 : 44743	CM	      7.3. Electrophilic Ketone Based HDACi             
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl	44777 : 44792	CM	ACi                      Trifluoromethyl ketones are known to be 
./___Corpus/Medline/xml/PMC4372801.xml	ketones	44793 : 44800	CM	         Trifluoromethyl ketones are known to be readily 
./___Corpus/Medline/xml/PMC4372801.xml	hydrated	44825 : 44833	RN	 are known to be readily hydrated and have been reported a
./___Corpus/Medline/xml/PMC4372801.xml	aspartyl	44881 : 44889	CM	 as potent inhibitors of aspartyl, cysteine and serine pro
./___Corpus/Medline/xml/PMC4372801.xml	cysteine	44891 : 44899	CM	 inhibitors of aspartyl, cysteine and serine proteases, as
./___Corpus/Medline/xml/PMC4372801.xml	serine	44904 : 44910	CM	f aspartyl, cysteine and serine proteases, as well as zi
./___Corpus/Medline/xml/PMC4372801.xml	zinc	44933 : 44937	CM	ne proteases, as well as zinc dependent enzymes. Trifl
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl	44957 : 44972	CM	 zinc dependent enzymes. Trifluoromethyl ketones attached to arom
./___Corpus/Medline/xml/PMC4372801.xml	ketones	44973 : 44980	CM	enzymes. Trifluoromethyl ketones attached to aromatic ami
./___Corpus/Medline/xml/PMC4372801.xml	amides	45002 : 45008	CM	nes attached to aromatic amides showed micromolar inhibi
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	45052 : 45056	CM	inhibitory activities as HDAC inhibitors in breast and
./___Corpus/Medline/xml/PMC4372801.xml	tetrapeptides	45130 : 45143	CM	 [148]. Similarly cyclic tetrapeptides containing trifluorometh
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	45155 : 45170	CM	tetrapeptides containing trifluoromethyl and pentafluoromethyl ke
./___Corpus/Medline/xml/PMC4372801.xml	pentafluoromethyl	45175 : 45192	CM	ning trifluoromethyl and pentafluoromethyl ketones as zinc binding 
./___Corpus/Medline/xml/PMC4372801.xml	ketones	45193 : 45200	CM	yl and pentafluoromethyl ketones as zinc binding function
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45204 : 45208	CM	afluoromethyl ketones as zinc binding functional group
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	45264 : 45268	CM	 also found to be potent HDAC inhibitors with promisin
./___Corpus/Medline/xml/PMC4372801.xml	Fluorinated	45324 : 45335	RN	cancer activities [149]. Fluorinated ketones are considerably
./___Corpus/Medline/xml/PMC4372801.xml	ketones	45336 : 45343	CM	ities [149]. Fluorinated ketones are considerably more el
./___Corpus/Medline/xml/PMC4372801.xml	fluoride	45449 : 45457	CM	ithdrawing effect of the fluoride. Therefore trifluorometh
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	45469 : 45484	CM	 the fluoride. Therefore trifluoromethyl ketones are readily hydr
./___Corpus/Medline/xml/PMC4372801.xml	ketones	45485 : 45492	CM	herefore trifluoromethyl ketones are readily hydrated in 
./___Corpus/Medline/xml/PMC4372801.xml	hydrated	45505 : 45513	RN	thyl ketones are readily hydrated in aqueous media at phys
./___Corpus/Medline/xml/PMC4372801.xml	aqueous	45517 : 45524	CJ	 are readily hydrated in aqueous media at physiological p
./___Corpus/Medline/xml/PMC4372801.xml	Trifluoromethyl	45552 : 45567	CM	dia at physiological pH. Trifluoromethyl ketones containing a thi
./___Corpus/Medline/xml/PMC4372801.xml	ketones	45568 : 45575	CM	ical pH. Trifluoromethyl ketones containing a thiophene l
./___Corpus/Medline/xml/PMC4372801.xml	thiophene	45589 : 45598	CM	hyl ketones containing a thiophene linker have been reporte
./___Corpus/Medline/xml/PMC4372801.xml	IIa	45634 : 45637	CM	e been reported as Class IIa selective HDAC inhibitor
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	45648 : 45652	CM	d as Class IIa selective HDAC inhibitors. A recent stu
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl ketone	45702 : 45724	CM	dy demonstrated that the trifluoromethyl ketone moiety served as a poten
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45751 : 45755	CM	oiety served as a potent zinc binding group [150]. The
./___Corpus/Medline/xml/PMC4372801.xml	silanediol	45803 : 45813	CM	he study also identified silanediol as a zinc binding group 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	45819 : 45823	CM	entified silanediol as a zinc binding group with poten
./___Corpus/Medline/xml/PMC4372801.xml	non-hydroxamate	45879 : 45894	CM	or future development of non-hydroxamate Class I and Class IIb HD
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	45917 : 45921	CM	te Class I and Class IIb HDAC inhibitors. Figure 2 sho
./___Corpus/Medline/xml/PMC4372801.xml	thioester	45975 : 45984	CM	tructures of some of the thioester and epoxide compounds th
./___Corpus/Medline/xml/PMC4372801.xml	epoxide	45989 : 45996	CM	ome of the thioester and epoxide compounds that are discu
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46141 : 46145	CM	ss of anticancer agents, HDAC inhibitors are also asso
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46264 : 46268	CM	observed with the use of HDAC inhibitors were thromboc
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46383 : 46387	CM	108,109]. In some cases, HDAC-induced thrombocytopenia
./___Corpus/Medline/xml/PMC4372801.xml	dehydration	46519 : 46530	RN	orexia, constipation and dehydration were also seen in patien
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46568 : 46572	CM	en in patients receiving HDAC inhibitors. Deaths have 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46641 : 46645	CM	inical studies involving HDAC inhibitors. For example,
./___Corpus/Medline/xml/PMC4372801.xml	mocetinostat	46676 : 46688	CM	itors. For example, when mocetinostat was tested in patients w
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	46929 : 46933	CM	tat [152] and many other HDAC inhibitors. Thus more st
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	47004 : 47008	CM	etermine the toxicity of HDAC inhibitors before a clin
./___Corpus/Medline/xml/PMC4372801.xml	Zinc	47143 : 47147	CM	   9. Basic Structure of Zinc Binding HDAC Inhibitors 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	47257 : 47261	CM	ally distinct classes of HDAC inhibitors (hydroxamic a
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	47274 : 47289	CM	sses of HDAC inhibitors (hydroxamic acid, benzamide, cyclic pepti
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	47291 : 47300	CM	bitors (hydroxamic acid, benzamide, cyclic peptide, short c
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	47330 : 47340	CM	lic peptide, short chain fatty acid) have been tested in cli
./___Corpus/Medline/xml/PMC4372801.xml	zinc	47406 : 47410	CM	terestingly, most of the zinc-dependent HDAC inhibitor
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	47421 : 47425	CM	st of the zinc-dependent HDAC inhibitors have common p
./___Corpus/Medline/xml/PMC4372801.xml	zinc	47645 : 47649	CM	 the binding pocket; (2) zinc binding domain (ZBD), su
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	47684 : 47699	CM	omain (ZBD), such as the hydroxamic acid, carboxylic acid or benz
./___Corpus/Medline/xml/PMC4372801.xml	carboxylic acid	47701 : 47716	CM	 as the hydroxamic acid, carboxylic acid or benzamide groups, whi
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	47720 : 47729	CM	acid, carboxylic acid or benzamide groups, which coordinate
./___Corpus/Medline/xml/PMC4372801.xml	Zn2+	47778 : 47782	CM	es to the active site of Zn2+ ion; and (3) a saturated
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	47945 : 47949	CM	tallographic analyses of HDAC in complex with hydroxam
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	47966 : 47977	CM	 of HDAC in complex with hydroxamate compounds have revealed 
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	48067 : 48078	CM	d and interacts with the amino acids near the entrance of the
./___Corpus/Medline/xml/PMC4372801.xml	34,154–	48228 : 48235	CPR	exes with the metal ion [34,154–156]. The linker serves t
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	48466 : 48470	CM	ucture of a few selected HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	48628 : 48632	CM	d selectivity in various HDAC inhibitors. In the case 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	48716 : 48731	CM	unctional groups contain hydroxamic acid, benzamides, thiols, ket
./___Corpus/Medline/xml/PMC4372801.xml	benzamides	48733 : 48743	CM	contain hydroxamic acid, benzamides, thiols, ketones or epox
./___Corpus/Medline/xml/PMC4372801.xml	thiols	48745 : 48751	CM	oxamic acid, benzamides, thiols, ketones or epoxides. Co
./___Corpus/Medline/xml/PMC4372801.xml	ketones	48753 : 48760	CM	cid, benzamides, thiols, ketones or epoxides. Comparing c
./___Corpus/Medline/xml/PMC4372801.xml	epoxides	48764 : 48772	CM	ides, thiols, ketones or epoxides. Comparing clinically im
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	48845 : 48858	CM	rinostat, entinostat and valproic acid that contain a hydroxama
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	48874 : 48885	CM	roic acid that contain a hydroxamate, benzamide and a carboxy
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	48887 : 48896	CM	t contain a hydroxamate, benzamide and a carboxylate metal 
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate	48903 : 48914	CM	oxamate, benzamide and a carboxylate metal binding moiety, re
./___Corpus/Medline/xml/PMC4372801.xml	IC50	48975 : 48979	CM	 a drastic change in the IC50 value was observed, when
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	49009 : 49020	CM	e was observed, when the hydroxamate (110–370 nM) [157,158] w
./___Corpus/Medline/xml/PMC4372801.xml	110–	49022 : 49026	CPR	d, when the hydroxamate (110–370 nM) [157,158] was cha
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	49061 : 49070	CM	57,158] was changed to a benzamide (2 μM) [159] or a carbox
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate	49089 : 49100	CM	zamide (2 μM) [159] or a carboxylate (50 μM) [160]. Thus the 
./___Corpus/Medline/xml/PMC4372801.xml	carboxylate acid	49139 : 49155	CM	. Thus the presence of a carboxylate acid or a benzamide resulted 
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	49161 : 49170	CM	 a carboxylate acid or a benzamide resulted in reduced inhi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	49270 : 49281	CM	-binding capacity than a hydroxamate group. Other studies als
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	49323 : 49338	CM	dies also confirmed that hydroxamic acid is generally a more pote
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49366 : 49370	CM	 generally a more potent HDAC inhibitor than carboxyli
./___Corpus/Medline/xml/PMC4372801.xml	carboxylic acid	49386 : 49401	CM	tent HDAC inhibitor than carboxylic acid [161]. Modification of t
./___Corpus/Medline/xml/PMC4372801.xml	hydrocarbons	49497 : 49509	CM	saturated or unsaturated hydrocarbons, including cyclic hydroc
./___Corpus/Medline/xml/PMC4372801.xml	hydrocarbons	49528 : 49540	CM	arbons, including cyclic hydrocarbons have also displaced vari
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49613 : 49617	CM	y activity. As a result, HDAC inhibitor design has inv
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49787 : 49791	CM	uctural requirements for HDAC inhibition is essential 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49892 : 49896	CM	of different isoforms of HDAC.                  10. Me
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49942 : 49946	CM	. Mechanism of action of HDAC inhibitors              
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	49979 : 49983	CM	ors                      HDAC inhibitors increase the 
./___Corpus/Medline/xml/PMC4372801.xml	histone	50017 : 50024	CM	rs increase the level of histone acetylation and the mech
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	50025 : 50036	RN	ase the level of histone acetylation and the mechanism for th
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	50131 : 50135	CM	iated with inhibition of HDAC activity. However, this 
./___Corpus/Medline/xml/PMC4372801.xml	histone	50262 : 50269	CM	e demonstrated increased histone acetylation in tumor sam
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	50270 : 50281	RN	trated increased histone acetylation in tumor samples despite
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	50341 : 50346	CM	inical effect [107,164]. HDACs can not only act on and 
./___Corpus/Medline/xml/PMC4372801.xml	histones	50378 : 50386	CM	t only act on and modify histones, but also have many diff
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	50585 : 50589	CM	 and cell invasion. Thus HDAC inhibitors exert multipl
./___Corpus/Medline/xml/PMC4372801.xml	oxygen	50755 : 50761	CM	n of autophagy, reactive oxygen species generation, and 
./___Corpus/Medline/xml/PMC4372801.xml	lead	51012 : 51016	CM	 pathways, both of which lead to caspase activation an
./___Corpus/Medline/xml/PMC4372801.xml	TNF	51159 : 51162	CM	, tumor necrosis factor (TNF) and TNF-related apoptos
./___Corpus/Medline/xml/PMC4372801.xml	TNF	51168 : 51171	CM	ecrosis factor (TNF) and TNF-related apoptosis-induci
./___Corpus/Medline/xml/PMC4372801.xml	TRAIL	51207 : 51212	CM	optosis-inducing ligand (TRAIL) to their respective cel
./___Corpus/Medline/xml/PMC4372801.xml	bishydroxamate	51462 : 51476	CM	h factors [165]. Suberic bishydroxamate induces apoptosis in mel
./___Corpus/Medline/xml/PMC4372801.xml	anti-	51591 : 51596	CPR	lating the expression of anti-apoptotic X-linked inhibi
./___Corpus/Medline/xml/PMC4372801.xml	X	51606 : 51607	CM	ession of anti-apoptotic X-linked inhibitor of apop
./___Corpus/Medline/xml/PMC4372801.xml	BH3	51788 : 51791	CM	scriptional induction of BH3-only pro-apoptotic prote
./___Corpus/Medline/xml/PMC4372801.xml	Bix	51845 : 51848	CM	ncoding genes (Bad, Bim, Bix, Noxa), the multi-domain
./___Corpus/Medline/xml/PMC4372801.xml	Noxa	51850 : 51854	CM	ng genes (Bad, Bim, Bix, Noxa), the multi-domain pro-a
./___Corpus/Medline/xml/PMC4372801.xml	BAK1	51893 : 51897	CM	omain pro-apoptotic gene BAK1 and genes encoding death
./___Corpus/Medline/xml/PMC4372801.xml	Apaf1	51987 : 51992	CM	hondrial damage (Diablo, Apaf1, Casp9, HtrA2 and CytC) 
./___Corpus/Medline/xml/PMC4372801.xml	HtrA2	52001 : 52006	CM	e (Diablo, Apaf1, Casp9, HtrA2 and CytC) in transformed
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2L1	52100 : 52106	CM	l genes, such as Bcl2A1, Bcl2L1 (encoding Bcl-xL) and Bc
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2L2	52129 : 52135	CM	L1 (encoding Bcl-xL) and Bcl2L2 (encoding Bcl-w), were c
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	52199 : 52204	CM	epressed in these cells. HDACi upregulated the expressi
./___Corpus/Medline/xml/PMC4372801.xml	Bmf	52258 : 52261	CM	f pro-apoptotic proteins Bmf, Bid, and Bim that belon
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52295 : 52299	CM	d Bim that belong to the Bcl2 family, and down regulat
./___Corpus/Medline/xml/PMC4372801.xml	anti-	52349 : 52354	CPR	ed the expression of the anti-apoptotic proteins of the
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52380 : 52384	CM	poptotic proteins of the Bcl2 family such as Bcl2 and 
./___Corpus/Medline/xml/PMC4372801.xml	Bcl2	52400 : 52404	CM	 the Bcl2 family such as Bcl2 and Bcl-x [21].         
./___Corpus/Medline/xml/PMC4372801.xml	G1	52502 : 52504	CM	uce cell cycle arrest at G1/S or G2/M transition, le
./___Corpus/Medline/xml/PMC4372801.xml	G2	52510 : 52512	CM	 cycle arrest at G1/S or G2/M transition, leading to
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	52572 : 52577	CM	iation and/or apoptosis. HDACi-mediated increase in CDK
./___Corpus/Medline/xml/PMC4372801.xml	CDK	52599 : 52602	CM	ACi-mediated increase in CDK inhibitor p21WAF1/CIP1 e
./___Corpus/Medline/xml/PMC4372801.xml	p21WAF1	52613 : 52620	CM	ncrease in CDK inhibitor p21WAF1/CIP1 expression leads to
./___Corpus/Medline/xml/PMC4372801.xml	CIP1	52621 : 52625	CM	in CDK inhibitor p21WAF1/CIP1 expression leads to cell
./___Corpus/Medline/xml/PMC4372801.xml	G1	52667 : 52669	CM	 to cell cycle arrest at G1/S [168]. Silencing of HD
./___Corpus/Medline/xml/PMC4372801.xml	HDAC3	52692 : 52697	CM	G1/S [168]. Silencing of HDAC3 has been found to induce
./___Corpus/Medline/xml/PMC4372801.xml	p21WAF1	52741 : 52748	CM	induce the expression of p21WAF1/CIP1 and cell cycle arre
./___Corpus/Medline/xml/PMC4372801.xml	CIP1	52749 : 52753	CM	he expression of p21WAF1/CIP1 and cell cycle arrest in
./___Corpus/Medline/xml/PMC4372801.xml	G2	52783 : 52785	CM	cell cycle arrest in the G2/M phase in colon cancer 
./___Corpus/Medline/xml/PMC4372801.xml	G1	52876 : 52878	CM	ote cell cycle arrest at G1/S and G2/M and subsequen
./___Corpus/Medline/xml/PMC4372801.xml	G2	52885 : 52887	CM	cycle arrest at G1/S and G2/M and subsequent apoptos
./___Corpus/Medline/xml/PMC4372801.xml	K562	52927 : 52931	CM	nt apoptosis of leukemic K562, HL60 and THP1 cells [17
./___Corpus/Medline/xml/PMC4372801.xml	HL60	52933 : 52937	CM	ptosis of leukemic K562, HL60 and THP1 cells [170].   
./___Corpus/Medline/xml/PMC4372801.xml	THP1	52942 : 52946	CM	 leukemic K562, HL60 and THP1 cells [170].            
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	53030 : 53035	CM	her mechanism of action, HDACi can block tumor angiogen
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53109 : 53112	CM	poxia inducible factors (HIF). Hypoxia upregulates ge
./___Corpus/Medline/xml/PMC4372801.xml	VEGF	53154 : 53158	CM	lates gene expression of VEGF by stabilizing the trans
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53199 : 53202	CM	the transcription factor HIF 1α and tumor suppressor 
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53265 : 53268	CM	el Lindau (VHL) degrades HIF 1α. Under hypoxic condit
./___Corpus/Medline/xml/PMC4372801.xml	hypoxic	53279 : 53286	CM	) degrades HIF 1α. Under hypoxic conditions trichostatin 
./___Corpus/Medline/xml/PMC4372801.xml	VHL	53348 : 53351	CM	been shown to upregulate VHL and p53 while downregula
./___Corpus/Medline/xml/PMC4372801.xml	p53	53356 : 53359	CM	wn to upregulate VHL and p53 while downregulating VEG
./___Corpus/Medline/xml/PMC4372801.xml	VEGF	53381 : 53385	CM	p53 while downregulating VEGF and HIF 1α to block angi
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53390 : 53393	CM	 downregulating VEGF and HIF 1α to block angiogenesis
./___Corpus/Medline/xml/PMC4372801.xml	anti-	53455 : 53460	CPR	i also contribute to the anti-angiogenic pathway by dis
./___Corpus/Medline/xml/PMC4372801.xml	HIF	53540 : 53543	CM	ne function and exposing HIF 1α to proteosomal degrad
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	53619 : 53623	CM	                         HDAC inhibitors indirectly da
./___Corpus/Medline/xml/PMC4372801.xml	chromatin	53680 : 53689	CM	A by inducing changes in chromatin conformation upon histon
./___Corpus/Medline/xml/PMC4372801.xml	histone	53708 : 53715	CM	omatin conformation upon histone acetylation that might e
./___Corpus/Medline/xml/PMC4372801.xml	acetylation	53716 : 53727	RN	onformation upon histone acetylation that might expose the DN
./___Corpus/Medline/xml/PMC4372801.xml	ROS	53786 : 53789	CM	ays, ionizing radiation, ROS and chemotherapeutic gen
./___Corpus/Medline/xml/PMC4372801.xml	lead	53881 : 53885	CM	 reaction can eventually lead to double strand breaks 
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	53933 : 53938	CM	s (DSBs) in DNA. The pan HDACi, vorinostat was shown to
./___Corpus/Medline/xml/PMC4372801.xml	LNCaP	54004 : 54009	CM	normal (HFS) and cancer (LNCaP, A549) cells [173]. Norm
./___Corpus/Medline/xml/PMC4372801.xml	DBSs	54185 : 54189	CM	he level of biomarker of DBSs in DNA, phosphorylated h
./___Corpus/Medline/xml/PMC4372801.xml	phosphorylated histone	54198 : 54220	CM	iomarker of DBSs in DNA, phosphorylated histone variant γH2AX, increased
./___Corpus/Medline/xml/PMC4372801.xml	γH2AX	54229 : 54234	CM	orylated histone variant γH2AX, increased with continue
./___Corpus/Medline/xml/PMC4372801.xml	NHEJ	54395 : 54399	CM	-homologous end joining (NHEJ). HDACi can downregulate
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	54402 : 54407	CM	gous end joining (NHEJ). HDACi can downregulate the lev
./___Corpus/Medline/xml/PMC4372801.xml	Ku70	54468 : 54472	CM	repair proteins, such as Ku70 and Ku86 that are involv
./___Corpus/Medline/xml/PMC4372801.xml	NHEJ	54503 : 54507	CM	u86 that are involved in NHEJ pathway [174,175]. Simil
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	54537 : 54542	CM	way [174,175]. Similarly HDACi suppressed the gene expr
./___Corpus/Medline/xml/PMC4372801.xml	RAD51	54602 : 54607	CM	DNA repair proteins like RAD51, BRCA1 and BRCA2 [176]. 
./___Corpus/Medline/xml/PMC4372801.xml	BRCA1	54609 : 54614	CM	air proteins like RAD51, BRCA1 and BRCA2 [176].        
./___Corpus/Medline/xml/PMC4372801.xml	BRCA2	54619 : 54624	CM	ns like RAD51, BRCA1 and BRCA2 [176].                  
./___Corpus/Medline/xml/PMC4372801.xml	oxygen	54693 : 54699	CM	  Generation of reactive oxygen species (ROS) is another
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54709 : 54712	CM	reactive oxygen species (ROS) is another key event in
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	54738 : 54743	CM	 is another key event in HDACi induced cell death, caus
./___Corpus/Medline/xml/PMC4372801.xml	N-acetylcysteine	54813 : 54829	CM	 radical scavengers like N-acetylcysteine reduce ROS generation wh
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54837 : 54840	CM	 N-acetylcysteine reduce ROS generation which in turn
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	54876 : 54881	CM	 which in turn abrogates HDACi mediated cell death [173
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	54913 : 54918	CM	ed cell death [173,177]. HDACi increase ROS production 
./___Corpus/Medline/xml/PMC4372801.xml	ROS	54928 : 54931	CM	173,177]. HDACi increase ROS production through downr
./___Corpus/Medline/xml/PMC4372801.xml	thiol	54990 : 54995	CM	 of thioredoxin (Trx), a thiol reductase that acts as a
./___Corpus/Medline/xml/PMC4372801.xml	ROS	55034 : 55037	CM	t acts as a scavenger of ROS, and through upregulatio
./___Corpus/Medline/xml/PMC4372801.xml	protein-2	55087 : 55096	CM	n of thioredoxin binding protein-2 (TBP-2), a protein that 
./___Corpus/Medline/xml/PMC4372801.xml	Trx	55130 : 55133	CM	 a protein that binds to Trx and blocks its reducing 
./___Corpus/Medline/xml/PMC4372801.xml	Trx	55252 : 55255	CM	llowed by suppression of Trx expression [179]. Togeth
./___Corpus/Medline/xml/PMC4372801.xml	HDACi	55323 : 55328	CM	eted mechanisms by which HDACi act upon cancer cell sur
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	55531 : 55535	CM	wn structural classes of HDAC inhibitors, there exist 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	55566 : 55570	CM	itors, there exist other HDAC inhibitors with differen
./___Corpus/Medline/xml/PMC4372801.xml	zinc	55597 : 55601	CM	nhibitors with different zinc binding groups, includin
./___Corpus/Medline/xml/PMC4372801.xml	thioesters	55628 : 55638	CM	inding groups, including thioesters, epoxides, epxoyketones,
./___Corpus/Medline/xml/PMC4372801.xml	epoxides	55640 : 55648	CM	s, including thioesters, epoxides, epxoyketones, thiols, d
./___Corpus/Medline/xml/PMC4372801.xml	epxoyketones	55650 : 55662	CM	ng thioesters, epoxides, epxoyketones, thiols, dithiols, keton
./___Corpus/Medline/xml/PMC4372801.xml	thiols	55664 : 55670	CM	 epoxides, epxoyketones, thiols, dithiols, ketones, hydr
./___Corpus/Medline/xml/PMC4372801.xml	dithiols	55672 : 55680	CM	s, epxoyketones, thiols, dithiols, ketones, hydroxypyridin
./___Corpus/Medline/xml/PMC4372801.xml	ketones	55682 : 55689	CM	tones, thiols, dithiols, ketones, hydroxypyridinethiones 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxypyridinethiones	55691 : 55713	CM	iols, dithiols, ketones, hydroxypyridinethiones and hydroxypyridone. Man
./___Corpus/Medline/xml/PMC4372801.xml	hydroxypyridone	55718 : 55733	CM	droxypyridinethiones and hydroxypyridone. Many other structural c
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	55782 : 55786	CM	classes that can inhibit HDAC activity may exist as we
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	55982 : 55986	CM	 agent by inhibiting the HDAC activity? Traditional hi
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	57037 : 57041	CM	 efficient and selective HDAC inhibitors have been con
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	57098 : 57102	CM	y intensified ever since HDAC inhibitors were found ac
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	57345 : 57349	CM	ctivity relationships of HDAC inhibitors. To this end,
./___Corpus/Medline/xml/PMC4372801.xml	cyclopeptide	57513 : 57525	CM	 structural analogues of cyclopeptide FR235222, an HDAC inhibi
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	57526 : 57534	CM	nalogues of cyclopeptide FR235222, an HDAC inhibitor, mole
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	57539 : 57543	CM	yclopeptide FR235222, an HDAC inhibitor, molecular doc
./___Corpus/Medline/xml/PMC4372801.xml	cis	57601 : 57604	CM	dies were conducted with cis and trans isomers of 10 
./___Corpus/Medline/xml/PMC4372801.xml	FR235222	57642 : 57650	CM	omers of 10 analogues of FR235222 and a homologous protein
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	57679 : 57684	CM	 a homologous protein of HDAC1 [180]. This study provid
./___Corpus/Medline/xml/PMC4372801.xml	181–	58222 : 58226	CPR	orted in the literature [181–183]. The structural deta
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	58426 : 58430	CM	or different isoforms of HDAC, or for rational drug de
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	58506 : 58510	CM	n also be applied to the HDAC inhibitors that are in c
./___Corpus/Medline/xml/PMC4372801.xml	isoform	58619 : 58626	CM	the drug more potent and isoform specific HDAC inhibitors
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	58636 : 58640	CM	ent and isoform specific HDAC inhibitors with potentia
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	59201 : 59205	CM	ns of chemically diverse HDAC inhibitors (SAHA, PCI-34
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	59218 : 59222	CM	diverse HDAC inhibitors (SAHA, PCI-34051 and C16) and 
./___Corpus/Medline/xml/PMC4372801.xml	C16	59238 : 59241	CM	ors (SAHA, PCI-34051 and C16) and the HDAC isoforms (
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	59251 : 59255	CM	I-34051 and C16) and the HDAC isoforms (8, 10 and 11) 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	59314 : 59318	CM	ree different classes of zinc-dependent enzyme were al
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	59539 : 59543	CM	interactions between the HDAC and the inhibitor at the
./___Corpus/Medline/xml/PMC4372801.xml	hydrogen	59674 : 59682	CM	are mainly determined by hydrogen bonds formed by the inhi
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	59992 : 60003	CM	subtle difference in the amino acids at the highly conserved 
./___Corpus/Medline/xml/PMC4372801.xml	M274	60058 : 60062	CM	e sites of HDAC isoform (M274 in HDAC8, E272 in HDAC10
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	60066 : 60071	CM	of HDAC isoform (M274 in HDAC8, E272 in HDAC10 and L268
./___Corpus/Medline/xml/PMC4372801.xml	E272	60073 : 60077	CM	 isoform (M274 in HDAC8, E272 in HDAC10 and L268 in HD
./___Corpus/Medline/xml/PMC4372801.xml	HDAC10	60081 : 60087	CM	 (M274 in HDAC8, E272 in HDAC10 and L268 in HDAC11) is r
./___Corpus/Medline/xml/PMC4372801.xml	L268	60092 : 60096	CM	DAC8, E272 in HDAC10 and L268 in HDAC11) is responsibl
./___Corpus/Medline/xml/PMC4372801.xml	HDAC11	60100 : 60106	CM	72 in HDAC10 and L268 in HDAC11) is responsible for the 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	60165 : 60169	CM	ty observed in different HDAC inhibitors. The importan
./___Corpus/Medline/xml/PMC4372801.xml	amino acids	60225 : 60236	CM	conserved tunnel forming amino acids and their influence in m
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	60377 : 60382	CM	simulations of wild type HDAC8, 10, and 11, and two mut
./___Corpus/Medline/xml/PMC4372801.xml	L268M	60413 : 60418	CM	and 11, and two mutants (L268M and L268E) of HDAC11 [18
./___Corpus/Medline/xml/PMC4372801.xml	L268E	60423 : 60428	CM	d two mutants (L268M and L268E) of HDAC11 [185]. Anothe
./___Corpus/Medline/xml/PMC4372801.xml	HDAC11	60433 : 60439	CM	nts (L268M and L268E) of HDAC11 [185]. Another MD simula
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	60582 : 60595	CM	ffecting the affinity of valproic acid to the HASC [186]. At th
./___Corpus/Medline/xml/PMC4372801.xml	valproic acid	60649 : 60662	CM	me time, the affinity of valproic acid toward the HASC was cons
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	60968 : 60972	CM	of different isoforms of HDAC and specific inhibitors 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	61031 : 61035	CM	. Thus MD simulations of HDAC enzyme in complex with t
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	61063 : 61067	CM	zyme in complex with the HDAC inhibitors, especially t
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	61318 : 61323	CM	in finding inhibitors of HDACs. Virtual screening is a 
./___Corpus/Medline/xml/PMC4372801.xml	non-hydroxamate	61747 : 61762	CM	ployed to identify novel non-hydroxamate HDAC inhibitors from the
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	61763 : 61767	CM	fy novel non-hydroxamate HDAC inhibitors from the NCI2
./___Corpus/Medline/xml/PMC4372801.xml	NCI2000	61788 : 61795	CM	HDAC inhibitors from the NCI2000 and Maybridge databases 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	61946 : 61951	CM	d and evaluated for both HDAC1 inhibitory activity and 
./___Corpus/Medline/xml/PMC4372801.xml	MCF-7	62020 : 62025	CM	an breast adenocarcinoma MCF-7 cells and human umbilica
./___Corpus/Medline/xml/PMC4372801.xml	HDAC6	62119 : 62124	CM	ual screening against an HDAC6 homology model using the
./___Corpus/Medline/xml/PMC4372801.xml	HDAC6	62190 : 62195	CM	ase had identified a new HDAC6 selective inhibitor and 
./___Corpus/Medline/xml/PMC4372801.xml	carbamate	62222 : 62231	CM	elective inhibitor and a carbamate derivative that acts as 
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamate	62287 : 62298	CM	rug in cell culture, for hydroxamate derived HDAC inhibitors 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	62307 : 62311	CM	 for hydroxamate derived HDAC inhibitors [190]. Simila
./___Corpus/Medline/xml/PMC4372801.xml	IC50	62444 : 62448	CM	ied one compound with an IC50 of 1.6 μM against HDAC8 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	62467 : 62472	CM	n IC50 of 1.6 μM against HDAC8 [191]. By means of virtu
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	62546 : 62550	CM	g simulations, six novel HDAC inhibitors with IC50 val
./___Corpus/Medline/xml/PMC4372801.xml	IC50	62567 : 62571	CM	vel HDAC inhibitors with IC50 values ranging from 1 to
./___Corpus/Medline/xml/PMC4372801.xml	zinc	62723 : 62727	CM	oups for the active site zinc ion, including N-[1,3,4]
./___Corpus/Medline/xml/PMC4372801.xml	N-[1,3,4]thiadiazol-2-yl sulfonamide	62743 : 62779	CM	site zinc ion, including N-[1,3,4]thiadiazol-2-yl sulfonamide, N-thiazol-2-yl sulfonam
./___Corpus/Medline/xml/PMC4372801.xml	N-thiazol-2-yl sulfonamide	62781 : 62807	CM	diazol-2-yl sulfonamide, N-thiazol-2-yl sulfonamide, and hydroxamic acid moi
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	62813 : 62828	CM	ol-2-yl sulfonamide, and hydroxamic acid moieties. In fact, a num
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	63043 : 63048	CM	r of Schistosoma mansoni HDAC8 (smHDAC8) for the treatm
./___Corpus/Medline/xml/PMC4372801.xml	Enamine	63198 : 63205	CM	ntified by screening the Enamine purchasable compound lib
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	64072 : 64076	CM	ures of many isoforms of HDAC are already available, t
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	64173 : 64177	CM	 out. Homology models of HDAC enzymes can also be used
./___Corpus/Medline/xml/PMC4372801.xml	isoform	64242 : 64249	CM	 structure of a specific isoform is unavailable. For our 
./___Corpus/Medline/xml/PMC4372801.xml	vitro	64400 : 64405	CM	purchased for testing in vitro and in vivo studies.    
./___Corpus/Medline/xml/PMC4372801.xml	lead	64543 : 64547	CM	tive biologically active lead compound by searching fo
./___Corpus/Medline/xml/PMC4372801.xml	lead	64774 : 64778	CM	e succeeded in finding a lead molecule that led to the
./___Corpus/Medline/xml/PMC4372801.xml	thiazole	64817 : 64825	CM	 led to the discovery of thiazole derivatives as novel inh
./___Corpus/Medline/xml/PMC4372801.xml	lead	65072 : 65076	CM	pable of identifying new lead with similar shape as we
./___Corpus/Medline/xml/PMC4372801.xml	lead	65137 : 65141	CM	rostatic properties to a lead query molecule. Using HD
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	65164 : 65168	CM	ad query molecule. Using HDAC inhibitors that are alre
./___Corpus/Medline/xml/PMC4372801.xml	lead	65223 : 65227	CM	n clinical trials as the lead query molecules, shape b
./___Corpus/Medline/xml/PMC4372801.xml	zinc	65329 : 65333	CM	 with entirely different zinc binding domain, linker, 
./___Corpus/Medline/xml/PMC4372801.xml	zinc	65496 : 65500	CM	us structurally distinct zinc binding domain, linker a
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	65574 : 65578	CM	urrently being tested by HDAC inhibitor assays.       
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	65703 : 65707	CM	mapping of several known HDAC inhibitors identified st
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	65804 : 65808	CM	ractions against Class I HDAC enzymes [198]. Apparentl
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	66640 : 66644	CM	ulate the interaction of HDAC inhibitors against Class
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	66673 : 66677	CM	ibitors against Class II HDAC enzymes [199]. It was sh
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	66874 : 66879	CM	re model also identified HDAC8 inhibitors as anticancer
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	67209 : 67213	CM	Activity Relationship of HDAC Inhibitors              
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	67545 : 67549	CM	e activity relationship (QSAR) provides a convenient m
./___Corpus/Medline/xml/PMC4372801.xml	2D-QSAR	67733 : 67740	CM	eld, application of both 2D-QSAR and 3D-QSAR modeling has
./___Corpus/Medline/xml/PMC4372801.xml	3D-QSAR	67745 : 67752	CM	tion of both 2D-QSAR and 3D-QSAR modeling has become an i
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	67837 : 67841	CM	process. For example, 3D QSAR relationships of a serie
./___Corpus/Medline/xml/PMC4372801.xml	lactam	67871 : 67877	CM	tionships of a series of lactam-based HDAC inhibitor wer
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	67884 : 67888	CM	a series of lactam-based HDAC inhibitor were used for 
./___Corpus/Medline/xml/PMC4372801.xml	lactam	67941 : 67947	CM	ther evaluation of novel lactam-based HDAC inhibitors [2
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	67954 : 67958	CM	on of novel lactam-based HDAC inhibitors [201]. This s
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68003 : 68007	CM	his study suggested that HDAC inhibitors which are sma
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68135 : 68139	CM	groups would show better HDAC inhibitory activities [2
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	68169 : 68173	CM	bitory activities [201]. QSAR studies also helped in t
./___Corpus/Medline/xml/PMC4372801.xml	γ-lactam	68248 : 68256	CM	biological evaluation of γ-lactam-based HDAC inhibitors [2
./___Corpus/Medline/xml/PMC4372801.xml	γ-	68256 : 68258	CPR	al evaluation of γ-lactam-based HDAC inhibitors [202
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68263 : 68267	CM	uation of γ-lactam-based HDAC inhibitors [202,203]. By
./___Corpus/Medline/xml/PMC4372801.xml	phenyl	68335 : 68341	CM	rent cap groups, such as phenyl, naphthyl, and thiopheny
./___Corpus/Medline/xml/PMC4372801.xml	naphthyl	68343 : 68351	CM	 groups, such as phenyl, naphthyl, and thiophenyl, it was 
./___Corpus/Medline/xml/PMC4372801.xml	thiophenyl	68357 : 68367	CM	as phenyl, naphthyl, and thiophenyl, it was observed that hy
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68451 : 68455	CM	 increase the potency of HDAC inhibition because of th
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68518 : 68522	CM	 interaction between the HDAC and γ-lactam inhibitor. 
./___Corpus/Medline/xml/PMC4372801.xml	γ-lactam	68527 : 68535	CM	ion between the HDAC and γ-lactam inhibitor. Similarly met
./___Corpus/Medline/xml/PMC4372801.xml	methoxy	68557 : 68564	CM	tam inhibitor. Similarly methoxy and trifluoromethyl subs
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	68569 : 68584	CM	r. Similarly methoxy and trifluoromethyl substitutions at the ort
./___Corpus/Medline/xml/PMC4372801.xml	ortho-	68611 : 68617	CPR	ubstitutions at the ortho-, meta-, para- position of the
./___Corpus/Medline/xml/PMC4372801.xml	meta-	68618 : 68623	CPR	tions at the ortho-, meta-, para- position of the cap g
./___Corpus/Medline/xml/PMC4372801.xml	para-	68625 : 68630	CPR	t the ortho-, meta-, para- position of the cap group sh
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68670 : 68674	CM	p group showed increased HDAC inhibition when the subs
./___Corpus/Medline/xml/PMC4372801.xml	trifluoromethyl	68708 : 68723	CM	on when the substituent (trifluoromethyl) is more lipophilic. Thu
./___Corpus/Medline/xml/PMC4372801.xml	lipophilic	68733 : 68743	CM	trifluoromethyl) is more lipophilic. Thus lipophilicity incr
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68825 : 68829	CM	n between the surface of HDAC active site and HDAC inh
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68846 : 68850	CM	 of HDAC active site and HDAC inhibitor, which in turn
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68889 : 68893	CM	ich in turn improves the HDAC inhibitor activity [203]
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	68949 : 68953	CM	cent survey of published QSAR studies of HDAC inhibito
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	68965 : 68969	CM	ublished QSAR studies of HDAC inhibitors revealed that
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	69203 : 69207	CM	nition group to optimize HDAC inhibition identified tw
./___Corpus/Medline/xml/PMC4372801.xml	lead	69234 : 69238	CM	nhibition identified two lead compounds that are poten
./___Corpus/Medline/xml/PMC4372801.xml	HDAC6	69279 : 69284	CM	are potent inhibitors of HDAC6 and HDAC8, but inactive 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC8	69289 : 69294	CM	 inhibitors of HDAC6 and HDAC8, but inactive against HD
./___Corpus/Medline/xml/PMC4372801.xml	HDAC1	69317 : 69322	CM	C8, but inactive against HDAC1 [205]. In SAHA-like HDAC
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	69333 : 69337	CM	 against HDAC1 [205]. In SAHA-like HDAC inhibitors, a 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	69343 : 69347	CM	DAC1 [205]. In SAHA-like HDAC inhibitors, a triazole r
./___Corpus/Medline/xml/PMC4372801.xml	triazole	69362 : 69370	CM	-like HDAC inhibitors, a triazole ring that joins the surf
./___Corpus/Medline/xml/PMC4372801.xml	HDACs	69483 : 69488	CM	ntial inhibition against HDACs [206]. Structure activit
./___Corpus/Medline/xml/PMC4372801.xml	triazole	69537 : 69545	CM	ty relationships of such triazole-linked hydroxamates disp
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamates	69553 : 69565	CM	 of such triazole-linked hydroxamates displayed a cap group-de
./___Corpus/Medline/xml/PMC4372801.xml	methylene	69632 : 69641	CM	e for either five or six methylene spacer groups, and showe
./___Corpus/Medline/xml/PMC4372801.xml	SAHA	69702 : 69706	CM	old greater potency than SAHA. Thus the QSAR studies g
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	69717 : 69721	CM	ency than SAHA. Thus the QSAR studies greatly aid in u
./___Corpus/Medline/xml/PMC4372801.xml	QSAR	69965 : 69969	CM	ibed here, including the QSAR studies, provide excelle
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70033 : 70037	CM	es to identify potential HDAC inhibitors, either using
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70073 : 70077	CM	, either using the known HDAC inhibitors or from scrat
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70174 : 70178	CM	n the synthesis of novel HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70252 : 70256	CM	rks                      HDAC inhibitors represent a p
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70404 : 70408	CM	al T-cell lymphoma. Many HDAC inhibitors are in differ
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70514 : 70518	CM	 and solid tumors. While HDAC inhibitors alone have di
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	70698 : 70702	CM	anticancer activities of HDAC inhibitors when they are
./___Corpus/Medline/xml/PMC4372801.xml	romidepsin	70791 : 70801	CM	 Even though vorinostat, romidepsin and belinostat are appro
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	71063 : 71067	CM	erscore the potential of HDAC inhibitors in cancer tre
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	71167 : 71171	CM	r activities, the use of HDAC inhibitors in other dise
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	71405 : 71409	CM	nt structural classes of HDAC inhibitors, the most com
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	71438 : 71442	CM	ibitors, the most common HDAC inhibitors are derivativ
./___Corpus/Medline/xml/PMC4372801.xml	hydroxamic acid	71498 : 71513	CM	four structural classes; hydroxamic acid, benzamide, short chain 
./___Corpus/Medline/xml/PMC4372801.xml	benzamide	71515 : 71524	CM	lasses; hydroxamic acid, benzamide, short chain fatty acid 
./___Corpus/Medline/xml/PMC4372801.xml	fatty acid	71538 : 71548	CM	, benzamide, short chain fatty acid or cyclic peptides. The 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	71884 : 71888	CM	he surface region in the HDAC can increase the inhibit
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	72017 : 72021	CM	e anticancer activity of HDAC inhibitors.             
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	72115 : 72119	CM	the clinical benefits of HDAC inhibitors in various di
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	72245 : 72249	CM	otent and tumor-specific HDAC inhibitors. However, dis
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73012 : 73016	CM	tent and enzyme specific HDAC inhibitors. Virtual scre
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73102 : 73106	CM	nhibitors for a specific HDAC enzyme. Both target base
./___Corpus/Medline/xml/PMC4372801.xml	isoform	73214 : 73221	CM	ed for identifying novel isoform specific HDAC inhibitors
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73231 : 73235	CM	g novel isoform specific HDAC inhibitors. Ligand based
./___Corpus/Medline/xml/PMC4372801.xml	lead	73358 : 73362	CM	rostatic properties to a lead query molecule, includin
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73389 : 73393	CM	uery molecule, including HDAC inhibitors that are in c
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73506 : 73510	CM	ew structural classes of HDAC inhibitors as anticancer
./___Corpus/Medline/xml/PMC4372801.xml	zinc	73662 : 73666	CM	ore regions, such as the zinc binding domain, linker a
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73715 : 73719	CM	and cap region, in known HDAC inhibitors including tho
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73822 : 73826	CM	more potent and specific HDAC inhibitors. Computer mod
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	73959 : 73963	CM	more potent and specific HDAC inhibitors. As such, cli
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	74120 : 74124	CM	ver a greater variety of HDAC inhibitors specific for 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	74200 : 74204	CM	o develop tumor specific HDAC inhibitors. This review 
./___Corpus/Medline/xml/PMC4372801.xml	HDAC	74368 : 74372	CM	the development of novel HDAC inhibitors as anticancer
./___Corpus/Medline/xml/PMC4372801.xml	NIMHD-NIH	74582 : 74591	CM	nal Institute of Health (NIMHD-NIH) through Grant number 2G
./___Corpus/Medline/xml/PMC4372801.xml	NIGMS-NIH	74716 : 74725	CM	nal Institute of Health (NIGMS-NIH) through grant number 1U
./___Corpus/Medline/xml/PMC4372801.xml	Histone	74964 : 74971	CM	erences                  Histone Deacetylase Inhibitors i
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	276 : 282	CM	herapies. In particular, cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	478 : 482	CM	feration by impinging on CDK4 or CDK6 complexes in the
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	486 : 490	CM	 by impinging on CDK4 or CDK6 complexes in the G1 phas
./___Corpus/Medline/xml/PMC4480421.xml	G1	508 : 510	CM	or CDK6 complexes in the G1 phase of the cell cycle.
./___Corpus/Medline/xml/PMC4480421.xml	G2	612 : 614	CM	d aspects of S phase and G2/M control mediated by CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	637 : 641	CM	G2/M control mediated by CDK2 and CDK1 are pivotal tum
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	646 : 650	CM	rol mediated by CDK2 and CDK1 are pivotal tumorigenic 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	750 : 753	CM	 clinical development of CDK inhibitors has historica
./___Corpus/Medline/xml/PMC4480421.xml	CDK	813 : 816	CM	hallenging, and numerous CDK inhibitors have demonstr
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	919 : 923	CM	we review the biology of CDKs, the rationale for thera
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1030 : 1033	CM	ical clinical results of CDK inhibitors. We also disc
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1066 : 1069	CM	ors. We also discuss how CDK inhibitors with high sel
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	1126 : 1130	CM	y (particularly for both CDK4 and CDK6), in combinatio
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	1135 : 1139	CM	ularly for both CDK4 and CDK6), in combination with pa
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	1271 : 1275	CM	          The biology of CDKs Integration of multiple 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	1339 : 1343	CM	hways through control of CDK4 and CDK6 activation     
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	1348 : 1352	CM	ough control of CDK4 and CDK6 activation              
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	1420 : 1424	CM	anding of the biology of CDKs is critical to decipheri
./___Corpus/Medline/xml/PMC4480421.xml	CDK	1483 : 1486	CM	inical results seen with CDK inhibitors, particularly
./___Corpus/Medline/xml/PMC4480421.xml	G0	1699 : 1701	CM	aintained in a quiescent G0 state. Tissue maintenanc
./___Corpus/Medline/xml/PMC4480421.xml	RAS	2014 : 2017	CM	th factors (for example, RAS, mitogen-activated prote
./___Corpus/Medline/xml/PMC4480421.xml	mitogen	2019 : 2026	CM	ctors (for example, RAS, mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4480421.xml	rapamycin	2083 : 2092	CM	 and mammalian target of rapamycin (mTOR)) and nuclear rece
./___Corpus/Medline/xml/PMC4480421.xml	mTOR	2094 : 2098	CM	ian target of rapamycin (mTOR)) and nuclear receptors 
./___Corpus/Medline/xml/PMC4480421.xml	oestrogen	2141 : 2150	CM	eptors (for example, the oestrogen receptor (ER) in mammary
./___Corpus/Medline/xml/PMC4480421.xml	ER	2161 : 2163	CM	 the oestrogen receptor (ER) in mammary epithelia) —
./___Corpus/Medline/xml/PMC4480421.xml	G0	2242 : 2244	CM	o drive progression from G0 or G1 phase into S phase
./___Corpus/Medline/xml/PMC4480421.xml	G1	2248 : 2250	CM	e progression from G0 or G1 phase into S phase throu
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2314 : 2318	CM	of the metazoan-specific CDK4 or CDK6 complex2,3,12,13
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2322 : 2326	CM	etazoan-specific CDK4 or CDK6 complex2,3,12,13. CDK4 a
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2345 : 2349	CM	r CDK6 complex2,3,12,13. CDK4 and CDK6 emerged phyloge
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2354 : 2358	CM	mplex2,3,12,13. CDK4 and CDK6 emerged phylogenetically
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2523 : 2527	CM	transition into S phase. CDK4 and CDK6 are structurall
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2532 : 2536	CM	n into S phase. CDK4 and CDK6 are structurally related
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2678 : 2682	CM	 studies have focused on CDK4 (REF. 14). CDK6 is parti
./___Corpus/Medline/xml/PMC4480421.xml	REF	2684 : 2687	CM	es have focused on CDK4 (REF. 14). CDK6 is particular
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2694 : 2698	CM	cused on CDK4 (REF. 14). CDK6 is particularly importan
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	2845 : 2849	CM	         The activity of CDK4 and CDK6 is primarily co
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	2854 : 2858	CM	The activity of CDK4 and CDK6 is primarily controlled 
./___Corpus/Medline/xml/PMC4480421.xml	D-	2910 : 2912	CPR	 their association with D-type cyclins (that is, cyc
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	2934 : 2940	CM	D-type cyclins (that is, cyclin D1, cyclin D2 and cyclin
./___Corpus/Medline/xml/PMC4480421.xml	D1	2941 : 2943	CM	cyclins (that is, cyclin D1, cyclin D2 and cyclin D3
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	2945 : 2951	CM	ins (that is, cyclin D1, cyclin D2 and cyclin D3)17,18. 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	2959 : 2965	CM	cyclin D1, cyclin D2 and cyclin D3)17,18. Among these, c
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	2989 : 2995	CM	n D3)17,18. Among these, cyclin D1 is the best character
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3044 : 3050	CM	rized. The expression of cyclin D1 is characterized as a
./___Corpus/Medline/xml/PMC4480421.xml	mitogenic	3104 : 3113	CM	layed-early’ response to mitogenic signalling, and intricat
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3232 : 3238	CM	hough less well studied, cyclin D3 conforms to a similar
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3275 : 3281	CM	 to a similar pattern as cyclin D1, whereas the regulati
./___Corpus/Medline/xml/PMC4480421.xml	D1	3282 : 3284	CM	imilar pattern as cyclin D1, whereas the regulation 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3312 : 3318	CM	hereas the regulation of cyclin D2 remains more enigmati
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3355 : 3361	CM	more enigmatic, although cyclin D2 also drives prolifera
./___Corpus/Medline/xml/PMC4480421.xml	D-	3463 : 3465	CPR	ession of paralogues of D-type cyclins is likely to 
./___Corpus/Medline/xml/PMC4480421.xml	D-	3563 : 3565	CPR	logy, wherein different D-type cyclins are expressed
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3602 : 3606	CM	are expressed to promote CDK4 or CDK6 activation3,25. 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3610 : 3614	CM	essed to promote CDK4 or CDK6 activation3,25.         
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3718 : 3722	CM	criptional regulation of CDK4 and CDK6, the stability,
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3727 : 3731	CM	l regulation of CDK4 and CDK6, the stability, intracel
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3794 : 3800	CM	ation and association of cyclin D with CDK4 and CDK6 are
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	3808 : 3812	CM	ciation of cyclin D with CDK4 and CDK6 are tightly reg
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	3817 : 3821	CM	f cyclin D with CDK4 and CDK6 are tightly regulated (F
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3870 : 3876	CM	FIG. 2a). In particular, cyclin D1 is unstable and activ
./___Corpus/Medline/xml/PMC4480421.xml	Phosphorylation	3953 : 3968	RN	toplasm and the nucleus. Phosphorylation of threonine 286 on cycl
./___Corpus/Medline/xml/PMC4480421.xml	threonine	3972 : 3981	CM	leus. Phosphorylation of threonine 286 on cyclin D1 activel
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	3989 : 3995	CM	tion of threonine 286 on cyclin D1 actively promotes its
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	4089 : 4093	CM	27. In contrast to other CDKs, for which cyclin associ
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	4105 : 4111	CM	to other CDKs, for which cyclin association seems to occ
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4169 : 4173	CM	ively spontaneously, for CDK4 and CDK6 this process is
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4178 : 4182	CM	ntaneously, for CDK4 and CDK6 this process is regulate
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4252 : 4256	CM	isms28. The inhibitor of CDK4 (INK4) proteins, which i
./___Corpus/Medline/xml/PMC4480421.xml	INK4	4258 : 4262	CM	. The inhibitor of CDK4 (INK4) proteins, which include
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	4288 : 4296	CM	 proteins, which include p16INK4A, p15INK4B, p18INK4C and 
./___Corpus/Medline/xml/PMC4480421.xml	p15INK4B	4298 : 4306	CM	 which include p16INK4A, p15INK4B, p18INK4C and p19INK4D, 
./___Corpus/Medline/xml/PMC4480421.xml	p18INK4C	4308 : 4316	CM	lude p16INK4A, p15INK4B, p18INK4C and p19INK4D, represent 
./___Corpus/Medline/xml/PMC4480421.xml	p19INK4D	4321 : 4329	CM	, p15INK4B, p18INK4C and p19INK4D, represent CDK4- and CDK
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4341 : 4345	CM	 and p19INK4D, represent CDK4- and CDK6-interacting pr
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4423 : 4427	CM	unction as inhibitors of CDK4 and CDK6 (REFS 3,29,30).
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4432 : 4436	CM	s inhibitors of CDK4 and CDK6 (REFS 3,29,30). The INK4
./___Corpus/Medline/xml/PMC4480421.xml	INK4	4457 : 4461	CM	CDK6 (REFS 3,29,30). The INK4 proteins weaken the bind
./___Corpus/Medline/xml/PMC4480421.xml	D-	4494 : 4496	CPR	s weaken the binding of D-type cyclins to CDK4 and C
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4511 : 4515	CM	ing of D-type cyclins to CDK4 and CDK6, and also inter
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4520 : 4524	CM	type cyclins to CDK4 and CDK6, and also interact with 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4574 : 4578	CM	the catalytic domains of CDK4 and CDK6 to potently sup
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4583 : 4587	CM	ytic domains of CDK4 and CDK6 to potently suppress kin
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	4679 : 4683	CM	fore negatively regulate CDK4 and CDK6 in response to 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	4688 : 4692	CM	tively regulate CDK4 and CDK6 in response to stress co
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	4742 : 4750	CM	nditions33. For example, p16INK4A is induced by multiple o
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	4904 : 4912	CM	ing34, overexpression of p16INK4A results in a profound G1
./___Corpus/Medline/xml/PMC4480421.xml	G1	4935 : 4937	CM	4A results in a profound G1 arrest of the cell cycle
./___Corpus/Medline/xml/PMC4480421.xml	p15INK4B	4975 : 4983	CM	e cell cycle. Similarly, p15INK4B is induced by transformi
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5084 : 5088	CM	al cell proliferation35. CDK4 and CDK6, similar to oth
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5093 : 5097	CM	roliferation35. CDK4 and CDK6, similar to other CDK pr
./___Corpus/Medline/xml/PMC4480421.xml	CDK	5116 : 5119	CM	d CDK6, similar to other CDK proteins, are also subje
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5182 : 5186	CM	horegulation36,37. Thus, CDK4 and CDK6 serve as key no
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5191 : 5195	CM	ion36,37. Thus, CDK4 and CDK6 serve as key nodes of in
./___Corpus/Medline/xml/PMC4480421.xml	D-	5411 : 5413	CPR	     The association of D-type cyclins with CDK4 and
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5430 : 5434	CM	n of D-type cyclins with CDK4 and CDK6 can induce kina
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5439 : 5443	CM	pe cyclins with CDK4 and CDK6 can induce kinase activi
./___Corpus/Medline/xml/PMC4480421.xml	CDKs38	5524 : 5530	CM	trum compared with other CDKs38. In particular, CDK4 and
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	5547 : 5551	CM	r CDKs38. In particular, CDK4 and CDK6 have a specific
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	5556 : 5560	CM	 In particular, CDK4 and CDK6 have a specific preferen
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	5596 : 5611	RN	cific preference for the phosphorylation of the tumour suppressor
./___Corpus/Medline/xml/PMC4480421.xml	RB	5661 : 5663	CM	 retinoblastoma protein (RB) and the related protein
./___Corpus/Medline/xml/PMC4480421.xml	RBL1	5710 : 5714	CM	eins p107 (also known as RBL1) and p130 (also known as
./___Corpus/Medline/xml/PMC4480421.xml	RB	5762 : 5764	CM	as RBL2)39,40 (FIG. 2b). RB, the first tumour suppre
./___Corpus/Medline/xml/PMC4480421.xml	RB	5845 : 5847	CM	sively studied41,42. The RB protein does not have ca
./___Corpus/Medline/xml/PMC4480421.xml	RB	5992 : 5994	CM	ll cycle. In particular, RB can bind to the E2F tran
./___Corpus/Medline/xml/PMC4480421.xml	E2F	6011 : 6014	CM	ular, RB can bind to the E2F transcription factors, r
./___Corpus/Medline/xml/PMC4480421.xml	E2Fs	6153 : 6157	CM	E2Fs41,42 (FIG. 2b). The E2Fs regulate the expression 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	6245 : 6253	CM	le control (for example, cyclin E (CCNE), CCNA and CCNB1),
./___Corpus/Medline/xml/PMC4480421.xml	CCNA	6262 : 6266	CM	xample, cyclin E (CCNE), CCNA and CCNB1), dNTP biosynt
./___Corpus/Medline/xml/PMC4480421.xml	CCNB1	6271 : 6276	CM	yclin E (CCNE), CCNA and CCNB1), dNTP biosynthesis (for
./___Corpus/Medline/xml/PMC4480421.xml	dNTP	6279 : 6283	CM	(CCNE), CCNA and CCNB1), dNTP biosynthesis (for exampl
./___Corpus/Medline/xml/PMC4480421.xml	dihydrofolate	6311 : 6324	CM	osynthesis (for example, dihydrofolate reductase (DHFR), ribonu
./___Corpus/Medline/xml/PMC4480421.xml	DHFR	6336 : 6340	CM	dihydrofolate reductase (DHFR), ribonucleotide reducta
./___Corpus/Medline/xml/PMC4480421.xml	ribonucleotide	6343 : 6357	CM	folate reductase (DHFR), ribonucleotide reductase M1 (RRM1) and 
./___Corpus/Medline/xml/PMC4480421.xml	RRM1	6372 : 6376	CM	nucleotide reductase M1 (RRM1) and RRM2) and mitotic p
./___Corpus/Medline/xml/PMC4480421.xml	RRM2	6382 : 6386	CM	 reductase M1 (RRM1) and RRM2) and mitotic progression
./___Corpus/Medline/xml/PMC4480421.xml	BUB1	6453 : 6457	CM	lo-like kinase 1 (PLK1), BUB1 mitotic checkpoint serin
./___Corpus/Medline/xml/PMC4480421.xml	serine	6477 : 6483	CM	 BUB1 mitotic checkpoint serine/threonine kinase (BUB1) 
./___Corpus/Medline/xml/PMC4480421.xml	threonine	6484 : 6493	CM	itotic checkpoint serine/threonine kinase (BUB1) and spindl
./___Corpus/Medline/xml/PMC4480421.xml	BUB1	6502 : 6506	CM	serine/threonine kinase (BUB1) and spindle checkpoint 
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	6557 : 6572	RN	rotein MAD2 (MAD2)). The phosphorylation of RB by CDK4 and CDK6 i
./___Corpus/Medline/xml/PMC4480421.xml	RB	6576 : 6578	CM	. The phosphorylation of RB by CDK4 and CDK6 initiat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	6582 : 6586	CM	phosphorylation of RB by CDK4 and CDK6 initiates an in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	6591 : 6595	CM	lation of RB by CDK4 and CDK6 initiates an intricate p
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	6630 : 6645	RN	 an intricate process of phosphorylation-mediated disruption of R
./___Corpus/Medline/xml/PMC4480421.xml	RB	6669 : 6671	CM	n-mediated disruption of RB function that releases E
./___Corpus/Medline/xml/PMC4480421.xml	E2F	6695 : 6698	CM	B function that releases E2F and initiates subsequent
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	6770 : 6774	CM	he cell cycle (FIG. 2c). CDK4 and CDK6 also phosphoryl
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	6779 : 6783	CM	ycle (FIG. 2c). CDK4 and CDK6 also phosphorylate forkh
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylate	6789 : 6802	CM	 2c). CDK4 and CDK6 also phosphorylate forkhead box protein M1 
./___Corpus/Medline/xml/PMC4480421.xml	M1	6824 : 6826	CM	ate forkhead box protein M1 (FOXM1), leading to stab
./___Corpus/Medline/xml/PMC4480421.xml	FOXM1	6828 : 6833	CM	forkhead box protein M1 (FOXM1), leading to stabilizati
./___Corpus/Medline/xml/PMC4480421.xml	FOXM1	6864 : 6869	CM	ding to stabilization of FOXM1 as a further mediator in
./___Corpus/Medline/xml/PMC4480421.xml	mitosis38	6951 : 6960	CM	d for progression though mitosis38 (FIG. 3).               
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7008 : 7012	CM	     Deregulation of the CDK4/6-RB-p16INK4A pathway in
./___Corpus/Medline/xml/PMC4480421.xml	6-RB-p16INK4A	7013 : 7026	CM	Deregulation of the CDK4/6-RB-p16INK4A pathway in cancer       
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7070 : 7074	CM	                     The CDK4/6–RB axis is critical to
./___Corpus/Medline/xml/PMC4480421.xml	6–	7075 : 7077	CPR	                The CDK4/6–RB axis is critical to ce
./___Corpus/Medline/xml/PMC4480421.xml	RB	7077 : 7079	CM	              The CDK4/6–RB axis is critical to cell
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	7282 : 7290	CM	promote the induction of p16INK4A as an intrinsic break to
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	7369 : 7377	CM	44-46. Overexpression of p16INK4A ultimately engages RB to
./___Corpus/Medline/xml/PMC4480421.xml	RB	7397 : 7399	CM	INK4A ultimately engages RB to suppress growth and c
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	7642 : 7650	CM	eans in tumours: loss of p16INK4A or loss of RB29,47. Loss
./___Corpus/Medline/xml/PMC4480421.xml	RB29,47	7662 : 7669	CM	s of p16INK4A or loss of RB29,47. Loss of p16INK4A uncoup
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	7679 : 7687	CM	loss of RB29,47. Loss of p16INK4A uncouples the oncogenic 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	7743 : 7747	CM	 from the suppression of CDK4 or CDK6 activity, wherea
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	7751 : 7755	CM	e suppression of CDK4 or CDK6 activity, whereas loss o
./___Corpus/Medline/xml/PMC4480421.xml	RB	7782 : 7784	CM	ctivity, whereas loss of RB deregulates downstream s
./___Corpus/Medline/xml/PMC4480421.xml	RB	7866 : 7868	CM	sistent with this model, RB is required for the cell
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	7919 : 7927	CM	cycle arrest mediated by p16INK4A (REFS 48,49). In additio
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	8013 : 8021	CM	-physiological levels of p16INK4A and are therefore insens
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	8080 : 8088	CM	additional expression of p16INK4A owing to the absence of 
./___Corpus/Medline/xml/PMC4480421.xml	RB29	8113 : 8117	CM	 owing to the absence of RB29.                        
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8201 : 8205	CM	nism of deregulating the CDK4/6–RB axis is the direct 
./___Corpus/Medline/xml/PMC4480421.xml	6–	8206 : 8208	CPR	of deregulating the CDK4/6–RB axis is the direct onc
./___Corpus/Medline/xml/PMC4480421.xml	RB	8208 : 8210	CM	 deregulating the CDK4/6–RB axis is the direct oncog
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8254 : 8258	CM	 oncogenic activation of CDK4 or CDK6 activity. Deregu
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	8262 : 8266	CM	ic activation of CDK4 or CDK6 activity. Deregulated cy
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	8289 : 8295	CM	K6 activity. Deregulated cyclin D1 protein expression, g
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	8478 : 8484	CM	ic oncogenic activity of cyclin D1 (REFS 17,18,51). Furt
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	8535 : 8539	CM	ermore, amplification of CDK4 and CDK6 is observed in 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	8544 : 8548	CM	mplification of CDK4 and CDK6 is observed in several d
./___Corpus/Medline/xml/PMC4480421.xml	RB	8743 : 8745	CM	e-specific. For example, RB loss is a hallmark of sm
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	8808 : 8814	CM	 cancer, deregulation of cyclin D1 is common in breast c
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	8858 : 8866	CM	east cancer, and loss of p16INK4A is particularly common i
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	8954 : 8958	CM	    Distal regulation of CDK2 and its deregulation in 
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	9024 : 9028	CM	            Although all CDKs have similarities, CDK2 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9048 : 9052	CM	 CDKs have similarities, CDK2 is structurally and func
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	9097 : 9101	CM	 functionally related to CDK1 (REF. 3). CDK2 has a con
./___Corpus/Medline/xml/PMC4480421.xml	REF	9103 : 9106	CM	ionally related to CDK1 (REF. 3). CDK2 has a consider
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9112 : 9116	CM	elated to CDK1 (REF. 3). CDK2 has a considerably broad
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9167 : 9171	CM	r substrate profile than CDK4 and CDK6, and it phospho
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9176 : 9180	CM	te profile than CDK4 and CDK6, and it phosphorylates a
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	9189 : 9203	CM	an CDK4 and CDK6, and it phosphorylates a large number of protei
./___Corpus/Medline/xml/PMC4480421.xml	p27KIP1	9280 : 9287	CM	rogression (for example, p27KIP1 and RB), DNA replication
./___Corpus/Medline/xml/PMC4480421.xml	RB	9292 : 9294	CM	for example, p27KIP1 and RB), DNA replication (for e
./___Corpus/Medline/xml/PMC4480421.xml	histone	9357 : 9364	CM	cation factors A and C), histone synthesis (for example, 
./___Corpus/Medline/xml/PMC4480421.xml	NPAT	9389 : 9393	CM	 synthesis (for example, NPAT), centrosome duplication
./___Corpus/Medline/xml/PMC4480421.xml	nucleophosmin	9433 : 9446	CM	uplication (for example, nucleophosmin (NPM)), among other proc
./___Corpus/Medline/xml/PMC4480421.xml	vitro	9495 : 9500	CM	cesses57-59 (FIG. 3). In vitro, CDK2 and its preferred 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9502 : 9506	CM	7-59 (FIG. 3). In vitro, CDK2 and its preferred E-type
./___Corpus/Medline/xml/PMC4480421.xml	E-	9526 : 9528	CPR	 CDK2 and its preferred E-type and A-type cyclin par
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	9543 : 9549	CM	ferred E-type and A-type cyclin partners assemble sponta
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9644 : 9648	CM	Much of the control over CDK2 involves the synthesis a
./___Corpus/Medline/xml/PMC4480421.xml	RB	9710 : 9712	CM	ity of the cyclins, with RB and E2F regulating the a
./___Corpus/Medline/xml/PMC4480421.xml	E2F	9717 : 9720	CM	the cyclins, with RB and E2F regulating the abundance
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9749 : 9753	CM	ulating the abundance of CDK2, cyclin E1 and cyclin E2
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	9755 : 9761	CM	g the abundance of CDK2, cyclin E1 and cyclin E2 transcr
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	9769 : 9775	CM	e of CDK2, cyclin E1 and cyclin E2 transcripts and prote
./___Corpus/Medline/xml/PMC4480421.xml	mitogen	9831 : 9838	CM	65. This process couples mitogen-mediated activation of C
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9862 : 9866	CM	n-mediated activation of CDK4 and CDK6 with the activa
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9871 : 9875	CM	d activation of CDK4 and CDK6 with the activation of C
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9899 : 9903	CM	6 with the activation of CDK2 (REFS 66,67) (FIG. 2c). 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	9943 : 9947	CM	FIG. 2c). In contrast to CDK4 and CDK6, CDK2 is not re
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	9952 : 9956	CM	 In contrast to CDK4 and CDK6, CDK2 is not regulated b
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	9958 : 9962	CM	ntrast to CDK4 and CDK6, CDK2 is not regulated by INK4
./___Corpus/Medline/xml/PMC4480421.xml	INK4	9983 : 9987	CM	CDK2 is not regulated by INK4 proteins30,68 but by the
./___Corpus/Medline/xml/PMC4480421.xml	CIP	10064 : 10067	CM	nase inhibitory protein (CIP/KIP) class of CDK inhibi
./___Corpus/Medline/xml/PMC4480421.xml	KIP	10068 : 10071	CM	 inhibitory protein (CIP/KIP) class of CDK inhibitors
./___Corpus/Medline/xml/PMC4480421.xml	CDK	10082 : 10085	CM	otein (CIP/KIP) class of CDK inhibitors, which bind t
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10112 : 10116	CM	nhibitors, which bind to CDK2–cyclin complexes and ren
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	10117 : 10123	CM	tors, which bind to CDK2–cyclin complexes and render the
./___Corpus/Medline/xml/PMC4480421.xml	p21CIP1	10181 : 10188	CM	ve60,69-71. For example, p21CIP1 acts as a DNA damage che
./___Corpus/Medline/xml/PMC4480421.xml	p27KIP1	10307 : 10314	CM	 DNA synthesis), whereas p27KIP1 is responsive to mitogen
./___Corpus/Medline/xml/PMC4480421.xml	mitogenic	10332 : 10341	CM	p27KIP1 is responsive to mitogenic signalling as a further 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10423 : 10427	CM	tion71,72. Additionally, CDK2 is regulated by phosphor
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	10444 : 10459	RN	ly, CDK2 is regulated by phosphorylation events73. Therefore, mul
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	10520 : 10524	CM	nisms in addition to the CDK4/6–RB axis can modulate t
./___Corpus/Medline/xml/PMC4480421.xml	6–	10525 : 10527	CPR	 in addition to the CDK4/6–RB axis can modulate the 
./___Corpus/Medline/xml/PMC4480421.xml	RB	10527 : 10529	CM	n addition to the CDK4/6–RB axis can modulate the ac
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10564 : 10568	CM	modulate the activity of CDK2 and subsequent DNA repli
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	10690 : 10694	CM	ear that deregulation of CDK2 also occurs frequently i
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	10761 : 10767	CM	f cancer74. Cyclin E1 or cyclin E2 amplifications are ke
./___Corpus/Medline/xml/PMC4480421.xml	Ectopic	10891 : 10898	CM	n cancers75-77 (FIG. 4). Ectopic expression of cyclin E b
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	10913 : 10921	CM	). Ectopic expression of cyclin E bypasses the need for CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	10944 : 10948	CM	 E bypasses the need for CDK4 or CDK6 activity to init
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	10952 : 10956	CM	ses the need for CDK4 or CDK6 activity to initiate the
./___Corpus/Medline/xml/PMC4480421.xml	E-	11047 : 11049	CPR	d that amplification of E-type cyclins may be oncoge
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	11152 : 11156	CM	ological requirement for CDK4 or CDK6 activity to init
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	11160 : 11164	CM	 requirement for CDK4 or CDK6 activity to initiate exp
./___Corpus/Medline/xml/PMC4480421.xml	E-	11201 : 11203	CPR	 initiate expression of E-type cyclins). The CDK inh
./___Corpus/Medline/xml/PMC4480421.xml	CDK	11221 : 11224	CM	 of E-type cyclins). The CDK inhibitor p27KIP1 is dow
./___Corpus/Medline/xml/PMC4480421.xml	p27KIP1	11235 : 11242	CM	lins). The CDK inhibitor p27KIP1 is downregulated in many
./___Corpus/Medline/xml/PMC4480421.xml	p27KIP1	11306 : 11313	CM	ough the genetic loss of p27KIP1 is fairly rare81,82.    
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	11352 : 11356	CM	e81,82.                  CDK1 is a key determinant of 
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	11422 : 11426	CM	ion                      CDK1 was cloned on the basis 
./___Corpus/Medline/xml/PMC4480421.xml	cdc2	11477 : 11481	CM	f complementarity to the cdc2 gene of Schizosaccharomy
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	11537 : 11541	CM	mbe83. The expression of CDK1 and associated cyclins (
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	11566 : 11572	CM	 and associated cyclins (cyclin A2 and cyclin B1) is coo
./___Corpus/Medline/xml/PMC4480421.xml	cyclin B1	11580 : 11589	CM	d cyclins (cyclin A2 and cyclin B1) is coordinated through 
./___Corpus/Medline/xml/PMC4480421.xml	E2F	11688 : 11691	CM	se include the canonical E2F and RB constituents, as 
./___Corpus/Medline/xml/PMC4480421.xml	RB	11696 : 11698	CM	de the canonical E2F and RB constituents, as well as
./___Corpus/Medline/xml/PMC4480421.xml	FOXM1	11749 : 11754	CM	the transcription factor FOXM1 and the DREAM (dimerizat
./___Corpus/Medline/xml/PMC4480421.xml	DREAM	11763 : 11768	CM	ion factor FOXM1 and the DREAM (dimerization partner, R
./___Corpus/Medline/xml/PMC4480421.xml	RB	11792 : 11794	CM	M (dimerization partner, RB-like, E2F and multivulva
./___Corpus/Medline/xml/PMC4480421.xml	E2F	11801 : 11804	CM	zation partner, RB-like, E2F and multivulval class B)
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	11976 : 11980	CM	clins that assemble with CDK1 are intrinsically unstab
./___Corpus/Medline/xml/PMC4480421.xml	ubiquitin	12029 : 12038	CM	ble and are regulated by ubiquitin-mediated degradation mec
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12109 : 12113	CM	mbly and localization of CDK1 complexes are regulated 
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12260 : 12264	CM	eriments have shown that CDK1 is required for mammalia
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12554 : 12558	CM	restrain the activity of CDK1 until DNA replication is
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12666 : 12670	CM	n of DNA replication and CDK1 activity is mediated by 
./___Corpus/Medline/xml/PMC4480421.xml	CHK1	12733 : 12737	CM	gnalling kinases such as CHK1 and WEE1, which suppress
./___Corpus/Medline/xml/PMC4480421.xml	WEE1	12742 : 12746	CM	kinases such as CHK1 and WEE1, which suppress the acti
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12779 : 12783	CM	suppress the activity of CDK1 via inhibitory phosphory
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation93	12799 : 12816	CM	y of CDK1 via inhibitory phosphorylation93, as well as through the 
./___Corpus/Medline/xml/PMC4480421.xml	phosphatases	12882 : 12894	CM	cle 25 (CDC25) family of phosphatases. At the onset of mitosis
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	12935 : 12939	CM	f mitosis, activation of CDK1 occurs rapidly through a
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	13001 : 13015	CM	edback loop whereby CDK1 phosphorylates and inactivates WEE1. CD
./___Corpus/Medline/xml/PMC4480421.xml	WEE1	13032 : 13036	CM	orylates and inactivates WEE1. CDK1 subsequently phosp
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	13038 : 13042	CM	es and inactivates WEE1. CDK1 subsequently phosphoryla
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	13056 : 13070	CM	 WEE1. CDK1 subsequently phosphorylates multiple substrates, lea
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	13369 : 13373	CM	nt on the attenuation of CDK1 activity through the deg
./___Corpus/Medline/xml/PMC4480421.xml	cyclin B1	13410 : 13419	CM	rough the degradation of cyclin B1 by the anaphase-promotin
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	13633 : 13637	CM	ed evidence to show that CDK1 activity is dysregulated
./___Corpus/Medline/xml/PMC4480421.xml	p53	13725 : 13728	CM	igenesis. Derangement of p53 signalling or of DNA dam
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	13809 : 13813	CM	s to the deregulation of CDK1 (REFS 97,98), and high c
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	13837 : 13843	CM	1 (REFS 97,98), and high cyclin B1 expression is general
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	13959 : 13963	CM	er, the requirement that CDK1 activity must be attenua
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	14048 : 14052	CM	aspects of uncoordinated CDK1 activity are likely to l
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	14234 : 14238	CM	dition to the well-known CDKs involved in regulating t
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	14311 : 14315	CM	 an equivalent number of CDKs involved in basal transc
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	14393 : 14397	CM	(FIG. 3). In particular, CDK8 is part of the mediator 
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	14473 : 14477	CM	lethora of genes101,102. CDK7 has a general role in th
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	14504 : 14519	RN	as a general role in the phosphorylation of the RNA polymerase II
./___Corpus/Medline/xml/PMC4480421.xml	RNA	14527 : 14530	CM	e phosphorylation of the RNA polymerase II carboxyter
./___Corpus/Medline/xml/PMC4480421.xml	carboxyterminal	14545 : 14560	CM	of the RNA polymerase II carboxyterminal domain that contributes 
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	14628 : 14632	CM	of transcription103, and CDK9 also phosphorylates RNA 
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylates	14638 : 14652	CM	iption103, and CDK9 also phosphorylates RNA polymerase II, there
./___Corpus/Medline/xml/PMC4480421.xml	CDK11	14728 : 14733	CM	 transcription. Finally, CDK11 acts on the splicing mac
./___Corpus/Medline/xml/PMC4480421.xml	CDK	14797 : 14800	CM	h of these contexts, the CDK activity is directed by 
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	14834 : 14840	CM	 is directed by specific cyclin interactions. Accumulati
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	14922 : 14926	CM	transcription-regulating CDKs may represent therapeuti
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	15029 : 15033	CM	      In addition to the CDKs involved in transcriptio
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	15099 : 15103	CM	there remains a class of CDKs, including CDK3 and CDK5
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15115 : 15119	CM	class of CDKs, including CDK3 and CDK5, for which the 
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15124 : 15128	CM	CDKs, including CDK3 and CDK5, for which the underlyin
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15178 : 15182	CM	g functions are elusive. CDK3 was found to be intrinsi
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15319 : 15323	CM	nant-negative version of CDK3 (REF. 72) (FIG. 3). Howe
./___Corpus/Medline/xml/PMC4480421.xml	REF	15325 : 15328	CM	egative version of CDK3 (REF. 72) (FIG. 3). However, 
./___Corpus/Medline/xml/PMC4480421.xml	CDK3	15426 : 15430	CM	ains harbour an inactive CDK3, suggesting that its rol
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15506 : 15510	CM	 readily compensated104. CDK5 was largely viewed as a 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	15691 : 15695	CM	any functions similar to CDK4 and CDK2 in driving prog
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	15700 : 15704	CM	ions similar to CDK4 and CDK2 in driving progression f
./___Corpus/Medline/xml/PMC4480421.xml	G1–S	15733 : 15737	CM	driving progression from G1–S and in RB phosphorylatio
./___Corpus/Medline/xml/PMC4480421.xml	RB	15745 : 15747	CM	ression from G1–S and in RB phosphorylation in medul
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	15748 : 15763	RN	sion from G1–S and in RB phosphorylation in medullary thyroid can
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	15803 : 15807	CM	hyroid cancer models106. CDK5 might therefore have pot
./___Corpus/Medline/xml/PMC4480421.xml	CDK	15973 : 15976	CM	 The first generation of CDK inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16041 : 16044	CM	e past 20 years, several CDK inhibitors have been dev
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16198 : 16201	CM	5). The first-generation CDK inhibitors developed wer
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	16332 : 16344	CM	 (an example of which is flavopiridol (also known as alvocidib
./___Corpus/Medline/xml/PMC4480421.xml	olomucine	16434 : 16443	CM	 some compounds, such as olomucine (not commercially develo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	16573 : 16577	CM	atively low affinity for CDK4 and CDK6). As the field 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	16582 : 16586	CM	ow affinity for CDK4 and CDK6). As the field of CDK bi
./___Corpus/Medline/xml/PMC4480421.xml	CDK	16605 : 16608	CM	d CDK6). As the field of CDK biology progressed in pa
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	16865 : 16869	CM	ly specific inhibitor of CDK1, CDK2 and CDK5; however,
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	16871 : 16875	CM	cific inhibitor of CDK1, CDK2 and CDK5; however, subse
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	16880 : 16884	CM	ibitor of CDK1, CDK2 and CDK5; however, subsequent dat
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	16997 : 17001	CM	hrough the inhibition of CDK7 and CDK9 (REF. 107).    
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17006 : 17010	CM	e inhibition of CDK7 and CDK9 (REF. 107).             
./___Corpus/Medline/xml/PMC4480421.xml	REF	17012 : 17015	CM	bition of CDK7 and CDK9 (REF. 107).                  
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17099 : 17111	CM	t-generation inhibitors, flavopiridol is the most extensively 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	17149 : 17152	CM	extensively investigated CDK inhibitor so far, with >
./___Corpus/Medline/xml/PMC4480421.xml	Flavopiridol	17272 : 17284	CM	y information S1 (box)). Flavopiridol is a semi-synthetic flav
./___Corpus/Medline/xml/PMC4480421.xml	flavonoid	17305 : 17314	CM	idol is a semi-synthetic flavonoid derived from rohitukine,
./___Corpus/Medline/xml/PMC4480421.xml	chromone	17342 : 17350	CM	rived from rohitukine, a chromone alkaloid, and has been s
./___Corpus/Medline/xml/PMC4480421.xml	alkaloid	17351 : 17359	CM	m rohitukine, a chromone alkaloid, and has been shown to i
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	17391 : 17395	CM	as been shown to inhibit CDK1, CDK2, CDK4, CDK6, CDK7 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	17397 : 17401	CM	n shown to inhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	17403 : 17407	CM	n to inhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (RE
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	17409 : 17413	CM	nhibit CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (REFS 108
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	17415 : 17419	CM	 CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (REFS 108,109).
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17424 : 17428	CM	K2, CDK4, CDK6, CDK7 and CDK9 (REFS 108,109). Although
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17454 : 17466	CM	(REFS 108,109). Although flavopiridol can induce cell cycle ar
./___Corpus/Medline/xml/PMC4480421.xml	G1	17499 : 17501	CM	uce cell cycle arrest in G1 and G2 phases, in certai
./___Corpus/Medline/xml/PMC4480421.xml	G2	17506 : 17508	CM	l cycle arrest in G1 and G2 phases, in certain conte
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	17599 : 17603	CM	 probably as a result of CDK7 and CDK9 inhibition that
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	17608 : 17612	CM	 as a result of CDK7 and CDK9 inhibition that leads to
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17720 : 17732	CM	broad-spectrum nature of flavopiridol results in substantial i
./___Corpus/Medline/xml/PMC4480421.xml	vitro	17759 : 17764	CM	esults in substantial in vitro activity, substantially 
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	17842 : 17854	CM	n vivo110. Consequently, flavopiridol did not meet the initial
./___Corpus/Medline/xml/PMC4480421.xml	CDK	17904 : 17907	CM	 high expectations for a CDK inhibitor, and low level
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18092 : 18104	CM	vidence to indicate that flavopiridol may have clinical activi
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	18192 : 18201	CM	h as chronic lymphocytic leukaemia (CLL) and mantle cell ly
./___Corpus/Medline/xml/PMC4480421.xml	CLL	18203 : 18206	CM	c lymphocytic leukaemia (CLL) and mantle cell lymphom
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18285 : 18297	CM	 also seems to influence flavopiridol efficacy. For example, a
./___Corpus/Medline/xml/PMC4480421.xml	lysis	18547 : 18552	RN	le responses, and tumour lysis syndrome was reported in
./___Corpus/Medline/xml/PMC4480421.xml	CLL	18613 : 18616	CM	ely 40% of patients with CLL treated with flavopirido
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol115	18630 : 18645	CM	ts with CLL treated with flavopiridol115. Despite these reports a
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18753 : 18765	CM	 and drug development of flavopiridol was consequently discont
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	18860 : 18872	CM	        In parallel with flavopiridol, roscovitine, a purine-b
./___Corpus/Medline/xml/PMC4480421.xml	purine	18889 : 18895	CM	opiridol, roscovitine, a purine-based CDK inhibitor, was
./___Corpus/Medline/xml/PMC4480421.xml	CDK	18902 : 18905	CM	covitine, a purine-based CDK inhibitor, was among the
./___Corpus/Medline/xml/PMC4480421.xml	APPRAISE	19158 : 19166	CM	ndomized Phase II trial (APPRAISE) that compared roscoviti
./___Corpus/Medline/xml/PMC4480421.xml	APPRAISE	19296 : 19304	CM	ll cell lung cancer. The APPRAISE study was terminated aft
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	19654 : 19658	CM	n inhibitors of multiple CDKs                      Fol
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	19698 : 19710	CM	       Following on from flavopiridol and roscovitine, other C
./___Corpus/Medline/xml/PMC4480421.xml	CDK	19734 : 19737	CM	l and roscovitine, other CDK inhibitors were develope
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	19807 : 19811	CM	creasing selectivity for CDK1 and CDK2 and/or increasi
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	19816 : 19820	CM	selectivity for CDK1 and CDK2 and/or increasing overal
./___Corpus/Medline/xml/PMC4480421.xml	CDK	19881 : 19884	CM	FIG. 5). Again, numerous CDK inhibitors seemed to be 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	20125 : 20128	CM	 these second-generation CDK inhibitors, dinaciclib (
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	20329 : 20333	CM	ghly potent inhibitor of CDK1, CDK2, CDK5 and CDK9 (ha
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	20335 : 20339	CM	otent inhibitor of CDK1, CDK2, CDK5 and CDK9 (half-max
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	20341 : 20345	CM	inhibitor of CDK1, CDK2, CDK5 and CDK9 (half-maximal i
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	20350 : 20354	CM	 of CDK1, CDK2, CDK5 and CDK9 (half-maximal inhibitory
./___Corpus/Medline/xml/PMC4480421.xml	IC50	20395 : 20399	CM	nhibitory concentration (IC50) values in the range of 
./___Corpus/Medline/xml/PMC4480421.xml	1–	20424 : 20426	CPR	) values in the range of 1–4 nM), with less activity
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	20460 : 20464	CM	th less activity against CDK4, CDK6 and CDK7 (IC50 val
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	20466 : 20470	CM	s activity against CDK4, CDK6 and CDK7 (IC50 values in
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	20475 : 20479	CM	y against CDK4, CDK6 and CDK7 (IC50 values in the rang
./___Corpus/Medline/xml/PMC4480421.xml	IC50	20481 : 20485	CM	nst CDK4, CDK6 and CDK7 (IC50 values in the range of 6
./___Corpus/Medline/xml/PMC4480421.xml	60–	20509 : 20512	CPR	0 values in the range of 60–100 nM). Compared to flav
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	20533 : 20545	CM	 60–100 nM). Compared to flavopiridol, dinaciclib exhibited su
./___Corpus/Medline/xml/PMC4480421.xml	RB	20616 : 20618	CM	regard to suppression of RB phosphorylation in cell-
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	20619 : 20634	RN	ard to suppression of RB phosphorylation in cell-based assays118.
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	21586 : 21595	CM	h advanced acute myeloid leukaemia (patients ≥60 years of a
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	21647 : 21656	CM	) or acute lymphoblastic leukaemia, no objective responses 
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	21931 : 21943	CM	d dinaciclib, similar to flavopiridol, demonstrated clinical a
./___Corpus/Medline/xml/PMC4480421.xml	CLL126	22004 : 22010	CM	pretreated patients with CLL126. Based on these data, a 
./___Corpus/Medline/xml/PMC4480421.xml	CLL	22090 : 22093	CM	dinaciclib in refractory CLL is ongoing. Therefore, d
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	22211 : 22223	CM	l malignancies, in which flavopiridol also had evidence of act
./___Corpus/Medline/xml/PMC4480421.xml	CDK	22299 : 22302	CM	                   Other CDK inhibitors include AT751
./___Corpus/Medline/xml/PMC4480421.xml	pyrazole 3-carboxyamide	22353 : 22376	CM	 (developed by Astex), a pyrazole 3-carboxyamide compound that acts as an
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	22415 : 22419	CM	 acts as an inhibitor of CDK1, CDK2, CDK4, CDK6 and CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	22421 : 22425	CM	as an inhibitor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	22427 : 22431	CM	inhibitor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT7519 h
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	22433 : 22437	CM	tor of CDK1, CDK2, CDK4, CDK6 and CDK9. AT7519 has bee
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	22442 : 22446	CM	K1, CDK2, CDK4, CDK6 and CDK9. AT7519 has been evaluat
./___Corpus/Medline/xml/PMC4480421.xml	bortezomib	22494 : 22504	CM	ated in combination with bortezomib in a Phase II clinical t
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	22753 : 22757	CM	oche) is an inhibitor of CDK1, CDK2 and CDK4 with less
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	22759 : 22763	CM	is an inhibitor of CDK1, CDK2 and CDK4 with less poten
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	22768 : 22772	CM	ibitor of CDK1, CDK2 and CDK4 with less potency for CD
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	22795 : 22799	CM	K4 with less potency for CDK7, glycogen synthase kinas
./___Corpus/Medline/xml/PMC4480421.xml	glycogen	22801 : 22809	CM	h less potency for CDK7, glycogen synthase kinase 3α (GSK3
./___Corpus/Medline/xml/PMC4480421.xml	GSK3β	22841 : 22846	CM	se kinase 3α (GSK3α) and GSK3β. R547 was tested in a Ph
./___Corpus/Medline/xml/PMC4480421.xml	Bristol	23092 : 23099	CM	BMS-387032; developed by Bristol-Myers Squibb), which was
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23179 : 23183	CM	 greater selectivity for CDK2 than CDK1 and CDK4, is n
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	23189 : 23193	CM	electivity for CDK2 than CDK1 and CDK4, is now recogni
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	23198 : 23202	CM	y for CDK2 than CDK1 and CDK4, is now recognized to al
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	23237 : 23241	CM	ecognized to also target CDK7 and CDK9. Two Phase I cl
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	23246 : 23250	CM	 to also target CDK7 and CDK9. Two Phase I clinical st
./___Corpus/Medline/xml/PMC4480421.xml	SNS-032	23286 : 23293	CM	 I clinical studies with SNS-032, one in 2010 in advanced
./___Corpus/Medline/xml/PMC4480421.xml	AZD5438	23474 : 23481	CM	rent. The development of AZD5438 (developed by Astra Zene
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	23556 : 23560	CM	ble, potent inhibitor of CDK1, CDK2 and CDK9 with less
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23562 : 23566	CM	otent inhibitor of CDK1, CDK2 and CDK9 with less selec
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	23571 : 23575	CM	ibitor of CDK1, CDK2 and CDK9 with less selectivity fo
./___Corpus/Medline/xml/PMC4480421.xml	CDK5	23602 : 23606	CM	ith less selectivity for CDK5 and CDK6 (REF. 131) — wa
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	23611 : 23615	CM	selectivity for CDK5 and CDK6 (REF. 131) — was discont
./___Corpus/Medline/xml/PMC4480421.xml	REF	23617 : 23620	CM	ivity for CDK5 and CDK6 (REF. 131) — was discontinued
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	23817 : 23821	CM	 — a potent inhibitor of CDK1, CDK2 and CDK4 — was als
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	23823 : 23827	CM	otent inhibitor of CDK1, CDK2 and CDK4 — was also disc
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	23832 : 23836	CM	ibitor of CDK1, CDK2 and CDK4 — was also discontinued 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24048 : 24051	CM	  Reasons for failure of CDK inhibitors with low sele
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24142 : 24145	CM	failure of non-selective CDK inhibitors in the clinic
./___Corpus/Medline/xml/PMC4480421.xml	CDK	24331 : 24334	CM	 action. For many of the CDK inhibitors with low spec
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	24562 : 24574	CM	tic effect. For example, flavopiridol has been associated with
./___Corpus/Medline/xml/PMC4480421.xml	CDK	25041 : 25044	CM	f studies conducted with CDK inhibitors with low spec
./___Corpus/Medline/xml/PMC4480421.xml	flavopiridol	25273 : 25285	CM	tential activity of both flavopiridol and dinaciclib in CLL an
./___Corpus/Medline/xml/PMC4480421.xml	CLL	25304 : 25307	CM	iridol and dinaciclib in CLL and the rare ‘extraordin
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	25565 : 25569	CM	e that the inhibition of CDKs that control transcripti
./___Corpus/Medline/xml/PMC4480421.xml	CDK	25744 : 25747	CM	ic window. Many of these CDK inhibitors target severa
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	25836 : 25840	CM	liferation (for example, CDK1) and survival (for examp
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	25869 : 25873	CM	d survival (for example, CDK9) of normal cells. This l
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26126 : 26129	CM	iated with non-selective CDK inhibitors include diarr
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26252 : 26255	CM	 case for selectivity of CDK inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	26380 : 26384	CM	 selectivity for certain CDKs is the key to the succes
./___Corpus/Medline/xml/PMC4480421.xml	CDK	26429 : 26432	CM	uccessful development of CDK inhibitors as therapeuti
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	26498 : 26502	CM	 Selective inhibitors of CDK2 might provide the abilit
./___Corpus/Medline/xml/PMC4480421.xml	cyclin E	26589 : 26597	CM	nts in tumours driven by cyclin E amplification. Emerging 
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	26650 : 26654	CM	a suggest that targeting CDK1 is toxic in certain cont
./___Corpus/Medline/xml/PMC4480421.xml	KRAS	26790 : 26794	CM	c lethal screens against KRAS mutations have indicated
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	26847 : 26851	CM	potential sensitivity to CDK1 knockdown, although foll
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	26918 : 26922	CM	 required137. Similarly, CDK1 or CDK9 inhibition is sy
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	26926 : 26930	CM	d137. Similarly, CDK1 or CDK9 inhibition is synthetica
./___Corpus/Medline/xml/PMC4480421.xml	CDK1	27002 : 27006	CM	,139. Pharmacologically, CDK1 inhibitors seem to poten
./___Corpus/Medline/xml/PMC4480421.xml	poly(ADP-ribose)	27064 : 27080	CM	erate with inhibitors of poly(ADP-ribose) polymerase140 by comprom
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27181 : 27185	CM	is to selectively target CDK7, CDK8 or CDK9, which are
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	27187 : 27191	CM	selectively target CDK7, CDK8 or CDK9, which are assoc
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	27195 : 27199	CM	ely target CDK7, CDK8 or CDK9, which are associated wi
./___Corpus/Medline/xml/PMC4480421.xml	CDK8	27330 : 27334	CM	o selective suppression. CDK8 may function as an oncop
./___Corpus/Medline/xml/PMC4480421.xml	β-catenin	27422 : 27431	CM	ing the transcription of β-catenin target genes141. A coval
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27473 : 27477	CM	 A covalent inhibitor of CDK7 (THZ1), which is relativ
./___Corpus/Medline/xml/PMC4480421.xml	THZ1	27479 : 27483	CM	alent inhibitor of CDK7 (THZ1), which is relatively sp
./___Corpus/Medline/xml/PMC4480421.xml	CDK7	27519 : 27523	CM	 relatively specific for CDK7 compared with other CDKs
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	27544 : 27548	CM	CDK7 compared with other CDKs, has shown activity in m
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	27640 : 27644	CM	a specific inhibitor for CDK9 (CDKI-73) that exhibited
./___Corpus/Medline/xml/PMC4480421.xml	CDKI-73	27646 : 27653	CM	ific inhibitor for CDK9 (CDKI-73) that exhibited activity
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	27699 : 27708	CM	vity in animal models of leukaemia was recently developed14
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27776 : 27780	CM	  Targeted inhibition of CDK4 and CDK6 Rationale for t
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27785 : 27789	CM	d inhibition of CDK4 and CDK6 Rationale for targeting 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27814 : 27818	CM	 Rationale for targeting CDK4 and CDK6                
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27823 : 27827	CM	e for targeting CDK4 and CDK6                      Bas
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	27918 : 27922	CM	c studies and studies of CDK4 and CDK6 deregulation in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	27927 : 27931	CM	 and studies of CDK4 and CDK6 deregulation in cancer, 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28008 : 28012	CM	d expectations arose for CDK4 and CDK6 inhibitors in t
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28017 : 28021	CM	tions arose for CDK4 and CDK6 inhibitors in the clinic
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28084 : 28088	CM	would expect that a pure CDK4 or CDK6 inhibitor would 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28092 : 28096	CM	pect that a pure CDK4 or CDK6 inhibitor would elicit a
./___Corpus/Medline/xml/PMC4480421.xml	G0	28162 : 28164	CM	e in tumours: cytostatic G0/G1 arrest. Second, this 
./___Corpus/Medline/xml/PMC4480421.xml	G1	28165 : 28167	CM	n tumours: cytostatic G0/G1 arrest. Second, this eff
./___Corpus/Medline/xml/PMC4480421.xml	RB	28246 : 28248	CM	ion of the engagement of RB to suppress gene express
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28389 : 28393	CM	 exhibit deregulation of CDK4 and CDK6 activity as opp
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28398 : 28402	CM	deregulation of CDK4 and CDK6 activity as opposed to o
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	28432 : 28436	CM	vity as opposed to other CDKs. Initial data from mouse
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28500 : 28504	CM	 confusion as to whether CDK4 and CDK6 were therapeuti
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28509 : 28513	CM	n as to whether CDK4 and CDK6 were therapeutic targets
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28615 : 28619	CM	y despite the absence of CDK4 and/or CDK6 (REFS 15,144
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28627 : 28631	CM	e absence of CDK4 and/or CDK6 (REFS 15,144) and in the
./___Corpus/Medline/xml/PMC4480421.xml	D-	28669 : 28671	CPR	) and in the absence of D-type cyclins145. These dat
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	28755 : 28759	CM	ry plasticity with other CDKs. Despite uncertainties a
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	28872 : 28876	CM	lear that attenuation of CDK4 and CDK6 activity could 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	28881 : 28885	CM	 attenuation of CDK4 and CDK6 activity could prevent t
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	28970 : 28976	CM	mour types. For example, cyclin D1 is crucial for the de
./___Corpus/Medline/xml/PMC4480421.xml	HER2	29040 : 29044	CM	ammary tumours driven by HER2 (also known as ERBB2)146
./___Corpus/Medline/xml/PMC4480421.xml	ERBB2)146	29060 : 29069	CM	n by HER2 (also known as ERBB2)146, and similar observation
./___Corpus/Medline/xml/PMC4480421.xml	NOTCH	29113 : 29118	CM	vations were obtained in NOTCH-driven T cell leukaemia 
./___Corpus/Medline/xml/PMC4480421.xml	leukaemia	29133 : 29142	CM	d in NOTCH-driven T cell leukaemia mouse models147 and cell
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	29295 : 29299	CM	ctive inhibitors of both CDK4 and CDK6 has markedly ch
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	29304 : 29308	CM	ibitors of both CDK4 and CDK6 has markedly changed the
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	29348 : 29352	CM	hanged the perception of CDKs as therapeutic targets i
./___Corpus/Medline/xml/PMC4480421.xml	pyrido[2,3-d]pyrimidin-7-one	29467 : 29495	CM	ation, it was found that pyrido[2,3-d]pyrimidin-7-one compounds with a 2-amino
./___Corpus/Medline/xml/PMC4480421.xml	2-amino pyridine	29513 : 29529	CM	n-7-one compounds with a 2-amino pyridine side chain at the C2 pos
./___Corpus/Medline/xml/PMC4480421.xml	C2	29548 : 29550	CM	ridine side chain at the C2 position act as CDK inhi
./___Corpus/Medline/xml/PMC4480421.xml	CDK	29567 : 29570	CM	t the C2 position act as CDK inhibitors with a high d
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	29620 : 29624	CM	egree of selectivity for CDK4 and CDK6 relative to oth
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	29629 : 29633	CM	selectivity for CDK4 and CDK6 relative to other CDKs14
./___Corpus/Medline/xml/PMC4480421.xml	CDKs149	29652 : 29659	CM	d CDK6 relative to other CDKs149 (FIG. 5). Subsequent opt
./___Corpus/Medline/xml/PMC4480421.xml	G1	29799 : 29801	CM	zer) that induced potent G1 arrest in cell culture a
./___Corpus/Medline/xml/PMC4480421.xml	G1–S	29895 : 29899	CM	rom the basic biology of G1–S transition, the effects 
./___Corpus/Medline/xml/PMC4480421.xml	RB	29986 : 29988	CM	presence of a functional RB protein, thus demonstrat
./___Corpus/Medline/xml/PMC4480421.xml	CDK	30095 : 30098	CM	previously described for CDK inhibitors150,151. Subse
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	30192 : 30196	CM	monstrated that specific CDK4 and CDK6 inhibitors arre
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	30201 : 30205	CM	d that specific CDK4 and CDK6 inhibitors arrest the ce
./___Corpus/Medline/xml/PMC4480421.xml	phosphorylation	30274 : 30289	RN	e downstream blockade of phosphorylation of RB, as well as the re
./___Corpus/Medline/xml/PMC4480421.xml	RB	30293 : 30295	CM	de of phosphorylation of RB, as well as the related 
./___Corpus/Medline/xml/PMC4480421.xml	S-phase	30395 : 30402	CM	he loss of expression of S-phase cyclins, nucleotide bios
./___Corpus/Medline/xml/PMC4480421.xml	nucleotide	30412 : 30422	CM	sion of S-phase cyclins, nucleotide biosynthesis, DNA replic
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	30505 : 30509	CM	atory genes152,153. Dual CDK4 and CDK6 inhibitors have
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	30514 : 30518	CM	es152,153. Dual CDK4 and CDK6 inhibitors have been sho
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	30847 : 30853	CM	nown as abemaciclib) and LEE011, respectively157-162. Ea
./___Corpus/Medline/xml/PMC4480421.xml	ATP	31076 : 31079	CM	nding to the specialized ATP-binding pocket of CDK4 a
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31098 : 31102	CM	ed ATP-binding pocket of CDK4 and CDK6 and specific in
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31107 : 31111	CM	nding pocket of CDK4 and CDK6 and specific interaction
./___Corpus/Medline/xml/PMC4480421.xml	ATP	31159 : 31162	CM	ons with residues in the ATP-binding cleft, although 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31257 : 31261	CM	is. In contrast to other CDK4- and CDK6-selective comp
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31267 : 31271	CM	trast to other CDK4- and CDK6-selective compounds, abe
./___Corpus/Medline/xml/PMC4480421.xml	CDK9	31314 : 31318	CM	ds, abemaciclib inhibits CDK9 in in vitro kinase assay
./___Corpus/Medline/xml/PMC4480421.xml	vitro	31325 : 31330	CM	clib inhibits CDK9 in in vitro kinase assays, although 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	31548 : 31552	CM	inical studies with dual CDK4 and CDK6 inhibitors (TAB
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	31557 : 31561	CM	udies with dual CDK4 and CDK6 inhibitors (TABLE 2). Re
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32048 : 32052	CM	ytostatic nature of dual CDK4 and CDK6 inhibitors resu
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	32057 : 32061	CM	 nature of dual CDK4 and CDK6 inhibitors resulted in p
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	32283 : 32289	CM	(which exhibits frequent cyclin D1 amplification) receiv
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32513 : 32517	CM	 a disease with frequent CDK4 amplification, also repo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	32598 : 32602	CM	e rates in patients with CDK4 amplification and RB exp
./___Corpus/Medline/xml/PMC4480421.xml	RB	32621 : 32623	CM	h CDK4 amplification and RB expression165,166. The r
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	32684 : 32690	CM	orted Phase I study with LEE011 monotherapy in patients 
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	32761 : 32767	CM	umours demonstrated that LEE011 was well tolerated, with
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	33178 : 33182	CM	I trials evaluating dual CDK4 and CDK6 inhibitors as m
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	33187 : 33191	CM	evaluating dual CDK4 and CDK6 inhibitors as monotherap
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	33361 : 33365	CM	al hallmarks of inducing CDK4 and CDK6 inhibition in p
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	33370 : 33374	CM	rks of inducing CDK4 and CDK6 inhibition in patients w
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	33515 : 33521	CM	icity of palbociclib and LEE011. Although neutropaenia i
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	33639 : 33645	CM	ted with palbociclib and LEE011 is distinct in that it i
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	33803 : 33809	CM	ly, both palbociclib and LEE011 are dosed intermittently
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34262 : 34266	CM	tion suggested that dual CDK4 and CDK6 inhibitors posi
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	34271 : 34275	CM	ested that dual CDK4 and CDK6 inhibitors positively in
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34576 : 34580	CM	 model155. Additionally, CDK4 and CDK6 inhibition has 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	34585 : 34589	CM	. Additionally, CDK4 and CDK6 inhibition has shown act
./___Corpus/Medline/xml/PMC4480421.xml	ER	34698 : 34700	CM	e acquired resistance to ER antagonists155,169,170. 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	34866 : 34870	CM	hat are regulated by the CDK4/6–RB-E2F axis, suggestin
./___Corpus/Medline/xml/PMC4480421.xml	6–	34871 : 34873	CPR	re regulated by the CDK4/6–RB-E2F axis, suggesting a
./___Corpus/Medline/xml/PMC4480421.xml	RB-E2F	34873 : 34879	CM	 regulated by the CDK4/6–RB-E2F axis, suggesting a basis
./___Corpus/Medline/xml/PMC4480421.xml	CDK	35052 : 35055	CM	equently transformed the CDK field.                  
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35250 : 35259	CM	 the aromatase inhibitor letrozole versus letrozole plus pa
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35267 : 35276	CM	hibitor letrozole versus letrozole plus palbociclib. Data f
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35364 : 35373	CM	tion of palbociclib plus letrozole elicited significant imp
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35457 : 35466	CM	e survival compared with letrozole alone (20.2 months compa
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	35672 : 35681	CM	a trend in favour of the letrozole plus palbociclib combina
./___Corpus/Medline/xml/PMC4480421.xml	April	35900 : 35905	CM	d Drug Administration in April 2013. ER-positive breast
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	35984 : 35988	CM	requent dysregulation of CDK4 and CDK6 activity due to
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	35993 : 35997	CM	ysregulation of CDK4 and CDK6 activity due to the over
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	36072 : 36078	CM	ion of the gene encoding cyclin D1 (CCND1). Those cancer
./___Corpus/Medline/xml/PMC4480421.xml	CCND1	36083 : 36088	CM	gene encoding cyclin D1 (CCND1). Those cancers with amp
./___Corpus/Medline/xml/PMC4480421.xml	CCND1	36127 : 36132	CM	rs with amplification of CCND1 seemed to derive no grea
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	36250 : 36256	CM	ct the central nature of cyclin D1 in promoting ER-posit
./___Corpus/Medline/xml/PMC4480421.xml	CCND1	36340 : 36345	CM	gardless of whether high CCND1 expression was due to am
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36602 : 36606	CM	sted each include a dual CDK4 and CDK6 inhibitor (abem
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36611 : 36615	CM	 include a dual CDK4 and CDK6 inhibitor (abemaciclib, 
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	36640 : 36646	CM	 inhibitor (abemaciclib, LEE011 or palbociclib) and a ho
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	36686 : 36695	CM	) and a hormone therapy (letrozole, anastrazole or fulvestr
./___Corpus/Medline/xml/PMC4480421.xml	anastrazole	36697 : 36708	CM	mone therapy (letrozole, anastrazole or fulvestrant) (TABLE 2
./___Corpus/Medline/xml/PMC4480421.xml	fulvestrant	36712 : 36723	CM	etrozole, anastrazole or fulvestrant) (TABLE 2).             
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36753 : 36757	CM	BLE 2).                  CDK4 and CDK6 inhibitor bioma
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36762 : 36766	CM	                CDK4 and CDK6 inhibitor biomarker stra
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	36941 : 36945	CM	that may respond to dual CDK4 and CDK6 inhibitors. The
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	36950 : 36954	CM	respond to dual CDK4 and CDK6 inhibitors. The most con
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37057 : 37061	CM	direct assessment of the CDK4–RB–p16INK4A pathway. Dat
./___Corpus/Medline/xml/PMC4480421.xml	RB	37062 : 37064	CM	t assessment of the CDK4–RB–p16INK4A pathway. Data f
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	37065 : 37073	CM	ssessment of the CDK4–RB–p16INK4A pathway. Data from multi
./___Corpus/Medline/xml/PMC4480421.xml	RB	37132 : 37134	CM	s have demonstrated that RB is necessary for the arr
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37174 : 37178	CM	or the arrest induced by CDK4 and CDK6 inhibition152-1
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37183 : 37187	CM	rest induced by CDK4 and CDK6 inhibition152-157,175,17
./___Corpus/Medline/xml/PMC4480421.xml	RB	37227 : 37229	CM	157,175,176, and loss of RB is therefore a marker of
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37269 : 37273	CM	 marker of resistance to CDK4 and CDK6 inhibition. Los
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37278 : 37282	CM	f resistance to CDK4 and CDK6 inhibition. Loss of RB r
./___Corpus/Medline/xml/PMC4480421.xml	RB	37303 : 37305	CM	CDK6 inhibition. Loss of RB results in supra-physiol
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	37351 : 37359	CM	siological expression of p16INK4A, which may also be a bio
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	37434 : 37442	CM	 example, high levels of p16INK4A are identified in malign
./___Corpus/Medline/xml/PMC4480421.xml	RB	37535 : 37537	CM	irus that can inactivate RB in cervical and in head 
./___Corpus/Medline/xml/PMC4480421.xml	RB	37613 : 37615	CM	ether dual assessment of RB loss and induction of p1
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	37638 : 37646	CM	RB loss and induction of p16INK4A expression is better tha
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37798 : 37802	CM	markers for tumours with CDK4 and/or CDK6 dependence o
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37810 : 37814	CM	tumours with CDK4 and/or CDK6 dependence or ‘addiction
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	37942 : 37948	CM	 be the amplification of cyclin D1 or CDK4 and CDK6, los
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	37955 : 37959	CM	fication of cyclin D1 or CDK4 and CDK6, loss of p16INK
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	37964 : 37968	CM	of cyclin D1 or CDK4 and CDK6, loss of p16INK4A or oth
./___Corpus/Medline/xml/PMC4480421.xml	p16INK4A	37978 : 37986	CM	r CDK4 and CDK6, loss of p16INK4A or other genetic alterat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38047 : 38051	CM	g to the deregulation of CDK4 or CDK6 activity. This c
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38055 : 38059	CM	 deregulation of CDK4 or CDK6 activity. This concept h
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	38165 : 38171	CM	lbociclib (LUNG-MAP) and LEE011 (SIGNATURE), in which pa
./___Corpus/Medline/xml/PMC4480421.xml	SIGNATURE	38173 : 38182	CM	b (LUNG-MAP) and LEE011 (SIGNATURE), in which patients with
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38274 : 38278	CM	e expected to deregulate CDK4 and CDK6 activity can be
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38283 : 38287	CM	d to deregulate CDK4 and CDK6 activity can be enrolled
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38381 : 38385	CM	           The future of CDK4 and CDK6 inhibitors     
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38390 : 38394	CM	  The future of CDK4 and CDK6 inhibitors              
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38475 : 38479	CM	l data suggest that dual CDK4 and CDK6 inhibitors coul
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38484 : 38488	CM	ggest that dual CDK4 and CDK6 inhibitors could have br
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38688 : 38692	CM	nefit the most from dual CDK4 and CDK6 inhibitors.    
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38697 : 38701	CM	 most from dual CDK4 and CDK6 inhibitors.             
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38841 : 38845	CM	ent tumour benefits from CDK4 and CDK6 inhibition. In 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38850 : 38854	CM	r benefits from CDK4 and CDK6 inhibition. In some tumo
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	38889 : 38893	CM	n. In some tumour types, CDK4 and CDK6 inhibition has 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	38898 : 38902	CM	e tumour types, CDK4 and CDK6 inhibition has a surpris
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39127 : 39131	CM	stance to the effects of CDK4 and CDK6 inhibition. For
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39136 : 39140	CM	 the effects of CDK4 and CDK6 inhibition. For example,
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39166 : 39170	CM	inhibition. For example, CDK4 and CDK6 suppression see
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39175 : 39179	CM	n. For example, CDK4 and CDK6 suppression seems to hav
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	39458 : 39462	CM	 In these cancers, other CDKs, particularly CDK2, are 
./___Corpus/Medline/xml/PMC4480421.xml	CDK2	39477 : 39481	CM	other CDKs, particularly CDK2, are likely to compensat
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39522 : 39526	CM	compensate for selective CDK4 and CDK6 inhibition. How
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39531 : 39535	CM	e for selective CDK4 and CDK6 inhibition. However, the
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	39598 : 39602	CM	 determine whether other CDKs can compensate for CDK4 
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39622 : 39626	CM	 CDKs can compensate for CDK4 and CDK6 inhibition are 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39631 : 39635	CM	 compensate for CDK4 and CDK6 inhibition are poorly un
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	39769 : 39773	CM	schedules for treatment. CDK4 and CDK6 inhibition anta
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	39778 : 39782	CM	 for treatment. CDK4 and CDK6 inhibition antagonizes t
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40033 : 40037	CM	evaluate scheduling with CDK4 and CDK6 inhibition, fol
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40042 : 40046	CM	scheduling with CDK4 and CDK6 inhibition, following th
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40099 : 40103	CM	oncept that release from CDK4 and CDK6 inhibition may 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40108 : 40112	CM	at release from CDK4 and CDK6 inhibition may synchroni
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40642 : 40646	CM	 is the potential use of CDK4 and CDK6 inhibition to p
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40651 : 40655	CM	otential use of CDK4 and CDK6 inhibition to protect no
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	40935 : 40939	CM	 potential for combining CDK4 and CDK6 inhibitors with
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	40944 : 40948	CM	l for combining CDK4 and CDK6 inhibitors with other ta
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41042 : 41046	CM	rk has demonstrated that CDK4 and CDK6 inhibition may 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41051 : 41055	CM	monstrated that CDK4 and CDK6 inhibition may be synerg
./___Corpus/Medline/xml/PMC4480421.xml	MEK	41091 : 41094	CM	 may be synergistic with MEK inhibition in NRAS-posit
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41169 : 41173	CM	y, in pancreatic cancer, CDK4 and CDK6 inhibition is s
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41178 : 41182	CM	creatic cancer, CDK4 and CDK6 inhibition is synergisti
./___Corpus/Medline/xml/PMC4480421.xml	phosphatidylinositol-4,5-bisphosphate	41320 : 41357	CM	 in cancers with mutated phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), catalyt
./___Corpus/Medline/xml/PMC4480421.xml	3-	41359 : 41361	CPR	ositol-4,5-bisphosphate 3-kinase (PI3K), catalytic s
./___Corpus/Medline/xml/PMC4480421.xml	PI3K	41368 : 41372	CM	5-bisphosphate 3-kinase (PI3K), catalytic subunit-α (P
./___Corpus/Medline/xml/PMC4480421.xml	PIK3CA	41396 : 41402	CM	K), catalytic subunit-α (PIK3CA), PI3K inhibitors may sy
./___Corpus/Medline/xml/PMC4480421.xml	PI3K	41405 : 41409	CM	ytic subunit-α (PIK3CA), PI3K inhibitors may synergize
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41440 : 41444	CM	itors may synergize with CDK4 and CDK6 inhibitors160. 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41449 : 41453	CM	 synergize with CDK4 and CDK6 inhibitors160. Studies w
./___Corpus/Medline/xml/PMC4480421.xml	LEE011	41482 : 41488	CM	ibitors160. Studies with LEE011 have incorporated this C
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	41512 : 41516	CM	1 have incorporated this CDK4 and CDK6 inhibitor into 
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	41521 : 41525	CM	corporated this CDK4 and CDK6 inhibitor into the tripl
./___Corpus/Medline/xml/PMC4480421.xml	PIK3CA	41573 : 41579	CM	plet combinations with a PIK3CA inhibitor (BYL719) and l
./___Corpus/Medline/xml/PMC4480421.xml	letrozole	41603 : 41612	CM	A inhibitor (BYL719) and letrozole (ClinicalTrials.gov iden
./___Corpus/Medline/xml/PMC4480421.xml	mTOR	41747 : 41751	CM	"}}NCT01872260), and the mTOR inhibitor everolimus wit
./___Corpus/Medline/xml/PMC4480421.xml	everolimus	41762 : 41772	CM	, and the mTOR inhibitor everolimus with exemestane in ER-po
./___Corpus/Medline/xml/PMC4480421.xml	exemestane	41778 : 41788	CM	nhibitor everolimus with exemestane in ER-positive breast ca
./___Corpus/Medline/xml/PMC4480421.xml	CDK4	42025 : 42029	CM	s are effective and that CDK4 and CDK6 inhibition coul
./___Corpus/Medline/xml/PMC4480421.xml	CDK6	42034 : 42038	CM	ective and that CDK4 and CDK6 inhibition could represe
./___Corpus/Medline/xml/PMC4480421.xml	CDK	42181 : 42184	CM	ion                      CDK complexes have critical 
./___Corpus/Medline/xml/PMC4480421.xml	CDK	42383 : 42386	CM	rials with non-selective CDK inhibitors, the importan
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	42455 : 42459	CM	f compounds for specific CDKs and of patient selection
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	42611 : 42615	CM	 agents against specific CDKs, companion diagnostics t
./___Corpus/Medline/xml/PMC4480421.xml	CDKs	42940 : 42944	CM	or the identification of CDKs, the promise of their se
./___Corpus/Medline/xml/PMC4480421.xml	NIH	43552 : 43555	CM	tional Cancer Institute (NIH/NCI) (CA129134 and CA188
./___Corpus/Medline/xml/PMC4480421.xml	NCI	43556 : 43559	CM	al Cancer Institute (NIH/NCI) (CA129134 and CA188650)
./___Corpus/Medline/xml/PMC4480421.xml	CA129134	43562 : 43570	CM	cer Institute (NIH/NCI) (CA129134 and CA188650). A.K.W. ac
./___Corpus/Medline/xml/PMC4480421.xml	NIH	43632 : 43635	CM	esearch funding from the NIH/NCI (CA163863).         
./___Corpus/Medline/xml/PMC4480421.xml	NCI	43636 : 43639	CM	rch funding from the NIH/NCI (CA163863).             
./___Corpus/Medline/xml/PMC4480421.xml	cyclin	43898 : 43904	CM	 and future of targeting cyclin-dependent kinases in can
./___Corpus/Medline/xml/PMC4569005.xml	meta-	2836 : 2841	CPR	d of genetically diverse meta-populations spread across
./___Corpus/Medline/xml/PMC4569005.xml	26–	11475 : 11478	CPR	e-bodied species.13, 17, 26–28 These characteristics 
./___Corpus/Medline/xml/PMC4569005.xml	bolide	17628 : 17634	CM	  Surgical resection and bolide impacts                 
./___Corpus/Medline/xml/PMC4569005.xml	bolide	17793 : 17799	CM	 devastation caused by a bolide impact.. In respect of c
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	21490 : 21497	CM	cally proliferate in the hypoxic regions that are only fo
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	21581 : 21588	CM	 avascular nature, these hypoxic regions are hard to targ
./___Corpus/Medline/xml/PMC4569005.xml	CTLA-4	22123 : 22129	CM	nment.50, 51 Blockade of CTLA-4 (cytotoxic T-lymphocyte 
./___Corpus/Medline/xml/PMC4569005.xml	PD-1	22169 : 22173	CM	ymphocyte protein 4) and PD-1–PD-L1 (programmed cell d
./___Corpus/Medline/xml/PMC4569005.xml	1–	22211 : 22213	CPR	ammed cell death protein 1–programmed cell death 1 l
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22465 : 22470	CPR	 The uses of ipilumimab (anti-CTLA4 monoclonal antibody
./___Corpus/Medline/xml/PMC4569005.xml	mAb	22497 : 22500	CM	LA4 monoclonal antibody [mAb]) to treat metastatic me
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22631 : 22636	CPR	e recently, trials of an anti-PD-1 mAb have shown durab
./___Corpus/Medline/xml/PMC4569005.xml	anti-	22788 : 22793	CPR	gher response rates with anti-PD-L1 therapy were seen i
./___Corpus/Medline/xml/PMC4569005.xml	lysis	23544 : 23549	RN	nd subsequently inducing lysis of malignant cells withi
./___Corpus/Medline/xml/PMC4569005.xml	VEGF	23799 : 23803	CM	that have high levels of VEGF production.58 Phase III 
./___Corpus/Medline/xml/PMC4569005.xml	E1B	24370 : 24373	CM	ations. For example, the E1B 55 kDa deletion in adeno
./___Corpus/Medline/xml/PMC4569005.xml	TP53	24465 : 24469	CM	cancer cells, but not in TP53 wild-type cells.61 These
./___Corpus/Medline/xml/PMC4569005.xml	oxygen	25582 : 25588	CM	ovide nutrients, such as oxygen, and the co-opting of st
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28160 : 28170	RN	ells have high levels of glycolysis that proceeds primarily 
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28217 : 28224	CM	ly through production of lactate in the cytosol, in a pro
./___Corpus/Medline/xml/PMC4569005.xml	cytosol	28232 : 28239	CM	uction of lactate in the cytosol, in a process known as a
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28271 : 28281	RN	process known as aerobic glycolysis, or the Warburg effect, 
./___Corpus/Medline/xml/PMC4569005.xml	phosphorylation	28350 : 28365	RN	mal process of oxidative phosphorylation of pyruvate that occurs 
./___Corpus/Medline/xml/PMC4569005.xml	pyruvate	28369 : 28377	CM	ative phosphorylation of pyruvate that occurs in the mitoc
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28429 : 28439	RN	ndria. The high level of glycolysis in cancer has led to eff
./___Corpus/Medline/xml/PMC4569005.xml	glucose	28479 : 28486	CM	led to efforts to target glucose metabolism.72, 73 2-deox
./___Corpus/Medline/xml/PMC4569005.xml	2-deoxyglucose	28505 : 28519	CM	lucose metabolism.72, 73 2-deoxyglucose has been used to inhibit
./___Corpus/Medline/xml/PMC4569005.xml	glucose	28545 : 28552	CM	has been used to inhibit glucose metabolism, but toxicity
./___Corpus/Medline/xml/PMC4569005.xml	normoxic	28675 : 28683	CM	onship can exist between normoxic and hypoxic cells, enabl
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	28688 : 28695	CM	ist between normoxic and hypoxic cells, enabling adaptati
./___Corpus/Medline/xml/PMC4569005.xml	Hypoxic	28750 : 28757	CM	 nutrient deprivation.77 Hypoxic cells extrude lactate as
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28772 : 28779	CM	77 Hypoxic cells extrude lactate as a byproduct of glycol
./___Corpus/Medline/xml/PMC4569005.xml	glycolysis	28798 : 28808	RN	actate as a byproduct of glycolysis, and this lactate can be
./___Corpus/Medline/xml/PMC4569005.xml	lactate	28819 : 28826	CM	 of glycolysis, and this lactate can be taken up via mono
./___Corpus/Medline/xml/PMC4569005.xml	monocarboxylate	28847 : 28862	CM	tate can be taken up via monocarboxylate transporters into normox
./___Corpus/Medline/xml/PMC4569005.xml	normoxic	28881 : 28889	CM	xylate transporters into normoxic cancer cells and used as
./___Corpus/Medline/xml/PMC4569005.xml	glucose	28965 : 28972	CM	g the tumour to overcome glucose deprivation.78 Targeting
./___Corpus/Medline/xml/PMC4569005.xml	monocarboxylate	28998 : 29013	CM	deprivation.78 Targeting monocarboxylate transporters in cancer c
./___Corpus/Medline/xml/PMC4569005.xml	nucleotides	29198 : 29209	CM	 into biomass, including nucleotides, amino acids, and lipids
./___Corpus/Medline/xml/PMC4569005.xml	amino acids	29211 : 29222	CM	, including nucleotides, amino acids, and lipids, which are n
./___Corpus/Medline/xml/PMC4569005.xml	lipids	29228 : 29234	CM	otides, amino acids, and lipids, which are needed to pro
./___Corpus/Medline/xml/PMC4569005.xml	Methotrexate	29537 : 29549	CM	for resistant species.80 Methotrexate and 5-fluorouracil are a
./___Corpus/Medline/xml/PMC4569005.xml	5-fluorouracil	29554 : 29568	CM	cies.80 Methotrexate and 5-fluorouracil are antimetabolites that
./___Corpus/Medline/xml/PMC4569005.xml	Bisphosphonates	30102 : 30117	CM	ive anticancer strategy. Bisphosphonates mimic pyrophosphates, an
./___Corpus/Medline/xml/PMC4569005.xml	pyrophosphates	30124 : 30138	CM	y. Bisphosphonates mimic pyrophosphates, and inhibit critical en
./___Corpus/Medline/xml/PMC4569005.xml	Bisphosphonates	30197 : 30212	CM	unctions in osteoclasts. Bisphosphonates can reduce the consequen
./___Corpus/Medline/xml/PMC4569005.xml	bisphosphonates	30363 : 30378	CM	 In early breast cancer, bisphosphonates improve breast-cancer-sp
./___Corpus/Medline/xml/PMC4569005.xml	87–	31375 : 31378	CPR	eclinical models.83, 84, 87–89                  Anti-
./___Corpus/Medline/xml/PMC4569005.xml	anti-	31522 : 31527	CPR	of neovascularization,90 anti-angiogenic therapies can 
./___Corpus/Medline/xml/PMC4569005.xml	tyrosine	31661 : 31669	CM	y inhibition of receptor tyrosine kinases or neutralizatio
./___Corpus/Medline/xml/PMC4569005.xml	VEGF	31699 : 31703	CM	ses or neutralization of VEGF or its receptors using m
./___Corpus/Medline/xml/PMC4569005.xml	anti-	32233 : 32238	CPR	a that was hoped for, as anti-angiogenic therapy select
./___Corpus/Medline/xml/PMC4569005.xml	hypoxic	32333 : 32340	CM	microvasculature creates hypoxic regions, which can exace
./___Corpus/Medline/xml/PMC4569005.xml	MET	32608 : 32611	CM	romotes invasion through MET signalling, and prepares
./___Corpus/Medline/xml/PMC4569005.xml	LOX	32675 : 32678	CM	atic niche by increasing LOX expression.95, 96 Strate
./___Corpus/Medline/xml/PMC4569005.xml	anti-	32719 : 32724	CPR	96 Strategies to combine anti-angiogenic agents with ME
./___Corpus/Medline/xml/PMC4569005.xml	MET	32747 : 32750	CM	i-angiogenic agents with MET inhibition are currently
./___Corpus/Medline/xml/PMC4569005.xml	anti-	32899 : 32904	CPR	ntuitively, low doses of anti-angiogenic agents can pro
./___Corpus/Medline/xml/PMC4569005.xml	anti-	33143 : 33148	CPR	mour’s habitat, low dose anti-angiogenic agents can mak
./___Corpus/Medline/xml/PMC4569005.xml	lipid	34197 : 34202	CM	n temperature, including lipid membranes, cytoskeletal 
./___Corpus/Medline/xml/PMC4569005.xml	42°C	34354 : 34358	CM	Mild hyperthermia (up to 42°C) can enhance immunogenic
./___Corpus/Medline/xml/PMC4569005.xml	42°C	34578 : 34582	CM	y.100 Hyperthermia above 42°C induces cytotoxic effect
./___Corpus/Medline/xml/PMC4569005.xml	HSPs	34843 : 34847	CM	ptosis.103 Inhibitors of HSPs, and HSP90 in particular
./___Corpus/Medline/xml/PMC4569005.xml	HSP90	34853 : 34858	CM	 Inhibitors of HSPs, and HSP90 in particular, are in cl
./___Corpus/Medline/xml/PMC4569005.xml	HSP	34957 : 34960	CM	ise.104 A combination of HSP inhibitors and hyperther
./___Corpus/Medline/xml/PMC4569005.xml	etoposide	35919 : 35928	CM	emotherapy consisting of etoposide, ifosfamide, and doxorub
./___Corpus/Medline/xml/PMC4569005.xml	ifosfamide	35930 : 35940	CM	consisting of etoposide, ifosfamide, and doxorubicin (EIA), 
./___Corpus/Medline/xml/PMC4569005.xml	doxorubicin	35946 : 35957	CM	oposide, ifosfamide, and doxorubicin (EIA), or with EIA combi
./___Corpus/Medline/xml/PMC4569005.xml	EIA	35959 : 35962	CM	famide, and doxorubicin (EIA), or with EIA combined w
./___Corpus/Medline/xml/PMC4569005.xml	EIA	35973 : 35976	CM	xorubicin (EIA), or with EIA combined with regional h
./___Corpus/Medline/xml/PMC4569005.xml	EIA	36024 : 36027	CM	 hyperthermia found that EIA with hyperthermia achiev
./___Corpus/Medline/xml/PMC4569005.xml	EIA	36102 : 36105	CM	 compared with 12.7% for EIA alone.111 Addition of hy
./___Corpus/Medline/xml/PMC4569005.xml	anti-	37544 : 37549	CPR	growth primarily through anti-angiogenic mechanisms.114
./___Corpus/Medline/xml/PMC4569005.xml	anti-	37839 : 37844	CPR	 in combination with new anti-angiogenic drugs, but def
./___Corpus/Medline/xml/PMC4569005.xml	BRCA	39677 : 39681	CM	or example, tumours with BRCA mutations), which are hi
./___Corpus/Medline/xml/PMC4569005.xml	ADP-ribose	39861 : 39871	CM	tion of the enzyme poly (ADP-ribose) polymerase.118 The sear
./___Corpus/Medline/xml/PMC4569005.xml	APOBEC	41371 : 41377	CM	 of mutational meltdown. APOBEC (apolipoprotein B mRNA e
./___Corpus/Medline/xml/PMC4569005.xml	mRNA	41396 : 41400	CM	APOBEC (apolipoprotein B mRNA editing enzyme, catalyti
./___Corpus/Medline/xml/PMC4569005.xml	APOBEC	41641 : 41647	CM	ppropriate activation of APOBEC has been implicated in c
./___Corpus/Medline/xml/PMC4569005.xml	10-fold	43453 : 43460	CM	gus is associated with a 10-fold increase in risk for pro
./___Corpus/Medline/xml/PMC4569005.xml	adenocarcinoma.132	43509 : 43527	CM	ogression to oesophageal adenocarcinoma.132 Nuclear pleiomorphism (d
./___Corpus/Medline/xml/PMC4569005.xml	PET	44892 : 44895	CM	 Functional imaging with PET tracers, such as 3′-deox
./___Corpus/Medline/xml/PMC4569005.xml	3′-deoxy-3′-[18F]-fluorothymidine	44913 : 44946	CM	ith PET tracers, such as 3′-deoxy-3′-[18F]-fluorothymidine, and others in developme
./___Corpus/Medline/xml/PMC4569005.xml	actin	46615 : 46620	CM	 vimentin, smooth-muscle actin, Twist-related protein 1
./___Corpus/Medline/xml/PMC4569005.xml	N-	46647 : 46649	CPR	Twist-related protein 1, N-cadherin, cadherin-11, AK
./___Corpus/Medline/xml/PMC4569005.xml	AKT2	46672 : 46676	CM	N-cadherin, cadherin-11, AKT2 (PKBβ), and PI3K-α. Amoe
./___Corpus/Medline/xml/PMC4569005.xml	PI3K-α	46689 : 46695	CM	rin-11, AKT2 (PKBβ), and PI3K-α. Amoeboid movement can b
./___Corpus/Medline/xml/PMC4569005.xml	RAC1	46775 : 46779	CM	ansforming protein RhoA, RAC1, RAC2, CDC42, actin-rela
./___Corpus/Medline/xml/PMC4569005.xml	RAC2	46781 : 46785	CM	ming protein RhoA, RAC1, RAC2, CDC42, actin-related pr
./___Corpus/Medline/xml/PMC4569005.xml	CDC42	46787 : 46792	CM	rotein RhoA, RAC1, RAC2, CDC42, actin-related proteins 
./___Corpus/Medline/xml/PMC4569005.xml	actin	46794 : 46799	CM	RhoA, RAC1, RAC2, CDC42, actin-related proteins 2 and 3
./___Corpus/Medline/xml/PMC4569005.xml	aquaporin-5.137	46830 : 46845	CM	ed proteins 2 and 3, and aquaporin-5.137 These markers could be a
./___Corpus/Medline/xml/PMC4569005.xml	anti-	49984 : 49989	CPR	utrient restriction, and anti-angiogenic therapy. Nutri
./___Corpus/Medline/xml/PMC4569005.xml	anti-	50399 : 50404	CPR	Habitat disruption using anti-angiogenic therapy and ma
./___Corpus/Medline/xml/PMC4569005.xml	formalin	52493 : 52501	CM	on could be assayed from formalin-fixed, paraffin-embedded
./___Corpus/Medline/xml/PMC4569005.xml	C.C.M	53467 : 53472	CM	nts                      C.C.M. is supported in part by
./___Corpus/Medline/xml/PMC4569005.xml	NIH	53581 : 53584	CM	American Cancer Society, NIH grants P01 CA91955, R01 
./___Corpus/Medline/xml/PMC4569005.xml	R01	53637 : 53640	CM	49566, R01 CA170595, and R01 CA140657 and CDMRP Breas
./___Corpus/Medline/xml/PMC4569005.xml	CDMRP	53654 : 53659	CM	95, and R01 CA140657 and CDMRP Breast Cancer Research P
./___Corpus/Medline/xml/PMC4569005.xml	PREDICT	53884 : 53891	CM	amework program 7 grants PREDICT and RESPONSIFY, and the 
./___Corpus/Medline/xml/PMC4569005.xml	RESPONSIFY	53896 : 53906	CM	ram 7 grants PREDICT and RESPONSIFY, and the European Resear
./___Corpus/Medline/xml/PMC4569005.xml	NIH	54034 : 54037	CM	dation (DEB-1021243) and NIH (R01-AI091646). C.H. is 
./___Corpus/Medline/xml/PMC4600408.xml	p53	887 : 890	CM	ion of tumor suppressors p53 and p16/pRB, but can be 
./___Corpus/Medline/xml/PMC4600408.xml	p16	895 : 898	CM	umor suppressors p53 and p16/pRB, but can be induced,
./___Corpus/Medline/xml/PMC4600408.xml	pRB	899 : 902	CM	 suppressors p53 and p16/pRB, but can be induced, alb
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	1197 : 1203	CM	 such as those targeting cyclin dependent kinases or com
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	1243 : 1247	CM	ses or components of the PI3K signaling pathway, may i
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	1735 : 1744	CM	genomic instability, and paracrine effects that may increas
./___Corpus/Medline/xml/PMC4600408.xml	lead	3678 : 3682	CM	at such knowledge should lead to measures that prevent
./___Corpus/Medline/xml/PMC4600408.xml	mitogenic	4336 : 4345	CM	 presence of appropriate mitogenic factors. While multiple 
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	4534 : 4549	CM	of senescence-associated heterochromatic foci (SAHF), and positiv
./___Corpus/Medline/xml/PMC4600408.xml	TTAGGG	5773 : 5779	CM	 the number of telomeric TTAGGG repeat sequences on the 
./___Corpus/Medline/xml/PMC4600408.xml	TTAGGG	5945 : 5951	CM	 through interactions of TTAGGG repeat sequences with a 
./___Corpus/Medline/xml/PMC4600408.xml	TTAGGG	6148 : 6154	CM	usion [3]. The telomeric TTAGGG repeats are replenished 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	6294 : 6299	CM	riptase protein subunit (hTERT, TERT) [5], [6], [7], an
./___Corpus/Medline/xml/PMC4600408.xml	TERT	6301 : 6305	CM	 protein subunit (hTERT, TERT) [5], [6], [7], an RNA t
./___Corpus/Medline/xml/PMC4600408.xml	RNA	6325 : 6328	CM	 TERT) [5], [6], [7], an RNA template (hTR, TERC) [8]
./___Corpus/Medline/xml/PMC4600408.xml	hTR	6339 : 6342	CM	], [7], an RNA template (hTR, TERC) [8], [9], [10], a
./___Corpus/Medline/xml/PMC4600408.xml	TERC	6344 : 6348	CM	], an RNA template (hTR, TERC) [8], [9], [10], and oth
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	6469 : 6474	CM	], [12]. The presence of hTERT and hTR are the minimum 
./___Corpus/Medline/xml/PMC4600408.xml	hTR	6479 : 6482	CM	he presence of hTERT and hTR are the minimum requirem
./___Corpus/Medline/xml/PMC4600408.xml	vitro	6557 : 6562	CM	f telomerase activity in vitro. Telomerase activity and
./___Corpus/Medline/xml/PMC4600408.xml	hTR	6667 : 6670	CM	th up-regulation of both hTR and hTERT, while overexp
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	6675 : 6680	CM	gulation of both hTR and hTERT, while overexpression of
./___Corpus/Medline/xml/PMC4600408.xml	hTR	6706 : 6709	CM	 while overexpression of hTR has been shown to boost 
./___Corpus/Medline/xml/PMC4600408.xml	ectopic	6835 : 6842	CM	at express endogenous or ectopic hTERT [13], [14], [15]. 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	6843 : 6848	CM	ss endogenous or ectopic hTERT [13], [14], [15]. Thus b
./___Corpus/Medline/xml/PMC4600408.xml	vitro	6951 : 6956	CM	y and telomere length in vitro, illustrating the fact t
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	7063 : 7068	CM	ase holoenzyme. Although hTERT was initially considered
./___Corpus/Medline/xml/PMC4600408.xml	hTR	7244 : 7247	CM	onstrated contexts where hTR limits telomerase enzyme
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	7372 : 7377	CM	ly embryonic stages, the hTERT gene and telomerase acti
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	7468 : 7473	CM	 tissues [19], [20]. The hTERT gene then undergoes repr
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	7602 : 7607	CM	 neonatal period onward, hTERT transcripts and telomera
./___Corpus/Medline/xml/PMC4600408.xml	vitro	7854 : 7859	CM	4], [25], [26], [27]. In vitro, attrition of TTAGGG rep
./___Corpus/Medline/xml/PMC4600408.xml	TTAGGG	7874 : 7880	CM	. In vitro, attrition of TTAGGG repeats upon successive 
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	8061 : 8070	CM	wed by cell enlargement, chromatin condensation, and vacuol
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	8342 : 8347	CM	senescence [28]. Ectopic hTERT expression in many cell 
./___Corpus/Medline/xml/PMC4600408.xml	p53	9150 : 9153	CM	al structures initiate a p53-mediated DNA damage resp
./___Corpus/Medline/xml/PMC4600408.xml	p16	9193 : 9196	CM	amage response [35]. The p16/pRB tumor suppressor pat
./___Corpus/Medline/xml/PMC4600408.xml	pRB	9197 : 9200	CM	e response [35]. The p16/pRB tumor suppressor pathway
./___Corpus/Medline/xml/PMC4600408.xml	p53	9527 : 9530	CM	pigenetic aberrations in p53 and/or p16/pRB pathways 
./___Corpus/Medline/xml/PMC4600408.xml	p16	9538 : 9541	CM	berrations in p53 and/or p16/pRB pathways enable othe
./___Corpus/Medline/xml/PMC4600408.xml	pRB	9542 : 9545	CM	ations in p53 and/or p16/pRB pathways enable otherwis
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10074 : 10077	CM	 breakage-fusion-bridge (BFB) cycles, which are initi
./___Corpus/Medline/xml/PMC4600408.xml	Chromatin	10205 : 10214	CM	bridges during anaphase. Chromatin bridges break as cells c
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10371 : 10374	CM	ures, which fuel further BFB events in daughter cells
./___Corpus/Medline/xml/PMC4600408.xml	BFB	10401 : 10404	CM	vents in daughter cells. BFB cycles continue until ab
./___Corpus/Medline/xml/PMC4600408.xml	OIS	11502 : 11505	CM	gene-induced senescence (OIS) often occurs independen
./___Corpus/Medline/xml/PMC4600408.xml	OIS	11662 : 11665	CM	 [58], [59], [60], [61]. OIS is observed after ectopi
./___Corpus/Medline/xml/PMC4600408.xml	ectopic	11684 : 11691	CM	]. OIS is observed after ectopic expression of oncogenic 
./___Corpus/Medline/xml/PMC4600408.xml	RAS	11716 : 11719	CM	 expression of oncogenic RAS, and many of its effecto
./___Corpus/Medline/xml/PMC4600408.xml	RAF	11779 : 11782	CM	ing activated mutants of RAF, MEK, B-RAF, PI3K, AKT, 
./___Corpus/Medline/xml/PMC4600408.xml	MEK	11784 : 11787	CM	ctivated mutants of RAF, MEK, B-RAF, PI3K, AKT, and P
./___Corpus/Medline/xml/PMC4600408.xml	B-RAF	11789 : 11794	CM	ted mutants of RAF, MEK, B-RAF, PI3K, AKT, and PIM [62]
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	11796 : 11800	CM	ants of RAF, MEK, B-RAF, PI3K, AKT, and PIM [62], [63]
./___Corpus/Medline/xml/PMC4600408.xml	AKT	11802 : 11805	CM	f RAF, MEK, B-RAF, PI3K, AKT, and PIM [62], [63], [64
./___Corpus/Medline/xml/PMC4600408.xml	PIM	11811 : 11814	CM	K, B-RAF, PI3K, AKT, and PIM [62], [63], [64], [65], 
./___Corpus/Medline/xml/PMC4600408.xml	CDC6	11873 : 11877	CM	 other oncogenes such as CDC6, cyclin E and STAT5 [67]
./___Corpus/Medline/xml/PMC4600408.xml	STAT5	11892 : 11897	CM	ch as CDC6, cyclin E and STAT5 [67]. Also, functional a
./___Corpus/Medline/xml/PMC4600408.xml	PTEN	11961 : 11965	CM	umor suppressors such as PTEN, pRB, Spn, and NF1, indu
./___Corpus/Medline/xml/PMC4600408.xml	pRB	11967 : 11970	CM	uppressors such as PTEN, pRB, Spn, and NF1, induces s
./___Corpus/Medline/xml/PMC4600408.xml	NF1	11981 : 11984	CM	h as PTEN, pRB, Spn, and NF1, induces senescence-like
./___Corpus/Medline/xml/PMC4600408.xml	OIS	12128 : 12131	CM	nges appears involved in OIS [69], [70], [71], [72]. 
./___Corpus/Medline/xml/PMC4600408.xml	S-phase	12268 : 12275	CM	f positive regulators of S-phase. Consequently, replicons
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	12396 : 12411	RN	 DNA damage response and phosphorylation of p53 by DNA damage res
./___Corpus/Medline/xml/PMC4600408.xml	p53	12415 : 12418	CM	e and phosphorylation of p53 by DNA damage response k
./___Corpus/Medline/xml/PMC4600408.xml	MAPK	12469 : 12473	CM	nases. Components of the MAPK cascade also increase th
./___Corpus/Medline/xml/PMC4600408.xml	ARF	12535 : 12538	CM	 of the tumor suppressor ARF [73], and initiate a neg
./___Corpus/Medline/xml/PMC4600408.xml	H	12608 : 12609	CM	that ultimately inhibits H/MDM2 [65], resulting in 
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	12610 : 12614	CM	at ultimately inhibits H/MDM2 [65], resulting in p53 s
./___Corpus/Medline/xml/PMC4600408.xml	p53	12634 : 12637	CM	/MDM2 [65], resulting in p53 stabilization.          
./___Corpus/Medline/xml/PMC4600408.xml	OIS	12847 : 12850	CM	d mouse, indicating that OIS occurs in vivo [74], [75
./___Corpus/Medline/xml/PMC4600408.xml	melanocytic	13010 : 13021	CM	reported in benign human melanocytic nevi (moles) [77]. Cells
./___Corpus/Medline/xml/PMC4600408.xml	B-Raf-E600	13092 : 13102	CM	ivated oncogene product (B-Raf-E600), express elevated level
./___Corpus/Medline/xml/PMC4600408.xml	p16	13153 : 13156	CM	 of the tumor suppressor p16, undergo long-term cell-
./___Corpus/Medline/xml/PMC4600408.xml	OIS	13339 : 13342	CM	that they have undergone OIS rather than replicative 
./___Corpus/Medline/xml/PMC4600408.xml	OIS	13442 : 13445	CM	others [79] suggest that OIS in nevi acts as a barrie
./___Corpus/Medline/xml/PMC4600408.xml	vitro	13689 : 13694	CM	cence in cancer cells in vitro and in vivo (reviewed in
./___Corpus/Medline/xml/PMC4600408.xml	ATM	13841 : 13844	CM	esponse mediators (e.g., ATM, ATR, Chk1, Chk2) as tho
./___Corpus/Medline/xml/PMC4600408.xml	ATR	13846 : 13849	CM	se mediators (e.g., ATM, ATR, Chk1, Chk2) as those ac
./___Corpus/Medline/xml/PMC4600408.xml	p53	14027 : 14030	CM	umor suppressors such as p53 or pRB often retain the 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	14034 : 14037	CM	ppressors such as p53 or pRB often retain the capacit
./___Corpus/Medline/xml/PMC4600408.xml	methylation	14317 : 14328	RN	(e.g., inhibition of DNA methylation or histone acetylation).
./___Corpus/Medline/xml/PMC4600408.xml	histone	14332 : 14339	CM	on of DNA methylation or histone acetylation). Still othe
./___Corpus/Medline/xml/PMC4600408.xml	acetylation	14340 : 14351	RN	A methylation or histone acetylation). Still other compounds 
./___Corpus/Medline/xml/PMC4600408.xml	mitogen	14489 : 14496	CM	, creating imbalances in mitogen signaling pathways [81].
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	14862 : 14873	CM	example, a dose of 25 nM doxorubicin is sufficient to induce 
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	15359 : 15368	CM	lity and pro-tumorigenic paracrine effects of senescent cel
./___Corpus/Medline/xml/PMC4600408.xml	p53	16094 : 16097	CM	ion of tumor suppressors p53 and p16, the former prot
./___Corpus/Medline/xml/PMC4600408.xml	p16	16102 : 16105	CM	umor suppressors p53 and p16, the former protein init
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	16254 : 16270	CM	ymphoma cells exposed to cyclophosphamide [91] and fibroblasts exp
./___Corpus/Medline/xml/PMC4600408.xml	B-RAF	16460 : 16465	CM	elanocytes which acquire B-RAF mutations [93], p16 acti
./___Corpus/Medline/xml/PMC4600408.xml	p16	16482 : 16485	CM	re B-RAF mutations [93], p16 activation and senescenc
./___Corpus/Medline/xml/PMC4600408.xml	p53	16535 : 16538	CM	e occur independently of p53 activation. Although p53
./___Corpus/Medline/xml/PMC4600408.xml	p53	16560 : 16563	CM	p53 activation. Although p53 and p16 are clearly invo
./___Corpus/Medline/xml/PMC4600408.xml	p16	16568 : 16571	CM	vation. Although p53 and p16 are clearly involved in 
./___Corpus/Medline/xml/PMC4600408.xml	p53	16765 : 16768	CM	       The importance of p53 in senescence was determ
./___Corpus/Medline/xml/PMC4600408.xml	p53	16812 : 16815	CM	determined by inhibiting p53 function with dominant n
./___Corpus/Medline/xml/PMC4600408.xml	p53	16866 : 16869	CM	gative mutants, specific p53 antisense mRNA, oligonuc
./___Corpus/Medline/xml/PMC4600408.xml	mRNA	16880 : 16884	CM	, specific p53 antisense mRNA, oligonucleotides or vir
./___Corpus/Medline/xml/PMC4600408.xml	p53	17156 : 17159	CM	h the transactivation of p53 in cultured cells [95]. 
./___Corpus/Medline/xml/PMC4600408.xml	p53	17258 : 17261	CM	e checkpoint activation, p53 is also activated in viv
./___Corpus/Medline/xml/PMC4600408.xml	p53	17306 : 17309	CM	n vivo [45]. Deletion of p53 attenuated the cellular 
./___Corpus/Medline/xml/PMC4600408.xml	p53	17416 : 17419	CM	. Proteins that regulate p53 have also been implicate
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	17461 : 17465	CM	mplicated in senescence. MDM2 has p53 ubiquitin ligase
./___Corpus/Medline/xml/PMC4600408.xml	p53	17470 : 17473	CM	 in senescence. MDM2 has p53 ubiquitin ligase activit
./___Corpus/Medline/xml/PMC4600408.xml	ubiquitin	17474 : 17483	CM	senescence. MDM2 has p53 ubiquitin ligase activity and form
./___Corpus/Medline/xml/PMC4600408.xml	p53	17538 : 17541	CM	autoregulatory loop with p53 [97]. Overexpression of 
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	17566 : 17570	CM	 [97]. Overexpression of MDM2 targets p53 for degradat
./___Corpus/Medline/xml/PMC4600408.xml	p53	17579 : 17582	CM	pression of MDM2 targets p53 for degradation and indu
./___Corpus/Medline/xml/PMC4600408.xml	p53	17622 : 17625	CM	n and induces functional p53 depletion [98]. Expressi
./___Corpus/Medline/xml/PMC4600408.xml	ARF	17698 : 17701	CM	regulated in senescence, ARF, can release p53 from MD
./___Corpus/Medline/xml/PMC4600408.xml	p53	17715 : 17718	CM	scence, ARF, can release p53 from MDM2 inhibition and
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	17724 : 17728	CM	RF, can release p53 from MDM2 inhibition and cause gro
./___Corpus/Medline/xml/PMC4600408.xml	ARF	17855 : 17858	CM	Fs) into culture induces ARF synthesis, which continu
./___Corpus/Medline/xml/PMC4600408.xml	ARF	18020 : 18023	CM	ibroblasts expressing an ARF antisense construct [100
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	18132 : 18136	CM	ation, overexpression of MDM2 in MEFs produces efficie
./___Corpus/Medline/xml/PMC4600408.xml	p53	18247 : 18250	CM	   Senescence effects of p53 are mediated in part thr
./___Corpus/Medline/xml/PMC4600408.xml	CDK	18308 : 18311	CM	reased expression of the CDK inhibitor p21WAF1 [101],
./___Corpus/Medline/xml/PMC4600408.xml	p21WAF1	18322 : 18329	CM	ion of the CDK inhibitor p21WAF1 [101], [102], [103]. p21
./___Corpus/Medline/xml/PMC4600408.xml	p21	18351 : 18354	CM	AF1 [101], [102], [103]. p21, in turn, prevents hyper
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylation	18374 : 18394	CM	. p21, in turn, prevents hyperphosphorylation and inactivation of pRB 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	18415 : 18418	CM	tion and inactivation of pRB [104], [105]. In some hu
./___Corpus/Medline/xml/PMC4600408.xml	p21	18469 : 18472	CM	an cells, elimination of p21 is sufficient to bypass 
./___Corpus/Medline/xml/PMC4600408.xml	p21	18548 : 18551	CM	 in MEFs, the absence of p21 does not prevent senesce
./___Corpus/Medline/xml/PMC4600408.xml	p53	18692 : 18695	CM	an independently mediate p53-induced senescence. Cand
./___Corpus/Medline/xml/PMC4600408.xml	p53	18726 : 18729	CM	ed senescence. Candidate p53 effectors include 14-3-3
./___Corpus/Medline/xml/PMC4600408.xml	14-	18748 : 18751	CPR	te p53 effectors include 14-3-3 and GADD45, which inh
./___Corpus/Medline/xml/PMC4600408.xml	GADD45	18759 : 18765	CM	ctors include 14-3-3 and GADD45, which inhibit G2/M tran
./___Corpus/Medline/xml/PMC4600408.xml	G2	18781 : 18783	CM	nd GADD45, which inhibit G2/M transition, or p53-dep
./___Corpus/Medline/xml/PMC4600408.xml	p53	18801 : 18804	CM	ibit G2/M transition, or p53-dependent transcriptiona
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	18845 : 18850	CM	criptional repression of c-Myc, which results in G1 cel
./___Corpus/Medline/xml/PMC4600408.xml	G1	18869 : 18871	CM	 c-Myc, which results in G1 cell cycle arrest [108].
./___Corpus/Medline/xml/PMC4600408.xml	p53	18930 : 18933	CM	gnals may cooperate with p53 to induce senescence. Fo
./___Corpus/Medline/xml/PMC4600408.xml	PPP1CA	18995 : 19001	CM	as-induced activation of PPP1CA, the catalytic subunit o
./___Corpus/Medline/xml/PMC4600408.xml	PP1α	19028 : 19032	CM	the catalytic subunit of PP1α, has been shown to be ne
./___Corpus/Medline/xml/PMC4600408.xml	p53	19118 : 19121	CM	 [109]. Independently of p53, PPP1CA can stabilize th
./___Corpus/Medline/xml/PMC4600408.xml	PPP1CA	19123 : 19129	CM	]. Independently of p53, PPP1CA can stabilize the active
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	19155 : 19171	CM	can stabilize the active unphosphorylated form of pRB. In MEFs, E2
./___Corpus/Medline/xml/PMC4600408.xml	pRB	19180 : 19183	CM	unphosphorylated form of pRB. In MEFs, E2F transcript
./___Corpus/Medline/xml/PMC4600408.xml	E2F	19194 : 19197	CM	ed form of pRB. In MEFs, E2F transcription factor ass
./___Corpus/Medline/xml/PMC4600408.xml	p53	19276 : 19279	CM	re downstream targets of p53-induced proliferation ar
./___Corpus/Medline/xml/PMC4600408.xml	p53	19348 : 19351	CM	ing a convergence of the p53 and p16/pRB pathways at 
./___Corpus/Medline/xml/PMC4600408.xml	p16	19356 : 19359	CM	nvergence of the p53 and p16/pRB pathways at the leve
./___Corpus/Medline/xml/PMC4600408.xml	pRB	19360 : 19363	CM	gence of the p53 and p16/pRB pathways at the level of
./___Corpus/Medline/xml/PMC4600408.xml	E2F	19389 : 19392	CM	pathways at the level of E2F. However, in many human 
./___Corpus/Medline/xml/PMC4600408.xml	p53	19447 : 19450	CM	, inactivation of either p53 or pRB (e.g., by viral o
./___Corpus/Medline/xml/PMC4600408.xml	pRB	19454 : 19457	CM	ivation of either p53 or pRB (e.g., by viral oncoprot
./___Corpus/Medline/xml/PMC4600408.xml	anti-	19490 : 19495	CPR	by viral oncoproteins or anti-sense oligonucleotides) i
./___Corpus/Medline/xml/PMC4600408.xml	p53	19645 : 19648	CM	uggest that although the p53 and pRB pathways interac
./___Corpus/Medline/xml/PMC4600408.xml	pRB	19653 : 19656	CM	hat although the p53 and pRB pathways interact, they 
./___Corpus/Medline/xml/PMC4600408.xml	p16	19752 : 19755	CM	e.                  3.2. p16/pRB                     
./___Corpus/Medline/xml/PMC4600408.xml	pRB	19756 : 19759	CM	                3.2. p16/pRB                      Whi
./___Corpus/Medline/xml/PMC4600408.xml	p16	19801 : 19804	CM	     While the causes of p16 induction remain to be d
./___Corpus/Medline/xml/PMC4600408.xml	p16	19905 : 19908	CM	cterized. The binding of p16 to cyclin dependent kina
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	19912 : 19918	CM	d. The binding of p16 to cyclin dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4600408.xml	D-	20046 : 20048	CPR	n of these kinases with D-type cyclins [114], thus a
./___Corpus/Medline/xml/PMC4600408.xml	p16	20151 : 20154	CM	nd inactivation of CDKs, p16 prevents phosphorylation
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	20164 : 20179	RN	on of CDKs, p16 prevents phosphorylation and inactivation of pRB 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20200 : 20203	CM	tion and inactivation of pRB and similar “pocket” pro
./___Corpus/Medline/xml/PMC4600408.xml	RB	20319 : 20321	CM	cures the differences in RB family functions that di
./___Corpus/Medline/xml/PMC4600408.xml	RB	20465 : 20467	CM	e the similarities among RB family proteins, defects
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20496 : 20499	CM	ily proteins, defects in pRB, but not in p107 or p130
./___Corpus/Medline/xml/PMC4600408.xml	p130	20520 : 20524	CM	 pRB, but not in p107 or p130, have been associated wi
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20586 : 20589	CM	cers. This suggests that pRB has unique tumor suppres
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20691 : 20694	CM	support of this concept, pRB has been shown to be pre
./___Corpus/Medline/xml/PMC4600408.xml	E2F	20747 : 20750	CM	entially associated with E2F targets involved in DNA 
./___Corpus/Medline/xml/PMC4600408.xml	OIS	20794 : 20797	CM	n DNA replication during OIS, and suppression of pRB,
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20818 : 20821	CM	 OIS, and suppression of pRB, but not p107 or p130, a
./___Corpus/Medline/xml/PMC4600408.xml	p130	20839 : 20843	CM	 of pRB, but not p107 or p130, allowed continued DNA s
./___Corpus/Medline/xml/PMC4600408.xml	RAS	20906 : 20909	CM	r induction of oncogenic RAS [115]. The pRB protein c
./___Corpus/Medline/xml/PMC4600408.xml	pRB	20921 : 20924	CM	oncogenic RAS [115]. The pRB protein contains multipl
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	20951 : 20966	RN	rotein contains multiple phosphorylation sites and interacts with
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21072 : 21075	CM	 whether the spectrum of pRB dependent changes in a g
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21181 : 21184	CM	mined by the duration of pRB activation or by qualita
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21229 : 21232	CM	alitative differences in pRB modifications/binding in
./___Corpus/Medline/xml/PMC4600408.xml	p16	21290 : 21293	CM	ns. Changes initiated by p16 expression are qualitati
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21392 : 21395	CM	lls undergoing transient pRB-dependent growth arrest.
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	21437 : 21441	CM	 arrest. For example, in U2OS cells exposed to p16, pR
./___Corpus/Medline/xml/PMC4600408.xml	p16	21459 : 21462	CM	in U2OS cells exposed to p16, pRB augments p130 at E2
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21464 : 21467	CM	OS cells exposed to p16, pRB augments p130 at E2F-reg
./___Corpus/Medline/xml/PMC4600408.xml	E2F	21485 : 21488	CM	16, pRB augments p130 at E2F-regulated promoters. Dea
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	21541 : 21550	CM	nd co-workers [116] used chromatin immunoprecipitation (ChI
./___Corpus/Medline/xml/PMC4600408.xml	ChIP	21572 : 21576	CM	tin immunoprecipitation (ChIP) assays to assess protei
./___Corpus/Medline/xml/PMC4600408.xml	E2F	21624 : 21627	CM	ein association with the E2F responsive cyclin E and 
./___Corpus/Medline/xml/PMC4600408.xml	cyclin E	21639 : 21647	CM	 with the E2F responsive cyclin E and A promoters. A 6-day
./___Corpus/Medline/xml/PMC4600408.xml	6-	21667 : 21669	CPR	lin E and A promoters. A 6-day induction of p16 resu
./___Corpus/Medline/xml/PMC4600408.xml	p16	21686 : 21689	CM	rs. A 6-day induction of p16 resulted in a dramatic i
./___Corpus/Medline/xml/PMC4600408.xml	pRB	21725 : 21728	CM	n a dramatic increase in pRB and E2F-4 associated wit
./___Corpus/Medline/xml/PMC4600408.xml	E2F-4	21733 : 21738	CM	atic increase in pRB and E2F-4 associated with these pr
./___Corpus/Medline/xml/PMC4600408.xml	histone	21837 : 21844	CM	the extent of binding to histone deacetylase HDAC1, SWI/S
./___Corpus/Medline/xml/PMC4600408.xml	deacetylase	21845 : 21856	ASE	nt of binding to histone deacetylase HDAC1, SWI/SNF chromatin
./___Corpus/Medline/xml/PMC4600408.xml	SWI	21864 : 21867	CM	stone deacetylase HDAC1, SWI/SNF chromatin remodeling
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	21872 : 21881	CM	acetylase HDAC1, SWI/SNF chromatin remodeling complex compo
./___Corpus/Medline/xml/PMC4600408.xml	BRG1	21912 : 21916	CM	eling complex components BRG1 and Brm, and polycomb gr
./___Corpus/Medline/xml/PMC4600408.xml	Brm	21921 : 21924	CM	plex components BRG1 and Brm, and polycomb group prot
./___Corpus/Medline/xml/PMC4600408.xml	HPC2	21953 : 21957	CM	d polycomb group protein HPC2 were noted.             
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22024 : 22027	CM	         Distinctions in pRB-associated phenotypes ma
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylated	22110 : 22124	CM	nctionality of different phosphorylated forms of pRB (Fig. 1). A
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22134 : 22137	CM	 phosphorylated forms of pRB (Fig. 1). Although growt
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	22189 : 22195	CM	factors are required for cyclin D1 synthesis, transientl
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	22281 : 22287	CM	n significant amounts of cyclin D3 associated with CDK4,
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	22307 : 22311	CM	yclin D3 associated with CDK4, and the level of CDK4 a
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	22330 : 22334	CM	h CDK4, and the level of CDK4 activity is sufficient f
./___Corpus/Medline/xml/PMC4600408.xml	CDK	22388 : 22391	CM	ell cycle progression if CDK inhibitors are removed [
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22465 : 22468	CM	y growth-arrested cells, pRB may be held preferential
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22501 : 22519	CM	held preferentially in a hypophosphorylated rather than an unphospho
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22535 : 22551	CM	horylated rather than an unphosphorylated state. While many past s
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylation	22612 : 22632	CM	 relied on the effect of hyperphosphorylation on the electrophoretic m
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22668 : 22671	CM	ctrophoretic mobility of pRB to distinguish the hyper
./___Corpus/Medline/xml/PMC4600408.xml	hyperphosphorylated	22691 : 22710	CM	f pRB to distinguish the hyperphosphorylated from the hypophosphoryla
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22720 : 22738	CM	rphosphorylated from the hypophosphorylated form, few have distingui
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22772 : 22788	CM	w have distinguished the unphosphorylated from the hypophosphoryla
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22798 : 22816	CM	nphosphorylated from the hypophosphorylated form [118]. E2Fs are mor
./___Corpus/Medline/xml/PMC4600408.xml	E2Fs	22829 : 22833	CM	osphorylated form [118]. E2Fs are more easily co-immun
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	22881 : 22899	CM	unoprecipitated with the hypophosphorylated form of pRB than the unp
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22908 : 22911	CM	pophosphorylated form of pRB than the unphosphorylate
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	22921 : 22937	CM	ted form of pRB than the unphosphorylated form of pRB in periphera
./___Corpus/Medline/xml/PMC4600408.xml	pRB	22946 : 22949	CM	unphosphorylated form of pRB in peripheral blood lymp
./___Corpus/Medline/xml/PMC4600408.xml	G1	23002 : 23004	CM	ytes (PBLs) during early G1 [119]. Interestingly, tr
./___Corpus/Medline/xml/PMC4600408.xml	p16	23043 : 23046	CM	stingly, transduction of p16 protein into PBLs leads 
./___Corpus/Medline/xml/PMC4600408.xml	PBLs	23060 : 23064	CM	tion of p16 protein into PBLs leads to loss of pRB hyp
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23082 : 23085	CM	to PBLs leads to loss of pRB hypophosphorylation and 
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylation	23086 : 23105	CM	BLs leads to loss of pRB hypophosphorylation and loss of detectable p
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23129 : 23132	CM	n and loss of detectable pRB association with E2F-4. 
./___Corpus/Medline/xml/PMC4600408.xml	E2F-4	23150 : 23155	CM	ble pRB association with E2F-4. The lack of detectable 
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23232 : 23248	CM	 reduced affinity of the unphosphorylated form of pRB for E2F-4, o
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23257 : 23260	CM	unphosphorylated form of pRB for E2F-4, or alternativ
./___Corpus/Medline/xml/PMC4600408.xml	E2F-4	23265 : 23270	CM	orylated form of pRB for E2F-4, or alternatively to rel
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	23324 : 23333	CM	e insolubility of larger chromatin complexes containing bot
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23360 : 23363	CM	omplexes containing both pRB and E2F-4. Regardless of
./___Corpus/Medline/xml/PMC4600408.xml	E2F-4	23368 : 23373	CM	 containing both pRB and E2F-4. Regardless of the inter
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23434 : 23437	CM	the results suggest that pRB maintained in a minimall
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23478 : 23494	CM	 minimally or completely unphosphorylated state in the presence of
./___Corpus/Medline/xml/PMC4600408.xml	p16	23520 : 23523	CM	state in the presence of p16, is likely to have prope
./___Corpus/Medline/xml/PMC4600408.xml	hypophosphorylated	23584 : 23602	CM	differ from those of the hypophosphorylated form. Confirmation of th
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23792 : 23795	CM	bal gene expression of a pRB allele refractory to cyc
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	23828 : 23843	RN	refractory to cyclin-CDK phosphorylation (the presumed state of p
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23867 : 23870	CM	n (the presumed state of pRB in the presence of p16) 
./___Corpus/Medline/xml/PMC4600408.xml	p16	23890 : 23893	CM	f pRB in the presence of p16) were compared to those 
./___Corpus/Medline/xml/PMC4600408.xml	E2F-2	23921 : 23926	CM	ere compared to those of E2F-2 overexpression. The targ
./___Corpus/Medline/xml/PMC4600408.xml	unphosphorylated	23958 : 23974	CM	pression. The targets of unphosphorylated pRB were consistent with
./___Corpus/Medline/xml/PMC4600408.xml	pRB	23975 : 23978	CM	gets of unphosphorylated pRB were consistent with gen
./___Corpus/Medline/xml/PMC4600408.xml	p16	24023 : 24026	CM	h genes downregulated by p16 overexpression, but show
./___Corpus/Medline/xml/PMC4600408.xml	E2F-2	24098 : 24103	CM	e to genes stimulated by E2F-2. Similar results using h
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	24133 : 24137	CM	ilar results using human U2OS cells were reported [121
./___Corpus/Medline/xml/PMC4600408.xml	pRB	24187 : 24190	CM	].                  3.3. pRB-mediated heterochromatin
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24200 : 24215	CM	       3.3. pRB-mediated heterochromatin formation during cellula
./___Corpus/Medline/xml/PMC4600408.xml	pRB	24274 : 24277	CM	nce                      pRB can play an active role 
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	24341 : 24356	CM	on of senescence-induced heterochromatic foci (SAHF) in human cel
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24535 : 24550	CM	normally associated with heterochromatin, such as histone H3 meth
./___Corpus/Medline/xml/PMC4600408.xml	histone	24560 : 24567	CM	heterochromatin, such as histone H3 methylated on lysine 
./___Corpus/Medline/xml/PMC4600408.xml	methylated	24571 : 24581	RN	atin, such as histone H3 methylated on lysine 9 (H3-K9Me), a
./___Corpus/Medline/xml/PMC4600408.xml	lysine	24585 : 24591	CM	histone H3 methylated on lysine 9 (H3-K9Me), and heteroc
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	24595 : 24602	CM	 methylated on lysine 9 (H3-K9Me), and heterochromatin pr
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24609 : 24624	CM	 lysine 9 (H3-K9Me), and heterochromatin protein 1 (HP1) proteins
./___Corpus/Medline/xml/PMC4600408.xml	HP1	24636 : 24639	CM	terochromatin protein 1 (HP1) proteins α, β, and γ. T
./___Corpus/Medline/xml/PMC4600408.xml	SAHF	24680 : 24684	CM	 and γ. The formation of SAHF was slow, taking several
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	24851 : 24866	CM	2F-target promoters with heterochromatin proteins. Notably, these
./___Corpus/Medline/xml/PMC4600408.xml	E1A	24945 : 24948	CM	ession of the adenoviral E1A protein, which inactivat
./___Corpus/Medline/xml/PMC4600408.xml	pRB	24976 : 24979	CM	otein, which inactivates pRB and prevents senescence.
./___Corpus/Medline/xml/PMC4600408.xml	BJ	25030 : 25032	CM	Interestingly, senescent BJ fibroblasts, which poorl
./___Corpus/Medline/xml/PMC4600408.xml	p16	25067 : 25070	CM	ts, which poorly express p16 and were less stably arr
./___Corpus/Medline/xml/PMC4600408.xml	SAHFs	25124 : 25129	CM	d [122], displayed fewer SAHFs than senescent fibroblas
./___Corpus/Medline/xml/PMC4600408.xml	p16	25188 : 25191	CM	xpress higher amounts of p16 [123].                  
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	25241 : 25250	CM	                     The chromatin-based role of pRB in tra
./___Corpus/Medline/xml/PMC4600408.xml	pRB	25265 : 25268	CM	 chromatin-based role of pRB in transcriptional repre
./___Corpus/Medline/xml/PMC4600408.xml	cyclin A	25430 : 25438	CM	r example, repression of cyclin A has been shown to be dep
./___Corpus/Medline/xml/PMC4600408.xml	SWI	25473 : 25476	CM	shown to be dependent on SWI/SNF chromatin remodeling
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	25481 : 25490	CM	 be dependent on SWI/SNF chromatin remodeling, whereas othe
./___Corpus/Medline/xml/PMC4600408.xml	histone	25588 : 25595	CM	shown to be dependent on histone deacetylases or polycomb
./___Corpus/Medline/xml/PMC4600408.xml	E2Fs	25689 : 25693	CM	126]. In addition to the E2Fs, pRB can also associate 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	25695 : 25698	CM	In addition to the E2Fs, pRB can also associate with 
./___Corpus/Medline/xml/PMC4600408.xml	HP1	25723 : 25726	CM	 can also associate with HP1 and histone methyltransf
./___Corpus/Medline/xml/PMC4600408.xml	histone	25731 : 25738	CM	o associate with HP1 and histone methyltransferases such 
./___Corpus/Medline/xml/PMC4600408.xml	SUV3-9H1	25766 : 25774	CM	thyltransferases such as SUV3-9H1, raising the possibility
./___Corpus/Medline/xml/PMC4600408.xml	pRB	25805 : 25808	CM	ing the possibility that pRB helps direct the process
./___Corpus/Medline/xml/PMC4600408.xml	histone	25837 : 25844	CM	ps direct the process of histone methylation and HP1 recr
./___Corpus/Medline/xml/PMC4600408.xml	methylation	25845 : 25856	RN	t the process of histone methylation and HP1 recruitment to E
./___Corpus/Medline/xml/PMC4600408.xml	HP1	25861 : 25864	CM	 histone methylation and HP1 recruitment to E2F respo
./___Corpus/Medline/xml/PMC4600408.xml	E2F	25880 : 25883	CM	n and HP1 recruitment to E2F responsive promoters dur
./___Corpus/Medline/xml/PMC4600408.xml	pRB	25958 : 25961	CM	t with this possibility, pRB showed colocalization wi
./___Corpus/Medline/xml/PMC4600408.xml	SAHFs	25989 : 25994	CM	owed colocalization with SAHFs in the nuclei of senesce
./___Corpus/Medline/xml/PMC4600408.xml	p16	26128 : 26131	CM	ork [127] has shown that p16-dependent repression by 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	26156 : 26159	CM	-dependent repression by pRB at E2F target gene promo
./___Corpus/Medline/xml/PMC4600408.xml	E2F	26163 : 26166	CM	ent repression by pRB at E2F target gene promoters in
./___Corpus/Medline/xml/PMC4600408.xml	E2F-1	26293 : 26298	CM	by the overexpression of E2F-1. Rather than displacing 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	26323 : 26326	CM	. Rather than displacing pRB, excess E2F-1 instead re
./___Corpus/Medline/xml/PMC4600408.xml	E2F-1	26335 : 26340	CM	n displacing pRB, excess E2F-1 instead recruits more pR
./___Corpus/Medline/xml/PMC4600408.xml	pRB	26363 : 26366	CM	-1 instead recruits more pRB, leading to direct trans
./___Corpus/Medline/xml/PMC4600408.xml	Rb	26427 : 26429	CM	repression. In contrast, Rb family members, p130 and
./___Corpus/Medline/xml/PMC4600408.xml	p107	26455 : 26459	CM	family members, p130 and p107, which have not been dem
./___Corpus/Medline/xml/PMC4600408.xml	E2F-1	26684 : 26689	CM	exes are displaceable by E2F-1. HP1, which interacts wi
./___Corpus/Medline/xml/PMC4600408.xml	HP1	26691 : 26694	CM	e displaceable by E2F-1. HP1, which interacts with pR
./___Corpus/Medline/xml/PMC4600408.xml	pRB	26717 : 26720	CM	P1, which interacts with pRB, is associated with thes
./___Corpus/Medline/xml/PMC4600408.xml	p16	26863 : 26866	CM	ficient growth arrest by p16/pRB in MEFs is dependent
./___Corpus/Medline/xml/PMC4600408.xml	pRB	26867 : 26870	CM	ent growth arrest by p16/pRB in MEFs is dependent on 
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	26895 : 26902	CM	 in MEFs is dependent on H3-K9Me, which provides a bindin
./___Corpus/Medline/xml/PMC4600408.xml	HP1	26938 : 26941	CM	vides a binding site for HP1. Differences in the stab
./___Corpus/Medline/xml/PMC4600408.xml	pRB	27044 : 27047	CM	e the different roles of pRB versus p130 and p107 in 
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	27230 : 27245	CM	ation and propagation of heterochromatin remain to be characteriz
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	27274 : 27281	CM	ain to be characterized, H3-K9Me, trimethylation of histo
./___Corpus/Medline/xml/PMC4600408.xml	trimethylation	27283 : 27297	RN	 characterized, H3-K9Me, trimethylation of histone H4 lysine 20 
./___Corpus/Medline/xml/PMC4600408.xml	histone	27301 : 27308	CM	-K9Me, trimethylation of histone H4 lysine 20 (H4-K20Me),
./___Corpus/Medline/xml/PMC4600408.xml	lysine	27312 : 27318	CM	ethylation of histone H4 lysine 20 (H4-K20Me), and recru
./___Corpus/Medline/xml/PMC4600408.xml	H4-K20Me	27323 : 27331	CM	of histone H4 lysine 20 (H4-K20Me), and recruitment of HP1
./___Corpus/Medline/xml/PMC4600408.xml	HP1	27353 : 27356	CM	0Me), and recruitment of HP1 appear to be involved [1
./___Corpus/Medline/xml/PMC4600408.xml	Trimethylation	27393 : 27407	RN	e involved [128], [129]. Trimethylation of heterochromatic histo
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatic	27411 : 27426	CM	[129]. Trimethylation of heterochromatic histone H3-K9 is accompl
./___Corpus/Medline/xml/PMC4600408.xml	histone	27427 : 27434	CM	ation of heterochromatic histone H3-K9 is accomplished by
./___Corpus/Medline/xml/PMC4600408.xml	Suv4-20H1	27495 : 27504	CM	nd Suv3-9H2 [130], while Suv4-20H1 and Suv4-20H2 trimethyla
./___Corpus/Medline/xml/PMC4600408.xml	trimethylate	27519 : 27531	CM	 Suv4-20H1 and Suv4-20H2 trimethylate histone H4-K20 [129]. pR
./___Corpus/Medline/xml/PMC4600408.xml	pRB	27554 : 27557	CM	te histone H4-K20 [129]. pRB physically interacts wit
./___Corpus/Medline/xml/PMC4600408.xml	methyltransferase	27595 : 27612	CM	nteracts with both these methyltransferase complexes, although the 
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	27726 : 27733	CM	31], [132]. Importantly, H3-K9Me was enriched at prolifer
./___Corpus/Medline/xml/PMC4600408.xml	SAHFs	27858 : 27863	CM	t with the appearance of SAHFs, but not in quiescent ce
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	27945 : 27952	CM	which is responsible for H3-K9Me, has been found to be re
./___Corpus/Medline/xml/PMC4600408.xml	OIS	27988 : 27991	CM	found to be required for OIS in murine lymphocyes, an
./___Corpus/Medline/xml/PMC4600408.xml	murine	27995 : 28001	CM	o be required for OIS in murine lymphocyes, and for supp
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28141 : 28156	CM	through the formation of heterochromatin at proliferation-promoti
./___Corpus/Medline/xml/PMC4600408.xml	pRB	28323 : 28326	CM	termined. In addition to pRB, H3-K9Me, and HP1, SAHFs
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	28328 : 28335	CM	ned. In addition to pRB, H3-K9Me, and HP1, SAHFs are know
./___Corpus/Medline/xml/PMC4600408.xml	HP1	28341 : 28344	CM	ion to pRB, H3-K9Me, and HP1, SAHFs are known to be e
./___Corpus/Medline/xml/PMC4600408.xml	SAHFs	28346 : 28351	CM	o pRB, H3-K9Me, and HP1, SAHFs are known to be enriched
./___Corpus/Medline/xml/PMC4600408.xml	histone	28382 : 28389	CM	nown to be enriched in a histone H2A variant, macroH2A, p
./___Corpus/Medline/xml/PMC4600408.xml	macroH2A	28403 : 28411	CM	n a histone H2A variant, macroH2A, previously associated w
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	28449 : 28458	CM	associated with silenced chromatin [133], and HMGA proteins
./___Corpus/Medline/xml/PMC4600408.xml	HMGA	28470 : 28474	CM	ced chromatin [133], and HMGA proteins, which appear t
./___Corpus/Medline/xml/PMC4600408.xml	histone	28569 : 28576	CM	evolutionarily conserved histone chaperones, HIRA and ASF
./___Corpus/Medline/xml/PMC4600408.xml	HIRA	28589 : 28593	CM	rved histone chaperones, HIRA and ASF1a, are also know
./___Corpus/Medline/xml/PMC4600408.xml	ASF1a	28598 : 28603	CM	one chaperones, HIRA and ASF1a, are also known to coope
./___Corpus/Medline/xml/PMC4600408.xml	pRB	28638 : 28641	CM	 known to cooperate with pRB in the formation of SAHF
./___Corpus/Medline/xml/PMC4600408.xml	SAHFs	28662 : 28667	CM	 pRB in the formation of SAHFs [134]. These proteins, h
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28760 : 28775	CM	transcriptionally silent heterochromatin in yeast, flies, and pla
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	28833 : 28848	CM	 generate more extensive heterochromatin domains at positions des
./___Corpus/Medline/xml/PMC4600408.xml	pRB	28884 : 28887	CM	 positions designated by pRB. In WI38 human fibroblas
./___Corpus/Medline/xml/PMC4600408.xml	WI38	28892 : 28896	CM	ns designated by pRB. In WI38 human fibroblasts induce
./___Corpus/Medline/xml/PMC4600408.xml	HIRA	29156 : 29160	CM	ucleosome density due to HIRA/ASF1a-mediated nucleosom
./___Corpus/Medline/xml/PMC4600408.xml	ASF1a	29161 : 29166	CM	some density due to HIRA/ASF1a-mediated nucleosome depo
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29204 : 29213	CM	leosome deposition. This chromatin condensation occurs prio
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	29263 : 29270	CM	r to the accumulation of H3-K9Me and deposition of HP1 an
./___Corpus/Medline/xml/PMC4600408.xml	HP1	29289 : 29292	CM	3-K9Me and deposition of HP1 and macroH2A in chromati
./___Corpus/Medline/xml/PMC4600408.xml	macroH2A	29297 : 29305	CM	nd deposition of HP1 and macroH2A in chromatin, leading to
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29309 : 29318	CM	n of HP1 and macroH2A in chromatin, leading to speculation 
./___Corpus/Medline/xml/PMC4600408.xml	HP1	29348 : 29351	CM	ding to speculation that HP1 proteins do not contribu
./___Corpus/Medline/xml/PMC4600408.xml	SAHF	29500 : 29504	CM	long-term maintenance of SAHF and the senescent state.
./___Corpus/Medline/xml/PMC4600408.xml	OIS	29578 : 29581	CM	using the same inducible OIS model has shown that the
./___Corpus/Medline/xml/PMC4600408.xml	histone	29636 : 29643	CM	al pattern of repressive histone marks was largely unchan
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	29756 : 29765	CM	nvolves repositioning of chromatin bearing pre-existing mar
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	29870 : 29877	CM	is work also showed that H3-K9Me and H3-K27Me marks were 
./___Corpus/Medline/xml/PMC4600408.xml	H3-K27Me	29882 : 29890	CM	 showed that H3-K9Me and H3-K27Me marks were not necessary
./___Corpus/Medline/xml/PMC4600408.xml	murine	30189 : 30195	CM	nce has been inferred in murine models of lung adenomas,
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	30805 : 30814	CM	n to be dependent on the chromatin-remodeling enzyme Suv3-9
./___Corpus/Medline/xml/PMC4600408.xml	p53	30866 : 30869	CM	 [74]. In another study, p53 and p16 were found to co
./___Corpus/Medline/xml/PMC4600408.xml	p16	30874 : 30877	CM	n another study, p53 and p16 were found to cooperate 
./___Corpus/Medline/xml/PMC4600408.xml	murine	30905 : 30911	CM	re found to cooperate in murine lymphoma cells, engaging
./___Corpus/Medline/xml/PMC4600408.xml	alkylating	30997 : 31007	RN	rrest in response to the alkylating agent, cyclophosphamide 
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	31015 : 31031	CM	to the alkylating agent, cyclophosphamide [91]. Mice bearing tumor
./___Corpus/Medline/xml/PMC4600408.xml	p16	31069 : 31072	CM	earing tumors capable of p16-induced senescence had a
./___Corpus/Medline/xml/PMC4600408.xml	p16	31176 : 31179	CM	se harboring tumors with p16 defects. The study showe
./___Corpus/Medline/xml/PMC4600408.xml	p16	31219 : 31222	CM	tudy showed further that p16 loss and disruption of a
./___Corpus/Medline/xml/PMC4600408.xml	Bcl2	31259 : 31263	CM	sruption of apoptosis by Bcl2 act independently to pro
./___Corpus/Medline/xml/PMC4600408.xml	p53	31337 : 31340	CM	 a prostate tumor model, p53-dependent cellular senes
./___Corpus/Medline/xml/PMC4600408.xml	PTEN	31431 : 31435	CM	of the tumor suppressor, PTEN [75]. Similar findings h
./___Corpus/Medline/xml/PMC4600408.xml	E2F-3	31481 : 31486	CM	gs have been reported in E2F-3 driven pituitary gland t
./___Corpus/Medline/xml/PMC4600408.xml	murine	31650 : 31656	CM	enerated using inducible murine models. In a model for p
./___Corpus/Medline/xml/PMC4600408.xml	p53	31680 : 31683	CM	e models. In a model for p53-dependent liver cancer, 
./___Corpus/Medline/xml/PMC4600408.xml	p53	31722 : 31725	CM	er cancer, the effect of p53 restoration was studied 
./___Corpus/Medline/xml/PMC4600408.xml	p53	31827 : 31830	CM	expressing a conditional p53 shRNA produced invasive 
./___Corpus/Medline/xml/PMC4600408.xml	p53	31901 : 31904	CM	n after re-expression of p53, the tumors underwent dr
./___Corpus/Medline/xml/PMC4600408.xml	p53	32432 : 32435	CM	expression of endogenous p53 leads to a senescence-li
./___Corpus/Medline/xml/PMC4600408.xml	cyclophosphamide	32913 : 32929	CM	eoadjuvant chemotherapy (cyclophosphamide, doxorubicin, and 5-fluo
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	32931 : 32942	CM	erapy (cyclophosphamide, doxorubicin, and 5-fluorouracil) wer
./___Corpus/Medline/xml/PMC4600408.xml	5-fluorouracil	32948 : 32962	CM	hamide, doxorubicin, and 5-fluorouracil) were found positive for
./___Corpus/Medline/xml/PMC4600408.xml	p53	33231 : 33234	CM	tumors bearing wild-type p53 alleles and exhibiting p
./___Corpus/Medline/xml/PMC4600408.xml	p16	33258 : 33261	CM	3 alleles and exhibiting p16 expression. Interestingl
./___Corpus/Medline/xml/PMC4600408.xml	lead	33999 : 34003	CM	n of senescent cells may lead to unregulated accumulat
./___Corpus/Medline/xml/PMC4600408.xml	p16	34247 : 34250	CM	l removal of accumulated p16 positive senescent cells
./___Corpus/Medline/xml/PMC4600408.xml	paracrine	34858 : 34867	CM	s, and undoubtedly using paracrine signals (secretion). Pro
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35002 : 35006	CM	ted Secretory Phenotype (SASP) [162]. Current data sup
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35178 : 35182	CM	 elements regulating the SASP include the DNA damage r
./___Corpus/Medline/xml/PMC4600408.xml	p38MAPK	35222 : 35229	CM	A damage response (DDR), p38MAPK, the JAK/STAT pathway an
./___Corpus/Medline/xml/PMC4600408.xml	JAK	35235 : 35238	CM	onse (DDR), p38MAPK, the JAK/STAT pathway and transcr
./___Corpus/Medline/xml/PMC4600408.xml	STAT	35239 : 35243	CM	 (DDR), p38MAPK, the JAK/STAT pathway and transcriptio
./___Corpus/Medline/xml/PMC4600408.xml	NF-κB	35286 : 35291	CM	cription factors such as NF-κB and C/EBPβ [163], [164],
./___Corpus/Medline/xml/PMC4600408.xml	EBPβ	35298 : 35302	CM	tors such as NF-κB and C/EBPβ [163], [164], [165], [16
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35387 : 35391	CM	                     The SASP was originally documente
./___Corpus/Medline/xml/PMC4600408.xml	mRNA	35529 : 35533	CM	lls [169]. Subsequently, mRNA profiling, targeted prot
./___Corpus/Medline/xml/PMC4600408.xml	RNA	35600 : 35603	CM	arrays), and genome-wide RNA interference screens hav
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35656 : 35660	CM	een used to characterize SASP factors and their effect
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35745 : 35749	CM	, [173], [174]. Multiple SASP factors have been direct
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35915 : 35919	CM	 [177]. While individual SASP components may vary depe
./___Corpus/Medline/xml/PMC4600408.xml	SASP	35993 : 35997	CM	ontext, a few ubiquitous SASP factors have emerged, in
./___Corpus/Medline/xml/PMC4600408.xml	IL6	36047 : 36050	CM	cluding pro-inflammatory IL6 and IL8, extracellular m
./___Corpus/Medline/xml/PMC4600408.xml	IL8	36055 : 36058	CM	pro-inflammatory IL6 and IL8, extracellular matrix re
./___Corpus/Medline/xml/PMC4600408.xml	MMP3	36092 : 36096	CM	llular matrix remodeling MMP3, and growth promoting Gr
./___Corpus/Medline/xml/PMC4600408.xml	SASP	36135 : 36139	CM	romoting GroA [170]. The SASP supports positive aspect
./___Corpus/Medline/xml/PMC4600408.xml	p53	36292 : 36295	CM	include reinforcement of p53-dependent growth arrest 
./___Corpus/Medline/xml/PMC4600408.xml	cytokine	36324 : 36332	CM	endent growth arrest via cytokine signaling loops [163], [
./___Corpus/Medline/xml/PMC4600408.xml	Paracrine	36363 : 36372	CM	ling loops [163], [164]. Paracrine activities include orche
./___Corpus/Medline/xml/PMC4600408.xml	SASP	36599 : 36603	CM	[156], [157], [159]. The SASP is also believed to modu
./___Corpus/Medline/xml/PMC4600408.xml	SASP	37220 : 37224	CM	ing cells exhibiting the SASP could create a protectiv
./___Corpus/Medline/xml/PMC4600408.xml	SASP	37383 : 37387	CM	ting effects of specific SASP factors have been shown 
./___Corpus/Medline/xml/PMC4600408.xml	vitro	37415 : 37420	CM	ctors have been shown in vitro and in vivo. For example
./___Corpus/Medline/xml/PMC4600408.xml	MMP3	37447 : 37451	CM	nd in vivo. For example, MMP3 secretion by senescent c
./___Corpus/Medline/xml/PMC4600408.xml	HGF	37597 : 37600	CM	[181] while secretion of HGF, AREG, or GroA increased
./___Corpus/Medline/xml/PMC4600408.xml	AREG	37602 : 37606	CM	 while secretion of HGF, AREG, or GroA increased proli
./___Corpus/Medline/xml/PMC4600408.xml	IL6	37696 : 37699	CM	 [174], [182]. Cytokines IL6 and IL8 promoted invasiv
./___Corpus/Medline/xml/PMC4600408.xml	IL8	37704 : 37707	CM	[182]. Cytokines IL6 and IL8 promoted invasiveness an
./___Corpus/Medline/xml/PMC4600408.xml	EMT	37772 : 37775	CM	 mesenchymal transition (EMT) of established cancer c
./___Corpus/Medline/xml/PMC4600408.xml	MMP3	37946 : 37950	CM	. This was attributed to MMP3 [183], but may also invo
./___Corpus/Medline/xml/PMC4600408.xml	MMPs	37985 : 37989	CM	t may also involve other MMPs secreted by senescent ce
./___Corpus/Medline/xml/PMC4600408.xml	VEGF	38038 : 38042	CM	ells [160]. Secretion of VEGF may be responsible for i
./___Corpus/Medline/xml/PMC4600408.xml	SASP	38196 : 38200	CM	ta support a role of the SASP in cancer recurrence. Fo
./___Corpus/Medline/xml/PMC4600408.xml	IL6	38236 : 38239	CM	recurrence. For example, IL6 secretion by senescent c
./___Corpus/Medline/xml/PMC4600408.xml	murine	38290 : 38296	CM	lls in post-chemotherapy murine thymus was sufficient to
./___Corpus/Medline/xml/PMC4600408.xml	SASP	38403 : 38407	CM	[167], [185]. Similarly, SASP factors were linked to r
./___Corpus/Medline/xml/PMC4600408.xml	murine	38466 : 38472	CM	 of chemotherapy treated murine mammary cancers [186]. F
./___Corpus/Medline/xml/PMC4600408.xml	murine	38516 : 38522	CM	86]. Finally, in another murine cancer model, secretion 
./___Corpus/Medline/xml/PMC4600408.xml	SASP	38550 : 38554	CM	ncer model, secretion of SASP factor WNT16B by senesce
./___Corpus/Medline/xml/PMC4600408.xml	WNT16B	38562 : 38568	CM	secretion of SASP factor WNT16B by senescent stromal cel
./___Corpus/Medline/xml/PMC4600408.xml	WNT16B	38709 : 38715	CM	. Importantly, increased WNT16B levels were also detecte
./___Corpus/Medline/xml/PMC4600408.xml	p53	39179 : 39182	CM	s-related signals (e.g., p53 inactivation) have the p
./___Corpus/Medline/xml/PMC4600408.xml	p53	39845 : 39848	CM	feration by inactivating p53 – provided the cells had
./___Corpus/Medline/xml/PMC4600408.xml	p16	39888 : 39891	CM	 cells had not expressed p16 [122]. Human mammary epi
./___Corpus/Medline/xml/PMC4600408.xml	p16	39972 : 39975	CM	ty to express functional p16 are prone to unstable gr
./___Corpus/Medline/xml/PMC4600408.xml	vitro	40459 : 40464	CM	vention of senescence in vitro occur during oncogenesis
./___Corpus/Medline/xml/PMC4600408.xml	p21	41247 : 41250	CM	icate that the status of p21 and p16, and associated 
./___Corpus/Medline/xml/PMC4600408.xml	p16	41255 : 41258	CM	at the status of p21 and p16, and associated tumor su
./___Corpus/Medline/xml/PMC4600408.xml	p53	41300 : 41303	CM	tumor suppressors (e.g., p53, pRB) play critical role
./___Corpus/Medline/xml/PMC4600408.xml	pRB	41305 : 41308	CM	 suppressors (e.g., p53, pRB) play critical roles.   
./___Corpus/Medline/xml/PMC4600408.xml	p16	41390 : 41393	CM	    The reversibility of p16-induced growth arrest ha
./___Corpus/Medline/xml/PMC4600408.xml	U2OS	41443 : 41447	CM	s been examined in human U2OS cells in which the trans
./___Corpus/Medline/xml/PMC4600408.xml	p16	41510 : 41513	CM	n exogenously introduced p16 gene was regulated by te
./___Corpus/Medline/xml/PMC4600408.xml	tetracycline	41536 : 41548	CM	16 gene was regulated by tetracycline [193]. Induction of p16 
./___Corpus/Medline/xml/PMC4600408.xml	p16	41569 : 41572	CM	line [193]. Induction of p16 for one day arrested mos
./___Corpus/Medline/xml/PMC4600408.xml	G1	41612 : 41614	CM	rested most cells in the G1 phase of the cell cycle;
./___Corpus/Medline/xml/PMC4600408.xml	p16	41673 : 41676	CM	nducer was then removed, p16 levels returned to basel
./___Corpus/Medline/xml/PMC4600408.xml	3–	41731 : 41733	CPR	nd growth resumed within 3–5 days. If, however, p16 
./___Corpus/Medline/xml/PMC4600408.xml	p16	41754 : 41757	CM	n 3–5 days. If, however, p16 was induced for 6 days, 
./___Corpus/Medline/xml/PMC4600408.xml	p16	41927 : 41930	CM	onstrated that sustained p16 expression is sufficient
./___Corpus/Medline/xml/PMC4600408.xml	p16	42031 : 42034	CM	t becomes independent of p16 expression after a defin
./___Corpus/Medline/xml/PMC4600408.xml	RB	42224 : 42226	CM	t each of the individual RB family proteins, p16 ind
./___Corpus/Medline/xml/PMC4600408.xml	p16	42244 : 42247	CM	dual RB family proteins, p16 induction still resulted
./___Corpus/Medline/xml/PMC4600408.xml	G1	42289 : 42291	CM	resulted in irreversible G1 growth arrest in each ca
./___Corpus/Medline/xml/PMC4600408.xml	RB	42411 : 42413	CM	bility of the individual RB family proteins to media
./___Corpus/Medline/xml/PMC4600408.xml	murine	42558 : 42564	CM	 reported in a number of murine and human cell types [19
./___Corpus/Medline/xml/PMC4600408.xml	p16	42672 : 42675	CM	tream regulators such as p16, cyclin D1 and CDK4, whi
./___Corpus/Medline/xml/PMC4600408.xml	cyclin	42677 : 42683	CM	 regulators such as p16, cyclin D1 and CDK4, which presu
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	42691 : 42695	CM	ch as p16, cyclin D1 and CDK4, which presumably affect
./___Corpus/Medline/xml/PMC4600408.xml	RB	42749 : 42751	CM	 regulation of all three RB family proteins simultan
./___Corpus/Medline/xml/PMC4600408.xml	RB	42835 : 42837	CM	ations in the individual RB family proteins themselv
./___Corpus/Medline/xml/PMC4600408.xml	p53	42975 : 42978	CM	ancer cells lacking both p53 and pRB tumor suppressor
./___Corpus/Medline/xml/PMC4600408.xml	pRB	42983 : 42986	CM	lls lacking both p53 and pRB tumor suppressors, are s
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	43131 : 43135	CM	l-molecule inhibitors of CDK4/6 may be effective even 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	43194 : 43197	CM	umors lacking functional pRB.                        
./___Corpus/Medline/xml/PMC4600408.xml	CDK	43269 : 43272	CM	sentative small molecule CDK inhibitor that has recen
./___Corpus/Medline/xml/PMC4600408.xml	serine	43431 : 43437	CM	ed against 39 individual serine, threonine, and tyrosine
./___Corpus/Medline/xml/PMC4600408.xml	threonine	43439 : 43448	CM	st 39 individual serine, threonine, and tyrosine kinases, r
./___Corpus/Medline/xml/PMC4600408.xml	tyrosine	43454 : 43462	CM	l serine, threonine, and tyrosine kinases, representing mo
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	43575 : 43579	CM	 selective inhibition of CDK4 and CDK6 [197], [198], [
./___Corpus/Medline/xml/PMC4600408.xml	CDK6	43584 : 43588	CM	e inhibition of CDK4 and CDK6 [197], [198], [199]. Imp
./___Corpus/Medline/xml/PMC4600408.xml	PD0332991	43628 : 43637	CM	[199]. Importantly, oral PD0332991 administration alone at 
./___Corpus/Medline/xml/PMC4600408.xml	PD0332991	44035 : 44044	CM	7]. Recent assessment of PD0332991 using short-term growth 
./___Corpus/Medline/xml/PMC4600408.xml	estrogen	44142 : 44150	CM	ng growth arrest of many estrogen receptor (ER) positive b
./___Corpus/Medline/xml/PMC4600408.xml	ER(−)	44221 : 44226	CM	es, but that a number of ER(−) lines were able to maint
./___Corpus/Medline/xml/PMC4600408.xml	pRB	44255 : 44258	CM	es were able to maintain pRB phosphorylation and prol
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	44259 : 44274	RN	ere able to maintain pRB phosphorylation and proliferation in its
./___Corpus/Medline/xml/PMC4600408.xml	ER(−)	44331 : 44336	CM	ce [200]. Several of the ER(−) cell lines exhibiting re
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44377 : 44381	CM	biting resistance to the CDK4/6 inhibitor retained pho
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylated	44403 : 44417	RN	DK4/6 inhibitor retained phosphorylated pRB in the presence of t
./___Corpus/Medline/xml/PMC4600408.xml	pRB	44418 : 44421	CM	 retained phosphorylated pRB in the presence of the C
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44445 : 44449	CM	B in the presence of the CDK4/6 inhibitor. This indica
./___Corpus/Medline/xml/PMC4600408.xml	CDK1	44511 : 44515	CM	ther kinase, most likely CDK1 or CDK2, was capable of 
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	44519 : 44523	CM	ase, most likely CDK1 or CDK2, was capable of phosphor
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylating	44540 : 44555	CM	 or CDK2, was capable of phosphorylating and inactivating pRB in 
./___Corpus/Medline/xml/PMC4600408.xml	pRB	44573 : 44576	CM	ylating and inactivating pRB in the absence of CDK4/6
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44595 : 44599	CM	ng pRB in the absence of CDK4/6 activity in these cell
./___Corpus/Medline/xml/PMC4600408.xml	ER(−)	44646 : 44651	CM	ell lines. Thus, in many ER(−) breast cancer cells, tar
./___Corpus/Medline/xml/PMC4600408.xml	CDK1	44686 : 44690	CM	ncer cells, targeting of CDK1 or CDK2 instead of, or i
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	44694 : 44698	CM	ls, targeting of CDK1 or CDK2 instead of, or in additi
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44730 : 44734	CM	d of, or in addition to, CDK4 may be required to initi
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	44944 : 44948	CM	ecent report that showed CDK4/6 inhibition protected E
./___Corpus/Medline/xml/PMC4600408.xml	ER(−)	44972 : 44977	CM	4/6 inhibition protected ER(−) breast cancer cells from
./___Corpus/Medline/xml/PMC4600408.xml	doxorubicin	45003 : 45014	CM	breast cancer cells from doxorubicin-mediated cytotoxicity [2
./___Corpus/Medline/xml/PMC4600408.xml	hTR	45531 : 45534	CM	 the genetic level, both hTR and hTERT genes have bee
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	45539 : 45544	CM	etic level, both hTR and hTERT genes have been reported
./___Corpus/Medline/xml/PMC4600408.xml	hTR	45612 : 45615	CM	n some tumors. Increased hTR gene copy number was det
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	45710 : 45715	CM	l carcinomas [202] while hTERT gene amplifications have
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	46101 : 46106	CM	 to regions close to the hTERT promoter, suggesting tha
./___Corpus/Medline/xml/PMC4600408.xml	nucleotide	46476 : 46486	CM	ssociation study, single nucleotide polymorphisms (SNPs) in 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	46701 : 46706	CM	ponded to genes encoding hTERT and hTR, as well as othe
./___Corpus/Medline/xml/PMC4600408.xml	hTR	46711 : 46714	CM	genes encoding hTERT and hTR, as well as other protei
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	46840 : 46845	CM	 multiple regions of the hTERT locus, including the pro
./___Corpus/Medline/xml/PMC4600408.xml	hTR	47134 : 47137	CM	                Both the hTR and hTERT genes are subj
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	47142 : 47147	CM	        Both the hTR and hTERT genes are subject to tum
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	47207 : 47214	CM	c epigenetic regulation. H3-K9Me marks were increased at 
./___Corpus/Medline/xml/PMC4600408.xml	hTR	47243 : 47246	CM	ks were increased at the hTR promoter in normal fibro
./___Corpus/Medline/xml/PMC4600408.xml	ALT	47293 : 47296	CM	broblasts and in several ALT cell lines with low hTR 
./___Corpus/Medline/xml/PMC4600408.xml	hTR	47317 : 47320	CM	 ALT cell lines with low hTR expression in comparison
./___Corpus/Medline/xml/PMC4600408.xml	hTR	47411 : 47414	CM	es, suggesting a role in hTR suppression, while H3-K4
./___Corpus/Medline/xml/PMC4600408.xml	H3-K4Ac	47434 : 47441	CM	n hTR suppression, while H3-K4Ac, H4-K4Ac, H3-K9Ac and H3
./___Corpus/Medline/xml/PMC4600408.xml	H4-K4Ac	47443 : 47450	CM	pression, while H3-K4Ac, H4-K4Ac, H3-K9Ac and H3-K4Me wer
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Ac	47452 : 47459	CM	 while H3-K4Ac, H4-K4Ac, H3-K9Ac and H3-K4Me were associa
./___Corpus/Medline/xml/PMC4600408.xml	H3-K4Me	47464 : 47471	CM	Ac, H4-K4Ac, H3-K9Ac and H3-K4Me were associated with hTR
./___Corpus/Medline/xml/PMC4600408.xml	hTR	47493 : 47496	CM	4Me were associated with hTR expression. Similar anal
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	47533 : 47538	CM	 Similar analysis of the hTERT promoter also revealed H
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Me	47562 : 47569	CM	T promoter also revealed H3-K9Me associated with transcri
./___Corpus/Medline/xml/PMC4600408.xml	H3-K4Ac	47635 : 47642	CM	ion and higher levels of H3-K4Ac, H4-K4Ac and H3-K9Ac in 
./___Corpus/Medline/xml/PMC4600408.xml	H4-K4Ac	47644 : 47651	CM	igher levels of H3-K4Ac, H4-K4Ac and H3-K9Ac in cancer ce
./___Corpus/Medline/xml/PMC4600408.xml	H3-K9Ac	47656 : 47663	CM	 of H3-K4Ac, H4-K4Ac and H3-K9Ac in cancer cells compared
./___Corpus/Medline/xml/PMC4600408.xml	H3-K4Me	47721 : 47728	CM	rmal fibroblasts, though H3-K4Me was not strongly associa
./___Corpus/Medline/xml/PMC4600408.xml	chromatin	47862 : 47871	CM	 In cancer cells lacking chromatin mediated silencing prese
./___Corpus/Medline/xml/PMC4600408.xml	hTR	48024 : 48027	CM	, transcription factors. hTR is generally expressed a
./___Corpus/Medline/xml/PMC4600408.xml	hTR	48252 : 48255	CM	r specific expression of hTR promoter-driven transgen
./___Corpus/Medline/xml/PMC4600408.xml	hTR	48340 : 48343	CM	tudies [214], [215]. The hTR gene promoter is activat
./___Corpus/Medline/xml/PMC4600408.xml	NF-Y	48374 : 48378	CM	promoter is activated by NF-Y, Sp1, pRB and HIF1, and 
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	48380 : 48383	CM	er is activated by NF-Y, Sp1, pRB and HIF1, and is su
./___Corpus/Medline/xml/PMC4600408.xml	pRB	48385 : 48388	CM	 activated by NF-Y, Sp1, pRB and HIF1, and is suppres
./___Corpus/Medline/xml/PMC4600408.xml	HIF1	48393 : 48397	CM	ed by NF-Y, Sp1, pRB and HIF1, and is suppressed by Sp
./___Corpus/Medline/xml/PMC4600408.xml	Sp3	48420 : 48423	CM	F1, and is suppressed by Sp3, MDM2 and active JNK sig
./___Corpus/Medline/xml/PMC4600408.xml	MDM2	48425 : 48429	CM	nd is suppressed by Sp3, MDM2 and active JNK signaling
./___Corpus/Medline/xml/PMC4600408.xml	JNK	48441 : 48444	CM	 by Sp3, MDM2 and active JNK signaling which causes a
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	48482 : 48485	CM	ich causes a switch from Sp1 to Sp3 binding at the en
./___Corpus/Medline/xml/PMC4600408.xml	Sp3	48489 : 48492	CM	ses a switch from Sp1 to Sp3 binding at the endogenou
./___Corpus/Medline/xml/PMC4600408.xml	hTR	48644 : 48647	CM	aid in the literature to hTR transcriptional mechanis
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	48731 : 48736	CM	        In contrast, the hTERT gene has been intensely 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	48815 : 48820	CM	loning in 1997 (Fig. 3). hTERT transcripts are nearly o
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	49189 : 49194	CM	iption factors including c-Myc, HIF1, ETS, E2F and Sp1/
./___Corpus/Medline/xml/PMC4600408.xml	HIF1	49196 : 49200	CM	factors including c-Myc, HIF1, ETS, E2F and Sp1/Sp3, w
./___Corpus/Medline/xml/PMC4600408.xml	ETS	49202 : 49205	CM	s including c-Myc, HIF1, ETS, E2F and Sp1/Sp3, which 
./___Corpus/Medline/xml/PMC4600408.xml	E2F	49207 : 49210	CM	luding c-Myc, HIF1, ETS, E2F and Sp1/Sp3, which integ
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	49215 : 49218	CM	-Myc, HIF1, ETS, E2F and Sp1/Sp3, which integrate hTE
./___Corpus/Medline/xml/PMC4600408.xml	Sp3	49219 : 49222	CM	, HIF1, ETS, E2F and Sp1/Sp3, which integrate hTERT t
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	49240 : 49245	CM	Sp1/Sp3, which integrate hTERT transcriptional response
./___Corpus/Medline/xml/PMC4600408.xml	HIF1	49389 : 49393	CM	], [221]. Interestingly, HIF1 is also involved in post
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	49449 : 49454	CM	criptional regulation of hTERT splicing [222].         
./___Corpus/Medline/xml/PMC4600408.xml	MAPK	49782 : 49786	CM	factor signaling through MAPK pathways increases hTERT
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	49806 : 49811	CM	 MAPK pathways increases hTERT expression in part via E
./___Corpus/Medline/xml/PMC4600408.xml	ETS	49835 : 49838	CM	T expression in part via ETS factors [223]. Interesti
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	49954 : 49959	CM	y point mutations in the hTERT core promoter occurring 
./___Corpus/Medline/xml/PMC4600408.xml	BRAF	50124 : 50128	CM	red more frequently than BRAF or NRAS mutations and ea
./___Corpus/Medline/xml/PMC4600408.xml	NRAS	50132 : 50136	CM	 frequently than BRAF or NRAS mutations and each gener
./___Corpus/Medline/xml/PMC4600408.xml	ETS	50185 : 50188	CM	rated a binding site for ETS family transcription fac
./___Corpus/Medline/xml/PMC4600408.xml	TCF	50233 : 50236	CM	n factors, including the TCF subgroup activated by MA
./___Corpus/Medline/xml/PMC4600408.xml	MAPK	50259 : 50263	CM	CF subgroup activated by MAPK and BRAF signaling.     
./___Corpus/Medline/xml/PMC4600408.xml	BRAF	50268 : 50272	CM	up activated by MAPK and BRAF signaling.              
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	50328 : 50333	CM	                   Other hTERT activation pathways that
./___Corpus/Medline/xml/PMC4600408.xml	CDK2	50441 : 50445	CM	lude those influenced by CDK2 and CDK4 [226] and AKT [
./___Corpus/Medline/xml/PMC4600408.xml	CDK4	50450 : 50454	CM	e influenced by CDK2 and CDK4 [226] and AKT [227], whe
./___Corpus/Medline/xml/PMC4600408.xml	AKT	50465 : 50468	CM	 CDK2 and CDK4 [226] and AKT [227], whereas deregulat
./___Corpus/Medline/xml/PMC4600408.xml	TGFβ	50544 : 50548	CM	lude those influenced by TGFβ [228], TNFα [229], and o
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	50650 : 50655	CM	ental pathways can cause hTERT expression. For example,
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	50685 : 50690	CM	ession. For example, the hTERT gene has been found to b
./___Corpus/Medline/xml/PMC4600408.xml	Wnt	50740 : 50743	CM	e a direct target of the Wnt signaling [231], [232], 
./___Corpus/Medline/xml/PMC4600408.xml	Wnt	50779 : 50782	CM	[231], [232], [233]. The Wnt signaling pathway is kno
./___Corpus/Medline/xml/PMC4600408.xml	Wnt	50883 : 50886	CM	cell renewal. Binding of Wnt ligand to its receptor F
./___Corpus/Medline/xml/PMC4600408.xml	GSK3β	50929 : 50934	CM	eptor Frizzled activates GSK3β kinase, which blocks ubi
./___Corpus/Medline/xml/PMC4600408.xml	ubiquitin	50956 : 50965	CM	K3β kinase, which blocks ubiquitin-dependent degradation of
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	50991 : 51000	CM	dependent degradation of β-catenin. Stabilized β-catenin en
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	51013 : 51022	CM	of β-catenin. Stabilized β-catenin enters the nucleus, form
./___Corpus/Medline/xml/PMC4600408.xml	LEF	51064 : 51067	CM	us, forms a complex with LEF/TCF, and activates a set
./___Corpus/Medline/xml/PMC4600408.xml	TCF	51068 : 51071	CM	forms a complex with LEF/TCF, and activates a set of 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	51119 : 51124	CM	f target genes including c-Myc. Myc protein binds to an
./___Corpus/Medline/xml/PMC4600408.xml	E-	51150 : 51152	CPR	 Myc protein binds to an E-box element in the hTERT 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51171 : 51176	CM	 an E-box element in the hTERT core promoter and activa
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51205 : 51210	CM	e promoter and activates hTERT transcription. In additi
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	51239 : 51248	CM	nscription. In addition, β-catenin can also form a complex 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51320 : 51325	CM	tor Klf4 and bind to the hTERT promoter directly [231].
./___Corpus/Medline/xml/PMC4600408.xml	kinome	51407 : 51413	CM	       Recently, a whole kinome siRNA screen in ovarian 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51473 : 51478	CM	ls for regulators of the hTERT promoter revealed at lea
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51558 : 51563	CM	 in pathways upstream of hTERT regulatory transcription
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51721 : 51726	CM	nd realistic to consider hTERT regulation in a systems 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	51901 : 51906	CM	tors. For example, while c-Myc has been shown to activa
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	51934 : 51939	CM	s been shown to activate hTERT transcription in cancer 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	52026 : 52031	CM	derate overexpression of c-Myc by itself is not suffici
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	52089 : 52094	CM	activation of endogenous hTERT genes in normal human ma
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	52305 : 52310	CM	actors bind the extended hTERT promoter region, co-oper
./___Corpus/Medline/xml/PMC4600408.xml	lead	52726 : 52730	CM	ell understood, it could lead to precise therapeutic a
./___Corpus/Medline/xml/PMC4600408.xml	ALT	53989 : 53992	CM	engthening of telomeres (ALT) mechanism exists for te
./___Corpus/Medline/xml/PMC4600408.xml	ALT	54153 : 54156	CM	ome studies suggest that ALT cells are not as biologi
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	55358 : 55373	RN	e nuclear translocation, phosphorylation, folding and turnover of
./___Corpus/Medline/xml/PMC4600408.xml	lead	55426 : 55430	CM	dividual components that lead to and regulate the rate
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	55703 : 55708	CM	 negative mutant form of hTERT (DN-hTERT) in tumor-deri
./___Corpus/Medline/xml/PMC4600408.xml	DN-hTERT	55710 : 55718	CM	ve mutant form of hTERT (DN-hTERT) in tumor-derived cell l
./___Corpus/Medline/xml/PMC4600408.xml	DN-hTERT	55996 : 56004	CM	rated that expression of DN-hTERT inhibited anchorage inde
./___Corpus/Medline/xml/PMC4600408.xml	DN-hTERT	56162 : 56170	CM	he inhibitory effects of DN-hTERT were also experimentally
./___Corpus/Medline/xml/PMC4600408.xml	AML	56223 : 56226	CM	monstrated using primary AML cells in vitro and in vi
./___Corpus/Medline/xml/PMC4600408.xml	vitro	56236 : 56241	CM	ing primary AML cells in vitro and in vivo using a muri
./___Corpus/Medline/xml/PMC4600408.xml	murine	56262 : 56268	CM	itro and in vivo using a murine model [248].            
./___Corpus/Medline/xml/PMC4600408.xml	hTR	56464 : 56467	CM	 acids (PNA) that target hTR, provided proof-of-princ
./___Corpus/Medline/xml/PMC4600408.xml	2′-O-MeRNA	56695 : 56705	CM	 human tumor cell lines, 2′-O-MeRNA, phosphoramidate and PNA
./___Corpus/Medline/xml/PMC4600408.xml	phosphoramidate	56707 : 56722	CM	 cell lines, 2′-O-MeRNA, phosphoramidate and PNA oligomers induce
./___Corpus/Medline/xml/PMC4600408.xml	PNA	56727 : 56730	CM	RNA, phosphoramidate and PNA oligomers induced telome
./___Corpus/Medline/xml/PMC4600408.xml	thio-phosphoroamidate	56892 : 56913	CM	In particular, a N3′–P5′ thio-phosphoroamidate oligonucleotide targeted
./___Corpus/Medline/xml/PMC4600408.xml	hTR	56971 : 56974	CM	template region of human hTR (GRN163) was shown to ha
./___Corpus/Medline/xml/PMC4600408.xml	GRN163	56976 : 56982	CM	ate region of human hTR (GRN163) was shown to have effic
./___Corpus/Medline/xml/PMC4600408.xml	lipid	57363 : 57368	CM	elomeres [257], [258]. A lipid conjugated form of GRN16
./___Corpus/Medline/xml/PMC4600408.xml	GRN163	57388 : 57394	CM	lipid conjugated form of GRN163, referred to as GRN163L 
./___Corpus/Medline/xml/PMC4600408.xml	GRN163L	57411 : 57418	CM	f GRN163, referred to as GRN163L or imetelstat, exhibited
./___Corpus/Medline/xml/PMC4600408.xml	G1	57746 : 57748	CM	ells (MSCs) to arrest in G1 phase of the cell cycle,
./___Corpus/Medline/xml/PMC4600408.xml	hTR	58306 : 58309	CM	g the template region of hTR as an effective approach
./___Corpus/Medline/xml/PMC4600408.xml	CNS	59347 : 59350	CM	logic disease, childhood CNS malignancies and the app
./___Corpus/Medline/xml/PMC4600408.xml	platinum	59767 : 59775	CM	enance therapy following platinum chemotherapy in patients
./___Corpus/Medline/xml/PMC4600408.xml	hTR	60549 : 60552	CM	le imetelstat, targeting hTR, was the first telomeras
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	60666 : 60671	CM	igonucleotides targeting hTERT mRNA have also been show
./___Corpus/Medline/xml/PMC4600408.xml	mRNA	60672 : 60676	CM	leotides targeting hTERT mRNA have also been shown to 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	60871 : 60876	CM	rative defect induced by hTERT inhibition was immediate
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61027 : 61032	CM	cleotide directed toward hTERT mRNA was also shown to s
./___Corpus/Medline/xml/PMC4600408.xml	mRNA	61033 : 61037	CM	de directed toward hTERT mRNA was also shown to sensit
./___Corpus/Medline/xml/PMC4600408.xml	AML	61124 : 61127	CM	ultures established from AML and CML patients to the 
./___Corpus/Medline/xml/PMC4600408.xml	CML	61132 : 61135	CM	established from AML and CML patients to the drug cis
./___Corpus/Medline/xml/PMC4600408.xml	cis-diamminedichloroplatinum	61157 : 61185	CM	CML patients to the drug cis-diamminedichloroplatinum. Ribozymes and small int
./___Corpus/Medline/xml/PMC4600408.xml	RNAs	61219 : 61223	CM	es and small interfering RNAs (siRNAs) targeting hTERT
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61243 : 61248	CM	 RNAs (siRNAs) targeting hTERT have also been employed 
./___Corpus/Medline/xml/PMC4600408.xml	anti-	61419 : 61424	CPR	[274], [275]. The potent anti-proliferative effects tha
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61501 : 61506	CM	 tumor cells depleted of hTERT are consistent with a bo
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61601 : 61606	CM	independent functions of hTERT and gene expression chan
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61660 : 61665	CM	induced by repression of hTERT [276], [277], [278], [27
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	61802 : 61807	CM	therapeutic targeting of hTERT, although the translatio
./___Corpus/Medline/xml/PMC4600408.xml	catechin	62219 : 62227	CM	the structure of the tea catechin, epigallocatechin-3-gall
./___Corpus/Medline/xml/PMC4600408.xml	epigallocatechin-3-gallate	62229 : 62255	CM	ure of the tea catechin, epigallocatechin-3-gallate (EGCG; see Section 8.4),
./___Corpus/Medline/xml/PMC4600408.xml	EGCG	62257 : 62261	CM	gallocatechin-3-gallate (EGCG; see Section 8.4), which
./___Corpus/Medline/xml/PMC4600408.xml	2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one	62498 : 62545	CM	ical classes and include 2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one (TMPI), Rhodacyanine (FJ
./___Corpus/Medline/xml/PMC4600408.xml	TMPI	62547 : 62551	CM	enyl]isothiazolin-3-one (TMPI), Rhodacyanine (FJ5002),
./___Corpus/Medline/xml/PMC4600408.xml	Rhodacyanine	62554 : 62566	CM	othiazolin-3-one (TMPI), Rhodacyanine (FJ5002), N-[3-[(2,3-dih
./___Corpus/Medline/xml/PMC4600408.xml	FJ5002	62568 : 62574	CM	ne (TMPI), Rhodacyanine (FJ5002), N-[3-[(2,3-dihydroxybe
./___Corpus/Medline/xml/PMC4600408.xml	N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide	62577 : 62641	CM	, Rhodacyanine (FJ5002), N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide (MST-312) and (E)-2-(3-(
./___Corpus/Medline/xml/PMC4600408.xml	MST-312	62643 : 62650	CM	-2,3-dihydroxybenzamide (MST-312) and (E)-2-(3-(naphthale
./___Corpus/Medline/xml/PMC4600408.xml	(E)-2-(3-(naphthalene-2-yl)but-2enamido)benzoic acid	62656 : 62708	CM	ybenzamide (MST-312) and (E)-2-(3-(naphthalene-2-yl)but-2enamido)benzoic acid (BIBR1532). BIBR1532 is 
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62710 : 62718	CM	t-2enamido)benzoic acid (BIBR1532). BIBR1532 is one of the
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62721 : 62729	CM	benzoic acid (BIBR1532). BIBR1532 is one of the more exten
./___Corpus/Medline/xml/PMC4600408.xml	vitro	62866 : 62871	CM	n of tumor cell lines in vitro and limit tumor formatio
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	62971 : 62979	CM	w concentration (10 μm), BIBR1532 had no effect on short-t
./___Corpus/Medline/xml/PMC4600408.xml	50–	63066 : 63069	CPR	s higher concentrations (50–80 μm) were acutely cytot
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	63222 : 63230	CM	igh concentration of the BIBR1532. The cytotoxic effects o
./___Corpus/Medline/xml/PMC4600408.xml	BIBR1532	63257 : 63265	CM	The cytotoxic effects of BIBR1532 were attributed to telom
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	63829 : 63833	CM	protein synthesis [290]. mTOR – a serine/threonine kin
./___Corpus/Medline/xml/PMC4600408.xml	serine	63838 : 63844	CM	ynthesis [290]. mTOR – a serine/threonine kinase – is fr
./___Corpus/Medline/xml/PMC4600408.xml	threonine	63845 : 63854	CM	s [290]. mTOR – a serine/threonine kinase – is frequently d
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	63937 : 63941	CM	. An association between mTOR and telomerase activity 
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	64004 : 64008	CM	n using the prototypical mTOR inhibitor rapamycin that
./___Corpus/Medline/xml/PMC4600408.xml	rapamycin	64019 : 64028	CM	totypical mTOR inhibitor rapamycin that, in addition to its
./___Corpus/Medline/xml/PMC4600408.xml	rapamycin	64204 : 64213	CM	t in a similar manner to rapamycin with respect to telomera
./___Corpus/Medline/xml/PMC4600408.xml	GV1001	64861 : 64867	CM	 1). Indeed one product, GV1001, has progressed to phase
./___Corpus/Medline/xml/PMC4600408.xml	gemcitabine	64960 : 64971	CM	used in combination with gemcitabine for the treatment of pan
./___Corpus/Medline/xml/PMC4600408.xml	clonogenic	65224 : 65234	CM	tion in the frequency of clonogenic progenitor cells or NOD/
./___Corpus/Medline/xml/PMC4600408.xml	NOD	65255 : 65258	CM	enic progenitor cells or NOD/SCID repopulating cells 
./___Corpus/Medline/xml/PMC4600408.xml	SCID	65259 : 65263	CM	 progenitor cells or NOD/SCID repopulating cells withi
./___Corpus/Medline/xml/PMC4600408.xml	Telomerase	65542 : 65552	CM	].                  8.4. Telomerase-directed gene therapy   
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	66046 : 66051	CM	erent, the promoters for hTERT and hTR are attractive c
./___Corpus/Medline/xml/PMC4600408.xml	hTR	66056 : 66059	CM	 promoters for hTERT and hTR are attractive candidate
./___Corpus/Medline/xml/PMC4600408.xml	vitro	66687 : 66692	CM	 targeted effectively in vitro. Critically, almost all 
./___Corpus/Medline/xml/PMC4600408.xml	hTR	67244 : 67247	CM	f systemically delivered hTR and hTERT-specific trans
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	67252 : 67257	CM	ically delivered hTR and hTERT-specific transgene expre
./___Corpus/Medline/xml/PMC4600408.xml	transgene	67267 : 67276	CM	d hTR and hTERT-specific transgene expression has been inve
./___Corpus/Medline/xml/PMC4600408.xml	RNA	68277 : 68280	CM	f the telomerase protein–RNA complex or posttranslati
./___Corpus/Medline/xml/PMC4600408.xml	berberine	68441 : 68450	CM	omerase was the compound berberine, leading to identificati
./___Corpus/Medline/xml/PMC4600408.xml	anti-	68497 : 68502	CPR	ation of the more potent anti-telomerase analogue FJ500
./___Corpus/Medline/xml/PMC4600408.xml	FJ5002	68522 : 68528	CM	anti-telomerase analogue FJ5002 [282], though this was n
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoids	69309 : 69320	CM	t telomerase include (a) isoprenoids – such as perillyl alcoh
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69331 : 69347	CM	a) isoprenoids – such as perillyl alcohol, genistein, and fisetin,
./___Corpus/Medline/xml/PMC4600408.xml	genistein	69349 : 69358	CM	uch as perillyl alcohol, genistein, and fisetin, (b) polyph
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	69364 : 69371	CM	 alcohol, genistein, and fisetin, (b) polyphenols – such 
./___Corpus/Medline/xml/PMC4600408.xml	polyphenols	69377 : 69388	CM	istein, and fisetin, (b) polyphenols – such as curcumin, resv
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	69399 : 69407	CM	b) polyphenols – such as curcumin, resveratrol, and EGCG, 
./___Corpus/Medline/xml/PMC4600408.xml	resveratrol	69409 : 69420	CM	nols – such as curcumin, resveratrol, and EGCG, (c) indole-3-
./___Corpus/Medline/xml/PMC4600408.xml	EGCG	69426 : 69430	CM	rcumin, resveratrol, and EGCG, (c) indole-3-carbinol, 
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	69436 : 69453	CM	sveratrol, and EGCG, (c) indole-3-carbinol, and (d) sulforaphane (T
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	69463 : 69475	CM	dole-3-carbinol, and (d) sulforaphane (Table 1).              
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoids	69535 : 69546	CM	               Among the isoprenoids, perillyl alcohol, a sma
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69548 : 69564	CM	  Among the isoprenoids, perillyl alcohol, a small, lipophilic pro
./___Corpus/Medline/xml/PMC4600408.xml	lipophilic	69575 : 69585	CM	rillyl alcohol, a small, lipophilic product of the plant mev
./___Corpus/Medline/xml/PMC4600408.xml	mevalonate	69607 : 69617	CM	lic product of the plant mevalonate biosynthetic pathway [30
./___Corpus/Medline/xml/PMC4600408.xml	Perillyl alcohol	69771 : 69787	CM	0], [311], [312], [313]. Perillyl alcohol acts on protein translat
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	69838 : 69842	CM	on through modulation of mTOR signaling in cultured pr
./___Corpus/Medline/xml/PMC4600408.xml	perillyl alcohol	69955 : 69971	CM	 [310]. Mechanistically, perillyl alcohol has been shown to disrup
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	70024 : 70028	CM	omplex formation between mTOR and hTERT, causing p70 S
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70033 : 70038	CM	rmation between mTOR and hTERT, causing p70 S6 kinase (
./___Corpus/Medline/xml/PMC4600408.xml	S6K	70063 : 70066	CM	, causing p70 S6 kinase (S6K), heat shock protein 90 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70104 : 70109	CM	 protein 90 (Hsp90), and hTERT to dissociate from the r
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	70166 : 70170	CM	ry-associated protein of mTOR (RAPTOR) [293], [294].  
./___Corpus/Medline/xml/PMC4600408.xml	isoprenoid	70252 : 70262	CM	     Genistein – another isoprenoid found in soy and fava be
./___Corpus/Medline/xml/PMC4600408.xml	4E-BP1	70373 : 70379	CM	e activity and attenuate 4E-BP1 phosphorylation, an indi
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	70380 : 70395	RN	ity and attenuate 4E-BP1 phosphorylation, an indicator of mTOR si
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	70413 : 70417	CM	ylation, an indicator of mTOR signaling [314], [315], 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70474 : 70479	CM	Genistein down-regulates hTERT levels by the inhibiting
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70505 : 70510	CM	levels by the inhibiting hTERT gene promoter activity i
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70612 : 70621	CM	 showed that exposure to genistein inhibited expression of 
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	70650 : 70655	CM	ibited expression of the c-Myc, possibly attenuating it
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70716 : 70721	CM	tional activation of the hTERT promoter; however, the i
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70767 : 70776	CM	he inhibitory effects of genistein on hTERT promoter activi
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70780 : 70785	CM	 effects of genistein on hTERT promoter activity likely
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	70872 : 70877	CM	e factors in addition to c-Myc. One contrasting study s
./___Corpus/Medline/xml/PMC4600408.xml	genistein	70913 : 70922	CM	asting study showed that genistein stimulated hTERT express
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	70934 : 70939	CM	hat genistein stimulated hTERT expression in reproducti
./___Corpus/Medline/xml/PMC4600408.xml	STAT3	70993 : 70998	CM	ancer cells by enhancing STAT3 activity [317], however,
./___Corpus/Medline/xml/PMC4600408.xml	genistein	71149 : 71158	CM	al inhibitory effects of genistein, treatment of lung cance
./___Corpus/Medline/xml/PMC4600408.xml	ethyl acetate	71200 : 71213	CM	ng cancer cells with the ethyl acetate fraction of ginger extra
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	71270 : 71275	CM	currently down regulated hTERT and c-Myc expression, wh
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	71280 : 71285	CM	down regulated hTERT and c-Myc expression, which result
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	71519 : 71534	RN	ion of the Akt dependent phosphorylation of hTERT and thereby inh
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	71538 : 71543	CM	ndent phosphorylation of hTERT and thereby inhibited hT
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	71566 : 71571	CM	RT and thereby inhibited hTERT translocation into the n
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	71654 : 71661	CM	y similar phytochemical, fisetin, decreases phosphorylati
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	71673 : 71688	RN	ical, fisetin, decreases phosphorylation of multiple proteins wit
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	71729 : 71733	CM	teins within the Akt and mTOR pathway, including PI3K,
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	71753 : 71757	CM	 mTOR pathway, including PI3K, mTOR, S6K and 4E-BP1 [3
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	71759 : 71763	CM	pathway, including PI3K, mTOR, S6K and 4E-BP1 [319], [
./___Corpus/Medline/xml/PMC4600408.xml	S6K	71765 : 71768	CM	y, including PI3K, mTOR, S6K and 4E-BP1 [319], [320].
./___Corpus/Medline/xml/PMC4600408.xml	4E-BP1	71773 : 71779	CM	ding PI3K, mTOR, S6K and 4E-BP1 [319], [320]. Furthermor
./___Corpus/Medline/xml/PMC4600408.xml	fisetin	71807 : 71814	CM	19], [320]. Furthermore, fisetin has shown antitumor effi
./___Corpus/Medline/xml/PMC4600408.xml	polyphenolic	71928 : 71940	CM	                   Among polyphenolic compounds, curcumin – a 
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	71952 : 71960	CM	 polyphenolic compounds, curcumin – a component of the spi
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	72177 : 72181	CM	is phytochemical reduces mTOR signaling by inhibiting 
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	72206 : 72221	RN	 signaling by inhibiting phosphorylation of S6K and 4E-BP1, and d
./___Corpus/Medline/xml/PMC4600408.xml	S6K	72225 : 72228	CM	iting phosphorylation of S6K and 4E-BP1, and disrupts
./___Corpus/Medline/xml/PMC4600408.xml	4E-BP1	72233 : 72239	CM	osphorylation of S6K and 4E-BP1, and disrupts the mTOR–R
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	72258 : 72262	CM	4E-BP1, and disrupts the mTOR–RAPTOR interaction [326]
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72330 : 72338	CM	ke other phytochemicals, curcumin has a range of pleiotrop
./___Corpus/Medline/xml/PMC4600408.xml	anti-	72462 : 72467	CPR	y of a range of pro- and anti-apoptotic proteins as wel
./___Corpus/Medline/xml/PMC4600408.xml	c-Myc	72535 : 72540	CM	gulatory factors such as c-Myc and the p53 family [324]
./___Corpus/Medline/xml/PMC4600408.xml	p53	72549 : 72552	CM	rs such as c-Myc and the p53 family [324]. In additio
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	72597 : 72601	CM	dition to its effects on mTOR, curcumin modulates addi
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72603 : 72611	CM	 to its effects on mTOR, curcumin modulates additional cel
./___Corpus/Medline/xml/PMC4600408.xml	JAK-STAT	72662 : 72670	CM	ular pathways, including JAK-STAT, NF-κB, and MAPK, that i
./___Corpus/Medline/xml/PMC4600408.xml	NF-κB	72672 : 72677	CM	ays, including JAK-STAT, NF-κB, and MAPK, that impact t
./___Corpus/Medline/xml/PMC4600408.xml	MAPK	72683 : 72687	CM	ing JAK-STAT, NF-κB, and MAPK, that impact telomerase 
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72784 : 72792	CM	 In breast cancer cells, curcumin down-regulation of the l
./___Corpus/Medline/xml/PMC4600408.xml	NFkB	72830 : 72834	CM	ion of the levels of the NFkB transcription factor has
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	72887 : 72892	CM	en proposed to attenuate hTERT expression [330]. In lun
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	72933 : 72941	CM	]. In lung cancer cells, curcumin stimulates the level of 
./___Corpus/Medline/xml/PMC4600408.xml	oxygen	72975 : 72981	CM	es the level of reactive oxygen species, which triggers 
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	73040 : 73043	CM	asome degradation of the Sp1 transcription factor lea
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	73088 : 73093	CM	r leading to the loss of hTERT gene expression [331]. C
./___Corpus/Medline/xml/PMC4600408.xml	Curcumin	73117 : 73125	CM	T gene expression [331]. Curcumin exposure was also shown 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	73192 : 73197	CM	cytoplasmic retention of hTERT protein by causing disso
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	73233 : 73238	CM	 causing dissociation of hTERT from its chaperone p23 [
./___Corpus/Medline/xml/PMC4600408.xml	Resveratrol	73269 : 73280	CM	its chaperone p23 [325]. Resveratrol, another natural phenol 
./___Corpus/Medline/xml/PMC4600408.xml	phenol	73298 : 73304	CM	eratrol, another natural phenol produced in many plants 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	73374 : 73379	CM	s been found to decrease hTERT protein levels and inhib
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	73460 : 73468	CM	333]. The combination of curcumin and resveratrol reduced 
./___Corpus/Medline/xml/PMC4600408.xml	resveratrol	73473 : 73484	CM	bination of curcumin and resveratrol reduced cancer incidence
./___Corpus/Medline/xml/PMC4600408.xml	PTEN	73513 : 73517	CM	uced cancer incidence in PTEN knockout mice [334]. EGC
./___Corpus/Medline/xml/PMC4600408.xml	EGCG	73539 : 73543	CM	TEN knockout mice [334]. EGCG is similar to curcumin i
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	73558 : 73566	CM	334]. EGCG is similar to curcumin in that it was found to 
./___Corpus/Medline/xml/PMC4600408.xml	JAK	73646 : 73649	CM	gnaling pathways such as JAK/STAT, MAPK, and PI3K/Akt
./___Corpus/Medline/xml/PMC4600408.xml	STAT	73650 : 73654	CM	ing pathways such as JAK/STAT, MAPK, and PI3K/Akt/mTOR
./___Corpus/Medline/xml/PMC4600408.xml	MAPK	73656 : 73660	CM	thways such as JAK/STAT, MAPK, and PI3K/Akt/mTOR [335]
./___Corpus/Medline/xml/PMC4600408.xml	PI3K	73666 : 73670	CM	h as JAK/STAT, MAPK, and PI3K/Akt/mTOR [335]. EGCG dow
./___Corpus/Medline/xml/PMC4600408.xml	mTOR	73675 : 73679	CM	STAT, MAPK, and PI3K/Akt/mTOR [335]. EGCG down-regulat
./___Corpus/Medline/xml/PMC4600408.xml	EGCG	73687 : 73691	CM	and PI3K/Akt/mTOR [335]. EGCG down-regulated telomeras
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	73936 : 73953	CM	atory properties include indole-3-carbinol, a naturally occurring h
./___Corpus/Medline/xml/PMC4600408.xml	hydrolysis	73977 : 73987	RN	l, a naturally occurring hydrolysis product of glucobrassici
./___Corpus/Medline/xml/PMC4600408.xml	glucobrassicin	73999 : 74013	CM	ng hydrolysis product of glucobrassicin, and the dietary isothio
./___Corpus/Medline/xml/PMC4600408.xml	isothiocyanate	74031 : 74045	CM	assicin, and the dietary isothiocyanate, sulforaphane, both from
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74047 : 74059	CM	 dietary isothiocyanate, sulforaphane, both from cruciferous v
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	74180 : 74197	CM	breast cancer cells with indole-3-carbinol induced cell cycle arres
./___Corpus/Medline/xml/PMC4600408.xml	estrogen	74247 : 74255	CM	t and disrupted combined estrogen receptor-alpha and Sp1-d
./___Corpus/Medline/xml/PMC4600408.xml	alpha	74265 : 74270	CM	mbined estrogen receptor-alpha and Sp1-driven transcrip
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	74275 : 74278	CM	rogen receptor-alpha and Sp1-driven transcription of 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	74307 : 74312	CM	ven transcription of the hTERT gene [340]. Chromatin im
./___Corpus/Medline/xml/PMC4600408.xml	Chromatin	74325 : 74334	CM	of the hTERT gene [340]. Chromatin immunoprecipitation anal
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	74382 : 74387	CM	alysis of the endogenous hTERT promoter showed that ind
./___Corpus/Medline/xml/PMC4600408.xml	indole-3-carbinol	74409 : 74426	CM	ERT promoter showed that indole-3-carbinol inhibited binding of bot
./___Corpus/Medline/xml/PMC4600408.xml	estrogen	74453 : 74461	CM	nhibited binding of both estrogen receptor-alpha and Sp1 t
./___Corpus/Medline/xml/PMC4600408.xml	alpha	74471 : 74476	CM	f both estrogen receptor-alpha and Sp1 to a composite e
./___Corpus/Medline/xml/PMC4600408.xml	Sp1	74481 : 74484	CM	rogen receptor-alpha and Sp1 to a composite estrogen 
./___Corpus/Medline/xml/PMC4600408.xml	estrogen	74500 : 74508	CM	a and Sp1 to a composite estrogen response-Sp1 element in 
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	74537 : 74542	CM	ponse-Sp1 element in the hTERT promoter [340]. Similar 
./___Corpus/Medline/xml/PMC4600408.xml	curcumin	74570 : 74578	CM	omoter [340]. Similar to curcumin, exposure to sulforaphan
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74592 : 74604	CM	to curcumin, exposure to sulforaphane elevated intracellular r
./___Corpus/Medline/xml/PMC4600408.xml	oxygen	74637 : 74643	CM	d intracellular reactive oxygen species in hepatocellula
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	74748 : 74753	CM	ked to the inhibition of hTERT gene expression [341]. I
./___Corpus/Medline/xml/PMC4600408.xml	sulforaphane	74839 : 74851	CM	 in breast cancer cells, sulforaphane suppressed Akt kinase ac
./___Corpus/Medline/xml/PMC4600408.xml	hTERT	74914 : 74919	CM	 resulted in the loss of hTERT phosphorylation [341].  
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	74920 : 74935	RN	ted in the loss of hTERT phosphorylation [341].                  
./___Corpus/Medline/xml/PMC4600408.xml	sulphated lipopolysaccharide	75086 : 75114	CM	icals. Axinelloside A, a sulphated lipopolysaccharide isolated from the marine
./___Corpus/Medline/xml/PMC4600408.xml	pentaoxazole	75354 : 75366	CM	is a natural macrocyclic pentaoxazole isolated from Streptomyc
./___Corpus/Medline/xml/PMC4600408.xml	vitro	75517 : 75522	CM	 of cancer cell lines in vitro as well as leukemia xeno
./___Corpus/Medline/xml/PMC4600408.xml	poly(ADP-ribose)	76137 : 76153	CM	terest is tankyrase 1, a poly(ADP-ribose) polymerase (PARP) family
./___Corpus/Medline/xml/PMC4600408.xml	TRF1	76223 : 76227	CM	es the shelterin protein TRF1 [349], [350]. By modifyi
./___Corpus/Medline/xml/PMC4600408.xml	TRF1	76255 : 76259	CM	49], [350]. By modifying TRF1, tankyrase 1 causes disp
./___Corpus/Medline/xml/PMC4600408.xml	TRF1	76296 : 76300	CM	1 causes displacement of TRF1 from the telomere, there
./___Corpus/Medline/xml/PMC4600408.xml	WNT	76969 : 76972	CM	of telomerase (e.g., the WNT/β-catenin pathway), this
./___Corpus/Medline/xml/PMC4600408.xml	β-catenin	76973 : 76982	CM	elomerase (e.g., the WNT/β-catenin pathway), this area of i
./___Corpus/Medline/xml/PMC4600408.xml	porphyrins	77484 : 77494	CM	telomere effects include porphyrins (TMPyP4), perylenes (PIP
./___Corpus/Medline/xml/PMC4600408.xml	TMPyP4	77496 : 77502	CM	ects include porphyrins (TMPyP4), perylenes (PIPER), acr
./___Corpus/Medline/xml/PMC4600408.xml	perylenes	77505 : 77514	CM	ude porphyrins (TMPyP4), perylenes (PIPER), acridine deriva
./___Corpus/Medline/xml/PMC4600408.xml	PIPER	77516 : 77521	CM	ins (TMPyP4), perylenes (PIPER), acridine derivatives (
./___Corpus/Medline/xml/PMC4600408.xml	acridine	77524 : 77532	CM	yP4), perylenes (PIPER), acridine derivatives (BRACO19, RH
./___Corpus/Medline/xml/PMC4600408.xml	BRACO19	77546 : 77553	CM	), acridine derivatives (BRACO19, RHPS4), quinoline-subst
./___Corpus/Medline/xml/PMC4600408.xml	RHPS4	77555 : 77560	CM	ne derivatives (BRACO19, RHPS4), quinoline-substituted 
./___Corpus/Medline/xml/PMC4600408.xml	quinoline	77563 : 77572	CM	atives (BRACO19, RHPS4), quinoline-substituted triazines an
./___Corpus/Medline/xml/PMC4600408.xml	triazines	77585 : 77594	CM	), quinoline-substituted triazines and natural products, su
./___Corpus/Medline/xml/PMC4600408.xml	cytosine	78233 : 78241	CM	lls to danunorubicin and cytosine-arabinoside, and was eff
./___Corpus/Medline/xml/PMC4600408.xml	arabinoside	78242 : 78253	CM	nunorubicin and cytosine-arabinoside, and was effectively com
./___Corpus/Medline/xml/PMC4600408.xml	tyrosine	78293 : 78301	CM	tively combined with the tyrosine kinase inhibitor imatini
./___Corpus/Medline/xml/PMC4600408.xml	imatinib	78319 : 78327	CM	yrosine kinase inhibitor imatinib to kill chronic myeloid 
./___Corpus/Medline/xml/PMC4600408.xml	retinoic acid	78962 : 78975	CM	iation pathways (such as retinoic acid [362]), may induce senes
./___Corpus/Medline/xml/PMC4600408.xml	p53	79910 : 79913	CM	ose tumors retain intact p53 responses [363], [364]. 
./___Corpus/Medline/xml/PMC4600408.xml	p53	79978 : 79981	CM	th genotoxins, wild-type p53 tumors show induction of
./___Corpus/Medline/xml/PMC4600408.xml	p21	80007 : 80010	CM	tumors show induction of p21 and SA-βgal, but not p16
./___Corpus/Medline/xml/PMC4600408.xml	p16	80032 : 80035	CM	p21 and SA-βgal, but not p16, and tumor growth often 
./___Corpus/Medline/xml/PMC4600408.xml	CDK	80194 : 80197	CM	urrent administration of CDK inhibitors that circumve
./___Corpus/Medline/xml/PMC4600408.xml	p16	80240 : 80243	CM	ircumvent defects in the p16/pRB pathway, causing the
./___Corpus/Medline/xml/PMC4600408.xml	pRB	80244 : 80247	CM	mvent defects in the p16/pRB pathway, causing the act
./___Corpus/Medline/xml/PMC4600408.xml	heterochromatin	80303 : 80318	CM	n of RB-family dependent heterochromatin formation at E2F-depende
./___Corpus/Medline/xml/PMC4600408.xml	E2F	80332 : 80335	CM	rochromatin formation at E2F-dependent promoters, and
./___Corpus/Medline/xml/PMC4600408.xml	ALT+	80589 : 80593	CM	e selective outgrowth of ALT+ cells [240].            
./___Corpus/Medline/xml/PMC4600408.xml	lead	81402 : 81406	CM	dated hits with improved lead-like qualities at the ea
./___Corpus/Medline/xml/PMC4600408.xml	phosphorylation	81760 : 81775	RN	porter activity, protein phosphorylation, or cell morphology. Imp
./___Corpus/Medline/xml/PMC4600408.xml	ALT	85411 : 85414	CM	esistant and/or activate ALT mechanisms for telomere 
./___Corpus/Medline/xml/PMC4600408.xml	arsenal	87046 : 87053	CM	ity, may well add to the arsenal available for combinator
./___Corpus/Medline/xml/PMC4600408.xml	Dr	87153 : 87155	CM	est                      Dr. Keith has collaborative
./___Corpus/Medline/xml/PMC4600408.xml	PY	87493 : 87495	CM	al Institutes of Health (PY: ES019458, GF: CA164095,
./___Corpus/Medline/xml/PMC4600408.xml	PY	87579 : 87581	CM	Cancer Research Program (PY: 17UB-8708), Cancer Rese
./___Corpus/Medline/xml/PMC4600408.xml	FR	87703 : 87705	CM	ute for Health Research (FR: MOP114962), Fonds de Re
./___Corpus/Medline/xml/PMC4600408.xml	FR	87752 : 87754	CM	 Recherche Québec Santé (FR: 22624), W.W. Smith Char
./___Corpus/Medline/xml/PMC4600408.xml	AM	87827 : 87829	CM	os III Health Institute (AM: CP10/00539), Basque Fou
./___Corpus/Medline/xml/PMC4600408.xml	CP10	87831 : 87835	CM	II Health Institute (AM: CP10/00539), Basque Foundatio
./___Corpus/Medline/xml/PMC4600408.xml	IKERBASQUE	87875 : 87885	CM	 Foundation for Science (IKERBASQUE) and Marie Curie CIG gra
./___Corpus/Medline/xml/PMC4600408.xml	CIG	87903 : 87906	CM	RBASQUE) and Marie Curie CIG grant (AM: 2012/712404),
./___Corpus/Medline/xml/PMC4600408.xml	AM	87914 : 87916	CM	d Marie Curie CIG grant (AM: 2012/712404), the Spani
./___Corpus/Medline/xml/PMC4600408.xml	ISCIII	87983 : 87989	CM	onomy and Competitivity, ISCIII (AC: PI12/00137, RTICC: 
./___Corpus/Medline/xml/PMC4600408.xml	PI12	87995 : 87999	CM	mpetitivity, ISCIII (AC: PI12/00137, RTICC: RD12/0036/
./___Corpus/Medline/xml/PMC4600408.xml	RD12	88014 : 88018	CM	 (AC: PI12/00137, RTICC: RD12/0036/0028), Regional Dev
./___Corpus/Medline/xml/PMC4600408.xml	MIS	88505 : 88508	CM	eek National funds grant MIS 379346 (AGG), COST Actio
./___Corpus/Medline/xml/PMC4600408.xml	CM1201	88541 : 88547	CM	(AGG), COST Action grant CM1201 (AGG), Italian Ministry 
./___Corpus/Medline/xml/PMC4600408.xml	AA	88615 : 88617	CM	the University of Italy (AA, EN), Japan Ministry of 
./___Corpus/Medline/xml/PMC4600408.xml	EN	88619 : 88621	CM	University of Italy (AA, EN), Japan Ministry of Educ
./___Corpus/Medline/xml/PMC4600408.xml	KA	88799 : 88801	CM	IUR-PRIN 20125S38FA_002 (KA), Italian Ministry of He
./___Corpus/Medline/xml/PMC4600408.xml	KA	88855 : 88857	CM	 grant GR-2011-02348047 (KA), Italian Association fo
./___Corpus/Medline/xml/PMC4600408.xml	AA	89000 : 89002	CM	), Terry Fox Foundation (AA), Zayed Center for Healt
./___Corpus/Medline/xml/PMC4600408.xml	AA	89039 : 89041	CM	ter for Health Sciences (AA), and Al-Jalila Foundati
./___Corpus/Medline/xml/PMC4600408.xml	AA	89070 : 89072	CM	nd Al-Jalila Foundation (AA).                  Refer
./___Corpus/Medline/xml/PMC4635070.xml	cyclooxygenase-2	650 : 666	CM	ation inhibitory factor, cyclooxygenase-2, transcription factor nu
./___Corpus/Medline/xml/PMC4635070.xml	alpha	734 : 739	CM	B, tumor necrosis factor alpha, inducible nitric oxide 
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	751 : 763	CM	 factor alpha, inducible nitric oxide synthase, protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	CXC	796 : 799	CM	e, protein kinase B, and CXC chemokines are reviewed 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	868 : 876	CM	flammatory targets while curcumin, resveratrol, epigalloca
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	878 : 889	CM	 targets while curcumin, resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4635070.xml	gallate	908 : 915	CM	ratrol, epigallocatechin gallate, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4635070.xml	genistein	917 : 926	CM	pigallocatechin gallate, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	928 : 936	CM	chin gallate, genistein, lycopene, and anthocyanins are re
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	942 : 954	CM	genistein, lycopene, and anthocyanins are reviewed as low-cost
./___Corpus/Medline/xml/PMC4635070.xml	10-fold	2671 : 2678	CM	cer has been found to be 10-fold higher in inflammatory b
./___Corpus/Medline/xml/PMC4635070.xml	penile	3466 : 3472	CM	has been associated with penile cancer [17]. Helicobacte
./___Corpus/Medline/xml/PMC4635070.xml	Helicobacter	3486 : 3498	CM	with penile cancer [17]. Helicobacter pylori (H. pylori) infec
./___Corpus/Medline/xml/PMC4635070.xml	H	3507 : 3508	CM	7]. Helicobacter pylori (H. pylori) infection and a
./___Corpus/Medline/xml/PMC4635070.xml	oxygen	4669 : 4675	CM	e generation of reactive oxygen species (ROS) and reacti
./___Corpus/Medline/xml/PMC4635070.xml	ROS	4685 : 4688	CM	reactive oxygen species (ROS) and reactive nitrogen s
./___Corpus/Medline/xml/PMC4635070.xml	nitrogen	4703 : 4711	CM	ecies (ROS) and reactive nitrogen species (RNS) capable of
./___Corpus/Medline/xml/PMC4635070.xml	RNS	4721 : 4724	CM	active nitrogen species (RNS) capable of damaging the
./___Corpus/Medline/xml/PMC4635070.xml	aldehydes	4803 : 4812	CM	 [22]. Free radicals and aldehydes, produced during chronic
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	5287 : 5299	CM	ns, oncogenes, inducible nitric oxide synthase (iNOS), cycloox
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	5310 : 5314	CM	e nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-
./___Corpus/Medline/xml/PMC4635070.xml	cyclooxygenase-2	5317 : 5333	CM	c oxide synthase (iNOS), cyclooxygenase-2 (COX-2), 5-lipoxygenase,
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	5335 : 5340	CM	iNOS), cyclooxygenase-2 (COX-2), 5-lipoxygenase, matrix
./___Corpus/Medline/xml/PMC4635070.xml	5-lipoxygenase	5343 : 5357	CM	yclooxygenase-2 (COX-2), 5-lipoxygenase, matrix metalloproteinas
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	5465 : 5471	CM	xia-inducible factor-1α (HIF-1α), nuclear factor-κB (NF-
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	5493 : 5498	CM	-1α), nuclear factor-κB (NF-κB), nuclear factor of acti
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	5592 : 5597	CM	tors of transcription 3 (STAT3), activator protein-1 (A
./___Corpus/Medline/xml/PMC4635070.xml	protein-1	5610 : 5619	CM	ion 3 (STAT3), activator protein-1 (AP-1), cAMP response bi
./___Corpus/Medline/xml/PMC4635070.xml	cAMP	5628 : 5632	CM	ivator protein-1 (AP-1), cAMP response binding protein
./___Corpus/Medline/xml/PMC4635070.xml	CBP	5664 : 5667	CM	se binding protein/p300 (CBP/p300), and CCAAT enhance
./___Corpus/Medline/xml/PMC4635070.xml	CCAAT	5679 : 5684	CM	ein/p300 (CBP/p300), and CCAAT enhancer binding protein
./___Corpus/Medline/xml/PMC4635070.xml	EBP	5713 : 5716	CM	ancer binding protein (C/EBP) [25–28]. Additionally, 
./___Corpus/Medline/xml/PMC4635070.xml	25–	5719 : 5722	CPR	binding protein (C/EBP) [25–28]. Additionally, activa
./___Corpus/Medline/xml/PMC4635070.xml	IκB	5791 : 5794	CM	tream kinases, including IκB kinase (IKK), protein ki
./___Corpus/Medline/xml/PMC4635070.xml	IKK	5803 : 5806	CM	s, including IκB kinase (IKK), protein kinase C (PKC)
./___Corpus/Medline/xml/PMC4635070.xml	mitogen	5833 : 5840	CM	 protein kinase C (PKC), mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	MAPK	5867 : 5871	CM	ctivated protein kinase (MAPK), and phosphoinositide-3
./___Corpus/Medline/xml/PMC4635070.xml	phosphoinositide-3	5878 : 5896	CM	otein kinase (MAPK), and phosphoinositide-3 kinase/Protein kinase B 
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	5922 : 5926	CM	kinase/Protein kinase B (PI3K)/AKT, are known to parti
./___Corpus/Medline/xml/PMC4635070.xml	AKT	5928 : 5931	CM	/Protein kinase B (PI3K)/AKT, are known to participat
./___Corpus/Medline/xml/PMC4635070.xml	NK	6571 : 6573	CM	tes, and natural killer (NK) cells serve as the fron
./___Corpus/Medline/xml/PMC4635070.xml	MDSC	7635 : 7639	CM	. Several factors induce MDSC differentiation arrest t
./___Corpus/Medline/xml/PMC4635070.xml	mitogenic	7840 : 7849	CM	ivated leukocytes supply mitogenic growth factors that stim
./___Corpus/Medline/xml/PMC4635070.xml	TH1	8007 : 8010	CM	per cells (e.g., subsets TH1, 2, 9, 10, 17, and 22) a
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	11277 : 11282	CM	inhibitory factor (MIF), COX-2, NF-κB, tumor necrosis f
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	11284 : 11289	CM	ory factor (MIF), COX-2, NF-κB, tumor necrosis factor a
./___Corpus/Medline/xml/PMC4635070.xml	alpha	11313 : 11318	CM	B, tumor necrosis factor alpha (TNF-α), iNOS, AKT and C
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	11328 : 11332	CM	is factor alpha (TNF-α), iNOS, AKT and CXC chemokines.
./___Corpus/Medline/xml/PMC4635070.xml	AKT	11334 : 11337	CM	tor alpha (TNF-α), iNOS, AKT and CXC chemokines.     
./___Corpus/Medline/xml/PMC4635070.xml	CXC	11342 : 11345	CM	a (TNF-α), iNOS, AKT and CXC chemokines.             
./___Corpus/Medline/xml/PMC4635070.xml	HPA	11477 : 11480	CM	lamic–pituitary–adrenal (HPA) axis (also known as the
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	11684 : 11692	CM	n [39] by the release of cortisol from the adrenal gland. 
./___Corpus/Medline/xml/PMC4635070.xml	corticotrophin	12038 : 12052	CM	the hypothalamus secrete corticotrophin-releasing hormone (CRH),
./___Corpus/Medline/xml/PMC4635070.xml	CRH	12072 : 12075	CM	ophin-releasing hormone (CRH), which in turn stimulat
./___Corpus/Medline/xml/PMC4635070.xml	adrenocorticotropic	12120 : 12139	CM	mulates the secretion of adrenocorticotropic hormone (ACTH) from the 
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12238 : 12246	CM	drenal cortex to promote cortisol release [40]. A negative
./___Corpus/Medline/xml/PMC4635070.xml	HPA	12300 : 12303	CM	dback loop completes the HPA circuit resulting in cor
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12325 : 12333	CM	HPA circuit resulting in cortisol suppressing the producti
./___Corpus/Medline/xml/PMC4635070.xml	CRH	12364 : 12367	CM	essing the production of CRH and ACTH through feedbac
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12535 : 12543	CM	ss response, but adrenal cortisol is also a vitally import
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	12697 : 12705	CM	responses. Specifically, cortisol achieves this mediation 
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	12812 : 12820	CM	ster immune/inflammatory cytokine MIF.                    
./___Corpus/Medline/xml/PMC4635070.xml	MIF	12864 : 12867	CM	                         MIF is released from macroph
./___Corpus/Medline/xml/PMC4635070.xml	glucocorticoids	12944 : 12959	CM	 have been stimulated by glucocorticoids, and is a potent proinfl
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	12993 : 13001	CM	a potent proinflammatory cytokine that binds to the CD74 m
./___Corpus/Medline/xml/PMC4635070.xml	CD74	13020 : 13024	CM	tokine that binds to the CD74 molecule on immune cells
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	13240 : 13248	CM	th low concentrations of cortisol which induce MIF [41], a
./___Corpus/Medline/xml/PMC4635070.xml	MIF	13262 : 13265	CM	of cortisol which induce MIF [41], and higher levels 
./___Corpus/Medline/xml/PMC4635070.xml	cortisol	13293 : 13301	CM	1], and higher levels of cortisol which result in decrease
./___Corpus/Medline/xml/PMC4635070.xml	MIF	13331 : 13334	CM	h result in decreases in MIF secretions [42]. As proi
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	13371 : 13379	CM	[42]. As proinflammatory cytokine, MIF overcomes the inhib
./___Corpus/Medline/xml/PMC4635070.xml	MIF	13381 : 13384	CM	roinflammatory cytokine, MIF overcomes the inhibitory
./___Corpus/Medline/xml/PMC4635070.xml	glucocorticoids	13421 : 13436	CM	he inhibitory effects of glucocorticoids on TNF-α, IL-1β, IL-6, a
./___Corpus/Medline/xml/PMC4635070.xml	IL-8	13464 : 13468	CM	 TNF-α, IL-1β, IL-6, and IL-8 production [43].        
./___Corpus/Medline/xml/PMC4635070.xml	MIF	13535 : 13538	CM	              In cancer, MIF is frequently elevated [
./___Corpus/Medline/xml/PMC4635070.xml	MIF	13663 : 13666	CM	ifically, the effects of MIF extends to multiple proc
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	13877 : 13882	CM	signaling is involved in COX-2 and PGE2 upregulation, t
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	13887 : 13891	CM	is involved in COX-2 and PGE2 upregulation, the activa
./___Corpus/Medline/xml/PMC4635070.xml	(ERK)-1	13967 : 13974	CM	signal-regulated kinases (ERK)-1/2 and AKT pathways, and 
./___Corpus/Medline/xml/PMC4635070.xml	AKT	13981 : 13984	CM	ed kinases (ERK)-1/2 and AKT pathways, and the regula
./___Corpus/Medline/xml/PMC4635070.xml	protein-1	14049 : 14058	CM	ctivation domain-binding protein-1 (JAB1), p53, Skp1–Cul1–F
./___Corpus/Medline/xml/PMC4635070.xml	p53	14067 : 14070	CM	inding protein-1 (JAB1), p53, Skp1–Cul1–F-box-protein
./___Corpus/Medline/xml/PMC4635070.xml	Cul1	14077 : 14081	CM	tein-1 (JAB1), p53, Skp1–Cul1–F-box-protein (SCF) ubiq
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1	14124 : 14129	CM	F) ubiquitin ligases and HIF-1, which are central to gr
./___Corpus/Medline/xml/PMC4635070.xml	MIF	14382 : 14385	CM	L) cells, the binding of MIF to CD74 induces NF-κB ac
./___Corpus/Medline/xml/PMC4635070.xml	CD74	14389 : 14393	CM	s, the binding of MIF to CD74 induces NF-κB activation
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	14402 : 14407	CM	g of MIF to CD74 induces NF-κB activation [51]. MIF con
./___Corpus/Medline/xml/PMC4635070.xml	NK	14500 : 14502	CM	gliomas by counteracting NK and cytotoxic T-cell-med
./___Corpus/Medline/xml/PMC4635070.xml	53–	14703 : 14706	CPR	or many types of cancer [53–57], Indeed several MIF-i
./___Corpus/Medline/xml/PMC4635070.xml	ISO-66	14814 : 14820	CM	cancer growth, including ISO-66, a synthetic MIF inhibit
./___Corpus/Medline/xml/PMC4635070.xml	MIF	14834 : 14837	CM	ding ISO-66, a synthetic MIF inhibitor which caused a
./___Corpus/Medline/xml/PMC4635070.xml	anti-	14999 : 15004	CPR	cer [58]. Recently human anti-MIF antibodies have been 
./___Corpus/Medline/xml/PMC4635070.xml	PC3 prostate	15105 : 15117	CM	nd invasion of the human PC3 prostate cancer cell line in vitr
./___Corpus/Medline/xml/PMC4635070.xml	vitro	15138 : 15143	CM	tate cancer cell line in vitro, and in a PC3-xenograft 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	15210 : 15215	CPR	vo. Treatment with human anti-MIF antibodies suppressed
./___Corpus/Medline/xml/PMC4635070.xml	MIF	15368 : 15371	CM	 it should be noted that MIF may also be crucial for 
./___Corpus/Medline/xml/PMC4635070.xml	Mycobacterium	15532 : 15545	CM	fied among patients with Mycobacterium tuberculosis (TB) bacter
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	15730 : 15738	CM	den and decreased innate cytokine production) and MIF-defi
./___Corpus/Medline/xml/PMC4635070.xml	MIF	15755 : 15758	CM	cytokine production) and MIF-deficient macrophages sh
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	15800 : 15808	CM	hages show a decrease in cytokine production and impaired 
./___Corpus/Medline/xml/PMC4635070.xml	mycobacterial	15833 : 15846	CM	 production and impaired mycobacterial killing. So MIF is a cru
./___Corpus/Medline/xml/PMC4635070.xml	arachidonic acid	16101 : 16117	CM	                     The arachidonic acid (AA) cascade (see Figure
./___Corpus/Medline/xml/PMC4635070.xml	AA	16119 : 16121	CM	   The arachidonic acid (AA) cascade (see Figure 1) 
./___Corpus/Medline/xml/PMC4635070.xml	COX-1	16249 : 16254	CM	lammatory response [60]. COX-1 and COX-2 are the primar
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	16259 : 16264	CM	response [60]. COX-1 and COX-2 are the primary regulato
./___Corpus/Medline/xml/PMC4635070.xml	AA	16335 : 16337	CM	e for the translation of AA into the several prostan
./___Corpus/Medline/xml/PMC4635070.xml	prostanoids	16355 : 16366	CM	n of AA into the several prostanoids, lipid mediators involve
./___Corpus/Medline/xml/PMC4635070.xml	lipid	16368 : 16373	CM	the several prostanoids, lipid mediators involved in ma
./___Corpus/Medline/xml/PMC4635070.xml	COX-1	16434 : 16439	CM	al functions [61]. While COX-1 is a constitutive enzyme
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	16534 : 16539	CM	ons, the inducible form, COX-2, is responsible for vari
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	16589 : 16594	CM	ous inflammatory events. COX-2 is readily available to 
./___Corpus/Medline/xml/PMC4635070.xml	AA	16661 : 16663	CM	enation and reduction of AA [62]. COX-1/COX-2, also 
./___Corpus/Medline/xml/PMC4635070.xml	COX-1	16670 : 16675	CM	nd reduction of AA [62]. COX-1/COX-2, also known as pro
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	16676 : 16681	CM	uction of AA [62]. COX-1/COX-2, also known as prostagla
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	16697 : 16710	CM	X-1/COX-2, also known as prostaglandin (PG) H synthase, transfo
./___Corpus/Medline/xml/PMC4635070.xml	H	16716 : 16717	CM	wn as prostaglandin (PG) H synthase, transforms AA 
./___Corpus/Medline/xml/PMC4635070.xml	AA	16739 : 16741	CM	) H synthase, transforms AA into PGG2, which is then
./___Corpus/Medline/xml/PMC4635070.xml	PGG2	16747 : 16751	CM	hase, transforms AA into PGG2, which is then reduced f
./___Corpus/Medline/xml/PMC4635070.xml	PGH2	16807 : 16811	CM	 by PGH synthase to form PGH2 [61]. PGH2 then further 
./___Corpus/Medline/xml/PMC4635070.xml	PGH2	16818 : 16822	CM	thase to form PGH2 [61]. PGH2 then further metabolizes
./___Corpus/Medline/xml/PMC4635070.xml	PG	16852 : 16854	CM	 further metabolizes via PG synthases into PGE2, PGD
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	16870 : 16874	CM	es via PG synthases into PGE2, PGD2, PGI2, PGF2α, and 
./___Corpus/Medline/xml/PMC4635070.xml	PGD2	16876 : 16880	CM	 PG synthases into PGE2, PGD2, PGI2, PGF2α, and TXA2, 
./___Corpus/Medline/xml/PMC4635070.xml	PGI2	16882 : 16886	CM	nthases into PGE2, PGD2, PGI2, PGF2α, and TXA2, which 
./___Corpus/Medline/xml/PMC4635070.xml	PGF2α	16888 : 16893	CM	s into PGE2, PGD2, PGI2, PGF2α, and TXA2, which are the
./___Corpus/Medline/xml/PMC4635070.xml	TXA2	16899 : 16903	CM	, PGD2, PGI2, PGF2α, and TXA2, which are then paired w
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	17012 : 17025	CM	roinflammatory messenger prostaglandin E2 (PGE2) has further be
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	17030 : 17034	CM	senger prostaglandin E2 (PGE2) has further been linked
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	17084 : 17088	CM	 to carcinogenesis [64]. PGE2 is an agonist towards pr
./___Corpus/Medline/xml/PMC4635070.xml	EP1–4	17176 : 17181	CM	ided into four subtypes, EP1–4 [63, 64]. The binding of
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	17207 : 17211	CM	[63, 64]. The binding of PGE2 to four PGE receptors al
./___Corpus/Medline/xml/PMC4635070.xml	PGE	17220 : 17223	CM	 binding of PGE2 to four PGE receptors along with het
./___Corpus/Medline/xml/PMC4635070.xml	GTP	17260 : 17263	CM	long with heterotrimeric GTP-binding proteins, result
./___Corpus/Medline/xml/PMC4635070.xml	adenylyl	17311 : 17319	CM	lts in the activation of adenylyl cyclase, stimulated via 
./___Corpus/Medline/xml/PMC4635070.xml	EP2	17344 : 17347	CM	 cyclase, stimulated via EP2 and EP4 binding, or phos
./___Corpus/Medline/xml/PMC4635070.xml	EP4	17352 : 17355	CM	, stimulated via EP2 and EP4 binding, or phospholipas
./___Corpus/Medline/xml/PMC4635070.xml	phospholipase	17368 : 17381	CM	 EP2 and EP4 binding, or phospholipase C, stimulated via EP1 an
./___Corpus/Medline/xml/PMC4635070.xml	EP1	17400 : 17403	CM	lipase C, stimulated via EP1 and EP3 binding [65]. Th
./___Corpus/Medline/xml/PMC4635070.xml	EP3	17408 : 17411	CM	, stimulated via EP1 and EP3 binding [65]. This stimu
./___Corpus/Medline/xml/PMC4635070.xml	PGE	17450 : 17453	CM	 This stimulation of the PGE receptors thus results i
./___Corpus/Medline/xml/PMC4635070.xml	AMP	17504 : 17507	CM	 the formation of cyclic AMP (cAMP) or the mobilizati
./___Corpus/Medline/xml/PMC4635070.xml	cAMP	17509 : 17513	CM	formation of cyclic AMP (cAMP) or the mobilization of 
./___Corpus/Medline/xml/PMC4635070.xml	calcium	17552 : 17559	CM	ization of intracellular calcium [65]. PGE2 has noted tum
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	17566 : 17570	CM	racellular calcium [65]. PGE2 has noted tumorigenic pr
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	17828 : 17833	CM	      Elevated levels of COX-2 have been associated wit
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	17927 : 17932	CM	 [66]. Overexpression of COX-2 has been associated with
./___Corpus/Medline/xml/PMC4635070.xml	67–	18021 : 18024	CPR	n several human cancers [67–71]. In human UV-induced 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18083 : 18088	CM	inogenesis, elevation of COX-2 activity is associated w
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	18174 : 18179	CM	y transcription factors (NF-κB, AP-1, STAT3 and others)
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	18187 : 18192	CM	on factors (NF-κB, AP-1, STAT3 and others) [72]. COX-2 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18211 : 18216	CM	 STAT3 and others) [72]. COX-2 is transcriptionally reg
./___Corpus/Medline/xml/PMC4635070.xml	73–	18345 : 18348	CPR	alone or in combination [73–75]. This leads to breast
./___Corpus/Medline/xml/PMC4635070.xml	68–	18434 : 18437	CPR	ostate and oral cancers [68–78]. COX-2 induces carcin
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18442 : 18447	CM	nd oral cancers [68–78]. COX-2 induces carcinogenesis t
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	18518 : 18526	CM	pathway, particularly in estrogen positive breast cancers,
./___Corpus/Medline/xml/PMC4635070.xml	COX	18568 : 18571	CM	cancers, and through the COX/lipoxygenase (LOX) pathw
./___Corpus/Medline/xml/PMC4635070.xml	lipoxygenase	18572 : 18584	CM	ers, and through the COX/lipoxygenase (LOX) pathway in estroge
./___Corpus/Medline/xml/PMC4635070.xml	LOX	18586 : 18589	CM	gh the COX/lipoxygenase (LOX) pathway in estrogen-ind
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	18602 : 18610	CM	ygenase (LOX) pathway in estrogen-independent breast tumor
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18674 : 18679	CM	ly, elevated activity of COX-2 has been found to be cor
./___Corpus/Medline/xml/PMC4635070.xml	EGFR	18763 : 18767	CM	gh altered redox induced EGFR-mediated activation of t
./___Corpus/Medline/xml/PMC4635070.xml	AKT	18818 : 18821	CM	e cell survival cascade (AKT/c-FLIP/COX-2), which res
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18829 : 18834	CM	ival cascade (AKT/c-FLIP/COX-2), which results in dimin
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	18957 : 18962	CM	The indirect role of the COX-2/PGE2 pathway in regulati
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	18963 : 18967	CM	direct role of the COX-2/PGE2 pathway in regulating th
./___Corpus/Medline/xml/PMC4635070.xml	M2	19072 : 19074	CM	 through IL-17 promoting M2 macrophage differentiati
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	19152 : 19157	CM	en cancer and stroma via COX-2 and indoleamine 2,3-diox
./___Corpus/Medline/xml/PMC4635070.xml	indoleamine	19162 : 19173	CM	and stroma via COX-2 and indoleamine 2,3-dioxygenase (IDO) pr
./___Corpus/Medline/xml/PMC4635070.xml	2,3-dioxygenase	19174 : 19189	CM	ia COX-2 and indoleamine 2,3-dioxygenase (IDO) promotes tumor pro
./___Corpus/Medline/xml/PMC4635070.xml	IDO	19191 : 19194	CM	leamine 2,3-dioxygenase (IDO) promotes tumor progress
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	19264 : 19269	CM	r patient survival [81]. COX-2 is also known to promote
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	19584 : 19589	CM	ntly it was shown that a COX-2 blockade inhibited accum
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	19705 : 19710	CM	raumatic stress [84]. So COX-2 inhibition may also prov
./___Corpus/Medline/xml/PMC4635070.xml	MDSC	19782 : 19786	CM	target for counteracting MDSC-mediated immune suppress
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	20161 : 20166	CM	                         COX-2 expression and its activ
./___Corpus/Medline/xml/PMC4635070.xml	NSAIDS	20274 : 20280	CM	etic and natural such as NSAIDS, capsaicin and curcumin 
./___Corpus/Medline/xml/PMC4635070.xml	capsaicin	20282 : 20291	CM	 natural such as NSAIDS, capsaicin and curcumin [86, 87]. R
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	20296 : 20304	CM	as NSAIDS, capsaicin and curcumin [86, 87]. Recently, mela
./___Corpus/Medline/xml/PMC4635070.xml	melatonin	20325 : 20334	CM	umin [86, 87]. Recently, melatonin has also been found to e
./___Corpus/Medline/xml/PMC4635070.xml	fisetin	20390 : 20397	CM	 the antitumor effect of fisetin by inhibiting COX-2/iNOS
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	20412 : 20417	CM	of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 sign
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	20418 : 20422	CM	etin by inhibiting COX-2/iNOS and NF-κB/p300 signaling
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	20427 : 20432	CM	nhibiting COX-2/iNOS and NF-κB/p300 signaling pathways 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	20518 : 20523	CM	effective way to inhibit COX-2 is with selective pharma
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	20578 : 20587	CM	ical inhibitors, notably rofecoxib, valdecoxib and celecoxi
./___Corpus/Medline/xml/PMC4635070.xml	valdecoxib	20589 : 20599	CM	tors, notably rofecoxib, valdecoxib and celecoxib. Several c
./___Corpus/Medline/xml/PMC4635070.xml	celecoxib	20604 : 20613	CM	ofecoxib, valdecoxib and celecoxib. Several clinical trials
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	20642 : 20647	CM	veral clinical trials of COX-2 inhibitors, including ro
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	20670 : 20679	CM	-2 inhibitors, including rofecoxib and celecoxib were perfo
./___Corpus/Medline/xml/PMC4635070.xml	celecoxib	20684 : 20693	CM	 including rofecoxib and celecoxib were performed and their
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	20902 : 20907	CM	d by daily use of 800 mg COX-2 inhibitors in patients w
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	20945 : 20956	CM	n patients with familial adenomatous polyposis [89]. However,
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	21091 : 21096	CM	lar risk associated with COX-2 inhibitors in a small pa
./___Corpus/Medline/xml/PMC4635070.xml	rofecoxib	21173 : 21182	CM	ing in the withdrawal of rofecoxib and valdecoxib in 2004 a
./___Corpus/Medline/xml/PMC4635070.xml	valdecoxib	21187 : 21197	CM	hdrawal of rofecoxib and valdecoxib in 2004 and 2005, respec
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	21312 : 21317	CM	e specific inhibitors of COX-2 for long-term preventati
./___Corpus/Medline/xml/PMC4635070.xml	NSAID	21402 : 21407	CM	, other than the classic NSAID, aspirin in lower dose. 
./___Corpus/Medline/xml/PMC4635070.xml	COX	21457 : 21460	CM	Long-term use of natural COX inhibitors, such as curc
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	21481 : 21489	CM	 COX inhibitors, such as curcumin and capsaicin has signif
./___Corpus/Medline/xml/PMC4635070.xml	capsaicin	21494 : 21503	CM	rs, such as curcumin and capsaicin has significant potentia
./___Corpus/Medline/xml/PMC4635070.xml	90–	21587 : 21590	CPR	gastrointestinal tumors [90–93]. The low bioavailabil
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	21751 : 21756	CM	tumors.                  NF-κB                      NF-
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	21778 : 21783	CM	-κB                      NF-κB transcription factors ar
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	21943 : 21948	CM	ole in oncogenesis [94]. NF-κB belongs to a class of tr
./___Corpus/Medline/xml/PMC4635070.xml	NF	22038 : 22040	CM	p65 (RelA), RelB, c-Rel, NF- κB1 and NF- κB2. NF- κB
./___Corpus/Medline/xml/PMC4635070.xml	κB1	22042 : 22045	CM	(RelA), RelB, c-Rel, NF- κB1 and NF- κB2. NF- κB1 and
./___Corpus/Medline/xml/PMC4635070.xml	NF	22050 : 22052	CM	RelB, c-Rel, NF- κB1 and NF- κB2. NF- κB1 and NF-κB2
./___Corpus/Medline/xml/PMC4635070.xml	NF	22059 : 22061	CM	el, NF- κB1 and NF- κB2. NF- κB1 and NF-κB2 are synt
./___Corpus/Medline/xml/PMC4635070.xml	κB1	22063 : 22066	CM	NF- κB1 and NF- κB2. NF- κB1 and NF-κB2 are synthesiz
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB2	22071 : 22077	CM	and NF- κB2. NF- κB1 and NF-κB2 are synthesized as pro-f
./___Corpus/Medline/xml/PMC4635070.xml	p100	22117 : 22121	CM	d as pro-forms, p105 and p100, which are proteolytical
./___Corpus/Medline/xml/PMC4635070.xml	p50	22169 : 22172	CM	ally processed to active p50 and p52 respectively [95
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	22246 : 22251	CM	                     All NF-κB family members form mono
./___Corpus/Medline/xml/PMC4635070.xml	Rel	22343 : 22346	CM	ral features including a Rel homology domain, which i
./___Corpus/Medline/xml/PMC4635070.xml	IκB	22482 : 22485	CM	nd to inhibitory protein IκB family of proteins (inhi
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	22520 : 22525	CM	 proteins (inhibitors of NF-κB) preventing their bindin
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	22749 : 22754	CM	 the fact that different NF-κB dimers have differential
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	22860 : 22865	CM	[99]. Therefore distinct NF-κB dimers induce different 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23037 : 23042	CM	nscriptional activity of NF-κB and indicative of rapid 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23067 : 23072	CM	 and indicative of rapid NF-κB /IκB association and re-
./___Corpus/Medline/xml/PMC4635070.xml	IκB	23074 : 23077	CM	dicative of rapid NF-κB /IκB association and re-assoc
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23155 : 23160	CM	                         NF-κB proteins are activated b
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	23187 : 23202	CM	roteins are activated by phosphorylation and polyubiquitination o
./___Corpus/Medline/xml/PMC4635070.xml	IκB	23229 : 23232	CM	nd polyubiquitination of IκB and subsequent proteasom
./___Corpus/Medline/xml/PMC4635070.xml	IκB	23273 : 23276	CM	proteasomal degradation. IκB phosphorylation is catal
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	23277 : 23292	RN	easomal degradation. IκB phosphorylation is catalyzed by an enzym
./___Corpus/Medline/xml/PMC4635070.xml	IκB	23338 : 23341	CM	nzyme complex containing IκB kinases (IKK1/IKKα and I
./___Corpus/Medline/xml/PMC4635070.xml	IKK1	23351 : 23355	CM	 containing IκB kinases (IKK1/IKKα and IKK2/IKKβ)) and
./___Corpus/Medline/xml/PMC4635070.xml	IKKα	23356 : 23360	CM	aining IκB kinases (IKK1/IKKα and IKK2/IKKβ)) and at l
./___Corpus/Medline/xml/PMC4635070.xml	IKK2	23365 : 23369	CM	B kinases (IKK1/IKKα and IKK2/IKKβ)) and at least one 
./___Corpus/Medline/xml/PMC4635070.xml	IKKβ	23370 : 23374	CM	ases (IKK1/IKKα and IKK2/IKKβ)) and at least one non-c
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23427 : 23432	CM	lytic accessory protein (NF-κB essential modulator, NEM
./___Corpus/Medline/xml/PMC4635070.xml	NEMO	23454 : 23458	CM	-κB essential modulator, NEMO, also called IKKγ) [100,
./___Corpus/Medline/xml/PMC4635070.xml	IKKγ	23472 : 23476	CM	lator, NEMO, also called IKKγ) [100, 101]. Furthermore
./___Corpus/Medline/xml/PMC4635070.xml	p50	23539 : 23542	CM	00 are cleaved to active p50 and p52 forms respective
./___Corpus/Medline/xml/PMC4635070.xml	p52	23547 : 23550	CM	leaved to active p50 and p52 forms respectively by ta
./___Corpus/Medline/xml/PMC4635070.xml	IκB	23636 : 23639	CM	somal degradation [102]. IκB and IKK complex bind to 
./___Corpus/Medline/xml/PMC4635070.xml	IKK	23644 : 23647	CM	gradation [102]. IκB and IKK complex bind to other co
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23729 : 23734	CM	 upstream kinases [103]. NF-κB inducing kinase (NIK) ph
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylates	23757 : 23771	CM	κB inducing kinase (NIK) phosphorylates and activates IKK1, mito
./___Corpus/Medline/xml/PMC4635070.xml	IKK1	23786 : 23790	CM	phorylates and activates IKK1, mitogen-activated prote
./___Corpus/Medline/xml/PMC4635070.xml	mitogen	23792 : 23799	CM	ates and activates IKK1, mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4635070.xml	MEKK2	23850 : 23855	CM	kinase kinase 1 (MEKK1), MEKK2, MEKK3 and transforming 
./___Corpus/Medline/xml/PMC4635070.xml	MEKK3	23857 : 23862	CM	kinase 1 (MEKK1), MEKK2, MEKK3 and transforming growth 
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	23900 : 23905	CM	ming growth factor beta (TGF-β) activating kinase 1 (TA
./___Corpus/Medline/xml/PMC4635070.xml	104–	23935 : 23939	CPR	ivating kinase 1 (TAK1) [104–106].                    
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	23983 : 23988	CM	                         NF-κB is activated by canonica
./___Corpus/Medline/xml/PMC4635070.xml	TNFR	24208 : 24212	CM	ecrosis factor receptor (TNFR) and antigen receptors. 
./___Corpus/Medline/xml/PMC4635070.xml	IL-1-β	24273 : 24279	CM	polysaccharide (LPS) and IL-1-β are typical stimulating 
./___Corpus/Medline/xml/PMC4635070.xml	β-	24462 : 24464	CPR	tion factor, lymphotoxin β-receptor (LTβR), CD40, re
./___Corpus/Medline/xml/PMC4635070.xml	CD40	24481 : 24485	CM	toxin β-receptor (LTβR), CD40, receptor activator for 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	24510 : 24515	CM	, receptor activator for NF-κB (RANK), TNFR2 and fn14 [
./___Corpus/Medline/xml/PMC4635070.xml	RANK	24517 : 24521	CM	tor activator for NF-κB (RANK), TNFR2 and fn14 [109]. 
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	24524 : 24529	CM	ivator for NF-κB (RANK), TNFR2 and fn14 [109]. These re
./___Corpus/Medline/xml/PMC4635070.xml	fn14	24534 : 24538	CM	 NF-κB (RANK), TNFR2 and fn14 [109]. These receptors s
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	24572 : 24577	CM	hese receptors stimulate NF-κB by activation of the kin
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	24614 : 24629	RN	on of the kinase NIK and phosphorylation of IKK1. IKK1 subsequent
./___Corpus/Medline/xml/PMC4635070.xml	IKK1	24633 : 24637	CM	K and phosphorylation of IKK1. IKK1 subsequently resul
./___Corpus/Medline/xml/PMC4635070.xml	IKK1	24639 : 24643	CM	phosphorylation of IKK1. IKK1 subsequently results in 
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	24668 : 24683	RN	 subsequently results in phosphorylation, ubiquitination and part
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	24789 : 24794	CM	-canonical activation of NF-κB is independent of the ac
./___Corpus/Medline/xml/PMC4635070.xml	IKK2	24829 : 24833	CM	ndent of the activity of IKK2 and NEMO [111].         
./___Corpus/Medline/xml/PMC4635070.xml	NEMO	24838 : 24842	CM	the activity of IKK2 and NEMO [111].                  
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	24905 : 24910	CM	        Upon activation, NF-κB dimers move to the nucle
./___Corpus/Medline/xml/PMC4635070.xml	Rel	24948 : 24951	CM	to the nucleus and their Rel homology domains are fre
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25167 : 25172	CM	rts point to the role of NF-κB in inflammation and indu
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25395 : 25400	CM	onical activation of the NF-κB signaling pathway [112].
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25426 : 25431	CM	signaling pathway [112]. NF-κB has a dual effect on inf
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25498 : 25503	CM	 hand, the activation of NF-κB, as part of the acute im
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25631 : 25636	CM	wever, the activation of NF-κB also results in up-regul
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	25897 : 25902	CM	nflammation [114]. Both, STAT3 and HIF1 pathways are in
./___Corpus/Medline/xml/PMC4635070.xml	HIF1	25907 : 25911	CM	n [114]. Both, STAT3 and HIF1 pathways are interconnec
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25945 : 25950	CM	 are interconnected with NF-κB signaling and interact w
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	25979 : 25984	CM	naling and interact with NF-κB. For example, the proinf
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	26019 : 26027	CM	ple, the proinflammatory cytokine IL-6, encoded by NF-κB t
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26045 : 26050	CM	ytokine IL-6, encoded by NF-κB target genes, is importa
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	26082 : 26087	CM	 genes, is important for STAT3 activation. STAT3 and NF
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	26100 : 26105	CM	nt for STAT3 activation. STAT3 and NF-κB also co-regula
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26110 : 26115	CM	T3 activation. STAT3 and NF-κB also co-regulate numerou
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26214 : 26219	CM	bservations suggest that NF-κB and STAT3 alone or in co
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	26224 : 26229	CM	s suggest that NF-κB and STAT3 alone or in combination 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26350 : 26355	CM	                         NF-κB activation is also invol
./___Corpus/Medline/xml/PMC4635070.xml	VEGF	26510 : 26514	CM	mors via upregulation of VEGF and its receptors [117, 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26563 : 26568	CM	 118]. The activation of NF-κB also causes an increase 
./___Corpus/Medline/xml/PMC4635070.xml	EMT	26730 : 26733	CM	-mesenchymal transition (EMT) [119], which enables ca
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26829 : 26834	CM	                         NF-κB-induced transcriptional 
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	26873 : 26879	CM	criptional regulation of HIF-1α is mediated by the recru
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	26918 : 26923	CM	y the recruitment of the NF-κB complex to the HIF-1α pr
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	26939 : 26945	CM	the NF-κB complex to the HIF-1α promoter [120]. Chronic 
./___Corpus/Medline/xml/PMC4635070.xml	transglutaminase	27019 : 27035	CM	lammatory protein tissue transglutaminase (TG2) reprograms the tra
./___Corpus/Medline/xml/PMC4635070.xml	TG2	27037 : 27040	CM	tissue transglutaminase (TG2) reprograms the transcri
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27141 : 27146	CM	nstitutive activation of NF-κB. TG2-induced NF-κB binds
./___Corpus/Medline/xml/PMC4635070.xml	TG2	27148 : 27151	CM	ive activation of NF-κB. TG2-induced NF-κB binds the 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27160 : 27165	CM	on of NF-κB. TG2-induced NF-κB binds the functional NF-
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27187 : 27192	CM	-κB binds the functional NF-κB binding site in HIF-1α p
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	27209 : 27215	CM	al NF-κB binding site in HIF-1α promoter and results in 
./___Corpus/Medline/xml/PMC4635070.xml	normoxic	27312 : 27320	CM	rotein levels even under normoxic conditions. Like NF-κB, 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27338 : 27343	CM	ormoxic conditions. Like NF-κB, HIF-1α is also consider
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	27345 : 27351	CM	 conditions. Like NF-κB, HIF-1α is also considered a neg
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27594 : 27599	CM	o aberrant activation of NF-κB and its downstream event
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	27627 : 27633	CM	d its downstream events (HIF-1α, Snail, Twist, and Zeb e
./___Corpus/Medline/xml/PMC4635070.xml	Zeb	27653 : 27656	CM	IF-1α, Snail, Twist, and Zeb expression) can induce E
./___Corpus/Medline/xml/PMC4635070.xml	EMT	27680 : 27683	CM	b expression) can induce EMT, stem cell-ness, and end
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	27934 : 27939	CM	under normal conditions, NF-κB plays an important role 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28047 : 28052	CM	 be practical to inhibit NF-κB on a sustained basis. Fo
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28134 : 28139	CM	 prolonged inhibition of NF-κB activity resulted in ani
./___Corpus/Medline/xml/PMC4635070.xml	IKK	28288 : 28291	CM	 bioactive inhibitors of IKK activity might be a pref
./___Corpus/Medline/xml/PMC4635070.xml	IKK	28416 : 28419	CM	te immunity. Ideally, an IKK/ NF-κB molecular-targete
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28421 : 28426	CM	munity. Ideally, an IKK/ NF-κB molecular-targeted inhib
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28470 : 28475	CM	 inhibitor would prevent NF-κB activation without any e
./___Corpus/Medline/xml/PMC4635070.xml	anti-	28677 : 28682	CPR	ddressed before targeted anti-IKK or NF-κB therapies be
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28689 : 28694	CM	ore targeted anti-IKK or NF-κB therapies become success
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28767 : 28772	CM	ut pronounced ability of NF-κB activation inhibitors to
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	28960 : 28965	CM	y strategy that inhibits NF-κB will need to be carefull
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	29110 : 29118	CM	is a key proinflammatory cytokine, secreted by inflammator
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	29581 : 29586	CM	marily via two receptors TNFR1 and TNFR2 [126]. TNF-α i
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	29591 : 29596	CM	 two receptors TNFR1 and TNFR2 [126]. TNF-α is a 17 kDa
./___Corpus/Medline/xml/PMC4635070.xml	amino acids	29648 : 29659	CM	rotein consisting of 157 amino acids that is a homotrimer in 
./___Corpus/Medline/xml/PMC4635070.xml	homotrimer	29670 : 29680	CM	57 amino acids that is a homotrimer in solution, and it is p
./___Corpus/Medline/xml/PMC4635070.xml	NK	29758 : 29760	CM	ages, T lymphocytes, and NK cells. However lower exp
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	29916 : 29921	CM	ls. Although TNF-α binds TNFR2 five times higher than T
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	29945 : 29950	CM	2 five times higher than TNFR1, TNFR1 initiates the maj
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	29952 : 29957	CM	times higher than TNFR1, TNFR1 initiates the majority o
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30038 : 30043	CM	ulting from TNF-α [127]. TNFR1 (p60) is expressed in al
./___Corpus/Medline/xml/PMC4635070.xml	p60	30045 : 30048	CM	from TNF-α [127]. TNFR1 (p60) is expressed in all cel
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	30089 : 30094	CM	n all cell types whereas TNFR2 (p80) is expressed mainl
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30149 : 30154	CM	immune cells [128]. Only TNFR1 contains the death domai
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	30193 : 30198	CM	death domain (DD) (i.e., TNFR2 does not contain the DD)
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30413 : 30418	CM	death inducing activity, TNFR1 also has the ability to 
./___Corpus/Medline/xml/PMC4635070.xml	homotrimer	30491 : 30501	CM	 signals. Binding to the homotrimer TNF-α, TNFR1 trimerizes 
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30509 : 30514	CM	to the homotrimer TNF-α, TNFR1 trimerizes the silencer 
./___Corpus/Medline/xml/PMC4635070.xml	SODD	30556 : 30560	CM	ilencer of death domain (SODD) protein that is release
./___Corpus/Medline/xml/PMC4635070.xml	TNFR	30598 : 30602	CM	t is released [130]. The TNFR-associated domain (TRADD
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30648 : 30653	CM	RADD) binds to the DD of TNFR1 and recruits other adapt
./___Corpus/Medline/xml/PMC4635070.xml	TNFR	30740 : 30744	CM	teracting protein (RIP), TNFR-associated factor 2 (TRA
./___Corpus/Medline/xml/PMC4635070.xml	(FADD)[131]	30807 : 30818	CM	-associated death domain (FADD)[131]. These adaptor proteins,
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	30936 : 30941	CM	ic signaling mediated by TNFR1 results in FADD binding 
./___Corpus/Medline/xml/PMC4635070.xml	FADD	30953 : 30957	CM	ated by TNFR1 results in FADD binding to caspase 8 and
./___Corpus/Medline/xml/PMC4635070.xml	cytochrome	31101 : 31111	CM	volves the mitochondrial cytochrome c release [132], which l
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	31252 : 31257	CM	          Alternatively, TNFR1 may signal survival proc
./___Corpus/Medline/xml/PMC4635070.xml	cIAP	31423 : 31427	CM	f the apoptosis protein (cIAP). Once TRAF-2 associates
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	31458 : 31463	CM	e TRAF-2 associates with TNFR1, cell survival pathways 
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	31522 : 31537	RN	ated through a series of phosphorylation steps resulting to the a
./___Corpus/Medline/xml/PMC4635070.xml	cFOS	31575 : 31579	CM	ing to the activation of cFOS/cJun transcription facto
./___Corpus/Medline/xml/PMC4635070.xml	MAPK	31610 : 31614	CM	transcription factors by MAPK and cJun N-terminal kina
./___Corpus/Medline/xml/PMC4635070.xml	N-	31625 : 31627	CPR	actors by MAPK and cJun N-terminal kinase (JNK) [133
./___Corpus/Medline/xml/PMC4635070.xml	JNK	31643 : 31646	CM	 cJun N-terminal kinase (JNK) [133, 134]. Activation 
./___Corpus/Medline/xml/PMC4635070.xml	RIP	31685 : 31688	CM	Activation of TRAF-2 and RIP is associated with activ
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	31726 : 31731	CM	d with activation of the NF-κB transcription factor via
./___Corpus/Medline/xml/PMC4635070.xml	IKK	31827 : 31830	CM	an inhibitor, κB kinase (IKK) [135]. The activation o
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	31871 : 31876	CM	ivation of cFos/cJun and NF-κB transcription factors me
./___Corpus/Medline/xml/PMC4635070.xml	anti-	31929 : 31934	CPR	tes the transcription of anti-apoptotic, proliferative 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	32001 : 32006	CM	 and inflammatory genes. NF-κB is the main survival tra
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	32091 : 32096	CM	-α-induced apoptosis, so NF-κB inhibition may be an eff
./___Corpus/Medline/xml/PMC4635070.xml	135–	32176 : 32180	CPR	inducing cancer therapy [135–137].                    
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	32238 : 32243	CM	           Inhibition of NF-κB is known to sensitize ca
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	32346 : 32351	CM	, it has been shown that NF-κB-induced expression of iN
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	32374 : 32378	CM	κB-induced expression of iNOS increases cancer cell su
./___Corpus/Medline/xml/PMC4635070.xml	NOS	32436 : 32439	CM	140, 141]. Inhibition of NOS can potentially sensitiz
./___Corpus/Medline/xml/PMC4635070.xml	ROS	32499 : 32502	CM	ells to TNF-α treatment. ROS are generated by TNF-α-m
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	32559 : 32564	CM	 apoptotic events, while NF-κB induces expression of RO
./___Corpus/Medline/xml/PMC4635070.xml	superoxide	32617 : 32627	CM	eutralizing enzymes like superoxide dismutase [142]. Recent 
./___Corpus/Medline/xml/PMC4635070.xml	tristetraprolin	32695 : 32710	CM	t the mRNA-decay protein tristetraprolin (TTP) interacts with TNF
./___Corpus/Medline/xml/PMC4635070.xml	TTP	32712 : 32715	CM	protein tristetraprolin (TTP) interacts with TNFR1 in
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	32732 : 32737	CM	lin (TTP) interacts with TNFR1 in a TRAF2-mediated fash
./___Corpus/Medline/xml/PMC4635070.xml	TRAF2	32743 : 32748	CM	nteracts with TNFR1 in a TRAF2-mediated fashion initiat
./___Corpus/Medline/xml/PMC4635070.xml	TTP	32815 : 32818	CM	ctivation. Inhibition of TTP ubiquitination results i
./___Corpus/Medline/xml/PMC4635070.xml	TNF	32854 : 32857	CM	tion results in enhanced TNF-induced apoptosis in cer
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	33034 : 33042	CM	h concentrations of this cytokine display antitumoral resp
./___Corpus/Medline/xml/PMC4635070.xml	murine	33075 : 33081	CM	 antitumoral response in murine model of sarcoma [144], 
./___Corpus/Medline/xml/PMC4635070.xml	ROS	33217 : 33220	CM	ng mechanism is based on ROS and RNS which can induce
./___Corpus/Medline/xml/PMC4635070.xml	146–	33287 : 33291	CPR	acilitate tumorigenesis [146–148]. TNF-α-mediated infl
./___Corpus/Medline/xml/PMC4635070.xml	H	33393 : 33394	CM	recent report shows that H. pylori strains produce 
./___Corpus/Medline/xml/PMC4635070.xml	H	33496 : 33497	CM	r in gastric epithelium. H. pylori isolated from ga
./___Corpus/Medline/xml/PMC4635070.xml	nucleolin	33640 : 33649	CM	er cells by cell surface nucleolin, a Tip-α receptor. The n
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	33721 : 33729	CM	 induces TNF-α and other cytokine genes expression and res
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	33762 : 33767	CM	xpression and results in NF-κB activation. Similarly, T
./___Corpus/Medline/xml/PMC4635070.xml	TNFR1	33805 : 33810	CM	Similarly, TNF-α through TNFR1, Noxo1, and Gna14 signal
./___Corpus/Medline/xml/PMC4635070.xml	Noxo1	33812 : 33817	CM	ly, TNF-α through TNFR1, Noxo1, and Gna14 signaling lea
./___Corpus/Medline/xml/PMC4635070.xml	H	33848 : 33849	CM	Gna14 signaling leads to H. pylori-mediated gastric
./___Corpus/Medline/xml/PMC4635070.xml	EMT	33972 : 33975	CM	 mesenchymal transition (EMT) in human gastric carcin
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34353 : 34356	CM	In Lewis lung carcinoma (LLC) cells-conditioned-mediu
./___Corpus/Medline/xml/PMC4635070.xml	TNF-α−	34473 : 34479	CM	d macrophages [152], and TNF-α−/− but not IL-6−/− mice i
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34517 : 34520	CM	-6−/− mice injected with LLC cells showed improved su
./___Corpus/Medline/xml/PMC4635070.xml	LLC	34628 : 34631	CM	ritical role of TNF-α in LLC metastasis [152]. Others
./___Corpus/Medline/xml/PMC4635070.xml	tetradecanoyl-phorbol-13-acetate-(TPA)	34707 : 34745	CM	nt mice are resistant to tetradecanoyl-phorbol-13-acetate-(TPA) induced skin carcinogene
./___Corpus/Medline/xml/PMC4635070.xml	αvβ3	35162 : 35166	CM	ted to downregulation of αvβ3 and the angiotensin sign
./___Corpus/Medline/xml/PMC4635070.xml	VEGF	35278 : 35282	CM	ssociated with increased VEGF, VEFGR, IL-8, and FGF ex
./___Corpus/Medline/xml/PMC4635070.xml	VEFGR	35284 : 35289	CM	ted with increased VEGF, VEFGR, IL-8, and FGF expressio
./___Corpus/Medline/xml/PMC4635070.xml	FGF	35301 : 35304	CM	d VEGF, VEFGR, IL-8, and FGF expression [156]. Furthe
./___Corpus/Medline/xml/PMC4635070.xml	TNFR	35635 : 35639	CM	, so targeting TNF-α and TNFR may be a viable option f
./___Corpus/Medline/xml/PMC4635070.xml	IgG1	35867 : 35871	CM	nfliximab, a recombinant IgG1 monoclonal antibody spec
./___Corpus/Medline/xml/PMC4635070.xml	TNFR2	36019 : 36024	CM	 extracellular domain of TNFR2 (p75) and the Fc portion
./___Corpus/Medline/xml/PMC4635070.xml	p75	36026 : 36029	CM	ellular domain of TNFR2 (p75) and the Fc portion of I
./___Corpus/Medline/xml/PMC4635070.xml	Fc	36039 : 36041	CM	n of TNFR2 (p75) and the Fc portion of IgG1 [160], a
./___Corpus/Medline/xml/PMC4635070.xml	IgG1	36053 : 36057	CM	5) and the Fc portion of IgG1 [160], adalimumb, a mono
./___Corpus/Medline/xml/PMC4635070.xml	IgG1	36113 : 36117	CM	 antibody of recombinant IgG1 [161], golimumab, a huma
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36144 : 36149	CPR	161], golimumab, a human anti-TNF-α monoclonal antibody
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36212 : 36217	CPR	ertolizumab, a humanized anti-TNF-α antibody with high 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36304 : 36309	CPR	or side effects of these anti-TNF-α agents are infectio
./___Corpus/Medline/xml/PMC4635070.xml	anti-	36675 : 36680	CPR	ting these patients with anti-TNF-α may increase the ra
./___Corpus/Medline/xml/PMC4635070.xml	167–	36721 : 36725	CPR	se the rate of lymphoma [167–169]. Skin cancer has als
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	36898 : 36906	CM	 So, although TNF-α is a cytokine with well-known anticanc
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	37255 : 37259	CM	tcomes.                  iNOS                      iNO
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	37281 : 37285	CM	NOS                      iNOS has been of interest in 
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	37356 : 37368	CM	overy of its metabolite, nitric oxide (NO) in the 1990´s. Over
./___Corpus/Medline/xml/PMC4635070.xml	NO	37370 : 37372	CM	etabolite, nitric oxide (NO) in the 1990´s. Over the
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	37435 : 37439	CM	imental data highlighted iNOS overexpression as a pivo
./___Corpus/Medline/xml/PMC4635070.xml	iNOS-NO	37566 : 37573	CM	publications support the iNOS-NO axis as a potential targ
./___Corpus/Medline/xml/PMC4635070.xml	NO	37651 : 37653	CM	hysiological conditions, NO is produced by the const
./___Corpus/Medline/xml/PMC4635070.xml	NOS	37695 : 37698	CM	he constitutive forms of NOS (cNOS and eNOS) and modu
./___Corpus/Medline/xml/PMC4635070.xml	cNOS	37700 : 37704	CM	nstitutive forms of NOS (cNOS and eNOS) and modulates 
./___Corpus/Medline/xml/PMC4635070.xml	eNOS	37709 : 37713	CM	e forms of NOS (cNOS and eNOS) and modulates pivotal c
./___Corpus/Medline/xml/PMC4635070.xml	iNOS-NO	37856 : 37863	CM	ammatory conditions, the iNOS-NO axis is upregulated, and
./___Corpus/Medline/xml/PMC4635070.xml	NO	37904 : 37906	CM	ated, and quickly yields NO-derived species with str
./___Corpus/Medline/xml/PMC4635070.xml	superoxide	38029 : 38039	CM	so produced (such as the superoxide anion). Once formed, NO-
./___Corpus/Medline/xml/PMC4635070.xml	NO	38061 : 38063	CM	ide anion). Once formed, NO-derived species can quic
./___Corpus/Medline/xml/PMC4635070.xml	lipids	38148 : 38154	CM	nts, including proteins, lipids and DNA. Therefore, the 
./___Corpus/Medline/xml/PMC4635070.xml	NO	38207 : 38209	CM	n carcinogenic effect of NO-derived metabolites is r
./___Corpus/Medline/xml/PMC4635070.xml	peroxynitrite	38318 : 38331	CM	y, as induced by the RNS peroxynitrite [174].                  
./___Corpus/Medline/xml/PMC4635070.xml	vitro	38402 : 38407	CM	Experimental data and in vitro studies have supported i
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	38431 : 38435	CM	o studies have supported iNOS as a viable target by de
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	38740 : 38744	CM	others. In the same way, iNOS up-regulation has been d
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	39384 : 39388	CM	tivity and expression of iNOS in cancer cells seems to
./___Corpus/Medline/xml/PMC4635070.xml	NO	39469 : 39471	CM	enerating high levels of NO and its derived species,
./___Corpus/Medline/xml/PMC4635070.xml	NO-iNOS	39621 : 39628	CM	ering with this enhanced NO-iNOS machinery may represent 
./___Corpus/Medline/xml/PMC4635070.xml	NO	39774 : 39776	CM	    Interfering with the NO dynamic is not a simple 
./___Corpus/Medline/xml/PMC4635070.xml	NO	39818 : 39820	CM	 simple task. In cancer, NO can be derived from both
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	40176 : 40180	CM	y be directed against a) iNOS activity, b) iNOS-derive
./___Corpus/Medline/xml/PMC4635070.xml	NO	40207 : 40209	CM	ctivity, b) iNOS-derived NO and c) mainstream regula
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	40242 : 40246	CM	mainstream regulators of iNOS expression. Regarding th
./___Corpus/Medline/xml/PMC4635070.xml	iNOS-NO	40273 : 40280	CM	xpression. Regarding the iNOS-NO axis, experimental appro
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	40347 : 40351	CM	xploited to either block iNOS or to scavenge NO in can
./___Corpus/Medline/xml/PMC4635070.xml	NO	40367 : 40369	CM	lock iNOS or to scavenge NO in cancer models, and in
./___Corpus/Medline/xml/PMC4635070.xml	aminoguanidine	40429 : 40443	CM	s include treatment with aminoguanidine [197], N(G)-nitro-L-argi
./___Corpus/Medline/xml/PMC4635070.xml	N(G)-nitro-L-arginine methyl ester	40451 : 40485	CM	th aminoguanidine [197], N(G)-nitro-L-arginine methyl ester [205], carboxy-PTIO [206
./___Corpus/Medline/xml/PMC4635070.xml	carboxy-PTIO	40493 : 40505	CM	nine methyl ester [205], carboxy-PTIO [206], tyrosine-kinase i
./___Corpus/Medline/xml/PMC4635070.xml	tyrosine	40513 : 40521	CM	05], carboxy-PTIO [206], tyrosine-kinase inhibitors [207],
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	40547 : 40552	CM	kinase inhibitors [207], TGF-β-like molecules [208], S-
./___Corpus/Medline/xml/PMC4635070.xml	S-methylisothiourea sulfate	40575 : 40602	CM	-β-like molecules [208], S-methylisothiourea sulfate [173] and some natural c
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	40727 : 40731	CM	mainstream regulators of iNOS expression may be quite 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	40924 : 40929	CM	L-1β [210], TNF-α [211], NF-κB [209] and STAT-1 [212], 
./___Corpus/Medline/xml/PMC4635070.xml	STAT-1	40940 : 40946	CM	α [211], NF-κB [209] and STAT-1 [212], among others. In 
./___Corpus/Medline/xml/PMC4635070.xml	NO	40977 : 40979	CM	, among others. In fact, NO blockage has reached pro
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	41191 : 41195	CM	acological impairment of iNOS functioning may be usefu
./___Corpus/Medline/xml/PMC4635070.xml	NO	41309 : 41311	CM	 high levels of systemic NO are reported in such pat
./___Corpus/Medline/xml/PMC4635070.xml	216–	41343 : 41347	CPR	ported in such patients [216–219].                    
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	41446 : 41450	CM	e efficacy and safety of iNOS inhibitors in humans, an
./___Corpus/Medline/xml/PMC4635070.xml	220–	41580 : 41584	CPR	portant adverse effects [220–222]. Vital functions suc
./___Corpus/Medline/xml/PMC4635070.xml	NO	41720 : 41722	CM	ologically controlled by NO - did not change after t
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	41781 : 41785	CM	ic administration of the iNOS inhibitor L-N6-(1-iminoe
./___Corpus/Medline/xml/PMC4635070.xml	L-N6-(1-iminoethyl)lysine 5-tetrazole amide	41796 : 41839	CM	on of the iNOS inhibitor L-N6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51) on healthy volun
./___Corpus/Medline/xml/PMC4635070.xml	SC-51	41841 : 41846	CM	ysine 5-tetrazole amide (SC-51) on healthy volunteers [
./___Corpus/Medline/xml/PMC4635070.xml	aminoguanidine	41915 : 41929	CM	ay, the use of nebulized aminoguanidine was tested in healthy in
./___Corpus/Medline/xml/PMC4635070.xml	NO	42082 : 42084	CM	scular functioning after NO blocking [221, 222]. Alt
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	42202 : 42206	CM	onducted to confirm that iNOS blockage will stop tumor
./___Corpus/Medline/xml/PMC4635070.xml	NO	42299 : 42301	CM	ns that are dependent on NO.                        
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	42454 : 42458	CM	experimental knockout of iNOS enhances the mortality o
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	42564 : 42568	CM	 immunosuppression after iNOS blockage in cancer model
./___Corpus/Medline/xml/PMC4635070.xml	220–	42688 : 42692	CPR	munosuppressive effects [220–222]                  AKT
./___Corpus/Medline/xml/PMC4635070.xml	AKT	42714 : 42717	CM	20–222]                  AKT                      Pro
./___Corpus/Medline/xml/PMC4635070.xml	phosphatidylinositol	42997 : 43017	CM	ing pathway known as the phosphatidylinositol 3-kinase/protein kinase-
./___Corpus/Medline/xml/PMC4635070.xml	3-	43019 : 43021	CPR	he phosphatidylinositol 3-kinase/protein kinase-B/ma
./___Corpus/Medline/xml/PMC4635070.xml	kinase-B	43035 : 43043	CM	nositol 3-kinase/protein kinase-B/mammalian target of rapa
./___Corpus/Medline/xml/PMC4635070.xml	rapamycin	43064 : 43073	CM	se-B/mammalian target of rapamycin (PI3K/AKT/mTOR) represen
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	43075 : 43079	CM	ian target of rapamycin (PI3K/AKT/mTOR) represents one
./___Corpus/Medline/xml/PMC4635070.xml	AKT	43080 : 43083	CM	arget of rapamycin (PI3K/AKT/mTOR) represents one of 
./___Corpus/Medline/xml/PMC4635070.xml	mTOR	43084 : 43088	CM	t of rapamycin (PI3K/AKT/mTOR) represents one of the i
./___Corpus/Medline/xml/PMC4635070.xml	AKT	43376 : 43379	CM	                         AKT was initially defined by
./___Corpus/Medline/xml/PMC4635070.xml	phosphatase	43577 : 43588	CM	ns downregulated via the phosphatase and tensin homologue (PT
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	43611 : 43615	CM	se and tensin homologue (PTEN) gene [224, 228, 229]. H
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	43665 : 43669	CM	owever, mutations in the PTEN gene, which are found in
./___Corpus/Medline/xml/PMC4635070.xml	lead	43723 : 43727	CM	eral human malignancies, lead towards the inhibition o
./___Corpus/Medline/xml/PMC4635070.xml	AKT	43754 : 43757	CM	owards the inhibition of AKT downregulation, which wo
./___Corpus/Medline/xml/PMC4635070.xml	dephosphorylation	43819 : 43836	RN	rmally occur through the dephosphorylation of PIP3, a product of PI
./___Corpus/Medline/xml/PMC4635070.xml	PIP3	43840 : 43844	CM	the dephosphorylation of PIP3, a product of PI3K activ
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	43859 : 43863	CM	on of PIP3, a product of PI3K activation [229, 230]. T
./___Corpus/Medline/xml/PMC4635070.xml	PKB	43986 : 43989	CM	enesis initiated through PKB activation may also resu
./___Corpus/Medline/xml/PMC4635070.xml	AKT	44220 : 44223	CM	luding critical roles by AKT in proliferation [232], 
./___Corpus/Medline/xml/PMC4635070.xml	glucose	44279 : 44286	CM	ance to apoptosis [233], glucose metabolism [234], cell m
./___Corpus/Medline/xml/PMC4635070.xml	AKT	44460 : 44463	CM	, studies of the role of AKT in phagocytosis, bacteri
./___Corpus/Medline/xml/PMC4635070.xml	AKT	44722 : 44725	CM	. Evidence suggests that AKT promotes NF-κB activatio
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	44735 : 44740	CM	ggests that AKT promotes NF-κB activation [238]. In viv
./___Corpus/Medline/xml/PMC4635070.xml	AKT	44818 : 44821	CM	edema) also suggest that AKT inhibitors prevent AKT p
./___Corpus/Medline/xml/PMC4635070.xml	AKT	44841 : 44844	CM	t AKT inhibitors prevent AKT phosphorylation and down
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	44845 : 44860	RN	T inhibitors prevent AKT phosphorylation and downregulate the exp
./___Corpus/Medline/xml/PMC4635070.xml	MCP-1,TNFα	44923 : 44933	CM	flammatory factors IL-6, MCP-1,TNFα and iNOS [239]. Similarl
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	44938 : 44942	CM	ors IL-6, MCP-1,TNFα and iNOS [239]. Similarly, in res
./___Corpus/Medline/xml/PMC4635070.xml	AKT	45018 : 45021	CM	earchers have found that AKT inhibition mediates a re
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	45075 : 45080	CM	ion in the activation of NF-κB and p38MAPK activity in 
./___Corpus/Medline/xml/PMC4635070.xml	SAP	45105 : 45108	CM	 and p38MAPK activity in SAP rats and a downregulatio
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	45138 : 45143	CM	 and a downregulation of NF-κB-dependent proinflammator
./___Corpus/Medline/xml/PMC4635070.xml	murine	45977 : 45983	CM	 shown in both human and murine CD4 T cells) and in vivo
./___Corpus/Medline/xml/PMC4635070.xml	CD4	45984 : 45987	CM	in both human and murine CD4 T cells) and in vivo tre
./___Corpus/Medline/xml/PMC4635070.xml	AKT	46355 : 46358	CM	           Consequently, AKT inhibition is being aggr
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	46529 : 46533	CM	244], and bladder [245]. PI3K and AKT inhibitors are s
./___Corpus/Medline/xml/PMC4635070.xml	AKT	46538 : 46541	CM	 bladder [245]. PI3K and AKT inhibitors are still in 
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	46652 : 46656	CM	s of compounds targeting PI3K already having been deve
./___Corpus/Medline/xml/PMC4635070.xml	CXC	47081 : 47084	CM	stance.                  CXC Chemokines              
./___Corpus/Medline/xml/PMC4635070.xml	8–	47513 : 47515	CPR	es are a group of small (8–14 kDa) heparin-binding p
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	47804 : 47812	CM	s constitute the largest cytokine family in humans [249]. 
./___Corpus/Medline/xml/PMC4635070.xml	cysteine	47856 : 47864	CM	249]. Chemokines contain cysteine residues at their N-term
./___Corpus/Medline/xml/PMC4635070.xml	N-	47884 : 47886	CPR	teine residues at their N-terminus and the position 
./___Corpus/Medline/xml/PMC4635070.xml	amino acids	47920 : 47931	CM	nd the position of these amino acids forms the basis for clas
./___Corpus/Medline/xml/PMC4635070.xml	CXC	47991 : 47994	CM	 into four major groups: CXC, CC, CX3C or C [248]. Mo
./___Corpus/Medline/xml/PMC4635070.xml	CC	47996 : 47998	CM	 four major groups: CXC, CC, CX3C or C [248]. Most c
./___Corpus/Medline/xml/PMC4635070.xml	CX3C	48000 : 48004	CM	r major groups: CXC, CC, CX3C or C [248]. Most chemoki
./___Corpus/Medline/xml/PMC4635070.xml	cysteine	48047 : 48055	CM	chemokines harbor a four-cysteine motif internally linked 
./___Corpus/Medline/xml/PMC4635070.xml	disulfide	48083 : 48092	CM	tif internally linked by disulfide bonds at conserved sites
./___Corpus/Medline/xml/PMC4635070.xml	calcium	48377 : 48384	CM	 messengers, cytoplasmic calcium mobilization, and the ac
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	48475 : 48479	CM	 cascades, including the PI3K/AKT pathway, the Ras/MAP
./___Corpus/Medline/xml/PMC4635070.xml	AKT	48480 : 48483	CM	ades, including the PI3K/AKT pathway, the Ras/MAPK ax
./___Corpus/Medline/xml/PMC4635070.xml	MAPK	48501 : 48505	CM	I3K/AKT pathway, the Ras/MAPK axis, and the Janus kina
./___Corpus/Medline/xml/PMC4635070.xml	STAT	48539 : 48543	CM	d the Janus kinase (JAK)/STAT cascade [250]. Chemokine
./___Corpus/Medline/xml/PMC4635070.xml	CXC	48719 : 48722	CM	mited to a discussion of CXC chemokines.             
./___Corpus/Medline/xml/PMC4635070.xml	CXCL8	49217 : 49222	CM	 [252]. For example, IL8/CXCL8 induces leukocyte cell m
./___Corpus/Medline/xml/PMC4635070.xml	CXCL10	49461 : 49467	CM	rast, chemokines such as CXCL10 can have angiostatic pro
./___Corpus/Medline/xml/PMC4635070.xml	CXCR3	49575 : 49580	CM	hocytes via the receptor CXCR3. The extents to which ch
./___Corpus/Medline/xml/PMC4635070.xml	myxofibrosarcomas	50043 : 50060	CM	, colon adenocarcinomas, myxofibrosarcomas, gastric carcinomas, and
./___Corpus/Medline/xml/PMC4635070.xml	254–	50151 : 50155	CPR	antitumorigenic effects [254–261]. However, the presen
./___Corpus/Medline/xml/PMC4635070.xml	NK	50186 : 50188	CM	However, the presence of NK cells is relatively infr
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51022 : 51025	CM	                         CXC chemokines and their rec
./___Corpus/Medline/xml/PMC4635070.xml	264–	51197 : 51201	CPR	 chemotherapeutic drugs [264–266] Chemokine receptors,
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51445 : 51448	CM	wing binding to a single CXC chemokine [264, 267]. Fo
./___Corpus/Medline/xml/PMC4635070.xml	CXCR1	51532 : 51537	CM	rface receptors of IL-8, CXCR1 and CXCR2 has diverse fu
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	51542 : 51547	CM	ptors of IL-8, CXCR1 and CXCR2 has diverse functions. I
./___Corpus/Medline/xml/PMC4635070.xml	CXCR1	51587 : 51592	CM	nctions. IL-8 binding to CXCR1 results in activation of
./___Corpus/Medline/xml/PMC4635070.xml	mitogenic	51618 : 51627	CM	results in activation of mitogenic signaling and increased 
./___Corpus/Medline/xml/PMC4635070.xml	ERK1	51652 : 51656	CM	 signaling and increased ERK1/2 MAP kinase activity. C
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	51680 : 51685	CM	1/2 MAP kinase activity. CXCR2 mediates angiogenesis, m
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	51746 : 51751	CM	vasion and activation of NF-κB mediated cell survival p
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	51822 : 51828	CM	ome receptors, e.g., the CXCL12 co-receptor CXCR7, also 
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	51841 : 51846	CM	, the CXCL12 co-receptor CXCR7, also binds CXCL11 and M
./___Corpus/Medline/xml/PMC4635070.xml	CXCL11	51859 : 51865	CM	ceptor CXCR7, also binds CXCL11 and MIF, and activates E
./___Corpus/Medline/xml/PMC4635070.xml	MIF	51870 : 51873	CM	7, also binds CXCL11 and MIF, and activates EGFRs ind
./___Corpus/Medline/xml/PMC4635070.xml	EGFRs	51889 : 51894	CM	1 and MIF, and activates EGFRs independently of their l
./___Corpus/Medline/xml/PMC4635070.xml	269–	51927 : 51931	CPR	dently of their ligands [269–272]. These complex and d
./___Corpus/Medline/xml/PMC4635070.xml	CXC	51976 : 51979	CM	and diverse functions of CXC chemokines and their rec
./___Corpus/Medline/xml/PMC4635070.xml	CXCL8-CXCR1	52296 : 52307	CM	. Several antagonists of CXCL8-CXCR1/CXCR2-mediated signaling
./___Corpus/Medline/xml/PMC4635070.xml	CXCR2	52308 : 52313	CM	tagonists of CXCL8-CXCR1/CXCR2-mediated signaling are i
./___Corpus/Medline/xml/PMC4635070.xml	SCH-527123	52436 : 52446	CM	ecule antagonists (e.g., SCH-527123, SCH-479833 [273]), and 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	52491 : 52496	CPR	 and adenoviral-mediated anti-sense gene transfer appro
./___Corpus/Medline/xml/PMC4635070.xml	CXCR1	52761 : 52766	CM	itors of IL-8 binding to CXCR1, such as repertaxin, has
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12-CXCR4	52886 : 52898	CM	]. Identification of the CXCL12-CXCR4/CXCR7 axis as a novel th
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	52899 : 52904	CM	tion of the CXCL12-CXCR4/CXCR7 axis as a novel therapeu
./___Corpus/Medline/xml/PMC4635070.xml	anti-	53035 : 53040	CPR	les of these are the anti- CXCR4 drug AMD3100 [279], th
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	53067 : 53073	CM	 drug AMD3100 [279], the CXCL12 analog CTCE-9908 [280, 2
./___Corpus/Medline/xml/PMC4635070.xml	anti-CXCL12	53112 : 53123	CM	908 [280, 281, 282], the anti-CXCL12 aptamer NOX-A12 [283], t
./___Corpus/Medline/xml/PMC4635070.xml	NOX-A12	53132 : 53139	CM	 the anti-CXCL12 aptamer NOX-A12 [283], the inhibitor of 
./___Corpus/Medline/xml/PMC4635070.xml	CXCR4	53164 : 53169	CM	 [283], the inhibitor of CXCR4 expression chalcone 4 [2
./___Corpus/Medline/xml/PMC4635070.xml	chalcone	53181 : 53189	CM	itor of CXCR4 expression chalcone 4 [284], and the CXCR7-s
./___Corpus/Medline/xml/PMC4635070.xml	CXCR7	53207 : 53212	CM	halcone 4 [284], and the CXCR7-specific inhibitors CCX2
./___Corpus/Medline/xml/PMC4635070.xml	CXCR4	53289 : 53294	CM	] and CCX754 [286, 287]. CXCR4 also has been targeted u
./___Corpus/Medline/xml/PMC4635070.xml	288–	53378 : 53382	CPR	ll molecule antagonists [288–291]. In addition, admini
./___Corpus/Medline/xml/PMC4635070.xml	CXCL4	53507 : 53512	CM	origenic effects such as CXCL4, CXCL9, and CXCL10 has b
./___Corpus/Medline/xml/PMC4635070.xml	CXCL9	53514 : 53519	CM	c effects such as CXCL4, CXCL9, and CXCL10 has been pro
./___Corpus/Medline/xml/PMC4635070.xml	CXCL10	53525 : 53531	CM	uch as CXCL4, CXCL9, and CXCL10 has been proposed as a p
./___Corpus/Medline/xml/PMC4635070.xml	292–	53624 : 53628	CPR	nd limit spreading [252, 292–295]. Thus, currently the
./___Corpus/Medline/xml/PMC4635070.xml	CXCL8	53724 : 53729	CM	therapy, such as CXCL-1, CXCL8 and CXCL12 and others in
./___Corpus/Medline/xml/PMC4635070.xml	CXCL12	53734 : 53740	CM	uch as CXCL-1, CXCL8 and CXCL12 and others in various st
./___Corpus/Medline/xml/PMC4635070.xml	NK	55085 : 55087	CM	s including lymphocytes, NK cells, and dendritic cel
./___Corpus/Medline/xml/PMC4635070.xml	murine	55398 : 55404	CM	 demonstrated in several murine models of anthracycline-
./___Corpus/Medline/xml/PMC4635070.xml	anthracycline	55415 : 55428	CM	several murine models of anthracycline-based chemotherapy that 
./___Corpus/Medline/xml/PMC4635070.xml	CCL2	55471 : 55475	CM	y that the inhibition of CCL2 or CCR2 might actually i
./___Corpus/Medline/xml/PMC4635070.xml	CCR2	55479 : 55483	CM	he inhibition of CCL2 or CCR2 might actually impair th
./___Corpus/Medline/xml/PMC4635070.xml	NSAIDs	56671 : 56677	CM	 antiinflammatory drugs (NSAIDs), in particular aspirin,
./___Corpus/Medline/xml/PMC4635070.xml	305–	57260 : 57264	CPR	portantly, side effects [305–308] that range from gast
./___Corpus/Medline/xml/PMC4635070.xml	NSAIDs	57352 : 57358	CM	troke). Thus, the use of NSAIDs in clinical practice for
./___Corpus/Medline/xml/PMC4635070.xml	309–	57805 : 57809	CPR	wth of neoplastic cells [309–315]. Indeed, several epi
./___Corpus/Medline/xml/PMC4635070.xml	316–	58065 : 58069	CPR	decrease in cancer risk [316–319]. A large number of p
./___Corpus/Medline/xml/PMC4635070.xml	320–	58221 : 58225	CPR	of inflammatory cascade [320–322] as well as modulatio
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	58514 : 58522	CM	that we have identified: curcumin, resveratrol, epigalloca
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	58524 : 58535	CM	ve identified: curcumin, resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4635070.xml	gallate	58554 : 58561	CM	ratrol, epigallocatechin gallate (EGCG), lycopenes, antho
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	58563 : 58567	CM	pigallocatechin gallate (EGCG), lycopenes, anthocyanin
./___Corpus/Medline/xml/PMC4635070.xml	lycopenes	58570 : 58579	CM	catechin gallate (EGCG), lycopenes, anthocyanins, and genis
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	58581 : 58593	CM	llate (EGCG), lycopenes, anthocyanins, and genistein.         
./___Corpus/Medline/xml/PMC4635070.xml	genistein	58599 : 58608	CM	penes, anthocyanins, and genistein.                  Curcum
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin

                    Curcumin	58627 : 58665	CM	istein.                  Curcumin                      Curcumin, (diferuloylmethane) is 
./___Corpus/Medline/xml/PMC4635070.xml	diferuloylmethane	58668 : 58685	CM	              Curcumin, (diferuloylmethane) is a component of golde
./___Corpus/Medline/xml/PMC4635070.xml	Curcuma	58718 : 58725	CM	omponent of golden spice Curcuma longa (commonly known as
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	58906 : 58914	CM	iinflammatory effects of curcumin have been demonstrated i
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59006 : 59014	CM	 research has shown that curcumin can also target cancer s
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59187 : 59195	CM	l and India, where daily curcumin uptake in diet has been 
./___Corpus/Medline/xml/PMC4635070.xml	50–	59240 : 59243	CPR	been assessed as high as 50–100 mg per day, no toxici
./___Corpus/Medline/xml/PMC4635070.xml	0.2g	59499 : 59503	CM	ric in 1993 at a dose of 0.2g/kg/day (CAS no. 8024−37−
./___Corpus/Medline/xml/PMC4635070.xml	CAS	59512 : 59515	CM	t a dose of 0.2g/kg/day (CAS no. 8024−37−1) for 13 we
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59802 : 59810	CM	f 3,500mg/kg body weight curcumin for 90 days in rats, dog
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	59987 : 59995	CM	United States recognized curcumin as a Generally Recognize
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60105 : 60113	CM	t oral administration of curcumin did not have any adverse
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	60401 : 60409	CM	s were not dose-related. Curcumin supplementation up to 8 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60626 : 60634	CM	anced colorectal cancer, curcumin supplementation ranging 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60780 : 60788	CM	                However, curcumin may have adverse effect 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60846 : 60854	CM	ollowing situations: (a) curcumin increases contraction in
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	60990 : 60998	CM	llstone. [331, 332]; (b) curcumin can increase the risk of
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61140 : 61148	CM	tion [333, 334]; and (c) curcumin also increases acid outp
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	61315 : 61323	CM	                         Curcumin has garnered significant
./___Corpus/Medline/xml/PMC4635070.xml	vitro	61564 : 61569	CM	le checkpoints [336]. In vitro studies indicate that cu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61592 : 61600	CM	ro studies indicate that curcumin can target numerous kina
./___Corpus/Medline/xml/PMC4635070.xml	phosphatases	61630 : 61642	CM	target numerous kinases, phosphatases, and enzymes [337]. For 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61676 : 61684	CM	ymes [337]. For example, curcumin can inactivate NF-κB [33
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	61700 : 61705	CM	 curcumin can inactivate NF-κB [338], and reduce COX-2 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	61724 : 61729	CM	 NF-κB [338], and reduce COX-2 expression [339] and dow
./___Corpus/Medline/xml/PMC4635070.xml	p53	61832 : 61835	CM	through interaction with p53 [340] and by increasing 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	61943 : 61951	CM	 [342]. In animal models curcumin prevents cancer developm
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	62022 : 62027	CM	 of TNF-α, interferon-γ (IFN-γ), and COX-2 [343]. So th
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	62034 : 62039	CM	nterferon-γ (IFN-γ), and COX-2 [343]. So the diverse bi
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62084 : 62092	CM	se biological effects of curcumin make this compound an at
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62262 : 62270	CM	                 Indeed, curcumin has been shown to inhibi
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62468 : 62476	CM	combination of 480 mg of curcumin and 20 mg of quercetin (
./___Corpus/Medline/xml/PMC4635070.xml	quercetin	62490 : 62499	CM	of curcumin and 20 mg of quercetin (three times daily) for 
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	62594 : 62605	CM	small number of familial adenomatous polyposis (FAP) patients
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62687 : 62695	CM	]. Similarly, 4 grams of curcumin daily for 1 month preven
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	62819 : 62827	CM	study also suggests that curcumin could work as chemothera
./___Corpus/Medline/xml/PMC4635070.xml	oxaliplatin	62913 : 62924	CM	cer cells sensitivity to oxaliplatin [347]. However, not all 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63020 : 63028	CM	temic bioavailability of curcumin is extremely poor [349].
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63187 : 63195	CM	ing clinical trials with curcumin registered for different
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63340 : 63348	CM	ation of the efficacy of curcumin as a chemopreventive or 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63601 : 63609	CM	sm, and excretion of the curcumin are considered the reaso
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63700 : 63708	CM	man subjects [350]. When curcumin was administered orally 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63787 : 63795	CM	ats, the majority of the curcumin was excreted in feces an
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	63875 : 63883	CM	cted in the urine [351]. Curcumin is biotransformed in the
./___Corpus/Medline/xml/PMC4635070.xml	glucuronides	63951 : 63963	CM	e liver converts it into glucuronides and curcumin sulfates [3
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	63968 : 63976	CM	it into glucuronides and curcumin sulfates [352, 353]. Als
./___Corpus/Medline/xml/PMC4635070.xml	sulfates	63977 : 63985	CM	lucuronides and curcumin sulfates [352, 353]. Also, reduct
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64021 : 64029	CM	. Also, reduction of the curcumin to tetrahydrocurcumin an
./___Corpus/Medline/xml/PMC4635070.xml	tetrahydrocurcumin	64033 : 64051	CM	ction of the curcumin to tetrahydrocurcumin and hexahydrocurcumin ha
./___Corpus/Medline/xml/PMC4635070.xml	hexahydrocurcumin	64056 : 64073	CM	o tetrahydrocurcumin and hexahydrocurcumin has been reported after 
./___Corpus/Medline/xml/PMC4635070.xml	353–	64144 : 64148	CPR	n rats, mice, and human [353–355]. Even intravenous an
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64209 : 64217	CM	toneal administration of curcumin in rats resulted in redu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64246 : 64254	CM	rats resulted in reduced curcumin and subsequently reduced
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64280 : 64288	CM	and subsequently reduced curcumin converted to monoglucuro
./___Corpus/Medline/xml/PMC4635070.xml	monoglucuronide	64302 : 64317	CM	ed curcumin converted to monoglucuronide conjugates [354]. Transf
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64354 : 64362	CM	[354]. Transformation of curcumin may result in loss of th
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64412 : 64420	CM	e biological activity of curcumin [353]. In pharmacokineti
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64474 : 64482	CM	d dynamic studies, serum curcumin concentrations peaked in
./___Corpus/Medline/xml/PMC4635070.xml	1–	64508 : 64510	CPR	concentrations peaked in 1–2 hours [356]. The peak s
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64558 : 64566	CM	 serum concentrations of curcumin were 0.5, 0.6, and 1.8 m
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64650 : 64658	CM	dose of 4, 6, and 8 g of curcumin, respectively. [356]    
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64752 : 64760	CM	systemic availability of curcumin is very low, it has been
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64833 : 64841	CM	that orally administered curcumin accumulates in gastroint
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	64981 : 64989	CM	 administered 3.6 g/d of curcumin orally for seven days, c
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65013 : 65021	CM	n orally for seven days, curcumin was detected in normal s
./___Corpus/Medline/xml/PMC4635070.xml	phospholipid	65174 : 65186	CM	nano-delivery systems or phospholipid-based delivery systems f
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65214 : 65222	CM	sed delivery systems for curcumin increase its accumulatio
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65319 : 65324	CM	l tract, that can target COX-2 as well as prostaglandin
./___Corpus/Medline/xml/PMC4635070.xml	359–	65386 : 65390	CPR	athway more effectively [359–362]. In vitro, curcumin 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	65399 : 65404	CM	ffectively [359–362]. In vitro, curcumin shows potentia
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65406 : 65414	CM	ely [359–362]. In vitro, curcumin shows potential as a COX
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65436 : 65441	CM	min shows potential as a COX-2 inhibitor, inhibiting th
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65482 : 65487	CM	biting the expression of COX-2 mRNA and enzymatic activ
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	65488 : 65492	CM	 the expression of COX-2 mRNA and enzymatic activities
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65521 : 65526	CM	 enzymatic activities of COX-2 protein in colonic epith
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	65588 : 65596	CM	 macrophages [363, 364]. Curcumin also inhibited the expre
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65630 : 65635	CM	ibited the expression of COX-2 mRNA and enzymatic activ
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	65636 : 65640	CM	 the expression of COX-2 mRNA and enzymatic activities
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65669 : 65674	CM	 enzymatic activities of COX-2 protein in colonic epith
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65782 : 65790	CM	                 Because curcumin can target prostaglandin
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	65802 : 65815	CM	ause curcumin can target prostaglandin biosynthesis, it can be 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	65862 : 65867	CM	be used in cancers where COX-2 activation plays an impo
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65952 : 65960	CM	vivo delivery systems of curcumin will result in a higher 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	65995 : 66003	CM	lt in a higher levels of curcumin accumulation in organs (
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	66088 : 66093	CM	l tract) that can target COX-2 as well as prostaglandin
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	66155 : 66163	CM	athway more effectively. Curcumin inhibited bile acid and 
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	66188 : 66201	CM	 inhibited bile acid and phorbol ester induced COX-2 mRNA expre
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	66210 : 66215	CM	nd phorbol ester induced COX-2 mRNA expression in gastr
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	66216 : 66220	CM	rbol ester induced COX-2 mRNA expression in gastrointe
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66297 : 66305	CM	5]. In mouse skin cells, curcumin inhibits phorbol ester-i
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	66315 : 66328	CM	cells, curcumin inhibits phorbol ester-induced expression of CO
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	66351 : 66356	CM	er-induced expression of COX-2 [348]. In a human non-sm
./___Corpus/Medline/xml/PMC4635070.xml	ectopic	66402 : 66409	CM	n-small cell lung cancer ectopic and orthotopic xenograft
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66448 : 66456	CM	c xenograft mouse model, curcumin reduced COX-2 expression
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	66465 : 66470	CM	 model, curcumin reduced COX-2 expression in subcutaneo
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	66628 : 66636	CM	val rate increase [366]. Curcumin inhibition of COX-2 in N
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	66651 : 66656	CM	. Curcumin inhibition of COX-2 in NSCLC cells was assoc
./___Corpus/Medline/xml/PMC4635070.xml	NSCLC	66660 : 66665	CM	n inhibition of COX-2 in NSCLC cells was associated wit
./___Corpus/Medline/xml/PMC4635070.xml	vitro	66768 : 66773	CM	             Notably, in vitro treatment of curcumin al
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	66787 : 66795	CM	y, in vitro treatment of curcumin also suppressed CXCL-8 p
./___Corpus/Medline/xml/PMC4635070.xml	CXCL-8	66812 : 66818	CM	curcumin also suppressed CXCL-8 production by human panc
./___Corpus/Medline/xml/PMC4635070.xml	CXCL1	66916 : 66921	CM	e inflammatory cytokines CXCL1 and CXCL2 in breast canc
./___Corpus/Medline/xml/PMC4635070.xml	CXCL2	66926 : 66931	CM	tory cytokines CXCL1 and CXCL2 in breast cancer cells v
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	66959 : 66964	CM	 breast cancer cells via NF-κB [367, 368]. In a Kras-me
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67023 : 67031	CM	ng cancer model in mice, curcumin inhibited the expression
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67251 : 67259	CM	m an immune perspective, curcumin suppresses the type 1 im
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67374 : 67382	CM	0]. But at the same time curcumin appears to act in a supp
./___Corpus/Medline/xml/PMC4635070.xml	vitro	67474 : 67479	CM	ects. For example, in in vitro tests aimed at studying 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67516 : 67524	CM	 at studying the role of curcumin in the prevention of tum
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	67605 : 67613	CM	l-based immune response, curcumin prevented the loss of T 
./___Corpus/Medline/xml/PMC4635070.xml	T(CM)	67677 : 67682	CM	d central memory T cell (T(CM))/effector memory T cell 
./___Corpus/Medline/xml/PMC4635070.xml	T(EM)	67708 : 67713	CM	/effector memory T cell (T(EM)) populations, reversed t
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	67852 : 67860	CM	 in tumor-bearing hosts. Curcumin also inhibited the suppr
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	67952 : 67957	CM	lating the production of TGF-β and IL-10) and enhanced 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	68051 : 68059	CM	er cells [371]. As well, curcumin significantly inhibited 
./___Corpus/Medline/xml/PMC4635070.xml	IDO	68101 : 68104	CM	hibited the induction of IDO expression (a key enzyme
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	68205 : 68210	CM	 tumors) and activity by IFN-γ in bone marrow-derived D
./___Corpus/Medline/xml/PMC4635070.xml	DCs	68234 : 68237	CM	γ in bone marrow-derived DCs, which appears to be an 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	68301 : 68309	CM	nomodulatory property of curcumin that may serve to streng
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol

                    Resveratrol	68389 : 68433	CM	 [372].                  Resveratrol                      Resveratrol (3,5,4'-trihydroxystilbe
./___Corpus/Medline/xml/PMC4635070.xml	3,5,4'-trihydroxystilbene	68435 : 68460	CM	            Resveratrol (3,5,4'-trihydroxystilbene), a compound found in th
./___Corpus/Medline/xml/PMC4635070.xml	polyphenol	68631 : 68641	CM	rties. It is a bioactive polyphenol and has antiinflammatory
./___Corpus/Medline/xml/PMC4635070.xml	vitro	68911 : 68916	CM	 phytochemical [373]. In vitro evidence of resveratrol 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	68929 : 68940	CM	3]. In vitro evidence of resveratrol efficacy is well describ
./___Corpus/Medline/xml/PMC4635070.xml	1hr	69168 : 69171	CM	trations occur at around 1hr, and levels of the paren
./___Corpus/Medline/xml/PMC4635070.xml	5g	69284 : 69286	CM	ven at high doses (up to 5g daily) [376]. Resveratro
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69301 : 69312	CM	 (up to 5g daily) [376]. Resveratrol works in animal models [
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69466 : 69477	CM	                         Resveratrol has been shown to have e
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	69686 : 69697	CM	y confirmed studies that resveratrol suppresses colitis [382,
./___Corpus/Medline/xml/PMC4635070.xml	384–	69746 : 69750	CPR	, 383] and pancreatitis [384–386]. Resveratrol targets
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	69756 : 69767	CM	 pancreatitis [384–386]. Resveratrol targets many of the key 
./___Corpus/Medline/xml/PMC4635070.xml	p53	69874 : 69877	CM	d induces apoptosis in a p53-dependent manner [387–38
./___Corpus/Medline/xml/PMC4635070.xml	387–	69896 : 69900	CPR	 a p53-dependent manner [387–389]. Interestingly, resv
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	69921 : 69932	CM	387–389]. Interestingly, resveratrol can induce the expressio
./___Corpus/Medline/xml/PMC4635070.xml	p53	69966 : 69969	CM	ce the expression of the p53 target, NAG-1 [non-stero
./___Corpus/Medline/xml/PMC4635070.xml	NSAID	70017 : 70022	CM	roidal antiinflammatory (NSAID) drug-activated gene-1],
./___Corpus/Medline/xml/PMC4635070.xml	gene-1	70039 : 70045	CM	y (NSAID) drug-activated gene-1], a member of the transf
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70178 : 70189	CM	 activities [390]. Also, resveratrol prevents pRb hyperphosph
./___Corpus/Medline/xml/PMC4635070.xml	pRb	70199 : 70202	CM	so, resveratrol prevents pRb hyperphosphorylation and
./___Corpus/Medline/xml/PMC4635070.xml	hyperphosphorylation	70203 : 70223	CM	resveratrol prevents pRb hyperphosphorylation and thus the inactivatio
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	70284 : 70295	CM	umor suppressor protein. Resveratrol also inhibits MMP-2 [391
./___Corpus/Medline/xml/PMC4635070.xml	MMP-9	70326 : 70331	CM	inhibits MMP-2 [391] and MMP-9 [392, 393], COX-1 [394],
./___Corpus/Medline/xml/PMC4635070.xml	COX-1	70344 : 70349	CM	1] and MMP-9 [392, 393], COX-1 [394], proinflammatory c
./___Corpus/Medline/xml/PMC4635070.xml	395–	70384 : 70388	CPR	oinflammatory cytokines [395–397], and growth factors 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70505 : 70516	CM	           Additionally, resveratrol has potent NF-κB-depende
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	70528 : 70533	CM	, resveratrol has potent NF-κB-dependent antiinflammato
./___Corpus/Medline/xml/PMC4635070.xml	vitro	70597 : 70602	CM	eventive effects both in vitro and in vivo, and impacts
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	70718 : 70723	CM	hrough the inhibition of NF-κB, resveratrol ameliorates
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	70725 : 70736	CM	the inhibition of NF-κB, resveratrol ameliorates diabetic vas
./___Corpus/Medline/xml/PMC4635070.xml	399–	71003 : 71007	CPR	chemotherapeutic agents [399–405]. Notably, resveratro
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71022 : 71033	CM	ents [399–405]. Notably, resveratrol has also been shown to i
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	71149 : 71154	CM	n this review, including COX-2 [406–408], MIF [409], TN
./___Corpus/Medline/xml/PMC4635070.xml	406–	71156 : 71160	CPR	review, including COX-2 [406–408], MIF [409], TNF-α [4
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	71190 : 71194	CM	 MIF [409], TNF-α [410], iNOS [411], AKT [412], and th
./___Corpus/Medline/xml/PMC4635070.xml	AKT	71202 : 71205	CM	TNF-α [410], iNOS [411], AKT [412], and the CXC group
./___Corpus/Medline/xml/PMC4635070.xml	CXC	71221 : 71224	CM	411], AKT [412], and the CXC group of cytokines [413]
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71287 : 71298	CM	, Cichocki et al. showed resveratrol inhibited 12-O-tetradeca
./___Corpus/Medline/xml/PMC4635070.xml	12-O-tetradecanoylphorbol-13-acetate	71309 : 71345	CM	ed resveratrol inhibited 12-O-tetradecanoylphorbol-13-acetate activated NF-κB, AP-1, C
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	71356 : 71361	CM	bol-13-acetate activated NF-κB, AP-1, COX-2, and iNOS i
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	71369 : 71374	CM	e activated NF-κB, AP-1, COX-2, and iNOS in mouse epide
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	71380 : 71384	CM	 NF-κB, AP-1, COX-2, and iNOS in mouse epidermis [414]
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71447 : 71458	CM	Kundu et al. showed that resveratrol inhibits phorbol ester-i
./___Corpus/Medline/xml/PMC4635070.xml	phorbol ester	71468 : 71481	CM	hat resveratrol inhibits phorbol ester-induced expression of CO
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	71504 : 71509	CM	er-induced expression of COX-2 and activation of NF-κB 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	71528 : 71533	CM	 COX-2 and activation of NF-κB in mouse skin by blockin
./___Corpus/Medline/xml/PMC4635070.xml	I-κB	71560 : 71564	CM	n mouse skin by blocking I-κB kinase activity [408]. D
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71596 : 71607	CM	 activity [408]. Dietary resveratrol (50–300 mg/kg) was found
./___Corpus/Medline/xml/PMC4635070.xml	50–	71609 : 71612	CPR	8]. Dietary resveratrol (50–300 mg/kg) was found to i
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	71733 : 71737	CM	s suppression of hepatic iNOS, 3-nitrotyrosine, COX-2 
./___Corpus/Medline/xml/PMC4635070.xml	3-nitrotyrosine	71739 : 71754	CM	ression of hepatic iNOS, 3-nitrotyrosine, COX-2 and NF-κB [415–41
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	71756 : 71761	CM	c iNOS, 3-nitrotyrosine, COX-2 and NF-κB [415–417].    
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	71766 : 71771	CM	nitrotyrosine, COX-2 and NF-κB [415–417].              
./___Corpus/Medline/xml/PMC4635070.xml	415–	71773 : 71777	CPR	rosine, COX-2 and NF-κB [415–417].                    
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	71867 : 71878	CM	ished clinical trials on resveratrol in humans have shown tha
./___Corpus/Medline/xml/PMC4635070.xml	glucose	71977 : 71984	CM	tivities. It can improve glucose and lipid metabolism, an
./___Corpus/Medline/xml/PMC4635070.xml	lipid	71989 : 71994	CM	 can improve glucose and lipid metabolism, and favorabl
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72271 : 72282	CM	asma pharmacokinetics of resveratrol in humans are also now r
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72605 : 72616	CM	the earliest research on resveratrol and immune function, Fal
./___Corpus/Medline/xml/PMC4635070.xml	vitro	72676 : 72681	CM	al. [421] showed that in vitro exposure to resveratrol 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72694 : 72705	CM	hat in vitro exposure to resveratrol produced a biphasic effe
./___Corpus/Medline/xml/PMC4635070.xml	anti-	72736 : 72741	CPR	ced a biphasic effect on anti-CD3/anti-CD28-induced dev
./___Corpus/Medline/xml/PMC4635070.xml	anti-	72745 : 72750	CPR	hasic effect on anti-CD3/anti-CD28-induced development 
./___Corpus/Medline/xml/PMC4635070.xml	anti-	72754 : 72759	CPR	ect on anti-CD3/anti-CD28-induced development of both I
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	72783 : 72788	CM	uced development of both IFN-γ - IL2- and IL4-producing
./___Corpus/Medline/xml/PMC4635070.xml	IL4	72800 : 72803	CM	of both IFN-γ - IL2- and IL4-producing CD8+ and CD4+ 
./___Corpus/Medline/xml/PMC4635070.xml	CD8+	72814 : 72818	CM	- IL2- and IL4-producing CD8+ and CD4+ T cells (with s
./___Corpus/Medline/xml/PMC4635070.xml	CD4+	72823 : 72827	CM	d IL4-producing CD8+ and CD4+ T cells (with stimulatio
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	72861 : 72872	CM	(with stimulation at low resveratrol concentrations and suppr
./___Corpus/Medline/xml/PMC4635070.xml	NK	73086 : 73088	CM	otoxic T lymphocytes and NK cell cytotoxic activity 
./___Corpus/Medline/xml/PMC4635070.xml	NK	73152 : 73154	CM	s biphasic modulation of NK cells has been confirmed
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73254 : 73265	CM	stration of low doses of resveratrol also inhibited Renca tum
./___Corpus/Medline/xml/PMC4635070.xml	CD8+	73375 : 73379	CM	sive amount of activated CD8+ T cells accumulating in 
./___Corpus/Medline/xml/PMC4635070.xml	(Th)-2	73477 : 73483	CM	e expression of T-helper (Th)-2 cytokines (e.g., IL-6 an
./___Corpus/Medline/xml/PMC4635070.xml	Th-1	73529 : 73533	CM	6 and IL-10) switched to Th-1 cytokines with dominance
./___Corpus/Medline/xml/PMC4635070.xml	(IFN)-γ	73573 : 73580	CM	 dominance of interferon (IFN)-γ, which increases the exp
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73647 : 73658	CM	 Renca cells. [423]. And resveratrol has also been shown to s
./___Corpus/Medline/xml/PMC4635070.xml	CD4	73705 : 73708	CM	o suppress tumor-derived CD4+CD25+ regulatory T cells
./___Corpus/Medline/xml/PMC4635070.xml	CD25+	73709 : 73714	CM	ppress tumor-derived CD4+CD25+ regulatory T cells (whic
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	73873 : 73884	CM	osts) in mice [424]. And resveratrol at low and noncytotoxic 
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	74058 : 74063	CM	 including expression of TGF-β in mice. This frees anti
./___Corpus/Medline/xml/PMC4635070.xml	(FOX)p3(+)	74182 : 74192	CM	 of forkhead box protein (FOX)p3(+) Tregs (without nonspecif
./___Corpus/Medline/xml/PMC4635070.xml	mice[425]	74307 : 74316	CM	bited lung metastasis in mice[425]. So the effects of resve
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	74336 : 74347	CM	[425]. So the effects of resveratrol on the antitumor capabil
./___Corpus/Medline/xml/PMC4635070.xml	gallate	74560 : 74567	CM	        Epigallocatechin gallate (EGCG)                  
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74569 : 74573	CM	pigallocatechin gallate (EGCG)                      EG
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74596 : 74600	CM	CG)                      EGCG is the most abundant cat
./___Corpus/Medline/xml/PMC4635070.xml	catechin	74622 : 74630	CM	GCG is the most abundant catechin in tea, is a potent anti
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74823 : 74827	CM	 of cancer prevention by EGCG in many animal studies, 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	74933 : 74937	CM	ing the effectiveness of EGCG as a superior medicine f
./___Corpus/Medline/xml/PMC4635070.xml	Methylation	75099 : 75110	RN	ism and bioavailability. Methylation, glucuronidation, sulfat
./___Corpus/Medline/xml/PMC4635070.xml	glucuronidation	75112 : 75127	CM	ailability. Methylation, glucuronidation, sulfation, and ring-fis
./___Corpus/Medline/xml/PMC4635070.xml	sulfation	75129 : 75138	CM	lation, glucuronidation, sulfation, and ring-fission metabo
./___Corpus/Medline/xml/PMC4635070.xml	P-glycoprotein	75280 : 75294	CM	that efflux transporters P-glycoprotein (Pgp), MRP1 and MRP2 pla
./___Corpus/Medline/xml/PMC4635070.xml	MRP1	75302 : 75306	CM	rs P-glycoprotein (Pgp), MRP1 and MRP2 play roles in t
./___Corpus/Medline/xml/PMC4635070.xml	MRP2	75311 : 75315	CM	oprotein (Pgp), MRP1 and MRP2 play roles in the absorp
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75539 : 75543	CM	 involved in the fate of EGCG, resulting in its low av
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75714 : 75718	CM	cted toxicity studies on EGCG. An oral dose delivering
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75752 : 75756	CM	 dose delivering 2000 mg EGCG preparation/kg was letha
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75817 : 75821	CM	whereas a dose of 200 mg EGCG/kg induced no toxicity. 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75876 : 75880	CM	ietary administration of EGCG to rats for 13 weeks was
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	75999 : 76003	CM	s were noted when 500 mg EGCG preparation/kg/day was a
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76307 : 76311	CM	e effect level of 500 mg EGCG/kg/day was established [
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76461 : 76465	CM	preventive potentials of EGCG, among which are its abi
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76624 : 76628	CM	e diversified effects of EGCG may explain its broad ph
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	76759 : 76763	CM	with a high cancer risk, EGCG has been shown to suppre
./___Corpus/Medline/xml/PMC4635070.xml	HBV	76865 : 76868	CM	viral properties against HBV and HCV [433, 434]), and
./___Corpus/Medline/xml/PMC4635070.xml	HCV	76873 : 76876	CM	operties against HBV and HCV [433, 434]), and pancrea
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77021 : 77025	CM	rate ulcerative colitis, EGCG (400–800 mg daily) showe
./___Corpus/Medline/xml/PMC4635070.xml	400–	77027 : 77031	CPR	lcerative colitis, EGCG (400–800 mg daily) showed a th
./___Corpus/Medline/xml/PMC4635070.xml	5-aminosalicylic	77110 : 77126	CM	s who were refractory to 5-aminosalicylic and/or azathioprine [436
./___Corpus/Medline/xml/PMC4635070.xml	azathioprine	77134 : 77146	CM	 5-aminosalicylic and/or azathioprine [436].                  
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77225 : 77229	CM	 extensive evidence that EGCG targets key players in i
./___Corpus/Medline/xml/PMC4635070.xml	vitro	77308 : 77313	CM	anism of its efficacy in vitro and in vivo against chro
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77411 : 77415	CM	. Noh et al. showed that EGCG improves Dermatophagoide
./___Corpus/Medline/xml/PMC4635070.xml	MIF	77540 : 77543	CM	use model by suppressing MIF [437]. In addition, EGCG
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77564 : 77568	CM	 MIF [437]. In addition, EGCG can inhibit TNF-α [438],
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	77594 : 77598	CM	can inhibit TNF-α [438], iNOS [439, 440], AKT [441], t
./___Corpus/Medline/xml/PMC4635070.xml	AKT	77611 : 77614	CM	 [438], iNOS [439, 440], AKT [441], the CXC group of 
./___Corpus/Medline/xml/PMC4635070.xml	CXC	77626 : 77629	CM	39, 440], AKT [441], the CXC group of cytokines [442]
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	77707 : 77712	CM	nscriptional activity of NF-κB, COX-2 expression and PG
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	77714 : 77719	CM	ional activity of NF-κB, COX-2 expression and PGE-2 syn
./___Corpus/Medline/xml/PMC4635070.xml	443–	77752 : 77756	CPR	ion and PGE-2 synthesis [443–448]. Additionally, EGCG 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	77776 : 77780	CM	[443–448]. Additionally, EGCG activates wild-type p53 
./___Corpus/Medline/xml/PMC4635070.xml	p53	77801 : 77804	CM	EGCG activates wild-type p53 [449–451], and protects 
./___Corpus/Medline/xml/PMC4635070.xml	449–	77806 : 77810	CPR	activates wild-type p53 [449–451], and protects from p
./___Corpus/Medline/xml/PMC4635070.xml	p53	77834 : 77837	CM	–451], and protects from p53 mutation [452]. It promo
./___Corpus/Medline/xml/PMC4635070.xml	pRb	77866 : 77869	CM	ation [452]. It promotes pRb hypophosphorylation and 
./___Corpus/Medline/xml/PMC4635070.xml	hypophosphorylation	77870 : 77889	CM	n [452]. It promotes pRb hypophosphorylation and activation of this t
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	78039 : 78043	CM	        In animal models EGCG prevents the development
./___Corpus/Medline/xml/PMC4635070.xml	adenomatous	78072 : 78083	CM	vents the development of adenomatous polyps in ApcMin/+ mice 
./___Corpus/Medline/xml/PMC4635070.xml	ApcMin	78094 : 78100	CM	of adenomatous polyps in ApcMin/+ mice [455, 456]. Some 
./___Corpus/Medline/xml/PMC4635070.xml	polyphenol	78341 : 78351	CM	gh urinary levels of tea polyphenol epigallocatechin (EGC) h
./___Corpus/Medline/xml/PMC4635070.xml	polyphenols	78631 : 78642	CM	460]. Doses of green tea polyphenols greater than 800 mg/day 
./___Corpus/Medline/xml/PMC4635070.xml	461–	78758 : 78762	CPR	in humans at this level [461–463]. Nonetheless, despit
./___Corpus/Medline/xml/PMC4635070.xml	vitro	78806 : 78811	CM	despite evidence from in vitro and non-human in vivo re
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79001 : 79005	CM	is protective [464]. But EGCG does target and suppress
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79271 : 79275	CM	m an immune perspective, EGCG significantly suppressed
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	79301 : 79306	CM	significantly suppressed IFN-γ production and the proli
./___Corpus/Medline/xml/PMC4635070.xml	vitro	79381 : 79386	CM	ood mononuclear cells in vitro [465]. It was also shown
./___Corpus/Medline/xml/PMC4635070.xml	IDO	79529 : 79532	CM	pression and function of IDO through the suppression 
./___Corpus/Medline/xml/PMC4635070.xml	STAT1	79560 : 79565	CM	rough the suppression of STAT1 activation [466]. In leu
./___Corpus/Medline/xml/PMC4635070.xml	BALB	79596 : 79600	CM	ation [466]. In leukemic BALB/c mice that received 5, 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	79641 : 79645	CM	eived 5, 20 and 40 mg/kg EGCG (orally) for two weeks, 
./___Corpus/Medline/xml/PMC4635070.xml	CD3	79701 : 79704	CM	reased the percentage of CD3, T-cell, CD19, B-cell, a
./___Corpus/Medline/xml/PMC4635070.xml	CD19	79714 : 79718	CM	rcentage of CD3, T-cell, CD19, B-cell, and Macrophage-
./___Corpus/Medline/xml/PMC4635070.xml	Mac-3	79754 : 79759	CM	nd Macrophage-3 antigen (Mac-3), and macrophages, but r
./___Corpus/Medline/xml/PMC4635070.xml	CD11b	79809 : 79814	CM	educed the percentage of CD11b (monocyte) cell surface 
./___Corpus/Medline/xml/PMC4635070.xml	NK	79933 : 79935	CM	g treatment and promoted NK cell activity at 40 mg/k
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	80128 : 80132	CM	       At the same time, EGCG appears to have a protec
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	80216 : 80220	CM	ction. This was shown in EGCG treatment of nicotine-su
./___Corpus/Medline/xml/PMC4635070.xml	nicotine	80234 : 80242	CM	own in EGCG treatment of nicotine-suppressed macrophages w
./___Corpus/Medline/xml/PMC4635070.xml	nicotine	80338 : 80346	CM	fection and diminished a nicotine-induced inhibition of cy
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	80369 : 80377	CM	ne-induced inhibition of cytokine production [468]. It was
./___Corpus/Medline/xml/PMC4635070.xml	methicillin	80554 : 80565	CM	 burn wound infection by methicillin-resistant Staphylococcus
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	80622 : 80630	CM	 [470].                  Lycopene                      Lyc
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	80652 : 80660	CM	ene                      Lycopene is a phytochemical that 
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	80731 : 80742	CM	 plant pigments known as carotenoids. Red colored lycopene is
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	80756 : 80764	CM	carotenoids. Red colored lycopene is lipophilic and natura
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	80854 : 80862	CM	. The richest sources of lycopene are tomatoes and tomato 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81089 : 81097	CM	e the bioavailability of lycopene [471, 472]. Research, da
./___Corpus/Medline/xml/PMC4635070.xml	1920s	81146 : 81151	CM	ating as far back as the 1920s, has shown that naturall
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	81188 : 81199	CM	that naturally occurring carotenoids, specifically beta-carot
./___Corpus/Medline/xml/PMC4635070.xml	beta-carotene	81214 : 81227	CM	arotenoids, specifically beta-carotene, have anticancer propert
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81335 : 81343	CM	 antioxidant activity of lycopene was twice that of beta-c
./___Corpus/Medline/xml/PMC4635070.xml	beta-carotene	81362 : 81375	CM	copene was twice that of beta-carotene there has been a growing
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81420 : 81428	CM	owing interest regarding lycopene as a possible anticancer
./___Corpus/Medline/xml/PMC4635070.xml	10–	81504 : 81507	CPR	                    Only 10–30% of the lycopene in di
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81518 : 81526	CM	      Only 10–30% of the lycopene in dietary sources can b
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81663 : 81671	CM	 has been suggested that lycopene is better absorbed when 
./___Corpus/Medline/xml/PMC4635070.xml	lipophilic	81738 : 81748	CM	ion with fats due to its lipophilic properties [474]. Once i
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81782 : 81790	CM	es [474]. Once ingested, lycopene is incorporated into lip
./___Corpus/Medline/xml/PMC4635070.xml	lipid	81812 : 81817	CM	ene is incorporated into lipid micelles and absorbed by
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	81975 : 81983	CM	eins are the carriers of lycopene in the blood stream and 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82037 : 82045	CM	means by which bioactive lycopene gains access to the vari
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82112 : 82120	CM	. High concentrations of lycopene have been found in the t
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	82232 : 82240	CM	                         Lycopene is a constituent of huma
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	82415 : 82423	CM	t various cancers [476]. Lycopene is a powerful antioxidan
./___Corpus/Medline/xml/PMC4635070.xml	oxygen	82510 : 82516	CM	cals which are activated oxygen molecules that can damag
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82656 : 82664	CM	ous studies suggest that lycopene and lycopene rich natura
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82669 : 82677	CM	uggest that lycopene and lycopene rich natural dietary pro
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	82934 : 82942	CM	great interest regarding lycopene and prostate cancer; abo
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83041 : 83049	CM	54) that have considered lycopene concern prostate cancer.
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83109 : 83117	CM	iation of a diet rich in lycopene from tomato-based foods 
./___Corpus/Medline/xml/PMC4635070.xml	481–	83213 : 83217	CPR	ted by multiple studies [481–485].                    
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	83464 : 83472	CM	ases and carcinogenesis. Lycopene has been found to increa
./___Corpus/Medline/xml/PMC4635070.xml	epoxide	83547 : 83554	CM	cation proteins (such as epoxide hydrolase-1) and protect
./___Corpus/Medline/xml/PMC4635070.xml	hydrolase-1	83555 : 83566	CM	roteins (such as epoxide hydrolase-1) and protective enzymes 
./___Corpus/Medline/xml/PMC4635070.xml	glutathione-S-transferase-omega-1	83600 : 83633	CM	tective enzymes (such as glutathione-S-transferase-omega-1, peroxiredoxin-1 and sul
./___Corpus/Medline/xml/PMC4635070.xml	peroxiredoxin-1	83635 : 83650	CM	e-S-transferase-omega-1, peroxiredoxin-1 and sulphide-quinone oxi
./___Corpus/Medline/xml/PMC4635070.xml	quinone	83664 : 83671	CM	xiredoxin-1 and sulphide-quinone oxidoreductase) [486]. O
./___Corpus/Medline/xml/PMC4635070.xml	oxidoreductase	83672 : 83686	CM	n-1 and sulphide-quinone oxidoreductase) [486]. Other studies ha
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83725 : 83733	CM	 studies have shown that lycopene downregulates the genes 
./___Corpus/Medline/xml/PMC4635070.xml	ROS	83811 : 83814	CM	ved in the generation of ROS, including ERO1-like pro
./___Corpus/Medline/xml/PMC4635070.xml	ERO1	83826 : 83830	CM	ration of ROS, including ERO1-like protein-a and CLIC-
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83877 : 83885	CM	IC-1 [487]. In addition, lycopene may prevent cancers, esp
./___Corpus/Medline/xml/PMC4635070.xml	vitro	83960 : 83965	CM	via other mechanisms. In vitro studies have shown that 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	83990 : 83998	CM	 studies have shown that lycopene-induced activation of th
./___Corpus/Medline/xml/PMC4635070.xml	(PPAR)-gamma-LXR alpha-ABCA1	84069 : 84097	CM	ator-activated receptors (PPAR)-gamma-LXR alpha-ABCA1 pathway is associated wi
./___Corpus/Medline/xml/PMC4635070.xml	LNCaP prostate	84152 : 84166	CM	creased proliferation of LNCaP prostate cancer cells [488, 489].
./___Corpus/Medline/xml/PMC4635070.xml	LNCaP	84197 : 84202	CM	r cells [488, 489]. When LNCaP cells were exposed to ly
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84225 : 84233	CM	aP cells were exposed to lycopene, a dose-dependent decrea
./___Corpus/Medline/xml/PMC4635070.xml	G0	84268 : 84270	CM	ependent decrease of the G0/G1 phase-related protein
./___Corpus/Medline/xml/PMC4635070.xml	G1	84271 : 84273	CM	ndent decrease of the G0/G1 phase-related protein, c
./___Corpus/Medline/xml/PMC4635070.xml	cyclin	84297 : 84303	CM	1 phase-related protein, cyclin D1, and an increase in t
./___Corpus/Medline/xml/PMC4635070.xml	cyclin	84331 : 84337	CM	, and an increase in the cyclin kinase inhibitors, p53, 
./___Corpus/Medline/xml/PMC4635070.xml	p53	84357 : 84360	CM	yclin kinase inhibitors, p53, p21 and p27 have been n
./___Corpus/Medline/xml/PMC4635070.xml	vitro	84449 : 84454	CM	e arrest [490]. Other in vitro studies suggest that lyc
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84476 : 84484	CM	tro studies suggest that lycopene may induce apoptosis in 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	84594 : 84602	CM	ling study revealed that lycopene may upregulate pro-apopt
./___Corpus/Medline/xml/PMC4635070.xml	vitro	84735 : 84740	CM	atic epithelial cells in vitro [487]. Lycopene has also
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	84748 : 84756	CM	al cells in vitro [487]. Lycopene has also been shown to s
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	84932 : 84940	CM	                         Lycopene has also been shown to h
./___Corpus/Medline/xml/PMC4635070.xml	vitro	85005 : 85010	CM	atory effects in both in vitro studies that assessed ma
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85087 : 85095	CM	 studies. In particular, lycopene has been associated with
./___Corpus/Medline/xml/PMC4635070.xml	492–	85229 : 85233	CPR	 stimulated macrophages [492–494]. Also, in a rat mode
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85321 : 85329	CM	-α were notably lower in lycopene-treated versus control a
./___Corpus/Medline/xml/PMC4635070.xml	TNF	85389 : 85392	CM	5]. Similarly, decreased TNF expression and secretion
./___Corpus/Medline/xml/PMC4635070.xml	vitro	85477 : 85482	CM	r of endothelial cell in vitro studies [496, 497]. Modu
./___Corpus/Medline/xml/PMC4635070.xml	ERK	85620 : 85623	CM	ntiinflammatory effects: ERK, NF-κB, JNK, and HMGB1 [
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	85625 : 85630	CM	flammatory effects: ERK, NF-κB, JNK, and HMGB1 [492–494
./___Corpus/Medline/xml/PMC4635070.xml	JNK	85632 : 85635	CM	ory effects: ERK, NF-κB, JNK, and HMGB1 [492–494, 496
./___Corpus/Medline/xml/PMC4635070.xml	HMGB1	85641 : 85646	CM	ts: ERK, NF-κB, JNK, and HMGB1 [492–494, 496, 497].    
./___Corpus/Medline/xml/PMC4635070.xml	492–	85648 : 85652	CPR	, NF-κB, JNK, and HMGB1 [492–494, 496, 497].          
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85737 : 85745	CM	not clear whether or not lycopene predisposes patients to 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	85842 : 85850	CM	is limited evidence that lycopene and other carotenoids ha
./___Corpus/Medline/xml/PMC4635070.xml	carotenoids	85861 : 85872	CM	 that lycopene and other carotenoids have antiinflammatory ef
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86032 : 86040	CM	r intravenously injected lycopene produced prolonged survi
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86157 : 86165	CM	acts.com, a total of 143 lycopene drug adverse event repor
./___Corpus/Medline/xml/PMC4635070.xml	FDA	86214 : 86217	CM	rts were reported to the FDA between January 2004 and
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86300 : 86308	CM	tious complications, but lycopene was not thought to be th
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86511 : 86519	CM	 anticancer perspective, lycopene treatment promoted promo
./___Corpus/Medline/xml/PMC4635070.xml	NK	86584 : 86586	CM	ocyte proliferation, and NK activity in vivo in mice
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	86657 : 86665	CM	tudy on mice showed that lycopene significantly attenuates
./___Corpus/Medline/xml/PMC4635070.xml	murine	86709 : 86715	CM	nuates the maturation of murine bone marrow-derived dend
./___Corpus/Medline/xml/PMC4635070.xml	CD80	86822 : 86826	CM	costimulatory molecules (CD80 and CD86) and major hist
./___Corpus/Medline/xml/PMC4635070.xml	CD86	86831 : 86835	CM	tory molecules (CD80 and CD86) and major histocompatib
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87006 : 87014	CM	        Studies in which lycopene was orally administered 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87130 : 87138	CM	 toxicity related to the lycopene in rats or mice, however
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87191 : 87199	CM	n a dog, accumulation of lycopene and vitamin A in the liv
./___Corpus/Medline/xml/PMC4635070.xml	vitamin A	87204 : 87213	CM	mulation of lycopene and vitamin A in the liver, and excess
./___Corpus/Medline/xml/PMC4635070.xml	vitamin A	87239 : 87248	CM	in the liver, and excess vitamin A in the kidneys were note
./___Corpus/Medline/xml/PMC4635070.xml	fatty	87306 : 87311	CM	pigmentation and colored fatty deposits in the liver we
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87391 : 87399	CM	ed high large amounts of lycopene daily over a period of y
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87505 : 87513	CM	tar rats that were given lycopene in their diets (a range 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	87968 : 87976	CM	                 Dietary lycopene, from eating fruits and 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88100 : 88108	CM	. The optimum dosage for lycopene has not been established
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88260 : 88268	CM	 some studies who took a lycopene-rich tomato supplement o
./___Corpus/Medline/xml/PMC4635070.xml	Lycopene	88422 : 88430	CM	tion, gas, and bloating. Lycopene at higher doses, especia
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	88769 : 88777	CM	ing antioxidants such as lycopene may interfere with radia
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	89288 : 89296	CM	s needed to confirm that lycopene-rich foods can help prev
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	89416 : 89424	CM	 benefits and effects of lycopene supplements and its mech
./___Corpus/Medline/xml/PMC4635070.xml	Anthocyanins	89491 : 89503	CM	n vivo.                  Anthocyanins                      A d
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	89553 : 89565	CM	iet rich in polyphenolic anthocyanins (ACs) has been reported 
./___Corpus/Medline/xml/PMC4635070.xml	ACs	89567 : 89570	CM	lyphenolic anthocyanins (ACs) has been reported as a 
./___Corpus/Medline/xml/PMC4635070.xml	N-nitrosomethylbenzylamine	89705 : 89731	CM	bited the development of N-nitrosomethylbenzylamine- induced esophageal canc
./___Corpus/Medline/xml/PMC4635070.xml	N-	89731 : 89733	CPR	-nitrosomethylbenzylamine- induced esophageal cancer
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	89857 : 89862	CM	ammatory biomarkers like COX-2, iNOS, p-NF-κB, and solu
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	89864 : 89868	CM	y biomarkers like COX-2, iNOS, p-NF-κB, and soluble ep
./___Corpus/Medline/xml/PMC4635070.xml	p-NF-κB	89870 : 89877	CM	arkers like COX-2, iNOS, p-NF-κB, and soluble epoxide hyd
./___Corpus/Medline/xml/PMC4635070.xml	epoxide	89891 : 89898	CM	OS, p-NF-κB, and soluble epoxide hydrolase (sEH)) and cyt
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	89920 : 89928	CM	ide hydrolase (sEH)) and cytokine, pentraxin-3 (PTX3) expr
./___Corpus/Medline/xml/PMC4635070.xml	pentraxin-3	89930 : 89941	CM	ase (sEH)) and cytokine, pentraxin-3 (PTX3) expression [505].
./___Corpus/Medline/xml/PMC4635070.xml	PTX3	89943 : 89947	CM	d cytokine, pentraxin-3 (PTX3) expression [505]. AC-ri
./___Corpus/Medline/xml/PMC4635070.xml	AC	89967 : 89969	CM	(PTX3) expression [505]. AC-rich black currant skin 
./___Corpus/Medline/xml/PMC4635070.xml	lipid	90069 : 90074	CM	wnregulation of abnormal lipid peroxidation, protein ox
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	90126 : 90130	CM	ation, and expression of iNOS and 3-nitrotyrosine (3-N
./___Corpus/Medline/xml/PMC4635070.xml	3-nitrotyrosine	90135 : 90150	CM	d expression of iNOS and 3-nitrotyrosine (3-NT) in a dose-respons
./___Corpus/Medline/xml/PMC4635070.xml	3-NT	90152 : 90156	CM	NOS and 3-nitrotyrosine (3-NT) in a dose-responsive fa
./___Corpus/Medline/xml/PMC4635070.xml	Nrf2	90283 : 90287	CM	 of hepatic antioxidant (Nrf2-regulated antioxidant pa
./___Corpus/Medline/xml/PMC4635070.xml	carcinogen	90323 : 90333	CM	antioxidant pathway) and carcinogen detoxifying enzymes, suc
./___Corpus/Medline/xml/PMC4635070.xml	NAD(P)H	90363 : 90370	CM	xifying enzymes, such as NAD(P)H:quinone oxidoreductase, 
./___Corpus/Medline/xml/PMC4635070.xml	quinone	90371 : 90378	CM	enzymes, such as NAD(P)H:quinone oxidoreductase, glutathi
./___Corpus/Medline/xml/PMC4635070.xml	oxidoreductase	90379 : 90393	CM	 such as NAD(P)H:quinone oxidoreductase, glutathione S-transfera
./___Corpus/Medline/xml/PMC4635070.xml	glutathione	90395 : 90406	CM	:quinone oxidoreductase, glutathione S-transferase, and uridi
./___Corpus/Medline/xml/PMC4635070.xml	S-	90407 : 90409	CPR	doreductase, glutathione S-transferase, and uridine 
./___Corpus/Medline/xml/PMC4635070.xml	uridine diphosphate	90426 : 90445	CM	hione S-transferase, and uridine diphosphate-glucuronosyltransferase 
./___Corpus/Medline/xml/PMC4635070.xml	glucuronosyltransferase	90446 : 90469	CM	 and uridine diphosphate-glucuronosyltransferase isoenzymes in diethylnit
./___Corpus/Medline/xml/PMC4635070.xml	diethylnitrosamine	90484 : 90502	CM	ransferase isoenzymes in diethylnitrosamine (DENA)-initiated hepatoc
./___Corpus/Medline/xml/PMC4635070.xml	DENA	90504 : 90508	CM	s in diethylnitrosamine (DENA)-initiated hepatocarcino
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	90570 : 90582	CM	ats [506]. Black currant anthocyanins also abrogated elevated 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	90637 : 90642	CM	mmatory markers, such as COX-2 and NF-κB, during DENA h
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	90647 : 90652	CM	rkers, such as COX-2 and NF-κB, during DENA hepatocarci
./___Corpus/Medline/xml/PMC4635070.xml	DENA	90661 : 90665	CM	 COX-2 and NF-κB, during DENA hepatocarcinogenesis in 
./___Corpus/Medline/xml/PMC4635070.xml	ACs	90740 : 90743	CM	                         ACs also exerted an antiinfl
./___Corpus/Medline/xml/PMC4635070.xml	H	90787 : 90788	CM	tiinflammatory effect in H. pylori-infected gastric
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	90849 : 90857	CM	 cells. The inflammatory cytokine IL-8 and ROS increase in
./___Corpus/Medline/xml/PMC4635070.xml	ROS	90867 : 90870	CM	matory cytokine IL-8 and ROS increase in the H. pylor
./___Corpus/Medline/xml/PMC4635070.xml	H	90887 : 90888	CM	 and ROS increase in the H. pylori-infected gastric
./___Corpus/Medline/xml/PMC4635070.xml	ACs	90929 : 90932	CM	d gastric mucosa. First, ACs inhibit the phosphorylat
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	90945 : 90960	RN	. First, ACs inhibit the phosphorylation of MAPKs, translocation 
./___Corpus/Medline/xml/PMC4635070.xml	MAPKs	90964 : 90969	CM	t the phosphorylation of MAPKs, translocation of NF-κB 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	90988 : 90993	CM	 MAPKs, translocation of NF-κB and IκBα degradation. Se
./___Corpus/Medline/xml/PMC4635070.xml	IκBα	90998 : 91002	CM	anslocation of NF-κB and IκBα degradation. Secondly, t
./___Corpus/Medline/xml/PMC4635070.xml	H	91044 : 91045	CM	ondly, they also inhibit H. pylori-induced iNOS and
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	91062 : 91066	CM	nhibit H. pylori-induced iNOS and COX-2 mRNA expressio
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	91071 : 91076	CM	 pylori-induced iNOS and COX-2 mRNA expression and IL-8
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	91077 : 91081	CM	i-induced iNOS and COX-2 mRNA expression and IL-8 prod
./___Corpus/Medline/xml/PMC4635070.xml	IL-8	91097 : 91101	CM	OX-2 mRNA expression and IL-8 production [508]. Additi
./___Corpus/Medline/xml/PMC4635070.xml	vitro	91137 : 91142	CM	 [508]. Additionally, in vitro studies showed that the 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91167 : 91179	CM	 studies showed that the anthocyanins inhibit the mRNA and/or 
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	91192 : 91196	CM	anthocyanins inhibit the mRNA and/or protein expressio
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	91233 : 91238	CM	ein expression levels of COX-2, NF-κB and various inter
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	91240 : 91245	CM	ression levels of COX-2, NF-κB and various interleukins
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91408 : 91420	CM	ese studies suggest that anthocyanins significantly inhibit in
./___Corpus/Medline/xml/PMC4635070.xml	nitric oxide	91486 : 91498	CM	atory mediators, such as nitric oxide (NO) and prostaglandin E
./___Corpus/Medline/xml/PMC4635070.xml	NO	91500 : 91502	CM	s, such as nitric oxide (NO) and prostaglandin E2, a
./___Corpus/Medline/xml/PMC4635070.xml	prostaglandin	91508 : 91521	CM	as nitric oxide (NO) and prostaglandin E2, as well as proinflam
./___Corpus/Medline/xml/PMC4635070.xml	Anthocyanins	91624 : 91636	CM	ignificant cytotoxicity. Anthocyanins also downregulated exces
./___Corpus/Medline/xml/PMC4635070.xml	NO	91690 : 91692	CM	 expression of inducible NO synthase, COX-2, TNF-α, 
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	91703 : 91708	CM	f inducible NO synthase, COX-2, TNF-α, and IL-1β in a d
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91786 : 91798	CM	erent cancers. Moreover, anthocyanins inhibited nuclear transl
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	91834 : 91839	CM	nuclear translocation of NF-κB and IκBα degradation as 
./___Corpus/Medline/xml/PMC4635070.xml	IκBα	91844 : 91848	CM	anslocation of NF-κB and IκBα degradation as well as p
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylating	91872 : 91887	RN	α degradation as well as phosphorylating MAPKs.                  
./___Corpus/Medline/xml/PMC4635070.xml	MAPKs	91888 : 91893	CM	 well as phosphorylating MAPKs.                        
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	91980 : 91992	CM	ntiinflammatory effects, anthocyanins have been shown to inhib
./___Corpus/Medline/xml/PMC4635070.xml	SKHep-1	92047 : 92054	CM	e growth and invasion of SKHep-1 cells through reduced ex
./___Corpus/Medline/xml/PMC4635070.xml	MMP-9	92091 : 92096	CM	gh reduced expression of MMP-9 and urokinase plasminoge
./___Corpus/Medline/xml/PMC4635070.xml	urokinase	92101 : 92110	CM	 expression of MMP-9 and urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4635070.xml	u-PA	92134 : 92138	CM	e plasminogen activator (u-PA) [511]. Similarly, a MMP
./___Corpus/Medline/xml/PMC4635070.xml	MMP-9	92160 : 92165	CM	-PA) [511]. Similarly, a MMP-9 and u-PA mediated reduct
./___Corpus/Medline/xml/PMC4635070.xml	u-PA	92170 : 92174	CM	. Similarly, a MMP-9 and u-PA mediated reduction of mi
./___Corpus/Medline/xml/PMC4635070.xml	A549	92254 : 92258	CM	ved in highly metastatic A549 human lung carcinoma cel
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-rutinoside	92294 : 92315	CM	 carcinoma cells through cyanidin 3-rutinoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	92320 : 92340	CM	yanidin 3-rutinoside and cyanidin 3-glucoside (anthocyanins). This inh
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92342 : 92354	CM	nd cyanidin 3-glucoside (anthocyanins). This inhibition was al
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	92436 : 92441	CM	 activation of c-Jun and NF-κB [512]. Treatment with an
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92464 : 92476	CM	κB [512]. Treatment with anthocyanins (such as delphinidin, cy
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	92486 : 92497	CM	th anthocyanins (such as delphinidin, cyanidin, and pelargoni
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	92499 : 92507	CM	ns (such as delphinidin, cyanidin, and pelargonidin) in no
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	92513 : 92525	CM	lphinidin, cyanidin, and pelargonidin) in normal human epiderm
./___Corpus/Medline/xml/PMC4635070.xml	UV-B	92577 : 92581	CM	 keratinocytes inhibited UV-B-mediated degradation and
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	92607 : 92622	RN	mediated degradation and phosphorylation of IκBα and activation o
./___Corpus/Medline/xml/PMC4635070.xml	IκBα	92626 : 92630	CM	n and phosphorylation of IκBα and activation of IKKα w
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	92704 : 92719	RN	uclear translocation and phosphorylation of NF-κB/p65 at Ser (536
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	92723 : 92728	CM	n and phosphorylation of NF-κB/p65 at Ser (536) [513]. 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	92831 : 92843	CM	st be exercised, because anthocyanins are often addressed as a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	92988 : 93002	CM	ome studies also look at anthocyanidins (which are similar to an
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93025 : 93037	CM	ns (which are similar to anthocyanins but without sugar moieti
./___Corpus/Medline/xml/PMC4635070.xml	sugar	93050 : 93055	CM	anthocyanins but without sugar moieties). Both anthocya
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93072 : 93084	CM	ut sugar moieties). Both anthocyanins and anthocyanidins (espe
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93089 : 93103	CM	). Both anthocyanins and anthocyanidins (especially cyanidin and
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	93116 : 93124	CM	thocyanidins (especially cyanidin and delphinidin) have be
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	93129 : 93140	CM	(especially cyanidin and delphinidin) have been subjected to 
./___Corpus/Medline/xml/PMC4635070.xml	tyrosine	93328 : 93336	CM	tion factors and protein tyrosine kinases. Water soluble a
./___Corpus/Medline/xml/PMC4635070.xml	Water	93346 : 93351	CM	rotein tyrosine kinases. Water soluble anthocyanins are
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	93360 : 93372	CM	e kinases. Water soluble anthocyanins are mostly 3-glucosides 
./___Corpus/Medline/xml/PMC4635070.xml	3-glucosides	93384 : 93396	CM	 anthocyanins are mostly 3-glucosides of the anthocyanidins. T
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93404 : 93418	CM	stly 3-glucosides of the anthocyanidins. The most common anthocy
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	93436 : 93450	CM	anidins. The most common anthocyanidins are pelargonidin, delphi
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	93455 : 93467	CM	ommon anthocyanidins are pelargonidin, delphinidin, peonidin, 
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	93469 : 93480	CM	nidins are pelargonidin, delphinidin, peonidin, petunidin, ma
./___Corpus/Medline/xml/PMC4635070.xml	malvidin	93503 : 93511	CM	in, peonidin, petunidin, malvidin and cyanidin. Peonidin 3
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	93516 : 93524	CM	 petunidin, malvidin and cyanidin. Peonidin 3-glucoside an
./___Corpus/Medline/xml/PMC4635070.xml	3-glucoside	93535 : 93546	CM	n and cyanidin. Peonidin 3-glucoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	93551 : 93571	CM	Peonidin 3-glucoside and cyanidin 3-glucoside extracted from black ric
./___Corpus/Medline/xml/PMC4635070.xml	SKHep-1	93660 : 93667	CM	e growth and invasion of SKHep-1 cells through reduced ex
./___Corpus/Medline/xml/PMC4635070.xml	MMP-9	93704 : 93709	CM	gh reduced expression of MMP-9 and urokinase plasminoge
./___Corpus/Medline/xml/PMC4635070.xml	urokinase	93714 : 93723	CM	 expression of MMP-9 and urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4635070.xml	u-PA	93747 : 93751	CM	e plasminogen activator (u-PA) [511]. Similarly, MMP-9
./___Corpus/Medline/xml/PMC4635070.xml	MMP-9	93771 : 93776	CM	(u-PA) [511]. Similarly, MMP-9 and u-PA mediated reduct
./___Corpus/Medline/xml/PMC4635070.xml	u-PA	93781 : 93785	CM	1]. Similarly, MMP-9 and u-PA mediated reduction of mi
./___Corpus/Medline/xml/PMC4635070.xml	A549	93865 : 93869	CM	ved in highly metastatic A549 human lung carcinoma cel
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-rutinoside	93905 : 93926	CM	 carcinoma cells through cyanidin 3-rutinoside and cyanidin 3-glucoside
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin 3-glucoside	93931 : 93951	CM	yanidin 3-rutinoside and cyanidin 3-glucoside (extracted from Morus al
./___Corpus/Medline/xml/PMC4635070.xml	Morus	93968 : 93973	CM	lucoside (extracted from Morus alba). This inhibition w
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	94060 : 94065	CM	 activation of c-Jun and NF-κB [512].                  
./___Corpus/Medline/xml/PMC4635070.xml	delphinidin	94146 : 94157	CM	with pomegranate-derived delphinidin, cyanidin, and pelargoni
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin	94159 : 94167	CM	ate-derived delphinidin, cyanidin, and pelargonidin in nor
./___Corpus/Medline/xml/PMC4635070.xml	pelargonidin	94173 : 94185	CM	lphinidin, cyanidin, and pelargonidin in normal human epiderma
./___Corpus/Medline/xml/PMC4635070.xml	UV-B	94236 : 94240	CM	 keratinocytes inhibited UV-B-mediated degradation and
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	94266 : 94281	RN	mediated degradation and phosphorylation of IκBα and activation o
./___Corpus/Medline/xml/PMC4635070.xml	IκBα	94285 : 94289	CM	n and phosphorylation of IκBα and activation of IKKα w
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	94363 : 94378	RN	uclear translocation and phosphorylation of NF-κB/p65 at Ser [513
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	94382 : 94387	CM	n and phosphorylation of NF-κB/p65 at Ser [513]. Based 
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94447 : 94461	CM	umulating evidence, pure anthocyanidins as well as berry extract
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidin	94502 : 94515	CM	y extracts enriched with anthocyanidin showed higher chemopreve
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	94587 : 94598	CM	berry extracts with high anthocyanin. The major points of con
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	94687 : 94699	CM	ndent interconversion of anthocyanins and anthocyanidins, a gr
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94704 : 94718	CM	sion of anthocyanins and anthocyanidins, a greater susceptibilit
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	94748 : 94762	CM	reater susceptibility of anthocyanidins (in comparison to the gl
./___Corpus/Medline/xml/PMC4635070.xml	glycosides	94785 : 94795	CM	ns (in comparison to the glycosides) to chemical decompositi
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	94974 : 94986	CM	of berry extract rich in anthocyanins have been reported by Hu
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidin	95053 : 95066	CM	4] who demonstrated that anthocyanidin rich fractions inhibit T
./___Corpus/Medline/xml/PMC4635070.xml	IL-2	95115 : 95119	CM	T-cell proliferation and IL-2 production on anti-CD3 p
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD3	95134 : 95142	CM	n and IL-2 production on anti-CD3 plus anti-CD28-activated
./___Corpus/Medline/xml/PMC4635070.xml	anti-	95148 : 95153	CPR	duction on anti-CD3 plus anti-CD28-activated primary hu
./___Corpus/Medline/xml/PMC4635070.xml	anti-	95157 : 95162	CPR	n anti-CD3 plus anti-CD28-activated primary human T-lym
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	95247 : 95261	CM	 very little research on anthocyanidins and the immune system in
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95446 : 95458	CM	se findings suggest that anthocyanins offer substantial chemop
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	95589 : 95600	CM	g the bioavailability of anthocyanin. Only a small portion of
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95642 : 95654	CM	rtion of orally ingested anthocyanins is absorbed (<1 %). Maxi
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95763 : 95775	CM	. About 68 % of absorbed anthocyanins are metabolized, and exc
./___Corpus/Medline/xml/PMC4635070.xml	monoglucuronides	95809 : 95825	CM	bolized, and excreted as monoglucuronides [515]. Low bioavailabili
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95860 : 95872	CM	w bioavailability of the anthocyanins is due to to their exten
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	95987 : 95999	CM	 gut microflora degrades anthocyanins to release simple phenol
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin glycosides	96177 : 96199	CM	rvation and suggest that anthocyanin glycosides remain intact during abs
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96271 : 96291	CM	h the bioavailability of cyanidin-3-glucoside and anthocyanin as shown
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanin	96296 : 96307	CM	cyanidin-3-glucoside and anthocyanin as shown through the abo
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96406 : 96426	CM	ystemic levels of parent cyanidin-3-glucoside and total anthocyanins a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96437 : 96449	CM	in-3-glucoside and total anthocyanins as 1.7% and 3.3% respect
./___Corpus/Medline/xml/PMC4635070.xml	C57BL6J	96483 : 96490	CM	and 3.3% respectively in C57BL6J mice that received cyani
./___Corpus/Medline/xml/PMC4635070.xml	cyanidin-3-glucoside	96510 : 96530	CM	7BL6J mice that received cyanidin-3-glucoside by oral gavage or tail v
./___Corpus/Medline/xml/PMC4635070.xml	vitro	96634 : 96639	CM	     Overall, in most in vitro and in vivo assays antho
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96659 : 96671	CM	vitro and in vivo assays anthocyanins are not genotoxic. Some 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	96749 : 96754	CM	 provided by a single in vitro study using pure anthocy
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanidins	96772 : 96786	CM	n vitro study using pure anthocyanidins. However, the genotoxici
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	96994 : 97006	CM	 were observed at 3 g/kg anthocyanins and 15 % of grape-skin e
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	97102 : 97114	CM	with 6 g/day unspecified anthocyanins extract or grape seed ex
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	97295 : 97307	CM	ty or carcinogenicity of anthocyanins [515].                  
./___Corpus/Medline/xml/PMC4635070.xml	GEN	97374 : 97377	CM	              Genistein (GEN) is a prominent isoflavo
./___Corpus/Medline/xml/PMC4635070.xml	isoflavone	97394 : 97404	CM	ein (GEN) is a prominent isoflavone which inhibits cell grow
./___Corpus/Medline/xml/PMC4635070.xml	vitro	97457 : 97462	CM	and induces apoptosis in vitro and in vivo without toxi
./___Corpus/Medline/xml/PMC4635070.xml	AKT	97526 : 97529	CM	]. It inhibits activated AKT, the downstream target o
./___Corpus/Medline/xml/PMC4635070.xml	GEN	97700 : 97703	CM	cer [523]. Additionally, GEN inhibits the activity of
./___Corpus/Medline/xml/PMC4635070.xml	Akt	97729 : 97732	CM	inhibits the activity of Akt-targets like FOXM1 in pa
./___Corpus/Medline/xml/PMC4635070.xml	FOXM1	97746 : 97751	CM	vity of Akt-targets like FOXM1 in pancreatic cancer cel
./___Corpus/Medline/xml/PMC4635070.xml	FOXO3	97789 : 97794	CM	c cancer cells [520] and FOXO3 [524] in colon cancer ce
./___Corpus/Medline/xml/PMC4635070.xml	AKT	97824 : 97827	CM	] in colon cancer cells. AKT also forms a complex wit
./___Corpus/Medline/xml/PMC4635070.xml	TERT	97860 : 97864	CM	rms a complex with human TERT, heat shock protein 90, 
./___Corpus/Medline/xml/PMC4635070.xml	p70S6	97889 : 97894	CM	, heat shock protein 90, p70S6 kinase and mTOR and GEN 
./___Corpus/Medline/xml/PMC4635070.xml	mTOR	97906 : 97910	CM	ein 90, p70S6 kinase and mTOR and GEN restrains the fo
./___Corpus/Medline/xml/PMC4635070.xml	GEN	97915 : 97918	CM	70S6 kinase and mTOR and GEN restrains the formation 
./___Corpus/Medline/xml/PMC4635070.xml	GEN	97993 : 97996	CM	 pancreatic cancer cells GEN inhibits growth via inac
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98042 : 98045	CM	inactivation of Notch- 1/AKT/FOXM1 [520]. Estrogen re
./___Corpus/Medline/xml/PMC4635070.xml	FOXM1	98046 : 98051	CM	tivation of Notch- 1/AKT/FOXM1 [520]. Estrogen receptor
./___Corpus/Medline/xml/PMC4635070.xml	Estrogen	98059 : 98067	CM	otch- 1/AKT/FOXM1 [520]. Estrogen receptor-β/AKT mediated 
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98079 : 98082	CM	20]. Estrogen receptor-β/AKT mediated inhibition was 
./___Corpus/Medline/xml/PMC4635070.xml	DLD-1	98124 : 98129	CM	ion was also observed in DLD-1 human colon adenocarcino
./___Corpus/Medline/xml/PMC4635070.xml	GEN	98170 : 98173	CM	nocarcinoma cells [526]. GEN also targets AKT and p21
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98187 : 98190	CM	 [526]. GEN also targets AKT and p21 WAF1/CIP1 in BRC
./___Corpus/Medline/xml/PMC4635070.xml	WAF1	98199 : 98203	CM	also targets AKT and p21 WAF1/CIP1 in BRCA1-mutant hum
./___Corpus/Medline/xml/PMC4635070.xml	CIP1	98204 : 98208	CM	targets AKT and p21 WAF1/CIP1 in BRCA1-mutant human br
./___Corpus/Medline/xml/PMC4635070.xml	GEN	98263 : 98266	CM	cancer cell lines [527], GEN induced AKT-mediated enh
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98275 : 98278	CM	lines [527], GEN induced AKT-mediated enhanced apopto
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98325 : 98328	CM	ptosis/downregulation of AKT has also been reported i
./___Corpus/Medline/xml/PMC4635070.xml	arsenic trioxide	98387 : 98403	CM	tion with compounds like arsenic trioxide in human hepatocellular 
./___Corpus/Medline/xml/PMC4635070.xml	gefitinib	98445 : 98454	CM	ellular carcinoma [528], gefitinib in NSCLS [529], gemcitab
./___Corpus/Medline/xml/PMC4635070.xml	NSCLS	98458 : 98463	CM	noma [528], gefitinib in NSCLS [529], gemcitabine in hu
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	98471 : 98482	CM	efitinib in NSCLS [529], gemcitabine in human osteosarcoma [5
./___Corpus/Medline/xml/PMC4635070.xml	cisplatin	98517 : 98526	CM	osteosarcoma [522, 530], cisplatin in cervical cancer cells
./___Corpus/Medline/xml/PMC4635070.xml	hypericin	98623 : 98632	CM	ma [532], photoactivated hypericin in breast cancer cells [
./___Corpus/Medline/xml/PMC4635070.xml	indole-3-carbinol	98666 : 98683	CM	t cancer cells [533] and indole-3-carbinol in human colon cancer HT
./___Corpus/Medline/xml/PMC4635070.xml	HT-29	98706 : 98711	CM	ol in human colon cancer HT-29 cells [534]. GEN also in
./___Corpus/Medline/xml/PMC4635070.xml	GEN	98725 : 98728	CM	ancer HT-29 cells [534]. GEN also inhibits the carcin
./___Corpus/Medline/xml/PMC4635070.xml	estradiol	98778 : 98787	CM	ogenic effect of 17 beta estradiol or bisphenol-A via ER/IG
./___Corpus/Medline/xml/PMC4635070.xml	bisphenol-A	98791 : 98802	CM	 of 17 beta estradiol or bisphenol-A via ER/IGF-1/AKT pathway
./___Corpus/Medline/xml/PMC4635070.xml	ER	98807 : 98809	CM	adiol or bisphenol-A via ER/IGF-1/AKT pathway in BG-
./___Corpus/Medline/xml/PMC4635070.xml	IGF-1	98810 : 98815	CM	ol or bisphenol-A via ER/IGF-1/AKT pathway in BG-1 ovar
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98816 : 98819	CM	bisphenol-A via ER/IGF-1/AKT pathway in BG-1 ovarian 
./___Corpus/Medline/xml/PMC4635070.xml	BG-1	98831 : 98835	CM	 ER/IGF-1/AKT pathway in BG-1 ovarian cancer cells [53
./___Corpus/Medline/xml/PMC4635070.xml	FOXO3	98886 : 98891	CM	] and also downregulates FOXO3 activity in colon cancer
./___Corpus/Medline/xml/PMC4635070.xml	MAPKs	98948 : 98953	CM	[524]. It also modulates MAPKs/AKT in cervical cancer c
./___Corpus/Medline/xml/PMC4635070.xml	AKT	98954 : 98957	CM	 It also modulates MAPKs/AKT in cervical cancer cells
./___Corpus/Medline/xml/PMC4635070.xml	GEN	99053 : 99056	CM	-induced mammospheres by GEN was similar to the AKT i
./___Corpus/Medline/xml/PMC4635070.xml	AKT	99076 : 99079	CM	y GEN was similar to the AKT inhibitor perifosine and
./___Corpus/Medline/xml/PMC4635070.xml	perifosine	99090 : 99100	CM	lar to the AKT inhibitor perifosine and was related to enhan
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	99146 : 99150	CM	nhanced tumor suppressor PTEN expressions [537]. Incre
./___Corpus/Medline/xml/PMC4635070.xml	ceramide	99180 : 99188	CM	essions [537]. Increased ceramide and lipid raft cholester
./___Corpus/Medline/xml/PMC4635070.xml	lipid	99193 : 99198	CM	. Increased ceramide and lipid raft cholesterol accompa
./___Corpus/Medline/xml/PMC4635070.xml	cholesterol	99204 : 99215	CM	 ceramide and lipid raft cholesterol accompanied with geniste
./___Corpus/Medline/xml/PMC4635070.xml	genistein	99233 : 99242	CM	esterol accompanied with genistein inhibited the cell viabi
./___Corpus/Medline/xml/PMC4635070.xml	p70S6k	99338 : 99344	CM	contribution of EGFR-AKT/p70S6k pathway and down-regulat
./___Corpus/Medline/xml/PMC4635070.xml	androgen	99376 : 99384	CM	y and down-regulation of androgen receptor [538, 539].    
./___Corpus/Medline/xml/PMC4635070.xml	genistein	99478 : 99487	CM	rts also show a distinct genistein effect whereby it induce
./___Corpus/Medline/xml/PMC4635070.xml	PI3K	99514 : 99518	CM	ffect whereby it induces PI3K/AKT nongenomic ER signal
./___Corpus/Medline/xml/PMC4635070.xml	AKT	99519 : 99522	CM	 whereby it induces PI3K/AKT nongenomic ER signaling 
./___Corpus/Medline/xml/PMC4635070.xml	ER	99534 : 99536	CM	uces PI3K/AKT nongenomic ER signaling to the histone
./___Corpus/Medline/xml/PMC4635070.xml	histone	99554 : 99561	CM	omic ER signaling to the histone methyltransferase enhanc
./___Corpus/Medline/xml/PMC4635070.xml	methyltransferase	99562 : 99579	CM	signaling to the histone methyltransferase enhancer of zeste homolo
./___Corpus/Medline/xml/PMC4635070.xml	EZH2	99609 : 99613	CM	ncer of zeste homolog 2 (EZH2). As a result, this phos
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylates	99634 : 99648	CM	EZH2). As a result, this phosphorylates and represses EZH2 and r
./___Corpus/Medline/xml/PMC4635070.xml	EZH2	99663 : 99667	CM	phorylates and represses EZH2 and reduces levels of H3
./___Corpus/Medline/xml/PMC4635070.xml	H3K27me3	99690 : 99698	CM	H2 and reduces levels of H3K27me3 repressive mark in chrom
./___Corpus/Medline/xml/PMC4635070.xml	chromatin	99718 : 99727	CM	27me3 repressive mark in chromatin during developmental rep
./___Corpus/Medline/xml/PMC4635070.xml	androgen	99838 : 99846	CM	n cancer cells, membrane androgen receptors (mAR) activati
./___Corpus/Medline/xml/PMC4635070.xml	mAR	99858 : 99861	CM	rane androgen receptors (mAR) activation inhibits the
./___Corpus/Medline/xml/PMC4635070.xml	AKT	99907 : 99910	CM	 the prosurvival signals AKT/Bad in vitro and in vivo
./___Corpus/Medline/xml/PMC4635070.xml	vitro	99918 : 99923	CM	vival signals AKT/Bad in vitro and in vivo and blocks m
./___Corpus/Medline/xml/PMC4635070.xml	actin	100058 : 100063	CM	 adhesion) signaling and actin reorganization, supporti
./___Corpus/Medline/xml/PMC4635070.xml	mAR	100127 : 100130	CM	l tumoristatic effect of mAR receptors. GEN inhibited
./___Corpus/Medline/xml/PMC4635070.xml	actin	100156 : 100161	CM	receptors. GEN inhibited actin reorganization and resto
./___Corpus/Medline/xml/PMC4635070.xml	mARs	100258 : 100262	CM	e tumoristatic effect of mARs [541].                  
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	100356 : 100364	CM	ve been raised about the estrogen-like effects of natural 
./___Corpus/Medline/xml/PMC4635070.xml	isoflavones	100389 : 100400	CM	-like effects of natural isoflavones (i.e., the possible prom
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	100434 : 100442	CM	he possible promotion of estrogen-sensitive cancers) [542–
./___Corpus/Medline/xml/PMC4635070.xml	542–	100463 : 100467	CPR	ogen-sensitive cancers) [542–544]. However, a recent n
./___Corpus/Medline/xml/PMC4635070.xml	meta-	100521 : 100526	CPR	d case-control study and meta-analysis of numerous epid
./___Corpus/Medline/xml/PMC4635070.xml	GEN	100607 : 100610	CM	erse correlation between GEN intake and breast cancer
./___Corpus/Medline/xml/PMC4635070.xml	GEN	100748 : 100751	CM	rified naturally derived GEN administered for up to 3
./___Corpus/Medline/xml/PMC4635070.xml	GEN	100873 : 100876	CM	se II clinical trials of GEN have considered normal d
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101021 : 101024	CM	s were treated with 2 mg GEN per kg body weight and c
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101303 : 101306	CM	d concentrations of free GEN were approximately 140 n
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101340 : 101343	CM	roximately 140 nM in the GEN-treated cohorts while co
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101497 : 101500	CM	ntrolled trial with oral GEN (300 or 600 mg/d) as the
./___Corpus/Medline/xml/PMC4635070.xml	G-2535	101547 : 101553	CM	the purified soy extract G-2535 and found that GEN was m
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101569 : 101572	CM	ct G-2535 and found that GEN was more effective at lo
./___Corpus/Medline/xml/PMC4635070.xml	EGFR	101639 : 101643	CM	er cancer tissue through EGFR phosphorylation but the 
./___Corpus/Medline/xml/PMC4635070.xml	phosphorylation	101644 : 101659	RN	ncer tissue through EGFR phosphorylation but the AKT pathway was 
./___Corpus/Medline/xml/PMC4635070.xml	AKT	101668 : 101671	CM	 phosphorylation but the AKT pathway was unaltered in
./___Corpus/Medline/xml/PMC4635070.xml	GEN	101765 : 101768	CM	e II clinical trial with GEN administered at a dose o
./___Corpus/Medline/xml/PMC4635070.xml	erlotinib	101877 : 101886	CM	study participation with erlotinib, and gemcitabine in adva
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	101892 : 101903	CM	tion with erlotinib, and gemcitabine in advanced pancreatic c
./___Corpus/Medline/xml/PMC4635070.xml	GEN	102166 : 102169	CM	r 12 months (approx 1 mg GEN per kilogram per day) wh
./___Corpus/Medline/xml/PMC4635070.xml	PSA	102265 : 102268	CM	ostate-specific antigen (PSA) when compared to that w
./___Corpus/Medline/xml/PMC4635070.xml	GEN	102462 : 102465	CM	r used soy extract (6 mg GEN per kg per day for 6 mon
./___Corpus/Medline/xml/PMC4635070.xml	PSA	102563 : 102566	CM	cing a decrease in their PSA levels.                 
./___Corpus/Medline/xml/PMC4635070.xml	GEN	102732 : 102735	CM	orted that sub-cutaneous GEN injections (8 mg/kg per 
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	102802 : 102810	CM	mized adult mice lead to estrogen receptor (ER) and non-ER
./___Corpus/Medline/xml/PMC4635070.xml	ER	102821 : 102823	CM	ad to estrogen receptor (ER) and non-ER-mediated inh
./___Corpus/Medline/xml/PMC4635070.xml	CD4(+)CD8(−)	102873 : 102885	CM	ibition of thymocyte and CD4(+)CD8(−) helper T cell lineage ma
./___Corpus/Medline/xml/PMC4635070.xml	GEN	102976 : 102979	CM	nia [514]. Additionally, GEN produced suppression of 
./___Corpus/Medline/xml/PMC4635070.xml	GEN	103090 : 103093	CM	n mice produced by serum GEN levels at 8 mg/kg per da
./___Corpus/Medline/xml/PMC4635070.xml	GEN	103190 : 103193	CM	fed human infants [514]. GEN also appears to compete 
./___Corpus/Medline/xml/PMC4635070.xml	17beta-estradiol	103234 : 103250	CM	 compete with endogenous 17beta-estradiol for estrogen receptors t
./___Corpus/Medline/xml/PMC4635070.xml	estrogen	103255 : 103263	CM	ous 17beta-estradiol for estrogen receptors to suppresses 
./___Corpus/Medline/xml/PMC4635070.xml	OVA	103356 : 103359	CM	0mg/kg GEN downregulated OVA-specific proliferative r
./___Corpus/Medline/xml/PMC4635070.xml	(Ig)G1	103448 : 103454	CM	evels and immunoglobulin (Ig)G1 without reduction in res
./___Corpus/Medline/xml/PMC4635070.xml	anti-CD3	103489 : 103497	CM	eduction in responses to anti-CD3 monoclonal (m)antibody a
./___Corpus/Medline/xml/PMC4635070.xml	CD11c(+)	103551 : 103559	CM	g-presenting activity of CD11c(+) dendritic cells [552]. A
./___Corpus/Medline/xml/PMC4635070.xml	GEN	103587 : 103590	CM	ndritic cells [552]. And GEN has also been shown to p
./___Corpus/Medline/xml/PMC4635070.xml	NK	103753 : 103755	CM	ing the ability of human NK cells to lyse breast can
./___Corpus/Medline/xml/PMC4635070.xml	lyse	103765 : 103769	CM	ity of human NK cells to lyse breast cancer cells [553
./___Corpus/Medline/xml/PMC4635070.xml	LDH	103931 : 103934	CM	hocyte proliferation and LDH release, and caused a si
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	103982 : 103987	CM	significant increment in IFN-γ in a mouse model of Huma
./___Corpus/Medline/xml/PMC4635070.xml	GEN	104139 : 104142	CM	 a control group) [554]. GEN also produced a signific
./___Corpus/Medline/xml/PMC4635070.xml	NK	104246 : 104248	CM	a potentiating effect on NK cells (but a decrease in
./___Corpus/Medline/xml/PMC4635070.xml	CD4(+)CD25(+)	104292 : 104305	CM	ase in the percentage of CD4(+)CD25(+) T cells), an increase in
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	104349 : 104354	CM	ase in the production of IFN-γ, and the activation of S
./___Corpus/Medline/xml/PMC4635070.xml	STAT1	104378 : 104383	CM	γ, and the activation of STAT1 and STAT4 in a 7,12-dime
./___Corpus/Medline/xml/PMC4635070.xml	STAT4	104388 : 104393	CM	 activation of STAT1 and STAT4 in a 7,12-dimethylbenz[a
./___Corpus/Medline/xml/PMC4635070.xml	7,12-dimethylbenz[a]anthracene	104399 : 104429	CM	 of STAT1 and STAT4 in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumor mod
./___Corpus/Medline/xml/PMC4635070.xml	DMBA	104431 : 104435	CM	methylbenz[a]anthracene (DMBA)-induced tumor model in 
./___Corpus/Medline/xml/PMC4635070.xml	GEN	104599 : 104602	CM	omodulatory potential of GEN appears to be quite nuan
./___Corpus/Medline/xml/PMC4635070.xml	MiR	104768 : 104771	CM	               MicroRNA (MiR)                      In
./___Corpus/Medline/xml/PMC4635070.xml	mRNAs	105073 : 105078	CM	0% of the protein-coding mRNAs [556, 557]. They are mas
./___Corpus/Medline/xml/PMC4635070.xml	RNAs	105613 : 105617	CM	et hundreds of messenger RNAs (mRNA)s and a single mRN
./___Corpus/Medline/xml/PMC4635070.xml	(mRNA)s	105618 : 105625	CM	ndreds of messenger RNAs (mRNA)s and a single mRNA is oft
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	105639 : 105643	CM	NAs (mRNA)s and a single mRNA is often the target of m
./___Corpus/Medline/xml/PMC4635070.xml	3’-UTR	105773 : 105779	CM	d with shorter length of 3’-UTR to avoid miR regulation 
./___Corpus/Medline/xml/PMC4635070.xml	560–	106105 : 106109	CPR	 or oncogenes (oncomir) [560–564].                    
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	106192 : 106196	CM	riptional fine tuning of mRNA and proteins levels by m
./___Corpus/Medline/xml/PMC4635070.xml	565–	106303 : 106307	CPR	ne regulatory processes [565–569]. They are involved i
./___Corpus/Medline/xml/PMC4635070.xml	570–	106440 : 106444	CPR	aptive immune responses [570–573]. Deregulated miR exp
./___Corpus/Medline/xml/PMC4635070.xml	574–	106553 : 106557	CPR	inflammatory conditions [574–576]. Importantly, miRs h
./___Corpus/Medline/xml/PMC4635070.xml	577–	106650 : 106654	CPR	downregulated in tumors [577–580]. Epidemiological stu
./___Corpus/Medline/xml/PMC4635070.xml	581–	106836 : 106840	CPR	mmation and cancer [569, 581–584].                  Mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	106897 : 106904	CM	155                      miR-155 is found on chromosome 2
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	107075 : 107080	CM	is miR is upregulated by NF-κB [566, 587, 588], which i
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107149 : 107156	CM	mation and cancer [589]. miR-155 is upregulated/activated
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107409 : 107416	CM	to be due to the role of miR-155 in mediating the product
./___Corpus/Medline/xml/PMC4635070.xml	Th17	107455 : 107459	CM	the production of IL-17 (Th17) and IFN-γ (Th1) produci
./___Corpus/Medline/xml/PMC4635070.xml	IFN-γ	107465 : 107470	CM	tion of IL-17 (Th17) and IFN-γ (Th1) producing CD4+ T c
./___Corpus/Medline/xml/PMC4635070.xml	Th1	107472 : 107475	CM	 IL-17 (Th17) and IFN-γ (Th1) producing CD4+ T cells 
./___Corpus/Medline/xml/PMC4635070.xml	CD4+	107487 : 107491	CM	nd IFN-γ (Th1) producing CD4+ T cells [592].          
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107545 : 107552	CM	                         miR-155 has been found at high l
./___Corpus/Medline/xml/PMC4635070.xml	594–	107637 : 107641	CPR	 other tumors [585, 590, 594–596]. Enforced overexpres
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107674 : 107681	CM	forced overexpression of miR-155 in mouse B cells is suff
./___Corpus/Medline/xml/PMC4635070.xml	murine	107724 : 107730	CM	is sufficient to trigger murine B cell lymphoma [597]. I
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107785 : 107792	CM	 also been reported that miR-155 acts as an oncogene by t
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	107863 : 107871	CM	ssor gene suppressors of cytokine signaling 1 (SOCS1) in b
./___Corpus/Medline/xml/PMC4635070.xml	SOCS1	107885 : 107890	CM	of cytokine signaling 1 (SOCS1) in breast cancer cells 
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	107956 : 107963	CM	lly, the upregulation of miR-155 by mutant p53 was report
./___Corpus/Medline/xml/PMC4635070.xml	p53	107974 : 107977	CM	ion of miR-155 by mutant p53 was reported to drive br
./___Corpus/Medline/xml/PMC4635070.xml	p53	108085 : 108088	CM	ression of tumor protein p53 induced nuclear protein 
./___Corpus/Medline/xml/PMC4635070.xml	TP53INP1	108116 : 108124	CM	duced nuclear protein 1 (TP53INP1) [600]. miR-155 may also
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	108133 : 108140	CM	tein 1 (TP53INP1) [600]. miR-155 may also play a role in 
./___Corpus/Medline/xml/PMC4635070.xml	RA	108215 : 108217	CM	nd rheumatoid arthritis (RA), where elevated levels 
./___Corpus/Medline/xml/PMC4635070.xml	RA	108323 : 108325	CM	d in synovial samples of RA patients [602]. Overall,
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	108351 : 108358	CM	patients [602]. Overall, miR-155 is emerging, then, as a 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	108479 : 108486	CM	146                      miR-146 is a miRNA family, consi
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108562 : 108570	CM	y conserved miRNA genes: miR-146a and miR-146b. miR-146 su
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	108575 : 108583	CM	iRNA genes: miR-146a and miR-146b. miR-146 suppresses infl
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	108585 : 108592	CM	: miR-146a and miR-146b. miR-146 suppresses inflammation 
./___Corpus/Medline/xml/PMC4635070.xml	5q	108661 : 108663	CM	tal region of chromosome 5q, which contains miR-146a
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108680 : 108688	CM	osome 5q, which contains miR-146a gene (5q33) in humans is
./___Corpus/Medline/xml/PMC4635070.xml	RA	108785 : 108787	CM	oimmune diseases such as RA [603], Crohn’s Disease [
./___Corpus/Medline/xml/PMC4635070.xml	Disease	108803 : 108810	ASE	uch as RA [603], Crohn’s Disease [604], asthma [605] and 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108852 : 108860	CM	05] and psoriasis [606]. miR-146a and miR-146b, when expre
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	108865 : 108873	CM	asis [606]. miR-146a and miR-146b, when expressed in highl
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	108970 : 108975	CM	n to negatively regulate NF-κB activity [607]. miR-146a
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	108992 : 109000	CM	te NF-κB activity [607]. miR-146a and miR-146b have also b
./___Corpus/Medline/xml/PMC4635070.xml	miR-146b	109005 : 109013	CM	vity [607]. miR-146a and miR-146b have also been found to 
./___Corpus/Medline/xml/PMC4635070.xml	RA	109061 : 109063	CM	o be highly expressed in RA synovial tissue [608]. A
./___Corpus/Medline/xml/PMC4635070.xml	RA	109096 : 109098	CM	l tissue [608]. Although RA is not a high cancer ris
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109365 : 109373	CM	is miR in such diseases. miR-146a also directly targets PG
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	109396 : 109400	CM	6a also directly targets PGE2 synthase and increased e
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109438 : 109446	CM	 increased expression of miR-146a in bone mesenchymal stem
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	109523 : 109527	CM	d with the inhibition of PGE2 synthase-2 (Ptges-2) and
./___Corpus/Medline/xml/PMC4635070.xml	synthase-2	109528 : 109538	CM	h the inhibition of PGE2 synthase-2 (Ptges-2) and the inhibi
./___Corpus/Medline/xml/PMC4635070.xml	PGE2	109571 : 109575	CM	2) and the inhibition of PGE2 release [609]. In contra
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	109606 : 109613	CM	se [609]. In contrast to miR-155, miR-146a limits T cell 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	109615 : 109623	CM	 In contrast to miR-155, miR-146a limits T cell activation
./___Corpus/Medline/xml/PMC4635070.xml	IRAK1	109908 : 109913	CM	tor-associated kinase 1 (IRAK1) and TNF receptor associ
./___Corpus/Medline/xml/PMC4635070.xml	TNF	109919 : 109922	CM	ted kinase 1 (IRAK1) and TNF receptor associated fact
./___Corpus/Medline/xml/PMC4635070.xml	(TRAF)6	109950 : 109957	CM	ceptor associated factor (TRAF)6 [610–612]. Finally, Xie 
./___Corpus/Medline/xml/PMC4635070.xml	610–	109959 : 109963	CPR	sociated factor (TRAF)6 [610–612]. Finally, Xie et al.
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	110030 : 110037	CM	d that the inhibition of miR-146 results in increased IL-
./___Corpus/Medline/xml/PMC4635070.xml	IRAK1	110127 : 110132	CM	 increased expression of IRAK1 [613]. Such studies, the
./___Corpus/Medline/xml/PMC4635070.xml	miR-146	110190 : 110197	CM	 highlight a key role of miR-146 in inflammation and canc
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110276 : 110282	CM	-21                      miR-21 is an oncomir. Its oncog
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	110411 : 110415	CM	suppressor genes such as PTEN [614], programmed cell d
./___Corpus/Medline/xml/PMC4635070.xml	p53	110549 : 110552	CM	[617], components of the p53 pathway [618] and also m
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	110622 : 110630	CM	bitory and pro-apoptotic cytokine TGF-β signaling [618] to
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	110631 : 110636	CM	d pro-apoptotic cytokine TGF-β signaling [618] to furth
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110697 : 110703	CM	its tumorigenic effects. miR-21 deregulation is a very e
./___Corpus/Medline/xml/PMC4635070.xml	PDAC	110805 : 110809	CM	c ductal adenocarcinoma (PDAC) [619]. miR-21 expressio
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	110818 : 110824	CM	ocarcinoma (PDAC) [619]. miR-21 expression is increased 
./___Corpus/Medline/xml/PMC4635070.xml	HCC	110941 : 110944	CM	epatocellular carcinoma (HCC) [620, 621]. With regard
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111000 : 111006	CM	ts role in inflammation, miR-21 expression has been show
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111218 : 111224	CM	. Similarly induction of miR-21 by IL-6 is a STAT3 depen
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	111238 : 111243	CM	n of miR-21 by IL-6 is a STAT3 dependent mechanism that
./___Corpus/Medline/xml/PMC4635070.xml	STAT3	111350 : 111355	CM	s [623]. It appears that STAT3 together with miR-21, mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111370 : 111376	CM	that STAT3 together with miR-21, miR-181b-1, PTEN and cy
./___Corpus/Medline/xml/PMC4635070.xml	miR-181b-1	111378 : 111388	CM	T3 together with miR-21, miR-181b-1, PTEN and cylindromatosi
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	111390 : 111394	CM	with miR-21, miR-181b-1, PTEN and cylindromatosis (CYL
./___Corpus/Medline/xml/PMC4635070.xml	HCC	111560 : 111563	CM	lon, prostrate, lung and HCC [581]. Finally, Schetter
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111646 : 111652	CM	correlation of IL-6 with miR-21 expression in human colo
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	111732 : 111738	CM	r supporting the role of miR-21 in linking inflammation 
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	111836 : 111845	CM	ter                      miR-17~92 (OncomiR-1) [562] is a c
./___Corpus/Medline/xml/PMC4635070.xml	polycistronic	111930 : 111943	CM	omosome 13 and encodes a polycistronic miR gene for six mature 
./___Corpus/Medline/xml/PMC4635070.xml	miR-17	111985 : 111991	CM	 mature functional miRs: miR-17, miR-18a, miR-19a, -20, 
./___Corpus/Medline/xml/PMC4635070.xml	miR-18a	111993 : 112000	CM	functional miRs: miR-17, miR-18a, miR-19a, -20, -19b and 
./___Corpus/Medline/xml/PMC4635070.xml	miR-19a	112002 : 112009	CM	l miRs: miR-17, miR-18a, miR-19a, -20, -19b and -92 [625]
./___Corpus/Medline/xml/PMC4635070.xml	SOCS1	112129 : 112134	CM	properties. For example, SOCS1, a gene frequently silen
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112241 : 112247	CM	stigator, is targeted by miR-19, elucidating the proinfl
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112293 : 112299	CM	inflammatory property of miR-19 and its possible link to
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	112351 : 112360	CM	umorigenesis [626, 627]. miR-17~92 clusters weaken TGF-β si
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	112377 : 112382	CM	iR-17~92 clusters weaken TGF-β signaling by functioning
./___Corpus/Medline/xml/PMC4635070.xml	phospho-SMAD2	112440 : 112453	CM	stream and downstream of phospho-SMAD2 as well as through direc
./___Corpus/Medline/xml/PMC4635070.xml	TGF-β	112494 : 112499	CM	ugh direct inhibition of TGF-β responsive genes [628]. 
./___Corpus/Medline/xml/PMC4635070.xml	miR-19b	112524 : 112531	CM	 responsive genes [628]. miR-19b positively regulates NF-
./___Corpus/Medline/xml/PMC4635070.xml	NF-κβ	112553 : 112558	CM	19b positively regulates NF-κβ signaling for proinflamm
./___Corpus/Medline/xml/PMC4635070.xml	cytokine	112589 : 112597	CM	ling for proinflammatory cytokine production, is involved 
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	112668 : 112673	CM	l negative regulators of NF-κB signaling, and plays a c
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	112771 : 112780	CM	ses [629]. Additionally, miR-17~92 is a well-established pl
./___Corpus/Medline/xml/PMC4635070.xml	Myc	112869 : 112872	CM	of this cluster and in a Myc-driven mouse model of B-
./___Corpus/Medline/xml/PMC4635070.xml	miR-19	112948 : 112954	CM	tumor development [562]. miR-19 can exert its oncogenic 
./___Corpus/Medline/xml/PMC4635070.xml	PTEN	113030 : 113034	CM	ion of tumor suppressors PTEN and Protein phosphatase 
./___Corpus/Medline/xml/PMC4635070.xml	PP2A	113062 : 113066	CM	d Protein phosphatase 2 (PP2A), pro-apoptotic molecule
./___Corpus/Medline/xml/PMC4635070.xml	AMP	113165 : 113168	CM	eath and Protein kinase, AMP-activated, alpha 1 catal
./___Corpus/Medline/xml/PMC4635070.xml	alpha	113180 : 113185	CM	n kinase, AMP-activated, alpha 1 catalytic subunit [630
./___Corpus/Medline/xml/PMC4635070.xml	630–	113207 : 113211	CPR	pha 1 catalytic subunit [630–632]. Overall, the miR-17
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	113230 : 113239	CM	 [630–632]. Overall, the miR-17~92 cluster, based on its ro
./___Corpus/Medline/xml/PMC4635070.xml	miR-196	113397 : 113404	CM	196                      miR-196 is considered an oncomir
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a	113591 : 113599	CM	thra et al. demonstrated miR-196a directly targets the ant
./___Corpus/Medline/xml/PMC4635070.xml	miR-196	113757 : 113764	CM	cinoma cell lines [634]. miR-196 is overexpressed in infl
./___Corpus/Medline/xml/PMC4635070.xml	c.313C	113930 : 113936	CM	RGM) protective variant (c.313C) but not the risk associ
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a-2	114017 : 114027	CM	o, the Rs11614913 SNP in miR-196a-2 may promote susceptibili
./___Corpus/Medline/xml/PMC4635070.xml	miR-196a	114138 : 114146	CM	flammatory properties of miR-196a support its role in infl
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	114243 : 114250	CM	663                      miR-663 is currently reported as
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	114353 : 114360	CM	airs the upregulation of miR-155 by inflammatory stimuli 
./___Corpus/Medline/xml/PMC4635070.xml	hypomethylated	114419 : 114433	RN	]. The overexpression of hypomethylated miR-663 induces chemothe
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	114434 : 114441	CM	ession of hypomethylated miR-663 induces chemotherapy res
./___Corpus/Medline/xml/PMC4635070.xml	sulfate	114524 : 114531	CM	lls by targeting heparan sulfate proteoglycan 2 (HSPG2) [
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114652 : 114657	CM	cer                      miR-9 is canonically induced b
./___Corpus/Medline/xml/PMC4635070.xml	NF-κβ	114684 : 114689	CM	s canonically induced by NF-κβ following TLR4 activatio
./___Corpus/Medline/xml/PMC4635070.xml	TLR4	114700 : 114704	CM	duced by NF-κβ following TLR4 activation in human neut
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	114784 : 114789	CM	ides feedback to repress NF-κB signaling through direct
./___Corpus/Medline/xml/PMC4635070.xml	p50	114828 : 114831	CM	ough direct targeting of p50 mRNA [640]. Overexpressi
./___Corpus/Medline/xml/PMC4635070.xml	mRNA	114832 : 114836	CM	 direct targeting of p50 mRNA [640]. Overexpression of
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114862 : 114867	CM	[640]. Overexpression of miR-9 by MYC/MYCN is involved 
./___Corpus/Medline/xml/PMC4635070.xml	MYC	114871 : 114874	CM	erexpression of miR-9 by MYC/MYCN is involved in canc
./___Corpus/Medline/xml/PMC4635070.xml	MYCN	114875 : 114879	CM	pression of miR-9 by MYC/MYCN is involved in cancer me
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	114992 : 114997	CM	flammation and cancer by miR-9. Several studies reporte
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115040 : 115047	CM	reported upregulation of miR-210 in hypoxic condition [64
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115051 : 115058	CM	regulation of miR-210 in hypoxic condition [643–645] and 
./___Corpus/Medline/xml/PMC4635070.xml	643–	115070 : 115074	CPR	10 in hypoxic condition [643–645] and its importance f
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115123 : 115130	CM	for cell survival [646]. miR-210 is a sensor for hypoxic 
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115147 : 115154	CM	 miR-210 is a sensor for hypoxic stress during tumorigene
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115200 : 115207	CM	genesis, where increased miR-210 expression inhibits tumo
./___Corpus/Medline/xml/PMC4635070.xml	hypoxic	115303 : 115310	CM	 to prevail in stressful hypoxic condition [647]. Thus, a
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	115405 : 115412	CM	rigenesis is mediated by miR-210. miRNA-16 is a putative 
./___Corpus/Medline/xml/PMC4635070.xml	648–	115511 : 115515	CPR	ariety of human cancers [648–654]. One recognized func
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	115548 : 115554	CM	e recognized function of miR-16 is that it controls the 
./___Corpus/Medline/xml/PMC4635070.xml	G1	115610 : 115612	CM	ycle primarily through a G1 cell cycle checkpoint [6
./___Corpus/Medline/xml/PMC4635070.xml	655–	115641 : 115645	CPR	l cycle checkpoint [649, 655–662].                    
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	115706 : 115712	CM	        The finding that miR-16 is upregulated in high c
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl arginine	115921 : 115938	CM	 Finally, inhibiting the peptidyl arginine deiminase (PAD) enzyme, 
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl-arginine	116016 : 116033	CM	nslational conversion of peptidyl-arginine to peptidyl-citrulline (
./___Corpus/Medline/xml/PMC4635070.xml	peptidyl-citrulline	116037 : 116056	CM	 of peptidyl-arginine to peptidyl-citrulline (“citrullination”) cause
./___Corpus/Medline/xml/PMC4635070.xml	citrullination	116059 : 116073	RN	to peptidyl-citrulline (“citrullination”) causes an increase in 
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	116098 : 116104	CM	”) causes an increase in miR-16 [663]. The fact that cit
./___Corpus/Medline/xml/PMC4635070.xml	citrullination	116126 : 116140	CM	-16 [663]. The fact that citrullination is thought to be an infl
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	116223 : 116229	CM	supports the notion that miR-16 is involved in the suppr
./___Corpus/Medline/xml/PMC4635070.xml	miR-125b	116278 : 116286	CM	ression of inflammation. miR-125b expression is decreased 
./___Corpus/Medline/xml/PMC4635070.xml	miR-125b	116479 : 116487	CM	rther down-regulation of miR-125b has been reported in sev
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	116650 : 116657	CM	t cancer [569]. Finally, miR-663 is currently reported as
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	116762 : 116769	CM	airs the upregulation of miR-155 by inflammatory stimuli 
./___Corpus/Medline/xml/PMC4635070.xml	Resveratrol	117253 : 117264	CM	, 667].                  Resveratrol                      Sin
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117297 : 117308	CM	              Since both resveratrol and miR influence cellul
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117372 : 117383	CM	 and disease conditions, resveratrol could act through miRs i
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117521 : 117532	CM	i and Michaille reviewed resveratrol, miRs, inflammation and 
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	117585 : 117596	CM	cer [668], and note that resveratrol has been shown to induce
./___Corpus/Medline/xml/PMC4635070.xml	miR-663	117640 : 117647	CM	induce the expression of miR-663, a tumor-suppressor and 
./___Corpus/Medline/xml/PMC4635070.xml	miR-155	117732 : 117739	CM	gulating proinflammatory miR-155 and oncogenic miR-21.   
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	117754 : 117760	CM	ry miR-155 and oncogenic miR-21.                  Curcum
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin

                    Curcumin	117779 : 117817	CM	miR-21.                  Curcumin                      Curcumin regulates the expression
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	117952 : 117957	CM	naling pathways, such as NF-κB, AKT, MAPK and other pat
./___Corpus/Medline/xml/PMC4635070.xml	AKT	117959 : 117962	CM	pathways, such as NF-κB, AKT, MAPK and other pathways
./___Corpus/Medline/xml/PMC4635070.xml	MAPK	117964 : 117968	CM	ays, such as NF-κB, AKT, MAPK and other pathways [669,
./___Corpus/Medline/xml/PMC4635070.xml	retinal	118091 : 118098	CM	 a spontaneously arising retinal pigment epithelia cell l
./___Corpus/Medline/xml/PMC4635070.xml	ARPE-19	118128 : 118135	CM	ent epithelia cell line (ARPE-19 cells), curcumin treatme
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118144 : 118152	CM	ll line (ARPE-19 cells), curcumin treatment lowers the exp
./___Corpus/Medline/xml/PMC4635070.xml	miR-17~92	118188 : 118197	CM	lowers the expression of miR-17~92 cluster and its pre-trea
./___Corpus/Medline/xml/PMC4635070.xml	H2O2	118239 : 118243	CM	pre-treatment attenuates H2O2 induced expression of mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-15b	118266 : 118273	CM	O2 induced expression of miR-15b, miR-21, miR-17, miR-196
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	118275 : 118281	CM	d expression of miR-15b, miR-21, miR-17, miR-196b and mi
./___Corpus/Medline/xml/PMC4635070.xml	miR-17	118283 : 118289	CM	sion of miR-15b, miR-21, miR-17, miR-196b and miR-9 [671
./___Corpus/Medline/xml/PMC4635070.xml	miR-196b	118291 : 118299	CM	miR-15b, miR-21, miR-17, miR-196b and miR-9 [671]. The cur
./___Corpus/Medline/xml/PMC4635070.xml	miR-9	118304 : 118309	CM	21, miR-17, miR-196b and miR-9 [671]. The curcumin anal
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118321 : 118329	CM	96b and miR-9 [671]. The curcumin analog CDF decreases pan
./___Corpus/Medline/xml/PMC4635070.xml	CDF	118337 : 118340	CM	71]. The curcumin analog CDF decreases pancreatic can
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	118452 : 118460	CM	ppressor miRs, Let-7 and miR-146a, which are typically los
./___Corpus/Medline/xml/PMC4635070.xml	gemcitabine	118544 : 118555	CM	mesenchymal phenotype of gemcitabine-resistant pancreatic can
./___Corpus/Medline/xml/PMC4635070.xml	CDF	118661 : 118664	CM	ng the cells with either CDF or curcumin which upregu
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	118668 : 118676	CM	cells with either CDF or curcumin which upregulates the ex
./___Corpus/Medline/xml/PMC4635070.xml	miR-200b	118713 : 118721	CM	ulates the expression of miR-200b and miR-200c [673]. Curc
./___Corpus/Medline/xml/PMC4635070.xml	Curcumin	118742 : 118750	CM	200b and miR-200c [673]. Curcumin also reduces miR-21 expr
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	118764 : 118770	CM	]. Curcumin also reduces miR-21 expression and activity 
./___Corpus/Medline/xml/PMC4635070.xml	Pdcd4	118871 : 118876	CM	zes the tumor suppressor Pdcd4 in colorectal cancer cel
./___Corpus/Medline/xml/PMC4635070.xml	miR-16	119013 : 119019	CM	tic effects of exogenous miR-16 in murine CLL cells [675
./___Corpus/Medline/xml/PMC4635070.xml	murine	119023 : 119029	CM	s of exogenous miR-16 in murine CLL cells [675]. Isoflav
./___Corpus/Medline/xml/PMC4635070.xml	Isoflavones	119047 : 119058	CM	 murine CLL cells [675]. Isoflavones regulate miR function by
./___Corpus/Medline/xml/PMC4635070.xml	miR-200	119107 : 119114	CM	y inducing expression of miR-200 and let-7 to reverse EMT
./___Corpus/Medline/xml/PMC4635070.xml	EMT	119136 : 119139	CM	200 and let-7 to reverse EMT phenotype [676]. Isoflav
./___Corpus/Medline/xml/PMC4635070.xml	Isoflavones	119157 : 119168	CM	rse EMT phenotype [676]. Isoflavones have also been shown to 
./___Corpus/Medline/xml/PMC4635070.xml	miR-146a	119204 : 119212	CM	been shown to upregulate miR-146a and target EGFR and IRAK
./___Corpus/Medline/xml/PMC4635070.xml	EGFR	119224 : 119228	CM	late miR-146a and target EGFR and IRAK-1/NF-κB signali
./___Corpus/Medline/xml/PMC4635070.xml	IRAK-1	119233 : 119239	CM	146a and target EGFR and IRAK-1/NF-κB signaling to inhib
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	119240 : 119245	CM	d target EGFR and IRAK-1/NF-κB signaling to inhibit pan
./___Corpus/Medline/xml/PMC4635070.xml	isoflavones	119342 : 119353	CM	es provide evidence that isoflavones regulate miRs involved i
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119478 : 119482	CM	easure.                  EGCG                      EGC
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119504 : 119508	CM	GCG                      EGCG is a major catechin in g
./___Corpus/Medline/xml/PMC4635070.xml	catechin	119520 : 119528	CM	         EGCG is a major catechin in green tea and has bee
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119620 : 119624	CM	inflammation and cancer. EGCG upregulates miR-210 in h
./___Corpus/Medline/xml/PMC4635070.xml	miR-210	119637 : 119644	CM	cancer. EGCG upregulates miR-210 in human and mouse lung 
./___Corpus/Medline/xml/PMC4635070.xml	HIF-1α	119764 : 119770	CM	ated by stabilization of HIF-1α [678]. EGCG antagonizes 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119778 : 119782	CM	ization of HIF-1α [678]. EGCG antagonizes androgen act
./___Corpus/Medline/xml/PMC4635070.xml	androgen	119795 : 119803	CM	 [678]. EGCG antagonizes androgen action and down-regulate
./___Corpus/Medline/xml/PMC4635070.xml	miR-21	119830 : 119836	CM	ction and down-regulates miR-21 and upregulates tumor su
./___Corpus/Medline/xml/PMC4635070.xml	miR-330	119870 : 119877	CM	gulates tumor suppressor miR-330 in prostate tumors of mi
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	119912 : 119916	CM	te tumors of mice [679]. EGCG has also been shown to d
./___Corpus/Medline/xml/PMC4635070.xml	miR-92	119973 : 119979	CM	 expression of oncomirs (miR-92, miR-93, and miR-106b) a
./___Corpus/Medline/xml/PMC4635070.xml	miR-93	119981 : 119987	CM	ion of oncomirs (miR-92, miR-93, and miR-106b) and incre
./___Corpus/Medline/xml/PMC4635070.xml	miR-106b	119993 : 120001	CM	irs (miR-92, miR-93, and miR-106b) and increase the expres
./___Corpus/Medline/xml/PMC4635070.xml	miR-7-1	120057 : 120064	CM	f tumor suppressor miRs (miR-7-1, miR-34a, and miR-99a) i
./___Corpus/Medline/xml/PMC4635070.xml	miR-34a	120066 : 120073	CM	uppressor miRs (miR-7-1, miR-34a, and miR-99a) in neurobl
./___Corpus/Medline/xml/PMC4635070.xml	miR-99a	120079 : 120086	CM	s (miR-7-1, miR-34a, and miR-99a) in neuroblastoma cells 
./___Corpus/Medline/xml/PMC4635070.xml	vitro	123512 : 123517	CM	es involving detailed in-vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4635070.xml	vitro	123717 : 123722	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4635070.xml	MIF	124954 : 124957	CM	gy. The selected targets MIF, COX-2, NF-κB, TNF-α, iN
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	124959 : 124964	CM	he selected targets MIF, COX-2, NF-κB, TNF-α, iNOS, AKT
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	124966 : 124971	CM	cted targets MIF, COX-2, NF-κB, TNF-α, iNOS, AKT and CX
./___Corpus/Medline/xml/PMC4635070.xml	iNOS	124980 : 124984	CM	IF, COX-2, NF-κB, TNF-α, iNOS, AKT and CXC chemokines 
./___Corpus/Medline/xml/PMC4635070.xml	AKT	124986 : 124989	CM	X-2, NF-κB, TNF-α, iNOS, AKT and CXC chemokines repre
./___Corpus/Medline/xml/PMC4635070.xml	CXC	124994 : 124997	CM	κB, TNF-α, iNOS, AKT and CXC chemokines represent a p
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	125381 : 125389	CM	o act on those targets, (curcumin, resveratrol, EGCG, geni
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	125391 : 125402	CM	hose targets, (curcumin, resveratrol, EGCG, genistein, lycope
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	125404 : 125408	CM	 (curcumin, resveratrol, EGCG, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4635070.xml	genistein	125410 : 125419	CM	umin, resveratrol, EGCG, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	125421 : 125429	CM	ratrol, EGCG, genistein, lycopene, and anthocyanins) are a
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	125435 : 125447	CM	genistein, lycopene, and anthocyanins) are all agents than hav
./___Corpus/Medline/xml/PMC4635070.xml	MiRs	125872 : 125876	CM	hese approaches on these MiRs.                        
./___Corpus/Medline/xml/PMC4635070.xml	MIF	126431 : 126434	CM	hes aimed at suppressing MIF, Cox-2, NF-κB, and TNF-α
./___Corpus/Medline/xml/PMC4635070.xml	NF-κB	126443 : 126448	CM	 suppressing MIF, Cox-2, NF-κB, and TNF-α, and in the u
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	126479 : 126487	CM	TNF-α, and in the use of curcumin (as a therapeutic approa
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	126530 : 126534	CM	 approach). By contrast, EGCG appears to have a protec
./___Corpus/Medline/xml/PMC4635070.xml	COX-2	126667 : 126672	CM	 also a nuanced picture. COX-2 inhibition and PI3K-Akt 
./___Corpus/Medline/xml/PMC4635070.xml	curcumin	126832 : 126840	CM	mune-related. Similarly, curcumin, resveratrol and EGCG ha
./___Corpus/Medline/xml/PMC4635070.xml	resveratrol	126842 : 126853	CM	ed. Similarly, curcumin, resveratrol and EGCG have also been 
./___Corpus/Medline/xml/PMC4635070.xml	EGCG	126858 : 126862	CM	urcumin, resveratrol and EGCG have also been shown to 
./___Corpus/Medline/xml/PMC4635070.xml	lycopene	126944 : 126952	CM	vorable manner. However, lycopene and genistein have demon
./___Corpus/Medline/xml/PMC4635070.xml	genistein	126957 : 126966	CM	r. However, lycopene and genistein have demonstrated a rang
./___Corpus/Medline/xml/PMC4635070.xml	CXC	127217 : 127220	CM	sed by the wide range of CXC Chemokines and their var
./___Corpus/Medline/xml/PMC4635070.xml	anthocyanins	127426 : 127438	CM	ted approaches, specific anthocyanins that appear to have the 
./___Corpus/Medline/xml/PMC4635070.xml	phospholipid	128431 : 128443	CM	, nano-delivery systems, phospholipid-based delivery systems a
./___Corpus/Medline/xml/PMC4635070.xml	359–	128492 : 128496	CPR	and other systems (c.f. [359–362]) will help address t
./___Corpus/Medline/xml/PMC4635070.xml	THALES	130318 : 130324	CM	esearch Funding Program: THALES (Grant number MIS 379346
./___Corpus/Medline/xml/PMC4635070.xml	Amin	130410 : 130414	CM	 Radical Chemistry’; Amr Amin was supported by the Ter
./___Corpus/Medline/xml/PMC4635070.xml	NO	130640 : 130642	CM	s supported by NIH Grant NO. R01 CA 156776-01; VA Me
./___Corpus/Medline/xml/PMC4635070.xml	156776-	130651 : 130658	CPR	 by NIH Grant NO. R01 CA 156776-01; VA Merit Award NO. BL
./___Corpus/Medline/xml/PMC4635070.xml	NO	130677 : 130679	CM	56776-01; VA Merit Award NO. BLR&D 1 01-BX001517-01;
./___Corpus/Medline/xml/PMC4635070.xml	01-	130689 : 130692	CPR	 Merit Award NO. BLR&D 1 01-BX001517-01; Diana M. Sta
./___Corpus/Medline/xml/PMC4635070.xml	W81XWH-12-1-0515	130815 : 130831	CM	itute, by DOD IDEA Award W81XWH-12-1-0515 and by the Huntsman Canc
./___Corpus/Medline/xml/PMC4635070.xml	FP7	131407 : 131410	CM	eventh Framework Program FP7/2007–2013 under Grant Ag
./___Corpus/Medline/xml/PMC4635070.xml	2007–	131411 : 131416	CPR	th Framework Program FP7/2007–2013 under Grant Agreemen
./___Corpus/Medline/xml/PMC4635070.xml	FT	131580 : 131582	CM	nd Technology, India (SR/FT/LS-063/2008); Richard L.
./___Corpus/Medline/xml/PMC4635070.xml	PDF	131912 : 131915	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4635070.xml	TG2	132567 : 132570	CM	ates patent # 8,765,797 (TG2 inhibitors and uses ther
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	842 : 848	CM	sources such as reactive oxygen species. One of the most
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	937 : 941	CM	re double-strand breaks (DSBs), whose massive cytotoxi
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	1464 : 1468	CM	signalling and repairing DSBs. These pathways collecti
./___Corpus/Medline/xml/PMC4693276.xml	DDR	2121 : 2124	CM	e part, have compromised DDR pathways, some of them b
./___Corpus/Medline/xml/PMC4693276.xml	anti-	2466 : 2471	CPR	 effects of DNA-damaging anti-cancer agents, particular
./___Corpus/Medline/xml/PMC4693276.xml	DSB	2609 : 2612	CM	iew of key inhibitors of DSB DNA damage signalling an
./___Corpus/Medline/xml/PMC4693276.xml	DDR	2791 : 2794	CM	the DNA Damage Response. DDR is a signal transduction
./___Corpus/Medline/xml/PMC4693276.xml	MRN	2981 : 2984	CM	 sensor proteins such as MRN (MRE11-RAD50-NSB1) or PA
./___Corpus/Medline/xml/PMC4693276.xml	MRE11-RAD50-NSB1	2986 : 3002	CM	or proteins such as MRN (MRE11-RAD50-NSB1) or PARP1 (Poly(ADP-ribo
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	3007 : 3012	CM	RN (MRE11-RAD50-NSB1) or PARP1 (Poly(ADP-ribose) Polyme
./___Corpus/Medline/xml/PMC4693276.xml	Poly(ADP-ribose)	3014 : 3030	CM	11-RAD50-NSB1) or PARP1 (Poly(ADP-ribose) Polymerase 1). These sen
./___Corpus/Medline/xml/PMC4693276.xml	ATM	3118 : 3121	CM	 telangiectasia mutated (ATM) or Rad3-related (ATR). 
./___Corpus/Medline/xml/PMC4693276.xml	ATR	3140 : 3143	CM	d (ATM) or Rad3-related (ATR). The signal is further 
./___Corpus/Medline/xml/PMC4693276.xml	SSBR	3346 : 3350	CM	gle-Strand Break Repair (SSBR—not discussed in this re
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	3502 : 3506	CM	-Homologous End-Joining (NHEJ). HR involves mediators 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	3539 : 3544	CM	volves mediators such as BRCA2, RAD51 and PALB2. NHEJ b
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	3546 : 3551	CM	mediators such as BRCA2, RAD51 and PALB2. NHEJ brings i
./___Corpus/Medline/xml/PMC4693276.xml	PALB2	3556 : 3561	CM	such as BRCA2, RAD51 and PALB2. NHEJ brings into play p
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	3563 : 3567	CM	 BRCA2, RAD51 and PALB2. NHEJ brings into play protein
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	3661 : 3665	CM	ytic subunit (DNA-PKcs), Ku70/80, Ligase IV and XRCC4.
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	3684 : 3689	CM	, Ku70/80, Ligase IV and XRCC4. During DDR pathway, cel
./___Corpus/Medline/xml/PMC4693276.xml	DDR	3698 : 3701	CM	ase IV and XRCC4. During DDR pathway, cells require e
./___Corpus/Medline/xml/PMC4693276.xml	ATM	3749 : 3752	CM	 effectors, activated by ATM and ATR, such as CHeckpo
./___Corpus/Medline/xml/PMC4693276.xml	ATR	3757 : 3760	CM	rs, activated by ATM and ATR, such as CHeckpoint Kina
./___Corpus/Medline/xml/PMC4693276.xml	CHK1	3791 : 3795	CM	 as CHeckpoint Kinase 1 (CHK1), Checkpoint Kinase 2 (C
./___Corpus/Medline/xml/PMC4693276.xml	Kinase	3809 : 3815	ASE	ase 1 (CHK1), Checkpoint Kinase 2 (CHK2) or p53 to arres
./___Corpus/Medline/xml/PMC4693276.xml	CHK2	3819 : 3823	CM	1), Checkpoint Kinase 2 (CHK2) or p53 to arrest the ce
./___Corpus/Medline/xml/PMC4693276.xml	p53	3828 : 3831	CM	point Kinase 2 (CHK2) or p53 to arrest the cell cycle
./___Corpus/Medline/xml/PMC4693276.xml	DDR	4033 : 4036	CM	 targeting the principal DDR actors allows the promot
./___Corpus/Medline/xml/PMC4693276.xml	DDR	4191 : 4194	CM	 different actors of the DDR pathway. Major inhibitor
./___Corpus/Medline/xml/PMC4693276.xml	ATM	4323 : 4326	CM	                  2. The ATM and ATR Kinases         
./___Corpus/Medline/xml/PMC4693276.xml	ATR	4331 : 4334	CM	          2. The ATM and ATR Kinases                 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	4368 : 4371	CM	                     The ATM (Ataxia-telangiectasia m
./___Corpus/Medline/xml/PMC4693276.xml	A-T	4486 : 4489	CM	d ataxia-telangiectasia (A-T) [3]. Ataxia telangiecta
./___Corpus/Medline/xml/PMC4693276.xml	ATR	4733 : 4736	CM	ataxia and Rad3-related (ATR) gene came to be known f
./___Corpus/Medline/xml/PMC4693276.xml	ATM	5055 : 5058	CM	osomal instability [10]. ATM and ATR belong to the ph
./___Corpus/Medline/xml/PMC4693276.xml	ATR	5063 : 5066	CM	nstability [10]. ATM and ATR belong to the phosphatid
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	5081 : 5101	CM	TM and ATR belong to the phosphatidylinositol 3-kinase-related kinase 
./___Corpus/Medline/xml/PMC4693276.xml	3-	5103 : 5105	CPR	he phosphatidylinositol 3-kinase-related kinase (PIK
./___Corpus/Medline/xml/PMC4693276.xml	PIKK	5127 : 5131	CM	3-kinase-related kinase (PIKK) family of serine/threon
./___Corpus/Medline/xml/PMC4693276.xml	serine	5143 : 5149	CM	 kinase (PIKK) family of serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	5150 : 5159	CM	 (PIKK) family of serine/threonine protein kinases, which a
./___Corpus/Medline/xml/PMC4693276.xml	DDR	5231 : 5234	CM	 These kinases are major DDR transducers, which propa
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	5338 : 5353	RN	nalling cascades through phosphorylation of numerous targets, inc
./___Corpus/Medline/xml/PMC4693276.xml	H2AX	5385 : 5389	CM	erous targets, including H2AX, p53 and the checkpoint 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	5481 : 5484	CM	ce of genomic integrity, ATM and ATR crucially halt t
./___Corpus/Medline/xml/PMC4693276.xml	ATR	5489 : 5492	CM	nomic integrity, ATM and ATR crucially halt the cell 
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	5673 : 5677	CM	the primary responder to DSBs, while ATR responds to a
./___Corpus/Medline/xml/PMC4693276.xml	ATR	5685 : 5688	CM	responder to DSBs, while ATR responds to a variety of
./___Corpus/Medline/xml/PMC4693276.xml	ATM	5932 : 5935	CM	fects of down-regulating ATM and ATR have been the fo
./___Corpus/Medline/xml/PMC4693276.xml	ATR	5940 : 5943	CM	 down-regulating ATM and ATR have been the focus of m
./___Corpus/Medline/xml/PMC4693276.xml	RNA	6037 : 6040	CM	ative, small interfering RNA (siRNA) depletion, or ch
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	6095 : 6103	CM	l inhibition (e.g., with caffeine) approaches [14,15,16,17
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6191 : 6194	CM	notype that emerged from ATM or ATR deficiencies was 
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6198 : 6201	CM	that emerged from ATM or ATR deficiencies was the inc
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6371 : 6374	CM	in therapeutically using ATM and ATR inhibitors as ra
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6379 : 6382	CM	peutically using ATM and ATR inhibitors as radio- or 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6553 : 6556	CM	g specific inhibitors of ATM/ATR has been long and wi
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6557 : 6560	CM	ecific inhibitors of ATM/ATR has been long and windin
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6694 : 6697	CM	reported to inhibit both ATM and ATR kinases and bloc
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6702 : 6705	CM	 to inhibit both ATM and ATR kinases and block checkp
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6863 : 6866	CM	 selective inhibitors of ATM and ATR has not yet paid
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6871 : 6874	CM	ve inhibitors of ATM and ATR has not yet paid off, so
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6973 : 6976	CM	rief summary of the dual ATM/ATR, ATM or ATR inhibito
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6977 : 6980	CM	 summary of the dual ATM/ATR, ATM or ATR inhibitors (
./___Corpus/Medline/xml/PMC4693276.xml	ATM	6982 : 6985	CM	ary of the dual ATM/ATR, ATM or ATR inhibitors (depic
./___Corpus/Medline/xml/PMC4693276.xml	ATR	6989 : 6992	CM	the dual ATM/ATR, ATM or ATR inhibitors (depicted in 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	7111 : 7114	CM	               2.1. Dual ATM/ATR Inhibitors 2.1.1. Ca
./___Corpus/Medline/xml/PMC4693276.xml	ATR	7115 : 7118	CM	           2.1. Dual ATM/ATR Inhibitors 2.1.1. Caffei
./___Corpus/Medline/xml/PMC4693276.xml	Caffeine	7137 : 7145	CM	TM/ATR Inhibitors 2.1.1. Caffeine, Wortmannin and LY294002
./___Corpus/Medline/xml/PMC4693276.xml	ATR	7210 : 7213	CM	       The PIKKs ATM and ATR present a high level of 
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7407 : 7415	CM	arly studies made use of caffeine or wortmannin to block t
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7419 : 7429	CM	 made use of caffeine or wortmannin to block the ATM and ATR
./___Corpus/Medline/xml/PMC4693276.xml	ATM	7443 : 7446	CM	 wortmannin to block the ATM and ATR kinases. Caffein
./___Corpus/Medline/xml/PMC4693276.xml	ATR	7451 : 7454	CM	nin to block the ATM and ATR kinases. Caffeine and wo
./___Corpus/Medline/xml/PMC4693276.xml	Caffeine	7464 : 7472	CM	the ATM and ATR kinases. Caffeine and wortmannin exhibited
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7477 : 7487	CM	TR kinases. Caffeine and wortmannin exhibited radio- and che
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	7607 : 7627	CM	rs that cross-react with phosphatidylinositol 3-kinases (PI3K) and PI3
./___Corpus/Medline/xml/PMC4693276.xml	3-	7629 : 7631	CPR	th phosphatidylinositol 3-kinases (PI3K) and PI3K-re
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	7639 : 7643	CM	tidylinositol 3-kinases (PI3K) and PI3K-related kinase
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	7649 : 7653	CM	tol 3-kinases (PI3K) and PI3K-related kinases includin
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7755 : 7763	CM	colleagues revealed that caffeine impaired resection durin
./___Corpus/Medline/xml/PMC4693276.xml	Sae2	7843 : 7847	CM	 the levels of nucleases Sae2 and Dna2 [23]. Neverthel
./___Corpus/Medline/xml/PMC4693276.xml	Dna2	7852 : 7856	CM	ls of nucleases Sae2 and Dna2 [23]. Nevertheless, caff
./___Corpus/Medline/xml/PMC4693276.xml	caffeine	7877 : 7885	CM	Dna2 [23]. Nevertheless, caffeine and wortmannin present a
./___Corpus/Medline/xml/PMC4693276.xml	wortmannin	7890 : 7900	CM	vertheless, caffeine and wortmannin present a lack of select
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8111 : 8115	CM	nthetic inhibitor of the PI3K family and PI3K-like fam
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8127 : 8131	CM	r of the PI3K family and PI3K-like family, named LY294
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8151 : 8159	CM	 PI3K-like family, named LY294002, was characterized at th
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8255 : 8263	CM	any [26]. In this study, LY294002 was used to inhibit PI3K
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8284 : 8288	CM	4002 was used to inhibit PI3K activity in human neutro
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8414 : 8422	CM	 segments. Subsequently, LY294002 was shown to be an inhib
./___Corpus/Medline/xml/PMC4693276.xml	ATM	8455 : 8458	CM	wn to be an inhibitor of ATM and ATR [27,28,29,30]. F
./___Corpus/Medline/xml/PMC4693276.xml	ATR	8463 : 8466	CM	 an inhibitor of ATM and ATR [27,28,29,30]. For the n
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	8543 : 8551	CM	itors were designed from LY294002. Although these show an 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8603 : 8607	CM	creased affinity for the PI3K family, there have been 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8699 : 8703	CM	cally by targeting other PI3K-related kinases and prot
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	8761 : 8765	CM	arently unrelated to the PI3K family as well [31,32]. 
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	8930 : 8934	CM	limitations of Torin1 (a mTOR selective inhibitor 1) [
./___Corpus/Medline/xml/PMC4693276.xml	ATR	9008 : 9011	CM	so a potent inhibitor of ATR, ATM and DNA-PK in PC3 A
./___Corpus/Medline/xml/PMC4693276.xml	ATM	9013 : 9016	CM	potent inhibitor of ATR, ATM and DNA-PK in PC3 AktS47
./___Corpus/Medline/xml/PMC4693276.xml	PC3	9031 : 9034	CM	f ATR, ATM and DNA-PK in PC3 AktS473D cells [34]. Int
./___Corpus/Medline/xml/PMC4693276.xml	anti-	9086 : 9091	CPR	estingly, it exhibits an anti-proliferative activity ac
./___Corpus/Medline/xml/PMC4693276.xml	KRAS	9207 : 9211	CM	ant growth inhibition of KRAS mutant lung tumours when
./___Corpus/Medline/xml/PMC4693276.xml	AZD6244	9262 : 9269	CM	used in combination with AZD6244 (MEK1/2 inhibitor).     
./___Corpus/Medline/xml/PMC4693276.xml	MEK1	9271 : 9275	CM	ombination with AZD6244 (MEK1/2 inhibitor).           
./___Corpus/Medline/xml/PMC4693276.xml	ATM	9436 : 9439	CM	icals Ltd discovered the ATM inhibitor KU-55933, whic
./___Corpus/Medline/xml/PMC4693276.xml	ATM	9637 : 9640	CM	competitive inhibitor of ATM [35]. KU-55933, with an 
./___Corpus/Medline/xml/PMC4693276.xml	IC50	9665 : 9669	CM	 [35]. KU-55933, with an IC50 of 13 nmol/L and a Ki of
./___Corpus/Medline/xml/PMC4693276.xml	Ki	9689 : 9691	CM	 IC50 of 13 nmol/L and a Ki of 2.2 nmol/L in vitro, 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	9709 : 9714	CM	nd a Ki of 2.2 nmol/L in vitro, showed a >100-fold high
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	9726 : 9734	CM	ol/L in vitro, showed a >100-fold higher potency against A
./___Corpus/Medline/xml/PMC4693276.xml	ATM	9758 : 9761	CM	d higher potency against ATM compared to other PIKK f
./___Corpus/Medline/xml/PMC4693276.xml	PIKK	9780 : 9784	CM	st ATM compared to other PIKK family members, with no 
./___Corpus/Medline/xml/PMC4693276.xml	p21	10058 : 10061	CM	 carcinoma cells through p21, in an ATM-dependent man
./___Corpus/Medline/xml/PMC4693276.xml	ATM	10069 : 10072	CM	cells through p21, in an ATM-dependent manner [38]. U
./___Corpus/Medline/xml/PMC4693276.xml	ATM	10156 : 10159	CM	haracterized the role of ATM in the overall regulatio
./___Corpus/Medline/xml/PMC4693276.xml	ribonucleotide	10189 : 10203	CM	he overall regulation of ribonucleotide reductase subunit expres
./___Corpus/Medline/xml/PMC4693276.xml	reductase	10204 : 10213	CM	lation of ribonucleotide reductase subunit expression/stabi
./___Corpus/Medline/xml/PMC4693276.xml	DAB2IP	10464 : 10470	CM	r cancer cells bearing a DAB2IP gene defect [40] and non
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	10724 : 10728	CM	prove the specificity of PI3K-like protein inhibitors,
./___Corpus/Medline/xml/PMC4693276.xml	AKT	10868 : 10871	CM	 damage response, reduce AKT phosphorylation and pros
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	10872 : 10887	RN	age response, reduce AKT phosphorylation and prosurvival signalli
./___Corpus/Medline/xml/PMC4693276.xml	AKT	10997 : 11000	CM	re by KU-60019 to reduce AKT phosphorylation and to m
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	11001 : 11016	RN	y KU-60019 to reduce AKT phosphorylation and to mediate radiosens
./___Corpus/Medline/xml/PMC4693276.xml	A-T	11054 : 11057	CM	te radiosensitization in A-T fibroblasts, suggested s
./___Corpus/Medline/xml/PMC4693276.xml	ATM	11103 : 11106	CM	ed specific targeting of ATM [37]. This drug has simi
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	11354 : 11369	RN	ocking radiation-induced phosphorylation of ATM downstream target
./___Corpus/Medline/xml/PMC4693276.xml	ATM	11373 : 11376	CM	duced phosphorylation of ATM downstream targets. Stud
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	11552 : 11556	CM	 shown to be harmful for PTEN mutant cancer cells in t
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	11665 : 11669	CM	ntroduction of wild-type PTEN [44]. Finally, it has be
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	11744 : 11755	CM	 significantly increases doxorubicin-induced chemosensitizati
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	11786 : 11791	CM	ed chemosensitization of MCF-7 cells, suppressing their
./___Corpus/Medline/xml/PMC4693276.xml	ATP	11986 : 11989	CM	                 Another ATP competitive inhibitor, K
./___Corpus/Medline/xml/PMC4693276.xml	KU	12165 : 12167	CM	ility, compared to other KU drugs [46]. KU-59403 was
./___Corpus/Medline/xml/PMC4693276.xml	SW620	12255 : 12260	CM	human cancer cell lines (SW620, LoVo, HCT116, and MDA-M
./___Corpus/Medline/xml/PMC4693276.xml	LoVo	12262 : 12266	CM	ancer cell lines (SW620, LoVo, HCT116, and MDA-MB-231)
./___Corpus/Medline/xml/PMC4693276.xml	HCT116	12268 : 12274	CM	cell lines (SW620, LoVo, HCT116, and MDA-MB-231) and was
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	12280 : 12290	CM	SW620, LoVo, HCT116, and MDA-MB-231) and was found to have a
./___Corpus/Medline/xml/PMC4693276.xml	ATM	12706 : 12709	CM	ic against inhibition of ATM-dependent phosphorylatio
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	12720 : 12735	RN	ibition of ATM-dependent phosphorylation events [47]. Rainey and 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	12809 : 12812	CM	 transient inhibition of ATM was sufficient to sensit
./___Corpus/Medline/xml/PMC4693276.xml	CP466722	12964 : 12972	CM	ent study has found that CP466722 is cytotoxic in both MCF
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	12994 : 12999	CM	722 is cytotoxic in both MCF-7 and SKBr-3 cell lines by
./___Corpus/Medline/xml/PMC4693276.xml	SKBr-3	13004 : 13010	CM	otoxic in both MCF-7 and SKBr-3 cell lines by inducing a
./___Corpus/Medline/xml/PMC4693276.xml	ATR	13202 : 13205	CM	 B (SchB) as a selective ATR inhibitor by screening h
./___Corpus/Medline/xml/PMC4693276.xml	ATM	13285 : 13288	CM	, although inhibition of ATM was also observed at hig
./___Corpus/Medline/xml/PMC4693276.xml	ATR	13383 : 13386	CM	B could be implicated in ATR inhibition, Tatewaki and
./___Corpus/Medline/xml/PMC4693276.xml	γ-	13488 : 13490	CPR	omers gomisin N (GN) and γ-schisandrin (γ-Sch), in w
./___Corpus/Medline/xml/PMC4693276.xml	γ-	13503 : 13505	CPR	 (GN) and γ-schisandrin (γ-Sch), in which the former
./___Corpus/Medline/xml/PMC4693276.xml	ATR	13657 : 13660	CM	pecific interaction with ATR. SchB can enhance doxoru
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	13679 : 13690	CM	th ATR. SchB can enhance doxorubicin-induced apoptosis of can
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	13760 : 13771	CM	rmal cells [51], prevent doxorubicin-induced chronic cardioto
./___Corpus/Medline/xml/PMC4693276.xml	anti-	13894 : 13899	CPR	as been implicated as an anti-UVB-induced damage agent 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	13902 : 13907	CPR	implicated as an anti-UVB-induced damage agent in HaCat
./___Corpus/Medline/xml/PMC4693276.xml	ATR	13966 : 13969	CM	3]. While its role as an ATR inhibitor is promising, 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	14065 : 14070	CPR	 a sensitizing agent for anti-cancer therapy.          
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14110 : 14116	CM	                  2.3.2. NU6027                      NU6
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14138 : 14144	CM	027                      NU6027 is a potent inhibitor of
./___Corpus/Medline/xml/PMC4693276.xml	ATR	14170 : 14173	CM	is a potent inhibitor of ATR activity in several brea
./___Corpus/Medline/xml/PMC4693276.xml	CDK2	14263 : 14267	CM	s initial discovery as a CDK2 inhibitor renders it les
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14319 : 14325	CM	interesting [54]. Still, NU6027 reduces G2/M arrest foll
./___Corpus/Medline/xml/PMC4693276.xml	G2	14334 : 14336	CM	]. Still, NU6027 reduces G2/M arrest following DNA d
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	14378 : 14383	CM	ng DNA damage, decreases RAD51 focus formation and incr
./___Corpus/Medline/xml/PMC4693276.xml	p53	14566 : 14569	CM	80 cells with functional p53 and mismatch repair (MMR
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14630 : 14636	CM	tive to a combination of NU6027 and cisplatin treatment,
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	14641 : 14650	CM	ombination of NU6027 and cisplatin treatment, whereas p53 m
./___Corpus/Medline/xml/PMC4693276.xml	p53	14670 : 14673	CM	latin treatment, whereas p53 mutant cells with functi
./___Corpus/Medline/xml/PMC4693276.xml	MMR	14703 : 14706	CM	nt cells with functional MMR are susceptible to temoz
./___Corpus/Medline/xml/PMC4693276.xml	temozolomide	14726 : 14738	CM	l MMR are susceptible to temozolomide (TMZ) combined with NU60
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	14740 : 14743	CM	eptible to temozolomide (TMZ) combined with NU6027. I
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14759 : 14765	CM	mide (TMZ) combined with NU6027. Importantly, NU6027 is 
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14780 : 14786	CM	ith NU6027. Importantly, NU6027 is synthetically lethal 
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP-ribose)	14875 : 14891	CM	impaired, either through poly(ADP-ribose) polymerase inhibition or
./___Corpus/Medline/xml/PMC4693276.xml	XRCC1	14928 : 14933	CM	inhibition or defects in XRCC1. Recently, Sultana et al
./___Corpus/Medline/xml/PMC4693276.xml	ATR	14976 : 14979	CM	a et al., confirmed that ATR inhibition by NU6027 lea
./___Corpus/Medline/xml/PMC4693276.xml	NU6027	14994 : 15000	CM	d that ATR inhibition by NU6027 leads to synthetic letha
./___Corpus/Medline/xml/PMC4693276.xml	XRCC1	15033 : 15038	CM	o synthetic lethality in XRCC1-deficient ovarian cancer
./___Corpus/Medline/xml/PMC4693276.xml	G2	15173 : 15175	CM	ouble-strand DNA breaks, G2/M cell cycle arrest and 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	15300 : 15304	CM	         In a screen for PI3K inhibitors, PI-124 and P
./___Corpus/Medline/xml/PMC4693276.xml	PI-124	15317 : 15323	CM	een for PI3K inhibitors, PI-124 and PI-103 were identifi
./___Corpus/Medline/xml/PMC4693276.xml	PI-103	15328 : 15334	CM	K inhibitors, PI-124 and PI-103 were identified as being
./___Corpus/Medline/xml/PMC4693276.xml	ATR	15381 : 15384	CM	ing potent inhibitors of ATR, but also of mTOR protei
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	15398 : 15402	CM	tors of ATR, but also of mTOR protein kinases [56]. Re
./___Corpus/Medline/xml/PMC4693276.xml	PI-103	15467 : 15473	CM	bination of olaparib and PI-103 has been shown to enhanc
./___Corpus/Medline/xml/PMC4693276.xml	TNBC	15558 : 15562	CM	-negative breast cancer (TNBC) cells and to significan
./___Corpus/Medline/xml/PMC4693276.xml	PI-103	15640 : 15646	CM	a mouse xenograft model. PI-103 inhibitor treatment was 
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	15697 : 15703	CM	ccompanied by persistent γ-H2AX foci, indicating delayed
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	15784 : 15789	CM	ssociated with decreased RAD51 and p-DNA-PK, but not AT
./___Corpus/Medline/xml/PMC4693276.xml	p-DNA-PK	15794 : 15802	CM	with decreased RAD51 and p-DNA-PK, but not ATR). Remarkabl
./___Corpus/Medline/xml/PMC4693276.xml	ATR	15812 : 15815	CM	51 and p-DNA-PK, but not ATR). Remarkably, PI-103 alo
./___Corpus/Medline/xml/PMC4693276.xml	PI-103	15830 : 15836	CM	ut not ATR). Remarkably, PI-103 alone increased poly(ADP
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP-ribose)	15853 : 15869	CM	, PI-103 alone increased poly(ADP-ribose) and phosphorylated extra
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylated	15874 : 15888	CM	sed poly(ADP-ribose) and phosphorylated extracellular signal-reg
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	15956 : 15961	CM	ls, while downregulating BRCA1 [57]. Consequently, the 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16001 : 16005	CM	ntly, the combination of PI3K signalling pathway and P
./___Corpus/Medline/xml/PMC4693276.xml	PARP	16029 : 16033	CM	K signalling pathway and PARP inhibitions could be a s
./___Corpus/Medline/xml/PMC4693276.xml	TNBC	16126 : 16130	CM	ation in BRCA-proficient TNBC.                  2.3.4.
./___Corpus/Medline/xml/PMC4693276.xml	NVP-BEZ235	16239 : 16249	CM	oughput screening (HTS), NVP-BEZ235 possesses significant in
./___Corpus/Medline/xml/PMC4693276.xml	ATR	16300 : 16303	CM	ibitory activity against ATR kinase [58]. However, it
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	16356 : 16360	CM	so presents affinity for mTOR and DNA-PKcs proteins, w
./___Corpus/Medline/xml/PMC4693276.xml	NVP-BEZ235	16474 : 16484	CM	ch is now focused on how NVP-BEZ235 can be used to block the
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16510 : 16514	CM	can be used to block the PI3K/Akt/mTOR pathway in blad
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	16519 : 16523	CM	ed to block the PI3K/Akt/mTOR pathway in bladder cance
./___Corpus/Medline/xml/PMC4693276.xml	NVP-BEZ235	16640 : 16650	CM	noma [62]. Particularly, NVP-BEZ235 is a potent radiosensiti
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	16781 : 16785	CM	 clinical trials for its PI3K/mTOR inhibitory function
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	16786 : 16790	CM	ical trials for its PI3K/mTOR inhibitory function.    
./___Corpus/Medline/xml/PMC4693276.xml	ATR	16973 : 16976	CM	wed that it possesses an ATR inhibitory activity, but
./___Corpus/Medline/xml/PMC4693276.xml	PI3Kα	17062 : 17067	CM	nhibit the activities of PI3Kα, mTOR and DNA-PKcs [58].
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	17069 : 17073	CM	the activities of PI3Kα, mTOR and DNA-PKcs [58]. ETP-4
./___Corpus/Medline/xml/PMC4693276.xml	G2	17195 : 17197	CM	nizing radiation-induced G2/M checkpoint and enhance
./___Corpus/Medline/xml/PMC4693276.xml	p53	17332 : 17335	CM	s specifically toxic for p53-deficient cells (the ove
./___Corpus/Medline/xml/PMC4693276.xml	cyclin E	17375 : 17383	CM	s (the overexpression of cyclin E enhances this effect). U
./___Corpus/Medline/xml/PMC4693276.xml	ATR	17655 : 17658	CM	s a potent and selective ATR inhibitor [64]. ATR inhi
./___Corpus/Medline/xml/PMC4693276.xml	ATR	17675 : 17678	CM	tive ATR inhibitor [64]. ATR inhibition by VE-821 blo
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	17770 : 17779	CM	s DNA damage mediated by cisplatin or gemcitabine. Of inter
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	17783 : 17794	CM	mediated by cisplatin or gemcitabine. Of interest, VE-821 pre
./___Corpus/Medline/xml/PMC4693276.xml	ATM	17846 : 17849	CM	nts low activity against ATM, DNA-PK and a large pane
./___Corpus/Medline/xml/PMC4693276.xml	ATR	18075 : 18078	CM	cells [68]. Accordingly, ATR inhibition by VE-821 lea
./___Corpus/Medline/xml/PMC4693276.xml	G2	18145 : 18147	CM	ion of radiation-induced G2/M arrest in cancer cells
./___Corpus/Medline/xml/PMC4693276.xml	ATR	18295 : 18298	CM	 of VE-821 as a powerful ATR inhibitor that radiosens
./___Corpus/Medline/xml/PMC4693276.xml	ATR	18501 : 18504	CM	 was the first selective ATR inhibitor to enter clini
./___Corpus/Medline/xml/PMC4693276.xml	vitro	18617 : 18622	CM	tested in a series of in vitro and in vivo lung cancer 
./___Corpus/Medline/xml/PMC4693276.xml	ATR	18681 : 18684	CM	X-970 was shown to block ATR activity in tumours and 
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	18746 : 18755	CM	 enhance the efficacy of cisplatin across a panel of patien
./___Corpus/Medline/xml/PMC4693276.xml	VX-970	18844 : 18850	CM	 These data suggest that VX-970 may have the potential t
./___Corpus/Medline/xml/PMC4693276.xml	NF-κB	19295 : 19300	CM	ppress the activation of NF-κB and increase E1-dependen
./___Corpus/Medline/xml/PMC4693276.xml	HPV16	19346 : 19351	CM	ndent replication of the HPV16 genome [71].            
./___Corpus/Medline/xml/PMC4693276.xml	AZ-20	19389 : 19394	CM	                  2.3.8. AZ-20                      Bel
./___Corpus/Medline/xml/PMC4693276.xml	sulfonylmorpholinopyrimidines	19433 : 19462	CM	        Belonging to the sulfonylmorpholinopyrimidines family, AZ-20 was synthe
./___Corpus/Medline/xml/PMC4693276.xml	AZ-20	19471 : 19476	CM	olinopyrimidines family, AZ-20 was synthetized by the A
./___Corpus/Medline/xml/PMC4693276.xml	ATR	19625 : 19628	CM	a selective affinity for ATR [72]. It compellingly in
./___Corpus/Medline/xml/PMC4693276.xml	LoVo	19674 : 19678	CM	y inhibits the growth of LoVo colorectal adenocarcinom
./___Corpus/Medline/xml/PMC4693276.xml	vitro	19721 : 19726	CM	arcinoma tumour cells in vitro and has high symptom-fre
./___Corpus/Medline/xml/PMC4693276.xml	AZD6738	19854 : 19861	CM	738                      AZD6738, developed by AstraZenec
./___Corpus/Medline/xml/PMC4693276.xml	AZ-20	19915 : 19920	CM	 2012, is an analogue of AZ-20, a potent and selective 
./___Corpus/Medline/xml/PMC4693276.xml	ATR	19945 : 19948	CM	, a potent and selective ATR inhibitor [36]. No data 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	20419 : 20424	CM	pporting pre-clinical in vitro and in vivo data [73] ({
./___Corpus/Medline/xml/PMC4693276.xml	serine	20702 : 20708	CM	med Chk1 or Check1, is a serine-threonine kinase. Chk1 i
./___Corpus/Medline/xml/PMC4693276.xml	threonine	20709 : 20718	CM	1 or Check1, is a serine-threonine kinase. Chk1 is encoded 
./___Corpus/Medline/xml/PMC4693276.xml	CHK1	20750 : 20754	CM	. Chk1 is encoded by the CHK1 (CHEK1) gene and is loca
./___Corpus/Medline/xml/PMC4693276.xml	CHEK1	20756 : 20761	CM	 is encoded by the CHK1 (CHEK1) gene and is located on 
./___Corpus/Medline/xml/PMC4693276.xml	11q22-23	20801 : 20809	CM	ocated on chromosome 11 (11q22-23) in humans. Chk1 is high
./___Corpus/Medline/xml/PMC4693276.xml	amino	20902 : 20907	CM	humans, particularly its amino-terminal catalytic domai
./___Corpus/Medline/xml/PMC4693276.xml	C-	20952 : 20954	CPR	domain [74]. Chk1 has a C-terminal regulatory SQ/TQ 
./___Corpus/Medline/xml/PMC4693276.xml	SQ	20973 : 20975	CM	 a C-terminal regulatory SQ/TQ domain which may be i
./___Corpus/Medline/xml/PMC4693276.xml	TQ	20976 : 20978	CM	C-terminal regulatory SQ/TQ domain which may be invo
./___Corpus/Medline/xml/PMC4693276.xml	G2	21251 : 21253	CM	the cell cycle from S to G2/M phase. Chk1 is also a 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	21350 : 21364	CM	onse to DNA damage, Chk1 phosphorylates and thus inhibits Cdc25 
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	21383 : 21388	CM	ylates and thus inhibits Cdc25 phosphatases, particular
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25A	21416 : 21422	CM	osphatases, particularly Cdc25A which is its main target
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	21461 : 21466	CM	main target. This causes Cdc25 degradation, inhibition 
./___Corpus/Medline/xml/PMC4693276.xml	Phosphorylation	21866 : 21881	RN	s.                  3.2. Phosphorylation of Chk1                 
./___Corpus/Medline/xml/PMC4693276.xml	ATR	21942 : 21945	CM	ctivation occurs through ATR-mediated phosphorylation
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	21955 : 21970	RN	urs through ATR-mediated phosphorylation of two conserved sites, 
./___Corpus/Medline/xml/PMC4693276.xml	Ser317	21995 : 22001	CM	 of two conserved sites, Ser317 and Ser345 [76]. These p
./___Corpus/Medline/xml/PMC4693276.xml	Ser345	22006 : 22012	CM	served sites, Ser317 and Ser345 [76]. These phosphorylat
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	22025 : 22040	RN	7 and Ser345 [76]. These phosphorylation events promote the autop
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	22060 : 22079	CM	ation events promote the autophosphorylation of Chk1 on Ser296, which
./___Corpus/Medline/xml/PMC4693276.xml	Ser296	22091 : 22097	CM	osphorylation of Chk1 on Ser296, which triggers its cell
./___Corpus/Medline/xml/PMC4693276.xml	pSer345	22175 : 22182	CM	 functions [77,78]. Chk1 pSer345 site has been described 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	22223 : 22238	RN	escribed as an important phosphorylation site for its catalytic a
./___Corpus/Medline/xml/PMC4693276.xml	chromatin	22399 : 22408	CM	release of Chk1 from the chromatin fraction into the solubl
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	22539 : 22553	RN	 and activated Chk1 then phosphorylates a number of downstream t
./___Corpus/Medline/xml/PMC4693276.xml	DSB	22650 : 22653	CM	 damage repair [81]. DNA DSB repair proteins involved
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	22732 : 22737	CM	 such as the key protein RAD51, have been identified am
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	22947 : 22961	CM	cally interacts with and phosphorylates RAD51 on Thr309, promoti
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	23008 : 23013	CM	oting the recruitment of RAD51 at DNA damage sites [82]
./___Corpus/Medline/xml/PMC4693276.xml	HU	23079 : 23081	CM	 Chk1 inhibitors impairs HU-induced RAD51 foci forma
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	23090 : 23095	CM	itors impairs HU-induced RAD51 foci formation, confirmi
./___Corpus/Medline/xml/PMC4693276.xml	DDR	23339 : 23342	CM	tion checkpoints and the DDR since this kinase is mai
./___Corpus/Medline/xml/PMC4693276.xml	G2	23387 : 23389	CM	s mainly responsible for G2/M checkpoint. The main c
./___Corpus/Medline/xml/PMC4693276.xml	p53	23582 : 23585	CM	ls suffer defects in the p53 pathway, cancer cells ha
./___Corpus/Medline/xml/PMC4693276.xml	G2	23642 : 23644	CM	aintain functional S and G2/M phases mediated by Chk
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	23784 : 23799	RN	atus is characterized by phosphorylation of Histone H3 (on Ser10)
./___Corpus/Medline/xml/PMC4693276.xml	Histone	23803 : 23810	CM	ed by phosphorylation of Histone H3 (on Ser10) and aberra
./___Corpus/Medline/xml/PMC4693276.xml	Ser10	23818 : 23823	CM	lation of Histone H3 (on Ser10) and aberrant mitotic sp
./___Corpus/Medline/xml/PMC4693276.xml	p53	23876 : 23879	CM	le formation [84]. These p53-related defects have bee
./___Corpus/Medline/xml/PMC4693276.xml	p53	24022 : 24025	CM	 to enhance apoptosis in p53-deficient tumour cell li
./___Corpus/Medline/xml/PMC4693276.xml	T-ALL	24515 : 24520	CM	 lymphoblastic leukemia (T-ALL) enables cellular prolif
./___Corpus/Medline/xml/PMC4693276.xml	G2	24811 : 24813	CM	ell survival by inducing G2 arrest and signalling to
./___Corpus/Medline/xml/PMC4693276.xml	UCN-01	25335 : 25341	CM	                  3.4.1. UCN-01 (7-Hydroxystaurosporine)
./___Corpus/Medline/xml/PMC4693276.xml	7-Hydroxystaurosporine	25343 : 25365	CM	          3.4.1. UCN-01 (7-Hydroxystaurosporine)                      Th
./___Corpus/Medline/xml/PMC4693276.xml	vitro	25495 : 25500	CM	equently been used in in vitro experiments but its nons
./___Corpus/Medline/xml/PMC4693276.xml	SCH900776	25747 : 25756	CM	tor (Previously Known as SCH900776) (Pyrazolo [1,5-a] Pyrim
./___Corpus/Medline/xml/PMC4693276.xml	Pyrazolo	25759 : 25767	CM	sly Known as SCH900776) (Pyrazolo [1,5-a] Pyrimidine Deriv
./___Corpus/Medline/xml/PMC4693276.xml	1,5-a	25769 : 25774	CM	as SCH900776) (Pyrazolo [1,5-a] Pyrimidine Derivative) 
./___Corpus/Medline/xml/PMC4693276.xml	Pyrimidine	25776 : 25786	CM	00776) (Pyrazolo [1,5-a] Pyrimidine Derivative)             
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	26088 : 26094	CM	sed on the assessment of γ-H2AX foci accumulation, known
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	26135 : 26139	CM	on, known as a marker of DSBs and collapsed replicatio
./___Corpus/Medline/xml/PMC4693276.xml	SCH900776	26192 : 26201	CM	orks. The Chk1 inhibitor SCH900776 was thus discovered [98]
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	26284 : 26290	CM	hly reactive. It induced γ-H2AX accumulation and suppres
./___Corpus/Medline/xml/PMC4693276.xml	pS296	26319 : 26324	CM	umulation and suppressed pS296 Chk1 autophosphorylation
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	26330 : 26349	CM	nd suppressed pS296 Chk1 autophosphorylation within two hours. This C
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	26411 : 26422	CM	r has been combined with gemcitabine treatment and has shown 
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	26615 : 26621	CM	rease and persistence of γ-H2AX foci. The ex vivo assay 
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	26663 : 26669	CM	o assay of intracellular γ-H2AX foci in gemtacibine-expo
./___Corpus/Medline/xml/PMC4693276.xml	gemtacibine	26678 : 26689	CM	acellular γ-H2AX foci in gemtacibine-exposed cells from patie
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	26916 : 26927	CM	hich HR is proficient to gemcitabine-radiation treatment [99]
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	27058 : 27069	CM	moted a sensitization to gemcitabine-radiation that is associ
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	27118 : 27123	CM	iated with inhibition of RAD51 foci formation. This res
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	27201 : 27206	CM	k1 in the recruitment of RAD51 on DNA damage sites. In 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	27357 : 27362	CPR	th pemetrexed, a classic anti-metabolite drug. The auth
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	27627 : 27634	CM	                  3.4.3. AZD7762                      AZD
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	27656 : 27663	CM	762                      AZD7762 is an ATP competitive Ch
./___Corpus/Medline/xml/PMC4693276.xml	ATP	27670 : 27673	CM	           AZD7762 is an ATP competitive Chk1 inhibit
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	28368 : 28375	CM	port, the combination of AZD7762 with gemcitabine and ion
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	28381 : 28392	CM	bination of AZD7762 with gemcitabine and ionizing radiation w
./___Corpus/Medline/xml/PMC4693276.xml	vitro	28432 : 28437	CM	adiation was assessed in vitro and allowed sensitizing 
./___Corpus/Medline/xml/PMC4693276.xml	G2	28523 : 28525	CM	dition to abrogating the G2/M checkpoint, the inhibi
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	28641 : 28648	CM	ion [83]. More recently, AZD7762-mediated sensitization h
./___Corpus/Medline/xml/PMC4693276.xml	vitro	28837 : 28842	CM	herapy [102,103]. The in vitro cytotoxicity of AZD7762 
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	28859 : 28866	CM	in vitro cytotoxicity of AZD7762 has also been investigat
./___Corpus/Medline/xml/PMC4693276.xml	MM	28897 : 28899	CM	lso been investigated on MM cell lines. Combined wit
./___Corpus/Medline/xml/PMC4693276.xml	melphalan	28951 : 28960	CM	alkyling agents, such as melphalan, AZD7762 promoted apopto
./___Corpus/Medline/xml/PMC4693276.xml	AZD7762	28962 : 28969	CM	ents, such as melphalan, AZD7762 promoted apoptosis and m
./___Corpus/Medline/xml/PMC4693276.xml	ATP	29163 : 29166	CM	e inhibitor for the Chk1 ATP site. Its specificity is
./___Corpus/Medline/xml/PMC4693276.xml	HGS	29422 : 29425	CM	ncer, high-grade serous (HGS) carcinoma, is character
./___Corpus/Medline/xml/PMC4693276.xml	HGS	29537 : 29540	CM	 [106]. The treatment of HGS cells by PF-477736 combi
./___Corpus/Medline/xml/PMC4693276.xml	T-ALL	29734 : 29739	CM	trated that treatment of T-ALL cells by PF-477736 promo
./___Corpus/Medline/xml/PMC4693276.xml	G2	29884 : 29886	CM	d with the abrogation of G2/M checkpoint in T-ALL ce
./___Corpus/Medline/xml/PMC4693276.xml	T-ALL	29903 : 29908	CM	on of G2/M checkpoint in T-ALL cells. Interestingly, th
./___Corpus/Medline/xml/PMC4693276.xml	vitro	30001 : 30006	CM	ormal thymocyte cells in vitro which shows the ability 
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30288 : 30297	CM	of the other inhibitors, LY2603618 binds to the ATP binding
./___Corpus/Medline/xml/PMC4693276.xml	ATP	30311 : 30314	CM	, LY2603618 binds to the ATP binding site of Chk1. Th
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30354 : 30363	CM	f Chk1. The phenotype of LY2603618-treated cells was simila
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30532 : 30541	CM	 the characterization of LY2603618 has been reported [107].
./___Corpus/Medline/xml/PMC4693276.xml	G2	30626 : 30628	CM	was able to abrogate the G2/M DNA damage checkpoint 
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	30688 : 30699	CM	ancer cells treated with gemcitabine and doxorubicine. It has
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicine	30704 : 30716	CM	ted with gemcitabine and doxorubicine. It has been demonstrate
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30748 : 30757	CM	s been demonstrated that LY2603618 potentiated the effect o
./___Corpus/Medline/xml/PMC4693276.xml	vitro	30804 : 30809	CM	t of DNA damage drugs in vitro. This result was also va
./___Corpus/Medline/xml/PMC4693276.xml	LY2603618	30885 : 30894	CM	mour xenograft approach. LY2603618 is the most advanced mol
./___Corpus/Medline/xml/PMC4693276.xml	CHR-124	31379 : 31386	CM	idates such as XL844 and CHR-124 have been proposed but t
./___Corpus/Medline/xml/PMC4693276.xml	serine	31686 : 31692	CM	                     The serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	31693 : 31702	CM	              The serine/threonine protein kinase Chk2 has 
./___Corpus/Medline/xml/PMC4693276.xml	SQ	31855 : 31857	CM	ree important domains: a SQ/TQ cluster domain (SCD),
./___Corpus/Medline/xml/PMC4693276.xml	TQ	31858 : 31860	CM	 important domains: a SQ/TQ cluster domain (SCD), a 
./___Corpus/Medline/xml/PMC4693276.xml	N-	31934 : 31936	CPR	) domain located at the N-terminus and a kinase doma
./___Corpus/Medline/xml/PMC4693276.xml	C-	31974 : 31976	CPR	 kinase domain near the C-terminus of the protein [1
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	32022 : 32026	CM	n [111]. In instances of DSBs, Chk2 is thought to be t
./___Corpus/Medline/xml/PMC4693276.xml	DDR	32161 : 32164	CM	nstream effectors of the DDR. Its activation is initi
./___Corpus/Medline/xml/PMC4693276.xml	ATM	32197 : 32200	CM	tivation is initiated by ATM phosphorylation on Thr68
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32201 : 32216	RN	tion is initiated by ATM phosphorylation on Thr68 and other resid
./___Corpus/Medline/xml/PMC4693276.xml	N-	32253 : 32255	CPR	d other residues in its N-terminus, which triggers c
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32311 : 32326	RN	ational changes and auto-phosphorylation on many residues for com
./___Corpus/Medline/xml/PMC4693276.xml	53BP1	32434 : 32439	CM	by many proteins such as 53BP1, MDC1, NBS1 [114,115,116
./___Corpus/Medline/xml/PMC4693276.xml	MDC1	32441 : 32445	CM	 proteins such as 53BP1, MDC1, NBS1 [114,115,116,117,1
./___Corpus/Medline/xml/PMC4693276.xml	NBS1	32447 : 32451	CM	ins such as 53BP1, MDC1, NBS1 [114,115,116,117,118]. T
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32562 : 32577	RN	gression by inactivating phosphorylation of Cdc25 family proteins
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25	32581 : 32586	CM	ating phosphorylation of Cdc25 family proteins (A, B an
./___Corpus/Medline/xml/PMC4693276.xml	p53	32674 : 32677	CM	 involved in DNA repair, p53 signalling, and apoptosi
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylates	32723 : 32737	CM	tosis. Among these, Chk2 phosphorylates BRCA2 on Thr3387, which 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	32738 : 32743	CM	ese, Chk2 phosphorylates BRCA2 on Thr3387, which is cri
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	32778 : 32783	CM	7, which is critical for RAD51 localization to DSBs [12
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	32800 : 32804	CM	or RAD51 localization to DSBs [120]. The kinase also f
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	32851 : 32856	CM	o facilitates HR through BRCA1 phosphorylation on Ser98
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	32857 : 32872	RN	litates HR through BRCA1 phosphorylation on Ser988 [121]. Chk2 in
./___Corpus/Medline/xml/PMC4693276.xml	Ser988	32876 : 32882	CM	BRCA1 phosphorylation on Ser988 [121]. Chk2 inhibitors (
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	33326 : 33332	CM	                    4.1. PV1019 ([7-Nitro-1H-Indole-2-Ca
./___Corpus/Medline/xml/PMC4693276.xml	7-Nitro-1H-Indole-2-Carboxylic Acid {(4-[1-(Guanidinohydrazone)-Ethyl]-Phenyl}-Amide]	33335 : 33420	CM	           4.1. PV1019 ([7-Nitro-1H-Indole-2-Carboxylic Acid {(4-[1-(Guanidinohydrazone)-Ethyl]-Phenyl}-Amide]                         
./___Corpus/Medline/xml/PMC4693276.xml	100,000-	33535 : 33543	CPR	as conducted on a 100,000-compounds library, using an immo
./___Corpus/Medline/xml/PMC4693276.xml	IMAP	33634 : 33638	CM	ence polarization assay (IMAP), a member of the guanid
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazones	33657 : 33675	CM	 (IMAP), a member of the guanidylhydrazones, named NSC109555, emerge
./___Corpus/Medline/xml/PMC4693276.xml	NSC109555	33683 : 33692	CM	uanidylhydrazones, named NSC109555, emerged as the sole hit
./___Corpus/Medline/xml/PMC4693276.xml	histone	33805 : 33812	CM	 Chk2 kinase activity on histone H1, but was not cell pen
./___Corpus/Medline/xml/PMC4693276.xml	H1	33813 : 33815	CM	nase activity on histone H1, but was not cell penetr
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazone	33873 : 33890	CM	]. Removal of the second guanidylhydrazone group and replacement of
./___Corpus/Medline/xml/PMC4693276.xml	aryl urea	33932 : 33941	CM	ement of one side of the aryl urea with a 7-nitroindole mot
./___Corpus/Medline/xml/PMC4693276.xml	7-nitroindole	33949 : 33962	CM	 of the aryl urea with a 7-nitroindole motif linked through an 
./___Corpus/Medline/xml/PMC4693276.xml	amide	33987 : 33992	CM	 motif linked through an amide gave rise to a new cell-
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34037 : 34043	CM	cell-penetrant molecule, PV1019, with improved affinity 
./___Corpus/Medline/xml/PMC4693276.xml	autophosphorylation	34207 : 34226	CM	ed by assessment of Chk2 autophosphorylation, and phosphorylation of 
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	34232 : 34247	RN	autophosphorylation, and phosphorylation of downstream targets Cd
./___Corpus/Medline/xml/PMC4693276.xml	Cdc25c	34270 : 34276	CM	on of downstream targets Cdc25c and HDMX. Other analogue
./___Corpus/Medline/xml/PMC4693276.xml	HDMX	34281 : 34285	CM	tream targets Cdc25c and HDMX. Other analogues of PV10
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34306 : 34312	CM	HDMX. Other analogues of PV1019 with increased cell perm
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34389 : 34395	CM	ve been developed [122]. PV1019 is the only guanidylhydr
./___Corpus/Medline/xml/PMC4693276.xml	guanidylhydrazone	34408 : 34425	CM	122]. PV1019 is the only guanidylhydrazone tested in cells to be ab
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34585 : 34591	CM	d by this study was that PV1019 potentiated effect of tw
./___Corpus/Medline/xml/PMC4693276.xml	camptothecin	34660 : 34672	CM	nhibitors, topotecan and camptothecin, or IR-treatment in vari
./___Corpus/Medline/xml/PMC4693276.xml	OVCAR-4	34766 : 34773	CM	varian cancer cell lines OVCAR-4 and 5, and the brain gli
./___Corpus/Medline/xml/PMC4693276.xml	PV1019	34859 : 34865	CM	he potentiation of IR by PV1019 (5 µM) was enhanced 1.4-
./___Corpus/Medline/xml/PMC4693276.xml	kinome	35067 : 35073	CM	                    In a kinome profiling study, Caldwel
./___Corpus/Medline/xml/PMC4693276.xml	2-(quinazolin-2-yl)-phenols	35156 : 35183	CM	ompound belonging to the 2-(quinazolin-2-yl)-phenols molecules that inhibited
./___Corpus/Medline/xml/PMC4693276.xml	CCT241533	35261 : 35270	CM	zation of the hit led to CCT241533 synthesis, a more effici
./___Corpus/Medline/xml/PMC4693276.xml	Asn352	35346 : 35352	CM	nteracts with Met304 and Asn352 of Chk2 via hydrogen bon
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	35365 : 35373	CM	4 and Asn352 of Chk2 via hydrogen bonds. CCT241533 had a h
./___Corpus/Medline/xml/PMC4693276.xml	CCT241533	35381 : 35390	CM	Chk2 via hydrogen bonds. CCT241533 had a high passive perme
./___Corpus/Medline/xml/PMC4693276.xml	SN38	35531 : 35535	CM	damaging agents, such as SN38, gemcitabine, mitomycin 
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	35537 : 35548	CM	ng agents, such as SN38, gemcitabine, mitomycin C, bleomycin 
./___Corpus/Medline/xml/PMC4693276.xml	mitomycin C	35550 : 35561	CM	ch as SN38, gemcitabine, mitomycin C, bleomycin or etoposide 
./___Corpus/Medline/xml/PMC4693276.xml	bleomycin	35563 : 35572	CM	emcitabine, mitomycin C, bleomycin or etoposide on p53-defi
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	35576 : 35585	CM	itomycin C, bleomycin or etoposide on p53-deficient cells H
./___Corpus/Medline/xml/PMC4693276.xml	p53	35589 : 35592	CM	leomycin or etoposide on p53-deficient cells HT29 and
./___Corpus/Medline/xml/PMC4693276.xml	HT29	35609 : 35613	CM	e on p53-deficient cells HT29 and HeLa, but interestin
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35618 : 35622	CM	deficient cells HT29 and HeLa, but interestingly poten
./___Corpus/Medline/xml/PMC4693276.xml	PARP	35668 : 35672	CM	otentiated effect of two PARP inhibitors AG14447 and o
./___Corpus/Medline/xml/PMC4693276.xml	AG14447	35684 : 35691	CM	t of two PARP inhibitors AG14447 and olaparib [129]. This
./___Corpus/Medline/xml/PMC4693276.xml	HT29	35760 : 35764	CM	ased cell growth in both HT29 and HeLa cancer cell lin
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35769 : 35773	CM	 growth in both HT29 and HeLa cancer cell lines in the
./___Corpus/Medline/xml/PMC4693276.xml	CCT241533	35827 : 35836	CM	sence of 1.5 µM and 3 µM CCT241533 respectively. Furthermor
./___Corpus/Medline/xml/PMC4693276.xml	CCT241533	35879 : 35888	CM	thermore, combination of CCT241533 and olaparib enhanced ap
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	35924 : 35928	CM	ib enhanced apoptosis in HeLa cells by potentiating PA
./___Corpus/Medline/xml/PMC4693276.xml	PARP	35951 : 35955	CM	La cells by potentiating PARP inhibitor cytotoxicity i
./___Corpus/Medline/xml/PMC4693276.xml	CCT241533	36046 : 36055	CM	ty of the combination of CCT241533 and olaparib was attribu
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	36119 : 36124	CM	2-mediated inhibition of BRCA1 phosphorylation and conc
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	36125 : 36140	RN	ated inhibition of BRCA1 phosphorylation and concomitant HR impai
./___Corpus/Medline/xml/PMC4693276.xml	2-(4-(4-Chlorophenoxy)Phenyl)-1H-Benzimidazole-5-Carboxamide	36194 : 36254	CM	t.                  4.3. 2-(4-(4-Chlorophenoxy)Phenyl)-1H-Benzimidazole-5-Carboxamide Hydrate/BML277/C3742    
./___Corpus/Medline/xml/PMC4693276.xml	Hydrate	36255 : 36262	RN	zimidazole-5-Carboxamide Hydrate/BML277/C3742            
./___Corpus/Medline/xml/PMC4693276.xml	benzimidazole	36354 : 36367	CM	or, which belongs to the benzimidazole class of inhibitors, was
./___Corpus/Medline/xml/PMC4693276.xml	2-arylbenzamidazole	36443 : 36462	CM	hroughput screening of a 2-arylbenzamidazole library for binding to p
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	36688 : 36696	CM	main interactions: (1) a hydrogen interaction between the 
./___Corpus/Medline/xml/PMC4693276.xml	benzimidazole	36721 : 36734	CM	 interaction between the benzimidazole H1 and the carbonyl grou
./___Corpus/Medline/xml/PMC4693276.xml	carbonyl	36746 : 36754	CM	benzimidazole H1 and the carbonyl group of Glu302 and the 
./___Corpus/Medline/xml/PMC4693276.xml	amide	36779 : 36784	CM	 group of Glu302 and the amide NH of Met304; (2) bindin
./___Corpus/Medline/xml/PMC4693276.xml	carboxamide	36818 : 36829	CM	t304; (2) binding of the carboxamide group with many residues
./___Corpus/Medline/xml/PMC4693276.xml	4-chlorophenyl	36910 : 36924	CM	d (3) interaction of the 4-chlorophenyl substituent with hydroph
./___Corpus/Medline/xml/PMC4693276.xml	Leu226	37006 : 37012	CM	rance of the ATP-pocket (Leu226, Leu236, Lys245, Leu303 
./___Corpus/Medline/xml/PMC4693276.xml	Leu236	37014 : 37020	CM	 the ATP-pocket (Leu226, Leu236, Lys245, Leu303 and Glu3
./___Corpus/Medline/xml/PMC4693276.xml	Lys245	37022 : 37028	CM	-pocket (Leu226, Leu236, Lys245, Leu303 and Glu305) [131
./___Corpus/Medline/xml/PMC4693276.xml	Leu303	37030 : 37036	CM	(Leu226, Leu236, Lys245, Leu303 and Glu305) [131]. This 
./___Corpus/Medline/xml/PMC4693276.xml	p53	37098 : 37101	CM	wed protective effect in p53 wild-type CD4+ and CD8+ 
./___Corpus/Medline/xml/PMC4693276.xml	CD4+	37112 : 37116	CM	 effect in p53 wild-type CD4+ and CD8+ T-cells exposed
./___Corpus/Medline/xml/PMC4693276.xml	CD8+	37121 : 37125	CM	n p53 wild-type CD4+ and CD8+ T-cells exposed to IR in
./___Corpus/Medline/xml/PMC4693276.xml	Debromohymenialdisine	37292 : 37313	CM	y.                  4.4. Debromohymenialdisine and Analogues           
./___Corpus/Medline/xml/PMC4693276.xml	debromohymenialdisine	37377 : 37398	CM	ed on the Chk2 inhibitor debromohymenialdisine identified in marine spo
./___Corpus/Medline/xml/PMC4693276.xml	pyrrole	37518 : 37525	CM	d by substitution of the pyrrole of the hymenialdisine co
./___Corpus/Medline/xml/PMC4693276.xml	indole	37561 : 37567	CM	enialdisine core with an indole group [132,133,134]. Thi
./___Corpus/Medline/xml/PMC4693276.xml	debromohymenialdisine	37681 : 37702	CM	 compared to the initial debromohymenialdisine. IR-treatment of non-mal
./___Corpus/Medline/xml/PMC4693276.xml	2-pyrrole	37869 : 37878	CM	 the substitution of the 2-pyrrole moiety with phenyl rings
./___Corpus/Medline/xml/PMC4693276.xml	phenyl	37891 : 37897	CM	he 2-pyrrole moiety with phenyl rings, increasing select
./___Corpus/Medline/xml/PMC4693276.xml	VRX0466617	38126 : 38136	CM	617                      VRX0466617 was synthesized using a 
./___Corpus/Medline/xml/PMC4693276.xml	isothiazole carboxamide	38260 : 38283	CM	ational starting from an isothiazole carboxamide identified by screening 
./___Corpus/Medline/xml/PMC4693276.xml	IC50	38377 : 38381	CM	nd selectivity for Chk2 (IC50 = 120 nM, Ki = 11 nM) co
./___Corpus/Medline/xml/PMC4693276.xml	Ki	38392 : 38394	CM	for Chk2 (IC50 = 120 nM, Ki = 11 nM) compared to Chk
./___Corpus/Medline/xml/PMC4693276.xml	IC50	38422 : 38426	CM	11 nM) compared to Chk1 (IC50 > 10 µM) [138]. This com
./___Corpus/Medline/xml/PMC4693276.xml	Phosphorylation	38535 : 38550	RN	kinase activity of Chk2. Phosphorylation on Ser19 and Ser33-35 wa
./___Corpus/Medline/xml/PMC4693276.xml	Ser19	38554 : 38559	CM	Chk2. Phosphorylation on Ser19 and Ser33-35 was inhibit
./___Corpus/Medline/xml/PMC4693276.xml	Ser33-35	38564 : 38572	CM	phorylation on Ser19 and Ser33-35 was inhibited in the pre
./___Corpus/Medline/xml/PMC4693276.xml	ATM	38628 : 38631	CM	of the molecule, but the ATM-dependent Thr68 phosphor
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	38648 : 38663	RN	 the ATM-dependent Thr68 phosphorylation of Chk2 was spared. HDMX
./___Corpus/Medline/xml/PMC4693276.xml	HDMX	38684 : 38688	CM	tion of Chk2 was spared. HDMX is a negative regulator 
./___Corpus/Medline/xml/PMC4693276.xml	p53	38716 : 38719	CM	 a negative regulator of p53 that is phosphorylated b
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylated	38728 : 38742	RN	regulator of p53 that is phosphorylated by Chk2 on Ser342 and Se
./___Corpus/Medline/xml/PMC4693276.xml	Ser342	38754 : 38760	CM	hosphorylated by Chk2 on Ser342 and Ser367 upon exposure
./___Corpus/Medline/xml/PMC4693276.xml	Ser367	38765 : 38771	CM	ed by Chk2 on Ser342 and Ser367 upon exposure to IR, lea
./___Corpus/Medline/xml/PMC4693276.xml	HDMX	38853 : 38857	CM	617 prevented IR-induced HDMX degradation in a concent
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	39005 : 39014	CM	ct of DNA-damaging drugs cisplatin and doxorubicin in MCF-7
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	39019 : 39030	CM	ging drugs cisplatin and doxorubicin in MCF-7 cancer cell lin
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	39034 : 39039	CM	latin and doxorubicin in MCF-7 cancer cell line, nor ta
./___Corpus/Medline/xml/PMC4693276.xml	taxol	39062 : 39067	CM	-7 cancer cell line, nor taxol in BJ-hTERT cells.      
./___Corpus/Medline/xml/PMC4693276.xml	BJ-hTERT	39071 : 39079	CM	 cell line, nor taxol in BJ-hTERT cells.                  
./___Corpus/Medline/xml/PMC4693276.xml	UCN-01	39156 : 39162	CM	small molecules, such as UCN-01 [139], AZD7762 [140], or
./___Corpus/Medline/xml/PMC4693276.xml	CHK2	39756 : 39760	CM	ty regarding the role of CHK2 inhibition and the conte
./___Corpus/Medline/xml/PMC4693276.xml	Poly(ADP) Ribose	39882 : 39898	CM	                  5. The Poly(ADP) Ribose Polymerase              
./___Corpus/Medline/xml/PMC4693276.xml	adenosine diphosphate	39937 : 39958	CM	                   Poly (adenosine diphosphate [ADP]) ribose polymerase
./___Corpus/Medline/xml/PMC4693276.xml	ADP	39960 : 39963	CM	 (adenosine diphosphate [ADP]) ribose polymerase (PAR
./___Corpus/Medline/xml/PMC4693276.xml	ribose	39966 : 39972	CM	osine diphosphate [ADP]) ribose polymerase (PARP) inhibi
./___Corpus/Medline/xml/PMC4693276.xml	PARP	39985 : 39989	CM	ADP]) ribose polymerase (PARP) inhibitors are a class 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	40161 : 40165	CM	ding of the functions of PARP enzymes in DNA repair. P
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	40189 : 40194	CM	P enzymes in DNA repair. PARP1 and PARP2 are the best s
./___Corpus/Medline/xml/PMC4693276.xml	PARP2	40199 : 40204	CM	in DNA repair. PARP1 and PARP2 are the best studied enz
./___Corpus/Medline/xml/PMC4693276.xml	PARP	40246 : 40250	CM	died enzymes out of a 17 PARP protein family [142,143]
./___Corpus/Medline/xml/PMC4693276.xml	PARP	40291 : 40295	CM	[142,143]. Activation of PARP upon DNA damage leads to
./___Corpus/Medline/xml/PMC4693276.xml	poly(ADP)-ribose	40338 : 40354	CM	eads to the synthesis of poly(ADP)-ribose (pADPr), which is one of
./___Corpus/Medline/xml/PMC4693276.xml	pADPr	40356 : 40361	CM	sis of poly(ADP)-ribose (pADPr), which is one of the ea
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	40466 : 40471	CM	n mammalian cells [144]. PARP1 catalysis the addition o
./___Corpus/Medline/xml/PMC4693276.xml	pADPr	40498 : 40503	CM	atalysis the addition of pADPr to chromatin-related pro
./___Corpus/Medline/xml/PMC4693276.xml	chromatin	40507 : 40516	CM	the addition of pADPr to chromatin-related proteins, increa
./___Corpus/Medline/xml/PMC4693276.xml	pADPr	40656 : 40661	CM	at DNA-damage sites in a pADPr-dependent manner [142,14
./___Corpus/Medline/xml/PMC4693276.xml	PARP	40732 : 40736	CM	                         PARP inhibitors are analogues
./___Corpus/Medline/xml/PMC4693276.xml	nicotinamide	40769 : 40781	CM	ors are analogues of the nicotinamide moiety of the NAD+ (nico
./___Corpus/Medline/xml/PMC4693276.xml	NAD+	40796 : 40800	CM	cotinamide moiety of the NAD+ (nicotinamide adenine di
./___Corpus/Medline/xml/PMC4693276.xml	nicotinamide adenine dinucleotide	40802 : 40835	CM	mide moiety of the NAD+ (nicotinamide adenine dinucleotide) [146,147,148] and their
./___Corpus/Medline/xml/PMC4693276.xml	PARP	40928 : 40932	CM	ubstrate binding site of PARP, acting as an effective 
./___Corpus/Medline/xml/PMC4693276.xml	CAT	40968 : 40971	CM	 an effective catalytic (CAT) inhibitor [146,147,149,
./___Corpus/Medline/xml/PMC4693276.xml	PARP	41013 : 41017	CM	147,149,150]. Inhibiting PARP catalysis blocks base ex
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	41158 : 41162	CM	SBs), which develop into DSBs in replicating cells. Su
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	41190 : 41194	CM	 replicating cells. Such DSBs require competent HR rep
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	41299 : 41304	CM	                     The BRCA1 and BRCA2 genes code for
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	41309 : 41314	CM	           The BRCA1 and BRCA2 genes code for proteins 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	41441 : 41446	CM	pathway. Normal cells of BRCA1/2 mutation carriers have
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	41484 : 41489	CM	arriers have one copy of BRCA1 or BRCA2 (BRCA1/2+/−), w
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	41493 : 41498	CM	ave one copy of BRCA1 or BRCA2 (BRCA1/2+/−), which allo
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	41500 : 41505	CM	 copy of BRCA1 or BRCA2 (BRCA1/2+/−), which allows them
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	41635 : 41639	CM	ever, when the wild-type BRCA is lost, these cells bec
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	41691 : 41695	CM	e defective in repairing DSBs by HR. Instead, these le
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	41772 : 41776	CM	rror-prone mechanisms of NHEJ leading to genomic insta
./___Corpus/Medline/xml/PMC4693276.xml	PARP	41890 : 41894	CM	ch of the development of PARP inhibitors has been focu
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	42128 : 42133	CM	genes, when treated with PARPi will fail to undergo nor
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	42201 : 42205	CM	s selective targeting of BRCA-deficient cancer cells b
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	42232 : 42237	CM	eficient cancer cells by PARPi introduces the concept o
./___Corpus/Medline/xml/PMC4693276.xml	PARP	42417 : 42421	CM	 is nonviable. Moreover, PARP has been suggested to pa
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	42565 : 42570	CM	aged site and recruiting MRE11 to catalyse DNA-end proc
./___Corpus/Medline/xml/PMC4693276.xml	PARP	42627 : 42631	CM	 Therefore by inhibiting PARP, stalled replication for
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	42863 : 42868	CM	scovery of such concept, PARPi have been developed with
./___Corpus/Medline/xml/PMC4693276.xml	CAT	42915 : 42918	CM	ith a highly efficacious CAT inhibitory concentration
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	43038 : 43043	CM	ondon, UK) was the first PARPi to demonstrate clinical 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	43080 : 43084	CM	ate clinical activity in BRCA mutation-associated canc
./___Corpus/Medline/xml/PMC4693276.xml	PARP	43159 : 43163	CM	ed that more than 90% of PARP enzymatic activity could
./___Corpus/Medline/xml/PMC4693276.xml	PARP	43330 : 43334	CM	single-agent activity of PARP inhibition in patients w
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	43409 : 43414	CM	etic loss of function of BRCA1-associated or BRCA2-asso
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	43429 : 43434	CM	n of BRCA1-associated or BRCA2-associated DNA repair [1
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	43515 : 43520	CM	own that, in addition to BRCA1/BRCA2 mutations, BRCA-li
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	43521 : 43526	CM	at, in addition to BRCA1/BRCA2 mutations, BRCA-like tum
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	43538 : 43542	CM	o BRCA1/BRCA2 mutations, BRCA-like tumours may also ha
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	43587 : 43592	CM	so have implications for PARPi-based therapy. These tum
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	43726 : 43730	CM	 patients with germ line BRCA mutations (gBRCAm) [159]
./___Corpus/Medline/xml/PMC4693276.xml	gBRCAm	43742 : 43748	CM	erm line BRCA mutations (gBRCAm) [159]. Furthermore, a w
./___Corpus/Medline/xml/PMC4693276.xml	PARP	43898 : 43902	CM	s to become sensitive to PARP inhibitors [160,161,162,
./___Corpus/Medline/xml/PMC4693276.xml	gBRCAm	44043 : 44049	CM	ical features similar to gBRCAm-associated tumours, prom
./___Corpus/Medline/xml/PMC4693276.xml	PARP	44115 : 44119	CM	l development of various PARP inhibitors either as sin
./___Corpus/Medline/xml/PMC4693276.xml	PARP	44307 : 44311	CM	    There are at least 8 PARP inhibitors (depicted in 
./___Corpus/Medline/xml/PMC4693276.xml	IC50	44453 : 44457	CM	rib) is a potent (PARP-1 IC50 = 5nM) oral PARP1/2 inhi
./___Corpus/Medline/xml/PMC4693276.xml	5nM	44460 : 44463	CM	 a potent (PARP-1 IC50 = 5nM) oral PARP1/2 inhibitor 
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	44470 : 44475	CM	(PARP-1 IC50 = 5nM) oral PARP1/2 inhibitor [156] whose 
./___Corpus/Medline/xml/PMC4693276.xml	FDA	44564 : 44567	CM	o the approval by the US FDA and the European commiss
./___Corpus/Medline/xml/PMC4693276.xml	FDA	44611 : 44614	CM	ommission (report on the FDA website) for the treatme
./___Corpus/Medline/xml/PMC4693276.xml	platinum	44659 : 44667	CM	eatment of patients with platinum-sensitive, recurrent, hi
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	44728 : 44733	CM	rous ovarian cancer with BRCA1 or BRCA2 mutations. This
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	44737 : 44742	CM	ian cancer with BRCA1 or BRCA2 mutations. This is the f
./___Corpus/Medline/xml/PMC4693276.xml	PARP	44798 : 44802	CM	pproval of a drug in the PARP inhibitor class and effo
./___Corpus/Medline/xml/PMC4693276.xml	anti-	45059 : 45064	CPR	luating olaparib for its anti-tumour activity in metast
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	45450 : 45455	CM	 olaparib monotherapy in BRCA1/2 mutation carriers of d
./___Corpus/Medline/xml/PMC4693276.xml	gBRCAm	45616 : 45622	CM	n and breast cancer. The gBRCAm-associated pancreatic ca
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	46050 : 46054	CM	uch as tumour suppressor PTEN [168]. Such event was la
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	46132 : 46136	CM	studies in xenografts of PTEN-deficient endometrial ca
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	46243 : 46247	CM	rther studies in whether PTEN loss can serve as a pote
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	46292 : 46297	CM	 potential biomarker for PARPi sensitivity [171,172,173
./___Corpus/Medline/xml/PMC4693276.xml	CT	46504 : 46506	CM	nventional chemotherapy (CT), also giving strong evi
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	46571 : 46576	CM	le biomarkers to predict PARPi resistance or response [
./___Corpus/Medline/xml/PMC4693276.xml	Inc	46675 : 46678	CM	 BioMarin Pharmaceutical Inc., Novato, CA, USA)      
./___Corpus/Medline/xml/PMC4693276.xml	CA	46689 : 46691	CM	maceutical Inc., Novato, CA, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	46742 : 46747	CM	  Talazoparib is an oral PARP1/2 inhibitor with greater
./___Corpus/Medline/xml/PMC4693276.xml	vitro	46776 : 46781	CM	nhibitor with greater in vitro activity than any other 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	46806 : 46810	CM	 activity than any other PARP inhibitor currently in d
./___Corpus/Medline/xml/PMC4693276.xml	IC50	46854 : 46858	CM	y in development (PARP-1 IC50 = 0.6 nM) [173]. Much li
./___Corpus/Medline/xml/PMC4693276.xml	BMN	46896 : 46899	CM	73]. Much like olaparib, BMN 673 has been shown to ca
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	46964 : 46969	CM	t synthetic lethality in BRCA1/2- and PTEN-deficient ce
./___Corpus/Medline/xml/PMC4693276.xml	2-	46971 : 46973	CPR	etic lethality in BRCA1/2- and PTEN-deficient cell l
./___Corpus/Medline/xml/PMC4693276.xml	PTEN	46977 : 46981	CM	ethality in BRCA1/2- and PTEN-deficient cell lines, wi
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	47257 : 47262	CM	r harbouring deleterious BRCA1/2 mutations. Furthermore
./___Corpus/Medline/xml/PMC4693276.xml	BMN	47289 : 47292	CM	 mutations. Furthermore, BMN 673 has also demonstrate
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	47359 : 47362	CM	he antitumour effects of TMZ, cisplatin (CIS), and ca
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	47364 : 47373	CM	titumour effects of TMZ, cisplatin (CIS), and carboplatin [
./___Corpus/Medline/xml/PMC4693276.xml	CIS	47375 : 47378	CM	fects of TMZ, cisplatin (CIS), and carboplatin [173].
./___Corpus/Medline/xml/PMC4693276.xml	carboplatin	47385 : 47396	CM	MZ, cisplatin (CIS), and carboplatin [173]. These therapeutic
./___Corpus/Medline/xml/PMC4693276.xml	pADPr	47481 : 47486	CM	le toxicity, evidence of pADPr inhibition in vivo in an
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	47825 : 47830	CM	gnancies and deleterious BRCA1/2 mutation-associated ca
./___Corpus/Medline/xml/PMC4693276.xml	Inc	47932 : 47935	CM	liparib (ABT-888; AbbVie Inc., North Chicago, IL, USA
./___Corpus/Medline/xml/PMC4693276.xml	IL	47953 : 47955	CM	Vie Inc., North Chicago, IL, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	Ki	48037 : 48039	CM	RP-1/2 inhibitor (PARP-1 Ki = 5nM) with nanomolar ce
./___Corpus/Medline/xml/PMC4693276.xml	5nM	48042 : 48045	CM	2 inhibitor (PARP-1 Ki = 5nM) with nanomolar cell-bas
./___Corpus/Medline/xml/PMC4693276.xml	CNS	48130 : 48133	CM	ility [176] and apparent CNS penetration [164]. Precl
./___Corpus/Medline/xml/PMC4693276.xml	CT	48262 : 48264	CM	eliparib potentiates the CT effect of a number of ag
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	48304 : 48307	CM	mber of agents including TMZ, platinum, and irinoteca
./___Corpus/Medline/xml/PMC4693276.xml	platinum	48309 : 48317	CM	of agents including TMZ, platinum, and irinotecan (CPT), a
./___Corpus/Medline/xml/PMC4693276.xml	CPT	48335 : 48338	CM	latinum, and irinotecan (CPT), as well as radiation [
./___Corpus/Medline/xml/PMC4693276.xml	platinum	48732 : 48740	CM	gs, with veliparib and a platinum agent, mFOLFOX-6 (modifi
./___Corpus/Medline/xml/PMC4693276.xml	mFOLFOX-6	48748 : 48757	CM	ib and a platinum agent, mFOLFOX-6 (modified 5-fluorouracil
./___Corpus/Medline/xml/PMC4693276.xml	5-fluorouracil	48768 : 48782	CM	ent, mFOLFOX-6 (modified 5-fluorouracil and oxaliplatin), for pa
./___Corpus/Medline/xml/PMC4693276.xml	oxaliplatin	48787 : 48798	CM	ified 5-fluorouracil and oxaliplatin), for patients with meta
./___Corpus/Medline/xml/PMC4693276.xml	MPC	48849 : 48852	CM	tatic pancreatic cancer (MPC). The combination has de
./___Corpus/Medline/xml/PMC4693276.xml	MPC	48910 : 48913	CM	ed promising efficacy in MPC, particularly in patient
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	48945 : 48950	CM	cularly in patients with BRCA2 gene mutations [180]. Ot
./___Corpus/Medline/xml/PMC4693276.xml	CT	49043 : 49045	CM	 combination with RT and CT, respectively, in variou
./___Corpus/Medline/xml/PMC4693276.xml	CO	49166 : 49168	CM	lovis Oncology, Boulder, CO, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	PARP	49229 : 49233	CM	b is an intravenous (IV) PARP inhibitor characterized 
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	49270 : 49275	CM	haracterized as a potent PARPi (PARP-1 IC50 = 2 nM) in 
./___Corpus/Medline/xml/PMC4693276.xml	IC50	49284 : 49288	CM	s a potent PARPi (PARP-1 IC50 = 2 nM) in cell based as
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	49545 : 49550	CM	 epigenetically silenced BRCA1/2, indicating a potentia
./___Corpus/Medline/xml/PMC4693276.xml	PARP	49586 : 49590	CM	ing a potential role for PARP inhibitors in sporadic h
./___Corpus/Medline/xml/PMC4693276.xml	ARIEL2	49790 : 49796	CM	linical trials, known as ARIEL2 ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4693276.xml	ARIEL3	49895 : 49901	CM	91344"}}NCT01891344) and ARIEL3 ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4693276.xml	platinum	50169 : 50177	CM	n with high-grade serous platinum-sensitive relapsed ovari
./___Corpus/Medline/xml/PMC4693276.xml	CT	50403 : 50405	CM	ociates the conventional CT agent fluorouracil (5FU)
./___Corpus/Medline/xml/PMC4693276.xml	fluorouracil	50412 : 50424	CM	he conventional CT agent fluorouracil (5FU), used as a source 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	50626 : 50631	CM	mphoid leukemia cells in vitro and in vivo. This study 
./___Corpus/Medline/xml/PMC4693276.xml	Inc	50877 : 50880	CM	raparib (MK-4827; Tesaro Inc., Waltham, MA, USA)     
./___Corpus/Medline/xml/PMC4693276.xml	MA	50892 : 50894	CM	7; Tesaro Inc., Waltham, MA, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	50955 : 50960	CM	b is an orally available PARPi, which demonstrates pote
./___Corpus/Medline/xml/PMC4693276.xml	PARP-2	51013 : 51019	CM	and selective PARP-1 and PARP-2 inhibitory activity (IC5
./___Corpus/Medline/xml/PMC4693276.xml	IC50	51041 : 51045	CM	P-2 inhibitory activity (IC50 = 3.8 and 2.1 nM respect
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	51128 : 51133	CM	studied in patients with BRCA1/2 mutations and sporadic
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	51287 : 51291	CM	itumour activity in both BRCA-deficient and sporadic c
./___Corpus/Medline/xml/PMC4693276.xml	vitro	51432 : 51437	CM	f neuroblastoma cells in vitro. When experimented in vi
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	51908 : 51911	CM	combination regimen with TMZ in recurrent Ewing sarco
./___Corpus/Medline/xml/PMC4693276.xml	INO-1001	52360 : 52368	CM	ce)                      INO-1001 is an IV PARPi that show
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	52432 : 52435	CM	o restore sensitivity to TMZ in a mismatch-repair (MM
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	52726 : 52731	CM	 predictive biomarker of PARPi responsiveness in patien
./___Corpus/Medline/xml/PMC4693276.xml	IB	52799 : 52801	CM	 melanoma. A most recent IB trial concluded that the
./___Corpus/Medline/xml/PMC4693276.xml	INO-1001	52845 : 52853	CM	at the administration of INO-1001 in combination with TMZ 
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	52874 : 52877	CM	1001 in combination with TMZ is safe for metastatic m
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	52969 : 52974	CM	als are ongoing for this PARPi.                  5.6. E
./___Corpus/Medline/xml/PMC4693276.xml	Co	53011 : 53013	CM	       5.6. E7016 (Eisai Co., Ltd; Tokyo, Japan)    
./___Corpus/Medline/xml/PMC4693276.xml	PARP	53088 : 53092	CM	s an orally bioavailable PARP inhibitor that can enhan
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53225 : 53228	CM	used in combination with TMZ and radiation [195]. It 
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53450 : 53453	CM	cacy in combination with TMZ in patients with maligna
./___Corpus/Medline/xml/PMC4693276.xml	Cephalon	53529 : 53537	CM	          5.7. CEP-9722 (Cephalon, Inc.; Frazer, PA, USA) 
./___Corpus/Medline/xml/PMC4693276.xml	Inc	53539 : 53542	CM	5.7. CEP-9722 (Cephalon, Inc.; Frazer, PA, USA)      
./___Corpus/Medline/xml/PMC4693276.xml	PA	53553 : 53555	CM	(Cephalon, Inc.; Frazer, PA, USA)                   
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	53755 : 53758	CM	types of tumour cells to TMZ, CPT and radiation. Conc
./___Corpus/Medline/xml/PMC4693276.xml	CPT	53760 : 53763	CM	 of tumour cells to TMZ, CPT and radiation. Concluded
./___Corpus/Medline/xml/PMC4693276.xml	MTD	53853 : 53856	CM	 maximum tolerated dose (MTD) in patients with advanc
./___Corpus/Medline/xml/PMC4693276.xml	gemcitabine	53984 : 53995	CM	 MTD in combination with gemcitabine and CIS in advanced soli
./___Corpus/Medline/xml/PMC4693276.xml	CIS	54000 : 54003	CM	ion with gemcitabine and CIS in advanced solid tumour
./___Corpus/Medline/xml/PMC4693276.xml	TMZ	54261 : 54264	CM	combination therapy with TMZ in patients with advance
./___Corpus/Medline/xml/PMC4693276.xml	PARP	54565 : 54569	CM	 Overall, the utility of PARP inhibitors as therapeuti
./___Corpus/Medline/xml/PMC4693276.xml	PARP	54936 : 54940	CM	: Mechanism of Action of PARP Inhibitors              
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55027 : 55031	CM	 clinically investigated PARP inhibitors, including ta
./___Corpus/Medline/xml/PMC4693276.xml	veliparib	55102 : 55111	CM	 olaparib, rucaparib and veliparib, are highly efficacious 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55150 : 55154	CM	fficacious at inhibiting PARP CAT activity, with very 
./___Corpus/Medline/xml/PMC4693276.xml	CAT	55155 : 55158	CM	cious at inhibiting PARP CAT activity, with very simi
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	55347 : 55352	CM	ely by the inhibition of PARP1 and PARP2 CAT activity. 
./___Corpus/Medline/xml/PMC4693276.xml	PARP2	55357 : 55362	CM	 inhibition of PARP1 and PARP2 CAT activity. However, s
./___Corpus/Medline/xml/PMC4693276.xml	CAT	55363 : 55366	CM	ition of PARP1 and PARP2 CAT activity. However, sever
./___Corpus/Medline/xml/PMC4693276.xml	CAT	55455 : 55458	CM	ted that, in addition to CAT inhibition, PARP inhibit
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55471 : 55475	CM	ition to CAT inhibition, PARP inhibitors have the capa
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	55517 : 55522	CM	the capacity of trapping PARP1 and PARP2 at SSB sites, 
./___Corpus/Medline/xml/PMC4693276.xml	PARP2	55527 : 55532	CM	ty of trapping PARP1 and PARP2 at SSB sites, possibly v
./___Corpus/Medline/xml/PMC4693276.xml	SSB	55536 : 55539	CM	pping PARP1 and PARP2 at SSB sites, possibly via a po
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55650 : 55654	CM	xibility and dynamics of PARP, enhancing its affinity 
./___Corpus/Medline/xml/PMC4693276.xml	SSB	55687 : 55690	CM	ing its affinity for the SSB repair intermediate [202
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55884 : 55888	CM	han genetic depletion of PARP [202,205]. This recent m
./___Corpus/Medline/xml/PMC4693276.xml	PARP	55947 : 55951	CM	of action is denominated PARP poisoning or trapping.  
./___Corpus/Medline/xml/PMC4693276.xml	CAT	56016 : 56019	CM	                      If CAT inhibition was the only 
./___Corpus/Medline/xml/PMC4693276.xml	IC50	56102 : 56106	CM	ould expect that similar IC50 values of CAT activity w
./___Corpus/Medline/xml/PMC4693276.xml	CAT	56117 : 56120	CM	t similar IC50 values of CAT activity would result in
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	56154 : 56159	CM	 would result in similar PARPi cytotoxicity potency. Wh
./___Corpus/Medline/xml/PMC4693276.xml	PARP	56236 : 56240	CM	ated that the ability of PARP inhibitors both in terms
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	56294 : 56298	CM	single-agent activity in BRCA-deficient cells and in t
./___Corpus/Medline/xml/PMC4693276.xml	alkylating	56359 : 56369	RN	ation of cancer cells to alkylating agents, differ by severa
./___Corpus/Medline/xml/PMC4693276.xml	25-	56535 : 56538	CPR	parib is approximately 25- to 100-fold more potent. O
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	56540 : 56548	CM	 is approximately 25- to 100-fold more potent. On the othe
./___Corpus/Medline/xml/PMC4693276.xml	10,000-fold	56604 : 56615	CM	, veliparib is ~1000- to 10,000-fold less potent than talazop
./___Corpus/Medline/xml/PMC4693276.xml	CAT	56772 : 56775	CM	lained by differences in CAT inhibition or by differe
./___Corpus/Medline/xml/PMC4693276.xml	PARP	56833 : 56837	CM	f-target activity of the PARP inhibitors. In fact, ola
./___Corpus/Medline/xml/PMC4693276.xml	PARP	56943 : 56947	CM	ainst 13 of the 17 human PARP family members and do no
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	57058 : 57063	CM	comparable to both these PARPi in its selectivity profi
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	57183 : 57188	CM	by the resistance effect PARP1 knock out cells acquired
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	57257 : 57262	CM	3]. Likewise, cells with PARP1 loss-of-function mutatio
./___Corpus/Medline/xml/PMC4693276.xml	100-fold	57294 : 57302	CM	f-function mutations are 100-fold more resistant to olapar
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	57383 : 57388	CM	These data indicate that PARP1 protein is the critical 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	57449 : 57453	CM	 the cytotoxic effect of PARP inhibitors, arguing agai
./___Corpus/Medline/xml/PMC4693276.xml	PARP	57702 : 57706	CM	hind such differences is PARP trapping, where PARP inh
./___Corpus/Medline/xml/PMC4693276.xml	PARP	57723 : 57727	CM	 is PARP trapping, where PARP inhibitors induce an all
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	57785 : 57790	CM	conformational change in PARP1 and PARP2, stabilizing t
./___Corpus/Medline/xml/PMC4693276.xml	PARP2	57795 : 57800	CM	onal change in PARP1 and PARP2, stabilizing their assoc
./___Corpus/Medline/xml/PMC4693276.xml	PARP	57954 : 57958	CM	onstrating that in fact, PARP inhibitors exert their c
./___Corpus/Medline/xml/PMC4693276.xml	PARP	58127 : 58131	CM	 widely across different PARP inhibitors [202,203]. Fi
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	58159 : 58164	CM	hibitors [202,203]. Five PARPi have been extensively te
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	58304 : 58309	CM	he PARP-DNA complexes by PARPi is reversible and these 
./___Corpus/Medline/xml/PMC4693276.xml	CAT	58453 : 58456	CM	Veliparib is primarily a CAT inhibitor with little tr
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	58537 : 58542	CM	h the effect observed in PARP1 loss-of-function mutant 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	58714 : 58718	CM	arib, and rucaparib trap PARP ~100-fold more efficient
./___Corpus/Medline/xml/PMC4693276.xml	PARP	58793 : 58797	CM	parib is the most potent PARP trapper studied to date,
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59004 : 59008	CM	cancer cytotoxicities of PARP inhibitors do not have a
./___Corpus/Medline/xml/PMC4693276.xml	CAT	59059 : 59062	CM	linear relationship with CAT inhibition, but instead 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59161 : 59165	CM	inical efficacy data for PARP inhibitors in cancer pat
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	59213 : 59217	CM	atients with deleterious BRCA gene mutations are consi
./___Corpus/Medline/xml/PMC4693276.xml	vitro	59260 : 59265	CM	e consistent with the in vitro cytotoxicity levels of t
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59293 : 59297	CM	totoxicity levels of the PARP inhibitors, nicely corre
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59376 : 59380	CM	with the ability to trap PARP [204].                  
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	59530 : 59535	CM	otency of equally strong PARP1 CAT inhibitors [202]. St
./___Corpus/Medline/xml/PMC4693276.xml	CAT	59536 : 59539	CM	 of equally strong PARP1 CAT inhibitors [202]. Studie
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59679 : 59683	CM	with the size or bulk of PARP inhibitors, which may ul
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59745 : 59749	CM	related to the degree of PARP trapping. It is understo
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59825 : 59829	CM	of structural data, that PARP inhibitors do in fact di
./___Corpus/Medline/xml/PMC4693276.xml	PARP	59957 : 59961	CM	Comparing to the bulkier PARP inhibitors, such as olap
./___Corpus/Medline/xml/PMC4693276.xml	PARP	60132 : 60136	CM	least potent in trapping PARP. Accordingly, it also do
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	60211 : 60216	CM	onformational changes on PARP1 in microsecond molecular
./___Corpus/Medline/xml/PMC4693276.xml	CAT	60327 : 60330	CM	ib demonstrates to cause CAT domain steric bumps on t
./___Corpus/Medline/xml/PMC4693276.xml	HD	60358 : 60360	CM	main steric bumps on the HD subdomain. These steric 
./___Corpus/Medline/xml/PMC4693276.xml	PARP1-DNA	60474 : 60483	CM	omains and stabilize the PARP1-DNA complex, therefore impli
./___Corpus/Medline/xml/PMC4693276.xml	HD	60519 : 60521	CM	herefore implicating the HD subdomain as a crucial s
./___Corpus/Medline/xml/PMC4693276.xml	methylpyrrolidine	60693 : 60710	CM	 can be explained by its methylpyrrolidine moiety being too small t
./___Corpus/Medline/xml/PMC4693276.xml	CAT	60772 : 60775	CM	ficant contacts with the CAT domain [176,210]. Furthe
./___Corpus/Medline/xml/PMC4693276.xml	PARP	60863 : 60867	CM	bitor size and degree of PARP trapping, a potent CAT i
./___Corpus/Medline/xml/PMC4693276.xml	CAT	60887 : 60890	CM	 PARP trapping, a potent CAT inhibitor in pre-clinica
./___Corpus/Medline/xml/PMC4693276.xml	PARP	61001 : 61005	CM	also shows low levels of PARP trapping activity [210,2
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	61060 : 61065	CM	However, among the bulky PARP1 inhibitors, no correlati
./___Corpus/Medline/xml/PMC4693276.xml	D-	61704 : 61706	CPR	ear to interact with the D-loop, localized at the ou
./___Corpus/Medline/xml/PMC4693276.xml	NAD+	61749 : 61753	CM	 the outer border of the NAD+ site. For instance, ruca
./___Corpus/Medline/xml/PMC4693276.xml	D-	61826 : 61828	CPR	ear to bind close to the D-loop, and olaparib forms 
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	61855 : 61863	CM	op, and olaparib forms a hydrogen bond with the D-loop res
./___Corpus/Medline/xml/PMC4693276.xml	D-	61878 : 61880	CPR	a hydrogen bond with the D-loop residue Met890 [210]
./___Corpus/Medline/xml/PMC4693276.xml	4-	62024 : 62026	CPR	212]. The stereospecific 4-fluorophenylsubstituent i
./___Corpus/Medline/xml/PMC4693276.xml	water	62116 : 62121	CM	he Met890 backbone via a water molecule and the Tyr889 
./___Corpus/Medline/xml/PMC4693276.xml	D-	62164 : 62166	CPR	Tyr889 side chain on the D-loop. This Tyr889 residue
./___Corpus/Medline/xml/PMC4693276.xml	D-	62518 : 62520	CPR	bitor interacts with the D-loop residues. These resi
./___Corpus/Medline/xml/PMC4693276.xml	HD	62581 : 62583	CM	ructurally linked to the HD subdomain. Therefore, st
./___Corpus/Medline/xml/PMC4693276.xml	CAT	62706 : 62709	CM	ional flexibility of the CAT domain. Additional studi
./___Corpus/Medline/xml/PMC4693276.xml	D-	62838 : 62840	CPR	chain flexibility of the D-loop residues, such as Ty
./___Corpus/Medline/xml/PMC4693276.xml	PARP	62874 : 62878	CM	dues, such as Tyr889, on PARP trapping [215].         
./___Corpus/Medline/xml/PMC4693276.xml	PARP	62963 : 62967	CM	ll, the effectiveness in PARP trapping may be an impor
./___Corpus/Medline/xml/PMC4693276.xml	PARP	63067 : 63071	CM	utic regimen involving a PARP inhibitor (single agent 
./___Corpus/Medline/xml/PMC4693276.xml	PARP	63217 : 63221	CM	xplains the differential PARP trapping between the inh
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	63386 : 63391	CM	s of the inhibitor-bound PARP1 CAT domain is a major st
./___Corpus/Medline/xml/PMC4693276.xml	CAT	63392 : 63395	CM	he inhibitor-bound PARP1 CAT domain is a major step i
./___Corpus/Medline/xml/PMC4693276.xml	MRE11-RAD50-NBS1	63491 : 63507	CM	                  6. The MRE11-RAD50-NBS1 Complex                 
./___Corpus/Medline/xml/PMC4693276.xml	MRE11-RAD50-NBS1	63541 : 63557	CM	                     The MRE11-RAD50-NBS1 (MRN) complex (Figure 2)
./___Corpus/Medline/xml/PMC4693276.xml	MRN	63559 : 63562	CM	   The MRE11-RAD50-NBS1 (MRN) complex (Figure 2) acts
./___Corpus/Medline/xml/PMC4693276.xml	DDR	63628 : 63631	CM	r and an effector in the DDR, with crucial roles in t
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	63695 : 63699	CM	signalling and repair of DSBs. Mre11 and Rad50 were or
./___Corpus/Medline/xml/PMC4693276.xml	NBS1	63909 : 63913	CM	ive to DNA damage [176]. NBS1 was later isolated as a 
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	63977 : 63982	CM	ternary complex, binding MRE11 and RAD50. Mutations in 
./___Corpus/Medline/xml/PMC4693276.xml	RAD50	63987 : 63992	CM	mplex, binding MRE11 and RAD50. Mutations in NBS1 gene 
./___Corpus/Medline/xml/PMC4693276.xml	NBS1	64007 : 64011	CM	 and RAD50. Mutations in NBS1 gene are linked to Nijme
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	64211 : 64216	CM	. In human, mutations in MRE11 cause A-T like disorder 
./___Corpus/Medline/xml/PMC4693276.xml	A-T	64223 : 64226	CM	mutations in MRE11 cause A-T like disorder [178] and 
./___Corpus/Medline/xml/PMC4693276.xml	RAD50	64253 : 64258	CM	ike disorder [178] and a RAD50 deficiency has been repo
./___Corpus/Medline/xml/PMC4693276.xml	NBS	64291 : 64294	CM	ncy has been reported in NBS-like disorder [179]. Nul
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	64409 : 64414	CM	y in mice [180,181,182]. MRE11 acts as a dimer [183], b
./___Corpus/Medline/xml/PMC4693276.xml	exo	64468 : 64471	CM	 DNA [184,185], presents exo- and endonuclease activi
./___Corpus/Medline/xml/PMC4693276.xml	exo-	64471 : 64475	CPR	A [184,185], presents exo- and endonuclease activities
./___Corpus/Medline/xml/PMC4693276.xml	RAD50	64558 : 64563	CM	 synapse DNA ends [183]. RAD50 carries an ATPase activi
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	64575 : 64581	CM	 [183]. RAD50 carries an ATPase activity used to maintai
./___Corpus/Medline/xml/PMC4693276.xml	NBS1	64643 : 64647	CM	n close proximity [188]. NBS1 recruits DNA repair and 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	64699 : 64702	CM	eckpoint proteins at the DSB site via phospho-depende
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	64756 : 64762	CM	nteractions, namely with γ-H2AX, checkpoint adaptor MDC1
./___Corpus/Medline/xml/PMC4693276.xml	MDC1	64783 : 64787	CM	H2AX, checkpoint adaptor MDC1 and HR regulator CtIP (C
./___Corpus/Medline/xml/PMC4693276.xml	CtIP	64805 : 64809	CM	or MDC1 and HR regulator CtIP (CtBP-interacting protei
./___Corpus/Medline/xml/PMC4693276.xml	MRN	64856 : 64859	CM	tein) [189,190,191,192]. MRN has been extensively stu
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	64932 : 64936	CM	role in the resection of DSBs that it owes to the endo
./___Corpus/Medline/xml/PMC4693276.xml	endo-	64961 : 64966	CPR	 that it owes to the endo- and exonuclease activities o
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	64993 : 64998	CM	xonuclease activities of MRE11. Resection contributes t
./___Corpus/Medline/xml/PMC4693276.xml	ATM	65097 : 65100	CM	 which are essential for ATM stimulation and subseque
./___Corpus/Medline/xml/PMC4693276.xml	DSB	65294 : 65297	CM	s a critical role in the DSB pathway choice by commit
./___Corpus/Medline/xml/PMC4693276.xml	MRN	65395 : 65398	CM	]. As dysfunction in the MRN functionality leads to h
./___Corpus/Medline/xml/PMC4693276.xml	ATM	65477 : 65480	CM	 agents by impairment of ATM pathway, inhibiting one 
./___Corpus/Medline/xml/PMC4693276.xml	MRN	65512 : 65515	CM	y, inhibiting one of the MRN complex components repre
./___Corpus/Medline/xml/PMC4693276.xml	MRN	65699 : 65702	CM	molecules inhibiting the MRN complex, a few MRE11 inh
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	65718 : 65723	CM	g the MRN complex, a few MRE11 inhibitors (depicted in 
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	65847 : 65852	CM	        Mirin, the first MRE11 inhibitor described, was
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	66037 : 66052	RN	inhibitory effect on the phosphorylation of a peptide derived fro
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	66079 : 66085	CM	f a peptide derived from γ-H2AX by ATM [197]. With the m
./___Corpus/Medline/xml/PMC4693276.xml	ATM	66089 : 66092	CM	e derived from γ-H2AX by ATM [197]. With the most eff
./___Corpus/Medline/xml/PMC4693276.xml	IC50	66143 : 66147	CM	cient inhibitory effect (IC50 = 66 µM), mirin appeared
./___Corpus/Medline/xml/PMC4693276.xml	MRN	66187 : 66190	CM	n appeared to target the MRN complex rather than ATM.
./___Corpus/Medline/xml/PMC4693276.xml	ATM	66211 : 66214	CM	 MRN complex rather than ATM. More specifically, miri
./___Corpus/Medline/xml/PMC4693276.xml	MRN	66264 : 66267	CM	n was found to block the MRN-dependent activation of 
./___Corpus/Medline/xml/PMC4693276.xml	ATM	66292 : 66295	CM	-dependent activation of ATM without affecting the ki
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	66349 : 66354	CM	 activity and to abolish MRE11 nuclease activity (100 µ
./___Corpus/Medline/xml/PMC4693276.xml	G2	66457 : 66459	CM	gation of the IR-induced G2/M checkpoint and failure
./___Corpus/Medline/xml/PMC4693276.xml	Mirin	66499 : 66504	CM	nd failure of HR repair. Mirin was later shown to down-
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	66538 : 66542	CM	r shown to down-regulate NHEJ repair efficiency as wel
./___Corpus/Medline/xml/PMC4693276.xml	PFM39	66815 : 66820	CM	n.                  6.2. PFM39, PFM01 and PFM03        
./___Corpus/Medline/xml/PMC4693276.xml	PFM01	66822 : 66827	CM	             6.2. PFM39, PFM01 and PFM03               
./___Corpus/Medline/xml/PMC4693276.xml	PFM03	66832 : 66837	CM	   6.2. PFM39, PFM01 and PFM03                      Rec
./___Corpus/Medline/xml/PMC4693276.xml	endo-	66927 : 66932	CPR	iscovered to inhibit endo- or exonuclease activity of M
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	66956 : 66961	CM	 exonuclease activity of MRE11 [196]. A library of mole
./___Corpus/Medline/xml/PMC4693276.xml	styryl	67037 : 67043	CM	with substituents in the styryl moiety and replacement o
./___Corpus/Medline/xml/PMC4693276.xml	pseudothiohydantoin	67074 : 67093	CM	y and replacement of the pseudothiohydantoin ring by rodanine moiety,
./___Corpus/Medline/xml/PMC4693276.xml	rodanine	67102 : 67110	CM	udothiohydantoin ring by rodanine moiety, was created. The
./___Corpus/Medline/xml/PMC4693276.xml	His61	67272 : 67277	CM	in. It appeared that the His61 (corresponds to His63 in
./___Corpus/Medline/xml/PMC4693276.xml	His63	67294 : 67299	CM	he His61 (corresponds to His63 in human MRE11) and Asn9
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	67309 : 67314	CM	sponds to His63 in human MRE11) and Asn93 residue may b
./___Corpus/Medline/xml/PMC4693276.xml	Asn93	67320 : 67325	CM	is63 in human MRE11) and Asn93 residue may be involved 
./___Corpus/Medline/xml/PMC4693276.xml	His61	67385 : 67390	CM	eraction with mirin. The His61 residue controls dsDNA e
./___Corpus/Medline/xml/PMC4693276.xml	Asn93	67455 : 67460	CM	y to the active site and Asn93 may interact with single
./___Corpus/Medline/xml/PMC4693276.xml	mirin	67533 : 67538	CM	his and the structure of mirin, three molecules where d
./___Corpus/Medline/xml/PMC4693276.xml	PMF39	67580 : 67585	CM	 where developed, namely PMF39, PFM01 and PFM03. PFM39,
./___Corpus/Medline/xml/PMC4693276.xml	PFM01	67587 : 67592	CM	developed, namely PMF39, PFM01 and PFM03. PFM39, which 
./___Corpus/Medline/xml/PMC4693276.xml	PFM03	67597 : 67602	CM	 namely PMF39, PFM01 and PFM03. PFM39, which has an ami
./___Corpus/Medline/xml/PMC4693276.xml	PFM39	67604 : 67609	CM	 PMF39, PFM01 and PFM03. PFM39, which has an amino grou
./___Corpus/Medline/xml/PMC4693276.xml	amino	67624 : 67629	CM	M03. PFM39, which has an amino group substituting the h
./___Corpus/Medline/xml/PMC4693276.xml	hydroxyl	67653 : 67661	CM	o group substituting the hydroxyl group, binds between the
./___Corpus/Medline/xml/PMC4693276.xml	His61	67687 : 67692	CM	group, binds between the His61 loop and the adjacent lo
./___Corpus/Medline/xml/PMC4693276.xml	Asn93-Lys97	67721 : 67732	CM	p and the adjacent loop (Asn93-Lys97) and inhibits the exonuc
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	67775 : 67780	CM	 exonuclease activity of MRE11, as mirin does. PFM01, w
./___Corpus/Medline/xml/PMC4693276.xml	PFM01	67797 : 67802	CM	of MRE11, as mirin does. PFM01, which has a rodanine ri
./___Corpus/Medline/xml/PMC4693276.xml	rodanine	67816 : 67824	CM	does. PFM01, which has a rodanine ring plus an isobutyl ch
./___Corpus/Medline/xml/PMC4693276.xml	isobutyl	67838 : 67846	CM	 a rodanine ring plus an isobutyl chain on the nitrogen, a
./___Corpus/Medline/xml/PMC4693276.xml	nitrogen	67860 : 67868	CM	an isobutyl chain on the nitrogen, and PFM03, which has a 
./___Corpus/Medline/xml/PMC4693276.xml	PFM03	67874 : 67879	CM	ain on the nitrogen, and PFM03, which has a sec-butyl c
./___Corpus/Medline/xml/PMC4693276.xml	sec-butyl	67893 : 67902	CM	, and PFM03, which has a sec-butyl chain, may bind near the
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	67947 : 67952	CM	r the dimer interface of MRE11 to inhibit its endonucle
./___Corpus/Medline/xml/PMC4693276.xml	PFM	68001 : 68004	CM	ease activity. The three PFM molecules induced a decr
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	68037 : 68042	CM	es induced a decrease in MRE11-dependent DSB resection 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68053 : 68056	CM	rease in MRE11-dependent DSB resection that was suppo
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	68182 : 68187	CM	 and impaired IR-induced RAD51 foci in G2 cells. Mirin 
./___Corpus/Medline/xml/PMC4693276.xml	G2	68196 : 68198	CM	IR-induced RAD51 foci in G2 cells. Mirin and PFM39 c
./___Corpus/Medline/xml/PMC4693276.xml	PFM39	68216 : 68221	CM	i in G2 cells. Mirin and PFM39 cause a G2 repair defect
./___Corpus/Medline/xml/PMC4693276.xml	G2	68230 : 68232	CM	 Mirin and PFM39 cause a G2 repair defect 8 h after 
./___Corpus/Medline/xml/PMC4693276.xml	PFM01	68298 : 68303	CM	HR deficient cells while PFM01 and PFM03 have no effect
./___Corpus/Medline/xml/PMC4693276.xml	PFM03	68308 : 68313	CM	nt cells while PFM01 and PFM03 have no effect, highligh
./___Corpus/Medline/xml/PMC4693276.xml	exo	68357 : 68360	CM	ghlighting the fact that exo- and endonuclease inhibi
./___Corpus/Medline/xml/PMC4693276.xml	exo-	68360 : 68364	CPR	ighting the fact that exo- and endonuclease inhibitors
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68407 : 68410	CM	ibitors confer different DSB repair phenotypes. PFM01
./___Corpus/Medline/xml/PMC4693276.xml	PFM01	68430 : 68435	CM	t DSB repair phenotypes. PFM01 and PFM03 enhanced NHEJ 
./___Corpus/Medline/xml/PMC4693276.xml	PFM03	68440 : 68445	CM	ir phenotypes. PFM01 and PFM03 enhanced NHEJ and reduce
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	68455 : 68459	CM	PFM01 and PFM03 enhanced NHEJ and reduced HR while PFM
./___Corpus/Medline/xml/PMC4693276.xml	PFM39	68481 : 68486	CM	HEJ and reduced HR while PFM39 inhibited HR but have no
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	68522 : 68526	CM	HR but have no effect on NHEJ. No translational applic
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	68853 : 68858	CM	                  7. The RAD51 Protein, a Central HR Pr
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	68910 : 68915	CM	ein                      RAD51 is an evolutionarily con
./___Corpus/Medline/xml/PMC4693276.xml	DSB	68978 : 68981	CM	inase that is central to DSB repair by HR (Figure 2) 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	69173 : 69178	CM	diator proteins, such as BRCA2, PALB2, and the RAD51 pa
./___Corpus/Medline/xml/PMC4693276.xml	PALB2	69180 : 69185	CM	proteins, such as BRCA2, PALB2, and the RAD51 paralogs,
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69195 : 69200	CM	as BRCA2, PALB2, and the RAD51 paralogs, RAD51 is recru
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69211 : 69216	CM	 and the RAD51 paralogs, RAD51 is recruited to the DSB 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	69237 : 69240	CM	AD51 is recruited to the DSB sites and polymerizes on
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69445 : 69450	CM	1,202,203]. The complete RAD51 crystal structure has no
./___Corpus/Medline/xml/PMC4693276.xml	BRC-RAD51	69531 : 69540	CM	ysis of the crystallized BRC-RAD51 fusion protein, NMR and 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69587 : 69592	CM	nd mutations analysis of RAD51 revealed that RAD51 hold
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69607 : 69612	CM	s of RAD51 revealed that RAD51 holds two domains: a N-t
./___Corpus/Medline/xml/PMC4693276.xml	N-	69635 : 69637	CPR	51 holds two domains: a N-terminal part that binds b
./___Corpus/Medline/xml/PMC4693276.xml	C-	69689 : 69691	CPR	h ssDNA and dsDNA and a C-terminal part that binds A
./___Corpus/Medline/xml/PMC4693276.xml	ATP	69715 : 69718	CM	terminal part that binds ATP [204,205]. In vitro, RAD
./___Corpus/Medline/xml/PMC4693276.xml	vitro	69733 : 69738	CM	 binds ATP [204,205]. In vitro, RAD51 recombinase activ
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69740 : 69745	CM	ATP [204,205]. In vitro, RAD51 recombinase activity is 
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	69851 : 69857	CM	change and DNA-dependent ATPase activity [200]. In vivo,
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	69983 : 69988	CM	 has been suggested that RAD51 regulation is important 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70223 : 70228	CM	sion or up-regulation of RAD51 while others, including 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70292 : 70297	CM	orectal cancers, exhibit RAD51 underexpression [212]. O
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70339 : 70344	CM	[212]. Overexpression of RAD51 has been shown to stimul
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70474 : 70479	CM	ments with siRNA against RAD51 have highlighted the pot
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70514 : 70519	CM	lighted the potential of RAD51 down-regulation at incre
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	70619 : 70624	CM	214,215]. In this light, RAD51 has become a recognized 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	70659 : 70664	CPR	e a recognized target to anti-cancer therapies and find
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	70904 : 70908	CM	s.                  7.1. DIDS                      DID
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	70930 : 70934	CM	IDS                      DIDS (4'-Diisothiocyanostilbe
./___Corpus/Medline/xml/PMC4693276.xml	4'-Diisothiocyanostilbene-2,2'-disulfonic acid	70936 : 70982	CM	                   DIDS (4'-Diisothiocyanostilbene-2,2'-disulfonic acid) has been previously kno
./___Corpus/Medline/xml/PMC4693276.xml	chloride	71037 : 71045	CM	r its ability to inhibit chloride channels [216]. By scree
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71140 : 71144	CM	. [217], have found that DIDS is able to inhibit RAD51
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71164 : 71169	CM	 DIDS is able to inhibit RAD51 strand-exchange activity
./___Corpus/Medline/xml/PMC4693276.xml	vitro	71207 : 71212	CM	nge activity. Further in vitro studies revealed that DI
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71235 : 71239	CM	ro studies revealed that DIDS inhibits both the ssDNA 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71294 : 71299	CM	sDNA-binding activity of RAD51, binds directly to RAD51
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71319 : 71324	CM	RAD51, binds directly to RAD51 and prevents DNA invasio
./___Corpus/Medline/xml/PMC4693276.xml	D-	71355 : 71357	CPR	revents DNA invasion and D-loop formation by RAD51. 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71375 : 71380	CM	 and D-loop formation by RAD51. Recently, Lamont et al.
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71429 : 71433	CM	. [218], have shown that DIDS provides an antileukemic
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71479 : 71484	CM	emic effect by targeting RAD51. In normal B cells, expr
./___Corpus/Medline/xml/PMC4693276.xml	cytidine	71538 : 71546	CM	on of activation-induced cytidine deaminase (AID) by antig
./___Corpus/Medline/xml/PMC4693276.xml	AID	71558 : 71561	CM	uced cytidine deaminase (AID) by antigenic stimulatio
./___Corpus/Medline/xml/PMC4693276.xml	AID	71745 : 71748	CM	ng neoplastic B cells to AID-mediated cytotoxicity [2
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71821 : 71825	CM	mont et al., showed that DIDS inhibits RAD51 foci form
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71835 : 71840	CM	howed that DIDS inhibits RAD51 foci formation and preve
./___Corpus/Medline/xml/PMC4693276.xml	AID	71919 : 71922	CM	the HR pathway to repair AID-induced DSB. The mechani
./___Corpus/Medline/xml/PMC4693276.xml	DSB	71931 : 71934	CM	ay to repair AID-induced DSB. The mechanism of action
./___Corpus/Medline/xml/PMC4693276.xml	DIDS	71963 : 71967	CM	e mechanism of action of DIDS on RAD51 is still unknow
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	71971 : 71976	CM	ism of action of DIDS on RAD51 is still unknown, but it
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72074 : 72079	CM	e DNA-binding domains of RAD51, preventing the recombin
./___Corpus/Medline/xml/PMC4693276.xml	Halenaquinone	72154 : 72167	CM	].                  7.2. Halenaquinone/Xestoquinone            
./___Corpus/Medline/xml/PMC4693276.xml	Xestoquinone	72168 : 72180	CM	      7.2. Halenaquinone/Xestoquinone                      Tak
./___Corpus/Medline/xml/PMC4693276.xml	marine	72254 : 72260	CM	e extract fractions from marine sponges in a D-loop form
./___Corpus/Medline/xml/PMC4693276.xml	D-	72274 : 72276	CPR	from marine sponges in a D-loop formation assay scre
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72359 : 72372	CM	 ability of the compound halenaquinone to significantly decreas
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72399 : 72404	CM	o significantly decrease RAD51 DNA-invasion and strand-
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72492 : 72505	CM	derivative molecule from halenaquinone, xestoquinone, that lack
./___Corpus/Medline/xml/PMC4693276.xml	xestoquinone	72507 : 72519	CM	cule from halenaquinone, xestoquinone, that lacked the oxygen 
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	72537 : 72543	CM	quinone, that lacked the oxygen at position C-3 had no e
./___Corpus/Medline/xml/PMC4693276.xml	C-3	72556 : 72559	CM	d the oxygen at position C-3 had no effect on RAD51 D
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72577 : 72582	CM	ion C-3 had no effect on RAD51 DNA pairing. The authors
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72656 : 72669	CM	Plasmonic Resonance that halenaquinone directly binds to RAD51,
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72688 : 72693	CM	uinone directly binds to RAD51, with a higher affinity 
./___Corpus/Medline/xml/PMC4693276.xml	xestoquinone	72723 : 72735	CM	h a higher affinity than xestoquinone. In vitro, halenaquinone
./___Corpus/Medline/xml/PMC4693276.xml	vitro	72740 : 72745	CM	ty than xestoquinone. In vitro, halenaquinone was found
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	72747 : 72760	CM	 xestoquinone. In vitro, halenaquinone was found to inhibit RAD
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72782 : 72787	CM	one was found to inhibit RAD51 binding to dsDNA but not
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72877 : 72882	CM	dose-dependent effect on RAD51 foci formation after IR 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72929 : 72934	CM	IR treatment, but not on RAD51 expression, suggesting t
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	72982 : 72987	CM	 that it interfered with RAD51 retention at DSB sites. 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	73001 : 73004	CM	 with RAD51 retention at DSB sites. Xestoquinone had 
./___Corpus/Medline/xml/PMC4693276.xml	Xestoquinone	73012 : 73024	CM	 retention at DSB sites. Xestoquinone had no effect on RAD51-d
./___Corpus/Medline/xml/PMC4693276.xml	oxygen	73101 : 73107	CM	ion, suggesting that the oxygen at position C-3 is impor
./___Corpus/Medline/xml/PMC4693276.xml	C-3	73120 : 73123	CM	t the oxygen at position C-3 is important for halenaq
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	73141 : 73154	CM	ion C-3 is important for halenaquinone activity on RAD51. No ot
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73167 : 73172	CM	alenaquinone activity on RAD51. No other investigation 
./___Corpus/Medline/xml/PMC4693276.xml	halenaquinone	73223 : 73236	CM	as been yet published on halenaquinone inhibitory effect.      
./___Corpus/Medline/xml/PMC4693276.xml	B02	73278 : 73281	CM	t.                  7.3. B02 and Derivatives         
./___Corpus/Medline/xml/PMC4693276.xml	FRET	73382 : 73386	CM	roughput method based on FRET (Fluorescence Resonance 
./___Corpus/Medline/xml/PMC4693276.xml	NIH	73475 : 73478	CM	lecules library from the NIH repository and identify 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73517 : 73522	CM	d identify inhibitors of RAD51 strand-exchange activity
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73625 : 73630	CM	erged as the most potent RAD51 inhibitors, as determine
./___Corpus/Medline/xml/PMC4693276.xml	D-	73660 : 73662	CPR	bitors, as determined by D-loop assays, and were tes
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73715 : 73720	CM	 for selectivity towards RAD51. B02 (3-(Phenylmethyl)-2
./___Corpus/Medline/xml/PMC4693276.xml	B02	73722 : 73725	CM	lectivity towards RAD51. B02 (3-(Phenylmethyl)-2-[(1E
./___Corpus/Medline/xml/PMC4693276.xml	3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone	73727 : 73795	CM	vity towards RAD51. B02 (3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone) was found the most effi
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73839 : 73844	CM	t efficient inhibitor of RAD51 activity (IC50 = 27,4 µM
./___Corpus/Medline/xml/PMC4693276.xml	IC50	73855 : 73859	CM	bitor of RAD51 activity (IC50 = 27,4 µM), with no effe
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	73919 : 73924	CM	, the E. coli homolog of RAD51, and structurally unrela
./___Corpus/Medline/xml/PMC4693276.xml	RAD54	73953 : 73958	CM	d structurally unrelated RAD54. B02 derivatives were th
./___Corpus/Medline/xml/PMC4693276.xml	B02	73960 : 73963	CM	turally unrelated RAD54. B02 derivatives were then sy
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	74009 : 74014	CM	n synthetized to develop RAD51 inhibitors of higher eff
./___Corpus/Medline/xml/PMC4693276.xml	B02-3a	74065 : 74071	CM	ciency. It revealed that B02-3a and B02-3b, which contai
./___Corpus/Medline/xml/PMC4693276.xml	B02-3b	74076 : 74082	CM	revealed that B02-3a and B02-3b, which contain an ethyl 
./___Corpus/Medline/xml/PMC4693276.xml	ethyl	74101 : 74106	CM	B02-3b, which contain an ethyl and a m-methylphenyl gro
./___Corpus/Medline/xml/PMC4693276.xml	m-methylphenyl	74113 : 74127	CM	h contain an ethyl and a m-methylphenyl group, respectively, ins
./___Corpus/Medline/xml/PMC4693276.xml	benzyl	74162 : 74168	CM	spectively, instead of a benzyl group, are at least as e
./___Corpus/Medline/xml/PMC4693276.xml	B02	74205 : 74208	CM	at least as efficient as B02 on RAD51 D-loop formatio
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	74212 : 74217	CM	t as efficient as B02 on RAD51 D-loop formation and str
./___Corpus/Medline/xml/PMC4693276.xml	D-	74218 : 74220	CPR	fficient as B02 on RAD51 D-loop formation and strand
./___Corpus/Medline/xml/PMC4693276.xml	B02	74365 : 74368	CM	 to assess the effect of B02 in a cellular environmen
./___Corpus/Medline/xml/PMC4693276.xml	B02	74422 : 74425	CM	 first study showed that B02 was also able to decreas
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	74452 : 74457	CM	as also able to decrease RAD51 foci formation by 3.8-fo
./___Corpus/Medline/xml/PMC4693276.xml	8-fold	74514 : 74520	CM	µM) and HR efficiency by 8-fold in HEK cells after IR tr
./___Corpus/Medline/xml/PMC4693276.xml	HEK	74524 : 74527	CM	 efficiency by 8-fold in HEK cells after IR treatment
./___Corpus/Medline/xml/PMC4693276.xml	B02	74586 : 74589	CM	he authors revealed that B02 sensitized RAD51 siRNA-t
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	74601 : 74606	CM	aled that B02 sensitized RAD51 siRNA-treated HEK293 cel
./___Corpus/Medline/xml/PMC4693276.xml	HEK293	74621 : 74627	CM	ized RAD51 siRNA-treated HEK293 cells to cisplatin and M
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	74637 : 74646	CM	-treated HEK293 cells to cisplatin and MEF cells to a combi
./___Corpus/Medline/xml/PMC4693276.xml	MEF	74651 : 74654	CM	3 cells to cisplatin and MEF cells to a combined MMS 
./___Corpus/Medline/xml/PMC4693276.xml	MMS	74675 : 74678	CM	 MEF cells to a combined MMS and PARP1 inhibitor (AZD
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	74683 : 74688	CM	ls to a combined MMS and PARP1 inhibitor (AZD2281) trea
./___Corpus/Medline/xml/PMC4693276.xml	B02	74771 : 74774	CM	23] tested the effect of B02 in combination with diff
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	74839 : 74848	CM	apeutics agents, such as etoposide, cisplatin, doxorubicin,
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	74850 : 74859	CM	ents, such as etoposide, cisplatin, doxorubicin, and topote
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	74861 : 74872	CM	as etoposide, cisplatin, doxorubicin, and topotecan, on the M
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	74896 : 74906	CM	n, and topotecan, on the MDA-MB-231 human breast cancer cell
./___Corpus/Medline/xml/PMC4693276.xml	B02	74938 : 74941	CM	breast cancer cell line. B02 was able to sensitize MD
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	74964 : 74974	CM	02 was able to sensitize MDA-MB-231 cells to all drug combin
./___Corpus/Medline/xml/PMC4693276.xml	B02	75036 : 75039	CM	most important effect of B02 being seen with cisplati
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	75056 : 75065	CM	t of B02 being seen with cisplatin. They also highlighted t
./___Corpus/Medline/xml/PMC4693276.xml	B02	75114 : 75117	CM	the inhibitory effect of B02 combined with cisplatin 
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	75132 : 75141	CM	ect of B02 combined with cisplatin treatment in mouse xenog
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	75184 : 75194	CM	e xenografts by studying MDA-MB-231 proliferation. B02 was a
./___Corpus/Medline/xml/PMC4693276.xml	B02	75210 : 75213	CM	DA-MB-231 proliferation. B02 was able to disrupt RAD5
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	75234 : 75239	CM	 B02 was able to disrupt RAD51 foci formation in MDA-MB
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	75258 : 75268	CM	 RAD51 foci formation in MDA-MB-231 cells in mouse xenograft
./___Corpus/Medline/xml/PMC4693276.xml	B02	75369 : 75372	CM	vestigated the effect of B02 on multiple myeloma (MM)
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75418 : 75429	CM	(MM) cells combined with doxorubicin treatment. Alone, doxoru
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75448 : 75459	CM	ubicin treatment. Alone, doxorubicin treatment induced RAD51 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	75478 : 75483	CM	ubicin treatment induced RAD51 foci formation in multip
./___Corpus/Medline/xml/PMC4693276.xml	B02	75553 : 75556	CM	ereas pre-treatment with B02 blocked doxorubicin-indu
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75565 : 75576	CM	eatment with B02 blocked doxorubicin-induced RAD51 foci forma
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	75585 : 75590	CM	cked doxorubicin-induced RAD51 foci formation and incre
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	75624 : 75630	CM	mation and increased the γ-H2AX foci number, due to unre
./___Corpus/Medline/xml/PMC4693276.xml	DSB	75662 : 75665	CM	umber, due to unrepaired DSB caused by the doxorubici
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	75680 : 75691	CM	paired DSB caused by the doxorubicin treatment. Using HR assa
./___Corpus/Medline/xml/PMC4693276.xml	B02	75740 : 75743	CM	ays, they estimated that B02 inhibits HR at least 6-f
./___Corpus/Medline/xml/PMC4693276.xml	6-fold	75765 : 75771	CM	B02 inhibits HR at least 6-fold.                  7.4. R
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	75795 : 75799	CM	d.                  7.4. RI-1 and RI-2                
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	75966 : 75971	CM	molecule able to inhibit RAD51 ssDNA binding, RI-1 (3-c
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	75987 : 75991	CM	bit RAD51 ssDNA binding, RI-1 (3-chloro-1-(3,4-dichlor
./___Corpus/Medline/xml/PMC4693276.xml	3-chloro-1-(3,4-dichlorophenyl)-4-morpholino-1H-pyrrole-2,5-dione	75993 : 76058	CM	D51 ssDNA binding, RI-1 (3-chloro-1-(3,4-dichlorophenyl)-4-morpholino-1H-pyrrole-2,5-dione). The mechanism of actio
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	76088 : 76092	CM	e mechanism of action of RI-1 was based on its chlorom
./___Corpus/Medline/xml/PMC4693276.xml	chloromaleimide	76110 : 76125	CM	of RI-1 was based on its chloromaleimide moiety, which binds cova
./___Corpus/Medline/xml/PMC4693276.xml	thiol	76164 : 76169	CM	 binds covalently to the thiol group of the Cys319 resi
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76183 : 76189	CM	o the thiol group of the Cys319 residue on RAD51 surface
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76201 : 76206	CM	of the Cys319 residue on RAD51 surface by a Michael add
./___Corpus/Medline/xml/PMC4693276.xml	IC50	76299 : 76303	CM	 to inhibit DNA binding (IC50 = 6.62 µM) and polymeriz
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76337 : 76342	CM	M) and polymerization of RAD51 during nucleofilament fo
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76403 : 76408	CM	 the interaction site on RAD51 surface is highly conser
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	76454 : 76458	CM	nserved among mammalian, RI-1 bound also Rad51 from Sa
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76511 : 76517	CM	aromyces cerevisiae, the Cys319 human RAD51 residue corr
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76524 : 76529	CM	visiae, the Cys319 human RAD51 residue corresponding to
./___Corpus/Medline/xml/PMC4693276.xml	Cys377	76559 : 76565	CM	due corresponding to its Cys377 residue, but not RecA wh
./___Corpus/Medline/xml/PMC4693276.xml	Cys319	76618 : 76624	CM	 the site is absent. The Cys319 residue of RAD51 is loca
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76636 : 76641	CM	t. The Cys319 residue of RAD51 is located on the interf
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76682 : 76687	CM	he interface between two RAD51 monomers. This site over
./___Corpus/Medline/xml/PMC4693276.xml	ATPase	76721 : 76727	CM	. This site overlaps the ATPase domain of RAD51, suggest
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76738 : 76743	CM	aps the ATPase domain of RAD51, suggesting RI-1 may pre
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	76756 : 76760	CM	ain of RAD51, suggesting RI-1 may prevent nucleofilame
./___Corpus/Medline/xml/PMC4693276.xml	ATP	76816 : 76819	CM	mation and also modulate ATP binding. RI-1 treatment 
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	76829 : 76833	CM	so modulate ATP binding. RI-1 treatment is associated 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	76873 : 76878	CM	ssociated with decreased RAD51 foci formation and incre
./___Corpus/Medline/xml/PMC4693276.xml	γ-H2AX	76908 : 76914	CM	 formation and increased γ-H2AX foci formation [226]. Im
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	76950 : 76954	CM	tion [226]. Importantly, RI-1 has been shown to produc
./___Corpus/Medline/xml/PMC4693276.xml	anti-	76984 : 76989	CPR	been shown to produce an anti-cancer effect (IC50 range
./___Corpus/Medline/xml/PMC4693276.xml	IC50	77004 : 77008	CM	e an anti-cancer effect (IC50 range from 5 µM to 30 µM
./___Corpus/Medline/xml/PMC4693276.xml	mitomycin-C	77056 : 77067	CM	µM) when associated with mitomycin-C treatment in four cell l
./___Corpus/Medline/xml/PMC4693276.xml	U2OS	77098 : 77102	CM	ment in four cell lines (U2OS, HeLa, MCF-7 and SH2038)
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	77104 : 77108	CM	n four cell lines (U2OS, HeLa, MCF-7 and SH2038).     
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	77110 : 77115	CM	 cell lines (U2OS, HeLa, MCF-7 and SH2038).            
./___Corpus/Medline/xml/PMC4693276.xml	SH2038	77120 : 77126	CM	s (U2OS, HeLa, MCF-7 and SH2038).                       
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	77169 : 77173	CM	                       A RI-1 analog, named RI-2 (1-(3
./___Corpus/Medline/xml/PMC4693276.xml	RI-2	77188 : 77192	CM	    A RI-1 analog, named RI-2 (1-(3,4-dichlorophenyl)-
./___Corpus/Medline/xml/PMC4693276.xml	1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione	77194 : 77270	CM	RI-1 analog, named RI-2 (1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione), was developed to reduc
./___Corpus/Medline/xml/PMC4693276.xml	RI-2	77384 : 77388	CM	 molecule in vivo [227]. RI-2 lacks the chloromaleimid
./___Corpus/Medline/xml/PMC4693276.xml	chloromaleimide	77399 : 77414	CM	vo [227]. RI-2 lacks the chloromaleimide-based reactivity that po
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	77456 : 77460	CM	 that potentially limits RI-1 use in animal models Thi
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	77513 : 77518	CM	ompound was able to bind RAD51 at the same location as 
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	77543 : 77547	CM	 at the same location as RI-1 does and inhibited DNA b
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	77591 : 77596	CM	 DNA binding function of RAD51 (IC50 = 44.17 µM) in a r
./___Corpus/Medline/xml/PMC4693276.xml	IC50	77598 : 77602	CM	nding function of RAD51 (IC50 = 44.17 µM) in a reversi
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	77642 : 77646	CM	 a reversible manner. As RI-1 (20 µM), RI-2 treatment 
./___Corpus/Medline/xml/PMC4693276.xml	RI-2	77656 : 77660	CM	manner. As RI-1 (20 µM), RI-2 treatment (60 µM) led to
./___Corpus/Medline/xml/PMC4693276.xml	RI-1	77761 : 77765	CM	l acceptor reactivity of RI-1.                  7.5. I
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	77789 : 77793	CM	1.                  7.5. IBR2 and IBR120              
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	77798 : 77804	CM	           7.5. IBR2 and IBR120                      IBR
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	77826 : 77830	CM	120                      IBR2 is a small molecule able
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	77867 : 77872	CM	molecule able to inhibit RAD51 by mimicking the effect 
./___Corpus/Medline/xml/PMC4693276.xml	BRC	77900 : 77903	CM	 mimicking the effect of BRC repeat binding to RAD51.
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	77922 : 77927	CM	of BRC repeat binding to RAD51. BRC repeats are structu
./___Corpus/Medline/xml/PMC4693276.xml	BRC	77929 : 77932	CM	repeat binding to RAD51. BRC repeats are structural m
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	77980 : 77985	CM	 motifs that confer upon BRCA2 the property to bind to 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	78010 : 78015	CM	 the property to bind to RAD51 [228]. IBR2 was discover
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78023 : 78027	CM	 to bind to RAD51 [228]. IBR2 was discovered by screen
./___Corpus/Medline/xml/PMC4693276.xml	Nanosyn	78075 : 78082	CM	ening a 24,000 molecules Nanosyn library using an inducib
./___Corpus/Medline/xml/PMC4693276.xml	BRC-RAD51	78184 : 78193	CM	cules capable to inhibit BRC-RAD51 interaction [229]. IBR2 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78213 : 78217	CM	RAD51 interaction [229]. IBR2 was shown to specificall
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	78252 : 78257	CM	 to specifically bind to RAD51 to prevent its multimeri
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78351 : 78355	CM	n. Consistent with this, IBR2 diminishes the efficienc
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	78401 : 78406	CM	iency of HR and inhibits RAD51 foci formation in MCF-7 
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	78425 : 78430	CM	 RAD51 foci formation in MCF-7 cells after IR treatment
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78473 : 78477	CM	eatment (20 µM for 8 h). IBR2-treated cells showed no 
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	78528 : 78533	CM	ffect of the molecule on RAD51 at the transcriptional l
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78568 : 78572	CM	anscriptional level, but IBR2 was found to promote RAD
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	78594 : 78599	CM	BR2 was found to promote RAD51 degradation through the 
./___Corpus/Medline/xml/PMC4693276.xml	ubiquitin	78624 : 78633	CM	 degradation through the ubiquitin-proteasome pathway. IBR2
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	78654 : 78658	CM	itin-proteasome pathway. IBR2 exhibited a potential th
./___Corpus/Medline/xml/PMC4693276.xml	K562	78818 : 78822	CM	er cell lines, including K562, HeLa, MBA-MD-231, MBA-M
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	78824 : 78828	CM	l lines, including K562, HeLa, MBA-MD-231, MBA-MD-435,
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-231	78830 : 78840	CM	s, including K562, HeLa, MBA-MD-231, MBA-MD-435, MBA-MD-468,
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-435	78842 : 78852	CM	 K562, HeLa, MBA-MD-231, MBA-MD-435, MBA-MD-468, MCF-7, T47D
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-468	78854 : 78864	CM	 MBA-MD-231, MBA-MD-435, MBA-MD-468, MCF-7, T47D and HBL100 
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	78866 : 78871	CM	 MBA-MD-435, MBA-MD-468, MCF-7, T47D and HBL100 (GI50 r
./___Corpus/Medline/xml/PMC4693276.xml	T47D	78873 : 78877	CM	-435, MBA-MD-468, MCF-7, T47D and HBL100 (GI50 range f
./___Corpus/Medline/xml/PMC4693276.xml	GI50	78890 : 78894	CM	 MCF-7, T47D and HBL100 (GI50 range from 11.5 to 16.0 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79105 : 79109	CM	ghlighted the promise of IBR2 as a treatment against h
./___Corpus/Medline/xml/PMC4693276.xml	CML	79164 : 79167	CM	o-treat cancers, such as CML resistant to imatinib (a
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79181 : 79189	CM	such as CML resistant to imatinib (a Bcr-abl inhibitor use
./___Corpus/Medline/xml/PMC4693276.xml	CML	79225 : 79228	CM	 inhibitor used to treat CML). For instance, IBR2 tre
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79245 : 79249	CM	reat CML). For instance, IBR2 treatment of murine cell
./___Corpus/Medline/xml/PMC4693276.xml	murine	79263 : 79269	CM	tance, IBR2 treatment of murine cells that express the i
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79293 : 79301	CM	e cells that express the imatinib-resistant mutant T315I B
./___Corpus/Medline/xml/PMC4693276.xml	T315I	79319 : 79324	CM	matinib-resistant mutant T315I Bcr-abl led to a decreas
./___Corpus/Medline/xml/PMC4693276.xml	T315I	79493 : 79498	CM	iency mice injected with T315I cells and treated with I
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79522 : 79526	CM	I cells and treated with IBR2 (100 mg/kg) showed a pro
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79597 : 79605	CM	red to mice treated with imatinib alone (125 mg/kg). Final
./___Corpus/Medline/xml/PMC4693276.xml	K562	79650 : 79654	CM	Finally, co-treatment of K562 human leukemia cells, a 
./___Corpus/Medline/xml/PMC4693276.xml	CML	79741 : 79744	CM	cell line derived from a CML patient, with IBR2 and i
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79759 : 79763	CM	from a CML patient, with IBR2 and imatinib showed an i
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	79768 : 79776	CM	L patient, with IBR2 and imatinib showed an increase of ap
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	79907 : 79911	CM	               Recently, IBR2 analogues were developed
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-468	80130 : 80140	CM	 breast cancer cell line MBA-MD-468. Four of them exhibited 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80205 : 80209	CM	fold greater effect than IBR2 (IC50 = 14.8 µM), especi
./___Corpus/Medline/xml/PMC4693276.xml	IC50	80211 : 80215	CM	reater effect than IBR2 (IC50 = 14.8 µM), especially t
./___Corpus/Medline/xml/PMC4693276.xml	isoindolinyl	80243 : 80255	CM	14.8 µM), especially the isoindolinyl derivative IBR120 (IC50 
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80267 : 80273	CM	 isoindolinyl derivative IBR120 (IC50 = 3.1 µM), which s
./___Corpus/Medline/xml/PMC4693276.xml	IC50	80275 : 80279	CM	linyl derivative IBR120 (IC50 = 3.1 µM), which showed 
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80366 : 80370	CM	ion activity compared to IBR2. IBR120 demonstrated ant
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80372 : 80378	CM	tivity compared to IBR2. IBR120 demonstrated anti-prolif
./___Corpus/Medline/xml/PMC4693276.xml	anti-	80392 : 80397	CPR	BR2. IBR120 demonstrated anti-proliferative activity in
./___Corpus/Medline/xml/PMC4693276.xml	K562	80472 : 80476	CM	breast cancer cell lines K562, MCF-7, MBA-MD-231, MBA-
./___Corpus/Medline/xml/PMC4693276.xml	MCF-7	80478 : 80483	CM	 cancer cell lines K562, MCF-7, MBA-MD-231, MBA-MD-361,
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-231	80485 : 80495	CM	 cell lines K562, MCF-7, MBA-MD-231, MBA-MD-361, MBA-MD-435,
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-361	80497 : 80507	CM	K562, MCF-7, MBA-MD-231, MBA-MD-361, MBA-MD-435, MBA-MD-468,
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-435	80509 : 80519	CM	 MBA-MD-231, MBA-MD-361, MBA-MD-435, MBA-MD-468, HsT578-T, T
./___Corpus/Medline/xml/PMC4693276.xml	MBA-MD-468	80521 : 80531	CM	 MBA-MD-361, MBA-MD-435, MBA-MD-468, HsT578-T, T47D, human o
./___Corpus/Medline/xml/PMC4693276.xml	T47D	80543 : 80547	CM	5, MBA-MD-468, HsT578-T, T47D, human osteosarcoma cell
./___Corpus/Medline/xml/PMC4693276.xml	U2OS	80578 : 80582	CM	n osteosarcoma cell line U2OS, human glioblastoma cell
./___Corpus/Medline/xml/PMC4693276.xml	T98G	80613 : 80617	CM	n glioblastoma cell line T98G and human cervical cell 
./___Corpus/Medline/xml/PMC4693276.xml	HeLa	80647 : 80651	CM	human cervical cell line HeLa), with IC50 in the low m
./___Corpus/Medline/xml/PMC4693276.xml	IC50	80659 : 80663	CM	al cell line HeLa), with IC50 in the low micromolar ra
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	80767 : 80772	CM	 docking analysis, three RAD51 residues (V189, Y191 and
./___Corpus/Medline/xml/PMC4693276.xml	V189	80783 : 80787	CM	s, three RAD51 residues (V189, Y191 and Q206) were ide
./___Corpus/Medline/xml/PMC4693276.xml	hydrogen	80833 : 80841	CM	 identified as potential hydrogen bonding sites for intera
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80877 : 80883	CM	tes for interaction with IBR120. As IBR2, IBR120 prevent
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80888 : 80892	CM	eraction with IBR120. As IBR2, IBR120 prevented RAD51 
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80894 : 80900	CM	on with IBR120. As IBR2, IBR120 prevented RAD51 multimer
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	80911 : 80916	CM	s IBR2, IBR120 prevented RAD51 multimerization and decr
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	80962 : 80966	CM	decreased HR efficiency. IBR2 and IBR120 also share st
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	80971 : 80977	CM	 HR efficiency. IBR2 and IBR120 also share structural si
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81044 : 81050	CM	entral ring structure in IBR120 being only one carbon sm
./___Corpus/Medline/xml/PMC4693276.xml	carbon	81066 : 81072	CM	in IBR120 being only one carbon smaller than that of IBR
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81094 : 81098	CM	bon smaller than that of IBR2. In contrast to IBR2, th
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81115 : 81119	CM	 of IBR2. In contrast to IBR2, the effects of IBR120 i
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81136 : 81142	CM	 to IBR2, the effects of IBR120 in vivo has not been yet
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81275 : 81279	CM	d structures involved in IBR2 and IBR120 inhibition of
./___Corpus/Medline/xml/PMC4693276.xml	IBR120	81284 : 81290	CM	res involved in IBR2 and IBR120 inhibition of RAD51, and
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	81305 : 81310	CM	and IBR120 inhibition of RAD51, and suggested the possi
./___Corpus/Medline/xml/PMC4693276.xml	IBR2	81355 : 81359	CM	possibility of improving IBR2 inhibitory activity on R
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	81383 : 81388	CM	2 inhibitory activity on RAD51.                        
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	81465 : 81470	CM	clinical trial involving RAD51 inhibitors has been init
./___Corpus/Medline/xml/PMC4693276.xml	CML	81636 : 81639	CM	to-treat cancers such as CML.                  8. The
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	81665 : 81670	CM	                  8. The RAD52 Protein                 
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82056 : 82061	CM	nd Annealing) [7]. Human RAD52 is structurally and bioc
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82138 : 82143	CM	 even if inactivation of RAD52 is not lethal in mice [2
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82173 : 82178	CM	ot lethal in mice [232]. RAD52 binds ssDNA, promotes DN
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	82231 : 82236	CM	nnealing, interacts with RAD51 to modulate its DNA stra
./___Corpus/Medline/xml/PMC4693276.xml	RPA	82330 : 82333	CM	tions and interacts with RPA [233,234]. Previous stud
./___Corpus/Medline/xml/PMC4693276.xml	N-	82383 : 82385	CPR	ies have shown that the N-terminal part of RAD52 is 
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82401 : 82406	CM	t the N-terminal part of RAD52 is involved in the oligo
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82582 : 82587	CM	ues in the groove of the RAD52 ring [235,236]. RAD52 al
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82604 : 82609	CM	he RAD52 ring [235,236]. RAD52 also possesses a second 
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82718 : 82723	CM	has lately characterized RAD52 as a lung cancer suscept
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82784 : 82789	CM	e, the region containing RAD52 gene was amplified in pa
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	82888 : 82893	CM	d that overexpression of RAD52 causes an increase in ce
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83063 : 83068	CM	ighlighted importance of RAD52 in human cancer cell lin
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	83109 : 83114	CM	 cell lines deficient in BRCA1, PALB2 [239] or BRCA2 [2
./___Corpus/Medline/xml/PMC4693276.xml	PALB2	83116 : 83121	CM	ines deficient in BRCA1, PALB2 [239] or BRCA2 [240], as
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	83131 : 83136	CM	in BRCA1, PALB2 [239] or BRCA2 [240], as its depletion 
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83262 : 83267	CM	tic strategies targeting RAD52 to treat PALB2, BRCA1 or
./___Corpus/Medline/xml/PMC4693276.xml	PALB2	83277 : 83282	CM	targeting RAD52 to treat PALB2, BRCA1 or BRCA2 mutant c
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	83284 : 83289	CM	ng RAD52 to treat PALB2, BRCA1 or BRCA2 mutant cancers 
./___Corpus/Medline/xml/PMC4693276.xml	BRCA2	83293 : 83298	CM	to treat PALB2, BRCA1 or BRCA2 mutant cancers might be 
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83390 : 83395	CM	een described to inhibit RAD52 whether it is by prevent
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83424 : 83429	CM	ther it is by preventing RAD52 ring formation, dissocia
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83459 : 83464	CM	 formation, dissociating RAD52 ring, preventing RAD52-D
./___Corpus/Medline/xml/PMC4693276.xml	RAD52-DNA	83482 : 83491	CM	g RAD52 ring, preventing RAD52-DNA binding or modulating RA
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83514 : 83519	CM	NA binding or modulating RAD52 post-transcriptional mod
./___Corpus/Medline/xml/PMC4693276.xml	RAD52	83814 : 83819	CM	 the characterization of RAD52 activity at both the bio
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	83936 : 83940	CM	-Homologous End-Joining (NHEJ) Proteins               
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	84000 : 84004	CM	-Homologous End-joining (NHEJ) is a major double-stran
./___Corpus/Medline/xml/PMC4693276.xml	DSB	84075 : 84078	CM	y, accounting for 75% of DSB repair in proliferating 
./___Corpus/Medline/xml/PMC4693276.xml	S-G2	84217 : 84221	CM	ed by HR which functions S-G2 phases, when the sister 
./___Corpus/Medline/xml/PMC4693276.xml	chromatid	84246 : 84255	CM	 phases, when the sister chromatid is available as a repair
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	84299 : 84303	CM	repair template [2,244]. NHEJ can be divided into two 
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	84361 : 84365	CM	 sub-pathways: classical NHEJ (C-NHEJ), the main canon
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	84367 : 84373	CM	athways: classical NHEJ (C-NHEJ), the main canonical DNA
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	84395 : 84401	CM	HEJ), the main canonical DNA-PK-dependent pathway, and a
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	84437 : 84441	CM	pathway, and alternative NHEJ (Alt-NHEJ) (Figure 3). A
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	84443 : 84451	CM	y, and alternative NHEJ (Alt-NHEJ) (Figure 3). A particula
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	84484 : 84488	CM	e 3). A particularity of NHEJ is the polyvalence of th
./___Corpus/Medline/xml/PMC4693276.xml	ligase	84541 : 84547	CM	uclease, polymerase, and ligase activities, which provid
./___Corpus/Medline/xml/PMC4693276.xml	DSB	84679 : 84682	CM	 can possibly arise at a DSB (e.g., DNA ends of varia
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	84932 : 84938	CM	                         C-NHEJ is composed of 3 steps: 
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	85018 : 85024	CM	ing and ligation. During C-NHEJ, the double-strand break
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	85071 : 85075	CM	eak is recognized by the Ku70/Ku80 complex, a dyad-sym
./___Corpus/Medline/xml/PMC4693276.xml	Ku80	85076 : 85080	CM	s recognized by the Ku70/Ku80 complex, a dyad-symmetri
./___Corpus/Medline/xml/PMC4693276.xml	Ku	85169 : 85171	CM	with its ring structure. Ku recruitment and binding 
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	85215 : 85219	CM	nding helps to stabilize NHEJ enzymes at the DNA termi
./___Corpus/Medline/xml/PMC4693276.xml	Ku	85256 : 85258	CM	the DNA termini. Indeed, Ku allows the recruitment o
./___Corpus/Medline/xml/PMC4693276.xml	Artemis	85299 : 85306	CM	uitment of DNA-PKcs, the Artemis complex, the λ and μ pol
./___Corpus/Medline/xml/PMC4693276.xml	XLF	85376 : 85379	CM	tion complex composed of XLF (XRCC4-like factor, also
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	85381 : 85386	CM	complex composed of XLF (XRCC4-like factor, also called
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	85424 : 85429	CM	 also called Cernunnos), XRCC4 and DNA ligase IV. The c
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	85505 : 85509	CM	serves as a platform for NHEJ repair. DNA-PKcs is a se
./___Corpus/Medline/xml/PMC4693276.xml	serine	85532 : 85538	CM	EJ repair. DNA-PKcs is a serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4693276.xml	threonine	85539 : 85548	CM	ir. DNA-PKcs is a serine/threonine protein kinase which bel
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	85585 : 85589	CM	ase which belongs to the PI3K (phosphatidylinositol 3-
./___Corpus/Medline/xml/PMC4693276.xml	phosphatidylinositol	85591 : 85611	CM	ich belongs to the PI3K (phosphatidylinositol 3-kinase) family. Severa
./___Corpus/Medline/xml/PMC4693276.xml	3-	85613 : 85615	CPR	K (phosphatidylinositol 3-kinase) family. Several ty
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	85665 : 85671	CM	pes of DNA ends activate DNA-PK, leading to its auto-pho
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	85693 : 85708	RN	-PK, leading to its auto-phosphorylation and the downstream phosp
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	85728 : 85743	RN	ation and the downstream phosphorylation of Artemis, an exo- and 
./___Corpus/Medline/xml/PMC4693276.xml	Artemis	85747 : 85754	CM	tream phosphorylation of Artemis, an exo- and endonucleas
./___Corpus/Medline/xml/PMC4693276.xml	exo	85759 : 85762	CM	orylation of Artemis, an exo- and endonuclease. As a 
./___Corpus/Medline/xml/PMC4693276.xml	exo-	85762 : 85766	CPR	lation of Artemis, an exo- and endonuclease. As a resu
./___Corpus/Medline/xml/PMC4693276.xml	DSB	85838 : 85841	CM	 can occur to render the DSB extremities competent fo
./___Corpus/Medline/xml/PMC4693276.xml	XLF-XRCC4-DNA	85901 : 85914	CM	. The recruitment of the XLF-XRCC4-DNA ligase IV complex can th
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	86060 : 86064	CM	e pairs and explains why NHEJ is not an entirely faith
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	86104 : 86110	CM	rely faithful mechanism. C-NHEJ is able to inhibit other
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	86192 : 86197	CM	ence of this inhibition, PARP1 and the MRN (MRE11–RAD50
./___Corpus/Medline/xml/PMC4693276.xml	MRN	86206 : 86209	CM	nhibition, PARP1 and the MRN (MRE11–RAD50–NBS1) compl
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	86211 : 86216	CM	tion, PARP1 and the MRN (MRE11–RAD50–NBS1) complex are 
./___Corpus/Medline/xml/PMC4693276.xml	RAD50	86217 : 86222	CM	PARP1 and the MRN (MRE11–RAD50–NBS1) complex are recrui
./___Corpus/Medline/xml/PMC4693276.xml	NBS1	86223 : 86227	CM	and the MRN (MRE11–RAD50–NBS1) complex are recruited t
./___Corpus/Medline/xml/PMC4693276.xml	DSB	86324 : 86327	CM	eak-ends is limited, the DSB can be repaired by the a
./___Corpus/Medline/xml/PMC4693276.xml	alt-NHEJ	86351 : 86359	CM	B can be repaired by the alt-NHEJ pathway, which implicate
./___Corpus/Medline/xml/PMC4693276.xml	XRCC1	86405 : 86410	CM	cates DNA ligase III and XRCC1. Alt-NHEJ functions as a
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	86412 : 86420	CM	NA ligase III and XRCC1. Alt-NHEJ functions as a backup re
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	86478 : 86484	CM	hway, detected only when C-NHEJ is compromised. In contr
./___Corpus/Medline/xml/PMC4693276.xml	C-NHEJ	86516 : 86522	CM	promised. In contrast to C-NHEJ, Alt-NHEJ is promoted by
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	86524 : 86532	CM	. In contrast to C-NHEJ, Alt-NHEJ is promoted by poly (ADP
./___Corpus/Medline/xml/PMC4693276.xml	ADP-ribose	86554 : 86564	CM	HEJ is promoted by poly (ADP-ribose) polymerase-1 (PARP-1) a
./___Corpus/Medline/xml/PMC4693276.xml	XRCC1	86682 : 86687	CM	 complementing factor 1 (XRCC1), DNA ligase IIIα, polyn
./___Corpus/Medline/xml/PMC4693276.xml	IIIα	86701 : 86705	CM	or 1 (XRCC1), DNA ligase IIIα, polynucleotide kinase (
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	86940 : 86944	CM	 regulatory heterodimer (Ku70 and Ku80 subunits) and a
./___Corpus/Medline/xml/PMC4693276.xml	Ku80	86949 : 86953	CM	ry heterodimer (Ku70 and Ku80 subunits) and a 460 kDa 
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	87041 : 87045	CM	hat DNA-PK is central to NHEJ, its loss results in ine
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	87089 : 87093	CM	in inefficient repair of DSBs, increasing sensitivity 
./___Corpus/Medline/xml/PMC4693276.xml	ATP	87424 : 87427	CM	n has been to target the ATP-binding site of the kina
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	87643 : 87647	CM	, activity against other PI3K proteins and poor pharma
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	87773 : 87779	CM	ific molecules targeting DNA-PK (depicted in Figure S6).
./___Corpus/Medline/xml/PMC4693276.xml	sterol	87877 : 87883	CM	         Wortmannin is a sterol-like fungal metabolite, 
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	87979 : 87983	CM	ive general inhibitor of PI3K that has been used to ta
./___Corpus/Medline/xml/PMC4693276.xml	ATM	88029 : 88032	CM	o target both DNA-PK and ATM. Wortmannin causes the i
./___Corpus/Medline/xml/PMC4693276.xml	alkylation	88069 : 88079	RN	 causes the irreversible alkylation of Lys802, which is loca
./___Corpus/Medline/xml/PMC4693276.xml	Lys802	88083 : 88089	CM	reversible alkylation of Lys802, which is located in the
./___Corpus/Medline/xml/PMC4693276.xml	ATP	88115 : 88118	CM	 which is located in the ATP-binding site of DNA-PKcs
./___Corpus/Medline/xml/PMC4693276.xml	phosphate	88165 : 88174	CM	Kcs and critical for the phosphate transfer reaction [247].
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88362 : 88370	CM	                  9.1.2. LY294002                      LY2
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88392 : 88400	CM	002                      LY294002, a morpholine-containing
./___Corpus/Medline/xml/PMC4693276.xml	morpholine	88404 : 88414	CM	             LY294002, a morpholine-containing chemical comp
./___Corpus/Medline/xml/PMC4693276.xml	vitro	88510 : 88515	CM	 most frequently used in vitro as a PI3K inhibitor [249
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	88521 : 88525	CM	ently used in vitro as a PI3K inhibitor [249]. It acts
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88635 : 88643	CM	ompetitive manner [248]. LY294002 has also been shown to i
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	88875 : 88883	CM	ic chemical structure of LY294002 has been used as the bas
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	88988 : 88994	CM	                  9.1.3. NU7026                      NU7
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89016 : 89022	CM	026                      NU7026 is a competitive and hig
./___Corpus/Medline/xml/PMC4693276.xml	ATM	89124 : 89127	CM	hows no activity against ATM and ATR and has a 60-fol
./___Corpus/Medline/xml/PMC4693276.xml	ATR	89132 : 89135	CM	activity against ATM and ATR and has a 60-fold select
./___Corpus/Medline/xml/PMC4693276.xml	60-fold	89146 : 89153	CM	st ATM and ATR and has a 60-fold selectivity towards DNA-
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	89193 : 89197	CM	wards DNA-PK compared to PI3K [251]. It has been shown
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89228 : 89234	CM	. It has been shown that NU7026 potentiates the cytotoxi
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89334 : 89340	CM	ment of leukemia. [252]. NU7026 enhances the growth inhi
./___Corpus/Medline/xml/PMC4693276.xml	idarubicin	89407 : 89417	CM	erapeutic agents such as idarubicin, daunorubicin, doxorubic
./___Corpus/Medline/xml/PMC4693276.xml	daunorubicin	89419 : 89431	CM	ents such as idarubicin, daunorubicin, doxorubicin, etoposide,
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	89433 : 89444	CM	darubicin, daunorubicin, doxorubicin, etoposide, amsacrine, m
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	89446 : 89455	CM	unorubicin, doxorubicin, etoposide, amsacrine, mitoxantrone
./___Corpus/Medline/xml/PMC4693276.xml	amsacrine	89457 : 89466	CM	 doxorubicin, etoposide, amsacrine, mitoxantrone but does n
./___Corpus/Medline/xml/PMC4693276.xml	mitoxantrone	89468 : 89480	CM	n, etoposide, amsacrine, mitoxantrone but does not potentiate 
./___Corpus/Medline/xml/PMC4693276.xml	camptothecin	89520 : 89532	CM	otentiate the effects of camptothecin or cytosine arabinoside.
./___Corpus/Medline/xml/PMC4693276.xml	cytosine arabinoside	89536 : 89556	CM	fects of camptothecin or cytosine arabinoside. However, considering th
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89835 : 89841	CM	of its high selectivity, NU7026 requires optimization fo
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	89896 : 89902	CM	nical use [253]. Lately, NU7026 has been shown to enhanc
./___Corpus/Medline/xml/PMC4693276.xml	DSB	90048 : 90051	CM	lained by an increase in DSB formation, resulting in 
./___Corpus/Medline/xml/PMC4693276.xml	G2	90076 : 90078	CM	 formation, resulting in G2/M cell arrest and possib
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90164 : 90170	CM	                  9.1.4. NU7441                      NU7
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90192 : 90198	CM	441                      NU7441 was designed from the LY
./___Corpus/Medline/xml/PMC4693276.xml	LY294002	90221 : 90229	CM	41 was designed from the LY294002 backbone with improved p
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90316 : 90322	CM	 In cultured cell lines, NU7441 showed strong inhibition
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	90351 : 90357	CM	wed strong inhibition of DNA-PK, caused persisting doxor
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	90377 : 90388	CM	NA-PK, caused persisting doxorubicin- and IR-induced DSBs, an
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	90405 : 90409	CM	orubicin- and IR-induced DSBs, and resulted in a modes
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90467 : 90473	CM	se in HR activity [255]. NU7441 has also been shown to i
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	90533 : 90542	CM	e cytotoxicity of IR and etoposide in SW620, LoVo, and V3-Y
./___Corpus/Medline/xml/PMC4693276.xml	SW620	90546 : 90551	CM	y of IR and etoposide in SW620, LoVo, and V3-YAC colon 
./___Corpus/Medline/xml/PMC4693276.xml	LoVo	90553 : 90557	CM	 and etoposide in SW620, LoVo, and V3-YAC colon cancer
./___Corpus/Medline/xml/PMC4693276.xml	V3-YAC	90563 : 90569	CM	side in SW620, LoVo, and V3-YAC colon cancer cells but n
./___Corpus/Medline/xml/PMC4693276.xml	V3	90619 : 90621	CM	ot in DNA-PKcs-deficient V3 cells, showing the speci
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90722 : 90728	CM	aft colon cancer models, NU7441 was maintained at concen
./___Corpus/Medline/xml/PMC4693276.xml	vitro	90797 : 90802	CM	for chemopotentiation in vitro for at least 4 h at non-
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	90849 : 90858	CM	on-toxic doses. Finally, etoposide-induced tumour growth de
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	90938 : 90944	CM	hout enhancing toxicity. NU7441 was further found to rad
./___Corpus/Medline/xml/PMC4693276.xml	leukaemic	90987 : 90996	CM	 to radiosensitize human leukaemic MOLT-4 cells, with the a
./___Corpus/Medline/xml/PMC4693276.xml	MOLT-4	90997 : 91003	CM	ensitize human leukaemic MOLT-4 cells, with the authors 
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91043 : 91049	CM	e authors proposing that NU7441 could be a platform for 
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91175 : 91181	CM	, it has been shown that NU7441 markedly sensitizes Hep3
./___Corpus/Medline/xml/PMC4693276.xml	Hep3B	91202 : 91207	CM	7441 markedly sensitizes Hep3B cells to the anti-prolif
./___Corpus/Medline/xml/PMC4693276.xml	anti-	91221 : 91226	CPR	tizes Hep3B cells to the anti-proliferative effects of 
./___Corpus/Medline/xml/PMC4693276.xml	harmine	91251 : 91258	CM	proliferative effects of harmine, a naturally occurring a
./___Corpus/Medline/xml/PMC4693276.xml	alkaloid	91282 : 91290	CM	e, a naturally occurring alkaloid with HR suppression abil
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	91332 : 91336	CM	ion ability that induces DSBs through the inhibition o
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	91363 : 91368	CM	hrough the inhibition of RAD51 recruitment. Interesting
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	91427 : 91431	CM	suggested that targeting NHEJ and HR could be used as 
./___Corpus/Medline/xml/PMC4693276.xml	anti-	91491 : 91496	CPR	hetic lethal approach in anti-cancer treatment [258]. F
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	91556 : 91562	CM	, it has been shown that NU7441 (and NU7026) could drama
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	91568 : 91574	CM	n shown that NU7441 (and NU7026) could dramatically enha
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	91621 : 91625	CM	nhance WAY-600 (a potent mTOR inhibitor) cytotoxic and
./___Corpus/Medline/xml/PMC4693276.xml	MCF7	91823 : 91827	CM	a panel of human breast (MCF7, T47D and MDA-MB-231) an
./___Corpus/Medline/xml/PMC4693276.xml	T47D	91829 : 91833	CM	l of human breast (MCF7, T47D and MDA-MB-231) and colo
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-231	91838 : 91848	CM	n breast (MCF7, T47D and MDA-MB-231) and colon (LoVo and SW6
./___Corpus/Medline/xml/PMC4693276.xml	LoVo	91861 : 91865	CM	d MDA-MB-231) and colon (LoVo and SW620) cancer cells.
./___Corpus/Medline/xml/PMC4693276.xml	SW620	91870 : 91875	CM	231) and colon (LoVo and SW620) cancer cells. This comp
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	91935 : 91950	RN	its cellular DNA-PK auto-phosphorylation and PI3K-mediated AKT ph
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	91955 : 91959	CM	auto-phosphorylation and PI3K-mediated AKT phosphoryla
./___Corpus/Medline/xml/PMC4693276.xml	AKT	91969 : 91972	CM	lation and PI3K-mediated AKT phosphorylation [260]. H
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	91973 : 91988	RN	on and PI3K-mediated AKT phosphorylation [260]. Hence, KU-0060648
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	92055 : 92059	CM	 inhibitor of DNA-PK and PI3K, which inhibits cell gro
./___Corpus/Medline/xml/PMC4693276.xml	NU7441	92291 : 92297	CM	wed that KU-0060648 (and NU7441 previously described) ca
./___Corpus/Medline/xml/PMC4693276.xml	Cas9	92336 : 92340	CM	scribed) can improve the Cas9-mediated genome editing 
./___Corpus/Medline/xml/PMC4693276.xml	icosahedron	92479 : 92490	CM	The name Icos comes from icosahedron, a twenty-sided polygon—
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	92621 : 92627	CM	compounds inhibiting the DNA-PK-dependent phosphorylatio
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	92638 : 92653	RN	ing the DNA-PK-dependent phosphorylation of a p53 peptide substra
./___Corpus/Medline/xml/PMC4693276.xml	p53	92659 : 92662	CM	ent phosphorylation of a p53 peptide substrate [262].
./___Corpus/Medline/xml/PMC4693276.xml	IC60211	92761 : 92768	CM	 potent kinase inhibitor IC60211, an arylmorpholine. Opti
./___Corpus/Medline/xml/PMC4693276.xml	arylmorpholine	92773 : 92787	CM	se inhibitor IC60211, an arylmorpholine. Optimization of this co
./___Corpus/Medline/xml/PMC4693276.xml	arylmorpholine	92884 : 92898	CM	tors that maintained the arylmorpholine structure, none of which
./___Corpus/Medline/xml/PMC4693276.xml	methyl ketone	92979 : 92992	CM	ns of <50 μM. IC86621, a methyl ketone derivative of IC60211, w
./___Corpus/Medline/xml/PMC4693276.xml	IC60211	93007 : 93014	CM	hyl ketone derivative of IC60211, was not the most active
./___Corpus/Medline/xml/PMC4693276.xml	ATM	93333 : 93336	CM	otein kinases, including ATM and ATR. However, the dr
./___Corpus/Medline/xml/PMC4693276.xml	ATR	93341 : 93344	CM	nases, including ATM and ATR. However, the drug has a
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	93405 : 93409	CM	inst the closely related PI3K. Surprisingly, IC86621 r
./___Corpus/Medline/xml/PMC4693276.xml	IC86621	93425 : 93432	CM	ated PI3K. Surprisingly, IC86621 reduced spontaneous HR b
./___Corpus/Medline/xml/PMC4693276.xml	I-SceI	93483 : 93489	CM	t also HR induced by the I-SceI nuclease [263]. The comp
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	93545 : 93549	CM	id not induce fusions in Ku70 knock-out mouse cells, s
./___Corpus/Medline/xml/PMC4693276.xml	morpholino-flavonoid	93864 : 93884	CM	 the most highly evolved morpholino-flavonoid and is 50-fold more sele
./___Corpus/Medline/xml/PMC4693276.xml	50-fold	93892 : 93899	CM	pholino-flavonoid and is 50-fold more selective for DNA-P
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	93939 : 93943	CM	 for DNA-PK than for the PI3K catalytic subunit p110β.
./___Corpus/Medline/xml/PMC4693276.xml	p110β	93962 : 93967	CM	e PI3K catalytic subunit p110β. At least 4 h exposure t
./___Corpus/Medline/xml/PMC4693276.xml	IC87361	94019 : 94026	CM	a 10 μM concentration of IC87361 was required for radiose
./___Corpus/Medline/xml/PMC4693276.xml	MCF7	94348 : 94352	CM	reast cancer cell lines (MCF7, BT-20 and MDA-MB-436) w
./___Corpus/Medline/xml/PMC4693276.xml	BT-20	94354 : 94359	CM	cancer cell lines (MCF7, BT-20 and MDA-MB-436) with dox
./___Corpus/Medline/xml/PMC4693276.xml	MDA-MB-436	94364 : 94374	CM	l lines (MCF7, BT-20 and MDA-MB-436) with doxorubicin or cis
./___Corpus/Medline/xml/PMC4693276.xml	doxorubicin	94381 : 94392	CM	-20 and MDA-MB-436) with doxorubicin or cisplatin in combinat
./___Corpus/Medline/xml/PMC4693276.xml	cisplatin	94396 : 94405	CM	436) with doxorubicin or cisplatin in combination with the 
./___Corpus/Medline/xml/PMC4693276.xml	OK-1035	94715 : 94722	CM	ave first indicated that OK-1035 was an inhibitor of DNA-
./___Corpus/Medline/xml/PMC4693276.xml	OK-1035	94809 : 94816	CM	ner [269]. Functionally, OK-1035 has been shown to affect
./___Corpus/Medline/xml/PMC4693276.xml	p53	94842 : 94845	CM	has been shown to affect p53 activity in cells follow
./___Corpus/Medline/xml/PMC4693276.xml	L5178Y	94935 : 94941	CM	repair in radioresistant L5178Y cells [271]. However, no
./___Corpus/Medline/xml/PMC4693276.xml	PI3K	95001 : 95005	CM	on concerning effects on PI3K-kinase activity or DSB r
./___Corpus/Medline/xml/PMC4693276.xml	DSB	95025 : 95028	CM	 PI3K-kinase activity or DSB repair was reported. Sto
./___Corpus/Medline/xml/PMC4693276.xml	OK-1035	95082 : 95089	CM	y et al. also found that OK-1035 is a weaker inhibitor of
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95331 : 95338	CM	752                      SU11752 is an ATP-competitive dr
./___Corpus/Medline/xml/PMC4693276.xml	SU11752	95602 : 95609	CM	e authors suggested that SU11752 could be used to develop
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	95659 : 95665	CM	 a new class of specific DNA-PK inhibitors.             
./___Corpus/Medline/xml/PMC4693276.xml	Vanillin	95702 : 95710	CM	                  9.1.9. Vanillin                      Sev
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	95783 : 95791	CM	ved compounds, including vanillin, cinnamaldehyde, coumari
./___Corpus/Medline/xml/PMC4693276.xml	cinnamaldehyde	95793 : 95807	CM	nds, including vanillin, cinnamaldehyde, coumarin, umbelliferone
./___Corpus/Medline/xml/PMC4693276.xml	coumarin	95809 : 95817	CM	anillin, cinnamaldehyde, coumarin, umbelliferone, anisalde
./___Corpus/Medline/xml/PMC4693276.xml	umbelliferone	95819 : 95832	CM	innamaldehyde, coumarin, umbelliferone, anisaldehyde and tannic
./___Corpus/Medline/xml/PMC4693276.xml	anisaldehyde	95834 : 95846	CM	coumarin, umbelliferone, anisaldehyde and tannic acid, are kno
./___Corpus/Medline/xml/PMC4693276.xml	acid	95858 : 95862	CM	 anisaldehyde and tannic acid, are known to possess mo
./___Corpus/Medline/xml/PMC4693276.xml	phenolic aldehyde vanillin	96023 : 96049	CM	[274]. Particularly, the phenolic aldehyde vanillin, derived from a species 
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	96122 : 96128	CM	so been shown to inhibit DNA-PK. Following IR of human o
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96177 : 96185	CM	ovarian carcinoma cells, vanillin specifically affected NH
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	96208 : 96212	CM	in specifically affected NHEJ and was selective for DN
./___Corpus/Medline/xml/PMC4693276.xml	ATM	96247 : 96250	CM	elective for DNA-PK over ATM and ATR [275]. Hence, th
./___Corpus/Medline/xml/PMC4693276.xml	ATR	96255 : 96258	CM	 for DNA-PK over ATM and ATR [275]. Hence, through th
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96304 : 96312	CM	h their specific action, vanillin-based molecules could be
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	96377 : 96381	CM	o investigate DNA-PK and NHEJ implication in DSB repai
./___Corpus/Medline/xml/PMC4693276.xml	DSB	96397 : 96400	CM	 and NHEJ implication in DSB repair. Recently, vanill
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96419 : 96427	CM	in DSB repair. Recently, vanillin was utilized to inhibit 
./___Corpus/Medline/xml/PMC4693276.xml	SF-1	96516 : 96520	CM	DNA-PK in the absence of SF-1 (a tissue-specific trans
./___Corpus/Medline/xml/PMC4693276.xml	vanillin	96735 : 96743	CM	lly beneficial impact of vanillin-based molecules in the p
./___Corpus/Medline/xml/PMC4693276.xml	NK314	96891 : 96896	CM	314                      NK314 is characterized as an a
./___Corpus/Medline/xml/PMC4693276.xml	anti-	96920 : 96925	CPR	4 is characterized as an anti-tumour agent possessing a
./___Corpus/Medline/xml/PMC4693276.xml	TOPOII	96990 : 96996	CM	 topoisomerase II alpha (TOPOII) [277,278,279]. Interest
./___Corpus/Medline/xml/PMC4693276.xml	NK314	97132 : 97137	CM	atomi et al. showed that NK314 could induce the degrada
./___Corpus/Medline/xml/PMC4693276.xml	DSB	97246 : 97249	CM	es, causing impaired DNA DSB repair [280]. The mechan
./___Corpus/Medline/xml/PMC4693276.xml	ATL	97389 : 97392	CM	als for the treatment of ATL, due to its impressive a
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	97487 : 97493	CM	 the potential for using DNA-PK inhibitors in the clinic
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	97639 : 97643	CM	ecule developed from the mTOR kinase inhibitor CC-223 
./___Corpus/Medline/xml/PMC4693276.xml	mTOR	97725 : 97729	CM	hibitor for DNA-PKcs and mTOR and the first clinical t
./___Corpus/Medline/xml/PMC4693276.xml	Nucleotide	97942 : 97952	CM	s.                  9.2. Nucleotide-Based Inhibitors of DNA-
./___Corpus/Medline/xml/PMC4693276.xml	GRN163L	98331 : 98338	CM	cussed.                  GRN163L                      GRN
./___Corpus/Medline/xml/PMC4693276.xml	GRN163L	98360 : 98367	CM	63L                      GRN163L (Imetelstat), is a 13-me
./___Corpus/Medline/xml/PMC4693276.xml	13-mer	98387 : 98393	CM	N163L (Imetelstat), is a 13-mer oligonucleotide initiall
./___Corpus/Medline/xml/PMC4693276.xml	GRN163L	98525 : 98532	CM	d colleagues showed that GRN163L inhibits DNA-PK phosphor
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	98549 : 98564	RN	 GRN163L inhibits DNA-PK phosphorylation and increases H2AX phosp
./___Corpus/Medline/xml/PMC4693276.xml	H2AX	98579 : 98583	CM	horylation and increases H2AX phosphorylation followin
./___Corpus/Medline/xml/PMC4693276.xml	phosphorylation	98584 : 98599	RN	ation and increases H2AX phosphorylation following treatment with
./___Corpus/Medline/xml/PMC4693276.xml	nucleotide	98629 : 98639	CM	owing treatment with the nucleotide analog fludarabine in CL
./___Corpus/Medline/xml/PMC4693276.xml	fludarabine	98647 : 98658	CM	th the nucleotide analog fludarabine in CLL lymphocytes [282]
./___Corpus/Medline/xml/PMC4693276.xml	CLL	98662 : 98665	CM	de analog fludarabine in CLL lymphocytes [282]. Inhib
./___Corpus/Medline/xml/PMC4693276.xml	GRN163L	98709 : 98716	CM	 Inhibition of DNA-PK by GRN163L has also been found to b
./___Corpus/Medline/xml/PMC4693276.xml	NU7026	98784 : 98790	CM	observed with the use of NU7026. Together these observat
./___Corpus/Medline/xml/PMC4693276.xml	GRN	98834 : 98837	CM	servations indicate that GRN 163L, in addition to inh
./___Corpus/Medline/xml/PMC4693276.xml	163L	98838 : 98842	CM	ations indicate that GRN 163L, in addition to inhibiti
./___Corpus/Medline/xml/PMC4693276.xml	GRN163L	98979 : 98986	CM	A damage repair. Whether GRN163L can be efficiently used 
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99188 : 99192	CM	r.                  9.3. Ku70/Ku80 Inhibitors         
./___Corpus/Medline/xml/PMC4693276.xml	Ku80	99193 : 99197	CM	               9.3. Ku70/Ku80 Inhibitors              
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99253 : 99257	CM	  It has been shown that Ku70/80 levels are increased 
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99415 : 99419	CM	wn that up-regulation of Ku70 expression in renal carc
./___Corpus/Medline/xml/PMC4693276.xml	786-	99461 : 99465	CPR	nal carcinoma cell line (786-O) could inhibit cell apo
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99561 : 99565	CM	 Conversely, deletion of Ku70 induces cell apoptosis a
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99684 : 99688	CM	bservations suggest that Ku70/Ku80 may be a potential 
./___Corpus/Medline/xml/PMC4693276.xml	Ku80	99689 : 99693	CM	ations suggest that Ku70/Ku80 may be a potential targe
./___Corpus/Medline/xml/PMC4693276.xml	Ku70	99814 : 99818	CM	cific inhibitors against Ku70/Ku80 have not been ident
./___Corpus/Medline/xml/PMC4693276.xml	Ku80	99819 : 99823	CM	 inhibitors against Ku70/Ku80 have not been identified
./___Corpus/Medline/xml/PMC4693276.xml	ATP	99939 : 99942	CM	    DNA ligase IV is the ATP-dependent DNA ligase tha
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	100000 : 100004	CM	zes the ligation step in NHEJ. Inhibiting the activity
./___Corpus/Medline/xml/PMC4693276.xml	vitro	100682 : 100687	CM	nterest, L189 used in in vitro DNA joining assays showe
./___Corpus/Medline/xml/PMC4693276.xml	MMS	100804 : 100807	CM	ased the cytotoxicity of MMS and IR in three cancer c
./___Corpus/Medline/xml/PMC4693276.xml	L189	100947 : 100951	CM	ence, this suggests that L189 could be used as a poten
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101153 : 101157	CM	                  9.4.2. SCR7                      SCR
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101179 : 101183	CM	CR7                      SCR7 is a L189 derivative tha
./___Corpus/Medline/xml/PMC4693276.xml	L189	101189 : 101193	CM	               SCR7 is a L189 derivative that was iden
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101273 : 101277	CM	 of DNA ligase IV [285]. SCR7 inhibits end-joining of 
./___Corpus/Medline/xml/PMC4693276.xml	DSB	101302 : 101305	CM	 inhibits end-joining of DSB by blocking ligase IV-me
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101346 : 101350	CM	ase IV-mediated joining. SCR7 interferes specifically 
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	101492 : 101496	CM	-dependent inhibition of NHEJ, SCR7 has been shown to 
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101498 : 101502	CM	dent inhibition of NHEJ, SCR7 has been shown to activa
./___Corpus/Medline/xml/PMC4693276.xml	SCR7	101619 : 101623	CM	ression in mouse models. SCR7 can also significantly e
./___Corpus/Medline/xml/PMC4693276.xml	etoposide	101698 : 101707	CM	-inducing agents (IR and etoposide) administered in combina
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	101743 : 101747	CM	red in combination. This NHEJ inhibitor offers therefo
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	101893 : 101898	CM	s.                  9.5. XRCC4 Inhibitors              
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	101931 : 101936	CM	ors                      XRCC4 may function as an addit
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	101967 : 101971	CM	unction as an additional NHEJ scaffolding protein, res
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	102034 : 102038	CM	the recruitment of other NHEJ factors to the site of t
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102074 : 102079	CM	 the site of the damage. XRCC4, in complex with ligase 
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	102129 : 102133	CM	IV, is implicated in the NHEJ ligation step.          
./___Corpus/Medline/xml/PMC4693276.xml	2-O-Feruloyl	102209 : 102221	CM	, Lithospermic Acid, and 2-O-Feruloyl Tartaric Acid           
./___Corpus/Medline/xml/PMC4693276.xml	TCM	102333 : 102336	CM	medicine (TCM) database, TCM Database@Taiwan, and hav
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102380 : 102385	CM	nd have identified three XRCC4 potent inhibitors [286].
./___Corpus/Medline/xml/PMC4693276.xml	Salvianolic acid	102411 : 102427	CM	potent inhibitors [286]. Salvianolic acid B, lithospermic acid, an
./___Corpus/Medline/xml/PMC4693276.xml	lithospermic acid	102431 : 102448	CM	86]. Salvianolic acid B, lithospermic acid, and 2-O-feruloyl tartar
./___Corpus/Medline/xml/PMC4693276.xml	2-O-feruloyl tartaric acid	102454 : 102480	CM	, lithospermic acid, and 2-O-feruloyl tartaric acid all bind to the DNA liga
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102529 : 102534	CM	ase IV binding region on XRCC4 (structures depicted in 
./___Corpus/Medline/xml/PMC4693276.xml	vitro	102682 : 102687	CM	re further assessment in vitro and in in vivo models. T
./___Corpus/Medline/xml/PMC4693276.xml	XRCC4	102743 : 102748	CM	, no inhibitor targeting XRCC4 has been described in vi
./___Corpus/Medline/xml/PMC4693276.xml	CML	102935 : 102938	CM	hronic myeloid leukemia (CML) patients, 50% of bone m
./___Corpus/Medline/xml/PMC4693276.xml	imatinib	103006 : 103014	CM	cells from patients with imatinib-resistant disease, as we
./___Corpus/Medline/xml/PMC4693276.xml	IIIα	103136 : 103140	CM	HEJ proteins, DNA ligase IIIα and PARP1, that correlat
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	103145 : 103150	CM	ins, DNA ligase IIIα and PARP1, that correlated with hy
./___Corpus/Medline/xml/PMC4693276.xml	PARP	103227 : 103231	CM	nation of DNA ligase and PARP inhibitors [287]. This s
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	103296 : 103304	CM	ncreased dependence upon Alt-NHEJ can be identified and ta
./___Corpus/Medline/xml/PMC4693276.xml	CML	103365 : 103368	CM	 significant fraction of CML patients having acquired
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	103478 : 103486	CM	t options available. The Alt-NHEJ targeting strategy is li
./___Corpus/Medline/xml/PMC4693276.xml	DSB	103606 : 103609	CM	that this abnormality in DSB repair may also occur in
./___Corpus/Medline/xml/PMC4693276.xml	anti-	103790 : 103795	CPR	 intrinsic resistance to anti-estrogens [288].         
./___Corpus/Medline/xml/PMC4693276.xml	DDR	104044 : 104047	CM	al rates. Several of the DDR inhibitors we reviewed h
./___Corpus/Medline/xml/PMC4693276.xml	DSB	104162 : 104165	CM	liminate cancer cells by DSB damage potentiation. Whi
./___Corpus/Medline/xml/PMC4693276.xml	vitro	104217 : 104222	CM	 some require further in vitro and in vivo testing, for
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	104257 : 104262	CM	vo testing, for instance RAD51 inhibitors, other have a
./___Corpus/Medline/xml/PMC4693276.xml	PARP	104357 : 104361	CM	e to do so. Among these, PARP inhibitors have shown th
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	104592 : 104596	CM	ed for use in women with BRCA-associated ovarian cance
./___Corpus/Medline/xml/PMC4693276.xml	PARP	104636 : 104640	CM	rian cancer. Promise for PARP inhibitors as a single a
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	104690 : 104694	CM	gent also extends beyond BRCA cancers, as they have sh
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	104779 : 104783	CM	ours bearing no germline BRCA mutations, including hig
./___Corpus/Medline/xml/PMC4693276.xml	ATM	104982 : 104985	CM	-telangiectasia mutated (ATM) is a protein which also
./___Corpus/Medline/xml/PMC4693276.xml	PARP	105054 : 105058	CM	 lethal interaction with PARP [290,291]. ATM is freque
./___Corpus/Medline/xml/PMC4693276.xml	ATM	105070 : 105073	CM	ion with PARP [290,291]. ATM is frequently altered or
./___Corpus/Medline/xml/PMC4693276.xml	ATM	105353 : 105356	CM	o cancers with disrupted ATM protein expression, spec
./___Corpus/Medline/xml/PMC4693276.xml	PARP	105647 : 105651	CM	 that the combination of PARP and ATM inhibitors has p
./___Corpus/Medline/xml/PMC4693276.xml	ATM	105656 : 105659	CM	 combination of PARP and ATM inhibitors has potential
./___Corpus/Medline/xml/PMC4693276.xml	p53	105728 : 105731	CM	ient gastric cancer with p53 inactivation. These find
./___Corpus/Medline/xml/PMC4693276.xml	p53	105799 : 105802	CM	spect of targeting other p53-deficient cancers with t
./___Corpus/Medline/xml/PMC4693276.xml	ATM	105846 : 105849	CM	with the combined use of ATM and PARP inhibitors, and
./___Corpus/Medline/xml/PMC4693276.xml	PARP	105854 : 105858	CM	 combined use of ATM and PARP inhibitors, and the poss
./___Corpus/Medline/xml/PMC4693276.xml	p53	105971 : 105974	CM	 in cancers harbouring a p53 disruption. PARPi are al
./___Corpus/Medline/xml/PMC4693276.xml	PARPi	105987 : 105992	CM	ouring a p53 disruption. PARPi are also effective in ce
./___Corpus/Medline/xml/PMC4693276.xml	RAD51	106034 : 106039	CM	ve in cells depleted for RAD51, RPA, RAD54, NSB1, MRE11
./___Corpus/Medline/xml/PMC4693276.xml	RPA	106041 : 106044	CM	ells depleted for RAD51, RPA, RAD54, NSB1, MRE11, ATR
./___Corpus/Medline/xml/PMC4693276.xml	RAD54	106046 : 106051	CM	depleted for RAD51, RPA, RAD54, NSB1, MRE11, ATR, ATM, 
./___Corpus/Medline/xml/PMC4693276.xml	NSB1	106053 : 106057	CM	d for RAD51, RPA, RAD54, NSB1, MRE11, ATR, ATM, Chk1, 
./___Corpus/Medline/xml/PMC4693276.xml	MRE11	106059 : 106064	CM	RAD51, RPA, RAD54, NSB1, MRE11, ATR, ATM, Chk1, and Chk
./___Corpus/Medline/xml/PMC4693276.xml	ATR	106066 : 106069	CM	RPA, RAD54, NSB1, MRE11, ATR, ATM, Chk1, and Chk2 [16
./___Corpus/Medline/xml/PMC4693276.xml	ATM	106071 : 106074	CM	RAD54, NSB1, MRE11, ATR, ATM, Chk1, and Chk2 [160]. H
./___Corpus/Medline/xml/PMC4693276.xml	PARP	106253 : 106257	CM	r, the implementation of PARP inhibitors faces conside
./___Corpus/Medline/xml/PMC4693276.xml	BRCA1	106316 : 106321	CM	itations in that not all BRCA1/2 breast cancer patients
./___Corpus/Medline/xml/PMC4693276.xml	PARP	106372 : 106376	CM	have shown a response to PARP inhibition [156] and res
./___Corpus/Medline/xml/PMC4693276.xml	NHEJ	106547 : 106551	CM	 clinical development of NHEJ inhibitors and more spec
./___Corpus/Medline/xml/PMC4693276.xml	PARP1	106669 : 106674	CM	d clinical evaluation of PARP1 inhibitors. As mentioned
./___Corpus/Medline/xml/PMC4693276.xml	DNA-PK	107157 : 107163	CM	riate dose and delivery, DNA-PK inhibitors could be comb
./___Corpus/Medline/xml/PMC4693276.xml	Alt-NHEJ	107331 : 107339	CM	gy was highlighted using Alt-NHEJ and HR (Figure 4). Deple
./___Corpus/Medline/xml/PMC4693276.xml	BRCA	107397 : 107401	CM	polymerase theta and the BRCA genes has a synergistic 
./___Corpus/Medline/xml/PMC4693276.xml	DSBs	107702 : 107706	CM	        In normal cells, DSBs are repaired by homologo
./___Corpus/Medline/xml/PMC4693276.xml	CHU	108121 : 108124	CM	pt and Sébastien Fortin (CHU de Québec) for discussio
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108413 : 108418	CM	4 (Fabrice Fleury; Denis Velic). Chemical structures we
./___Corpus/Medline/xml/PMC4693276.xml	ACD	108461 : 108464	CM	ures were depicted using ACD/ChemSketch from ACD/Labs
./___Corpus/Medline/xml/PMC4693276.xml	ACD	108481 : 108484	CM	sing ACD/ChemSketch from ACD/Labs.                  S
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108597 : 108602	CM	                   Denis Velic, Anthony M. Couturier, M
./___Corpus/Medline/xml/PMC4693276.xml	Velic	108771 : 108776	CM	y M. Couturier and Denis Velic designed the figures.   
./___Corpus/Medline/xml/PMC4720504.xml	anti-	130 : 135	CPR	om the body. Most of the anti-cancer therapies trigger 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	330 : 335	CPR	rly the activation of an anti-apoptotic systems, allows
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	1146 : 1154	CM	approaches including (a) gossypol; (b) epigallocatechin-3-
./___Corpus/Medline/xml/PMC4720504.xml	anti-	1357 : 1362	CPR	the design of successful anti-cancer strategies that ov
./___Corpus/Medline/xml/PMC4720504.xml	GLOBOCAN	1545 : 1553	CM	        According to the GLOBOCAN factsheet (http://globoc
./___Corpus/Medline/xml/PMC4720504.xml	5-	1894 : 1896	CPR	8% (15.6 million) of the 5-year prevalent cancer cas
./___Corpus/Medline/xml/PMC4720504.xml	anti-	4837 : 4842	CPR	e over expression of the anti-apoptotic molecules. Orig
./___Corpus/Medline/xml/PMC4720504.xml	BH3	4929 : 4932	CM	sis signaling focused on BH3 pathway proteins leading
./___Corpus/Medline/xml/PMC4720504.xml	BH3	5076 : 5079	CM	o-survival and pro-death BH3 members. When the balanc
./___Corpus/Medline/xml/PMC4720504.xml	anti-	5478 : 5483	CPR	 that interfere with the anti-apoptotic pathways protei
./___Corpus/Medline/xml/PMC4720504.xml	BCL2L2	5667 : 5673	CM	), Bcl-2-like-protein-2 (BCL2L2/Bcl-w) and Bcl-2 related
./___Corpus/Medline/xml/PMC4720504.xml	Bfl1	5714 : 5718	CM	2 related protein A1 (A1/Bfl1). Nevertheless, most of 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	7442 : 7445	CM	apoptotic members of the BH3 family to prevent mitoch
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	7505 : 7515	CM	re formation and prevent cytochrome c release and initiation
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	7792 : 7797	CM	vates nuclear factor-κB (NF-κB) by a signaling mechanis
./___Corpus/Medline/xml/PMC4720504.xml	Raf-1	7838 : 7843	CM	 mechanism that involves Raf-1/MEKK-1-mediated activati
./___Corpus/Medline/xml/PMC4720504.xml	MEKK-1	7844 : 7850	CM	nism that involves Raf-1/MEKK-1-mediated activation of i
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	7887 : 7892	CM	tivation of inhibitor of NF-κB kinase subunit beta (IKK
./___Corpus/Medline/xml/PMC4720504.xml	IKKβ	7914 : 7918	CM	-κB kinase subunit beta (IKKβ) [12]. Mortenson and col
./___Corpus/Medline/xml/PMC4720504.xml	AKT	8022 : 8025	CM	ncreases the activity of AKT and IKK as well as NF-κB
./___Corpus/Medline/xml/PMC4720504.xml	IKK	8030 : 8033	CM	 the activity of AKT and IKK as well as NF-κB transcr
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	8045 : 8050	CM	f AKT and IKK as well as NF-κB transcriptional activity
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	8339 : 8345	CM	ds to the maintenance of cyclin D1a expression, an activ
./___Corpus/Medline/xml/PMC4720504.xml	mitogen	8401 : 8408	CM	at may occur through p38 mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	carbonic	8572 : 8580	CM	dulate the expression of carbonic anhydrase IX (CAIX), vas
./___Corpus/Medline/xml/PMC4720504.xml	CAIX	8595 : 8599	CM	f carbonic anhydrase IX (CAIX), vascular endothelial g
./___Corpus/Medline/xml/PMC4720504.xml	pAKT	8649 : 8653	CM	rowth factor (VEGF), and pAKT in prostate cancer cell 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	9082 : 9087	CPR	target the entire set of anti-apoptotic proteins or the
./___Corpus/Medline/xml/PMC4720504.xml	perforin	9575 : 9583	CM	ediated cytotoxicity and perforin-granzyme-dependent killi
./___Corpus/Medline/xml/PMC4720504.xml	serine	9943 : 9949	CM	mily [20]. Granzyme A, a serine protease, causes cell de
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	10177 : 10187	CM	sruption with subsequent cytochrome c release. Initiators of
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	10316 : 10326	CM	ed by the interaction of cytochrome c, Apaf-1, d-ATP/ATP and
./___Corpus/Medline/xml/PMC4720504.xml	Apaf-1	10330 : 10336	CM	raction of cytochrome c, Apaf-1, d-ATP/ATP and procaspas
./___Corpus/Medline/xml/PMC4720504.xml	d-ATP	10338 : 10343	CM	of cytochrome c, Apaf-1, d-ATP/ATP and procaspase-9 wit
./___Corpus/Medline/xml/PMC4720504.xml	ATP	10344 : 10347	CM	ochrome c, Apaf-1, d-ATP/ATP and procaspase-9 with su
./___Corpus/Medline/xml/PMC4720504.xml	procaspase-9	10352 : 10364	CM	c, Apaf-1, d-ATP/ATP and procaspase-9 with subsequent initiati
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10461 : 10466	CPR	 of Bcl-2 and associated anti-apoptotic proteins Bcl-xL
./___Corpus/Medline/xml/PMC4720504.xml	Bf1	10503 : 10506	CM	oteins Bcl-xL, Mcl-1, A1/Bf1 and Bcl-w occurs in subs
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10882 : 10887	CPR	r the development of new anti-cancer agents [23,24].   
./___Corpus/Medline/xml/PMC4720504.xml	anti-	10992 : 10997	CPR	ia-1 (Mcl-1) is a potent anti-apoptotic protein, a memb
./___Corpus/Medline/xml/PMC4720504.xml	BH3	11855 : 11858	CM	to date are the Bad-like BH3 mimetics [29]. ABT-737, 
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	11874 : 11881	CM	-like BH3 mimetics [29]. ABT-737, one of these mimetics, 
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	12040 : 12047	CM	rated that resistance to ABT-737 is linked to high expres
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	12317 : 12324	CM	ncreatic cancer cells to ABT-737-induced apoptosis, indic
./___Corpus/Medline/xml/PMC4720504.xml	CTNNB1	13831 : 13837	CM	-associated protein β 1 (CTNNB1) mutations, which are pr
./___Corpus/Medline/xml/PMC4720504.xml	CTNNB1	13965 : 13971	CM	it was demonstrated that CTNNB1 mutant CCLs are sensitiv
./___Corpus/Medline/xml/PMC4720504.xml	CCLs	13979 : 13983	CM	rated that CTNNB1 mutant CCLs are sensitive to navitoc
./___Corpus/Medline/xml/PMC4720504.xml	ABT-199	14133 : 14140	CM	ity was not observed for ABT-199, a Bcl-2-specific inhibi
./___Corpus/Medline/xml/PMC4720504.xml	β-catenin	14349 : 14358	CM	t knockdown of Bcl-xL in β-catenin-active CCLs impairs prol
./___Corpus/Medline/xml/PMC4720504.xml	β-	14358 : 14360	CPR	wn of Bcl-xL in β-catenin-active CCLs impairs prolif
./___Corpus/Medline/xml/PMC4720504.xml	CCLs	14366 : 14370	CM	l-xL in β-catenin-active CCLs impairs proliferation, i
./___Corpus/Medline/xml/PMC4720504.xml	CTNNB1	14452 : 14458	CM	target for navitoclax in CTNNB1 mutant cancers. So drug 
./___Corpus/Medline/xml/PMC4720504.xml	pan-Bcl-2	14681 : 14690	CM	h is the argument for a “pan-Bcl-2” SMI – a compound which 
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	15002 : 15010	CM	son why natural compound gossypol from cotton seed has att
./___Corpus/Medline/xml/PMC4720504.xml	anti-	15114 : 15119	CPR	has been developed as an anti-cancer agent for clinical
./___Corpus/Medline/xml/PMC4720504.xml	39–	15914 : 15917	CPR	ertain anticancer drugs [39–41]. The majority of rele
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	16022 : 16038	CM	cs including vorinostat, cyclophosphamide, and imatinib have demon
./___Corpus/Medline/xml/PMC4720504.xml	imatinib	16044 : 16052	CM	t, cyclophosphamide, and imatinib have demonstrated that a
./___Corpus/Medline/xml/PMC4720504.xml	42–	16206 : 16209	CPR	the acquired resistance [42–44]. Furthermore, accumul
./___Corpus/Medline/xml/PMC4720504.xml	fate	18192 : 18196	CM	                    Cell fate dictated by autophagy is
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	18261 : 18269	CM	everal factors including beclin-1, PI3K, mTOR, Bcl-2, and 
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	18271 : 18275	CM	tors including beclin-1, PI3K, mTOR, Bcl-2, and p53, w
./___Corpus/Medline/xml/PMC4720504.xml	mTOR	18277 : 18281	CM	ncluding beclin-1, PI3K, mTOR, Bcl-2, and p53, which a
./___Corpus/Medline/xml/PMC4720504.xml	p53	18294 : 18297	CM	, PI3K, mTOR, Bcl-2, and p53, which are associated wi
./___Corpus/Medline/xml/PMC4720504.xml	Beclin-1	18352 : 18360	CM	ny human disorders [53]. Beclin-1, also called Atg6, is a 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	18410 : 18413	CM	Bcl-2-homology domain 3 (BH3) protein, that interacts
./___Corpus/Medline/xml/PMC4720504.xml	Vps34	18444 : 18449	CM	ein, that interacts with Vps34 (a class III PI3K), Vps1
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	18463 : 18467	CM	 with Vps34 (a class III PI3K), Vps15 (a myristoylated
./___Corpus/Medline/xml/PMC4720504.xml	Vps15	18470 : 18475	CM	ps34 (a class III PI3K), Vps15 (a myristoylated kinase)
./___Corpus/Medline/xml/PMC4720504.xml	myristoylated	18479 : 18492	RN	lass III PI3K), Vps15 (a myristoylated kinase), and UV irradiat
./___Corpus/Medline/xml/PMC4720504.xml	UVRAG	18566 : 18571	CM	d tumor suppressor gene (UVRAG) to form a multi-protein
./___Corpus/Medline/xml/PMC4720504.xml	anti-	18735 : 18740	CPR	this process include the anti-apoptotic proteins of the
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	18804 : 18812	CM	 which can interact with beclin-1 and inhibit the function
./___Corpus/Medline/xml/PMC4720504.xml	anti-	18997 : 19002	CPR	apoptosis resistance via anti-apoptotic Bcl-2 family me
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19229 : 19237	CM	nhibitory complexes with beclin-1 [56]. For example, soraf
./___Corpus/Medline/xml/PMC4720504.xml	sorafenib	19257 : 19266	CM	lin-1 [56]. For example, sorafenib-activated autophagic dea
./___Corpus/Medline/xml/PMC4720504.xml	HCC	19323 : 19326	CM	epatocellular carcinoma (HCC) cells is mediated by th
./___Corpus/Medline/xml/PMC4720504.xml	apogossypolone	19399 : 19413	CM	 Mcl-1. On the contrary, apogossypolone, a potent anticancer age
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19524 : 19532	CM	 the interaction between beclin-1 and Bcl-2/xL and induces
./___Corpus/Medline/xml/PMC4720504.xml	xL	19543 : 19545	CM	tween beclin-1 and Bcl-2/xL and induces protective a
./___Corpus/Medline/xml/PMC4720504.xml	HCC	19582 : 19585	CM	 protective autophagy in HCC cells [57]. The role of 
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19610 : 19618	CM	 cells [57]. The role of beclin-1 interactome in the cross
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	19717 : 19725	CM	zes that disturbances in beclin-1-dependent autophagy can 
./___Corpus/Medline/xml/PMC4720504.xml	ADP	19857 : 19860	CM	                     The ADP ribosylation factor (ARF
./___Corpus/Medline/xml/PMC4720504.xml	ribosylation	19861 : 19873	RN	                 The ADP ribosylation factor (ARF) tumor suppr
./___Corpus/Medline/xml/PMC4720504.xml	ARF	19882 : 19885	CM	ADP ribosylation factor (ARF) tumor suppressor is exp
./___Corpus/Medline/xml/PMC4720504.xml	mitogenic	19948 : 19957	CM	cumulated in response to mitogenic stimuli conveyed by onco
./___Corpus/Medline/xml/PMC4720504.xml	ARF	20013 : 20016	CM	signals. The majority of ARF localizes to the nucleol
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	20089 : 20098	CM	re it antagonizes the E3 ubiquitin ligase muring double min
./___Corpus/Medline/xml/PMC4720504.xml	MDM2	20130 : 20134	CM	 muring double minute 2 (MDM2) to provoke MDM2 degrada
./___Corpus/Medline/xml/PMC4720504.xml	MDM2	20147 : 20151	CM	nute 2 (MDM2) to provoke MDM2 degradation, thereby sta
./___Corpus/Medline/xml/PMC4720504.xml	p53	20185 : 20188	CM	ion, thereby stabilizing p53 protein [58,59]. A minor
./___Corpus/Medline/xml/PMC4720504.xml	ARF	20226 : 20229	CM	59]. A minor fraction of ARF (smARF) with a smaller m
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	20513 : 20521	CM	the complex formation of beclin-1 with Bcl-xL, leading to 
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	20570 : 20578	CM	 an increased ability of beclin-1 to perform its autophagi
./___Corpus/Medline/xml/PMC4720504.xml	ARF	20835 : 20838	CM	 a critical regulator of ARF-mediated autophagy [64].
./___Corpus/Medline/xml/PMC4720504.xml	ARF	20874 : 20877	CM	utophagy [64]. Recently, ARF has also been identified
./___Corpus/Medline/xml/PMC4720504.xml	ARF	20949 : 20952	CM	ced tumors and a lack of ARF function is associated w
./___Corpus/Medline/xml/PMC4720504.xml	p53	20999 : 21002	CM	d with the inhibition of p53 tumor suppressor functio
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21409 : 21412	CM	ence also indicates that ROS are implicated in autoph
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21503 : 21506	CM	tly, the deregulation of ROS formation during autopha
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21624 : 21627	CM	drug resistance [67,68]. ROS, especially mitochondria
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21654 : 21657	CM	especially mitochondrial ROS, serve as signaling mole
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	21724 : 21732	CM	 autophagy [69]. Atg4, a cysteine protease which cleaves A
./___Corpus/Medline/xml/PMC4720504.xml	LC3	21761 : 21764	CM	tease which cleaves Atg8/LC3 from the outer membrane 
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21838 : 21841	CM	geted and inactivated by ROS, leading to the lipidati
./___Corpus/Medline/xml/PMC4720504.xml	ROS	21967 : 21970	CM	e regulation of cellular ROS production by eliminatin
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22048 : 22051	CM	y produce high levels of ROS which, in turn, limits c
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22388 : 22391	CM	, mitigating accumulated ROS and protecting cell inte
./___Corpus/Medline/xml/PMC4720504.xml	5-fluorouracil	22515 : 22529	CM	anticancer drugs such as 5-fluorouracil (5-FU) elicit protective
./___Corpus/Medline/xml/PMC4720504.xml	5-FU	22531 : 22535	CM	 such as 5-fluorouracil (5-FU) elicit protective autop
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22645 : 22648	CM	ld enhance apoptosis via ROS formation.              
./___Corpus/Medline/xml/PMC4720504.xml	beclin-1	22758 : 22766	CM	autophagic genes such as beclin-1 and ATG5 has also been o
./___Corpus/Medline/xml/PMC4720504.xml	ATG5	22771 : 22775	CM	nes such as beclin-1 and ATG5 has also been observed t
./___Corpus/Medline/xml/PMC4720504.xml	oxaliplatin	22814 : 22825	CM	 observed to enhance the oxaliplatin-induced ROS production a
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22834 : 22837	CM	 the oxaliplatin-induced ROS production and cell deat
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22944 : 22947	CM	autophagy in eliminating ROS-induced cell death [73].
./___Corpus/Medline/xml/PMC4720504.xml	ROS	22986 : 22989	CM	death [73]. Furthermore, ROS-induced DNA damage activ
./___Corpus/Medline/xml/PMC4720504.xml	poly(ADP-ribose) polymerase-1(PARP-1)	23045 : 23082	CM	he enzymatic activity of poly(ADP-ribose) polymerase-1(PARP-1), which has been demonstr
./___Corpus/Medline/xml/PMC4720504.xml	AMP	23155 : 23158	CM	ve autophagy through the AMP-activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23251 : 23254	CM	tance of cancer cells to ROS production by chemothera
./___Corpus/Medline/xml/PMC4720504.xml	74–	23293 : 23296	CPR	 chemotherapeutic drugs [74–76]. Thus, modulating the
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23371 : 23374	CM	ry mechanism of cells to ROS, such as through the use
./___Corpus/Medline/xml/PMC4720504.xml	ROS	23527 : 23530	CM	cancer cells by blocking ROS-mediated protective auto
./___Corpus/Medline/xml/PMC4720504.xml	vitro	23970 : 23975	CM	.                  4. In vitro and in vivo necrotic cel
./___Corpus/Medline/xml/PMC4720504.xml	Na+	24472 : 24475	CM	tegrity, rapid influx of Na+, Ca2+, and water, result
./___Corpus/Medline/xml/PMC4720504.xml	Ca2+	24477 : 24481	CM	ty, rapid influx of Na+, Ca2+, and water, resulting in
./___Corpus/Medline/xml/PMC4720504.xml	water	24487 : 24492	CM	influx of Na+, Ca2+, and water, resulting in cytoplasmi
./___Corpus/Medline/xml/PMC4720504.xml	oxygen	24964 : 24970	CM	n, heat, trauma, lack of oxygen due to the blockage of b
./___Corpus/Medline/xml/PMC4720504.xml	CD4	26125 : 26128	CM	ple, HIV-1 shows to kill CD4+T lymphocytes by necrosi
./___Corpus/Medline/xml/PMC4720504.xml	karyolysis	26725 : 26735	RN	o the cytoplasm known as karyolysis. The second pathway of n
./___Corpus/Medline/xml/PMC4720504.xml	fluoromethyl ketone	27450 : 27469	CM	 inhibitor, such as zVAD fluoromethyl ketone. Unlike apoptosis, necro
./___Corpus/Medline/xml/PMC4720504.xml	FLICE	27791 : 27796	CM	atory molecules, such as FLICE-like inhibitory protein 
./___Corpus/Medline/xml/PMC4720504.xml	cIAP1	27976 : 27981	CM	peat-containing protein (cIAP1 and cIAP2). At the molec
./___Corpus/Medline/xml/PMC4720504.xml	cIAP2	27986 : 27991	CM	ining protein (cIAP1 and cIAP2). At the molecular level
./___Corpus/Medline/xml/PMC4720504.xml	TNFR1	28163 : 28168	CM	crosis factor receptor 1/TNFR1), by cell-surface toll-l
./___Corpus/Medline/xml/PMC4720504.xml	DAI	28211 : 28214	CM	 toll-like receptors, by DAI (which may act as a cyto
./___Corpus/Medline/xml/PMC4720504.xml	RNA	28253 : 28256	CM	t as a cytoplasmic viral RNA sensor). The continuing 
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	28681 : 28691	CM	ost abundant proteins in eukaryotic cells. It is an enzymati
./___Corpus/Medline/xml/PMC4720504.xml	ATPase	28742 : 28748	CM	 chaperone molecule with ATPase activity that is highly 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	29196 : 29201	CPR	ated kinases and several anti-apoptotic factors within 
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	29230 : 29237	CM	totic factors within the cytosol that overall favor resis
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	29432 : 29436	CM	 limited to Akt, mutated BRAF, EGFR, JAK2 and the inhi
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	29438 : 29442	CM	ed to Akt, mutated BRAF, EGFR, JAK2 and the inhibitor 
./___Corpus/Medline/xml/PMC4720504.xml	JAK2	29444 : 29448	CM	Akt, mutated BRAF, EGFR, JAK2 and the inhibitor of apo
./___Corpus/Medline/xml/PMC4720504.xml	JAK2	29643 : 29647	CM	o apoptosis. The kinase, JAK2, was recently shown to b
./___Corpus/Medline/xml/PMC4720504.xml	JAK2	29802 : 29806	CM	 almost always harbors a JAK2 mutation. In line with t
./___Corpus/Medline/xml/PMC4720504.xml	JAK2	29859 : 29863	CM	interaction of hsp90 and JAK2, a novel hsp90 inhibitor
./___Corpus/Medline/xml/PMC4720504.xml	JAK2	29940 : 29944	CM	interaction and depleted JAK2 protein levels in vitro 
./___Corpus/Medline/xml/PMC4720504.xml	vitro	29963 : 29968	CM	d JAK2 protein levels in vitro and in vivo. Hsp90 signa
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	30051 : 30059	CM	 mediating resistance to tyrosine kinase inhibition (TKI) 
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30113 : 30117	CM	tment, specifically with EGFR inhibitory molecules, su
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	30148 : 30157	CM	itory molecules, such as erlotinib and gefitinib. These mol
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	30162 : 30171	CM	s, such as erlotinib and gefitinib. These molecules particu
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30217 : 30221	CM	ticularly target mutated EGFR within the intracellular
./___Corpus/Medline/xml/PMC4720504.xml	ATP	30247 : 30250	CM	within the intracellular ATP binding domain, especial
./___Corpus/Medline/xml/PMC4720504.xml	L858R	30306 : 30311	CM	nt mutations in exon 21 (L858R) and deletion located in
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30562 : 30566	CM	ted depletion of mutated EGFR with subsequent suppress
./___Corpus/Medline/xml/PMC4720504.xml	p-Akt	30598 : 30603	CM	ubsequent suppression of p-Akt, causing cell death. Mor
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	30635 : 30641	CM	ng cell death. Moreover, 17-AAG, a derivative of geldana
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30709 : 30713	CM	ently suppressed mutated EGFR compared to the wild-typ
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30852 : 30856	CM	 initially responsive to EGFR inhibition due to select
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30885 : 30889	CM	ibition due to selective EGFR mutation in exon 19 or e
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	30965 : 30969	CM	cause in the presence of EGFR sensitizing mutations, t
./___Corpus/Medline/xml/PMC4720504.xml	T790M	31040 : 31045	CM	y mutations, such as the T790M EGFR mutation, which in 
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	31046 : 31050	CM	tions, such as the T790M EGFR mutation, which in turn 
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	31097 : 31106	CM	rn confers resistance to erlotinib/gefitinib. One option to
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	31107 : 31116	CM	 resistance to erlotinib/gefitinib. One option to bypass a 
./___Corpus/Medline/xml/PMC4720504.xml	T790M	31141 : 31146	CM	. One option to bypass a T790M mediated resistance is t
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	31215 : 31223	CM	f so called irreversible tyrosine kinase inhibitors. Howev
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31329 : 31335	CM	c inhibition of hsp90 by 17-AAG [92]. Shimamura et al. [
./___Corpus/Medline/xml/PMC4720504.xml	murine	31387 : 31393	CM	] have demonstrated in a murine model of lung cancer, ha
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	31443 : 31447	CM	rboring both an exon 21 (EGFR inhibitor sensitizing mu
./___Corpus/Medline/xml/PMC4720504.xml	T790M	31509 : 31514	CM	the resistance mutation (T790M), that 17-DMAG (a deriva
./___Corpus/Medline/xml/PMC4720504.xml	17-DMAG	31522 : 31529	CM	e mutation (T790M), that 17-DMAG (a derivative of 17-AAG 
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31547 : 31553	CM	17-DMAG (a derivative of 17-AAG with optimized in vivo p
./___Corpus/Medline/xml/PMC4720504.xml	T790M	31638 : 31643	CM	h in the presence of the T790M mutation, indicating tha
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	31726 : 31730	CM	while strategy to combat EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	31731 : 31739	CM	 strategy to combat EGFR tyrosine kinase inhibitor resista
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	31907 : 31913	CM	nfavorable properties of 17-AAG derived molecules, alter
./___Corpus/Medline/xml/PMC4720504.xml	Ganetespib	31989 : 31999	CM	 tested. One of which is Ganetespib that was recently explor
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	32083 : 32087	CM	including ones harboring EGFR inhibitor resistance med
./___Corpus/Medline/xml/PMC4720504.xml	Ganetespib	32130 : 32140	CM	nce mediating mutations. Ganetespib behaved superiorly compa
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	32172 : 32178	CM	d superiorly compared to 17-AAG and accumulated within n
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	32439 : 32446	CM	ence and function in the cytosol, but recent evidence als
./___Corpus/Medline/xml/PMC4720504.xml	anti-	32685 : 32690	CPR	ibition of hsp90 elicits anti-cancer activity in tumor 
./___Corpus/Medline/xml/PMC4720504.xml	TNF	33031 : 33034	CM	hondrial hsp90; mHsp90), TNF receptor-associated prot
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33066 : 33071	CM	or-associated protein 1 (TRAP1) and the cell death prom
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33133 : 33138	CM	n Cyclophilin-D (Cyp-D). TRAP1 is a molecule that share
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33278 : 33283	CM	th hsp90. Akin to hsp90, TRAP1 reveals ATPase activity 
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	33395 : 33401	CM	cin derivatives, such as 17-AAG. Favoring TRAP1 as a sui
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33412 : 33417	CM	such as 17-AAG. Favoring TRAP1 as a suitable “druggable
./___Corpus/Medline/xml/PMC4720504.xml	β-hydroxyisovalerylshikonin	33722 : 33749	CM	] have demonstrated that β-hydroxyisovalerylshikonin, a plant derivative with
./___Corpus/Medline/xml/PMC4720504.xml	anti-	33775 : 33780	CPR	 a plant derivative with anti-cancer activity, depleted
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33806 : 33811	CM	ancer activity, depleted TRAP1 levels in mitochondria i
./___Corpus/Medline/xml/PMC4720504.xml	DMS114	33838 : 33844	CM	evels in mitochondria in DMS114 (lung cancer) and HL60 (
./___Corpus/Medline/xml/PMC4720504.xml	HL60	33863 : 33867	CM	DMS114 (lung cancer) and HL60 (leukemia) cells, respec
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	33947 : 33952	CM	 mitochondria, hsp90 and TRAP1 inhibit mitochondrial pe
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	34339 : 34345	CM	molecules was a modified 17-AAG (Ant-GA) molecule that h
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	34516 : 34521	CM	 inhibit both mhsp90 and TRAP1. Despite its modificatio
./___Corpus/Medline/xml/PMC4720504.xml	TP53	34742 : 34746	CM	ath independent of their TP53 status, suggesting that 
./___Corpus/Medline/xml/PMC4720504.xml	p53	34864 : 34867	CM	re presence of wild-type p53 which is amongst the mos
./___Corpus/Medline/xml/PMC4720504.xml	cyclosporine-A	35120 : 35134	CM	licited by Ant-GA, since cyclosporine-A, an inhibitory molecule 
./___Corpus/Medline/xml/PMC4720504.xml	MPT	35162 : 35165	CM	n inhibitory molecule of MPT mediated cell death miti
./___Corpus/Medline/xml/PMC4720504.xml	anti-	35683 : 35688	CPR	l form of shepherdin had anti-cancer activity in severa
./___Corpus/Medline/xml/PMC4720504.xml	vitro	36481 : 36486	CM	t leukemia cells both in vitro and in vivo [98]. Later 
./___Corpus/Medline/xml/PMC4720504.xml	TRAP1	36637 : 36642	CM	nteracting directly with TRAP1 and mhsp90. Consistent w
./___Corpus/Medline/xml/PMC4720504.xml	MPT	36714 : 36717	CM	cs, shepherdin induces a MPT-dependent cell death spe
./___Corpus/Medline/xml/PMC4720504.xml	cyclosporine-A	36877 : 36891	CM	lines, pretreatment with cyclosporine-A, an inhibitor of the MPT
./___Corpus/Medline/xml/PMC4720504.xml	MPT	36913 : 36916	CM	e-A, an inhibitor of the MPT, attenuated shepherdin-m
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	37095 : 37105	CM	ation of intermembranous cytochrome c into the cytosol, did 
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	37117 : 37124	CM	us cytochrome c into the cytosol, did not significantly s
./___Corpus/Medline/xml/PMC4720504.xml	MPT	37295 : 37298	CM	and mainly relies on the MPT pore in the presence of 
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	37474 : 37481	CM	ical effects both in the cytosol and within mitochondria.
./___Corpus/Medline/xml/PMC4720504.xml	17-AAG	37688 : 37694	CM	nitribs are derived from 17-AAG and structurally contain
./___Corpus/Medline/xml/PMC4720504.xml	anti-	37918 : 37923	CPR	They are associated with anti-tumor activity in a numbe
./___Corpus/Medline/xml/PMC4720504.xml	Eukaryotic	38409 : 38419	CM	nce                      Eukaryotic 26S proteasome is a 2.5 
./___Corpus/Medline/xml/PMC4720504.xml	19S	38480 : 38483	CM	omplex consisting of two 19S regulatory particles and
./___Corpus/Medline/xml/PMC4720504.xml	20S	38513 : 38516	CM	latory particles and one 20S catalytic core [101]. Ea
./___Corpus/Medline/xml/PMC4720504.xml	19S	38544 : 38547	CM	talytic core [101]. Each 19S regulatory particle is c
./___Corpus/Medline/xml/PMC4720504.xml	20S	38682 : 38685	CM	ylated proteins into the 20S catalytic core, and the 
./___Corpus/Medline/xml/PMC4720504.xml	20S	38793 : 38796	CM	n of large proteins. The 20S catalytic core harbors s
./___Corpus/Medline/xml/PMC4720504.xml	α-	38835 : 38837	CPR	e harbors seven distinct α-subunits and β-subunits a
./___Corpus/Medline/xml/PMC4720504.xml	β-	38850 : 38852	CPR	 distinct α-subunits and β-subunits arranged in a α7
./___Corpus/Medline/xml/PMC4720504.xml	β-	38933 : 38935	CPR	ich mainly three sets of β-subunits, β1 (caspase-lik
./___Corpus/Medline/xml/PMC4720504.xml	peptidyl-glutamyl	38965 : 38982	CM	its, β1 (caspase-like or peptidyl-glutamyl peptide-hydrolyzing (PGP
./___Corpus/Medline/xml/PMC4720504.xml	hydrolyzing	38991 : 39002	RN	eptidyl-glutamyl peptide-hydrolyzing (PGPH)-like), β2 (trypsi
./___Corpus/Medline/xml/PMC4720504.xml	PGPH	39004 : 39008	CM	myl peptide-hydrolyzing (PGPH)-like), β2 (trypsin-like
./___Corpus/Medline/xml/PMC4720504.xml	N-	39225 : 39227	CPR	 a special group termed N-terminal nucleophile hydro
./___Corpus/Medline/xml/PMC4720504.xml	N-	39297 : 39299	CPR	s the side chain of the N-terminal residue as the ca
./___Corpus/Medline/xml/PMC4720504.xml	102–	39345 : 39349	CPR	e catalytic nucleophile [102–104]. All three catalytic
./___Corpus/Medline/xml/PMC4720504.xml	β-	39375 : 39377	CPR	04]. All three catalytic β-subunits react with pepti
./___Corpus/Medline/xml/PMC4720504.xml	OH	39439 : 39441	CM	substrates through their OH group of the N-terminal 
./___Corpus/Medline/xml/PMC4720504.xml	N-	39456 : 39458	CPR	h their OH group of the N-terminal threonine (Thr1),
./___Corpus/Medline/xml/PMC4720504.xml	threonine	39466 : 39475	CM	 group of the N-terminal threonine (Thr1), resulting in pro
./___Corpus/Medline/xml/PMC4720504.xml	Thr1	39477 : 39481	CM	he N-terminal threonine (Thr1), resulting in protein b
./___Corpus/Medline/xml/PMC4720504.xml	amino acids	39557 : 39568	CM	ragments of less than 10 amino acids. It has been well docume
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	39699 : 39705	CM	 turnover of cyclins and cyclin-dependent kinase inhibit
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	39835 : 39844	CM	arrest. In addition, the ubiquitin-proteasomal system can a
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	40003 : 40008	CM	val or apoptosis such as NF-κB, p53, as well as apoptot
./___Corpus/Medline/xml/PMC4720504.xml	p53	40010 : 40013	CM	apoptosis such as NF-κB, p53, as well as apoptotic pr
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	40793 : 40803	CM	thetic compounds such as bortezomib and many natural product
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol epigallocatechin-3-gallate	40844 : 40881	CM	l products such as plant polyphenol epigallocatechin-3-gallate (EGCG) [107]. Although t
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	40883 : 40887	CM	gallocatechin-3-gallate (EGCG) [107]. Although the mec
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	41089 : 41099	CM	The clinical efficacy of bortezomib in multiple myeloma and 
./___Corpus/Medline/xml/PMC4720504.xml	IκBα	41336 : 41340	CM	proteasome also degrades IκBα, an important inhibitor 
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	41394 : 41399	CM	he tumor survival factor NF-κB. Many physical (i.e., ra
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylation	41540 : 41555	RN	h factors) agents induce phosphorylation, ubiquitination and subs
./___Corpus/Medline/xml/PMC4720504.xml	IκBα	41602 : 41606	CM	ubsequent degradation of IκBα by the proteasome, freei
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	41637 : 41642	CM	e proteasome, freeing up NF-κB to translocate to the nu
./___Corpus/Medline/xml/PMC4720504.xml	NFKB	41771 : 41775	CM	 [108,109]. For example, NFKB upregulates the anti-apo
./___Corpus/Medline/xml/PMC4720504.xml	anti-	41792 : 41797	CPR	le, NFKB upregulates the anti-apoptotic protein Bcl-2 a
./___Corpus/Medline/xml/PMC4720504.xml	IκBα	41918 : 41922	CM	hibiting the proteasome, IκBα will accumulate which wi
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	41958 : 41963	CM	ulate which will inhibit NF-κB from promoting tumor sur
./___Corpus/Medline/xml/PMC4720504.xml	p53	42065 : 42068	CM	ing the tumor suppressor p53. Many tumor cells inacti
./___Corpus/Medline/xml/PMC4720504.xml	p53	42098 : 42101	CM	y tumor cells inactivate p53 by over expressing p53 m
./___Corpus/Medline/xml/PMC4720504.xml	p53	42121 : 42124	CM	e p53 by over expressing p53 master regulator MDM2 [1
./___Corpus/Medline/xml/PMC4720504.xml	MDM2	42142 : 42146	CM	ing p53 master regulator MDM2 [110]. In human tumors t
./___Corpus/Medline/xml/PMC4720504.xml	MDM2	42188 : 42192	CM	tumors that over express MDM2, the inhibition of prote
./___Corpus/Medline/xml/PMC4720504.xml	p53	42291 : 42294	CM	poptosis by accumulating p53. It has been observed th
./___Corpus/Medline/xml/PMC4720504.xml	CEP1612	42322 : 42329	CM	t has been observed that CEP1612, a dipeptidyl proteasome
./___Corpus/Medline/xml/PMC4720504.xml	dipeptidyl	42333 : 42343	CM	observed that CEP1612, a dipeptidyl proteasome inhibitor, wa
./___Corpus/Medline/xml/PMC4720504.xml	cytochrome	42868 : 42878	CM	x/Bcl-2, associated with cytochrome c release and apoptosis 
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	43028 : 43037	CM	tein is degraded through ubiquitin/proteasome-dependent pat
./___Corpus/Medline/xml/PMC4720504.xml	anti-	43235 : 43240	CPR	nge the ratio of pro- to anti-apoptotic proteins, which
./___Corpus/Medline/xml/PMC4720504.xml	RNA	43693 : 43696	CM	nisms such as non-coding RNA (microRNAs) and DNA meth
./___Corpus/Medline/xml/PMC4720504.xml	methylation	43717 : 43728	RN	 RNA (microRNAs) and DNA methylation are important drivers th
./___Corpus/Medline/xml/PMC4720504.xml	taxane	44417 : 44423	CM	 Studies have shown that taxane resistance in breast can
./___Corpus/Medline/xml/PMC4720504.xml	taxane	44576 : 44582	CM	e gradual development of taxane resistance over a relati
./___Corpus/Medline/xml/PMC4720504.xml	platinum	45001 : 45009	CM	ollateral sensitivity to platinum agents, as seen for taxa
./___Corpus/Medline/xml/PMC4720504.xml	taxane	45030 : 45036	CM	inum agents, as seen for taxane resistant breast cancer.
./___Corpus/Medline/xml/PMC4720504.xml	anti-	45192 : 45197	CPR	h acquired resistance to anti-endocrine agents such as 
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	45222 : 45231	CM	endocrine agents such as tamoxifen and also faslodex (fulve
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	45294 : 45303	CM	stance to agents such as tamoxifen is a major concern when 
./___Corpus/Medline/xml/PMC4720504.xml	prophylactic	45411 : 45423	CM	east cancer, both in the prophylactic and adjuvant settings.  
./___Corpus/Medline/xml/PMC4720504.xml	cDNA	45588 : 45592	CM	 been studied. Using the cDNA microarrays of several c
./___Corpus/Medline/xml/PMC4720504.xml	vitro	45688 : 45693	CM	nt to cytotoxic drugs in vitro, candidate genes have be
./___Corpus/Medline/xml/PMC4720504.xml	methylation	45796 : 45807	RN	t can reverse epigenetic methylation a number of drug resista
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46028 : 46039	RN	ilencing – generally via methylation of the CpG islands in th
./___Corpus/Medline/xml/PMC4720504.xml	CpG	46047 : 46050	CM	y via methylation of the CpG islands in the promoter 
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	46287 : 46298	CM	stance to paclitaxel and carboplatin and showed that resistan
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	46372 : 46383	CM	with cross-resistance to carboplatin, occurred with loss of t
./___Corpus/Medline/xml/PMC4720504.xml	G2	46411 : 46413	CM	ccurred with loss of the G2 checkpoint and apoptosis
./___Corpus/Medline/xml/PMC4720504.xml	Kinase-2	46494 : 46502	CM	s included the Polo Like Kinase-2 (PLK2) that was down-reg
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	46504 : 46508	CM	 the Polo Like Kinase-2 (PLK2) that was down-regulated
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46550 : 46561	RN	egulated due to acquired methylation in the CpG-island at the
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	46753 : 46757	CM	 decreased expression of PLK2 and increasing CpG islan
./___Corpus/Medline/xml/PMC4720504.xml	CpG	46773 : 46776	CM	n of PLK2 and increasing CpG island methylation. Base
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46784 : 46795	RN	nd increasing CpG island methylation. Based on these studies 
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46885 : 46896	RN	erapeutic stress induces methylation in the CpG island of spe
./___Corpus/Medline/xml/PMC4720504.xml	CpG	46904 : 46907	CM	duces methylation in the CpG island of specific “resi
./___Corpus/Medline/xml/PMC4720504.xml	methylation	46990 : 47001	RN	fect leads to increasing methylation as the level of resistan
./___Corpus/Medline/xml/PMC4720504.xml	6-mercaptopurine	47094 : 47110	CM	ibed in cells exposed to 6-mercaptopurine [117]. A study by Matthe
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47208 : 47212	CM	a on chemosensitivity in PLK2-deficient tumors. Here, 
./___Corpus/Medline/xml/PMC4720504.xml	camptothecin	47260 : 47272	CM	, complete resistance to camptothecin pointed to interplay bet
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47333 : 47337	CM	mor microenvironment and PLK2 expression, whereas in t
./___Corpus/Medline/xml/PMC4720504.xml	PLK2	47464 : 47468	CM	e study also showed that PLK2 can inhibit mTOR signali
./___Corpus/Medline/xml/PMC4720504.xml	mTOR	47481 : 47485	CM	ed that PLK2 can inhibit mTOR signaling under the infl
./___Corpus/Medline/xml/PMC4720504.xml	p53	47529 : 47532	CM	e influence of wild-type p53 control. Furthermore, it
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	47577 : 47583	CM	e, it was found that the cyclin-dependent kinase inhibit
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47717 : 47728	CM	has also been shown that carboplatin-resistant ovarian cancer
./___Corpus/Medline/xml/PMC4720504.xml	methylation	47774 : 47785	RN	ncer cells show promoter methylation in the CpG island of the
./___Corpus/Medline/xml/PMC4720504.xml	CpG	47793 : 47796	CM	moter methylation in the CpG island of the promoter. 
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47844 : 47855	CM	. By silencing otherwise carboplatin-sensitive cells using si
./___Corpus/Medline/xml/PMC4720504.xml	carboplatin	47910 : 47921	CM	irected against p57kip2, carboplatin resistance was recapitul
./___Corpus/Medline/xml/PMC4720504.xml	platinum	48056 : 48064	CM	ith a sub-lethal dose of platinum agents [119]. However, t
./___Corpus/Medline/xml/PMC4720504.xml	methylation	48240 : 48251	RN	low p57kip2 and promoter methylation and its association with
./___Corpus/Medline/xml/PMC4720504.xml	platinum	48310 : 48318	CM	rognosis and evidence of platinum-refractory disease.     
./___Corpus/Medline/xml/PMC4720504.xml	nucleotide	48838 : 48848	CM	there will be changes in nucleotide sequence at the site of 
./___Corpus/Medline/xml/PMC4720504.xml	RNAs	49053 : 49057	CM	omprises 5 small nuclear RNAs complexed with several a
./___Corpus/Medline/xml/PMC4720504.xml	mRNA	49637 : 49641	CM	be the result of variant mRNA that is tumor-suppressiv
./___Corpus/Medline/xml/PMC4720504.xml	SC-35	49783 : 49788	CM	cing factors – including SC-35 (a member of the serine 
./___Corpus/Medline/xml/PMC4720504.xml	serine	49806 : 49812	CM	g SC-35 (a member of the serine rich splicing factors: s
./___Corpus/Medline/xml/PMC4720504.xml	mRNA	49902 : 49906	CM	ontrolling the extent of mRNA splicing into active for
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	50057 : 50066	CM	h acquired resistance to cisplatin have been shown to under
./___Corpus/Medline/xml/PMC4720504.xml	SC-35	50100 : 50105	CM	n shown to under express SC-35. Demethylation analyses 
./___Corpus/Medline/xml/PMC4720504.xml	Demethylation	50107 : 50120	RN	 to under express SC-35. Demethylation analyses have revealed t
./___Corpus/Medline/xml/PMC4720504.xml	arginine	50170 : 50178	CM	hat the splicing factor, arginine/serine-rich 2 (SRSF2) ge
./___Corpus/Medline/xml/PMC4720504.xml	serine	50179 : 50185	CM	plicing factor, arginine/serine-rich 2 (SRSF2) gene is s
./___Corpus/Medline/xml/PMC4720504.xml	SRSF2	50194 : 50199	CM	 arginine/serine-rich 2 (SRSF2) gene is silenced via me
./___Corpus/Medline/xml/PMC4720504.xml	methylation	50222 : 50233	RN	F2) gene is silenced via methylation of CpG islands in the pr
./___Corpus/Medline/xml/PMC4720504.xml	CpG	50237 : 50240	CM	enced via methylation of CpG islands in the promoter 
./___Corpus/Medline/xml/PMC4720504.xml	methylated	50532 : 50542	RN	response by detection of methylated DNA in cancer patients. 
./___Corpus/Medline/xml/PMC4720504.xml	DNA	50543 : 50546	CM	 detection of methylated DNA in cancer patients.     
./___Corpus/Medline/xml/PMC4720504.xml	RNA	50826 : 50829	CM	. SR proteins contain an RNA-binding domain and a cha
./___Corpus/Medline/xml/PMC4720504.xml	SRSF2	50866 : 50871	CM	ain and a characteristic SRSF2 – otherwise referred to 
./___Corpus/Medline/xml/PMC4720504.xml	CpG	50956 : 50959	CM	 17 and contains a large CpG island. SR proteins cont
./___Corpus/Medline/xml/PMC4720504.xml	SF2	51138 : 51141	CM	ctivity. Factors such as SF2/ASF and SC35 are associa
./___Corpus/Medline/xml/PMC4720504.xml	ASF	51142 : 51145	CM	ity. Factors such as SF2/ASF and SC35 are associated 
./___Corpus/Medline/xml/PMC4720504.xml	SC35	51150 : 51154	CM	tors such as SF2/ASF and SC35 are associated with tran
./___Corpus/Medline/xml/PMC4720504.xml	E2F1	51305 : 51309	CM	king in conjunction with E2F1 was shown to be upregula
./___Corpus/Medline/xml/PMC4720504.xml	E2F1	51406 : 51410	CM	 lung cancer cell lines. E2F1, which is an established
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	51551 : 51567	CM	-damaging agents such as cyclophosphamide. The upregulation accomp
./___Corpus/Medline/xml/PMC4720504.xml	SC-35	51598 : 51603	CM	upregulation accompanies SC-35 induction and there is e
./___Corpus/Medline/xml/PMC4720504.xml	SC-35	51641 : 51646	CM	d there is evidence that SC-35 is a direct target of E2
./___Corpus/Medline/xml/PMC4720504.xml	E2F1	51669 : 51673	CM	35 is a direct target of E2F1. Further, SC-35 inhibiti
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylated	51782 : 51796	RN	ing agents. SC-35 in its phosphorylated form is necessary for ap
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	51867 : 51876	CM	motherapy treatment with cisplatin and is up-regulated foll
./___Corpus/Medline/xml/PMC4720504.xml	miR-221	52344 : 52351	CM	nificant upregulation of miR-221 and miR222 demonstrate m
./___Corpus/Medline/xml/PMC4720504.xml	miR222	52356 : 52362	CM	egulation of miR-221 and miR222 demonstrate marked downr
./___Corpus/Medline/xml/PMC4720504.xml	SC-35	52400 : 52405	CM	marked downregulation of SC-35, a target gene for both 
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	52730 : 52740	CM	n of proteins inside the eukaryotic cell is an evolutionaril
./___Corpus/Medline/xml/PMC4720504.xml	eukaryotic	53320 : 53330	CM	cluding cancer [130]. In eukaryotic cells, the cytosol and t
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	53342 : 53349	CM	In eukaryotic cells, the cytosol and the nucleus intercom
./___Corpus/Medline/xml/PMC4720504.xml	RNAs	53617 : 53621	CM	port of various types of RNAs [133], and proteins [134
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin-β	53852 : 53865	CM	roteins belonging to the karyopherin-β family [135]. Karyopheri
./___Corpus/Medline/xml/PMC4720504.xml	Karyopherins-β	53880 : 53894	CM	yopherin-β family [135]. Karyopherins-β accomplish either nuclea
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin	54020 : 54031	CM	ortins [137]. Generally, karyopherin-mediated transport occur
./___Corpus/Medline/xml/PMC4720504.xml	NPC	54070 : 54073	CM	sport occurs through the NPC, which acts as a gateway
./___Corpus/Medline/xml/PMC4720504.xml	karyopherins-β	54142 : 54156	CM	e nucleus [138]. Most of karyopherins-β interact directly with t
./___Corpus/Medline/xml/PMC4720504.xml	Karyopherin-α	54244 : 54257	CM	 adapter proteins [139]. Karyopherin-α, known also as importin-
./___Corpus/Medline/xml/PMC4720504.xml	NPC	54429 : 54432	CM	oteins must traverse the NPC following their cytoplas
./___Corpus/Medline/xml/PMC4720504.xml	karyopherins	54573 : 54585	CM	e aberrant expression of karyopherins has been consistently ob
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	54722 : 54726	CM	me maintenance region 1 (CRM1) is a karyopherin that e
./___Corpus/Medline/xml/PMC4720504.xml	karyopherin	54733 : 54744	CM	nce region 1 (CRM1) is a karyopherin that exports different p
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	54820 : 54824	CM	cleus of the cell [142]. CRM1 is the major exporter of
./___Corpus/Medline/xml/PMC4720504.xml	leucine	54914 : 54921	CM	nctions by recognizing a leucine rich nuclear exclusion s
./___Corpus/Medline/xml/PMC4720504.xml	hydrolysis	55088 : 55098	RN	olves RanGTP binding and hydrolysis to RanGDP [143].        
./___Corpus/Medline/xml/PMC4720504.xml	FOXO3a	55335 : 55341	CM	 promoting TSPs (such as FOXO3a, p27, Ikβ and prostate a
./___Corpus/Medline/xml/PMC4720504.xml	p27	55343 : 55346	CM	ng TSPs (such as FOXO3a, p27, Ikβ and prostate apopto
./___Corpus/Medline/xml/PMC4720504.xml	Ikβ	55348 : 55351	CM	Ps (such as FOXO3a, p27, Ikβ and prostate apoptosis r
./___Corpus/Medline/xml/PMC4720504.xml	Par-4	55386 : 55391	CM	ate apoptosis response 4/Par-4) is not sufficient for t
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	55470 : 55474	CM	on as over-expression of CRM1 in cancer cells results 
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	55585 : 55589	CM	this, over-expression of CRM1 has been associated with
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	55744 : 55748	CM	ognostic significance of CRM1 in multiple cancers has 
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	56255 : 56259	CM	d for the development of CRM1 targeted drug for cancer
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	56348 : 56352	CM	           Inhibition of XPO1 is one approach to resto
./___Corpus/Medline/xml/PMC4720504.xml	TSPs	56428 : 56432	CM	d activation of multiple TSPs, allowing them to functi
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	56510 : 56514	CM	, targeted inhibition of CRM1 using specific small mol
./___Corpus/Medline/xml/PMC4720504.xml	Leptomycin	56608 : 56618	CM	feasible strategy [149]. Leptomycin B (LMB) was the first na
./___Corpus/Medline/xml/PMC4720504.xml	LMB	56622 : 56625	CM	egy [149]. Leptomycin B (LMB) was the first natural a
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	56690 : 56694	CM	 to irreversibly inhibit XPO1 [150]. LMB is a secondar
./___Corpus/Medline/xml/PMC4720504.xml	LMB	56702 : 56705	CM	ibly inhibit XPO1 [150]. LMB is a secondary metabolit
./___Corpus/Medline/xml/PMC4720504.xml	anti-	56803 : 56808	CPR	y discovered as a potent anti-fungal antibiotic [151]. 
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	56904 : 56908	CM	 nuclear export inhibits XPO1 and works by alkylating 
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	56922 : 56932	CM	hibits XPO1 and works by alkylating and inhibiting XPO1 thro
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	56948 : 56952	CM	lkylating and inhibiting XPO1 through glycosylation of
./___Corpus/Medline/xml/PMC4720504.xml	glycosylation	56961 : 56974	RN	 inhibiting XPO1 through glycosylation of a cysteine residue (c
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	56980 : 56988	CM	rough glycosylation of a cysteine residue (cysteine 529) [
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	56998 : 57006	CM	n of a cysteine residue (cysteine 529) [152]. Nevertheless
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57033 : 57036	CM	29) [152]. Nevertheless, LMB demonstrated marked toxi
./___Corpus/Medline/xml/PMC4720504.xml	Leptomycin A	57189 : 57201	CM	ed [153]. Another agent, Leptomycin A (LMA) was discovered tog
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57237 : 57240	CM	discovered together with LMB and showed potency twice
./___Corpus/Medline/xml/PMC4720504.xml	LMB	57277 : 57280	CM	potency twice as that of LMB [150]. However, its clin
./___Corpus/Medline/xml/PMC4720504.xml	CBS9106	57389 : 57396	CM	e, reversible inhibitor, CBS9106, with XPO1 degrading act
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	57403 : 57407	CM	inhibitor, CBS9106, with XPO1 degrading activity, was 
./___Corpus/Medline/xml/PMC4720504.xml	vitro	57504 : 57509	CM	e myeloma cells, both in vitro and in vivo [154]. The d
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	57669 : 57673	CM	 selective inhibitors of XPO1 mediated nuclear (SINE) 
./___Corpus/Medline/xml/PMC4720504.xml	SINE	57692 : 57696	CM	f XPO1 mediated nuclear (SINE) have been described [15
./___Corpus/Medline/xml/PMC4720504.xml	SINE	57725 : 57729	CM	ve been described [155]. SINE compounds bind irreversi
./___Corpus/Medline/xml/PMC4720504.xml	Cys528	57765 : 57771	CM	bind irreversibly to the Cys528 NES recognizing residue 
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	57799 : 57803	CM	S recognizing residue in XPO1 and block its ability to
./___Corpus/Medline/xml/PMC4720504.xml	SINE	57859 : 57863	CM	to cargo proteins [156]. SINE have been shown to poten
./___Corpus/Medline/xml/PMC4720504.xml	anti-	58079 : 58084	CPR	 malignancies [159]. The anti-proliferative activity of
./___Corpus/Medline/xml/PMC4720504.xml	SINE	58110 : 58114	CM	roliferative activity of SINE against pancreatic ducta
./___Corpus/Medline/xml/PMC4720504.xml	SINE	58292 : 58296	CM	 the orally bioavailable SINE KPT-330 have rapidly acc
./___Corpus/Medline/xml/PMC4720504.xml	CRM1	58443 : 58447	CM	                         CRM1 carries essential roles 
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	58571 : 58575	CM	nical feasibility of any XPO1 targeted strategy has a 
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	58682 : 58686	CM	 of the first generation XPO1 inhibitor LMB were well 
./___Corpus/Medline/xml/PMC4720504.xml	LMB	58697 : 58700	CM	eneration XPO1 inhibitor LMB were well defined, the d
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	59013 : 59017	CM	uation of the effects of XPO1 inhibition. As recently 
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	59087 : 59091	CM	 and independent groups, XPO1 interferes with importan
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	59327 : 59331	CM	quired to optimize novel XPO1 inhibitors for applicati
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	59684 : 59688	CM	ssess the consequence of XPO1 inhibition on single pat
./___Corpus/Medline/xml/PMC4720504.xml	MAPK	59768 : 59772	CM	en able to shed light on MAPK/ERK and NF-κB signaling 
./___Corpus/Medline/xml/PMC4720504.xml	ERK	59773 : 59776	CM	le to shed light on MAPK/ERK and NF-κB signaling when
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	59781 : 59786	CM	ed light on MAPK/ERK and NF-κB signaling when their nuc
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	59919 : 59923	CM	 applied successfully in XPO1 related research. Howeve
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	60033 : 60037	CM	erences in the effect of XPO1 inhibition on realignmen
./___Corpus/Medline/xml/PMC4720504.xml	XPO1	60442 : 60446	CM	d to the optimization of XPO1 inhibitor therapies in t
./___Corpus/Medline/xml/PMC4720504.xml	GBM	60730 : 60733	CM	glioblastoma multiforme (GBM) is the most prevalent b
./___Corpus/Medline/xml/PMC4720504.xml	GBM	60938 : 60941	CM	sible for development of GBM. Apoptosis resistance pl
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61046 : 61049	CM	malignant progression in GBM. GBM patients have a poo
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61051 : 61054	CM	nant progression in GBM. GBM patients have a poor pro
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	61156 : 61166	RN	y, radiotherapy, and the alkylating chemotherapy with TMZ ar
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	61185 : 61188	CM	lating chemotherapy with TMZ are the standard first l
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61231 : 61234	CM	first line treatment for GBM patients [166,167]. Comb
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	61310 : 61313	CM	gy with radiotherapy and TMZ significantly improves t
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61436 : 61439	CM	nts with newly diagnosed GBM [168,169]. Therapeutic e
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	61473 : 61476	CM	]. Therapeutic effect of TMZ on GBM cells depends on 
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61480 : 61483	CM	apeutic effect of TMZ on GBM cells depends on the epi
./___Corpus/Medline/xml/PMC4720504.xml	O6-methylguanine-DNA-methyltransferase	61533 : 61571	CM	genetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene by promoter 
./___Corpus/Medline/xml/PMC4720504.xml	MGMT	61573 : 61577	CM	e-DNA-methyltransferase (MGMT) gene by promoter methyl
./___Corpus/Medline/xml/PMC4720504.xml	methylation	61596 : 61607	RN	 (MGMT) gene by promoter methylation [170]. MGMT counteracts 
./___Corpus/Medline/xml/PMC4720504.xml	MGMT	61615 : 61619	CM	moter methylation [170]. MGMT counteracts chemotherapy
./___Corpus/Medline/xml/PMC4720504.xml	O6-alkylated	61705 : 61717	CM	 structural integrity of O6-alkylated bases. Unmethylated MGMT
./___Corpus/Medline/xml/PMC4720504.xml	Unmethylated	61725 : 61737	RN	y of O6-alkylated bases. Unmethylated MGMT promoter is frequen
./___Corpus/Medline/xml/PMC4720504.xml	MGMT	61738 : 61742	CM	ated bases. Unmethylated MGMT promoter is frequently o
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	61836 : 61839	CM	eem to respond poorly to TMZ treatment [171]. Until n
./___Corpus/Medline/xml/PMC4720504.xml	GBM	61916 : 61919	CM	ative drug treatment for GBM. Thus, understanding the
./___Corpus/Medline/xml/PMC4720504.xml	GBM	62126 : 62129	CM	r targeted therapies for GBM patients.               
./___Corpus/Medline/xml/PMC4720504.xml	Erlotinib	62178 : 62187	CM	                         Erlotinib and gefitinib, which are
./___Corpus/Medline/xml/PMC4720504.xml	gefitinib	62192 : 62201	CM	           Erlotinib and gefitinib, which are two epidermal
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	62251 : 62255	CM	 growth factor receptor (EGFR) tyrosine kinase inhibit
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	62257 : 62265	CM	h factor receptor (EGFR) tyrosine kinase inhibitors, have 
./___Corpus/Medline/xml/PMC4720504.xml	GBM	62309 : 62312	CM	 have been evaluated for GBM treatment. The low molec
./___Corpus/Medline/xml/PMC4720504.xml	GBM	62447 : 62450	CM	Recent studies show that GBM patients with amplified 
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	62492 : 62496	CM	plified or overexpressed EGFR responded better to erlo
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	62517 : 62526	CM	EGFR responded better to erlotinib than patients with norma
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	62553 : 62557	CM	han patients with normal EGFR levels [172] and the res
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylation	62638 : 62653	RN	 Akt activation. So, Akt phosphorylation may be a direct result o
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	62690 : 62694	CM	rect result of increased EGFR activity. Thus, treatmen
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	62726 : 62730	CM	ty. Thus, treatment with EGFR inhibitors can show bett
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	62832 : 62840	CM	at treatment with single tyrosine kinase inhibitor like er
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	62863 : 62872	CM	ne kinase inhibitor like erlotinib could not effectively in
./___Corpus/Medline/xml/PMC4720504.xml	RTK	62941 : 62944	CM	aling because many other RTK were co-activated in GBM
./___Corpus/Medline/xml/PMC4720504.xml	GBM	62966 : 62969	CM	RTK were co-activated in GBM cells [173,174]. Two oth
./___Corpus/Medline/xml/PMC4720504.xml	c-Met	63060 : 63065	CM	tor receptor (PDGFR) and c-Met or hepatocyte growth fac
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	63132 : 63136	CM	R), are also involved in EGFR function and in maintain
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	63396 : 63399	CM	erapeutic effects [176]. TMZ causes cell cycle arrest
./___Corpus/Medline/xml/PMC4720504.xml	G2	63428 : 63430	CM	ses cell cycle arrest at G2/M phase and EGFR inhibit
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	63443 : 63447	CM	arrest at G2/M phase and EGFR inhibitors prevent cells
./___Corpus/Medline/xml/PMC4720504.xml	G1	63497 : 63499	CM	 from progressing beyond G1 and may therefore compro
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	63592 : 63596	CM	fic agents [177]. As the EGFR tyrosine kinase inhibito
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	63597 : 63605	CM	gents [177]. As the EGFR tyrosine kinase inhibitors show l
./___Corpus/Medline/xml/PMC4720504.xml	GBM	63738 : 63741	CM	ctionally active drug in GBM patients. However, the l
./___Corpus/Medline/xml/PMC4720504.xml	EGFR	63921 : 63925	CM	icient inhibition of the EGFR signaling.              
./___Corpus/Medline/xml/PMC4720504.xml	anti-	63998 : 64003	CPR	  Many inhibitors of the anti-apoptotic members of the 
./___Corpus/Medline/xml/PMC4720504.xml	GBM	64231 : 64234	CM	ed the clinical trial in GBM patients. Brain tumors t
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64275 : 64280	CPR	 tumors that overexpress anti-apoptotic Bcl-2 and Bcl-x
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	64354 : 64361	CM	d with their inhibitors. ABT-737, a recently developed Bc
./___Corpus/Medline/xml/PMC4720504.xml	vitro	64460 : 64465	CM	ioblastoma cells both in vitro and in vivo by releasing
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	64657 : 64662	CM	optosis-inducing ligand (TRAIL) as well as to other ant
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64684 : 64689	CPR	AIL) as well as to other anti-cancer drugs. But, cells 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	64759 : 64764	CPR	on of Mcl-1, which is an anti-apoptotic protein of the 
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	64838 : 64845	CM	to be less responsive to ABT-737 treatment. So, combinati
./___Corpus/Medline/xml/PMC4720504.xml	GBM	64949 : 64952	CM	 novel strategy to treat GBM. Recent investigations i
./___Corpus/Medline/xml/PMC4720504.xml	BH3	64995 : 64998	CM	tions indicated that the BH3-binding compound HA14-1 
./___Corpus/Medline/xml/PMC4720504.xml	HA14-1	65016 : 65022	CM	the BH3-binding compound HA14-1 can enhance the sensitiv
./___Corpus/Medline/xml/PMC4720504.xml	Gossypol	65124 : 65132	CM	 and chemotherapy [180]. Gossypol (AT-101), which is a mul
./___Corpus/Medline/xml/PMC4720504.xml	AT-101	65134 : 65140	CM	therapy [180]. Gossypol (AT-101), which is a multi-targe
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol	65170 : 65180	CM	ich is a multi-targeting polyphenol derived from cotton plan
./___Corpus/Medline/xml/PMC4720504.xml	GBMs	65295 : 65299	CM	 trials for treatment of GBMs [181]. Gossypol binds to
./___Corpus/Medline/xml/PMC4720504.xml	Gossypol	65307 : 65315	CM	treatment of GBMs [181]. Gossypol binds to the BH3 pocket 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	65329 : 65332	CM	]. Gossypol binds to the BH3 pocket of anti-apoptotic
./___Corpus/Medline/xml/PMC4720504.xml	anti-	65343 : 65348	CPR	nds to the BH3 pocket of anti-apoptotic Bcl-2 proteins 
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	65461 : 65469	CM	t that administration of gossypol (20 mg/day) is well tole
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	65579 : 65587	CM	ate. A Phase II trial of gossypol in recurrent GBM is unde
./___Corpus/Medline/xml/PMC4720504.xml	GBM	65601 : 65604	CM	of gossypol in recurrent GBM is underway to detect it
./___Corpus/Medline/xml/PMC4720504.xml	XIAP	65782 : 65786	CM	AP) family proteins like XIAP, cIAP1, cIAP2, ILP2, ML-
./___Corpus/Medline/xml/PMC4720504.xml	cIAP1	65788 : 65793	CM	mily proteins like XIAP, cIAP1, cIAP2, ILP2, ML-IAP, an
./___Corpus/Medline/xml/PMC4720504.xml	cIAP2	65795 : 65800	CM	oteins like XIAP, cIAP1, cIAP2, ILP2, ML-IAP, and survi
./___Corpus/Medline/xml/PMC4720504.xml	ILP2	65802 : 65806	CM	like XIAP, cIAP1, cIAP2, ILP2, ML-IAP, and survivin ar
./___Corpus/Medline/xml/PMC4720504.xml	GMB	65875 : 65878	CM	hibition of apoptosis in GMB [184,185]. The IAP famil
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	65996 : 66000	CM	tosis repeat containing (BIRC) proteins. These BIRC pr
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66018 : 66022	CM	g (BIRC) proteins. These BIRC proteins can inhibit apo
./___Corpus/Medline/xml/PMC4720504.xml	caspase-9	66108 : 66117	CM	 different caspases like caspase-9, caspase-7, and caspase-
./___Corpus/Medline/xml/PMC4720504.xml	caspase-7	66119 : 66128	CM	caspases like caspase-9, caspase-7, and caspase-3, which ar
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	66134 : 66143	CM	aspase-9, caspase-7, and caspase-3, which are actively invo
./___Corpus/Medline/xml/PMC4720504.xml	GBM	66244 : 66247	CM	oblastoma [186]. In most GBM patients, high levels of
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66273 : 66277	CM	patients, high levels of BIRC proteins have been detec
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66328 : 66332	CM	ed. Therefore, targeting BIRC proteins to make active 
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66612 : 66616	CM	e inhibitors directed to BIRC proteins to identify a p
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66768 : 66772	CM	 has been performed with BIRC inhibitors in GBM. A rec
./___Corpus/Medline/xml/PMC4720504.xml	GBM	66787 : 66790	CM	 with BIRC inhibitors in GBM. A recent report showed 
./___Corpus/Medline/xml/PMC4720504.xml	BIRC-4	66820 : 66826	CM	ecent report showed that BIRC-4 (XIAP) inhibitors synerg
./___Corpus/Medline/xml/PMC4720504.xml	XIAP	66828 : 66832	CM	port showed that BIRC-4 (XIAP) inhibitors synergize wi
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	66930 : 66934	CM	osis [189] and targeting BIRC proteins can sensitize c
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	66967 : 66972	CM	s can sensitize cells to TRAIL for induction of apoptos
./___Corpus/Medline/xml/PMC4720504.xml	BIRC	67064 : 67068	CM	ated that the endogenous BIRC inhibitor Smac can signi
./___Corpus/Medline/xml/PMC4720504.xml	anti-	67115 : 67120	CPR	gnificantly increase the anti-cancer efficacy of TRAIL 
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	67139 : 67144	CM	 anti-cancer efficacy of TRAIL in an intracranial gliob
./___Corpus/Medline/xml/PMC4720504.xml	histone	67230 : 67237	CM	the use of inhibitors of histone deacetylase and of the p
./___Corpus/Medline/xml/PMC4720504.xml	deacetylase	67238 : 67249	CM	of inhibitors of histone deacetylase and of the proteasome in
./___Corpus/Medline/xml/PMC4720504.xml	GBM	67670 : 67673	CM	 apoptosis resistance in GBM.                  9.2. R
./___Corpus/Medline/xml/PMC4720504.xml	dacarbazine	68001 : 68012	CM	entional therapy such as dacarbazine or TMZ. The RAF/MAP kina
./___Corpus/Medline/xml/PMC4720504.xml	TMZ	68016 : 68019	CM	y such as dacarbazine or TMZ. The RAF/MAP kinase path
./___Corpus/Medline/xml/PMC4720504.xml	RAF	68025 : 68028	CM	 dacarbazine or TMZ. The RAF/MAP kinase pathway has a
./___Corpus/Medline/xml/PMC4720504.xml	MAP	68029 : 68032	CM	arbazine or TMZ. The RAF/MAP kinase pathway has attra
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	68108 : 68112	CM	ivating mutations of the BRAF serine/threonine kinase 
./___Corpus/Medline/xml/PMC4720504.xml	serine	68113 : 68119	CM	ng mutations of the BRAF serine/threonine kinase has bee
./___Corpus/Medline/xml/PMC4720504.xml	threonine	68120 : 68129	CM	tions of the BRAF serine/threonine kinase has been detected
./___Corpus/Medline/xml/PMC4720504.xml	NRAS	68211 : 68215	CM	Other mutations occur in NRAS, MEK1, MEK2 as well as c
./___Corpus/Medline/xml/PMC4720504.xml	MEK1	68217 : 68221	CM	mutations occur in NRAS, MEK1, MEK2 as well as c-Kit. 
./___Corpus/Medline/xml/PMC4720504.xml	MEK2	68223 : 68227	CM	ons occur in NRAS, MEK1, MEK2 as well as c-Kit. Activa
./___Corpus/Medline/xml/PMC4720504.xml	MAPK	68296 : 68300	CM	ts in the stimulation of MAPK and PI3K/AKT pathways re
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	68305 : 68309	CM	 stimulation of MAPK and PI3K/AKT pathways resulting i
./___Corpus/Medline/xml/PMC4720504.xml	AKT	68310 : 68313	CM	ulation of MAPK and PI3K/AKT pathways resulting in bo
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	68523 : 68528	CM	elanoma tumors including NF-κB. Raf inhibitors in gener
./___Corpus/Medline/xml/PMC4720504.xml	Raf	68530 : 68533	CM	 tumors including NF-κB. Raf inhibitors in general an
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	68569 : 68573	CM	 in general and specific BRAF inhibitors, including ve
./___Corpus/Medline/xml/PMC4720504.xml	ERK1	68695 : 68699	CM	cts are often limited by ERK1/2 pathway reactivation v
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	68783 : 68787	CM	tance to apoptosis using BRAF specific inhibitors is m
./___Corpus/Medline/xml/PMC4720504.xml	NRAS	68849 : 68853	CM	part, by the presence of NRAS mutation and required sw
./___Corpus/Medline/xml/PMC4720504.xml	isoform	68904 : 68911	CM	tch in activation of RAF isoform, CRAF. Furthermore, rebo
./___Corpus/Medline/xml/PMC4720504.xml	CRAF	68913 : 68917	CM	tivation of RAF isoform, CRAF. Furthermore, rebound me
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	68985 : 68989	CM	r initial treatment with BRAF specific inhibitors is a
./___Corpus/Medline/xml/PMC4720504.xml	PI3K	69052 : 69056	CM	h elevated activation of PI3K/Akt pathway.            
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	69160 : 69165	CM	Bcl-2 positive regulator NF-κB is a key player in human
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	69225 : 69230	CM	tumorigenesis. Canonical NF-κB activation in melanoma c
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	69348 : 69353	CM	an melanoma, a number of NF-κB-dependent chemokines are
./___Corpus/Medline/xml/PMC4720504.xml	CXC	69429 : 69432	CM	at high levels including CXC ligand 8 (CXCL8 or IL8),
./___Corpus/Medline/xml/PMC4720504.xml	CXCL8	69443 : 69448	CM	 including CXC ligand 8 (CXCL8 or IL8), interleukin-8 [
./___Corpus/Medline/xml/PMC4720504.xml	CXCL1	69479 : 69484	CM	8), interleukin-8 [192], CXCL1, melanoma growth stimula
./___Corpus/Medline/xml/PMC4720504.xml	MGSA	69526 : 69530	CM	 stimulatory activity or MGSA [193], CCL5 (regulated o
./___Corpus/Medline/xml/PMC4720504.xml	CCL5	69538 : 69542	CM	 activity or MGSA [193], CCL5 (regulated on activation
./___Corpus/Medline/xml/PMC4720504.xml	RANTES	69606 : 69612	CM	pressed and secreted, or RANTES [194] and CCL2 (monocyte
./___Corpus/Medline/xml/PMC4720504.xml	CCL2	69623 : 69627	CM	ted, or RANTES [194] and CCL2 (monocyte chemotactic pr
./___Corpus/Medline/xml/PMC4720504.xml	protein-1	69650 : 69659	CM	L2 (monocyte chemotactic protein-1), or MCP1 [195]. In late
./___Corpus/Medline/xml/PMC4720504.xml	MCP1	69665 : 69669	CM	emotactic protein-1), or MCP1 [195]. In late stages of
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	69731 : 69736	CM	melanoma, hyperactivated NF-κB inhibits pro-apoptotic p
./___Corpus/Medline/xml/PMC4720504.xml	factor-1	69843 : 69851	CM	ctor receptor-associated factor-1 (TRAF-1) and TRAF-2 [196
./___Corpus/Medline/xml/PMC4720504.xml	TRAF-1	69853 : 69859	CM	tor-associated factor-1 (TRAF-1) and TRAF-2 [196] to inh
./___Corpus/Medline/xml/PMC4720504.xml	TNF-R1	69893 : 69899	CM	F-2 [196] to inhibit the TNF-R1/caspase-8-mediated pro-a
./___Corpus/Medline/xml/PMC4720504.xml	caspase-8	69900 : 69909	CM	6] to inhibit the TNF-R1/caspase-8-mediated pro-apoptotic p
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	69941 : 69946	CM	ed pro-apoptotic pathway TRAIL decoy receptor, inhibiti
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	69978 : 69983	CM	receptor, inhibiting the TRAIL-mediated cell-death path
./___Corpus/Medline/xml/PMC4720504.xml	phosphatase-1	70048 : 70061	CM	and (iii) Fas-associated phosphatase-1 (FAP-1) [199], which dow
./___Corpus/Medline/xml/PMC4720504.xml	FAP-1	70063 : 70068	CM	ssociated phosphatase-1 (FAP-1) [199], which down-regul
./___Corpus/Medline/xml/PMC4720504.xml	FAS-R	70098 : 70103	CM	9], which down-regulates FAS-R trafficking from cytopla
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	70212 : 70217	CM	 melanoma, activation of NF-κB also enhances several an
./___Corpus/Medline/xml/PMC4720504.xml	anti-	70240 : 70245	CPR	κB also enhances several anti-apoptotic molecules such 
./___Corpus/Medline/xml/PMC4720504.xml	caspase-8	70309 : 70318	CM	f apoptosis (IAP) [201], caspase-8 (FLICE) and inhibitory p
./___Corpus/Medline/xml/PMC4720504.xml	FLICE	70320 : 70325	CM	 (IAP) [201], caspase-8 (FLICE) and inhibitory protein 
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	70364 : 70369	CM	ry protein (FLIP) [202]. NF-κB also promotes Myc activi
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	70443 : 70449	CM	cle regulatory proteins, cyclin D1 and cyclin dependent 
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	70457 : 70463	CM	 proteins, cyclin D1 and cyclin dependent kinase 2 (CDK2
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	70638 : 70642	CM	ells harbor mutations in BRAF signaling protein [205].
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	70668 : 70672	CM	signaling protein [205]. BRAF is part of the Raf famil
./___Corpus/Medline/xml/PMC4720504.xml	Raf	70688 : 70691	CM	05]. BRAF is part of the Raf family of serine/threoni
./___Corpus/Medline/xml/PMC4720504.xml	serine	70702 : 70708	CM	art of the Raf family of serine/threonine kinases, which
./___Corpus/Medline/xml/PMC4720504.xml	threonine	70709 : 70718	CM	the Raf family of serine/threonine kinases, which are effec
./___Corpus/Medline/xml/PMC4720504.xml	ERK	70779 : 70782	CM	 small GTPase RAS in the ERK/MAPK pathway. This pathw
./___Corpus/Medline/xml/PMC4720504.xml	tyrosine	70876 : 70884	CM	ceptors such as receptor tyrosine kinases and G-protein-co
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	70926 : 70930	CM	otein-coupled receptors. BRAF transduces signals throu
./___Corpus/Medline/xml/PMC4720504.xml	mitogen	70958 : 70965	CM	ansduces signals through mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4720504.xml	MAPK	71009 : 71013	CM	kinase (MAPK) [206,207]. MAPK promotes regulation of c
./___Corpus/Medline/xml/PMC4720504.xml	RAS	71217 : 71220	CM	s to the activation of a RAS family member, any of th
./___Corpus/Medline/xml/PMC4720504.xml	H	71262 : 71263	CM	ny of the three isoforms H, N, and K-RAS. Activated
./___Corpus/Medline/xml/PMC4720504.xml	K-RAS	71272 : 71277	CM	three isoforms H, N, and K-RAS. Activated RAS then bind
./___Corpus/Medline/xml/PMC4720504.xml	RAS	71289 : 71292	CM	 N, and K-RAS. Activated RAS then binds and activates
./___Corpus/Medline/xml/PMC4720504.xml	Raf	71366 : 71369	CM	ins, including the three Raf members (ARAF, BRAF and 
./___Corpus/Medline/xml/PMC4720504.xml	ARAF	71379 : 71383	CM	g the three Raf members (ARAF, BRAF and CRAF), leading
./___Corpus/Medline/xml/PMC4720504.xml	BRAF	71385 : 71389	CM	three Raf members (ARAF, BRAF and CRAF), leading to su
./___Corpus/Medline/xml/PMC4720504.xml	CRAF	71394 : 71398	CM	 members (ARAF, BRAF and CRAF), leading to subsequent 
./___Corpus/Medline/xml/PMC4720504.xml	MEK1	71468 : 71472	CM	ade of kinases including MEK1/2 and ERK1/2. Activated 
./___Corpus/Medline/xml/PMC4720504.xml	ERK1	71479 : 71483	CM	ses including MEK1/2 and ERK1/2. Activated ERK in turn
./___Corpus/Medline/xml/PMC4720504.xml	ERK	71497 : 71500	CM	/2 and ERK1/2. Activated ERK in turn specifically pho
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylates	71522 : 71536	CM	ERK in turn specifically phosphorylates a number of nuclear and 
./___Corpus/Medline/xml/PMC4720504.xml	ETS	71598 : 71601	CM	substrates including the ETS transcription factor, wh
./___Corpus/Medline/xml/PMC4720504.xml	Erk1	71741 : 71745	CM	 with these assumptions, Erk1/2 signaling has been sho
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	71807 : 71812	CM	t melanoma cells against TRAIL-induced apoptosis by inh
./___Corpus/Medline/xml/PMC4720504.xml	cytosol	71876 : 71883	CM	location of Bax from the cytosol to mitochondria and that
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	71925 : 71930	CM	and that this may reduce TRAIL-mediated release of Smac
./___Corpus/Medline/xml/PMC4720504.xml	DIABLO	71956 : 71962	CM	mediated release of Smac/DIABLO and induction of apoptos
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	72180 : 72184	CM	c ductal adenocarcinoma (PDAC) is among the most letha
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	72430 : 72434	CM	atment approaches [210]. PDAC tumors are very heteroge
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	72869 : 72873	CM	ghly resistant subset of PDAC cancer stem cells (CSCs)
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	73061 : 73065	CM	of different regimens in PDAC has been attributed to t
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	73284 : 73288	CM	ffective regimen against PDAC CSCs, and key molecules 
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	73349 : 73353	CM	e desmoplastic stroma in PDAC will provide biomarkers 
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	73998 : 74002	CM	on of Bcl-2 can suppress PDAC growth in vitro and in v
./___Corpus/Medline/xml/PMC4720504.xml	vitro	74013 : 74018	CM	 suppress PDAC growth in vitro and in vivo [217]. Very 
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	74146 : 74150	CM	 small molecule drugs in PDAC. Both these studies coll
./___Corpus/Medline/xml/PMC4720504.xml	BH3	74218 : 74221	CM	t targeted inhibition of BH3 family proteins could be
./___Corpus/Medline/xml/PMC4720504.xml	PDAC	74285 : 74289	CM	apeutic strategy against PDAC.                  9.4. A
./___Corpus/Medline/xml/PMC4720504.xml	Wnt	74953 : 74956	CM	(CSCs). Dysregulation of Wnt, Notch, Hedgehog and/or 
./___Corpus/Medline/xml/PMC4720504.xml	TGF-β	74981 : 74986	CM	, Notch, Hedgehog and/or TGF-β signaling pathways that 
./___Corpus/Medline/xml/PMC4720504.xml	CSCs	75060 : 75064	CM	ation and maintenance of CSCs leads to the development
./___Corpus/Medline/xml/PMC4720504.xml	colonic	75371 : 75378	CM	etected in 60% (6/10) of colonic carcinomas, all of which
./___Corpus/Medline/xml/PMC4720504.xml	mRNA	75658 : 75662	CM	iderable levels of bcl-2 mRNA and protein. These resul
./___Corpus/Medline/xml/PMC4720504.xml	vitro	76306 : 76311	CM	f co-cultured T cells in vitro. FasL expressed in esoph
./___Corpus/Medline/xml/PMC4720504.xml	Caspase-1	77205 : 77214	CM	defects in colon tumors. Caspase-1 is also downregulated in
./___Corpus/Medline/xml/PMC4720504.xml	p53	77276 : 77279	CM	r. The high frequency of p53 mutations in late-stage 
./___Corpus/Medline/xml/PMC4720504.xml	androgen	78102 : 78110	CM	as been shown to promote androgen ablation resistance [221
./___Corpus/Medline/xml/PMC4720504.xml	230–	78919 : 78923	CPR	 and targeted therapies [230–232]. Besides Bcl-2 and M
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	78969 : 78974	CM	nd Mcl-1 overexpression, TRAIL induced apoptosis resist
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	79072 : 79077	CM	233]. The development of TRAIL resistance is both genet
./___Corpus/Medline/xml/PMC4720504.xml	GLOBACON	79517 : 79525	CM	ty in the western world (GLOBACON). Despite the advances i
./___Corpus/Medline/xml/PMC4720504.xml	p-glycoprotein	80237 : 80251	CM	the apoptotic machinery, p-glycoprotein and the multidrug resist
./___Corpus/Medline/xml/PMC4720504.xml	HER-2	80297 : 80302	CM	sistance protein family, HER-2/neu gene amplification a
./___Corpus/Medline/xml/PMC4720504.xml	p53	80459 : 80462	CM	ptor family, DNA ploidy, p53 gene mutations, cyclin E
./___Corpus/Medline/xml/PMC4720504.xml	p27	80492 : 80495	CM	 mutations, cyclin E and p27 dysregulation that cumul
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80729 : 80732	CM	g Bcl-1, Mcl-1 and other BH3 family members [237]. Th
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80799 : 80802	CM	rom the observation that BH3 mimetic ABT-737 can sens
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	80811 : 80818	CM	rvation that BH3 mimetic ABT-737 can sensitize BH3 protei
./___Corpus/Medline/xml/PMC4720504.xml	BH3	80833 : 80836	CM	ic ABT-737 can sensitize BH3 protein over-expressing 
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	81063 : 81073	CM	 as proteasome inhibitor bortezomib treatment causes suppres
./___Corpus/Medline/xml/PMC4720504.xml	MDRs	81106 : 81110	CM	nt causes suppression of MDRs leading to induction of 
./___Corpus/Medline/xml/PMC4720504.xml	CLL	81718 : 81721	CM	ic lymphocytic leukemia (CLL) is the most common B-ce
./___Corpus/Medline/xml/PMC4720504.xml	CD5	81832 : 81835	CM	e accumulation of mature CD5 positive B lymphocytes i
./___Corpus/Medline/xml/PMC4720504.xml	CLL	81920 : 81923	CM	d lymphoid organs [241]. CLL disease is generally ass
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82096 : 82099	CM	vival signals within the CLL cells cause a cell death
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82170 : 82173	CM	tudies suggest that most CLL clones include activated
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82433 : 82436	CM	                      In CLL, defects in the intrinsi
./___Corpus/Medline/xml/PMC4720504.xml	CD95	82550 : 82554	CM	can be resistant to both CD95/Fas [245] and TRAIL deat
./___Corpus/Medline/xml/PMC4720504.xml	TRAIL	82569 : 82574	CM	 both CD95/Fas [245] and TRAIL death receptors inductio
./___Corpus/Medline/xml/PMC4720504.xml	anti-	82708 : 82713	CPR	roteins, classified into anti-apoptotic (Bcl-2, Bcl-XL,
./___Corpus/Medline/xml/PMC4720504.xml	Noxa	82806 : 82810	CM	Bak, Bim, Bad, Bid, Hrk, Noxa, Puma) members [247]. In
./___Corpus/Medline/xml/PMC4720504.xml	anti-	82862 : 82867	CPR	LL the overexpression of anti-apoptotic proteins has im
./___Corpus/Medline/xml/PMC4720504.xml	CLL	82977 : 82980	CM	on of Bcl-2 is common in CLL patients and is associat
./___Corpus/Medline/xml/PMC4720504.xml	IgVH	83187 : 83191	CM	, such as disease stage, IgVH mutation status, ZAP-70 
./___Corpus/Medline/xml/PMC4720504.xml	ZAP-70	83209 : 83215	CM	e, IgVH mutation status, ZAP-70 positivity and CD38 expr
./___Corpus/Medline/xml/PMC4720504.xml	CD38	83231 : 83235	CM	s, ZAP-70 positivity and CD38 expression [250] and, wa
./___Corpus/Medline/xml/PMC4720504.xml	CLL	83313 : 83316	CM	the clinical outcomes of CLL patients [251,252]. In B
./___Corpus/Medline/xml/PMC4720504.xml	BCR	83428 : 83431	CM	mily proteins, including BCR, cytokine signaling and 
./___Corpus/Medline/xml/PMC4720504.xml	cytokine	83433 : 83441	CM	proteins, including BCR, cytokine signaling and microRNA. 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83532 : 83537	CPR	ger up-regulation of the anti-apoptotic proteins Mcl-1,
./___Corpus/Medline/xml/PMC4720504.xml	BCR	83588 : 83591	CM	A1 and Bcl-xL [253,254]. BCR signaling has been repor
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylating	83740 : 83755	CM	aintain cell survival by phosphorylating and inactivating the pro
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83854 : 83859	CPR	 Given the key role that anti-apoptotic proteins play i
./___Corpus/Medline/xml/PMC4720504.xml	CLL	83886 : 83889	CM	optotic proteins play in CLL, they became an attracti
./___Corpus/Medline/xml/PMC4720504.xml	anti-	83978 : 83983	CPR	rapeutic agents, such as anti-sense methodology [258], 
./___Corpus/Medline/xml/PMC4720504.xml	BH3	84048 : 84051	CM	 mimicking the action of BH3 domain [259], and microR
./___Corpus/Medline/xml/PMC4720504.xml	miRNA-15a	84088 : 84097	CM	], and microRNAs (mainly miRNA-15a and miRNA-16-1) [260]. F
./___Corpus/Medline/xml/PMC4720504.xml	miRNA-16-1	84102 : 84112	CM	As (mainly miRNA-15a and miRNA-16-1) [260]. For several deca
./___Corpus/Medline/xml/PMC4720504.xml	CLL	84165 : 84168	CM	, front-line therapy for CLL has been represented by 
./___Corpus/Medline/xml/PMC4720504.xml	alkylating	84208 : 84218	CM	sented by treatment with alkylating agents and purine analog
./___Corpus/Medline/xml/PMC4720504.xml	purine	84230 : 84236	CM	th alkylating agents and purine analogs [261]. Recently,
./___Corpus/Medline/xml/PMC4720504.xml	CD20	84396 : 84400	CM	oclonal antibody against CD20, administrated in combin
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	84436 : 84447	CM	ated in combination with fludarabine or fludarabine plus cycl
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	84451 : 84462	CM	tion with fludarabine or fludarabine plus cyclophosphamide [2
./___Corpus/Medline/xml/PMC4720504.xml	cyclophosphamide	84468 : 84484	CM	bine or fludarabine plus cyclophosphamide [262,263]. Nevertheless,
./___Corpus/Medline/xml/PMC4720504.xml	CLL	84641 : 84644	CM	 specific agents against CLL remains of high interest
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	84779 : 84787	CM	seed extract derivative, gossypol, which acts as a BH3-mim
./___Corpus/Medline/xml/PMC4720504.xml	265–	84974 : 84978	CPR	ers to induce apoptosis [265–267]. However, despite th
./___Corpus/Medline/xml/PMC4720504.xml	APL	85300 : 85303	CM	ocytic leukemia (APML or APL for short) is a subtype 
./___Corpus/Medline/xml/PMC4720504.xml	APL	85365 : 85368	CM	logenous leukemia (AML). APL is characterized by an a
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85500 : 85513	CM	nslocation involving the retinoic acid receptor alpha (RARα or 
./___Corpus/Medline/xml/PMC4720504.xml	alpha	85523 : 85528	CM	e retinoic acid receptor alpha (RARα or RARA) gene and 
./___Corpus/Medline/xml/PMC4720504.xml	RARα	85530 : 85534	CM	oic acid receptor alpha (RARα or RARA) gene and is dis
./___Corpus/Medline/xml/PMC4720504.xml	RARA	85538 : 85542	CM	 receptor alpha (RARα or RARA) gene and is distinguish
./___Corpus/Medline/xml/PMC4720504.xml	AML	85590 : 85593	CM	shed from other forms of AML by its responsiveness to
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85629 : 85642	CM	ponsiveness to all-trans retinoic acid therapy. The role of Bcl
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	85706 : 85719	CM	 apoptosis resistance to retinoic acid therapy has been intensi
./___Corpus/Medline/xml/PMC4720504.xml	retinoic acid	86078 : 86091	CM	 the course of all trans retinoic acid (ATRA)-induced neutrophi
./___Corpus/Medline/xml/PMC4720504.xml	ATRA	86093 : 86097	CM	all trans retinoic acid (ATRA)-induced neutrophil/gran
./___Corpus/Medline/xml/PMC4720504.xml	APL	86152 : 86155	CM	te differentiation of an APL-derived cell line. This 
./___Corpus/Medline/xml/PMC4720504.xml	mTOR	86264 : 86268	CM	 Bcl-2 and inhibition of mTOR activity. Further, other
./___Corpus/Medline/xml/PMC4720504.xml	BH3	86320 : 86323	CM	tudies have shown that a BH3 domain mimetic, JY-1-106
./___Corpus/Medline/xml/PMC4720504.xml	JY-1-106	86340 : 86348	CM	at a BH3 domain mimetic, JY-1-106, which antagonizes the a
./___Corpus/Medline/xml/PMC4720504.xml	anti-	86372 : 86377	CPR	6, which antagonizes the anti-apoptotic BCL-2 family me
./___Corpus/Medline/xml/PMC4720504.xml	BCL-xL	86437 : 86443	CM	ll lymphoma-extra large (BCL-xL) and myeloid cell leukem
./___Corpus/Medline/xml/PMC4720504.xml	APL	86553 : 86556	CM	 cell viability in HL-60 APL cells alone and in combi
./___Corpus/Medline/xml/PMC4720504.xml	BCL-xL	86721 : 86727	CM	udies indicate that dual BCL-xL/MCL-1 inhibitors and ret
./___Corpus/Medline/xml/PMC4720504.xml	APL	86787 : 86790	CM	ld work cooperatively in APL.                  10. Ro
./___Corpus/Medline/xml/PMC4720504.xml	ROS	88224 : 88227	CM	e phytochemicals against ROS chemically converts them
./___Corpus/Medline/xml/PMC4720504.xml	thiols	88316 : 88322	CM	a high reactivity toward thiols and can lead to the loss
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	88564 : 88573	CM	 example, in lung cells, quercetin efficiently protects aga
./___Corpus/Medline/xml/PMC4720504.xml	H2O2	88603 : 88607	CM	ciently protects against H2O2-induced DNA damage, but 
./___Corpus/Medline/xml/PMC4720504.xml	GSH	88689 : 88692	CM	cted by the reduction in GSH level, an increase in LD
./___Corpus/Medline/xml/PMC4720504.xml	LDH	88715 : 88718	CM	SH level, an increase in LDH leakage and cytosolic-fr
./___Corpus/Medline/xml/PMC4720504.xml	calcium	88746 : 88753	CM	akage and cytosolic-free calcium concentration [270]. Que
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin	88775 : 88784	CM	ium concentration [270]. Quercetin may also form quercetin–
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	88799 : 88808	CM	 Quercetin may also form quercetin–quinone (QQ) species whe
./___Corpus/Medline/xml/PMC4720504.xml	quinone	88809 : 88816	CM	 may also form quercetin–quinone (QQ) species when the mo
./___Corpus/Medline/xml/PMC4720504.xml	QQ	88818 : 88820	CM	 form quercetin–quinone (QQ) species when the molecu
./___Corpus/Medline/xml/PMC4720504.xml	QQ	88879 : 88881	CM	loyed as an antioxidant. QQ, like other semiquinone 
./___Corpus/Medline/xml/PMC4720504.xml	semiquinone	88894 : 88905	CM	ioxidant. QQ, like other semiquinone radicals and quinones, i
./___Corpus/Medline/xml/PMC4720504.xml	quinones	88919 : 88927	CM	semiquinone radicals and quinones, is toxic because of its
./___Corpus/Medline/xml/PMC4720504.xml	arylate	88964 : 88971	CM	ecause of its ability to arylate protein thiols. Protecti
./___Corpus/Medline/xml/PMC4720504.xml	thiols	88980 : 88986	CM	ility to arylate protein thiols. Protection against QQ m
./___Corpus/Medline/xml/PMC4720504.xml	QQ	89007 : 89009	CM	iols. Protection against QQ may arise from GSH which
./___Corpus/Medline/xml/PMC4720504.xml	GSH	89025 : 89028	CM	gainst QQ may arise from GSH which, when present at t
./___Corpus/Medline/xml/PMC4720504.xml	QQ	89091 : 89093	CM	entration, quickly traps QQ [271]. Accordingly with 
./___Corpus/Medline/xml/PMC4720504.xml	erythroid	89315 : 89324	CM	f2-Keap1 (nuclear factor erythroid 2-related factor 2-Kelch
./___Corpus/Medline/xml/PMC4720504.xml	2-	89326 : 89328	CPR	uclear factor erythroid 2-related factor 2-Kelch-lik
./___Corpus/Medline/xml/PMC4720504.xml	2-	89342 : 89344	CPR	ythroid 2-related factor 2-Kelch-like ECH associated
./___Corpus/Medline/xml/PMC4720504.xml	2-	89349 : 89351	CPR	 2-related factor 2-Kelch-like ECH associated protei
./___Corpus/Medline/xml/PMC4720504.xml	ECH	89355 : 89358	CM	ated factor 2-Kelch-like ECH associated protein 1) si
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90585 : 90588	CM	pecific diseases such as CLL, a form leukemia which r
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90665 : 90668	CM	. In fact, patients with CLL may survive for many yea
./___Corpus/Medline/xml/PMC4720504.xml	CLL	90801 : 90804	CM	ease. This feature makes CLL patients ideal models to
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	91669 : 91673	CM	.                  10.1. EGCG                      Mec
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	91728 : 91739	CM	tic studies suggest that polyphenols have multiple intracellu
./___Corpus/Medline/xml/PMC4720504.xml	isoflavones	91891 : 91902	CM	 as green tea catechins, isoflavones, anthocyanins, anthocyan
./___Corpus/Medline/xml/PMC4720504.xml	anthocyanins	91904 : 91916	CM	 catechins, isoflavones, anthocyanins, anthocyanidins, quercet
./___Corpus/Medline/xml/PMC4720504.xml	anthocyanidins	91918 : 91932	CM	oflavones, anthocyanins, anthocyanidins, quercetin (3,3′,4 5,7-p
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	91934 : 91943	CM	cyanins, anthocyanidins, quercetin (3,3′,4 5,7-pentahydroxy
./___Corpus/Medline/xml/PMC4720504.xml	5,7-pentahydroxyflavone	91952 : 91975	CM	idins, quercetin (3,3′,4 5,7-pentahydroxyflavone), apigenin and curcumin 
./___Corpus/Medline/xml/PMC4720504.xml	apigenin	91978 : 91986	CM	,7-pentahydroxyflavone), apigenin and curcumin have been i
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	91991 : 91999	CM	xyflavone), apigenin and curcumin have been identified as 
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	92117 : 92127	CM	 compared to velcade and bortezomib and may be ideal candida
./___Corpus/Medline/xml/PMC4720504.xml	polyphenol	92326 : 92336	CM	 derived agent green tea polyphenol that has been demonstrat
./___Corpus/Medline/xml/PMC4720504.xml	ubiquitin	92409 : 92418	CM	through targeting of the ubiquitin/proteasome pathway.     
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	92564 : 92568	CM	 studies have identified EGCG as the most potent chemo
./___Corpus/Medline/xml/PMC4720504.xml	277–	92748 : 92752	CPR	growth and angiogenesis [277–280]. More recently EGCG 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	92772 : 92776	CM	[277–280]. More recently EGCG has been found to affect
./___Corpus/Medline/xml/PMC4720504.xml	p27	92844 : 92847	CM	lated proteins including p27, Bcl-2 or Bcr-Abl oncopr
./___Corpus/Medline/xml/PMC4720504.xml	MMP-9	92922 : 92927	CM	loproteinases (MMP-2 and MMP-9) [281], the androgen rec
./___Corpus/Medline/xml/PMC4720504.xml	androgen	92940 : 92948	CM	-2 and MMP-9) [281], the androgen receptor, EGF receptor, 
./___Corpus/Medline/xml/PMC4720504.xml	EGF	92959 : 92962	CM	, the androgen receptor, EGF receptor, activator prot
./___Corpus/Medline/xml/PMC4720504.xml	1(AP1)	92992 : 92998	CM	ptor, activator proteins 1(AP1), and some cell cycle reg
./___Corpus/Medline/xml/PMC4720504.xml	282–	93032 : 93036	CPR	e cell cycle regulators [282–284]. Based on their stud
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93147 : 93151	CM	able to demonstrate that EGCG (in GTE) induces apoptos
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	93207 : 93213	CM	ll growth inhibition and cyclin kinase inhibitor WAF-1/p
./___Corpus/Medline/xml/PMC4720504.xml	p21	93237 : 93240	CM	n kinase inhibitor WAF-1/p21-mediated cell cycle-dysr
./___Corpus/Medline/xml/PMC4720504.xml	cDNA	93282 : 93286	CM	cle-dysregulation. Using cDNA microarrays, they also o
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93323 : 93327	CM	, they also observed the EGCG treatment of prostate ca
./___Corpus/Medline/xml/PMC4720504.xml	GTEs	93541 : 93545	CM	 These data confirm that GTEs exert potent and selecti
./___Corpus/Medline/xml/PMC4720504.xml	vitro	93576 : 93581	CM	 potent and selective in vitro and in vivo pro-apoptoti
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93690 : 93694	CM	eral mechanisms by which EGCG may operate in prostate 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93735 : 93739	CM	prostate carcinogenesis, EGCG has been demonstrated to
./___Corpus/Medline/xml/PMC4720504.xml	IkB-α	93875 : 93880	CM	g to the accumulation of IkB-α and p27 proteins, and gr
./___Corpus/Medline/xml/PMC4720504.xml	p27	93885 : 93888	CM	ccumulation of IkB-α and p27 proteins, and growth arr
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	93966 : 93970	CM	f proteasome activity by EGCG occurred at or near phys
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	94137 : 94148	CM	t a mixture of green tea polyphenols (polyphenon E) is equall
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94150 : 94162	CM	f green tea polyphenols (polyphenon E) is equally potent inhib
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	94229 : 94233	CM	ome activity as purified EGCG [287]. Polyphenon E pref
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94457 : 94469	CM	ent manner. Treatment of polyphenon E, at all used concentrati
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	94655 : 94659	CM	lls. Similar to purified EGCG, using a cell-free prote
./___Corpus/Medline/xml/PMC4720504.xml	20S	94809 : 94812	CM	y of the purified rabbit 20S proteasome with an IC50 
./___Corpus/Medline/xml/PMC4720504.xml	IC50	94832 : 94836	CM	t 20S proteasome with an IC50 value of 0.88 µM. To inv
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	94878 : 94890	CM	. To investigate whether polyphenon E specifically inhibits th
./___Corpus/Medline/xml/PMC4720504.xml	PGPH	94976 : 94980	CM	vity, its effects on the PGPH-like and trypsin-like ac
./___Corpus/Medline/xml/PMC4720504.xml	20S	95030 : 95033	CM	tivities of the purified 20S proteasome were determin
./___Corpus/Medline/xml/PMC4720504.xml	PGPH	95085 : 95089	CM	. Polyphenon E inhibited PGPH-like activity of the pur
./___Corpus/Medline/xml/PMC4720504.xml	20S	95127 : 95130	CM	y of the purified rabbit 20S proteasome with an IC50 
./___Corpus/Medline/xml/PMC4720504.xml	IC50	95150 : 95154	CM	t 20S proteasome with an IC50 value of 7 µM. The IC50 
./___Corpus/Medline/xml/PMC4720504.xml	IC50	95174 : 95178	CM	 IC50 value of 7 µM. The IC50 value for trypsin-like a
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	95253 : 95265	CM	 thus demonstrating that polyphenon E preferentially inhibits 
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon	95421 : 95431	CM	e effect of 2 mg/diet of Polyphenon E in a phase I/II clinic
./___Corpus/Medline/xml/PMC4720504.xml	CLL	95481 : 95484	CM	al trial on asymptomatic CLL patients (Rai stage 0 to
./___Corpus/Medline/xml/PMC4720504.xml	flavopiridol	95731 : 95743	CM	reatment [288,289]. Also flavopiridol, a semisynthetic flavono
./___Corpus/Medline/xml/PMC4720504.xml	flavonoidal	95761 : 95772	CM	piridol, a semisynthetic flavonoidal alkaloid, originated fro
./___Corpus/Medline/xml/PMC4720504.xml	alkaloid	95773 : 95781	CM	emisynthetic flavonoidal alkaloid, originated from an Indi
./___Corpus/Medline/xml/PMC4720504.xml	cyclin	95852 : 95858	CM	r its ability to inhibit cyclin-dependent kinases, achie
./___Corpus/Medline/xml/PMC4720504.xml	CLL	95943 : 95946	CM	n patients with relapsed CLL, including those with hi
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	96293 : 96297	CM	e proteasome activity by EGCG may be the primary pathw
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	96362 : 96366	CM	 catechins, specifically EGCG, induce prostate epithel
./___Corpus/Medline/xml/PMC4720504.xml	IκB-α	96487 : 96492	CM	inhibition pathway i.e., IκB-α protein expression, accu
./___Corpus/Medline/xml/PMC4720504.xml	p27	96529 : 96532	CM	ression, accumulation of p27 proteins and decreasing 
./___Corpus/Medline/xml/PMC4720504.xml	NFKB	96557 : 96561	CM	 proteins and decreasing NFKB DNA-binding activity, an
./___Corpus/Medline/xml/PMC4720504.xml	HGPIN	96710 : 96715	CM	reasing progression from HGPIN to prostate [292,293] – 
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	96766 : 96776	CM	imilar to the effects of bortezomib and velcade (PS-341) [29
./___Corpus/Medline/xml/PMC4720504.xml	294–	96799 : 96803	CPR	ib and velcade (PS-341) [294–296].                    
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	97123 : 97133	CM	 have been observed with bortezomib. Therefore, it is necess
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	97231 : 97241	CM	 with similar potency to bortezomib or different novel prote
./___Corpus/Medline/xml/PMC4720504.xml	ester	97363 : 97368	CM	ugh it is clear that the ester carbon of EGCG is import
./___Corpus/Medline/xml/PMC4720504.xml	carbon	97369 : 97375	CM	 is clear that the ester carbon of EGCG is important for
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97379 : 97383	CM	that the ester carbon of EGCG is important for mediati
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97447 : 97451	CM	ome-inhibitory activity, EGCG is very unstable under p
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97524 : 97528	CM	. Therefore, a series of EGCG analogs are evolving tha
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97611 : 97615	CM	y and bioavailability of EGCG. Among them, peracetate-
./___Corpus/Medline/xml/PMC4720504.xml	peracetate	97629 : 97639	CM	ity of EGCG. Among them, peracetate-protected or the pro-dru
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97669 : 97673	CM	ected or the pro-drug of EGCG was found to have increa
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97825 : 97829	CM	s and tumors compared to EGCG, suggesting its potentia
./___Corpus/Medline/xml/PMC4720504.xml	GTPs	97961 : 97965	CM	trials have demonstrated GTPs, specifically EGCG, have
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	97980 : 97984	CM	rated GTPs, specifically EGCG, have a completely diffe
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	98038 : 98048	CM	 chemical structure from bortezomib. Most importantly, (−)-E
./___Corpus/Medline/xml/PMC4720504.xml	(−)-EGCG	98068 : 98076	CM	zomib. Most importantly, (−)-EGCG and other catechin mixtu
./___Corpus/Medline/xml/PMC4720504.xml	catechin	98087 : 98095	CM	ntly, (−)-EGCG and other catechin mixtures at varying dose
./___Corpus/Medline/xml/PMC4720504.xml	AEs	98219 : 98222	CM	contrast to the observed AEs seen in the bortezomib t
./___Corpus/Medline/xml/PMC4720504.xml	bortezomib	98235 : 98245	CM	observed AEs seen in the bortezomib trials, and thus appear 
./___Corpus/Medline/xml/PMC4720504.xml	catechin	98389 : 98397	CM	       In green tea, the catechin EGCG has been extensivel
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	98398 : 98402	CM	 green tea, the catechin EGCG has been extensively stu
./___Corpus/Medline/xml/PMC4720504.xml	(−)-EGCG	98567 : 98575	CM	Both naturally-occurring (−)-EGCG and synthetic enantiomer
./___Corpus/Medline/xml/PMC4720504.xml	(+)-EGCG	98601 : 98609	CM	and synthetic enantiomer (+)-EGCG are able to potently and
./___Corpus/Medline/xml/PMC4720504.xml	IC50	98740 : 98744	CM	an irreversible way with IC50 range 86–194 nM in vitro
./___Corpus/Medline/xml/PMC4720504.xml	86–	98751 : 98754	CPR	ible way with IC50 range 86–194 nM in vitro and 1–10 
./___Corpus/Medline/xml/PMC4720504.xml	vitro	98764 : 98769	CM	 IC50 range 86–194 nM in vitro and 1–10 µM in vivo [280
./___Corpus/Medline/xml/PMC4720504.xml	1–	98774 : 98776	CPR	e 86–194 nM in vitro and 1–10 µM in vivo [280]. Of n
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	98806 : 98810	CM	 in vivo [280]. Of note, EGCG is able to interact with
./___Corpus/Medline/xml/PMC4720504.xml	β5i	98900 : 98903	CM	 proteasome but also the β5i subunit in interferon-γ 
./___Corpus/Medline/xml/PMC4720504.xml	BrAAP	98972 : 98977	CM	teasome (referring to as BrAAP activity) with even high
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99091 : 99095	CM	emosensitizing effect of EGCG and other catechins in v
./___Corpus/Medline/xml/PMC4720504.xml	vitro	99119 : 99124	CM	G and other catechins in vitro and in vivo. It has also
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99166 : 99170	CM	has also been shown that EGCG reversed drug resistance
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99238 : 99242	CM	 drug efflux transporter P-gp. For example, Kitagawa e
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99342 : 99346	CM	cellular accumulation of P-gp substrates in human cerv
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99429 : 99433	CM	he chemosensitization by EGCG through the inhibition o
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99460 : 99464	CM	hrough the inhibition of P-gp expression/activity has 
./___Corpus/Medline/xml/PMC4720504.xml	P-gp	99635 : 99639	CM	port studies mediated by P-gp) [300] and tamoxifen-res
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	99651 : 99660	CM	iated by P-gp) [300] and tamoxifen-resistant MCF-7 human br
./___Corpus/Medline/xml/PMC4720504.xml	MCF-7	99671 : 99676	CM	 and tamoxifen-resistant MCF-7 human breast cancer cell
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	99757 : 99768	CM	graft mouse models using doxorubicin-resistant KB-A1 cells [3
./___Corpus/Medline/xml/PMC4720504.xml	KB-A1	99779 : 99784	CM	ng doxorubicin-resistant KB-A1 cells [302] or doxorubic
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	99800 : 99811	CM	ant KB-A1 cells [302] or doxorubicin-resistant BEL-7404/DOX h
./___Corpus/Medline/xml/PMC4720504.xml	DOX	99831 : 99834	CM	bicin-resistant BEL-7404/DOX hepatocarcinoma cells [3
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	99879 : 99888	CM	ls [303]. The study with tamoxifen-resistant MCF-7 cells al
./___Corpus/Medline/xml/PMC4720504.xml	MCF-7	99899 : 99904	CM	with tamoxifen-resistant MCF-7 cells also found that EG
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99927 : 99931	CM	-7 cells also found that EGCG was able to inhibit the 
./___Corpus/Medline/xml/PMC4720504.xml	BCRP	99972 : 99976	CM	ibit the activity of the BCRP transporter [304]. EGCG 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	99996 : 100000	CM	 BCRP transporter [304]. EGCG was also reported to enh
./___Corpus/Medline/xml/PMC4720504.xml	temozolomide	100065 : 100077	CM	ivity of glioblastoma to temozolomide, and of prostate carcino
./___Corpus/Medline/xml/PMC4720504.xml	doxorubicin	100108 : 100119	CM	of prostate carcinoma to doxorubicin [305], and of breast car
./___Corpus/Medline/xml/PMC4720504.xml	ectopic	100188 : 100195	CM	l [306] in corresponding ectopic or orthotopic xenograft 
./___Corpus/Medline/xml/PMC4720504.xml	peracetate	100251 : 100261	CM	models. Furthermore, the peracetate-protected prodrug of EGC
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	100283 : 100287	CM	ate-protected prodrug of EGCG also exhibited a chemose
./___Corpus/Medline/xml/PMC4720504.xml	daunorubicin	100420 : 100432	CM	onventional chemotherapy daunorubicin and cytosine arabinoside
./___Corpus/Medline/xml/PMC4720504.xml	cytosine arabinoside	100437 : 100457	CM	therapy daunorubicin and cytosine arabinoside [307]. A very recent stu
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	100529 : 100540	CM	er-based nanoparticle of polyphenols EGCG and theaflavin reta
./___Corpus/Medline/xml/PMC4720504.xml	20-fold	100605 : 100612	CM	 effectiveness with over 20-fold dose advantage than EGCG
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	100633 : 100637	CM	fold dose advantage than EGCG/theaflavin in exerting a
./___Corpus/Medline/xml/PMC4720504.xml	anti-	100661 : 100666	CPR	G/theaflavin in exerting anti-cancer effects and also e
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	100716 : 100725	CM	nhanced the potential of cisplatin in several different tum
./___Corpus/Medline/xml/PMC4720504.xml	309–	101106 : 101110	CPR	erated in these studies [309–311]. After a temporary s
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	101148 : 101152	CM	 temporary suspension of EGCG in clinical trials by th
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101272 : 101284	CM	ity, a tea extract named polyphenon E further proved the safet
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	101318 : 101329	CM	proved the safety of tea polyphenols. In a polyphenon E phase
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101336 : 101348	CM	of tea polyphenols. In a polyphenon E phase I clinical trial i
./___Corpus/Medline/xml/PMC4720504.xml	Polyphenon	101564 : 101574	CM	aily oral consumption of Polyphenon E. A phase II trial usin
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101605 : 101617	CM	phase II trial using 2 g polyphenon E twice a day to evaluate 
./___Corpus/Medline/xml/PMC4720504.xml	CLL	101706 : 101709	CM	lerated by patients with CLL and durable declines in 
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	101876 : 101888	CM	o clinical studies using polyphenon E in combination with erlo
./___Corpus/Medline/xml/PMC4720504.xml	erlotinib	101909 : 101918	CM	on E in combination with erlotinib are currently ongoing in
./___Corpus/Medline/xml/PMC4720504.xml	polyphenon E	102086 : 102098	CM	emosensitizing effect of polyphenon E in clinical settings rem
./___Corpus/Medline/xml/PMC4720504.xml	vitro	102153 : 102158	CM	to be determined. The in vitro and in vivo studies sugg
./___Corpus/Medline/xml/PMC4720504.xml	polyphenols	102196 : 102207	CM	studies suggest that tea polyphenols (especially EGCG) may se
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	102220 : 102224	CM	 polyphenols (especially EGCG) may serve as powerful a
./___Corpus/Medline/xml/PMC4720504.xml	Resveratrol	102358 : 102369	CM	.                  10.2. Resveratrol                      Iso
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102429 : 102440	CM	 the skin of red grapes, resveratrol received much attention 
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102664 : 102675	CM	pposedly major source of resveratrol). Later on a number of l
./___Corpus/Medline/xml/PMC4720504.xml	anti-	102734 : 102739	CPR	es have demonstrated the anti-cancer activity of resver
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102758 : 102769	CM	 anti-cancer activity of resveratrol in multiple tumor models
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	102826 : 102837	CM	es have since shown that resveratrol can reverse apoptosis re
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103034 : 103045	CM	cently demonstrated that resveratrol can augment paclitaxel t
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103189 : 103200	CM	eagues [313] showed that resveratrol can overcome chemoresist
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103278 : 103289	CM	asophyrangeal carcinoma, resveratrol has been shown to cause 
./___Corpus/Medline/xml/PMC4720504.xml	ER	103327 : 103329	CM	wn to cause expansion of ER, and ER caspase mediated
./___Corpus/Medline/xml/PMC4720504.xml	ER	103335 : 103337	CM	use expansion of ER, and ER caspase mediated apoptos
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103408 : 103419	CM	it was demonstrated that resveratrol sensitizes tamoxifen in 
./___Corpus/Medline/xml/PMC4720504.xml	tamoxifen	103431 : 103440	CM	t resveratrol sensitizes tamoxifen in estrogen receptor res
./___Corpus/Medline/xml/PMC4720504.xml	estrogen	103444 : 103452	CM	 sensitizes tamoxifen in estrogen receptor resistance brea
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103567 : 103578	CM	315]. In a glioma model, resveratrol was shown to suppress X 
./___Corpus/Medline/xml/PMC4720504.xml	X	103601 : 103602	CM	ol was shown to suppress X linked inhibitor of apop
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103735 : 103746	CM	stigate the mechanism of resveratrol mediated chemosensitizat
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	103953 : 103964	CM	osis inducing effects of resveratrol in different cancer mode
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104004 : 104015	CM	ancer models. Aside from resveratrol, studies have also focus
./___Corpus/Medline/xml/PMC4720504.xml	piceatannol	104068 : 104079	CM	on its biological analog piceatannol as well. For example, Fa
./___Corpus/Medline/xml/PMC4720504.xml	piceatannol	104149 : 104160	CM	 [318] demonstrated that piceatannol enhances cisplatin sensi
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	104170 : 104179	CM	hat piceatannol enhances cisplatin sensitivity in ovarian c
./___Corpus/Medline/xml/PMC4720504.xml	p53	104228 : 104231	CM	cancer via modulation of p53, X-linked inhibitor of a
./___Corpus/Medline/xml/PMC4720504.xml	X	104233 : 104234	CM	r via modulation of p53, X-linked inhibitor of apop
./___Corpus/Medline/xml/PMC4720504.xml	anti-	104369 : 104374	CPR	employed to assess their anti-apoptotic effects in in v
./___Corpus/Medline/xml/PMC4720504.xml	vitro	104398 : 104403	CM	-apoptotic effects in in vitro models of CLL. For examp
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104414 : 104417	CM	ts in in vitro models of CLL. For example, resveratro
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104432 : 104443	CM	els of CLL. For example, resveratrol (3,4′,5-trihydroxystilbe
./___Corpus/Medline/xml/PMC4720504.xml	3,4′,5-trihydroxystilbene	104445 : 104470	CM	or example, resveratrol (3,4′,5-trihydroxystilbene), a phytoalexin well kno
./___Corpus/Medline/xml/PMC4720504.xml	phytoalexin	104475 : 104486	CM	5-trihydroxystilbene), a phytoalexin well known for its healt
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104577 : 104580	CM	LL cells (derived from a CLL patient resistant to flu
./___Corpus/Medline/xml/PMC4720504.xml	fludarabine	104602 : 104613	CM	CLL patient resistant to fludarabine) and in B cells isolated
./___Corpus/Medline/xml/PMC4720504.xml	CLL	104644 : 104647	CM	in B cells isolated from CLL patients; instead, norma
./___Corpus/Medline/xml/PMC4720504.xml	10–	104770 : 104773	CPR	f this compound, used at 10–50 µM concentration, was 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	104837 : 104842	CPR	a down-regulation of two anti-apoptotic proteins, induc
./___Corpus/Medline/xml/PMC4720504.xml	nitric oxide	104872 : 104884	CM	otic proteins, inducible nitric oxide synthase and Bcl-2 [319,
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	104974 : 104985	CM	t oral administration of resveratrol (5 g/day) for 4 weeks, t
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105018 : 105021	CM	y) for 4 weeks, to three CLL patients, decreased circ
./___Corpus/Medline/xml/PMC4720504.xml	O	105099 : 105100	CM	nts and directly lowered O-linked β-N-acetylglucosa
./___Corpus/Medline/xml/PMC4720504.xml	O-	105100 : 105102	CPR	ts and directly lowered O-linked β-N-acetylglucosami
./___Corpus/Medline/xml/PMC4720504.xml	β-N-acetylglucosamine	105108 : 105129	CM	irectly lowered O-linked β-N-acetylglucosamine (O-GlcNAc) levels in leu
./___Corpus/Medline/xml/PMC4720504.xml	O-GlcNAc	105131 : 105139	CM	d β-N-acetylglucosamine (O-GlcNAc) levels in leukemic cell
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105245 : 105248	CM	 result considering that CLL cells are characterized 
./___Corpus/Medline/xml/PMC4720504.xml	O-GlcNAc	105342 : 105350	CM	nslationally modified by O-GlcNAc moieties [321]. Resverat
./___Corpus/Medline/xml/PMC4720504.xml	Resveratrol	105367 : 105378	CM	O-GlcNAc moieties [321]. Resveratrol, in combination with que
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	105400 : 105409	CM	rol, in combination with quercetin, induced apoptosis and c
./___Corpus/Medline/xml/PMC4720504.xml	G1	105457 : 105459	CM	 cell cycle arrest in G0/G1 in human 232B4 cell line
./___Corpus/Medline/xml/PMC4720504.xml	CLL	105498 : 105501	CM	4 cell line derived from CLL [322]. Collectively, the
./___Corpus/Medline/xml/PMC4720504.xml	resveratrol	105584 : 105595	CM	te that grape derivative resveratrol and its analogs can eith
./___Corpus/Medline/xml/PMC4720504.xml	Curcumin

                    Curcumin	105733 : 105771	CM	.                  10.3. Curcumin                      Curcumin, which is the major comp
./___Corpus/Medline/xml/PMC4720504.xml	anti-	105885 : 105890	CPR	es. The first reports on anti-cancer activity of curcum
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	105909 : 105917	CM	 anti-cancer activity of curcumin were reported in 1985 [3
./___Corpus/Medline/xml/PMC4720504.xml	anti-	106017 : 106022	CPR	eported on the different anti-cancer mechanisms of curc
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106043 : 106051	CM	nti-cancer mechanisms of curcumin and related analogs (num
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106164 : 106172	CM	otis inducing effects of curcumin and analogs in cancer ce
./___Corpus/Medline/xml/PMC4720504.xml	B-CLL	106338 : 106343	CM	              In primary B-CLL cells curcumin induced a
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106350 : 106358	CM	  In primary B-CLL cells curcumin induced apoptosis with a
./___Corpus/Medline/xml/PMC4720504.xml	EC50	106389 : 106393	CM	ed apoptosis with a mean EC50 of 5.5 µM, fourfold lowe
./___Corpus/Medline/xml/PMC4720504.xml	EC50	106429 : 106433	CM	 fourfold lower than the EC50 observed in normal monon
./___Corpus/Medline/xml/PMC4720504.xml	NF-κB	106502 : 106507	CM	µM). The molecule blocks NF-κB signaling, probably thro
./___Corpus/Medline/xml/PMC4720504.xml	IκB	106550 : 106553	CM	ly through inhibition of IκB [325]. Some authors obse
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106634 : 106642	CM	in primary B-cells using curcumin in association with othe
./___Corpus/Medline/xml/PMC4720504.xml	rapamycin	106696 : 106705	CM	tural compounds, such as rapamycin and EGCG. In the former 
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	106710 : 106714	CM	s, such as rapamycin and EGCG. In the former case, the
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	106890 : 106898	CM	ential administration of curcumin and EGCG led to a substa
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	106903 : 106907	CM	stration of curcumin and EGCG led to a substantial inc
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	107044 : 107052	CM	s showing the potency of curcumin in overcoming resistance
./___Corpus/Medline/xml/PMC4720504.xml	curcumin	107115 : 107123	CM	. The synergism shown by curcumin with other natural compo
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin

                    Quercetin	107272 : 107312	CM	.                  10.4. Quercetin                      Quercetin a phytochemical found in
./___Corpus/Medline/xml/PMC4720504.xml	anti-	107425 : 107430	CPR	own for its antioxidant, anti-inflammatory, anti-prolif
./___Corpus/Medline/xml/PMC4720504.xml	anti-	107444 : 107449	CPR	dant, anti-inflammatory, anti-proliferative and apoptot
./___Corpus/Medline/xml/PMC4720504.xml	Quercetin	107535 : 107544	CM	animal models [329,330]. Quercetin at relatively low concen
./___Corpus/Medline/xml/PMC4720504.xml	10–	107579 : 107582	CPR	vely low concentrations (10–20 µM) is able to down-re
./___Corpus/Medline/xml/PMC4720504.xml	CLL	107678 : 107681	CM	he B-cells isolated from CLL patients [331,332], with
./___Corpus/Medline/xml/PMC4720504.xml	quercetin	107839 : 107848	CM	udies have reported that quercetin affects Hh, Wnt, as well
./___Corpus/Medline/xml/PMC4720504.xml	Hh	107857 : 107859	CM	d that quercetin affects Hh, Wnt, as well as Notch s
./___Corpus/Medline/xml/PMC4720504.xml	Wnt	107861 : 107864	CM	at quercetin affects Hh, Wnt, as well as Notch signal
./___Corpus/Medline/xml/PMC4720504.xml	CLL	107953 : 107956	CM	 of the molecule against CLL [333].                  
./___Corpus/Medline/xml/PMC4720504.xml	Isothiocyanates	107987 : 108002	CM	.                  10.5. Isothiocyanates                      Sev
./___Corpus/Medline/xml/PMC4720504.xml	isothiocyanates	108095 : 108110	CM	ventive activity of many isothiocyanates (ITCs), occurring in cru
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	108112 : 108116	CM	of many isothiocyanates (ITCs), occurring in crucifero
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108256 : 108268	CM	ignaling pathways [334]. Sulforaphane, a well-studied ITC, res
./___Corpus/Medline/xml/PMC4720504.xml	ITC	108285 : 108288	CM	oraphane, a well-studied ITC, restored chemosensitivi
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108319 : 108322	CM	ored chemosensitivity to DOX in mouse fibroblasts wit
./___Corpus/Medline/xml/PMC4720504.xml	p53	108349 : 108352	CM	n mouse fibroblasts with p53 mutated at codon 220 [33
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108518 : 108530	CM	f chemotherapy response. Sulforaphane was able to increase the
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108568 : 108571	CM	increase the efficacy of DOX, allowing its administra
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108694 : 108706	CM	. The mechanism by which Sulforaphane reversed DOX resistance 
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108716 : 108719	CM	ch Sulforaphane reversed DOX resistance involves a ra
./___Corpus/Medline/xml/PMC4720504.xml	glutathione	108761 : 108772	CM	ves a rapid depletion of glutathione that renders cells more 
./___Corpus/Medline/xml/PMC4720504.xml	DOX	108812 : 108815	CM	ells more susceptible to DOX-induced oxidative stress
./___Corpus/Medline/xml/PMC4720504.xml	N-acetyl-cysteine	108940 : 108957	CM	that, pre-treatment with N-acetyl-cysteine, a glutathione precursor
./___Corpus/Medline/xml/PMC4720504.xml	glutathione	108961 : 108972	CM	ith N-acetyl-cysteine, a glutathione precursor, prevented Sul
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	108994 : 109006	CM	one precursor, prevented Sulforaphane plus DOX-induced apoptos
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109012 : 109015	CM	vented Sulforaphane plus DOX-induced apoptosis. Since
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109063 : 109066	CM	ce the clinical doses of DOX currently being used dur
./___Corpus/Medline/xml/PMC4720504.xml	phenylethyl	109195 : 109206	CM	 analyzed the ability of phenylethyl ITC (PEITC) to enhance t
./___Corpus/Medline/xml/PMC4720504.xml	PEITC	109212 : 109217	CM	lity of phenylethyl ITC (PEITC) to enhance the cytotoxi
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109289 : 109292	CM	toxic) concentrations of DOX in human breast carcinom
./___Corpus/Medline/xml/PMC4720504.xml	HER2	109362 : 109366	CM	fected with the oncogene HER2. PEITC increased the cyt
./___Corpus/Medline/xml/PMC4720504.xml	PEITC	109368 : 109373	CM	 with the oncogene HER2. PEITC increased the cytotoxici
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109404 : 109407	CM	ased the cytotoxicity of DOX. Moreover, DOX treatment
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109419 : 109422	CM	xicity of DOX. Moreover, DOX treatment suppressed HER
./___Corpus/Medline/xml/PMC4720504.xml	HER2	109444 : 109448	CM	DOX treatment suppressed HER2 expression modestly, whe
./___Corpus/Medline/xml/PMC4720504.xml	PEITC	109497 : 109502	CM	ereas the combination of PEITC with DOX markedly decrea
./___Corpus/Medline/xml/PMC4720504.xml	DOX	109508 : 109511	CM	ombination of PEITC with DOX markedly decreased the e
./___Corpus/Medline/xml/PMC4720504.xml	HER2	109549 : 109553	CM	reased the expression of HER2 and the phosphorylation 
./___Corpus/Medline/xml/PMC4720504.xml	phosphorylation	109562 : 109577	RN	pression of HER2 and the phosphorylation of STAT3, known to play 
./___Corpus/Medline/xml/PMC4720504.xml	STAT3	109581 : 109586	CM	d the phosphorylation of STAT3, known to play a critica
./___Corpus/Medline/xml/PMC4720504.xml	PARP	109753 : 109757	CM	leavage of caspase 3 and PARP as compared to individua
./___Corpus/Medline/xml/PMC4720504.xml	Sulforaphane	109865 : 109877	CM	ls, co-administration of Sulforaphane potentiated the growth i
./___Corpus/Medline/xml/PMC4720504.xml	oxaliplatin	109924 : 109935	CM	h inhibition activity of oxaliplatin through a reduction of i
./___Corpus/Medline/xml/PMC4720504.xml	ATP	109973 : 109976	CM	duction of intracellular ATP levels, activation of ca
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	109999 : 110008	CM	TP levels, activation of caspase-3, DNA fragmentation, and 
./___Corpus/Medline/xml/PMC4720504.xml	PARP	110033 : 110037	CM	, DNA fragmentation, and PARP cleavage [340]. Cisplati
./___Corpus/Medline/xml/PMC4720504.xml	Cisplatin	110054 : 110063	CM	and PARP cleavage [340]. Cisplatin was also tested in combi
./___Corpus/Medline/xml/PMC4720504.xml	PEITC	110100 : 110105	CM	sted in combination with PEITC in endometrial cancer ce
./___Corpus/Medline/xml/PMC4720504.xml	BITC	110148 : 110152	CM	ncer cells [341] or with BITC in leukemia cells [342].
./___Corpus/Medline/xml/PMC4720504.xml	caspase-3	110225 : 110234	CM	y induced an increase in caspase-3 activity and increased l
./___Corpus/Medline/xml/PMC4720504.xml	PARP	110276 : 110280	CM	reased levels of cleaved PARP. Such effects were not c
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110414 : 110418	CM	sensitization induced by ITCs was partly mediated by E
./___Corpus/Medline/xml/PMC4720504.xml	ERK	110442 : 110445	CM	s was partly mediated by ERK and Noxa activation. Int
./___Corpus/Medline/xml/PMC4720504.xml	Noxa	110450 : 110454	CM	rtly mediated by ERK and Noxa activation. Interestingl
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110579 : 110583	CM	                         ITCs also enhanced the effica
./___Corpus/Medline/xml/PMC4720504.xml	cisplatin	110614 : 110623	CM	enhanced the efficacy of cisplatin when used against human 
./___Corpus/Medline/xml/PMC4720504.xml	platinum	110705 : 110713	CM	 [343]. Neither cellular platinum accumulation nor DNA pla
./___Corpus/Medline/xml/PMC4720504.xml	platination	110735 : 110746	RN	num accumulation nor DNA platination accounts for this effect
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110836 : 110840	CM	nduction of apoptosis by ITCs [344]. ITCs covalently m
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	110848 : 110852	CM	apoptosis by ITCs [344]. ITCs covalently modify cystei
./___Corpus/Medline/xml/PMC4720504.xml	cysteine	110871 : 110879	CM	. ITCs covalently modify cysteine residues in tubulin, res
./___Corpus/Medline/xml/PMC4720504.xml	tubulin	110892 : 110899	CM	ify cysteine residues in tubulin, resulting in tubulin co
./___Corpus/Medline/xml/PMC4720504.xml	tubulin	110914 : 110921	CM	in tubulin, resulting in tubulin conformational changes, 
./___Corpus/Medline/xml/PMC4720504.xml	Tubulin	111014 : 111021	CM	nd ultimately apoptosis. Tubulin-binding agents such as p
./___Corpus/Medline/xml/PMC4720504.xml	platinum	111094 : 111102	CM	used in combination with platinum drugs to treat non-small
./___Corpus/Medline/xml/PMC4720504.xml	β-tubulin	111158 : 111167	CM	lung cancer [345]. Thus, β-tubulin depletion may correlate 
./___Corpus/Medline/xml/PMC4720504.xml	platinum	111230 : 111238	CM	ant for sensitization to platinum compounds by ITCs.      
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111252 : 111256	CM	to platinum compounds by ITCs.                        
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111355 : 111359	CM	ted above indicates that EGCG and ITCs have an enormou
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111364 : 111368	CM	 indicates that EGCG and ITCs have an enormous potenti
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111499 : 111503	CM	sound a cautionary note. EGCG and ITCs are able to inc
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	111508 : 111512	CM	autionary note. EGCG and ITCs are able to increase Nrf
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111534 : 111538	CM	TCs are able to increase Nrf2 expression [346], a key 
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111756 : 111760	CM	cells by upregulation of Nrf2 signaling, thereby yield
./___Corpus/Medline/xml/PMC4720504.xml	Nrf2	111861 : 111865	CM	logic induction of Keap1–Nrf2-signaling axis allows fo
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	111997 : 112001	CM	re suggesting the use of EGCG or ITCs in patients with
./___Corpus/Medline/xml/PMC4720504.xml	ITCs	112005 : 112009	CM	sting the use of EGCG or ITCs in patients with establi
./___Corpus/Medline/xml/PMC4720504.xml	Marine	112113 : 112119	CM	.                  10.6. Marine derived agents with apop
./___Corpus/Medline/xml/PMC4720504.xml	anti-	112284 : 112289	CPR	owed many other types of anti-cancer compounds from mar
./___Corpus/Medline/xml/PMC4720504.xml	marine	112311 : 112317	CM	ti-cancer compounds from marine sources as well. A key w
./___Corpus/Medline/xml/PMC4720504.xml	Marine	112357 : 112363	CM	l. A key word search on ‘Marine anticancer agents’ revea
./___Corpus/Medline/xml/PMC4720504.xml	marine	112498 : 112504	CM	ic inducing potential of marine derived compounds in can
./___Corpus/Medline/xml/PMC4720504.xml	349–	112573 : 112577	CPR	animal xenograft models [349–358]. For those seeking a
./___Corpus/Medline/xml/PMC4720504.xml	marine	112867 : 112873	CM	l agents (both plant and marine derived) can impact impo
./___Corpus/Medline/xml/PMC4720504.xml	anti-	114403 : 114408	CPR	 cancer’s biology (i.e., anti-carcinogenic) we noted th
./___Corpus/Medline/xml/PMC4720504.xml	anti-	114740 : 114745	CPR	rcinogenic potential and anti-carcinogenic potential), 
./___Corpus/Medline/xml/PMC4720504.xml	anti-	115494 : 115499	CPR	xhibit a large number of anti-carcinogenic actions acro
./___Corpus/Medline/xml/PMC4720504.xml	vitro	116076 : 116081	CM	es involving detailed in vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4720504.xml	vitro	116281 : 116286	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4720504.xml	gossypol	118072 : 118080	CM	opment of agents such as gossypol and synthetic compounds 
./___Corpus/Medline/xml/PMC4720504.xml	ABT-737	118118 : 118125	CM	c compounds particularly ABT-737 that have entered clinic
./___Corpus/Medline/xml/PMC4720504.xml	EGCG	118667 : 118671	CM	e of natural agents such EGCG were highlighted. The ro
./___Corpus/Medline/xml/PMC4720504.xml	CLL	119014 : 119017	CM	stoma, multiple myeloma, CLL, prostate cancer, breast
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120327 : 120330	CM	nts                      NIH Grants R21 1R21CA1698480
./___Corpus/Medline/xml/PMC4720504.xml	RMM	120379 : 120382	CM	01 and 1R21CA17597401 to RMM is acknowledged. This wo
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120626 : 120629	CM	FLXS011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA
./___Corpus/Medline/xml/PMC4720504.xml	NCI	120630 : 120633	CM	011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA1272
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120697 : 120700	CM	A184788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos 
./___Corpus/Medline/xml/PMC4720504.xml	CA22453	120705 : 120712	CM	to Q.P. Dou, and NIH P30 CA22453 to Karmanos Cancer Insti
./___Corpus/Medline/xml/PMC4720504.xml	NIH	120958 : 120961	CM	versity (TMU101-AE3-Y19) NIH Grant K08 NS083732 to MD
./___Corpus/Medline/xml/PMC4720504.xml	MDS	120984 : 120987	CM	IH Grant K08 NS083732 to MDS is acknowledged. Dr. Gia
./___Corpus/Medline/xml/PMC4720504.xml	2013-	121078 : 121083	CPR	Research Scholar program 2013-14. Work in CF’s lab desc
./___Corpus/Medline/xml/PMC4720504.xml	CF’s	121095 : 121099	CM	program 2013-14. Work in CF’s lab described here was s
./___Corpus/Medline/xml/PMC4720504.xml	NIH	121257 : 121260	CM	t G. Yedjou acknowledges NIH grant 5G12RR013459-13 th
./___Corpus/Medline/xml/PMC4720504.xml	THALES	121614 : 121620	CM	esearch Funding Program: THALES (Grant number MIS 379346
./___Corpus/Medline/xml/PMC4720504.xml	Amin	122229 : 122233	CM	ipt for publication. Amr Amin was supported partially 
./___Corpus/Medline/xml/PMC4720504.xml	NIH	122358 : 122361	CM	rry Fox Foundation 2014. NIH grant 1 R21 CA188818 01A
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	252 : 258	CM	important for delivering oxygen and nutrients to growing
./___Corpus/Medline/xml/PMC4737670.xml	anti-	567 : 572	CPR	is has become a clinical anti-cancer strategy in line w
./___Corpus/Medline/xml/PMC4737670.xml	anti-	777 : 782	CPR	 the clinically approved anti-angiogenic drugs in use t
./___Corpus/Medline/xml/PMC4737670.xml	anti-	939 : 944	CPR	 time. Also, some of the anti-angiogenic drugs are toxi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	1790 : 1795	CPR	 develop a complementary anti-angiogenesis treatment op
./___Corpus/Medline/xml/PMC4737670.xml	anti-	2103 : 2108	CPR	ll suited as targets for anti-angiogenic therapy: (1) e
./___Corpus/Medline/xml/PMC4737670.xml	anti-	2547 : 2552	CPR	rature on broadly acting anti-angiogenic natural produc
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	2743 : 2757	CM	ochemical compounds: (1) oleanolic acid, (2) tripterine, (3) sil
./___Corpus/Medline/xml/PMC4737670.xml	tripterine	2763 : 2773	CM	 (1) oleanolic acid, (2) tripterine, (3) silibinin, (4) curc
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	2794 : 2802	CM	rine, (3) silibinin, (4) curcumin, (5) epigallocatechin-ga
./___Corpus/Medline/xml/PMC4737670.xml	gallate	2825 : 2832	CM	in, (5) epigallocatechin-gallate, (6) kaempferol, (7) mel
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	2838 : 2848	CM	llocatechin-gallate, (6) kaempferol, (7) melatonin, (8) ente
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	2854 : 2863	CM	ate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) 
./___Corpus/Medline/xml/PMC4737670.xml	enterolactone	2869 : 2882	CM	erol, (7) melatonin, (8) enterolactone, (9) withaferin A and (1
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	2910 : 2921	CM	9) withaferin A and (10) resveratrol. We suggest that these p
./___Corpus/Medline/xml/PMC4737670.xml	anti-	3565 : 3570	CPR	 of combinations of such anti-angiogenic compounds whic
./___Corpus/Medline/xml/PMC4737670.xml	anti-	3621 : 3626	CPR	 could be used in potent anti-tumor cocktails, for enha
./___Corpus/Medline/xml/PMC4737670.xml	anti-	3729 : 3734	CPR	mvention of single-agent anti-angiogenic resistance, as
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	4884 : 4888	CM	dothelial growth factor (VEGF), fibroblast growth fact
./___Corpus/Medline/xml/PMC4737670.xml	factor-2	4909 : 4917	CM	VEGF), fibroblast growth factor-2 (FGF-2), interleukin-8 (
./___Corpus/Medline/xml/PMC4737670.xml	FGF-2	4919 : 4924	CM	roblast growth factor-2 (FGF-2), interleukin-8 (IL-8), 
./___Corpus/Medline/xml/PMC4737670.xml	PlGF	4974 : 4978	CM	placental growth factor (PlGF), transforming growth fa
./___Corpus/Medline/xml/PMC4737670.xml	-beta	5007 : 5012	CM	ransforming growth factor-beta (TGFbeta), platelet deri
./___Corpus/Medline/xml/PMC4737670.xml	anti-	5583 : 5588	CPR	te the levels of pro- or anti-angiogenic gene expressio
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	5928 : 5932	CM	ber of factors including VEGF receptor (VEGFR)-3 (for 
./___Corpus/Medline/xml/PMC4737670.xml	(VEGFR)-3	5942 : 5951	CM	 including VEGF receptor (VEGFR)-3 (for lymphatic endotheli
./___Corpus/Medline/xml/PMC4737670.xml	(Dll)-4	6079 : 6086	CM	ligand delta-like ligand (Dll)-4 have been shown to contr
./___Corpus/Medline/xml/PMC4737670.xml	4–	8219 : 8221	CPR	ge, where the density is 4–10 times greater than ins
./___Corpus/Medline/xml/PMC4737670.xml	anti-	8773 : 8778	CPR	for impaired delivery of anti-cancer drugs as well as o
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	8802 : 8808	CM	-cancer drugs as well as oxygen, the former being critic
./___Corpus/Medline/xml/PMC4737670.xml	mitogenic	9617 : 9626	CM	ignaling aspects of both mitogenic growth and directing the
./___Corpus/Medline/xml/PMC4737670.xml	alpha	10430 : 10435	CM	on factors composed from alpha and beta subunits, which
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	10537 : 10544	CM	vercome the effects of a hypoxic environment. There are t
./___Corpus/Medline/xml/PMC4737670.xml	HIF1alpha	10593 : 10602	CM	three HIFalpha subunits, HIF1alpha, HIF2alpha, HIF3alpha, w
./___Corpus/Medline/xml/PMC4737670.xml	HIF2alpha	10604 : 10613	CM	pha subunits, HIF1alpha, HIF2alpha, HIF3alpha, which are re
./___Corpus/Medline/xml/PMC4737670.xml	HIF3alpha	10615 : 10624	CM	s, HIF1alpha, HIF2alpha, HIF3alpha, which are regulated in 
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	10652 : 10658	CM	hich are regulated in an oxygen dependent manner. HIFalp
./___Corpus/Medline/xml/PMC4737670.xml	hydroxylated	10699 : 10711	RN	r. HIFalpha subunits are hydroxylated by prolyl hydroxylases (
./___Corpus/Medline/xml/PMC4737670.xml	prolyl	10715 : 10721	CM	nits are hydroxylated by prolyl hydroxylases (PHDs) [21]
./___Corpus/Medline/xml/PMC4737670.xml	hydroxylases	10722 : 10734	ASE	e hydroxylated by prolyl hydroxylases (PHDs) [21] allowing HIF
./___Corpus/Medline/xml/PMC4737670.xml	PHDs	10736 : 10740	CM	 by prolyl hydroxylases (PHDs) [21] allowing HIFalpha 
./___Corpus/Medline/xml/PMC4737670.xml	VHL	10817 : 10820	CM	y the von Hippel–Lindau (VHL) ubiquitin-ligase comple
./___Corpus/Medline/xml/PMC4737670.xml	VHL	10853 : 10856	CM	tin-ligase complex [22]. VHL poly-ubiquitinates HIFal
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	10966 : 10972	CM	d degradation. Under low oxygen conditions PHDs have red
./___Corpus/Medline/xml/PMC4737670.xml	PHDs	10984 : 10988	CM	er low oxygen conditions PHDs have reduced activity, a
./___Corpus/Medline/xml/PMC4737670.xml	VHL	11053 : 11056	CM	alpha subunits to escape VHL-mediated degradation. HI
./___Corpus/Medline/xml/PMC4737670.xml	glucose	11328 : 11335	CM	sses such as metabolism (glucose transporter (GLUT)-1, he
./___Corpus/Medline/xml/PMC4737670.xml	(GLUT)-1	11348 : 11356	CM	ism (glucose transporter (GLUT)-1, hexokinase (HK)-1), cel
./___Corpus/Medline/xml/PMC4737670.xml	hexokinase	11358 : 11368	CM	se transporter (GLUT)-1, hexokinase (HK)-1), cell growth (cy
./___Corpus/Medline/xml/PMC4737670.xml	cyclin	11391 : 11397	CM	se (HK)-1), cell growth (cyclin (CCN)-D1 [23]) and also 
./___Corpus/Medline/xml/PMC4737670.xml	(CCN)-D1	11398 : 11406	CM	-1), cell growth (cyclin (CCN)-D1 [23]) and also angiogene
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	11460 : 11464	CM	 such as erythropoietin, VEGF and PDGF [24] (summarize
./___Corpus/Medline/xml/PMC4737670.xml	PDGF	11469 : 11473	CM	erythropoietin, VEGF and PDGF [24] (summarized in Fig.
./___Corpus/Medline/xml/PMC4737670.xml	VHL	11556 : 11559	CM	f the machinery (such as VHL or other components) reg
./___Corpus/Medline/xml/PMC4737670.xml	HIF	11592 : 11595	CM	r components) regulating HIF stability can result in 
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	11620 : 11626	CM	 stability can result in oxygen-independent constitutive
./___Corpus/Medline/xml/PMC4737670.xml	HIF	11827 : 11830	CM	ditional factors besides HIF-mediated VEGF transcript
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	11840 : 11844	CM	ors besides HIF-mediated VEGF transcriptional activati
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	11911 : 11915	CM	 identified as promoting VEGF expression under hypoxic
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	11933 : 11940	CM	ng VEGF expression under hypoxic conditions. Environmenta
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	11993 : 11999	CM	tress as a result of low oxygen and proper nutrient depr
./___Corpus/Medline/xml/PMC4737670.xml	glucose	12041 : 12048	CM	ent deprivation, such as glucose deprivation, are capable
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	12086 : 12090	CM	 are capable of inducing VEGF mRNA stabilization resul
./___Corpus/Medline/xml/PMC4737670.xml	Hypoxic	12191 : 12198	CM	 angiogenic growth [26]. Hypoxic stress has also been des
./___Corpus/Medline/xml/PMC4737670.xml	rapamycin	12599 : 12608	CM	d by mammalian target of rapamycin (mTOR) family translatio
./___Corpus/Medline/xml/PMC4737670.xml	mTOR	12610 : 12614	CM	ian target of rapamycin (mTOR) family translational si
./___Corpus/Medline/xml/PMC4737670.xml	mTOR	12731 : 12735	CM	 (reviewed in [28]), and mTOR drugs are already in the
./___Corpus/Medline/xml/PMC4737670.xml	LN	13085 : 13087	CM	in sentinel lymph nodes (LN) that accept afferent ly
./___Corpus/Medline/xml/PMC4737670.xml	LN	13516 : 13518	CM	associated with positive LN metastasis as well as po
./___Corpus/Medline/xml/PMC4737670.xml	anti-	13984 : 13989	CPR	by a balance of pro- and anti-lymphangiogenesis factors
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	14093 : 14097	CM	ctors are members of the VEGF family, most predominant
./___Corpus/Medline/xml/PMC4737670.xml	-D	14136 : 14138	CM	predominantly VEGF-C and -D, through interactions wi
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR-3	14180 : 14187	CM	tions with in particular VEGFR-3, with some additional ev
./___Corpus/Medline/xml/PMC4737670.xml	VEGF-A	14223 : 14229	CM	 additional evidence for VEGF-A interacting with VEGFR-2
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR-2	14247 : 14254	CM	 VEGF-A interacting with VEGFR-2 (reviewed in [38]). Thes
./___Corpus/Medline/xml/PMC4737670.xml	LN	14312 : 14314	CM	s were found to increase LN metastasis and their exp
./___Corpus/Medline/xml/PMC4737670.xml	FGF-2	14502 : 14507	CM	giogenic factors include FGF-2 and the key receptor FGF
./___Corpus/Medline/xml/PMC4737670.xml	FGF	14529 : 14532	CM	F-2 and the key receptor FGF receptor (FGFR)-1 [45], 
./___Corpus/Medline/xml/PMC4737670.xml	(FGFR)-1	14542 : 14550	CM	ey receptor FGF receptor (FGFR)-1 [45], [46], [47], hepato
./___Corpus/Medline/xml/PMC4737670.xml	c-met	14625 : 14630	CM	and the cognate receptor c-met [48], insulin-like growt
./___Corpus/Medline/xml/PMC4737670.xml	(IGF)-1	14665 : 14672	CM	ulin-like growth factors (IGF)-1, -2 and IGF receptor (IG
./___Corpus/Medline/xml/PMC4737670.xml	IGF	14681 : 14684	CM	 factors (IGF)-1, -2 and IGF receptor (IGFR) [49], [5
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	14740 : 14748	CM	hrinB-2 and Eph receptor tyrosine kinase [51], Ang-1, -2 a
./___Corpus/Medline/xml/PMC4737670.xml	Ang-1	14762 : 14767	CM	or tyrosine kinase [51], Ang-1, -2 and Tie2 [52], PDGF-
./___Corpus/Medline/xml/PMC4737670.xml	Tie2	14776 : 14780	CM	nase [51], Ang-1, -2 and Tie2 [52], PDGF-BB and PDGF r
./___Corpus/Medline/xml/PMC4737670.xml	PDGF	14799 : 14803	CM	d Tie2 [52], PDGF-BB and PDGF receptor (PDGFR)alpha an
./___Corpus/Medline/xml/PMC4737670.xml	(PDGFR)alpha	14813 : 14825	CM	DGF-BB and PDGF receptor (PDGFR)alpha and -beta [53], growth h
./___Corpus/Medline/xml/PMC4737670.xml	-beta	14830 : 14835	CM	eceptor (PDGFR)alpha and -beta [53], growth hormone and
./___Corpus/Medline/xml/PMC4737670.xml	LN	15105 : 15107	CM	lymphangiogenesis in the LN itself, so as to prepare
./___Corpus/Medline/xml/PMC4737670.xml	LN	15240 : 15242	CM	ogenesis at the sentinel LN appears to occur beforeh
./___Corpus/Medline/xml/PMC4737670.xml	LN	15371 : 15373	CM	56], suggesting that the LN (possibly conditioned by
./___Corpus/Medline/xml/PMC4737670.xml	VEGF-A	15432 : 15438	CM	tumor effectors, such as VEGF-A or VEGF-C) helps to prov
./___Corpus/Medline/xml/PMC4737670.xml	LN	15620 : 15622	CM	ssociated with increased LN metastases (reviewed in 
./___Corpus/Medline/xml/PMC4737670.xml	podoplanin	16825 : 16835	CM	effectors (which include podoplanin, spleen tyrosine kinase 
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	16844 : 16852	CM	clude podoplanin, spleen tyrosine kinase (SYK)/SH2-domain 
./___Corpus/Medline/xml/PMC4737670.xml	SLP-76	16917 : 16923	CM	ocyte protein of 76 kDa (SLP-76), Rac1/Ras homology gene
./___Corpus/Medline/xml/PMC4737670.xml	Rac1	16926 : 16930	CM	tein of 76 kDa (SLP-76), Rac1/Ras homology gene family
./___Corpus/Medline/xml/PMC4737670.xml	(Spred)-1	17012 : 17021	CM	d EVH1-domain containing (Spred)-1, -2 molecules) and exami
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	18880 : 18884	CM	und to directly regulate VEGF levels and were responsi
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	18951 : 18955	CM	ted night-time spikes in VEGF which are very important
./___Corpus/Medline/xml/PMC4737670.xml	hypoxic	20135 : 20142	CM	        Tumors are often hypoxic in spite of high vascula
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	20335 : 20341	CM	n cause of high reactive oxygen species (ROS) formation 
./___Corpus/Medline/xml/PMC4737670.xml	ROS	20351 : 20354	CM	reactive oxygen species (ROS) formation within the tu
./___Corpus/Medline/xml/PMC4737670.xml	(IL)-1alpha	21469 : 21480	CM	ry cytokines interleukin (IL)-1alpha and IL-1beta as well as 
./___Corpus/Medline/xml/PMC4737670.xml	IL-1beta	21485 : 21493	CM	erleukin (IL)-1alpha and IL-1beta as well as a wide panel 
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	21600 : 21604	CM	ammatory cells including VEGF and matrix-metalloprotei
./___Corpus/Medline/xml/PMC4737670.xml	MMPs	21636 : 21640	CM	trix-metalloproteinases (MMPs) may contribute to angio
./___Corpus/Medline/xml/PMC4737670.xml	anti-	22316 : 22321	CPR	 providing resistance to anti-angiogenic therapy.      
./___Corpus/Medline/xml/PMC4737670.xml	anti-	23148 : 23153	CPR	tumor hypoxia. Recently, anti-angiogenic therapy has be
./___Corpus/Medline/xml/PMC4737670.xml	EMT	23328 : 23331	CM	 mesenchymal transition (EMT) [80], [81], [82]. Anti-
./___Corpus/Medline/xml/PMC4737670.xml	anti-	23528 : 23533	CPR	ia [83], indicating that anti-angiogenic therapy-induce
./___Corpus/Medline/xml/PMC4737670.xml	anti-	24049 : 24054	CPR	ia sub-maximal dosing of anti-angiogenic drugs [19]. Th
./___Corpus/Medline/xml/PMC4737670.xml	anti-	24299 : 24304	CPR	          3. Targets for anti-angiogenic therapy       
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	24696 : 24700	CM	ibodies targeted against VEGF (bevacizumab) [86] or fu
./___Corpus/Medline/xml/PMC4737670.xml	mTOR	24871 : 24875	CM	rs include inhibitors of mTOR, cyclo-oxygenase (COX) o
./___Corpus/Medline/xml/PMC4737670.xml	cyclo-oxygenase	24877 : 24892	CM	lude inhibitors of mTOR, cyclo-oxygenase (COX) or heat shock prot
./___Corpus/Medline/xml/PMC4737670.xml	COX	24894 : 24897	CM	f mTOR, cyclo-oxygenase (COX) or heat shock protein 9
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	24925 : 24930	CM	r heat shock protein 90 (HSP90) [88], [89]. These group
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	25191 : 25199	CM	nic receptors are mainly tyrosine kinase inhibitors (soraf
./___Corpus/Medline/xml/PMC4737670.xml	sorafenib	25219 : 25228	CM	osine kinase inhibitors (sorafenib, sunitinib, pazopanib, r
./___Corpus/Medline/xml/PMC4737670.xml	sunitinib	25230 : 25239	CM	e inhibitors (sorafenib, sunitinib, pazopanib, regorafenib 
./___Corpus/Medline/xml/PMC4737670.xml	pazopanib	25241 : 25250	CM	s (sorafenib, sunitinib, pazopanib, regorafenib or axitinib
./___Corpus/Medline/xml/PMC4737670.xml	VEGF-A	25672 : 25678	CM	 mostly via neutralizing VEGF-A, -C or -D-induced recept
./___Corpus/Medline/xml/PMC4737670.xml	-D	25686 : 25688	CM	utralizing VEGF-A, -C or -D-induced receptor activat
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	25785 : 25793	CM	lication of a variety of tyrosine kinase inhibitors such a
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR3	25893 : 25899	CM	mice through blockade of VEGFR3 autophosphorylation [93]
./___Corpus/Medline/xml/PMC4737670.xml	autophosphorylation	25900 : 25919	RN	rough blockade of VEGFR3 autophosphorylation [93]. Other agents in cl
./___Corpus/Medline/xml/PMC4737670.xml	PTK787	25967 : 25973	CM	clinical testing include PTK787/ZK222584 (Phase III – co
./___Corpus/Medline/xml/PMC4737670.xml	BAY43-9006	26016 : 26026	CM	II – colorectal cancer); BAY43-9006 (Phase II, multiple carc
./___Corpus/Medline/xml/PMC4737670.xml	anti-	26183 : 26188	CPR	ors). These, among other anti-lymphangiogenic agents un
./___Corpus/Medline/xml/PMC4737670.xml	anti-	26363 : 26368	CPR	otherapy could also have anti-angiogenic activity, part
./___Corpus/Medline/xml/PMC4737670.xml	cyclophosphamide	26500 : 26516	CM	on of chemotherapy (e.g. cyclophosphamide, methotrexate or capecit
./___Corpus/Medline/xml/PMC4737670.xml	methotrexate	26518 : 26530	CM	 (e.g. cyclophosphamide, methotrexate or capecitabine) in dose
./___Corpus/Medline/xml/PMC4737670.xml	anti-	26729 : 26734	CPR	in clinic, may also have anti-angiogenic activity in vi
./___Corpus/Medline/xml/PMC4737670.xml	vitro	26757 : 26762	CM	i-angiogenic activity in vitro or in vivo [96] as: (1) 
./___Corpus/Medline/xml/PMC4737670.xml	doxorubicin	26804 : 26815	CM	as: (1) paclitaxel [97], doxorubicin and thalidomide [98] whi
./___Corpus/Medline/xml/PMC4737670.xml	thalidomide	26820 : 26831	CM	el [97], doxorubicin and thalidomide [98] which seems to be m
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	26882 : 26886	CM	diated via inhibition of VEGF and bFGF [99]; (2) celec
./___Corpus/Medline/xml/PMC4737670.xml	bFGF	26891 : 26895	CM	a inhibition of VEGF and bFGF [99]; (2) celecoxib, whi
./___Corpus/Medline/xml/PMC4737670.xml	celecoxib	26906 : 26915	CM	 VEGF and bFGF [99]; (2) celecoxib, which may cause a time-
./___Corpus/Medline/xml/PMC4737670.xml	bisphosphonates	26999 : 27014	CM	 angiogenic markers; (3) bisphosphonates may have anti-angiogenic
./___Corpus/Medline/xml/PMC4737670.xml	anti-	27024 : 27029	CPR	bisphosphonates may have anti-angiogenic effects [100] 
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	27071 : 27075	CM	s [100] via reduction of VEGF and PDGF serum levels [1
./___Corpus/Medline/xml/PMC4737670.xml	PDGF	27080 : 27084	CM	ia reduction of VEGF and PDGF serum levels [101]; (4) 
./___Corpus/Medline/xml/PMC4737670.xml	rapamycin	27136 : 27145	CM	3K inhibitors (including rapamycin analogues as temsirolimu
./___Corpus/Medline/xml/PMC4737670.xml	temsirolimus	27159 : 27171	CM	g rapamycin analogues as temsirolimus (CCI-779) and everolimus
./___Corpus/Medline/xml/PMC4737670.xml	CCI-779	27173 : 27180	CM	alogues as temsirolimus (CCI-779) and everolimus (RAD001)
./___Corpus/Medline/xml/PMC4737670.xml	everolimus	27186 : 27196	CM	msirolimus (CCI-779) and everolimus (RAD001)) decrease tumor
./___Corpus/Medline/xml/PMC4737670.xml	RAD001	27198 : 27204	CM	CCI-779) and everolimus (RAD001)) decrease tumor angioge
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	27277 : 27287	CM	4] via the inhibition of HIF-1alpha caused by the blockade o
./___Corpus/Medline/xml/PMC4737670.xml	mTOR	27314 : 27318	CM	aused by the blockade of mTOR activity.               
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	27419 : 27427	CM	onoclonal antibodies and tyrosine kinase inhibitors have g
./___Corpus/Medline/xml/PMC4737670.xml	anti-	27735 : 27740	CPR	ns include the fact that anti-angiogenic agents can imp
./___Corpus/Medline/xml/PMC4737670.xml	cytokine	28036 : 28044	CM	more than one angiogenic cytokine and the fact that during
./___Corpus/Medline/xml/PMC4737670.xml	anti-	28234 : 28239	CPR	 for achieving sustained anti-tumor responses [74]. We 
./___Corpus/Medline/xml/PMC4737670.xml	EC	28822 : 28824	CM	mor vasculature, such as EC migration/tip cell forma
./___Corpus/Medline/xml/PMC4737670.xml	anti-	29051 : 29056	CPR	as candidate targets for anti-angiogenic natural compou
./___Corpus/Medline/xml/PMC4737670.xml	anti-	29809 : 29814	CPR	 of chemotherapeutics or anti-angiogenic drugs. Fruits,
./___Corpus/Medline/xml/PMC4737670.xml	Curcuma	29994 : 30001	CM	um (European mistletoe), Curcuma longa (turmeric), Scutel
./___Corpus/Medline/xml/PMC4737670.xml	Panax	30257 : 30262	CM	er officinalis (ginger), Panax ginseng (ginseng), Rabdo
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30418 : 30423	CPR	hytochemicals exhibiting anti-cancer, and in particular
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30449 : 30454	CPR	ancer, and in particular anti-angiogenesis activities. 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30812 : 30817	CPR	ently been evaluated for anti-lymphangiogenic and anti-
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30837 : 30842	CPR	anti-lymphangiogenic and anti-angiogenic properties in 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	30951 : 30956	CPR	hanisms underlying their anti-lymphangiogenic features 
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	31269 : 31274	CM	]; (2) the inhibition of COX-2 expression and IL-1beta 
./___Corpus/Medline/xml/PMC4737670.xml	IL-1beta	31290 : 31298	CM	 of COX-2 expression and IL-1beta production and the subse
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR-3	31357 : 31364	CM	uction in VEGF-C-induced VEGFR-3 phosphorylation, as obse
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	31365 : 31380	RN	n VEGF-C-induced VEGFR-3 phosphorylation, as observed with wogoni
./___Corpus/Medline/xml/PMC4737670.xml	wogonin	31399 : 31406	CM	lation, as observed with wogonin [113]; and (3) the down-
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR3	31445 : 31451	CM	) the down-regulation of VEGFR3 and small GTPases, as we
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR3	31500 : 31506	CM	ell as the inhibition of VEGFR3-mediated extracellular-s
./___Corpus/Medline/xml/PMC4737670.xml	(ERK)-1	31554 : 31561	CM	-signal regulated kinase (ERK)-1 and -2 phosphorylation b
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	31569 : 31584	RN	ed kinase (ERK)-1 and -2 phosphorylation by cryptotanshinone [114
./___Corpus/Medline/xml/PMC4737670.xml	anti-	31640 : 31645	CPR	 mechanisms behind their anti-angiogenic effects includ
./___Corpus/Medline/xml/PMC4737670.xml	MMPs	31691 : 31695	CM	clude: (1) inhibition of MMPs, (2) prevention of capil
./___Corpus/Medline/xml/PMC4737670.xml	MMP	31905 : 31908	CM	                         MMP inhibition blocks the de
./___Corpus/Medline/xml/PMC4737670.xml	MMP	32210 : 32213	CM	regarding the effects on MMP/tissue inhibitor of meta
./___Corpus/Medline/xml/PMC4737670.xml	TIMP	32254 : 32258	CM	r of metalloproteinases (TIMP) system as MMP inhibitor
./___Corpus/Medline/xml/PMC4737670.xml	MMP	32270 : 32273	CM	einases (TIMP) system as MMP inhibitors in clinical t
./___Corpus/Medline/xml/PMC4737670.xml	anti-	32458 : 32463	CPR	tudies have shown potent anti-tumorigenic activities of
./___Corpus/Medline/xml/PMC4737670.xml	MMPs	32494 : 32498	CM	genic activities of many MMPs including MMP-9 [116], [
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	32509 : 32514	CM	s of many MMPs including MMP-9 [116], [117], [118], [11
./___Corpus/Medline/xml/PMC4737670.xml	TIMPs	32572 : 32577	CM	], [121]. In the case of TIMPs both tumor protective an
./___Corpus/Medline/xml/PMC4737670.xml	TIMP-1	32749 : 32755	CM	umor and serum levels of TIMP-1 have been associated wit
./___Corpus/Medline/xml/PMC4737670.xml	mitogen	33265 : 33272	CM	nclude the modulation of mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4737670.xml	MAPK	33299 : 33303	CM	ctivated protein kinase (MAPK) and Akt signaling, inhi
./___Corpus/Medline/xml/PMC4737670.xml	(AP)-1	33356 : 33362	CM	ion of activator protein (AP)-1 activation, and the down
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	33402 : 33406	CM	d the down-regulation of VEGF, transforming growth fac
./___Corpus/Medline/xml/PMC4737670.xml	(TGF)-beta	33435 : 33445	CM	ansforming growth factor (TGF)-beta, MMP-9, as well as the u
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	33447 : 33452	CM	rowth factor (TGF)-beta, MMP-9, as well as the upregula
./___Corpus/Medline/xml/PMC4737670.xml	TIMP-1	33485 : 33491	CM	l as the upregulation of TIMP-1 which lead to reduction 
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	33617 : 33628	CM	                4.1. Tea polyphenols                      Tea
./___Corpus/Medline/xml/PMC4737670.xml	polyphenolic	33872 : 33884	CM	d to large quantities of polyphenolic compounds known as catec
./___Corpus/Medline/xml/PMC4737670.xml	EC	33942 : 33944	CM	ich include epicatechin (EC), epigallocatechin (EGC)
./___Corpus/Medline/xml/PMC4737670.xml	epicatechin-3-gallate	33971 : 33992	CM	 epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epigallocatec
./___Corpus/Medline/xml/PMC4737670.xml	ECG	33994 : 33997	CM	, epicatechin-3-gallate (ECG), and epigallocatechin-3
./___Corpus/Medline/xml/PMC4737670.xml	epigallocatechin-3-gallate	34004 : 34030	CM	hin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG) particularly in g
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34032 : 34036	CM	gallocatechin-3-gallate (EGCG) particularly in green t
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	34114 : 34125	CM	lavins in black tea. Tea polyphenols have been shown to act o
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34217 : 34221	CM	 pathways. For instance, EGCG has been found to direct
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34423 : 34427	CM	genesis inhibitor [133]. EGCG also inhibits VEGF produ
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	34442 : 34446	CM	133]. EGCG also inhibits VEGF production in MDA-MB231 
./___Corpus/Medline/xml/PMC4737670.xml	MDA-MB231	34461 : 34470	CM	ibits VEGF production in MDA-MB231 breast cancer cells and 
./___Corpus/Medline/xml/PMC4737670.xml	c-fos	34591 : 34596	CM	ion of protein kinase C, c-fos and c-jun RNA transcript
./___Corpus/Medline/xml/PMC4737670.xml	RNA	34607 : 34610	CM	inase C, c-fos and c-jun RNA transcripts, suggesting 
./___Corpus/Medline/xml/PMC4737670.xml	AP-1	34640 : 34644	CM	scripts, suggesting that AP-1 responsive regions prese
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	34685 : 34689	CM	ons present in the human VEGF promoter may be involved
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34817 : 34821	CM	an gastric cancer cells, EGCG inhibited MMP-2 and MMP-
./___Corpus/Medline/xml/PMC4737670.xml	MMP-2	34832 : 34837	CM	er cells, EGCG inhibited MMP-2 and MMP-9 while inducing
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	34842 : 34847	CM	EGCG inhibited MMP-2 and MMP-9 while inducing the activ
./___Corpus/Medline/xml/PMC4737670.xml	TIMP-1	34896 : 34902	CM	vity of their inhibitors TIMP-1 and TIMP-2 [135], [136],
./___Corpus/Medline/xml/PMC4737670.xml	TIMP-2	34907 : 34913	CM	ir inhibitors TIMP-1 and TIMP-2 [135], [136], [137], [13
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	34972 : 34976	CM	man breast cancer cells, EGCG treatment reduced MMP-2 
./___Corpus/Medline/xml/PMC4737670.xml	MMP-2	34995 : 35000	CM	, EGCG treatment reduced MMP-2 activity and the express
./___Corpus/Medline/xml/PMC4737670.xml	FAK	35055 : 35058	CM	f focal adhesion kinase (FAK), membrane type-1-MMP (M
./___Corpus/Medline/xml/PMC4737670.xml	MT1-MMP	35082 : 35089	CM	K), membrane type-1-MMP (MT1-MMP), nuclear factor (NF)-ka
./___Corpus/Medline/xml/PMC4737670.xml	(NF)-kappaB	35107 : 35118	CM	MT1-MMP), nuclear factor (NF)-kappaB, VEGF, and the adhesion 
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	35120 : 35124	CM	lear factor (NF)-kappaB, VEGF, and the adhesion of cel
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35267 : 35271	CM	rated in animal studies. EGCG also targets urokinase p
./___Corpus/Medline/xml/PMC4737670.xml	urokinase	35285 : 35294	CM	udies. EGCG also targets urokinase plasminogen activator (u
./___Corpus/Medline/xml/PMC4737670.xml	u-PA	35318 : 35322	CM	e plasminogen activator (u-PA), leading to a down-regu
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	35357 : 35361	CM	 to a down-regulation of VEGF production in tumor cell
./___Corpus/Medline/xml/PMC4737670.xml	AP-1	35417 : 35421	CM	subsequent repression of AP-1, NF-kappaB and signal tr
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	35423 : 35432	CM	uent repression of AP-1, NF-kappaB and signal transducer an
./___Corpus/Medline/xml/PMC4737670.xml	(STAT)-1	35486 : 35494	CM	tivator of transcription (STAT)-1 transcription factor pat
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35538 : 35542	CM	or pathway [140], [141]. EGCG furthermore inhibits ary
./___Corpus/Medline/xml/PMC4737670.xml	aryl hydrocarbon	35564 : 35580	CM	GCG furthermore inhibits aryl hydrocarbon receptor (AhR)-AhR-media
./___Corpus/Medline/xml/PMC4737670.xml	(AhR)-AhR	35590 : 35599	CM	ryl hydrocarbon receptor (AhR)-AhR-mediated transcription b
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	35637 : 35642	CM	nscription by binding to HSP90. Furthermore, a range of
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	35730 : 35734	CM	ves are more potent than EGCG in a luciferase refoldin
./___Corpus/Medline/xml/PMC4737670.xml	luciferase	35740 : 35750	CM	re potent than EGCG in a luciferase refolding assay for HSP9
./___Corpus/Medline/xml/PMC4737670.xml	HSP90	35771 : 35776	CM	rase refolding assay for HSP90 activity [106]. In trans
./___Corpus/Medline/xml/PMC4737670.xml	transgenic	35796 : 35806	CM	HSP90 activity [106]. In transgenic adenocarcinoma of the mo
./___Corpus/Medline/xml/PMC4737670.xml	TRAMP	35845 : 35850	CM	a of the mouse prostate (TRAMP) mice, green tea polyphe
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	35868 : 35878	CM	 (TRAMP) mice, green tea polyphenol infusion resulted in mar
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	35971 : 35975	CM	 and metastasis, notably VEGF, uPA, MMP-2, and MMP-9 [
./___Corpus/Medline/xml/PMC4737670.xml	uPA	35977 : 35980	CM	etastasis, notably VEGF, uPA, MMP-2, and MMP-9 [142].
./___Corpus/Medline/xml/PMC4737670.xml	MMP-2	35982 : 35987	CM	asis, notably VEGF, uPA, MMP-2, and MMP-9 [142]. In a d
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	35993 : 35998	CM	ly VEGF, uPA, MMP-2, and MMP-9 [142]. In a dimethylamin
./___Corpus/Medline/xml/PMC4737670.xml	dimethylaminoazobenzene	36011 : 36034	CM	2, and MMP-9 [142]. In a dimethylaminoazobenzene (DAB) induced hepatoma m
./___Corpus/Medline/xml/PMC4737670.xml	DAB	36036 : 36039	CM	dimethylaminoazobenzene (DAB) induced hepatoma model,
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	36093 : 36104	CM	inistration of black tea polyphenols not only reduced the inc
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	36219 : 36223	CM	esis [143]. In addition, EGCG targets tissue plasminog
./___Corpus/Medline/xml/PMC4737670.xml	plasminogen	36239 : 36250	CM	ion, EGCG targets tissue plasminogen activator (t-PA), which 
./___Corpus/Medline/xml/PMC4737670.xml	t-PA	36262 : 36266	CM	e plasminogen activator (t-PA), which is one of the cr
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	36517 : 36521	CM	y with the inhibition of VEGF, NF-kappaB, c-fos and cy
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	36523 : 36532	CM	 the inhibition of VEGF, NF-kappaB, c-fos and cyclin D1 pro
./___Corpus/Medline/xml/PMC4737670.xml	c-fos	36534 : 36539	CM	tion of VEGF, NF-kappaB, c-fos and cyclin D1 promoter a
./___Corpus/Medline/xml/PMC4737670.xml	cyclin	36544 : 36550	CM	GF, NF-kappaB, c-fos and cyclin D1 promoter activity, bu
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin

                    Curcumin	36670 : 36708	CM	].                  4.2. Curcumin                      Curcumin is a polyphenol isolated
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	36714 : 36724	CM	           Curcumin is a polyphenol isolated from Curcuma lo
./___Corpus/Medline/xml/PMC4737670.xml	Curcuma	36739 : 36746	CM	polyphenol isolated from Curcuma longa. As a yellow dye, 
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	36771 : 36779	CM	 longa. As a yellow dye, curcumin has been used widely for
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	36926 : 36934	CM	y inflammatory diseases. Curcumin and tetrahydro-curcumin,
./___Corpus/Medline/xml/PMC4737670.xml	tetrahydro	36939 : 36949	CM	y diseases. Curcumin and tetrahydro-curcumin, one of its met
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	36950 : 36958	CM	 Curcumin and tetrahydro-curcumin, one of its metabolites 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37021 : 37026	CPR	ensively investigated as anti-inflammatory and anti-can
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37043 : 37048	CPR	as anti-inflammatory and anti-cancer molecules [147], [
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	37079 : 37087	CM	 molecules [147], [148]. Curcumin inhibits the expression 
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR-1	37156 : 37163	CM	 factor receptor (EGFR), VEGFR-1, VEGFR-2 and VEGFR-3, an
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR-3	37177 : 37184	CM	R), VEGFR-1, VEGFR-2 and VEGFR-3, and the kinase activity
./___Corpus/Medline/xml/PMC4737670.xml	FAK	37221 : 37224	CM	nase activity of Src and FAK, which are responsible f
./___Corpus/Medline/xml/PMC4737670.xml	Curcumin	37344 : 37352	CM	ity and migration [149]. Curcumin also reduces the MMP-2 a
./___Corpus/Medline/xml/PMC4737670.xml	MMP-2	37370 : 37375	CM	urcumin also reduces the MMP-2 and MMP-9 expression, al
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	37380 : 37385	CM	so reduces the MMP-2 and MMP-9 expression, along with t
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	37540 : 37548	CM	. Oral administration of curcumin in nude mice xenografted
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	37700 : 37705	CM	of angiogenic biomarkers COX-2 and serum levels of VEGF
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	37726 : 37730	CM	OX-2 and serum levels of VEGF were significantly reduc
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	37765 : 37773	CM	ificantly reduced in the curcumin-treated group [151]. Thi
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	37819 : 37823	CM	 This inhibition of both VEGF and VEGFR in different c
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR	37828 : 37833	CM	ibition of both VEGF and VEGFR in different cancers, ha
./___Corpus/Medline/xml/PMC4737670.xml	anti-	37939 : 37944	CPR	tigations as a potential anti-angiogenesis agent [152].
./___Corpus/Medline/xml/PMC4737670.xml	Resveratrol

                    Resveratrol	37992 : 38036	CM	].                  4.3. Resveratrol                      Resveratrol (3,4′,5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4737670.xml	3,4′,5-trihydroxy-trans-stilbene	38038 : 38070	CM	            Resveratrol (3,4′,5-trihydroxy-trans-stilbene), a dietary polyphenol d
./___Corpus/Medline/xml/PMC4737670.xml	polyphenol	38083 : 38093	CM	ans-stilbene), a dietary polyphenol derived from grapes, ber
./___Corpus/Medline/xml/PMC4737670.xml	Resveratrol	38272 : 38283	CM	sis [153], [154], [155]. Resveratrol inhibits capillary endot
./___Corpus/Medline/xml/PMC4737670.xml	diethylnitrosamine	38390 : 38408	CM	 [130]. It also prevents diethylnitrosamine-initiated and phenobarbi
./___Corpus/Medline/xml/PMC4737670.xml	phenobarbital	38423 : 38436	CM	itrosamine-initiated and phenobarbital-promoted hepatocarcinoge
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	38582 : 38586	CM	iogenesis by suppressing VEGF expression through down-
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	38625 : 38635	CM	rough down-regulation of HIF-1alpha [156]. In in vitro studi
./___Corpus/Medline/xml/PMC4737670.xml	vitro	38649 : 38654	CM	 HIF-1alpha [156]. In in vitro studies, resveratrol was
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	38664 : 38675	CM	6]. In in vitro studies, resveratrol was reported to inhibit 
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	38793 : 38803	CM	oma cells by attenuating HIF-1alpha [157], [158]. Through ab
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	38840 : 38844	CM	]. Through abrogation of VEGF-mediated tyrosine phosph
./___Corpus/Medline/xml/PMC4737670.xml	tyrosine	38854 : 38862	CM	ogation of VEGF-mediated tyrosine phosphorylation of vascu
./___Corpus/Medline/xml/PMC4737670.xml	phosphorylation	38863 : 38878	RN	f VEGF-mediated tyrosine phosphorylation of vascular endothelial 
./___Corpus/Medline/xml/PMC4737670.xml	beta-catenin	38917 : 38929	CM	ndothelial cadherins and beta-catenin, resveratrol further pre
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	38931 : 38942	CM	herins and beta-catenin, resveratrol further prevents cytokin
./___Corpus/Medline/xml/PMC4737670.xml	cytokine	38960 : 38968	CM	eratrol further prevents cytokine-induced vascular leakage
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	39076 : 39080	CM	anisms include: blocking VEGF- and FGF-receptor-mediat
./___Corpus/Medline/xml/PMC4737670.xml	MAPK	39108 : 39112	CM	nd FGF-receptor-mediated MAPK activation, inhibiting A
./___Corpus/Medline/xml/PMC4737670.xml	Akt	39136 : 39139	CM	K activation, inhibiting Akt- and MAPK-driven HIF-1al
./___Corpus/Medline/xml/PMC4737670.xml	MAPK	39145 : 39149	CM	ion, inhibiting Akt- and MAPK-driven HIF-1alpha basal 
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39157 : 39167	CM	ing Akt- and MAPK-driven HIF-1alpha basal expression and its
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39256 : 39266	CM	oteasomal degradation of HIF-1alpha, inhibiting phosphatidyl
./___Corpus/Medline/xml/PMC4737670.xml	phosphatidyl inositol (PI)-3K	39279 : 39308	CM	f HIF-1alpha, inhibiting phosphatidyl inositol (PI)-3K/Akt and Ras/mitogen/extr
./___Corpus/Medline/xml/PMC4737670.xml	mitogen	39321 : 39328	CM	itol (PI)-3K/Akt and Ras/mitogen/extracellular signal-reg
./___Corpus/Medline/xml/PMC4737670.xml	MEK	39368 : 39371	CM	signal-regulated kinase (MEK)/ERK pathways, and activ
./___Corpus/Medline/xml/PMC4737670.xml	ERK	39373 : 39376	CM	l-regulated kinase (MEK)/ERK pathways, and activation
./___Corpus/Medline/xml/PMC4737670.xml	(FOX)O	39418 : 39424	CM	tivation of forkhead box (FOX)O transcription factors [1
./___Corpus/Medline/xml/PMC4737670.xml	stilbene	39540 : 39548	CM	rthermore, the synthetic stilbene derivatives of resveratr
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39564 : 39575	CM	 stilbene derivatives of resveratrol have stronger inhibitory
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39629 : 39640	CM	ect on angiogenesis than resveratrol, as measured by cell pro
./___Corpus/Medline/xml/PMC4737670.xml	stilbene	39754 : 39762	CM	[160]. For instance, the stilbene derivative rhapoantigeni
./___Corpus/Medline/xml/PMC4737670.xml	HIF-1alpha	39854 : 39864	CM	ate cancer cells through HIF-1alpha degradation [161]. Likew
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	39894 : 39905	CM	adation [161]. Likewise, resveratrol and a series of natural 
./___Corpus/Medline/xml/PMC4737670.xml	stilbenes	39943 : 39952	CM	 of natural or synthetic stilbenes inhibit the growth of co
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	40030 : 40034	CM	e through attenuation of VEGF and pro-MMP-9 [162]. Whi
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	40142 : 40153	CM	y different indications, resveratrol is yet to be clinically 
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	40288 : 40298	CM	s.                  4.4. Flavonoids                      In 
./___Corpus/Medline/xml/PMC4737670.xml	polyphenols	40337 : 40348	CM	        In the family of polyphenols, flavonoids have been fo
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	40350 : 40360	CM	e family of polyphenols, flavonoids have been found to suppr
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40407 : 40412	CPR	ppress tumorigenesis via anti-angiogenesis, anti-oxidan
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40426 : 40431	CPR	s via anti-angiogenesis, anti-oxidant as well as anti-p
./___Corpus/Medline/xml/PMC4737670.xml	anti-	40450 : 40455	CPR	 anti-oxidant as well as anti-proliferation effects on 
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	40571 : 40581	CM	lial cells [163], [164]. Flavonoids, including flavones (api
./___Corpus/Medline/xml/PMC4737670.xml	flavones	40593 : 40601	CM	]. Flavonoids, including flavones (apigenin, luteolin), fl
./___Corpus/Medline/xml/PMC4737670.xml	apigenin	40603 : 40611	CM	ids, including flavones (apigenin, luteolin), flavanols (q
./___Corpus/Medline/xml/PMC4737670.xml	luteolin	40613 : 40621	CM	ding flavones (apigenin, luteolin), flavanols (quercetin, 
./___Corpus/Medline/xml/PMC4737670.xml	flavanols	40624 : 40633	CM	es (apigenin, luteolin), flavanols (quercetin, kaempferol),
./___Corpus/Medline/xml/PMC4737670.xml	quercetin	40635 : 40644	CM	n, luteolin), flavanols (quercetin, kaempferol), flavanones
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	40646 : 40656	CM	), flavanols (quercetin, kaempferol), flavanones (hesperetin
./___Corpus/Medline/xml/PMC4737670.xml	flavanones	40659 : 40669	CM	(quercetin, kaempferol), flavanones (hesperetin, naringenin)
./___Corpus/Medline/xml/PMC4737670.xml	hesperetin	40671 : 40681	CM	kaempferol), flavanones (hesperetin, naringenin), anthocyani
./___Corpus/Medline/xml/PMC4737670.xml	naringenin	40683 : 40693	CM	 flavanones (hesperetin, naringenin), anthocyanins (cyanidin
./___Corpus/Medline/xml/PMC4737670.xml	anthocyanins	40696 : 40708	CM	hesperetin, naringenin), anthocyanins (cyanidin, delphinidin) 
./___Corpus/Medline/xml/PMC4737670.xml	cyanidin	40710 : 40718	CM	ringenin), anthocyanins (cyanidin, delphinidin) and isofla
./___Corpus/Medline/xml/PMC4737670.xml	delphinidin	40720 : 40731	CM	 anthocyanins (cyanidin, delphinidin) and isoflavones (geneis
./___Corpus/Medline/xml/PMC4737670.xml	isoflavones	40737 : 40748	CM	anidin, delphinidin) and isoflavones (geneistein, daidzein) f
./___Corpus/Medline/xml/PMC4737670.xml	daidzein	40762 : 40770	CM	isoflavones (geneistein, daidzein) function as scavengers 
./___Corpus/Medline/xml/PMC4737670.xml	ROS	40829 : 40832	CM	adicals and thus inhibit ROS formation and hypoxia-si
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	40884 : 40889	CM	aling cascades, modulate COX-2, and inhibit EGFR, IGFR-
./___Corpus/Medline/xml/PMC4737670.xml	EGFR	40903 : 40907	CM	ulate COX-2, and inhibit EGFR, IGFR-1 and NF-kappaB si
./___Corpus/Medline/xml/PMC4737670.xml	IGFR-1	40909 : 40915	CM	COX-2, and inhibit EGFR, IGFR-1 and NF-kappaB signaling 
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	40920 : 40929	CM	inhibit EGFR, IGFR-1 and NF-kappaB signaling pathways [165]
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	40970 : 40980	CM	ays [165]. For instance, kaempferol (3,5,7-trihydroxy-2-(4-h
./___Corpus/Medline/xml/PMC4737670.xml	3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one	40982 : 41040	CM	or instance, kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) has been reported to re
./___Corpus/Medline/xml/PMC4737670.xml	Kaempferol	41104 : 41114	CM	ancer risk [166], [167]. Kaempferol exhibits anti-inflammato
./___Corpus/Medline/xml/PMC4737670.xml	anti-	41124 : 41129	CPR	67]. Kaempferol exhibits anti-inflammatory effects thro
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	41187 : 41192	CM	bition of IL-4 [168] and COX-2 expression by suppressin
./___Corpus/Medline/xml/PMC4737670.xml	NF-kappaB	41268 : 41277	CM	rther down-regulates the NF-kappaB pathway [170]. Flavonoid
./___Corpus/Medline/xml/PMC4737670.xml	Flavonoids	41293 : 41303	CM	NF-kappaB pathway [170]. Flavonoids furthermore inhibit angi
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	41397 : 41402	CM	ing interaction with the COX-2 and lipoxygenase-5 enzym
./___Corpus/Medline/xml/PMC4737670.xml	lipoxygenase-5	41407 : 41421	CM	ction with the COX-2 and lipoxygenase-5 enzymes, EGFR and the hu
./___Corpus/Medline/xml/PMC4737670.xml	EGFR	41431 : 41435	CM	 lipoxygenase-5 enzymes, EGFR and the human epidermal 
./___Corpus/Medline/xml/PMC4737670.xml	(HER)-2	41483 : 41490	CM	l growth factor receptor (HER)-2 intracellular signaling 
./___Corpus/Medline/xml/PMC4737670.xml	MMP-2	41813 : 41818	CM	d that silibinin inhibit MMP-2 expression and suppresse
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	41982 : 41992	CM	ther naturally occurring flavonoids have been showing anti-a
./___Corpus/Medline/xml/PMC4737670.xml	anti-	42011 : 42016	CPR	onoids have been showing anti-angiogenesis and anti-oxi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	42033 : 42038	CPR	ng anti-angiogenesis and anti-oxidant effects via inter
./___Corpus/Medline/xml/PMC4737670.xml	myricetin	42117 : 42126	CM	g pathways. For example, myricetin has been shown to inhibi
./___Corpus/Medline/xml/PMC4737670.xml	I-kappaBalpha	42229 : 42242	CM	d prevent degradation of I-kappaBalpha and I-kappakBbeta in tum
./___Corpus/Medline/xml/PMC4737670.xml	I-kappakBbeta	42247 : 42260	CM	ion of I-kappaBalpha and I-kappakBbeta in tumor necrosis factor
./___Corpus/Medline/xml/PMC4737670.xml	Sulforaphane	42327 : 42339	CM	endothelial cells [175]. Sulforaphane has been demonstrated to
./___Corpus/Medline/xml/PMC4737670.xml	VEGFR2	42373 : 42379	CM	 demonstrated to inhibit VEGFR2 at the transcriptional l
./___Corpus/Medline/xml/PMC4737670.xml	licochalcone A	42479 : 42493	CM	Studies also showed that licochalcone A (LicA), a major constitu
./___Corpus/Medline/xml/PMC4737670.xml	Glycyrrhiza	42525 : 42536	CM	, a major constituent of Glycyrrhiza inflata, significantly i
./___Corpus/Medline/xml/PMC4737670.xml	CT-26	42732 : 42737	CM	y inhibits the growth of CT-26 colon cancer implants in
./___Corpus/Medline/xml/PMC4737670.xml	BALB	42763 : 42767	CM	colon cancer implants in BALB/c mice, with fewer CD31-
./___Corpus/Medline/xml/PMC4737670.xml	CD31	42787 : 42791	CM	 BALB/c mice, with fewer CD31- and Ki-67-positive cell
./___Corpus/Medline/xml/PMC4737670.xml	flavonoid	42877 : 42886	CM	oliquiritigenin, another flavonoid found in G. inflata inhi
./___Corpus/Medline/xml/PMC4737670.xml	DU145	42976 : 42981	CM	n prostate cancer cells (DU145 and LNCaP) mediated by d
./___Corpus/Medline/xml/PMC4737670.xml	LNCaP	42986 : 42991	CM	 cancer cells (DU145 and LNCaP) mediated by decreased c
./___Corpus/Medline/xml/PMC4737670.xml	N-	43022 : 43024	CPR	ated by decreased c-Jun N-terminal kinase (JNK)/AP-1
./___Corpus/Medline/xml/PMC4737670.xml	AP-1	43045 : 43049	CM	 N-terminal kinase (JNK)/AP-1 signaling and reduced pr
./___Corpus/Medline/xml/PMC4737670.xml	flavonoids	43168 : 43178	CM	gs provide evidence that flavonoids inhibit angiogenesis in 
./___Corpus/Medline/xml/PMC4737670.xml	vitro	43203 : 43208	CM	 inhibit angiogenesis in vitro and in vivo, via antioxi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43239 : 43244	CPR	n vivo, via antioxidant, anti-inflammatory and anti-ang
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43261 : 43266	CPR	t, anti-inflammatory and anti-angiogenic signaling path
./___Corpus/Medline/xml/PMC4737670.xml	Terpenoids	43351 : 43361	CM	ids                      Terpenoids are the most diverse con
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43507 : 43512	CPR	 and sterols, exhibiting anti-inflammatory and anti-car
./___Corpus/Medline/xml/PMC4737670.xml	anti-	43529 : 43534	CPR	ng anti-inflammatory and anti-carcinogenic properties [
./___Corpus/Medline/xml/PMC4737670.xml	terpenoid	43644 : 43653	CM	           The bioactive terpenoid, tripterine, also known 
./___Corpus/Medline/xml/PMC4737670.xml	tripterine	43655 : 43665	CM	The bioactive terpenoid, tripterine, also known as celastrol
./___Corpus/Medline/xml/PMC4737670.xml	quinine methide	43694 : 43709	CM	so known as celastrol, a quinine methide triterpenoid is the most
./___Corpus/Medline/xml/PMC4737670.xml	Trypterigium	43788 : 43800	CM	derived from the root of Trypterigium wilfordii. Tripterine mo
./___Corpus/Medline/xml/PMC4737670.xml	Tripterine	43812 : 43822	CM	 Trypterigium wilfordii. Tripterine modulates the expression
./___Corpus/Medline/xml/PMC4737670.xml	MMP-9	43903 : 43908	CM	d metastatic activities (MMP-9, intercellular adhesion 
./___Corpus/Medline/xml/PMC4737670.xml	(ICAM)-1	43942 : 43950	CM	llular adhesion molecule (ICAM)-1, VEGF) and those involve
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	43952 : 43956	CM	esion molecule (ICAM)-1, VEGF) and those involved in c
./___Corpus/Medline/xml/PMC4737670.xml	(IAP)-1	44026 : 44033	CM	tor of apoptosis protein (IAP)-1, X-linked (X)-IAP, B-cel
./___Corpus/Medline/xml/PMC4737670.xml	X	44035 : 44036	CM	optosis protein (IAP)-1, X-linked (X)-IAP, B-cell l
./___Corpus/Medline/xml/PMC4737670.xml	(X)-IAP	44044 : 44051	CM	rotein (IAP)-1, X-linked (X)-IAP, B-cell lymphoma (Bcl)-2
./___Corpus/Medline/xml/PMC4737670.xml	(Bcl)-2	44069 : 44076	CM	(X)-IAP, B-cell lymphoma (Bcl)-2, Bcl-xL, flice inhibitor
./___Corpus/Medline/xml/PMC4737670.xml	cyclin	44153 : 44159	CM	) or cell proliferation (cyclin D1, COX-2) in tumor cell
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	44164 : 44169	CM	roliferation (cyclin D1, COX-2) in tumor cells [183], [
./___Corpus/Medline/xml/PMC4737670.xml	anti-	44250 : 44255	CPR	idence for its potential anti-angiogenic and anti-tumor
./___Corpus/Medline/xml/PMC4737670.xml	anti-	44270 : 44275	CPR	tial anti-angiogenic and anti-tumor activities.        
./___Corpus/Medline/xml/PMC4737670.xml	Escin	44331 : 44336	CM	                         Escin is a pentacyclic triterp
./___Corpus/Medline/xml/PMC4737670.xml	pentacyclic	44342 : 44353	CM	              Escin is a pentacyclic triterpenoid which is is
./___Corpus/Medline/xml/PMC4737670.xml	sodium	44457 : 44463	CM	 chestnuts) [185]. Escin sodium has been shown to inhibi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	44536 : 44541	CPR	ation and motility. This anti-angiogenic activity was m
./___Corpus/Medline/xml/PMC4737670.xml	ERK	44595 : 44598	CM	ted partly by inhibiting ERK and p38 MAPK pathways, w
./___Corpus/Medline/xml/PMC4737670.xml	MAPK	44607 : 44611	CM	y inhibiting ERK and p38 MAPK pathways, which are invo
./___Corpus/Medline/xml/PMC4737670.xml	steroidal	44756 : 44765	CJ	 Withaferin A is a major steroidal lactone constituent of t
./___Corpus/Medline/xml/PMC4737670.xml	lactone	44766 : 44773	CM	n A is a major steroidal lactone constituent of the medic
./___Corpus/Medline/xml/PMC4737670.xml	anti-	44993 : 44998	CPR	thaferin A exerts potent anti-angiogenic activity in vi
./___Corpus/Medline/xml/PMC4737670.xml	500-	45034 : 45038	CPR	activity in vivo even at 500-times lower dose than tha
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45081 : 45086	CPR	han that exerting direct anti-tumor activity [188], [18
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45151 : 45156	CPR	nds toward a more potent anti-angiogenic rather than an
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45179 : 45184	CPR	i-angiogenic rather than anti-tumorigenic effects are a
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	45256 : 45267	CM	 phytochemicals (such as tubulysin A as discussed below) sugg
./___Corpus/Medline/xml/PMC4737670.xml	carotenoids	45428 : 45439	CM	            In addition, carotenoids have anti-cancer activit
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45445 : 45450	CPR	dition, carotenoids have anti-cancer activity in breast
./___Corpus/Medline/xml/PMC4737670.xml	alpha-carotene	45528 : 45542	CM	arotenoid group includes alpha-carotene, beta-carotene, lycopene
./___Corpus/Medline/xml/PMC4737670.xml	beta-carotene	45544 : 45557	CM	includes alpha-carotene, beta-carotene, lycopene, lutein, astax
./___Corpus/Medline/xml/PMC4737670.xml	lycopene	45559 : 45567	CM	carotene, beta-carotene, lycopene, lutein, astaxanthin, cr
./___Corpus/Medline/xml/PMC4737670.xml	lutein	45569 : 45575	CM	beta-carotene, lycopene, lutein, astaxanthin, cryptoxant
./___Corpus/Medline/xml/PMC4737670.xml	cryptoxanthin	45590 : 45603	CM	ne, lutein, astaxanthin, cryptoxanthin and zeaxanthin [190], [1
./___Corpus/Medline/xml/PMC4737670.xml	zeaxanthin	45608 : 45618	CM	nthin, cryptoxanthin and zeaxanthin [190], [191]. The anti-o
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45637 : 45642	CPR	anthin [190], [191]. The anti-oxidant action is one of 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	45699 : 45704	CPR	sumed mechanisms for the anti-angiogenic effects of the
./___Corpus/Medline/xml/PMC4737670.xml	carotenoids	45730 : 45741	CM	ngiogenic effects of the carotenoids.                  4.6. P
./___Corpus/Medline/xml/PMC4737670.xml	Phytoestrogens	45765 : 45779	CM	s.                  4.6. Phytoestrogens                      Phy
./___Corpus/Medline/xml/PMC4737670.xml	Phytoestrogens	45801 : 45815	CM	ens                      Phytoestrogens are plant compounds whic
./___Corpus/Medline/xml/PMC4737670.xml	estrogen	45870 : 45878	CM	 structurally similar to estrogen. Thereby, these compound
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46051 : 46065	CM	are two major classes of phytoestrogens, isoflavones, found in s
./___Corpus/Medline/xml/PMC4737670.xml	isoflavones	46067 : 46078	CM	asses of phytoestrogens, isoflavones, found in soy at high co
./___Corpus/Medline/xml/PMC4737670.xml	isoflavone	46340 : 46350	CM	), the representative of isoflavone, and enterolactone (ENL)
./___Corpus/Medline/xml/PMC4737670.xml	enterolactone	46356 : 46369	CM	ative of isoflavone, and enterolactone (ENL) is the main active
./___Corpus/Medline/xml/PMC4737670.xml	ENL	46371 : 46374	CM	vone, and enterolactone (ENL) is the main active and 
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46590 : 46604	CM	ontains large amounts of phytoestrogens, and accordingly, the in
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46724 : 46738	CM	95], [196]. In the diet, phytoestrogens are consumed in combinat
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	46779 : 46793	CM	 combination and various phytoestrogens may have different effec
./___Corpus/Medline/xml/PMC4737670.xml	vitro	46940 : 46945	CM	ous cancer cell types in vitro [197]. However, the pro-
./___Corpus/Medline/xml/PMC4737670.xml	estrogenic	46970 : 46980	CM	 [197]. However, the pro-estrogenic effects of GEN in breast
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogen	47061 : 47074	CM	ion with this particular phytoestrogen in hormone-dependent can
./___Corpus/Medline/xml/PMC4737670.xml	lignan	47156 : 47162	CM	as the major circulating lignan in the human body, the m
./___Corpus/Medline/xml/PMC4737670.xml	ENL	47233 : 47236	CM	gnans are converted into ENL. ENL inhibits cancer gro
./___Corpus/Medline/xml/PMC4737670.xml	ENL	47238 : 47241	CM	 are converted into ENL. ENL inhibits cancer growth i
./___Corpus/Medline/xml/PMC4737670.xml	As	47486 : 47488	CM	ues                      As outlined above, there is
./___Corpus/Medline/xml/PMC4737670.xml	anti-	47641 : 47646	CPR	ticularly with regard to anti-angiogenesis. Furthermore
./___Corpus/Medline/xml/PMC4737670.xml	anti-	47711 : 47716	CPR	molecules exhibit potent anti-angiogenic activity simil
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	47819 : 47827	CM	linical use. For example curcumin, EGCG, finasteride and b
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	47829 : 47833	CM	e. For example curcumin, EGCG, finasteride and barrigt
./___Corpus/Medline/xml/PMC4737670.xml	finasteride	47835 : 47846	CM	 example curcumin, EGCG, finasteride and barrigtozenol demons
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	47900 : 47904	CM	ed comparable effects on VEGF receptor inactivation as
./___Corpus/Medline/xml/PMC4737670.xml	pazopanib	47930 : 47939	CM	receptor inactivation as pazopanib, the reference drug [202
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	47973 : 47981	CM	erence drug [202]. 10 μM curcumin significantly inhibited 
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	48006 : 48010	CM	 significantly inhibited VEGF-induced HUVEC migration 
./___Corpus/Medline/xml/PMC4737670.xml	HUVEC	48019 : 48024	CM	y inhibited VEGF-induced HUVEC migration to a higher de
./___Corpus/Medline/xml/PMC4737670.xml	anti-	48103 : 48108	CPR	entration of a synthetic anti-angiogenic agent – the se
./___Corpus/Medline/xml/PMC4737670.xml	PDE4	48141 : 48145	CM	ic agent – the selective PDE4 inhibitor rolipram (41%)
./___Corpus/Medline/xml/PMC4737670.xml	rolipram	48156 : 48164	CM	selective PDE4 inhibitor rolipram (41%) [203]. Furthermore
./___Corpus/Medline/xml/PMC4737670.xml	EC50	48195 : 48199	CM	 [203]. Furthermore, the EC50 dose–responses are usual
./___Corpus/Medline/xml/PMC4737670.xml	anti-	48237 : 48242	CPR	es are usually lower for anti-angiogenic effects vs. cy
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	48352 : 48363	CM	al products. For example tubulysin A, a natural compound of m
./___Corpus/Medline/xml/PMC4737670.xml	myxobacterial	48387 : 48400	CM	A, a natural compound of myxobacterial origin, which inhibits t
./___Corpus/Medline/xml/PMC4737670.xml	tubulin	48424 : 48431	CM	l origin, which inhibits tubulin polymerization has an EC
./___Corpus/Medline/xml/PMC4737670.xml	EC50	48454 : 48458	CM	in polymerization has an EC50 for endothelial cell pro
./___Corpus/Medline/xml/PMC4737670.xml	tubulysin A	48592 : 48603	CM	e synthetic derivates of tubulysin A, AU816 and JB337, exhibi
./___Corpus/Medline/xml/PMC4737670.xml	AU816	48605 : 48610	CM	erivates of tubulysin A, AU816 and JB337, exhibit simil
./___Corpus/Medline/xml/PMC4737670.xml	JB337	48615 : 48620	CM	f tubulysin A, AU816 and JB337, exhibit similar differe
./___Corpus/Medline/xml/PMC4737670.xml	EC50	48651 : 48655	CM	bit similar differences; EC50 of AU816 for endothelial
./___Corpus/Medline/xml/PMC4737670.xml	AU816	48659 : 48664	CM	lar differences; EC50 of AU816 for endothelial cell pro
./___Corpus/Medline/xml/PMC4737670.xml	JB337	48776 : 48781	CM	eration is 10 nM and for JB337 the EC50 levels are 14 n
./___Corpus/Medline/xml/PMC4737670.xml	EC50	48786 : 48790	CM	 10 nM and for JB337 the EC50 levels are 14 nM compare
./___Corpus/Medline/xml/PMC4737670.xml	water	48975 : 48980	CM	phytochemicals have poor water solubility and low bioav
./___Corpus/Medline/xml/PMC4737670.xml	anti-	49530 : 49535	CPR	r example in the case of anti-lymphatic drugs, nano-car
./___Corpus/Medline/xml/PMC4737670.xml	anti-	49921 : 49926	CPR	ntly for the delivery of anti-cancer phytochemicals [20
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	50016 : 50020	CM	d that nano-encapsulated EGCG retains its biological e
./___Corpus/Medline/xml/PMC4737670.xml	10-fold	50069 : 50076	CM	effectiveness, with over 10-fold dose advantage compared 
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	50120 : 50124	CM	pared to nonencapsulated EGCG for exerting its pro-apo
./___Corpus/Medline/xml/PMC4737670.xml	anti-	50161 : 50166	CPR	g its pro-apoptotic, and anti-angiogenic effects. Encap
./___Corpus/Medline/xml/PMC4737670.xml	kaempferol	50203 : 50213	CM	ffects. Encapsulation of kaempferol with nanoparticles signi
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	50398 : 50406	CM	rmore, nano-encapsulated curcumin has increased in vivo tu
./___Corpus/Medline/xml/PMC4737670.xml	anti-	50435 : 50440	CPR	 increased in vivo tumor anti-angiogenic activity relat
./___Corpus/Medline/xml/PMC4737670.xml	lipid	50511 : 50516	CM	ulated form [211]. Solid lipid nano-encapsulation of be
./___Corpus/Medline/xml/PMC4737670.xml	berbarine	50539 : 50548	CM	id nano-encapsulation of berbarine also increased inhibitio
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51230 : 51244	CM	arly useful in rendering oleanolic acid attractive for therapeut
./___Corpus/Medline/xml/PMC4737670.xml	Oleanolic acid	51286 : 51300	CM	herapeutic applications. Oleanolic acid is an oleanane-type trit
./___Corpus/Medline/xml/PMC4737670.xml	oleanane	51307 : 51315	CM	ns. Oleanolic acid is an oleanane-type triterpenoid that i
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51420 : 51434	CM	tudies demonstrated that oleanolic acid has anti-angiogenic effe
./___Corpus/Medline/xml/PMC4737670.xml	anti-	51439 : 51444	CPR	 that oleanolic acid has anti-angiogenic effects on bov
./___Corpus/Medline/xml/PMC4737670.xml	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	51569 : 51613	CM	ne assay [214]. However, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), the synthetic de
./___Corpus/Medline/xml/PMC4737670.xml	CDDO	51615 : 51619	CM	an-1,9-dien-28-oic acid (CDDO), the synthetic derivati
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	51650 : 51664	CM	 synthetic derivative of oleanolic acid, its C-28 methyl ester (
./___Corpus/Medline/xml/PMC4737670.xml	methyl ester	51675 : 51687	CM	oleanolic acid, its C-28 methyl ester (CDDO-Me) and C-28 imida
./___Corpus/Medline/xml/PMC4737670.xml	CDDO-Me	51689 : 51696	CM	, its C-28 methyl ester (CDDO-Me) and C-28 imidazole (CDD
./___Corpus/Medline/xml/PMC4737670.xml	imidazole	51707 : 51716	CM	ester (CDDO-Me) and C-28 imidazole (CDDO-Im), are all shown
./___Corpus/Medline/xml/PMC4737670.xml	CDDO-Im	51718 : 51725	CM	-Me) and C-28 imidazole (CDDO-Im), are all shown to be po
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	51962 : 51966	CM	Matrigel and inhibit the VEGF-induced ERK-1 and -2 pat
./___Corpus/Medline/xml/PMC4737670.xml	ERK-1	51975 : 51980	CM	inhibit the VEGF-induced ERK-1 and -2 pathway in HUVECs
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	52047 : 52052	CM	 has been suggested that COX-2 overexpression may lead 
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	52152 : 52157	CM	efore, inhibition of the COX-2 pathway might prevent ca
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52216 : 52221	CPR	sis and angiogenesis via anti-inflammatory signaling. F
./___Corpus/Medline/xml/PMC4737670.xml	CDDO-Me	52258 : 52265	CM	 signaling. For example, CDDO-Me has been shown as an eff
./___Corpus/Medline/xml/PMC4737670.xml	COX-2	52310 : 52315	CM	n effective inhibitor of COX-2 and tumor growth in brea
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52539 : 52544	CPR	ytochemicals, as a novel anti-tumor treatment option in
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52598 : 52603	CPR	 future. Moreover, their anti-angiogenic properties cou
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52761 : 52766	CPR	ants in combination with anti-angiogenic drugs is promi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	52855 : 52860	CPR	 a deleterious result of anti-angiogenic cancer treatme
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	53167 : 53171	CM	l antioxidants including EGCG, melatonin, resveratrol 
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	53173 : 53182	CM	oxidants including EGCG, melatonin, resveratrol and silibin
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	53184 : 53195	CM	cluding EGCG, melatonin, resveratrol and silibinin [143], [15
./___Corpus/Medline/xml/PMC4737670.xml	anti-	53403 : 53408	CPR	ould be the very goal of anti-angiogenic treatment and 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	53673 : 53678	CPR	 poorer outcome from the anti-angiogenic treatment. Als
./___Corpus/Medline/xml/PMC4737670.xml	anti-	53787 : 53792	CPR	nesis the combination of anti-inflammatory phytochemica
./___Corpus/Medline/xml/PMC4737670.xml	anti-	53825 : 53830	CPR	tory phytochemicals with anti-angiogenic drugs may prov
./___Corpus/Medline/xml/PMC4737670.xml	anti-	54061 : 54066	CPR	 cells are thought to be anti-tumorigenic and important
./___Corpus/Medline/xml/PMC4737670.xml	late	54463 : 54467	CM	is not only required for late-stage progressive diseas
./___Corpus/Medline/xml/PMC4737670.xml	anti-	54979 : 54984	CPR	ever also aim to achieve anti-angiogenic treatment effi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	55210 : 55215	CPR	st appropriate drugs for anti-angiogenic treatment in c
./___Corpus/Medline/xml/PMC4737670.xml	anti-	55301 : 55306	CPR	0 suitable, prototypical anti-angiogenic therapeutic ap
./___Corpus/Medline/xml/PMC4737670.xml	anti-	55849 : 55854	CPR	may not achieve the full anti-angiogenic function, a mi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	56142 : 56147	CPR	cessfully applied to the anti-angiogenic treatment of p
./___Corpus/Medline/xml/PMC4737670.xml	anti-	56632 : 56637	CPR	safer than the synthetic anti-angiogenesis inhibitors i
./___Corpus/Medline/xml/PMC4737670.xml	prophylactic	56726 : 56738	CM	ay even be considered as prophylactic (angioprevention) agents
./___Corpus/Medline/xml/PMC4737670.xml	anti-	57326 : 57331	CPR	-agent therapies such as anti-VEGF drugs, the cocktail 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	57541 : 57546	CPR	o commercially available anti-VEGF drugs.              
./___Corpus/Medline/xml/PMC4737670.xml	anti-	58846 : 58851	CPR	igm of phytochemicals as anti-angiogenic treatment opti
./___Corpus/Medline/xml/PMC4737670.xml	anti-	59360 : 59365	CPR	e identified targets for anti-angiogenic therapy and th
./___Corpus/Medline/xml/PMC4737670.xml	anti-	60345 : 60350	CPR	ts showing both pro- and anti-potential), the effects a
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61066 : 61077	CM	, our suggested approach resveratrol was found to both inhibi
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61192 : 61203	CM	e cell intersecting the “resveratrol” column with the “Invasi
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61639 : 61644	CPR	effective as alternative anti-angiogenic agents while a
./___Corpus/Medline/xml/PMC4737670.xml	oleanolic acid	61755 : 61769	CM	he same time. Especially oleanolic acid, silibinin, curcumin, EG
./___Corpus/Medline/xml/PMC4737670.xml	curcumin	61782 : 61790	CM	eanolic acid, silibinin, curcumin, EGCG, melatonin and res
./___Corpus/Medline/xml/PMC4737670.xml	EGCG	61792 : 61796	CM	id, silibinin, curcumin, EGCG, melatonin and resveratr
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	61798 : 61807	CM	libinin, curcumin, EGCG, melatonin and resveratrol, have st
./___Corpus/Medline/xml/PMC4737670.xml	resveratrol	61812 : 61823	CM	min, EGCG, melatonin and resveratrol, have strong synergistic
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61863 : 61868	CPR	ynergistic actions, i.e. anti-tumorigenic effects in al
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61954 : 61959	CPR	ition to being effective anti-tumor-angiogenic agents. 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	61964 : 61969	CPR	eing effective anti-tumor-angiogenic agents. It would b
./___Corpus/Medline/xml/PMC4737670.xml	VEGF	62200 : 62204	CM	                     The VEGF pathway holds the key in
./___Corpus/Medline/xml/PMC4737670.xml	anti-	62477 : 62482	CPR	of patients treated with anti-VEGF drugs. It is clear t
./___Corpus/Medline/xml/PMC4737670.xml	VEGF-VEGFR2	62657 : 62668	CM	n placed on blocking the VEGF-VEGFR2 pathway. Using small syn
./___Corpus/Medline/xml/PMC4737670.xml	anti-	62780 : 62785	CPR	ssible to achieve better anti-angiogenic effects in tum
./___Corpus/Medline/xml/PMC4737670.xml	phytoestrogens	63391 : 63405	CM	 the potential for using phytoestrogens in treatment of ER-posit
./___Corpus/Medline/xml/PMC4737670.xml	melatonin	63459 : 63468	CM	breast cancer or that of melatonin in treating cancer in pe
./___Corpus/Medline/xml/PMC4737670.xml	anti-	63833 : 63838	CPR	esired optimal effect of anti-angiogenic treatment is a
./___Corpus/Medline/xml/PMC4737670.xml	oxygen	64094 : 64100	CM	ced delivery of not only oxygen and nutrients but also d
./___Corpus/Medline/xml/PMC4737670.xml	anti-	64192 : 64197	CPR	ue that such a result of anti-angiogenic treatment may 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	65071 : 65076	CPR	e considered to withdraw anti-angiogenic treatment if i
./___Corpus/Medline/xml/PMC4737670.xml	anti-	65802 : 65807	CPR	 they are also receiving anti-VEGF drugs as the ones in
./___Corpus/Medline/xml/PMC4737670.xml	meta-	66119 : 66124	CPR	s. For example, a recent meta-analysis of randomized pl
./___Corpus/Medline/xml/PMC4737670.xml	Vitamin E	66378 : 66387	CM	in future efforts [235]. Vitamin E and high doses of beta-c
./___Corpus/Medline/xml/PMC4737670.xml	beta-carotene	66406 : 66419	CM	amin E and high doses of beta-carotene have been shown to incre
./___Corpus/Medline/xml/PMC4737670.xml	anti-	66718 : 66723	CPR	 example, currently used anti-VEGF drugs cause a marked
./___Corpus/Medline/xml/PMC4737670.xml	endocrine	66869 : 66878	CM	 as the thymus and other endocrine glands, intestine and ot
./___Corpus/Medline/xml/PMC4737670.xml	anti-	67052 : 67057	CPR	 potent and broad-acting anti-angiogenic activity – may
./___Corpus/Medline/xml/PMC4737670.xml	anti-	67649 : 67654	CPR	y leading to synergistic anti-angiogenic effects while 
./___Corpus/Medline/xml/PMC4737670.xml	anti-	69792 : 69797	CPR	native to other types of anti-cancer drugs available to
./___Corpus/Medline/xml/PMC4737670.xml	anti-	69965 : 69970	CPR	safer and more effective anti-cancer treatment in the f
./___Corpus/Medline/xml/PMC4737670.xml	W.K.R	70167 : 70172	CM	 C.D., X.Y., M.F., A.A., W.K.R., D.G., G.R.N., B.E.R., 
./___Corpus/Medline/xml/PMC4737670.xml	G.R.N	70181 : 70186	CM	.F., A.A., W.K.R., D.G., G.R.N., B.E.R., D.R., Y.C.C. a
./___Corpus/Medline/xml/PMC4737670.xml	B.E.R	70189 : 70194	CM	., W.K.R., D.G., G.R.N., B.E.R., D.R., Y.C.C. and L.D.J
./___Corpus/Medline/xml/PMC4737670.xml	Y.C.C	70203 : 70208	CM	., G.R.N., B.E.R., D.R., Y.C.C. and L.D.J. wrote the ma
./___Corpus/Medline/xml/PMC4737670.xml	L.D.J	70214 : 70219	CM	B.E.R., D.R., Y.C.C. and L.D.J. wrote the manuscript, K
./___Corpus/Medline/xml/PMC4737670.xml	A.G.G	70255 : 70260	CM	 manuscript, K.H., H.F., A.G.G., S.H., A.A., E.N., A.A.
./___Corpus/Medline/xml/PMC4737670.xml	S.S.A	70287 : 70292	CM	 S.H., A.A., E.N., A.A., S.S.A., B.H., X.Y., G.G., D.B.
./___Corpus/Medline/xml/PMC4737670.xml	M.R.C	70319 : 70324	CM	 B.H., X.Y., G.G., D.B., M.R.C., K.A., S.C., D.H., S.I.
./___Corpus/Medline/xml/PMC4737670.xml	S.I.M	70345 : 70350	CM	.R.C., K.A., S.C., D.H., S.I.M., A.A., A.B. and N.K. pr
./___Corpus/Medline/xml/PMC4737670.xml	Mr	70581 : 70583	CM	  We would like to thank Mr. Leroy Lowe for his visi
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71042 : 71045	CM	r. Arreola was funded by NIH NRSA grant F31CA154080. 
./___Corpus/Medline/xml/PMC4737670.xml	COST	71188 : 71192	CM	ork grant MIS-379346 and COST action CM1201. Dr. Amede
./___Corpus/Medline/xml/PMC4737670.xml	CM1201	71200 : 71206	CM	S-379346 and COST action CM1201. Dr. Amedei was funded b
./___Corpus/Medline/xml/PMC4737670.xml	Amin	71302 : 71306	CM	inistry of Research. Dr. Amin was partially funded by 
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71522 : 71525	CM	Competitive Research and NIH grants 5P20RR016477 and 
./___Corpus/Medline/xml/PMC4737670.xml	5P20RR016477	71533 : 71545	CM	 Research and NIH grants 5P20RR016477 and 8P20GM104434. Dr. Da
./___Corpus/Medline/xml/PMC4737670.xml	Dabrosin	71568 : 71576	CM	77 and 8P20GM104434. Dr. Dabrosin was funded by the Swedis
./___Corpus/Medline/xml/PMC4737670.xml	NIH	71758 : 71761	CM	alicka was funded by the NIH. Dr. Niccolai was funded
./___Corpus/Medline/xml/PMC4737670.xml	AIRC	72048 : 72052	CM	iriolo was funded by the AIRC. Dr. Fuster was funded b
./___Corpus/Medline/xml/PMC4737670.xml	Fuster	72058 : 72064	CM	 funded by the AIRC. Dr. Fuster was funded by the NIH/NH
./___Corpus/Medline/xml/PMC4737670.xml	NIH	72083 : 72086	CM	Fuster was funded by the NIH/NHLBI grant R01HL107652 
./___Corpus/Medline/xml/PMC4737670.xml	NHLBI	72087 : 72092	CM	er was funded by the NIH/NHLBI grant R01HL107652 and an
./___Corpus/Medline/xml/PMC4737670.xml	NIH	72255 : 72258	CM	t. Dr. Yin was funded by NIH/NHLBI grant T32HL098062.
./___Corpus/Medline/xml/PMC4737670.xml	NHLBI	72259 : 72264	CM	r. Yin was funded by NIH/NHLBI grant T32HL098062.      
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	59 : 63	CM	ncer of zeste homolog 2 (EZH2) is a candidate oncogeni
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	223 : 227	CM	ers. Therefore, blocking EZH2 enzyme activity may pres
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	319 : 323	CM	reatment of cancers with EZH2 overexpression including
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	472 : 476	CM	ll molecule inhibitor of EZH2, which inhibited breast 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	530 : 537	CM	r growth and metastasis. ZLD1039 considerably inhibited E
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	561 : 565	CM	9 considerably inhibited EZH2 methyltransferase activi
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	566 : 583	ASE	siderably inhibited EZH2 methyltransferase activity with nanomolar 
./___Corpus/Medline/xml/PMC4751454.xml	histone-3 lysine-27	634 : 653	CM	otency, decreased global histone-3 lysine-27 (H3K27) methylation, and
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	655 : 660	CM	bal histone-3 lysine-27 (H3K27) methylation, and reacti
./___Corpus/Medline/xml/PMC4751454.xml	methylation	662 : 673	RN	tone-3 lysine-27 (H3K27) methylation, and reactivated silence
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	821 : 825	CM	conditional silencing of EZH2, its inhibition by ZLD10
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	845 : 852	CM	 EZH2, its inhibition by ZLD1039 decreased cell prolifera
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	978 : 985	CM	ograft-bearing mice with ZLD1039 led to tumor growth regr
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	1112 : 1116	CM	st cancer progression on EZH2 activity and the usefuln
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	1148 : 1155	CM	ty and the usefulness of ZLD1039 as a promising treatment
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	1257 : 1264	CM	ical characterization of ZLD1039 as a potent and selectiv
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	1304 : 1308	CM	d selective inhibitor of EZH2                      Rec
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	1348 : 1352	CM	       Recently, several EZH2 small molecule inhibitor
./___Corpus/Medline/xml/PMC4751454.xml	pyridones23,24,25,26	1448 : 1468	CM	ucturally related to the pyridones23,24,25,26. We previously designed 
./___Corpus/Medline/xml/PMC4751454.xml	pyridone	1539 : 1547	CM	ous compounds based on a pyridone-containing chemical scaf
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	1627 : 1631	CM	al chemistry to identify EZH2 small molecule inhibitor
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	1663 : 1670	CM	molecule inhibitors, and ZLD1039 (Fig. 1a) was selected a
./___Corpus/Medline/xml/PMC4751454.xml	lead	1701 : 1705	CM	 1a) was selected as the lead compound for its desirab
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	1815 : 1819	CM	says using reconstituted PRC2, ZLD1039 showed potent a
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	1821 : 1828	CM	sing reconstituted PRC2, ZLD1039 showed potent and concen
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	1885 : 1889	CM	-dependent inhibition of PRC2 enzymatic activity again
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	1917 : 1921	CM	zymatic activity against EZH2 wild-type as well as Y64
./___Corpus/Medline/xml/PMC4751454.xml	Y641F	1943 : 1948	CM	ZH2 wild-type as well as Y641F, and A677G mutant enzyme
./___Corpus/Medline/xml/PMC4751454.xml	A677G	1954 : 1959	CM	pe as well as Y641F, and A677G mutant enzymes with half
./___Corpus/Medline/xml/PMC4751454.xml	IC50	2019 : 2023	CM	nhibitory concentration (IC50) values of 5.6 ± 0.36, 1
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	2146 : 2153	CM	e of inhibition (MOI) of ZLD1039, S-adenosylmethionine (S
./___Corpus/Medline/xml/PMC4751454.xml	S-adenosylmethionine	2155 : 2175	CM	bition (MOI) of ZLD1039, S-adenosylmethionine (SAM) and H3 peptide com
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2177 : 2180	CM	9, S-adenosylmethionine (SAM) and H3 peptide competit
./___Corpus/Medline/xml/PMC4751454.xml	H3	2186 : 2188	CM	osylmethionine (SAM) and H3 peptide competition expe
./___Corpus/Medline/xml/PMC4751454.xml	IC50	2326 : 2330	CM	petitive inhibition, the IC50 for ZLD1039 inhibition o
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	2335 : 2342	CM	inhibition, the IC50 for ZLD1039 inhibition of EZH2 incre
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	2357 : 2361	CM	or ZLD1039 inhibition of EZH2 increased linearly with 
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2414 : 2417	CM	reasing concentration of SAM (Fig. 1c,d). However, th
./___Corpus/Medline/xml/PMC4751454.xml	1c,d	2424 : 2428	CM	ncentration of SAM (Fig. 1c,d). However, the IC50 was 
./___Corpus/Medline/xml/PMC4751454.xml	IC50	2444 : 2448	CM	Fig. 1c,d). However, the IC50 was independent of the p
./___Corpus/Medline/xml/PMC4751454.xml	1e	2510 : 2512	CM	rate concentration (Fig. 1e). These results suggest 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	2542 : 2549	CM	ese results suggest that ZLD1039 inhibited EZH2 competiti
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	2560 : 2564	CM	t that ZLD1039 inhibited EZH2 competitively and non-co
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2604 : 2607	CM	and non-competitive with SAM and the peptide substrat
./___Corpus/Medline/xml/PMC4751454.xml	S-adenosylhomocysteine	2762 : 2784	CM	talytic reaction product S-adenosylhomocysteine (SAH) inhibited EZH2 in 
./___Corpus/Medline/xml/PMC4751454.xml	SAH	2786 : 2789	CM	 S-adenosylhomocysteine (SAH) inhibited EZH2 in an SA
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	2801 : 2805	CM	cysteine (SAH) inhibited EZH2 in an SAM-competitive ma
./___Corpus/Medline/xml/PMC4751454.xml	SAM	2872 : 2875	CM	apping binding sites for SAM and SAH have been confir
./___Corpus/Medline/xml/PMC4751454.xml	SAH	2880 : 2883	CM	inding sites for SAM and SAH have been confirmed by c
./___Corpus/Medline/xml/PMC4751454.xml	PMTs28	2955 : 2961	CM	is of the two ligands of PMTs28. To determine whether ZL
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	2984 : 2991	CM	28. To determine whether ZLD1039 bound in a mutually excl
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3034 : 3037	CM	ly exclusive manner with SAH, the reaction velocity o
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3064 : 3067	CM	the reaction velocity of SAH in the presence of sever
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3105 : 3112	CM	nce of several different ZLD1039 concentrations was detec
./___Corpus/Medline/xml/PMC4751454.xml	1f	3159 : 3161	CM	tected. As shown in Fig. 1f, the data were best fit 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3255 : 3262	CM	lly exclusive binding of ZLD1039 and SAH.                
./___Corpus/Medline/xml/PMC4751454.xml	SAH	3267 : 3270	CM	e binding of ZLD1039 and SAH.                        
./___Corpus/Medline/xml/PMC4751454.xml	SAM	3342 : 3345	CM	ve data suggest that the SAM binding pocket of the EZ
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	3368 : 3372	CM	AM binding pocket of the EZH2 SET domain was the most 
./___Corpus/Medline/xml/PMC4751454.xml	SET	3373 : 3376	CM	nding pocket of the EZH2 SET domain was the most plau
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3423 : 3430	CM	lausible binding site of ZLD1039. However, definitive pro
./___Corpus/Medline/xml/PMC4751454.xml	SET	3480 : 3483	CM	of of binding within the SET domain of EZH2 requires 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	3494 : 3498	CM	within the SET domain of EZH2 requires structural conf
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	3585 : 3589	CM	ds. Recently, the intact PRC2 and EZH2 crystal structu
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	3594 : 3598	CM	tly, the intact PRC2 and EZH2 crystal structures were 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039-EZH2	3668 : 3680	CM	tructural studies of the ZLD1039-EZH2 co-crystal structure may
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3743 : 3750	CM	irm the binding site for ZLD1039.                        
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3832 : 3839	CM	the inhibitory effect of ZLD1039 against a panel of HMTs 
./___Corpus/Medline/xml/PMC4751454.xml	HMTs	3859 : 3863	CM	D1039 against a panel of HMTs other than EZH2. ZLD1039
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	3875 : 3879	CM	panel of HMTs other than EZH2. ZLD1039 displayed a 14-
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	3881 : 3888	CM	of HMTs other than EZH2. ZLD1039 displayed a 14-fold sele
./___Corpus/Medline/xml/PMC4751454.xml	14-fold	3901 : 3908	CM	ZH2. ZLD1039 displayed a 14-fold selectivity for EZH2 ove
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	3925 : 3929	CM	 14-fold selectivity for EZH2 over the closely related
./___Corpus/Medline/xml/PMC4751454.xml	EZH1	3955 : 3959	CM	over the closely related EZH1 and >10,000-fold selecti
./___Corpus/Medline/xml/PMC4751454.xml	10,000-	3965 : 3972	CPR	losely related EZH1 and >10,000-fold selectivity over 10 
./___Corpus/Medline/xml/PMC4751454.xml	HMTs	4003 : 4007	CM	electivity over 10 other HMTs tested (Fig. 1g,h and Su
./___Corpus/Medline/xml/PMC4751454.xml	1g,h	4021 : 4025	CM	 other HMTs tested (Fig. 1g,h and Supplementary Table 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	4108 : 4115	CM	cal results suggest that ZLD1039 is a potent and selectiv
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	4155 : 4159	CM	d selective inhibitor of EZH2.                  Intrac
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	4206 : 4211	CM	racellular inhibition of H3K27 methylation             
./___Corpus/Medline/xml/PMC4751454.xml	methylation	4212 : 4223	RN	ular inhibition of H3K27 methylation                      Pre
./___Corpus/Medline/xml/PMC4751454.xml	RNA	4300 : 4303	CM	nterfering/short hairpin RNA (si/shRNA) to knock down
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	4329 : 4333	CM	(si/shRNA) to knock down EZH2 or other components of P
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4357 : 4361	CM	2 or other components of PRC2 showed that breast and p
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4432 : 4436	CM	were highly dependent on PRC2 for proliferation18,19,2
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	4500 : 4507	CM	we tested the ability of ZLD1039 to block methylation of 
./___Corpus/Medline/xml/PMC4751454.xml	methylation	4517 : 4528	RN	lity of ZLD1039 to block methylation of H3K27 in breast cance
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	4532 : 4537	CM	 to block methylation of H3K27 in breast cancer cells. 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	4562 : 4569	CM	 in breast cancer cells. ZLD1039 inhibited the H3K27me3 a
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4584 : 4592	CM	s. ZLD1039 inhibited the H3K27me3 and H3K27me2 levels in M
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me2	4597 : 4605	CM	hibited the H3K27me3 and H3K27me2 levels in MCF-7 and MDA-
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	4616 : 4621	CM	3 and H3K27me2 levels in MCF-7 and MDA-MB-231 cells in 
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	4626 : 4636	CM	7me2 levels in MCF-7 and MDA-MB-231 cells in a dose-dependen
./___Corpus/Medline/xml/PMC4751454.xml	2a,b	4676 : 4680	CM	e-dependent manner (Fig. 2a,b) whereas the H3 and EZH2
./___Corpus/Medline/xml/PMC4751454.xml	H3	4694 : 4696	CM	 (Fig. 2a,b) whereas the H3 and EZH2 were not affect
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	4701 : 4705	CM	2a,b) whereas the H3 and EZH2 were not affected. The r
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4768 : 4776	CM	te that the reduction of H3K27me3 by ZLD1039 was due to th
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	4780 : 4787	CM	reduction of H3K27me3 by ZLD1039 was due to the direct in
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	4824 : 4828	CM	the direct inhibition of EZH2 methyltransferase activi
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	4829 : 4846	ASE	irect inhibition of EZH2 methyltransferase activity but not degrada
./___Corpus/Medline/xml/PMC4751454.xml	histone	4879 : 4886	CM	y but not degradation of histone H3 or PRC2. Quantificati
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	4893 : 4897	CM	adation of histone H3 or PRC2. Quantification of H3K27
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	4917 : 4925	CM	 PRC2. Quantification of H3K27me3 using an enzyme-linked i
./___Corpus/Medline/xml/PMC4751454.xml	IC50	4988 : 4992	CM	assay (ELISA) yielded an IC50 of 0.29 ± 0.09 μM in MCF
./___Corpus/Medline/xml/PMC4751454.xml	2C	5033 : 5035	CM	μM in MCF-7cells in Fig. 2C. Similar results were ob
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	5095 : 5099	CM	 other breast cancer and EZH2 mutant lymphoma cell lin
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	5227 : 5232	CM	e study was performed in MCF-7 and MDA-MB-231 cells to 
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	5237 : 5247	CM	s performed in MCF-7 and MDA-MB-231 cells to elucidate the u
./___Corpus/Medline/xml/PMC4751454.xml	H3K27	5300 : 5305	CM	rlying mechanisms of the H3K27 methylation inhibition b
./___Corpus/Medline/xml/PMC4751454.xml	methylation	5306 : 5317	RN	 mechanisms of the H3K27 methylation inhibition by ZLD1039. T
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	5332 : 5339	CM	ethylation inhibition by ZLD1039. The H3K27me3 level was 
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	5345 : 5353	CM	hibition by ZLD1039. The H3K27me3 level was decreased 48 h
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	5385 : 5392	CM	was decreased 48 h after ZLD1039 treatment and reached th
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	5483 : 5490	CM	 test the specificity of ZLD1039, other histone methyl ma
./___Corpus/Medline/xml/PMC4751454.xml	histone methyl	5498 : 5512	CM	ficity of ZLD1039, other histone methyl markers were examined an
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	5662 : 5669	CM	               Impact of ZLD1039 on breast cancer cell gr
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	5754 : 5758	CM	hether downregulation of EZH2 contributes to the growt
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	5857 : 5861	CM	ndent siRNAs specific to EZH2 were designed and transf
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	5907 : 5917	CM	ansfected into MCF-7 and MDA-MB-231 cells. Two siRNAs, named
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	5983 : 5987	CM	EZH2#3, knocked down the EZH2 level by ~80% (Fig. 3a).
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	6164 : 6168	CM	er cells is dependent on EZH2.                        
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	6227 : 6234	CM	      To explore whether ZLD1039 treatment has a similar 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	6287 : 6291	CM	ect on cell viability as EZH2 knockdown, the in vitro 
./___Corpus/Medline/xml/PMC4751454.xml	vitro	6310 : 6315	CM	s EZH2 knockdown, the in vitro antiproliferative activi
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	6348 : 6355	CM	liferative activities of ZLD1039 against various breast c
./___Corpus/Medline/xml/PMC4751454.xml	3–	6421 : 6423	CPR	 were examined using the 3–(4,5-dimethylthiazol–2-yl
./___Corpus/Medline/xml/PMC4751454.xml	(4,5-dimethylthiazol–2-yl)-2,5-diphenyltetrazolium bromide	6423 : 6481	CM	ere examined using the 3–(4,5-dimethylthiazol–2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Eight huma
./___Corpus/Medline/xml/PMC4751454.xml	MTT	6483 : 6486	CM	enyltetrazolium bromide (MTT) method. Eight human bre
./___Corpus/Medline/xml/PMC4751454.xml	ZR-75-1	6575 : 6582	CM	netic backgrounds namely ZR-75-1, ZR-75-30, MCF-7, MDA-MB
./___Corpus/Medline/xml/PMC4751454.xml	ZR-75-30	6584 : 6592	CM	kgrounds namely ZR-75-1, ZR-75-30, MCF-7, MDA-MB-231, MDA-
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	6601 : 6611	CM	R-75-1, ZR-75-30, MCF-7, MDA-MB-231, MDA-MB-468, SKBR-3, BT4
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-468	6613 : 6623	CM	5-30, MCF-7, MDA-MB-231, MDA-MB-468, SKBR-3, BT474, and MDA-
./___Corpus/Medline/xml/PMC4751454.xml	SKBR-3	6625 : 6631	CM	 MDA-MB-231, MDA-MB-468, SKBR-3, BT474, and MDA-MB-435S 
./___Corpus/Medline/xml/PMC4751454.xml	BT474	6633 : 6638	CM	231, MDA-MB-468, SKBR-3, BT474, and MDA-MB-435S were ch
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-435S	6644 : 6655	CM	-468, SKBR-3, BT474, and MDA-MB-435S were chosen for this ass
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	6712 : 6719	CM	 dose-response curves of ZLD1039 and IC50 values are show
./___Corpus/Medline/xml/PMC4751454.xml	IC50	6724 : 6728	CM	se curves of ZLD1039 and IC50 values are shown in Fig.
./___Corpus/Medline/xml/PMC4751454.xml	S2b	6780 : 6783	CM	c and Supplementary Fig. S2b, respectively. ZLD1039 s
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	6799 : 6806	CM	 Fig. S2b, respectively. ZLD1039 showed considerable dose
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	6928 : 6933	CM	d. Among the cell lines, MCF-7 and ZR-75-1 were the mos
./___Corpus/Medline/xml/PMC4751454.xml	ZR-75-1	6938 : 6945	CM	he cell lines, MCF-7 and ZR-75-1 were the most sensitive 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	6973 : 6980	CM	re the most sensitive to ZLD1039 with IC50 values of 0.99
./___Corpus/Medline/xml/PMC4751454.xml	IC50	6986 : 6990	CM	ensitive to ZLD1039 with IC50 values of 0.99 ± 0.23 an
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	7085 : 7092	CM	, the time-course of the ZLD1039-induced effects was exam
./___Corpus/Medline/xml/PMC4751454.xml	3d,e	7297 : 7301	CM	level after 4 days (Fig. 3d,e).                       
./___Corpus/Medline/xml/PMC4751454.xml	clonogenic	7363 : 7373	CM	    Then, we conducted a clonogenic assay to further evaluat
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	7434 : 7441	CM	roliferative activity of ZLD1039. As shown in Fig. 3f and
./___Corpus/Medline/xml/PMC4751454.xml	S2c	7486 : 7489	CM	f and Supplementary Fig. S2c, both the size and the n
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	7523 : 7528	CM	e size and the number of MCF-7, MDA-MB-231, and 4T1 clo
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	7530 : 7540	CM	and the number of MCF-7, MDA-MB-231, and 4T1 clones were dec
./___Corpus/Medline/xml/PMC4751454.xml	4T1	7546 : 7549	CM	f MCF-7, MDA-MB-231, and 4T1 clones were decreased ev
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	7602 : 7609	CM	at low concentrations of ZLD1039.                  Induct
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	7676 : 7683	CM	 arrest and apoptosis by ZLD1039 in breast cancer cells  
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	7754 : 7758	CM	o understand the role of EZH2 in the inhibition of the
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	7901 : 7908	CM	ls treated with 2 μmol/L ZLD1039 for 1–7 days, a substant
./___Corpus/Medline/xml/PMC4751454.xml	1–	7913 : 7915	CPR	ith 2 μmol/L ZLD1039 for 1–7 days, a substantial acc
./___Corpus/Medline/xml/PMC4751454.xml	G0	7962 : 7964	CM	accumulation of cells in G0/G1phase was detected (Fi
./___Corpus/Medline/xml/PMC4751454.xml	G0	8028 : 8030	CM	rcentage of cells in the G0/G1phase increased 2 days
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8062 : 8069	CM	e increased 2 days after ZLD1039 treatment and reached th
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	8130 : 8135	CM	evel after 4 days. Then, MCF-7 and MDA-MB-231 cells wer
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	8140 : 8150	CM	 4 days. Then, MCF-7 and MDA-MB-231 cells were treated with 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8204 : 8211	CM	easing concentrations of ZLD1039 up to 2 and 5 μmol/L, re
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	8360 : 8366	CM	ious cyclins and related cyclin-dependent kinases. There
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	8429 : 8435	CM	rmined the expression of cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8476 : 8483	CM	es (CDKs) and cyclins in ZLD1039-treated cells. As shown 
./___Corpus/Medline/xml/PMC4751454.xml	4c	8516 : 8518	CM	 cells. As shown in Fig. 4c, cyclin D and CDK2 prote
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	8520 : 8526	CM	ls. As shown in Fig. 4c, cyclin D and CDK2 protein level
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	8533 : 8537	CM	in Fig. 4c, cyclin D and CDK2 protein levels were decr
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8599 : 8606	CM	4 days of treatment with ZLD1039, whereas cyclin E was in
./___Corpus/Medline/xml/PMC4751454.xml	G0	8746 : 8748	CM	with the accumulation of G0/G1 population in the flu
./___Corpus/Medline/xml/PMC4751454.xml	G1	8749 : 8751	CM	h the accumulation of G0/G1 population in the fluore
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8875 : 8882	CM	nduction of apoptosis by ZLD1039 treatment using Annexin 
./___Corpus/Medline/xml/PMC4751454.xml	propidium iodide	8909 : 8925	CM	reatment using Annexin V/propidium iodide (PI) staining. Exposure 
./___Corpus/Medline/xml/PMC4751454.xml	PI	8927 : 8929	CM	exin V/propidium iodide (PI) staining. Exposure of M
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	8953 : 8958	CM	I) staining. Exposure of MCF-7 and MDA-MB-231 cells to 
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	8963 : 8973	CM	g. Exposure of MCF-7 and MDA-MB-231 cells to ZLD1039 for 4 d
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	8983 : 8990	CM	 and MDA-MB-231 cells to ZLD1039 for 4 days significantly
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	9161 : 9168	CM	nduction of apoptosis by ZLD1039, we examined the express
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	9230 : 9237	CM	osis-related proteins in ZLD1039-treated cells (Fig. 4d).
./___Corpus/Medline/xml/PMC4751454.xml	4d	9258 : 9260	CM	1039-treated cells (Fig. 4d). Indeed, the B-lymphoma
./___Corpus/Medline/xml/PMC4751454.xml	X	9339 : 9340	CM	l-2 and Bcl-2 associated X protein (BAX) were decre
./___Corpus/Medline/xml/PMC4751454.xml	BAX	9350 : 9353	CM	-2 associated X protein (BAX) were decreased and incr
./___Corpus/Medline/xml/PMC4751454.xml	4d	9510 : 9512	CM	ing concentrations (Fig. 4d). Taken together, these 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	9573 : 9577	CM	icate that inhibition of EZH2 by ZLD1039 may considera
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	9581 : 9588	CM	at inhibition of EZH2 by ZLD1039 may considerable block c
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	9751 : 9758	CM	sed genes reactivated by ZLD1039 in breast cancer cells  
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	9803 : 9807	CM	lls                      EZH2 is associated with trans
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	9903 : 9910	CM	erefore, we examined the ZLD1039-induced gene-expression 
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	9946 : 9951	CM	ne-expression changes in MCF-7 cells using gene express
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	10098 : 10105	CM	han down-regulated after ZLD1039 treatment (Fig. 5A), whi
./___Corpus/Medline/xml/PMC4751454.xml	EZH2’s	10153 : 10159	CM	hich was consistent with EZH2’s role in transcriptional 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	10253 : 10260	CM	s that were regulated by ZLD1039 through EZH2 inhibition,
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	10269 : 10273	CM	lated by ZLD1039 through EZH2 inhibition, we performed
./___Corpus/Medline/xml/PMC4751454.xml	P	10381 : 10382	CM	 of the microarray data (P < 0.05, Fig. 5B). Cell c
./___Corpus/Medline/xml/PMC4751454.xml	cytokine	10416 : 10424	CM	Fig. 5B). Cell cycle and cytokine-cytokine receptor intera
./___Corpus/Medline/xml/PMC4751454.xml	cytokine	10425 : 10433	CM	 Cell cycle and cytokine-cytokine receptor interaction-ass
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	10689 : 10696	CM	hat were up-regulated by ZLD1039 and validated their expr
./___Corpus/Medline/xml/PMC4751454.xml	qRT-PCR	10806 : 10813	CM	lymerase chain reaction (qRT-PCR, Fig. 5C). Among the gen
./___Corpus/Medline/xml/PMC4751454.xml	5C	10820 : 10822	CM	 reaction (qRT-PCR, Fig. 5C). Among the genes, RUNX3
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	10842 : 10847	CM	g. 5C). Among the genes, RUNX3, CDKN1C, and CDH1 were c
./___Corpus/Medline/xml/PMC4751454.xml	CDKN1C	10849 : 10855	CM	 Among the genes, RUNX3, CDKN1C, and CDH1 were considera
./___Corpus/Medline/xml/PMC4751454.xml	CDH1	10861 : 10865	CM	enes, RUNX3, CDKN1C, and CDH1 were considerable up-reg
./___Corpus/Medline/xml/PMC4751454.xml	4c	10915 : 10917	CM	ulated. As shown in Fig. 4c, the RUNX3 gene downstre
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	10923 : 10928	CM	As shown in Fig. 4c, the RUNX3 gene downstream protein 
./___Corpus/Medline/xml/PMC4751454.xml	p21	10953 : 10956	CM	 gene downstream protein p21 was recovered while CDK2
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	10977 : 10981	CM	 p21 was recovered while CDK2 and cyclin D were decrea
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	10986 : 10992	CM	recovered while CDK2 and cyclin D were decreased. Collec
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	11052 : 11059	CM	ese results suggest that ZLD1039 inhibited EZH2 enzyme ac
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	11070 : 11074	CM	t that ZLD1039 inhibited EZH2 enzyme activity, up-regu
./___Corpus/Medline/xml/PMC4751454.xml	CDK	11105 : 11108	CM	e activity, up-regulated CDK inhibition, lead to cell
./___Corpus/Medline/xml/PMC4751454.xml	lead	11121 : 11125	CM	egulated CDK inhibition, lead to cell cycle arrest and
./___Corpus/Medline/xml/PMC4751454.xml	5D,E	11167 : 11171	CM	rest and apoptosis (Fig. 5D,E).                  Anti-
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	11214 : 11221	CM	  Anti-tumor activity of ZLD1039 in breast xenograft anim
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	11315 : 11322	CM	he antitumor activity of ZLD1039 in vivo, three breast tu
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	11375 : 11380	CM	 xenograft models namely MCF-7, MDA-MB-231, and 4T1 cel
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	11382 : 11392	CM	aft models namely MCF-7, MDA-MB-231, and 4T1 cell lines mode
./___Corpus/Medline/xml/PMC4751454.xml	4T1	11398 : 11401	CM	y MCF-7, MDA-MB-231, and 4T1 cell lines models were u
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	11464 : 11471	CM	tudy. In all the models, ZLD1039 markedly induced tumor g
./___Corpus/Medline/xml/PMC4751454.xml	6a,b,c	11552 : 11558	CM	e-dependent manner (Fig. 6a,b,c and Supplementary Fig. S
./___Corpus/Medline/xml/PMC4751454.xml	S4a	11582 : 11585	CM	c and Supplementary Fig. S4a). TGI levels of 86.1 and
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	11659 : 11669	CM	200 and 250 mg/kg in the MDA-MB-231 and 4T1 cell models, res
./___Corpus/Medline/xml/PMC4751454.xml	4T1	11674 : 11677	CM	kg in the MDA-MB-231 and 4T1 cell models, respectivel
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	11712 : 11717	CM	ls, respectively. In the MCF-7 cell model, the highest 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12008 : 12015	CM	acokinetic properties of ZLD1039 (Supplementary Table S4)
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12073 : 12080	CM	ing oral administration, ZLD1039 was rapidly absorbed wit
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12274 : 12281	CM	.36 h in rats. Moreover, ZLD1039 was well tolerated with 
./___Corpus/Medline/xml/PMC4751454.xml	S4b	12393 : 12396	CM	oups (Supplementary Fig. S4b), which was confirmed by
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12561 : 12568	CM	o examine the effects of ZLD1039 on cell cycle and apopto
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	12606 : 12611	CM	e and apoptosis in vivo, MCF-7 tumors were harvested on
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12665 : 12672	CM	 14 after treatment with ZLD1039 for immunohistochemistry
./___Corpus/Medline/xml/PMC4751454.xml	deoxynucleotidyl	12711 : 12727	CM	tochemistry and terminal deoxynucleotidyl transferase (TdT) dUTP n
./___Corpus/Medline/xml/PMC4751454.xml	TdT	12741 : 12744	CM	nucleotidyl transferase (TdT) dUTP nick-end labelling
./___Corpus/Medline/xml/PMC4751454.xml	dUTP	12746 : 12750	CM	otidyl transferase (TdT) dUTP nick-end labelling (TUNE
./___Corpus/Medline/xml/PMC4751454.xml	TUNEL	12771 : 12776	CM	dUTP nick-end labelling (TUNEL) assays. As depicted in 
./___Corpus/Medline/xml/PMC4751454.xml	6d,e	12806 : 12810	CM	ays. As depicted in Fig. 6d,e, ZLD1039 potently inhibi
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	12812 : 12819	CM	s depicted in Fig. 6d,e, ZLD1039 potently inhibited the e
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	12857 : 12863	CM	ibited the expression of cyclin D (from 57 ± 5.4 to 13.8
./___Corpus/Medline/xml/PMC4751454.xml	p21	12919 : 12922	CM	%) and increased that of p21 (from 8 ± 1.9 to 33.6 ± 
./___Corpus/Medline/xml/PMC4751454.xml	TUNEL	13122 : 13127	CM	r increase in apoptosis (TUNEL- positive cells, from 2.
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	13267 : 13274	CM	hese results showed that ZLD1039 regulated the expression
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	13493 : 13500	CM	metastatic activities of ZLD1039 against breast cancer ce
./___Corpus/Medline/xml/PMC4751454.xml	vitro	13532 : 13537	CM	t breast cancer cells in vitro and in vivo             
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	13600 : 13604	CM	ious studies showed that EZH2 promotes migration and i
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	13716 : 13723	CM	r assessed the effect of ZLD1039 on tumor metastasis. MDA
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	13745 : 13755	CM	039 on tumor metastasis. MDA-MB-231 and 4T1 cells were used 
./___Corpus/Medline/xml/PMC4751454.xml	4T1	13760 : 13763	CM	tastasis. MDA-MB-231 and 4T1 cells were used for the 
./___Corpus/Medline/xml/PMC4751454.xml	7a	13917 : 13919	CM	bility. As shown in Fig. 7a, ZLD1039 potently blocke
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	13921 : 13928	CM	ty. As shown in Fig. 7a, ZLD1039 potently blocked the inv
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	13966 : 13976	CM	cked the invasion of the MDA-MB-231 and 4T1 cells with invas
./___Corpus/Medline/xml/PMC4751454.xml	4T1	13981 : 13984	CM	on of the MDA-MB-231 and 4T1 cells with invasion inhi
./___Corpus/Medline/xml/PMC4751454.xml	MMP-2	14105 : 14110	CM	matrix metalloproteinase MMP-2, MMP-9, and E-cadherin, 
./___Corpus/Medline/xml/PMC4751454.xml	MMP-9	14112 : 14117	CM	metalloproteinase MMP-2, MMP-9, and E-cadherin, which a
./___Corpus/Medline/xml/PMC4751454.xml	E-	14123 : 14125	CPR	einase MMP-2, MMP-9, and E-cadherin, which are consi
./___Corpus/Medline/xml/PMC4751454.xml	4T1	14223 : 14226	CM	nvasion were detected in 4T1 cells. As shown in Fig. 
./___Corpus/Medline/xml/PMC4751454.xml	7b	14251 : 14253	CM	 cells. As shown in Fig. 7b, MMP-2 and MMP-9 was dec
./___Corpus/Medline/xml/PMC4751454.xml	MMP-2	14255 : 14260	CM	ls. As shown in Fig. 7b, MMP-2 and MMP-9 was decreased,
./___Corpus/Medline/xml/PMC4751454.xml	MMP-9	14265 : 14270	CM	wn in Fig. 7b, MMP-2 and MMP-9 was decreased, whereas E
./___Corpus/Medline/xml/PMC4751454.xml	E-	14294 : 14296	CPR	9 was decreased, whereas E-cadherin was increased af
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	14325 : 14332	CM	erin was increased after ZLD1039 treatment.              
./___Corpus/Medline/xml/PMC4751454.xml	4T1	14386 : 14389	CM	                     The 4T1 murine breast cancer cel
./___Corpus/Medline/xml/PMC4751454.xml	murine	14390 : 14396	CM	                 The 4T1 murine breast cancer cell line 
./___Corpus/Medline/xml/PMC4751454.xml	BALB	14520 : 14524	CM	ung after inoculation in BALB/C female mice. Therefore
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	14581 : 14588	CM	vestigated the effect of ZLD1039 on 4T1 lung metastasis. 
./___Corpus/Medline/xml/PMC4751454.xml	4T1	14592 : 14595	CM	the effect of ZLD1039 on 4T1 lung metastasis. On day 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	14704 : 14711	CM	 markedly reduced in the ZLD1039-treated mice compared wi
./___Corpus/Medline/xml/PMC4751454.xml	haematoxylin	14826 : 14838	CM	f the intact lungs using haematoxylin and eosin (H&E) staining
./___Corpus/Medline/xml/PMC4751454.xml	eosin	14843 : 14848	CM	s using haematoxylin and eosin (H&E) staining confirmed
./___Corpus/Medline/xml/PMC4751454.xml	H&E	14850 : 14853	CM	 haematoxylin and eosin (H&E) staining confirmed that
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	14924 : 14931	CM	etastatic nodules in the ZLD1039-treated group was fewer 
./___Corpus/Medline/xml/PMC4751454.xml	7d	15001 : 15003	CM	icle-treated group (Fig. 7d). Then, the expression o
./___Corpus/Medline/xml/PMC4751454.xml	MMP-2	15030 : 15035	CM	 Then, the expression of MMP-2, MMP-9, and E-cadherin w
./___Corpus/Medline/xml/PMC4751454.xml	MMP-9	15037 : 15042	CM	the expression of MMP-2, MMP-9, and E-cadherin was dete
./___Corpus/Medline/xml/PMC4751454.xml	E-	15048 : 15050	CPR	ion of MMP-2, MMP-9, and E-cadherin was detected in 
./___Corpus/Medline/xml/PMC4751454.xml	4T1	15075 : 15078	CM	cadherin was detected in 4T1 graft tumors treated wit
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	15105 : 15112	CM	raft tumors treated with ZLD1039 for 18 days, using an im
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	15210 : 15217	CM	ated that treatment with ZLD1039 substantially inhibited 
./___Corpus/Medline/xml/PMC4751454.xml	MMP-2	15260 : 15265	CM	ibited the expression of MMP-2 and MMP-9 and increased 
./___Corpus/Medline/xml/PMC4751454.xml	MMP-9	15270 : 15275	CM	 expression of MMP-2 and MMP-9 and increased that of E-
./___Corpus/Medline/xml/PMC4751454.xml	E-	15298 : 15300	CPR	-9 and increased that of E-cadherin (from 57.1 ± 4.4
./___Corpus/Medline/xml/PMC4751454.xml	vitro	15448 : 15453	CM	ch was similar to the in vitro results (Fig. 7e). Moreo
./___Corpus/Medline/xml/PMC4751454.xml	7e	15468 : 15470	CM	e in vitro results (Fig. 7e). Moreover, the gene exp
./___Corpus/Medline/xml/PMC4751454.xml	CDH1	15524 : 15528	CM	ion arrays revealed that CDH1 was up-regulated by EZH2
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	15549 : 15553	CM	CDH1 was up-regulated by EZH2 inhibition following ZLD
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	15575 : 15582	CM	ZH2 inhibition following ZLD1039 treatment (Fig. 5C). The
./___Corpus/Medline/xml/PMC4751454.xml	5C	15599 : 15601	CM	 ZLD1039 treatment (Fig. 5C). Therefore, the antimet
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	15646 : 15653	CM	timetastatic activity of ZLD1039 may be due to the recove
./___Corpus/Medline/xml/PMC4751454.xml	CDH1	15684 : 15688	CM	e due to the recovery of CDH1 (E-cadherin), and associ
./___Corpus/Medline/xml/PMC4751454.xml	E-	15690 : 15692	CPR	to the recovery of CDH1 (E-cadherin), and associated
./___Corpus/Medline/xml/PMC4751454.xml	MMP-2	15723 : 15728	CM	in), and associated with MMP-2 and MMP-9 (Fig. 5D,E).  
./___Corpus/Medline/xml/PMC4751454.xml	MMP-9	15733 : 15738	CM	ssociated with MMP-2 and MMP-9 (Fig. 5D,E).            
./___Corpus/Medline/xml/PMC4751454.xml	5D,E	15745 : 15749	CM	th MMP-2 and MMP-9 (Fig. 5D,E).                  Discu
./___Corpus/Medline/xml/PMC4751454.xml	HMTs	15805 : 15809	CM	                     The HMTs are an epigenetic enzyme
./___Corpus/Medline/xml/PMC4751454.xml	HMTs	15959 : 15963	CM	ations discovered in the HMTs have been shown to drive
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	16029 : 16033	CM	cancers32,33. The enzyme EZH2 is the catalytic subunit
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	16066 : 16070	CM	catalytic subunit of the PRC2 and acts on HMT to catal
./___Corpus/Medline/xml/PMC4751454.xml	HMT	16083 : 16086	CM	 of the PRC2 and acts on HMT to catalyse the site-spe
./___Corpus/Medline/xml/PMC4751454.xml	methylation	16117 : 16128	RN	talyse the site-specific methylation of H3K2734. Importantly,
./___Corpus/Medline/xml/PMC4751454.xml	H3K2734	16132 : 16139	CM	-specific methylation of H3K2734. Importantly, PRC2 maint
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	16154 : 16158	CM	of H3K2734. Importantly, PRC2 maintains the transcript
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	16329 : 16337	CM	st that up-regulation of H3K27me3 levels by EZH2 overexpre
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	16348 : 16352	CM	on of H3K27me3 levels by EZH2 overexpression or mutati
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	16623 : 16627	CM	       Overexpression of EZH2 is frequently detected i
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	16766 : 16770	CM	prognosis13,14. Notably, EZH2 appears to be not only a
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	16894 : 16898	CM	 similar to an oncogene. EZH2 disruption by si/shRNA, 
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferases	16967 : 16985	CM	and general inhibitor of methyltransferases), or both has decreased 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	17196 : 17200	CM	acological inhibition of EZH2 using a novel EZH2 inhib
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	17215 : 17219	CM	on of EZH2 using a novel EZH2 inhibitor ZLD1039, reduc
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	17230 : 17237	CM	g a novel EZH2 inhibitor ZLD1039, reduced cell proliferat
./___Corpus/Medline/xml/PMC4751454.xml	PRC2	17479 : 17483	CM	ncy of breast cancers on PRC2 activity and provide evi
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	17553 : 17557	CM	acological inhibition of EZH2 could provide a basis fo
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	18001 : 18005	CM	gnificantly induced when EZH2 was depleted. In this st
./___Corpus/Medline/xml/PMC4751454.xml	BAX	18085 : 18088	CM	2 and increased level of BAX were observed in breast 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	18132 : 18139	CM	reast cancer cells after ZLD1039 treatment. Activation of
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	18340 : 18347	CM	e apoptosis induction by ZLD1039 might be mediated by EZH
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	18369 : 18373	CM	039 might be mediated by EZH2 disturbance as well as d
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	18479 : 18483	CM	                   Since EZH2 acts as a transcriptiona
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	18761 : 18768	CM	han down-regulated after ZLD1039 treatment in the microar
./___Corpus/Medline/xml/PMC4751454.xml	EZH2′s	18833 : 18839	CM	hich was consistent with EZH2′s role in transcriptional 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	18903 : 18907	CM	 addition, inhibition of EZH2 by ZLD1039 restored the 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	18911 : 18918	CM	n, inhibition of EZH2 by ZLD1039 restored the expression 
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	18991 : 18996	CM	s and tumor suppressors. RUNX3 is an established breast
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19111 : 19119	CM	ulation is controlled by H3K27me3 through EZH238. In this 
./___Corpus/Medline/xml/PMC4751454.xml	EZH238	19128 : 19134	CM	lled by H3K27me3 through EZH238. In this study, the expr
./___Corpus/Medline/xml/PMC4751454.xml	RUNX3	19169 : 19174	CM	study, the expression of RUNX3 was recovered by ZLD1039
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	19192 : 19199	CM	f RUNX3 was recovered by ZLD1039, which led to the up-reg
./___Corpus/Medline/xml/PMC4751454.xml	p21	19258 : 19261	CM	f the downstream protein p21 (Fig. 4c). The CDKN1C ha
./___Corpus/Medline/xml/PMC4751454.xml	4c	19268 : 19270	CM	stream protein p21 (Fig. 4c). The CDKN1C has been re
./___Corpus/Medline/xml/PMC4751454.xml	CDKN1C	19277 : 19283	CM	otein p21 (Fig. 4c). The CDKN1C has been reported to be 
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	19320 : 19324	CM	ported to be targeted by EZH2-mediated H3K27me3 in bre
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19334 : 19342	CM	argeted by EZH2-mediated H3K27me3 in breast cancer, which 
./___Corpus/Medline/xml/PMC4751454.xml	p57	19396 : 19399	CM	des the tumor suppressor p57 protein39. Following tre
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	19436 : 19443	CM	Following treatment with ZLD1039, the recovery of CDKN1C 
./___Corpus/Medline/xml/PMC4751454.xml	CDKN1C	19461 : 19467	CM	ZLD1039, the recovery of CDKN1C expression was observed.
./___Corpus/Medline/xml/PMC4751454.xml	p21	19508 : 19511	CM	observed. The downstream p21 and p57 are all CDK inhi
./___Corpus/Medline/xml/PMC4751454.xml	p57	19516 : 19519	CM	. The downstream p21 and p57 are all CDK inhibitors, 
./___Corpus/Medline/xml/PMC4751454.xml	CDK	19528 : 19531	CM	ream p21 and p57 are all CDK inhibitors, which lead t
./___Corpus/Medline/xml/PMC4751454.xml	lead	19550 : 19554	CM	ll CDK inhibitors, which lead to the reduction of CDK2
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	19575 : 19579	CM	lead to the reduction of CDK2, CDK4/6, and cyclin D an
./___Corpus/Medline/xml/PMC4751454.xml	CDK4	19581 : 19585	CM	o the reduction of CDK2, CDK4/6, and cyclin D and dela
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	19593 : 19599	CM	ion of CDK2, CDK4/6, and cyclin D and delay the G0/G1 ce
./___Corpus/Medline/xml/PMC4751454.xml	G0	19616 : 19618	CM	d cyclin D and delay the G0/G1 cell-cycle transition
./___Corpus/Medline/xml/PMC4751454.xml	G1	19619 : 19621	CM	yclin D and delay the G0/G1 cell-cycle transition. H
./___Corpus/Medline/xml/PMC4751454.xml	CDK2	19665 : 19669	CM	ion. Here, we found that CDK2 and cyclin D decreased a
./___Corpus/Medline/xml/PMC4751454.xml	cyclin	19674 : 19680	CM	, we found that CDK2 and cyclin D decreased after ZLD103
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	19699 : 19706	CM	cyclin D decreased after ZLD1039 treatment, consistent wi
./___Corpus/Medline/xml/PMC4751454.xml	G0	19738 : 19740	CM	ent, consistent with the G0/G1 arrest in cell-cycle 
./___Corpus/Medline/xml/PMC4751454.xml	G1	19741 : 19743	CM	, consistent with the G0/G1 arrest in cell-cycle ana
./___Corpus/Medline/xml/PMC4751454.xml	CDH1	19784 : 19788	CM	cycle analysis. Finally, CDH1 encodes the metastasis-r
./___Corpus/Medline/xml/PMC4751454.xml	E-	19828 : 19830	CPR	tastasis-related protein E-cadherin and has been rep
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	19883 : 19891	CM	ed to be associated with H3K27me3 levels in the promoter40
./___Corpus/Medline/xml/PMC4751454.xml	promoter40	19906 : 19916	CM	h H3K27me3 levels in the promoter40. ZLD1039 inhibited breas
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	19918 : 19925	CM	evels in the promoter40. ZLD1039 inhibited breast cancer 
./___Corpus/Medline/xml/PMC4751454.xml	CDH1	20011 : 20015	CM	ly by the suppression of CDH1. Therefore, the combined
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	20052 : 20059	CM	 the combined effects of ZLD1039-mediated EZH2 inhibition
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	20069 : 20073	CM	ects of ZLD1039-mediated EZH2 inhibition on several ca
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	20308 : 20312	CM	 the interaction between EZH2 and other chromatin modi
./___Corpus/Medline/xml/PMC4751454.xml	chromatin	20323 : 20332	CM	n between EZH2 and other chromatin modifiers such as histon
./___Corpus/Medline/xml/PMC4751454.xml	histone	20351 : 20358	CM	omatin modifiers such as histone deacetylases and DNA met
./___Corpus/Medline/xml/PMC4751454.xml	deacetylases	20359 : 20371	CM	odifiers such as histone deacetylases and DNA methyltransferas
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferases41	20380 : 20400	CM	one deacetylases and DNA methyltransferases41. Future studies are need
./___Corpus/Medline/xml/PMC4751454.xml	H3K27me3	20545 : 20553	CM	ivated by decreasing the H3K27me3 level alone. Furthermore
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	20659 : 20663	CM	w to develop and use the EZH2 inhibitor as a single ag
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	20839 : 20843	CM	we have characterized an EZH2 inhibitor, ZLD1039 that 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	20855 : 20862	CM	rized an EZH2 inhibitor, ZLD1039 that showed considerable
./___Corpus/Medline/xml/PMC4751454.xml	vitro	20915 : 20920	CM	titumor activity both in vitro and in vivo. Combined wi
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	21152 : 21156	CM	acological inhibition of EZH2 enzymatic activity could
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	21308 : 21312	CM	, which are dependent on EZH2 enzymatic activity and Z
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	21336 : 21343	CM	2 enzymatic activity and ZLD1039 is worth being optimized
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	21536 : 21541	CM	breast cancer cell lines MCF-7, ZR-75-1, ZR-75-30, SKBR
./___Corpus/Medline/xml/PMC4751454.xml	ZR-75-1	21543 : 21550	CM	cancer cell lines MCF-7, ZR-75-1, ZR-75-30, SKBR3, BT-474
./___Corpus/Medline/xml/PMC4751454.xml	ZR-75-30	21552 : 21560	CM	ll lines MCF-7, ZR-75-1, ZR-75-30, SKBR3, BT-474, MDA-MB-2
./___Corpus/Medline/xml/PMC4751454.xml	SKBR3	21562 : 21567	CM	CF-7, ZR-75-1, ZR-75-30, SKBR3, BT-474, MDA-MB-231, MDA
./___Corpus/Medline/xml/PMC4751454.xml	BT-474	21569 : 21575	CM	R-75-1, ZR-75-30, SKBR3, BT-474, MDA-MB-231, MDA-MB-468,
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	21577 : 21587	CM	ZR-75-30, SKBR3, BT-474, MDA-MB-231, MDA-MB-468, and MDA-MB-
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-468	21589 : 21599	CM	BR3, BT-474, MDA-MB-231, MDA-MB-468, and MDA-MB-435S were al
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-435S	21605 : 21616	CM	-MB-231, MDA-MB-468, and MDA-MB-435S were all acquired from t
./___Corpus/Medline/xml/PMC4751454.xml	ATCC	21678 : 21682	CM	Type Culture Collection (ATCC, Manassas, VA, USA). The
./___Corpus/Medline/xml/PMC4751454.xml	VA	21694 : 21696	CM	lection (ATCC, Manassas, VA, USA). The cells were cu
./___Corpus/Medline/xml/PMC4751454.xml	amikacin sulphate	21877 : 21894	CM	ine serum (FBS) and 0.1% amikacin sulphate under humidified conditi
./___Corpus/Medline/xml/PMC4751454.xml	CO2	21931 : 21934	CM	ified conditions with 5% CO2 at 37 °C. No further aut
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	22011 : 22018	CM	or the tumor cell lines. ZLD1039 was synthesized at the S
./___Corpus/Medline/xml/PMC4751454.xml	China)22	22110 : 22118	CM	uan University, Sichuan, China)22.                  Bioche
./___Corpus/Medline/xml/PMC4751454.xml	histone	22201 : 22208	CM	The enzyme levels of the histone methyltransferase panel 
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	22209 : 22226	ASE	me levels of the histone methyltransferase panel were determined us
./___Corpus/Medline/xml/PMC4751454.xml	methyltransferase	22441 : 22458	CM	mined using an AlphaLISA methyltransferase assay kit (PerkinElmer, 
./___Corpus/Medline/xml/PMC4751454.xml	MA	22483 : 22485	CM	 assay kit (PerkinElmer, MA, USA) according to the m
./___Corpus/Medline/xml/PMC4751454.xml	IHC	22664 : 22667	CM	                 The IF, IHC, and WB analyses were co
./___Corpus/Medline/xml/PMC4751454.xml	WB	22673 : 22675	CM	        The IF, IHC, and WB analyses were conducted 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	22945 : 22952	CM	s that were treated with ZLD1039 for 4 days at different 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	23471 : 23478	CM	icated concentrations of ZLD1039 for 4 days, and cell via
./___Corpus/Medline/xml/PMC4751454.xml	MTT	23534 : 23537	CM	 was determined using an MTT (Sigma-Aldrich, St. Loui
./___Corpus/Medline/xml/PMC4751454.xml	St	23554 : 23556	CM	g an MTT (Sigma-Aldrich, St. Louis, MO, USA) assay. 
./___Corpus/Medline/xml/PMC4751454.xml	IC50	23585 : 23589	CM	uis, MO, USA) assay. The IC50 values were calculated u
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	23709 : 23716	CM	 cells were treated with ZLD1039 for 14 days, fixed with 
./___Corpus/Medline/xml/PMC4751454.xml	methanol	23741 : 23749	CM	 for 14 days, fixed with methanol, and then stained with c
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	23971 : 23978	CM	cell cycle analyses, the ZLD1039-treated cells were fixed
./___Corpus/Medline/xml/PMC4751454.xml	PI	24025 : 24027	CM	xed and stained with the PI staining solution for 10
./___Corpus/Medline/xml/PMC4751454.xml	fluorescein isothiocyanate	24265 : 24291	CM	ysed using an Annexin V- fluorescein isothiocyanate (FITC) apoptosis detecti
./___Corpus/Medline/xml/PMC4751454.xml	FITC	24293 : 24297	CM	orescein isothiocyanate (FITC) apoptosis detection kit
./___Corpus/Medline/xml/PMC4751454.xml	IN	24345 : 24347	CM	it (Roche, Indianapolis, IN, USA) according to the m
./___Corpus/Medline/xml/PMC4751454.xml	24-	24553 : 24556	CPR	y, the upper chambers of 24-well transwell plates (Mi
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	24869 : 24876	CM	ferent concentrations of ZLD1039. After a 24-h incubation
./___Corpus/Medline/xml/PMC4751454.xml	24-h	24886 : 24890	CM	ions of ZLD1039. After a 24-h incubation, the non-migr
./___Corpus/Medline/xml/PMC4751454.xml	paraformaldehyde	25016 : 25032	CM	cells were fixed with 4% paraformaldehyde and stained with 0.05% c
./___Corpus/Medline/xml/PMC4751454.xml	RNA	25440 : 25443	CM	nghai, China). The total RNA was purified from MCF-7 
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	25462 : 25467	CM	al RNA was purified from MCF-7 cells after dimethyl sul
./___Corpus/Medline/xml/PMC4751454.xml	dimethyl sulphoxide	25480 : 25499	CM	d from MCF-7 cells after dimethyl sulphoxide (DMSO) or ZLD1039 (1.5 μ
./___Corpus/Medline/xml/PMC4751454.xml	DMSO	25501 : 25505	CM	ter dimethyl sulphoxide (DMSO) or ZLD1039 (1.5 μM) tre
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	25510 : 25517	CM	hyl sulphoxide (DMSO) or ZLD1039 (1.5 μM) treatment for 3
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	25816 : 25823	CM	ed pairwise contrasts of ZLD1039-treated versus the contr
./___Corpus/Medline/xml/PMC4751454.xml	P	25928 : 25929	CM	using fold-change >2 and P < 0.05 (Student t-test).
./___Corpus/Medline/xml/PMC4751454.xml	gCTL_	25990 : 25995	CM	ential gene expressions (gCTL_ vs. gZ1039-T_, P < 0.05)
./___Corpus/Medline/xml/PMC4751454.xml	qRT-PCR	26093 : 26100	CM	  SiRNA transfection and qRT-PCR analysis                
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	26179 : 26183	CM	with validated siRNA for EZH2 at a concentration of 10
./___Corpus/Medline/xml/PMC4751454.xml	SA	26286 : 26288	CM	t (Polyplus-transfection SA, NY, USA). The EZH2 gene
./___Corpus/Medline/xml/PMC4751454.xml	NY	26290 : 26292	CM	olyplus-transfection SA, NY, USA). The EZH2 gene tar
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	26304 : 26308	CM	ection SA, NY, USA). The EZH2 gene target-specific siR
./___Corpus/Medline/xml/PMC4751454.xml	qRT-PCR	26461 : 26468	CM	entary Table S2. For the qRT-PCR analyses of mRNAs, total
./___Corpus/Medline/xml/PMC4751454.xml	mRNAs	26481 : 26486	CM	 the qRT-PCR analyses of mRNAs, total RNA was isolated 
./___Corpus/Medline/xml/PMC4751454.xml	RNA	26494 : 26497	CM	analyses of mRNAs, total RNA was isolated using TRIZO
./___Corpus/Medline/xml/PMC4751454.xml	TRIZOL	26517 : 26523	CM	l RNA was isolated using TRIZOL and reverse transcribed 
./___Corpus/Medline/xml/PMC4751454.xml	cDNA	26551 : 26555	CM	d reverse transcribed to cDNA using the PrimeScript 1s
./___Corpus/Medline/xml/PMC4751454.xml	qRT-PCR	26613 : 26620	CM	 cDNA Synthesis kit. The qRT-PCR reactions were performed
./___Corpus/Medline/xml/PMC4751454.xml	PCR	26682 : 26685	CM	Green technology and the PCR primers are listed in Su
./___Corpus/Medline/xml/PMC4751454.xml	MCF-7	27083 : 27088	CM	                 For the MCF-7 tumor xenograft model, B
./___Corpus/Medline/xml/PMC4751454.xml	BALB	27112 : 27116	CM	7 tumor xenograft model, BALB/c nude mice received 5 ×
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	27323 : 27330	CM	nto four groups (n = 5). ZLD1039 or the vehicle consistin
./___Corpus/Medline/xml/PMC4751454.xml	polyoxyethylenated	27374 : 27392	RN	sisting of 12.5% each of polyoxyethylenated castor oil (EL) and etha
./___Corpus/Medline/xml/PMC4751454.xml	ethanol	27413 : 27420	CM	ated castor oil (EL) and ethanol (ETOH) in normal saline 
./___Corpus/Medline/xml/PMC4751454.xml	ETOH	27422 : 27426	CM	or oil (EL) and ethanol (ETOH) in normal saline (NS) w
./___Corpus/Medline/xml/PMC4751454.xml	saline	27438 : 27444	CM	ethanol (ETOH) in normal saline (NS) was administered at
./___Corpus/Medline/xml/PMC4751454.xml	NS	27446 : 27448	CM	(ETOH) in normal saline (NS) was administered at the
./___Corpus/Medline/xml/PMC4751454.xml	MDA-MB-231	27602 : 27612	CM	                     The MDA-MB-231 donor tumors were first 
./___Corpus/Medline/xml/PMC4751454.xml	BALB	27738 : 27742	CM	 into the right flank of BALB/c nude mice. The donor t
./___Corpus/Medline/xml/PMC4751454.xml	BALB	27881 : 27885	CM	ously implanted into the BALB/c nude mice. After impla
./___Corpus/Medline/xml/PMC4751454.xml	70–	27944 : 27947	CPR	mice with tumors ranging 70–120 mm3 were selected and
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	28028 : 28035	CM	 efficacy study (n = 5). ZLD1039 or the vehicle was admin
./___Corpus/Medline/xml/PMC4751454.xml	4T1	28149 : 28152	CM	                     The 4T1 breast cancer cells have
./___Corpus/Medline/xml/PMC4751454.xml	mice42	28293 : 28299	CM	eks after inoculation in mice42. In this study, 5 × 105 
./___Corpus/Medline/xml/PMC4751454.xml	4T1	28324 : 28327	CM	. In this study, 5 × 105 4T1 cells (0.1 mL cell suspe
./___Corpus/Medline/xml/PMC4751454.xml	BALB	28412 : 28416	CM	 into the right flank of BALB/c female mice. About 4 d
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	28603 : 28610	CM	to three groups (n = 5). ZLD1039 or vehicle was administe
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	29042 : 29049	CM	e-Dawley rats dosed with ZLD1039 was collected in pre-chi
./___Corpus/Medline/xml/PMC4751454.xml	K2-ethylenediaminetetraacetic acid	29079 : 29113	CM	collected in pre-chilled K2-ethylenediaminetetraacetic acid (EDTA) tubes at pre-spec
./___Corpus/Medline/xml/PMC4751454.xml	EDTA	29115 : 29119	CM	diaminetetraacetic acid (EDTA) tubes at pre-specified 
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	29238 : 29245	CM	nd the concentrations of ZLD1039 were determined using li
./___Corpus/Medline/xml/PMC4751454.xml	BALB	29389 : 29393	CM	clinical symptoms of the BALB/C mice orally administer
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	29428 : 29435	CM	ally administered 2 g/kg ZLD1039 were observed. Blood was
./___Corpus/Medline/xml/PMC4751454.xml	H&E	29676 : 29679	CM	 organs of the mice were H&E stained for pathology ex
./___Corpus/Medline/xml/PMC4751454.xml	X	30059 : 30060	CM	cite this article: Song, X. et al. Selective inhibi
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	30093 : 30097	CM	 Selective inhibition of EZH2 by ZLD1039 blocks H3K27m
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	30101 : 30108	CM	ve inhibition of EZH2 by ZLD1039 blocks H3K27methylation 
./___Corpus/Medline/xml/PMC4751454.xml	H3K27methylation	30116 : 30132	RN	f EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti
./___Corpus/Medline/xml/PMC4751454.xml	anti-	30153 : 30158	CPR	tion and leads to potent anti-tumor activity in breast 
./___Corpus/Medline/xml/PMC4751454.xml	Co	30381 : 30383	CM	peloa Medical Technology Co., Ltd. The funders had n
./___Corpus/Medline/xml/PMC4751454.xml	Y	30778 : 30779	CM	paper. T.Y., N.W., Y.W., Y. S., F.Y. and L.Y. revie
./___Corpus/Medline/xml/PMC4751454.xml	EZH2	30925 : 30929	CM	 Selective inhibition of EZH2 by ZLD1039 blocks H3K27m
./___Corpus/Medline/xml/PMC4751454.xml	ZLD1039	30933 : 30940	CM	ve inhibition of EZH2 by ZLD1039 blocks H3K27methylation 
./___Corpus/Medline/xml/PMC4751454.xml	H3K27methylation	30948 : 30964	RN	f EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti
./___Corpus/Medline/xml/PMC4751454.xml	anti-	30985 : 30990	CPR	tion and leads to potent anti-tumor activity in breast 
./___Corpus/Medline/xml/PMC4770715.xml	actin	34 : 39	CM	                     The actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	actin	338 : 343	CM	ed how inhibition of the actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	LIM	384 : 387	CM	 cytoskeleton regulatory LIM kinases could be used in
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	476 : 480	CM	. A previously-described LIMK inhibitor (LIMKi) induce
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	492 : 497	CM	escribed LIMK inhibitor (LIMKi) induced dose-dependent 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	683 : 688	CM	inhibitors. By combining LIMKi with 366 compounds from 
./___Corpus/Medline/xml/PMC4770715.xml	GSK	717 : 720	CM	h 366 compounds from the GSK Published Kinase Inhibit
./___Corpus/Medline/xml/PMC4770715.xml	Kinase	731 : 737	ASE	s from the GSK Published Kinase Inhibitor Set, effective
./___Corpus/Medline/xml/PMC4770715.xml	EGFR	825 : 829	CM	ase inhibitors including EGFR, p38 and Raf. These find
./___Corpus/Medline/xml/PMC4770715.xml	Raf	839 : 842	CM	 including EGFR, p38 and Raf. These findings encourag
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	921 : 931	CM	at led to development of CRT0105446 and CRT0105950, which po
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105950	936 : 946	CM	opment of CRT0105446 and CRT0105950, which potently block LI
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	969 : 974	CM	50, which potently block LIMK1 and LIMK2 activity in vi
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	979 : 984	CM	potently block LIMK1 and LIMK2 activity in vitro, and i
./___Corpus/Medline/xml/PMC4770715.xml	vitro	997 : 1002	CM	K1 and LIMK2 activity in vitro, and inhibit cofilin pho
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	1024 : 1039	RN	tro, and inhibit cofilin phosphorylation and increase αTubulin ac
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	1062 : 1073	RN	on and increase αTubulin acetylation in cells. CRT0105446 and
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	1266 : 1270	CM	cantly sensitive to both LIMK inhibitors. These large-
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	1335 : 1339	CM	ave identified effective LIMK inhibitor drug combinati
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	1413 : 1417	CM	 types. In addition, the LIMK inhibitory compounds CRT
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	1606 : 1611	CM	The LIM kinases 1 and 2 (LIMK1 and LIMK2) are central r
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	1616 : 1621	CM	nases 1 and 2 (LIMK1 and LIMK2) are central regulators 
./___Corpus/Medline/xml/PMC4770715.xml	actin	1741 : 1746	CM	activity and filamentous actin (F-actin) stability have
./___Corpus/Medline/xml/PMC4770715.xml	F-actin	1748 : 1755	CM	y and filamentous actin (F-actin) stability have been ext
./___Corpus/Medline/xml/PMC4770715.xml	4–	1887 : 1889	CPR	haracterized mechanisms [4–6]. Given their cytoskele
./___Corpus/Medline/xml/PMC4770715.xml	7–	2098 : 2100	CPR	invasion and metastasis [7–9]. More recent studies h
./___Corpus/Medline/xml/PMC4770715.xml	LIM	2144 : 2147	CM	dies have shown that the LIM kinases modulate additio
./___Corpus/Medline/xml/PMC4770715.xml	4–	2269 : 2271	CPR	liferation and survival [4–6]. LIMK activity also co
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	2275 : 2279	CM	tion and survival [4–6]. LIMK activity also contribute
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	2406 : 2410	CM	adiation, while blocking LIMK activity reverses this r
./___Corpus/Medline/xml/PMC4770715.xml	10–	2476 : 2479	CPR	n increases sensitivity [10–14]. These observations h
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	2558 : 2562	CM	towards the discovery of LIMK inhibitors as potential 
./___Corpus/Medline/xml/PMC4770715.xml	15–	2686 : 2689	CPR	f combination therapies [15–17].                     
./___Corpus/Medline/xml/PMC4770715.xml	lead	3766 : 3770	CM	nic transformation often lead to reliance upon heat-sh
./___Corpus/Medline/xml/PMC4770715.xml	actin	4022 : 4027	CM	s and alterations in the actin and microtubule cytoskel
./___Corpus/Medline/xml/PMC4770715.xml	15–	4209 : 4212	CPR	 of certain tumor types [15–17]. Unbiased screening m
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	4435 : 4439	CM	number of small molecule LIMK inhibitors have been dis
./___Corpus/Medline/xml/PMC4770715.xml	21–	4476 : 4479	CPR	have been discovered [6, 21–25] and several have been
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	4732 : 4736	CM	ma [29]. To identify how LIMK inhibitors might best be
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	4827 : 4831	CM	screens. In the first, a LIMK inhibitor was combined w
./___Corpus/Medline/xml/PMC4770715.xml	GSK	4896 : 4899	CM	-targeting drugs, or the GSK published kinase inhibit
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	5062 : 5066	CM	In the second, two novel LIMK inhibitors we developed 
./___Corpus/Medline/xml/PMC4770715.xml	anti-	5195 : 5200	CPR	ant sensitivity to their anti-proliferative effects. Th
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	5420 : 5424	CM	gnificant sensitivity to LIMK inhibition.             
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	5462 : 5466	CM	                 RESULTS LIMK inhibition affects micro
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	5561 : 5565	CM	        To determine how LIMK inhibition affects cance
./___Corpus/Medline/xml/PMC4770715.xml	N-{5-[2-(2,6-Dichloro-phenyl)-5-difluoromethyl-2H-pyrazol-3-yl]-thiazol-2-yl}-isobutyramide	5657 : 5748	CM	mall molecular inhibitor N-{5-[2-(2,6-Dichloro-phenyl)-5-difluoromethyl-2H-pyrazol-3-yl]-thiazol-2-yl}-isobutyramide (compound 3 in [21]; her
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	5795 : 5800	CM	hereafter referred to as LIMKi) that blocks both LIMK1 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	5819 : 5824	CM	 LIMKi) that blocks both LIMK1 (7 nM IC50 in vitro) and
./___Corpus/Medline/xml/PMC4770715.xml	IC50	5831 : 5835	CM	 blocks both LIMK1 (7 nM IC50 in vitro) and LIMK2 (8 n
./___Corpus/Medline/xml/PMC4770715.xml	vitro	5839 : 5844	CM	both LIMK1 (7 nM IC50 in vitro) and LIMK2 (8 nM IC50) a
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	5850 : 5855	CM	(7 nM IC50 in vitro) and LIMK2 (8 nM IC50) activity. Th
./___Corpus/Medline/xml/PMC4770715.xml	IC50	5862 : 5866	CM	n vitro) and LIMK2 (8 nM IC50) activity. The results o
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	5918 : 5923	CM	selectivity profiling of LIMKi at 10 μM against 287 kin
./___Corpus/Medline/xml/PMC4770715.xml	kinome	6009 : 6015	CM	y [31] was mapped onto a kinome phylogenetic tree [32] i
./___Corpus/Medline/xml/PMC4770715.xml	1A	6062 : 6064	CM	] in Supplemental Figure 1A. To compare specificity 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6109 : 6114	CM	city quantitatively, the LIMKi S(35) selectivity score 
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6115 : 6120	CM	uantitatively, the LIMKi S(35) selectivity score (a rat
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6235 : 6240	CM	kinases) was compared to S(35) values for 38 additional
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6351 : 6356	CM	(Supplemental Figure 1B; LIMKi indicated in blue). Furt
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6435 : 6440	CM	upplemental Figure 1B of LIMKi S(1) (i.e. proportion of
./___Corpus/Medline/xml/PMC4770715.xml	S(1)	6441 : 6445	CM	ental Figure 1B of LIMKi S(1) (i.e. proportion of kina
./___Corpus/Medline/xml/PMC4770715.xml	S(10)	6493 : 6498	CM	nases inhibited by 99%), S(10) (proportion of kinases i
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	6544 : 6549	CM	es inhibited by 90%) and S(35) selectivity scores indic
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6603 : 6608	CM	 the high selectivity of LIMKi. At 10 μM LIMKi, only 13
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6619 : 6624	CM	ivity of LIMKi. At 10 μM LIMKi, only 13 kinase targets 
./___Corpus/Medline/xml/PMC4770715.xml	ADCK3	6650 : 6655	CM	 only 13 kinase targets (ADCK3, ALK4, AMPKα1, AMPKα2, B
./___Corpus/Medline/xml/PMC4770715.xml	ALK4	6657 : 6661	CM	3 kinase targets (ADCK3, ALK4, AMPKα1, AMPKα2, BRSK1, 
./___Corpus/Medline/xml/PMC4770715.xml	AMPKα1	6663 : 6669	CM	se targets (ADCK3, ALK4, AMPKα1, AMPKα2, BRSK1, BRSK2, D
./___Corpus/Medline/xml/PMC4770715.xml	AMPKα2	6671 : 6677	CM	ts (ADCK3, ALK4, AMPKα1, AMPKα2, BRSK1, BRSK2, DCAMKL1, 
./___Corpus/Medline/xml/PMC4770715.xml	BRSK1	6679 : 6684	CM	3, ALK4, AMPKα1, AMPKα2, BRSK1, BRSK2, DCAMKL1, DCAMKL2
./___Corpus/Medline/xml/PMC4770715.xml	BRSK2	6686 : 6691	CM	, AMPKα1, AMPKα2, BRSK1, BRSK2, DCAMKL1, DCAMKL2, DDR1,
./___Corpus/Medline/xml/PMC4770715.xml	DCAMKL1	6693 : 6700	CM	1, AMPKα2, BRSK1, BRSK2, DCAMKL1, DCAMKL2, DDR1, FGFR1, P
./___Corpus/Medline/xml/PMC4770715.xml	DCAMKL2	6702 : 6709	CM	, BRSK1, BRSK2, DCAMKL1, DCAMKL2, DDR1, FGFR1, PAK3, PCTA
./___Corpus/Medline/xml/PMC4770715.xml	DDR1	6711 : 6715	CM	BRSK2, DCAMKL1, DCAMKL2, DDR1, FGFR1, PAK3, PCTAIRE1) 
./___Corpus/Medline/xml/PMC4770715.xml	FGFR1	6717 : 6722	CM	 DCAMKL1, DCAMKL2, DDR1, FGFR1, PAK3, PCTAIRE1) in addi
./___Corpus/Medline/xml/PMC4770715.xml	PAK3	6724 : 6728	CM	1, DCAMKL2, DDR1, FGFR1, PAK3, PCTAIRE1) in addition t
./___Corpus/Medline/xml/PMC4770715.xml	PCTAIRE1	6730 : 6738	CM	MKL2, DDR1, FGFR1, PAK3, PCTAIRE1) in addition to LIMK1 an
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	6755 : 6760	CM	PCTAIRE1) in addition to LIMK1 and LIMK2 were inhibited
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	6765 : 6770	CM	in addition to LIMK1 and LIMK2 were inhibited by > 65% 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6843 : 6848	CM	dose-dependent effect of LIMKi on inhibiting LIMK activ
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	6863 : 6867	CM	t of LIMKi on inhibiting LIMK activity by treating A54
./___Corpus/Medline/xml/PMC4770715.xml	A549	6889 : 6893	CM	IMK activity by treating A549 human lung adenocarcinom
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	6955 : 6959	CM	 cells for 18 hours with DMSO vehicle or 1, 3 or 10 μM
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	6985 : 6990	CM	vehicle or 1, 3 or 10 μM LIMKi [9, 21] and western blot
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	7024 : 7039	RN	and western blotting for phosphorylation of cofilin, a well-chara
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	7073 : 7077	CM	in, a well-characterized LIMK substrate [9] (Figure ​(
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7179 : 7184	CM	nization was affected by LIMKi in non-dividing cells by
./___Corpus/Medline/xml/PMC4770715.xml	A549	7219 : 7223	CM	viding cells by treating A549 cells for 24 hours with 
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	7248 : 7252	CM	 cells for 24 hours with DMSO vehicle or 3 or 10 μM LI
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7275 : 7280	CM	SO vehicle or 3 or 10 μM LIMKi. Representative images s
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7371 : 7376	CM	rphology with increasing LIMKi dose (Figure ​(Figure1B)
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7520 : 7525	CM	e analysed the effect of LIMKi on αTubulin acetylation 
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7538 : 7549	RN	ect of LIMKi on αTubulin acetylation [33]. Confocal images of
./___Corpus/Medline/xml/PMC4770715.xml	A549	7575 : 7579	CM	[33]. Confocal images of A549 cells co-stained with an
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	7621 : 7640	CM	 with antibodies against acetylated-αTubulin (Figure ​(Figure1C;1C; g
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7774 : 7785	RN	ent increase in αTubulin acetylation after 24-hour LIMKi trea
./___Corpus/Medline/xml/PMC4770715.xml	24-	7792 : 7795	CPR	ubulin acetylation after 24-hour LIMKi treatment. Qua
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7800 : 7805	CM	cetylation after 24-hour LIMKi treatment. Quantificatio
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	7901 : 7912	RN	ate increase in αTubulin acetylation in response to 3 μM LIMK
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7933 : 7938	CM	tion in response to 3 μM LIMKi, and a significant incre
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	7988 : 7993	CM	ase in response to 10 μM LIMKi treatment, relative to D
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	8017 : 8021	CM	i treatment, relative to DMSO vehicle control. These r
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	8071 : 8075	CM	esults indicate that the LIMK inhibitor affected micro
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	8222 : 8226	CM	 investigate the role of LIMK in mitosis, we analyzed 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	8265 : 8270	CM	e analyzed the effect of LIMKi on mitotic spindle morph
./___Corpus/Medline/xml/PMC4770715.xml	A549	8302 : 8306	CM	otic spindle morphology. A549 cells were treated for 2
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	8344 : 8348	CM	reated for 24 hours with DMSO vehicle, 3 or 10 μM LIMK
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	8369 : 8374	CM	DMSO vehicle, 3 or 10 μM LIMKi, then fixed and stained 
./___Corpus/Medline/xml/PMC4770715.xml	4′,6-diamidino-2-phenylindole	8440 : 8469	CM	tibody and the DNA stain 4′,6-diamidino-2-phenylindole (DAPI). We observed sign
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	8471 : 8475	CM	iamidino-2-phenylindole (DAPI). We observed significan
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	8580 : 8585	CM	nization with increasing LIMKi concentrations, includin
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	9177 : 9182	CM	ncreased with increasing LIMKi concentration, with sign
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	9275 : 9280	CM	al cells with increasing LIMKi concentration (Figure ​(
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	9364 : 9368	CM	ed that treatment with a LIMK inhibitory compound had 
./___Corpus/Medline/xml/PMC4770715.xml	A549	9506 : 9510	CM	 with the sensitivity of A549 cells to LIMKi, active p
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	9520 : 9525	CM	itivity of A549 cells to LIMKi, active phosphorylated L
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	9534 : 9548	CM	9 cells to LIMKi, active phosphorylated LIM kinases have been pr
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	9662 : 9666	CM	rosomes [34]. To test if LIMK activity was important f
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	9701 : 9705	CM	was important for active LIMK localization and mitotic
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	9773 : 9778	CM	 we tested the effect of LIMKi on active phosphorylated
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	9789 : 9803	CM	ffect of LIMKi on active phosphorylated LIMK (p-LIMK) and γTubul
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	9804 : 9808	CM	on active phosphorylated LIMK (p-LIMK) and γTubulin co
./___Corpus/Medline/xml/PMC4770715.xml	p-LIMK	9810 : 9816	CM	ive phosphorylated LIMK (p-LIMK) and γTubulin co-localiz
./___Corpus/Medline/xml/PMC4770715.xml	A549	9858 : 9862	CM	-localization in mitotic A549 cells (Figure ​(Figure3A
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	9914 : 9919	CM	3A). Treatment with 3 μM LIMKi had no effect on p-LIMK 
./___Corpus/Medline/xml/PMC4770715.xml	p-LIMK	9937 : 9943	CM	M LIMKi had no effect on p-LIMK localization, indicating
./___Corpus/Medline/xml/PMC4770715.xml	p-LIMK	9974 : 9980	CM	ization, indicating that p-LIMK localization to centroso
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	10029 : 10033	CM	omes is independent from LIMK activity (Figure ​(Figur
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	10112 : 10117	CM	vious results [12], 3 μM LIMKi eliminated basal and ind
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	10155 : 10170	RN	asal and induced cofilin phosphorylation, indicating inhibition o
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	10197 : 10201	CM	indicating inhibition of LIMK activity, while only sli
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	10241 : 10245	CM	e only slightly reducing LIMK phosphorylation (Figure 
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	10246 : 10261	RN	y slightly reducing LIMK phosphorylation (Figure ​(Figure3C).3C).
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10344 : 10355	CM	on of the vinca alkaloid Vincristine (5 nM), which did not de
./___Corpus/Medline/xml/PMC4770715.xml	p-LIMK	10442 : 10448	CM	5] had a small effect on p-LIMK and γTubulin co-localiza
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10527 : 10538	CM	 The combination of 5 nM Vincristine and 3 μM LIMKi had a sig
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	10548 : 10553	CM	 nM Vincristine and 3 μM LIMKi had a significant effect
./___Corpus/Medline/xml/PMC4770715.xml	p-LIMK	10582 : 10588	CM	 a significant effect on p-LIMK and γTubulin co-localiza
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	10631 : 10635	CM	ocalization greater than DMSO vehicle or Vincristine a
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	10647 : 10658	CM	ter than DMSO vehicle or Vincristine alone (Figure ​(Figure3B
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	10745 : 10750	CM	mages show that combined LIMKi and vincristine treatmen
./___Corpus/Medline/xml/PMC4770715.xml	vincristine	10755 : 10766	CM	 that combined LIMKi and vincristine treatment also had the s
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	10887 : 10891	CM	between microtubules and LIMK function in mitosis (Fig
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11015 : 11020	CM	feration is inhibited by LIMKi combined with microtubul
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11125 : 11130	CM	           The effect of LIMKi combined with Vincristin
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11145 : 11156	CM	t of LIMKi combined with Vincristine on mitotic spindle integ
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11204 : 11209	CM	egrity led us to test if LIMKi would have a combination
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11283 : 11288	CM	roliferation. While 3 μM LIMKi alone did not affect A54
./___Corpus/Medline/xml/PMC4770715.xml	A549	11310 : 11314	CM	MKi alone did not affect A549 cell numbers, when treat
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11372 : 11383	CM	a concentration range of Vincristine in the presence of 3 μM 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11408 : 11413	CM	 in the presence of 3 μM LIMKi or DMSO in a 3-day assay
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	11417 : 11421	CM	resence of 3 μM LIMKi or DMSO in a 3-day assay based o
./___Corpus/Medline/xml/PMC4770715.xml	3-	11427 : 11429	CPR	 3 μM LIMKi or DMSO in a 3-day assay based on counti
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11512 : 11523	CM	as a ~2 fold decrease in Vincristine EC50 in the presence of 
./___Corpus/Medline/xml/PMC4770715.xml	EC50	11524 : 11528	CM	 decrease in Vincristine EC50 in the presence of LIMKi
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11548 : 11553	CM	 EC50 in the presence of LIMKi, indicating a synergisti
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11600 : 11611	CM	stic cooperation between Vincristine and LIMKi (Figure ​(Figu
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11616 : 11621	CM	 between Vincristine and LIMKi (Figure ​(Figure4A).4A).
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	11691 : 11702	CM	fects of fixed ratios of Vincristine (0.625-5 nM) and LIMKi (
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11720 : 11725	CM	ristine (0.625-5 nM) and LIMKi (2.5-20 μM) concentratio
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	11951 : 11956	CM	-Talalay method [36] for LIMKi concentrations < 10 μM (
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	12028 : 12035	CM	. Furthermore, there was ~2-fold difference in Vincristin
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12050 : 12061	CM	as ~2-fold difference in Vincristine EC50 between spontaneous
./___Corpus/Medline/xml/PMC4770715.xml	EC50	12062 : 12066	CM	ifference in Vincristine EC50 between spontaneously im
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	12265 : 12270	CM	he combined treatment of LIMKi and Vincristine decrease
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12275 : 12286	CM	d treatment of LIMKi and Vincristine decreased cell numbers, 
./___Corpus/Medline/xml/PMC4770715.xml	propidium iodide	12384 : 12400	CM	d cell sorting (FACS) of propidium iodide (PI) stained cells. The 
./___Corpus/Medline/xml/PMC4770715.xml	PI	12402 : 12404	CM	CS) of propidium iodide (PI) stained cells. The prop
./___Corpus/Medline/xml/PMC4770715.xml	4N	12451 : 12453	CM	roportions of cells with 4N DNA content, indicative 
./___Corpus/Medline/xml/PMC4770715.xml	G2	12481 : 12483	CM	A content, indicative of G2/M cell cycle phases, wer
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12539 : 12550	CM	ressively increased with Vincristine concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	12589 : 12594	CM	 when combined with 3 μM LIMKi (Figure ​(Figure4D,4D, l
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	12648 : 12653	CM	panel) or with increased LIMKi concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12692 : 12703	CM	 when combined with 5 nM Vincristine (Figure ​(Figure4D,4D, r
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	12752 : 12756	CM	right panel) relative to DMSO vehicle control. In addi
./___Corpus/Medline/xml/PMC4770715.xml	2N	12807 : 12809	CM	ion, the proportion of < 2N DNA content, typically a
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	12924 : 12935	CM	increased with increased Vincristine concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	12974 : 12979	CM	 when combined with 3 μM LIMKi (Figure ​(Figure4E,4E, l
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure4E,4E	12988 : 13001	CM	 with 3 μM LIMKi (Figure ​(Figure4E,4E, left panel) or with inc
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13033 : 13038	CM	panel) or with increased LIMKi concentration when combi
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	13077 : 13088	CM	 when combined with 5 nM Vincristine (Figure ​(Figure4E,4E, r
./___Corpus/Medline/xml/PMC4770715.xml	​(Figure4E,4E	13097 : 13110	CM	5 nM Vincristine (Figure ​(Figure4E,4E, right panel) relative t
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	13137 : 13141	CM	right panel) relative to DMSO vehicle control. Taken t
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13226 : 13231	CM	t the combined effect of LIMKi and a microtubule polyme
./___Corpus/Medline/xml/PMC4770715.xml	G2	13343 : 13345	CM	sis, leading to impaired G2/M cell cycle progression
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	13485 : 13496	CM	 effect was specific for Vincristine, we tested additional mi
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13564 : 13569	CM	g drugs with and without LIMKi. The microtubule polymer
./___Corpus/Medline/xml/PMC4770715.xml	Vinorelbine	13613 : 13624	CM	olymerization inhibitors Vinorelbine (Figure ​(Figure4F)4F) a
./___Corpus/Medline/xml/PMC4770715.xml	Colchicine	13652 : 13662	CM	igure ​(Figure4F)4F) and Colchicine (Figure ​(Figure4G)4G) h
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	13698 : 13705	CM	Figure4G)4G) had similar ~2-fold decreases in EC50 in the
./___Corpus/Medline/xml/PMC4770715.xml	EC50	13719 : 13723	CM	lar ~2-fold decreases in EC50 in the presence of LIMKi
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13743 : 13748	CM	 EC50 in the presence of LIMKi. These results indicate 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13778 : 13783	CM	se results indicate that LIMKi synergizes with agents t
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13864 : 13869	CM	zation.                  LIMKi potentiates kinase inhib
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	13999 : 14004	CM	ive interactions between LIMKi and microtubule polymeri
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	14129 : 14133	CM	 would also combine with LIMK inhibition to block canc
./___Corpus/Medline/xml/PMC4770715.xml	GSK	14231 : 14234	CM	was undertaken using the GSK published kinase inhibit
./___Corpus/Medline/xml/PMC4770715.xml	A549	14319 : 14323	CM	 kinase inhibitors [30]. A549 cells were treated with 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	14419 : 14424	CM	 in the presence of 3 μM LIMKi or DMSO. Compounds havin
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	14428 : 14432	CM	resence of 3 μM LIMKi or DMSO. Compounds having either
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	14655 : 14660	CM	 when combined with 3 μM LIMKi were selected as 20 hits
./___Corpus/Medline/xml/PMC4770715.xml	2-fold	14749 : 14755	CM	 produced a greater than 2-fold decrease in absolute EC5
./___Corpus/Medline/xml/PMC4770715.xml	EC50	14777 : 14781	CM	old decrease in absolute EC50 when combined with 3 μM 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	14806 : 14811	CM	 when combined with 3 μM LIMKi (Figure ​(Figure5C)5C) w
./___Corpus/Medline/xml/PMC4770715.xml	GSK	15222 : 15225	CM	ata for the 63 hits from GSK were clustered by pairwi
./___Corpus/Medline/xml/PMC4770715.xml	TM4	15329 : 15332	CM	ct distance option using TM4 [37] (Figure ​(Figure5E)
./___Corpus/Medline/xml/PMC4770715.xml	VEGFR	15500 : 15505	CM	 designated targets were VEGFR or VEGFR/TIE2, GSK3, AKT
./___Corpus/Medline/xml/PMC4770715.xml	VEGFR	15509 : 15514	CM	ed targets were VEGFR or VEGFR/TIE2, GSK3, AKT, CDK2 an
./___Corpus/Medline/xml/PMC4770715.xml	TIE2	15515 : 15519	CM	gets were VEGFR or VEGFR/TIE2, GSK3, AKT, CDK2 and IGF
./___Corpus/Medline/xml/PMC4770715.xml	GSK3	15521 : 15525	CM	ere VEGFR or VEGFR/TIE2, GSK3, AKT, CDK2 and IGF1R. Ho
./___Corpus/Medline/xml/PMC4770715.xml	AKT	15527 : 15530	CM	GFR or VEGFR/TIE2, GSK3, AKT, CDK2 and IGF1R. However
./___Corpus/Medline/xml/PMC4770715.xml	CDK2	15532 : 15536	CM	r VEGFR/TIE2, GSK3, AKT, CDK2 and IGF1R. However, the 
./___Corpus/Medline/xml/PMC4770715.xml	IGF1R	15541 : 15546	CM	IE2, GSK3, AKT, CDK2 and IGF1R. However, the broad spec
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	15903 : 15907	CM	ogical interactions with LIMK signaling, including PLK
./___Corpus/Medline/xml/PMC4770715.xml	PLK1	15929 : 15933	CM	IMK signaling, including PLK1, RAF, EGFR/ErbB2 and p38
./___Corpus/Medline/xml/PMC4770715.xml	RAF	15935 : 15938	CM	gnaling, including PLK1, RAF, EGFR/ErbB2 and p38. The
./___Corpus/Medline/xml/PMC4770715.xml	EGFR	15940 : 15944	CM	ng, including PLK1, RAF, EGFR/ErbB2 and p38. These res
./___Corpus/Medline/xml/PMC4770715.xml	ErbB2	15945 : 15950	CM	ncluding PLK1, RAF, EGFR/ErbB2 and p38. These results i
./___Corpus/Medline/xml/PMC4770715.xml	p38	15955 : 15958	CM	LK1, RAF, EGFR/ErbB2 and p38. These results indicate 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	16050 : 16054	CM	e drug combinations with LIMK inhibitors, in addition 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	16221 : 16225	CM	      Discovery of novel LIMK inhibitors              
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	16293 : 16297	CM	potential for the use of LIMK inhibitors as cancer che
./___Corpus/Medline/xml/PMC4770715.xml	lead	16548 : 16552	CM	wing iterative rounds of lead optimization medicinal c
./___Corpus/Medline/xml/PMC4770715.xml	vitro	16593 : 16598	CM	dicinal chemistry and in vitro enzyme assays, two compo
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	16655 : 16659	CM	re developed with potent LIMK inhibitory activity; N-{
./___Corpus/Medline/xml/PMC4770715.xml	N-{5-[3-(4-Methoxy-2-trifluoromethyl-phenyl)-pyridin-4-yl]-hiazol-2-yl}-isobutyramide	16681 : 16766	CM	IMK inhibitory activity; N-{5-[3-(4-Methoxy-2-trifluoromethyl-phenyl)-pyridin-4-yl]-hiazol-2-yl}-isobutyramide (CRT0105446; Figure ​Fig
./___Corpus/Medline/xml/PMC4770715.xml	4-{5-[3-(2-Chloro-4-methyl-phenyl)-pyridin-4-yl]-thiazol-2-ylamino}-phenol	16805 : 16879	CM	Figure ​Figure6A)6A) and 4-{5-[3-(2-Chloro-4-methyl-phenyl)-pyridin-4-yl]-thiazol-2-ylamino}-phenol (CRT0105950; Figure ​Fig
./___Corpus/Medline/xml/PMC4770715.xml	vitro	16997 : 17002	CM	rles et al. [39]. The in vitro IC50 values for LIMK1 an
./___Corpus/Medline/xml/PMC4770715.xml	IC50	17003 : 17007	CM	t al. [39]. The in vitro IC50 values for LIMK1 and LIM
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	17019 : 17024	CM	in vitro IC50 values for LIMK1 and LIMK2 were 8 nM and 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	17029 : 17034	CM	C50 values for LIMK1 and LIMK2 were 8 nM and 32 nM resp
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	17072 : 17082	CM	d 32 nM respectively for CRT0105446, and 0.3 nM and 1 nM res
./___Corpus/Medline/xml/PMC4770715.xml	kinome	17367 : 17373	CM	le 6), and mapped onto a kinome phylogenetic tree [32] i
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	17473 : 17483	CM	cificity quantitatively, CRT0105446 and CRT0105950 S(35) sel
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17499 : 17504	CM	RT0105446 and CRT0105950 S(35) selectivity scores (Figu
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17662 : 17667	CM	inases, were compared to S(35) values for 38 additional
./___Corpus/Medline/xml/PMC4770715.xml	S(1)	17839 : 17843	CM	re ​Figure6C6C depicting S(1) (i.e. proportion of kina
./___Corpus/Medline/xml/PMC4770715.xml	S(10)	17891 : 17896	CM	nases inhibited by 99%), S(10) (proportion of kinases i
./___Corpus/Medline/xml/PMC4770715.xml	S(35)	17942 : 17947	CM	es inhibited by 90%) and S(35) selectivity scores depic
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	18002 : 18012	CM	e greater selectivity of CRT0105446 relative to the more pot
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	18131 : 18141	CM	 cell-based potencies of CRT0105446 and CRT0105950 with LIMK
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	18162 : 18167	CM	5446 and CRT0105950 with LIMKi using three read-outs: c
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18199 : 18214	RN	three read-outs: cofilin phosphorylation, αTubulin acetylation an
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	18225 : 18236	RN	hosphorylation, αTubulin acetylation and three-dimensional (3
./___Corpus/Medline/xml/PMC4770715.xml	3-	18260 : 18262	CPR	n and three-dimensional (3-D) extracellular matrix i
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	18364 : 18375	RN	t at increasing αTubulin acetylation (Figure ​(Figure7A)7A) a
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18422 : 18437	RN	) and decreasing cofilin phosphorylation (Figure ​(Figure7B)7B) i
./___Corpus/Medline/xml/PMC4770715.xml	A549	18464 : 18468	CM	Figure ​(Figure7B)7B) in A549 lung cancer cells. To mo
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	18527 : 18531	CM	ely determine cell-based LIMK inhibitor activity, MCF7
./___Corpus/Medline/xml/PMC4770715.xml	MCF7	18552 : 18556	CM	LIMK inhibitor activity, MCF7 breast cancer cells were
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	18603 : 18614	CM	ere treated with 2 μg/mL doxorubicin, which strongly increase
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	18649 : 18664	RN	rongly increases cofilin phosphorylation through increased p53-me
./___Corpus/Medline/xml/PMC4770715.xml	p53	18683 : 18686	CM	lation through increased p53-mediated transcription o
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	18713 : 18718	CM	ediated transcription of LIMK2 and RhoC genes [12] to i
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	18839 : 18843	CM	arying concentrations of LIMK inhibitors for 18 hr, th
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylated	18940 : 18954	CM	escence determination of phosphorylated cofilin intensity. Dose-
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19049 : 19064	RN	pounds inhibited cofilin phosphorylation, with LIMKi being ~2-fol
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	19071 : 19076	CM	in phosphorylation, with LIMKi being ~2-fold more poten
./___Corpus/Medline/xml/PMC4770715.xml	~2-fold	19083 : 19090	CM	lation, with LIMKi being ~2-fold more potent than CRT0105
./___Corpus/Medline/xml/PMC4770715.xml	7-fold	19123 : 19129	CM	tent than CRT0105950 and 7-fold more potent than CRT0105
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	19147 : 19157	CM	 7-fold more potent than CRT0105446 in this assay format (Fi
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	19237 : 19241	CM	ionally established that LIMK inhibition resulted in d
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19283 : 19298	RN	ted in decreased cofilin phosphorylation in MDAMB231 human breast
./___Corpus/Medline/xml/PMC4770715.xml	MDAMB231	19302 : 19310	CM	filin phosphorylation in MDAMB231 human breast cancer cell
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	19375 : 19380	CM	the effect of a range of LIMKi and CRT0105950 concentra
./___Corpus/Medline/xml/PMC4770715.xml	phospho-cofilin	19414 : 19429	CM	105950 concentrations on phospho-cofilin levels. As shown in Figu
./___Corpus/Medline/xml/PMC4770715.xml	​and7E,7E	19473 : 19482	CM	n Figure ​Figure7D7D and ​and7E,7E, both inhibitors induced
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	19544 : 19559	RN	ent decreases in cofilin phosphorylation. Finally, the inverse in
./___Corpus/Medline/xml/PMC4770715.xml	3-	19594 : 19596	CPR	 the inverse invasion of 3-D matrigel by MDAMB231 br
./___Corpus/Medline/xml/PMC4770715.xml	MDAMB231	19610 : 19618	CM	asion of 3-D matrigel by MDAMB231 breast cancer cells abov
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	19697 : 19702	CM	cantly inhibited by 3 μM LIMKi, CRT0105446 and CRT01059
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	19704 : 19714	CM	inhibited by 3 μM LIMKi, CRT0105446 and CRT0105950 (Figure ​
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	19803 : 19808	CM	vious observations using LIMKi [9]. These results are c
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	19896 : 19900	CM	ing potent inhibitors of LIMK activity in cells.      
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	19981 : 19985	CM	ancer cells sensitive to LIMK inhibitors              
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	20089 : 20093	CM	 sensitivity to chemical LIMK inhibitors, a screen was
./___Corpus/Medline/xml/PMC4770715.xml	EC50	20325 : 20329	CM	 By comparing calculated EC50 values for cell lines (S
./___Corpus/Medline/xml/PMC4770715.xml	7-	20373 : 20375	CPR	nes (Supplemental Tables 7-8) within a given cancer 
./___Corpus/Medline/xml/PMC4770715.xml	9-	20455 : 20457	CPR	ines (Supplemental Table 9-10), significantly (p < 0
./___Corpus/Medline/xml/PMC4770715.xml	EC50	20578 : 20582	CM	re8A8A shows natural log EC50 values (in μM) of CRT010
./___Corpus/Medline/xml/PMC4770715.xml	μM	20594 : 20596	CM	ural log EC50 values (in μM) of CRT0105950 for each 
./___Corpus/Medline/xml/PMC4770715.xml	EC50	20688 : 20692	CM	red line indicating mean EC50 and arranged in order of
./___Corpus/Medline/xml/PMC4770715.xml	EC50	20729 : 20733	CM	d in order of their mean EC50 from low to high values.
./___Corpus/Medline/xml/PMC4770715.xml	EC50	20780 : 20784	CM	es. Relative to the mean EC50 of CRT0105950 for all ca
./___Corpus/Medline/xml/PMC4770715.xml	EC50	21122 : 21126	CM	s), relative to the mean EC50 of all cancer cells to C
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	21150 : 21160	CM	0 of all cancer cells to CRT0105446 (238 μM).               
./___Corpus/Medline/xml/PMC4770715.xml	μM	21166 : 21168	CM	cells to CRT0105446 (238 μM).                       
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	21295 : 21305	CM	the on-target effects of CRT0105446 and CRT0105950, we plott
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105950	21310 : 21320	CM	ffects of CRT0105446 and CRT0105950, we plotted the mean EC5
./___Corpus/Medline/xml/PMC4770715.xml	EC50	21342 : 21346	CM	950, we plotted the mean EC50 values for both drugs of
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	21566 : 21576	CM	ignificantly affected by CRT0105446 are depicted with orange
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	21991 : 21995	CM	cantly sensitive to both LIMK inhibitors, with 6 addit
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	22540 : 22544	CM	f neuroblastoma cells to LIMK inhibitors, we tested 6 
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	22617 : 22622	CM	s for their responses to LIMKi (Figure 10A). When the m
./___Corpus/Medline/xml/PMC4770715.xml	EC50	22663 : 22667	CM	hen the mean natural log EC50 values of LIMKi for thes
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	22678 : 22683	CM	tural log EC50 values of LIMKi for these 6 cell lines w
./___Corpus/Medline/xml/PMC4770715.xml	EC50	22750 : 22754	CM	RT0105950 and CRT0105446 EC50 values for the 27 neurob
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	22820 : 22825	CM	es from the screen, both LIMKi and CRT0105950 were sign
./___Corpus/Medline/xml/PMC4770715.xml	10B	22938 : 22941	CM	 from each other (Figure 10B), consistent with their 
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	23016 : 23031	RN	or inhibition of cofilin phosphorylation, tubulin acetylation and
./___Corpus/Medline/xml/PMC4770715.xml	tubulin	23033 : 23040	CM	cofilin phosphorylation, tubulin acetylation and matrix i
./___Corpus/Medline/xml/PMC4770715.xml	acetylation	23041 : 23052	RN	phosphorylation, tubulin acetylation and matrix invasion (Fig
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	23131 : 23135	CM	rate the requirement for LIMK activity in neuroblastom
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	23185 : 23190	CM	a cells, we knocked down LIMK1 and LIMK2, either by com
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	23195 : 23200	CM	e knocked down LIMK1 and LIMK2, either by combining two
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	23250 : 23255	CM	 siRNA oligonucleotides (LIMK1+LIMK2) or using an siRNA
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	23256 : 23261	CM	 oligonucleotides (LIMK1+LIMK2) or using an siRNA oligo
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-AS	23352 : 23359	CM	ion of both proteins, in SK-N-AS and SK-N-SH cells (Figur
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-SH	23364 : 23371	CM	proteins, in SK-N-AS and SK-N-SH cells (Figure 10C). Rela
./___Corpus/Medline/xml/PMC4770715.xml	NTC	23429 : 23432	CM	a non-targeting control (NTC) oligonucleotide, both f
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	23465 : 23469	CM	ucleotide, both forms of LIMK knockdown significantly 
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-AS	23534 : 23541	CM	astoma cell viability in SK-N-AS cells (Figure 10D) and S
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-SH	23565 : 23572	CM	S cells (Figure 10D) and SK-N-SH cells (Figure 10E).     
./___Corpus/Medline/xml/PMC4770715.xml	actin	23706 : 23711	CM	 roles in regulating the actin cytoskeleton through the
./___Corpus/Medline/xml/PMC4770715.xml	anti-	23832 : 23837	CPR	as potential targets for anti-metastasis therapy [1, 15
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	23898 : 23903	CM	as recently emerged that LIMK1 and LIMK2 also influence
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	23908 : 23913	CM	y emerged that LIMK1 and LIMK2 also influence microtubu
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	24027 : 24031	CM	which is consistent with LIMK inhibitors being potenti
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	24127 : 24131	CM	the effect of inhibiting LIMK activity on microtubule 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	24367 : 24371	CM	l drug combinations with LIMK inhibition were identifi
./___Corpus/Medline/xml/PMC4770715.xml	EGFR	24410 : 24414	CM	re identified, including EGFR and Raf kinases. Previou
./___Corpus/Medline/xml/PMC4770715.xml	Raf	24419 : 24422	CM	fied, including EGFR and Raf kinases. Previous resear
./___Corpus/Medline/xml/PMC4770715.xml	anti-	24510 : 24515	CPR	 cancer cell lines to 55 anti-cancer drugs revealed tha
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	24551 : 24556	CM	s revealed that elevated LIMK2 expression was significa
./___Corpus/Medline/xml/PMC4770715.xml	bleomycin	24662 : 24671	CM	oisomerase I inhibitors, bleomycin derivatives and anthracy
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	24711 : 24722	CM	d anthracyclines such as doxorubicin) independent of the tiss
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	24813 : 24818	CM	A damaging agents induce LIMK2 expression via p53, whil
./___Corpus/Medline/xml/PMC4770715.xml	p53	24834 : 24837	CM	uce LIMK2 expression via p53, while inhibition or kno
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	24872 : 24877	CM	hibition or knockdown of LIMK2 activity increased sensi
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	24993 : 24997	CM	ings are consistent with LIMK activity being an import
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	25142 : 25146	CM	ancer types sensitive to LIMK inhibition, 656 cancer c
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	25215 : 25225	CM	ened with dose ranges of CRT0105446 and CRT0105950 that enab
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	25354 : 25358	CM	cantly sensitive to both LIMK inhibitors; rhabdomyosar
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	25514 : 25525	CM	lected for resistance to Vincristine had increased LIMK2 expr
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	25540 : 25545	CM	incristine had increased LIMK2 expression, while LIMK2 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	25564 : 25569	CM	 LIMK2 expression, while LIMK2 knockdown led to the for
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	25668 : 25679	CM	d neuroblastoma cells to Vincristine and Vinblastine [13]. Fu
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	25715 : 25720	CM	stine [13]. Furthermore, LIMK2 knockdown increased cell
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	25869 : 25873	CM	ith a prominent role for LIMK signalling in neuroblast
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	25955 : 25959	CM	           The two novel LIMK inhibitors described in 
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	26003 : 26013	CM	ed in the present study, CRT0105446 and CRT0105950, are pote
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105950	26018 : 26028	CM	nt study, CRT0105446 and CRT0105950, are potent inhibitors o
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	26055 : 26060	CM	are potent inhibitors of LIMK1 and LIMK2 that will enab
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	26065 : 26070	CM	 inhibitors of LIMK1 and LIMK2 that will enable further
./___Corpus/Medline/xml/PMC4770715.xml	A549	26234 : 26238	CM	ion                      A549 non-small cell lung aden
./___Corpus/Medline/xml/PMC4770715.xml	MDAMB231	26275 : 26283	CM	ell lung adenocarcinoma, MDAMB231 and MCF7 breast cancer a
./___Corpus/Medline/xml/PMC4770715.xml	MCF7	26288 : 26292	CM	ocarcinoma, MDAMB231 and MCF7 breast cancer and neurob
./___Corpus/Medline/xml/PMC4770715.xml	MHH-NB-11	26337 : 26346	CM	euroblastoma cell lines (MHH-NB-11, LAN-6, SH-SY5Y, SK-N-BE
./___Corpus/Medline/xml/PMC4770715.xml	LAN-6	26348 : 26353	CM	a cell lines (MHH-NB-11, LAN-6, SH-SY5Y, SK-N-BE-2c, SK
./___Corpus/Medline/xml/PMC4770715.xml	SH-SY5Y	26355 : 26362	CM	lines (MHH-NB-11, LAN-6, SH-SY5Y, SK-N-BE-2c, SK-N-AS, SK
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-BE-2c	26364 : 26374	CM	H-NB-11, LAN-6, SH-SY5Y, SK-N-BE-2c, SK-N-AS, SK-N-SH, SK-N-
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-AS	26376 : 26383	CM	-6, SH-SY5Y, SK-N-BE-2c, SK-N-AS, SK-N-SH, SK-N-MC, IMR-3
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-SH	26385 : 26392	CM	5Y, SK-N-BE-2c, SK-N-AS, SK-N-SH, SK-N-MC, IMR-32) were c
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-MC	26394 : 26401	CM	BE-2c, SK-N-AS, SK-N-SH, SK-N-MC, IMR-32) were cultured a
./___Corpus/Medline/xml/PMC4770715.xml	IMR-32	26403 : 26409	CM	-N-AS, SK-N-SH, SK-N-MC, IMR-32) were cultured according
./___Corpus/Medline/xml/PMC4770715.xml	ATCC	26438 : 26442	CM	re cultured according to ATCC guidelines. Cell identit
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	26727 : 26746	CM	l Signaling Technology), acetylated-αTubulin (Novus Biologicals), pLI
./___Corpus/Medline/xml/PMC4770715.xml	pLIMK	26768 : 26773	CM	lin (Novus Biologicals), pLIMK (Thr508 - LIMK1, Thr505 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	26784 : 26789	CM	gicals), pLIMK (Thr508 - LIMK1, Thr505 - LIMK2; Abcam o
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	26800 : 26805	CM	Thr508 - LIMK1, Thr505 - LIMK2; Abcam or Cell Signaling
./___Corpus/Medline/xml/PMC4770715.xml	Abcam	26807 : 26812	CM	- LIMK1, Thr505 - LIMK2; Abcam or Cell Signaling Techno
./___Corpus/Medline/xml/PMC4770715.xml	phospho-cofilin	26862 : 26877	CM	logy), γTubulin (Sigma), phospho-cofilin (Ser3; Cell Signaling Te
./___Corpus/Medline/xml/PMC4770715.xml	Ser3	26879 : 26883	CM	Sigma), phospho-cofilin (Ser3; Cell Signaling Technolo
./___Corpus/Medline/xml/PMC4770715.xml	Abcam	26922 : 26927	CM	ng Technology), cofilin (Abcam) and ERK2 (Ab122; CJ Mar
./___Corpus/Medline/xml/PMC4770715.xml	ERK2	26933 : 26937	CM	gy), cofilin (Abcam) and ERK2 (Ab122; CJ Marshall, Ins
./___Corpus/Medline/xml/PMC4770715.xml	lysis	27085 : 27090	RN	ere lysed with 500 μl of lysis buffer (1x Tris-buffered
./___Corpus/Medline/xml/PMC4770715.xml	1x	27099 : 27101	CM	 500 μl of lysis buffer (1x Tris-buffered saline (TB
./___Corpus/Medline/xml/PMC4770715.xml	EDTA	27148 : 27152	CM	(TBS), 1% Triton-X, 1 nM EDTA, 0.2 mM Na3VO4, 20 mM Na
./___Corpus/Medline/xml/PMC4770715.xml	Na3VO4	27161 : 27167	CM	ton-X, 1 nM EDTA, 0.2 mM Na3VO4, 20 mM NaF, 1 mM PMSF, a
./___Corpus/Medline/xml/PMC4770715.xml	NaF	27175 : 27178	CM	TA, 0.2 mM Na3VO4, 20 mM NaF, 1 mM PMSF, and cOmplete
./___Corpus/Medline/xml/PMC4770715.xml	PMSF	27185 : 27189	CM	 Na3VO4, 20 mM NaF, 1 mM PMSF, and cOmplete Mini prote
./___Corpus/Medline/xml/PMC4770715.xml	plate	27256 : 27261	CM	ktail (Roche)) per 10 cm plate. Lysates were cleared by
./___Corpus/Medline/xml/PMC4770715.xml	10-	27287 : 27290	CPR	 Lysates were cleared by 10-minute centrifugation and
./___Corpus/Medline/xml/PMC4770715.xml	LI-COR	27568 : 27574	CM	infrared imaging system (LI-COR).                  Immun
./___Corpus/Medline/xml/PMC4770715.xml	Zeiss710	27781 : 27789	CM	mages were acquired on a Zeiss710 laser-scanning confocal 
./___Corpus/Medline/xml/PMC4770715.xml	ZEN2010	27842 : 27849	CM	roscope and processed in ZEN2010 (Zeiss).                
./___Corpus/Medline/xml/PMC4770715.xml	acetylated-αTubulin	27969 : 27988	CM	luorescence intensity of acetylated-αTubulin was quantified in ImageJ
./___Corpus/Medline/xml/PMC4770715.xml	A549	28722 : 28726	CM	say                      A549 cells were plated in 96-
./___Corpus/Medline/xml/PMC4770715.xml	96-	28748 : 28751	CPR	549 cells were plated in 96-well plates at 2000 cells
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	28911 : 28916	CM	 in the presence of 3 μM LIMKi or DMSO, for 72 hours. S
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	28920 : 28924	CM	resence of 3 μM LIMKi or DMSO, for 72 hours. Surviving
./___Corpus/Medline/xml/PMC4770715.xml	paraformaldehyde	28975 : 28991	CM	cells were fixed with 4% paraformaldehyde and stained with 250 ng/
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	29019 : 29023	CM	d stained with 250 ng/ml DAPI. Experiments were repeat
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	29309 : 29313	CM	d as percent change from DMSO-treated control and EC50
./___Corpus/Medline/xml/PMC4770715.xml	EC50	29334 : 29338	CM	DMSO-treated control and EC50 values were calculated f
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	29497 : 29502	CM	with serial dilutions of LIMKi (2.5-20 μM) and Vincrist
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	29519 : 29530	CM	of LIMKi (2.5-20 μM) and Vincristine (0.625-5 nM) alone or in
./___Corpus/Medline/xml/PMC4770715.xml	CalcuSyn	29766 : 29774	CM	ers were determined with CalcuSyn [36]. Neuroblastoma cell
./___Corpus/Medline/xml/PMC4770715.xml	G2	29953 : 29955	CM	              Sub-G1 and G2/M quantification        
./___Corpus/Medline/xml/PMC4770715.xml	G2	30156 : 30158	CM	sub-G1 DNA content or in G2/M phase were measured an
./___Corpus/Medline/xml/PMC4770715.xml	384-	30315 : 30319	CPR	at 350 cells per well in 384-well plates, in 5 technic
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	30532 : 30537	CM	 in the presence of 3 μM LIMKi or DMSO, for 72 hours. V
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30541 : 30545	CM	resence of 3 μM LIMKi or DMSO, for 72 hours. Vincristi
./___Corpus/Medline/xml/PMC4770715.xml	Vincristine	30561 : 30572	CM	i or DMSO, for 72 hours. Vincristine was used as a positive c
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30608 : 30612	CM	s a positive control and DMSO (final 0.4%) was used as
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	30689 : 30693	CM	were fixed, stained with DAPI, and nuclei of surviving
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30843 : 30847	CM	r relative to the median DMSO alone-treated cell numbe
./___Corpus/Medline/xml/PMC4770715.xml	EC50	30887 : 30891	CM	cell number and absolute EC50 values were calculated f
./___Corpus/Medline/xml/PMC4770715.xml	LIMKi	30952 : 30957	CM	pound in the presence of LIMKi or DMSO control using th
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	30961 : 30965	CM	the presence of LIMKi or DMSO control using the Vortex
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	31048 : 31058	CM	            Synthesis of CRT0105446 and CRT0105950 Discovery
./___Corpus/Medline/xml/PMC4770715.xml	CRT0105446	31101 : 31111	CM	scovery and synthesis of CRT0105446 and CRT0105950 as descri
./___Corpus/Medline/xml/PMC4770715.xml	Kinase	31164 : 31170	ASE	 in Charles et al. [39]. Kinase selectivity profiling Se
./___Corpus/Medline/xml/PMC4770715.xml	phosphorylation	31285 : 31300	RN	scribed in [42]. Cofilin phosphorylation quantification          
./___Corpus/Medline/xml/PMC4770715.xml	MCF7	31337 : 31341	CM	ion                      MCF7 human breast cancer cell
./___Corpus/Medline/xml/PMC4770715.xml	polystyrene	31409 : 31420	CM	×103 cells/well in black polystyrene glass-bottomed 96 well p
./___Corpus/Medline/xml/PMC4770715.xml	doxorubicin	31491 : 31502	CM	 next day with 0.2 μg/mL doxorubicin plus indicated LIMK inhi
./___Corpus/Medline/xml/PMC4770715.xml	LIMK	31518 : 31522	CM	xorubicin plus indicated LIMK inhibitor concentrations
./___Corpus/Medline/xml/PMC4770715.xml	paraformaldehyde	31595 : 31611	CM	re washed, fixed with 4% paraformaldehyde, permeabilized with 0.5%
./___Corpus/Medline/xml/PMC4770715.xml	phospho-Ser3	31752 : 31764	CM	 rabbit antibody against phospho-Ser3 cofilin, then Alexa 488 
./___Corpus/Medline/xml/PMC4770715.xml	Alexa	31779 : 31784	CM	ospho-Ser3 cofilin, then Alexa 488 anti-rabbit antibody
./___Corpus/Medline/xml/PMC4770715.xml	anti-	31789 : 31794	CPR	 cofilin, then Alexa 488 anti-rabbit antibody (Invitrog
./___Corpus/Medline/xml/PMC4770715.xml	DAPI	31868 : 31872	CM	n (Molecular Probes) and DAPI (Sigma). After washing, 
./___Corpus/Medline/xml/PMC4770715.xml	phospho-Ser3	31975 : 31987	CM	system (PerkinElmer) and phospho-Ser3 cofilin fluorescence int
./___Corpus/Medline/xml/PMC4770715.xml	DMSO	32152 : 32156	CM	d as percent change from DMSO alone-treated control fo
./___Corpus/Medline/xml/PMC4770715.xml	EC50	32227 : 32231	CM	eplicate determinations. EC50 values were calculated f
./___Corpus/Medline/xml/PMC4770715.xml	MDAMB231	32347 : 32355	CM	  Inverse invasion assay MDAMB231 human breast cancer cell
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-AS	32543 : 32550	CM	own                      SK-N-AS or SK-N-SH cells were tr
./___Corpus/Medline/xml/PMC4770715.xml	SK-N-SH	32554 : 32561	CM	              SK-N-AS or SK-N-SH cells were transiently t
./___Corpus/Medline/xml/PMC4770715.xml	Gold	32690 : 32694	CM	 well, using DreamFectTM Gold transfection reagent (OZ
./___Corpus/Medline/xml/PMC4770715.xml	96-	32811 : 32814	CPR	at 500 cells per well in 96-well plates and incubated
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	32992 : 32997	CM	facturer's instructions. LIMK1 and LIMK2 ON-TARGETplus 
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	33002 : 33007	CM	 instructions. LIMK1 and LIMK2 ON-TARGETplus siRNA SMAR
./___Corpus/Medline/xml/PMC4770715.xml	5′-	33099 : 33102	CPR	, sense strand sequence: 5′-AGGCTATCAAGGTGACACA-3′; N
./___Corpus/Medline/xml/PMC4770715.xml	24-	33265 : 33268	CPR	ach assay were plated in 24-well plates and lysed aft
./___Corpus/Medline/xml/PMC4770715.xml	LIMK1	33306 : 33311	CM	nd lysed after 72 hours. LIMK1 and LIMK2 protein levels
./___Corpus/Medline/xml/PMC4770715.xml	LIMK2	33316 : 33321	CM	fter 72 hours. LIMK1 and LIMK2 protein levels were dete
./___Corpus/Medline/xml/PMC4770715.xml	GSK	33616 : 33619	CM	cknowledgments Thanks to GSK for provision of PKIS. F
./___Corpus/Medline/xml/PMC4770715.xml	CONFLICTS	33653 : 33662	CM	ision of PKIS. Footnotes CONFLICTS OF INTEREST The authors 
./___Corpus/Medline/xml/PMC4770715.xml	A12478	33773 : 33779	CM	d by Cancer Research UK (A12478, A12966, A18276). REFERE
./___Corpus/Medline/xml/PMC4819002.xml	imatinib	5055 : 5063	CM	ey include drugs such as imatinib, an inhibitor of the tyr
./___Corpus/Medline/xml/PMC4819002.xml	tyrosine	5085 : 5093	CM	nib, an inhibitor of the tyrosine kinase enzyme BCR-ABL, w
./___Corpus/Medline/xml/PMC4819002.xml	sunitinib	5267 : 5276	CM	eceptor (VEGFR), such as sunitinib, sorafenib and bevacizum
./___Corpus/Medline/xml/PMC4819002.xml	sorafenib	5278 : 5287	CM	GFR), such as sunitinib, sorafenib and bevacizumab, used in
./___Corpus/Medline/xml/PMC4819002.xml	gefitinib	5496 : 5505	CM	eptor (EGFR) inhibitors (gefitinib, erlotinib) used in lung
./___Corpus/Medline/xml/PMC4819002.xml	erlotinib	5507 : 5516	CM	) inhibitors (gefitinib, erlotinib) used in lung cancer, an
./___Corpus/Medline/xml/PMC4819002.xml	Her2	5547 : 5551	CM	 in lung cancer, and the Her2 inhibitor trastuzumab us
./___Corpus/Medline/xml/PMC4819002.xml	ADP ribose	5680 : 5690	CM	fied by research on poly ADP ribose polymerase (PARP) inhibi
./___Corpus/Medline/xml/PMC4819002.xml	methylation	6669 : 6680	RN	t by alterations such as methylation of DNA or modification o
./___Corpus/Medline/xml/PMC4819002.xml	histone	6711 : 6718	CM	A or modification of the histone protein associated with 
./___Corpus/Medline/xml/PMC4819002.xml	OR	7265 : 7267	CM	grades 3 and 4 toxicity (OR=1.52), treatment discont
./___Corpus/Medline/xml/PMC4819002.xml	OR	7302 : 7304	CM	eatment discontinuation (OR=1.33) and toxic deaths (
./___Corpus/Medline/xml/PMC4819002.xml	OR	7329 : 7331	CM	=1.33) and toxic deaths (OR = 1.40) [7]. This worsen
./___Corpus/Medline/xml/PMC4819002.xml	Sunitinib	7614 : 7623	CM	ertheless still limited. Sunitinib, for instance, extends o
./___Corpus/Medline/xml/PMC4819002.xml	docetaxel	8562 : 8571	CM	d the chemotherapy agent docetaxel was recently found to ex
./___Corpus/Medline/xml/PMC4819002.xml	Her-2	8682 : 8687	CM	nts whose tumors express Her-2 by 15.7 months [11].    
./___Corpus/Medline/xml/PMC4819002.xml	late	9316 : 9320	CM	me successes in treating late stage cancers refractory
./___Corpus/Medline/xml/PMC4819002.xml	23–	13982 : 13985	CPR	s make this a challenge [23–26].                     
./___Corpus/Medline/xml/PMC4819002.xml	fate	17805 : 17809	CM	wth: cell survival, cell fate and genome maintenance. 
./___Corpus/Medline/xml/PMC4819002.xml	sorafenib	18885 : 18894	CM	amic networks [33]. Even sorafenib, which inhibits multiple
./___Corpus/Medline/xml/PMC4819002.xml	phosphatidylinositide	19027 : 19048	CM	talk in pathways such as phosphatidylinositide 3-kinase/protein kinase 
./___Corpus/Medline/xml/PMC4819002.xml	3-	19050 : 19052	CPR	s phosphatidylinositide 3-kinase/protein kinase B (P
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	19076 : 19080	CM	kinase/protein kinase B (PI3K/Akt) and Janus kinase (J
./___Corpus/Medline/xml/PMC4819002.xml	(JAK)-STAT	19103 : 19113	CM	3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-induced signali
./___Corpus/Medline/xml/PMC4819002.xml	EMT	19186 : 19189	CM	-mesenchymal transition (EMT) [34]. Conventional drug
./___Corpus/Medline/xml/PMC4819002.xml	nine	20099 : 20103	CM	tical-based targeting of nine “pathways of progression
./___Corpus/Medline/xml/PMC4819002.xml	nine	20219 : 20223	CM	cancer patients [3]. The nine growth pathways are prol
./___Corpus/Medline/xml/PMC4819002.xml	C-	21214 : 21216	CPR	pecific targets such as C-reactive protein (CRP) [37
./___Corpus/Medline/xml/PMC4819002.xml	κ-beta	21281 : 21287	CM	6 (IL-6), nuclear factor κ-beta (NF-κB) [38], prostaglan
./___Corpus/Medline/xml/PMC4819002.xml	NF-κB	21289 : 21294	CM	, nuclear factor κ-beta (NF-κB) [38], prostaglandin E2 
./___Corpus/Medline/xml/PMC4819002.xml	leukotriene	21323 : 21334	CM	8], prostaglandin E2 and leukotriene B4 [39] for inflammation
./___Corpus/Medline/xml/PMC4819002.xml	Her-2	24524 : 24529	CM	 alone, tests range from Her-2 testing, the basis of tr
./___Corpus/Medline/xml/PMC4819002.xml	nine	25581 : 25585	CM	e hallmarks, and Block’s nine pathways of progression 
./___Corpus/Medline/xml/PMC4819002.xml	prophylactic	26436 : 26448	CM	m approach that has both prophylactic and therapeutic potentia
./___Corpus/Medline/xml/PMC4819002.xml	triptolide	28399 : 28409	CM	pproaches. For instance, triptolide, a component of the Chin
./___Corpus/Medline/xml/PMC4819002.xml	Tripterygium	28443 : 28455	CM	nent of the Chinese herb Tripterygium wilfordii, is known to c
./___Corpus/Medline/xml/PMC4819002.xml	lead	34318 : 34322	CM	following specialists: a lead author with demonstrated
./___Corpus/Medline/xml/PMC4819002.xml	lead	35555 : 35559	CM	derstood that this could lead to as many as 110 target
./___Corpus/Medline/xml/PMC4819002.xml	2–	37370 : 37372	CPR	ed is limited, with just 2–8 per patient, which coul
./___Corpus/Medline/xml/PMC4819002.xml	cytochrome	38123 : 38133	CM	rough such mechanisms as cytochrome P450 modification [52], 
./___Corpus/Medline/xml/PMC4819002.xml	FOX0	38691 : 38695	CM	ppressor forkhead box 0 (FOX0) normally causes apoptos
./___Corpus/Medline/xml/PMC4819002.xml	FOX0	38727 : 38731	CM	lly causes apoptosis. If FOX0 is inactivated in cancer
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	38803 : 38807	CM	 upstream from it is the PI3K/Akt1 signaling pathway, 
./___Corpus/Medline/xml/PMC4819002.xml	mitogen	38880 : 38887	CM	ly be targeted [53]. The mitogen-activated protein kinase
./___Corpus/Medline/xml/PMC4819002.xml	mitogen	38951 : 38958	CM	-signal regulated kinase/mitogen/extracellular signal-reg
./___Corpus/Medline/xml/PMC4819002.xml	MEK	38998 : 39001	CM	signal-regulated kinase (MEK) pathway, however, can a
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	39072 : 39076	CM	 compensatory pathway to PI3K/Akt1. So, in order to ef
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	42025 : 42036	CM	own phytochemicals, e.g. resveratrol, epigallocatechin gallat
./___Corpus/Medline/xml/PMC4819002.xml	gallate	42055 : 42062	CM	ratrol, epigallocatechin gallate (EGCG), curcumin, lycope
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	42064 : 42068	CM	pigallocatechin gallate (EGCG), curcumin, lycopene and
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	42071 : 42079	CM	catechin gallate (EGCG), curcumin, lycopene and others, wa
./___Corpus/Medline/xml/PMC4819002.xml	lycopene	42081 : 42089	CM	allate (EGCG), curcumin, lycopene and others, was recently
./___Corpus/Medline/xml/PMC4819002.xml	61–	43009 : 43012	CPR	e laboratory and clinic [61–63], but the quality of o
./___Corpus/Medline/xml/PMC4819002.xml	2–	44275 : 44277	CPR	ls in the Japanese diet (2–3 servings daily, contain
./___Corpus/Medline/xml/PMC4819002.xml	25–	44306 : 44309	CPR	rvings daily, containing 25–50 mg isoflavones) may be
./___Corpus/Medline/xml/PMC4819002.xml	isoflavones	44315 : 44326	CM	ily, containing 25–50 mg isoflavones) may be associated with 
./___Corpus/Medline/xml/PMC4819002.xml	isoflavone	44485 : 44495	CM	ative effects of the soy isoflavone genistein on breast canc
./___Corpus/Medline/xml/PMC4819002.xml	67–	44905 : 44908	CPR	ysiology and metabolism [67–69]. A basic complication
./___Corpus/Medline/xml/PMC4819002.xml	70–	45590 : 45593	CPR	 multi-component agents [70–72].                  3. 
./___Corpus/Medline/xml/PMC4819002.xml	anti-	46395 : 46400	CPR	signaling and evasion of anti-growth signaling, two hal
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	47942 : 47953	CM	g nutraceuticals such as resveratrol [73,74].                
./___Corpus/Medline/xml/PMC4819002.xml	selenium	49848 : 49856	CM	ivity. Vitamins D and B, selenium, carotenoids, PARP inhib
./___Corpus/Medline/xml/PMC4819002.xml	carotenoids	49858 : 49869	CM	amins D and B, selenium, carotenoids, PARP inhibitors, resver
./___Corpus/Medline/xml/PMC4819002.xml	PARP	49871 : 49875	CM	, selenium, carotenoids, PARP inhibitors, resveratrol,
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	49888 : 49899	CM	enoids, PARP inhibitors, resveratrol, and isothiocyanates are
./___Corpus/Medline/xml/PMC4819002.xml	isothiocyanates	49905 : 49920	CM	bitors, resveratrol, and isothiocyanates are priority approaches 
./___Corpus/Medline/xml/PMC4819002.xml	anti-	50093 : 50098	CPR	 immortality, evasion of anti-growth signaling, tumor p
./___Corpus/Medline/xml/PMC4819002.xml	73,76–	50172 : 50178	CPR	nd oncogenic metabolism [73,76–82].                  3.2
./___Corpus/Medline/xml/PMC4819002.xml	hypoxic	50659 : 50666	CM	ith the development of a hypoxic environment [85,86], thi
./___Corpus/Medline/xml/PMC4819002.xml	EMT	51703 : 51706	CM	iogenesis, by undergoing EMT, by altering the balance
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	51865 : 51869	CM	tural compounds (such as EGCG) have been found to inhi
./___Corpus/Medline/xml/PMC4819002.xml	90–	51953 : 51956	CPR	ribute to proliferation [90–92]. Many of these compou
./___Corpus/Medline/xml/PMC4819002.xml	factor-1	53338 : 53346	CM	ng are hypoxia-inducible factor-1 (HIF-1) signaling, NF-κB
./___Corpus/Medline/xml/PMC4819002.xml	HIF-1	53348 : 53353	CM	oxia-inducible factor-1 (HIF-1) signaling, NF-κB signal
./___Corpus/Medline/xml/PMC4819002.xml	NF-κB	53366 : 53371	CM	tor-1 (HIF-1) signaling, NF-κB signaling, PI3K/Akt sign
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	53383 : 53387	CM	naling, NF-κB signaling, PI3K/Akt signaling, wingless-
./___Corpus/Medline/xml/PMC4819002.xml	Wnt	53455 : 53458	CM	 tumor integration site (Wnt) (β-catenin) signaling, 
./___Corpus/Medline/xml/PMC4819002.xml	β-	53461 : 53463	CPR	 integration site (Wnt) (β-catenin) signaling, insul
./___Corpus/Medline/xml/PMC4819002.xml	IGF-1R	53520 : 53526	CM	 growth factor receptor (IGF-1R) signaling, cell cycle [
./___Corpus/Medline/xml/PMC4819002.xml	cyclin	53551 : 53557	CM	) signaling, cell cycle [cyclin-dependent kinases (CDKs)
./___Corpus/Medline/xml/PMC4819002.xml	androgen	53593 : 53601	CM	kinases (CDKs)/cyclins], androgen receptor signaling, and 
./___Corpus/Medline/xml/PMC4819002.xml	estrogen	53626 : 53634	CM	 receptor signaling, and estrogen receptor signaling. Poss
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	53695 : 53703	CM	eutic approaches include curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4819002.xml	genistein	53705 : 53714	CM	oaches include curcumin, genistein and resveratrol.        
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	53719 : 53730	CM	 curcumin, genistein and resveratrol.                  3.3 Ev
./___Corpus/Medline/xml/PMC4819002.xml	anti-	53961 : 53966	CPR	 have internal programs (anti-growth signaling) to oppo
./___Corpus/Medline/xml/PMC4819002.xml	anti-	54086 : 54091	CPR	 must somehow evade many anti-growth signals. In genera
./___Corpus/Medline/xml/PMC4819002.xml	anti-	54119 : 54124	CPR	wth signals. In general, anti-growth signaling is media
./___Corpus/Medline/xml/PMC4819002.xml	p53	54291 : 54294	CM	es, which indicates that p53 is the most frequently m
./___Corpus/Medline/xml/PMC4819002.xml	PTEN	54360 : 54364	CM	pressor gene followed by PTEN, APC, ATM, BRCA2, VHL, R
./___Corpus/Medline/xml/PMC4819002.xml	APC	54366 : 54369	CM	r gene followed by PTEN, APC, ATM, BRCA2, VHL, RB, CD
./___Corpus/Medline/xml/PMC4819002.xml	ATM	54371 : 54374	CM	e followed by PTEN, APC, ATM, BRCA2, VHL, RB, CDKN2A,
./___Corpus/Medline/xml/PMC4819002.xml	BRCA2	54376 : 54381	CM	lowed by PTEN, APC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 
./___Corpus/Medline/xml/PMC4819002.xml	VHL	54383 : 54386	CM	y PTEN, APC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 and W
./___Corpus/Medline/xml/PMC4819002.xml	RB	54388 : 54390	CM	N, APC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1. 
./___Corpus/Medline/xml/PMC4819002.xml	CDKN2A	54392 : 54398	CM	PC, ATM, BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1.         
./___Corpus/Medline/xml/PMC4819002.xml	BRCA1	54400 : 54405	CM	 BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1.                
./___Corpus/Medline/xml/PMC4819002.xml	WT1	54410 : 54413	CM	L, RB, CDKN2A, BRCA1 and WT1.                        
./___Corpus/Medline/xml/PMC4819002.xml	RB	54616 : 54618	CM	 many cases, the loss of RB is due to defects in ups
./___Corpus/Medline/xml/PMC4819002.xml	INK4	54693 : 54697	CM	 such as inactivation of INK4. Loss of p16ink4a result
./___Corpus/Medline/xml/PMC4819002.xml	CDK4	54751 : 54755	CM	 unopposed activation of CDK4/6, which phosphorylates 
./___Corpus/Medline/xml/PMC4819002.xml	phosphorylates	54765 : 54779	CM	ivation of CDK4/6, which phosphorylates the RB protein thereby a
./___Corpus/Medline/xml/PMC4819002.xml	RB	54784 : 54786	CM	which phosphorylates the RB protein thereby activati
./___Corpus/Medline/xml/PMC4819002.xml	E2F	54814 : 54817	CM	otein thereby activating E2F-mediated transcription o
./___Corpus/Medline/xml/PMC4819002.xml	p53	55003 : 55006	CM	e to chromosomal loss is p53 [95]. In fact, more than
./___Corpus/Medline/xml/PMC4819002.xml	p53	55063 : 55066	CM	 all tumors have loss of p53 tumor suppressive functi
./___Corpus/Medline/xml/PMC4819002.xml	p53	55113 : 55116	CM	ctions. Recently, mutant p53 has gained renewed atten
./___Corpus/Medline/xml/PMC4819002.xml	p53	55226 : 55229	CM	essive functions, mutant p53 gains oncogenic/tumor pr
./___Corpus/Medline/xml/PMC4819002.xml	methylation	55386 : 55397	RN	eins, which includes DNA methylation, histone methylation and
./___Corpus/Medline/xml/PMC4819002.xml	histone	55399 : 55406	CM	ncludes DNA methylation, histone methylation and acetylat
./___Corpus/Medline/xml/PMC4819002.xml	methylation	55407 : 55418	RN	DNA methylation, histone methylation and acetylation, is anot
./___Corpus/Medline/xml/PMC4819002.xml	acetylation	55423 : 55434	RN	 histone methylation and acetylation, is another mechanism th
./___Corpus/Medline/xml/PMC4819002.xml	anti-	55489 : 55494	CPR	 which tumor cells evade anti-growth signaling. Many tu
./___Corpus/Medline/xml/PMC4819002.xml	hypermethylation	55573 : 55589	CM	n found to have promoter hypermethylation in cancers [97]. Finally
./___Corpus/Medline/xml/PMC4819002.xml	anti-	55616 : 55621	CPR	n cancers [97]. Finally, anti-growth signaling plays a 
./___Corpus/Medline/xml/PMC4819002.xml	p53	55808 : 55811	CM	 mostly retain wild-type p53 and have better prognosi
./___Corpus/Medline/xml/PMC4819002.xml	histone	56043 : 56050	CM	elopment. At least three histone deacetylase inhibitors, 
./___Corpus/Medline/xml/PMC4819002.xml	deacetylase	56051 : 56062	CM	. At least three histone deacetylase inhibitors, belinostat, 
./___Corpus/Medline/xml/PMC4819002.xml	romidepsin	56102 : 56112	CM	linostat, vorinostat and romidepsin, are currently approved 
./___Corpus/Medline/xml/PMC4819002.xml	98–	56283 : 56286	CPR	ying epigenetic changes [98–102]. Thus, approaches to
./___Corpus/Medline/xml/PMC4819002.xml	anti-	56321 : 56326	CPR	, approaches to activate anti-growth signaling will ope
./___Corpus/Medline/xml/PMC4819002.xml	anti-	56470 : 56475	CPR	 prioritized targets for anti-growth signaling are RB, 
./___Corpus/Medline/xml/PMC4819002.xml	RB	56496 : 56498	CM	nti-growth signaling are RB, p53, phosphatase and te
./___Corpus/Medline/xml/PMC4819002.xml	p53	56500 : 56503	CM	growth signaling are RB, p53, phosphatase and tensin 
./___Corpus/Medline/xml/PMC4819002.xml	phosphatase	56505 : 56516	ASE	h signaling are RB, p53, phosphatase and tensin homolog (PTEN
./___Corpus/Medline/xml/PMC4819002.xml	PTEN	56537 : 56541	CM	tase and tensin homolog (PTEN), Hippo, growth differen
./___Corpus/Medline/xml/PMC4819002.xml	GDF15	56585 : 56590	CM	fferentiation factor 15 (GDF15), AT-rich interactive do
./___Corpus/Medline/xml/PMC4819002.xml	AT	56593 : 56595	CM	ation factor 15 (GDF15), AT-rich interactive domain 
./___Corpus/Medline/xml/PMC4819002.xml	1A	56620 : 56622	CM	-rich interactive domain 1A (ARID1A), Notch, IGF-1R 
./___Corpus/Medline/xml/PMC4819002.xml	ARID1A	56624 : 56630	CM	h interactive domain 1A (ARID1A), Notch, IGF-1R and othe
./___Corpus/Medline/xml/PMC4819002.xml	IGF-1R	56640 : 56646	CM	main 1A (ARID1A), Notch, IGF-1R and others. The approach
./___Corpus/Medline/xml/PMC4819002.xml	E2F	56694 : 56697	CM	ches are inactivation of E2F by down regulation of pR
./___Corpus/Medline/xml/PMC4819002.xml	pRb	56720 : 56723	CM	2F by down regulation of pRb using CDK inhibitors, ac
./___Corpus/Medline/xml/PMC4819002.xml	CDK	56730 : 56733	CM	 regulation of pRb using CDK inhibitors, activation o
./___Corpus/Medline/xml/PMC4819002.xml	p53	56799 : 56802	CM	-regulation of wild-type p53, activation of PTEN to i
./___Corpus/Medline/xml/PMC4819002.xml	PTEN	56818 : 56822	CM	-type p53, activation of PTEN to inhibit PI3K-AKT, act
./___Corpus/Medline/xml/PMC4819002.xml	PI3K-AKT	56834 : 56842	CM	ation of PTEN to inhibit PI3K-AKT, activation of Hippo pat
./___Corpus/Medline/xml/PMC4819002.xml	YAP	56953 : 56956	CM	hancer activator domain (YAP/TEAD) activity, inductio
./___Corpus/Medline/xml/PMC4819002.xml	TEAD	56957 : 56961	CM	er activator domain (YAP/TEAD) activity, induction of 
./___Corpus/Medline/xml/PMC4819002.xml	GDF15	56986 : 56991	CM	) activity, induction of GDF15 through p53 activation, 
./___Corpus/Medline/xml/PMC4819002.xml	p53	57000 : 57003	CM	duction of GDF15 through p53 activation, activation o
./___Corpus/Medline/xml/PMC4819002.xml	ARID1A	57030 : 57036	CM	ctivation, activation of ARID1A, blocking Notch pathway,
./___Corpus/Medline/xml/PMC4819002.xml	IGF-1R	57080 : 57086	CM	thway, and inhibition of IGF-1R to restore tumor suppres
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	57175 : 57179	CM	for these approaches are EGCG, luteolin, curcumin, gen
./___Corpus/Medline/xml/PMC4819002.xml	luteolin	57181 : 57189	CM	ese approaches are EGCG, luteolin, curcumin, genistein, re
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	57191 : 57199	CM	ches are EGCG, luteolin, curcumin, genistein, resveratrol,
./___Corpus/Medline/xml/PMC4819002.xml	genistein	57201 : 57210	CM	GCG, luteolin, curcumin, genistein, resveratrol, withaferin
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	57212 : 57223	CM	in, curcumin, genistein, resveratrol, withaferin A, and degue
./___Corpus/Medline/xml/PMC4819002.xml	anti-	57287 : 57292	CPR	re, while the evasion of anti-growth signaling is a cri
./___Corpus/Medline/xml/PMC4819002.xml	anti-	58825 : 58830	CPR	he overexpression of the anti-apoptotic molecules. B-ce
./___Corpus/Medline/xml/PMC4819002.xml	RNAs	59599 : 59603	CM	ticularly the non-coding RNAs/ microRNAs, are also of 
./___Corpus/Medline/xml/PMC4819002.xml	nicotinamide dinucleotide disulfide thiol	59686 : 59727	CM	pinpointed, such as ecto-nicotinamide dinucleotide disulfide thiol exchanger protein (ENOX)
./___Corpus/Medline/xml/PMC4819002.xml	1(CRM1)	59821 : 59828	CM	onal maintenance protein 1(CRM1), along with specific str
./___Corpus/Medline/xml/PMC4819002.xml	EGFR	60086 : 60090	CM	somes, and inhibition of EGFR and Akt. Approaches to t
./___Corpus/Medline/xml/PMC4819002.xml	gossypol	60136 : 60144	CM	to these targets include gossypol, UMI-77, EGCG, triptolid
./___Corpus/Medline/xml/PMC4819002.xml	UMI-77	60146 : 60152	CM	argets include gossypol, UMI-77, EGCG, triptolide, PXD, 
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	60154 : 60158	CM	nclude gossypol, UMI-77, EGCG, triptolide, PXD, seline
./___Corpus/Medline/xml/PMC4819002.xml	triptolide	60160 : 60170	CM	 gossypol, UMI-77, EGCG, triptolide, PXD, selinexor, and inh
./___Corpus/Medline/xml/PMC4819002.xml	PXD	60172 : 60175	CM	MI-77, EGCG, triptolide, PXD, selinexor, and inhibito
./___Corpus/Medline/xml/PMC4819002.xml	EGFR	60206 : 60210	CM	nexor, and inhibitors of EGFR and Akt. Collectively, t
./___Corpus/Medline/xml/PMC4819002.xml	mitogenic	61235 : 61244	CM	 presence of appropriate mitogenic factors, is a specific r
./___Corpus/Medline/xml/PMC4819002.xml	p53	61531 : 61534	CM	ion of tumor suppressors p53 and p16/pRB [108,109], b
./___Corpus/Medline/xml/PMC4819002.xml	p16	61539 : 61542	CM	umor suppressors p53 and p16/pRB [108,109], but can s
./___Corpus/Medline/xml/PMC4819002.xml	cyclin	61910 : 61916	CM	cancer cells by blocking cyclin-dependent kinase mediate
./___Corpus/Medline/xml/PMC4819002.xml	rapamycin	64474 : 64483	CM	RT), mammalian target of rapamycin (mTOR), CDK4/6, CDK 1/2/
./___Corpus/Medline/xml/PMC4819002.xml	mTOR	64485 : 64489	CM	ian target of rapamycin (mTOR), CDK4/6, CDK 1/2/5/9, A
./___Corpus/Medline/xml/PMC4819002.xml	CDK4	64492 : 64496	CM	get of rapamycin (mTOR), CDK4/6, CDK 1/2/5/9, Akt and 
./___Corpus/Medline/xml/PMC4819002.xml	CDK	64500 : 64503	CM	apamycin (mTOR), CDK4/6, CDK 1/2/5/9, Akt and PI3K. S
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	64521 : 64525	CM	/6, CDK 1/2/5/9, Akt and PI3K. Several approaches dese
./___Corpus/Medline/xml/PMC4819002.xml	genistein	64692 : 64701	CM	hese include imetelstat, genistein, perillyl alcohol, palbo
./___Corpus/Medline/xml/PMC4819002.xml	perillyl alcohol	64703 : 64719	CM	e imetelstat, genistein, perillyl alcohol, palbociclib, dinaciclib
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	64746 : 64754	CM	palbociclib, dinaciclib, curcumin and EGCG.               
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	64759 : 64763	CM	dinaciclib, curcumin and EGCG.                  3.6 Dy
./___Corpus/Medline/xml/PMC4819002.xml	glucose	64921 : 64928	CM	cer cells show increased glucose uptake and produce lacta
./___Corpus/Medline/xml/PMC4819002.xml	lactate	64948 : 64955	CM	ucose uptake and produce lactate. This characteristic is 
./___Corpus/Medline/xml/PMC4819002.xml	lipids	65545 : 65551	CM	 support biosynthesis of lipids, proteins, nucleic acids
./___Corpus/Medline/xml/PMC4819002.xml	lead	65739 : 65743	CM	oss of tumor suppressors lead directly to changes in m
./___Corpus/Medline/xml/PMC4819002.xml	glucose	65858 : 65865	CM	s. Several components of glucose and glutamine metabolism
./___Corpus/Medline/xml/PMC4819002.xml	glutamine	65870 : 65879	CM	omponents of glucose and glutamine metabolism have emerged 
./___Corpus/Medline/xml/PMC4819002.xml	glucose	65956 : 65963	CM	metabolism in cancer. In glucose metabolism, hexokinase 2
./___Corpus/Medline/xml/PMC4819002.xml	hexokinase	65976 : 65986	CM	. In glucose metabolism, hexokinase 2 (HK2), 6-phosphofructo
./___Corpus/Medline/xml/PMC4819002.xml	HK2	65990 : 65993	CM	etabolism, hexokinase 2 (HK2), 6-phosphofructo-2-kina
./___Corpus/Medline/xml/PMC4819002.xml	6-phosphofructo-2	65996 : 66013	CM	ism, hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biph
./___Corpus/Medline/xml/PMC4819002.xml	6-	66013 : 66015	CPR	 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphos
./___Corpus/Medline/xml/PMC4819002.xml	fructose-2,6-biphosphatase	66021 : 66047	CM	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and pyruvate 
./___Corpus/Medline/xml/PMC4819002.xml	PFKFB3	66051 : 66057	CM	ose-2,6-biphosphatase 3 (PFKFB3) and pyruvate kinase iso
./___Corpus/Medline/xml/PMC4819002.xml	pyruvate	66063 : 66071	CM	osphatase 3 (PFKFB3) and pyruvate kinase isoform M2 (PKM2)
./___Corpus/Medline/xml/PMC4819002.xml	PKM2	66091 : 66095	CM	uvate kinase isoform M2 (PKM2) all regulate glycolytic
./___Corpus/Medline/xml/PMC4819002.xml	glycolytic	66110 : 66120	CM	m M2 (PKM2) all regulate glycolytic flux. Using a “kitchen s
./___Corpus/Medline/xml/PMC4819002.xml	glycolysis	66162 : 66172	RN	itchen sink” analogy for glycolysis, both HK2 and PFKFB3 are
./___Corpus/Medline/xml/PMC4819002.xml	HK2	66179 : 66182	CM	ogy for glycolysis, both HK2 and PFKFB3 are regulator
./___Corpus/Medline/xml/PMC4819002.xml	PFKFB3	66187 : 66193	CM	glycolysis, both HK2 and PFKFB3 are regulators of the fa
./___Corpus/Medline/xml/PMC4819002.xml	PKM2	66258 : 66262	CM	up the sink. Conversely, PKM2 regulates the drain. Can
./___Corpus/Medline/xml/PMC4819002.xml	glycolytic	66365 : 66375	CM	n, which over-spills the glycolytic pathway and provides met
./___Corpus/Medline/xml/PMC4819002.xml	glycolysis	66560 : 66570	RN	or “unplug the drain” in glycolysis, limiting cellular growt
./___Corpus/Medline/xml/PMC4819002.xml	glutamine	66649 : 66658	CM	ave also determined that glutamine is used as a fuel (gluta
./___Corpus/Medline/xml/PMC4819002.xml	glutaminolysis	66678 : 66692	CM	amine is used as a fuel (glutaminolysis) in proliferating cancer
./___Corpus/Medline/xml/PMC4819002.xml	Glutamine	66725 : 66734	CM	liferating cancer cells. Glutamine oxidation can provide ca
./___Corpus/Medline/xml/PMC4819002.xml	carbon	66757 : 66763	CM	ne oxidation can provide carbon and nitrogen for growth,
./___Corpus/Medline/xml/PMC4819002.xml	nitrogen	66768 : 66776	CM	n can provide carbon and nitrogen for growth, and therefor
./___Corpus/Medline/xml/PMC4819002.xml	3-bromopyruvate	67891 : 67906	CM	ld be mentioned, such as 3-bromopyruvate, 1-(4-pyridinyl)-3-(2-qu
./___Corpus/Medline/xml/PMC4819002.xml	1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one	67908 : 67955	CM	such as 3-bromopyruvate, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3-aminophe
./___Corpus/Medline/xml/PMC4819002.xml	PFK	67957 : 67960	CM	nolinyl)-2-propen-1-one (PFK-15), 6-[(3-aminophenyl)m
./___Corpus/Medline/xml/PMC4819002.xml	6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2’,3	67966 : 68046	CM	2-propen-1-one (PFK-15), 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2’,3’:4,5]pyrrolo[2,3-d]pyrid
./___Corpus/Medline/xml/PMC4819002.xml	4,5]pyrrolo[2,3-d]pyridazin-5-one	68048 : 68081	CM	ulfinyl)-5H-thieno[2’,3’:4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46), dichloroaceta
./___Corpus/Medline/xml/PMC4819002.xml	TEPP-46	68083 : 68090	CM	o[2,3-d]pyridazin-5-one (TEPP-46), dichloroacetate, hexac
./___Corpus/Medline/xml/PMC4819002.xml	dichloroacetate	68093 : 68108	CM	ridazin-5-one (TEPP-46), dichloroacetate, hexachlorophene, bis-2-
./___Corpus/Medline/xml/PMC4819002.xml	hexachlorophene	68110 : 68125	CM	PP-46), dichloroacetate, hexachlorophene, bis-2-(5-phenylacet-ami
./___Corpus/Medline/xml/PMC4819002.xml	bis-2-(5-phenylacet-amido-1,2,3-thiadiazol-2-yl)ethyl sulfide	68127 : 68188	CM	cetate, hexachlorophene, bis-2-(5-phenylacet-amido-1,2,3-thiadiazol-2-yl)ethyl sulfide (BPTES) and 2,3-Dihydrox
./___Corpus/Medline/xml/PMC4819002.xml	BPTES	68190 : 68195	CM	azol-2-yl)ethyl sulfide (BPTES) and 2,3-Dihydroxy-6-Met
./___Corpus/Medline/xml/PMC4819002.xml	2,3-Dihydroxy-6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar	68201 : 68266	CM	thyl sulfide (BPTES) and 2,3-Dihydroxy-6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic acid (FX11), but
./___Corpus/Medline/xml/PMC4819002.xml	2,3-	68266 : 68270	CPR	4-propyl-1-naphthalenecar-boxylic acid (FX11), but dat
./___Corpus/Medline/xml/PMC4819002.xml	FX11	68281 : 68285	CM	thalenecar-boxylic acid (FX11), but data for these mus
./___Corpus/Medline/xml/PMC4819002.xml	121–	69633 : 69637	CPR	ogenesis and metastasis [121–123]. Inflammation is als
./___Corpus/Medline/xml/PMC4819002.xml	oxygen	69737 : 69743	CM	e generation of reactive oxygen species (ROS) and reacti
./___Corpus/Medline/xml/PMC4819002.xml	ROS	69753 : 69756	CM	reactive oxygen species (ROS) and reactive nitrogen s
./___Corpus/Medline/xml/PMC4819002.xml	nitrogen	69771 : 69779	CM	ecies (ROS) and reactive nitrogen species which can damage
./___Corpus/Medline/xml/PMC4819002.xml	aldehydes	69859 : 69868	CM	[124]. Free radicals and aldehydes, produced during chronic
./___Corpus/Medline/xml/PMC4819002.xml	cyclooxygenase-2	71360 : 71376	CM	ation inhibitory factor, cyclooxygenase-2 (COX-2), NF-κB, tumor ne
./___Corpus/Medline/xml/PMC4819002.xml	COX-2	71378 : 71383	CM	actor, cyclooxygenase-2 (COX-2), NF-κB, tumor necrosis 
./___Corpus/Medline/xml/PMC4819002.xml	NF-κB	71386 : 71391	CM	yclooxygenase-2 (COX-2), NF-κB, tumor necrosis factor a
./___Corpus/Medline/xml/PMC4819002.xml	alpha	71415 : 71420	CM	B, tumor necrosis factor alpha (TNF-α), inducible nitri
./___Corpus/Medline/xml/PMC4819002.xml	nitric oxide	71440 : 71452	CM	alpha (TNF-α), inducible nitric oxide synthase (iNOS), Akt, an
./___Corpus/Medline/xml/PMC4819002.xml	iNOS	71463 : 71467	CM	e nitric oxide synthase (iNOS), Akt, and chemokines ar
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	71636 : 71644	CM	ppression. Additionally, curcumin, resveratrol, EGCG, geni
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	71646 : 71657	CM	 Additionally, curcumin, resveratrol, EGCG, genistein, lycope
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	71659 : 71663	CM	, curcumin, resveratrol, EGCG, genistein, lycopene, an
./___Corpus/Medline/xml/PMC4819002.xml	genistein	71665 : 71674	CM	umin, resveratrol, EGCG, genistein, lycopene, and anthocyan
./___Corpus/Medline/xml/PMC4819002.xml	lycopene	71676 : 71684	CM	ratrol, EGCG, genistein, lycopene, and anthocyanins are fo
./___Corpus/Medline/xml/PMC4819002.xml	anthocyanins	71690 : 71702	CM	genistein, lycopene, and anthocyanins are forms of low-cost ch
./___Corpus/Medline/xml/PMC4819002.xml	oleanoic acid	74820 : 74833	CM	0 identified targets are oleanoic acid, tripterine, silibinin, 
./___Corpus/Medline/xml/PMC4819002.xml	tripterine	74835 : 74845	CM	rgets are oleanoic acid, tripterine, silibinin, curcumin, EG
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	74858 : 74866	CM	, tripterine, silibinin, curcumin, EGCG, kaempferol, melat
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	74868 : 74872	CM	ne, silibinin, curcumin, EGCG, kaempferol, melatonin, 
./___Corpus/Medline/xml/PMC4819002.xml	kaempferol	74874 : 74884	CM	libinin, curcumin, EGCG, kaempferol, melatonin, enterolacton
./___Corpus/Medline/xml/PMC4819002.xml	melatonin	74886 : 74895	CM	cumin, EGCG, kaempferol, melatonin, enterolactone, withafer
./___Corpus/Medline/xml/PMC4819002.xml	enterolactone	74897 : 74910	CM	, kaempferol, melatonin, enterolactone, withaferin A and resver
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	74929 : 74940	CM	actone, withaferin A and resveratrol. Further study is needed
./___Corpus/Medline/xml/PMC4819002.xml	prophylactic	75110 : 75122	CM	oxicity and their use in prophylactic regimens.               
./___Corpus/Medline/xml/PMC4819002.xml	EMT	76414 : 76417	CM	volved in the process of EMT have all been subject to
./___Corpus/Medline/xml/PMC4819002.xml	E-	77367 : 77369	CPR	tasis such disruption of E-cadherin and tight juncti
./___Corpus/Medline/xml/PMC4819002.xml	urokinase	77433 : 77442	CM	ling pathways, including urokinase-type plasminogen activat
./___Corpus/Medline/xml/PMC4819002.xml	plasminogen	77448 : 77459	CM	including urokinase-type plasminogen activator, PI3K/AKT, foc
./___Corpus/Medline/xml/PMC4819002.xml	PI3K	77471 : 77475	CM	e plasminogen activator, PI3K/AKT, focal adhesion kina
./___Corpus/Medline/xml/PMC4819002.xml	AKT	77476 : 77479	CM	sminogen activator, PI3K/AKT, focal adhesion kinase, 
./___Corpus/Medline/xml/PMC4819002.xml	β-	77504 : 77506	CPR	, focal adhesion kinase, β-catenin/zinc finger E-box
./___Corpus/Medline/xml/PMC4819002.xml	zinc	77514 : 77518	CM	hesion kinase, β-catenin/zinc finger E-box-binding hom
./___Corpus/Medline/xml/PMC4819002.xml	E-	77526 : 77528	CPR	e, β-catenin/zinc finger E-box-binding homeobox 1 an
./___Corpus/Medline/xml/PMC4819002.xml	E-	77531 : 77533	CPR	catenin/zinc finger E-box-binding homeobox 1 and tra
./___Corpus/Medline/xml/PMC4819002.xml	(TGF)-β	77582 : 77589	CM	ansforming growth factor (TGF)-β, together with inactivat
./___Corpus/Medline/xml/PMC4819002.xml	metalloproteinase-9	77674 : 77693	CM	nd suppression of matrix metalloproteinase-9 (MMP-9) activity should 
./___Corpus/Medline/xml/PMC4819002.xml	fatty acids gamma-linolenic acid	78198 : 78230	CM	gether with diet-derived fatty acids gamma-linolenic acid and eicosapentaenoic aci
./___Corpus/Medline/xml/PMC4819002.xml	eicosapentaenoic acid	78235 : 78256	CM	gamma-linolenic acid and eicosapentaenoic acid and inhibitory compounds
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	79380 : 79391	CM	uding: the inhibition of cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4819002.xml	ROS	79419 : 79422	CM	nthesis and metabolites, ROS and hypoxia, macrophage 
./___Corpus/Medline/xml/PMC4819002.xml	endoglin	79554 : 79562	CM	is, fibrosis inhibition, endoglin, and cytokine signaling.
./___Corpus/Medline/xml/PMC4819002.xml	cytokine	79568 : 79576	CM	nhibition, endoglin, and cytokine signaling. These program
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	79936 : 79947	CM	 tumor microenvironment (cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4819002.xml	ROS	79975 : 79978	CM	nthesis and metabolites, ROS and hypoxia), inflammati
./___Corpus/Medline/xml/PMC4819002.xml	cytokine	80204 : 80212	CM	osis, angiogenesis), and cytokine-mediated regulatory prog
./___Corpus/Medline/xml/PMC4819002.xml	endoglin	80249 : 80257	CM	gulatory programs (IL-6, endoglin, and JAK). We have parti
./___Corpus/Medline/xml/PMC4819002.xml	JAK	80263 : 80266	CM	ams (IL-6, endoglin, and JAK). We have particularly f
./___Corpus/Medline/xml/PMC4819002.xml	berberine	80543 : 80552	CM	nd the microenvironment (berberine), others more specifical
./___Corpus/Medline/xml/PMC4819002.xml	ROS	80587 : 80590	CM	more specifically target ROS (resveratrol, desoxyrhap
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	80592 : 80603	CM	specifically target ROS (resveratrol, desoxyrhapontigenin), m
./___Corpus/Medline/xml/PMC4819002.xml	desoxyrhapontigenin	80605 : 80624	CM	target ROS (resveratrol, desoxyrhapontigenin), macrophage conversion 
./___Corpus/Medline/xml/PMC4819002.xml	indoleamine	80662 : 80673	CM	 conversion (onionin A), indoleamine 2,3-dioxygenase (IDO) re
./___Corpus/Medline/xml/PMC4819002.xml	2,3-dioxygenase	80674 : 80689	CM	(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of dend
./___Corpus/Medline/xml/PMC4819002.xml	IDO	80691 : 80694	CM	leamine 2,3-dioxygenase (IDO) regulation of dendritic
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	80727 : 80731	CM	tion of dendritic cells (EGCG), cholesterol synthesis 
./___Corpus/Medline/xml/PMC4819002.xml	cholesterol	80734 : 80745	CM	 dendritic cells (EGCG), cholesterol synthesis (genistein), f
./___Corpus/Medline/xml/PMC4819002.xml	genistein	80757 : 80766	CM	, cholesterol synthesis (genistein), fibrosis (naringenin),
./___Corpus/Medline/xml/PMC4819002.xml	naringenin	80779 : 80789	CM	s (genistein), fibrosis (naringenin), inflammation and immun
./___Corpus/Medline/xml/PMC4819002.xml	piperine	80827 : 80835	CM	on and immune signaling (piperine) and JAK signaling (zeru
./___Corpus/Medline/xml/PMC4819002.xml	JAK	80841 : 80844	CM	signaling (piperine) and JAK signaling (zerumbone). T
./___Corpus/Medline/xml/PMC4819002.xml	protein-4	81968 : 81977	CM	 T-lymphocyte-associated protein-4 (CTLA-4) [143] or progra
./___Corpus/Medline/xml/PMC4819002.xml	PD1	82027 : 82030	CM	mmed cell death protein (PD1/PD-L1) [144] is consider
./___Corpus/Medline/xml/PMC4819002.xml	PD-L1	82031 : 82036	CM	 cell death protein (PD1/PD-L1) [144] is considered an 
./___Corpus/Medline/xml/PMC4819002.xml	anti-	82098 : 82103	CPR	ticancer strategy. Also, anti-PD-1 antibodies are showi
./___Corpus/Medline/xml/PMC4819002.xml	Th1	82309 : 82312	CM	ic and include enhancing Th1 responses, enhancing γδ 
./___Corpus/Medline/xml/PMC4819002.xml	146–	82699 : 82703	CPR	45], and phytochemicals [146–148]. Phytochemicals (the
./___Corpus/Medline/xml/PMC4819002.xml	polyphenol resveratrol	83030 : 83052	CM	l as astaxanthin and the polyphenol resveratrol analogue HS-1793. There 
./___Corpus/Medline/xml/PMC4819002.xml	As	83556 : 83558	CM	ews                      As described above, a cross
./___Corpus/Medline/xml/PMC4819002.xml	1–	83873 : 83875	CPR	and summarized in Tables 1–3. Supplemental table S1,
./___Corpus/Medline/xml/PMC4819002.xml	vitro	88663 : 88668	CM	es involving detailed in vitro and in vivo findings. In
./___Corpus/Medline/xml/PMC4819002.xml	vitro	88868 : 88873	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4819002.xml	lead	91231 : 91235	CM	ther mechanisms that may lead to toxicities.          
./___Corpus/Medline/xml/PMC4819002.xml	estrogen	93360 : 93368	CM	ally among patients with estrogen receptor-negative cancer
./___Corpus/Medline/xml/PMC4819002.xml	155–	93596 : 93600	CPR	tion as measured by CRP [155–158]. Low fat diets, weig
./___Corpus/Medline/xml/PMC4819002.xml	anthocyanins	93650 : 93662	CM	ht loss and supplements (anthocyanins and fish oil) have been 
./___Corpus/Medline/xml/PMC4819002.xml	159–	93762 : 93766	CPR	and signaling molecules [159–162]. Mind-body intervent
./___Corpus/Medline/xml/PMC4819002.xml	165–	94106 : 94110	CPR	ivity, and sex hormones [165–168]. While much work rem
./___Corpus/Medline/xml/PMC4819002.xml	vitro	94921 : 94926	CM	                  5.3 In vitro research                
./___Corpus/Medline/xml/PMC4819002.xml	vitro	94972 : 94977	CM	          An array of in vitro models is available for 
./___Corpus/Medline/xml/PMC4819002.xml	NF-κB	95277 : 95282	CM	nt on a molecule such as NF-κB, which is at the interse
./___Corpus/Medline/xml/PMC4819002.xml	vitro	95721 : 95726	CM	ts are another useful in vitro model.                  
./___Corpus/Medline/xml/PMC4819002.xml	vitro	96512 : 96517	CM	ch often begin at the in vitro level, are also needed [
./___Corpus/Medline/xml/PMC4819002.xml	vitro	96872 : 96877	CM	l-characterized using in vitro models, and that deliver
./___Corpus/Medline/xml/PMC4819002.xml	isoflavones	97835 : 97846	CM	heir blood levels of soy isoflavones after these are administ
./___Corpus/Medline/xml/PMC4819002.xml	Isoflavone	97936 : 97946	CM	perimental routes [173]. Isoflavone levels in rodent blood 2
./___Corpus/Medline/xml/PMC4819002.xml	176–	100029 : 100033	CPR	een noted after surgery [176–181]. Further, there is r
./___Corpus/Medline/xml/PMC4819002.xml	182–	100218 : 100222	CPR	 proteins after surgery [182–185]. This period is not 
./___Corpus/Medline/xml/PMC4819002.xml	186–	100637 : 100641	CPR	ively in small studies. [186–188]. These agents upregu
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	100760 : 100764	CM	ssing the combination of EGCG and silibinin in colorec
./___Corpus/Medline/xml/PMC4819002.xml	189–	100870 : 100874	CPR	fore and after surgery. [189–191]. Such trials represe
./___Corpus/Medline/xml/PMC4819002.xml	Li	101669 : 101671	CM	erbals, were reviewed by Li et al. [192]. Only 16% o
./___Corpus/Medline/xml/PMC4819002.xml	CONSORT	102231 : 102238	CM	rds of Reporting Trials (CONSORT) randomized trial report
./___Corpus/Medline/xml/PMC4819002.xml	Panax	102375 : 102380	CM	 of published studies of Panax ginseng, which is common
./___Corpus/Medline/xml/PMC4819002.xml	vitro	103393 : 103398	CM	 phytochemicals. Most in vitro work on single phytochem
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	103863 : 103871	CM	cross hallmarks, such as curcumin and resveratrol, and ana
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	103876 : 103887	CM	ks, such as curcumin and resveratrol, and analyze combination
./___Corpus/Medline/xml/PMC4819002.xml	phenethyl isothiocyanate	104156 : 104180	CM	-spectrum agent, such as phenethyl isothiocyanate [197]. Research is also 
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	104452 : 104463	CM	red, especially with the polyphenols. One of the main issues 
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	104524 : 104533	CM	compounds, which include quercetin, green tea catechins, cu
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	104556 : 104564	CM	in, green tea catechins, curcumin and others, is ensuring 
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	104615 : 104624	CM	hat circulating doses of aglycones (one of the active forms
./___Corpus/Medline/xml/PMC4819002.xml	200–	104776 : 104780	CPR	t doses safe for humans (200–500 mg/day), only conjuga
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	104860 : 104869	CM	odstream. As an example, quercetin is not found in the plas
./___Corpus/Medline/xml/PMC4819002.xml	aglycone	104900 : 104908	CM	t found in the plasma as aglycone or as the parent glycosi
./___Corpus/Medline/xml/PMC4819002.xml	glycosides	104926 : 104936	CM	glycone or as the parent glycosides: at the doses usually em
./___Corpus/Medline/xml/PMC4819002.xml	methyl	105026 : 105032	CM	 be found exclusively as methyl, sulfate or glucuronic a
./___Corpus/Medline/xml/PMC4819002.xml	sulfate	105034 : 105041	CM	d exclusively as methyl, sulfate or glucuronic acid conju
./___Corpus/Medline/xml/PMC4819002.xml	glucuronic acid	105045 : 105060	CM	ly as methyl, sulfate or glucuronic acid conjugates [198]. This o
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	105175 : 105184	CM	 phytochemicals: if free aglycones are absent in vivo after
./___Corpus/Medline/xml/PMC4819002.xml	vitro	105352 : 105357	CM	es, largely described in vitro?                        
./___Corpus/Medline/xml/PMC4819002.xml	flavonoids	105468 : 105478	CM	conjugated forms of some flavonoids (e.g. quercetin) may be 
./___Corpus/Medline/xml/PMC4819002.xml	quercetin	105485 : 105494	CM	of some flavonoids (e.g. quercetin) may be biologically act
./___Corpus/Medline/xml/PMC4819002.xml	aglycones	105617 : 105626	CM	d, regenerating the free aglycones. To sustain these hypoth
./___Corpus/Medline/xml/PMC4819002.xml	polyphenol	105738 : 105748	CM	 mechanisms of uptake of polyphenol metabolites and the subs
./___Corpus/Medline/xml/PMC4819002.xml	vitro	105873 : 105878	CM	pure compounds tested in vitro may shed light on these 
./___Corpus/Medline/xml/PMC4819002.xml	2–	105952 : 105954	CPR	, pharmacological doses (2–4 g/day) administered ora
./___Corpus/Medline/xml/PMC4819002.xml	vitro	106578 : 106583	CM	trum of research from in vitro studies to clinical tria
./___Corpus/Medline/xml/PMC4819002.xml	indomethacin	106854 : 106866	CM	hat was found to contain indomethacin, warfarin and synthetic 
./___Corpus/Medline/xml/PMC4819002.xml	warfarin	106868 : 106876	CM	to contain indomethacin, warfarin and synthetic estrogens,
./___Corpus/Medline/xml/PMC4819002.xml	estrogens	106891 : 106900	CM	, warfarin and synthetic estrogens, leading to its withdraw
./___Corpus/Medline/xml/PMC4819002.xml	BZL101	110390 : 110396	CM	 and Phase Ib studies of BZL101, an extract of Scutellar
./___Corpus/Medline/xml/PMC4819002.xml	4-	110514 : 110516	CPR	ited States [219,220]. A 4-herb combination originat
./___Corpus/Medline/xml/PMC4819002.xml	PHY906	110578 : 110584	CM	tional Chinese medicine, PHY906, has been the subject of
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	111696 : 111707	CM	e a mixture of green tea polyphenols known as Polyphenon E an
./___Corpus/Medline/xml/PMC4819002.xml	Croton	111854 : 111860	CM	the South American plant Croton lechleri, approved for H
./___Corpus/Medline/xml/PMC4819002.xml	cytochrome	113123 : 113133	CM	on), contains the strong cytochrome P450 3A4 inducer hyperfo
./___Corpus/Medline/xml/PMC4819002.xml	hyperforin	113151 : 113161	CM	ochrome P450 3A4 inducer hyperforin, which is known to reduc
./___Corpus/Medline/xml/PMC4819002.xml	sunitinib	113342 : 113351	CM	ential interactions with sunitinib [229], with hepatotoxic 
./___Corpus/Medline/xml/PMC4819002.xml	bortezomib	113398 : 113408	CM	ic drugs [230], and with bortezomib. On the other hand, posi
./___Corpus/Medline/xml/PMC4819002.xml	erlotinib	113489 : 113498	CM	erved with green tea and erlotinib, a combination now in cl
./___Corpus/Medline/xml/PMC4819002.xml	Curcumin	113544 : 113552	CM	n clinical trials [231]. Curcumin is one of several natura
./___Corpus/Medline/xml/PMC4819002.xml	late	114041 : 114045	CM	e stress is increased in late-stage disease [236], whi
./___Corpus/Medline/xml/PMC4819002.xml	oxygen	114199 : 114205	CM	s caused by the reactive oxygen species generated by man
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	114559 : 114570	CM	ioxidants, including the polyphenols, manifest pro-oxidant pr
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	114800 : 114811	CM	ulti-targeted actions of polyphenols such as curcumin and EGC
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	114820 : 114828	CM	s of polyphenols such as curcumin and EGCG [241]. However,
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	114833 : 114837	CM	ols such as curcumin and EGCG [241]. However, activity
./___Corpus/Medline/xml/PMC4819002.xml	ROS	114915 : 114918	CM	depends on generation of ROS which should not be abro
./___Corpus/Medline/xml/PMC4819002.xml	2013–	118480 : 118485	CPR	ave received approval in 2013–2014 by the US FDA, inclu
./___Corpus/Medline/xml/PMC4819002.xml	ceritinib	118515 : 118524	CM	by the US FDA, including ceritinib (anaplastic lymphoma kin
./___Corpus/Medline/xml/PMC4819002.xml	VEGFR2	118578 : 118584	CM	inhibitor), ramucirumab (VEGFR2 blocker), ibrutinib (Bru
./___Corpus/Medline/xml/PMC4819002.xml	ibrutinib	118595 : 118604	CM	irumab (VEGFR2 blocker), ibrutinib (Bruton’s tyrosine kinas
./___Corpus/Medline/xml/PMC4819002.xml	tyrosine	118615 : 118623	CM	er), ibrutinib (Bruton’s tyrosine kinase inhibitor), trame
./___Corpus/Medline/xml/PMC4819002.xml	trametinib	118643 : 118653	CM	osine kinase inhibitor), trametinib (MEK inhibitor) and dabr
./___Corpus/Medline/xml/PMC4819002.xml	MEK	118655 : 118658	CM	 inhibitor), trametinib (MEK inhibitor) and dabrafeni
./___Corpus/Medline/xml/PMC4819002.xml	trametinib	118962 : 118972	CM	ents, the combination of trametinib and dabrafenib was appro
./___Corpus/Medline/xml/PMC4819002.xml	6–	119042 : 119044	CPR	 2014, due to the rapid (6–7 months) development of 
./___Corpus/Medline/xml/PMC4819002.xml	nine	119188 : 119192	CM	arks of cancer [27], the nine pathways of progression 
./___Corpus/Medline/xml/PMC4819002.xml	polyphenols	121708 : 121719	CM	ation of poorly absorbed polyphenols and other phytochemicals
./___Corpus/Medline/xml/PMC4819002.xml	201–	121746 : 121750	CPR	nd other phytochemicals [201–203].                    
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	122401 : 122409	CM	ample, among approaches, curcumin, genistein, resveratrol 
./___Corpus/Medline/xml/PMC4819002.xml	genistein	122411 : 122420	CM	ng approaches, curcumin, genistein, resveratrol and EGCG bo
./___Corpus/Medline/xml/PMC4819002.xml	resveratrol	122422 : 122433	CM	es, curcumin, genistein, resveratrol and EGCG boast a wealth 
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	122438 : 122442	CM	nistein, resveratrol and EGCG boast a wealth of fundam
./___Corpus/Medline/xml/PMC4819002.xml	tripterine	122516 : 122526	CM	other approaches such as tripterine, oleanoic acid and witha
./___Corpus/Medline/xml/PMC4819002.xml	oleanoic acid	122528 : 122541	CM	ches such as tripterine, oleanoic acid and withaferin A will re
./___Corpus/Medline/xml/PMC4819002.xml	EGCG	123520 : 123524	CM	ent study suggested that EGCG lowers the concentration
./___Corpus/Medline/xml/PMC4819002.xml	curcumin	123553 : 123561	CM	ers the concentration of curcumin needed to reduce prolife
./___Corpus/Medline/xml/PMC4819002.xml	BZL101	124429 : 124435	CM	acts such as PHY 906 and BZL101 mentioned above have dem
./___Corpus/Medline/xml/PMC4819002.xml	Amin	128267 : 128271	CM	                     Amr Amin was funded by Terry Fox 
./___Corpus/Medline/xml/PMC4819002.xml	TF-13-20	128315 : 128323	CM	y Fox Foundation Grant # TF-13-20 and UAEU Program for Adv
./___Corpus/Medline/xml/PMC4819002.xml	31S118	128372 : 128378	CM	vanced Research (UPAR) # 31S118; Jack Arbiser was funded
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128407 : 128410	CM	ck Arbiser was funded by NIH AR47901; Alexandra Arreo
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128452 : 128455	CM	ra Arreola was funded by NIH NRSA Grant F31CA154080; 
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128510 : 128513	CM	Arzumanyan was funded by NIH (NIAID) R01: Combination
./___Corpus/Medline/xml/PMC4819002.xml	NIAID	128515 : 128520	CM	anyan was funded by NIH (NIAID) R01: Combination therap
./___Corpus/Medline/xml/PMC4819002.xml	HBV	128561 : 128564	CM	on therapies for chronic HBV, liver disease, and canc
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128652 : 128655	CM	rS. Azmi is supported by NIH R21CA188818 as well as f
./___Corpus/Medline/xml/PMC4819002.xml	Inc	128698 : 128701	CM	ll as from SkyFoundation Inc. Michigan; Fabian Benenc
./___Corpus/Medline/xml/PMC4819002.xml	NIH	128746 : 128749	CM	enencia was supported by NIH Grant R15 CA137499-01; A
./___Corpus/Medline/xml/PMC4819002.xml	CRUK	128861 : 128865	CM	on Oncology Centre Fund, CRUK (www.cancerresearchuk.or
./___Corpus/Medline/xml/PMC4819002.xml	ISCIII	129011 : 129017	CM	onomy and Competitivity, ISCIII (Fis: PI12/00137, RTICC:
./___Corpus/Medline/xml/PMC4819002.xml	PI12	129024 : 129028	CM	petitivity, ISCIII (Fis: PI12/00137, RTICC: RD12/0036/
./___Corpus/Medline/xml/PMC4819002.xml	RD12	129043 : 129047	CM	(Fis: PI12/00137, RTICC: RD12/0036/0028) co-funded by 
./___Corpus/Medline/xml/PMC4819002.xml	FEDER	129072 : 129077	CM	/0036/0028) co-funded by FEDER from Regional Developmen
./___Corpus/Medline/xml/PMC4819002.xml	PI-0135-2010	129247 : 129259	CM	 the Junta de Andalucia (PI-0135-2010 and PI-0306-2012). His w
./___Corpus/Medline/xml/PMC4819002.xml	PIE13	129352 : 129357	CM	ible thanks to the Grant PIE13/0004 co-funded by the IS
./___Corpus/Medline/xml/PMC4819002.xml	ISCIII	129380 : 129386	CM	13/0004 co-funded by the ISCIII and FEDER funds; Stephan
./___Corpus/Medline/xml/PMC4819002.xml	FEDER	129391 : 129396	CM	funded by the ISCIII and FEDER funds; Stephanie C. Case
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129440 : 129443	CM	. Casey was supported by NIH grant F32CA177139; Mrinm
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129564 : 129567	CM	vedi was supported by an NIH NCCAM grant (K01AT007324
./___Corpus/Medline/xml/PMC4819002.xml	NIH	129633 : 129636	CM	Chen was supported by an NIH NCI grant (R33 CA161873-
./___Corpus/Medline/xml/PMC4819002.xml	NCI	129637 : 129640	CM	 was supported by an NIH NCI grant (R33 CA161873-02);
./___Corpus/Medline/xml/PMC4819002.xml	NIH	130054 : 130057	CM	ch was also supported by NIH grants (P20RR016477 and 
./___Corpus/Medline/xml/PMC4819002.xml	#IG10636	130316 : 130324	CM	 Research (AIRC) - grant #IG10636, and #15403; Helen M. Co
./___Corpus/Medline/xml/PMC4819002.xml	Dabrosin	130645 : 130653	CM	te University; Charlotta Dabrosin acknowledges financial s
./___Corpus/Medline/xml/PMC4819002.xml	IG14536	130867 : 130874	CM	ion for Cancer Research (IG14536 to G.D.); Santanu Dasgup
./___Corpus/Medline/xml/PMC4819002.xml	CPRIT	131067 : 131072	CM	was supported in part by CPRIT, the Cancer Prevention a
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131164 : 131167	CM	. Diehl was supported by NIH National Institute of Di
./___Corpus/Medline/xml/PMC4819002.xml	NIDDK	131234 : 131239	CM	ive and Kidney Diseases (NIDDK), the NIH National Insti
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131246 : 131249	CM	ey Diseases (NIDDK), the NIH National Institute on Al
./___Corpus/Medline/xml/PMC4819002.xml	Alcohol	131272 : 131279	CM	IH National Institute on Alcohol Abuse and Alcoholism (NI
./___Corpus/Medline/xml/PMC4819002.xml	NIAAA	131302 : 131307	CM	ol Abuse and Alcoholism (NIAAA), Gilead and Shire Pharm
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131383 : 131386	CM	s partially supported by NIH/NCI (1R01CA20009, 5R01CA
./___Corpus/Medline/xml/PMC4819002.xml	NCI	131387 : 131390	CM	rtially supported by NIH/NCI (1R01CA20009, 5R01CA1272
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131443 : 131446	CM	05 and R21CA184788), and NIH P30 CA22453 (to Karmanos
./___Corpus/Medline/xml/PMC4819002.xml	Bristol	131858 : 131865	CM	o Pharmaceutical, Roche, Bristol Myers Squibb, Bayer Phar
./___Corpus/Medline/xml/PMC4819002.xml	NIH	131962 : 131965	CM	itelson was supported by NIH/NIAID grant AI076535; De
./___Corpus/Medline/xml/PMC4819002.xml	NIAID	131966 : 131971	CM	son was supported by NIH/NIAID grant AI076535; Dean W. 
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132021 : 132024	CM	Felsher was supported by NIH grants (R01CA170378, U54
./___Corpus/Medline/xml/PMC4819002.xml	U54CA149145	132046 : 132057	CM	NIH grants (R01CA170378, U54CA149145, and U54CA143907); Lynne
./___Corpus/Medline/xml/PMC4819002.xml	U54CA143907	132063 : 132074	CM	170378, U54CA149145, and U54CA143907); Lynnette R Ferguson wa
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132228 : 132231	CM	restone was supported by NIH Public Service grant CA1
./___Corpus/Medline/xml/PMC4819002.xml	CA164095	132253 : 132261	CM	NIH Public Service grant CA164095 awarded from the Nationa
./___Corpus/Medline/xml/PMC4819002.xml	AICR	132455 : 132459	CM	, and a unique applicant AICR project grant"; Mark M. 
./___Corpus/Medline/xml/PMC4819002.xml	Fuster	132484 : 132490	CM	 project grant"; Mark M. Fuster was supported by NIH gra
./___Corpus/Medline/xml/PMC4819002.xml	NIH	132508 : 132511	CM	 Fuster was supported by NIH grant R01-HL107652; Alex
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133146 : 133149	CM	icka was supported by by NIH NCI grant NCIRO1 28704; 
./___Corpus/Medline/xml/PMC4819002.xml	NCI	133150 : 133153	CM	 was supported by by NIH NCI grant NCIRO1 28704; Petr
./___Corpus/Medline/xml/PMC4819002.xml	NCIRO1	133160 : 133166	CM	rted by by NIH NCI grant NCIRO1 28704; Petr Heneberg was
./___Corpus/Medline/xml/PMC4819002.xml	PRVOUK	133263 : 133269	CM	projects UNCE 204015 and PRVOUK P31/2012, by the Czech S
./___Corpus/Medline/xml/PMC4819002.xml	15-03834Y	133321 : 133330	CM	ence Foundation projects 15-03834Y and P301/12/1686, by the
./___Corpus/Medline/xml/PMC4819002.xml	AZV	133386 : 133389	CM	 Health Research Council AZV project 15-32432A, and b
./___Corpus/Medline/xml/PMC4819002.xml	15-32432A	133398 : 133407	CM	arch Council AZV project 15-32432A, and by the Internal Gra
./___Corpus/Medline/xml/PMC4819002.xml	NT13663-3	133498 : 133507	CM	e Czech Republic project NT13663-3/2012; Matthew D. Hirsche
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133746 : 133749	CM	ing (P30AG028716-01) and NIH/NCI training grants to D
./___Corpus/Medline/xml/PMC4819002.xml	NCI	133750 : 133753	CM	(P30AG028716-01) and NIH/NCI training grants to Duke 
./___Corpus/Medline/xml/PMC4819002.xml	T32-CA059365-19	133790 : 133805	CM	ants to Duke University (T32-CA059365-19 and 5T32-CA059365); Lorn
./___Corpus/Medline/xml/PMC4819002.xml	5T32-CA059365	133810 : 133823	CM	ity (T32-CA059365-19 and 5T32-CA059365); Lorne J. Hofseth was s
./___Corpus/Medline/xml/PMC4819002.xml	NIH	133860 : 133863	CM	Hofseth was supported by NIH grants (1R01CA151304, 1R
./___Corpus/Medline/xml/PMC4819002.xml	1R03CA1711326	133886 : 133899	CM	IH grants (1R01CA151304, 1R03CA1711326, and 1P01AT003961); Kany
./___Corpus/Medline/xml/PMC4819002.xml	CCMP102-RD-112	134168 : 134182	CM	lfare(CCMP101-RD-031 and CCMP102-RD-112) and Tzu-Chi University(
./___Corpus/Medline/xml/PMC4819002.xml	A4B	134606 : 134609	CM	on, and Welsh Government A4B scheme; Lee W. Jones was
./___Corpus/Medline/xml/PMC4819002.xml	NIH	134672 : 134675	CM	 part by grants from the NIH NCI; W Nicol Keith was s
./___Corpus/Medline/xml/PMC4819002.xml	NCI	134676 : 134679	CM	t by grants from the NIH NCI; W Nicol Keith was suppo
./___Corpus/Medline/xml/PMC4819002.xml	CRUK	134769 : 134773	CM	on Oncology Centre Fund, CRUK (www.cancerresearchuk.or
./___Corpus/Medline/xml/PMC4819002.xml	NIH	134855 : 134858	CM	kar was supported by the NIH Intramural Research Prog
./___Corpus/Medline/xml/PMC4819002.xml	Le	135126 : 135128	CM	(NRF-2005-0093837); Anne Le was supported by Sol Gol
./___Corpus/Medline/xml/PMC4819002.xml	Le	135273 : 135275	CM	 NIHR21CA169757 (to Anne Le); Michael A. Lea was fun
./___Corpus/Medline/xml/PMC4819002.xml	ICT	135484 : 135487	CM	the Ministry of Science, ICT & Future Planning (MSIP)
./___Corpus/Medline/xml/PMC4819002.xml	2011-	135538 : 135543	CPR	 Republic of Korea (Nos. 2011-0017639 and 2011-0030001)
./___Corpus/Medline/xml/PMC4819002.xml	2011-	135555 : 135560	CPR	a (Nos. 2011-0017639 and 2011-0030001) and by a NIH gra
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135578 : 135581	CM	d 2011-0030001) and by a NIH grant R01 CA100816; Lian
./___Corpus/Medline/xml/PMC4819002.xml	R01	135588 : 135591	CM	0001) and by a NIH grant R01 CA100816; Liang-Tzung Li
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135754 : 135757	CM	cknowledges support from NIH awards (CA168997 and AI1
./___Corpus/Medline/xml/PMC4819002.xml	NIH	135924 : 135927	CM	 Health Services Grants: NIH R01CA156776 and VA-BLR&D
./___Corpus/Medline/xml/PMC4819002.xml	NIH	136036 : 136039	CM	cknowledges support from NIH awards (P01AG034906 and 
./___Corpus/Medline/xml/PMC4819002.xml	#Ig15221	136666 : 136674	CM	 Research (AIRC) - grant #Ig15221; Ander Matheu is funded 
./___Corpus/Medline/xml/PMC4819002.xml	AM	136731 : 136733	CM	os III Health Institute (AM: CP10/00539), Basque Fou
./___Corpus/Medline/xml/PMC4819002.xml	CP10	136735 : 136739	CM	II Health Institute (AM: CP10/00539), Basque Foundatio
./___Corpus/Medline/xml/PMC4819002.xml	IKERBASQUE	136779 : 136789	CM	 Foundation for Science (IKERBASQUE) and Marie Curie CIG gra
./___Corpus/Medline/xml/PMC4819002.xml	CIG	136807 : 136810	CM	RBASQUE) and Marie Curie CIG grant (AM: 2012/712404);
./___Corpus/Medline/xml/PMC4819002.xml	AM	136818 : 136820	CM	d Marie Curie CIG grant (AM: 2012/712404); Christoph
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137266 : 137269	CM	ti received support from NIH NIDDK, NIH NIAAA, and Sh
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137277 : 137280	CM	 support from NIH NIDDK, NIH NIAAA, and Shire Pharmac
./___Corpus/Medline/xml/PMC4819002.xml	BMBF	137778 : 137782	CM	r Bildung und Forschung, BMBF) grant number 16SV5536K,
./___Corpus/Medline/xml/PMC4819002.xml	16SV5536K	137797 : 137806	CM	hung, BMBF) grant number 16SV5536K, and by the European Com
./___Corpus/Medline/xml/PMC4819002.xml	FP7	137840 : 137843	CM	the European Commission (FP7 259679 “IDEAL”); Peter L
./___Corpus/Medline/xml/PMC4819002.xml	NIH	137896 : 137899	CM	edersen was supported by NIH Grant CA-10951; Brad Poo
./___Corpus/Medline/xml/PMC4819002.xml	Le	138074 : 138076	CM	 NIHR21CA169757 (to Anne Le); Satya Prakash was supp
./___Corpus/Medline/xml/PMC4819002.xml	NIH	138208 : 138211	CM	ello was supported by an NIH grant (P01AG034906-01A1)
./___Corpus/Medline/xml/PMC4819002.xml	NIH	138346 : 138349	CM	mell was supported by an NIH grant (R01HL108006); Swa
./___Corpus/Medline/xml/PMC4819002.xml	FP7	138515 : 138518	CM	nth Framework Programme (FP7/2007– 2013) under grant 
./___Corpus/Medline/xml/PMC4819002.xml	2007–	138519 : 138524	CPR	Framework Programme (FP7/2007– 2013) under grant agreem
./___Corpus/Medline/xml/PMC4819002.xml	FP7	138701 : 138704	CM	eventh Framework Program FP7/2007–2013 under grant ag
./___Corpus/Medline/xml/PMC4819002.xml	2007–	138705 : 138710	CPR	th Framework Program FP7/2007–2013 under grant agreemen
./___Corpus/Medline/xml/PMC4819002.xml	FR	138832 : 138834	CM	ute for Health Research (FR: MOP114962, MOP125857), 
./___Corpus/Medline/xml/PMC4819002.xml	MOP114962	138836 : 138845	CM	for Health Research (FR: MOP114962, MOP125857), Fonds de Re
./___Corpus/Medline/xml/PMC4819002.xml	FR	138892 : 138894	CM	 Recherche Québec Santé (FR: 22624), and the Terry F
./___Corpus/Medline/xml/PMC4819002.xml	FR	138942 : 138944	CM	 Fox Research Institute (FR: 1030); Gian Luigi Russo
./___Corpus/Medline/xml/PMC4819002.xml	2013–	139059 : 139064	CPR	Research Scholar Program 2013–14; Isidro Sanchez-Garcia
./___Corpus/Medline/xml/PMC4819002.xml	FEDER	139116 : 139121	CM	s partially supported by FEDER and by MICINN (SAF2012-3
./___Corpus/Medline/xml/PMC4819002.xml	MICINN	139129 : 139135	CM	upported by FEDER and by MICINN (SAF2012-32810), by NIH 
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139156 : 139159	CM	CINN (SAF2012-32810), by NIH grant (R01 CA109335-04A1
./___Corpus/Medline/xml/PMC4819002.xml	León	139210 : 139214	CM	, by Junta de Castilla y León (BIO/SA06/13) and by the
./___Corpus/Medline/xml/PMC4819002.xml	BIO	139216 : 139219	CM	unta de Castilla y León (BIO/SA06/13) and by the ARIM
./___Corpus/Medline/xml/PMC4819002.xml	SA06	139220 : 139224	CM	 de Castilla y León (BIO/SA06/13) and by the ARIMMORA 
./___Corpus/Medline/xml/PMC4819002.xml	ARIMMORA	139240 : 139248	CM	(BIO/SA06/13) and by the ARIMMORA project (FP7-ENV-2011, E
./___Corpus/Medline/xml/PMC4819002.xml	FP7-ENV-2011	139258 : 139270	CM	by the ARIMMORA project (FP7-ENV-2011, European Union Seventh 
./___Corpus/Medline/xml/PMC4819002.xml	FP7	139440 : 139443	CM	European Union under the FP7 program; Andrew J. Sande
./___Corpus/Medline/xml/PMC4819002.xml	A4B	139608 : 139611	CM	on, and Welsh Government A4B scheme; Neeraj K. Saxena
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139673 : 139676	CM	ed by grant funding from NIH NIDDK (K01DK077137, R03D
./___Corpus/Medline/xml/PMC4819002.xml	NIH	139749 : 139752	CM	 was partially funded by NIH NCI grants (R01CA131294,
./___Corpus/Medline/xml/PMC4819002.xml	NCI	139753 : 139756	CM	 partially funded by NIH NCI grants (R01CA131294, R21
./___Corpus/Medline/xml/PMC4819002.xml	R01CA131294	139765 : 139776	CM	unded by NIH NCI grants (R01CA131294, R21 CA155686), the Avon
./___Corpus/Medline/xml/PMC4819002.xml	NINDS	139945 : 139950	CM	nal Institute of Health, NINDS grant K08NS083732, and t
./___Corpus/Medline/xml/PMC4819002.xml	13-20-23-SIEG	140095 : 140108	CM	r Research, Grant Number 13-20-23-SIEG; Neetu Singh was support
./___Corpus/Medline/xml/PMC4819002.xml	FT	140195 : 140197	CM	ience and Technology (SR/FT/LS-063/2008), New Delhi,
./___Corpus/Medline/xml/PMC4819002.xml	CAMPUS-QUARC	140454 : 140466	CM	nomy and Finance Project CAMPUS-QUARC, within program FESR Cam
./___Corpus/Medline/xml/PMC4819002.xml	W81XWH-12-1-0515	140642 : 140658	CM	P01CA073992), IDEA Award W81XWH-12-1-0515 from the Department of D
./___Corpus/Medline/xml/PMC4819002.xml	CTSI-2013-P03	140937 : 140950	CM	I) Pilot Research Grant (CTSI-2013-P03) and SEEDS You Choose Aw
./___Corpus/Medline/xml/PMC4819002.xml	DoD	141013 : 141016	CM	. Tran was funded by the DoD (W81XWH-11-1-0272 and W8
./___Corpus/Medline/xml/PMC4819002.xml	W81XWH-11-1-0272	141018 : 141034	CM	n was funded by the DoD (W81XWH-11-1-0272 and W81XWH-13-1-0182), a
./___Corpus/Medline/xml/PMC4819002.xml	W81XWH-13-1-0182	141039 : 141055	CM	oD (W81XWH-11-1-0272 and W81XWH-13-1-0182), a Kimmel Translational
./___Corpus/Medline/xml/PMC4819002.xml	122688-	141131 : 141138	CPR	), an ACS Scholar award (122688-RSG-12-196-01-TBG) and th
./___Corpus/Medline/xml/PMC4819002.xml	NIH	141165 : 141168	CM	G-12-196-01-TBG) and the NIH (R01CA166348); Kathryn E
./___Corpus/Medline/xml/PMC4819002.xml	NIH	141928 : 141931	CM	Xin Yin was supported by NIH/National Heart, Lung, an
./___Corpus/Medline/xml/PMC4819002.xml	NIH	142030 : 142033	CM	yue Zhu was supported by NIH grant R01GM071725;, Mass
./___Corpus/Medline/xml/PMC4819002.xml	N.5	142226 : 142229	CM	 the RegioneCampania L.R:N.5, the European National F
./___Corpus/Medline/xml/PMC4819002.xml	PON01-02388	142259 : 142270	CM	 European National Funds PON01-02388/12007-2013.             
./___Corpus/Medline/xml/PMC4819002.xml	12007-	142271 : 142277	CPR	tional Funds PON01-02388/12007-2013.                  Fo
./___Corpus/Medline/xml/PMC4819002.xml	PDF	142365 : 142368	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4819002.xml	honokiol	143159 : 143167	CM	involving derivatives of honokiol and NADPH oxidase inhibi
./___Corpus/Medline/xml/PMC4819002.xml	NADPH	143172 : 143177	CM	ivatives of honokiol and NADPH oxidase inhibitors. He h
./___Corpus/Medline/xml/PMC4819002.xml	NADPH	143261 : 143266	CM	s for the development of NADPH oxidase inhibitors; Penn
./___Corpus/Medline/xml/PMC4819002.xml	anti-	143760 : 143765	CPR	ts for methods regarding anti-CD 137 and adaptive CTL t
./___Corpus/Medline/xml/PMC4819002.xml	CTL	143785 : 143788	CM	anti-CD 137 and adaptive CTL therapeutics; Valter D. 
./___Corpus/Medline/xml/PMC4819002.xml	L-	143845 : 143847	CPR	as an equity interest in L-Nutra, a company that dev
./___Corpus/Medline/xml/PMC4819002.xml	TG2	143987 : 143990	CM	 India Patent 8.765.797, TG2 inhibitors and uses ther
./___Corpus/Medline/xml/PMC4819002.xml	Inc	144165 : 144168	CM	tipodean Pharmaceuticals Inc. which is trying to comm
./___Corpus/Medline/xml/PMC4896392.xml	anti-	108 : 113	CPR	teins present attractive anti-cancer targets owing to t
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	217 : 220	CM	erpolar mitotic kinesins Eg5 and HSET have opposing m
./___Corpus/Medline/xml/PMC4896392.xml	HSET	225 : 229	CM	mitotic kinesins Eg5 and HSET have opposing motor func
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	471 : 474	CM	developing inhibitors of Eg5 and HSET, with an emphas
./___Corpus/Medline/xml/PMC4896392.xml	HSET	479 : 483	CM	ng inhibitors of Eg5 and HSET, with an emphasis on str
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	735 : 738	CM	clinical experience with Eg5 inhibitors, recent findi
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1134 : 1141	CM	om the polymerisation of tubulin monomers, and microtubul
./___Corpus/Medline/xml/PMC4896392.xml	GDP	1204 : 1207	CM	rugs may hyper-stabilise GDP-bound polymerised tubuli
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1226 : 1233	CM	se GDP-bound polymerised tubulin, for example taxanes and
./___Corpus/Medline/xml/PMC4896392.xml	taxanes	1247 : 1254	CM	sed tubulin, for example taxanes and epothilones, or act 
./___Corpus/Medline/xml/PMC4896392.xml	alkaloids	1347 : 1356	CM	bules, for example vinca alkaloids and colchicine. Both cla
./___Corpus/Medline/xml/PMC4896392.xml	colchicine	1361 : 1371	CM	mple vinca alkaloids and colchicine. Both classes of molecul
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	1524 : 1531	CM	 in cell division, where tubulin polymerisation and depol
./___Corpus/Medline/xml/PMC4896392.xml	anti-	2053 : 2058	CPR	ins represent attractive anti-cancer targets owing to t
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-5	2400 : 2409	CM	e proteins belong to the kinesin-5 family, and are found in
./___Corpus/Medline/xml/PMC4896392.xml	eukaryotic	2435 : 2445	CM	family, and are found in eukaryotic organisms [4]. The mitot
./___Corpus/Medline/xml/PMC4896392.xml	ATP	2733 : 2736	CM	egrity [5]. Kinesins use ATP hydrolysis to generate m
./___Corpus/Medline/xml/PMC4896392.xml	hydrolysis	2737 : 2747	RN	ty [5]. Kinesins use ATP hydrolysis to generate movement alo
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	3486 : 3489	CM	 the mitotic kinesins is Eg5 (also known as KIF11, ki
./___Corpus/Medline/xml/PMC4896392.xml	KIF11	3505 : 3510	CM	ns is Eg5 (also known as KIF11, kinesin-5 or KSP) and i
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-5	3512 : 3521	CM	g5 (also known as KIF11, kinesin-5 or KSP) and is involved 
./___Corpus/Medline/xml/PMC4896392.xml	KSP	3525 : 3528	CM	n as KIF11, kinesin-5 or KSP) and is involved in form
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	3649 : 3652	CM	or its maintenance [10]. Eg5 is thought to exist as a
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	3861 : 3866	CM	plusend directed kinesin KIF15 has been shown to act co
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	3908 : 3911	CM	o act cooperatively with Eg5 to promote bipolar spind
./___Corpus/Medline/xml/PMC4896392.xml	HSET	3970 : 3974	CM	ly [11,12]. In contrast, HSET (also known as KIFC1) is
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	4060 : 4063	CM	antagonistically towards Eg5 but whose role is also i
./___Corpus/Medline/xml/PMC4896392.xml	13–	4116 : 4119	CPR	ipolar spindle assembly [13–15]. HSET has also been i
./___Corpus/Medline/xml/PMC4896392.xml	HSET	4124 : 4128	CM	pindle assembly [13–15]. HSET has also been implicated
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	4594 : 4597	CM	ructural features of the Eg5 and HSET kinesins, as il
./___Corpus/Medline/xml/PMC4896392.xml	HSET	4602 : 4606	CM	 features of the Eg5 and HSET kinesins, as illustrated
./___Corpus/Medline/xml/PMC4896392.xml	Eg5-ADP-Mg	4639 : 4649	CM	s, as illustrated in the Eg5-ADP-Mg crystal structure (Figur
./___Corpus/Medline/xml/PMC4896392.xml	ATP	4940 : 4943	CM	binding domains, one for ATP and one for microtubules
./___Corpus/Medline/xml/PMC4896392.xml	N-	5003 : 5005	CPR	 can be classified into N-type kinesins where the mo
./___Corpus/Medline/xml/PMC4896392.xml	N-	5052 : 5054	CPR	 motor domain is at the N-terminus (e.g. Eg5), M-typ
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	5068 : 5071	CM	 at the N-terminus (e.g. Eg5), M-type where the motor
./___Corpus/Medline/xml/PMC4896392.xml	C-	5137 : 5139	CPR	ed by other domains, or C-type where the motor domai
./___Corpus/Medline/xml/PMC4896392.xml	C-	5183 : 5185	CPR	 domain is close to the C-terminus (e.g. HSET) [17].
./___Corpus/Medline/xml/PMC4896392.xml	HSET	5199 : 5203	CM	 to the C-terminus (e.g. HSET) [17]. Kinesins typicall
./___Corpus/Medline/xml/PMC4896392.xml	amino acids	5568 : 5579	CM	y, consisting of ca. 350 amino acids, are highly conserved an
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	5611 : 5614	CM	ighly conserved and thus Eg5 and HSET bear strong str
./___Corpus/Medline/xml/PMC4896392.xml	HSET	5619 : 5623	CM	nserved and thus Eg5 and HSET bear strong structural r
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	5718 : 5721	CM	osing mitotic functions. Eg5 consists of eight antipa
./___Corpus/Medline/xml/PMC4896392.xml	phosphate	5901 : 5910	CM	sheet, surrounded by the phosphate binding loop (P-loop; be
./___Corpus/Medline/xml/PMC4896392.xml	β-phosphate	5976 : 5987	CM	 which tightly binds the β-phosphate group of ATP/ADP, and sw
./___Corpus/Medline/xml/PMC4896392.xml	ATP	5997 : 6000	CM	the β-phosphate group of ATP/ADP, and switch motifs I
./___Corpus/Medline/xml/PMC4896392.xml	ADP	6001 : 6004	CM	β-phosphate group of ATP/ADP, and switch motifs I (be
./___Corpus/Medline/xml/PMC4896392.xml	γ-phosphate	6147 : 6158	CM	presence or absence of a γ-phosphate group[17,19]. The α2 hel
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	6316 : 6319	CM	een proposed to modulate Eg5 function by interacting 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	6404 : 6408	CM	 motif is common to both HSET and Eg5, but the differe
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	6413 : 6416	CM	 common to both HSET and Eg5, but the difference in a
./___Corpus/Medline/xml/PMC4896392.xml	amino acid	6440 : 6450	CM	5, but the difference in amino acid chain length is striking
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	6516 : 6519	CM	le the loop 5 element of Eg5 consists of 17 amino aci
./___Corpus/Medline/xml/PMC4896392.xml	amino acids	6535 : 6546	CM	nt of Eg5 consists of 17 amino acids [20], it has been report
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-14	6579 : 6589	CM	t has been reported that kinesin-14 family members can have 
./___Corpus/Medline/xml/PMC4896392.xml	C-	6682 : 6684	CPR	                 At the C-terminus of the motor doma
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	6971 : 6974	CM	 The neck linker enables Eg5 movement in the directio
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	7227 : 7237	CM	ee of flexibility in its nucleotide bound state. However, it
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	7371 : 7374	CM	es conserved only in the Eg5 subfamily [20]. This rev
./___Corpus/Medline/xml/PMC4896392.xml	L12	7485 : 7488	CM	es which consists of α4, L12 and α5 and is connected 
./___Corpus/Medline/xml/PMC4896392.xml	L11	7529 : 7532	CM	onnected to switch II by L11, which in the ATP-bound 
./___Corpus/Medline/xml/PMC4896392.xml	ATP	7547 : 7550	CM	 II by L11, which in the ATP-bound state adopts a con
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	7652 : 7655	CM	17].                  2. Eg5 and HSET as Therapeutic 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	7660 : 7664	CM	              2. Eg5 and HSET as Therapeutic Targets 2
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	7693 : 7696	CM	Therapeutic Targets 2.1. Eg5 Target Validation       
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	7775 : 7778	CM	 roles in cell division, Eg5 and HSET both represent 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	7783 : 7787	CM	n cell division, Eg5 and HSET both represent potential
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	7851 : 7854	CM	ive therapeutic targets. Eg5 is reportedly selectivel
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8010 : 8013	CM	. An association of high Eg5 expression and poor clin
./___Corpus/Medline/xml/PMC4896392.xml	Transgenic	8223 : 8233	CM	tic adenocarcinoma [26]. Transgenic mice overexpressing Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8254 : 8257	CM	enic mice overexpressing Eg5 suffer chromosome misseg
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8408 : 8411	CM	imals [27]. Depletion of Eg5 using endonuclease-prepa
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	8458 : 8462	CM	epared siRNA (esiRNA) in HeLa cells distinctively show
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8627 : 8630	CM	 Similarly, depletion of Eg5 using alternative method
./___Corpus/Medline/xml/PMC4896392.xml	ASO	8686 : 8689	CM	 as antisense oligomers (ASO) or siRNA in other cell 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8800 : 8803	CM	ll death [28]. Targeting Eg5 with siRNA has been show
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	8927 : 8930	CM	suggesting that clinical Eg5 inhibition may provide a
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9062 : 9065	CM	fects [29]. Depletion of Eg5 using ASO treatment in C
./___Corpus/Medline/xml/PMC4896392.xml	ASO	9072 : 9075	CM	. Depletion of Eg5 using ASO treatment in CaP and LNC
./___Corpus/Medline/xml/PMC4896392.xml	CaP	9089 : 9092	CM	5 using ASO treatment in CaP and LNCaP prostate cance
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP prostate	9097 : 9111	CM	ASO treatment in CaP and LNCaP prostate cancer cell lines reduce
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9143 : 9146	CM	 cell lines reduced both Eg5 mRNA and Eg5 protein lev
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9156 : 9159	CM	educed both Eg5 mRNA and Eg5 protein levels, resultin
./___Corpus/Medline/xml/PMC4896392.xml	G2	9223 : 9225	CM	ndent growth inhibition, G2/M arrest and apoptosis. 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5-ASO	9274 : 9281	CM	 Interestingly, low dose Eg5-ASO seemed to antagonise the
./___Corpus/Medline/xml/PMC4896392.xml	ASO	9349 : 9352	CM	 of paclitaxel. In vivo, ASO monotherapy decreased bo
./___Corpus/Medline/xml/PMC4896392.xml	CaP	9380 : 9383	CM	notherapy decreased both CaP and LNCaP tumour growth,
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP	9388 : 9393	CM	y decreased both CaP and LNCaP tumour growth, but combi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9514 : 9517	CM	0]. In vivo knockdown of Eg5 was also effective in UG
./___Corpus/Medline/xml/PMC4896392.xml	UG87	9540 : 9544	CM	g5 was also effective in UG87 glioblastoma and MDA-MB-
./___Corpus/Medline/xml/PMC4896392.xml	MDA-MB-231	9562 : 9572	CM	in UG87 glioblastoma and MDA-MB-231 breast cancer [28], ovar
./___Corpus/Medline/xml/PMC4896392.xml	EPP85	9630 : 9635	CM	er and melanoma [31] and EPP85 pancreatic tumour xenogr
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9715 : 9718	CM	                         Eg5 was found to be highly e
./___Corpus/Medline/xml/PMC4896392.xml	leukaemia	9788 : 9797	CM	isis chronic myelogenous leukaemia (BC-CML) patient samples
./___Corpus/Medline/xml/PMC4896392.xml	tyrosine	9910 : 9918	CM	nhibition of the Bcr-Abl tyrosine kinase by imatinib was s
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	9929 : 9937	CM	r-Abl tyrosine kinase by imatinib was shown to downregulat
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	9964 : 9967	CM	as shown to downregulate Eg5 expression in imatinib-s
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	9982 : 9990	CM	gulate Eg5 expression in imatinib-sensitive, but not in im
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	10013 : 10021	CM	ib-sensitive, but not in imatinib-resistant or kinase-nega
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	10091 : 10094	CM	]. However, knockdown of Eg5 using ASO technology ind
./___Corpus/Medline/xml/PMC4896392.xml	ASO	10101 : 10104	CM	, knockdown of Eg5 using ASO technology induced G2/M 
./___Corpus/Medline/xml/PMC4896392.xml	G2	10124 : 10126	CM	g ASO technology induced G2/M arrest and cell death 
./___Corpus/Medline/xml/PMC4896392.xml	imatinib	10159 : 10167	CM	t and cell death in both imatinib-sensitive and resistant 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	10223 : 10226	CM	ines, suggesting that an Eg5 inhibitor could be used 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	10339 : 10342	CM	 kinase inhibitors [32]. Eg5 expression in patients w
./___Corpus/Medline/xml/PMC4896392.xml	cyclin B1	10426 : 10435	CM	CLC) was correlated with cyclin B1 expression and appeared 
./___Corpus/Medline/xml/PMC4896392.xml	platinum	10549 : 10557	CM	ents in combination with platinum therapy. In this study, 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	10728 : 10732	CM	].                  2.2. HSET Target Validation       
./___Corpus/Medline/xml/PMC4896392.xml	HSET	10807 : 10811	CM	NA-mediated depletion of HSET also resulted in perturb
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	10938 : 10941	CM	 that observed following Eg5 depletion as, in contras
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	11008 : 11012	CM	ive monoaster formation, HeLa cells treated with HSET 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11032 : 11036	CM	 HeLa cells treated with HSET esiRNA exhibited multipo
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	11083 : 11087	CM	ipolar spindles [14]. In HeLa cells, HSET siRNA result
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11095 : 11099	CM	les [14]. In HeLa cells, HSET siRNA resulted in format
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11200 : 11204	CM	formation [15]. However, HSET depletion in breast canc
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11431 : 11435	CM	amplified controls [34]. HSET is believed to play a ke
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11767 : 11771	CM	, clinical inhibition of HSET may provide a therapy fo
./___Corpus/Medline/xml/PMC4896392.xml	HSET	11866 : 11870	CM	                         HSET siRNA induced multipolar
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12140 : 12144	CM	ntrosomes. Additionally, HSET depletion did not enhanc
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12240 : 12244	CM	This data suggested that HSET may be involved in bipol
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12399 : 12403	CM	erised the expression of HSET in numerous human breast
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12459 : 12463	CM	r cell lines showed that HSET was highly expressed in 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12617 : 12621	CM	NA-mediated knockdown of HSET in two of the cancer cel
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12770 : 12774	CM	             Clinically, HSET overexpression has been 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	12903 : 12907	CM	 patients [38]. Elevated HSET gene expression has been
./___Corpus/Medline/xml/PMC4896392.xml	HSET	13122 : 13126	CM	. Additionally, in NSCLC HSET expression was found to 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	13269 : 13272	CM	40].                  3. Eg5 Chemical Probes: Structu
./___Corpus/Medline/xml/PMC4896392.xml	(S)-trityl-L-cysteine	13499 : 13520	CM	cal probes monastrol and (S)-trityl-L-cysteine (STLC) which specificall
./___Corpus/Medline/xml/PMC4896392.xml	STLC	13522 : 13526	CM	d (S)-trityl-L-cysteine (STLC) which specifically targ
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	13554 : 13557	CM	hich specifically target Eg5 have been extensively st
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	13830 : 13833	CM	esentative Structures of Eg5 Inhibitors              
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	13930 : 13933	CM	ibitory activity against Eg5 have been identified, an
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	14038 : 14041	CM	le, we will focus on the Eg5 inhibitors with reported
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	14265 : 14268	CM	ified as an inhibitor of Eg5, and was discovered by a
./___Corpus/Medline/xml/PMC4896392.xml	ATP	14368 : 14371	CM	43]. Characterised as an ATP non-competitive, reversi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5-ADP	14584 : 14591	CM	such as monastrol to the Eg5-ADP complex prevented the fo
./___Corpus/Medline/xml/PMC4896392.xml	ADP	14690 : 14693	CM	 Firstly, the release of ADP from the protein is inhi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	14972 : 14975	CM	n of the inhibitor-bound Eg5 complex in 2004 confirme
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	15144 : 15154	CM	tuated 12Å away from the nucleotide binding site (Figure 4a)
./___Corpus/Medline/xml/PMC4896392.xml	(S)-monastrol	15249 : 15262	CM	The crystal structure of (S)-monastrol (1), the more potent of 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	15317 : 15320	CM	wo enantiomers, bound to Eg5 highlighted a number of 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	15419 : 15422	CM	gure 4b. The majority of Eg5 inhibitors described to 
./___Corpus/Medline/xml/PMC4896392.xml	L5	15484 : 15486	CM	similar areas within the L5/α2/α3 pocket, including 
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	15707 : 15717	CM	the opposite enantiomer, (R)-Mon-97 2(R), showed higher affi
./___Corpus/Medline/xml/PMC4896392.xml	ADP	15813 : 15816	CM	n the allosteric site of ADP-bound Eg5. (R)-Mon-97 di
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	15823 : 15826	CM	steric site of ADP-bound Eg5. (R)-Mon-97 differs from
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	15828 : 15838	CM	c site of ADP-bound Eg5. (R)-Mon-97 differs from monastrol i
./___Corpus/Medline/xml/PMC4896392.xml	ethyl ester	15874 : 15885	CM	om monastrol in that the ethyl ester is replaced with a bulky
./___Corpus/Medline/xml/PMC4896392.xml	acetophenone	15911 : 15923	CM	is replaced with a bulky acetophenone group, and one of the ni
./___Corpus/Medline/xml/PMC4896392.xml	nitrogen	15946 : 15954	CM	ne group, and one of the nitrogen atoms of the dihydropyri
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	15968 : 15991	CM	he nitrogen atoms of the dihydropyrimidinethione motif is methylated. The
./___Corpus/Medline/xml/PMC4896392.xml	methylated	16001 : 16011	RN	yrimidinethione motif is methylated. These subtle structural
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	16106 : 16116	CM	ntation which placed the lipophilic phenyl ring of the aceto
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	16117 : 16123	CM	ch placed the lipophilic phenyl ring of the acetophenone
./___Corpus/Medline/xml/PMC4896392.xml	acetophenone	16136 : 16148	CM	hilic phenyl ring of the acetophenone group in the hydrophobic
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidine	16207 : 16224	CM	eviously occupied by the dihydropyrimidine core of monastrol, and t
./___Corpus/Medline/xml/PMC4896392.xml	thioxo	16252 : 16258	CM	re of monastrol, and the thioxo group pointing towards t
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	16331 : 16339	CM	ace, making a network of hydrogen-bond interactions with t
./___Corpus/Medline/xml/PMC4896392.xml	water	16367 : 16372	CM	nd interactions with two water molecules [44]. Interest
./___Corpus/Medline/xml/PMC4896392.xml	(S)-enantiomer	16408 : 16422	CM	[44]. Interestingly, the (S)-enantiomer 2(S) was also reasonably
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	16463 : 16466	CM	easonably potent against Eg5 which warns against the 
./___Corpus/Medline/xml/PMC4896392.xml	1-	16797 : 16799	CPR	l protein structures of 1- and 2(R)-bound Eg5 are ve
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	16814 : 16817	CM	res of 1- and 2(R)-bound Eg5 are very similar, result
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	16990 : 17013	CM	 and cellular potency of dihydropyrimidinethione-based inhibitors resulte
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17074 : 17090	CM	scovery of enastron (3), dimethylenastron (4) and fluorastrol (5).
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethiones	17203 : 17227	CM	ese structurally related dihydropyrimidinethiones, whereby enastron and di
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17250 : 17266	CM	es, whereby enastron and dimethylenastron bind primarily in the (S
./___Corpus/Medline/xml/PMC4896392.xml	(R)-enantiomer	17330 : 17344	CM	n (Figure 5b), while the (R)-enantiomer of fluorastrol binds pre
./___Corpus/Medline/xml/PMC4896392.xml	3-phenol	17386 : 17394	CM	inds preferentially. The 3-phenol group is common to all t
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17555 : 17571	CM	cy gains in enastron and dimethylenastron were attributed to the r
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	17689 : 17692	CM	nt exposed sub-pocket of Eg5. Despite pointing toward
./___Corpus/Medline/xml/PMC4896392.xml	dimethyl	17732 : 17740	CM	ing towards solvent, the dimethyl groups of dimethylenastr
./___Corpus/Medline/xml/PMC4896392.xml	dimethylenastron	17751 : 17767	CM	, the dimethyl groups of dimethylenastron maintain hydrophobic con
./___Corpus/Medline/xml/PMC4896392.xml	methyl	17852 : 17858	CM	, and significantly, one methyl group makes a CH-π inter
./___Corpus/Medline/xml/PMC4896392.xml	CH-π	17873 : 17877	CM	one methyl group makes a CH-π interaction with Tyr211.
./___Corpus/Medline/xml/PMC4896392.xml	(R)-fluorastrol	17947 : 17962	CM	ased cellular potency of (R)-fluorastrol relative to (R)-Mon-97 i
./___Corpus/Medline/xml/PMC4896392.xml	(R)-Mon-97	17975 : 17985	CM	-fluorastrol relative to (R)-Mon-97 in terms of growth inhib
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	18021 : 18027	CM	f growth inhibition in a HCT116 cell line (see Table 1) 
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	18101 : 18109	CM	he ability of one of the fluorine atoms to form multipolar
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	18205 : 18213	CM	nally, the electron rich fluorine atoms are in close proxi
./___Corpus/Medline/xml/PMC4896392.xml	Arg221	18267 : 18273	CM	 to a positively charged Arg221 residue, and the resulti
./___Corpus/Medline/xml/PMC4896392.xml	π-	18348 : 18350	CPR	matic ring which makes a π-stacking interaction with
./___Corpus/Medline/xml/PMC4896392.xml	salt	18380 : 18384	CM	ing interaction with the salt bridge formed by Glu116 
./___Corpus/Medline/xml/PMC4896392.xml	Arg221	18413 : 18419	CM	dge formed by Glu116 and Arg221 is more favourably posit
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	18481 : 18492	CM	o the negatively charged carboxylate of Glu116, which could b
./___Corpus/Medline/xml/PMC4896392.xml	Glu116	18496 : 18502	CM	y charged carboxylate of Glu116, which could be partly r
./___Corpus/Medline/xml/PMC4896392.xml	(R)-fluorastrol	18647 : 18662	CM	ay data is available for (R)-fluorastrol, it is not possible to d
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	18971 : 18974	CM	conformational states of Eg5 could also be contributi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	19095 : 19098	CM	      The flexibility of Eg5 to accommodate structura
./___Corpus/Medline/xml/PMC4896392.xml	tetrahydro-β-carboline	19335 : 19357	CM	                   While tetrahydro-β-carboline inhibitors (Table 1, com
./___Corpus/Medline/xml/PMC4896392.xml	6-	19389 : 19391	CPR	tors (Table 1, compounds 6-9) were discovered indepe
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidinethione	19581 : 19604	CM	me binding region as the dihydropyrimidinethione based analogues [45]. Hi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	19691 : 19694	CM	stly potent inhibitor of Eg5 and incorporation of a m
./___Corpus/Medline/xml/PMC4896392.xml	methyl	19718 : 19724	CM	5 and incorporation of a methyl group to give 7 improved
./___Corpus/Medline/xml/PMC4896392.xml	Leu214	19831 : 19837	CM	ntacts in the lipophilic Leu214 region. While the compou
./___Corpus/Medline/xml/PMC4896392.xml	(R)-enantiomer	19898 : 19912	CM	reened as racemates, the (R)-enantiomer of 7 bound preferentiall
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	19942 : 19945	CM	 bound preferentially to Eg5 (PDB 3K3B, not shown), a
./___Corpus/Medline/xml/PMC4896392.xml	PDB	19947 : 19950	CM	d preferentially to Eg5 (PDB 3K3B, not shown), and th
./___Corpus/Medline/xml/PMC4896392.xml	phenolic	20013 : 20021	CM	ucture revealed that the phenolic motif makes a hydrogen b
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	20036 : 20044	CM	e phenolic motif makes a hydrogen bonding interaction with
./___Corpus/Medline/xml/PMC4896392.xml	Glu118	20070 : 20076	CM	bonding interaction with Glu118 (2.6Å), thus mimicking t
./___Corpus/Medline/xml/PMC4896392.xml	OH	20104 : 20106	CM	.6Å), thus mimicking the OH group of monastrol. A se
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	20136 : 20144	CM	p of monastrol. A second hydrogen bond is evident between 
./___Corpus/Medline/xml/PMC4896392.xml	tetrahydro-β-carboline	20183 : 20205	CM	nt between the NH of the tetrahydro-β-carboline core and Glu116 (3.1Å) a
./___Corpus/Medline/xml/PMC4896392.xml	Glu116	20215 : 20221	CM	dro-β-carboline core and Glu116 (3.1Å) and a third is id
./___Corpus/Medline/xml/PMC4896392.xml	amide	20267 : 20272	CM	s identified between the amide carbonyl lone pair and t
./___Corpus/Medline/xml/PMC4896392.xml	carbonyl	20273 : 20281	CM	tified between the amide carbonyl lone pair and the main-c
./___Corpus/Medline/xml/PMC4896392.xml	amide	20311 : 20316	CM	 pair and the main-chain amide NH of Arg119, although w
./___Corpus/Medline/xml/PMC4896392.xml	Arg119	20323 : 20329	CM	e main-chain amide NH of Arg119, although with suboptima
./___Corpus/Medline/xml/PMC4896392.xml	phenol	20568 : 20574	CM	rmed. Interestingly, the phenol motif which presents a m
./___Corpus/Medline/xml/PMC4896392.xml	fluorophenyl	20695 : 20707	CM	essfully replaced with a fluorophenyl group (9) without signif
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	20799 : 20802	CM	 structure of 9 bound to Eg5 has not been reported, t
./___Corpus/Medline/xml/PMC4896392.xml	dihydropyrimidine	20956 : 20973	CM	ntation as seen with the dihydropyrimidine-based analogues, or a ps
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	21003 : 21011	CM	d analogues, or a pseudo hydrogen-bonding interaction betw
./___Corpus/Medline/xml/PMC4896392.xml	fluorine	21044 : 21052	CM	 interaction between the fluorine atom and the key Glu118 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	21080 : 21083	CM	om and the key Glu118 of Eg5 could be possible explan
./___Corpus/Medline/xml/PMC4896392.xml	(S)-Trityl-L-Cysteine	21138 : 21159	CM	s.                  3.3. (S)-Trityl-L-Cysteine (STLC) and Analogues    
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21161 : 21165	CM	. (S)-Trityl-L-Cysteine (STLC) and Analogues          
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21202 : 21206	CM	ues                      STLC (10) was identified as a
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	21281 : 21284	CM	 reversible inhibitor of Eg5 in both basal and microt
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21360 : 21364	CM	al assays. Additionally, STLC caused mitotic arrest in
./___Corpus/Medline/xml/PMC4896392.xml	HeLa	21390 : 21394	CM	caused mitotic arrest in HeLa cells. The binding site 
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21422 : 21426	CM	lls. The binding site of STLC is the same as that of m
./___Corpus/Medline/xml/PMC4896392.xml	L5	21475 : 21477	CM	monastrol, occupying the L5/α2/α3 allosteric pocket.
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21512 : 21516	CM	osteric pocket. However, STLC had much tighter binding
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21720 : 21724	CM	phic studies showed that STLC makes a number of hydrop
./___Corpus/Medline/xml/PMC4896392.xml	π-	21756 : 21758	CPR	a number of hydrophobic, π-stacking and hydrogen bon
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	21771 : 21779	CM	rophobic, π-stacking and hydrogen bonding interactions wit
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	21806 : 21809	CM	onding interactions with Eg5 (Figure 6). Most strikin
./___Corpus/Medline/xml/PMC4896392.xml	STLC	21878 : 21882	CM	the interactions between STLC and Eg5 revealed from th
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	21887 : 21890	CM	actions between STLC and Eg5 revealed from the co-cry
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	21957 : 21960	CM	ies, but the sequence of Eg5 conformational changes u
./___Corpus/Medline/xml/PMC4896392.xml	STLC	22192 : 22196	CM	 for the optimisation of STLC-based inhibitors have be
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	22392 : 22398	CM	tionally interchangeable phenyl rings increased potency 
./___Corpus/Medline/xml/PMC4896392.xml	(S)-methoxytrityl-L-cysteine	22494 : 22522	CM	core of the protein e.g. (S)-methoxytrityl-L-cysteine (11), while bulkier hydr
./___Corpus/Medline/xml/PMC4896392.xml	trityl	22595 : 22601	CM	re not productive as the trityl group rotates to place t
./___Corpus/Medline/xml/PMC4896392.xml	sulfur	22730 : 22736	CM	the metabolically labile sulfur atom and isosteric repla
./___Corpus/Medline/xml/PMC4896392.xml	carbon	22775 : 22781	CM	teric replacement with a carbon linkage gave a series of
./___Corpus/Medline/xml/PMC4896392.xml	triphenylbutanamines	22807 : 22827	CM	linkage gave a series of triphenylbutanamines [49,57] exemplified by c
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	22946 : 22952	CM	ge of cancer cell lines (HCT116, LNCaP, K562, PC3, BxPC-
./___Corpus/Medline/xml/PMC4896392.xml	LNCaP	22954 : 22959	CM	ncer cell lines (HCT116, LNCaP, K562, PC3, BxPC-3 and N
./___Corpus/Medline/xml/PMC4896392.xml	K562	22961 : 22965	CM	ll lines (HCT116, LNCaP, K562, PC3, BxPC-3 and NCI-HI2
./___Corpus/Medline/xml/PMC4896392.xml	PC3	22967 : 22970	CM	es (HCT116, LNCaP, K562, PC3, BxPC-3 and NCI-HI299) a
./___Corpus/Medline/xml/PMC4896392.xml	BxPC-3	22972 : 22978	CM	CT116, LNCaP, K562, PC3, BxPC-3 and NCI-HI299) and gave 
./___Corpus/Medline/xml/PMC4896392.xml	NCI-HI299	22983 : 22992	CM	P, K562, PC3, BxPC-3 and NCI-HI299) and gave regressions of
./___Corpus/Medline/xml/PMC4896392.xml	LXFS538	23053 : 23060	CM	eous tumour xenograft of LXFS538 lung cancer cells follow
./___Corpus/Medline/xml/PMC4896392.xml	IP	23092 : 23094	CM	ancer cells following an IP dosing schedule [49].   
./___Corpus/Medline/xml/PMC4896392.xml	STLC	23221 : 23225	CM	d tricyclic analogues of STLC have been reported, whic
./___Corpus/Medline/xml/PMC4896392.xml	STLC	23331 : 23335	CM	actions observed between STLC and the protein while re
./___Corpus/Medline/xml/PMC4896392.xml	(S)-methoxytrityl-L-cysteine	23400 : 23428	CM	 Indeed, ring closure of (S)-methoxytrityl-L-cysteine with an ethylene linker 
./___Corpus/Medline/xml/PMC4896392.xml	ethylene	23437 : 23445	CM	rityl-L-cysteine with an ethylene linker to give a seven-m
./___Corpus/Medline/xml/PMC4896392.xml	carbocycle	23484 : 23494	CM	e a seven-membered fused carbocycle (13) displayed a twelve-
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	23612 : 23618	CM	t in cytotoxicity in the HCT116 cell line. In vivo activ
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	23653 : 23659	CM	. In vivo activity in an HCT116 colon cancer xenograft m
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	23779 : 23782	CM	     3.4. The Pathway of Eg5 Structural Changes eluci
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	23873 : 23876	CM	       The binding of an Eg5 inhibitor results in a w
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	24090 : 24093	CM	d its analogues bound to Eg5 provided insight into th
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	24401 : 24404	CM	ormational change of the Eg5 motor domain. The first 
./___Corpus/Medline/xml/PMC4896392.xml	STLC	24762 : 24766	CM	ed intermediate state of STLC-bound Eg5 corroborated t
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	24773 : 24776	CM	iate state of STLC-bound Eg5 corroborated the conclus
./___Corpus/Medline/xml/PMC4896392.xml	FRET	24817 : 24821	CM	e conclusions drawn from FRET studies on the intermedi
./___Corpus/Medline/xml/PMC4896392.xml	STLC	24933 : 24937	CM	nfirming that binding of STLC causes drug-induced tran
./___Corpus/Medline/xml/PMC4896392.xml	L5	25012 : 25014	CM	inct stages; 1. The loop L5 in native Eg5 swings rou
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	25025 : 25028	CM	1. The loop L5 in native Eg5 swings round to close th
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	25325 : 25328	CM	r-bound complex [54]. As Eg5 has a unique, extended l
./___Corpus/Medline/xml/PMC4896392.xml	L5	25414 : 25416	CM	er kinesins with shorter L5 motifs such as HSET exhi
./___Corpus/Medline/xml/PMC4896392.xml	HSET	25432 : 25436	CM	horter L5 motifs such as HSET exhibit similar conforma
./___Corpus/Medline/xml/PMC4896392.xml	HSET	25513 : 25517	CM	ion.                  4. HSET inhibitors as chemical t
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	25636 : 25639	CM	ss tractable target than Eg5, the recent emergence of
./___Corpus/Medline/xml/PMC4896392.xml	HSET	25788 : 25792	CM	s the potential role for HSET inhibitors in cancer the
./___Corpus/Medline/xml/PMC4896392.xml	CW069	25898 : 25903	CM	cterised chemical tools, CW069 (17) was identified usin
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26086 : 26090	CM	. An in silico model for HSET binding was developed, b
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	26150 : 26153	CM	e existing inhibitors of Eg5 mined from the CHEMBL da
./___Corpus/Medline/xml/PMC4896392.xml	CHEMBL	26169 : 26175	CM	rs of Eg5 mined from the CHEMBL database. Owing to the h
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	26264 : 26267	CM	 in the motor domains of Eg5 and HSET it was rational
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26272 : 26276	CM	motor domains of Eg5 and HSET it was rationalised that
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26316 : 26320	CM	lised that inhibitors of HSET binding L5/α2/α3 would b
./___Corpus/Medline/xml/PMC4896392.xml	L5	26329 : 26331	CM	hibitors of HSET binding L5/α2/α3 would be identifie
./___Corpus/Medline/xml/PMC4896392.xml	γ-lactone benzoic acid	26507 : 26529	CM	e of which, containing a γ-lactone benzoic acid moiety, was selective fo
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26556 : 26560	CM	oiety, was selective for HSET over Eg5. Hit expansion 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	26566 : 26569	CM	 selective for HSET over Eg5. Hit expansion led to th
./___Corpus/Medline/xml/PMC4896392.xml	CW069	26609 : 26614	CM	 led to the discovery of CW069 which inhibits HSET sele
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26630 : 26634	CM	 of CW069 which inhibits HSET selectively with modest 
./___Corpus/Medline/xml/PMC4896392.xml	CW069	26709 : 26714	CM	4 analogues tested, only CW069 displayed any activity a
./___Corpus/Medline/xml/PMC4896392.xml	HSET	26746 : 26750	CM	yed any activity against HSET, indicating a narrow str
./___Corpus/Medline/xml/PMC4896392.xml	PDB	26915 : 26918	CM	g mode prediction (using PDB files 2REP and 1I16 with
./___Corpus/Medline/xml/PMC4896392.xml	1I16	26934 : 26938	CM	using PDB files 2REP and 1I16 with CW069 plus one othe
./___Corpus/Medline/xml/PMC4896392.xml	CW069	26944 : 26949	CM	files 2REP and 1I16 with CW069 plus one other analogue)
./___Corpus/Medline/xml/PMC4896392.xml	HSET	27041 : 27045	CM	n enthalpic energies for HSET and Eg5 which were consi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27050 : 27053	CM	ic energies for HSET and Eg5 which were consistent wi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27114 : 27117	CM	ctivity observed against Eg5. The model predicted a k
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	27145 : 27153	CM	he model predicted a key hydrogen bond interaction between
./___Corpus/Medline/xml/PMC4896392.xml	Arg521	27179 : 27185	CM	bond interaction between Arg521 and the carboxylate of C
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	27194 : 27205	CM	n between Arg521 and the carboxylate of CW069, which appeared
./___Corpus/Medline/xml/PMC4896392.xml	CW069	27209 : 27214	CM	1 and the carboxylate of CW069, which appeared to be re
./___Corpus/Medline/xml/PMC4896392.xml	HSET	27286 : 27290	CM	ctivity observed between HSET and Eg5, where the analo
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27295 : 27298	CM	bserved between HSET and Eg5, where the analogous res
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	27382 : 27390	CM	d interactions included; hydrogen-bond interactions betwee
./___Corpus/Medline/xml/PMC4896392.xml	CO	27426 : 27428	CM	actions between backbone CO and NH of Gly423, Leu517
./___Corpus/Medline/xml/PMC4896392.xml	NH	27433 : 27435	CM	 between backbone CO and NH of Gly423, Leu517 and th
./___Corpus/Medline/xml/PMC4896392.xml	Leu517	27447 : 27453	CM	one CO and NH of Gly423, Leu517 and the carboxylate and 
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	27462 : 27473	CM	f Gly423, Leu517 and the carboxylate and amine groups of CW06
./___Corpus/Medline/xml/PMC4896392.xml	amine	27478 : 27483	CM	 and the carboxylate and amine groups of CW069. Interes
./___Corpus/Medline/xml/PMC4896392.xml	CW069	27494 : 27499	CM	late and amine groups of CW069. Interestingly, a struct
./___Corpus/Medline/xml/PMC4896392.xml	CW069	27551 : 27556	CM	ally similar analogue of CW069 was not HSET selective, 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	27565 : 27569	CM	nalogue of CW069 was not HSET selective, which was rat
./___Corpus/Medline/xml/PMC4896392.xml	HSET	27697 : 27701	CM	hain length of loop 5 in HSET relative to Eg5, HSET L5
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27714 : 27717	CM	op 5 in HSET relative to Eg5, HSET L5 was found to be
./___Corpus/Medline/xml/PMC4896392.xml	HSET	27719 : 27723	CM	in HSET relative to Eg5, HSET L5 was found to be extre
./___Corpus/Medline/xml/PMC4896392.xml	L5	27724 : 27726	CM	ET relative to Eg5, HSET L5 was found to be extremel
./___Corpus/Medline/xml/PMC4896392.xml	glycine	27784 : 27791	CM	c, particularly around a glycine rich motif which is not 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27827 : 27830	CM	 which is not present in Eg5. This resulted in openin
./___Corpus/Medline/xml/PMC4896392.xml	CW069	27889 : 27894	CM	binding pocket, allowing CW069 to be accommodated, wher
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	27923 : 27926	CM	be accommodated, whereas Eg5 consistently showed part
./___Corpus/Medline/xml/PMC4896392.xml	CW069	28034 : 28039	CM	ak biochemical activity, CW069 was shown to increase mu
./___Corpus/Medline/xml/PMC4896392.xml	MDA-MB-231	28157 : 28167	CM	pernumerary centrosomes (MDA-MB-231 and BT549) without alter
./___Corpus/Medline/xml/PMC4896392.xml	BT549	28172 : 28177	CM	trosomes (MDA-MB-231 and BT549) without altering bipola
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	28290 : 28294	CM	].                  4.2. AZ82                      Hig
./___Corpus/Medline/xml/PMC4896392.xml	HSET	28448 : 28452	CM	d to identify the potent HSET inhibitor AZ82 (18). Imp
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	28463 : 28467	CM	he potent HSET inhibitor AZ82 (18). Impressively, over
./___Corpus/Medline/xml/PMC4896392.xml	HTS	28558 : 28561	CM	week using an integrated HTS, synthesis and screening
./___Corpus/Medline/xml/PMC4896392.xml	HSET	28652 : 28656	CM	 the chemical series. An HSET selective inhibitor with
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	28743 : 28746	CM	other kinesins including Eg5, AZ82 bound to the HSET/
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	28748 : 28752	CM	 kinesins including Eg5, AZ82 bound to the HSET/microt
./___Corpus/Medline/xml/PMC4896392.xml	HSET	28766 : 28770	CM	g Eg5, AZ82 bound to the HSET/microtubule binary compl
./___Corpus/Medline/xml/PMC4896392.xml	HSET	28835 : 28839	CM	d microtubule-stimulated HSET ATPase activity. Co-sedi
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	28892 : 28896	CM	tation analysis revealed AZ82 to be ATP/ADP competitiv
./___Corpus/Medline/xml/PMC4896392.xml	ATP	28903 : 28906	CM	ysis revealed AZ82 to be ATP/ADP competitive, stabili
./___Corpus/Medline/xml/PMC4896392.xml	ADP	28907 : 28910	CM	 revealed AZ82 to be ATP/ADP competitive, stabilising
./___Corpus/Medline/xml/PMC4896392.xml	HSET	28939 : 28943	CM	petitive, stabilising an HSET state with a higher affi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	29027 : 29030	CM	 mode of action from the Eg5 inhibitor monastrol whic
./___Corpus/Medline/xml/PMC4896392.xml	ADP	29066 : 29069	CM	monastrol which inhibits ADP release from the protein
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	29113 : 29116	CM	rotein and results in an Eg5 conformational state wit
./___Corpus/Medline/xml/PMC4896392.xml	ED	29226 : 29228	CM	lysis/mass spectrometry (ED/MS) and fluorescent nucl
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	29249 : 29259	CM	 (ED/MS) and fluorescent nucleotide exchange experiments als
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	29301 : 29305	CM	ents also suggested that AZ82 bound to the HSET/microt
./___Corpus/Medline/xml/PMC4896392.xml	HSET	29319 : 29323	CM	d that AZ82 bound to the HSET/microtubule complex, not
./___Corpus/Medline/xml/PMC4896392.xml	HSET	29349 : 29353	CM	microtubule complex, not HSET or microtubules alone [6
./___Corpus/Medline/xml/PMC4896392.xml	HSET	29462 : 29466	CM	 no crystal structure of HSET with an inhibitor bound 
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	29599 : 29603	CM	difficult in the case of AZ82 despite its high affinit
./___Corpus/Medline/xml/PMC4896392.xml	HSET	29690 : 29694	CM	e to the requirement for HSET to be in the microtubule
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	29740 : 29744	CM	bule-bound state to bind AZ82. In order to gain insigh
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	29933 : 29937	CM	structural similarity of AZ82 to GSK923295, a compound
./___Corpus/Medline/xml/PMC4896392.xml	GSK923295	29941 : 29950	CM	al similarity of AZ82 to GSK923295, a compound which binds 
./___Corpus/Medline/xml/PMC4896392.xml	L5	29992 : 29994	CM	h binds in the analogous L5/α2/α3 allosteric binding
./___Corpus/Medline/xml/PMC4896392.xml	CENP-E	30063 : 30069	CM	cturally related kinesin CENP-E, the model incorporated 
./___Corpus/Medline/xml/PMC4896392.xml	CENP-E	30119 : 30125	CM	aspects of the inhibited CENP-E protein [65] as well as 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	30176 : 30179	CM	he crystal structures of Eg5 bound to the clinical ca
./___Corpus/Medline/xml/PMC4896392.xml	ADP	30232 : 30235	CM	date EMD-534085 [66] and ADP-bound HSET. The homology
./___Corpus/Medline/xml/PMC4896392.xml	HSET	30242 : 30246	CM	34085 [66] and ADP-bound HSET. The homology model sugg
./___Corpus/Medline/xml/PMC4896392.xml	thiophene	30286 : 30295	CM	model suggested that the thiophene ring was buried deeply i
./___Corpus/Medline/xml/PMC4896392.xml	Phe542	30382 : 30388	CM	romatic rings of Tyr461, Phe542 and the aliphatic chain 
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	30428 : 30443	CM	tic chain of Glu421. The trifluoromethyl moiety of the biaryl gro
./___Corpus/Medline/xml/PMC4896392.xml	L5	30512 : 30514	CM	n a pocket formed by the L5 loop, and the polar pyrr
./___Corpus/Medline/xml/PMC4896392.xml	pyrrolidine	30535 : 30546	CM	e L5 loop, and the polar pyrrolidine tail was directed toward
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	30577 : 30587	CM	was directed towards the nucleotide binding site [61,64]. Th
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	30625 : 30629	CM	 [61,64]. The ability of AZ82 to reverse the monopolar
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	30710 : 30713	CM	lowing treatment with an Eg5 inhibitor and cause cent
./___Corpus/Medline/xml/PMC4896392.xml	HSET	30845 : 30849	CM	dence that inhibition of HSET presents an alternative 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	30968 : 30971	CM	ion.                  5. Eg5 inhibitor clinical candi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	31027 : 31030	CM	                     The Eg5 inhibitors which have be
./___Corpus/Medline/xml/PMC4896392.xml	ATP	31099 : 31102	CM	nical trials to date are ATP noncompetitive and targe
./___Corpus/Medline/xml/PMC4896392.xml	L5	31133 : 31135	CM	mpetitive and target the L5/α2/α3 allosteric pocket 
./___Corpus/Medline/xml/PMC4896392.xml	nine	31179 : 31183	CM	ocket (Table 3). Despite nine inhibitors reaching the 
./___Corpus/Medline/xml/PMC4896392.xml	4SC-205	31346 : 31353	CM	lthough the structure of 4SC-205 is undisclosed). Since t
./___Corpus/Medline/xml/PMC4896392.xml	STLC	31457 : 31461	CM	as that of monastrol and STLC, a common mode of inhibi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	31535 : 31538	CM	overy and development of Eg5 inhibitors has been revi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	31756 : 31759	CM	5.1. Binding features of Eg5 clinical candidates     
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	31881 : 31894	CM	each the clinic, and the quinazolinone-based scaffold of this i
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	32078 : 32091	CM	development. A family of quinazolinone-containing analogues wer
./___Corpus/Medline/xml/PMC4896392.xml	IC50	32232 : 32236	CM	ial properties including IC50 values below 1 μM, as we
./___Corpus/Medline/xml/PMC4896392.xml	sub-10	32267 : 32273	CM	s below 1 μM, as well as sub-10 μM in vitro potency in c
./___Corpus/Medline/xml/PMC4896392.xml	vitro	32280 : 32285	CM	 as well as sub-10 μM in vitro potency in cells and gre
./___Corpus/Medline/xml/PMC4896392.xml	100-fold	32320 : 32328	CM	n cells and greater than 100-fold selectivity over a panel
./___Corpus/Medline/xml/PMC4896392.xml	ethylamine	32485 : 32495	CM	ngth and basicity of the ethylamine side-chain, the requirem
./___Corpus/Medline/xml/PMC4896392.xml	4-	32528 : 32530	CPR	ain, the requirement for 4-substitution on the benza
./___Corpus/Medline/xml/PMC4896392.xml	benzamide	32550 : 32559	CM	or 4-substitution on the benzamide group and the required s
./___Corpus/Medline/xml/PMC4896392.xml	α-amino	32623 : 32630	CM	d stereochemistry at the α-amino group. The resulting can
./___Corpus/Medline/xml/PMC4896392.xml	Ki	32685 : 32687	CM	e compound ispinesib had Ki < 1 nM, GI50 < 1 nM in t
./___Corpus/Medline/xml/PMC4896392.xml	GI50	32696 : 32700	CM	ispinesib had Ki < 1 nM, GI50 < 1 nM in the SKOV3 huma
./___Corpus/Medline/xml/PMC4896392.xml	SKOV3	32715 : 32720	CM	1 nM, GI50 < 1 nM in the SKOV3 human ovarian carcinoma 
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	32761 : 32768	CJ	arcinoma cell line, good aqueous solubility and oral bioa
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	32933 : 32946	CM	3921 (20), with the core quinazolinone heterocycle being replac
./___Corpus/Medline/xml/PMC4896392.xml	chromenone	32979 : 32989	CM	ycle being replaced by a chromenone. This subtle change impr
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	33036 : 33039	CM	mproved activity against Eg5 giving a remarkably pote
./___Corpus/Medline/xml/PMC4896392.xml	Ki	33078 : 33080	CM	rkably potent inhibitor (Ki = 0.1 nM) with dose-depe
./___Corpus/Medline/xml/PMC4896392.xml	IC50	33224 : 33228	CM	scovery of AZD-4877 (21, IC50 = 2 nM), also in clinica
./___Corpus/Medline/xml/PMC4896392.xml	quinazoline	33278 : 33289	CM	l development, where the quinazoline is replaced by an isothi
./___Corpus/Medline/xml/PMC4896392.xml	isothiazolo[5,4-d]pyrimidin-4-one	33308 : 33341	CM	zoline is replaced by an isothiazolo[5,4-d]pyrimidin-4-one [72]. While the quinazol
./___Corpus/Medline/xml/PMC4896392.xml	quinazolinone	33358 : 33371	CM	in-4-one [72]. While the quinazolinone Arq621 (22) has more str
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	33819 : 33827	CM	arkably, only one direct hydrogen-bonding interaction is c
./___Corpus/Medline/xml/PMC4896392.xml	aminopropyl	34009 : 34020	CM	the ternary complex, the aminopropyl side-chain is disordered
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	34207 : 34210	CM	or the identification of Eg5 inhibitor scaffolds, wit
./___Corpus/Medline/xml/PMC4896392.xml	hexahydro-2H-pyrano[3,2-c]quinolone	34320 : 34355	CM	her clinical candidates; hexahydro-2H-pyrano[3,2-c]quinolone (HHPQ) compound EMD-5340
./___Corpus/Medline/xml/PMC4896392.xml	HHPQ	34357 : 34361	CM	-pyrano[3,2-c]quinolone (HHPQ) compound EMD-534085 (23
./___Corpus/Medline/xml/PMC4896392.xml	2,5-dihydropyrrole	34401 : 34419	CM	534085 (23) [66] and the 2,5-dihydropyrrole MK-0731 (24) [77,78]. Th
./___Corpus/Medline/xml/PMC4896392.xml	ARRY-520	34466 : 34474	CM	 The clinical candidates ARRY-520, 25 [79] and LY2523355, 
./___Corpus/Medline/xml/PMC4896392.xml	LY2523355	34488 : 34497	CM	es ARRY-520, 25 [79] and LY2523355, 26 [80] bear structural
./___Corpus/Medline/xml/PMC4896392.xml	2,5-dihydropyrrole	34563 : 34581	CM	MK-0731, but replace the 2,5-dihydropyrrole core with a 1,3,4-thiadi
./___Corpus/Medline/xml/PMC4896392.xml	1,3,4-thiadiazoline	34594 : 34613	CM	hydropyrrole core with a 1,3,4-thiadiazoline motif. Despite the struc
./___Corpus/Medline/xml/PMC4896392.xml	thiophene	34768 : 34777	CM	eatures (Figure 8b). The thiophene-containing chemical prob
./___Corpus/Medline/xml/PMC4896392.xml	HTS	34886 : 34889	CM	nd were identified via a HTS approach [51].          
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	34951 : 34966	CM	                 The C-9 trifluoromethyl substituent of EMD-53408
./___Corpus/Medline/xml/PMC4896392.xml	chloroquinazolinone	35035 : 35054	CM	osition analogous to the chloroquinazolinone moiety of ispinesib, but
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	35134 : 35141	CJ	34085 serves to increase aqueous solubility of the lipoph
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	35160 : 35170	CM	queous solubility of the lipophilic core, pointing towards s
./___Corpus/Medline/xml/PMC4896392.xml	lipophilic	35279 : 35289	CM	inetic properties of the lipophilic core, but is not reporte
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	35578 : 35581	CM	. Clinical outcomes with Eg5 inhibitors              
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	35626 : 35629	CM	             Despite all Eg5 inhibitors reaching clin
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	35812 : 35815	CM	ointing to date, as many Eg5 inhibitors have failed t
./___Corpus/Medline/xml/PMC4896392.xml	4SC-205	36232 : 36239	CM	evelopment; ARRY-520 and 4SC-205 (Table 3). The reasons f
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	36293 : 36296	CM	he poor activity of many Eg5 inhibitors in the clinic
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	36707 : 36710	CM	ost vascular cells [83]. Eg5 is almost exclusively ex
./___Corpus/Medline/xml/PMC4896392.xml	G2	36817 : 36819	CM	ugh some is expressed in G2. As a result, drugs targ
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	36850 : 36853	CM	 result, drugs targeting Eg5 may only have a therapeu
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	37309 : 37312	CM	ical data using the oral Eg5 inhibitor 4SC-205 indica
./___Corpus/Medline/xml/PMC4896392.xml	4SC-205	37323 : 37330	CM	g the oral Eg5 inhibitor 4SC-205 indicated that a continu
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	37780 : 37785	CM	the bipolar spindle [8], KIF15 (kinesin-12) has been pr
./___Corpus/Medline/xml/PMC4896392.xml	kinesin-12	37787 : 37797	CM	olar spindle [8], KIF15 (kinesin-12) has been proposed as a 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	37857 : 37860	CM	compensatory kinesin for Eg5. Evidence to suggest tha
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	37887 : 37892	CM	Evidence to suggest that KIF15 drives bipolar spindle a
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	37943 : 37946	CM	sembly in the absence of Eg5, compensating for its in
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	38133 : 38136	CM	sation and comparison to Eg5. In contrast to Eg5, KIF
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	38153 : 38156	CM	n to Eg5. In contrast to Eg5, KIF15 does not contain 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38158 : 38163	CM	Eg5. In contrast to Eg5, KIF15 does not contain a secon
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	38190 : 38200	CM	oes not contain a second nucleotide-independent microtubule-
./___Corpus/Medline/xml/PMC4896392.xml	C-	38246 : 38248	CPR	ule-binding site in its C-terminal tail, and operate
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	38372 : 38375	CM	otetrameric structure of Eg5. Owing to the structural
./___Corpus/Medline/xml/PMC4896392.xml	TPX2	38522 : 38526	CM	eting protein for Xklp2 (TPX2), which complexes to KIF
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38548 : 38553	CM	PX2), which complexes to KIF15 through its C-terminus, 
./___Corpus/Medline/xml/PMC4896392.xml	C-	38567 : 38569	CPR	es to KIF15 through its C-terminus, promoting centro
./___Corpus/Medline/xml/PMC4896392.xml	TPX2	38626 : 38630	CM	paration. Interestingly, TPX2 is also known to interac
./___Corpus/Medline/xml/PMC4896392.xml	TPX2	38805 : 38809	CM	-8745 was increased when TPX2 was depleted with siRNA 
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	38879 : 38884	CM	efore been proposed that KIF15 and its protein-protein 
./___Corpus/Medline/xml/PMC4896392.xml	TPX2	38926 : 38930	CM	protein interaction with TPX2 represent interesting th
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	39018 : 39021	CM	y in combination with an Eg5 inhibitor [11,88,89]. Cl
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	39284 : 39287	CM	The effectiveness of the Eg5 candidate SB-743921 was 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	39546 : 39549	CM	nation for resistance to Eg5 inhibition is proposed. 
./___Corpus/Medline/xml/PMC4896392.xml	L5	39622 : 39624	CM	d that the flexible loop L5 which is coupled to the 
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	39649 : 39659	CM	 which is coupled to the nucleotide binding site and the nec
./___Corpus/Medline/xml/PMC4896392.xml	ADP	39755 : 39758	CM	ity, serve to accelerate ADP release during the initi
./___Corpus/Medline/xml/PMC4896392.xml	amino acid	39874 : 39884	CM	observation that a seven amino acid deletion within L5 can s
./___Corpus/Medline/xml/PMC4896392.xml	L5	39901 : 39903	CM	ino acid deletion within L5 can still hydrolyse ATP 
./___Corpus/Medline/xml/PMC4896392.xml	hydrolyse	39914 : 39923	RN	tion within L5 can still hydrolyse ATP suggests that L5 is 
./___Corpus/Medline/xml/PMC4896392.xml	ATP	39924 : 39927	CM	n L5 can still hydrolyse ATP suggests that L5 is not 
./___Corpus/Medline/xml/PMC4896392.xml	L5	39942 : 39944	CM	rolyse ATP suggests that L5 is not essential to prom
./___Corpus/Medline/xml/PMC4896392.xml	L5	40048 : 40050	CM	inhibitors targeting the L5/α2/α3 allosteric site ar
./___Corpus/Medline/xml/PMC4896392.xml	ADP	40118 : 40121	CM	ally slow the release of ADP, doubts have arisen rega
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	40369 : 40372	CM	gests the development of Eg5 inhibitors with an alter
./___Corpus/Medline/xml/PMC4896392.xml	CENP-E	40858 : 40864	CM	x pumps as seen with the CENP-E inhibitor GSK923295 [93]
./___Corpus/Medline/xml/PMC4896392.xml	GSK923295	40875 : 40884	CM	ith the CENP-E inhibitor GSK923295 [93], or mutations withi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	40989 : 40992	CM	conferring resistance to Eg5 inhibitors targeting the
./___Corpus/Medline/xml/PMC4896392.xml	L5	41018 : 41020	CM	inhibitors targeting the L5/α2/α3 site has already b
./___Corpus/Medline/xml/PMC4896392.xml	94–	41059 : 41062	CPR	s already been reported [94–97], representing another
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	41129 : 41132	CM	 clinical application of Eg5 inhibitors.             
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	41288 : 41291	CM	ed-fit binding pocket of Eg5 can confer drug resistan
./___Corpus/Medline/xml/PMC4896392.xml	STLC	41337 : 41341	CM	stance to the inhibitors STLC and monastrol, both bioc
./___Corpus/Medline/xml/PMC4896392.xml	alanine	41467 : 41474	CM	ingle point mutations by alanine scanning mutagenesis led
./___Corpus/Medline/xml/PMC4896392.xml	STLC	41556 : 41560	CM	ance to monastrol and/or STLC, strongly suggesting tha
./___Corpus/Medline/xml/PMC4896392.xml	R119A	41673 : 41678	CM	g. Three mutant strains (R119A, D130A and L214A; See on
./___Corpus/Medline/xml/PMC4896392.xml	D130A	41680 : 41685	CM	e mutant strains (R119A, D130A and L214A; See online ap
./___Corpus/Medline/xml/PMC4896392.xml	L214A	41690 : 41695	CM	trains (R119A, D130A and L214A; See online appendix Fig
./___Corpus/Medline/xml/PMC4896392.xml	Arg119	42022 : 42028	CM	ctive inhibitor binding. Arg119 is located at the entran
./___Corpus/Medline/xml/PMC4896392.xml	phenol	42145 : 42151	CM	ments of both monastrol (phenol ring) and STLC (trityl m
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42162 : 42166	CM	astrol (phenol ring) and STLC (trityl motif) make hydr
./___Corpus/Medline/xml/PMC4896392.xml	trityl	42168 : 42174	CM	 (phenol ring) and STLC (trityl motif) make hydrophobic 
./___Corpus/Medline/xml/PMC4896392.xml	Leu214	42252 : 42258	CM	s of Asp130 (loop 5) and Leu214 (helix α3) point towards
./___Corpus/Medline/xml/PMC4896392.xml	CH-π	42343 : 42347	CM	 hydrophobic contacts or CH-π interactions (refer to s
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42410 : 42414	CM	nd 3.3 for monastrol and STLC binding modes, respectiv
./___Corpus/Medline/xml/PMC4896392.xml	STLC	42530 : 42534	CM	istance to monastrol and STLC in the presence of wild-
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	42564 : 42567	CM	he presence of wild-type Eg5, suggesting that an Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	42588 : 42591	CM	 Eg5, suggesting that an Eg5 tetramer consisting of a
./___Corpus/Medline/xml/PMC4896392.xml	tetramer	42592 : 42600	CM	, suggesting that an Eg5 tetramer consisting of a combinat
./___Corpus/Medline/xml/PMC4896392.xml	isoform	42921 : 42928	CM	activation of Raf kinase isoform heterodimers upon inhibi
./___Corpus/Medline/xml/PMC4896392.xml	MAPK	43008 : 43012	CM	oxical activation of the MAPK signalling pathway in ce
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	43267 : 43270	CM	ting multiple mutants of Eg5, this could overcome thi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	43368 : 43371	CM	                         Eg5 mutants resistant to cli
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	43526 : 43529	CM	patients treated with an Eg5 inhibitor. Long-term exp
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	43563 : 43569	CM	r. Long-term exposure of HCT116 colorectal cell lines to
./___Corpus/Medline/xml/PMC4896392.xml	3000-fold	43682 : 43691	CM	ant cell line which was >3000-fold less sensitive to the dr
./___Corpus/Medline/xml/PMC4896392.xml	tubulin	43778 : 43785	CM	cytotoxic drug including tubulin-targeting agents [101]. 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	43832 : 43835	CM	]. DNA sequencing of the Eg5 motor domain from the re
./___Corpus/Medline/xml/PMC4896392.xml	D130V	43942 : 43947	CM	conferring resistance as D130V (also one of the point-m
./___Corpus/Medline/xml/PMC4896392.xml	STLC	44028 : 44032	CM	istance to monastrol and STLC) and A133D. Potency dete
./___Corpus/Medline/xml/PMC4896392.xml	A133D	44038 : 44043	CM	 monastrol and STLC) and A133D. Potency determinations 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	44116 : 44119	CM	he two mutant strains of Eg5 revealed that the D130V 
./___Corpus/Medline/xml/PMC4896392.xml	D130V	44138 : 44143	CM	of Eg5 revealed that the D130V is the more resistant of
./___Corpus/Medline/xml/PMC4896392.xml	A133	44328 : 44332	CM	binding pocket. D130 and A133 are involved in an exten
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	44373 : 44381	CM	 an extensive network of hydrogen bond interactions, which
./___Corpus/Medline/xml/PMC4896392.xml	L5	44446 : 44448	CM	 of stabilising the loop L5 in an inward conformatio
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	44602 : 44605	CM	to the second generation Eg5 inhibitor SB-743921.    
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	44762 : 44765	CM	ed that mutated forms of Eg5 had improved enthalpic i
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	45048 : 45051	CM	cture of inhibitor-bound Eg5 A133D mutant did not rev
./___Corpus/Medline/xml/PMC4896392.xml	A133D	45052 : 45057	CM	e of inhibitor-bound Eg5 A133D mutant did not reveal an
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	45296 : 45299	CM	d that the resistance of Eg5 towards SB-743921 was th
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45407 : 45415	CM	cal rearrangement of the hydrogen bonding interactions and
./___Corpus/Medline/xml/PMC4896392.xml	salt	45441 : 45445	CM	bonding interactions and salt-bridging in the alloster
./___Corpus/Medline/xml/PMC4896392.xml	Arg138	45506 : 45512	CM	In the wild-type protein Arg138, Ala133, and Asp130 form
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45551 : 45559	CM	Asp130 form a network of hydrogen bonds and there is a sal
./___Corpus/Medline/xml/PMC4896392.xml	salt	45581 : 45585	CM	gen bonds and there is a salt bridge which exists betw
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45625 : 45631	CM	xists between Glu128 and Lys207 [95,103]. In the A133D v
./___Corpus/Medline/xml/PMC4896392.xml	A133D	45649 : 45654	CM	 Lys207 [95,103]. In the A133D variant, Arg138 formed a
./___Corpus/Medline/xml/PMC4896392.xml	Arg138	45664 : 45670	CM	]. In the A133D variant, Arg138 formed a salt bridge wit
./___Corpus/Medline/xml/PMC4896392.xml	salt	45680 : 45684	CM	variant, Arg138 formed a salt bridge with the newly in
./___Corpus/Medline/xml/PMC4896392.xml	carboxylate	45718 : 45729	CM	ith the newly introduced carboxylate of Asp133, breaking the 
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45780 : 45786	CM	ridge between Glu128 and Lys207 and allowing a new hydro
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	45806 : 45814	CM	ys207 and allowing a new hydrogen bond interaction to form
./___Corpus/Medline/xml/PMC4896392.xml	Lys207	45848 : 45854	CM	eraction to form between Lys207 and His141. These change
./___Corpus/Medline/xml/PMC4896392.xml	His141	45859 : 45865	CM	 form between Lys207 and His141. These changes rigidify 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	46054 : 46057	CM	ty of the ligand towards Eg5. Additionally, key resid
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	46263 : 46266	CM	uctuations. In wild-type Eg5, residue A133 was identi
./___Corpus/Medline/xml/PMC4896392.xml	A133	46276 : 46280	CM	n wild-type Eg5, residue A133 was identified as such a
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	46380 : 46390	CM	rough the protein to the nucleotide site when binding the in
./___Corpus/Medline/xml/PMC4896392.xml	A133	46429 : 46433	CM	ding the inhibitor. When A133 was mutated, the energy 
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	46596 : 46606	CM	 energy gates within the nucleotide site are unaffected, ena
./___Corpus/Medline/xml/PMC4896392.xml	ATP	46644 : 46647	CM	ffected, enabling normal ATP hydrolysis and thus Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	hydrolysis	46648 : 46658	RN	ted, enabling normal ATP hydrolysis and thus Eg5 motor funct
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	46668 : 46671	CM	 ATP hydrolysis and thus Eg5 motor function. This unp
./___Corpus/Medline/xml/PMC4896392.xml	L5	46822 : 46824	CM	y point mutations in the L5/α2/α3 binding site are h
./___Corpus/Medline/xml/PMC4896392.xml	HSET	47254 : 47258	CM	lopment of inhibitors of HSET lags those of Eg5, and t
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	47273 : 47276	CM	rs of HSET lags those of Eg5, and the binding mode of
./___Corpus/Medline/xml/PMC4896392.xml	HSET	47377 : 47381	CM	ble to determine whether HSET is susceptible to such ‘
./___Corpus/Medline/xml/PMC4896392.xml	HSET	47717 : 47721	CM	t for the development of HSET inhibitors as well as fo
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	47755 : 47758	CM	rs as well as for future Eg5 inhibitors.             
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	47831 : 47834	CM	   The mutant strains of Eg5 may prove to be useful s
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	47901 : 47904	CM	 the discovery of future Eg5 inhibitors. The STLC-res
./___Corpus/Medline/xml/PMC4896392.xml	STLC	47921 : 47925	CM	ture Eg5 inhibitors. The STLC-resistant cell lines D13
./___Corpus/Medline/xml/PMC4896392.xml	D130A	47947 : 47952	CM	TLC-resistant cell lines D130A and L214A have shown uti
./___Corpus/Medline/xml/PMC4896392.xml	L214A	47957 : 47962	CM	ant cell lines D130A and L214A have shown utility in di
./___Corpus/Medline/xml/PMC4896392.xml	L5	48064 : 48066	CM	ckets from the classical L5/α2/α3 targeted inhibitor
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	48593 : 48596	CM	ing the effectiveness of Eg5 L5/α2/α3 allosteric inhi
./___Corpus/Medline/xml/PMC4896392.xml	L5	48597 : 48599	CM	the effectiveness of Eg5 L5/α2/α3 allosteric inhibit
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	48769 : 48772	CM	d allosteric site within Eg5 has been identified, wit
./___Corpus/Medline/xml/PMC4896392.xml	Biphenyl	48907 : 48915	CM	).                  7.1. Biphenyl-Based Inhibitors        
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	48971 : 48979	CM	        In 2007 a set of biphenyl-based inhibitors of Eg5 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	49000 : 49003	CM	enyl-based inhibitors of Eg5 were identified followin
./___Corpus/Medline/xml/PMC4896392.xml	GSK-1	49175 : 49180	CM	highly potent inhibitors GSK-1 (28) and GSK-2 (29). Fur
./___Corpus/Medline/xml/PMC4896392.xml	GSK-2	49190 : 49195	CM	nhibitors GSK-1 (28) and GSK-2 (29). Further characteri
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	49315 : 49318	CM	ompetitive inhibitors of Eg5 [106]. GSK-1 and GSK-2 b
./___Corpus/Medline/xml/PMC4896392.xml	GSK-2	49336 : 49341	CM	 of Eg5 [106]. GSK-1 and GSK-2 bound to the ispinesib-r
./___Corpus/Medline/xml/PMC4896392.xml	D130V	49375 : 49380	CM	 the ispinesib-resistant D130V and A133D mutants of Eg5
./___Corpus/Medline/xml/PMC4896392.xml	A133D	49385 : 49390	CM	esib-resistant D130V and A133D mutants of Eg5, indicati
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	49402 : 49405	CM	30V and A133D mutants of Eg5, indicating that a bindi
./___Corpus/Medline/xml/PMC4896392.xml	HCT116	49533 : 49539	CM	d potent activity in the HCT116 colon cancer cell line (
./___Corpus/Medline/xml/PMC4896392.xml	IC50	49564 : 49568	CM	 colon cancer cell line (IC50 = 36 nM) giving a phenot
./___Corpus/Medline/xml/PMC4896392.xml	phenyltrifluoromethyldiazirine	49918 : 49948	CM	ue containing a reactive phenyltrifluoromethyldiazirine motif (GSK-3, 30) allowe
./___Corpus/Medline/xml/PMC4896392.xml	GSK-3	49956 : 49961	CM	romethyldiazirine motif (GSK-3, 30) allowed covalent mo
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	50004 : 50007	CM	lent modification of the Eg5 protein. Labelled Eg5 mo
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	50026 : 50029	CM	he Eg5 protein. Labelled Eg5 motor domain was purifie
./___Corpus/Medline/xml/PMC4896392.xml	284-	50168 : 50172	CPR	DI-TOF revealed residues 284-297 as the site of ligand
./___Corpus/Medline/xml/PMC4896392.xml	Leu295	50276 : 50282	CM	 specifically identified Leu295 as the site of labelling
./___Corpus/Medline/xml/PMC4896392.xml	Leu295	50309 : 50315	CM	s the site of labelling. Leu295 is located in the middle
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	50604 : 50614	CM	ode is distinct from the nucleotide binding site [106].     
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	50684 : 50692	CM	              A range of biphenyl based inhibitors with si
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	50806 : 50814	CM	in the identification of PVZB1194 (31), an ATP-competitive
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	50853 : 50856	CM	competitive inhibitor of Eg5 [107]. PVZB1194 was even
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	50864 : 50872	CM	 inhibitor of Eg5 [107]. PVZB1194 was eventually successfu
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	50922 : 50932	CM	lly co-crystallised with nucleotide-unbound Eg5 (Figure 10a;
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	50941 : 50944	CM	 with nucleotide-unbound Eg5 (Figure 10a; See Figure 
./___Corpus/Medline/xml/PMC4896392.xml	monastrol-ADP	50990 : 51003	CM	ure 10b for overlay with monastrol-ADP-bound Eg5), owing to the
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	51010 : 51013	CM	with monastrol-ADP-bound Eg5), owing to the ability o
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	51063 : 51066	CM	f this ligand to bind to Eg5 without the presence of 
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	51109 : 51115	CM	nce of microtubules. The phenyl ring of Tyr104 formed a 
./___Corpus/Medline/xml/PMC4896392.xml	3-fluoro	51170 : 51178	CM	ing interaction with the 3-fluoro, 4-trifluoromethylphenyl
./___Corpus/Medline/xml/PMC4896392.xml	4-trifluoromethylphenyl	51180 : 51203	CM	ction with the 3-fluoro, 4-trifluoromethylphenyl ring, while Tyr352 stack
./___Corpus/Medline/xml/PMC4896392.xml	sulfonamide	51240 : 51251	CM	 Tyr352 stacked with the sulfonamide phenyl group, which made
./___Corpus/Medline/xml/PMC4896392.xml	phenyl	51252 : 51258	CM	ked with the sulfonamide phenyl group, which made additi
./___Corpus/Medline/xml/PMC4896392.xml	Leu292	51320 : 51326	CM	 Waals interactions with Leu292 and Leu293. A network of
./___Corpus/Medline/xml/PMC4896392.xml	Leu293	51331 : 51337	CM	ractions with Leu292 and Leu293. A network of hydrogen b
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	51352 : 51360	CM	and Leu293. A network of hydrogen bonds existed between Ty
./___Corpus/Medline/xml/PMC4896392.xml	Ser269	51402 : 51408	CM	tween Tyr104, Glu345 and Ser269 which formed the wall of
./___Corpus/Medline/xml/PMC4896392.xml	trifluoromethyl	51486 : 51501	CM	ing pocket. Finally, the trifluoromethyl group made a series of v
./___Corpus/Medline/xml/PMC4896392.xml	Ile332	51565 : 51571	CM	nteractions with Tyr104, Ile332, Ala334, Tyr352 and Ala3
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	51694 : 51702	CM	gh degree of potency for PVZB1194 for Eg5, there were no d
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	51707 : 51710	CM	potency for PVZB1194 for Eg5, there were no direct hy
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	51733 : 51741	CM	g5, there were no direct hydrogen bonding interactions obs
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	51970 : 51978	CM	bilise the bottom of the PVZB1194-binding pocket. The impo
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	52046 : 52054	CM	-linker conformation for PVZB1194 binding was investigated
./___Corpus/Medline/xml/PMC4896392.xml	ATPase	52163 : 52169	CM	the structure. While the ATPase function was retained, P
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	52193 : 52201	CM	e function was retained, PVZB1194 was found to be forty-fo
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	52408 : 52416	CM	chemical result that the biphenyl-based compounds were ATP
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52459 : 52469	CM	ere ATP-competitive, the nucleotide binding site was void of
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52495 : 52498	CM	binding site was void of ATP or ADP. The surface mode
./___Corpus/Medline/xml/PMC4896392.xml	ADP	52502 : 52505	CM	 site was void of ATP or ADP. The surface model of th
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52532 : 52535	CM	The surface model of the ATP-binding site showed that
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52609 : 52619	CM	space to accommodate the nucleotide, as a result of Glu129 a
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	52685 : 52693	CM	ing the site. Binding of PVZB1194 caused Tyr104 of strand 
./___Corpus/Medline/xml/PMC4896392.xml	ATP	52878 : 52881	CM	 the conformation of the ATP-binding site and prevent
./___Corpus/Medline/xml/PMC4896392.xml	nucleotide	52910 : 52920	CM	ding site and preventing nucleotide binding.                
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	52996 : 53004	CM	 novel mode of action of biphenyl-based Eg5 inhibitors has
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	53011 : 53014	CM	action of biphenyl-based Eg5 inhibitors has stimulate
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	53196 : 53204	CM	al restriction about the biphenyl junction, through develo
./___Corpus/Medline/xml/PMC4896392.xml	carboline	53238 : 53247	CM	, through development of carboline and carbazole scaffolds,
./___Corpus/Medline/xml/PMC4896392.xml	carbazole	53252 : 53261	CM	lopment of carboline and carbazole scaffolds, resulting in 
./___Corpus/Medline/xml/PMC4896392.xml	carbazole	53359 : 53368	CM	ely the planarity of the carbazole compounds resulted in ve
./___Corpus/Medline/xml/PMC4896392.xml	aqueous	53401 : 53408	CJ	ds resulted in very poor aqueous solubility, rendering th
./___Corpus/Medline/xml/PMC4896392.xml	diarylamine	53501 : 53512	CM	. Ring opening to give a diarylamine-based scaffold gave equi
./___Corpus/Medline/xml/PMC4896392.xml	Benzimidazole	53634 : 53647	CM	].                  7.2. Benzimidazole-based inhibitors        
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazoles	53742 : 53756	CM	novel set of substituted benzimidazoles shown to target Eg5 was 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	53773 : 53776	CM	idazoles shown to target Eg5 was reported. The abilit
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	53900 : 53903	CM	erved that they bound to Eg5 in the presence of ispin
./___Corpus/Medline/xml/PMC4896392.xml	D130V	53952 : 53957	CM	nesib. Direct binding to D130V, A133D and the D130V-A13
./___Corpus/Medline/xml/PMC4896392.xml	A133D	53959 : 53964	CM	Direct binding to D130V, A133D and the D130V-A133D doub
./___Corpus/Medline/xml/PMC4896392.xml	D130V-A133D	53973 : 53984	CM	 to D130V, A133D and the D130V-A133D double Eg5 mutants was a
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	53992 : 53995	CM	d the D130V-A133D double Eg5 mutants was also observe
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazole	54117 : 54130	CM	g site was targeted. The benzimidazole compounds were initially
./___Corpus/Medline/xml/PMC4896392.xml	ATP	54168 : 54171	CM	re initially shown to be ATP non-competitive, which i
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	54217 : 54225	CM	ch is in contrast to the biphenyl second-site binders [110
./___Corpus/Medline/xml/PMC4896392.xml	aminobenzimidazole	54294 : 54312	CM	the binding site for the aminobenzimidazole-based compound BI8 (34) 
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54328 : 54331	CM	imidazole-based compound BI8 (34) was accomplished wi
./___Corpus/Medline/xml/PMC4896392.xml	biphenyl	54488 : 54496	CM	 a similar region as the biphenyl compounds, BI8 was found
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54508 : 54511	CM	 the biphenyl compounds, BI8 was found to bind in the
./___Corpus/Medline/xml/PMC4896392.xml	L5	54879 : 54881	CM	cribed for the classical L5/α2/α3 inhibitors. The po
./___Corpus/Medline/xml/PMC4896392.xml	BI8	54915 : 54918	CM	hibitors. The potency of BI8 for Eg5 could be explain
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	54923 : 54926	CM	. The potency of BI8 for Eg5 could be explained as a 
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55103 : 55106	CM	s between the binding of BI8 and PVZB1194 to Eg5, i.e
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	55111 : 55119	CM	n the binding of BI8 and PVZB1194 to Eg5, i.e. shared bind
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	55123 : 55126	CM	g of BI8 and PVZB1194 to Eg5, i.e. shared binding to 
./___Corpus/Medline/xml/PMC4896392.xml	Leu292	55176 : 55182	CM	residues Tyr104, Tyr352, Leu292, there are some striking
./___Corpus/Medline/xml/PMC4896392.xml	PVZB1194	55260 : 55268	CM	ck-linker is docked with PVZB1194 bound and undocked with 
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55293 : 55296	CM	 bound and undocked with BI8. The difference in the p
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55395 : 55398	CM	 structure also rendered BI8 different from L5/α2/α3 
./___Corpus/Medline/xml/PMC4896392.xml	L5	55414 : 55416	CM	dered BI8 different from L5/α2/α3 inhibitors such as
./___Corpus/Medline/xml/PMC4896392.xml	STLC	55442 : 55446	CM	α2/α3 inhibitors such as STLC, whose crystal structure
./___Corpus/Medline/xml/PMC4896392.xml	BI8	55658 : 55661	CM	pocket was unaffected by BI8 binding, resulting in an
./___Corpus/Medline/xml/PMC4896392.xml	BI8-Eg5	55837 : 55844	CM	structure refinement for BI8-Eg5, electron density in a s
./___Corpus/Medline/xml/PMC4896392.xml	a4	56312 : 56314	CM	hically identified novel a4/a6 site. Deconvolution o
./___Corpus/Medline/xml/PMC4896392.xml	hydrogen	56644 : 56652	CM	ement of the strength of hydrogen bonding interactions in 
./___Corpus/Medline/xml/PMC4896392.xml	benzimidazole	56789 : 56802	CM	Counter-screening of the benzimidazole-based Eg5 inhibitors aga
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	56809 : 56812	CM	 the benzimidazole-based Eg5 inhibitors against HSET 
./___Corpus/Medline/xml/PMC4896392.xml	HSET	56832 : 56836	CM	d Eg5 inhibitors against HSET highlighted a number wit
./___Corpus/Medline/xml/PMC4896392.xml	HSET	56870 : 56874	CM	ted a number with weaker HSET inhibitory activity [113
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	56994 : 56997	CM	inical data thus far for Eg5 inhibitors as a monother
./___Corpus/Medline/xml/PMC4896392.xml	4SC-205	57111 : 57118	CM	clinical trial data with 4SC-205 showed stable disease wa
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	57163 : 57166	CM	se was achieved with the Eg5 inhibitor monotherapy do
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	57578 : 57581	CM	ile some combinations of Eg5 inhibitor with other che
./___Corpus/Medline/xml/PMC4896392.xml	docetaxel	57705 : 57714	CM	5992 in combination with docetaxel in solid tumours, precli
./___Corpus/Medline/xml/PMC4896392.xml	KIF15	57880 : 57885	CM	arly an Aurora A [91] or KIF15/TPX2 inhibitor [89] shou
./___Corpus/Medline/xml/PMC4896392.xml	TPX2	57886 : 57890	CM	n Aurora A [91] or KIF15/TPX2 inhibitor [89] should on
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	58056 : 58059	CM	 improve the efficacy of Eg5 inhibitors. This highlig
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	58508 : 58511	CM	e pathways [114]. Should Eg5 inhibitors with an alter
./___Corpus/Medline/xml/PMC4896392.xml	ATP	58644 : 58647	CM	itors with the classical ATP non-competitive inhibito
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	58739 : 58742	CM	rest. Dual inhibition of Eg5 at both allosteric bindi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	58853 : 58856	CM	rresting the motility of Eg5 along microtubules, and 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	58938 : 58941	CM	rug-resistant strains of Eg5 emerging by targeting tw
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	59159 : 59162	CM	lopment of resistance to Eg5 inhibitors is highly lik
./___Corpus/Medline/xml/PMC4896392.xml	L5	59225 : 59227	CM	arly those targeting the L5/α2/α3 binding site. The 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	59332 : 59335	CM	 following inhibition of Eg5 by SB-743921 led to the 
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	59747 : 59750	CM	 binding site within the Eg5 protein, with chemical t
./___Corpus/Medline/xml/PMC4896392.xml	L5	60019 : 60021	CM	mechanisms affecting the L5/α2/α3 allosteric site, b
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	60063 : 60066	CM	 site, but by inhibiting Eg5 in an ATP-competitive ma
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	60295 : 60298	CM	chieving selectivity for Eg5 over HSET has not proven
./___Corpus/Medline/xml/PMC4896392.xml	HSET	60304 : 60308	CM	selectivity for Eg5 over HSET has not proven to be a c
./___Corpus/Medline/xml/PMC4896392.xml	L5	60384 : 60386	CM	lopment at the classical L5/α2/α3 allosteric site, w
./___Corpus/Medline/xml/PMC4896392.xml	L5	60459 : 60461	CM	y the differences in the L5 region of the two protei
./___Corpus/Medline/xml/PMC4896392.xml	HSET	60539 : 60543	CM	tallographic evidence of HSET binding is available, th
./___Corpus/Medline/xml/PMC4896392.xml	HSET	60614 : 60618	CM	ites of the two specific HSET inhibitors AZ82 and CW06
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	60630 : 60634	CM	specific HSET inhibitors AZ82 and CW069 have not yet b
./___Corpus/Medline/xml/PMC4896392.xml	CW069	60639 : 60644	CM	HSET inhibitors AZ82 and CW069 have not yet been elucid
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	60690 : 60694	CM	ucidated. Interestingly, AZ82 has been identified as a
./___Corpus/Medline/xml/PMC4896392.xml	HSET	60750 : 60754	CM	competitive inhibitor of HSET. As the only ATP-competi
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	60798 : 60801	CM	ompetitive inhibitors of Eg5 identified to date occup
./___Corpus/Medline/xml/PMC4896392.xml	L5	60871 : 60873	CM	 distinct to that of the L5/α2/α3 site, and not from
./___Corpus/Medline/xml/PMC4896392.xml	ATP	60927 : 60930	CM	ect interaction with the ATP site, it is possible tha
./___Corpus/Medline/xml/PMC4896392.xml	AZ82	61006 : 61010	CM	titive mode of action of AZ82 also results from struct
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	61158 : 61161	CM	     The large number of Eg5 clinical candidates spre
./___Corpus/Medline/xml/PMC4896392.xml	HSET	61254 : 61258	CM	recent identification of HSET chemical tools, demonstr
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	61625 : 61628	CM	mechano-chemistry of the Eg5 kinesin has proceeded in
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	61830 : 61833	CM	n the druggable sites on Eg5 and HSET are not yet ful
./___Corpus/Medline/xml/PMC4896392.xml	HSET	61838 : 61842	CM	uggable sites on Eg5 and HSET are not yet fully unders
./___Corpus/Medline/xml/PMC4896392.xml	HSET	61969 : 61973	CM	he development of future HSET and Eg5 clinical candida
./___Corpus/Medline/xml/PMC4896392.xml	Eg5	61978 : 61981	CM	pment of future HSET and Eg5 clinical candidates, and
./___Corpus/Medline/xml/PMC4896392.xml	CRUK	62242 : 62246	CM	 and Cancer Research UK [CRUK] grant no. C309/A11566. 
./___Corpus/Medline/xml/PMC4896392.xml	SMM	62343 : 62346	CM	            The authors (SMM and IC) are employees of
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	381 : 388	CM	and the development of a hypoxic environment which favors
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	896 : 904	CM	natural compounds (e.g., curcumin, resveratrol, indole-3-c
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	906 : 917	CM	mpounds (e.g., curcumin, resveratrol, indole-3-carbinol, bras
./___Corpus/Medline/xml/PMC4898971.xml	indole-3-carbinol	919 : 936	CM	, curcumin, resveratrol, indole-3-carbinol, brassinin, sulforaphane
./___Corpus/Medline/xml/PMC4898971.xml	brassinin	938 : 947	CM	trol, indole-3-carbinol, brassinin, sulforaphane, epigalloc
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	949 : 961	CM	e-3-carbinol, brassinin, sulforaphane, epigallocatechin-3-gall
./___Corpus/Medline/xml/PMC4898971.xml	epigallocatechin-3-gallate	963 : 989	CM	brassinin, sulforaphane, epigallocatechin-3-gallate, genistein, ellagitannin
./___Corpus/Medline/xml/PMC4898971.xml	genistein	991 : 1000	CM	gallocatechin-3-gallate, genistein, ellagitannins, lycopene
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	1017 : 1025	CM	enistein, ellagitannins, lycopene and quercetin) have been
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	1030 : 1039	CM	agitannins, lycopene and quercetin) have been found to inhi
./___Corpus/Medline/xml/PMC4898971.xml	kappa	1172 : 1177	CM	factor 1, nuclear factor kappa B, phosphoinositide 3 ki
./___Corpus/Medline/xml/PMC4898971.xml	phosphoinositide	1181 : 1197	CM	 nuclear factor kappa B, phosphoinositide 3 kinase/Akt, insulin-li
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	1251 : 1254	CM	rowth factor receptor 1, Wnt, cell cycle associated p
./___Corpus/Medline/xml/PMC4898971.xml	androgen	1299 : 1307	CM	ted proteins, as well as androgen and estrogen receptor si
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	1312 : 1320	CM	 as well as androgen and estrogen receptor signaling). Thi
./___Corpus/Medline/xml/PMC4898971.xml	EMT	3004 : 3007	CM	 mesenchymal transition (EMT) and cell migration, res
./___Corpus/Medline/xml/PMC4898971.xml	1-	3126 : 3128	CPR	th of tissue stem cells [1-5], as well as angiogenes
./___Corpus/Medline/xml/PMC4898971.xml	6-	3157 : 3159	CPR	as well as angiogenesis [6-9] (Table 1). Autophagy a
./___Corpus/Medline/xml/PMC4898971.xml	EMT	4549 : 4552	CM	 in tissue architecture (EMT and migration), formatio
./___Corpus/Medline/xml/PMC4898971.xml	EMT	5953 : 5956	CM	             2. How does EMT contribute to tumor prol
./___Corpus/Medline/xml/PMC4898971.xml	EMT	6018 : 6021	CM	                    When EMT occurs in adult tissues 
./___Corpus/Medline/xml/PMC4898971.xml	EMT	6349 : 6352	CM	 closely associated with EMT [11], because they suppr
./___Corpus/Medline/xml/PMC4898971.xml	E-	6402 : 6404	CPR	ess epithelial cadherin (E-cadherin) expression [12-
./___Corpus/Medline/xml/PMC4898971.xml	12-	6426 : 6429	CPR	(E-cadherin) expression [12-14], which normally facil
./___Corpus/Medline/xml/PMC4898971.xml	EMT	6556 : 6559	CM	nation. Snail associated EMT is normally under string
./___Corpus/Medline/xml/PMC4898971.xml	15-	6600 : 6603	CPR	er stringent regulation [15-17], but when that is los
./___Corpus/Medline/xml/PMC4898971.xml	17-	6650 : 6653	CPR	lost, cancer may appear [17-19]. Increased expression
./___Corpus/Medline/xml/PMC4898971.xml	15,20-	6788 : 6794	CPR	or by apoptotic stimuli [15,20-24]. Elevated Snail1/2 re
./___Corpus/Medline/xml/PMC4898971.xml	E-	7157 : 7159	CPR	          Snail1 induced E-cadherin depletion is ass
./___Corpus/Medline/xml/PMC4898971.xml	30-	7372 : 7375	CPR	urvival in human cancer [30-33]. Cells expressing Sna
./___Corpus/Medline/xml/PMC4898971.xml	CSC	7535 : 7538	CM	is of cancer stem cells (CSC) (described below). CSCs
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	7559 : 7563	CM	(CSC) (described below). CSCs are resistant to cell cy
./___Corpus/Medline/xml/PMC4898971.xml	EMT	7730 : 7733	CM	mation. Cells undergoing EMT, and cells with properti
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	7764 : 7768	CM	cells with properties of CSCs are resistant to typical
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	8018 : 8026	CM	atural products, such as curcumin and epigallocatechin-3-g
./___Corpus/Medline/xml/PMC4898971.xml	epigallocatechin-3-gallate	8031 : 8057	CM	ts, such as curcumin and epigallocatechin-3-gallate (EGCG) [34] (see below),
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	8059 : 8063	CM	gallocatechin-3-gallate (EGCG) [34] (see below), sugge
./___Corpus/Medline/xml/PMC4898971.xml	EMT	8165 : 8168	CM	developed in the future. EMT may occur prior to tumor
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	8293 : 8297	CM	of hypoxia. In addition, CSCs drive tumor formation. T
./___Corpus/Medline/xml/PMC4898971.xml	HIFs	8512 : 8516	CM	poxia inducible factors [HIFs]                      Ca
./___Corpus/Medline/xml/PMC4898971.xml	oxygen	8781 : 8787	CM	roenvironment, where low oxygen tension, low glucose lev
./___Corpus/Medline/xml/PMC4898971.xml	glucose	8801 : 8808	CM	 low oxygen tension, low glucose levels, and an acidic ex
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	8934 : 8939	CM	poxia inducible factors, HIF-1 and HIF-2, are upregulat
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	9047 : 9051	CM	nstitutive activation of PI3K signaling or inactivatin
./___Corpus/Medline/xml/PMC4898971.xml	VHL	9145 : 9148	CM	Lindau tumor suppressor, VHL [35-37], which normally 
./___Corpus/Medline/xml/PMC4898971.xml	35-	9150 : 9153	CPR	u tumor suppressor, VHL [35-37], which normally deace
./___Corpus/Medline/xml/PMC4898971.xml	deacetylates	9173 : 9185	CM	 [35-37], which normally deacetylates HIF-1α, leading to HIF-1
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	9186 : 9192	CM	ch normally deacetylates HIF-1α, leading to HIF-1α polyu
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	9205 : 9211	CM	lates HIF-1α, leading to HIF-1α polyubiquitination and p
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	9355 : 9365	RN	intermediate metabolism (glycolysis) and pH regulation, whic
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	9462 : 9468	CM	                         HIF-1α stimulates production of
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	9744 : 9748	CM	 growth factor receptor (EGFR), resulting in continuou
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	9807 : 9814	CM	rative signaling. In the hypoxic environment, constitutiv
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	9899 : 9903	CM	hways (e.g., Ras [1] and PI3K [2]) stabilizes HIF-1 an
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	9920 : 9925	CM	and PI3K [2]) stabilizes HIF-1 and may result in “oncog
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10044 : 10048	CM	arcinoma. In the case of PI3K, constitutive activation
./___Corpus/Medline/xml/PMC4898971.xml	phosphatase	10155 : 10166	CM	pressor genes (e.g., the phosphatase and tensin homolog [PTEN
./___Corpus/Medline/xml/PMC4898971.xml	PTEN	10187 : 10191	CM	tase and tensin homolog [PTEN]), from activating mutat
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10228 : 10232	CM	ivating mutations in the PI3K complex itself, or from 
./___Corpus/Medline/xml/PMC4898971.xml	tyrosine	10288 : 10296	CM	nt signaling in receptor tyrosine kinases [40]. Elevated P
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	10320 : 10324	CM	e kinases [40]. Elevated PI3K stimulates the mechanist
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	10362 : 10371	CM	he mechanistic target of rapamycin (mTOR) [35], and ATP pro
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	10373 : 10377	CM	tic target of rapamycin (mTOR) [35], and ATP productio
./___Corpus/Medline/xml/PMC4898971.xml	ATP	10389 : 10392	CM	pamycin (mTOR) [35], and ATP production [41,42], both
./___Corpus/Medline/xml/PMC4898971.xml	HIF	10549 : 10552	CM	design of small molecule HIF inhibitors, by enhanced 
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	10592 : 10597	CM	 enhanced degradation of HIF-1 via inhibition of heat s
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	10664 : 10668	CM	Hsp90), or by inhibiting mTOR [43].                   
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	10794 : 10809	RN	to switch from oxidative phosphorylation to glycolytic metabolism
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	10813 : 10823	CM	ative phosphorylation to glycolytic metabolism as their prim
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	10901 : 10911	CM	reases the expression of glycolytic enzymes and glucose tran
./___Corpus/Medline/xml/PMC4898971.xml	glucose	10924 : 10931	CM	f glycolytic enzymes and glucose transporters 1 and 3 [1]
./___Corpus/Medline/xml/PMC4898971.xml	glucose	10975 : 10982	CM	 3 [1], which facilitate glucose uptake necessitated by i
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	11018 : 11028	RN	essitated by inefficient glycolysis. HIF-1 channels glucose 
./___Corpus/Medline/xml/PMC4898971.xml	glucose	11045 : 11052	CM	ycolysis. HIF-1 channels glucose towards glycolysis, and 
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	11061 : 11071	RN	channels glucose towards glycolysis, and represses mitochond
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	11164 : 11174	CM	dative damage. Increased glycolytic metabolism promotes ATP 
./___Corpus/Medline/xml/PMC4898971.xml	ATP	11195 : 11198	CM	ytic metabolism promotes ATP production to sustain ce
./___Corpus/Medline/xml/PMC4898971.xml	oxygen	11258 : 11264	CM	ration in the absence of oxygen. The development of glyc
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	11285 : 11295	CM	ygen. The development of glycolytic inhibitors has shown pro
./___Corpus/Medline/xml/PMC4898971.xml	vitro	11338 : 11343	CM	own promising results in vitro [43]. Energy depletion a
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	11393 : 11397	CM	nd hypoxia also suppress mTOR signaling through activa
./___Corpus/Medline/xml/PMC4898971.xml	ATM	11461 : 11464	CM	 telangiectasia mutated (ATM, involved in cell cycle 
./___Corpus/Medline/xml/PMC4898971.xml	ATM	11590 : 11593	CM	 damage responses. Thus, ATM or checkpoint 1 inhibito
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	11750 : 11756	CM	                         HIF-1α also promotes autophagy,
./___Corpus/Medline/xml/PMC4898971.xml	IRE1	12004 : 12008	CM	ophagy via inhibition of IRE1 (a serine/threonine prot
./___Corpus/Medline/xml/PMC4898971.xml	serine	12012 : 12018	CM	ia inhibition of IRE1 (a serine/threonine protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	threonine	12019 : 12028	CM	bition of IRE1 (a serine/threonine protein kinase/endoribon
./___Corpus/Medline/xml/PMC4898971.xml	ER	12105 : 12107	CM	ll gene expression under ER stress) may increase the
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	12170 : 12177	CM	of cells to apoptosis in hypoxic environments [43]. Eleva
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	12206 : 12211	CM	ironments [43]. Elevated HIF-1 levels may also increase
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12245 : 12255	CM	ay also increase de novo fatty acid synthesis [44,45] by upr
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12293 : 12303	CM	4,45] by upregulation of fatty acid synthase (FAS) transcrip
./___Corpus/Medline/xml/PMC4898971.xml	sterol	12359 : 12365	CM	This is mediated through sterol regulatory element bindi
./___Corpus/Medline/xml/PMC4898971.xml	fatty acid	12469 : 12479	CM	FAS or HIF-1 might block fatty acid synthesis mediated growt
./___Corpus/Medline/xml/PMC4898971.xml	lactic acid	12598 : 12609	CM	H due to accumulation of lactic acid during hypoxia, intracel
./___Corpus/Medline/xml/PMC4898971.xml	HIF	12685 : 12688	CM	r neutral as a result of HIF-mediated up regulation/a
./___Corpus/Medline/xml/PMC4898971.xml	amiloride	12810 : 12819	CM	zymes. These include the amiloride sensitive Na+/H+ Exchang
./___Corpus/Medline/xml/PMC4898971.xml	Na+	12830 : 12833	CM	 the amiloride sensitive Na+/H+ Exchanger, the H+/lac
./___Corpus/Medline/xml/PMC4898971.xml	H+	12834 : 12836	CM	 amiloride sensitive Na+/H+ Exchanger, the H+/lactat
./___Corpus/Medline/xml/PMC4898971.xml	H+	12852 : 12854	CM	ve Na+/H+ Exchanger, the H+/lactate cotransporter (m
./___Corpus/Medline/xml/PMC4898971.xml	lactate	12855 : 12862	CM	Na+/H+ Exchanger, the H+/lactate cotransporter (monocarbo
./___Corpus/Medline/xml/PMC4898971.xml	monocarboxylate	12878 : 12893	CM	+/lactate cotransporter (monocarboxylate transporter, MCT4), and 
./___Corpus/Medline/xml/PMC4898971.xml	MCT4	12907 : 12911	CM	carboxylate transporter, MCT4), and carbonic anhydrase
./___Corpus/Medline/xml/PMC4898971.xml	carbonic	12918 : 12926	CM	 transporter, MCT4), and carbonic anhydrase (CA) IX and XI
./___Corpus/Medline/xml/PMC4898971.xml	anhydrase	12927 : 12936	CM	ter, MCT4), and carbonic anhydrase (CA) IX and XII [6]. Alt
./___Corpus/Medline/xml/PMC4898971.xml	CA	12938 : 12940	CM	 and carbonic anhydrase (CA) IX and XII [6]. Althoug
./___Corpus/Medline/xml/PMC4898971.xml	XII	12949 : 12952	CM	ic anhydrase (CA) IX and XII [6]. Although specific i
./___Corpus/Medline/xml/PMC4898971.xml	MCT4	12990 : 12994	CM	h specific inhibitors of MCT4 are not available, disru
./___Corpus/Medline/xml/PMC4898971.xml	CA	13101 : 13103	CM	timetastatic activity of CA inhibitors in xenografts
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	14275 : 14285	RN	d those with upregulated glycolysis. Thus, the transition fr
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	14835 : 14841	CM	s and cytokines [47,48]. HIF-1α is activated by these pr
./___Corpus/Medline/xml/PMC4898971.xml	alpha	14927 : 14932	CM	de tumor necrosis factor alpha (TNF-α) and interleukin-
./___Corpus/Medline/xml/PMC4898971.xml	cyclooxygenase	14985 : 14999	CM	(IL-1β). Proinflammatory cyclooxygenase 2 (COX2) also mediates I
./___Corpus/Medline/xml/PMC4898971.xml	COX2	15003 : 15007	CM	matory cyclooxygenase 2 (COX2) also mediates IL-1β-ind
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	15037 : 15043	CM	o mediates IL-1β-induced HIF-1α expression through produ
./___Corpus/Medline/xml/PMC4898971.xml	E2	15091 : 15093	CM	duction of prostaglandin E2 (PGE2). This leads to ac
./___Corpus/Medline/xml/PMC4898971.xml	PGE2	15095 : 15099	CM	ion of prostaglandin E2 (PGE2). This leads to activati
./___Corpus/Medline/xml/PMC4898971.xml	mitogen	15138 : 15145	CM	to activation of the ras-mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	COX2	15219 : 15223	CM	aintains the prosurvival COX2/PGE2 pathway. Src is ano
./___Corpus/Medline/xml/PMC4898971.xml	PGE2	15224 : 15228	CM	ins the prosurvival COX2/PGE2 pathway. Src is another 
./___Corpus/Medline/xml/PMC4898971.xml	VEGF	15319 : 15323	CM	dothelial growth factor (VEGF) and PGE2-mediated trans
./___Corpus/Medline/xml/PMC4898971.xml	PGE2	15329 : 15333	CM	growth factor (VEGF) and PGE2-mediated transactivation
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	15362 : 15366	CM	iated transactivation of EGFR. In addition, β-catenin-
./___Corpus/Medline/xml/PMC4898971.xml	β-	15381 : 15383	CPR	on of EGFR. In addition, β-catenin-HIF-1 interaction
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	15439 : 15444	CM	ts in the enhancement of HIF-1 transcriptional activity
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	15491 : 15496	CM	ity [8,49]. Importantly, HIF-1 is also activated in TAM
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	15529 : 15536	CM	 activated in TAMs under hypoxic conditions [50,51], resu
./___Corpus/Medline/xml/PMC4898971.xml	kappa	15604 : 15609	CM	lation of nuclear factor kappa B (NF-κB), and further i
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	15613 : 15618	CM	 nuclear factor kappa B (NF-κB), and further inflammato
./___Corpus/Medline/xml/PMC4898971.xml	cytokine	15646 : 15654	CM	and further inflammatory cytokine production, including su
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	15701 : 15706	CM	 sustained elevations in HIF-1. This feedback promotes 
./___Corpus/Medline/xml/PMC4898971.xml	HIFs	15761 : 15765	CM	 progression [52]. Thus, HIFs link hypoxia, chronic in
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	15986 : 15991	CM	 hypoxia in general, and NF-κB in particular, might del
./___Corpus/Medline/xml/PMC4898971.xml	HIF	16120 : 16123	CM	arly in cell types where HIF promotes early steps of 
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	16281 : 16286	CM	tenuate the induction of HIF-1 (see below), thereby pot
./___Corpus/Medline/xml/PMC4898971.xml	amino acids	16642 : 16653	CM	ll survival by recycling amino acids and energy, which are bo
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	16891 : 16901	RN	iferation [55], enhanced glycolysis [56], hypoxia [57], and 
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	17309 : 17313	CM	ers                      mTOR, which is part of a larg
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	17363 : 17372	CM	er mechanistic target of rapamycin complex 1 (mTORC1), norm
./___Corpus/Medline/xml/PMC4898971.xml	mTORC1	17384 : 17390	CM	 of rapamycin complex 1 (mTORC1), normally inhibits auto
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	17427 : 17431	CM	inhibits autophagy. When mTOR is inhibited by stress s
./___Corpus/Medline/xml/PMC4898971.xml	HIF	17470 : 17473	CM	by stress signals (e.g., HIF, dysregulated PI3K/Akt a
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	17488 : 17492	CM	(e.g., HIF, dysregulated PI3K/Akt and elevated p53) [6
./___Corpus/Medline/xml/PMC4898971.xml	p53	17510 : 17513	CM	ed PI3K/Akt and elevated p53) [63,64], the Beclin 1/c
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	17547 : 17551	CM	, the Beclin 1/class III PI3K complex is activated [65
./___Corpus/Medline/xml/PMC4898971.xml	isoform	17862 : 17869	CM	ules (e.g., Bcl-2 larger isoform, Bcl-XL), known as BH3 m
./___Corpus/Medline/xml/PMC4898971.xml	BH3	17889 : 17892	CM	oform, Bcl-XL), known as BH3 mimetics (ABT-737/263, o
./___Corpus/Medline/xml/PMC4898971.xml	ABT-737	17903 : 17910	CM	, known as BH3 mimetics (ABT-737/263, obatoclax), can com
./___Corpus/Medline/xml/PMC4898971.xml	1-Bcl-2	17965 : 17972	CM	ively disrupt the Beclin 1-Bcl-2/Bcl-xL interaction to tr
./___Corpus/Medline/xml/PMC4898971.xml	mTORC1	18046 : 18052	CM	 apoptosis. A variety of mTORC1 inhibitors have been con
./___Corpus/Medline/xml/PMC4898971.xml	rapamycin	18145 : 18154	CM	iferation. These include rapamycin, temsirolimus, deforolim
./___Corpus/Medline/xml/PMC4898971.xml	temsirolimus	18156 : 18168	CM	These include rapamycin, temsirolimus, deforolimus, metformin 
./___Corpus/Medline/xml/PMC4898971.xml	deforolimus	18170 : 18181	CM	rapamycin, temsirolimus, deforolimus, metformin [68,69], the 
./___Corpus/Medline/xml/PMC4898971.xml	metformin	18183 : 18192	CM	msirolimus, deforolimus, metformin [68,69], the dual PI3K-m
./___Corpus/Medline/xml/PMC4898971.xml	PI3K-mTOR	18211 : 18220	CM	formin [68,69], the dual PI3K-mTOR inhibitors NVP-BEZ235 [7
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	18378 : 18390	CM	. Interestingly, several polyphenolic compounds, such as resve
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	18410 : 18421	CM	nolic compounds, such as resveratrol [74], curcumin [75], rot
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	18428 : 18436	CM	uch as resveratrol [74], curcumin [75], rottlerin, geniste
./___Corpus/Medline/xml/PMC4898971.xml	genistein	18454 : 18463	CM	urcumin [75], rottlerin, genistein, and quercetin [76], wer
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	18469 : 18478	CM	ottlerin, genistein, and quercetin [76], were reported to i
./___Corpus/Medline/xml/PMC4898971.xml	alkylating	19100 : 19110	RN	ensitizes tumor cells to alkylating agents and cetuximab [81
./___Corpus/Medline/xml/PMC4898971.xml	TNF	19253 : 19256	CM	tized resistant cells to TNF related apoptosis induci
./___Corpus/Medline/xml/PMC4898971.xml	3-methyladenine	19588 : 19603	CM	Early inhibitors include 3-methyladenine, wortmannin and LY294022
./___Corpus/Medline/xml/PMC4898971.xml	wortmannin	19605 : 19615	CM	include 3-methyladenine, wortmannin and LY294022, which targ
./___Corpus/Medline/xml/PMC4898971.xml	LY294022	19620 : 19628	CM	ladenine, wortmannin and LY294022, which target the class 
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	19657 : 19661	CM	ich target the class III PI3K [83]. Late stage inhibit
./___Corpus/Medline/xml/PMC4898971.xml	bafilomycin	19721 : 19732	CM	e the antimalarial drugs bafilomycin A1 (which targets a vacu
./___Corpus/Medline/xml/PMC4898971.xml	adenosine	19762 : 19771	CM	which targets a vacuolar adenosine triphosphatase) [84], as
./___Corpus/Medline/xml/PMC4898971.xml	monensin	19805 : 19813	CM	hatase) [84], as well as monensin and chloroquine, both of
./___Corpus/Medline/xml/PMC4898971.xml	chloroquine	19818 : 19829	CM	 as well as monensin and chloroquine, both of which prevent t
./___Corpus/Medline/xml/PMC4898971.xml	taxanes	19926 : 19933	CM	 disrupting agents (e.g. taxanes, nocodizole, colchicine 
./___Corpus/Medline/xml/PMC4898971.xml	nocodizole	19935 : 19945	CM	ng agents (e.g. taxanes, nocodizole, colchicine and vinca al
./___Corpus/Medline/xml/PMC4898971.xml	colchicine	19947 : 19957	CM	.g. taxanes, nocodizole, colchicine and vinca alkaloids) inh
./___Corpus/Medline/xml/PMC4898971.xml	alkaloids	19968 : 19977	CM	le, colchicine and vinca alkaloids) inhibit fusion of autop
./___Corpus/Medline/xml/PMC4898971.xml	clomipramine	20117 : 20129	CM	 autophagy. In addition, clomipramine (an anti-depressant) and
./___Corpus/Medline/xml/PMC4898971.xml	anti-	20134 : 20139	CPR	dition, clomipramine (an anti-depressant) and lucanthon
./___Corpus/Medline/xml/PMC4898971.xml	bafilomycin	20898 : 20909	CM	rs of autophagy, such as bafilomycin A1 [88,89], feroniellin 
./___Corpus/Medline/xml/PMC4898971.xml	oblongifolin	20945 : 20957	CM	, feroniellin A [90] and oblongifolin C [91].                 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21028 : 21032	CM	th of Cancer Stem Cells (CSCs) 5.1 Distinguishing feat
./___Corpus/Medline/xml/PMC4898971.xml	SCs	21126 : 21129	CM	             Stem cells (SCs) and CSCs share similar 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21135 : 21139	CM	    Stem cells (SCs) and CSCs share similar characteri
./___Corpus/Medline/xml/PMC4898971.xml	92-	21304 : 21307	CPR	is, and chemoresistance [92-103]. What distinguishes 
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21332 : 21336	CM	103]. What distinguishes CSCs from adult SCs is the ab
./___Corpus/Medline/xml/PMC4898971.xml	fate	21439 : 21443	CM	esulting in altered cell fate and unregulated cell gro
./___Corpus/Medline/xml/PMC4898971.xml	Hh	21497 : 21499	CM	[94]. Aberrant Hedgehog (Hh), Notch and Wnt pathways
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	21512 : 21515	CM	Hedgehog (Hh), Notch and Wnt pathways, either through
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21708 : 21712	CM	n of adult stem cells to CSCs [103]. Further, the PTEN
./___Corpus/Medline/xml/PMC4898971.xml	PTEN	21733 : 21737	CM	CSCs [103]. Further, the PTEN tumor suppressor maintai
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	21806 : 21810	CM	 in quiescence, while in CSCs, PTEN is often mutated o
./___Corpus/Medline/xml/PMC4898971.xml	PTEN	21812 : 21816	CM	iescence, while in CSCs, PTEN is often mutated or dele
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22022 : 22026	CM	ns a small proportion of CSCs that initiate/maintain m
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22307 : 22311	CM	ions [106]. In contrast, CSCs divide symmetrically int
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22604 : 22608	CM	 while therapy resistant CSCs become reactivated and p
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22690 : 22694	CM	ses might mean little if CSCs determine outcome [107],
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	22736 : 22740	CM	e [107], suggesting that CSCs are the cells that must 
./___Corpus/Medline/xml/PMC4898971.xml	SC	23001 : 23003	CM	ions in long lived adult SC [109], only cells with s
./___Corpus/Medline/xml/PMC4898971.xml	110-	23138 : 23142	CPR	intestine [109], breast [110-112] and hematopoetic cel
./___Corpus/Medline/xml/PMC4898971.xml	SC	23473 : 23475	CM	ate relationship between SC, mutation, and tumor dev
./___Corpus/Medline/xml/PMC4898971.xml	SC	23556 : 23558	CM	line mutations in tissue SC (e.g., in colon cancer a
./___Corpus/Medline/xml/PMC4898971.xml	119-	23922 : 23926	CPR	and pancreatic cancers) [119-122]. This will influence
./___Corpus/Medline/xml/PMC4898971.xml	octamer	24616 : 24623	CM	he transcription factors octamer binding transcription fa
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	24842 : 24846	CM	ation [123] (Fig. 3). If CSCs arise through a reprogra
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	24929 : 24933	CM	intervention that target CSCs may be critical for the 
./___Corpus/Medline/xml/PMC4898971.xml	CML	25310 : 25313	CM	primary tumors (e.g., in CML, melanoma, breast cancer
./___Corpus/Medline/xml/PMC4898971.xml	124-	25387 : 25391	CPR	ncer, and osteosarcoma) [124-128], and help to prevent
./___Corpus/Medline/xml/PMC4898971.xml	G1	25989 : 25991	CM	s, therapies that target G1 regulators (such as cycl
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	26012 : 26018	CM	t G1 regulators (such as cyclin D), cyclin dependent kin
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	26023 : 26029	CM	tors (such as cyclin D), cyclin dependent kinase 4 (cdk4
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	26050 : 26054	CM	clin dependent kinase 4 (cdk4) or p27, or apoptotic re
./___Corpus/Medline/xml/PMC4898971.xml	p27	26059 : 26062	CM	ndent kinase 4 (cdk4) or p27, or apoptotic regulators
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	26163 : 26166	CM	 developmental pathways, Wnt/β-catenin and Hh, appear
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	26167 : 26176	CM	elopmental pathways, Wnt/β-catenin and Hh, appear important
./___Corpus/Medline/xml/PMC4898971.xml	Hh	26181 : 26183	CM	hways, Wnt/β-catenin and Hh, appear important in the
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26236 : 26239	CM	lf renewing potential of CSC [131,132]. Wnt and Hh ar
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	26251 : 26254	CM	ential of CSC [131,132]. Wnt and Hh are generally ina
./___Corpus/Medline/xml/PMC4898971.xml	Hh	26259 : 26261	CM	f CSC [131,132]. Wnt and Hh are generally inactive i
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26346 : 26349	CM	tivated in adult SCs and CSC. The metastasis suppress
./___Corpus/Medline/xml/PMC4898971.xml	mitogen	26383 : 26390	CM	astasis suppressor gene, mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	26513 : 26517	CM	hrough the activation of MAPK p38 [133-135], suggestin
./___Corpus/Medline/xml/PMC4898971.xml	133-	26523 : 26527	CPR	 activation of MAPK p38 [133-135], suggesting they may
./___Corpus/Medline/xml/PMC4898971.xml	CXCR-4	26708 : 26714	CM	 corresponding receptor (CXCR-4) interaction is required
./___Corpus/Medline/xml/PMC4898971.xml	MM	26784 : 26786	CM	e, and multiple myeloma (MM) CSC colonization and su
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26788 : 26791	CM	nd multiple myeloma (MM) CSC colonization and subsequ
./___Corpus/Medline/xml/PMC4898971.xml	MM	26849 : 26851	CM	scence [136]. In CML and MM, CSC can be mobilized fr
./___Corpus/Medline/xml/PMC4898971.xml	CSC	26853 : 26856	CM	ce [136]. In CML and MM, CSC can be mobilized from qu
./___Corpus/Medline/xml/PMC4898971.xml	G-CSF	26968 : 26973	CM	lony stimulating factor (G-CSF), which degrades CXCL-12
./___Corpus/Medline/xml/PMC4898971.xml	CXCR-4	27023 : 27029	CM	, or by an antagonist of CXCR-4 [137]. In the clinic, ho
./___Corpus/Medline/xml/PMC4898971.xml	G-CSF	27061 : 27066	CM	 In the clinic, however, G-CSF has had mixed results, s
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	27112 : 27116	CM	s, since it impacts both CSCs and adult SCs [137]. Thu
./___Corpus/Medline/xml/PMC4898971.xml	CSC	27267 : 27270	CM	                  As the CSC fate decision is most li
./___Corpus/Medline/xml/PMC4898971.xml	fate	27271 : 27275	CM	              As the CSC fate decision is most likely 
./___Corpus/Medline/xml/PMC4898971.xml	CCAAT	27411 : 27416	CM	 processes. For example, CCAAT/enhancer binding protein
./___Corpus/Medline/xml/PMC4898971.xml	alpha	27442 : 27447	CM	enhancer binding protein alpha (C/EBPα) appears to regu
./___Corpus/Medline/xml/PMC4898971.xml	EBPα	27451 : 27455	CM	binding protein alpha (C/EBPα) appears to regulate mye
./___Corpus/Medline/xml/PMC4898971.xml	G1	27631 : 27633	CM	8,139] that promotes the G1- to S-phase transition a
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	27638 : 27645	CM	that promotes the G1- to S-phase transition and enhances 
./___Corpus/Medline/xml/PMC4898971.xml	SCs	27694 : 27697	CM	 the movement of hepatic SCs out of a quiescent state
./___Corpus/Medline/xml/PMC4898971.xml	glycogen	27819 : 27827	CM	iopoietin-1, inactivates glycogen synthase kinase 3β (GSK3
./___Corpus/Medline/xml/PMC4898971.xml	GSK3β	27848 : 27853	CM	ogen synthase kinase 3β (GSK3β) via phosphorylation, th
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	27859 : 27874	RN	se kinase 3β (GSK3β) via phosphorylation, thereby releasing activ
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	27901 : 27910	CM	thereby releasing active β-catenin, which then migrates to 
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	28429 : 28435	CM	ression is controlled by cyclin-cdk complexes, that incl
./___Corpus/Medline/xml/PMC4898971.xml	cdk	28436 : 28439	CM	 is controlled by cyclin-cdk complexes, that include 
./___Corpus/Medline/xml/PMC4898971.xml	cdk	28464 : 28467	CM	 complexes, that include cdk interacting protein p21C
./___Corpus/Medline/xml/PMC4898971.xml	p21CIP1	28488 : 28495	CM	 cdk interacting protein p21CIP1, kinase inhibitory prote
./___Corpus/Medline/xml/PMC4898971.xml	p27KIP1	28532 : 28539	CM	ibitory proteins (Kips) (p27KIP1, p57KIP2), and INhibitor
./___Corpus/Medline/xml/PMC4898971.xml	p57KIP2	28541 : 28548	CM	roteins (Kips) (p27KIP1, p57KIP2), and INhibitors of CDK4
./___Corpus/Medline/xml/PMC4898971.xml	CDK4	28569 : 28573	CM	KIP2), and INhibitors of CDK4 (INK4s: p16INK4a, p15INK
./___Corpus/Medline/xml/PMC4898971.xml	INK4s	28575 : 28580	CM	 and INhibitors of CDK4 (INK4s: p16INK4a, p15INK4b, p18
./___Corpus/Medline/xml/PMC4898971.xml	p16INK4a	28582 : 28590	CM	hibitors of CDK4 (INK4s: p16INK4a, p15INK4b, p18INK4c, p19
./___Corpus/Medline/xml/PMC4898971.xml	p15INK4b	28592 : 28600	CM	f CDK4 (INK4s: p16INK4a, p15INK4b, p18INK4c, p19INK4d), wh
./___Corpus/Medline/xml/PMC4898971.xml	p18INK4c	28602 : 28610	CM	K4s: p16INK4a, p15INK4b, p18INK4c, p19INK4d), which activa
./___Corpus/Medline/xml/PMC4898971.xml	p19INK4d	28612 : 28620	CM	K4a, p15INK4b, p18INK4c, p19INK4d), which activate and inh
./___Corpus/Medline/xml/PMC4898971.xml	G1	28691 : 28693	CM	 respectively [143]. The G1 phase of the cell cycle 
./___Corpus/Medline/xml/PMC4898971.xml	G1	28990 : 28992	CM	als, the cell arrests in G1. Thus, cancer can be tho
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29356 : 29358	CM	     6.1 Retinoblastoma (Rb) pathway                
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29393 : 29395	CM	                     The Rb pathway (INK4-cyclin D-c
./___Corpus/Medline/xml/PMC4898971.xml	INK4-cyclin D-cdk4	29405 : 29423	CM	         The Rb pathway (INK4-cyclin D-cdk4/6-Rb), which controls th
./___Corpus/Medline/xml/PMC4898971.xml	6-Rb	29424 : 29428	CM	hway (INK4-cyclin D-cdk4/6-Rb), which controls the G1-
./___Corpus/Medline/xml/PMC4898971.xml	G1-S	29450 : 29454	CM	-Rb), which controls the G1-S phase transition, is uni
./___Corpus/Medline/xml/PMC4898971.xml	Cyclin D-cdk4	29514 : 29527	CM	srupted in human cancer. Cyclin D-cdk4/6 complexes initiate G1 
./___Corpus/Medline/xml/PMC4898971.xml	G1	29549 : 29551	CM	dk4/6 complexes initiate G1 progression by phosphory
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylating	29567 : 29582	CM	itiate G1 progression by phosphorylating (inactivating) Rb, thus 
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29598 : 29600	CM	orylating (inactivating) Rb, thus relieving transcri
./___Corpus/Medline/xml/PMC4898971.xml	Rb-E2F	29651 : 29657	CM	tional repression by the Rb-E2F complex (Fig. 4). Follow
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29686 : 29688	CM	plex (Fig. 4). Following Rb phosphorylation, E2F is 
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	29689 : 29704	RN	x (Fig. 4). Following Rb phosphorylation, E2F is released, induci
./___Corpus/Medline/xml/PMC4898971.xml	E2F	29706 : 29709	CM	wing Rb phosphorylation, E2F is released, inducing tr
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	29769 : 29776	CM	n of genes necessary for S-phase entry. Although Rb loss 
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29793 : 29795	CM	 S-phase entry. Although Rb loss occurs in some tumo
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29859 : 29861	CM	cancers retain wild type Rb, and instead have mutate
./___Corpus/Medline/xml/PMC4898971.xml	Rb	29935 : 29937	CM	e proteins that regulate Rb. In other tumor types, c
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	30202 : 30208	CM	       The gene encoding cyclin D is the second most amp
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	30379 : 30385	CM	eutic target. In cancer, cyclin D-cdk4/6 activity may be
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	30386 : 30392	CM	arget. In cancer, cyclin D-cdk4/6 activity may be increa
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30424 : 30428	CM	vity may be increased by cdk4 and cdk6 amplification, 
./___Corpus/Medline/xml/PMC4898971.xml	cdk6	30433 : 30437	CM	be increased by cdk4 and cdk6 amplification, mutation 
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30465 : 30469	CM	plification, mutation of cdk4 to an inhibitor resistan
./___Corpus/Medline/xml/PMC4898971.xml	INK4	30517 : 30521	CM	ant form, or loss of the INK4 inhibitors. Perhaps the 
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	30679 : 30683	CM	er, where palbociclib, a cdk4/6 specific inhibitor, de
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	30787 : 30795	CM	ctor receptor 2 (HER2)+, estrogen receptor (ER)+ postmenop
./___Corpus/Medline/xml/PMC4898971.xml	(ER)+	30805 : 30810	CM	ER2)+, estrogen receptor (ER)+ postmenopausal women. In
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	30852 : 30858	CM	omen. In addition, since cyclin D is transcriptionally l
./___Corpus/Medline/xml/PMC4898971.xml	mitogenic	30892 : 30901	CM	nscriptionally linked to mitogenic signaling pathways, is e
./___Corpus/Medline/xml/PMC4898971.xml	GSK3β	30977 : 30982	CM	ll cycle, is degraded by GSK3β (which itself is a thera
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31087 : 31093	CM	al trials, suggests that cyclin D may be an important ta
./___Corpus/Medline/xml/PMC4898971.xml	cyclin E	31216 : 31224	CM	        Amplification of cyclin E or cdk2 is detected in s
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31228 : 31232	CM	ification of cyclin E or cdk2 is detected in some tumo
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31295 : 31301	CM	this is rare compared to cyclin D-cdk4/6 [145]. Cyclin E
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	31302 : 31308	CM	 rare compared to cyclin D-cdk4/6 [145]. Cyclin E-cdk2 m
./___Corpus/Medline/xml/PMC4898971.xml	Cyclin	31318 : 31324	CM	o cyclin D-cdk4/6 [145]. Cyclin E-cdk2 may be a good tar
./___Corpus/Medline/xml/PMC4898971.xml	E-	31325 : 31327	CPR	n D-cdk4/6 [145]. Cyclin E-cdk2 may be a good target
./___Corpus/Medline/xml/PMC4898971.xml	Rb	31398 : 31400	CM	s a major consequence of Rb dependent phosphorylatio
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	31411 : 31426	RN	sequence of Rb dependent phosphorylation. However, cdk2 activates
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31437 : 31441	CM	hosphorylation. However, cdk2 activates origins of DNA
./___Corpus/Medline/xml/PMC4898971.xml	Rb	31550 : 31552	CM	ors. Inactivation of the Rb checkpoint may also trig
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31581 : 31587	CM	ckpoint may also trigger cyclin E-cdk2 independent funct
./___Corpus/Medline/xml/PMC4898971.xml	E-	31588 : 31590	CPR	 may also trigger cyclin E-cdk2 independent function
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	31680 : 31684	CM	cence. Moreover, several cdk2 inhibitors have failed i
./___Corpus/Medline/xml/PMC4898971.xml	Cdk	31769 : 31772	CM	ns.                  6.3 Cdk inhbitors               
./___Corpus/Medline/xml/PMC4898971.xml	cdk	31808 : 31811	CM	                     The cdk inhibitors of the INK4 c
./___Corpus/Medline/xml/PMC4898971.xml	INK4	31830 : 31834	CM	he cdk inhibitors of the INK4 class block cyclin D-cdk
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	31847 : 31853	CM	 of the INK4 class block cyclin D-cdk4/6 activity. They 
./___Corpus/Medline/xml/PMC4898971.xml	D-cdk4	31854 : 31860	CM	 INK4 class block cyclin D-cdk4/6 activity. They do not 
./___Corpus/Medline/xml/PMC4898971.xml	INK4s	32013 : 32018	CM	erapeutic restoration of INK4s presented problems, in t
./___Corpus/Medline/xml/PMC4898971.xml	INK4	32182 : 32186	CM	igenetic inactivation of INK4 is due to extensive CpG 
./___Corpus/Medline/xml/PMC4898971.xml	CpG	32207 : 32210	CM	INK4 is due to extensive CpG methylation [146] raisin
./___Corpus/Medline/xml/PMC4898971.xml	methylation	32211 : 32222	RN	 is due to extensive CpG methylation [146] raising the possib
./___Corpus/Medline/xml/PMC4898971.xml	methylation	32301 : 32312	RN	apable of modulating DNA methylation such as EGCG, folate, an
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	32321 : 32325	CM	 DNA methylation such as EGCG, folate, and genistein a
./___Corpus/Medline/xml/PMC4898971.xml	folate	32327 : 32333	CM	ethylation such as EGCG, folate, and genistein are poten
./___Corpus/Medline/xml/PMC4898971.xml	genistein	32339 : 32348	CM	uch as EGCG, folate, and genistein are potential agents cap
./___Corpus/Medline/xml/PMC4898971.xml	INK4	32394 : 32398	CM	 capable of reactivating INK4 genes [147].            
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	32490 : 32496	CM	essor, p27Kip1, inhibits cyclin E-cdk2, which would pote
./___Corpus/Medline/xml/PMC4898971.xml	E-	32497 : 32499	CPR	p27Kip1, inhibits cyclin E-cdk2, which would potenti
./___Corpus/Medline/xml/PMC4898971.xml	p27	32549 : 32552	CM	ally block tumor growth. p27 levels are reduced postt
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	32644 : 32648	CM	, resulting in increased cdk2 activity [148]. Re-expre
./___Corpus/Medline/xml/PMC4898971.xml	p27	32682 : 32685	CM	 [148]. Re-expression of p27 could be achieved by int
./___Corpus/Medline/xml/PMC4898971.xml	S-phase	32746 : 32753	CM	th protein turnover. The S-phase kinase associated protei
./___Corpus/Medline/xml/PMC4898971.xml	ubiquitin	32799 : 32808	CM	otein 2 (Skp2) is the E3 ubiquitin ligase responsible for p
./___Corpus/Medline/xml/PMC4898971.xml	p27	32832 : 32835	CM	n ligase responsible for p27 degradation. Thus, Skp2 
./___Corpus/Medline/xml/PMC4898971.xml	p27	32864 : 32867	CM	radation. Thus, Skp2 and p27 expression is inversely 
./___Corpus/Medline/xml/PMC4898971.xml	Bortezomib	32914 : 32924	CM	ly correlated [149,150]. Bortezomib-mediated proteosomal inh
./___Corpus/Medline/xml/PMC4898971.xml	p27	33147 : 33150	CM	 be less toxic. However, p27 inhibits cdk1 and prolif
./___Corpus/Medline/xml/PMC4898971.xml	cdk1	33160 : 33164	CM	c. However, p27 inhibits cdk1 and proliferation of cdk
./___Corpus/Medline/xml/PMC4898971.xml	cdk2−	33186 : 33191	CM	dk1 and proliferation of cdk2−/− mouse embryo fibroblas
./___Corpus/Medline/xml/PMC4898971.xml	cyclin D-cdk4	33244 : 33257	CM	 and also stabilizes the cyclin D-cdk4 complex, suggesting that
./___Corpus/Medline/xml/PMC4898971.xml	p27	33293 : 33296	CM	uggesting that targeting p27 may have global, deleter
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	33559 : 33563	CM	ction pathways (Bcr-Abl, EGFR, HER2, c-Met, and Raf). 
./___Corpus/Medline/xml/PMC4898971.xml	HER2	33565 : 33569	CM	pathways (Bcr-Abl, EGFR, HER2, c-Met, and Raf). While 
./___Corpus/Medline/xml/PMC4898971.xml	c-Met	33571 : 33576	CM	ys (Bcr-Abl, EGFR, HER2, c-Met, and Raf). While these h
./___Corpus/Medline/xml/PMC4898971.xml	Raf	33582 : 33585	CM	, EGFR, HER2, c-Met, and Raf). While these have initi
./___Corpus/Medline/xml/PMC4898971.xml	fate	33924 : 33928	CM	t cell proliferation and fate, and that are targets fo
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	34007 : 34010	CM	ds.                  7.1 Wnt/β-catenin signaling     
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34011 : 34020	CM	                 7.1 Wnt/β-catenin signaling               
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	34052 : 34055	CM	ing                      Wnt/β-catenin signaling is a
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34056 : 34065	CM	                     Wnt/β-catenin signaling is a developme
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	34503 : 34506	CM	                Aberrant Wnt/β-catenin signaling is i
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34507 : 34516	CM	            Aberrant Wnt/β-catenin signaling is implicated 
./___Corpus/Medline/xml/PMC4898971.xml	158-	34600 : 34604	CPR	tal and breast cancers) [158-162]. Most involve stabil
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	34640 : 34649	CM	involve stabilization of β-catenin by mutation which is oft
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	34739 : 34742	CM	 Alternatively, aberrant Wnt signaling is due to eith
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	34817 : 34820	CM	gative regulators of the Wnt signaling pathway, such 
./___Corpus/Medline/xml/PMC4898971.xml	Wnt-1	34951 : 34956	CM	 as disheveled [162]. In Wnt-1 transgenic mice, expande
./___Corpus/Medline/xml/PMC4898971.xml	transgenic	34957 : 34967	CM	sheveled [162]. In Wnt-1 transgenic mice, expanded mammary s
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	35139 : 35148	CM	nstitutive activation of β-catenin appears to promote the s
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	35341 : 35344	CM	ral compounds that block Wnt signaling (see below).  
./___Corpus/Medline/xml/PMC4898971.xml	1-	35488 : 35490	CPR	embrane receptors (Notch 1-4) for membrane bound lig
./___Corpus/Medline/xml/PMC4898971.xml	JAG1	35521 : 35525	CM	 membrane bound ligands (JAG1, JAG2, delta-like 1-4). 
./___Corpus/Medline/xml/PMC4898971.xml	JAG2	35527 : 35531	CM	ane bound ligands (JAG1, JAG2, delta-like 1-4). Upon b
./___Corpus/Medline/xml/PMC4898971.xml	1-	35544 : 35546	CPR	 (JAG1, JAG2, delta-like 1-4). Upon binding, Notch r
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	35700 : 35706	CM	it targets genes such as cyclin D [165], p21CIP1 [166], 
./___Corpus/Medline/xml/PMC4898971.xml	p21CIP1	35716 : 35723	CM	 such as cyclin D [165], p21CIP1 [166], NF-κB [167], and 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	35731 : 35736	CM	 D [165], p21CIP1 [166], NF-κB [167], and c-myc [168-17
./___Corpus/Medline/xml/PMC4898971.xml	c-myc	35748 : 35753	CM	 [166], NF-κB [167], and c-myc [168-170]. Notch protein
./___Corpus/Medline/xml/PMC4898971.xml	168-	35755 : 35759	CPR	 NF-κB [167], and c-myc [168-170]. Notch proteins cont
./___Corpus/Medline/xml/PMC4898971.xml	fate	35906 : 35910	CM	also contributes to cell fate in embryonic development
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	36110 : 36114	CM	signaling is detected in CSCs in breast cancer [175-17
./___Corpus/Medline/xml/PMC4898971.xml	175-	36133 : 36137	CPR	n CSCs in breast cancer [175-177], embryonal brain tum
./___Corpus/Medline/xml/PMC4898971.xml	93,94,178,180-	36286 : 36300	CPR	nd, and lung carcinomas [93,94,178,180-182]. In breast cancer, c
./___Corpus/Medline/xml/PMC4898971.xml	vitro	36414 : 36419	CM	mary epithelial cells in vitro and resulted in the appe
./___Corpus/Medline/xml/PMC4898971.xml	183-	36493 : 36497	CPR	ntiated adenocarcinomas [183-187]. Further, HER2 [188-
./___Corpus/Medline/xml/PMC4898971.xml	HER2	36512 : 36516	CM	omas [183-187]. Further, HER2 [188-190], Akt [191], si
./___Corpus/Medline/xml/PMC4898971.xml	188-	36518 : 36522	CPR	183-187]. Further, HER2 [188-190], Akt [191], signal t
./___Corpus/Medline/xml/PMC4898971.xml	STAT3	36588 : 36593	CM	ivator of transcription (STAT3) [101], NF-κB [192] were
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	36602 : 36607	CM	scription (STAT3) [101], NF-κB [192] were found to cros
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	36660 : 36664	CM	alk with Notch in breast CSCs [172], suggesting that N
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	36781 : 36788	CM	gh these signals. In the hypoxic environment, HIFs activa
./___Corpus/Medline/xml/PMC4898971.xml	HIFs	36802 : 36806	CM	the hypoxic environment, HIFs activate Notch [3] and t
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	37021 : 37028	CM	ive and proliferate in a hypoxic microenvironment. Natura
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	37074 : 37085	CM	tural compounds, such as resveratrol (see below) [194], down 
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37150 : 37154	CM	ription of the Notch and PI3K/Akt pathways and may pre
./___Corpus/Medline/xml/PMC4898971.xml	IGF	37251 : 37254	CM	ulin-like growth factor (IGF) signaling              
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37456 : 37460	CM	urvival by activation of PI3K/Akt and Ras/Raf/extracel
./___Corpus/Medline/xml/PMC4898971.xml	Raf	37473 : 37476	CM	tion of PI3K/Akt and Ras/Raf/extracellular signal reg
./___Corpus/Medline/xml/PMC4898971.xml	195-	37516 : 37520	CPR	signal regulated kinase [195-197]. Recently, Nanog was
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	37610 : 37614	CM	ning the self renewal of CSCs through the IGF-1 signal
./___Corpus/Medline/xml/PMC4898971.xml	IGF-1	37627 : 37632	CM	ewal of CSCs through the IGF-1 signaling in hepatocellu
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	37751 : 37755	CM	pathways, such as Notch, EGFR, leptin and promotes the
./___Corpus/Medline/xml/PMC4898971.xml	leptin	37757 : 37763	CM	ys, such as Notch, EGFR, leptin and promotes the transit
./___Corpus/Medline/xml/PMC4898971.xml	SC	37801 : 37803	CM	 the transition of adult SC to CSCs [172,199,200].  
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	37807 : 37811	CM	ransition of adult SC to CSCs [172,199,200].          
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37848 : 37852	CM	0].                  7.4 PI3K/Akt/mTOR signaling      
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	37857 : 37861	CM	            7.4 PI3K/Akt/mTOR signaling               
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	37897 : 37901	CM	                     The PI3K/Akt/mTOR pathway plays a
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	37906 : 37910	CM	            The PI3K/Akt/mTOR pathway plays a central 
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38028 : 38032	CM	n tumor cells [201,202]. mTOR is a ser/thr kinase that
./___Corpus/Medline/xml/PMC4898971.xml	thr	38042 : 38045	CM	[201,202]. mTOR is a ser/thr kinase that is a downstr
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	38084 : 38088	CM	s a downstream target of PI3K/Akt in many types of can
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38141 : 38145	CM	. Aberrant activation of mTOR by mutations or gene amp
./___Corpus/Medline/xml/PMC4898971.xml	EMT	38224 : 38227	CM	ncer cell proliferation, EMT [204], and resistance to
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	38319 : 38323	CM	                         PI3K/Akt/mTOR signaling plays
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38328 : 38332	CM	                PI3K/Akt/mTOR signaling plays a key ro
./___Corpus/Medline/xml/PMC4898971.xml	CSC	38363 : 38366	CM	ling plays a key role in CSC biology because this pat
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38470 : 38474	CM	hy stem cells [191,207]. mTOR inhibition also suppress
./___Corpus/Medline/xml/PMC4898971.xml	EMT	38502 : 38505	CM	hibition also suppresses EMT and CSC-like characteris
./___Corpus/Medline/xml/PMC4898971.xml	CSC	38510 : 38513	CM	 also suppresses EMT and CSC-like characteristics in 
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38586 : 38590	CM	. However, inhibition of mTOR is complex because sever
./___Corpus/Medline/xml/PMC4898971.xml	mTORC1	38660 : 38666	CM	s in this pathway [e.g., mTORC1, S6 kinase 1 and eukaryo
./___Corpus/Medline/xml/PMC4898971.xml	eukaryotic	38684 : 38694	CM	 mTORC1, S6 kinase 1 and eukaryotic translation initiation f
./___Corpus/Medline/xml/PMC4898971.xml	4E	38725 : 38727	CM	lation initiation factor 4E binding protein 1 may be
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	38769 : 38773	CM	1 may be regulated in an mTOR independent manner [209-
./___Corpus/Medline/xml/PMC4898971.xml	209-	38794 : 38798	CPR	mTOR independent manner [209-214]. Another challenge i
./___Corpus/Medline/xml/PMC4898971.xml	COXEN	38985 : 38990	CM	Xpression ExtrapolatioN (COXEN) model [215-217].       
./___Corpus/Medline/xml/PMC4898971.xml	215-	38999 : 39003	CPR	apolatioN (COXEN) model [215-217].                  7.
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39030 : 39035	CM	7].                  7.5 NF-κB signaling               
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39067 : 39072	CM	ing                      NF-κB transcription factors re
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39231 : 39236	CM	phoid organ development. NF-κB is activated in many can
./___Corpus/Medline/xml/PMC4898971.xml	218-	39267 : 39271	CPR	tivated in many cancers [218-220] by many divergent st
./___Corpus/Medline/xml/PMC4898971.xml	RNA	39484 : 39487	CM	roteins, double stranded RNA, and physical and chemic
./___Corpus/Medline/xml/PMC4898971.xml	220-	39526 : 39530	CPR	 and chemical stressors [220-222]. These events contri
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39626 : 39631	CM	inogenesis. For example, NF-κB activation may be requir
./___Corpus/Medline/xml/PMC4898971.xml	CSC	39677 : 39680	CM	quired for human ovarian CSC metastases [223], in hum
./___Corpus/Medline/xml/PMC4898971.xml	CSC	39717 : 39720	CM	[223], in human cervical CSC growth and migration [22
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	39793 : 39797	CM	erentiating glioblastoma CSCs from acquiring a mature 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39871 : 39876	CM	225]. Mammary epithelial NF-κB also regulates the self-
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	39919 : 39923	CM	e self-renewal of breast CSCs [226]. Thus, NF-κB is an
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	39937 : 39942	CM	breast CSCs [226]. Thus, NF-κB is an important therapeu
./___Corpus/Medline/xml/PMC4898971.xml	Hh	40058 : 40060	CM	ing                      Hh signaling controls tissu
./___Corpus/Medline/xml/PMC4898971.xml	227-	40161 : 40165	CPR	in a variety of tissues [227-230]. In vertebrates, thr
./___Corpus/Medline/xml/PMC4898971.xml	Hh	40193 : 40195	CM	]. In vertebrates, three Hh ligands [Sonic Hedgehog 
./___Corpus/Medline/xml/PMC4898971.xml	trans-	40273 : 40279	CPR	Indian Hedgehog] bind to trans-membrane receptors [Patch
./___Corpus/Medline/xml/PMC4898971.xml	Ptch1	40308 : 40313	CM	rane receptors [Patched (Ptch1 or Ptch2)]. Upon ligand 
./___Corpus/Medline/xml/PMC4898971.xml	Ptch2	40317 : 40322	CM	ptors [Patched (Ptch1 or Ptch2)]. Upon ligand binding, 
./___Corpus/Medline/xml/PMC4898971.xml	CSC	40648 : 40651	CM	           Regulation of CSC proliferation in various
./___Corpus/Medline/xml/PMC4898971.xml	MM	40756 : 40758	CM	ncreatic adenocarcinoma, MM and CML is through Hh si
./___Corpus/Medline/xml/PMC4898971.xml	CML	40763 : 40766	CM	c adenocarcinoma, MM and CML is through Hh signaling 
./___Corpus/Medline/xml/PMC4898971.xml	Hh	40778 : 40780	CM	a, MM and CML is through Hh signaling [97,233-241]. 
./___Corpus/Medline/xml/PMC4898971.xml	97,233-	40792 : 40799	CPR	is through Hh signaling [97,233-241]. Use of the SMO anta
./___Corpus/Medline/xml/PMC4898971.xml	SMO	40816 : 40819	CM	[97,233-241]. Use of the SMO antagonist cyclopamine o
./___Corpus/Medline/xml/PMC4898971.xml	cyclopamine	40831 : 40842	CM	se of the SMO antagonist cyclopamine or the Hh ligand neutral
./___Corpus/Medline/xml/PMC4898971.xml	Hh	40850 : 40852	CM	onist cyclopamine or the Hh ligand neutralizing anti
./___Corpus/Medline/xml/PMC4898971.xml	5E1	40882 : 40885	CM	nd neutralizing antibody 5E1 induced terminal differe
./___Corpus/Medline/xml/PMC4898971.xml	clonogenic	40931 : 40941	CM	ferentiation and loss of clonogenic growth in gastric CSCs f
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	40960 : 40964	CM	ogenic growth in gastric CSCs from primary tumors [242
./___Corpus/Medline/xml/PMC4898971.xml	Hh	41034 : 41036	CM	of CML also suggest that Hh regulates the self renew
./___Corpus/Medline/xml/PMC4898971.xml	Hh	41195 : 41197	CM	natural compounds. Thus, Hh affects CSCs self renewa
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	41206 : 41210	CM	pounds. Thus, Hh affects CSCs self renewal and differe
./___Corpus/Medline/xml/PMC4898971.xml	Hh	41318 : 41320	CM	d leukemia cells through Hh, and this effect was blo
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	41374 : 41385	CM	 by the natural compound resveratrol. Shh-Gli signaling contr
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	41448 : 41452	CM	cteristics of pancreatic CSCs, and these are inhibited
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	41492 : 41504	CM	 inhibited by the use of sulforaphane [132,245].              
./___Corpus/Medline/xml/PMC4898971.xml	nonalcoholic	41712 : 41724	CM	cancer is exemplified by nonalcoholic fatty liver disease (NAF
./___Corpus/Medline/xml/PMC4898971.xml	fatty	41725 : 41730	CM	mplified by nonalcoholic fatty liver disease (NAFLD) [2
./___Corpus/Medline/xml/PMC4898971.xml	triglyceride	41803 : 41815	CM	erations that range from triglyceride accumulation in hepatocy
./___Corpus/Medline/xml/PMC4898971.xml	nonalcoholic	41888 : 41900	CM	tosis with inflammation (nonalcoholic steatohepatitis or NASH)
./___Corpus/Medline/xml/PMC4898971.xml	NASH	41920 : 41924	CM	holic steatohepatitis or NASH), with or without fibros
./___Corpus/Medline/xml/PMC4898971.xml	NASH	41963 : 41967	CM	hout fibrosis [247,248]. NASH patients with liver fibr
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42078 : 42081	CM	epatocellular carcinoma (HCC). At the molecular level
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42116 : 42126	CM	molecular level, altered methionine metabolism plays an esse
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42202 : 42205	CM	r bases of NAFLD related HCC.                        
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42352 : 42362	CM	elevated serum levels of methionine [250,251]. The latter is
./___Corpus/Medline/xml/PMC4898971.xml	methionine	42414 : 42424	CM	ssociated with decreased methionine adenosyltransferase (MAT
./___Corpus/Medline/xml/PMC4898971.xml	MAT	42446 : 42449	CM	ine adenosyltransferase (MAT), and the product of its
./___Corpus/Medline/xml/PMC4898971.xml	S-adenosylmethionine	42485 : 42505	CM	product of its reaction, S-adenosylmethionine (SAM) [252,253]. MAT def
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42507 : 42510	CM	n, S-adenosylmethionine (SAM) [252,253]. MAT deficien
./___Corpus/Medline/xml/PMC4898971.xml	MAT	42523 : 42526	CM	hionine (SAM) [252,253]. MAT deficient mice developed
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42568 : 42571	CM	eveloped chronic hepatic SAM deficiency, display incr
./___Corpus/Medline/xml/PMC4898971.xml	HCC	42643 : 42646	CM	nd spontaneously develop HCC [254]. SAM is a major me
./___Corpus/Medline/xml/PMC4898971.xml	methyl	42669 : 42675	CM	CC [254]. SAM is a major methyl donor, where it mediates
./___Corpus/Medline/xml/PMC4898971.xml	methylation reactions	42718 : 42739	RN	ediates up to 85% of the methylation reactions in the liver, thereby pr
./___Corpus/Medline/xml/PMC4898971.xml	glutathione	42840 : 42851	CM	ursor of the antioxidant glutathione (GSH), both are decrease
./___Corpus/Medline/xml/PMC4898971.xml	GSH	42853 : 42856	CM	antioxidant glutathione (GSH), both are decreased in 
./___Corpus/Medline/xml/PMC4898971.xml	SAM	42939 : 42942	CM	t of these patients with SAM increased GSH levels and
./___Corpus/Medline/xml/PMC4898971.xml	GSH	42953 : 42956	CM	ients with SAM increased GSH levels and improved surv
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43031 : 43034	CM	g the therapeutic use of SAM to treat liver diseases 
./___Corpus/Medline/xml/PMC4898971.xml	glycine	43100 : 43107	CM	y, mice deficient in the glycine N-methyltransferase gene
./___Corpus/Medline/xml/PMC4898971.xml	N-	43108 : 43110	CPR	deficient in the glycine N-methyltransferase gene, w
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43175 : 43178	CM	e enzyme responsible for SAM catabolism, developed el
./___Corpus/Medline/xml/PMC4898971.xml	SAM	43210 : 43213	CM	lism, developed elevated SAM, methionine, serum trans
./___Corpus/Medline/xml/PMC4898971.xml	methionine	43215 : 43225	CM	 developed elevated SAM, methionine, serum transaminase leve
./___Corpus/Medline/xml/PMC4898971.xml	transaminase	43233 : 43245	CM	d SAM, methionine, serum transaminase levels [258], hepatic st
./___Corpus/Medline/xml/PMC4898971.xml	HCC	43292 : 43295	CM	 steatosis, fibrosis and HCC [258-261]. Therefore, al
./___Corpus/Medline/xml/PMC4898971.xml	258-	43297 : 43301	CPR	tosis, fibrosis and HCC [258-261]. Therefore, altered 
./___Corpus/Medline/xml/PMC4898971.xml	methionine	43326 : 43336	CM	261]. Therefore, altered methionine metabolism resulted in i
./___Corpus/Medline/xml/PMC4898971.xml	MAT	43412 : 43415	CM	ough decreased levels of MAT and GSH.                
./___Corpus/Medline/xml/PMC4898971.xml	GSH	43420 : 43423	CM	reased levels of MAT and GSH.                        
./___Corpus/Medline/xml/PMC4898971.xml	ATP	43508 : 43511	CM	ting cells require rapid ATP generation, increased bi
./___Corpus/Medline/xml/PMC4898971.xml	p53	43664 : 43667	CM	e, the tumor suppressor, p53, stimulates glycolytic e
./___Corpus/Medline/xml/PMC4898971.xml	glycolytic	43680 : 43690	CM	pressor, p53, stimulates glycolytic enzymes and the pentose 
./___Corpus/Medline/xml/PMC4898971.xml	pentose phosphate	43707 : 43724	CM	ycolytic enzymes and the pentose phosphate pathway, which provide s
./___Corpus/Medline/xml/PMC4898971.xml	isoform	43809 : 43816	CM	sis. In addition, the M2 isoform of pyruvate kinase (PKM2
./___Corpus/Medline/xml/PMC4898971.xml	pyruvate	43820 : 43828	CM	ition, the M2 isoform of pyruvate kinase (PKM2), which con
./___Corpus/Medline/xml/PMC4898971.xml	PKM2	43837 : 43841	CM	form of pyruvate kinase (PKM2), which converts phospho
./___Corpus/Medline/xml/PMC4898971.xml	phosphoenolpyruvate	43859 : 43878	CM	e (PKM2), which converts phosphoenolpyruvate to pyruvate, attenuates 
./___Corpus/Medline/xml/PMC4898971.xml	pyruvate	43882 : 43890	CM	s phosphoenolpyruvate to pyruvate, attenuates glycolysis, 
./___Corpus/Medline/xml/PMC4898971.xml	glycolysis	43903 : 43913	RN	 to pyruvate, attenuates glycolysis, thereby providing precu
./___Corpus/Medline/xml/PMC4898971.xml	PKM2	44028 : 44032	CM	In these same reactions, PKM2 also promotes the develo
./___Corpus/Medline/xml/PMC4898971.xml	nicotinamine adenine dinucleotide phosphate	44066 : 44109	CM	motes the development of nicotinamine adenine dinucleotide phosphate (NADPH) which provides r
./___Corpus/Medline/xml/PMC4898971.xml	NADPH	44111 : 44116	CM	 dinucleotide phosphate (NADPH) which provides reducing
./___Corpus/Medline/xml/PMC4898971.xml	NADPH	44212 : 44217	CM	 quenches free radicals. NADPH also contributes importa
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	44461 : 44467	CM	 responsive genes (e.g., HIF-1α) and cell survival [266,
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	44839 : 44850	CM	is context, many natural polyphenols (see below) alter cancer
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	45059 : 45067	CM	          9. The role of estrogen and androgen receptors i
./___Corpus/Medline/xml/PMC4898971.xml	androgen	45072 : 45080	CM	The role of estrogen and androgen receptors in cancer cell
./___Corpus/Medline/xml/PMC4898971.xml	paracrine	45258 : 45267	CM	issues. This encompasses paracrine, autocrine, and intracri
./___Corpus/Medline/xml/PMC4898971.xml	17β-estradiol	45819 : 45832	CM	long term treatment with 17β-estradiol (E2) results in DNA dama
./___Corpus/Medline/xml/PMC4898971.xml	E2	45834 : 45836	CM	ment with 17β-estradiol (E2) results in DNA damage a
./___Corpus/Medline/xml/PMC4898971.xml	estrogens	45939 : 45948	CM	at physiological levels, estrogens and other hormones are c
./___Corpus/Medline/xml/PMC4898971.xml	G1	46029 : 46031	CM	te mitosis by shortening G1 and promoting entry into
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	46541 : 46549	CM	                     Two estrogen receptors (i.e., ERα and
./___Corpus/Medline/xml/PMC4898971.xml	ERα	46567 : 46570	CM	strogen receptors (i.e., ERα and ERβ) and one androge
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	46575 : 46578	CM	receptors (i.e., ERα and ERβ) and one androgen recept
./___Corpus/Medline/xml/PMC4898971.xml	androgen	46588 : 46596	CM	e., ERα and ERβ) and one androgen receptor (AR) mediate th
./___Corpus/Medline/xml/PMC4898971.xml	AR	46607 : 46609	CM	d one androgen receptor (AR) mediate the mitogenic e
./___Corpus/Medline/xml/PMC4898971.xml	mitogenic	46623 : 46632	CM	eceptor (AR) mediate the mitogenic effects of estrogens and
./___Corpus/Medline/xml/PMC4898971.xml	estrogens	46644 : 46653	CM	the mitogenic effects of estrogens and androgens, respectiv
./___Corpus/Medline/xml/PMC4898971.xml	androgens	46658 : 46667	CM	effects of estrogens and androgens, respectively. After lig
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	46842 : 46850	CM	scription machinery onto estrogen or androgen responsive e
./___Corpus/Medline/xml/PMC4898971.xml	androgen	46854 : 46862	CM	chinery onto estrogen or androgen responsive elements, res
./___Corpus/Medline/xml/PMC4898971.xml	AR	47069 : 47071	CM	 membrane bound forms of AR and ER [276]. For some c
./___Corpus/Medline/xml/PMC4898971.xml	ER	47076 : 47078	CM	ne bound forms of AR and ER [276]. For some cancers,
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	47185 : 47189	CM	egulated kinase 1 in the MAPK family and via Akt in th
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	47216 : 47220	CM	amily and via Akt in the PI3K pathway. These ERα-depen
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47236 : 47239	CM	 the PI3K pathway. These ERα-dependent pathways trans
./___Corpus/Medline/xml/PMC4898971.xml	277-	47321 : 47325	CPR	c and migration signals [277-279]. In this context, me
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47359 : 47362	CM	this context, membranous ERα staining was observed in
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47448 : 47451	CM	 tumor was classified as ERα negative on the basis of
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47477 : 47480	CM	negative on the basis of ERα nuclear expression. Memb
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47510 : 47513	CM	ear expression. Membrane ERα expressing breast cancer
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylated	47585 : 47599	CM	ositive correlation with phosphorylated Akt and HER2 overexpress
./___Corpus/Medline/xml/PMC4898971.xml	HER2	47608 : 47612	CM	h phosphorylated Akt and HER2 overexpression [280], th
./___Corpus/Medline/xml/PMC4898971.xml	ERα	47717 : 47720	CM	oma’ [281]. In addition, ERα plasma membrane localiza
./___Corpus/Medline/xml/PMC4898971.xml	IGFR1	47776 : 47781	CM	nd its interactions with IGFR1 and EGFR/ErbB2 may be on
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	47786 : 47790	CM	eractions with IGFR1 and EGFR/ErbB2 may be one of the 
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	47791 : 47796	CM	ions with IGFR1 and EGFR/ErbB2 may be one of the mechan
./___Corpus/Medline/xml/PMC4898971.xml	Androgen	47906 : 47914	CM	 cancer cells [282,283]. Androgen independent prostate can
./___Corpus/Medline/xml/PMC4898971.xml	IGFR-1	47963 : 47969	CM	ncer is also mediated by IGFR-1/IGF-1 [284] and elevated
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	47995 : 47999	CM	IGF-1 [284] and elevated EGFR/ErbB-2 [285], combined w
./___Corpus/Medline/xml/PMC4898971.xml	ErbB-2	48000 : 48006	CM	 [284] and elevated EGFR/ErbB-2 [285], combined with dow
./___Corpus/Medline/xml/PMC4898971.xml	STAT	48076 : 48080	CM	] and Janus kinase (JAK)/STAT [288] and MAPK signaling
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	48091 : 48095	CM	ase (JAK)/STAT [288] and MAPK signaling. These pathway
./___Corpus/Medline/xml/PMC4898971.xml	AR	48131 : 48133	CM	 These pathways activate AR, which translocates to t
./___Corpus/Medline/xml/PMC4898971.xml	androgen	48448 : 48456	CM	has been demonstrated in androgen dependent tumors, the ut
./___Corpus/Medline/xml/PMC4898971.xml	andogen	48511 : 48518	CM	 of natural compounds in andogen independent tumors will 
./___Corpus/Medline/xml/PMC4898971.xml	andogen	48578 : 48585	CM	n the mechanisms whereby andogen independence is achieved
./___Corpus/Medline/xml/PMC4898971.xml	AR	48629 : 48631	CM	hieved. This may include AR overexpression, AR mutat
./___Corpus/Medline/xml/PMC4898971.xml	AR	48648 : 48650	CM	clude AR overexpression, AR mutations, altered recru
./___Corpus/Medline/xml/PMC4898971.xml	dihydrotestosterone	48753 : 48772	CM	ntratumoral synthesis of dihydrotestosterone, which binds to and acti
./___Corpus/Medline/xml/PMC4898971.xml	AR	48807 : 48809	CM	nds to and activates the AR in the androgen dependen
./___Corpus/Medline/xml/PMC4898971.xml	androgen	48817 : 48825	CM	 activates the AR in the androgen dependent phase of prost
./___Corpus/Medline/xml/PMC4898971.xml	ERα	48922 : 48925	CM	         Deregulation of ERα- and ERβ-mediated signal
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	48931 : 48934	CM	Deregulation of ERα- and ERβ-mediated signal transduc
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	49052 : 49060	CM	 may explain the role of estrogen in promoting breast canc
./___Corpus/Medline/xml/PMC4898971.xml	ERα	49112 : 49115	CM	 [275]. In this respect, ERα positive breast tumors a
./___Corpus/Medline/xml/PMC4898971.xml	E2	49213 : 49215	CM	ailability of endogenous E2 (e.g., aromatase inhibit
./___Corpus/Medline/xml/PMC4898971.xml	ERα	49248 : 49251	CM	aromatase inhibitors) or ERα transcriptional activity
./___Corpus/Medline/xml/PMC4898971.xml	4OH-tamoxifen	49284 : 49297	CM	iptional activity (e.g., 4OH-tamoxifen) [290]. The same drugs c
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	49334 : 49337	CM	 same drugs could act on ERβ signaling, even if the e
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	49498 : 49501	CM	 a selective agonist for ERβ could promote strong ant
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	49609 : 49612	CM	 prostate tissues, where ERβ functions as a growth re
./___Corpus/Medline/xml/PMC4898971.xml	ERα	49682 : 49685	CM	nt negative inhibitor of ERα-mediated proliferation [
./___Corpus/Medline/xml/PMC4898971.xml	ER	49779 : 49781	CM	f the membrane initiated ER signaling in tumors has 
./___Corpus/Medline/xml/PMC4898971.xml	ERs	49851 : 49854	CM	 Nuclear localization of ERs [294,295] is now conside
./___Corpus/Medline/xml/PMC4898971.xml	ERs	49975 : 49978	CM	ave been shown to target ERs extranuclear mechanisms 
./___Corpus/Medline/xml/PMC4898971.xml	ER	50451 : 50453	CM	 would rely on targeting ER membrane proliferative a
./___Corpus/Medline/xml/PMC4898971.xml	laminin	51284 : 51291	CM	, collagen, fibronectin, laminin and proteoglycan complex
./___Corpus/Medline/xml/PMC4898971.xml	EGF	51365 : 51368	CM	flammatory cells release EGF, VEGF, fibroblast growth
./___Corpus/Medline/xml/PMC4898971.xml	VEGF	51370 : 51374	CM	atory cells release EGF, VEGF, fibroblast growth facto
./___Corpus/Medline/xml/PMC4898971.xml	factor-2	51394 : 51402	CM	 VEGF, fibroblast growth factor-2 (FGF-2), chemokines, cyt
./___Corpus/Medline/xml/PMC4898971.xml	FGF-2	51404 : 51409	CM	roblast growth factor-2 (FGF-2), chemokines, cytokines,
./___Corpus/Medline/xml/PMC4898971.xml	297-	51502 : 51506	CPR	o promote tumorigenesis [297-299]. Continued tumor gro
./___Corpus/Medline/xml/PMC4898971.xml	VEGF	51619 : 51623	CM	ch occurs in response to VEGF and FGF-2 secreted from 
./___Corpus/Medline/xml/PMC4898971.xml	FGF-2	51628 : 51633	CM	 in response to VEGF and FGF-2 secreted from tumor cell
./___Corpus/Medline/xml/PMC4898971.xml	300-	51688 : 51692	CPR	sulting in angiogenesis [300-302]. Adipocytes in the t
./___Corpus/Medline/xml/PMC4898971.xml	leptin	51778 : 51784	CM	kines’ [303,304] such as leptin, adiponectin, hepatocyte
./___Corpus/Medline/xml/PMC4898971.xml	Paracrine	52086 : 52095	CM	inflammation and cancer. Paracrine factors from tumor cells
./___Corpus/Medline/xml/PMC4898971.xml	etoposide	52900 : 52909	CM	is, include vinblastine, etoposide, teniposide, homoharring
./___Corpus/Medline/xml/PMC4898971.xml	camptothecin	52945 : 52957	CM	e, homoharringtonine and camptothecin derivatives [312]. Epide
./___Corpus/Medline/xml/PMC4898971.xml	imatinib	53489 : 53497	CM	de Bcr-Abl kinase (e.g., imatinib [313], nilotinib [314], 
./___Corpus/Medline/xml/PMC4898971.xml	nilotinib	53505 : 53514	CM	e (e.g., imatinib [313], nilotinib [314], and ponatinib [31
./___Corpus/Medline/xml/PMC4898971.xml	ponatinib	53526 : 53535	CM	3], nilotinib [314], and ponatinib [315]), EGFR (gefitinib 
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	53544 : 53548	CM	], and ponatinib [315]), EGFR (gefitinib [316] and erl
./___Corpus/Medline/xml/PMC4898971.xml	gefitinib	53550 : 53559	CM	 ponatinib [315]), EGFR (gefitinib [316] and erlotinib [317
./___Corpus/Medline/xml/PMC4898971.xml	erlotinib	53570 : 53579	CM	GFR (gefitinib [316] and erlotinib [317]), HER2/ErbB2 (lapa
./___Corpus/Medline/xml/PMC4898971.xml	HER2	53588 : 53592	CM	6] and erlotinib [317]), HER2/ErbB2 (lapatinib [318]),
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	53593 : 53598	CM	d erlotinib [317]), HER2/ErbB2 (lapatinib [318]), and c
./___Corpus/Medline/xml/PMC4898971.xml	lapatinib	53600 : 53609	CM	inib [317]), HER2/ErbB2 (lapatinib [318]), and c-Met (crizo
./___Corpus/Medline/xml/PMC4898971.xml	c-Met	53622 : 53627	CM	2 (lapatinib [318]), and c-Met (crizotinib [319]). Alth
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	53834 : 53838	CM	ration of chemoresistant CSCs [320,321]. Given that ca
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin

                    Curcumin	54160 : 54198	CM	r.                  11.1 Curcumin                      Curcumin (diferuloylmethane), a y
./___Corpus/Medline/xml/PMC4898971.xml	diferuloylmethane	54200 : 54217	CM	               Curcumin (diferuloylmethane), a yellow spice and phe
./___Corpus/Medline/xml/PMC4898971.xml	phenolic	54239 : 54247	CM	ane), a yellow spice and phenolic compound derived from th
./___Corpus/Medline/xml/PMC4898971.xml	Curcuma	54280 : 54287	CM	d derived from the plant Curcuma longa, is one of the mos
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	54412 : 54420	CM	5). The consumption of a curcumin rich diet is inversely c
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54494 : 54502	CM	uman malignancies [323]. Curcumin blocks cancer cell proli
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	54549 : 54552	CM	oliferation by targeting Wnt (Table 2), NF-κB, STAT3,
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	54564 : 54569	CM	targeting Wnt (Table 2), NF-κB, STAT3, PI3K/Akt [324] (
./___Corpus/Medline/xml/PMC4898971.xml	STAT3	54571 : 54576	CM	ng Wnt (Table 2), NF-κB, STAT3, PI3K/Akt [324] (Fig. 6)
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	54578 : 54582	CM	(Table 2), NF-κB, STAT3, PI3K/Akt [324] (Fig. 6) and m
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	54606 : 54610	CM	K/Akt [324] (Fig. 6) and mTOR [325]. Curcumin also has
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54618 : 54626	CM	(Fig. 6) and mTOR [325]. Curcumin also has fewer side effe
./___Corpus/Medline/xml/PMC4898971.xml	Curcumin	54692 : 54700	CM	ional therapy [326,327]. Curcumin indirectly affects tumor
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	54896 : 54904	CM	roliferative activity of curcumin against pancreatic cance
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	54985 : 54992	CM	diated by modulating the miR-200 family, which in turn re
./___Corpus/Medline/xml/PMC4898971.xml	EMT	55025 : 55028	CM	 which in turn regulates EMT [328]. Further, curcumin
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55045 : 55053	CM	ates EMT [328]. Further, curcumin and its synthetic analog
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55094 : 55102	CM	ic analog, diflourinated curcumin, downregulate miR-21 exp
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	55117 : 55123	CM	d curcumin, downregulate miR-21 expression [329] and red
./___Corpus/Medline/xml/PMC4898971.xml	miR-15a	55193 : 55200	CM	of Bcl-2 by upregulating miR-15a and miR-15b [330], indic
./___Corpus/Medline/xml/PMC4898971.xml	miR-15b	55205 : 55212	CM	upregulating miR-15a and miR-15b [330], indicating that c
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55236 : 55244	CM	b [330], indicating that curcumin impacts upon proliferati
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55329 : 55337	CM	ms. A major problem with curcumin is its low bioavailabili
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55432 : 55440	CM	of structural analogs of curcumin, stabilization of curcum
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55459 : 55467	CM	rcumin, stabilization of curcumin with adjuvants (e.g., pi
./___Corpus/Medline/xml/PMC4898971.xml	piperine	55490 : 55498	CM	in with adjuvants (e.g., piperine), liposomal and nanopart
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	55539 : 55547	CM	 nanoparticle associated curcumin, and the development of 
./___Corpus/Medline/xml/PMC4898971.xml	curcumin phospholipid	55572 : 55593	CM	, and the development of curcumin phospholipid complexes, aimed at incr
./___Corpus/Medline/xml/PMC4898971.xml	Indole-3-carbinol	55712 : 55729	CM	].                  11.2 Indole-3-carbinol, 3,3-diindolylmethane, s
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	55731 : 55751	CM	 11.2 Indole-3-carbinol, 3,3-diindolylmethane, sulforaphane and brassi
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	55753 : 55765	CM	l, 3,3-diindolylmethane, sulforaphane and brassinin           
./___Corpus/Medline/xml/PMC4898971.xml	Indole-3-carbinol	55801 : 55818	CM	nin                      Indole-3-carbinol, a natural hydrolysis pr
./___Corpus/Medline/xml/PMC4898971.xml	hydrolysis	55830 : 55840	RN	le-3-carbinol, a natural hydrolysis product of glucobrassici
./___Corpus/Medline/xml/PMC4898971.xml	glucobrassicin	55852 : 55866	CM	al hydrolysis product of glucobrassicin in cruciferous vegetable
./___Corpus/Medline/xml/PMC4898971.xml	IGFR1	55967 : 55972	CM	lating expression of the IGFR1, the insulin receptor su
./___Corpus/Medline/xml/PMC4898971.xml	substrate-1	55995 : 56006	CM	R1, the insulin receptor substrate-1, and by triggering degra
./___Corpus/Medline/xml/PMC4898971.xml	ERα	56045 : 56048	CM	ering degradation of the ERα [332]. Such vegetables a
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	56085 : 56097	CM	 vegetables also contain sulforaphane, a naturally occurring o
./___Corpus/Medline/xml/PMC4898971.xml	organosulfur	56121 : 56133	CM	e, a naturally occurring organosulfur compound formed by the h
./___Corpus/Medline/xml/PMC4898971.xml	hydrolysis	56157 : 56167	RN	r compound formed by the hydrolysis of glucosinolates. Sulfo
./___Corpus/Medline/xml/PMC4898971.xml	glucosinolates	56171 : 56185	CM	med by the hydrolysis of glucosinolates. Sulforaphane may lower 
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56187 : 56199	CM	lysis of glucosinolates. Sulforaphane may lower the risk of co
./___Corpus/Medline/xml/PMC4898971.xml	sulforaphane	56272 : 56284	CM	aps other cancers [333]. sulforaphane blocks proliferation, in
./___Corpus/Medline/xml/PMC4898971.xml	vitro	56336 : 56341	CM	ces cell cycle arrest in vitro, and has anticancer acti
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56395 : 56407	CM	 in animal models [334]. Sulforaphane also suppresses NF-κB an
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	56424 : 56429	CM	oraphane also suppresses NF-κB and the Wnt/β-catenin se
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	56438 : 56441	CM	suppresses NF-κB and the Wnt/β-catenin self renewal p
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	56442 : 56451	CM	resses NF-κB and the Wnt/β-catenin self renewal pathways in
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	56477 : 56481	CM	self renewal pathways in CSCs [335,336] (Fig. 6). Sulf
./___Corpus/Medline/xml/PMC4898971.xml	Sulforaphane	56502 : 56514	CM	CSCs [335,336] (Fig. 6). Sulforaphane appears to synergize wit
./___Corpus/Medline/xml/PMC4898971.xml	sorafenib	56541 : 56550	CM	ppears to synergize with sorafenib in shrinking pancreatic 
./___Corpus/Medline/xml/PMC4898971.xml	EMT	56627 : 56630	CM	ation, angiogenesis, and EMT [337]. Another indole co
./___Corpus/Medline/xml/PMC4898971.xml	indole	56646 : 56652	CM	, and EMT [337]. Another indole compound derived from cr
./___Corpus/Medline/xml/PMC4898971.xml	brassinin	56699 : 56708	CM	 cruciferous vegetables, brassinin, arrests cancer cells in
./___Corpus/Medline/xml/PMC4898971.xml	G1	56734 : 56736	CM	 arrests cancer cells in G1 via blocking PI3K signal
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	56750 : 56754	CM	cells in G1 via blocking PI3K signaling and upregulati
./___Corpus/Medline/xml/PMC4898971.xml	p21	56782 : 56785	CM	gnaling and upregulating p21 and p27 [338]. In compar
./___Corpus/Medline/xml/PMC4898971.xml	p27	56790 : 56793	CM	and upregulating p21 and p27 [338]. In comparison, 3,
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	56816 : 56836	CM	27 [338]. In comparison, 3,3-diindolylmethane increased the expression
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	56865 : 56871	CM	reased the expression of miR-21 which reduced the expres
./___Corpus/Medline/xml/PMC4898971.xml	3,3-diindolylmethane	56971 : 56991	CM	molog A [339]. Moreover, 3,3-diindolylmethane has been shown to increa
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	57036 : 57043	CM	ncrease the level of the miR-200 family in pancreatic can
./___Corpus/Medline/xml/PMC4898971.xml	EMT	57093 : 57096	CM	cer cells, which impacts EMT [328].                  
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57126 : 57137	CM	].                  11.3 Resveratrol                      Res
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57159 : 57170	CM	rol                      Resveratrol (3,4',5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4898971.xml	3,4',5-trihydroxy-trans-stilbene	57172 : 57204	CM	            Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a polyphenolic compo
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	57211 : 57223	CM	oxy-trans-stilbene) is a polyphenolic compound found in the sk
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57308 : 57319	CM	and mulberries (Fig. 5). Resveratrol appears to have antiagin
./___Corpus/Medline/xml/PMC4898971.xml	340-	57418 : 57422	CPR	r prevention activities [340-342]. In cancer preventio
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	57450 : 57461	CM	]. In cancer prevention, resveratrol blocks proliferation, pr
./___Corpus/Medline/xml/PMC4898971.xml	p53	57598 : 57601	CM	ulated kinase signaling, p53, Rb/E2F, cyclins and cdk
./___Corpus/Medline/xml/PMC4898971.xml	Rb	57603 : 57605	CM	d kinase signaling, p53, Rb/E2F, cyclins and cdks. I
./___Corpus/Medline/xml/PMC4898971.xml	E2F	57606 : 57609	CM	inase signaling, p53, Rb/E2F, cyclins and cdks. It se
./___Corpus/Medline/xml/PMC4898971.xml	TNF	57671 : 57674	CM	ls to extrinsic (Fas and TNF related apoptosis induci
./___Corpus/Medline/xml/PMC4898971.xml	lipid	57787 : 57792	CM	calization into membrane lipid rafts [243] and promotes
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	57905 : 57916	CM	rvivin and Bcl-XL [344]. Resveratrol suppresses the activity 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	57999 : 58004	CM	 in proliferation (e.g., NF-κB, activating protein 1 an
./___Corpus/Medline/xml/PMC4898971.xml	MAPKs	58069 : 58074	CM	wth response protein 1), MAPKs and tyrosine kinases (e.
./___Corpus/Medline/xml/PMC4898971.xml	tyrosine	58079 : 58087	CM	se protein 1), MAPKs and tyrosine kinases (e.g., Src) [345
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58128 : 58139	CM	Src) [345,346] (Fig. 6). Resveratrol also inhibits the prolif
./___Corpus/Medline/xml/PMC4898971.xml	AR	58211 : 58213	CM	ncer cells by inhibiting AR transcriptional activity
./___Corpus/Medline/xml/PMC4898971.xml	PTEN	58252 : 58256	CM	al activity, stimulating PTEN expression, and by block
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	58289 : 58304	RN	ion, and by blocking Akt phosphorylation [347]. Resveratrol block
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58312 : 58323	CM	t phosphorylation [347]. Resveratrol blocks the activity of β
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	58347 : 58356	CM	l blocks the activity of β-catenin by preventing its accumu
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	58465 : 58476	CM	actor 3 [347] (Table 2). Resveratrol suppresses IGFR1 and Wnt
./___Corpus/Medline/xml/PMC4898971.xml	IGFR1	58488 : 58493	CM	. Resveratrol suppresses IGFR1 and Wnt pathways in colo
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	58498 : 58501	CM	rol suppresses IGFR1 and Wnt pathways in colon cancer
./___Corpus/Medline/xml/PMC4898971.xml	vitro	58549 : 58554	CM	er cells [348]. Thus, in vitro studies strongly support
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58591 : 58602	CM	ongly support a role for resveratrol in mediating cell cycle 
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58710 : 58721	CM	            Ingestion of resveratrol rich grape powder in hum
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	58779 : 58782	CM	ressed expression of the Wnt target genes, cyclin D1 
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	58797 : 58803	CM	of the Wnt target genes, cyclin D1 and axin in normal co
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	58858 : 58861	CM	 mucosa, suggesting that Wnt pathway inhibition may c
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	58899 : 58910	CM	bition may contribute to resveratrol-mediated colon cancer pr
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	58976 : 58979	CM	Constitutively activated Wnt is also proinflammatory 
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	59100 : 59111	CM	d chronic tissue damage, resveratrol may also prevent tumor o
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59260 : 59271	CM	                         Resveratrol blocks PI3K and Akt sign
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	59279 : 59283	CM	      Resveratrol blocks PI3K and Akt signaling, which
./___Corpus/Medline/xml/PMC4898971.xml	cdk2	59358 : 59362	CM	[351], by downregulating cdk2, cyclin D1 and prolifera
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	59364 : 59370	CM	 by downregulating cdk2, cyclin D1 and proliferative cel
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	59433 : 59444	CM	igen. In ovarian cancer, resveratrol downregulates Akt and ER
./___Corpus/Medline/xml/PMC4898971.xml	ERK	59467 : 59470	CM	ol downregulates Akt and ERK signaling [352] (Fig. 6)
./___Corpus/Medline/xml/PMC4898971.xml	Akt	59543 : 59546	CM	te cancer growth via the Akt/miR-21 pathway [353]. Re
./___Corpus/Medline/xml/PMC4898971.xml	miR-21	59547 : 59553	CM	ancer growth via the Akt/miR-21 pathway [353]. Resveratr
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59569 : 59580	CM	kt/miR-21 pathway [353]. Resveratrol also suppresses phosphor
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	59597 : 59612	RN	veratrol also suppresses phosphorylation of the NF-κB inhibitor, 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	59620 : 59625	CM	s phosphorylation of the NF-κB inhibitor, IκB [354], th
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	59667 : 59672	CM	354], thereby inhibiting NF-κB [355]. Resveratrol also 
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59680 : 59691	CM	 inhibiting NF-κB [355]. Resveratrol also inhibits Hh [356] a
./___Corpus/Medline/xml/PMC4898971.xml	Hh	59706 : 59708	CM	esveratrol also inhibits Hh [356] and Jak2/STAT3 sig
./___Corpus/Medline/xml/PMC4898971.xml	STAT3	59724 : 59729	CM	hibits Hh [356] and Jak2/STAT3 signaling [357], which c
./___Corpus/Medline/xml/PMC4898971.xml	Resveratrol	59908 : 59919	CM	                         Resveratrol was shown to inhibit pro
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	59959 : 59964	CM	nhibit proliferation and NF-κB signaling in chemically 
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60046 : 60057	CM	 [358,359]. In addition, resveratrol affected the expression 
./___Corpus/Medline/xml/PMC4898971.xml	C2	60113 : 60115	CM	and forkhead box protein C2 by regulating miR-520h [
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60162 : 60173	CM	h [360], suggesting that resveratrol, like cucumin, mediates 
./___Corpus/Medline/xml/PMC4898971.xml	cucumin	60180 : 60187	CM	g that resveratrol, like cucumin, mediates its effects vi
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	60277 : 60288	CM	n vivo studies show that resveratrol has antitumor activity, 
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	60916 : 60926	CM	t.                  11.4 Flavonoids                      Fla
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	60948 : 60958	CM	ids                      Flavonoids are polyphenolic herbal 
./___Corpus/Medline/xml/PMC4898971.xml	polyphenolic	60963 : 60975	CM	          Flavonoids are polyphenolic herbal constituents with
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	61103 : 61113	CM	d anticancer activities. Flavonoids inhibit hormone related 
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61246 : 61256	CM	. Upon receptor binding, flavonoids reduce ERα association w
./___Corpus/Medline/xml/PMC4898971.xml	ERα	61264 : 61267	CM	nding, flavonoids reduce ERα association with the pla
./___Corpus/Medline/xml/PMC4898971.xml	ERα	61313 : 61316	CM	 plasma membrane, impair ERα dependent proliferative 
./___Corpus/Medline/xml/PMC4898971.xml	ERα	61409 : 61412	CM	hrough the activation of ERα-mediated p38/MAPK [365-3
./___Corpus/Medline/xml/PMC4898971.xml	p38	61422 : 61425	CM	tivation of ERα-mediated p38/MAPK [365-367]. This may
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	61426 : 61430	CM	tion of ERα-mediated p38/MAPK [365-367]. This may expl
./___Corpus/Medline/xml/PMC4898971.xml	365-	61432 : 61436	CPR	f ERα-mediated p38/MAPK [365-367]. This may explain th
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61518 : 61528	CM	e dietary consumption of flavonoids and the incidence of hor
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	61680 : 61690	CM	tential medicinal use of flavonoids for the treatment of ER 
./___Corpus/Medline/xml/PMC4898971.xml	ER	61712 : 61714	CM	ids for the treatment of ER related cancers, their l
./___Corpus/Medline/xml/PMC4898971.xml	Flavonoids	61860 : 61870	CM	, has limited their use. Flavonoids were reported to exhibit
./___Corpus/Medline/xml/PMC4898971.xml	P-glycoprotein	61940 : 61954	CM	ty to that of well known P-glycoprotein [P-gp] inhibitors (e.g.,
./___Corpus/Medline/xml/PMC4898971.xml	P-gp	61956 : 61960	CM	ll known P-glycoprotein [P-gp] inhibitors (e.g., verap
./___Corpus/Medline/xml/PMC4898971.xml	verapamil	61980 : 61989	CM	[P-gp] inhibitors (e.g., verapamil and cyclosporine), witho
./___Corpus/Medline/xml/PMC4898971.xml	cyclosporine	61994 : 62006	CM	ors (e.g., verapamil and cyclosporine), without toxicity to no
./___Corpus/Medline/xml/PMC4898971.xml	flavonoids	62055 : 62065	CM	ormal cells [371]. Thus, flavonoids have the potential of be
./___Corpus/Medline/xml/PMC4898971.xml	vincristine	62216 : 62227	CM	case with paclitaxel and vincristine in multidrug resistant t
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62416 : 62420	CM	t due to the presence of EGCG and other polyphenols (F
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	62431 : 62442	CM	esence of EGCG and other polyphenols (Fig. 5). EGCG suppresse
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62453 : 62457	CM	er polyphenols (Fig. 5). EGCG suppresses AR expression
./___Corpus/Medline/xml/PMC4898971.xml	AR	62469 : 62471	CM	Fig. 5). EGCG suppresses AR expression and signaling
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62498 : 62502	CM	xpression and signaling. EGCG also blocks the nuclear 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	62544 : 62549	CM	nuclear translocation of NF-κB as a result of decreased
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	62588 : 62593	CM	f decreased inhibitor of NF-κB kinase activity, thereby
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	62665 : 62676	CM	proliferation. Green tea polyphenols also downregulate MAPK a
./___Corpus/Medline/xml/PMC4898971.xml	VEGF	62713 : 62717	CM	gulate MAPK activity and VEGF production leading to a 
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62785 : 62789	CM	tion [374]. In addition, EGCG inhibits β-catenin nucle
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	62799 : 62808	CM	 addition, EGCG inhibits β-catenin nuclear accumulation and
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62894 : 62898	CM	genes (Fig. 6, Table 2). EGCG also exerts part of its 
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	62987 : 62991	CM	mechanisms. For example, EGCG can reverse CpG island h
./___Corpus/Medline/xml/PMC4898971.xml	CpG	63004 : 63007	CM	xample, EGCG can reverse CpG island hypermethylation 
./___Corpus/Medline/xml/PMC4898971.xml	hypermethylation	63015 : 63031	RN	G can reverse CpG island hypermethylation of various methylation s
./___Corpus/Medline/xml/PMC4898971.xml	methylation	63043 : 63054	RN	ermethylation of various methylation silenced genes and react
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63109 : 63113	CM	 their expression [375]. EGCG also upregulates such mi
./___Corpus/Medline/xml/PMC4898971.xml	miR-16	63146 : 63152	CM	regulates such miRNAs as miR-16, let-7c, miR-18, miR-25,
./___Corpus/Medline/xml/PMC4898971.xml	miR-18	63162 : 63168	CM	iRNAs as miR-16, let-7c, miR-18, miR-25, and miR-92 and 
./___Corpus/Medline/xml/PMC4898971.xml	miR-25	63170 : 63176	CM	 miR-16, let-7c, miR-18, miR-25, and miR-92 and downregu
./___Corpus/Medline/xml/PMC4898971.xml	miR-92	63182 : 63188	CM	-7c, miR-18, miR-25, and miR-92 and downregulates miR-12
./___Corpus/Medline/xml/PMC4898971.xml	miR-129	63207 : 63214	CM	miR-92 and downregulates miR-129, miR-196, miR-200, miR-3
./___Corpus/Medline/xml/PMC4898971.xml	miR-196	63216 : 63223	CM	d downregulates miR-129, miR-196, miR-200, miR-342, and m
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	63225 : 63232	CM	ulates miR-129, miR-196, miR-200, miR-342, and miR-526 [3
./___Corpus/Medline/xml/PMC4898971.xml	miR-342	63234 : 63241	CM	R-129, miR-196, miR-200, miR-342, and miR-526 [376]. Furt
./___Corpus/Medline/xml/PMC4898971.xml	miR-526	63247 : 63254	CM	6, miR-200, miR-342, and miR-526 [376]. Furtheremore, EGC
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63276 : 63280	CM	526 [376]. Furtheremore, EGCG affects the expression o
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1α	63307 : 63313	CM	ffects the expression of HIF-1α through the regulation o
./___Corpus/Medline/xml/PMC4898971.xml	miR-210	63340 : 63347	CM	hrough the regulation of miR-210 [377]. EGCG protects aga
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63355 : 63359	CM	lation of miR-210 [377]. EGCG protects against oxidati
./___Corpus/Medline/xml/PMC4898971.xml	lipids	63415 : 63421	CM	age of DNA, proteins and lipids by acting as a chaperone
./___Corpus/Medline/xml/PMC4898971.xml	VEGFR1	63505 : 63511	CM	ignaling pathways (e.g., VEGFR1/R2, EGFR/HER2, PI3K/Akt,
./___Corpus/Medline/xml/PMC4898971.xml	EGFR	63516 : 63520	CM	thways (e.g., VEGFR1/R2, EGFR/HER2, PI3K/Akt, IGF/IGFR
./___Corpus/Medline/xml/PMC4898971.xml	HER2	63521 : 63525	CM	s (e.g., VEGFR1/R2, EGFR/HER2, PI3K/Akt, IGF/IGFR1, an
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	63527 : 63531	CM	., VEGFR1/R2, EGFR/HER2, PI3K/Akt, IGF/IGFR1, and MAPK
./___Corpus/Medline/xml/PMC4898971.xml	IGF	63537 : 63540	CM	R2, EGFR/HER2, PI3K/Akt, IGF/IGFR1, and MAPK) [378], 
./___Corpus/Medline/xml/PMC4898971.xml	IGFR1	63541 : 63546	CM	EGFR/HER2, PI3K/Akt, IGF/IGFR1, and MAPK) [378], and st
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	63552 : 63556	CM	PI3K/Akt, IGF/IGFR1, and MAPK) [378], and strongly inh
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63647 : 63651	CM	nd Bcl-2 [379]. However, EGCG promoted DNA damage in m
./___Corpus/Medline/xml/PMC4898971.xml	leukaemic	63681 : 63690	CM	oted DNA damage in mouse leukaemic monocyte macrophage RAW 
./___Corpus/Medline/xml/PMC4898971.xml	RAW	63711 : 63714	CM	emic monocyte macrophage RAW 264.7 and human promyelo
./___Corpus/Medline/xml/PMC4898971.xml	HL-60	63754 : 63759	CM	n promyelocytic leukemia HL-60 cell lines in a dose dep
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63805 : 63809	CM	 dependent manner [380]. EGCG has also been associated
./___Corpus/Medline/xml/PMC4898971.xml	EGCG	63990 : 63994	CM	roperties and targets of EGCG and many other natural c
./___Corpus/Medline/xml/PMC4898971.xml	isoflavone	64356 : 64366	CM	         Genistein is an isoflavone in soy that inhibits pro
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	64503 : 64508	CM	ig. 5). Genistein blocks NF-κB [384], promotes apoptosi
./___Corpus/Medline/xml/PMC4898971.xml	EGF	64623 : 64626	CM	ive activity by blocking EGF signaling through forkhe
./___Corpus/Medline/xml/PMC4898971.xml	O3	64658 : 64660	CM	ing through forkhead box O3 activity [386,387], has 
./___Corpus/Medline/xml/PMC4898971.xml	transgenic	65034 : 65044	CM	te carcinogenesis in the transgenic adenocarcinoma of the mo
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65106 : 65115	CM	 model via inhibition of β-catenin signaling [392]. Treatme
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	65156 : 65159	CM	. Treatment also reduced Wnt signaling in mammary epi
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65280 : 65289	CM	e 2). Genistein inhibits β-catenin/TCF transcriptional acti
./___Corpus/Medline/xml/PMC4898971.xml	TCF	65290 : 65293	CM	stein inhibits β-catenin/TCF transcriptional activity
./___Corpus/Medline/xml/PMC4898971.xml	GSK3-β	65329 : 65335	CM	ional activity, promotes GSK3-β activation (which phosph
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylates	65354 : 65368	CM	GSK3-β activation (which phosphorylates and promotes degradation
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	65397 : 65406	CM	 promotes degradation of β-catenin), and upregulates expres
./___Corpus/Medline/xml/PMC4898971.xml	E-	65439 : 65441	CPR	pregulates expression of E-cadherin (Fig. 6, Table 2
./___Corpus/Medline/xml/PMC4898971.xml	phytoestrogen	65474 : 65487	CM	 (Fig. 6, Table 2). As a phytoestrogen, genistein acts through 
./___Corpus/Medline/xml/PMC4898971.xml	genistein	65489 : 65498	CM	 2). As a phytoestrogen, genistein acts through binding to 
./___Corpus/Medline/xml/PMC4898971.xml	ER	65527 : 65529	CM	s through binding to the ER. ERα activation leads to
./___Corpus/Medline/xml/PMC4898971.xml	ERα	65531 : 65534	CM	rough binding to the ER. ERα activation leads to cell
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	65585 : 65588	CM	proliferation [395], and ERβ activation promotes cell
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	65641 : 65644	CM	r differentiation [396]. ERβ signaling counteracts ER
./___Corpus/Medline/xml/PMC4898971.xml	ERα	65667 : 65670	CM	Rβ signaling counteracts ERα related proliferation. G
./___Corpus/Medline/xml/PMC4898971.xml	ERβ	65729 : 65732	CM	preferentially activates ERβ-mediated gene transcript
./___Corpus/Medline/xml/PMC4898971.xml	genistein	65863 : 65872	CM	rentiation. In addition, genistein affects the expression o
./___Corpus/Medline/xml/PMC4898971.xml	miR-200	65934 : 65941	CM	8], such as upregulating miR-200 [328]. However, its ther
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66024 : 66033	CM	been consistent, in that genistein exhibited a cancer promo
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66237 : 66246	CM	ation dependent, because genistein inhibited cell prolifera
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	66316 : 66324	CM	rations and activated of estrogen signaling at low concent
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66408 : 66417	CM	exploit the potential of genistein and limit off target eff
./___Corpus/Medline/xml/PMC4898971.xml	EGF	66656 : 66659	CM	n coupled to recombinant EGF and then used to treat p
./___Corpus/Medline/xml/PMC4898971.xml	EGFR+	66697 : 66702	CM	d to treat patients with EGFR+ breast cancer [401]. Add
./___Corpus/Medline/xml/PMC4898971.xml	genistein	66756 : 66765	CM	nal human studies, where genistein is coupled to specific l
./___Corpus/Medline/xml/PMC4898971.xml	polyphenols	67017 : 67028	CM	agitannins are bioactive polyphenols found in berries and pom
./___Corpus/Medline/xml/PMC4898971.xml	hydrolyzed	67210 : 67220	RN	the blood stream but are hydrolyzed to ellagic acid. They ar
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	67379 : 67384	CM	tion by interfering with NF-κB activity [402]. Ellagita
./___Corpus/Medline/xml/PMC4898971.xml	Urolithin	67554 : 67563	CM	ated angiogenesis [403]. Urolithin significantly inhibited 
./___Corpus/Medline/xml/PMC4898971.xml	testosterone	67588 : 67600	CM	 significantly inhibited testosterone induced MCF-7aro cell pr
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	67818 : 67827	CM	n through suppression of β-catenin and NF-κB pathways in di
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	67832 : 67837	CM	ression of β-catenin and NF-κB pathways in diethylnitro
./___Corpus/Medline/xml/PMC4898971.xml	diethylnitrosamine	67850 : 67868	CM	in and NF-κB pathways in diethylnitrosamine induced hepatocarcinogen
./___Corpus/Medline/xml/PMC4898971.xml	PSA	68004 : 68007	CM	ostate specific antigen (PSA) levels after primary tr
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68208 : 68216	CM	].                  11.8 Lycopene                      Lyc
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68238 : 68246	CM	ene                      Lycopene is a lipid soluble carot
./___Corpus/Medline/xml/PMC4898971.xml	lipid	68252 : 68257	CM	           Lycopene is a lipid soluble carotenoid molec
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68343 : 68351	CM	ed fruit and vegetables. Lycopene has a significant antiox
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68449 : 68457	CM	hown that consumption of lycopene is inversely related to 
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68515 : 68523	CM	ostate cancer [408,409]. Lycopene blocked cell growth in b
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	68607 : 68612	CM	ncer cells by inhibiting NF-κB activity [410]. In colon
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68652 : 68660	CM	. In colon cancer cells, lycopene inhibited Akt signaling.
./___Corpus/Medline/xml/PMC4898971.xml	Lycopene	68686 : 68694	CM	inhibited Akt signaling. Lycopene treatment suppressed Akt
./___Corpus/Medline/xml/PMC4898971.xml	phosphorylation	68746 : 68761	RN	ctivation, increased the phosphorylation (inactivation) of β-cate
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	68780 : 68789	CM	lation (inactivation) of β-catenin, and stimulated expressi
./___Corpus/Medline/xml/PMC4898971.xml	cdk	68820 : 68823	CM	stimulated expression of cdk inhibitor p27Kip1 [411].
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	68862 : 68870	CM	Kip1 [411]. In addition, lycopene inhibited IGF-1-mediated
./___Corpus/Medline/xml/PMC4898971.xml	IGF-1	68881 : 68886	CM	tion, lycopene inhibited IGF-1-mediated Akt and AR sign
./___Corpus/Medline/xml/PMC4898971.xml	AR	68904 : 68906	CM	d IGF-1-mediated Akt and AR signaling in rat prostat
./___Corpus/Medline/xml/PMC4898971.xml	AR	68952 : 68954	CM	state cancer and reduced AR and β-catenin nuclear lo
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	68959 : 68968	CM	ancer and reduced AR and β-catenin nuclear localization [41
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69048 : 69056	CM	ver, failed to show that lycopene altered cell proliferati
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69146 : 69154	CM	ven these circumstances, lycopene and many other natural p
./___Corpus/Medline/xml/PMC4898971.xml	vitamin	69223 : 69230	CM	ly available as herb and vitamin supplements that are not
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	69408 : 69416	CM	ed to clarify the use of lycopene in cancer therapy.      
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin

                    Quercetin	69458 : 69498	CM	y.                  11.9 Quercetin                      Quercetin, a natural protective bi
./___Corpus/Medline/xml/PMC4898971.xml	bioflavonoid	69521 : 69533	CM	in, a natural protective bioflavonoid, possesses diverse pharm
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin	69665 : 69674	CM	tiangiogenic activities. Quercetin, at nontoxic concentrati
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	69736 : 69740	CM	cantly inhibited Akt and mTOR. Moreover, quercetin exh
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	69752 : 69761	CM	 Akt and mTOR. Moreover, quercetin exhibited antitumor acti
./___Corpus/Medline/xml/PMC4898971.xml	Quercetin	69886 : 69895	CM	graft mouse model [414]. Quercetin inhibited P-gp function 
./___Corpus/Medline/xml/PMC4898971.xml	P-gp	69906 : 69910	CM	14]. Quercetin inhibited P-gp function and consequentl
./___Corpus/Medline/xml/PMC4898971.xml	tamoxifen	70013 : 70022	CM	ents [415]. Furthermore, tamoxifen underwent extensive hepa
./___Corpus/Medline/xml/PMC4898971.xml	P-gp	70095 : 70099	CM	strate for the efflux of P-gp, breast cancer resistanc
./___Corpus/Medline/xml/PMC4898971.xml	cytochrome	70218 : 70228	CM	 the metabolizing enzyme cytochrome P450, family 3, subfamil
./___Corpus/Medline/xml/PMC4898971.xml	quercetin	70299 : 70308	CM	 resistance transporter, quercetin increased the absorption
./___Corpus/Medline/xml/PMC4898971.xml	tamoxifen	70361 : 70370	CM	d the bioavailability of tamoxifen [416].                  
./___Corpus/Medline/xml/PMC4898971.xml	13-cis-retinoic acid	70535 : 70555	CM	or proliferation such as 13-cis-retinoic acid which significantly inte
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	70608 : 70613	CM	res with the activity of NF-κB, c-Fos, activated transc
./___Corpus/Medline/xml/PMC4898971.xml	c-Fos	70615 : 70620	CM	h the activity of NF-κB, c-Fos, activated transcription
./___Corpus/Medline/xml/PMC4898971.xml	factor-2	70646 : 70654	CM	 activated transcription factor-2, and cyclic adenosine mo
./___Corpus/Medline/xml/PMC4898971.xml	adenosine monophosphate	70667 : 70690	CM	ion factor-2, and cyclic adenosine monophosphate response element binding
./___Corpus/Medline/xml/PMC4898971.xml	parthenolide	70820 : 70832	CM	atural products, such as parthenolide, the active component in
./___Corpus/Medline/xml/PMC4898971.xml	Parthenolide	70954 : 70966	CM	inflammatory activities. Parthenolide exhibited strong NF-κB- 
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	70984 : 70989	CM	enolide exhibited strong NF-κB- and STAT-inhibition med
./___Corpus/Medline/xml/PMC4898971.xml	Momordica	71239 : 71248	CM	r example, bitter melon (Momordica charantia), which is use
./___Corpus/Medline/xml/PMC4898971.xml	421-	71664 : 71668	CPR	ty of cancer cell lines [421-424]. To appreciate their
./___Corpus/Medline/xml/PMC4898971.xml	lycopene	72600 : 72608	CM	mechanisms. For example, lycopene supplements reduced tumo
./___Corpus/Medline/xml/PMC4898971.xml	PSA	72644 : 72647	CM	s reduced tumor size and PSA levels in localized pros
./___Corpus/Medline/xml/PMC4898971.xml	AR	72743 : 72745	CM	t with the inhibition of AR nuclear translocation th
./___Corpus/Medline/xml/PMC4898971.xml	vitro	72789 : 72794	CM	ion that was found by in vitro studies. Many of these b
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	74389 : 74397	CM	pounds, a combination of curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4898971.xml	genistein	74399 : 74408	CM	combination of curcumin, genistein and resveratrol is sugge
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	74413 : 74424	CM	 curcumin, genistein and resveratrol is suggested because the
./___Corpus/Medline/xml/PMC4898971.xml	vitro	74636 : 74641	CM	sed experimentally in in vitro studies vastly exceeds t
./___Corpus/Medline/xml/PMC4898971.xml	428-	77791 : 77795	CPR	anism genome assemblies [428-431], new genome based te
./___Corpus/Medline/xml/PMC4898971.xml	ENCODE	78964 : 78970	CM	peutically targeted. The ENCODE project has functionally
./___Corpus/Medline/xml/PMC4898971.xml	NCBI's	79195 : 79201	CM	curated databases (e.g., NCBI's GenBank, Sanger Institut
./___Corpus/Medline/xml/PMC4898971.xml	California	79243 : 79253	CM	Institute, University of California, Santa Cruz Genome Brows
./___Corpus/Medline/xml/PMC4898971.xml	E-	81272 : 81274	CPR	ked in order to maintain E-cadherin expression and t
./___Corpus/Medline/xml/PMC4898971.xml	EMT	81330 : 81333	CM	integrity and to prevent EMT. Once E-cadherin is lost
./___Corpus/Medline/xml/PMC4898971.xml	E-	81340 : 81342	CPR	and to prevent EMT. Once E-cadherin is lost, and hyp
./___Corpus/Medline/xml/PMC4898971.xml	mTOR	81500 : 81504	CM	Hsp90, topoisomerase, or mTOR. Targeting the generatio
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	81545 : 81549	CM	generation and growth of CSCs will be a major challeng
./___Corpus/Medline/xml/PMC4898971.xml	CSCs	81637 : 81641	CM	ntified pathways between CSCs and SCs. Maintaining CSC
./___Corpus/Medline/xml/PMC4898971.xml	SCs	81646 : 81649	CM	athways between CSCs and SCs. Maintaining CSC dormanc
./___Corpus/Medline/xml/PMC4898971.xml	CSC	81663 : 81666	CM	SCs and SCs. Maintaining CSC dormancy may prevent rea
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	81877 : 81880	CM	 be done. Antagonists of Wnt, Hh and MAPK p38 signali
./___Corpus/Medline/xml/PMC4898971.xml	Hh	81882 : 81884	CM	one. Antagonists of Wnt, Hh and MAPK p38 signaling m
./___Corpus/Medline/xml/PMC4898971.xml	MAPK	81889 : 81893	CM	tagonists of Wnt, Hh and MAPK p38 signaling may be of 
./___Corpus/Medline/xml/PMC4898971.xml	EBPα	81957 : 81961	CM	this, while increasing C/EBPα expression, which promot
./___Corpus/Medline/xml/PMC4898971.xml	CSC	82017 : 82020	CM	ferentiation, might push CSC into a therapy sensitive
./___Corpus/Medline/xml/PMC4898971.xml	β-catenin	82068 : 82077	CM	ve state. In addition to β-catenin, there is rationale to s
./___Corpus/Medline/xml/PMC4898971.xml	HER2	82128 : 82132	CM	ek antagonists of Notch, HER2/ErbB2 and the IGF-1/IGFR
./___Corpus/Medline/xml/PMC4898971.xml	ErbB2	82133 : 82138	CM	tagonists of Notch, HER2/ErbB2 and the IGF-1/IGFR1 sign
./___Corpus/Medline/xml/PMC4898971.xml	IGF-1	82147 : 82152	CM	otch, HER2/ErbB2 and the IGF-1/IGFR1 signaling pathways
./___Corpus/Medline/xml/PMC4898971.xml	IGFR1	82153 : 82158	CM	HER2/ErbB2 and the IGF-1/IGFR1 signaling pathways, sinc
./___Corpus/Medline/xml/PMC4898971.xml	fate	82211 : 82215	CM	hese are central to cell fate decisions and are often 
./___Corpus/Medline/xml/PMC4898971.xml	cyclin	82328 : 82334	CM	l be important to target cyclin D and cdk4/6. Among horm
./___Corpus/Medline/xml/PMC4898971.xml	cdk4	82341 : 82345	CM	t to target cyclin D and cdk4/6. Among hormone sensiti
./___Corpus/Medline/xml/PMC4898971.xml	ER	82382 : 82384	CM	rmone sensitive cancers, ER and AR are prime targets
./___Corpus/Medline/xml/PMC4898971.xml	AR	82389 : 82391	CM	ensitive cancers, ER and AR are prime targets for th
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	82987 : 82992	CM	re as well. For example, HIF-1 signaling is an importan
./___Corpus/Medline/xml/PMC4898971.xml	hypoxic	83206 : 83213	CM	urvival and growth under hypoxic conditions, it may be a 
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	83409 : 83414	CM	ly that drugs that block HIF-1 signaling will be effect
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	83533 : 83537	CM	her pathways, inhibiting PI3K/Akt signaling would bloc
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	83603 : 83606	CM	lmarks, while inhibiting Wnt signaling would block at
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	83686 : 83691	CM	Table 6). Since blocking NF-κB or Wnt signaling promote
./___Corpus/Medline/xml/PMC4898971.xml	Wnt	83695 : 83698	CM	 Since blocking NF-κB or Wnt signaling promote or sup
./___Corpus/Medline/xml/PMC4898971.xml	androgen	83935 : 83943	CM	ly promote the growth of androgen and estrogen dependent t
./___Corpus/Medline/xml/PMC4898971.xml	estrogen	83948 : 83956	CM	e growth of androgen and estrogen dependent tumors (Table 
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	84741 : 84749	CM	rmed. Table 7 shows that curcumin, which targets HIF-1, NF
./___Corpus/Medline/xml/PMC4898971.xml	HIF-1	84765 : 84770	CM	 curcumin, which targets HIF-1, NF-κB, and PI3K/Akt sig
./___Corpus/Medline/xml/PMC4898971.xml	NF-κB	84772 : 84777	CM	in, which targets HIF-1, NF-κB, and PI3K/Akt signaling 
./___Corpus/Medline/xml/PMC4898971.xml	PI3K	84783 : 84787	CM	argets HIF-1, NF-κB, and PI3K/Akt signaling (Table 5),
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	84972 : 84983	CM	f the 10 hallmarks while resveratrol is effective in 8 of 10.
./___Corpus/Medline/xml/PMC4898971.xml	genistein	85235 : 85244	CM	reported. In the case of genistein, it is not clear whether
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	85423 : 85434	CM	moting inflammation. For resveratrol, different reports docum
./___Corpus/Medline/xml/PMC4898971.xml	curcumin	85814 : 85822	CM	combination therapy with curcumin, genistein and resveratr
./___Corpus/Medline/xml/PMC4898971.xml	genistein	85824 : 85833	CM	n therapy with curcumin, genistein and resveratrol may be e
./___Corpus/Medline/xml/PMC4898971.xml	resveratrol	85838 : 85849	CM	 curcumin, genistein and resveratrol may be effective against
./___Corpus/Medline/xml/PMC4898971.xml	1-	86108 : 86110	CPR	                 Authors 1-13 contributed to the bul
./___Corpus/Medline/xml/PMC4898971.xml	NIH	86269 : 86272	CM	manyan were supported by NIH (AI076535) and by Temple
./___Corpus/Medline/xml/PMC4898971.xml	THALES	86810 : 86816	CM	esearch Funding Program: THALES (MIS 379346) and COST Ac
./___Corpus/Medline/xml/PMC4898971.xml	Dr	86885 : 86887	CM	etic Radical Chemistry.’ Dr. Amedei was supported by
./___Corpus/Medline/xml/PMC4898971.xml	Amin	86977 : 86981	CM	University of Italy. Dr. Amin was supported by the Ter
./___Corpus/Medline/xml/PMC4898971.xml	FEDER	87199 : 87204	CM	-Garcia was supported by FEDER, by MICINN (SAF2012-3281
./___Corpus/Medline/xml/PMC4898971.xml	MICINN	87209 : 87215	CM	s supported by FEDER, by MICINN (SAF2012-32810), by NIH 
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87236 : 87239	CM	CINN (SAF2012-32810), by NIH (R01 CA109335-04A1), by 
./___Corpus/Medline/xml/PMC4898971.xml	León	87284 : 87288	CM	, by Junta de Castilla y León (BIO/SA06/13), by the AR
./___Corpus/Medline/xml/PMC4898971.xml	BIO	87290 : 87293	CM	unta de Castilla y León (BIO/SA06/13), by the ARIMMOR
./___Corpus/Medline/xml/PMC4898971.xml	SA06	87294 : 87298	CM	 de Castilla y León (BIO/SA06/13), by the ARIMMORA pro
./___Corpus/Medline/xml/PMC4898971.xml	ARIMMORA	87311 : 87319	CM	ón (BIO/SA06/13), by the ARIMMORA project (FP7-ENV-2011, E
./___Corpus/Medline/xml/PMC4898971.xml	FP7-ENV-2011	87329 : 87341	CM	by the ARIMMORA project (FP7-ENV-2011, EU 7th Framework Progra
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87449 : 87452	CM	Dr. Sharma was funded by NIH grants (R01CA131294, CA1
./___Corpus/Medline/xml/PMC4898971.xml	R01CA131294	87461 : 87472	CM	as funded by NIH grants (R01CA131294, CA155686), the Avon Fou
./___Corpus/Medline/xml/PMC4898971.xml	NIH	87604 : 87607	CM	upported by a grant from NIH (K01DK077137 and R03DK08
./___Corpus/Medline/xml/PMC4898971.xml	FT	87758 : 87760	CM	nd Technology, India (SR/FT/LS-063/2008). Dr. Honoki
./___Corpus/Medline/xml/PMC4898971.xml	AIRC	87980 : 87984	CM	ion for Cancer Research (AIRC - grant #IG10636). Dr. A
./___Corpus/Medline/xml/PMC4898971.xml	#IG10636	87993 : 88001	CM	r Research (AIRC - grant #IG10636). Dr. Aquilano was suppo
./___Corpus/Medline/xml/PMC4898971.xml	MIUR-PRIN	88034 : 88043	CM	quilano was supported by MIUR-PRIN (20125S38FA_002) and Min
./___Corpus/Medline/xml/PMC4898971.xml	PDF	88346 : 88349	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4905370.xml	Poly(ADP-ribose)	30 : 46	CM	ACT                      Poly(ADP-ribose) polymerases (PARPs) are 
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribosyl)ation	116 : 138	RN	of enzymes that catalyze poly(ADP-ribosyl)ation (PARylation) and/or mono
./___Corpus/Medline/xml/PMC4905370.xml	mono(ADP-ribosyl)ation	159 : 181	CM	tion (PARylation) and/or mono(ADP-ribosyl)ation (MARylation), two post-t
./___Corpus/Medline/xml/PMC4905370.xml	MARylation	183 : 193	CM	 mono(ADP-ribosyl)ation (MARylation), two post-translational
./___Corpus/Medline/xml/PMC4905370.xml	DDR	336 : 339	CM	the DNA damage response (DDR). PARP1, the most abunda
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	342 : 347	CM	A damage response (DDR). PARP1, the most abundant famil
./___Corpus/Medline/xml/PMC4905370.xml	PARylating	502 : 512	RN	s to their resolution by PARylating multiple DDR players. Re
./___Corpus/Medline/xml/PMC4905370.xml	DDR	577 : 580	CM	uggests that, along with DDR, activated PARP1 mediate
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	592 : 597	CM	long with DDR, activated PARP1 mediates a series of pro
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	780 : 785	CM	and/or overactivation of PARP1 or other PARP enzymes ha
./___Corpus/Medline/xml/PMC4905370.xml	PARP	795 : 799	CM	vation of PARP1 or other PARP enzymes has been reporte
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	922 : 927	CM	rmacologic inhibitors of PARP1 and PARP2 have been asse
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	932 : 937	CM	 inhibitors of PARP1 and PARP2 have been assessed in pr
./___Corpus/Medline/xml/PMC4905370.xml	PARP	1169 : 1173	CM	e describe the impact of PARP enzymes and PARylation i
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	1256 : 1261	CM	f cancer cell killing by PARP1 inactivation, and summar
./___Corpus/Medline/xml/PMC4905370.xml	PARP	1387 : 1391	CM	d therapeutic profile of PARP inhibitors in cancer pat
./___Corpus/Medline/xml/PMC4905370.xml	Poly(ADP-ribosyl)ation	1488 : 1510	RN	ion                      Poly(ADP-ribosyl)ation (PARylation) is a post-t
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	1605 : 1621	CM	alyzed by members of the poly(ADP-ribose) polymerase (PARP) enzyme
./___Corpus/Medline/xml/PMC4905370.xml	PARP	1634 : 1638	CM	(ADP-ribose) polymerase (PARP) enzyme family (i.e., PA
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	1661 : 1666	CM	RP) enzyme family (i.e., PARP1, PARP2, tankyrase, TRF1-
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	1668 : 1673	CM	yme family (i.e., PARP1, PARP2, tankyrase, TRF1-interac
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	1719 : 1729	CM	eracting ankyrin-related ADP-ribose polymerase [TNKS] and TN
./___Corpus/Medline/xml/PMC4905370.xml	TNKS	1742 : 1746	CM	d ADP-ribose polymerase [TNKS] and TNKS2) and has cruc
./___Corpus/Medline/xml/PMC4905370.xml	TNKS2	1752 : 1757	CM	se polymerase [TNKS] and TNKS2) and has crucial functio
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	1927 : 1937	CM	multibranched polymer of ADP-ribose units from the respirato
./___Corpus/Medline/xml/PMC4905370.xml	nicotinamide adenine dinucleotide	1975 : 2008	CM	he respiratory co-enzyme nicotinamide adenine dinucleotide (NAD+) to DNA or multipl
./___Corpus/Medline/xml/PMC4905370.xml	NAD+	2010 : 2014	CM	de adenine dinucleotide (NAD+) to DNA or multiple acce
./___Corpus/Medline/xml/PMC4905370.xml	PARP	2266 : 2270	CM	ver, most members of the PARP family, which includes 1
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	2361 : 2371	CM	e covalent attachment of ADP-ribose onto acceptor proteins a
./___Corpus/Medline/xml/PMC4905370.xml	mono(ADP-ribose)	2409 : 2425	CM	r proteins as a monomer (mono(ADP-ribose), MAR) instead of a polym
./___Corpus/Medline/xml/PMC4905370.xml	MAR	2427 : 2430	CM	nomer (mono(ADP-ribose), MAR) instead of a polymer (P
./___Corpus/Medline/xml/PMC4905370.xml	PAR	2454 : 2457	CM	R) instead of a polymer (PAR) (reviewed in ref. 6).6 
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribosyltransferase	2531 : 2553	CM	rs to suggest the use of ADP-ribosyltransferase (ARTD) as an official un
./___Corpus/Medline/xml/PMC4905370.xml	ARTD	2555 : 2559	CM	 ADP-ribosyltransferase (ARTD) as an official unifying
./___Corpus/Medline/xml/PMC4905370.xml	PARP	2648 : 2652	CM	view of functions of the PARP family can be found in s
./___Corpus/Medline/xml/PMC4905370.xml	PARylation	2739 : 2749	RN	                         PARylation is considered to be a ke
./___Corpus/Medline/xml/PMC4905370.xml	DDR	2809 : 2812	CM	the DNA damage response (DDR), a complex signal trans
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	2974 : 2979	CM	stability.17-21 To date, PARP1, PARP2, and PARP3 are th
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	2981 : 2986	CM	ty.17-21 To date, PARP1, PARP2, and PARP3 are the only 
./___Corpus/Medline/xml/PMC4905370.xml	PARP3	2992 : 2997	CM	 date, PARP1, PARP2, and PARP3 are the only family memb
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	3131 : 3136	CM	A damage,7,10,15,22 with PARP1 being responsible for th
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	3209 : 3214	CM	0% of the lesions.3,4,23 PARP1, the most abundant isofo
./___Corpus/Medline/xml/PMC4905370.xml	isoform	3234 : 3241	CM	PARP1, the most abundant isoform of the PARP enzyme famil
./___Corpus/Medline/xml/PMC4905370.xml	PARP	3249 : 3253	CM	 abundant isoform of the PARP enzyme family, is a nucl
./___Corpus/Medline/xml/PMC4905370.xml	SSBs	3342 : 3346	CM	th single-strand breaks (SSBs) and double-strand break
./___Corpus/Medline/xml/PMC4905370.xml	(DSBs),24,25	3373 : 3385	CM	and double-strand breaks (DSBs),24,25 and thereby participates
./___Corpus/Medline/xml/PMC4905370.xml	(BER),26-31 nucleotide	3486 : 3508	CM	ing base excision repair (BER),26-31 nucleotide excision repair (NER),32
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	3658 : 3663	CM	                         PARP1 contains 6 functional do
./___Corpus/Medline/xml/PMC4905370.xml	amino	3697 : 3702	CM	 6 functional domains: 3 amino (N)-terminal homologous 
./___Corpus/Medline/xml/PMC4905370.xml	zinc	3727 : 3731	CM	 (N)-terminal homologous zinc finger (Zn) domains, 2 o
./___Corpus/Medline/xml/PMC4905370.xml	Zn	3740 : 3742	CM	 homologous zinc finger (Zn) domains, 2 of which (Zn
./___Corpus/Medline/xml/PMC4905370.xml	Zn1	3765 : 3768	CM	Zn) domains, 2 of which (Zn1 and Zn2) are responsible
./___Corpus/Medline/xml/PMC4905370.xml	Zn2	3773 : 3776	CM	ins, 2 of which (Zn1 and Zn2) are responsible for DNA
./___Corpus/Medline/xml/PMC4905370.xml	Zn3	3838 : 3841	CM	ction whereas the third (Zn3) couples DNA binding and
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	3940 : 3945	CM	t cancer 1, early onset (BRCA1) C-terminal (BRCT) regio
./___Corpus/Medline/xml/PMC4905370.xml	C-	3948 : 3950	CPR	 1, early onset (BRCA1) C-terminal (BRCT) region and
./___Corpus/Medline/xml/PMC4905370.xml	tryptophan	3980 : 3990	CM	al (BRCT) region and the tryptophan, glycine, and arginine (
./___Corpus/Medline/xml/PMC4905370.xml	glycine	3992 : 3999	CM	gion and the tryptophan, glycine, and arginine (WGR) modu
./___Corpus/Medline/xml/PMC4905370.xml	arginine	4005 : 4013	CM	tryptophan, glycine, and arginine (WGR) module, both of wh
./___Corpus/Medline/xml/PMC4905370.xml	WGR	4015 : 4018	CM	, glycine, and arginine (WGR) module, both of which a
./___Corpus/Medline/xml/PMC4905370.xml	carboxy	4092 : 4099	CM	rotein interactions; and carboxy (C)-terminal catalytic d
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	4160 : 4170	CM	h sequentially transfers ADP-ribose subunits from the donor 
./___Corpus/Medline/xml/PMC4905370.xml	NAD+	4195 : 4199	CM	 subunits from the donor NAD+ to acceptor proteins.5,2
./___Corpus/Medline/xml/PMC4905370.xml	SSBs	4317 : 4321	CM	 of DNA lesions, such as SSBs, DSBs, DNA crosslinks, a
./___Corpus/Medline/xml/PMC4905370.xml	DSBs	4323 : 4327	CM	A lesions, such as SSBs, DSBs, DNA crosslinks, and sta
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	4376 : 4381	CM	alled replication forks, PARP1 engages at the site of d
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	4480 : 4485	CM	ates that the binding of PARP1 to damaged DNA via the 3
./___Corpus/Medline/xml/PMC4905370.xml	N-	4512 : 4514	CPR	o damaged DNA via the 3 N-terminal Zn domains induce
./___Corpus/Medline/xml/PMC4905370.xml	Zn	4522 : 4524	CM	DNA via the 3 N-terminal Zn domains induces a confor
./___Corpus/Medline/xml/PMC4905370.xml	WGR	4579 : 4582	CM	nal rearrangement in the WGR domain, which in turn le
./___Corpus/Medline/xml/PMC4905370.xml	PARP	4692 : 4696	CM	he catalytic activity of PARP is allosterically enhanc
./___Corpus/Medline/xml/PMC4905370.xml	10-	4726 : 4729	CPR	llosterically enhanced 10- to 500-fold within 15 to 3
./___Corpus/Medline/xml/PMC4905370.xml	500-fold	4731 : 4739	CM	erically enhanced 10- to 500-fold within 15 to 30 s of DNA
./___Corpus/Medline/xml/PMC4905370.xml	PARP	4792 : 4796	CM	nding. The activation of PARP results in massive synth
./___Corpus/Medline/xml/PMC4905370.xml	PAR	4879 : 4882	CM	long linear and branched PAR chains (PAR polymers) on
./___Corpus/Medline/xml/PMC4905370.xml	PAR	4891 : 4894	CM	and branched PAR chains (PAR polymers) on several pro
./___Corpus/Medline/xml/PMC4905370.xml	histones	4983 : 4991	CM	uding nucleosomal/linker histones, topoisomerase I, and PA
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	5014 : 5019	CM	es, topoisomerase I, and PARP1 itself.3,43-45          
./___Corpus/Medline/xml/PMC4905370.xml	PARylation	5073 : 5083	RN	                         PARylation contributes to DNA damag
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5195 : 5198	CM	gative charge carried by PAR polymers induces extensi
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5226 : 5235	CM	lymers induces extensive chromatin relaxation at the damage
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5294 : 5297	CM	,47 Second, once formed, PAR polymers are recognized 
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5348 : 5351	CM	y a panoply of proteins (PAR-binding proteins) via on
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5387 : 5390	CM	oteins) via one of the 4 PAR-binding domains identifi
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5453 : 5456	CM	viewed in ref. 6).6 This PAR-mediated recruitment con
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5493 : 5502	CM	cruitment contributes to chromatin remodeling and sets the 
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5584 : 5587	CM	 Third, the formation of PAR polymers diminishes the 
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	5624 : 5629	CM	minishes the affinity of PARP1 and histones for DNA, pr
./___Corpus/Medline/xml/PMC4905370.xml	histones	5634 : 5642	CM	he affinity of PARP1 and histones for DNA, providing a mec
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	5687 : 5692	CM	a mechanism for removing PARP1 from damaged DNA and res
./___Corpus/Medline/xml/PMC4905370.xml	chromatin	5724 : 5733	CM	amaged DNA and restoring chromatin compaction.55-57 Further
./___Corpus/Medline/xml/PMC4905370.xml	hydrolyze	5817 : 5826	CM	onized by 2 enzymes that hydrolyze PAR, poly(ADP-ribose) gl
./___Corpus/Medline/xml/PMC4905370.xml	PAR	5827 : 5830	CM	2 enzymes that hydrolyze PAR, poly(ADP-ribose) glycoh
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	5832 : 5848	CM	ymes that hydrolyze PAR, poly(ADP-ribose) glycohydrolase (PARG) an
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribosylhydrolase	5875 : 5895	CM	lycohydrolase (PARG) and ADP-ribosylhydrolase like 2 (ADPRHL2, best kn
./___Corpus/Medline/xml/PMC4905370.xml	ADPRHL2	5904 : 5911	CM	ribosylhydrolase like 2 (ADPRHL2, best known as ARH3).58,
./___Corpus/Medline/xml/PMC4905370.xml	O-acyl-ADP-ribose	5948 : 5965	CM	 as ARH3).58,59 Of note, O-acyl-ADP-ribose deacylase 1 (OARD1, best
./___Corpus/Medline/xml/PMC4905370.xml	OARD1	5979 : 5984	CM	-ADP-ribose deacylase 1 (OARD1, best known as TARG1) is
./___Corpus/Medline/xml/PMC4905370.xml	TARG1	6000 : 6005	CM	 1 (OARD1, best known as TARG1) is believed to be respo
./___Corpus/Medline/xml/PMC4905370.xml	ADP-ribose	6065 : 6075	CM	 removal of the terminal ADP-ribose monomer.60 The concerted
./___Corpus/Medline/xml/PMC4905370.xml	PAR	6133 : 6136	CM	of these enzymes removes PAR polymers from PARP1, res
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	6151 : 6156	CM	emoves PAR polymers from PARP1, restoring its ability t
./___Corpus/Medline/xml/PMC4905370.xml	PARylation	6326 : 6336	RN	 evidence indicates that PARylation by this arsenal of enzym
./___Corpus/Medline/xml/PMC4905370.xml	arsenal	6345 : 6352	CM	 that PARylation by this arsenal of enzymatic tools not o
./___Corpus/Medline/xml/PMC4905370.xml	fate	6491 : 6495	CM	DNA but also drives cell fate decisions in response to
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	6596 : 6601	CM	.14 Indeed, the roles of PARP1 in the cell span from ma
./___Corpus/Medline/xml/PMC4905370.xml	PARP	6706 : 6710	CM	hanatos).61-64 Moreover, PARP hyperactivation (for ins
./___Corpus/Medline/xml/PMC4905370.xml	DDR	6748 : 6751	CM	ion (for instance during DDR) may deplete intracellul
./___Corpus/Medline/xml/PMC4905370.xml	NAD+	6789 : 6793	CM	 intracellular stores of NAD+ thus undermining NAD+-de
./___Corpus/Medline/xml/PMC4905370.xml	NAD+	6811 : 6815	CM	of NAD+ thus undermining NAD+-dependent processes, inc
./___Corpus/Medline/xml/PMC4905370.xml	glucose	6868 : 6875	CM	ing (but not limited to) glucose metabolism,3,41 and/or l
./___Corpus/Medline/xml/PMC4905370.xml	PARP	7032 : 7036	CM	eir contribution to DDR, PARP enzymes, and in particul
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	7064 : 7069	CM	zymes, and in particular PARP1, have been extensively e
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	7264 : 7269	CM	e therapeutic benefit of PARP1/2 inhibitors, especially
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	7415 : 7420	CM	mited to) the HR players BRCA1 and BRCA2. On the basis 
./___Corpus/Medline/xml/PMC4905370.xml	BRCA2	7425 : 7430	CM	the HR players BRCA1 and BRCA2. On the basis of these o
./___Corpus/Medline/xml/PMC4905370.xml	PARP	7542 : 7546	CM	d for the first time the PARP inhibitor olaparib for p
./___Corpus/Medline/xml/PMC4905370.xml	PARP	7787 : 7791	CM	akthrough therapy to the PARP inhibitor rucaparib for 
./___Corpus/Medline/xml/PMC4905370.xml	platinum	7925 : 7933	CM	t least 2 prior lines of platinum-based chemotherapy (http
./___Corpus/Medline/xml/PMC4905370.xml	PARP	8091 : 8095	CM	ribe the contribution of PARP to cancer and discuss pr
./___Corpus/Medline/xml/PMC4905370.xml	PARP	8191 : 8195	CM	g the therapeutic use of PARP inhibitors for cancer th
./___Corpus/Medline/xml/PMC4905370.xml	PARP	8244 : 8248	CM	herapy.                  PARP activity and cancer     
./___Corpus/Medline/xml/PMC4905370.xml	PARP	8312 : 8316	CM	   The precise effect of PARP enzymes and PARylation o
./___Corpus/Medline/xml/PMC4905370.xml	PARylation	8329 : 8339	RN	fect of PARP enzymes and PARylation on tumorigenesis is comp
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	8558 : 8563	CM	 oncosuppressive role of PARP1 and PARP2. Nevertheless,
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	8568 : 8573	CM	essive role of PARP1 and PARP2. Nevertheless, Parp-1−/−
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	8886 : 8891	CM	 however, the absence of PARP1 or PARP2 rendered mice s
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	8895 : 8900	CM	 the absence of PARP1 or PARP2 rendered mice sensitive 
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	8959 : 8969	RN	maging agents, including alkylating compounds and ionizing r
./___Corpus/Medline/xml/PMC4905370.xml	Tp53	9080 : 9084	CM	tion related protein 53 (Tp53) in Parp1−/− and Parp2−/
./___Corpus/Medline/xml/PMC4905370.xml	DNAPk	9205 : 9210	CM	de (Prkdc, best known as DNAPk) in Parp1−/− mice76 prom
./___Corpus/Medline/xml/PMC4905370.xml	mice76	9224 : 9230	CM	wn as DNAPk) in Parp1−/− mice76 promoted or accelerated 
./___Corpus/Medline/xml/PMC4905370.xml	hypoxic	9388 : 9395	CM	77 as well as an altered hypoxic response,78 whereas mice
./___Corpus/Medline/xml/PMC4905370.xml	carcinogen	9815 : 9825	CM	ility to mutation and/or carcinogen-induced tumorigenesis in
./___Corpus/Medline/xml/PMC4905370.xml	poly(ADP-ribose)	9994 : 10010	CM	in Parg−/− mice (lacking poly(ADP-ribose) glycohydrolase) treated 
./___Corpus/Medline/xml/PMC4905370.xml	glycohydrolase	10011 : 10025	ASE	lacking poly(ADP-ribose) glycohydrolase) treated with diethylnit
./___Corpus/Medline/xml/PMC4905370.xml	diethylnitrosamine92	10040 : 10060	CM	ohydrolase) treated with diethylnitrosamine92 suggesting the importanc
./___Corpus/Medline/xml/PMC4905370.xml	PAR	10110 : 10113	CM	e of a balanced level of PAR for maintaining genomic 
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	10237 : 10242	CM	ppressing tumorigenesis, PARP1 activity also seems to b
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	10317 : 10322	CM	l survival. Mutations of PARP1 are in fact quite rare i
./___Corpus/Medline/xml/PMC4905370.xml	nucleotide	10376 : 10386	CM	ncer, even though single-nucleotide polymorphisms of the gen
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	10422 : 10427	CM	sms of the gene encoding PARP1, including V762A, have b
./___Corpus/Medline/xml/PMC4905370.xml	V762A	10439 : 10444	CM	ncoding PARP1, including V762A, have been associated wi
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	10565 : 10570	CM	ion of the expression of PARP1 and/or an increased leve
./___Corpus/Medline/xml/PMC4905370.xml	PAR	10600 : 10603	CM	or an increased level of PAR has been found in multip
./___Corpus/Medline/xml/PMC4905370.xml	colon,108-112	10780 : 10793	CM	reast,103-106 cervix,107 colon,108-112 endometrium,103,113 live
./___Corpus/Medline/xml/PMC4905370.xml	PARP	10929 : 10933	CM	ion or overactivation of PARP enzyme has also been obs
./___Corpus/Medline/xml/PMC4905370.xml	PARP	11106 : 11110	CM	n some of these settings PARP deregulation has been li
./___Corpus/Medline/xml/PMC4905370.xml	PARP	11377 : 11381	CM	e findings indicate that PARP activity has a dual role
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	11603 : 11608	CM	lished.                  PARP1 in cancer therapy       
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	11670 : 11675	CM	   The idea of employing PARP1 inhibitors as antineopla
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	11876 : 11881	CM	 development of specific PARP1 inhibitors. On theoretic
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	11917 : 11922	CM	. On theoretical grounds PARP1 may be indirectly inhibi
./___Corpus/Medline/xml/PMC4905370.xml	NAD+	11964 : 11968	CM	y inhibited by depleting NAD+, the substrate of PARyla
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	12080 : 12085	CM	he catalytic activity of PARP1 and PARP2 (hereafter ref
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	12090 : 12095	CM	ic activity of PARP1 and PARP2 (hereafter referred to a
./___Corpus/Medline/xml/PMC4905370.xml	PARP	12122 : 12126	CM	hereafter referred to as PARP inhibitors for the sake 
./___Corpus/Medline/xml/PMC4905370.xml	MK-4827),135	12317 : 12329	CM	niraparib (also known as MK-4827),135 iniparib (also known as 
./___Corpus/Medline/xml/PMC4905370.xml	GPI21016),140	12432 : 12445	CM	139 E7016 (also known as GPI21016),140 and INO-1001,141 has bee
./___Corpus/Medline/xml/PMC4905370.xml	INO-1001,141	12450 : 12462	CM	own as GPI21016),140 and INO-1001,141 has been the most widely
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	12699 : 12704	CM	oth based on the role of PARP1 in repairing DNA lesions
./___Corpus/Medline/xml/PMC4905370.xml	PARP	12754 : 12758	CM	. In the first approach, PARP inhibitors are given in 
./___Corpus/Medline/xml/PMC4905370.xml	PARP	12929 : 12933	CM	 showing the activity of PARP inhibitors in boosting t
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	12986 : 12996	RN	tumor killing effects of alkylating agents, topoisomerase I 
./___Corpus/Medline/xml/PMC4905370.xml	vitro	13064 : 13069	CM	ing radiation, either in vitro in tumor cell lines or i
./___Corpus/Medline/xml/PMC4905370.xml	PARP	13398 : 13402	CM	roach, the abrogation of PARP enzymatic activity is us
./___Corpus/Medline/xml/PMC4905370.xml	PARP	14094 : 14098	CM	ded strong evidence that PARP inhibitor monotherapy ef
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	14174 : 14179	CM	cells with dysfunctional BRCA1 and BRCA2.151,152 In the
./___Corpus/Medline/xml/PMC4905370.xml	PARP	14217 : 14221	CM	1,152 In these settings, PARP inhibitors as a standalo
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutant	14407 : 14418	CM	ificity. Besides killing BRCA-mutant cancers, PARP inhibitors
./___Corpus/Medline/xml/PMC4905370.xml	PARP	14428 : 14432	CM	ing BRCA-mutant cancers, PARP inhibitors have also bee
./___Corpus/Medline/xml/PMC4905370.xml	CHEK2	14866 : 14871	CM	 in checkpoint kinase 2 (CHEK2, best known as CHK2) in 
./___Corpus/Medline/xml/PMC4905370.xml	CHK2	14887 : 14891	CM	 2 (CHEK2, best known as CHK2) in sarcoma, breast canc
./___Corpus/Medline/xml/PMC4905370.xml	phosphatase	14960 : 14971	CM	 and brain tumors;166 in phosphatase and tensin homolog (PTEN
./___Corpus/Medline/xml/PMC4905370.xml	PARP	15433 : 15437	CM	hus might be targeted by PARP inhibitors.176-181 Recen
./___Corpus/Medline/xml/PMC4905370.xml	POLQ	15556 : 15560	CM	eta (Polθ, also known as POLQ); a DNA polymerase invol
./___Corpus/Medline/xml/PMC4905370.xml	PARP	15712 : 15716	CM	f HR-deficient tumors to PARP inhibitors.182 In partic
./___Corpus/Medline/xml/PMC4905370.xml	POLQ	15813 : 15817	CM	arian tumors overexpress POLQ and rely on POLQ-mediate
./___Corpus/Medline/xml/PMC4905370.xml	POLQ	15830 : 15834	CM	express POLQ and rely on POLQ-mediated repair for thei
./___Corpus/Medline/xml/PMC4905370.xml	POLQ	15902 : 15906	CM	this study, depletion of POLQ enhanced the killing eff
./___Corpus/Medline/xml/PMC4905370.xml	PARP	15938 : 15942	CM	ed the killing effect of PARP inhibitors in HR-deficie
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	16020 : 16025	CM	ether with evidence that PARP1 recruits POLQ to DSBs,18
./___Corpus/Medline/xml/PMC4905370.xml	POLQ	16035 : 16039	CM	ence that PARP1 recruits POLQ to DSBs,183 highlight a 
./___Corpus/Medline/xml/PMC4905370.xml	DSBs,183	16043 : 16051	CM	t PARP1 recruits POLQ to DSBs,183 highlight a role of PARP
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16072 : 16076	CM	,183 highlight a role of PARP activity in alt-NHEJ. Fu
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16129 : 16133	CM	er supporting the use of PARP inhibitors in HR-impaire
./___Corpus/Medline/xml/PMC4905370.xml	phosphatidylinositol	16182 : 16202	CM	ed tumors, inhibition of phosphatidylinositol 3-kinases (PI3K) or cycl
./___Corpus/Medline/xml/PMC4905370.xml	3-	16204 : 16206	CPR	of phosphatidylinositol 3-kinases (PI3K) or cyclin-d
./___Corpus/Medline/xml/PMC4905370.xml	PI3K	16214 : 16218	CM	tidylinositol 3-kinases (PI3K) or cyclin-dependent kin
./___Corpus/Medline/xml/PMC4905370.xml	cyclin	16223 : 16229	CM	itol 3-kinases (PI3K) or cyclin-dependent kinase 1 (CDK1
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16313 : 16317	CM	RCA-proficient cancer to PARP inactivation by affectin
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	16344 : 16349	CM	nactivation by affecting BRCA1/2 expression184-186 or f
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	16433 : 16438	CM	, recent observations in BRCA1-deficient mice seem to s
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16505 : 16509	CM	hemopreventive effect of PARP inhibitors,188 although 
./___Corpus/Medline/xml/PMC4905370.xml	PAR	16580 : 16583	CM	 is required. Also, high PAR levels are reported to p
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16631 : 16635	CM	 predict the response to PARP inhibitors.189-191      
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16812 : 16816	CM	e synthetic lethality of PARP inhibitors in HR-defecti
./___Corpus/Medline/xml/PMC4905370.xml	PARP	16946 : 16950	CM	he catalytic activity of PARP results in abrogation of
./___Corpus/Medline/xml/PMC4905370.xml	BER	16976 : 16979	CM	results in abrogation of BER and the consequent accum
./___Corpus/Medline/xml/PMC4905370.xml	SSBs	17015 : 17019	CM	nsequent accumulation of SSBs, which, once converted t
./___Corpus/Medline/xml/PMC4905370.xml	DSBs	17046 : 17050	CM	which, once converted to DSBs during S-phase or upon r
./___Corpus/Medline/xml/PMC4905370.xml	S-phase	17058 : 17065	CM	converted to DSBs during S-phase or upon replication fork
./___Corpus/Medline/xml/PMC4905370.xml	DSB	17200 : 17203	CM	naged by the error-prone DSB repair pathway of NHEJ.1
./___Corpus/Medline/xml/PMC4905370.xml	PARP	17263 : 17267	CM	hird model suggests that PARP inhibitors trap PARP1 an
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	17284 : 17289	CM	hat PARP inhibitors trap PARP1 and PARP2 at the DNA les
./___Corpus/Medline/xml/PMC4905370.xml	PARP2	17294 : 17299	CM	nhibitors trap PARP1 and PARP2 at the DNA lesion site t
./___Corpus/Medline/xml/PMC4905370.xml	DDR	17358 : 17361	CM	eventing access of other DDR players and provoking ob
./___Corpus/Medline/xml/PMC4905370.xml	PARP	17491 : 17495	CM	t evidence suggests that PARP inhibitors exert killing
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	17571 : 17583	CM	h the DNA-damaging agent temozolomide primarily by trapping PA
./___Corpus/Medline/xml/PMC4905370.xml	PARP	17786 : 17790	CM	icate that inhibition of PARP activity may be an effec
./___Corpus/Medline/xml/PMC4905370.xml	PARP	17999 : 18003	CM	linical investigation of PARP inhibitors Completed cli
./___Corpus/Medline/xml/PMC4905370.xml	PARP	18178 : 18182	CM	shed aimed at evaluating PARP inhibitors as standalone
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	18303 : 18307	CM	 cancers often harboring BRCA mutations or displaying 
./___Corpus/Medline/xml/PMC4905370.xml	cysteine	18660 : 18668	CM	o non-selectively modify cysteine-containing proteins in t
./___Corpus/Medline/xml/PMC4905370.xml	fide	18741 : 18745	CM	fore probably not a bona fide PARP inhibitor.136,137  
./___Corpus/Medline/xml/PMC4905370.xml	PARP	18746 : 18750	CM	probably not a bona fide PARP inhibitor.136,137       
./___Corpus/Medline/xml/PMC4905370.xml	PARP	18786 : 18790	CM	136,137                  PARP inhibitors as monotherap
./___Corpus/Medline/xml/PMC4905370.xml	GI	19191 : 19193	CM	d mild gastrointestinal (GI) symptoms, fatigue, and 
./___Corpus/Medline/xml/PMC4905370.xml	GI	19392 : 19394	CM	e effects, in particular GI symptoms, are reported f
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	19422 : 19431	CM	mptoms, are reported for veliparib as a single agent.218   
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	19757 : 19762	CM	ive in cancers harboring BRCA1 or BRCA2 mutations;206,2
./___Corpus/Medline/xml/PMC4905370.xml	BRCA2	19766 : 19771	CM	ncers harboring BRCA1 or BRCA2 mutations;206,209 an ove
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	19846 : 19851	CM	e of 46% was observed in BRCA1/2-mutated ovarian cancer
./___Corpus/Medline/xml/PMC4905370.xml	2-	19852 : 19854	CPR	6% was observed in BRCA1/2-mutated ovarian cancer, a
./___Corpus/Medline/xml/PMC4905370.xml	platinum	19894 : 19902	CM	 cancer, associated with platinum sensitivity.209 Moreover
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	20066 : 20071	CM	n and breast cancer from BRCA1 or BRCA2 mutation carrie
./___Corpus/Medline/xml/PMC4905370.xml	BRCA2	20075 : 20080	CM	ast cancer from BRCA1 or BRCA2 mutation carriers as wel
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	20291 : 20295	CM	cacy of olaparib against BRCA-deficient tumors has bee
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	20651 : 20655	CM	laparib was effective in BRCA-deficient patients with 
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	20988 : 20993	CM	 II studies performed in BRCA1- or BRCA2-mutated ovaria
./___Corpus/Medline/xml/PMC4905370.xml	PFS	21149 : 21152	CM	ogression-free survival (PFS) were found between olap
./___Corpus/Medline/xml/PMC4905370.xml	doxorubicin,212	21209 : 21224	CM	rsus pegylated liposomal doxorubicin,212 and in the latter no obj
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	21405 : 21410	CM	ubjects with non-mutated BRCA1 or BRCA2 (ORR 24%),214 w
./___Corpus/Medline/xml/PMC4905370.xml	BRCA2	21414 : 21419	CM	ith non-mutated BRCA1 or BRCA2 (ORR 24%),214 whereas no
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	21684 : 21693	CM	 phase II clinical trial veliparib was active in women with
./___Corpus/Medline/xml/PMC4905370.xml	platinum	21846 : 21854	CM	 of 26% (20% and 35% for platinum-resistant and platinum-s
./___Corpus/Medline/xml/PMC4905370.xml	platinum	21869 : 21877	CM	r platinum-resistant and platinum-sensitive patients, resp
./___Corpus/Medline/xml/PMC4905370.xml	PFS	22033 : 22036	CM	b significantly improved PFS among patients who had r
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22079 : 22087	CM	o had received 2 or more platinum-based regimens and who h
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22167 : 22175	CM	nse to their most recent platinum-based regimen (median PF
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	22288 : 22292	CM	reover, when considering BRCA mutation status, median 
./___Corpus/Medline/xml/PMC4905370.xml	PFS	22317 : 22320	CM	 mutation status, median PFS (but not overall surviva
./___Corpus/Medline/xml/PMC4905370.xml	mo)219	22431 : 22437	CM	 groups (11.2 mo vs. 4.3 mo)219 (Table 1).              
./___Corpus/Medline/xml/PMC4905370.xml	FDA	22516 : 22519	CM	en by this evidence, the FDA recently granted acceler
./___Corpus/Medline/xml/PMC4905370.xml	PARP	22565 : 22569	CM	elerated approval to the PARP inhibitor olaparib for p
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	22664 : 22668	CM	y inherited mutations of BRCA and have previously rece
./___Corpus/Medline/xml/PMC4905370.xml	PARP	22844 : 22848	CM	erapy designation to the PARP inhibitor rucaparib as m
./___Corpus/Medline/xml/PMC4905370.xml	platinum	22970 : 22978	CM	t least 2 lines of prior platinum-containing therapy, with
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	23004 : 23016	CM	containing therapy, with BRCA-mutated tumors, inclusive of bot
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	23064 : 23068	CM	oth germline and somatic BRCA mutations.              
./___Corpus/Medline/xml/PMC4905370.xml	PARP	23097 : 23101	CM	ations.                  PARP inhibitors as radio- or 
./___Corpus/Medline/xml/PMC4905370.xml	dacarbazine	23364 : 23375	CM	peutic agents, including dacarbazine (an alkylating agent app
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	23380 : 23390	RN	ncluding dacarbazine (an alkylating agent approved by the FD
./___Corpus/Medline/xml/PMC4905370.xml	FDA	23413 : 23416	CM	ng agent approved by the FDA for the treatment of pat
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	23490 : 23499	CM	oma and melanoma220);221 cisplatin and gemcitabine (a plati
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	23504 : 23515	CM	ma220);221 cisplatin and gemcitabine (a platinum derivative c
./___Corpus/Medline/xml/PMC4905370.xml	platinum	23519 : 23527	CM	latin and gemcitabine (a platinum derivative compound and 
./___Corpus/Medline/xml/PMC4905370.xml	nucleoside	23570 : 23580	CM	nd and an antimetabolite nucleoside, respectively, that are 
./___Corpus/Medline/xml/PMC4905370.xml	FDA	23736 : 23739	CM	nhibitor approved by the FDA for use alone or with ot
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	23919 : 23928	CM	arib in combination with cisplatin and gemcitabine was asso
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	23933 : 23944	CM	ation with cisplatin and gemcitabine was associated with myel
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	24114 : 24123	CM	ression was observed for veliparib combined with topotecan 
./___Corpus/Medline/xml/PMC4905370.xml	INO-1001,234	24244 : 24256	CM	ell as for veliparib,233 INO-1001,234 or rucaparib237 administ
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	24300 : 24312	CM	ministered together with temozolomide (an alkylating agent cur
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	24317 : 24327	RN	er with temozolomide (an alkylating agent currently used to 
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	24568 : 24577	CM	ability of olaparib plus cisplatin regimen,238 but not that
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	24620 : 24631	CM	ot that of olaparib plus carboplatin (a platinum derivative a
./___Corpus/Medline/xml/PMC4905370.xml	platinum	24635 : 24643	CM	arib plus carboplatin (a platinum derivative approved by t
./___Corpus/Medline/xml/PMC4905370.xml	FDA	24671 : 24674	CM	rivative approved by the FDA for the treatment of sol
./___Corpus/Medline/xml/PMC4905370.xml	tyrosine	25088 : 25096	CM	43-245) and cediranib (a tyrosine kinase inhibitor of vasc
./___Corpus/Medline/xml/PMC4905370.xml	taxane	25338 : 25344	CM	crotubular poison of the taxane family approved by the F
./___Corpus/Medline/xml/PMC4905370.xml	FDA	25368 : 25371	CM	e family approved by the FDA for use alone or with ot
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	25502 : 25513	CM	-254),255 paclitaxel and carboplatin followed by olaparib mai
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	25586 : 25602	CM	6 veliparib and low-dose cyclophosphamide (an alkylating agent wit
./___Corpus/Medline/xml/PMC4905370.xml	alkylating	25607 : 25617	RN	ose cyclophosphamide (an alkylating agent with immunogenic p
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide,264	25854 : 25870	CM	therapy,263 CEP-9722 and temozolomide,264 and rucaparib and temozo
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide265	25889 : 25904	CM	de,264 and rucaparib and temozolomide265 were all well tolerated 
./___Corpus/Medline/xml/PMC4905370.xml	PARP	26060 : 26064	CM	egarding the efficacy of PARP inhibitor-based regimens
./___Corpus/Medline/xml/PMC4905370.xml	dacarbazine221	26296 : 26310	CM	ministered together with dacarbazine221 or with cisplatin plus g
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	26319 : 26328	CM	h dacarbazine221 or with cisplatin plus gemcitabine228 in p
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine228	26334 : 26348	CM	1 or with cisplatin plus gemcitabine228 in patients with advance
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	26426 : 26438	CM	b was used together with temozolomide in individuals with mela
./___Corpus/Medline/xml/PMC4905370.xml	mo);237	26556 : 26563	CM	ian overall survival 9.9 mo);237 (3) veliparib was combin
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	26596 : 26608	CM	iparib was combined with temozolomide in children with recurre
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	27026 : 27038	CM	 CEP-9722 was given with temozolomide to patients with advance
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	27117 : 27129	CM	O-1001 was combined with temozolomide in subjects with melanom
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	27206 : 27222	CM	 veliparib to a low-dose cyclophosphamide regimen did not improve 
./___Corpus/Medline/xml/PMC4905370.xml	PFS	27279 : 27282	CM	ponse rate or the median PFS in patients with pretrea
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	27545 : 27554	CM	) olaparib combined with cisplatin in breast or ovarian can
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	27606 : 27611	CM	r patients with germline BRCA1/2 mutations (ORR of 43% 
./___Corpus/Medline/xml/PMC4905370.xml	TNBC	27771 : 27775	CM	patients with metastatic TNBC (37% of patients with a 
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	28100 : 28111	CM	) olaparib combined with carboplatin in BRCA1- or BRCA2-mutat
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	28115 : 28120	CM	ined with carboplatin in BRCA1- or BRCA2-mutated breast
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	28264 : 28275	CM	ther with paclitaxel and carboplatin followed by olaparib mai
./___Corpus/Medline/xml/PMC4905370.xml	platinum	28338 : 28346	CM	therapy in patients with platinum-sensitive, recurrent, hi
./___Corpus/Medline/xml/PMC4905370.xml	PFS	28403 : 28406	CM	e serous ovarian cancer (PFS 12.2 mo vs 9.6 mo for ol
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	28557 : 28561	CM	ported for patients with BRCA mutations);256 (6) velip
./___Corpus/Medline/xml/PMC4905370.xml	cyclophosphamide	28611 : 28627	CM	arib in combination with cyclophosphamide in a subset of BRCA-muta
./___Corpus/Medline/xml/PMC4905370.xml	BRCA-mutated	28643 : 28655	CM	osphamide in a subset of BRCA-mutated patients (7 patients wit
./___Corpus/Medline/xml/PMC4905370.xml	mo)263	29035 : 29041	CM	values of 3.5 mo and 4.9 mo)263 (Table 1). These latter 
./___Corpus/Medline/xml/PMC4905370.xml	PARP	29255 : 29259	CM	e further development of PARP-based regimens.         
./___Corpus/Medline/xml/PMC4905370.xml	PARP	29590 : 29594	CM	therapeutic potential of PARP inhibitors in cancer pat
./___Corpus/Medline/xml/PMC4905370.xml	platinum	30132 : 30140	CM	ing conventional [mostly platinum-based] chemotherapy regi
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	30242 : 30247	CM	rformed in patients with BRCA1/2 (or other HR player)-m
./___Corpus/Medline/xml/PMC4905370.xml	BRCA	32231 : 32235	CM	 patients with recurrent BRCA-deficient ovarian cancer
./___Corpus/Medline/xml/PMC4905370.xml	PARP	32630 : 32634	CM	ion to olaparib, 3 other PARP inhibitors are being emp
./___Corpus/Medline/xml/PMC4905370.xml	platinum	32834 : 32842	CM	rformed in patients with platinum-sensitive ovarian cancer
./___Corpus/Medline/xml/PMC4905370.xml	platinum	33314 : 33322	CM	cancer who have received platinum-based chemotherapy ({"ty
./___Corpus/Medline/xml/PMC4905370.xml	nucleoside	33678 : 33688	CM	orectal cancers267], the nucleoside analog gemcitabine, or e
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	33696 : 33707	CM	], the nucleoside analog gemcitabine, or eribulin or vinorelb
./___Corpus/Medline/xml/PMC4905370.xml	vinorelbine	33724 : 33735	CM	citabine, or eribulin or vinorelbine [2 antimitotic agents, t
./___Corpus/Medline/xml/PMC4905370.xml	FDA	33798 : 33801	CM	hich was approved by the FDA for use alone or with ci
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	33824 : 33833	CM	DA for use alone or with cisplatin to treat non-small cell 
./___Corpus/Medline/xml/PMC4905370.xml	EMBRACA	33942 : 33949	CM	 advanced breast cancer (EMBRACA) ({"type":"clinical-tria
./___Corpus/Medline/xml/PMC4905370.xml	PARP	34113 : 34117	CM	         Among the other PARP inhibitors given as stan
./___Corpus/Medline/xml/PMC4905370.xml	platinum	34640 : 34648	CM	ng used in patients with platinum-sensitive ovarian, fallo
./___Corpus/Medline/xml/PMC4905370.xml	BRCA1	35558 : 35563	CM	27151"}}NCT02127151), or BRCA1/2 mutation-associated ov
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	36620 : 36629	CM	 the clinical profile of veliparib in advanced solid tumors
./___Corpus/Medline/xml/PMC4905370.xml	PARP	36917 : 36921	CM	fety and tolerability of PARP inhibitors in combinatio
./___Corpus/Medline/xml/PMC4905370.xml	PARP	37038 : 37042	CM	                         PARP inhibitors employed in P
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	37388 : 37399	CM	h is being combined with carboplatin and paclitaxel or paclit
./___Corpus/Medline/xml/PMC4905370.xml	NCT02163694"}}NCT02163694	37535 : 37560	CM	"NCT02163694","term_id":"NCT02163694"}}NCT02163694 and {"type":"clinical-tr
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	37877 : 37886	CM	46) cancer. In addition, veliparib is being combined with t
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	37910 : 37922	CM	b is being combined with temozolomide in a phase II/III study 
./___Corpus/Medline/xml/PMC4905370.xml	O-6-methylguanine-DNA	38015 : 38036	CM	blastoma multiforme with O-6-methylguanine-DNA methyltransferase (MGMT)
./___Corpus/Medline/xml/PMC4905370.xml	MGMT	38056 : 38060	CM	e-DNA methyltransferase (MGMT) promoter hypermethylati
./___Corpus/Medline/xml/PMC4905370.xml	hypermethylation	38071 : 38087	CM	nsferase (MGMT) promoter hypermethylation ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4905370.xml	PARP	38311 : 38315	CM	e therapeutic profile of PARP inhibitors in combinator
./___Corpus/Medline/xml/PMC4905370.xml	anastrozole	38482 : 38493	CM	stered together with (1) anastrozole or letrozole (2 aromatas
./___Corpus/Medline/xml/PMC4905370.xml	letrozole	38497 : 38506	CM	 with (1) anastrozole or letrozole (2 aromatase inhibitors 
./___Corpus/Medline/xml/PMC4905370.xml	tamoxifen	38616 : 38625	CM	opausal women271-273) or tamoxifen (a nonsteroidal selectiv
./___Corpus/Medline/xml/PMC4905370.xml	estrogen	38652 : 38660	CM	a nonsteroidal selective estrogen receptor modulator appro
./___Corpus/Medline/xml/PMC4905370.xml	FDA	38696 : 38699	CM	odulator approved by the FDA for the treatment and pr
./___Corpus/Medline/xml/PMC4905370.xml	itraconazole	38896 : 38908	CM	3351"}}NCT02093351); (2) itraconazole (an FDA-approved antifun
./___Corpus/Medline/xml/PMC4905370.xml	rifampicin	39127 : 39137	CM	0028"}}NCT01900028); (3) rifampicin (a cytochrome P450, fami
./___Corpus/Medline/xml/PMC4905370.xml	cytochrome	39141 : 39151	CM	0028); (3) rifampicin (a cytochrome P450, family 3, subfamil
./___Corpus/Medline/xml/PMC4905370.xml	CYP3A4	39196 : 39202	CM	family A, polypeptide 4, CYP3A4, inducer278) in subjects
./___Corpus/Medline/xml/PMC4905370.xml	rapamycin	40173 : 40182	CM	s of mammalian target of rapamycin complex 1/2 [mTORC1/2] o
./___Corpus/Medline/xml/PMC4905370.xml	mTORC1	40196 : 40202	CM	f rapamycin complex 1/2 [mTORC1/2] or AKT, respectively,
./___Corpus/Medline/xml/PMC4905370.xml	AKT	40209 : 40212	CM	omplex 1/2 [mTORC1/2] or AKT, respectively, with anti
./___Corpus/Medline/xml/PMC4905370.xml	PI3K	40556 : 40560	CM	02338622); (6) BKM120 (a PI3K inhibitor283 whose thera
./___Corpus/Medline/xml/PMC4905370.xml	NCT01623349"}}NCT01623349	40746 : 40771	CM	"NCT01623349","term_id":"NCT01623349"}}NCT01623349); (7) bevacizumab, cispl
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	40791 : 40800	CM	23349); (7) bevacizumab, cisplatin, and paclitaxel in indiv
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	40982 : 40993	CM	1990"}}NCT02121990); (8) carboplatin and paclitaxel in subjec
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	41151 : 41163	CM	0376"}}NCT01650376); (9) temozolomide in patients with Ewing s
./___Corpus/Medline/xml/PMC4905370.xml	androgen	41324 : 41332	CM	aterone (an FDA-approved androgen biosynthesis inhibitor28
./___Corpus/Medline/xml/PMC4905370.xml	prednisone	41364 : 41374	CM	thesis inhibitor284) and prednisone/prednisolone (2 FDA-appr
./___Corpus/Medline/xml/PMC4905370.xml	prednisolone	41375 : 41387	CM	bitor284) and prednisone/prednisolone (2 FDA-approved glucocor
./___Corpus/Medline/xml/PMC4905370.xml	gonadotropin	41582 : 41594	CM	2217); (11) degarelix (a gonadotropin-releasing hormone antago
./___Corpus/Medline/xml/PMC4905370.xml	FDA	41642 : 41645	CM	gonistic approved by the FDA for the treatment of adv
./___Corpus/Medline/xml/PMC4905370.xml	serine	42160 : 42166	CM	and (13) AZD6738 (an ATR serine/threonine kinase inhibit
./___Corpus/Medline/xml/PMC4905370.xml	threonine	42167 : 42176	CM	) AZD6738 (an ATR serine/threonine kinase inhibitor whose a
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	42508 : 42519	CM	 being (1) combined with carboplatin and paclitaxel-based reg
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	42712 : 42723	CM	used in combination with carboplatin and paclitaxel or either
./___Corpus/Medline/xml/PMC4905370.xml	FOLFIRI	42749 : 42756	CM	and paclitaxel or either FOLFIRI (irinotecan, leucovorin,
./___Corpus/Medline/xml/PMC4905370.xml	5-	42782 : 42784	CPR	(irinotecan, leucovorin, 5-flourouracil, and irinote
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	42936 : 42948	CM	033551"}}NCT02033551) or temozolomide in breast cancer ({"type
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	43377 : 43388	CM	on with radiotherapy and gemcitabine in pancreatic cancer pat
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	43532 : 43544	CM	8478); (5) combined with temozolomide in patients with lung ca
./___Corpus/Medline/xml/PMC4905370.xml	floxuridine	43692 : 43703	CM	; (6) used together with floxuridine (an antimetabolite that 
./___Corpus/Medline/xml/PMC4905370.xml	fluorouracil	43746 : 43758	CM	e that is metabolized to fluorouracil and other metabolites wi
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	44017 : 44028	CM	on with topotecan and/or carboplatin in individuals with ovar
./___Corpus/Medline/xml/PMC4905370.xml	5-fluorouracil	44303 : 44317	CM	 (8) given together with 5-fluorouracil (an antimetabolite fluor
./___Corpus/Medline/xml/PMC4905370.xml	fluoropyrimidine	44337 : 44353	CM	racil (an antimetabolite fluoropyrimidine commonly used for the ad
./___Corpus/Medline/xml/PMC4905370.xml	folic acid	44476 : 44486	CM	(an active metabolite of folic acid approved by the FDA in c
./___Corpus/Medline/xml/PMC4905370.xml	FDA	44503 : 44506	CM	lic acid approved by the FDA in combination with fluo
./___Corpus/Medline/xml/PMC4905370.xml	fluorouracil	44527 : 44539	CM	 FDA in combination with fluorouracil as palliative treatment 
./___Corpus/Medline/xml/PMC4905370.xml	oxaliplatin	44621 : 44632	CM	ctal cancer292,293), and oxaliplatin (an FDA-approved cisplat
./___Corpus/Medline/xml/PMC4905370.xml	cisplatin	44650 : 44659	CM	iplatin (an FDA-approved cisplatin derivative294,295) in pa
./___Corpus/Medline/xml/PMC4905370.xml	FOLFIRI	44838 : 44845	CM	ned with bevacizumab and FOLFIRI in subjects with colorec
./___Corpus/Medline/xml/PMC4905370.xml	platinum	45006 : 45014	CM	used in combination with platinum-based agents and either 
./___Corpus/Medline/xml/PMC4905370.xml	etoposide	45039 : 45048	CM	-based agents and either etoposide (an FDA-approved inhibit
./___Corpus/Medline/xml/PMC4905370.xml	gemcitabine	45196 : 45207	CM	 malignancies296,297) or gemcitabine in individuals with lung
./___Corpus/Medline/xml/PMC4905370.xml	prednisone	45605 : 45615	CM	her with abiraterone and prednisone in patients with prostat
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	45839 : 45848	CM	ectiveness and safety of veliparib together with lapatinib 
./___Corpus/Medline/xml/PMC4905370.xml	lapatinib	45863 : 45872	CM	 veliparib together with lapatinib (a tyrosine kinase inhib
./___Corpus/Medline/xml/PMC4905370.xml	tyrosine	45876 : 45884	CM	gether with lapatinib (a tyrosine kinase inhibitor current
./___Corpus/Medline/xml/PMC4905370.xml	letrozole	45953 : 45962	CM	ion with capecitabine or letrozole to treat advanced or met
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46341 : 46350	CM	e safety and efficacy of veliparib in combination with radi
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46571 : 46580	CM	ety, and tolerability of veliparib combined with whole-brai
./___Corpus/Medline/xml/PMC4905370.xml	veliparib	46912 : 46921	CM	 the clinical profile of veliparib in combination with carb
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	46942 : 46953	CM	arib in combination with carboplatin and paclitaxel in advanc
./___Corpus/Medline/xml/PMC4905370.xml	PARP	47422 : 47426	CM	     Regarding the other PARP inhibitors, niraparib an
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	47483 : 47495	CM	 are being combined with temozolomide in subjects with Ewing s
./___Corpus/Medline/xml/PMC4905370.xml	carboplatin	47994 : 48005	CM	g used together with (1) carboplatin and paclitaxel in indivi
./___Corpus/Medline/xml/PMC4905370.xml	TNBCs	48226 : 48231	CM	lid tumors or metastatic TNBCs ({"type":"clinical-trial
./___Corpus/Medline/xml/PMC4905370.xml	temozolomide	48335 : 48347	CM	"}}NCT02358200); and (2) temozolomide and/or irinotecan in ind
./___Corpus/Medline/xml/PMC4905370.xml	PARP	48911 : 48915	CM	 therapeutic benefits of PARP inhibitors alone or in c
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	49178 : 49183	CM	Nonetheless, the role of PARP1 in the preservation of g
./___Corpus/Medline/xml/PMC4905370.xml	PARP	49260 : 49264	CM	elective inactivation of PARP family members other tha
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	49291 : 49296	CM	amily members other than PARP1 ascribed to PARP inhibit
./___Corpus/Medline/xml/PMC4905370.xml	PARP	49309 : 49313	CM	r than PARP1 ascribed to PARP inhibitors, the toxicity
./___Corpus/Medline/xml/PMC4905370.xml	PARP	49480 : 49484	CM	thal strategies based on PARP inhibitors may cast doub
./___Corpus/Medline/xml/PMC4905370.xml	PARP	49619 : 49623	CM	hanisms of resistance to PARP inhibitors acquired by H
./___Corpus/Medline/xml/PMC4905370.xml	BRCA2;302-304	49785 : 49798	CM	uence and/or function of BRCA2;302-304 somatic mutations of tum
./___Corpus/Medline/xml/PMC4905370.xml	p53	49834 : 49837	CM	tations of tumor protein p53 binding protein 1 (TP53B
./___Corpus/Medline/xml/PMC4905370.xml	TP53BP1	49857 : 49864	CM	n p53 binding protein 1 (TP53BP1 best known as 53BP1) or 
./___Corpus/Medline/xml/PMC4905370.xml	53BP1	49879 : 49884	CM	1 (TP53BP1 best known as 53BP1) or loss of MAD2 mitotic
./___Corpus/Medline/xml/PMC4905370.xml	MAD2	49897 : 49901	CM	own as 53BP1) or loss of MAD2 mitotic arrest deficient
./___Corpus/Medline/xml/PMC4905370.xml	MAD2L2	49935 : 49941	CM	arrest deficient-like 2 (MAD2L2, best known as REV7), wh
./___Corpus/Medline/xml/PMC4905370.xml	REV7	49957 : 49961	CM	2 (MAD2L2, best known as REV7), which are believed to 
./___Corpus/Medline/xml/PMC4905370.xml	ATP	50041 : 50044	CM	-307 and upregulation of ATP-binding cassette, sub-fa
./___Corpus/Medline/xml/PMC4905370.xml	MDR	50077 : 50080	CM	 cassette, sub-family B (MDR/TAP), member 1 (ABCB1, a
./___Corpus/Medline/xml/PMC4905370.xml	TAP	50081 : 50084	CM	sette, sub-family B (MDR/TAP), member 1 (ABCB1, also 
./___Corpus/Medline/xml/PMC4905370.xml	ABCB1	50097 : 50102	CM	y B (MDR/TAP), member 1 (ABCB1, also known as multidrug
./___Corpus/Medline/xml/PMC4905370.xml	MDR1	50150 : 50154	CM	ug resistance protein 1, MDR1, or P-glycoprotein, P-GP
./___Corpus/Medline/xml/PMC4905370.xml	P-glycoprotein	50159 : 50173	CM	ance protein 1, MDR1, or P-glycoprotein, P-GP), which increases 
./___Corpus/Medline/xml/PMC4905370.xml	P-GP	50175 : 50179	CM	MDR1, or P-glycoprotein, P-GP), which increases drug e
./___Corpus/Medline/xml/PMC4905370.xml	PARP	50255 : 50259	CM	s being involved in DDR, PARP enzymes regulate many fu
./___Corpus/Medline/xml/PMC4905370.xml	PARP	50620 : 50624	CM	er layers of complexity, PARP enzymes have been linked
./___Corpus/Medline/xml/PMC4905370.xml	kappa-light	50743 : 50754	CM	se (ERK), nuclear factor kappa-light-chain-enhancer of activa
./___Corpus/Medline/xml/PMC4905370.xml	Wnt	50819 : 50822	CM	-kB), and wingless-type (Wnt)/β-catenin pathways.322-
./___Corpus/Medline/xml/PMC4905370.xml	β-catenin	50824 : 50833	CM	 and wingless-type (Wnt)/β-catenin pathways.322-325 PARP ac
./___Corpus/Medline/xml/PMC4905370.xml	PARP	50851 : 50855	CM	catenin pathways.322-325 PARP activity is also involve
./___Corpus/Medline/xml/PMC4905370.xml	MARylation	50932 : 50942	RN	 maintenance,326 whereas MARylation has been shown to regula
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	51111 : 51116	CM	a cytoprotective role of PARP1 and PAR in response to i
./___Corpus/Medline/xml/PMC4905370.xml	PAR	51121 : 51124	CM	ective role of PARP1 and PAR in response to intrinsic
./___Corpus/Medline/xml/PMC4905370.xml	FDA	51267 : 51270	CM	roval of olaparib by the FDA as a maintenance therapy
./___Corpus/Medline/xml/PMC4905370.xml	platinum	51314 : 51322	CM	herapy for patients with platinum-sensitive high-grade ser
./___Corpus/Medline/xml/PMC4905370.xml	PARP	51422 : 51426	CM	 showing the efficacy of PARP inhibitors in the adjuva
./___Corpus/Medline/xml/PMC4905370.xml	PARP1	51511 : 51516	CM	y for the advancement of PARP1 inhibitors in clinics. N
./___Corpus/Medline/xml/PMC4905370.xml	PARP	51734 : 51738	CM	ng of the biology of the PARP enzyme family and the id
./___Corpus/Medline/xml/PMC4905370.xml	PARP	51815 : 51819	CM	redictive biomarkers for PARP inhibitor-based therapie
./___Corpus/Medline/xml/PMC4905370.xml	RF_GR-2011	52420 : 52430	CM	o Italiano della Salute (RF_GR-2011–02351355), the Programma
./___Corpus/Medline/xml/PMC4905370.xml	PARP	52601 : 52605	CM	Trial watch – inhibiting PARP enzymes for anticancer t
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	635 : 646	CM	ition of targets such as cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	683 : 689	CM	nd metabolites, reactive oxygen species and hypoxia, mac
./___Corpus/Medline/xml/PMC4930000.xml	indoleamine	749 : 760	CM	tivation and conversion, indoleamine 2, 3-dioxygenase regulat
./___Corpus/Medline/xml/PMC4930000.xml	3-dioxygenase	764 : 777	CM	nversion, indoleamine 2, 3-dioxygenase regulation of dendritic 
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	893 : 901	CM	is, fibrosis inhibition, endoglin, and Janus kinase signal
./___Corpus/Medline/xml/PMC4930000.xml	berberine	1165 : 1174	CM	natural products such as berberine, resveratrol, onionin A,
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	1176 : 1187	CM	ducts such as berberine, resveratrol, onionin A, epigallocate
./___Corpus/Medline/xml/PMC4930000.xml	gallate	1217 : 1224	CM	onin A, epigallocatechin gallate, genistein, curcumin, na
./___Corpus/Medline/xml/PMC4930000.xml	genistein	1226 : 1235	CM	pigallocatechin gallate, genistein, curcumin, naringenin, d
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	1237 : 1245	CM	chin gallate, genistein, curcumin, naringenin, desoxyrhapo
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	1247 : 1257	CM	te, genistein, curcumin, naringenin, desoxyrhapontigenin, pi
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	1259 : 1278	CM	n, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone
./___Corpus/Medline/xml/PMC4930000.xml	piperine	1280 : 1288	CM	in, desoxyrhapontigenin, piperine, and zerumbone, that may
./___Corpus/Medline/xml/PMC4930000.xml	5–	2535 : 2537	CPR	 tumor microenvironment [5–8]. Hence, the manipulati
./___Corpus/Medline/xml/PMC4930000.xml	anti-	4642 : 4647	CPR	y mediate their reported anti-cancer effects through th
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	4734 : 4742	CM	nd ​and2,2, Tables 1 and ​and2).2). Our list is not a comp
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	5172 : 5183	CM	 tumor microenvironment (cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	5220 : 5226	CM	nd metabolites, reactive oxygen species (ROS) and hypoxi
./___Corpus/Medline/xml/PMC4930000.xml	ROS	5236 : 5239	CM	reactive oxygen species (ROS) and hypoxia, inflammati
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	5470 : 5478	CM	osis, angiogenesis), and cytokine mediated regulatory prog
./___Corpus/Medline/xml/PMC4930000.xml	(IL)-6	5521 : 5527	CM	ry programs (interleukin (IL)-6, endoglin, and Janus-ass
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	5529 : 5537	CM	ams (interleukin (IL)-6, endoglin, and Janus-associated ki
./___Corpus/Medline/xml/PMC4930000.xml	JAK	5568 : 5571	CM	Janus-associated kinase (JAK)) (Figure 1, Tables 1 an
./___Corpus/Medline/xml/PMC4930000.xml	berberine	5892 : 5901	CM	nd the microenvironment (berberine), others more specifical
./___Corpus/Medline/xml/PMC4930000.xml	ROS	5936 : 5939	CM	more specifically target ROS (resveratrol, desoxyrhap
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	5941 : 5952	CM	specifically target ROS (resveratrol, desoxyrhapontigenin) ma
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	5954 : 5973	CM	target ROS (resveratrol, desoxyrhapontigenin) macrophage conversion (
./___Corpus/Medline/xml/PMC4930000.xml	indoleamine	6010 : 6021	CM	 conversion (onionin A), indoleamine 2,3-dioxygenase (IDO) re
./___Corpus/Medline/xml/PMC4930000.xml	2,3-dioxygenase	6022 : 6037	CM	(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of dend
./___Corpus/Medline/xml/PMC4930000.xml	IDO	6039 : 6042	CM	leamine 2,3-dioxygenase (IDO) regulation of dendritic
./___Corpus/Medline/xml/PMC4930000.xml	epigallocatechin-3-gallate	6075 : 6101	CM	tion of dendritic cells (epigallocatechin-3-gallate (EGCG)), cholesterol syn
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	6103 : 6107	CM	gallocatechin-3-gallate (EGCG)), cholesterol synthesis
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	6111 : 6122	CM	echin-3-gallate (EGCG)), cholesterol synthesis (genistein), f
./___Corpus/Medline/xml/PMC4930000.xml	genistein	6134 : 6143	CM	, cholesterol synthesis (genistein), fibrosis (naringenin),
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	6156 : 6166	CM	s (genistein), fibrosis (naringenin), inflammation and immun
./___Corpus/Medline/xml/PMC4930000.xml	piperine	6204 : 6212	CM	on and immune signaling (piperine), vascular endothelial g
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	6251 : 6255	CM	dothelial growth factor (VEGF) inhibition (curcumin), 
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	6269 : 6277	CM	actor (VEGF) inhibition (curcumin), and JAK signaling (zer
./___Corpus/Medline/xml/PMC4930000.xml	JAK	6284 : 6287	CM	hibition (curcumin), and JAK signaling (zerumbone). T
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	6386 : 6394	CM	 (Figure 1, Tables 1 and ​and2).2). These agents generally
./___Corpus/Medline/xml/PMC4930000.xml	anti-	7887 : 7892	CPR	pro-cancer potential and anti-tumorigenic potential, we
./___Corpus/Medline/xml/PMC4930000.xml	vitro	8885 : 8890	CM	ting of only a single in vitro study involving a single
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	9394 : 9405	CM	          2. Targets 2.1 Cholesterol synthesis and its metabo
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	9461 : 9472	CM	                     The cholesterol pathway has general impo
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	9762 : 9773	CM	                         Cholesterol synthesis and metabolite
./___Corpus/Medline/xml/PMC4930000.xml	9–	9855 : 9857	CPR	ology of carcinogenesis [9–11]. Cholesterol and its 
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	9862 : 9873	CM	f carcinogenesis [9–11]. Cholesterol and its metabolites have
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	9992 : 10003	CM	ar growth and signaling. Cholesterol and its metabolites are 
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	10200 : 10211	CM	activation of oncogenes. Cholesterol is critical to normal ho
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	10269 : 10280	CM	lar and immune function. Cholesterol is specially localized i
./___Corpus/Medline/xml/PMC4930000.xml	lipid	10307 : 10312	CM	s specially localized in lipid rafts, which are membran
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	10678 : 10689	CM	                         Cholesterol was first identified in 
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	10745 : 10756	CM	ones [13]. Subsequently, cholesterol was found to be importan
./___Corpus/Medline/xml/PMC4930000.xml	vitamin	10971 : 10978	CM	esis of hormones such as vitamin D, testosterone, progest
./___Corpus/Medline/xml/PMC4930000.xml	testosterone	10982 : 10994	CM	mones such as vitamin D, testosterone, progesterone, cortisol 
./___Corpus/Medline/xml/PMC4930000.xml	progesterone	10996 : 11008	CM	vitamin D, testosterone, progesterone, cortisol and estradiol,
./___Corpus/Medline/xml/PMC4930000.xml	cortisol	11010 : 11018	CM	tosterone, progesterone, cortisol and estradiol, the regul
./___Corpus/Medline/xml/PMC4930000.xml	estradiol	11023 : 11032	CM	ogesterone, cortisol and estradiol, the regulation of cellu
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	11124 : 11135	CM	products [9,10]. Indeed, cholesterol and its metabolites are 
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	11191 : 11202	RN	al to the regulation via prenylation of many oncogenes includ
./___Corpus/Medline/xml/PMC4930000.xml	RAS	11231 : 11234	CM	many oncogenes including RAS and perhaps MYC [14,15].
./___Corpus/Medline/xml/PMC4930000.xml	MYC	11247 : 11250	CM	ncluding RAS and perhaps MYC [14,15]. Cholesterol bio
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	11260 : 11271	CM	and perhaps MYC [14,15]. Cholesterol biosynthesis generally a
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	11548 : 11559	CM	                         Cholesterol biosynthesis has been we
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	11604 : 11615	CM	en well defined [16,17]. Cholesterol is generally synthesized
./___Corpus/Medline/xml/PMC4930000.xml	acetyl	11690 : 11696	CM	ith one molecule each of acetyl CoA and acetoacetyl CoA 
./___Corpus/Medline/xml/PMC4930000.xml	acetoacetyl	11705 : 11716	CM	e each of acetyl CoA and acetoacetyl CoA [18]. Cholesterol is
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11717 : 11720	CM	etyl CoA and acetoacetyl CoA [18]. Cholesterol is reg
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	11727 : 11738	CM	nd acetoacetyl CoA [18]. Cholesterol is regulated in the endo
./___Corpus/Medline/xml/PMC4930000.xml	sterol	11784 : 11790	CM	endoplasmic reticulum by sterol regulatory element-bindi
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	11848 : 11859	CM	in (SREBP) 1 and 2 [19]. Cholesterol synthesis is controlled 
./___Corpus/Medline/xml/PMC4930000.xml	beta-hydroxy	11927 : 11939	CM	tic reaction mediated by beta-hydroxy- beta-methylglutaryl CoA
./___Corpus/Medline/xml/PMC4930000.xml	beta-methylglutaryl	11941 : 11960	CM	ediated by beta-hydroxy- beta-methylglutaryl CoA reductase (HMG- CoA)
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11961 : 11964	CM	oxy- beta-methylglutaryl CoA reductase (HMG- CoA) [20
./___Corpus/Medline/xml/PMC4930000.xml	reductase	11965 : 11974	CM	 beta-methylglutaryl CoA reductase (HMG- CoA) [20]. Many st
./___Corpus/Medline/xml/PMC4930000.xml	HMG	11976 : 11979	CM	lglutaryl CoA reductase (HMG- CoA) [20]. Many studies
./___Corpus/Medline/xml/PMC4930000.xml	CoA	11981 : 11984	CM	aryl CoA reductase (HMG- CoA) [20]. Many studies sugg
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12018 : 12029	CM	any studies suggest that cholesterol and its metabolites play
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12170 : 12181	CM	del studies suggest that cholesterol biosynthesis is causativ
./___Corpus/Medline/xml/PMC4930000.xml	21–	12227 : 12230	CPR	ative for tumorigenesis [21–23]. Similarly, in transg
./___Corpus/Medline/xml/PMC4930000.xml	transgenic	12249 : 12259	CM	s [21–23]. Similarly, in transgenic mouse models of oncogene
./___Corpus/Medline/xml/PMC4930000.xml	HMG-CoA	12388 : 12395	CM	eated with inhibitors of HMG-CoA reductase [24,25], which
./___Corpus/Medline/xml/PMC4930000.xml	RAS	12471 : 12474	CM	d with the inhibition of RAS and MYC oncogenes, respe
./___Corpus/Medline/xml/PMC4930000.xml	MYC	12479 : 12482	CM	he inhibition of RAS and MYC oncogenes, respectively.
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12633 : 12644	CM	ving agents that inhibit cholesterol metabolism reduce the ri
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12703 : 12714	CM	cer [26]. Notably, serum cholesterol and cancer risk appears 
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	12891 : 12902	CM	ting increased levels of cholesterol in tumors compared to no
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13016 : 13027	CM	n programs that regulate cholesterol biosynthesis through the
./___Corpus/Medline/xml/PMC4930000.xml	HMG-CoA	13069 : 13076	CM	ough the upregulation of HMG-CoA reductase activity [30,3
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13173 : 13184	CM	 uptake of extracellular cholesterol through the LDL receptor
./___Corpus/Medline/xml/PMC4930000.xml	LDL	13197 : 13200	CM	 cholesterol through the LDL receptor [32,33] and dec
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13246 : 13257	CM	 decreased expression of cholesterol exporter ATP binding cas
./___Corpus/Medline/xml/PMC4930000.xml	ATP	13267 : 13270	CM	 of cholesterol exporter ATP binding cassette transpo
./___Corpus/Medline/xml/PMC4930000.xml	ABCA1	13304 : 13309	CM	cassette transporter A1 (ABCA1) [33–35]. Finally, obesi
./___Corpus/Medline/xml/PMC4930000.xml	33–	13312 : 13315	CPR	 transporter A1 (ABCA1) [33–35]. Finally, obesity and
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13346 : 13357	CM	inally, obesity and high cholesterol level is associated with
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	13486 : 13497	CM	                         Cholesterol metabolites play a key r
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	13589 : 13600	CM	ear oncogene activation. Cholesterol metabolites are key to t
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	13665 : 13676	RN	f many oncogenes through prenylation including the RAS oncoge
./___Corpus/Medline/xml/PMC4930000.xml	RAS	13691 : 13694	CM	renylation including the RAS oncogene [25]. In turn, 
./___Corpus/Medline/xml/PMC4930000.xml	MYC	13755 : 13758	CM	to the regulation of the MYC oncogene [24,25]. Thus, 
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	13783 : 13794	CM	 oncogene [24,25]. Thus, cholesterol metabolism is likely pla
./___Corpus/Medline/xml/PMC4930000.xml	Cholesterol	13849 : 13860	CM	a role in tumorigenesis. Cholesterol is a key component of ce
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	14024 : 14035	CM	 potential importance of cholesterol biosynthesis in cancer h
./___Corpus/Medline/xml/PMC4930000.xml	HMG-CoA	14105 : 14112	CM	t interest in the use of HMG-CoA reductase inhibitors, st
./___Corpus/Medline/xml/PMC4930000.xml	37–	14193 : 14196	CPR	vention of human cancer [37–41].                  2.2
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14247 : 14250	CM	ROS                      ROS influences the tumor mic
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14384 : 14387	CM	evention of cancer [42]. ROS can be defined as oxygen
./___Corpus/Medline/xml/PMC4930000.xml	oxygen	14406 : 14412	CM	]. ROS can be defined as oxygen radicals and non-radical
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14590 : 14593	CM	ted in the generation of ROS are nicotinamide adenine
./___Corpus/Medline/xml/PMC4930000.xml	nicotinamide adenine dinucleotide phosphate	14598 : 14641	CM	he generation of ROS are nicotinamide adenine dinucleotide phosphate (NADPH), myeloperoxidase
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	14643 : 14648	CM	 dinucleotide phosphate (NADPH), myeloperoxidase (MPO) 
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	14677 : 14685	CM	yeloperoxidase (MPO) and xanthine oxidoreductase (XOR). Th
./___Corpus/Medline/xml/PMC4930000.xml	oxidoreductase	14686 : 14700	CM	idase (MPO) and xanthine oxidoreductase (XOR). The non-enzymatic
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14749 : 14752	CM	c reaction that produces ROS is through the mitochond
./___Corpus/Medline/xml/PMC4930000.xml	iron	14827 : 14831	CM	s the use of “catalytic” iron or copper ions. ROS are 
./___Corpus/Medline/xml/PMC4930000.xml	copper	14835 : 14841	CM	e of “catalytic” iron or copper ions. ROS are involved i
./___Corpus/Medline/xml/PMC4930000.xml	ROS	14848 : 14851	CM	ic” iron or copper ions. ROS are involved in various 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15084 : 15087	CM	5]. Excess production of ROS may ultimately lead to t
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15169 : 15172	CM	                         ROS contributes to tumorigen
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15277 : 15280	CM	r microenvironment [46]. ROS levels in cancer cells a
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15394 : 15397	CM	 as cancer cells produce ROS via mitochondria [49]. D
./___Corpus/Medline/xml/PMC4930000.xml	anti-	15441 : 15446	CPR	49]. Deregulation of the anti-oxidant machinery of the 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15616 : 15619	CM	ncement in the levels of ROS in the matrix [49] that 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15692 : 15695	CM	ole in the regulation of ROS [50–52].                
./___Corpus/Medline/xml/PMC4930000.xml	50–	15697 : 15700	CPR	n the regulation of ROS [50–52].                     
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15761 : 15764	CM	       The regulation of ROS is important to tumorige
./___Corpus/Medline/xml/PMC4930000.xml	superoxide	15821 : 15831	CM	The mitochondrial enzyme superoxide dismutase 2 (SOD2) [53,5
./___Corpus/Medline/xml/PMC4930000.xml	SOD2	15845 : 15849	CM	 superoxide dismutase 2 (SOD2) [53,54] regulates tumor
./___Corpus/Medline/xml/PMC4930000.xml	ROS	15943 : 15946	CM	r genes are regulated by ROS, including the phosphata
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	15962 : 15973	CM	ed by ROS, including the phosphatase and tensin homologue (PT
./___Corpus/Medline/xml/PMC4930000.xml	mitogen	16032 : 16039	CM	 suppressor [56,57], the mitogen activated protein kinase
./___Corpus/Medline/xml/PMC4930000.xml	ERK	16121 : 16124	CM	ignal regulated kinases (ERK) pathway [58–60]. ROS le
./___Corpus/Medline/xml/PMC4930000.xml	58–	16135 : 16138	CPR	d kinases (ERK) pathway [58–60]. ROS levels have been
./___Corpus/Medline/xml/PMC4930000.xml	ROS	16143 : 16146	CM	s (ERK) pathway [58–60]. ROS levels have been shown t
./___Corpus/Medline/xml/PMC4930000.xml	anti-	16301 : 16306	CPR	cells [62]. Finally, the anti-neoplastic properties of 
./___Corpus/Medline/xml/PMC4930000.xml	tamoxifen	16419 : 16428	CM	operties [63], including tamoxifen [63,64] and sulphasalazi
./___Corpus/Medline/xml/PMC4930000.xml	ROS	16485 : 16488	CM	66]. The manipulation of ROS levels could be therapeu
./___Corpus/Medline/xml/PMC4930000.xml	M1	17041 : 17043	CM	 of macrophages from an “M1” to an “M2” phenotype [6
./___Corpus/Medline/xml/PMC4930000.xml	M2	17052 : 17054	CM	ages from an “M1” to an “M2” phenotype [68]. Physiol
./___Corpus/Medline/xml/PMC4930000.xml	M1	17114 : 17116	CM	ctivated macrophages, or M1-type macrophages, produc
./___Corpus/Medline/xml/PMC4930000.xml	IL	17181 : 17183	CM	h as IL-1β, IL-8, IL-12, IL-15, IL-18, IL-23 and tum
./___Corpus/Medline/xml/PMC4930000.xml	(TNF)-α	17227 : 17234	CM	nd tumor necrosis factor (TNF)-α in response to signaling
./___Corpus/Medline/xml/PMC4930000.xml	Th1	17481 : 17484	CM	ote the development of a Th1 immune response to elimi
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	17662 : 17670	CM	igher levels of IL-10, a cytokine that alters the differen
./___Corpus/Medline/xml/PMC4930000.xml	Th1	17738 : 17741	CM	 away from the cytotoxic Th1 response [70]. M2 macrop
./___Corpus/Medline/xml/PMC4930000.xml	(TGF)-β	17829 : 17836	CM	ansforming growth factor (TGF)-β, a cytokine that can dam
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	17840 : 17848	CM	growth factor (TGF)-β, a cytokine that can dampen the abil
./___Corpus/Medline/xml/PMC4930000.xml	CD4+	18372 : 18376	CM	tigens through MHC II to CD4+ T cells and to cross-pre
./___Corpus/Medline/xml/PMC4930000.xml	MHC-I	18406 : 18411	CM	lls and to cross-present MHC-I to CD8+ T cells [72]. Fo
./___Corpus/Medline/xml/PMC4930000.xml	CD8+	18415 : 18419	CM	o cross-present MHC-I to CD8+ T cells [72]. Following 
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	18532 : 18537	CM	PS) or interferon-gamma (IFN-γ), macrophages upregulate
./___Corpus/Medline/xml/PMC4930000.xml	CD80	18608 : 18612	CM	les such as MHC-class I, CD80, CD83 and CD86, enabling
./___Corpus/Medline/xml/PMC4930000.xml	CD83	18614 : 18618	CM	ch as MHC-class I, CD80, CD83 and CD86, enabling T cel
./___Corpus/Medline/xml/PMC4930000.xml	CD86	18623 : 18627	CM	-class I, CD80, CD83 and CD86, enabling T cells to ful
./___Corpus/Medline/xml/PMC4930000.xml	M2	18852 : 18854	CM	 Thus, IL-12 can convert M2 into M1 macrophages. Thi
./___Corpus/Medline/xml/PMC4930000.xml	M1	18860 : 18862	CM	L-12 can convert M2 into M1 macrophages. This can en
./___Corpus/Medline/xml/PMC4930000.xml	CD8+	18916 : 18920	CM	 antigen presentation to CD8+ T cells and improved ant
./___Corpus/Medline/xml/PMC4930000.xml	anti-	18942 : 18947	CPR	D8+ T cells and improved anti-tumor immunity [74].     
./___Corpus/Medline/xml/PMC4930000.xml	PD-L1	19182 : 19187	CM	ogrammed death-ligand 1 (PD-L1) [73]. This can engage t
./___Corpus/Medline/xml/PMC4930000.xml	PD-1	19215 : 19219	CM	73]. This can engage the PD-1 receptors on T cells and
./___Corpus/Medline/xml/PMC4930000.xml	PD-1	19318 : 19322	CM	ns. Therapies that block PD-1 and PD-L1 may be effecti
./___Corpus/Medline/xml/PMC4930000.xml	PD-L1	19327 : 19332	CM	pies that block PD-1 and PD-L1 may be effective for the
./___Corpus/Medline/xml/PMC4930000.xml	IDO	19603 : 19606	CM	er.                  2.4 IDO                      DCs
./___Corpus/Medline/xml/PMC4930000.xml	anti-	19805 : 19810	CPR	 key players in inducing anti-tumor immune responses. D
./___Corpus/Medline/xml/PMC4930000.xml	DCs	19956 : 19959	CM	 tolerogenic function of DCs has been associated with
./___Corpus/Medline/xml/PMC4930000.xml	B7	20032 : 20034	CM	 molecules including the B7 family members and PD-L1
./___Corpus/Medline/xml/PMC4930000.xml	PD-L1	20054 : 20059	CM	he B7 family members and PD-L1, B7-H2, B7-H3, B7-H4 and
./___Corpus/Medline/xml/PMC4930000.xml	B7-H2	20061 : 20066	CM	amily members and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [
./___Corpus/Medline/xml/PMC4930000.xml	B7-H3	20068 : 20073	CM	embers and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [82–89].
./___Corpus/Medline/xml/PMC4930000.xml	B7-H4	20075 : 20080	CM	and PD-L1, B7-H2, B7-H3, B7-H4 and BTLA [82–89].       
./___Corpus/Medline/xml/PMC4930000.xml	BTLA	20085 : 20089	CM	 B7-H2, B7-H3, B7-H4 and BTLA [82–89].                
./___Corpus/Medline/xml/PMC4930000.xml	82–	20091 : 20094	CPR	, B7-H3, B7-H4 and BTLA [82–89].                     
./___Corpus/Medline/xml/PMC4930000.xml	DCs	20170 : 20173	CM	ne tolerance mediated by DCs appears to be mediated b
./___Corpus/Medline/xml/PMC4930000.xml	nitric oxide	20329 : 20341	CM	 These include inducible nitric oxide synthase, which generate
./___Corpus/Medline/xml/PMC4930000.xml	nitric oxide	20368 : 20380	CM	ynthase, which generates nitric oxide, arginase-1, which deple
./___Corpus/Medline/xml/PMC4930000.xml	arginase-1	20382 : 20392	CM	 generates nitric oxide, arginase-1, which depletes the mili
./___Corpus/Medline/xml/PMC4930000.xml	arginine	20423 : 20431	CM	h depletes the milieu of arginine, and IDO, which degrades
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20437 : 20440	CM	 milieu of arginine, and IDO, which degrades the esse
./___Corpus/Medline/xml/PMC4930000.xml	amino acid tryptophan	20471 : 20492	CM	h degrades the essential amino acid tryptophan (TRP) and catalyzes the 
./___Corpus/Medline/xml/PMC4930000.xml	TRP	20494 : 20497	CM	l amino acid tryptophan (TRP) and catalyzes the gener
./___Corpus/Medline/xml/PMC4930000.xml	kynurenine	20531 : 20541	CM	alyzes the generation of kynurenine (KYN) [90–95].          
./___Corpus/Medline/xml/PMC4930000.xml	KYN	20543 : 20546	CM	eneration of kynurenine (KYN) [90–95].               
./___Corpus/Medline/xml/PMC4930000.xml	90–	20549 : 20552	CPR	ion of kynurenine (KYN) [90–95].                     
./___Corpus/Medline/xml/PMC4930000.xml	96–	20668 : 20671	CPR	ainst tumor development [96–100]. DCs harboring activ
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20698 : 20701	CM	0]. DCs harboring active IDO have been detected in th
./___Corpus/Medline/xml/PMC4930000.xml	101–	20776 : 20780	CPR	or draining lymph nodes [101–103]. These cells can sup
./___Corpus/Medline/xml/PMC4930000.xml	IDO	20832 : 20835	CM	ess T cell functions via IDO activation by two mechan
./___Corpus/Medline/xml/PMC4930000.xml	KYN	20881 : 20884	CM	chanisms. In the case of KYN, upon interaction with t
./___Corpus/Medline/xml/PMC4930000.xml	aryl hydrocarbon	20912 : 20928	CM	pon interaction with the aryl hydrocarbon receptor, this molecule 
./___Corpus/Medline/xml/PMC4930000.xml	NK	21008 : 21010	CM	iferation of T cells and NK cells, promote regulator
./___Corpus/Medline/xml/PMC4930000.xml	DC	21086 : 21088	CM	ation, and inhibition of DC immunogenicity [90,91,10
./___Corpus/Medline/xml/PMC4930000.xml	TRP	21136 : 21139	CM	104]. In addition, rapid TRP depletion from the micro
./___Corpus/Medline/xml/PMC4930000.xml	CD8	21228 : 21231	CM	ells, inducing anergy in CD8 cytotoxic T cells and pr
./___Corpus/Medline/xml/PMC4930000.xml	CD4	21264 : 21267	CM	ic T cells and promoting CD4 differentiation towards 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21376 : 21379	CM	mor cells can synthetize IDO. But, it is not clear if
./___Corpus/Medline/xml/PMC4930000.xml	KYN	21431 : 21434	CM	he major contributors to KYN generation and TRP deple
./___Corpus/Medline/xml/PMC4930000.xml	TRP	21450 : 21453	CM	rs to KYN generation and TRP depletion in the tumor m
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21603 : 21606	CM	egardless of the source, IDO activation can induce im
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21663 : 21666	CM	pression. High levels of IDO are correlated with poor
./___Corpus/Medline/xml/PMC4930000.xml	107–	21703 : 21707	CPR	ted with poor prognosis [107–112]. IDO inhibition can 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21713 : 21716	CM	oor prognosis [107–112]. IDO inhibition can suppress 
./___Corpus/Medline/xml/PMC4930000.xml	113–	21771 : 21775	CPR	 growth in mouse models [113–117]. Hence, IDO inhibito
./___Corpus/Medline/xml/PMC4930000.xml	IDO	21788 : 21791	CM	models [113–117]. Hence, IDO inhibitors may be useful
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	21904 : 21908	CM	er.                  2.5 VEGF                      VEG
./___Corpus/Medline/xml/PMC4930000.xml	VEGF-A	22007 : 22013	CM	 They comprise a family (VEGF-A, -B, -C, -D, -E and plac
./___Corpus/Medline/xml/PMC4930000.xml	-B	22015 : 22017	CM	mprise a family (VEGF-A, -B, -C, -D, -E and placenta
./___Corpus/Medline/xml/PMC4930000.xml	-C	22019 : 22021	CM	se a family (VEGF-A, -B, -C, -D, -E and placenta gro
./___Corpus/Medline/xml/PMC4930000.xml	-D	22023 : 22025	CM	 family (VEGF-A, -B, -C, -D, -E and placenta growth 
./___Corpus/Medline/xml/PMC4930000.xml	-E	22027 : 22029	CM	ily (VEGF-A, -B, -C, -D, -E and placenta growth fact
./___Corpus/Medline/xml/PMC4930000.xml	PGF	22058 : 22061	CM	 placenta growth factor [PGF]) of growth factors that
./___Corpus/Medline/xml/PMC4930000.xml	cysteine	22121 : 22129	CM	nserved pattern of eight cysteine residues [118–120]. In p
./___Corpus/Medline/xml/PMC4930000.xml	118–	22140 : 22144	CPR	eight cysteine residues [118–120]. In particular, VEGF
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	22241 : 22245	CM	d usually referred to as VEGF) has the capability to a
./___Corpus/Medline/xml/PMC4930000.xml	mitogen	22283 : 22290	CM	ability to act both as a mitogen, stimulating the prolife
./___Corpus/Medline/xml/PMC4930000.xml	118–	22416 : 22420	CPR	ty to attract monocytes [118–120].                    
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	22506 : 22510	CM	four different isoforms (VEGF 121, 165, 189 and 206), 
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	22610 : 22614	CM	The properties of native VEGF most closely correspond 
./___Corpus/Medline/xml/PMC4930000.xml	isoform	22692 : 22699	CM	s the predominant VEGF-A isoform [118]. VEGF participates
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	22707 : 22711	CM	nt VEGF-A isoform [118]. VEGF participates in differen
./___Corpus/Medline/xml/PMC4930000.xml	118–	22818 : 22822	CPR	ling, and embryogenesis [118–120]. VEGF has been shown
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	22828 : 22832	CM	embryogenesis [118–120]. VEGF has been shown to partic
./___Corpus/Medline/xml/PMC4930000.xml	121–	23014 : 23018	CPR	formation of neovessels [121–123]. VEGF alone can init
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	23078 : 23082	CM	ngiogenic cascade [124]. VEGF is secreted by most huma
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	23128 : 23132	CM	human cancers [124], and VEGF expression can be correl
./___Corpus/Medline/xml/PMC4930000.xml	125–	23235 : 23239	CPR	 types of cancer tumors [125–128].                    
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	23283 : 23287	CM	                         VEGF interacts with common re
./___Corpus/Medline/xml/PMC4930000.xml	VEGFR-1	23321 : 23328	CM	s with common receptors (VEGFR-1, VEGFR-2, VEGFR-3 and ne
./___Corpus/Medline/xml/PMC4930000.xml	neuropilin-1	23351 : 23363	CM	-1, VEGFR-2, VEGFR-3 and neuropilin-1) [129]. They comprise a 
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	23407 : 23415	CM	ise a family of receptor tyrosine kinases (RTKs) showing s
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	23550 : 23558	CM	e region and a consensus tyrosine sequence that is interru
./___Corpus/Medline/xml/PMC4930000.xml	118–	23615 : 23619	CPR	 a kinase-insert domain [118–120]. VEGF-A also interac
./___Corpus/Medline/xml/PMC4930000.xml	mitogenic	23849 : 23858	CM	EGFR-1 is able to induce mitogenic and pro-survival signal 
./___Corpus/Medline/xml/PMC4930000.xml	VEGFR-1	24183 : 24190	CM	n of monocytes. Finally, VEGFR-1 can heterodimerize with 
./___Corpus/Medline/xml/PMC4930000.xml	VEGFR-2	24215 : 24222	CM	 can heterodimerize with VEGFR-2, leading to a transactiv
./___Corpus/Medline/xml/PMC4930000.xml	118–	24362 : 24366	CPR	enesis and angiogenesis [118–120]. Upon ligand binding
./___Corpus/Medline/xml/PMC4930000.xml	VEGFR-2	24393 : 24400	CM	0]. Upon ligand binding, VEGFR-2 dimerizes and autophosph
./___Corpus/Medline/xml/PMC4930000.xml	autophosphorylates	24415 : 24433	CM	g, VEGFR-2 dimerizes and autophosphorylates on multiple tyrosine res
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	24446 : 24454	CM	osphorylates on multiple tyrosine residues. Ligation of VE
./___Corpus/Medline/xml/PMC4930000.xml	VEGFR-2	24477 : 24484	CM	ne residues. Ligation of VEGFR-2 by VEGF results in the p
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	24488 : 24492	CM	. Ligation of VEGFR-2 by VEGF results in the phosphory
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	24508 : 24523	RN	2 by VEGF results in the phosphorylation of different proteins su
./___Corpus/Medline/xml/PMC4930000.xml	PI-3	24554 : 24558	CM	fferent proteins such as PI-3-kinase, RAS GTPase-activ
./___Corpus/Medline/xml/PMC4930000.xml	RAS	24567 : 24570	CM	ins such as PI-3-kinase, RAS GTPase-activating protei
./___Corpus/Medline/xml/PMC4930000.xml	SRC	24602 : 24605	CM	-activating protein, the SRC protein family, and the 
./___Corpus/Medline/xml/PMC4930000.xml	RAF-MEK-ERK	24648 : 24659	CM	nd the proteins from the RAF-MEK-ERK pathway [119,120,135]. V
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	24778 : 24782	CM	 and angiogenesis. Thus, VEGF and its receptors are co
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	24946 : 24950	CM	                         VEGF has been the target for 
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	25044 : 25048	CM	lonal antibody targeting VEGF (bevacizumab/avastin) ha
./___Corpus/Medline/xml/PMC4930000.xml	138–	25256 : 25260	CPR	combinatorial therapies [138–140]. Aflibercept/VEGF-tr
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	25320 : 25324	CM	 as a decoy receptor for VEGF. This compound has antit
./___Corpus/Medline/xml/PMC4930000.xml	137,141–	25364 : 25372	CPR	 has antitumor efficacy [137,141–144]. Finally, RTK inhibi
./___Corpus/Medline/xml/PMC4930000.xml	RTK	25387 : 25390	CM	 [137,141–144]. Finally, RTK inhibitors such as sunit
./___Corpus/Medline/xml/PMC4930000.xml	sunitinib	25410 : 25419	CM	, RTK inhibitors such as sunitinib and sorafenib have activ
./___Corpus/Medline/xml/PMC4930000.xml	sorafenib	25424 : 25433	CM	rs such as sunitinib and sorafenib have activity in gastric
./___Corpus/Medline/xml/PMC4930000.xml	CXCR4	25798 : 25803	CM	TGF-β, IL-1, IL-6, IL-8, CXCR4, CXCL12, and monocyte-ch
./___Corpus/Medline/xml/PMC4930000.xml	CXCL12	25805 : 25811	CM	IL-1, IL-6, IL-8, CXCR4, CXCL12, and monocyte-chemotacti
./___Corpus/Medline/xml/PMC4930000.xml	HGF	25905 : 25908	CM	ed growth factor (PDGF), HGF, stromal-cell-derived fa
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	25948 : 25952	CM	derived factor 1 (SDF1), VEGF, and basic fibroblast gr
./___Corpus/Medline/xml/PMC4930000.xml	bFGF	25990 : 25994	CM	ibroblast growth factor (bFGF) [147].                 
./___Corpus/Medline/xml/PMC4930000.xml	ECM	26190 : 26193	CM	nce the breakdown of the ECM and aid in cancer cells 
./___Corpus/Medline/xml/PMC4930000.xml	EMT	26365 : 26368	CM	 mesenchymal transition (EMT), a process that trigger
./___Corpus/Medline/xml/PMC4930000.xml	EMT	26507 : 26510	CM	 properties of stemness. EMT may be a biomarker of po
./___Corpus/Medline/xml/PMC4930000.xml	150–	26654 : 26658	CPR	th many types of cancer [150–152]. Thus, the targeted 
./___Corpus/Medline/xml/PMC4930000.xml	actin	27042 : 27047	CM	eletion of smooth muscle actin positive myofibroblasts 
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	27497 : 27505	CM	 IL-6 is an inflammatory cytokine associated with innate i
./___Corpus/Medline/xml/PMC4930000.xml	TNFα	27708 : 27712	CM	ls can produce IL-1α and TNFα [155]. The dysregulation
./___Corpus/Medline/xml/PMC4930000.xml	IL-6Rα	27986 : 27992	CM	membrane-bound receptor (IL-6Rα/gp80) and signal transdu
./___Corpus/Medline/xml/PMC4930000.xml	glycoprotein	28021 : 28033	CM	0) and signal transducer glycoprotein (gp130), a receptor for 
./___Corpus/Medline/xml/PMC4930000.xml	155–	28093 : 28097	CPR	such as IL-11 and IL-27 [155–158]. The expression of s
./___Corpus/Medline/xml/PMC4930000.xml	IL-6Rα	28129 : 28135	CM	he expression of surface IL-6Rα is limited mostly to imm
./___Corpus/Medline/xml/PMC4930000.xml	157,159–	28287 : 28295	CPR	thelial and tumor cells [157,159–161]. The soluble form of
./___Corpus/Medline/xml/PMC4930000.xml	IL-6R	28325 : 28330	CM	 The soluble form of the IL-6R (sIL-6R) is able to inte
./___Corpus/Medline/xml/PMC4930000.xml	sIL-6R	28332 : 28338	CM	luble form of the IL-6R (sIL-6R) is able to interact wit
./___Corpus/Medline/xml/PMC4930000.xml	IL-6Rα	28487 : 28493	CM	s lacking membrane-bound IL-6Rα can still be influenced 
./___Corpus/Medline/xml/PMC4930000.xml	157,159–	28561 : 28569	CPR	in the microenvironment [157,159–162]. IL-6 activates JAK 
./___Corpus/Medline/xml/PMC4930000.xml	JAK	28590 : 28593	CM	159–162]. IL-6 activates JAK and the signal transduce
./___Corpus/Medline/xml/PMC4930000.xml	JAK	28654 : 28657	CM	vators of transcription (JAK/STAT) activating STAT3 [
./___Corpus/Medline/xml/PMC4930000.xml	STAT	28658 : 28662	CM	rs of transcription (JAK/STAT) activating STAT3 [155,1
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	28675 : 28680	CM	on (JAK/STAT) activating STAT3 [155,163,164]. STAT3 lea
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	28696 : 28701	CM	ing STAT3 [155,163,164]. STAT3 leads to cancer cell sur
./___Corpus/Medline/xml/PMC4930000.xml	172–	29133 : 29137	CPR	elate with poor outcome [172–181]. Finally, IL-6 can i
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	29186 : 29190	CM	induce the production of VEGF in cancer cells or tumor
./___Corpus/Medline/xml/PMC4930000.xml	182–	29234 : 29238	CPR	 tumor-associated cells [182–184]. Thus, IL-6 can prom
./___Corpus/Medline/xml/PMC4930000.xml	CNTO	29414 : 29418	CM	IL6 antibody (siltuximab/CNTO 328) increases the cytot
./___Corpus/Medline/xml/PMC4930000.xml	melphalan	29503 : 29512	CM	gs such as paclitaxel or melphalan [185–187] and decreased 
./___Corpus/Medline/xml/PMC4930000.xml	185–	29514 : 29518	CPR	paclitaxel or melphalan [185–187] and decreased tumor 
./___Corpus/Medline/xml/PMC4930000.xml	188–	29691 : 29695	CPR	udied in human patients [188–190]. Some effect was obs
./___Corpus/Medline/xml/PMC4930000.xml	anti-	29797 : 29802	CPR	. Similarly, a humanized anti-IL-6R antibody, tocilizum
./___Corpus/Medline/xml/PMC4930000.xml	193–	29912 : 29916	CPR	 in preclinical studies [193–195]. This antibody has b
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30031 : 30039	CM	7].                  2.8 Endoglin                      End
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30061 : 30069	CM	lin                      Endoglin (CD105) is a homodynamic
./___Corpus/Medline/xml/PMC4930000.xml	glycoprotein	30095 : 30107	CM	(CD105) is a homodynamic glycoprotein growth factor co-recepto
./___Corpus/Medline/xml/PMC4930000.xml	TGF-β	30138 : 30143	CM	h factor co-receptor for TGF-β in endothelial tissue th
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30244 : 30252	CM	ar remodeling [198,199]. Endoglin modulates SMAD phosphory
./___Corpus/Medline/xml/PMC4930000.xml	SMAD	30263 : 30267	CM	199]. Endoglin modulates SMAD phosphorylation and may 
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	30268 : 30283	RN	 Endoglin modulates SMAD phosphorylation and may control cell adh
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30601 : 30609	CM	lt from dysregulation of endoglin co-receptor functions [2
./___Corpus/Medline/xml/PMC4930000.xml	Endoglin	30639 : 30647	CM	eceptor functions [201]. Endoglin expression is observed i
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30746 : 30754	CM	is [202]. Inhibiting the endoglin pathway may be useful fo
./___Corpus/Medline/xml/PMC4930000.xml	TRC105	30820 : 30826	CM	of cancer [203,204]. The TRC105 antibody has high avidit
./___Corpus/Medline/xml/PMC4930000.xml	endoglin	30857 : 30865	CM	ody has high avidity for endoglin-binding and may have act
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31082 : 31085	CM	                     The JAK family includes the rece
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	31126 : 31134	CM	 the receptor-associated tyrosine kinases JAK1, JAK2, JAK3
./___Corpus/Medline/xml/PMC4930000.xml	JAK1	31143 : 31147	CM	ociated tyrosine kinases JAK1, JAK2, JAK3 and Tyk2 tha
./___Corpus/Medline/xml/PMC4930000.xml	JAK2	31149 : 31153	CM	d tyrosine kinases JAK1, JAK2, JAK3 and Tyk2 that are 
./___Corpus/Medline/xml/PMC4930000.xml	JAK3	31155 : 31159	CM	sine kinases JAK1, JAK2, JAK3 and Tyk2 that are import
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31301 : 31304	CM	rigenesis [207,208]. The JAK pathway is generally cri
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31407 : 31410	CM	lassical examples is the JAK-mediated STAT3 tyrosine 
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	31420 : 31425	CM	ples is the JAK-mediated STAT3 tyrosine phosphorylation
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	31426 : 31434	CM	s the JAK-mediated STAT3 tyrosine phosphorylation in respo
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	31435 : 31450	RN	-mediated STAT3 tyrosine phosphorylation in response to IL-6 fami
./___Corpus/Medline/xml/PMC4930000.xml	JAK2	31588 : 31592	CM	            Mutations in JAK2 and more commonly in JAK
./___Corpus/Medline/xml/PMC4930000.xml	JAK2	31614 : 31618	CM	AK2 and more commonly in JAK2 or SOCS1 have been impli
./___Corpus/Medline/xml/PMC4930000.xml	SOCS1	31622 : 31627	CM	more commonly in JAK2 or SOCS1 have been implicated in 
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31677 : 31680	CM	tumorigenesis [212]. The JAK/STAT3 pathway is constit
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	31681 : 31686	CM	rigenesis [212]. The JAK/STAT3 pathway is constitutivel
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31826 : 31829	CM	15,216]. IL-6 – mediated JAK/STAT paracrine signaling
./___Corpus/Medline/xml/PMC4930000.xml	STAT	31830 : 31834	CM	16]. IL-6 – mediated JAK/STAT paracrine signaling is c
./___Corpus/Medline/xml/PMC4930000.xml	217–	31887 : 31891	CPR	only observed in cancer [217–219].                    
./___Corpus/Medline/xml/PMC4930000.xml	JAK	31935 : 31938	CM	                         JAK signaling is important t
./___Corpus/Medline/xml/PMC4930000.xml	EMT	32053 : 32056	CM	ck cancer, IL-6 mediates EMT and increases metastatic
./___Corpus/Medline/xml/PMC4930000.xml	CCL5	32167 : 32171	CM	obulinemia, dysregulated CCL5 expression modulates IL-
./___Corpus/Medline/xml/PMC4930000.xml	IgM	32249 : 32252	CM	, resulting in increased IgM secretion by malignant c
./___Corpus/Medline/xml/PMC4930000.xml	JAK	32290 : 32293	CM	 malignant cells via the JAK/STAT pathway [221]. Panc
./___Corpus/Medline/xml/PMC4930000.xml	STAT	32294 : 32298	CM	ignant cells via the JAK/STAT pathway [221]. Pancreati
./___Corpus/Medline/xml/PMC4930000.xml	JAK	32471 : 32474	CM	suppressor cells via the JAK/STAT3-dependent mechanis
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	32475 : 32480	CM	ressor cells via the JAK/STAT3-dependent mechanism [222
./___Corpus/Medline/xml/PMC4930000.xml	AZD1480	32532 : 32539	CM	 In lung carcinogenesis, AZD1480 inhibits STAT3 activatio
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	32549 : 32554	CM	enesis, AZD1480 inhibits STAT3 activation in tumor-asso
./___Corpus/Medline/xml/PMC4930000.xml	AZD1480	32689 : 32696	CM	l-mediated angiogenesis. AZD1480 blocks angiogenesis, lun
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	32889 : 32894	CM	 as in human xenografts. STAT3 activation in cancer cel
./___Corpus/Medline/xml/PMC4930000.xml	AZD1480	32982 : 32989	CM	environment-mediated and AZD1480-inhibited lung cancer pr
./___Corpus/Medline/xml/PMC4930000.xml	TLR4	33100 : 33104	CM	erapeutic effects of the TLR4 and TLR9 agonist complex
./___Corpus/Medline/xml/PMC4930000.xml	TLR9	33109 : 33113	CM	 effects of the TLR4 and TLR9 agonist complexes agains
./___Corpus/Medline/xml/PMC4930000.xml	JAK	33219 : 33222	CM	use of inhibitors of the JAK/STAT pathway (such as th
./___Corpus/Medline/xml/PMC4930000.xml	STAT	33223 : 33227	CM	of inhibitors of the JAK/STAT pathway (such as the AG4
./___Corpus/Medline/xml/PMC4930000.xml	AG490	33249 : 33254	CM	TAT pathway (such as the AG490 antagonist). Such combin
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	33353 : 33358	CM	th of melanoma cells via IFN-γ/STAT1 activation and att
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	33359 : 33364	CM	melanoma cells via IFN-γ/STAT1 activation and attenuate
./___Corpus/Medline/xml/PMC4930000.xml	AG490	33475 : 33480	CM	-6 blocking antibody and AG490 and JAK inhibitor I bloc
./___Corpus/Medline/xml/PMC4930000.xml	JAK	33485 : 33488	CM	g antibody and AG490 and JAK inhibitor I blocks STAT3
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	33508 : 33513	CM	d JAK inhibitor I blocks STAT3 phosphorylation decreasi
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	33514 : 33529	RN	inhibitor I blocks STAT3 phosphorylation decreasing resistance to
./___Corpus/Medline/xml/PMC4930000.xml	JAK	33576 : 33579	CM	 to apoptosis [225]. The JAK/STAT3-dependent accumula
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	33580 : 33585	CM	apoptosis [225]. The JAK/STAT3-dependent accumulation o
./___Corpus/Medline/xml/PMC4930000.xml	S1PR1	33664 : 33669	CM	endent on an increase in S1PR1 protein in CD4+ T cells,
./___Corpus/Medline/xml/PMC4930000.xml	CD4+	33681 : 33685	CM	ease in S1PR1 protein in CD4+ T cells, while the JAK/S
./___Corpus/Medline/xml/PMC4930000.xml	JAK	33705 : 33708	CM	 CD4+ T cells, while the JAK/STAT3 pathway inhibition
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	33709 : 33714	CM	+ T cells, while the JAK/STAT3 pathway inhibition in T 
./___Corpus/Medline/xml/PMC4930000.xml	AZD1480	33876 : 33883	CM	ly completely blocked by AZD1480 [226]. The GP130-IL6ST/J
./___Corpus/Medline/xml/PMC4930000.xml	JAK1	33907 : 33911	CM	0 [226]. The GP130-IL6ST/JAK1 signaling generates acto
./___Corpus/Medline/xml/PMC4930000.xml	JAK	34072 : 34075	CM	e, the inhibition of the JAK pathway could be useful 
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	34265 : 34274	CM	ine                      Berberine (Figure 2) is quaternary
./___Corpus/Medline/xml/PMC4930000.xml	ammonium	34300 : 34308	CM	(Figure 2) is quaternary ammonium salt from the protoberbe
./___Corpus/Medline/xml/PMC4930000.xml	isoquinoline	34347 : 34359	CM	 protoberberine group of isoquinoline alkaloids with general a
./___Corpus/Medline/xml/PMC4930000.xml	anti-	34383 : 34388	CPR	e alkaloids with general anti-neoplastic properites [22
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	34421 : 34430	CM	ic properites [227,228]. Berberine has a low bioavailabiliy
./___Corpus/Medline/xml/PMC4930000.xml	lipidic	34734 : 34741	CM	s impact on glucidic and lipidic profiles in patients wit
./___Corpus/Medline/xml/PMC4930000.xml	berberine	34835 : 34844	CM	e metabolized product of berberine also acts as an original
./___Corpus/Medline/xml/PMC4930000.xml	berberine	34963 : 34972	CM	nary excreted product of berberine is believed to be jatror
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35103 : 35112	CM	e or dietary supplement, berberine has shown activity again
./___Corpus/Medline/xml/PMC4930000.xml	fatty	35335 : 35340	CM	a, diabetes, obesity and fatty liver disease. Currently
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35439 : 35448	CM	inical studies regarding berberine (www.clinicaltrials.org)
./___Corpus/Medline/xml/PMC4930000.xml	Adenosine mono-phosphate	35606 : 35630	CM	een widely investigated. Adenosine mono-phosphate kinase (AMPK) is a nutri
./___Corpus/Medline/xml/PMC4930000.xml	AMPK	35639 : 35643	CM	e mono-phosphate kinase (AMPK) is a nutrient sensor pr
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35675 : 35684	CM	nutrient sensor protein; berberine activates AMPK in a dose
./___Corpus/Medline/xml/PMC4930000.xml	AMPK	35695 : 35699	CM	ein; berberine activates AMPK in a dose and time-depen
./___Corpus/Medline/xml/PMC4930000.xml	berberine	35770 : 35779	CM	. The data suggests that berberine-induced AMPK inhibits co
./___Corpus/Medline/xml/PMC4930000.xml	AMPK	35788 : 35792	CM	s that berberine-induced AMPK inhibits complex I of th
./___Corpus/Medline/xml/PMC4930000.xml	anti-	35907 : 35912	CPR	so observed with the anti-diabetic drugs metformin and 
./___Corpus/Medline/xml/PMC4930000.xml	metformin	35923 : 35932	CM	 the anti-diabetic drugs metformin and rosiglitazone. In li
./___Corpus/Medline/xml/PMC4930000.xml	rosiglitazone	35937 : 35950	CM	etic drugs metformin and rosiglitazone. In lipid metabolism, th
./___Corpus/Medline/xml/PMC4930000.xml	lipid	35955 : 35960	CM	in and rosiglitazone. In lipid metabolism, the lipid-lo
./___Corpus/Medline/xml/PMC4930000.xml	lipid	35977 : 35982	CM	In lipid metabolism, the lipid-lowering effect of berbe
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36002 : 36011	CM	lipid-lowering effect of berberine is believed to be relate
./___Corpus/Medline/xml/PMC4930000.xml	LDL-C	36070 : 36075	CM	ilization of the hepatic LDL-C receptor (LDLR) by an ER
./___Corpus/Medline/xml/PMC4930000.xml	LDLR	36086 : 36090	CM	 hepatic LDL-C receptor (LDLR) by an ERK-dependent pat
./___Corpus/Medline/xml/PMC4930000.xml	ERK	36098 : 36101	CM	-C receptor (LDLR) by an ERK-dependent pathway and al
./___Corpus/Medline/xml/PMC4930000.xml	LDLR	36170 : 36174	CM	nscriptional activity of LDLR promoter by a c-Jun N te
./___Corpus/Medline/xml/PMC4930000.xml	3T3L1	36233 : 36238	CM	nase (JNK) [240,241]. In 3T3L1 cells, berberine has bee
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36246 : 36255	CM	40,241]. In 3T3L1 cells, berberine has been shown to reduce
./___Corpus/Medline/xml/PMC4930000.xml	adipogenic	36285 : 36295	CM	been shown to reduce key adipogenic enzymes in vitro such as
./___Corpus/Medline/xml/PMC4930000.xml	vitro	36307 : 36312	CM	ey adipogenic enzymes in vitro such as fatty acid synth
./___Corpus/Medline/xml/PMC4930000.xml	fatty acid	36321 : 36331	CM	enzymes in vitro such as fatty acid synthase, acetyl-coenzym
./___Corpus/Medline/xml/PMC4930000.xml	acetyl-coenzyme A	36342 : 36359	CM	 as fatty acid synthase, acetyl-coenzyme A (acetyl-CoA) carboxylase
./___Corpus/Medline/xml/PMC4930000.xml	acetyl-CoA	36361 : 36371	CM	hase, acetyl-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA s
./___Corpus/Medline/xml/PMC4930000.xml	carboxylase	36373 : 36384	CM	-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA synthase, and 
./___Corpus/Medline/xml/PMC4930000.xml	acyl-CoA	36386 : 36394	CM	acetyl-CoA) carboxylase, acyl-CoA synthase, and lipoprotei
./___Corpus/Medline/xml/PMC4930000.xml	lipase	36421 : 36427	CM	ynthase, and lipoprotein lipase [242]. Furthermore, berb
./___Corpus/Medline/xml/PMC4930000.xml	berberine	36448 : 36457	CM	pase [242]. Furthermore, berberine has been shown to inhibi
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	36484 : 36495	CM	as been shown to inhibit cholesterol and triglyceride synthes
./___Corpus/Medline/xml/PMC4930000.xml	triglyceride	36500 : 36512	CM	 inhibit cholesterol and triglyceride synthesis in hepatic cel
./___Corpus/Medline/xml/PMC4930000.xml	AMP	36558 : 36561	CM	 cells via activation of AMP kinase [243].           
./___Corpus/Medline/xml/PMC4930000.xml	anti-	36626 : 36631	CPR	             Berberine’s anti-neoplastic effects have b
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	36677 : 36686	CM	ve been noted [244,245]. Berberine appears to suppress infl
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	36767 : 36776	CM	lammatory stimuli [246]. Berberine at 10–20 mcg/mL concentr
./___Corpus/Medline/xml/PMC4930000.xml	10–	36780 : 36783	CPR	muli [246]. Berberine at 10–20 mcg/mL concentrations,
./___Corpus/Medline/xml/PMC4930000.xml	vitro	36812 : 36817	CM	cg/mL concentrations, in vitro, has been shown to sligh
./___Corpus/Medline/xml/PMC4930000.xml	JAK3	37017 : 37021	CM	 selective inhibition of JAK3 by berberine may also me
./___Corpus/Medline/xml/PMC4930000.xml	berberine	37025 : 37034	CM	ve inhibition of JAK3 by berberine may also mediate immunos
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37077 : 37086	CM	immunosuppression [248]. Berberine exerts its anti-tumor ef
./___Corpus/Medline/xml/PMC4930000.xml	anti-	37098 : 37103	CPR	8]. Berberine exerts its anti-tumor effects via various
./___Corpus/Medline/xml/PMC4930000.xml	JAK3	37307 : 37311	CM	omodulatory effects, via JAK3 inhibition, might also i
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37363 : 37372	CM	act cancer growth [248]. Berberine has been found to enhanc
./___Corpus/Medline/xml/PMC4930000.xml	doxorubicin	37419 : 37430	CM	ance the cytotoxicity of doxorubicin, which suggests that thi
./___Corpus/Medline/xml/PMC4930000.xml	berberine	37571 : 37580	CM	 The cytotoxic effect of berberine has been demonstrated fo
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37773 : 37782	CM	                         Berberine has a caspase-independen
./___Corpus/Medline/xml/PMC4930000.xml	IMCE	37833 : 37837	CM	 apoptotic effect on the IMCE colon cancer cell line b
./___Corpus/Medline/xml/PMC4930000.xml	YAMC	37900 : 37904	CM	al colonocyte cell line, YAMC [250]. Berberine also in
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	37912 : 37921	CM	e cell line, YAMC [250]. Berberine also induces cytotoxicit
./___Corpus/Medline/xml/PMC4930000.xml	caspase-3	37983 : 37992	CM	se cell cycle arrest and caspase-3-dependent apoptosis in g
./___Corpus/Medline/xml/PMC4930000.xml	251–	38071 : 38075	CPR	rostate carcinoma cells [251–253]. The apoptotic effec
./___Corpus/Medline/xml/PMC4930000.xml	berberine	38105 : 38114	CM	 The apoptotic effect of berberine is associated with upreg
./___Corpus/Medline/xml/PMC4930000.xml	p53	38185 : 38188	CM	optotic genes Fas, FasL, p53, and Bax [254–256]. Berb
./___Corpus/Medline/xml/PMC4930000.xml	254–	38199 : 38203	CPR	Fas, FasL, p53, and Bax [254–256]. Berberine has an an
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38209 : 38218	CM	 p53, and Bax [254–256]. Berberine has an anti-angiogenic e
./___Corpus/Medline/xml/PMC4930000.xml	anti-	38226 : 38231	CPR	4–256]. Berberine has an anti-angiogenic effect related
./___Corpus/Medline/xml/PMC4930000.xml	MMP-1	38284 : 38289	CM	 decreased expression of MMP-1, MMP-2 and MMP-9 [257–25
./___Corpus/Medline/xml/PMC4930000.xml	MMP-9	38301 : 38306	CM	sion of MMP-1, MMP-2 and MMP-9 [257–259].              
./___Corpus/Medline/xml/PMC4930000.xml	257–	38308 : 38312	CPR	 MMP-1, MMP-2 and MMP-9 [257–259].                    
./___Corpus/Medline/xml/PMC4930000.xml	ammonium	38372 : 38380	CM	         As a quaternary ammonium, berberine’s solubility 
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38413 : 38422	CM	ine’s solubility is low. Berberine use is hampered by its l
./___Corpus/Medline/xml/PMC4930000.xml	berberine	38660 : 38669	CM	crease the absorption of berberine, including the rotary-ev
./___Corpus/Medline/xml/PMC4930000.xml	isopropyl myristate	38762 : 38781	CM	 nanoemulsification with isopropyl myristate/glycerin [261], and lipi
./___Corpus/Medline/xml/PMC4930000.xml	glycerin	38782 : 38790	CM	with isopropyl myristate/glycerin [261], and lipisomal inc
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	38833 : 38842	CM	mal incorporation [262]. Berberine manufactured with the na
./___Corpus/Medline/xml/PMC4930000.xml	anti-	38960 : 38965	CPR	 and optimization of its anti-inflammatory, anti-angiog
./___Corpus/Medline/xml/PMC4930000.xml	anti-	38979 : 38984	CPR	f its anti-inflammatory, anti-angiogenic [263], and ant
./___Corpus/Medline/xml/PMC4930000.xml	Berberine	39032 : 39041	CM	nticancer effects [264]. Berberine has potential as an anti
./___Corpus/Medline/xml/PMC4930000.xml	anti-	39062 : 39067	CPR	rine has potential as an anti-cancer agent [250]. The m
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39198 : 39209	CM	ed.                  3.2 Resveratrol                      Res
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39231 : 39242	CM	rol                      Resveratrol (3,4′,5-trihydroxy-trans
./___Corpus/Medline/xml/PMC4930000.xml	3,4′,5-trihydroxy-trans-stilbene	39244 : 39276	CM	            Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a polyphenolic compo
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	39283 : 39295	CM	oxy-trans-stilbene) is a polyphenolic compound that functional
./___Corpus/Medline/xml/PMC4930000.xml	anti-	39352 : 39357	CPR	ngs to phytoalexins with anti-ROS activity. Resveratrol
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39371 : 39382	CM	 with anti-ROS activity. Resveratrol is produced through stil
./___Corpus/Medline/xml/PMC4930000.xml	stilbene	39403 : 39411	CM	trol is produced through stilbene synthase [265] in respon
./___Corpus/Medline/xml/PMC4930000.xml	malonyl	39501 : 39508	CM	s conditions [267] using malonyl- coenzyme A (CoA) and p-
./___Corpus/Medline/xml/PMC4930000.xml	coenzyme A	39510 : 39520	CM	ons [267] using malonyl- coenzyme A (CoA) and p-coumaroyl Co
./___Corpus/Medline/xml/PMC4930000.xml	CoA	39522 : 39525	CM	ing malonyl- coenzyme A (CoA) and p-coumaroyl CoA as 
./___Corpus/Medline/xml/PMC4930000.xml	p-coumaroyl	39531 : 39542	CM	yl- coenzyme A (CoA) and p-coumaroyl CoA as precursors. This 
./___Corpus/Medline/xml/PMC4930000.xml	CoA	39543 : 39546	CM	 A (CoA) and p-coumaroyl CoA as precursors. This comp
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	39676 : 39687	CM	                         Resveratrol is naturally occurring i
./___Corpus/Medline/xml/PMC4930000.xml	pine	39798 : 39802	CM	raspberries, mulberries, pine, and grapes [269]. Relat
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	39848 : 39859	CM	elatively high levels of resveratrol present in fresh grape s
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	39992 : 40003	CM	rent conjugated forms of resveratrol were detected in plants.
./___Corpus/Medline/xml/PMC4930000.xml	Trans-resveratrol	40029 : 40046	CM	were detected in plants. Trans-resveratrol exists in glycosylated f
./___Corpus/Medline/xml/PMC4930000.xml	glycosylated	40057 : 40069	CM	ns-resveratrol exists in glycosylated forms and has cis and tr
./___Corpus/Medline/xml/PMC4930000.xml	methyl	40141 : 40147	CM	jugations, including 1–2 methyl groups, sulfate group, a
./___Corpus/Medline/xml/PMC4930000.xml	sulfate	40156 : 40163	CM	uding 1–2 methyl groups, sulfate group, and fatty acids, 
./___Corpus/Medline/xml/PMC4930000.xml	fatty acids	40175 : 40186	CM	oups, sulfate group, and fatty acids, were also observed [270
./___Corpus/Medline/xml/PMC4930000.xml	Glycosylation	40214 : 40227	RN	ere also observed [270]. Glycosylation increases stability, sol
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	40334 : 40345	CM	dditionally, it protects resveratrol from oxidative degradati
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	40418 : 40429	CM	                         Resveratrol metabolism in human body
./___Corpus/Medline/xml/PMC4930000.xml	water	40482 : 40487	CM	cludes its conversion to water-soluble trans-resveratro
./___Corpus/Medline/xml/PMC4930000.xml	trans-resveratrol-3-O-glucuronide	40496 : 40529	CM	version to water-soluble trans-resveratrol-3-O-glucuronide and trans-resveratrol-3-
./___Corpus/Medline/xml/PMC4930000.xml	trans-resveratrol-3-O-sulfate	40534 : 40563	CM	trol-3-O-glucuronide and trans-resveratrol-3-O-sulfate by liver phase-2 drug-me
./___Corpus/Medline/xml/PMC4930000.xml	phase-2	40573 : 40580	CM	rol-3-O-sulfate by liver phase-2 drug-metabolizing enzyme
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	40732 : 40743	CM	r than the half- life of resveratrol (8–14 min) [272]. Concen
./___Corpus/Medline/xml/PMC4930000.xml	8–	40745 : 40747	CPR	lf- life of resveratrol (8–14 min) [272]. Concentrat
./___Corpus/Medline/xml/PMC4930000.xml	vitro	40829 : 40834	CM	re used for different in vitro studies, while concentra
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	40938 : 40949	CM	in animal studies [273]. Resveratrol and its metabolism produ
./___Corpus/Medline/xml/PMC4930000.xml	14C-trans-resveratrol	41072 : 41093	CM	e oral administration of 14C-trans-resveratrol in Balb/c mice [274], wh
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	41133 : 41144	CM	 [274], whereas 24.6% of resveratrol and its metabolites were
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41463 : 41466	CM	are the main inducers of ROS production. The imbalanc
./___Corpus/Medline/xml/PMC4930000.xml	glutathione	41555 : 41566	CM	duced redox couples like glutathione (GSH/GSSG) or NADPH/NADP
./___Corpus/Medline/xml/PMC4930000.xml	GSH	41568 : 41571	CM	ouples like glutathione (GSH/GSSG) or NADPH/NADP+ cau
./___Corpus/Medline/xml/PMC4930000.xml	GSSG	41572 : 41576	CM	es like glutathione (GSH/GSSG) or NADPH/NADP+ cause RO
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	41581 : 41586	CM	lutathione (GSH/GSSG) or NADPH/NADP+ cause ROS accumula
./___Corpus/Medline/xml/PMC4930000.xml	NADP+	41587 : 41592	CM	ione (GSH/GSSG) or NADPH/NADP+ cause ROS accumulation [
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41599 : 41602	CM	SG) or NADPH/NADP+ cause ROS accumulation [277]. High
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41638 : 41641	CM	on [277]. High levels of ROS react with cellular comp
./___Corpus/Medline/xml/PMC4930000.xml	lipids	41702 : 41708	CM	uding DNA, proteins, and lipids leading to cellular and 
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	41754 : 41765	CM	and tissue damage [278]. Resveratrol and other dietary stilbe
./___Corpus/Medline/xml/PMC4930000.xml	stilbenes	41784 : 41793	CM	ratrol and other dietary stilbenes reduce oxidative stress 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	41860 : 41863	CM	as a direct scavenger of ROS [279] or as an inhibitor
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	41892 : 41897	CM	9] or as an inhibitor of NADPH oxidase expression and x
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	41921 : 41929	CM	H oxidase expression and xanthine oxidase activity [280]. 
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	41930 : 41937	CM	 expression and xanthine oxidase activity [280]. Resverat
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	41954 : 41965	CM	 oxidase activity [280]. Resveratrol has low toxicity [281]. 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	42013 : 42018	CPR	. Various studies report anti-cancer effects [282–284],
./___Corpus/Medline/xml/PMC4930000.xml	282–	42034 : 42038	CPR	ort anti-cancer effects [282–284], including the suppr
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42236 : 42239	CM	 and molecules that keep ROS under normal physiologic
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42369 : 42372	CM	tabolism, which increase ROS production and cause per
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42512 : 42515	CM	use massive increases in ROS production [289]. Resver
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	42534 : 42545	CM	in ROS production [289]. Resveratrol inhibits ROS and reduces
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42555 : 42558	CM	9]. Resveratrol inhibits ROS and reduces oxidative st
./___Corpus/Medline/xml/PMC4930000.xml	ROS	42622 : 42625	CM	 decreases intracellular ROS production and oxidative
./___Corpus/Medline/xml/PMC4930000.xml	Nrf2	42737 : 42741	CM	 which is a repressor of Nrf2 [291]. In a rat model of
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	42789 : 42800	CM	of hepatocarcinogenesis, resveratrol was found to upregulate 
./___Corpus/Medline/xml/PMC4930000.xml	Nrf2	42833 : 42837	CM	nd to upregulate hepatic Nrf2 [292]. In another study,
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	43011 : 43022	CM	sed in rats treated with resveratrol [293]. Additionally, res
./___Corpus/Medline/xml/PMC4930000.xml	resveratrol	43044 : 43055	CM	rol [293]. Additionally, resveratrol reduced oxidative stress
./___Corpus/Medline/xml/PMC4930000.xml	Resveratrol	43372 : 43383	CM	and diabetic rats [296]. Resveratrol is a candidate for the t
./___Corpus/Medline/xml/PMC4930000.xml	ROS	43474 : 43477	CM	ers by the inhibition of ROS.                  3.3 On
./___Corpus/Medline/xml/PMC4930000.xml	Allium	43565 : 43571	CM	 is a natural product in Allium vegetables that has rece
./___Corpus/Medline/xml/PMC4930000.xml	anti-	43686 : 43691	CPR	activity that could have anti-neoplastic activity. The 
./___Corpus/Medline/xml/PMC4930000.xml	Allium	43731 : 43737	CM	vity. The consumption of Allium vegetables is associated
./___Corpus/Medline/xml/PMC4930000.xml	55–	43849 : 43852	CPR	logical study reported a 55–80% reduction of odds rat
./___Corpus/Medline/xml/PMC4930000.xml	Allium	44183 : 44189	CM	 scallions belong to the Allium family. Previously ident
./___Corpus/Medline/xml/PMC4930000.xml	Allium	44251 : 44257	CM	ive compounds in onions (Allium cepa) are flavonoids and
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	44268 : 44278	CM	onions (Allium cepa) are flavonoids and phenols [298]. Flavo
./___Corpus/Medline/xml/PMC4930000.xml	phenols	44283 : 44290	CM	cepa) are flavonoids and phenols [298]. Flavonoids are th
./___Corpus/Medline/xml/PMC4930000.xml	Flavonoids	44298 : 44308	CM	noids and phenols [298]. Flavonoids are the largest family o
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	44335 : 44347	CM	re the largest family of polyphenolic compounds and as such th
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	44381 : 44392	CM	s and as such the names “polyphenols” and “flavonoids” may, a
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	44399 : 44409	CM	names “polyphenols” and “flavonoids” may, at times, be used 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	44555 : 44560	CPR	 damaged cells via their anti-inflammatory effects. [29
./___Corpus/Medline/xml/PMC4930000.xml	299–	44583 : 44587	CPR	i-inflammatory effects. [299–302].                    
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44670 : 44680	CM	effects of onion-derived polyphenol extracts have recently b
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44727 : 44737	CM	y been investigated. The polyphenol extract from A. cepa can
./___Corpus/Medline/xml/PMC4930000.xml	p53	44872 : 44875	CM	 pathway by upregulating p53 and Bax proteins as well
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	44961 : 44971	CM	rthermore, onion-derived polyphenol extract induced caspase-
./___Corpus/Medline/xml/PMC4930000.xml	vitro	45056 : 45061	CM	n leukemia cell lines in vitro has been attributed, at 
./___Corpus/Medline/xml/PMC4930000.xml	PI3K	45122 : 45126	CM	rt, to inhibition of the PI3K/AKT signaling pathway [3
./___Corpus/Medline/xml/PMC4930000.xml	AKT	45127 : 45130	CM	o inhibition of the PI3K/AKT signaling pathway [303].
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	45256 : 45267	CM	ens are related to their polyphenols and flavonoids [304]. Th
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	45272 : 45282	CM	to their polyphenols and flavonoids [304]. The lipid soluble
./___Corpus/Medline/xml/PMC4930000.xml	lipid	45294 : 45299	CM	nd flavonoids [304]. The lipid soluble organosulfur com
./___Corpus/Medline/xml/PMC4930000.xml	organosulfur	45308 : 45320	CM	[304]. The lipid soluble organosulfur compounds present in oni
./___Corpus/Medline/xml/PMC4930000.xml	carcinogen	45482 : 45492	CM	sm for the inhibition of carcinogen activation by onion extr
./___Corpus/Medline/xml/PMC4930000.xml	cytochrome	45554 : 45564	CM	ves may be inhibition of cytochrome P450 2E1, which is activ
./___Corpus/Medline/xml/PMC4930000.xml	xenobiotic	45609 : 45619	CM	activated by a number of xenobiotic substances [306].       
./___Corpus/Medline/xml/PMC4930000.xml	organosulfur	45700 : 45712	CM	 Onions are also rich in organosulfur compounds. These phytoch
./___Corpus/Medline/xml/PMC4930000.xml	diallyl disulfide	45756 : 45773	CM	hytochemicals, including diallyl disulfide, S-allylcysteine and ajo
./___Corpus/Medline/xml/PMC4930000.xml	S-allylcysteine	45775 : 45790	CM	uding diallyl disulfide, S-allylcysteine and ajoene, protect agai
./___Corpus/Medline/xml/PMC4930000.xml	ajoene	45795 : 45801	CM	ide, S-allylcysteine and ajoene, protect against chemica
./___Corpus/Medline/xml/PMC4930000.xml	carcinogen	45874 : 45884	CM	nimal models by altering carcinogen metabolism [307–310]. Re
./___Corpus/Medline/xml/PMC4930000.xml	307–	45897 : 45901	CPR	g carcinogen metabolism [307–310]. Recently, onionin A
./___Corpus/Medline/xml/PMC4930000.xml	3,4-dimethyl-5-(1E-propenyl)-tetrahydrothiophen-2-sulfoxide-S-oxide	45966 : 46033	CM	311] and identified as a 3,4-dimethyl-5-(1E-propenyl)-tetrahydrothiophen-2-sulfoxide-S-oxide. Onionin A may inhibit T
./___Corpus/Medline/xml/PMC4930000.xml	M2	46134 : 46136	CM	0- induced activation of M2 macrophage by assessing 
./___Corpus/Medline/xml/PMC4930000.xml	M2	46190 : 46192	CM	expression of the unique M2 marker CD163. Onionin A 
./___Corpus/Medline/xml/PMC4930000.xml	CD163	46200 : 46205	CM	 of the unique M2 marker CD163. Onionin A significantly
./___Corpus/Medline/xml/PMC4930000.xml	CD163	46260 : 46265	CM	ressed the expression of CD163 at concentrations of 10 
./___Corpus/Medline/xml/PMC4930000.xml	30μM	46297 : 46301	CM	centrations of 10 μM and 30μM. These results suggest t
./___Corpus/Medline/xml/PMC4930000.xml	anti-	46410 : 46415	CPR	gent may be useful as an anti-cancer agent.            
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46450 : 46454	CM	nt.                  3.4 EGCG                      EGC
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46476 : 46480	CM	GCG                      EGCG inhibits IDO expression 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	46490 : 46493	CM	           EGCG inhibits IDO expression in human canc
./___Corpus/Medline/xml/PMC4930000.xml	polyphenols	46704 : 46715	CM	 Green tea contains many polyphenols, in particular EGCG, whi
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46731 : 46735	CM	lyphenols, in particular EGCG, which have been shown t
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	46874 : 46878	CM	d therapeutic effects of EGCG are attributed to the br
./___Corpus/Medline/xml/PMC4930000.xml	anti-	46916 : 46921	CPR	ed to the broad-spectrum anti-cancer abilities of this 
./___Corpus/Medline/xml/PMC4930000.xml	polyphenol	46946 : 46956	CM	cancer abilities of this polyphenol, including inhibition of
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47088 : 47092	CM	                         EGCG has also been found to i
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47142 : 47145	CM	nhibit the expression of IDO, which is a key enzyme i
./___Corpus/Medline/xml/PMC4930000.xml	tryptophan	47258 : 47268	CM	lls through depletion of tryptophan. Many cytokine-dependent
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	47275 : 47283	CM	tion of tryptophan. Many cytokine-dependent and independen
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47345 : 47348	CM	pathways are involved in IDO expression. Interferon-s
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47383 : 47386	CM	n. Interferon-stimulated IDO activation is, however, 
./___Corpus/Medline/xml/PMC4930000.xml	JAK	47427 : 47430	CM	however, mediated by the JAK/STAT signaling pathway [
./___Corpus/Medline/xml/PMC4930000.xml	STAT	47431 : 47435	CM	ver, mediated by the JAK/STAT signaling pathway [316].
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47507 : 47511	CM	evidence suggesting that EGCG interferes with JAK/STAT
./___Corpus/Medline/xml/PMC4930000.xml	JAK	47528 : 47531	CM	hat EGCG interferes with JAK/STAT-regulated IDO activ
./___Corpus/Medline/xml/PMC4930000.xml	STAT	47532 : 47536	CM	EGCG interferes with JAK/STAT-regulated IDO activation
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47547 : 47550	CM	 with JAK/STAT-regulated IDO activation, resulting in
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47595 : 47598	CM	ng in the suppression of IDO and IDO-related downstre
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47603 : 47606	CM	e suppression of IDO and IDO-related downstream gene 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47703 : 47707	CM	                         EGCG has been shown to suppre
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47735 : 47738	CM	s been shown to suppress IDO expression through inhib
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	47769 : 47774	CM	ssion through inhibiting IFN-γ induced in human oral ca
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	47843 : 47848	CM	7]. The translocation of STAT1 into the nucleus, which 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	47929 : 47932	CM	criptional activation of IDO, was blocked by EGCG. Ch
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47949 : 47953	CM	n of IDO, was blocked by EGCG. Chen et al. [317] also 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	47990 : 47994	CM	. [317] also showed that EGCG significantly suppressed
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48024 : 48039	RN	ificantly suppressed the phosphorylation of protein kinase C (PKC
./___Corpus/Medline/xml/PMC4930000.xml	JAKs	48072 : 48076	CM	ein kinase C (PKC-δ) and JAKs, resulting in inhibition
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	48105 : 48110	CM	sulting in inhibition of IFN-γ-stimulated STAT1 phospho
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	48122 : 48127	CM	tion of IFN-γ-stimulated STAT1 phosphorylation. Similar
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48128 : 48143	RN	f IFN-γ-stimulated STAT1 phosphorylation. Similarly, another grou
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48188 : 48192	CM	 group demonstrated that EGCG blocks IDO expression in
./___Corpus/Medline/xml/PMC4930000.xml	IDO	48200 : 48203	CM	strated that EGCG blocks IDO expression in human colo
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	48289 : 48294	CM	el through inhibition of STAT1 phosphorylation, which c
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	48295 : 48310	RN	ough inhibition of STAT1 phosphorylation, which consequently supp
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	48358 : 48363	CM	ppressed the activity of STAT1-activated sequence eleme
./___Corpus/Medline/xml/PMC4930000.xml	IDO	48399 : 48402	CM	sequence elements of the IDO promoter, IFN-stimulated
./___Corpus/Medline/xml/PMC4930000.xml	IFN	48413 : 48416	CM	nts of the IDO promoter, IFN-stimulated response elem
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	48456 : 48461	CM	ponse element (ISRE) and IFN-γ- activation sequence (GA
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48534 : 48538	CM	                         EGCG was found to exhibit ant
./___Corpus/Medline/xml/PMC4930000.xml	anti-	48560 : 48565	CPR	GCG was found to exhibit anti-IDO activities in murine 
./___Corpus/Medline/xml/PMC4930000.xml	murine	48583 : 48589	CM	t anti-IDO activities in murine bone marrow-derived dend
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48641 : 48645	CM	tic cells (BMDCs) [319]. EGCG blocked the binding of p
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylated	48669 : 48683	RN	G blocked the binding of phosphorylated STAT1 to INF regulatory 
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	48684 : 48689	CM	inding of phosphorylated STAT1 to INF regulatory factor
./___Corpus/Medline/xml/PMC4930000.xml	INF	48693 : 48696	CM	 phosphorylated STAT1 to INF regulatory factor-1 (IRF
./___Corpus/Medline/xml/PMC4930000.xml	factor-1	48708 : 48716	CM	 STAT1 to INF regulatory factor-1 (IRF-1) promoter, in res
./___Corpus/Medline/xml/PMC4930000.xml	IRF-1	48718 : 48723	CM	INF regulatory factor-1 (IRF-1) promoter, in response t
./___Corpus/Medline/xml/PMC4930000.xml	IFN-γ	48750 : 48755	CM	promoter, in response to IFN-γ stimulation. The express
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin	48787 : 48800	CM	ation. The expression of prostaglandin E2 (PGE2) and cyclooxyge
./___Corpus/Medline/xml/PMC4930000.xml	PGE2	48805 : 48809	CM	ion of prostaglandin E2 (PGE2) and cyclooxygenase (COX
./___Corpus/Medline/xml/PMC4930000.xml	cyclooxygenase	48815 : 48829	CM	staglandin E2 (PGE2) and cyclooxygenase (COX-2) was also signifi
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	48831 : 48836	CM	GE2) and cyclooxygenase (COX-2) was also significantly 
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	48874 : 48878	CM	gnificantly inhibited in EGCG-treated murine BMDCs. Ov
./___Corpus/Medline/xml/PMC4930000.xml	murine	48887 : 48893	CM	nhibited in EGCG-treated murine BMDCs. Over expression o
./___Corpus/Medline/xml/PMC4930000.xml	PGE2	48920 : 48924	CM	MDCs. Over expression of PGE2, a bioactive lipid, and 
./___Corpus/Medline/xml/PMC4930000.xml	lipid	48938 : 48943	CM	ion of PGE2, a bioactive lipid, and COX-2, the key enzy
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	48949 : 48954	CM	, a bioactive lipid, and COX-2, the key enzyme in prost
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin	48974 : 48987	CM	COX-2, the key enzyme in prostaglandin biosynthesis, is often a
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49090 : 49094	CM	The inhibitory effect of EGCG on COX-2 expression has 
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	49098 : 49103	CM	bitory effect of EGCG on COX-2 expression has also been
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49292 : 49296	CM	monstrated the effect of EGCG on azoxymethane (AOM)-in
./___Corpus/Medline/xml/PMC4930000.xml	azoxymethane	49300 : 49312	CM	ed the effect of EGCG on azoxymethane (AOM)-induced preneoplas
./___Corpus/Medline/xml/PMC4930000.xml	AOM	49314 : 49317	CM	of EGCG on azoxymethane (AOM)-induced preneoplastic l
./___Corpus/Medline/xml/PMC4930000.xml	F344	49352 : 49356	CM	preneoplastic lesions in F344 rat through suppression 
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49384 : 49387	CM	t through suppression of IDO expression. EGCG-treated
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49400 : 49404	CM	ssion of IDO expression. EGCG-treated rats exhibited s
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49509 : 49512	CM	ch had overexpression of IDO. The mRNA expression of 
./___Corpus/Medline/xml/PMC4930000.xml	mRNA	49518 : 49522	CM	erexpression of IDO. The mRNA expression of COX-2 in A
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	49537 : 49542	CM	. The mRNA expression of COX-2 in AOM-treated rat was a
./___Corpus/Medline/xml/PMC4930000.xml	AOM	49546 : 49549	CM	A expression of COX-2 in AOM-treated rat was also inh
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49584 : 49588	CM	at was also inhibited by EGCG treatment [323].        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49644 : 49648	CM	                         EGCG inhbits the JAK/STAT sig
./___Corpus/Medline/xml/PMC4930000.xml	JAK	49661 : 49664	CM	        EGCG inhbits the JAK/STAT signaling pathway. 
./___Corpus/Medline/xml/PMC4930000.xml	STAT	49665 : 49669	CM	    EGCG inhbits the JAK/STAT signaling pathway. Pre-t
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49708 : 49712	CM	hway. Pre-treatment with EGCG lead to suppression of S
./___Corpus/Medline/xml/PMC4930000.xml	STAT1	49736 : 49741	CM	G lead to suppression of STAT1 phosphorylation and IRF-
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	49742 : 49757	RN	 to suppression of STAT1 phosphorylation and IRF-1 expression on 
./___Corpus/Medline/xml/PMC4930000.xml	IRF-1	49762 : 49767	CM	TAT1 phosphorylation and IRF-1 expression on different 
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	49888 : 49893	CM	patocarcinoma [324,325]. STAT3 is associated with const
./___Corpus/Medline/xml/PMC4930000.xml	IDO	49926 : 49929	CM	ciated with constitutive IDO expression in human canc
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	49970 : 49974	CM	uman cancer cells [326]. EGCG inhibits the phosphoryla
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	49988 : 50003	CM	[326]. EGCG inhibits the phosphorylation and expression of both J
./___Corpus/Medline/xml/PMC4930000.xml	JAK3	50027 : 50031	CM	n and expression of both JAK3 and STAT3 proteins in pa
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	50036 : 50041	CM	ression of both JAK3 and STAT3 proteins in pancreatic c
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50085 : 50089	CM	atic cancer cells [327]. EGCG decreases the levels of 
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylated-STAT3	50114 : 50134	CM	 decreases the levels of phosphorylated-STAT3 proteins stimulated by i
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50291 : 50295	CM	ilability of IGFs [328]. EGCG inhibits STAT3 in head a
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	50305 : 50310	CM	GFs [328]. EGCG inhibits STAT3 in head and neck cancer 
./___Corpus/Medline/xml/PMC4930000.xml	JAK	50388 : 50391	CM	]. The inhibition of the JAK/STAT pathway through EGC
./___Corpus/Medline/xml/PMC4930000.xml	STAT	50392 : 50396	CM	he inhibition of the JAK/STAT pathway through EGCG may
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50413 : 50417	CM	JAK/STAT pathway through EGCG may be useful to regulat
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50444 : 50447	CM	ay be useful to regulate IDO.                        
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50487 : 50491	CM	                         EGCG has anti-cancer properti
./___Corpus/Medline/xml/PMC4930000.xml	anti-	50496 : 50501	CPR	                EGCG has anti-cancer properties. The ab
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50535 : 50539	CM	operties. The ability of EGCG to act as a multi-target
./___Corpus/Medline/xml/PMC4930000.xml	JAK	50588 : 50591	CM	ting agent in regulating JAK/STAT signaling and JAK/S
./___Corpus/Medline/xml/PMC4930000.xml	STAT	50592 : 50596	CM	 agent in regulating JAK/STAT signaling and JAK/STAT-m
./___Corpus/Medline/xml/PMC4930000.xml	JAK	50611 : 50614	CM	g JAK/STAT signaling and JAK/STAT-mediated IDO is rem
./___Corpus/Medline/xml/PMC4930000.xml	STAT	50615 : 50619	CM	K/STAT signaling and JAK/STAT-mediated IDO is remarkab
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50629 : 50632	CM	ng and JAK/STAT-mediated IDO is remarkable. The combi
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50676 : 50680	CM	 combinative efficacy of EGCG with a number of chemoth
./___Corpus/Medline/xml/PMC4930000.xml	tamoxifen	50729 : 50738	CM	herapeutic drugs such as tamoxifen and paclitaxel has shown
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	50790 : 50794	CM	ynergistic effect [331], EGCG is a candidate as a canc
./___Corpus/Medline/xml/PMC4930000.xml	IDO	50843 : 50846	CM	cer therapy by targeting IDO.                  3.5 Ge
./___Corpus/Medline/xml/PMC4930000.xml	7-trihydroxyisoflavone	50917 : 50939	CM	        Genistein (4′,5, 7-trihydroxyisoflavone), a polyphenolic isoflav
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic isoflavone	50944 : 50967	CM	trihydroxyisoflavone), a polyphenolic isoflavone, is found in soy product
./___Corpus/Medline/xml/PMC4930000.xml	cholesterol	51018 : 51029	CM	 and appears to modulate cholesterol metabolism. It has low b
./___Corpus/Medline/xml/PMC4930000.xml	water	51081 : 51086	CM	availability due to poor water solubility, extensive in
./___Corpus/Medline/xml/PMC4930000.xml	anti-	51387 : 51392	CPR	enistein may mediate its anti-cancer effects through nu
./___Corpus/Medline/xml/PMC4930000.xml	(NF)-κB	51430 : 51437	CM	s through nuclear factor (NF)-κB modulation, reduction of
./___Corpus/Medline/xml/PMC4930000.xml	AKT	51463 : 51466	CM	modulation, reduction of AKT protein level, downregul
./___Corpus/Medline/xml/PMC4930000.xml	androgen	51500 : 51508	CM	level, downregulation of androgen-mediated carcinogenesis,
./___Corpus/Medline/xml/PMC4930000.xml	anti-	51611 : 51616	CPR	 Genistein has potential anti-cancer activity against p
./___Corpus/Medline/xml/PMC4930000.xml	mevalonate	51792 : 51802	CM	 Elevated HMGR activity, mevalonate, and protein prenylation
./___Corpus/Medline/xml/PMC4930000.xml	prenylation	51816 : 51827	RN	 mevalonate, and protein prenylation is associated with tumor
./___Corpus/Medline/xml/PMC4930000.xml	HMGR	51905 : 51909	CM	s been shown to suppress HMGR and preent tumor growth 
./___Corpus/Medline/xml/PMC4930000.xml	LDL	51973 : 51976	CM	istein also can increase LDL receptor and decrease HM
./___Corpus/Medline/xml/PMC4930000.xml	lipid	52080 : 52085	CM	as many other effects on lipid metabolism that could co
./___Corpus/Medline/xml/PMC4930000.xml	anti-	52126 : 52131	CPR	 could contribute to its anti-neoplastic properties [34
./___Corpus/Medline/xml/PMC4930000.xml	genistein	52198 : 52207	CM	s important to note that genistein may have pro-proliferati
./___Corpus/Medline/xml/PMC4930000.xml	347–	52261 : 52265	CPR	ffects in some contexts [347–350].                  3.
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin

                    Curcumin	52292 : 52330	CM	0].                  3.6 Curcumin                      Curcumin (diferuloylmethane), the
./___Corpus/Medline/xml/PMC4930000.xml	diferuloylmethane	52332 : 52349	CM	               Curcumin (diferuloylmethane), the active ingredient 
./___Corpus/Medline/xml/PMC4930000.xml	Curcuma	52407 : 52414	CM	urmeric spice from plant Curcuma longa, belongs to the gr
./___Corpus/Medline/xml/PMC4930000.xml	polyphenolic	52446 : 52458	CM	 belongs to the group of polyphenolic herbal compounds and has
./___Corpus/Medline/xml/PMC4930000.xml	anti-	52522 : 52527	CPR	ficial effects including anti-tumorigenic action that a
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	52576 : 52580	CM	appears to be related to VEGF inhibition. Powder of tu
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	52728 : 52736	CM	es [351]. In addition to curcumin, turmeric contains minor
./___Corpus/Medline/xml/PMC4930000.xml	demethoxycurcumin	52780 : 52797	CM	 minor fractions such as demethoxycurcumin, bisdemethoxycurcumin, a
./___Corpus/Medline/xml/PMC4930000.xml	bisdemethoxycurcumin	52799 : 52819	CM	ch as demethoxycurcumin, bisdemethoxycurcumin, and the cyclocurcumin [
./___Corpus/Medline/xml/PMC4930000.xml	cyclocurcumin	52829 : 52842	CM	methoxycurcumin, and the cyclocurcumin [352]. Curcumin has been
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	52850 : 52858	CM	the cyclocurcumin [352]. Curcumin has been implicated as s
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53006 : 53014	CM	                         Curcumin downregulates the expres
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53047 : 53051	CM	ulates the expression of VEGF in prostate cancer cells
./___Corpus/Medline/xml/PMC4930000.xml	avb3	53141 : 53145	CM	5]. Osteopontin/integrin avb3 signaling through MMP9 a
./___Corpus/Medline/xml/PMC4930000.xml	MMP9	53164 : 53168	CM	n avb3 signaling through MMP9 activation increases VEG
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53190 : 53194	CM	MP9 activation increases VEGF and angiostatin expressi
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53262 : 53270	CM	cer cells and conversely curcumin reduces VEGF expression 
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53279 : 53283	CM	versely curcumin reduces VEGF expression [355], suppre
./___Corpus/Medline/xml/PMC4930000.xml	MMP9	53313 : 53317	CM	ession [355], suppresses MMP9 activity in prostate can
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53357 : 53365	CM	ostate cancer cells. The curcumin-derived analogue CDF inh
./___Corpus/Medline/xml/PMC4930000.xml	CDF	53383 : 53386	CM	urcumin-derived analogue CDF inhibits VEGF as well as
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53396 : 53400	CM	ed analogue CDF inhibits VEGF as well as IL-6 and canc
./___Corpus/Medline/xml/PMC4930000.xml	EZH2	53471 : 53475	CM	e genes Nanog, Oct4, and EZH2 in vitro and in vivo [35
./___Corpus/Medline/xml/PMC4930000.xml	vitro	53479 : 53484	CM	Nanog, Oct4, and EZH2 in vitro and in vivo [356]. Simil
./___Corpus/Medline/xml/PMC4930000.xml	CDF	53515 : 53518	CM	n vivo [356]. Similarly, CDF reduced VEGF and IL-6 ex
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53527 : 53531	CM	. Similarly, CDF reduced VEGF and IL-6 expression in p
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53584 : 53592	CM	tate cancer cells [357]. Curcumin inhibited migration and 
./___Corpus/Medline/xml/PMC4930000.xml	MMP-2	53675 : 53680	CM	ls through inhibition of MMP-2 and MMP-9 and suppressio
./___Corpus/Medline/xml/PMC4930000.xml	MMP-9	53685 : 53690	CM	 inhibition of MMP-2 and MMP-9 and suppression of VEGF 
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	53710 : 53714	CM	MMP-9 and suppression of VEGF expression [358]. Long-t
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	53755 : 53763	CM	]. Long-term exposure to curcumin was investigated in the 
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	53820 : 53828	CM	f lymphoma-bearing mice. Curcumin treatment induced activa
./___Corpus/Medline/xml/PMC4930000.xml	HIF-1a	53881 : 53887	CM	n stress activated genes HIF-1a, MYC, and LDH activity t
./___Corpus/Medline/xml/PMC4930000.xml	MYC	53889 : 53892	CM	 activated genes HIF-1a, MYC, and LDH activity to nor
./___Corpus/Medline/xml/PMC4930000.xml	LDH	53898 : 53901	CM	d genes HIF-1a, MYC, and LDH activity to normal level
./___Corpus/Medline/xml/PMC4930000.xml	MMP-9	54010 : 54015	CM	denced by reduced MMP-2, MMP-9, PKC-a and VEGF levels [
./___Corpus/Medline/xml/PMC4930000.xml	PKC-a	54017 : 54022	CM	by reduced MMP-2, MMP-9, PKC-a and VEGF levels [359].  
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	54027 : 54031	CM	 MMP-2, MMP-9, PKC-a and VEGF levels [359].           
./___Corpus/Medline/xml/PMC4930000.xml	IkB	54182 : 54185	CM	 processes. IL-1 induced IkB alpha phosphorylation an
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	54192 : 54207	RN	. IL-1 induced IkB alpha phosphorylation and inhibition of downst
./___Corpus/Medline/xml/PMC4930000.xml	NF-κB	54237 : 54242	CM	inhibition of downstream NF-κB, which leads to expressi
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54365 : 54373	CM	 and angiogenesis [360]. Curcumin treatment blocked IL-1 a
./___Corpus/Medline/xml/PMC4930000.xml	VEGF	54401 : 54405	CM	eatment blocked IL-1 and VEGF expression in chondrosar
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	54451 : 54459	CM	osarcoma cells. Further, curcumin inhibited IL-1 beta-indu
./___Corpus/Medline/xml/PMC4930000.xml	NF-κB	54505 : 54510	CM	induced angiogenesis and NF-κB-related gene expression 
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54542 : 54550	CM	d gene expression [361]. Curcumin is one of the main const
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	54699 : 54707	CM	s using up to 8000 mg of curcumin per day for 3 months fou
./___Corpus/Medline/xml/PMC4930000.xml	Curcumin	54821 : 54829	CM	 six human trials [362]. Curcumin has extremely low system
./___Corpus/Medline/xml/PMC4930000.xml	aqueous	54891 : 54898	CJ	bility, owing to its low aqueous solubility and poor stab
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	54951 : 54961	CM	ty.                  3.7 Naringenin                      Nar
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	54983 : 54993	CM	nin                      Naringenin has good prospects as an
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	55119 : 55129	CM	ffect on fibrosis [363]. Naringenin significantly reduces lu
./___Corpus/Medline/xml/PMC4930000.xml	BALB	55189 : 55193	CM	ses in mice (C57BL/6 and BALB/c) with pulmonary fibros
./___Corpus/Medline/xml/PMC4930000.xml	HSC-T6	55348 : 55354	CM	latory T cells [364]. In HSC-T6 cells, naringenin exerts
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	55362 : 55372	CM	 [364]. In HSC-T6 cells, naringenin exerts antifibrogenic ef
./___Corpus/Medline/xml/PMC4930000.xml	phosphorylation	55473 : 55488	RN	3 protein expression and phosphorylation through TGF-beta signali
./___Corpus/Medline/xml/PMC4930000.xml	TGF-beta	55497 : 55505	CM	 phosphorylation through TGF-beta signaling [365] and the 
./___Corpus/Medline/xml/PMC4930000.xml	N-	55558 : 55560	CPR	nregulation of vimentin, N-cadherin, MMP2 and MMP9 [
./___Corpus/Medline/xml/PMC4930000.xml	MMP2	55570 : 55574	CM	of vimentin, N-cadherin, MMP2 and MMP9 [366]. Naringen
./___Corpus/Medline/xml/PMC4930000.xml	MMP9	55579 : 55583	CM	in, N-cadherin, MMP2 and MMP9 [366]. Naringenin inhibi
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	55591 : 55601	CM	in, MMP2 and MMP9 [366]. Naringenin inhibits the viral assem
./___Corpus/Medline/xml/PMC4930000.xml	estrogen	55763 : 55771	CM	istic activities towards estrogen [369]. This also might i
./___Corpus/Medline/xml/PMC4930000.xml	bisphenol	55845 : 55854	CM	nst the food contaminant bisphenol A [370]. Hence, naringen
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	55871 : 55881	CM	isphenol A [370]. Hence, naringenin exerts inhibitory effect
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	56036 : 56046	CM	                         Naringenin has low bioavailability 
./___Corpus/Medline/xml/PMC4930000.xml	naringenin-7-O-glucuronide	56161 : 56187	CM	e principal metabolites, naringenin-7-O-glucuronide and naringenin-4′-O-gluc
./___Corpus/Medline/xml/PMC4930000.xml	naringenin-4′-O-glucuronide	56192 : 56219	CM	enin-7-O-glucuronide and naringenin-4′-O-glucuronide peaks at 6h after intake
./___Corpus/Medline/xml/PMC4930000.xml	glucuronide	56433 : 56444	CM	ssue distribution. A NRG glucuronide have same affinity for h
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	56491 : 56501	CM	r human serum albumin as naringenin. Efforts are in way to i
./___Corpus/Medline/xml/PMC4930000.xml	NRG	56596 : 56599	CM	echniques like combining NRG with β-cyclodextrin thro
./___Corpus/Medline/xml/PMC4930000.xml	β-cyclodextrin	56605 : 56619	CM	 like combining NRG with β-cyclodextrin through solid dispersion
./___Corpus/Medline/xml/PMC4930000.xml	NRG	56767 : 56770	CM	 significant increase in NRG absorption compared to N
./___Corpus/Medline/xml/PMC4930000.xml	NRG	56794 : 56797	CM	G absorption compared to NRG alone. Area under the dr
./___Corpus/Medline/xml/PMC4930000.xml	0–	56856 : 56858	CPR	tration time curve (AUC) 0–24h was significantly hig
./___Corpus/Medline/xml/PMC4930000.xml	24h	56858 : 56861	CM	ation time curve (AUC) 0–24h was significantly higher
./___Corpus/Medline/xml/PMC4930000.xml	NRG	56932 : 56935	CM	ed with pure drugs. Even NRG-loaded nanoparticles sho
./___Corpus/Medline/xml/PMC4930000.xml	anti-lipid	56973 : 56983	CM	articles showed enhanced anti-lipid peroxidative antiprolife
./___Corpus/Medline/xml/PMC4930000.xml	naringenin	57111 : 57121	CM	fficacy compared to free naringenin in 7, 12-dimethylbenz(a)
./___Corpus/Medline/xml/PMC4930000.xml	12-dimethylbenz(a)anthracene	57128 : 57156	CM	to free naringenin in 7, 12-dimethylbenz(a)anthracene (DMBA)-induced oral carc
./___Corpus/Medline/xml/PMC4930000.xml	DMBA	57158 : 57162	CM	methylbenz(a)anthracene (DMBA)-induced oral carcinogen
./___Corpus/Medline/xml/PMC4930000.xml	Naringenin	57199 : 57209	CM	al carcinogenesis [374]. Naringenin flavonoids present in GJ
./___Corpus/Medline/xml/PMC4930000.xml	flavonoids	57210 : 57220	CM	enesis [374]. Naringenin flavonoids present in GJF demonstra
./___Corpus/Medline/xml/PMC4930000.xml	GJF	57232 : 57235	CM	in flavonoids present in GJF demonstrate multiple int
./___Corpus/Medline/xml/PMC4930000.xml	CYP3A4 isoenzyme	57414 : 57430	CM	d inhibition of gut wall CYP3A4 isoenzyme, P-glycoprotein multi-dr
./___Corpus/Medline/xml/PMC4930000.xml	P-glycoprotein	57432 : 57446	CM	t wall CYP3A4 isoenzyme, P-glycoprotein multi-drug resistance pr
./___Corpus/Medline/xml/PMC4930000.xml	vitro	57579 : 57584	CM	een evaluated through in vitro and in vivo studies [375
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57637 : 57656	CM	6].                  3.8 Desoxyrhapontigenin                      Des
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57678 : 57697	CM	nin                      Desoxyrhapontigenin (3,5-dihydroxy-4′-O-meth
./___Corpus/Medline/xml/PMC4930000.xml	3,5-dihydroxy-4′-O-methylresveratrol	57699 : 57735	CM	    Desoxyrhapontigenin (3,5-dihydroxy-4′-O-methylresveratrol) is an antioxidant [377]
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57762 : 57781	CM	is an antioxidant [377]. Desoxyrhapontigenin may be useful in the mod
./___Corpus/Medline/xml/PMC4930000.xml	cytochrome	57857 : 57867	CM	environment. It inhibits cytochrome P450 enzymes [378,379], 
./___Corpus/Medline/xml/PMC4930000.xml	ROS	57906 : 57909	CM	[378,379], inflammation, ROS, and associated pathways
./___Corpus/Medline/xml/PMC4930000.xml	380–	57936 : 57940	CPR	and associated pathways [380–385].                    
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	57984 : 58003	CM	                         Desoxyrhapontigenin affects ROS and inflamma
./___Corpus/Medline/xml/PMC4930000.xml	ROS	58012 : 58015	CM	oxyrhapontigenin affects ROS and inflammation. This o
./___Corpus/Medline/xml/PMC4930000.xml	NF-κB	58126 : 58131	CM	3] and the inhibition of NF-κB and AP-1, reduced produc
./___Corpus/Medline/xml/PMC4930000.xml	AP-1	58136 : 58140	CM	 inhibition of NF-κB and AP-1, reduced production of C
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	58164 : 58169	CM	1, reduced production of COX-2, TNF-α, and IL-6, and re
./___Corpus/Medline/xml/PMC4930000.xml	carrageenan	58218 : 58229	CM	educed inflammation in a carrageenan-induced animal inflammat
./___Corpus/Medline/xml/PMC4930000.xml	Desoxyrhapontigenin	58271 : 58290	CM	nflammation model [385]. Desoxyrhapontigenin is produced by plants [3
./___Corpus/Medline/xml/PMC4930000.xml	anti-	58342 : 58347	CPR	] and its cyototoxic and anti-proliferative effects are
./___Corpus/Medline/xml/PMC4930000.xml	387–	58389 : 58393	CPR	ects are dose-dependent [387–390]. Thus, desoxyrhapont
./___Corpus/Medline/xml/PMC4930000.xml	desoxyrhapontigenin	58405 : 58424	CM	pendent [387–390]. Thus, desoxyrhapontigenin may be useful as a thera
./___Corpus/Medline/xml/PMC4930000.xml	ROS	58495 : 58498	CM	e through its effects on ROS and inflammation.       
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	58538 : 58546	CM	on.                  3.9 Piperine                      Pip
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	58568 : 58576	CM	ine                      Piperine (1-piperoyl piperidine) 
./___Corpus/Medline/xml/PMC4930000.xml	1-piperoyl piperidine	58578 : 58599	CM	               Piperine (1-piperoyl piperidine) is the principal alkalo
./___Corpus/Medline/xml/PMC4930000.xml	alkaloid	58618 : 58626	CM	ridine) is the principal alkaloid in black (Piper nigrum) 
./___Corpus/Medline/xml/PMC4930000.xml	anti-	58712 : 58717	CPR	has potentially multiple anti-cancer activities. It is 
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	58858 : 58866	CM	                         Piperine has low toxicity [392]. 
./___Corpus/Medline/xml/PMC4930000.xml	vitro	58912 : 58917	CM	2]. Additionally, the in vitro absorption rate of piper
./___Corpus/Medline/xml/PMC4930000.xml	piperine	58937 : 58945	CM	vitro absorption rate of piperine is relatively high compa
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	59007 : 59015	CM	er natural products like curcumin without any metabolic mo
./___Corpus/Medline/xml/PMC4930000.xml	piperine	59054 : 59062	CM	etabolic modification of piperine during the absorption pr
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59100 : 59108	CM	bsorption process [393]. Piperine is widely used as a bioa
./___Corpus/Medline/xml/PMC4930000.xml	rifampicin	59230 : 59240	CM	 the antimicrobial agent rifampicin [394], nevirapine which 
./___Corpus/Medline/xml/PMC4930000.xml	(HIV)-1	59319 : 59326	CM	n immunodeficiency virus (HIV)-1 reverse transcriptase [3
./___Corpus/Medline/xml/PMC4930000.xml	curcumin	59359 : 59367	CM	 transcriptase [395] and curcumin which has anticancer pro
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59407 : 59415	CM	cancer properties [396]. Piperine has various biological e
./___Corpus/Medline/xml/PMC4930000.xml	anti-	59484 : 59489	CPR	tioxidant activity [397] anti-inflammatory effect by in
./___Corpus/Medline/xml/PMC4930000.xml	PMA	59523 : 59526	CM	ory effect by inhibiting PMA-induced COX-2 [398].    
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	59535 : 59540	CM	y inhibiting PMA-induced COX-2 [398].                  
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59586 : 59594	CM	                         Piperine has significant anti-can
./___Corpus/Medline/xml/PMC4930000.xml	anti-	59611 : 59616	CPR	Piperine has significant anti-cancer effects [399]. Dif
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59829 : 59837	CM	ation of MMPs [402,403]. Piperine exerts chemopreventive a
./___Corpus/Medline/xml/PMC4930000.xml	benzo(a)pyrene	59905 : 59919	CM	me carcinogens including benzo(a)pyrene-induced lung carcinogene
./___Corpus/Medline/xml/PMC4930000.xml	DMBA	59958 : 59962	CM	carcinogenesis [404] and DMBA- induced skin carcinogen
./___Corpus/Medline/xml/PMC4930000.xml	Piperine	59999 : 60007	CM	in carcinogenesis [405]. Piperine, with its low toxicity a
./___Corpus/Medline/xml/PMC4930000.xml	anti-	60042 : 60047	CPR	 low toxicity and potent anti-angiogenic activity, may 
./___Corpus/Medline/xml/PMC4930000.xml	sesquiterpene	60220 : 60233	CM	            Zerumbone, a sesquiterpene, exerts its anticancer e
./___Corpus/Medline/xml/PMC4930000.xml	JAK	60290 : 60293	CM	hrough modulation of the JAK/STAT pathway. In renal c
./___Corpus/Medline/xml/PMC4930000.xml	STAT	60294 : 60298	CM	gh modulation of the JAK/STAT pathway. In renal cell c
./___Corpus/Medline/xml/PMC4930000.xml	STAT-3	60433 : 60439	CM	inhibits the activity of STAT-3 through suppressing its 
./___Corpus/Medline/xml/PMC4930000.xml	c-SRC	60481 : 60486	CM	ing its upstream kinases c-SRC, JAK-1 and JAK-2. Pervan
./___Corpus/Medline/xml/PMC4930000.xml	JAK-1	60488 : 60493	CM	 upstream kinases c-SRC, JAK-1 and JAK-2. Pervanadate, 
./___Corpus/Medline/xml/PMC4930000.xml	JAK-2	60498 : 60503	CM	kinases c-SRC, JAK-1 and JAK-2. Pervanadate, a protein 
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	60528 : 60536	CM	. Pervanadate, a protein tyrosine phosphatase (PTP) inhibi
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	60537 : 60548	CM	date, a protein tyrosine phosphatase (PTP) inhibitor treatmen
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	60625 : 60630	CM	nduced downregulation of STAT3, suggesting the involvem
./___Corpus/Medline/xml/PMC4930000.xml	tyrosine	60675 : 60683	CM	olvement of a PTP. SHP-1 tyrosine phosphatase interacts wi
./___Corpus/Medline/xml/PMC4930000.xml	phosphatase	60684 : 60695	CM	of a PTP. SHP-1 tyrosine phosphatase interacts with STAT3 and
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	60711 : 60716	CM	osphatase interacts with STAT3 and is induced by zerumb
./___Corpus/Medline/xml/PMC4930000.xml	SHP-1	60764 : 60769	CM	mbone. Upon knockdown of SHP-1 by siRNA, the ability of
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	60816 : 60821	CM	 of zerumbone to inhibit STAT3 activation-mediated apop
./___Corpus/Medline/xml/PMC4930000.xml	SHP-1	60898 : 60903	CM	sting the involvement of SHP-1 in its action. Zerumbone
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	60949 : 60954	CM	bone not only suppresses STAT3 but also reduces the exp
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	61001 : 61006	CM	expression of downstream STAT3-regulated gene products 
./___Corpus/Medline/xml/PMC4930000.xml	STAT3	61125 : 61130	CM	 Hence, zerumbone blocks STAT3 activation, leading to s
./___Corpus/Medline/xml/PMC4930000.xml	JAK	61291 : 61294	CM	nhibitor of constitutive JAK/STAT as well as IL-6 sti
./___Corpus/Medline/xml/PMC4930000.xml	STAT	61295 : 61299	CM	itor of constitutive JAK/STAT as well as IL-6 stimulat
./___Corpus/Medline/xml/PMC4930000.xml	JAK-2	61508 : 61513	CM	 mediated through active JAK-2/STAT-3 pathway [407,408]
./___Corpus/Medline/xml/PMC4930000.xml	STAT-3	61514 : 61520	CM	ted through active JAK-2/STAT-3 pathway [407,408]. Zerum
./___Corpus/Medline/xml/PMC4930000.xml	cisplatin	61555 : 61564	CM	407,408]. Zerumbone with cisplatin showed a synergistic ant
./___Corpus/Medline/xml/PMC4930000.xml	BALB	61652 : 61656	CM	lial neoplasia in female BALB/c mice through serum IL-
./___Corpus/Medline/xml/PMC4930000.xml	JAK	61719 : 61722	CM	ome cases, inhibition of JAK -2/STAT-3- mediated sign
./___Corpus/Medline/xml/PMC4930000.xml	STAT-3	61726 : 61732	CM	es, inhibition of JAK -2/STAT-3- mediated signaling path
./___Corpus/Medline/xml/PMC4930000.xml	PARP	61791 : 61795	CM	ced cytotoxicity through PARP cleavage in a human pros
./___Corpus/Medline/xml/PMC4930000.xml	G2	61939 : 61941	CM	ted through induction of G2/M arrest and decreased c
./___Corpus/Medline/xml/PMC4930000.xml	CDK1	61974 : 61978	CM	t and decreased cyclinB1/CDK1 protein level in HL-60 c
./___Corpus/Medline/xml/PMC4930000.xml	TRAIL	62374 : 62379	CM	of functional p53 [414], TRAIL-induced death receptor i
./___Corpus/Medline/xml/PMC4930000.xml	CXC	62565 : 62568	CM	     Zerumbone inhibited CXC chemokine receptor-4 exp
./___Corpus/Medline/xml/PMC4930000.xml	nitrite	62870 : 62877	CM	 decreased the levels of nitrite and prostaglandin (E2) w
./___Corpus/Medline/xml/PMC4930000.xml	prostaglandin	62882 : 62895	CM	he levels of nitrite and prostaglandin (E2) with unchanged COX-
./___Corpus/Medline/xml/PMC4930000.xml	COX-1	62916 : 62921	CM	ndin (E2) with unchanged COX-1 expression in LPA and ga
./___Corpus/Medline/xml/PMC4930000.xml	LPA	62936 : 62939	CM	nged COX-1 expression in LPA and gamma irradiated inc
./___Corpus/Medline/xml/PMC4930000.xml	NO	62971 : 62973	CM	mma irradiated increased NO synthase and COX-2 as we
./___Corpus/Medline/xml/PMC4930000.xml	COX-2	62987 : 62992	CM	ncreased NO synthase and COX-2 as well as release of TN
./___Corpus/Medline/xml/PMC4930000.xml	RAW	63024 : 63027	CM	l as release of TNF-α in RAW 264.7 mouse macrophages 
./___Corpus/Medline/xml/PMC4930000.xml	419–	63053 : 63057	CPR	264.7 mouse macrophages [419–421]. Zerumbone suppresse
./___Corpus/Medline/xml/PMC4930000.xml	TPA	63084 : 63087	CM	1]. Zerumbone suppressed TPA-induced activation of EB
./___Corpus/Medline/xml/PMC4930000.xml	EBV	63110 : 63113	CM	PA-induced activation of EBV, LOX-1 mRNA expression [
./___Corpus/Medline/xml/PMC4930000.xml	mRNA	63121 : 63125	CM	activation of EBV, LOX-1 mRNA expression [422], O2- an
./___Corpus/Medline/xml/PMC4930000.xml	O2	63144 : 63146	CM	1 mRNA expression [422], O2- anion generation throug
./___Corpus/Medline/xml/PMC4930000.xml	O2-	63146 : 63149	CPR	mRNA expression [422], O2- anion generation through N
./___Corpus/Medline/xml/PMC4930000.xml	NADPH	63173 : 63178	CM	anion generation through NADPH oxidase in DMSO differen
./___Corpus/Medline/xml/PMC4930000.xml	DMSO	63190 : 63194	CM	through NADPH oxidase in DMSO differentiated human pro
./___Corpus/Medline/xml/PMC4930000.xml	xanthine	63265 : 63273	CM	HL-60) cells and through xanthine oxidase in AS52 Chinese 
./___Corpus/Medline/xml/PMC4930000.xml	oxidase	63274 : 63281	CM	lls and through xanthine oxidase in AS52 Chinese hamster 
./___Corpus/Medline/xml/PMC4930000.xml	p38	63528 : 63531	CM	ed hyperglycemia induced p38 mediated inflammatory re
./___Corpus/Medline/xml/PMC4930000.xml	molecule-1	63690 : 63700	CM	f intercellular adhesion molecule-1, MCP-1, TGF-β1 and fibro
./___Corpus/Medline/xml/PMC4930000.xml	TGF-β1	63709 : 63715	CM	esion molecule-1, MCP-1, TGF-β1 and fibronectin in nephr
./___Corpus/Medline/xml/PMC4930000.xml	vitro	63768 : 63773	CM	thic rats. The proven in vitro and in vivo pharmacologi
./___Corpus/Medline/xml/PMC4930000.xml	lipid	63949 : 63954	CM	ne-loaded nanostructured lipid carriers have also been 
./___Corpus/Medline/xml/PMC4930000.xml	​and2).2	64331 : 64339	CM	nd ​and2,2, Tables 1 and ​and2).2). Our list is not exhaus
./___Corpus/Medline/xml/PMC4930000.xml	anti-	65016 : 65021	CPR	ported to have potential anti-neoplastic and/or tumor p
./___Corpus/Medline/xml/PMC4930000.xml	cytokine	65725 : 65733	CM	f cellular, humoral, and cytokine mediated programs and th
./___Corpus/Medline/xml/PMC4930000.xml	EGCG	68149 : 68153	CM	ting a Phase I trial for EGCG. The authors thank the I
./___Corpus/Medline/xml/PMC4930000.xml	EN	68221 : 68223	CM	 University of Italy (to EN, AA), the National Insti
./___Corpus/Medline/xml/PMC4930000.xml	AA	68225 : 68227	CM	versity of Italy (to EN, AA), the National Institute
./___Corpus/Medline/xml/PMC4930000.xml	SPK	68265 : 68268	CM	al Institutes of Health (SPK, DH), National Institute
./___Corpus/Medline/xml/PMC4930000.xml	DH	68270 : 68272	CM	stitutes of Health (SPK, DH), National Institutes of
./___Corpus/Medline/xml/PMC4930000.xml	ICBP	68344 : 68348	CM	01CA170378, U01CA188383, ICBP and ICMIC (to SCC, DWF),
./___Corpus/Medline/xml/PMC4930000.xml	ICMIC	68353 : 68358	CM	8, U01CA188383, ICBP and ICMIC (to SCC, DWF), an NIH R1
./___Corpus/Medline/xml/PMC4930000.xml	SCC	68363 : 68366	CM	8383, ICBP and ICMIC (to SCC, DWF), an NIH R15 CA1374
./___Corpus/Medline/xml/PMC4930000.xml	DWF	68368 : 68371	CM	 ICBP and ICMIC (to SCC, DWF), an NIH R15 CA137499-01
./___Corpus/Medline/xml/PMC4930000.xml	FB	68398 : 68400	CM	 an NIH R15 CA137499-01 (FB), a startup fund from Oh
./___Corpus/Medline/xml/PMC4930000.xml	RSAC	68443 : 68447	CM	from Ohio University, an RSAC grant (RP1206) from the 
./___Corpus/Medline/xml/PMC4930000.xml	OU	68516 : 68518	CM	 Osteopathic Medicine at OU (to FB), Prostate and Ov
./___Corpus/Medline/xml/PMC4930000.xml	FB	68523 : 68525	CM	athic Medicine at OU (to FB), Prostate and Ovarian C
./___Corpus/Medline/xml/PMC4930000.xml	THALES	68873 : 68879	CM	esearch Funding Program: THALES (Grant number MIS 379346
./___Corpus/Medline/xml/PMC4930000.xml	AGG	68965 : 68968	CM	 Radical Chemistry,’ (to AGG), the Charles University
./___Corpus/Medline/xml/PMC4930000.xml	PRVOUK	69029 : 69035	CM	projects UNCE 204015 and PRVOUK P31/2012, by the Czech S
./___Corpus/Medline/xml/PMC4930000.xml	NT13663-3	69189 : 69198	CM	e Czech Republic project NT13663-3/2012 (to PH), the Minist
./___Corpus/Medline/xml/PMC4930000.xml	PH	69208 : 69210	CM	oject NT13663-3/2012 (to PH), the Ministry of Educat
./___Corpus/Medline/xml/PMC4930000.xml	KH	69306 : 69308	CM	Japan (No. 24590493) (to KH), and private donations 
./___Corpus/Medline/xml/PMC4930000.xml	PDF	69562 : 69565	CM	's Disclaimer: This is a PDF file of an unedited manu
./___Corpus/Medline/xml/PMC4951238.xml	Dopamine	30 : 38	CM	act                      Dopamine and cAMP-regulated phosp
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	43 : 47	CM	            Dopamine and cAMP-regulated phosphoprotein
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	58 : 72	CM	amine and cAMP-regulated phosphoprotein Mr 32,000 (DARPP-32), al
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	84 : 92	CM	hosphoprotein Mr 32,000 (DARPP-32), also known as phosphop
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein phosphatase-1	109 : 137	CM	DARPP-32), also known as phosphoprotein phosphatase-1 regulatory subunit 1B (P
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	214 : 222	CM	overed as a substrate of dopamine-activated protein kinase
./___Corpus/Medline/xml/PMC4951238.xml	PKA	251 : 254	CM	ivated protein kinase A (PKA) in the neostriatum in t
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	295 : 310	RN	atum in the brain. While phosphorylation at Thr-34 by PKA convert
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	314 : 320	CM	While phosphorylation at Thr-34 by PKA converts DARPP-32
./___Corpus/Medline/xml/PMC4951238.xml	PKA	324 : 327	CM	phorylation at Thr-34 by PKA converts DARPP-32 into a
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	337 : 345	CM	t Thr-34 by PKA converts DARPP-32 into a potent inhibitor 
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	381 : 392	CM	ent inhibitor of protein phosphatase 1 (PP1), phosphorylation
./___Corpus/Medline/xml/PMC4951238.xml	PP1	396 : 399	CM	f protein phosphatase 1 (PP1), phosphorylation at Thr
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	402 : 417	RN	ein phosphatase 1 (PP1), phosphorylation at Thr-75 transforms DAR
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	421 : 427	CM	PP1), phosphorylation at Thr-75 transforms DARPP-32 into
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	439 : 447	CM	ion at Thr-75 transforms DARPP-32 into an inhibitor of PKA
./___Corpus/Medline/xml/PMC4951238.xml	PKA	469 : 472	CM	-32 into an inhibitor of PKA. Through regulation of D
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	496 : 504	CM	A. Through regulation of DARPP-32 phosphorylation and modu
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	505 : 520	RN	h regulation of DARPP-32 phosphorylation and modulation of protei
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	547 : 558	CM	nd modulation of protein phosphatase and kinase activities, D
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	582 : 590	CM	e and kinase activities, DARPP-32 plays a critical role in
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	702 : 710	CM	al effects controlled by dopamine and other neurotransmitt
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	813 : 821	CM	s. Altered expression of DARPP-32 and its truncated isofor
./___Corpus/Medline/xml/PMC4951238.xml	isoform	840 : 847	CM	RPP-32 and its truncated isoform (t-DARPP), specifically 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	849 : 856	CM	d its truncated isoform (t-DARPP), specifically in the pr
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	981 : 989	CM	r. Moreover, cleavage of DARPP-32 by calpain has been impl
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	1083 : 1091	CM	 of the genomic locus of DARPP-32 at 17q12 has been descri
./___Corpus/Medline/xml/PMC4951238.xml	17q12	1095 : 1100	CM	mic locus of DARPP-32 at 17q12 has been described in se
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	1140 : 1148	CM	ibed in several cancers. DARPP-32 and t-DARPP are frequent
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	1153 : 1160	CM	al cancers. DARPP-32 and t-DARPP are frequently overexpre
./___Corpus/Medline/xml/PMC4951238.xml	mRNA	1197 : 1201	CM	tly overexpressed at the mRNA and protein levels in ad
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	1378 : 1386	CM	-angiogenic functions of DARPP-32 in cancer. Overexpressio
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	1416 : 1424	CM	ancer. Overexpression of DARPP-32 and t-DARPP also promote
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	1429 : 1436	CM	pression of DARPP-32 and t-DARPP also promotes chemothera
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	1620 : 1628	CM	thways. The expansion of DARPP-32 research from neurotrans
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	1954 : 1968	CM	1] investigated proteins phosphorylated by calcium- and cyclic-A
./___Corpus/Medline/xml/PMC4951238.xml	calcium	1972 : 1979	CM	oteins phosphorylated by calcium- and cyclic-AMP (cAMP)-a
./___Corpus/Medline/xml/PMC4951238.xml	cyclic-AMP	1985 : 1995	CM	orylated by calcium- and cyclic-AMP (cAMP)-activated protein
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	1997 : 2001	CM	calcium- and cyclic-AMP (cAMP)-activated protein kinas
./___Corpus/Medline/xml/PMC4951238.xml	32-kDa	2041 : 2047	CM	tein kinases. Notably, a 32-kDa protein was found abunda
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	2122 : 2137	RN	 the neostriatum. As the phosphorylation of this protein was regu
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2171 : 2179	CM	protein was regulated by dopamine and cAMP, it was named D
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	2184 : 2188	CM	egulated by dopamine and cAMP, it was named DARPP-32 (
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	2203 : 2211	CM	e and cAMP, it was named DARPP-32 (dopamine and cAMP-regul
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2213 : 2221	CM	, it was named DARPP-32 (dopamine and cAMP-regulated phosp
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	2226 : 2230	CM	d DARPP-32 (dopamine and cAMP-regulated phosphoprotein
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein	2241 : 2255	CM	amine and cAMP-regulated phosphoprotein Mr 32,000) [2]. In addit
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	2298 : 2306	CM	n addition to the brain, DARPP-32 is expressed in adrenal 
./___Corpus/Medline/xml/PMC4951238.xml	3-	2371 : 2373	CPR	, and parathyroid cells [3-5]. Because it was shown 
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase-1	2417 : 2430	CM	shown to inhibit protein phosphatase-1 (PP1) following phosphor
./___Corpus/Medline/xml/PMC4951238.xml	PP1	2432 : 2435	CM	t protein phosphatase-1 (PP1) following phosphorylati
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	2447 : 2462	RN	hatase-1 (PP1) following phosphorylation of Thr-34 by protein kin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	2466 : 2472	CM	owing phosphorylation of Thr-34 by protein kinase A (PKA
./___Corpus/Medline/xml/PMC4951238.xml	PKA	2494 : 2497	CM	-34 by protein kinase A (PKA) [6], DARPP-32 is also k
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	2504 : 2512	CM	tein kinase A (PKA) [6], DARPP-32 is also known as phospho
./___Corpus/Medline/xml/PMC4951238.xml	phosphoprotein phosphatase-1	2530 : 2558	CM	ARPP-32 is also known as phosphoprotein phosphatase-1 regulatory subunit 1B (P
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	2592 : 2600	CM	ry subunit 1B (PPP1R1B). DARPP-32 has been shown to play a
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	2713 : 2721	CM	nd behavioral effects of dopamine on dopaminoceptive neuro
./___Corpus/Medline/xml/PMC4951238.xml	7-	2768 : 2770	CPR	urons (for reviews, see [7-9]). DARPP-32 has also be
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	2775 : 2783	CM	for reviews, see [7-9]). DARPP-32 has also been implicated
./___Corpus/Medline/xml/PMC4951238.xml	serotonin	2876 : 2885	CM	nsmitter systems such as serotonin and glutamate, in respon
./___Corpus/Medline/xml/PMC4951238.xml	glutamate	2890 : 2899	CM	ms such as serotonin and glutamate, in response to a variet
./___Corpus/Medline/xml/PMC4951238.xml	17q12	3034 : 3039	CM	requent amplification of 17q12, the locus of DARPP-32, 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3054 : 3062	CM	n of 17q12, the locus of DARPP-32, in gastric and esophage
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3155 : 3163	CM	this group reported that DARPP-32 and its truncated isofor
./___Corpus/Medline/xml/PMC4951238.xml	isoform	3182 : 3189	CM	RPP-32 and its truncated isoform; they cloned and named t
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	3213 : 3220	CM	m; they cloned and named t-DARPP, are amplified and overe
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3338 : 3346	CM	f studies on the role of DARPP-32 and t-DARPP in different
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	3351 : 3358	CM	the role of DARPP-32 and t-DARPP in different biological 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3480 : 3488	CM	efly outline the role of DARPP-32 in neurotransmission and
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3631 : 3639	CM	 biological functions of DARPP-32 and t-DARPP in human car
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	3644 : 3651	CM	unctions of DARPP-32 and t-DARPP in human carcinogenesis.
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3708 : 3716	CM	           MODULATION OF DARPP-32 IN NEUROTRANSMISSION AND
./___Corpus/Medline/xml/PMC4951238.xml	NEUROTRANSMISSION	3720 : 3737	CM	ODULATION OF DARPP-32 IN NEUROTRANSMISSION AND CNS DISORDERS       
./___Corpus/Medline/xml/PMC4951238.xml	CNS	3742 : 3745	CM	IN NEUROTRANSMISSION AND CNS DISORDERS               
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	3816 : 3824	CM	overy three decades ago, DARPP-32 has been shown in a larg
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	3954 : 3962	CM	eurotransmitters such as dopamine, glutamate, serotonin, a
./___Corpus/Medline/xml/PMC4951238.xml	glutamate	3964 : 3973	CM	itters such as dopamine, glutamate, serotonin, adenosine, a
./___Corpus/Medline/xml/PMC4951238.xml	serotonin	3975 : 3984	CM	 as dopamine, glutamate, serotonin, adenosine, and gamma-am
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	3986 : 3995	CM	e, glutamate, serotonin, adenosine, and gamma-aminobutyric 
./___Corpus/Medline/xml/PMC4951238.xml	gamma-aminobutyric acid	4001 : 4024	CM	erotonin, adenosine, and gamma-aminobutyric acid (GABA) [9, 15, 16]. In r
./___Corpus/Medline/xml/PMC4951238.xml	GABA	4026 : 4030	CM	gamma-aminobutyric acid (GABA) [9, 15, 16]. In respons
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4134 : 4149	RN	ransmitters regulate the phosphorylation state of DARPP-32, which
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	4159 : 4167	CM	phosphorylation state of DARPP-32, which converts it to an
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	4223 : 4234	CM	itor of either a protein phosphatase (PP1) or a protein kinas
./___Corpus/Medline/xml/PMC4951238.xml	PP1	4236 : 4239	CM	r a protein phosphatase (PP1) or a protein kinase (PK
./___Corpus/Medline/xml/PMC4951238.xml	PKA	4262 : 4265	CM	P1) or a protein kinase (PKA). The state of phosphory
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4281 : 4296	RN	nase (PKA). The state of phosphorylation of DARPP-32 is regulated
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	4300 : 4308	CM	te of phosphorylation of DARPP-32 is regulated by tonic ac
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	4345 : 4353	CM	d by tonic activation of dopamine D1 and D2 receptors, and
./___Corpus/Medline/xml/PMC4951238.xml	D2	4361 : 4363	CM	ation of dopamine D1 and D2 receptors, and adenosine
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	4379 : 4388	CM	D1 and D2 receptors, and adenosine A2A receptor [17]. DARPP
./___Corpus/Medline/xml/PMC4951238.xml	A2A	4389 : 4392	CM	receptors, and adenosine A2A receptor [17]. DARPP-32 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	4408 : 4416	CM	osine A2A receptor [17]. DARPP-32 may be phosphorylated at
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	4424 : 4438	RN	or [17]. DARPP-32 may be phosphorylated at Thr-34 by PKA in dist
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	4442 : 4448	CM	may be phosphorylated at Thr-34 by PKA in distinct subpo
./___Corpus/Medline/xml/PMC4951238.xml	PKA	4452 : 4455	CM	sphorylated at Thr-34 by PKA in distinct subpopulatio
./___Corpus/Medline/xml/PMC4951238.xml	D1	4527 : 4529	CM	rons that express either D1 or A2A receptors [18, 19
./___Corpus/Medline/xml/PMC4951238.xml	A2A	4533 : 4536	CM	hat express either D1 or A2A receptors [18, 19]. Like
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	4562 : 4570	CM	receptors [18, 19]. Like dopamine, adenosine acts on A2A r
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	4572 : 4581	CM	[18, 19]. Like dopamine, adenosine acts on A2A receptor, us
./___Corpus/Medline/xml/PMC4951238.xml	A2A	4590 : 4593	CM	amine, adenosine acts on A2A receptor, using cAMP as 
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	4610 : 4614	CM	s on A2A receptor, using cAMP as a mediator in the pro
./___Corpus/Medline/xml/PMC4951238.xml	PKA	4656 : 4659	CM	 the process, activating PKA and increasing DARPP-32 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	4675 : 4683	CM	ating PKA and increasing DARPP-32 phosphorylation at Thr-3
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4684 : 4699	RN	 and increasing DARPP-32 phosphorylation at Thr-34 [20]. The D2 r
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	4703 : 4709	CM	PP-32 phosphorylation at Thr-34 [20]. The D2 receptor ex
./___Corpus/Medline/xml/PMC4951238.xml	D2	4720 : 4722	CM	tion at Thr-34 [20]. The D2 receptor exists as two d
./___Corpus/Medline/xml/PMC4951238.xml	D2L	4810 : 4813	CM	tive splicing: the long (D2L) and the short (D2S) [21
./___Corpus/Medline/xml/PMC4951238.xml	D2S	4830 : 4833	CM	ong (D2L) and the short (D2S) [21]. The D2S receptor 
./___Corpus/Medline/xml/PMC4951238.xml	D2S	4845 : 4848	CM	he short (D2S) [21]. The D2S receptor specifically re
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	4894 : 4909	CM	y regulates the state of phosphorylation and activity of tyrosine
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	4926 : 4934	CM	rylation and activity of tyrosine hydroxylase (TH) in nigr
./___Corpus/Medline/xml/PMC4951238.xml	hydroxylase	4935 : 4946	CM	and activity of tyrosine hydroxylase (TH) in nigrostriatal pr
./___Corpus/Medline/xml/PMC4951238.xml	TH	4948 : 4950	CM	of tyrosine hydroxylase (TH) in nigrostriatal presyn
./___Corpus/Medline/xml/PMC4951238.xml	D2L	5004 : 5007	CM	c terminals, whereas the D2L receptor is mainly invol
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	5057 : 5065	CM	ved in the regulation of DARPP-32 phosphorylation in posts
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5066 : 5081	RN	e regulation of DARPP-32 phosphorylation in postsynaptic striatal
./___Corpus/Medline/xml/PMC4951238.xml	D2	5152 : 5154	CM	 [22]. Activation of the D2 receptor decreases DARPP
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	5174 : 5182	CM	he D2 receptor decreases DARPP-32 phosphorylation by two d
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5183 : 5198	RN	eptor decreases DARPP-32 phosphorylation by two different mechani
./___Corpus/Medline/xml/PMC4951238.xml	D2	5282 : 5284	CM	s that co-express D1 and D2 classes of dopamine rece
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	5296 : 5304	CM	ess D1 and D2 classes of dopamine receptors, activation of
./___Corpus/Medline/xml/PMC4951238.xml	D2	5330 : 5332	CM	receptors, activation of D2 receptors decreases cAMP
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	5353 : 5357	CM	f D2 receptors decreases cAMP levels. When D2 receptor
./___Corpus/Medline/xml/PMC4951238.xml	D2	5371 : 5373	CM	reases cAMP levels. When D2 receptors are co-express
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	5406 : 5415	CM	rs are co-expressed with adenosine A2A receptor, it can res
./___Corpus/Medline/xml/PMC4951238.xml	A2A	5416 : 5419	CM	expressed with adenosine A2A receptor, it can result 
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	5461 : 5465	CM	 result in a decrease of cAMP levels, decreasing the a
./___Corpus/Medline/xml/PMC4951238.xml	PKA	5506 : 5509	CM	ing the activity of both PKA and in phosphorylation o
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5517 : 5532	RN	ivity of both PKA and in phosphorylation of DARPP-32 at Thr-34. S
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	5536 : 5544	CM	nd in phosphorylation of DARPP-32 at Thr-34. Second, activ
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5548 : 5554	CM	orylation of DARPP-32 at Thr-34. Second, activation of D
./___Corpus/Medline/xml/PMC4951238.xml	D2	5578 : 5580	CM	4. Second, activation of D2 receptor leads to an inc
./___Corpus/Medline/xml/PMC4951238.xml	Ca2+	5614 : 5618	CM	 leads to an increase in Ca2+ levels and increased act
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	5660 : 5671	CM	ased activity of protein phosphatase 2B (PP-2B), resulting in
./___Corpus/Medline/xml/PMC4951238.xml	PP-2B	5676 : 5681	CM	 protein phosphatase 2B (PP-2B), resulting in an increa
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	5712 : 5729	RN	ulting in an increase in dephosphorylation of DARPP-32 at Thr-34 [2
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	5733 : 5741	CM	 in dephosphorylation of DARPP-32 at Thr-34 [23]. In the i
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5745 : 5751	CM	orylation of DARPP-32 at Thr-34 [23]. In the intact stri
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	5802 : 5810	CM	tum, a blockade of tonic dopamine D2 receptor activation i
./___Corpus/Medline/xml/PMC4951238.xml	D2	5811 : 5813	CM	ockade of tonic dopamine D2 receptor activation incr
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	5844 : 5852	CM	tor activation increases DARPP-32 phosphorylation at Thr-3
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	5853 : 5868	RN	ation increases DARPP-32 phosphorylation at Thr-34 and can be cou
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	5872 : 5878	CM	PP-32 phosphorylation at Thr-34 and can be counteracted 
./___Corpus/Medline/xml/PMC4951238.xml	adenosine	5922 : 5931	CM	acted by blocking either adenosine A2A or dopamine D1 recep
./___Corpus/Medline/xml/PMC4951238.xml	A2A	5932 : 5935	CM	locking either adenosine A2A or dopamine D1 receptors
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	5939 : 5947	CM	 either adenosine A2A or dopamine D1 receptors [17].      
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6009 : 6024	RN	                     The phosphorylation of DARPP-32 at Thr-34 co
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	6028 : 6036	CM	  The phosphorylation of DARPP-32 at Thr-34 converts it in
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	6040 : 6046	CM	orylation of DARPP-32 at Thr-34 converts it into a poten
./___Corpus/Medline/xml/PMC4951238.xml	PP1	6086 : 6089	CM	to a potent inhibitor of PP1 [6, 24, 25]. PP1 is invo
./___Corpus/Medline/xml/PMC4951238.xml	PP1	6103 : 6106	CM	itor of PP1 [6, 24, 25]. PP1 is involved in regulatin
./___Corpus/Medline/xml/PMC4951238.xml	phosphoproteins	6167 : 6182	CM	ity of a large number of phosphoproteins, including voltage-depen
./___Corpus/Medline/xml/PMC4951238.xml	sodium	6212 : 6218	CM	luding voltage-dependent sodium and calcium channels, th
./___Corpus/Medline/xml/PMC4951238.xml	calcium	6223 : 6230	CM	age-dependent sodium and calcium channels, the electrogen
./___Corpus/Medline/xml/PMC4951238.xml	Na+	6263 : 6266	CM	s, the electrogenic pump Na+, K+-ATPase, and neurotra
./___Corpus/Medline/xml/PMC4951238.xml	K+	6268 : 6270	CM	e electrogenic pump Na+, K+-ATPase, and neurotransmi
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	6316 : 6324	CM	nsmitter receptors [26]. DARPP-32-mediated inhibition of P
./___Corpus/Medline/xml/PMC4951238.xml	PP1	6348 : 6351	CM	2-mediated inhibition of PP1 increases the phosphoryl
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6366 : 6381	RN	ion of PP1 increases the phosphorylation of neurotransmitter rece
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	6513 : 6521	CM	colleagues reported that DARPP-32 was converted into an in
./___Corpus/Medline/xml/PMC4951238.xml	PKA	6557 : 6560	CM	ted into an inhibitor of PKA when phosphorylated at T
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	6566 : 6580	CM	an inhibitor of PKA when phosphorylated at Thr-75 by cyclin-depe
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	6584 : 6590	CM	A when phosphorylated at Thr-75 by cyclin-dependent kina
./___Corpus/Medline/xml/PMC4951238.xml	cyclin	6594 : 6600	CM	sphorylated at Thr-75 by cyclin-dependent kinase 5 (Cdk5
./___Corpus/Medline/xml/PMC4951238.xml	Cdk5	6621 : 6625	CM	clin-dependent kinase 5 (Cdk5) [27]. Decreasing phosph
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-75	6644 : 6658	CM	 (Cdk5) [27]. Decreasing phospho-Thr-75 DARPP-32 in striatal sli
./___Corpus/Medline/xml/PMC4951238.xml	Cdk5	6700 : 6704	CM	atal slices, either by a Cdk5-specific inhibitor or by
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	6772 : 6780	CM	 altered mice, increases dopamine-induced phosphorylation 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	6789 : 6804	RN	creases dopamine-induced phosphorylation of PKA substrates and au
./___Corpus/Medline/xml/PMC4951238.xml	PKA	6808 : 6811	CM	duced phosphorylation of PKA substrates and augments 
./___Corpus/Medline/xml/PMC4951238.xml	calcium	6855 : 6862	CM	ments peak voltage-gated calcium currents [28, 29]. This 
./___Corpus/Medline/xml/PMC4951238.xml	amino acid	6932 : 6942	CM	ding on which particular amino acid residue is phosphorylate
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	6954 : 6968	CM	ar amino acid residue is phosphorylated, DARPP-32 can function a
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	6970 : 6978	CM	sidue is phosphorylated, DARPP-32 can function as either a
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	7016 : 7027	CM	 as either a kinase or a phosphatase inhibitor. This unique d
./___Corpus/Medline/xml/PMC4951238.xml	CK1	7243 : 7246	CM	        Casein kinase 1 (CK1) can phosphorylate DARPP
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylate	7252 : 7265	CM	asein kinase 1 (CK1) can phosphorylate DARPP-32 at Ser-137, whi
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	7278 : 7285	CM	hosphorylate DARPP-32 at Ser-137, which has an important 
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7350 : 7367	RN	 because it inhibits the dephosphorylation of Thr-34 by calcineurin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	7371 : 7377	CM	the dephosphorylation of Thr-34 by calcineurin. This inh
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Ser-137	7432 : 7447	CM	on takes place only when phospho-Ser-137 and phospho-Thr-34 are p
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-34	7452 : 7466	CM	when phospho-Ser-137 and phospho-Thr-34 are present on the same 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	7491 : 7499	CM	 are present on the same DARPP-32 molecule [30]. Phosphory
./___Corpus/Medline/xml/PMC4951238.xml	Phosphorylation	7515 : 7530	RN	 DARPP-32 molecule [30]. Phosphorylation of DARPP-32 by CK1, whic
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	7534 : 7542	CM	[30]. Phosphorylation of DARPP-32 by CK1, which is highly 
./___Corpus/Medline/xml/PMC4951238.xml	CK1	7546 : 7549	CM	orylation of DARPP-32 by CK1, which is highly active 
./___Corpus/Medline/xml/PMC4951238.xml	PP1	7638 : 7641	CM	r its ability to inhibit PP1 [30]. DARPP-32 phosphory
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	7648 : 7656	CM	ity to inhibit PP1 [30]. DARPP-32 phosphorylated by CK1 is
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	7657 : 7671	RN	hibit PP1 [30]. DARPP-32 phosphorylated by CK1 is a substrate fo
./___Corpus/Medline/xml/PMC4951238.xml	CK1	7675 : 7678	CM	RPP-32 phosphorylated by CK1 is a substrate for prote
./___Corpus/Medline/xml/PMC4951238.xml	phosphatases	7706 : 7718	CM	 a substrate for protein phosphatases 2A and 2C. However, in s
./___Corpus/Medline/xml/PMC4951238.xml	2C	7726 : 7728	CM	tein phosphatases 2A and 2C. However, in substantia 
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7767 : 7784	RN	substantia nigra slices, dephosphorylation of Ser-137 was markedly 
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	7788 : 7795	CM	es, dephosphorylation of Ser-137 was markedly sensitive t
./___Corpus/Medline/xml/PMC4951238.xml	okadaic acid	7895 : 7907	CM	ected by the presence of okadaic acid under conditions where d
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	7931 : 7948	RN	d under conditions where dephosphorylation of Thr-34 by protein pho
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	7952 : 7958	CM	ere dephosphorylation of Thr-34 by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	7970 : 7981	CM	ion of Thr-34 by protein phosphatase 2A was inhibited. This s
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Ser-137	8032 : 8047	CM	ggests that, in neurons, phospho-Ser-137 DARPP-32 is dephosphoryl
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylated	8060 : 8076	CM	spho-Ser-137 DARPP-32 is dephosphorylated by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	8088 : 8099	CM	hosphorylated by protein phosphatase 2C, but not 2A. Thus, DA
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	8122 : 8130	CM	se 2C, but not 2A. Thus, DARPP-32 appears to be a componen
./___Corpus/Medline/xml/PMC4951238.xml	phosphatases	8184 : 8196	CM	 a regulatory cascade of phosphatases in which dephosphorylati
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	8206 : 8223	RN	of phosphatases in which dephosphorylation of Ser-137 by protein ph
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	8227 : 8234	CM	ich dephosphorylation of Ser-137 by protein phosphatase 2
./___Corpus/Medline/xml/PMC4951238.xml	phosphatase	8246 : 8257	CM	on of Ser-137 by protein phosphatase 2C facilitates dephospho
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	8273 : 8290	RN	osphatase 2C facilitates dephosphorylation of Thr-34 by calcineurin
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	8294 : 8300	CM	tes dephosphorylation of Thr-34 by calcineurin, removing
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	8330 : 8334	CM	alcineurin, removing the cAMP-induced inhibition of PP
./___Corpus/Medline/xml/PMC4951238.xml	PP1	8357 : 8360	CM	MP-induced inhibition of PP1 [31]. DARPP-32 is also p
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	8367 : 8375	CM	 inhibition of PP1 [31]. DARPP-32 is also phosphorylated o
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylated	8384 : 8398	RN	1 [31]. DARPP-32 is also phosphorylated on Ser-45 and Ser-102 by
./___Corpus/Medline/xml/PMC4951238.xml	Ser-45	8402 : 8408	CM	s also phosphorylated on Ser-45 and Ser-102 by casein ki
./___Corpus/Medline/xml/PMC4951238.xml	Ser-102	8413 : 8420	CM	phorylated on Ser-45 and Ser-102 by casein kinase 2 (CK2)
./___Corpus/Medline/xml/PMC4951238.xml	CK2	8441 : 8444	CM	-102 by casein kinase 2 (CK2) [32]. Phosphorylation b
./___Corpus/Medline/xml/PMC4951238.xml	Phosphorylation	8452 : 8467	RN	ein kinase 2 (CK2) [32]. Phosphorylation by CK2 has no effect on 
./___Corpus/Medline/xml/PMC4951238.xml	CK2	8471 : 8474	CM	[32]. Phosphorylation by CK2 has no effect on the pot
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	8507 : 8515	CM	effect on the potency of DARPP-32 as an inhibitor of PP1, 
./___Corpus/Medline/xml/PMC4951238.xml	PP1	8535 : 8538	CM	PP-32 as an inhibitor of PP1, which strictly depends 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	8566 : 8581	RN	hich strictly depends on phosphorylation of Thr-34 by cAMP-depend
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	8585 : 8591	CM	ds on phosphorylation of Thr-34 by cAMP-dependent protei
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	8595 : 8599	CM	phorylation of Thr-34 by cAMP-dependent protein kinase
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	8716 : 8723	CM	llowing the discovery of t-DARPP by El-Rifai's group in c
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	8827 : 8834	CM	t that the expression of t-DARPP transcript is altered in
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	8963 : 8970	CM	l cortex, and the higher t-DARPP expression was associate
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9085 : 9093	CM	a selective reduction in DARPP-32 expression in the prefro
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9200 : 9208	CM	at altered expression of DARPP-32 may be associated with t
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9313 : 9321	CM	investigated the role of DARPP-32 in Alzheimer's disease (
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9366 : 9374	CM	ase (AD), and found that DARPP-32 is cleaved at Thr-153 by
./___Corpus/Medline/xml/PMC4951238.xml	Thr-153	9389 : 9396	CM	t DARPP-32 is cleaved at Thr-153 by calpain, which reduce
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	9427 : 9442	RN	lpain, which reduces the phosphorylation of cAMP-response element
./___Corpus/Medline/xml/PMC4951238.xml	CREB	9485 : 9489	CM	element-binding protein (CREB), a target of PP1 and im
./___Corpus/Medline/xml/PMC4951238.xml	PP1	9504 : 9507	CM	tein (CREB), a target of PP1 and important for cognit
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9562 : 9570	CM	unction. The cleavage of DARPP-32 induces loss of its inhi
./___Corpus/Medline/xml/PMC4951238.xml	PP1	9614 : 9617	CM	s inhibitory function on PP1. The data suggest a nove
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9675 : 9683	CM	ism by which cleavage of DARPP-32 leads to dysregulation o
./___Corpus/Medline/xml/PMC4951238.xml	CREB	9710 : 9714	CM	eads to dysregulation of CREB signaling in AD [36].   
./___Corpus/Medline/xml/PMC4951238.xml	IDENTIFICATION	9754 : 9768	CM	D [36].                  IDENTIFICATION AND IMPLICATION OF DARPP
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	9788 : 9796	CM	ATION AND IMPLICATION OF DARPP-32 IN CANCER               
./___Corpus/Medline/xml/PMC4951238.xml	17q12	9934 : 9939	CM	ent amplification at the 17q12 locus in several maligna
./___Corpus/Medline/xml/PMC4951238.xml	17q	10091 : 10094	CM	expression levels of the 17q amplicon-specific genes 
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	10176 : 10181	CM	bers of 18 genes such as ERBB2, TOP2A, GRB7, and expres
./___Corpus/Medline/xml/PMC4951238.xml	TOP2A	10183 : 10188	CM	 18 genes such as ERBB2, TOP2A, GRB7, and expression se
./___Corpus/Medline/xml/PMC4951238.xml	GRB7	10190 : 10194	CM	es such as ERBB2, TOP2A, GRB7, and expression sequence
./___Corpus/Medline/xml/PMC4951238.xml	EST	10225 : 10228	CM	expression sequence tag (EST {"type":"entrez-nucleoti
./___Corpus/Medline/xml/PMC4951238.xml	EST	10405 : 10408	CM	eagues demonstrated that EST {"type":"entrez-nucleoti
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	10635 : 10643	CM	ere first to report that DARPP-32 is the target gene for o
./___Corpus/Medline/xml/PMC4951238.xml	EST	10685 : 10688	CM	ne for overexpression of EST {"type":"entrez-nucleoti
./___Corpus/Medline/xml/PMC4951238.xml	EST	10857 : 10860	CM	 analyses indicated that EST {"type":"entrez-nucleoti
./___Corpus/Medline/xml/PMC4951238.xml	3′-	10991 : 10994	CPR	09 corresponded to the 3′-untranslated region of the 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	11019 : 11027	CM	translated region of the DARPP-32 gene. Further analyses o
./___Corpus/Medline/xml/PMC4951238.xml	ESTs	11065 : 11069	CM	r analyses of the nearby ESTs, two ESTs ({"type":"entr
./___Corpus/Medline/xml/PMC4951238.xml	ESTs	11075 : 11079	CM	 of the nearby ESTs, two ESTs ({"type":"entrez-nucleot
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	11345 : 11353	CM	erlap with the 5′ end of DARPP-32 exon 1. An additional 46
./___Corpus/Medline/xml/PMC4951238.xml	bp	11380 : 11382	CM	xon 1. An additional 467 bp untranslated mRNA sequen
./___Corpus/Medline/xml/PMC4951238.xml	mRNA	11396 : 11400	CM	onal 467 bp untranslated mRNA sequence of DARPP-32 was
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	11413 : 11421	CM	nslated mRNA sequence of DARPP-32 was identified upstream 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	11563 : 11571	CM	verified the full-length DARPP-32 cDNA sequence ({"type":"
./___Corpus/Medline/xml/PMC4951238.xml	cDNA	11572 : 11576	CM	the full-length DARPP-32 cDNA sequence ({"type":"entre
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	11740 : 11748	CM	tional splice variant of DARPP-32 was cloned from gastric 
./___Corpus/Medline/xml/PMC4951238.xml	isoform	11920 : 11927	CM	71) and termed truncated isoform of DARPP (t-DARPP) [14].
./___Corpus/Medline/xml/PMC4951238.xml	DARPP	11931 : 11936	CM	med truncated isoform of DARPP (t-DARPP) [14]. The nove
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	11938 : 11945	CM	ncated isoform of DARPP (t-DARPP) [14]. The novel molecul
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	11973 : 11980	CM	14]. The novel molecule, t-DARPP, has a unique alternativ
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12045 : 12053	CM	cated within intron 1 of DARPP-32. While DARPP-32 encodes 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12061 : 12069	CM	ron 1 of DARPP-32. While DARPP-32 encodes 204 amino acids 
./___Corpus/Medline/xml/PMC4951238.xml	amino acids	12082 : 12093	CM	ile DARPP-32 encodes 204 amino acids protein containing four 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12118 : 12133	RN	 protein containing four phosphorylation sites (Thr-34, Thr-75, S
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	12141 : 12147	CM	r phosphorylation sites (Thr-34, Thr-75, Ser-102, and Se
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	12149 : 12155	CM	orylation sites (Thr-34, Thr-75, Ser-102, and Ser-137), 
./___Corpus/Medline/xml/PMC4951238.xml	Ser-102	12157 : 12164	CM	n sites (Thr-34, Thr-75, Ser-102, and Ser-137), t-DARPP e
./___Corpus/Medline/xml/PMC4951238.xml	Ser-137	12170 : 12177	CM	34, Thr-75, Ser-102, and Ser-137), t-DARPP encodes 168 am
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	12180 : 12187	CM	, Ser-102, and Ser-137), t-DARPP encodes 168 amino acids 
./___Corpus/Medline/xml/PMC4951238.xml	amino acids	12200 : 12211	CM	37), t-DARPP encodes 168 amino acids protein lacking the Thr-
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	12232 : 12238	CM	cids protein lacking the Thr-34 phosphorylation site rel
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12239 : 12254	RN	otein lacking the Thr-34 phosphorylation site related to PP1 inhi
./___Corpus/Medline/xml/PMC4951238.xml	PP1	12271 : 12274	CM	rylation site related to PP1 inhibition but maintains
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	12316 : 12331	RN	aintains the other three phosphorylation sites (Figure ​(Figure2)
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12391 : 12399	CM	mitant overexpression of DARPP-32 and t-DARPP was demonstr
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	12404 : 12411	CM	pression of DARPP-32 and t-DARPP was demonstrated in 68% 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12527 : 12535	CM	equent overexpression of DARPP-32 and t-DARPP in adenocarc
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	12540 : 12547	CM	pression of DARPP-32 and t-DARPP in adenocarcinomas of th
./___Corpus/Medline/xml/PMC4951238.xml	40-	12603 : 12606	CPR	st, prostate, and colon [40-43]. These findings sugge
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12639 : 12647	CM	se findings suggest that DARPP-32 proteins could be implic
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12794 : 12802	CM	e the functional role of DARPP-32 and t-DARPP primarily in
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	12807 : 12814	CM	nal role of DARPP-32 and t-DARPP primarily in gastric can
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	12992 : 13000	CM	d to examine the role of DARPP-32 in the multistep cascade
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	13148 : 13156	CM	r tissues indicated that DARPP-32 is overexpressed in earl
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32-STARD3	13651 : 13666	CM	Notably, the presence of DARPP-32-STARD3 fusion transcript, which
./___Corpus/Medline/xml/PMC4951238.xml	RNA	13719 : 13722	CM	pears to be generated by RNA processing without chrom
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32-STARD3	13903 : 13918	CM	ssues. Overexpression of DARPP-32-STARD3 significantly increases 
./___Corpus/Medline/xml/PMC4951238.xml	vitro	13980 : 13985	CM	er cell proliferation in vitro and gastric tumor xenogr
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	14083 : 14087	CM	ted by activation of the PI3K/AKT signaling pathway [4
./___Corpus/Medline/xml/PMC4951238.xml	AKT	14088 : 14091	CM	y activation of the PI3K/AKT signaling pathway [47]. 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32-STARD3	14153 : 14168	CM	gs strongly suggest that DARPP-32-STARD3 fusion transcript promot
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14284 : 14292	CM	stigation on the role of DARPP-32 in gastric tumorigenesis
./___Corpus/Medline/xml/PMC4951238.xml	CD44	14340 : 14344	CM	is through regulation of CD44 splicing [48]. The findi
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14388 : 14396	CM	 findings indicated that DARPP-32 positively regulates the
./___Corpus/Medline/xml/PMC4951238.xml	isoform	14504 : 14511	CM	expression of the splice isoform, CD44E, in gastric cance
./___Corpus/Medline/xml/PMC4951238.xml	CD44E	14513 : 14518	CM	n of the splice isoform, CD44E, in gastric cancer cells
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14579 : 14587	CM	ic studies revealed that DARPP-32 associates with SRp20 sp
./___Corpus/Medline/xml/PMC4951238.xml	SRp20	14604 : 14609	CM	DARPP-32 associates with SRp20 splicing factor in a pro
./___Corpus/Medline/xml/PMC4951238.xml	SRp20	14668 : 14673	CM	lex, thereby stabilizing SRp20 protein and increasing i
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14727 : 14735	CM	xpression. Modulation of DARPP-32 expression indicated tha
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14762 : 14770	CM	xpression indicated that DARPP-32 regulates the SRp20-depe
./___Corpus/Medline/xml/PMC4951238.xml	SRp20	14785 : 14790	CM	t DARPP-32 regulates the SRp20-dependent CD44E splicing
./___Corpus/Medline/xml/PMC4951238.xml	CD44E	14801 : 14806	CM	ates the SRp20-dependent CD44E splicing and gastric tum
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	14925 : 14933	CM	equent overexpression of DARPP-32, SRp20 and CD44E protein
./___Corpus/Medline/xml/PMC4951238.xml	SRp20	14935 : 14940	CM	rexpression of DARPP-32, SRp20 and CD44E proteins in hu
./___Corpus/Medline/xml/PMC4951238.xml	CD44E	14945 : 14950	CM	n of DARPP-32, SRp20 and CD44E proteins in human gastri
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15036 : 15044	CM	ng an important role for DARPP-32 in gastric tumorigenesis
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15108 : 15116	CM	cent report, the role of DARPP-32 and t-DARPP in breast tu
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	15121 : 15128	CM	the role of DARPP-32 and t-DARPP in breast tumorigenesis 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15222 : 15230	CM	del [49]. In contrast to DARPP-32, which was expressed in 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	15303 : 15310	CM	ssue and in some tumors, t-DARPP was exclusively expresse
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15378 : 15386	CM	al or higher levels than DARPP-32, suggesting that t-DARPP
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	15404 : 15411	CM	ARPP-32, suggesting that t-DARPP plays a predominant role
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15487 : 15495	CM	Notably, knockout of the DARPP-32 gene in MMTV (mouse mamm
./___Corpus/Medline/xml/PMC4951238.xml	MMTV	15504 : 15508	CM	 of the DARPP-32 gene in MMTV (mouse mammary tumor vir
./___Corpus/Medline/xml/PMC4951238.xml	promoter)-PyMT	15536 : 15550	CM	ouse mammary tumor virus promoter)-PyMT (polyoma middle T oncoge
./___Corpus/Medline/xml/PMC4951238.xml	transgenic	15579 : 15589	CM	lyoma middle T oncogene) transgenic mammary tumor mice reduc
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15675 : 15683	CM	ng the important role of DARPP-32 proteins in breast tumor
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15740 : 15748	CM	s [49].                  DARPP-32 proteins in cancer cell 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15859 : 15867	CM	report demonstrated that DARPP-32 proteins could protect c
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	15988 : 15996	CM	nt in studies where both DARPP-32 and t-DARPP protected ga
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	16001 : 16008	CM	 where both DARPP-32 and t-DARPP protected gastric cancer
./___Corpus/Medline/xml/PMC4951238.xml	camptothecin	16048 : 16060	CM	ric cancer cells against camptothecin, sodium butyrate, and ce
./___Corpus/Medline/xml/PMC4951238.xml	sodium butyrate	16062 : 16077	CM	ls against camptothecin, sodium butyrate, and ceramide treatments
./___Corpus/Medline/xml/PMC4951238.xml	ceramide	16083 : 16091	CM	in, sodium butyrate, and ceramide treatments in a p53-inde
./___Corpus/Medline/xml/PMC4951238.xml	p53	16108 : 16111	CM	ceramide treatments in a p53-independent mechanism [3
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	16154 : 16162	CM	nism [39]. Expression of DARPP-32 and t-DARPP preserved th
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	16167 : 16174	CM	pression of DARPP-32 and t-DARPP preserved the mitochondr
./___Corpus/Medline/xml/PMC4951238.xml	camptothecin	16242 : 16254	CM	potential in response to camptothecin, and this was associated
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16305 : 16309	CM	with increased levels of Bcl2 protein [39]. Notably, t
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	16367 : 16375	CM	urvival function of both DARPP-32 and t-DARPP depends on T
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	16380 : 16387	CM	ion of both DARPP-32 and t-DARPP depends on Thr-75 phosph
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	16399 : 16405	CM	2 and t-DARPP depends on Thr-75 phosphorylation residue 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	16406 : 16421	RN	-DARPP depends on Thr-75 phosphorylation residue [39]. A subseque
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	16499 : 16506	CM	pro-survival function of t-DARPP involves increased AKT k
./___Corpus/Medline/xml/PMC4951238.xml	AKT	16526 : 16529	CM	DARPP involves increased AKT kinase activity and high
./___Corpus/Medline/xml/PMC4951238.xml	phospho-AKT	16565 : 16576	CM	ivity and high levels of phospho-AKT (Ser-473) and phospho-GS
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	16578 : 16585	CM	h levels of phospho-AKT (Ser-473) and phospho-GSK3β (Ser-
./___Corpus/Medline/xml/PMC4951238.xml	phospho-GSK3β	16591 : 16604	CM	hospho-AKT (Ser-473) and phospho-GSK3β (Ser-9) proteins in gast
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	16606 : 16611	CM	-473) and phospho-GSK3β (Ser-9) proteins in gastric can
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	16693 : 16700	CM	 study demonstrated that t-DARPP activates CREB and ATF-1
./___Corpus/Medline/xml/PMC4951238.xml	CREB	16711 : 16715	CM	d that t-DARPP activates CREB and ATF-1 transcription 
./___Corpus/Medline/xml/PMC4951238.xml	ATF-1	16720 : 16725	CM	DARPP activates CREB and ATF-1 transcription factors, w
./___Corpus/Medline/xml/PMC4951238.xml	CREB	16765 : 16769	CM	factors, which bind to a CREB response element (CRE) o
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16796 : 16800	CM	esponse element (CRE) on Bcl2 promoter, in an AKT-depe
./___Corpus/Medline/xml/PMC4951238.xml	AKT	16817 : 16820	CM	 on Bcl2 promoter, in an AKT-dependent mechanism, lea
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16870 : 16874	CM	ding to up-regulation of Bcl2 expression and increased
./___Corpus/Medline/xml/PMC4951238.xml	ceramide	16929 : 16937	CM	 survival in response to ceramide [50]. A recent report in
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	16975 : 16983	CM	nt report indicated that DARPP-32 binds Bcl2 and calcineur
./___Corpus/Medline/xml/PMC4951238.xml	Bcl2	16990 : 16994	CM	ated that DARPP-32 binds Bcl2 and calcineurin (CaN) in
./___Corpus/Medline/xml/PMC4951238.xml	CaN	17012 : 17015	CM	ds Bcl2 and calcineurin (CaN) in a complex with inosi
./___Corpus/Medline/xml/PMC4951238.xml	inositol 1,4,5-triphosphate	17035 : 17062	CM	 (CaN) in a complex with inositol 1,4,5-triphosphate receptor (InsP3R, a ubiq
./___Corpus/Medline/xml/PMC4951238.xml	Ca2+	17108 : 17112	CM	ubiquitous intracellular Ca2+ channel), which induces 
./___Corpus/Medline/xml/PMC4951238.xml	Ca	17175 : 17177	CM	edback loop that reduces Ca+2 release and apoptosis 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	17216 : 17231	RN	 apoptosis by decreasing phosphorylation of InsP3R in chronic lym
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	17336 : 17344	CM	this mechanism involving DARPP-32 might be exploited by Bc
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	17463 : 17471	CM	nd, one study found that DARPP-32 reversed the multidrug r
./___Corpus/Medline/xml/PMC4951238.xml	Adriamycin	17515 : 17525	CM	drug resistance (MDR) of Adriamycin (ADR)-resistant gastric 
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17527 : 17530	CM	nce (MDR) of Adriamycin (ADR)-resistant gastric adeno
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17580 : 17583	CM	carcinoma cells (SGC7901/ADR), as these cells were si
./___Corpus/Medline/xml/PMC4951238.xml	vincristine	17634 : 17645	CM	nificantly sensitized to vincristine, ADR, 5-fluorouacil, and
./___Corpus/Medline/xml/PMC4951238.xml	ADR	17647 : 17650	CM	nsitized to vincristine, ADR, 5-fluorouacil, and cisp
./___Corpus/Medline/xml/PMC4951238.xml	5-fluorouacil	17652 : 17665	CM	zed to vincristine, ADR, 5-fluorouacil, and cisplatin in respon
./___Corpus/Medline/xml/PMC4951238.xml	cisplatin	17671 : 17680	CM	 ADR, 5-fluorouacil, and cisplatin in response to DARPP-32 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	17696 : 17704	CM	cisplatin in response to DARPP-32 up-regulation [52]. Base
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	17896 : 17904	CM	 In a study, the role of DARPP-32 in mediating resistance 
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	17932 : 17941	CM	 mediating resistance to gefitinib, a small tyrosine kinase
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	17951 : 17959	CM	ce to gefitinib, a small tyrosine kinase inhibitor specifi
./___Corpus/Medline/xml/PMC4951238.xml	EGFR	17990 : 17994	CM	e inhibitor specific for EGFR, was investigated in gas
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18059 : 18067	CM	e data demonstrated that DARPP-32 expression blocks gefiti
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	18086 : 18095	CM	RPP-32 expression blocks gefitinib-induced apoptosis in gas
./___Corpus/Medline/xml/PMC4951238.xml	AKT	18178 : 18181	CM	anied with activation of AKT, increased stability of 
./___Corpus/Medline/xml/PMC4951238.xml	EGFR	18210 : 18214	CM	creased stability of the EGFR protein, and the colocal
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18250 : 18258	CM	nd the colocalization of DARPP-32 with EGFR in a complex w
./___Corpus/Medline/xml/PMC4951238.xml	EGFR	18264 : 18268	CM	ization of DARPP-32 with EGFR in a complex with ERBB3 
./___Corpus/Medline/xml/PMC4951238.xml	ERBB3	18287 : 18292	CM	h EGFR in a complex with ERBB3 on the cell membrane [53
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18362 : 18370	CM	tigations concluded that DARPP-32 promotion of EGFR/ERBB3 
./___Corpus/Medline/xml/PMC4951238.xml	EGFR	18384 : 18388	CM	at DARPP-32 promotion of EGFR/ERBB3 protein interactio
./___Corpus/Medline/xml/PMC4951238.xml	ERBB3	18389 : 18394	CM	RPP-32 promotion of EGFR/ERBB3 protein interaction lead
./___Corpus/Medline/xml/PMC4951238.xml	EGFR	18424 : 18428	CM	ein interaction leads to EGFR phosphorylation and acti
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	18429 : 18444	RN	nteraction leads to EGFR phosphorylation and activation of PI3K-A
./___Corpus/Medline/xml/PMC4951238.xml	PI3K-AKT	18463 : 18471	CM	lation and activation of PI3K-AKT signaling, thereby incre
./___Corpus/Medline/xml/PMC4951238.xml	gefitinib	18520 : 18529	CM	easing cell survival and gefitinib resistance in gastric ca
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18584 : 18592	CM	cells [53]. In a report, DARPP-32 was implicated in mediat
./___Corpus/Medline/xml/PMC4951238.xml	TRAIL	18635 : 18640	CM	 mediating resistance to TRAIL (TNF-related apoptosis-i
./___Corpus/Medline/xml/PMC4951238.xml	TNF	18642 : 18645	CM	ing resistance to TRAIL (TNF-related apoptosis-induci
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18724 : 18732	CM	 The data indicated that DARPP-32 expression suppresses TR
./___Corpus/Medline/xml/PMC4951238.xml	TRAIL	18755 : 18760	CM	32 expression suppresses TRAIL-induced apoptosis, accom
./___Corpus/Medline/xml/PMC4951238.xml	caspase-8	18844 : 18853	CM	elease and activation of caspase-8, -9, and -3 in gastric c
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	18934 : 18942	CM	tigations indicated that DARPP-32 induces the expression o
./___Corpus/Medline/xml/PMC4951238.xml	STAT3	19027 : 19032	CM	hrough activation of Src/STAT3 signaling. In addition, 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	19057 : 19065	CM	 signaling. In addition, DARPP-32 has been shown to preven
./___Corpus/Medline/xml/PMC4951238.xml	TRAIL	19096 : 19101	CM	een shown to prevent the TRAIL-induced caspase-dependen
./___Corpus/Medline/xml/PMC4951238.xml	NF-κBp65	19140 : 19148	CM	se-dependent cleavage of NF-κBp65, thereby maintaining the
./___Corpus/Medline/xml/PMC4951238.xml	NF-κB	19186 : 19191	CM	ntaining the activity of NF-κB activity and the express
./___Corpus/Medline/xml/PMC4951238.xml	FLIPs	19252 : 19257	CM	target, the pro-survival FLIPs (FLICE-inhibitory protei
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	19322 : 19330	CM	he findings suggest that DARPP-32 promotes TRAIL resistanc
./___Corpus/Medline/xml/PMC4951238.xml	TRAIL	19340 : 19345	CM	t that DARPP-32 promotes TRAIL resistance whereby it su
./___Corpus/Medline/xml/PMC4951238.xml	FLIPs	19459 : 19464	CM	regulation of Bcl-xL and FLIPs, respectively [54].     
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	19547 : 19554	CM	 In a study, the role of t-DARPP in resistance to trastuz
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	19627 : 19632	CM	oclonal antibody against ERBB2 receptor, was investigat
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	19707 : 19714	CM	 The data indicated that t-DARPP expression was up-regula
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	19825 : 19832	CM	ls. Genetic knockdown of t-DARPP sensitized these resista
./___Corpus/Medline/xml/PMC4951238.xml	caspase-3	19921 : 19930	CM	 increased activation of caspase-3 and apoptosis. Mechanist
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	19984 : 19991	CM	tudies demonstrated that t-DARPP was associated with the 
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	20060 : 20065	CM	k protein 90 (HSP90) and ERBB2 in a protein complex, su
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20104 : 20111	CM	complex, suggesting that t-DARPP mediates trastuzumab res
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	20166 : 20171	CM	ce through regulation of ERBB2 receptor in trastuzumab-
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20266 : 20273	CM	ent study confirmed that t-DARPP overexpression was assoc
./___Corpus/Medline/xml/PMC4951238.xml	AKT	20309 : 20312	CM	sion was associated with AKT activation and trastuzum
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20408 : 20415	CM	 findings indicated that t-DARPP overexpression and Thr-7
./___Corpus/Medline/xml/PMC4951238.xml	Thr-75	20435 : 20441	CM	DARPP overexpression and Thr-75 t-DARPP residue are esse
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20442 : 20449	CM	verexpression and Thr-75 t-DARPP residue are essential fo
./___Corpus/Medline/xml/PMC4951238.xml	AKT	20476 : 20479	CM	esidue are essential for AKT activation and trastuzum
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	20569 : 20577	CM	n, the study showed that DARPP-32 promotes resistance to t
./___Corpus/Medline/xml/PMC4951238.xml	DARPP32	20636 : 20643	CM	b, and overexpression of DARPP32 is associated with poor 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20739 : 20746	CM	her study indicated that t-DARPP, but not DARPP-32, was o
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	20756 : 20764	CM	ed that t-DARPP, but not DARPP-32, was overexpressed in a 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	20854 : 20861	CM	s, and demonstrated that t-DARPP overexpression was suffi
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	20962 : 20979	RN	ess trastuzumab-mediated dephosphorylation of AKT in sensitive brea
./___Corpus/Medline/xml/PMC4951238.xml	AKT	20983 : 20986	CM	ted dephosphorylation of AKT in sensitive breast canc
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	21056 : 21063	CM	ent study has shown that t-DARPP overexpression in HER2-p
./___Corpus/Medline/xml/PMC4951238.xml	lapatinib	21170 : 21179	CM	cer cells in response to lapatinib by suppressing lapatinib
./___Corpus/Medline/xml/PMC4951238.xml	lapatinib	21195 : 21204	CM	lapatinib by suppressing lapatinib-induced BIM accumulation
./___Corpus/Medline/xml/PMC4951238.xml	BIM	21213 : 21216	CM	essing lapatinib-induced BIM accumulation [40]. A rel
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	21268 : 21275	CM	ed report indicated that t-DARPP promotes trastuzumab res
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	21330 : 21335	CM	ce through regulation of ERBB2 receptor in esophageal a
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	21389 : 21396	CM	carcinoma [57]. In fact, t-DARPP was shown to counteract 
./___Corpus/Medline/xml/PMC4951238.xml	caspase-3	21474 : 21483	CM	s, inhibit activation of caspase-3, and suppress trastuzuma
./___Corpus/Medline/xml/PMC4951238.xml	dephosphorylation	21518 : 21535	RN	ress trastuzumab-induced dephosphorylation of ERBB2 and AKT protein
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	21539 : 21544	CM	ced dephosphorylation of ERBB2 and AKT proteins. Howeve
./___Corpus/Medline/xml/PMC4951238.xml	AKT	21549 : 21552	CM	phorylation of ERBB2 and AKT proteins. However, knock
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	21596 : 21603	CM	 knockdown of endogenous t-DARPP reversed these effects a
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	21713 : 21720	CM	tudy also indicated that t-DARPP associates with ERBB2, t
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	21737 : 21742	CM	 t-DARPP associates with ERBB2, thus increasing its pro
./___Corpus/Medline/xml/PMC4951238.xml	ERBB2	21839 : 21844	CM	 of trastuzumab with the ERBB2 receptor in esophageal a
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	21912 : 21920	CM	s [57].                  DARPP-32 proteins in cancer cell 
./___Corpus/Medline/xml/PMC4951238.xml	mRNA	22012 : 22016	CM	    A study demonstrated mRNA overexpression of t-DARP
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22035 : 22042	CM	d mRNA overexpression of t-DARPP in 36% of breast cancers
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22172 : 22179	CM	ed to absent to very low t-DARPP expression in normal mam
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	22254 : 22262	CM	rotein overexpression of DARPP-32/t-DARPP was observed in 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22263 : 22270	CM	erexpression of DARPP-32/t-DARPP was observed in 35.5% of
./___Corpus/Medline/xml/PMC4951238.xml	vitro	22373 : 22378	CM	cinomas (43.7%) [41]. In vitro studies demonstrated tha
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22427 : 22434	CM	at the overexpression of t-DARPP promotes cell proliferat
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	22492 : 22507	RN	ciated with induction of phosphorylation of AKT (Ser-473) and its
./___Corpus/Medline/xml/PMC4951238.xml	AKT	22511 : 22514	CM	on of phosphorylation of AKT (Ser-473) and its target
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	22516 : 22523	CM	 phosphorylation of AKT (Ser-473) and its target GSK-3β (
./___Corpus/Medline/xml/PMC4951238.xml	GSK-3β	22540 : 22546	CM	(Ser-473) and its target GSK-3β (Ser-9) in breast cancer
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	22548 : 22553	CM	) and its target GSK-3β (Ser-9) in breast cancer cells.
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22607 : 22614	CM	 knockdown of endogenous t-DARPP or inhibition of PI3K re
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	22632 : 22636	CM	t-DARPP or inhibition of PI3K reversed these effects, 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22704 : 22711	CM	e pro-growth function of t-DARPP depends on PI3K in breas
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	22723 : 22727	CM	on of t-DARPP depends on PI3K in breast cancer [41]. I
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22783 : 22790	CM	lated study, the role of t-DARPP in regulating β-catenin 
./___Corpus/Medline/xml/PMC4951238.xml	β-catenin	22805 : 22814	CM	of t-DARPP in regulating β-catenin signaling and proliferat
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	22943 : 22950	CM	d that the expression of t-DARPP increased cell prolifera
./___Corpus/Medline/xml/PMC4951238.xml	β-catenin	23005 : 23014	CM	and led to activation of β-catenin through phosphorylation 
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	23023 : 23038	RN	ion of β-catenin through phosphorylation of AKT (Ser-473) and GSK
./___Corpus/Medline/xml/PMC4951238.xml	AKT	23042 : 23045	CM	rough phosphorylation of AKT (Ser-473) and GSK-3β (Se
./___Corpus/Medline/xml/PMC4951238.xml	Ser-473	23047 : 23054	CM	 phosphorylation of AKT (Ser-473) and GSK-3β (Ser-9) in a
./___Corpus/Medline/xml/PMC4951238.xml	GSK-3β	23060 : 23066	CM	ion of AKT (Ser-473) and GSK-3β (Ser-9) in a PI3K-depend
./___Corpus/Medline/xml/PMC4951238.xml	Ser-9	23068 : 23073	CM	KT (Ser-473) and GSK-3β (Ser-9) in a PI3K-dependent mec
./___Corpus/Medline/xml/PMC4951238.xml	PI3K	23080 : 23084	CM	 and GSK-3β (Ser-9) in a PI3K-dependent mechanism [58]
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23253 : 23261	CM	d that overexpression of DARPP-32 in breast cancer cells t
./___Corpus/Medline/xml/PMC4951238.xml	DDR1	23298 : 23302	CM	ancer cells that express DDR1, a receptor tyrosine kin
./___Corpus/Medline/xml/PMC4951238.xml	tyrosine	23315 : 23323	CM	express DDR1, a receptor tyrosine kinase, significantly im
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23380 : 23388	CM	cell migration. However, DARPP-32 expression in DDR1-defic
./___Corpus/Medline/xml/PMC4951238.xml	DDR1	23403 : 23407	CM	, DARPP-32 expression in DDR1-deficient cells had no e
./___Corpus/Medline/xml/PMC4951238.xml	DDR1	23482 : 23486	CM	It was demonstrated that DDR1 associates with DARPP-32
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23503 : 23511	CM	hat DDR1 associates with DARPP-32 in a protein complex, wh
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	23569 : 23584	RN	lates migration, and the phosphorylation of Thr-34 residue is req
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34	23588 : 23594	CM	d the phosphorylation of Thr-34 residue is required for 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23619 : 23627	CM	 residue is required for DARPP-32 function to impair migra
./___Corpus/Medline/xml/PMC4951238.xml	PKA	23714 : 23717	CM	 further supported using PKA inhibitors that abrogate
./___Corpus/Medline/xml/PMC4951238.xml	anti-	23748 : 23753	CPR	itors that abrogated the anti-migratory effect of DARPP
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23773 : 23781	CM	anti-migratory effect of DARPP-32 [59]. A related study in
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	23833 : 23839	CM	stigated the role of the Wnt-5a signaling pathway in reg
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	23872 : 23880	CM	ng pathway in regulating DARPP-32-dependent inhibition of 
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	23981 : 23987	CM	dicated that recombinant Wnt-5a induced cAMP elevation, 
./___Corpus/Medline/xml/PMC4951238.xml	cAMP	23996 : 24000	CM	combinant Wnt-5a induced cAMP elevation, leading to ac
./___Corpus/Medline/xml/PMC4951238.xml	PKA	24037 : 24040	CM	leading to activation of PKA, phosphorylation of Thr-
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	24042 : 24057	RN	ng to activation of PKA, phosphorylation of Thr-34-DARPP-32, and 
./___Corpus/Medline/xml/PMC4951238.xml	Thr-34-DARPP-32	24061 : 24076	CM	 PKA, phosphorylation of Thr-34-DARPP-32, and inhibition of cell 
./___Corpus/Medline/xml/PMC4951238.xml	PP1	24164 : 24167	CM	d that the inhibition of PP1 by phospho-Thr-34-DARPP-
./___Corpus/Medline/xml/PMC4951238.xml	phospho-Thr-34-DARPP-32	24171 : 24194	CM	the inhibition of PP1 by phospho-Thr-34-DARPP-32 potentiated the Wnt-5a-m
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	24211 : 24217	CM	DARPP-32 potentiated the Wnt-5a-mediated phosphorylation
./___Corpus/Medline/xml/PMC4951238.xml	phosphorylation	24227 : 24242	RN	ated the Wnt-5a-mediated phosphorylation of CREB, a known PP1 sub
./___Corpus/Medline/xml/PMC4951238.xml	CREB	24246 : 24250	CM	iated phosphorylation of CREB, a known PP1 substrate. 
./___Corpus/Medline/xml/PMC4951238.xml	PP1	24260 : 24263	CM	ylation of CREB, a known PP1 substrate. Additionally,
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a-DARPP-32-CREB	24307 : 24327	CM	nally, inhibition of the Wnt-5a-DARPP-32-CREB pathway, by expression o
./___Corpus/Medline/xml/PMC4951238.xml	CREB	24372 : 24376	CM	ion of dominant negative CREB, reduced the anti-migrat
./___Corpus/Medline/xml/PMC4951238.xml	anti-	24390 : 24395	CPR	gative CREB, reduced the anti-migratory effect of DARPP
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	24415 : 24423	CM	anti-migratory effect of DARPP-32 in response to Wnt-5a [6
./___Corpus/Medline/xml/PMC4951238.xml	Wnt-5a	24439 : 24445	CM	 DARPP-32 in response to Wnt-5a [60]. On the other hand,
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	24497 : 24505	CM	nother study showed that DARPP-32 overexpression promotes 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	24594 : 24602	CM	pro-invasive function of DARPP-32 was associated with an i
./___Corpus/Medline/xml/PMC4951238.xml	MT1-MMP	24702 : 24709	CM	atrix metalloproteinase (MT1-MMP) and CXC-chemokine recep
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	24741 : 24746	CM	XC-chemokine receptor 4 (CXCR4) proteins. Consistent wi
./___Corpus/Medline/xml/PMC4951238.xml	MT1-MMP	24786 : 24793	CM	sistent with the role of MT1-MMP in activating MMPs, a su
./___Corpus/Medline/xml/PMC4951238.xml	MMPs	24808 : 24812	CM	of MT1-MMP in activating MMPs, a substantial increase 
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	24925 : 24930	CM	hibition or knockdown of CXCR4 suppressed DARPP-32-indu
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	24942 : 24950	CM	down of CXCR4 suppressed DARPP-32-induced cell invasion. F
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	25014 : 25022	CM	stic studies showed that DARPP-32 and CXCR4 coexist in the
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25027 : 25032	CM	showed that DARPP-32 and CXCR4 coexist in the same prot
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25104 : 25109	CM	o increased stability of CXCR4 protein because of reduc
./___Corpus/Medline/xml/PMC4951238.xml	CXCL12	25190 : 25196	CM	eatment with its ligand, CXCL12. These findings demonstr
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	25230 : 25238	CM	indings demonstrate that DARPP-32 enhances gastric cancer 
./___Corpus/Medline/xml/PMC4951238.xml	CXCR4	25291 : 25296	CM	l invasion by regulating CXCR4-mediated activation of t
./___Corpus/Medline/xml/PMC4951238.xml	MT1-MMP	25324 : 25331	CM	diated activation of the MT1-MMP/MMP2 pathway [61]. A pro
./___Corpus/Medline/xml/PMC4951238.xml	MMP2	25332 : 25336	CM	ctivation of the MT1-MMP/MMP2 pathway [61]. A prospect
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	25496 : 25504	CM	 and 1997, revealed that DARPP-32 was highly expressed in 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	25644 : 25652	CM	 analysis indicated that DARPP-32 expression in primary co
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	25831 : 25839	CM	nt report indicated that DARPP-32 promotes angiogenesis th
./___Corpus/Medline/xml/PMC4951238.xml	ANGPT2	25900 : 25906	CM	ation of angiopoietin 2 (ANGPT2) in gastric cancer [63].
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	25953 : 25960	CM	3]. In fact, DARPP-32 or t-DARPP positively regulates mRN
./___Corpus/Medline/xml/PMC4951238.xml	mRNA	25982 : 25986	CM	RPP positively regulates mRNA and protein expression a
./___Corpus/Medline/xml/PMC4951238.xml	ANGPT2	26027 : 26033	CM	ression and secretion of ANGPT2 in gastric cancer cells,
./___Corpus/Medline/xml/PMC4951238.xml	ANGPT2	26147 : 26153	CM	ns confirmed the role of ANGPT2 in mediating DARPP-32-in
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26167 : 26175	CM	e of ANGPT2 in mediating DARPP-32-induced angiogenesis, an
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26216 : 26224	CM	nesis, and revealed that DARPP-32 proteins regulate ANGPT2
./___Corpus/Medline/xml/PMC4951238.xml	ANGPT2	26243 : 26249	CM	RPP-32 proteins regulate ANGPT2 expression through activ
./___Corpus/Medline/xml/PMC4951238.xml	STAT3	26283 : 26288	CM	on through activation of STAT3. Notably, DARPP-32 induc
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26299 : 26307	CM	ation of STAT3. Notably, DARPP-32 induces ANGPT2 expressio
./___Corpus/Medline/xml/PMC4951238.xml	ANGPT2	26316 : 26322	CM	otably, DARPP-32 induces ANGPT2 expression in human gast
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26468 : 26476	CM	atic diagram summarizing DARPP-32-regulated signaling path
./___Corpus/Medline/xml/PMC4951238.xml	CONCLUSIONS	26579 : 26590	CM	gure33.                  CONCLUSIONS AND PERSPECTIVES        
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26698 : 26706	CM	 decades has established DARPP-32 as a major integrator of
./___Corpus/Medline/xml/PMC4951238.xml	dopamine	26753 : 26761	CM	 of neurotransmission by dopamine and other neurotransmitt
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26889 : 26897	CM	ecent reports implicated DARPP-32 and t-DARPP proteins in 
./___Corpus/Medline/xml/PMC4951238.xml	t-DARPP	26902 : 26909	CM	 implicated DARPP-32 and t-DARPP proteins in CNS disorder
./___Corpus/Medline/xml/PMC4951238.xml	CNS	26922 : 26925	CM	 and t-DARPP proteins in CNS disorders and neurodegen
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	26980 : 26988	CM	ve diseases. The role of DARPP-32 proteins in tumorigenesi
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	27146 : 27154	CM	 unveil new functions of DARPP-32 (Figure ​(Figure4).4). C
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	27254 : 27262	CM	ts strongly suggest that DARPP-32 proteins have potential 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	27582 : 27590	CM	l inhibitors that target DARPP-32 and its signaling pathwa
./___Corpus/Medline/xml/PMC4951238.xml	CONFLICTS	28205 : 28214	CM	               Footnotes CONFLICTS OF INTEREST There is no 
./___Corpus/Medline/xml/PMC4951238.xml	DARPP-32	28272 : 28280	CM	 of interest. REFERENCES DARPP-32: from neurotransmission 
./___Corpus/Medline/xml/PMC4967469.xml	methylation	398 : 409	RN	 number alterations, DNA methylation, and gene expression) ca
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	1557 : 1561	CM	The Cancer Genome Atlas (TCGA) and the International C
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylation	3176 : 3192	CM	 number alterations, and hypermethylation across a total of 11,289
./___Corpus/Medline/xml/PMC4967469.xml	methylated	3363 : 3373	RN	fications/deletions, and methylated gene promoters (Figure 1
./___Corpus/Medline/xml/PMC4967469.xml	S1A	3408 : 3411	CM	oters (Figure 1A; Tables S1A–S1D). These oncogenic al
./___Corpus/Medline/xml/PMC4967469.xml	S1D	3412 : 3415	CM	s (Figure 1A; Tables S1A–S1D). These oncogenic altera
./___Corpus/Medline/xml/PMC4967469.xml	1C	3567 : 3569	CM	ll lines (Figures 1B and 1C; Table S1E) screened wit
./___Corpus/Medline/xml/PMC4967469.xml	S1E	3577 : 3580	CM	Figures 1B and 1C; Table S1E) screened with 265 anti-
./___Corpus/Medline/xml/PMC4967469.xml	anti-	3600 : 3605	CPR	e S1E) screened with 265 anti-cancer compounds (Figures
./___Corpus/Medline/xml/PMC4967469.xml	1D	3631 : 3633	CM	ancer compounds (Figures 1D and ​andS1;S1; Table S1F
./___Corpus/Medline/xml/PMC4967469.xml	S1F	3655 : 3658	CM	 1D and ​andS1;S1; Table S1F). We have carried out an
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	4295 : 4299	CM	n tumors using data from TCGA, ICGC, and other studies
./___Corpus/Medline/xml/PMC4967469.xml	ICGC	4301 : 4305	CM	rs using data from TCGA, ICGC, and other studies (Figu
./___Corpus/Medline/xml/PMC4967469.xml	S1C	4343 : 4346	CM	tudies (Figure 1A; Table S1C). The map consisted of (
./___Corpus/Medline/xml/PMC4967469.xml	WES	4451 : 4454	CM	 whole-exome sequencing (WES) data is consistent with
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	4552 : 4557	CM	nt copy number segments (RACSs) from SNP6 array profile
./___Corpus/Medline/xml/PMC4967469.xml	SNP6	4564 : 4568	CM	er segments (RACSs) from SNP6 array profiles, and 3) h
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	4592 : 4607	CM	6 array profiles, and 3) hypermethylated informative 5′C-phosphat
./___Corpus/Medline/xml/PMC4967469.xml	5′C-phosphate-G-3′	4620 : 4638	CM	ermethylated informative 5′C-phosphate-G-3′ sites in gene promoters 
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	4664 : 4669	CM	sites in gene promoters (iCpGs) from DNA methylation da
./___Corpus/Medline/xml/PMC4967469.xml	methylation	4680 : 4691	RN	omoters (iCpGs) from DNA methylation data, hereafter collecti
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	4764 : 4768	CM	ncer functional events” (CFEs). We identified CFEs by 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	4785 : 4789	CM	s” (CFEs). We identified CFEs by combining data across
./___Corpus/Medline/xml/PMC4967469.xml	S2A	4898 : 4901	CM	cancer specific) (Tables S2A, S2D, and S2H).         
./___Corpus/Medline/xml/PMC4967469.xml	S2D	4903 : 4906	CM	r specific) (Tables S2A, S2D, and S2H).              
./___Corpus/Medline/xml/PMC4967469.xml	S2H	4912 : 4915	CM	c) (Tables S2A, S2D, and S2H).                       
./___Corpus/Medline/xml/PMC4967469.xml	S1A	5118 : 5121	CM	 28 cancer types (Tables S1A–S1D). CGs were detected 
./___Corpus/Medline/xml/PMC4967469.xml	S1D	5122 : 5125	CM	cancer types (Tables S1A–S1D). CGs were detected per 
./___Corpus/Medline/xml/PMC4967469.xml	S2A	5377 : 5380	CM	 pan-cancer genes (Table S2A). We further added nine 
./___Corpus/Medline/xml/PMC4967469.xml	nine	5400 : 5404	CM	e S2A). We further added nine genes identified as puta
./___Corpus/Medline/xml/PMC4967469.xml	COSMIC	5486 : 5492	CM	al., 2014). We mined the COSMIC database to identify lik
./___Corpus/Medline/xml/PMC4967469.xml	0–	5681 : 5683	CPR	ons (median n = 2, range 0–64), consistent with prev
./___Corpus/Medline/xml/PMC4967469.xml	ADMIRE	5836 : 5842	CM	Ss were identified using ADMIRE for the analysis of 8,23
./___Corpus/Medline/xml/PMC4967469.xml	S1D	5943 : 5946	CM	Dyk et al., 2013) (Table S1D; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	6017 : 6022	CM	tal, 851 cancer-specific RACSs were gained (286 segment
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	6094 : 6099	CM	ts), with a median of 19 RACSs per tumor type (Table S2
./___Corpus/Medline/xml/PMC4967469.xml	S2D	6122 : 6125	CM	Ss per tumor type (Table S2D). The median number of g
./___Corpus/Medline/xml/PMC4967469.xml	RACS	6167 : 6171	CM	ber of genes within each RACS was 15 for amplified reg
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	6286 : 6290	CM	ne amplifications (e.g., EGFR, ERBB2, MET, and MYC) an
./___Corpus/Medline/xml/PMC4967469.xml	ERBB2	6292 : 6297	CM	lifications (e.g., EGFR, ERBB2, MET, and MYC) and homoz
./___Corpus/Medline/xml/PMC4967469.xml	MET	6299 : 6302	CM	ions (e.g., EGFR, ERBB2, MET, and MYC) and homozygous
./___Corpus/Medline/xml/PMC4967469.xml	MYC	6308 : 6311	CM	., EGFR, ERBB2, MET, and MYC) and homozygous deletion
./___Corpus/Medline/xml/PMC4967469.xml	CDKN2A	6345 : 6351	CM	ozygous deletions (e.g., CDKN2A, PTEN, and RB1) were cap
./___Corpus/Medline/xml/PMC4967469.xml	PTEN	6353 : 6357	CM	deletions (e.g., CDKN2A, PTEN, and RB1) were captured,
./___Corpus/Medline/xml/PMC4967469.xml	RB1	6363 : 6366	CM	(e.g., CDKN2A, PTEN, and RB1) were captured, with 320
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	6566 : 6571	CM	r set (due to overlap in RACSs across cancer types) was
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	6650 : 6655	CM	 results, comprising 425 RACSs (117 amplified and 308 d
./___Corpus/Medline/xml/PMC4967469.xml	S2D	6696 : 6699	CM	and 308 deleted) (Tables S2D–S2F).                   
./___Corpus/Medline/xml/PMC4967469.xml	S2F	6700 : 6703	CM	308 deleted) (Tables S2D–S2F).                       
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	6744 : 6749	CM	                         iCpGs were identified using DN
./___Corpus/Medline/xml/PMC4967469.xml	methylation	6776 : 6787	RN	ere identified using DNA methylation array data for 6,166 tum
./___Corpus/Medline/xml/PMC4967469.xml	S1D	6855 : 6858	CM	g 21 cancer types (Table S1D). We defined 378 iCpGs b
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	6876 : 6881	CM	ble S1D). We defined 378 iCpGs based on a multimodal di
./___Corpus/Medline/xml/PMC4967469.xml	methylation	6926 : 6937	RN	al distribution of their methylation signal in at least one c
./___Corpus/Medline/xml/PMC4967469.xml	S2H	6981 : 6984	CM	 one cancer type (Tables S2H and S2I). This also esta
./___Corpus/Medline/xml/PMC4967469.xml	S2I	6989 : 6992	CM	cer type (Tables S2H and S2I). This also established 
./___Corpus/Medline/xml/PMC4967469.xml	methylated	7081 : 7091	RN	ne such regions as hyper-methylated in the cell lines (Table
./___Corpus/Medline/xml/PMC4967469.xml	S2J	7117 : 7120	CM	in the cell lines (Table S2J; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	7305 : 7309	CM	ed 1,699 cancer-specific CFEs, which were further merg
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	7366 : 7370	CM	 1,273 unique pan-cancer CFEs (Figure S2A).           
./___Corpus/Medline/xml/PMC4967469.xml	S2A	7379 : 7382	CM	 pan-cancer CFEs (Figure S2A).                  Oncog
./___Corpus/Medline/xml/PMC4967469.xml	WES	7687 : 7690	CM	l lines analyzed through WES (n = 1,001), copy number
./___Corpus/Medline/xml/PMC4967469.xml	methylation	7762 : 7773	RN	ssion (n = 968), and DNA methylation (n = 957) (http://cancer
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	7879 : 7883	CM	ssified according to the TCGA tissue labels (Figure 2A
./___Corpus/Medline/xml/PMC4967469.xml	S1A	7917 : 7920	CM	abels (Figure 2A; Tables S1A and S1E). Molecular alte
./___Corpus/Medline/xml/PMC4967469.xml	S1E	7925 : 7928	CM	igure 2A; Tables S1A and S1E). Molecular alterations 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8002 : 8006	CM	 were filtered using the CFEs identified in the primar
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8087 : 8091	CM	t of clinically relevant CFEs for the cell lines (Figu
./___Corpus/Medline/xml/PMC4967469.xml	1C	8119 : 8121	CM	r the cell lines (Figure 1C).                       
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8186 : 8190	CM	 Of the 1,273 pan-cancer CFEs identified in patient tu
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	8363 : 8368	CM	nce was greatest for the RACSs (100% of 425; Table S2G)
./___Corpus/Medline/xml/PMC4967469.xml	S2G	8389 : 8392	CM	ACSs (100% of 425; Table S2G), followed by iCpGs (338
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	8407 : 8412	CM	 Table S2G), followed by iCpGs (338 of 378, 89%; Table 
./___Corpus/Medline/xml/PMC4967469.xml	S2J	8437 : 8440	CM	 (338 of 378, 89%; Table S2J) and CGs (300 of 470, 64
./___Corpus/Medline/xml/PMC4967469.xml	CGs	8446 : 8449	CM	378, 89%; Table S2J) and CGs (300 of 470, 64%; Table 
./___Corpus/Medline/xml/PMC4967469.xml	S2C	8474 : 8477	CM	 (300 of 470, 64%; Table S2C). When considering cance
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8513 : 8517	CM	sidering cancer-specific CFEs, concordance was highest
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8547 : 8551	CM	cordance was highest for CFEs occurring in at least 5%
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8607 : 8611	CM	tients (median of 86% of CFEs covered across cancer ty
./___Corpus/Medline/xml/PMC4967469.xml	S1A	8657 : 8660	CM	r types; Figure 2A; Data S1A). Coverage of CFEs varie
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8675 : 8679	CM	; Data S1A). Coverage of CFEs varied by cancer type, a
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8734 : 8738	CM	en we include infrequent CFEs (occurring in < 5% of pa
./___Corpus/Medline/xml/PMC4967469.xml	S2B	8871 : 8874	CM	n coverage = 46%; Figure S2B). CFEs absent in cell li
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	8877 : 8881	CM	rage = 46%; Figure S2B). CFEs absent in cell lines are
./___Corpus/Medline/xml/PMC4967469.xml	S2K	8925 : 8928	CM	es are reported in Table S2K.                        
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9009 : 9013	CM	between the frequency of CFEs in cell lines and patien
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9122 : 9126	CM	for all three classes of CFEs (Figures 2B and ​andS2C;
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	9274 : 9278	CM	based on the presence of CFEs in cell lines and tumors
./___Corpus/Medline/xml/PMC4967469.xml	S2D	9508 : 9511	CM	y expected 1%]) (Figures S2D and S2E; Table S2M; Supp
./___Corpus/Medline/xml/PMC4967469.xml	S2E	9516 : 9519	CM	ed 1%]) (Figures S2D and S2E; Table S2M; Supplemental
./___Corpus/Medline/xml/PMC4967469.xml	S2E	9721 : 9724	CM	rs, respectively (Figure S2E).                       
./___Corpus/Medline/xml/PMC4967469.xml	R	9921 : 9922	CM	same cancer type (median R = 0.75 across all 13 pat
./___Corpus/Medline/xml/PMC4967469.xml	S3A	9972 : 9975	CM	hways) (Figure 3A; Table S3A).                       
./___Corpus/Medline/xml/PMC4967469.xml	methylation	10250 : 10261	RN	is analysis by including methylation data and by jointly anal
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	10518 : 10522	CM	t least one of the 1,250 CFEs [Tables S3B and S3C]) yi
./___Corpus/Medline/xml/PMC4967469.xml	S3B	10531 : 10534	CM	f the 1,250 CFEs [Tables S3B and S3C]) yielded four c
./___Corpus/Medline/xml/PMC4967469.xml	S3C	10539 : 10542	CM	250 CFEs [Tables S3B and S3C]) yielded four classes r
./___Corpus/Medline/xml/PMC4967469.xml	H	10584 : 10585	CM	lasses referred to as M, H, CD, and CA (Table S3D; 
./___Corpus/Medline/xml/PMC4967469.xml	CD	10587 : 10589	CM	ses referred to as M, H, CD, and CA (Table S3D; Supp
./___Corpus/Medline/xml/PMC4967469.xml	CA	10595 : 10597	CM	rred to as M, H, CD, and CA (Table S3D; Supplemental
./___Corpus/Medline/xml/PMC4967469.xml	CG	10673 : 10675	CM	 Class M is enriched for CG mutations, class H for h
./___Corpus/Medline/xml/PMC4967469.xml	H	10693 : 10694	CM	 for CG mutations, class H for hypermethylation of 
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylation	10699 : 10715	RN	G mutations, class H for hypermethylation of iCpGs, and classes CD
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	10719 : 10724	CM	 for hypermethylation of iCpGs, and classes CD and CA f
./___Corpus/Medline/xml/PMC4967469.xml	CD	10738 : 10740	CM	on of iCpGs, and classes CD and CA for deleted and a
./___Corpus/Medline/xml/PMC4967469.xml	CA	10745 : 10747	CM	CpGs, and classes CD and CA for deleted and amplifie
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	10774 : 10779	CM	or deleted and amplified RACSs, respectively (Figures 3
./___Corpus/Medline/xml/PMC4967469.xml	3B	10803 : 10805	CM	s, respectively (Figures 3B and ​andS3;S3; Tables S3
./___Corpus/Medline/xml/PMC4967469.xml	S3E	10828 : 10831	CM	3B and ​andS3;S3; Tables S3E, S3F, and S3H; Data S1B)
./___Corpus/Medline/xml/PMC4967469.xml	S3F	10833 : 10836	CM	d ​andS3;S3; Tables S3E, S3F, and S3H; Data S1B). We 
./___Corpus/Medline/xml/PMC4967469.xml	S3H	10842 : 10845	CM	S3; Tables S3E, S3F, and S3H; Data S1B). We observed 
./___Corpus/Medline/xml/PMC4967469.xml	S1B	10852 : 10855	CM	 S3E, S3F, and S3H; Data S1B). We observed a high con
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	10922 : 10926	CM	the predominant class of CFEs in primary tumors and ce
./___Corpus/Medline/xml/PMC4967469.xml	GBM	11023 : 11026	CM	 types, exceptions being GBM, KIRC, and PRAD) (Figure
./___Corpus/Medline/xml/PMC4967469.xml	KIRC	11028 : 11032	CM	s, exceptions being GBM, KIRC, and PRAD) (Figure 3C; T
./___Corpus/Medline/xml/PMC4967469.xml	PRAD	11038 : 11042	CM	ons being GBM, KIRC, and PRAD) (Figure 3C; Table S3G; 
./___Corpus/Medline/xml/PMC4967469.xml	S1B	11072 : 11075	CM	gure 3C; Table S3G; Data S1B).                       
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	11479 : 11483	CM	      To investigate how CFEs detected in primary tumo
./___Corpus/Medline/xml/PMC4967469.xml	1C	11590 : 11592	CM	el of cell lines (Figure 1C; Tables S2C, S2G, and S2
./___Corpus/Medline/xml/PMC4967469.xml	S2C	11601 : 11604	CM	lines (Figure 1C; Tables S2C, S2G, and S2J). Cell lin
./___Corpus/Medline/xml/PMC4967469.xml	S2G	11606 : 11609	CM	 (Figure 1C; Tables S2C, S2G, and S2J). Cell lines un
./___Corpus/Medline/xml/PMC4967469.xml	S2J	11615 : 11618	CM	1C; Tables S2C, S2G, and S2J). Cell lines underwent e
./___Corpus/Medline/xml/PMC4967469.xml	IC50	12086 : 12090	CM	 to model sensitivity as IC50 (drug concentration that
./___Corpus/Medline/xml/PMC4967469.xml	AUC	12145 : 12148	CM	ces viability by 50%) or AUC (area under the dose-res
./___Corpus/Medline/xml/PMC4967469.xml	S4A	12201 : 12204	CM	se curve) values (Tables S4A and S4B).               
./___Corpus/Medline/xml/PMC4967469.xml	S4B	12209 : 12212	CM	) values (Tables S4A and S4B).                       
./___Corpus/Medline/xml/PMC4967469.xml	1D	12413 : 12415	CM	n cancer biology (Figure 1D; Table S1F). These 265 c
./___Corpus/Medline/xml/PMC4967469.xml	S1F	12423 : 12426	CM	iology (Figure 1D; Table S1F). These 265 compounds in
./___Corpus/Medline/xml/PMC4967469.xml	IC50	12671 : 12675	CM	lation between replicate IC50 values with a median Pea
./___Corpus/Medline/xml/PMC4967469.xml	R	12718 : 12719	CM	ian Pearson correlation (R) = 0.65 (0.78 for the co
./___Corpus/Medline/xml/PMC4967469.xml	IC50	12765 : 12769	CM	e compounds with most of IC50 values falling within th
./___Corpus/Medline/xml/PMC4967469.xml	FET	12941 : 12944	CM	ian Fisher’s exact test [FET] log10 p value = −26) (F
./___Corpus/Medline/xml/PMC4967469.xml	AUC	13006 : 13009	CM	luster analysis based on AUC values confirmed that co
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	13307 : 13311	CM	fine the contribution of CFEs to the prediction of dru
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	13363 : 13368	CM	sensitivity (Figure 1E). ANOVA was used to identify sin
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	13397 : 13401	CM	 used to identify single CFEs as markers of drug respo
./___Corpus/Medline/xml/PMC4967469.xml	RACS	13627 : 13631	CM	olecular data type (CGs, RACS, iCpGs, and gene express
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	13633 : 13638	CM	ar data type (CGs, RACS, iCpGs, and gene expression) in
./___Corpus/Medline/xml/PMC4967469.xml	IC50	13738 : 13742	CM	tency, all analyses used IC50 values. We carried out a
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	14013 : 14018	CM	          For pan-cancer ANOVA, the set of CFEs include
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	14031 : 14035	CM	cancer ANOVA, the set of CFEs included 267 CGs, 407 RA
./___Corpus/Medline/xml/PMC4967469.xml	BCR-ABL	14089 : 14096	CM	 and three gene fusions (BCR-ABL, EWSR1-FLI1, and EWSR1-X
./___Corpus/Medline/xml/PMC4967469.xml	EWSR1-FLI1	14098 : 14108	CM	e gene fusions (BCR-ABL, EWSR1-FLI1, and EWSR1-X). Overall, 
./___Corpus/Medline/xml/PMC4967469.xml	EWSR1-X	14114 : 14121	CM	BCR-ABL, EWSR1-FLI1, and EWSR1-X). Overall, for the 265 c
./___Corpus/Medline/xml/PMC4967469.xml	FDR	14286 : 14289	CM	 a false discovery rate [FDR] < 25%; Figure 4A), with
./___Corpus/Medline/xml/PMC4967469.xml	S4A	14367 : 14370	CM	er-specific hits (Figure S4A; Table S4C). A subset of
./___Corpus/Medline/xml/PMC4967469.xml	S4C	14378 : 14381	CM	 hits (Figure S4A; Table S4C). A subset of 262 CFE-dr
./___Corpus/Medline/xml/PMC4967469.xml	CD	14554 : 14556	CM	ltas (Δs) and Cohen’s D (CD) (Supplemental Experimen
./___Corpus/Medline/xml/PMC4967469.xml	S4C	14917 : 14920	CM	ctions (Figure 4A; Table S4C). The effect size was fr
./___Corpus/Medline/xml/PMC4967469.xml	CD	15033 : 15035	CM	pan-cancer associations (CD > 1 for 100% and 30% of 
./___Corpus/Medline/xml/PMC4967469.xml	S4D	15087 : 15090	CM	ts, respectively) (Table S4D). A possible explanation
./___Corpus/Medline/xml/PMC4967469.xml	S4B	15436 : 15439	CM	nsampling alone (Figures S4B and S4C; Supplemental Ex
./___Corpus/Medline/xml/PMC4967469.xml	S4C	15444 : 15447	CM	g alone (Figures S4B and S4C; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	15678 : 15682	CM	verall, 233 of 674 (34%) CFEs were significantly assoc
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	15766 : 15771	CM	t one compound, and more RACSs (62%) were associated wi
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	15868 : 15872	CM	 of these two classes of CFEs varied by cancer type an
./___Corpus/Medline/xml/PMC4967469.xml	3C	15940 : 15942	CM	heir prevalence (Figures 3C and ​andS4S4G).         
./___Corpus/Medline/xml/PMC4967469.xml	S4H	16190 : 16193	CM	ogical processes (Figure S4H; Table S1F), CFEs best e
./___Corpus/Medline/xml/PMC4967469.xml	S1F	16201 : 16204	CM	esses (Figure S4H; Table S1F), CFEs best explained se
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	16207 : 16211	CM	(Figure S4H; Table S1F), CFEs best explained sensitivi
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	16262 : 16266	CM	y to compounds targeting EGFR and ABL signaling, mitos
./___Corpus/Medline/xml/PMC4967469.xml	ABL	16271 : 16274	CM	ounds targeting EGFR and ABL signaling, mitosis, and 
./___Corpus/Medline/xml/PMC4967469.xml	TOR	16370 : 16373	CM	y to compounds targeting TOR, IGF1R, and WNT signalin
./___Corpus/Medline/xml/PMC4967469.xml	IGF1R	16375 : 16380	CM	compounds targeting TOR, IGF1R, and WNT signaling. For 
./___Corpus/Medline/xml/PMC4967469.xml	WNT	16386 : 16389	CM	argeting TOR, IGF1R, and WNT signaling. For the latte
./___Corpus/Medline/xml/PMC4967469.xml	S1F	16557 : 16560	CM	argeted compounds (Table S1F) associated with at leas
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	16744 : 16748	CM	ant interactions between CFEs and cytotoxics tended to
./___Corpus/Medline/xml/PMC4967469.xml	CD	16811 : 16813	CM	ler effect size (average CD 0.96 vs. 1.32) and less 
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	16941 : 16946	CM	            We performed ANOVA on randomly downsampled 
./___Corpus/Medline/xml/PMC4967469.xml	S4D	17289 : 17292	CM	 500 cell lines (Figures S4D–S4F; Supplemental Experi
./___Corpus/Medline/xml/PMC4967469.xml	S4F	17293 : 17296	CM	 cell lines (Figures S4D–S4F; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	17519 : 17524	CM	logies.                  ANOVA Identifies Known and Nov
./___Corpus/Medline/xml/PMC4967469.xml	BRAF	17789 : 17793	CM	s between alterations in BRAF, ERBB2, EGFR, and the BC
./___Corpus/Medline/xml/PMC4967469.xml	ERBB2	17795 : 17800	CM	een alterations in BRAF, ERBB2, EGFR, and the BCR-ABL f
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	17802 : 17806	CM	erations in BRAF, ERBB2, EGFR, and the BCR-ABL fusion 
./___Corpus/Medline/xml/PMC4967469.xml	KRAS	17937 : 17941	CM	 as associations between KRAS, PDGFR, PIK3CA, PTEN, CD
./___Corpus/Medline/xml/PMC4967469.xml	PDGFR	17943 : 17948	CM	sociations between KRAS, PDGFR, PIK3CA, PTEN, CDKN2A, N
./___Corpus/Medline/xml/PMC4967469.xml	PIK3CA	17950 : 17956	CM	ons between KRAS, PDGFR, PIK3CA, PTEN, CDKN2A, NRAS, TP5
./___Corpus/Medline/xml/PMC4967469.xml	PTEN	17958 : 17962	CM	een KRAS, PDGFR, PIK3CA, PTEN, CDKN2A, NRAS, TP53, and
./___Corpus/Medline/xml/PMC4967469.xml	CDKN2A	17964 : 17970	CM	AS, PDGFR, PIK3CA, PTEN, CDKN2A, NRAS, TP53, and FLT3 wi
./___Corpus/Medline/xml/PMC4967469.xml	NRAS	17972 : 17976	CM	R, PIK3CA, PTEN, CDKN2A, NRAS, TP53, and FLT3 with dru
./___Corpus/Medline/xml/PMC4967469.xml	TP53	17978 : 17982	CM	3CA, PTEN, CDKN2A, NRAS, TP53, and FLT3 with drugs tha
./___Corpus/Medline/xml/PMC4967469.xml	FLT3	17988 : 17992	CM	 CDKN2A, NRAS, TP53, and FLT3 with drugs that target t
./___Corpus/Medline/xml/PMC4967469.xml	4B	18070 : 18072	CM	ucts or pathways (Figure 4B; Table S4C). Moreover, w
./___Corpus/Medline/xml/PMC4967469.xml	S4C	18080 : 18083	CM	thways (Figure 4B; Table S4C). Moreover, we observed 
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	18126 : 18130	CM	served a secondary T790M EGFR mutation in lung adenoca
./___Corpus/Medline/xml/PMC4967469.xml	LUAD	18164 : 18168	CM	 in lung adenocarcinoma (LUAD) and resistance to EGFR-
./___Corpus/Medline/xml/PMC4967469.xml	Gefitinib	18213 : 18222	CM	EGFR-targeted therapies (Gefitinib and Afatinib) (Godin-Hey
./___Corpus/Medline/xml/PMC4967469.xml	Afatinib	18227 : 18235	CM	therapies (Gefitinib and Afatinib) (Godin-Heymann et al., 
./___Corpus/Medline/xml/PMC4967469.xml	NRAS	18304 : 18308	CM	as well as resistance of NRAS mutated melanoma patient
./___Corpus/Medline/xml/PMC4967469.xml	BRAF	18340 : 18344	CM	d melanoma patients to a BRAF inhibitor (Figure 4B; Ta
./___Corpus/Medline/xml/PMC4967469.xml	4B	18363 : 18365	CM	a BRAF inhibitor (Figure 4B; Table S4C) (Su et al., 
./___Corpus/Medline/xml/PMC4967469.xml	S4C	18373 : 18376	CM	ibitor (Figure 4B; Table S4C) (Su et al., 2012).     
./___Corpus/Medline/xml/PMC4967469.xml	Su	18379 : 18381	CM	 (Figure 4B; Table S4C) (Su et al., 2012).          
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	18505 : 18509	CM	 of interactions between CFEs in cancer pathways (EGFR
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	18530 : 18534	CM	CFEs in cancer pathways (EGFR, ERK-MAPK, PI3K-MTOR, an
./___Corpus/Medline/xml/PMC4967469.xml	ERK-MAPK	18536 : 18544	CM	n cancer pathways (EGFR, ERK-MAPK, PI3K-MTOR, and DNA repa
./___Corpus/Medline/xml/PMC4967469.xml	PI3K-MTOR	18546 : 18555	CM	athways (EGFR, ERK-MAPK, PI3K-MTOR, and DNA repair and cell
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	18631 : 18635	CM	nd drugs targeting those CFEs (Figure S4I). For exampl
./___Corpus/Medline/xml/PMC4967469.xml	S4I	18644 : 18647	CM	eting those CFEs (Figure S4I). For example, compounds
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	18683 : 18687	CM	ple, compounds targeting EGFR signaling showed potent 
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	18735 : 18739	CM	t activity in cells with EGFR and ERBB2 alterations, b
./___Corpus/Medline/xml/PMC4967469.xml	ERBB2	18744 : 18749	CM	y in cells with EGFR and ERBB2 alterations, but were in
./___Corpus/Medline/xml/PMC4967469.xml	RAS	18859 : 18862	CM	ignaling, such as mutant RAS.                        
./___Corpus/Medline/xml/PMC4967469.xml	4C	19124 : 19126	CM	ded in the test) (Figure 4C; Table S4C). For example
./___Corpus/Medline/xml/PMC4967469.xml	S4C	19134 : 19137	CM	 test) (Figure 4C; Table S4C). For example, at the pa
./___Corpus/Medline/xml/PMC4967469.xml	U2AF1	19178 : 19183	CM	at the pan-cancer level, U2AF1 mutations associate with
./___Corpus/Medline/xml/PMC4967469.xml	FLT3	19233 : 19237	CM	 sensitivity to multiple FLT3 inhibitors, such as AC22
./___Corpus/Medline/xml/PMC4967469.xml	CD	19281 : 19283	CM	s AC220 (p = 8.3 × 10−8, CD = 2.5), Sorafenib (p = 3
./___Corpus/Medline/xml/PMC4967469.xml	Sorafenib	19292 : 19301	CM	= 8.3 × 10−8, CD = 2.5), Sorafenib (p = 3.04 × 10−6, CD = 2
./___Corpus/Medline/xml/PMC4967469.xml	CD	19320 : 19322	CM	afenib (p = 3.04 × 10−6, CD = 2.8), Sunitinib (p = 5
./___Corpus/Medline/xml/PMC4967469.xml	Sunitinib	19331 : 19340	CM	 3.04 × 10−6, CD = 2.8), Sunitinib (p = 5.6 × 10−5, CD = 2.
./___Corpus/Medline/xml/PMC4967469.xml	CD	19358 : 19360	CM	nitinib (p = 5.6 × 10−5, CD = 2.5), and XL-184 (p = 
./___Corpus/Medline/xml/PMC4967469.xml	CD	19397 : 19399	CM	 XL-184 (p = 1.3 × 10−4, CD = 1.9); PTEN mutations a
./___Corpus/Medline/xml/PMC4967469.xml	PTEN	19408 : 19412	CM	= 1.3 × 10−4, CD = 1.9); PTEN mutations associate with
./___Corpus/Medline/xml/PMC4967469.xml	AKT	19456 : 19459	CM	e with sensitivity to an AKT inhibitor in COAD/READ (
./___Corpus/Medline/xml/PMC4967469.xml	COAD	19473 : 19477	CM	y to an AKT inhibitor in COAD/READ (p = 3.5 × 10−6, CD
./___Corpus/Medline/xml/PMC4967469.xml	READ	19478 : 19482	CM	an AKT inhibitor in COAD/READ (p = 3.5 × 10−6, CD = 2.
./___Corpus/Medline/xml/PMC4967469.xml	CD	19500 : 19502	CM	AD/READ (p = 3.5 × 10−6, CD = 2.4). The chemotherape
./___Corpus/Medline/xml/PMC4967469.xml	Mitomycin	19532 : 19541	CM	4). The chemotherapeutic Mitomycin C is widely used to trea
./___Corpus/Medline/xml/PMC4967469.xml	BLCA	19568 : 19572	CM	 is widely used to treat BLCA, and here, we detect, in
./___Corpus/Medline/xml/PMC4967469.xml	BLCA	19602 : 19606	CM	 here, we detect, in the BLCA specific analysis, a sen
./___Corpus/Medline/xml/PMC4967469.xml	TP53	19670 : 19674	CM	action with mutations in TP53 (p = 9.9 × 10−5, CD = 2.
./___Corpus/Medline/xml/PMC4967469.xml	CD	19692 : 19694	CM	in TP53 (p = 9.9 × 10−5, CD = 2.8) that are highly p
./___Corpus/Medline/xml/PMC4967469.xml	LUSC	19752 : 19756	CM	 in this cancer type. In LUSC cells, loss-of-function 
./___Corpus/Medline/xml/PMC4967469.xml	methyltransferase	19802 : 19819	ASE	ion mutations in the DNA methyltransferase MLL2 are associated with
./___Corpus/Medline/xml/PMC4967469.xml	anti-	19873 : 19878	CPR	sitivity to the clinical anti-androgen Bicalutamide (p 
./___Corpus/Medline/xml/PMC4967469.xml	Bicalutamide	19887 : 19899	CM	e clinical anti-androgen Bicalutamide (p = 6.02 ∼ 10−4, CD = 3
./___Corpus/Medline/xml/PMC4967469.xml	CD	19918 : 19920	CM	tamide (p = 6.02 ∼ 10−4, CD = 3); the BCL-2 inhibito
./___Corpus/Medline/xml/PMC4967469.xml	ABT-263	19948 : 19955	CM	3); the BCL-2 inhibitor, ABT-263, shows activity in COAD/
./___Corpus/Medline/xml/PMC4967469.xml	COAD	19975 : 19979	CM	T-263, shows activity in COAD/READ cells that harbor f
./___Corpus/Medline/xml/PMC4967469.xml	READ	19980 : 19984	CM	, shows activity in COAD/READ cells that harbor focal 
./___Corpus/Medline/xml/PMC4967469.xml	MET	20027 : 20030	CM	 focal amplifications of MET (p = 1.02 × 10−4, CD = 2
./___Corpus/Medline/xml/PMC4967469.xml	CD	20049 : 20051	CM	of MET (p = 1.02 × 10−4, CD = 2.8) or FOXA1/CRNKL1 (
./___Corpus/Medline/xml/PMC4967469.xml	FOXA1	20062 : 20067	CM	.02 × 10−4, CD = 2.8) or FOXA1/CRNKL1 (p = 1.31 × 10−4,
./___Corpus/Medline/xml/PMC4967469.xml	CRNKL1	20068 : 20074	CM	10−4, CD = 2.8) or FOXA1/CRNKL1 (p = 1.31 × 10−4, CD = 2
./___Corpus/Medline/xml/PMC4967469.xml	CD	20093 : 20095	CM	CRNKL1 (p = 1.31 × 10−4, CD = 2.2), events found in 
./___Corpus/Medline/xml/PMC4967469.xml	BCL6	20201 : 20205	CM	s in the co-repressor of BCL6, BCOR, statistically int
./___Corpus/Medline/xml/PMC4967469.xml	BCOR	20207 : 20211	CM	he co-repressor of BCL6, BCOR, statistically interact 
./___Corpus/Medline/xml/PMC4967469.xml	CD	20254 : 20256	CM	teract (p = 2.04 × 10−5, CD = 3.5) with sensitivity 
./___Corpus/Medline/xml/PMC4967469.xml	PKC	20286 : 20289	CM	5) with sensitivity to a PKC beta inhibitor in STAD (
./___Corpus/Medline/xml/PMC4967469.xml	STAD	20308 : 20312	CM	 a PKC beta inhibitor in STAD (Figure 4D), and deletio
./___Corpus/Medline/xml/PMC4967469.xml	RACS	20345 : 20349	CM	 4D), and deletions of a RACS (2q37.3) containing MTER
./___Corpus/Medline/xml/PMC4967469.xml	MTERFD2	20370 : 20377	CM	RACS (2q37.3) containing MTERFD2 and SNED1 is associated 
./___Corpus/Medline/xml/PMC4967469.xml	SNED1	20382 : 20387	CM	) containing MTERFD2 and SNED1 is associated with resis
./___Corpus/Medline/xml/PMC4967469.xml	HDAC	20425 : 20429	CM	d with resistance to the HDAC inhibitor Vorinostat (p 
./___Corpus/Medline/xml/PMC4967469.xml	CD	20468 : 20470	CM	inostat (p = 5.4 × 10−7, CD = 4; Figure 4D) in OV ce
./___Corpus/Medline/xml/PMC4967469.xml	OV	20490 : 20492	CM	7, CD = 4; Figure 4D) in OV cell lines.             
./___Corpus/Medline/xml/PMC4967469.xml	S4C	20652 : 20655	CM	own cancer genes (Tables S4C and S2D). For these regi
./___Corpus/Medline/xml/PMC4967469.xml	S2D	20660 : 20663	CM	er genes (Tables S4C and S2D). For these regions, the
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21051 : 21055	CM	zed that combinations of CFEs could, in some contexts,
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	21247 : 21253	CM	t to continuous output” (LOBICO) to find the optimal log
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21297 : 21301	CM	al logic model combining CFEs to explain the IC50 valu
./___Corpus/Medline/xml/PMC4967469.xml	IC50	21317 : 21321	CM	ning CFEs to explain the IC50 values for a drug, for e
./___Corpus/Medline/xml/PMC4967469.xml	RAS	21358 : 21361	CM	a drug, for example, “if RAS or RAF mutated, then sen
./___Corpus/Medline/xml/PMC4967469.xml	RAF	21365 : 21368	CM	 for example, “if RAS or RAF mutated, then sensitive 
./___Corpus/Medline/xml/PMC4967469.xml	MEK	21396 : 21399	CM	tated, then sensitive to MEK inhibition” (Knijnenburg
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	21440 : 21446	CM	ijnenburg et al., 2016). LOBICO binarizes the IC50s, lab
./___Corpus/Medline/xml/PMC4967469.xml	IC50s	21461 : 21466	CM	6). LOBICO binarizes the IC50s, labeling cell lines as 
./___Corpus/Medline/xml/PMC4967469.xml	IC50s	21559 : 21564	CM	ther with the continuous IC50s to find optimal models (
./___Corpus/Medline/xml/PMC4967469.xml	S5C	21595 : 21598	CM	nd optimal models (Table S5C) (Supplemental Experimen
./___Corpus/Medline/xml/PMC4967469.xml	5-fold	21652 : 21658	CM	Procedures). We employed 5-fold cross-validation (CV) to
./___Corpus/Medline/xml/PMC4967469.xml	CFE	21781 : 21784	CM	els, ranging from single CFE predictor models to comp
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	21848 : 21852	CM	t models with up to four CFEs. We required solutions t
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	21951 : 21956	CM	atures included the CGs, RACSs, gene fusions, and binar
./___Corpus/Medline/xml/PMC4967469.xml	S5A	22084 : 22087	CM	f the cell lines (Figure S5A; Tables S5A, S5B, and S5
./___Corpus/Medline/xml/PMC4967469.xml	S5A	22096 : 22099	CM	ines (Figure S5A; Tables S5A, S5B, and S5D). The latt
./___Corpus/Medline/xml/PMC4967469.xml	S5B	22101 : 22104	CM	(Figure S5A; Tables S5A, S5B, and S5D). The latter is
./___Corpus/Medline/xml/PMC4967469.xml	S5D	22110 : 22113	CM	5A; Tables S5A, S5B, and S5D). The latter is based on
./___Corpus/Medline/xml/PMC4967469.xml	S5B	22220 : 22223	CM	ikh et al., 2010) (Table S5B; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	22264 : 22270	CM	xperimental Procedures). LOBICO was executed for each dr
./___Corpus/Medline/xml/PMC4967469.xml	S5E	22425 : 22428	CM	,112 logic models (Table S5E).                       
./___Corpus/Medline/xml/PMC4967469.xml	IC50s	22548 : 22553	CM	f 265) of the drugs, the IC50s were better explained th
./___Corpus/Medline/xml/PMC4967469.xml	FDR	22620 : 22623	CM	ance (p value < 0.05 and FDR < 5%). Across the cancer
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	22944 : 22950	CM	ncer and cancer-specific LOBICO analyses identified pred
./___Corpus/Medline/xml/PMC4967469.xml	S5B	23335 : 23338	CM	pecific datasets (Figure S5B). This is in agreement w
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	23371 : 23376	CM	is in agreement with the ANOVA analysis, where larger e
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	23557 : 23563	CM	cially well-predicted by LOBICO (Figure S5C).           
./___Corpus/Medline/xml/PMC4967469.xml	S5C	23572 : 23575	CM	dicted by LOBICO (Figure S5C).                       
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	23699 : 23704	CM	ug response, followed by RACSs and the pathway activiti
./___Corpus/Medline/xml/PMC4967469.xml	S5A	23769 : 23772	CM	 gene expression (Figure S5A; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	24029 : 24033	CM	ponse beyond the genomic CFEs (Costello et al., 2014) 
./___Corpus/Medline/xml/PMC4967469.xml	S5D	24066 : 24069	CM	lo et al., 2014) (Figure S5D).                       
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	24110 : 24116	CM	                         LOBICO uncovered many known, as
./___Corpus/Medline/xml/PMC4967469.xml	S5F	24177 : 24180	CM	vel, associations (Table S5F). Figure 5C depicts a se
./___Corpus/Medline/xml/PMC4967469.xml	5C	24190 : 24192	CM	ions (Table S5F). Figure 5C depicts a selection of p
./___Corpus/Medline/xml/PMC4967469.xml	KRAS	24374 : 24378	CM	 the “or” combination of KRAS or BRAF improved the pre
./___Corpus/Medline/xml/PMC4967469.xml	BRAF	24382 : 24386	CM	” combination of KRAS or BRAF improved the precision a
./___Corpus/Medline/xml/PMC4967469.xml	MEK	24505 : 24508	CM	nsitivity to a number of MEK and RAF inhibitors (e.g.
./___Corpus/Medline/xml/PMC4967469.xml	RAF	24513 : 24516	CM	y to a number of MEK and RAF inhibitors (e.g., Tramet
./___Corpus/Medline/xml/PMC4967469.xml	Trametinib	24535 : 24545	CM	nd RAF inhibitors (e.g., Trametinib in Figures 5C and 5D).  
./___Corpus/Medline/xml/PMC4967469.xml	5C	24557 : 24559	CM	., Trametinib in Figures 5C and 5D).                
./___Corpus/Medline/xml/PMC4967469.xml	5C	24682 : 24684	CM	th higher recall (Figure 5C, right quadrants) as com
./___Corpus/Medline/xml/PMC4967469.xml	HNSC	24761 : 24765	CM	ctor model. For example, HNSC cell lines that have an 
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	24790 : 24794	CM	 cell lines that have an EGFR amplification or a SMAD4
./___Corpus/Medline/xml/PMC4967469.xml	SMAD4	24814 : 24819	CM	 EGFR amplification or a SMAD4 mutation account for 45%
./___Corpus/Medline/xml/PMC4967469.xml	ERRB2	24891 : 24896	CM	l lines sensitive to the ERRB2/EGFR inhibitor Afatinib,
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	24897 : 24901	CM	s sensitive to the ERRB2/EGFR inhibitor Afatinib, wher
./___Corpus/Medline/xml/PMC4967469.xml	Afatinib	24912 : 24920	CM	the ERRB2/EGFR inhibitor Afatinib, whereas considering onl
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	24951 : 24955	CM	eas considering only the EGFR amplified cell lines acc
./___Corpus/Medline/xml/PMC4967469.xml	5C	25129 : 25131	CM	higher precision (Figure 5C, left quadrants). For ex
./___Corpus/Medline/xml/PMC4967469.xml	BRCA	25163 : 25167	CM	quadrants). For example, BRCA cell lines that lack a d
./___Corpus/Medline/xml/PMC4967469.xml	FAT1	25207 : 25211	CM	t lack a deletion of the FAT1/IRF2 locus and are TP53 
./___Corpus/Medline/xml/PMC4967469.xml	IRF2	25212 : 25216	CM	k a deletion of the FAT1/IRF2 locus and are TP53 mutan
./___Corpus/Medline/xml/PMC4967469.xml	TP53	25231 : 25235	CM	 FAT1/IRF2 locus and are TP53 mutant show increased se
./___Corpus/Medline/xml/PMC4967469.xml	ERRB2	25277 : 25282	CM	eased sensitivity to the ERRB2/EGFR inhibitor Lapatinib
./___Corpus/Medline/xml/PMC4967469.xml	EGFR	25283 : 25287	CM	sensitivity to the ERRB2/EGFR inhibitor Lapatinib. Thi
./___Corpus/Medline/xml/PMC4967469.xml	Lapatinib	25298 : 25307	CM	the ERRB2/EGFR inhibitor Lapatinib. This is achieved at hig
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	25470 : 25476	CM	igure 5F). Collectively, LOBICO analysis highlights the 
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	25840 : 25844	CM	 Cell Line Encyclopedia (CCLE) (Barretina et al., 2012
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	25916 : 25920	CM	peutics Response Portal (CTRP; second version) (Seasho
./___Corpus/Medline/xml/PMC4967469.xml	GDSC	26104 : 26108	CM	hereafter referred to as GDSC). The shared set consist
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	26180 : 26184	CM	nd 76 compounds from the CTRP study (Tables S4I–S4K) a
./___Corpus/Medline/xml/PMC4967469.xml	S4I	26199 : 26202	CM	m the CTRP study (Tables S4I–S4K) and 389 cell lines 
./___Corpus/Medline/xml/PMC4967469.xml	S4K	26203 : 26206	CM	e CTRP study (Tables S4I–S4K) and 389 cell lines and 
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	26253 : 26257	CM	nd 15 compounds from the CCLE study (Tables S4E–S4G; S
./___Corpus/Medline/xml/PMC4967469.xml	S4E	26272 : 26275	CM	m the CCLE study (Tables S4E–S4G; Supplemental Experi
./___Corpus/Medline/xml/PMC4967469.xml	IC50	26351 : 26355	CM	tion was performed using IC50 values from the GDSC and
./___Corpus/Medline/xml/PMC4967469.xml	GDSC	26372 : 26376	CM	ing IC50 values from the GDSC and CCLE studies and AUC
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	26381 : 26385	CM	values from the GDSC and CCLE studies and AUC values f
./___Corpus/Medline/xml/PMC4967469.xml	AUC	26398 : 26401	CM	DSC and CCLE studies and AUC values from the CTRP stu
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	26418 : 26422	CM	 and AUC values from the CTRP study (where IC50 values
./___Corpus/Medline/xml/PMC4967469.xml	IC50	26436 : 26440	CM	om the CTRP study (where IC50 values were not reported
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	26519 : 26524	CM	            We performed ANOVA on the overlapping set o
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	26603 : 26607	CM	lidated 53% (19 of 36 on CTRP) and 86% (6 of 7 on CCLE
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	26628 : 26632	CM	CTRP) and 86% (6 of 7 on CCLE) of the testable sensiti
./___Corpus/Medline/xml/PMC4967469.xml	GDSC	26693 : 26697	CM	ations identified in the GDSC, and 21% (6 of 29 on CTR
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	26719 : 26723	CM	DSC, and 21% (6 of 29 on CTRP) and 0% (0 of 7 on CCLE)
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	26743 : 26747	CM	 CTRP) and 0% (0 of 7 on CCLE) of testable resistance 
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	26816 : 26820	CM	.05, Fisher’s exact test CTRP: p = 8.1 × 10−9; CCLE: p
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	26838 : 26842	CM	st CTRP: p = 8.1 × 10−9; CCLE: p = 0.01; Figures S4J a
./___Corpus/Medline/xml/PMC4967469.xml	S4J	26862 : 26865	CM	 CCLE: p = 0.01; Figures S4J and S4K; Tables S4H and 
./___Corpus/Medline/xml/PMC4967469.xml	S4K	26870 : 26873	CM	 = 0.01; Figures S4J and S4K; Tables S4H and S4L; Sup
./___Corpus/Medline/xml/PMC4967469.xml	S4H	26882 : 26885	CM	ures S4J and S4K; Tables S4H and S4L; Supplemental Ex
./___Corpus/Medline/xml/PMC4967469.xml	S4L	26890 : 26893	CM	 and S4K; Tables S4H and S4L; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	GDSC	27034 : 27038	CM	was observed between the GDSC dataset and the other tw
./___Corpus/Medline/xml/PMC4967469.xml	R	27075 : 27076	CM	 the other two datasets (R = 0.86 for CTRP and R = 
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	27088 : 27092	CM	o datasets (R = 0.86 for CTRP and R = 0.86 for CCLE; F
./___Corpus/Medline/xml/PMC4967469.xml	R	27097 : 27098	CM	s (R = 0.86 for CTRP and R = 0.86 for CCLE; Figures
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	27110 : 27114	CM	or CTRP and R = 0.86 for CCLE; Figures S4J and S4K). S
./___Corpus/Medline/xml/PMC4967469.xml	S4J	27124 : 27127	CM	= 0.86 for CCLE; Figures S4J and S4K). Similarly, usi
./___Corpus/Medline/xml/PMC4967469.xml	S4K	27132 : 27135	CM	or CCLE; Figures S4J and S4K). Similarly, using LOBIC
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	27155 : 27161	CM	d S4K). Similarly, using LOBICO, we validated 44% (17 of
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	27220 : 27224	CM	estable models using the CTRP, including both single a
./___Corpus/Medline/xml/PMC4967469.xml	R	27377 : 27378	CM	etween the two datasets (R = 0.96; Figures S5E and 
./___Corpus/Medline/xml/PMC4967469.xml	S5E	27395 : 27398	CM	asets (R = 0.96; Figures S5E and S5F; Data S1C). Thus
./___Corpus/Medline/xml/PMC4967469.xml	S5F	27403 : 27406	CM	 = 0.96; Figures S5E and S5F; Data S1C). Thus, even w
./___Corpus/Medline/xml/PMC4967469.xml	S1C	27413 : 27416	CM	igures S5E and S5F; Data S1C). Thus, even within the 
./___Corpus/Medline/xml/PMC4967469.xml	S4E	27766 : 27769	CM	s are provided in Tables S4E–S4L and S5G, Data S1C, a
./___Corpus/Medline/xml/PMC4967469.xml	S4L	27770 : 27773	CM	e provided in Tables S4E–S4L and S5G, Data S1C, and S
./___Corpus/Medline/xml/PMC4967469.xml	S5G	27778 : 27781	CM	ed in Tables S4E–S4L and S5G, Data S1C, and Supplemen
./___Corpus/Medline/xml/PMC4967469.xml	S1C	27788 : 27791	CM	es S4E–S4L and S5G, Data S1C, and Supplemental Experi
./___Corpus/Medline/xml/PMC4967469.xml	EN	28115 : 28117	CM	ensitivity (elastic net [EN] regression and Random F
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	28207 : 28212	CM	t features, we used CGs, RACSs, iCpGs, and gene express
./___Corpus/Medline/xml/PMC4967469.xml	iCpGs	28214 : 28219	CM	res, we used CGs, RACSs, iCpGs, and gene expression dat
./___Corpus/Medline/xml/PMC4967469.xml	EN	28303 : 28305	CM	       Here, we refer to EN models using IC50 values
./___Corpus/Medline/xml/PMC4967469.xml	IC50	28319 : 28323	CM	refer to EN models using IC50 values (Table S4A), but 
./___Corpus/Medline/xml/PMC4967469.xml	S4A	28338 : 28341	CM	using IC50 values (Table S4A), but very similar resul
./___Corpus/Medline/xml/PMC4967469.xml	S6A	28422 : 28425	CM	rests (Figure S6F; Table S6A). We assessed the predic
./___Corpus/Medline/xml/PMC4967469.xml	R	28518 : 28519	CM	correlation coefficient (R) of observed versus pred
./___Corpus/Medline/xml/PMC4967469.xml	IC50	28550 : 28554	CM	bserved versus predicted IC50 values. For each of the 
./___Corpus/Medline/xml/PMC4967469.xml	S6G	28773 : 28776	CM	5 as predictive (Figures S6G and S6H; Supplemental Ex
./___Corpus/Medline/xml/PMC4967469.xml	S6H	28781 : 28784	CM	dictive (Figures S6G and S6H; Supplemental Experiment
./___Corpus/Medline/xml/PMC4967469.xml	CG	29045 : 29047	CM	rison, genomic features (CG mutations and RACSs alte
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	29062 : 29067	CM	atures (CG mutations and RACSs alterations) performed p
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	29186 : 29191	CM	rongly correlated, while RACSs and CGs are less correla
./___Corpus/Medline/xml/PMC4967469.xml	CGs	29196 : 29199	CM	related, while RACSs and CGs are less correlated with
./___Corpus/Medline/xml/PMC4967469.xml	S6A	29249 : 29252	CM	 the tissue type (Figure S6A). This is consistent wit
./___Corpus/Medline/xml/PMC4967469.xml	6B	29484 : 29486	CM	ecific analyses (Figures 6B and 6C). For each drug, 
./___Corpus/Medline/xml/PMC4967469.xml	6C	29491 : 29493	CM	analyses (Figures 6B and 6C). For each drug, we iden
./___Corpus/Medline/xml/PMC4967469.xml	lead	29620 : 29624	CM	del, referred to as the “lead model”. Notably, paired 
./___Corpus/Medline/xml/PMC4967469.xml	lead	29694 : 29698	CM	 contributed to the most lead models in both the pan-c
./___Corpus/Medline/xml/PMC4967469.xml	4B	29820 : 29822	CM	l cancer types) (Figures 4B and 4C). In the pan-canc
./___Corpus/Medline/xml/PMC4967469.xml	4C	29827 : 29829	CM	r types) (Figures 4B and 4C). In the pan-cancer anal
./___Corpus/Medline/xml/PMC4967469.xml	lead	29871 : 29875	CM	cer analysis, all of the lead models use gene expressi
./___Corpus/Medline/xml/PMC4967469.xml	6D	29917 : 29919	CM	expression data (Figures 6D and 6E), but for 211 dru
./___Corpus/Medline/xml/PMC4967469.xml	6E	29924 : 29926	CM	ion data (Figures 6D and 6E), but for 211 drugs (∼86
./___Corpus/Medline/xml/PMC4967469.xml	methylation	29992 : 30003	RN	re improved by including methylation, RACSs, CGs, or any comb
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	30005 : 30010	CM	y including methylation, RACSs, CGs, or any combination
./___Corpus/Medline/xml/PMC4967469.xml	S6E	30179 : 30182	CM	 expression (Figures S6B–S6E).                       
./___Corpus/Medline/xml/PMC4967469.xml	lead	30270 : 30274	CM	nalysis, the majority of lead models are based solely 
./___Corpus/Medline/xml/PMC4967469.xml	6D	30329 : 30331	CM	nomics features (Figures 6D and 6E). For 120 cases (
./___Corpus/Medline/xml/PMC4967469.xml	6E	30336 : 30338	CM	features (Figures 6D and 6E). For 120 cases (∼38%) t
./___Corpus/Medline/xml/PMC4967469.xml	lead	30366 : 30370	CM	For 120 cases (∼38%) the lead model is based on genomi
./___Corpus/Medline/xml/PMC4967469.xml	RACS	30413 : 30417	CM	 genomics alone (CGs and RACS). We found that genomics
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30463 : 30474	RN	mics in combination with methylation provided an additional 1
./___Corpus/Medline/xml/PMC4967469.xml	lead	30502 : 30506	CM	ovided an additional 117 lead models (∼37%), whereas g
./___Corpus/Medline/xml/PMC4967469.xml	lead	30611 : 30615	CM	 19 (∼6%). The remaining lead models use methylation a
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30627 : 30638	RN	emaining lead models use methylation alone (∼7%), gene expres
./___Corpus/Medline/xml/PMC4967469.xml	lead	30835 : 30839	CM	is, ∼74% (237 of 319) of lead models were explained by
./___Corpus/Medline/xml/PMC4967469.xml	methylation	30910 : 30921	RN	ne or when combined with methylation (Figures 6D and 6E).    
./___Corpus/Medline/xml/PMC4967469.xml	6D	30931 : 30933	CM	ith methylation (Figures 6D and 6E).                
./___Corpus/Medline/xml/PMC4967469.xml	6E	30938 : 30940	CM	hylation (Figures 6D and 6E).                  Discu
./___Corpus/Medline/xml/PMC4967469.xml	COSMIC	31325 : 31331	CM	investigated through the COSMIC and Genomics of Drug Sen
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	32004 : 32008	CM	         The majority of CFEs identified from a broad 
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	32215 : 32219	CM	 far from complete; many CFEs occurring at low to mode
./___Corpus/Medline/xml/PMC4967469.xml	EML4-ALK	32559 : 32567	CM	bor the drug sensitizing EML4-ALK gene fusion [Soda et al.
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	33570 : 33574	CM	 “logic” combinations of CFEs consistently perform bet
./___Corpus/Medline/xml/PMC4967469.xml	BRAF	33707 : 33711	CM	rom the observation that BRAF mutant melanoma patients
./___Corpus/Medline/xml/PMC4967469.xml	BRAF	33750 : 33754	CM	ma patients treated with BRAF inhibitors show heteroge
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	34236 : 34240	CM	endent datasets from the CCLE and CTRP. Consistent wit
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	34245 : 34249	CM	tasets from the CCLE and CTRP. Consistent with previou
./___Corpus/Medline/xml/PMC4967469.xml	CFE	35023 : 35026	CM	cal models, the defining CFE is present in clinical p
./___Corpus/Medline/xml/PMC4967469.xml	alkylating	35167 : 35177	RN	ure 7). For example, the alkylating agent Temozolamide (used
./___Corpus/Medline/xml/PMC4967469.xml	Temozolamide	35184 : 35196	CM	le, the alkylating agent Temozolamide (used to treat glioblast
./___Corpus/Medline/xml/PMC4967469.xml	MYC	35255 : 35258	CM	forme) shows activity in MYC amplified colorectal can
./___Corpus/Medline/xml/PMC4967469.xml	CFE	35425 : 35428	CM	ples harbor at least one CFE, or logic combination of
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	35454 : 35458	CM	 or logic combination of CFEs, associated with increas
./___Corpus/Medline/xml/PMC4967469.xml	COAD	35536 : 35540	CM	om 0.63% (OV) to 83.61% (COAD/READ) (Figure 7; Tables 
./___Corpus/Medline/xml/PMC4967469.xml	READ	35541 : 35545	CM	63% (OV) to 83.61% (COAD/READ) (Figure 7; Tables S7A–S
./___Corpus/Medline/xml/PMC4967469.xml	methylation	36089 : 36100	RN	ls, with the addition of methylation data further improving o
./___Corpus/Medline/xml/PMC4967469.xml	methylation	36392 : 36403	RN	ber alterations, and DNA methylation profiles might be the mo
./___Corpus/Medline/xml/PMC4967469.xml	vitro	36894 : 36899	CM	iated with the use of in vitro cancer cell lines. Nonet
./___Corpus/Medline/xml/PMC4967469.xml	COSMIC	37660 : 37666	CM	 were assembled from the COSMIC database. 1,001 cell lin
./___Corpus/Medline/xml/PMC4967469.xml	S1E	37729 : 37732	CM	ded in this study (Table S1E). Variants and copy numb
./___Corpus/Medline/xml/PMC4967469.xml	PCR	38023 : 38026	CM	e identified by targeted PCR sequencing or split prob
./___Corpus/Medline/xml/PMC4967469.xml	S2C	38111 : 38114	CM	n (FISH) analysis (Table S2C).                  Varia
./___Corpus/Medline/xml/PMC4967469.xml	COSMIC	38432 : 38438	CM	line consistent with the COSMIC database (Vagrent: https
./___Corpus/Medline/xml/PMC4967469.xml	Methylation	38522 : 38533	RN	RViko).                  Methylation Data                    
./___Corpus/Medline/xml/PMC4967469.xml	methylation	38599 : 38610	RN	mors, raw data for 6,035 methylation samples, covering 18 tum
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	38670 : 38674	CM	were downloaded from the TCGA data portal. For the cel
./___Corpus/Medline/xml/PMC4967469.xml	R	38883 : 38884	CM	e preprocessed using the R Bioconductor package Min
./___Corpus/Medline/xml/PMC4967469.xml	CpG	38918 : 38921	CM	ctor package Minfi. Only CpG site probes falling on t
./___Corpus/Medline/xml/PMC4967469.xml	TSS1500	39007 : 39014	CM	s were considered, i.e., TSS1500, TSS200, 5′ UTR, and 1st
./___Corpus/Medline/xml/PMC4967469.xml	TSS200	39016 : 39022	CM	nsidered, i.e., TSS1500, TSS200, 5′ UTR, and 1st exon. P
./___Corpus/Medline/xml/PMC4967469.xml	UTR	39027 : 39030	CM	.e., TSS1500, TSS200, 5′ UTR, and 1st exon. Probes co
./___Corpus/Medline/xml/PMC4967469.xml	SNPs	39064 : 39068	CM	 exon. Probes containing SNPs and non-specific probes,
./___Corpus/Medline/xml/PMC4967469.xml	Methylation	39169 : 39180	RN	h a gene were discarded. Methylation beta values of CpG islan
./___Corpus/Medline/xml/PMC4967469.xml	CpG	39196 : 39199	CM	thylation beta values of CpG islands were averaged ac
./___Corpus/Medline/xml/PMC4967469.xml	CpG	39229 : 39232	CM	nds were averaged across CpG sites.                  
./___Corpus/Medline/xml/PMC4967469.xml	CpG	39483 : 39486	CM	ions and the informative CpG islands is detailed in t
./___Corpus/Medline/xml/PMC4967469.xml	RPMI	39668 : 39672	CM	ng exponential growth in RPMI or DMEM/F12 were lysed w
./___Corpus/Medline/xml/PMC4967469.xml	DMEM	39676 : 39680	CM	ential growth in RPMI or DMEM/F12 were lysed with TRIz
./___Corpus/Medline/xml/PMC4967469.xml	F12	39681 : 39684	CM	l growth in RPMI or DMEM/F12 were lysed with TRIzol (
./___Corpus/Medline/xml/PMC4967469.xml	TRIzol	39701 : 39707	CM	DMEM/F12 were lysed with TRIzol (Life Technologies) and 
./___Corpus/Medline/xml/PMC4967469.xml	−70°C	39742 : 39747	CM	hnologies) and stored at −70°C. Following chloroform ex
./___Corpus/Medline/xml/PMC4967469.xml	chloroform	39759 : 39769	CM	ored at −70°C. Following chloroform extraction, total RNA wa
./___Corpus/Medline/xml/PMC4967469.xml	RNA	39788 : 39791	CM	roform extraction, total RNA was isolated using the R
./___Corpus/Medline/xml/PMC4967469.xml	DNase	39841 : 39846	ASE	Neasy Mini Kit (QIAGEN). DNase digestion was followed b
./___Corpus/Medline/xml/PMC4967469.xml	RNA	39914 : 39917	CM	 (Agencourt Bioscience). RNA integrity was confirmed 
./___Corpus/Medline/xml/PMC4967469.xml	(IC50),and	40713 : 40723	CM	inhibitory concentration (IC50),and area under the curve [AU
./___Corpus/Medline/xml/PMC4967469.xml	AUC	40746 : 40749	CM	nd area under the curve [AUC]) through a multilevel m
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	40935 : 40940	CM	        For each drug an ANOVA model was fitted to corr
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	41030 : 41034	CM	ancer Functional Events (CFEs), as described in Garnet
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	41213 : 41218	CM	edures. The downsampling ANOVA simulation studies are d
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	41311 : 41317	CM	ocedures. We applied the LOBICO (Knijnenburg et al., 201
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	41591 : 41596	CM	Conceptualization, F.I., T.A.K., D.J.V., G.R.B., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	41599 : 41604	CM	alization, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	41607 : 41612	CM	n, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., L.F.A.W
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	41615 : 41620	CM	 T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., L.F.A.W., J.S.-
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	41623 : 41627	CM	 D.J.V., G.R.B., M.P.M., M.Sc., L.F.A.W., J.S.-R., U.M
./___Corpus/Medline/xml/PMC4967469.xml	L.F.A.W	41630 : 41637	CM	, G.R.B., M.P.M., M.Sc., L.F.A.W., J.S.-R., U.M., and M.J
./___Corpus/Medline/xml/PMC4967469.xml	J.S.-R	41640 : 41646	CM	M.P.M., M.Sc., L.F.A.W., J.S.-R., U.M., and M.J.G.; Meth
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	41659 : 41664	CM	A.W., J.S.-R., U.M., and M.J.G.; Methodology, F.I., T.A
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	41686 : 41691	CM	J.G.; Methodology, F.I., T.A.K., D.J.V., G.R.B., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	41694 : 41699	CM	thodology, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	41702 : 41707	CM	y, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., S.B., U
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	41710 : 41715	CM	 T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., S.B., U.M., and
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	41718 : 41722	CM	 D.J.V., G.R.B., M.P.M., M.Sc., S.B., U.M., and M.J.G.
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	41741 : 41746	CM	, M.Sc., S.B., U.M., and M.J.G.; Software, F.I., T.A.K.
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	41765 : 41770	CM	 M.J.G.; Software, F.I., T.A.K., D.J.V., M.P.M., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	41773 : 41778	CM	 Software, F.I., T.A.K., D.J.V., M.P.M., M.Sc., T.C., H
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	41781 : 41786	CM	e, F.I., T.A.K., D.J.V., M.P.M., M.Sc., T.C., H.L., and
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	41789 : 41793	CM	 T.A.K., D.J.V., M.P.M., M.Sc., T.C., H.L., and E.v.D.
./___Corpus/Medline/xml/PMC4967469.xml	E.v.D	41812 : 41817	CM	, M.Sc., T.C., H.L., and E.v.D.; Validation, F.I., T.A.
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	41838 : 41843	CM	.v.D.; Validation, F.I., T.A.K., D.J.V., M.P.M., N.A., 
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	41846 : 41851	CM	alidation, F.I., T.A.K., D.J.V., M.P.M., N.A., S.B., H.
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	41854 : 41859	CM	n, F.I., T.A.K., D.J.V., M.P.M., N.A., S.B., H.L., P.G.
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	41890 : 41895	CM	., S.B., H.L., P.G., and M.J.G.; Formal Analysis, F.I.,
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	41921 : 41926	CM	; Formal Analysis, F.I., T.A.K., D.J.V., M.P.M., and M.
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	41929 : 41934	CM	 Analysis, F.I., T.A.K., D.J.V., M.P.M., and M.Sc.; Inv
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	41937 : 41942	CM	s, F.I., T.A.K., D.J.V., M.P.M., and M.Sc.; Investigati
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	41949 : 41953	CM	.K., D.J.V., M.P.M., and M.Sc.; Investigation, G.R.B.,
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	41971 : 41976	CM	nd M.Sc.; Investigation, G.R.B., S.B., P.G., T.M., and 
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	42018 : 42023	CM	M., and L.R.; Resources, D.J.V., G.R.B., M.Sc., E.G., S
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	42026 : 42031	CM	L.R.; Resources, D.J.V., G.R.B., M.Sc., E.G., S.B., H.L
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	42034 : 42038	CM	sources, D.J.V., G.R.B., M.Sc., E.G., S.B., H.L., P.G.
./___Corpus/Medline/xml/PMC4967469.xml	E.v.D	42065 : 42070	CM	 E.G., S.B., H.L., P.G., E.v.D., H.C., H.d.S., H.H., T.
./___Corpus/Medline/xml/PMC4967469.xml	H.d.S	42079 : 42084	CM	.L., P.G., E.v.D., H.C., H.d.S., H.H., T.M., S.M., L.R.
./___Corpus/Medline/xml/PMC4967469.xml	R.K.E	42117 : 42122	CM	 T.M., S.M., L.R., X.D., R.K.E., Q.L., X.M., J.W., T.Z.
./___Corpus/Medline/xml/PMC4967469.xml	N.S.G	42149 : 42154	CM	 Q.L., X.M., J.W., T.Z., N.S.G., S.S., D.T., N.L.-B., P
./___Corpus/Medline/xml/PMC4967469.xml	N.L.-B	42169 : 42175	CM	.Z., N.S.G., S.S., D.T., N.L.-B., P.R.-M., M.E., D.A.H.,
./___Corpus/Medline/xml/PMC4967469.xml	P.R.-M	42178 : 42184	CM	G., S.S., D.T., N.L.-B., P.R.-M., M.E., D.A.H., C.H.B., 
./___Corpus/Medline/xml/PMC4967469.xml	D.A.H	42193 : 42198	CM	 N.L.-B., P.R.-M., M.E., D.A.H., C.H.B., U.M., and M.J.
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42201 : 42206	CM	, P.R.-M., M.E., D.A.H., C.H.B., U.M., and M.J.G.; Data
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42219 : 42224	CM	.A.H., C.H.B., U.M., and M.J.G.; Data Curation, F.I., D
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	42248 : 42253	CM	G.; Data Curation, F.I., D.J.V., G.R.B., M.Sc., E.G., H
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	42256 : 42261	CM	 Curation, F.I., D.J.V., G.R.B., M.Sc., E.G., H.L., P.G
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	42264 : 42268	CM	n, F.I., D.J.V., G.R.B., M.Sc., E.G., H.L., P.G., H.C.
./___Corpus/Medline/xml/PMC4967469.xml	H.d.S	42295 : 42300	CM	 E.G., H.L., P.G., H.C., H.d.S., H.H., S.M., S.S., M.So
./___Corpus/Medline/xml/PMC4967469.xml	M.So	42321 : 42325	CM	.d.S., H.H., S.M., S.S., M.So., D.T., N.L.B., P.R.-M.,
./___Corpus/Medline/xml/PMC4967469.xml	N.L.B	42334 : 42339	CM	S.M., S.S., M.So., D.T., N.L.B., P.R.-M., L.F.A.W., J.S
./___Corpus/Medline/xml/PMC4967469.xml	P.R.-M	42342 : 42348	CM	S., M.So., D.T., N.L.B., P.R.-M., L.F.A.W., J.S.-R., U.M
./___Corpus/Medline/xml/PMC4967469.xml	L.F.A.W	42351 : 42358	CM	, D.T., N.L.B., P.R.-M., L.F.A.W., J.S.-R., U.M., and M.J
./___Corpus/Medline/xml/PMC4967469.xml	J.S.-R	42361 : 42367	CM	L.B., P.R.-M., L.F.A.W., J.S.-R., U.M., and M.J.G.; Writ
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42380 : 42385	CM	A.W., J.S.-R., U.M., and M.J.G.; Writing – Original Dra
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	42420 : 42425	CM	 – Original Draft, F.I., T.A.K., D.J.V., G.R.B., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	42428 : 42433	CM	nal Draft, F.I., T.A.K., D.J.V., G.R.B., M.P.M., U.M., 
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	42436 : 42441	CM	t, F.I., T.A.K., D.J.V., G.R.B., M.P.M., U.M., and M.J.
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	42444 : 42449	CM	 T.A.K., D.J.V., G.R.B., M.P.M., U.M., and M.J.G.; Writ
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42462 : 42467	CM	.R.B., M.P.M., U.M., and M.J.G.; Writing – Review & Edi
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	42504 : 42509	CM	 Review & Editing, F.I., T.A.K., D.J.V., G.R.B., M.P.M.
./___Corpus/Medline/xml/PMC4967469.xml	D.J.V	42512 : 42517	CM	& Editing, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc.,
./___Corpus/Medline/xml/PMC4967469.xml	G.R.B	42520 : 42525	CM	g, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., N.A., L
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	42528 : 42533	CM	 T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., N.A., L.F.A.W.,
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	42536 : 42540	CM	 D.J.V., G.R.B., M.P.M., M.Sc., N.A., L.F.A.W., J.S.-R
./___Corpus/Medline/xml/PMC4967469.xml	L.F.A.W	42549 : 42556	CM	B., M.P.M., M.Sc., N.A., L.F.A.W., J.S.-R., U.M., and M.J
./___Corpus/Medline/xml/PMC4967469.xml	J.S.-R	42559 : 42565	CM	, M.Sc., N.A., L.F.A.W., J.S.-R., U.M., and M.J.G.; Visu
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42578 : 42583	CM	A.W., J.S.-R., U.M., and M.J.G.; Visualization, F.I., T
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	42607 : 42612	CM	G.; Visualization, F.I., T.A.K., M.P.M., M.Sc., and E.G
./___Corpus/Medline/xml/PMC4967469.xml	M.P.M	42615 : 42620	CM	alization, F.I., T.A.K., M.P.M., M.Sc., and E.G.; Super
./___Corpus/Medline/xml/PMC4967469.xml	M.Sc	42623 : 42627	CM	n, F.I., T.A.K., M.P.M., M.Sc., and E.G.; Supervision,
./___Corpus/Medline/xml/PMC4967469.xml	D.A.H	42653 : 42658	CM	, and E.G.; Supervision, D.A.H., M.R.S., C.H.B., L.F.A.
./___Corpus/Medline/xml/PMC4967469.xml	M.R.S	42661 : 42666	CM	G.; Supervision, D.A.H., M.R.S., C.H.B., L.F.A.W., J.S.
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42669 : 42674	CM	rvision, D.A.H., M.R.S., C.H.B., L.F.A.W., J.S.-R., U.M
./___Corpus/Medline/xml/PMC4967469.xml	L.F.A.W	42677 : 42684	CM	 D.A.H., M.R.S., C.H.B., L.F.A.W., J.S.-R., U.M., and M.J
./___Corpus/Medline/xml/PMC4967469.xml	J.S.-R	42687 : 42693	CM	.R.S., C.H.B., L.F.A.W., J.S.-R., U.M., and M.J.G.; Proj
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42706 : 42711	CM	A.W., J.S.-R., U.M., and M.J.G.; Project Administration
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42754 : 42759	CM	tration, F.I., U.M., and M.J.G.; Funding Acquisition, D
./___Corpus/Medline/xml/PMC4967469.xml	D.A.H	42783 : 42788	CM	G.; Funding Acquisition, D.A.H., C.H.B., M.R.S., L.F.A.
./___Corpus/Medline/xml/PMC4967469.xml	C.H.B	42791 : 42796	CM	ing Acquisition, D.A.H., C.H.B., M.R.S., L.F.A.W., J.S.
./___Corpus/Medline/xml/PMC4967469.xml	M.R.S	42799 : 42804	CM	isition, D.A.H., C.H.B., M.R.S., L.F.A.W., J.S.-R., U.M
./___Corpus/Medline/xml/PMC4967469.xml	L.F.A.W	42807 : 42814	CM	 D.A.H., C.H.B., M.R.S., L.F.A.W., J.S.-R., U.M., and M.J
./___Corpus/Medline/xml/PMC4967469.xml	J.S.-R	42817 : 42823	CM	.H.B., M.R.S., L.F.A.W., J.S.-R., U.M., and M.J.G.      
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	42836 : 42841	CM	A.W., J.S.-R., U.M., and M.J.G.                  Acknow
./___Corpus/Medline/xml/PMC4967469.xml	T.A.K	43088 : 43093	CM	octoral (ESPOD) program. T.A.K. was supported by the Na
./___Corpus/Medline/xml/PMC4967469.xml	FP7	43333 : 43336	CM	e of the European Union (FP7/2007-2013; 600388) and t
./___Corpus/Medline/xml/PMC4967469.xml	2007-	43337 : 43342	CPR	 the European Union (FP7/2007-2013; 600388) and the Age
./___Corpus/Medline/xml/PMC4967469.xml	ACCIÓ	43436 : 43441	CM	Government of Catalonia (ACCIÓ). N.L.-B. was supported 
./___Corpus/Medline/xml/PMC4967469.xml	La	43469 : 43471	CM	N.L.-B. was supported by La Fundació la Marató de TV
./___Corpus/Medline/xml/PMC4967469.xml	TV3	43494 : 43497	CM	La Fundació la Marató de TV3. M.E. was funded by the 
./___Corpus/Medline/xml/PMC4967469.xml	ISCIII	43650 : 43656	CM	te of Health Carlos III (ISCIII) under the Integrated Pr
./___Corpus/Medline/xml/PMC4967469.xml	PIE13	43702 : 43707	CM	d Project of Excellence (PIE13/00022), the Spanish Canc
./___Corpus/Medline/xml/PMC4967469.xml	RD12	43753 : 43757	CM	Cancer Research Network (RD12/0036/0039), the Health a
./___Corpus/Medline/xml/PMC4967469.xml	2014-	43856 : 43861	CPR	Generalitat de Catalunya 2014-SGR 633, and the Cellex F
./___Corpus/Medline/xml/PMC4967469.xml	He	43988 : 43990	CM	lowship. We thank Aiqing He for expression data and 
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	44055 : 44061	CM	 for assistance with the LOBICO framework. We thank P. C
./___Corpus/Medline/xml/PMC4967469.xml	H	44163 : 44164	CM	an, C. Alsinet Armengol, H. Francies, V. Grinkevich
./___Corpus/Medline/xml/PMC4967469.xml	P.R.-M	44232 : 44238	CM	upo for useful comments. P.R.-M., H.C., and H.d.S. are e
./___Corpus/Medline/xml/PMC4967469.xml	H.d.S	44251 : 44256	CM	ents. P.R.-M., H.C., and H.d.S. are employees and share
./___Corpus/Medline/xml/PMC4967469.xml	Bristol	44292 : 44299	CM	yees and shareholders of Bristol-Myers Squibb. Research i
./___Corpus/Medline/xml/PMC4967469.xml	M.J.G	44330 : 44335	CM	 Squibb. Research in the M.J.G. lab is supported in par
./___Corpus/Medline/xml/PMC4967469.xml	methylation	44814 : 44825	RN	er, transcriptional, and methylation data reported in this pa
./___Corpus/Medline/xml/PMC4967469.xml	EGA	44873 : 44876	CM	paper are, respectively, EGA: EGAS00001000978, GEO: {
./___Corpus/Medline/xml/PMC4967469.xml	E-	44995 : 44997	CPR	68379, and ArrayExpress: E-MTAB-3610.               
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	45144 : 45148	CM	inition of corresponding TCGA labels, indicating the t
./___Corpus/Medline/xml/PMC4967469.xml	TCGA	45650 : 45654	CM	 instability status, and TCGA identifier mapping acros
./___Corpus/Medline/xml/PMC4967469.xml	AUC	46102 : 46105	CM	ound clustering based on AUC pattern similarity. (A) 
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	46399 : 46404	CM	 amplification/deletion (RACSs). (E) Pan-Cancer/Cancer-
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	46438 : 46443	CM	n-Cancer/Cancer-Specific RACSs mapping. (F) Full list o
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	46470 : 46475	CM	apping. (F) Full list of RACSs copy number alterations 
./___Corpus/Medline/xml/PMC4967469.xml	RACSs	46546 : 46551	CM	ry tumors. (G) Full list RACSs CNAs found in cell lines
./___Corpus/Medline/xml/PMC4967469.xml	H	46600 : 46601	CM	s.                      (H) Full list of informativ
./___Corpus/Medline/xml/PMC4967469.xml	CpG	46628 : 46631	CM	Full list of informative CpG islands with hyperlinks 
./___Corpus/Medline/xml/PMC4967469.xml	CpG	46759 : 46762	CM	Full list of informative CpG islands found hypermethy
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	46777 : 46792	CM	mative CpG islands found hypermethylated in primary tumors. (J) F
./___Corpus/Medline/xml/PMC4967469.xml	CpG	46841 : 46844	CM	Full list of informative CpG islands found hypermethy
./___Corpus/Medline/xml/PMC4967469.xml	hypermethylated	46859 : 46874	CM	mative CpG islands found hypermethylated in cell lines.          
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	46941 : 46945	CM	ancer Functional Events (CFEs) identified in primary t
./___Corpus/Medline/xml/PMC4967469.xml	CFE	47085 : 47088	CM	correlation scores among CFE alteration frequency pro
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	47780 : 47784	CM	ancer Functional Events (CFEs) across cell lines and t
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	47883 : 47887	CM	e been included and only CFEs occurring in at least on
./___Corpus/Medline/xml/PMC4967469.xml	CFE	47962 : 47965	CM	h at least one occurring CFE have been included.     
./___Corpus/Medline/xml/PMC4967469.xml	CFEs	48162 : 48166	CM	D) Identified classes of CFEs and cell-line/tumor samp
./___Corpus/Medline/xml/PMC4967469.xml	CFE	48200 : 48203	CM	-line/tumor samples. (E) CFE type enrichments of the 
./___Corpus/Medline/xml/PMC4967469.xml	CFE	48292 : 48295	CM	ositions. (F) Individual CFE enrichments of the ident
./___Corpus/Medline/xml/PMC4967469.xml	H	48476 : 48477	CM	lysis.                  (H) Copy number amplificati
./___Corpus/Medline/xml/PMC4967469.xml	IC50	48559 : 48563	CM	 identified classes. (A) IC50 values across all screen
./___Corpus/Medline/xml/PMC4967469.xml	AUC	48674 : 48677	CM	the dose-response curve (AUC) scores across all scree
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	48795 : 48800	CM	Full list of significant ANOVA interactions (both Pan-c
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	49003 : 49008	CM	ncer and Cancer-Specific ANOVA interaction effect sizes
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	49155 : 49159	CM	ne Encyclopedia dataset (CCLE; Barretina et al., 2012)
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	49262 : 49266	CM	etween our study and the CCLE (Barretina et al., 2012)
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	49378 : 49382	CM	nd Activity area for the CCLE, and IC50s s and Area un
./___Corpus/Medline/xml/PMC4967469.xml	S4E	49507 : 49510	CM	 and compounds in Tables S4E and S4F, together with a
./___Corpus/Medline/xml/PMC4967469.xml	S4F	49515 : 49518	CM	pounds in Tables S4E and S4F, together with additiona
./___Corpus/Medline/xml/PMC4967469.xml	H	49677 : 49678	CM	                        (H) Set of significant and 
./___Corpus/Medline/xml/PMC4967469.xml	CCLE	49788 : 49792	CM	that are testable on the CCLE and have been validated 
./___Corpus/Medline/xml/PMC4967469.xml	S4E	49906 : 49909	CM	 and compounds in Tables S4E and S4F, together with h
./___Corpus/Medline/xml/PMC4967469.xml	S4F	49914 : 49917	CM	pounds in Tables S4E and S4F, together with hyperlink
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	50175 : 50179	CM	elopment (2015 version) (CTRP, Seashore-Ludlow et al.,
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	50309 : 50313	CM	etween our study and the CTRP (Seashore-Ludlow et al.,
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	50453 : 50457	CM	 dose response curve for CTRP, and IC50s and Area unde
./___Corpus/Medline/xml/PMC4967469.xml	IC50s	50463 : 50468	CM	onse curve for CTRP, and IC50s and Area under the respo
./___Corpus/Medline/xml/PMC4967469.xml	S4I	50580 : 50583	CM	 and compounds in Tables S4I and S4J, together with a
./___Corpus/Medline/xml/PMC4967469.xml	S4J	50588 : 50591	CM	pounds in Tables S4I and S4J, together with additiona
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	50868 : 50872	CM	that are testable on the CTRP and have been validated 
./___Corpus/Medline/xml/PMC4967469.xml	S4I	50986 : 50989	CM	 and compounds in Tables S4I and S4J, together with h
./___Corpus/Medline/xml/PMC4967469.xml	S4J	50994 : 50997	CM	pounds in Tables S4I and S4J, together with hyperlink
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51413 : 51419	CM	Full list of significant LOBICO models, with hyperlinks 
./___Corpus/Medline/xml/PMC4967469.xml	OR	51561 : 51563	CM	 (F) Interesting AND and OR combinations uncovered b
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51590 : 51596	CM	ombinations uncovered by LOBICO. (G) LOBICO models for C
./___Corpus/Medline/xml/PMC4967469.xml	LOBICO	51602 : 51608	CM	uncovered by LOBICO. (G) LOBICO models for CTRP validati
./___Corpus/Medline/xml/PMC4967469.xml	CTRP	51620 : 51624	CM	O. (G) LOBICO models for CTRP validation (legend in fi
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	51870 : 51875	CM	rkers identified through ANOVA in the primary tumor sam
./___Corpus/Medline/xml/PMC4967469.xml	ANOVA	52004 : 52009	CM	rkers identified through ANOVA in the primary tumor sam
./___Corpus/Medline/xml/PMC5123381.xml	Ager1	225 : 230	CM	                   Casey Ager1, Matthew Reilley2, Court
./___Corpus/Medline/xml/PMC5123381.xml	Nicholas1	259 : 268	CM	tthew Reilley2, Courtney Nicholas1, Todd Bartkowiak1, Ashvi
./___Corpus/Medline/xml/PMC5123381.xml	STING	950 : 955	CM	nistration of either the STING agonist c-di-GMP (CDG) o
./___Corpus/Medline/xml/PMC5123381.xml	c-di-GMP	964 : 972	CM	either the STING agonist c-di-GMP (CDG) or dendritic cell 
./___Corpus/Medline/xml/PMC5123381.xml	CDG	974 : 977	CM	 STING agonist c-di-GMP (CDG) or dendritic cell (DC) 
./___Corpus/Medline/xml/PMC5123381.xml	DC	998 : 1000	CM	(CDG) or dendritic cell (DC) growth factor Flt3-liga
./___Corpus/Medline/xml/PMC5123381.xml	αCTLA-4	1104 : 1111	CM	eckpoint modulation with αCTLA-4, αPD-1, and α4-1BB in a 
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	1113 : 1118	CM	modulation with αCTLA-4, αPD-1, and α4-1BB in a bilater
./___Corpus/Medline/xml/PMC5123381.xml	α4-1BB	1124 : 1130	CM	with αCTLA-4, αPD-1, and α4-1BB in a bilateral subcutane
./___Corpus/Medline/xml/PMC5123381.xml	CDG	1286 : 1289	CM	eckpoint modulators with CDG at a single lesion can a
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	1472 : 1480	CM	usly on both flanks with TRAMP-C2 prostate adenocarcinoma,
./___Corpus/Medline/xml/PMC5123381.xml	STING	1778 : 1783	CM	Intratumoral delivery of STING agonist CDG alone potent
./___Corpus/Medline/xml/PMC5123381.xml	CDG	1792 : 1795	CM	elivery of STING agonist CDG alone potently rejects a
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	1832 : 1840	CM	tly rejects all injected TRAMP-C2 tumors, but fails to gen
./___Corpus/Medline/xml/PMC5123381.xml	αCTLA-4	1938 : 1945	CM	stemic administration of αCTLA-4, αPD-1, and α4-1BB cures
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	1947 : 1952	CM	ministration of αCTLA-4, αPD-1, and α4-1BB cures 40 % o
./___Corpus/Medline/xml/PMC5123381.xml	α4-1BB	1958 : 1964	CM	n of αCTLA-4, αPD-1, and α4-1BB cures 40 % of mice with 
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	1999 : 2007	CM	% of mice with bilateral TRAMP-C2, and concurrent administ
./___Corpus/Medline/xml/PMC5123381.xml	CDG	2042 : 2045	CM	urrent administration of CDG at one or both flanks en
./___Corpus/Medline/xml/PMC5123381.xml	αCTLA-4	2239 : 2246	CM	t. Intratumoral low-dose αCTLA-4, αPD-1, and α4-1BB at a 
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	2248 : 2253	CM	umoral low-dose αCTLA-4, αPD-1, and α4-1BB at a single 
./___Corpus/Medline/xml/PMC5123381.xml	α4-1BB	2259 : 2265	CM	dose αCTLA-4, αPD-1, and α4-1BB at a single flank induce
./___Corpus/Medline/xml/PMC5123381.xml	CDG	2359 : 2362	CM	urrent administration of CDG enhances systemic immuni
./___Corpus/Medline/xml/PMC5123381.xml	STING	2447 : 2452	CM	bserve that the level of STING activation required to m
./___Corpus/Medline/xml/PMC5123381.xml	STING	2590 : 2595	CM	ize. Functionally, local STING activation complements i
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	2670 : 2674	CM	dulation to reduce local MDSC infiltration, enhance CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8	2697 : 2700	CM	SC infiltration, enhance CD8:Treg ratios, and downreg
./___Corpus/Medline/xml/PMC5123381.xml	M2	2735 : 2737	CM	os, and downregulate the M2 macrophage marker CD206.
./___Corpus/Medline/xml/PMC5123381.xml	CD206	2756 : 2761	CM	the M2 macrophage marker CD206. In contrast, local Flt3
./___Corpus/Medline/xml/PMC5123381.xml	STING	3003 : 3008	CM	            Intratumoral STING activation via CDG or DC
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3024 : 3027	CM	ral STING activation via CDG or DC expansion with Flt
./___Corpus/Medline/xml/PMC5123381.xml	DC	3031 : 3033	CM	NG activation via CDG or DC expansion with Flt3L pot
./___Corpus/Medline/xml/PMC5123381.xml	αCTLA-4	3117 : 3124	CM	f systemically-delivered αCTLA-4, αPD-1, and α4-1BB again
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	3126 : 3131	CM	cally-delivered αCTLA-4, αPD-1, and α4-1BB against mult
./___Corpus/Medline/xml/PMC5123381.xml	α4-1BB	3137 : 3143	CM	ered αCTLA-4, αPD-1, and α4-1BB against multi-focal TRAM
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	3164 : 3172	CM	-1BB against multi-focal TRAMP-C2 prostate cancer. The abs
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3216 : 3219	CM	he abscopal potential of CDG alone is weak, in contra
./___Corpus/Medline/xml/PMC5123381.xml	CDG	3284 : 3287	CM	ervations, but combining CDG with low-dose checkpoint
./___Corpus/Medline/xml/PMC5123381.xml	anti-	3697 : 3702	CPR	for optimal induction of anti-tumor CD8+ T cell respons
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	3708 : 3712	CM	 induction of anti-tumor CD8+ T cell responses        
./___Corpus/Medline/xml/PMC5123381.xml	Y	3842 : 3843	CM	, Rebecca S Reeves, Lisa Y Ngo, Peter Berglund, Jan
./___Corpus/Medline/xml/PMC5123381.xml	endoprotease	4200 : 4212	CM	 use of fusion proteins, endoprotease cleavage sites, or inter
./___Corpus/Medline/xml/PMC5123381.xml	Up	4763 : 4765	CM	ods                      Up to five vector genome pl
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	5160 : 5167	CM	zygous vector particles. qRT-PCR was used to determine to
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	5442 : 5450	CM	nicity via intracellular cytokine staining. Two tumor mode
./___Corpus/Medline/xml/PMC5123381.xml	B16	5527 : 5530	CM	erapeutic efficacy: 1) a B16 melanoma model, where tu
./___Corpus/Medline/xml/PMC5123381.xml	2–	5607 : 5609	CPR	n the flank and measured 2–3 times per week; and 2) 
./___Corpus/Medline/xml/PMC5123381.xml	CT26	5647 : 5651	CM	eek; and 2) a metastatic CT26 colon carcinoma model, w
./___Corpus/Medline/xml/PMC5123381.xml	17–	5757 : 5760	CPR	 nodules were enumerated 17–19 days post-tumor inocul
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	5852 : 5859	CM	           Titrations by qRT-PCR of multiple ZVex-Multi v
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	6010 : 6018	CM	sociated antigens (e.g., NY-ESO-1, MAGE-A3) and two immuno
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	6020 : 6027	CM	ntigens (e.g., NY-ESO-1, MAGE-A3) and two immuno-modulato
./___Corpus/Medline/xml/PMC5123381.xml	anti-	6069 : 6074	CPR	modulators (e.g., IL-12, anti-CTLA-4 or anti-PD-L1) wer
./___Corpus/Medline/xml/PMC5123381.xml	anti-	6084 : 6089	CPR	., IL-12, anti-CTLA-4 or anti-PD-L1) were highly reprod
./___Corpus/Medline/xml/PMC5123381.xml	TAAs	6306 : 6310	CM	lls against all targeted TAAs and exhibited improved t
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	6451 : 6460	CM	lti is a next generation DC-tropic vector platform designed
./___Corpus/Medline/xml/PMC5123381.xml	anti-	7127 : 7132	CPR	mma are required for the anti-tumor efficacy of combina
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	7177 : 7182	CM	mbination-treatment with NKG2A and PD-1/PD-L1 checkpoin
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	7187 : 7191	CM	treatment with NKG2A and PD-1/PD-L1 checkpoint inhibit
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	7192 : 7197	CM	ment with NKG2A and PD-1/PD-L1 checkpoint inhibitors in
./___Corpus/Medline/xml/PMC5123381.xml	Denis1	7289 : 7295	CM	                Caroline Denis1, Hormas Ghadially2, Thom
./___Corpus/Medline/xml/PMC5123381.xml	W	7372 : 7373	CM	 Nicolas Fuseri1, Robert W Wilkinson2, Nicolai Wagt
./___Corpus/Medline/xml/PMC5123381.xml	Andre1	7428 : 7434	CM	, Yannis Morel1, Pascale Andre1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	IPH2201	7497 : 7504	CM	            Monalizumab (IPH2201) is a first-in-class hum
./___Corpus/Medline/xml/PMC5123381.xml	IgG4	7536 : 7540	CM	first-in-class humanized IgG4 targeting NKG2A, which i
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	7551 : 7556	CM	humanized IgG4 targeting NKG2A, which is expressed as h
./___Corpus/Medline/xml/PMC5123381.xml	CD94	7597 : 7601	CM	ssed as heterodimer with CD94 on the surface of NK, γδ
./___Corpus/Medline/xml/PMC5123381.xml	γδT	7624 : 7627	CM	94 on the surface of NK, γδT and tumor infiltrating C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	7651 : 7655	CM	T and tumor infiltrating CD8+ T cells. This inhibitory
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	7699 : 7704	CM	bitory receptor binds to HLA-E in humans and to Qa-1b i
./___Corpus/Medline/xml/PMC5123381.xml	Qa-1b	7722 : 7727	CM	o HLA-E in humans and to Qa-1b in mice. HLA-E is freque
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	7737 : 7742	CM	ns and to Qa-1b in mice. HLA-E is frequently up-regulat
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A+	7814 : 7820	CM	otecting from killing by NKG2A+ cells. Monalizumab block
./___Corpus/Medline/xml/PMC5123381.xml	CD94-NKG2A	7858 : 7868	CM	izumab blocks binding of CD94-NKG2A to HLA-E, reducing inhib
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	7872 : 7877	CM	binding of CD94-NKG2A to HLA-E, reducing inhibitory sig
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	7952 : 7956	CM	NK and T cell responses. PD-1/PD-L1 inhibitors are suc
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	7957 : 7962	CM	d T cell responses. PD-1/PD-L1 inhibitors are successfu
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8073 : 8078	CM	rs. Combined blockade of NKG2A/HLA-E and PD-1/PD-L1 may
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	8079 : 8084	CM	mbined blockade of NKG2A/HLA-E and PD-1/PD-L1 may be a 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8089 : 8093	CM	ckade of NKG2A/HLA-E and PD-1/PD-L1 may be a promising
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	8094 : 8099	CM	 of NKG2A/HLA-E and PD-1/PD-L1 may be a promising strat
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8301 : 8306	CM	 of combined blockade of NKG2A/HLA-E and PD-1/PD-L1 in 
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	8307 : 8312	CM	mbined blockade of NKG2A/HLA-E and PD-1/PD-L1 in vivo, 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8317 : 8321	CM	ckade of NKG2A/HLA-E and PD-1/PD-L1 in vivo, anti-mous
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	8322 : 8327	CM	 of NKG2A/HLA-E and PD-1/PD-L1 in vivo, anti-mouse NKG2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8337 : 8342	CPR	 and PD-1/PD-L1 in vivo, anti-mouse NKG2A and PD-1 anti
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8348 : 8353	CM	D-L1 in vivo, anti-mouse NKG2A and PD-1 antibodies were
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8358 : 8362	CM	vo, anti-mouse NKG2A and PD-1 antibodies were used in 
./___Corpus/Medline/xml/PMC5123381.xml	A20	8407 : 8410	CM	d in mice engrafted with A20 mouse B lymphoma cell li
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8446 : 8451	CM	mphoma cell line. For in vitro assays, anti-PD-L1 antib
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8460 : 8465	CPR	ne. For in vitro assays, anti-PD-L1 antibody durvalumab
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	8529 : 8533	CM	mab were tested in human PBMC staphylococcal enterotox
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8634 : 8639	CM	        When cultured in vitro, the A20 cells express l
./___Corpus/Medline/xml/PMC5123381.xml	A20	8645 : 8648	CM	n cultured in vitro, the A20 cells express ligands fo
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8675 : 8679	CM	ells express ligands for PD-1 but not for NKG2A. Expos
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8692 : 8697	CM	nds for PD-1 but not for NKG2A. Exposure to IFN-γ in vi
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	8711 : 8716	CM	t for NKG2A. Exposure to IFN-γ in vitro, or subcutaneou
./___Corpus/Medline/xml/PMC5123381.xml	vitro	8720 : 8725	CM	2A. Exposure to IFN-γ in vitro, or subcutaneous injecti
./___Corpus/Medline/xml/PMC5123381.xml	Qa-1b	8786 : 8791	CM	e, induced expression of Qa-1b, resulting in a tumor mo
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	8834 : 8839	CM	umor model co-expressing PD-L1 and Qa-1b. Monotherapy w
./___Corpus/Medline/xml/PMC5123381.xml	Qa-1b	8844 : 8849	CM	 co-expressing PD-L1 and Qa-1b. Monotherapy with PD-1 o
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8868 : 8872	CM	 Qa-1b. Monotherapy with PD-1 or NKG2A blockers result
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8876 : 8881	CM	Monotherapy with PD-1 or NKG2A blockers resulted in mod
./___Corpus/Medline/xml/PMC5123381.xml	anti-	8912 : 8917	CPR	ers resulted in moderate anti-tumor efficacy while trea
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	8968 : 8973	CM	ment with combination of NKG2A and PD-1 blockers result
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	8978 : 8982	CM	combination of NKG2A and PD-1 blockers resulted in a s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	9027 : 9032	CPR	n a significantly higher anti-tumor immunity, and an in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	9127 : 9131	CM	pletion of either NK, or CD8+ T cells, or IFN-γ was en
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	9144 : 9149	CM	 NK, or CD8+ T cells, or IFN-γ was enough to abrogate t
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	9189 : 9193	CM	abrogate the efficacy of PD-1 and NKG2A blockade, indi
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	9198 : 9203	CM	the efficacy of PD-1 and NKG2A blockade, indicating tha
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	9434 : 9438	CM	n humans, well-validated PBMC-based assays were used w
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	9659 : 9667	CM	itude of the increase in cytokine secretion was dependent 
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	9728 : 9733	CM	uction of high levels of IFN-γ. Since IFN-γ is known to
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	9741 : 9746	CM	h levels of IFN-γ. Since IFN-γ is known to induce HLA-E
./___Corpus/Medline/xml/PMC5123381.xml	HLA-E	9766 : 9771	CM	IFN-γ is known to induce HLA-E this suggests that block
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	9803 : 9808	CM	uggests that blockade of NKG2A could have a beneficial 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	9901 : 9905	CM	the combined blockade of PD-1/PD-L1.                  
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	9906 : 9911	CM	ombined blockade of PD-1/PD-L1.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	NKG2A	10007 : 10012	CM	a indicate that blocking NKG2A in conjunction with PD-1
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	10033 : 10037	CM	KG2A in conjunction with PD-1/PD-L1 checkpoint inhibit
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	10038 : 10043	CM	in conjunction with PD-1/PD-L1 checkpoint inhibitors pr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	10085 : 10090	CPR	itors provides increased anti-tumor efficacy mediated b
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	10117 : 10122	CM	mor efficacy mediated by IFN-γ and support the rational
./___Corpus/Medline/xml/PMC5123381.xml	KEYNOTE-029	10349 : 10360	CM	th ipilimumab: data from KEYNOTE-029                         
./___Corpus/Medline/xml/PMC5123381.xml	Ribas3	10444 : 10450	CM	atteo S Carlino2, Antoni Ribas3, John A Thompson4, Toni 
./___Corpus/Medline/xml/PMC5123381.xml	K	10475 : 10476	CM	, John A Thompson4, Toni K Choueiri5, F Stephen Hod
./___Corpus/Medline/xml/PMC5123381.xml	anti-	11269 : 11274	CPR	ce of treatment-emergent anti-drug antibodies (ADA) of 
./___Corpus/Medline/xml/PMC5123381.xml	ADA	11291 : 11294	CM	nt anti-drug antibodies (ADA) of < 1 %. We present da
./___Corpus/Medline/xml/PMC5123381.xml	KEYNOTE-029	11439 : 11450	CM	pilimumab in the phase I KEYNOTE-029 study.                  
./___Corpus/Medline/xml/PMC5123381.xml	KEYNOTE-029	11504 : 11515	CM	ods                      KEYNOTE-029 included 2 cohorts that 
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	11853 : 11856	CM	 plus ipilimumab 1 mg/kg Q3W followed by pembrolizuma
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	11891 : 11894	CM	by pembrolizumab 2 mg/kg Q3W for up to 2 years. Pembr
./___Corpus/Medline/xml/PMC5123381.xml	3-	12130 : 12132	CPR	noassay using a standard 3-tiered approach (drug tol
./___Corpus/Medline/xml/PMC5123381.xml	ADA	12201 : 12204	CM	g/mL) was used to detect ADA in serum.               
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	12715 : 12718	CM	or pembrolizumab 2 mg/kg Q3W given as monotherapy (Fi
./___Corpus/Medline/xml/PMC5123381.xml	ADA	12806 : 12809	CM	ma who provided postdose ADA samples, 156 (97.5 %) we
./___Corpus/Medline/xml/PMC5123381.xml	ADA	12927 : 12930	CM	e for treatment-emergent ADA. Best overall response i
./___Corpus/Medline/xml/PMC5123381.xml	ADA	13090 : 13093	CM	C had treatment-emergent ADA.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	ADA	13267 : 13270	CM	e the risk of developing ADA in patients with advance
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	13612 : 13616	CM	with T-Vec combined with BRAF inhibition and anti-PD-1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	13632 : 13637	CPR	with BRAF inhibition and anti-PD-1 in genetically engin
./___Corpus/Medline/xml/PMC5123381.xml	murine	13668 : 13674	CM	n genetically engineered murine melanoma                
./___Corpus/Medline/xml/PMC5123381.xml	Simoes2	13756 : 13763	CM	trell1, Zoe Blake1, Ines Simoes2, Yichun Fu1, Takuro Sait
./___Corpus/Medline/xml/PMC5123381.xml	Fu1	13772 : 13775	CM	e1, Ines Simoes2, Yichun Fu1, Takuro Saito3, Yingzhi 
./___Corpus/Medline/xml/PMC5123381.xml	Lu1	13811 : 13814	CM	ito3, Yingzhi Qian1, Yan Lu1, Yvonne M Saenger4      
./___Corpus/Medline/xml/PMC5123381.xml	FDA	13986 : 13989	CM	and Drug Administration (FDA) approved for the treatm
./___Corpus/Medline/xml/PMC5123381.xml	lysis	14135 : 14140	RN	s of action: direct cell lysis and immune activation. C
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	14378 : 14382	CM	ed cell death protein 1 (PD-1) on infiltrating T cells
./___Corpus/Medline/xml/PMC5123381.xml	anti-	14459 : 14464	CPR	ial synergy of T-Vec and anti-PD-1 (αPD-1).            
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	14470 : 14475	CM	 of T-Vec and anti-PD-1 (αPD-1).                  Metho
./___Corpus/Medline/xml/PMC5123381.xml	murine	14564 : 14570	CM	 and spatially regulated murine model of BRAFCA PTEN−/− 
./___Corpus/Medline/xml/PMC5123381.xml	BRAFCA	14580 : 14586	CM	egulated murine model of BRAFCA PTEN−/− spontaneous mela
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	14763 : 14767	CM	omparing combinations of BRAF inhibition (BRAFi), αPD-
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	14788 : 14793	CM	BRAF inhibition (BRAFi), αPD-1, and T–Vec (Table 1). Tu
./___Corpus/Medline/xml/PMC5123381.xml	​and4).4	15090 : 15098	CM	pare groups (Figs. 3 and ​and4).4). Mice treated with trip
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	15227 : 15232	CM	 + BRAFi with or without αPD-1 have longer survival com
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	15354 : 15358	CM	hows increase in percent CD3+/CD45+ cells in tumors of
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	15359 : 15364	CM	increase in percent CD3+/CD45+ cells in tumors of mice 
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	15414 : 15419	CM	treated with combination αPD-1 + T-Vec compared to the 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	15482 : 15486	CM	ingle drug arms. Percent CD8+/CD3+ cells in tumors tre
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	15487 : 15491	CM	 drug arms. Percent CD8+/CD3+ cells in tumors treated 
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	15639 : 15645	CM	Additionally, percent of FOXP3+/CD4+ cells in tumors app
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	15646 : 15650	CM	nally, percent of FOXP3+/CD4+ cells in tumors appears 
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	15745 : 15751	CM	g. 6) while no change in FOXP3+/CD4+ populations was obs
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	15752 : 15756	CM	hile no change in FOXP3+/CD4+ populations was observed
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	15814 : 15819	CM	rs from groups receiving αPD-1 without T-Vec or in drai
./___Corpus/Medline/xml/PMC5123381.xml	αPD-1	15979 : 15984	CM	ation therapy of BRAFi + αPD-1 + T-Vec is more effectiv
./___Corpus/Medline/xml/PMC5123381.xml	Amgen	16467 : 16472	CM	ma Research Alliance and Amgen (Amgen-CUMC-MRA Establis
./___Corpus/Medline/xml/PMC5123381.xml	Pten	16667 : 16671	CM	f(V600E) cooperates with Pten loss to induce metastati
./___Corpus/Medline/xml/PMC5123381.xml	544–	16733 : 16737	CPR	Nature Genetics 2009, 41:544–552.                     
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	16785 : 16803	CM	                    P194 Phosphatidylserine targeting antibody in co
./___Corpus/Medline/xml/PMC5123381.xml	anti-	16900 : 16905	CPR	diation therapy promotes anti-cancer activity in mouse 
./___Corpus/Medline/xml/PMC5123381.xml	De	16999 : 17001	CM	   Sadna Budhu1, Olivier De Henau1, Roberta Zappasod
./___Corpus/Medline/xml/PMC5123381.xml	Zappasodi1	17018 : 17028	CM	ivier De Henau1, Roberta Zappasodi1, Kyle Schlunegger2, Bruc
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	17186 : 17204	CM	und                      Phosphatidylserine (PS) is a phospholipid t
./___Corpus/Medline/xml/PMC5123381.xml	PS	17206 : 17208	CM	     Phosphatidylserine (PS) is a phospholipid that 
./___Corpus/Medline/xml/PMC5123381.xml	phospholipid	17215 : 17227	CM	phatidylserine (PS) is a phospholipid that is exposed on the s
./___Corpus/Medline/xml/PMC5123381.xml	PS	17319 : 17321	CM	s and tumor endothelium. PS has been shown to promot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17348 : 17353	CPR	as been shown to promote anti-inflammatory and immunosu
./___Corpus/Medline/xml/PMC5123381.xml	PS	17450 : 17452	CM	. Antibodies that target PS have been shown to react
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17483 : 17488	CPR	been shown to reactivate anti-tumor immunity by repolar
./___Corpus/Medline/xml/PMC5123381.xml	M1	17553 : 17555	CM	ociated macrophages to a M1-like phenotype, reducing
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	17595 : 17600	CM	, reducing the number of MDSCs in tumors and promote th
./___Corpus/Medline/xml/PMC5123381.xml	APCs	17673 : 17677	CM	ic cells into functional APCs. In a B16 melanoma model
./___Corpus/Medline/xml/PMC5123381.xml	B16	17684 : 17687	CM	to functional APCs. In a B16 melanoma model, targetin
./___Corpus/Medline/xml/PMC5123381.xml	PS	17714 : 17716	CM	elanoma model, targeting PS in combination with immu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	17811 : 17816	CPR	 a significantly greater anti-cancer effect than either
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	17893 : 17897	CM	ion was shown to enhance CD4+ and CD8+ T cell infiltra
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	17902 : 17906	CM	hown to enhance CD4+ and CD8+ T cell infiltration and 
./___Corpus/Medline/xml/PMC5123381.xml	PS	18642 : 18644	CM	an antibody that targets PS (1 N11) and an immune ch
./___Corpus/Medline/xml/PMC5123381.xml	anti-	18688 : 18693	CPR	une checkpoint blockade (anti-PD-1) using the mouse B16
./___Corpus/Medline/xml/PMC5123381.xml	B16	18715 : 18718	CM	ti-PD-1) using the mouse B16 melanoma model. Tumor su
./___Corpus/Medline/xml/PMC5123381.xml	PS	18912 : 18914	CM	amined the expression of PS on immune cells infiltra
./___Corpus/Medline/xml/PMC5123381.xml	B16	18944 : 18947	CM	mmune cells infiltrating B16 melanomas. CD11b + myelo
./___Corpus/Medline/xml/PMC5123381.xml	PS	19013 : 19015	CM	ed the highest levels of PS on their surface whereas
./___Corpus/Medline/xml/PMC5123381.xml	B16	19053 : 19056	CM	face whereas T cells and B16 tumor cells express litt
./___Corpus/Medline/xml/PMC5123381.xml	PS	19090 : 19092	CM	lls express little to no PS. These data suggest that
./___Corpus/Medline/xml/PMC5123381.xml	PS	19128 : 19130	CM	a suggest that targeting PS in B16 melanoma would in
./___Corpus/Medline/xml/PMC5123381.xml	B16	19134 : 19137	CM	est that targeting PS in B16 melanoma would induce a 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19504 : 19509	CPR	ody synergizes with both anti-PD-1 and radiation therap
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19547 : 19552	CPR	ation therapy to improve anti-cancer activity and overa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19676 : 19681	CPR	ody, tumor radiation and anti-PD-1 treatment displayed 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	19719 : 19724	CPR	t displayed even greater anti-cancer and survival benef
./___Corpus/Medline/xml/PMC5123381.xml	PS	19990 : 19992	CM	ure clinical trials with PS targeting in melanoma an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20089 : 20094	CPR	        P195 A novel anti-human LAG-3 antibody in combi
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	20096 : 20101	CM	 P195 A novel anti-human LAG-3 antibody in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20135 : 20140	CPR	 in combination with anti-human PD-1 (REGN2810) shows e
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	20142 : 20146	CM	bination with anti-human PD-1 (REGN2810) shows enhance
./___Corpus/Medline/xml/PMC5123381.xml	REGN2810	20148 : 20156	CM	on with anti-human PD-1 (REGN2810) shows enhanced anti-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	20173 : 20178	CPR	REGN2810) shows enhanced anti-tumor activity in PD-1 x 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	20196 : 20200	CM	d anti-tumor activity in PD-1 x LAG-3 dual-humanized m
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	20203 : 20208	CM	tumor activity in PD-1 x LAG-3 dual-humanized mice and 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	20800 : 20804	CM	 one of these receptors, PD-1, yield positive response
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21053 : 21057	CM	ncept, mice deficient in PD-1 and LAG-3, an inhibitory
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	21062 : 21067	CM	ce deficient in PD-1 and LAG-3, an inhibitory checkpoin
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21127 : 21131	CM	 often co-expressed with PD-1 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21180 : 21185	CPR	onment, exhibit enhanced anti-tumor activity. Here, we 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21232 : 21237	CPR	we demonstrate increased anti-tumor efficacy of a combi
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21266 : 21271	CPR	r efficacy of a combined anti–human PD-1 (hPD-1) and an
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21277 : 21281	CM	of a combined anti–human PD-1 (hPD-1) and anti–human L
./___Corpus/Medline/xml/PMC5123381.xml	hPD-1	21283 : 21288	CM	ombined anti–human PD-1 (hPD-1) and anti–human LAG-3 (h
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21294 : 21299	CPR	i–human PD-1 (hPD-1) and anti–human LAG-3 (hLAG-3) ther
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	21305 : 21310	CM	1 (hPD-1) and anti–human LAG-3 (hLAG-3) therapy using f
./___Corpus/Medline/xml/PMC5123381.xml	hLAG-3	21312 : 21318	CM	1) and anti–human LAG-3 (hLAG-3) therapy using fully hum
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21386 : 21390	CM	bodies in dual humanized PD-1 x LAG-3 mice. The pharma
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	21393 : 21398	CM	in dual humanized PD-1 x LAG-3 mice. The pharmacokineti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21454 : 21459	CPR	 toxicology of the novel anti-hLAG-3 antibody were asse
./___Corpus/Medline/xml/PMC5123381.xml	anti-	21616 : 21621	CPR	EGN2810, a high affinity anti-hPD-1 monoclonal antibody
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21659 : 21663	CM	nal antibody that blocks PD-1 interaction with PD-L1 a
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	21681 : 21686	CM	ks PD-1 interaction with PD-L1 and PD-L2, and a novel h
./___Corpus/Medline/xml/PMC5123381.xml	PD-L2	21691 : 21696	CM	teraction with PD-L1 and PD-L2, and a novel high affini
./___Corpus/Medline/xml/PMC5123381.xml	anti–	21735 : 21740	CPR	high affinity monoclonal anti–hLAG-3 antibody, which bl
./___Corpus/Medline/xml/PMC5123381.xml	hLAG-3	21740 : 21746	CM	affinity monoclonal anti–hLAG-3 antibody, which blocks t
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	21774 : 21779	CM	tibody, which blocks the LAG-3/MHC II interaction were 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	21780 : 21783	CM	, which blocks the LAG-3/MHC II interaction were gene
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	21830 : 21834	CM	enerated. Dual humanized PD-1 x LAG-3 mice were engine
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	21837 : 21842	CM	d. Dual humanized PD-1 x LAG-3 mice were engineered by 
./___Corpus/Medline/xml/PMC5123381.xml	Pdcd1	21912 : 21917	CM	ellular domains of mouse Pdcd1 and Lag3 with the corres
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	21922 : 21926	CM	mains of mouse Pdcd1 and Lag3 with the corresponding r
./___Corpus/Medline/xml/PMC5123381.xml	hPD-1	21961 : 21966	CM	corresponding regions of hPD-1 and hLAG-3 and were used
./___Corpus/Medline/xml/PMC5123381.xml	hLAG-3	21971 : 21977	CM	ing regions of hPD-1 and hLAG-3 and were used for testin
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	22083 : 22087	CM	 Expression of humanized PD-1 and LAG-3 were analyzed 
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	22092 : 22097	CM	on of humanized PD-1 and LAG-3 were analyzed by flow cy
./___Corpus/Medline/xml/PMC5123381.xml	hLAG-3	22142 : 22148	CM	ow cytometry. Binding of hLAG-3 to mouse MHC II was conf
./___Corpus/Medline/xml/PMC5123381.xml	MHC	22158 : 22161	CM	nding of hLAG-3 to mouse MHC II was confirmed with a 
./___Corpus/Medline/xml/PMC5123381.xml	hPD-1	22222 : 22227	CM	on assay, and binding of hPD-1 to mouse PD-L1 was confi
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	22237 : 22242	CM	inding of hPD-1 to mouse PD-L1 was confirmed using surf
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22314 : 22319	CPR	 The pharmacokinetics of anti-hLAG-3 antibody following
./___Corpus/Medline/xml/PMC5123381.xml	4-	22393 : 22395	CPR	 the safety profile in a 4-week weekly i.v. dose reg
./___Corpus/Medline/xml/PMC5123381.xml	i.v	22407 : 22410	CM	ofile in a 4-week weekly i.v. dose regimen of up to 5
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22607 : 22612	CPR	ce with a combination of anti-hPD-1 and anti-hLAG-3 ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22622 : 22627	CPR	nation of anti-hPD-1 and anti-hLAG-3 antibodies trigger
./___Corpus/Medline/xml/PMC5123381.xml	anti-	22783 : 22788	CPR	additive, dose dependent anti-tumor effect compared to 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23057 : 23062	CPR	ation phase. Exposure to anti-hLAG-3 increased in a dos
./___Corpus/Medline/xml/PMC5123381.xml	NOAEL	23249 : 23254	CM	ed-adverse-effect level (NOAEL) could be established up
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23355 : 23360	CPR	             Preclinical anti-tumor efficacy of combine
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23400 : 23405	CPR	of combined REGN2810 and anti-hLAG-3 antibody treatment
./___Corpus/Medline/xml/PMC5123381.xml	anti-	23492 : 23497	CPR	etic and safety data for anti-hLAG-3 antibody in cynomo
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	23665 : 23670	CM	     P196 Combination of PD-L1 blockade with oncolytic 
./___Corpus/Medline/xml/PMC5123381.xml	Carpi3	23851 : 23857	CM	Federica Frascaro2, Sara Carpi3, Siri Tähtinen1, Sara Fe
./___Corpus/Medline/xml/PMC5123381.xml	Erkko	24007 : 24012	CM	i Ranki5, Lukasz Kyruk1, Erkko Ylösmäki1, Vincenzo Ceru
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	24213 : 24217	CM	nancies. The blockade of PD-1 or CTLA-4 receptors repr
./___Corpus/Medline/xml/PMC5123381.xml	milestone	24252 : 24261	CM	 receptors represented a milestone in the history of immuno
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	24526 : 24531	CM	d that disruption of the PD-L1/PD-1 axis would synergiz
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	24532 : 24536	CM	 disruption of the PD-L1/PD-1 axis would synergize wit
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	24577 : 24584	CM	rgize with our oncolytic vaccine platform PeptiCRAd.     
./___Corpus/Medline/xml/PMC5123381.xml	murine	24659 : 24665	CM	                 We used murine B16OVA in vivo tumor mod
./___Corpus/Medline/xml/PMC5123381.xml	B16OVA	24666 : 24672	CM	          We used murine B16OVA in vivo tumor models and
./___Corpus/Medline/xml/PMC5123381.xml	B16OVA	24846 : 24852	CM	e found that high-burden B16OVA tumors were refractory t
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	25033 : 25038	CM	ination of PeptiCRAd and PD-L1 blockade. The therapy si
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	25185 : 25191	CM	contralaterally injected B16F10 cells suggested the pres
./___Corpus/Medline/xml/PMC5123381.xml	PD-1pos	25452 : 25459	CM	percentage of activated (PD-1pos TIM-3neg) T lymphocytes 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1pos	25520 : 25527	CM	the amount of exhausted (PD-1pos TIM-3pos) cells compared
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	25660 : 25664	CM	mber of antigen specific CD8+ T cells compared to othe
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	25738 : 25743	CM	nly the combination with PD-L1 blockade could significa
./___Corpus/Medline/xml/PMC5123381.xml	pentamer	25824 : 25832	CM	 activated and exhausted pentamer positive cells (p = 0.00
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	25896 : 25900	CM	g that by disrupting the PD-1/PD-L1 axis we could decr
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	25901 : 25906	CM	t by disrupting the PD-1/PD-L1 axis we could decrease t
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26056 : 26060	CM	 influenced the state of CD4+ and CD8+ T lymphocytes. 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26065 : 26069	CM	ed the state of CD4+ and CD8+ T lymphocytes. In fact, 
./___Corpus/Medline/xml/PMC5123381.xml	TIM-3	26094 : 26099	CM	 T lymphocytes. In fact, TIM-3 expression was increased
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26192 : 26196	CM	lymphoid T cells. In the CD8+ compartment, the express
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	26228 : 26232	CM	tment, the expression of PD-1 on the surface seemed to
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26310 : 26314	CM	micro-environment, while CD4+ T cells had a high expre
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	26348 : 26352	CM	had a high expression of PD-1 also in lymphoid organs.
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	26421 : 26425	CM	found that the levels of PD-1 were significantly highe
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	26455 : 26459	CM	 significantly higher on CD8+ T cells than on CD4+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	26476 : 26480	CM	 on CD8+ T cells than on CD4+ T cells into the tumor m
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	26810 : 26815	CM	gen-specific T cells and PD-L1 blockade prevented their
./___Corpus/Medline/xml/PMC5123381.xml	vitro	26977 : 26982	CM	                 P197 In vitro evaluation of immunother
./___Corpus/Medline/xml/PMC5123381.xml	Xi	27174 : 27176	CM	   Fabio Cerignoli, Biao Xi, Garret Guenther, Naiche
./___Corpus/Medline/xml/PMC5123381.xml	Yu	27203 : 27205	CM	Garret Guenther, Naichen Yu, Lincoln Muir, Leyna Zha
./___Corpus/Medline/xml/PMC5123381.xml	vitro	27280 : 27285	CM	                      In vitro characterization of reag
./___Corpus/Medline/xml/PMC5123381.xml	vitro	27470 : 27475	CM	ies. However, current in vitro assays like Chromium-51,
./___Corpus/Medline/xml/PMC5123381.xml	Chromium-51	27488 : 27499	CM	ent in vitro assays like Chromium-51, ATP-based luminescence 
./___Corpus/Medline/xml/PMC5123381.xml	ATP	27501 : 27504	CM	assays like Chromium-51, ATP-based luminescence or fl
./___Corpus/Medline/xml/PMC5123381.xml	384-	28061 : 28065	CPR	rodes embedded in 96 and 384-wells cell culture plates
./___Corpus/Medline/xml/PMC5123381.xml	vitro	28190 : 28195	CM	rimary tumor cells as in vitro models for immunotherapy
./___Corpus/Medline/xml/PMC5123381.xml	96-	28282 : 28285	CPR	lls on electrodes coated 96-well plates and monitored
./___Corpus/Medline/xml/PMC5123381.xml	BiTEs	28451 : 28456	CM	et ratios in presence of BiTEs antibodies and/or anti P
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	28480 : 28484	CM	s antibodies and/or anti PD-1/PD-L1 antibodies. Impeda
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	28485 : 28490	CM	ibodies and/or anti PD-1/PD-L1 antibodies. Impedance si
./___Corpus/Medline/xml/PMC5123381.xml	anti-	28819 : 28824	CPR	wells are coated with an anti-CD40 antibody. The coatin
./___Corpus/Medline/xml/PMC5123381.xml	EpCAM	29060 : 29065	CM	easing concentrations of EpCAM/CD3 BiTE, we demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	CD3	29066 : 29069	CM	 concentrations of EpCAM/CD3 BiTE, we demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	BiTE	29070 : 29074	CM	centrations of EpCAM/CD3 BiTE, we demonstrated the sui
./___Corpus/Medline/xml/PMC5123381.xml	CAR-T	29446 : 29451	CM	obtained with engineered CAR-T cells against CD19 or NK
./___Corpus/Medline/xml/PMC5123381.xml	CD19	29466 : 29470	CM	ered CAR-T cells against CD19 or NK cell lines, demons
./___Corpus/Medline/xml/PMC5123381.xml	384-	29935 : 29939	CPR	ore, the availability of 384-well format and minimal s
./___Corpus/Medline/xml/PMC5123381.xml	alpha	30229 : 30234	CM	98 Tumor necrosis factor alpha and interleukin-2 expres
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	30280 : 30284	CM	pressing adenovirus plus PD-1 blockade as a boost for 
./___Corpus/Medline/xml/PMC5123381.xml	João	30445 : 30449	CM	rascón1, Mikko Siurala1, João Santos1, Riikka Havunen2
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	31120 : 31124	CM	tumor necrosis factor α (TNFα) and interleukin (IL)-2,
./___Corpus/Medline/xml/PMC5123381.xml	(IL)-2	31142 : 31148	CM	α (TNFα) and interleukin (IL)-2, two cytokines that will
./___Corpus/Medline/xml/PMC5123381.xml	anti-	31277 : 31282	CPR	e other hand, the use of anti-PD-1 will avoid exhaustio
./___Corpus/Medline/xml/PMC5123381.xml	B16-OVA	31588 : 31595	CM	vo model of subcutaneous B16-OVA melanoma-bearing mice. T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	31938 : 31943	CPR	 also optimize viral and anti-PD-1 administration regim
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	33173 : 33177	CM	 modified adenovirus and PD-1 blockade is an efficient
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	33309 : 33316	CM	                    P199 IMM-101 primes for increased com
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	33512 : 33519	CM	und                      IMM-101, a heat-killed borate-bu
./___Corpus/Medline/xml/PMC5123381.xml	borate	33535 : 33541	CM	  IMM-101, a heat-killed borate-buffered whole cell prod
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	33573 : 33586	CM	ed whole cell product of Mycobacterium obuense has been shown t
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	33635 : 33643	CM	to enhance cell mediated cytokine responses and innate imm
./___Corpus/Medline/xml/PMC5123381.xml	5-	33857 : 33859	CPR	ion [2] has shown a 30 % 5-year survival. Combined w
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	33888 : 33899	CM	 survival. Combined with gemcitabine in metastatic pancreatic
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	33970 : 33981	CM	 survival advantage over gemcitabine monotherapy is seen [3].
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	34145 : 34152	CM	itial stabilisation with IMM-101, who showed CR after che
./___Corpus/Medline/xml/PMC5123381.xml	CPI	34198 : 34201	CM	 check point inhibitors (CPI) ipilimumab (n = 2), pem
./___Corpus/Medline/xml/PMC5123381.xml	BT	34290 : 34292	CM	M melanoma left forearm, BT 3.7 mm, 1 positive lymph
./___Corpus/Medline/xml/PMC5123381.xml	Aldara	34364 : 34370	CM	se treated with surgery, Aldara and low dose IL-2. 2010 
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	34421 : 34428	CM	ulmonary mets, commenced IMM-101, no response (initial SD
./___Corpus/Medline/xml/PMC5123381.xml	SD	34451 : 34453	CM	01, no response (initial SD). 2011 given Ipilimumab.
./___Corpus/Medline/xml/PMC5123381.xml	decarbazine	34627 : 34638	CM	posits. Gastric surgery, decarbazine. Commenced IMM-101 with 
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	34650 : 34657	CM	, decarbazine. Commenced IMM-101 with cyberknife to lung 
./___Corpus/Medline/xml/PMC5123381.xml	BT	34800 : 34802	CM	 M melanoma, left cheek, BT 2.4 mm. Regional lymph n
./___Corpus/Medline/xml/PMC5123381.xml	April	34882 : 34887	CM	 left neck dissection in April 2014. Developed paracard
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	34989 : 34996	CM	eous deposits. Commenced IMM-101 with initial shrinkage. 
./___Corpus/Medline/xml/PMC5123381.xml	CT	35155 : 35157	CM	   Patient 1 - CR on Pet CT, maintained through 2016
./___Corpus/Medline/xml/PMC5123381.xml	CPI’s	35361 : 35366	CM	          The CR rate to CPI’s is disappointing, < 1 % 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	35442 : 35446	CM	ession is predictive for PD-1 responses and although C
./___Corpus/Medline/xml/PMC5123381.xml	CPI	35470 : 35473	CM	1 responses and although CPI combinations are clearly
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	35528 : 35535	CM	ed, most are very toxic. IMM-101 is relatively free of to
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	35577 : 35581	CM	ee of toxicity, enhances PD-1 expression in pre-clinic
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	35762 : 35769	CM	tions, we speculate that IMM-101 primes for CPI’s and pro
./___Corpus/Medline/xml/PMC5123381.xml	CPI’s	35781 : 35786	CM	 that IMM-101 primes for CPI’s and propose a trial prim
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	35820 : 35827	CM	ose a trial priming with IMM-101, followed by anti-PD-1 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	35841 : 35846	CPR	ith IMM-101, followed by anti-PD-1 antibodies.         
./___Corpus/Medline/xml/PMC5123381.xml	anti-	35965 : 35970	CPR	teria activate γδ T-cell anti-tumour responses via cyto
./___Corpus/Medline/xml/PMC5123381.xml	535–	36103 : 36107	CPR	herapy. CeII 2012, 61(4):535–547.                     
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	36278 : 36285	CM	erability of intradermal IMM-101 in melanoma. Ann Oncol 2
./___Corpus/Medline/xml/PMC5123381.xml	1314–	36321 : 36326	CPR	a. Ann Oncol 2012, 23(5):1314–1319.                    
./___Corpus/Medline/xml/PMC5123381.xml	Gemcitabine	36433 : 36444	CM	label, phase II study of Gemcitabine with and without IMM-101
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	36462 : 36469	CM	itabine with and without IMM-101 for advanced pancreatic 
./___Corpus/Medline/xml/PMC5123381.xml	W	36780 : 36781	CM	Alicia Gamble, Elizabeth W Grogan, John Krisko, Iri
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	36890 : 36897	CM	und                      AGS-003 is an individualized, au
./___Corpus/Medline/xml/PMC5123381.xml	DC	36970 : 36972	CM	-loaded, dendritic cell (DC) immunotherapy currently
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	37135 : 37139	CM	d-of-care. Antibodies to PD-1 on activated T cells or 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	37164 : 37169	CM	 on activated T cells or PD-L1 expressed on APCs have n
./___Corpus/Medline/xml/PMC5123381.xml	APCs	37183 : 37187	CM	ls or PD-L1 expressed on APCs have now been approved f
./___Corpus/Medline/xml/PMC5123381.xml	DC	37477 : 37479	CM	s are limited. Since the DC-based immunotherapy, AGS
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	37501 : 37508	CM	 DC-based immunotherapy, AGS-003, expresses high levels o
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	37535 : 37540	CM	expresses high levels of PD-L1, combinations with check
./___Corpus/Medline/xml/PMC5123381.xml	DCs	37620 : 37623	CM	itical signal protecting DCs during the early CTL act
./___Corpus/Medline/xml/PMC5123381.xml	CTL	37641 : 37644	CM	ing DCs during the early CTL activation phase in vivo
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	37727 : 37734	CM	eckpoint inhibitors with AGS-003 may, therefore, impede t
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	37794 : 37801	CM	d mechanism of action of AGS-003, which is the induction 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	37844 : 37847	CM	uction of tumor-specific CTL responses. Results deriv
./___Corpus/Medline/xml/PMC5123381.xml	vitro	37883 : 37888	CM	 Results derived from in vitro modeling of DCs inducing
./___Corpus/Medline/xml/PMC5123381.xml	DCs	37901 : 37904	CM	rom in vitro modeling of DCs inducing T cell response
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38083 : 38088	CPR	 was of interest to test anti-PD-1/anti-PD-L1 antibody 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38093 : 38098	CPR	terest to test anti-PD-1/anti-PD-L1 antibody therapy in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	38124 : 38129	CM	D-L1 antibody therapy in vitro in combination with DCs 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38150 : 38153	CM	itro in combination with DCs representative of AGS-00
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	38172 : 38179	CM	th DCs representative of AGS-003, to observe the effects 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	38255 : 38258	CM	have on antigen-specific CTL proliferation and functi
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38345 : 38348	CM	ods                      DCs derived from monocytes w
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	38400 : 38406	CM	e co-electroporated with MART-1 RNA and CD40 ligand RNA 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	38407 : 38410	CM	ectroporated with MART-1 RNA and CD40 ligand RNA to r
./___Corpus/Medline/xml/PMC5123381.xml	CD40	38415 : 38419	CM	ated with MART-1 RNA and CD40 ligand RNA to represent 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	38427 : 38430	CM	RT-1 RNA and CD40 ligand RNA to represent AGS-003 DC 
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	38444 : 38451	CM	 ligand RNA to represent AGS-003 DC products. In vitro co
./___Corpus/Medline/xml/PMC5123381.xml	DC	38452 : 38454	CM	RNA to represent AGS-003 DC products. In vitro co-cu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	38468 : 38473	CM	 AGS-003 DC products. In vitro co-cultures were set up 
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	38514 : 38518	CM	e set up with autologous CTLs and MART-1/CD40L DCs in 
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	38523 : 38529	CM	with autologous CTLs and MART-1/CD40L DCs in the presenc
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	38530 : 38535	CM	tologous CTLs and MART-1/CD40L DCs in the presence of a
./___Corpus/Medline/xml/PMC5123381.xml	DCs	38536 : 38539	CM	us CTLs and MART-1/CD40L DCs in the presence of anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38559 : 38564	CPR	L DCs in the presence of anti-PD-1 or anti-PD-L1 antibo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38572 : 38577	CPR	presence of anti-PD-1 or anti-PD-L1 antibodies. In some
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	38614 : 38618	CM	dies. In some instances, PD-1 expression was hyper exp
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	38692 : 38696	CM	oporating MART-1-specfic CTLs with PD-1 RNA. Subsequen
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	38702 : 38706	CM	MART-1-specfic CTLs with PD-1 RNA. Subsequent expansio
./___Corpus/Medline/xml/PMC5123381.xml	RNA	38707 : 38710	CM	1-specfic CTLs with PD-1 RNA. Subsequent expansion of
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	38736 : 38742	CM	 Subsequent expansion of MART-1-specific CTLs and multi-
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	38752 : 38756	CM	nsion of MART-1-specific CTLs and multi-functional res
./___Corpus/Medline/xml/PMC5123381.xml	anti-	38936 : 38941	CPR	        Combination with anti-PD-1 antibody did not did
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	39006 : 39012	CM	 affect the expansion of MART-1-specific CTL responses; 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	39022 : 39025	CM	nsion of MART-1-specific CTL responses; however, if P
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	39049 : 39053	CM	L responses; however, if PD-1 was hyper-expressed on p
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	39099 : 39105	CM	on previously stimulated MART-1-specific CTLs responses 
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	39115 : 39119	CM	imulated MART-1-specific CTLs responses were diminishe
./___Corpus/Medline/xml/PMC5123381.xml	CTL	39184 : 39187	CM	tibody blocking restored CTL function in the presence
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	39231 : 39235	CM	esence of high levels of PD-1 expression. Interestingl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	39263 : 39268	CPR	pression. Interestingly, anti-PD-L1 antibody blocking r
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	39325 : 39331	CM	 in suppression of early MART-1-specific CTL expansion a
./___Corpus/Medline/xml/PMC5123381.xml	CTL	39341 : 39344	CM	of early MART-1-specific CTL expansion and subsequent
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	39493 : 39500	CM	t that the sequencing of AGS-003 therapy and checkpoint b
./___Corpus/Medline/xml/PMC5123381.xml	CTL	39560 : 39563	CM	 important to allow full CTL activation by the DCs pr
./___Corpus/Medline/xml/PMC5123381.xml	DCs	39582 : 39585	CM	ll CTL activation by the DCs prior to anti-PD-1/PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	39595 : 39600	CPR	tion by the DCs prior to anti-PD-1/PD-L1 therapy. Moreo
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	39605 : 39610	CM	e DCs prior to anti-PD-1/PD-L1 therapy. Moreover the hi
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	39652 : 39657	CM	r the high expression of PD-L1 on DCs may serve as a “d
./___Corpus/Medline/xml/PMC5123381.xml	DCs	39661 : 39664	CM	h expression of PD-L1 on DCs may serve as a “don’t ki
./___Corpus/Medline/xml/PMC5123381.xml	DC	39751 : 39753	CM	 prevent deletion of the DC prior to full signal del
./___Corpus/Medline/xml/PMC5123381.xml	CTL	39807 : 39810	CM	y during early phases of CTL activation.             
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	39859 : 39863	CM	      P201 Targeting the PD-1/PD-L1 signaling pathway 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	39864 : 39869	CM	 P201 Targeting the PD-1/PD-L1 signaling pathway for th
./___Corpus/Medline/xml/PMC5123381.xml	Yu	39948 : 39950	CM	asis Pooja Dhupkar, Ling Yu, Eugenie S Kleinerman, N
./___Corpus/Medline/xml/PMC5123381.xml	5-	40161 : 40163	CPR	emotherapy advances, the 5-year survival of pulmonar
./___Corpus/Medline/xml/PMC5123381.xml	25-	40212 : 40215	CPR	ry metastatic OS remains 25-30 %. Immunotherapy is on
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	40385 : 40389	CM	etermine if blocking the PD-1/PD-L1 immunosuppressive 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	40390 : 40395	CM	ine if blocking the PD-1/PD-L1 immunosuppressive signal
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	40440 : 40444	CM	ignaling pathway using a PD-1 checkpoint inhibitor wil
./___Corpus/Medline/xml/PMC5123381.xml	anti-	40523 : 40528	CPR	etastasis. Anti-PD-1 and anti-PD-L1 antibodies have exh
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	40666 : 40670	CM	e that disruption of the PD-1/PD-L1 signaling pathway 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	40671 : 40676	CM	t disruption of the PD-1/PD-L1 signaling pathway using 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	40701 : 40706	CPR	 signaling pathway using anti-PD-1 antibody has an effe
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	40895 : 40900	CM	ing were used to analyze PD-L1 expression in 7 differen
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	41000 : 41005	CM	is was used to determine PD-L1 expression in OS lung me
./___Corpus/Medline/xml/PMC5123381.xml	murine	41128 : 41134	CM	t the effect of blocking murine PD-1 in OS lung metastas
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	41135 : 41139	CM	ffect of blocking murine PD-1 in OS lung metastases. T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	41185 : 41190	CPR	s. Therapeutic effect of anti-PD-1 treatment was measur
./___Corpus/Medline/xml/PMC5123381.xml	Ki-67	41307 : 41312	CM	sure cell proliferation (Ki-67), apoptosis (TUNEL) and 
./___Corpus/Medline/xml/PMC5123381.xml	TUNEL	41326 : 41331	CM	tion (Ki-67), apoptosis (TUNEL) and cleaved-caspase 3 e
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	41516 : 41523	CM	ignaling pathway such as p-Stat3 and p-Erk1/2. The Simple
./___Corpus/Medline/xml/PMC5123381.xml	p-Erk1	41528 : 41534	CM	hway such as p-Stat3 and p-Erk1/2. The Simple PCI softwa
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	41682 : 41687	CM	vealed surface and total PD-L1 expression in five out o
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	41840 : 41845	CM	mbranous and cytoplasmic PD-L1 expression. Using a huma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	41925 : 41930	CPR	ed therapeutic effect of anti-PD-1 therapy as the numbe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42004 : 42009	CPR	astases decreased in the anti-PD-1 treated group as com
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42276 : 42281	CPR	metastases. In addition, anti-PD-1 therapy caused a dec
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	42315 : 42320	CM	apy caused a decrease in PD-L1 expression in the lung t
./___Corpus/Medline/xml/PMC5123381.xml	p-ERK1	42382 : 42388	CM	bly due to a decrease in p-ERK1/2 and p-Stat3 expression
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	42395 : 42402	CM	decrease in p-ERK1/2 and p-Stat3 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	42496 : 42500	CM	clude that targeting the PD-1/PD-L1 axis could be used
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	42501 : 42506	CM	 that targeting the PD-1/PD-L1 axis could be used to tr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42579 : 42584	CPR	 Therapeutic efficacy of anti-PD-1 may be due to an inc
./___Corpus/Medline/xml/PMC5123381.xml	p-Stat3	42702 : 42709	CM	d that inhibition of the p-Stat3/PD-L1 pathway may be the
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	42710 : 42715	CM	nhibition of the p-Stat3/PD-L1 pathway may be the mecha
./___Corpus/Medline/xml/PMC5123381.xml	anti-	42784 : 42789	CPR	OS lung metastases after anti-PD-1 treatment.          
./___Corpus/Medline/xml/PMC5123381.xml	I-HDAC	42868 : 42874	CM	P202 Effect of the class I-HDAC inhibitor entinostat and
./___Corpus/Medline/xml/PMC5123381.xml	histone	43496 : 43503	CM	 Epigenetic therapy with histone deacetylase (HDAC) inhib
./___Corpus/Medline/xml/PMC5123381.xml	deacetylase	43504 : 43515	CM	tic therapy with histone deacetylase (HDAC) inhibitors has sh
./___Corpus/Medline/xml/PMC5123381.xml	I-HDAC	43722 : 43728	CM	y. Entinostat is a class I-HDAC inhibitor undergoing tri
./___Corpus/Medline/xml/PMC5123381.xml	vitro	44293 : 44298	CM	 (n = 7) were exposed in vitro for 48 hours to clinical
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	44392 : 44397	CM	tat, or vehicle control. PBMCs were then analyzed by mu
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	44544 : 44548	CM	ed 9 classic cell types [CD4+ and CD8+ T cells, regula
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	44553 : 44557	CM	sic cell types [CD4+ and CD8+ T cells, regulatory T ce
./___Corpus/Medline/xml/PMC5123381.xml	pDC	44669 : 44672	CM	acytoid dendritic cells (pDC), natural killer cells (
./___Corpus/Medline/xml/PMC5123381.xml	NKT	44726 : 44729	CM	 natural killer T cells (NKT), and myeloid derived su
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	44770 : 44774	CM	erived suppressor cells (MDSC)], and 114 refined subse
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	45104 : 45108	CM	e frequency of activated CD4+ T cells, activated matur
./___Corpus/Medline/xml/PMC5123381.xml	cDCs	45171 : 45175	CM	ntigen presenting cells (cDCs), and highly immature MD
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	45198 : 45203	CM	Cs), and highly immature MDSCs, as well as decreased to
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	45388 : 45392	CM	e frequency of activated CD4+ T cells, highly immature
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	45418 : 45423	CM	T cells, highly immature MDSCs, and NKT cells.         
./___Corpus/Medline/xml/PMC5123381.xml	NKT	45429 : 45432	CM	ghly immature MDSCs, and NKT cells.                  
./___Corpus/Medline/xml/PMC5123381.xml	4D	45961 : 45963	CM	y blockade of semaphorin 4D to facilitate immune-med
./___Corpus/Medline/xml/PMC5123381.xml	Foster1	46156 : 46163	CM	 Maria Scrivens1, Cathie Foster1, Alan Howell1, Leslie Ba
./___Corpus/Medline/xml/PMC5123381.xml	Balch1	46186 : 46192	CM	r1, Alan Howell1, Leslie Balch1, Alyssa Knapp1, John E L
./___Corpus/Medline/xml/PMC5123381.xml	Paris1	46231 : 46237	CM	1, John E Leonard1, Mark Paris1, Terry Fisher1, Siwen Hu
./___Corpus/Medline/xml/PMC5123381.xml	Fisher1	46245 : 46252	CM	ard1, Mark Paris1, Terry Fisher1, Siwen Hu-Lieskovan2, An
./___Corpus/Medline/xml/PMC5123381.xml	Ribas2	46282 : 46288	CM	en Hu-Lieskovan2, Antoni Ribas2, Ernest Smith1, Maurice 
./___Corpus/Medline/xml/PMC5123381.xml	4D	46410 : 46412	CM	ovel role for semaphorin 4D (SEMA4D, CD100) in modul
./___Corpus/Medline/xml/PMC5123381.xml	SEMA4D	46414 : 46420	CM	 role for semaphorin 4D (SEMA4D, CD100) in modulating th
./___Corpus/Medline/xml/PMC5123381.xml	CD100	46422 : 46427	CM	r semaphorin 4D (SEMA4D, CD100) in modulating the tumor
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	46620 : 46624	CM	ade reduces expansion of MDSC, shifts the balance of M
./___Corpus/Medline/xml/PMC5123381.xml	M1	46648 : 46650	CM	C, shifts the balance of M1/M2, T effector/T regulat
./___Corpus/Medline/xml/PMC5123381.xml	M2	46651 : 46653	CM	shifts the balance of M1/M2, T effector/T regulatory
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	47033 : 47041	CM	, functional assays, and cytokine, chemokine and gene expr
./___Corpus/Medline/xml/PMC5123381.xml	VX15	47181 : 47185	CM	I trial for single agent VX15/2503 was completed.     
./___Corpus/Medline/xml/PMC5123381.xml	SEMA4D	47252 : 47258	CM	lts                      SEMA4D restricts migration of m
./___Corpus/Medline/xml/PMC5123381.xml	vitro	47349 : 47354	CM	ressive myeloid cells in vitro. Strong expression of SE
./___Corpus/Medline/xml/PMC5123381.xml	SEMA4D	47377 : 47383	CM	ro. Strong expression of SEMA4D at the invasive margins 
./___Corpus/Medline/xml/PMC5123381.xml	APCs	47574 : 47578	CM	recruitment of activated APCs and T lymphocytes into t
./___Corpus/Medline/xml/PMC5123381.xml	Th1	47775 : 47778	CM	 shift towards increased Th1 cytokines and CTL-recrui
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	47856 : 47860	CM	rent reduction in Treg-, MDSC-, and M2-macrophage prom
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	47903 : 47907	CM	ge promoting chemokines (CCL2, CXCL1, CXCL5). Accordin
./___Corpus/Medline/xml/PMC5123381.xml	CXCL1	47909 : 47914	CM	moting chemokines (CCL2, CXCL1, CXCL5). Accordingly, an
./___Corpus/Medline/xml/PMC5123381.xml	CXCL5	47916 : 47921	CM	chemokines (CCL2, CXCL1, CXCL5). Accordingly, an increa
./___Corpus/Medline/xml/PMC5123381.xml	Teff	47952 : 47956	CM	ordingly, an increase in Teff:Treg ratio (3x, p < 0.00
./___Corpus/Medline/xml/PMC5123381.xml	3x	47969 : 47971	CM	ease in Teff:Treg ratio (3x, p < 0.005) and CTL acti
./___Corpus/Medline/xml/PMC5123381.xml	CTL	47988 : 47991	CM	atio (3x, p < 0.005) and CTL activity (4x, p < 0.0001
./___Corpus/Medline/xml/PMC5123381.xml	4x	48002 : 48004	CM	0.005) and CTL activity (4x, p < 0.0001) was observe
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	48208 : 48213	CM	significant increases in CXCL9, Gzmb, CCR5, Stat1, Lag3
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	48221 : 48225	CM	ncreases in CXCL9, Gzmb, CCR5, Stat1, Lag3, Ptprc, Cii
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	48234 : 48238	CM	XCL9, Gzmb, CCR5, Stat1, Lag3, Ptprc, Ciita, Pdcd1 (PD
./___Corpus/Medline/xml/PMC5123381.xml	Pdcd1	48254 : 48259	CM	at1, Lag3, Ptprc, Ciita, Pdcd1 (PD-1), and Itga1. These
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	48261 : 48265	CM	g3, Ptprc, Ciita, Pdcd1 (PD-1), and Itga1. These coord
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48466 : 48471	CPR	oma models. Importantly, anti-SEMA4D antibody can furth
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48597 : 48602	CPR	ngly, the combination of anti-SEMA4D with anti-CTLA-4 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	48614 : 48619	CPR	tion of anti-SEMA4D with anti-CTLA-4 acts synergistical
./___Corpus/Medline/xml/PMC5123381.xml	SEMA4D	48790 : 48796	CM	 monotherapy (p < 0.01). SEMA4D antibody treatment was w
./___Corpus/Medline/xml/PMC5123381.xml	48–	49022 : 49025	CPR	t duration of treatment, 48–55 weeks, included colore
./___Corpus/Medline/xml/PMC5123381.xml	RECIST	49127 : 49133	CM	ad a partial response by RECIST.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	SEMA4D	49199 : 49205	CM	           Inhibition of SEMA4D represents a novel mecha
./___Corpus/Medline/xml/PMC5123381.xml	Ib	49354 : 49356	CM	tumor progression. Phase Ib/IIa trials of combinatio
./___Corpus/Medline/xml/PMC5123381.xml	IIa	49357 : 49360	CM	or progression. Phase Ib/IIa trials of combination th
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	49525 : 49535	CM	ycomimetic antagonist to E-selectin and CXCR4, GMI-1359, wit
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	49540 : 49545	CM	gonist to E-selectin and CXCR4, GMI-1359, with an anti-
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	49547 : 49555	CM	to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	49565 : 49570	CPR	CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates
./___Corpus/Medline/xml/PMC5123381.xml	murine	49676 : 49682	CM	complete response in the murine CT26 tumor model        
./___Corpus/Medline/xml/PMC5123381.xml	CT26	49683 : 49687	CM	e response in the murine CT26 tumor model             
./___Corpus/Medline/xml/PMC5123381.xml	anti-	49863 : 49868	CPR	 T cells (Treg) modulate anti-tumor immunity by suppres
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	49988 : 49993	CM	atory receptors, such as PD-L1, and respond to homing s
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	50111 : 50121	CM	ndothelial cell protein, E-selectin, and the CXCR4 ligand, S
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	50131 : 50136	CM	ein, E-selectin, and the CXCR4 ligand, SDF-1. GMI-1359 
./___Corpus/Medline/xml/PMC5123381.xml	SDF-1	50145 : 50150	CM	n, and the CXCR4 ligand, SDF-1. GMI-1359 is a small mol
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	50152 : 50160	CM	the CXCR4 ligand, SDF-1. GMI-1359 is a small molecule glyc
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	50262 : 50272	CM	ibitory activity against E-selectin and SDF-1. The aim of th
./___Corpus/Medline/xml/PMC5123381.xml	SDF-1	50277 : 50282	CM	y against E-selectin and SDF-1. The aim of the current 
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	50333 : 50341	CM	tudy was to determine if GMI-1359 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50371 : 50376	CPR	e or in combination with anti-mPD-L1 antibody affected 
./___Corpus/Medline/xml/PMC5123381.xml	CT26	50423 : 50427	CM	ed the in vivo growth of CT26 colon carcinoma and to a
./___Corpus/Medline/xml/PMC5123381.xml	CT26.WT	50638 : 50645	CM	ubcutaneously with 5x105 CT26.WT tumor cells. Three days 
./___Corpus/Medline/xml/PMC5123381.xml	saline	50730 : 50736	CM	group) were treated with saline, GMI-1359 (40 mg/kg for 
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	50738 : 50746	CM	ere treated with saline, GMI-1359 (40 mg/kg for 12 consecu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50809 : 50814	CPR	sotype control antibody (anti-KLH) or anti-mPD-L1 antib
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50822 : 50827	CPR	l antibody (anti-KLH) or anti-mPD-L1 antibody (10 F.9G2
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	50916 : 50924	CM	), or the combination of GMI-1359 and anti-mPD-L1 or anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50929 : 50934	CPR	bination of GMI-1359 and anti-mPD-L1 or anti-KLH. On da
./___Corpus/Medline/xml/PMC5123381.xml	anti-	50944 : 50949	CPR	-1359 and anti-mPD-L1 or anti-KLH. On day 15, tumors an
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	51030 : 51034	CM	cised and T cells (total CD4+ and CD8+, and CCR7+/CD62
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	51039 : 51043	CM	 T cells (total CD4+ and CD8+, and CCR7+/CD62L+ subset
./___Corpus/Medline/xml/PMC5123381.xml	CCR7+	51049 : 51054	CM	total CD4+ and CD8+, and CCR7+/CD62L+ subsets of each),
./___Corpus/Medline/xml/PMC5123381.xml	CD62L+	51055 : 51061	CM	CD4+ and CD8+, and CCR7+/CD62L+ subsets of each), regula
./___Corpus/Medline/xml/PMC5123381.xml	CD4	51106 : 51109	CM	egulatory T cells (Treg; CD4/CD25/FoxP3), and myeloid
./___Corpus/Medline/xml/PMC5123381.xml	CD25	51110 : 51114	CM	atory T cells (Treg; CD4/CD25/FoxP3), and myeloid deri
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	51161 : 51165	CM	erived suppressor cells (MDSC; CD11b+/Gr1+) were deter
./___Corpus/Medline/xml/PMC5123381.xml	CD11b+	51167 : 51173	CM	 suppressor cells (MDSC; CD11b+/Gr1+) were determined by
./___Corpus/Medline/xml/PMC5123381.xml	Gr1+	51174 : 51178	CM	ssor cells (MDSC; CD11b+/Gr1+) were determined by flow
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	51386 : 51394	CM	 groups and single agent GMI-1359 were all identified with
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51469 : 51474	CPR	contrast, treatment with anti-mPD-L1 alone or in combin
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	51510 : 51518	CM	e or in combination with GMI-1359 produced a 40 % complete
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51603 : 51608	CPR	e to CR was shorter when anti-mPD-L1 was combined with 
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	51633 : 51641	CM	mPD-L1 was combined with GMI-1359 compared to anti-mPD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51654 : 51659	CPR	ith GMI-1359 compared to anti-mPD-L1 alone (14 vs. 23 d
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	51792 : 51800	CM	combination therapy with GMI-1359 and anti-mPD-L1 reduced 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51805 : 51810	CPR	herapy with GMI-1359 and anti-mPD-L1 reduced the percen
./___Corpus/Medline/xml/PMC5123381.xml	saline	51875 : 51881	CM	mpared to treatment with saline, GMI-1359 or anti-mPD-L1
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	51883 : 51891	CM	o treatment with saline, GMI-1359 or anti-mPD-L1 as single
./___Corpus/Medline/xml/PMC5123381.xml	anti-	51895 : 51900	CPR	with saline, GMI-1359 or anti-mPD-L1 as single treatmen
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52179 : 52184	CPR	 combined treatment with anti-PD-L1 and GMI-1359 was an
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	52194 : 52202	CM	ment with anti-PD-L1 and GMI-1359 was an attenuated respon
./___Corpus/Medline/xml/PMC5123381.xml	E-selectin	52400 : 52410	CM	emonstrate that the dual E-selectin/CXCR4 antagonist, GMI-13
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4	52411 : 52416	CM	that the dual E-selectin/CXCR4 antagonist, GMI-1359, in
./___Corpus/Medline/xml/PMC5123381.xml	GMI-1359	52429 : 52437	CM	lectin/CXCR4 antagonist, GMI-1359, in combination with ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52459 : 52464	CPR	359, in combination with anti-mPD-L1 antibody attenuate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52620 : 52625	CPR	 rapid immunotherapeutic anti-tumor response.          
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	52706 : 52724	CM	05 Antibody targeting of phosphatidylserine enhances the anti-tumor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52738 : 52743	CPR	tidylserine enhances the anti-tumor responses of ibruti
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	52762 : 52771	CM	 anti-tumor responses of ibrutinib and anti-PD-1 therapy in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	52776 : 52781	CPR	sponses of ibrutinib and anti-PD-1 therapy in a mouse t
./___Corpus/Medline/xml/PMC5123381.xml	Phosphatidylserine	52944 : 52962	CM	und                      Phosphatidylserine (PS) is a phospholipid n
./___Corpus/Medline/xml/PMC5123381.xml	PS	52964 : 52966	CM	     Phosphatidylserine (PS) is a phospholipid norma
./___Corpus/Medline/xml/PMC5123381.xml	phospholipid	52973 : 52985	CM	phatidylserine (PS) is a phospholipid normally residing in the
./___Corpus/Medline/xml/PMC5123381.xml	PS	53236 : 53238	CM	 of antibodies targeting PS induces the recruitment 
./___Corpus/Medline/xml/PMC5123381.xml	PS	53401 : 53403	CM	unosuppressive action of PS. Recent studies have dem
./___Corpus/Medline/xml/PMC5123381.xml	anti-	53479 : 53484	CPR	g antibodies enhance the anti-tumor activity of immune 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	53552 : 53556	CM	y blockade to CTLA-4 and PD-1 in mouse breast and mela
./___Corpus/Medline/xml/PMC5123381.xml	Ibrutinib	53600 : 53609	CM	d melanoma tumor models. Ibrutinib is an approved anticance
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	53720 : 53728	CM	alent inhibitor Bruton's tyrosine kinase (BTK) in B cell t
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	53814 : 53823	CM	studies demonstrate that ibrutinib in combination with anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	53844 : 53849	CPR	inib in combination with anti-PD-1 antibody blockade in
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	53945 : 53954	CM	ression, suggesting that ibrutinib may inhibit interleukin-
./___Corpus/Medline/xml/PMC5123381.xml	ITK	54006 : 54009	CM	inducible T cell kinase (ITK) and promote Th1 anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	Th1	54023 : 54026	CM	kinase (ITK) and promote Th1 anti-tumor responses.   
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54027 : 54032	CPR	se (ITK) and promote Th1 anti-tumor responses.         
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54202 : 54211	CM	geting antibody mch1N11, ibrutinib and anti-PD-1 antibody i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54216 : 54221	CPR	y mch1N11, ibrutinib and anti-PD-1 antibody in C57Bl/6 
./___Corpus/Medline/xml/PMC5123381.xml	C57Bl	54238 : 54243	CM	nd anti-PD-1 antibody in C57Bl/6 mice bearing triple ne
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54440 : 54445	CPR	 control at 10 mg/kg qw, anti-PD-1 at 2.5 mg/kg qw or i
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54469 : 54478	CM	-PD-1 at 2.5 mg/kg qw or ibrutinib 6 mg/kg or vehicle qd x 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	54636 : 54641	CM	 treated animals. The in vitro sensitivity of E0771 tum
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54678 : 54687	CM	 of E0771 tumor cells to ibrutinib was compared to the drug
./___Corpus/Medline/xml/PMC5123381.xml	vitro	54863 : 54868	CM	ell line is resistant in vitro to 10 mM ibrutinib. Tumo
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54878 : 54887	CM	istant in vitro to 10 mM ibrutinib. Tumor bearing mice trea
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	54930 : 54939	CM	ce treated with mch1N11, ibrutinib or anti-PD-1 alone had 2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	54943 : 54948	CPR	th mch1N11, ibrutinib or anti-PD-1 alone had 22.2 %, 23
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	55031 : 55040	CM	 The TGI for mch1N11 and ibrutinib was 30.5 %, ibrutinib an
./___Corpus/Medline/xml/PMC5123381.xml	ibrutinib	55053 : 55062	CM	nd ibrutinib was 30.5 %, ibrutinib and anti-PD-1 was 34.5 %
./___Corpus/Medline/xml/PMC5123381.xml	anti-	55067 : 55072	CPR	as 30.5 %, ibrutinib and anti-PD-1 was 34.5 %, mch1N11 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	55101 : 55106	CPR	 was 34.5 %, mch1N11 and anti-PD-1 was 36.1 %. The trip
./___Corpus/Medline/xml/PMC5123381.xml	PS	55360 : 55362	CM	f inhibitors that target PS, ITK and the PD-1/PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	ITK	55364 : 55367	CM	hibitors that target PS, ITK and the PD-1/PD-L1 axis 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	55376 : 55380	CM	t target PS, ITK and the PD-1/PD-L1 axis in the tumor 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	55381 : 55386	CM	get PS, ITK and the PD-1/PD-L1 axis in the tumor microe
./___Corpus/Medline/xml/PMC5123381.xml	OX40L	55573 : 55578	CM	06 Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) combi
./___Corpus/Medline/xml/PMC5123381.xml	ICOSL	55580 : 55585	CM	-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) combination 
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	55590 : 55596	CM	ulator (OX40L, ICOSL, or 4-1BBL) combination vaccine imp
./___Corpus/Medline/xml/PMC5123381.xml	Xin	55758 : 55761	CM	de Silva, Louise Giffin, Xin Xu, Jason Rose, Taylor H
./___Corpus/Medline/xml/PMC5123381.xml	Xu	55762 : 55764	CM	ilva, Louise Giffin, Xin Xu, Jason Rose, Taylor H Sc
./___Corpus/Medline/xml/PMC5123381.xml	H	55785 : 55786	CM	n Xu, Jason Rose, Taylor H Schreiber Background    
./___Corpus/Medline/xml/PMC5123381.xml	10-	56022 : 56025	CPR	ed by the fact that only 10-40 % of patients respond 
./___Corpus/Medline/xml/PMC5123381.xml	Fc-OX40L	56595 : 56603	CM	th T cell costimulation (Fc-OX40L), into a single tumor ce
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	56899 : 56903	CM	priming antigen-specific CD8+ T cells (peak: 13.3 % of
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	56935 : 56939	CM	s (peak: 13.3 % of total CD8+), even more so than a le
./___Corpus/Medline/xml/PMC5123381.xml	OX40	56970 : 56974	CM	n more so than a leading OX40 agonist antibody (8.4 %)
./___Corpus/Medline/xml/PMC5123381.xml	CD127	57064 : 57069	CM	ssociated with increased CD127 + KLRG-1- memory precurs
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	57124 : 57128	CM	lls and antigen-specific CD4+ proliferation, with redu
./___Corpus/Medline/xml/PMC5123381.xml	Fc-OX40L	57213 : 57221	CM	antly, vaccine-expressed Fc-OX40L stimulated IFNγ+, TNFα+,
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ+	57233 : 57238	CM	ssed Fc-OX40L stimulated IFNγ+, TNFα+, granzyme-b + and
./___Corpus/Medline/xml/PMC5123381.xml	TNFα+	57240 : 57245	CM	-OX40L stimulated IFNγ+, TNFα+, granzyme-b + and IL-2+ 
./___Corpus/Medline/xml/PMC5123381.xml	IL-2+	57264 : 57269	CM	 TNFα+, granzyme-b + and IL-2+ by antigen-specific CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	57290 : 57294	CM	L-2+ by antigen-specific CD8+ T cells. This pharmacody
./___Corpus/Medline/xml/PMC5123381.xml	anti-	57341 : 57346	CPR	odynamic signature of an anti-tumor immune response pre
./___Corpus/Medline/xml/PMC5123381.xml	MC38	57412 : 57416	CM	rejection of established MC38, CT26 and B16.F10 tumors
./___Corpus/Medline/xml/PMC5123381.xml	CT26	57418 : 57422	CM	ion of established MC38, CT26 and B16.F10 tumors. Addi
./___Corpus/Medline/xml/PMC5123381.xml	B16.F10	57427 : 57434	CM	tablished MC38, CT26 and B16.F10 tumors. Additionally, te
./___Corpus/Medline/xml/PMC5123381.xml	tetramer	57457 : 57465	CM	10 tumors. Additionally, tetramer analysis of antigen-spec
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	57495 : 57499	CM	ysis of antigen-specific CD8+ T cells (in all 3 tumor 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	57604 : 57607	CM	nfiltrating lymphocytes (TIL), suggesting that ComPAC
./___Corpus/Medline/xml/PMC5123381.xml	Fc-TL1A	57848 : 57855	CM	p96-Ig along with either Fc-TL1A, Fc-4-1BBL or Fc-ICOSL. 
./___Corpus/Medline/xml/PMC5123381.xml	Fc-4-1BBL	57857 : 57866	CM	ong with either Fc-TL1A, Fc-4-1BBL or Fc-ICOSL. Each costim
./___Corpus/Medline/xml/PMC5123381.xml	Fc-ICOSL	57870 : 57878	CM	er Fc-TL1A, Fc-4-1BBL or Fc-ICOSL. Each costimulator/vacci
./___Corpus/Medline/xml/PMC5123381.xml	anti-	58515 : 58520	CPR	y (ADCC) mediated by the anti-PD-L1 antibody avelumab o
./___Corpus/Medline/xml/PMC5123381.xml	R	58706 : 58707	CM	 Massimo Fantini1, Sofia R Gameiro1, Karin M Knudso
./___Corpus/Medline/xml/PMC5123381.xml	W	58823 : 58824	CM	1, Italia Grenga1, James W Hodge1, Kwong Y Tsang1, 
./___Corpus/Medline/xml/PMC5123381.xml	Y	58839 : 58840	CM	1, James W Hodge1, Kwong Y Tsang1, Jeffrey Schlom1 
./___Corpus/Medline/xml/PMC5123381.xml	Chromatin	58914 : 58923	CM	und                      Chromatin deacetylation is a major
./___Corpus/Medline/xml/PMC5123381.xml	deacetylation	58924 : 58937	RN	               Chromatin deacetylation is a major determinant i
./___Corpus/Medline/xml/PMC5123381.xml	histone	59141 : 59148	CM	g aberrant expression of histone deacetylases (HDACs), ha
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	59697 : 59701	CM	int inhibitors targeting PD-1/PD-L1 interactions are p
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	59702 : 59707	CM	nhibitors targeting PD-1/PD-L1 interactions are promisi
./___Corpus/Medline/xml/PMC5123381.xml	IgG1	59838 : 59842	CM	velumab is a fully human IgG1 mAb monoclonal antibody 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	59881 : 59885	CM	l antibody that inhibits PD-1/PD-L1 interaction by tar
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	59886 : 59891	CM	ibody that inhibits PD-1/PD-L1 interaction by targeting
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	59917 : 59922	CM	interaction by targeting PD-L1, and mediates ADCC again
./___Corpus/Medline/xml/PMC5123381.xml	vitro	59982 : 59987	CM	xpressing tumor cells in vitro. We examined the sensiti
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60258 : 60262	CM	y to vorinostat (3uM) or DMSO for 4 consecutive days, 
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60316 : 60320	CM	o entinostat (500 nM) or DMSO for 72 h, prior to being
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	60376 : 60381	CM	ned for (a) cell-surface PD-L1 expression or (b) used a
./___Corpus/Medline/xml/PMC5123381.xml	lysis	60421 : 60426	RN	(b) used as target cells lysis assay where NK cells fro
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	60536 : 60541	CM	ct of HDAC inhibitors on PD-L1 expression in vivo, fema
./___Corpus/Medline/xml/PMC5123381.xml	NCI-H460	60600 : 60608	CM	mice were implanted with NCI-H460 (lung) or PC-3 (prostate
./___Corpus/Medline/xml/PMC5123381.xml	PC-3	60619 : 60623	CM	 with NCI-H460 (lung) or PC-3 (prostate) carcinoma cel
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60717 : 60721	CM	eceived 4 daily doses of DMSO or vorinostat (150 mg/kg
./___Corpus/Medline/xml/PMC5123381.xml	DMSO	60835 : 60839	CM	stat (20 mg/kg, p.o.) or DMSO 72 h prior to tumor exci
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	60932 : 60937	CM	ll-surface expression of PD-L1 by immunofluorescence.  
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD16	61177 : 61186	CM	ated by avelumab; 2) the anti-CD16 neutralizing mAb signifi
./___Corpus/Medline/xml/PMC5123381.xml	lysis	61246 : 61251	RN	reases avelumab-mediated lysis of target cells exposed 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	61344 : 61349	CM	bitors can enhance tumor PD-L1 expression in vitro and 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	61364 : 61369	CM	umor PD-L1 expression in vitro and in vivo in prostate 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	61538 : 61543	CM	 without increased tumor PD-L1 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	61699 : 61704	CM	stat with mAbs targeting PD-L1, including for patients 
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	61878 : 61896	CM	nal antibodies targeting phosphatidylserine enhance combinational ac
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	61970 : 61974	CM	ckpoint targeting agents LAG3 and PD-1 in murine breas
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	61979 : 61983	CM	argeting agents LAG3 and PD-1 in murine breast tumors 
./___Corpus/Medline/xml/PMC5123381.xml	murine	61987 : 61993	CM	 agents LAG3 and PD-1 in murine breast tumors           
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	62164 : 62182	CM	ted that the addition of phosphatidylserine (PS) targeting antibodie
./___Corpus/Medline/xml/PMC5123381.xml	PS	62184 : 62186	CM	n of phosphatidylserine (PS) targeting antibodies to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	62212 : 62217	CPR	 targeting antibodies to anti-programmed death ligand 1
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	62244 : 62248	CM	ogrammed death ligand 1 (PD-1) therapy in murine tripl
./___Corpus/Medline/xml/PMC5123381.xml	murine	62261 : 62267	CM	gand 1 (PD-1) therapy in murine triple negative breast c
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	62501 : 62505	CM	ocyte activation gene 3 (LAG3) mRNA increased in respo
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	62507 : 62511	CM	activation gene 3 (LAG3) mRNA increased in response to
./___Corpus/Medline/xml/PMC5123381.xml	PS	62537 : 62539	CM	increased in response to PS and PD-1 treatments. Thi
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	62544 : 62548	CM	ed in response to PS and PD-1 treatments. This suggest
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	62575 : 62579	CM	reatments. This suggests LAG3 may act to attenuate T c
./___Corpus/Medline/xml/PMC5123381.xml	O	62636 : 62637	CM	ivation in TNBC during I/O therapeutic regimens; ho
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	62686 : 62690	CM	owever, it is unknown if PD-1 and LAG3 function cooper
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	62695 : 62699	CM	t is unknown if PD-1 and LAG3 function cooperatively i
./___Corpus/Medline/xml/PMC5123381.xml	PS	62771 : 62773	CM	ergy, and whether adding PS blocking antibodies can 
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	62835 : 62839	CM	nce the effectiveness of LAG3 and/or LAG3 + PD-1 thera
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	62847 : 62851	CM	ctiveness of LAG3 and/or LAG3 + PD-1 therapies.       
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	62854 : 62858	CM	ss of LAG3 and/or LAG3 + PD-1 therapies.              
./___Corpus/Medline/xml/PMC5123381.xml	C57bl	62940 : 62945	CM	 Animal studies utilized C57bl/6 mice implanted with th
./___Corpus/Medline/xml/PMC5123381.xml	murine	62972 : 62978	CM	 mice implanted with the murine TNBC model E0771. Immuno
./___Corpus/Medline/xml/PMC5123381.xml	phosphatidylserine	63157 : 63175	CM	ents utilized a specific phosphatidylserine targeting antibody (ch1N
./___Corpus/Medline/xml/PMC5123381.xml	ch1N11	63196 : 63202	CM	rine targeting antibody (ch1N11), anti-PD-1, or anti-LAG
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63205 : 63210	CPR	eting antibody (ch1N11), anti-PD-1, or anti-LAG3 alone 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63219 : 63224	CPR	 (ch1N11), anti-PD-1, or anti-LAG3 alone or in combinat
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	63382 : 63386	CM	lts                      LAG3 and PD-1 were co-express
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	63391 : 63395	CM	                LAG3 and PD-1 were co-expressed on T c
./___Corpus/Medline/xml/PMC5123381.xml	PS	63474 : 63476	CM	ith antibodies targeting PS, PD-1, and LAG3 alone in
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	63478 : 63482	CM	antibodies targeting PS, PD-1, and LAG3 alone in combi
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	63488 : 63492	CM	 targeting PS, PD-1, and LAG3 alone in combination wit
./___Corpus/Medline/xml/PMC5123381.xml	PS	63564 : 63566	CM	ted that the addition of PS blocking antibodies to a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63590 : 63595	CPR	S blocking antibodies to anti-PD-1 therapy or LAG3 had 
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	63611 : 63615	CM	 to anti-PD-1 therapy or LAG3 had significantly greate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63642 : 63647	CPR	ad significantly greater anti-tumor activity than eithe
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	63702 : 63706	CM	gle agent. Comparison of PD-1 + LAG3 combinational the
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	63709 : 63713	CM	nt. Comparison of PD-1 + LAG3 combinational therapy vs
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	63747 : 63751	CM	ional therapy vs. single PD-1 or LAG3 treatments showe
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	63755 : 63759	CM	erapy vs. single PD-1 or LAG3 treatments showed modera
./___Corpus/Medline/xml/PMC5123381.xml	anti-	63794 : 63799	CPR	s showed moderately more anti-tumor activity than singl
./___Corpus/Medline/xml/PMC5123381.xml	PS	63863 : 63865	CM	however, the addition of PS blocking antibodies to e
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64003 : 64007	CM	ed in the combination of LAG3 + PD-1 treatment. Furthe
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64010 : 64014	CM	he combination of LAG3 + PD-1 treatment. Further compa
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64048 : 64052	CM	t. Further comparison of PD-1 + LAG3 vs. PS + PD-1 + L
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64055 : 64059	CM	her comparison of PD-1 + LAG3 vs. PS + PD-1 + LAG3 tre
./___Corpus/Medline/xml/PMC5123381.xml	PS	64064 : 64066	CM	rison of PD-1 + LAG3 vs. PS + PD-1 + LAG3 treatments
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64069 : 64073	CM	 of PD-1 + LAG3 vs. PS + PD-1 + LAG3 treatments demons
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64076 : 64080	CM	1 + LAG3 vs. PS + PD-1 + LAG3 treatments demonstrated 
./___Corpus/Medline/xml/PMC5123381.xml	PS	64126 : 64128	CM	ted that the addition of PS blocking antibodies resu
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64293 : 64297	CM	als than observed in the PD-1 + LAG3 treatment group. 
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64300 : 64304	CM	n observed in the PD-1 + LAG3 treatment group. FACS an
./___Corpus/Medline/xml/PMC5123381.xml	FACS	64322 : 64326	CM	 + LAG3 treatment group. FACS and NanoString immunopro
./___Corpus/Medline/xml/PMC5123381.xml	PS	64419 : 64421	CM	wed that the addition of PS blocking antibodies to a
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64507 : 64511	CM	uding the combination of PD-1 + LAG3, resulted in enha
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64514 : 64518	CM	he combination of PD-1 + LAG3, resulted in enhanced tu
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	64629 : 64634	CM	erived suppressor cells (MDSCs), and enhanced cytokines
./___Corpus/Medline/xml/PMC5123381.xml	PS	64793 : 64795	CM	a demonstrate that while PS, LAG3, and PD-1 therapie
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	64797 : 64801	CM	monstrate that while PS, LAG3, and PD-1 therapies each
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	64807 : 64811	CM	that while PS, LAG3, and PD-1 therapies each have effi
./___Corpus/Medline/xml/PMC5123381.xml	O	64869 : 64870	CM	TNBC as single agents, I/O treatments that include 
./___Corpus/Medline/xml/PMC5123381.xml	PS	64895 : 64897	CM	 treatments that include PS blocking antibodies offe
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	65138 : 65143	CM	 P209 The immunoreceptor TIGIT regulates anti-tumor imm
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65154 : 65159	CPR	receptor TIGIT regulates anti-tumor immunity Jane Groga
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65318 : 65323	CPR	to re-activate exhausted anti-tumor immune responses wi
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	65415 : 65419	CM	bitory receptors such as PD-1/PD-L1 or CTLA-4 have dem
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	65420 : 65425	CM	y receptors such as PD-1/PD-L1 or CTLA-4 have demonstra
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	65496 : 65501	CM	potential in the clinic. TIGIT (a PVR-nectin family mem
./___Corpus/Medline/xml/PMC5123381.xml	anti-	65624 : 65629	CPR	cells, shown to regulate anti-tumor immunity. Activatio
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	65659 : 65664	CM	 immunity. Activation of TIGIT on T and NK cells limits
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	65714 : 65722	CM	 proliferation, effector cytokine production, and killing 
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	65801 : 65806	CM	gh affinity receptor for TIGIT is PVR, and the counter 
./___Corpus/Medline/xml/PMC5123381.xml	PVR	65810 : 65813	CM	ty receptor for TIGIT is PVR, and the counter agonist
./___Corpus/Medline/xml/PMC5123381.xml	CD226	65851 : 65856	CM	nter agonist receptor is CD226, all of which are member
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	65909 : 65914	CM	f the PVR-nectin family. TIGIT is elevated in the tumor
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	66052 : 66056	CM	immune receptors such as PD-1. However, the spatial an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	66197 : 66202	CPR	e cell-types involved in anti-tumor immunity, remains u
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	66281 : 66286	CM	ods                      TIGIT, CD226 and PD-L1 blockad
./___Corpus/Medline/xml/PMC5123381.xml	CD226	66288 : 66293	CM	                  TIGIT, CD226 and PD-L1 blockade will 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	66298 : 66303	CM	        TIGIT, CD226 and PD-L1 blockade will be assesse
./___Corpus/Medline/xml/PMC5123381.xml	CT26	66367 : 66371	CM	al syngeneic tumor model CT26 and MC38. To determine w
./___Corpus/Medline/xml/PMC5123381.xml	MC38	66376 : 66380	CM	eic tumor model CT26 and MC38. To determine which immu
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	66680 : 66685	CM	nce microscopy to assess TIGIT, CD226 and PVR cellular 
./___Corpus/Medline/xml/PMC5123381.xml	CD226	66687 : 66692	CM	roscopy to assess TIGIT, CD226 and PVR cellular express
./___Corpus/Medline/xml/PMC5123381.xml	PVR	66697 : 66700	CM	 assess TIGIT, CD226 and PVR cellular expression.    
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	66824 : 66829	CM	 antibody co-blockade of TIGIT and PD-L1 enhanced CD8+ 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	66834 : 66839	CM	co-blockade of TIGIT and PD-L1 enhanced CD8+ T cell eff
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	66849 : 66853	CM	TIGIT and PD-L1 enhanced CD8+ T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	66922 : 66927	CM	ificant tumor clearance. TIGIT is expressed on CD8+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	66944 : 66948	CM	e. TIGIT is expressed on CD8+ T cell, Treg and NK cell
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	66997 : 67002	CM	ls. Specific ablation of TIGIT on CD8+ T cells resulted
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	67006 : 67010	CM	fic ablation of TIGIT on CD8+ T cells resulted in tumo
./___Corpus/Medline/xml/PMC5123381.xml	PVR	67069 : 67072	CM	ce, and was dependent on PVR in the host tissue. Immu
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	67213 : 67218	CM	 Therapeutic blockade of TIGIT may result in improved e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	67306 : 67311	CPR	n conjunction with other anti-cancer therapies includin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	67358 : 67363	CPR	ding those that modulate anti-tumor immune responses, a
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	67480 : 67485	CM	icate that inhibition of TIGIT with a blocking mAb may 
./___Corpus/Medline/xml/PMC5123381.xml	CD226	67518 : 67523	CM	blocking mAb may release CD226 to activate tumor-specif
./___Corpus/Medline/xml/PMC5123381.xml	TIGIT	67628 : 67633	CM	of T cell suppression by TIGIT on regulatory T cells. A
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	67887 : 67893	CM	                    P210 CC-122 in combination with immu
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	68230 : 68236	CM	und                      CC-122 binds the E3 ubiquitin l
./___Corpus/Medline/xml/PMC5123381.xml	E3	68247 : 68249	CM	        CC-122 binds the E3 ubiquitin ligase CRL4CRB
./___Corpus/Medline/xml/PMC5123381.xml	ubiquitin	68250 : 68259	CM	     CC-122 binds the E3 ubiquitin ligase CRL4CRBN resultin
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	68448 : 68454	CM	lignancies indicate that CC-122 exerts immunomodulatory 
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	68626 : 68632	CM	ctor and memory subsets. CC-122 is in clinical developme
./___Corpus/Medline/xml/PMC5123381.xml	HCC	68747 : 68750	CM	epatocellular carcinoma (HCC) as a single agent ({"ty
./___Corpus/Medline/xml/PMC5123381.xml	vitro	68978 : 68983	CM	ckpoint antibodies in in vitro models of T cell activat
./___Corpus/Medline/xml/PMC5123381.xml	Carboxyfluorescein	69117 : 69135	CM	ods                      Carboxyfluorescein succinimidyl ester (CFSE
./___Corpus/Medline/xml/PMC5123381.xml	ester	69149 : 69154	CM	fluorescein succinimidyl ester (CFSE) based proliferati
./___Corpus/Medline/xml/PMC5123381.xml	CFSE	69156 : 69160	CM	cein succinimidyl ester (CFSE) based proliferation, cy
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	69183 : 69191	CM	SE) based proliferation, cytokine production and immune co
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	69299 : 69303	CM	blood mononuclear cells (PBMC) from healthy donors fol
./___Corpus/Medline/xml/PMC5123381.xml	3-	69674 : 69676	CPR	                    In a 3-day CD3-stimulated PBMC a
./___Corpus/Medline/xml/PMC5123381.xml	CD3	69680 : 69683	CM	              In a 3-day CD3-stimulated PBMC assay, C
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	69695 : 69699	CM	n a 3-day CD3-stimulated PBMC assay, CC-122 (1-10 μM) 
./___Corpus/Medline/xml/PMC5123381.xml	1-	69715 : 69717	CPR	ated PBMC assay, CC-122 (1-10 μM) treatment elevated
./___Corpus/Medline/xml/PMC5123381.xml	μM	69720 : 69722	CM	PBMC assay, CC-122 (1-10 μM) treatment elevated HLA-
./___Corpus/Medline/xml/PMC5123381.xml	HLA-DR	69743 : 69749	CM	0 μM) treatment elevated HLA-DR, a marker of T cell acti
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	69813 : 69817	CM	-5.5 and 3.2-5.3 fold in CD4+ and CD8+ T cells, respec
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	69822 : 69826	CM	3.2-5.3 fold in CD4+ and CD8+ T cells, respectively. P
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	69867 : 69871	CM	tively. Proliferation of CD4+ and CD8+ T cells from CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	69876 : 69880	CM	roliferation of CD4+ and CD8+ T cells from CD3-stimula
./___Corpus/Medline/xml/PMC5123381.xml	CD3	69894 : 69897	CM	4+ and CD8+ T cells from CD3-stimulated PBMC treated 
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	69909 : 69913	CM	ells from CD3-stimulated PBMC treated with vehicle, CC
./___Corpus/Medline/xml/PMC5123381.xml	CFSE	70003 : 70007	CM	ination was assessed via CFSE staining. The percentage
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	70066 : 70070	CM	ferating vehicle-treated CD4+ and CD8+ cells was 37 % 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	70075 : 70079	CM	vehicle-treated CD4+ and CD8+ cells was 37 % and 40 %,
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	70139 : 70145	CM	to nivo (45 % and 47 %), CC-122 (54 % and 68 %) and the 
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	70214 : 70218	CM	nd 74 %). SEB stimulated PBMC were treated with CC-122
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-L1	70264 : 70271	CM	-122 (40nM), and nivo or α-PD-L1 (0.1-100 μg/ml) resultin
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	70376 : 70382	CM	vely. The combination of CC-122 with either nivo or α-PD
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-L1	70403 : 70410	CM	-122 with either nivo or α-PD-L1 (10 μg/ml) resulted in s
./___Corpus/Medline/xml/PMC5123381.xml	IL-2	70446 : 70450	CM	 resulted in synergistic IL-2 secretion levels of 873 
./___Corpus/Medline/xml/PMC5123381.xml	MLR	70510 : 70513	CM	/ml, respectively. In an MLR assay, the combination o
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-L1	70579 : 70586	CM	 with nivo (10 μg/ml) or α-PD-L1 (10 μg/ml) resulted in s
./___Corpus/Medline/xml/PMC5123381.xml	IL-2	70622 : 70626	CM	 resulted in synergistic IL-2 and IFNγ secretion. Fina
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	70631 : 70635	CM	 in synergistic IL-2 and IFNγ secretion. Finally, the 
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	70675 : 70681	CM	ally, the combination of CC-122 and nivo or CC-122 and α
./___Corpus/Medline/xml/PMC5123381.xml	CC-122	70694 : 70700	CM	on of CC-122 and nivo or CC-122 and α-PD-L1 significantl
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-L1	70705 : 70712	CM	2 and nivo or CC-122 and α-PD-L1 significantly increased 
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	70737 : 70741	CM	 significantly increased PBMC-mediated cytotoxicity of
./___Corpus/Medline/xml/PMC5123381.xml	anti-	70925 : 70930	CPR	combination with nivo or anti-PD-L1 antibodies results 
./___Corpus/Medline/xml/PMC5123381.xml	Ubiquitin	71276 : 71285	CM	                    P211 Ubiquitin-specific protease 6 (USP
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71307 : 71311	CM	tin-specific protease 6 (USP6) oncogene confers dramat
./___Corpus/Medline/xml/PMC5123381.xml	BSTTs	71548 : 71553	CM	 and soft tissue tumors (BSTTs) represent a heterogeneo
./___Corpus/Medline/xml/PMC5123381.xml	BSTTs	71673 : 71678	CM	d to other malignancies, BSTTs are poorly understood, w
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71835 : 71839	CM	de-ubiquitylating enzyme USP6 is the key etiologic age
./___Corpus/Medline/xml/PMC5123381.xml	BSTTs	71885 : 71890	CM	 agent in several benign BSTTs, and is selectively over
./___Corpus/Medline/xml/PMC5123381.xml	BSTTs	71968 : 71973	CM	as, a malignant class of BSTTs [1]. USP6 drives tumorig
./___Corpus/Medline/xml/PMC5123381.xml	USP6	71979 : 71983	CM	nant class of BSTTs [1]. USP6 drives tumorigenesis by 
./___Corpus/Medline/xml/PMC5123381.xml	STAT	72099 : 72103	CM	zation and activation of STAT transcription factors [2
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72233 : 72237	CM	ng, we hypothesized that USP6 overexpression in sarcom
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72436 : 72440	CM	ods                      USP6 was expressed in a doxyc
./___Corpus/Medline/xml/PMC5123381.xml	doxycycline	72460 : 72471	CM	 USP6 was expressed in a doxycycline-inducible manner in vari
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72612 : 72616	CM	arcoma, and liposarcoma. USP6 expression levels were c
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72751 : 72755	CM	lts                      USP6 conferred exquisite sens
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	72860 : 72865	CM	ts of IFN. Activation of STAT1 and STAT3 were both enha
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	72870 : 72875	CM	 Activation of STAT1 and STAT3 were both enhanced and p
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72937 : 72941	CM	sarcoma cells expressing USP6 upon IFN treatment. RNA-
./___Corpus/Medline/xml/PMC5123381.xml	USP6	72992 : 72996	CM	equencing confirmed that USP6 induces an IFN response 
./___Corpus/Medline/xml/PMC5123381.xml	ISG	73125 : 73128	CM	erferon-stimulated gene (ISG) expression. The ISGs sy
./___Corpus/Medline/xml/PMC5123381.xml	ISGs	73146 : 73150	CM	ne (ISG) expression. The ISGs synergistically induced 
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73178 : 73182	CM	nergistically induced by USP6 and IFN include a large 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	73216 : 73221	CPR	include a large group of anti-tumor and immunomodulator
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	73280 : 73285	CM	the pro-apoptotic ligand TRAIL was dramatically elevate
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73421 : 73425	CM	nergistically induced by USP6 and IFN included chemoki
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73571 : 73575	CM	ons                      USP6 overexpression sensitize
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	73648 : 73653	CM	 simultaneously inducing TRAIL-mediated death and stimu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	73729 : 73734	CPR	oduce immune stimulatory/anti-tumorigenic chemokines an
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73906 : 73910	CM	arcomas that overexpress USP6.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	TRE17	73988 : 73993	CM	 Oliveira A, Chou M: The TRE17/USP6 oncogene: a riddle 
./___Corpus/Medline/xml/PMC5123381.xml	USP6	73994 : 73998	CM	ira A, Chou M: The TRE17/USP6 oncogene: a riddle wrapp
./___Corpus/Medline/xml/PMC5123381.xml	Ed	74077 : 74079	CM	gma. Front Biosci (Schol Ed) 2012, 4:321–340.       
./___Corpus/Medline/xml/PMC5123381.xml	321–	74089 : 74093	CPR	iosci (Schol Ed) 2012, 4:321–340.                     
./___Corpus/Medline/xml/PMC5123381.xml	R	74154 : 74155	CM	       2. Quick L, Young R, Henrich I, Wang X, Asma
./___Corpus/Medline/xml/PMC5123381.xml	X	74173 : 74174	CM	Young R, Henrich I, Wang X, Asmann Y, Oliveira A, C
./___Corpus/Medline/xml/PMC5123381.xml	Y	74183 : 74184	CM	enrich I, Wang X, Asmann Y, Oliveira A, Chou M: Jak
./___Corpus/Medline/xml/PMC5123381.xml	USP6	74256 : 74260	CM	sential effectors of the USP6/TRE17 oncogene in tumori
./___Corpus/Medline/xml/PMC5123381.xml	TRE17	74261 : 74266	CM	al effectors of the USP6/TRE17 oncogene in tumorigenesi
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	74364 : 74371	CM	                    P212 CPI-444: a potent and selective 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	74409 : 74418	CM	d selective inhibitor of adenosine 2A receptor (A2AR) induc
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	74432 : 74436	CM	f adenosine 2A receptor (A2AR) induces anti-tumor resp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	74446 : 74451	CPR	 receptor (A2AR) induces anti-tumor responses alone and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	74497 : 74502	CPR	 and in combination with anti-PD-L1                    
./___Corpus/Medline/xml/PMC5123381.xml	Ho	74584 : 74586	CM	, Stephen Willingham, Po Ho, Carmen Choy, Ginna Lapo
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	74717 : 74726	CM	  Elevated extracellular adenosine in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	74838 : 74842	CM	is through signaling via A2AR on immune cells. CPI-444
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	74860 : 74867	CM	ia A2AR on immune cells. CPI-444 is a potent, oral, selec
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	74897 : 74901	CM	 potent, oral, selective A2AR antagonist that has been
./___Corpus/Medline/xml/PMC5123381.xml	Ib	74953 : 74955	CM	ell tolerated in phase I/Ib studies.                
./___Corpus/Medline/xml/PMC5123381.xml	MC38	75051 : 75055	CM	dies were performed with MC38 mouse tumor models and p
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	75093 : 75098	CM	models and primary human PBMCs. Based on these results,
./___Corpus/Medline/xml/PMC5123381.xml	Ib	75150 : 75152	CM	e have initiated a phase Ib trial to examine safety,
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	75220 : 75227	CM	markers, and efficacy of CPI-444 as single agent and in c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	75268 : 75273	CPR	 and in combination with anti-PD-L1 antibody, atezolizu
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75540 : 75549	CM	rated cross-talk between adenosine and PD-1/PD-L1 pathways,
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	75554 : 75558	CM	lk between adenosine and PD-1/PD-L1 pathways, providin
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	75559 : 75564	CM	tween adenosine and PD-1/PD-L1 pathways, providing rati
./___Corpus/Medline/xml/PMC5123381.xml	MC38	75623 : 75627	CM	 combination therapy. In MC38, anti-PD-L1 treatment re
./___Corpus/Medline/xml/PMC5123381.xml	anti-	75629 : 75634	CPR	nation therapy. In MC38, anti-PD-L1 treatment resulted 
./___Corpus/Medline/xml/PMC5123381.xml	CD39	75671 : 75675	CM	ent resulted in elevated CD39 and CD73 expression on T
./___Corpus/Medline/xml/PMC5123381.xml	CD73	75680 : 75684	CM	ted in elevated CD39 and CD73 expression on T cells, c
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75755 : 75764	CM	sed capacity to generate adenosine. The adenosine analog NE
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	75770 : 75779	CM	 generate adenosine. The adenosine analog NECA inhibited TC
./___Corpus/Medline/xml/PMC5123381.xml	NECA	75787 : 75791	CM	ne. The adenosine analog NECA inhibited TCR-mediated E
./___Corpus/Medline/xml/PMC5123381.xml	ERK	75815 : 75818	CM	A inhibited TCR-mediated ERK phosphorylation and prod
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	75819 : 75834	RN	hibited TCR-mediated ERK phosphorylation and production of IL-2 a
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	75862 : 75866	CM	d production of IL-2 and IFNγ in human PBMCs; these in
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	75876 : 75881	CM	f IL-2 and IFNγ in human PBMCs; these inhibitory effect
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	75924 : 75931	CM	 effects were blocked by CPI-444. Treatment of MC38 with 
./___Corpus/Medline/xml/PMC5123381.xml	MC38	75946 : 75950	CM	by CPI-444. Treatment of MC38 with CPI-444 led to inhi
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	75956 : 75963	CM	. Treatment of MC38 with CPI-444 led to inhibition of tum
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	76050 : 76057	CM	~30 % of mice. Combining CPI-444 with anti-PD-L1 synergis
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76063 : 76068	CPR	. Combining CPI-444 with anti-PD-L1 synergistically inh
./___Corpus/Medline/xml/PMC5123381.xml	MC38	76192 : 76196	CM	 were re-challenged with MC38, tumors were uniformly r
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	76241 : 76248	CM	mly rejected, indicating CPI-444 induced systemic anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76266 : 76271	CPR	CPI-444 induced systemic anti-tumor memory. CD8+ deplet
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	76285 : 76289	CM	temic anti-tumor memory. CD8+ depletion abrogated effi
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	76322 : 76329	CM	on abrogated efficacy of CPI-444 ± anti-PD-L1 treatment. 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	76332 : 76337	CPR	ed efficacy of CPI-444 ± anti-PD-L1 treatment. Biomarke
./___Corpus/Medline/xml/PMC5123381.xml	Ib	76395 : 76397	CM	s from the ongoing phase Ib trial demonstrate CPI-44
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	76416 : 76423	CM	ase Ib trial demonstrate CPI-444 neutralizes A2AR signali
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	76436 : 76440	CM	rate CPI-444 neutralizes A2AR signaling and activates 
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	76507 : 76511	CM	une response. To measure A2AR inhibition, peripheral b
./___Corpus/Medline/xml/PMC5123381.xml	NECA	76569 : 76573	CM	ples were activated with NECA and pCREB quantified usi
./___Corpus/Medline/xml/PMC5123381.xml	pCREB	76578 : 76583	CM	 activated with NECA and pCREB quantified using flow cy
./___Corpus/Medline/xml/PMC5123381.xml	A2AR	76617 : 76621	CM	ed using flow cytometry. A2AR signaling was robustly i
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	76802 : 76806	CM	ow cytometry analysis of PD-1/CD8 frequency in all con
./___Corpus/Medline/xml/PMC5123381.xml	CD8	76807 : 76810	CM	tometry analysis of PD-1/CD8 frequency in all continu
./___Corpus/Medline/xml/PMC5123381.xml	CPI-444	77070 : 77077	CM	n total, this shows that CPI-444 exhibits functional inhi
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	77112 : 77121	CM	functional inhibition of adenosine signaling, and treatment
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77191 : 77196	CPR	activation of markers of anti-tumor immunity. This is t
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	77297 : 77306	CM	er patients receiving an adenosine antagonist.             
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	77399 : 77403	CM	erapeutics targeting the PD-1/L1 axis provide preclini
./___Corpus/Medline/xml/PMC5123381.xml	L1	77404 : 77406	CM	utics targeting the PD-1/L1 axis provide preclinical
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77432 : 77437	CPR	axis provide preclinical anti-tumor efficacy while mini
./___Corpus/Medline/xml/PMC5123381.xml	H	77708 : 77709	CM	, Shouchun Liu, Jennifer H Richardson, W Michael Ka
./___Corpus/Medline/xml/PMC5123381.xml	W	77722 : 77723	CM	, Jennifer H Richardson, W Michael Kavanaugh, James
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77899 : 77904	CPR	shing potent and durable anti-tumor immunity against ma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	77994 : 77999	CPR	 same mechanisms control anti-tumor immunity and self-t
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	78190 : 78194	CM	int inhibitors targeting PD-1 and CTLA-4 increase clin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	78367 : 78372	CPR	fore needed that provide anti-tumor activity without dy
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	78517 : 78522	CM	ed Probody therapeutics (Pb-Tx) that are proteolyticall
./___Corpus/Medline/xml/PMC5123381.xml	anti-	78676 : 78681	CPR	l tissue while retaining anti-tumor activity. Pb-Tx are
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	78697 : 78702	CM	ing anti-tumor activity. Pb-Tx are “masked” to attenuat
./___Corpus/Medline/xml/PMC5123381.xml	vitro	78908 : 78913	CM	                      In vitro, the masked PD-1 Pb-Tx h
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	78926 : 78930	CM	    In vitro, the masked PD-1 Pb-Tx had reduced affini
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	78931 : 78936	CM	n vitro, the masked PD-1 Pb-Tx had reduced affinity for
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	78968 : 78972	CM	duced affinity for mouse PD-1 relative to the parental
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79144 : 79148	CM	ibodies to CTLA-4 and to PD-1, and the PD-1 Pb-Tx indu
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79158 : 79162	CM	A-4 and to PD-1, and the PD-1 Pb-Tx induced 10 %, 30 %
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79163 : 79168	CM	nd to PD-1, and the PD-1 Pb-Tx induced 10 %, 30 %, and 
./___Corpus/Medline/xml/PMC5123381.xml	CRs	79226 : 79229	CM	plete tumor regressions (CRs) against established MC3
./___Corpus/Medline/xml/PMC5123381.xml	MC38	79251 : 79255	CM	CRs) against established MC38 tumors, respectively. In
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79298 : 79303	CPR	ely. In combination with anti-CTLA-4, both PD-1 antibod
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79316 : 79320	CM	n with anti-CTLA-4, both PD-1 antibody and Pb-Tx induc
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79334 : 79339	CM	, both PD-1 antibody and Pb-Tx induced 80 % CRs and gen
./___Corpus/Medline/xml/PMC5123381.xml	CRs	79353 : 79356	CM	y and Pb-Tx induced 80 % CRs and generated effective 
./___Corpus/Medline/xml/PMC5123381.xml	10-	79426 : 79429	CPR	t tumor re-challenge. In 10-week-old NOD mice, a 1 or
./___Corpus/Medline/xml/PMC5123381.xml	10-	79433 : 79436	CPR	 re-challenge. In 10-week-old NOD mice, a 1 or 10 mpk
./___Corpus/Medline/xml/PMC5123381.xml	NOD	79438 : 79441	CM	hallenge. In 10-week-old NOD mice, a 1 or 10 mpk sing
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79477 : 79482	CPR	or 10 mpk single dose of anti-PD-1 antibody induced dia
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79576 : 79580	CM	, while a 10 mpk dose of PD-1 Pb-Tx yielded only 14 % 
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79581 : 79586	CM	le a 10 mpk dose of PD-1 Pb-Tx yielded only 14 % diseas
./___Corpus/Medline/xml/PMC5123381.xml	NOD	79654 : 79657	CM	elayed onset. In younger NOD mice, the CTLA-4/PD-1 an
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79675 : 79679	CM	ger NOD mice, the CTLA-4/PD-1 antibody combination ind
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79770 : 79774	CM	t, mice administered the PD-1 Pb-Tx/CTLA-4 antibody co
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79775 : 79780	CM	ce administered the PD-1 Pb-Tx/CTLA-4 antibody combinat
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79886 : 79891	CM	ed with a PD-L1-targeted Pb-Tx.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	79945 : 79949	CM	s                      A PD-1 targeted Pb-Tx provided 
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	79959 : 79964	CM	         A PD-1 targeted Pb-Tx provided equivalent anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	79985 : 79990	CPR	b-Tx provided equivalent anti-tumor efficacy in mice to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80068 : 80073	CPR	dy while protecting from anti-PD-1-mediated autoimmunit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80077 : 80082	CPR	protecting from anti-PD-1-mediated autoimmunity, both a
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	80198 : 80202	CM	results demonstrate that PD-1 Pb-Tx retain anti-tumor 
./___Corpus/Medline/xml/PMC5123381.xml	Pb-Tx	80203 : 80208	CM	ts demonstrate that PD-1 Pb-Tx retain anti-tumor effica
./___Corpus/Medline/xml/PMC5123381.xml	anti-	80216 : 80221	CPR	e that PD-1 Pb-Tx retain anti-tumor efficacy with impro
./___Corpus/Medline/xml/PMC5123381.xml	estrogen	81164 : 81172	CM	ted by signaling via the estrogen receptor (ER), we hypoth
./___Corpus/Medline/xml/PMC5123381.xml	vitro	81502 : 81507	CM	ast tumors was tested in vitro by treatment of ER+ (MCF
./___Corpus/Medline/xml/PMC5123381.xml	ER+	81524 : 81527	CM	in vitro by treatment of ER+ (MCF7 cells) and ER + PR
./___Corpus/Medline/xml/PMC5123381.xml	MCF7	81529 : 81533	CM	tro by treatment of ER+ (MCF7 cells) and ER + PR+ (T47
./___Corpus/Medline/xml/PMC5123381.xml	PR+	81550 : 81553	CM	R+ (MCF7 cells) and ER + PR+ (T47D cells) with differ
./___Corpus/Medline/xml/PMC5123381.xml	T47D	81555 : 81559	CM	CF7 cells) and ER + PR+ (T47D cells) with different do
./___Corpus/Medline/xml/PMC5123381.xml	ER	81615 : 81617	CM	 the clinically approved ER modulator, tamoxifen. In
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	81629 : 81638	CM	y approved ER modulator, tamoxifen. In vivo modulation of t
./___Corpus/Medline/xml/PMC5123381.xml	6–	81714 : 81716	CPR	as tested by inoculating 6–7 week old Balb/cJ female
./___Corpus/Medline/xml/PMC5123381.xml	cJ	81732 : 81734	CM	lating 6–7 week old Balb/cJ female mice with 4 T1 br
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	81803 : 81812	CM	d by oral treatment with tamoxifen. Increase in lactation p
./___Corpus/Medline/xml/PMC5123381.xml	vitro	81898 : 81903	CM	bumin) was assayed by in vitro Luciferase assays follow
./___Corpus/Medline/xml/PMC5123381.xml	Luciferase	81904 : 81914	ASE	 was assayed by in vitro Luciferase assays followed by confi
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	82197 : 82206	CM	ing mice with or without tamoxifen administration and compa
./___Corpus/Medline/xml/PMC5123381.xml	vitro	82303 : 82308	CM	                  Our in vitro studies on human tumors 
./___Corpus/Medline/xml/PMC5123381.xml	murine	82345 : 82351	CM	human tumors and in vivo murine studies show that antago
./___Corpus/Medline/xml/PMC5123381.xml	ER	82388 : 82390	CM	w that antagonism of the ER via tamoxifen treatment 
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	82395 : 82404	CM	antagonism of the ER via tamoxifen treatment can substantia
./___Corpus/Medline/xml/PMC5123381.xml	alpha	82490 : 82495	CM	ctation proteins such as alpha lactalbumin on breast tu
./___Corpus/Medline/xml/PMC5123381.xml	2–	82558 : 82560	CPR	 that whereas at least a 2–3 fold increased expressi
./___Corpus/Medline/xml/PMC5123381.xml	DC	83234 : 83236	CM	limiting factors such as DC trafficking, antigen pre
./___Corpus/Medline/xml/PMC5123381.xml	ENCORE	83691 : 83697	CM	/confirmation results of ENCORE 601, a phase Ib/II, open
./___Corpus/Medline/xml/PMC5123381.xml	Ib	83711 : 83713	CM	s of ENCORE 601, a phase Ib/II, open-label study of 
./___Corpus/Medline/xml/PMC5123381.xml	ENT	83750 : 83753	CM	bel study of entinostat (ENT) in combination with pem
./___Corpus/Medline/xml/PMC5123381.xml	PEMBRO	83790 : 83796	CM	tion with pembrolizumab (PEMBRO) in patients with non-sm
./___Corpus/Medline/xml/PMC5123381.xml	ENT	84199 : 84202	CM	und                      ENT is an oral, class I sele
./___Corpus/Medline/xml/PMC5123381.xml	histone	84233 : 84240	CM	 oral, class I selective histone deacetylase (HDAC) inhib
./___Corpus/Medline/xml/PMC5123381.xml	deacetylase	84241 : 84252	CM	lass I selective histone deacetylase (HDAC) inhibitor shown i
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	84355 : 84360	CM	erived suppressor cells (MDSCs) and regulatory T cells 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	84417 : 84422	CPR	 and produce synergistic anti-tumor responses when comb
./___Corpus/Medline/xml/PMC5123381.xml	ENCORE	84487 : 84493	CM	e checkpoint inhibition. ENCORE 601 is a phase Ib/II stu
./___Corpus/Medline/xml/PMC5123381.xml	Ib	84509 : 84511	CM	n. ENCORE 601 is a phase Ib/II study designed to eva
./___Corpus/Medline/xml/PMC5123381.xml	ENT	84542 : 84545	CM	udy designed to evaluate ENT plus PEMBRO in patients 
./___Corpus/Medline/xml/PMC5123381.xml	PEMBRO	84551 : 84557	CM	ned to evaluate ENT plus PEMBRO in patients with advance
./___Corpus/Medline/xml/PMC5123381.xml	Ib	84618 : 84620	CM	e objective of the phase Ib dose escalation/confirma
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	84706 : 84710	CM	commended phase II dose (RP2D).                  Metho
./___Corpus/Medline/xml/PMC5123381.xml	anti-	84802 : 84807	CPR	e III/IV NSCLC (previous anti-PD-1/PD-L1 therapy was pe
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	84812 : 84817	CM	SCLC (previous anti-PD-1/PD-L1 therapy was permitted) w
./___Corpus/Medline/xml/PMC5123381.xml	QW	84907 : 84909	CM	phase. ENT 3 mg and 5 mg QW PO + PEMBRO 200 mg Q3W I
./___Corpus/Medline/xml/PMC5123381.xml	PO	84910 : 84912	CM	se. ENT 3 mg and 5 mg QW PO + PEMBRO 200 mg Q3W IV i
./___Corpus/Medline/xml/PMC5123381.xml	PEMBRO	84915 : 84921	CM	NT 3 mg and 5 mg QW PO + PEMBRO 200 mg Q3W IV in 21-day 
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	84929 : 84932	CM	mg QW PO + PEMBRO 200 mg Q3W IV in 21-day cycles were
./___Corpus/Medline/xml/PMC5123381.xml	21-	84939 : 84942	CPR	 PEMBRO 200 mg Q3W IV in 21-day cycles were explored 
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	84995 : 84999	CM	determine the safety and RP2D, followed by a dose-conf
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85122 : 85127	CM	e studies included tumor PD-L1 expression and phenotypi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	85345 : 85350	CPR	hich progressed on prior anti-PD-1/PD-L1 therapy) were 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85355 : 85360	CM	essed on prior anti-PD-1/PD-L1 therapy) were treated wi
./___Corpus/Medline/xml/PMC5123381.xml	ENT	85388 : 85391	CM	erapy) were treated with ENT plus PEMBRO; 13 in the d
./___Corpus/Medline/xml/PMC5123381.xml	PEMBRO	85397 : 85403	CM	re treated with ENT plus PEMBRO; 13 in the dose escalati
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85540 : 85545	CM	mg). Of 20 patients with PD-L1 expression results, 7 pa
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85588 : 85593	CM	s, 7 patients (35 %) had PD-L1 < 1 %, 8 (40 %) had PD-L
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85614 : 85619	CM	D-L1 < 1 %, 8 (40 %) had PD-L1 1-49 %, and 5 (25 %) had
./___Corpus/Medline/xml/PMC5123381.xml	1-	85620 : 85622	CPR	 1 %, 8 (40 %) had PD-L1 1-49 %, and 5 (25 %) had PD
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	85645 : 85650	CM	1-49 %, and 5 (25 %) had PD-L1 ≥ 50 %. During dose esca
./___Corpus/Medline/xml/PMC5123381.xml	anti-	85717 : 85722	CPR	 previously treated with anti-PD-1 therapy experienced 
./___Corpus/Medline/xml/PMC5123381.xml	DLT	85749 : 85752	CM	-1 therapy experienced a DLT at Cycle 2 Day 15 (ENT 3
./___Corpus/Medline/xml/PMC5123381.xml	DLTs	85831 : 85835	CM	hepatitis), and no other DLTs were observed. Among all
./___Corpus/Medline/xml/PMC5123381.xml	hypophosphatemia	85923 : 85939	CM	ent-related AEs included hypophosphatemia (9 %), neutropenia (5 %)
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	86031 : 86042	CM	(5 %), elevated alkaline phosphatase (5 %) and immune-mediate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	86132 : 86137	CPR	ts previously exposed to anti-PD-1/PD-L1, best response
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	86142 : 86147	CM	sly exposed to anti-PD-1/PD-L1, best response includes 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	86203 : 86208	CPR	nd 3 PD. Of 11 evaluable anti-PD-1/PD-L1 naïve patients
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	86213 : 86218	CM	f 11 evaluable anti-PD-1/PD-L1 naïve patients, best res
./___Corpus/Medline/xml/PMC5123381.xml	PD	86275 : 86277	CM	ncludes 1 PR, 1 SD and 9 PD. A reduction in peripher
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	86305 : 86309	CM	 reduction in peripheral MDSC levels was observed betw
./___Corpus/Medline/xml/PMC5123381.xml	PMN-MDSCs	86426 : 86435	CM	edian decrease of 40.7 % PMN-MDSCs; 67.3 % M-MDSCs).       
./___Corpus/Medline/xml/PMC5123381.xml	M-MDSCs	86444 : 86451	CM	40.7 % PMN-MDSCs; 67.3 % M-MDSCs).                  Concl
./___Corpus/Medline/xml/PMC5123381.xml	ENT	86509 : 86512	CM	                    5 mg ENT weekly combined with PEM
./___Corpus/Medline/xml/PMC5123381.xml	PEMBRO	86534 : 86540	CM	ENT weekly combined with PEMBRO has a manageable safety 
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	86619 : 86624	CM	amic effects on reducing MDSCs, and will be further exp
./___Corpus/Medline/xml/PMC5123381.xml	CTL	87060 : 87063	CM	 to promote intratumoral CTL infiltration            
./___Corpus/Medline/xml/PMC5123381.xml	H	87221 : 87222	CM	jer4, Julie Urban3, Lisa H Butterfield2, William Go
./___Corpus/Medline/xml/PMC5123381.xml	Zeh3	87263 : 87267	CM	illiam Gooding2, Herbert Zeh3, David Bartlett4        
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	87388 : 87392	CM	or tissues with effector CD8+ T cells (CTLs) is associ
./___Corpus/Medline/xml/PMC5123381.xml	CTL	87595 : 87598	CM	nhance the production of CTL chemokines in tumor lesi
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	87760 : 87764	CM	dels demonstrate that a) TLR3-based combinatorial adju
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	87994 : 87998	CM	ssues; b) combination of TLR3 ligands with IFNa synerg
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	88012 : 88016	CM	ion of TLR3 ligands with IFNa synergistically amplifie
./___Corpus/Medline/xml/PMC5123381.xml	COX2	88186 : 88190	CM	c) that the inclusion of COX2 blockers prevents the in
./___Corpus/Medline/xml/PMC5123381.xml	10-	88370 : 88373	CPR	/II clinical trial (UPCI 10-131/{"type":"clinical-tri
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	88579 : 88583	CM	mod (Ampligen; selective TLR3 ligand) combined with In
./___Corpus/Medline/xml/PMC5123381.xml	celecoxib	88624 : 88633	CM	d with Intron A and oral celecoxib, in patients with resect
./___Corpus/Medline/xml/PMC5123381.xml	11–	88718 : 88721	CPR	ur phase I/II trial UPCI 11–128 ({"type":"clinical-tr
./___Corpus/Medline/xml/PMC5123381.xml	celecoxib	88949 : 88958	CM	 and Intron A (with oral celecoxib) in cisplatin-treated pa
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	88963 : 88972	CM	(with oral celecoxib) in cisplatin-treated patients with re
./___Corpus/Medline/xml/PMC5123381.xml	UPCI	89095 : 89099	CM	the completed phase I of UPCI 10–131, we observed very
./___Corpus/Medline/xml/PMC5123381.xml	10–	89100 : 89103	CPR	ompleted phase I of UPCI 10–131, we observed very goo
./___Corpus/Medline/xml/PMC5123381.xml	CTL	89234 : 89237	CM	lective disappearance of CTL-, TH1- and NK cell marke
./___Corpus/Medline/xml/PMC5123381.xml	TH1	89240 : 89243	CM	e disappearance of CTL-, TH1- and NK cell markers fro
./___Corpus/Medline/xml/PMC5123381.xml	24–	89291 : 89294	CPR	rom circulation, lasting 24–48 hours after rintatolim
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	89420 : 89426	CM	d intratumoral ratios of CXCL10 (CTL-attractant) to CCL2
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	89447 : 89452	CM	CL10 (CTL-attractant) to CCL22 (Treg-attractant) and CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8α	89475 : 89479	CM	22 (Treg-attractant) and CD8α (CTL marker) to FoxP3 (T
./___Corpus/Medline/xml/PMC5123381.xml	CTL	89481 : 89484	CM	eg-attractant) and CD8α (CTL marker) to FoxP3 (Treg m
./___Corpus/Medline/xml/PMC5123381.xml	11–	89730 : 89733	CPR	y-implemented study UPCI 11–128 provides preliminary 
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	89872 : 89881	CM	mor microenvironments in cisplatin-treated ovarian cancer p
./___Corpus/Medline/xml/PMC5123381.xml	CTL	90099 : 90102	CM	ely enhance intratumoral CTL infiltration. Verificati
./___Corpus/Medline/xml/PMC5123381.xml	NIH	90491 : 90494	CM	ect was supported by the NIH grants P01 CA132714 and 
./___Corpus/Medline/xml/PMC5123381.xml	P50	90519 : 90522	CM	 grants P01 CA132714 and P50 CA159981. Rintatolimod w
./___Corpus/Medline/xml/PMC5123381.xml	MTA	90565 : 90568	CM	limod was provided under MTA by Hemispherx Bio.      
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	90879 : 90886	CM	ized cell immunotherapy, AGS-003, and predict functional 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	90940 : 90944	CM	vity in combination with PD-1 checkpoint inhibitor and
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	90970 : 90979	CM	checkpoint inhibitor and sunitinib                         
./___Corpus/Medline/xml/PMC5123381.xml	AGS003	91298 : 91304	CM	und                      AGS003 is an immunotherapy cons
./___Corpus/Medline/xml/PMC5123381.xml	DCs	91367 : 91370	CM	ologous dendritic cells (DCs) electroporated with amp
./___Corpus/Medline/xml/PMC5123381.xml	RNA	91414 : 91417	CM	th amplified total tumor RNA plus synthetic CD40L RNA
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	91433 : 91438	CM	tumor RNA plus synthetic CD40L RNA and is currently bei
./___Corpus/Medline/xml/PMC5123381.xml	RNA	91439 : 91442	CM	RNA plus synthetic CD40L RNA and is currently being t
./___Corpus/Medline/xml/PMC5123381.xml	AGS003	91687 : 91693	CM	ore thoroughly study the AGS003 mechanism of action and 
./___Corpus/Medline/xml/PMC5123381.xml	DC	91841 : 91843	CM	                   Mouse DC precursors were processe
./___Corpus/Medline/xml/PMC5123381.xml	AGS003	91942 : 91948	CM	processed to manufacture AGS003. Bone marrow cells from 
./___Corpus/Medline/xml/PMC5123381.xml	7–	91973 : 91975	CPR	. Bone marrow cells from 7–10 week old Balb/c mice w
./___Corpus/Medline/xml/PMC5123381.xml	GMCSF	92019 : 92024	CM	mice were incubated with GMCSF and IL4 and matured with
./___Corpus/Medline/xml/PMC5123381.xml	IL4	92029 : 92032	CM	incubated with GMCSF and IL4 and matured with TNFa, I
./___Corpus/Medline/xml/PMC5123381.xml	TNFa	92050 : 92054	CM	and IL4 and matured with TNFa, IFNg and PGE2. Mature D
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	92056 : 92060	CM	4 and matured with TNFa, IFNg and PGE2. Mature DCs wer
./___Corpus/Medline/xml/PMC5123381.xml	PGE2	92065 : 92069	CM	ured with TNFa, IFNg and PGE2. Mature DCs were electro
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92078 : 92081	CM	a, IFNg and PGE2. Mature DCs were electroporated with
./___Corpus/Medline/xml/PMC5123381.xml	RNA	92119 : 92122	CM	porated with total tumor RNA from RENCA tumor plus sy
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	92128 : 92133	CM	ith total tumor RNA from RENCA tumor plus synthetic mCD
./___Corpus/Medline/xml/PMC5123381.xml	mCD40L	92155 : 92161	CM	NCA tumor plus synthetic mCD40L RNA and injected i.p. to
./___Corpus/Medline/xml/PMC5123381.xml	RNA	92162 : 92165	CM	or plus synthetic mCD40L RNA and injected i.p. to tre
./___Corpus/Medline/xml/PMC5123381.xml	i.p	92179 : 92182	CM	 mCD40L RNA and injected i.p. to treat syngeneic BALB
./___Corpus/Medline/xml/PMC5123381.xml	BALB	92203 : 92207	CM	 i.p. to treat syngeneic BALB/c mice in an orthotopic 
./___Corpus/Medline/xml/PMC5123381.xml	AGS003	92286 : 92292	CM	was utilized to test the AGS003-like mouse DCs as a sing
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92304 : 92307	CM	st the AGS003-like mouse DCs as a single agent or in 
./___Corpus/Medline/xml/PMC5123381.xml	mPD-1	92353 : 92358	CM	 in combination with the mPD-1 checkpoint inhibitor.   
./___Corpus/Medline/xml/PMC5123381.xml	murine	92469 : 92475	CM	 successfully developing murine DCs with similar propert
./___Corpus/Medline/xml/PMC5123381.xml	DCs	92476 : 92479	CM	sfully developing murine DCs with similar properties 
./___Corpus/Medline/xml/PMC5123381.xml	AGS003	92507 : 92513	CM	th similar properties to AGS003, including phenotype (CD
./___Corpus/Medline/xml/PMC5123381.xml	CD80	92536 : 92540	CM	03, including phenotype (CD80, CD83, CD86, MHCI, CCR7)
./___Corpus/Medline/xml/PMC5123381.xml	CD83	92542 : 92546	CM	cluding phenotype (CD80, CD83, CD86, MHCI, CCR7), secr
./___Corpus/Medline/xml/PMC5123381.xml	CD86	92548 : 92552	CM	g phenotype (CD80, CD83, CD86, MHCI, CCR7), secretion 
./___Corpus/Medline/xml/PMC5123381.xml	MHCI	92554 : 92558	CM	otype (CD80, CD83, CD86, MHCI, CCR7), secretion of IL1
./___Corpus/Medline/xml/PMC5123381.xml	CCR7	92560 : 92564	CM	(CD80, CD83, CD86, MHCI, CCR7), secretion of IL12 indu
./___Corpus/Medline/xml/PMC5123381.xml	IL12	92580 : 92584	CM	HCI, CCR7), secretion of IL12 induced by CD40L RNA and
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	92596 : 92601	CM	etion of IL12 induced by CD40L RNA and induction of CD8
./___Corpus/Medline/xml/PMC5123381.xml	RNA	92602 : 92605	CM	of IL12 induced by CD40L RNA and induction of CD8 + C
./___Corpus/Medline/xml/PMC5123381.xml	CD8	92623 : 92626	CM	40L RNA and induction of CD8 + CD28 + CD45RA- memory 
./___Corpus/Medline/xml/PMC5123381.xml	CD28	92629 : 92633	CM	A and induction of CD8 + CD28 + CD45RA- memory T cells
./___Corpus/Medline/xml/PMC5123381.xml	DC	92712 : 92714	CM	, as a single agent, the DC therapy was superior to 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	92739 : 92742	CM	 therapy was superior to PBS controls at increasing m
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	92901 : 92906	CM	n of the amplified total RENCA cell RNA based on compar
./___Corpus/Medline/xml/PMC5123381.xml	RNA	92912 : 92915	CM	plified total RENCA cell RNA based on comparison with
./___Corpus/Medline/xml/PMC5123381.xml	RNA	92952 : 92955	CM	mparison with irrelevant RNA controls. In addition, t
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	93073 : 93077	CM	d when combined with the PD-1 checkpoint inhibitor and
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	93103 : 93112	CM	checkpoint inhibitor and sunitinib.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	RNA	93227 : 93230	CM	of amplified total tumor RNA in directing immune resp
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	93470 : 93474	CM	nefit when combined with PD-1 checkpoint inhibition an
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	93501 : 93510	CM	heckpoint inhibition and sunitinib as the standard therapy 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	93759 : 93763	CM	 treatment with low-dose CD40 and TLR4 agonists overco
./___Corpus/Medline/xml/PMC5123381.xml	TLR4	93768 : 93772	CM	t with low-dose CD40 and TLR4 agonists overcomes resis
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	93806 : 93810	CM	 overcomes resistance to PD-1 blockade to control tumo
./___Corpus/Medline/xml/PMC5123381.xml	Campesato1	93898 : 93908	CM	 N. Khalil1, Luis Felipe Campesato1, Yanyun Li2, Taha Mergho
./___Corpus/Medline/xml/PMC5123381.xml	Li2	93917 : 93920	CM	elipe Campesato1, Yanyun Li2, Taha Merghoub2, Jedd D.
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94056 : 94061	CPR	eckpoint blockade (i.e., anti-PD-1, PD-L1, and/or CTLA-
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	94067 : 94072	CM	ockade (i.e., anti-PD-1, PD-L1, and/or CTLA-4) also dem
./___Corpus/Medline/xml/PMC5123381.xml	APCs	94309 : 94313	CM	 a source of immunogenic APCs capable of priming anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94333 : 94338	CPR	 APCs capable of priming anti-tumor T cells.           
./___Corpus/Medline/xml/PMC5123381.xml	B16	94447 : 94450	CM	kade resistant syngeneic B16 murine model with establ
./___Corpus/Medline/xml/PMC5123381.xml	murine	94451 : 94457	CM	 resistant syngeneic B16 murine model with established (
./___Corpus/Medline/xml/PMC5123381.xml	anti-	94624 : 94629	CPR	o overcome resistance to anti-PD-1 therapy. Such agents
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	94900 : 94904	CM	       In the setting of PD-1 blockade, we found that 
./___Corpus/Medline/xml/PMC5123381.xml	TLR4	94961 : 94965	CM	moral treatment with the TLR4 agonist monophosphoryl l
./___Corpus/Medline/xml/PMC5123381.xml	monophosphoryl lipid A	94974 : 94996	CM	nt with the TLR4 agonist monophosphoryl lipid A (MPL) and low-dose CD40 
./___Corpus/Medline/xml/PMC5123381.xml	MPL	94998 : 95001	CM	 monophosphoryl lipid A (MPL) and low-dose CD40 agoni
./___Corpus/Medline/xml/PMC5123381.xml	CD40	95016 : 95020	CM	pid A (MPL) and low-dose CD40 agonist monoclonal antib
./___Corpus/Medline/xml/PMC5123381.xml	anti-	95066 : 95071	CPR	ntibody (mAb) induces an anti-tumor T cell response. CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	95094 : 95098	CM	i-tumor T cell response. CD8+ T cells subsequently inf
./___Corpus/Medline/xml/PMC5123381.xml	CD86	95305 : 95309	CM	latory markers including CD86 within 3 hours of treatm
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	95552 : 95556	CM	filtrated with activated CD8+ T cells, and showed a ma
./___Corpus/Medline/xml/PMC5123381.xml	RAG1	95683 : 95687	CM	 tumors was abolished in RAG1-deficient animals lackin
./___Corpus/Medline/xml/PMC5123381.xml	fur	95801 : 95804	CM	n at 90 days, developing fur depigmentation at both t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	95951 : 95956	CPR	esting a highly specific anti-tumor response. Notably, 
./___Corpus/Medline/xml/PMC5123381.xml	MPL	96008 : 96011	CM	stemic administration of MPL and CD40 at 25-fold high
./___Corpus/Medline/xml/PMC5123381.xml	CD40	96016 : 96020	CM	dministration of MPL and CD40 at 25-fold higher dose w
./___Corpus/Medline/xml/PMC5123381.xml	25-fold	96024 : 96031	CM	ation of MPL and CD40 at 25-fold higher dose was less eff
./___Corpus/Medline/xml/PMC5123381.xml	TLR4	96203 : 96207	CM	 treatment with combined TLR4 and CD40 agonists induce
./___Corpus/Medline/xml/PMC5123381.xml	CD40	96212 : 96216	CM	t with combined TLR4 and CD40 agonists induces anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	96234 : 96239	CPR	nd CD40 agonists induces anti-tumor T cells which in tu
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	96681 : 96687	CM	                    P219 CA-170, a first in class oral s
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	97679 : 97685	CM	ave mobility challenges. CA-170 is a small molecule, ora
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	97745 : 97750	CM	ilable antagonist of the PD-L1, PD-L2 and VISTA/PD-1H i
./___Corpus/Medline/xml/PMC5123381.xml	PD-L2	97752 : 97757	CM	antagonist of the PD-L1, PD-L2 and VISTA/PD-1H immune c
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	97762 : 97767	CM	 of the PD-L1, PD-L2 and VISTA/PD-1H immune checkpoint 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	97768 : 97773	CM	e PD-L1, PD-L2 and VISTA/PD-1H immune checkpoint pathwa
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	97849 : 97855	CM	hase I clinical testing. CA-170 was developed through a 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	98021 : 98026	CM	ndependently mediated by PD-L1, PD-L2 and VISTA/PD-1H i
./___Corpus/Medline/xml/PMC5123381.xml	PD-L2	98028 : 98033	CM	ently mediated by PD-L1, PD-L2 and VISTA/PD-1H in funct
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	98038 : 98043	CM	ated by PD-L1, PD-L2 and VISTA/PD-1H in functional assa
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	98044 : 98049	CM	y PD-L1, PD-L2 and VISTA/PD-1H in functional assays.   
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	98118 : 98124	CM	ods                      CA-170 inhibition of the PD-1/P
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	98143 : 98147	CM	CA-170 inhibition of the PD-1/PD-L1/2 or VISTA/PD-1H s
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	98148 : 98153	CM	0 inhibition of the PD-1/PD-L1/2 or VISTA/PD-1H signali
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	98159 : 98164	CM	n of the PD-1/PD-L1/2 or VISTA/PD-1H signaling has been
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	98165 : 98170	CM	he PD-1/PD-L1/2 or VISTA/PD-1H signaling has been infer
./___Corpus/Medline/xml/PMC5123381.xml	vitro	98209 : 98214	CM	 been inferred though in vitro T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	98331 : 98336	CM	e presence of inhibitory PD-L1, PD-L2 or VISTA/PD-1H pr
./___Corpus/Medline/xml/PMC5123381.xml	PD-L2	98338 : 98343	CM	nce of inhibitory PD-L1, PD-L2 or VISTA/PD-1H proteins.
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	98347 : 98352	CM	hibitory PD-L1, PD-L2 or VISTA/PD-1H proteins. CA-170 s
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	98353 : 98358	CM	ry PD-L1, PD-L2 or VISTA/PD-1H proteins. CA-170 selecti
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	98369 : 98375	CM	or VISTA/PD-1H proteins. CA-170 selectivity was tested a
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	98465 : 98470	CM	ckpoint pathways CTLA-4, LAG-3, BTLA or the immune co-s
./___Corpus/Medline/xml/PMC5123381.xml	BTLA	98472 : 98476	CM	 pathways CTLA-4, LAG-3, BTLA or the immune co-stimula
./___Corpus/Medline/xml/PMC5123381.xml	B7	98506 : 98508	CM	he immune co-stimulatory B7/CD28 pathway in function
./___Corpus/Medline/xml/PMC5123381.xml	CD28	98509 : 98513	CM	immune co-stimulatory B7/CD28 pathway in functional as
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	98544 : 98550	CM	ay in functional assays. CA-170 in vivo antitumor activi
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	98816 : 98822	CM	lts                      CA-170 exhibits potent immune r
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	98894 : 98898	CM	able to that of blocking PD-1 or VISTA/PD-1H antibodie
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	98902 : 98907	CM	that of blocking PD-1 or VISTA/PD-1H antibodies when te
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	98908 : 98913	CM	f blocking PD-1 or VISTA/PD-1H antibodies when tested i
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	98994 : 98999	CM	ure the proliferation or IFN-γ secretion of T lymphocyt
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	99068 : 99073	CM	e presence of inhibitory PD-L1, PD-L2 or VISTA/PD-1H pr
./___Corpus/Medline/xml/PMC5123381.xml	PD-L2	99075 : 99080	CM	nce of inhibitory PD-L1, PD-L2 or VISTA/PD-1H proteins.
./___Corpus/Medline/xml/PMC5123381.xml	VISTA	99084 : 99089	CM	hibitory PD-L1, PD-L2 or VISTA/PD-1H proteins. CA-170 d
./___Corpus/Medline/xml/PMC5123381.xml	PD-1H	99090 : 99095	CM	ry PD-L1, PD-L2 or VISTA/PD-1H proteins. CA-170 does no
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	99106 : 99112	CM	or VISTA/PD-1H proteins. CA-170 does not exhibit off tar
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	99166 : 99171	CM	activity against CTLA-4, LAG-3, BTLA pathways or the B7
./___Corpus/Medline/xml/PMC5123381.xml	BTLA	99173 : 99177	CM	y against CTLA-4, LAG-3, BTLA pathways or the B7/CD28 
./___Corpus/Medline/xml/PMC5123381.xml	B7	99194 : 99196	CM	-3, BTLA pathways or the B7/CD28 pathway in function
./___Corpus/Medline/xml/PMC5123381.xml	CD28	99197 : 99201	CM	 BTLA pathways or the B7/CD28 pathway in functional as
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	99278 : 99284	CM	ice, orally administered CA-170 inhibits the growth of s
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	99422 : 99426	CM	on of tumor infiltrating CD8+ T cells in a dose depend
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	99558 : 99564	CM	tes, orally administered CA-170 shows no signs of toxici
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	99645 : 99651	CM	for 28 consecutive days. CA-170 exhibits an oral bioavai
./___Corpus/Medline/xml/PMC5123381.xml	CA-170	100021 : 100027	CM	 clinical development of CA-170, the first oral, small m
./___Corpus/Medline/xml/PMC5123381.xml	murine	100237 : 100243	CM	LA-4 blockade eradicates murine tumors by promoting anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	100264 : 100269	CPR	rine tumors by promoting anti-cancer immunity          
./___Corpus/Medline/xml/PMC5123381.xml	Jasmin	100323 : 100329	CM	                         Jasmin Leshem1, Xiu-fen Liu1, T
./___Corpus/Medline/xml/PMC5123381.xml	Xiu	100339 : 100342	CM	         Jasmin Leshem1, Xiu-fen Liu1, Tapan Bera1, M
./___Corpus/Medline/xml/PMC5123381.xml	fen	100343 : 100346	CM	     Jasmin Leshem1, Xiu-fen Liu1, Tapan Bera1, Masak
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	100755 : 100759	CM	ation and drug efficacy. SS1P and RG7787 are immunotox
./___Corpus/Medline/xml/PMC5123381.xml	RG7787	100764 : 100770	CM	 drug efficacy. SS1P and RG7787 are immunotoxins that co
./___Corpus/Medline/xml/PMC5123381.xml	anti-	100807 : 100812	CPR	oxins that consist of an anti-mesothelin antibody fragm
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	100964 : 100968	CM	ed onset of responses to SS1P treatment that persisted
./___Corpus/Medline/xml/PMC5123381.xml	anti-	101098 : 101103	CPR	that immunotoxins elicit anti-tumor immunity that can b
./___Corpus/Medline/xml/PMC5123381.xml	anti-	101160 : 101165	CPR	er potentiated by adding anti-CTLA-4 antibodies (aCTLA-
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	101184 : 101191	CM	 anti-CTLA-4 antibodies (aCTLA-4).                  Metho
./___Corpus/Medline/xml/PMC5123381.xml	66C14-M	101279 : 101286	CM	pothesis, we constructed 66C14-M murine breast cancer cel
./___Corpus/Medline/xml/PMC5123381.xml	murine	101287 : 101293	CM	, we constructed 66C14-M murine breast cancer cell line 
./___Corpus/Medline/xml/PMC5123381.xml	BALB	101391 : 101395	CM	 The cells were grown in BALB/c mice transgenic for hu
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	101403 : 101413	CM	ere grown in BALB/c mice transgenic for human mesothelin, be
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	101492 : 101496	CM	ild type mice. RG7787 or SS1P were injected directly i
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	101571 : 101578	CM	verage size >80 mm3) and aCTLA-4 was administered IP.    
./___Corpus/Medline/xml/PMC5123381.xml	IP	101596 : 101598	CM	aCTLA-4 was administered IP.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	101679 : 101686	CM	 that the combination of aCTLA-4 with RG7787 or SS1P indu
./___Corpus/Medline/xml/PMC5123381.xml	RG7787	101692 : 101698	CM	bination of aCTLA-4 with RG7787 or SS1P induced complete
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	101702 : 101706	CM	f aCTLA-4 with RG7787 or SS1P induced complete remissi
./___Corpus/Medline/xml/PMC5123381.xml	P	101838 : 101839	CM	ompared to mono-therapy (P < 0.001). No cures were 
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	101878 : 101885	CM	cures were obtained when aCTLA-4, RG7787, or SS1P were gi
./___Corpus/Medline/xml/PMC5123381.xml	RG7787	101887 : 101893	CM	e obtained when aCTLA-4, RG7787, or SS1P were given sepa
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	101898 : 101902	CM	when aCTLA-4, RG7787, or SS1P were given separately. I
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	101982 : 101989	CM	onding mice treated with aCTLA-4 and SS1P had more abunda
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	101994 : 101998	CM	treated with aCTLA-4 and SS1P had more abundant tumor-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	102036 : 102040	CM	ndant tumor-infiltrating CD8+ T cells compared to mice
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	102079 : 102086	CM	red to mice treated with aCTLA-4 or SS1P alone (P < 0.05)
./___Corpus/Medline/xml/PMC5123381.xml	SS1P	102090 : 102094	CM	 treated with aCTLA-4 or SS1P alone (P < 0.05) and tha
./___Corpus/Medline/xml/PMC5123381.xml	P	102102 : 102103	CM	h aCTLA-4 or SS1P alone (P < 0.05) and that the res
./___Corpus/Medline/xml/PMC5123381.xml	anti-	102174 : 102179	CPR	n mice were treated with anti-CD8 antibodies. Furthermo
./___Corpus/Medline/xml/PMC5123381.xml	66C14-M	102303 : 102310	CM	 with the same number of 66C14-M or the parental cells (n
./___Corpus/Medline/xml/PMC5123381.xml	anti-	102503 : 102508	CPR	nism responsible for the anti-tumor effect, we combined
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	102534 : 102541	CM	umor effect, we combined aCTLA-4 with a mutant RG7787 tha
./___Corpus/Medline/xml/PMC5123381.xml	RG7787	102556 : 102562	CM	ed aCTLA-4 with a mutant RG7787 that is unable to kill 6
./___Corpus/Medline/xml/PMC5123381.xml	66C14-M	102586 : 102593	CM	7 that is unable to kill 66C14-M cells and found that the
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	102689 : 102696	CM	 than that achieved with aCTLA-4 monotherapy. Some bacter
./___Corpus/Medline/xml/PMC5123381.xml	MAMP	102880 : 102884	CM	ur result indicates that MAMP recognition does not exp
./___Corpus/Medline/xml/PMC5123381.xml	aCTLA-4	103060 : 103067	CM	stemic administration of aCTLA-4 induced a high rate of i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	103266 : 103271	CPR	 P221 Adjuvant effect of anti-PD-L1 in boosting HER2-ta
./___Corpus/Medline/xml/PMC5123381.xml	Hu1	103388 : 103391	CM	ia1, Yang Xia1, Yangyang Hu1, Yi Wang2, Yangyi Bao2, 
./___Corpus/Medline/xml/PMC5123381.xml	Yi	103393 : 103395	CM	Yang Xia1, Yangyang Hu1, Yi Wang2, Yangyi Bao2, Fu D
./___Corpus/Medline/xml/PMC5123381.xml	Dai2	103419 : 103423	CM	i Wang2, Yangyi Bao2, Fu Dai2, Shiang Huang3, Elaine H
./___Corpus/Medline/xml/PMC5123381.xml	Elaine	103440 : 103446	CM	 Fu Dai2, Shiang Huang3, Elaine Hurt4, Robert E Hollings
./___Corpus/Medline/xml/PMC5123381.xml	anti-	103618 : 103623	CPR	 immunotherapy utilizing anti-CD3 x anti-HER2 bispecifi
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	103629 : 103638	CM	apy utilizing anti-CD3 x anti-HER2 bispecific antibody (HER
./___Corpus/Medline/xml/PMC5123381.xml	(HER2Bi)-armed	103659 : 103673	CM	HER2 bispecific antibody (HER2Bi)-armed T cells benefited both H
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	103697 : 103702	CM	d T cells benefited both HER2+ patients and patients wi
./___Corpus/Medline/xml/PMC5123381.xml	HER2	103738 : 103742	CM	nd patients with 1 or 2+ HER2 expression, ones that wo
./___Corpus/Medline/xml/PMC5123381.xml	ALDH	103891 : 103895	CM	r stem cell (CSC) marker ALDH in HER2+ breast cancer c
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	103899 : 103904	CM	ell (CSC) marker ALDH in HER2+ breast cancer cells (ALD
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	103969 : 103974	CM	much higher than that in HER2− breast cancer cells (ALD
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	104066 : 104071	CM	cers that are considered HER2−, HER2 is actually select
./___Corpus/Medline/xml/PMC5123381.xml	HER2	104073 : 104077	CM	at are considered HER2−, HER2 is actually selectively 
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed	104208 : 104220	CM	e surprising result that HER2Bi-armed T cells, while intended 
./___Corpus/Medline/xml/PMC5123381.xml	HER2	104255 : 104259	CM	while intended to target HER2, seemed to benefit HER2−
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	104279 : 104284	CM	 HER2, seemed to benefit HER2− patients after adoptive 
./___Corpus/Medline/xml/PMC5123381.xml	HER2	104386 : 104390	CM	    We tested the “mouse HER2” (neu) expression on ALD
./___Corpus/Medline/xml/PMC5123381.xml	mHER2	104462 : 104467	CM	 cells (mouse TNBC). For mHER2 targeting in animal mode
./___Corpus/Medline/xml/PMC5123381.xml	anti-	104509 : 104514	CPR	mal models, we generated anti-mouse HER2-CD3 bispecific
./___Corpus/Medline/xml/PMC5123381.xml	HER2-CD3	104520 : 104528	CM	 we generated anti-mouse HER2-CD3 bispecific (mHER2Bi) tha
./___Corpus/Medline/xml/PMC5123381.xml	mHER2Bi	104541 : 104548	CM	use HER2-CD3 bispecific (mHER2Bi) that binds to mouse HER
./___Corpus/Medline/xml/PMC5123381.xml	HER2	104570 : 104574	CM	2Bi) that binds to mouse HER2 and mouse CD3.          
./___Corpus/Medline/xml/PMC5123381.xml	CD3	104585 : 104588	CM	 to mouse HER2 and mouse CD3.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed	104636 : 104648	CM	lts                      HER2Bi-armed T cells used in the clin
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	104713 : 104717	CM	ed ALDHhigh human breast CSCs isolated from MCF7 (HER2
./___Corpus/Medline/xml/PMC5123381.xml	MCF7	104732 : 104736	CM	reast CSCs isolated from MCF7 (HER2−) tumor significan
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	104738 : 104743	CM	CSCs isolated from MCF7 (HER2−) tumor significantly mor
./___Corpus/Medline/xml/PMC5123381.xml	MCF7	104783 : 104787	CM	cantly more than ALDHlow MCF7 cells in vitro, while th
./___Corpus/Medline/xml/PMC5123381.xml	vitro	104797 : 104802	CM	an ALDHlow MCF7 cells in vitro, while the same HER2Bi-a
./___Corpus/Medline/xml/PMC5123381.xml	HER2Bi-armed	104819 : 104831	CM	in vitro, while the same HER2Bi-armed T cells killed ALDHhigh 
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	104869 : 104873	CM	ed ALDHhigh human breast CSCs (ALDHhighHER2+) isolated
./___Corpus/Medline/xml/PMC5123381.xml	BT474	104904 : 104909	CM	highHER2+) isolated from BT474 (HER2+) tumor equally to
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	104911 : 104916	CM	2+) isolated from BT474 (HER2+) tumor equally to ALDHlo
./___Corpus/Medline/xml/PMC5123381.xml	BT474	104943 : 104948	CM	tumor equally to ALDHlow BT474 cells (ALDHlowHER2+). We
./___Corpus/Medline/xml/PMC5123381.xml	mHER2	104990 : 104995	CM	R2+). We also found that mHER2 was selectively expresse
./___Corpus/Medline/xml/PMC5123381.xml	HER2	105126 : 105130	CM	uman breast cancers that HER2 is selectively expressed
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105159 : 105163	CM	selectively expressed on CSCs, even in HER2− murine tu
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	105173 : 105178	CM	pressed on CSCs, even in HER2− murine tumors, such as 4
./___Corpus/Medline/xml/PMC5123381.xml	murine	105179 : 105185	CM	d on CSCs, even in HER2− murine tumors, such as 4 T1. In
./___Corpus/Medline/xml/PMC5123381.xml	vitro	105211 : 105216	CM	tumors, such as 4 T1. In vitro, the mHER2Bi-armed T cel
./___Corpus/Medline/xml/PMC5123381.xml	anti-	105463 : 105468	CPR	 host. Administration of anti-mouse PD-L1 during mHER2B
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	105474 : 105479	CM	nistration of anti-mouse PD-L1 during mHER2Bi-armed T c
./___Corpus/Medline/xml/PMC5123381.xml	HER2	105762 : 105766	CM	 selective expression of HER2 on CSCs, HER2-targeted T
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105770 : 105774	CM	ve expression of HER2 on CSCs, HER2-targeted T cell th
./___Corpus/Medline/xml/PMC5123381.xml	HER2−	105819 : 105824	CM	ll therapy could benefit HER2− hosts as well as HER2+ h
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	105842 : 105847	CM	t HER2− hosts as well as HER2+ hosts via immune destruc
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	105880 : 105885	CM	ia immune destruction of HER2+ CSCs, and use of anti-PD
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	105886 : 105890	CM	une destruction of HER2+ CSCs, and use of anti-PD-L1 c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	105903 : 105908	CPR	f HER2+ CSCs, and use of anti-PD-L1 could significantly
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	106300 : 106304	CM	c ductal adenocarcinoma (PDAC) is the fourth leading c
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	106416 : 106420	CM	ions other than surgery. PDAC is characterized by dens
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	106525 : 106533	CM	s of the proinflammatory cytokine interleukin-6 (IL-6). Ou
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	106615 : 106619	CM	rted that higher IL-6 in PDAC patients is strongly ass
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	107084 : 107089	CM	e cross-talk between the STAT3 and MEK pathways. Thus, 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	107094 : 107097	CM	lk between the STAT3 and MEK pathways. Thus, we hypot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107231 : 107236	CPR	r targeted therapeutics (anti-PD-L1 and cobimetinib) in
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107246 : 107257	CM	apeutics (anti-PD-L1 and cobimetinib) in pancreatic cancer.  
./___Corpus/Medline/xml/PMC5123381.xml	Ab	107384 : 107386	CM	nducted with antibodies (Ab) blocking IL-6, in combi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107449 : 107454	CPR	heckpoint immunotherapy (anti-PD-L1) or MEK inhibition 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	107464 : 107467	CM	otherapy (anti-PD-L1) or MEK inhibition (cobimetinib)
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107480 : 107491	CM	D-L1) or MEK inhibition (cobimetinib). Experiments were condu
./___Corpus/Medline/xml/PMC5123381.xml	KPC	107550 : 107553	CM	ice bearing subcutaneous KPC-derived MT5 tumors; orth
./___Corpus/Medline/xml/PMC5123381.xml	MT5	107562 : 107565	CM	subcutaneous KPC-derived MT5 tumors; orthotopically i
./___Corpus/Medline/xml/PMC5123381.xml	KPC-luciferase	107598 : 107612	CM	 orthotopically injected KPC-luciferase expressing tumor cells i
./___Corpus/Medline/xml/PMC5123381.xml	CD2F1	107679 : 107684	CM	nd Colon26 tumor bearing CD2F1 mice to determine effect
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107805 : 107810	CPR	6 blockade combined with anti-PD-L1 (p < 0.02) or cobim
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	107830 : 107841	CM	anti-PD-L1 (p < 0.02) or cobimetinib (p = 0.007) elicited ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	107863 : 107868	CPR	nib (p = 0.007) elicited anti-tumor efficacy in mice be
./___Corpus/Medline/xml/PMC5123381.xml	KPC	107912 : 107915	CM	ice bearing subcutaneous KPC derived MT5 tumors, comp
./___Corpus/Medline/xml/PMC5123381.xml	MT5	107924 : 107927	CM	subcutaneous KPC derived MT5 tumors, compared to vehi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	108000 : 108005	CPR	kade in combination with anti-PD-L1 antibodies limited 
./___Corpus/Medline/xml/PMC5123381.xml	KPC-luciferase	108057 : 108071	CM	mor growth of orthotopic KPC-luciferase expressing tumor cells c
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108239 : 108250	CM	kade in combination with cobimetinib on a classically accepte
./___Corpus/Medline/xml/PMC5123381.xml	CD2F1	108299 : 108304	CM	ed tumor cachexia model (CD2F1 mice bearing Colon26 tum
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108358 : 108369	CM	. Only mice treated with cobimetinib or the combination of IL
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108402 : 108413	CM	combination of IL-6 plus cobimetinib resulted in significant 
./___Corpus/Medline/xml/PMC5123381.xml	cobimetinib	108577 : 108588	CM	e or in combination with cobimetinib prevented tumor-induced 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	109169 : 109173	CM	 the setting of combined PD-1 and CTLA-4 blockade     
./___Corpus/Medline/xml/PMC5123381.xml	P	109245 : 109246	CM	 Macedo Gonzales, Austin P Huffman, Ximi K Wang, Ra
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	109353 : 109357	CM	ockade of the CTLA-4 and PD-1 immune checkpoint molecu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	109629 : 109634	CPR	onment which dampens the anti-tumor response. Thus, ide
./___Corpus/Medline/xml/PMC5123381.xml	anti-	109908 : 109913	CPR	olecules are involved in anti-tumor responses by studyi
./___Corpus/Medline/xml/PMC5123381.xml	murine	109956 : 109962	CM	 studying both human and murine melanoma.               
./___Corpus/Medline/xml/PMC5123381.xml	RNA	110019 : 110022	CM	ods                      RNA sequencing data were obt
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	110185 : 110192	CM	ly injected with 100,000 B16-F10 cells in the flank and s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	110278 : 110283	CPR	ry analysis. Anti-PD-1 + anti-CTLA-4 blocking antibodie
./___Corpus/Medline/xml/PMC5123381.xml	PBS	110313 : 110316	CM	4 blocking antibodies or PBS were injected intraperit
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	110502 : 110506	CM	inflammatory chemokines (CCL2, CCL5, CXCL9, CXCL10) an
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	110508 : 110512	CM	matory chemokines (CCL2, CCL5, CXCL9, CXCL10) and thei
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	110514 : 110519	CM	 chemokines (CCL2, CCL5, CXCL9, CXCL10) and their recep
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	110521 : 110527	CM	ines (CCL2, CCL5, CXCL9, CXCL10) and their receptors (CC
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110550 : 110554	CM	10) and their receptors (CCR2, CCR5, CXCR3) were overe
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	110556 : 110560	CM	d their receptors (CCR2, CCR5, CXCR3) were overexpress
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	110562 : 110567	CM	r receptors (CCR2, CCR5, CXCR3) were overexpressed in h
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110671 : 110675	CM	tering demonstrated that CCR2, CCR5 and CCL2 were asso
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	110677 : 110681	CM	 demonstrated that CCR2, CCR5 and CCL2 were associated
./___Corpus/Medline/xml/PMC5123381.xml	CCL2	110686 : 110690	CM	ated that CCR2, CCR5 and CCL2 were associated with CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD68	110712 : 110716	CM	CL2 were associated with CD68 and CD14 genes while CXC
./___Corpus/Medline/xml/PMC5123381.xml	CD14	110721 : 110725	CM	associated with CD68 and CD14 genes while CXCR3, CCL5,
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	110738 : 110743	CM	D68 and CD14 genes while CXCR3, CCL5, CXCL9 and CXCL10 
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	110745 : 110749	CM	 CD14 genes while CXCR3, CCL5, CXCL9 and CXCL10 were a
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	110751 : 110756	CM	genes while CXCR3, CCL5, CXCL9 and CXCL10 were associat
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	110761 : 110767	CM	e CXCR3, CCL5, CXCL9 and CXCL10 were associated with CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8A	110789 : 110793	CM	L10 were associated with CD8A, CD8B and T-bet genes. M
./___Corpus/Medline/xml/PMC5123381.xml	CD8B	110795 : 110799	CM	re associated with CD8A, CD8B and T-bet genes. Moreove
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	110867 : 110872	CM	ng of tumor-infiltrating CD45+ cells from B16-F10 tumor
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	110884 : 110891	CM	trating CD45+ cells from B16-F10 tumor-bearing mice revea
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	110937 : 110941	CM	evealed higher levels of CCR2. Interestingly, monocyti
./___Corpus/Medline/xml/PMC5123381.xml	monocytic	110958 : 110967	CM	 of CCR2. Interestingly, monocytic myeloid-derived suppress
./___Corpus/Medline/xml/PMC5123381.xml	M-MDSCs	111002 : 111009	CM	erived suppressor cells (M-MDSCs) and inflammatory dendri
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	111096 : 111103	CM	of these receptors. When B16-F10 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	111141 : 111146	CPR	g mice were treated with anti-PD-1/anti-CTLA-4 antibodi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	111151 : 111156	CPR	e treated with anti-PD-1/anti-CTLA-4 antibodies, we obs
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	111249 : 111254	CM	 and increased levels of CD45+ cells (p < 0.05), CD8+ T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111273 : 111277	CM	 CD45+ cells (p < 0.05), CD8+ T cells (p < 0.05) and i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	111311 : 111314	CM	(p < 0.05) and increased CD8/Treg ratio (p < 0.01) in
./___Corpus/Medline/xml/PMC5123381.xml	M-MDSC	111388 : 111394	CM	 however, the numbers of M-MDSC were not reduced. More i
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	111431 : 111435	CM	duced. More importantly, CCR2 and CCR5 were still high
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	111440 : 111444	CM	re importantly, CCR2 and CCR5 were still high within t
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	111474 : 111479	CM	 still high within total CD45+ cells (26-30 %) and M-MD
./___Corpus/Medline/xml/PMC5123381.xml	26-	111487 : 111490	CPR	ithin total CD45+ cells (26-30 %) and M-MDSCs (54-71 
./___Corpus/Medline/xml/PMC5123381.xml	M-MDSCs	111500 : 111507	CM	D45+ cells (26-30 %) and M-MDSCs (54-71 %) in both treate
./___Corpus/Medline/xml/PMC5123381.xml	54-	111509 : 111512	CPR	s (26-30 %) and M-MDSCs (54-71 %) in both treated and
./___Corpus/Medline/xml/PMC5123381.xml	CCR1	111633 : 111637	CM	reased the expression of CCR1 (p < 0.05) and CXCR3 (p 
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	111653 : 111658	CM	n of CCR1 (p < 0.05) and CXCR3 (p < 0.05) in CD8+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111673 : 111677	CM	 and CXCR3 (p < 0.05) in CD8+ T cells, without increas
./___Corpus/Medline/xml/PMC5123381.xml	CCR2	111716 : 111720	CM	out increasing levels of CCR2 and CCR5.               
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	111725 : 111729	CM	asing levels of CCR2 and CCR5.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	111857 : 111861	CM	eases the trafficking of CD8+ T cells into the tumor u
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	111895 : 111900	CM	into the tumor using the CXCL9/CXCL10-CXCR3 axis but do
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10-CXCR3	111901 : 111913	CM	he tumor using the CXCL9/CXCL10-CXCR3 axis but does not affect
./___Corpus/Medline/xml/PMC5123381.xml	CCL2-CCR2	111943 : 111952	CM	 but does not affect the CCL2-CCR2 and CCL5-CCR5 axis that 
./___Corpus/Medline/xml/PMC5123381.xml	CCL5-CCR5	111957 : 111966	CM	affect the CCL2-CCR2 and CCL5-CCR5 axis that are critical f
./___Corpus/Medline/xml/PMC5123381.xml	M-MDSCs	111994 : 112001	CM	is that are critical for M-MDSCs trafficking into the mel
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	112273 : 112282	CM	    P224 Targeting tumor glutamine metabolism with CB-839 e
./___Corpus/Medline/xml/PMC5123381.xml	glucose	112692 : 112699	CM	ential nutrients such as glucose and glutamine. Within th
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	112704 : 112713	CM	ents such as glucose and glutamine. Within the tumor microe
./___Corpus/Medline/xml/PMC5123381.xml	anti-	112878 : 112883	CPR	on and suppression of an anti-tumor immune response. En
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	112947 : 112951	CM	mune checkpoints such as PD-1 further suppresses T cel
./___Corpus/Medline/xml/PMC5123381.xml	glutaminase	113198 : 113209	CM	ne response. CB-839 is a glutaminase inhibitor currently in p
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113272 : 113281	CM	gy trials. CB-839 blocks glutamine consumption by tumors le
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113324 : 113333	CM	mors leading to elevated glutamine levels in the tumor micr
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113412 : 113421	CM	gh demand of T cells for glutamine, we hypothesized that CB
./___Corpus/Medline/xml/PMC5123381.xml	anti-	113552 : 113557	CPR	ion and lead to enhanced anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	Ex	113627 : 113629	CM	ods                      Ex vivo T cell activation w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	113672 : 113677	CPR	ation was performed with anti-CD3/CD28 on CD3+ cells is
./___Corpus/Medline/xml/PMC5123381.xml	CD28	113681 : 113685	CM	 performed with anti-CD3/CD28 on CD3+ cells isolated f
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	113689 : 113693	CM	ed with anti-CD3/CD28 on CD3+ cells isolated from huma
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	113720 : 113725	CM	ells isolated from human PBMCs. Changes in mRNA express
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	113738 : 113742	CM	 human PBMCs. Changes in mRNA expression after T cell 
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	113869 : 113874	CM	e conducted in syngeneic CT-26 or B16 tumor models.    
./___Corpus/Medline/xml/PMC5123381.xml	B16	113878 : 113881	CM	ed in syngeneic CT-26 or B16 tumor models.           
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	113978 : 113987	CM	vation in the absence of glutamine inhibited cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	114084 : 114088	CM	ion markers. Analysis of mRNA expression also showed s
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	114206 : 114210	CM	ustion markers including PD-1, CTLA-4 and BTLA, sugges
./___Corpus/Medline/xml/PMC5123381.xml	BTLA	114223 : 114227	CM	cluding PD-1, CTLA-4 and BTLA, suggesting that T cell 
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114281 : 114290	CM	vation in the absence of glutamine may be sufficient to ind
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114383 : 114392	CM	howed that CB-839 blocks glutamine consumption in tumors le
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114552 : 114561	CM	hlighting differences in glutamine utilization pathways bet
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	114679 : 114688	CM	of CB-839 elevated tumor glutamine levels, consistent with 
./___Corpus/Medline/xml/PMC5123381.xml	glutaminase	114733 : 114744	CM	with inhibition of tumor glutaminase. Combination of CB-839 w
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	114778 : 114782	CM	tion of CB-839 with anti PD-1 or anti PD-L1 in the syn
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	114791 : 114796	CM	9 with anti PD-1 or anti PD-L1 in the syngeneic CT-26 c
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	114814 : 114819	CM	i PD-L1 in the syngeneic CT-26 colon model augmented tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	114926 : 114931	CPR	CB-839 also enhanced the anti-tumor activity of checkpo
./___Corpus/Medline/xml/PMC5123381.xml	B16	114978 : 114981	CM	kpoint inhibitors in the B16 melanoma model. Depletio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	115011 : 115015	CM	noma model. Depletion of CD8+ T cells from tumor-beari
./___Corpus/Medline/xml/PMC5123381.xml	anti-	115064 : 115069	CPR	ing animals reversed the anti-tumor effects of the comb
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	115515 : 115523	CM	                    P225 Arginase inhibitor CB-1158 allevi
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	115534 : 115541	CM	 P225 Arginase inhibitor CB-1158 alleviates immunosuppres
./___Corpus/Medline/xml/PMC5123381.xml	anti-	115584 : 115589	CPR	suppression and enhances anti-tumor responses as a sing
./___Corpus/Medline/xml/PMC5123381.xml	Li	115797 : 115799	CM	ross, Tony Huang, Weiqun Li, Andy MacKinnon, Gisele 
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	115999 : 116009	CM	iller (NK) cells require L-arginine for proliferation. Argin
./___Corpus/Medline/xml/PMC5123381.xml	Arginine	116029 : 116037	CM	inine for proliferation. Arginine depletion by arginase in
./___Corpus/Medline/xml/PMC5123381.xml	arginase	116051 : 116059	CM	n. Arginine depletion by arginase in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	116161 : 116169	CM	th tumor immune evasion. Arginase is expressed by myeloid-
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	116220 : 116225	CM	erived suppressor cells (MDSCs) and polymorphonuclear c
./___Corpus/Medline/xml/PMC5123381.xml	arginine	116321 : 116329	CM	n is expected to restore arginine levels and relieve immun
./___Corpus/Medline/xml/PMC5123381.xml	anti-	116379 : 116384	CPR	osuppression, leading to anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	116467 : 116474	CM	            We developed CB-1158, a potent and selective 
./___Corpus/Medline/xml/PMC5123381.xml	arginase	116527 : 116535	CM	ll molecule inhibitor of arginase (IC50 = 98 nM). The acti
./___Corpus/Medline/xml/PMC5123381.xml	IC50	116537 : 116541	CM	e inhibitor of arginase (IC50 = 98 nM). The activity o
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	116568 : 116575	CM	 98 nM). The activity of CB-1158 was examined ex vivo usi
./___Corpus/Medline/xml/PMC5123381.xml	murine	116687 : 116693	CM	ients, and in vivo using murine syngeneic tumor models. 
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	116718 : 116726	CM	 syngeneic tumor models. Arginase abundance in cancer pati
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	116906 : 116911	CM	 of T cells with PMNs or MDSCs, CB-1158 reverses PMN- o
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	116913 : 116920	CM	ells with PMNs or MDSCs, CB-1158 reverses PMN- or MDSC-me
./___Corpus/Medline/xml/PMC5123381.xml	PMN	116930 : 116933	CM	 MDSCs, CB-1158 reverses PMN- or MDSC-mediated immuno
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	116938 : 116942	CM	CB-1158 reverses PMN- or MDSC-mediated immunosuppressi
./___Corpus/Medline/xml/PMC5123381.xml	arginine	116982 : 116990	CM	osuppression by blocking arginine depletion, thereby allow
./___Corpus/Medline/xml/PMC5123381.xml	Th1	117154 : 117157	CM	of cytokines involved in Th1-type adaptive immunity, 
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117229 : 117236	CM	ersed by the addition of CB-1158. In vivo, CB-1158 has hi
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117247 : 117254	CM	ion of CB-1158. In vivo, CB-1158 has high oral bioavailab
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117358 : 117365	CM	e, twice daily dosing of CB-1158 causes dose-dependent ph
./___Corpus/Medline/xml/PMC5123381.xml	arginine	117434 : 117442	CM	ases in plasma and tumor arginine levels associated with s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	117479 : 117484	CPR	ciated with single agent anti-tumor efficacy in multipl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	117533 : 117538	CPR	le syngeneic models. The anti-tumor efficacy of CB-1158
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117556 : 117563	CM	e anti-tumor efficacy of CB-1158 is abrogated in immunoco
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	117630 : 117634	CM	 via depletion of either CD8+ T cells or NK cells, con
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117717 : 117724	CM	ism of action. Moreover, CB-1158 enhances CD8+ T cell inf
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	117734 : 117738	CM	reover, CB-1158 enhances CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	Th1	117799 : 117802	CM	 increases expression of Th1 cytokines, T cell and NK
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	117931 : 117938	CM	nomodulatory activity of CB-1158 supports the potential o
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	118043 : 118050	CM	ndard-of-care therapies. CB-1158 enhances the anti-tumor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118064 : 118069	CPR	es. CB-1158 enhances the anti-tumor efficacy of checkpo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118120 : 118125	CPR	nt inhibitors, including anti-PD-L1 and epacadostat in 
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	118154 : 118160	CM	1 and epacadostat in the B16F10 model. Moreover, CB-1158
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	118178 : 118185	CM	 B16F10 model. Moreover, CB-1158 enhances the anti-tumor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	118199 : 118204	CPR	er, CB-1158 enhances the anti-tumor efficacy of standar
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	118307 : 118314	CM	he clinical potential of CB-1158, the abundance of argina
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118333 : 118341	CM	B-1158, the abundance of arginase in tumors and plasma fro
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	118432 : 118440	CM	histotypes was surveyed. Arginase-expressing PMN infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	PMN	118452 : 118455	CM	yed. Arginase-expressing PMN infiltrates are abundant
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118513 : 118521	CM	iple tumor types. Plasma arginase levels are elevated in c
./___Corpus/Medline/xml/PMC5123381.xml	arginine	118632 : 118640	CM	ed with decreased plasma arginine.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	118742 : 118749	CM	 clinical development of CB-1158, a first-in-class argina
./___Corpus/Medline/xml/PMC5123381.xml	arginase	118768 : 118776	CM	B-1158, a first-in-class arginase inhibitor, as a novel im
./___Corpus/Medline/xml/PMC5123381.xml	CB-1158	118929 : 118936	CM	the clinical activity of CB-1158 in cancer patients has b
./___Corpus/Medline/xml/PMC5123381.xml	anti-	119875 : 119880	CPR	eckpoint blockade (e.g., anti-CTLA-4 antibody-based tre
./___Corpus/Medline/xml/PMC5123381.xml	anti-	119917 : 119922	CPR	ody-based treatments and anti-PD-1 antibody-based treat
./___Corpus/Medline/xml/PMC5123381.xml	TIL	119981 : 119984	CM	d adoptive T cell (e.g., TIL) transfer lymphocytes in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120243 : 120248	CPR	 tumor-bearing host with anti-CTLA-4 and/or anti-PD-1 a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120262 : 120267	CPR	 with anti-CTLA-4 and/or anti-PD-1 antibodies, and sple
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120459 : 120464	CPR	rapy results in superior anti-tumor immunity compared t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120627 : 120632	CPR	donor and recipient with anti-PD-1 and anti-CTLA-4 anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120641 : 120646	CPR	pient with anti-PD-1 and anti-CTLA-4 antibodies induces
./___Corpus/Medline/xml/PMC5123381.xml	CD8	120713 : 120716	CM	rity of recipients, in a CD8, NK, and IFNγ-dependent 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	120726 : 120730	CM	ients, in a CD8, NK, and IFNγ-dependent manner, despit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	120859 : 120864	CPR	ransfer) induces minimal anti-tumor effect. Furthermore
./___Corpus/Medline/xml/PMC5123381.xml	IL	121041 : 121043	CM	 in vivo serum levels of IL-15 and IL-7, higher ex v
./___Corpus/Medline/xml/PMC5123381.xml	IL-7	121051 : 121055	CM	erum levels of IL-15 and IL-7, higher ex vivo levels o
./___Corpus/Medline/xml/PMC5123381.xml	IL-15R	121082 : 121088	CM	higher ex vivo levels of IL-15R and IL-7 -receptors expr
./___Corpus/Medline/xml/PMC5123381.xml	IL-7	121093 : 121097	CM	ivo levels of IL-15R and IL-7 -receptors expression on
./___Corpus/Medline/xml/PMC5123381.xml	CD8s	121123 : 121127	CM	-receptors expression on CD8s, in vitro STAT5 phosphor
./___Corpus/Medline/xml/PMC5123381.xml	vitro	121132 : 121137	CM	s expression on CD8s, in vitro STAT5 phosphorylation in
./___Corpus/Medline/xml/PMC5123381.xml	STAT5	121138 : 121143	CM	ession on CD8s, in vitro STAT5 phosphorylation in respo
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	121144 : 121159	RN	 on CD8s, in vitro STAT5 phosphorylation in response to common γ-
./___Corpus/Medline/xml/PMC5123381.xml	γ-	121182 : 121184	CPR	on in response to common γ-chain cytokines, in vivo 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	121280 : 121285	CM	te tumor antigen, and in vitro production of IFNγ and T
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	121300 : 121304	CM	d in vitro production of IFNγ and TNF production in re
./___Corpus/Medline/xml/PMC5123381.xml	TNF	121309 : 121312	CM	o production of IFNγ and TNF production in response t
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	121502 : 121510	CM	 the above observations (cytokine production, proliferatio
./___Corpus/Medline/xml/PMC5123381.xml	anti-	121538 : 121543	CPR	oduction, proliferation, anti-tumor effect) on specific
./___Corpus/Medline/xml/PMC5123381.xml	γ-	121576 : 121578	CPR	fect) on specific common γ-chain cytokines, the role
./___Corpus/Medline/xml/PMC5123381.xml	anti-	121763 : 121768	CPR	ize the amplification of anti-tumor immunity observed. 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	121853 : 121861	CM	   P227 Immunomodulatory cytokine blockade in combination 
./___Corpus/Medline/xml/PMC5123381.xml	murine	121910 : 121916	CM	 with CTLA-4 blockade in murine models of pancreatic can
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	122615 : 122623	CM	 systemic alterations in cytokine expression that shape th
./___Corpus/Medline/xml/PMC5123381.xml	CD8	122962 : 122965	CM	 (IL-10) and circulating CD8 + CTLA-4+ cells were cor
./___Corpus/Medline/xml/PMC5123381.xml	CTLA-4+	122968 : 122975	CM	0) and circulating CD8 + CTLA-4+ cells were correlated wi
./___Corpus/Medline/xml/PMC5123381.xml	murine	123387 : 123393	CM	 syngeneic, subcutaneous murine pancreatic tumor cells d
./___Corpus/Medline/xml/PMC5123381.xml	;LSL	123444 : 123448	CM	rived from LSL-Kras G12D ;LSL- p53 R172H ;Pdx1-Cr and 
./___Corpus/Medline/xml/PMC5123381.xml	p53	123450 : 123453	CM	from LSL-Kras G12D ;LSL- p53 R172H ;Pdx1-Cr and in a 
./___Corpus/Medline/xml/PMC5123381.xml	p53	123554 : 123557	CM	l, harboring Kras G12D ; p53 R172H and Brca2 mutation
./___Corpus/Medline/xml/PMC5123381.xml	R172H	123558 : 123563	CM	arboring Kras G12D ; p53 R172H and Brca2 mutation (KPC-
./___Corpus/Medline/xml/PMC5123381.xml	KPC-BRCA2	123584 : 123593	CM	172H and Brca2 mutation (KPC-BRCA2). Relevant immune biomar
./___Corpus/Medline/xml/PMC5123381.xml	P	123887 : 123888	CM	to both isotype control (P = 0.0001) and anti-CTLA-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	123903 : 123908	CPR	control (P = 0.0001) and anti-CTLA-4 alone (P = 0.0207)
./___Corpus/Medline/xml/PMC5123381.xml	P	123922 : 123923	CM	) and anti-CTLA-4 alone (P = 0.0207). Treatment wit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124012 : 124017	CPR	kade in combination with anti-CTLA-4 slowed tumor growt
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124111 : 124116	CPR	inferior to single agent anti-CTLA-4. FACS analysis of 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	124257 : 124261	CM	roportion of circulating CD4+ central memory cells (CD
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	124292 : 124297	CM	al memory cells (CD62L + CD44+). Blockade of IL-6 and C
./___Corpus/Medline/xml/PMC5123381.xml	Th1	124405 : 124408	CM	 increase in circulating Th1 cells while both isotype
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124446 : 124451	CPR	both isotype control and anti-IL-6 had significantly mo
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	124503 : 124507	CM	 naïve systemic T cells (CD4+/CD8 + CD62L + CD44-). IH
./___Corpus/Medline/xml/PMC5123381.xml	CD8	124508 : 124511	CM	e systemic T cells (CD4+/CD8 + CD62L + CD44-). IHC an
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	124575 : 124579	CM	d increased infiltrating CD3+ cells throughout the tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	124946 : 124951	CPR	 augment the efficacy of anti-CTLA-4 in murine models o
./___Corpus/Medline/xml/PMC5123381.xml	murine	124961 : 124967	CM	ficacy of anti-CTLA-4 in murine models of pancreatic can
./___Corpus/Medline/xml/PMC5123381.xml	Th1	125059 : 125062	CM	ne biomarkers to promote Th1 immune responses.       
./___Corpus/Medline/xml/PMC5123381.xml	GITR	125199 : 125203	CM	e with the addition of a GITR-ligand fusion protein   
./___Corpus/Medline/xml/PMC5123381.xml	Y	125243 : 125244	CM	protein                  Y Maurice Morillon1, Scott
./___Corpus/Medline/xml/PMC5123381.xml	W Greiner1	125304 : 125314	CM	2, Jeffrey Schlom1, John W Greiner1 Background              
./___Corpus/Medline/xml/PMC5123381.xml	Teff	125705 : 125709	CM	ecific effector T cells (Teff). GITR, an activating re
./___Corpus/Medline/xml/PMC5123381.xml	GITR	125712 : 125716	CM	effector T cells (Teff). GITR, an activating receptor 
./___Corpus/Medline/xml/PMC5123381.xml	GITR	125940 : 125944	CM	. Activation upregulates GITR on Teff and Tregs, which
./___Corpus/Medline/xml/PMC5123381.xml	Teff	125948 : 125952	CM	tion upregulates GITR on Teff and Tregs, which however
./___Corpus/Medline/xml/PMC5123381.xml	GITR	126035 : 126039	CM	s, selectively targeting GITR can deliver activating s
./___Corpus/Medline/xml/PMC5123381.xml	rMVA	126284 : 126288	CM	odified vaccinia Ankara (rMVA-), fowlpox (rF-)] were e
./___Corpus/Medline/xml/PMC5123381.xml	rF	126301 : 126303	CM	Ankara (rMVA-), fowlpox (rF-)] were engineered to ex
./___Corpus/Medline/xml/PMC5123381.xml	CEA	126340 : 126343	CM	ineered to express human CEA and murine costimulatory
./___Corpus/Medline/xml/PMC5123381.xml	murine	126348 : 126354	CM	to express human CEA and murine costimulatory molecules,
./___Corpus/Medline/xml/PMC5123381.xml	B7.1	126380 : 126384	CM	costimulatory molecules, B7.1, ICAM-1 and LFA-3 (TRICO
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	126386 : 126392	CM	ulatory molecules, B7.1, ICAM-1 and LFA-3 (TRICOM); term
./___Corpus/Medline/xml/PMC5123381.xml	LFA-3	126397 : 126402	CM	ecules, B7.1, ICAM-1 and LFA-3 (TRICOM); termed rMVA- o
./___Corpus/Medline/xml/PMC5123381.xml	TRICOM	126404 : 126410	CM	 B7.1, ICAM-1 and LFA-3 (TRICOM); termed rMVA- or rF-CEA
./___Corpus/Medline/xml/PMC5123381.xml	rMVA	126420 : 126424	CM	d LFA-3 (TRICOM); termed rMVA- or rF-CEA-TRICOM. A pri
./___Corpus/Medline/xml/PMC5123381.xml	rF-CEA-TRICOM	126429 : 126442	CM	TRICOM); termed rMVA- or rF-CEA-TRICOM. A prime-boost strategy 
./___Corpus/Medline/xml/PMC5123381.xml	rMVA-CEA-TRICOM	126510 : 126525	CM	priming vaccine utilized rMVA-CEA-TRICOM while rF-CEA-TRICOM prov
./___Corpus/Medline/xml/PMC5123381.xml	rF-CEA-TRICOM	126532 : 126545	CM	ed rMVA-CEA-TRICOM while rF-CEA-TRICOM provided the boost. The 
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	126633 : 126643	CM	n can break tolerance in transgenic mice expressing human CE
./___Corpus/Medline/xml/PMC5123381.xml	CEA	126666 : 126669	CM	ic mice expressing human CEA. GITR was targeted with 
./___Corpus/Medline/xml/PMC5123381.xml	GITR	126671 : 126675	CM	ce expressing human CEA. GITR was targeted with a fusi
./___Corpus/Medline/xml/PMC5123381.xml	murine	126764 : 126770	CM	 extracellular domain of murine GITR-ligand molecularly 
./___Corpus/Medline/xml/PMC5123381.xml	GITR	126771 : 126775	CM	ellular domain of murine GITR-ligand molecularly fused
./___Corpus/Medline/xml/PMC5123381.xml	murine	126831 : 126837	CM	trimerization domain and murine IgG2a-Fc. Murine colon a
./___Corpus/Medline/xml/PMC5123381.xml	IgG2a-Fc	126838 : 126846	CM	zation domain and murine IgG2a-Fc. Murine colon adenocarci
./___Corpus/Medline/xml/PMC5123381.xml	Murine	126848 : 126854	CM	ain and murine IgG2a-Fc. Murine colon adenocarcinoma cel
./___Corpus/Medline/xml/PMC5123381.xml	CEA	126899 : 126902	CM	a cells expressing human CEA (MC32A) were implanted s
./___Corpus/Medline/xml/PMC5123381.xml	CEA	126944 : 126947	CM	lanted subcutaneously in CEA. Tg mice and treated wit
./___Corpus/Medline/xml/PMC5123381.xml	IgG2a	126982 : 126987	CM	and treated with control IgG2a, GITRL-FP, rMVA/rF-CEA-T
./___Corpus/Medline/xml/PMC5123381.xml	rMVA	126999 : 127003	CM	control IgG2a, GITRL-FP, rMVA/rF-CEA-TRICOM, or rMVA/r
./___Corpus/Medline/xml/PMC5123381.xml	rF-CEA-TRICOM	127004 : 127017	CM	ol IgG2a, GITRL-FP, rMVA/rF-CEA-TRICOM, or rMVA/rF-CEA-TRICOM +
./___Corpus/Medline/xml/PMC5123381.xml	rMVA	127022 : 127026	CM	, rMVA/rF-CEA-TRICOM, or rMVA/rF-CEA-TRICOM + GITRL-FP
./___Corpus/Medline/xml/PMC5123381.xml	rF-CEA-TRICOM	127027 : 127040	CM	A/rF-CEA-TRICOM, or rMVA/rF-CEA-TRICOM + GITRL-FP.             
./___Corpus/Medline/xml/PMC5123381.xml	MVA	127170 : 127173	CM	GITRL-FP concurrent with MVA/rF-CEA-TRICOM and modest
./___Corpus/Medline/xml/PMC5123381.xml	rF-CEA-TRICOM	127174 : 127187	CM	L-FP concurrent with MVA/rF-CEA-TRICOM and modest improvements 
./___Corpus/Medline/xml/PMC5123381.xml	GITR	127260 : 127264	CM	sulted. GITRL-FP targets GITR expressing cells, delive
./___Corpus/Medline/xml/PMC5123381.xml	IgG2a-Fc	127324 : 127332	CM	ating signals, while the IgG2a-Fc depletes via Fc-mediated
./___Corpus/Medline/xml/PMC5123381.xml	Fc	127346 : 127348	CM	he IgG2a-Fc depletes via Fc-mediated effector functi
./___Corpus/Medline/xml/PMC5123381.xml	Teff	127698 : 127702	CM	letion of both Tregs and Teff. Single dose GITRL-FP ab
./___Corpus/Medline/xml/PMC5123381.xml	MVA-CEA-TRICOM	127895 : 127909	CM	n of Teff in response to MVA-CEA-TRICOM as shown by a 20 % incre
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	127968 : 127972	CM	oliferating intratumoral CD4+ Teff compared to GITRL-F
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	128018 : 128024	CM	RL-FP monotherapy, and a 2-fold increase in activated pe
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	128058 : 128062	CM	 in activated peripheral CD8+ Teff. Reduced tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128485 : 128489	CM	 Elucidating the role of CD47 in innate lymphoid cell-
./___Corpus/Medline/xml/PMC5123381.xml	R	128543 : 128544	CM	ated tumor therapy Pulak R. Nath1, Anthony L. Schwa
./___Corpus/Medline/xml/PMC5123381.xml	Maric2	128582 : 128588	CM	ony L. Schwartz1, Dragan Maric2, David D. Roberts1 Backg
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128640 : 128644	CM	und                      CD47 is a ubiquitous cell sur
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	128766 : 128771	CM	and its counter-receptor SIRPα on phagocytes and antige
./___Corpus/Medline/xml/PMC5123381.xml	APCs	128816 : 128820	CM	ntigen presenting cells (APCs). CD47 is highly express
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128823 : 128827	CM	presenting cells (APCs). CD47 is highly expressed acro
./___Corpus/Medline/xml/PMC5123381.xml	CD47	128999 : 129003	CM	ole for thrombospondin-1/CD47 signaling on cytotoxic T
./___Corpus/Medline/xml/PMC5123381.xml	CTL	129042 : 129045	CM	cytotoxic T lymphocytes (CTL) to limit target tumor c
./___Corpus/Medline/xml/PMC5123381.xml	CD47	129296 : 129300	CM	we evaluated the role of CD47 in NK and other ILCs hom
./___Corpus/Medline/xml/PMC5123381.xml	ILCs	129317 : 129321	CM	 of CD47 in NK and other ILCs homeostasis within the l
./___Corpus/Medline/xml/PMC5123381.xml	CD47	129543 : 129547	CM	antisense suppression of CD47 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	129577 : 129582	CPR	e or in combination with anti-CTLA-4 blockade. C57Bl/6 
./___Corpus/Medline/xml/PMC5123381.xml	C57Bl	129599 : 129604	CM	th anti-CTLA-4 blockade. C57Bl/6 mice were injected wit
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	129631 : 129637	CM	 mice were injected with B16F10 melanoma in the hind lim
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	129739 : 129754	CM	, mice were treated with CD47-morpholino, anti-CTLA-4, or combine
./___Corpus/Medline/xml/PMC5123381.xml	anti-	129756 : 129761	CPR	ed with CD47-morpholino, anti-CTLA-4, or combined treat
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	129862 : 129877	CM	  Treatment of mice with CD47-morpholino increased the frequencie
./___Corpus/Medline/xml/PMC5123381.xml	perforin	130056 : 130064	CM	ed higher granzyme B and perforin mRNA expression in the C
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	130065 : 130069	CM	 granzyme B and perforin mRNA expression in the CD3−CD
./___Corpus/Medline/xml/PMC5123381.xml	CD3−CD4−CD8−	130088 : 130100	CM	n mRNA expression in the CD3−CD4−CD8− cells compared to the CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	130123 : 130127	CM	8− cells compared to the CD8+ cells from spleens of CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	130332 : 130336	CM	rγt as compared to their CD4+ counterparts, suggesting
./___Corpus/Medline/xml/PMC5123381.xml	ILC1	130395 : 130399	CM	y fall within the NK and ILC1 lineages. Indeed, lineag
./___Corpus/Medline/xml/PMC5123381.xml	NK1.1+	130496 : 130502	CM	ed higher frequencies of NK1.1+ and CD127+ cells compare
./___Corpus/Medline/xml/PMC5123381.xml	CD127+	130507 : 130513	CM	requencies of NK1.1+ and CD127+ cells compared to wildty
./___Corpus/Medline/xml/PMC5123381.xml	littermate	130541 : 130551	CM	lls compared to wildtype littermate controls. These cells in
./___Corpus/Medline/xml/PMC5123381.xml	CD47-morpholino	130700 : 130715	CM	nt with a combination of CD47-morpholino and anti-CTLA-4 antibody
./___Corpus/Medline/xml/PMC5123381.xml	anti-	130720 : 130725	CPR	n of CD47-morpholino and anti-CTLA-4 antibody, which re
./___Corpus/Medline/xml/PMC5123381.xml	CD47	130877 : 130881	CM	ggest that deficiency of CD47 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	130975 : 130980	CPR	ypes of ILCs with potent anti-tumor properties. The mec
./___Corpus/Medline/xml/PMC5123381.xml	CD47	131021 : 131025	CM	. The mechanism by which CD47 controls the homeostatic
./___Corpus/Medline/xml/PMC5123381.xml	CD47	131191 : 131195	CM	Soto-Pantoja DR, et al.: CD47 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	6771–	131317 : 131322	CPR	apy. Cancer Res 2014, 74:6771–6783.                    
./___Corpus/Medline/xml/PMC5123381.xml	365–	131492 : 131496	CPR	 T cells. Cell 2016, 164:365–377.                     
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	131586 : 131590	CM	titumor effectiveness of PD-1 inhibition in immunother
./___Corpus/Medline/xml/PMC5123381.xml	DC	132193 : 132195	CM	mor-infiltrating CTLs by DC vaccines together with c
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	132356 : 132360	CM	stant “cold” tumors into PD-1-sensitive ones.         
./___Corpus/Medline/xml/PMC5123381.xml	MC38	132472 : 132476	CM	n cancer (transplantable MC38 and ID8 models) bearing 
./___Corpus/Medline/xml/PMC5123381.xml	ID8	132481 : 132484	CM	(transplantable MC38 and ID8 models) bearing mice, we
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	132555 : 132559	CM	al therapeutic effect of PD-1 inhibition alone or comb
./___Corpus/Medline/xml/PMC5123381.xml	DC	132594 : 132596	CM	n alone or combined with DC vaccine. However, combin
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	132681 : 132685	CM	ciated chemokines, using TLR3 ligand polyI:polyC12U, i
./___Corpus/Medline/xml/PMC5123381.xml	COX2	132726 : 132730	CM	lyC12U, interferon-a and COX2 blockers, resulted in a 
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	132810 : 132814	CM	rs of tumor-infiltrating CTLs recognizing cancer-assoc
./___Corpus/Medline/xml/PMC5123381.xml	DC	133073 : 133075	CM	      This combinatorial DC-based vaccination approa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133227 : 133232	CPR	cluded as a component of anti-tumor therapeutic approac
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	133447 : 133453	CM	y PEGylated human IL-10 (AM0010) and anti-tumor activity
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133459 : 133464	CPR	human IL-10 (AM0010) and anti-tumor activity in renal c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133525 : 133530	CPR	 and in combination with anti-PD-1                     
./___Corpus/Medline/xml/PMC5123381.xml	P	133595 : 133596	CM	   Aung Naing1, Kyriakos P Papadopoulos2, Karen A A
./___Corpus/Medline/xml/PMC5123381.xml	Brown9	133840 : 133846	CM	r VanVlasselaer9, Gail L Brown9, Nizar M Tannir1, Martin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	133969 : 133974	CPR	 IL-10 is regarded as an anti-inflammatory cytokine, bu
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	133987 : 133995	CM	 as an anti-inflammatory cytokine, but it is at least equa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	134094 : 134098	CM	ion of antigen activated CD8+ T cells. Activation of C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	134122 : 134126	CM	+ T cells. Activation of CD8+ T cells through the T ce
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	134192 : 134196	CM	ates IL-10 receptors and PD-1 on the cells. This provi
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	134265 : 134271	CM	 rationale for combining AM0010 and anti-PD-1 for the tr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134276 : 134281	CPR	for combining AM0010 and anti-PD-1 for the treatment of
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134383 : 134388	CPR	ted the tolerability and anti-tumor activity of AM0010 
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	134406 : 134412	CM	d anti-tumor activity of AM0010 alone and in combination
./___Corpus/Medline/xml/PMC5123381.xml	anti-	134443 : 134448	CPR	 and in combination with anti-PD-1 immune checkpoint in
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	134574 : 134580	CM	ed RCC were treated with AM0010 (daily SC) alone or in c
./___Corpus/Medline/xml/PMC5123381.xml	SC	134588 : 134590	CM	eated with AM0010 (daily SC) alone or in combination
./___Corpus/Medline/xml/PMC5123381.xml	AMO010	134923 : 134929	CM	able), were treated with AMO010 alone (20 mg/kg). Eight 
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	135108 : 135114	CM	lts                      AM0010 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135144 : 135149	CPR	e or in combination with anti-PD-1 was tolerated well (
./___Corpus/Medline/xml/PMC5123381.xml	TrAEs	135220 : 135225	CM	xceeding 16 months). All TrAEs were transient and TrAEs
./___Corpus/Medline/xml/PMC5123381.xml	TrAEs	135245 : 135250	CM	TrAEs were transient and TrAEs leading to study discont
./___Corpus/Medline/xml/PMC5123381.xml	endocrine	135341 : 135350	CM	colitis, pneumonitis, or endocrine disruptions. G3/4 TrAEs 
./___Corpus/Medline/xml/PMC5123381.xml	TrAEs	135369 : 135374	CM	ocrine disruptions. G3/4 TrAEs in monotherapy included 
./___Corpus/Medline/xml/PMC5123381.xml	ALT	135459 : 135462	CM	), thrombocytopenia (2), ALT/AST increase (2) and fat
./___Corpus/Medline/xml/PMC5123381.xml	AST	135463 : 135466	CM	hrombocytopenia (2), ALT/AST increase (2) and fatigue
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	135497 : 135503	CM	ase (2) and fatigue (2). AM0010 combination with anti-PD
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135521 : 135526	CPR	 AM0010 combination with anti-PD-1 did not increase TrA
./___Corpus/Medline/xml/PMC5123381.xml	TrAEs	135548 : 135553	CM	ti-PD-1 did not increase TrAEs. Objective responses (PR
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	135676 : 135682	CM	), in 4 of 8 patients in AM0010/pembrolizumab (50 %). Pr
./___Corpus/Medline/xml/PMC5123381.xml	PFS	135732 : 135735	CM	ogression-free survival (PFS) was 3 and 9.4 months, r
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	135777 : 135783	CM	onths, respectively. The AM0010/nivolumab cohort is curr
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	135827 : 135833	CM	s currently in progress. AM0010 alone and also in combin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	135869 : 135874	CPR	also in combination with anti-PD-1 increased Th1 cytoki
./___Corpus/Medline/xml/PMC5123381.xml	Th1	135889 : 135892	CM	with anti-PD-1 increased Th1 cytokines (IL-18, IFNg, 
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	135911 : 135915	CM	ed Th1 cytokines (IL-18, IFNg, TNFa), CD8+ T cell asso
./___Corpus/Medline/xml/PMC5123381.xml	TNFa	135917 : 135921	CM	 cytokines (IL-18, IFNg, TNFa), CD8+ T cell associated
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	135924 : 135928	CM	nes (IL-18, IFNg, TNFa), CD8+ T cell associated effect
./___Corpus/Medline/xml/PMC5123381.xml	PD-1+	136120 : 136125	CM	liferation of activated, PD-1+/LAG-3+ CD8+ T cells in t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	136133 : 136137	CM	 activated, PD-1+/LAG-3+ CD8+ T cells in the blood of 
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	136189 : 136195	CM	tients were increased on AM0010. In contrast, the prolif
./___Corpus/Medline/xml/PMC5123381.xml	TGFb	136248 : 136252	CM	tion of FoxP3+ Tregs and TGFb was decreased. AM0010 al
./___Corpus/Medline/xml/PMC5123381.xml	anti-	136289 : 136294	CPR	ed. AM0010 alone or with anti-PD-1 induced oligoclonal 
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	136605 : 136611	CM	ons                      AM0010 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	136641 : 136646	CPR	e or in combination with anti-PD-1 is well-tolerated. T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	136709 : 136713	CM	ctivity and the observed CD8+ T cell activation encour
./___Corpus/Medline/xml/PMC5123381.xml	AM0010	136772 : 136778	CM	continued exploration of AM0010 in phase III studies.   
./___Corpus/Medline/xml/PMC5123381.xml	(LAG)-3	137131 : 137138	CM	mphocyte activation gene (LAG)-3, alone and in combinatio
./___Corpus/Medline/xml/PMC5123381.xml	Gopal2	137289 : 137295	CM	      Evan Lipson1, Ajay Gopal2, Sattva S Neelapu3, Phil
./___Corpus/Medline/xml/PMC5123381.xml	P	137358 : 137359	CM	 Stephen Spurgeon5, John P Leonard6, F Stephen Hodi
./___Corpus/Medline/xml/PMC5123381.xml	Mitra10	137524 : 137531	CM	Raphael Clynes10, Priyam Mitra10, Satyendra Suryawanshi10
./___Corpus/Medline/xml/PMC5123381.xml	K	137587 : 137588	CM	las Gladstone1, Margaret K Callahan12              
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	137746 : 137751	CM	ation. Signaling through LAG-3 and other T cell inhibit
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	137821 : 137825	CM	ding programmed death-1 (PD-1), can lead to T cell exh
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	137961 : 137966	CM	simultaneous blockade of LAG-3 and PD-1 may function sy
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	137971 : 137975	CM	us blockade of LAG-3 and PD-1 may function synergistic
./___Corpus/Medline/xml/PMC5123381.xml	IgG4	138157 : 138161	CM	MS-986016, a fully human IgG4 monoclonal antibody that
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	138195 : 138200	CM	al antibody that targets LAG-3, alone and in combinatio
./___Corpus/Medline/xml/PMC5123381.xml	anti-	138243 : 138248	CPR	bination with nivolumab (anti-PD-1) in patients with ad
./___Corpus/Medline/xml/PMC5123381.xml	56-	138431 : 138434	CPR	volumab every 14 days in 56-day cycles during dose es
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	139148 : 139153	CM	 peripheral blood T cell LAG-3 receptor occupancy (RO; 
./___Corpus/Medline/xml/PMC5123381.xml	RO	139174 : 139176	CM	AG-3 receptor occupancy (RO; 74-99 %) were observed 
./___Corpus/Medline/xml/PMC5123381.xml	74-	139178 : 139181	CPR	 receptor occupancy (RO; 74-99 %) were observed with 
./___Corpus/Medline/xml/PMC5123381.xml	MTD	139275 : 139278	CM	 maximum tolerated dose (MTD) was not reached with BM
./___Corpus/Medline/xml/PMC5123381.xml	MTD	139354 : 139357	CM	uations to determine the MTD for the combination are 
./___Corpus/Medline/xml/PMC5123381.xml	DLTs	139593 : 139597	CM	ckpoint blocking agents. DLTs among patients receiving
./___Corpus/Medline/xml/PMC5123381.xml	(G)3	139658 : 139662	CM	n therapy included grade (G)3 mucositis, G4 ventricula
./___Corpus/Medline/xml/PMC5123381.xml	G4	139674 : 139676	CM	ed grade (G)3 mucositis, G4 ventricular fibrillation
./___Corpus/Medline/xml/PMC5123381.xml	G4	139703 : 139705	CM	entricular fibrillation, G4 elevated lipase, and G4 
./___Corpus/Medline/xml/PMC5123381.xml	lipase	139715 : 139721	CM	ibrillation, G4 elevated lipase, and G4 myocarditis. Mos
./___Corpus/Medline/xml/PMC5123381.xml	G4	139727 : 139729	CM	 G4 elevated lipase, and G4 myocarditis. Most TRAEs 
./___Corpus/Medline/xml/PMC5123381.xml	1–	139765 : 139767	CPR	s. Most TRAEs were grade 1–2. TRAEs leading to disco
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	139980 : 139985	CM	ession was observed with LAG-3 monotherapy, and with co
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	140969 : 140976	CM	combination treatment of IMM-101, a heat-killed whole cel
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	141018 : 141031	CM	hole cell preparation of Mycobacterium obuense (NCTC 13365) wit
./___Corpus/Medline/xml/PMC5123381.xml	Brown1	141163 : 141169	CM	   James Crooks1, Sheila Brown1, Audrey Gauthier2, Marc 
./___Corpus/Medline/xml/PMC5123381.xml	CPI	141605 : 141608	CM	f checkpoint inhibitors (CPI) has yielded significant
./___Corpus/Medline/xml/PMC5123381.xml	CPI	141711 : 141714	CM	combination treatment of CPI with immunomodulating th
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	141821 : 141828	CM	erapeutics is developing IMM-101, an immunotherapeutic ag
./___Corpus/Medline/xml/PMC5123381.xml	Mycobacterium	141906 : 141919	CM	hole cell preparation of Mycobacterium obuense (NCTC 13365), wh
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	142099 : 142106	CM	lone and in combination, IMM-101 is well-tolerated. Addit
./___Corpus/Medline/xml/PMC5123381.xml	IMAGE-1	142213 : 142220	CM	urvival were observed in IMAGE-1, a randomized open-label
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	142407 : 142418	CM	72), in combination with gemcitabine in advanced pancreatic d
./___Corpus/Medline/xml/PMC5123381.xml	vitro	142528 : 142533	CM	        We found that in vitro exposure of IMM-101 prim
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	142546 : 142553	CM	hat in vitro exposure of IMM-101 primes in vitro generate
./___Corpus/Medline/xml/PMC5123381.xml	vitro	142564 : 142569	CM	ure of IMM-101 primes in vitro generated murine dendrit
./___Corpus/Medline/xml/PMC5123381.xml	murine	142580 : 142586	CM	rimes in vitro generated murine dendritic cells (DC) and
./___Corpus/Medline/xml/PMC5123381.xml	DC	142604 : 142606	CM	 murine dendritic cells (DC) and human monocyte-deri
./___Corpus/Medline/xml/PMC5123381.xml	DC	142635 : 142637	CM	d human monocyte-derived DC in a dose dependent mann
./___Corpus/Medline/xml/PMC5123381.xml	DC	142690 : 142692	CM	and functionally affects DC by enhancing their abili
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	142762 : 142769	CM	esent antigen. Moreover, IMM-101 activated DC promote T c
./___Corpus/Medline/xml/PMC5123381.xml	DC	142780 : 142782	CM	eover, IMM-101 activated DC promote T cell secretion
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	142811 : 142816	CM	mote T cell secretion of IFN-γ following re-stimulation
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	142918 : 142925	CM	ter adoptive transfer of IMM-101 primed DC into naïve rec
./___Corpus/Medline/xml/PMC5123381.xml	DC	142933 : 142935	CM	ansfer of IMM-101 primed DC into naïve recipient mic
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	143007 : 143014	CM	d whether the effects of IMM-101 on innate and adaptive i
./___Corpus/Medline/xml/PMC5123381.xml	CPI	143100 : 143103	CM	e therapeutic benefit of CPI treatment (anti-CTLA-4 o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143115 : 143120	CPR	enefit of CPI treatment (anti-CTLA-4 or anti-PD-1) in t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143130 : 143135	CPR	reatment (anti-CTLA-4 or anti-PD-1) in two murine xenog
./___Corpus/Medline/xml/PMC5123381.xml	murine	143148 : 143154	CM	A-4 or anti-PD-1) in two murine xenograft models using B
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	143178 : 143185	CM	e xenograft models using B16-F10, a mouse melanoma cell l
./___Corpus/Medline/xml/PMC5123381.xml	EMT6	143219 : 143223	CM	 melanoma cell line, and EMT6, a mouse breast cell lin
./___Corpus/Medline/xml/PMC5123381.xml	CPI	143454 : 143457	CM	combination treatment of CPI and IMM-101 on tumor bur
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	143462 : 143469	CM	ion treatment of CPI and IMM-101 on tumor burden. We also
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	143530 : 143534	CM	ignificant change to the CD8+/Treg ratio at the tumor 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	143581 : 143586	CM	or site. We performed in vitro stimulation (antigenic a
./___Corpus/Medline/xml/PMC5123381.xml	IMM-101	143919 : 143926	CM	l clinical evaluation of IMM-101 in combination treatment
./___Corpus/Medline/xml/PMC5123381.xml	anti-	143957 : 143962	CPR	mbination treatment with anti-PD-1 treatment is being u
./___Corpus/Medline/xml/PMC5123381.xml	2016-	144017 : 144022	CPR	aken (EudraCT identifier 2016-001459-28).              
./___Corpus/Medline/xml/PMC5123381.xml	murine	144169 : 144175	CM	nt extends survival in a murine xenograft model of HER2+
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	144195 : 144200	CM	urine xenograft model of HER2+ human breast cancer brai
./___Corpus/Medline/xml/PMC5123381.xml	BCBM	144368 : 144372	CM	cancer brain metastases (BCBM) occur in up to 14.3 % o
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	144464 : 144469	CM	tor receptor 2 positive (HER2+) primary tumors [1]. Int
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	144516 : 144525	CM	Intravenous trastuzumab (anti-HER2 monoclonal antibody (mAb
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	144599 : 144604	CM	urvival in patients with HER2+ systemic disease but doe
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	144680 : 144685	CM	n barrier (BBB) to treat HER2+ BCBM effectively [2]. In
./___Corpus/Medline/xml/PMC5123381.xml	BCBM	144686 : 144690	CM	ier (BBB) to treat HER2+ BCBM effectively [2]. Intrath
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	144774 : 144779	CM	urvival in patients with HER2+ BCBM [3] but requires re
./___Corpus/Medline/xml/PMC5123381.xml	Adeno	144950 : 144955	CM	delivery across the BBB. Adeno-associated viral vectors
./___Corpus/Medline/xml/PMC5123381.xml	AAV9	145007 : 145011	CM	particularly serotype 9 (AAV9), can safely and efficie
./___Corpus/Medline/xml/PMC5123381.xml	transgene	145201 : 145210	CM	g-term expression of the transgene product [4].            
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	145307 : 145312	CM	ize a xenograft model of HER2+ BCBM using BT474.M1 huma
./___Corpus/Medline/xml/PMC5123381.xml	Rag1−	145416 : 145421	CM	 the brain parenchyma of Rag1−/− mice. AAV9.trastuzumab
./___Corpus/Medline/xml/PMC5123381.xml	Rag1−	145659 : 145664	CM	 Median survival (MS) of Rag1−/− mice receiving IT AAV9
./___Corpus/Medline/xml/PMC5123381.xml	AAV9	145861 : 145865	CM	ys, n = 8, p = 0.0012*), AAV9 expressing an irrelevant
./___Corpus/Medline/xml/PMC5123381.xml	AAV9	145942 : 145946	CM	n = 10, p = 0.0027*), or AAV9 without a transgene (MS 
./___Corpus/Medline/xml/PMC5123381.xml	transgene	145957 : 145966	CM	027*), or AAV9 without a transgene (MS = 50 days, n = 4, p 
./___Corpus/Medline/xml/PMC5123381.xml	murine	146339 : 146345	CM	 increases survival in a murine xenograft model of HER2+
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	146365 : 146370	CM	urine xenograft model of HER2+ BCBM, thus showing promi
./___Corpus/Medline/xml/PMC5123381.xml	BCBM	146371 : 146375	CM	xenograft model of HER2+ BCBM, thus showing promise as
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	146401 : 146406	CM	 thus showing promise as HER2+ BCBM treatment and, more
./___Corpus/Medline/xml/PMC5123381.xml	BCBM	146407 : 146411	CM	showing promise as HER2+ BCBM treatment and, more broa
./___Corpus/Medline/xml/PMC5123381.xml	prophylactic	146446 : 146458	CM	 and, more broadly, as a prophylactic measure for patients wit
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	146485 : 146490	CM	easure for patients with HER2+ primary disease to exten
./___Corpus/Medline/xml/PMC5123381.xml	BCBM	146541 : 146545	CM	 survival in the case of BCBM.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	H	146608 : 146609	CM	             1. Kennecke H, et al.: Metastatic beha
./___Corpus/Medline/xml/PMC5123381.xml	3271–	146688 : 146693	CPR	s. J Clin Oncol 2010, 28:3271–3277.                    
./___Corpus/Medline/xml/PMC5123381.xml	2-	146813 : 146815	CPR	l growth factor receptor 2-positive breast cancer: f
./___Corpus/Medline/xml/PMC5123381.xml	1–	146890 : 146892	CPR	 Radiat Oncol J 2016, 34:1–9.                       
./___Corpus/Medline/xml/PMC5123381.xml	13–	147162 : 147165	CPR	ast Cancer Res 2013, 139:13–22.                      
./___Corpus/Medline/xml/PMC5123381.xml	AAV9	147330 : 147334	CM	es following delivery of AAV9 into the cisterna magna.
./___Corpus/Medline/xml/PMC5123381.xml	TLR	147512 : 147515	CM	l cancers with synthetic TLR agonists and checkpoint 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	147968 : 147972	CM	idence worldwide. Though PD-1/PD-L1 blockade is effect
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	147973 : 147978	CM	e worldwide. Though PD-1/PD-L1 blockade is effective in
./___Corpus/Medline/xml/PMC5123381.xml	anti-	148085 : 148090	CPR	combination therapy with anti-PD-1 and synthetic agonis
./___Corpus/Medline/xml/PMC5123381.xml	(TLR)7	148141 : 148147	CM	s of toll-like receptors (TLR)7 and TLR9 in mouse models
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	148152 : 148156	CM	ike receptors (TLR)7 and TLR9 in mouse models represen
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	148240 : 148245	CM	ositive and HPV-negative HNSCC, respectively. We hypoth
./___Corpus/Medline/xml/PMC5123381.xml	TLR	148314 : 148317	CM	ratumoral treatment with TLR agonists could activate 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	148556 : 148560	CM	ls on tumor infiltrating CD8+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	SCC-7	148646 : 148651	CM	neic tumor mouse models, SCC-7 cells (HPV-negative)/C3H
./___Corpus/Medline/xml/PMC5123381.xml	C3H	148673 : 148676	CM	C-7 cells (HPV-negative)/C3H background and MEER cell
./___Corpus/Medline/xml/PMC5123381.xml	MEER	148692 : 148696	CM	tive)/C3H background and MEER cells (HPV-positive)/C57
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	148906 : 148910	CM	only the right side with TLR7 or TLR9 agonists with or
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	148914 : 148918	CM	 right side with TLR7 or TLR9 agonists with or without
./___Corpus/Medline/xml/PMC5123381.xml	anti-	148974 : 148979	CPR	peritoneal injections of anti-PD-1 mAb. Lymphocytes wer
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	149162 : 149166	CM	ptor (TCR) repertoire of CD8+ T cells in the tumor and
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	149404 : 149408	CM	herapies of intratumoral TLR7 or TLR9 agonists with an
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	149412 : 149416	CM	 of intratumoral TLR7 or TLR9 agonists with anti-PD-1 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	149431 : 149436	CPR	R7 or TLR9 agonists with anti-PD-1 suppressed tumor pro
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	149608 : 149612	CM	mbination treatment with TLR7 agonists and anti-PD-1 i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	149626 : 149631	CPR	t with TLR7 agonists and anti-PD-1 increased the M1/M2 
./___Corpus/Medline/xml/PMC5123381.xml	M1	149650 : 149652	CM	 anti-PD-1 increased the M1/M2 ratio in CD11b+F4/80+
./___Corpus/Medline/xml/PMC5123381.xml	M2	149653 : 149655	CM	ti-PD-1 increased the M1/M2 ratio in CD11b+F4/80+ tu
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	149743 : 149747	CM	. Ex vivo treatment with TLR7 agonist upregulated the 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	149810 : 149814	CM	 costimulatory molecules CD40, CD80, and decreased the
./___Corpus/Medline/xml/PMC5123381.xml	CD80	149816 : 149820	CM	mulatory molecules CD40, CD80, and decreased the expre
./___Corpus/Medline/xml/PMC5123381.xml	CD206	149860 : 149865	CM	 the expression level of CD206 (M2-macrophage marker). 
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	149919 : 149923	CM	combination therapy with TLR7 agonist increased the fr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	149959 : 149963	CM	creased the frequency of CD8+ T cells in both sides of
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ+	150017 : 150022	CM	ors and spleen. Elevated IFNγ+ activated T cell populat
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	150089 : 150093	CM	in mice treated with the TLR7 ligand and anti-PD-1 the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150105 : 150110	CPR	with the TLR7 ligand and anti-PD-1 therapy (Fig. 23). T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150165 : 150170	CPR	pertoire analysis showed anti-PD-1 increased clonal exp
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	150213 : 150217	CM	nal expansion of splenic CD8+ T cells (Fig. 24).      
./___Corpus/Medline/xml/PMC5123381.xml	TLR	150316 : 150319	CM	combination therapy with TLR agonists and anti-PD-1 s
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150333 : 150338	CPR	py with TLR agonists and anti-PD-1 suppressed progressi
./___Corpus/Medline/xml/PMC5123381.xml	CD8	150484 : 150487	CM	pansion of low frequency CD8+T cell population by ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150509 : 150514	CPR	CD8+T cell population by anti-PD-1, and recruitment and
./___Corpus/Medline/xml/PMC5123381.xml	TLR	150608 : 150611	CM	ratumoral treatment with TLR ligands.                
./___Corpus/Medline/xml/PMC5123381.xml	Dr	150685 : 150687	CM	                We thank Dr. John Lee in Sanford Res
./___Corpus/Medline/xml/PMC5123381.xml	HNC	150747 : 150750	CM	 kindly provided us with HNC cells. This work was sup
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	150963 : 150969	CM	ombinatorial blockade of CSF-1R and PD-L1 enhances anti-
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	150974 : 150979	CM	l blockade of CSF-1R and PD-L1 enhances anti-tumor effi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	150989 : 150994	CPR	SF-1R and PD-L1 enhances anti-tumor efficacy           
./___Corpus/Medline/xml/PMC5123381.xml	Li1	151069 : 151072	CM	   David Schaer1, Yanxia Li1, Julie Dobkin1, Michael 
./___Corpus/Medline/xml/PMC5123381.xml	Hall1	151115 : 151120	CM	ichael Amatulli1, Gerald Hall1, Thompson Doman2, Jason 
./___Corpus/Medline/xml/PMC5123381.xml	Kauh3	151271 : 151276	CM	avid Surguladze1, John S Kauh3, Ruslan Novosiadly1, Mic
./___Corpus/Medline/xml/PMC5123381.xml	Kalos1	151306 : 151312	CM	lan Novosiadly1, Michael Kalos1, Kyla Driscoll1         
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	151497 : 151501	CM	Although blockade of the PD-1/L1 axis alone has led to
./___Corpus/Medline/xml/PMC5123381.xml	L1	151502 : 151504	CM	ugh blockade of the PD-1/L1 axis alone has led to du
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	151705 : 151711	CM	ating factor receptor 1 (CSF-1R) expressing tumor associ
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	151947 : 151951	CM	 many malignancies where PD-1/L1 blockade has shown so
./___Corpus/Medline/xml/PMC5123381.xml	L1	151952 : 151954	CM	 malignancies where PD-1/L1 blockade has shown some 
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	151999 : 152005	CM	some or little activity. CSF-1R has been implicated for 
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	152194 : 152200	CM	ession in cancer. As the CSF-1R Inhibitor LY3022855 has 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	152279 : 152284	CM	ting in combination with PD-L1 blockade, it is importan
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	152549 : 152555	CM	ne modulating effects of CSF-1R inhibition, we developed
./___Corpus/Medline/xml/PMC5123381.xml	anti-	152584 : 152589	CPR	ibition, we developed an anti-mouse CSF-1R surrogate an
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	152595 : 152601	CM	 developed an anti-mouse CSF-1R surrogate antibody CS7. 
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152621 : 152624	CM	SF-1R surrogate antibody CS7. CS7 blocks CSF-1 bindin
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152626 : 152629	CM	 surrogate antibody CS7. CS7 blocks CSF-1 binding to 
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	152654 : 152660	CM	 blocks CSF-1 binding to CSF-1R and inhibits in vitro pr
./___Corpus/Medline/xml/PMC5123381.xml	vitro	152677 : 152682	CM	o CSF-1R and inhibits in vitro proliferation and differ
./___Corpus/Medline/xml/PMC5123381.xml	CS7	152855 : 152858	CM	notherapy treatment with CS7 causes intra-tumor deple
./___Corpus/Medline/xml/PMC5123381.xml	F4	152903 : 152905	CM	depletion of ~50-60 % of F4/80+ TAMs leading to a mo
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	153193 : 153199	CM	roenvironment. Combining CSF-1R blockade with anti-PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	153214 : 153219	CPR	ing CSF-1R blockade with anti-PD-L1 enhances the contro
./___Corpus/Medline/xml/PMC5123381.xml	CS7	153713 : 153716	CM	sed efficacy. Effects of CS7 were dose-dependent, sug
./___Corpus/Medline/xml/PMC5123381.xml	CS7	153775 : 153778	CM	hat while lower doses of CS7 are able to cause TAM de
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	153879 : 153885	CM	s more complete block of CSF-1R.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	153981 : 153987	CM	rate that combination of CSF-1R blockade with PD-L1 chec
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	154002 : 154007	CM	 of CSF-1R blockade with PD-L1 checkpoint inhibition al
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	154154 : 154160	CM	ly that the mechanism of CSF-1R blockade immunotherapy m
./___Corpus/Medline/xml/PMC5123381.xml	A21	154365 : 154368	CM	ic virus, coxsackievirus A21 in combination with pemb
./___Corpus/Medline/xml/PMC5123381.xml	Ib	154438 : 154440	CM	d cancer patients: phase Ib KEYNOTE 200 (STORM study
./___Corpus/Medline/xml/PMC5123381.xml	KEYNOTE	154441 : 154448	CM	ancer patients: phase Ib KEYNOTE 200 (STORM study)       
./___Corpus/Medline/xml/PMC5123381.xml	STORM	154454 : 154459	CM	s: phase Ib KEYNOTE 200 (STORM study)                  
./___Corpus/Medline/xml/PMC5123381.xml	Ralph2	154529 : 154535	CM	 Hardev Pandha1, Christy Ralph2, Kevin Harrington3, Bren
./___Corpus/Medline/xml/PMC5123381.xml	R	154663 : 154664	CM	 David Mansfield7, David R Kaufman8, Emmett Schmidt
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	154826 : 154831	CM	     Coxsackievirus A21 (CVA21, CAVATAK) is a naturally
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	154833 : 154840	CM	xsackievirus A21 (CVA21, CAVATAK) is a naturally-occurrin
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	154867 : 154873	CM	is a naturally-occurring ICAM-1 targeted oncolytic immun
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	154972 : 154976	CM	rammed death receptor-1 (PD-1) blocking antibody that 
./___Corpus/Medline/xml/PMC5123381.xml	i.v	155232 : 155235	CM	med that combinations of i.v. CVA21 + anti-PD-1 mAbs 
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	155237 : 155242	CM	hat combinations of i.v. CVA21 + anti-PD-1 mAbs mediate
./___Corpus/Medline/xml/PMC5123381.xml	anti-	155245 : 155250	CPR	inations of i.v. CVA21 + anti-PD-1 mAbs mediated signif
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	155386 : 155391	CM	 that the combination of CVA21 + pembrolizumab may tran
./___Corpus/Medline/xml/PMC5123381.xml	Ib	155478 : 155480	CM	nic. We describe a phase Ib study assessing safety a
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	155523 : 155528	CM	afety and efficacy of IV CVA21 ± pembrolizumab in advan
./___Corpus/Medline/xml/PMC5123381.xml	STORM	155638 : 155643	CM	             The phase I STORM (systemic treatment of r
./___Corpus/Medline/xml/PMC5123381.xml	KEYNOTE	155691 : 155698	CM	 resistant malignancies; KEYNOTE 200) primary objectives 
./___Corpus/Medline/xml/PMC5123381.xml	DLT	155763 : 155766	CM	ose-limiting toxicities (DLT) of CVA21 ± pembrolizuma
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	155771 : 155776	CM	ting toxicities (DLT) of CVA21 ± pembrolizumab. Seconda
./___Corpus/Medline/xml/PMC5123381.xml	PFS	155859 : 155862	CM	y irRECIST 1.1 criteria, PFS, and OS. Treatment Part 
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	155912 : 155917	CM	A: pts were infused with CVA21 in 100 mL saline in Coho
./___Corpus/Medline/xml/PMC5123381.xml	saline	155928 : 155934	CM	sed with CVA21 in 100 mL saline in Cohort 1 (n = 3), at 
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	155977 : 155983	CM	3), at a dose of 1 x 108 TCID50, in Cohort 2 (n = 3) at 
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	156026 : 156032	CM	 3) at a dose of 3 x 108 TCID50 and in Cohort 3 (n = 10)
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	156079 : 156085	CM	10) at a dose of 1 x 109 TCID50 on study days 1, 3, 5, 2
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	156116 : 156119	CM	udy days 1, 3, 5, 22 and Q3W for 6 additional infusio
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	156218 : 156223	CM	 B: pts are infused with CVA21 in 100 mL saline + pembr
./___Corpus/Medline/xml/PMC5123381.xml	saline	156234 : 156240	CM	sed with CVA21 in 100 mL saline + pembrolizumab. In Coho
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	156279 : 156284	CM	ab. In Cohort 1 (n = 3), CVA21 is administered at a dos
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	156322 : 156328	CM	red at a dose of 1 x 108 TCID50, in Cohort 2 (n = 3) at 
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	156371 : 156377	CM	 3) at a dose of 3 x 108 TCID50 and in Cohort 3 (n = ~80
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	156425 : 156431	CM	80) at a dose of 1 x 109 TCID50 on study days 1, 3, 5, 8
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	156466 : 156469	CM	days 1, 3, 5, 8, 29, and Q3W for 6 additional infusio
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	156549 : 156552	CM	all cohorts at 200 mg IV Q3W from Day 8 for up to 2 y
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	156598 : 156603	CM	 2 years. Treatment with CVA21 ± pembrolizumab will con
./___Corpus/Medline/xml/PMC5123381.xml	PD	156656 : 156658	CM	ue until confirmed CR or PD (whichever comes first) 
./___Corpus/Medline/xml/PMC5123381.xml	DLT	156703 : 156706	CM	rst) per irRECIST 1.1 or DLT. Part B, Cohort 1 enroll
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	156810 : 156815	CM	          IV delivery of CVA21 to all patients in Part 
./___Corpus/Medline/xml/PMC5123381.xml	AE’s	156909 : 156913	CM	e 3 or 4 product-related AE’s.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	156965 : 156970	CM	ons                      CVA21 tumor targeting in patie
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	157098 : 157103	CM	onfirmed by detection of CVA21 viral RNA in tumor biops
./___Corpus/Medline/xml/PMC5123381.xml	RNA	157110 : 157113	CM	detection of CVA21 viral RNA in tumor biopsies at stu
./___Corpus/Medline/xml/PMC5123381.xml	p53	157371 : 157374	CM	238 Mutational status of p53 can influence its recogn
./___Corpus/Medline/xml/PMC5123381.xml	p53	157487 : 157490	CM	und                      p53 was reported to be an at
./___Corpus/Medline/xml/PMC5123381.xml	p53	157698 : 157701	CM	s. Peptides derived from p53 are presented by class I
./___Corpus/Medline/xml/PMC5123381.xml	MHC	157727 : 157730	CM	are presented by class I MHC molecules and may act as
./___Corpus/Medline/xml/PMC5123381.xml	p53	157809 : 157812	CM	ich could be targeted by p53-specific T cells. Intere
./___Corpus/Medline/xml/PMC5123381.xml	p53	157924 : 157927	CM	cant correlation between p53 expression levels in tum
./___Corpus/Medline/xml/PMC5123381.xml	p53-TCR	157981 : 157988	CM	and their recognition by p53-TCR transduced T cells.     
./___Corpus/Medline/xml/PMC5123381.xml	p53	158118 : 158121	CM	the mutational status of p53 on its presentation by t
./___Corpus/Medline/xml/PMC5123381.xml	MHC	158149 : 158152	CM	 its presentation by the MHC system and on T cell ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	158174 : 158179	CPR	MHC system and on T cell anti-tumor reactivity, we gene
./___Corpus/Medline/xml/PMC5123381.xml	p53	158225 : 158228	CM	generated several mutant p53 constructs and expressed
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2+	158262 : 158269	CM	ts and expressed them in HLA-A2+/p53- cells. Upon co-cult
./___Corpus/Medline/xml/PMC5123381.xml	p53	158270 : 158273	CM	xpressed them in HLA-A2+/p53- cells. Upon co-culture 
./___Corpus/Medline/xml/PMC5123381.xml	p53	158303 : 158306	CM	ls. Upon co-culture with p53-specific T cells, we mea
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	158405 : 158413	CM	target cells by means of cytokine secretion, marker upregu
./___Corpus/Medline/xml/PMC5123381.xml	p53	158490 : 158493	CM	d in parallel determined p53 expression levels by int
./___Corpus/Medline/xml/PMC5123381.xml	p53	158577 : 158580	CM	ned the impact of mutant p53 expression on cell cycle
./___Corpus/Medline/xml/PMC5123381.xml	caspase-3	158673 : 158682	CM	he pro-apoptotic protein caspase-3.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	p53	158761 : 158764	CM	sults show that selected p53 mutations altering prote
./___Corpus/Medline/xml/PMC5123381.xml	p53	158815 : 158818	CM	n stability can modulate p53 presentation to T cells,
./___Corpus/Medline/xml/PMC5123381.xml	p53	158921 : 158924	CM	y correlated to measured p53 protein levels.         
./___Corpus/Medline/xml/PMC5123381.xml	p53	158997 : 159000	CM	                   Thus, p53 may behave differently t
./___Corpus/Medline/xml/PMC5123381.xml	p53	159196 : 159199	CM	ancer patients targeting p53.                        
./___Corpus/Medline/xml/PMC5123381.xml	Fc	159244 : 159246	CM	                    P239 Fc gamma receptor IV mediat
./___Corpus/Medline/xml/PMC5123381.xml	anti-	159328 : 159333	CPR	ng regulatory T cells by anti-CTLA-4 antibody is promot
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	159364 : 159368	CM	 antibody is promoted by TLR1/2 agonist and hence its 
./___Corpus/Medline/xml/PMC5123381.xml	FDA	159726 : 159729	CM	lockade therapies to get FDA approval for treating me
./___Corpus/Medline/xml/PMC5123381.xml	TLRs	160135 : 160139	CM	cognition receptors like TLRs have been shown to have 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160164 : 160169	CPR	 have been shown to have anti-tumor effects in various 
./___Corpus/Medline/xml/PMC5123381.xml	TLR	160359 : 160362	CM	e innate immune arm like TLR ligand with the adaptive
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	160457 : 160461	CM	use model. We identified TLR1/2 ligand Pam3CSK4 as inn
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160530 : 160535	CPR	odulator to combine with anti-CTLA-4 antibody in this c
./___Corpus/Medline/xml/PMC5123381.xml	B16	160650 : 160653	CM	right flank with 3 × 105 B16/F10 and considered day 0
./___Corpus/Medline/xml/PMC5123381.xml	F10	160654 : 160657	CM	t flank with 3 × 105 B16/F10 and considered day 0. In
./___Corpus/Medline/xml/PMC5123381.xml	B16	160688 : 160691	CM	onsidered day 0. Initial B16/F10 challenge was double
./___Corpus/Medline/xml/PMC5123381.xml	F10	160692 : 160695	CM	dered day 0. Initial B16/F10 challenge was doubled to
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160856 : 160861	CPR	i.p) injection of 100 μg anti-CTLA-4 antibody and intra
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	160909 : 160913	CM	ratumoral injection with TLR1/2 ligand on every third 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	160993 : 160998	CPR	till day 12. The dose of anti-CTLA-4 antibody was doubl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161111 : 161116	CPR	ay 14, only two doses of anti-CTLA-4 antibody and TLR l
./___Corpus/Medline/xml/PMC5123381.xml	TLR	161136 : 161139	CM	anti-CTLA-4 antibody and TLR ligands were given on Da
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	161428 : 161432	CM	dies show that combining TLR1/2 ligand Pam3CSK4 with a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161456 : 161461	CPR	1/2 ligand Pam3CSK4 with anti-CTLA-4 antibody decreases
./___Corpus/Medline/xml/PMC5123381.xml	anti-	161550 : 161555	CPR	gnificantly, compared to anti-CTLA-4 antibody treatment
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	161617 : 161621	CM	ur studies we found both CD4+ and CD8+ T cells to be i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	161626 : 161630	CM	s we found both CD4+ and CD8+ T cells to be important 
./___Corpus/Medline/xml/PMC5123381.xml	FcγRIV	161858 : 161864	CM	ls modulated by enhanced FcγRIV expression on macrophage
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	162001 : 162005	CM	s suggest that combining TLR1/2 ligand with anti-CTLA-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	162020 : 162025	CPR	ining TLR1/2 ligand with anti-CTLA-4 antibody will be a
./___Corpus/Medline/xml/PMC5123381.xml	TLR1	162122 : 162126	CM	and it also suggest that TLR1/2 ligand modulate FcγRIV
./___Corpus/Medline/xml/PMC5123381.xml	FcγRIV	162145 : 162151	CM	t TLR1/2 ligand modulate FcγRIV expression, which can be
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	162598 : 162602	CM	rgeted therapies against PD-1, PD-L1, and CTLA-4 are c
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	162604 : 162609	CM	 therapies against PD-1, PD-L1, and CTLA-4 are currentl
./___Corpus/Medline/xml/PMC5123381.xml	PRR	162954 : 162957	CM	n recognition receptors (PRR) such as toll-like recep
./___Corpus/Medline/xml/PMC5123381.xml	PRR	163141 : 163144	CM	sic ability to stimulate PRR, the oncolytic propertie
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163230 : 163235	CPR	 also for the priming of anti-tumor immune responses. H
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163275 : 163280	CPR	sponses. Hypothesis: Can anti-infectious vaccines be us
./___Corpus/Medline/xml/PMC5123381.xml	PRR	163323 : 163326	CM	s be used as a source or PRR agonists and/or oncolyti
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	163428 : 163438	CM	     We tested a TLR-Luc transgenic cell line for screening 
./___Corpus/Medline/xml/PMC5123381.xml	TLR	163470 : 163473	CM	ine for screening of the TLR agonist activity of anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163494 : 163499	CPR	 TLR agonist activity of anti-infectious vaccines. Cyto
./___Corpus/Medline/xml/PMC5123381.xml	SRB	163581 : 163584	CM	ccines was determined by SRB test and IncuCyte imagin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	163980 : 163985	CPR	t commercially available anti-infectious vaccines do ha
./___Corpus/Medline/xml/PMC5123381.xml	PRR	164013 : 164016	CM	ectious vaccines do have PRR agonist properties. Inte
./___Corpus/Medline/xml/PMC5123381.xml	NF-Kb	164347 : 164352	CM	ies and can activate the NF-Kb pathway in a TLR and IRF
./___Corpus/Medline/xml/PMC5123381.xml	TLR	164366 : 164369	CM	e the NF-Kb pathway in a TLR and IRF3 independent man
./___Corpus/Medline/xml/PMC5123381.xml	IRF3	164374 : 164378	CM	-Kb pathway in a TLR and IRF3 independent manner. Thes
./___Corpus/Medline/xml/PMC5123381.xml	vitro	164408 : 164413	CM	pendent manner. These in vitro biological properties tr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	164459 : 164464	CPR	s translate into in vivo anti-tumor activity. Intra-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	164516 : 164521	CPR	al rotavirus therapy has anti-tumor effects which are p
./___Corpus/Medline/xml/PMC5123381.xml	NSG	164605 : 164608	CM	ted by their activity in NSG xenograft models of huma
./___Corpus/Medline/xml/PMC5123381.xml	murine	164687 : 164693	CM	mmunocompetent syngeneic murine tumor models of neurobla
./___Corpus/Medline/xml/PMC5123381.xml	OX40	165119 : 165123	CM	tivation markers such as OX40/CD137 and CD86 on T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD137	165124 : 165129	CM	ion markers such as OX40/CD137 and CD86 on T cells and 
./___Corpus/Medline/xml/PMC5123381.xml	CD86	165134 : 165138	CM	s such as OX40/CD137 and CD86 on T cells and APC, resp
./___Corpus/Medline/xml/PMC5123381.xml	APC	165154 : 165157	CM	 and CD86 on T cells and APC, respectively.          
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165425 : 165430	CPR	a-tumoral priming of the anti-tumor immunity with oncol
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165556 : 165561	CPR	o overcome resistance to anti-PD-1/anti-CTLA-4 therapy 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	165566 : 165571	CPR	 resistance to anti-PD-1/anti-CTLA-4 therapy in patient
./___Corpus/Medline/xml/PMC5123381.xml	HPV	165793 : 165796	CM	or human papillomavirus (HPV) + squamous cell cancer 
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	165843 : 165848	CM	er of the head and neck (SCCHN): preliminary phase I re
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	166057 : 166061	CM	 for cervical cancer and HPV+ head and neck cancer may
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	166203 : 166207	CM	 Axalimogene filolisbac (AXAL or ADXS11-001) is an irr
./___Corpus/Medline/xml/PMC5123381.xml	ADXS11-001	166211 : 166221	CM	gene filolisbac (AXAL or ADXS11-001) is an irreversibly atte
./___Corpus/Medline/xml/PMC5123381.xml	O	166290 : 166291	CM	ocytogenes-listeriolysin O (Lm-LLO) immunotherapy b
./___Corpus/Medline/xml/PMC5123381.xml	Lm-LLO	166293 : 166299	CM	togenes-listeriolysin O (Lm-LLO) immunotherapy bioengine
./___Corpus/Medline/xml/PMC5123381.xml	HPV	166343 : 166346	CM	engineered to secrete an HPV E7 tLLO fusion protein t
./___Corpus/Medline/xml/PMC5123381.xml	tLLO	166350 : 166354	CM	red to secrete an HPV E7 tLLO fusion protein that indu
./___Corpus/Medline/xml/PMC5123381.xml	HPV	166383 : 166386	CM	ion protein that induces HPV-specific cytotoxic T cel
./___Corpus/Medline/xml/PMC5123381.xml	IgG1	166508 : 166512	CM	ive, high-affinity human IgG1 mAb that blocks PD-L1 bi
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	166529 : 166534	CM	man IgG1 mAb that blocks PD-L1 binding to PD-1 (IC50 0.
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	166546 : 166550	CM	 blocks PD-L1 binding to PD-1 (IC50 0.1 nM) and CD80 (
./___Corpus/Medline/xml/PMC5123381.xml	IC50	166552 : 166556	CM	s PD-L1 binding to PD-1 (IC50 0.1 nM) and CD80 (B7.1; 
./___Corpus/Medline/xml/PMC5123381.xml	CD80	166569 : 166573	CM	o PD-1 (IC50 0.1 nM) and CD80 (B7.1; IC50 0.04 nM). Th
./___Corpus/Medline/xml/PMC5123381.xml	B7.1	166575 : 166579	CM	 (IC50 0.1 nM) and CD80 (B7.1; IC50 0.04 nM). The PD-1
./___Corpus/Medline/xml/PMC5123381.xml	IC50	166581 : 166585	CM	 0.1 nM) and CD80 (B7.1; IC50 0.04 nM). The PD-1/PD-L1
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	166600 : 166604	CM	B7.1; IC50 0.04 nM). The PD-1/PD-L1 pathway is an impo
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	166605 : 166610	CM	 IC50 0.04 nM). The PD-1/PD-L1 pathway is an important 
./___Corpus/Medline/xml/PMC5123381.xml	anti–	166752 : 166757	CPR	nstrate combination AXAL/anti–PD-1 treatment significan
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	166757 : 166761	CM	te combination AXAL/anti–PD-1 treatment significantly 
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	167000 : 167004	CM	291055"}}NCT02291055) of AXAL + durvalumab in patients
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	167105 : 167109	CM	cal cancer or metastatic HPV+ SCCHN, who progressed on
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	167110 : 167115	CM	ancer or metastatic HPV+ SCCHN, who progressed on ≥1 pl
./___Corpus/Medline/xml/PMC5123381.xml	platinum	167138 : 167146	CM	HN, who progressed on ≥1 platinum-based therapy. The prima
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167322 : 167326	CM	commended phase II dose (RP2D) of AXAL (1 × 109 colony
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	167331 : 167335	CM	 phase II dose (RP2D) of AXAL (1 × 109 colony-forming 
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	167458 : 167463	CM	esign. Part A includes a SCCHN expansion cohort (N = 20
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167497 : 167501	CM	n cohort (N = 20) at the RP2D to evaluate efficacy. Pa
./___Corpus/Medline/xml/PMC5123381.xml	RECIST	167561 : 167567	CM	evaluate tumor response (RECIST and immune-related RECIS
./___Corpus/Medline/xml/PMC5123381.xml	RECIST	167587 : 167593	CM	ECIST and immune-related RECIST) of durvalumab monothera
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	167625 : 167629	CM	rvalumab monotherapy and AXAL + durvalumab combination
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	167670 : 167674	CM	mbination therapy at the RP2D in recurrent/metastatic 
./___Corpus/Medline/xml/PMC5123381.xml	ECOG	167948 : 167952	CM	 mg/kg: N = 6); 91 % had ECOG performance status 0, 73
./___Corpus/Medline/xml/PMC5123381.xml	RP2D	168692 : 168696	CM	e not yet available. The RP2D was declared at durvalum
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	168740 : 168744	CM	rvalumab 10 mg/kg q2wk + AXAL 1 × 109 colony-forming u
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	168849 : 168853	CM	      The combination of AXAL/durvalumab appears safe 
./___Corpus/Medline/xml/PMC5123381.xml	17-beta-hydroxywithanolide	169226 : 169252	CM	         P242 A specific 17-beta-hydroxywithanolide (LG-02) sensitizes cance
./___Corpus/Medline/xml/PMC5123381.xml	LG-02	169254 : 169259	CM	beta-hydroxywithanolide (LG-02) sensitizes cancer cells
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	169313 : 169318	CM	apoptosis in response to TRAIL and toll-like receptor (
./___Corpus/Medline/xml/PMC5123381.xml	TLR	169343 : 169346	CM	 and toll-like receptor (TLR) ligands                
./___Corpus/Medline/xml/PMC5123381.xml	Xu3	169434 : 169437	CM	 Alan D Brooks2, Ya-Ming Xu3, Kithsiri Wijeratne3, Le
./___Corpus/Medline/xml/PMC5123381.xml	AA	169467 : 169469	CM	hsiri Wijeratne3, Leslie AA Gunatilaka4, Thomas J Sa
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	169948 : 169953	CM	optosis inducing ligand (TRAIL) has shown considerable 
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	170100 : 170105	CM	 inherently resistant to TRAIL-mediated apoptosis and r
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	170254 : 170259	CM	hat can be combined with TRAIL to improve its efficacy.
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	170330 : 170334	CM	also described a role of TLR3 signaling for initiating
./___Corpus/Medline/xml/PMC5123381.xml	17β-hydroxywithanolide	170488 : 170510	CM	t, withanolide E (WE), a 17β-hydroxywithanolide (17-BHW) and a natural p
./___Corpus/Medline/xml/PMC5123381.xml	17-BHW	170512 : 170518	CM	 17β-hydroxywithanolide (17-BHW) and a natural product d
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	170636 : 170641	CM	nsitizing tumor cells to TRAIL-mediated apoptosis by re
./___Corpus/Medline/xml/PMC5123381.xml	anti-	170696 : 170701	CPR	g cellular levels of the anti-apoptotic protein cFLIP. 
./___Corpus/Medline/xml/PMC5123381.xml	cFLIP	170719 : 170724	CM	e anti-apoptotic protein cFLIP.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	17-BHWs	170823 : 170830	CM	eened a small library of 17-BHWs and have identified seve
./___Corpus/Medline/xml/PMC5123381.xml	LG-02	171035 : 171040	CM	the 30 compounds tested, LG-02 was found to be 4–5 fold
./___Corpus/Medline/xml/PMC5123381.xml	4–	171057 : 171059	CPR	d, LG-02 was found to be 4–5 fold more potent than W
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	171148 : 171153	CM	ic signaling in response TRAIL as well as to the synthe
./___Corpus/Medline/xml/PMC5123381.xml	poly(I	171198 : 171204	CM	ynthetic polynucleotide, poly(I:C), which is known to mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171233 : 171238	CPR	 which is known to mimic anti-viral responses by activa
./___Corpus/Medline/xml/PMC5123381.xml	TLR	171268 : 171271	CM	 responses by activating TLR (toll-like receptor) sig
./___Corpus/Medline/xml/PMC5123381.xml	LG-02	171334 : 171339	CM	-tumor administration of LG-02 and poly(I:C) in a xenog
./___Corpus/Medline/xml/PMC5123381.xml	poly(I	171344 : 171350	CM	inistration of LG-02 and poly(I:C) in a xenograft M14 me
./___Corpus/Medline/xml/PMC5123381.xml	M14	171369 : 171372	CM	poly(I:C) in a xenograft M14 melanoma model provided 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171610 : 171615	CPR	ecreases not only in the anti-apoptotic cFLIP proteins 
./___Corpus/Medline/xml/PMC5123381.xml	cFLIP	171625 : 171630	CM	ly in the anti-apoptotic cFLIP proteins but also in a n
./___Corpus/Medline/xml/PMC5123381.xml	LG-02	171695 : 171700	CM	ncluding livin following LG-02 treatment. To date there
./___Corpus/Medline/xml/PMC5123381.xml	anti-	171814 : 171819	CPR	cing levels of different anti-apoptotic proteins.      
./___Corpus/Medline/xml/PMC5123381.xml	17-BHWs	171916 : 171923	CM	us, we hypothesized that 17-BHWs represent a unique NP sc
./___Corpus/Medline/xml/PMC5123381.xml	NP	171943 : 171945	CM	-BHWs represent a unique NP scaffold, structural mod
./___Corpus/Medline/xml/PMC5123381.xml	TLR	172048 : 172051	CM	sitizers of apoptosis by TLR signaling that utilizes 
./___Corpus/Medline/xml/PMC5123381.xml	TNF	172116 : 172119	CM	thway similar to that of TNF death receptor signaling
./___Corpus/Medline/xml/PMC5123381.xml	17-BHWs	172167 : 172174	CM	ng. Further studies with 17-BHWs could lead to the identi
./___Corpus/Medline/xml/PMC5123381.xml	TNF	172300 : 172303	CM	ling in response to both TNF death receptor family me
./___Corpus/Medline/xml/PMC5123381.xml	NCI	172402 : 172405	CM	knowledgements Funded by NCI Contract HHSN26120080000
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	172495 : 172499	CM	al administration of the TLR7/8 agonist MEDI9197 inhib
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	172510 : 172518	CM	on of the TLR7/8 agonist MEDI9197 inhibits tumor growth an
./___Corpus/Medline/xml/PMC5123381.xml	P	172625 : 172626	CM	                    John P Vasilakos1, Tesha Alston
./___Corpus/Medline/xml/PMC5123381.xml	Iwen	172686 : 172690	CM	ovedi2, James Elvecrog1, Iwen Grigsby1, Ronald Herbst3
./___Corpus/Medline/xml/PMC5123381.xml	W	172867 : 172868	CM	Katharina Vogel2, Robert W Wilkinson2              
./___Corpus/Medline/xml/PMC5123381.xml	TLR	172949 : 172952	CM	     Toll-like receptor (TLR) agonists, such as the T
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	172976 : 172980	CM	R) agonists, such as the TLR7 agonist imiquimod, have 
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	172989 : 172998	CM	such as the TLR7 agonist imiquimod, have been evaluated top
./___Corpus/Medline/xml/PMC5123381.xml	TLR	173244 : 173247	CM	stemic administration of TLR agonists in cancer patie
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	173325 : 173333	CM	efficacy, in part due to cytokine-induced systemic adverse
./___Corpus/Medline/xml/PMC5123381.xml	imidazoquinoline	173429 : 173445	CM	 Therefore, a lipophilic imidazoquinoline, MEDI9197, was designed 
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	173447 : 173455	CM	philic imidazoquinoline, MEDI9197, was designed to be reta
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	173696 : 173704	CM	umoral (IT) administered MEDI9197 were evaluated in 4 diff
./___Corpus/Medline/xml/PMC5123381.xml	qPCR	173918 : 173922	CM	 profile was assessed by qPCR, histology, and flow cyt
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174026 : 174034	CM	herapy using IT injected MEDI9197 in conjunction with CTLA
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	174065 : 174070	CM	njunction with CTLA-4 or PD-L1 antibodies were evaluate
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174144 : 174152	CM	lts                      MEDI9197 is a human TLR7/8 agonis
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	174164 : 174168	CM	     MEDI9197 is a human TLR7/8 agonist. Following IT 
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174339 : 174347	CM	e detected in the serum. MEDI9197 mediates antitumor activ
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	174427 : 174433	CM	nd enhanced survival) in B16F10 luc, B16-OVA, 4 T1, and 
./___Corpus/Medline/xml/PMC5123381.xml	B16-OVA	174439 : 174446	CM	survival) in B16F10 luc, B16-OVA, 4 T1, and CT-26 mouse t
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	174458 : 174463	CM	 luc, B16-OVA, 4 T1, and CT-26 mouse tumor models. Admi
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174502 : 174510	CM	odels. Administration of MEDI9197 by the IT route and by t
./___Corpus/Medline/xml/PMC5123381.xml	SC	174538 : 174540	CM	 the IT route and by the SC route away from the tumo
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174610 : 174618	CM	the antitumor effects of MEDI9197 require IT administratio
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174655 : 174663	CM	administration. IT dosed MEDI9197 modulates the local immu
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174793 : 174801	CM	ptive immunity. IT dosed MEDI9197 induces tumor necrosis, 
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	174929 : 174937	CM	ys postdose. IT injected MEDI9197 increases the number of 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	174981 : 174985	CM	er of tumor infiltrating CD8+ T cells, while concomita
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	175059 : 175063	CM	er of tumor infiltrating CD4+ T cells. Moreover, MEDI9
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	175083 : 175091	CM	 CD4+ T cells. Moreover, MEDI9197 induces prolonged activa
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	175181 : 175189	CM	tionally, combination of MEDI9197 with CTLA-4 and PD-L1 an
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	175206 : 175211	CM	MEDI9197 with CTLA-4 and PD-L1 antibodies enhances the 
./___Corpus/Medline/xml/PMC5123381.xml	TLR7	175387 : 175391	CM	IT administration of the TLR7/8 agonist MEDI9197 is re
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	175402 : 175410	CM	on of the TLR7/8 agonist MEDI9197 is retained in the tumor
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	175619 : 175627	CM	the antitumor effects of MEDI9197 are further enhanced by 
./___Corpus/Medline/xml/PMC5123381.xml	MEDI9197	175708 : 175716	CM	oint blockade therapies. MEDI9197 is currently being evalu
./___Corpus/Medline/xml/PMC5123381.xml	P53	176613 : 176616	CM	lated from a mutant Kras/P53 mouse pancreatic cancer 
./___Corpus/Medline/xml/PMC5123381.xml	KPC	176642 : 176645	CM	mouse pancreatic cancer (KPC). The clones were charac
./___Corpus/Medline/xml/PMC5123381.xml	MAP	177153 : 177156	CM	owed different levels of MAP kinase signaling, unique
./___Corpus/Medline/xml/PMC5123381.xml	vitro	177222 : 177227	CM	ifferent growth rates in vitro and tumor growth rates i
./___Corpus/Medline/xml/PMC5123381.xml	25-fold	177346 : 177353	CM	 drugs revealed an up to 25-fold varying in vitro sensiti
./___Corpus/Medline/xml/PMC5123381.xml	vitro	177365 : 177370	CM	up to 25-fold varying in vitro sensitivity of the clone
./___Corpus/Medline/xml/PMC5123381.xml	MEK	177680 : 177683	CM	sensitivity of clones to MEK or PI3K inhibition was n
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	177687 : 177691	CM	vity of clones to MEK or PI3K inhibition was not predi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	177832 : 177837	CPR	sitivity of clones to an anti-PD-1 checkpoint inhibitor
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	178483 : 178487	CM	 a novel brain penetrant IDO1 inhibitor               
./___Corpus/Medline/xml/PMC5123381.xml	Dalvie1	178651 : 178658	CM	, Jenny Chaplin1, Deepak Dalvie1, Sofie Denies2, Coraline
./___Corpus/Medline/xml/PMC5123381.xml	De	178684 : 178686	CM	 Sofie Denies2, Coraline De Maeseneire2, JunLi Feng1
./___Corpus/Medline/xml/PMC5123381.xml	Li1	178853 : 178856	CM	laire Letellier2, Wenlin Li1, Karen Maegley1, Reece M
./___Corpus/Medline/xml/PMC5123381.xml	Nichol	178892 : 178898	CM	gley1, Reece Marillier2, Nichol Miller1, Brion Murray1, 
./___Corpus/Medline/xml/PMC5123381.xml	Miller1	178899 : 178906	CM	Reece Marillier2, Nichol Miller1, Brion Murray1, Romain P
./___Corpus/Medline/xml/PMC5123381.xml	Al	179049 : 179051	CM	irangam1, Jim Solowiej1, Al Stewart1, Nicole Streine
./___Corpus/Medline/xml/PMC5123381.xml	Streiner1	179069 : 179078	CM	ej1, Al Stewart1, Nicole Streiner1, Vince Torti1, Konstanti
./___Corpus/Medline/xml/PMC5123381.xml	Torti1	179086 : 179092	CM	 Nicole Streiner1, Vince Torti1, Konstantinos Tsaparikos
./___Corpus/Medline/xml/PMC5123381.xml	tryptophan	179246 : 179256	CM	              Tumors use tryptophan-catabolizing enzymes suc
./___Corpus/Medline/xml/PMC5123381.xml	indoleamine	179286 : 179297	CM	bolizing enzymes such as indoleamine 2–3 dioxygenase (IDO1) t
./___Corpus/Medline/xml/PMC5123381.xml	2–	179298 : 179300	CPR	ymes such as indoleamine 2–3 dioxygenase (IDO1) to i
./___Corpus/Medline/xml/PMC5123381.xml	dioxygenase	179302 : 179313	CM	 such as indoleamine 2–3 dioxygenase (IDO1) to induce an immu
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179315 : 179319	CM	leamine 2–3 dioxygenase (IDO1) to induce an immunosupp
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179365 : 179369	CM	suppressive environment. IDO1 is induced in response t
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179508 : 179512	CM	 Treg function. As such, IDO1 is a nexus for the induc
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179765 : 179769	CM	ive, orally bioavailable IDO1 inhibitor, PF-06840003. 
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179877 : 179881	CM	ions of PF-06840003 with IDO1 will be presented, and r
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	179986 : 179990	CM	-06840003 bound to human IDO1. In addition, binding st
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	180060 : 180064	CM	nd ferric forms of human IDO1 have been performed. The
./___Corpus/Medline/xml/PMC5123381.xml	tryptophan	180128 : 180138	CM	st that PF-06840003 is a tryptophan non-competitive, non-hem
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	180173 : 180177	CM	titive, non-heme binding IDO1 inhibitor. Key in vitro 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	180196 : 180201	CM	g IDO1 inhibitor. Key in vitro and in vivo pharmacology
./___Corpus/Medline/xml/PMC5123381.xml	ADME	180295 : 180299	CM	eckpoint inhibitors, and ADME data of PF-06840003 will
./___Corpus/Medline/xml/PMC5123381.xml	ADME	180374 : 180378	CM	3 shows a very favorable ADME profile (solubility, hum
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	180726 : 180730	CM	-06840003 is a selective IDO1 inhibitor with very favo
./___Corpus/Medline/xml/PMC5123381.xml	PK	180777 : 180779	CM	avorable predicted human PK characteristics. Its pro
./___Corpus/Medline/xml/PMC5123381.xml	QD	180850 : 180852	CM	n half-life should allow QD administration. CNS pene
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	180963 : 180968	CM	oint antagonists against PD-L1 cause enhanced IDO1 expr
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	180984 : 180988	CM	nst PD-L1 cause enhanced IDO1 expression and enhanced 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181021 : 181026	CPR	ion and enhanced in vivo anti-tumor efficacy in combina
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181415 : 181420	CPR	           P246 Enhanced anti-tumor effect of combinati
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	181461 : 181472	CM	combination therapy with NHS-muIL-12 and anti-PD-L1 antibody 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181477 : 181482	CPR	apy with NHS-muIL-12 and anti-PD-L1 antibody (avelumab)
./___Corpus/Medline/xml/PMC5123381.xml	Xu1	181585 : 181588	CM	                Chunxiao Xu1, Yanping Zhang2, Giorgio
./___Corpus/Medline/xml/PMC5123381.xml	Qi2	181644 : 181647	CM	ian2, Guozhong Qin2, Jin Qi2, Xiaomei Xu2, Bo Marelli
./___Corpus/Medline/xml/PMC5123381.xml	Xu2	181657 : 181660	CM	g Qin2, Jin Qi2, Xiaomei Xu2, Bo Marelli2, Huakui Yu2
./___Corpus/Medline/xml/PMC5123381.xml	Bo	181662 : 181664	CM	2, Jin Qi2, Xiaomei Xu2, Bo Marelli2, Huakui Yu2, Wi
./___Corpus/Medline/xml/PMC5123381.xml	Yu2	181682 : 181685	CM	Xu2, Bo Marelli2, Huakui Yu2, Wilson Guzman2, Rober T
./___Corpus/Medline/xml/PMC5123381.xml	Tighe2	181709 : 181715	CM	2, Wilson Guzman2, Rober Tighe2, Rachel Salazar2, Kin-Mi
./___Corpus/Medline/xml/PMC5123381.xml	Lo2	181743 : 181746	CM	achel Salazar2, Kin-Ming Lo2, Jessie English2, Laszlo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181929 : 181934	CPR	ne checkpoint inhibitors anti-PD-1 or PD-L1 induce dura
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	181942 : 181947	CM	 inhibitors anti-PD-1 or PD-L1 induce durable anti-tumo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	181963 : 181968	CPR	 or PD-L1 induce durable anti-tumor responses in some p
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182348 : 182353	CPR	sing strategy to improve anti-tumor efficacy. NHS-IL-12
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182582 : 182587	CPR	10718C) is a fully human anti-PD-L1 IgG1 monoclonal ant
./___Corpus/Medline/xml/PMC5123381.xml	IgG1	182593 : 182597	CM	a fully human anti-PD-L1 IgG1 monoclonal antibody desi
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	182650 : 182655	CM	d to selectively bind to PD-L1 and competitively inhibi
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	182701 : 182705	CM	hibit it from binding to PD-1, which has shown antitum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	182880 : 182885	CPR	dies described here, the anti-tumor efficacy of combina
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	182957 : 182968	CM	elumab and the surrogate NHS-muIL-12 was investigated in an o
./___Corpus/Medline/xml/PMC5123381.xml	EMT-6	183003 : 183008	CM	tigated in an orthotopic EMT-6 breast cancer model’    
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	183091 : 183102	CM	          Treatment with NHS-muIL-12 and avelumab generated a
./___Corpus/Medline/xml/PMC5123381.xml	anti-	183138 : 183143	CPR	ab generated an enhanced anti-tumor effect relative to 
./___Corpus/Medline/xml/PMC5123381.xml	EMT-6	183370 : 183375	CM	against rechallenge with EMT-6 tumor cells and the sign
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183521 : 183525	CM	mulated cytotoxic NK and CD8+ T cell proliferation. NH
./___Corpus/Medline/xml/PMC5123381.xml	NHS-muIL-12	183548 : 183559	CM	8+ T cell proliferation. NHS-muIL-12 treatment induced CD8+ T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183578 : 183582	CM	uIL-12 treatment induced CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	183786 : 183790	CM	he function of exhausted CD8+ T cells in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	184172 : 184176	CM	ng effects of CTLA-4 and PD-1 blockade on follicular h
./___Corpus/Medline/xml/PMC5123381.xml	Zappasodi1	184299 : 184309	CM	                 Roberta Zappasodi1, Sadna Budhu1, Matthew D
./___Corpus/Medline/xml/PMC5123381.xml	Li1	184418 : 184421	CM	mi1, Hong Zhong1, Yanyun Li1, Cailian Liu1, Daniel Hi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	184586 : 184591	CPR	 underlying the improved anti-tumor activity of combine
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	184629 : 184633	CM	y of combined CTLA-4 and PD-1 blockade is not yet well
./___Corpus/Medline/xml/PMC5123381.xml	CD4	184701 : 184704	CM	ported that expansion of CD4+Foxp3− T cells expressin
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	184731 : 184735	CM	oxp3− T cells expressing PD-1 (4PD-1hi) was associated
./___Corpus/Medline/xml/PMC5123381.xml	anti-	184846 : 184851	CPR	antibody was added to an anti-melanoma vaccine in B16-m
./___Corpus/Medline/xml/PMC5123381.xml	vitro	185203 : 185208	CM	as tested in standard in vitro suppression assays and 3
./___Corpus/Medline/xml/PMC5123381.xml	anti-	185551 : 185556	CPR	ction of tumor burden in anti-CTLA-4-treated and naïve 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	185562 : 185567	CPR	mor burden in anti-CTLA-4-treated and naïve B16-bearing
./___Corpus/Medline/xml/PMC5123381.xml	Teff	185687 : 185691	CM	between effector T cell (Teff) and 4PD-1hi inversely c
./___Corpus/Medline/xml/PMC5123381.xml	cell-(Tfh)	185967 : 185977	CM	t of follicular helper T cell-(Tfh)-associated genes in 4PD-
./___Corpus/Medline/xml/PMC5123381.xml	CD4	186056 : 186059	CM	tory T cells (Tregs) and CD4+Foxp3−PD-1− T cells. We 
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	186114 : 186124	CM	fore immunized Foxp3-GFP transgenic mice with sheep red bloo
./___Corpus/Medline/xml/PMC5123381.xml	sRBC	186158 : 186162	CM	h sheep red blood cells (sRBC) to boost development of
./___Corpus/Medline/xml/PMC5123381.xml	Tfh	186188 : 186191	CM	 to boost development of Tfh and test their function 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186219 : 186224	CM	d test their function in vitro. 4PD-1hi from sRBC-treat
./___Corpus/Medline/xml/PMC5123381.xml	sRBC	186239 : 186243	CM	n in vitro. 4PD-1hi from sRBC-treated animals inhibite
./___Corpus/Medline/xml/PMC5123381.xml	Tfh	186386 : 186389	CM	s and according to their Tfh-like phenotype, 4PD-1hi 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186463 : 186468	CM	maturation of B cells in vitro. Moreover, concurrent PD
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	186491 : 186495	CM	ro. Moreover, concurrent PD-1 and CTLA-4 blockade, eit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	186556 : 186561	CPR	r in combination with an anti-melanoma vaccine, prevent
./___Corpus/Medline/xml/PMC5123381.xml	anti-	186634 : 186639	CPR	d significantly improved anti-tumor responses in mice. 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	186714 : 186718	CM	mumab increased, whereas PD-1 blockade reduced, circul
./___Corpus/Medline/xml/PMC5123381.xml	CD25	186792 : 186796	CM	dvantage of differential CD25 expression in 4PD-1hi an
./___Corpus/Medline/xml/PMC5123381.xml	Teff	186966 : 186970	CM	 Human 4PD-1hi inhibited Teff functions in vitro and e
./___Corpus/Medline/xml/PMC5123381.xml	vitro	186984 : 186989	CM	ibited Teff functions in vitro and expressed Tfh-associ
./___Corpus/Medline/xml/PMC5123381.xml	Tfh	187004 : 187007	CM	s in vitro and expressed Tfh-associated markers, thus
./___Corpus/Medline/xml/PMC5123381.xml	Tfh	187172 : 187175	CM	suppression functions of Tfh-like cells expanded by C
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	187345 : 187349	CM	We provide evidence that PD-1 blockade counteracts ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	187371 : 187376	CPR	D-1 blockade counteracts anti-CTLA-4-mediated 4PD-1hi i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	187382 : 187387	CPR	e counteracts anti-CTLA-4-mediated 4PD-1hi induction, t
./___Corpus/Medline/xml/PMC5123381.xml	WT1	187840 : 187843	CM	                    P248 WT1 peptide vaccine in Monta
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	187863 : 187872	CM	8 WT1 peptide vaccine in Montanide or poly-ICLC triggers di
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	187876 : 187885	CM	 vaccine in Montanide or poly-ICLC triggers different immun
./___Corpus/Medline/xml/PMC5123381.xml	anti-	188357 : 188362	CPR	ntigens can augment host anti-tumor immune response and
./___Corpus/Medline/xml/PMC5123381.xml	WT1	188428 : 188431	CM	ontrol in some patients. WT1 is a defined leukemia-as
./___Corpus/Medline/xml/PMC5123381.xml	CML	188525 : 188528	CM	t over-expressed in AML, CML, ALL, and other tumors. 
./___Corpus/Medline/xml/PMC5123381.xml	ALL	188530 : 188533	CM	r-expressed in AML, CML, ALL, and other tumors. WT1 i
./___Corpus/Medline/xml/PMC5123381.xml	WT1	188553 : 188556	CM	, ALL, and other tumors. WT1 is highly antigenic and 
./___Corpus/Medline/xml/PMC5123381.xml	WT1	188680 : 188683	CM	or vaccination to induce WT1-specific immune response
./___Corpus/Medline/xml/PMC5123381.xml	WT1	188951 : 188954	CM	receive vaccination with WT1 126–134 peptide (RMFPNAP
./___Corpus/Medline/xml/PMC5123381.xml	126–	188955 : 188959	CPR	ive vaccination with WT1 126–134 peptide (RMFPNAPYL) i
./___Corpus/Medline/xml/PMC5123381.xml	RMFPNAPYL	188972 : 188981	CM	ith WT1 126–134 peptide (RMFPNAPYL) in either Montanide or 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	188993 : 189002	CM	de (RMFPNAPYL) in either Montanide or poly-ICLC (TLR3 agoni
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189006 : 189015	CM	) in either Montanide or poly-ICLC (TLR3 agonist). Four pat
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	189017 : 189021	CM	 Montanide or poly-ICLC (TLR3 agonist). Four patients 
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189073 : 189076	CM	re randomized to receive WT1 in Montanide and three w
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	189080 : 189089	CM	omized to receive WT1 in Montanide and three were randomize
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189127 : 189130	CM	re randomized to receive WT1 in poly-ICLC. The vaccin
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189134 : 189143	CM	omized to receive WT1 in poly-ICLC. The vaccine was adminis
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189356 : 189359	CM	was collected to monitor WT1 transcript levels, antig
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189396 : 189400	CM	levels, antigen-specific CD8+ T cell responses, and TC
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189491 : 189494	CM	                   After WT1 vaccination, three of fo
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	189538 : 189547	CM	 of four patients in the Montanide arm had deceased WT1 lev
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189565 : 189568	CM	ntanide arm had deceased WT1 levels in circulation de
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	189603 : 189610	CM	 circulation detected by qRT-PCR, and two of these demons
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189652 : 189655	CM	e demonstrated augmented WT1-specific CD8+ T cell res
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189665 : 189669	CM	d augmented WT1-specific CD8+ T cell responses detecte
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	189699 : 189704	CM	ll responses detected by IFN-γ ELISPOT assay. All three
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189771 : 189774	CM	 clonal enrichment after WT1 vaccination suggested by
./___Corpus/Medline/xml/PMC5123381.xml	alpha	189804 : 189809	CM	ination suggested by TCR alpha and beta CDR3 sequencing
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	189819 : 189823	CM	ed by TCR alpha and beta CDR3 sequencing. In contrast,
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	189876 : 189885	CM	 the two patients on the poly-ICLC arm, no increase in WT1-
./___Corpus/Medline/xml/PMC5123381.xml	WT1	189906 : 189909	CM	ICLC arm, no increase in WT1-specific CD8+ T cell res
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	189919 : 189923	CM	increase in WT1-specific CD8+ T cell responses was det
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	189957 : 189962	CM	esponses was detected by IFN-γ ELISPOT assay, and no cl
./___Corpus/Medline/xml/PMC5123381.xml	alpha	190023 : 190028	CM	ment was detected by TCR alpha/beta sequencing. Interes
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190115 : 190118	CM	s demonstrated decreased WT1 transcript levels in cir
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	190164 : 190171	CM	 circulation detected by qRT-PCR and remained in remissio
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190230 : 190233	CM	 after the initiation of WT1 vaccination.            
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190336 : 190339	CM	ow that vaccination with WT1 peptide emulsified in Mo
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	190362 : 190371	CM	T1 peptide emulsified in Montanide is a superior vaccine st
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190422 : 190425	CM	ategy based on increased WT1-specific CD8+ T cell res
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	190435 : 190439	CM	n increased WT1-specific CD8+ T cell responses with TC
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	190495 : 190499	CM	al and specific TCR beta CDR3 enrichment and decreased
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190525 : 190528	CM	enrichment and decreased WT1 transcripts as a measure
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190614 : 190617	CM	ct that vaccination with WT1 peptide in poly-ICLC non
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	190629 : 190638	CM	tion with WT1 peptide in poly-ICLC nonetheless was associat
./___Corpus/Medline/xml/PMC5123381.xml	WT1	190681 : 190684	CM	ssociated with decreased WT1 transcripts suggests tha
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	190814 : 190823	CM	ct on dendritic cells of poly-ICLC alone.                  
./___Corpus/Medline/xml/PMC5123381.xml	HPV	190926 : 190929	CM	ed human papillomavirus (HPV) E7 cancer vaccine (AXAL
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	190950 : 190954	CM	(HPV) E7 cancer vaccine (AXAL) with CD137 agonist anti
./___Corpus/Medline/xml/PMC5123381.xml	CD137	190961 : 190966	CM	ncer vaccine (AXAL) with CD137 agonist antibody provide
./___Corpus/Medline/xml/PMC5123381.xml	Ju	191108 : 191110	CM	                Xiaoming Ju, Rachelle Kosoff, Kimber
./___Corpus/Medline/xml/PMC5123381.xml	HPV	191263 : 191266	CM	und                      HPV can cause cervical, anal
./___Corpus/Medline/xml/PMC5123381.xml	penile	191310 : 191316	CM	, anal, vulvar, vaginal, penile, and oropharyngeal cance
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	191345 : 191349	CM	d oropharyngeal cancers. AXAL is a genetically enginee
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	191613 : 191617	CM	th checkpoint inhibitor (PD-1 or PD-L1) antibodies. To
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	191621 : 191626	CM	point inhibitor (PD-1 or PD-L1) antibodies. To identify
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	191706 : 191710	CM	otherapies, we evaluated AXAL ± antibodies for T cell 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	191809 : 191813	CM	oint inhibitors: CTLA-4, PD-1, TIM-3, LAG-3; co-stimul
./___Corpus/Medline/xml/PMC5123381.xml	TIM-3	191815 : 191820	CM	nhibitors: CTLA-4, PD-1, TIM-3, LAG-3; co-stimulators: 
./___Corpus/Medline/xml/PMC5123381.xml	CD137	191845 : 191850	CM	, LAG-3; co-stimulators: CD137, OX40, GITR, and CD40) i
./___Corpus/Medline/xml/PMC5123381.xml	OX40	191852 : 191856	CM	; co-stimulators: CD137, OX40, GITR, and CD40) in a mo
./___Corpus/Medline/xml/PMC5123381.xml	GITR	191858 : 191862	CM	timulators: CD137, OX40, GITR, and CD40) in a mouse HP
./___Corpus/Medline/xml/PMC5123381.xml	CD40	191868 : 191872	CM	: CD137, OX40, GITR, and CD40) in a mouse HPV-positive
./___Corpus/Medline/xml/PMC5123381.xml	TC1	191981 : 191984	CM	 C57BL/6 female mice and TC1 cells (C57BL/6 mouse lun
./___Corpus/Medline/xml/PMC5123381.xml	HPV16	192048 : 192053	CM	ells co-transfected with HPV16 E6 and E7 and activated 
./___Corpus/Medline/xml/PMC5123381.xml	E6	192054 : 192056	CM	o-transfected with HPV16 E6 and E7 and activated Ras
./___Corpus/Medline/xml/PMC5123381.xml	E7	192061 : 192063	CM	fected with HPV16 E6 and E7 and activated Ras) were 
./___Corpus/Medline/xml/PMC5123381.xml	ATCC	192127 : 192131	CM	Jackson Laboratories and ATCC, respectively. All antib
./___Corpus/Medline/xml/PMC5123381.xml	TC1	192254 : 192257	CM	 the hind-leg flank with TC1 cells. AXAL ± the respec
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	192265 : 192269	CM	eg flank with TC1 cells. AXAL ± the respective antibod
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	192706 : 192710	CM	sted in combination with AXAL, CD137 and CTLA-4 antibo
./___Corpus/Medline/xml/PMC5123381.xml	CD137	192712 : 192717	CM	n combination with AXAL, CD137 and CTLA-4 antibodies we
./___Corpus/Medline/xml/PMC5123381.xml	CD137	192860 : 192865	CM	 with prior reports that CD137 is expressed on natural 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	193055 : 193058	CM	ealed increased TILs and CD8/Treg ratio, and decrease
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193147 : 193152	CM	103-positive Tregs after CD137 + AXAL treatment versus 
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	193155 : 193159	CM	tive Tregs after CD137 + AXAL treatment versus treatme
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	193253 : 193258	CM	creases were observed in PD-L1 expression on tumor cell
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	193289 : 193293	CM	ssion on tumor cells and PD-1 expression on CD8-positi
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193372 : 193377	CM	e tumor regression after CD137 + AXAL treatment (n = 5)
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	193380 : 193384	CM	regression after CD137 + AXAL treatment (n = 5) were s
./___Corpus/Medline/xml/PMC5123381.xml	TC1	193439 : 193442	CM	uently rechallenged with TC1 cells. Two mice remained
./___Corpus/Medline/xml/PMC5123381.xml	6–	193518 : 193520	CPR	rmination (an additional 6–7 weeks); the other 3 had
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	193603 : 193607	CM	ersus controls. CTLA-4 + AXAL treatment resulted in co
./___Corpus/Medline/xml/PMC5123381.xml	AXAL	193782 : 193786	CM	ons                      AXAL demonstrated strong anti
./___Corpus/Medline/xml/PMC5123381.xml	CD137	193908 : 193913	CM	ally in combination with CD137 and CTLA-4 antibodies. M
./___Corpus/Medline/xml/PMC5123381.xml	anti-	193983 : 193988	CPR	suggest that addition of anti-PD-1 to anti-CD137 + AXAL
./___Corpus/Medline/xml/PMC5123381.xml	anti-	193996 : 194001	CPR	addition of anti-PD-1 to anti-CD137 + AXAL could be a p
./___Corpus/Medline/xml/PMC5123381.xml	anti-CD137	194158 : 194168	CM	 Kohrt HE: Rationale for anti-CD137 cancer immunotherapy. Eu
./___Corpus/Medline/xml/PMC5123381.xml	112–	194213 : 194217	CPR	y. Eur J Cancer 2016, 54:112–119.                  Com
./___Corpus/Medline/xml/PMC5123381.xml	murine	194382 : 194388	CM	antitumoral effects in a murine model of cancer therapy 
./___Corpus/Medline/xml/PMC5123381.xml	Fu2	194585 : 194588	CM	ena J Mauceri1, Yang-Xin Fu2, Ralph R Weichselbaum1  
./___Corpus/Medline/xml/PMC5123381.xml	R	194596 : 194597	CM	ri1, Yang-Xin Fu2, Ralph R Weichselbaum1           
./___Corpus/Medline/xml/PMC5123381.xml	CD4-Cre	195317 : 195324	CM	ere obtained by crossing CD4-Cre or Lck-cre mice with R26
./___Corpus/Medline/xml/PMC5123381.xml	s.c	195467 : 195470	CM	ncer cells were injected s.c. into EYFP+ T cell repor
./___Corpus/Medline/xml/PMC5123381.xml	WBI	195631 : 195634	CM	 whole-body irradiation (WBI) while their tumor was s
./___Corpus/Medline/xml/PMC5123381.xml	EYFP+	195748 : 195753	CM	reserving tumor-resident EYFP+ T cells. Following bone-
./___Corpus/Medline/xml/PMC5123381.xml	2C	195831 : 195833	CM	sRed+Rag−/− cells, EGFP+ 2C CD8+ T cells specific fo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	195834 : 195838	CM	d+Rag−/− cells, EGFP+ 2C CD8+ T cells specific for the
./___Corpus/Medline/xml/PMC5123381.xml	SIY	195864 : 195867	CM	T cells specific for the SIY antigen were adoptively 
./___Corpus/Medline/xml/PMC5123381.xml	3–	195948 : 195950	CPR	ly infiltrating T cells. 3–4 days after 2C transfer,
./___Corpus/Medline/xml/PMC5123381.xml	2C	195963 : 195965	CM	 T cells. 3–4 days after 2C transfer, some mice rece
./___Corpus/Medline/xml/PMC5123381.xml	Gy	196133 : 196135	CM	(ii) a single dose of 20 Gy (SBRT model) showed that
./___Corpus/Medline/xml/PMC5123381.xml	SBRT	196137 : 196141	CM	 a single dose of 20 Gy (SBRT model) showed that a sig
./___Corpus/Medline/xml/PMC5123381.xml	EYFP+	196204 : 196209	CM	ortion of tumor-resident EYFP+ T cells were still detec
./___Corpus/Medline/xml/PMC5123381.xml	MC38	196463 : 196467	CM	treated tumors. Treating MC38 tumor-bearing mice with 
./___Corpus/Medline/xml/PMC5123381.xml	WBI	196512 : 196515	CM	with increasing doses of WBI (1–10 Gy) showed that tu
./___Corpus/Medline/xml/PMC5123381.xml	1–	196517 : 196519	CPR	increasing doses of WBI (1–10 Gy) showed that tumor-
./___Corpus/Medline/xml/PMC5123381.xml	Gy	196522 : 196524	CM	asing doses of WBI (1–10 Gy) showed that tumor-resid
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine 1-phosphate	196688 : 196711	CM	Gy local IR and systemic sphingosine 1-phosphate receptor agonist FTY720,
./___Corpus/Medline/xml/PMC5123381.xml	FTY720	196729 : 196735	CM	osphate receptor agonist FTY720, suggest that tumor-resi
./___Corpus/Medline/xml/PMC5123381.xml	YX	197107 : 197109	CM	       1. Burnette B, Fu YX, Weichselbaum RR: The co
./___Corpus/Medline/xml/PMC5123381.xml	mRCC	197499 : 197503	CM	ors for the treatment of mRCC: implications for combin
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	197544 : 197551	CM	or combined therapy with AGS-003, an autologous dendritic
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	197711 : 197718	CM	und                      AGS-003, is an autologous dendri
./___Corpus/Medline/xml/PMC5123381.xml	DC	197753 : 197755	CM	tologous dendritic cell (DC) immunotherapy consistin
./___Corpus/Medline/xml/PMC5123381.xml	DCs	197793 : 197796	CM	py consisting of matured DCs co-electroporated with a
./___Corpus/Medline/xml/PMC5123381.xml	RNA	197847 : 197850	CM	plified autologous tumor RNA and CD40L RNA. AGS-003, 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	197861 : 197864	CM	gous tumor RNA and CD40L RNA. AGS-003, is being evalu
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	197866 : 197873	CM	tumor RNA and CD40L RNA. AGS-003, is being evaluated in t
./___Corpus/Medline/xml/PMC5123381.xml	ADAPT	197909 : 197914	CM	evaluated in the pivotal ADAPT phase III clinical trial
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198113 : 198122	CM	 response combination of sunitinib + AGS-003 was greater th
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	198125 : 198132	CM	mbination of sunitinib + AGS-003 was greater than sunitin
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198150 : 198159	CM	AGS-003 was greater than sunitinib alone. The standard-of-c
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	198188 : 198196	CM	ne. The standard-of-care tyrosine kinase inhibitors includ
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	198225 : 198234	CM	ase inhibitors including sunitinib, sorafinib, axitinib, pa
./___Corpus/Medline/xml/PMC5123381.xml	sorafinib	198236 : 198245	CM	ors including sunitinib, sorafinib, axitinib, pazopanib, ca
./___Corpus/Medline/xml/PMC5123381.xml	pazopanib	198257 : 198266	CM	ib, sorafinib, axitinib, pazopanib, cabozantinib and tivoza
./___Corpus/Medline/xml/PMC5123381.xml	tivozanib	198285 : 198294	CM	opanib, cabozantinib and tivozanib, and the mTOR inhibitors
./___Corpus/Medline/xml/PMC5123381.xml	mTOR	198304 : 198308	CM	b and tivozanib, and the mTOR inhibitors, everolimus a
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	198321 : 198331	CM	and the mTOR inhibitors, everolimus and temsirolimus, are an
./___Corpus/Medline/xml/PMC5123381.xml	temsirolimus	198336 : 198348	CM	hibitors, everolimus and temsirolimus, are anti-angiogenic the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	198354 : 198359	CPR	us and temsirolimus, are anti-angiogenic therapeutics t
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	198637 : 198644	CM	munotherapeutic, such as AGS-003, may be ineffective, if 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	198719 : 198722	CM	impedes the induction of CTL responses in vivo, which
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	198793 : 198800	CM	anism of action (MOA) of AGS-003. Therefore, it was of in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	198862 : 198867	CM	st these combinations in vitro with DCs representative 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	198873 : 198876	CM	mbinations in vitro with DCs representative of AGS-00
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	198895 : 198902	CM	th DCs representative of AGS-003 to observe the effects o
./___Corpus/Medline/xml/PMC5123381.xml	CTL	198969 : 198972	CM	rapy on antigen-specific CTL proliferation and CTL fu
./___Corpus/Medline/xml/PMC5123381.xml	CTL	198991 : 198994	CM	ic CTL proliferation and CTL functional responses.   
./___Corpus/Medline/xml/PMC5123381.xml	DCs	199063 : 199066	CM	ods                      DCs derived from normal dono
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	199131 : 199137	CM	e co-electroporated with MART-1 RNA and CD40L RNA to rep
./___Corpus/Medline/xml/PMC5123381.xml	RNA	199138 : 199141	CM	ectroporated with MART-1 RNA and CD40L RNA to represe
./___Corpus/Medline/xml/PMC5123381.xml	RNA	199152 : 199155	CM	ith MART-1 RNA and CD40L RNA to represent AGS-003 DC 
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	199169 : 199176	CM	d CD40L RNA to represent AGS-003 DC products. In vitro co
./___Corpus/Medline/xml/PMC5123381.xml	DC	199177 : 199179	CM	RNA to represent AGS-003 DC products. In vitro co-cu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	199193 : 199198	CM	 AGS-003 DC products. In vitro co-cultures were set up 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	199239 : 199243	CM	e set up with autologous CD8+ T cells and MART-1/CD40L
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	199256 : 199262	CM	ologous CD8+ T cells and MART-1/CD40L-DCs in the presenc
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	199497 : 199503	CM	 Subsequent expansion of MART-1 specific CTLs and multi-
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	199513 : 199517	CM	nsion of MART-1 specific CTLs and multi-functional res
./___Corpus/Medline/xml/PMC5123381.xml	vitro	199648 : 199653	CM	                  Our in vitro analysis demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	sunitinib	199681 : 199690	CM	alysis demonstrated that sunitinib, axitinib, cabozantinib,
./___Corpus/Medline/xml/PMC5123381.xml	tivozanib	199716 : 199725	CM	 axitinib, cabozantinib, tivozanib, everolimus and temsirol
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	199727 : 199737	CM	cabozantinib, tivozanib, everolimus and temsirolimus did not
./___Corpus/Medline/xml/PMC5123381.xml	temsirolimus	199742 : 199754	CM	ivozanib, everolimus and temsirolimus did not impact the primi
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	199803 : 199809	CM	ing nor proliferation of MART-1-specific CTL responses. 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	199819 : 199822	CM	ation of MART-1-specific CTL responses. Furthermore, 
./___Corpus/Medline/xml/PMC5123381.xml	CD28+	199909 : 199914	CM	t multi-functionality of CD28+/CD45RA− effector/memory 
./___Corpus/Medline/xml/PMC5123381.xml	CD45RA−	199915 : 199922	CM	i-functionality of CD28+/CD45RA− effector/memory CTL. How
./___Corpus/Medline/xml/PMC5123381.xml	CTL	199939 : 199942	CM	/CD45RA− effector/memory CTL. However, sorafenib, whe
./___Corpus/Medline/xml/PMC5123381.xml	sorafenib	199953 : 199962	CM	tor/memory CTL. However, sorafenib, when present in the CTL
./___Corpus/Medline/xml/PMC5123381.xml	CTL	199984 : 199987	CM	nib, when present in the CTL/DC co-cultures, did sign
./___Corpus/Medline/xml/PMC5123381.xml	DC	199988 : 199990	CM	 when present in the CTL/DC co-cultures, did signifi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	200029 : 200034	CPR	did significantly impair anti-MART-1-specific CTL expan
./___Corpus/Medline/xml/PMC5123381.xml	anti-	200040 : 200045	CPR	cantly impair anti-MART-1-specific CTL expansion and CT
./___Corpus/Medline/xml/PMC5123381.xml	CTL	200050 : 200053	CM	air anti-MART-1-specific CTL expansion and CTL multi-
./___Corpus/Medline/xml/PMC5123381.xml	CTL	200068 : 200071	CM	ecific CTL expansion and CTL multi-functionality.    
./___Corpus/Medline/xml/PMC5123381.xml	DCs	200154 : 200157	CM	              Autologous DCs co-electroporated with M
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	200181 : 200187	CM	s co-electroporated with MART-1 RNA/CD40L RNA exhibit a 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	200188 : 200191	CM	ectroporated with MART-1 RNA/CD40L RNA exhibit a simi
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	200192 : 200197	CM	oporated with MART-1 RNA/CD40L RNA exhibit a similar MO
./___Corpus/Medline/xml/PMC5123381.xml	RNA	200198 : 200201	CM	ed with MART-1 RNA/CD40L RNA exhibit a similar MOA in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	200227 : 200232	CM	exhibit a similar MOA in vitro to AGS-003 administered 
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	200236 : 200243	CM	 similar MOA in vitro to AGS-003 administered in vivo, wh
./___Corpus/Medline/xml/PMC5123381.xml	DC	200279 : 200281	CM	ed in vivo, whereby both DC preparations induce anti
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	200336 : 200340	CM	pecific multi-functional CTLs. Understanding the MOA o
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	200367 : 200374	CM	Understanding the MOA of AGS-003 in vitro, allows for the
./___Corpus/Medline/xml/PMC5123381.xml	vitro	200378 : 200383	CM	ng the MOA of AGS-003 in vitro, allows for the testing 
./___Corpus/Medline/xml/PMC5123381.xml	AGS-003	200640 : 200647	CM	mpatible with the MOA of AGS-003, the induction of effect
./___Corpus/Medline/xml/PMC5123381.xml	CTL	200682 : 200685	CM	ction of effector/memory CTL responses, and that each
./___Corpus/Medline/xml/PMC5123381.xml	Wu2	201166 : 201169	CM	     Yanyan Han1, Yeting Wu2, Chou Yang2, Jing Huang2
./___Corpus/Medline/xml/PMC5123381.xml	Wu3	201204 : 201207	CM	g2, Jing Huang2, Dongyun Wu3, Jin Li3, Xiaoling Liang
./___Corpus/Medline/xml/PMC5123381.xml	Li3	201213 : 201216	CM	Huang2, Dongyun Wu3, Jin Li3, Xiaoling Liang1, Xiangj
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	201422 : 201427	CM	ated autologous T cells (MASCT) was a safe treatment, w
./___Corpus/Medline/xml/PMC5123381.xml	HCC	201562 : 201565	CM	epatocellular carcinoma (HCC). In this study, we inve
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	201615 : 201620	CM	stigated the dynamics of MASCT-induced immune responses
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	201828 : 201833	CM	(BCLC) were treated with MASCT for three courses after 
./___Corpus/Medline/xml/PMC5123381.xml	mDCs	201972 : 201976	CM	 mature dendritic cells (mDCs) pulsed with a peptide p
./___Corpus/Medline/xml/PMC5123381.xml	mDCs	202094 : 202098	CM	ous T cells activated by mDCs described above. Each co
./___Corpus/Medline/xml/PMC5123381.xml	14–	202135 : 202138	CPR	bove. Each course lasted 14–15 weeks.                
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	202222 : 202227	CM	er repeated treatment of MASCT, the frequency of regula
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	202282 : 202287	CM	T cells in the patients’ PBMCs was significantly decrea
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	202575 : 202579	CM	ol were also measured by IFNγ ELISPOT assay. These spe
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	202743 : 202748	CM	during the treatments of MASCT. After 1 course of treat
./___Corpus/Medline/xml/PMC5123381.xml	CCND1	203070 : 203075	CM	vivin (7/13), cyclin D1 (CCND1, 6/13), carcinoembryonic
./___Corpus/Medline/xml/PMC5123381.xml	CEA	203110 : 203113	CM	arcinoembryonic antigen (CEA, 5/13), and HBV DNA poly
./___Corpus/Medline/xml/PMC5123381.xml	HBV	203126 : 203129	CM	antigen (CEA, 5/13), and HBV DNA polymerase (5/13). T
./___Corpus/Medline/xml/PMC5123381.xml	MASCT	203585 : 203590	CM	r repeated treatments of MASCT, providing evidence to s
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	203919 : 203926	CM	s expressing mesothelin (CRS-207) with immuno-modulatory 
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	203960 : 203976	CM	muno-modulatory doses of cyclophosphamide, combined with chemother
./___Corpus/Medline/xml/PMC5123381.xml	MPM	204054 : 204057	CM	nt pleural mesothelioma (MPM)                        
./___Corpus/Medline/xml/PMC5123381.xml	W	204169 : 204170	CM	3, Hedy L Kindler4, Evan W Alley5, Somayeh Honarman
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	204436 : 204443	CM	und                      CRS-207 is live, attenuated, dou
./___Corpus/Medline/xml/PMC5123381.xml	LADD	204504 : 204508	CM	 Listeria monocytogenes (LADD) engineered to express m
./___Corpus/Medline/xml/PMC5123381.xml	MPM	204616 : 204619	CM	veral cancers, including MPM, an aggressive treatment
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	204685 : 204692	CM	ase with poor prognosis. CRS-207 activates innate and ada
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	204867 : 204874	CM	immune-mediated killing. CRS-207 in combination with stan
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	204929 : 204938	CM	of care (SOC) pemetrexed/cisplatin demonstrated clinical ac
./___Corpus/Medline/xml/PMC5123381.xml	Ib	204981 : 204983	CM	ical activity in a phase Ib study. Low-dose cyclopho
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	205000 : 205016	CM	phase Ib study. Low-dose cyclophosphamide (Cy) has been shown to d
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205018 : 205020	CM	w-dose cyclophosphamide (Cy) has been shown to decre
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	205136 : 205143	CM	linical data demonstrate CRS-207 with low-dose Cy improve
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205158 : 205160	CM	te CRS-207 with low-dose Cy improves survival in a m
./___Corpus/Medline/xml/PMC5123381.xml	murine	205184 : 205190	CM	y improves survival in a murine lung metastasis model.  
./___Corpus/Medline/xml/PMC5123381.xml	Ib	205315 : 205317	CM	 2 cohorts in this phase Ib study. Eligibility requi
./___Corpus/Medline/xml/PMC5123381.xml	MPM	205370 : 205373	CM	 unresectable, untreated MPM, ECOG 0 or 1, and adequa
./___Corpus/Medline/xml/PMC5123381.xml	ECOG	205375 : 205379	CM	sectable, untreated MPM, ECOG 0 or 1, and adequate org
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	205492 : 205501	CM	art, 6 cycles pemetrexed/cisplatin 3 weeks apart, followed 
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	205591 : 205598	CM	table patients continued CRS-207 every 8 weeks. Patients 
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205644 : 205646	CM	nts in Cohort 2 received Cy (200 mg/m2) 1 day prior 
./___Corpus/Medline/xml/PMC5123381.xml	m2	205655 : 205657	CM	rt 2 received Cy (200 mg/m2) 1 day prior to each CRS
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	205679 : 205686	CM	/m2) 1 day prior to each CRS-207. Safety, immunogenicity,
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205852 : 205854	CM	s were enrolled into the Cy/CRS-207 cohort of this s
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	205855 : 205862	CM	ere enrolled into the Cy/CRS-207 cohort of this study; 77
./___Corpus/Medline/xml/PMC5123381.xml	Cy	205927 : 205929	CM	 age 70. The most common Cy/CRS-207 related adverse 
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	205930 : 205937	CM	e 70. The most common Cy/CRS-207 related adverse events (
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206134 : 206136	CM	uable patients receiving Cy/CRS-207 + chemotherapy, 
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	206137 : 206144	CM	le patients receiving Cy/CRS-207 + chemotherapy, 86 % (19
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206381 : 206383	CM	ng 3 PR after 2 doses of Cy/CRS-207 prior to chemoth
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	206384 : 206391	CM	3 PR after 2 doses of Cy/CRS-207 prior to chemotherapy in
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206628 : 206630	CM	mune-modulating doses of Cy to a regimen of CRS-207 
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	206647 : 206654	CM	es of Cy to a regimen of CRS-207 and SOC chemotherapy app
./___Corpus/Medline/xml/PMC5123381.xml	SOC	206659 : 206662	CM	a regimen of CRS-207 and SOC chemotherapy appears to 
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	206762 : 206769	CM	pared to those receiving CRS-207 alone with chemotherapy.
./___Corpus/Medline/xml/PMC5123381.xml	Cy	206865 : 206867	CM	ity following 2 doses of Cy/CRS-207 prior to chemoth
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	206868 : 206875	CM	 following 2 doses of Cy/CRS-207 prior to chemotherapy (3
./___Corpus/Medline/xml/PMC5123381.xml	20-	207055 : 207058	CPR	lished response rates of 20-41 % with chemotherapy al
./___Corpus/Medline/xml/PMC5123381.xml	Cy	207156 : 207158	CM	arranted to evaluate the Cy/CRS-207 + chemotherapy r
./___Corpus/Medline/xml/PMC5123381.xml	CRS-207	207159 : 207166	CM	anted to evaluate the Cy/CRS-207 + chemotherapy regimen a
./___Corpus/Medline/xml/PMC5123381.xml	MPM	207209 : 207212	CM	gimen as a treatment for MPM.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	Ib	207443 : 207445	CM	              P254 Phase Ib trial of RNActive® cance
./___Corpus/Medline/xml/PMC5123381.xml	Koch1	207714 : 207719	CM	                  Sven D Koch1, Martin Sebastian2, Chri
./___Corpus/Medline/xml/PMC5123381.xml	Früh4	207765 : 207770	CM	Christian Weiss3, Martin Früh4, Miklos Pless5, Richard 
./___Corpus/Medline/xml/PMC5123381.xml	Pall8	207829 : 207834	CM	, Wolfgang Hilbe7, Georg Pall8, Thomas Wehler9, Jürgen 
./___Corpus/Medline/xml/PMC5123381.xml	Wehler9	207843 : 207850	CM	be7, Georg Pall8, Thomas Wehler9, Jürgen Alt9, Helge Bisc
./___Corpus/Medline/xml/PMC5123381.xml	Geissler11	207891 : 207901	CM	elge Bischoff10, Michael Geissler11, Frank Griesinger12, Jen
./___Corpus/Medline/xml/PMC5123381.xml	Doener1	207978 : 207985	CM	apachristofilou14, Fatma Doener1, Mariola Fotin-Mleczek1,
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	208342 : 208346	CM	istically with RNActive® mRNA vaccines to enhance anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	208367 : 208372	CPR	mRNA vaccines to enhance anti-tumor effects and increas
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	208487 : 208491	CM	ine comprising optimized mRNA constituents encoding si
./___Corpus/Medline/xml/PMC5123381.xml	NSCLC	208518 : 208523	CM	onstituents encoding six NSCLC-associated antigens. Int
./___Corpus/Medline/xml/PMC5123381.xml	Ib	208569 : 208571	CM	 Interim data of a phase Ib study, employing local R
./___Corpus/Medline/xml/PMC5123381.xml	BI1361849	208647 : 208656	CM	ediated tumor control by BI1361849, have been previously pu
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	209012 : 209016	CM	 with/without activating EGFR mutations). Pts received
./___Corpus/Medline/xml/PMC5123381.xml	anti-	209229 : 209234	CPR	ntil start of subsequent anti-cancer therapy. Maintenan
./___Corpus/Medline/xml/PMC5123381.xml	EGFR-TKIs	209282 : 209291	CM	ance pemetrexed (mP) and EGFR-TKIs were allowed where indic
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	209415 : 209423	CM	functional intracellular cytokine staining, IFN-g ELISpot,
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	209434 : 209439	CM	lular cytokine staining, IFN-g ELISpot, and ELISA in pr
./___Corpus/Medline/xml/PMC5123381.xml	mP	209718 : 209720	CM	nrolled. 15 pts received mP, two received EGFR TKIs.
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	209735 : 209739	CM	eceived mP, two received EGFR TKIs. Most frequent AEs 
./___Corpus/Medline/xml/PMC5123381.xml	mP	209981 : 209983	CM	 was observed in a pt on mP, 13 pts (52 %) experienc
./___Corpus/Medline/xml/PMC5123381.xml	SD	210011 : 210013	CM	3 pts (52 %) experienced SD (8 pts on mP, 2 pts on E
./___Corpus/Medline/xml/PMC5123381.xml	mP	210024 : 210026	CM	experienced SD (8 pts on mP, 2 pts on EGFR-TKI and 3
./___Corpus/Medline/xml/PMC5123381.xml	mP	210725 : 210727	CM	mbined with local RT and mP treatment. Shrinkage of 
./___Corpus/Medline/xml/PMC5123381.xml	34(supl)	211068 : 211076	CM	es 1. J Clin Oncol 2016, 34(supl):Abstr e20627.           
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211142 : 211150	CM	Overcoming resistance to tyrosine kinase inhibitor by natu
./___Corpus/Medline/xml/PMC5123381.xml	Yu	211348 : 211350	CM	oyeon Kim1, Seulki Kim1, Yu Soo Lee1, Bhumsuk Keam2,
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211463 : 211471	CM	                Receptor tyrosine kinase signals are alter
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	211512 : 211520	CM	are altered in NSCLC and tyrosine kinase inhibitors (TKIs)
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	211624 : 211628	CM	ons (e.g. ALK fusion and EGFR). Although TKIs are sens
./___Corpus/Medline/xml/PMC5123381.xml	TKI	212076 : 212079	CM	ods                      TKI-resistant NSCLC cell lin
./___Corpus/Medline/xml/PMC5123381.xml	H3122CR1	212108 : 212116	CM	istant NSCLC cell lines (H3122CR1, H3122LR1, H3122CR1LR1, 
./___Corpus/Medline/xml/PMC5123381.xml	H3122CR1LR1	212128 : 212139	CM	nes (H3122CR1, H3122LR1, H3122CR1LR1, EBC-R1, EBC-R2, PC-9GR,
./___Corpus/Medline/xml/PMC5123381.xml	EBC-R1	212141 : 212147	CM	, H3122LR1, H3122CR1LR1, EBC-R1, EBC-R2, PC-9GR, and PC-
./___Corpus/Medline/xml/PMC5123381.xml	EBC-R2	212149 : 212155	CM	R1, H3122CR1LR1, EBC-R1, EBC-R2, PC-9GR, and PC-9ER) wer
./___Corpus/Medline/xml/PMC5123381.xml	PC-9GR	212157 : 212163	CM	2CR1LR1, EBC-R1, EBC-R2, PC-9GR, and PC-9ER) were establ
./___Corpus/Medline/xml/PMC5123381.xml	PC-9ER	212169 : 212175	CM	-R1, EBC-R2, PC-9GR, and PC-9ER) were established from N
./___Corpus/Medline/xml/PMC5123381.xml	NCI-H3122	212199 : 212208	CM	R) were established from NCI-H3122 (EML4-ALK fusion), EBC-1
./___Corpus/Medline/xml/PMC5123381.xml	EML4-ALK	212210 : 212218	CM	ablished from NCI-H3122 (EML4-ALK fusion), EBC-1 (MET ampl
./___Corpus/Medline/xml/PMC5123381.xml	EBC-1	212228 : 212233	CM	H3122 (EML4-ALK fusion), EBC-1 (MET amplification), and
./___Corpus/Medline/xml/PMC5123381.xml	MET	212235 : 212238	CM	EML4-ALK fusion), EBC-1 (MET amplification), and PC-9
./___Corpus/Medline/xml/PMC5123381.xml	PC-9	212259 : 212263	CM	(MET amplification), and PC-9 (EGFR exon 19 deletion) 
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	212265 : 212269	CM	mplification), and PC-9 (EGFR exon 19 deletion) after 
./___Corpus/Medline/xml/PMC5123381.xml	ceritinib	212329 : 212338	CM	 exposure to crizotinib, ceritinib, capmatinib, gefitinib, 
./___Corpus/Medline/xml/PMC5123381.xml	gefitinib	212352 : 212361	CM	, ceritinib, capmatinib, gefitinib, and erlotinib. NK cytot
./___Corpus/Medline/xml/PMC5123381.xml	erlotinib	212367 : 212376	CM	pmatinib, gefitinib, and erlotinib. NK cytotoxicity and ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	212457 : 212462	CPR	ytotoxicity (ADCC) using anti-EGFR monoclonal antibody 
./___Corpus/Medline/xml/PMC5123381.xml	NK92-CD16	212539 : 212548	CM	ed using ‘off-the-shelf’ NK92-CD16 cell line as effectors a
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	212672 : 212676	CM	cell receptors and total EGFR were analyzed by flow cy
./___Corpus/Medline/xml/PMC5123381.xml	TKI	212764 : 212767	CM	                 Most of TKI-resistant NSCLC cell lin
./___Corpus/Medline/xml/PMC5123381.xml	NK92-CD16	212820 : 212829	CM	were more susceptible to NK92-CD16 cells compared with thei
./___Corpus/Medline/xml/PMC5123381.xml	TKI	212977 : 212980	CM	 %, 30.2 % and 39.1 % in TKI-resistant H3122 group wi
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	213098 : 213104	CM	.8 %). The expression of ICAM-1, which is a ligand for L
./___Corpus/Medline/xml/PMC5123381.xml	LFA-1	213128 : 213133	CM	1, which is a ligand for LFA-1 in NK cells, is higher i
./___Corpus/Medline/xml/PMC5123381.xml	TKI	213160 : 213163	CM	n NK cells, is higher in TKI-resistant NSCLC cells th
./___Corpus/Medline/xml/PMC5123381.xml	ICAM1-CD11a	213226 : 213237	CM	l cells. When we blocked ICAM1-CD11a interaction during a cyt
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	213420 : 213424	CM	xpression level of total EGFR in resistant cells.     
./___Corpus/Medline/xml/PMC5123381.xml	TKI	213495 : 213498	CM	ons                      TKI-resistant NSCLC cells ar
./___Corpus/Medline/xml/PMC5123381.xml	NK92	213543 : 213547	CM	ls are more sensitive to NK92 cell-mediated cytotoxici
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	213623 : 213629	CM	dent on up-regulation of ICAM-1 via an immunological syn
./___Corpus/Medline/xml/PMC5123381.xml	mAb	213702 : 213705	CM	ximab, an EGFR-targeting mAb, significantly increases
./___Corpus/Medline/xml/PMC5123381.xml	TKI	213755 : 213758	CM	 NK cell cytotoxicity in TKI-resistant NSCLC cells. T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	214035 : 214040	CPR	mic chemotherapy induces anti-tumor immunity in a murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	214060 : 214066	CM	anti-tumor immunity in a murine model of pancreatic canc
./___Corpus/Medline/xml/PMC5123381.xml	Amod	214222 : 214226	CM	 Hao Liu, John Mullinax, Amod A Sarnaik               
./___Corpus/Medline/xml/PMC5123381.xml	xanthene	214303 : 214311	CM	        Rose Bengal is a xanthene dye that has been utiliz
./___Corpus/Medline/xml/PMC5123381.xml	IL	214431 : 214433	CM	almology. Intralesional (IL) Rose Bengal (PV-10) has
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	214448 : 214453	CM	sional (IL) Rose Bengal (PV-10) has been shown in murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	214473 : 214479	CM	PV-10) has been shown in murine models and melanoma clin
./___Corpus/Medline/xml/PMC5123381.xml	IL	214644 : 214646	CM	taken to measure whether IL PV-10 can induce systemi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	214673 : 214678	CPR	V-10 can induce systemic anti-tumor effects alone or in
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	214721 : 214732	CM	e or in combination with gemcitabine (Gem) therapy in a murin
./___Corpus/Medline/xml/PMC5123381.xml	Gem	214734 : 214737	CM	nation with gemcitabine (Gem) therapy in a murine mod
./___Corpus/Medline/xml/PMC5123381.xml	murine	214752 : 214758	CM	abine (Gem) therapy in a murine model of pancreatic canc
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	214855 : 214861	CM	   C57BL/6 mice received Panc02 pancreatic tumor cells s
./___Corpus/Medline/xml/PMC5123381.xml	SC	214901 : 214903	CM	or cells subcutaneously (SC) on one flank to establi
./___Corpus/Medline/xml/PMC5123381.xml	IL	214980 : 214982	CM	, tumor was treated with IL PV-10. Control mice rece
./___Corpus/Medline/xml/PMC5123381.xml	phosphate	215015 : 215024	CM	Control mice received IL phosphate buffered saline (PBS). T
./___Corpus/Medline/xml/PMC5123381.xml	saline	215034 : 215040	CM	ed IL phosphate buffered saline (PBS). Tumor growth was 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215042 : 215045	CM	osphate buffered saline (PBS). Tumor growth was measu
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215127 : 215133	CM	ted and co-cultured with Panc02 or irrelevant B16 cells.
./___Corpus/Medline/xml/PMC5123381.xml	B16	215148 : 215151	CM	ith Panc02 or irrelevant B16 cells. Supernatants were
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215198 : 215204	CM	ere collected to measure Panc02-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	IL	215276 : 215278	CM	To measure the effect of IL PV-10 on the growth of a
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215347 : 215353	CM	der tumor, mice received Panc02 cells in bilateral flank
./___Corpus/Medline/xml/PMC5123381.xml	IL	215420 : 215422	CM	right tumor was injected IL with PV-10 or PBS. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	215428 : 215433	CM	mor was injected IL with PV-10 or PBS. Tumor sizes were
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215437 : 215440	CM	njected IL with PV-10 or PBS. Tumor sizes were measur
./___Corpus/Medline/xml/PMC5123381.xml	IL	215590 : 215592	CM	combination therapy with IL PV-10 and systemic Gem, 
./___Corpus/Medline/xml/PMC5123381.xml	Gem	215612 : 215615	CM	th IL PV-10 and systemic Gem, mice bearing a single o
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215652 : 215658	CM	ng a single or bilateral Panc02 tumors were treated with
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	215684 : 215689	CM	tumors were treated with PV-10 alone or in combination 
./___Corpus/Medline/xml/PMC5123381.xml	Gem	215719 : 215722	CM	e or in combination with Gem. Mice received 60 mg/kg 
./___Corpus/Medline/xml/PMC5123381.xml	Gem	215747 : 215750	CM	. Mice received 60 mg/kg Gem intraperitoneally (IP) t
./___Corpus/Medline/xml/PMC5123381.xml	IP	215770 : 215772	CM	g Gem intraperitoneally (IP) twice per week.        
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	215857 : 215863	CM	    C57BL/6 mice bearing Panc02 tumors treated with IL P
./___Corpus/Medline/xml/PMC5123381.xml	IL	215884 : 215886	CM	nc02 tumors treated with IL PV-10 had significantly 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	215949 : 215952	CM	s than mice treated with PBS (p < 0.001). A significa
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	216032 : 216038	CM	roduction in response to Panc02 was measured in the sple
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	216092 : 216097	CM	tes of mice treated with PV-10 as compared to mice trea
./___Corpus/Medline/xml/PMC5123381.xml	PBS	216131 : 216134	CM	red to mice treated with PBS (p < 0.05). Mice with bi
./___Corpus/Medline/xml/PMC5123381.xml	IL	216222 : 216224	CM	ssion of tumors injected IL with PV-10 and there was
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	216230 : 216235	CM	 tumors injected IL with PV-10 and there was a reductio
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	216297 : 216303	CM	reated (bystander) flank Panc02 tumor (p < 0.01). Gem th
./___Corpus/Medline/xml/PMC5123381.xml	Gem	216322 : 216325	CM	Panc02 tumor (p < 0.01). Gem therapy in combination w
./___Corpus/Medline/xml/PMC5123381.xml	IL	216354 : 216356	CM	rapy in combination with IL PV-10 injection led to e
./___Corpus/Medline/xml/PMC5123381.xml	IL	216429 : 216431	CM	n (p < 0.05) compared to IL PV-10 or Gem alone in bo
./___Corpus/Medline/xml/PMC5123381.xml	Gem	216441 : 216444	CM	 compared to IL PV-10 or Gem alone in both a single t
./___Corpus/Medline/xml/PMC5123381.xml	IL	216604 : 216606	CM	ted pancreatic tumors by IL injection of PV-10 in co
./___Corpus/Medline/xml/PMC5123381.xml	PV-10	216620 : 216625	CM	umors by IL injection of PV-10 in concomitant tumor sup
./___Corpus/Medline/xml/PMC5123381.xml	anti-	216684 : 216689	CPR	 induction of a systemic anti-tumor response. Addition 
./___Corpus/Medline/xml/PMC5123381.xml	Gem	216717 : 216720	CM	or response. Addition of Gem chemotherapy enhances th
./___Corpus/Medline/xml/PMC5123381.xml	IL	216758 : 216760	CM	 enhances the effects of IL PV-10 therapy. Given tha
./___Corpus/Medline/xml/PMC5123381.xml	IL	216878 : 216880	CM	, combination therapy of IL PV-10 combined with Gem 
./___Corpus/Medline/xml/PMC5123381.xml	Gem	216901 : 216904	CM	f IL PV-10 combined with Gem may benefit patients wit
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	217048 : 217052	CM	 following radiation and PD-1 inhibition              
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	217588 : 217592	CM	ith radiation and either PD-1 inhibition or combined C
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	217623 : 217627	CM	ition or combined CTLA-4/PD-1 blockade. We previously 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	217840 : 217844	CM	combining radiation with PD-1 inhibitors with or witho
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	218161 : 218165	CM	palliative radiation and PD-1 inhibitors, either befor
./___Corpus/Medline/xml/PMC5123381.xml	1–	218387 : 218389	CPR	diation (median 2, range 1–6) and a median of 4 PD-1
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	218410 : 218414	CM	e 1–6) and a median of 4 PD-1 inhibitor cycles (range 
./___Corpus/Medline/xml/PMC5123381.xml	1–	218439 : 218441	CPR	 inhibitor cycles (range 1–66). Sixteen patients rec
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	218483 : 218487	CM	ents received concurrent PD-1/CTLA-4 blockade. Sites i
./___Corpus/Medline/xml/PMC5123381.xml	WBRT	218649 : 218653	CM	se sites, and the use of WBRT/SRS were balanced before
./___Corpus/Medline/xml/PMC5123381.xml	SRS	218654 : 218657	CM	tes, and the use of WBRT/SRS were balanced before ver
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	218705 : 218709	CM	ersus after the start of PD-1 therapy. Median survival
./___Corpus/Medline/xml/PMC5123381.xml	anti-	218754 : 218759	CPR	vival following start of anti-PD-1 therapy was 192, 394
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	218942 : 218946	CM	mutations and concurrent PD-1/CTLA-4 inhibition, there
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219056 : 219060	CM	d following the start of PD-1 directed treatment and i
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219192 : 219196	CM	the impact of concurrent PD-1/CTLA-4 checkpoint blocka
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219386 : 219390	CM	with radiation following PD-1/CTLA-4 blockade, and 4/8
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219455 : 219459	CM	nts continued to receive PD-1 therapy after radiation.
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219723 : 219727	CM	y administered following PD-1 blockade was associated 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	219972 : 219976	CM	d with concurrent CTLA-4/PD-1 blockade. These data sug
./___Corpus/Medline/xml/PMC5123381.xml	anti-	220055 : 220060	CPR	in patients treated with anti-PD-1 therapy may allow fo
./___Corpus/Medline/xml/PMC5123381.xml	RA	220235 : 220237	CM	              1. Chandra RA, Wilhite TJ, Balboni TA,
./___Corpus/Medline/xml/PMC5123381.xml	CD47	220514 : 220518	CM	d blockade of CTLA-4 and CD47 with tumor irradiation e
./___Corpus/Medline/xml/PMC5123381.xml	R	220636 : 220637	CM	thony L Schwartz1, Pulak R Nath1, Elizabeth Lessey-
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	221005 : 221014	CM	g cytotoxic T lymphocyte antigen-4 (CTLA-4) have proven eff
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221402 : 221406	CM	oratory is investigating CD47 blockade for the treatme
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221486 : 221490	CM	 competent mouse models. CD47 expression is frequently
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221631 : 221635	CM	lls in the tumor stroma. CD47 blockade on CD8+ T cells
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	221648 : 221652	CM	stroma. CD47 blockade on CD8+ T cells or tumor cells s
./___Corpus/Medline/xml/PMC5123381.xml	CD47	221816 : 221820	CM	xplore the potential for CD47 blockade to improve the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	221863 : 221868	CPR	ve the response rates to anti-CTLA-4 therapy alone or i
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	222050 : 222056	CM	re inoculated with 1x106 B16F10 melanoma cells into the 
./___Corpus/Medline/xml/PMC5123381.xml	10Gy	222120 : 222124	CM	b and treated with local 10Gy irradiation combined wit
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222177 : 222181	CM	TLA-4 blocking antibody, CD47 translational blocking m
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222205 : 222215	CM	7 translational blocking morpholino, or the combination of C
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222259 : 222263	CM	n of CTLA-4 antibody and CD47 morpholino. Subjects wer
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222264 : 222274	CM	CTLA-4 antibody and CD47 morpholino. Subjects were humanely 
./___Corpus/Medline/xml/PMC5123381.xml	qPCR	222342 : 222346	CM	mors were analyzed using qPCR to evaluate granzyme B a
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	222374 : 222379	CM	 evaluate granzyme B and FOXP3 mRNA expression. Tumors 
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	222380 : 222384	CM	ate granzyme B and FOXP3 mRNA expression. Tumors were 
./___Corpus/Medline/xml/PMC5123381.xml	H&E	222436 : 222439	CM	ctioned and subjected to H&E and anti-CD8 staining.  
./___Corpus/Medline/xml/PMC5123381.xml	anti-	222444 : 222449	CPR	and subjected to H&E and anti-CD8 staining.            
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222672 : 222676	CM	mbination with CTLA-4 or CD47 increased immune cell in
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222769 : 222773	CM	adiation with CTLA-4 and CD47 showed widespread tumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	222866 : 222870	CM	 groups treated with the CD47 morpholino also exhibite
./___Corpus/Medline/xml/PMC5123381.xml	morpholino	222871 : 222881	CM	ps treated with the CD47 morpholino also exhibited focal hem
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	222967 : 222972	CM	en combined with CTLA-4. FOXP3 mRNA expression showed a
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	222973 : 222977	CM	bined with CTLA-4. FOXP3 mRNA expression showed a two-
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223019 : 223023	CM	d a two-fold increase in CD47/CTLA-4-treated mice, whi
./___Corpus/Medline/xml/PMC5123381.xml	4-fold	223072 : 223078	CM	ich further increased to 4-fold when administered with I
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	223117 : 223121	CM	ered with IR. Granzyme B mRNA expression increased 3.5
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223168 : 223172	CM	3.5 fold with the CTLA-4/CD47/IR combination. Overall 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223264 : 223268	CM	combination of IR/CTLA-4/CD47 blockade was 75 % at 50 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	223425 : 223429	CM	bination with CTLA-4 and CD47 checkpoint blockade can 
./___Corpus/Medline/xml/PMC5123381.xml	CD137	223692 : 223697	CM	 (ADCC) by combining the CD137 antibody urelumab with r
./___Corpus/Medline/xml/PMC5123381.xml	H	223856 : 223857	CM	                    Neil H Segal1, Manish Sharma2, 
./___Corpus/Medline/xml/PMC5123381.xml	Le3	223889 : 223892	CM	, Manish Sharma2, Dung T Le3, Patrick A Ott4, Robert 
./___Corpus/Medline/xml/PMC5123381.xml	Ferris5	223919 : 223926	CM	Patrick A Ott4, Robert L Ferris5, Andrew D Zelenetz1, Sat
./___Corpus/Medline/xml/PMC5123381.xml	Gu11	224122 : 224126	CM	 Suba Krishnan11, Xuemin Gu11, Jaclyn Neely11, Satyend
./___Corpus/Medline/xml/PMC5123381.xml	CD137	224259 : 224264	CM	 Urelumab, a fully human CD137 agonistic monoclonal ant
./___Corpus/Medline/xml/PMC5123381.xml	Ib	224615 : 224617	CM	y was evaluated in phase Ib studies of urelumab comb
./___Corpus/Medline/xml/PMC5123381.xml	anti-	224663 : 224668	CPR	combined with rituximab (anti-CD20 mAb) in patients wit
./___Corpus/Medline/xml/PMC5123381.xml	mAb	224673 : 224676	CM	ith rituximab (anti-CD20 mAb) in patients with refrac
./___Corpus/Medline/xml/PMC5123381.xml	anti-	224748 : 224753	CPR	n lymphoma or cetuximab (anti-EGFR mAb) in patients wit
./___Corpus/Medline/xml/PMC5123381.xml	CRC	224810 : 224813	CM	ctory colorectal cancer (CRC) or squamous cell carcin
./___Corpus/Medline/xml/PMC5123381.xml	B-NHL	225191 : 225196	CM	with relapsed/refractory B-NHL received urelumab at 0.1
./___Corpus/Medline/xml/PMC5123381.xml	80-	225289 : 225292	CPR	alent to 0.1 mg/kg in an 80-kg patient; initiated bas
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	225366 : 225369	CM	kinetic and safety data) Q3W plus rituximab 375 mg/m2
./___Corpus/Medline/xml/PMC5123381.xml	QW	225395 : 225397	CM	plus rituximab 375 mg/m2 QW (4 doses); during expans
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	225492 : 225497	CM	e large B cell lymphoma (DLBCL) or follicular lymphoma 
./___Corpus/Medline/xml/PMC5123381.xml	Q3W	225715 : 225718	CM	lumab (0.1 mg/kg or 8 mg Q3W) plus cetuximab (400 mg/
./___Corpus/Medline/xml/PMC5123381.xml	Q1W	225770 : 225773	CM	 on week 1 and 250 mg/m2 Q1W thereafter) in patients 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	225814 : 225817	CM	patients with metastatic CRC or SCCHN. Primary endpoi
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	225821 : 225826	CM	s with metastatic CRC or SCCHN. Primary endpoints were 
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	225955 : 225960	CM	ents included those with DLBCL (n = 29), FL (n = 17), C
./___Corpus/Medline/xml/PMC5123381.xml	FL	225971 : 225973	CM	ose with DLBCL (n = 29), FL (n = 17), CRC (n = 47), 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	225984 : 225987	CM	L (n = 29), FL (n = 17), CRC (n = 47), and SCCHN (n =
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	226002 : 226007	CM	= 17), CRC (n = 47), and SCCHN (n = 19). Overall, 2–3 %
./___Corpus/Medline/xml/PMC5123381.xml	2–	226027 : 226029	CPR	SCCHN (n = 19). Overall, 2–3 % of patients discontin
./___Corpus/Medline/xml/PMC5123381.xml	ALT	226128 : 226131	CM	 experienced a grade 3/4 ALT elevation (Fig. 25). One
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	226271 : 226275	CM	d. Apparent increases in IFNγ-induced cytokines were o
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	226337 : 226341	CM	 activated/proliferating CD8+ cells and cytotoxic NK c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	226497 : 226501	CM	 tumors, the increase in CD8+ and NK cells was not obs
./___Corpus/Medline/xml/PMC5123381.xml	DLBCL	226612 : 226617	CM	imab were 10 % (3/29) in DLBCL and 35 % (6/17) in FL (F
./___Corpus/Medline/xml/PMC5123381.xml	CRC	226731 : 226734	CM	tuximab in patients with CRC or SCCHN.               
./___Corpus/Medline/xml/PMC5123381.xml	SCCHN	226738 : 226743	CM	 in patients with CRC or SCCHN.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	ATM	227511 : 227514	CM	                    P260 ATM is essential for the rad
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	227592 : 227600	CM	of the immunosuppressive cytokine activin-A by breast canc
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	227811 : 227815	CM	ming growth factor beta (TGFβ) superfamily. Recent evi
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	228023 : 228027	CM	reaks (DSBs) induce actA mRNA and protein [2]. The ata
./___Corpus/Medline/xml/PMC5123381.xml	ATM	228080 : 228083	CM	 telangiectasia-mutated (ATM) kinase is activated at 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	228293 : 228298	CPR	RT-induced activation of anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	doxycycline	228443 : 228454	CM	 engineered to express a doxycycline (dox) inducible shRNA si
./___Corpus/Medline/xml/PMC5123381.xml	RT-qPCR	228667 : 228674	CM	Inhba gene expression by RT-qPCR as well as secretion of 
./___Corpus/Medline/xml/PMC5123381.xml	ATM	228730 : 228733	CM	y ELISA. To determine if ATM controls the expression 
./___Corpus/Medline/xml/PMC5123381.xml	ATM	228807 : 228810	CM	h inducible knockdown of ATM were also generated (4T1
./___Corpus/Medline/xml/PMC5123381.xml	s.c	228890 : 228893	CM	nd 4T1shNS were injected s.c. in syngeneic BALB/c mic
./___Corpus/Medline/xml/PMC5123381.xml	BALB	228908 : 228912	CM	jected s.c. in syngeneic BALB/c mice on day 0. Knockdo
./___Corpus/Medline/xml/PMC5123381.xml	ATM	228943 : 228946	CM	e on day 0. Knockdown of ATM and Inhba genes was indu
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	229310 : 229314	CM	. Secreted actA promoted CD4+ T cells conversion into 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	229370 : 229375	CM	tory T (Tregs) cells. In vitro, knockdown of ATM abolis
./___Corpus/Medline/xml/PMC5123381.xml	ATM	229390 : 229393	CM	. In vitro, knockdown of ATM abolished both Inhba gen
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	229592 : 229596	CM	ivation of intra-tumoral CD8+ T cells. 4T1shInhba and 
./___Corpus/Medline/xml/PMC5123381.xml	ATM	229774 : 229777	CM	 These data suggest that ATM plays a critical role in
./___Corpus/Medline/xml/PMC5123381.xml	ATM	229917 : 229920	CM	ted tumor. Inhibition of ATM may increase tumor radio
./___Corpus/Medline/xml/PMC5123381.xml	W81XWH-13-1-0012	230130 : 230146	CM	post-doctoral fellowship W81XWH-13-1-0012. References 1. Loomans H
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	230274 : 230283	CM	                    P261 Adenosine regulates tumor response
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	230365 : 230371	CM	itment and activation of CD103+ DCs                  Eri
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230372 : 230375	CM	and activation of CD103+ DCs                  Erik We
./___Corpus/Medline/xml/PMC5123381.xml	anti-	230700 : 230705	CPR	es by triggering de novo anti-tumor immune responses to
./___Corpus/Medline/xml/PMC5123381.xml	ATP	230821 : 230824	CM	n induces the release of ATP in a dose-dependent mann
./___Corpus/Medline/xml/PMC5123381.xml	ATP	230857 : 230860	CM	se-dependent manner [1]. ATP enhances recruitment and
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230917 : 230920	CM	tion of dendritic cells (DCs), including CD103+ DCs r
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	230933 : 230939	CM	c cells (DCs), including CD103+ DCs recently identified 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	230940 : 230943	CM	 (DCs), including CD103+ DCs recently identified as t
./___Corpus/Medline/xml/PMC5123381.xml	DC	230975 : 230977	CM	ly identified as the key DC subset responsible for c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	231049 : 231053	CM	umor-derived antigens to CD8+ T cells. To determine wh
./___Corpus/Medline/xml/PMC5123381.xml	ATP	231104 : 231107	CM	ther rapid conversion of ATP to immunosuppressive ade
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	231129 : 231138	CM	ATP to immunosuppressive adenosine could contribute to the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	231207 : 231212	CPR	high dose RT to activate anti-tumor immunity we inhibit
./___Corpus/Medline/xml/PMC5123381.xml	CD73	231258 : 231262	CM	ibited the rate-limiting CD73 ectonucleotidase.       
./___Corpus/Medline/xml/PMC5123381.xml	WT	231338 : 231340	CM	              Wild type (WT) or BATF3−/− mice (ablat
./___Corpus/Medline/xml/PMC5123381.xml	BATF3−	231345 : 231351	CM	       Wild type (WT) or BATF3−/− mice (ablated developm
./___Corpus/Medline/xml/PMC5123381.xml	CD8a+	231383 : 231388	CM	 (ablated development of CD8a+/CD103+ DCs) were inocula
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	231389 : 231395	CM	ted development of CD8a+/CD103+ DCs) were inoculated s.c
./___Corpus/Medline/xml/PMC5123381.xml	DCs	231396 : 231399	CM	elopment of CD8a+/CD103+ DCs) were inoculated s.c. wi
./___Corpus/Medline/xml/PMC5123381.xml	s.c	231417 : 231420	CM	03+ DCs) were inoculated s.c. with the poorly immunog
./___Corpus/Medline/xml/PMC5123381.xml	TSA	231474 : 231477	CM	 breast cancer cell line TSA on day 0 and assigned to
./___Corpus/Medline/xml/PMC5123381.xml	Ab	231531 : 231533	CM	atment with: (1) control Ab; (2) anti-CD73 (TY/23 Ab
./___Corpus/Medline/xml/PMC5123381.xml	anti-	231539 : 231544	CPR	ith: (1) control Ab; (2) anti-CD73 (TY/23 Ab); (3) RT (
./___Corpus/Medline/xml/PMC5123381.xml	TY	231550 : 231552	CM	ntrol Ab; (2) anti-CD73 (TY/23 Ab); (3) RT (20 Gy); 
./___Corpus/Medline/xml/PMC5123381.xml	Ab	231556 : 231558	CM	Ab; (2) anti-CD73 (TY/23 Ab); (3) RT (20 Gy); (4) RT
./___Corpus/Medline/xml/PMC5123381.xml	Gy	231572 : 231574	CM	3 (TY/23 Ab); (3) RT (20 Gy); (4) RT + TY/23. TY/23 
./___Corpus/Medline/xml/PMC5123381.xml	TY	231586 : 231588	CM	(3) RT (20 Gy); (4) RT + TY/23. TY/23 (200 μg) was a
./___Corpus/Medline/xml/PMC5123381.xml	TY	231593 : 231595	CM	(20 Gy); (4) RT + TY/23. TY/23 (200 μg) was administ
./___Corpus/Medline/xml/PMC5123381.xml	Gy	231703 : 231705	CM	o the tumor as single 20 Gy dose on day 12. On day 1
./___Corpus/Medline/xml/PMC5123381.xml	DCs	231791 : 231794	CM	ow cytometry analysis of DCs and T cells. Mice were m
./___Corpus/Medline/xml/PMC5123381.xml	ADO	231953 : 231956	CM	reated mice, blockade of ADO generation by anti-CD73 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	231971 : 231976	CPR	ade of ADO generation by anti-CD73 resulted in increase
./___Corpus/Medline/xml/PMC5123381.xml	CD103	232019 : 232024	CM	ncreased infiltration of CD103 + DCs (8.9 ± 2.6 % of DC
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232027 : 232030	CM	 infiltration of CD103 + DCs (8.9 ± 2.6 % of DCs in R
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232047 : 232050	CM	03 + DCs (8.9 ± 2.6 % of DCs in RT + TY/23 v. 3.5 ± 2
./___Corpus/Medline/xml/PMC5123381.xml	TY	232059 : 232061	CM	9 ± 2.6 % of DCs in RT + TY/23 v. 3.5 ± 2.8 % of DCs
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232083 : 232086	CM	 TY/23 v. 3.5 ± 2.8 % of DCs in RT) expressing elevat
./___Corpus/Medline/xml/PMC5123381.xml	CD40	232143 : 232147	CM	ls of activation markers CD40 and CD86 compared to mic
./___Corpus/Medline/xml/PMC5123381.xml	CD86	232152 : 232156	CM	ivation markers CD40 and CD86 compared to mice treated
./___Corpus/Medline/xml/PMC5123381.xml	CD8	232238 : 232241	CM	associated with improved CD8 + T cell/Tregs ratio (5 
./___Corpus/Medline/xml/PMC5123381.xml	TY	232280 : 232282	CM	s ratio (5 ± 2.8 in RT + TY/23 v. 0.8 ± 0.2 in RT). 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	232320 : 232324	CM	0.2 in RT). Importantly, CD73 blockade had no effect b
./___Corpus/Medline/xml/PMC5123381.xml	TY	232481 : 232483	CM	n: 385 ± 525 mm3 in RT + TY/23 v. 1036 ± 727 mm3 in 
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	232549 : 232555	CM	with the hypothesis that CD103+ DC are essential for ant
./___Corpus/Medline/xml/PMC5123381.xml	DC	232556 : 232558	CM	e hypothesis that CD103+ DC are essential for anti-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	232577 : 232582	CPR	03+ DC are essential for anti-tumor responses, the ther
./___Corpus/Medline/xml/PMC5123381.xml	CD73	232630 : 232634	CM	erapeutic effect of RT + CD73 blockade was abrogated i
./___Corpus/Medline/xml/PMC5123381.xml	BATF3−	232661 : 232667	CM	lockade was abrogated in BATF3−/− mice.                 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	232758 : 232767	CM	a indicate a key role of adenosine generated in the irradia
./___Corpus/Medline/xml/PMC5123381.xml	anti-	232830 : 232835	CPR	hindering development of anti-tumor immune responses an
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	232921 : 232927	CM	ffect, the inhibition of CD103+ DCs. Blockade of adenosi
./___Corpus/Medline/xml/PMC5123381.xml	DCs	232928 : 232931	CM	the inhibition of CD103+ DCs. Blockade of adenosine g
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	232945 : 232954	CM	 CD103+ DCs. Blockade of adenosine generation is a promisin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	233019 : 233024	CPR	nhance radiation-induced anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	EB	233099 : 233101	CM	               1. Golden EB, Frances D, Pellicciotta
./___Corpus/Medline/xml/PMC5123381.xml	SC	233174 : 233176	CM	rcellos-Hoff M, Formenti SC: Radiation fosters dose-
./___Corpus/Medline/xml/PMC5123381.xml	P	233571 : 233572	CM	                 Michael P Gustafson, AriCeli DiCos
./___Corpus/Medline/xml/PMC5123381.xml	Allan	233695 : 233700	CM	tineau, Bruce D Johnson, Allan B Dietz                 
./___Corpus/Medline/xml/PMC5123381.xml	%BF	234620 : 234623	CM	M) and percent body fat (%BF) were calculated from DE
./___Corpus/Medline/xml/PMC5123381.xml	DEXA	234646 : 234650	CM	BF) were calculated from DEXA (Dual-energy X-ray absor
./___Corpus/Medline/xml/PMC5123381.xml	CD15+	235332 : 235337	CM	maximal exercise whereas CD15+ granulocytes demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	CD45RO+	235732 : 235739	CM	 elevated percentages of CD45RO+ memory CD4+ T cells and 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	235747 : 235751	CM	ntages of CD45RO+ memory CD4+ T cells and elevated pro
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	235788 : 235792	CM	 elevated proportions of CD4+ T cells expressing the n
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	235862 : 235866	CM	ator programmed death-1 (PD-1). Finally, we identified
./___Corpus/Medline/xml/PMC5123381.xml	Y	236331 : 236332	CM	    1. Gustafson MP, Lin Y, Maas ML, Van Keulen VP,
./___Corpus/Medline/xml/PMC5123381.xml	P	236366 : 236367	CM	, Van Keulen VP, Johnson P, Peikert T, et al.: A me
./___Corpus/Medline/xml/PMC5123381.xml	β-	236570 : 236572	CPR	        P263 Blockade of β-adrenergic receptor signa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	236611 : 236616	CPR	eptor signaling enhances anti-tumor immunity while incr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	236961 : 236966	CPR	umor cells and stimulate anti-tumor immunity, but radio
./___Corpus/Medline/xml/PMC5123381.xml	norepinephrine	237077 : 237091	CM	nt studies indicate that norepinephrine (NE) released from sympa
./___Corpus/Medline/xml/PMC5123381.xml	NE	237093 : 237095	CM	ate that norepinephrine (NE) released from sympathet
./___Corpus/Medline/xml/PMC5123381.xml	β-	237191 : 237193	CPR	 tumor cell survival via β-adrenergic receptor (β-AR
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237214 : 237218	CM	a β-adrenergic receptor (β-AR) activation. Work from o
./___Corpus/Medline/xml/PMC5123381.xml	NE	237376 : 237378	CM	 stress which stimulates NE release. Moreover, we sh
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237413 : 237417	CM	Moreover, we showed that β-AR signaling in mouse tumor
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237507 : 237511	CM	ance, and treatment with β-AR antagonists (β-blockers)
./___Corpus/Medline/xml/PMC5123381.xml	β-	237525 : 237527	CPR	t with β-AR antagonists (β-blockers) reversed this e
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237603 : 237607	CM	d us to hypothesize that β-AR signaling promotes radio
./___Corpus/Medline/xml/PMC5123381.xml	anti-	237677 : 237682	CPR	cells but suppresses the anti-tumor immune response.   
./___Corpus/Medline/xml/PMC5123381.xml	vitro	237754 : 237759	CM	                      In vitro, we used Pan02 (abundant
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237785 : 237789	CM	 we used Pan02 (abundant β-AR expression) and 4 T1 tum
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	237827 : 237831	CM	and 4 T1 tumor cells (no β-AR expression). We treated 
./___Corpus/Medline/xml/PMC5123381.xml	isoproterenol	237886 : 237899	CM	 with the pan-β-agonist, isoproterenol, and performed clonogeni
./___Corpus/Medline/xml/PMC5123381.xml	clonogenic	237915 : 237925	CM	roterenol, and performed clonogenic assays examining surviva
./___Corpus/Medline/xml/PMC5123381.xml	0–	237980 : 237982	CPR	various radiation doses (0–8 Gy). In vivo, we implan
./___Corpus/Medline/xml/PMC5123381.xml	Gy	237984 : 237986	CM	ous radiation doses (0–8 Gy). In vivo, we implanted 
./___Corpus/Medline/xml/PMC5123381.xml	CT26.CL25	238011 : 238020	CM	). In vivo, we implanted CT26.CL25 tumor cells subcutaneous
./___Corpus/Medline/xml/PMC5123381.xml	SCID	238080 : 238084	CM	e leg of immunodeficient SCID mice and immune-competen
./___Corpus/Medline/xml/PMC5123381.xml	BALB	238111 : 238115	CM	ice and immune-competent BALB/c mice. When tumors beca
./___Corpus/Medline/xml/PMC5123381.xml	β-	238191 : 238193	CPR	domized to receive daily β-blocker or PBS injections
./___Corpus/Medline/xml/PMC5123381.xml	PBS	238204 : 238207	CM	ceive daily β-blocker or PBS injections followed by r
./___Corpus/Medline/xml/PMC5123381.xml	vitro	238374 : 238379	CM	                      In vitro, isoproterenol treatment
./___Corpus/Medline/xml/PMC5123381.xml	isoproterenol	238381 : 238394	CM	               In vitro, isoproterenol treatment significantly 
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	238552 : 238556	CM	or cells suggesting that β-AR signaling enhances radio
./___Corpus/Medline/xml/PMC5123381.xml	SCID	238652 : 238656	CM	y slowed tumor growth in SCID mice. However, combining
./___Corpus/Medline/xml/PMC5123381.xml	β-	238682 : 238684	CPR	mice. However, combining β-blockade with radiation s
./___Corpus/Medline/xml/PMC5123381.xml	β-	238772 : 238774	CPR	diation, indicating that β-blockade was sensitizing 
./___Corpus/Medline/xml/PMC5123381.xml	BALB	238881 : 238885	CM	ment in immune-competent BALB/c mice and again observe
./___Corpus/Medline/xml/PMC5123381.xml	β-	238970 : 238972	CPR	growth in mice receiving β-blockade and radiation co
./___Corpus/Medline/xml/PMC5123381.xml	β-	239040 : 239042	CPR	n alone. To determine if β-blockade was enhancing an
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239065 : 239070	CPR	β-blockade was enhancing anti-tumor immunity in radiate
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	239182 : 239186	CM	 significant increase in CD4+ and CD8+ T cells express
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	239191 : 239195	CM	ant increase in CD4+ and CD8+ T cells expressing IFN-g
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	239215 : 239220	CM	 CD8+ T cells expressing IFN-g and granzyme B in the gr
./___Corpus/Medline/xml/PMC5123381.xml	β-	239259 : 239261	CPR	B in the group receiving β-blockade and radiation co
./___Corpus/Medline/xml/PMC5123381.xml	β-	239345 : 239347	CPR	n alone, indicating that β-blockade was also stimula
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239377 : 239382	CPR	ade was also stimulating anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	β-AR	239488 : 239492	CM	 this data suggests that β-AR blockade decreases tumor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	239571 : 239576	CPR	imultaneously bolstering anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	murine	239796 : 239802	CM	herapeutic resistance in murine tumour models through β2
./___Corpus/Medline/xml/PMC5123381.xml	Xu	240097 : 240099	CM	illiam J Turbitt, Yitong Xu, Andrea Mastro, Connie J
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	240848 : 240852	CM	e tumor cell vaccine and PD-1 checkpoint blockade on t
./___Corpus/Medline/xml/PMC5123381.xml	BALB	240958 : 240962	CM	                  Female BALB/c mice were randomized t
./___Corpus/Medline/xml/PMC5123381.xml	20-	241068 : 241071	CPR	tenance (WM) groups (n = 20-24/group). After 8 weeks,
./___Corpus/Medline/xml/PMC5123381.xml	luciferase	241146 : 241156	ASE	ally injected with 5x104 luciferase-transfected 4 T1.2 cells
./___Corpus/Medline/xml/PMC5123381.xml	9-	241331 : 241333	CPR	ed into vaccination (n = 9-12/group) or vehicle cont
./___Corpus/Medline/xml/PMC5123381.xml	11-	241367 : 241370	CPR	 or vehicle control (n = 11-12/group) groups and admi
./___Corpus/Medline/xml/PMC5123381.xml	VAX	241429 : 241432	CM	irradiated 4 T1.2 cells (VAX) or vehicle (VEH) contro
./___Corpus/Medline/xml/PMC5123381.xml	VAX	241570 : 241573	CM	e dual administration of VAX plus PD-1 checkpoint blo
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	241579 : 241583	CM	ministration of VAX plus PD-1 checkpoint blockade (10 
./___Corpus/Medline/xml/PMC5123381.xml	WM	241636 : 241638	CM	kg/mouse) is enhanced in WM tumor-bearing mice.     
./___Corpus/Medline/xml/PMC5123381.xml	WG	241751 : 241753	CM	 significantly less than WG groups over the course o
./___Corpus/Medline/xml/PMC5123381.xml	WM	241843 : 241845	CM	gnificant effect of both WM and VAX alone on primary
./___Corpus/Medline/xml/PMC5123381.xml	VAX	241850 : 241853	CM	nt effect of both WM and VAX alone on primary tumor g
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	241909 : 241913	CM	(p < 0.0001) and splenic IFNγ production (p = 0.010) a
./___Corpus/Medline/xml/PMC5123381.xml	WM	241963 : 241965	CM	nd an additive effect of WM + VAX on primary tumor g
./___Corpus/Medline/xml/PMC5123381.xml	VAX	241968 : 241971	CM	 additive effect of WM + VAX on primary tumor growth 
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	242103 : 242108	CM	 accumulation of splenic MDSCs (p = 0.021). A pilot stu
./___Corpus/Medline/xml/PMC5123381.xml	VAX	242192 : 242195	CM	e dual administration of VAX and anti-PD-1 in WG mice
./___Corpus/Medline/xml/PMC5123381.xml	anti-	242200 : 242205	CPR	dministration of VAX and anti-PD-1 in WG mice; however,
./___Corpus/Medline/xml/PMC5123381.xml	WG	242213 : 242215	CM	 of VAX and anti-PD-1 in WG mice; however, experimen
./___Corpus/Medline/xml/PMC5123381.xml	VAX	242284 : 242287	CM	e dual administration of VAX and PD-1 checkpoint bloc
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	242292 : 242296	CM	dministration of VAX and PD-1 checkpoint blockade in W
./___Corpus/Medline/xml/PMC5123381.xml	WM	242320 : 242322	CM	1 checkpoint blockade in WM cohorts are currently un
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	242621 : 242625	CM	es, and reducing splenic MDSC levels in this metastati
./___Corpus/Medline/xml/PMC5123381.xml	NIH	242848 : 242851	CM	his work is supported by NIH grant R21 CA209144. P265
./___Corpus/Medline/xml/PMC5123381.xml	R21	242858 : 242861	CM	s supported by NIH grant R21 CA209144. P265 Multi-spe
./___Corpus/Medline/xml/PMC5123381.xml	R	243045 : 243046	CM	, Cordelia Dunai1, Bruce R Blazar2, Dan Longo3, Rob
./___Corpus/Medline/xml/PMC5123381.xml	K	243091 : 243092	CM	, Robert Rebhun1, Steven K Grossenbacher1, Arta Mon
./___Corpus/Medline/xml/PMC5123381.xml	murine	243453 : 243459	CM	n patients. Our previous murine studies revealed that ob
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	244387 : 244395	CM	ermined by intracellular cytokine expression and Ki67 posi
./___Corpus/Medline/xml/PMC5123381.xml	Ki67	244411 : 244415	CM	 cytokine expression and Ki67 positivity.             
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	244495 : 244499	CM	    We observed elevated PD-1 expression in CD4+ and C
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	244514 : 244518	CM	vated PD-1 expression in CD4+ and CD8+ T cells in ≥12-
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	244523 : 244527	CM	1 expression in CD4+ and CD8+ T cells in ≥12-month-old
./___Corpus/Medline/xml/PMC5123381.xml	12-	244540 : 244543	CPR	D4+ and CD8+ T cells in ≥12-month-old (mo) mice compa
./___Corpus/Medline/xml/PMC5123381.xml	12-	244548 : 244551	CPR	CD8+ T cells in ≥12-month-old (mo) mice compared to 7
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	244637 : 244642	CM	 expression of TNF-α and IFN-γ expression, and decrease
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	244721 : 244725	CM	mulation. Interestingly, PD-1 expression, proportions 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	244786 : 244794	CM	d effector memory cells, cytokine expression levels and pr
./___Corpus/Medline/xml/PMC5123381.xml	DIO	244931 : 244934	CM	Conversely, T cells from DIO 13mo mice appeared simil
./___Corpus/Medline/xml/PMC5123381.xml	NHPs	245044 : 245048	CM	nally more exhausted. In NHPs, while PD-1 expression d
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	245056 : 245060	CM	xhausted. In NHPs, while PD-1 expression did not diffe
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	245179 : 245183	CM	creased proliferation in CD4+ memory T cells of obese 
./___Corpus/Medline/xml/PMC5123381.xml	mitogen	245251 : 245258	CM	ed. Similarly, decreased mitogen responses in T cells fro
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	245403 : 245407	CM	obesity appear to impact PD-1 expression and T cell fu
./___Corpus/Medline/xml/PMC5123381.xml	NHPs	245459 : 245463	CM	tion. Data from dogs and NHPs suggest these findings m
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	245794 : 245804	CM	  P266 Disruption of the L-arginine balance in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	arginase	245868 : 245876	CM	with a recombinant human arginase 1 (AEB1102) sensitizes c
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	245880 : 245887	CM	binant human arginase 1 (AEB1102) sensitizes cancer to im
./___Corpus/Medline/xml/PMC5123381.xml	arginase	246037 : 246045	CM	                   Human arginase I (hArgI) is a Mn2+-depe
./___Corpus/Medline/xml/PMC5123381.xml	Mn2+	246061 : 246065	CM	 arginase I (hArgI) is a Mn2+-dependent enzyme that di
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	246172 : 246176	CM	erived suppressor cells (MDSC) express human arginase 
./___Corpus/Medline/xml/PMC5123381.xml	arginase	246192 : 246200	CM	lls (MDSC) express human arginase I (hArgI) and nitric-oxi
./___Corpus/Medline/xml/PMC5123381.xml	nitric	246215 : 246221	CM	n arginase I (hArgI) and nitric-oxide synthase (NOS), wh
./___Corpus/Medline/xml/PMC5123381.xml	oxide	246222 : 246227	CM	ase I (hArgI) and nitric-oxide synthase (NOS), which co
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246278 : 246288	CM	trol the availability of L-arginine in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246378 : 246388	CM	of T cells. Depletion of L-arginine by MDSC has been correla
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	246392 : 246396	CM	pletion of L-arginine by MDSC has been correlated to i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	246441 : 246446	CPR	 to impairment of T cell anti-tumor function and tumor 
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246542 : 246552	CM	ession of enzymes of the L-arginine biosynthetic pathway in 
./___Corpus/Medline/xml/PMC5123381.xml	CD34+	246647 : 246652	CM	ow mononuclear cells and CD34+ cells showed low levels 
./___Corpus/Medline/xml/PMC5123381.xml	ornithine	246680 : 246689	CM	lls showed low levels of ornithine transcarbamylase (OTC) a
./___Corpus/Medline/xml/PMC5123381.xml	OTC	246708 : 246711	CM	ithine transcarbamylase (OTC) and argininosuccinate s
./___Corpus/Medline/xml/PMC5123381.xml	argininosuccinate	246717 : 246734	CM	anscarbamylase (OTC) and argininosuccinate synthase (ASS), suggesti
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246818 : 246828	CM	 exogenous/extracellular L-arginine for physiological functi
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	246893 : 246903	CM	, long term depletion of L-arginine may negatively impact th
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	246930 : 246934	CM	ay negatively impact the MDSC population and therefore
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	247057 : 247064	CM	ing a recombinant hArgI (AEB1102), developed by replaceme
./___Corpus/Medline/xml/PMC5123381.xml	Mn2+	247099 : 247103	CM	ed by replacement of the Mn2+ natural cofactor with Co
./___Corpus/Medline/xml/PMC5123381.xml	Co2+	247126 : 247130	CM	2+ natural cofactor with Co2+ which results in signifi
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	247307 : 247314	CM	       Administration of AEB1102 results in chronic deple
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	247347 : 247357	CM	 in chronic depletion of L-arginine in serum to levels below
./___Corpus/Medline/xml/PMC5123381.xml	murine	247393 : 247399	CM	o levels below 1 μM. The murine CT26 colon-cancer model 
./___Corpus/Medline/xml/PMC5123381.xml	CT26	247400 : 247404	CM	s below 1 μM. The murine CT26 colon-cancer model was d
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	247439 : 247446	CM	cer model was dosed with AEB1102 alone and in combination
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247477 : 247482	CPR	 and in combination with anti-PD-L1 and anti-PD-1 monoc
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247492 : 247497	CPR	tion with anti-PD-L1 and anti-PD-1 monoclonal antibodie
./___Corpus/Medline/xml/PMC5123381.xml	CT26	247599 : 247603	CM	    In vivo treatment of CT26 mice with AEB1102 monoth
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	247614 : 247621	CM	atment of CT26 mice with AEB1102 monotherapy resulted in 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	247812 : 247816	CM	y antibodies that target PD-1 and PD-L1 resulted in a 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	247821 : 247826	CM	ies that target PD-1 and PD-L1 resulted in a 0 % (p = 0
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	247934 : 247941	CM	, combination therapy of AEB1102 with anti-PD-1 (ILS 67 %
./___Corpus/Medline/xml/PMC5123381.xml	anti-	247947 : 247952	CPR	 therapy of AEB1102 with anti-PD-1 (ILS 67 %, p < 0.001
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	247982 : 247987	CM	(ILS 67 %, p < 0.001) or PD-L1 (ILS 67 %, p < 0.001) mA
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248052 : 248057	CPR	additive and synergistic anti-tumor effect compared to 
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	248082 : 248089	CM	tumor effect compared to AEB1102 alone and immunotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	248230 : 248240	CM	rate that disrupting the L-arginine physiological balance in
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	248366 : 248373	CM	 tumor to immunotherapy. AEB1102 is currently in phase I 
./___Corpus/Medline/xml/PMC5123381.xml	AEB1102	248488 : 248495	CM	 clinical combination of AEB1102 with anti-PD-1 and anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248501 : 248506	CPR	bination of AEB1102 with anti-PD-1 and anti-PD-L1 mAbs 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	248515 : 248520	CPR	B1102 with anti-PD-1 and anti-PD-L1 mAbs to further imp
./___Corpus/Medline/xml/PMC5123381.xml	Metformin	248601 : 248610	CM	s.                  P267 Metformin treatment synergizes wit
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	248637 : 248641	CM	reatment synergizes with PD-1 blockade therapy by redu
./___Corpus/Medline/xml/PMC5123381.xml	Nicole	248685 : 248691	CM	y reducing tumor hypoxia Nicole Scharping1, Ashley V Men
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	249000 : 249004	CM	bitory molecules such as PD-1. PD-1 blockade therapy h
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	249006 : 249010	CM	 molecules such as PD-1. PD-1 blockade therapy has bec
./___Corpus/Medline/xml/PMC5123381.xml	anti-	249118 : 249123	CPR	ients fail to respond to anti-PD-1 therapy. It has beco
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	249204 : 249210	CM	he lack of nutrients and oxygen in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	B16	249513 : 249516	CM	ods                      B16 and MC38 were injected i
./___Corpus/Medline/xml/PMC5123381.xml	MC38	249521 : 249525	CM	                 B16 and MC38 were injected into mice 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	249612 : 249617	CPR	pable with either 0.2 mg anti-PD-1 or hamster IgG isoty
./___Corpus/Medline/xml/PMC5123381.xml	IgG	249633 : 249636	CM	 mg anti-PD-1 or hamster IgG isotype control, injecte
./___Corpus/Medline/xml/PMC5123381.xml	metformin	249708 : 249717	CM	ritoneally, and 50 mg/kg metformin or PBS, injected every 2
./___Corpus/Medline/xml/PMC5123381.xml	PBS	249721 : 249724	CM	nd 50 mg/kg metformin or PBS, injected every 2 days i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	249767 : 249771	CM	 days intraperitoneally. CD8+ T cells were isolated fr
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	249849 : 249857	CM	d tested for hypoxia and cytokine production by flow cytom
./___Corpus/Medline/xml/PMC5123381.xml	vitro	249972 : 249977	CM	lar analysis was done in vitro with B16, MC38, and SIIN
./___Corpus/Medline/xml/PMC5123381.xml	B16	249983 : 249986	CM	s was done in vitro with B16, MC38, and SIINFEKL stim
./___Corpus/Medline/xml/PMC5123381.xml	MC38	249988 : 249992	CM	 done in vitro with B16, MC38, and SIINFEKL stimulated
./___Corpus/Medline/xml/PMC5123381.xml	SIINFEKL	249998 : 250006	CM	itro with B16, MC38, and SIINFEKL stimulated OT-1 cells ha
./___Corpus/Medline/xml/PMC5123381.xml	OT-1	250018 : 250022	CM	 and SIINFEKL stimulated OT-1 cells harvested from spl
./___Corpus/Medline/xml/PMC5123381.xml	B16	250135 : 250138	CM	            We show that B16, a melanoma resistant to
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	250164 : 250168	CM	 a melanoma resistant to PD-1 therapy, and MC38, a col
./___Corpus/Medline/xml/PMC5123381.xml	MC38	250182 : 250186	CM	ant to PD-1 therapy, and MC38, a colon adenocarcinoma 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	250234 : 250238	CM	a partially sensitive to PD-1 blockade, consume differ
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	250278 : 250284	CM	ume different amounts of oxygen and as a result, produce
./___Corpus/Medline/xml/PMC5123381.xml	hypoxic	250319 : 250326	CM	result, produce distinct hypoxic environments in vivo. Th
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250438 : 250447	CM	ed by treating mice with metformin, a type II diabetes drug
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	250576 : 250582	CM	r cells to inhibit their oxygen consumption. As hypoxia 
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250666 : 250675	CM	vo, we hypothesized that metformin-induced mitigation of tu
./___Corpus/Medline/xml/PMC5123381.xml	metformin	250781 : 250790	CM	e also show that pairing metformin with PD-1 blockade thera
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	250796 : 250800	CM	t pairing metformin with PD-1 blockade therapy results
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	250900 : 250904	CM	tumor clearance, even in PD-1 insensitive tumor models
./___Corpus/Medline/xml/PMC5123381.xml	alpha-fetoprotein	251379 : 251396	CM	      P268 Tumor-derived alpha-fetoprotein (tAFP) inhibits dendriti
./___Corpus/Medline/xml/PMC5123381.xml	H	251509 : 251510	CM	, Greg M Delgoffe2, Lisa H Butterfield1 Background 
./___Corpus/Medline/xml/PMC5123381.xml	alpha-fetoprotein	251618 : 251635	CM	une suppressive role for alpha-fetoprotein (AFP), an oncofetal anti
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251637 : 251640	CM	e for alpha-fetoprotein (AFP), an oncofetal antigen e
./___Corpus/Medline/xml/PMC5123381.xml	HCC	251717 : 251720	CM	patocellular carcinomas (HCC). AFP-L3 is the major is
./___Corpus/Medline/xml/PMC5123381.xml	AFP-L3	251723 : 251729	CM	llular carcinomas (HCC). AFP-L3 is the major isoform pre
./___Corpus/Medline/xml/PMC5123381.xml	isoform	251743 : 251750	CM	CC). AFP-L3 is the major isoform present in the serum of 
./___Corpus/Medline/xml/PMC5123381.xml	HCC	251775 : 251778	CM	 present in the serum of HCC patients and is associat
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251855 : 251858	CM	sis. While tumor-derived AFP (tAFP) contains >80 % of
./___Corpus/Medline/xml/PMC5123381.xml	AFP-L3	251884 : 251890	CM	(tAFP) contains >80 % of AFP-L3, cord blood serum-derive
./___Corpus/Medline/xml/PMC5123381.xml	AFP	251917 : 251920	CM	cord blood serum-derived AFP (nAFP) contains less tha
./___Corpus/Medline/xml/PMC5123381.xml	nAFP	251922 : 251926	CM	blood serum-derived AFP (nAFP) contains less than 5 % 
./___Corpus/Medline/xml/PMC5123381.xml	AFP-L3	251954 : 251960	CM	ontains less than 5 % of AFP-L3. Our previous work shows
./___Corpus/Medline/xml/PMC5123381.xml	AFP	252030 : 252033	CM	tured in the presence of AFP (in particular tAFP), di
./___Corpus/Medline/xml/PMC5123381.xml	DC	252093 : 252095	CM	ed into dendritic cells (DC), retained a monocyte-li
./___Corpus/Medline/xml/PMC5123381.xml	DC	252163 : 252165	CM	 decreased expression of DC maturation markers, and 
./___Corpus/Medline/xml/PMC5123381.xml	DC	252291 : 252293	CM	tantly, monocyte-derived DC cultured in the presence
./___Corpus/Medline/xml/PMC5123381.xml	AFP	252423 : 252426	CM	e examined the effect of AFP on DC cellular metabolis
./___Corpus/Medline/xml/PMC5123381.xml	DC	252430 : 252432	CM	ned the effect of AFP on DC cellular metabolism.    
./___Corpus/Medline/xml/PMC5123381.xml	OVA	252673 : 252676	CM	e of 10 μg/mL ovalbumin (OVA), nAFP or tAFP (n = 3-5 
./___Corpus/Medline/xml/PMC5123381.xml	3-	252697 : 252699	CPR	(OVA), nAFP or tAFP (n = 3-5 HD per experiment). DC 
./___Corpus/Medline/xml/PMC5123381.xml	HD	252701 : 252703	CM	), nAFP or tAFP (n = 3-5 HD per experiment). DC were
./___Corpus/Medline/xml/PMC5123381.xml	DC	252721 : 252723	CM	 3-5 HD per experiment). DC were collected and teste
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	252902 : 252917	RN	 expression of oxidative phosphorylation (OXPHOS)-related protein
./___Corpus/Medline/xml/PMC5123381.xml	OXPHOS	252919 : 252925	CM	idative phosphorylation (OXPHOS)-related proteins, inclu
./___Corpus/Medline/xml/PMC5123381.xml	PGC1α	252994 : 252999	CM	port chain proteins, and PGC1α levels (western blot and
./___Corpus/Medline/xml/PMC5123381.xml	DC	253088 : 253090	CM	lts                      DC cultured in the presence
./___Corpus/Medline/xml/PMC5123381.xml	nAFP	253119 : 253123	CM	tured in the presence of nAFP and tAFP, had reduced mi
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	253259 : 253265	CM	a reduction in the basal oxygen consumption rate (OCR) i
./___Corpus/Medline/xml/PMC5123381.xml	nAFP-DC	253292 : 253299	CM	onsumption rate (OCR) in nAFP-DC and a more severe reduct
./___Corpus/Medline/xml/PMC5123381.xml	tAFP-DC	253344 : 253351	CM	eduction in basal OCR in tAFP-DC. We also show that while
./___Corpus/Medline/xml/PMC5123381.xml	glycolysis	253415 : 253425	RN	 metabolism is affected, glycolysis of DCs was not affected.
./___Corpus/Medline/xml/PMC5123381.xml	DCs	253429 : 253432	CM	 affected, glycolysis of DCs was not affected. Our da
./___Corpus/Medline/xml/PMC5123381.xml	DC	253497 : 253499	CM	 the changes observed in DC metabolism occur within 
./___Corpus/Medline/xml/PMC5123381.xml	AFP	253536 : 253539	CM	occur within 24 hours of AFP exposure and that tAFP i
./___Corpus/Medline/xml/PMC5123381.xml	glycolysis	253648 : 253658	RN	compensatory increase in glycolysis in the first 24–48 hours
./___Corpus/Medline/xml/PMC5123381.xml	24–	253672 : 253675	CPR	 glycolysis in the first 24–48 hours. We also show di
./___Corpus/Medline/xml/PMC5123381.xml	OXPHOS	253789 : 253795	CM	proteins responsible for OXPHOS in DC exposed to nAFP an
./___Corpus/Medline/xml/PMC5123381.xml	DC	253799 : 253801	CM	esponsible for OXPHOS in DC exposed to nAFP and tAFP
./___Corpus/Medline/xml/PMC5123381.xml	PGC1α	253911 : 253916	CM	mitochondrial regulator, PGC1α, in nAFP and tAFP-DC.   
./___Corpus/Medline/xml/PMC5123381.xml	tAFP-DC	253930 : 253937	CM	ator, PGC1α, in nAFP and tAFP-DC.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	AFP	254048 : 254051	CM	ound negative effects of AFP, specifically tAFP on mi
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	254285 : 254296	CM	 P269 Treg cells utilize lactic acid to fuel immune suppressi
./___Corpus/Medline/xml/PMC5123381.xml	glycolytic	255042 : 255052	CM	acid, a product of tumor glycolytic metabolism that is abund
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255234 : 255245	CM	substrates, particularly lactic acid, that allows them to mai
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255393 : 255404	CM	r hypothesis we employed lactic acid treatment of conventiona
./___Corpus/Medline/xml/PMC5123381.xml	lactate	255519 : 255526	CM	hich Slc16a1, encoding a lactate transporter, can be spec
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	255606 : 255615	CM	, constitutively or in a tamoxifen-induced manner. We also 
./___Corpus/Medline/xml/PMC5123381.xml	13C	255649 : 255652	CM	manner. We also employed 13C-labeled lactic acid coup
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	255661 : 255672	CM	lso employed 13C-labeled lactic acid coupled to mass spectrom
./___Corpus/Medline/xml/PMC5123381.xml	monocarboxylate	256044 : 256059	CM	al Treg cells upregulate monocarboxylate transporters (MCT 1, enc
./___Corpus/Medline/xml/PMC5123381.xml	MCT2	256104 : 256108	CM	, encoded by Slc16a1 and MCT2, encoded by Slc16a7) whi
./___Corpus/Medline/xml/PMC5123381.xml	carbons	256167 : 256174	CM	ly transport short chain carbons, including lactic acid, 
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	256186 : 256197	CM	chain carbons, including lactic acid, both into and out of ce
./___Corpus/Medline/xml/PMC5123381.xml	MCT1	256241 : 256245	CM	 of cells. We found that MCT1 null Treg cells have a d
./___Corpus/Medline/xml/PMC5123381.xml	MCT1	256313 : 256317	CM	ive capacity compared to MCT1 competent Treg cells. We
./___Corpus/Medline/xml/PMC5123381.xml	lactate	256391 : 256398	CM	rmacologic inhibition of lactate metabolism in tumor-bear
./___Corpus/Medline/xml/PMC5123381.xml	lactic acid	256562 : 256573	CM	termine specifically how lactic acid is utilized by intratumo
./___Corpus/Medline/xml/PMC5123381.xml	MCT1	256824 : 256828	CM	e populations. Targeting MCT1 in Treg cells and dimini
./___Corpus/Medline/xml/PMC5123381.xml	MCT1	256962 : 256966	CM	pecially while combining MCT1 inhibition with a therap
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257048 : 257053	CPR	 cell functions, such as anti-PD-1 checkpoint blockade.
./___Corpus/Medline/xml/PMC5123381.xml	Salgado1	257301 : 257309	CM	          Alfonso Cortés Salgado1, Meghan Campo2, Anita Gi
./___Corpus/Medline/xml/PMC5123381.xml	Lawrence2	257373 : 257382	CM	 Ainara Soria1, Donald P Lawrence2, Javier Cortés1, Ryan J 
./___Corpus/Medline/xml/PMC5123381.xml	iCI	257523 : 257526	CM	e checkpoint inhibitors (iCI), the recognition and pr
./___Corpus/Medline/xml/PMC5123381.xml	IMD	257653 : 257656	CM	mmune-mediated diarrhea (IMD) is crucial. IMD is comm
./___Corpus/Medline/xml/PMC5123381.xml	IMD	257670 : 257673	CM	arrhea (IMD) is crucial. IMD is commonly managed with
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	257742 : 257751	CM	and in severe cases, the TNF-alpha inhibitor infliximab (IN
./___Corpus/Medline/xml/PMC5123381.xml	INF	257774 : 257777	CM	ha inhibitor infliximab (INF) however little is known
./___Corpus/Medline/xml/PMC5123381.xml	INF	257817 : 257820	CM	e is known on the impact INF has on patient outcomes.
./___Corpus/Medline/xml/PMC5123381.xml	iCI	257945 : 257948	CM	46 patients treated with iCI (anti-CTLA-4, anti-PD-1 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257950 : 257955	CPR	tients treated with iCI (anti-CTLA-4, anti-PD-1 or comb
./___Corpus/Medline/xml/PMC5123381.xml	anti-	257963 : 257968	CPR	d with iCI (anti-CTLA-4, anti-PD-1 or combination thera
./___Corpus/Medline/xml/PMC5123381.xml	3–	258073 : 258075	CPR	2015 who developed grade 3–4 IMD with 96 % of cases 
./___Corpus/Medline/xml/PMC5123381.xml	IMD	258077 : 258080	CM	 who developed grade 3–4 IMD with 96 % of cases confi
./___Corpus/Medline/xml/PMC5123381.xml	INF	258281 : 258284	CM	d evaluate for impact of INF on outcomes. Kaplan-Meie
./___Corpus/Medline/xml/PMC5123381.xml	PFS	258369 : 258372	CM	used to calculate OS and PFS.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	IMD	258453 : 258456	CM	6 patients who developed IMD, 60.9 % were treated wit
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	258544 : 258548	CM	 with combination CTLA-4/PD-1 inhibition and 8.7 % wit
./___Corpus/Medline/xml/PMC5123381.xml	anti-	258575 : 258580	CPR	nhibition and 8.7 % with anti-PD-1 therapy alone. Media
./___Corpus/Medline/xml/PMC5123381.xml	INF	258777 : 258780	CM	had neither steroids nor INF. Of the remaining 44, 17
./___Corpus/Medline/xml/PMC5123381.xml	INF	258835 : 258838	CM	%) had both steroids and INF and 27 (59 %) had steroi
./___Corpus/Medline/xml/PMC5123381.xml	INF	259033 : 259036	CM	ith steroids followed by INF, the median time on ster
./___Corpus/Medline/xml/PMC5123381.xml	INF	259075 : 259078	CM	ime on steroids prior to INF was 24 days; median time
./___Corpus/Medline/xml/PMC5123381.xml	INF	259194 : 259197	CM	17 patients who received INF, 53 % required 1 dose, 3
./___Corpus/Medline/xml/PMC5123381.xml	ECOG	259278 : 259282	CM	oses. When stratified by ECOG PS and adjusted for como
./___Corpus/Medline/xml/PMC5123381.xml	PS	259283 : 259285	CM	 When stratified by ECOG PS and adjusted for comorbi
./___Corpus/Medline/xml/PMC5123381.xml	INF	259318 : 259321	CM	usted for comorbidities, INF therapy was a significan
./___Corpus/Medline/xml/PMC5123381.xml	PFS	259361 : 259364	CM	significant predictor of PFS with a 76 % reduction co
./___Corpus/Medline/xml/PMC5123381.xml	INF	259516 : 259519	CM	 = 0.02). Treatment with INF was not a predictor of O
./___Corpus/Medline/xml/PMC5123381.xml	IMD	259651 : 259654	CM	          Development of IMD is a common ir-AEs. The 
./___Corpus/Medline/xml/PMC5123381.xml	IMD	259706 : 259709	CM	g between development of IMD and the administration o
./___Corpus/Medline/xml/PMC5123381.xml	INF	259736 : 259739	CM	nd the administration of INF in our study renders it 
./___Corpus/Medline/xml/PMC5123381.xml	INF	259790 : 259793	CM	ifficult to determine if INF significantly shortens s
./___Corpus/Medline/xml/PMC5123381.xml	INF	259883 : 259886	CM	rate the significance of INF use on PFS. Though this 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	259894 : 259897	CM	gnificance of INF use on PFS. Though this finding req
./___Corpus/Medline/xml/PMC5123381.xml	Transaminitis	260149 : 260162	CM	                    P271 Transaminitis on PD-1/L1 inhibitors; t
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	260166 : 260170	CM	   P271 Transaminitis on PD-1/L1 inhibitors; the diffi
./___Corpus/Medline/xml/PMC5123381.xml	L1	260171 : 260173	CM	71 Transaminitis on PD-1/L1 inhibitors; the difficul
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	260461 : 260465	CM	known to occur with anti PD-1/L1 inhibition and may mi
./___Corpus/Medline/xml/PMC5123381.xml	L1	260466 : 260468	CM	 to occur with anti PD-1/L1 inhibition and may mimic
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	260632 : 260645	CM	metastasis who developed transaminitis with anti-PD-1/L1 inhibi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	260651 : 260656	CPR	loped transaminitis with anti-PD-1/L1 inhibitors using 
./___Corpus/Medline/xml/PMC5123381.xml	L1	260661 : 260663	CM	saminitis with anti-PD-1/L1 inhibitors using CTCAE v
./___Corpus/Medline/xml/PMC5123381.xml	ver4.0	260687 : 260693	CM	1 inhibitors using CTCAE ver4.0 and RECIST ver1.1.      
./___Corpus/Medline/xml/PMC5123381.xml	ver1.1	260705 : 260711	CM	 CTCAE ver4.0 and RECIST ver1.1.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	260855 : 260868	CM	stasis developed grade 2 transaminitis and RUQ pain after 2 dos
./___Corpus/Medline/xml/PMC5123381.xml	RUQ	260873 : 260876	CM	rade 2 transaminitis and RUQ pain after 2 doses of ni
./___Corpus/Medline/xml/PMC5123381.xml	taxol	261036 : 261041	CM	ontinued and switched to taxol. His hepatomegaly and as
./___Corpus/Medline/xml/PMC5123381.xml	CT	261266 : 261268	CM	r metastasis was seen on CT scan. Case 3: A 69 year 
./___Corpus/Medline/xml/PMC5123381.xml	MEDI4736	261407 : 261415	CM	ilizing tremelimumab and MEDI4736. He had grade 1 transami
./___Corpus/Medline/xml/PMC5123381.xml	CT	261469 : 261471	CM	s with stable disease on CT scan post 4 cycles. He c
./___Corpus/Medline/xml/PMC5123381.xml	MEDI4736	261508 : 261516	CM	 cycles. He continued on MEDI4736, developed grade 2 trans
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	261536 : 261549	CM	I4736, developed grade 2 transaminitis and CT scan showed progr
./___Corpus/Medline/xml/PMC5123381.xml	CT	261554 : 261556	CM	rade 2 transaminitis and CT scan showed progression 
./___Corpus/Medline/xml/PMC5123381.xml	carboplatin	261621 : 261632	CM	asis. He was switched to carboplatin/5FU with weekly cetuxima
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	261871 : 261875	CM	with liver metastasis on PD-1/L1 inhibitors. Case 1 ap
./___Corpus/Medline/xml/PMC5123381.xml	L1	261876 : 261878	CM	liver metastasis on PD-1/L1 inhibitors. Case 1 appea
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	262065 : 262078	CM	nt inhibitors. Grade 3/4 transaminitis may require high-dose co
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	262138 : 262142	CM	ids [1]. Toxicities with PD-1/L1 antibodies may also v
./___Corpus/Medline/xml/PMC5123381.xml	L1	262143 : 262145	CM	1]. Toxicities with PD-1/L1 antibodies may also vary
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	262380 : 262384	CM	r metastasis patients on PD-1/L1 therapy may be more p
./___Corpus/Medline/xml/PMC5123381.xml	L1	262385 : 262387	CM	astasis patients on PD-1/L1 therapy may be more pron
./___Corpus/Medline/xml/PMC5123381.xml	transaminitis	262647 : 262660	CM	er consensus to evaluate transaminitis following checkpoint inh
./___Corpus/Medline/xml/PMC5123381.xml	JS	262786 : 262788	CM	                1. Weber JS, et al.: Toxicities of I
./___Corpus/Medline/xml/PMC5123381.xml	2092–	262870 : 262875	CPR	r. J Clin Oncol 2015, 33:2092–2099.                    
./___Corpus/Medline/xml/PMC5123381.xml	Docetaxel	262958 : 262967	CM	et al.: Nivolumab versus Docetaxel in Advanced Squamous-Cel
./___Corpus/Medline/xml/PMC5123381.xml	123–	263045 : 263049	CPR	. N Engl J Med 2015, 373:123–135.                     
./___Corpus/Medline/xml/PMC5123381.xml	JS	263101 : 263103	CM	                3. Weber JS, et al.: Nivolumab versu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	263199 : 263204	CPR	oma who progressed after anti-CTLA-4 treatment (CheckMa
./___Corpus/Medline/xml/PMC5123381.xml	375–	263312 : 263316	CPR	l. Lancet Oncol 2015, 16:375–384.                  Con
./___Corpus/Medline/xml/PMC5123381.xml	alpha	263473 : 263478	CM	of human T cell receptor alpha and beta V-regions from 
./___Corpus/Medline/xml/PMC5123381.xml	NGS	263736 : 263739	CM	t-generation sequencing (NGS) provides detailed seque
./___Corpus/Medline/xml/PMC5123381.xml	alpha	263865 : 263870	CM	e cognate pairing of TCR alpha and beta chains is lost 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	263900 : 263903	CM	beta chains is lost once RNA extraction is performed 
./___Corpus/Medline/xml/PMC5123381.xml	alpha	264031 : 264036	CM	cation of both human TCR alpha and beta chains from sin
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264206 : 264209	CM	uring the first round of PCR, reverse transcription a
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264237 : 264240	CM	everse transcription and PCR is performed with nested
./___Corpus/Medline/xml/PMC5123381.xml	alpha	264303 : 264308	CM	rimers covering both the alpha and beta locus with comm
./___Corpus/Medline/xml/PMC5123381.xml	C-	264434 : 264436	CPR	primers. Included on the C-region gene primer is an 
./___Corpus/Medline/xml/PMC5123381.xml	nucleotide	264471 : 264481	CM	e primer is an in-line 6 nucleotide barcode, which serves as
./___Corpus/Medline/xml/PMC5123381.xml	plate	264509 : 264514	CM	rcode, which serves as a plate identifier so that multi
./___Corpus/Medline/xml/PMC5123381.xml	96-	264543 : 264546	CPR	ntifier so that multiple 96-well (or 384-well) plates
./___Corpus/Medline/xml/PMC5123381.xml	384-	264555 : 264559	CPR	hat multiple 96-well (or 384-well) plates may be multi
./___Corpus/Medline/xml/PMC5123381.xml	RT-PCR1	264631 : 264638	CM	uencing flow cell. After RT-PCR1, the first round PCR1 pr
./___Corpus/Medline/xml/PMC5123381.xml	PCR1	264656 : 264660	CM	RT-PCR1, the first round PCR1 products are rescued usi
./___Corpus/Medline/xml/PMC5123381.xml	SPRI	264688 : 264692	CM	oducts are rescued using SPRI beads. A second PCR is p
./___Corpus/Medline/xml/PMC5123381.xml	PCR	264709 : 264712	CM	ing SPRI beads. A second PCR is performed with dual-i
./___Corpus/Medline/xml/PMC5123381.xml	PCR1	264808 : 264812	CM	aptors introduced during PCR1 and provide plate positi
./___Corpus/Medline/xml/PMC5123381.xml	plate	264825 : 264830	CM	 during PCR1 and provide plate positional information f
./___Corpus/Medline/xml/PMC5123381.xml	GUI	265048 : 265051	CM	ired-end read). An iPair GUI was also developed to en
./___Corpus/Medline/xml/PMC5123381.xml	plate	265123 : 265128	CM	 paired-receptors on the plate and to aid with identifi
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	265346 : 265350	CM	cer patient’s peripheral CD4+ lymphocytes as part of a
./___Corpus/Medline/xml/PMC5123381.xml	RNA	265677 : 265680	CM	in was also performed on RNA from remaining cells, an
./___Corpus/Medline/xml/PMC5123381.xml	alpha	265732 : 265737	CM	the observed single cell alpha and beta chains are typi
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	266159 : 266163	CM	 variable gene region of TCRs, allowing for a more com
./___Corpus/Medline/xml/PMC5123381.xml	Boehm2	266576 : 266582	CM	ashaswi Shrestha2, Jesse Boehm2, W Nicholas Haining1    
./___Corpus/Medline/xml/PMC5123381.xml	W	266584 : 266585	CM	Shrestha2, Jesse Boehm2, W Nicholas Haining1       
./___Corpus/Medline/xml/PMC5123381.xml	MC38	267532 : 267536	CM	 Mouse tumor cell lines (MC38 colon carcinoma, B16 mel
./___Corpus/Medline/xml/PMC5123381.xml	B16	267554 : 267557	CM	s (MC38 colon carcinoma, B16 melanoma) were engineere
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	267763 : 267767	CM	The Cancer Genome Atlas (TCGA) [1]. These cell lines f
./___Corpus/Medline/xml/PMC5123381.xml	anti-	267959 : 267964	CPR	erapeutic vaccination or anti-PD-1 checkpoint blockade.
./___Corpus/Medline/xml/PMC5123381.xml	Phospho-Inositol	268356 : 268372	CM	           A mutation in Phospho-Inositol 3 Kinase (PI3K), PIK3CA 
./___Corpus/Medline/xml/PMC5123381.xml	Kinase	268375 : 268381	ASE	on in Phospho-Inositol 3 Kinase (PI3K), PIK3CA c.3140A >
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268383 : 268387	CM	ospho-Inositol 3 Kinase (PI3K), PIK3CA c.3140A > G, co
./___Corpus/Medline/xml/PMC5123381.xml	PIK3CA	268390 : 268396	CM	nositol 3 Kinase (PI3K), PIK3CA c.3140A > G, consistentl
./___Corpus/Medline/xml/PMC5123381.xml	B16	268459 : 268462	CM	n representation in both B16 and MC38 immunotherapy-t
./___Corpus/Medline/xml/PMC5123381.xml	MC38	268467 : 268471	CM	entation in both B16 and MC38 immunotherapy-treated tu
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268724 : 268728	CM	tive catalytic domain of PI3K, PIK3CA H1047R. MC38 tum
./___Corpus/Medline/xml/PMC5123381.xml	PIK3CA	268730 : 268736	CM	atalytic domain of PI3K, PIK3CA H1047R. MC38 tumors homo
./___Corpus/Medline/xml/PMC5123381.xml	MC38	268745 : 268749	CM	 of PI3K, PIK3CA H1047R. MC38 tumors homogenously expr
./___Corpus/Medline/xml/PMC5123381.xml	PIK3CA	268781 : 268787	CM	 homogenously expressing PIK3CA H1047R and implanted int
./___Corpus/Medline/xml/PMC5123381.xml	H1047R	268788 : 268794	CM	nously expressing PIK3CA H1047R and implanted into wild 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	268850 : 268855	CPR	ice failed to respond to anti-PD-1 therapy, while tumor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	268939 : 268944	CPR	sed after treatment with anti-PD-1. Pharmacologic PI3K 
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	268964 : 268968	CM	anti-PD-1. Pharmacologic PI3K inhibition resensitized 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	269018 : 269023	CPR	tumors to treatment with anti-PD-1. PD-1-treated PIK3CA
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	269029 : 269033	CM	reatment with anti-PD-1. PD-1-treated PIK3CA H1047R tu
./___Corpus/Medline/xml/PMC5123381.xml	PIK3CA	269042 : 269048	CM	 anti-PD-1. PD-1-treated PIK3CA H1047R tumors had fewer 
./___Corpus/Medline/xml/PMC5123381.xml	H1047R	269049 : 269055	CM	D-1. PD-1-treated PIK3CA H1047R tumors had fewer infiltr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	269086 : 269090	CM	s had fewer infiltrating CD8+ T cells as measured by i
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269239 : 269243	CM	ons                      PI3K has, in addition to its 
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269364 : 269368	CM	 activating mutations in PI3K may be useful as a predi
./___Corpus/Medline/xml/PMC5123381.xml	PI3K	269555 : 269559	CM	 checkpoint blockade and PI3K inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	333–	269728 : 269732	CPR	 types. Nature 2013, 502:333–339.                     
./___Corpus/Medline/xml/PMC5123381.xml	R	269908 : 269909	CM	ma                  Kyle R Cron1, Ayelet Sivan1, Ke
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	270041 : 270045	CM	 tumor infiltration with CD8+ T cells and an associate
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	270589 : 270593	CM	tigate this possibility, TCGA RNAseq data were used to
./___Corpus/Medline/xml/PMC5123381.xml	SNP	270707 : 270710	CM	 signature, and germline SNP data from the same patie
./___Corpus/Medline/xml/PMC5123381.xml	GWAS	270766 : 270770	CM	re utilized to perform a GWAS against the gene signatu
./___Corpus/Medline/xml/PMC5123381.xml	SNP	270845 : 270848	CM	p hit, a minor allele of SNP rs1483185, was significa
./___Corpus/Medline/xml/PMC5123381.xml	GTEX	270981 : 270985	CM	 Interrogation using the GTEX database revealed lower 
./___Corpus/Medline/xml/PMC5123381.xml	SNP	271051 : 271054	CM	in association with this SNP, arguing for a loss-of-f
./___Corpus/Medline/xml/PMC5123381.xml	BM	271358 : 271360	CM	onstituted with knockout BM grew B16.SIY tumors more
./___Corpus/Medline/xml/PMC5123381.xml	B16.SIY	271366 : 271373	CM	ed with knockout BM grew B16.SIY tumors more slowly and h
./___Corpus/Medline/xml/PMC5123381.xml	SIY+	271419 : 271423	CM	nd had higher numbers of SIY+ CD8+ T cells in both the
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	271424 : 271428	CM	d higher numbers of SIY+ CD8+ T cells in both the tumo
./___Corpus/Medline/xml/PMC5123381.xml	WT	271522 : 271524	CM	s the spleen compared to WT engrafted mice. Addition
./___Corpus/Medline/xml/PMC5123381.xml	SIY+	271571 : 271575	CM	ionally, 80 % of splenic SIY+ CD8+ T cells had an acti
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	271576 : 271580	CM	ly, 80 % of splenic SIY+ CD8+ T cells had an activated
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	271606 : 271611	CM	T cells had an activated CD44+ CD62L− phenotype in knoc
./___Corpus/Medline/xml/PMC5123381.xml	CD62L−	271612 : 271618	CM	s had an activated CD44+ CD62L− phenotype in knockout re
./___Corpus/Medline/xml/PMC5123381.xml	WT	271667 : 271669	CM	ecipients versus 40 % in WT recipients. The TIL popu
./___Corpus/Medline/xml/PMC5123381.xml	TIL	271686 : 271689	CM	 % in WT recipients. The TIL populations from KO reci
./___Corpus/Medline/xml/PMC5123381.xml	KO	271707 : 271709	CM	The TIL populations from KO recipients also showed h
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	271828 : 271832	CM	as well as expression of PD-1, Lag3, and 4-1BB indicat
./___Corpus/Medline/xml/PMC5123381.xml	Lag3	271834 : 271838	CM	l as expression of PD-1, Lag3, and 4-1BB indicating an
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	271844 : 271849	CM	ssion of PD-1, Lag3, and 4-1BB indicating antigen-speci
./___Corpus/Medline/xml/PMC5123381.xml	KO	271912 : 271914	CM	nistically, T cells from KO mice showed no obvious i
./___Corpus/Medline/xml/PMC5123381.xml	CD11c+	272007 : 272013	CM	 significant increase in CD11c+ CD8+ dendritic cells was
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	272014 : 272018	CM	icant increase in CD11c+ CD8+ dendritic cells was obse
./___Corpus/Medline/xml/PMC5123381.xml	KO	272051 : 272053	CM	ic cells was observed in KO BM recipients, suggestin
./___Corpus/Medline/xml/PMC5123381.xml	APCs	272114 : 272118	CM	e effect at the level of APCs.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	272274 : 272279	CPR	 to improved spontaneous anti-tumor immunity. The devel
./___Corpus/Medline/xml/PMC5123381.xml	Graphene oxide	272488 : 272502	CM	                    P275 Graphene oxide and amino functionalized
./___Corpus/Medline/xml/PMC5123381.xml	amino	272507 : 272512	CM	 P275 Graphene oxide and amino functionalized graphene 
./___Corpus/Medline/xml/PMC5123381.xml	graphene	272528 : 272536	CM	and amino functionalized graphene characterization for imm
./___Corpus/Medline/xml/PMC5123381.xml	Fuoco3	272724 : 272730	CM	uter Hendrickx2, Claudia Fuoco3, Filomena Spada3, France
./___Corpus/Medline/xml/PMC5123381.xml	graphene	273004 : 273012	CM	el nanomaterials such as graphene and its derivatives in b
./___Corpus/Medline/xml/PMC5123381.xml	graphene	273119 : 273127	CM	olecular interactions of graphene nanomaterials with human
./___Corpus/Medline/xml/PMC5123381.xml	graphene oxide	273287 : 273301	CM	e modulation mediated by graphene oxide (GO) or nanomaterials in
./___Corpus/Medline/xml/PMC5123381.xml	GO	273303 : 273305	CM	iated by graphene oxide (GO) or nanomaterials in gen
./___Corpus/Medline/xml/PMC5123381.xml	graphene	273590 : 273598	CM	]. The impact exerted by graphene and GO exposure on the i
./___Corpus/Medline/xml/PMC5123381.xml	GO	273603 : 273605	CM	 exerted by graphene and GO exposure on the immune s
./___Corpus/Medline/xml/PMC5123381.xml	graphene	273822 : 273830	CM	ization of the impact of graphene nanomaterials on immune 
./___Corpus/Medline/xml/PMC5123381.xml	GO	273983 : 273985	CM	econvolute the effect of GO flakes (between 1–2 grap
./___Corpus/Medline/xml/PMC5123381.xml	1–	274002 : 274004	CPR	ct of GO flakes (between 1–2 graphene layers) functi
./___Corpus/Medline/xml/PMC5123381.xml	graphene	274006 : 274014	CM	f GO flakes (between 1–2 graphene layers) functionalized b
./___Corpus/Medline/xml/PMC5123381.xml	amino	274097 : 274102	CM	dipolar-cycloaddition of amino groups (GONH2) on 15 imm
./___Corpus/Medline/xml/PMC5123381.xml	GONH2	274111 : 274116	CM	ddition of amino groups (GONH2) on 15 immune cell popul
./___Corpus/Medline/xml/PMC5123381.xml	GO	274407 : 274409	CM	 the biocompatibility of GO in all the sub-populatio
./___Corpus/Medline/xml/PMC5123381.xml	GONH2	274456 : 274461	CM	tion analyzed (Fig. 27). GONH2 was found to be a potent
./___Corpus/Medline/xml/PMC5123381.xml	GO	274619 : 274621	CM	tomic analysis. Notably, GO mainly modulated cell me
./___Corpus/Medline/xml/PMC5123381.xml	GONH2	274656 : 274661	CM	dulated cell metabolism. GONH2 instead did not have an 
./___Corpus/Medline/xml/PMC5123381.xml	CXCR3	275002 : 275007	CM	lper 1 chemokines (i.e., CXCR3 and CCR5 ligands), criti
./___Corpus/Medline/xml/PMC5123381.xml	CCR5	275012 : 275016	CM	mokines (i.e., CXCR3 and CCR5 ligands), critical for t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	275072 : 275077	CPR	elopment of an effective anti-tumor immune response [3]
./___Corpus/Medline/xml/PMC5123381.xml	GONH2	275206 : 275211	CM	modulatory properties of GONH2 represent the proof of p
./___Corpus/Medline/xml/PMC5123381.xml	FM	275429 : 275431	CM	, Sgarrella F, Marincola FM, Bianco A, Delogu LG: Im
./___Corpus/Medline/xml/PMC5123381.xml	carbon	275464 : 275470	CM	 A, Delogu LG: Impact of carbon nanotubes and graphene o
./___Corpus/Medline/xml/PMC5123381.xml	graphene	275485 : 275493	CM	 of carbon nanotubes and graphene on immune cells. J Trans
./___Corpus/Medline/xml/PMC5123381.xml	201–	275681 : 275685	CPR	erapy. Cell 2015, 161(2):201–204. 3. Galon J, Angell H
./___Corpus/Medline/xml/PMC5123381.xml	11–	275855 : 275858	CPR	tures. Immunity 2013, 39:11–26.                      
./___Corpus/Medline/xml/PMC5123381.xml	GEO	275913 : 275916	CM	            P276 Curated GEO dataset collection for d
./___Corpus/Medline/xml/PMC5123381.xml	Miller6	276239 : 276246	CM	amien Chaussabel1, Lance Miller6, Davide Bedognetti1     
./___Corpus/Medline/xml/PMC5123381.xml	GEO	276679 : 276682	CM	Gene Expression Omnibus (GEO) of which more than 1200
./___Corpus/Medline/xml/PMC5123381.xml	GXB	277053 : 277056	CM	ne expression browser or GXB [1].                  Me
./___Corpus/Medline/xml/PMC5123381.xml	GEO	277144 : 277147	CM	project, we uploaded the GEO datasets we recently use
./___Corpus/Medline/xml/PMC5123381.xml	GXB	277223 : 277226	CM	r immune subtypes to the GXB application and annotate
./___Corpus/Medline/xml/PMC5123381.xml	GEO	277290 : 277293	CM	 collating data from the GEO database entries, the ma
./___Corpus/Medline/xml/PMC5123381.xml	GEO	277497 : 277500	CM	e imported as part of 14 GEO datasets, 1728 of which 
./___Corpus/Medline/xml/PMC5123381.xml	GEO	277662 : 277665	CM	SE9151) was deposited in GEO in an incompatible forma
./___Corpus/Medline/xml/PMC5123381.xml	CELL	277731 : 277735	CM	reprocessed from the raw CELL files into a normalized 
./___Corpus/Medline/xml/PMC5123381.xml	LD	278787 : 278789	CM	               2. Miller LD, et al.: Immunogenic sub
./___Corpus/Medline/xml/PMC5123381.xml	600–	278924 : 278928	CPR	r Immunol Res 2016, 4(7):600–610.                     
./___Corpus/Medline/xml/PMC5123381.xml	Niazi2	279448 : 279454	CM	hrooz Rabizadeh2, Kayvan Niazi2, Steven Benz2           
./___Corpus/Medline/xml/PMC5123381.xml	everolimus	279580 : 279590	CM	 such as trastuzumab and everolimus have durable clinical be
./___Corpus/Medline/xml/PMC5123381.xml	HER2	279673 : 279677	CM	the relevant biomarkers (HER2 and mTOR respectively). 
./___Corpus/Medline/xml/PMC5123381.xml	mTOR	279682 : 279686	CM	ant biomarkers (HER2 and mTOR respectively). Triple ne
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	279842 : 279846	CM	notherapy agents against PD-1/CTLA-4 for patients with
./___Corpus/Medline/xml/PMC5123381.xml	RNA	280116 : 280119	CM	le genome sequencing and RNA sequencing data from The
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	280166 : 280170	CM	The Cancer Genome Atlas (TCGA) to identify neoepitopes
./___Corpus/Medline/xml/PMC5123381.xml	vitro	280490 : 280495	CM	                  Our in vitro studies on human tumors 
./___Corpus/Medline/xml/PMC5123381.xml	murine	280532 : 280538	CM	human tumors and in vivo murine studies show that antago
./___Corpus/Medline/xml/PMC5123381.xml	ER	280575 : 280577	CM	w that antagonism of the ER via tamoxifen           
./___Corpus/Medline/xml/PMC5123381.xml	tamoxifen	280582 : 280591	CM	antagonism of the ER via tamoxifen                         
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	280667 : 280671	CM	750 cancer patients from TCGA, containing a mixture of
./___Corpus/Medline/xml/PMC5123381.xml	HLA	281229 : 281232	CM	predicted each patient’s HLA typing using only omics 
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	281608 : 281612	CM	              Within the TCGA dataset, the majority of
./___Corpus/Medline/xml/PMC5123381.xml	HER2+	281761 : 281766	CM	f breast cancers such as HER2+, do we identify neoepito
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	282094 : 282100	CM	     P278 A genome-scale CRISPR screen to identify essen
./___Corpus/Medline/xml/PMC5123381.xml	cytolysis	282754 : 282763	RN	y impair T cell mediated cytolysis.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	282938 : 282944	CM	 a ‘two cell-type’ (2CT) CRISPR assay system consisting 
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR-Cas9	283039 : 283050	CM	 as targets. We combined CRISPR-Cas9 screen datasets with TCG
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	283072 : 283076	CM	as9 screen datasets with TCGA gene expression datasets
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	283917 : 283923	CM	oad applicability of 2CT CRISPR screens to study the int
./___Corpus/Medline/xml/PMC5123381.xml	Angiuoli	284246 : 284254	CM	        James White, Sam Angiuoli, Mark Sausen, Sian Jones
./___Corpus/Medline/xml/PMC5123381.xml	exonic	285570 : 285576	CM	ble to interrogate large exonic regions and detect cance
./___Corpus/Medline/xml/PMC5123381.xml	late	286061 : 286065	CM	load in large cohorts of late stage cancer patients an
./___Corpus/Medline/xml/PMC5123381.xml	EML4-NTRK3	286279 : 286289	CM	ibrosarcoma with a novel EML4-NTRK3 fusion using immunogenom
./___Corpus/Medline/xml/PMC5123381.xml	Sims1	286403 : 286408	CM	              Jennifer S Sims1, Sunjay M Barton1, Robyn
./___Corpus/Medline/xml/PMC5123381.xml	Lu1	286511 : 286514	CM	uz1, Andrew T Turk1, Yan Lu1, Christopher F Mazzeo2, 
./___Corpus/Medline/xml/PMC5123381.xml	Saenger3	286582 : 286590	CM	ffrey N Bruce1, Yvonne M Saenger3, Darrell J Yamashiro1, E
./___Corpus/Medline/xml/PMC5123381.xml	P	286621 : 286622	CM	ell J Yamashiro1, Eileen P Connolly1               
./___Corpus/Medline/xml/PMC5123381.xml	1-	286888 : 286890	CPR	ve studied the case of a 1-year-old boy with congeni
./___Corpus/Medline/xml/PMC5123381.xml	1-	286894 : 286896	CPR	died the case of a 1-year-old boy with congenital fi
./___Corpus/Medline/xml/PMC5123381.xml	EML4-NTRK3	286958 : 286968	CM	forearm) bearing a novel EML4-NTRK3 fusion [1] who developed
./___Corpus/Medline/xml/PMC5123381.xml	MANTRA	287423 : 287429	CM	tochemistry (mIHC) using MANTRA (for biomarkers DAPI, CD
./___Corpus/Medline/xml/PMC5123381.xml	DAPI	287446 : 287450	CM	g MANTRA (for biomarkers DAPI, CD3, CD4, CD8, CD68, HL
./___Corpus/Medline/xml/PMC5123381.xml	CD3	287452 : 287455	CM	RA (for biomarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR,
./___Corpus/Medline/xml/PMC5123381.xml	CD4	287457 : 287460	CM	or biomarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	287462 : 287465	CM	omarkers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67)
./___Corpus/Medline/xml/PMC5123381.xml	CD68	287467 : 287471	CM	ers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67), we i
./___Corpus/Medline/xml/PMC5123381.xml	HLA-DR	287473 : 287479	CM	PI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67), we investiga
./___Corpus/Medline/xml/PMC5123381.xml	Ki67	287485 : 287489	CM	, CD8, CD68, HLA-DR, and Ki67), we investigated the re
./___Corpus/Medline/xml/PMC5123381.xml	EML4-NTRK3	287838 : 287848	CM	mors identified the same EML4-NTRK3 fusion, validating their
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	288127 : 288131	CM	by a very low density of CD4+ and CD8+ T cells. This i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	288136 : 288140	CM	 low density of CD4+ and CD8+ T cells. This infiltrati
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	288197 : 288201	CM	markedly increased (both CD4+ and CD8+ T cells) post-r
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	288206 : 288210	CM	increased (both CD4+ and CD8+ T cells) post-radiothera
./___Corpus/Medline/xml/PMC5123381.xml	trans-acting	288374 : 288386	CM	pends on infiltration by trans-acting anti-tumor T cells. TCRs
./___Corpus/Medline/xml/PMC5123381.xml	anti-	288387 : 288392	CPR	ltration by trans-acting anti-tumor T cells. TCRseq of 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	288421 : 288424	CM	r T cells. TCRseq of the TIL populations revealed lit
./___Corpus/Medline/xml/PMC5123381.xml	CDR3	288685 : 288689	CM	g a larger percentage of CDR3 sequences with one anoth
./___Corpus/Medline/xml/PMC5123381.xml	TIL	288887 : 288890	CM	more, the breadth of the TIL repertoire and its bindi
./___Corpus/Medline/xml/PMC5123381.xml	trans-acting	289082 : 289094	CM	between the evolution of trans-acting immunity and antigen-dri
./___Corpus/Medline/xml/PMC5123381.xml	anti-	289228 : 289233	CPR	ur results, particularly anti-tumor T cell specificitie
./___Corpus/Medline/xml/PMC5123381.xml	EML4-NTRK3	289575 : 289585	CM	n of a novel fusion gene EML4-NTRK3 in a case of recurrent c
./___Corpus/Medline/xml/PMC5123381.xml	dinucleotides	289785 : 289798	CM	             P281 Cyclic dinucleotides activating STING are a s
./___Corpus/Medline/xml/PMC5123381.xml	STING	289810 : 289815	CM	dinucleotides activating STING are a safe and effective
./___Corpus/Medline/xml/PMC5123381.xml	Bell1	289995 : 290000	CM	ao3, Rom Leidner1, Bryan Bell1, Kristina Young2, Michae
./___Corpus/Medline/xml/PMC5123381.xml	Pap	290519 : 290522	CM	e those based around the Pap smear for cervical carci
./___Corpus/Medline/xml/PMC5123381.xml	HPV+	290648 : 290652	CM	alignant transformation. HPV+ tumors represent a large
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290798 : 290801	CM	t human papilloma virus (HPV) can prevent HPV infecti
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290815 : 290818	CM	 virus (HPV) can prevent HPV infection and thus preve
./___Corpus/Medline/xml/PMC5123381.xml	HPV	290846 : 290849	CM	fection and thus prevent HPV-associated malignancies.
./___Corpus/Medline/xml/PMC5123381.xml	alpha	291127 : 291132	CM	es, including interferon alpha and imiquimod have been 
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	291137 : 291146	CM	ing interferon alpha and imiquimod have been added to excis
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	291404 : 291414	CM	                  In the transgenic mouse model carrying the
./___Corpus/Medline/xml/PMC5123381.xml	Kras(G12D)	291467 : 291477	CM	tant tumor-driving genes Kras(G12D) and p53(R172H) that are 
./___Corpus/Medline/xml/PMC5123381.xml	HPV	291913 : 291916	CM	g that closely resembles HPV-associated papilloma in 
./___Corpus/Medline/xml/PMC5123381.xml	alpha	291999 : 292004	CM	ules, such as interferon alpha, and innate stimuli, suc
./___Corpus/Medline/xml/PMC5123381.xml	imiquimod	292034 : 292043	CM	 innate stimuli, such as imiquimod, have shown efficacy but
./___Corpus/Medline/xml/PMC5123381.xml	STING	292398 : 292403	CM	tor of INterferon Genes (STING) are strong inducers of 
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	292443 : 292447	CM	ducers of type I IFN and TNFα and can cause rapid regr
./___Corpus/Medline/xml/PMC5123381.xml	STING	292553 : 292558	CM	 we tested the effect of STING ligands on papilloma in 
./___Corpus/Medline/xml/PMC5123381.xml	STING	292663 : 292668	CM	 We tested the effect of STING ligands on papilloma in 
./___Corpus/Medline/xml/PMC5123381.xml	STING	292714 : 292719	CM	 in mice. Treatment with STING ligands causes rapid reg
./___Corpus/Medline/xml/PMC5123381.xml	murine	292767 : 292773	CM	egression of spontaneous murine papilloma, and may repre
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	292984 : 292994	CM	y in macrophages lacking CD47-SIRPα restraint initiates pote
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	293135 : 293145	CM	                     The CD47-SIRPα interaction serves as th
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	293286 : 293291	CM	inhibitory signaling via SIRPα cytoplasmic ITIMs and ty
./___Corpus/Medline/xml/PMC5123381.xml	ITIMs	293304 : 293309	CM	ng via SIRPα cytoplasmic ITIMs and tyrosine phosphatase
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	293314 : 293322	CM	Pα cytoplasmic ITIMs and tyrosine phosphatase SHP-1/2. Thi
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	293323 : 293334	ASE	asmic ITIMs and tyrosine phosphatase SHP-1/2. This signaling 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	293484 : 293488	CM	regulating expression of CD47 to evade immunological e
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	293593 : 293603	CM	mperative, deficiency of CD47-SIRPα does not manifest enhanc
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	293730 : 293740	CM	omenon suggests that the CD47-SIRPα mechanism alone provides
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα−	293998 : 294004	CM	        Establishment of SIRPα−/− mice. Ex vivo and in v
./___Corpus/Medline/xml/PMC5123381.xml	B16	294111 : 294114	CM	 and cancer cells (i.e., B16 melanoma, MC38 colon can
./___Corpus/Medline/xml/PMC5123381.xml	MC38	294125 : 294129	CM	lls (i.e., B16 melanoma, MC38 colon cancer, LLC lung c
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294144 : 294147	CM	noma, MC38 colon cancer, LLC lung cancer and EL4 lymp
./___Corpus/Medline/xml/PMC5123381.xml	EL4	294164 : 294167	CM	cer, LLC lung cancer and EL4 lymphoma). Identificatio
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	294338 : 294343	CM	        Mice depleted of SIRPα display activated macrop
./___Corpus/Medline/xml/PMC5123381.xml	B16	294415 : 294418	CM	rd self-RBC or engrafted B16 and LLC tumors under inf
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294423 : 294426	CM	RBC or engrafted B16 and LLC tumors under inflammator
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα−	294557 : 294563	CM	te that macrophages from SIRPα−/− or CD47−/−, and even W
./___Corpus/Medline/xml/PMC5123381.xml	CD47−	294569 : 294574	CM	ophages from SIRPα−/− or CD47−/−, and even WT mice, are
./___Corpus/Medline/xml/PMC5123381.xml	WT	294587 : 294589	CM	−/− or CD47−/−, and even WT mice, are generally inco
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	294780 : 294784	CM	-17, LPS, IL-6, IL-1β or TNFα, but not IFNɣ, markedly 
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	294794 : 294798	CM	, IL-1β or TNFα, but not IFNɣ, markedly initiates pote
./___Corpus/Medline/xml/PMC5123381.xml	B16	294901 : 294904	CM	-mediated eradication of B16, LLC, MC38, and EL4 canc
./___Corpus/Medline/xml/PMC5123381.xml	LLC	294906 : 294909	CM	ated eradication of B16, LLC, MC38, and EL4 cancer ce
./___Corpus/Medline/xml/PMC5123381.xml	MC38	294911 : 294915	CM	eradication of B16, LLC, MC38, and EL4 cancer cells, p
./___Corpus/Medline/xml/PMC5123381.xml	EL4	294921 : 294924	CM	n of B16, LLC, MC38, and EL4 cancer cells, providing 
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	294967 : 294977	CM	viding an absence of the CD47-SIRPα restraint. Capitalizing 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	295005 : 295013	CM	straint. Capitalizing on cytokine/LPS-activated SIRPα−/− m
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα−	295028 : 295034	CM	n cytokine/LPS-activated SIRPα−/− macrophages targeting 
./___Corpus/Medline/xml/PMC5123381.xml	B16	295118 : 295121	CM	hese macrophages against B16 melanoma and demonstrate
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα−	295190 : 295196	CM	on of lung metastases in SIRPα−/− mice and in WT mice in
./___Corpus/Medline/xml/PMC5123381.xml	WT	295211 : 295213	CM	 in SIRPα−/− mice and in WT mice into which SIRPα−/−
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα−	295230 : 295236	CM	nd in WT mice into which SIRPα−/− macrophage-induced can
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	295805 : 295815	CM	 and perturbation of the CD47-SIRPα interaction would lead t
./___Corpus/Medline/xml/PMC5123381.xml	PNAS	295993 : 295997	CM	 press for publishing in PNAS.)                       
./___Corpus/Medline/xml/PMC5123381.xml	STING	296076 : 296081	CM	kemia immunity following STING agonist therapy requires
./___Corpus/Medline/xml/PMC5123381.xml	Xiufen	296181 : 296187	CM	          Emily Curran1, Xiufen Chen2, Leticia P Corrale
./___Corpus/Medline/xml/PMC5123381.xml	P	296203 : 296204	CM	1, Xiufen Chen2, Leticia P Corrales1, Justin Kline3
./___Corpus/Medline/xml/PMC5123381.xml	STING	296298 : 296303	CM	tor of Interferon Genes (STING) pathway has been implic
./___Corpus/Medline/xml/PMC5123381.xml	STING	296410 : 296415	CM	 system “senses” cancer. STING pathway activation leads
./___Corpus/Medline/xml/PMC5123381.xml	STING	296639 : 296644	CM	umors. Administration of STING agonists induces broad i
./___Corpus/Medline/xml/PMC5123381.xml	STING	296809 : 296814	CM	ent efficacy of systemic STING agonist therapy in murin
./___Corpus/Medline/xml/PMC5123381.xml	murine	296834 : 296840	CM	STING agonist therapy in murine AML models. Unlike the a
./___Corpus/Medline/xml/PMC5123381.xml	STING	296876 : 296881	CM	. Unlike the activity of STING agonists in solid tumor 
./___Corpus/Medline/xml/PMC5123381.xml	AML	296977 : 296980	CM	dent effect in mice with AML, leading us to hypothesi
./___Corpus/Medline/xml/PMC5123381.xml	STING	297071 : 297076	CM	for the effectiveness of STING agonist therapy in mice 
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297219 : 297222	CM	red to express the model SIY peptide antigen (C1498.S
./___Corpus/Medline/xml/PMC5123381.xml	murine	297363 : 297369	CM	eated with the selective murine STING agonist, DMXAA (5,
./___Corpus/Medline/xml/PMC5123381.xml	STING	297370 : 297375	CM	ith the selective murine STING agonist, DMXAA (5,6-dime
./___Corpus/Medline/xml/PMC5123381.xml	DMXAA	297385 : 297390	CM	ve murine STING agonist, DMXAA (5,6-dimethylxanthenone-
./___Corpus/Medline/xml/PMC5123381.xml	5,6-dimethylxanthenone-4-acetic acid	297392 : 297428	CM	ne STING agonist, DMXAA (5,6-dimethylxanthenone-4-acetic acid), or vehicle control.   
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297511 : 297514	CM	           Surprisingly, SIY/Kb pentamer and intracel
./___Corpus/Medline/xml/PMC5123381.xml	Kb	297515 : 297517	CM	       Surprisingly, SIY/Kb pentamer and intracellul
./___Corpus/Medline/xml/PMC5123381.xml	pentamer	297518 : 297526	CM	    Surprisingly, SIY/Kb pentamer and intracellular cytoki
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	297545 : 297553	CM	ntamer and intracellular cytokine staining followed by flo
./___Corpus/Medline/xml/PMC5123381.xml	SIY	297652 : 297655	CM	 expansion of functional SIY-reactive CD8+ T cells in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	297665 : 297669	CM	 functional SIY-reactive CD8+ T cells in both wildtype
./___Corpus/Medline/xml/PMC5123381.xml	DMXAA	297734 : 297739	CM	mice. Survival following DMXAA treatment was significan
./___Corpus/Medline/xml/PMC5123381.xml	TNF-a	297887 : 297892	CM	tream cytokines, such as TNF-a or IL-6 may partially me
./___Corpus/Medline/xml/PMC5123381.xml	STING	297923 : 297928	CM	-6 may partially mediate STING-dependent immune effects
./___Corpus/Medline/xml/PMC5123381.xml	STING	297994 : 297999	CM	ring hosts. For example, STING pathway activation led t
./___Corpus/Medline/xml/PMC5123381.xml	TNF-a	298050 : 298055	CM	 significantly increased TNF-a levels in both wildtype 
./___Corpus/Medline/xml/PMC5123381.xml	3-fold	298100 : 298106	CM	type and Ifnar −/− mice (3-fold and 6-fold, respectively
./___Corpus/Medline/xml/PMC5123381.xml	6-fold	298111 : 298117	CM	nar −/− mice (3-fold and 6-fold, respectively). Based on
./___Corpus/Medline/xml/PMC5123381.xml	TNF-a	298202 : 298207	CM	activating properties of TNF-a, we speculate that it ma
./___Corpus/Medline/xml/PMC5123381.xml	STING	298282 : 298287	CM	 the positive effects of STING activation in leukemia. 
./___Corpus/Medline/xml/PMC5123381.xml	STING	298402 : 298407	CM	ur data demonstrate that STING-mediated enhancement of 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	298432 : 298437	CPR	-mediated enhancement of anti-leukemia immunity are at 
./___Corpus/Medline/xml/PMC5123381.xml	STING	298631 : 298636	CM	unotherapeutic effect of STING agonists in AML.TNF-a is
./___Corpus/Medline/xml/PMC5123381.xml	AML.TNF-a	298649 : 298658	CM	ect of STING agonists in AML.TNF-a is significantly increas
./___Corpus/Medline/xml/PMC5123381.xml	STING	298696 : 298701	CM	ntly increased following STING activation and may be me
./___Corpus/Medline/xml/PMC5123381.xml	STING	298844 : 298849	CM	 the mechanisms by which STING activation mediates anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	298870 : 298875	CPR	TING activation mediates anti-cancer effects may differ
./___Corpus/Medline/xml/PMC5123381.xml	Ethan	299162 : 299167	CM	         Cordelia Dunai, Ethan G Aguilar, Lam T Khuat, 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	299571 : 299574	CM	ith varying affinity for MHC class I molecules. In ge
./___Corpus/Medline/xml/PMC5123381.xml	AML	299817 : 299820	CM	 acute myeloid leukemia (AML). Patients who are not e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300097 : 300102	CPR	wn to be critical for an anti-leukemia response. Here w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300180 : 300185	CPR	on of NK cell subsets to anti-leukemia responses in the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300525 : 300530	CPR	icensed NK cell subsets (anti-Ly49C/I and anti-Ly49G2, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	300542 : 300547	CPR	ubsets (anti-Ly49C/I and anti-Ly49G2, respectively). Su
./___Corpus/Medline/xml/PMC5123381.xml	C1498	301594 : 301599	CM	effect on survival after C1498 challenge. NK cell subse
./___Corpus/Medline/xml/PMC5123381.xml	anti-	301694 : 301699	CPR	sed playing the dominant anti-leukemia role post-HSCT, 
./___Corpus/Medline/xml/PMC5123381.xml	M1	302549 : 302551	CM	 to polarize into either M1 cells, which have potent
./___Corpus/Medline/xml/PMC5123381.xml	anti-	302577 : 302582	CPR	cells, which have potent anti-tumor capabilities, or M2
./___Corpus/Medline/xml/PMC5123381.xml	M2	302605 : 302607	CM	i-tumor capabilities, or M2 macrophages which promot
./___Corpus/Medline/xml/PMC5123381.xml	M2	302805 : 302807	CM	st tumors are considered M2 macrophages and a high t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	303401 : 303406	CPR	-tumor macrophages to an anti-tumor phenotype.         
./___Corpus/Medline/xml/PMC5123381.xml	TMP195	303548 : 303554	CM	lass IIa HDAC inhibitor (TMP195) influenced human monocy
./___Corpus/Medline/xml/PMC5123381.xml	vitro	303641 : 303646	CM	ctors CSF-1 and CSF-2 in vitro. Here, we utilize a macr
./___Corpus/Medline/xml/PMC5123381.xml	TMP195	303759 : 303765	CM	demonstrate that in vivo TMP195 treatment alters the tum
./___Corpus/Medline/xml/PMC5123381.xml	TMP195	303937 : 303943	CM	lts                      TMP195 induces recruitment and 
./___Corpus/Medline/xml/PMC5123381.xml	TMP195	304071 : 304077	CM	. Furthermore, combining TMP195 with chemotherapy regime
./___Corpus/Medline/xml/PMC5123381.xml	anti-	304336 : 304341	CPR	vel means to harness the anti-tumor potential of macrop
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	304560 : 304565	CM	a promoter stimulator-1 (IPS-1)                  Richar
./___Corpus/Medline/xml/PMC5123381.xml	W	304666 : 304667	CM	abeth Guirado2, Geoffrey W Stone2 Background       
./___Corpus/Medline/xml/PMC5123381.xml	anti-	304756 : 304761	CPR	promotes the activity of anti-tumor CD8+ T cells. IFN i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	304767 : 304771	CM	e activity of anti-tumor CD8+ T cells. IFN induced by 
./___Corpus/Medline/xml/PMC5123381.xml	STING	304855 : 304860	CM	tor of interferon genes (STING) activators has shown re
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	304939 : 304943	CM	edal” when combined with PD-1/PD-L1 checkpoint blockad
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	304944 : 304949	CM	 when combined with PD-1/PD-L1 checkpoint blockade in m
./___Corpus/Medline/xml/PMC5123381.xml	STING	304992 : 304997	CM	de in mouse models. Like STING, IPS-1 (also called MAVS
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	304999 : 305004	CM	ouse models. Like STING, IPS-1 (also called MAVS, Cardi
./___Corpus/Medline/xml/PMC5123381.xml	MAVS	305018 : 305022	CM	TING, IPS-1 (also called MAVS, Cardif, or VISA) can le
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	305076 : 305081	CM	o strong IFN production. IPS-1 is normally activated by
./___Corpus/Medline/xml/PMC5123381.xml	RNAs	305113 : 305117	CM	mally activated by viral RNAs bound to RIG-I which in 
./___Corpus/Medline/xml/PMC5123381.xml	RIG-I	305127 : 305132	CM	d by viral RNAs bound to RIG-I which in turn modifies I
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	305156 : 305161	CM	I which in turn modifies IPS-1 so that it clusters onto
./___Corpus/Medline/xml/PMC5123381.xml	RIG-I	305254 : 305259	CM	 circumvent the need for RIG-I, this study fused IPS-1 
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	305278 : 305283	CM	 RIG-I, this study fused IPS-1 with the membrane cluste
./___Corpus/Medline/xml/PMC5123381.xml	N-	305315 : 305317	CPR	he membrane clustering, N-terminal region of EBV lat
./___Corpus/Medline/xml/PMC5123381.xml	EBV	305335 : 305338	CM	ng, N-terminal region of EBV latent membrane protein 
./___Corpus/Medline/xml/PMC5123381.xml	LMP1	305366 : 305370	CM	tent membrane protein 1 (LMP1).                  Metho
./___Corpus/Medline/xml/PMC5123381.xml	N-	305424 : 305426	CPR	                    The N-terminus of the Epstein-Ba
./___Corpus/Medline/xml/PMC5123381.xml	EBV	305461 : 305464	CM	 the Epstein-Barr virus (EBV) LMP1 protein contains 6
./___Corpus/Medline/xml/PMC5123381.xml	N-	305583 : 305585	CPR	Genetically fusing this N-terminal region to IPS-1 f
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	305603 : 305608	CM	his N-terminal region to IPS-1 forms LMP1-IPS-1 which i
./___Corpus/Medline/xml/PMC5123381.xml	LMP1-IPS-1	305615 : 305625	CM	al region to IPS-1 forms LMP1-IPS-1 which is a constitutivel
./___Corpus/Medline/xml/PMC5123381.xml	IPS-1	305670 : 305675	CM	tively activated form of IPS-1. The resulting nucleic a
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	305734 : 305738	CM	nce was tested either as mRNA, plasmid DNA, or by vira
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	305794 : 305797	CM	very using adenovirus 5 (Ad5) (Ad5-LMP1-IPS-1).      
./___Corpus/Medline/xml/PMC5123381.xml	Ad5-LMP1-IPS-1	305800 : 305814	CM	sing adenovirus 5 (Ad5) (Ad5-LMP1-IPS-1).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	Ad5-LMP1-IPS-1	305901 : 305915	CM	ic cells transduced with Ad5-LMP1-IPS-1 upregulated CD80 and CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD80	305928 : 305932	CM	5-LMP1-IPS-1 upregulated CD80 and CD86 and produced la
./___Corpus/Medline/xml/PMC5123381.xml	CD86	305937 : 305941	CM	S-1 upregulated CD80 and CD86 and produced large amoun
./___Corpus/Medline/xml/PMC5123381.xml	TNF	305982 : 305985	CM	rge amounts of IL-12 and TNF. 293 cells transfected w
./___Corpus/Medline/xml/PMC5123381.xml	LMP1-IPS-1	306014 : 306024	CM	3 cells transfected with LMP1-IPS-1 plasmid DNA produced hig
./___Corpus/Medline/xml/PMC5123381.xml	IFN-α	306061 : 306066	CM	 produced high levels of IFN-α, IFN-β, and chemokines. 
./___Corpus/Medline/xml/PMC5123381.xml	IFN-β	306068 : 306073	CM	ed high levels of IFN-α, IFN-β, and chemokines. By micr
./___Corpus/Medline/xml/PMC5123381.xml	mRNAs	306115 : 306120	CM	 By microarray analysis, mRNAs for IFN-associated genes
./___Corpus/Medline/xml/PMC5123381.xml	IFN	306125 : 306128	CM	rray analysis, mRNAs for IFN-associated genes were st
./___Corpus/Medline/xml/PMC5123381.xml	Ad5-LMP1-IPS-1	306203 : 306217	CM	vo, mice vaccinated with Ad5-LMP1-IPS-1 plus Ad5 expressing HIV 
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	306223 : 306226	CM	with Ad5-LMP1-IPS-1 plus Ad5 expressing HIV Gag were 
./___Corpus/Medline/xml/PMC5123381.xml	LMP1-IPS-1	306357 : 306367	CM	ons                      LMP1-IPS-1 shares similar activitie
./___Corpus/Medline/xml/PMC5123381.xml	STING	306409 : 306414	CM	ctivities with activated STING. Whereas STING activator
./___Corpus/Medline/xml/PMC5123381.xml	STING	306424 : 306429	CM	activated STING. Whereas STING activators are small mol
./___Corpus/Medline/xml/PMC5123381.xml	LMP1-IPS-1	306462 : 306472	CM	ors are small molecules, LMP1-IPS-1 is constitutively active
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	306543 : 306547	CM	 sequence can be used as mRNA, plasmid DNA, part of a 
./___Corpus/Medline/xml/PMC5123381.xml	NIH	306700 : 306703	CM	            Supported by NIH grant R21AI093294 and Fl
./___Corpus/Medline/xml/PMC5123381.xml	R21AI093294	306710 : 306721	CM	  Supported by NIH grant R21AI093294 and Florida Dept. Health
./___Corpus/Medline/xml/PMC5123381.xml	4KF03	306785 : 306790	CM	ansfer Feasibility Award 4KF03.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	JM	306861 : 306863	CM	     1. Gupta S, Termini JM, Issac B, Guirado E, Sto
./___Corpus/Medline/xml/PMC5123381.xml	MAVS	306917 : 306921	CM	W: Constitutively Active MAVS Inhibits HIV-1 Replicati
./___Corpus/Medline/xml/PMC5123381.xml	Fcγ	307092 : 307095	CM	      P287 Modulation of Fcγ receptor function by HLA
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	307117 : 307122	CM	Fcγ receptor function by HLA-G                      Chr
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	307298 : 307303	CM	und                      HLA-G is a non-classical major
./___Corpus/Medline/xml/PMC5123381.xml	MHC	307357 : 307360	CM	tocompatibility complex (MHC) molecule expressed at t
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	307539 : 307544	CM	 through interactions of HLA-G with its receptors, ILT2
./___Corpus/Medline/xml/PMC5123381.xml	ILT2	307565 : 307569	CM	LA-G with its receptors, ILT2 and ILT4, which are expr
./___Corpus/Medline/xml/PMC5123381.xml	ILT4	307574 : 307578	CM	 its receptors, ILT2 and ILT4, which are expressed pri
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	307685 : 307690	CM	tand the effect of tumor HLA-G expression on myeloid im
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	307763 : 307768	CM	vestigated the effect of HLA-G on Fcγ receptor signalin
./___Corpus/Medline/xml/PMC5123381.xml	Fcγ	307772 : 307775	CM	d the effect of HLA-G on Fcγ receptor signaling—a mye
./___Corpus/Medline/xml/PMC5123381.xml	Fcγ	308075 : 308078	CM	ic antibody, we examined Fcγ receptor effector functi
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	308257 : 308262	CM	           We found that HLA-G inhibits signaling downs
./___Corpus/Medline/xml/PMC5123381.xml	FcγR	308296 : 308300	CM	 signaling downstream of FcγR activation in a monocyti
./___Corpus/Medline/xml/PMC5123381.xml	monocytic	308317 : 308326	CM	 of FcγR activation in a monocytic cell line and in primary
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	308376 : 308381	CM	 monocytes. Furthermore, HLA-G expression on tumor targ
./___Corpus/Medline/xml/PMC5123381.xml	FcγR	308508 : 308512	CM	ges as well as decreased FcγR-induced production of in
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	308591 : 308596	CM	ffects were dependent on HLA-G interaction with its rec
./___Corpus/Medline/xml/PMC5123381.xml	ILT2	308629 : 308633	CM	tion with its receptors, ILT2 and ILT4.               
./___Corpus/Medline/xml/PMC5123381.xml	ILT4	308638 : 308642	CM	 its receptors, ILT2 and ILT4.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	308726 : 308731	CM	dings suggest a role for HLA-G in promoting tumor immun
./___Corpus/Medline/xml/PMC5123381.xml	HLA-G	308799 : 308804	CM	as a novel mechanism for HLA-G-mediated inhibition of a
./___Corpus/Medline/xml/PMC5123381.xml	CTL	308966 : 308969	CM	une genes in response to CTL attack                  
./___Corpus/Medline/xml/PMC5123381.xml	Gfeller1	309111 : 309119	CM	, Donata Rimoldi1, David Gfeller1, Mauro Delorenzi2, Silvi
./___Corpus/Medline/xml/PMC5123381.xml	CTL	309399 : 309402	CM	 cytotoxic T lymphocyte (CTL) attack.                
./___Corpus/Medline/xml/PMC5123381.xml	MART1	309569 : 309574	CM	ere cultured with MelanA/MART1-specific CD8+ T cells an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	309584 : 309588	CM	th MelanA/MART1-specific CD8+ T cells and characterize
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	309985 : 309989	CM	nce of melanoma-specific CD8+ T cells. However, still 
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	310148 : 310152	CM	cells revealed increased mRNA levels of genes associat
./___Corpus/Medline/xml/PMC5123381.xml	DDX58	310219 : 310224	CM	crobial immune response: DDX58, TLR3, AIM2, MyD88, NFKB
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	310226 : 310230	CM	 immune response: DDX58, TLR3, AIM2, MyD88, NFKB, IFIT
./___Corpus/Medline/xml/PMC5123381.xml	AIM2	310232 : 310236	CM	e response: DDX58, TLR3, AIM2, MyD88, NFKB, IFITM3, an
./___Corpus/Medline/xml/PMC5123381.xml	MyD88	310238 : 310243	CM	onse: DDX58, TLR3, AIM2, MyD88, NFKB, IFITM3, and ISG15
./___Corpus/Medline/xml/PMC5123381.xml	NFKB	310245 : 310249	CM	DX58, TLR3, AIM2, MyD88, NFKB, IFITM3, and ISG15 after
./___Corpus/Medline/xml/PMC5123381.xml	IFITM3	310251 : 310257	CM	TLR3, AIM2, MyD88, NFKB, IFITM3, and ISG15 after co-cult
./___Corpus/Medline/xml/PMC5123381.xml	ISG15	310263 : 310268	CM	MyD88, NFKB, IFITM3, and ISG15 after co-culture. Upregu
./___Corpus/Medline/xml/PMC5123381.xml	DDX58	310360 : 310365	CM	innate immune responses. DDX58 (also RIG-I) and TLR3 se
./___Corpus/Medline/xml/PMC5123381.xml	RIG-I	310372 : 310377	CM	e responses. DDX58 (also RIG-I) and TLR3 sense intracel
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	310383 : 310387	CM	. DDX58 (also RIG-I) and TLR3 sense intracellular vira
./___Corpus/Medline/xml/PMC5123381.xml	RNA	310414 : 310417	CM	ense intracellular viral RNA, and AIM2 recognizes cyt
./___Corpus/Medline/xml/PMC5123381.xml	AIM2	310423 : 310427	CM	acellular viral RNA, and AIM2 recognizes cytosolic dou
./___Corpus/Medline/xml/PMC5123381.xml	MyD88	310470 : 310475	CM	lic double-stranded DNA. MyD88 acts as an adaptor downs
./___Corpus/Medline/xml/PMC5123381.xml	TLRs	310509 : 310513	CM	an adaptor downstream of TLRs and signals to NFκB. IFI
./___Corpus/Medline/xml/PMC5123381.xml	NFκB	310529 : 310533	CM	m of TLRs and signals to NFκB. IFITM3, a transmembrane
./___Corpus/Medline/xml/PMC5123381.xml	IFITM3	310535 : 310541	CM	LRs and signals to NFκB. IFITM3, a transmembrane protein
./___Corpus/Medline/xml/PMC5123381.xml	ISG15	310607 : 310612	CM	 entry into its host and ISG15 has multiple anti-viral 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	310626 : 310631	CPR	t and ISG15 has multiple anti-viral roles including ind
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	310793 : 310797	CM	-specific interaction of CTLs with melanoma cells and 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	310839 : 310843	CM	lls and were mediated by IFNγ and TNFα, two cytokines 
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	310848 : 310852	CM	ere mediated by IFNγ and TNFα, two cytokines secreted 
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	311096 : 311100	CM	 increased expression of IDO1 and the inhibitory recep
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	311136 : 311141	CM	hibitory receptor ligand PD-L1. Here we show that in ad
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	311256 : 311260	CM	ond to melanoma-specific CTLs with a cytokine-driven u
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	311268 : 311276	CM	oma-specific CTLs with a cytokine-driven upregulation of g
./___Corpus/Medline/xml/PMC5123381.xml	anti-	311626 : 311631	CPR	 promoting both pro- and anti-tumor immune mechanisms. 
./___Corpus/Medline/xml/PMC5123381.xml	R	311759 : 311760	CM	etrova, M. De Palma, and R. Debets for discussions 
./___Corpus/Medline/xml/PMC5123381.xml	K	311860 : 311861	CM	llonel, N. Montandon and K. Mühlethaler for technic
./___Corpus/Medline/xml/PMC5123381.xml	IDO	311920 : 311923	CM	and B. van den Eynde for IDO-specific antibody.      
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	312094 : 312100	CM	colorectal cancer target GUCY2C by next-generation seque
./___Corpus/Medline/xml/PMC5123381.xml	Bo	312164 : 312166	CM	         Tara S Abraham, Bo Xiang, Michael S Magee, 
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	312283 : 312287	CM	ifying T cell receptors (TCRs) targeting self-antigens
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	312438 : 312442	CM	he enormous diversity of TCRs and low abundance of ant
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	312522 : 312526	CM	tification of individual TCRs difficult. Moreover, tol
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	312699 : 312703	CM	ne a process to identify TCRs from CD4+ T cells recogn
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	312709 : 312713	CM	ss to identify TCRs from CD4+ T cells recognizing the 
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	312762 : 312768	CM	 intestinal self-antigen GUCY2C, an emerging target in c
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	312825 : 312831	CM	al cancer immunotherapy. GUCY2C-specific CD4+ T cells we
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	312841 : 312845	CM	therapy. GUCY2C-specific CD4+ T cells were identified 
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	312979 : 312983	CM	ts quantified individual TCRs, permitting synthesis an
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	313063 : 313067	CM	hat were engineered into CD4+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313123 : 313129	CM	lts                      GUCY2C recognition by engineere
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	313156 : 313160	CM	ecognition by engineered CD4+ T cells in vitro confirm
./___Corpus/Medline/xml/PMC5123381.xml	vitro	313172 : 313177	CM	gineered CD4+ T cells in vitro confirmed TCR specificit
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313445 : 313451	CM	naïve T cells expressing GUCY2C-specific TCR transgenes,
./___Corpus/Medline/xml/PMC5123381.xml	vitro	313508 : 313513	CM	ng us to validate our in vitro findings of GUCY2C recog
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313526 : 313532	CM	our in vitro findings of GUCY2C recognition following GU
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313555 : 313561	CM	2C recognition following GUCY2C vaccination.            
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	313630 : 313640	CM	                    This transgenic TCR model system can be 
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313717 : 313723	CM	e mechanisms restricting GUCY2C-specific immunotherapy, 
./___Corpus/Medline/xml/PMC5123381.xml	GUCY2C	313776 : 313782	CM	ilitating 2nd-generation GUCY2C vaccine design. Moreover
./___Corpus/Medline/xml/PMC5123381.xml	TCRs	313870 : 313874	CM	te self-antigen specific TCRs may be employed for canc
./___Corpus/Medline/xml/PMC5123381.xml	BMSC	314984 : 314988	CM	ry little is known about BMSC homeostasis in patients 
./___Corpus/Medline/xml/PMC5123381.xml	FACS	315389 : 315393	CM	                   Using FACS analysis supported by Im
./___Corpus/Medline/xml/PMC5123381.xml	Lin-CD45-CD133	315490 : 315504	CM	ations of BMSCs, such as Lin-CD45-CD133 + CXCR4+ very small embr
./___Corpus/Medline/xml/PMC5123381.xml	CXCR4+	315507 : 315513	CM	such as Lin-CD45-CD133 + CXCR4+ very small embryonic/epi
./___Corpus/Medline/xml/PMC5123381.xml	epiblast	315535 : 315543	CM	R4+ very small embryonic/epiblast-like stem cells (VSELs),
./___Corpus/Medline/xml/PMC5123381.xml	CD45-STRO-1	315569 : 315580	CM	like stem cells (VSELs), CD45-STRO-1 + CD105+ mesenchymal ste
./___Corpus/Medline/xml/PMC5123381.xml	CD105+	315583 : 315589	CM	s (VSELs), CD45-STRO-1 + CD105+ mesenchymal stem cells (
./___Corpus/Medline/xml/PMC5123381.xml	CD133+	315632 : 315638	CM	cells (MSCs), Lin-CD45 + CD133+ hematopoietic stem/proge
./___Corpus/Medline/xml/PMC5123381.xml	CD34	315688 : 315692	CM	nitor cells (HSPCs), and CD34 +/ KDR +/ CD31 +/ CD45- 
./___Corpus/Medline/xml/PMC5123381.xml	CD31	315703 : 315707	CM	PCs), and CD34 +/ KDR +/ CD31 +/ CD45- endothelial pro
./___Corpus/Medline/xml/PMC5123381.xml	CD45	315711 : 315715	CM	d CD34 +/ KDR +/ CD31 +/ CD45- endothelial progenitor 
./___Corpus/Medline/xml/PMC5123381.xml	GISTs	315890 : 315895	CM	5) other gastric tumors (GISTs, NENs, lymphomas; n = 15
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	315989 : 315997	CM	evels of stromal-derived factor-1 (SDF-1), complement-deri
./___Corpus/Medline/xml/PMC5123381.xml	SDF-1	315999 : 316004	CM	tromal-derived factor-1 (SDF-1), complement-derived ana
./___Corpus/Medline/xml/PMC5123381.xml	C3a	316052 : 316055	CM	naphylatoxins/molecules (C3a, C5a, C5b-9), cytokines 
./___Corpus/Medline/xml/PMC5123381.xml	C5a	316057 : 316060	CM	latoxins/molecules (C3a, C5a, C5b-9), cytokines (IL-1
./___Corpus/Medline/xml/PMC5123381.xml	C5b-9	316062 : 316067	CM	ins/molecules (C3a, C5a, C5b-9), cytokines (IL-1, IL-6,
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	316120 : 316124	CM	-8, IL-10, IL-17, IL-23, TNFα), growth factors (HGF, F
./___Corpus/Medline/xml/PMC5123381.xml	HGF	316143 : 316146	CM	, TNFα), growth factors (HGF, FGF, IGF-1) and immunom
./___Corpus/Medline/xml/PMC5123381.xml	FGF	316148 : 316151	CM	α), growth factors (HGF, FGF, IGF-1) and immunomodula
./___Corpus/Medline/xml/PMC5123381.xml	lipids	316191 : 316197	CM	munomodulatory bioactive lipids (sphingosine-1-phosphate
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine-1-phosphate	316199 : 316222	CM	latory bioactive lipids (sphingosine-1-phosphate–S1P and lipoxin A4) were
./___Corpus/Medline/xml/PMC5123381.xml	S1P	316223 : 316226	CM	(sphingosine-1-phosphate–S1P and lipoxin A4) were mea
./___Corpus/Medline/xml/PMC5123381.xml	lipoxin	316231 : 316238	CM	sine-1-phosphate–S1P and lipoxin A4) were measured using 
./___Corpus/Medline/xml/PMC5123381.xml	SDF-1	316711 : 316716	CM	h the systemic levels of SDF-1, which were comparable b
./___Corpus/Medline/xml/PMC5123381.xml	C5b-9	316836 : 316841	CM	ntly increased levels of C5b-9, interleukins (IL-6, IL-
./___Corpus/Medline/xml/PMC5123381.xml	HGF	316877 : 316880	CM	ins (IL-6, IL-8, IL-23), HGF and bioactive lipids (S1
./___Corpus/Medline/xml/PMC5123381.xml	lipids	316895 : 316901	CM	L-23), HGF and bioactive lipids (S1P, lipoxin A4) were s
./___Corpus/Medline/xml/PMC5123381.xml	S1P	316903 : 316906	CM	GF and bioactive lipids (S1P, lipoxin A4) were strong
./___Corpus/Medline/xml/PMC5123381.xml	lipoxin	316908 : 316915	CM	d bioactive lipids (S1P, lipoxin A4) were strongly associ
./___Corpus/Medline/xml/PMC5123381.xml	lipids	317315 : 317321	CM	th factors and bioactive lipids, but not SDF-1, seem to 
./___Corpus/Medline/xml/PMC5123381.xml	SDF-1	317331 : 317336	CM	ioactive lipids, but not SDF-1, seem to be significant 
./___Corpus/Medline/xml/PMC5123381.xml	CTL	317856 : 317859	CM	cytotoxic T lymphocytes (CTL) and natural killer (NK)
./___Corpus/Medline/xml/PMC5123381.xml	51Cr	317965 : 317969	CM	formed using 51chromium (51Cr) and calcein release ass
./___Corpus/Medline/xml/PMC5123381.xml	calcein	317975 : 317982	CM	ng 51chromium (51Cr) and calcein release assays. The assa
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	318139 : 318143	CM	ubjected to cytolysis by CTLs or NK cells (effector), 
./___Corpus/Medline/xml/PMC5123381.xml	lysis	318223 : 318228	RN	bels into the media upon lysis. The amount of labels in
./___Corpus/Medline/xml/PMC5123381.xml	IMR32	318897 : 318902	CM	nd K562 (suspension) and IMR32 (adherent) were used as 
./___Corpus/Medline/xml/PMC5123381.xml	calcein	318987 : 318994	CM	 were first stained with calcein AM, and seeded at 10,000
./___Corpus/Medline/xml/PMC5123381.xml	96-	319045 : 319048	CPR	cells/well in a standard 96-well microplate. The dono
./___Corpus/Medline/xml/PMC5123381.xml	plate	319209 : 319214	CM	nd 0.3125:1. The 96 well plate was then scanned and ana
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319317 : 319322	RN	and 4 h to measure the % lysis of target cells.        
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319418 : 319423	RN	ults showed increasing % lysis as incubation time and E
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319545 : 319550	RN	5:1, and 0.3125:1, the % lysis were 99, 93, 75, 52, 30,
./___Corpus/Medline/xml/PMC5123381.xml	IMR32	319602 : 319607	CM	nd 7 %, respectively for IMR32. The K562 cells showed s
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319641 : 319646	RN	2 cells showed similar % lysis results. In addition, th
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319685 : 319690	RN	ddition, the change in % lysis over time was monitored 
./___Corpus/Medline/xml/PMC5123381.xml	lysis	319757 : 319762	RN	es, showing increasing % lysis from 1 to 4 hours.      
./___Corpus/Medline/xml/PMC5123381.xml	plate	320051 : 320056	CM	l research. In addition, plate-based image cytometry en
./___Corpus/Medline/xml/PMC5123381.xml	HLA	320242 : 320245	CM	                P292 The HLA-associated phosphoproteo
./___Corpus/Medline/xml/PMC5123381.xml	phosphoproteome	320257 : 320272	CM	 P292 The HLA-associated phosphoproteome as a new target for immu
./___Corpus/Medline/xml/PMC5123381.xml	Ruth4	320512 : 320517	CM	2, Ellen Speers3, Nicola Ruth4, Gabriel Wong4, Robert T
./___Corpus/Medline/xml/PMC5123381.xml	Thimme1	320541 : 320548	CM	4, Gabriel Wong4, Robert Thimme1, David Adams4, Mark Cobb
./___Corpus/Medline/xml/PMC5123381.xml	Adams4	320556 : 320562	CM	4, Robert Thimme1, David Adams4, Mark Cobbold2          
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320653 : 320656	CM	epatocellular carcinoma (HCC) is the sixth most commo
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320736 : 320739	CM	nce and mortality. Since HCC is believed to be immuno
./___Corpus/Medline/xml/PMC5123381.xml	HCC	320995 : 320998	CM	. However, only very few HCC-specific tumor antigens 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	321227 : 321242	RN	nt and augmented protein phosphorylation and in such way modified
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321321 : 321336	CM	generate cancer-specific phosphopeptides. These are presented by 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	321361 : 321364	CM	. These are presented by MHC class I molecules and re
./___Corpus/Medline/xml/PMC5123381.xml	HCC	321448 : 321451	CM	is study was to identify HCC-associated, MHC class I-
./___Corpus/Medline/xml/PMC5123381.xml	MHC	321464 : 321467	CM	identify HCC-associated, MHC class I-bound phosphopep
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321482 : 321497	CM	iated, MHC class I-bound phosphopeptides (MHC-I-pP) and to assess
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	321499 : 321507	CM	I-bound phosphopeptides (MHC-I-pP) and to assess immunity 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	321706 : 321709	CM	, tissues were lysed and MHC class-I complexes affini
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321757 : 321772	CM	nity purified. The bound phosphopeptides were eluted, enriched an
./___Corpus/Medline/xml/PMC5123381.xml	MHC	321850 : 321853	CM	pectrometry. We compared MHC class I-bound phosphopep
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	321868 : 321883	CM	mpared MHC class I-bound phosphopeptides (MHC-I-pP) found on heal
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	321885 : 321893	CM	I-bound phosphopeptides (MHC-I-pP) found on healthy, cirrh
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	322011 : 322016	CM	tion. To assess immunity PBMCs, intrahepatic lymphocyte
./___Corpus/Medline/xml/PMC5123381.xml	HCC	322168 : 322171	CM	hronic liver disease and HCC, and analyzed using mult
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	322218 : 322226	CM	ultiplexed intracellular cytokine staining. Additionally, 
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	322251 : 322259	CM	 staining. Additionally, MHC-I-pP-specific CD8+ T cells fr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	322269 : 322273	CM	nally, MHC-I-pP-specific CD8+ T cells from IHLs and TI
./___Corpus/Medline/xml/PMC5123381.xml	IHLs	322287 : 322291	CM	ecific CD8+ T cells from IHLs and TILs were expanded i
./___Corpus/Medline/xml/PMC5123381.xml	TILs	322296 : 322300	CM	8+ T cells from IHLs and TILs were expanded in a large
./___Corpus/Medline/xml/PMC5123381.xml	anti-	322370 : 322375	CPR	 expansion protocol with anti-CD3, IL-2 and irradiated 
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	322510 : 322518	CM	 over 300 HCC-associated MHC-I-pP presented by various HLA
./___Corpus/Medline/xml/PMC5123381.xml	HLA	322540 : 322543	CM	-pP presented by various HLA molecules. Many of the n
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	322584 : 322592	CM	 of the novel identified MHC-I-pP were derived from protei
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	322706 : 322714	CM	signaling-pathways. More MHC-I-pP were displayed in a grea
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	322860 : 322864	CM	cirrhosis and up to HCC. CD8+ T cell responses were fo
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	323259 : 323267	CM	s therefore suggest that MHC-I-pP may be the target of can
./___Corpus/Medline/xml/PMC5123381.xml	MHC-I-pP	323371 : 323379	CM	 a directed expansion of MHC-I-pP-specific CD8+ T cells wa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	323389 : 323393	CM	ion of MHC-I-pP-specific CD8+ T cells was possible in 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	323498 : 323501	CM	cell therapy. Therefore, MHC class-I bound phosphopep
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	323516 : 323531	CM	efore, MHC class-I bound phosphopeptides represent an attractive 
./___Corpus/Medline/xml/PMC5123381.xml	CTA	323877 : 323880	CM	 Cancer testis antigens (CTA) represent one type of t
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	324174 : 324182	CM	patocellular carcinomas. NY-ESO-1 has emerged as a promisi
./___Corpus/Medline/xml/PMC5123381.xml	CTA	324306 : 324309	CM	tcome [1, 2]. Reports on CTA expression in breast can
./___Corpus/Medline/xml/PMC5123381.xml	vitro	324701 : 324706	CM	alyses were performed in vitro to evaluate our in silic
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	324851 : 324855	CM	            We mined the TCGA and NCBI GEO repositorie
./___Corpus/Medline/xml/PMC5123381.xml	NCBI	324860 : 324864	CM	   We mined the TCGA and NCBI GEO repositories for CTA
./___Corpus/Medline/xml/PMC5123381.xml	GEO	324865 : 324868	CM	 mined the TCGA and NCBI GEO repositories for CTA exp
./___Corpus/Medline/xml/PMC5123381.xml	CTA	324886 : 324889	CM	CBI GEO repositories for CTA expression in TNBC and f
./___Corpus/Medline/xml/PMC5123381.xml	DKKL1	324954 : 324959	CM	s moderate expression of DKKL1, LDHC, MAGE-A3, PIWIL2, 
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	324961 : 324965	CM	ate expression of DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1,
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	324967 : 324974	CM	pression of DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1, PRAME, P
./___Corpus/Medline/xml/PMC5123381.xml	PIWIL2	324976 : 324982	CM	of DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1, PRAME, PRSS50 an
./___Corpus/Medline/xml/PMC5123381.xml	PLAC1	324984 : 324989	CM	, LDHC, MAGE-A3, PIWIL2, PLAC1, PRAME, PRSS50 and TSGA1
./___Corpus/Medline/xml/PMC5123381.xml	PRAME	324991 : 324996	CM	 MAGE-A3, PIWIL2, PLAC1, PRAME, PRSS50 and TSGA10 in ce
./___Corpus/Medline/xml/PMC5123381.xml	PRSS50	324998 : 325004	CM	3, PIWIL2, PLAC1, PRAME, PRSS50 and TSGA10 in cell lines
./___Corpus/Medline/xml/PMC5123381.xml	TSGA10	325009 : 325015	CM	PLAC1, PRAME, PRSS50 and TSGA10 in cell lines and tumor 
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	325066 : 325074	CM	pecimens. Interestingly, NY-ESO-1 expression was not found
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	325245 : 325249	CM	TNBC subtypes, confirmed LDHC, MAGE-A3 and PRAME to be
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	325251 : 325258	CM	ubtypes, confirmed LDHC, MAGE-A3 and PRAME to be good can
./___Corpus/Medline/xml/PMC5123381.xml	PRAME	325263 : 325268	CM	firmed LDHC, MAGE-A3 and PRAME to be good candidate tar
./___Corpus/Medline/xml/PMC5123381.xml	LDHC	325673 : 325677	CM	to determine the role of LDHC, PRAME and MAGE-A3 in TN
./___Corpus/Medline/xml/PMC5123381.xml	PRAME	325679 : 325684	CM	ermine the role of LDHC, PRAME and MAGE-A3 in TNBC deve
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	325689 : 325696	CM	 role of LDHC, PRAME and MAGE-A3 in TNBC development and 
./___Corpus/Medline/xml/PMC5123381.xml	LHDC	326027 : 326031	CM	ry findings suggest that LHDC, MAGE-A3 and PRAME could
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	326033 : 326040	CM	dings suggest that LHDC, MAGE-A3 and PRAME could be good 
./___Corpus/Medline/xml/PMC5123381.xml	PRAME	326045 : 326050	CM	t that LHDC, MAGE-A3 and PRAME could be good targets fo
./___Corpus/Medline/xml/PMC5123381.xml	H	326183 : 326184	CM	 1. Gnjatic S, Nishikawa H, Jungbluth AA et al.: NY
./___Corpus/Medline/xml/PMC5123381.xml	AA	326196 : 326198	CM	, Nishikawa H, Jungbluth AA et al.: NY-ESO-1: review
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	326207 : 326215	CM	 H, Jungbluth AA et al.: NY-ESO-1: review of an immunogeni
./___Corpus/Medline/xml/PMC5123381.xml	1–	326281 : 326283	CPR	 Adv Cancer Res 2006, 95:1–30.                      
./___Corpus/Medline/xml/PMC5123381.xml	460–	326565 : 326569	CPR	Eur J Cancer 2011, 47(3):460–469.                     
./___Corpus/Medline/xml/PMC5123381.xml	Wu	326637 : 326639	CM	3. Rooney MS, Shukla SA, Wu CJ, et al.: Molecular an
./___Corpus/Medline/xml/PMC5123381.xml	CJ	326640 : 326642	CM	Rooney MS, Shukla SA, Wu CJ, et al.: Molecular and g
./___Corpus/Medline/xml/PMC5123381.xml	48–	326764 : 326767	CPR	ity. Cell 2015, 160(1–2):48–61.                      
./___Corpus/Medline/xml/PMC5123381.xml	PROCLAIM	326893 : 326901	CM	 high dose IL-2 from the PROCLAIM registry                
./___Corpus/Medline/xml/PMC5123381.xml	KK	326957 : 326959	CM	                 Michael KK Wong1, Michael Morse2, D
./___Corpus/Medline/xml/PMC5123381.xml	Morse2	326975 : 326981	CM	ichael KK Wong1, Michael Morse2, David F McDermott3, Jos
./___Corpus/Medline/xml/PMC5123381.xml	P	327090 : 327091	CM	ua7, Tharak Rao7, Janice P Dutcher8                
./___Corpus/Medline/xml/PMC5123381.xml	HD	327166 : 327168	CM	         High dose IL-2 (HD IL-2) can provide durabl
./___Corpus/Medline/xml/PMC5123381.xml	PROCLAIMSM	327291 : 327301	CM	l cell carcinoma (mRCC). PROCLAIMSM [http://www.proclaimregi
./___Corpus/Medline/xml/PMC5123381.xml	HD	327474 : 327476	CM	nt experience sequencing HD IL-2 with immune checkpo
./___Corpus/Medline/xml/PMC5123381.xml	HD	327721 : 327723	CM	ved at least one dose of HD IL-2. Statistics and sur
./___Corpus/Medline/xml/PMC5123381.xml	mFU	327937 : 327940	CM	with a median follow-up (mFU) of 22 months. The overa
./___Corpus/Medline/xml/PMC5123381.xml	SD	328197 : 328199	CM	riencing stable disease (SD, n = 92) and progressive
./___Corpus/Medline/xml/PMC5123381.xml	PD	328234 : 328236	CM	and progressive disease (PD, n = 186) was 29.3 and 1
./___Corpus/Medline/xml/PMC5123381.xml	mRCC	328303 : 328307	CM	ctively. The mOS for all mRCC patients (n = 412) was N
./___Corpus/Medline/xml/PMC5123381.xml	SD	328468 : 328470	CM	n = 14), PR (n = 53), or SD (n = 146) mOS was NR whi
./___Corpus/Medline/xml/PMC5123381.xml	PD	328515 : 328517	CM	R while in patients with PD (n = 169), mOS was 17 mo
./___Corpus/Medline/xml/PMC5123381.xml	mOS	328529 : 328532	CM	ients with PD (n = 169), mOS was 17 months. In mM, tw
./___Corpus/Medline/xml/PMC5123381.xml	HD	328589 : 328591	CM	s were further analyzed; HD IL-2 followed by ipilimu
./___Corpus/Medline/xml/PMC5123381.xml	HD	328647 : 328649	CM	one (IL-2 then IPI), and HD IL-2 followed by PD-1/PD
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	328667 : 328671	CM	 and HD IL-2 followed by PD-1/PD-L1 inhibitors with or
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	328672 : 328677	CM	HD IL-2 followed by PD-1/PD-L1 inhibitors with or witho
./___Corpus/Medline/xml/PMC5123381.xml	IPI	328735 : 328738	CM	mumab (IL-2 then aPD-1 ± IPI, Table 2). In mRCC, surv
./___Corpus/Medline/xml/PMC5123381.xml	HD	328793 : 328795	CM	based on TT or ICB after HD IL-2 was analyzed (Table
./___Corpus/Medline/xml/PMC5123381.xml	HD	328856 : 328858	CM	al of patients receiving HD IL-2 as first line with 
./___Corpus/Medline/xml/PMC5123381.xml	IL-2	329010 : 329014	CM	analysis of the national IL-2 registry suggests that H
./___Corpus/Medline/xml/PMC5123381.xml	HD	329038 : 329040	CM	2 registry suggests that HD IL-2 continues to be a v
./___Corpus/Medline/xml/PMC5123381.xml	mRCC	329110 : 329114	CM	tion for eligible mM and mRCC patients. Attainment of 
./___Corpus/Medline/xml/PMC5123381.xml	SD	329139 : 329141	CM	 patients. Attainment of SD is clinically relevant a
./___Corpus/Medline/xml/PMC5123381.xml	HD	329184 : 329186	CM	evant and contributes to HD IL-2’s survival benefit.
./___Corpus/Medline/xml/PMC5123381.xml	HD	329241 : 329243	CM	ort for investigation of HD IL-2 in combination or s
./___Corpus/Medline/xml/PMC5123381.xml	ICB	329281 : 329284	CM	ination or sequence with ICB is warranted.           
./___Corpus/Medline/xml/PMC5123381.xml	Tetrahydrouridine	329522 : 329539	CM	                    P295 Tetrahydrouridine and decitabine combinati
./___Corpus/Medline/xml/PMC5123381.xml	p53	329571 : 329574	CM	citabine combination for p53-independent cytoreductio
./___Corpus/Medline/xml/PMC5123381.xml	Yogen	329665 : 329670	CM	              Kai Kang1, Yogen Saunthararajah2, Vamsidh
./___Corpus/Medline/xml/PMC5123381.xml	anti-	329916 : 329921	CPR	kpoint inhibitors (e.g., anti-PD-1). Unfortunately, the
./___Corpus/Medline/xml/PMC5123381.xml	DNMT1	330342 : 330347	CM	NA methyl-transferase 1 (DNMT1), and DNMT1 has been val
./___Corpus/Medline/xml/PMC5123381.xml	DNMT1	330354 : 330359	CM	ansferase 1 (DNMT1), and DNMT1 has been validated as a 
./___Corpus/Medline/xml/PMC5123381.xml	MYC	330580 : 330583	CM	that directly antagonize MYC, to produce p53-independ
./___Corpus/Medline/xml/PMC5123381.xml	p53	330596 : 330599	CM	tagonize MYC, to produce p53-independent cell cycle e
./___Corpus/Medline/xml/PMC5123381.xml	DNMT1	330684 : 330689	CM	ecitabine (Dec) depletes DNMT1 and can potentially tran
./___Corpus/Medline/xml/PMC5123381.xml	CDA	330824 : 330827	CM	combined an inhibitor of CDA, tetrahydrouridine (THU)
./___Corpus/Medline/xml/PMC5123381.xml	tetrahydrouridine	330829 : 330846	CM	ned an inhibitor of CDA, tetrahydrouridine (THU), with reduced dose
./___Corpus/Medline/xml/PMC5123381.xml	THU	330848 : 330851	CM	 CDA, tetrahydrouridine (THU), with reduced doses of 
./___Corpus/Medline/xml/PMC5123381.xml	DNMT1	330914 : 330919	CM	 objective that depletes DNMT1 while avoiding a high Cm
./___Corpus/Medline/xml/PMC5123381.xml	BL6	331034 : 331037	CM	                     C57/BL6 mice were inoculated wit
./___Corpus/Medline/xml/PMC5123381.xml	LL3	331064 : 331067	CM	ice were inoculated with LL3 cells by tail vein. Mice
./___Corpus/Medline/xml/PMC5123381.xml	PBS	331145 : 331148	CM	groups were treated with PBS, Dec (0.2 mg/kg s.c. 3X/
./___Corpus/Medline/xml/PMC5123381.xml	s.c	331165 : 331168	CM	with PBS, Dec (0.2 mg/kg s.c. 3X/wk), or THU-Dec (10/
./___Corpus/Medline/xml/PMC5123381.xml	s.c	331203 : 331206	CM	or THU-Dec (10/0.1 mg/kg s.c. 3X/wk). Peripheral bloo
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	331257 : 331261	CM	 was collected to detect MDSC and T lymphocytes. Survi
./___Corpus/Medline/xml/PMC5123381.xml	H&E	331370 : 331373	CM	mined by flow cytometry, H&E staining, Western blot a
./___Corpus/Medline/xml/PMC5123381.xml	33a	331567 : 331570	CM	ian survival days) (Fig. 33a). Tumor DNMT1 and MYC pr
./___Corpus/Medline/xml/PMC5123381.xml	DNMT1	331579 : 331584	CM	 days) (Fig. 33a). Tumor DNMT1 and MYC protein decrease
./___Corpus/Medline/xml/PMC5123381.xml	MYC	331589 : 331592	CM	g. 33a). Tumor DNMT1 and MYC protein decreased to a s
./___Corpus/Medline/xml/PMC5123381.xml	33b	331729 : 331732	CM	al increase in p27 (Fig. 33b). THU-Dec preserved peri
./___Corpus/Medline/xml/PMC5123381.xml	33c	331820 : 331823	CM	 lymphocyte counts (Fig. 33c), while substantially de
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	331872 : 331876	CM	ecreasing the numbers of MDSC (Fig. 33d). THU-Dec also
./___Corpus/Medline/xml/PMC5123381.xml	33d	331883 : 331886	CM	he numbers of MDSC (Fig. 33d). THU-Dec also significa
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A1	331972 : 331979	CM	herapy antigenic targets MAGE-A1 and MAGE-A3 to a greater
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A3	331984 : 331991	CM	enic targets MAGE-A1 and MAGE-A3 to a greater extent than
./___Corpus/Medline/xml/PMC5123381.xml	33e	332038 : 332041	CM	han Dec (p < 0.01) (Fig. 33e). THU-Dec treatment also
./___Corpus/Medline/xml/PMC5123381.xml	INFγ	332145 : 332149	CM	increased the release of INFγ and expression of PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	332168 : 332173	CM	f INFγ and expression of PD-L1 in tumor cells, compared
./___Corpus/Medline/xml/PMC5123381.xml	PBS	332215 : 332218	CM	compared to Dec alone or PBS (Fig. 33f).             
./___Corpus/Medline/xml/PMC5123381.xml	33f	332225 : 332228	CM	o Dec alone or PBS (Fig. 33f).                  Concl
./___Corpus/Medline/xml/PMC5123381.xml	THU	332293 : 332296	CM	             Addition of THU to Dec, to address pharm
./___Corpus/Medline/xml/PMC5123381.xml	p53	332392 : 332395	CM	mune-priming and induced p53-independent cell cycle e
./___Corpus/Medline/xml/PMC5123381.xml	Umbelliferon-α-D-glucopyranosyl-(2I	332683 : 332718	CM	                    P296 Umbelliferon-α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranosi
./___Corpus/Medline/xml/PMC5123381.xml	1II)-α-D-glucopyranoside	332721 : 332745	CM	α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranoside: a potential candidate a
./___Corpus/Medline/xml/PMC5123381.xml	Diethylnitrosamine	333082 : 333100	CM	rough various toxicants. Diethylnitrosamine (DEN) is a potent hepato
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333102 : 333105	CM	nts. Diethylnitrosamine (DEN) is a potent hepatocarci
./___Corpus/Medline/xml/PMC5123381.xml	hepatocarcinogen	333119 : 333135	CM	samine (DEN) is a potent hepatocarcinogen and hepatotoxin, which i
./___Corpus/Medline/xml/PMC5123381.xml	umbelliferone	333284 : 333297	CM	s are the rich source of umbelliferone, which are the secondary
./___Corpus/Medline/xml/PMC5123381.xml	umbelliferon-α-D-glucopyranosyl-(2I	333517 : 333552	CM	 exemplify the effect of umbelliferon-α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranosi
./___Corpus/Medline/xml/PMC5123381.xml	1II)-α-D-glucopyranoside	333555 : 333579	CM	α-D-glucopyranosyl-(2I → 1II)-α-D-glucopyranoside (UFD) on tissue protecti
./___Corpus/Medline/xml/PMC5123381.xml	UFD	333581 : 333584	CM	II)-α-D-glucopyranoside (UFD) on tissue protection, c
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333669 : 333672	CM	dative stress induced by DEN.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	DEN	333827 : 333830	CM	eritoneally injection of DEN (200 mg/kg). The rats we
./___Corpus/Medline/xml/PMC5123381.xml	lipid peroxides	333975 : 333990	CM	ker of oxidative stress (lipid peroxides, reduced glutathione and
./___Corpus/Medline/xml/PMC5123381.xml	glutathione	334000 : 334011	CM	lipid peroxides, reduced glutathione and conjugated dienes), 
./___Corpus/Medline/xml/PMC5123381.xml	dienes	334027 : 334033	CM	utathione and conjugated dienes), liver enzyme parameter
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334310 : 334313	CM	clearly demonstrated the UFD dose-dependently inhibit
./___Corpus/Medline/xml/PMC5123381.xml	kappa	334565 : 334570	CM	lation of nuclear factor-kappa B (NF-κB) signaling path
./___Corpus/Medline/xml/PMC5123381.xml	NF-κB	334574 : 334579	CM	 nuclear factor-kappa B (NF-κB) signaling pathway may c
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334679 : 334682	CM	mor inhibitory effect of UFD against experimental tox
./___Corpus/Medline/xml/PMC5123381.xml	UFD	334835 : 334838	CM	m the present study that UFD inhibits the DEN-initiat
./___Corpus/Medline/xml/PMC5123381.xml	DEN	334852 : 334855	CM	dy that UFD inhibits the DEN-initiated hepatocarcinog
./___Corpus/Medline/xml/PMC5123381.xml	anti-	334937 : 334942	CPR	matory cytokines via the anti-inflammatory mechanism.  
./___Corpus/Medline/xml/PMC5123381.xml	SHIATS	335116 : 335122	CM	ulty of Health Sciences, SHIATS.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	R	335190 : 335191	CM	        1. Kumar V, Khan R, Kazmi I, Afzal M, Al-Ab
./___Corpus/Medline/xml/PMC5123381.xml	Afzal	335202 : 335207	CM	umar V, Khan R, Kazmi I, Afzal M, Al-Abbasi FA, Anwar F
./___Corpus/Medline/xml/PMC5123381.xml	FA	335221 : 335223	CM	mi I, Afzal M, Al-Abbasi FA, Anwar F: Fixed dose com
./___Corpus/Medline/xml/PMC5123381.xml	loperamide	335265 : 335275	CM	dose combination therapy loperamide and niacin ameliorates d
./___Corpus/Medline/xml/PMC5123381.xml	diethylnitrosamine	335299 : 335317	CM	e and niacin ameliorates diethylnitrosamine-induced liver carcinogen
./___Corpus/Medline/xml/PMC5123381.xml	67996–	335391 : 335397	CPR	ts. RSC Advances 2015, 5:67996–68002.                   
./___Corpus/Medline/xml/PMC5123381.xml	β-D-galactopyranoside	335500 : 335521	CM	Abbasi FA: Umbelliferone β-D-galactopyranoside inhibits chemically indu
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	335661 : 335666	CM	mation: possible role of NF-kB. Toxicol Res 2015.      
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	335746 : 335756	CM	   P297 Novel and shared neoantigen derived from histone 3 v
./___Corpus/Medline/xml/PMC5123381.xml	histone	335770 : 335777	CM	 neoantigen derived from histone 3 variant H3.3 K27M muta
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	335788 : 335792	CM	d from histone 3 variant H3.3 K27M mutation – characte
./___Corpus/Medline/xml/PMC5123381.xml	K27M	335793 : 335797	CM	m histone 3 variant H3.3 K27M mutation – characterizat
./___Corpus/Medline/xml/PMC5123381.xml	Zinal	335947 : 335952	CM	                         Zinal Chheda1, Gary Kohanbash1
./___Corpus/Medline/xml/PMC5123381.xml	Okada1	335999 : 336005	CM	sh1, John Sidney2, Kaori Okada1, Shruti Shrivastav1, Die
./___Corpus/Medline/xml/PMC5123381.xml	Hou1	336152 : 336156	CM	Alessandro Sette2, Yafei Hou1, Hideho Okada1          
./___Corpus/Medline/xml/PMC5123381.xml	histone	336486 : 336493	CM	 replication-independent histone 3 variant H3.3 [1]. Appr
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336504 : 336508	CM	endent histone 3 variant H3.3 [1]. Approximately 70 % 
./___Corpus/Medline/xml/PMC5123381.xml	DIPG	336561 : 336565	CM	midline gliomas, such as DIPG, harbor the amino-acid s
./___Corpus/Medline/xml/PMC5123381.xml	amino-acid	336578 : 336588	CM	such as DIPG, harbor the amino-acid substitution from lysine
./___Corpus/Medline/xml/PMC5123381.xml	lysine	336607 : 336613	CM	o-acid substitution from lysine (K) to methionine (M) at
./___Corpus/Medline/xml/PMC5123381.xml	K	336615 : 336616	CM	ubstitution from lysine (K) to methionine (M) at th
./___Corpus/Medline/xml/PMC5123381.xml	methionine	336621 : 336631	CM	ution from lysine (K) to methionine (M) at the position 27 o
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336658 : 336662	CM	M) at the position 27 of H3.3 (the H3.3 K27M mutation 
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336668 : 336672	CM	position 27 of H3.3 (the H3.3 K27M mutation hereafter)
./___Corpus/Medline/xml/PMC5123381.xml	K27M	336673 : 336677	CM	ion 27 of H3.3 (the H3.3 K27M mutation hereafter). The
./___Corpus/Medline/xml/PMC5123381.xml	K27M	336703 : 336707	CM	mutation hereafter). The K27M mutation in DIPG is univ
./___Corpus/Medline/xml/PMC5123381.xml	DIPG	336720 : 336724	CM	r). The K27M mutation in DIPG is universally associate
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336813 : 336817	CM	atients with non-mutated H3.3.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	336890 : 336894	CM	We evaluated whether the H3.3 K27M mutation can induce
./___Corpus/Medline/xml/PMC5123381.xml	K27M	336895 : 336899	CM	aluated whether the H3.3 K27M mutation can induce spec
./___Corpus/Medline/xml/PMC5123381.xml	CTL	336953 : 336956	CM	 cytotoxic T lymphocyte (CTL) responses in human leuk
./___Corpus/Medline/xml/PMC5123381.xml	(HLA)-A2+	336995 : 337004	CM	 human leukocyte antigen (HLA)-A2+ CD8+ T cells as a neoant
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	337005 : 337009	CM	kocyte antigen (HLA)-A2+ CD8+ T cells as a neoantigen 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	337023 : 337033	CM	A)-A2+ CD8+ T cells as a neoantigen epitope. Competitive bin
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2	337148 : 337154	CM	of synthetic peptides to HLA-A2. α- and β-chain cDNAs fr
./___Corpus/Medline/xml/PMC5123381.xml	α-	337157 : 337159	CPR	tic peptides to HLA-A2. α- and β-chain cDNAs from a 
./___Corpus/Medline/xml/PMC5123381.xml	β-	337163 : 337165	CPR	ptides to HLA-A2. α- and β-chain cDNAs from a high-a
./___Corpus/Medline/xml/PMC5123381.xml	cDNAs	337171 : 337176	CM	o HLA-A2. α- and β-chain cDNAs from a high-affinity T c
./___Corpus/Medline/xml/PMC5123381.xml	cDNA	337252 : 337256	CM	oned by amplification of cDNA Ends–PCR (RACE-PCR).    
./___Corpus/Medline/xml/PMC5123381.xml	PCR	337262 : 337265	CM	plification of cDNA Ends–PCR (RACE-PCR).             
./___Corpus/Medline/xml/PMC5123381.xml	vitro	337327 : 337332	CM	                      In vitro stimulation of HLA-A2+ d
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2+	337348 : 337355	CM	 In vitro stimulation of HLA-A2+ donor-derived CD8+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	337370 : 337374	CM	of HLA-A2+ donor-derived CD8+ T cells with a synthetic
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337425 : 337429	CM	peptide encompassing the H3.3 K27M mutation (the H3.3.
./___Corpus/Medline/xml/PMC5123381.xml	K27M	337430 : 337434	CM	de encompassing the H3.3 K27M mutation (the H3.3.K27M 
./___Corpus/Medline/xml/PMC5123381.xml	H3.3.K27M	337449 : 337458	CM	 H3.3 K27M mutation (the H3.3.K27M epitope hereafter) induc
./___Corpus/Medline/xml/PMC5123381.xml	CTL	337486 : 337489	CM	itope hereafter) induced CTL lines which recognized n
./___Corpus/Medline/xml/PMC5123381.xml	H3.3.K27M	337536 : 337545	CM	d not only the synthetic H3.3.K27M epitope peptide loaded o
./___Corpus/Medline/xml/PMC5123381.xml	T2	337572 : 337574	CM	pitope peptide loaded on T2 cells but also lysed HLA
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2+	337596 : 337603	CM	 T2 cells but also lysed HLA-A2+ DIPG cell lines which en
./___Corpus/Medline/xml/PMC5123381.xml	DIPG	337604 : 337608	CM	s but also lysed HLA-A2+ DIPG cell lines which endogen
./___Corpus/Medline/xml/PMC5123381.xml	H3.3.K27M	337650 : 337659	CM	 endogenously harbor the H3.3.K27M mutation. On the other h
./___Corpus/Medline/xml/PMC5123381.xml	CTL	337689 : 337692	CM	tion. On the other hand, CTL lines did not react to H
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2+	337716 : 337723	CM	L lines did not react to HLA-A2+, H3.3 K27M mutation-nega
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337725 : 337729	CM	id not react to HLA-A2+, H3.3 K27M mutation-negative c
./___Corpus/Medline/xml/PMC5123381.xml	K27M	337730 : 337734	CM	t react to HLA-A2+, H3.3 K27M mutation-negative cells 
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	337779 : 337783	CM	ells or HLA-A2-negative, H3.3 K27M mutation + cells. T
./___Corpus/Medline/xml/PMC5123381.xml	K27M	337784 : 337788	CM	or HLA-A2-negative, H3.3 K27M mutation + cells. The H3
./___Corpus/Medline/xml/PMC5123381.xml	H3.3.K27M	337811 : 337820	CM	7M mutation + cells. The H3.3.K27M epitope peptide, but not
./___Corpus/Medline/xml/PMC5123381.xml	Kd	337907 : 337909	CM	d an excellent affinity (Kd 151 nM) to HLA-A2. Furth
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2	337921 : 337927	CM	 affinity (Kd 151 nM) to HLA-A2. Furthermore, CTL clones
./___Corpus/Medline/xml/PMC5123381.xml	CTL	337942 : 337945	CM	 to HLA-A2. Furthermore, CTL clones with high and spe
./___Corpus/Medline/xml/PMC5123381.xml	α-	338116 : 338118	CPR	 been created to encode α- and β-chain cDNAs from a 
./___Corpus/Medline/xml/PMC5123381.xml	β-	338122 : 338124	CPR	created to encode α- and β-chain cDNAs from a high-a
./___Corpus/Medline/xml/PMC5123381.xml	cDNAs	338130 : 338135	CM	to encode α- and β-chain cDNAs from a high-affinity TCR
./___Corpus/Medline/xml/PMC5123381.xml	alanine	338337 : 338344	CM	of clinical application, alanine scanning demonstrated th
./___Corpus/Medline/xml/PMC5123381.xml	amino-acid	338380 : 338390	CM	emonstrated that the key amino-acid sequence motif in the ep
./___Corpus/Medline/xml/PMC5123381.xml	NIH	338789 : 338792	CM	tudy is supported by the NIH/NINDS (1R01NS096954), V 
./___Corpus/Medline/xml/PMC5123381.xml	NINDS	338793 : 338798	CM	 is supported by the NIH/NINDS (1R01NS096954), V Founda
./___Corpus/Medline/xml/PMC5123381.xml	1R01NS096954	338800 : 338812	CM	ported by the NIH/NINDS (1R01NS096954), V Foundation and Parke
./___Corpus/Medline/xml/PMC5123381.xml	K	338995 : 338996	CM	Jones DT, Pfaff E, Jacob K, et al.: Driver mutation
./___Corpus/Medline/xml/PMC5123381.xml	histone	339026 : 339033	CM	al.: Driver mutations in histone H3.3 and chromatin remod
./___Corpus/Medline/xml/PMC5123381.xml	H3.3	339034 : 339038	CM	ver mutations in histone H3.3 and chromatin remodellin
./___Corpus/Medline/xml/PMC5123381.xml	chromatin	339043 : 339052	CM	ions in histone H3.3 and chromatin remodelling genes in pae
./___Corpus/Medline/xml/PMC5123381.xml	226–	339116 : 339120	CPR	astoma. Nature 2012, 482:226–31.                      
./___Corpus/Medline/xml/PMC5123381.xml	fucosylation	339171 : 339183	RN	                P298 The fucosylation inhibitor 2-fluorofucose
./___Corpus/Medline/xml/PMC5123381.xml	2-fluorofucose	339194 : 339208	CM	e fucosylation inhibitor 2-fluorofucose exhibits anti-tumor acti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	339218 : 339223	CPR	 2-fluorofucose exhibits anti-tumor activity and modula
./___Corpus/Medline/xml/PMC5123381.xml	vitro	339281 : 339286	CM	ne cell activity both in vitro and in vivo             
./___Corpus/Medline/xml/PMC5123381.xml	Che-Leung	339385 : 339394	CM	g Zeng, Vincent FS Shih, Che-Leung Law, Peter D Senter, Shy
./___Corpus/Medline/xml/PMC5123381.xml	2-Fluorofucose	339497 : 339511	CM	und                      2-Fluorofucose (2FF) is a small molecul
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339513 : 339516	CM	         2-Fluorofucose (2FF) is a small molecule inh
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein	339551 : 339563	CM	ll molecule inhibitor of glycoprotein fucosylation. 2FF-mediat
./___Corpus/Medline/xml/PMC5123381.xml	fucosylation	339564 : 339576	RN	nhibitor of glycoprotein fucosylation. 2FF-mediated afucosylat
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339578 : 339581	CM	ycoprotein fucosylation. 2FF-mediated afucosylation o
./___Corpus/Medline/xml/PMC5123381.xml	afucosylation	339591 : 339604	RN	cosylation. 2FF-mediated afucosylation of cancer cells results 
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339695 : 339698	CM	re, T cells treated with 2FF during expansion show in
./___Corpus/Medline/xml/PMC5123381.xml	DCs	339815 : 339818	CM	ologous dendritic cells (DCs), and reduced regulatory
./___Corpus/Medline/xml/PMC5123381.xml	2FF	339909 : 339912	CM	 of immune activity [1]. 2FF has shown promising in v
./___Corpus/Medline/xml/PMC5123381.xml	anti-	339941 : 339946	CPR	 shown promising in vivo anti-tumor activity, both alon
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	340006 : 340013	CM	ombination with a cancer vaccine, which appears to be dep
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340084 : 340087	CM	 activity. Specifically, 2FF elicits growth delay in 
./___Corpus/Medline/xml/PMC5123381.xml	murine	340142 : 340148	CM	enerally refractory 4 T1 murine breast cancer model, whe
./___Corpus/Medline/xml/PMC5123381.xml	NSG	340244 : 340247	CM	s run in immunodeficient NSG mice.                  M
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340356 : 340359	CM	e modulatory activity of 2FF, tumor infiltrating immu
./___Corpus/Medline/xml/PMC5123381.xml	CMV	340509 : 340512	CM	tigen recall function of CMV reactive T cells expande
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340544 : 340547	CM	ve T cells expanded with 2FF was assessed by culturin
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340597 : 340600	CM	g T cells and autologous DCs with CMV peptides and mo
./___Corpus/Medline/xml/PMC5123381.xml	CMV	340606 : 340609	CM	 and autologous DCs with CMV peptides and monitoring 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	340634 : 340638	CM	 peptides and monitoring IFNγ and IL-12p70 production.
./___Corpus/Medline/xml/PMC5123381.xml	IL-12p70	340643 : 340651	CM	 and monitoring IFNγ and IL-12p70 production. We also used
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340733 : 340736	CM	ombinatorial activity of 2FF treated T cells with ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	340758 : 340763	CPR	2FF treated T cells with anti-PD-1 antibodies.         
./___Corpus/Medline/xml/PMC5123381.xml	2FF	340826 : 340829	CM	lts                      2FF treatment in the 4 T1 mu
./___Corpus/Medline/xml/PMC5123381.xml	murine	340852 : 340858	CM	FF treatment in the 4 T1 murine model reduced the number
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340930 : 340933	CM	 and increased activated DCs. These DCs showed a mild
./___Corpus/Medline/xml/PMC5123381.xml	DCs	340941 : 340944	CM	sed activated DCs. These DCs showed a mild increase i
./___Corpus/Medline/xml/PMC5123381.xml	CD83	340994 : 340998	CM	n the maturation markers CD83, CD86, and MHCII. The ef
./___Corpus/Medline/xml/PMC5123381.xml	CD86	341000 : 341004	CM	maturation markers CD83, CD86, and MHCII. The effects 
./___Corpus/Medline/xml/PMC5123381.xml	MHCII	341010 : 341015	CM	 markers CD83, CD86, and MHCII. The effects observed in
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341066 : 341071	CM	vivo recapitulate our in vitro observations with human 
./___Corpus/Medline/xml/PMC5123381.xml	DC	341115 : 341117	CM	human T cells and T cell/DC co-cultures, and demonst
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341166 : 341169	CM	trate the translation of 2FF immune modulatory activi
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341205 : 341210	CM	ulatory activity from in vitro to in vivo. Since 2FF re
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341229 : 341232	CM	 vitro to in vivo. Since 2FF reduces the regulatory T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341295 : 341300	CPR	ion, an effect seen with anti-CTLA-4 antibodies, we pos
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	341338 : 341342	CM	dies, we postulated that PD-1 checkpoint blockade anti
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341388 : 341391	CM	antibodies would enhance 2FF-treated T cell function.
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341438 : 341441	CM	on. T cells treated with 2FF during expansion showed 
./___Corpus/Medline/xml/PMC5123381.xml	CMV	341476 : 341479	CM	pansion showed increased CMV antigen specific respons
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341545 : 341548	CM	ures that contained both 2FF-treated T cells and anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341569 : 341574	CPR	 2FF-treated T cells and anti-PD-1 antibody showed incr
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	341629 : 341633	CM	 levels of production of IFNγ and IL-12p70 above those
./___Corpus/Medline/xml/PMC5123381.xml	IL-12p70	341638 : 341646	CM	f production of IFNγ and IL-12p70 above those seen with ei
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341738 : 341741	CM	t that co-treatment with 2FF and anti-PD-1 antibody c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	341746 : 341751	CPR	o-treatment with 2FF and anti-PD-1 antibody can lead to
./___Corpus/Medline/xml/PMC5123381.xml	vitro	341825 : 341830	CM	fic T cell activation in vitro.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	2FF	341908 : 341911	CM	verall, we conclude that 2FF may promote a more activ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	342022 : 342027	CPR	ty for an effective host anti-tumor immune response alo
./___Corpus/Medline/xml/PMC5123381.xml	2FF	342150 : 342153	CM	linical trial evaluating 2FF in advanced solid tumors
./___Corpus/Medline/xml/PMC5123381.xml	JJ	342249 : 342251	CM	                1. Field JJ, et al.: Understanding t
./___Corpus/Medline/xml/PMC5123381.xml	2FF	342292 : 342295	CM	tanding the mechanism of 2FF-induced immune modulatio
./___Corpus/Medline/xml/PMC5123381.xml	Phosphopeptides	342416 : 342431	CM	5.                  P299 Phosphopeptides as novel tumor antigens 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	342785 : 342788	CM	ts in colorectal cancer (CRC). Memory CD8+ T cell inf
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	342798 : 342802	CM	tal cancer (CRC). Memory CD8+ T cell infiltration is n
./___Corpus/Medline/xml/PMC5123381.xml	CRC	342880 : 342883	CM	 prognostic indicator in CRC, and it is known that th
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343131 : 343134	CM	se of immunotherapies in CRC, despite their efficacy 
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343192 : 343207	CM	 cancer types. Recently, phosphopeptides have emerged as strong c
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	343341 : 343356	RN	eads to aberrant protein phosphorylation. Here, we identify CRC-a
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343376 : 343379	CM	ation. Here, we identify CRC-associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343391 : 343406	CM	 identify CRC-associated phosphopeptides and assess the tumor-res
./___Corpus/Medline/xml/PMC5123381.xml	CRC	343599 : 343602	CM	 and healthy tissue from CRC patients, to identify tu
./___Corpus/Medline/xml/PMC5123381.xml	MHC	343640 : 343643	CM	 identify tumor-specific MHC class I associated phosp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343663 : 343678	CM	c MHC class I associated phosphopeptides. Phosphopeptides were en
./___Corpus/Medline/xml/PMC5123381.xml	Phosphopeptides	343680 : 343695	CM	ociated phosphopeptides. Phosphopeptides were enriched using immo
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	343886 : 343901	CM	d their responses to the phosphopeptides assessed using multiplex
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	343943 : 343951	CM	ultiplexed intracellular cytokine staining. Cytolytic acti
./___Corpus/Medline/xml/PMC5123381.xml	CD107a	344034 : 344040	CM	 surface mobilization of CD107a. Healthy donor responses
./___Corpus/Medline/xml/PMC5123381.xml	europium	344144 : 344152	CM	onality assessed using a europium release killing assay.  
./___Corpus/Medline/xml/PMC5123381.xml	MHC	344262 : 344265	CM	ied 133 tumor-associated MHC class I phosphopeptides 
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344274 : 344289	CM	r-associated MHC class I phosphopeptides from CRC, with different
./___Corpus/Medline/xml/PMC5123381.xml	CRC	344295 : 344298	CM	s I phosphopeptides from CRC, with different HLA-rest
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344382 : 344397	CM	3.1 times more different phosphopeptides identified on primary ca
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	344628 : 344636	CM	hrough analysis of TIL’s cytokine responses to these phosp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344656 : 344671	CM	okine responses to these phosphopeptides, we have established tha
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	344875 : 344890	CM	led in response to these phosphopeptides. Up to 0.7 % of expanded
./___Corpus/Medline/xml/PMC5123381.xml	TILs	344916 : 344920	CM	 Up to 0.7 % of expanded TILs targeted each phosphopep
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptide	344935 : 344949	CM	anded TILs targeted each phosphopeptide, comparable with respons
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345036 : 345051	CM	o these tumor-associated phosphopeptides represents a biological 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345245 : 345248	CM	 to many (58 %) of these CRC-associated phosphopeptid
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345260 : 345275	CM	 of these CRC-associated phosphopeptides. These phosphopeptide-sp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptide	345283 : 345297	CM	d phosphopeptides. These phosphopeptide-specific T cells are rea
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345353 : 345356	CM	xpanded ex vivo and kill CRC cell lines. Thus, MHC cl
./___Corpus/Medline/xml/PMC5123381.xml	MHC	345375 : 345378	CM	ll CRC cell lines. Thus, MHC class I associated phosp
./___Corpus/Medline/xml/PMC5123381.xml	phosphopeptides	345398 : 345413	CM	, MHC class I associated phosphopeptides are ideal immunotherapeu
./___Corpus/Medline/xml/PMC5123381.xml	MHC	345582 : 345585	CM	n of this novel class of MHC class I antigens in CRC 
./___Corpus/Medline/xml/PMC5123381.xml	CRC	345606 : 345609	CM	 MHC class I antigens in CRC offers new hope for the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	345774 : 345779	CPR	esponse to atezolizumab (anti-PD-L1), with sloughing of
./___Corpus/Medline/xml/PMC5123381.xml	anti-	346077 : 346082	CPR	bidity. Atezolizumab, an anti-PD-L1 checkpoint inhibito
./___Corpus/Medline/xml/PMC5123381.xml	platinum	346191 : 346199	CM	ter progression on/after platinum-containing chemotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	April	346556 : 346561	CM	ive UC of the bladder in April 2013. Patient completed 
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	346612 : 346623	CM	 cycles of ‘neoadjuvant’ gemcitabine/cisplatin but had progre
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	346624 : 346633	CM	neoadjuvant’ gemcitabine/cisplatin but had progression, he 
./___Corpus/Medline/xml/PMC5123381.xml	docetaxel	346684 : 346693	CM	hen received 6 cycles of docetaxel & investigational agent 
./___Corpus/Medline/xml/PMC5123381.xml	platinum	346950 : 346958	CM	200 mg every 21 days, in platinum-pretreated advanced UC. 
./___Corpus/Medline/xml/PMC5123381.xml	UC	346979 : 346981	CM	inum-pretreated advanced UC. Screening CT showed the
./___Corpus/Medline/xml/PMC5123381.xml	CT	346993 : 346995	CM	d advanced UC. Screening CT showed the bladder lumen
./___Corpus/Medline/xml/PMC5123381.xml	ECOG	347257 : 347261	CM	overall quality of life (ECOG PS 1, normal GFR, Hgb 10
./___Corpus/Medline/xml/PMC5123381.xml	PS	347262 : 347264	CM	ll quality of life (ECOG PS 1, normal GFR, Hgb 10.2 
./___Corpus/Medline/xml/PMC5123381.xml	GFR	347275 : 347278	CM	 life (ECOG PS 1, normal GFR, Hgb 10.2 on Cycle 1 Day
./___Corpus/Medline/xml/PMC5123381.xml	1(C1D1)	347304 : 347311	CM	 Hgb 10.2 on Cycle 1 Day 1(C1D1). Tumor tissue analysis s
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	347347 : 347352	CM	sue analysis showed high PD-L1 expression in both tumor
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	347433 : 347437	CM	) and tumor cells (TC2), TCGA subtype IV (Basal), and 
./___Corpus/Medline/xml/PMC5123381.xml	MB	347498 : 347500	CM	tional load of 18.02 Mut/MB (compared to IMvigor210,
./___Corpus/Medline/xml/PMC5123381.xml	MB	347554 : 347556	CM	ort 2 median of 8.11 Mut/MB). At C2D1 visit, he alre
./___Corpus/Medline/xml/PMC5123381.xml	C2D1	347562 : 347566	CM	dian of 8.11 Mut/MB). At C2D1 visit, he already had ma
./___Corpus/Medline/xml/PMC5123381.xml	C3D1	347972 : 347976	CM	hrough urethra. Scans at C3D1 demonstrated great respo
./___Corpus/Medline/xml/PMC5123381.xml	C10D1	348089 : 348094	CM	uality of life. Scans at C10D1 showed that the bladder 
./___Corpus/Medline/xml/PMC5123381.xml	ECOG	348444 : 348448	CM	nies urinary issues, has ECOG PS 0, with durable compl
./___Corpus/Medline/xml/PMC5123381.xml	PS	348449 : 348451	CM	urinary issues, has ECOG PS 0, with durable complete
./___Corpus/Medline/xml/PMC5123381.xml	platinum	348611 : 348619	CM	le responses in advanced platinum-resistant urothelial can
./___Corpus/Medline/xml/PMC5123381.xml	anti-	348977 : 348982	CPR	inical immunological and anti-tumor data of the new ena
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	349017 : 349021	CM	 of the new enantiomeric TLR9 agonist EnanDIM         
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	349168 : 349172	CM	und                      TLR9 agonists have shown anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	349193 : 349198	CPR	TLR9 agonists have shown anti-tumor effects, modulating
./___Corpus/Medline/xml/PMC5123381.xml	non-methylated	349329 : 349343	RN	DNA molecules containing non-methylated CG-motifs for TLR9 activ
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	349358 : 349362	CM	methylated CG-motifs for TLR9 activation have been est
./___Corpus/Medline/xml/PMC5123381.xml	phosphodiester	349521 : 349535	CM	valently-closed, natural phosphodiester (PO) backbone and ii) si
./___Corpus/Medline/xml/PMC5123381.xml	PO	349537 : 349539	CM	 natural phosphodiester (PO) backbone and ii) single
./___Corpus/Medline/xml/PMC5123381.xml	ii	349554 : 349556	CM	iester (PO) backbone and ii) single-stranded, oligod
./___Corpus/Medline/xml/PMC5123381.xml	CpG-ODN	349598 : 349605	CM	, oligodeoxynucleotides (CpG-ODN) in most cases chemicall
./___Corpus/Medline/xml/PMC5123381.xml	phosphorothioates	349646 : 349663	CM	chemically-stabilized by phosphorothioates (PTO) in their phosphate
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349665 : 349668	CM	ed by phosphorothioates (PTO) in their phosphate moie
./___Corpus/Medline/xml/PMC5123381.xml	phosphate	349679 : 349688	CM	othioates (PTO) in their phosphate moieties. However, PTO m
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349708 : 349711	CM	phate moieties. However, PTO modifications produce of
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	349894 : 349898	CM	       A novel family of TLR9 agonists avoids the off-
./___Corpus/Medline/xml/PMC5123381.xml	PTO	349941 : 349944	CM	he off-target effects of PTO-modified CpG-ODN: linear
./___Corpus/Medline/xml/PMC5123381.xml	CpG-ODN	349954 : 349961	CM	 effects of PTO-modified CpG-ODN: linear single-stranded 
./___Corpus/Medline/xml/PMC5123381.xml	ODN	349986 : 349989	CM	: linear single-stranded ODN synthesized using L-deox
./___Corpus/Medline/xml/PMC5123381.xml	L-deoxyribonucleotides	350008 : 350030	CM	ed ODN synthesized using L-deoxyribonucleotides (natural enantiomers of 
./___Corpus/Medline/xml/PMC5123381.xml	D-deoxyribonucleotides	350055 : 350077	CM	 (natural enantiomers of D-deoxyribonucleotides) at their 3’-ends - Enan
./___Corpus/Medline/xml/PMC5123381.xml	deoxyribose	350129 : 350140	CM	M®. The vast majority of deoxyribose in organisms consists of
./___Corpus/Medline/xml/PMC5123381.xml	D-deoxyribose	350166 : 350179	CM	in organisms consists of D-deoxyribose, thus co-evolved nucleas
./___Corpus/Medline/xml/PMC5123381.xml	L-deoxyribose	350221 : 350234	CM	 nucleases are blind for L-deoxyribose - thereby leaving L-prot
./___Corpus/Medline/xml/PMC5123381.xml	L-	350254 : 350256	CPR	ibose - thereby leaving L-protected ODN intact. We s
./___Corpus/Medline/xml/PMC5123381.xml	ODN	350265 : 350268	CM	reby leaving L-protected ODN intact. We selected nucl
./___Corpus/Medline/xml/PMC5123381.xml	nucleotide	350289 : 350299	CM	 ODN intact. We selected nucleotide sequences of EnanDIM® us
./___Corpus/Medline/xml/PMC5123381.xml	IFN-alpha	350346 : 350355	CM	 using high secretion of IFN-alpha and IP-10 from human per
./___Corpus/Medline/xml/PMC5123381.xml	IP-10	350360 : 350365	CM	cretion of IFN-alpha and IP-10 from human peripheral bl
./___Corpus/Medline/xml/PMC5123381.xml	MFD	350460 : 350463	CM	a maximum feasible dose (MFD) approach: Mice received
./___Corpus/Medline/xml/PMC5123381.xml	anti-	350660 : 350665	CPR	 used to investigate the anti-tumor effect of EnanDIM® 
./___Corpus/Medline/xml/PMC5123381.xml	CT26	350695 : 350699	CM	 effect of EnanDIM® in a CT26 tumor model.            
./___Corpus/Medline/xml/PMC5123381.xml	pDC	350880 : 350883	CM	 monocytes, NK cells and pDC) and their prominent ind
./___Corpus/Medline/xml/PMC5123381.xml	IFN-alpha	350918 : 350927	CM	r prominent induction of IFN-alpha and IP-10 secretion in v
./___Corpus/Medline/xml/PMC5123381.xml	IP-10	350932 : 350937	CM	duction of IFN-alpha and IP-10 secretion in vitro. Enan
./___Corpus/Medline/xml/PMC5123381.xml	vitro	350951 : 350956	CM	a and IP-10 secretion in vitro. EnanDIM744, an EnanDIM5
./___Corpus/Medline/xml/PMC5123381.xml	L-nucleotide	351015 : 351027	CM	t with additional 5’-end L-nucleotide protection, was also use
./___Corpus/Medline/xml/PMC5123381.xml	MFD	351058 : 351061	CM	ction, was also used for MFD studies. Safety assessme
./___Corpus/Medline/xml/PMC5123381.xml	IP-10	351326 : 351331	CM	se-dependent increase of IP-10 levels in serum was obse
./___Corpus/Medline/xml/PMC5123381.xml	L-nucleotides	351440 : 351453	CM	15 days, confirming that L-nucleotides in EnanDIM® do not alter
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	351516 : 351520	CM	profile known from other TLR9 agonists. First data fro
./___Corpus/Medline/xml/PMC5123381.xml	CT26	351551 : 351555	CM	sts. First data from the CT26 tumor model showed that 
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	351719 : 351723	CM	nanDIM®, a new family of TLR9 agonists, broadly activa
./___Corpus/Medline/xml/PMC5123381.xml	murine	351899 : 351905	CM	growth was observed in a murine CT26 tumor model. Theref
./___Corpus/Medline/xml/PMC5123381.xml	CT26	351906 : 351910	CM	was observed in a murine CT26 tumor model. Therefore E
./___Corpus/Medline/xml/PMC5123381.xml	MHC	352125 : 352128	CM	302 Loading of recycling MHC class I molecules with a
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	352205 : 352209	CM	tides leads to efficient CD8+ T cell-mediated tumor ce
./___Corpus/Medline/xml/PMC5123381.xml	P	352269 : 352270	CM	                  Julian P Sefrin, Lars Hillringhau
./___Corpus/Medline/xml/PMC5123381.xml	Yu	352449 : 352451	CM	immunotherapy. Recently, Yu et al.[1] efficiently de
./___Corpus/Medline/xml/PMC5123381.xml	EBV	352504 : 352507	CM	ered Epstein-Barr virus (EBV) antigens to lymphoma ce
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	352603 : 352607	CM	ever, they only obtained CD4+ T cell activation, as ex
./___Corpus/Medline/xml/PMC5123381.xml	MHC	352671 : 352674	CM	duced proteins enter the MHC class II antigen process
./___Corpus/Medline/xml/PMC5123381.xml	ATPPs	352776 : 352781	CM	thogen-derived peptides (ATPPs), which deliver and rele
./___Corpus/Medline/xml/PMC5123381.xml	MHC	352832 : 352835	CM	se mature, virus-derived MHC class I peptides in an e
./___Corpus/Medline/xml/PMC5123381.xml	MHC	352887 : 352890	CM	osomal compartment where MHC is loaded with peptide, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	352934 : 352938	CM	tide, thereby triggering CD8+ T cell activation and tu
./___Corpus/Medline/xml/PMC5123381.xml	ATPPs	353072 : 353077	CM	-armed antibodies called ATPPs, by coupling virus-deriv
./___Corpus/Medline/xml/PMC5123381.xml	MHC	353105 : 353108	CM	y coupling virus-derived MHC class I peptides to tumo
./___Corpus/Medline/xml/PMC5123381.xml	lactate	353374 : 353381	CM	n of interferon-gamma or lactate dehydrogenase (LDH) rele
./___Corpus/Medline/xml/PMC5123381.xml	dehydrogenase	353382 : 353395	CM	erferon-gamma or lactate dehydrogenase (LDH) release. Human PBM
./___Corpus/Medline/xml/PMC5123381.xml	LDH	353397 : 353400	CM	r lactate dehydrogenase (LDH) release. Human PBMCs or
./___Corpus/Medline/xml/PMC5123381.xml	vitro	353495 : 353500	CM	as effector cells for in vitro functionality assays and
./___Corpus/Medline/xml/PMC5123381.xml	MDA-MB231	353546 : 353555	CM	 and in vivo efficacy in MDA-MB231 breast cancer subcutaneo
./___Corpus/Medline/xml/PMC5123381.xml	ATPP	353679 : 353683	CM	ging revealed that after ATPP binding to the antigen a
./___Corpus/Medline/xml/PMC5123381.xml	MHC	353825 : 353828	CM	nd loaded onto recycling MHC class I complexes. MHC-p
./___Corpus/Medline/xml/PMC5123381.xml	MHC	353848 : 353851	CM	g MHC class I complexes. MHC-peptide complexes are su
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	353966 : 353970	CM	tion of peptide-specific CD8+ T cells. Treatment of va
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354066 : 354070	CM	tion of peptide-specific CD8+ memory T cells and subse
./___Corpus/Medline/xml/PMC5123381.xml	lysis	354101 : 354106	RN	y T cells and subsequent lysis of target cells in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	354126 : 354131	CM	lysis of target cells in vitro. Similar results were ob
./___Corpus/Medline/xml/PMC5123381.xml	7200-fold	354278 : 354287	CM	ictions. Intriguingly, a 7200-fold higher amount of free pe
./___Corpus/Medline/xml/PMC5123381.xml	ATPP	354325 : 354329	CM	t of free peptide versus ATPP was required for compara
./___Corpus/Medline/xml/PMC5123381.xml	MHC	354446 : 354449	CM	e antigen processing for MHC class I binding revealed
./___Corpus/Medline/xml/PMC5123381.xml	MHC	354484 : 354487	CM	inding revealed that the MHC class I antigen processi
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	354555 : 354560	CM	t involved. Importantly, PBMCs, where only 0.5 % of CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354582 : 354586	CM	MCs, where only 0.5 % of CD8+ T cells were antigen spe
./___Corpus/Medline/xml/PMC5123381.xml	lysis	354650 : 354655	RN	d significant tumor cell lysis at an E:T cell ratio of 
./___Corpus/Medline/xml/PMC5123381.xml	ATPP	354686 : 354690	CM	 E:T cell ratio of 1:10. ATPP activated peptide specif
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	354718 : 354722	CM	tivated peptide specific CD8+ T cells induced tumor gr
./___Corpus/Medline/xml/PMC5123381.xml	ATPP	354853 : 354857	CM	sults demonstrate potent ATPP-mediated anti-tumor effi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	354867 : 354872	CPR	ate potent ATPP-mediated anti-tumor efficacy, independe
./___Corpus/Medline/xml/PMC5123381.xml	MHC	354909 : 354912	CM	cy, independently of the MHC class I antigen processi
./___Corpus/Medline/xml/PMC5123381.xml	X	355122 : 355123	CM	                   1. Yu X, et al.: Antigen-armed a
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	355223 : 355227	CM	ctivate antigen-specific CD4+ T cells. Blood 2015, 125
./___Corpus/Medline/xml/PMC5123381.xml	1601–	355253 : 355258	CPR	T cells. Blood 2015, 125:1601–1610.                    
./___Corpus/Medline/xml/PMC5123381.xml	ADC	355409 : 355412	CM	antibody-drug conjugate (ADC), activates monocytes th
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	355634 : 355641	CM	rvetuximab soravtansine (IMGN853) is an ADC, comprising a
./___Corpus/Medline/xml/PMC5123381.xml	ADC	355649 : 355652	CM	vtansine (IMGN853) is an ADC, comprising a humanized 
./___Corpus/Medline/xml/PMC5123381.xml	FRα	355677 : 355680	CM	, comprising a humanized FRα-binding M9346A antibody 
./___Corpus/Medline/xml/PMC5123381.xml	M9346A	355689 : 355695	CM	 a humanized FRα-binding M9346A antibody linked to the t
./___Corpus/Medline/xml/PMC5123381.xml	tubulin	355719 : 355726	CM	A antibody linked to the tubulin-disrupting maytansinoid,
./___Corpus/Medline/xml/PMC5123381.xml	DM4	355752 : 355755	CM	disrupting maytansinoid, DM4. IMGN853 binds to FRα on
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	355757 : 355764	CM	pting maytansinoid, DM4. IMGN853 binds to FRα on cancer c
./___Corpus/Medline/xml/PMC5123381.xml	FRα	355774 : 355777	CM	d, DM4. IMGN853 binds to FRα on cancer cells and is i
./___Corpus/Medline/xml/PMC5123381.xml	DM4	355815 : 355818	CM	lls and is internalized; DM4 is released through enzy
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	355955 : 355962	CM	division and cell death. IMGN853 shows promising single-a
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	356092 : 356099	CM	ents in a phase I study. IMGN853 is entering FORWARD I, a
./___Corpus/Medline/xml/PMC5123381.xml	Ib	356249 : 356251	CM	pembrolizumab in a phase Ib/II study, FORWARD II. He
./___Corpus/Medline/xml/PMC5123381.xml	FORWARD	356262 : 356269	CM	 in a phase Ib/II study, FORWARD II. Here we have explore
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	356327 : 356334	CM	ial mechanism(s) whereby IMGN853 can show enhanced activi
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	356478 : 356485	CM	at examine the impact of IMGN853 treatment of tumor cells
./___Corpus/Medline/xml/PMC5123381.xml	vitro	356533 : 356538	CM	ls on human monocytes in vitro.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	356622 : 356626	CM	blood mononuclear cells (PBMC) from normal donors were
./___Corpus/Medline/xml/PMC5123381.xml	KB	356682 : 356684	CM	ated with FRα-expressing KB tumor cells in the prese
./___Corpus/Medline/xml/PMC5123381.xml	PMBC	356744 : 356748	CM	t articles for two days. PMBC were then analyzed for a
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	356938 : 356945	CM	ine the direct impact of IMGN853 on KB cells.            
./___Corpus/Medline/xml/PMC5123381.xml	KB	356949 : 356951	CM	ect impact of IMGN853 on KB cells.                  
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	357005 : 357012	CM	lts                      IMGN853 treatment of PBMC did no
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	357026 : 357030	CM	    IMGN853 treatment of PBMC did not affect monocytes
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	357071 : 357075	CM	monocytes. Incubation of PBMC with KB cells decreased 
./___Corpus/Medline/xml/PMC5123381.xml	KB	357081 : 357083	CM	 Incubation of PBMC with KB cells decreased the CD86
./___Corpus/Medline/xml/PMC5123381.xml	CD86+	357104 : 357109	CM	h KB cells decreased the CD86+ monocytes from ~30 % to 
./___Corpus/Medline/xml/PMC5123381.xml	DM4	357157 : 357160	CM	o ~10 %, and addition of DM4, the free payload of IMG
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	357182 : 357189	CM	DM4, the free payload of IMGN853, reversed the CD86 expre
./___Corpus/Medline/xml/PMC5123381.xml	CD86	357204 : 357208	CM	of IMGN853, reversed the CD86 expression to basal leve
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	357263 : 357270	CM	ntriguingly, addition of IMGN853, but not non-targeting A
./___Corpus/Medline/xml/PMC5123381.xml	ADC	357294 : 357297	CM	3, but not non-targeting ADC, increased the activated
./___Corpus/Medline/xml/PMC5123381.xml	CD14+	357387 : 357392	CM	e obtained with isolated CD14+ monocytes, indicating th
./___Corpus/Medline/xml/PMC5123381.xml	KB	357605 : 357607	CM	ultures of monocytes and KB cells treated with a mix
./___Corpus/Medline/xml/PMC5123381.xml	M9346A	357640 : 357646	CM	reated with a mixture of M9346A and DM4, and not with M9
./___Corpus/Medline/xml/PMC5123381.xml	DM4	357651 : 357654	CM	 a mixture of M9346A and DM4, and not with M9346A or 
./___Corpus/Medline/xml/PMC5123381.xml	M9346A	357669 : 357675	CM	6A and DM4, and not with M9346A or DM4 alone, suggesting
./___Corpus/Medline/xml/PMC5123381.xml	DM4	357679 : 357682	CM	, and not with M9346A or DM4 alone, suggesting both c
./___Corpus/Medline/xml/PMC5123381.xml	ADC	357724 : 357727	CM	g both components of the ADC are necessary. Furthermo
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	357769 : 357776	CM	urthermore, a variant of IMGN853 with a point mutation th
./___Corpus/Medline/xml/PMC5123381.xml	FcγR	357818 : 357822	CM	ation that abrogates the FcγR binding only produced th
./___Corpus/Medline/xml/PMC5123381.xml	DM4	357887 : 357890	CM	f monocyte activation as DM4 treatment, suggesting th
./___Corpus/Medline/xml/PMC5123381.xml	Fc	357933 : 357935	CM	ting the significance of Fc/FcγR interaction. Finall
./___Corpus/Medline/xml/PMC5123381.xml	FcγR	357936 : 357940	CM	g the significance of Fc/FcγR interaction. Finally, tr
./___Corpus/Medline/xml/PMC5123381.xml	KB	357976 : 357978	CM	n. Finally, treatment of KB cells with IMGN853 incre
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	357990 : 357997	CM	eatment of KB cells with IMGN853 increased calreticulin, 
./___Corpus/Medline/xml/PMC5123381.xml	ATP	358022 : 358025	CM	 increased calreticulin, ATP and HMGB1, three immunog
./___Corpus/Medline/xml/PMC5123381.xml	HMGB1	358030 : 358035	CM	ed calreticulin, ATP and HMGB1, three immunogenic cell 
./___Corpus/Medline/xml/PMC5123381.xml	KB	358182 : 358184	CM	atment of FRα-expressing KB cells with IMGN853 induc
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	358196 : 358203	CM	expressing KB cells with IMGN853 induces activation of co
./___Corpus/Medline/xml/PMC5123381.xml	Fc	358256 : 358258	CM	ltured monocytes through Fc/FcγR interaction and upr
./___Corpus/Medline/xml/PMC5123381.xml	FcγR	358259 : 358263	CM	red monocytes through Fc/FcγR interaction and upregula
./___Corpus/Medline/xml/PMC5123381.xml	IMGN853	358391 : 358398	CM	e clinical evaluation of IMGN853 and a checkpoint inhibit
./___Corpus/Medline/xml/PMC5123381.xml	El	359042 : 359044	CM	, Vincent Thomas2, Meddy El Alaoui1, Sébastien Papot
./___Corpus/Medline/xml/PMC5123381.xml	Dyson5	359096 : 359102	CM	 Charles Dumontet4, Mike Dyson5, John McCafferty5, Said 
./___Corpus/Medline/xml/PMC5123381.xml	El	359127 : 359129	CM	, John McCafferty5, Said El Alaoui2                 
./___Corpus/Medline/xml/PMC5123381.xml	ADC	359243 : 359246	CM	o highly toxic agents or ADC (antibody-drug conjugate
./___Corpus/Medline/xml/PMC5123381.xml	transglutaminase	360310 : 360326	CM	peptide library, and the transglutaminase colorometric assay, we i
./___Corpus/Medline/xml/PMC5123381.xml	glutamine	360407 : 360416	CM	 that were recognized as glutamine donor substrates with im
./___Corpus/Medline/xml/PMC5123381.xml	ZQG	360499 : 360502	CM	 known peptides (such as ZQG, LLQG, etc.). As a proof
./___Corpus/Medline/xml/PMC5123381.xml	LLQG	360504 : 360508	CM	n peptides (such as ZQG, LLQG, etc.). As a proof-of-co
./___Corpus/Medline/xml/PMC5123381.xml	HER2	360608 : 360612	CM	with Kadcyla® (targeting HER2) recently approved.     
./___Corpus/Medline/xml/PMC5123381.xml	Her2	360737 : 360741	CM	fferent recombinant anti Her2 IgG1 mAb carrying optimi
./___Corpus/Medline/xml/PMC5123381.xml	IgG1	360742 : 360746	CM	nt recombinant anti Her2 IgG1 mAb carrying optimized e
./___Corpus/Medline/xml/PMC5123381.xml	transglutaminase	360952 : 360968	CM	pounds through bacterial transglutaminase (mTG) enzymatic reaction
./___Corpus/Medline/xml/PMC5123381.xml	mTG	360970 : 360973	CM	terial transglutaminase (mTG) enzymatic reaction. We 
./___Corpus/Medline/xml/PMC5123381.xml	Her2-ADC	361124 : 361132	CM	eactivity of CovIsoLink™ Her2-ADC. Using mTG, we obtained 
./___Corpus/Medline/xml/PMC5123381.xml	mTG	361140 : 361143	CM	IsoLink™ Her2-ADC. Using mTG, we obtained site specif
./___Corpus/Medline/xml/PMC5123381.xml	antiHer2	361240 : 361248	CM	 optimized linker on the antiHer2 IgG1 antibody. By HIC an
./___Corpus/Medline/xml/PMC5123381.xml	IgG1	361249 : 361253	CM	d linker on the antiHer2 IgG1 antibody. By HIC analysi
./___Corpus/Medline/xml/PMC5123381.xml	DAR	361322 : 361325	CM	pecific and reproducible DAR reaching DAR2 depending 
./___Corpus/Medline/xml/PMC5123381.xml	DAR2	361335 : 361339	CM	eproducible DAR reaching DAR2 depending on drugs and e
./___Corpus/Medline/xml/PMC5123381.xml	vitro	361391 : 361396	CM	erimental conditions. In vitro and In vivo characteriza
./___Corpus/Medline/xml/PMC5123381.xml	Her2	361524 : 361528	CM	e currently performed in Her2 positive models by compa
./___Corpus/Medline/xml/PMC5123381.xml	T-DM1	361573 : 361578	CM	comparison with Kadcyla (T-DM1).                  Concl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	361709 : 361714	CPR	variety of antitumor (or anti-stromal) antibodies since
./___Corpus/Medline/xml/PMC5123381.xml	anti-	362025 : 362030	CPR	y of antibodies with low anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	HCC	362402 : 362405	CM	epatocellular carcinoma (HCC), a hypervascular tumor,
./___Corpus/Medline/xml/PMC5123381.xml	HCC	362594 : 362597	CM	le in the development of HCC, which occur due to vira
./___Corpus/Medline/xml/PMC5123381.xml	alcohol	362694 : 362701	CM	y carcinogens as well as alcohol abuses. We have found th
./___Corpus/Medline/xml/PMC5123381.xml	acid	362736 : 362740	CM	e have found that gallic acid, a dietary flavonoids pr
./___Corpus/Medline/xml/PMC5123381.xml	flavonoids	362752 : 362762	CM	t gallic acid, a dietary flavonoids present in various plant
./___Corpus/Medline/xml/PMC5123381.xml	diethyl nitrosamine	362795 : 362814	CM	 in various plants avoid diethyl nitrosamine (DENA) induced hepatic c
./___Corpus/Medline/xml/PMC5123381.xml	DENA	362816 : 362820	CM	oid diethyl nitrosamine (DENA) induced hepatic carcino
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363052 : 363056	CM	hepatic cytokines in the DENA induced carcinogenesis r
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363132 : 363136	CM	ods                      DENA (200 mg/kg) used for the
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363203 : 363207	CM	 in the Wistar rats. The DENA treated rats were divide
./___Corpus/Medline/xml/PMC5123381.xml	alpha	363352 : 363357	CM	ks different biochemical alpha feto-protein (AFP), seru
./___Corpus/Medline/xml/PMC5123381.xml	AFP	363372 : 363375	CM	ical alpha feto-protein (AFP), serum glutamate oxaloa
./___Corpus/Medline/xml/PMC5123381.xml	glutamate oxaloacetate	363384 : 363406	CM	eto-protein (AFP), serum glutamate oxaloacetate transaminase (SGOT), ser
./___Corpus/Medline/xml/PMC5123381.xml	glutamate pyruvate	363434 : 363452	CM	ansaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alk
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	363483 : 363494	CM	aminase (SGPT), alkaline phosphatase (ALP); hematological par
./___Corpus/Medline/xml/PMC5123381.xml	ALP	363496 : 363499	CM	), alkaline phosphatase (ALP); hematological paramete
./___Corpus/Medline/xml/PMC5123381.xml	RBC	363550 : 363553	CM	s viz., red blood cells (RBC), white blood cells (WBC
./___Corpus/Medline/xml/PMC5123381.xml	Hb	363593 : 363595	CM	cells (WBC), hemoglobin (Hb), erythrocytes sedimenta
./___Corpus/Medline/xml/PMC5123381.xml	lipid	363663 : 363668	CM	ntioxidant markers viz., lipid peroxidation (LPO), supe
./___Corpus/Medline/xml/PMC5123381.xml	superoxide	363689 : 363699	CM	ipid peroxidation (LPO), superoxide dismutase (SOD), catalas
./___Corpus/Medline/xml/PMC5123381.xml	glutathione	363741 : 363752	CM	 catalase (CAT), reduced glutathione (GSH); inflammatory medi
./___Corpus/Medline/xml/PMC5123381.xml	GSH	363754 : 363757	CM	T), reduced glutathione (GSH); inflammatory mediators
./___Corpus/Medline/xml/PMC5123381.xml	TNF	363814 : 363817	CM	tumor necrosis factor-α (TNF--α), interlukin-6 (IL-6)
./___Corpus/Medline/xml/PMC5123381.xml	DENA	363931 : 363935	CM	lts                      DENA induced rats received th
./___Corpus/Medline/xml/PMC5123381.xml	P	364121 : 364122	CM	arameters significantly (P < 0.001) altered at effe
./___Corpus/Medline/xml/PMC5123381.xml	DENA	364554 : 364558	CM	hemoprotective effect of DENA induced hepatocarcinogen
./___Corpus/Medline/xml/PMC5123381.xml	α-	364742 : 364744	CPR	   1. Kumar V: Effect of α-magostin on nitrosamine i
./___Corpus/Medline/xml/PMC5123381.xml	nitrosamine	364756 : 364767	CM	 Effect of α-magostin on nitrosamine induced hepatic carcinog
./___Corpus/Medline/xml/PMC5123381.xml	1–	364847 : 364849	CPR	Oncol 2015, 26 (suppl_9):1–7.                       
./___Corpus/Medline/xml/PMC5123381.xml	rosiglitazone	364929 : 364942	CM	l.: Anticancer effect of rosiglitazone in rats treated with Nni
./___Corpus/Medline/xml/PMC5123381.xml	Nnitrosodiethylamine	364964 : 364984	CM	one in rats treated with Nnitrosodiethylamine via inhibition of DNA sy
./___Corpus/Medline/xml/PMC5123381.xml	loperamide	365173 : 365183	CM	dose combination therapy loperamide and niacin ameliorates d
./___Corpus/Medline/xml/PMC5123381.xml	diethylnitrosamine	365207 : 365225	CM	e and niacin ameliorates diethylnitrosamine-induced liver carcinogen
./___Corpus/Medline/xml/PMC5123381.xml	67996–	365299 : 365305	CPR	ts. RSC Advances 2015, 5:67996–68002.                  O
./___Corpus/Medline/xml/PMC5123381.xml	MEK	365450 : 365453	CM	VEC) can be augmented by MEK inhibition in melanoma c
./___Corpus/Medline/xml/PMC5123381.xml	K	365534 : 365535	CM	                 Praveen K Bommareddy1, Howard L Ka
./___Corpus/Medline/xml/PMC5123381.xml	W	365608 : 365609	CM	Frederick Kohlhapp1, Ann W Silk1, Sachin Jhawar1, T
./___Corpus/Medline/xml/PMC5123381.xml	RNA	366119 : 366122	CM	ncluding double-stranded RNA-dependent protein kinase
./___Corpus/Medline/xml/PMC5123381.xml	PKR	366149 : 366152	CM	ependent protein kinase (PKR). It is thought that the
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	366178 : 366182	CM	. It is thought that the MAPK pathway interacts with P
./___Corpus/Medline/xml/PMC5123381.xml	PKR	366206 : 366209	CM	K pathway interacts with PKR, but the mechanism is po
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	366261 : 366265	CM	ly understood. Since the MAPK pathway is frequently mu
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	366354 : 366358	CM	etermine if mutations in BRAF or NRAS might enhance T-
./___Corpus/Medline/xml/PMC5123381.xml	NRAS	366362 : 366366	CM	 if mutations in BRAF or NRAS might enhance T-VEC-medi
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	366441 : 366445	CM	r sought to determine if BRAF or MEK inhibition might 
./___Corpus/Medline/xml/PMC5123381.xml	MEK	366449 : 366452	CM	 to determine if BRAF or MEK inhibition might influen
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	366602 : 366606	CM	 lines were selected for BRAF, NRAS, and other mutatio
./___Corpus/Medline/xml/PMC5123381.xml	NRAS	366608 : 366612	CM	 were selected for BRAF, NRAS, and other mutations for
./___Corpus/Medline/xml/PMC5123381.xml	1–	366755 : 366757	CPR	e of T-VEC doses (MOI of 1–0.001). Cell viability wa
./___Corpus/Medline/xml/PMC5123381.xml	MEK	366912 : 366915	CM	y treated with T-VEC and MEK inhibitors (trametinib o
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	366928 : 366938	CM	-VEC and MEK inhibitors (trametinib or PD0325901 at doses 10
./___Corpus/Medline/xml/PMC5123381.xml	100nM-1nM	366961 : 366970	CM	ib or PD0325901 at doses 100nM-1nM) or BRAF inhibitor (vemu
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	366975 : 366979	CM	1 at doses 100nM-1nM) or BRAF inhibitor (vemurafenib, 
./___Corpus/Medline/xml/PMC5123381.xml	100nM-1nM	367004 : 367013	CM	 inhibitor (vemurafenib, 100nM-1nM) and cell viability dete
./___Corpus/Medline/xml/PMC5123381.xml	NSG	367097 : 367100	CM	 vivo viral propagation, NSG mice were challenged wit
./___Corpus/Medline/xml/PMC5123381.xml	PFU	367191 : 367194	CM	reated with T-VEC (3x106 PFU) and/or trametinib (0.3 
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	367203 : 367213	CM	T-VEC (3x106 PFU) and/or trametinib (0.3 mg/kg) on day 10 an
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein	367337 : 367349	CM	immunoblotting for HSV-1 glycoprotein D. Statistical compariso
./___Corpus/Medline/xml/PMC5123381.xml	P	367450 : 367451	CM	he Student’s t test with P < 0.05 being considered 
./___Corpus/Medline/xml/PMC5123381.xml	lysis	367591 : 367596	RN	re highly susceptible to lysis by T-VEC although this e
./___Corpus/Medline/xml/PMC5123381.xml	MOI	367648 : 367651	CM	ect was reduced when the MOI was decreased to 0.001 f
./___Corpus/Medline/xml/PMC5123381.xml	BRAF	367724 : 367728	CM	s no correlation between BRAF or NRAS mutation status 
./___Corpus/Medline/xml/PMC5123381.xml	NRAS	367732 : 367736	CM	relation between BRAF or NRAS mutation status and cell
./___Corpus/Medline/xml/PMC5123381.xml	trametinib	367927 : 367937	CM	combination of T-VEC and trametinib significantly increased 
./___Corpus/Medline/xml/PMC5123381.xml	P	367981 : 367982	CM	eased cancer cell death (P < 0.01). A similar effec
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368032 : 368035	CM	t was seen with a second MEK inhibitor (PD0325901; P 
./___Corpus/Medline/xml/PMC5123381.xml	P	368058 : 368059	CM	EK inhibitor (PD0325901; P < 0.001).               
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368150 : 368153	CM	ombination of T-VEC with MEK inhibition resulted in e
./___Corpus/Medline/xml/PMC5123381.xml	vitro	368189 : 368194	CM	 resulted in enhanced in vitro tumor cell killing and v
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368247 : 368250	CM	l propagation. Combining MEK inhibitors with T-VEC re
./___Corpus/Medline/xml/PMC5123381.xml	MEK	368417 : 368420	CM	ight limit resistance to MEK inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein	368553 : 368565	CM	ing GM-CSF induces HSV-1 glycoprotein B-specific T cell respon
./___Corpus/Medline/xml/PMC5123381.xml	K	368697 : 368698	CM	                 Praveen K Bommareddy1, Frederick K
./___Corpus/Medline/xml/PMC5123381.xml	GM-CSF	368947 : 368953	CM	 type 1 (HSV-1) encoding GM-CSF, called talimogene laher
./___Corpus/Medline/xml/PMC5123381.xml	lysis	369156 : 369161	RN	tors and results in cell lysis and induction of anti-tu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369179 : 369184	CPR	l lysis and induction of anti-tumor immunity. We previo
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	369225 : 369231	CM	We previously identified MART-1-specific CD8+ effector T
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	369241 : 369245	CM	entified MART-1-specific CD8+ effector T cells within 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369385 : 369390	CPR	 T cell responses to the anti-tumor activity following 
./___Corpus/Medline/xml/PMC5123381.xml	murine	369535 : 369541	CM	 T cells, we developed a murine-adapted model in which t
./___Corpus/Medline/xml/PMC5123381.xml	murine	369627 : 369633	CM	with the substitution of murine GM-CSF (mTVEC) in place 
./___Corpus/Medline/xml/PMC5123381.xml	mTVEC	369642 : 369647	CM	tution of murine GM-CSF (mTVEC) in place of the human g
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369698 : 369703	CPR	ne. We hypothesized that anti-viral T cell responses mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	369750 : 369755	CPR	 might contribute to the anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	BL6	369821 : 369824	CM	                     C57/BL6 mice were challenged wit
./___Corpus/Medline/xml/PMC5123381.xml	PFU	369930 : 369933	CM	nk (day 0). mTVEC (3*106 PFU) was injected into the r
./___Corpus/Medline/xml/PMC5123381.xml	2–	370017 : 370019	CPR	owth was monitored every 2–3 days by caliper measure
./___Corpus/Medline/xml/PMC5123381.xml	glycoprotein	370250 : 370262	CM	ed using gp100 and HSV-1 glycoprotein B tetramers. Statistics 
./___Corpus/Medline/xml/PMC5123381.xml	P	370335 : 370336	CM	he Student’s t test with P < 0.05 being considered 
./___Corpus/Medline/xml/PMC5123381.xml	mTVEC	370434 : 370439	CM	lts                      mTVEC resulted in significant 
./___Corpus/Medline/xml/PMC5123381.xml	P	370577 : 370578	CM	cted, left flank tumors (P < 0.0001). We observed a
./___Corpus/Medline/xml/PMC5123381.xml	P	370742 : 370743	CM	n the un-injected sites (P < 0.01). The pattern and
./___Corpus/Medline/xml/PMC5123381.xml	gB	370946 : 370948	CM	by infiltration of HSV-1 gB-specific CD8+ T cells th
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	370958 : 370962	CM	ion of HSV-1 gB-specific CD8+ T cells that peaked at d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	371054 : 371058	CM	rved that HSV-1-specific CD8+ T cells trafficked to un
./___Corpus/Medline/xml/PMC5123381.xml	HSV-1-GM-CSF	371242 : 371254	CM	 indicate that oncolytic HSV-1-GM-CSF mediates anti-tumor ther
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371264 : 371269	CPR	ic HSV-1-GM-CSF mediates anti-tumor therapeutic respons
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371355 : 371360	CPR	atment induces a typical anti-viral innate and adaptive
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371524 : 371529	CPR	 These data suggest that anti-viral T cell responses ma
./___Corpus/Medline/xml/PMC5123381.xml	anti-	371574 : 371579	CPR	es may contribute to the anti-tumor effects of HSV-1-ba
./___Corpus/Medline/xml/PMC5123381.xml	VV	371867 : 371869	CM	olytic vaccinia viruses (VV) have shown antitumor ac
./___Corpus/Medline/xml/PMC5123381.xml	VVs	371998 : 372001	CM	 due to the inability of VVs to kill all tumor cells.
./___Corpus/Medline/xml/PMC5123381.xml	CD47	372259 : 372263	CM	or responses by blocking CD47 and providing a phagocyt
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	372370 : 372375	CM	h-affinity ectodomain of SIRPα fused to IgG4 Fc (SIRPα-
./___Corpus/Medline/xml/PMC5123381.xml	IgG4	372385 : 372389	CM	domain of SIRPα fused to IgG4 Fc (SIRPα-Fc). We propos
./___Corpus/Medline/xml/PMC5123381.xml	Fc	372390 : 372392	CM	n of SIRPα fused to IgG4 Fc (SIRPα-Fc). We propose t
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	372394 : 372402	CM	 SIRPα fused to IgG4 Fc (SIRPα-Fc). We propose to adapt th
./___Corpus/Medline/xml/PMC5123381.xml	VVs	372452 : 372455	CM	is approach to oncolytic VVs and hypothesize that an 
./___Corpus/Medline/xml/PMC5123381.xml	VV	372490 : 372492	CM	hesize that an oncolytic VV genetically modified to 
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	372525 : 372533	CM	ally modified to express SIRPα-Fc (SIRPα-Fc-VV) has enhanc
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VV	372535 : 372546	CM	ied to express SIRPα-Fc (SIRPα-Fc-VV) has enhanced antitumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD47+	372686 : 372691	CM	 we genetically modified CD47+ tumor cells (OV10.315, M
./___Corpus/Medline/xml/PMC5123381.xml	MC38	372715 : 372719	CM	+ tumor cells (OV10.315, MC38, Raji) with lentiviral v
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	372760 : 372765	CM	tiviral vectors encoding SIRPα or SIRPα-Fc.            
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	372769 : 372777	CM	ectors encoding SIRPα or SIRPα-Fc.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	vitro	372828 : 372833	CM	                      In vitro, OV10.315.SIRPα-Fc cells
./___Corpus/Medline/xml/PMC5123381.xml	M1	372888 : 372890	CM	 readily phagocytosed by M1 and M2 macrophages in co
./___Corpus/Medline/xml/PMC5123381.xml	M2	372895 : 372897	CM	y phagocytosed by M1 and M2 macrophages in compariso
./___Corpus/Medline/xml/PMC5123381.xml	NSG	373118 : 373121	CM	lls post IV injection in NSG mice resulting in a sign
./___Corpus/Medline/xml/PMC5123381.xml	MC38.SIRPα-Fc	373226 : 373239	CM	 rejected MC38.SIRPα and MC38.SIRPα-Fc cells post SC injection 
./___Corpus/Medline/xml/PMC5123381.xml	SC	373251 : 373253	CM	MC38.SIRPα-Fc cells post SC injection in contrast to
./___Corpus/Medline/xml/PMC5123381.xml	MC38	373286 : 373290	CM	on in contrast to 0/4 NT MC38 cells (p < 0.05). Having
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	373333 : 373341	CM	 Having established that SIRPα-Fc expression in tumor cell
./___Corpus/Medline/xml/PMC5123381.xml	VVs	373417 : 373420	CM	tic effect, we generated VVs encoding either SIRPα or
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	373437 : 373442	CM	ated VVs encoding either SIRPα or SIRPα-Fc (SIRPα-VV or
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	373446 : 373454	CM	encoding either SIRPα or SIRPα-Fc (SIRPα-VV or SIRPα-Fc-VV
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-VV	373456 : 373464	CM	ither SIRPα or SIRPα-Fc (SIRPα-VV or SIRPα-Fc-VV). In vitr
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VV	373468 : 373479	CM	or SIRPα-Fc (SIRPα-VV or SIRPα-Fc-VV). In vitro, both SIRPα-V
./___Corpus/Medline/xml/PMC5123381.xml	vitro	373485 : 373490	CM	α-VV or SIRPα-Fc-VV). In vitro, both SIRPα-VV and SIRPα
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-VV	373497 : 373505	CM	α-Fc-VV). In vitro, both SIRPα-VV and SIRPα-Fc-VV had simi
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VV	373510 : 373521	CM	vitro, both SIRPα-VV and SIRPα-Fc-VV had similar oncolytic ac
./___Corpus/Medline/xml/PMC5123381.xml	VV	373574 : 373576	CM	ity compared to parental VV (VSC20). The expression 
./___Corpus/Medline/xml/PMC5123381.xml	VSC20	373578 : 373583	CM	compared to parental VV (VSC20). The expression and sec
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	373618 : 373623	CM	ression and secretion of SIRPα and SIRPα-Fc was confirm
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	373628 : 373636	CM	d secretion of SIRPα and SIRPα-Fc was confirmed by FACS an
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VV	373696 : 373707	CM	 co-culture assays, only SIRPα-Fc-VV was able to induce M1 an
./___Corpus/Medline/xml/PMC5123381.xml	M1	373727 : 373729	CM	Fc-VV was able to induce M1 and M2 macrophage killin
./___Corpus/Medline/xml/PMC5123381.xml	M2	373734 : 373736	CM	as able to induce M1 and M2 macrophage killing. Base
./___Corpus/Medline/xml/PMC5123381.xml	vitro	373785 : 373790	CM	ed on our encouraging in vitro experiments, we have ini
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VV	373873 : 373884	CM	e safety and efficacy of SIRPα-Fc-VV in the MC38 C57BL/6 mode
./___Corpus/Medline/xml/PMC5123381.xml	MC38	373892 : 373896	CM	cy of SIRPα-Fc-VV in the MC38 C57BL/6 model.          
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	374009 : 374017	CM	at tumor cells secreting SIRPα-Fc are readily phagocytosed
./___Corpus/Medline/xml/PMC5123381.xml	M1	374046 : 374048	CM	 readily phagocytosed by M1 and M2 macrophages and h
./___Corpus/Medline/xml/PMC5123381.xml	M2	374053 : 374055	CM	y phagocytosed by M1 and M2 macrophages and have red
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc-VVs	374162 : 374174	CM	mal models. In addition, SIRPα-Fc-VVs readily infect tumor cel
./___Corpus/Medline/xml/PMC5123381.xml	VVs	374281 : 374284	CM	ncolytic viruses such as VVs with SIRPα-Fc has the po
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα-Fc	374290 : 374298	CM	viruses such as VVs with SIRPα-Fc has the potential to imp
./___Corpus/Medline/xml/PMC5123381.xml	Ad11	374452 : 374456	CM	 immune responses by the Ad11/Ad3 chimeric oncolytic g
./___Corpus/Medline/xml/PMC5123381.xml	Ad3	374457 : 374460	CM	ne responses by the Ad11/Ad3 chimeric oncolytic group
./___Corpus/Medline/xml/PMC5123381.xml	Brown1	374571 : 374577	CM	 Sam Illingworth1, Alice Brown1, Kerry Fisher1, Len Seym
./___Corpus/Medline/xml/PMC5123381.xml	Fisher1	374585 : 374592	CM	th1, Alice Brown1, Kerry Fisher1, Len Seymour2, Brian Cha
./___Corpus/Medline/xml/PMC5123381.xml	OVs	374986 : 374989	CM	mor. Viral properties of OVs may also be able to enga
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	375313 : 375317	CM	erapies. Enadenotucirev (EnAd) is a chimeric Ad11/Ad3 
./___Corpus/Medline/xml/PMC5123381.xml	Ad11	375333 : 375337	CM	rev (EnAd) is a chimeric Ad11/Ad3 group B oncolytic ad
./___Corpus/Medline/xml/PMC5123381.xml	Ad3	375338 : 375341	CM	EnAd) is a chimeric Ad11/Ad3 group B oncolytic adenov
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	375467 : 375470	CM	Unlike the group C virus Ad5, EnAd does not bind to c
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	375472 : 375476	CM	e the group C virus Ad5, EnAd does not bind to cells v
./___Corpus/Medline/xml/PMC5123381.xml	CD46	375538 : 375542	CM	eceptor but instead uses CD46 which is expressed by in
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	375670 : 375674	CM	evaluating the effect of EnAd on innate immune respons
./___Corpus/Medline/xml/PMC5123381.xml	vitro	375711 : 375716	CM	mmune responses using in vitro immature human monocyte-
./___Corpus/Medline/xml/PMC5123381.xml	DC	375766 : 375768	CM	derived dendritic cells (DC) as a model suppressive 
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	375854 : 375858	CM	lts                      EnAd induced up-regulation of
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	376027 : 376031	CM	comparing the effects of EnAd to those of Ad5 indicate
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	376044 : 376047	CM	ects of EnAd to those of Ad5 indicated that the activ
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	376096 : 376100	CM	vation was selective for EnAd, was particle-mediated a
./___Corpus/Medline/xml/PMC5123381.xml	CD46	376141 : 376145	CM	ediated and dependent on CD46 binding. In order to und
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	376341 : 376345	CM	ocyte reaction approach. EnAd-treated DCs selectively 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	376354 : 376357	CM	n approach. EnAd-treated DCs selectively stimulated s
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	376427 : 376431	CM	nses, including enhanced IFNg production. The data sup
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	376462 : 376466	CM	ction. The data supports EnAd as a good candidate OV f
./___Corpus/Medline/xml/PMC5123381.xml	OV	376487 : 376489	CM	EnAd as a good candidate OV for steering the respons
./___Corpus/Medline/xml/PMC5123381.xml	Th1	376564 : 376567	CM	thin the tumor towards a Th1 phenotype for enhanced e
./___Corpus/Medline/xml/PMC5123381.xml	EnAd	376711 : 376715	CM	nt oncolytic properties, EnAd particles may also funct
./___Corpus/Medline/xml/PMC5123381.xml	APCs	376864 : 376868	CM	o-inflammatory phenotype APCs, which should also syner
./___Corpus/Medline/xml/PMC5123381.xml	CD40L-armed	376990 : 377001	CM	                    P310 CD40L-armed oncolytic LOAd viruses c
./___Corpus/Medline/xml/PMC5123381.xml	LOAd	377012 : 377016	CM	10 CD40L-armed oncolytic LOAd viruses control growth o
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	377043 : 377048	CM	iruses control growth of CD40+ T24 bladder cancer via b
./___Corpus/Medline/xml/PMC5123381.xml	T24	377049 : 377052	CM	 control growth of CD40+ T24 bladder cancer via both 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377091 : 377095	CM	r via both oncolysis and CD40-mediated apoptosis      
./___Corpus/Medline/xml/PMC5123381.xml	CD40-CD40L	377306 : 377316	CM	und                      CD40-CD40L signaling is a powerful 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377391 : 377395	CM	in cancer immunotherapy. CD40 stimulation of immune ce
./___Corpus/Medline/xml/PMC5123381.xml	Th1	377433 : 377436	CM	of immune cells drives a Th1 anti-tumor response but 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	377437 : 377442	CPR	mmune cells drives a Th1 anti-tumor response but CD40 s
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377461 : 377465	CM	 anti-tumor response but CD40 stimulation on tumor cel
./___Corpus/Medline/xml/PMC5123381.xml	FASL	377572 : 377576	CM	 to the up-regulation of FASL, tumor necrosis factor a
./___Corpus/Medline/xml/PMC5123381.xml	alpha	377600 : 377605	CM	L, tumor necrosis factor alpha (TNFα), and TNF-related 
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	377607 : 377611	CM	r necrosis factor alpha (TNFα), and TNF-related apopto
./___Corpus/Medline/xml/PMC5123381.xml	TNF	377618 : 377621	CM	factor alpha (TNFα), and TNF-related apoptosis-induct
./___Corpus/Medline/xml/PMC5123381.xml	TRAIL	377658 : 377663	CM	ptosis-inducting ligand (TRAIL) on tumor cells after CD
./___Corpus/Medline/xml/PMC5123381.xml	CD40-CD40L	377686 : 377696	CM	IL) on tumor cells after CD40-CD40L interaction. Also, CD40 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	377716 : 377720	CM	CD40L interaction. Also, CD40 signaling in tumor cells
./___Corpus/Medline/xml/PMC5123381.xml	LOAd	377811 : 377815	CM	h the binding of TRAF 2. LOAd viruses are oncolytic ad
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	377884 : 377889	CM	ode a trimerized form of CD40L (TMZ-CD40L) alone (LOAd7
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	377891 : 377900	CM	rimerized form of CD40L (TMZ-CD40L) alone (LOAd700) or in c
./___Corpus/Medline/xml/PMC5123381.xml	LOAd700	377909 : 377916	CM	CD40L (TMZ-CD40L) alone (LOAd700) or in combination with 
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	377941 : 377947	CM	) or in combination with 4-1BBL (LOAd703). In the curren
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	377949 : 377956	CM	combination with 4-1BBL (LOAd703). In the current study, 
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	377993 : 377998	CM	rrent study, the role of CD40L on CD40+ tumor cells has
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378002 : 378007	CM	dy, the role of CD40L on CD40+ tumor cells has been elu
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378130 : 378135	CM	 post virus infection of CD40+ T24 tumor cells was inve
./___Corpus/Medline/xml/PMC5123381.xml	T24	378136 : 378139	CM	virus infection of CD40+ T24 tumor cells was investig
./___Corpus/Medline/xml/PMC5123381.xml	vitro	378172 : 378177	CM	ells was investigated in vitro by MTS assay. To further
./___Corpus/Medline/xml/PMC5123381.xml	MTS	378181 : 378184	CM	investigated in vitro by MTS assay. To further invest
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	378241 : 378246	CM	he cell death induced by CD40L signaling apart from onc
./___Corpus/Medline/xml/PMC5123381.xml	LOAd	378285 : 378289	CM	rt from oncolysis due to LOAd virus infection, monocyt
./___Corpus/Medline/xml/PMC5123381.xml	LOAd(−)	378359 : 378366	CM	cells were infected with LOAd(−) and LOAd700 and then co-
./___Corpus/Medline/xml/PMC5123381.xml	LOAd700	378371 : 378378	CM	nfected with LOAd(−) and LOAd700 and then co-cultured wit
./___Corpus/Medline/xml/PMC5123381.xml	T24	378405 : 378408	CM	nd then co-cultured with T24 cells. Apoptosis inducti
./___Corpus/Medline/xml/PMC5123381.xml	7-AAD	378528 : 378533	CM	ometry for Annexin V and 7-AAD. In a T24 xenograft mode
./___Corpus/Medline/xml/PMC5123381.xml	T24	378540 : 378543	CM	nnexin V and 7-AAD. In a T24 xenograft model using Nu
./___Corpus/Medline/xml/PMC5123381.xml	Nu	378566 : 378568	CM	24 xenograft model using Nu/Nu immunodeficient mice,
./___Corpus/Medline/xml/PMC5123381.xml	Nu	378569 : 378571	CM	xenograft model using Nu/Nu immunodeficient mice, LO
./___Corpus/Medline/xml/PMC5123381.xml	LOAd	378594 : 378598	CM	Nu immunodeficient mice, LOAd viruses expressing human
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	378624 : 378633	CM	viruses expressing human TMZ-CD40L that does not cross-reac
./___Corpus/Medline/xml/PMC5123381.xml	murine	378663 : 378669	CM	 does not cross-react to murine CD40 was used (6x) to ev
./___Corpus/Medline/xml/PMC5123381.xml	CD40	378670 : 378674	CM	ot cross-react to murine CD40 was used (6x) to evaluat
./___Corpus/Medline/xml/PMC5123381.xml	LOAd(−)	378719 : 378726	CM	aluate in vivo efficacy. LOAd(−) was used as a control of
./___Corpus/Medline/xml/PMC5123381.xml	PBS	378784 : 378787	CM	control by oncolysis and PBS-treated controls determi
./___Corpus/Medline/xml/PMC5123381.xml	LOAd	378886 : 378890	CM	                     The LOAd viruses induced oncolysi
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	378924 : 378929	CM	induced oncolysis of the CD40+ urinary bladder cancer T
./___Corpus/Medline/xml/PMC5123381.xml	T24	378953 : 378956	CM	+ urinary bladder cancer T24 cell line independently 
./___Corpus/Medline/xml/PMC5123381.xml	transgene	378984 : 378993	CM	ll line independently of transgene expression. However, inf
./___Corpus/Medline/xml/PMC5123381.xml	T24	379024 : 379027	CM	ssion. However, infected T24 showed a significant dec
./___Corpus/Medline/xml/PMC5123381.xml	LOAd(−)	379138 : 379145	CM	sing LOAd700 compared to LOAd(−). Co-culture of LOAd-infe
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	379202 : 379211	CM	ndritic cells expressing TMZ-CD40L or not with T24 led to a
./___Corpus/Medline/xml/PMC5123381.xml	T24	379224 : 379227	CM	ng TMZ-CD40L or not with T24 led to an increased indu
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	379320 : 379329	CM	ndritic cells expressing TMZ-CD40L. In vivo, both LOAd(−) a
./___Corpus/Medline/xml/PMC5123381.xml	LOAd(−)	379345 : 379352	CM	TMZ-CD40L. In vivo, both LOAd(−) and LOAd703 treatment le
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	379357 : 379364	CM	n vivo, both LOAd(−) and LOAd703 treatment led to a decre
./___Corpus/Medline/xml/PMC5123381.xml	PBS	379419 : 379422	CM	tumor growth compared to PBS-treated animals. When TM
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	379445 : 379454	CM	BS-treated animals. When TMZ-CD40L was expressed (e.g. LOAd
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	379475 : 379482	CM	D40L was expressed (e.g. LOAd703), tumor control was fast
./___Corpus/Medline/xml/PMC5123381.xml	LOAd(−)	379585 : 379592	CM	h compared to 3/5 in the LOAd(−)-treated group, demonstra
./___Corpus/Medline/xml/PMC5123381.xml	CD40	379655 : 379659	CM	tional growth control by CD40-induced tumor cell death
./___Corpus/Medline/xml/PMC5123381.xml	CD40	379698 : 379702	CM	 cell death. Models with CD40- tumor cells (Panc01, H7
./___Corpus/Medline/xml/PMC5123381.xml	Panc01	379717 : 379723	CM	 with CD40- tumor cells (Panc01, H727, SKOV3) responded 
./___Corpus/Medline/xml/PMC5123381.xml	H727	379725 : 379729	CM	40- tumor cells (Panc01, H727, SKOV3) responded simila
./___Corpus/Medline/xml/PMC5123381.xml	SKOV3	379731 : 379736	CM	mor cells (Panc01, H727, SKOV3) responded similarly to 
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	379796 : 379805	CM	rus and virus expressing TMZ-CD40L.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	379884 : 379893	CM	colytic viruses encoding TMZ-CD40L have an increased killin
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	379933 : 379938	CM	sed killing capacity via CD40L-mediated killing of CD40
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	379959 : 379964	CM	D40L-mediated killing of CD40+ tumor cells.            
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380102 : 380107	CPR	y genes that promotes an anti-tumor response           
./___Corpus/Medline/xml/PMC5123381.xml	Ståhle1	380218 : 380225	CM	 Jessica Wenthe1, Magnus Ståhle1, Justyna Jarblad-Leja3, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380513 : 380518	CPR	e from a pro-tumor to an anti-tumor response. There are
./___Corpus/Medline/xml/PMC5123381.xml	anti-	380565 : 380570	CPR	are many ways to achieve anti-tumor immunity, for examp
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	380644 : 380649	CM	unostimulatory pathways. CD40L interactions with its re
./___Corpus/Medline/xml/PMC5123381.xml	CD40	380681 : 380685	CM	ctions with its receptor CD40 on dendritic cells leads
./___Corpus/Medline/xml/PMC5123381.xml	Th1	380767 : 380770	CM	d polarization towards a Th1 response. CD40L can also
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	380781 : 380786	CM	 towards a Th1 response. CD40L can also reduce the leve
./___Corpus/Medline/xml/PMC5123381.xml	M2	380845 : 380847	CM	oid suppressor cells and M2 macrophages as well as i
./___Corpus/Medline/xml/PMC5123381.xml	CD40	380891 : 380895	CM	l as induce apoptosis in CD40 positive tumor cells. 4-
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	380918 : 380923	CM	40 positive tumor cells. 4-1BB ligand (4-1BBL) interact
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	380932 : 380938	CM	mor cells. 4-1BB ligand (4-1BBL) interactions with its r
./___Corpus/Medline/xml/PMC5123381.xml	4-1BB	380971 : 380976	CM	ctions with its receptor 4-1BB on T cells leads to acti
./___Corpus/Medline/xml/PMC5123381.xml	CMV	381115 : 381118	CM	olytic adenovirus with a CMV-driven transgene cassett
./___Corpus/Medline/xml/PMC5123381.xml	transgene	381126 : 381135	CM	ovirus with a CMV-driven transgene cassette containing the 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	381210 : 381214	CM	imerized, membrane-bound CD40 ligand (TMZ-CD40L) and t
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	381223 : 381232	CM	brane-bound CD40 ligand (TMZ-CD40L) and the full length 4-1
./___Corpus/Medline/xml/PMC5123381.xml	4-1BBL	381254 : 381260	CM	40L) and the full length 4-1BBL.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	381388 : 381395	CM	onors were infected with LOAd703 and analyzed for cell de
./___Corpus/Medline/xml/PMC5123381.xml	Panc01	381515 : 381521	CM	e with established human Panc01 tumors were treated twic
./___Corpus/Medline/xml/PMC5123381.xml	vitro	381613 : 381618	CM	 tumor size. Both the in vitro and in vivo experiments 
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	381677 : 381688	CM	ated in combination with gemcitabine. Dendritic cells were in
./___Corpus/Medline/xml/PMC5123381.xml	CMV	381822 : 381825	CM	ls were also pulsed with CMV peptides and co-cultured
./___Corpus/Medline/xml/PMC5123381.xml	CD14	381867 : 381871	CM	cultured with autologous CD14- cells to investigate th
./___Corpus/Medline/xml/PMC5123381.xml	CMV+	381911 : 381915	CM	stigate the expansion of CMV+ T cells by flow cytometr
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	381989 : 381996	CM	lts                      LOAd703 decreased the viability 
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	382199 : 382206	CM	cells. Mice treated with LOAd703 had a decreased tumor bu
./___Corpus/Medline/xml/PMC5123381.xml	PBS	382248 : 382251	CM	tumor burden compared to PBS treated animals. LOAd703
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	382269 : 382276	CM	 to PBS treated animals. LOAd703 could be successfully co
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	382313 : 382324	CM	ccessfully combined with gemcitabine without any negative eff
./___Corpus/Medline/xml/PMC5123381.xml	vitro	382375 : 382380	CM	cts on oncolysis both in vitro and in vivo. Dendritic c
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	382424 : 382431	CM	itic cells infected with LOAd703 showed a mature phenotyp
./___Corpus/Medline/xml/PMC5123381.xml	CD83	382477 : 382481	CM	otype with expression of CD83, CD86, and secretion of 
./___Corpus/Medline/xml/PMC5123381.xml	CD86	382483 : 382487	CM	with expression of CD83, CD86, and secretion of cytoki
./___Corpus/Medline/xml/PMC5123381.xml	IL12p70	382538 : 382545	CM	es, chemokines including IL12p70 and IFNγ. The dendritic 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	382550 : 382554	CM	es including IL12p70 and IFNγ. The dendritic cells wer
./___Corpus/Medline/xml/PMC5123381.xml	CMV+	382631 : 382635	CM	 expand antigen-specific CMV+ T cells and NK cells.   
./___Corpus/Medline/xml/PMC5123381.xml	LOAd703	382723 : 382730	CM	          In conclusion, LOAd703 is a novel oncolytic vir
./___Corpus/Medline/xml/PMC5123381.xml	Th1	382828 : 382831	CM	d the immune system with Th1 type response from dendr
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383639 : 383642	CM	erred to as desmoplasia. IL6 drives STAT3 activation 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	383650 : 383655	CM	 desmoplasia. IL6 drives STAT3 activation leading to tr
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383866 : 383869	CM	ry cells (Tregs). Hence, IL6, which is overexpressed 
./___Corpus/Medline/xml/PMC5123381.xml	IL6	383966 : 383969	CM	of desmoplasia. Further, IL6 is associated to poor pr
./___Corpus/Medline/xml/PMC5123381.xml	IL6	384048 : 384051	CM	 In order to target both IL6 and induce immune activa
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	384107 : 384114	CM	the oncolytic adenovirus LOAd713 was developed. It is dou
./___Corpus/Medline/xml/PMC5123381.xml	anti-	384157 : 384162	CPR	 is double-armed with an anti-IL6 receptor antibody sin
./___Corpus/Medline/xml/PMC5123381.xml	scFv	384213 : 384217	CM	le chain fragment (aIL6R scFv) aiming to disrupt IL6 s
./___Corpus/Medline/xml/PMC5123381.xml	IL6	384237 : 384240	CM	 scFv) aiming to disrupt IL6 signaling and a trimeriz
./___Corpus/Medline/xml/PMC5123381.xml	CD40	384283 : 384287	CM	rimerized membrane-bound CD40 ligand (TMZ-CD40L) that 
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	384296 : 384305	CM	brane-bound CD40 ligand (TMZ-CD40L) that drives Th1 immunit
./___Corpus/Medline/xml/PMC5123381.xml	Th1	384319 : 384322	CM	 (TMZ-CD40L) that drives Th1 immunity.               
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	384379 : 384386	CM	ods                      LOAd713 is an Ad5/35 virus that 
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	384393 : 384396	CM	           LOAd713 is an Ad5/35 virus that replicates
./___Corpus/Medline/xml/PMC5123381.xml	CD46	384569 : 384573	CM	otype 35 fiber to target CD46 expressed by most tumors
./___Corpus/Medline/xml/PMC5123381.xml	CMV	384602 : 384605	CM	ressed by most tumors. A CMV-driven transgene cassett
./___Corpus/Medline/xml/PMC5123381.xml	transgene	384613 : 384622	CM	ost tumors. A CMV-driven transgene cassette with the transg
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	384656 : 384665	CM	 with the transgenes for TMZ-CD40L and aIL6R scFv was added
./___Corpus/Medline/xml/PMC5123381.xml	scFv	384676 : 384680	CM	 for TMZ-CD40L and aIL6R scFv was added into the genom
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	384724 : 384731	CM	 genome. The activity of LOAd713 was evaluated by 1) infe
./___Corpus/Medline/xml/PMC5123381.xml	MTS	384826 : 384829	CM	ing their viability in a MTS cytotoxicity assays (onc
./___Corpus/Medline/xml/PMC5123381.xml	DC	384902 : 384904	CM	g human dendritic cells (DC) and performing phenotyp
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	384958 : 384966	CM	ssays by flow cytometry, cytokine arrays and lymphocyte st
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	385193 : 385200	CM	lts                      LOAd713 had oncolytic capacity i
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	385363 : 385370	CM	late cells infected with LOAd713 did not lose viability. 
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	385404 : 385411	CM	lose viability. However, LOAd713 significantly decreased 
./___Corpus/Medline/xml/PMC5123381.xml	factor-5	385514 : 385522	CM	 beta, fibroblast growth factor-5 (FGF-5) and collagen typ
./___Corpus/Medline/xml/PMC5123381.xml	FGF-5	385524 : 385529	CM	roblast growth factor-5 (FGF-5) and collagen type I, al
./___Corpus/Medline/xml/PMC5123381.xml	alpha	385689 : 385694	CM	 their expression of IL1 alpha, IL6, IL8, CXCL10 and CC
./___Corpus/Medline/xml/PMC5123381.xml	IL6	385696 : 385699	CM	expression of IL1 alpha, IL6, IL8, CXCL10 and CCL20, 
./___Corpus/Medline/xml/PMC5123381.xml	IL8	385701 : 385704	CM	ssion of IL1 alpha, IL6, IL8, CXCL10 and CCL20, which
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	385706 : 385712	CM	 of IL1 alpha, IL6, IL8, CXCL10 and CCL20, which may bot
./___Corpus/Medline/xml/PMC5123381.xml	CCL20	385717 : 385722	CM	ha, IL6, IL8, CXCL10 and CCL20, which may both promote 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	385802 : 385805	CM	ocytes. LOAd713-infected DCs showed an increased leve
./___Corpus/Medline/xml/PMC5123381.xml	CD83	385862 : 385866	CM	turation markers such as CD83 and IL12 as shown by flo
./___Corpus/Medline/xml/PMC5123381.xml	IL12	385871 : 385875	CM	markers such as CD83 and IL12 as shown by flow cytomet
./___Corpus/Medline/xml/PMC5123381.xml	DCs	385937 : 385940	CM	ex methodology, and such DCs could expand antigen-spe
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	386030 : 386037	CM	ons                      LOAd713 is an oncolytic adenovir
./___Corpus/Medline/xml/PMC5123381.xml	IL6	386089 : 386092	CM	 aiming to interrupt the IL6/IL6R pathway resulting i
./___Corpus/Medline/xml/PMC5123381.xml	IL6R	386093 : 386097	CM	ing to interrupt the IL6/IL6R pathway resulting in red
./___Corpus/Medline/xml/PMC5123381.xml	TMZ-CD40L	386172 : 386181	CM	esmoplasia. Further, via TMZ-CD40L, LOAd713 can activate DC
./___Corpus/Medline/xml/PMC5123381.xml	LOAd713	386183 : 386190	CM	 Further, via TMZ-CD40L, LOAd713 can activate DCs to driv
./___Corpus/Medline/xml/PMC5123381.xml	DCs	386204 : 386207	CM	0L, LOAd713 can activate DCs to drive lymphocyte resp
./___Corpus/Medline/xml/PMC5123381.xml	K	386460 : 386461	CM	, Sharad Goyal2, Praveen K Bommareddy1, Tomas Paneq
./___Corpus/Medline/xml/PMC5123381.xml	96-	387411 : 387414	CPR	a cell lines cultured in 96-well plates (7x103 cells 
./___Corpus/Medline/xml/PMC5123381.xml	7x103	387427 : 387432	CM	tured in 96-well plates (7x103 cells per well) were tre
./___Corpus/Medline/xml/PMC5123381.xml	P	387766 : 387767	CM	ter initial treatment. A P value < 0.05 obtained us
./___Corpus/Medline/xml/PMC5123381.xml	UACC62	387956 : 387962	CM	            Treatment of UACC62 melanoma cells with T-VE
./___Corpus/Medline/xml/PMC5123381.xml	P	388075 : 388076	CM	ompared to no treatment (P < 0.013), while treatmen
./___Corpus/Medline/xml/PMC5123381.xml	P	388167 : 388168	CM	ificant decrease (2.1 %, P = 0.42). However, combin
./___Corpus/Medline/xml/PMC5123381.xml	TVEC	388213 : 388217	CM	ombination RT (8 Gy) and TVEC (1 MOI) resulted in a si
./___Corpus/Medline/xml/PMC5123381.xml	P	388286 : 388287	CM	in cell viability (21 %, P < 0.001) compared with n
./___Corpus/Medline/xml/PMC5123381.xml	vitro	388624 : 388629	CM	d T-VEC results in an in vitro decrease in melanoma cel
./___Corpus/Medline/xml/PMC5123381.xml	CAPRA	389237 : 389242	CM	4 Interim results of the CAPRA clinical trial: CAVATAK 
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	389259 : 389266	CM	he CAPRA clinical trial: CAVATAK and pemrolizumab in adva
./___Corpus/Medline/xml/PMC5123381.xml	K	389448 : 389449	CM	 Daniel Medina1, Praveen K Bommareddy1, Darren Shaf
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAKä	389556 : 389564	CM	und                      CAVATAKä is a novel bio-selected 
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	389638 : 389643	CM	utic Coxsackievirus A21 (CVA21) strain. Intratumoral (i
./___Corpus/Medline/xml/PMC5123381.xml	i.t	389667 : 389670	CM	1) strain. Intratumoral (i.t.) CAVATAKä injection can
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAKä	389673 : 389681	CM	ain. Intratumoral (i.t.) CAVATAKä injection can induce sel
./___Corpus/Medline/xml/PMC5123381.xml	g-INF	389761 : 389766	CM	mmune-cell infiltration, g-INF response gene up-regulat
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	389806 : 389811	CM	up-regulation, increased PD-L1 expression, tumor cell l
./___Corpus/Medline/xml/PMC5123381.xml	lysis	389835 : 389840	RN	1 expression, tumor cell lysis and systemic immune resp
./___Corpus/Medline/xml/PMC5123381.xml	i.t	389974 : 389977	CM	led that combinations of i.t. CVA21 and anti-PD-1 blo
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	389979 : 389984	CM	hat combinations of i.t. CVA21 and anti-PD-1 blockade m
./___Corpus/Medline/xml/PMC5123381.xml	anti-	389989 : 389994	CPR	ations of i.t. CVA21 and anti-PD-1 blockade mediate sig
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAKä	390147 : 390155	CM	al evaluates combination CAVATAKä and pembrolizumab based 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	390207 : 390212	CM	 increased expression of PD-L1 following virus administ
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	390320 : 390325	CM	nts with increased tumor PD-L1.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	i.t	390400 : 390403	CM	is is a phase I trial of i.t. CVA21 and pembrolizumab
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	390405 : 390410	CM	 a phase I trial of i.t. CVA21 and pembrolizumab for tr
./___Corpus/Medline/xml/PMC5123381.xml	IIIC-IVM1c	390473 : 390483	CM	eated unresectable Stage IIIC-IVM1c melanoma. Patients recei
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	390525 : 390531	CM	ts receive up to 3 x 108 TCID50 CVA21 i.t. on days 1,3,5
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	390532 : 390537	CM	ive up to 3 x 108 TCID50 CVA21 i.t. on days 1,3,5,8 and
./___Corpus/Medline/xml/PMC5123381.xml	3w	390667 : 390669	CM	mab (2 mg/kg) i.v. every 3w starting day 8. The prim
./___Corpus/Medline/xml/PMC5123381.xml	PFS	390863 : 390866	CM	n-free survival at 12 m, PFS hazard ratio, 1y and ove
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	391023 : 391028	CM	lanoma-specific T cells, PD-L1 expression and Th1/Th2 g
./___Corpus/Medline/xml/PMC5123381.xml	Th1	391044 : 391047	CM	ls, PD-L1 expression and Th1/Th2 gene expression prof
./___Corpus/Medline/xml/PMC5123381.xml	Th2	391048 : 391051	CM	PD-L1 expression and Th1/Th2 gene expression profiles
./___Corpus/Medline/xml/PMC5123381.xml	NCI	391128 : 391131	CM	y will be assessed using NCI CTCAE. Response will uti
./___Corpus/Medline/xml/PMC5123381.xml	CTCAE	391132 : 391137	CM	ll be assessed using NCI CTCAE. Response will utilize S
./___Corpus/Medline/xml/PMC5123381.xml	To-date	391454 : 391461	CM	lts                      To-date, 10 subjects have been e
./___Corpus/Medline/xml/PMC5123381.xml	PD	391534 : 391536	CM	t leaving the study with PD and another patient with
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	391690 : 391695	CM	onal symptoms related to CVA21 and standard pembrolizum
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	391929 : 391934	CM	ion systemic exposure to CVA21.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	392009 : 392014	CM	  At present combination CVA21 and pembrolizumab appear
./___Corpus/Medline/xml/PMC5123381.xml	CVA21	392313 : 392318	CM	se data set. Combination CVA21 and pembrolizumab may re
./___Corpus/Medline/xml/PMC5123381.xml	cytosine	392617 : 392625	CM	   P315 Gene transfer of cytosine deaminase with Toca 511 
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorocytosine	392680 : 392696	CM	ubsequent treatment with 5-fluorocytosine induces anti-tumor immun
./___Corpus/Medline/xml/PMC5123381.xml	anti-	392705 : 392710	CPR	5-fluorocytosine induces anti-tumor immunity           
./___Corpus/Medline/xml/PMC5123381.xml	cytosine	393033 : 393041	CM	licating vector encoding cytosine deaminase to selectively
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorocytosine	393131 : 393147	CM	nation with the prodrug, 5-fluorocytosine (5-FC), Toca 511 and 5-F
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393149 : 393153	CM	odrug, 5-fluorocytosine (5-FC), Toca 511 and 5-FC kill
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393169 : 393173	CM	ine (5-FC), Toca 511 and 5-FC kill tumor cells by loca
./___Corpus/Medline/xml/PMC5123381.xml	5-fluorouracil	393214 : 393228	CM	s by local production of 5-fluorouracil (5-FU), and induce a loc
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	393230 : 393234	CM	ction of 5-fluorouracil (5-FU), and induce a local imm
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393335 : 393339	CM	vival after cessation of 5-FC treatment. The work desc
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393466 : 393470	CM	lowing administration of 5-FC as well as the role of T
./___Corpus/Medline/xml/PMC5123381.xml	anti-	393515 : 393520	CPR	 of T cells in long-term anti-tumor immune memory.     
./___Corpus/Medline/xml/PMC5123381.xml	Tu-2449SC	393613 : 393622	CM	 mouse glioma cell line, Tu-2449SC (2 % pretransduced with 
./___Corpus/Medline/xml/PMC5123381.xml	B6C3F1	393688 : 393694	CM	jected subcutaneously in B6C3F1 mice. 5-FC (500 mg/kg, I
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393701 : 393705	CM	aneously in B6C3F1 mice. 5-FC (500 mg/kg, IP, SID) or 
./___Corpus/Medline/xml/PMC5123381.xml	IP	393718 : 393720	CM	1 mice. 5-FC (500 mg/kg, IP, SID) or PBS treatment w
./___Corpus/Medline/xml/PMC5123381.xml	SID	393722 : 393725	CM	ce. 5-FC (500 mg/kg, IP, SID) or PBS treatment was in
./___Corpus/Medline/xml/PMC5123381.xml	PBS	393730 : 393733	CM	 (500 mg/kg, IP, SID) or PBS treatment was initiated 
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	393933 : 393937	CM	 6, 9, and 14 days after 5-FC start, tumors were harve
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394125 : 394129	CM	nt in mice that received 5-FC vs. PBS control. By day 
./___Corpus/Medline/xml/PMC5123381.xml	PBS	394134 : 394137	CM	e that received 5-FC vs. PBS control. By day 6 post 5
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394161 : 394165	CM	S control. By day 6 post 5-FC treatment initiation, tu
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	394258 : 394262	CM	erived suppressor cells (MDSC), and monocyte populatio
./___Corpus/Medline/xml/PMC5123381.xml	PBS	394347 : 394350	CM	eated tumors compared to PBS controls. This myeloid c
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394455 : 394459	CM	thers [1] using systemic 5-FU but was complemented by 
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394542 : 394546	CM	file with high levels of 5-FU in tumor tissue and unde
./___Corpus/Medline/xml/PMC5123381.xml	5-FU	394590 : 394594	CM	d undetectable levels of 5-FU in the plasma, thus avoi
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394664 : 394668	CM	oxicity. At 14 days post 5-FC treatment start, TAM and
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	394694 : 394698	CM	treatment start, TAM and MDSC remained reduced in tumo
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	394755 : 394759	CM	reated animals, and both CD4+ and CD8+ T cells were si
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	394764 : 394768	CM	imals, and both CD4+ and CD8+ T cells were significant
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	394849 : 394853	CM	oted that treatment with 5-FC induced high expression 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	394881 : 394885	CM	duced high expression of IFNγ in CD8+ T cells and pola
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	394889 : 394893	CM	gh expression of IFNγ in CD8+ T cells and polarized CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	394916 : 394920	CM	8+ T cells and polarized CD4+ T helper cells away from
./___Corpus/Medline/xml/PMC5123381.xml	Th2	394946 : 394949	CM	T helper cells away from Th2 and Th17 differentiation
./___Corpus/Medline/xml/PMC5123381.xml	Th17	394954 : 394958	CM	 cells away from Th2 and Th17 differentiation pathways
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	395063 : 395067	CM	 of animals treated with 5-FC and such animals resiste
./___Corpus/Medline/xml/PMC5123381.xml	Tu-2449	395304 : 395311	CM	 established, orthotopic Tu-2449 tumors in recipient naïv
./___Corpus/Medline/xml/PMC5123381.xml	5-FC	395461 : 395465	CM	              Toca 511 + 5-FC treatment results in red
./___Corpus/Medline/xml/PMC5123381.xml	anti-	395622 : 395627	CPR	imately establishment of anti-tumor immune response.   
./___Corpus/Medline/xml/PMC5123381.xml	5-Fluorouracil	395778 : 395792	CM	 M, Chevriaux A, et al.: 5-Fluorouracil selectively kills tumor-
./___Corpus/Medline/xml/PMC5123381.xml	3052–	395943 : 395948	CPR	. Cancer Res 2010, 70(8):3052–3061.                    
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396113 : 396118	CPR	through viral evasion of anti-viral T cells            
./___Corpus/Medline/xml/PMC5123381.xml	OV	396379 : 396381	CM	oe to oncolytic viruses (OV). It is a friend because
./___Corpus/Medline/xml/PMC5123381.xml	OV	396407 : 396409	CM	. It is a friend because OV rely on anti-tumor cytot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396418 : 396423	CPR	riend because OV rely on anti-tumor cytotoxic T lymphoc
./___Corpus/Medline/xml/PMC5123381.xml	CTL	396454 : 396457	CM	cytotoxic T lymphocytes (CTL) for a major component o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	396675 : 396680	CPR	production. In this way, anti-viral CTL limit the numbe
./___Corpus/Medline/xml/PMC5123381.xml	CTL	396686 : 396689	CM	 In this way, anti-viral CTL limit the number of vira
./___Corpus/Medline/xml/PMC5123381.xml	CTL	396779 : 396782	CM	ion of tumor neo-antigen CTL necessary for achieving 
./___Corpus/Medline/xml/PMC5123381.xml	OV	396855 : 396857	CM	es. BeneVir’s T-Stealth™ OV arming technology blocks
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397069 : 397074	CPR	tumor cells invisible to anti-viral CTL. By evading ant
./___Corpus/Medline/xml/PMC5123381.xml	CTL	397080 : 397083	CM	 invisible to anti-viral CTL. By evading anti-viral C
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397096 : 397101	CPR	ti-viral CTL. By evading anti-viral CTL, T-Stealth™ arm
./___Corpus/Medline/xml/PMC5123381.xml	CTL	397107 : 397110	CM	L. By evading anti-viral CTL, T-Stealth™ armed OV kil
./___Corpus/Medline/xml/PMC5123381.xml	OV	397129 : 397131	CM	al CTL, T-Stealth™ armed OV kill more cancer cells i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397243 : 397248	CPR	in enhanced induction of anti-tumor CTL. T-Stealth™ arm
./___Corpus/Medline/xml/PMC5123381.xml	CTL	397254 : 397257	CM	 induction of anti-tumor CTL. T-Stealth™ armed OV are
./___Corpus/Medline/xml/PMC5123381.xml	OV	397276 : 397278	CM	or CTL. T-Stealth™ armed OV are designed to combine 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397396 : 397401	CPR	ause ICI facilitate both anti-tumor as well as anti-vir
./___Corpus/Medline/xml/PMC5123381.xml	anti-	397418 : 397423	CPR	th anti-tumor as well as anti-viral CTL effector functi
./___Corpus/Medline/xml/PMC5123381.xml	CTL	397429 : 397432	CM	or as well as anti-viral CTL effector function in the
./___Corpus/Medline/xml/PMC5123381.xml	OV	397531 : 397533	CM	 vs. foe dynamic between OV and the immune system.  
./___Corpus/Medline/xml/PMC5123381.xml	OV	397659 : 397661	CM	lication competent HSV-1 OV encoding T-Stealth™ tech
./___Corpus/Medline/xml/PMC5123381.xml	murine	397763 : 397769	CM	th™ technology or encode murine GM-CSF. These viruses we
./___Corpus/Medline/xml/PMC5123381.xml	murine	397920 : 397926	CM	rs in multiple syngeneic murine tumor models.           
./___Corpus/Medline/xml/PMC5123381.xml	murine	398067 : 398073	CM	h™ technology or express murine GM-CSF, the T-Stealth™ a
./___Corpus/Medline/xml/PMC5123381.xml	OV	398103 : 398105	CM	SF, the T-Stealth™ armed OV persisted longer in the 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398184 : 398189	CPR	hanced the generation of anti-tumor CTL. Simultaneous t
./___Corpus/Medline/xml/PMC5123381.xml	CTL	398195 : 398198	CM	generation of anti-tumor CTL. Simultaneous treatment 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	398279 : 398283	CM	ed HSV-1 and ICI against PD-1 and CTLA-4 yielded syner
./___Corpus/Medline/xml/PMC5123381.xml	murine	398351 : 398357	CM	an aggressive bi-lateral murine tumor model. Detailed an
./___Corpus/Medline/xml/PMC5123381.xml	HSV-1	398467 : 398472	CM	hat the T-Stealth™ armed HSV-1 induces greater infiltra
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	398505 : 398509	CM	 greater infiltration of CD8+ CTL and significantly in
./___Corpus/Medline/xml/PMC5123381.xml	CTL	398510 : 398513	CM	ter infiltration of CD8+ CTL and significantly increa
./___Corpus/Medline/xml/PMC5123381.xml	OV	398636 : 398638	CM	ealth™ technology allows OV to resist premature clea
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398672 : 398677	CPR	t premature clearance by anti-viral CTL. Because ICI en
./___Corpus/Medline/xml/PMC5123381.xml	CTL	398683 : 398686	CM	 clearance by anti-viral CTL. Because ICI enhance the
./___Corpus/Medline/xml/PMC5123381.xml	anti-	398723 : 398728	CPR	I enhance the ability of anti-viral CTL to clear OV fro
./___Corpus/Medline/xml/PMC5123381.xml	CTL	398734 : 398737	CM	he ability of anti-viral CTL to clear OV from the tum
./___Corpus/Medline/xml/PMC5123381.xml	OV	398747 : 398749	CM	 anti-viral CTL to clear OV from the tumor microenvi
./___Corpus/Medline/xml/PMC5123381.xml	OV	398800 : 398802	CM	onment, T-Stealth™ armed OV hold great promise for s
./___Corpus/Medline/xml/PMC5123381.xml	OV	398910 : 398912	CM	e first T-Stealth™ armed OV is currently undergoing 
./___Corpus/Medline/xml/PMC5123381.xml	cGMP	398937 : 398941	CM	 is currently undergoing cGMP manufacturing and a phas
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	399098 : 399105	CM	 an innovative oncolytic vaccine platform to tilt immune 
./___Corpus/Medline/xml/PMC5123381.xml	Erkko	399224 : 399229	CM	nen1, Cristian Capasso2, Erkko Ylösmäki2, Vincenzo Ceru
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399346 : 399351	CPR	valuated to activate the anti-tumor immunity for combin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399700 : 399705	CPR	on can induce a cellular anti-tumor response. However, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	399744 : 399749	CPR	. However, virus-induced anti-tumor responses seem to b
./___Corpus/Medline/xml/PMC5123381.xml	anti-	400073 : 400078	CPR	vate clinically relevant anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	MHC	400200 : 400203	CM	s vaccine platform where MHC I-restricted immunogenic
./___Corpus/Medline/xml/PMC5123381.xml	SIINFEKL	400424 : 400432	CM	assical proof-of-concept SIINFEKL peptide (the chicken ova
./___Corpus/Medline/xml/PMC5123381.xml	vitro	400644 : 400649	CM	approach in different in vitro and immunocompetent in v
./___Corpus/Medline/xml/PMC5123381.xml	murine	400688 : 400694	CM	petent in vivo models of murine and human melanoma.     
./___Corpus/Medline/xml/PMC5123381.xml	MHC	401253 : 401256	CM	ly cross-presented in an MHC I restricted manner and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	401397 : 401401	CM	ency of peptide-specific CD8+ T cells were clearly ele
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	401603 : 401610	CM	RAd is a novel oncolytic vaccine platform which innovativ
./___Corpus/Medline/xml/PMC5123381.xml	anti-	401703 : 401708	CPR	topes to enable a robust anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402039 : 402043	CM	e efficacy and safety of HF10 oncolytic virus immunoth
./___Corpus/Medline/xml/PMC5123381.xml	HI	402187 : 402189	CM	                  Robert HI Andtbacka1, Merrick Ross
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402465 : 402469	CM	und                      HF10, an attenuated, replicat
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402611 : 402615	CM	tic viral immunotherapy. HF10 (intratumoral injection)
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402804 : 402808	CM	ether the combination of HF10 and the immune checkpoin
./___Corpus/Medline/xml/PMC5123381.xml	HF10	402895 : 402899	CM	 the antitumor effect of HF10.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	IIIB	402972 : 402976	CM	Ipi naïve pts with stage IIIB, IIIC or IV unresectable
./___Corpus/Medline/xml/PMC5123381.xml	IIIC	402978 : 402982	CM	ïve pts with stage IIIB, IIIC or IV unresectable melan
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403026 : 403030	CM	 melanoma were enrolled. HF10 was administered intratu
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	403101 : 403107	CM	r multiple tumors (1x107 TCID50/mL, up to 5 mL/dose); 4 
./___Corpus/Medline/xml/PMC5123381.xml	IIIB	403694 : 403698	CM	of which 20 % were stage IIIB, 43 % stage IIIC, and 37
./___Corpus/Medline/xml/PMC5123381.xml	IIIC	403711 : 403715	CM	e stage IIIB, 43 % stage IIIC, and 37 % stage IV melan
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403750 : 403754	CM	 stage IV melanoma. Most HF10-related adverse events (
./___Corpus/Medline/xml/PMC5123381.xml	G2	403791 : 403793	CM	erse events (AEs) were ≤ G2, similar to HF10 monothe
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403806 : 403810	CM	s) were ≤ G2, similar to HF10 monotherapy. No DLTs wer
./___Corpus/Medline/xml/PMC5123381.xml	DLTs	403827 : 403831	CM	 to HF10 monotherapy. No DLTs were reported; 3 G4 AEs 
./___Corpus/Medline/xml/PMC5123381.xml	G3	403904 : 403906	CM	ment related. 30.4 % had G3 AEs. HF10-related G3 AEs
./___Corpus/Medline/xml/PMC5123381.xml	HF10	403912 : 403916	CM	ated. 30.4 % had G3 AEs. HF10-related G3 AEs (n = 3) w
./___Corpus/Medline/xml/PMC5123381.xml	BORR	404066 : 404070	CM	aluable pts, preliminary BORR at 24 wks was 42 % and o
./___Corpus/Medline/xml/PMC5123381.xml	Th1	404520 : 404523	CM	≥2 fold induction of the Th1 cytokines IFN-gamma and/
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	404551 : 404560	CM	tokines IFN-gamma and/or TNF-alpha compared to baseline at 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	404734 : 404742	CM	tical analysis of T cell cytokine induction in response to
./___Corpus/Medline/xml/PMC5123381.xml	HF10	404872 : 404876	CM	             Combination HF10 and ipi treatment is saf
./___Corpus/Medline/xml/PMC5123381.xml	Th1	405016 : 405019	CM	re pts. Peripheral blood Th1 cytokine upregulation ma
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	405020 : 405028	CM	ts. Peripheral blood Th1 cytokine upregulation may be a po
./___Corpus/Medline/xml/PMC5123381.xml	HF10	405084 : 405088	CM	l marker for response in HF10 + ipi treatment.        
./___Corpus/Medline/xml/PMC5123381.xml	CALM	405158 : 405162	CM	           P319 Phase II CALM extension study: intratu
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	405193 : 405200	CM	sion study: intratumoral CAVATAK™ increases immune-cell i
./___Corpus/Medline/xml/PMC5123381.xml	HI	405393 : 405395	CM	                  Robert HI Andtbacka1, Brendan Curt
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	405587 : 405594	CM	und                      CAVATAK™, an oncolytic immunothe
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	405704 : 405711	CM	umoral (IT) injection of CAVATAK can induce preferential 
./___Corpus/Medline/xml/PMC5123381.xml	lysis	405763 : 405768	RN	mor cell infection, cell lysis and enhancement of a sys
./___Corpus/Medline/xml/PMC5123381.xml	anti-	405799 : 405804	CPR	nhancement of a systemic anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	CALM	405840 : 405844	CM	e response. The phase II CALM study investigated the e
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	405894 : 405901	CM	fficacy and safety of IT CAVATAK in 57 patients (pts) wit
./___Corpus/Medline/xml/PMC5123381.xml	DRR	405989 : 405992	CM	firmed ORR of 28.1 % and DRR (>6 mths) of 21.1 %. Pre
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	406083 : 406090	CM	erstanding the impact of CAVATAK on immune cell infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	CALM	406319 : 406323	CM	                  In the CALM extension study a cohort
./___Corpus/Medline/xml/PMC5123381.xml	TCID50	406400 : 406406	CM	s received up to 3 x 108 TCID50 CAVATAK IT on study days
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	406407 : 406414	CM	ved up to 3 x 108 TCID50 CAVATAK IT on study days 1, 3, 5
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	406836 : 406843	CM	ssessment in this study, CAVATAK-treated lesions from 6 p
./___Corpus/Medline/xml/PMC5123381.xml	DC	407128 : 407130	CM	playing disease control (DC) compared to progressing
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	407198 : 407202	CM	cular elevated levels of CD8+ cells and PD-L1+ cells. 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1+	407213 : 407219	CM	levels of CD8+ cells and PD-L1+ cells. NanoString® RNA a
./___Corpus/Medline/xml/PMC5123381.xml	RNA	407239 : 407242	CM	D-L1+ cells. NanoString® RNA analysis of pre- and pos
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	407383 : 407388	CM	int molecules, including PD-L1, CTLA-4, IDO, TIM-3 and 
./___Corpus/Medline/xml/PMC5123381.xml	IDO	407398 : 407401	CM	including PD-L1, CTLA-4, IDO, TIM-3 and LAG-3 in lesi
./___Corpus/Medline/xml/PMC5123381.xml	TIM-3	407403 : 407408	CM	ding PD-L1, CTLA-4, IDO, TIM-3 and LAG-3 in lesions exh
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	407413 : 407418	CM	, CTLA-4, IDO, TIM-3 and LAG-3 in lesions exhibiting DC
./___Corpus/Medline/xml/PMC5123381.xml	DC	407441 : 407443	CM	-3 in lesions exhibiting DC compared to progressing 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	407616 : 407619	CM	rferon-induced and viral RNA response genes. Of notab
./___Corpus/Medline/xml/PMC5123381.xml	DC	407694 : 407696	CM	rential up-regulation in DC lesions of CD122 (a comp
./___Corpus/Medline/xml/PMC5123381.xml	CD122	407708 : 407713	CM	ulation in DC lesions of CD122 (a component of the IL-2
./___Corpus/Medline/xml/PMC5123381.xml	anti-	407818 : 407823	CPR	al prognostic marker for anti-tumor activity by anti-CT
./___Corpus/Medline/xml/PMC5123381.xml	anti-	407841 : 407846	CPR	r anti-tumor activity by anti-CTLA-4 blockade strategie
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	407887 : 407894	CM	strategies. In addition, CAVATAK treatment initiated the 
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	408143 : 408150	CM	hanges in TME induced by CAVATAK support combination ther
./___Corpus/Medline/xml/PMC5123381.xml	anti-	408215 : 408220	CPR	 checkpoints, especially anti-CTLA-4. There is an ongoi
./___Corpus/Medline/xml/PMC5123381.xml	Ib	408254 : 408256	CM	here is an ongoing phase Ib study of CAVATAK + ipili
./___Corpus/Medline/xml/PMC5123381.xml	CAVATAK	408266 : 408273	CM	ngoing phase Ib study of CAVATAK + ipilimumab showing hig
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	408492 : 408497	CM	ic adenovirus coding for CD40L as an enabler of dendrit
./___Corpus/Medline/xml/PMC5123381.xml	Zafar1	408582 : 408588	CM	                   Sadia Zafar1, Suvi Parviainen1, Mikko
./___Corpus/Medline/xml/PMC5123381.xml	Bramante1	408680 : 408689	CM	, Siri Tähtinen1, Simona Bramante1, Lotta Vassilev1, Hongji
./___Corpus/Medline/xml/PMC5123381.xml	DC	408868 : 408870	CM	         Dendritic cell (DC) therapy is currently co
./___Corpus/Medline/xml/PMC5123381.xml	DCs	409094 : 409097	CM	e biological function of DCs. Therefore, clinical out
./___Corpus/Medline/xml/PMC5123381.xml	DC	409133 : 409135	CM	, clinical outcomes with DC therapy have often been 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	409539 : 409543	CM	 armed adenoviruses with CD40 ligand (CD40L), best kno
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	409552 : 409557	CM	iruses with CD40 ligand (CD40L), best known for its cap
./___Corpus/Medline/xml/PMC5123381.xml	Ad3-hTERT-CMV-hCD40L	409729 : 409749	CM	onstructed a novel virus Ad3-hTERT-CMV-hCD40L which features Ad3 for e
./___Corpus/Medline/xml/PMC5123381.xml	Ad3	409765 : 409768	CM	MV-hCD40L which features Ad3 for enhanced tumor trans
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	409894 : 409899	CM	ng tumor selectivity and CD40L, a potent stimulator of 
./___Corpus/Medline/xml/PMC5123381.xml	calcium phosphate	410039 : 410056	CM	3 cells using a standard calcium phosphate method. Then, HeLa cells
./___Corpus/Medline/xml/PMC5123381.xml	HeLa	410071 : 410075	CM	 phosphate method. Then, HeLa cells were infected with
./___Corpus/Medline/xml/PMC5123381.xml	Ad3-GFP	410128 : 410135	CM	e cell lysate containing Ad3-GFP virus for further virus 
./___Corpus/Medline/xml/PMC5123381.xml	MTS	410345 : 410348	CM	 of surviving cells with MTS assay. To deeply dissect
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	410377 : 410382	CM	ay. To deeply dissect if CD40L encoding adenovirus can 
./___Corpus/Medline/xml/PMC5123381.xml	murine	410459 : 410465	CM	ironment, we generated a murine version of the virus (Ad
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	410488 : 410491	CM	ne version of the virus (Ad5/3-CMV-mCD40L).          
./___Corpus/Medline/xml/PMC5123381.xml	3-CMV-mCD40L	410492 : 410504	CM	ersion of the virus (Ad5/3-CMV-mCD40L).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	Ad3	410672 : 410675	CM	mvented by using a fully Ad3 platform. As human [1] a
./___Corpus/Medline/xml/PMC5123381.xml	Ad3	410746 : 410749	CM	ve shown, the ability of Ad3 to successfully reach tu
./___Corpus/Medline/xml/PMC5123381.xml	DC	410860 : 410862	CM	n immunocompetent model, DC therapy in combination w
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	410891 : 410894	CM	rapy in combination with Ad5/3-CMV-mCD40L showed pote
./___Corpus/Medline/xml/PMC5123381.xml	3-CMV-mCD40L	410895 : 410907	CM	 in combination with Ad5/3-CMV-mCD40L showed potent antitumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	411056 : 411061	CM	he adenovirus expressing CD40L and DCs combination trea
./___Corpus/Medline/xml/PMC5123381.xml	DCs	411066 : 411069	CM	rus expressing CD40L and DCs combination treatment co
./___Corpus/Medline/xml/PMC5123381.xml	RANTES	411215 : 411221	CM	e 1 cytokines IFN-gamma, RANTES, and TNF-alpha and the r
./___Corpus/Medline/xml/PMC5123381.xml	TNF-alpha	411227 : 411236	CM	s IFN-gamma, RANTES, and TNF-alpha and the reduction of imm
./___Corpus/Medline/xml/PMC5123381.xml	O	411532 : 411533	CM	             1. Hemminki O, Diaconu I, Cerullo V, e
./___Corpus/Medline/xml/PMC5123381.xml	Ad3-hTERT-E1A	411565 : 411578	CM	nu I, Cerullo V, et al.: Ad3-hTERT-E1A, a Fully Serotype 3 onco
./___Corpus/Medline/xml/PMC5123381.xml	1821–	411688 : 411693	CPR	ancer. Mol Ther 2012, 20:1821–1830.                  Pr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	412064 : 412068	CM	tor immune cells such as CD8+ cells and natural killer
./___Corpus/Medline/xml/PMC5123381.xml	lyse	412124 : 412128	CM	cells is to identify and lyse target cells. NK cell - 
./___Corpus/Medline/xml/PMC5123381.xml	chromium	412265 : 412273	CM	e release of radioactive chromium from target cells follow
./___Corpus/Medline/xml/PMC5123381.xml	lysis	412302 : 412307	RN	m target cells following lysis. These assays are labori
./___Corpus/Medline/xml/PMC5123381.xml	lysis	412420 : 412425	RN	ct minor changes in cell lysis. We have previously deve
./___Corpus/Medline/xml/PMC5123381.xml	T2	412969 : 412971	CM	et cells. K562, A549 and T2 tumor cells were used as
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	413046 : 413050	CM	blood mononuclear cells (PBMC) as effector cells. When
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	413120 : 413124	CM	y in 96 well format, the PBMC were plated in serial di
./___Corpus/Medline/xml/PMC5123381.xml	MHC	413488 : 413491	CM	(one of which had intact MHC receptors) with three di
./___Corpus/Medline/xml/PMC5123381.xml	chromium	413711 : 413719	CM	t cell visualization and chromium release assay in a 96-we
./___Corpus/Medline/xml/PMC5123381.xml	96-	413739 : 413742	CPR	omium release assay in a 96-well format required the 
./___Corpus/Medline/xml/PMC5123381.xml	MHC	414317 : 414320	CM	ontrol target cells with MHC receptors are not suscep
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	414648 : 414652	CM	lar value when access to PBMC is limited, such as in p
./___Corpus/Medline/xml/PMC5123381.xml	INT230-6	414780 : 414788	CM	ntratumoral injection of INT230-6 induces protective T cel
./___Corpus/Medline/xml/PMC5123381.xml	H	414845 : 414846	CM	ity Anja C Bloom1, Lewis H Bender2, Ian B Walters2,
./___Corpus/Medline/xml/PMC5123381.xml	lysis	415402 : 415407	RN	beyond direct tumor cell lysis. One major aspect is tha
./___Corpus/Medline/xml/PMC5123381.xml	anti-	415779 : 415784	CPR	 strong and long lasting anti-tumor T cell responses.  
./___Corpus/Medline/xml/PMC5123381.xml	INT230-6	415926 : 415934	CM	e cytotoxic formulation, INT230-6, was administered intrat
./___Corpus/Medline/xml/PMC5123381.xml	murine	416017 : 416023	CM	nto subcutaneous 300 mm3 murine Colon26 tumors.         
./___Corpus/Medline/xml/PMC5123381.xml	INT230-6	416271 : 416279	CM	he protection induced by INT230-6. Mice with CR were prote
./___Corpus/Medline/xml/PMC5123381.xml	CD4	416428 : 416431	CM	tection was abrogated by CD4/CD8 double depletion pri
./___Corpus/Medline/xml/PMC5123381.xml	CD8	416432 : 416435	CM	ion was abrogated by CD4/CD8 double depletion prior t
./___Corpus/Medline/xml/PMC5123381.xml	CTL	416612 : 416615	CM	gp70 containing the AH-1 CTL epitope. AH-1-specific C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	416639 : 416643	CM	L epitope. AH-1-specific CD8+ T cells were detected ex
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	416783 : 416787	CM	 confirming induction of CD8+ T cell specific response
./___Corpus/Medline/xml/PMC5123381.xml	INT230-6	416834 : 416842	CM	nses to tumor cells upon INT230-6 treatment.              
./___Corpus/Medline/xml/PMC5123381.xml	INT230-6	416911 : 416919	CM	                  Hence, INT230-6 given locally to treat t
./___Corpus/Medline/xml/PMC5123381.xml	Fluorine-19	417044 : 417055	CM	                    P323 Fluorine-19 nuclear magnetic resonan
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	417117 : 417127	CM	track and quantify human transgenic T cell biodistribution i
./___Corpus/Medline/xml/PMC5123381.xml	murine	417154 : 417160	CM	 cell biodistribution in murine studies of glioblastoma 
./___Corpus/Medline/xml/PMC5123381.xml	GBM	417502 : 417505	CM	ise for the treatment of GBM. To uncover the mechanis
./___Corpus/Medline/xml/PMC5123381.xml	EGFRvIII	418047 : 418055	CM	surface antibody against EGFRvIII, a common receptor in GB
./___Corpus/Medline/xml/PMC5123381.xml	CAR-T	418163 : 418168	CM	 those of naïve T cells. CAR-T cells and naïve T cells 
./___Corpus/Medline/xml/PMC5123381.xml	perfluorocarbon	418229 : 418244	CM	ellularly labeled with a perfluorocarbon (PFC) emulsion ex vivo a
./___Corpus/Medline/xml/PMC5123381.xml	PFC	418246 : 418249	CM	 with a perfluorocarbon (PFC) emulsion ex vivo and in
./___Corpus/Medline/xml/PMC5123381.xml	SCID	418298 : 418302	CM	njected intravenously in SCID mice bearing bilateral s
./___Corpus/Medline/xml/PMC5123381.xml	U87	418345 : 418348	CM	teral subcutaneous human U87 tumors engineered to exp
./___Corpus/Medline/xml/PMC5123381.xml	EGFRvIII	418378 : 418386	CM	rs engineered to express EGFRvIII. Tumor growth was monito
./___Corpus/Medline/xml/PMC5123381.xml	fluorine-19	418520 : 418531	CM	 were then harvested for fluorine-19 NMR measurements to quan
./___Corpus/Medline/xml/PMC5123381.xml	fluorine	418565 : 418573	CM	urements to quantify the fluorine content and apparent cel
./___Corpus/Medline/xml/PMC5123381.xml	fluorine	419404 : 419412	CM	recipients had twice the fluorine signal compared to CAR T
./___Corpus/Medline/xml/PMC5123381.xml	19F	419721 : 419724	CM	            To conclude, 19F NMR analysis, in conjunc
./___Corpus/Medline/xml/PMC5123381.xml	fate	419967 : 419971	CM	cell biodistribution and fate in preclinical studies. 
./___Corpus/Medline/xml/PMC5123381.xml	19F	420032 : 420035	CM	ently performing in vivo 19F MRI studies using the PF
./___Corpus/Medline/xml/PMC5123381.xml	PFC	420058 : 420061	CM	9F MRI studies using the PFC technology.             
./___Corpus/Medline/xml/PMC5123381.xml	anti-	420214 : 420219	CPR	erapy reveals functional anti-tumor antibodies within e
./___Corpus/Medline/xml/PMC5123381.xml	IgG	420252 : 420255	CM	tibodies within expanded IgG lineages                
./___Corpus/Medline/xml/PMC5123381.xml	Sokolove2	420426 : 420435	CM	 Yann Chong Tan1, Jeremy Sokolove2, Dongkyoon Kim1, Kevin W
./___Corpus/Medline/xml/PMC5123381.xml	PCR	421362 : 421365	CM	h reverse transcription, PCR and next generation sequ
./___Corpus/Medline/xml/PMC5123381.xml	vitro	421632 : 421637	CM	binant antibodies for in vitro and in vivo testing.    
./___Corpus/Medline/xml/PMC5123381.xml	CDR	421881 : 421884	CM	 of germline gene usage, CDR lengths, and levels of s
./___Corpus/Medline/xml/PMC5123381.xml	vitro	422557 : 422562	CM	ir ability to mediate in vitro cancer cell killing thro
./___Corpus/Medline/xml/PMC5123381.xml	ADCC	422620 : 422624	CM	ous mechanisms including ADCC, ADC, and/or ADCP. Prote
./___Corpus/Medline/xml/PMC5123381.xml	ADC	422626 : 422629	CM	chanisms including ADCC, ADC, and/or ADCP. Protein ar
./___Corpus/Medline/xml/PMC5123381.xml	ADCP	422638 : 422642	CM	luding ADCC, ADC, and/or ADCP. Protein arrays are bein
./___Corpus/Medline/xml/PMC5123381.xml	anti-	423059 : 423064	CPR	 patient antibodies have anti-tumor activity and suppor
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	423189 : 423197	CM	                    P325 Cytokine profile of sipuleucel-T 
./___Corpus/Medline/xml/PMC5123381.xml	P	423366 : 423367	CM	Charles G Drake1, Daniel P Petrylak2, Emmanuel S An
./___Corpus/Medline/xml/PMC5123381.xml	Antonarakis1	423390 : 423402	CM	 P Petrylak2, Emmanuel S Antonarakis1, Adam S Kibel3, Nancy N 
./___Corpus/Medline/xml/PMC5123381.xml	Vu4	423441 : 423444	CM	3, Nancy N Chang4, Tuyen Vu4, Dwayne Campogan4, Heath
./___Corpus/Medline/xml/PMC5123381.xml	Trager4	423489 : 423496	CM	Heather Haynes4, James B Trager4, Nadeem A Sheikh4, David
./___Corpus/Medline/xml/PMC5123381.xml	FDA	423649 : 423652	CM	otherapy approved by the FDA for treatment of asympto
./___Corpus/Medline/xml/PMC5123381.xml	(mCRPC)[1]	423756 : 423766	CM	esistant prostate cancer (mCRPC)[1]; it is manufactured from
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	423874 : 423880	CM	tured with the immunogen PA2024, a fusion of prostatic a
./___Corpus/Medline/xml/PMC5123381.xml	phosphatase	423909 : 423920	CM	fusion of prostatic acid phosphatase (PAP) conjugated to gran
./___Corpus/Medline/xml/PMC5123381.xml	PAP	423922 : 423925	CM	static acid phosphatase (PAP) conjugated to granulocy
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	424024 : 424030	CM	 and T cell responses to PA2024 and/or PAP correlate wit
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424038 : 424041	CM	sponses to PA2024 and/or PAP correlate with improved 
./___Corpus/Medline/xml/PMC5123381.xml	mCRPC	424107 : 424112	CM	 in sipuleucel-T–treated mCRPC patients [2]. To better 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424199 : 424203	CM	l responses, we assessed CD4+ and CD8+ T cells for pro
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	424208 : 424212	CM	es, we assessed CD4+ and CD8+ T cells for proliferatio
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424254 : 424262	CM	iferation, intracellular cytokine production, and cytokine
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424279 : 424287	CM	cytokine production, and cytokine release after PA2024 or 
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	424302 : 424308	CM	d cytokine release after PA2024 or PAP stimulation.     
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424312 : 424315	CM	 release after PA2024 or PAP stimulation.            
./___Corpus/Medline/xml/PMC5123381.xml	mCRPC	424421 : 424426	CM	rom sipuleucel-T–treated mCRPC patients (STRIDE) and no
./___Corpus/Medline/xml/PMC5123381.xml	STRIDE	424437 : 424443	CM	–treated mCRPC patients (STRIDE) and nonmetastatic, bioc
./___Corpus/Medline/xml/PMC5123381.xml	PC	424507 : 424509	CM	rrent, hormone-sensitive PC patients (STAND). Sample
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	424598 : 424603	CM	nth 6 post–sipuleucel-T. PBMCs were cultured in vitro a
./___Corpus/Medline/xml/PMC5123381.xml	vitro	424621 : 424626	CM	. PBMCs were cultured in vitro and stimulated with eith
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	424654 : 424660	CM	d stimulated with either PA2024 or PAP. CD4+ and CD8+ T 
./___Corpus/Medline/xml/PMC5123381.xml	PAP	424664 : 424667	CM	ed with either PA2024 or PAP. CD4+ and CD8+ T cells w
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424669 : 424673	CM	th either PA2024 or PAP. CD4+ and CD8+ T cells were as
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	424678 : 424682	CM	 PA2024 or PAP. CD4+ and CD8+ T cells were assessed (n
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	424761 : 424766	CM	r intracellular IL-2 and IFN-γ. The cytokine profile wa
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	424772 : 424780	CM	ular IL-2 and IFN-γ. The cytokine profile was confirmed in
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	424963 : 424969	CM	 Compared with baseline, PA2024-specific proliferating C
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	424993 : 424997	CM	4-specific proliferating CD4+ and CD8+ T cells had inc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	425002 : 425006	CM	c proliferating CD4+ and CD8+ T cells had increased in
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	425052 : 425057	CM	d intracellular IL-2 and IFN-γ at week 6 and month 6 wi
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425105 : 425108	CM	with a similar trend for PAP-specific proliferating T
./___Corpus/Medline/xml/PMC5123381.xml	​(Table4).4	425147 : 425158	CM	iferating T cells (Table ​(Table4).4). Compared with unstimul
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	425213 : 425219	CM	controls, a significant >2-fold increase in PA2024-stimu
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	425232 : 425238	CM	cant >2-fold increase in PA2024-stimulated IL-2 and IFN-
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	425259 : 425264	CM	2024-stimulated IL-2 and IFN-γ in supernatant was obser
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425337 : 425340	CM	er baseline (p < 0.001). PAP-stimulated IL-2 and IFN-
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	425361 : 425366	CM	 PAP-stimulated IL-2 and IFN-γ supernatant levels incre
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	425445 : 425450	CM	gnificantly elevated for IFN-γ at wk 6 (p < 0.10).     
./___Corpus/Medline/xml/PMC5123381.xml	PA2024	425562 : 425568	CM	rapy generated a de novo PA2024-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	425615 : 425623	CM	nse, as indicated by the cytokine release profile. The PAP
./___Corpus/Medline/xml/PMC5123381.xml	PAP	425645 : 425648	CM	ine release profile. The PAP-stimulated cytokine prof
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	425660 : 425668	CM	file. The PAP-stimulated cytokine profile suggests that pr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	425800 : 425805	CPR	uleucel-T reactivated an anti-PAP response in memory T 
./___Corpus/Medline/xml/PMC5123381.xml	PC	425888 : 425890	CM	uppressive mechanisms in PC.                  Acknow
./___Corpus/Medline/xml/PMC5123381.xml	PhD	425999 : 426002	CM	ovided by Brian R. Haas, PhD, were funded by Dendreon
./___Corpus/Medline/xml/PMC5123381.xml	Inc	426045 : 426048	CM	endreon Pharmaceuticals, Inc.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	PROVENGE	426348 : 426356	CM	                      1. PROVENGE® (sipuleucel-T) prescrib
./___Corpus/Medline/xml/PMC5123381.xml	Pdf	426547 : 426550	CM	w.valeant.com/Portals/25/Pdf/PI/Provenge-PI.pdf. Acce
./___Corpus/Medline/xml/PMC5123381.xml	PI	426551 : 426553	CM	leant.com/Portals/25/Pdf/PI/Provenge-PI.pdf. Accesse
./___Corpus/Medline/xml/PMC5123381.xml	137–	426666 : 426670	CPR	unol Immunother 2013, 62:137–147.                     
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	426701 : 426709	CM	                    P326 NKTR-255: an IL-15-based therapeu
./___Corpus/Medline/xml/PMC5123381.xml	IL	426714 : 426716	CM	       P326 NKTR-255: an IL-15-based therapeutic wit
./___Corpus/Medline/xml/PMC5123381.xml	15-	426719 : 426722	CPR	  P326 NKTR-255: an IL-15-based therapeutic with opti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	426777 : 426782	CPR	 biological activity and anti-tumor efficacy           
./___Corpus/Medline/xml/PMC5123381.xml	Quach1	427004 : 427010	CM	lapur1, Peiwen Kuo1, Phi Quach1, Lawrence Fong3, Deborah
./___Corpus/Medline/xml/PMC5123381.xml	H	427036 : 427037	CM	 Lawrence Fong3, Deborah H Charych1, Jonathan Zalev
./___Corpus/Medline/xml/PMC5123381.xml	Charych1	427038 : 427046	CM	awrence Fong3, Deborah H Charych1, Jonathan Zalevsky1     
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	427234 : 427242	CM	rapeutic, but the native cytokine has poor drug-like prope
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	427274 : 427282	CM	or drug-like properties. NKTR-255 is a novel immunotherape
./___Corpus/Medline/xml/PMC5123381.xml	IL	427351 : 427353	CM	ng of polymer-engineered IL-15 designed to optimally
./___Corpus/Medline/xml/PMC5123381.xml	IL	427390 : 427392	CM	 to optimally engage the IL-15 receptor complex and 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	427479 : 427487	CM	 vivo. Here we show that NKTR-255 has greatly improved pla
./___Corpus/Medline/xml/PMC5123381.xml	IL	427547 : 427549	CM	mor exposure relative to IL-15, induces NK and CD8+ 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	427569 : 427573	CM	to IL-15, induces NK and CD8+ T cell activation and pr
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	427747 : 427755	CM	kinetics and affinity of NKTR-255 for IL-15Rα were measure
./___Corpus/Medline/xml/PMC5123381.xml	IL-15Rα	427760 : 427767	CM	affinity of NKTR-255 for IL-15Rα were measured by surface
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	427902 : 427910	CM	eating CTLL-2 cells with NKTR-255 at a range of concentrat
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	427954 : 427969	RN	entrations and measuring phosphorylation of STAT5 in cell lysate 
./___Corpus/Medline/xml/PMC5123381.xml	STAT5	427973 : 427978	CM	uring phosphorylation of STAT5 in cell lysate by immuno
./___Corpus/Medline/xml/PMC5123381.xml	IL	428102 : 428104	CM	venous administration of IL-15 and NKTR-255 in norma
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428112 : 428120	CM	inistration of IL-15 and NKTR-255 in normal mice and in mi
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	428170 : 428176	CM	ce bearing sub-cutaneous B16F10 and CT-26 tumors, with a
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	428181 : 428186	CM	sub-cutaneous B16F10 and CT-26 tumors, with analytes qu
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428349 : 428357	CM	from peripheral blood of NKTR-255-treated and IL-15-treate
./___Corpus/Medline/xml/PMC5123381.xml	IL	428370 : 428372	CM	 of NKTR-255-treated and IL-15-treated normal mice a
./___Corpus/Medline/xml/PMC5123381.xml	15-	428375 : 428378	CPR	KTR-255-treated and IL-15-treated normal mice and fro
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	428482 : 428490	CM	e carrying sub-cutaneous TRAMP-C2 tumors. Efficacy was det
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	428566 : 428574	CM	 volume of sub-cutaneous TRAMP-C2 and CT-26, with q5dx3 tr
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	428579 : 428584	CM	b-cutaneous TRAMP-C2 and CT-26, with q5dx3 treatment wi
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428612 : 428620	CM	ith q5dx3 treatment with NKTR-255.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428668 : 428676	CM	lts                      NKTR-255 binds to IL-15Rα, and in
./___Corpus/Medline/xml/PMC5123381.xml	STAT5	428707 : 428712	CM	 to IL-15Rα, and induces STAT5 phosphorylation in CTLL-
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	428713 : 428728	RN	-15Rα, and induces STAT5 phosphorylation in CTLL-2 cells with sub
./___Corpus/Medline/xml/PMC5123381.xml	EC50	428764 : 428768	CM	cells with sub-nanomolar EC50. Following intravenous a
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428808 : 428816	CM	ravenous administration, NKTR-255 demonstrates a greatly r
./___Corpus/Medline/xml/PMC5123381.xml	IL	428875 : 428877	CM	earance rate compared to IL-15, with plasma t1/2 of 
./___Corpus/Medline/xml/PMC5123381.xml	22-	428902 : 428905	CPR	-15, with plasma t1/2 of 22-26 h versus <1 h for IL-1
./___Corpus/Medline/xml/PMC5123381.xml	IL	428926 : 428928	CM	 22-26 h versus <1 h for IL-15. Tumor exposure of NK
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	428951 : 428959	CM	IL-15. Tumor exposure of NKTR-255 was 50-fold greater than
./___Corpus/Medline/xml/PMC5123381.xml	50-fold	428964 : 428971	CM	exposure of NKTR-255 was 50-fold greater than IL-15 in B1
./___Corpus/Medline/xml/PMC5123381.xml	IL	428985 : 428987	CM	was 50-fold greater than IL-15 in B16F10-bearing C57
./___Corpus/Medline/xml/PMC5123381.xml	Bl6	429013 : 429016	CM	15 in B16F10-bearing C57/Bl6 mice and 110-fold greate
./___Corpus/Medline/xml/PMC5123381.xml	110-fold	429026 : 429034	CM	bearing C57/Bl6 mice and 110-fold greater in CT-26-bearing
./___Corpus/Medline/xml/PMC5123381.xml	CT-26-bearing	429046 : 429059	CM	 and 110-fold greater in CT-26-bearing Balb/c mice. Immunopheno
./___Corpus/Medline/xml/PMC5123381.xml	Ki-67	429137 : 429142	CM	e showed an induction of Ki-67 and CD122 expression in 
./___Corpus/Medline/xml/PMC5123381.xml	CD122	429147 : 429152	CM	n induction of Ki-67 and CD122 expression in NK cells, 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	429241 : 429249	CM	. In tumor-bearing mice, NKTR-255 treatment resulted in an
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429285 : 429288	CM	resulted in an increased CD8:CD4 and CD8:Treg ratio i
./___Corpus/Medline/xml/PMC5123381.xml	CD4	429289 : 429292	CM	lted in an increased CD8:CD4 and CD8:Treg ratio in tu
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429297 : 429300	CM	an increased CD8:CD4 and CD8:Treg ratio in tumor and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	429363 : 429366	CM	n increased frequency of CD8+TNF+IFNγ+ T cells. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	TNF	429367 : 429370	CM	creased frequency of CD8+TNF+IFNγ+ T cells. Tumor gro
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ+	429371 : 429376	CM	sed frequency of CD8+TNF+IFNγ+ T cells. Tumor growth in
./___Corpus/Medline/xml/PMC5123381.xml	CT-26	429431 : 429436	CM	ion was observed in both CT-26 and TRAMP-C2 models.    
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	429441 : 429449	CM	served in both CT-26 and TRAMP-C2 models.                 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	429508 : 429516	CM	ons                      NKTR-255 treatment results in sus
./___Corpus/Medline/xml/PMC5123381.xml	IL	429548 : 429550	CM	ent results in sustained IL-15 activity which induce
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	429577 : 429581	CM	5 activity which induces CD8+ T cell and NK cell activ
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-255	429717 : 429725	CM	ring mice. The design of NKTR-255 enables a potential drug
./___Corpus/Medline/xml/PMC5123381.xml	IL	429791 : 429793	CM	c strategy for accessing IL-15-based immunotherapy. 
./___Corpus/Medline/xml/PMC5123381.xml	15-	429796 : 429799	CPR	ategy for accessing IL-15-based immunotherapy.       
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	429884 : 429892	CM	7 Anti-tumor activity of NKTR-214; a CD122-biased agonist 
./___Corpus/Medline/xml/PMC5123381.xml	H	430201 : 430202	CM	en K Doberstein, Deborah H Charych                 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	430260 : 430268	CM	und                      NKTR-214 is a novel agonist of th
./___Corpus/Medline/xml/PMC5123381.xml	IL-2R	430384 : 430389	CM	nal to the heterodimeric IL-2R complex (IL-2Rbg). Here 
./___Corpus/Medline/xml/PMC5123381.xml	murine	430503 : 430509	CM	mechanism of action in a murine tumor model.            
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	430630 : 430636	CM	established subcutaneous B16F10 melanoma tumors were tre
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	430671 : 430679	CM	tumors were treated with NKTR-214 (q9dx3) or aldesleukin (
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	430776 : 430784	CM	e were treated once with NKTR-214 or with five daily admin
./___Corpus/Medline/xml/PMC5123381.xml	TIL	430879 : 430882	CM	nfiltrating lymphocytes (TIL) were assessed by flow c
./___Corpus/Medline/xml/PMC5123381.xml	sphingosine-1-phosphate	431112 : 431135	CM	hocytes to efficacy, the sphingosine-1-phosphate receptor modulator FTY72
./___Corpus/Medline/xml/PMC5123381.xml	FTY720	431155 : 431161	CM	phate receptor modulator FTY720 was administered daily a
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431214 : 431222	CM	e or in combination with NKTR-214.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	431288 : 431294	CM	       In the aggressive B16F10 model, vehicle-treated t
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431433 : 431441	CM	g time (TVQT) of 5 days. NKTR-214 showed better efficacy t
./___Corpus/Medline/xml/PMC5123381.xml	FTY720	431510 : 431516	CM	QT 16.7 versus 10 days). FTY720 significantly decreased 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431602 : 431610	CM	treatment, efficacy with NKTR-214 was reduced by 39 % but 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	431673 : 431676	CM	y abrogated. Analysis of TIL demonstrated that both N
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431700 : 431708	CM	L demonstrated that both NKTR-214 and aldesleukin led to a
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431776 : 431784	CM	vated NK cells. However, NKTR-214 administration led to si
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	431863 : 431867	CM	ases in total and memory CD8+ T cells, while the effec
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	431928 : 431936	CM	esleukin were transient. NKTR-214 also reduced the percent
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	432077 : 432085	CM	parameter. Consequently, NKTR-214 increased the average CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	432108 : 432112	CM	14 increased the average CD8+ T cell/Treg ratio to >40
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	432320 : 432328	CM	 changes in cell number, NKTR-214 treatment also induced m
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	432570 : 432578	CM	of the IL-2 pathway with NKTR-214 cannot be achieved even 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	432743 : 432748	CPR	ytes associated with the anti-tumor activity of NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	432766 : 432774	CM	e anti-tumor activity of NKTR-214 arise from T cells stimu
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	432866 : 432874	CM	nd the lymphoid tissues. NKTR-214 is currently being evalu
./___Corpus/Medline/xml/PMC5123381.xml	murine	433146 : 433152	CM	ctric field treatment of murine melanomas initiates an i
./___Corpus/Medline/xml/PMC5123381.xml	NPES	433435 : 433439	CM	Pulse Electro-Signaling (NPES) is a non-thermal, local
./___Corpus/Medline/xml/PMC5123381.xml	B6	434087 : 434089	CM	               14 female B6/J albino mice were given
./___Corpus/Medline/xml/PMC5123381.xml	B16-GFP	434149 : 434156	CM	al injections of 500,000 B16-GFP cells in 15uL HBSS. Upon
./___Corpus/Medline/xml/PMC5123381.xml	HBSS	434171 : 434175	CM	00 B16-GFP cells in 15uL HBSS. Upon reaching 5 mm in t
./___Corpus/Medline/xml/PMC5123381.xml	NPES	434411 : 434415	CM	weeks after resection or NPES treatment, both the six 
./___Corpus/Medline/xml/PMC5123381.xml	NPES	434474 : 434478	CM	y resected mice and four NPES-treated mice were inject
./___Corpus/Medline/xml/PMC5123381.xml	B16-GFP	434519 : 434526	CM	re injected with 200,000 B16-GFP cells into the lateral t
./___Corpus/Medline/xml/PMC5123381.xml	NPES	434563 : 434567	CM	the lateral tail vein. 4 NPES treated mice were not ch
./___Corpus/Medline/xml/PMC5123381.xml	B16-GFP	434793 : 434800	CM	s injection with 200,000 B16-GFP melanoma cells, mice wit
./___Corpus/Medline/xml/PMC5123381.xml	NPES	434912 : 434916	CM	astases/mouse. Mice with NPES ablation of the primary 
./___Corpus/Medline/xml/PMC5123381.xml	NPES	435020 : 435024	CM	ous challenge. Mice with NPES ablation of the primary 
./___Corpus/Medline/xml/PMC5123381.xml	NPES	435185 : 435189	CM	nic cell death caused by NPES treatment of primary tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	435229 : 435234	CPR	rimary tumors stimulates anti-tumor immunity to a subse
./___Corpus/Medline/xml/PMC5123381.xml	B16-GFP	435292 : 435299	CM	allenge with intravenous B16-GFP cells, extending the vac
./___Corpus/Medline/xml/PMC5123381.xml	R	435468 : 435469	CM	           1. Nuccitelli R, Tran K, Lui K, Huynh J,
./___Corpus/Medline/xml/PMC5123381.xml	K	435476 : 435477	CM	   1. Nuccitelli R, Tran K, Lui K, Huynh J, Athos B
./___Corpus/Medline/xml/PMC5123381.xml	K	435483 : 435484	CM	uccitelli R, Tran K, Lui K, Huynh J, Athos B, Kreis
./___Corpus/Medline/xml/PMC5123381.xml	P	435524 : 435525	CM	s B, Kreis M, Nuccitelli P, De Fabo EC: Non-thermal
./___Corpus/Medline/xml/PMC5123381.xml	De	435527 : 435529	CM	, Kreis M, Nuccitelli P, De Fabo EC: Non-thermal nan
./___Corpus/Medline/xml/PMC5123381.xml	murine	435585 : 435591	CM	roablation of UV-Induced murine melanomas stimulates an 
./___Corpus/Medline/xml/PMC5123381.xml	618–	435668 : 435672	CPR	ll Melanoma Res 2012, 25:618–629.                     
./___Corpus/Medline/xml/PMC5123381.xml	NPES	435977 : 435981	CM	Pulse Electro-Signaling (NPES) is a non-thermal, local
./___Corpus/Medline/xml/PMC5123381.xml	CD8	436403 : 436406	CM	ondary tumor growth in a CD8-dependent manner [1]. He
./___Corpus/Medline/xml/PMC5123381.xml	NPES	436450 : 436454	CM	1]. Here we determine if NPES treatment results in the
./___Corpus/Medline/xml/PMC5123381.xml	MCA205	436685 : 436691	CM	arate cancer cell lines (MCA205, McA-RH7777, Jurkat E6-1
./___Corpus/Medline/xml/PMC5123381.xml	McA-RH7777	436693 : 436703	CM	ncer cell lines (MCA205, McA-RH7777, Jurkat E6-1) with NPES.
./___Corpus/Medline/xml/PMC5123381.xml	E6-1	436712 : 436716	CM	A205, McA-RH7777, Jurkat E6-1) with NPES. One million 
./___Corpus/Medline/xml/PMC5123381.xml	NPES	436723 : 436727	CM	H7777, Jurkat E6-1) with NPES. One million cells were 
./___Corpus/Medline/xml/PMC5123381.xml	5–	436885 : 436887	CPR	d ranging in energy from 5–50 J/mL. The pulse parame
./___Corpus/Medline/xml/PMC5123381.xml	24-	437097 : 437100	CPR	cells were seeded into a 24-well plate and incubated 
./___Corpus/Medline/xml/PMC5123381.xml	plate	437105 : 437110	CM	re seeded into a 24-well plate and incubated at 37 °C f
./___Corpus/Medline/xml/PMC5123381.xml	24-	437138 : 437141	CPR	d incubated at 37 °C for 24-hours. Cell culture super
./___Corpus/Medline/xml/PMC5123381.xml	HMGB1	437210 : 437215	CM	ted to measure levels of HMGB1 and ATP. Cells were also
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437220 : 437223	CM	sure levels of HMGB1 and ATP. Cells were also harvest
./___Corpus/Medline/xml/PMC5123381.xml	NPES	437390 : 437394	CM	lts                      NPES induced all three marker
./___Corpus/Medline/xml/PMC5123381.xml	HMGB1	437459 : 437464	CM	energy-dependent manner. HMGB1 release and calreticulin
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437572 : 437575	CM	ell lines. Extracellular ATP followed a different pat
./___Corpus/Medline/xml/PMC5123381.xml	MCA-205	437706 : 437713	CM	f at 25 J/mL in both the MCA-205 and McA-RH7777 cell line
./___Corpus/Medline/xml/PMC5123381.xml	McA-RH7777	437718 : 437728	CM	 in both the MCA-205 and McA-RH7777 cell lines. ATP levels i
./___Corpus/Medline/xml/PMC5123381.xml	ATP	437741 : 437744	CM	d McA-RH7777 cell lines. ATP levels in the Jurkat cel
./___Corpus/Medline/xml/PMC5123381.xml	NPES	437953 : 437957	CM	reating tumor cells with NPES. This can explain why we
./___Corpus/Medline/xml/PMC5123381.xml	NPES	438023 : 438027	CM	ike effect after in vivo NPES treatment, inhibiting se
./___Corpus/Medline/xml/PMC5123381.xml	R	438182 : 438183	CM	           1. Nuccitelli R, Berridge JC, Mallon Z, 
./___Corpus/Medline/xml/PMC5123381.xml	JC	438194 : 438196	CM	. Nuccitelli R, Berridge JC, Mallon Z, Kreis M, Atho
./___Corpus/Medline/xml/PMC5123381.xml	P	438237 : 438238	CM	s M, Athos B, Nuccitelli P: Nanoelectroablation of 
./___Corpus/Medline/xml/PMC5123381.xml	murine	438263 : 438269	CM	: Nanoelectroablation of murine tumors triggers a CD8-de
./___Corpus/Medline/xml/PMC5123381.xml	CD8	438288 : 438291	CM	murine tumors triggers a CD8-dependent inhibition of 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	438753 : 438758	CPR	 two critical aspects of anti-tumor immunity: generatio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	438856 : 438860	CM	esponses (i.e. cytotoxic CD8+ T, CTLs) and the means t
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	438924 : 438928	CM	ffective infiltration of CTLs into the tumor microenvi
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	439211 : 439215	CM	ease numbers of specific CTLs in murine tumors.       
./___Corpus/Medline/xml/PMC5123381.xml	murine	439219 : 439225	CM	bers of specific CTLs in murine tumors.                 
./___Corpus/Medline/xml/PMC5123381.xml	DC	439498 : 439500	CM	cialized dendritic cell (DC) vaccine, with augmented
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	439589 : 439593	CM	 tumor-specific effector CTLs, and the combinatorial s
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	439675 : 439679	CM	 the vaccination-induced CTLs to tumors.              
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	440089 : 440099	CM	                    P331 Bortezomib enhances expression of e
./___Corpus/Medline/xml/PMC5123381.xml	anti-	440145 : 440150	CPR	of effector molecules in anti-tumor CD8+ lymphocytes by
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	440156 : 440160	CM	 molecules in anti-tumor CD8+ lymphocytes by modulatin
./___Corpus/Medline/xml/PMC5123381.xml	Anil	440305 : 440309	CM	Thomas1, Samuel Pellom1, Anil Shanker3 Background     
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	440765 : 440775	CM	ved proteasome inhibitor bortezomib, which also sensitizes t
./___Corpus/Medline/xml/PMC5123381.xml	NICD	440892 : 440896	CM	RNA regulation affecting NICD–NFκB crosstalk.         
./___Corpus/Medline/xml/PMC5123381.xml	NFκB	440897 : 440901	CM	egulation affecting NICD–NFκB crosstalk.              
./___Corpus/Medline/xml/PMC5123381.xml	saline	441081 : 441087	CM	t groups are as follows: saline alone, bortezomib alone,
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441095 : 441105	CM	s follows: saline alone, bortezomib alone, tumor (4 T1 breas
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441169 : 441179	CM	2x106) alone, or tumor + bortezomib administration. Tumor-be
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	441502 : 441512	CM	h 1 mg/kg body weight of bortezomib intra-veneously. After 4
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	441626 : 441630	CM	es will be harvested and CD8+ T cells will be purified
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	441751 : 441758	CM	l effector molecules and miR-155 expression will be analy
./___Corpus/Medline/xml/PMC5123381.xml	RT-qPCR	441809 : 441816	CM	ed by flow cytometry and RT-qPCR.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	441864 : 441874	CM	lts                      Bortezomib administration modulates
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	441916 : 441920	CM	odulates Notch system in CD8+ T cells isolated from tu
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	441963 : 441973	CM	from tumor-bearing mice. Bortezomib improves cytolytic T lym
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442016 : 442026	CM	c T lymphocyte function. Bortezomib abrogates the negative e
./___Corpus/Medline/xml/PMC5123381.xml	GSI	442083 : 442086	CM	f g-secretase inhibitor (GSI) on T cell effector mole
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442118 : 442128	CM	cell effector molecules. Bortezomib abrogates GSI effect and
./___Corpus/Medline/xml/PMC5123381.xml	GSI	442139 : 442142	CM	es. Bortezomib abrogates GSI effect and stimulates No
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442181 : 442185	CM	imulates Notch genes via NICD cleavage and/or NFkB act
./___Corpus/Medline/xml/PMC5123381.xml	NFkB	442202 : 442206	CM	via NICD cleavage and/or NFkB activation. Bortezomib i
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442219 : 442229	CM	 and/or NFkB activation. Bortezomib intersects with both can
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442262 : 442266	CM	cts with both canonical (NICD) and non-canonical (NFkB
./___Corpus/Medline/xml/PMC5123381.xml	NFkB	442287 : 442291	CM	NICD) and non-canonical (NFkB) pathway. Bortezomib upr
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442302 : 442312	CM	anonical (NFkB) pathway. Bortezomib upregulates miR-155 expr
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442325 : 442332	CM	. Bortezomib upregulates miR-155 expression in the presen
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442370 : 442377	CM	n the presence of tumor. miR-155 expression is suppressed
./___Corpus/Medline/xml/PMC5123381.xml	GSI	442451 : 442454	CM	ignaling is inhibited by GSI. Notch target gene expre
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442504 : 442511	CM	ssion is suppressed when miR-155 is inhibited.           
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442576 : 442586	CM	ons                      Bortezomib modulates Notch signalin
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442748 : 442758	CM	s in tumor-bearing mice. Bortezomib presents the opportunity
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	442850 : 442854	CM	simultaneously improving CD8+ T cell function via NICD
./___Corpus/Medline/xml/PMC5123381.xml	NICD	442875 : 442879	CM	CD8+ T cell function via NICD and NFkB activation lead
./___Corpus/Medline/xml/PMC5123381.xml	NFkB	442884 : 442888	CM	ll function via NICD and NFkB activation leading to ef
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	442948 : 442958	CM	titumor immune function. Bortezomib has the ability to incre
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	442987 : 442994	CM	 the ability to increase miR-155 expression even when Not
./___Corpus/Medline/xml/PMC5123381.xml	GSI	443046 : 443049	CM	 signaling is blocked by GSI, suggesting an interplay
./___Corpus/Medline/xml/PMC5123381.xml	miR-155	443093 : 443100	CM	erplay between Notch and miR-155 affecting expression of 
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	443174 : 443184	CM	s.                  P332 Bortezomib improves adoptive T cell
./___Corpus/Medline/xml/PMC5123381.xml	Anil	443349 : 443353	CM	oks4, Thomas J. Sayers5, Anil Shanker3                
./___Corpus/Medline/xml/PMC5123381.xml	anti-	443570 : 443575	CPR	ity and poor efficacy of anti-cancer immunotherapy. The
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	443767 : 443777	CM	tic proteasome inhibitor bortezomib sensitizes solid tumors 
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	443933 : 443943	CM	estigated the effects of bortezomib on T cell responses in i
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444058 : 444068	CM	tigated the potential of bortezomib in modulating the antitu
./___Corpus/Medline/xml/PMC5123381.xml	Bortezomib	444188 : 444198	CM	lts                      Bortezomib did not decrease MHC cla
./___Corpus/Medline/xml/PMC5123381.xml	MHC	444216 : 444219	CM	tezomib did not decrease MHC class I/II-associated an
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444291 : 444301	CM	cognate T cells. Rather, bortezomib stabilized the expressio
./___Corpus/Medline/xml/PMC5123381.xml	CD3ζ	444347 : 444351	CM	ssion of T cell receptor CD3ζ and IL2 receptor-α, whil
./___Corpus/Medline/xml/PMC5123381.xml	IL2	444356 : 444359	CM	T cell receptor CD3ζ and IL2 receptor-α, while mainta
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	444390 : 444394	CM	tor-α, while maintaining IFNγ secretion to improve Fas
./___Corpus/Medline/xml/PMC5123381.xml	lysis	444436 : 444441	RN	rove FasL-mediated tumor lysis. Notably, bortezomib inc
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444452 : 444462	CM	ed tumor lysis. Notably, bortezomib increased tumor cell sur
./___Corpus/Medline/xml/PMC5123381.xml	Rag2−	444617 : 444622	CM	-bearing immunodeficient Rag2−/− mice, bortezomib treat
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444631 : 444641	CM	odeficient Rag2−/− mice, bortezomib treatment after adoptive
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444757 : 444767	CM	rvival. We observed that bortezomib treatment also resulted 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	444805 : 444809	CM	so resulted in increased CD8+ T lymphocyte IFNγ secret
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	444823 : 444827	CM	reased CD8+ T lymphocyte IFNγ secretion and expression
./___Corpus/Medline/xml/PMC5123381.xml	perforin	444876 : 444884	CM	n of effector molecules, perforin and granzyme B, as well 
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	444989 : 444999	CM	-bearing mice. Moreover, bortezomib promoted CD8+ T cell nuc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	445009 : 445013	CM	ver, bortezomib promoted CD8+ T cell nuclear factor-κB
./___Corpus/Medline/xml/PMC5123381.xml	NFκB	445040 : 445044	CM	 cell nuclear factor-κB (NFκB) activity by increasing 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	445083 : 445097	CM	increasing the total and phosphorylated levels of the IκB kinase
./___Corpus/Medline/xml/PMC5123381.xml	IκB	445112 : 445115	CM	phorylated levels of the IκB kinase and IκBα as well 
./___Corpus/Medline/xml/PMC5123381.xml	IκBα	445127 : 445131	CM	ls of the IκB kinase and IκBα as well as the cytoplasm
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	445181 : 445195	CM	ic and nuclear levels of phosphorylated p65. In addition, Bzb tr
./___Corpus/Medline/xml/PMC5123381.xml	Bzb	445214 : 445217	CM	ylated p65. In addition, Bzb treatment increased the 
./___Corpus/Medline/xml/PMC5123381.xml	IL	445296 : 445298	CM	nterleukins IL-2, IL-12, IL-15, and increased prosph
./___Corpus/Medline/xml/PMC5123381.xml	prosphorylation	445317 : 445332	RN	12, IL-15, and increased prosphorylation of STAT3/5. Along with t
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	445336 : 445341	CM	eased prosphorylation of STAT3/5. Along with these immu
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	445389 : 445399	CM	munostimulatory effects, bortezomib administration reduced n
./___Corpus/Medline/xml/PMC5123381.xml	bortezomib	445586 : 445596	CM	 novel insights on using bortezomib not only as an agent to 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	445785 : 445793	CM	g lymphocyte-stimulatory cytokine signaling, thereby overc
./___Corpus/Medline/xml/PMC5123381.xml	Su1	446047 : 446050	CM	                  Yu-Lin Su1, Tomasz Adamus2, Qifang 
./___Corpus/Medline/xml/PMC5123381.xml	Adamus2	446059 : 446066	CM	      Yu-Lin Su1, Tomasz Adamus2, Qifang Zhang2, Sergey N
./___Corpus/Medline/xml/PMC5123381.xml	Marcin	446100 : 446106	CM	Zhang2, Sergey Nechaev2, Marcin Kortylewski2 Background 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	446288 : 446293	CM	as oncogenic/tolerogenic STAT3, their delivery to targe
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	446431 : 446436	CM	strategy for delivery of STAT3 siRNA, decoy DNA or anti
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	446526 : 446530	CM	cells as conjugates with TLR9 ligand, CpG oligonucleot
./___Corpus/Medline/xml/PMC5123381.xml	CpG	446539 : 446542	CM	ugates with TLR9 ligand, CpG oligonucleotide. The CpG
./___Corpus/Medline/xml/PMC5123381.xml	CpG-STAT3	446564 : 446573	CM	CpG oligonucleotide. The CpG-STAT3 inhibitors (CSIs) proved
./___Corpus/Medline/xml/PMC5123381.xml	MV4-11	447038 : 447044	CM	es (RAW264.7), leukemia (MV4-11) and prostate cancer cel
./___Corpus/Medline/xml/PMC5123381.xml	DU145	447073 : 447078	CM	d prostate cancer cells (DU145, PC3, TRAMP-C2), for the
./___Corpus/Medline/xml/PMC5123381.xml	PC3	447080 : 447083	CM	ate cancer cells (DU145, PC3, TRAMP-C2), for their ab
./___Corpus/Medline/xml/PMC5123381.xml	TRAMP-C2	447085 : 447093	CM	ancer cells (DU145, PC3, TRAMP-C2), for their ability to s
./___Corpus/Medline/xml/PMC5123381.xml	ONT	447171 : 447174	CM	s into EVs following the ONT uptake. The loaded EVs w
./___Corpus/Medline/xml/PMC5123381.xml	FACS	447369 : 447373	CM	iency (fluorescent assay/FACS). The biodistribution of
./___Corpus/Medline/xml/PMC5123381.xml	CpG-siRNACy3	447441 : 447453	CM	nd fluorescently labeled CpG-siRNACy3 was assessed after intra
./___Corpus/Medline/xml/PMC5123381.xml	EV	447613 : 447615	CM	oncentrations of CSIs in EV-free medium for 72 h res
./___Corpus/Medline/xml/PMC5123381.xml	CSIs	447844 : 447848	CM	ted EVs were loaded with CSIs. The EVs had an average 
./___Corpus/Medline/xml/PMC5123381.xml	100-	447885 : 447889	CPR	d an average diameter of 100-150 nm depending on donor
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	448064 : 448068	CM	ntial positive effect of TLR9 signaling on EV secretio
./___Corpus/Medline/xml/PMC5123381.xml	EV	448082 : 448084	CM	ect of TLR9 signaling on EV secretion. The EV/CSIs w
./___Corpus/Medline/xml/PMC5123381.xml	EV	448100 : 448102	CM	ing on EV secretion. The EV/CSIs were internalized m
./___Corpus/Medline/xml/PMC5123381.xml	TLR	448356 : 448359	CM	target gene silencing or TLR-dependent NF-kB activati
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	448370 : 448375	CM	lencing or TLR-dependent NF-kB activation. Systemic inj
./___Corpus/Medline/xml/PMC5123381.xml	TLR9+	448733 : 448738	CM	mmunostimulatory ONTs to TLR9+ immune and cancer cells.
./___Corpus/Medline/xml/PMC5123381.xml	EV	448804 : 448806	CM	dies will verify whether EV/CSIs will allow for impr
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	450047 : 450053	CM	his approach we analyzed B16BL6 murine melanoma tumors i
./___Corpus/Medline/xml/PMC5123381.xml	murine	450054 : 450060	CM	roach we analyzed B16BL6 murine melanoma tumors in mice 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	450098 : 450103	CPR	ors in mice treated with anti-CTLA-4, anti-PD-1, or con
./___Corpus/Medline/xml/PMC5123381.xml	anti-	450111 : 450116	CPR	reated with anti-CTLA-4, anti-PD-1, or control antibody
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	451227 : 451231	CM	standing that CTLA-4 and PD-1 regulate T cell activity
./___Corpus/Medline/xml/PMC5123381.xml	MDACC	451548 : 451553	CM	ments We acknowledge the MDACC core facility NCI Suppor
./___Corpus/Medline/xml/PMC5123381.xml	P	451619 : 451620	CM	72. References 1. Sharma P, Allison JP: The future 
./___Corpus/Medline/xml/PMC5123381.xml	56–	451693 : 451696	CPR	erapy. Science 2015, 348:56–61.                      
./___Corpus/Medline/xml/PMC5123381.xml	CG	451743 : 451745	CM	   2. Topalian SL, Drake CG, Pardoll DM; Immune chec
./___Corpus/Medline/xml/PMC5123381.xml	450–	451857 : 451861	CPR	py. Cancer Cell 2015, 27:450–461.                     
./___Corpus/Medline/xml/PMC5123381.xml	DR	451951 : 451953	CM	VI, Ornatsky OI, Bandura DR, George TC. An introduct
./___Corpus/Medline/xml/PMC5123381.xml	TC	451962 : 451964	CM	y OI, Bandura DR, George TC. An introduction to mass
./___Corpus/Medline/xml/PMC5123381.xml	955–	452046 : 452050	CPR	lications. CeII 2013, 62:955–965.                  Sur
./___Corpus/Medline/xml/PMC5123381.xml	R	452336 : 452337	CM	root, Joe Chang, Kenneth R Hess, Adi Diab, Padmanee
./___Corpus/Medline/xml/PMC5123381.xml	NLR	452559 : 452562	CM	hil-to-lymphocyte ratio (NLR) is a negative prognosti
./___Corpus/Medline/xml/PMC5123381.xml	NCT	452788 : 452791	CM	-trial","attrs":{"text":"NCT 02239900","term_id":"NCT
./___Corpus/Medline/xml/PMC5123381.xml	ALC	452913 : 452916	CM	olute lymphocyte counts (ALC) or decreased neutrophil
./___Corpus/Medline/xml/PMC5123381.xml	NC	452950 : 452952	CM	eased neutrophil counts (NC) will have increased sur
./___Corpus/Medline/xml/PMC5123381.xml	NC	453086 : 453088	CM	ients. Blood samples for NC and ALC were collected a
./___Corpus/Medline/xml/PMC5123381.xml	ALC	453093 : 453096	CM	Blood samples for NC and ALC were collected at baseli
./___Corpus/Medline/xml/PMC5123381.xml	CT	453227 : 453229	CM	mor size was measured by CT scan at baseline, betwee
./___Corpus/Medline/xml/PMC5123381.xml	1–	453296 : 453298	CPR	of ipilimumab, and every 1–3 months thereafter and r
./___Corpus/Medline/xml/PMC5123381.xml	NLR	453743 : 453746	CM	t-points used were 5 for NLR and 5x109/L for NC. Asso
./___Corpus/Medline/xml/PMC5123381.xml	5x109	453751 : 453756	CM	 used were 5 for NLR and 5x109/L for NC. Associations w
./___Corpus/Medline/xml/PMC5123381.xml	NC	453763 : 453765	CM	 for NLR and 5x109/L for NC. Associations were consi
./___Corpus/Medline/xml/PMC5123381.xml	NC	453902 : 453904	CM	                Baseline NC correlated with tumor gr
./___Corpus/Medline/xml/PMC5123381.xml	NC	453975 : 453977	CM	= 0.0069). High baseline NC (>5 x 109/L) was a signi
./___Corpus/Medline/xml/PMC5123381.xml	NC	454118 : 454120	CM	ients with high baseline NC had a best response of s
./___Corpus/Medline/xml/PMC5123381.xml	NC	454230 : 454232	CM	tients with low baseline NC. Baseline NC predicted s
./___Corpus/Medline/xml/PMC5123381.xml	NC	454243 : 454245	CM	ow baseline NC. Baseline NC predicted survival (HR =
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454307 : 454310	CM	0.0006), as did baseline NLR (HR = 2.570, p = 0.0049)
./___Corpus/Medline/xml/PMC5123381.xml	NC	454337 : 454339	CM	HR = 2.570, p = 0.0049). NC at the time of the secon
./___Corpus/Medline/xml/PMC5123381.xml	NC	454434 : 454436	CM	l more strongly than did NC at baseline (HR = 4.598,
./___Corpus/Medline/xml/PMC5123381.xml	NC	454497 : 454499	CM	). Both end-of-treatment NC and NLR were associated 
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454504 : 454507	CM	 end-of-treatment NC and NLR were associated with sur
./___Corpus/Medline/xml/PMC5123381.xml	NC	454539 : 454541	CM	ssociated with survival (NC: HR = 4.881, p < 0.0001;
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454567 : 454570	CM	 HR = 4.881, p < 0.0001; NLR: HR = 5.055, p < 0.0001)
./___Corpus/Medline/xml/PMC5123381.xml	ALC	454692 : 454695	CM	 = 0.025), a decrease in ALC (rho = −0.34, p = 0.0031
./___Corpus/Medline/xml/PMC5123381.xml	NC	454742 : 454744	CM	031), and an increase in NC (rho = 0.394 p = 0.0022)
./___Corpus/Medline/xml/PMC5123381.xml	NC	454859 : 454861	CM	suggest that having high NC or NLR is a strong negat
./___Corpus/Medline/xml/PMC5123381.xml	NLR	454865 : 454868	CM	t that having high NC or NLR is a strong negative pro
./___Corpus/Medline/xml/PMC5123381.xml	anti-	455521 : 455526	CPR	l responses and enhanced anti-tumor protection         
./___Corpus/Medline/xml/PMC5123381.xml	DCs	456038 : 456041	CM	o human dendritic cells (DCs) for optimal priming of 
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456066 : 456069	CM	) for optimal priming of TAA-specific CD8+ T cells. W
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	456079 : 456083	CM	 priming of TAA-specific CD8+ T cells. We have previou
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456170 : 456173	CM	 or repeatedly with ZVex/TAA developed strong, dose-d
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456229 : 456232	CM	nt, multifunctional, and TAA-specific cytotoxic T cel
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456338 : 456341	CM	w that priming with ZVex/TAA and boosting with adenov
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	456379 : 456382	CM	 with adenoviral vector (Ad5) encoding the same antig
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456442 : 456445	CM	y increased frequency of TAA-specific T cells and imp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	456476 : 456481	CPR	fic T cells and improved anti-tumor efficacy.          
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	456582 : 456585	CM	munogenicity of ZVex and Ad5 expressing human NY-ESO-
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	456603 : 456611	CM	and Ad5 expressing human NY-ESO-1 and murine TRP-1, BALB/c
./___Corpus/Medline/xml/PMC5123381.xml	murine	456616 : 456622	CM	ssing human NY-ESO-1 and murine TRP-1, BALB/c or C57BL/6
./___Corpus/Medline/xml/PMC5123381.xml	BALB	456630 : 456634	CM	-ESO-1 and murine TRP-1, BALB/c or C57BL/6 female mice
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456685 : 456688	CM	were immunized with ZVex/TAA or Ad5/TAA twice, 21 day
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	456692 : 456695	CM	munized with ZVex/TAA or Ad5/TAA twice, 21 days apart
./___Corpus/Medline/xml/PMC5123381.xml	TAA	456696 : 456699	CM	zed with ZVex/TAA or Ad5/TAA twice, 21 days apart. Sp
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	456810 : 456818	CM	zation via intracellular cytokine staining. To evaluate th
./___Corpus/Medline/xml/PMC5123381.xml	murine	456892 : 456898	CM	munization regimens, two murine tumor models were used: 
./___Corpus/Medline/xml/PMC5123381.xml	B16	456928 : 456931	CM	r models were used: 1) a B16 melanoma model, where tu
./___Corpus/Medline/xml/PMC5123381.xml	2–	457008 : 457010	CPR	n the flank and measured 2–3 per week; and 2) a meta
./___Corpus/Medline/xml/PMC5123381.xml	CT26	457042 : 457046	CM	eek; and 2) a metastatic CT26 colon carcinoma model ex
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	457086 : 457094	CM	a model expressing human NY-ESO-1, where tumor cells were 
./___Corpus/Medline/xml/PMC5123381.xml	17–	457178 : 457181	CPR	 nodules were enumerated 17–19 days post-tumor inocul
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457273 : 457276	CM	           Repeated ZVex/TAA administration (homologo
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457353 : 457356	CM	ntained the frequency of TAA-specific CD8+ T cells at
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	457366 : 457370	CM	requency of TAA-specific CD8+ T cells at peak levels. 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	457461 : 457466	CPR	 regimen did not improve anti-tumor control in the CT26
./___Corpus/Medline/xml/PMC5123381.xml	CT26	457487 : 457491	CM	nti-tumor control in the CT26 lung metastasis model, i
./___Corpus/Medline/xml/PMC5123381.xml	B16	457546 : 457549	CM	ayed tumor growth in the B16 tumor model, suggesting 
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457699 : 457702	CM	zed repeatedly with ZVex/TAA, mice primed with ZVex/T
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457726 : 457729	CM	A, mice primed with ZVex/TAA and boosted with Ad5/TAA
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	457747 : 457750	CM	Vex/TAA and boosted with Ad5/TAA (heterologous prime-
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457751 : 457754	CM	TAA and boosted with Ad5/TAA (heterologous prime-boos
./___Corpus/Medline/xml/PMC5123381.xml	10-fold	457792 : 457799	CM	s prime-boost) generated 10-fold increase in frequency of
./___Corpus/Medline/xml/PMC5123381.xml	TAA	457825 : 457828	CM	increase in frequency of TAA-specific CD8+ T cells ca
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	457838 : 457842	CM	requency of TAA-specific CD8+ T cells capable of produ
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	457872 : 457876	CM	lls capable of producing IFNg, TNF, and/or IL-2. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	TNF	457878 : 457881	CM	pable of producing IFNg, TNF, and/or IL-2. Tumor-bear
./___Corpus/Medline/xml/PMC5123381.xml	TAA	458180 : 458183	CM	be used to generate more TAA-specific T cells, leadin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	458230 : 458235	CPR	ding to more efficacious anti-tumor control.           
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	458310 : 458319	CM	               ZVex is a DC-tropic vector platform that eff
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	458384 : 458388	CM	 robust antigen-specific CD8+ T cell responses that al
./___Corpus/Medline/xml/PMC5123381.xml	DC-tropic	458632 : 458641	CM	ther enhance this unique DC-tropic gene delivery platform, 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	458709 : 458714	CPR	ing T cell effectors and anti-tumor efficacy.          
./___Corpus/Medline/xml/PMC5123381.xml	Ascarateil1	458822 : 458833	CM	cancer vaccines Stephane Ascarateil1, Marie Eve Koziol2 Backg
./___Corpus/Medline/xml/PMC5123381.xml	Water	459231 : 459236	CM	ncers such as adjuvants. Water-in-oil (W/O) emulsions r
./___Corpus/Medline/xml/PMC5123381.xml	W	459245 : 459246	CM	adjuvants. Water-in-oil (W/O) emulsions represent a
./___Corpus/Medline/xml/PMC5123381.xml	O	459247 : 459248	CM	juvants. Water-in-oil (W/O) emulsions represent an 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	459382 : 459391	CM	hese emulsions, based on Montanide™ ISA 51VG adjuvant, have
./___Corpus/Medline/xml/PMC5123381.xml	NP	459801 : 459803	CM	 25 μg of nucleoprotein (NP) alone or with the Monta
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	459823 : 459832	CM	n (NP) alone or with the Montanide™ ISA 51 VG at weeks 0 an
./___Corpus/Medline/xml/PMC5123381.xml	NP	459956 : 459958	CM	 h and restimulated with NP antigen. IFNɣ response i
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	459968 : 459972	CM	mulated with NP antigen. IFNɣ response is followed by 
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	460006 : 460014	CM	 is followed by ELISpot. Cytokine secretions into the medi
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	460057 : 460061	CM	he medium (supernatant) (TNFα, IL-2, IFNɣ) were measur
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	460069 : 460073	CM	upernatant) (TNFα, IL-2, IFNɣ) were measured by ELISA.
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460130 : 460134	CM	ct populations of memory CD8+ T cells were evaluated b
./___Corpus/Medline/xml/PMC5123381.xml	NP	460253 : 460255	CM	     Mice immunized with NP associated with the Mont
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460276 : 460285	CM	h NP associated with the Montanide™ ISA 51 VG elicited an i
./___Corpus/Medline/xml/PMC5123381.xml	anti-	460321 : 460326	CPR	 elicited an increase in anti-NP T cells, CD4+ and CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	460338 : 460342	CM	ease in anti-NP T cells, CD4+ and CD8+ T cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460347 : 460351	CM	nti-NP T cells, CD4+ and CD8+ T cell responses. We obs
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	460407 : 460411	CM	 significant increase of IFNɣ response in the group va
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	460526 : 460530	CM	sed 6 times, 5 times for CD4+ population and more than
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	460568 : 460572	CM	nd more than 4 times for CD8+ T cell population. Mice 
./___Corpus/Medline/xml/PMC5123381.xml	NP	460616 : 460618	CM	 Mice immunized with the NP associated to the Montan
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460637 : 460646	CM	the NP associated to the Montanide™ ISA 51 VG showed an inc
./___Corpus/Medline/xml/PMC5123381.xml	TNFα	460680 : 460684	CM	VG showed an increase in TNFα, IL-2, and IFNɣ cytokine
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	460696 : 460700	CM	rease in TNFα, IL-2, and IFNɣ cytokine secretion. Mice
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	460701 : 460709	CM	 in TNFα, IL-2, and IFNɣ cytokine secretion. Mice immunize
./___Corpus/Medline/xml/PMC5123381.xml	NP	460741 : 460743	CM	ion. Mice immunized with NP antigen associated with 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460772 : 460781	CM	igen associated with the Montanide™ ISA 51 VG elicited a hi
./___Corpus/Medline/xml/PMC5123381.xml	CD44+	460906 : 460911	CM	es. The higher amount of CD44+ CD62L+ (TCM sub-populati
./___Corpus/Medline/xml/PMC5123381.xml	CD62L+	460912 : 460918	CM	e higher amount of CD44+ CD62L+ (TCM sub-population) in 
./___Corpus/Medline/xml/PMC5123381.xml	TCM	460920 : 460923	CM	 amount of CD44+ CD62L+ (TCM sub-population) in mice 
./___Corpus/Medline/xml/PMC5123381.xml	NP	460963 : 460965	CM	) in mice immunized with NP associated to Montanide™
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	460980 : 460989	CM	ed with NP associated to Montanide™ ISA 51 VG showed an inc
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	461129 : 461138	CM	       Vaccines based on Montanide™ ISA 51 VG are strong in
./___Corpus/Medline/xml/PMC5123381.xml	IFNɣ	461288 : 461292	CM	They induce an important IFNɣ TH1 polarized response, 
./___Corpus/Medline/xml/PMC5123381.xml	TH1	461293 : 461296	CM	induce an important IFNɣ TH1 polarized response, and 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	461328 : 461332	CM	zed response, and potent CD8+ T cell response. Montani
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	461350 : 461359	CM	nt CD8+ T cell response. Montanide™ ISA 51 VG is an interes
./___Corpus/Medline/xml/PMC5123381.xml	Glycosylated	461642 : 461654	CM	s.                  P338 Glycosylated and methylated peptides 
./___Corpus/Medline/xml/PMC5123381.xml	methylated	461659 : 461669	RN	   P338 Glycosylated and methylated peptides as neoantigens 
./___Corpus/Medline/xml/PMC5123381.xml	Bai3	461800 : 461804	CM	, Paisley T Myers3, Dina Bai3, Jeffrey Shabanowitz3, D
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	462339 : 462353	CM	t signaling. Previously, phosphorylated peptides have been ident
./___Corpus/Medline/xml/PMC5123381.xml	O	462451 : 462452	CM	ty several peptides with O-linked β-N-acetylglucosa
./___Corpus/Medline/xml/PMC5123381.xml	O-	462452 : 462454	CPR	y several peptides with O-linked β-N-acetylglucosami
./___Corpus/Medline/xml/PMC5123381.xml	β-N-acetylglucosamine	462460 : 462481	CM	l peptides with O-linked β-N-acetylglucosamine (O-GlcNAc) modifications
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	462483 : 462491	CM	d β-N-acetylglucosamine (O-GlcNAc) modifications, with som
./___Corpus/Medline/xml/PMC5123381.xml	methylated	462536 : 462546	RN	h some that also contain methylated arginine residues. O-Glc
./___Corpus/Medline/xml/PMC5123381.xml	arginine	462547 : 462555	CM	 also contain methylated arginine residues. O-GlcNAc is a 
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	462566 : 462574	CM	lated arginine residues. O-GlcNAc is a PTM that modulates 
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	462693 : 462708	RN	scades also regulated by phosphorylation. Thus, O-GlcNAcylated pe
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	462716 : 462730	RN	y phosphorylation. Thus, O-GlcNAcylated peptides may represent c
./___Corpus/Medline/xml/PMC5123381.xml	MHC	462839 : 462842	CM	               We eluted MHC class-I associated pepti
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	462913 : 462927	CM	ient samples to identify O-GlcNAcylated antigens, using enrichme
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	463054 : 463058	CM	nses were assessed using IFNγ ELISpot and multiplexed 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	463097 : 463105	CM	ultiplexed intracellular cytokine staining. Functionality 
./___Corpus/Medline/xml/PMC5123381.xml	europium	463151 : 463159	CM	ity was assessed using a europium-release killing assay.  
./___Corpus/Medline/xml/PMC5123381.xml	MHC	463251 : 463254	CM	   We have identified 36 MHC class I associated O-Glc
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463274 : 463282	CM	6 MHC class I associated O-GlcNAc neoantigens from primary
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463283 : 463294	CM	ss I associated O-GlcNAc neoantigens from primary leukemia sa
./___Corpus/Medline/xml/PMC5123381.xml	mitogen	463450 : 463457	CM	 pathways, including the mitogen activated protein kinase
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	463484 : 463488	CM	ctivated protein kinase (MAPK) and retinoblastoma (RB1
./___Corpus/Medline/xml/PMC5123381.xml	HLA-B*0702	463616 : 463626	CM	ested. 71 % (5/7) of the HLA-B*0702 O-GlcNAcylated neoantige
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	463627 : 463641	RN	 (5/7) of the HLA-B*0702 O-GlcNAcylated neoantigens tested were 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	463642 : 463653	CM	LA-B*0702 O-GlcNAcylated neoantigens tested were immunogenic,
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	463744 : 463748	CM	g multifunctional memory CD8+ T cell responses to them
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463915 : 463923	CM	o antigen indicated that O-GlcNAc-specific T cells may kil
./___Corpus/Medline/xml/PMC5123381.xml	O-	463923 : 463925	CPR	n indicated that O-GlcNAc-specific T cells may kill.
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	463962 : 463970	CM	lls may kill. Indeed, an O-GlcNAc-specific T cell line was
./___Corpus/Medline/xml/PMC5123381.xml	O-	463970 : 463972	CPR	kill. Indeed, an O-GlcNAc-specific T cell line was g
./___Corpus/Medline/xml/PMC5123381.xml	methylated	464213 : 464223	RN	pecifically targeted the methylated arginine in the peptide 
./___Corpus/Medline/xml/PMC5123381.xml	arginine	464224 : 464232	CM	 targeted the methylated arginine in the peptide with the 
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAc	464257 : 464265	CM	 in the peptide with the O-GlcNAc modification.           
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464330 : 464344	CM	ons                      O-GlcNAcylated neoantigens derive from 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464345 : 464356	CM	          O-GlcNAcylated neoantigens derive from aberrations 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	464453 : 464457	CM	nts and are immunogenic. CD8+ T cells targeting these 
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464482 : 464496	CM	 T cells targeting these O-GlcNAcylated neoantigens specifically
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464497 : 464508	CM	ing these O-GlcNAcylated neoantigens specifically recognize a
./___Corpus/Medline/xml/PMC5123381.xml	PTM	464550 : 464553	CM	ognize and kill only the PTM antigen. Therefore, thes
./___Corpus/Medline/xml/PMC5123381.xml	O-GlcNAcylated	464580 : 464594	CM	ntigen. Therefore, these O-GlcNAcylated neoantigens provide logi
./___Corpus/Medline/xml/PMC5123381.xml	neoantigens	464595 : 464606	CM	re, these O-GlcNAcylated neoantigens provide logical targets 
./___Corpus/Medline/xml/PMC5123381.xml	Dai1	464849 : 464853	CM	                 Peihong Dai1, Weiyi Wang1, Ning Yang1
./___Corpus/Medline/xml/PMC5123381.xml	MVA	465023 : 465026	CM	d vaccinia virus Ankara (MVA) is a highly attenuated 
./___Corpus/Medline/xml/PMC5123381.xml	MVA	465140 : 465143	CM	us diseases and cancers. MVA has a 31-kb deletion of 
./___Corpus/Medline/xml/PMC5123381.xml	31-	465150 : 465153	CPR	s and cancers. MVA has a 31-kb deletion of the parent
./___Corpus/Medline/xml/PMC5123381.xml	MVA	465286 : 465289	CM	on. The investigation of MVA as cancer therapeutics h
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	465452 : 465459	CM	 delivery of recombinant MVAΔE3L (with deletion of vaccin
./___Corpus/Medline/xml/PMC5123381.xml	E3	465504 : 465506	CM	accinia virulence factor E3) expressing human flt3L 
./___Corpus/Medline/xml/PMC5123381.xml	Fms	465532 : 465535	CM	 expressing human flt3L (Fms-like tyrosine kinase 3 l
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	465541 : 465549	CM	ng human flt3L (Fms-like tyrosine kinase 3 ligand) would p
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	465601 : 465608	CM	vide in situ therapeutic vaccine effects. Flt3L plays a c
./___Corpus/Medline/xml/PMC5123381.xml	DC	465668 : 465670	CM	le in the development of DC subsets, including CD103
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	465690 : 465696	CM	of DC subsets, including CD103+/CD8α+ DCs, which are cri
./___Corpus/Medline/xml/PMC5123381.xml	DCs	465703 : 465706	CM	, including CD103+/CD8α+ DCs, which are critical for 
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	465851 : 465858	CM	 the immune responses of B16-F10 murine melanoma cells an
./___Corpus/Medline/xml/PMC5123381.xml	murine	465859 : 465865	CM	une responses of B16-F10 murine melanoma cells and MC38 
./___Corpus/Medline/xml/PMC5123381.xml	MC38	465885 : 465889	CM	urine melanoma cells and MC38 murine colon adenocarcin
./___Corpus/Medline/xml/PMC5123381.xml	murine	465890 : 465896	CM	 melanoma cells and MC38 murine colon adenocarcinoma cel
./___Corpus/Medline/xml/PMC5123381.xml	MVA	465961 : 465964	CM	endritic cells to either MVA or MVAΔE3L infection. We
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	465968 : 465975	CM	c cells to either MVA or MVAΔE3L infection. We compared t
./___Corpus/Medline/xml/PMC5123381.xml	MVA	466040 : 466043	CM	intratumoral delivery of MVA vs. MVAΔE3L in two synge
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	466048 : 466055	CM	oral delivery of MVA vs. MVAΔE3L in two syngeneic bilater
./___Corpus/Medline/xml/PMC5123381.xml	thymidine	466199 : 466208	CM	ous recombination at the thymidine kinase (TK) locus. We co
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	466306 : 466313	CM	f MVAΔE3L-TK−-hFlt3L vs. MVAΔE3L in bilateral tumor impla
./___Corpus/Medline/xml/PMC5123381.xml	MVA∆E3L	466414 : 466421	CM	           We found that MVA∆E3L infection of B16-F10 and
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	466435 : 466442	CM	hat MVA∆E3L infection of B16-F10 and MC38 induces higher 
./___Corpus/Medline/xml/PMC5123381.xml	MC38	466447 : 466451	CM	infection of B16-F10 and MC38 induces higher levels of
./___Corpus/Medline/xml/PMC5123381.xml	IFN-β	466477 : 466482	CM	induces higher levels of IFN-β, IL-6, CCL4 and CCL5 tha
./___Corpus/Medline/xml/PMC5123381.xml	CCL4	466490 : 466494	CM	r levels of IFN-β, IL-6, CCL4 and CCL5 than MVA. MVA∆E
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	466499 : 466503	CM	of IFN-β, IL-6, CCL4 and CCL5 than MVA. MVA∆E3L-induct
./___Corpus/Medline/xml/PMC5123381.xml	MVA	466509 : 466512	CM	IL-6, CCL4 and CCL5 than MVA. MVA∆E3L-induction of ty
./___Corpus/Medline/xml/PMC5123381.xml	cDCs	466549 : 466553	CM	duction of type I IFN in cDCs is mainly dependent on t
./___Corpus/Medline/xml/PMC5123381.xml	cGAS	466581 : 466585	CM	 mainly dependent on the cGAS/STING pathway. Intratumo
./___Corpus/Medline/xml/PMC5123381.xml	STING	466586 : 466591	CM	ly dependent on the cGAS/STING pathway. Intratumoral in
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	466627 : 466634	CM	ntratumoral injection of MVAΔE3L is more efficacious than
./___Corpus/Medline/xml/PMC5123381.xml	MVA	466660 : 466663	CM	is more efficacious than MVA in tumor eradication and
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	466805 : 466809	CM	r induction of activated CD8+ and CD4+ effector T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	466814 : 466818	CM	on of activated CD8+ and CD4+ effector T cells in both
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	466882 : 466889	CM	non-injected tumors from MVAΔE3L-treated mice compared wi
./___Corpus/Medline/xml/PMC5123381.xml	MVA	466917 : 466920	CM	eated mice compared with MVA-treated mice. Furthermor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	467009 : 467014	CPR	−-hFlt3L exerts stronger anti-tumor effects than MVAΔE3
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	467033 : 467040	CM	 anti-tumor effects than MVAΔE3L in a murine melanoma bil
./___Corpus/Medline/xml/PMC5123381.xml	murine	467046 : 467052	CM	ffects than MVAΔE3L in a murine melanoma bilateral impla
./___Corpus/Medline/xml/PMC5123381.xml	MC38	467195 : 467199	CM	ejected a lethal dose of MC38 challenge.              
./___Corpus/Medline/xml/PMC5123381.xml	MVA	467309 : 467312	CM	ntratumoral injection of MVA or MVAΔE3L leads to alte
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	467316 : 467323	CM	oral injection of MVA or MVAΔE3L leads to alteration of t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	467466 : 467471	CPR	itment and activation of anti-tumor CD8+ and CD4+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	467477 : 467481	CM	activation of anti-tumor CD8+ and CD4+ T cells. MVAΔE3
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	467486 : 467490	CM	n of anti-tumor CD8+ and CD4+ T cells. MVAΔE3L is a st
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	467500 : 467507	CM	r CD8+ and CD4+ T cells. MVAΔE3L is a stronger immune act
./___Corpus/Medline/xml/PMC5123381.xml	MVA	467544 : 467547	CM	er immune activator than MVA. Intratumoral delivery o
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	467618 : 467625	CM	is more efficacious than MVAΔE3L. Current studies focuses
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	467696 : 467702	CM	g immune cells including CD103+ DCs and CD8+ cytotoxic T
./___Corpus/Medline/xml/PMC5123381.xml	DCs	467703 : 467706	CM	e cells including CD103+ DCs and CD8+ cytotoxic T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	467711 : 467715	CM	including CD103+ DCs and CD8+ cytotoxic T cells in MVA
./___Corpus/Medline/xml/PMC5123381.xml	MVAΔE3L	467760 : 467767	CM	n MVAΔE3L-TK−-hFlt3L vs. MVAΔE3L-treated mice.           
./___Corpus/Medline/xml/PMC5123381.xml	9-	467867 : 467869	CPR	the immunogenicity of a 9-peptide breast cancer vacc
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	467903 : 467912	CM	east cancer vaccine plus poly-ICLC in stage IB-IIIA breast 
./___Corpus/Medline/xml/PMC5123381.xml	nine	468643 : 468647	CM	 A vaccine consisting of nine-class I MHC-restricted b
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	468725 : 468729	CM	ides was combined with a TLR3, poly-ICLC) along with a
./___Corpus/Medline/xml/PMC5123381.xml	poly-ICLC	468731 : 468740	CM	as combined with a TLR3, poly-ICLC) along with a helper pep
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A1	468848 : 468855	CM	re encoded by the genes: MAGE-A1, −A3, −A10, CEA, NY-ESO-
./___Corpus/Medline/xml/PMC5123381.xml	−A3	468857 : 468860	CM	d by the genes: MAGE-A1, −A3, −A10, CEA, NY-ESO-1, an
./___Corpus/Medline/xml/PMC5123381.xml	−A10	468862 : 468866	CM	the genes: MAGE-A1, −A3, −A10, CEA, NY-ESO-1, and HER2
./___Corpus/Medline/xml/PMC5123381.xml	CEA	468868 : 468871	CM	nes: MAGE-A1, −A3, −A10, CEA, NY-ESO-1, and HER2. The
./___Corpus/Medline/xml/PMC5123381.xml	NY-ESO-1	468873 : 468881	CM	MAGE-A1, −A3, −A10, CEA, NY-ESO-1, and HER2. The peptides 
./___Corpus/Medline/xml/PMC5123381.xml	HER2	468887 : 468891	CM	−A10, CEA, NY-ESO-1, and HER2. The peptides lack tumor
./___Corpus/Medline/xml/PMC5123381.xml	estrogen	469127 : 469135	CM	Five of the patients had estrogen receptor positive diseas
./___Corpus/Medline/xml/PMC5123381.xml	HER2	469173 : 469177	CM	itive disease. None were HER2 amplified.              
./___Corpus/Medline/xml/PMC5123381.xml	endocrine	469892 : 469901	CM	tween patients receiving endocrine therapy and those not re
./___Corpus/Medline/xml/PMC5123381.xml	endocrine	469934 : 469943	CM	 and those not receiving endocrine therapy. The peptides fr
./___Corpus/Medline/xml/PMC5123381.xml	CEA	469971 : 469974	CM	erapy. The peptides from CEA and MAGE-A1 were immunog
./___Corpus/Medline/xml/PMC5123381.xml	MAGE-A1	469979 : 469986	CM	he peptides from CEA and MAGE-A1 were immunogenic.       
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	470168 : 470175	CM	nd feasible. An adjuvant poly-IC plus helper peptide mixt
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	470525 : 470533	CM	                    P341 NKTR-214, an engineered cytokine,
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	470549 : 470557	CM	 NKTR-214, an engineered cytokine, synergizes and improves
./___Corpus/Medline/xml/PMC5123381.xml	anti-	470595 : 470600	CPR	and improves efficacy of anti-cancer vaccination in the
./___Corpus/Medline/xml/PMC5123381.xml	murine	470651 : 470657	CM	treatment of established murine melanoma tumors         
./___Corpus/Medline/xml/PMC5123381.xml	Hiep	470759 : 470763	CM	Fa'ak2, Louise Janssen1, Hiep Khong1, Zhilan Xiao1, Ya
./___Corpus/Medline/xml/PMC5123381.xml	Diab1	470847 : 470852	CM	 Christina Vianden1, Adi Diab1, Jonathan Zalevsky3, Ute
./___Corpus/Medline/xml/PMC5123381.xml	Hoch3	470878 : 470883	CM	 Jonathan Zalevsky3, Ute Hoch3, Willem W Overwijk1     
./___Corpus/Medline/xml/PMC5123381.xml	W	470892 : 470893	CM	vsky3, Ute Hoch3, Willem W Overwijk1               
./___Corpus/Medline/xml/PMC5123381.xml	IL-2	471147 : 471151	CM	ssociated with high dose IL-2 treatment limited its fu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	471189 : 471194	CPR	mited its further use in anti-cancer therapies. NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	471212 : 471220	CM	n anti-cancer therapies. NKTR-214, which is an engineered 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	471250 : 471258	CM	ch is an engineered IL-2 cytokine, was designed to provide
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	471344 : 471352	CM	ent alternative to IL-2. NKTR-214 provides sustained activ
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	471518 : 471526	CM	tudies demonstrated that NKTR-214 can expand tumor-infiltr
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	471740 : 471748	CM	 we investigated whether NKTR-214 can promote expansion an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	471832 : 471836	CM	 tumor specific effector CD8+ T cells using the murine
./___Corpus/Medline/xml/PMC5123381.xml	murine	471855 : 471861	CM	r CD8+ T cells using the murine B16 melanoma model. We a
./___Corpus/Medline/xml/PMC5123381.xml	B16	471862 : 471865	CM	T cells using the murine B16 melanoma model. We also 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	471902 : 471910	CM	del. We also studied how NKTR-214 impacts the localization
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	471948 : 471952	CM	localization of effector CD8+ T cells and Tregs to tum
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472066 : 472074	CM	understand the effect of NKTR-214 on antigen-specific CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472095 : 472099	CM	-214 on antigen-specific CD8+ T cells, we adoptively t
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	472160 : 472170	CM	naïve gp100-specific TCR transgenic pmel-1 CD8+ T cells into
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472178 : 472182	CM	ic TCR transgenic pmel-1 CD8+ T cells into mice bearin
./___Corpus/Medline/xml/PMC5123381.xml	B16	472234 : 472237	CM	established subcutaneous B16 tumors, followed by vacc
./___Corpus/Medline/xml/PMC5123381.xml	anti-	472287 : 472292	CPR	ination (gp100 peptide + anti-CD40 mAb + TLR-7 agonist)
./___Corpus/Medline/xml/PMC5123381.xml	TLR-7	472303 : 472308	CM	eptide + anti-CD40 mAb + TLR-7 agonist) alone or in com
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472347 : 472355	CM	e or in combination with NKTR-214 or IL-2. Mice then recei
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472384 : 472392	CM	IL-2. Mice then received NKTR-214 or IL-2 every 8 days. Tu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472518 : 472522	CM	ation of effector pmel-1 CD8+ T cells and CD4+ Foxp3+ 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	472535 : 472539	CM	 pmel-1 CD8+ T cells and CD4+ Foxp3+ Tregs in tumor an
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472634 : 472642	CM	lts                      NKTR-214 efficiently synergized w
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472784 : 472792	CM	o vaccination with IL-2. NKTR-214 enhanced pmel-1 CD8+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472809 : 472813	CM	NKTR-214 enhanced pmel-1 CD8+ T cell numbers and decre
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	472889 : 472897	CM	pressive Tregs in tumor. NKTR-214 was able to stably maint
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	472949 : 472953	CM	n a high ratio of pmel-1 CD8+ T cells over Tregs in tu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473033 : 473037	CM	induction of very strong CD8+ T cell responses and ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	473059 : 473064	CPR	D8+ T cell responses and anti-tumor activity, no gross 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	473162 : 473170	CM	ons                      NKTR-214 synergizes with vaccinat
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473274 : 473278	CM	infiltration of effector CD8+ T cells without promotin
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	473405 : 473413	CM	l results establish that NKTR-214 is highly effective in i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	473448 : 473452	CM	 effective in increasing CD8+ effector T cell response
./___Corpus/Medline/xml/PMC5123381.xml	anti-	473491 : 473496	CPR	ll responses with potent anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	473765 : 473780	RN	 for cells via oxidative phosphorylation. Reactive oxygen species
./___Corpus/Medline/xml/PMC5123381.xml	oxygen	473791 : 473797	CM	hosphorylation. Reactive oxygen species, a byproduct of 
./___Corpus/Medline/xml/PMC5123381.xml	TAMAs	474123 : 474128	CM	 mitochondrial antigens (TAMAs) are potentially immunog
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	474386 : 474391	CM	ochondrial proteins from RENCA cells.                  
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	474470 : 474475	CM	Our dendritic cell-based RENCA mitochondrial lysate vac
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	474606 : 474611	CM	n against challenge with RENCA cells when used in a pro
./___Corpus/Medline/xml/PMC5123381.xml	prophylactic	474633 : 474645	CM	NCA cells when used in a prophylactic or therapeutic setting. 
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	474695 : 474700	CM	By sequencing mtDNA from RENCA cells, we identified two
./___Corpus/Medline/xml/PMC5123381.xml	COX1	474745 : 474749	CM	d two mutated molecules: COX1 and ND5. Peptide vaccine
./___Corpus/Medline/xml/PMC5123381.xml	ND5	474754 : 474757	CM	ated molecules: COX1 and ND5. Peptide vaccines genera
./___Corpus/Medline/xml/PMC5123381.xml	COX1	474813 : 474817	CM	om mitochondrial-encoded COX1 but not from ND5 had the
./___Corpus/Medline/xml/PMC5123381.xml	ND5	474831 : 474834	CM	ncoded COX1 but not from ND5 had therapeutic properti
./___Corpus/Medline/xml/PMC5123381.xml	RENCA	474873 : 474878	CM	ic properties similar to RENCA mitochondrial protein pr
./___Corpus/Medline/xml/PMC5123381.xml	TAMAs	474994 : 474999	CM	esults demonstrated that TAMAs can elicit effective ant
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	475162 : 475168	CM	 P343 Integrin activator 7HP349 enhances anti-CTLA-4 ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	475178 : 475183	CPR	ctivator 7HP349 enhances anti-CTLA-4 antibody-based can
./___Corpus/Medline/xml/PMC5123381.xml	Marathi4	475383 : 475391	CM	d J Biediger4, Upendra K Marathi4, Willem W Overwijk1     
./___Corpus/Medline/xml/PMC5123381.xml	W	475400 : 475401	CM	endra K Marathi4, Willem W Overwijk1               
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	475763 : 475772	CM	 the integrins very late antigen-4 (VLA-4) and lymphocyte f
./___Corpus/Medline/xml/PMC5123381.xml	antigen-1	475816 : 475825	CM	cyte function-associated antigen-1 (LFA-1) on activated T c
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	475904 : 475910	CM	 of an integrin agonist, 7HP349, on promoting intratumor
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476007 : 476012	CPR	ckpoint blockade-induced anti-tumor activity.          
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476100 : 476106	CM	o evaluate the effect of 7HP349 in promoting checkpoint 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476148 : 476153	CPR	ckpoint blockade-induced anti-tumor immunity, we combin
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476189 : 476194	CPR	ity, we combined it with anti-CTLA-4 therapy in the sta
./___Corpus/Medline/xml/PMC5123381.xml	B16	476269 : 476272	CM	established subcutaneous B16 melanoma [4].           
./___Corpus/Medline/xml/PMC5123381.xml	molecule-1	476392 : 476402	CM	d vascular cell adhesion molecule-1 (VCAM-1) and intercellul
./___Corpus/Medline/xml/PMC5123381.xml	VCAM-1	476404 : 476410	CM	ell adhesion molecule-1 (VCAM-1) and intercellular cell 
./___Corpus/Medline/xml/PMC5123381.xml	molecule-1	476444 : 476454	CM	ercellular cell adhesion molecule-1 (ICAM-1) expression on t
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	476456 : 476462	CM	ell adhesion molecule-1 (ICAM-1) expression on tumor vas
./___Corpus/Medline/xml/PMC5123381.xml	Teff	476598 : 476602	CM	CD44hi effector T cells (Teff) and inflammatory monocy
./___Corpus/Medline/xml/PMC5123381.xml	ICAM-1	476662 : 476668	CM	and granulocytes (Gran). ICAM-1 antibody blockade or gen
./___Corpus/Medline/xml/PMC5123381.xml	Teff	476738 : 476742	CM	 reduced accumulation of Teff and tumor control. Intra
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476793 : 476799	CM	umoral administration of 7HP349 enhanced CD8+ T cell acc
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	476809 : 476813	CM	ation of 7HP349 enhanced CD8+ T cell accumulation and 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476882 : 476887	CPR	red to mice treated with anti-CTLA-4 monotherapy or wit
./___Corpus/Medline/xml/PMC5123381.xml	P	476931 : 476932	CM	or with vehicle control (P < 0.01). Mice treated wi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	476960 : 476965	CPR	0.01). Mice treated with anti-CTLA-4 and 7HP349 showed 
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	476976 : 476982	CM	ted with anti-CTLA-4 and 7HP349 showed increased depigme
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	477158 : 477164	CM	stemic administration of 7HP349 in combination with anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477185 : 477190	CPR	P349 in combination with anti-CTLA-4 therapy, resulting
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477258 : 477263	CPR	ree survival compared to anti-CTLA-4 monotherapy (33 %)
./___Corpus/Medline/xml/PMC5123381.xml	P	477290 : 477291	CM	LA-4 monotherapy (33 %) (P < 0.01).                
./___Corpus/Medline/xml/PMC5123381.xml	7HP349	477403 : 477409	CM	 adhesion molecules with 7HP349 is a promising approach 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	477449 : 477454	CPR	 approach to enhance the anti-cancer activity of checkp
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	477581 : 477585	CM	kpoint molecules such as PD-1 and PD-L1.              
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	477590 : 477595	CM	lecules such as PD-1 and PD-L1.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	P	477656 : 477657	CM	               1. Sharma P, Allison JP: Immune chec
./___Corpus/Medline/xml/PMC5123381.xml	205–	477789 : 477793	CPR	tential. Cell 2015, 161, 205–214.                     
./___Corpus/Medline/xml/PMC5123381.xml	663–	477971 : 477975	CPR	ment. Sem Oncol 2015, 42:663–671.                     
./___Corpus/Medline/xml/PMC5123381.xml	AB	478037 : 478039	CM	      3. Peske JD, Woods AB, Engelhard VH: Control o
./___Corpus/Medline/xml/PMC5123381.xml	CD8	478066 : 478069	CM	Engelhard VH: Control of CD8 T-Cell Infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	263–	478164 : 478168	CPR	Adv Cancer Res 2015, 128:263–307.                     
./___Corpus/Medline/xml/PMC5123381.xml	antigen-4	478343 : 478352	CM	n cytotoxic T lymphocyte antigen-4 blockade in combination 
./___Corpus/Medline/xml/PMC5123381.xml	B16	478384 : 478387	CM	de in combination with a B16 melanoma vaccine: compar
./___Corpus/Medline/xml/PMC5123381.xml	481–	478465 : 478469	CPR	apy. J Exp Med 2001, 194:481–489.                     
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	478531 : 478540	CM	      P344 Intramuscular anti-HER2 antibody gene transfer a
./___Corpus/Medline/xml/PMC5123381.xml	mAb	479718 : 479721	CM	ions and gradual in vivo mAb production and buildup a
./___Corpus/Medline/xml/PMC5123381.xml	murine	480098 : 480104	CM	rized trastuzumab or its murine precursor 4D5 encoded in
./___Corpus/Medline/xml/PMC5123381.xml	4D5	480115 : 480118	CM	 or its murine precursor 4D5 encoded in plasmid DNA (
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480143 : 480147	CM	 encoded in plasmid DNA (pDNA). Following intramuscula
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480174 : 480178	CM	 Following intramuscular pDNA injection and electropor
./___Corpus/Medline/xml/PMC5123381.xml	HER2	480259 : 480263	CM	easured with ELISA using HER2-coated plates. In vivo t
./___Corpus/Medline/xml/PMC5123381.xml	BT474	480348 : 480353	CM	nsfer was evaluated in a BT474 breast cancer mouse mode
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480483 : 480487	CM	transfer of the encoding pDNA in BALB/c mice, trastuzu
./___Corpus/Medline/xml/PMC5123381.xml	BALB	480491 : 480495	CM	 of the encoding pDNA in BALB/c mice, trastuzumab was 
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480655 : 480659	CM	n was lost 10 days after pDNA delivery, because of an 
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480780 : 480784	CM	 delivery of trastuzumab pDNA in immune compromised mi
./___Corpus/Medline/xml/PMC5123381.xml	RAG2−	480813 : 480818	CM	immune compromised mice (RAG2−/−gammaC−/− and athymic n
./___Corpus/Medline/xml/PMC5123381.xml	4D5	480871 : 480874	CM	 mice) or by delivery of 4D5 pDNA, thus matching the 
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	480875 : 480879	CM	e) or by delivery of 4D5 pDNA, thus matching the mAb s
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	481144 : 481148	CM	adjusted by adapting the pDNA dose or administering ad
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	481182 : 481186	CM	administering additional pDNA doses. In a BT474 xenogr
./___Corpus/Medline/xml/PMC5123381.xml	BT474	481199 : 481204	CM	itional pDNA doses. In a BT474 xenograft mouse model, i
./___Corpus/Medline/xml/PMC5123381.xml	4D5	481261 : 481264	CM	cular electrotransfer of 4D5 pDNA induced significant
./___Corpus/Medline/xml/PMC5123381.xml	pDNA	481265 : 481269	CM	r electrotransfer of 4D5 pDNA induced significant anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	481290 : 481295	CPR	pDNA induced significant anti-tumor responses compared 
./___Corpus/Medline/xml/PMC5123381.xml	anti-HER2	481519 : 481528	CM	expression in mice using anti-HER2 mAbs as demonstrator. On
./___Corpus/Medline/xml/PMC5123381.xml	MHC	481875 : 481878	CM	 Antigen presentation by MHC is central to the develo
./___Corpus/Medline/xml/PMC5123381.xml	MHC	482339 : 482342	CM	ll renal cell carcinoma. MHC I-peptide complexes were
./___Corpus/Medline/xml/PMC5123381.xml	HLA	482497 : 482500	CM	 grade but heterogeneous HLA haplotypes. Peptides wer
./___Corpus/Medline/xml/PMC5123381.xml	MHC	482775 : 482778	CM	ichment and detection of MHC- associated peptides, wi
./___Corpus/Medline/xml/PMC5123381.xml	MHC	482926 : 482929	CM	or peptides presented by MHC I. Differential expressi
./___Corpus/Medline/xml/PMC5123381.xml	3-fold	483058 : 483064	CM	antially overexpressed (>3-fold) in the tumor tissue, wi
./___Corpus/Medline/xml/PMC5123381.xml	HLA	483165 : 483168	CM	. In many cases multiple HLA allele-specific peptides
./___Corpus/Medline/xml/PMC5123381.xml	amino acid	483564 : 483574	CM	n fusions (37 %), single amino acid substitutions (25 %) and
./___Corpus/Medline/xml/PMC5123381.xml	Rizell1	484492 : 484499	CM	                  Magnus Rizell1, Malin Sternby1, Bengt A
./___Corpus/Medline/xml/PMC5123381.xml	Malin	484501 : 484506	CM	         Magnus Rizell1, Malin Sternby1, Bengt Andersso
./___Corpus/Medline/xml/PMC5123381.xml	DCs	484779 : 484782	CM	where initially infected DCs act as a pure adjuvant, 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	484922 : 484925	CM	non-infected "bystander" DCs. Accordingly, we have de
./___Corpus/Medline/xml/PMC5123381.xml	DCs	485037 : 485040	CM	ocyte-derived allogeneic DCs producing high levels of
./___Corpus/Medline/xml/PMC5123381.xml	HCC	485232 : 485235	CM	epatocellular carcinoma (HCC) where included in a pha
./___Corpus/Medline/xml/PMC5123381.xml	INTUVAX	485290 : 485297	CM	II study. Vaccine cells (INTUVAX) were produced from a le
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	485426 : 485433	CM	p-frozen. Three doses of vaccine cells (10–20 million cel
./___Corpus/Medline/xml/PMC5123381.xml	10–	485441 : 485444	CPR	 doses of vaccine cells (10–20 million cells/dose) we
./___Corpus/Medline/xml/PMC5123381.xml	alpha	485537 : 485542	CM	overlapping peptides for alpha fetoprotein (AFP) and hu
./___Corpus/Medline/xml/PMC5123381.xml	AFP	485556 : 485559	CM	s for alpha fetoprotein (AFP) and human telomerase re
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	485650 : 485654	CM	entire protein sequence, CD8+ T cell responses could b
./___Corpus/Medline/xml/PMC5123381.xml	HLA	485720 : 485723	CM	ardless of the patient's HLA-type.                  R
./___Corpus/Medline/xml/PMC5123381.xml	sorafenib	485908 : 485917	CM	 systemic treatment with sorafenib while 3 patients were na
./___Corpus/Medline/xml/PMC5123381.xml	INTUVAX	485969 : 485976	CM	e to systemic treatment. INTUVAX was generally well toler
./___Corpus/Medline/xml/PMC5123381.xml	AFP	486161 : 486164	CM	exhibited an increase of AFP and/or hTERT specific an
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	486211 : 486215	CM	 and IFN-gamma producing CD8+ T cells 1 week after the
./___Corpus/Medline/xml/PMC5123381.xml	mOS	486324 : 486327	CM	Median overall survival (mOS) for the fully treated p
./___Corpus/Medline/xml/PMC5123381.xml	INTUVAX	486374 : 486381	CM	d patient subgroup given INTUVAX as second-line systemic 
./___Corpus/Medline/xml/PMC5123381.xml	INTUVAX	486527 : 486534	CM	three patients receiving INTUVAX as first-line systemic t
./___Corpus/Medline/xml/PMC5123381.xml	INTUVAX	486771 : 486778	CM	5 months after the first INTUVAX dose.                  C
./___Corpus/Medline/xml/PMC5123381.xml	DCs	486920 : 486923	CM	oinflammatory allogeneic DCs induces a CTL-mediated s
./___Corpus/Medline/xml/PMC5123381.xml	CTL	486934 : 486937	CM	allogeneic DCs induces a CTL-mediated systemic anti-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	486956 : 486961	CPR	 a CTL-mediated systemic anti-tumor response in a major
./___Corpus/Medline/xml/PMC5123381.xml	HCC	486993 : 486996	CM	esponse in a majority of HCC patients that this respo
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	487290 : 487300	CM	           P347 Nanodisc neoantigen vaccination combined wit
./___Corpus/Medline/xml/PMC5123381.xml	Ochyl	487430 : 487435	CM	        Rui Kuai, Lukasz Ochyl, Anna Schwendeman, James
./___Corpus/Medline/xml/PMC5123381.xml	RNA	487548 : 487551	CM	t of next-generation DNA/RNA sequencing technology, p
./___Corpus/Medline/xml/PMC5123381.xml	Ag	487990 : 487992	CM	 co-delivery of antigen (Ag) and adjuvants to lympho
./___Corpus/Medline/xml/PMC5123381.xml	sHDL	488174 : 488178	CM	igh density lipoprotein (sHDL) nanodiscs, with an esta
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488310 : 488312	CM	can be simply mixed with Ag peptides and adjuvants, 
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488556 : 488558	CM	efficiently co-delivered Ag and CpG, a Toll-like rec
./___Corpus/Medline/xml/PMC5123381.xml	CpG	488563 : 488566	CM	ntly co-delivered Ag and CpG, a Toll-like receptor-9 
./___Corpus/Medline/xml/PMC5123381.xml	Ag	488656 : 488658	CM	moted strong and durable Ag presentation on antigen-
./___Corpus/Medline/xml/PMC5123381.xml	47-fold	488738 : 488745	CM	nanodiscs elicited up to 47-fold greater frequency of tum
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	488773 : 488783	CM	eater frequency of tumor neoantigen-specific CD8+ T lymphocy
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	488793 : 488797	CM	umor neoantigen-specific CD8+ T lymphocytes (CTLs) tha
./___Corpus/Medline/xml/PMC5123381.xml	31-fold	488850 : 488857	CM	oluble vaccines and even 31-fold greater than arguably th
./___Corpus/Medline/xml/PMC5123381.xml	CTL	488894 : 488897	CM	n arguably the strongest CTL adjuvant in clinical tri
./___Corpus/Medline/xml/PMC5123381.xml	CpG	488933 : 488936	CM	n clinical trials (i.e., CpG in Montanide). Moreover,
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	488940 : 488949	CM	cal trials (i.e., CpG in Montanide). Moreover, in mice bear
./___Corpus/Medline/xml/PMC5123381.xml	sHDL	489010 : 489014	CM	olon tumors, therapeutic sHDL vaccination led to signi
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	489057 : 489062	CM	o significantly enhanced IFN-γ+TNF-α+ Ag-specific CTL r
./___Corpus/Medline/xml/PMC5123381.xml	Ag	489070 : 489072	CM	ly enhanced IFN-γ+TNF-α+ Ag-specific CTL responses t
./___Corpus/Medline/xml/PMC5123381.xml	CTL	489082 : 489085	CM	IFN-γ+TNF-α+ Ag-specific CTL responses that substanti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	489288 : 489293	CPR	ne checkpoint inhibitor, anti-PD-1 (α-PD-1), ~88 % of M
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	489299 : 489305	CM	nt inhibitor, anti-PD-1 (α-PD-1), ~88 % of MC-38 tumor-b
./___Corpus/Medline/xml/PMC5123381.xml	MC-38	489317 : 489322	CM	-PD-1 (α-PD-1), ~88 % of MC-38 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	CpG	489384 : 489387	CM	as the soluble peptide + CpG vaccine combined with α-
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	489410 : 489416	CM	pG vaccine combined with α-PD-1 therapy cured only 25 % 
./___Corpus/Medline/xml/PMC5123381.xml	MC-38	489498 : 489503	CM	letely protected against MC-38 cell re-challenge admini
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	489613 : 489619	CM	 treat a more aggressive B16F10 melanoma model, multiple
./___Corpus/Medline/xml/PMC5123381.xml	MHC	489645 : 489648	CM	melanoma model, multiple MHC class I and class II epi
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ+	489786 : 489792	CM	 tumor antigen-specific, IFN-γ+ CD8+ and CD4+ T cells in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	489793 : 489797	CM	antigen-specific, IFN-γ+ CD8+ and CD4+ T cells in peri
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	489802 : 489806	CM	pecific, IFN-γ+ CD8+ and CD4+ T cells in peripheral bl
./___Corpus/Medline/xml/PMC5123381.xml	Ag	489903 : 489905	CM	r the soluble vaccine or Ag + CpG + Montanide group.
./___Corpus/Medline/xml/PMC5123381.xml	CpG	489908 : 489911	CM	 soluble vaccine or Ag + CpG + Montanide group. More 
./___Corpus/Medline/xml/PMC5123381.xml	Montanide	489914 : 489923	CM	le vaccine or Ag + CpG + Montanide group. More strikingly, 
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	490006 : 490012	CM	nation was combined with α-PD-1/α-CTLA-4 therapy, ~90 % 
./___Corpus/Medline/xml/PMC5123381.xml	α-CTLA-4	490013 : 490021	CM	was combined with α-PD-1/α-CTLA-4 therapy, ~90 % B16F10 tu
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	490037 : 490043	CM	/α-CTLA-4 therapy, ~90 % B16F10 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	490189 : 490195	CM	ble peptide vaccine plus α-PD-1/α-CTLA-4 therapy.       
./___Corpus/Medline/xml/PMC5123381.xml	α-CTLA-4	490196 : 490204	CM	tide vaccine plus α-PD-1/α-CTLA-4 therapy.                
./___Corpus/Medline/xml/PMC5123381.xml	W	490950 : 490951	CM	ong, Peter Lauer, Thomas W Dubensky, Chan C Whiting
./___Corpus/Medline/xml/PMC5123381.xml	LADD	491530 : 491534	CM	 Listeria monocytogenes (LADD) platform which has been
./___Corpus/Medline/xml/PMC5123381.xml	pLADD-MC38	491727 : 491737	CM	6 mice were treated with pLADD-MC38 and anti-PD-1. MC38 muta
./___Corpus/Medline/xml/PMC5123381.xml	anti-	491742 : 491747	CPR	ated with pLADD-MC38 and anti-PD-1. MC38 mutated epitop
./___Corpus/Medline/xml/PMC5123381.xml	MC38	491753 : 491757	CM	LADD-MC38 and anti-PD-1. MC38 mutated epitopes [4] wer
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	491809 : 491819	CM	expressed as a synthetic neoantigen protein from the Listeri
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	491915 : 491919	CM	ne responses measured by IFNg ELISpot.                
./___Corpus/Medline/xml/PMC5123381.xml	murine	492048 : 492054	CM	pecific neoepitopes from murine MC38 tumor cells (pLADD-
./___Corpus/Medline/xml/PMC5123381.xml	MC38	492055 : 492059	CM	 neoepitopes from murine MC38 tumor cells (pLADD-MC38)
./___Corpus/Medline/xml/PMC5123381.xml	pLADD-MC38	492073 : 492083	CM	murine MC38 tumor cells (pLADD-MC38). Administration of pLAD
./___Corpus/Medline/xml/PMC5123381.xml	pLADD-MC38	492104 : 492114	CM	MC38). Administration of pLADD-MC38 in mice induces cellular
./___Corpus/Medline/xml/PMC5123381.xml	anti-	492256 : 492261	CPR	 also showed synergistic anti-tumor efficacy of pLADD-M
./___Corpus/Medline/xml/PMC5123381.xml	pLADD-MC38	492279 : 492289	CM	c anti-tumor efficacy of pLADD-MC38 and anti-PD-1. To effect
./___Corpus/Medline/xml/PMC5123381.xml	anti-	492294 : 492299	CPR	ficacy of pLADD-MC38 and anti-PD-1. To effectively tran
./___Corpus/Medline/xml/PMC5123381.xml	pLADD	492330 : 492335	CM	To effectively translate pLADD into the clinic, we have
./___Corpus/Medline/xml/PMC5123381.xml	LADD	492401 : 492405	CM	accelerated, small-scale LADD manufacturing process.  
./___Corpus/Medline/xml/PMC5123381.xml	pLADD	492479 : 492484	CM	ons                      pLADD is an attractive immunot
./___Corpus/Medline/xml/PMC5123381.xml	LADD	492581 : 492585	CM	ic neoantigens using the LADD platform to take advanta
./___Corpus/Medline/xml/PMC5123381.xml	pLADD	492911 : 492916	CM	ty and immunogenicity of pLADD in subjects with advance
./___Corpus/Medline/xml/PMC5123381.xml	AA	493129 : 493131	CM	adian S, Hundal J, Petti AA, et al.: A dendritic cel
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	493214 : 493224	CM	nd diversity of melanoma neoantigen-specific T cells. Cancer
./___Corpus/Medline/xml/PMC5123381.xml	803–	493271 : 493275	CPR	cer Immunother 2015, 348:803–808.                     
./___Corpus/Medline/xml/PMC5123381.xml	Lu	493361 : 493363	CM	e S, Gros A, Robbins PF, Lu YC, Dudley ME, et al.: C
./___Corpus/Medline/xml/PMC5123381.xml	ME	493375 : 493377	CM	obbins PF, Lu YC, Dudley ME, et al.: Cancer immunoth
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	493435 : 493439	CM	sed on mutation-specific CD4+ T cells in a patient wit
./___Corpus/Medline/xml/PMC5123381.xml	641–	493503 : 493507	CPR	ancer. Science 2014, 344:641–645.                     
./___Corpus/Medline/xml/PMC5123381.xml	69–	493637 : 493640	CPR	erapy. Science 2015, 348:69–73.                      
./___Corpus/Medline/xml/PMC5123381.xml	P	493729 : 493730	CM	la S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, e
./___Corpus/Medline/xml/PMC5123381.xml	572–	493872 : 493876	CPR	encing. Nature 2014, 515:572–576.                  P34
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	493959 : 493963	CM	stem cell-vaccine in the PD-1/PD-L1 blockade          
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	493964 : 493969	CM	cell-vaccine in the PD-1/PD-L1 blockade                
./___Corpus/Medline/xml/PMC5123381.xml	Xin	494000 : 494003	CM	ade                      Xin Chen1, Yangyang Hu2, Yan
./___Corpus/Medline/xml/PMC5123381.xml	Hu2	494020 : 494023	CM	     Xin Chen1, Yangyang Hu2, Yang Xia2, Li Zhou1, Ya
./___Corpus/Medline/xml/PMC5123381.xml	Li	494036 : 494038	CM	Yangyang Hu2, Yang Xia2, Li Zhou1, Yangyi Bao3, Shia
./___Corpus/Medline/xml/PMC5123381.xml	Elaine	494087 : 494093	CM	ang Huang4, Xiubao Ren5, Elaine Hurt6, Robert E Hollings
./___Corpus/Medline/xml/PMC5123381.xml	DCs	494403 : 494406	CM	-pulsed dendritic cells (DCs). Using mouse models we 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	494449 : 494452	CM	els we demonstrated that DCs pulsed with CSCs enriche
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	494465 : 494469	CM	ted that DCs pulsed with CSCs enriched by virtue of th
./___Corpus/Medline/xml/PMC5123381.xml	ALDH	494527 : 494531	CM	ession of the CSC marker ALDH (termed CSC-DC) signific
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	494803 : 494808	CM	 a process involving the PD-L1/PD-1 axis. Immunological
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	494809 : 494813	CM	cess involving the PD-L1/PD-1 axis. Immunologically ta
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	494846 : 494850	CM	mmunologically targeting CSCs while simultaneously blo
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	494881 : 494886	CM	 simultaneously blocking PD-L1/PD-1-mediated immune sup
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	494887 : 494891	CM	taneously blocking PD-L1/PD-1-mediated immune suppress
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495103 : 495108	CPR	ated the effect of using anti-PD-L1 to block immunosupp
./___Corpus/Medline/xml/PMC5123381.xml	BALB	495297 : 495301	CM	y carcinoma syngeneic to BALB/c mice, and found that 4
./___Corpus/Medline/xml/PMC5123381.xml	6-	495353 : 495355	CPR	1 tumors contain approx. 6-10 % ALDEFLUOR+/ALDHhigh 
./___Corpus/Medline/xml/PMC5123381.xml	ALDEFLUOR+	495360 : 495370	CM	s contain approx. 6-10 % ALDEFLUOR+/ALDHhigh cells, and that
./___Corpus/Medline/xml/PMC5123381.xml	ALDEFLUOR−	495471 : 495481	CM	city compared to bulk or ALDEFLUOR−/ALDHlow cells. Inoculati
./___Corpus/Medline/xml/PMC5123381.xml	CSCs	495666 : 495670	CM	           ALDHhigh 4 T1 CSCs expressed PD-L1. 4 T1 AL
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	495681 : 495686	CM	high 4 T1 CSCs expressed PD-L1. 4 T1 ALDHhigh CSC-DC va
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495719 : 495724	CPR	LDHhigh CSC-DC vaccine + anti-PD-L1 administration sign
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495857 : 495862	CPR	DHhigh CSC-DC vaccine or anti-PD-L1 administration alon
./___Corpus/Medline/xml/PMC5123381.xml	anti-	495935 : 495940	CPR	ation increased systemic anti-4 T1 CSC immunity induced
./___Corpus/Medline/xml/PMC5123381.xml	IgG	496038 : 496041	CM	ased production of total IgG in the serum samples col
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496145 : 496150	CPR	 CSC-DC vaccination with anti-PD-L1 administration. The
./___Corpus/Medline/xml/PMC5123381.xml	Ab	496386 : 496388	CM	ence of such binding was Ab-mediated ALDHhigh 4 T1 C
./___Corpus/Medline/xml/PMC5123381.xml	lysis	496416 : 496421	RN	diated ALDHhigh 4 T1 CSC lysis via complement dependent
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496577 : 496582	CPR	 CSC-DC vaccination with anti-PD-L1 administration kill
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496793 : 496798	CPR	n that administration of anti-PD-L1 could significantly
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	496869 : 496876	CM	c efficacy of the CSC-DC vaccine, and that this effect wa
./___Corpus/Medline/xml/PMC5123381.xml	anti-	496944 : 496949	CPR	body and T cell-mediated anti-CSC immunity.            
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	497025 : 497033	CM	 P350 Immunotherapy with INO-3112 (plasmids encoding HPV16
./___Corpus/Medline/xml/PMC5123381.xml	HPV16	497053 : 497058	CM	-3112 (plasmids encoding HPV16 and HPV18 E6/E7 antigens
./___Corpus/Medline/xml/PMC5123381.xml	HPV18	497063 : 497068	CM	smids encoding HPV16 and HPV18 E6/E7 antigens and IL-12
./___Corpus/Medline/xml/PMC5123381.xml	E6	497069 : 497071	CM	encoding HPV16 and HPV18 E6/E7 antigens and IL-12) i
./___Corpus/Medline/xml/PMC5123381.xml	E7	497072 : 497074	CM	oding HPV16 and HPV18 E6/E7 antigens and IL-12) indu
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497174 : 497177	CM	 tissue in patients with HPV associated head and neck
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	497228 : 497234	CM	squamous cell carcinoma (HNSCCa)                        
./___Corpus/Medline/xml/PMC5123381.xml	Zane	497490 : 497494	CM	an Duff2, David Weiner5, Zane Yang2, Mark Bagarazzi2  
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	497647 : 497655	CM	nd immunogenicity of the INO-3112 in subjects with HPV-ass
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497673 : 497676	CM	NO-3112 in subjects with HPV-associated HNSCCa. INO-3
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	497688 : 497694	CM	ects with HPV-associated HNSCCa. INO-3112 was shown to b
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	497696 : 497704	CM	h HPV-associated HNSCCa. INO-3112 was shown to be safe and
./___Corpus/Medline/xml/PMC5123381.xml	HPV	497752 : 497755	CM	nd immunogenic, inducing HPV-specific CD8+ T cell res
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	497765 : 497769	CM	c, inducing HPV-specific CD8+ T cell responses [1].   
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	497897 : 497905	CM	horts. Cohort 1 received INO-3112 pre- and post-surgery. C
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	497947 : 497955	CM	rgery. Cohort 2 received INO-3112 after completion of cisp
./___Corpus/Medline/xml/PMC5123381.xml	cisplatin	497976 : 497985	CM	3112 after completion of cisplatin based chemoradiation. He
./___Corpus/Medline/xml/PMC5123381.xml	CD8	498210 : 498213	CM	chemistry techniques for CD8 and FoxP3. In addition, 
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	498318 : 498323	CM	lls capable of secreting IFN-γ in response to HPV antig
./___Corpus/Medline/xml/PMC5123381.xml	HPV	498339 : 498342	CM	ing IFN-γ in response to HPV antigen stimulation.    
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	498675 : 498683	CM	ved at least one dose of INO-3112 on average 14 days (rang
./___Corpus/Medline/xml/PMC5123381.xml	post-INO-3112	498769 : 498782	CM	surgery. Paired pre- and post-INO-3112 therapy tumor samples we
./___Corpus/Medline/xml/PMC5123381.xml	CD8	498848 : 498851	CM	 five of the 6 subjects. CD8 positive T cell counts i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499134 : 499137	CM	ubjects showed increased CD8:FoxP3 ratio post INO-311
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	499155 : 499163	CM	sed CD8:FoxP3 ratio post INO-3112, average 60.3 % increase
./___Corpus/Medline/xml/PMC5123381.xml	HPV	499292 : 499295	CM	r analysis of peripheral HPV-specific T cell response
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	499325 : 499330	CM	ific T cell responses by IFN-γ ELISpot. Four subjects e
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	499411 : 499419	CM	 response magnitude post INO-3112 compared to baseline (ra
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499500 : 499503	CM	ubjects with increase in CD8 positive cells in tumor 
./___Corpus/Medline/xml/PMC5123381.xml	PFS	499679 : 499682	CM	progression-free; median PFS of 17 months (range 12 t
./___Corpus/Medline/xml/PMC5123381.xml	HPV	499855 : 499858	CM	ot response magnitude to HPV 16 (3.33 to 16.67 SFU) a
./___Corpus/Medline/xml/PMC5123381.xml	CD8	499901 : 499904	CM	 SFU) and no increase in CD8/FoxP3 ratio (0.95 to 0.6
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	499953 : 499961	CM	60) in tumor tissue post INO-3112 developed progressive di
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	500008 : 500016	CM	 disease (11 months post INO-3112).                  Concl
./___Corpus/Medline/xml/PMC5123381.xml	INO-3112	500100 : 500108	CM	results demonstrate that INO-3112 DNA-based immunotherapy 
./___Corpus/Medline/xml/PMC5123381.xml	HPV	500226 : 500229	CM	 tissue in subjects with HPV associated HNSCCa.      
./___Corpus/Medline/xml/PMC5123381.xml	HNSCCa	500241 : 500247	CM	ects with HPV associated HNSCCa.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	500567 : 500572	CPR	th pembrolizumab elicits anti-tumor responses in patien
./___Corpus/Medline/xml/PMC5123381.xml	mCRPC	500655 : 500660	CM	sistant prostate cancer (mCRPC)                        
./___Corpus/Medline/xml/PMC5123381.xml	Straus1	500773 : 500780	CM	, Mary Jane Staab1, Jane Straus1, Brian Rekoske2, Glenn L
./___Corpus/Medline/xml/PMC5123381.xml	anti-	500879 : 500884	CPR	    In our evaluation of anti-tumor DNA vaccines as tre
./___Corpus/Medline/xml/PMC5123381.xml	murine	500964 : 500970	CM	e have recently shown in murine models that, depending o
./___Corpus/Medline/xml/PMC5123381.xml	MHC	501071 : 501074	CM	 DNA and the strength of MHC:TCR affinity of CD8+ T c
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	501091 : 501095	CM	h of MHC:TCR affinity of CD8+ T cells elicited with va
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	501170 : 501174	CM	express higher levels of PD-1 or LAG-3 [1]. Blockade o
./___Corpus/Medline/xml/PMC5123381.xml	LAG-3	501178 : 501183	CM	higher levels of PD-1 or LAG-3 [1]. Blockade of these r
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	501267 : 501274	CM	f T cell activation with vaccine produced anti-tumor resp
./___Corpus/Medline/xml/PMC5123381.xml	anti-	501284 : 501289	CPR	on with vaccine produced anti-tumor responses in vivo. 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	501431 : 501435	CM	th a DNA vaccine develop PD-1-regulated T cells [2]. T
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	501498 : 501502	CM	 suggested that combined PD-1 blockade with vaccinatio
./___Corpus/Medline/xml/PMC5123381.xml	anti-	501552 : 501557	CPR	n should elicit superior anti-tumor responses in patien
./___Corpus/Medline/xml/PMC5123381.xml	PAP	501761 : 501764	CM	f a DNA vaccine encoding PAP (pTVG-HP) when delivered
./___Corpus/Medline/xml/PMC5123381.xml	pTVG-HP	501766 : 501773	CM	NA vaccine encoding PAP (pTVG-HP) when delivered in combi
./___Corpus/Medline/xml/PMC5123381.xml	mCRPC	501857 : 501862	CM	izumab, in patients with mCRPC. Serial biopsies, blood 
./___Corpus/Medline/xml/PMC5123381.xml	FLT	501910 : 501913	CM	d draws, and exploratory FLT PET/CT imaging are being
./___Corpus/Medline/xml/PMC5123381.xml	CT	501918 : 501920	CM	 and exploratory FLT PET/CT imaging are being conduc
./___Corpus/Medline/xml/PMC5123381.xml	PSA	502213 : 502216	CM	n have experienced serum PSA declines, and 3 of 6 hav
./___Corpus/Medline/xml/PMC5123381.xml	PAP	502363 : 502366	CM	l response. Expansion of PAP-specific Th1-biased T ce
./___Corpus/Medline/xml/PMC5123381.xml	CT	502462 : 502464	CM	les. Exploratory FLT PET/CT imaging has demonstrated
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	502623 : 502627	CM	ons                      PD-1 pathway inhibitors have 
./___Corpus/Medline/xml/PMC5123381.xml	Inc	503271 : 503274	CM	rd and Madison Vaccines, Inc.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	BT	503516 : 503518	CM	              1. Rekoske BT, Smith HA, Olson BM, Mar
./___Corpus/Medline/xml/PMC5123381.xml	HA	503526 : 503528	CM	    1. Rekoske BT, Smith HA, Olson BM, Maricque BB, 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	503564 : 503568	CM	 Maricque BB, McNeel DG: PD-1 or PD-L1 blockade restor
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	503572 : 503577	CM	e BB, McNeel DG: PD-1 or PD-L1 blockade restores antitu
./___Corpus/Medline/xml/PMC5123381.xml	SSX2	503625 : 503629	CM	tumor efficacy following SSX2 epitope-modified DNA vac
./___Corpus/Medline/xml/PMC5123381.xml	946–	503700 : 503704	CPR	ncer Immunol Res 2015, 3:946–955.2.                   
./___Corpus/Medline/xml/PMC5123381.xml	BT	503760 : 503762	CM	              2. Rekoske BT, Olson BM, McNeel DG: An
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	503844 : 503848	CM	 cancer patients elicits PD-1/PD-L1 regulated antigen-
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	503849 : 503854	CM	er patients elicits PD-1/PD-L1 regulated antigen-specif
./___Corpus/Medline/xml/PMC5123381.xml	TLR	504024 : 504027	CM	plus toll-like receptor (TLR) agonists LPS or polyICL
./___Corpus/Medline/xml/PMC5123381.xml	Grosh1	504207 : 504213	CM	, Gina Petroni1, William Grosh1, Nikole Varhegyi1, Kim B
./___Corpus/Medline/xml/PMC5123381.xml	H	504303 : 504304	CM	Nadejda Galeassi1, Donna H Deacon2, Elizabeth Gaugh
./___Corpus/Medline/xml/PMC5123381.xml	murine	504465 : 504471	CM	not been optimized. In a murine model, vaccines with IFA
./___Corpus/Medline/xml/PMC5123381.xml	IFA	504493 : 504496	CM	ine model, vaccines with IFA may deplete circulating 
./___Corpus/Medline/xml/PMC5123381.xml	TLR	504551 : 504554	CM	ls, but vaccination with TLR agonists plus CD40 antib
./___Corpus/Medline/xml/PMC5123381.xml	CD40	504569 : 504573	CM	n with TLR agonists plus CD40 antibody induces strong,
./___Corpus/Medline/xml/PMC5123381.xml	CD8	504607 : 504610	CM	 induces strong, durable CD8 responses. An alternate 
./___Corpus/Medline/xml/PMC5123381.xml	CD40	504656 : 504660	CM	ate approach to ligating CD40 is to activate CD4+ T ce
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	504676 : 504680	CM	ting CD40 is to activate CD4+ T cells, to upregulate C
./___Corpus/Medline/xml/PMC5123381.xml	CD40L	504704 : 504709	CM	+ T cells, to upregulate CD40L. The present study tests
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	504844 : 504848	CM	tides (12MP) to activate CD8+ T cells and a tetanus to
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	504904 : 504908	CM	eptide (Tet) to activate CD4+ T cells, plus either of 
./___Corpus/Medline/xml/PMC5123381.xml	IFA	504967 : 504970	CM	gonists, with or without IFA. We hypothesized that va
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	505007 : 505011	CM	sized that vaccines with TLR3 agonist polyICLC or TLR4
./___Corpus/Medline/xml/PMC5123381.xml	TLR4	505032 : 505036	CM	TLR3 agonist polyICLC or TLR4 agonist lipopolysacchari
./___Corpus/Medline/xml/PMC5123381.xml	IFA	505154 : 505157	CM	cell responses than when IFA was included.           
./___Corpus/Medline/xml/PMC5123381.xml	TLR	505436 : 505439	CM	, receiving 12MP + Tet + TLR agonist (a) without IFA,
./___Corpus/Medline/xml/PMC5123381.xml	IFA	505460 : 505463	CM	 TLR agonist (a) without IFA, (b) plus IFA in the fir
./___Corpus/Medline/xml/PMC5123381.xml	IFA	505474 : 505477	CM	a) without IFA, (b) plus IFA in the first vaccine onl
./___Corpus/Medline/xml/PMC5123381.xml	IFA	505522 : 505525	CM	e only (V1), or (c) plus IFA in all six vaccines (V6)
./___Corpus/Medline/xml/PMC5123381.xml	CTCAE	505578 : 505583	CM	oxicities were recorded (CTCAE v4). T cell responses we
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	505625 : 505629	CM	onses were measured with IFNγ ELISpot either ex vivo, 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	505674 : 505679	CM	ivo, or 14 days after in vitro stimulation (IVS).      
./___Corpus/Medline/xml/PMC5123381.xml	DLTs	505759 : 505763	CM	           There were no DLTs in Cohort 1 (LPS) but tw
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	505833 : 505837	CM	6, subgroups 2b and 2c). CD8+ T cell responses to 12MP
./___Corpus/Medline/xml/PMC5123381.xml	(a)-(c)	506104 : 506111	CM	, and 78 % for subgroups (a)-(c), respectively (Fig. 58).
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506194 : 506197	CM	of highest magnitude for IFA V6. IVS CD8 responses an
./___Corpus/Medline/xml/PMC5123381.xml	CD8	506206 : 506209	CM	agnitude for IFA V6. IVS CD8 responses and ex vivo CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4	506232 : 506235	CM	D8 responses and ex vivo CD4 responses were also impr
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506282 : 506285	CM	mproved with addition of IFA.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506401 : 506404	CM	uvant when combined with IFA; the optimal biologic do
./___Corpus/Medline/xml/PMC5123381.xml	100–	506439 : 506443	CPR	mal biologic dose may be 100–400 EU. All regimens were
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506512 : 506515	CM	te recent concerns about IFA, this study demonstrates
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506557 : 506560	CM	nstrates that in humans, IFA enhanced magnitude and d
./___Corpus/Medline/xml/PMC5123381.xml	TLR	506649 : 506652	CM	e vaccines when added to TLR agonists. Thus, combinat
./___Corpus/Medline/xml/PMC5123381.xml	IFA	506697 : 506700	CM	bination strategies with IFA and LPS and/or pICLC off
./___Corpus/Medline/xml/PMC5123381.xml	pICLC	506716 : 506721	CM	 with IFA and LPS and/or pICLC offer promise for next g
./___Corpus/Medline/xml/PMC5123381.xml	GMCSF	506930 : 506935	CM	ngineered bi-shRNA furin GMCSF plasmid/autologous tumor
./___Corpus/Medline/xml/PMC5123381.xml	EWS	507003 : 507006	CM	astatic Ewing’s sarcoma (EWS)                        
./___Corpus/Medline/xml/PMC5123381.xml	Barve1	507071 : 507077	CM	Maurizio Ghisoli1, Minal Barve1, Robert Mennel2, Gladice
./___Corpus/Medline/xml/PMC5123381.xml	Senzer5	507136 : 507143	CM	n3, Luisa Manning4, Neil Senzer5, John Nemunaitis5       
./___Corpus/Medline/xml/PMC5123381.xml	EWS	507211 : 507214	CM	und                      EWS is an aggressive, rare (
./___Corpus/Medline/xml/PMC5123381.xml	10–	507260 : 507263	CPR	re (10 cases per million 10–19 year old children) ped
./___Corpus/Medline/xml/PMC5123381.xml	2-	507638 : 507640	CPR	 of the patients, have a 2-year survival of 7 %. The
./___Corpus/Medline/xml/PMC5123381.xml	3-	507798 : 507800	CPR	 We recently completed a 3-year follow-up of a prosp
./___Corpus/Medline/xml/PMC5123381.xml	1x10e6	507872 : 507878	CM	 study of Vigil vaccine (1x10e6 - 1x10e7 cells/ID inject
./___Corpus/Medline/xml/PMC5123381.xml	1x10e7	507881 : 507887	CM	 Vigil vaccine (1x10e6 - 1x10e7 cells/ID injection 1x/mo
./___Corpus/Medline/xml/PMC5123381.xml	ID	507894 : 507896	CM	e (1x10e6 - 1x10e7 cells/ID injection 1x/mo) in recu
./___Corpus/Medline/xml/PMC5123381.xml	1x	507907 : 507909	CM	x10e7 cells/ID injection 1x/mo) in recurrent/refract
./___Corpus/Medline/xml/PMC5123381.xml	EWS	507938 : 507941	CM	 in recurrent/refractory EWS patients (n = 16) and co
./___Corpus/Medline/xml/PMC5123381.xml	1-	508215 : 508217	CPR	pecifically, we observed 1-year actual survival of 7
./___Corpus/Medline/xml/PMC5123381.xml	EWS	508524 : 508527	CM	peutic index in advanced EWS. A randomized multi-site
./___Corpus/Medline/xml/PMC5123381.xml	gemcitabine	508579 : 508590	CM	tudy comparing Vigil vs. gemcitabine/Taxotere in third-line m
./___Corpus/Medline/xml/PMC5123381.xml	EWS	508625 : 508628	CM	in third-line metastatic EWS has been initiated to se
./___Corpus/Medline/xml/PMC5123381.xml	WT1	508827 : 508830	CM	ate cancer patients with WT1 peptide-pulsed dendritic
./___Corpus/Medline/xml/PMC5123381.xml	WT1	509344 : 509347	CM	received Wilms’ tumor 1 (WT1) peptide-pulsed dendriti
./___Corpus/Medline/xml/PMC5123381.xml	DC	509380 : 509382	CM	e-pulsed dendritic cell (DC) vaccination in combinat
./___Corpus/Medline/xml/PMC5123381.xml	TLR	509438 : 509441	CM	th a toll-like receptor (TLR) 4 agonist, OK432.      
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509454 : 509459	CM	eceptor (TLR) 4 agonist, OK432.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	57–	509528 : 509531	CPR	    Twelve patients aged 57–82 years were enrolled in
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509587 : 509590	CM	resent study. Autologous DCs were generated by cultur
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509719 : 509722	CM	lony stimulating factor. DCs were then loaded with sy
./___Corpus/Medline/xml/PMC5123381.xml	WT1	509777 : 509780	CM	ic peptides derived from WT1 following maturation by 
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509826 : 509831	CM	 by prostaglandin E2 and OK432. DCs and OK432 were admi
./___Corpus/Medline/xml/PMC5123381.xml	DCs	509833 : 509836	CM	staglandin E2 and OK432. DCs and OK432 were administe
./___Corpus/Medline/xml/PMC5123381.xml	OK432	509841 : 509846	CM	in E2 and OK432. DCs and OK432 were administered intrad
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	509919 : 509926	CM	or 7 times. Induction of vaccine-induced T cell responses
./___Corpus/Medline/xml/PMC5123381.xml	HLA-tetramer	509974 : 509986	CM	es was evaluated using a HLA-tetramer assay, an intracellular 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	510011 : 510019	CM	 assay, an intracellular cytokine staining assay and a flo
./___Corpus/Medline/xml/PMC5123381.xml	DC	510361 : 510363	CM	ients achieving SD after DC vaccination (responder) 
./___Corpus/Medline/xml/PMC5123381.xml	WT1	510537 : 510540	CM	ncrease in positivity of WT1-specific CD8+ T cells wa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	510550 : 510554	CM	sitivity of WT1-specific CD8+ T cells was observed in 
./___Corpus/Medline/xml/PMC5123381.xml	IFNɤ	510831 : 510835	CM	Similarly, intracellular IFNɤ staining assay showed th
./___Corpus/Medline/xml/PMC5123381.xml	WT1	510882 : 510885	CM	 that marked increase in WT1 specific IFNɤ-producing 
./___Corpus/Medline/xml/PMC5123381.xml	IFNɤ	510895 : 510899	CM	increase in WT1 specific IFNɤ-producing CD8+ T cells i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	510910 : 510914	CM	 specific IFNɤ-producing CD8+ T cells in responders co
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	511094 : 511099	CM	erived suppressor cells (MDSCs) was observed in respond
./___Corpus/Medline/xml/PMC5123381.xml	monocytic MDSCs	511203 : 511218	CM	lute number of Tregs and monocytic MDSCs was moderate (9.0 % and 
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	511322 : 511327	CM	e number of granulocytic MDSCs (61.0 %) was observed, i
./___Corpus/Medline/xml/PMC5123381.xml	DC	511367 : 511369	CM	bserved, indicating that DC vaccination may contribu
./___Corpus/Medline/xml/PMC5123381.xml	DC	511500 : 511502	CM	ons                      DC vaccine-based immunother
./___Corpus/Medline/xml/PMC5123381.xml	DC	511710 : 511712	CM	ese results suggest that DC vaccination might be a p
./___Corpus/Medline/xml/PMC5123381.xml	Ib	511883 : 511885	CM	              P355 Phase Ib trial of two folate bind
./___Corpus/Medline/xml/PMC5123381.xml	folate	511899 : 511905	CM	55 Phase Ib trial of two folate binding protein peptide 
./___Corpus/Medline/xml/PMC5123381.xml	E39	511948 : 511951	CM	eptide booster vaccines (E39 and J65) in breast and o
./___Corpus/Medline/xml/PMC5123381.xml	J65	511956 : 511959	CM	ooster vaccines (E39 and J65) in breast and ovarian c
./___Corpus/Medline/xml/PMC5123381.xml	Hale1	512063 : 512068	CM	aitlin M Peace1, Diane F Hale1, Timothy J Vreeland2, Do
./___Corpus/Medline/xml/PMC5123381.xml	O	512098 : 512099	CM	othy J Vreeland2, Doreen O Jackson1, John S Berry3,
./___Corpus/Medline/xml/PMC5123381.xml	O	512183 : 512184	CM	t1, Guy T Clifton1, Mark O Hardin4, Anne Toms5, Na 
./___Corpus/Medline/xml/PMC5123381.xml	Na	512206 : 512208	CM	k O Hardin4, Anne Toms5, Na Qiao5, Jennifer Litton5,
./___Corpus/Medline/xml/PMC5123381.xml	Folate	512326 : 512332	CM	und                      Folate binding protein (FBP) is
./___Corpus/Medline/xml/PMC5123381.xml	E39	512418 : 512421	CM	 An immunogenic peptide (E39) and an attenuated versi
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	512781 : 512785	CM	ced cell death (AICD) of CTLs after over-stimulation. 
./___Corpus/Medline/xml/PMC5123381.xml	E39	512862 : 512865	CM	cific immune response to E39 and J65 after different 
./___Corpus/Medline/xml/PMC5123381.xml	J65	512870 : 512873	CM	mune response to E39 and J65 after different combinat
./___Corpus/Medline/xml/PMC5123381.xml	Ib	513046 : 513048	CM	ded, single-center phase Ib trial. Patients with bre
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2+	513163 : 513170	CM	e therapy were enrolled. HLA-A2+ patients were stratified
./___Corpus/Medline/xml/PMC5123381.xml	PVS	513257 : 513260	CM	 primary vaccine series (PVS) received either six ino
./___Corpus/Medline/xml/PMC5123381.xml	E39	513300 : 513303	CM	er six inoculations with E39, three E39, then three J
./___Corpus/Medline/xml/PMC5123381.xml	E39	513311 : 513314	CM	ulations with E39, three E39, then three J65 or three
./___Corpus/Medline/xml/PMC5123381.xml	J65	513327 : 513330	CM	9, three E39, then three J65 or three J65, then three
./___Corpus/Medline/xml/PMC5123381.xml	J65	513340 : 513343	CM	 then three J65 or three J65, then three E39. Ex vivo
./___Corpus/Medline/xml/PMC5123381.xml	E39	513356 : 513359	CM	or three J65, then three E39. Ex vivo immunologic rec
./___Corpus/Medline/xml/PMC5123381.xml	E39	513396 : 513399	CM	munologic recognition of E39 was assessed by clonal e
./___Corpus/Medline/xml/PMC5123381.xml	CTL	513461 : 513464	CM	cytotoxic T lymphocytes (CTL) and in vivo response by
./___Corpus/Medline/xml/PMC5123381.xml	DTH	513521 : 513524	CM	d-type hypersensitivity (DTH). The 6-month post-PVS i
./___Corpus/Medline/xml/PMC5123381.xml	6-	513531 : 513533	CPR	ersensitivity (DTH). The 6-month post-PVS immunologi
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513628 : 513631	CM	icant residual immunity (SRI), defined as ≥2-fold inc
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	513646 : 513652	CM	unity (SRI), defined as ≥2-fold increase from pre-PVS in
./___Corpus/Medline/xml/PMC5123381.xml	E39	513678 : 513681	CM	increase from pre-PVS in E39-specific CD8 + T cells. 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	513691 : 513694	CM	 pre-PVS in E39-specific CD8 + T cells. Patients were
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513749 : 513752	CM	ed into two groups: with SRI (SRI) and without (nSRI)
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513754 : 513757	CM	to two groups: with SRI (SRI) and without (nSRI). Pat
./___Corpus/Medline/xml/PMC5123381.xml	nSRI	513772 : 513776	CM	h SRI (SRI) and without (nSRI). Patients within each g
./___Corpus/Medline/xml/PMC5123381.xml	E39	513851 : 513854	CM	ne booster of either J65/E39 resulting in four groups
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513881 : 513884	CM	esulting in four groups: SRI receiving E39 (SRI-E39),
./___Corpus/Medline/xml/PMC5123381.xml	E39	513895 : 513898	CM	ur groups: SRI receiving E39 (SRI-E39), SRI receiving
./___Corpus/Medline/xml/PMC5123381.xml	SRI	513910 : 513913	CM	receiving E39 (SRI-E39), SRI receiving J65 (SRI-J65),
./___Corpus/Medline/xml/PMC5123381.xml	J65	513924 : 513927	CM	(SRI-E39), SRI receiving J65 (SRI-J65), nSRI receivin
./___Corpus/Medline/xml/PMC5123381.xml	SRI-J65	513929 : 513936	CM	E39), SRI receiving J65 (SRI-J65), nSRI receiving E39 (nS
./___Corpus/Medline/xml/PMC5123381.xml	nSRI	513939 : 513943	CM	receiving J65 (SRI-J65), nSRI receiving E39 (nSRI-E39)
./___Corpus/Medline/xml/PMC5123381.xml	E39	513954 : 513957	CM	SRI-J65), nSRI receiving E39 (nSRI-E39), nSRI receivi
./___Corpus/Medline/xml/PMC5123381.xml	nSRI	513970 : 513974	CM	eceiving E39 (nSRI-E39), nSRI receiving J65 (nSRI-J65)
./___Corpus/Medline/xml/PMC5123381.xml	J65	513985 : 513988	CM	SRI-E39), nSRI receiving J65 (nSRI-J65). Immunologic 
./___Corpus/Medline/xml/PMC5123381.xml	nSRI-J65	513990 : 513998	CM	39), nSRI receiving J65 (nSRI-J65). Immunologic data was g
./___Corpus/Medline/xml/PMC5123381.xml	1-	514035 : 514037	CPR	ic data was gathered at 1- and 6-months post-booster
./___Corpus/Medline/xml/PMC5123381.xml	6-	514041 : 514043	CPR	a was gathered at 1- and 6-months post-booster. This
./___Corpus/Medline/xml/PMC5123381.xml	SRI-J65	514211 : 514218	CM	ter arms (SRI-E39:n = 9; SRI-J65:n = 7; nSRI-E39:n = 7; n
./___Corpus/Medline/xml/PMC5123381.xml	nSRI-J65	514242 : 514250	CM	5:n = 7; nSRI-E39:n = 7; nSRI-J65:n = 5). There were no cl
./___Corpus/Medline/xml/PMC5123381.xml	1–	514357 : 514359	CPR	dverse events were grade 1–2. When comparing DTH pre
./___Corpus/Medline/xml/PMC5123381.xml	DTH	514377 : 514380	CM	rade 1–2. When comparing DTH pre-booster and at 1 and
./___Corpus/Medline/xml/PMC5123381.xml	6-	514406 : 514408	CPR	pre-booster and at 1 and 6-months post-booster there
./___Corpus/Medline/xml/PMC5123381.xml	SRI	514474 : 514477	CM	cant differences between SRI vs nSRI (p = 0.350, p = 
./___Corpus/Medline/xml/PMC5123381.xml	nSRI	514481 : 514485	CM	fferences between SRI vs nSRI (p = 0.350, p = 0.276, p
./___Corpus/Medline/xml/PMC5123381.xml	E39	514535 : 514538	CM	 = 0.133, respectively), E39 vs. J65 (p = 0.270, p = 
./___Corpus/Medline/xml/PMC5123381.xml	J65	514543 : 514546	CM	, respectively), E39 vs. J65 (p = 0.270, p = 0.329, p
./___Corpus/Medline/xml/PMC5123381.xml	6-	514679 : 514681	CPR	 delta-CTL from pre- and 6-months post-booster, rega
./___Corpus/Medline/xml/PMC5123381.xml	SRI	514716 : 514719	CM	t-booster, regardless of SRI, patients boosted with J
./___Corpus/Medline/xml/PMC5123381.xml	J65	514743 : 514746	CM	I, patients boosted with J65 had increased CTL (+0.02
./___Corpus/Medline/xml/PMC5123381.xml	CTL	514761 : 514764	CM	d with J65 had increased CTL (+0.02) while those boos
./___Corpus/Medline/xml/PMC5123381.xml	E39	514798 : 514801	CM	while those boosted with E39 had decreased CTL (−0.07
./___Corpus/Medline/xml/PMC5123381.xml	CTL	514816 : 514819	CM	d with E39 had decreased CTL (−0.07, p = 0.077). Ther
./___Corpus/Medline/xml/PMC5123381.xml	E39	514967 : 514970	CM	                    Both E39 and J65 are safe, well t
./___Corpus/Medline/xml/PMC5123381.xml	J65	514975 : 514978	CM	            Both E39 and J65 are safe, well tolerated
./___Corpus/Medline/xml/PMC5123381.xml	CTL	515115 : 515118	CM	appear to have increased CTL response to boosting reg
./___Corpus/Medline/xml/PMC5123381.xml	SRI	515154 : 515157	CM	o boosting regardless of SRI after the PVS. This is c
./___Corpus/Medline/xml/PMC5123381.xml	PVS	515168 : 515171	CM	ardless of SRI after the PVS. This is consistent with
./___Corpus/Medline/xml/PMC5123381.xml	E39	515286 : 515289	CM	, which has a maintained E39 specific immunity.      
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	515545 : 515555	CM	       P356 Genome-scale neoantigen screening using ATLAS™ p
./___Corpus/Medline/xml/PMC5123381.xml	ATLAS	515572 : 515577	CM	oantigen screening using ATLAS™ prioritizes candidates 
./___Corpus/Medline/xml/PMC5123381.xml	CPI	515992 : 515995	CM	of checkpoint inhibitor (CPI) therapy in treating som
./___Corpus/Medline/xml/PMC5123381.xml	CPI	516173 : 516176	CM	nfluences the outcome of CPI therapies. Capitalizing 
./___Corpus/Medline/xml/PMC5123381.xml	neoantigen	516337 : 516347	CM	n. Current approaches to neoantigen prioritization involve m
./___Corpus/Medline/xml/PMC5123381.xml	ATLAS	516603 : 516608	CM	tigens empirically using ATLAS™, a technology developed
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	516853 : 516857	CM	blood mononuclear cells (PBMC) and tumor biopsies from
./___Corpus/Medline/xml/PMC5123381.xml	O	517181 : 517182	CM	expressing listeriolysin O. Polypeptide expression 
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	517283 : 517288	CM	Western blotting. Frozen PBMCs, collected pre- and post
./___Corpus/Medline/xml/PMC5123381.xml	MDDC	517360 : 517364	CM	 derive dendritic cells (MDDC), and CD8+ T cells were 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517371 : 517375	CM	dritic cells (MDDC), and CD8+ T cells were enriched an
./___Corpus/Medline/xml/PMC5123381.xml	MDDC	517465 : 517469	CM	 clones were pulsed onto MDDC in an ordered array, the
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517513 : 517517	CM	y, then co-cultured with CD8+ T cells overnight. T cel
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	517658 : 517666	CM	as clones that induced a cytokine response that exceeded 3
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	517908 : 517912	CM	              Peripheral CD8+ T cells, screened agains
./___Corpus/Medline/xml/PMC5123381.xml	CPI	518043 : 518046	CM	ive neoantigens prior to CPI intervention and seven p
./___Corpus/Medline/xml/PMC5123381.xml	CPI	518493 : 518496	CM	By profiling natural and CPI-enhanced immunity to neo
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	518820 : 518824	CM	cine against endosialin (TEM1 or CD248)               
./___Corpus/Medline/xml/PMC5123381.xml	CD248	518828 : 518833	CM	inst endosialin (TEM1 or CD248)                      Pi
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	519036 : 519040	CM	or endothelial marker 1 (TEM1; also known as endosiali
./___Corpus/Medline/xml/PMC5123381.xml	CD248	519070 : 519075	CM	o known as endosialin or CD248) is a protein found on t
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	519208 : 519212	CM	 Here, we tested whether TEM1 has potential as a thera
./___Corpus/Medline/xml/PMC5123381.xml	cDNA	519321 : 519325	CM	competent mice with Tem1 cDNA fused to the minimal dom
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	519506 : 519510	CM	-TT vaccination elicited CD8+ and/or CD4+ T cell respo
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	519518 : 519522	CM	ion elicited CD8+ and/or CD4+ T cell responses against
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	519563 : 519567	CM	s against immunodominant TEM1 protein sequences. Proph
./___Corpus/Medline/xml/PMC5123381.xml	Prophylactic	519587 : 519599	CM	 TEM1 protein sequences. Prophylactic immunization of animals 
./___Corpus/Medline/xml/PMC5123381.xml	murine	519685 : 519691	CM	mor formation in several murine tumor models. Therapeuti
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	519805 : 519809	CM	ncreased infiltration of CD3+ T cells into the tumor, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	519918 : 519922	CM	accination also elicited CD8+ cytotoxic T cell respons
./___Corpus/Medline/xml/PMC5123381.xml	murine	519958 : 519964	CM	T cell responses against murine tumor-specific antigens.
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	520228 : 520232	CM	widespread expression of TEM1 on the vasculature of di
./___Corpus/Medline/xml/PMC5123381.xml	TEM1	520305 : 520309	CM	 conclude that targeting TEM1 has therapeutic potentia
./___Corpus/Medline/xml/PMC5123381.xml	Hafnium oxide	520383 : 520396	CM	y.                  P358 Hafnium oxide nanoparticle, a radiatio
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	520451 : 520458	CM	ancer for in situ cancer vaccine Sébastien Paris1, Agnes 
./___Corpus/Medline/xml/PMC5123381.xml	Paris1	520469 : 520475	CM	cancer vaccine Sébastien Paris1, Agnes Pottier1, Laurent
./___Corpus/Medline/xml/PMC5123381.xml	Agnes	520477 : 520482	CM	accine Sébastien Paris1, Agnes Pottier1, Laurent Levy1,
./___Corpus/Medline/xml/PMC5123381.xml	Bo	520508 : 520510	CM	Pottier1, Laurent Levy1, Bo Lu2 Background          
./___Corpus/Medline/xml/PMC5123381.xml	Hafnium oxide	520831 : 520844	CM	 successful combination. Hafnium oxide (HfO2) nanoparticles, un
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	520846 : 520850	CM	bination. Hafnium oxide (HfO2) nanoparticles, undergoi
./___Corpus/Medline/xml/PMC5123381.xml	HMGB1	521419 : 521424	CM	gh mobility group box 1 (HMGB1) protein and liberation 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine-5’-triphosphate	521452 : 521477	CM	rotein and liberation of adenosine-5’-triphosphate (ATP) – were examined on
./___Corpus/Medline/xml/PMC5123381.xml	ATP	521479 : 521482	CM	enosine-5’-triphosphate (ATP) – were examined on huma
./___Corpus/Medline/xml/PMC5123381.xml	24-	521556 : 521559	CPR	ss human cancer types, 24- to 96-hrs post-treatment w
./___Corpus/Medline/xml/PMC5123381.xml	96-	521561 : 521564	CPR	man cancer types, 24- to 96-hrs post-treatment with H
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	521588 : 521592	CM	-hrs post-treatment with HfO2 nanoparticles and exposu
./___Corpus/Medline/xml/PMC5123381.xml	4Gy	521641 : 521644	CM	ure to irradiation (from 4Gy to 15 Gy). CT 26 (murine
./___Corpus/Medline/xml/PMC5123381.xml	Gy	521651 : 521653	CM	adiation (from 4Gy to 15 Gy). CT 26 (murine colorect
./___Corpus/Medline/xml/PMC5123381.xml	CT	521656 : 521658	CM	ion (from 4Gy to 15 Gy). CT 26 (murine colorectal ca
./___Corpus/Medline/xml/PMC5123381.xml	murine	521663 : 521669	CM	om 4Gy to 15 Gy). CT 26 (murine colorectal cancer cells)
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	521719 : 521723	CM	 treated with or without HfO2 nanoparticles were expos
./___Corpus/Medline/xml/PMC5123381.xml	6Gy	521767 : 521770	CM	 exposed to irradiation (6Gy). Irradiated cells (1.10
./___Corpus/Medline/xml/PMC5123381.xml	BALB	521847 : 521851	CM	eously into the flank of BALB/c mice (vaccination phas
./___Corpus/Medline/xml/PMC5123381.xml	CT	521929 : 521931	CM	ere challenged with live CT 26 tumor cells (3.105) (
./___Corpus/Medline/xml/PMC5123381.xml	vitro	522155 : 522160	CM	                      In vitro, human cancer cell lines
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522199 : 522203	CM	 cell lines treated with HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	HCT116	522365 : 522371	CM	 tested human cell lines HCT116 (radiosensitive colorect
./___Corpus/Medline/xml/PMC5123381.xml	HMGB1	522467 : 522472	CM	toma), the generation of HMGB1 from cells treated with 
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522497 : 522501	CM	 from cells treated with HfO2 nanoparticles and expose
./___Corpus/Medline/xml/PMC5123381.xml	4Gy	522531 : 522534	CM	particles and exposed to 4Gy and 10Gy respectively, w
./___Corpus/Medline/xml/PMC5123381.xml	10Gy	522539 : 522543	CM	s and exposed to 4Gy and 10Gy respectively, was superi
./___Corpus/Medline/xml/PMC5123381.xml	6Gy	522620 : 522623	CM	 from cells treated with 6Gy and 15Gy alone respectiv
./___Corpus/Medline/xml/PMC5123381.xml	15Gy	522628 : 522632	CM	lls treated with 6Gy and 15Gy alone respectively. In v
./___Corpus/Medline/xml/PMC5123381.xml	CT	522708 : 522710	CM	e protected against live CT 26 challenge was markedl
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522791 : 522795	CM	 with cells treated with HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	6Gy	522821 : 522824	CM	nanoparticles exposed to 6Gy versus 6Gy alone (66 % v
./___Corpus/Medline/xml/PMC5123381.xml	6Gy	522832 : 522835	CM	es exposed to 6Gy versus 6Gy alone (66 % vs 33 % resp
./___Corpus/Medline/xml/PMC5123381.xml	HfO2	522921 : 522925	CM	ons                      HfO2 nanoparticles exposed to
./___Corpus/Medline/xml/PMC5123381.xml	Irina	523478 : 523483	CM	ie Hamdy2, Adrian Hill1, Irina Redchenko1              
./___Corpus/Medline/xml/PMC5123381.xml	FDA	523639 : 523642	CM	cine was approved by the FDA. Sipuleucel-T is a perso
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	523814 : 523821	CM	advanced prostate cancer vaccine, ProstVac-VF, is based o
./___Corpus/Medline/xml/PMC5123381.xml	MVA	524731 : 524734	CM	d vaccinia Ankara virus, MVA, is the most potent stra
./___Corpus/Medline/xml/PMC5123381.xml	ChAdOx1	524959 : 524966	CM	ings, simian adenovirus, ChAdOx1, and MVA were engineered
./___Corpus/Medline/xml/PMC5123381.xml	MVA	524972 : 524975	CM	adenovirus, ChAdOx1, and MVA were engineered to expre
./___Corpus/Medline/xml/PMC5123381.xml	B16	525416 : 525419	CM	lenge with the syngeneic B16 melanoma cell line expre
./___Corpus/Medline/xml/PMC5123381.xml	ChAd-MVA	525587 : 525595	CM	 in vaccinated mice. The ChAd-MVA vaccination platform sig
./___Corpus/Medline/xml/PMC5123381.xml	ChAd-MVA	525797 : 525805	CM	kingly, a combination of ChAd-MVA vaccine with anti-PD-1 m
./___Corpus/Medline/xml/PMC5123381.xml	anti-	525819 : 525824	CPR	of ChAd-MVA vaccine with anti-PD-1 mAb resulted in 80 %
./___Corpus/Medline/xml/PMC5123381.xml	ChAdOx1.5	526174 : 526183	CM	derway in the UK to test ChAdOx1.5 T4-MVA.5 T4 vaccination 
./___Corpus/Medline/xml/PMC5123381.xml	IL2	526788 : 526791	CM	   P360 Peptide vaccines/IL2 complex combination expa
./___Corpus/Medline/xml/PMC5123381.xml	CTL	527183 : 527186	CM	ccines induce suboptimal CTL responses (both in the q
./___Corpus/Medline/xml/PMC5123381.xml	CTL	527304 : 527307	CM	hed tumors. In contrast, CTL adoptive cell therapy (A
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	527523 : 527530	CM	 high quality endogenous TR-CTLs using peptide vaccines w
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	527808 : 527815	CM	-associated antigens and poly-IC (BiVax), which showed pr
./___Corpus/Medline/xml/PMC5123381.xml	BiVax	527817 : 527822	CM	ed antigens and poly-IC (BiVax), which showed promising
./___Corpus/Medline/xml/PMC5123381.xml	BiVax	527895 : 527900	CM	 Mice were injected with BiVax (120 μg of peptide and 5
./___Corpus/Medline/xml/PMC5123381.xml	Poly-IC	527933 : 527940	CM	 of peptide and 50 μg of Poly-IC) on day 0 and 12. Mouse 
./___Corpus/Medline/xml/PMC5123381.xml	IL-2Fc	527993 : 527999	CM	2cxCD25, IL-2cxCD122, or IL-2Fc (20 μg/mouse) was inject
./___Corpus/Medline/xml/PMC5123381.xml	BiVax	528218 : 528223	CM	improved the efficacy of BiVax by utilizing IL-2/anti-I
./___Corpus/Medline/xml/PMC5123381.xml	IL-2	528237 : 528241	CM	cy of BiVax by utilizing IL-2/anti-IL-2 antibody compl
./___Corpus/Medline/xml/PMC5123381.xml	anti-	528242 : 528247	CPR	 BiVax by utilizing IL-2/anti-IL-2 antibody complexes (
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528272 : 528278	CM	IL-2 antibody complexes (IL-2cx). The combination of BiV
./___Corpus/Medline/xml/PMC5123381.xml	BiVax	528300 : 528305	CM	2cx). The combination of BiVax with IL-2cx (BiVaxIL-2cx
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528311 : 528317	CM	ombination of BiVax with IL-2cx (BiVaxIL-2cx) induced a 
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	528370 : 528377	CM	ust amount of endogenous TR-CTLs (~40 million TR-CTLs/spl
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	528391 : 528398	CM	ous TR-CTLs (~40 million TR-CTLs/spleen) in a peptide dos
./___Corpus/Medline/xml/PMC5123381.xml	vitro	528487 : 528492	CM	le to recognize tumor in vitro as shown by ELISPOT assa
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	528551 : 528558	CM	er, BiVaxIL-2cx-expanded TR-CTLs were able to significant
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	528592 : 528598	CM	e to significantly delay B16F10 melanoma growth, enhance
./___Corpus/Medline/xml/PMC5123381.xml	IL-2cx	528717 : 528723	CM	 of mice. The timing for IL-2cx administration was criti
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	528811 : 528819	CM	 peptide vaccines before cytokine administration was cruci
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	528861 : 528868	CM	as crucial to expand the TR-CTLs.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	529015 : 529022	CM	to expand huge number of TR-CTLs with good quality that a
./___Corpus/Medline/xml/PMC5123381.xml	TR-CTLs	529199 : 529206	CM	ritical in expanding the TR-CTLs by peptide vaccines. Fin
./___Corpus/Medline/xml/PMC5123381.xml	HI	529509 : 529511	CM	                  1. Cho HI, Barrios K, Lee YR, Lino
./___Corpus/Medline/xml/PMC5123381.xml	K	529521 : 529522	CM	      1. Cho HI, Barrios K, Lee YR, Linowski AK, Ce
./___Corpus/Medline/xml/PMC5123381.xml	YR	529528 : 529530	CM	. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E: B
./___Corpus/Medline/xml/PMC5123381.xml	poly-IC	529571 : 529578	CM	elis E: BiVax: a peptide/poly-IC subunit vaccine that mim
./___Corpus/Medline/xml/PMC5123381.xml	anti-	529653 : 529658	CPR	icits vast and effective anti-tumor CD8 T-cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8	529664 : 529667	CM	and effective anti-tumor CD8 T-cell responses. Cancer
./___Corpus/Medline/xml/PMC5123381.xml	787–	529725 : 529729	CPR	 Immunother. 2013, 62(4):787–799.                     
./___Corpus/Medline/xml/PMC5123381.xml	HPV	530183 : 530186	CM	   Human papillomavirus (HPV) type 16 is associated w
./___Corpus/Medline/xml/PMC5123381.xml	HPV	530310 : 530313	CM	 (HNSCC), and many other HPV-associated tumors. Curre
./___Corpus/Medline/xml/PMC5123381.xml	HPV-16	530341 : 530347	CM	sociated tumors. Current HPV-16 vaccines utilize viral c
./___Corpus/Medline/xml/PMC5123381.xml	E6	530466 : 530468	CM	Many HNSCC express early E6/E7 rather than late vira
./___Corpus/Medline/xml/PMC5123381.xml	E7	530469 : 530471	CM	y HNSCC express early E6/E7 rather than late viral g
./___Corpus/Medline/xml/PMC5123381.xml	E7	530634 : 530636	CM	g established tumors. E6/E7, the early proteins of H
./___Corpus/Medline/xml/PMC5123381.xml	HPV-16	530660 : 530666	CM	7, the early proteins of HPV-16, have a transforming cap
./___Corpus/Medline/xml/PMC5123381.xml	E6	530861 : 530863	CM	tic vaccine that targets E6/E7 may prove more effect
./___Corpus/Medline/xml/PMC5123381.xml	E7	530864 : 530866	CM	 vaccine that targets E6/E7 may prove more effective
./___Corpus/Medline/xml/PMC5123381.xml	MHC	530958 : 530961	CM	fying and characterizing MHC class I-restricted immun
./___Corpus/Medline/xml/PMC5123381.xml	E6	531015 : 531017	CM	ic peptides derived from E6/E7 proteins is essential
./___Corpus/Medline/xml/PMC5123381.xml	E7	531018 : 531020	CM	peptides derived from E6/E7 proteins is essential fo
./___Corpus/Medline/xml/PMC5123381.xml	HPV-16	531090 : 531096	CM	loping vaccines to treat HPV-16-induced carcinomas, and 
./___Corpus/Medline/xml/PMC5123381.xml	9-mer	531334 : 531339	CM	ic HLA-A*0201-restricted 9-mer epitopes and agonist epi
./___Corpus/Medline/xml/PMC5123381.xml	E6	531373 : 531375	CM	 and agonist epitopes of E6 and E7. We selected two 
./___Corpus/Medline/xml/PMC5123381.xml	E7	531380 : 531382	CM	onist epitopes of E6 and E7. We selected two E6- and
./___Corpus/Medline/xml/PMC5123381.xml	E6	531400 : 531402	CM	 and E7. We selected two E6- and one E7-derived pept
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A*0201	531503 : 531513	CM	with high affinities for HLA-A*0201 molecules. The immunogen
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	531677 : 531680	CM	 cells infected with the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vec
./___Corpus/Medline/xml/PMC5123381.xml	E2b	531687 : 531690	CM	ected with the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector and no
./___Corpus/Medline/xml/PMC5123381.xml	E7Δ	531698 : 531701	CM	the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector and normal human 
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	531762 : 531766	CM	blood mononuclear cells (PBMC). The Ad5 [E1-, E2b-]–E6
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	531773 : 531776	CM	uclear cells (PBMC). The Ad5 [E1-, E2b-]–E6 Δ/E7Δ vec
./___Corpus/Medline/xml/PMC5123381.xml	E2b	531783 : 531786	CM	ls (PBMC). The Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector contai
./___Corpus/Medline/xml/PMC5123381.xml	E7Δ	531794 : 531797	CM	The Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector contains mutation
./___Corpus/Medline/xml/PMC5123381.xml	E6	531836 : 531838	CM	ns mutations that render E6/E7 nononcogenic, while p
./___Corpus/Medline/xml/PMC5123381.xml	E7	531839 : 531841	CM	mutations that render E6/E7 nononcogenic, while pres
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	532004 : 532007	CM	dritic cells, as well as Ad5 [E1-, E2b-]–E6 Δ/E7Δ vec
./___Corpus/Medline/xml/PMC5123381.xml	E2b	532014 : 532017	CM	ls, as well as Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector-infect
./___Corpus/Medline/xml/PMC5123381.xml	E7Δ	532025 : 532028	CM	 as Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector-infected dendriti
./___Corpus/Medline/xml/PMC5123381.xml	Ad5	532143 : 532146	CM	 cells infected with the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vec
./___Corpus/Medline/xml/PMC5123381.xml	E2b	532153 : 532156	CM	ected with the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector. Compa
./___Corpus/Medline/xml/PMC5123381.xml	E7Δ	532164 : 532167	CM	the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector. Compared to nati
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	532274 : 532279	CM	hanced the production of IFN-γ by peptide-activated hum
./___Corpus/Medline/xml/PMC5123381.xml	HPV	532358 : 532361	CM	n tumor cells expressing HPV in an MHC-restricted man
./___Corpus/Medline/xml/PMC5123381.xml	vaccine	532587 : 532594	CM	pitopes into therapeutic vaccine platforms and for the ex
./___Corpus/Medline/xml/PMC5123381.xml	HPV	532639 : 532642	CM	he ex vivo generation of HPV-specific human T cells. 
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	532732 : 532743	CM	62 Liposome-encapsulated doxorubicin is a promising adjuvant 
./___Corpus/Medline/xml/PMC5123381.xml	mTERT	532796 : 532801	CM	increase the efficacy of mTERT DNA-vaccine             
./___Corpus/Medline/xml/PMC5123381.xml	anti-	533225 : 533230	CPR	 part by facilitating an anti-tumor immune response. Th
./___Corpus/Medline/xml/PMC5123381.xml	anti-	533565 : 533570	CPR	pulations that limit the anti-tumor immune effect. Doxi
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	533591 : 533596	CM	nti-tumor immune effect. Doxil (pegylated liposomal dox
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533618 : 533629	CM	xil (pegylated liposomal doxorubicin) possesses specific immu
./___Corpus/Medline/xml/PMC5123381.xml	ID8	533831 : 533834	CM	eally (i.p.) with 5 x106 ID8 cells. For chemotherapeu
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	533934 : 533939	CM	on of either 50 mg/m2 of Doxil (doxorubicin HCl liposom
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533941 : 533952	CM	ither 50 mg/m2 of Doxil (doxorubicin HCl liposome injection) 
./___Corpus/Medline/xml/PMC5123381.xml	doxorubicin	533992 : 534003	CM	njection) or 50 mg/m2 of doxorubicin. DNA immunization (mTERT
./___Corpus/Medline/xml/PMC5123381.xml	BTX	534197 : 534200	CM	n was carried out with a BTX electroporator intramusc
./___Corpus/Medline/xml/PMC5123381.xml	ID8	534310 : 534313	CM	epletion, tumor-free and ID8 tumor-bearing mice were 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	534351 : 534356	CPR	g mice were treated with anti-asialo GM1.              
./___Corpus/Medline/xml/PMC5123381.xml	GM1	534363 : 534366	CM	treated with anti-asialo GM1.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	534440 : 534445	CM	ere, we characterize how Doxil treatment is able to imp
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	534649 : 534654	CM	, NK cells isolated from Doxil-treated mice produce gre
./___Corpus/Medline/xml/PMC5123381.xml	(IFN)-γ	534706 : 534713	CM	er amounts of interferon (IFN)-γ compared to isolated NK 
./___Corpus/Medline/xml/PMC5123381.xml	Th-1	534785 : 534789	CM	ice, promoting selective Th-1 polarization of naïve CD
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	534812 : 534816	CM	-1 polarization of naïve CD4+ T cells. These immune mo
./___Corpus/Medline/xml/PMC5123381.xml	CD8	534963 : 534966	CM	pand an antigen-specific CD8 + T cell population. Thi
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	535168 : 535173	CM	et totally abrogated the Doxil immune adjuvant activity
./___Corpus/Medline/xml/PMC5123381.xml	Doxil	535212 : 535217	CM	nt activity. We combined Doxil with a DNA-vaccine encod
./___Corpus/Medline/xml/PMC5123381.xml	ID8	535541 : 535544	CM	vaccination schedules in ID8 ovarian tumor-bearing mi
./___Corpus/Medline/xml/PMC5123381.xml	anti-	535674 : 535679	CPR	re related to a specific anti-TERT CD8+ T cell response
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	535684 : 535688	CM	 to a specific anti-TERT CD8+ T cell response. This da
./___Corpus/Medline/xml/PMC5123381.xml	HLA	536304 : 536307	CM	de treatment in terms of HLA restriction. In addition
./___Corpus/Medline/xml/PMC5123381.xml	SLP	536512 : 536515	CM	ge, we planned to design SLP vaccines containing mult
./___Corpus/Medline/xml/PMC5123381.xml	CTL	536569 : 536572	CM	 cytotoxic T lymphocyte (CTL) epitopes which are rest
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A2	536604 : 536610	CM	pes which are restricted HLA-A2, A24, A3 supertype, resp
./___Corpus/Medline/xml/PMC5123381.xml	A24	536612 : 536615	CM	h are restricted HLA-A2, A24, A3 supertype, respectiv
./___Corpus/Medline/xml/PMC5123381.xml	SLP	536717 : 536720	CM	confirm whether designed SLP vaccines could induce al
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	536813 : 536818	CM	onfirmations using human PBMCs or expensive HLA-express
./___Corpus/Medline/xml/PMC5123381.xml	Murine	536980 : 536986	CM	ods                      Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	murine	537106 : 537112	CM	uffer and incubated with murine i20s immunoproteasome fo
./___Corpus/Medline/xml/PMC5123381.xml	N-	537446 : 537448	CPR	peptides fragments from N-terminal. In order to comp
./___Corpus/Medline/xml/PMC5123381.xml	CTL	537520 : 537523	CM	 to the peptide specific CTL induction, the SLPs were
./___Corpus/Medline/xml/PMC5123381.xml	HLA-A	537565 : 537570	CM	LPs were administered to HLA-A knock-in mice and the CT
./___Corpus/Medline/xml/PMC5123381.xml	CTL	537593 : 537596	CM	-A knock-in mice and the CTL induction was analyzed u
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	537626 : 537631	CM	ction was analyzed using IFN-γ ELISPOT assay.          
./___Corpus/Medline/xml/PMC5123381.xml	murine	537718 : 537724	CM	We applied 4 SLPs to the murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	Arg	537911 : 537914	CM	ions of intact epitopes, Arg added epitopes, and Arg-
./___Corpus/Medline/xml/PMC5123381.xml	Arg-Arg	537935 : 537942	CM	 Arg added epitopes, and Arg-Arg added epitopes to the N-
./___Corpus/Medline/xml/PMC5123381.xml	N-	537966 : 537968	CPR	g added epitopes to the N-terminus at any time point
./___Corpus/Medline/xml/PMC5123381.xml	C-	538035 : 538037	CPR	omal digestion of exact C-terminus of CTL epitope is
./___Corpus/Medline/xml/PMC5123381.xml	CTL	538048 : 538051	CM	n of exact C-terminus of CTL epitope is known to be a
./___Corpus/Medline/xml/PMC5123381.xml	CTLs	538240 : 538244	CM	 able to induce specific CTLs, but 4 epitopes were det
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	538316 : 538321	CM	tope”. Compared with the IFN-γ ELISPOT assay, the resul
./___Corpus/Medline/xml/PMC5123381.xml	murine	538352 : 538358	CM	OT assay, the results of murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	CTL	538434 : 538437	CM	y matched the results of CTL induction (11 of 12 epit
./___Corpus/Medline/xml/PMC5123381.xml	Murine	538527 : 538533	CM	ons                      Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	CTL	538585 : 538588	CM	 assay could predict the CTL induction with a high de
./___Corpus/Medline/xml/PMC5123381.xml	murine	538649 : 538655	CM	uracy. We concluded that murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	538733 : 538738	CM	 prognostic approach for IFN-γ ELISPOT assay using an H
./___Corpus/Medline/xml/PMC5123381.xml	SLP	538899 : 538902	CM	ortant for the design of SLP vaccines. Murine-immunop
./___Corpus/Medline/xml/PMC5123381.xml	Murine	538913 : 538919	CM	 design of SLP vaccines. Murine-immunoproteasome digesti
./___Corpus/Medline/xml/PMC5123381.xml	SLP	539003 : 539006	CM	 “suitable” multi-valent SLP vaccines.               
./___Corpus/Medline/xml/PMC5123381.xml	DC	539174 : 539176	CM	ptome of dendritic cell (DC) subsets in tonsillar ca
./___Corpus/Medline/xml/PMC5123381.xml	TC	539207 : 539209	CM	ets in tonsillar cancer (TC) and benign tonsils     
./___Corpus/Medline/xml/PMC5123381.xml	Malin	539358 : 539363	CM	brekt1, Lennart Greiff2, Malin Lindstedt1              
./___Corpus/Medline/xml/PMC5123381.xml	HNC	539446 : 539449	CM	   Head and neck cancer (HNC), including TC, is the 6
./___Corpus/Medline/xml/PMC5123381.xml	TC	539462 : 539464	CM	 cancer (HNC), including TC, is the 6th most common 
./___Corpus/Medline/xml/PMC5123381.xml	DC	539695 : 539697	CM	ic approaches. Arguably, DC-mediated immunotherapy i
./___Corpus/Medline/xml/PMC5123381.xml	DCs	539779 : 539782	CM	outstanding potential of DCs to elicit tumor-specific
./___Corpus/Medline/xml/PMC5123381.xml	DC	539938 : 539940	CM	myeloid and plasmacytoid DC subsets in TC and benign
./___Corpus/Medline/xml/PMC5123381.xml	TC	539952 : 539954	CM	asmacytoid DC subsets in TC and benign tonsils to fu
./___Corpus/Medline/xml/PMC5123381.xml	DC	540007 : 540009	CM	ll a descriptive need of DC characterization in DC-m
./___Corpus/Medline/xml/PMC5123381.xml	DC	540030 : 540032	CM	f DC characterization in DC-mediated immunotherapy c
./___Corpus/Medline/xml/PMC5123381.xml	TC	540128 : 540130	CM	        From biopsies of TC tissue (n = 4) and benig
./___Corpus/Medline/xml/PMC5123381.xml	DC	540174 : 540176	CM	 benign tonsils (n = 4), DC subsets were identified 
./___Corpus/Medline/xml/PMC5123381.xml	8-	540223 : 540225	CPR	ed and sorted through an 8-color flow cytometry Ab p
./___Corpus/Medline/xml/PMC5123381.xml	Ab	540246 : 540248	CM	n 8-color flow cytometry Ab panel. Sorted cells were
./___Corpus/Medline/xml/PMC5123381.xml	TC	540356 : 540358	CM	ofiles of the subsets in TC were compared to their p
./___Corpus/Medline/xml/PMC5123381.xml	TC	540843 : 540845	CM	imately 15 benign and 10 TC samples).               
./___Corpus/Medline/xml/PMC5123381.xml	DCs	540902 : 540905	CM	lts                      DCs were more frequent among
./___Corpus/Medline/xml/PMC5123381.xml	CD45+	540931 : 540936	CM	were more frequent among CD45+ leukocytes in TC compare
./___Corpus/Medline/xml/PMC5123381.xml	TC	540951 : 540953	CM	mong CD45+ leukocytes in TC compared to benign tonsi
./___Corpus/Medline/xml/PMC5123381.xml	CD11c+	541012 : 541018	CM	owed an elevated myeloid CD11c+/plasmacytoid CD123+ rati
./___Corpus/Medline/xml/PMC5123381.xml	CD123+	541032 : 541038	CM	loid CD11c+/plasmacytoid CD123+ ratio. In agreement, som
./___Corpus/Medline/xml/PMC5123381.xml	CD123+	541140 : 541146	CM	 different subsets where CD123+ DCs were less frequent i
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541147 : 541150	CM	ent subsets where CD123+ DCs were less frequent in TC
./___Corpus/Medline/xml/PMC5123381.xml	TC	541173 : 541175	CM	Cs were less frequent in TC compared to benign tonsi
./___Corpus/Medline/xml/PMC5123381.xml	CD1c−	541209 : 541214	CM	 to benign tonsils while CD1c− CD141− DCs were more fre
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541222 : 541225	CM	nsils while CD1c− CD141− DCs were more frequent. In c
./___Corpus/Medline/xml/PMC5123381.xml	DC	541303 : 541305	CM	erences were detected in DC subsets’ gene expression
./___Corpus/Medline/xml/PMC5123381.xml	TC	541348 : 541350	CM	ression profiles between TC and benign tonsils. List
./___Corpus/Medline/xml/PMC5123381.xml	CD206	541483 : 541488	CM	 at protein level, e.g., CD206 and CD207 on the CD1c+ D
./___Corpus/Medline/xml/PMC5123381.xml	CD207	541493 : 541498	CM	n level, e.g., CD206 and CD207 on the CD1c+ DCs in TC a
./___Corpus/Medline/xml/PMC5123381.xml	CD1c+	541506 : 541511	CM	, CD206 and CD207 on the CD1c+ DCs in TC and benign ton
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541512 : 541515	CM	6 and CD207 on the CD1c+ DCs in TC and benign tonsils
./___Corpus/Medline/xml/PMC5123381.xml	TC	541519 : 541521	CM	D207 on the CD1c+ DCs in TC and benign tonsils.     
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541592 : 541595	CM	ons                      DCs are present in TC and be
./___Corpus/Medline/xml/PMC5123381.xml	TC	541611 : 541613	CM	      DCs are present in TC and benign tonsil tissue
./___Corpus/Medline/xml/PMC5123381.xml	DCs	541744 : 541747	CM	 profiles. Surprisingly, DCs may therefore not be mar
./___Corpus/Medline/xml/PMC5123381.xml	TC	541814 : 541816	CM	 the microenvironment in TC (as may be the case for 
./___Corpus/Medline/xml/PMC5123381.xml	DC	541906 : 541908	CM	rk suggests a maintained DC functionality and potent
./___Corpus/Medline/xml/PMC5123381.xml	DC	541972 : 541974	CM	 possibility of tailored DC-mediated immunotherapy f
./___Corpus/Medline/xml/PMC5123381.xml	TC	542002 : 542004	CM	diated immunotherapy for TC. This is now facilitated
./___Corpus/Medline/xml/PMC5123381.xml	anti-	542133 : 542138	CPR	of favored cell-mediated anti-tumor responses. Further 
./___Corpus/Medline/xml/PMC5123381.xml	HNCs	542237 : 542241	CM	findings extend to other HNCs remains to be examined. 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	542353 : 542358	CPR	itizes ovarian cancer to anti-PD-1 antibody therapy by 
./___Corpus/Medline/xml/PMC5123381.xml	(IL)-10	542745 : 542752	CM	s, including interleukin (IL)-10 [1]. We hypothesized tha
./___Corpus/Medline/xml/PMC5123381.xml	DC	542953 : 542955	CM	        Dendritic cells (DC) in mice treated with 30
./___Corpus/Medline/xml/PMC5123381.xml	murine	543046 : 543052	CM	ab) were analyzed in two murine tumor models [2, 3]. In 
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	543291 : 543297	CM	ldtype or IL10-knockout (IL10KO) mice treated with 500ug
./___Corpus/Medline/xml/PMC5123381.xml	anti-	543326 : 543331	CPR	ce treated with 500ug of anti-PD-1 antibody on days 17 
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	543606 : 543612	CM	nt increased stimulatory CD103+ DC (18 % to 30 % in ID8o
./___Corpus/Medline/xml/PMC5123381.xml	DC	543613 : 543615	CM	eased stimulatory CD103+ DC (18 % to 30 % in ID8ova;
./___Corpus/Medline/xml/PMC5123381.xml	DC	543701 : 543703	CM	eased suppressive Lair1+ DC in the peritoneal tumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	543815 : 543819	CM	ated with an increase in CD8+ T cells and a decrease i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	543864 : 543868	CM	ase in regulatory FoxP3+ CD4+ T cells (45 % to 30 %). 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	543911 : 543915	CM	30 %). The proportion of CD4+ and CD8+ T cells produci
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	543920 : 543924	CM	e proportion of CD4+ and CD8+ T cells producing interf
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	544035 : 544041	CM	was observed in 100 % of IL10KO mice treated with PD-1 a
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	544060 : 544064	CM	IL10KO mice treated with PD-1 antibody but treatment d
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	544241 : 544247	CM	nrichment of stimulatory CD103+ DC in the tumor microenv
./___Corpus/Medline/xml/PMC5123381.xml	DC	544248 : 544250	CM	nt of stimulatory CD103+ DC in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	IL-10R	544286 : 544292	CM	or microenvironment with IL-10R blockade, associated wit
./___Corpus/Medline/xml/PMC5123381.xml	IL10KO	544462 : 544468	CM	cant survival benefit in IL10KO mice receiving anti-PD-1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	544484 : 544489	CPR	in IL10KO mice receiving anti-PD-1 antibody. These data
./___Corpus/Medline/xml/PMC5123381.xml	DB	544671 : 544673	CM	                1. Flies DB, Higuchi T, Harris JC, J
./___Corpus/Medline/xml/PMC5123381.xml	JC	544693 : 544695	CM	es DB, Higuchi T, Harris JC, Jha V, Gimotty PA, Adam
./___Corpus/Medline/xml/PMC5123381.xml	Jha	544697 : 544700	CM	B, Higuchi T, Harris JC, Jha V, Gimotty PA, Adams SF:
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	544806 : 544812	CM	city of tumor-associated CD103+ dendritic cells in late-
./___Corpus/Medline/xml/PMC5123381.xml	KF	544997 : 544999	CM	                 2. Roby KF, Taylor CC, Sweetwood JP
./___Corpus/Medline/xml/PMC5123381.xml	CC	545008 : 545010	CM	      2. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, 
./___Corpus/Medline/xml/PMC5123381.xml	JP	545022 : 545024	CM	KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfi
./___Corpus/Medline/xml/PMC5123381.xml	Y	545032 : 545033	CM	 CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et a
./___Corpus/Medline/xml/PMC5123381.xml	JL	545040 : 545042	CM	etwood JP, Cheng Y, Pace JL, Tawfik O, et al.: Devel
./___Corpus/Medline/xml/PMC5123381.xml	O	545051 : 545052	CM	Cheng Y, Pace JL, Tawfik O, et al.: Development of 
./___Corpus/Medline/xml/PMC5123381.xml	585–	545163 : 545167	CPR	 Carcinogenesis 2000, 21:585–591.                     
./___Corpus/Medline/xml/PMC5123381.xml	DC	545222 : 545224	CM	             3. Connolly DC, Bao R, Nikitin AY, Step
./___Corpus/Medline/xml/PMC5123381.xml	R	545230 : 545231	CM	     3. Connolly DC, Bao R, Nikitin AY, Stephens KC
./___Corpus/Medline/xml/PMC5123381.xml	KC	545254 : 545256	CM	 R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al.
./___Corpus/Medline/xml/PMC5123381.xml	TW	545264 : 545266	CM	n AY, Stephens KC, Poole TW, Hua X, et al.: Female m
./___Corpus/Medline/xml/PMC5123381.xml	X	545272 : 545273	CM	ephens KC, Poole TW, Hua X, et al.: Female mice chi
./___Corpus/Medline/xml/PMC5123381.xml	MISIIR	545367 : 545373	CM	TAg under control of the MISIIR promoter develop epithel
./___Corpus/Medline/xml/PMC5123381.xml	1389–	545438 : 545443	CPR	cer. Cancer Res 2003, 63:1389–1397.                  P3
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	545475 : 545483	CM	                P366 Axl tyrosine kinase is a key mediator
./___Corpus/Medline/xml/PMC5123381.xml	Py117	546258 : 546263	CM	unologically responsive (Py117) and unresponsive (Py811
./___Corpus/Medline/xml/PMC5123381.xml	PyMT	546317 : 546321	CM	yngeneic tumors from the PyMT mammary carcinoma model 
./___Corpus/Medline/xml/PMC5123381.xml	Py117	546540 : 546545	CM	 differences between the Py117 and Py8119 tumors. The C
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	546569 : 546575	CM	7 and Py8119 tumors. The CRISPR/Cas9 technology was used
./___Corpus/Medline/xml/PMC5123381.xml	Cas9	546576 : 546580	CM	y8119 tumors. The CRISPR/Cas9 technology was used to k
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	546631 : 546639	CM	ockout Axl, a TAM family tyrosine kinase. We confirmed sig
./___Corpus/Medline/xml/PMC5123381.xml	clonogenic	546765 : 546775	CM	nsic radiosensitivity by clonogenic survival, determined cel
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	547073 : 547081	CM	antigen presentation and cytokine production. Lastly, we d
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	547287 : 547291	CM	, we combined radiation, PD-1, and CTLA-4 therapy to d
./___Corpus/Medline/xml/PMC5123381.xml	RPPA	547436 : 547440	CM	               Through a RPPA, we identified differenc
./___Corpus/Medline/xml/PMC5123381.xml	EMT	547554 : 547557	CM	 mesenchymal transition (EMT). Then we knocked out Ax
./___Corpus/Medline/xml/PMC5123381.xml	EMT	547673 : 547676	CM	nstivity but altered the EMT phenotype, resulted in g
./___Corpus/Medline/xml/PMC5123381.xml	Gy	547761 : 547763	CM	adiosensitivity after 20 Gy in mice. Key features of
./___Corpus/Medline/xml/PMC5123381.xml	MHCI	547821 : 547825	CM	 knockouts were enhanced MHCI expression and decreased
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	548127 : 548131	CM	ckout tumors and greater CD8+ T cells at baseline. Ten
./___Corpus/Medline/xml/PMC5123381.xml	CD8	548198 : 548201	CM	tion there was increased CD8 and CD4+ T cells and dec
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	548206 : 548210	CM	re was increased CD8 and CD4+ T cells and decreased ma
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	548332 : 548337	CM	s supported by increased PD-L1 and FoxP3+ T regs in Axl
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	548463 : 548467	CM	sponse was obtained with PD-1 and CTLA-4 inhibition in
./___Corpus/Medline/xml/PMC5123381.xml	Ajina1	548954 : 548960	CM	                   Reham Ajina1, Shangzi Wang1, Jill Smi
./___Corpus/Medline/xml/PMC5123381.xml	III2	549049 : 549053	CM	nski1, Emanuel Petricoin III2, Louis M Weiner1        
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	549154 : 549158	CM	c ductal adenocarcinoma (PDAC) is the fourth leading c
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	549230 : 549234	CM	n the United States [1]. PDAC is characterized by onco
./___Corpus/Medline/xml/PMC5123381.xml	KRAS	549265 : 549269	CM	aracterized by oncogenic KRAS mutations and resistance
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	549368 : 549372	CM	 growth factor receptor (EGFR) is required for KRAS-in
./___Corpus/Medline/xml/PMC5123381.xml	KRAS	549390 : 549394	CM	r (EGFR) is required for KRAS-induced pancreatic tumor
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	549442 : 549446	CM	origenesis [3]. Although EGFR network activation repre
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	549506 : 549510	CM	ssible therapy target in PDAC, the anti-EGFR small mol
./___Corpus/Medline/xml/PMC5123381.xml	anti-	549516 : 549521	CPR	rapy target in PDAC, the anti-EGFR small molecule erlot
./___Corpus/Medline/xml/PMC5123381.xml	erlotinib	549541 : 549550	CM	anti-EGFR small molecule erlotinib has minimal therapeutic 
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	549717 : 549721	CM	pment and progression of PDAC [2]. Accordingly, we exp
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	549795 : 549799	CM	ne selection pressure on EGFR and related signaling pa
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	549847 : 549853	CM	pathways using syngeneic Panc02 pancreatic cancer models
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	549933 : 549939	CM	                  1 X106 Panc02 cells were injected subc
./___Corpus/Medline/xml/PMC5123381.xml	B6.CB17	549994 : 550001	CM	ously in immunocompetent B6.CB17 (WT) and immunodeficient
./___Corpus/Medline/xml/PMC5123381.xml	WT	550003 : 550005	CM	immunocompetent B6.CB17 (WT) and immunodeficient B6.
./___Corpus/Medline/xml/PMC5123381.xml	SzJ	550045 : 550048	CM	icient B6.CB17-Prkdcscid/SzJ (SCID) mice (16mice/grou
./___Corpus/Medline/xml/PMC5123381.xml	SCID	550050 : 550054	CM	t B6.CB17-Prkdcscid/SzJ (SCID) mice (16mice/group). On
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylated	550200 : 550214	CM	 (18 total proteins, 107 phosphorylated species) to evaluate pro
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	550643 : 550649	CM	            As expected, Panc02 tumors grow more slowly 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	550850 : 550856	CM	protein activity between Panc02 tumors engrafted in the 
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	551121 : 551125	CM	 selective activation of EGFR, ERK/MAPK, JAK/STAT, AMP
./___Corpus/Medline/xml/PMC5123381.xml	ERK	551127 : 551130	CM	tive activation of EGFR, ERK/MAPK, JAK/STAT, AMPK and
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	551131 : 551135	CM	 activation of EGFR, ERK/MAPK, JAK/STAT, AMPK and TGFβ
./___Corpus/Medline/xml/PMC5123381.xml	JAK	551137 : 551140	CM	ation of EGFR, ERK/MAPK, JAK/STAT, AMPK and TGFβ/Smad
./___Corpus/Medline/xml/PMC5123381.xml	STAT	551141 : 551145	CM	n of EGFR, ERK/MAPK, JAK/STAT, AMPK and TGFβ/Smad sign
./___Corpus/Medline/xml/PMC5123381.xml	AMPK	551147 : 551151	CM	GFR, ERK/MAPK, JAK/STAT, AMPK and TGFβ/Smad signaling 
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	551156 : 551160	CM	MAPK, JAK/STAT, AMPK and TGFβ/Smad signaling pathways 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	551299 : 551305	CM	on pressure in syngeneic Panc02 pancreatic cancer models
./___Corpus/Medline/xml/PMC5123381.xml	KD	551611 : 551613	CM	    1. Siegel RL, Miller KD, Jemal A: Cancer statist
./___Corpus/Medline/xml/PMC5123381.xml	7–	551678 : 551680	CPR	ancer J Clin 2016, 66(1):7–30.                      
./___Corpus/Medline/xml/PMC5123381.xml	LR	551732 : 551734	CM	               2. Brunet LR, Hagemann T, Andrew G, M
./___Corpus/Medline/xml/PMC5123381.xml	e1112942	551921 : 551929	CM	ncoimmunology 2016, 5(4):e1112942.                        
./___Corpus/Medline/xml/PMC5123381.xml	KK	552003 : 552005	CM	 CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C,
./___Corpus/Medline/xml/PMC5123381.xml	PK	552050 : 552052	CM	to C, Teichmann N, Mazur PK, et al.: EGF receptor is
./___Corpus/Medline/xml/PMC5123381.xml	KRAS	552091 : 552095	CM	receptor is required for KRAS-induced pancreatic tumor
./___Corpus/Medline/xml/PMC5123381.xml	304–	552154 : 552158	CPR	 Cancer Cell 2012, 22(3):304–317.                     
./___Corpus/Medline/xml/PMC5123381.xml	RK	552211 : 552213	CM	               4. Kelley RK, Ko AH: Erlotinib in the
./___Corpus/Medline/xml/PMC5123381.xml	Ko	552215 : 552217	CM	           4. Kelley RK, Ko AH: Erlotinib in the tre
./___Corpus/Medline/xml/PMC5123381.xml	Erlotinib	552222 : 552231	CM	    4. Kelley RK, Ko AH: Erlotinib in the treatment of adva
./___Corpus/Medline/xml/PMC5123381.xml	83–	552301 : 552304	CPR	er. Biologics 2008, 2(1):83–95.                      
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552393 : 552396	CM	al analysis on FoxP3 and CD8 positive IHC stained T c
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552745 : 552748	CM	een that the presence of CD8 (cytotoxic T cell marker
./___Corpus/Medline/xml/PMC5123381.xml	CD8	552794 : 552797	CM	rker), as well as a high CD8/FoxP3 ratio, indicates a
./___Corpus/Medline/xml/PMC5123381.xml	p3	552877 : 552879	CM	rvival. The forkhead box p3 (FoxP3) regulatory T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553393 : 553396	CM	es, we aimed to quantify CD8 and FoxP3 immune cell re
./___Corpus/Medline/xml/PMC5123381.xml	chromogen	553662 : 553671	CM	for FoxP3 (brown nuclear chromogen) and CD8 (red membrane c
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553677 : 553680	CM	n nuclear chromogen) and CD8 (red membrane chromogen)
./___Corpus/Medline/xml/PMC5123381.xml	chromogen	553695 : 553704	CM	n) and CD8 (red membrane chromogen). Image analysis was per
./___Corpus/Medline/xml/PMC5123381.xml	CD8	553910 : 553913	CM	dentify and count FoxP3, CD8, and dual labelled cells
./___Corpus/Medline/xml/PMC5123381.xml	CD8	554468 : 554471	CM	ndicated higher FoxP3 to CD8 ratios 100 μm inside the
./___Corpus/Medline/xml/PMC5123381.xml	CD8	554685 : 554688	CM	es with shorter FoxP3 to CD8 cell distances in the st
./___Corpus/Medline/xml/PMC5123381.xml	K	555187 : 555188	CM	    1. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin
./___Corpus/Medline/xml/PMC5123381.xml	Y	555197 : 555198	CM	aguchi S, Wing K, Onishi Y, Prieto-Martin P and Yam
./___Corpus/Medline/xml/PMC5123381.xml	P	555214 : 555215	CM	 Onishi Y, Prieto-Martin P and Yamaguchi: Regulator
./___Corpus/Medline/xml/PMC5123381.xml	1105–	555315 : 555320	CPR	Int Immunol 2009, 21(10):1105–1111.                    
./___Corpus/Medline/xml/PMC5123381.xml	CD8	555402 : 555405	CM	biased agonist increases CD8 + T Cells and natural ki
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	555500 : 555508	CM	ing cold tumors hot with NKTR-214                         
./___Corpus/Medline/xml/PMC5123381.xml	Hoch3	555713 : 555718	CM	 Jonathan Zalevsky3, Ute Hoch3, Patrick Hwu1, Mario Snz
./___Corpus/Medline/xml/PMC5123381.xml	Snzol2	555740 : 555746	CM	ch3, Patrick Hwu1, Mario Snzol2, Michael Hurwitz2, Adi D
./___Corpus/Medline/xml/PMC5123381.xml	Diab1	555770 : 555775	CM	2, Michael Hurwitz2, Adi Diab1                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	555984 : 555992	CM	h checkpoint inhibitors. NKTR-214 provides sustained activ
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	556146 : 556154	CM	ical models demonstrated NKTR-214 preferentially expands e
./___Corpus/Medline/xml/PMC5123381.xml	CD8	556187 : 556190	CM	ntially expands effector CD8 + T cells and NK cells w
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	556384 : 556392	CM	as initiated to evaluate NKTR-214 safety and efficacy and 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	556582 : 556590	CM	 dose-expansion study of NKTR-214 in patients with locally
./___Corpus/Medline/xml/PMC5123381.xml	anti-	556938 : 556943	CPR	kinetics and preliminary anti-tumor activity of NKTR-21
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	556961 : 556969	CM	y anti-tumor activity of NKTR-214 are being evaluated. NKT
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	556991 : 556999	CM	214 are being evaluated. NKTR-214 is administered IV q2-q3
./___Corpus/Medline/xml/PMC5123381.xml	q2-q3	557019 : 557024	CM	R-214 is administered IV q2-q3 weeks in an outpatient s
./___Corpus/Medline/xml/PMC5123381.xml	MEL	557237 : 557240	CM	 enrolled (RCC [n = 12], MEL [n = 4], CRC [n = 1]; UB
./___Corpus/Medline/xml/PMC5123381.xml	CRC	557250 : 557253	CM	C [n = 12], MEL [n = 4], CRC [n = 1]; UBC [n = 1]). 7
./___Corpus/Medline/xml/PMC5123381.xml	UBC	557263 : 557266	CM	EL [n = 4], CRC [n = 1]; UBC [n = 1]). 7/12 (58 %) pa
./___Corpus/Medline/xml/PMC5123381.xml	8-	557333 : 557335	CPR	 disease at initial 6 or 8-week scan with 9 patients
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	557407 : 557415	CM	utpatient treatment with NKTR-214 was well tolerated and t
./___Corpus/Medline/xml/PMC5123381.xml	MTD	557443 : 557446	CM	s well tolerated and the MTD has not been reached. On
./___Corpus/Medline/xml/PMC5123381.xml	DLTs	557493 : 557497	CM	 One patient experienced DLTs (Grade 3 syncope and hyp
./___Corpus/Medline/xml/PMC5123381.xml	10-fold	557818 : 557825	CM	or IHC revealed an up to 10-fold increase from baseline i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	557852 : 557855	CM	ncrease from baseline in CD8 + T cells and NK cells i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	557966 : 557969	CM	Most of the infiltrating CD8 + T cells were newly pro
./___Corpus/Medline/xml/PMC5123381.xml	Ki67+	558006 : 558011	CM	ere newly proliferative (Ki67+) and cell-surface PD-1 e
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	558030 : 558034	CM	(Ki67+) and cell-surface PD-1 expression was increased
./___Corpus/Medline/xml/PMC5123381.xml	2-fold	558066 : 558072	CM	sion was increased up to 2-fold. Analyses of blood sampl
./___Corpus/Medline/xml/PMC5123381.xml	Ki67+	558131 : 558136	CM	 concordant increases in Ki67+ immune cells, PD-1+ CD8 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1+	558151 : 558156	CM	s in Ki67+ immune cells, PD-1+ CD8 + T cells, and NK ce
./___Corpus/Medline/xml/PMC5123381.xml	CD8	558157 : 558160	CM	i67+ immune cells, PD-1+ CD8 + T cells, and NK cells 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	558215 : 558223	CM	s after a single dose of NKTR-214. The study continues to 
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	558315 : 558323	CM	ons                      NKTR-214 results in substantial i
./___Corpus/Medline/xml/PMC5123381.xml	CD8	558365 : 558368	CM	antial increases in both CD8 + T cells and NK cells i
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	558509 : 558517	CM	 continued evaluation of NKTR-214 and the potential advant
./___Corpus/Medline/xml/PMC5123381.xml	NKTR-214	558560 : 558568	CM	 advantages of combining NKTR-214 with a variety of immuno
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	558900 : 558905	CM	                    P370 NF-kB p50 promotes the suppres
./___Corpus/Medline/xml/PMC5123381.xml	p50	558906 : 558909	CM	              P370 NF-kB p50 promotes the suppressive
./___Corpus/Medline/xml/PMC5123381.xml	M2	558935 : 558937	CM	promotes the suppressive M2 phenotype of tumor-assoc
./___Corpus/Medline/xml/PMC5123381.xml	GBM	559282 : 559285	CM	rly uniformly fatal. The GBM microenvironment include
./___Corpus/Medline/xml/PMC5123381.xml	M2	559396 : 559398	CM	ntly assume a pro-tumor “M2” phenotype rather than a
./___Corpus/Medline/xml/PMC5123381.xml	M1	559442 : 559444	CM	than a pro-inflammatory “M1” phenotype. The inhibito
./___Corpus/Medline/xml/PMC5123381.xml	p50	559472 : 559475	CM	henotype. The inhibitory p50 subunit of the NF-kB tra
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	559491 : 559496	CM	itory p50 subunit of the NF-kB transcription factor exh
./___Corpus/Medline/xml/PMC5123381.xml	p50	559607 : 559610	CM	larized macrophages, and p50 knockdown/deletion suppr
./___Corpus/Medline/xml/PMC5123381.xml	M2	559655 : 559657	CM	suppresses expression of M2-associated factors [1, 2
./___Corpus/Medline/xml/PMC5123381.xml	p50	559716 : 559719	CM	othesize that absence of p50 will convert TAMs to an 
./___Corpus/Medline/xml/PMC5123381.xml	M1	559744 : 559746	CM	 will convert TAMs to an M1 phenotype that will redu
./___Corpus/Medline/xml/PMC5123381.xml	13–	559977 : 559980	CPR	ing. Brains were removed 13–16 days after implantatio
./___Corpus/Medline/xml/PMC5123381.xml	RT-qPCR	560034 : 560041	CM	r flow cytometry (FC) or RT-qPCR analysis. Depleting anti
./___Corpus/Medline/xml/PMC5123381.xml	clodronate	560110 : 560120	CM	tered by i.p. injection; clodronate by tail vein injection. 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	560197 : 560202	CM	 from spleens, skewed in vitro with cytokines and block
./___Corpus/Medline/xml/PMC5123381.xml	PMA	560282 : 560285	CM	-2, then stimulated with PMA/ionomycin. Cells were as
./___Corpus/Medline/xml/PMC5123381.xml	ionomycin	560286 : 560295	CM	then stimulated with PMA/ionomycin. Cells were assessed for
./___Corpus/Medline/xml/PMC5123381.xml	Th	560321 : 560323	CM	 Cells were assessed for Th or Tc1 skewing by FC or 
./___Corpus/Medline/xml/PMC5123381.xml	Tc1	560327 : 560330	CM	 were assessed for Th or Tc1 skewing by FC or ELISA. 
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	560401 : 560406	CM	lts                      p50(−/−) mice exhibit signific
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	560491 : 560496	CM	 and prolonged survival. p50(−/−) tumor CD11b + myeloid
./___Corpus/Medline/xml/PMC5123381.xml	M1	560546 : 560548	CM	 cells express increased M1-associated and decreased
./___Corpus/Medline/xml/PMC5123381.xml	M2	560574 : 560576	CM	associated and decreased M2-associated mRNAs relativ
./___Corpus/Medline/xml/PMC5123381.xml	mRNAs	560588 : 560593	CM	 decreased M2-associated mRNAs relative to WT mice. FC 
./___Corpus/Medline/xml/PMC5123381.xml	WT	560606 : 560608	CM	ciated mRNAs relative to WT mice. FC indicates gliom
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	560643 : 560648	CM	indicates glioma-bearing p50(−/−) brains contain fewer 
./___Corpus/Medline/xml/PMC5123381.xml	M2	560693 : 560695	CM	ewer TAMs expressing the M2 marker CD206/MRC1, as we
./___Corpus/Medline/xml/PMC5123381.xml	CD206	560703 : 560708	CM	expressing the M2 marker CD206/MRC1, as well as fewer T
./___Corpus/Medline/xml/PMC5123381.xml	MRC1	560709 : 560713	CM	sing the M2 marker CD206/MRC1, as well as fewer Tregs,
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	560749 : 560753	CM	s fewer Tregs, increased IFNg-producing CD4+ T cells, 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	560764 : 560768	CM	increased IFNg-producing CD4+ T cells, and increased g
./___Corpus/Medline/xml/PMC5123381.xml	B+	560801 : 560803	CM	, and increased granzyme B+ CD8+ T cells. Transplant
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	560804 : 560808	CM	nd increased granzyme B+ CD8+ T cells. Transplant of p
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	560832 : 560837	CM	+ T cells. Transplant of p50(−/−) bone marrow into leth
./___Corpus/Medline/xml/PMC5123381.xml	WT	560878 : 560880	CM	into lethally-irradiated WT recipients confers a sig
./___Corpus/Medline/xml/PMC5123381.xml	Clodronate	560957 : 560967	CM	 upon tumor inoculation. Clodronate-mediated macrophage depl
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	561034 : 561039	CM	urvival of tumor-bearing p50(−/−) mice but has no effec
./___Corpus/Medline/xml/PMC5123381.xml	WT	561069 : 561071	CM	ice but has no effect on WT mice. Depletion of CD4+ 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	561091 : 561095	CM	on WT mice. Depletion of CD4+ T cells markedly reduces
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	561147 : 561152	CM	urvival in tumor-bearing p50(−/−) mice whereas depletio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	561182 : 561186	CM	ice whereas depletion of CD8+ T cells has no effect. W
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	561259 : 561264	CM	defect in the ability of p50(−/−) naïve splenic CD4+ T 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	561282 : 561286	CM	f p50(−/−) naïve splenic CD4+ T cells to differentiate
./___Corpus/Medline/xml/PMC5123381.xml	Th1	561324 : 561327	CM	ifferentiate into Tregs, Th1, Th17, or Th2 subsets; h
./___Corpus/Medline/xml/PMC5123381.xml	Th17	561329 : 561333	CM	entiate into Tregs, Th1, Th17, or Th2 subsets; however
./___Corpus/Medline/xml/PMC5123381.xml	Th2	561338 : 561341	CM	nto Tregs, Th1, Th17, or Th2 subsets; however, p50(−/
./___Corpus/Medline/xml/PMC5123381.xml	p50(−	561360 : 561365	CM	or Th2 subsets; however, p50(−/−) naïve splenic CD8+ T 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	561383 : 561387	CM	, p50(−/−) naïve splenic CD8+ T cells exhibit enhanced
./___Corpus/Medline/xml/PMC5123381.xml	IFNg	561432 : 561436	CM	anced ability to produce IFNg, TNFa, and granzyme B.  
./___Corpus/Medline/xml/PMC5123381.xml	TNFa	561438 : 561442	CM	ability to produce IFNg, TNFa, and granzyme B.        
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	561510 : 561515	CM	ons                      NF-kB p50 is an important modu
./___Corpus/Medline/xml/PMC5123381.xml	p50	561516 : 561519	CM	                   NF-kB p50 is an important modulato
./___Corpus/Medline/xml/PMC5123381.xml	p50	561661 : 561664	CM	ss tumor-permissive when p50 is absent. Targeted dele
./___Corpus/Medline/xml/PMC5123381.xml	p50	561697 : 561700	CM	nt. Targeted deletion of p50 from TAMs and/or T cells
./___Corpus/Medline/xml/PMC5123381.xml	GBM	561778 : 561781	CM	peutic for patients with GBM.                  Refere
./___Corpus/Medline/xml/PMC5123381.xml	p50	561854 : 561857	CM	   1. Saccani A, et al.: p50 nuclear factor-κB overex
./___Corpus/Medline/xml/PMC5123381.xml	M1	561932 : 561934	CM	ted macrophages inhibits M1 inflammatory responses a
./___Corpus/Medline/xml/PMC5123381.xml	11432–	562008 : 562014	CPR	 Cancer Res 2006, 66(23):11432–11440.                   
./___Corpus/Medline/xml/PMC5123381.xml	M2	562093 : 562095	CM	C, et al.: Tolerance and M2 (alternative) macrophage
./___Corpus/Medline/xml/PMC5123381.xml	p50	562172 : 562175	CM	rocesses orchestrated by p50 nuclear factor κB. Proc 
./___Corpus/Medline/xml/PMC5123381.xml	κB	562191 : 562193	CM	ed by p50 nuclear factor κB. Proc Natl Acad Sci 2009
./___Corpus/Medline/xml/PMC5123381.xml	14978–	562228 : 562234	CPR	l Acad Sci 2009, 106(35):14978–14983.                   
./___Corpus/Medline/xml/PMC5123381.xml	P	562506 : 562507	CM	Greg M Delgoffe2, Robert P Edwards2, Tyler Curiel3,
./___Corpus/Medline/xml/PMC5123381.xml	Th17	562632 : 562636	CM	und                      Th17 and regulatory T (Treg) 
./___Corpus/Medline/xml/PMC5123381.xml	IL17	563262 : 563266	CM	            We have used IL17 (Il17a Cre Rosa26 eYFP) 
./___Corpus/Medline/xml/PMC5123381.xml	eYFP	563285 : 563289	CM	d IL17 (Il17a Cre Rosa26 eYFP) and Treg (B6.129(Cg)-Fo
./___Corpus/Medline/xml/PMC5123381.xml	Th17	563358 : 563362	CM	) reporter mice to study Th17 cell plasticity and Th17
./___Corpus/Medline/xml/PMC5123381.xml	(n)Treg	563621 : 563628	CM	t in addition to natural (n)Treg and induced (i)Treg cell
./___Corpus/Medline/xml/PMC5123381.xml	Th17	563688 : 563692	CM	d from naïve precursors, Th17 cells are a novel source
./___Corpus/Medline/xml/PMC5123381.xml	P3	563748 : 563750	CM	mor-induced forkhead box P3 (Foxp3+) cells by progre
./___Corpus/Medline/xml/PMC5123381.xml	IL17A	563822 : 563827	CM	n into immunosuppressive IL17A+Foxp3+ and ex-Th17 Foxp3
./___Corpus/Medline/xml/PMC5123381.xml	ex-Th17	563839 : 563846	CM	ressive IL17A+Foxp3+ and ex-Th17 Foxp3+ cells. Transcript
./___Corpus/Medline/xml/PMC5123381.xml	IL17A	563958 : 563963	CM	tion of 119 genes in the IL17A+Foxp3+ cells compared to
./___Corpus/Medline/xml/PMC5123381.xml	IL17A+	563989 : 563995	CM	Foxp3+ cells compared to IL17A+ Foxp3neg Th17 cells (Th1
./___Corpus/Medline/xml/PMC5123381.xml	Th17	564005 : 564009	CM	pared to IL17A+ Foxp3neg Th17 cells (Th17-Treg plastic
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564163 : 564167	CM	low cytometry of plastic IL17+Foxp3+ cells. The immuno
./___Corpus/Medline/xml/PMC5123381.xml	IL17A	564218 : 564223	CM	etabolism of the plastic IL17A+Foxp3+ subset revealed a
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	564319 : 564323	CM	g the immune function of CD4+ T cells and to modulate 
./___Corpus/Medline/xml/PMC5123381.xml	Th	564375 : 564377	CM	rans) differentiation of Th cells, which thereby con
./___Corpus/Medline/xml/PMC5123381.xml	Th17	564645 : 564649	CM	ations about the role of Th17 cells in tumor immune su
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564729 : 564733	CM	n alternative source for IL17+Foxp3+ and IL17negFoxp3+
./___Corpus/Medline/xml/PMC5123381.xml	IL17	564932 : 564936	CM	cer and identifies novel IL17/Treg- associated targets
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565154 : 565158	CM	te with the phenotype of CD4+ tumor infiltrating T cel
./___Corpus/Medline/xml/PMC5123381.xml	Ebner2	565319 : 565325	CM	, Olivia Squalls2, Peggy Ebner2, Katherine Waugh2, John 
./___Corpus/Medline/xml/PMC5123381.xml	Palmer6	565420 : 565427	CM	 Martin McCarter5, Brent Palmer6, Jeffrey Kern7, Dario Vi
./___Corpus/Medline/xml/PMC5123381.xml	5-	565612 : 565614	CPR	and immunotherapies, the 5-year survival rate for al
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	565750 : 565754	CM	y has been on subsets of CD8+ and CD4+ tumor infiltrat
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565759 : 565763	CM	n on subsets of CD8+ and CD4+ tumor infiltrating lymph
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	565840 : 565846	CM	or infiltrating B cells (TIL-Bs) have been reported in t
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	565910 : 565914	CM	id structures (TLS) with CD4+ TILs, both positively co
./___Corpus/Medline/xml/PMC5123381.xml	APCs	566102 : 566106	CM	ntigen presenting cells (APCs). We hypothesized that T
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	566130 : 566136	CM	s). We hypothesized that TIL-Bs help generate potent, lo
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566233 : 566237	CM	enting tumor antigens to CD4+ TILs.                  M
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	566459 : 566465	CM	 number and phenotype of TIL-Bs via flow cytometery and 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	566564 : 566569	CM	en presentation assay in vitro to assay APC function.  
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566823 : 566827	CM	 we found three types of CD4+ TIL responses when TIL-B
./___Corpus/Medline/xml/PMC5123381.xml	TIL	566828 : 566831	CM	ound three types of CD4+ TIL responses when TIL-Bs pr
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	566847 : 566853	CM	 CD4+ TIL responses when TIL-Bs presented autologous tum
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	566922 : 566926	CM	were activated responder CD4+ TILs that proliferated w
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	566969 : 566975	CM	rated when combined with TIL-Bs alone, which indicates s
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567144 : 567148	CM	tumor lysate to elicit a CD4+ TIL response, and there 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	567149 : 567152	CM	 lysate to elicit a CD4+ TIL response, and there were
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567186 : 567190	CM	, and there were patient CD4+ TILs that did not respon
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567244 : 567250	CM	 antigen presentation by TIL-Bs. Within the activated an
./___Corpus/Medline/xml/PMC5123381.xml	TIL-B	567312 : 567317	CM	sociated responders, the TIL-B phenotype associated wit
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567348 : 567352	CM	type associated with the CD4+ TIL phenotype; if the TI
./___Corpus/Medline/xml/PMC5123381.xml	TIL	567353 : 567356	CM	associated with the CD4+ TIL phenotype; if the TIL-Bs
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567375 : 567381	CM	4+ TIL phenotype; if the TIL-Bs were activated (CD69 + C
./___Corpus/Medline/xml/PMC5123381.xml	CD69	567398 : 567402	CM	e TIL-Bs were activated (CD69 + CD27 + CD21+), the CD4
./___Corpus/Medline/xml/PMC5123381.xml	CD27	567405 : 567409	CM	s were activated (CD69 + CD27 + CD21+), the CD4+ TILs 
./___Corpus/Medline/xml/PMC5123381.xml	CD21+	567412 : 567417	CM	activated (CD69 + CD27 + CD21+), the CD4+ TILs were T h
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567424 : 567428	CM	D69 + CD27 + CD21+), the CD4+ TILs were T helper (anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	567449 : 567454	CPR	CD4+ TILs were T helper (anti-tumor) CD4+ T cells and i
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567461 : 567465	CM	re T helper (anti-tumor) CD4+ T cells and if the TIL-B
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567485 : 567491	CM	 CD4+ T cells and if the TIL-Bs were exhausted (CD69-CD2
./___Corpus/Medline/xml/PMC5123381.xml	CD69-CD27-CD21	567508 : 567522	CM	e TIL-Bs were exhausted (CD69-CD27-CD21-), the CD4+ TILs were T 
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567530 : 567534	CM	d (CD69-CD27-CD21-), the CD4+ TILs were T regulatory c
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567601 : 567607	CM	 These data suggest that TIL-Bs affect the phenotype and
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567645 : 567649	CM	henotype and function of CD4+ TILs in NSCLC patient tu
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567745 : 567751	CM	          In conclusion, TIL-Bs are increased in NSCLC p
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	567841 : 567845	CM	en to and associate with CD4+ TILs in the tumor microe
./___Corpus/Medline/xml/PMC5123381.xml	TIL-Bs	567897 : 567903	CM	ironment. Determining if TIL-Bs are activated or exhaust
./___Corpus/Medline/xml/PMC5123381.xml	anti-	567984 : 567989	CPR	mine the extent of their anti-tumor function. Ultimatel
./___Corpus/Medline/xml/PMC5123381.xml	TIL-B	568073 : 568078	CM	lp predict how to target TIL-B functions in future immu
./___Corpus/Medline/xml/PMC5123381.xml	AI007505	568200 : 568208	CM	               T32 grant AI007505, the American Cancer Soc
./___Corpus/Medline/xml/PMC5123381.xml	RSG	568244 : 568247	CM	can Cancer Society grant RSG LIB-114645, Cancer Leagu
./___Corpus/Medline/xml/PMC5123381.xml	CCSG	568378 : 568382	CM	ard 5P50CA058187-20, and CCSG CA 046934, and CCTSI UL1
./___Corpus/Medline/xml/PMC5123381.xml	CCTSI	568398 : 568403	CM	 and CCSG CA 046934, and CCTSI UL1 TR 001082.          
./___Corpus/Medline/xml/PMC5123381.xml	PGG	568470 : 568473	CM	            P373 Imprime PGG, a novel pathogen associ
./___Corpus/Medline/xml/PMC5123381.xml	M1	568546 : 568548	CM	(PAMP) treatment elicits M1-like transcriptional pro
./___Corpus/Medline/xml/PMC5123381.xml	O	568790 : 568791	CM	n, Keith Gordon, Takashi O Kangas, Steven Leonardo,
./___Corpus/Medline/xml/PMC5123381.xml	M2	569049 : 569051	CM	duced immunosuppression; M2-like TAMs being one of t
./___Corpus/Medline/xml/PMC5123381.xml	β-	569187 : 569189	CPR	ministered soluble yeast β-1,3/1,6 glucan is being c
./___Corpus/Medline/xml/PMC5123381.xml	glucan	569197 : 569203	CM	 soluble yeast β-1,3/1,6 glucan is being clinically deve
./___Corpus/Medline/xml/PMC5123381.xml	anti-	569282 : 569287	CPR	or-targeting antibodies, anti-angiogenics, and checkpoi
./___Corpus/Medline/xml/PMC5123381.xml	M2	569701 : 569703	CM	been shown to repolarize M2 macrophages to an anti-t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	569722 : 569727	CPR	ize M2 macrophages to an anti-tumor M1-like orientation
./___Corpus/Medline/xml/PMC5123381.xml	M1	569733 : 569735	CM	ophages to an anti-tumor M1-like orientation in huma
./___Corpus/Medline/xml/PMC5123381.xml	BMDM	570052 : 570056	CM	row-derived macrophages (BMDM) prepared from Imprime- 
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	570134 : 570141	CM	e mice were evaluated by qRT-PCR. Imprime was tested in c
./___Corpus/Medline/xml/PMC5123381.xml	anti-	570185 : 570190	CPR	d in combination with an anti-angiogenic agent, DC101 (
./___Corpus/Medline/xml/PMC5123381.xml	DC101	570208 : 570213	CM	n anti-angiogenic agent, DC101 (α-VEGFR2 Mab) in H441 N
./___Corpus/Medline/xml/PMC5123381.xml	α-	570215 : 570217	CPR	angiogenic agent, DC101 (α-VEGFR2 Mab) in H441 NSCLC
./___Corpus/Medline/xml/PMC5123381.xml	anti-	570305 : 570310	CPR	 and in combination with anti-TRP1 tumor-targeting anti
./___Corpus/Medline/xml/PMC5123381.xml	TA-99	570340 : 570345	CM	tumor-targeting antibody TA-99 in B16 experimental lung
./___Corpus/Medline/xml/PMC5123381.xml	B16	570349 : 570352	CM	geting antibody TA-99 in B16 experimental lung metast
./___Corpus/Medline/xml/PMC5123381.xml	FFPE	570413 : 570417	CM	 Immunohistochemistry of FFPE tumor tissue or lung tis
./___Corpus/Medline/xml/PMC5123381.xml	qRT-PCR	570508 : 570515	CM	lts                      qRT-PCR analyses of Imprime-trea
./___Corpus/Medline/xml/PMC5123381.xml	BMDM	570544 : 570548	CM	lyses of Imprime-treated BMDM from tumor-free mice rev
./___Corpus/Medline/xml/PMC5123381.xml	M1	570594 : 570596	CM	 revealed an increase in M1 markers (iNOS, PD-L1, IL
./___Corpus/Medline/xml/PMC5123381.xml	iNOS	570606 : 570610	CM	 increase in M1 markers (iNOS, PD-L1, IL-12b, TNF-a, C
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	570612 : 570617	CM	ase in M1 markers (iNOS, PD-L1, IL-12b, TNF-a, CXCL9, C
./___Corpus/Medline/xml/PMC5123381.xml	TNF-a	570627 : 570632	CM	rs (iNOS, PD-L1, IL-12b, TNF-a, CXCL9, CXCL10, and CXCL
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	570634 : 570639	CM	S, PD-L1, IL-12b, TNF-a, CXCL9, CXCL10, and CXCL11) wit
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	570641 : 570647	CM	1, IL-12b, TNF-a, CXCL9, CXCL10, and CXCL11) with a coin
./___Corpus/Medline/xml/PMC5123381.xml	CXCL11	570653 : 570659	CM	NF-a, CXCL9, CXCL10, and CXCL11) with a coincident decre
./___Corpus/Medline/xml/PMC5123381.xml	M2	570691 : 570693	CM	a coincident decrease in M2 markers (CD206, YM-1, Fi
./___Corpus/Medline/xml/PMC5123381.xml	CD206	570703 : 570708	CM	 decrease in M2 markers (CD206, YM-1, Fizz1, and CCL17)
./___Corpus/Medline/xml/PMC5123381.xml	YM-1	570710 : 570714	CM	se in M2 markers (CD206, YM-1, Fizz1, and CCL17). Impr
./___Corpus/Medline/xml/PMC5123381.xml	CCL17	570727 : 570732	CM	(CD206, YM-1, Fizz1, and CCL17). Imprime’s M1-polarizat
./___Corpus/Medline/xml/PMC5123381.xml	M1	570854 : 570856	CM	atment alone upregulated M1-like genes in TAMs as we
./___Corpus/Medline/xml/PMC5123381.xml	DC101	570944 : 570949	CM	rowth when combined with DC101, an agent that also modu
./___Corpus/Medline/xml/PMC5123381.xml	B16	571062 : 571065	CM	was also observed in the B16 experimental lung metast
./___Corpus/Medline/xml/PMC5123381.xml	TA-99	571139 : 571144	CM	bination of Imprime with TA-99 significantly reduced bo
./___Corpus/Medline/xml/PMC5123381.xml	B16	571195 : 571198	CM	h the number and size of B16 lung metastases. Immunoh
./___Corpus/Medline/xml/PMC5123381.xml	M1	571323 : 571325	CM	ng CD11b + cells with an M1 phenotype evidenced by i
./___Corpus/Medline/xml/PMC5123381.xml	iNOS	571361 : 571365	CM	evidenced by increase in iNOS expression.             
./___Corpus/Medline/xml/PMC5123381.xml	M2	571495 : 571497	CM	rime, by reorienting the M2 macrophages to an M1-lik
./___Corpus/Medline/xml/PMC5123381.xml	M1	571516 : 571518	CM	the M2 macrophages to an M1-like polarization state 
./___Corpus/Medline/xml/PMC5123381.xml	X	571717 : 571718	CM	          1. Chan A, Qui X, Jonas AB, Patchen ML, B
./___Corpus/Medline/xml/PMC5123381.xml	AB	571726 : 571728	CM	 1. Chan A, Qui X, Jonas AB, Patchen ML, Bose N: Imp
./___Corpus/Medline/xml/PMC5123381.xml	PGG	571758 : 571761	CM	chen ML, Bose N: Imprime PGG, a yeast β-glucan immuno
./___Corpus/Medline/xml/PMC5123381.xml	β-glucan	571771 : 571779	CM	 N: Imprime PGG, a yeast β-glucan immunomodulator, has the
./___Corpus/Medline/xml/PMC5123381.xml	M2	571852 : 571854	CM	e human monocyte-derived M2 macrophages to M1 phenot
./___Corpus/Medline/xml/PMC5123381.xml	M1	571870 : 571872	CM	erived M2 macrophages to M1 phenotype. JITC 2014, 2(
./___Corpus/Medline/xml/PMC5123381.xml	Nitin	572111 : 572116	CM	             Ravi Gupta, Nitin Mandloi, Kiran Paul, Ash
./___Corpus/Medline/xml/PMC5123381.xml	anti-	572564 : 572569	CPR	rminants of a productive anti-tumor immune response is 
./___Corpus/Medline/xml/PMC5123381.xml	NGS	572827 : 572830	CM	ompartments, an unbiased NGS approach is a powerful m
./___Corpus/Medline/xml/PMC5123381.xml	NGS	573060 : 573063	CM	r proprietary integrated NGS-based immuno-genomics pl
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	573121 : 573125	CM	ncoPept™, to analyze the TCGA somatic mutation and gen
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	573918 : 573922	CM	ays associated with high CD8+ T cell infiltration. The
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	574592 : 574596	CM	her inflammation, higher CD8+ T cell infiltration, IFN
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	574618 : 574623	CM	D8+ T cell infiltration, IFN-g signaling and high PD-1 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	574643 : 574647	CM	IFN-g signaling and high PD-1 and PD-L1 level providin
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	574652 : 574657	CM	naling and high PD-1 and PD-L1 level providing a basis 
./___Corpus/Medline/xml/PMC5123381.xml	NGS	574830 : 574833	CM	idea that application of NGS in a clinical setting ha
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	575140 : 575145	CM	nvironment expression of PD-L1 and CD8+ T cell infiltra
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575150 : 575154	CM	 expression of PD-L1 and CD8+ T cell infiltration     
./___Corpus/Medline/xml/PMC5123381.xml	Yu	575192 : 575194	CM	tration                  Yu Chen, Jing Lin, Yun-bin 
./___Corpus/Medline/xml/PMC5123381.xml	Ye	575219 : 575221	CM	 Chen, Jing Lin, Yun-bin Ye, Chun-wei Xu, Gang Chen,
./___Corpus/Medline/xml/PMC5123381.xml	Xu	575232 : 575234	CM	in, Yun-bin Ye, Chun-wei Xu, Gang Chen, Zeng-qing Gu
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	575602 : 575607	CM	ing to the expression of PD-L1 and infiltration of CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575628 : 575632	CM	D-L1 and infiltration of CD8+ T cells.                
./___Corpus/Medline/xml/PMC5123381.xml	D2	575732 : 575734	CM	patients with a curative D2 gastrectomy were enrolle
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	575772 : 575777	CM	were enrolled (Table 6). PD-L1 and CD8+ T cell status w
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	575782 : 575786	CM	led (Table 6). PD-L1 and CD8+ T cell status were evalu
./___Corpus/Medline/xml/PMC5123381.xml	SP142	575869 : 575874	CM	ing specific antibodies (SP142, SP16). The samples were
./___Corpus/Medline/xml/PMC5123381.xml	SP16	575876 : 575880	CM	cific antibodies (SP142, SP16). The samples were class
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576095 : 576100	CM	ples, there was positive PD-L1 expression (TC1/2/3 or I
./___Corpus/Medline/xml/PMC5123381.xml	TC1	576113 : 576116	CM	sitive PD-L1 expression (TC1/2/3 or IC1/2/3) in 60.3 
./___Corpus/Medline/xml/PMC5123381.xml	IC1	576124 : 576127	CM	1 expression (TC1/2/3 or IC1/2/3) in 60.3 % (112/186)
./___Corpus/Medline/xml/PMC5123381.xml	65a	576171 : 576174	CM	2/186) of patients (Fig. 65a). A significant correlat
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576215 : 576220	CM	 correlation between the PD-L1 expression and the inten
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576253 : 576257	CM	ion and the intensity of CD8+ T cell infiltration (p =
./___Corpus/Medline/xml/PMC5123381.xml	65b	576295 : 576298	CM	tration (p = 0.000, Fig. 65b) was found. According to
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1+	576389 : 576395	CM	ME was divided into both PD-L1+ and CD8+ T cell positive
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576400 : 576404	CM	ded into both PD-L1+ and CD8+ T cell positive (type I)
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576436 : 576441	CM	 positive (type I), both PD-L1 and CD8+ T cell negative
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576446 : 576450	CM	(type I), both PD-L1 and CD8+ T cell negative (type II
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576478 : 576483	CM	cell negative (type II), PD-L1 positive but CD8+ T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576497 : 576501	CM	 II), PD-L1 positive but CD8+ T cell negative (type II
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576534 : 576539	CM	negative (type III), and PD-L1 negative but CD8+ T cell
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576553 : 576557	CM	, and PD-L1 negative but CD8+ T cell positive (type IV
./___Corpus/Medline/xml/PMC5123381.xml	65c	576663 : 576666	CM	.9 %, respectively (Fig. 65c, Fig. 66, Table 7). The 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	576705 : 576710	CM	le 7). The expression of STAT3, and pSTAT3, rather than
./___Corpus/Medline/xml/PMC5123381.xml	pSTAT3	576716 : 576722	CM	expression of STAT3, and pSTAT3, rather than STAT1 and p
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	576736 : 576741	CM	 and pSTAT3, rather than STAT1 and pSTAT1, was signific
./___Corpus/Medline/xml/PMC5123381.xml	pSTAT1	576746 : 576752	CM	3, rather than STAT1 and pSTAT1, was significantly corre
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576792 : 576796	CM	ntly correlated with the CD8+ T cell infiltration, and
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	576822 : 576827	CM	T cell infiltration, and PD-L1 status (Fig. 67, Fig. 68
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	576855 : 576859	CM	atus (Fig. 67, Fig. 68). CD8+ T cell infiltration was 
./___Corpus/Medline/xml/PMC5123381.xml	DFS	576937 : 576940	CM	h disease-free survival (DFS) and overall survival (O
./___Corpus/Medline/xml/PMC5123381.xml	69a	577017 : 577020	CM	, Table 8, Table 9, Fig. 69a). The DFS and OS of pati
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577027 : 577030	CM	 Table 9, Fig. 69a). The DFS and OS of patients with 
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577175 : 577178	CM	ignificant difference in DFS and OS between type I an
./___Corpus/Medline/xml/PMC5123381.xml	69c	577341 : 577344	CM	= 0.806, p = 0.808; Fig. 69c). The hazard ratios of D
./___Corpus/Medline/xml/PMC5123381.xml	DFS	577368 : 577371	CM	c). The hazard ratios of DFS and OS numerically favor
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	577581 : 577586	CM	fication of TME based on PD-L1 expression and CD8+ T ce
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	577602 : 577606	CM	 on PD-L1 expression and CD8+ T cell infiltration in g
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	577650 : 577655	CM	n in gastric cancer. The PD-L1 expression was significa
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	577705 : 577709	CM	ntly correlated with the CD8+ T cell infiltration. Imm
./___Corpus/Medline/xml/PMC5123381.xml	RNA	579080 : 579083	CM	, a genome-wide targeted RNA expression assay that pr
./___Corpus/Medline/xml/PMC5123381.xml	NGS	579164 : 579167	CM	iplex RT-PCR followed by NGS. The GeneNet 19 K assay 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	579486 : 579489	CM	. The developed targeted RNA expression platform prof
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	579933 : 579937	CM	tection of low abundance mRNA transcripts as well as a
./___Corpus/Medline/xml/PMC5123381.xml	Yi	580530 : 580532	CM	                         Yi Zheng, Carla Coltharp, D
./___Corpus/Medline/xml/PMC5123381.xml	7-	581419 : 581421	CPR	 robust, fully-automated 7-color mIHC procedure that
./___Corpus/Medline/xml/PMC5123381.xml	Formalin	581824 : 581832	CM	ods                      Formalin-fixed paraffin-embedded 
./___Corpus/Medline/xml/PMC5123381.xml	7-	582874 : 582876	CPR	t we developed for Opal™ 7-color mIHC is a robust me
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	583006 : 583010	CM	                    P378 EGFR/JAK2 inhibition downregu
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	583011 : 583015	CM	               P378 EGFR/JAK2 inhibition downregulates
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	583059 : 583067	CM	ulates immunosuppressive cytokine secretion in head and ne
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	583358 : 583362	CM	                     The EGFR, which is overexpressed 
./___Corpus/Medline/xml/PMC5123381.xml	HNC	583431 : 583434	CM	f head and neck cancers (HNC), activates the Janus ki
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	583467 : 583471	CM	ates the Janus kinase 2 (JAK2)/signal transducer and a
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	583525 : 583530	CM	ator of transcription 3 (STAT3) pathway leading to carc
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	583567 : 583572	CM	ading to carcinogenesis. STAT3 plays a major role in pr
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	583745 : 583749	CM	 (VEGF), IL-6, IL-10 and TGFβ, which in turn activate 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	583774 : 583779	CM	, which in turn activate STAT3 in tumor-associated supp
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	583929 : 583933	CM	t. Cetuximab, a specific EGFR blocking mAb, downregula
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	583962 : 583966	CM	cking mAb, downregulates EGFR-mediated STAT3 activatio
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	583976 : 583981	CM	nregulates EGFR-mediated STAT3 activation; however, oth
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	584009 : 584014	CM	tivation; however, other STAT3 activating pathways exis
./___Corpus/Medline/xml/PMC5123381.xml	IL-6R	584061 : 584066	CM	xist. The IL-6 receptor (IL-6R) constitutes a major EGF
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	584088 : 584092	CM	-6R) constitutes a major EGFR-independent STAT3 activa
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	584105 : 584110	CM	a major EGFR-independent STAT3 activating pathway in HN
./___Corpus/Medline/xml/PMC5123381.xml	HNC	584133 : 584136	CM	T3 activating pathway in HNC. Given that JAK2 is comm
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	584149 : 584153	CM	thway in HNC. Given that JAK2 is common signaling mole
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	584191 : 584195	CM	gnaling molecule to both EGFR and IL-6R pathways we hy
./___Corpus/Medline/xml/PMC5123381.xml	IL-6R	584200 : 584205	CM	olecule to both EGFR and IL-6R pathways we hypothesized
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	584245 : 584249	CM	pothesized that combined EGFR and JAK2 inhibition may 
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	584254 : 584258	CM	d that combined EGFR and JAK2 inhibition may downregul
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	584287 : 584292	CM	ibition may downregulate STAT3-dependent production of 
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	584392 : 584396	CM	ods                      mRNA expression for the cytok
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	584507 : 584511	CM	the cancer genome atlas (TCGA) repository. Protein con
./___Corpus/Medline/xml/PMC5123381.xml	NCT	584678 : 584681	CM	ant trial (UPCI #08-013, NCT #01218048) were determin
./___Corpus/Medline/xml/PMC5123381.xml	HNC	584839 : 584842	CM	n we show that tumors of HNC patients annotated in Th
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	584890 : 584894	CM	The Cancer Genome Atlas (TCGA) express higher immunosu
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	584949 : 584953	CM	sive cytokines including TGFβ, IL-10, VEGFA and IDO th
./___Corpus/Medline/xml/PMC5123381.xml	VEGFA	584962 : 584967	CM	s including TGFβ, IL-10, VEGFA and IDO than control tis
./___Corpus/Medline/xml/PMC5123381.xml	IDO	584972 : 584975	CM	g TGFβ, IL-10, VEGFA and IDO than control tissues and
./___Corpus/Medline/xml/PMC5123381.xml	IL-17A	585068 : 585074	CM	kines such as IL-12A and IL-17A, confirming the view of 
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	585218 : 585222	CM	activation. In addition, EGFR and JAK2 inhibition down
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	585227 : 585231	CM	n. In addition, EGFR and JAK2 inhibition downregulate 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	585256 : 585261	CM	 inhibition downregulate STAT3 activation and secretion
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	585314 : 585319	CM	 these immunosuppressive STAT3-dependent cytokines in v
./___Corpus/Medline/xml/PMC5123381.xml	vitro	585343 : 585348	CM	3-dependent cytokines in vitro, providing evidence that
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	585397 : 585401	CM	t supports targeting the EGFR/JAK2/STAT3 mediated supp
./___Corpus/Medline/xml/PMC5123381.xml	JAK2	585402 : 585406	CM	ports targeting the EGFR/JAK2/STAT3 mediated suppressi
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	585407 : 585412	CM	 targeting the EGFR/JAK2/STAT3 mediated suppressive tum
./___Corpus/Medline/xml/PMC5123381.xml	HNC	585564 : 585567	CM	linically relevant since HNC patients that were treat
./___Corpus/Medline/xml/PMC5123381.xml	NCT	585661 : 585664	CM	ant trial (UPCI #08-013, NCT #01218048) who are resis
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	585741 : 585745	CM	ave significantly higher TGFβ concentration and a lowe
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	585790 : 585798	CM	 lower immunostimulatory cytokine profile in plasma, which
./___Corpus/Medline/xml/PMC5123381.xml	EGFR	585885 : 585889	CM	 in those patients where EGFR blockade is not sufficie
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	586364 : 586369	CM	Treg killing through the TNFR2 receptor via dominant an
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	586812 : 586817	CM	rosis factor receptor 2 (TNFR2) is a target protein wit
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587117 : 587122	CM	cts of the newly-created TNFR2 antibody antagonists on 
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587362 : 587367	CM	 cells lines express the TNFR2 oncogene and the effects
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587400 : 587405	CM	e and the effects of the TNFR2 antagonistic antibody on
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587500 : 587505	CM	lts                      TNFR2 antagonists inhibited Tr
./___Corpus/Medline/xml/PMC5123381.xml	OVCAR3	587680 : 587686	CM	ancer cell lines such as OVCAR3 express the TNFR2 oncoge
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587699 : 587704	CM	ch as OVCAR3 express the TNFR2 oncogene and were rapidl
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587756 : 587761	CM	and completely killed by TNFR2 antagonistic antibodies,
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	587874 : 587879	CM	                Dominant TNFR2 antagonists demonstrate 
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	588038 : 588043	CM	ripheral blood. Blocking TNFR2 signaling with antagonis
./___Corpus/Medline/xml/PMC5123381.xml	TNFR2	588159 : 588164	CM	an tumors expressing the TNFR2 oncogene.               
./___Corpus/Medline/xml/PMC5123381.xml	Lu1	588324 : 588327	CM	ell1, Edward Stack2, Yan Lu1, Daisuke Izaki3, Kristen
./___Corpus/Medline/xml/PMC5123381.xml	White-Stern4	588397 : 588409	CM	4, Paul Armenta4, Ashley White-Stern4, Yichun Fu4, Zoe Blake1,
./___Corpus/Medline/xml/PMC5123381.xml	Fu4	588418 : 588421	CM	ley White-Stern4, Yichun Fu4, Zoe Blake1, Douglas Mar
./___Corpus/Medline/xml/PMC5123381.xml	formalin	588878 : 588886	CM	s of immune cells within formalin-fixed paraffin-embedded 
./___Corpus/Medline/xml/PMC5123381.xml	FFPE	588912 : 588916	CM	fixed paraffin-embedded (FFPE) tissues. In early stage
./___Corpus/Medline/xml/PMC5123381.xml	TIL	589313 : 589316	CM	prove on the accuracy of TIL quantitation for the pur
./___Corpus/Medline/xml/PMC5123381.xml	FFPE	589509 : 589513	CM	 patients with available FFPE primary melanoma tissue 
./___Corpus/Medline/xml/PMC5123381.xml	II-III	589624 : 589630	CM	y population of 20 stage II-III melanoma patients diagno
./___Corpus/Medline/xml/PMC5123381.xml	DAPI	589958 : 589962	CM	g Opal multiplex IHC for DAPI, CD3 (LN10, Leica), CD8 
./___Corpus/Medline/xml/PMC5123381.xml	CD3	589964 : 589967	CM	 multiplex IHC for DAPI, CD3 (LN10, Leica), CD8 (4B11
./___Corpus/Medline/xml/PMC5123381.xml	LN10	589969 : 589973	CM	iplex IHC for DAPI, CD3 (LN10, Leica), CD8 (4B11, Leic
./___Corpus/Medline/xml/PMC5123381.xml	CD8	589983 : 589986	CM	DAPI, CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1
./___Corpus/Medline/xml/PMC5123381.xml	4B11	589988 : 589992	CM	 CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1, Biog
./___Corpus/Medline/xml/PMC5123381.xml	CD68	590002 : 590006	CM	ica), CD8 (4B11, Leica), CD68 (KP1, Biogenex), SOX10 (
./___Corpus/Medline/xml/PMC5123381.xml	KP1	590008 : 590011	CM	CD8 (4B11, Leica), CD68 (KP1, Biogenex), SOX10 (BC34,
./___Corpus/Medline/xml/PMC5123381.xml	SOX10	590024 : 590029	CM	), CD68 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR 
./___Corpus/Medline/xml/PMC5123381.xml	BC34	590031 : 590035	CM	 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR (LN-3,
./___Corpus/Medline/xml/PMC5123381.xml	LN-3	590055 : 590059	CM	(BC34, Biocare), HLA-DR (LN-3, Abcam) and Ki67 (MIB1, 
./___Corpus/Medline/xml/PMC5123381.xml	Abcam	590061 : 590066	CM	 Biocare), HLA-DR (LN-3, Abcam) and Ki67 (MIB1, Abcam) 
./___Corpus/Medline/xml/PMC5123381.xml	Ki67	590072 : 590076	CM	HLA-DR (LN-3, Abcam) and Ki67 (MIB1, Abcam) (Fig. 72).
./___Corpus/Medline/xml/PMC5123381.xml	MIB1	590078 : 590082	CM	 (LN-3, Abcam) and Ki67 (MIB1, Abcam) (Fig. 72). Cell 
./___Corpus/Medline/xml/PMC5123381.xml	Abcam	590084 : 590089	CM	, Abcam) and Ki67 (MIB1, Abcam) (Fig. 72). Cell phenoty
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590321 : 590324	CM	 spatial distribution of CD3 + CD8+ cells analyzed as
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590327 : 590331	CM	al distribution of CD3 + CD8+ cells analyzed as shown 
./___Corpus/Medline/xml/PMC5123381.xml	TIBCO	590444 : 590449	CM	, and Spotfire software (TIBCO).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590511 : 590514	CM	            We find that CD3 + CD8+ cells are closer 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590517 : 590521	CM	      We find that CD3 + CD8+ cells are closer to CD68
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	590542 : 590547	CM	CD8+ cells are closer to CD68+ cells in patients who we
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590630 : 590633	CM	p < 0.0001). Conversely, CD3 + CD8+ cells are further
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590636 : 590640	CM	0001). Conversely, CD3 + CD8+ cells are further from S
./___Corpus/Medline/xml/PMC5123381.xml	SOX10	590664 : 590669	CM	+ cells are further from SOX10 + Ki67- tumor cells in r
./___Corpus/Medline/xml/PMC5123381.xml	Ki67	590672 : 590676	CM	are further from SOX10 + Ki67- tumor cells in recurren
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	590749 : 590754	CM	.0001). HLA-DR status of CD68+ or SOX10+ cells did not 
./___Corpus/Medline/xml/PMC5123381.xml	SOX10+	590758 : 590764	CM	LA-DR status of CD68+ or SOX10+ cells did not alter thes
./___Corpus/Medline/xml/PMC5123381.xml	CD3	590835 : 590838	CM	ns (Fig. 74). Density of CD3 + CD8+ cells did not dif
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	590841 : 590845	CM	g. 74). Density of CD3 + CD8+ cells did not differ sig
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	591122 : 591127	CM	tact between T cells and CD68+ antigen presenting cells
./___Corpus/Medline/xml/PMC5123381.xml	2000–	591334 : 591339	CPR	the complete HICC cohort 2000–2012 is ongoing and resul
./___Corpus/Medline/xml/PMC5123381.xml	anti-	591483 : 591488	CPR	on of potent and durable anti-tumor immunity by intratu
./___Corpus/Medline/xml/PMC5123381.xml	Hix	591624 : 591627	CM	                   Laura Hix Glickman1, David B Kanne
./___Corpus/Medline/xml/PMC5123381.xml	P	591737 : 591738	CM	George Katibah1, Leticia P Corrales3, Justin L Leon
./___Corpus/Medline/xml/PMC5123381.xml	Tallarico5	591913 : 591923	CM	Jeffery M McKenna5, John Tallarico5, Steven Bender4, Chudi N
./___Corpus/Medline/xml/PMC5123381.xml	W	592022 : 592023	CM	omas F Gajewski7, Thomas W Dubensky1               
./___Corpus/Medline/xml/PMC5123381.xml	IFN-β	592257 : 592262	CM	 signature. Induction of IFN-β in this context is depen
./___Corpus/Medline/xml/PMC5123381.xml	STING	592343 : 592348	CM	tor of interferon genes (STING), a critical component o
./___Corpus/Medline/xml/PMC5123381.xml	STING	592438 : 592443	CM	he innate immune system. STING is activated by binding 
./___Corpus/Medline/xml/PMC5123381.xml	dinucleotides	592478 : 592491	CM	ted by binding of cyclic dinucleotides (CDNs) produced by an in
./___Corpus/Medline/xml/PMC5123381.xml	CDNs	592493 : 592497	CM	of cyclic dinucleotides (CDNs) produced by an intracel
./___Corpus/Medline/xml/PMC5123381.xml	cGAS	592536 : 592540	CM	an intracellular enzyme, cGAS, in response to the pres
./___Corpus/Medline/xml/PMC5123381.xml	STING	592614 : 592619	CM	en or tumor-derived DNA. STING induction of IFN within 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	592714 : 592718	CM	f tumor antigen-specific CD8+ T cell immunity. We hypo
./___Corpus/Medline/xml/PMC5123381.xml	STING	592778 : 592783	CM	hat direct activation of STING in the TME by intratumor
./___Corpus/Medline/xml/PMC5123381.xml	CDNs	592839 : 592843	CM	) injection of synthetic CDNs would induce potent anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	592864 : 592869	CPR	CDNs would induce potent anti-tumor immunity against a 
./___Corpus/Medline/xml/PMC5123381.xml	CDNs	593039 : 593043	CM	ing a panel of synthetic CDNs, we selected ADU-S100 (M
./___Corpus/Medline/xml/PMC5123381.xml	ADU-S100	593057 : 593065	CM	thetic CDNs, we selected ADU-S100 (MIW815) for clinical de
./___Corpus/Medline/xml/PMC5123381.xml	STING	593159 : 593164	CM	ently activate all human STING alleles, elicit profound
./___Corpus/Medline/xml/PMC5123381.xml	anti-	593292 : 593297	CPR	els, and promote durable anti-tumor immunity.          
./___Corpus/Medline/xml/PMC5123381.xml	ADU-S100	593373 : 593381	CM	           A bell-shaped ADU-S100 dose response curve was 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593483 : 593487	CM	uction of tumor-specific CD8+ T cell immunity, and pro
./___Corpus/Medline/xml/PMC5123381.xml	STING	593601 : 593606	CM	studies demonstrate that STING-mediated anti-tumor immu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	593616 : 593621	CPR	rate that STING-mediated anti-tumor immunity is due in 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	593695 : 593703	CM	lammatory TNF-α-mediated cytokine response, as well as a t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593742 : 593746	CM	well as a tumor-specific CD8+ T cell response. Studies
./___Corpus/Medline/xml/PMC5123381.xml	STING−	593798 : 593804	CM	n chimeric wild-type and STING−/− mice showed that while
./___Corpus/Medline/xml/PMC5123381.xml	STING	593830 : 593835	CM	− mice showed that while STING signaling in the tumor s
./___Corpus/Medline/xml/PMC5123381.xml	STING	593917 : 593922	CM	o acute tumor rejection, STING signaling in the hematop
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	593995 : 593999	CM	equired for induction of CD8+ T cell mediated anti-tum
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594016 : 594021	CPR	 of CD8+ T cell mediated anti-tumor immunity. Anti-tumo
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	594129 : 594135	CM	nt inhibitors, including α-PD-1 and α-CTLA-4, informing 
./___Corpus/Medline/xml/PMC5123381.xml	α-CTLA-4	594140 : 594148	CM	rs, including α-PD-1 and α-CTLA-4, informing future clinic
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594288 : 594293	CPR	nate and T cell-mediated anti-tumor immunity via activa
./___Corpus/Medline/xml/PMC5123381.xml	STING	594326 : 594331	CM	munity via activation of STING in the TME demonstrates 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	594575 : 594580	CPR	olerability and possible anti-tumor effects in subjects
./___Corpus/Medline/xml/PMC5123381.xml	ADU-S100	594717 : 594725	CM	ven repeated IT doses of ADU-S100.                  Trial 
./___Corpus/Medline/xml/PMC5123381.xml	Bell2	595274 : 595279	CM	zalez Gugel1, Charles JM Bell2, Adiel Munk1, Luciana Mu
./___Corpus/Medline/xml/PMC5123381.xml	TIM-3	595679 : 595684	CM	of inhibitory receptors (TIM-3, KIRB1 and KIRNKAT2), ii
./___Corpus/Medline/xml/PMC5123381.xml	KIRB1	595686 : 595691	CM	bitory receptors (TIM-3, KIRB1 and KIRNKAT2), ii) down-
./___Corpus/Medline/xml/PMC5123381.xml	KIRNKAT2	595696 : 595704	CM	eptors (TIM-3, KIRB1 and KIRNKAT2), ii) down-regulation of
./___Corpus/Medline/xml/PMC5123381.xml	ii	595707 : 595709	CM	-3, KIRB1 and KIRNKAT2), ii) down-regulation of acti
./___Corpus/Medline/xml/PMC5123381.xml	NKG2D	595752 : 595757	CM	of activating receptors (NKG2D and NKp46), IL-2R and tr
./___Corpus/Medline/xml/PMC5123381.xml	NKp46	595762 : 595767	CM	ing receptors (NKG2D and NKp46), IL-2R and transcriptio
./___Corpus/Medline/xml/PMC5123381.xml	IL-2R	595770 : 595775	CM	ptors (NKG2D and NKp46), IL-2R and transcription factor
./___Corpus/Medline/xml/PMC5123381.xml	iii	595824 : 595827	CM	rs (T-bet and Eomes) and iii) loss of IFN-g productio
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	595837 : 595842	CM	 Eomes) and iii) loss of IFN-g production, proliferatio
./___Corpus/Medline/xml/PMC5123381.xml	Tim-3	595970 : 595975	CM	y checkpoint blockade of Tim-3 [2]. Most strikingly, ho
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	596201 : 596205	CM	 little or no CTLA-4 (or PD-1 or PDL-1) [3]. Here we i
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	596519 : 596524	CM	f: (i) cytotoxicity (ii) IFN-γ production and iii) prol
./___Corpus/Medline/xml/PMC5123381.xml	iii	596540 : 596543	CM	ii) IFN-γ production and iii) proliferation. In addit
./___Corpus/Medline/xml/PMC5123381.xml	HIST1H1C	596705 : 596713	CM	modification indicators (HIST1H1C, HIST1H4I, ZNF286B, HIST
./___Corpus/Medline/xml/PMC5123381.xml	HIST1H4I	596715 : 596723	CM	on indicators (HIST1H1C, HIST1H4I, ZNF286B, HIST2H2BE) whe
./___Corpus/Medline/xml/PMC5123381.xml	HIST2H2BE	596734 : 596743	CM	1H1C, HIST1H4I, ZNF286B, HIST2H2BE) whereas IL-2/IL-12 stim
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	596797 : 596801	CM	ed NK cells up regulated mRNA encoding cytokines (IFN-
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	596822 : 596827	CM	mRNA encoding cytokines (IFN-γ, IL-1β, IL-6 and TNF) an
./___Corpus/Medline/xml/PMC5123381.xml	TNF	596845 : 596848	CM	 (IFN-γ, IL-1β, IL-6 and TNF) and chemokines (CCL3, C
./___Corpus/Medline/xml/PMC5123381.xml	CCL3	596866 : 596870	CM	and TNF) and chemokines (CCL3, CXCL1, CXCL3), as well 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL1	596872 : 596877	CM	F) and chemokines (CCL3, CXCL1, CXCL3), as well as the 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL3	596879 : 596884	CM	chemokines (CCL3, CXCL1, CXCL3), as well as the express
./___Corpus/Medline/xml/PMC5123381.xml	vitro	597124 : 597129	CM	 can became exhausted in vitro through a pathway driven
./___Corpus/Medline/xml/PMC5123381.xml	Ceacam-1	597158 : 597166	CM	ough a pathway driven by Ceacam-1 and found evidence of NK
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	597213 : 597219	CM	 NK cell exhaustion in a B16BL6 melanoma model.         
./___Corpus/Medline/xml/PMC5123381.xml	CyTOF	597369 : 597374	CM	s cytometry measurement (CyTOF), Flow cytometry, Poly (
./___Corpus/Medline/xml/PMC5123381.xml	RT-PCR	597423 : 597429	CM	(A) RNAseq, Quantitative RT-PCR, Western Blot and tumor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	597887 : 597892	CPR	hat facilitate effective anti-tumor immune responses.  
./___Corpus/Medline/xml/PMC5123381.xml	murine	597955 : 597961	CM	   NK cell exhaustion in murine melanoma model          
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	598029 : 598035	CM	e show how NK cells from B16BL6 tumor bearing mice becam
./___Corpus/Medline/xml/PMC5123381.xml	Tim-3	598135 : 598140	CM	expressed high levels of Tim-3 and Ceacam-1 when isolat
./___Corpus/Medline/xml/PMC5123381.xml	Ceacam-1	598145 : 598153	CM	high levels of Tim-3 and Ceacam-1 when isolated from B16BL
./___Corpus/Medline/xml/PMC5123381.xml	B16BL6	598173 : 598179	CM	cam-1 when isolated from B16BL6 tumors compared with C57
./___Corpus/Medline/xml/PMC5123381.xml	YAC-1	598336 : 598341	CM	ced cytotoxicity against YAC-1 target cells compared wi
./___Corpus/Medline/xml/PMC5123381.xml	WT	598389 : 598391	CM	with NK cells from blood WT non-tumor bearing mice. 
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	598590 : 598595	CM	omal fibroblasts promote Wnt5a expression and suppress 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	598633 : 598638	CPR	nd suppress responses to anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	598849 : 598857	CM	F-β is a multifunctional cytokine that suppresses many fac
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	599047 : 599051	CM	f type I TGF-β receptor (TBRI) inhibitors to augment t
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	599124 : 599132	CM	nt inhibition. The TGF-β cytokine also plays a role in cel
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	599250 : 599255	CM	g melanoma expression of Wnt5a, a ligand previously ass
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599307 : 599312	CPR	iated with resistance to anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	BRAFV600EPTEN−	599403 : 599417	CM	               Using the BRAFV600EPTEN−/− transgenic melanoma mo
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	599420 : 599430	CM	ing the BRAFV600EPTEN−/− transgenic melanoma model, we inves
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	599477 : 599481	CM	vestigated the impact of TBRI inhibition on anti-CTLA-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599496 : 599501	CPR	ct of TBRI inhibition on anti-CTLA-4 antibody and anti-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599521 : 599526	CPR	anti-CTLA-4 antibody and anti-PD-1 antibody immunothera
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599630 : 599635	CPR	d with the generation of anti-tumor immunity. Immunohis
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	599725 : 599729	CM	 to assess the effect of TBRI inhibition on the tumor 
./___Corpus/Medline/xml/PMC5123381.xml	MAF	599807 : 599810	CM	a-associated fibroblast (MAF) lines were generated an
./___Corpus/Medline/xml/PMC5123381.xml	MAFs	599898 : 599902	CM	examine the influence of MAFs on anti-PD-1 antibody th
./___Corpus/Medline/xml/PMC5123381.xml	anti-	599906 : 599911	CPR	the influence of MAFs on anti-PD-1 antibody therapy. Me
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600022 : 600027	CPR	 underlying mechanism of anti-PD-1 antibody resistance.
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	600099 : 600103	CM	lts                      TBRI inhibition synergistical
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600140 : 600145	CPR	synergistically enhances anti-CTLA-4 antibody immunothe
./___Corpus/Medline/xml/PMC5123381.xml	BRAFV600EPTEN−	600182 : 600196	CM	ody immunotherapy in the BRAFV600EPTEN−/− transgenic melanoma mo
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	600199 : 600209	CM	 in the BRAFV600EPTEN−/− transgenic melanoma model but fails
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600246 : 600251	CPR	del but fails to augment anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	600346 : 600350	CM	ry and flow cytometry of TBRI-treated melanomas reveal
./___Corpus/Medline/xml/PMC5123381.xml	MAF	600397 : 600400	CM	eals an expansion of the MAF population while in vitr
./___Corpus/Medline/xml/PMC5123381.xml	vitro	600421 : 600426	CM	 MAF population while in vitro experiments show TBRI in
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	600444 : 600448	CM	n vitro experiments show TBRI inhibition to enhance fi
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	600507 : 600511	CM	proliferation (Fig. 80). TBRI inhibition augments anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	600532 : 600537	CPR	TBRI inhibition augments anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	BRAFV600EPTEN−	600577 : 600591	CM	herapy in a stromal-poor BRAFV600EPTEN−/− transplant tumor model
./___Corpus/Medline/xml/PMC5123381.xml	BRAFV600EPTEN−	600651 : 600665	CM	 co-transplantation of a BRAFV600EPTEN−/− melanoma-derived MAF c
./___Corpus/Medline/xml/PMC5123381.xml	MAF	600685 : 600688	CM	PTEN−/− melanoma-derived MAF cell line reverses this 
./___Corpus/Medline/xml/PMC5123381.xml	MAFs	600731 : 600735	CM	s this effect (Fig. 81). MAFs were found to express hi
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	600824 : 600829	CM	h melanoma expression of Wnt5a in resected melanoma tis
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	600899 : 600903	CM	o-cultures revealed that TBRI-treated MAFs promote mel
./___Corpus/Medline/xml/PMC5123381.xml	MAFs	600912 : 600916	CM	vealed that TBRI-treated MAFs promote melanoma express
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	600948 : 600953	CM	e melanoma expression of Wnt5a and suppress PD-L1 expre
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	600967 : 600972	CM	on of Wnt5a and suppress PD-L1 expression both in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	600992 : 600997	CM	PD-L1 expression both in vitro and in vivo (Fig. 82). S
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	601034 : 601039	CM	 (Fig. 82). Silencing of Wnt5a expression by the BRAFV6
./___Corpus/Medline/xml/PMC5123381.xml	BRAFV600EPTEN−	601058 : 601072	CM	 Wnt5a expression by the BRAFV600EPTEN−/− melanoma model enhance
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	601099 : 601104	CM	 melanoma model enhances PD-L1 expression and eliminate
./___Corpus/Medline/xml/PMC5123381.xml	MAFs	601145 : 601149	CM	eliminates the impact of MAFs on responses to anti-PD-
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601166 : 601171	CPR	 of MAFs on responses to anti-PD-1 antibody therapy.   
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601320 : 601325	CPR	troma on the efficacy of anti-PD-1 antibody therapy and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601446 : 601451	CPR	e significant effects on anti-PD-1 antibody therapy out
./___Corpus/Medline/xml/PMC5123381.xml	Wnt5a	601514 : 601519	CM	mediated upregulation of Wnt5a represents an important 
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	601544 : 601553	CM	 represents an important paracrine signaling pathway that c
./___Corpus/Medline/xml/PMC5123381.xml	TBRI	601652 : 601656	CM	lanoma microenvironment. TBRI inhibition should be fur
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601716 : 601721	CPR	ated in combination with anti-CTLA-4 antibody therapy a
./___Corpus/Medline/xml/PMC5123381.xml	Wnt	601749 : 601752	CM	A-4 antibody therapy and Wnt signaling blockade repre
./___Corpus/Medline/xml/PMC5123381.xml	anti-	601819 : 601824	CPR	 approach for augmenting anti-PD-1 antibody therapy in 
./___Corpus/Medline/xml/PMC5123381.xml	tyrosine	602444 : 602452	CM	is dependent on Bruton's tyrosine kinase (BTK) and phospho
./___Corpus/Medline/xml/PMC5123381.xml	phosphoinositide	602470 : 602486	CM	yrosine kinase (BTK) and phosphoinositide 3-kinase delta (PI3Kδ) a
./___Corpus/Medline/xml/PMC5123381.xml	3-	602488 : 602490	CPR	K) and phosphoinositide 3-kinase delta (PI3Kδ) activ
./___Corpus/Medline/xml/PMC5123381.xml	PI3Kδ	602503 : 602508	CM	nositide 3-kinase delta (PI3Kδ) activity. Acalabrutinib
./___Corpus/Medline/xml/PMC5123381.xml	PI3Kδ	602720 : 602725	CM	a selective inhibitor of PI3Kδ. We hypothesized that th
./___Corpus/Medline/xml/PMC5123381.xml	anti-	602890 : 602895	CPR	h checkpoint inhibition (anti-PD-L1 mAb) for tumors con
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603051 : 603054	CM	B cells in the syngeneic ID8 ovarian tumor model, we 
./___Corpus/Medline/xml/PMC5123381.xml	GFP	603108 : 603111	CM	tively transferred IL-10/GFP reporter B cells into mi
./___Corpus/Medline/xml/PMC5123381.xml	μMT	603173 : 603176	CM	 for functional B cells (μMT) then orthotopically imp
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603222 : 603225	CM	 implanted the mice with ID8 cells; GFP expression wa
./___Corpus/Medline/xml/PMC5123381.xml	GFP	603233 : 603236	CM	the mice with ID8 cells; GFP expression was analyzed 
./___Corpus/Medline/xml/PMC5123381.xml	luciferase	603324 : 603334	CM	topically implanted with luciferase-transduced ID8 cells wer
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603346 : 603349	CM	th luciferase-transduced ID8 cells were treated with 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	603420 : 603425	CPR	-319 in combination with anti-PD-L1. Both oral agents w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	603482 : 603487	CPR	ed 15 mg/kg twice daily; anti-PD-L1 (10 F.9G2) was dose
./___Corpus/Medline/xml/PMC5123381.xml	GFP	603888 : 603891	CM	reconstituted with IL-10/GFP, many tumor-infiltrating
./___Corpus/Medline/xml/PMC5123381.xml	GFP	603933 : 603936	CM	ltrating cells expressed GFP, consistent with a regul
./___Corpus/Medline/xml/PMC5123381.xml	ID8	603991 : 603994	CM	 B cell phenotype in the ID8 tumor microenvironment, 
./___Corpus/Medline/xml/PMC5123381.xml	GFP	604027 : 604030	CM	icroenvironment, whereas GFP expression was not obser
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604213 : 604218	CPR	 0.027), acalabrutinib + anti-PD-L1 (p = 0.037), acalab
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604298 : 604303	CPR	 acalabrutinib/ACP-319 + anti-PD-L1 (p = 0.036), but no
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604335 : 604340	CPR	p = 0.036), but not with anti-PD-L1 alone (p = 0.104), 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604409 : 604414	CPR	le-treated controls. All anti-PD-L1 groups had increase
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	604441 : 604445	CM	-L1 groups had increased CD8+ T cells in peritoneal la
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604614 : 604619	CPR	brutinib synergized with anti-PD-L1 to decrease PD-L1+ 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1+	604637 : 604643	CM	h anti-PD-L1 to decrease PD-L1+ macrophages in bone marr
./___Corpus/Medline/xml/PMC5123381.xml	anti-	604724 : 604729	CPR	 acalabrutinib/ACP-319 + anti-PD-L1, histology scores w
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605017 : 605022	CPR	 acalabrutinib/ACP-319 + anti-PD-L1 increased tumor-inf
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	605057 : 605061	CM	eased tumor-infiltrating CD8+ T cells (p = 0.026).    
./___Corpus/Medline/xml/PMC5123381.xml	PI3Kδ	605182 : 605187	CM	at inhibition of BTK and PI3Kδ targets both regulatory 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605290 : 605295	CPR	vironment. Combined with anti-PD-L1, acalabrutinib alon
./___Corpus/Medline/xml/PMC5123381.xml	anti-	605350 : 605355	CPR	with ACP-319 promotes an anti-tumor response against ov
./___Corpus/Medline/xml/PMC5123381.xml	270–	605544 : 605548	CPR	ancer Discov 2016, 6(3): 270–285.                     
./___Corpus/Medline/xml/PMC5123381.xml	CD73	605674 : 605678	CM	ffects of small-molecule CD73 inhibitors on tumor biol
./___Corpus/Medline/xml/PMC5123381.xml	Yu	605805 : 605807	CM	Joanne BL Tan, Ada Chen, Yu Chen, Timothy Park, Jay 
./___Corpus/Medline/xml/PMC5123381.xml	P	605832 : 605833	CM	 Chen, Timothy Park, Jay P Powers, Holly Sexton, Gu
./___Corpus/Medline/xml/PMC5123381.xml	Xu	605863 : 605865	CM	rs, Holly Sexton, Guifen Xu, Steve W Young, Ulrike S
./___Corpus/Medline/xml/PMC5123381.xml	W	605873 : 605874	CM	Sexton, Guifen Xu, Steve W Young, Ulrike Schindler 
./___Corpus/Medline/xml/PMC5123381.xml	ATP	605977 : 605980	CM	 levels of extracellular ATP (eATP) have been documen
./___Corpus/Medline/xml/PMC5123381.xml	eATP	605982 : 605986	CM	ls of extracellular ATP (eATP) have been documented in
./___Corpus/Medline/xml/PMC5123381.xml	eATP	606031 : 606035	CM	ed in many solid tumors. eATP, which enhances activati
./___Corpus/Medline/xml/PMC5123381.xml	hydrolyzed	606107 : 606117	CM	ng cells, is efficiently hydrolyzed to adenosine by extra-ce
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606121 : 606130	CM	fficiently hydrolyzed to adenosine by extra-cellular CD39 (
./___Corpus/Medline/xml/PMC5123381.xml	CD39	606149 : 606153	CM	nosine by extra-cellular CD39 (ATP → AMP) and CD73 (AM
./___Corpus/Medline/xml/PMC5123381.xml	ATP	606155 : 606158	CM	 by extra-cellular CD39 (ATP → AMP) and CD73 (AMP → a
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606161 : 606164	CM	tra-cellular CD39 (ATP → AMP) and CD73 (AMP → adenosi
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606170 : 606174	CM	lar CD39 (ATP → AMP) and CD73 (AMP → adenosine). Adeno
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606176 : 606179	CM	39 (ATP → AMP) and CD73 (AMP → adenosine). Adenosine 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606182 : 606191	CM	P → AMP) and CD73 (AMP → adenosine). Adenosine is a potent 
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	606194 : 606203	CM	 CD73 (AMP → adenosine). Adenosine is a potent inhibitor of
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606261 : 606265	CM	and NK activation. Thus, CD73 has drawn interest as a 
./___Corpus/Medline/xml/PMC5123381.xml	CT26	606346 : 606350	CM	 target. We describe the CT26 tumor model to character
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606394 : 606398	CM	racterize the effects of CD73 inhibition on tumor biol
./___Corpus/Medline/xml/PMC5123381.xml	AMP	606438 : 606441	CM	tumor biology and plasma AMP/adenosine levels as mark
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	606442 : 606451	CM	r biology and plasma AMP/adenosine levels as markers of sys
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606482 : 606486	CM	s as markers of systemic CD73 inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	606551 : 606555	CM	                   Human PBMC and mouse spleen/blood/t
./___Corpus/Medline/xml/PMC5123381.xml	CT26	606732 : 606736	CM	subcutaneous (106 cells) CT26 tumors was initiated at 
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	606858 : 606864	CM	otype control; vehicle + α-PD-1; A000830 + α-PD-1).     
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	606876 : 606882	CM	icle + α-PD-1; A000830 + α-PD-1).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	CD73	606931 : 606935	CM	lts                      CD73 expression was high in a
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	606986 : 606990	CM	l subsets of human blood CD8+ T cells, B cells, and Tr
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	607041 : 607045	CM	g, but not Treg-depleted CD4+ T cells. CD39 was broadl
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607055 : 607059	CM	g-depleted CD4+ T cells. CD39 was broadly expressed on
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607198 : 607202	CM	, B cells, and activated CD8+ T cells. CD73 expression
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607212 : 607216	CM	 activated CD8+ T cells. CD73 expression was higher on
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607327 : 607331	CM	ets). On B and NK cells, CD73 expression was similar b
./___Corpus/Medline/xml/PMC5123381.xml	CT26	607407 : 607411	CM	 In Balb/c mice carrying CT26 tumors, CD73 expression 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607420 : 607424	CM	ce carrying CT26 tumors, CD73 expression in TILs was l
./___Corpus/Medline/xml/PMC5123381.xml	TILs	607439 : 607443	CM	mors, CD73 expression in TILs was limited to T cells a
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	607471 : 607475	CM	s limited to T cells and MDSC; CD73 expression was inc
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607477 : 607481	CM	ted to T cells and MDSC; CD73 expression was increased
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607510 : 607514	CM	ression was increased on CD8+ TIL relative to splenic 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	607515 : 607518	CM	on was increased on CD8+ TIL relative to splenic CD8+
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607539 : 607543	CM	 TIL relative to splenic CD8+ T cells from tumor-beari
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607621 : 607625	CM	r than in normal splenic CD8+ T cells. Human blood CD8
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607647 : 607651	CM	D8+ T cells. Human blood CD8+ T cells exhibit robust C
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607675 : 607679	CM	+ T cells exhibit robust CD39 and CD73 activity, which
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607684 : 607688	CM	 exhibit robust CD39 and CD73 activity, which can be b
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607723 : 607727	CM	 which can be blocked by CD39 and CD73 inhibitors, res
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607732 : 607736	CM	n be blocked by CD39 and CD73 inhibitors, respectively
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	607776 : 607780	CM	spectively. Mouse spleen CD8+ T cells also showed a lo
./___Corpus/Medline/xml/PMC5123381.xml	CD39	607833 : 607837	CM	 but detectable level of CD39 and CD73 activity. Plasm
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607842 : 607846	CM	ctable level of CD39 and CD73 activity. Plasma AMP:ade
./___Corpus/Medline/xml/PMC5123381.xml	AMP	607864 : 607867	CM	nd CD73 activity. Plasma AMP:adenosine ratios were ~1
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	607868 : 607877	CM	D73 activity. Plasma AMP:adenosine ratios were ~15X higher 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	607905 : 607909	CM	tios were ~15X higher in CD73 KO than in gender- and a
./___Corpus/Medline/xml/PMC5123381.xml	KO	607910 : 607912	CM	were ~15X higher in CD73 KO than in gender- and age-
./___Corpus/Medline/xml/PMC5123381.xml	WT	607945 : 607947	CM	 gender- and age-matched WT mice. Similarly, plasma 
./___Corpus/Medline/xml/PMC5123381.xml	AMP	607972 : 607975	CM	 mice. Similarly, plasma AMP:adenosine ratios were in
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	607976 : 607985	CM	e. Similarly, plasma AMP:adenosine ratios were increased in
./___Corpus/Medline/xml/PMC5123381.xml	WT	608011 : 608013	CM	ratios were increased in WT mice dosed with a CD73 i
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608032 : 608036	CM	 in WT mice dosed with a CD73 inhibitor. Administratio
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608089 : 608093	CM	f a novel small-molecule CD73 inhibitor (A000830) to C
./___Corpus/Medline/xml/PMC5123381.xml	CT26	608117 : 608121	CM	3 inhibitor (A000830) to CT26 tumor-bearing mice resul
./___Corpus/Medline/xml/PMC5123381.xml	α-PD-1	608248 : 608254	CM	rved in combination with α-PD-1. Co-administration of A0
./___Corpus/Medline/xml/PMC5123381.xml	α-	608290 : 608292	CPR	stration of A000830 with α-PD-1antibody increased th
./___Corpus/Medline/xml/PMC5123381.xml	TIL	608329 : 608332	CM	 increased the number of TIL relative to control or s
./___Corpus/Medline/xml/PMC5123381.xml	CT26	608441 : 608445	CM	               Syngeneic CT26 colon tumors provide an 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608511 : 608515	CM	to assess the effects of CD73 inhibition on tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	AMP	608585 : 608588	CM	ration. Plasma levels of AMP/adenosine provide a simp
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	608589 : 608598	CM	on. Plasma levels of AMP/adenosine provide a simple way of 
./___Corpus/Medline/xml/PMC5123381.xml	CD73	608643 : 608647	CM	y of monitoring systemic CD73 inhibition.             
./___Corpus/Medline/xml/PMC5123381.xml	WISP1	608703 : 608708	CM	                    P386 WISP1 stimulates melanoma cell
./___Corpus/Medline/xml/PMC5123381.xml	EMT	608791 : 608794	CM	–mesenchymal transition (EMT) through both autocrine 
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	608823 : 608832	CM	rough both autocrine and paracrine signaling               
./___Corpus/Medline/xml/PMC5123381.xml	WNT1	609125 : 609129	CM	t. One soluble signal is WNT1 inducible signaling path
./___Corpus/Medline/xml/PMC5123381.xml	WISP1	609169 : 609174	CM	aling pathway protein 1 (WISP1), a secreted matricellul
./___Corpus/Medline/xml/PMC5123381.xml	anti-	609388 : 609393	CPR	sion, but also represses anti-tumor immunity through a 
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609418 : 609427	CM	tumor immunity through a paracrine mechanism [2]. Here, our
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609540 : 609549	CM	umor cell behavior, from paracrine, that is a mediator of i
./___Corpus/Medline/xml/PMC5123381.xml	WISP1	609613 : 609618	CM	ommunication, effects of WISP1 on tumor growth.        
./___Corpus/Medline/xml/PMC5123381.xml	B16	609706 : 609709	CM	 Wisp1 in mouse melanoma B16 cells was knocked out us
./___Corpus/Medline/xml/PMC5123381.xml	CRISPR	609742 : 609748	CM	as knocked out using the CRISPR/Cas9 system to evaluate 
./___Corpus/Medline/xml/PMC5123381.xml	Cas9	609749 : 609753	CM	ked out using the CRISPR/Cas9 system to evaluate its r
./___Corpus/Medline/xml/PMC5123381.xml	vitro	609830 : 609835	CM	 and metastasis using in vitro and in vivo assays. We a
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	609950 : 609959	CM	ompare the autocrine and paracrine effects on in vitro tumo
./___Corpus/Medline/xml/PMC5123381.xml	vitro	609974 : 609979	CM	 paracrine effects on in vitro tumor cell invasion assa
./___Corpus/Medline/xml/PMC5123381.xml	vitro	610093 : 610098	CM	                      In vitro, Wisp1 disruption increa
./___Corpus/Medline/xml/PMC5123381.xml	B16	610251 : 610254	CM	n and invasion. In vivo, B16 cells without Wisp1 exhi
./___Corpus/Medline/xml/PMC5123381.xml	EMT	610408 : 610411	CM	–mesenchymal transition (EMT) markers were down-regul
./___Corpus/Medline/xml/PMC5123381.xml	EMT	610562 : 610565	CM	e mechanism of Wisp1 for EMT gene activation and enha
./___Corpus/Medline/xml/PMC5123381.xml	NIH3T3	610711 : 610717	CM	um from mouse fibroblast NIH3T3 cells with Wisp1 knockou
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	610780 : 610789	CM	ression also supported a paracrine scenario in which fibrob
./___Corpus/Medline/xml/PMC5123381.xml	MEK	610905 : 610908	CM	s activated both Akt and MEK/ERK signaling, repressed
./___Corpus/Medline/xml/PMC5123381.xml	ERK	610909 : 610912	CM	tivated both Akt and MEK/ERK signaling, repressed E-c
./___Corpus/Medline/xml/PMC5123381.xml	E-	610934 : 610936	CPR	ERK signaling, repressed E-cadherin, and upregulated
./___Corpus/Medline/xml/PMC5123381.xml	EMT	610970 : 610973	CM	 and upregulated certain EMT genes. Kinase inhibition
./___Corpus/Medline/xml/PMC5123381.xml	Kinase	610981 : 610987	ASE	lated certain EMT genes. Kinase inhibition confirmed the
./___Corpus/Medline/xml/PMC5123381.xml	EMT	611045 : 611048	CM	nce of both pathways for EMT gene regulation.        
./___Corpus/Medline/xml/PMC5123381.xml	WISP1	611214 : 611219	CM	vasion and metastasis by WISP1 through directly inducti
./___Corpus/Medline/xml/PMC5123381.xml	EMT	611250 : 611253	CM	gh directly induction of EMT in tumor cells and indir
./___Corpus/Medline/xml/PMC5123381.xml	DJ	611419 : 611421	CM	               1. Klinke DJ, Horvath N, Cuppett V, W
./___Corpus/Medline/xml/PMC5123381.xml	Wu	611445 : 611447	CM	J, Horvath N, Cuppett V, Wu Y, Deng W, Kanj R: Inter
./___Corpus/Medline/xml/PMC5123381.xml	Y	611448 : 611449	CM	Horvath N, Cuppett V, Wu Y, Deng W, Kanj R: Interlo
./___Corpus/Medline/xml/PMC5123381.xml	W	611456 : 611457	CM	N, Cuppett V, Wu Y, Deng W, Kanj R: Interlocked pos
./___Corpus/Medline/xml/PMC5123381.xml	R	611464 : 611465	CM	tt V, Wu Y, Deng W, Kanj R: Interlocked positive an
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	611534 : 611543	CM	 network motifs regulate β-catenin activity in the adherens
./___Corpus/Medline/xml/PMC5123381.xml	Biol	611591 : 611595	CM	ns junction pathway. Mol Biol Cell 2015, 26:4135–4148.
./___Corpus/Medline/xml/PMC5123381.xml	4135–	611610 : 611615	CPR	. Mol Biol Cell 2015, 26:4135–4148.                    
./___Corpus/Medline/xml/PMC5123381.xml	JS	611704 : 611706	CM	bers E, McGray AJR, Ware JS, Bramson JL, Klinke DJ: 
./___Corpus/Medline/xml/PMC5123381.xml	JL	611716 : 611718	CM	ay AJR, Ware JS, Bramson JL, Klinke DJ: A quantitati
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	611775 : 611784	CM	ems approach to identify paracrine mechanisms that locally 
./___Corpus/Medline/xml/PMC5123381.xml	B16	611859 : 611862	CM	to Interleukin-12 in the B16 melanoma model. Integr B
./___Corpus/Medline/xml/PMC5123381.xml	Biol	611886 : 611890	CM	6 melanoma model. Integr Biol (Camb) 2012, 4:925–936. 
./___Corpus/Medline/xml/PMC5123381.xml	925–	611906 : 611910	CPR	tegr Biol (Camb) 2012, 4:925–936.                     
./___Corpus/Medline/xml/PMC5123381.xml	STAT	611962 : 611966	CM	                P387 Jak/STAT signaling as a mediator 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	612047 : 612052	CM	reatic stellate cells in vitro and caerulein-induced pa
./___Corpus/Medline/xml/PMC5123381.xml	Mace1	612158 : 612163	CM	 Hannah M Komar1, Thomas Mace1, Gregory Serpa1, Omar El
./___Corpus/Medline/xml/PMC5123381.xml	PSC	612388 : 612391	CM	ncreatic stellate cells (PSC) are implicated in the p
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	612465 : 612469	CM	c ductal adenocarcinoma (PDAC) and chronic pancreatiti
./___Corpus/Medline/xml/PMC5123381.xml	CP	612497 : 612499	CM	nd chronic pancreatitis (CP). These cells orchestrat
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	612579 : 612583	CM	mmune suppression in the PDAC microenvironment. As suc
./___Corpus/Medline/xml/PMC5123381.xml	PSC	612611 : 612614	CM	croenvironment. As such, PSC may facilitate resistanc
./___Corpus/Medline/xml/PMC5123381.xml	STAT	612722 : 612726	CM	ctivate inflammatory Jak/STAT and MAPK signaling in an
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	612731 : 612735	CM	nflammatory Jak/STAT and MAPK signaling in an autocrin
./___Corpus/Medline/xml/PMC5123381.xml	paracrine	612766 : 612775	CM	ling in an autocrine and paracrine manner. We hypothesized 
./___Corpus/Medline/xml/PMC5123381.xml	STAT	612824 : 612828	CM	 that inhibiting the Jak/STAT or MAPK pathways may lim
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	612832 : 612836	CM	hibiting the Jak/STAT or MAPK pathways may limit featu
./___Corpus/Medline/xml/PMC5123381.xml	vitro	612979 : 612984	CM	                      In vitro studies utilized immorta
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613015 : 613018	CM	es utilized immortalized PSC lines, and primary PSC f
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613038 : 613041	CM	d PSC lines, and primary PSC from patients with CP an
./___Corpus/Medline/xml/PMC5123381.xml	CP	613061 : 613063	CM	y PSC from patients with CP and PDAC. Cytokine/chemo
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	613068 : 613072	CM	rom patients with CP and PDAC. Cytokine/chemokine expr
./___Corpus/Medline/xml/PMC5123381.xml	Cytokine	613074 : 613082	CM	tients with CP and PDAC. Cytokine/chemokine expression was
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613160 : 613163	CM	a multiplex immunoassay. PSC supernatants were utiliz
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	613228 : 613232	CM	functionally suppressive MDSC in vitro. PSC were treat
./___Corpus/Medline/xml/PMC5123381.xml	vitro	613236 : 613241	CM	ally suppressive MDSC in vitro. PSC were treated with r
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613243 : 613246	CM	ppressive MDSC in vitro. PSC were treated with ruxoli
./___Corpus/Medline/xml/PMC5123381.xml	ruxolitinib	613265 : 613276	CM	o. PSC were treated with ruxolitinib (Jak1/2 inhibitor), or M
./___Corpus/Medline/xml/PMC5123381.xml	MEK162	613300 : 613306	CM	b (Jak1/2 inhibitor), or MEK162 (MEK inhibitor) purchase
./___Corpus/Medline/xml/PMC5123381.xml	MEK	613308 : 613311	CM	2 inhibitor), or MEK162 (MEK inhibitor) purchased com
./___Corpus/Medline/xml/PMC5123381.xml	MTT	613379 : 613382	CM	ability was assessed via MTT assay. Immunoblot analys
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	613463 : 613468	CM	 effect of inhibitors on STAT3, MAPK, and apoptotic pat
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	613470 : 613474	CM	 of inhibitors on STAT3, MAPK, and apoptotic pathways.
./___Corpus/Medline/xml/PMC5123381.xml	ruxolitinib	613776 : 613787	CM	 received oral gavage of ruxolitinib at 90 mg/kg 2X/day. Panc
./___Corpus/Medline/xml/PMC5123381.xml	2X	613800 : 613802	CM	 ruxolitinib at 90 mg/kg 2X/day. Pancreata from thes
./___Corpus/Medline/xml/PMC5123381.xml	H&E	613851 : 613854	CM	se mice were stained for H&E, Masson’s Trichrome, and
./___Corpus/Medline/xml/PMC5123381.xml	Trichrome	613865 : 613874	CM	tained for H&E, Masson’s Trichrome, and αSMA.              
./___Corpus/Medline/xml/PMC5123381.xml	αSMA	613880 : 613884	CM	 Masson’s Trichrome, and αSMA.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	PSC	613936 : 613939	CM	                     All PSC displayed constitutive a
./___Corpus/Medline/xml/PMC5123381.xml	STAT	613981 : 613985	CM	tutive activation of Jak/STAT and MAPK pathways. PSC s
./___Corpus/Medline/xml/PMC5123381.xml	MAPK	613990 : 613994	CM	tivation of Jak/STAT and MAPK pathways. PSC supernatan
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614005 : 614008	CM	/STAT and MAPK pathways. PSC supernatants contained r
./___Corpus/Medline/xml/PMC5123381.xml	MCP-1	614075 : 614080	CM	oluble factors including MCP-1, IL-6, and VEGF (up to 3
./___Corpus/Medline/xml/PMC5123381.xml	VEGF	614092 : 614096	CM	cluding MCP-1, IL-6, and VEGF (up to 31,000, 19,000, a
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	614161 : 614165	CM	espectively). Culture of PBMC from healthy human donor
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614197 : 614200	CM	ealthy human donors with PSC supernatants promoted di
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	614242 : 614246	CM	moted differentiation of MDSC (CD33+CD11b+HLADRlo) tha
./___Corpus/Medline/xml/PMC5123381.xml	CD33	614248 : 614252	CM	differentiation of MDSC (CD33+CD11b+HLADRlo) that func
./___Corpus/Medline/xml/PMC5123381.xml	CD3	614326 : 614329	CM	iferation of autologous, CD3/CD28-stimulated T cells.
./___Corpus/Medline/xml/PMC5123381.xml	CD28	614330 : 614334	CM	ation of autologous, CD3/CD28-stimulated T cells. This
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	614419 : 614424	CM	neutralizing antibody or STAT3 inhibitor to culture med
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	614480 : 614485	CM	dicating a role for IL-6/STAT3 signaling in PSC-derived
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614499 : 614502	CM	 IL-6/STAT3 signaling in PSC-derived immune suppressi
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614544 : 614547	CM	uppression. Treatment of PSC with ruxolitinib reduced
./___Corpus/Medline/xml/PMC5123381.xml	ruxolitinib	614553 : 614564	CM	n. Treatment of PSC with ruxolitinib reduced STAT3 phosphoryl
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	614573 : 614578	CM	with ruxolitinib reduced STAT3 phosphorylation, decreas
./___Corpus/Medline/xml/PMC5123381.xml	phosphorylation	614579 : 614594	RN	uxolitinib reduced STAT3 phosphorylation, decreased growth (40 % 
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614681 : 614684	CM	duce apoptosis. Instead, PSC exhibited a dose-depende
./___Corpus/Medline/xml/PMC5123381.xml	αSMA	614724 : 614728	CM	se-dependent decrease in αSMA, a marker of PSC activat
./___Corpus/Medline/xml/PMC5123381.xml	PSC	614742 : 614745	CM	ase in αSMA, a marker of PSC activation. In contrast,
./___Corpus/Medline/xml/PMC5123381.xml	MEK162	614786 : 614792	CM	contrast, treatment with MEK162 had no effect on growth 
./___Corpus/Medline/xml/PMC5123381.xml	murine	614837 : 614843	CM	owth or activation. In a murine model of caerulein-induc
./___Corpus/Medline/xml/PMC5123381.xml	ruxolitinib	614913 : 614924	CM	pancreatitis, short-term ruxolitinib treatment resulted in si
./___Corpus/Medline/xml/PMC5123381.xml	STAT	615074 : 615078	CM	ata suggest that the Jak/STAT pathway promotes immune 
./___Corpus/Medline/xml/PMC5123381.xml	STAT	615229 : 615233	CM	ture studies whereby Jak/STAT inhibition may reduce de
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	615362 : 615367	CM	            P388 Role of STAT1 induced CXCL10 in tumor 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	615376 : 615382	CM	88 Role of STAT1 induced CXCL10 in tumor progression and
./___Corpus/Medline/xml/PMC5123381.xml	Au	615538 : 615540	CM	   Madhuri Koti, Katrina Au, Nichole Peterson, Peter
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	615739 : 615744	CM	ported the presence of a STAT1 associated distinct T he
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	615977 : 615982	CM	e also demonstrated that STAT1 enhanced the prognostic 
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	616133 : 616138	CM	to elucidate the role of STAT1 induced CXCL10 in HGSC t
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616147 : 616153	CM	he role of STAT1 induced CXCL10 in HGSC tumor immune mic
./___Corpus/Medline/xml/PMC5123381.xml	HGSC	616157 : 616161	CM	 STAT1 induced CXCL10 in HGSC tumor immune microenviro
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616211 : 616214	CM	nment in the established ID8 mouse model of HGSC.    
./___Corpus/Medline/xml/PMC5123381.xml	HGSC	616230 : 616234	CM	ished ID8 mouse model of HGSC.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616282 : 616285	CM	ods                      ID8 mouse ovarian cancer cel
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616371 : 616377	CM	onstructs to overexpress CXCL10. In vitro cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	vitro	616382 : 616387	CM	o overexpress CXCL10. In vitro cell proliferation and m
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616499 : 616505	CM	sic effects of increased CXCL10 expression. For in vivo 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616543 : 616549	CM	For in vivo studies, the CXCL10 overexpressing and contr
./___Corpus/Medline/xml/PMC5123381.xml	ID8	616577 : 616580	CM	erexpressing and control ID8 cells were implanted via
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	616739 : 616747	CM	e subjected to multiplex cytokine analysis using a mouse 3
./___Corpus/Medline/xml/PMC5123381.xml	31-	616771 : 616774	CPR	e analysis using a mouse 31-plex assay. RNA isolated 
./___Corpus/Medline/xml/PMC5123381.xml	RNA	616786 : 616789	CM	g a mouse 31-plex assay. RNA isolated from tumor tiss
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	616995 : 617001	CM	nce genes. The effect of CXCL10 on the tumor vasculature
./___Corpus/Medline/xml/PMC5123381.xml	HGSC	617030 : 617034	CM	the tumor vasculature of HGSC TME was evaluated by CD3
./___Corpus/Medline/xml/PMC5123381.xml	CD31	617056 : 617060	CM	GSC TME was evaluated by CD31 immunofluorescence stain
./___Corpus/Medline/xml/PMC5123381.xml	ID8	617240 : 617243	CM	on in mice injected with ID8 CXCL10 overexpressing ce
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	617244 : 617250	CM	n mice injected with ID8 CXCL10 overexpressing cells com
./___Corpus/Medline/xml/PMC5123381.xml	ID8	617295 : 617298	CM	s compared to those with ID8 vector control cells was
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	617344 : 617352	CM	 was observed. Multiplex cytokine analysis of malignant as
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	617432 : 617437	CM	ession of IL-6, VEGF and CXCL9 between the two groups. 
./___Corpus/Medline/xml/PMC5123381.xml	CD31	617462 : 617466	CM	 between the two groups. CD31 endothelial cell marker 
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	617894 : 617900	CM	fferential expression of CXCL10 in HGSC tumors potential
./___Corpus/Medline/xml/PMC5123381.xml	HGSC	617904 : 617908	CM	 expression of CXCL10 in HGSC tumors potentially contr
./___Corpus/Medline/xml/PMC5123381.xml	STAT1	618142 : 618147	CM	lying differential tumor STAT1 and CXCL10 expression an
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	618152 : 618158	CM	erential tumor STAT1 and CXCL10 expression and its role 
./___Corpus/Medline/xml/PMC5123381.xml	HGSC	618284 : 618288	CM	omodulatory therapies in HGSC.                  Acknow
./___Corpus/Medline/xml/PMC5123381.xml	PIF	618442 : 618445	CM	Pre-implantation factor (PIF) – blocks proliferation 
./___Corpus/Medline/xml/PMC5123381.xml	Toth1	618666 : 618671	CM	i1, Emil Farkas1, Laszlo Toth1, Mihaly Ujhelyi1, Akos S
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619137 : 619140	CM	rived, immune-regulatory PIF regulates this process. 
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619175 : 619178	CM	 this process. Synthetic PIF peptide transposes endog
./___Corpus/Medline/xml/PMC5123381.xml	FDA	619269 : 619272	CM	elevant models and is in FDA fast track clinical tria
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619435 : 619438	CM	9562). Having shown that PIF reduces metastatic melan
./___Corpus/Medline/xml/PMC5123381.xml	NSG	619468 : 619471	CM	ces metastatic melanoma (NSG/H199 model), human melan
./___Corpus/Medline/xml/PMC5123381.xml	1642-	619662 : 619667	CPR	ttee approval (ETT TUKEB 1642-02/2010), minor tissue sa
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619860 : 619863	CM	cultures with or without PIF and further analyzed by 
./___Corpus/Medline/xml/PMC5123381.xml	PIF	619970 : 619973	CM	lts                      PIF treatment (250 nm) delay
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620089 : 620092	CM	d cultures. Importantly, PIF increased the expression
./___Corpus/Medline/xml/PMC5123381.xml	disialylated glycosphingolipid	620121 : 620151	CM	reased the expression of disialylated glycosphingolipid tumor associated antigen
./___Corpus/Medline/xml/PMC5123381.xml	FACS	620268 : 620272	CM	ed by immunofluorescence FACS cell sorting and confoca
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620352 : 620355	CM	ootprint). Assessment of PIF effect on tumor associat
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620472 : 620475	CM	ons                      PIF reduces proliferation an
./___Corpus/Medline/xml/PMC5123381.xml	glycosphingolipid	620537 : 620554	CM	ly or indirectly promote glycosphingolipid-type tumor associated an
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620642 : 620645	CM	or footprint visibility, PIF may help trigger immune-
./___Corpus/Medline/xml/PMC5123381.xml	PIF	620709 : 620712	CM	ancer response. Overall, PIF use for tumor targeting 
./___Corpus/Medline/xml/PMC5123381.xml	LLC	620946 : 620949	CM	 1214104/2014, BioIncept LLC sPIF (proprietary).     
./___Corpus/Medline/xml/PMC5123381.xml	JK	621028 : 621030	CM	                1. Perry JK, Lins RJ, Lobie PE, Mitc
./___Corpus/Medline/xml/PMC5123381.xml	451–	621209 : 621213	CPR	ancy. Clin Sci 2009, 118:451–457.                     
./___Corpus/Medline/xml/PMC5123381.xml	R	621267 : 621268	CM	              2. Shainer R, Almogi-Hazan O, Berger 
./___Corpus/Medline/xml/PMC5123381.xml	O	621283 : 621284	CM	 Shainer R, Almogi-Hazan O, Berger A, et al.: PIF P
./___Corpus/Medline/xml/PMC5123381.xml	PIF	621304 : 621307	CM	zan O, Berger A, et al.: PIF Provides Comprehensive P
./___Corpus/Medline/xml/PMC5123381.xml	DOI	621398 : 621401	CM	logies. Oncotarget 2016, DOI:10.18632/oncotarget.1063
./___Corpus/Medline/xml/PMC5123381.xml	O	621506 : 621507	CM	iszkay G, Blank M, Csuka O, Balatoni T, Toth L, et 
./___Corpus/Medline/xml/PMC5123381.xml	11–	621699 : 621702	CPR	ue. Immunol Res 2015, 61:11–23.                      
./___Corpus/Medline/xml/PMC5123381.xml	Y	621778 : 621779	CM	r M, Zhou J, Yang L, Gao Y, Wu F, Schoeberlein A, e
./___Corpus/Medline/xml/PMC5123381.xml	Wu	621781 : 621783	CM	, Zhou J, Yang L, Gao Y, Wu F, Schoeberlein A, et al
./___Corpus/Medline/xml/PMC5123381.xml	13882–	621925 : 621931	CPR	ad Sci USA 2014, 111(38):13882–13887.                  P
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	621960 : 621965	CM	7.                  P390 PD-L1 expressing myeloid cells
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	622009 : 622015	CM	 cells limit response to CSF-1R targeted therapy        
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	622790 : 622798	CM	cy of colony stimulating factor-1 receptor (CSF-1R)+ macro
./___Corpus/Medline/xml/PMC5123381.xml	(CSF-1R)+	622808 : 622817	CM	lating factor-1 receptor (CSF-1R)+ macrophages in human MM,
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	622925 : 622931	CM	 therapeutic blockade of CSF-1R instigated activation of
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	622957 : 622961	CM	instigated activation of CD8+ T cells in primary tumor
./___Corpus/Medline/xml/PMC5123381.xml	CSF1R	623222 : 623227	CM	sponse to combined chemo/CSF1R inhibition, we identifie
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	623281 : 623286	CM	ogrammed death ligand 1 (PD-L1) as an abundant immune c
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	623444 : 623449	CM	 combination blockade of PD-L1 with CSF-1R would improv
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	623455 : 623461	CM	n blockade of PD-L1 with CSF-1R would improve survival b
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623496 : 623500	CM	rove survival by driving CD8+ T cell activation and cy
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	623658 : 623664	CM	ombination therapy using CSF-1R/PD-L1 inhibitors enhance
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	623665 : 623670	CM	ion therapy using CSF-1R/PD-L1 inhibitors enhanced acti
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623701 : 623705	CM	itors enhanced activated CD8+ T cell frequency and fur
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623843 : 623847	CM	imal survival. Activated CD8+ T cells, in both primary
./___Corpus/Medline/xml/PMC5123381.xml	Ki-67	623964 : 623969	CM	rked by co-expression of Ki-67 with PD-1 and EOMES. CD8
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	623975 : 623979	CM	expression of Ki-67 with PD-1 and EOMES. CD8+ T cells 
./___Corpus/Medline/xml/PMC5123381.xml	EOMES	623984 : 623989	CM	n of Ki-67 with PD-1 and EOMES. CD8+ T cells were essen
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	623991 : 623995	CM	-67 with PD-1 and EOMES. CD8+ T cells were essential f
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	624046 : 624052	CM	r therapeutic benefit of CSF-1R/PD-L1 combination therap
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	624053 : 624058	CM	peutic benefit of CSF-1R/PD-L1 combination therapy sinc
./___Corpus/Medline/xml/PMC5123381.xml	BOTH	624485 : 624489	CM	roenvironments to impact BOTH primary tumor responses 
./___Corpus/Medline/xml/PMC5123381.xml	SK	624614 : 624616	CM	nts                      SK acknowledges support fro
./___Corpus/Medline/xml/PMC5123381.xml	NIH	624737 : 624740	CM	wledges support from the NIH/NCI, DOD BCRP Era of Hop
./___Corpus/Medline/xml/PMC5123381.xml	NCI	624741 : 624744	CM	ges support from the NIH/NCI, DOD BCRP Era of Hope Sc
./___Corpus/Medline/xml/PMC5123381.xml	DOD	624746 : 624749	CM	upport from the NIH/NCI, DOD BCRP Era of Hope Scholar
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	625043 : 625048	CM	h.                  P391 CD56+ cell infiltration correl
./___Corpus/Medline/xml/PMC5123381.xml	W	625256 : 625257	CM	, Edward B Stelow1, Todd W Bauer1, Craig L Slingluf
./___Corpus/Medline/xml/PMC5123381.xml	Jr3	625284 : 625287	CM	auer1, Craig L Slingluff Jr3, Osama E Rahma4         
./___Corpus/Medline/xml/PMC5123381.xml	CC	625373 : 625375	CM	     Cholangiocarcinoma (CC) is an uncommon malignan
./___Corpus/Medline/xml/PMC5123381.xml	CC	625589 : 625591	CM	 characterization of the CC TME is not well understo
./___Corpus/Medline/xml/PMC5123381.xml	CC	625679 : 625681	CM	e analysis of the TME of CC in order to identify new
./___Corpus/Medline/xml/PMC5123381.xml	CC	625828 : 625830	CM	nalysis was conducted of CC tumor samples at the Uni
./___Corpus/Medline/xml/PMC5123381.xml	2000–	625880 : 625885	CPR	versity of Virginia from 2000–2014. Tissue microarrays 
./___Corpus/Medline/xml/PMC5123381.xml	TMAs	625911 : 625915	CM	014. Tissue microarrays (TMAs) were constructed of 3–4
./___Corpus/Medline/xml/PMC5123381.xml	3–	625937 : 625939	CPR	MAs) were constructed of 3–4 cores from each tumor a
./___Corpus/Medline/xml/PMC5123381.xml	CD4	626150 : 626153	CM	ositive effector signal (CD4, CD8, CD14, CD40, CD45, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	626155 : 626158	CM	ve effector signal (CD4, CD8, CD14, CD40, CD45, CD45R
./___Corpus/Medline/xml/PMC5123381.xml	CD14	626160 : 626164	CM	fector signal (CD4, CD8, CD14, CD40, CD45, CD45RO, CD5
./___Corpus/Medline/xml/PMC5123381.xml	CD40	626166 : 626170	CM	 signal (CD4, CD8, CD14, CD40, CD45, CD45RO, CD56, CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD45	626172 : 626176	CM	l (CD4, CD8, CD14, CD40, CD45, CD45RO, CD56, CD68, CD6
./___Corpus/Medline/xml/PMC5123381.xml	CD45RO	626178 : 626184	CM	, CD8, CD14, CD40, CD45, CD45RO, CD56, CD68, CD69, CD83,
./___Corpus/Medline/xml/PMC5123381.xml	CD56	626186 : 626190	CM	D14, CD40, CD45, CD45RO, CD56, CD68, CD69, CD83, granz
./___Corpus/Medline/xml/PMC5123381.xml	CD68	626192 : 626196	CM	D40, CD45, CD45RO, CD56, CD68, CD69, CD83, granzyme, a
./___Corpus/Medline/xml/PMC5123381.xml	CD69	626198 : 626202	CM	D45, CD45RO, CD56, CD68, CD69, CD83, granzyme, and OX4
./___Corpus/Medline/xml/PMC5123381.xml	CD83	626204 : 626208	CM	D45RO, CD56, CD68, CD69, CD83, granzyme, and OX40) and
./___Corpus/Medline/xml/PMC5123381.xml	OX40	626224 : 626228	CM	D69, CD83, granzyme, and OX40) and a negative suppress
./___Corpus/Medline/xml/PMC5123381.xml	CD163	626271 : 626276	CM	uppressor signal (FoxP3, CD163, TIM3, LAG3, and IDO). T
./___Corpus/Medline/xml/PMC5123381.xml	TIM3	626278 : 626282	CM	or signal (FoxP3, CD163, TIM3, LAG3, and IDO). TMAs we
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	626284 : 626288	CM	nal (FoxP3, CD163, TIM3, LAG3, and IDO). TMAs were sca
./___Corpus/Medline/xml/PMC5123381.xml	IDO	626294 : 626297	CM	, CD163, TIM3, LAG3, and IDO). TMAs were scanned usin
./___Corpus/Medline/xml/PMC5123381.xml	TMAs	626300 : 626304	CM	3, TIM3, LAG3, and IDO). TMAs were scanned using the L
./___Corpus/Medline/xml/PMC5123381.xml	SCN400	626334 : 626340	CM	 scanned using the Leica SCN400 and was analyzed using t
./___Corpus/Medline/xml/PMC5123381.xml	p-	626622 : 626624	CPR	proportional hazard with p-values < 0.05 being consi
./___Corpus/Medline/xml/PMC5123381.xml	CC	626743 : 626745	CM	             Ninety-nine CC tumors were available fo
./___Corpus/Medline/xml/PMC5123381.xml	CC	626855 : 626857	CM	, 37 hilar and 36 distal CC. In univariate analysis,
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	626894 : 626899	CM	ate analysis, increasing CD56+ (HR: 1.75; CI: 1.24-2.46
./___Corpus/Medline/xml/PMC5123381.xml	CI	626911 : 626913	CM	reasing CD56+ (HR: 1.75; CI: 1.24-2.46), p + (HR: 1.
./___Corpus/Medline/xml/PMC5123381.xml	CI	626942 : 626944	CM	24-2.46), p + (HR: 1.07; CI: 1.02-1.12, p = 0.007) i
./___Corpus/Medline/xml/PMC5123381.xml	CD163+	627028 : 627034	CM	ted with worse survival. CD163+ infiltration trended tow
./___Corpus/Medline/xml/PMC5123381.xml	CI	627110 : 627112	CM	e in survival (HR: 1.19; CI: 0.9-1.43, p = 0.06) whi
./___Corpus/Medline/xml/PMC5123381.xml	CD40+	627140 : 627145	CM	.9-1.43, p = 0.06) while CD40+ infiltration trended tow
./___Corpus/Medline/xml/PMC5123381.xml	CI	627221 : 627223	CM	e in survival (HR: 0.66; CI: 0.42-1.05, p = 0.08).  
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	627297 : 627302	CM	ons                      CD56+ cell infiltration into c
./___Corpus/Medline/xml/PMC5123381.xml	CD56+	627499 : 627504	CM	nderstand to the role of CD56+ cells in CC.            
./___Corpus/Medline/xml/PMC5123381.xml	CC	627514 : 627516	CM	e role of CD56+ cells in CC.                  P392 D
./___Corpus/Medline/xml/PMC5123381.xml	Adams2	627699 : 627705	CM	g2, Kate A Saser2, Homer Adams2, Christina E Tognon1, Te
./___Corpus/Medline/xml/PMC5123381.xml	W	627784 : 627785	CM	, Marc Loriaux1, Jeffery W Tyner1, Brian J Druker3,
./___Corpus/Medline/xml/PMC5123381.xml	Tyner1	627786 : 627792	CM	Marc Loriaux1, Jeffery W Tyner1, Brian J Druker3, Evan F
./___Corpus/Medline/xml/PMC5123381.xml	AML	628025 : 628028	CM	 acute myeloid leukemia (AML). The goal of the immuno
./___Corpus/Medline/xml/PMC5123381.xml	AML	628166 : 628169	CM	 marrow of patients with AML, understand their differ
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	628586 : 628594	CM	on the proliferative and cytokine production capacity of T
./___Corpus/Medline/xml/PMC5123381.xml	CyTOF	628780 : 628785	CM	ed using mass cytometry (CyTOF). Primary AML bone marro
./___Corpus/Medline/xml/PMC5123381.xml	AML	628796 : 628799	CM	tometry (CyTOF). Primary AML bone marrow samples were
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	629020 : 629028	CM	oliferative capacity and cytokine production profile of AM
./___Corpus/Medline/xml/PMC5123381.xml	CD3	629090 : 629093	CM	w T cells in response to CD3 stimulation in the conte
./___Corpus/Medline/xml/PMC5123381.xml	CD3	629865 : 629868	CM	oliferate in response to CD3 ligation. We have found 
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	629992 : 630000	CM	T cell proliferation and cytokine production.             
./___Corpus/Medline/xml/PMC5123381.xml	CD4	630432 : 630435	CM	            P393 Tim-3 + CD4 + CD25hiFOXP3+ regulator
./___Corpus/Medline/xml/PMC5123381.xml	CD25hiFOXP3+	630438 : 630450	CM	      P393 Tim-3 + CD4 + CD25hiFOXP3+ regulatory T cells under
./___Corpus/Medline/xml/PMC5123381.xml	Lu1	630568 : 630571	CM	  Zhuqing Liu1, Shanhong Lu1, Lawrence P Kane2, Rober
./___Corpus/Medline/xml/PMC5123381.xml	P	630582 : 630583	CM	, Shanhong Lu1, Lawrence P Kane2, Robert L Ferris3 
./___Corpus/Medline/xml/PMC5123381.xml	Kane2	630584 : 630589	CM	Shanhong Lu1, Lawrence P Kane2, Robert L Ferris3 Backgr
./___Corpus/Medline/xml/PMC5123381.xml	Ferris3	630600 : 630607	CM	wrence P Kane2, Robert L Ferris3 Background              
./___Corpus/Medline/xml/PMC5123381.xml	TIL	630793 : 630796	CM	nfiltrating lymphocytes (TIL). Tim-3 was first identi
./___Corpus/Medline/xml/PMC5123381.xml	Th1	630829 : 630832	CM	 was first identified on Th1 T cells as a negative re
./___Corpus/Medline/xml/PMC5123381.xml	Tim-3	630980 : 630985	CM	f human Tregs expressing Tim-3 remains unclear.        
./___Corpus/Medline/xml/PMC5123381.xml	Tim-3	631096 : 631101	CM	fresh HNSCC TIL based on Tim-3 expression. Gene express
./___Corpus/Medline/xml/PMC5123381.xml	RNA	631155 : 631158	CM	profiling and NanoString RNA analysis were used to co
./___Corpus/Medline/xml/PMC5123381.xml	Tim-3+	631266 : 631272	CM	d phenotypic features of Tim-3+ and Tim-3− Treg in fresh
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	631309 : 631314	CM	Treg in freshly isolated HNSCC patient TILs were tested
./___Corpus/Medline/xml/PMC5123381.xml	TIL	631446 : 631449	CM	3+ Treg from human HNSCC TIL display a more effector-
./___Corpus/Medline/xml/PMC5123381.xml	CD39	631625 : 631629	CM	ore robust expression of CD39, CTLA-4, PD-1, granzyme 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	631639 : 631643	CM	ression of CD39, CTLA-4, PD-1, granzyme B, IFN-γ recep
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	631657 : 631662	CM	TLA-4, PD-1, granzyme B, IFN-γ receptor and IFN-γ by fl
./___Corpus/Medline/xml/PMC5123381.xml	IFN-γ	631676 : 631681	CM	me B, IFN-γ receptor and IFN-γ by flow cytometry. Despi
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	631791 : 631795	CM	ity for inhibiting naïve CD8+ T cell proliferation and
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	631832 : 631840	CM	iferation and subsequent cytokine production than Tim-3− T
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	631955 : 631960	CM	ly reversed by exogenous IFN-g treatment.              
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	632201 : 632209	CM	T cell proliferation and cytokine production. Induction of
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	632235 : 632240	CM	production. Induction of IFN-g by successful immunother
./___Corpus/Medline/xml/PMC5123381.xml	PD-1+	632439 : 632444	CM	                    P394 PD-1+/OX40+ Tregs in head and 
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	632445 : 632450	CM	              P394 PD-1+/OX40+ Tregs in head and neck s
./___Corpus/Medline/xml/PMC5123381.xml	Lu1	632590 : 632593	CM	idanna Shayan1, Shanhong Lu1, Robert L Ferris2 Backgr
./___Corpus/Medline/xml/PMC5123381.xml	Ferris2	632604 : 632611	CM	, Shanhong Lu1, Robert L Ferris2 Background              
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	632644 : 632650	CM	und                      FOXP3+ regulatory T cells (Treg
./___Corpus/Medline/xml/PMC5123381.xml	TIL	632922 : 632925	CM	nfiltrating lymphocytes (TIL) with multiple immune ch
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	632990 : 632994	CM	or expression, including PD-1 and OX40, directly from 
./___Corpus/Medline/xml/PMC5123381.xml	OX40	632999 : 633003	CM	sion, including PD-1 and OX40, directly from head and 
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633162 : 633167	CM	ted from freshly excised HNSCC tumors and matched perip
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633240 : 633245	CM	etry was conducted using HNSCC lymphocytes and in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	633265 : 633270	CM	HNSCC lymphocytes and in vitro functional assays were p
./___Corpus/Medline/xml/PMC5123381.xml	TIL	633317 : 633320	CM	e performed using sorted TIL or circulating T cells. 
./___Corpus/Medline/xml/PMC5123381.xml	CD4	633391 : 633394	CM	lts                      CD4+CD25hiFOXP3+ Tregs were 
./___Corpus/Medline/xml/PMC5123381.xml	CD25hiFOXP3+	633395 : 633407	CM	                     CD4+CD25hiFOXP3+ Tregs were more frequent
./___Corpus/Medline/xml/PMC5123381.xml	HNSCC	633436 : 633441	CM	gs were more frequent in HNSCC TIL vs PBL (52.7 % vs 11
./___Corpus/Medline/xml/PMC5123381.xml	TIL	633442 : 633445	CM	e more frequent in HNSCC TIL vs PBL (52.7 % vs 11.5 %
./___Corpus/Medline/xml/PMC5123381.xml	PBL	633449 : 633452	CM	frequent in HNSCC TIL vs PBL (52.7 % vs 11.5 % of CD4
./___Corpus/Medline/xml/PMC5123381.xml	CD4	633474 : 633477	CM	PBL (52.7 % vs 11.5 % of CD4+CD25hi immune infiltrate
./___Corpus/Medline/xml/PMC5123381.xml	84a	633518 : 633521	CM	nfiltrate, n = 10) (Fig. 84a). HNSCC Tregs expressed 
./___Corpus/Medline/xml/PMC5123381.xml	OX40	633577 : 633581	CM	icantly higher levels of OX40 (70.8 % of FOXP3+ cell p
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	633593 : 633599	CM	evels of OX40 (70.8 % of FOXP3+ cell population, n = 10 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	633636 : 633640	CM	tion, n = 10 tumors) and PD-1 (26.6 %, n = 9) than Tre
./___Corpus/Medline/xml/PMC5123381.xml	84b	633769 : 633772	CM	ion (p + CD25high) (Fig. 84b). Double-positive (PD-1+
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	633792 : 633796	CM	. 84b). Double-positive (PD-1+OX40+) TIL Tregs had a m
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	633797 : 633802	CM	). Double-positive (PD-1+OX40+) TIL Tregs had a more su
./___Corpus/Medline/xml/PMC5123381.xml	TIL	633804 : 633807	CM	le-positive (PD-1+OX40+) TIL Tregs had a more suppres
./___Corpus/Medline/xml/PMC5123381.xml	PD-1+	633869 : 633874	CM	pe than single-positive (PD-1+ or OX40+) TIL Tregs (Fig
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	633878 : 633883	CM	ingle-positive (PD-1+ or OX40+) TIL Tregs (Fig. 84c, 84
./___Corpus/Medline/xml/PMC5123381.xml	TIL	633885 : 633888	CM	ositive (PD-1+ or OX40+) TIL Tregs (Fig. 84c, 84d), i
./___Corpus/Medline/xml/PMC5123381.xml	84c	633901 : 633904	CM	r OX40+) TIL Tregs (Fig. 84c, 84d), including the abi
./___Corpus/Medline/xml/PMC5123381.xml	TGF-b	633974 : 633979	CM	and to express IL-10 and TGF-b–associated LAP (Fig. 84e
./___Corpus/Medline/xml/PMC5123381.xml	84e	634001 : 634004	CM	F-b–associated LAP (Fig. 84e). Double-positive (PD-1+
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	634024 : 634028	CM	. 84e). Double-positive (PD-1+OX40+) TIL Tregs also si
./___Corpus/Medline/xml/PMC5123381.xml	OX40+	634029 : 634034	CM	). Double-positive (PD-1+OX40+) TIL Tregs also signific
./___Corpus/Medline/xml/PMC5123381.xml	TIL	634036 : 634039	CM	le-positive (PD-1+OX40+) TIL Tregs also significantly
./___Corpus/Medline/xml/PMC5123381.xml	OX40	634104 : 634108	CM	ctor T cells. Triggering OX40 with the an agonistic mA
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	634219 : 634223	CM	ng to increased effector CD4+ or CD8+ T cell prolifera
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	634227 : 634231	CM	creased effector CD4+ or CD8+ T cell proliferation.   
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	634360 : 634364	CM	going efforts to improve PD-1 or OX40-based immunother
./___Corpus/Medline/xml/PMC5123381.xml	OX40	634368 : 634372	CM	forts to improve PD-1 or OX40-based immunotherapy in H
./___Corpus/Medline/xml/PMC5123381.xml	W	634669 : 634670	CM	ane, Jamie Booth, Amanda W. Lund Background        
./___Corpus/Medline/xml/PMC5123381.xml	murine	635100 : 635106	CM	umor microenvironment of murine melanoma remains complet
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	635261 : 635265	CM	ous metastatic melanoma (TCGA), we identified positive
./___Corpus/Medline/xml/PMC5123381.xml	S-100	635878 : 635883	CM	ection of 10 biomarkers (S-100, CD8a, CD68, CD31, D2-40
./___Corpus/Medline/xml/PMC5123381.xml	CD8a	635885 : 635889	CM	of 10 biomarkers (S-100, CD8a, CD68, CD31, D2-40, Lyve
./___Corpus/Medline/xml/PMC5123381.xml	CD68	635891 : 635895	CM	biomarkers (S-100, CD8a, CD68, CD31, D2-40, Lyve1, Pro
./___Corpus/Medline/xml/PMC5123381.xml	CD31	635897 : 635901	CM	kers (S-100, CD8a, CD68, CD31, D2-40, Lyve1, Prox1, Fa
./___Corpus/Medline/xml/PMC5123381.xml	D2-40	635903 : 635908	CM	S-100, CD8a, CD68, CD31, D2-40, Lyve1, Prox1, FasL, PD-
./___Corpus/Medline/xml/PMC5123381.xml	Lyve1	635910 : 635915	CM	CD8a, CD68, CD31, D2-40, Lyve1, Prox1, FasL, PD-L1, PD-
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	635930 : 635935	CM	-40, Lyve1, Prox1, FasL, PD-L1, PD-1) within a single F
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	635937 : 635941	CM	ve1, Prox1, FasL, PD-L1, PD-1) within a single FFPE se
./___Corpus/Medline/xml/PMC5123381.xml	FFPE	635959 : 635963	CM	1, PD-1) within a single FFPE section. Tissue regions 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636036 : 636040	CM	ma borders and show high CD8+ T cell infiltrates are s
./___Corpus/Medline/xml/PMC5123381.xml	CD68	636588 : 636592	CM	ematopoietic infiltrate (CD68 and CD8) also appear to 
./___Corpus/Medline/xml/PMC5123381.xml	CD8	636597 : 636600	CM	tic infiltrate (CD68 and CD8) also appear to demonstr
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636750 : 636754	CM	ssels, blood vessels and CD8+ T cells are enriched in 
./___Corpus/Medline/xml/PMC5123381.xml	CD68+	636793 : 636798	CM	nriched in stroma, while CD68+ cells are homogenously d
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	636976 : 636980	CM	erestingly, intratumoral CD8+ T cells and stromal lymp
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	637083 : 637087	CM	            Intratumoral CD8+ T cells are predictive o
./___Corpus/Medline/xml/PMC5123381.xml	anti-	637343 : 637348	CPR	iltrates and the in situ anti-tumor response. Our data,
./___Corpus/Medline/xml/PMC5123381.xml	anti-	637527 : 637532	CPR	 active component of the anti-tumor immune response. Fu
./___Corpus/Medline/xml/PMC5123381.xml	CD103	637760 : 637765	CM	                    P396 CD103 and CD49a expression on 
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	637770 : 637775	CM	          P396 CD103 and CD49a expression on melanoma-d
./___Corpus/Medline/xml/PMC5123381.xml	Jr2	637981 : 637984	CM	guez1, Craig L Slingluff Jr2, Victor H Engelhard1 Bac
./___Corpus/Medline/xml/PMC5123381.xml	H	637993 : 637994	CM	 L Slingluff Jr2, Victor H Engelhard1 Background   
./___Corpus/Medline/xml/PMC5123381.xml	TRM	638062 : 638065	CM	 Tissue resident memory (TRM) cells are found in cert
./___Corpus/Medline/xml/PMC5123381.xml	TRM	638169 : 638172	CM	ions that generate them. TRM formation is induced by 
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	638197 : 638201	CM	 formation is induced by TGFβ and has been associated 
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638247 : 638252	CM	ted with upregulation of CD103 and CD49a. Interaction o
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	638257 : 638262	CM	pregulation of CD103 and CD49a. Interaction of CD103 an
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638279 : 638284	CM	nd CD49a. Interaction of CD103 and CD49a with their res
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	638289 : 638294	CM	Interaction of CD103 and CD49a with their respective li
./___Corpus/Medline/xml/PMC5123381.xml	TRM	638370 : 638373	CM	long term persistence of TRM cells in peripheral tiss
./___Corpus/Medline/xml/PMC5123381.xml	CD103	638449 : 638454	CM	 increased expression of CD103 and CD49a has been obser
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	638459 : 638464	CM	 expression of CD103 and CD49a has been observed on tum
./___Corpus/Medline/xml/PMC5123381.xml	TIL	638518 : 638521	CM	nfiltrating lymphocytes (TIL) compared to PBMCs. Thes
./___Corpus/Medline/xml/PMC5123381.xml	PBMCs	638535 : 638540	CM	ocytes (TIL) compared to PBMCs. These phenotypic simila
./___Corpus/Medline/xml/PMC5123381.xml	TIL	638597 : 638600	CM	suggest that a subset of TIL might function as TRM. H
./___Corpus/Medline/xml/PMC5123381.xml	TRM	638619 : 638622	CM	of TIL might function as TRM. However, the impact of 
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	638699 : 638703	CM	tion and/or differential TGFβ expression levels on thi
./___Corpus/Medline/xml/PMC5123381.xml	TIL	638742 : 638745	CM	vels on this property of TIL is currently unknown.   
./___Corpus/Medline/xml/PMC5123381.xml	B16-OVA	638878 : 638885	CM	were injected with 4x105 B16-OVA or B16-F1-shTGFb/shNEG c
./___Corpus/Medline/xml/PMC5123381.xml	vitro	639201 : 639206	CM	r flow cytometry. For in vitro studies, bulk splenocyte
./___Corpus/Medline/xml/PMC5123381.xml	OT-1	639234 : 639238	CM	udies, bulk splenocytes (OT-1 mice) or PBMC (human nor
./___Corpus/Medline/xml/PMC5123381.xml	PBMC	639248 : 639252	CM	lenocytes (OT-1 mice) or PBMC (human normal donor) wer
./___Corpus/Medline/xml/PMC5123381.xml	2–	639292 : 639294	CPR	donor) were cultured for 2–7 days in presence of CD3
./___Corpus/Medline/xml/PMC5123381.xml	CD3	639316 : 639319	CM	 2–7 days in presence of CD3 and CD28 stimulating ant
./___Corpus/Medline/xml/PMC5123381.xml	CD28	639324 : 639328	CM	s in presence of CD3 and CD28 stimulating antibodies a
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	639379 : 639383	CM	d/or 5 ng/ml recombinant TGFβ.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	murine	639461 : 639467	CM	 we demonstrate that, in murine B16-OVA and human melano
./___Corpus/Medline/xml/PMC5123381.xml	B16-OVA	639468 : 639475	CM	onstrate that, in murine B16-OVA and human melanoma tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639503 : 639507	CM	d human melanoma tumors, CD8+ TIL co-express CD49a and
./___Corpus/Medline/xml/PMC5123381.xml	TIL	639508 : 639511	CM	an melanoma tumors, CD8+ TIL co-express CD49a and CD1
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	639523 : 639528	CM	ors, CD8+ TIL co-express CD49a and CD103. Additionally,
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639533 : 639538	CM	TIL co-express CD49a and CD103. Additionally, relative 
./___Corpus/Medline/xml/PMC5123381.xml	CD49a	639577 : 639582	CM	, relative expression of CD49a and CD103 differs on TIL
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639587 : 639592	CM	 expression of CD49a and CD103 differs on TIL in subcut
./___Corpus/Medline/xml/PMC5123381.xml	TIL	639604 : 639607	CM	49a and CD103 differs on TIL in subcutaneous versus i
./___Corpus/Medline/xml/PMC5123381.xml	murine	639647 : 639653	CM	s versus intraperitoneal murine tumors, as well as betwe
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	639774 : 639782	CM	tified a small subset of CD103pos CD8+ TIL that express CD
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639783 : 639787	CM	small subset of CD103pos CD8+ TIL that express CD127 a
./___Corpus/Medline/xml/PMC5123381.xml	CD127	639805 : 639810	CM	os CD8+ TIL that express CD127 and CD69. However, the m
./___Corpus/Medline/xml/PMC5123381.xml	CD69	639815 : 639819	CM	L that express CD127 and CD69. However, the majority o
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	639846 : 639854	CM	However, the majority of CD103pos CD8+ TIL express no CD12
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	639855 : 639859	CM	the majority of CD103pos CD8+ TIL express no CD127. La
./___Corpus/Medline/xml/PMC5123381.xml	TIL	639860 : 639863	CM	ajority of CD103pos CD8+ TIL express no CD127. Lastly
./___Corpus/Medline/xml/PMC5123381.xml	CD127	639875 : 639880	CM	3pos CD8+ TIL express no CD127. Lastly, we show that, d
./___Corpus/Medline/xml/PMC5123381.xml	CD103	639954 : 639959	CM	edge on the induction of CD103 expression by TGFβ, secr
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	639974 : 639978	CM	n of CD103 expression by TGFβ, secretion of this cytok
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	639998 : 640006	CM	 TGFβ, secretion of this cytokine by tumor cells is not re
./___Corpus/Medline/xml/PMC5123381.xml	CD103	640042 : 640047	CM	ells is not required for CD103 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	640249 : 640253	CM	hich may be dependent on TGFβ levels. Furthermore, we 
./___Corpus/Medline/xml/PMC5123381.xml	CD103pos	640308 : 640316	CM	d that a small subset of CD103pos CD8+ TIL appear to be au
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	640317 : 640321	CM	small subset of CD103pos CD8+ TIL appear to be authent
./___Corpus/Medline/xml/PMC5123381.xml	TIL	640322 : 640325	CM	 subset of CD103pos CD8+ TIL appear to be authentic T
./___Corpus/Medline/xml/PMC5123381.xml	TRM	640349 : 640352	CM	L appear to be authentic TRM, however the majority ma
./___Corpus/Medline/xml/PMC5123381.xml	TIL	640452 : 640455	CM	ially anergic/exhausted, TIL. Taken together, our res
./___Corpus/Medline/xml/PMC5123381.xml	CD103	640529 : 640534	CM	stions about the role of CD103 on non-TRM-like TIL and 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	640551 : 640554	CM	of CD103 on non-TRM-like TIL and the importance of TG
./___Corpus/Medline/xml/PMC5123381.xml	TGFβ	640577 : 640581	CM	IL and the importance of TGFβ in the establishment of 
./___Corpus/Medline/xml/PMC5123381.xml	TIL	640612 : 640615	CM	e establishment of these TIL.                        
./___Corpus/Medline/xml/PMC5123381.xml	GARP	640748 : 640752	CM	ic surface expression of GARP                         
./___Corpus/Medline/xml/PMC5123381.xml	Wu	640818 : 640820	CM	essandra Metelli, Bill X Wu, Caroline W Fugle, Rachi
./___Corpus/Medline/xml/PMC5123381.xml	Caroline	640822 : 640830	CM	ndra Metelli, Bill X Wu, Caroline W Fugle, Rachidi Saleh, 
./___Corpus/Medline/xml/PMC5123381.xml	W	640831 : 640832	CM	lli, Bill X Wu, Caroline W Fugle, Rachidi Saleh, Sh
./___Corpus/Medline/xml/PMC5123381.xml	Wu	640876 : 640878	CM	eh, Shaoli Sun, Jennifer Wu, Bei Liu, Zihai Li      
./___Corpus/Medline/xml/PMC5123381.xml	Li	640895 : 640897	CM	nifer Wu, Bei Liu, Zihai Li                  Backgro
./___Corpus/Medline/xml/PMC5123381.xml	TGF-β	640959 : 640964	CM	             The role of TGF-β in oncogenesis and immun
./___Corpus/Medline/xml/PMC5123381.xml	TGF-β	641039 : 641044	CM	zed [1]. Membrane Latent TGF-β is highly expressed on t
./___Corpus/Medline/xml/PMC5123381.xml	GARP	641188 : 641192	CM	ons Predominant Protein (GARP). Several lines of evide
./___Corpus/Medline/xml/PMC5123381.xml	GARP	641234 : 641238	CM	of evidence suggest that GARP enhances the conversion 
./___Corpus/Medline/xml/PMC5123381.xml	TGF-β	641286 : 641291	CM	n of the membrane Latent TGF-β in its active form [2]. 
./___Corpus/Medline/xml/PMC5123381.xml	GARP	641591 : 641595	CM	 was performed by ELISA. GARP function in metastatic a
./___Corpus/Medline/xml/PMC5123381.xml	GARP	641694 : 641698	CM	preclinical models where GARP expression was either en
./___Corpus/Medline/xml/PMC5123381.xml	anti-	641767 : 641772	CPR	own. Therapeutic role of anti-GARP antibody was assesse
./___Corpus/Medline/xml/PMC5123381.xml	GARP	641910 : 641914	CM	   We herein report that GARP is aberrantly expressed 
./___Corpus/Medline/xml/PMC5123381.xml	GARP	642111 : 642115	CM	portantly, expression of GARP inversely correlates wit
./___Corpus/Medline/xml/PMC5123381.xml	GARP	642203 : 642207	CM	 the presence of soluble GARP in prostate cancer patie
./___Corpus/Medline/xml/PMC5123381.xml	GARP	642283 : 642287	CM	concentration of soluble GARP is higher in cancer pati
./___Corpus/Medline/xml/PMC5123381.xml	GARP	642389 : 642393	CM	trategies, we found that GARP expression in multiple a
./___Corpus/Medline/xml/PMC5123381.xml	TGF-β	642477 : 642482	CM	ioavailability of active TGF-β, promoted regulatory T l
./___Corpus/Medline/xml/PMC5123381.xml	anti-	642668 : 642673	CPR	ly, we tested a panel of anti-GARP antibodies, alone an
./___Corpus/Medline/xml/PMC5123381.xml	cyclophosphamide	642720 : 642736	CM	 and in combination with cyclophosphamide, in a mouse model of mam
./___Corpus/Medline/xml/PMC5123381.xml	anti-	642817 : 642822	CPR	at they have significant anti-tumor activity especially
./___Corpus/Medline/xml/PMC5123381.xml	GARP	642963 : 642967	CM	        We conclude that GARP is expressed on several 
./___Corpus/Medline/xml/PMC5123381.xml	GARP	643075 : 643079	CM	gnosis. Mechanistically, GARP increases the availabili
./___Corpus/Medline/xml/PMC5123381.xml	GARP-TGF-β	643215 : 643225	CM	observations, we propose GARP-TGF-β as a novel oncogenic axi
./___Corpus/Medline/xml/PMC5123381.xml	R	643384 : 643385	CM	              1. Derynck R, Akhurst RJ, Balmain A: 
./___Corpus/Medline/xml/PMC5123381.xml	RJ	643395 : 643397	CM	   1. Derynck R, Akhurst RJ, Balmain A: TGF-beta sig
./___Corpus/Medline/xml/PMC5123381.xml	TGF-beta	643410 : 643418	CM	, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppr
./___Corpus/Medline/xml/PMC5123381.xml	117–	643493 : 643497	CPR	sion. Nat Genet 2001, 29:117–129.                     
./___Corpus/Medline/xml/PMC5123381.xml	DQ	643548 : 643550	CM	                 2. Tran DQ, et al.: GARP (LRRC32) i
./___Corpus/Medline/xml/PMC5123381.xml	GARP	643560 : 643564	CM	     2. Tran DQ, et al.: GARP (LRRC32) is essential fo
./___Corpus/Medline/xml/PMC5123381.xml	TGF-beta	643624 : 643632	CM	ace expression of latent TGF-beta on platelets and activat
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3+	643660 : 643666	CM	 platelets and activated FOXP3+ regulatory T cells. PNAS
./___Corpus/Medline/xml/PMC5123381.xml	PNAS	643687 : 643691	CM	XP3+ regulatory T cells. PNAS 2009, 106:13445–13450.  
./___Corpus/Medline/xml/PMC5123381.xml	13445–	643702 : 643708	CPR	 T cells. PNAS 2009, 106:13445–13450.                   
./___Corpus/Medline/xml/PMC5123381.xml	Morris1	643939 : 643946	CM	              Zachary S. Morris1, Emily I Guy1, Clinton H
./___Corpus/Medline/xml/PMC5123381.xml	R	644021 : 644022	CM	nica M Gressett1, Lauryn R Werner1, Stephen D Gilli
./___Corpus/Medline/xml/PMC5123381.xml	hu14.18-IL2	644311 : 644322	CM	umoral (IT) injection of hu14.18-IL2 immunocytokine (IC, anti
./___Corpus/Medline/xml/PMC5123381.xml	anti-	644343 : 644348	CPR	-IL2 immunocytokine (IC, anti-GD2 antibody linked to IL
./___Corpus/Medline/xml/PMC5123381.xml	IL2	644371 : 644374	CM	i-GD2 antibody linked to IL2) in mice bearing a singl
./___Corpus/Medline/xml/PMC5123381.xml	B78(GD2+)	644898 : 644907	CM	ith one or two syngeneic B78(GD2+) melanomas or Panc02(GD2-
./___Corpus/Medline/xml/PMC5123381.xml	GD2+	644935 : 644939	CM	lanomas or Panc02(GD2- & GD2+ subclones) pancreatic tu
./___Corpus/Medline/xml/PMC5123381.xml	IgG	645088 : 645091	CM	d by IT-IC or IT-control IgG (50 μg days 6–10 after R
./___Corpus/Medline/xml/PMC5123381.xml	6–	645104 : 645106	CPR	-control IgG (50 μg days 6–10 after RT). C57BL/6 DER
./___Corpus/Medline/xml/PMC5123381.xml	B78(GD2+)	645468 : 645477	CM	  In mice bearing single B78(GD2+) or Panc02(GD2+) tumors, 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2+)	645481 : 645493	CM	ring single B78(GD2+) or Panc02(GD2+) tumors, combined treatme
./___Corpus/Medline/xml/PMC5123381.xml	B78	645657 : 645660	CM	ast, in mice bearing two B78 tumors or two Panc02 tum
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	645675 : 645681	CM	ng two B78 tumors or two Panc02 tumors, treatment with R
./___Corpus/Medline/xml/PMC5123381.xml	GD2+	645725 : 645729	CM	with RT and IT-IC to the GD2+ tumor did not improve tu
./___Corpus/Medline/xml/PMC5123381.xml	B78	645867 : 645870	CM	n mice bearing a treated B78 tumor and an untreated d
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2-)	645902 : 645914	CM	and an untreated distant Panc02(GD2-) tumor or those bearing a
./___Corpus/Medline/xml/PMC5123381.xml	Panc02(GD2+)	645948 : 645960	CM	 those bearing a treated Panc02(GD2+) tumor and an untreated d
./___Corpus/Medline/xml/PMC5123381.xml	B78(GD2+)	645992 : 646001	CM	and an untreated distant B78(GD2+) tumor. In these mice wit
./___Corpus/Medline/xml/PMC5123381.xml	B78	646235 : 646238	CM	-IC. In mice bearing two B78 tumors, one treated with
./___Corpus/Medline/xml/PMC5123381.xml	DEREG	646301 : 646306	CM	, depletion of Tregs (in DEREG mice or by anti-CTLA-4 I
./___Corpus/Medline/xml/PMC5123381.xml	anti-	646318 : 646323	CPR	egs (in DEREG mice or by anti-CTLA-4 IgG2a mAb in C57Bl
./___Corpus/Medline/xml/PMC5123381.xml	IgG2a	646330 : 646335	CM	G mice or by anti-CTLA-4 IgG2a mAb in C57Bl/6 mice) fac
./___Corpus/Medline/xml/PMC5123381.xml	C57Bl	646343 : 646348	CM	anti-CTLA-4 IgG2a mAb in C57Bl/6 mice) facilitated a re
./___Corpus/Medline/xml/PMC5123381.xml	B78	646472 : 646475	CM	in mice bearing a single B78 tumor.                  
./___Corpus/Medline/xml/PMC5123381.xml	anti-	646680 : 646685	CPR	 untreated tumors on the anti-tumor efficacy of RT and 
./___Corpus/Medline/xml/PMC5123381.xml	ZS	646806 : 646808	CM	               1. Morris ZS, et al.: In situ tumor v
./___Corpus/Medline/xml/PMC5123381.xml	3929–	646922 : 646927	CPR	ody. Cancer Res 2016, 76:3929–3941.                    
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	647554 : 647558	CM	strated the existence of CD8+ T cells within the tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	647665 : 647669	CM	umor. A portion of these CD8+ T cells are specific to 
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	647923 : 647930	CM	lenged C57BL/6 mice with B16-F10 (105) tumor cells via in
./___Corpus/Medline/xml/PMC5123381.xml	B6	648127 : 648129	CM	lung] to the infection). B6 mice were infected with 
./___Corpus/Medline/xml/PMC5123381.xml	H1N1	648167 : 648171	CM	fected with influenza (A/H1N1/PR8) expressing OVA257–2
./___Corpus/Medline/xml/PMC5123381.xml	PR8	648172 : 648175	CM	d with influenza (A/H1N1/PR8) expressing OVA257–264 (
./___Corpus/Medline/xml/PMC5123381.xml	OVA257	648188 : 648194	CM	 (A/H1N1/PR8) expressing OVA257–264 (FLU-OVA; 10,000 pfu
./___Corpus/Medline/xml/PMC5123381.xml	FLU-OVA	648200 : 648207	CM	) expressing OVA257–264 (FLU-OVA; 10,000 pfu; intranasal 
./___Corpus/Medline/xml/PMC5123381.xml	2–	648255 : 648257	CPR	l administration). Every 2–3 days tumor growth was m
./___Corpus/Medline/xml/PMC5123381.xml	OVA	648454 : 648457	CM	ed by flow cytometry for OVA-specific CD8+ T cells (r
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648467 : 648471	CM	tometry for OVA-specific CD8+ T cells (representing in
./___Corpus/Medline/xml/PMC5123381.xml	tetramer	648526 : 648534	CM	za-specific cells) using tetramer staining. Statistics wer
./___Corpus/Medline/xml/PMC5123381.xml	P	648620 : 648621	CM	est and comparisons with P < 0.05 were considered s
./___Corpus/Medline/xml/PMC5123381.xml	FLU-OVA	648745 : 648752	CM	fection of the lung with FLU-OVA expectedly lead to the e
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648789 : 648793	CM	lead to the expansion of CD8+ T cells specific for OVA
./___Corpus/Medline/xml/PMC5123381.xml	OVA257	648815 : 648821	CM	D8+ T cells specific for OVA257–264 in the lung. Unexpec
./___Corpus/Medline/xml/PMC5123381.xml	OVA257	648911 : 648917	CM	e distal accumulation of OVA257–264-specific T cells (up
./___Corpus/Medline/xml/PMC5123381.xml	264-	648921 : 648925	CPR	ccumulation of OVA257–264-specific T cells (up to 23 %
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	648958 : 648962	CM	cells (up to 23 % of all CD8+ T cells; P < 0.01) in th
./___Corpus/Medline/xml/PMC5123381.xml	P	648972 : 648973	CM	3 % of all CD8+ T cells; P < 0.01) in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	P	649065 : 649066	CM	lerated of tumor growth (P < 0.001). Importantly, i
./___Corpus/Medline/xml/PMC5123381.xml	B16	649108 : 649111	CM	antly, in the context of B16 melanoma in the lung, in
./___Corpus/Medline/xml/PMC5123381.xml	FLU-OVA	649161 : 649168	CM	fection of the lung with FLU-OVA resulted in reduced B16 
./___Corpus/Medline/xml/PMC5123381.xml	B16	649189 : 649192	CM	-OVA resulted in reduced B16 melanoma foci compared t
./___Corpus/Medline/xml/PMC5123381.xml	P	649249 : 649250	CM	fection (38 % reduction; P < 0.01). Melanoma foci w
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	649343 : 649347	CM	 combination FLU-OVA and PD-1 blocking anybody (P < 0.
./___Corpus/Medline/xml/PMC5123381.xml	P	649366 : 649367	CM	d PD-1 blocking anybody (P < 0.01).                
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	649922 : 649926	CM	ent of pathogen-specific CD8+ T cells in the tumor mic
./___Corpus/Medline/xml/PMC5123381.xml	Brech1	650245 : 650251	CM	                Dorothee Brech1, Tobias Straub2, Martin 
./___Corpus/Medline/xml/PMC5123381.xml	Straub2	650260 : 650267	CM	 Dorothee Brech1, Tobias Straub2, Martin Irmler3, Johanne
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	650642 : 650646	CM	cribed that infiltrating CD8+ T effector cells and NK 
./___Corpus/Medline/xml/PMC5123381.xml	CD209+	650947 : 650953	CM	re in close contact with CD209+ myeloid cells, which is 
./___Corpus/Medline/xml/PMC5123381.xml	DC	651080 : 651082	CM	unusual co-expression of DC and macrophage markers. 
./___Corpus/Medline/xml/PMC5123381.xml	DCs	651266 : 651269	CM	iched-in-renal-carcinoma DCs” (ercDCs) [3]. For a dee
./___Corpus/Medline/xml/PMC5123381.xml	vitro	651740 : 651745	CM	uspensions and blood; in vitro generation of reference 
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	651959 : 651963	CM	The Cancer Genome Atlas (TCGA; http://cancergenome.nih
./___Corpus/Medline/xml/PMC5123381.xml	M1	652209 : 652211	CM	bined characteristics of M1- and M2-macrophages and 
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	652517 : 652521	CM	ng the gene signature to TCGA ccRCC expression data (R
./___Corpus/Medline/xml/PMC5123381.xml	RNA	652545 : 652548	CM	A ccRCC expression data (RNA Seq) revealed a signific
./___Corpus/Medline/xml/PMC5123381.xml	P	653315 : 653316	CM	     References 1. Prinz P, et al.: J Immunol 2012,
./___Corpus/Medline/xml/PMC5123381.xml	5990–	653350 : 653355	CPR	 J Immunol 2012, 188(12):5990–6000. 2. Prinz P, et al.:
./___Corpus/Medline/xml/PMC5123381.xml	P	653370 : 653371	CM	(12):5990–6000. 2. Prinz P, et al.: Int J Cancer 20
./___Corpus/Medline/xml/PMC5123381.xml	1832–	653407 : 653412	CPR	nt J Cancer 2014, 135(8):1832–1841. 3. Figel A-M, Brech
./___Corpus/Medline/xml/PMC5123381.xml	A-M	653427 : 653430	CM	5(8):1832–1841. 3. Figel A-M, Brech D, et al.: Am J P
./___Corpus/Medline/xml/PMC5123381.xml	436–	653474 : 653478	CPR	Am J Pathol 2011, 179(1):436–451.                     
./___Corpus/Medline/xml/PMC5123381.xml	murine	653551 : 653557	CM	o-Signaling treatment of murine tumors significantly red
./___Corpus/Medline/xml/PMC5123381.xml	NPES	653801 : 653805	CM	Pulse Electro-Signaling (NPES) refers to the applicati
./___Corpus/Medline/xml/PMC5123381.xml	murine	654069 : 654075	CM	ve previously found that murine cells and tumors exposed
./___Corpus/Medline/xml/PMC5123381.xml	NPES	654120 : 654124	CM	posed to the appropriate NPES can be stimulated to und
./___Corpus/Medline/xml/PMC5123381.xml	CD8	654267 : 654270	CM	y reject that tumor in a CD8-dependent manner. In add
./___Corpus/Medline/xml/PMC5123381.xml	NPES	654382 : 654386	CM	 sub-dermal injection of NPES-treated tumor cells [1].
./___Corpus/Medline/xml/PMC5123381.xml	NPES	654553 : 654557	CM	ronment before and after NPES treatment.              
./___Corpus/Medline/xml/PMC5123381.xml	Murine	654615 : 654621	CM	ods                      Murine MCA205 fibrosarcoma cell
./___Corpus/Medline/xml/PMC5123381.xml	MCA205	654622 : 654628	CM	                  Murine MCA205 fibrosarcoma cells were 
./___Corpus/Medline/xml/PMC5123381.xml	B6	654689 : 654691	CM	bdermally into syngeneic B6 mice to form a tumor. On
./___Corpus/Medline/xml/PMC5123381.xml	NPES	654784 : 654788	CM	 treated it in vivo with NPES (1300 pulses, 300 ns, 30
./___Corpus/Medline/xml/PMC5123381.xml	NPES	655269 : 655273	CM	      Tumor treatment by NPES results in a significant
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	655327 : 655331	CM	uction in both Tregs and CD8+ T cells within the tumor
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	655467 : 655471	CM	igher levels of Treg and CD8+ T cells than those with 
./___Corpus/Medline/xml/PMC5123381.xml	NPES	655688 : 655692	CM	        We conclude that NPES treatment reduces the nu
./___Corpus/Medline/xml/PMC5123381.xml	R	655922 : 655923	CM	           1. Nuccitelli R, Berridge JC, Mallon Z, 
./___Corpus/Medline/xml/PMC5123381.xml	JC	655934 : 655936	CM	. Nuccitelli R, Berridge JC, Mallon Z, Kreis M, Atho
./___Corpus/Medline/xml/PMC5123381.xml	P	655977 : 655978	CM	s M, Athos B, Nuccitelli P: Nanoelectroablation of 
./___Corpus/Medline/xml/PMC5123381.xml	Murine	656003 : 656009	CM	: Nanoelectroablation of Murine Tumors Triggers a CD8-De
./___Corpus/Medline/xml/PMC5123381.xml	CD8	656028 : 656031	CM	Murine Tumors Triggers a CD8-Dependent Inhibition of 
./___Corpus/Medline/xml/PMC5123381.xml	factor-1	656183 : 656191	CM	eting colony stimulating factor-1 receptor (CSF-1R) with S
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	656202 : 656208	CM	ating factor-1 receptor (CSF-1R) with SNDX-6352, a novel
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	656215 : 656224	CM	1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R tar
./___Corpus/Medline/xml/PMC5123381.xml	anti-	656234 : 656239	CPR	 with SNDX-6352, a novel anti-CSF-1R targeted antibody 
./___Corpus/Medline/xml/PMC5123381.xml	Wolfreys2	656328 : 656337	CM	eter Ordentlich1, Alison Wolfreys2, Andre Da Costa3, John S
./___Corpus/Medline/xml/PMC5123381.xml	Andrea	656369 : 656375	CM	 Da Costa3, John Silva2, Andrea Crosby2, Ludovicus Stael
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	656499 : 656505	CM	und                      CSF-1R is expressed on immunosu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	656732 : 656737	CPR	tion of TAMs can enhance anti-tumor immune responses. S
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	656761 : 656770	CM	-tumor immune responses. SNDX-6352 is a humanized IgG4 mono
./___Corpus/Medline/xml/PMC5123381.xml	IgG4	656786 : 656790	CM	SNDX-6352 is a humanized IgG4 monoclonal antibody with
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	656838 : 656844	CM	th high affinity against CSF-1R under investigation for 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	656956 : 656961	CM	                      In vitro binding studies, functio
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	657062 : 657071	CM	utilized to characterize SNDX-6352 and a surrogate rodent a
./___Corpus/Medline/xml/PMC5123381.xml	Ab535	657105 : 657110	CM	rrogate rodent antibody, Ab535. Reported toxicology and
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	657165 : 657174	CM	macodynamics studies for SNDX-6352 were in cynomolgus monke
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	657249 : 657258	CM	lts                      SNDX-6352 binds to human CSF-1R (K
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	657274 : 657280	CM	SNDX-6352 binds to human CSF-1R (KD 4-8pM, Fc-tagged con
./___Corpus/Medline/xml/PMC5123381.xml	KD	657282 : 657284	CM	2 binds to human CSF-1R (KD 4-8pM, Fc-tagged constru
./___Corpus/Medline/xml/PMC5123381.xml	4-	657285 : 657287	CPR	inds to human CSF-1R (KD 4-8pM, Fc-tagged construct)
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	657353 : 657359	CM	s with cynomolgus monkey CSF-1R but not rodent CSF-1R. S
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	657375 : 657381	CM	ey CSF-1R but not rodent CSF-1R. SNDX-6352 has been show
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	657383 : 657392	CM	R but not rodent CSF-1R. SNDX-6352 has been shown to inhibi
./___Corpus/Medline/xml/PMC5123381.xml	IC50	657431 : 657435	CM	n to inhibit both CSF-1 (IC50 270pM) and IL-34 (IC50 1
./___Corpus/Medline/xml/PMC5123381.xml	IC50	657454 : 657458	CM	 (IC50 270pM) and IL-34 (IC50 100pM) induced MCP-1 rel
./___Corpus/Medline/xml/PMC5123381.xml	tCSF-1	657550 : 657556	CM	ty of macrophages during tCSF-1-mediated differentiation
./___Corpus/Medline/xml/PMC5123381.xml	vitro	657593 : 657598	CM	fferentiation process in vitro (IC50 455pM). A dual lig
./___Corpus/Medline/xml/PMC5123381.xml	IC50	657600 : 657604	CM	iation process in vitro (IC50 455pM). A dual ligand bl
./___Corpus/Medline/xml/PMC5123381.xml	Ab535	657663 : 657668	CM	rrogate rodent antibody, Ab535, was generated for precl
./___Corpus/Medline/xml/PMC5123381.xml	MC38	657760 : 657764	CM	t tumor growth in colon (MC38), breast (MCF-7, MDA-MB-
./___Corpus/Medline/xml/PMC5123381.xml	MDA-MB-231	657782 : 657792	CM	n (MC38), breast (MCF-7, MDA-MB-231) and prostate (PC-3) can
./___Corpus/Medline/xml/PMC5123381.xml	PC-3	657808 : 657812	CM	DA-MB-231) and prostate (PC-3) cancer models and enhan
./___Corpus/Medline/xml/PMC5123381.xml	MC38	657874 : 657878	CM	eckpoint blockade in the MC38 model. A 13-week toxicol
./___Corpus/Medline/xml/PMC5123381.xml	13-	657888 : 657891	CPR	ade in the MC38 model. A 13-week toxicology study in 
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	657987 : 657996	CM	venous administration of SNDX-6352 at 10, 30, and 100 mg/kg
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	658164 : 658170	CM	rd and may be related to CSF-1R pharmacology, as it has 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	658220 : 658225	CPR	been observed with other anti-CSF-1R molecules, includi
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	658361 : 658370	CM	to the mode of action of SNDX-6352. Clinical pathology chan
./___Corpus/Medline/xml/PMC5123381.xml	aspartate	658434 : 658443	CM	ose-related increases in aspartate transferase, alanine tra
./___Corpus/Medline/xml/PMC5123381.xml	alanine	658457 : 658464	CM	n aspartate transferase, alanine transferase and glutamat
./___Corpus/Medline/xml/PMC5123381.xml	glutamate	658481 : 658490	CM	 alanine transferase and glutamate dehydrogenase levels cor
./___Corpus/Medline/xml/PMC5123381.xml	dehydrogenase	658491 : 658504	CM	ransferase and glutamate dehydrogenase levels correlating with 
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	658529 : 658538	CM	 levels correlating with SNDX-6352 exposure but not transla
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1R	658664 : 658670	CM	acological inhibition of CSF-1R on Kupffer cells within 
./___Corpus/Medline/xml/PMC5123381.xml	CSF-1	658836 : 658841	CM	ose-related increases in CSF-1 plasma concentration and
./___Corpus/Medline/xml/PMC5123381.xml	CD14	658895 : 658899	CM	reases in non-classical (CD14 + CD16+) monocytes and m
./___Corpus/Medline/xml/PMC5123381.xml	CD16+	658902 : 658907	CM	in non-classical (CD14 + CD16+) monocytes and markers o
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	659038 : 659047	CM	 rapidly reversible upon SNDX-6352 clearance. Changes in bo
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	659196 : 659205	CM	text of this study. Upon SNDX-6352 clearance, all parameter
./___Corpus/Medline/xml/PMC5123381.xml	SNDX-6352	659318 : 659327	CM	ons                      SNDX-6352 is a novel, high affinit
./___Corpus/Medline/xml/PMC5123381.xml	IgG4	659364 : 659368	CM	 high affinity humanized IgG4 anti-CSF-1R antibody ava
./___Corpus/Medline/xml/PMC5123381.xml	anti-	659369 : 659374	CPR	 affinity humanized IgG4 anti-CSF-1R antibody available
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	659515 : 659521	CM	CD47 monoclonal antibody SRF231 is a potent inducer of m
./___Corpus/Medline/xml/PMC5123381.xml	anti-	659597 : 659602	CPR	ell phagocytosis and has anti-tumor activity in preclin
./___Corpus/Medline/xml/PMC5123381.xml	Caroline	659712 : 659720	CM	Paterson, Andrew C Lake, Caroline M Armet, Rachel W O'Conn
./___Corpus/Medline/xml/PMC5123381.xml	W	659737 : 659738	CM	Caroline M Armet, Rachel W O'Connor, Jonathan A Hil
./___Corpus/Medline/xml/PMC5123381.xml	CD47	659922 : 659926	CM	und                      CD47 has been identified as a
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660038 : 660042	CM	on multiple tumor types. CD47 negatively regulates pha
./___Corpus/Medline/xml/PMC5123381.xml	alpha	660123 : 660128	CM	ignal regulatory protein alpha (SIRPα), an inhibitory p
./___Corpus/Medline/xml/PMC5123381.xml	SIRPα	660130 : 660135	CM	egulatory protein alpha (SIRPα), an inhibitory protein 
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660205 : 660209	CM	ages. High expression of CD47 on tumors contributes to
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	660309 : 660319	CM	e. Agents that block the CD47-SIRPα interaction are promisin
./___Corpus/Medline/xml/PMC5123381.xml	CD47+	660401 : 660406	CM	ore phagocytic uptake of CD47+ tumor cells in vitro and
./___Corpus/Medline/xml/PMC5123381.xml	vitro	660422 : 660427	CM	 of CD47+ tumor cells in vitro and attenuate tumor grow
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	660485 : 660491	CM	vo. Here we characterize SRF231, one of a panel of fully
./___Corpus/Medline/xml/PMC5123381.xml	CD47	660523 : 660527	CM	f a panel of fully human CD47 antibodies, and demonstr
./___Corpus/Medline/xml/PMC5123381.xml	transgenic	660716 : 660726	CM	ies were generated using transgenic mice carrying human V re
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	660761 : 660767	CM	ying human V regions and SRF231 was subsequently enginee
./___Corpus/Medline/xml/PMC5123381.xml	vitro	660830 : 660835	CM	l Fc-region variants. In vitro phagocytosis assays were
./___Corpus/Medline/xml/PMC5123381.xml	CFSE	661016 : 661020	CM	w cytometric analysis of CFSE-labeled target cells aft
./___Corpus/Medline/xml/PMC5123381.xml	CD14+	661064 : 661069	CM	ls after incubation with CD14+ macrophages. For in vivo
./___Corpus/Medline/xml/PMC5123381.xml	SCID	661104 : 661108	CM	es. For in vivo studies, SCID mice were injected subcu
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661249 : 661255	CM	lts                      SRF231 binds with high affinity
./___Corpus/Medline/xml/PMC5123381.xml	CD47	661290 : 661294	CM	h high affinity to human CD47 and is a potent blocker 
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	661326 : 661336	CM	 a potent blocker of the CD47-SIRPα interaction. SRF231 enha
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661350 : 661356	CM	 CD47-SIRPα interaction. SRF231 enhances phagocytic upta
./___Corpus/Medline/xml/PMC5123381.xml	vitro	661431 : 661436	CM	 and tumor cell lines in vitro, and does so irrespectiv
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661491 : 661497	CM	macrophage polarization. SRF231-mediated tumor cell phag
./___Corpus/Medline/xml/PMC5123381.xml	CD47	661617 : 661621	CM	portantly, since loss of CD47 expression serves as a m
./___Corpus/Medline/xml/PMC5123381.xml	RBC	661685 : 661688	CM	damaged red blood cells (RBC) and promotes their phag
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661731 : 661737	CM	ir phagocytic clearance, SRF231 does not enhance phagocy
./___Corpus/Medline/xml/PMC5123381.xml	RBC	661818 : 661821	CM	n of human or cynomolgus RBC, despite binding to thes
./___Corpus/Medline/xml/PMC5123381.xml	Fc	661905 : 661907	CM	relative contribution of Fc receptor (FcR) interacti
./___Corpus/Medline/xml/PMC5123381.xml	FcR	661918 : 661921	CM	ribution of Fc receptor (FcR) interactions on SRF231 
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661939 : 661945	CM	or (FcR) interactions on SRF231 mediated activity, we ge
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	661996 : 662002	CM	erated and characterized SRF231 isotypes both with and w
./___Corpus/Medline/xml/PMC5123381.xml	FcR	662152 : 662155	CM	er or no ability to bind FcR. In a tumor xenograft mo
./___Corpus/Medline/xml/PMC5123381.xml	anti-	662236 : 662241	CPR	-specific differences in anti-tumor activity despite ha
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662352 : 662358	CM	ons                      SRF231 binds with high affinity
./___Corpus/Medline/xml/PMC5123381.xml	CD47	662387 : 662391	CM	ds with high affinity to CD47 and potently disrupts th
./___Corpus/Medline/xml/PMC5123381.xml	CD47-SIRPα	662418 : 662428	CM	nd potently disrupts the CD47-SIRPα interaction. SRF231 is u
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662442 : 662448	CM	 CD47-SIRPα interaction. SRF231 is unique in its ability
./___Corpus/Medline/xml/PMC5123381.xml	RBC	662533 : 662536	CM	cytosis without inducing RBC phagocytosis or hemagglu
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662584 : 662590	CM	lutination. In addition, SRF231 shows potent in vivo ant
./___Corpus/Medline/xml/PMC5123381.xml	anti-	662612 : 662617	CPR	231 shows potent in vivo anti-tumor efficacy in preclin
./___Corpus/Medline/xml/PMC5123381.xml	SRF231	662704 : 662710	CM	in combination settings. SRF231 is currently in IND-enab
./___Corpus/Medline/xml/PMC5123381.xml	CD73	662880 : 662884	CM	l molecule inhibitors of CD73 promote human CD8+ T cel
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	662899 : 662903	CM	rs of CD73 promote human CD8+ T cell activation and po
./___Corpus/Medline/xml/PMC5123381.xml	P	663050 : 663051	CM	                     Jay P. Powers, Annette Becker,
./___Corpus/Medline/xml/PMC5123381.xml	R	663096 : 663097	CM	cker, Ada Chen, Manmohan R Leleti, Eric Newcomb, Ho
./___Corpus/Medline/xml/PMC5123381.xml	W	663173 : 663174	CM	er, Joanne BL Tan, Steve W Young, Juan C Jaen      
./___Corpus/Medline/xml/PMC5123381.xml	ATP	663288 : 663291	CM	nvironment extracellular ATP is sequentially hydrolyz
./___Corpus/Medline/xml/PMC5123381.xml	hydrolyzed	663308 : 663318	CM	ular ATP is sequentially hydrolyzed to adenosine by the ecto
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663322 : 663331	CM	quentially hydrolyzed to adenosine by the ecto-nucleotidase
./___Corpus/Medline/xml/PMC5123381.xml	CD39	663358 : 663362	CM	y the ecto-nucleotidases CD39 (ATP → AMP) and CD73 (AM
./___Corpus/Medline/xml/PMC5123381.xml	ATP	663364 : 663367	CM	ecto-nucleotidases CD39 (ATP → AMP) and CD73 (AMP → a
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663370 : 663373	CM	ucleotidases CD39 (ATP → AMP) and CD73 (AMP → adenosi
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663379 : 663383	CM	ses CD39 (ATP → AMP) and CD73 (AMP → adenosine). Adeno
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663385 : 663388	CM	39 (ATP → AMP) and CD73 (AMP → adenosine). Adenosine 
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663391 : 663400	CM	P → AMP) and CD73 (AMP → adenosine). Adenosine is a potent 
./___Corpus/Medline/xml/PMC5123381.xml	Adenosine	663403 : 663412	CM	 CD73 (AMP → adenosine). Adenosine is a potent inhibitor of
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663524 : 663528	CM	, and thus inhibition of CD73 has recently generated m
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663667 : 663671	CM	l molecule inhibitors of CD73.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	CD73	663719 : 663723	CM	ods                      CD73 inhibitor in vitro poten
./___Corpus/Medline/xml/PMC5123381.xml	vitro	663737 : 663742	CM	       CD73 inhibitor in vitro potency was assessed by 
./___Corpus/Medline/xml/PMC5123381.xml	hydrolysis	663781 : 663791	RN	ssessed by measuring the hydrolysis of AMP to adenosine in t
./___Corpus/Medline/xml/PMC5123381.xml	AMP	663795 : 663798	CM	suring the hydrolysis of AMP to adenosine in the pres
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	663802 : 663811	CM	the hydrolysis of AMP to adenosine in the presence of varyi
./___Corpus/Medline/xml/PMC5123381.xml	hCD73	663889 : 663894	CM	endogenously expressing (hCD73/SKOV-3; mCD73/E771) and 
./___Corpus/Medline/xml/PMC5123381.xml	mCD73	663903 : 663908	CM	xpressing (hCD73/SKOV-3; mCD73/E771) and stably over-ex
./___Corpus/Medline/xml/PMC5123381.xml	hCD73	663943 : 663948	CM	 stably over-expressing (hCD73/CHO; hCD39/CHO) cells. S
./___Corpus/Medline/xml/PMC5123381.xml	CHO	663949 : 663952	CM	y over-expressing (hCD73/CHO; hCD39/CHO) cells. Selec
./___Corpus/Medline/xml/PMC5123381.xml	hCD39	663954 : 663959	CM	r-expressing (hCD73/CHO; hCD39/CHO) cells. Selectivity 
./___Corpus/Medline/xml/PMC5123381.xml	CHO	663960 : 663963	CM	essing (hCD73/CHO; hCD39/CHO) cells. Selectivity was 
./___Corpus/Medline/xml/PMC5123381.xml	CHO	664023 : 664026	CM	n transiently expressing CHO cells (mCD73, NTPDase2, 
./___Corpus/Medline/xml/PMC5123381.xml	mCD73	664034 : 664039	CM	ly expressing CHO cells (mCD73, NTPDase2, NTPDase3, and
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	664090 : 664094	CM	NTPDase8). Activity in a CD8+ T cell functional assay 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	664151 : 664155	CM	essed in human and mouse CD8+ T cells which were pretr
./___Corpus/Medline/xml/PMC5123381.xml	CD3	664276 : 664279	CM	 by stimulation (3 days; CD3/CD28 ± 50 mM AMP). Cell 
./___Corpus/Medline/xml/PMC5123381.xml	CD28	664280 : 664284	CM	stimulation (3 days; CD3/CD28 ± 50 mM AMP). Cell activ
./___Corpus/Medline/xml/PMC5123381.xml	AMP	664293 : 664296	CM	3 days; CD3/CD28 ± 50 mM AMP). Cell activation, proli
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664388 : 664392	CM	ified by flow cytometry. CD73 inhibition in a tumor se
./___Corpus/Medline/xml/PMC5123381.xml	CT26	664454 : 664458	CM	sessed in a subcutaneous CT26 tumor model in Balb/c mi
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664623 : 664627	CM	ntrol + isotype control, CD73 inhibitor A000830 + isot
./___Corpus/Medline/xml/PMC5123381.xml	anti-	664683 : 664688	CPR	ntrol, vehicle control + anti-PD-1 Ab, and A000830 + an
./___Corpus/Medline/xml/PMC5123381.xml	Ab	664693 : 664695	CM	icle control + anti-PD-1 Ab, and A000830 + anti-PD-1
./___Corpus/Medline/xml/PMC5123381.xml	anti-	664711 : 664716	CPR	i-PD-1 Ab, and A000830 + anti-PD-1 Ab.                 
./___Corpus/Medline/xml/PMC5123381.xml	Ab	664721 : 664723	CM	 and A000830 + anti-PD-1 Ab.                  Result
./___Corpus/Medline/xml/PMC5123381.xml	CD73	664868 : 664872	CM	 selective inhibitors of CD73 (hCD73/CHO IC50 = 1 nM a
./___Corpus/Medline/xml/PMC5123381.xml	hCD73	664874 : 664879	CM	tive inhibitors of CD73 (hCD73/CHO IC50 = 1 nM and 0.03
./___Corpus/Medline/xml/PMC5123381.xml	CHO	664880 : 664883	CM	nhibitors of CD73 (hCD73/CHO IC50 = 1 nM and 0.03 nM 
./___Corpus/Medline/xml/PMC5123381.xml	IC50	664884 : 664888	CM	itors of CD73 (hCD73/CHO IC50 = 1 nM and 0.03 nM respe
./___Corpus/Medline/xml/PMC5123381.xml	AMP	664978 : 664981	CM	locked the conversion of AMP to adenosine in human CD
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	664985 : 664994	CM	the conversion of AMP to adenosine in human CD8+ T cells (I
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	665004 : 665008	CM	MP to adenosine in human CD8+ T cells (IC50 = 0.2 and 
./___Corpus/Medline/xml/PMC5123381.xml	IC50	665018 : 665022	CM	e in human CD8+ T cells (IC50 = 0.2 and 0.008 nM respe
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665078 : 665087	CM	y) and robustly reversed adenosine-mediated inhibition of p
./___Corpus/Medline/xml/PMC5123381.xml	CD25	665126 : 665130	CM	bition of proliferation, CD25 expression, and IFN-g an
./___Corpus/Medline/xml/PMC5123381.xml	IFN-g	665147 : 665152	CM	on, CD25 expression, and IFN-g and granzyme B productio
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	665188 : 665192	CM	me B production in human CD8+ T cells. The compounds a
./___Corpus/Medline/xml/PMC5123381.xml	10,000-	665239 : 665246	CPR	s are highly selective (>10,000-fold) against related ect
./___Corpus/Medline/xml/PMC5123381.xml	nucleotidases	665273 : 665286	ASE	ld) against related ecto-nucleotidases (CD39, NTPDases2/3/8) as
./___Corpus/Medline/xml/PMC5123381.xml	CD39	665288 : 665292	CM	ated ecto-nucleotidases (CD39, NTPDases2/3/8) as well 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	665522 : 665527	CPR	e in combination with an anti-PD-1 antibody resulted in
./___Corpus/Medline/xml/PMC5123381.xml	CT26	665574 : 665578	CM	 in robust inhibition of CT26 tumor growth, greater th
./___Corpus/Medline/xml/PMC5123381.xml	CD73	665775 : 665779	CM	itors of mouse and human CD73 exemplified by A000830 a
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665857 : 665866	CM	 block the generation of adenosine from AMP, reverse adenos
./___Corpus/Medline/xml/PMC5123381.xml	AMP	665872 : 665875	CM	ration of adenosine from AMP, reverse adenosine-media
./___Corpus/Medline/xml/PMC5123381.xml	adenosine	665885 : 665894	CM	nosine from AMP, reverse adenosine-mediated inhibition of h
./___Corpus/Medline/xml/PMC5123381.xml	anti-	665979 : 665984	CPR	nd demonstrate promising anti-tumor activity when dosed
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	666030 : 666034	CM	osed in combination with PD-1 blockade.               
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666109 : 666116	CM	munobiology landscape in mucosal melanoma Suthee Rapisuwo
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	666282 : 666286	CM	 number of pre-treatment CD8+ T lymphocytes and PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	666305 : 666310	CM	t CD8+ T lymphocytes and PD-L1 expression at the invasi
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	666482 : 666486	CM	e agent therapy with the PD-1 inhibitor, pembrolizumab
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	666540 : 666544	CM	 2]. Association between CD8+ T cell numbers or PD-L1 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	666563 : 666568	CM	n CD8+ T cell numbers or PD-L1 expression and response 
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666635 : 666642	CM	e-checkpoint blockade in mucosal melanoma has not been es
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	666747 : 666754	CM	  Four cases of advanced mucosal melanoma were each stain
./___Corpus/Medline/xml/PMC5123381.xml	CD8	666806 : 666809	CM	 with antibodies against CD8, and PD-L1 (SP-142; rabb
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	666815 : 666820	CM	ibodies against CD8, and PD-L1 (SP-142; rabbit monoclon
./___Corpus/Medline/xml/PMC5123381.xml	HMB-45	666894 : 666900	CM	cience). A pan-melanoma (HMB-45, MART-1, and tyrosinase)
./___Corpus/Medline/xml/PMC5123381.xml	MART-1	666902 : 666908	CM	 A pan-melanoma (HMB-45, MART-1, and tyrosinase), mouse 
./___Corpus/Medline/xml/PMC5123381.xml	tyrosinase	666914 : 666924	CM	oma (HMB-45, MART-1, and tyrosinase), mouse monoclonal antib
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667159 : 667163	CM	ge optical density (OD). CD8+ T cells and PD-L1 cells 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	667176 : 667181	CM	y (OD). CD8+ T cells and PD-L1 cells density were measu
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	667376 : 667381	CM	        The breakdown of PD-L1 and CD8 immunohistochemi
./___Corpus/Medline/xml/PMC5123381.xml	CD8	667386 : 667389	CM	e breakdown of PD-L1 and CD8 immunohistochemistry (IH
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	667506 : 667511	CM	cribed in Fig. 86. Tumor PD-L1 staining was negative in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667558 : 667562	CM	 in all tumors measured. CD8+ T cells are non-brisk in
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667652 : 667656	CM	ancy in density of total CD8+ T cells. CD8+ T cells at
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667666 : 667670	CM	y of total CD8+ T cells. CD8+ T cells at the invasive 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	667837 : 667841	CM	ny definitive pattern of CD8+ T cells or PD-L1 express
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	667853 : 667858	CM	ttern of CD8+ T cells or PD-L1 expression in a small ca
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	667896 : 667903	CM	n a small case series of mucosal melanoma. To further add
./___Corpus/Medline/xml/PMC5123381.xml	mucosal	667954 : 667961	CM	ess the immunobiology of mucosal melanoma and its microen
./___Corpus/Medline/xml/PMC5123381.xml	Mucosal	668187 : 668194	CM	n Patients with Advanced Mucosal or Acral Lentiginous Mel
./___Corpus/Medline/xml/PMC5123381.xml	JL	668609 : 668611	CM	              1. Messina JL, Fenstermacher DA, Eschr
./___Corpus/Medline/xml/PMC5123381.xml	X	668646 : 668647	CM	acher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, 
./___Corpus/Medline/xml/PMC5123381.xml	MC	668668 : 668670	CM	Qu X, Berglund AE, Lloyd MC, et al.: 12-Chemokine ge
./___Corpus/Medline/xml/PMC5123381.xml	12-	668680 : 668683	CPR	nd AE, Lloyd MC, et al.: 12-Chemokine gene signature 
./___Corpus/Medline/xml/PMC5123381.xml	PC	668878 : 668880	CM	                2. Tumeh PC, Harview CL, Yearley JH,
./___Corpus/Medline/xml/PMC5123381.xml	EJ	668926 : 668928	CM	 JH, Shintaku IP, Taylor EJ, Robert L, et al.: PD-1 
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	668948 : 668952	CM	or EJ, Robert L, et al.: PD-1 blockade induces respons
./___Corpus/Medline/xml/PMC5123381.xml	568–	669045 : 669049	CPR	. Nature 2014, 515(7528):568–571.                     
./___Corpus/Medline/xml/PMC5123381.xml	H	669105 : 669106	CM	            3. Shu J, Fu H, Qiu G, Kaye P, Ilyas M:
./___Corpus/Medline/xml/PMC5123381.xml	P	669120 : 669121	CM	Shu J, Fu H, Qiu G, Kaye P, Ilyas M: Segmenting ove
./___Corpus/Medline/xml/PMC5123381.xml	Biol	669224 : 669228	CM	. Conf Proc IEEE Eng Med Biol Soc 2013, 2013:5445–5448
./___Corpus/Medline/xml/PMC5123381.xml	5445–	669244 : 669249	CPR	 Med Biol Soc 2013, 2013:5445–5448.                  P4
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	669324 : 669328	CM	ant chemerin upregulates PTEN activity in human tumors
./___Corpus/Medline/xml/PMC5123381.xml	CMKLR1	669358 : 669364	CM	vity in human tumors via CMKLR1 Keith R. Rennier, Robert
./___Corpus/Medline/xml/PMC5123381.xml	anti-	669482 : 669487	CPR	     The balance between anti-tumor effector and immuno
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	669659 : 669663	CM	tase and tensin homolog (PTEN) modulation can directly
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	669755 : 669759	CM	pecifically, the loss of PTEN has been shown to promot
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	669940 : 669944	CM	ggesting upregulation of PTEN activity may have a favo
./___Corpus/Medline/xml/PMC5123381.xml	RARRES2	669993 : 670000	CM	orable impact. Chemerin (RARRES2; retinoic acid receptor 
./___Corpus/Medline/xml/PMC5123381.xml	retinoic acid	670002 : 670015	CM	pact. Chemerin (RARRES2; retinoic acid receptor responder 2) is
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	670238 : 670246	CM	pressive chemoattractant cytokine, capable of recruiting i
./___Corpus/Medline/xml/PMC5123381.xml	RARRES2	670306 : 670313	CM	ctor cells into the TME. RARRES2 is commonly downregulate
./___Corpus/Medline/xml/PMC5123381.xml	methylome	670438 : 670447	CM	roarray studies. Several methylome-wide studies in various 
./___Corpus/Medline/xml/PMC5123381.xml	RARRES2	670500 : 670507	CM	or types have identified RARRES2 as one of the most hyper
./___Corpus/Medline/xml/PMC5123381.xml	hypermethylated	670527 : 670542	CM	RRES2 as one of the most hypermethylated genes, potentially leadi
./___Corpus/Medline/xml/PMC5123381.xml	vitro	670817 : 670822	CM	to exogenous chemerin in vitro. Results                
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	670920 : 670924	CM	n was able to upregulate PTEN expression, a key cell s
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	671001 : 671005	CM	heckpoint. Specifically, mRNA and protein analyses sho
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	671062 : 671066	CM	nificant upregulation of PTEN after 48 hour chemerin e
./___Corpus/Medline/xml/PMC5123381.xml	CMKLR1	671324 : 671330	CM	 found that knockdown of CMKLR1 – the main chemerin rece
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	671440 : 671444	CM	-induced upregulation of PTEN, suggesting chemerin’s e
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	671478 : 671482	CM	ing chemerin’s effect on PTEN expression in tumor cell
./___Corpus/Medline/xml/PMC5123381.xml	RARRES2	671612 : 671619	CM	ate the role of chemerin/RARRES2 suppression within the t
./___Corpus/Medline/xml/PMC5123381.xml	anti-	671927 : 671932	CPR	s multiple mechanisms of anti-tumor action.            
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	672061 : 672065	CM	g that chemerin augments PTEN activity via CMKLR1. Thu
./___Corpus/Medline/xml/PMC5123381.xml	CMKLR1	672079 : 672085	CM	gments PTEN activity via CMKLR1. Thus, chemerin-driven i
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	672119 : 672123	CM	hemerin-driven increased PTEN expression and activity 
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	672266 : 672270	CM	, but also by augmenting PTEN expression within the TM
./___Corpus/Medline/xml/PMC5123381.xml	PTEN	672376 : 672380	CM	n-driven upregulation of PTEN activity and its effects
./___Corpus/Medline/xml/PMC5123381.xml	IL	672471 : 672473	CM	      P407 Regulation of IL-15 in the tumor microenv
./___Corpus/Medline/xml/PMC5123381.xml	STING	672514 : 672519	CM	 microenvironment by the STING pathway                 
./___Corpus/Medline/xml/PMC5123381.xml	IL	672710 : 672712	CM	           Expression of IL-15 within the tumor corr
./___Corpus/Medline/xml/PMC5123381.xml	IL	672877 : 672879	CM	ately, the regulation of IL-15 within the tumor micr
./___Corpus/Medline/xml/PMC5123381.xml	STING	673014 : 673019	CM	tor of Interferon Genes (STING) pathway are potent indu
./___Corpus/Medline/xml/PMC5123381.xml	IL	673060 : 673062	CM	tent inducers of soluble IL-15 complexes (sIL-15c) i
./___Corpus/Medline/xml/PMC5123381.xml	STING	673109 : 673114	CM	) in vivo [2]. Since the STING pathway is important for
./___Corpus/Medline/xml/PMC5123381.xml	STING	673290 : 673295	CM	ent and are regulated by STING signaling.              
./___Corpus/Medline/xml/PMC5123381.xml	IFNAR1−	673374 : 673381	CM	    C57BL/6, IL-15Ra−/−, IFNAR1−/− and Tmem173−/− mice we
./___Corpus/Medline/xml/PMC5123381.xml	B16-F10	673433 : 673440	CM	 challenged with 300,000 B16-F10 melanoma cells by s.c. i
./___Corpus/Medline/xml/PMC5123381.xml	s.c	673459 : 673462	CM	16-F10 melanoma cells by s.c. injection. Tumors of va
./___Corpus/Medline/xml/PMC5123381.xml	STING	673611 : 673616	CM	ISAs. For stimulation of STING pathway, mice were admin
./___Corpus/Medline/xml/PMC5123381.xml	c-di-GMP	673649 : 673657	CM	, mice were administered c-di-GMP (25ug/mouse) via intratu
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	673747 : 673751	CM	sure proliferation, OT-I CD8+ T cells were CFSE labell
./___Corpus/Medline/xml/PMC5123381.xml	CFSE	673765 : 673769	CM	, OT-I CD8+ T cells were CFSE labelled and adoptively 
./___Corpus/Medline/xml/PMC5123381.xml	IL-15Ra−	673825 : 673833	CM	erred into wild-type and IL-15Ra−/− mice. Tumors, spleens 
./___Corpus/Medline/xml/PMC5123381.xml	IFNAR1−	674210 : 674217	CM	ma. Tumors isolated from IFNAR1−/− mice contained decreas
./___Corpus/Medline/xml/PMC5123381.xml	sIL-15c	674255 : 674262	CM	ined decreased levels of sIL-15c, but interestingly, thos
./___Corpus/Medline/xml/PMC5123381.xml	STING	674325 : 674330	CM	om mice with a defective STING pathway had normal level
./___Corpus/Medline/xml/PMC5123381.xml	STING	674410 : 674415	CM	ype I IFN-dependent, but STING-independent pathway was 
./___Corpus/Medline/xml/PMC5123381.xml	IL	674466 : 674468	CM	equired for intratumoral IL-15 regulation. Nonethele
./___Corpus/Medline/xml/PMC5123381.xml	STING	674522 : 674527	CM	intratumoral delivery of STING agonists enhanced produc
./___Corpus/Medline/xml/PMC5123381.xml	B16	674571 : 674574	CM	production of sIL-15c in B16 tumors. Whereas treatmen
./___Corpus/Medline/xml/PMC5123381.xml	STING	674616 : 674621	CM	treatment of tumors with STING agonists promoted tumor 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	674702 : 674706	CM	ration of tumor-specific CD8+ T cells, these effects w
./___Corpus/Medline/xml/PMC5123381.xml	IL-15Ra−	674755 : 674763	CM	were severely blunted in IL-15Ra−/− mice.                 
./___Corpus/Medline/xml/PMC5123381.xml	IL	674851 : 674853	CM	e findings indicate that IL-15 is a critical factor 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	674892 : 674897	CPR	cal factor mediating the anti-tumor responses induced b
./___Corpus/Medline/xml/PMC5123381.xml	STING	674924 : 674929	CM	mor responses induced by STING signaling.              
./___Corpus/Medline/xml/PMC5123381.xml	HK	675021 : 675023	CM	cnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, F
./___Corpus/Medline/xml/PMC5123381.xml	SM	675289 : 675291	CM	              2. Anthony SM, Howard ME, Hailemichael
./___Corpus/Medline/xml/PMC5123381.xml	ME	675300 : 675302	CM	   2. Anthony SM, Howard ME, Hailemichael Y, Overwij
./___Corpus/Medline/xml/PMC5123381.xml	Y	675317 : 675318	CM	 Howard ME, Hailemichael Y, Overwijk WW, Schluns KS
./___Corpus/Medline/xml/PMC5123381.xml	IL35	675575 : 675579	CM	ved inhibitory cytokines IL35 and IL10 promote T cell 
./___Corpus/Medline/xml/PMC5123381.xml	IL10	675584 : 675588	CM	itory cytokines IL35 and IL10 promote T cell dysfuncti
./___Corpus/Medline/xml/PMC5123381.xml	CD4+	675825 : 675829	CM	 specialized suppressive CD4+ T cell sub-population ca
./___Corpus/Medline/xml/PMC5123381.xml	anti-	676019 : 676024	CPR	, Tregs block beneficial anti-tumor immune responses an
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676694 : 676698	CM	g suppressive cytokines, IL35 and IL10, in the tumor s
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676703 : 676707	CM	sive cytokines, IL35 and IL10, in the tumor setting, w
./___Corpus/Medline/xml/PMC5123381.xml	B16F10	676743 : 676749	CM	mor setting, we injected B16F10 tumors intradermally int
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676817 : 676821	CM	ce bearing reporters for IL35 and IL10 (Foxp3 CreYFP.E
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676826 : 676830	CM	g reporters for IL35 and IL10 (Foxp3 CreYFP.Ebi3 tdTom
./___Corpus/Medline/xml/PMC5123381.xml	GFP	676862 : 676865	CM	 CreYFP.Ebi3 tdTom .IL10 GFP). This enabled tracking 
./___Corpus/Medline/xml/PMC5123381.xml	IL35	676924 : 676928	CM	expressing/co-expressing IL35 and IL10 in the tumor mi
./___Corpus/Medline/xml/PMC5123381.xml	IL10	676933 : 676937	CM	g/co-expressing IL35 and IL10 in the tumor microenviro
./___Corpus/Medline/xml/PMC5123381.xml	IL35	677021 : 677025	CM	eriments in mice bearing IL35-deficient Tregs (Foxp3 C
./___Corpus/Medline/xml/PMC5123381.xml	IL10	677072 : 677076	CM	3 Cre-YFP .Ebi3 L/L) and IL10-deficient Tregs (Foxp3 C
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677219 : 677223	CM	ines on tumor growth and CD8+ T cell effector function
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	677331 : 677339	CM	y studies using the dual cytokine reporter mice reveal dis
./___Corpus/Medline/xml/PMC5123381.xml	IL35	677402 : 677406	CM	ions of Tregs expressing IL35 and IL10 in the B16 tumo
./___Corpus/Medline/xml/PMC5123381.xml	IL10	677411 : 677415	CM	regs expressing IL35 and IL10 in the B16 tumor microen
./___Corpus/Medline/xml/PMC5123381.xml	B16	677423 : 677426	CM	ing IL35 and IL10 in the B16 tumor microenvironment, 
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677757 : 677761	CM	itory receptors (IRs) on CD8+ T cells in both floxed e
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	677922 : 677926	CM	i-IR+ exhausted state on CD8+ T cells in tumors.      
./___Corpus/Medline/xml/PMC5123381.xml	IR+	678017 : 678020	CM	    The dramatic loss of IR+ T cells in mice bearing 
./___Corpus/Medline/xml/PMC5123381.xml	IL35	678045 : 678049	CM	 T cells in mice bearing IL35 and IL10-deficient Tregs
./___Corpus/Medline/xml/PMC5123381.xml	IL10	678054 : 678058	CM	in mice bearing IL35 and IL10-deficient Tregs highligh
./___Corpus/Medline/xml/PMC5123381.xml	Th1	679413 : 679416	CM	 subsets with or without Th1 immune signatures. We id
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	679776 : 679780	CM	The Cancer Genome Atlas (TCGA) were assessed with Kapl
./___Corpus/Medline/xml/PMC5123381.xml	Th1	679971 : 679974	CM	 ovarian cancers lacking Th1 immune signatures, and w
./___Corpus/Medline/xml/PMC5123381.xml	FLG	680084 : 680087	CM	rmal tissues: filaggrin (FLG), tumor-associated calci
./___Corpus/Medline/xml/PMC5123381.xml	calcium	680107 : 680114	CM	 (FLG), tumor-associated calcium signal transducer 2 (TAC
./___Corpus/Medline/xml/PMC5123381.xml	TACSTD2	680136 : 680143	CM	ium signal transducer 2 (TACSTD2), and 6 desmosomal prote
./___Corpus/Medline/xml/PMC5123381.xml	DST	680173 : 680176	CM	d 6 desmosomal proteins (DST, DSC3, DSP, PPL, PKP3, a
./___Corpus/Medline/xml/PMC5123381.xml	DSC3	680178 : 680182	CM	esmosomal proteins (DST, DSC3, DSP, PPL, PKP3, and JUP
./___Corpus/Medline/xml/PMC5123381.xml	DSP	680184 : 680187	CM	mal proteins (DST, DSC3, DSP, PPL, PKP3, and JUP). Th
./___Corpus/Medline/xml/PMC5123381.xml	PPL	680189 : 680192	CM	roteins (DST, DSC3, DSP, PPL, PKP3, and JUP). This as
./___Corpus/Medline/xml/PMC5123381.xml	PKP3	680194 : 680198	CM	ns (DST, DSC3, DSP, PPL, PKP3, and JUP). This associat
./___Corpus/Medline/xml/PMC5123381.xml	JUP	680204 : 680207	CM	SC3, DSP, PPL, PKP3, and JUP). This association was v
./___Corpus/Medline/xml/PMC5123381.xml	DST	680283 : 680286	CM	lanoma metastases, where DST expression alone was suf
./___Corpus/Medline/xml/PMC5123381.xml	FLG	680374 : 680377	CM	immune signatures, while FLG and the other 6 putative
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	680635 : 680639	CM	7 ovarian cancers in the TCGA further supported these 
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	680759 : 680768	CM	s largely independent of β-catenin/WNT and endothelin recep
./___Corpus/Medline/xml/PMC5123381.xml	WNT	680769 : 680772	CM	independent of β-catenin/WNT and endothelin receptor 
./___Corpus/Medline/xml/PMC5123381.xml	FLG	680971 : 680974	CM	0.01). This was true for FLG for melanoma (p = 0.012)
./___Corpus/Medline/xml/PMC5123381.xml	DST	681040 : 681043	CM	cer (p = 0.006), whereas DST overexpression was negat
./___Corpus/Medline/xml/PMC5123381.xml	CD8	681090 : 681093	CM	gatively associated with CD8 gene expression, but not
./___Corpus/Medline/xml/PMC5123381.xml	FLG	681210 : 681213	CM	       Overexpression of FLG or DST identifies 2 dist
./___Corpus/Medline/xml/PMC5123381.xml	DST	681217 : 681220	CM	Overexpression of FLG or DST identifies 2 distinct pa
./___Corpus/Medline/xml/PMC5123381.xml	NCI	681735 : 681738	CM	d by Steven A Rosenberg (NCI). Some results here are 
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	681796 : 681800	CM	on data generated by the TCGA Research Network: http:/
./___Corpus/Medline/xml/PMC5123381.xml	PMID	681864 : 681868	CM	nih.gov (Cerami, et al., PMID 22588877; Gao J, et al.,
./___Corpus/Medline/xml/PMC5123381.xml	PMID	681894 : 681898	CM	22588877; Gao J, et al., PMID 23550210).              
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	682006 : 682010	CM	r immune evasion against CD8+ effector T cells using i
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	682160 : 682164	CM	und                      CD8+ T cell infiltration into
./___Corpus/Medline/xml/PMC5123381.xml	Wnt	682577 : 682580	CM	 pathways, including the Wnt/β-catenin pathway, resul
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	682581 : 682590	CM	hways, including the Wnt/β-catenin pathway, result in a lac
./___Corpus/Medline/xml/PMC5123381.xml	Wnt	682734 : 682737	CM	cally, activation of the Wnt/β-catenin signaling path
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	682738 : 682747	CM	y, activation of the Wnt/β-catenin signaling pathway in the
./___Corpus/Medline/xml/PMC5123381.xml	DCs	682896 : 682899	CM	uitment of Batf3-lineage DCs. However, it was not cle
./___Corpus/Medline/xml/PMC5123381.xml	anti-	683060 : 683065	CPR	e presence of a systemic anti-tumor immune response. In
./___Corpus/Medline/xml/PMC5123381.xml	murine	683313 : 683319	CM	estions we used GEMs for murine melanoma with or without
./___Corpus/Medline/xml/PMC5123381.xml	Wnt	683363 : 683366	CM	ithout activation of the Wnt/β-catenin signaling path
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683367 : 683376	CM	ut activation of the Wnt/β-catenin signaling pathway and en
./___Corpus/Medline/xml/PMC5123381.xml	SIY	683441 : 683444	CM	resses the model antigen SIY (SIYRYYGL).             
./___Corpus/Medline/xml/PMC5123381.xml	SIYRYYGL	683446 : 683454	CM	s the model antigen SIY (SIYRYYGL).                  Resul
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683575 : 683584	CM	-intrinsic activation of β-catenin was capable to mediate s
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683723 : 683732	CM	r T cell infiltration in β-catenin negative tumors was furt
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	683860 : 683869	CM	h were never observed in β-catenin positive non-T cell infl
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684037 : 684046	CM	in tumors with activated β-catenin signaling. Using intravi
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684127 : 684136	CM	hile effector T cells in β-catenin negative tumors made dir
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	684272 : 684281	CM	ffector T cells found in β-catenin positive tumor failed to
./___Corpus/Medline/xml/PMC5123381.xml	CXCL9	684479 : 684484	CM	ession of the chemokines CXCL9 and CXCL10 in tumor with
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	684489 : 684495	CM	the chemokines CXCL9 and CXCL10 in tumor with activated 
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684574 : 684580	CM	are normally produced by CD103+ Batf3-driven DCs.       
./___Corpus/Medline/xml/PMC5123381.xml	DCs	684594 : 684597	CM	d by CD103+ Batf3-driven DCs.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684682 : 684688	CM	 support the notion that CD103+ dendritic cells within t
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	684766 : 684770	CM	e essential for effector CD8+ T cell recruitment and m
./___Corpus/Medline/xml/PMC5123381.xml	CD103+	684826 : 684832	CM	y. Strategies to promote CD103+ dendritic cell accumulat
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685076 : 685086	CM	ix metalloproteinases by cysteamine regulates tumor invasion
./___Corpus/Medline/xml/PMC5123381.xml	H	685220 : 685221	CM	i, Pamela Leland, Bharat H Joshi, Raj K Puri Backgr
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685306 : 685316	CM	y, we have reported that cysteamine, an anti-oxidant aminoth
./___Corpus/Medline/xml/PMC5123381.xml	anti-	685321 : 685326	CPR	rted that cysteamine, an anti-oxidant aminothiol, inhib
./___Corpus/Medline/xml/PMC5123381.xml	aminothiol	685334 : 685344	CM	teamine, an anti-oxidant aminothiol, inhibited the tumor inv
./___Corpus/Medline/xml/PMC5123381.xml	vitro	685378 : 685383	CM	ed the tumor invasion in vitro and metastasis of pancre
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685509 : 685519	CM	 shown that subcutaneous cysteamine treatment improves the s
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685643 : 685653	CM	ein, we examined whether cysteamine can inhibit invasion and
./___Corpus/Medline/xml/PMC5123381.xml	anti-	685785 : 685790	CPR	We examined cysteamine’s anti-invasion effects in 6 hum
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685947 : 685957	CM	he cytotoxic activity of cysteamine in vitro and measured th
./___Corpus/Medline/xml/PMC5123381.xml	vitro	685961 : 685966	CM	ctivity of cysteamine in vitro and measured the effect 
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	685994 : 686004	CM	d measured the effect of cysteamine on matrix metalloprotein
./___Corpus/Medline/xml/PMC5123381.xml	MMP	686035 : 686038	CM	trix metalloproteinases (MMP), which are known to be 
./___Corpus/Medline/xml/PMC5123381.xml	anti-	686103 : 686108	CPR	astasis. We examined the anti-metastatic effect of cyst
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686129 : 686139	CM	nti-metastatic effect of cysteamine in two orthotopic murine
./___Corpus/Medline/xml/PMC5123381.xml	murine	686158 : 686164	CM	eamine in two orthotopic murine models of human ovarian 
./___Corpus/Medline/xml/PMC5123381.xml	IGROV-1	686243 : 686250	CM	al metastases. A2780 and IGROV-1 ovarian cancer cells wer
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686487 : 686497	CM	ion, increasing doses of cysteamine (0, 100, or 250 mg/kg/da
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686662 : 686672	CM	        We observed that cysteamine inhibited cell invasion 
./___Corpus/Medline/xml/PMC5123381.xml	vitro	686700 : 686705	CM	hibited cell invasion in vitro in a concentration-depen
./___Corpus/Medline/xml/PMC5123381.xml	MMP	686764 : 686767	CM	er. Similar to invasion, MMP activity was inhibited b
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686794 : 686804	CM	ctivity was inhibited by cysteamine in a concentration-depen
./___Corpus/Medline/xml/PMC5123381.xml	anti-	686863 : 686868	CPR	er. We next examined the anti-metastatic effect of cyst
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	686889 : 686899	CM	nti-metastatic effect of cysteamine on peritoneal metastasis
./___Corpus/Medline/xml/PMC5123381.xml	murine	686943 : 686949	CM	stasis in two orthotopic murine models of human ovarian 
./___Corpus/Medline/xml/PMC5123381.xml	Cysteamine	686982 : 686992	CM	of human ovarian cancer. Cysteamine significantly decreased 
./___Corpus/Medline/xml/PMC5123381.xml	IGROV-1	687130 : 687137	CM	in A2780 and p < 0.05 in IGROV-1 xenografts compared to u
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	687398 : 687408	CM	d at the highest dose of cysteamine. Similar to the in vitro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	687428 : 687433	CM	amine. Similar to the in vitro results, MMP activity wa
./___Corpus/Medline/xml/PMC5123381.xml	MMP	687443 : 687446	CM	to the in vitro results, MMP activity was significant
./___Corpus/Medline/xml/PMC5123381.xml	IGROV-1	687518 : 687525	CM	y tumors in both A2780 & IGROV-1 xenograft models treated
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	687556 : 687566	CM	raft models treated with cysteamine (p < 0.05). Tumor growth
./___Corpus/Medline/xml/PMC5123381.xml	IGROV-1	687891 : 687898	CM	0 in A2780 and 0.9800 in IGROV-1 xenografts).            
./___Corpus/Medline/xml/PMC5123381.xml	cysteamine	688003 : 688013	CM	esults, we conclude that cysteamine may be a useful therapeu
./___Corpus/Medline/xml/PMC5123381.xml	anti-	688113 : 688118	CPR	ation-therapy with other anti-cancer agents such as can
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	688211 : 688216	CM	      P412 Validation of FGFR3 activation in non-T cell
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	688785 : 688790	CM	herapy. We observed that FGFR3 activating mutations wer
./___Corpus/Medline/xml/PMC5123381.xml	GEO	689194 : 689197	CM	were downloaded from the GEO database and preprocesse
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	689365 : 689369	CM	725 genes from our prior TCGA analysis, and repeated u
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	690137 : 690141	CM	 with bladder cancers in TCGA (48 % vs. 33 %). We conf
./___Corpus/Medline/xml/PMC5123381.xml	CD8A	690223 : 690227	CM	on between expression of CD8A and FGFR3 (P < 0.0001). 
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	690232 : 690237	CM	n expression of CD8A and FGFR3 (P < 0.0001). Furthermor
./___Corpus/Medline/xml/PMC5123381.xml	P	690239 : 690240	CM	ssion of CD8A and FGFR3 (P < 0.0001). Furthermore, 
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	690265 : 690270	CM	 < 0.0001). Furthermore, FGFR3 overexpressing tumors by
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	690357 : 690362	CM	ntly lower expression of PD-L1, IDO1, LAG3, and TIM3 (a
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	690364 : 690368	CM	wer expression of PD-L1, IDO1, LAG3, and TIM3 (all P ≤
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	690370 : 690374	CM	pression of PD-L1, IDO1, LAG3, and TIM3 (all P ≤ 0.01)
./___Corpus/Medline/xml/PMC5123381.xml	TIM3	690380 : 690384	CM	f PD-L1, IDO1, LAG3, and TIM3 (all P ≤ 0.01). The asso
./___Corpus/Medline/xml/PMC5123381.xml	P	690390 : 690391	CM	DO1, LAG3, and TIM3 (all P ≤ 0.01). The association
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	690425 : 690430	CM	 The association between FGFR3 and FOXP3 was not signif
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	690435 : 690440	CM	iation between FGFR3 and FOXP3 was not significant (P =
./___Corpus/Medline/xml/PMC5123381.xml	P	690462 : 690463	CM	XP3 was not significant (P = 0.41). CD8A was concor
./___Corpus/Medline/xml/PMC5123381.xml	CD8A	690473 : 690477	CM	 significant (P = 0.41). CD8A was concordantly express
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	690510 : 690515	CM	cordantly expressed with PD-L1, IDO1, LAG3, FOXP3, and 
./___Corpus/Medline/xml/PMC5123381.xml	IDO1	690517 : 690521	CM	ly expressed with PD-L1, IDO1, LAG3, FOXP3, and TIM3 (
./___Corpus/Medline/xml/PMC5123381.xml	LAG3	690523 : 690527	CM	ressed with PD-L1, IDO1, LAG3, FOXP3, and TIM3 (P < 0.
./___Corpus/Medline/xml/PMC5123381.xml	FOXP3	690529 : 690534	CM	 with PD-L1, IDO1, LAG3, FOXP3, and TIM3 (P < 0.0001), 
./___Corpus/Medline/xml/PMC5123381.xml	TIM3	690540 : 690544	CM	, IDO1, LAG3, FOXP3, and TIM3 (P < 0.0001), consistent
./___Corpus/Medline/xml/PMC5123381.xml	P	690546 : 690547	CM	, LAG3, FOXP3, and TIM3 (P < 0.0001), consistent wi
./___Corpus/Medline/xml/PMC5123381.xml	TCGA	690585 : 690589	CM	onsistent with data from TCGA. Finally, differentially
./___Corpus/Medline/xml/PMC5123381.xml	β-catenin	690778 : 690787	CM	 data set, activation of β-catenin, PPARG and SMARCA4 pathw
./___Corpus/Medline/xml/PMC5123381.xml	PPARG	690789 : 690794	CM	activation of β-catenin, PPARG and SMARCA4 pathways was
./___Corpus/Medline/xml/PMC5123381.xml	SMARCA4	690799 : 690806	CM	 of β-catenin, PPARG and SMARCA4 pathways was observed (P
./___Corpus/Medline/xml/PMC5123381.xml	P	690830 : 690831	CM	4 pathways was observed (P < 0.0001).              
./___Corpus/Medline/xml/PMC5123381.xml	FGFR3	691101 : 691106	CM	to activating mutations, FGFR3 overexpression occurs pr
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	691194 : 691199	CM	d immune subtype lacking PD-L1 expression.             
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	691311 : 691317	CM	ncer microenvironment by poly-I:C and selective TLR3 lig
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	691334 : 691338	CM	y poly-I:C and selective TLR3 ligand, rintatolimod    
./___Corpus/Medline/xml/PMC5123381.xml	P	691433 : 691434	CM	es-Mary Mogundo2, Robert P Edwards2, Pawel Kalinski
./___Corpus/Medline/xml/PMC5123381.xml	5-	691542 : 691544	CPR	ry and chemotherapy, the 5-year survival rate for pa
./___Corpus/Medline/xml/PMC5123381.xml	TLR-3	691718 : 691723	CM	h level of synergy among TLR-3 ligands, IFNa and COX-2 
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	691733 : 691737	CM	rgy among TLR-3 ligands, IFNa and COX-2 blockers in in
./___Corpus/Medline/xml/PMC5123381.xml	COX-2	691742 : 691747	CM	 TLR-3 ligands, IFNa and COX-2 blockers in inducing che
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	691922 : 691927	CM	ited local production of CCL22, the chemokine implicate
./___Corpus/Medline/xml/PMC5123381.xml	4-	692222 : 692224	CPR	cimens were divided into 4-mm biopsies and cultured 
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	692281 : 692285	CM	hours in the presence of IFNa, indomethacin (COX-1/2 i
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	692287 : 692299	CM	in the presence of IFNa, indomethacin (COX-1/2 inhibitor) or/a
./___Corpus/Medline/xml/PMC5123381.xml	COX-1	692301 : 692306	CM	e of IFNa, indomethacin (COX-1/2 inhibitor) or/and one 
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	692348 : 692352	CM	and one of two synthetic TLR3 ligands Poly-I:C (non-se
./___Corpus/Medline/xml/PMC5123381.xml	Poly-I	692361 : 692367	CM	o synthetic TLR3 ligands Poly-I:C (non-selective activat
./___Corpus/Medline/xml/PMC5123381.xml	TLR3	692398 : 692402	CM	n-selective activator of TLR3) rintatolimod (Ampligen)
./___Corpus/Medline/xml/PMC5123381.xml	mRNA	692480 : 692484	CM	psies were harvested for mRNA as well as for confocal 
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	692563 : 692567	CM	atants were analyzed for CCL5, CXCL10 and CCL22 concen
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	692569 : 692575	CM	 were analyzed for CCL5, CXCL10 and CCL22 concentration.
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	692580 : 692585	CM	zed for CCL5, CXCL10 and CCL22 concentration. Alternati
./___Corpus/Medline/xml/PMC5123381.xml	PE01	692655 : 692659	CM	arian cancer cell lines (PE01 and PE04) or monocyte-de
./___Corpus/Medline/xml/PMC5123381.xml	PE04	692664 : 692668	CM	cer cell lines (PE01 and PE04) or monocyte-derived mac
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	692791 : 692795	CM	rmed using pre-activated CD8+ T cells and supernatants
./___Corpus/Medline/xml/PMC5123381.xml	TLR-3	692961 : 692966	CM	 that the combination of TLR-3 ligands, IFNa and COX1/2
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	692976 : 692980	CM	nation of TLR-3 ligands, IFNa and COX1/2 blockers sele
./___Corpus/Medline/xml/PMC5123381.xml	COX1	692985 : 692989	CM	 TLR-3 ligands, IFNa and COX1/2 blockers selectively i
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	693045 : 693049	CM	the desirable chemokines CCL5 and CXCL10 and suppresse
./___Corpus/Medline/xml/PMC5123381.xml	CXCL10	693054 : 693060	CM	able chemokines CCL5 and CXCL10 and suppressed CCL22 in 
./___Corpus/Medline/xml/PMC5123381.xml	CCL22	693076 : 693081	CM	nd CXCL10 and suppressed CCL22 in ovarian cancer with s
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	693185 : 693189	CM	ell lines. Unexpectedly, IFNa + poly-I:C but not IFNa 
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693192 : 693198	CM	es. Unexpectedly, IFNa + poly-I:C but not IFNa + rintato
./___Corpus/Medline/xml/PMC5123381.xml	IFNa	693209 : 693213	CM	 IFNa + poly-I:C but not IFNa + rintatolimod, also pro
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	693266 : 693270	CM	ed the expression of the MDSC attractant CXCL12, which
./___Corpus/Medline/xml/PMC5123381.xml	CXCL12	693282 : 693288	CM	n of the MDSC attractant CXCL12, which was reversed thro
./___Corpus/Medline/xml/PMC5123381.xml	COX-2	693329 : 693334	CM	rsed through addition of COX-2 inhibitors. Furthermore,
./___Corpus/Medline/xml/PMC5123381.xml	CCL5	693377 : 693381	CM	ermore, the induction of CCL5 was enhanced by the addi
./___Corpus/Medline/xml/PMC5123381.xml	COX1	693414 : 693418	CM	anced by the addition of COX1/2 inhibitor. Compared to
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693444 : 693450	CM	2 inhibitor. Compared to poly-I:C, the positive effects 
./___Corpus/Medline/xml/PMC5123381.xml	TLR-3	693492 : 693497	CM	effects of the selective TLR-3 ligand, rintatolimod, we
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	693558 : 693570	CM	ndent on the addition of indomethacin.                  Conclu
./___Corpus/Medline/xml/PMC5123381.xml	poly-I	693881 : 693887	CM	for the first time, that poly-I:C induces undesirable CO
./___Corpus/Medline/xml/PMC5123381.xml	COX2	693910 : 693914	CM	-I:C induces undesirable COX2-dependent suppressive fa
./___Corpus/Medline/xml/PMC5123381.xml	COX-1	693994 : 693999	CM	 through addition of the COX-1/2 inhibitor, indomethaci
./___Corpus/Medline/xml/PMC5123381.xml	indomethacin	694013 : 694025	CM	f the COX-1/2 inhibitor, indomethacin, or through usage of the
./___Corpus/Medline/xml/PMC5123381.xml	TLR-3	694061 : 694066	CM	h usage of the selective TLR-3 ligand, rintatolimod.   
./___Corpus/Medline/xml/PMC5123381.xml	JS	694164 : 694166	CM	. Holschneider CH, Berek JS: Ovarian cancer: epidemi
./___Corpus/Medline/xml/PMC5123381.xml	3–	694257 : 694259	CPR	emin Surg Oncol 2000, 19:3–10.                      
./___Corpus/Medline/xml/PMC5123381.xml	R	694315 : 694316	CM	           2. Muthuswamy R, Berk E, Junecko BF et a
./___Corpus/Medline/xml/PMC5123381.xml	NF-kappaB	694345 : 694354	CM	rk E, Junecko BF et al.: NF-kappaB hyperactivation in tumor
./___Corpus/Medline/xml/PMC5123381.xml	3735–	694537 : 694542	CPR	lls. Cancer Res 2012, 72:3735–3743.                    
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	694591 : 694595	CM	                    P414 TLR9 expression in prostate c
./___Corpus/Medline/xml/PMC5123381.xml	pSTAT3+	694701 : 694708	CM	mediated accumulation of pSTAT3+ myeloid-derived suppress
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695369 : 695373	CM	r, Toll-Like Receptor 9 (TLR9). TLR9 signaling through
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695376 : 695380	CM	-Like Receptor 9 (TLR9). TLR9 signaling through NF-kB/
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	695399 : 695404	CM	. TLR9 signaling through NF-kB/RELA and STAT3 promoted 
./___Corpus/Medline/xml/PMC5123381.xml	RELA	695405 : 695409	CM	 signaling through NF-kB/RELA and STAT3 promoted tumor
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	695414 : 695419	CM	g through NF-kB/RELA and STAT3 promoted tumor propagati
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695555 : 695559	CM	of cancer cell-intrinsic TLR9 signaling on the composi
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695686 : 695690	CM	 For temporal control of TLR9 expression, we introduce
./___Corpus/Medline/xml/PMC5123381.xml	tetracycline	695717 : 695729	CM	xpression, we introduced tetracycline-inducible TLR9 expressio
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695740 : 695744	CM	d tetracycline-inducible TLR9 expression system (Tet-O
./___Corpus/Medline/xml/PMC5123381.xml	Myc	695787 : 695790	CM	 (Tet-On) into mouse Ras/Myc-driven (RM9) prostate ca
./___Corpus/Medline/xml/PMC5123381.xml	RM9	695799 : 695802	CM	to mouse Ras/Myc-driven (RM9) prostate cancer cells. 
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	695890 : 695894	CM	        The induction of TLR9 expression in RM9 tumors
./___Corpus/Medline/xml/PMC5123381.xml	RM9	695909 : 695912	CM	on of TLR9 expression in RM9 tumors in vivo correlate
./___Corpus/Medline/xml/PMC5123381.xml	PMN-MDSCs	696016 : 696025	CM	erived suppressor cells (PMN-MDSCs; CD11b+Ly6CINTLy6GHI). T
./___Corpus/Medline/xml/PMC5123381.xml	Ly6CINTLy6GHI	696033 : 696046	CM	 cells (PMN-MDSCs; CD11b+Ly6CINTLy6GHI). The PMN-MDSC in TLR9HI
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	696115 : 696120	CM	ated levels of activated STAT3, a master regulator of i
./___Corpus/Medline/xml/PMC5123381.xml	MDSC	696162 : 696166	CM	tor of immunosuppressive MDSC activities. Accordingly,
./___Corpus/Medline/xml/PMC5123381.xml	PMN-MDSCs	696209 : 696218	CM	dingly, tumor-associated PMN-MDSCs isolated from TLR9HI-, b
./___Corpus/Medline/xml/PMC5123381.xml	TLR9HI	696233 : 696239	CM	 PMN-MDSCs isolated from TLR9HI-, but not from TLR9LO- R
./___Corpus/Medline/xml/PMC5123381.xml	TLR9LO	696255 : 696261	CM	om TLR9HI-, but not from TLR9LO- RM9 tumors, expressed h
./___Corpus/Medline/xml/PMC5123381.xml	RM9	696263 : 696266	CM	I-, but not from TLR9LO- RM9 tumors, expressed high l
./___Corpus/Medline/xml/PMC5123381.xml	Arginase-1	696335 : 696345	CM	essive mediators such as Arginase-1 and IL-10, and showed au
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	696423 : 696427	CM	on T cell proliferation. TLR9 expression in mouse and 
./___Corpus/Medline/xml/PMC5123381.xml	LNCaP	696459 : 696464	CM	sion in mouse and human (LNCaP and PC3) prostate cancer
./___Corpus/Medline/xml/PMC5123381.xml	PC3	696469 : 696472	CM	use and human (LNCaP and PC3) prostate cancer cells r
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	696516 : 696524	CM	ells resulted in altered cytokine/chemokine secretion with
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	696593 : 696601	CM	lation of an IL-6 family cytokine, leukemia inhibitory fac
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	696785 : 696789	CM	cts. On molecular level, TLR9 triggered direct binding
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	696822 : 696827	CM	ed direct binding of the NF-kB and STAT3 to the LIF pro
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	696832 : 696837	CM	binding of the NF-kB and STAT3 to the LIF promoter as v
./___Corpus/Medline/xml/PMC5123381.xml	chromatin	696873 : 696882	CM	 promoter as verified by chromatin immunoprecipitation (ChI
./___Corpus/Medline/xml/PMC5123381.xml	ChIP	696904 : 696908	CM	tin immunoprecipitation (ChIP) assays. The antibody-me
./___Corpus/Medline/xml/PMC5123381.xml	pSTAT3+	697057 : 697064	CM	n in the accumulation of pSTAT3+ PMN-MDSCs. Finally, we u
./___Corpus/Medline/xml/PMC5123381.xml	PMN-MDSCs	697065 : 697074	CM	 accumulation of pSTAT3+ PMN-MDSCs. Finally, we used an oli
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	697138 : 697143	CM	ased approach to inhibit STAT3 in TLR9 expressing RM9 t
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	697147 : 697151	CM	oach to inhibit STAT3 in TLR9 expressing RM9 tumor cel
./___Corpus/Medline/xml/PMC5123381.xml	RM9	697163 : 697166	CM	STAT3 in TLR9 expressing RM9 tumor cells and in tumor
./___Corpus/Medline/xml/PMC5123381.xml	PMN-MDSCs	697225 : 697234	CM	ed myeloid cells such as PMN-MDSCs. Local injection of CpG-
./___Corpus/Medline/xml/PMC5123381.xml	CpG-STAT3	697255 : 697264	CM	DSCs. Local injection of CpG-STAT3 inhibitor reduced growth
./___Corpus/Medline/xml/PMC5123381.xml	RM9 prostate	697293 : 697305	CM	ibitor reduced growth of RM9 prostate tumors at the treated an
./___Corpus/Medline/xml/PMC5123381.xml	TLR9	697478 : 697482	CM	           Collectively, TLR9 signaling in prostate ca
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	697578 : 697586	CM	ronment through altering cytokine and chemokine and subseq
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	697630 : 697635	CM	subsequent activation of STAT3 in tumor-infiltrated mye
./___Corpus/Medline/xml/PMC5123381.xml	TLR9+ prostate	697740 : 697754	CM	c potential of targeting TLR9+ prostate cancer cells and tumor-a
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	697855 : 697860	CM	d tolerogenic effects of STAT3 signaling in the tumor m
./___Corpus/Medline/xml/PMC5123381.xml	anti-	698206 : 698211	CPR	          To enhance the anti-tumor effects of current 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698395 : 698399	CM	an clear cell carcinoma (OCCC), the second most major 
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	698604 : 698610	CM	A transcriptional factor HNF-1β preferentially activated
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698645 : 698649	CM	ially activated in human OCCC contributes to various m
./___Corpus/Medline/xml/PMC5123381.xml	glucose	698724 : 698731	CM	ding chemoresistance and glucose metabolism. In this stud
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	698789 : 698795	CM	ve investigated roles of HNF-1β in the immunosuppressive
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698839 : 698843	CM	essive activity of human OCCC.                  Method
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	698959 : 698963	CM	trating T cells in human OCCC tissues. We have evaluat
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	699011 : 699017	CM	ated the contribution of HNF-1β activation in OCCC to th
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699032 : 699036	CM	 of HNF-1β activation in OCCC to the suppression of DC
./___Corpus/Medline/xml/PMC5123381.xml	DC	699059 : 699061	CM	CC to the suppression of DC function through the pro
./___Corpus/Medline/xml/PMC5123381.xml	vitro	699105 : 699110	CM	he production of IL-6 in vitro and in vivo. Finally, we
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699242 : 699246	CM	ess IL-6 production from OCCC and evaluated their effe
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699360 : 699364	CM	-infiltrating T cells in OCCC were significantly fewer
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	699461 : 699467	CM	 serous ovarian cancers. HNF-1β knockdown and overexpres
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	699523 : 699529	CM	xperiments revealed that HNF-1β induced IL-6 and IL-8 pr
./___Corpus/Medline/xml/PMC5123381.xml	IL-8	699547 : 699551	CM	 HNF-1β induced IL-6 and IL-8 production via NF-κB and
./___Corpus/Medline/xml/PMC5123381.xml	NF-κB	699567 : 699572	CM	 and IL-8 production via NF-κB and STAT3 activation in 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	699577 : 699582	CM	production via NF-κB and STAT3 activation in OCCC. Supp
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699597 : 699601	CM	 and STAT3 activation in OCCC. Suppressive activities 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699635 : 699639	CM	sive activities of human OCCC cell line culture supern
./___Corpus/Medline/xml/PMC5123381.xml	DC	699714 : 699716	CM	derived dendritic cells (DC) were reduced in vitro b
./___Corpus/Medline/xml/PMC5123381.xml	vitro	699734 : 699739	CM	lls (DC) were reduced in vitro by knockdown of HNF-1β p
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	699756 : 699762	CM	in vitro by knockdown of HNF-1β partly through decrease 
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	699809 : 699815	CM	se of IL-6. Knockdown of HNF-1β in a human OCCC cell lin
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699827 : 699831	CM	own of HNF-1β in a human OCCC cell line resulted in th
./___Corpus/Medline/xml/PMC5123381.xml	murine	699904 : 699910	CM	 stimulatory activity of murine DC in nude mice implante
./___Corpus/Medline/xml/PMC5123381.xml	DC	699911 : 699913	CM	atory activity of murine DC in nude mice implanted w
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	699948 : 699952	CM	ice implanted with human OCCC partly through decrease 
./___Corpus/Medline/xml/PMC5123381.xml	STAT-3	700075 : 700081	CM	ving activity to inhibit STAT-3 or NF-κB were found to s
./___Corpus/Medline/xml/PMC5123381.xml	NF-κB	700085 : 700090	CM	ity to inhibit STAT-3 or NF-κB were found to suppress I
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700135 : 700139	CM	ess IL-6 production from OCCC and to restore immuno-co
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	700247 : 700253	CM	ons                      HNF-1β activation in human OCCC
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700274 : 700278	CM	F-1β activation in human OCCC is a possible upstream e
./___Corpus/Medline/xml/PMC5123381.xml	IL-8	700355 : 700359	CM	osuppression by IL-6 and IL-8 production via NF-κB and
./___Corpus/Medline/xml/PMC5123381.xml	NF-κB	700375 : 700380	CM	 and IL-8 production via NF-κB and STAT3 activation and
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	700385 : 700390	CM	production via NF-κB and STAT3 activation and that comb
./___Corpus/Medline/xml/PMC5123381.xml	HNF-1β	700442 : 700448	CM	ation of drugs targeting HNF-1β/STAT3/NF-kB pathway may 
./___Corpus/Medline/xml/PMC5123381.xml	STAT3	700449 : 700454	CM	f drugs targeting HNF-1β/STAT3/NF-kB pathway may enhanc
./___Corpus/Medline/xml/PMC5123381.xml	NF-kB	700455 : 700460	CM	s targeting HNF-1β/STAT3/NF-kB pathway may enhance the 
./___Corpus/Medline/xml/PMC5123381.xml	OCCC	700525 : 700529	CM	rent immunotherapies for OCCC patients.               
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	700846 : 700850	CM	c ductal adenocarcinoma (PDAC) is characterized by a f
./___Corpus/Medline/xml/PMC5123381.xml	anti-	701092 : 701097	CPR	ape via sequestration of anti-tumor CD8+ T cells, upreg
./___Corpus/Medline/xml/PMC5123381.xml	CD8+	701103 : 701107	CM	uestration of anti-tumor CD8+ T cells, upregulation of
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	701192 : 701200	CM	n, and immunosuppressive cytokine production and polarizat
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	701393 : 701399	CM	etent C57BL/6 mice using Panc02 cells. From days 7-20, m
./___Corpus/Medline/xml/PMC5123381.xml	7-	701417 : 701419	CPR	 Panc02 cells. From days 7-20, mice were treated wit
./___Corpus/Medline/xml/PMC5123381.xml	FAP	701446 : 701449	CM	, mice were treated with FAP inhibitor UAMC-1110 or c
./___Corpus/Medline/xml/PMC5123381.xml	UAMC-1110	701460 : 701469	CM	eated with FAP inhibitor UAMC-1110 or control. Radiation (R
./___Corpus/Medline/xml/PMC5123381.xml	10Gy	701608 : 701612	CM	ation Research Platform, 10Gy x 3 daily fractions on d
./___Corpus/Medline/xml/PMC5123381.xml	Panc02	701695 : 701701	CM	ice were challenged with Panc02 or Panc02-SIY cells and 
./___Corpus/Medline/xml/PMC5123381.xml	Panc02-SIY	701705 : 701715	CM	hallenged with Panc02 or Panc02-SIY cells and radiated 10Gy 
./___Corpus/Medline/xml/PMC5123381.xml	10Gy	701735 : 701739	CM	2-SIY cells and radiated 10Gy x 3 on days 14-16. Tumor
./___Corpus/Medline/xml/PMC5123381.xml	14-	701752 : 701755	CPR	adiated 10Gy x 3 on days 14-16. Tumors were measured,
./___Corpus/Medline/xml/PMC5123381.xml	SIY	701997 : 702000	CM	arvested and pulsed with SIY peptide and tested for i
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	702038 : 702046	CM	tested for intracellular cytokine production on day 14 and
./___Corpus/Medline/xml/PMC5123381.xml	M1	702168 : 702170	CM	s performed to determine M1 vs M2 polarization. Tumo
./___Corpus/Medline/xml/PMC5123381.xml	M2	702174 : 702176	CM	ormed to determine M1 vs M2 polarization. Tumor cyto
./___Corpus/Medline/xml/PMC5123381.xml	cytokine	702227 : 702235	CM	ines were assessed using cytokine bead assay.             
./___Corpus/Medline/xml/PMC5123381.xml	UAMC-1110	702294 : 702303	CM	lts                      UAMC-1110 alone had no effect on t
./___Corpus/Medline/xml/PMC5123381.xml	UAMC-1110	702465 : 702474	CM	tment with radiation and UAMC-1110 resulted in two temporal
./___Corpus/Medline/xml/PMC5123381.xml	UAMC-1110	702704 : 702713	CM	tage over RT. At day 14, UAMC-1110 treatment resulted in fe
./___Corpus/Medline/xml/PMC5123381.xml	CD11b+	702779 : 702785	CM	 At day 23, RT increased CD11b+ tumor infiltrates, MDSCs
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	702805 : 702810	CM	D11b+ tumor infiltrates, MDSCs, and CD3+ infiltrates. T
./___Corpus/Medline/xml/PMC5123381.xml	CD3+	702816 : 702820	CM	 infiltrates, MDSCs, and CD3+ infiltrates. Tumor immun
./___Corpus/Medline/xml/PMC5123381.xml	UAMC-1110	702927 : 702936	CM	mbination treatment with UAMC-1110 increased collagen depos
./___Corpus/Medline/xml/PMC5123381.xml	FAP	703053 : 703056	CM	red to wildtype control. FAP KO tumors had fewer macr
./___Corpus/Medline/xml/PMC5123381.xml	KO	703057 : 703059	CM	to wildtype control. FAP KO tumors had fewer macroph
./___Corpus/Medline/xml/PMC5123381.xml	MDSCs	703093 : 703098	CM	ad fewer macrophages and MDSCs, and more antigen-specif
./___Corpus/Medline/xml/PMC5123381.xml	FAP	703260 : 703263	CM	 tested a novel specific FAP inhibitor with radiation
./___Corpus/Medline/xml/PMC5123381.xml	murine	703294 : 703300	CM	itor with radiation in a murine PDAC model. We found FAP
./___Corpus/Medline/xml/PMC5123381.xml	PDAC	703301 : 703305	CM	th radiation in a murine PDAC model. We found FAP inhi
./___Corpus/Medline/xml/PMC5123381.xml	FAP	703322 : 703325	CM	ine PDAC model. We found FAP inhibition favorably alt
./___Corpus/Medline/xml/PMC5123381.xml	CAFs	703537 : 703541	CM	selectively expressed by CAFs, inhibition of its funct
./___Corpus/Medline/xml/PMC5123381.xml	CAFs	703677 : 703681	CM	mprehensive targeting of CAFs may be required to influ
./___Corpus/Medline/xml/PMC5123381.xml	Arginase	703910 : 703918	CM	k.                  P417 Arginase 2 blockage and reduction
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	703947 : 703952	CM	lockage and reduction of PD-L1 expression in renal cell
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	704408 : 704412	CM	e FDA has approved novel PD-1 immunotherapies, which h
./___Corpus/Medline/xml/PMC5123381.xml	arginase	704806 : 704814	CM	ying the role the enzyme arginase 2 (ARG2) plays in the ex
./___Corpus/Medline/xml/PMC5123381.xml	ARG2	704818 : 704822	CM	e the enzyme arginase 2 (ARG2) plays in the expression
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	704851 : 704856	CM	ays in the expression of PD-L1 in RCC tumors. Different
./___Corpus/Medline/xml/PMC5123381.xml	ARG2	704892 : 704896	CM	ors. Different levels of ARG2 expression in RCC contri
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	705220 : 705225	CM	s that the expression of PD-L1 in RCC tumors is regulat
./___Corpus/Medline/xml/PMC5123381.xml	ARG2	705256 : 705260	CM	C tumors is regulated by ARG2 and blocking this enzyme
./___Corpus/Medline/xml/PMC5123381.xml	murine	705408 : 705414	CM	                   Three murine RCC cell lines, CL-2 (lo
./___Corpus/Medline/xml/PMC5123381.xml	low-ARG2	705437 : 705445	CM	ne RCC cell lines, CL-2 (low-ARG2), CL-19 (high-ARG2), and
./___Corpus/Medline/xml/PMC5123381.xml	median-ARG2	705478 : 705489	CM	 (high-ARG2), and Renca (median-ARG2) were cultured at differ
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	705579 : 705583	CM	e presence or absence of IFNγ and ARG2 inhibitor BEC. 
./___Corpus/Medline/xml/PMC5123381.xml	ARG2	705588 : 705592	CM	e or absence of IFNγ and ARG2 inhibitor BEC. Expressio
./___Corpus/Medline/xml/PMC5123381.xml	BEC	705603 : 705606	CM	 IFNγ and ARG2 inhibitor BEC. Expression of PD-L1 was
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	705622 : 705627	CM	bitor BEC. Expression of PD-L1 was assessed by flow cyt
./___Corpus/Medline/xml/PMC5123381.xml	MTT	705683 : 705686	CM	, tumor cell survival by MTT assay, ARG activity by e
./___Corpus/Medline/xml/PMC5123381.xml	ARG	705694 : 705697	CM	l survival by MTT assay, ARG activity by enzymatic as
./___Corpus/Medline/xml/PMC5123381.xml	L-arginine	705748 : 705758	CM	ays and supernatants for L-arginine by HPLC.                
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	705814 : 705819	CM	lts                      PD-L1 expression was similar b
./___Corpus/Medline/xml/PMC5123381.xml	CL-2	705851 : 705855	CM	sion was similar between CL-2 and CL-19 cell lines (17
./___Corpus/Medline/xml/PMC5123381.xml	17-	705878 : 705881	CPR	-2 and CL-19 cell lines (17-20 %) that significantly 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	705940 : 705944	CM	 up to 95 % after 6 h of IFNγ stimulation (2.5 U/ML). 
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	706030 : 706035	CM	utive high expression of PD-L1 in Renca cells (85-90 %)
./___Corpus/Medline/xml/PMC5123381.xml	85-	706052 : 706055	CPR	of PD-L1 in Renca cells (85-90 %) in non-stimulated c
./___Corpus/Medline/xml/PMC5123381.xml	ARG2	706115 : 706119	CM	 cells were treated with ARG2 inhibitor, PD-L1 express
./___Corpus/Medline/xml/PMC5123381.xml	PD-L1	706131 : 706136	CM	ted with ARG2 inhibitor, PD-L1 expression decreased 5 f
./___Corpus/Medline/xml/PMC5123381.xml	CL-2	706168 : 706172	CM	sion decreased 5 fold in CL-2 and CL19 cells but had n
./___Corpus/Medline/xml/PMC5123381.xml	CL19	706177 : 706181	CM	eased 5 fold in CL-2 and CL19 cells but had not effect
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	706246 : 706250	CM	. High concentrations of IFNγ (10U/ML) had cytotoxic e
./___Corpus/Medline/xml/PMC5123381.xml	10U	706252 : 706255	CM	 concentrations of IFNγ (10U/ML) had cytotoxic effect
./___Corpus/Medline/xml/PMC5123381.xml	CL-2	706285 : 706289	CM	had cytotoxic effects in CL-2 and CL-19 but not in Ren
./___Corpus/Medline/xml/PMC5123381.xml	PD-1	706612 : 706616	CM	benefit or not from anti PD-1 therapy. 2) The role of 
./___Corpus/Medline/xml/PMC5123381.xml	IFNγ	706641 : 706645	CM	 therapy. 2) The role of IFNγ in this process is uncle
./___Corpus/Medline/xml/PMC5123381.xml	Li	708659 : 708661	CM	.hin@mehsel.nimsaj. Qiao Li, Email: ude.hcimu.dem@il
./___Corpus/Medline/xml/PMC5123381.xml	Y	709002 : 709003	CM	uso@nniuqcm.rehpotsirhC. Y. Maurice Morillon, Email
./___Corpus/Medline/xml/PMC5123381.xml	R	709059 : 709060	CM	hin@nollirom.sevy. Pulak R. Nath, Email: vog.hin@ht
./___Corpus/Medline/xml/PMC5123381.xml	P	709716 : 709717	CM	g.hin.liam@pyrawet. John P. Vasilakos, Email: moc.m
./___Corpus/Medline/xml/PMC5123381.xml	Xu	709864 : 709866	CM	@sehtyw.nitram. Chunxiao Xu, Email: moc.onoresdme@ux
./___Corpus/Medline/xml/PMC5123381.xml	H	710472 : 710473	CM	n@ztrawhcs.ynohtna. Neil H. Segal, Email: gro.ccksm
./___Corpus/Medline/xml/PMC5123381.xml	P	712383 : 712384	CM	egolom@tdimhcsam. Julian P. Sefrin, Email: moc.ehco
./___Corpus/Medline/xml/PMC5123381.xml	Anil	713842 : 713846	CM	de.cmm.liame@41kcirnera. Anil Shanker, Email: ude.cmm@
./___Corpus/Medline/xml/PMC5123381.xml	Su	713888 : 713890	CM	ude.cmm@reknahsa. Yu-Lin Su, Email: gro.hoc@usluy. S
./___Corpus/Medline/xml/PMC5123381.xml	Li	714664 : 714666	CM	: moc.oruda@gnoelm. Qiao Li, Email: ude.hcimu@iloaiq
./___Corpus/Medline/xml/PMC5123381.xml	H	715788 : 715789	CM	e.ttip@onurbt. Anissa S. H. Chan, Email: moc.arehto
./___Corpus/Medline/xml/PMC5123381.xml	Hix	716166 : 716169	CM	.aibmuloc@9212gdr. Laura Hix Glickman, Email: moc.oru
./___Corpus/Medline/xml/PMC5123381.xml	W	716791 : 716792	CM	: ude.cmpu@5zuil. Amanda W. Lund, Email: ude.usho@a
./___Corpus/Medline/xml/PMC5123381.xml	P	717237 : 717238	CM	noecafrus@nosretapa. Jay P. Powers, Email: moc.oibs
./___Corpus/Medline/xml/PMC5123381.xml	Jr	717458 : 717460	CM	was. Craig L. Slingluff, Jr, Email: ude.ainigriv@h8s
./___Corpus/Medline/xml/PMC5352101.xml	IGF	62 : 65	CM	ulin-like growth factor (IGF) signaling system plays 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	288 : 293	CM	) and its primary ligand IGF-I are important for mainta
./___Corpus/Medline/xml/PMC5352101.xml	BCR-ABL1	977 : 985	CM	ms. The discovery of the BCR-ABL1 fusion oncogene and defi
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	1130 : 1138	CM	e development of BCR-ABL tyrosine kinase inhibitors such a
./___Corpus/Medline/xml/PMC5352101.xml	imatinib	1165 : 1173	CM	inase inhibitors such as imatinib, nilotinib, and dasatini
./___Corpus/Medline/xml/PMC5352101.xml	nilotinib	1175 : 1184	CM	bitors such as imatinib, nilotinib, and dasatinib, which ha
./___Corpus/Medline/xml/PMC5352101.xml	dasatinib	1190 : 1199	CM	imatinib, nilotinib, and dasatinib, which have improved the
./___Corpus/Medline/xml/PMC5352101.xml	10-	1225 : 1228	CPR	 which have improved the 10-year survival rate drasti
./___Corpus/Medline/xml/PMC5352101.xml	CML	1262 : 1265	CM	ival rate drastically in CML patients, from 20% to 85
./___Corpus/Medline/xml/PMC5352101.xml	1–	1293 : 1295	CPR	tients, from 20% to 85% [1–5]. In patients diagnosed
./___Corpus/Medline/xml/PMC5352101.xml	anti-CD20	1395 : 1404	CM	lymphoma, the use of the anti-CD20 antibody rituximab has r
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	2141 : 2146	CM	) and its primary ligand IGF-I play significant roles i
./___Corpus/Medline/xml/PMC5352101.xml	7–	2290 : 2292	CPR	cellular transformation [7–10]. IGF-IR is also thoug
./___Corpus/Medline/xml/PMC5352101.xml	13–	3032 : 3035	CPR	 skin, and soft tissues [13–17]. In contrast, less st
./___Corpus/Medline/xml/PMC5352101.xml	18–	3159 : 3162	CPR	hematological neoplasms [18–24]. In this review, we d
./___Corpus/Medline/xml/PMC5352101.xml	IGF	3439 : 3442	CM	es.                  THE IGF SIGNALING SYSTEM Overvie
./___Corpus/Medline/xml/PMC5352101.xml	SIGNALING	3443 : 3452	CM	                 THE IGF SIGNALING SYSTEM Overview         
./___Corpus/Medline/xml/PMC5352101.xml	IGF	3494 : 3497	CM	                     The IGF signaling system plays s
./___Corpus/Medline/xml/PMC5352101.xml	IGF	3653 : 3656	CM	al adult physiology. The IGF system includes four rec
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	3882 : 3887	CM	e main ligands: insulin, IGF-I, and IGF-II. IR, IGF-IR,
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	4036 : 4041	CM	of insulin to IGF-IR and IGF-I to IR is at least 100-fo
./___Corpus/Medline/xml/PMC5352101.xml	100-fold	4060 : 4068	CM	 IGF-I to IR is at least 100-fold less [25]. IGF-I and IGF
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	4080 : 4085	CM	east 100-fold less [25]. IGF-I and IGF-II signaling is 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	4139 : 4144	CM	ated through IGF-IR; but IGF-I has at least 3-fold high
./___Corpus/Medline/xml/PMC5352101.xml	3-fold	4158 : 4164	CM	; but IGF-I has at least 3-fold higher binding affinity 
./___Corpus/Medline/xml/PMC5352101.xml	IGF	4216 : 4219	CM	an does IGF-II [25]. The IGF system also includes reg
./___Corpus/Medline/xml/PMC5352101.xml	IGF	4271 : 4274	CM	atory proteins, known as IGF binding proteins (IGFBPs
./___Corpus/Medline/xml/PMC5352101.xml	IGF	4315 : 4318	CM	s (IGFBPs) that regulate IGF signaling. Although up t
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP-6	4428 : 4435	CM	s, only IGFBP-1 thorough IGFBP-6 are considered true IGFB
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	4536 : 4541	CM	igh binding affinity for IGF-I and IGF-II [26].        
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	4625 : 4633	CM	    IGF-IR is a receptor tyrosine kinase that is structura
./___Corpus/Medline/xml/PMC5352101.xml	disulfide	4750 : 4759	CM	ts that are connected by disulfide bonds to form the functi
./___Corpus/Medline/xml/PMC5352101.xml	cysteine	4897 : 4905	CM	acellular and contains a cysteine rich domain that forms t
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	4970 : 4975	CM	ing site for its ligands IGF-I, IGF-II, and, to a much 
./___Corpus/Medline/xml/PMC5352101.xml	24-	5077 : 5080	CPR	 extracellular domain, a 24-residue hydrophobic trans
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	5170 : 5180	CM	c region that shares 84% amino acid sequence identity with t
./___Corpus/Medline/xml/PMC5352101.xml	Tyrosine	5217 : 5225	CM	entity with the IR [27]. Tyrosine 950 is the binding site 
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	5269 : 5274	CM	 site for its substrates IRS-1 and SHC, among others. T
./___Corpus/Medline/xml/PMC5352101.xml	SHC	5279 : 5282	CM	its substrates IRS-1 and SHC, among others. The intra
./___Corpus/Medline/xml/PMC5352101.xml	ATP	5352 : 5355	CM	he β subunit contains an ATP binding site at lysine 1
./___Corpus/Medline/xml/PMC5352101.xml	lysine	5372 : 5378	CM	s an ATP binding site at lysine 1003. It also contains a
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5477 : 5485	CM	ade up of three critical tyrosine residues at positions 11
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5553 : 5559	CM	, which form part of the YXXXYY moiety (Y is a tyrosine 
./___Corpus/Medline/xml/PMC5352101.xml	Y	5568 : 5569	CM	rt of the YXXXYY moiety (Y is a tyrosine and X is a
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5575 : 5583	CM	he YXXXYY moiety (Y is a tyrosine and X is a non-tyrosine 
./___Corpus/Medline/xml/PMC5352101.xml	X	5588 : 5589	CM	ety (Y is a tyrosine and X is a non-tyrosine amino 
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	5608 : 5618	CM	 and X is a non-tyrosine amino acid residues). It is importa
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5663 : 5669	CM	portant to note that the YXXXYY moiety is also present i
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5786 : 5794	CM	nase (ALK) and leukocyte tyrosine kinase receptors [28–30]
./___Corpus/Medline/xml/PMC5352101.xml	28–	5813 : 5816	CPR	rosine kinase receptors [28–30]. The tyrosine residue
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	5825 : 5833	CM	e receptors [28–30]. The tyrosine residues within the YXXX
./___Corpus/Medline/xml/PMC5352101.xml	YXXXYY	5854 : 5860	CM	sine residues within the YXXXYY moiety become phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	5875 : 5889	RN	the YXXXYY moiety become phosphorylated upon ligand binding-indu
./___Corpus/Medline/xml/PMC5352101.xml	C-	6101 : 6103	CPR	                    The C-terminus domain of IGF-IR 
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6145 : 6153	CM	 IGF-IR contains several tyrosine and serine residues. The
./___Corpus/Medline/xml/PMC5352101.xml	serine	6158 : 6164	CM	ins several tyrosine and serine residues. These residues
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	6194 : 6208	RN	dues. These residues are phosphorylated, probably to induce mito
./___Corpus/Medline/xml/PMC5352101.xml	mitogenic	6229 : 6238	CM	ated, probably to induce mitogenic effects, but how their p
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6262 : 6277	RN	c effects, but how their phosphorylation actually contributes to 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6419 : 6434	RN	o its ligands causes the phosphorylation of tyrosine residues loc
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6438 : 6446	CM	s the phosphorylation of tyrosine residues located in the 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	6516 : 6530	CM	n of its β subunit. Once phosphorylated, tyrosine 950 provides a
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	6532 : 6540	CM	it. Once phosphorylated, tyrosine 950 provides a docking s
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1-4	6601 : 6608	CM	-IR substrates including IRS-1-4 and SHC proteins, which,
./___Corpus/Medline/xml/PMC5352101.xml	SHC	6613 : 6616	CM	es including IRS-1-4 and SHC proteins, which, in turn
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	6692 : 6707	RN	on substrate binding and phosphorylation of docking sites, downst
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	6772 : 6776	CM	is activated through the PI3K/AKT, MAPK, and STAT path
./___Corpus/Medline/xml/PMC5352101.xml	AKT	6777 : 6780	CM	tivated through the PI3K/AKT, MAPK, and STAT pathways
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	6782 : 6786	CM	ed through the PI3K/AKT, MAPK, and STAT pathways and m
./___Corpus/Medline/xml/PMC5352101.xml	STAT	6792 : 6796	CM	 the PI3K/AKT, MAPK, and STAT pathways and may stimula
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	6859 : 6868	CM	l growth in an autocrine/paracrine manner [31–33] (Figure ​
./___Corpus/Medline/xml/PMC5352101.xml	31–	6877 : 6880	CPR	ocrine/paracrine manner [31–33] (Figure ​(Figure33). 
./___Corpus/Medline/xml/PMC5352101.xml	34–	7306 : 7309	CPR	tal and cardiac muscles [34–38]. IGF-IR also plays ro
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	7947 : 7952	CM	r the marked decrease in IGF-I levels leads to generali
./___Corpus/Medline/xml/PMC5352101.xml	40–	8108 : 8111	CPR	 nervous system [35, 38, 40–43]. Mice lacking the ent
./___Corpus/Medline/xml/PMC5352101.xml	20-	8546 : 8549	CPR	th [12]. Within the past 20-30 years, evidence has em
./___Corpus/Medline/xml/PMC5352101.xml	RM11A	9331 : 9336	CM	ation. For example, when RM11A murine breast cancer cel
./___Corpus/Medline/xml/PMC5352101.xml	murine	9337 : 9343	CM	 For example, when RM11A murine breast cancer cells that
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	9427 : 9432	CM	IGF-IR were treated with IGF-I or IGF-II, the prolifera
./___Corpus/Medline/xml/PMC5352101.xml	RM11A	9591 : 9596	CM	he other hand, wild-type RM11A cells expressing low lev
./___Corpus/Medline/xml/PMC5352101.xml	IGF	9660 : 9663	CM	had a robust response to IGF stimulation, most likely
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	9781 : 9786	CM	IR is still dependent on IGF-I stimulation. Therefore, 
./___Corpus/Medline/xml/PMC5352101.xml	3T3	10176 : 10179	CM	6, 47]. For instance, in 3T3-like fibroblasts, the IG
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	10331 : 10336	CM	n after stimulation with IGF-I [46]. Similarly, in a pa
./___Corpus/Medline/xml/PMC5352101.xml	PANC-1	10381 : 10387	CM	 a pancreatic cell line, PANC-1, the observed increase i
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	10501 : 10506	CM	range required to enable IGF-I-stimulated growth and th
./___Corpus/Medline/xml/PMC5352101.xml	IGF	10839 : 10842	CM	              Studies on IGF system in normal epithel
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	10982 : 10987	CM	 one of two ways through IGF-I: (1) hepatic production 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11015 : 11020	CM	1) hepatic production of IGF-I can increase serum IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11040 : 11045	CM	IGF-I can increase serum IGF-I, which in turn may act i
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11212 : 11217	CM	 (2) local production of IGF-I by stromal cells that su
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	11283 : 11292	CM	igenic cells serves as a paracrine stimulator of the IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11394 : 11399	CM	the interactions between IGF-I and IGF-IR enhance tumor
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11540 : 11545	CM	n prostate cancer cells, IGF-I is thought to indirectly
./___Corpus/Medline/xml/PMC5352101.xml	androgen	11585 : 11593	CM	indirectly stimulate the androgen receptor via crosstalk w
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	11723 : 11728	CM	The oncogenic effects of IGF-I/IGF-IR interactions have
./___Corpus/Medline/xml/PMC5352101.xml	IGFs	11883 : 11887	CM	rmal colonic mucosa, and IGFs in colonic malignant muc
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	11958 : 11967	CM	 effects via IGF-IR in a paracrine manner [51–53].         
./___Corpus/Medline/xml/PMC5352101.xml	51–	11976 : 11979	CPR	R in a paracrine manner [51–53].                     
./___Corpus/Medline/xml/PMC5352101.xml	AML	12304 : 12307	CM	te myelogenous leukemia (AML) and acute lymphoblastic
./___Corpus/Medline/xml/PMC5352101.xml	56–	12349 : 12352	CPR	oblastic leukemia (ALL) [56–64]. In addition, studies
./___Corpus/Medline/xml/PMC5352101.xml	CLL	12592 : 12595	CM	ic lymphocytic leukemia (CLL), and CML [20–24, 65].  
./___Corpus/Medline/xml/PMC5352101.xml	CML	12602 : 12605	CM	ytic leukemia (CLL), and CML [20–24, 65].            
./___Corpus/Medline/xml/PMC5352101.xml	20–	12607 : 12610	CPR	leukemia (CLL), and CML [20–24, 65].                 
./___Corpus/Medline/xml/PMC5352101.xml	mannose-6-phosphate	12804 : 12823	CM	s the cation-independent mannose-6-phosphate receptor, acts as a rese
./___Corpus/Medline/xml/PMC5352101.xml	66–	13027 : 13030	CPR	 tumor growth signaling [66–68]. Therefore, IGF-IIR i
./___Corpus/Medline/xml/PMC5352101.xml	69–	13358 : 13361	CPR	 gastrointestinal tract [69–71]. In addition, loss of
./___Corpus/Medline/xml/PMC5352101.xml	72–	13502 : 13505	CPR	eck, and breast cancers [72–76]. While loss of hetero
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	13835 : 13840	CM	7, 78].                  IGF-I and IGF-II              
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	13873 : 13878	CM	-II                      IGF-I is a single-chain peptid
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	13929 : 13939	CM	 that shares 62% and 40% amino acid sequence identities with
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14007 : 14012	CM	ulin, respectively [79]. IGF-I is synthesized in a vari
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	14129 : 14138	CM	n may have autocrine and paracrine effector functions, unli
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14300 : 14305	CM	 80]. Liver secretion of IGF-I is regulated by the grow
./___Corpus/Medline/xml/PMC5352101.xml	GH	14342 : 14344	CM	d by the growth hormone (GH), which signals peripher
./___Corpus/Medline/xml/PMC5352101.xml	glucose	14429 : 14436	CM	 is tightly regulated by glucose uptake [80, 81]. Therefo
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14529 : 14534	CM	tabolic effects, whereas IGF-I is essentially a growth 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14627 : 14632	CM	                         IGF-I is a ~7.6 kDa 70 amino a
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	14650 : 14660	CM	  IGF-I is a ~7.6 kDa 70 amino acid single chain polypeptide
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14769 : 14774	CM	increasing evidence that IGF-I might provide a major li
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	14982 : 14987	CM	 not necessarily secrete IGF-I, high concentrations of 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	15024 : 15029	CM	ntrations of circulating IGF-I, which is secreted by th
./___Corpus/Medline/xml/PMC5352101.xml	82–	15217 : 15220	CPR	d progression of cancer [82–86]. Mouse models have sh
./___Corpus/Medline/xml/PMC5352101.xml	androgen	15274 : 15282	CM	reduced proliferation of androgen-dependent prostate cance
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	15318 : 15323	CM	prostate cancer cells in IGF-I-deficient hosts relative
./___Corpus/Medline/xml/PMC5352101.xml	transgenic	15447 : 15457	CM	ate epithelium from Igf1 transgenic mice [88]. In breast can
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	15519 : 15524	CM	been shown that elevated IGF-I levels can reduce the sy
./___Corpus/Medline/xml/PMC5352101.xml	estrogen	15646 : 15654	CM	n the bioavailability of estrogen. Estrogen has been demon
./___Corpus/Medline/xml/PMC5352101.xml	Estrogen	15656 : 15664	CM	vailability of estrogen. Estrogen has been demonstrated to
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	15733 : 15738	CM	ion of IGF-IR as well as IRS-1 and IRS-2, which synergi
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	15743 : 15748	CM	-IR as well as IRS-1 and IRS-2, which synergistically p
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	15801 : 15805	CM	ntiate the activation of MAPK [89].                   
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	15874 : 15884	CM	 IGF-II is a ~7.5 kDa 67 amino acid single chain mitogenic p
./___Corpus/Medline/xml/PMC5352101.xml	mitogenic	15898 : 15907	CM	 amino acid single chain mitogenic polypeptide that is prod
./___Corpus/Medline/xml/PMC5352101.xml	90–	15962 : 15965	CPR	mainly by the liver [68, 90–93]. It is also synthesiz
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	16096 : 16105	CM	 through an autocrine or paracrine manner, similar to IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	16125 : 16130	CM	crine manner, similar to IGF-I [94, 95]. Physiologicall
./___Corpus/Medline/xml/PMC5352101.xml	96–	16316 : 16319	CPR	ion, and metabolism [90, 96–104]. Unlike IGF-I that i
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	16332 : 16337	CM	ism [90, 96–104]. Unlike IGF-I that is tightly regulate
./___Corpus/Medline/xml/PMC5352101.xml	GH	16367 : 16369	CM	 is tightly regulated by GH, genetic factors, such a
./___Corpus/Medline/xml/PMC5352101.xml	107–	16882 : 16886	CPR	e-induced transcription [107–112]. IGF-II is believed 
./___Corpus/Medline/xml/PMC5352101.xml	IR-A	16970 : 16974	CM	gh IGF-IR, IR isoform A (IR-A), and IGF-IR/IR-A hybrid
./___Corpus/Medline/xml/PMC5352101.xml	IR-A	16988 : 16992	CM	orm A (IR-A), and IGF-IR/IR-A hybrid receptors. Simila
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	17022 : 17027	CM	id receptors. Similar to IGF-I, the binding of IGF-II t
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	17098 : 17102	CM	stream signaling via the PI3K/AKT and MAPK pathways [1
./___Corpus/Medline/xml/PMC5352101.xml	AKT	17103 : 17106	CM	m signaling via the PI3K/AKT and MAPK pathways [113].
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	17111 : 17115	CM	ing via the PI3K/AKT and MAPK pathways [113]. IGF-II i
./___Corpus/Medline/xml/PMC5352101.xml	vitro	17291 : 17296	CM	en demonstrated using in vitro and in vivo experimental
./___Corpus/Medline/xml/PMC5352101.xml	114–	17375 : 17379	CPR	cer patients' specimens [114–120]. Moreover, in vivo s
./___Corpus/Medline/xml/PMC5352101.xml	SIGNALING	17672 : 17681	CM	          ROLE OF IGF-IR SIGNALING IN HEMATOLOGICAL MALIGNA
./___Corpus/Medline/xml/PMC5352101.xml	PCM	17774 : 17777	CM	    Plasma cell myeloma (PCM) accounts for approximat
./___Corpus/Medline/xml/PMC5352101.xml	PCM	18016 : 18019	CM	ment. The development of PCM occurs in steps. Normal 
./___Corpus/Medline/xml/PMC5352101.xml	G1	18085 : 18087	CM	 usually arrested in the G1 phase of the cell cycle;
./___Corpus/Medline/xml/PMC5352101.xml	PCM	18132 : 18135	CM	ycle; however, malignant PCM cells exhibit uncontroll
./___Corpus/Medline/xml/PMC5352101.xml	PCM	18187 : 18190	CM	 cell cycle progression. PCM cells initially reside i
./___Corpus/Medline/xml/PMC5352101.xml	123–	18427 : 18431	CPR	urrounding angiogenesis [123–125]. The plasma cells th
./___Corpus/Medline/xml/PMC5352101.xml	PCM	18696 : 18699	CM	-6R) signaling decreases PCM tumor growth in vitro an
./___Corpus/Medline/xml/PMC5352101.xml	vitro	18716 : 18721	CM	ases PCM tumor growth in vitro and in vivo [126–129].  
./___Corpus/Medline/xml/PMC5352101.xml	126–	18735 : 18739	CPR	th in vitro and in vivo [126–129].                    
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	18832 : 18837	CM	has also been shown that IGF-I induces the growth and d
./___Corpus/Medline/xml/PMC5352101.xml	PCM	18876 : 18879	CM	rowth and development of PCM through activation of IG
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	18963 : 18968	CM	tudies demonstrated that IGF-I is capable of increasing
./___Corpus/Medline/xml/PMC5352101.xml	PCM	19072 : 19075	CM	proliferation of several PCM cell lines. The effects 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19103 : 19108	CM	ll lines. The effects of IGF-I were reversed when an an
./___Corpus/Medline/xml/PMC5352101.xml	anti-	19131 : 19136	CPR	-I were reversed when an anti-IGF-IR blocking antibody 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19238 : 19243	CM	 of an important role of IGF-I/IGF-IR signaling in PCM,
./___Corpus/Medline/xml/PMC5352101.xml	PCM	19264 : 19267	CM	GF-I/IGF-IR signaling in PCM, studies from different 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19320 : 19325	CM	s showed that IGF-IR and IGF-I are highly expressed in 
./___Corpus/Medline/xml/PMC5352101.xml	PCM	19350 : 19353	CM	 are highly expressed in PCM, and that the IGF-I/IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19368 : 19373	CM	sed in PCM, and that the IGF-I/IGF-IR signaling axis, a
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19605 : 19610	CM	nal relationship between IGF-I/IGF-IR and IL-6 in PCM. 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19664 : 19669	CM	ne model, the effects of IGF-I and IL-6 on PCM cells ap
./___Corpus/Medline/xml/PMC5352101.xml	PCM	19682 : 19685	CM	cts of IGF-I and IL-6 on PCM cells appeared to be exe
./___Corpus/Medline/xml/PMC5352101.xml	anti-	19739 : 19744	CPR	d independently. Indeed, anti-IGF-IR/IGF-I antibodies f
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19751 : 19756	CM	tly. Indeed, anti-IGF-IR/IGF-I antibodies failed to blo
./___Corpus/Medline/xml/PMC5352101.xml	anti-	19839 : 19844	CPR	6. In a similar fashion, anti-IL-6/gp130 antibodies wer
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19911 : 19916	CM	reversing the effects of IGF-I [133]. Importantly, IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	19937 : 19942	CM	GF-I [133]. Importantly, IGF-I and IL-6 were found to i
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	20057 : 20062	CM	In support of this idea, IGF-I/IGF-IR axis induced its 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	20121 : 20136	RN	redominantly through the phosphorylation of IRS-1 protein, which 
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	20140 : 20145	CM	h the phosphorylation of IRS-1 protein, which is consid
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	20196 : 20201	CM	red a major substrate of IGF-I/IGF-IR signaling [31, 13
./___Corpus/Medline/xml/PMC5352101.xml	PCM	20281 : 20284	CM	promoted the survival of PCM cells through the phosph
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	20303 : 20318	RN	of PCM cells through the phosphorylation of STAT3. Both signaling
./___Corpus/Medline/xml/PMC5352101.xml	STAT3	20322 : 20327	CM	h the phosphorylation of STAT3. Both signaling pathways
./___Corpus/Medline/xml/PMC5352101.xml	RAS	20389 : 20392	CM	fficiently activated the RAS/ERK/MAPK survival-promot
./___Corpus/Medline/xml/PMC5352101.xml	ERK	20393 : 20396	CM	iently activated the RAS/ERK/MAPK survival-promoting 
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	20397 : 20401	CM	ly activated the RAS/ERK/MAPK survival-promoting syste
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylate	20471 : 20484	CM	model, IL-6 was found to phosphorylate/activate IGF-IR receptor
./___Corpus/Medline/xml/PMC5352101.xml	PCM	20513 : 20516	CM	ivate IGF-IR receptor in PCM cell lines [136]. Intere
./___Corpus/Medline/xml/PMC5352101.xml	PCM	20570 : 20573	CM	gly, IL-6 stimulation of PCM cells was associated wit
./___Corpus/Medline/xml/PMC5352101.xml	IL-6Rα	20623 : 20629	CM	h co-localization of the IL-6Rα with IGF-IRβ at lipid ra
./___Corpus/Medline/xml/PMC5352101.xml	IGF-IRβ	20635 : 20642	CM	ation of the IL-6Rα with IGF-IRβ at lipid rafts.         
./___Corpus/Medline/xml/PMC5352101.xml	lipid	20646 : 20651	CM	e IL-6Rα with IGF-IRβ at lipid rafts.                  
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	20697 : 20702	CM	                         IGF-I/IGF-IR axis supports the
./___Corpus/Medline/xml/PMC5352101.xml	PCM	20740 : 20743	CM	supports the survival of PCM cells not only via signa
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	20781 : 20786	CM	ly via signaling through IRS-1 but also by singling thr
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	20816 : 20821	CM	also by singling through IRS-2. The IRS-2/PI3K/p70S6K p
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	20827 : 20832	CM	gling through IRS-2. The IRS-2/PI3K/p70S6K pathway was 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	20833 : 20837	CM	through IRS-2. The IRS-2/PI3K/p70S6K pathway was found
./___Corpus/Medline/xml/PMC5352101.xml	p70S6K	20838 : 20844	CM	gh IRS-2. The IRS-2/PI3K/p70S6K pathway was found to be 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	20953 : 20958	CM	stream interactions with IGF-I/IGF-IR [19]. When IRS-2/
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	20977 : 20982	CM	 IGF-I/IGF-IR [19]. When IRS-2/PI3K/p70S6K pathway is c
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	20983 : 20987	CM	/IGF-IR [19]. When IRS-2/PI3K/p70S6K pathway is consti
./___Corpus/Medline/xml/PMC5352101.xml	p70S6K	20988 : 20994	CM	IR [19]. When IRS-2/PI3K/p70S6K pathway is constitutivel
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	21054 : 21059	CM	d, the direct binding of IRS-2 with IGF-IR, regardless 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	21087 : 21092	CM	th IGF-IR, regardless of IGF-I stimulation, induces dow
./___Corpus/Medline/xml/PMC5352101.xml	PCM	21287 : 21290	CM	induces proliferation of PCM cells                   
./___Corpus/Medline/xml/PMC5352101.xml	PCM	21321 : 21324	CM	                      In PCM, IGF-I/IGF-IR signaling 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	21326 : 21331	CM	                 In PCM, IGF-I/IGF-IR signaling inhibit
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	21455 : 21459	CM	 two distinct pathways - PI3K/AKT and MAPK. Which of t
./___Corpus/Medline/xml/PMC5352101.xml	AKT	21460 : 21463	CM	distinct pathways - PI3K/AKT and MAPK. Which of the t
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	21468 : 21472	CM	 pathways - PI3K/AKT and MAPK. Which of the two proces
./___Corpus/Medline/xml/PMC5352101.xml	cytochrome C	21677 : 21689	CM	bition of the release of cytochrome C from the mitochondria af
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	21740 : 21744	CM	er the activation of the PI3K/AKT pathway. Activated A
./___Corpus/Medline/xml/PMC5352101.xml	AKT	21745 : 21748	CM	e activation of the PI3K/AKT pathway. Activated AKT p
./___Corpus/Medline/xml/PMC5352101.xml	AKT	21768 : 21771	CM	K/AKT pathway. Activated AKT phosphorylates the pro-a
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	21772 : 21786	CM	T pathway. Activated AKT phosphorylates the pro-apoptotic protei
./___Corpus/Medline/xml/PMC5352101.xml	BAD	21813 : 21816	CM	he pro-apoptotic protein BAD. Upon phosphorylation, B
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	21823 : 21838	RN	ptotic protein BAD. Upon phosphorylation, BAD becomes dissociated
./___Corpus/Medline/xml/PMC5352101.xml	BAD	21840 : 21843	CM	D. Upon phosphorylation, BAD becomes dissociated from
./___Corpus/Medline/xml/PMC5352101.xml	anti-	21869 : 21874	CPR	becomes dissociated from anti-apoptotic BCL-2 and seque
./___Corpus/Medline/xml/PMC5352101.xml	14-	21929 : 21932	CPR	d by the adaptor protein 14-3-3. These processes prev
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22098 : 22102	CM	or the activation of the PI3K/AKT pathway in PCM is th
./___Corpus/Medline/xml/PMC5352101.xml	AKT	22103 : 22106	CM	e activation of the PI3K/AKT pathway in PCM is the la
./___Corpus/Medline/xml/PMC5352101.xml	PCM	22118 : 22121	CM	 the PI3K/AKT pathway in PCM is the lack of the PTEN 
./___Corpus/Medline/xml/PMC5352101.xml	PTEN	22141 : 22145	CM	n PCM is the lack of the PTEN tumor suppressor protein
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22196 : 22200	CM	 a negative regulator of PI3K/AKT activity [139, 140].
./___Corpus/Medline/xml/PMC5352101.xml	AKT	22201 : 22204	CM	gative regulator of PI3K/AKT activity [139, 140]. The
./___Corpus/Medline/xml/PMC5352101.xml	anti-	22230 : 22235	CPR	activity [139, 140]. The anti-apoptotic effect of PI3K/
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22255 : 22259	CM	anti-apoptotic effect of PI3K/AKT signaling after IGF-
./___Corpus/Medline/xml/PMC5352101.xml	AKT	22260 : 22263	CM	apoptotic effect of PI3K/AKT signaling after IGF-I st
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	22280 : 22285	CM	PI3K/AKT signaling after IGF-I stimulation was found to
./___Corpus/Medline/xml/PMC5352101.xml	PTEN	22346 : 22350	CM	d upon overexpression of PTEN in PCM cell lines lackin
./___Corpus/Medline/xml/PMC5352101.xml	PCM	22354 : 22357	CM	verexpression of PTEN in PCM cell lines lacking PTEN,
./___Corpus/Medline/xml/PMC5352101.xml	PTEN	22377 : 22381	CM	n PCM cell lines lacking PTEN, suggesting that the los
./___Corpus/Medline/xml/PMC5352101.xml	PTEN	22411 : 22415	CM	gesting that the loss of PTEN is also responsible for 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	22468 : 22471	CM	ontrolled IGF-IR-induced AKT activity in these cells 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	22576 : 22580	CM	as the activation of the PI3K/AKT pathway by IGF-IR ap
./___Corpus/Medline/xml/PMC5352101.xml	AKT	22581 : 22584	CM	e activation of the PI3K/AKT pathway by IGF-IR appear
./___Corpus/Medline/xml/PMC5352101.xml	PCM	22668 : 22671	CM	hibition of apoptosis in PCM, activation of the MAPK 
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	22691 : 22695	CM	n PCM, activation of the MAPK pathway is believed to b
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	22801 : 22806	CM	[138]. Ligand binding of IGF-I to IGF-IR allows the pho
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	22828 : 22843	RN	F-I to IGF-IR allows the phosphorylation of the SHC substrate, wh
./___Corpus/Medline/xml/PMC5352101.xml	SHC	22851 : 22854	CM	e phosphorylation of the SHC substrate, which in turn
./___Corpus/Medline/xml/PMC5352101.xml	RAS	22903 : 22906	CM	n leads to activation of RAS that subsequently activa
./___Corpus/Medline/xml/PMC5352101.xml	RAF	22939 : 22942	CM	bsequently activates the RAF kinase on its serine/thr
./___Corpus/Medline/xml/PMC5352101.xml	serine	22957 : 22963	CM	es the RAF kinase on its serine/threonine residues. As a
./___Corpus/Medline/xml/PMC5352101.xml	threonine	22964 : 22973	CM	RAF kinase on its serine/threonine residues. As a result, a
./___Corpus/Medline/xml/PMC5352101.xml	RAF	23007 : 23010	CM	. As a result, activated RAF phosphorylates and activ
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	23011 : 23025	CM	 a result, activated RAF phosphorylates and activates MEK, which
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23040 : 23043	CM	phorylates and activates MEK, which then phosphorylat
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylates	23056 : 23070	CM	ctivates MEK, which then phosphorylates and activates MAPK, lead
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23085 : 23089	CM	phorylates and activates MAPK, leading to the prolifer
./___Corpus/Medline/xml/PMC5352101.xml	PCM	23123 : 23126	CM	 to the proliferation of PCM cells [141].            
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23266 : 23270	CM	IR-induced activation of PI3K/AKT versus IGF-IR-induce
./___Corpus/Medline/xml/PMC5352101.xml	AKT	23271 : 23274	CM	duced activation of PI3K/AKT versus IGF-IR-induced ac
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23311 : 23315	CM	IR-induced activation of MAPK, more recent studies hav
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23383 : 23387	CM	rosstalk” exists between PI3K/AKT and MAPK and that th
./___Corpus/Medline/xml/PMC5352101.xml	AKT	23388 : 23391	CM	alk” exists between PI3K/AKT and MAPK and that this c
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23396 : 23400	CM	sts between PI3K/AKT and MAPK and that this crosstalk 
./___Corpus/Medline/xml/PMC5352101.xml	PCM	23441 : 23444	CM	rosstalk is critical for PCM tumor progression [141, 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	23501 : 23506	CM	n this model, binding of IGF-I to IGF-IR induces phosph
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	23525 : 23540	RN	 IGF-I to IGF-IR induces phosphorylation of RAF, MEK, and MAPK. H
./___Corpus/Medline/xml/PMC5352101.xml	RAF	23544 : 23547	CM	duces phosphorylation of RAF, MEK, and MAPK. However,
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23549 : 23552	CM	 phosphorylation of RAF, MEK, and MAPK. However, inhi
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23558 : 23562	CM	ylation of RAF, MEK, and MAPK. However, inhibition of 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23587 : 23591	CM	. However, inhibition of PI3K using the LY294002 inhib
./___Corpus/Medline/xml/PMC5352101.xml	LY294002	23602 : 23610	CM	bition of PI3K using the LY294002 inhibitor resulted in th
./___Corpus/Medline/xml/PMC5352101.xml	MEK	23651 : 23654	CM	ted in the inhibition of MEK and MAPK without interfe
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23659 : 23663	CM	he inhibition of MEK and MAPK without interfering with
./___Corpus/Medline/xml/PMC5352101.xml	RAF	23716 : 23719	CM	e activation of upstream RAF [141]. This suggests tha
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23750 : 23754	CM	. This suggests that the PI3K pathway is capable of re
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23806 : 23810	CM	lating the activation of MAPK, bypassing upstream acti
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	23884 : 23888	CM	Alternatively, using the MAPK inhibitor PD98059 did no
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	23947 : 23951	CM	gnificant effects on the PI3K pathway, alluding to the
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	24017 : 24021	CM	crosstalk is mediated by PI3K, and not vice versa.    
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24121 : 24130	CM	shion, it was shown that rapamycin-induced mTOR inhibition 
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	24139 : 24143	CM	n that rapamycin-induced mTOR inhibition decreased the
./___Corpus/Medline/xml/PMC5352101.xml	serine	24169 : 24175	CM	inhibition decreased the serine phosphorylation of IRS-1
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	24176 : 24191	RN	ion decreased the serine phosphorylation of IRS-1, which was asso
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	24195 : 24200	CM	erine phosphorylation of IRS-1, which was associated wi
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	24243 : 24248	CM	ated with a compensatory IGF-I downstream signaling via
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	24278 : 24282	CM	stream signaling via the PI3K/AKT pathway [142]. It wa
./___Corpus/Medline/xml/PMC5352101.xml	AKT	24283 : 24286	CM	m signaling via the PI3K/AKT pathway [142]. It was no
./___Corpus/Medline/xml/PMC5352101.xml	anti-	24416 : 24421	CPR	ng the PCM cells with an anti-IGF-IR antibody hindered 
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24461 : 24470	CM	 hindered the ability of rapamycin to activate AKT. Related
./___Corpus/Medline/xml/PMC5352101.xml	AKT	24483 : 24486	CM	of rapamycin to activate AKT. Related observations we
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	24567 : 24575	CM	udy utilizing the IGF-IR tyrosine kinase inhibitor picropo
./___Corpus/Medline/xml/PMC5352101.xml	picropodophyllin	24593 : 24609	CM	yrosine kinase inhibitor picropodophyllin (PPP), where it was foun
./___Corpus/Medline/xml/PMC5352101.xml	PPP	24611 : 24614	CM	ibitor picropodophyllin (PPP), where it was found tha
./___Corpus/Medline/xml/PMC5352101.xml	PPP	24641 : 24644	CM	 where it was found that PPP significantly sensitized
./___Corpus/Medline/xml/PMC5352101.xml	PCM	24680 : 24683	CM	tly sensitized RPMI 8226 PCM cells to rapamycin and S
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	24693 : 24702	CM	d RPMI 8226 PCM cells to rapamycin and SB203580, a MAPK inh
./___Corpus/Medline/xml/PMC5352101.xml	SB203580	24707 : 24715	CM	M cells to rapamycin and SB203580, a MAPK inhibitor [143].
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	24719 : 24723	CM	apamycin and SB203580, a MAPK inhibitor [143]. These o
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	24818 : 24822	CM	le crosstalk between the mTOR and IGF pathways in PCM 
./___Corpus/Medline/xml/PMC5352101.xml	IGF	24827 : 24830	CM	alk between the mTOR and IGF pathways in PCM [142, 14
./___Corpus/Medline/xml/PMC5352101.xml	PCM	24843 : 24846	CM	mTOR and IGF pathways in PCM [142, 144].             
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	24936 : 24941	CM	 the effects mediated by IGF-I, in vitro experiments ha
./___Corpus/Medline/xml/PMC5352101.xml	vitro	24946 : 24951	CM	ts mediated by IGF-I, in vitro experiments have shown t
./___Corpus/Medline/xml/PMC5352101.xml	dexamethasone	25029 : 25042	CM	oliferation and protects dexamethasone-treated PCM cells from a
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25051 : 25054	CM	ts dexamethasone-treated PCM cells from apoptosis [14
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25239 : 25242	CM	ediated proliferation of PCM cells was executed throu
./___Corpus/Medline/xml/PMC5352101.xml	anti-	25290 : 25295	CPR	ough IGF-IR. Whether the anti-apoptotic effects of IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	25426 : 25431	CM	s almost as effective as IGF-I in protecting the PCM ce
./___Corpus/Medline/xml/PMC5352101.xml	dexamethasone	25465 : 25478	CM	cting the PCM cells from dexamethasone-induced apoptosis [145].
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25573 : 25576	CM	vasion, and migration of PCM cells                   
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	25604 : 25609	CM	lls                      IGF-I/IGF-IR signaling is also
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25667 : 25670	CM	d in critical aspects of PCM dissemination, including
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25774 : 25777	CM	al features of malignant PCM cells during homing is t
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	25895 : 25900	CM	ronment. In this regard, IGF-I acts as a chemo-attracta
./___Corpus/Medline/xml/PMC5352101.xml	PCM	25932 : 25935	CM	s a chemo-attractant for PCM cells that increases the
./___Corpus/Medline/xml/PMC5352101.xml	glycoprotein	26000 : 26012	CM	the extracellular matrix glycoprotein fibronectin [146]. This 
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	26119 : 26123	CM	stream targets including PI3K/AKT [146]. In addition, 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	26124 : 26127	CM	m targets including PI3K/AKT [146]. In addition, IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	26148 : 26153	CM	/AKT [146]. In addition, IGF-I can rapidly and transien
./___Corpus/Medline/xml/PMC5352101.xml	PCM	26367 : 26370	CM	s to further adhesion of PCM cells to fibronectin [14
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	26403 : 26418	RN	o fibronectin [146]. The phosphorylation of IGF-IR, IRS-1, and PI
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	26430 : 26435	CM	osphorylation of IGF-IR, IRS-1, and PI3K leads to the c
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	26441 : 26445	CM	on of IGF-IR, IRS-1, and PI3K leads to the co-localiza
./___Corpus/Medline/xml/PMC5352101.xml	lipid	26504 : 26509	CM	GF-IR and β1 integrin on lipid rafts in the cell membra
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	26615 : 26620	CM	has also been shown that IGF-I triggers the polymerizat
./___Corpus/Medline/xml/PMC5352101.xml	F-actin	26652 : 26659	CM	rs the polymerization of F-actin, induces phosphorylation
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	26669 : 26684	RN	tion of F-actin, induces phosphorylation of FAK and paxillin, and
./___Corpus/Medline/xml/PMC5352101.xml	FAK	26688 : 26691	CM	duces phosphorylation of FAK and paxillin, and enhanc
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	26855 : 26860	CM	oenvironment [146, 148]. IGF-I induces the migration of
./___Corpus/Medline/xml/PMC5352101.xml	PCM	26886 : 26889	CM	induces the migration of PCM cells in an AKT-dependen
./___Corpus/Medline/xml/PMC5352101.xml	AKT	26902 : 26905	CM	ation of PCM cells in an AKT-dependent or -independen
./___Corpus/Medline/xml/PMC5352101.xml	PKD	26960 : 26963	CM	ner, such as through the PKD or RhoA/PKC pathway [146
./___Corpus/Medline/xml/PMC5352101.xml	PKC	26972 : 26975	CM	 through the PKD or RhoA/PKC pathway [146, 149, 150].
./___Corpus/Medline/xml/PMC5352101.xml	anti-	27039 : 27044	CPR	her demonstrated when an anti-IGF-I antibody, anti-β1 i
./___Corpus/Medline/xml/PMC5352101.xml	anti-	27060 : 27065	CPR	 an anti-IGF-I antibody, anti-β1 integrin antibody or P
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27089 : 27093	CM	-β1 integrin antibody or PI3K inhibitor abrogated IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	27114 : 27119	CM	PI3K inhibitor abrogated IGF-I-induced transmigration [
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	27261 : 27266	CM	         Upregulation of IGF-I/IGF-IR signaling is prev
./___Corpus/Medline/xml/PMC5352101.xml	AML	27337 : 27340	CM	s of leukemia, including AML, B-ALL, T-ALL, CML, and 
./___Corpus/Medline/xml/PMC5352101.xml	B-ALL	27342 : 27347	CM	leukemia, including AML, B-ALL, T-ALL, CML, and CLL.   
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	27349 : 27354	CM	a, including AML, B-ALL, T-ALL, CML, and CLL.          
./___Corpus/Medline/xml/PMC5352101.xml	CML	27356 : 27359	CM	uding AML, B-ALL, T-ALL, CML, and CLL.               
./___Corpus/Medline/xml/PMC5352101.xml	CLL	27365 : 27368	CM	, B-ALL, T-ALL, CML, and CLL.                        
./___Corpus/Medline/xml/PMC5352101.xml	AML	27460 : 27463	CM	s been reported in human AML cells and autocrine IGF-
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	27484 : 27489	CM	 AML cells and autocrine IGF-I production has been sugg
./___Corpus/Medline/xml/PMC5352101.xml	AML	27557 : 27560	CM	le in drug resistance in AML [18, 56, 57]. Furthermor
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27619 : 27623	CM	tutive activation of the PI3K/AKT signaling pathway is
./___Corpus/Medline/xml/PMC5352101.xml	AKT	27624 : 27627	CM	e activation of the PI3K/AKT signaling pathway is bel
./___Corpus/Medline/xml/PMC5352101.xml	AML	27699 : 27702	CM	roles in the survival of AML cells [151, 152]. Consti
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	27748 : 27752	CM	nstitutive activation of PI3K/AKT, at least in part, r
./___Corpus/Medline/xml/PMC5352101.xml	AKT	27753 : 27756	CM	utive activation of PI3K/AKT, at least in part, resul
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	27799 : 27804	CM	, results from autocrine IGF-I release and activation o
./___Corpus/Medline/xml/PMC5352101.xml	AML	27865 : 27868	CM	hich was shown in 70% of AML samples [18, 57]Several 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	27896 : 27901	CM	mples [18, 57]Several in vitro studies using different 
./___Corpus/Medline/xml/PMC5352101.xml	AML	28005 : 28008	CM	l of targeting IGF-IR in AML. For example, NVP-ADW742
./___Corpus/Medline/xml/PMC5352101.xml	AKT	28081 : 28084	CM	bitor of IGF-IR, induces AKT dephosphorylation, which
./___Corpus/Medline/xml/PMC5352101.xml	dephosphorylation	28085 : 28102	RN	r of IGF-IR, induces AKT dephosphorylation, which subsequently decr
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	28137 : 28152	RN	bsequently decreases p38 phosphorylation and downregulates antiap
./___Corpus/Medline/xml/PMC5352101.xml	AML	28211 : 28214	CM	roteins such as BCL-2 in AML cells [60]. Inhibition o
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	28261 : 28276	RN	n of constitutive IGF-IR phosphorylation as well as downstream si
./___Corpus/Medline/xml/PMC5352101.xml	MEK	28317 : 28320	CM	stream signaling through MEK and AKT was also demonst
./___Corpus/Medline/xml/PMC5352101.xml	AKT	28325 : 28328	CM	ignaling through MEK and AKT was also demonstrated af
./___Corpus/Medline/xml/PMC5352101.xml	AML	28519 : 28522	CM	EW541 sensitized primary AML blasts and cell lines to
./___Corpus/Medline/xml/PMC5352101.xml	etoposide	28548 : 28557	CM	blasts and cell lines to etoposide-induced apoptosis throug
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	28584 : 28593	CM	nduced apoptosis through caspase-3 cleavage, in addition to
./___Corpus/Medline/xml/PMC5352101.xml	AML	28714 : 28717	CM	         In addition, in AML, it has also been shown 
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	28747 : 28751	CM	has also been shown that mTOR inhibition using rapamyc
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	28769 : 28778	CM	at mTOR inhibition using rapamycin overactivates PI3K/AKT b
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	28793 : 28797	CM	 rapamycin overactivates PI3K/AKT by upregulating IGF-
./___Corpus/Medline/xml/PMC5352101.xml	AKT	28798 : 28801	CM	mycin overactivates PI3K/AKT by upregulating IGF-I/IG
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	28818 : 28823	CM	PI3K/AKT by upregulating IGF-I/IGF-IR signaling, in a f
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	28941 : 28946	CM	rough enhancing not only IRS-1 expression but also IRS-
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	28967 : 28972	CM	RS-1 expression but also IRS-2 expression. Using 19 AML
./___Corpus/Medline/xml/PMC5352101.xml	AML	28994 : 28997	CM	S-2 expression. Using 19 AML samples with constitutiv
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	29024 : 29028	CM	amples with constitutive PI3K/AKT activation, the rapa
./___Corpus/Medline/xml/PMC5352101.xml	AKT	29029 : 29032	CM	s with constitutive PI3K/AKT activation, the rapamyci
./___Corpus/Medline/xml/PMC5352101.xml	rapamycin	29049 : 29058	CM	PI3K/AKT activation, the rapamycin-derivative inhibitor eve
./___Corpus/Medline/xml/PMC5352101.xml	everolimus	29080 : 29090	CM	cin-derivative inhibitor everolimus increased AKT phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	AKT	29101 : 29104	CM	tor everolimus increased AKT phosphorylation by upreg
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	29105 : 29120	RN	everolimus increased AKT phosphorylation by upregulating the expr
./___Corpus/Medline/xml/PMC5352101.xml	IRS-2	29155 : 29160	CM	lating the expression of IRS-2 via an IGF-I/IGF-IR auto
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	29168 : 29173	CM	pression of IRS-2 via an IGF-I/IGF-IR autocrine loop [5
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	29251 : 29255	CM	rosstalk between IGF-IR, PI3K/AKT, and mTOR in AML.   
./___Corpus/Medline/xml/PMC5352101.xml	AKT	29256 : 29259	CM	alk between IGF-IR, PI3K/AKT, and mTOR in AML.       
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	29265 : 29269	CM	en IGF-IR, PI3K/AKT, and mTOR in AML.                 
./___Corpus/Medline/xml/PMC5352101.xml	AML	29273 : 29276	CM	R, PI3K/AKT, and mTOR in AML.                        
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29347 : 29350	CM	elodysplastic syndromes (MDS) arise from clonal hemat
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29522 : 29525	CM	roximately, one third of MDS patients experience prog
./___Corpus/Medline/xml/PMC5352101.xml	AML	29561 : 29564	CM	xperience progression to AML [154]. Decreased apoptos
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29666 : 29669	CM	e in the pathogenesis of MDS and probably in its tran
./___Corpus/Medline/xml/PMC5352101.xml	AML	29708 : 29711	CM	in its transformation to AML [155–157]. Recently, IGF
./___Corpus/Medline/xml/PMC5352101.xml	155–	29713 : 29717	CPR	s transformation to AML [155–157]. Recently, IGF-IR ha
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29773 : 29776	CM	 shown to be involved in MDS pathogenesis and its tra
./___Corpus/Medline/xml/PMC5352101.xml	AML	29816 : 29819	CM	nd its transformation to AML. Compared with normal my
./___Corpus/Medline/xml/PMC5352101.xml	mRNA	29876 : 29880	CM	ells, IGF-IR protein and mRNA expression is enhanced i
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29907 : 29910	CM	xpression is enhanced in MDS cells, and this enhancem
./___Corpus/Medline/xml/PMC5352101.xml	AML	29969 : 29972	CM	ases with progression to AML. In addition, in both MD
./___Corpus/Medline/xml/PMC5352101.xml	MDS	29995 : 29998	CM	ML. In addition, in both MDS and AML, apoptotic signa
./___Corpus/Medline/xml/PMC5352101.xml	AML	30003 : 30006	CM	ddition, in both MDS and AML, apoptotic signals are p
./___Corpus/Medline/xml/PMC5352101.xml	CML	30281 : 30284	CM	GF-IR was upregulated in CML cell lines, and the expr
./___Corpus/Medline/xml/PMC5352101.xml	CML	30385 : 30388	CM	 with the progression of CML. For instance, IGF-IR wa
./___Corpus/Medline/xml/PMC5352101.xml	CML	30493 : 30496	CM	se and accelerated phase CML, respectively, but the e
./___Corpus/Medline/xml/PMC5352101.xml	CML	30582 : 30585	CM	atients with blast phase CML. Treatment of CML cells 
./___Corpus/Medline/xml/PMC5352101.xml	CML	30600 : 30603	CM	 phase CML. Treatment of CML cells with PPP, an IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	PPP	30615 : 30618	CM	atment of CML cells with PPP, an IGF-IR small molecul
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	30766 : 30780	RN	F-IR decreased activated/phosphorylated AKT and STAT5 as well as
./___Corpus/Medline/xml/PMC5352101.xml	AKT	30781 : 30784	CM	activated/phosphorylated AKT and STAT5 as well as dow
./___Corpus/Medline/xml/PMC5352101.xml	STAT5	30789 : 30794	CM	d/phosphorylated AKT and STAT5 as well as downregulated
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	30845 : 30854	CM	BCL-2, BCL-XL, and basal caspase-3 and was associated with 
./___Corpus/Medline/xml/PMC5352101.xml	G2	30964 : 30966	CM	cell cycle arrest at the G2/M-phase, which was media
./___Corpus/Medline/xml/PMC5352101.xml	cyclin B1	31019 : 31028	CM	 through upregulation of cyclin B1 and downregulation of cy
./___Corpus/Medline/xml/PMC5352101.xml	cyclin E	31051 : 31059	CM	B1 and downregulation of cyclin E and pCdc2 [21].         
./___Corpus/Medline/xml/PMC5352101.xml	pCdc2	31064 : 31069	CM	gulation of cyclin E and pCdc2 [21].                   
./___Corpus/Medline/xml/PMC5352101.xml	IGF	31169 : 31172	CM	nvolvement of c-myb with IGF system in inducing the p
./___Corpus/Medline/xml/PMC5352101.xml	CML	31213 : 31216	CM	ing the proliferation of CML cells was demonstrated [
./___Corpus/Medline/xml/PMC5352101.xml	C-	31247 : 31249	CPR	 was demonstrated [159]. C-myb plays an important ro
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	31453 : 31458	CM	 significant increase in IGF-I, IGF-II, and IGF-IR expr
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP-3	31509 : 31516	CM	ssion, and a decrease in IGFBP-3 expression, which promot
./___Corpus/Medline/xml/PMC5352101.xml	CML	31544 : 31547	CM	pression, which promotes CML cell proliferation [159]
./___Corpus/Medline/xml/PMC5352101.xml	anti-	31590 : 31595	CPR	n [159]. Of note is that anti-IGF-IR antibodies inhibit
./___Corpus/Medline/xml/PMC5352101.xml	AKT	31758 : 31761	CM	ular signaling pathways, AKT and ERK. The activation 
./___Corpus/Medline/xml/PMC5352101.xml	ERK	31766 : 31769	CM	naling pathways, AKT and ERK. The activation of AKT a
./___Corpus/Medline/xml/PMC5352101.xml	AKT	31789 : 31792	CM	d ERK. The activation of AKT and ERK by c-myb was abr
./___Corpus/Medline/xml/PMC5352101.xml	ERK	31797 : 31800	CM	he activation of AKT and ERK by c-myb was abrogated b
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP-3	31838 : 31845	CM	 abrogated by IGF-IR and IGFBP-3 antibodies. These findin
./___Corpus/Medline/xml/PMC5352101.xml	IGF	31979 : 31982	CM	of the components of the IGF system in CML.          
./___Corpus/Medline/xml/PMC5352101.xml	CML	31993 : 31996	CM	nts of the IGF system in CML.                        
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	32056 : 32061	CM	     The contribution of IGF-I/IGF-IR signaling to CLL 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32082 : 32085	CM	GF-I/IGF-IR signaling to CLL has also been investigat
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	32132 : 32137	CM	gated. It was shown that IGF-I and IGF-IR participate i
./___Corpus/Medline/xml/PMC5352101.xml	paracrine	32174 : 32183	CM	participate in autocrine/paracrine loops to promote the sur
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32217 : 32220	CM	 promote the survival of CLL cells [160]. High levels
./___Corpus/Medline/xml/PMC5352101.xml	mRNA	32268 : 32272	CM	ls of IGF-IR protein and mRNA expression were detected
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32301 : 32304	CM	ression were detected in CLL cells and positively cor
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	32422 : 32427	CM	as also shown that serum IGF-I was elevated in CLL pati
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32444 : 32447	CM	um IGF-I was elevated in CLL patients, but the level 
./___Corpus/Medline/xml/PMC5352101.xml	GH	32475 : 32477	CM	tients, but the level of GH remained unchanged, sugg
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	32538 : 32543	CM	 autocrine production of IGF-I by CLL cells results in 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32547 : 32550	CM	e production of IGF-I by CLL cells results in increas
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	32594 : 32599	CM	ncreased levels of serum IGF-I, independently of GH, an
./___Corpus/Medline/xml/PMC5352101.xml	GH	32618 : 32620	CM	 IGF-I, independently of GH, and can stimulate IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32658 : 32661	CM	mulate IGF-IR to promote CLL cell survival. Moreover,
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32752 : 32755	CM	ession of IGF-IR gene in CLL was associted with bad p
./___Corpus/Medline/xml/PMC5352101.xml	IGHV	32811 : 32815	CM	tic indicators including IGHV gene unmutated status, h
./___Corpus/Medline/xml/PMC5352101.xml	CD38	32844 : 32848	CM	e unmutated status, high CD38 expression, trisomy 12, 
./___Corpus/Medline/xml/PMC5352101.xml	del(11)(q23)	32877 : 32889	CM	ression, trisomy 12, and del(11)(q23) [161]. Furthermore, the 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	32977 : 32980	CM	ectierized a subgroup of CLL patients with NOTCH1 mut
./___Corpus/Medline/xml/PMC5352101.xml	NOTCH1	32995 : 33001	CM	oup of CLL patients with NOTCH1 mutation. In a separate 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	33071 : 33074	CM	GF-IR inhibitors reduced CLL cell viability and induc
./___Corpus/Medline/xml/PMC5352101.xml	sorafenib	33240 : 33249	CM	rmore, it was found that sorafenib, a multikinase inhibitor
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	33335 : 33343	CM	sion as well as decrease tyrosine kinase activity, suggest
./___Corpus/Medline/xml/PMC5352101.xml	sorafenib	33395 : 33404	CM	g IGF-IR is a target for sorafenib in CLL.                 
./___Corpus/Medline/xml/PMC5352101.xml	CLL	33408 : 33411	CM	 target for sorafenib in CLL.                        
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	33499 : 33504	CM	so been accompalished in T-ALL and B-ALL to study the e
./___Corpus/Medline/xml/PMC5352101.xml	B-ALL	33509 : 33514	CM	compalished in T-ALL and B-ALL to study the effects of 
./___Corpus/Medline/xml/PMC5352101.xml	IGFs	33564 : 33568	CM	not only IGF-IR but also IGFs. For instance, one study
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	33639 : 33644	CM	eristics of insulin, IR, IGF-I, IGF-II, and GH binding 
./___Corpus/Medline/xml/PMC5352101.xml	GH	33658 : 33660	CM	, IR, IGF-I, IGF-II, and GH binding in 18 establishe
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	33687 : 33692	CM	inding in 18 established T-ALL and B-ALL cell lines [16
./___Corpus/Medline/xml/PMC5352101.xml	B-ALL	33697 : 33702	CM	18 established T-ALL and B-ALL cell lines [162]. IGF-IR
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	33808 : 33813	CM	ferentially expressed in T-ALL cell lines and IR was pr
./___Corpus/Medline/xml/PMC5352101.xml	B-ALL	33864 : 33869	CM	ferentially expressed in B-ALL cell lines. In addition,
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	33984 : 33989	CM	t binding affinities for IGF-I, IGF-II, and insulin in 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	34130 : 34135	CM	teins in ALL. Another in vitro study used FL5.12, a mur
./___Corpus/Medline/xml/PMC5352101.xml	FL5.12	34147 : 34153	CM	ther in vitro study used FL5.12, a murine pro B-ALL cell
./___Corpus/Medline/xml/PMC5352101.xml	murine	34157 : 34163	CM	tro study used FL5.12, a murine pro B-ALL cell line, to 
./___Corpus/Medline/xml/PMC5352101.xml	B-ALL	34168 : 34173	CM	sed FL5.12, a murine pro B-ALL cell line, to further el
./___Corpus/Medline/xml/PMC5352101.xml	Y1251F	34301 : 34307	CM	l line contains a Y1250F/Y1251F double-mutant IGF-IR, wh
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	34386 : 34391	CM	induction in response to IGF-I withdrawal and deficient
./___Corpus/Medline/xml/PMC5352101.xml	163–	34524 : 34528	CPR	isplay mitotic activity [163–166]. This study showed t
./___Corpus/Medline/xml/PMC5352101.xml	FL5.12	34561 : 34567	CM	is study showed that the FL5.12 cells had impaired phosp
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	34587 : 34602	RN	L5.12 cells had impaired phosphorylation of JNK, SHC, and MAPK up
./___Corpus/Medline/xml/PMC5352101.xml	JNK	34606 : 34609	CM	aired phosphorylation of JNK, SHC, and MAPK upon IGF-
./___Corpus/Medline/xml/PMC5352101.xml	SHC	34611 : 34614	CM	 phosphorylation of JNK, SHC, and MAPK upon IGF-I sti
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	34620 : 34624	CM	ylation of JNK, SHC, and MAPK upon IGF-I stimulation, 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	34630 : 34635	CM	 JNK, SHC, and MAPK upon IGF-I stimulation, but IGF-I-i
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	34653 : 34658	CM	n IGF-I stimulation, but IGF-I-induced phosphorylation 
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	34667 : 34682	RN	ation, but IGF-I-induced phosphorylation of AKT was comparable to
./___Corpus/Medline/xml/PMC5352101.xml	AKT	34686 : 34689	CM	duced phosphorylation of AKT was comparable to that i
./___Corpus/Medline/xml/PMC5352101.xml	JNK	34809 : 34812	CM	cifically abrogating the JNK, SHC, and MAPK pathways 
./___Corpus/Medline/xml/PMC5352101.xml	SHC	34814 : 34817	CM	ally abrogating the JNK, SHC, and MAPK pathways [163]
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	34823 : 34827	CM	gating the JNK, SHC, and MAPK pathways [163].         
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	35073 : 35078	CM	IGF-IR overexpression in T-ALL. It was shown that Notch
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	35475 : 35480	CM	quired to fully suppress T-ALL [167]. Another study sho
./___Corpus/Medline/xml/PMC5352101.xml	microRNA-99a	35539 : 35551	CM	the forced expression of microRNA-99a and microRNA-100 inhibit
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	35608 : 35612	CM	expression of IGF-IR and mTOR, as well as the downstre
./___Corpus/Medline/xml/PMC5352101.xml	MCL1	35659 : 35663	CM	tream oncogenic proteins MCL1 and the FK506-binding pr
./___Corpus/Medline/xml/PMC5352101.xml	FK506	35672 : 35677	CM	ic proteins MCL1 and the FK506-binding protein 51 in T-
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	35700 : 35705	CM	06-binding protein 51 in T-ALL cell lines. Importantly,
./___Corpus/Medline/xml/PMC5352101.xml	microRNA-99a	35731 : 35743	CM	cell lines. Importantly, microRNA-99a and microRNA-100 were si
./___Corpus/Medline/xml/PMC5352101.xml	vitro	35926 : 35931	CM	    Evidence based on in vitro studies showed that targ
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36049 : 36052	CM	e, one study showed that PPP efficiently decreased ce
./___Corpus/Medline/xml/PMC5352101.xml	G2	36102 : 36104	CM	ll viability and induced G2/M-phase cell cycle arres
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	36152 : 36157	CM	est in Jurkat and Molt-3 T-ALL cell lines, with no effe
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36210 : 36213	CM	on normal T lymphocytes. PPP was also able to increas
./___Corpus/Medline/xml/PMC5352101.xml	PARP	36280 : 36284	CM	of cleaved caspase 3 and PARP and downregulate the ant
./___Corpus/Medline/xml/PMC5352101.xml	anti-	36306 : 36311	CPR	ARP and downregulate the anti-apoptotic proteins BCL-2 
./___Corpus/Medline/xml/PMC5352101.xml	PPP	36394 : 36397	CM	cell death. Furthermore, PPP decreased the phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	36412 : 36427	RN	rmore, PPP decreased the phosphorylation of AKT and MAPK in T-ALL
./___Corpus/Medline/xml/PMC5352101.xml	AKT	36431 : 36434	CM	d the phosphorylation of AKT and MAPK in T-ALL cells 
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	36439 : 36443	CM	osphorylation of AKT and MAPK in T-ALL cells [64].    
./___Corpus/Medline/xml/PMC5352101.xml	T-ALL	36447 : 36452	CM	ation of AKT and MAPK in T-ALL cells [64].             
./___Corpus/Medline/xml/PMC5352101.xml	MPN	36512 : 36515	CM	proliferative neoplasms (MPN) other than CML         
./___Corpus/Medline/xml/PMC5352101.xml	PV	36723 : 36725	CM	tics. Polycythemia vera (PV), primary myelofibrosis,
./___Corpus/Medline/xml/PMC5352101.xml	MPN	36817 : 36820	CM	t frequently encountered MPN.                        
./___Corpus/Medline/xml/PMC5352101.xml	IGF	36872 : 36875	CM	             The role of IGF/IGF-IR signaling in MPN 
./___Corpus/Medline/xml/PMC5352101.xml	MPN	36896 : 36899	CM	 IGF/IGF-IR signaling in MPN has been investigated in
./___Corpus/Medline/xml/PMC5352101.xml	PV	36991 : 36993	CM	these studies focused on PV. An earlier study showed
./___Corpus/Medline/xml/PMC5352101.xml	erythroid	37046 : 37055	CM	at the early circulating erythroid progenitors collected fr
./___Corpus/Medline/xml/PMC5352101.xml	PV	37083 : 37085	CM	ogenitors collected from PV patients and maintained 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	37174 : 37179	CM	 enhanced sensitivity to IGF-I, much more pronounced th
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	37312 : 37317	CM	probable contribution of IGF-I/IGF-IR signaling to PV p
./___Corpus/Medline/xml/PMC5352101.xml	PV	37338 : 37340	CM	GF-I/IGF-IR signaling to PV pathogenesis. Notably, t
./___Corpus/Medline/xml/PMC5352101.xml	PV	37398 : 37400	CM	tivity of the cells from PV patients to IGF-I substa
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	37413 : 37418	CM	ells from PV patients to IGF-I substantially exceeded t
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	37523 : 37528	CM	e the molecular basis of IGF-I hypersensitivity, the sa
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	37583 : 37588	CM	oup found that basal and IGF-I-stimulated levels of IGF
./___Corpus/Medline/xml/PMC5352101.xml	IGF-IRβ	37610 : 37617	CM	F-I-stimulated levels of IGF-IRβ subunit's tyrosine phosp
./___Corpus/Medline/xml/PMC5352101.xml	tyrosine	37628 : 37636	CM	els of IGF-IRβ subunit's tyrosine phosphorylation were mor
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	37637 : 37652	RN	F-IRβ subunit's tyrosine phosphorylation were more enhanced in ci
./___Corpus/Medline/xml/PMC5352101.xml	PV	37724 : 37726	CM	cells from patients with PV than in cells from norma
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP-1	37785 : 37792	CM	uals [170]. Furthermore, IGFBP-1 was shown to be signific
./___Corpus/Medline/xml/PMC5352101.xml	PV	37835 : 37837	CM	ignificantly elevated in PV patients. Functionally, 
./___Corpus/Medline/xml/PMC5352101.xml	erythroid	37928 : 37937	CM	d stimulatory effects on erythroid burst formation in vitro
./___Corpus/Medline/xml/PMC5352101.xml	vitro	37957 : 37962	CM	hroid burst formation in vitro [171]. Subsequent contra
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	38032 : 38047	RN	no differences in IGF-IR phosphorylation levels in PV patients ve
./___Corpus/Medline/xml/PMC5352101.xml	PV	38058 : 38060	CM	hosphorylation levels in PV patients versus healthy 
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP	38161 : 38166	CM	supported alterations in IGFBP levels including increas
./___Corpus/Medline/xml/PMC5352101.xml	IGFBP-3	38229 : 38236	CM	2, and -4, and decreased IGFBP-3 in these patients. More 
./___Corpus/Medline/xml/PMC5352101.xml	JAK2V617F	38289 : 38298	CM	ently, the expression of JAK2V617F mutant, a hallmark molec
./___Corpus/Medline/xml/PMC5352101.xml	PV	38337 : 38339	CM	lmark molecular event in PV, was found to render Ba/
./___Corpus/Medline/xml/PMC5352101.xml	Ba	38361 : 38363	CM	 PV, was found to render Ba/F3 cells hypersensitive 
./___Corpus/Medline/xml/PMC5352101.xml	F3	38364 : 38366	CM	, was found to render Ba/F3 cells hypersensitive to 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	38391 : 38396	CM	 cells hypersensitive to IGF-I stimulation, providing a
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	38455 : 38460	CM	r evidence that connects IGF-I/IGF-IR signaling to PV [
./___Corpus/Medline/xml/PMC5352101.xml	PV	38481 : 38483	CM	GF-I/IGF-IR signaling to PV [173].                  
./___Corpus/Medline/xml/PMC5352101.xml	Arsenite	38529 : 38537	CM	                         Arsenite-inducible RNA-associated
./___Corpus/Medline/xml/PMC5352101.xml	RNA	38548 : 38551	CM	      Arsenite-inducible RNA-associated protein-like 
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	38577 : 38583	CM	associated protein-like (AIRAPL) is an evolutionary cons
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	38696 : 38702	CM	 study demonstrated that AIRAPL-deficient mice develop a
./___Corpus/Medline/xml/PMC5352101.xml	MPN	38744 : 38747	CM	evelop a fully penetrant MPN-like disease [174]. Furt
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	38847 : 38853	CM	ndings demonstrated that AIRAPL promotes the ubiquitinat
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	39009 : 39015	CM	 cell death. The lack of AIRAPL and its inhibitory effec
./___Corpus/Medline/xml/PMC5352101.xml	MPN	39117 : 39120	CM	ad to the development of MPN. This intriguing idea wa
./___Corpus/Medline/xml/PMC5352101.xml	MPN	39200 : 39203	CM	rgeting IGF-IR prevented MPN in AIRAPL-deficient mice
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	39207 : 39213	CM	 IGF-IR prevented MPN in AIRAPL-deficient mice as well a
./___Corpus/Medline/xml/PMC5352101.xml	AIRAPL	39307 : 39313	CM	nd (2) the expression of AIRAPL was found to be commonly
./___Corpus/Medline/xml/PMC5352101.xml	MPN	39356 : 39359	CM	ommonly lacking in human MPN samples [174].          
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	39775 : 39783	CM	ophosmin-ALK-expressing (NPM-ALK+) T-cell lymphoma [22]. I
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	39834 : 39839	CM	 this regard, IGF-IR and IGF-I are widely overexpressed
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	39868 : 39876	CM	 widely overexpressed in NPM-ALK+ T-cell lymphoma cell lin
./___Corpus/Medline/xml/PMC5352101.xml	ALK+	39911 : 39915	CM	mphoma cell lines and in ALK+ lymphoma tumors from pat
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	40196 : 40204	CM	 65]. Transfection of an NPM-ALK+ T-cell lymphoma cell lin
./___Corpus/Medline/xml/PMC5352101.xml	pIGF-IR	40278 : 40285	CM	 significantly increased pIGF-IR, and transfection with w
./___Corpus/Medline/xml/PMC5352101.xml	pNPM-ALK	40355 : 40363	CM	ced a marked increase in pNPM-ALK [22, 65]. Transfection o
./___Corpus/Medline/xml/PMC5352101.xml	PPP	40512 : 40515	CM	ntagonism of IGF-IR with PPP decreased cell viability
./___Corpus/Medline/xml/PMC5352101.xml	G2	40564 : 40566	CM	y, induced apoptosis and G2/M-phase cell-cycle arres
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	40646 : 40654	CM	 and colony formation of NPM-ALK+ T-cell lymphoma cells [2
./___Corpus/Medline/xml/PMC5352101.xml	ALK	40781 : 40784	CM	small molecule IGF-IR/IR/ALK inhibitor, was utilized 
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	40891 : 40899	CM	ion of IGF-IR, including NPM-ALK+ T-cell lymphoma [177].  
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	40994 : 41002	CM	ore, in our lab, we used NPM-ALK+ T-cell lymphoma as a can
./___Corpus/Medline/xml/PMC5352101.xml	isoform-1	41230 : 41239	CM	scription factors Ikaros isoform-1 (Ik-1) and myeloid zinc 
./___Corpus/Medline/xml/PMC5352101.xml	Ik-1	41241 : 41245	CM	actors Ikaros isoform-1 (Ik-1) and myeloid zinc finger
./___Corpus/Medline/xml/PMC5352101.xml	zinc	41259 : 41263	CM	orm-1 (Ik-1) and myeloid zinc finger 1 (MZF1) are mark
./___Corpus/Medline/xml/PMC5352101.xml	MZF1	41274 : 41278	CM	d myeloid zinc finger 1 (MZF1) are markedly decreased 
./___Corpus/Medline/xml/PMC5352101.xml	Ik-1	41348 : 41352	CM	portantly, we found that Ik-1 and MZF1 are capable of 
./___Corpus/Medline/xml/PMC5352101.xml	MZF1	41357 : 41361	CM	, we found that Ik-1 and MZF1 are capable of down-regu
./___Corpus/Medline/xml/PMC5352101.xml	mRNA	41504 : 41508	CM	ult of decreasing IGF-IR mRNA and protein expression, 
./___Corpus/Medline/xml/PMC5352101.xml	Ik-1	41538 : 41542	CM	protein expression, both Ik-1 and MZF1 also decreased 
./___Corpus/Medline/xml/PMC5352101.xml	MZF1	41547 : 41551	CM	xpression, both Ik-1 and MZF1 also decreased the expre
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylated	41585 : 41599	CM	reased the expression of phosphorylated IGF-IR, which subsequent
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	41641 : 41656	RN	bsequently decreased the phosphorylation of important downstream 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	41708 : 41711	CM	gnaling proteins such as AKT and IRS-1. Ectopic expre
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	41716 : 41721	CM	proteins such as AKT and IRS-1. Ectopic expression of t
./___Corpus/Medline/xml/PMC5352101.xml	Ectopic	41723 : 41730	CM	s such as AKT and IRS-1. Ectopic expression of these tran
./___Corpus/Medline/xml/PMC5352101.xml	mRNA	41910 : 41914	CM	that the decay of IGF-IR mRNA is significantly delayed
./___Corpus/Medline/xml/PMC5352101.xml	NPM-ALK+	41943 : 41951	CM	significantly delayed in NPM-ALK+ T-cell lymphoma cell lin
./___Corpus/Medline/xml/PMC5352101.xml	GH	42175 : 42177	CM	lesser extent, a role of GH in regulating IGF-IR exp
./___Corpus/Medline/xml/PMC5352101.xml	EL4	42248 : 42251	CM	nstrated in mouse T-cell EL4 lymphoma cells. It was s
./___Corpus/Medline/xml/PMC5352101.xml	GH	42342 : 42344	CM	expression of endogenous GH was an increase in the e
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	42382 : 42387	CM	ase in the expression of IGF-I and IGF-IR, which mediat
./___Corpus/Medline/xml/PMC5352101.xml	GH	42495 : 42497	CM	As mentioned previously, GH regulates the secretion 
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	42525 : 42530	CM	gulates the secretion of IGF-I by the liver, although I
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	42554 : 42559	CM	I by the liver, although IGF-I concentrations can arise
./___Corpus/Medline/xml/PMC5352101.xml	GH	42602 : 42604	CM	n arise independently of GH. The EL4 lymphoma model 
./___Corpus/Medline/xml/PMC5352101.xml	EL4	42610 : 42613	CM	independently of GH. The EL4 lymphoma model may demon
./___Corpus/Medline/xml/PMC5352101.xml	GH	42694 : 42696	CM	regulation of IGF-IR via GH [175].                  
./___Corpus/Medline/xml/PMC5352101.xml	PPP	42911 : 42914	CM	n of IGF-IR by siRNA and PPP downregulated pIRS-1, pA
./___Corpus/Medline/xml/PMC5352101.xml	pIRS-1	42929 : 42935	CM	NA and PPP downregulated pIRS-1, pAKT, and pSTAT3 and in
./___Corpus/Medline/xml/PMC5352101.xml	pAKT	42937 : 42941	CM	PP downregulated pIRS-1, pAKT, and pSTAT3 and induced 
./___Corpus/Medline/xml/PMC5352101.xml	pSTAT3	42947 : 42953	CM	ulated pIRS-1, pAKT, and pSTAT3 and induced caspase-3 cl
./___Corpus/Medline/xml/PMC5352101.xml	caspase-3	42966 : 42975	CM	, and pSTAT3 and induced caspase-3 cleavage in MCL. To our 
./___Corpus/Medline/xml/PMC5352101.xml	MCL	42988 : 42991	CM	ed caspase-3 cleavage in MCL. To our knowledge, these
./___Corpus/Medline/xml/PMC5352101.xml	IRS-1	43068 : 43073	CM	report the expression of IRS-1 and pIRS-1 in MCL, which
./___Corpus/Medline/xml/PMC5352101.xml	pIRS-1	43078 : 43084	CM	 expression of IRS-1 and pIRS-1 in MCL, which suggests t
./___Corpus/Medline/xml/PMC5352101.xml	MCL	43088 : 43091	CM	n of IRS-1 and pIRS-1 in MCL, which suggests that the
./___Corpus/Medline/xml/PMC5352101.xml	HL	43284 : 43286	CM	    In Hodgkin lymphoma (HL), a recent study demonst
./___Corpus/Medline/xml/PMC5352101.xml	pIGF-IR	43375 : 43382	CM	55% of the patients, and pIGF-IR was detectable in only 3
./___Corpus/Medline/xml/PMC5352101.xml	pIGF-IR	43464 : 43471	CM	s that were analyzed for pIGF-IR expression [179]. In vit
./___Corpus/Medline/xml/PMC5352101.xml	vitro	43493 : 43498	CM	-IR expression [179]. In vitro experiments showed that 
./___Corpus/Medline/xml/PMC5352101.xml	HL	43548 : 43550	CM	the mitotic potential of HL cells is highly dependen
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	43580 : 43585	CM	s is highly dependent on IGF-I, as treatment with the l
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	43638 : 43653	RN	nd resulted in increased phosphorylation of IGF-IR, AKT, and ERK 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	43665 : 43668	CM	osphorylation of IGF-IR, AKT, and ERK in L428 and L12
./___Corpus/Medline/xml/PMC5352101.xml	ERK	43674 : 43677	CM	tion of IGF-IR, AKT, and ERK in L428 and L1236 HL cel
./___Corpus/Medline/xml/PMC5352101.xml	L428	43681 : 43685	CM	 IGF-IR, AKT, and ERK in L428 and L1236 HL cells. Trea
./___Corpus/Medline/xml/PMC5352101.xml	HL	43696 : 43698	CM	nd ERK in L428 and L1236 HL cells. Treatment with PP
./___Corpus/Medline/xml/PMC5352101.xml	PPP	43721 : 43724	CM	HL cells. Treatment with PPP was able to induce cell 
./___Corpus/Medline/xml/PMC5352101.xml	G2	43771 : 43773	CM	ll growth inhibition via G2/M-phase cell cycle arres
./___Corpus/Medline/xml/PMC5352101.xml	5-	43881 : 43883	CPR	her overall survival and 5-year progression-free sur
./___Corpus/Medline/xml/PMC5352101.xml	HL	44034 : 44036	CM	 a prognostic marker for HL patients. This same phen
./___Corpus/Medline/xml/PMC5352101.xml	HL	44186 : 44188	CM	 patients with classical HL. However, this study als
./___Corpus/Medline/xml/PMC5352101.xml	MET	44276 : 44279	CM	 closely associated with MET receptor expression, whi
./___Corpus/Medline/xml/PMC5352101.xml	HL	44515 : 44517	CM	or the better outcome of HL patients with IGF-IR exp
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	44636 : 44641	CM	e large B-cell lymphoma (DLBCL) occurs in adults, and t
./___Corpus/Medline/xml/PMC5352101.xml	60-	44727 : 44730	CPR	esults in improvement in 60-70% of patients. Nonethel
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	44940 : 44945	CM	induce cellular death in DLBCL in vitro: PPP and NVP-AE
./___Corpus/Medline/xml/PMC5352101.xml	vitro	44949 : 44954	CM	llular death in DLBCL in vitro: PPP and NVP-AEW541 [181
./___Corpus/Medline/xml/PMC5352101.xml	PPP	44956 : 44959	CM	death in DLBCL in vitro: PPP and NVP-AEW541 [181]. As
./___Corpus/Medline/xml/PMC5352101.xml	PPP	45008 : 45011	CM	s in other studies using PPP, DLBCL cells underwent a
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	45013 : 45018	CM	other studies using PPP, DLBCL cells underwent apoptosi
./___Corpus/Medline/xml/PMC5352101.xml	G2	45147 : 45149	CM	h was hindered through a G2/M-phase cell cycle arres
./___Corpus/Medline/xml/PMC5352101.xml	G0	45218 : 45220	CM	mination of cells in the G0/G1 phase of the cell cyc
./___Corpus/Medline/xml/PMC5352101.xml	PPP	45273 : 45276	CM	 Interestingly, however, PPP did not decrease the pho
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45298 : 45313	RN	PPP did not decrease the phosphorylation of IGF-IR at Tyr1131/Tyr
./___Corpus/Medline/xml/PMC5352101.xml	AKT	45369 : 45372	CM	r its downstream targets AKT and ERK1/2, suggesting a
./___Corpus/Medline/xml/PMC5352101.xml	ERK1	45377 : 45381	CM	wnstream targets AKT and ERK1/2, suggesting another po
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45497 : 45512	RN	 significantly inhibited phosphorylation of IGF-IR at Tyr1131/Tyr
./___Corpus/Medline/xml/PMC5352101.xml	AKT	45546 : 45549	CM	R at Tyr1131/Tyr1136 and AKT, while ERK1/2 phosphoryl
./___Corpus/Medline/xml/PMC5352101.xml	ERK1	45557 : 45561	CM	1/Tyr1136 and AKT, while ERK1/2 phosphorylation was le
./___Corpus/Medline/xml/PMC5352101.xml	phosphorylation	45564 : 45579	RN	36 and AKT, while ERK1/2 phosphorylation was less affected, sugge
./___Corpus/Medline/xml/PMC5352101.xml	DLBCL	45693 : 45698	CM	re effective therapy for DLBCL [181].                  
./___Corpus/Medline/xml/PMC5352101.xml	INHIBITORS	45790 : 45800	CM	CAL EVALUATION OF IGF-IR INHIBITORS AND MECHANISMS OF RESIST
./___Corpus/Medline/xml/PMC5352101.xml	MECHANISMS	45805 : 45815	CM	OF IGF-IR INHIBITORS AND MECHANISMS OF RESISTANCE TO THESE I
./___Corpus/Medline/xml/PMC5352101.xml	INHIBITORS	45839 : 45849	CM	S OF RESISTANCE TO THESE INHIBITORS                         
./___Corpus/Medline/xml/PMC5352101.xml	amino acid	46025 : 46035	CM	res a high percentage of amino acid sequence identity with I
./___Corpus/Medline/xml/PMC5352101.xml	IGF-I	46357 : 46362	CM	 the circulating ligands IGF-I or IGF-II, which prevent
./___Corpus/Medline/xml/PMC5352101.xml	anti-	46509 : 46514	CPR	ity of IGF-IR [182]. The anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	183–	46771 : 46775	CPR	gh the inhibition of IR [183–187]. Table ​Table11 list
./___Corpus/Medline/xml/PMC5352101.xml	RED	47020 : 47023	CM	neoplasms highlighted in RED.                        
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47081 : 47086	CPR	       An example of the anti-IGF-IR blocking antibodie
./___Corpus/Medline/xml/PMC5352101.xml	AVE1642	47116 : 47123	CM	R blocking antibodies is AVE1642, which had encouraging e
./___Corpus/Medline/xml/PMC5352101.xml	vitro	47158 : 47163	CM	d encouraging effects in vitro and in vivo in animal mo
./___Corpus/Medline/xml/PMC5352101.xml	188–	47348 : 47352	CPR	reast cancer metastasis [188–191]. Furthermore, it was
./___Corpus/Medline/xml/PMC5352101.xml	192–	47484 : 47488	CPR	n early clinical trials [192–194]. In addition, the IM
./___Corpus/Medline/xml/PMC5352101.xml	IMC-A12	47511 : 47518	CM	2–194]. In addition, the IMC-A12 (cixutumumab) anti-IGF-I
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47533 : 47538	CPR	he IMC-A12 (cixutumumab) anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	vitro	47602 : 47607	CM	cer growth inhibition in vitro and in xenograft models 
./___Corpus/Medline/xml/PMC5352101.xml	195–	47633 : 47637	CPR	and in xenograft models [195–198]. The efficacy of thi
./___Corpus/Medline/xml/PMC5352101.xml	183–	47773 : 47777	CPR	ther therapeutic agents [183–185, 199–202]. In additio
./___Corpus/Medline/xml/PMC5352101.xml	199–	47782 : 47786	CPR	apeutic agents [183–185, 199–202]. In addition to AVE1
./___Corpus/Medline/xml/PMC5352101.xml	AVE1642	47807 : 47814	CM	199–202]. In addition to AVE1642 and cixutumumab, several
./___Corpus/Medline/xml/PMC5352101.xml	anti-	47846 : 47851	CPR	xutumumab, several other anti-IGF-IR monoclonal antibod
./___Corpus/Medline/xml/PMC5352101.xml	ATP	48105 : 48108	CM	for the binding site for ATP within the IGF-IR kinase
./___Corpus/Medline/xml/PMC5352101.xml	vitro	48161 : 48166	CM	main. For example, in in vitro and in vivo preclinical 
./___Corpus/Medline/xml/PMC5352101.xml	PPP	48199 : 48202	CM	vivo preclinical models, PPP was shown to demonstrate
./___Corpus/Medline/xml/PMC5352101.xml	21–	48338 : 48341	CPR	e arrest, and apoptosis [21–23, 56, 64, 203–216]. Bec
./___Corpus/Medline/xml/PMC5352101.xml	203–	48353 : 48357	CPR	poptosis [21–23, 56, 64, 203–216]. Because of promisin
./___Corpus/Medline/xml/PMC5352101.xml	PPP	48421 : 48424	CM	outcomes, the effects of PPP have also been explored 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	48568 : 48573	CM	extensively tested in in vitro and in vivo preclinical 
./___Corpus/Medline/xml/PMC5352101.xml	218–	48653 : 48657	CPR	 cell types [56, 57, 61, 218–240]. Some of the small m
./___Corpus/Medline/xml/PMC5352101.xml	mRNA	49265 : 49269	CM	ion of IGF-IR protein or mRNA is required to achieve a
./___Corpus/Medline/xml/PMC5352101.xml	241–	49330 : 49334	CPR	ponse to the inhibitors [241–245]. Although an inheren
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49440 : 49445	CPR	se primary resistance to anti-IGF-IR antibodies or smal
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49571 : 49576	CPR	econdary resistance when anti-IGF-IR antibodies are use
./___Corpus/Medline/xml/PMC5352101.xml	anti-	49614 : 49619	CPR	dies are used. After the anti-IGF-IR antibody/IGF-IR co
./___Corpus/Medline/xml/PMC5352101.xml	IGF	49988 : 49991	CM	rom other members of the IGF system receptors includi
./___Corpus/Medline/xml/PMC5352101.xml	IR-A	50040 : 50044	CM	ing the IR, particularly IR-A and to a lesser extent I
./___Corpus/Medline/xml/PMC5352101.xml	IR-B	50068 : 50072	CM	A and to a lesser extent IR-B [244, 246–248]. Moreover
./___Corpus/Medline/xml/PMC5352101.xml	246–	50079 : 50083	CPR	lesser extent IR-B [244, 246–248]. Moreover, the hybri
./___Corpus/Medline/xml/PMC5352101.xml	IR-A	50126 : 50130	CM	e hybrid receptor IGF-IR/IR-A has also been suggested 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	50356 : 50359	CM	n is the upregulation of AKT/mTOR signaling pathway. 
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	50360 : 50364	CM	 the upregulation of AKT/mTOR signaling pathway. It wa
./___Corpus/Medline/xml/PMC5352101.xml	AKTmTOR	50445 : 50452	CM	IR induces activation of AKTmTOR, resulting in a feedback
./___Corpus/Medline/xml/PMC5352101.xml	AKT	50506 : 50509	CM	thesis and activation of AKT as well as of epidermal 
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	50558 : 50562	CM	 growth factor receptor (EGFR) family and survivin. Th
./___Corpus/Medline/xml/PMC5352101.xml	249–	50734 : 50738	CPR	ells [32, 234, 236, 241, 249–252]. Similarly, potentia
./___Corpus/Medline/xml/PMC5352101.xml	ERK	50771 : 50774	CM	milarly, potentiation of ERK/MAPK signaling has been 
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	50775 : 50779	CM	rly, potentiation of ERK/MAPK signaling has been impli
./___Corpus/Medline/xml/PMC5352101.xml	SRC	50929 : 50932	CM	t a bypass activation of SRC kinases family induces s
./___Corpus/Medline/xml/PMC5352101.xml	SRC	51033 : 51036	CM	r cells [254]. Activated SRC acts through integrin α5
./___Corpus/Medline/xml/PMC5352101.xml	SIGNALING	51538 : 51547	CM	                  IGF-IR SIGNALING INDUCES RESISTANCE TO DI
./___Corpus/Medline/xml/PMC5352101.xml	256–	51892 : 51896	CPR	herapy and radiotherapy [256–263]. Moreover, IGF-IR ha
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	52071 : 52075	CM	iscent to the effects of EGFR family of kinases on inh
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	52310 : 52314	CM	re with the signaling of EGFR/HER2 kinases family [264
./___Corpus/Medline/xml/PMC5352101.xml	HER2	52315 : 52319	CM	th the signaling of EGFR/HER2 kinases family [264–270]
./___Corpus/Medline/xml/PMC5352101.xml	264–	52336 : 52340	CPR	GFR/HER2 kinases family [264–270]. This phenomenon has
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	52513 : 52517	CM	ation between IGF-IR and EGFR/HER2 contributes to the 
./___Corpus/Medline/xml/PMC5352101.xml	HER2	52518 : 52522	CM	 between IGF-IR and EGFR/HER2 contributes to the resis
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	52556 : 52560	CM	tes to the resistance to EGFR inhibitors [271, 272]. I
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	52631 : 52635	CM	nce to the inhibition of EGFR, IGF-IR has been shown t
./___Corpus/Medline/xml/PMC5352101.xml	estrogen	52803 : 52811	CM	hrough modulation of the estrogen and androgen receptors (
./___Corpus/Medline/xml/PMC5352101.xml	androgen	52816 : 52824	CM	tion of the estrogen and androgen receptors (breast and pr
./___Corpus/Medline/xml/PMC5352101.xml	PCM	52904 : 52907	CM	 proteasome degradation (PCM), ALK kinase (NSCLC), AT
./___Corpus/Medline/xml/PMC5352101.xml	NSCLC	52922 : 52927	CM	ation (PCM), ALK kinase (NSCLC), ATM-related kinase (AT
./___Corpus/Medline/xml/PMC5352101.xml	ATM	52930 : 52933	CM	CM), ALK kinase (NSCLC), ATM-related kinase (ATR; bre
./___Corpus/Medline/xml/PMC5352101.xml	ATR	52950 : 52953	CM	LC), ATM-related kinase (ATR; breast cancer), and the
./___Corpus/Medline/xml/PMC5352101.xml	factor-1	52998 : 53006	CM	d the colony-stimulating factor-1 receptor (CSF-1R; glioma
./___Corpus/Medline/xml/PMC5352101.xml	CSF-1R	53017 : 53023	CM	ating factor-1 receptor (CSF-1R; gliomas) [273–279]. Alt
./___Corpus/Medline/xml/PMC5352101.xml	273–	53035 : 53039	CPR	eptor (CSF-1R; gliomas) [273–279]. Although the mechan
./___Corpus/Medline/xml/PMC5352101.xml	anti-	53311 : 53316	CPR	nt to the effects of the anti-EGFR/HER2 antibody trastu
./___Corpus/Medline/xml/PMC5352101.xml	HER2	53321 : 53325	CM	effects of the anti-EGFR/HER2 antibody trastuzumab, IG
./___Corpus/Medline/xml/PMC5352101.xml	SRC	53386 : 53389	CM	s resistance through the SRC/FAK/FoxM1 signaling [280
./___Corpus/Medline/xml/PMC5352101.xml	FAK	53390 : 53393	CM	sistance through the SRC/FAK/FoxM1 signaling [280]. O
./___Corpus/Medline/xml/PMC5352101.xml	MAPK	53480 : 53484	CM	mediated upregulation of MAPK/ERK signaling could be a
./___Corpus/Medline/xml/PMC5352101.xml	ERK	53485 : 53488	CM	ted upregulation of MAPK/ERK signaling could be anoth
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	53663 : 53667	CM	ity of IGF-IR to enhance PI3K/AKT/mTOR signaling, whic
./___Corpus/Medline/xml/PMC5352101.xml	AKT	53668 : 53671	CM	f IGF-IR to enhance PI3K/AKT/mTOR signaling, which co
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	53672 : 53676	CM	F-IR to enhance PI3K/AKT/mTOR signaling, which could b
./___Corpus/Medline/xml/PMC5352101.xml	NSCLC	53843 : 53848	CM	including breast cancer, NSCLC, and head and neck squam
./___Corpus/Medline/xml/PMC5352101.xml	EGFR	54006 : 54010	CM	chemotherapeutic agents, EGFR small molecule inhibitor
./___Corpus/Medline/xml/PMC5352101.xml	gefitinib	54037 : 54046	CM	mall molecule inhibitors gefitinib and erlotinib, and AKT s
./___Corpus/Medline/xml/PMC5352101.xml	erlotinib	54051 : 54060	CM	inhibitors gefitinib and erlotinib, and AKT small molecule 
./___Corpus/Medline/xml/PMC5352101.xml	AKT	54066 : 54069	CM	tinib and erlotinib, and AKT small molecule inhibitor
./___Corpus/Medline/xml/PMC5352101.xml	PI3K	54161 : 54165	CM	-induced upregulation of PI3K/AKT/mTOR appears to indu
./___Corpus/Medline/xml/PMC5352101.xml	AKT	54166 : 54169	CM	ced upregulation of PI3K/AKT/mTOR appears to induce i
./___Corpus/Medline/xml/PMC5352101.xml	mTOR	54170 : 54174	CM	upregulation of PI3K/AKT/mTOR appears to induce its ef
./___Corpus/Medline/xml/PMC5352101.xml	CONCLUSIONS	55078 : 55089	CM	1, 282]                  CONCLUSIONS                      In 
./___Corpus/Medline/xml/PMC5352101.xml	vitro	55802 : 55807	CM	              Several in vitro and in vivo experimental
./___Corpus/Medline/xml/PMC5352101.xml	PCM	55940 : 55943	CM	maintain the survival of PCM, leukemia, and lymphoma.
./___Corpus/Medline/xml/PMC5352101.xml	vitro	56227 : 56232	CM	nt antitumor activity in vitro and in animal models.   
./___Corpus/Medline/xml/PMC5352101.xml	vitro	56517 : 56522	CM	 as conclusive as the in vitro and animal research. We 
./___Corpus/Medline/xml/PMC5352101.xml	pIGF-IR	57426 : 57433	CM	ssibly the expression of pIGF-IR was first performed in t
./___Corpus/Medline/xml/PMC5352101.xml	R01CA151533	58277 : 58288	CM	 work is supported by an R01CA151533 grant from the National 
./___Corpus/Medline/xml/PMC5352101.xml	H.M.A	58339 : 58344	CM	ancer Institute (NCI) to H.M.A., an R21CA170035 grant f
./___Corpus/Medline/xml/PMC5352101.xml	A.O.K	58384 : 58389	CM	35 grant from the NCI to A.O.K., and by grant 145207207
./___Corpus/Medline/xml/PMC5352101.xml	CONFLICTS	58687 : 58696	CM	               Footnotes CONFLICTS OF INTERESTS The authors
./___Corpus/PubMed/xml/28572720.xml	tyrosine	128 : 136	CM	ors for the non-receptor tyrosine kinase Pyk2.            
./___Corpus/PubMed/xml/28582447.xml	YM155	39 : 44	CM	               Action of YM155 on clear cell renal cell
./___Corpus/PubMed/xml/28588489.xml	Vitro	69 : 74	CM	s Osteosarcoma Growth In Vitro and Inhibits Wnt Signali
./___Corpus/PubMed/xml/28611670.xml	Epigallocatechin-3	47 : 65	CM	       Identification of Epigallocatechin-3- Gallate as an Inhibitor
./___Corpus/PubMed/xml/28611670.xml	Gallate	67 : 74	CM	n of Epigallocatechin-3- Gallate as an Inhibitor of Phosp
./___Corpus/PubMed/xml/28611670.xml	Phosphoglycerate	94 : 110	CM	llate as an Inhibitor of Phosphoglycerate Mutase 1.               
./___Corpus/PubMed/xml/28638737.xml	anti-CD73	53 : 62	CM	 Selective activation of anti-CD73 mechanisms in control of
./___Corpus/PubMed/xml/28719608.xml	Cholesterol	29 : 40	CM	                         Cholesterol esterification inhibitio
./___Corpus/PubMed/xml/28719608.xml	esterification	41 : 55	RN	             Cholesterol esterification inhibition and imatinib 
./___Corpus/PubMed/xml/28719608.xml	imatinib	71 : 79	CM	ification inhibition and imatinib treatment synergisticall
./___Corpus/PubMed/xml/28727840.xml	tyrosine	61 : 69	CM	hibition of Fes and Flt3 tyrosine kinases potently inhibit
./___Corpus/PubMed/xml/28740365.xml	ceritinib	42 : 51	CM	            Spotlight on ceritinib in the treatment of ALK+
./___Corpus/PubMed/xml/28740365.xml	ALK+	72 : 76	CM	inib in the treatment of ALK+ NSCLC: design, developme
./___Corpus/PubMed/xml/28787001.xml	YM155	29 : 34	CM	                         YM155 as an inhibitor of cance
./___Corpus/PubMed/xml/28787001.xml	autophosphorylation	94 : 113	CM	 simultaneously inhibits autophosphorylation of epidermal growth fact
./___Corpus/PubMed/xml/28787001.xml	G9a	154 : 157	CM	owth factor receptor and G9a-mediated stemness in lun
./___Corpus/PubMed/xml/28790837.xml	PARP	90 : 94	CM	ture of a newly approved PARP inhibitor for ovarian ca
./___Corpus/PubMed/xml/28848348.xml	folate	64 : 70	CM	y nanocarriers targeting folate receptor and encapsulati
./___Corpus/PubMed/xml/28848348.xml	2-deoxyglucose	98 : 112	CM	ceptor and encapsulating 2-deoxyglucose and α-tocopheryl succina
./___Corpus/PubMed/xml/28848348.xml	succinate	130 : 139	CM	glucose and α-tocopheryl succinate enhance anti-tumor effec
./___Corpus/PubMed/xml/28848348.xml	anti-	148 : 153	CPR	pheryl succinate enhance anti-tumor effect in vivo.    
./___Corpus/PubMed/xml/28848451.xml	Syndecan-4	111 : 121	CM	ast) Muscle: Function of Syndecan-4 and Glypican-1 in Adult 
./___Corpus/PubMed/xml/28848451.xml	Glypican-1	126 : 136	CM	nction of Syndecan-4 and Glypican-1 in Adult Myoblast Prolif
./___Corpus/PubMed/xml/28855816.xml	Cyclin	72 : 78	CM	novel inhibitors against Cyclin Dependent Kinase 9/Cycli
./___Corpus/PubMed/xml/28855816.xml	Kinase	89 : 95	ASE	against Cyclin Dependent Kinase 9/Cyclin T1 complex as: 
./___Corpus/PubMed/xml/28855816.xml	Cyclin	98 : 104	CM	yclin Dependent Kinase 9/Cyclin T1 complex as: Anti canc
./___Corpus/PubMed/xml/28928866.xml	CT-721	29 : 35	CM	                         CT-721, a Potent Bcr-Abl Inhibi
./___Corpus/PubMed/xml/28928866.xml	Vitro	87 : 92	CM	r, Exhibits Excellent In Vitro and In Vivo Efficacy in 
./___Corpus/PubMed/xml/28955993.xml	LSD1	29 : 33	CM	                         LSD1/KDM1 isoform LSD1+8a con
./___Corpus/PubMed/xml/28955993.xml	isoform	39 : 46	CM	               LSD1/KDM1 isoform LSD1+8a contributes to n
./___Corpus/PubMed/xml/28955993.xml	LSD1	47 : 51	CM	       LSD1/KDM1 isoform LSD1+8a contributes to neural
